6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
another O
section O
of O
the O
label O
[ O
see O
Warnings O
and O
Precautions O
( O
5 O
) O
] O
: O
* O
Non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
infectious I-OSE_Labeled_AE
pneumonitis I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
Infections B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

* O
Angioedema B-NonOSE_AE
with O
concomitant O
use O
of O
ACE O
inhibitors O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

* O
Stomatitis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

* O
Renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

* O
Impaired B-OSE_Labeled_AE
wound I-OSE_Labeled_AE
healing I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
. O

Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
the O
adverse O
reaction O
rates O
observed O
can O
not O
be O
directly O
compared O
to O
rates O
in O
other O
trials O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

EXCERPT O
: O
Advanced O
HR+ O
BC O
, O
advanced O
NET O
, O
advanced O
RCC O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
=30 O
% O
) O
include O
stomatitis O
, O
infections O
, O
rash O
, O
fatigue O
, O
diarrhea O
, O
edema O
, O
abdominal O
pain O
, O
nausea O
, O
fever O
, O
asthenia O
, O
cough O
, O
headache O
and O
decreased O
appetite O
. O

( O
6.1 O
, O
6.2 O
, O
6.3 O
) O
Renal O
angiomyolipoma O
with O
TSC O
: O
Most O
common O
adverse O
reaction O
( O
incidence O
> O
= O
30 O
% O
) O
is O
stomatitis O
. O

( O
6.4 O
) O
SEGA O
with O
TSC O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
30 O
% O
) O
are O
stomatitis O
and O
respiratory O
tract O
infection O
. O

( O
6.5 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Novartis O
Pharmaceuticals O
Corporation O
at O
1-888-669-6682 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Study O
Experience O
in O
Advanced O
Hormone O
Receptor-Positive O
, O
HER2-Negative O
Breast O
Cancer O
The O
efficacy O
and O
safety O
of O
AFINITOR O
( O
10 O
mg/day O
) O
plus O
exemestane O
( O
25 O
mg/day O
) O
( O
n=485 O
) O
versus O
placebo O
plus O
exemestane O
( O
25 O
mg/day O
) O
( O
n=239 O
) O
was O
evaluated O
in O
a O
randomized O
, O
controlled O
trial O
( O
BOLERO-2 O
) O
in O
patients O
with O
advanced B-Not_AE_Candidate
or I-Not_AE_Candidate
metastatic I-Not_AE_Candidate
hormone I-Not_AE_Candidate
receptor I-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
, I-Not_AE_Candidate
HER I-Not_AE_Candidate
2 I-Not_AE_Candidate
- I-Not_AE_Candidate
negative I-Not_AE_Candidate
breast I-Not_AE_Candidate
cancer I-Not_AE_Candidate
. O

The O
median O
age O
of O
patients O
was O
61 O
years O
( O
range O
28-93 O
years O
) O
, O
and O
75 O
% O
were O
Caucasian O
. O

Safety O
results O
are O
based O
on O
a O
median O
follow-up O
of O
approximately O
13 O
months O
. O

The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
=30 O
% O
) O
were O
stomatitis B-OSE_Labeled_AE
, O
infections B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
and O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
. O

The O
most O
common O
Grade O
3/4 O
adverse O
reactions O
( O
incidence O
> O
=2 O
% O
) O
were O
stomatitis B-OSE_Labeled_AE
, O
infections B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
pneumonitis B-OSE_Labeled_AE
, O
and O
diarrhea B-OSE_Labeled_AE
. O

The O
most O
common O
laboratory O
abnormalities O
( O
incidence O
> O
=50 O
% O
) O
were O
hypercholesterolemia B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
aspartate I-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
AST I-OSE_Labeled_AE
) O
, O
anemia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
lymphopenia B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
alanine I-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
) O
, O
and O
hypertriglyceridemia B-OSE_Labeled_AE
. O

The O
most O
common O
Grade O
3/4 O
laboratory O
abnormalities O
( O
incidence O
> O
= O
3 O
% O
) O
were O
lymphopenia B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
potassium I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
AST I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
, O
and O
thrombocytopenia B-OSE_Labeled_AE
. O

Fatal B-NonOSE_AE
adverse O
reactions O
occurred O
more O
frequently O
in O
patients O
who O
received O
AFINITOR O
plus O
exemestane O
( O
2 O
% O
) O
compared O
to O
patients O
on O
the O
placebo O
plus O
exemestane O
arm O
( O
0.4 O
% O
) O
. O

The O
rates O
of O
treatment-emergent O
adverse O
events O
resulting O
in O
permanent O
discontinuation O
were O
24 O
% O
and O
5 O
% O
for O
the O
AFINITOR O
plus O
exemestane O
and O
placebo O
plus O
exemestane O
treatment O
groups O
, O
respectively O
. O

Dose O
adjustments O
( O
interruptions O
or O
reductions O
) O
were O
more O
frequent O
among O
patients O
in O
the O
AFINITOR O
plus O
exemestane O
arm O
than O
in O
the O
placebo O
plus O
exemestane O
arm O
( O
63 O
% O
versus O
14 O
% O
) O
. O

Table O
2 O
compares O
the O
incidence O
of O
treatment-emergent O
adverse O
reactions O
reported O
with O
an O
incidence O
of O
> O
=10 O
% O
for O
patients O
receiving O
AFINITOR O
10 O
mg O
daily O
versus O
placebo O
. O

Table O
2 O
: O
Adverse O
Reactions O
Reported O
> O
=10 O
% O
of O
Patients O
with O
Advanced O
HR+ O
BC* O
Grading O
according O
to O
CTCAE O
Version O
3.0 O
* O
160 O
patients O
( O
33.2 O
% O
) O
were O
exposed O
to O
AFINITOR O
therapy O
for O
a O
period O
of O
> O
= O
32 O
weeks O
a O
Exemestane O
( O
25 O
mg/day O
) O
b O
Includes O
stomatitis B-OSE_Labeled_AE
, O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
aphthous B-OSE_Labeled_AE
stomatitis I-OSE_Labeled_AE
, O
glossodynia B-OSE_Labeled_AE
, O
gingival B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
glossitis B-OSE_Labeled_AE
and O
lip B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
c O
Includes O
all O
preferred O
terms O
within O
the O
' B-NonOSE_AE
infections I-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
' I-NonOSE_AE
system O
organ O
class O
, O
the O
most O
common O
being O
nasopharyngitis B-OSE_Labeled_AE
( O
10 O
% O
) O
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
10 O
% O
) O
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
5 O
% O
) O
, O
pneumonia B-OSE_Labeled_AE
( O
4 O
% O
) O
, O
bronchitis B-OSE_Labeled_AE
( O
4 O
% O
) O
, O
cystitis B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
sinusitis B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
and O
also O
including O
candidiasis B-OSE_Labeled_AE
( O
< O
1 O
% O
) O
, O
and O
sepsis B-OSE_Labeled_AE
( O
< O
1 O
% O
) O
, O
and O
hepatitis B-OSE_Labeled_AE
C I-OSE_Labeled_AE
( O
< O
1 O
% O
) O
. O

d O
Includes O
pneumonitis B-OSE_Labeled_AE
, O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
lung B-OSE_Labeled_AE
infiltration I-OSE_Labeled_AE
, O
and O
pulmonary B-OSE_Labeled_AE
fibrosis I-OSE_Labeled_AE
e O
Exposure O
to O
AFINITOR O
or O
placebo O
AFINITOR O
( O
10 O
mg/day O
) O
+ O
exemestane O
a O
N=482 O
Placebo O
+ O
exemestane O
a O
N=238 O
All O
Grades O
Grade O
3 O
Grade O
4 O
All O
Grades O
Grade O
3 O
Grade O
4 O
% O
% O
% O
% O
% O
% O
Any O
adverse O
reaction O
100 O
41 O
9 O
90 O
22 O
5 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Stomatitis B-OSE_Labeled_AE
b O
67 O
8 O
0 O
11 O
0.8 O
0 O
Diarrhea B-OSE_Labeled_AE
33 O
2 O
0.2 O
18 O
0.8 O
0 O
Nausea B-OSE_Labeled_AE
29 O
0.2 O
0.2 O
28 O
1 O
0 O
Vomiting B-OSE_Labeled_AE
17 O
0.8 O
0.2 O
12 O
0.8 O
0 O
Constipation B-OSE_Labeled_AE
14 O
0.4 O
0 O
13 O
0.4 O
0 O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
11 O
0 O
0 O
7 O
0 O
0 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
36 O
4 O
0.4 O
27 O
1 O
0 O
Edema B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
19 O
1 O
0 O
6 O
0.4 O
0 O
Pyrexia B-OSE_Labeled_AE
15 O
0.2 O
0 O
7 O
0.4 O
0 O
Asthenia B-OSE_Labeled_AE
13 O
2 O
0.2 O
4 O
0 O
0 O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Infections B-OSE_Labeled_AE
c O
50 O
4 O
1 O
25 O
2 O
0 O
Investigations B-NonOSE_AE
Weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
25 O
1 O
0 O
6 O
0 O
0 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
30 O
1 O
0 O
12 O
0.4 O
0 O
Hyperglycemia B-OSE_Labeled_AE
14 O
5 O
0.4 O
2 O
0.4 O
0 O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
20 O
0.8 O
0 O
17 O
0 O
0 O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
14 O
0.2 O
0 O
10 O
0.8 O
0 O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
9 O
0.4 O
0 O
11 O
2 O
0 O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Dysgeusia B-OSE_Labeled_AE
22 O
0.2 O
0 O
6 O
0 O
0 O
Headache B-OSE_Labeled_AE
21 O
0.4 O
0 O
14 O
0 O
0 O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
13 O
0.2 O
0 O
8 O
0 O
0 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
24 O
0.6 O
0 O
12 O
0 O
0 O
Dyspnea B-OSE_Labeled_AE
21 O
4 O
0.2 O
11 O
0.8 O
0.4 O
Epistaxis B-OSE_Labeled_AE
17 O
0 O
0 O
1 O
0 O
0 O
Pneumonitis B-OSE_Labeled_AE
d O
19 O
4 O
0.2 O
0.4 O
0 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
39 O
1 O
0 O
6 O
0 O
0 O
Pruritus B-OSE_Labeled_AE
13 O
0.2 O
0 O
5 O
0 O
0 O
Alopecia B-OSE_Labeled_AE
10 O
0 O
0 O
5 O
0 O
0 O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hot B-OSE_Labeled_AE
flush I-OSE_Labeled_AE
6 O
0 O
0 O
14 O
0 O
0 O
Median O
duration O
of O
treatment O
e O
23.9 O
weeks O
13.4 O
weeks O
Key O
observed O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
are O
presented O
in O
Table O
3 O
. O

Table O
3 O
: O
Key O
Laboratory O
Abnormalities O
Reported O
in O
> O
=10 O
% O
of O
Patients O
with O
Advanced O
HR+ O
BC O
Grading O
according O
to O
CTCAE O
Version O
3.0 O
a O
Exemestane O
( O
25 O
mg/day O
) O
b O
Reflects O
corresponding O
adverse O
drug O
reaction O
reports O
of O
anemia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
lymphopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
and O
thrombocytopenia B-OSE_Labeled_AE
( O
collectively O
as O
pancytopenia B-OSE_Labeled_AE
) O
, O
which O
occurred O
at O
lower O
frequency O
. O

Laboratory O
parameter O
AFINITOR O
( O
10 O
mg/day O
) O
+ O
exemestane O
a O
N=482 O
Placebo O
+ O
exemestane O
a O
N=238 O
All O
Grades O
Grade O
3 O
Grade O
4 O
All O
Grades O
Grade O
3 O
Grade O
4 O
% O
% O
% O
% O
% O
% O
Hematology B-NonOSE_AE
b O
Hemoglobin B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
68 O
6 O
0.6 O
40 O
0.8 O
0.4 O
WBC B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
58 O
1 O
0 O
28 O
5 O
0.8 O
Platelets B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
54 O
3 O
0.2 O
5 O
0 O
0.4 O
Lymphocytes B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
54 O
11 O
0.6 O
37 O
5 O
0.8 O
Neutrophils B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
31 O
2 O
0 O
11 O
0.8 O
0.8 O
Clinical B-NonOSE_AE
chemistry I-NonOSE_AE
Glucose B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
69 O
9 O
0.4 O
44 O
0.8 O
0.4 O
Cholesterol B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
70 O
0.6 O
0.2 O
38 O
0.8 O
0.8 O
Aspartate B-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
AST I-OSE_Labeled_AE
) I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
69 O
4 O
0.2 O
45 O
3 O
0.4 O
Alanine B-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
) I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
51 O
4 O
0.2 O
29 O
5 O
0 O
Triglycerides B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
50 O
0.8 O
0 O
26 O
0 O
0 O
Albumin B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
33 O
0.8 O
0 O
16 O
0.8 O
0 O
Potassium B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
29 O
4 O
0.2 O
7 O
1 O
0 O
Creatinine B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
24 O
2 O
0.2 O
13 O
0 O
0 O
Topical O
Prophylaxis O
for O
Stomatitis O
In O
a O
single O
arm O
study O
( O
SWISH O
; O
N=92 O
) O
in O
postmenopausal B-Not_AE_Candidate
women O
with O
hormone B-Not_AE_Candidate
receptor I-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
, I-Not_AE_Candidate
HER I-Not_AE_Candidate
2 I-Not_AE_Candidate
- I-Not_AE_Candidate
negative I-Not_AE_Candidate
breast I-Not_AE_Candidate
cancer I-Not_AE_Candidate
beginning O
AFINITOR O
( O
10 O
mg/day O
) O
plus O
exemestane O
( O
25 O
mg/day O
) O
, O
patients O
started O
dexamethasone O
0.5mg/5mL O
alcohol-free O
mouthwash O
( O
10 O
mL O
swished O
for O
2 O
minutes O
and O
spat O
, O
4 O
times O
daily O
for O
8 O
weeks O
) O
concurrently O
with O
AFINITOR O
and O
exemestane O
. O

No O
food O
or O
drink O
was O
to O
be O
consumed O
for O
at O
least O
1 O
hour O
after O
swishing O
and O
spitting O
the O
dexamethasone O
mouthwash O
. O

The O
primary O
objective O
of O
this O
study O
was O
to O
assess O
the O
incidence O
of O
Grade O
> O
= O
2 O
stomatitis B-NonOSE_AE
within O
8 O
weeks O
. O

The O
incidence O
of O
Grade O
> O
= O
2 O
stomatitis B-OSE_Labeled_AE
within O
8 O
weeks O
was O
2 O
% O
, O
which O
was O
lower O
than O
the O
33 O
% O
reported O
in O
the O
BOLERO-2 O
trial O
. O

The O
incidence O
of O
Grade O
1 O
stomatitis B-OSE_Labeled_AE
was O
19 O
% O
. O

No O
cases O
of O
Grade O
3 O
or O
4 O
stomatitis B-NonOSE_AE
were O
reported O
. O

Oral B-OSE_Labeled_AE
candidiasis I-OSE_Labeled_AE
was O
reported O
in O
2 O
% O
of O
patients O
in O
this O
study O
compared O
to O
0.2 O
% O
in O
the O
BOLERO-2 O
trial O
. O

6.2 O
Clinical O
Study O
Experience O
in O
Advanced O
Neuroendocrine O
Tumors O
Advanced O
Pancreatic O
Neuroendocrine O
Tumors O
( O
PNET O
) O
In O
a O
randomized O
, O
controlled O
trial O
( O
RADIANT-3 O
) O
of O
AFINITOR O
( O
n=204 O
) O
versus O
placebo O
( O
n=203 O
) O
in O
patients O
with O
advanced B-Not_AE_Candidate
PNET I-Not_AE_Candidate
the O
median O
age O
of O
patients O
was O
58 O
years O
( O
range O
20-87 O
) O
, O
79 O
% O
were O
White O
, O
and O
55 O
% O
were O
male O
. O

Patients O
on O
the O
placebo O
arm O
could O
cross O
over O
to O
open-label O
AFINITOR O
upon O
disease O
progression O
. O

The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
30 O
% O
) O
were O
stomatitis B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
and O
headache B-OSE_Labeled_AE
. O

The O
most O
common O
Grade O
3-4 O
adverse O
reactions O
( O
incidence O
> O
= O
5 O
% O
) O
were O
stomatitis B-OSE_Labeled_AE
and O
diarrhea B-OSE_Labeled_AE
. O

The O
most O
common O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
( O
incidence O
> O
= O
50 O
% O
) O
were O
decreased B-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
alkaline B-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
hypercholesterolemia B-OSE_Labeled_AE
, O
bicarbonate B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
and O
increased B-OSE_Labeled_AE
aspartate I-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
AST I-OSE_Labeled_AE
) O
. O

The O
most O
common O
Grade O
3-4 O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
( O
incidence O
> O
= O
3 O
% O
) O
were O
hyperglycemia B-OSE_Labeled_AE
, O
lymphopenia B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
, O
hypophosphatemia B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
alkaline I-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
aspartate I-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
AST I-OSE_Labeled_AE
) O
, O
potassium B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
and O
thrombocytopenia B-OSE_Labeled_AE
. O

Deaths B-NonOSE_AE
during O
double-blind O
treatment O
where O
an O
adverse O
event O
was O
the O
primary O
cause O
occurred O
in O
seven O
patients O
on O
AFINITOR O
and O
one O
patient O
on O
placebo O
. O

Causes O
of O
death B-NonOSE_AE
on O
the O
AFINITOR O
arm O
included O
one O
case O
of O
each O
of O
the O
following O
: O
acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
, O
acute B-NonOSE_AE
respiratory I-NonOSE_AE
distress I-NonOSE_AE
, O
cardiac B-NonOSE_AE
arrest I-NonOSE_AE
, O
death B-NonOSE_AE
( O
cause O
unknown O
) O
, O
hepatic B-NonOSE_AE
failure I-NonOSE_AE
, O
pneumonia B-NonOSE_AE
, O
and O
sepsis B-NonOSE_AE
. O

There O
was O
one O
death B-NonOSE_AE
due O
to O
pulmonary B-NonOSE_AE
embolism I-NonOSE_AE
on O
the O
placebo O
arm O
. O

After O
cross-over O
to O
open-label O
AFINITOR O
, O
there O
were O
three O
additional O
deaths B-NonOSE_AE
, O
one O
due O
to O
hypoglycemia B-NonOSE_AE
and O
cardiac B-NonOSE_AE
arrest I-NonOSE_AE
in O
a O
patient O
with O
insulinoma B-Not_AE_Candidate
, O
one O
due O
to O
myocardial B-NonOSE_AE
infarction I-NonOSE_AE
with O
congestive B-NonOSE_AE
heart I-NonOSE_AE
failure I-NonOSE_AE
, O
and O
the O
other O
due O
to O
sudden B-NonOSE_AE
death I-NonOSE_AE
. O

The O
rates O
of O
treatment-emergent O
adverse O
events O
resulting O
in O
permanent O
discontinuation O
were O
20 O
% O
and O
6 O
% O
for O
the O
AFINITOR O
and O
placebo O
treatment O
groups O
, O
respectively O
. O

Dose O
delay O
or O
reduction O
was O
necessary O
in O
61 O
% O
of O
everolimus O
patients O
and O
29 O
% O
of O
placebo O
patients O
. O

Grade O
3-4 O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
occurred O
in O
six O
patients O
in O
the O
everolimus O
arm O
and O
three O
patients O
in O
the O
placebo O
arm O
. O

Thrombotic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
included O
five O
patients O
with O
pulmonary B-OSE_Labeled_AE
embolus I-OSE_Labeled_AE
in O
the O
everolimus O
arm O
and O
one O
in O
the O
placebo O
arm O
as O
well O
as O
three O
patients O
with O
thrombosis B-OSE_Labeled_AE
in O
the O
everolimus O
arm O
and O
two O
in O
the O
placebo O
arm O
. O

Table O
4 O
compares O
the O
incidence O
of O
treatment-emergent O
adverse O
reactions O
reported O
with O
an O
incidence O
of O
> O
=10 O
% O
for O
patients O
receiving O
AFINITOR O
10 O
mg O
daily O
versus O
placebo O
. O

Table O
4 O
: O
Adverse O
Reactions O
Reported O
> O
=10 O
% O
of O
Patients O
with O
Advanced O
PNET O
Grading O
according O
to O
CTCAE O
Version O
3.0 O
a O
Includes O
stomatitis B-OSE_Labeled_AE
, O
aphthous B-OSE_Labeled_AE
stomatitis I-OSE_Labeled_AE
, O
gingival B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
/swelling/ulceration O
, O
glossitis B-OSE_Labeled_AE
, O
glossodynia B-OSE_Labeled_AE
, O
lip B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
and O
mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
. O

b O
Includes O
diarrhea B-OSE_Labeled_AE
, O
enteritis B-OSE_Labeled_AE
, O
enterocolitis B-OSE_Labeled_AE
, O
colitis B-OSE_Labeled_AE
, O
defecation B-OSE_Labeled_AE
urgency I-OSE_Labeled_AE
, O
and O
steatorrhea B-OSE_Labeled_AE
. O

c O
Includes O
pneumonitis B-OSE_Labeled_AE
, O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
fibrosis I-OSE_Labeled_AE
and O
restrictive B-OSE_Labeled_AE
pulmonary I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
. O

AFINITOR O
N=204 O
Placebo O
N=203 O
All O
Grades O
Grade O
3 O
Grade O
4 O
All O
Grades O
Grade O
3 O
Grade O
4 O
% O
% O
% O
% O
% O
% O
Any O
adverse O
reaction O
100 O
49 O
13 O
98 O
32 O
8 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Stomatitis B-OSE_Labeled_AE
a O
70 O
7 O
0 O
20 O
0 O
0 O
Diarrhea B-OSE_Labeled_AE
b O
50 O
5 O
0.5 O
25 O
3 O
0 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
36 O
4 O
0 O
32 O
6 O
1 O
Nausea B-OSE_Labeled_AE
32 O
2 O
0 O
33 O
2 O
0 O
Vomiting B-OSE_Labeled_AE
29 O
1 O
0 O
21 O
2 O
0 O
Constipation B-OSE_Labeled_AE
14 O
0 O
0 O
13 O
0.5 O
0 O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
11 O
0 O
0 O
4 O
0 O
0 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
/ O
malaise B-OSE_Labeled_AE
45 O
3 O
0.5 O
27 O
2 O
0.5 O
Edema B-OSE_Labeled_AE
( O
general O
and O
peripheral I-OSE_Labeled_AE
) O
39 O
1 O
0.5 O
12 O
1 O
0 O
Fever B-OSE_Labeled_AE
31 O
0.5 O
0.5 O
13 O
0.5 O
0 O
Asthenia B-OSE_Labeled_AE
19 O
3 O
0 O
20 O
3 O
0 O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Nasopharyngitis B-OSE_Labeled_AE
/ O
rhinitis B-OSE_Labeled_AE
/ O
URI B-OSE_Labeled_AE
25 O
0 O
0 O
13 O
0 O
0 O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
16 O
0 O
0 O
6 O
0.5 O
0 O
Investigations B-NonOSE_AE
Weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
28 O
0.5 O
0 O
11 O
0 O
0 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
30 O
1 O
0 O
18 O
1 O
0 O
Diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
10 O
2 O
0 O
0.5 O
0 O
0 O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
15 O
1 O
0.5 O
7 O
0.5 O
0 O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
15 O
1 O
0 O
11 O
1 O
0 O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
14 O
0.5 O
0 O
6 O
1 O
0 O
Muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
10 O
0 O
0 O
4 O
0 O
0 O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
/ O
migraine B-OSE_Labeled_AE
30 O
0.5 O
0 O
15 O
1 O
0 O
Dysgeusia B-OSE_Labeled_AE
19 O
0 O
0 O
5 O
0 O
0 O
Dizziness B-OSE_Labeled_AE
12 O
0.5 O
0 O
7 O
0 O
0 O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
14 O
0 O
0 O
8 O
0 O
0 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
/ O
productive B-OSE_Labeled_AE
cough I-OSE_Labeled_AE
25 O
0.5 O
0 O
13 O
0 O
0 O
Epistaxis B-OSE_Labeled_AE
22 O
0 O
0 O
1 O
0 O
0 O
Dyspnea B-OSE_Labeled_AE
/ O
dyspnea B-OSE_Labeled_AE
exertional I-OSE_Labeled_AE
20 O
2 O
0.5 O
7 O
0.5 O
0 O
Pneumonitis B-OSE_Labeled_AE
c O
17 O
3 O
0.5 O
0 O
0 O
0 O
Oropharyngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
11 O
0 O
0 O
6 O
0 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
59 O
0.5 O
0 O
19 O
0 O
0 O
Nail B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
22 O
0.5 O
0 O
2 O
0 O
0 O
Pruritus B-OSE_Labeled_AE
/ O
pruritus B-OSE_Labeled_AE
generalized I-OSE_Labeled_AE
21 O
0 O
0 O
13 O
0 O
0 O
Dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
/ O
xeroderma B-OSE_Labeled_AE
13 O
0 O
0 O
6 O
0 O
0 O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
13 O
1 O
0 O
6 O
1 O
0 O
Median O
duration O
of O
treatment O
( O
wks O
) O
37 O
16 O
In O
female O
patients O
aged O
18 O
to O
55 O
years O
, O
irregular B-OSE_Labeled_AE
menstruation I-OSE_Labeled_AE
occurred O
in O
5 O
of O
46 O
( O
11 O
% O
) O
AFINITOR-treated O
females O
and O
none O
of O
the O
33 O
females O
in O
the O
placebo O
group O
. O

Key O
observed O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
are O
presented O
in O
Table O
5 O
. O

Table O
5 O
: O
Key O
Laboratory O
Abnormalities O
Reported O
in O
> O
=10 O
% O
of O
Patients O
with O
Advanced O
PNET O
Grading O
according O
to O
CTCAE O
Version O
3.0 O
Laboratory O
parameter O
AFINITOR O
N=204 O
Placebo O
N=203 O
All O
Grades O
Grade O
3-4 O
All O
Grades O
Grade O
3-4 O
% O
% O
% O
% O
Hematology B-NonOSE_AE
Hemoglobin B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
86 O
15 O
63 O
1 O
Lymphocytes B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
45 O
16 O
22 O
4 O
Platelets B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
45 O
3 O
11 O
0 O
WBC B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
43 O
2 O
13 O
0 O
Neutrophils B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
30 O
4 O
17 O
2 O
Clinical B-NonOSE_AE
chemistry I-NonOSE_AE
Alkaline B-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
74 O
8 O
66 O
8 O
Glucose B-OSE_Labeled_AE
( I-OSE_Labeled_AE
fasting I-OSE_Labeled_AE
) I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
75 O
17 O
53 O
6 O
Cholesterol B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
66 O
0.5 O
22 O
0 O
Bicarbonate B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
56 O
0 O
40 O
0 O
Aspartate B-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
AST I-OSE_Labeled_AE
) I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
56 O
4 O
41 O
4 O
Alanine B-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
) I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
48 O
2 O
35 O
2 O
Phosphate B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
40 O
10 O
14 O
3 O
Triglycerides B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
39 O
0 O
10 O
0 O
Calcium B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
37 O
0.5 O
12 O
0 O
Potassium B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
23 O
4 O
5 O
0 O
Creatinine B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
19 O
2 O
14 O
0 O
Sodium B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
16 O
1 O
16 O
1 O
Albumin B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
13 O
1 O
8 O
0 O
Bilirubin B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
10 O
1 O
14 O
2 O
Potassium B-NonOSE_AE
increased I-NonOSE_AE
7 O
0 O
10 O
0.5 O
Unresectable O
, O
Locally O
Advanced O
or O
Metastatic O
, O
Well-Differentiated O
, O
Non-Functional O
Neuroendocrine O
Tumors O
of O
Gastrointestinal O
or O
Lung O
Origin O
In O
a O
randomized O
, O
controlled O
trial O
( O
RADIANT-4 O
) O
of O
AFINITOR O
( O
n=202 O
treated O
) O
versus O
placebo O
( O
n=98 O
treated O
) O
in O
patients O
with O
advanced B-Not_AE_Candidate
non I-Not_AE_Candidate
- I-Not_AE_Candidate
functional I-Not_AE_Candidate
NET I-Not_AE_Candidate
of O
GI O
or O
lung O
origin O
, O
the O
median O
age O
of O
patients O
was O
63 O
years O
( O
range O
22-86 O
) O
, O
76 O
% O
were O
White O
, O
and O
53 O
% O
were O
female O
. O

The O
median O
duration O
of O
exposure O
to O
AFINITOR O
was O
9.3 O
months O
; O
64 O
% O
of O
patients O
were O
treated O
for O
> O
= O
6 O
months O
and O
39 O
% O
were O
treated O
for O
> O
= O
12 O
months O
. O

AFINITOR O
was O
discontinued O
for O
adverse O
reactions O
in O
29 O
% O
of O
patients O
, O
dose O
reduction O
or O
delay O
was O
required O
in O
70 O
% O
of O
AFINITOR-treated O
patients O
. O

Serious O
adverse O
reactions O
occurred O
in O
42 O
% O
of O
AFINITOR-treated O
patients O
and O
included O
3 O
fatal B-NonOSE_AE
events O
( O
cardiac B-NonOSE_AE
failure I-NonOSE_AE
, O
respiratory B-NonOSE_AE
failure I-NonOSE_AE
, O
and O
septic B-NonOSE_AE
shock I-NonOSE_AE
) O
. O

Table O
6 O
and O
Table O
7 O
summarize O
the O
incidence O
of O
adverse O
reactions O
of O
AFINITOR O
occurring O
at O
an O
incidence O
of O
> O
=10 O
% O
and O
at O
> O
=5 O
% O
absolute O
incidence O
over O
placebo O
( O
all O
Grades O
) O
or O
> O
=2 O
% O
higher O
incidence O
over O
placebo O
( O
Grade O
3 O
and O
4 O
) O
. O

Table O
6 O
: O
Adverse O
Reactions O
in O
> O
=10 O
% O
of O
AFINITOR-Treated O
Patients O
with O
Non-Functional O
NET O
of O
Gastrointestinal O
or O
Lung O
Origin O
Grading O
according O
to O
NCI O
CTCAE O
Version O
4.03 O
a O
Includes O
stomatitis B-OSE_Labeled_AE
, O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
aphthous B-OSE_Labeled_AE
stomatitis I-OSE_Labeled_AE
, O
gingival B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
glossitis B-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
and O
mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
. O

b O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
lower B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
pneumonia B-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
) O
, O
abscess B-OSE_Labeled_AE
, O
pyelonephritis B-OSE_Labeled_AE
, O
septic B-OSE_Labeled_AE
shock I-OSE_Labeled_AE
and O
viral B-OSE_Labeled_AE
myocarditis I-OSE_Labeled_AE
. O

c O
Includes O
pneumonitis B-OSE_Labeled_AE
and O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
. O

AFINITOR O
N=202 O
Placebo O
N=98 O
All O
Grades O
Grade O
3 O
Grade O
4 O
All O
Grades O
Grade O
3 O
Grade O
4 O
% O
% O
% O
% O
% O
% O
Any O
adverse O
reaction O
99 O
57 O
12 O
89 O
21 O
7 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Stomatitis B-OSE_Labeled_AE
a O
63 O
9 O
0 O
22 O
0 O
0 O
Diarrhea B-OSE_Labeled_AE
41 O
8 O
1 O
31 O
2 O
0 O
Nausea B-OSE_Labeled_AE
26 O
3 O
1 O
17 O
1 O
0 O
Vomiting B-OSE_Labeled_AE
15 O
4 O
0 O
12 O
2 O
0 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
39 O
3 O
0 O
6 O
1 O
0 O
Fatigue B-OSE_Labeled_AE
37 O
4 O
1 O
36 O
1 O
0 O
Asthenia B-OSE_Labeled_AE
23 O
2 O
1 O
8 O
0 O
0 O
Pyrexia B-OSE_Labeled_AE
23 O
1 O
1 O
8 O
0 O
0 O
Infections B-NonOSE_AE
Infections B-OSE_Labeled_AE
b O
58 O
8 O
3 O
29 O
1 O
1 O
Investigations B-NonOSE_AE
Decreased B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
22 O
1 O
0 O
17 O
1 O
0 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
22 O
1 O
0 O
17 O
1 O
0 O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Dysgeusia B-OSE_Labeled_AE
18 O
1 O
0 O
4 O
0 O
0 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
27 O
0 O
0 O
20 O
0 O
0 O
Dyspnea B-OSE_Labeled_AE
20 O
3 O
0 O
11 O
1 O
1 O
Pneumonitis B-OSE_Labeled_AE
c O
16 O
2 O
0 O
2 O
0 O
0 O
Epistaxis B-OSE_Labeled_AE
13 O
1 O
0 O
3 O
0 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
30 O
1 O
0 O
9 O
0 O
0 O
Pruritus B-OSE_Labeled_AE
17 O
1 O
0 O
9 O
0 O
0 O
Table O
7 O
: O
Laboratory O
Abnormalities O
in O
> O
=10 O
% O
of O
AFINITOR-Treated O
Patients O
with O
Non-Functional O
NET O
of O
Gastrointestinal O
or O
Lung O
Origin O
Grading O
according O
to O
NCI O
CTCAE O
Version O
4.03 O
AFINITOR O
N=202 O
Placebo O
N=98 O
All O
Grades O
Grade O
3 O
Grade O
4 O
All O
Grades O
Grade O
3 O
Grade O
4 O
% O
% O
% O
% O
% O
% O
Hematology B-NonOSE_AE
Anemia B-OSE_Labeled_AE
81 O
5 O
0 O
41 O
2 O
0 O
Lymphopenia B-OSE_Labeled_AE
66 O
15 O
2 O
32 O
2 O
0 O
Leukopenia B-OSE_Labeled_AE
49 O
2 O
0 O
17 O
0 O
0 O
Thrombocytopenia B-OSE_Labeled_AE
33 O
2 O
1 O
11 O
0 O
0 O
Neutropenia B-OSE_Labeled_AE
32 O
2 O
0 O
15 O
3 O
0 O
Clinical B-NonOSE_AE
chemistry I-NonOSE_AE
Hypercholesterolemia B-OSE_Labeled_AE
71 O
0 O
0 O
37 O
0 O
0 O
Elevated B-OSE_Labeled_AE
Aspartate I-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
AST I-OSE_Labeled_AE
) O
57 O
1 O
1 O
34 O
2 O
0 O
Hyperglycemia B-OSE_Labeled_AE
( O
fasting O
) O
55 O
6 O
0 O
36 O
1 O
0 O
Elevated B-OSE_Labeled_AE
Alanine I-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
) O
46 O
5 O
1 O
39 O
1 O
0 O
Hypophosphatemia B-OSE_Labeled_AE
43 O
4 O
0 O
15 O
2 O
0 O
Hypertriglyceridemia B-OSE_Labeled_AE
30 O
3 O
1 O
8 O
1 O
0 O
Hypokalemia B-OSE_Labeled_AE
27 O
4 O
2 O
12 O
3 O
0 O
Hypoalbuminemia B-OSE_Labeled_AE
18 O
0 O
0 O
8 O
0 O
0 O
6.3 O
Clinical O
Study O
Experience O
in O
Advanced O
Renal O
Cell O
Carcinoma O
The O
data O
described O
below O
reflect O
exposure O
to O
AFINITOR O
( O
n=274 O
) O
and O
placebo O
( O
n=137 O
) O
in O
a O
randomized O
, O
controlled O
trial O
( O
RECORD-1 O
) O
in O
patients O
with O
metastatic B-Not_AE_Candidate
renal I-Not_AE_Candidate
cell I-Not_AE_Candidate
carcinoma I-Not_AE_Candidate
who O
received O
prior O
treatment O
with O
sunitinib O
and/or O
sorafenib O
. O

The O
median O
age O
of O
patients O
was O
61 O
years O
( O
range O
27-85 O
) O
, O
88 O
% O
were O
Caucasian O
, O
and O
78 O
% O
were O
male O
. O

The O
median O
duration O
of O
blinded O
study O
treatment O
was O
141 O
days O
( O
range O
19-451 O
days O
) O
for O
patients O
receiving O
AFINITOR O
and O
60 O
days O
( O
range O
21-295 O
days O
) O
for O
those O
receiving O
placebo O
. O

The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
=30 O
% O
) O
were O
stomatitis B-OSE_Labeled_AE
, O
infections B-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
and O
diarrhea B-OSE_Labeled_AE
. O

The O
most O
common O
Grade O
3-4 O
adverse O
reactions O
( O
incidence O
> O
=3 O
% O
) O
were O
infections B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
, O
pneumonitis B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
and O
asthenia B-OSE_Labeled_AE
. O

The O
most O
common O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
( O
incidence O
> O
=50 O
% O
) O
were O
anemia B-OSE_Labeled_AE
, O
hypercholesterolemia B-OSE_Labeled_AE
, O
hypertriglyceridemia B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
lymphopenia B-OSE_Labeled_AE
, O
and O
increased B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
. O

The O
most O
common O
Grade O
3-4 O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
( O
incidence O
> O
=3 O
% O
) O
were O
lymphopenia B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
, O
hypophosphatemia B-OSE_Labeled_AE
, O
and O
hypercholesterolemia B-OSE_Labeled_AE
. O

Deaths B-NonOSE_AE
due O
to O
acute B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
0.7 O
% O
) O
, O
infection B-OSE_Labeled_AE
( O
0.7 O
% O
) O
, O
and O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
0.4 O
% O
) O
were O
observed O
on O
the O
AFINITOR O
arm O
but O
none O
on O
the O
placebo O
arm O
. O

The O
rates O
of O
treatment-emergent O
adverse O
events O
( O
irrespective O
of O
causality O
) O
resulting O
in O
permanent O
discontinuation O
were O
14 O
% O
and O
3 O
% O
for O
the O
AFINITOR O
and O
placebo O
treatment O
groups O
, O
respectively O
. O

The O
most O
common O
adverse O
reactions O
( O
irrespective O
of O
causality O
) O
leading O
to O
treatment O
discontinuation O
were O
pneumonitis B-OSE_Labeled_AE
and O
dyspnea B-OSE_Labeled_AE
. O

Infections B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
and O
pneumonitis B-OSE_Labeled_AE
were O
the O
most O
common O
reasons O
for O
treatment O
delay O
or O
dose O
reduction O
. O

The O
most O
common O
medical O
interventions O
required O
during O
AFINITOR O
treatment O
were O
for O
infections B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
, O
and O
stomatitis B-OSE_Labeled_AE
. O

Table O
8 O
compares O
the O
incidence O
of O
treatment-emergent O
adverse O
reactions O
reported O
with O
an O
incidence O
of O
> O
=10 O
% O
for O
patients O
receiving O
AFINITOR O
10 O
mg O
daily O
versus O
placebo O
. O

Within O
each O
MedDRA O
system O
organ O
class O
, O
the O
adverse O
reactions O
are O
presented O
in O
order O
of O
decreasing O
frequency O
. O

Table O
8 O
: O
Adverse O
Reactions O
Reported O
in O
at O
Least O
10 O
% O
of O
Patients O
with O
RCC O
and O
at O
a O
Higher O
Rate O
in O
the O
AFINITOR O
Arm O
than O
in O
the O
Placebo O
Arm O
Grading O
according O
to O
CTCAE O
Version O
3.0 O
a O
Stomatitis B-OSE_Labeled_AE
( O
including O
aphthous B-OSE_Labeled_AE
stomatitis I-OSE_Labeled_AE
) O
, O
and O
mouth B-OSE_Labeled_AE
and O
tongue O
ulceration I-OSE_Labeled_AE
. O

b O
Includes O
all O
preferred O
terms O
within O
the O
' B-NonOSE_AE
infections I-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
' I-NonOSE_AE
system O
organ O
class O
, O
the O
most O
common O
being O
nasopharyngitis B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
pneumonia B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
5 O
% O
) O
, O
bronchitis B-OSE_Labeled_AE
( O
4 O
% O
) O
, O
and O
sinusitis B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
and O
also O
including O
aspergillosis B-OSE_Labeled_AE
( O
< O
1 O
% O
) O
, O
candidiasis B-OSE_Labeled_AE
( O
< O
1 O
% O
) O
, O
and O
sepsis B-OSE_Labeled_AE
( O
< O
1 O
% O
) O
. O

c O
Includes O
pneumonitis B-OSE_Labeled_AE
, O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
lung B-OSE_Labeled_AE
infiltration I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
alveolar I-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
, O
and O
alveolitis B-OSE_Labeled_AE
. O

AFINITOR O
10 O
mg/day O
N=274 O
Placebo O
N=137 O
All O
Grades O
Grade O
3 O
Grade O
4 O
All O
Grades O
Grade O
3 O
Grade O
4 O
% O
% O
% O
% O
% O
% O
Any O
a O
dverse O
r O
eaction O
97 O
52 O
13 O
93 O
23 O
5 O
Gastrointestinal B-NonOSE_AE
d I-NonOSE_AE
isorders I-NonOSE_AE
Stomatitis B-OSE_Labeled_AE
a O
44 O
4 O
< O
1 O
8 O
0 O
0 O
Diarrhea B-OSE_Labeled_AE
30 O
1 O
0 O
7 O
0 O
0 O
Nausea B-OSE_Labeled_AE
26 O
1 O
0 O
19 O
0 O
0 O
Vomiting B-OSE_Labeled_AE
20 O
2 O
0 O
12 O
0 O
0 O
Infections B-NonOSE_AE
and I-NonOSE_AE
i I-NonOSE_AE
nfestations I-NonOSE_AE
b O
37 O
7 O
3 O
18 O
1 O
0 O
General B-NonOSE_AE
d I-NonOSE_AE
isorders I-NonOSE_AE
and I-NonOSE_AE
a I-NonOSE_AE
dministration I-NonOSE_AE
s I-NonOSE_AE
ite I-NonOSE_AE
c I-NonOSE_AE
onditions I-NonOSE_AE
Asthenia B-OSE_Labeled_AE
33 O
3 O
< O
1 O
23 O
4 O
0 O
Fatigue B-OSE_Labeled_AE
31 O
5 O
0 O
27 O
3 O
< O
1 O
Edema B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
25 O
< O
1 O
0 O
8 O
< O
1 O
0 O
Pyrexia B-OSE_Labeled_AE
20 O
< O
1 O
0 O
9 O
0 O
0 O
Mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
19 O
1 O
0 O
1 O
0 O
0 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
t I-NonOSE_AE
horacic I-NonOSE_AE
and I-NonOSE_AE
m I-NonOSE_AE
ediastinal I-NonOSE_AE
d I-NonOSE_AE
isorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
30 O
< O
1 O
0 O
16 O
0 O
0 O
Dyspnea B-OSE_Labeled_AE
24 O
6 O
1 O
15 O
3 O
0 O
Epistaxis B-OSE_Labeled_AE
18 O
0 O
0 O
0 O
0 O
0 O
Pneumonitis B-OSE_Labeled_AE
c O
14 O
4 O
0 O
0 O
0 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
s I-NonOSE_AE
ubcutaneous I-NonOSE_AE
t I-NonOSE_AE
issue I-NonOSE_AE
d I-NonOSE_AE
isorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
29 O
1 O
0 O
7 O
0 O
0 O
Pruritus B-OSE_Labeled_AE
14 O
< O
1 O
0 O
7 O
0 O
0 O
Dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
13 O
< O
1 O
0 O
5 O
0 O
0 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
n I-NonOSE_AE
utrition I-NonOSE_AE
d I-NonOSE_AE
isorders I-NonOSE_AE
Anorexia B-OSE_Labeled_AE
25 O
1 O
0 O
14 O
< O
1 O
0 O
Nervous B-NonOSE_AE
s I-NonOSE_AE
ystem I-NonOSE_AE
d I-NonOSE_AE
isorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
19 O
< O
1 O
< O
1 O
9 O
< O
1 O
0 O
Dysgeusia B-OSE_Labeled_AE
10 O
0 O
0 O
2 O
0 O
0 O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
c I-NonOSE_AE
onnective I-NonOSE_AE
t I-NonOSE_AE
issue I-NonOSE_AE
d I-NonOSE_AE
isorders I-NonOSE_AE
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
10 O
1 O
0 O
7 O
0 O
0 O
Medi O
an O
d O
uration O
of O
t O
reatment O
( O
d O
) O
141 O
60 O
Other O
notable O
adverse O
reactions O
occurring O
more O
frequently O
with O
AFINITOR O
than O
with O
placebo O
, O
but O
with O
an O
incidence O
of O
< O
10 O
% O
include O
: O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
9 O
% O
) O
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
( O
8 O
% O
) O
, O
hemorrhoids B-OSE_Labeled_AE
( O
5 O
% O
) O
, O
dysphagia B-OSE_Labeled_AE
( O
4 O
% O
) O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
: O
Weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
( O
9 O
% O
) O
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
5 O
% O
) O
, O
chills B-OSE_Labeled_AE
( O
4 O
% O
) O
, O
impaired B-OSE_Labeled_AE
wound I-OSE_Labeled_AE
healing I-OSE_Labeled_AE
( O
< O
1 O
% O
) O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
: O
Pleural B-OSE_Labeled_AE
effusion I-OSE_Labeled_AE
( O
7 O
% O
) O
, O
pharyngolaryngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
4 O
% O
) O
, O
rhinorrhea B-OSE_Labeled_AE
( O
3 O
% O
) O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
Hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
foot I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( O
reported O
as O
palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
erythrodysesthesia I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
) O
( O
5 O
% O
) O
, O
nail B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
( O
5 O
% O
) O
, O
erythema B-OSE_Labeled_AE
( O
4 O
% O
) O
, O
onychoclasis B-OSE_Labeled_AE
( O
4 O
% O
) O
, O
skin B-OSE_Labeled_AE
lesion I-OSE_Labeled_AE
( O
4 O
% O
) O
, O
acneiform B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
( O
3 O
% O
) O
, O
angioedema B-OSE_Labeled_AE
( O
< O
1 O
% O
) O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
: O
Exacerbation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
pre I-OSE_Labeled_AE
- I-OSE_Labeled_AE
existing I-OSE_Labeled_AE
diabetes I-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
( O
2 O
% O
) O
, O
new B-OSE_Labeled_AE
onset I-OSE_Labeled_AE
of I-OSE_Labeled_AE
diabetes I-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
( O
< O
1 O
% O
) O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
: O
Insomnia B-OSE_Labeled_AE
( O
9 O
% O
) O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
Dizziness B-OSE_Labeled_AE
( O
7 O
% O
) O
, O
paresthesia B-OSE_Labeled_AE
( O
5 O
% O
) O
Eye B-NonOSE_AE
disorders I-NonOSE_AE
: O
Eyelid B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
( O
4 O
% O
) O
, O
conjunctivitis B-OSE_Labeled_AE
( O
2 O
% O
) O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
: O
Hypertension B-OSE_Labeled_AE
( O
4 O
% O
) O
, O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
( O
< O
1 O
% O
) O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
: O
Renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
3 O
% O
) O
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
Tachycardia B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
congestive B-OSE_Labeled_AE
cardiac I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
1 O
% O
) O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
Jaw B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
3 O
% O
) O
Hematologic B-NonOSE_AE
disorders I-NonOSE_AE
: O
Hemorrhage B-OSE_Labeled_AE
( O
3 O
% O
) O
Key O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
are O
presented O
in O
Table O
9 O
. O

Table O
9 O
: O
Key O
Laboratory O
Abnormalities O
Reported O
in O
Patients O
with O
RCC O
at O
a O
Higher O
Rate O
in O
the O
AFINITOR O
Arm O
than O
the O
Placebo O
Arm O
Grading O
according O
to O
CTCAE O
Version O
3.0 O
a O
Reflects O
corresponding O
adverse O
drug O
reaction O
reports O
of O
anemia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
lymphopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
and O
thrombocytopenia B-OSE_Labeled_AE
( O
collectively O
pancytopenia B-OSE_Labeled_AE
) O
, O
which O
occurred O
at O
lower O
frequency O
. O

Laboratory O
p O
arameter O
AFINITOR O
10 O
mg/day O
N=274 O
Placebo O
N=137 O
All O
Grades O
Grade O
3 O
Grade O
4 O
All O
Grades O
Grade O
3 O
Grade O
4 O
% O
% O
% O
% O
% O
% O
Hematology B-NonOSE_AE
a O
Hemoglobin B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
92 O
12 O
1 O
79 O
5 O
< O
1 O
Lymphocytes B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
51 O
16 O
2 O
28 O
5 O
0 O
Platelets B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
23 O
1 O
0 O
2 O
0 O
< O
1 O
Neutrophils B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
14 O
0 O
< O
1 O
4 O
0 O
0 O
Clinical B-NonOSE_AE
c I-NonOSE_AE
hemistry I-NonOSE_AE
Cholesterol B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
77 O
4 O
0 O
35 O
0 O
0 O
Triglycerides B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
73 O
< O
1 O
0 O
34 O
0 O
0 O
Glucose B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
57 O
15 O
< O
1 O
25 O
1 O
0 O
Creatinine B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
50 O
1 O
0 O
34 O
0 O
0 O
Phosphate B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
37 O
6 O
0 O
8 O
0 O
0 O
Aspartate B-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
AST I-OSE_Labeled_AE
) I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
25 O
< O
1 O
< O
1 O
7 O
0 O
0 O
Alanine B-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
) I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
21 O
1 O
0 O
4 O
0 O
0 O
Bilirubin B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
3 O
< O
1 O
< O
1 O
2 O
0 O
0 O
6.4 O
Clinical O
Study O
Experience O
in O
Renal O
Angiomyolipoma O
with O
Tuberous O
Sclerosis O
Complex O
The O
data O
described O
below O
are O
based O
on O
a O
randomized O
( O
2:1 O
) O
, O
double-blind O
, O
placebo-controlled O
trial O
( O
EXIST-2 O
) O
of O
AFINITOR O
in O
118 O
patients O
with O
renal B-Not_AE_Candidate
angiomyolipoma I-Not_AE_Candidate
as I-Not_AE_Candidate
a I-Not_AE_Candidate
feature I-Not_AE_Candidate
of I-Not_AE_Candidate
TSC I-Not_AE_Candidate
( O
n=113 O
) O
or O
sporadic B-Not_AE_Candidate
lymphangioleiomyomatosis I-Not_AE_Candidate
( O
n=5 O
) O
. O

The O
median O
age O
of O
patients O
was O
31 O
years O
( O
range O
18 O
to O
61 O
years O
) O
, O
89 O
% O
were O
Caucasian O
, O
and O
34 O
% O
were O
male O
. O

The O
median O
duration O
of O
blinded O
study O
treatment O
was O
48 O
weeks O
( O
range O
2 O
to O
115 O
weeks O
) O
for O
patients O
receiving O
AFINITOR O
and O
45 O
weeks O
( O
range O
9 O
to O
115 O
weeks O
) O
for O
those O
receiving O
placebo O
. O

The O
most O
common O
adverse O
reaction O
reported O
for O
AFINITOR O
( O
incidence O
> O
=30 O
% O
) O
was O
stomatitis B-OSE_Labeled_AE
. O

The O
most O
common O
Grade O
3-4 O
adverse O
reactions O
( O
incidence O
> O
=2 O
% O
) O
were O
stomatitis B-OSE_Labeled_AE
and O
amenorrhea B-OSE_Labeled_AE
. O

The O
most O
common O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
( O
incidence O
> O
=50 O
% O
) O
were O
hypercholesterolemia B-OSE_Labeled_AE
, O
hypertriglyceridemia B-OSE_Labeled_AE
, O
and O
anemia B-OSE_Labeled_AE
. O

The O
most O
common O
Grade O
3-4 O
laboratory B-NonOSE_AE
abnormality I-NonOSE_AE
( O
incidence O
> O
=3 O
% O
) O
was O
hypophosphatemia B-OSE_Labeled_AE
. O

The O
rate O
of O
adverse O
reactions O
resulting O
in O
permanent O
discontinuation O
was O
3.8 O
% O
in O
the O
AFINITOR-treated O
patients O
. O

Adverse O
reactions O
leading O
to O
permanent O
discontinuation O
in O
the O
AFINITOR O
arm O
were O
hypersensitivity B-OSE_Labeled_AE
/ O
angioedema B-OSE_Labeled_AE
/ O
bronchospasm B-OSE_Labeled_AE
, O
convulsion B-OSE_Labeled_AE
, O
and O
hypophosphatemia B-OSE_Labeled_AE
. O

Dose O
adjustments O
( O
interruptions O
or O
reductions O
) O
due O
to O
adverse O
reactions O
occurred O
in O
52 O
% O
of O
AFINITOR-treated O
patients O
. O

The O
most O
common O
adverse O
reaction O
leading O
to O
AFINITOR O
dose O
adjustment O
was O
stomatitis B-OSE_Labeled_AE
. O

Table O
10 O
compares O
the O
incidence O
of O
adverse O
reactions O
reported O
with O
an O
incidence O
of O
> O
=10 O
% O
for O
patients O
receiving O
AFINITOR O
and O
occurring O
more O
frequently O
with O
AFINITOR O
than O
with O
placebo O
. O

Laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
are O
described O
separately O
in O
Table O
11 O
. O

Table O
10 O
: O
Adverse O
Reactions O
Reported O
in O
> O
=10 O
% O
of O
AFINITOR-treated O
Patients O
with O
Renal O
Angiomyolipoma O
Grading O
according O
to O
CTCAE O
Version O
3.0 O
a O
Includes O
stomatitis B-OSE_Labeled_AE
, O
aphthous B-OSE_Labeled_AE
stomatitis I-OSE_Labeled_AE
, O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
gingival B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
glossitis B-OSE_Labeled_AE
, O
and O
glossodynia B-OSE_Labeled_AE
. O

AFINITOR O
N=79 O
Placebo O
N=39 O
All O
Grades O
% O
Grade O
3 O
% O
Grade O
4 O
% O
All O
Grades O
% O
Grade O
3 O
% O
Grade O
4 O
% O
Any O
adverse O
reaction O
100 O
25 O
5 O
97 O
8 O
5 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Stomatitis B-OSE_Labeled_AE
a O
78 O
6 O
0 O
23 O
0 O
0 O
Vomiting B-OSE_Labeled_AE
15 O
0 O
0 O
5 O
0 O
0 O
Diarrhea B-OSE_Labeled_AE
14 O
0 O
0 O
5 O
0 O
0 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
13 O
0 O
0 O
8 O
0 O
0 O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
11 O
0 O
0 O
5 O
0 O
0 O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
13 O
0 O
0 O
5 O
0 O
0 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
20 O
0 O
0 O
13 O
0 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Acne B-OSE_Labeled_AE
22 O
0 O
0 O
5 O
0 O
0 O
Amenorrhea B-OSE_Labeled_AE
occurred O
in O
15 O
% O
of O
AFINITOR-treated O
females O
( O
8 O
of O
52 O
) O
and O
4 O
% O
( O
1 O
of O
26 O
) O
of O
females O
in O
the O
placebo O
group O
. O

Other O
adverse O
reactions O
involving O
the O
female O
reproductive O
system O
were O
menorrhagia B-OSE_Labeled_AE
( O
10 O
% O
) O
, O
menstrual B-OSE_Labeled_AE
irregularities I-OSE_Labeled_AE
( O
10 O
% O
) O
, O
and O
vaginal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
( O
8 O
% O
) O
. O

The O
following O
additional O
adverse O
reactions O
occurred O
in O
less O
than O
10 O
% O
of O
AFINITOR-treated O
patients O
: O
epistaxis B-OSE_Labeled_AE
( O
9 O
% O
) O
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
( O
6 O
% O
) O
, O
otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
( O
6 O
% O
) O
, O
depression B-OSE_Labeled_AE
( O
5 O
% O
) O
, O
abnormal B-OSE_Labeled_AE
taste I-OSE_Labeled_AE
( O
5 O
% O
) O
, O
increased B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
luteinizing I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
( I-OSE_Labeled_AE
LH I-OSE_Labeled_AE
) I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
( O
4 O
% O
) O
, O
increased B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
follicle I-OSE_Labeled_AE
stimulating I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
( I-OSE_Labeled_AE
FSH I-OSE_Labeled_AE
) I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
( O
3 O
% O
) O
, O
hypersensitivity B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
ovarian B-OSE_Labeled_AE
cyst I-OSE_Labeled_AE
( O
3 O
% O
) O
, O
pneumonitis B-OSE_Labeled_AE
( O
1 O
% O
) O
, O
and O
angioedema B-OSE_Labeled_AE
( O
1 O
% O
) O
. O

Table O
11 O
: O
Key O
Laboratory O
Abnormalities O
Reported O
in O
AFINITOR-treated O
Patients O
with O
Renal O
Angiomyolipoma O
Grading O
according O
to O
CTCAE O
Version O
3.0 O
AFINITOR O
N=79 O
Placebo O
N=39 O
All O
Grades O
% O
Grade O
3 O
% O
Grade O
4 O
% O
All O
Grades O
% O
Grade O
3 O
% O
Grade O
4 O
% O
Hematology B-NonOSE_AE
Anemia B-OSE_Labeled_AE
61 O
0 O
0 O
49 O
0 O
0 O
Leucopenia B-OSE_Labeled_AE
37 O
0 O
0 O
21 O
0 O
0 O
Neutropenia B-NonOSE_AE
25 O
0 O
1 O
26 O
0 O
0 O
Lymphopenia B-OSE_Labeled_AE
20 O
1 O
0 O
8 O
0 O
0 O
Thrombocytopenia B-OSE_Labeled_AE
19 O
0 O
0 O
3 O
0 O
0 O
Clinical B-NonOSE_AE
chemistry I-NonOSE_AE
Hypercholesterolemia B-OSE_Labeled_AE
85 O
1 O
0 O
46 O
0 O
0 O
Hypertriglyceridemia B-OSE_Labeled_AE
52 O
0 O
0 O
10 O
0 O
0 O
Hypophosphatemia B-OSE_Labeled_AE
49 O
5 O
0 O
15 O
0 O
0 O
Alkaline B-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
32 O
1 O
0 O
10 O
0 O
0 O
Elevated B-OSE_Labeled_AE
aspartate I-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
AST I-OSE_Labeled_AE
) O
23 O
1 O
0 O
8 O
0 O
0 O
Elevated B-OSE_Labeled_AE
alanine I-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
) O
20 O
1 O
0 O
15 O
0 O
0 O
Fasting B-OSE_Labeled_AE
hyperglycemia I-OSE_Labeled_AE
14 O
0 O
0 O
8 O
0 O
0 O
Updated O
safety O
information O
from O
112 O
patients O
treated O
with O
AFINITOR O
for O
a O
median O
duration O
of O
3.9 O
years O
identified O
the O
following O
additional O
adverse O
reactions O
and O
key O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
: O
increased B-OSE_Labeled_AE
partial I-OSE_Labeled_AE
thromboplastin I-OSE_Labeled_AE
time I-OSE_Labeled_AE
( O
63 O
% O
) O
, O
increased B-OSE_Labeled_AE
prothrombin I-OSE_Labeled_AE
time I-OSE_Labeled_AE
( O
40 O
% O
) O
, O
decreased B-OSE_Labeled_AE
fibrinogen I-OSE_Labeled_AE
( O
38 O
% O
) O
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
31 O
% O
) O
, O
proteinuria B-OSE_Labeled_AE
( O
18 O
% O
) O
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
16 O
% O
) O
, O
pruritus B-OSE_Labeled_AE
( O
12 O
% O
) O
, O
gastroenteritis B-OSE_Labeled_AE
( O
12 O
% O
) O
, O
myalgia B-OSE_Labeled_AE
( O
11 O
% O
) O
, O
and O
pneumonia B-OSE_Labeled_AE
( O
10 O
% O
) O
. O

6.5 O
Clinical O
Study O
Experience O
in O
Subependymal O
Giant O
Cell O
Astrocytoma O
with O
Tuberous O
Sclerosis O
Complex O
The O
data O
described O
below O
are O
based O
on O
a O
randomized O
( O
2:1 O
) O
, O
double-blind O
, O
placebo-controlled O
trial O
( O
EXIST-1 O
) O
of O
AFINITOR O
in O
117 O
patients O
with O
subependymal B-Not_AE_Candidate
giant I-Not_AE_Candidate
cell I-Not_AE_Candidate
astrocytoma I-Not_AE_Candidate
( I-Not_AE_Candidate
SEGA I-Not_AE_Candidate
) I-Not_AE_Candidate
and I-Not_AE_Candidate
tuberous I-Not_AE_Candidate
sclerosis I-Not_AE_Candidate
complex I-Not_AE_Candidate
( I-Not_AE_Candidate
TSC I-Not_AE_Candidate
) O
. O

The O
median O
age O
of O
patients O
was O
9.5 O
years O
( O
range O
0.8 O
to O
26 O
years O
) O
, O
93 O
% O
were O
Caucasian O
, O
and O
57 O
% O
were O
male O
. O

The O
median O
duration O
of O
blinded O
study O
treatment O
was O
52 O
weeks O
( O
range O
24 O
to O
89 O
weeks O
) O
for O
patients O
receiving O
AFINITOR O
and O
47 O
weeks O
( O
range O
14 O
to O
88 O
weeks O
) O
for O
those O
receiving O
placebo O
. O

The O
most O
common O
adverse O
reactions O
reported O
for O
AFINITOR O
( O
incidence O
> O
= O
30 O
% O
) O
were O
stomatitis B-OSE_Labeled_AE
and O
respiratory B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
. O

The O
most O
common O
Grade O
3-4 O
adverse O
reactions O
( O
incidence O
> O
=2 O
% O
) O
were O
stomatitis B-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
aggression B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
and O
amenorrhea B-OSE_Labeled_AE
. O

The O
most O
common O
key O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
( O
incidence O
> O
=50 O
% O
) O
were O
hypercholesterolemia B-OSE_Labeled_AE
and O
elevated B-OSE_Labeled_AE
partial I-OSE_Labeled_AE
thromboplastin I-OSE_Labeled_AE
time I-OSE_Labeled_AE
. O

The O
most O
common O
Grade O
3-4 O
laboratory B-NonOSE_AE
abnormality I-NonOSE_AE
( O
incidence O
> O
=3 O
% O
) O
was O
neutropenia B-OSE_Labeled_AE
. O

There O
were O
no O
adverse O
reactions O
resulting O
in O
permanent O
discontinuation O
. O

Dose O
adjustments O
( O
interruptions O
or O
reductions O
) O
due O
to O
adverse O
reactions O
occurred O
in O
55 O
% O
of O
AFINITOR-treated O
patients O
. O

The O
most O
common O
adverse O
reaction O
leading O
to O
AFINITOR O
dose O
adjustment O
was O
stomatitis B-OSE_Labeled_AE
. O

Table O
12 O
compares O
the O
incidence O
of O
adverse O
reactions O
reported O
with O
an O
incidence O
of O
> O
=10 O
% O
for O
patients O
receiving O
AFINITOR O
and O
occurring O
more O
frequently O
with O
AFINITOR O
than O
with O
placebo O
. O

Laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
are O
described O
separately O
in O
Table O
13 O
. O

Table O
12 O
: O
Adverse O
Reactions O
Reported O
in O
> O
= O
10 O
% O
of O
AFINITOR-treated O
Patients O
with O
SEGA O
in O
EXIST-1 O
Grading O
according O
to O
CTCAE O
Version O
3.0 O
a O
Includes O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
and O
lip B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
b O
Includes O
respiratory B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
and O
respiratory B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
viral I-OSE_Labeled_AE
c O
Includes O
gastroenteritis B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
viral I-OSE_Labeled_AE
, O
and O
gastrointestinal B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
d O
Includes O
agitation B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
panic B-OSE_Labeled_AE
attack I-OSE_Labeled_AE
, O
aggression B-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
behavior I-OSE_Labeled_AE
, O
and O
obsessive B-OSE_Labeled_AE
compulsive I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
e O
Includes O
rash B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
generalized I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
macular I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
maculo I-OSE_Labeled_AE
- I-OSE_Labeled_AE
papular I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
papular I-OSE_Labeled_AE
, O
dermatitis B-OSE_Labeled_AE
allergic I-OSE_Labeled_AE
, O
and O
urticaria B-OSE_Labeled_AE
AFINITOR O
N=78 O
Placebo O
N=39 O
All O
Grades O
% O
Grade O
3 O
% O
Grade O
4 O
% O
All O
Grades O
% O
Grade O
3 O
% O
Grade O
4 O
% O
Any B-NonOSE_AE
adverse I-NonOSE_AE
reaction I-NonOSE_AE
97 O
36 O
3 O
92 O
23 O
3 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Stomatitis B-OSE_Labeled_AE
a O
62 O
9 O
0 O
26 O
3 O
0 O
Vomiting B-OSE_Labeled_AE
22 O
1 O
0 O
13 O
0 O
0 O
Diarrhea B-OSE_Labeled_AE
17 O
0 O
0 O
5 O
0 O
0 O
Constipation B-OSE_Labeled_AE
10 O
0 O
0 O
3 O
0 O
0 O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Respiratory B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
b O
31 O
1 O
1 O
23 O
0 O
0 O
Gastroenteritis B-OSE_Labeled_AE
c O
10 O
4 O
1 O
3 O
0 O
0 O
Pharyngitis B-OSE_Labeled_AE
streptococcal I-OSE_Labeled_AE
10 O
0 O
0 O
3 O
0 O
0 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Pyrexia B-OSE_Labeled_AE
23 O
6 O
0 O
18 O
3 O
0 O
Fatigue B-OSE_Labeled_AE
14 O
0 O
0 O
3 O
0 O
0 O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
Anxiety B-OSE_Labeled_AE
, O
aggression B-OSE_Labeled_AE
or O
other O
behavioral B-OSE_Labeled_AE
disturbance I-OSE_Labeled_AE
d O
21 O
5 O
0 O
3 O
0 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
e O
21 O
0 O
0 O
8 O
0 O
0 O
Acne B-OSE_Labeled_AE
10 O
0 O
0 O
5 O
0 O
0 O
Amenorrhea B-OSE_Labeled_AE
occurred O
in O
17 O
% O
of O
AFINITOR-treated O
females O
aged O
10 O
to O
55 O
years O
( O
3 O
of O
18 O
) O
and O
none O
of O
the O
females O
in O
the O
placebo O
group O
. O

For O
this O
same O
group O
of O
AFINITOR-treated O
females O
, O
the O
following O
menstrual B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
were O
reported O
: O
dysmenorrhea B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
menorrhagia B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
metrorrhagia B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
and O
unspecified B-OSE_Labeled_AE
menstrual I-OSE_Labeled_AE
irregularity I-OSE_Labeled_AE
( O
6 O
% O
) O
. O

The O
following O
additional O
adverse O
reactions O
occurred O
in O
less O
than O
10 O
% O
of O
AFINITOR-treated O
patients O
: O
nausea B-OSE_Labeled_AE
( O
8 O
% O
) O
, O
pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
( O
8 O
% O
) O
, O
insomnia B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
pneumonia B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
epistaxis B-OSE_Labeled_AE
( O
5 O
% O
) O
, O
hypersensitivity B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
increased B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
luteinizing I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
( I-OSE_Labeled_AE
LH I-OSE_Labeled_AE
) I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
( O
1 O
% O
) O
and O
pneumonitis B-OSE_Labeled_AE
( O
1 O
% O
) O
. O

Table O
13 O
: O
Key O
Laboratory O
Abnormalities O
Reported O
in O
AFINITOR-treated O
Patients O
with O
SEGA O
in O
EXIST-1 O
Grading O
according O
to O
CTCAE O
Version O
3.0 O
AFINITOR O
N=78 O
Placebo O
N=39 O
All O
Grades O
% O
Grade O
3 O
% O
Grade O
4 O
% O
All O
Grades O
% O
Grade O
3 O
% O
Grade O
4 O
% O
Hematology B-NonOSE_AE
Elevated B-OSE_Labeled_AE
partial I-OSE_Labeled_AE
thromboplastin I-OSE_Labeled_AE
time I-OSE_Labeled_AE
72 O
3 O
0 O
44 O
5 O
0 O
Neutropenia B-OSE_Labeled_AE
46 O
9 O
0 O
41 O
3 O
0 O
Anemia B-OSE_Labeled_AE
41 O
0 O
0 O
21 O
0 O
0 O
Clinical B-NonOSE_AE
chemistry I-NonOSE_AE
Hypercholesterolemia B-OSE_Labeled_AE
81 O
0 O
0 O
39 O
0 O
0 O
Elevated B-OSE_Labeled_AE
aspartate I-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
AST I-OSE_Labeled_AE
) O
33 O
0 O
0 O
0 O
0 O
0 O
Hypertriglyceridemia B-OSE_Labeled_AE
27 O
0 O
0 O
15 O
0 O
0 O
Elevated B-OSE_Labeled_AE
alanine I-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
) O
18 O
0 O
0 O
3 O
0 O
0 O
Hypophosphatemia B-OSE_Labeled_AE
9 O
1 O
0 O
3 O
0 O
0 O
Updated O
safety O
information O
from O
111 O
patients O
treated O
with O
AFINITOR O
for O
a O
median O
duration O
of O
47 O
months O
identified O
the O
following O
additional O
notable O
adverse O
reactions O
and O
key O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
: O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
( O
14 O
% O
) O
, O
hyperglycemia B-OSE_Labeled_AE
( O
13 O
% O
) O
, O
hypertension B-OSE_Labeled_AE
( O
11 O
% O
) O
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
9 O
% O
) O
, O
decreased B-OSE_Labeled_AE
fibrinogen I-OSE_Labeled_AE
( O
8 O
% O
) O
, O
cellulitis B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
5 O
% O
) O
, O
decreased B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
( O
5 O
% O
) O
, O
elevated B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
( O
5 O
% O
) O
, O
and O
azospermia B-OSE_Labeled_AE
( O
1 O
% O
) O
. O

6.6 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post O
approval O
use O
of O
AFINITOR O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
: O
acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
, O
cholecystitis B-OSE_Labeled_AE
, O
cholelithiasis B-OSE_Labeled_AE
, O
arterial B-OSE_Labeled_AE
thrombotic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
reflex B-OSE_Labeled_AE
sympathetic I-OSE_Labeled_AE
dystrophy I-OSE_Labeled_AE
, O
and O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
with O
some O
cases O
reported O
with O
pulmonary B-NonOSE_AE
hypertension I-NonOSE_AE
( O
including O
pulmonary B-NonOSE_AE
arterial I-NonOSE_AE
hypertension I-NonOSE_AE
) O
as O
a O
secondary O
event O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Non-infectious O
pneumonitis O
: O
Monitor O
for O
clinical O
symptoms O
or O
radiological O
changes O
; O
fatal O
cases O
have O
occurred O
. O

Manage O
by O
dose O
reduction O
or O
discontinuation O
until O
symptoms O
resolve O
, O
and O
consider O
use O
of O
corticosteroids O
. O

( O
5.1 O
) O
* O
Infections O
: O
Increased O
risk O
of O
infections O
, O
some O
fatal O
. O

Monitor O
for O
signs O
and O
symptoms O
, O
and O
treat O
promptly O
. O

( O
5.2 O
) O
* O
Angioedema O
: O
Patients O
taking O
concomitant O
ACE O
inhibitor O
therapy O
may O
be O
at O
increased O
risk O
for O
angioedema O
. O

( O
5.3 O
) O
* O
Stomatitis O
: O
Stomatitis O
, O
including O
mouth O
ulcers O
and O
oral O
mucositis O
, O
occurs O
in O
most O
patients O
treated O
with O
AFINITOR O
. O

Initiation O
of O
topical O
treatment O
with O
dexamethasone O
mouthwash O
when O
starting O
AFINITOR O
reduces O
the O
incidence O
and O
severity O
of O
stomatitis O
. O

( O
5.4 O
, O
6.1 O
) O
* O
Renal O
failure O
: O
Cases O
of O
renal O
failure O
( O
including O
acute O
renal O
failure O
) O
, O
some O
with O
a O
fatal O
outcome O
, O
have O
been O
observed O
. O

( O
5.5 O
) O
* O
Impaired O
wound O
healing O
: O
Increased O
risk O
of O
wound-related O
complications O
. O

Monitor O
signs O
and O
symptoms O
. O

Exercise O
caution O
in O
the O
peri-surgical O
period O
. O

( O
5.6 O
) O
* O
Laboratory O
test O
alterations O
: O
Elevations O
of O
serum O
creatinine O
, O
urinary O
protein O
, O
blood O
glucose O
, O
and O
lipids O
may O
occur O
. O

Decreases O
in O
hemoglobin O
, O
neutrophils O
, O
and O
platelets O
may O
also O
occur O
. O

Monitor O
renal O
function O
, O
blood O
glucose O
, O
lipids O
, O
and O
hematologic O
parameters O
prior O
to O
treatment O
and O
periodically O
thereafter O
. O

( O
5.8 O
) O
* O
Vaccinations O
: O
Avoid O
live O
vaccines O
and O
close O
contact O
with O
those O
who O
have O
received O
live O
vaccines O
. O

( O
5.11 O
) O
* O
Embryo-Fetal O
Toxicity O
: O
Can O
cause O
fetal O
harm O
. O

Advise O
patients O
of O
reproductive O
potential O
of O
the O
potential O
risk O
to O
a O
fetus O
and O
to O
use O
effective O
contraception O
. O

( O
5.12 O
, O
8.1 O
, O
8.3 O
) O
5.1 O
Non-infectious O
Pneumonitis O
Non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
infectious I-OSE_Labeled_AE
pneumonitis I-OSE_Labeled_AE
is O
a O
class O
effect O
of O
rapamycin O
derivatives O
, O
including O
AFINITOR O
. O

Non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
infectious I-OSE_Labeled_AE
pneumonitis I-OSE_Labeled_AE
was O
reported O
in O
up O
to O
19 O
% O
of O
patients O
treated O
with O
AFINITOR O
in O
clinical O
trials O
, O
some O
cases O
reported O
with O
pulmonary B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
( O
including O
pulmonary B-OSE_Labeled_AE
arterial I-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
) O
as O
a O
secondary O
event O
. O

The O
incidence O
of O
Common O
Terminology O
Criteria O
( O
CTC O
) O
Grade O
3 O
and O
4 O
non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
infectious I-OSE_Labeled_AE
pneumonitis I-OSE_Labeled_AE
was O
up O
to O
4.0 O
% O
and O
up O
to O
0.2 O
% O
, O
respectively O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
, O
6.2 O
, O
6.3 O
, O
6.4 O
, O
6.5 O
) O
] O
. O

Fatal B-NonOSE_AE
outcomes O
have O
been O
observed O
. O

Consider O
a O
diagnosis O
of O
non B-NonOSE_AE
- I-NonOSE_AE
infectious I-NonOSE_AE
pneumonitis I-NonOSE_AE
in O
patients O
presenting O
with O
non-specific O
respiratory O
signs O
and O
symptoms O
such O
as O
hypoxia B-NonOSE_AE
, O
pleural B-NonOSE_AE
effusion I-NonOSE_AE
, O
cough B-NonOSE_AE
, O
or O
dyspnea B-NonOSE_AE
, O
and O
in O
whom O
infectious B-Not_AE_Candidate
, O
neoplastic B-Not_AE_Candidate
, O
and O
other O
causes O
have O
been O
excluded O
by O
means O
of O
appropriate O
investigations O
. O

Opportunistic B-NonOSE_AE
infections I-NonOSE_AE
such O
as O
pneumocystis B-NonOSE_AE
jiroveci I-NonOSE_AE
pneumonia I-NonOSE_AE
( I-NonOSE_AE
PJP I-NonOSE_AE
) O
should O
be O
considered O
in O
the O
differential O
diagnosis O
. O

Advise O
patients O
to O
report O
promptly O
any O
new O
or O
worsening B-NonOSE_AE
respiratory I-NonOSE_AE
symptoms I-NonOSE_AE
. O

Patients O
who O
develop O
radiological O
changes O
suggestive O
of O
non B-NonOSE_AE
- I-NonOSE_AE
infectious I-NonOSE_AE
pneumonitis I-NonOSE_AE
and O
have O
few O
or O
no O
symptoms O
may O
continue O
AFINITOR O
therapy O
without O
dose O
alteration O
. O

Imaging O
appears O
to O
overestimate O
the O
incidence O
of O
clinical O
pneumonitis B-NonOSE_AE
. O

If O
symptoms O
are O
moderate O
, O
consider O
interrupting O
therapy O
until O
symptoms O
improve O
. O

The O
use O
of O
corticosteroids O
may O
be O
indicated O
. O

AFINITOR O
may O
be O
reintroduced O
at O
a O
daily O
dose O
approximately O
50 O
% O
lower O
than O
the O
dose O
previously O
administered O
[ O
see O
Table O
1 O
in O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

For O
cases O
of O
Grade O
3 O
non B-NonOSE_AE
- I-NonOSE_AE
infectious I-NonOSE_AE
pneumonitis I-NonOSE_AE
, O
interrupt O
AFINITOR O
until O
resolution O
to O
less O
than O
or O
equal O
to O
Grade O
1 O
. O

AFINITOR O
may O
be O
re-introduced O
at O
a O
daily O
dose O
approximately O
50 O
% O
lower O
than O
the O
dose O
previously O
administered O
depending O
on O
the O
individual O
clinical O
circumstances O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

If O
toxicity O
recurs O
at O
Grade O
3 O
, O
consider O
discontinuation O
of O
AFINITOR O
. O

For O
cases O
of O
Grade O
4 O
non B-NonOSE_AE
- I-NonOSE_AE
infectious I-NonOSE_AE
pneumonitis I-NonOSE_AE
, O
discontinue O
AFINITOR O
. O

Corticosteroids O
may O
be O
indicated O
until O
clinical O
symptoms O
resolve O
. O

For O
patients O
who O
require O
use O
of O
corticosteroids O
for O
treatment O
of O
non B-NonOSE_AE
- I-NonOSE_AE
infectious I-NonOSE_AE
pneumonitis I-NonOSE_AE
, O
prophylaxis O
for O
PJP B-NonOSE_AE
may O
be O
considered O
. O

The O
development O
of O
pneumonitis B-OSE_Labeled_AE
has O
been O
reported O
even O
at O
a O
reduced O
dose O
. O

5.2 O
Infections O
AFINITOR O
has O
immunosuppressive B-OSE_Labeled_AE
properties O
and O
may O
predispose O
patients O
to O
bacterial B-OSE_Labeled_AE
, O
fungal O
, O
viral O
, O
or O
protozoal O
infections I-OSE_Labeled_AE
, O
including O
infections B-OSE_Labeled_AE
with I-OSE_Labeled_AE
opportunistic I-OSE_Labeled_AE
pathogens I-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
, O
6.2 O
, O
6.3 O
, O
6.4 O
, O
6.5 O
) O
] O
. O

Localized B-OSE_Labeled_AE
and O
systemic O
infections I-OSE_Labeled_AE
, O
including O
pneumonia B-OSE_Labeled_AE
, O
mycobacterial B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
other O
bacterial B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
invasive B-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
such O
as O
aspergillosis B-OSE_Labeled_AE
, O
candidiasis B-OSE_Labeled_AE
, O
or O
pneumocystis B-OSE_Labeled_AE
jiroveci I-OSE_Labeled_AE
pneumonia I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PJP I-OSE_Labeled_AE
) O
and O
viral B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
including O
reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
B I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
have O
occurred O
in O
patients O
taking O
AFINITOR O
. O

Some O
of O
these O
infections B-NonOSE_AE
have O
been O
severe O
( O
e.g. O
, O
leading O
to O
sepsis B-NonOSE_AE
, O
respiratory B-NonOSE_AE
or O
hepatic O
failure I-NonOSE_AE
) O
or O
fatal B-NonOSE_AE
. O

Physicians O
and O
patients O
should O
be O
aware O
of O
the O
increased O
risk O
of O
infection B-NonOSE_AE
with O
AFINITOR O
. O

Complete O
treatment O
of O
pre-existing O
invasive B-Not_AE_Candidate
fungal I-Not_AE_Candidate
infections I-Not_AE_Candidate
prior O
to O
starting O
treatment O
with O
AFINITOR O
. O

While O
taking O
AFINITOR O
, O
be O
vigilant O
for O
signs O
and O
symptoms O
of O
infection B-NonOSE_AE
; O
if O
a O
diagnosis O
of O
an O
infection B-NonOSE_AE
is O
made O
, O
institute O
appropriate O
treatment O
promptly O
and O
consider O
interruption O
or O
discontinuation O
of O
AFINITOR O
. O

If O
a O
diagnosis O
of O
invasive B-NonOSE_AE
systemic I-NonOSE_AE
fungal I-NonOSE_AE
infection I-NonOSE_AE
is O
made O
, O
discontinue O
AFINITOR O
and O
treat O
with O
appropriate O
antifungal O
therapy O
. O

Pneumocystis B-OSE_Labeled_AE
jiroveci I-OSE_Labeled_AE
pneumonia I-OSE_Labeled_AE
, O
some O
with O
a O
fatal B-NonOSE_AE
outcome O
, O
has O
been O
reported O
in O
patients O
who O
received O
everolimus O
. O

This O
may O
be O
associated O
with O
concomitant O
use O
of O
corticosteroids O
or O
other O
immunosuppressive B-NonOSE_AE
agents O
. O

Prophylaxis O
for O
PJP B-NonOSE_AE
should O
be O
considered O
when O
concomitant O
use O
of O
corticosteroids O
or O
other O
immunosuppressive B-NonOSE_AE
agents O
are O
required O
. O

5.3 O
Angioedema O
with O
Concomitant O
Use O
of O
Angiotensin-Converting O
Enzyme O
( O
ACE O
) O
Inhibitors O
Patients O
taking O
concomitant O
ACE O
inhibitor O
therapy O
may O
be O
at O
increased O
risk O
for O
angioedema B-NonOSE_AE
( O
e.g. O
, O
swelling B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
airways O
or O
tongue I-NonOSE_AE
, O
with O
or O
without O
respiratory B-NonOSE_AE
impairment I-NonOSE_AE
) O
. O

In O
a O
pooled O
analysis O
of O
randomized O
double-blind O
oncology O
clinical O
trials O
, O
the O
incidence O
of O
angioedema B-NonOSE_AE
in O
patients O
taking O
everolimus O
with O
an O
ACE O
inhibitor O
was O
6.8 O
% O
compared O
to O
1.3 O
% O
in O
the O
control O
arm O
with O
an O
ACE O
inhibitor O
. O

5.4 O
Stomatitis O
Stomatitis B-OSE_Labeled_AE
, O
including O
mouth B-OSE_Labeled_AE
ulcers I-OSE_Labeled_AE
and O
oral B-OSE_Labeled_AE
mucositis I-OSE_Labeled_AE
, O
has O
occurred O
in O
patients O
treated O
with O
AFINITOR O
at O
an O
incidence O
ranging O
from O
44 O
% O
-78 O
% O
across O
the O
clinical O
trial O
experience O
. O

Grade O
3 O
or O
4 O
stomatitis B-OSE_Labeled_AE
was O
reported O
in O
4 O
% O
-9 O
% O
of O
patients O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
, O
6.2 O
, O
6.3 O
, O
6.4 O
, O
6.5 O
) O
] O
. O

Stomatitis B-OSE_Labeled_AE
most O
often O
occurs O
within O
the O
first O
8 O
weeks O
of O
treatment O
. O

When O
starting O
AFINITOR O
, O
initiating O
dexamethasone O
alcohol-free O
oral O
solution O
as O
a O
swish O
and O
spit O
mouthwash O
reduces O
the O
incidence O
and O
severity O
of O
stomatitis B-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.4 O
) O
] O
. O

If O
stomatitis B-NonOSE_AE
does O
occur O
, O
mouthwashes O
and/or O
other O
topical O
treatments O
are O
recommended O
, O
but O
alcohol- O
, O
hydrogen O
peroxide- O
, O
iodine- O
, O
or O
thyme- O
containing O
products O
should O
be O
avoided O
as O
they O
may O
exacerbate O
the O
condition O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

Antifungal O
agents O
should O
not O
be O
used O
unless O
fungal B-NonOSE_AE
infection I-NonOSE_AE
has O
been O
diagnosed O
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

5.5 O
Renal O
Failure O
Cases O
of O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
including O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
) O
, O
some O
with O
a O
fatal B-NonOSE_AE
outcome O
, O
have O
been O
observed O
in O
patients O
treated O
with O
AFINITOR O
[ O
see O
Laboratory O
Tests O
and O
Monitoring O
( O
5.8 O
) O
] O
. O

5.6 O
Impaired O
Wound O
Healing O
Everolimus O
delays B-OSE_Labeled_AE
wound I-OSE_Labeled_AE
healing I-OSE_Labeled_AE
and O
increases O
the O
occurrence O
of O
wound B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
complications I-OSE_Labeled_AE
like O
wound B-OSE_Labeled_AE
dehiscence I-OSE_Labeled_AE
, O
wound B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
incisional B-OSE_Labeled_AE
hernia I-OSE_Labeled_AE
, O
lymphocele B-OSE_Labeled_AE
, O
and O
seroma B-OSE_Labeled_AE
. O

These O
wound B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
complications I-NonOSE_AE
may O
require O
surgical O
intervention O
. O

Exercise O
caution O
with O
the O
use O
of O
AFINITOR O
in O
the O
peri-surgical O
period O
. O

5.7 O
Geriatric O
Patients O
In O
the O
randomized O
advanced O
hormone B-Not_AE_Candidate
receptor I-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
, I-Not_AE_Candidate
HER I-Not_AE_Candidate
2 I-Not_AE_Candidate
- I-Not_AE_Candidate
negative I-Not_AE_Candidate
breast I-Not_AE_Candidate
cancer I-Not_AE_Candidate
study O
( O
BOLERO-2 O
) O
, O
the O
incidence O
of O
deaths B-NonOSE_AE
due O
to O
any O
cause O
within O
28 O
days O
of O
the O
last O
AFINITOR O
dose O
was O
6 O
% O
in O
patients O
> O
= O
65 O
years O
of O
age O
compared O
to O
2 O
% O
in O
patients O
< O
65 O
years O
of O
age O
. O

Adverse O
reactions O
leading O
to O
permanent O
treatment O
discontinuation O
occurred O
in O
33 O
% O
of O
patients O
> O
= O
65 O
years O
of O
age O
compared O
to O
17 O
% O
in O
patients O
< O
65 O
years O
of O
age O
. O

Careful O
monitoring O
and O
appropriate O
dose O
adjustments O
for O
adverse O
reactions O
are O
recommended O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
] O
. O

5.8 O
Laboratory O
Tests O
and O
Monitoring O
Renal O
Function O
Elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
and O
proteinuria B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
taking O
AFINITOR O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
, O
6.2 O
, O
6.3 O
, O
6.4 O
, O
6.5 O
) O
] O
. O

Monitoring O
of O
renal O
function O
, O
including O
measurement O
of O
blood O
urea O
nitrogen O
( O
BUN O
) O
, O
urinary O
protein O
, O
or O
serum O
creatinine O
, O
is O
recommended O
prior O
to O
the O
start O
of O
AFINITOR O
therapy O
and O
periodically O
thereafter O
. O

Renal O
function O
of O
patients O
should O
be O
monitored O
particularly O
where O
patients O
have O
additional O
risk O
factors O
that O
may O
further O
impair B-NonOSE_AE
renal I-NonOSE_AE
function I-NonOSE_AE
. O

Blood O
Glucose O
and O
Lipids O
Hyperglycemia B-OSE_Labeled_AE
, O
hyperlipidemia B-OSE_Labeled_AE
, O
and O
hypertriglyceridemia B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
taking O
AFINITOR O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
, O
6.2 O
, O
6.3 O
, O
6.4 O
, O
6.5 O
) O
] O
. O

Monitoring O
of O
fasting O
serum O
glucose O
and O
lipid O
profile O
is O
recommended O
prior O
to O
the O
start O
of O
AFINITOR O
therapy O
and O
periodically O
thereafter O
as O
well O
as O
management O
with O
appropriate O
medical O
therapy O
. O

More O
frequent O
monitoring O
is O
recommended O
when O
AFINITOR O
is O
co-administered O
with O
other O
drugs O
that O
may O
induce O
hyperglycemia B-NonOSE_AE
. O

When O
possible O
, O
optimal O
glucose O
and O
lipid O
control O
should O
be O
achieved O
before O
starting O
a O
patient O
on O
AFINITOR O
. O

Hematologic O
Parameters O
Decreased B-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
, O
lymphocytes O
, O
neutrophils O
, O
and O
platelets O
have O
been O
reported O
in O
patients O
taking O
AFINITOR O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
, O
6.2 O
, O
6.3 O
, O
6.4 O
, O
6.5 O
) O
] O
. O

Monitoring O
of O
complete O
blood O
count O
is O
recommended O
prior O
to O
the O
start O
of O
AFINITOR O
therapy O
and O
periodically O
thereafter O
. O

5.9 O
Drug-Drug O
Interactions O
Due O
to O
significant O
increases O
in O
exposure O
of O
everolimus O
, O
co-administration O
with O
strong O
CYP3A4/PgP O
inhibitors O
should O
be O
avoided O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
, O
2.5 O
) O
and O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

A O
reduction O
of O
the O
AFINITOR O
dose O
is O
recommended O
when O
co-administered O
with O
a O
moderate O
CYP3A4/PgP O
inhibitor O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
, O
2.5 O
) O
and O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

An O
increase O
in O
the O
AFINITOR O
dose O
is O
recommended O
when O
co-administered O
with O
a O
strong O
CYP3A4/PgP O
inducer O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
, O
2.5 O
) O
and O
Drug O
Interactions O
( O
7.2 O
) O
] O
. O

5.10 O
Hepatic O
Impairment O
Exposure O
to O
everolimus O
was O
increased O
in O
patients O
with O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
[ O
see O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

For O
advanced B-Not_AE_Candidate
HR I-Not_AE_Candidate
+ I-Not_AE_Candidate
BC I-Not_AE_Candidate
, O
advanced B-Not_AE_Candidate
NET I-Not_AE_Candidate
, O
advanced B-Not_AE_Candidate
RCC I-Not_AE_Candidate
, O
and O
renal B-Not_AE_Candidate
angiomyolipoma I-Not_AE_Candidate
with I-Not_AE_Candidate
TSC I-Not_AE_Candidate
patients O
with O
severe O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
( O
Child-Pugh O
class O
C O
) O
, O
AFINITOR O
may O
be O
used O
at O
a O
reduced O
dose O
if O
the O
desired O
benefit O
outweighs O
the O
risk O
. O

For O
patients O
with O
mild O
( O
Child-Pugh O
class O
A O
) O
or O
moderate O
( O
Child-Pugh O
class O
B O
) O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
a O
dose O
reduction O
is O
recommended O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
and O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

For O
patients O
with O
SEGA B-Not_AE_Candidate
and O
mild O
or O
moderate O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
adjust O
the O
dose O
of O
AFINITOR O
Tablets O
or O
AFINITOR O
DISPERZ O
based O
on O
therapeutic O
drug O
monitoring O
. O

For O
patients O
with O
SEGA B-Not_AE_Candidate
and O
severe O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
reduce O
the O
starting O
dose O
of O
AFINITOR O
Tablets O
or O
AFINITOR O
DISPERZ O
by O
approximately O
50 O
% O
and O
adjust O
subsequent O
doses O
based O
on O
therapeutic O
drug O
monitoring O
[ O
see O
Dosage O
and O
Administration O
( O
2.4 O
, O
2.5 O
) O
] O
. O

5.11 O
Vaccinations O
During O
AFINITOR O
treatment O
, O
avoid O
the O
use O
of O
live O
vaccines O
and O
avoid O
close O
contact O
with O
individuals O
who O
have O
received O
live O
vaccines O
( O
e.g. O
, O
intranasal B-NonOSE_AE
influenza I-NonOSE_AE
, O
measles O
, O
mumps O
, O
rubella O
, O
oral O
polio O
, O
BCG O
, O
yellow O
fever O
, O
varicella O
, O
and O
TY21a O
typhoid O
vaccines I-NonOSE_AE
) O
. O

For O
pediatric O
patients O
with O
SEGA B-Not_AE_Candidate
that O
do O
not O
require O
immediate O
treatment O
, O
complete O
the O
recommended O
childhood O
series O
of O
live O
virus O
vaccinations O
according O
to O
American O
Council O
on O
Immunization O
Practices O
( O
ACIP O
) O
guidelines O
prior O
to O
the O
start O
of O
therapy O
. O

An O
accelerated O
vaccination O
schedule O
may O
be O
appropriate O
. O

5.12 O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Based O
on O
animal O
studies O
and O
the O
mechanism O
of O
action O
[ O
see O
Clinical O
Pharmacology O
( O
12.1 O
) O
] O
, O
AFINITOR O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
. O

In O
animal O
studies O
, O
everolimus O
caused O
embryo B-NonOSE_AE
- I-NonOSE_AE
fetal I-NonOSE_AE
toxicities I-NonOSE_AE
in O
rats O
when O
administered O
during O
the O
period O
of O
organogenesis O
at O
maternal O
exposures O
that O
were O
lower O
than O
human O
exposures O
at O
the O
clinical O
dose O
of O
10 O
mg O
daily O
. O

Advise O
pregnant B-Not_AE_Candidate
women O
of O
the O
potential O
risk B-NonOSE_AE
to I-NonOSE_AE
a I-NonOSE_AE
fetus I-NonOSE_AE
. O

Advise O
female O
patients O
of O
reproductive O
potential O
to O
avoid O
becoming O
pregnant B-NonOSE_AE
and O
to O
use O
effective O
contraception O
during O
treatment O
with O
AFINITOR O
and O
for O
8 O
weeks O
after O
the O
last O
dose O
. O

Advise O
male O
patients O
with O
female O
partners O
of O
reproductive O
potential O
to O
use O
effective O
contraception O
during O
treatment O
with O
AFINITOR O
and O
for O
4 O
weeks O
after O
the O
last O
dose O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
, O
8.3 O
) O
] O
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
5 O
% O
) O
are O
acne O
, O
application O
site O
reaction O
, O
abnormal O
lab O
tests O
, O
and O
prostatic O
disorders O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
AbbVie O
Inc O
. O
at O
1-800-633-9110 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trial O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Clinical O
Trials O
in O
Hypogonadal O
Men O
Table O
1 O
shows O
the O
incidence O
of O
all O
adverse O
events O
judged O
by O
the O
investigator O
to O
be O
at O
least O
possibly O
related O
to O
treatment O
with O
AndroGel O
1 O
% O
and O
reported O
by O
> O
1 O
% O
of O
patients O
in O
a O
180 O
Day O
, O
Phase O
3 O
study O
. O

Table O
1 O
: O
Adverse O
Events O
Possibly O
, O
Probably O
or O
Definitely O
Related O
to O
Use O
of O
AndroGel O
1 O
% O
in O
the O
180-Day O
Controlled O
Clinical O
Trial O
* O
Lab B-NonOSE_AE
test I-NonOSE_AE
abnormal I-NonOSE_AE
occurred O
in O
nine O
patients O
with O
one O
or O
more O
of O
the O
following O
events O
reported O
: O
elevated B-OSE_Labeled_AE
hemoglobin O
or O
hematocrit I-OSE_Labeled_AE
, O
hyperlipidemia B-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
triglycerides I-OSE_Labeled_AE
, O
hypokalemia B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
HDL I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
total I-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
. O

** O
Prostate B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
included O
five O
patients O
with O
enlarged B-OSE_Labeled_AE
prostate I-OSE_Labeled_AE
, O
one O
with O
BPH B-OSE_Labeled_AE
, O
and O
one O
with O
elevated B-OSE_Labeled_AE
PSA I-OSE_Labeled_AE
results O
. O

*** O
Testis B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
were O
reported O
in O
two O
patients O
: O
one O
with O
left B-OSE_Labeled_AE
varicocele I-OSE_Labeled_AE
and O
one O
with O
slight O
sensitivity B-OSE_Labeled_AE
of I-OSE_Labeled_AE
left I-OSE_Labeled_AE
testis I-OSE_Labeled_AE
. O

Adverse O
Event O
Dose O
of O
AndroGel O
1 O
% O
50 O
mg O
75 O
mg O
100 O
mg O
N O
= O
77 O
N O
= O
40 O
N O
= O
78 O
Acne B-OSE_Labeled_AE
1 O
% O
3 O
% O
8 O
% O
Alopecia B-OSE_Labeled_AE
1 O
% O
0 O
% O
1 O
% O
Application B-OSE_Labeled_AE
Site I-OSE_Labeled_AE
Reaction I-OSE_Labeled_AE
5 O
% O
3 O
% O
4 O
% O
Asthenia B-OSE_Labeled_AE
0 O
% O
3 O
% O
1 O
% O
Depression B-OSE_Labeled_AE
1 O
% O
0 O
% O
1 O
% O
Emotional B-OSE_Labeled_AE
Lability I-OSE_Labeled_AE
0 O
% O
3 O
% O
3 O
% O
Gynecomastia B-OSE_Labeled_AE
1 O
% O
0 O
% O
3 O
% O
Headache B-OSE_Labeled_AE
4 O
% O
3 O
% O
0 O
% O
Hypertension B-OSE_Labeled_AE
3 O
% O
0 O
% O
3 O
% O
Lab B-NonOSE_AE
Test I-NonOSE_AE
Abnormal I-NonOSE_AE
* O
6 O
% O
5 O
% O
3 O
% O
Libido B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
0 O
% O
3 O
% O
1 O
% O
Nervousness B-OSE_Labeled_AE
0 O
% O
3 O
% O
1 O
% O
Pain B-OSE_Labeled_AE
Breast I-OSE_Labeled_AE
1 O
% O
3 O
% O
1 O
% O
Prostate B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
* I-OSE_Labeled_AE
* I-OSE_Labeled_AE
3 O
% O
3 O
% O
5 O
% O
Testis B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
*** O
3 O
% O
0 O
% O
0 O
% O
Other O
less O
common O
adverse O
reactions O
, O
reported O
in O
fewer O
than O
1 O
% O
of O
patients O
included O
: O
amnesia B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
discolored B-OSE_Labeled_AE
hair I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
, O
hirsutism B-OSE_Labeled_AE
, O
hostility B-OSE_Labeled_AE
, O
impaired B-OSE_Labeled_AE
urination I-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
penis B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
, O
and O
vasodilation B-OSE_Labeled_AE
. O

In O
this O
180 O
day O
clinical O
trial O
, O
skin B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
at I-OSE_Labeled_AE
the I-OSE_Labeled_AE
site I-OSE_Labeled_AE
of I-OSE_Labeled_AE
application I-OSE_Labeled_AE
were O
reported O
with O
AndroGel O
1 O
% O
, O
but O
none O
was O
severe O
enough O
to O
require O
treatment O
or O
discontinuation O
of O
drug O
. O

Six O
patients O
( O
4 O
% O
) O
in O
this O
trial O
had O
adverse O
events O
that O
led O
to O
discontinuation O
of O
AndroGel O
1 O
% O
. O

These O
events O
included O
: O
cerebral B-NonOSE_AE
hemorrhage I-NonOSE_AE
, O
convulsion B-NonOSE_AE
( O
neither O
of O
which O
were O
considered O
related O
to O
AndroGel O
1 O
% O
administration O
) O
, O
depression B-OSE_Labeled_AE
, O
sadness B-OSE_Labeled_AE
, O
memory B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
prostate I-OSE_Labeled_AE
specific I-OSE_Labeled_AE
antigen I-OSE_Labeled_AE
, O
and O
hypertension B-OSE_Labeled_AE
. O

No O
AndroGel O
1 O
% O
patient O
discontinued O
due O
to O
skin B-NonOSE_AE
reactions I-NonOSE_AE
. O

In O
a O
separate O
uncontrolled O
pharmacokinetic O
study O
of O
10 O
patients O
, O
two O
had O
adverse O
events O
associated O
with O
AndroGel O
1 O
% O
; O
these O
were O
asthenia B-OSE_Labeled_AE
and O
depression B-OSE_Labeled_AE
in O
one O
patient O
and O
increased B-OSE_Labeled_AE
libido I-OSE_Labeled_AE
and O
hyperkinesia B-OSE_Labeled_AE
in O
the O
other O
. O

In O
a O
3 O
year O
, O
flexible O
dose O
, O
extension O
study O
, O
the O
incidence O
of O
all O
adverse O
events O
judged O
by O
the O
investigator O
to O
be O
at O
least O
possibly O
related O
to O
treatment O
with O
AndroGel O
1 O
% O
and O
reported O
by O
> O
1 O
% O
of O
patients O
is O
shown O
in O
Table O
2 O
. O

Table O
2 O
: O
Adverse O
Events O
Possibly O
, O
Probably O
or O
Definitely O
Related O
to O
Use O
of O
AndroGel O
1 O
% O
in O
the O
3 O
Year O
, O
Flexible O
Dose O
, O
Extension O
Study O
Adverse O
Event O
Percent O
of O
Subjects O
( O
N O
= O
162 O
) O
+ O
Lab B-NonOSE_AE
test I-NonOSE_AE
abnormal I-NonOSE_AE
occurred O
in O
15 O
patients O
with O
one O
or O
more O
of O
the O
following O
events O
reported O
: O
elevated B-OSE_Labeled_AE
AST I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
testosterone I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
hemoglobin O
or O
hematocrit I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
LDL I-OSE_Labeled_AE
ratio I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
triglycerides I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
HDL I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
. O

* O
Urinary B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
included O
nocturia B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
hesitancy I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
urgency I-OSE_Labeled_AE
and O
weak B-OSE_Labeled_AE
urinary I-OSE_Labeled_AE
stream I-OSE_Labeled_AE
. O

** O
Testis B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
included O
three O
patients O
. O

There O
were O
two O
with O
a O
non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
palpable I-OSE_Labeled_AE
testis I-OSE_Labeled_AE
and O
one O
with O
slight O
right B-OSE_Labeled_AE
testicular I-OSE_Labeled_AE
tenderness I-OSE_Labeled_AE
. O

Lab B-NonOSE_AE
Test I-NonOSE_AE
Abnormal I-NonOSE_AE
+ O
9.3 O
Skin B-OSE_Labeled_AE
dry I-OSE_Labeled_AE
1.9 O
Application B-OSE_Labeled_AE
Site I-OSE_Labeled_AE
Reaction I-OSE_Labeled_AE
5.6 O
Acne B-OSE_Labeled_AE
3.1 O
Pruritus B-OSE_Labeled_AE
1.9 O
Enlarged B-OSE_Labeled_AE
Prostate I-OSE_Labeled_AE
11.7 O
Carcinoma B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Prostate I-OSE_Labeled_AE
1.2 O
Urinary B-OSE_Labeled_AE
Symptoms I-OSE_Labeled_AE
* O
3.7 O
Testis B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
** O
1.9 O
Gynecomastia B-OSE_Labeled_AE
2.5 O
Anemia B-OSE_Labeled_AE
2.5 O
Two O
patients O
reported O
serious O
adverse O
events O
considered O
possibly O
related O
to O
treatment O
: O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
DVT I-OSE_Labeled_AE
) O
and O
prostate B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
requiring O
a O
transurethral O
resection O
of O
the O
prostate O
( O
TURP O
) O
. O

Discontinuation O
for O
adverse O
events O
in O
this O
study O
included O
: O
two O
patients O
with O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
one O
with O
kidney B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
and O
five O
with O
prostate B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
( O
including O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
PSA I-OSE_Labeled_AE
in O
4 O
patients O
, O
and O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
PSA I-OSE_Labeled_AE
with O
prostate B-OSE_Labeled_AE
enlargement I-OSE_Labeled_AE
in O
a O
fifth O
patient O
) O
. O

Increases O
in O
Serum O
PSA O
Observed O
in O
Clinical O
Trials O
of O
Hypogonadal O
Men O
During O
the O
initial O
6-month O
study O
, O
the O
mean O
change O
in O
PSA B-OSE_Labeled_AE
values I-OSE_Labeled_AE
had O
a O
statistically O
significant O
increase I-OSE_Labeled_AE
of O
0.26 O
ng/mL O
. O

Serum O
PSA O
was O
measured O
every O
6 O
months O
thereafter O
in O
the O
162 O
hypogonadal B-Not_AE_Candidate
men O
on O
AndroGel O
1 O
% O
in O
the O
3-year O
extension O
study O
. O

There O
was O
no O
additional O
statistically O
significant O
increase B-NonOSE_AE
observed O
in O
mean O
PSA I-NonOSE_AE
from O
6 O
months O
through O
36 O
months O
. O

However O
, O
there O
were O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
PSA I-OSE_Labeled_AE
observed O
in O
approximately O
18 O
% O
of O
individual O
patients O
. O

The O
overall O
mean O
change O
from O
baseline O
in O
serum O
PSA O
values O
for O
the O
entire O
group O
from O
month O
6 O
to O
36 O
was O
0.11 O
ng/mL O
. O

Twenty-nine O
patients O
( O
18 O
% O
) O
met O
the O
per-protocol O
criterion O
for O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
PSA I-OSE_Labeled_AE
, O
defined O
as O
> O
2X O
the O
baseline O
or O
any O
single O
serum O
PSA B-OSE_Labeled_AE
> I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
ng I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mL I-OSE_Labeled_AE
. O

Most O
of O
these O
( O
25/29 O
) O
met O
this O
criterion O
by O
at O
least O
doubling B-OSE_Labeled_AE
of I-OSE_Labeled_AE
their I-OSE_Labeled_AE
PSA I-OSE_Labeled_AE
from O
baseline O
. O

In O
most O
cases O
where O
PSA B-OSE_Labeled_AE
at I-OSE_Labeled_AE
least I-OSE_Labeled_AE
doubled I-OSE_Labeled_AE
( O
22/25 O
) O
, O
the O
maximum O
serum O
PSA O
value O
was O
still O
< O
2 O
ng/mL O
. O

The O
first O
occurrence O
of O
a O
pre-specified O
, O
post-baseline O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
PSA I-OSE_Labeled_AE
was O
seen O
at O
or O
prior O
to O
Month O
12 O
in O
most O
of O
the O
patients O
who O
met O
this O
criterion O
( O
23 O
of O
29 O
; O
79 O
% O
) O
. O

Four O
patients O
met O
this O
criterion O
by O
having O
a O
serum O
PSA B-OSE_Labeled_AE
> I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
ng I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mL I-OSE_Labeled_AE
and O
in O
these O
, O
maximum O
serum O
PSA O
values O
were O
6.2 O
ng/mL O
, O
6.6 O
ng/mL O
, O
6.7 O
ng/mL O
, O
and O
10.7 O
ng/mL O
. O

In O
two O
of O
these O
patients O
, O
prostate B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
was O
detected O
on O
biopsy O
. O

The O
first O
patient O
's O
PSA O
levels O
were O
4.7 O
ng/mL O
and O
6.2 O
ng/mL O
at O
baseline O
and O
at O
Month O
6/Final O
, O
respectively O
. O

The O
second O
patient O
's O
PSA O
levels O
were O
4.2 O
ng/mL O
, O
5.2 O
ng/mL O
, O
5.8 O
ng/mL O
, O
and O
6.6 O
ng/mL O
at O
baseline O
, O
Month O
6 O
, O
Month O
12 O
, O
and O
Final O
, O
respectively O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post O
approval O
use O
of O
AndroGel O
1 O
% O
. O

Because O
the O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
( O
Table O
3 O
) O
. O

Table O
3 O
: O
Adverse O
Drug O
Reactions O
from O
Postmarketing O
Experience O
of O
AndroGel O
1 O
% O
by O
MedDRA O
System O
Organ O
Class O
Blood B-NonOSE_AE
and I-NonOSE_AE
the I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
Elevated B-OSE_Labeled_AE
Hgb I-OSE_Labeled_AE
, O
Hct O
( O
polycythemia B-OSE_Labeled_AE
) O
Cardiovascular B-NonOSE_AE
disorders I-NonOSE_AE
: O
Myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
stroke B-OSE_Labeled_AE
Endocrine B-NonOSE_AE
disorders I-NonOSE_AE
: O
Hirsutism B-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
Nausea B-OSE_Labeled_AE
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
reactions I-NonOSE_AE
: O
Asthenia B-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
malaise B-OSE_Labeled_AE
Genitourinary B-NonOSE_AE
disorders I-NonOSE_AE
: O
Impaired B-OSE_Labeled_AE
urination I-OSE_Labeled_AE
Hepatobiliary B-NonOSE_AE
disorders I-NonOSE_AE
: O
Abnormal B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
( O
e.g O
. O

transaminases O
, O
elevated B-OSE_Labeled_AE
GGTP O
, O
bilirubin I-OSE_Labeled_AE
) O
Investigations B-NonOSE_AE
: O
Elevated B-OSE_Labeled_AE
PSA I-OSE_Labeled_AE
, O
electrolyte B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
( O
nitrogen O
, O
calcium O
, O
potassium O
, O
phosphorus O
, O
sodium O
) O
, O
changes B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
lipids I-OSE_Labeled_AE
( O
hyperlipidemia B-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
triglycerides I-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
HDL I-OSE_Labeled_AE
) O
, O
impaired B-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
tolerance I-OSE_Labeled_AE
, O
fluctuating B-OSE_Labeled_AE
testosterone I-OSE_Labeled_AE
concentrations I-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
Neoplasms B-NonOSE_AE
benign I-NonOSE_AE
, I-NonOSE_AE
malignant I-NonOSE_AE
and I-NonOSE_AE
unspecified I-NonOSE_AE
( I-NonOSE_AE
cysts I-NonOSE_AE
and I-NonOSE_AE
polyps I-NonOSE_AE
) O
: O
Prostate B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
Nervous B-NonOSE_AE
system I-NonOSE_AE
: O
Headache B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
sleep B-OSE_Labeled_AE
apnea I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
: O
Depression B-OSE_Labeled_AE
, O
emotional B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
libido I-OSE_Labeled_AE
, O
nervousness B-OSE_Labeled_AE
, O
hostility B-OSE_Labeled_AE
, O
amnesia B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
Reproductive B-NonOSE_AE
system I-NonOSE_AE
and I-NonOSE_AE
breast I-NonOSE_AE
disorders I-NonOSE_AE
: O
Gynecomastia B-OSE_Labeled_AE
, O
mastodynia B-OSE_Labeled_AE
, O
prostatic B-OSE_Labeled_AE
enlargement I-OSE_Labeled_AE
, O
testicular B-OSE_Labeled_AE
atrophy I-OSE_Labeled_AE
, O
oligospermia B-OSE_Labeled_AE
, O
priapism B-OSE_Labeled_AE
( O
frequent O
or O
prolonged B-OSE_Labeled_AE
erections I-OSE_Labeled_AE
) O
Respiratory B-NonOSE_AE
disorders I-NonOSE_AE
: O
Dyspnea B-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
Acne B-OSE_Labeled_AE
, O
alopecia B-OSE_Labeled_AE
, O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
( O
pruritus B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
discolored B-OSE_Labeled_AE
hair I-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
) O
, O
sweating B-OSE_Labeled_AE
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
: O
Hypertension B-OSE_Labeled_AE
, O
vasodilation B-OSE_Labeled_AE
( O
hot B-OSE_Labeled_AE
flushes I-OSE_Labeled_AE
) O
, O
venous B-OSE_Labeled_AE
thromboembolism I-OSE_Labeled_AE
Secondary O
Exposure O
to O
Testosterone O
in O
Children O
Cases O
of O
secondary B-OSE_Labeled_AE
exposure I-OSE_Labeled_AE
to O
testosterone O
resulting O
in O
virilization O
of O
ch O
ildren B-OSE_Labeled_AE
  I-OSE_Labeled_AE
I I-OSE_Labeled_AE
- I-OSE_Labeled_AE
OSE I-OSE_Labeled_AE
_Labeled_AE O
have O
been O
reported O
in O
postmarket O
surveillance O
. O

Signs O
and O
symptoms O
of O
these O
reported O
cases O
have O
included O
enlargement B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
clitoris I-NonOSE_AE
( O
with O
surgical O
intervention O
) O
or O
the O
penis O
, O
development B-NonOSE_AE
of I-NonOSE_AE
pubic I-NonOSE_AE
hair I-NonOSE_AE
, O
increased B-NonOSE_AE
erections I-NonOSE_AE
and O
libido O
, O
aggressive B-NonOSE_AE
behavior I-NonOSE_AE
, O
and O
advanced B-NonOSE_AE
bone I-NonOSE_AE
age I-NonOSE_AE
. O

In O
most O
cases O
with O
a O
reported O
outcome O
, O
these O
signs O
and O
symptoms O
were O
reported O
to O
have O
regressed O
with O
removal O
of O
the O
testosterone O
gel O
exposure O
. O

In O
a O
few O
cases O
, O
however O
, O
enlarged B-NonOSE_AE
genitalia I-NonOSE_AE
did O
not O
fully O
return O
to O
age O
appropriate O
normal O
size O
, O
and O
bone B-NonOSE_AE
age I-NonOSE_AE
remained I-NonOSE_AE
modestly I-NonOSE_AE
greater I-NonOSE_AE
than I-NonOSE_AE
chronological I-NonOSE_AE
age I-NonOSE_AE
. O

In O
some O
of O
the O
cases O
, O
direct O
contact O
with O
the O
sites O
of O
application O
on O
the O
skin O
of O
men O
using O
testosterone O
gel O
was O
reported O
. O

In O
at O
least O
one O
reported O
case O
, O
the O
reporter O
considered O
the O
possibility O
of O
secondary O
exposure O
from O
items O
such O
as O
the O
testosterone O
gel O
user O
's O
shirts O
and/or O
other O
fabric O
, O
such O
as O
towels O
and O
sheets O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

BOXED O
WARNING O
: O
WARNING O
: O
SECONDARY O
EXPOSURE O
TO O
TESTOSTERONE O
WARNING O
: O
SECONDARY O
EXPOSURE O
TO O
TESTOSTERONE O
* O
Virilization B-OSE_Labeled_AE
has O
been O
reported O
in O
children B-OSE_Labeled_AE
who I-OSE_Labeled_AE
were I-OSE_Labeled_AE
secondarily I-OSE_Labeled_AE
exposed I-OSE_Labeled_AE
to I-OSE_Labeled_AE
testosterone I-OSE_Labeled_AE
gel I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
and O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

* O
Children O
should O
avoid O
contact O
with O
unwashed O
or O
unclothed O
application O
sites O
in O
men O
using O
testosterone O
gel O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
and O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

* O
Healthcare O
providers O
should O
advise O
patients O
to O
strictly O
adhere O
to O
recommended O
instructions O
for O
use O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
, O
Warnings O
and O
Precautions O
( O
5.2 O
) O
and O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
SECONDARY O
EXPOSURE O
TO O
TESTOSTERONE O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Virilization O
has O
been O
reported O
in O
children O
who O
were O
secondarily O
exposed O
to O
testosterone O
gel O
. O

( O
5.2 O
, O
6.2 O
) O
* O
Children O
should O
avoid O
contact O
with O
unwashed O
or O
unclothed O
application O
sites O
in O
men O
using O
testosterone O
gel O
. O

( O
2.2 O
, O
5.2 O
) O
* O
Healthcare O
providers O
should O
advise O
patients O
to O
strictly O
adhere O
to O
recommended O
instructions O
for O
use O
. O

( O
2.2 O
, O
5.2 O
, O
17 O
) O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Monitor O
patients O
with O
benign O
prostatic O
hyperplasia O
( O
BPH O
) O
for O
worsening O
of O
signs O
and O
symptoms O
of O
BPH O
. O

( O
5.1 O
) O
* O
Avoid O
unintentional O
exposure O
of O
women O
or O
children O
to O
AndroGel O
1 O
% O
. O

Secondary O
exposure O
to O
testosterone O
can O
produce O
signs O
of O
virilization O
. O

AndroGel O
1 O
% O
should O
be O
discontinued O
until O
the O
cause O
of O
virilization O
is O
identified O
. O

( O
5.2 O
) O
* O
Venous O
thromboembolism O
( O
VTE O
) O
, O
including O
deep O
vein O
thrombosis O
( O
DVT O
) O
and O
pulmonary O
embolism O
( O
PE O
) O
have O
been O
reported O
in O
patients O
using O
testosterone O
products O
. O

Evaluate O
patients O
with O
signs O
or O
symptoms O
consistent O
with O
DVT O
or O
PE O
. O

( O
5.4 O
) O
* O
Some O
postmarketing O
studies O
have O
shown O
an O
increased O
risk O
of O
myocardial O
infarction O
and O
stroke O
associated O
with O
use O
of O
testosterone O
replacement O
therapy O
. O

( O
5.5 O
) O
* O
Exogenous O
administration O
of O
androgens O
may O
lead O
to O
azoospermia O
. O

( O
5.8 O
) O
* O
Edema O
, O
with O
or O
without O
congestive O
heart O
failure O
( O
CHF O
) O
, O
may O
be O
a O
complication O
in O
patients O
with O
preexisting O
cardiac O
, O
renal O
, O
or O
hepatic O
disease O
. O

( O
5.10 O
, O
6.2 O
) O
* O
Sleep O
apnea O
may O
occur O
in O
those O
with O
risk O
factors O
. O

( O
5.12 O
) O
* O
Monitor O
serum O
testosterone O
, O
prostate O
specific O
antigen O
( O
PSA O
) O
, O
hemoglobin O
, O
hematocrit O
, O
liver O
function O
tests O
, O
and O
lipid O
concentrations O
periodically O
. O

( O
5.1 O
, O
5.3 O
, O
5.9 O
, O
5.13 O
) O
* O
AndroGel O
1 O
% O
is O
flammable O
until O
dry O
. O

( O
5.16 O
) O
5.1 O
Worsening O
of O
Benign O
Prostatic O
Hyperplasia O
( O
BPH O
) O
and O
Potential O
Risk O
of O
Prostate O
Cancer O
* O
Patients O
with O
BPH B-Not_AE_Candidate
treated O
with O
androgens O
are O
at O
an O
increased O
risk O
for O
worsening B-OSE_Labeled_AE
of O
signs O
and O
symptoms O
of O
BPH I-OSE_Labeled_AE
. O

Monitor O
patients O
with O
BPH B-Not_AE_Candidate
for O
worsening O
signs O
and O
symptoms O
. O

* O
Patients O
treated O
with O
androgens O
may O
be O
at O
increased O
risk O
for O
prostate B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
. O

Evaluate O
patients O
for O
prostate B-NonOSE_AE
cancer I-NonOSE_AE
prior O
to O
initiating O
and O
during O
treatment O
with O
androgens O
[ O
see O
Contraindications O
( O
4 O
) O
, O
Adverse O
Reactions O
( O
6.1 O
) O
and O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
. O

5.2 O
Potential O
for O
Secondary O
Exposure O
to O
Testosterone O
Cases O
of O
secondary B-OSE_Labeled_AE
exposure I-OSE_Labeled_AE
resulting O
in O
virilization O
of O
ch O
ildren B-OSE_Labeled_AE
  I-OSE_Labeled_AE
I I-OSE_Labeled_AE
- I-OSE_Labeled_AE
OSE I-OSE_Labeled_AE
_Labeled_AE O
have O
been O
reported O
in O
postmarketing O
surveillance O
. O

Signs O
and O
symptoms O
have O
included O
enlargement B-NonOSE_AE
of I-NonOSE_AE
the O
penis O
or O
clitoris I-NonOSE_AE
, O
development B-NonOSE_AE
of I-NonOSE_AE
pubic I-NonOSE_AE
hair I-NonOSE_AE
, O
increased B-NonOSE_AE
erections I-NonOSE_AE
and O
libido O
, O
aggressive B-NonOSE_AE
behavior I-NonOSE_AE
, O
and O
advanced B-NonOSE_AE
bone I-NonOSE_AE
age I-NonOSE_AE
. O

In O
most O
cases O
, O
these O
signs O
and O
symptoms O
regressed O
with O
removal O
of O
the O
exposure O
to O
testosterone O
gel O
. O

In O
a O
few O
cases O
, O
however O
, O
enlarged B-NonOSE_AE
genitalia I-NonOSE_AE
did O
not O
fully O
return O
to O
age-appropriate O
normal O
size O
, O
and O
bone B-NonOSE_AE
age I-NonOSE_AE
remained I-NonOSE_AE
modestly I-NonOSE_AE
greater I-NonOSE_AE
than O
chronological O
age O
. O

The O
risk O
of O
transfer O
was O
increased O
in O
some O
of O
these O
cases O
by O
not O
adhering O
to O
precautions O
for O
the O
appropriate O
use O
of O
the O
topical O
testosterone O
product O
. O

Children O
and O
women O
should O
avoid O
contact O
with O
unwashed O
or O
unclothed O
application O
sites O
in O
men O
using O
AndroGel O
1 O
% O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
and O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

Inappropriate O
changes B-NonOSE_AE
in I-NonOSE_AE
genital I-NonOSE_AE
size I-NonOSE_AE
or O
development O
of O
pubic O
hair O
or O
libido O
in I-NonOSE_AE
children I-NonOSE_AE
, O
or O
changes B-NonOSE_AE
in I-NonOSE_AE
body I-NonOSE_AE
hair I-NonOSE_AE
distribution I-NonOSE_AE
, O
significant O
increase O
in O
acne B-NonOSE_AE
, O
or O
other O
signs O
of O
virilization B-NonOSE_AE
in O
adult O
women O
should O
be O
brought O
to O
the O
attention O
of O
a O
physician O
and O
the O
possibility O
of O
secondary B-NonOSE_AE
exposure I-NonOSE_AE
to I-NonOSE_AE
testosterone I-NonOSE_AE
gel I-NonOSE_AE
should O
also O
be O
brought O
to O
the O
attention O
of O
a O
physician O
. O

Testosterone O
gel O
should O
be O
promptly O
discontinued O
until O
the O
cause O
of O
virilization B-NonOSE_AE
has O
been O
identified O
. O

5.3 O
Polycythemia B-OSE_Labeled_AE
Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hematocrit I-OSE_Labeled_AE
, O
reflective O
of O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
red I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
mass I-OSE_Labeled_AE
, O
may O
require O
lowering O
or O
discontinuation O
of O
testosterone O
. O

Check O
hematocrit O
prior O
to O
initiating O
treatment O
. O

It O
would O
also O
be O
appropriate O
to O
re-evaluate O
the O
hematocrit O
3 O
to O
6 O
months O
after O
starting O
treatment O
, O
and O
then O
annually O
. O

If O
hematocrit B-NonOSE_AE
becomes I-NonOSE_AE
elevated I-NonOSE_AE
, O
stop O
therapy O
until O
hematocrit B-NonOSE_AE
decreases I-NonOSE_AE
to O
an O
acceptable O
concentration O
. O

An O
increase B-NonOSE_AE
in I-NonOSE_AE
red I-NonOSE_AE
blood I-NonOSE_AE
cell I-NonOSE_AE
mass I-NonOSE_AE
may O
increase O
the O
risk O
of O
thromboembolic B-NonOSE_AE
events I-NonOSE_AE
. O

5.4 O
Venous O
Thromboembolism O
There O
have O
been O
postmarketing O
reports O
of O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
including O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
DVT I-OSE_Labeled_AE
) O
and O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PE I-OSE_Labeled_AE
) O
, O
in O
patients O
using O
testosterone O
products O
such O
as O
AndroGel O
1 O
% O
. O

Evaluate O
patients O
who O
report O
symptoms O
of O
pain B-NonOSE_AE
, O
edema O
, O
warmth O
and O
erythema O
in I-NonOSE_AE
the O
lower I-NonOSE_AE
extremity I-NonOSE_AE
for O
DVT B-NonOSE_AE
and O
those O
who O
present O
with O
acute O
shortness B-NonOSE_AE
of I-NonOSE_AE
breath I-NonOSE_AE
for O
PE B-NonOSE_AE
. O

If O
a O
venous B-NonOSE_AE
thromboembolic I-NonOSE_AE
event I-NonOSE_AE
is O
suspected O
, O
discontinue O
treatment O
with O
AndroGel O
1 O
% O
and O
initiate O
appropriate O
workup O
and O
management O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

5.5 O
Cardiovascular O
Risk O
Long O
term O
clinical O
safety O
trials O
have O
not O
been O
conducted O
to O
assess O
the O
cardiovascular O
outcomes O
of O
testosterone O
replacement O
therapy O
in O
men O
. O

To O
date O
, O
epidemiologic O
studies O
and O
randomized O
controlled O
trials O
have O
been O
inconclusive O
for O
determining O
the O
risk O
of O
major B-NonOSE_AE
adverse I-NonOSE_AE
cardiovascular I-NonOSE_AE
events I-NonOSE_AE
( I-NonOSE_AE
MACE I-NonOSE_AE
) O
, O
such O
as O
non-fatal O
myocardial B-NonOSE_AE
infarction I-NonOSE_AE
, O
non-fatal O
stroke B-NonOSE_AE
, O
and O
cardiovascular B-NonOSE_AE
death I-NonOSE_AE
, O
with O
the O
use O
of O
testosterone O
compared O
to O
non-use O
. O

Some O
studies O
, O
but O
not O
all O
, O
have O
reported O
an O
increased O
risk O
of O
MACE B-OSE_Labeled_AE
in O
association O
with O
use O
of O
testosterone O
replacement O
therapy O
in O
men O
. O

Patients O
should O
be O
informed O
of O
this O
possible O
risk O
when O
deciding O
whether O
to O
use O
or O
to O
continue O
to O
use O
AndroGel O
1 O
% O
. O

5.6 O
Abuse O
of O
Testosterone O
and O
Monitoring O
of O
Serum O
Testosterone O
Concentrations O
Testosterone O
has O
been O
subject O
to O
abuse B-OSE_Labeled_AE
, O
typically O
at O
doses O
higher O
than O
recommended O
for O
the O
approved O
indication O
and O
in O
combination O
with O
other O
anabolic O
androgenic O
steroids O
. O

Anabolic O
androgenic O
steroid O
abuse B-NonOSE_AE
can O
lead O
to O
serious O
cardiovascular B-NonOSE_AE
and O
psychiatric O
adverse I-NonOSE_AE
reactions I-NonOSE_AE
[ O
see O
Drug O
Abuse O
and O
Dependence O
( O
9 O
) O
] O
. O

If O
testosterone O
abuse B-NonOSE_AE
is O
suspected O
, O
check O
serum O
testosterone O
concentrations O
to O
ensure O
they O
are O
within O
therapeutic O
range O
. O

However O
, O
testosterone O
levels O
may O
be O
in O
the O
normal O
or O
subnormal O
range O
in O
men O
abusing O
synthetic O
testosterone O
derivatives O
. O

Counsel O
patients O
concerning O
the O
serious O
adverse O
reactions O
associated O
with O
abuse B-NonOSE_AE
of O
testosterone O
and O
anabolic O
androgenic O
steroids O
. O

Conversely O
, O
consider O
the O
possibility O
of O
testosterone O
and O
anabolic O
androgenic O
steroid O
abuse B-NonOSE_AE
in O
suspected O
patients O
who O
present O
with O
serious O
cardiovascular B-NonOSE_AE
or O
psychiatric O
adverse I-NonOSE_AE
events I-NonOSE_AE
. O

5.7 O
Use O
in O
Women O
Due O
to O
lack O
of O
controlled O
evaluations O
in O
women O
and O
potential O
virilizing B-NonOSE_AE
effects I-NonOSE_AE
, O
AndroGel O
1 O
% O
is O
not O
indicated O
for O
use O
in O
women O
[ O
see O
Contraindications O
( O
4 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.1 O
, O
8.3 O
) O
] O
. O

5.8 O
Potential O
for O
Adverse O
Effects O
on O
Spermatogenesis O
With O
large O
doses O
of O
exogenous O
androgens O
, O
including O
AndroGel O
1 O
% O
, O
spermatogenesis B-OSE_Labeled_AE
may I-OSE_Labeled_AE
be I-OSE_Labeled_AE
suppressed I-OSE_Labeled_AE
through O
feedback O
inhibition O
of O
pituitary O
follicle-stimulating O
hormone O
( O
FSH O
) O
which O
could O
possibly O
lead O
to O
adverse B-OSE_Labeled_AE
effects I-OSE_Labeled_AE
on I-OSE_Labeled_AE
semen I-OSE_Labeled_AE
parameters I-OSE_Labeled_AE
including I-OSE_Labeled_AE
sperm I-OSE_Labeled_AE
count I-OSE_Labeled_AE
. O

5.9 O
Hepatic O
Adverse O
Effects O
Prolonged O
use O
of O
high O
doses O
of O
orally O
active O
17-alpha-alkyl O
androgens O
( O
e.g. O
, O
methyltestosterone O
) O
has O
been O
associated O
with O
serious O
hepatic B-NonOSE_AE
adverse I-NonOSE_AE
effects I-NonOSE_AE
( O
peliosis B-NonOSE_AE
hepatis I-NonOSE_AE
, O
hepatic B-NonOSE_AE
neoplasms I-NonOSE_AE
, O
cholestatic B-NonOSE_AE
hepatitis I-NonOSE_AE
, O
and O
jaundice B-NonOSE_AE
) O
. O

Peliosis B-NonOSE_AE
hepatis I-NonOSE_AE
can O
be O
a O
life-threatening O
or O
fatal O
complication O
. O

Long-term O
therapy O
with O
intramuscular O
testosterone O
enanthate O
has O
produced O
multiple O
hepatic B-NonOSE_AE
adenomas I-NonOSE_AE
. O

AndroGel O
1 O
% O
is O
not O
known O
to O
cause O
these O
adverse O
effects O
. O

5.10 O
Edema O
Androgens O
, O
including O
AndroGel O
1 O
% O
, O
may O
promote O
retention B-OSE_Labeled_AE
of I-OSE_Labeled_AE
sodium O
and O
water I-OSE_Labeled_AE
. O

Edema B-OSE_Labeled_AE
, O
with O
or O
without O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
may O
be O
a O
serious O
complication O
in O
patients O
with O
preexisting O
cardiac B-Not_AE_Candidate
, O
renal O
, O
or O
hepatic O
disease I-Not_AE_Candidate
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

5.11 O
Gynecomastia O
Gynecomastia B-OSE_Labeled_AE
may O
develop O
and O
persist O
in O
patients O
being O
treated O
with O
androgens O
, O
including O
AndroGel O
1 O
% O
, O
for O
hypogonadism B-Not_AE_Candidate
. O

5.12 O
Sleep O
Apnea O
The O
treatment O
of O
hypogonadal B-Not_AE_Candidate
men O
with O
testosterone O
may O
potentiate O
sleep B-OSE_Labeled_AE
apnea I-OSE_Labeled_AE
in O
some O
patients O
, O
especially O
those O
with O
risk O
factors O
such O
as O
obesity B-Not_AE_Candidate
or O
chronic B-Not_AE_Candidate
lung I-Not_AE_Candidate
diseases I-Not_AE_Candidate
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

5.13 O
Lipids O
Changes B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
lipid I-OSE_Labeled_AE
profile I-OSE_Labeled_AE
may O
require O
dose O
adjustment O
or O
discontinuation O
of O
testosterone O
therapy O
. O

5.14 O
Hypercalcemia B-OSE_Labeled_AE
Androgens O
, O
including O
AndroGel O
1 O
% O
, O
should O
be O
used O
with O
caution O
in O
cancer B-Not_AE_Candidate
patients I-Not_AE_Candidate
at O
risk O
of O
hypercalcemia B-Not_AE_Candidate
( O
and O
associated O
hypercalciuria B-Not_AE_Candidate
) O
. O

Regular O
monitoring O
of O
serum B-NonOSE_AE
calcium I-NonOSE_AE
concentrations O
is O
recommended O
in O
these O
patients O
. O

5.15 O
Decreased O
Thyroxine-binding O
Globulin O
Androgens O
, O
including O
AndroGel O
1 O
% O
, O
may O
decrease B-OSE_Labeled_AE
concentrations I-OSE_Labeled_AE
of I-OSE_Labeled_AE
thyroxin I-OSE_Labeled_AE
- I-OSE_Labeled_AE
binding I-OSE_Labeled_AE
globulins I-OSE_Labeled_AE
, O
resulting O
in O
decreased B-OSE_Labeled_AE
total I-OSE_Labeled_AE
T I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
concentrations I-OSE_Labeled_AE
and O
increased B-OSE_Labeled_AE
resin I-OSE_Labeled_AE
uptake I-OSE_Labeled_AE
of I-OSE_Labeled_AE
T3 O
and O
T I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
. O

Free O
thyroid O
hormone O
concentrations O
remain O
unchanged O
, O
however O
, O
and O
there O
is O
no O
clinical O
evidence O
of O
thyroid B-NonOSE_AE
dysfunction I-NonOSE_AE
. O

5.16 O
Flammability O
Alcohol O
based O
products O
, O
including O
AndroGel O
1 O
% O
, O
are O
flammable O
; O
therefore O
, O
patients O
should O
be O
advised O
to O
avoid O
fire O
, O
flame O
or O
smoking O
until O
the O
AndroGel O
1 O
% O
has O
dried O
. O

6 O
ADVERSE O
REACTIONS O
LABA O
, O
such O
as O
vilanterol O
, O
one O
of O
the O
active O
ingredients O
in O
ANORO O
ELLIPTA O
, O
increase O
the O
risk O
of O
asthma B-OSE_Labeled_AE
-related O
death B-NonOSE_AE
. O

ANORO O
ELLIPTA O
is O
not O
indicated O
for O
the O
treatment O
of O
asthma B-Not_AE_Candidate
. O

[ O
See O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
. O
] O

The O
following O
adverse O
reactions O
are O
described O
in O
greater O
detail O
in O
other O
sections O
: O
* O
Paradoxical B-OSE_Labeled_AE
bronchospasm I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Cardiovascular B-OSE_Labeled_AE
effects I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Worsening O
of O
narrow B-OSE_Labeled_AE
- I-OSE_Labeled_AE
angle I-OSE_Labeled_AE
glaucoma I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Worsening O
of O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
=1 O
% O
and O
more O
common O
than O
placebo O
) O
include O
pharyngitis O
, O
sinusitis O
, O
lower O
respiratory O
tract O
infection O
, O
constipation O
, O
diarrhea O
, O
pain O
in O
extremity O
, O
muscle O
spasms O
, O
neck O
pain O
, O
and O
chest O
pain O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
GlaxoSmithKline O
at O
1-888-825-5249 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
http O
: O
//www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
with O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
clinical O
program O
for O
ANORO O
ELLIPTA O
included O
8,138 O
subjects O
with O
COPD B-Not_AE_Candidate
in O
four O
6-month O
lung O
function O
trials O
, O
one O
12-month O
long-term O
safety O
study O
, O
and O
9 O
other O
trials O
of O
shorter O
duration O
. O

A O
total O
of O
1,124 O
subjects O
have O
received O
at O
least O
1 O
dose O
of O
ANORO O
ELLIPTA O
( O
umeclidinium/vilanterol O
62.5 O
mcg/25 O
mcg O
) O
, O
and O
1,330 O
subjects O
have O
received O
a O
higher O
dose O
of O
umeclidinium/vilanterol O
( O
125 O
mcg/25 O
mcg O
) O
. O

The O
safety O
data O
described O
below O
are O
based O
on O
the O
four O
6-month O
and O
the O
one O
12-month O
trials O
. O

Adverse O
reactions O
observed O
in O
the O
other O
trials O
were O
similar O
to O
those O
observed O
in O
the O
confirmatory O
trials O
. O

6-Month O
Trials O
: O
The O
incidence O
of O
adverse O
reactions O
associated O
with O
ANORO O
ELLIPTA O
in O
Table O
1 O
is O
based O
on O
four O
6-month O
trials O
: O
2 O
placebo-controlled O
trials O
( O
Trials O
1 O
and O
2 O
; O
n O
= O
1,532 O
and O
n O
= O
1,489 O
, O
respectively O
) O
and O
2 O
active-controlled O
trials O
( O
Trials O
3 O
and O
4 O
; O
n O
= O
843 O
and O
n O
= O
869 O
, O
respectively O
) O
. O

Of O
the O
4,733 O
subjects O
, O
68 O
% O
were O
male O
and O
84 O
% O
were O
Caucasian O
. O

They O
had O
a O
mean O
age O
of O
63 O
years O
and O
an O
average O
smoking O
history O
of O
45 O
pack-years O
, O
with O
50 O
% O
identified O
as O
current O
smokers O
. O

At O
screening O
, O
the O
mean O
post-bronchodilator O
percent O
predicted O
forced O
expiratory O
volume O
in O
1 O
second O
( O
FEV1 O
) O
was O
48 O
% O
( O
range O
: O
13 O
% O
to O
76 O
% O
) O
, O
the O
mean O
post-bronchodilator O
FEV1/forced O
vital O
capacity O
( O
FVC O
) O
ratio O
was O
0.47 O
( O
range O
: O
0.13 O
to O
0.78 O
) O
, O
and O
the O
mean O
percent O
reversibility O
was O
14 O
% O
( O
range O
: O
-45 O
% O
to O
109 O
% O
) O
. O

Subjects O
received O
1 O
dose O
once O
daily O
of O
the O
following O
: O
ANORO O
ELLIPTA O
, O
umeclidinium/vilanterol O
125 O
mcg/25 O
mcg O
, O
umeclidinium O
62.5 O
mcg O
, O
umeclidinium O
125 O
mcg O
, O
vilanterol O
25 O
mcg O
, O
active O
control O
, O
or O
placebo O
. O

Table O
1 O
. O

Adverse O
Reactions O
With O
ANORO O
ELLIPTA O
With O
> O
=1 O
% O
Incidence O
and O
More O
Common O
Than O
With O
Placebo O
in O
Subjects O
With O
Chronic O
Obstructive O
Pulmonary O
Disease O
Adverse O
Reaction O
Placebo O
( O
n O
= O
555 O
) O
% O
ANORO O
ELLIPTA O
( O
n O
= O
842 O
) O
% O
Umeclidinium O
62.5 O
mcg O
( O
n O
= O
418 O
) O
% O
Vilanterol O
25 O
mcg O
( O
n O
= O
1,034 O
) O
% O
Infections B-NonOSE_AE
and O
infestations O
Pharyngitis B-OSE_Labeled_AE
< O
1 O
2 O
1 O
2 O
Sinusitis B-OSE_Labeled_AE
< O
1 O
1 O
< O
1 O
1 O
Lower B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
< O
1 O
1 O
< O
1 O
< O
1 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Constipation B-OSE_Labeled_AE
< O
1 O
1 O
< O
1 O
< O
1 O
Diarrhea B-OSE_Labeled_AE
1 O
2 O
< O
1 O
2 O
Musculoskeletal B-NonOSE_AE
and O
connective O
tissue O
disorder I-NonOSE_AE
s O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
1 O
2 O
< O
1 O
2 O
Muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
< O
1 O
1 O
< O
1 O
< O
1 O
Neck B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
< O
1 O
1 O
< O
1 O
< O
1 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and O
administration O
site O
conditions O
Chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
< O
1 O
1 O
< O
1 O
< O
1 O
Other O
adverse O
reactions O
with O
ANORO O
ELLIPTA O
observed O
with O
an O
incidence O
less O
than O
1 O
% O
but O
more O
common O
than O
with O
placebo O
included O
the O
following O
: O
productive B-OSE_Labeled_AE
cough I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
gastroesophageal B-OSE_Labeled_AE
reflux I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
chest I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
extrasystoles I-OSE_Labeled_AE
, O
supraventricular B-OSE_Labeled_AE
extrasystoles I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
and O
conjunctivitis B-OSE_Labeled_AE
. O

12-Month O
Trial O
: O
In O
a O
long-term O
safety O
trial O
, O
335 O
subjects O
were O
treated O
for O
up O
to O
12 O
months O
with O
umeclidinium/vilanterol O
125 O
mcg/25 O
mcg O
or O
placebo O
. O

The O
demographic O
and O
baseline O
characteristics O
of O
the O
long-term O
safety O
trial O
were O
similar O
to O
those O
of O
the O
placebo-controlled O
efficacy O
trials O
described O
above O
. O

Adverse O
reactions O
that O
occurred O
with O
a O
frequency O
of O
greater O
than O
or O
equal O
to O
1 O
% O
in O
the O
group O
receiving O
umeclidinium/vilanterol O
125 O
mcg/25 O
mcg O
that O
exceeded O
that O
in O
placebo O
in O
this O
trial O
were O
: O
headache B-OSE_Labeled_AE
, O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
vertigo B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
pleuritic B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
viral B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
toothache B-OSE_Labeled_AE
, O
and O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
. O

BOXED O
WARNING O
: O
WARNING O
: O
ASTHMA-RELATED O
DEATH O
WARNING O
: O
ASTHMA-RELATED O
DEATH O
Long-acting O
beta2-adrenergic O
agonists O
( O
LABA O
) O
increase O
the O
risk O
of O
asthma B-NonOSE_AE
-related O
death B-NonOSE_AE
. O

Data O
from O
a O
large O
placebo-controlled O
US O
trial O
that O
compared O
the O
safety O
of O
another O
LABA O
( O
salmeterol O
) O
with O
placebo O
added O
to O
usual O
asthma B-Not_AE_Candidate
therapy O
showed O
an O
increase O
in O
asthma B-NonOSE_AE
-related O
deaths B-NonOSE_AE
in O
subjects O
receiving O
salmeterol O
. O

This O
finding O
with O
salmeterol O
is O
considered O
a O
class O
effect O
of O
all O
LABA O
, O
including O
vilanterol O
, O
one O
of O
the O
active O
ingredients O
in O
ANOROTM O
ELLIPTA O
( O
r O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

The O
safety O
and O
efficacy O
of O
ANORO O
ELLIPTA O
in O
patients O
with O
asthma B-Not_AE_Candidate
have O
not O
been O
established O
. O

ANORO O
ELLIPTA O
is O
not O
indicated O
for O
the O
treatment O
of O
asthma B-Not_AE_Candidate
. O

EXCERPT O
: O
WARNING O
: O
ASTHMA-RELATED O
DEATH O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Long-acting O
beta2-adrenergic O
agonists O
( O
LABA O
) O
, O
such O
as O
vilanterol O
, O
one O
of O
the O
active O
ingredients O
in O
ANORO O
ELLIPTA O
, O
increase O
the O
risk O
of O
asthma-related O
death O
. O

A O
placebo-controlled O
trial O
with O
another O
LABA O
( O
salmeterol O
) O
showed O
an O
increase O
in O
asthma-related O
deaths O
in O
subjects O
receiving O
salmeterol O
. O

This O
finding O
with O
salmeterol O
is O
considered O
a O
class O
effect O
of O
all O
LABA O
, O
including O
vilanterol O
. O

( O
5.1 O
) O
* O
The O
safety O
and O
efficacy O
of O
ANORO O
ELLIPTA O
in O
patients O
with O
asthma O
have O
not O
been O
established O
. O

ANORO O
ELLIPTA O
is O
not O
indicated O
for O
the O
treatment O
of O
asthma O
. O

( O
5.1 O
) O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
LABA O
increase O
the O
risk O
of O
asthma-related O
death O
. O

( O
5.1 O
) O
* O
Do O
not O
initiate O
in O
acutely O
deteriorating O
COPD O
or O
to O
treat O
acute O
symptoms O
. O

( O
5.2 O
) O
* O
Do O
not O
use O
in O
combination O
with O
an O
additional O
medicine O
containing O
LABA O
because O
of O
risk O
of O
overdose O
. O

( O
5.3 O
) O
* O
If O
paradoxical O
bronchospasm O
occurs O
, O
discontinue O
ANORO O
ELLIPTA O
and O
institute O
alternative O
therapy O
. O

( O
5.5 O
) O
* O
Use O
with O
caution O
in O
patients O
with O
cardiovascular O
disorders O
( O
5.7 O
) O
* O
Use O
with O
caution O
in O
patients O
with O
convulsive O
disorders O
, O
thyrotoxicosis O
, O
diabetes O
mellitus O
, O
and O
ketoacidosis O
. O

( O
5.8 O
) O
* O
Worsening O
of O
narrow-angle O
glaucoma O
may O
occur O
. O

Use O
with O
caution O
in O
patients O
with O
narrow-angle O
glaucoma O
and O
instruct O
patients O
to O
contact O
a O
physician O
immediately O
if O
symptoms O
occur O
. O

( O
5.9 O
) O
* O
Worsening O
of O
urinary O
retention O
may O
occur O
. O

Use O
with O
caution O
in O
patients O
with O
prostatic O
hyperplasia O
or O
bladder-neck O
obstruction O
and O
instruct O
patients O
to O
contact O
a O
physician O
immediately O
if O
symptoms O
occur O
. O

( O
5.10 O
) O
* O
Be O
alert O
to O
hypokalemia O
and O
hyperglycemia O
. O

( O
5.11 O
) O
5.1 O
Asthma-Related O
Death O
* O
Data O
from O
a O
large O
placebo-controlled O
trial O
in O
subjects O
with O
asthma B-Not_AE_Candidate
showed O
that O
LABA O
may O
increase O
the O
risk O
of O
asthma B-NonOSE_AE
-related O
death B-NonOSE_AE
. O

Data O
are O
not O
available O
to O
determine O
whether O
the O
rate O
of O
death B-NonOSE_AE
in O
patients O
with O
COPD B-Not_AE_Candidate
is O
increased O
by O
LABA O
. O

* O
A O
28-week O
, O
placebo-controlled O
, O
US O
trial O
comparing O
the O
safety O
of O
another O
LABA O
( O
salmeterol O
) O
with O
placebo O
, O
each O
added O
to O
usual O
asthma O
therapy O
, O
showed O
an O
increase O
in O
asthma B-NonOSE_AE
-related O
deaths B-NonOSE_AE
in O
subjects O
receiving O
salmeterol O
( O
13/13,176 O
in O
subjects O
treated O
with O
salmeterol O
vs O
. O
3/13,179 O
in O
subjects O
treated O
with O
placebo O
; O
relative O
risk O
: O
4.37 O
[ O
95 O
% O
CI O
: O
1.25 O
, O
15.34 O
] O
) O
. O

The O
increased O
risk O
of O
asthma B-OSE_Labeled_AE
-related O
death B-NonOSE_AE
is O
considered O
a O
class O
effect O
of O
LABA O
, O
including O
vilanterol O
, O
one O
of O
the O
active O
ingredients O
in O
ANORO O
ELLIPTA O
. O

* O
No O
trial O
adequate O
to O
determine O
whether O
the O
rate O
of O
asthma B-NonOSE_AE
-related O
death B-NonOSE_AE
is O
increased O
in O
subjects O
treated O
with O
ANORO O
ELLIPTA O
has O
been O
conducted O
. O

The O
safety O
and O
efficacy O
of O
ANORO O
ELLIPTA O
in O
patients O
with O
asthma B-Not_AE_Candidate
have O
not O
been O
established O
. O

ANORO O
ELLIPTA O
is O
not O
indicated O
for O
the O
treatment O
of O
asthma B-Not_AE_Candidate
. O

5.2 O
Deterioration O
of O
Disease O
and O
Acute O
Episodes O
ANORO O
ELLIPTA O
should O
not O
be O
initiated O
in O
patients O
during O
rapidly O
deteriorating O
or O
potentially O
life-threatening O
episodes O
of O
COPD B-Not_AE_Candidate
. O

ANORO O
ELLIPTA O
has O
not O
been O
studied O
in O
subjects O
with O
acutely O
deteriorating O
COPD B-Not_AE_Candidate
. O

The O
initiation O
of O
ANORO O
ELLIPTA O
in O
this O
setting O
is O
not O
appropriate O
. O

ANORO O
ELLIPTA O
should O
not O
be O
used O
for O
the O
relief O
of O
acute O
symptoms O
, O
i.e. O
, O
as O
rescue O
therapy O
for O
the O
treatment O
of O
acute O
episodes O
of O
bronchospasm B-Not_AE_Candidate
. O

ANORO O
ELLIPTA O
has O
not O
been O
studied O
in O
the O
relief O
of O
acute O
symptoms O
and O
extra O
doses O
should O
not O
be O
used O
for O
that O
purpose O
. O

Acute O
symptoms O
should O
be O
treated O
with O
an O
inhaled O
, O
short-acting O
beta2-agonist O
. O

When O
beginning O
treatment O
with O
ANORO O
ELLIPTA O
, O
patients O
who O
have O
been O
taking O
oral O
or O
inhaled O
, O
short-acting O
beta2-agonists O
on O
a O
regular O
basis O
( O
e.g. O
, O
4 O
times O
a O
day O
) O
should O
be O
instructed O
to O
discontinue O
the O
regular O
use O
of O
these O
drugs O
and O
to O
use O
them O
only O
for O
symptomatic O
relief O
of O
acute B-NonOSE_AE
respiratory I-NonOSE_AE
symptoms I-NonOSE_AE
. O

When O
prescribing O
ANORO O
ELLIPTA O
, O
the O
healthcare O
provider O
should O
also O
prescribe O
an O
inhaled O
, O
short-acting O
beta2-agonist O
and O
instruct O
the O
patient O
on O
how O
it O
should O
be O
used O
. O

Increasing O
inhaled O
, O
short-acting O
beta2-agonist O
use O
is O
a O
signal O
of O
deteriorating O
disease O
for O
which O
prompt O
medical O
attention O
is O
indicated O
. O

COPD B-Not_AE_Candidate
may O
deteriorate O
acutely O
over O
a O
period O
of O
hours O
or O
chronically O
over O
several O
days O
or O
longer O
. O

If O
ANORO O
ELLIPTA O
no O
longer O
controls O
symptoms O
of O
bronchoconstriction B-NonOSE_AE
; O
the O
patient O
's O
inhaled O
, O
short-acting O
beta2-agonist O
becomes O
less O
effective O
; O
or O
the O
patient O
needs O
more O
short-acting O
beta2-agonist O
than O
usual O
, O
these O
may O
be O
markers O
of O
deterioration O
of O
disease O
. O

In O
this O
setting O
a O
re-evaluation O
of O
the O
patient O
and O
the O
COPD B-Not_AE_Candidate
treatment O
regimen O
should O
be O
undertaken O
at O
once O
. O

Increasing O
the O
daily O
dose O
of O
ANORO O
ELLIPTA O
beyond O
the O
recommended O
dose O
is O
not O
appropriate O
in O
this O
situation O
. O

5.3 O
Excessive O
Use O
of O
ANORO O
ELLIPTA O
and O
Use O
With O
Other O
Long-Acting O
Beta2-Agonists O
ANORO O
ELLIPTA O
should O
not O
be O
used O
more O
often O
than O
recommended O
, O
at O
higher O
doses O
than O
recommended O
, O
or O
in O
conjunction O
with O
other O
medicines O
containing O
LABA O
, O
as O
an O
overdose B-NonOSE_AE
may O
result O
. O

Clinically O
significant O
cardiovascular B-NonOSE_AE
effects I-NonOSE_AE
and O
fatalities O
have O
been O
reported O
in O
association O
with O
excessive O
use O
of O
inhaled O
sympathomimetic O
drugs O
. O

Patients O
using O
ANORO O
ELLIPTA O
should O
not O
use O
another O
medicine O
containing O
a O
LABA O
( O
e.g. O
, O
salmeterol O
, O
formoterol O
fumarate O
, O
arformoterol O
tartrate O
, O
indacaterol O
) O
for O
any O
reason O
. O

5.4 O
Drug O
Interactions O
With O
Strong O
Cytochrome O
P450 O
3A4 O
Inhibitors O
Caution O
should O
be O
exercised O
when O
considering O
the O
coadministration O
of O
ANORO O
ELLIPTA O
with O
long-term O
ketoconazole O
and O
other O
known O
strong O
cytochrome O
P450 O
3A4 O
( O
CYP3A4 O
) O
inhibitors O
( O
e.g. O
, O
ritonavir O
, O
clarithromycin O
, O
conivaptan O
, O
indinavir O
, O
itraconazole O
, O
lopinavir O
, O
nefazodone O
, O
nelfinavir O
, O
saquinavir O
, O
telithromycin O
, O
troleandomycin O
, O
voriconazole O
) O
because O
increased O
cardiovascular B-NonOSE_AE
adverse I-NonOSE_AE
effects I-NonOSE_AE
may O
occur O
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
, O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

5.5 O
Paradoxical O
Bronchospasm O
As O
with O
other O
inhaled O
medicines O
, O
ANORO O
ELLIPTA O
can O
produce O
paradoxical B-OSE_Labeled_AE
bronchospasm I-OSE_Labeled_AE
, O
which O
may O
be O
life O
threatening O
. O

If O
paradoxical B-NonOSE_AE
bronchospasm I-NonOSE_AE
occurs O
following O
dosing O
with O
ANORO O
ELLIPTA O
, O
it O
should O
be O
treated O
immediately O
with O
an O
inhaled O
, O
short-acting O
bronchodilator O
; O
ANORO O
ELLIPTA O
should O
be O
discontinued O
immediately O
; O
and O
alternative O
therapy O
should O
be O
instituted O
. O

5.6 O
Hypersensitivity O
Reactions O
Hypersensitivity B-OSE_Labeled_AE
reactions O
may O
occur O
after O
administration O
of O
ANORO O
ELLIPTA O
. O

There O
have O
been O
reports O
of O
anaphylactic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
in O
patients O
with O
severe O
milk B-Not_AE_Candidate
protein I-Not_AE_Candidate
allergy I-Not_AE_Candidate
after O
inhalation O
of O
other O
powder O
products O
containing O
lactose O
; O
therefore O
, O
patients O
with O
severe O
milk B-Not_AE_Candidate
protein I-Not_AE_Candidate
allergy I-Not_AE_Candidate
should O
not O
use O
ANORO O
ELLIPTA O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

5.7 O
Cardiovascular O
Effects O
Vilanterol O
, O
like O
other O
beta2-agonists O
, O
can O
produce O
a O
clinically O
significant O
cardiovascular B-OSE_Labeled_AE
effect I-OSE_Labeled_AE
in O
some O
patients O
as O
measured O
by O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
pulse I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
, O
systolic O
or O
diastolic O
blood O
pressure O
, O
or O
symptoms O
[ O
see O
Clinical O
Pharmacology O
( O
12.2 O
) O
] O
. O

If O
such O
effects O
occur O
, O
ANORO O
ELLIPTA O
may O
need O
to O
be O
discontinued O
. O

In O
addition O
, O
beta-agonists O
have O
been O
reported O
to O
produce O
electrocardiographic B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
, O
such O
as O
flattening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
t I-OSE_Labeled_AE
he O
T O
wave I-OSE_Labeled_AE
, O
prolongation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
QTc I-OSE_Labeled_AE
interval I-OSE_Labeled_AE
, O
and O
ST B-OSE_Labeled_AE
segment I-OSE_Labeled_AE
depression I-OSE_Labeled_AE
, O
although O
the O
clinical O
significance O
of O
these O
findings O
is O
unknown O
. O

Therefore O
, O
ANORO O
ELLIPTA O
should O
be O
used O
with O
caution O
in O
patients O
with O
cardiovascular B-Not_AE_Candidate
disorders I-Not_AE_Candidate
, O
especially O
coronary B-Not_AE_Candidate
insufficiency I-Not_AE_Candidate
, O
cardiac B-Not_AE_Candidate
arrhythmias I-Not_AE_Candidate
, O
and O
hypertension B-Not_AE_Candidate
. O

5.8 O
Coexisting O
Conditions O
ANORO O
ELLIPTA O
, O
like O
all O
medicines O
containing O
sympathomimetic O
amines O
, O
should O
be O
used O
with O
caution O
in O
patients O
with O
convulsive B-Not_AE_Candidate
disorders I-Not_AE_Candidate
or O
thyrotoxicosis B-Not_AE_Candidate
and O
in O
those O
who O
are O
unusually O
responsive O
to O
sympathomimetic O
amines O
. O

Doses O
of O
the O
related O
beta2-adrenoceptor O
agonist O
albuterol O
, O
when O
administered O
intravenously O
, O
have O
been O
reported O
to O
aggravate O
preexisting O
diabetes B-NonOSE_AE
mellitus I-NonOSE_AE
and O
ketoacidosis B-NonOSE_AE
. O

5.9 O
Worsening O
of O
Narrow B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Angle I-OSE_Labeled_AE
Glaucoma I-OSE_Labeled_AE
ANORO O
ELLIPTA O
should O
be O
used O
with O
caution O
in O
patients O
with O
narrow B-Not_AE_Candidate
- I-Not_AE_Candidate
angle I-Not_AE_Candidate
glaucoma I-Not_AE_Candidate
. O

Prescribers O
and O
patients O
should O
be O
alert O
for O
signs O
and O
symptoms O
of O
acute B-NonOSE_AE
narrow I-NonOSE_AE
- I-NonOSE_AE
angle I-NonOSE_AE
glaucoma I-NonOSE_AE
( O
e.g. O
, O
eye B-NonOSE_AE
pain I-NonOSE_AE
or O
discomfort B-NonOSE_AE
, O
blurred B-NonOSE_AE
vision I-NonOSE_AE
, O
visual B-NonOSE_AE
halos I-NonOSE_AE
or O
colored O
images O
in O
association O
with O
red B-NonOSE_AE
eyes I-NonOSE_AE
from O
conjunctival B-NonOSE_AE
congestion I-NonOSE_AE
and O
corneal B-NonOSE_AE
edema I-NonOSE_AE
) O
. O

Instruct O
patients O
to O
consult O
a O
physician O
immediately O
if O
any O
of O
these O
signs O
or O
symptoms O
develops O
. O

5.10 O
Worsening O
of O
Urinary B-OSE_Labeled_AE
Retention I-OSE_Labeled_AE
ANORO O
ELLIPTA O
should O
be O
used O
with O
caution O
in O
patients O
with O
urinary B-Not_AE_Candidate
retention I-Not_AE_Candidate
. O

Prescribers O
and O
patients O
should O
be O
alert O
for O
signs O
and O
symptoms O
of O
urinary B-NonOSE_AE
retention I-NonOSE_AE
( O
e.g. O
, O
difficulty B-NonOSE_AE
passing I-NonOSE_AE
urine I-NonOSE_AE
, O
painful B-NonOSE_AE
urination I-NonOSE_AE
) O
, O
especially O
in O
patients O
with O
prostatic B-Not_AE_Candidate
hyperplasia I-Not_AE_Candidate
or O
bladder B-Not_AE_Candidate
- I-Not_AE_Candidate
neck I-Not_AE_Candidate
obstruction I-Not_AE_Candidate
. O

Instruct O
patients O
to O
consult O
a O
physician O
immediately O
if O
any O
of O
these O
signs O
or O
symptoms O
develops O
. O

5.11 O
Hypokalemia O
and O
Hyperglycemia O
Beta-adrenergic O
agonist O
medicines O
may O
produce O
significant O
hypokalemia B-OSE_Labeled_AE
in O
some O
patients O
, O
possibly O
through O
intracellular O
shunting O
, O
which O
has O
the O
potential O
to O
produce O
adverse O
cardiovascular B-NonOSE_AE
effects I-NonOSE_AE
. O

The O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
potassium I-OSE_Labeled_AE
is O
usually O
transient O
, O
not O
requiring O
supplementation O
. O

Beta-agonist O
medicines O
may O
produce O
transient O
hyperglycemia B-OSE_Labeled_AE
in O
some O
patients O
. O

In O
4 O
clinical O
trials O
of O
6-month O
duration O
evaluating O
ANORO O
ELLIPTA O
in O
subjects O
with O
COPD B-Not_AE_Candidate
, O
there O
was O
no O
evidence O
of O
a O
treatment O
effect O
on O
serum O
glucose O
or O
potassium O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
label O
: O
* O
Increased O
Mortality B-NonOSE_AE
, O
Myocardial B-OSE_Labeled_AE
Infarction I-OSE_Labeled_AE
, O
Stroke B-OSE_Labeled_AE
, O
and O
Thromboembolism B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Increased O
Mortality B-NonOSE_AE
and/or O
Increased O
Risk O
of O
Tumor B-OSE_Labeled_AE
Progression I-OSE_Labeled_AE
or O
Recurrence O
in O
Patients O
with O
Cancer B-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Hypertension B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Seizures B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
PRCA B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Serious O
allergic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Severe O
Cutaneous B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Patients O
with O
CKD B-Not_AE_Candidate
: O
Adverse O
reactions O
in O
> O
= O
10 O
% O
of O
Aranesp-treated O
patients O
in O
clinical O
studies O
were O
hypertension B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
and O
procedural B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
( O
6.1 O
) O
. O

* O
Patients O
with O
Cancer B-Not_AE_Candidate
Receiving O
Chemotherapy O
: O
Adverse O
reactions O
in O
> O
= O
1 O
% O
of O
Aranesp-treated O
patients O
in O
clinical O
studies O
were O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
and O
thrombovascular B-OSE_Labeled_AE
events I-OSE_Labeled_AE
( O
6.1 O
) O
. O

EXCERPT O
: O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Amgen O
Medical O
Information O
at O
1-800-77-AMGEN O
( O
1-800-772-6436 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trial O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
other O
drugs O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Patients O
with O
Chronic O
Kidney O
Disease O
Adult O
Patients O
Adverse O
reactions O
were O
determined O
based O
on O
pooled O
data O
from O
5 O
randomized O
, O
active-controlled O
studies O
of O
Aranesp O
with O
a O
total O
of O
1357 O
patients O
( O
Aranesp O
766 O
, O
epoetin O
alfa O
591 O
) O
. O

The O
median O
duration O
of O
exposure O
for O
patients O
receiving O
Aranesp O
was O
340 O
days O
, O
with O
580 O
patients O
exposed O
for O
greater O
than O
6 O
months O
and O
360 O
patients O
exposed O
for O
greater O
than O
1 O
year O
. O

The O
median O
( O
25th O
, O
75th O
percentiles O
) O
weight-adjusted O
dose O
of O
Aranesp O
was O
0.50 O
mcg/kg O
( O
0.32 O
, O
0.81 O
) O
. O

The O
median O
( O
range O
) O
age O
for O
patients O
administered O
Aranesp O
was O
62 O
years O
( O
18 O
to O
88 O
) O
. O

In O
the O
Aranesp O
group O
, O
55 O
% O
were O
male O
, O
72 O
% O
were O
white O
, O
83 O
% O
were O
receiving O
dialysis O
, O
and O
17 O
% O
were O
not O
receiving O
dialysis O
. O

Table O
5 O
lists O
adverse O
reactions O
occurring O
in O
> O
= O
5 O
% O
of O
patients O
treated O
with O
Aranesp O
. O

Table O
5 O
. O

Adverse O
Reactions O
Occurring O
in O
> O
= O
5 O
% O
of O
Patients O
with O
CKD O
Adverse O
Reaction O
Patients O
Treated O
w O
ith O
Aranesp O
( O
n O
= O
766 O
) O
Hypertension B-OSE_Labeled_AE
31 O
% O
Dyspnea B-OSE_Labeled_AE
17 O
% O
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
17 O
% O
Cough B-OSE_Labeled_AE
12 O
% O
Procedural B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
10 O
% O
Angina B-OSE_Labeled_AE
pectoris I-OSE_Labeled_AE
8 O
% O
Vascular B-OSE_Labeled_AE
access I-OSE_Labeled_AE
complications I-OSE_Labeled_AE
8 O
% O
Fluid B-OSE_Labeled_AE
overload I-OSE_Labeled_AE
7 O
% O
Rash B-OSE_Labeled_AE
/ O
Erythema B-OSE_Labeled_AE
5 O
% O
Arteriovenous B-OSE_Labeled_AE
graft I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
5 O
% O
Rates O
of O
adverse O
reactions O
with O
Aranesp O
therapy O
were O
similar O
to O
those O
observed O
with O
other O
recombinant O
erythropoietins O
in O
these O
studies O
. O

Pediatric O
Patients O
Adverse O
reactions O
were O
determined O
based O
on O
pooled O
data O
from O
2 O
randomized O
, O
controlled O
trials O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

In O
one O
study O
, O
Aranesp O
was O
administered O
to O
81 O
pediatric O
patients O
with O
CKD B-Not_AE_Candidate
who O
had O
stable O
hemoglobin O
concentrations O
while O
previously O
receiving O
epoetin O
alfa O
. O

In O
a O
second O
study O
, O
Aranesp O
was O
administered O
to O
114 O
anemic O
pediatric O
patients O
with O
CKD B-Not_AE_Candidate
receiving O
or O
not O
receiving O
dialysis O
for O
initial O
treatment O
of O
anemia B-Not_AE_Candidate
. O

In O
these O
studies O
, O
the O
most O
frequently O
reported O
serious O
adverse O
reactions O
with O
Aranesp O
were O
hypertension B-OSE_Labeled_AE
and O
convulsions B-OSE_Labeled_AE
. O

The O
most O
commonly O
reported O
adverse O
reactions O
were O
hypertension B-OSE_Labeled_AE
, O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
and O
convulsions B-OSE_Labeled_AE
. O

Aranesp O
administration O
was O
discontinued O
because O
of O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
in O
2 O
patients O
and O
hypertension B-OSE_Labeled_AE
in O
3 O
patients O
. O

Patients O
with O
Cancer O
Receiving O
Chemotherapy O
Adverse O
reactions O
were O
based O
on O
data O
from O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
of O
Aranesp O
in O
597 O
patients O
( O
Aranesp O
301 O
, O
placebo O
296 O
) O
with O
extensive O
stage O
small B-Not_AE_Candidate
cell I-Not_AE_Candidate
lung I-Not_AE_Candidate
cancer I-Not_AE_Candidate
( I-Not_AE_Candidate
SCLC I-Not_AE_Candidate
) O
receiving O
platinum-based O
chemotherapy O
. O

All O
patients O
were O
white O
, O
64 O
% O
were O
male O
, O
and O
the O
median O
age O
was O
61 O
years O
( O
range O
: O
28 O
to O
82 O
years O
) O
; O
25 O
% O
of O
the O
study O
population O
were O
from O
North O
America O
, O
Western O
Europe O
, O
and O
Australia O
. O

Patients O
received O
Aranesp O
at O
a O
dose O
of O
300 O
mcg O
or O
placebo O
weekly O
for O
4 O
weeks O
then O
every O
3 O
weeks O
for O
a O
total O
of O
24 O
weeks O
, O
and O
the O
median O
duration O
of O
exposure O
was O
19 O
weeks O
( O
range O
: O
1 O
to O
26 O
weeks O
) O
. O

Adverse O
reactions O
were O
also O
based O
on O
data O
from O
7 O
randomized O
, O
double-blind O
, O
placebo-controlled O
studies O
, O
including O
the O
SCLC O
study O
described O
above O
, O
that O
enrolled O
2112 O
patients O
( O
Aranesp O
1203 O
, O
placebo O
909 O
) O
with O
non B-Not_AE_Candidate
- I-Not_AE_Candidate
myeloid I-Not_AE_Candidate
malignancies I-Not_AE_Candidate
. O

Most O
patients O
were O
white O
( O
95 O
% O
) O
, O
male O
( O
52 O
% O
) O
, O
and O
the O
median O
age O
was O
63 O
years O
( O
range O
: O
18 O
to O
91 O
years O
) O
; O
73 O
% O
of O
the O
study O
population O
were O
from O
North O
America O
, O
Western O
Europe O
, O
and O
Australia O
. O

Dosing O
and O
schedules O
varied O
by O
study O
from O
once O
weekly O
to O
once O
every O
4 O
weeks O
, O
and O
the O
median O
duration O
of O
exposure O
was O
12 O
weeks O
( O
range O
: O
1 O
to O
27 O
weeks O
) O
. O

Table O
6 O
. O

Thrombovascular O
Adverse O
Reactions O
in O
Patients O
Receiving O
Chemotherapy O
SCLC O
Study O
All O
Placebo O
- O
controlled O
Studies O
Adverse O
Reaction O
Aranesp O
( O
n O
= O
301 O
) O
Placebo O
( O
n O
= O
296 O
) O
Aranesp O
( O
n O
= O
1203 O
) O
Placebo O
( O
n O
= O
909 O
) O
Thromboembolic B-OSE_Labeled_AE
Adverse I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
, O
n O
( O
% O
) O
24 O
( O
8.0 O
% O
) O
13 O
( O
4.4 O
% O
) O
73 O
( O
6.1 O
% O
) O
37 O
( O
4.1 O
% O
) O
Arterial O
10 O
( O
3.3 O
% O
) O
3 O
( O
1.0 O
% O
) O
15 O
( O
1.2 O
% O
) O
5 O
( O
0.6 O
% O
) O
Myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
5 O
( O
1.7 O
% O
) O
0 O
7 O
( O
0.6 O
% O
) O
2 O
( O
0.2 O
% O
) O
Venous O
14 O
( O
4.7 O
% O
) O
10 O
( O
3.4 O
% O
) O
60 O
( O
5.0 O
% O
) O
32 O
( O
3.5 O
% O
) O
Pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
5 O
( O
1.7 O
% O
) O
3 O
( O
1.0 O
% O
) O
16 O
( O
1.3 O
% O
) O
6 O
( O
0.7 O
% O
) O
Cerebrovascular B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
* I-OSE_Labeled_AE
14 O
( O
4.7 O
% O
) O
9 O
( O
3.0 O
% O
) O
20 O
( O
1.7 O
% O
) O
17 O
( O
1.9 O
% O
) O
* O
" B-OSE_Labeled_AE
Cerebrovascular I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
" I-OSE_Labeled_AE
encompasses O
CNS B-OSE_Labeled_AE
hemorrhages I-OSE_Labeled_AE
and O
cerebrovascular B-OSE_Labeled_AE
accidents I-OSE_Labeled_AE
( O
ischemic O
and O
hemorrhagic O
) O
. O

Events O
in O
this O
category O
may O
also O
be O
included O
under O
" B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O
'' O

In O
addition O
to O
the O
thrombovascular B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
and O
edema B-OSE_Labeled_AE
occurred O
at O
a O
higher O
incidence O
in O
patients O
taking O
Aranesp O
compared O
to O
patients O
on O
placebo O
. O

Among O
all O
placebo-controlled O
studies O
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
13.2 O
% O
vs O
. O
9.4 O
% O
) O
and O
edema B-OSE_Labeled_AE
( O
12.8 O
% O
vs O
. O
9.7 O
% O
) O
were O
reported O
more O
frequently O
in O
patients O
receiving O
Aranesp O
compared O
to O
the O
placebo O
group O
. O

In O
the O
SCLC B-Not_AE_Candidate
study O
the O
incidence O
of O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
10.3 O
% O
vs O
. O
3.4 O
% O
) O
and O
edema B-OSE_Labeled_AE
( O
5.6 O
% O
vs O
. O
5.1 O
% O
) O
in O
the O
Aranesp-treated O
patients O
compared O
to O
those O
receiving O
placebo O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
postmarketing O
use O
of O
Aranesp O
. O

Because O
postmarketing O
reporting O
of O
adverse O
reactions O
is O
voluntary O
and O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

* O
Seizures B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
PRCA B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Serious O
allergic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Severe O
Cutaneous B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
6.3 O
Immunogenicity O
As O
with O
all O
therapeutic O
proteins O
, O
there O
is O
a O
potential O
for O
immunogenicity B-OSE_Labeled_AE
. O

In O
clinical O
studies O
, O
the O
percentage O
of O
patients O
with O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
Aranesp I-OSE_Labeled_AE
was O
examined O
using O
the O
Biacore O
( O
r O
) O
assay O
. O

Sera O
from O
1501 O
patients O
with O
CKD B-Not_AE_Candidate
and O
1159 O
patients O
with O
cancer B-Not_AE_Candidate
were O
tested O
. O

At O
baseline O
, O
prior O
to O
Aranesp O
treatment O
, O
binding B-Not_AE_Candidate
antibodies I-Not_AE_Candidate
were I-Not_AE_Candidate
detected I-Not_AE_Candidate
in O
59 O
patients O
( O
4 O
% O
) O
with O
CKD B-Not_AE_Candidate
and O
36 O
patients O
with O
cancer B-Not_AE_Candidate
( O
3 O
% O
) O
. O

During O
Aranesp O
therapy O
( O
range O
: O
22 O
to O
177 O
weeks O
) O
, O
a O
follow-up O
sample O
was O
taken O
. O

One O
additional O
patient O
with O
CKD B-Not_AE_Candidate
and O
8 O
additional O
patients O
with O
cancer B-Not_AE_Candidate
developed O
antibodies B-OSE_Labeled_AE
capable I-OSE_Labeled_AE
of I-OSE_Labeled_AE
binding I-OSE_Labeled_AE
Aranesp I-OSE_Labeled_AE
. O

In O
two O
studies O
of O
pediatric O
patients O
with O
CKD B-Not_AE_Candidate
aged O
2-16 O
, O
20 O
of O
111 O
patients O
with O
CKD B-Not_AE_Candidate
( O
18 O
% O
) O
receiving O
dialysis O
and O
6 O
of O
69 O
patients O
( O
9 O
% O
) O
not O
receiving O
dialysis O
had O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
ESA I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
at O
baseline O
. O

During O
therapy O
, O
4 O
additional O
patients O
receiving O
dialysis O
and O
4 O
additional O
patients O
not O
receiving O
dialysis O
developed O
antibodies B-OSE_Labeled_AE
capable I-OSE_Labeled_AE
of I-OSE_Labeled_AE
binding I-OSE_Labeled_AE
Aranesp I-OSE_Labeled_AE
. O

None O
of O
the O
patients O
had O
antibodies B-NonOSE_AE
capable I-NonOSE_AE
of I-NonOSE_AE
neutralizing I-NonOSE_AE
the I-NonOSE_AE
activity I-NonOSE_AE
of I-NonOSE_AE
Aranesp I-NonOSE_AE
or O
endogenous O
erythropoietin O
at O
baseline O
or O
at O
end O
of O
study O
. O

No O
clinical O
sequelae O
consistent O
with O
PRCA B-NonOSE_AE
were O
associated O
with O
the O
presence B-NonOSE_AE
of I-NonOSE_AE
these O
antibodies I-NonOSE_AE
. O

The O
incidence O
of O
antibody B-NonOSE_AE
formation I-NonOSE_AE
is O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
. O

Additionally O
, O
the O
observed O
incidence O
of O
antibody B-NonOSE_AE
( O
including O
neutralizing O
a O
ntibody B-NonOSE_AE
) I-NonOSE_AE
positivity I-NonOSE_AE
  I-NonOSE_AE
I-NonOSE_AE O
in O
an O
assay O
may O
be O
influenced O
by O
several O
factors O
, O
including O
assay O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
Aranesp I-NonOSE_AE
with O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
other I-NonOSE_AE
products I-NonOSE_AE
may O
be O
misleading O
. O

Neutralizing B-NonOSE_AE
antibodies I-NonOSE_AE
to I-NonOSE_AE
darbepoetin I-NonOSE_AE
alfa I-NonOSE_AE
that I-NonOSE_AE
cross I-NonOSE_AE
- I-NonOSE_AE
react I-NonOSE_AE
with I-NonOSE_AE
endogenous I-NonOSE_AE
erythropoietin I-NonOSE_AE
and O
other O
ESAs O
can O
result O
in O
PRCA B-NonOSE_AE
or O
severe O
anemia B-NonOSE_AE
( O
with O
or O
without O
other O
cytopenias B-NonOSE_AE
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
. O

BOXED O
WARNING O
: O
WARNING O
: O
ESAs O
INCREASE O
THE O
RISK O
OF O
DEATH O
, O
MYOCARDIAL B-OSE_Labeled_AE
INFARCTION I-OSE_Labeled_AE
, O
STROKE O
, O
VENOUS B-OSE_Labeled_AE
THROMBOEMBOLISM I-OSE_Labeled_AE
, O
THROMBOSIS B-OSE_Labeled_AE
OF I-OSE_Labeled_AE
VASCULAR I-OSE_Labeled_AE
ACCESS I-OSE_Labeled_AE
ANDTUMOR O
PROGRESSION O
OR O
RECURRENCE O
WARNING O
: O
ESAs O
INCREASE O
THE O
RISK O
OF O
DEATH O
, O
MYOCARDIAL O
INFARCTION O
, O
STROKE O
, O
VENOUS O
THROMBOEMBOLISM O
, O
THROMBOSIS O
OF O
VASCULAR O
ACCESS O
AND O
TUMOR O
PROGRESSION O
OR O
RECURRENCE O
Chronic B-Not_AE_Candidate
Kidney I-Not_AE_Candidate
Disease I-Not_AE_Candidate
: O
* O
In O
controlled O
trials O
, O
patients O
experienced O
greater O
risks O
for O
death B-NonOSE_AE
, O
serious O
adverse B-OSE_Labeled_AE
cardiovascular I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
and O
stroke B-OSE_Labeled_AE
when O
administered O
erythropoiesis-stimulating O
agents O
( O
ESAs O
) O
to O
target O
a O
hemoglobin O
level O
of O
greater O
than O
11 O
g/dL O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
No O
trial O
has O
identified O
a O
hemoglobin O
target O
level O
, O
Aranesp O
dose O
, O
or O
dosing O
strategy O
that O
does O
not O
increase O
these O
risks O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

* O
Use O
the O
lowest O
Aranesp O
dose O
sufficient O
to O
reduce O
the O
need O
for O
red O
blood O
cell O
( O
RBC O
) O
transfusions O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Cancer B-Not_AE_Candidate
: O
* O
ESAs O
shortened O
overall O
survival O
and/or O
increased O
the O
risk O
of O
tumor B-OSE_Labeled_AE
progression I-OSE_Labeled_AE
or O
recurrence O
in O
clinical O
studies O
of O
patients O
with O
breast B-Not_AE_Candidate
, O
non-small O
cell O
lung O
, O
head O
and O
neck O
, O
lymphoid O
, O
and O
cervical O
cancers I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

* O
To O
decrease O
these O
risks O
, O
as O
well O
as O
the O
risk O
of O
serious O
cardiovascular B-NonOSE_AE
and O
thromboembolic O
reactions I-NonOSE_AE
, O
use O
the O
lowest O
dose O
needed O
to O
avoid O
RBC O
transfusions O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

* O
Use O
ESAs O
only O
for O
anemia B-Not_AE_Candidate
from I-Not_AE_Candidate
myelosuppressive I-Not_AE_Candidate
chemotherapy I-Not_AE_Candidate
[ O
see O
Indications O
and O
Usage O
( O
1.2 O
) O
] O
. O

* O
ESAs O
are O
not O
indicated O
for O
patients O
receiving O
myelosuppressive B-Not_AE_Candidate
chemotherapy I-Not_AE_Candidate
when O
the O
anticipated O
outcome O
is O
cure O
[ O
see O
Indications O
and O
Usage O
( O
1.3 O
) O
] O
. O

* O
Discontinue O
following O
the O
completion O
of O
a O
chemotherapy O
course O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
ESAs O
INCREASE O
THE O
RISK O
OF O
DEATH O
, O
MYOCARDIAL O
INFARCTION O
, O
STROKE O
, O
VENOUS O
THROMBOEMBOLISM O
, O
THROMBOSIS O
OF O
VASCULAR O
ACCESS O
AND O
TUMOR O
PROGRESSION O
OR O
RECURRENCE O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

Chronic O
Kidney O
Disease O
: O
* O
In O
controlled O
trials O
, O
patients O
experienced O
greater O
risks O
for O
death O
, O
serious O
adverse O
cardiovascular O
reactions O
, O
and O
stroke O
when O
administered O
erythropoiesis-stimulating O
agents O
( O
ESAs O
) O
to O
target O
a O
hemoglobin O
level O
of O
greater O
than O
11 O
g/dL O
( O
5.1 O
) O
. O

* O
No O
trial O
has O
identified O
a O
hemoglobin O
target O
level O
, O
Aranesp O
dose O
, O
or O
dosing O
strategy O
that O
does O
not O
increase O
these O
risks O
( O
2.2 O
) O
. O

* O
Use O
the O
lowest O
Aranesp O
dose O
sufficient O
to O
reduce O
the O
need O
for O
red O
blood O
cell O
( O
RBC O
) O
transfusions O
( O
5.1 O
) O
. O

Cancer O
: O
* O
ESAs O
shortened O
overall O
survival O
and/or O
increased O
the O
risk O
of O
tumor O
progression O
or O
recurrence O
in O
clinical O
studies O
of O
patients O
with O
breast O
, O
non-small O
cell O
lung O
, O
head O
and O
neck O
, O
lymphoid O
, O
and O
cervical O
cancers O
( O
5.2 O
) O
. O

* O
Use O
the O
lowest O
dose O
to O
avoid O
RBC O
transfusions O
( O
2.3 O
) O
. O

* O
Use O
ESAs O
only O
for O
anemia O
from O
myelosuppressive O
chemotherapy O
( O
1.2 O
) O
. O

* O
ESAs O
are O
not O
indicated O
for O
patients O
receiving O
myelosuppressive O
chemotherapy O
when O
the O
anticipated O
outcome O
is O
cure O
( O
1.3 O
) O
. O

* O
Discontinue O
following O
the O
completion O
of O
a O
chemotherapy O
course O
( O
2.3 O
) O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Increased O
Mortality O
, O
Myocardial O
Infarction O
, O
Stroke O
, O
and O
Thromboembolism O
: O
Using O
Aranesp O
to O
target O
a O
hemoglobin O
level O
of O
greater O
than O
11 O
g/dL O
increases O
the O
risk O
of O
serious O
adverse O
cardiovascular O
reactions O
and O
has O
not O
been O
shown O
to O
provide O
additional O
benefit O
( O
5.1 O
and O
14.1 O
) O
. O

Use O
caution O
in O
patients O
with O
coexistent O
cardiovascular O
disease O
and O
stroke O
( O
5.1 O
) O
. O

* O
Increased O
Mortality O
and/or O
Increased O
Risk O
of O
Tumor O
Progression O
or O
Recurrence O
in O
Patients O
with O
Cancer O
( O
5.2 O
) O
. O

* O
Hypertension O
: O
Control O
hypertension O
prior O
to O
initiating O
and O
during O
treatment O
with O
Aranesp O
( O
5.3 O
) O
. O

* O
Seizures O
: O
Aranesp O
increases O
the O
risk O
for O
seizures O
in O
patients O
with O
CKD O
( O
5.4 O
) O
.Increase O
monitoring O
of O
these O
patients O
for O
changes O
in O
seizure O
frequency O
or O
premonitory O
symptoms O
( O
5.4 O
) O
. O

* O
PRCA O
: O
If O
severe O
anemia O
and O
low O
reticulocyte O
count O
develop O
during O
Aranesp O
treatment O
, O
withhold O
Aranesp O
and O
evaluate O
for O
PRCA O
( O
5.6 O
) O
. O

* O
Serious O
Allergic O
Reactions O
: O
Discontinue O
Aranesp O
and O
manage O
reactions O
( O
5.7 O
) O
. O

* O
Severe O
Cutaneous O
Reactions O
: O
Discontinue O
Aranesp O
( O
5.8 O
) O
. O

5.1 O
Increased O
Mortality O
, O
Myocardial O
Infarction O
, O
Stroke O
, O
and O
Thromboembolism O
* O
In O
controlled O
clinical O
trials O
of O
patients O
with O
CKD B-Not_AE_Candidate
comparing O
higher O
hemoglobin O
targets O
( O
13 O
- O
14 O
g/dL O
) O
to O
lower O
targets O
( O
9 O
- O
11.3 O
g/dL O
) O
, O
Aranesp O
and O
other O
ESAs O
increased O
the O
risk O
of O
death B-NonOSE_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
stroke B-OSE_Labeled_AE
, O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
thrombosis B-OSE_Labeled_AE
of I-OSE_Labeled_AE
hemodialysis I-OSE_Labeled_AE
vascular I-OSE_Labeled_AE
access I-OSE_Labeled_AE
, O
and O
other O
thromboembolic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
in O
the O
higher O
target O
groups O
. O

* O
Using O
Aranesp O
to O
target O
a O
hemoglobin B-NonOSE_AE
level I-NonOSE_AE
of I-NonOSE_AE
greater I-NonOSE_AE
than I-NonOSE_AE
1 I-NonOSE_AE
1 I-NonOSE_AE
g I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
increases O
the O
risk O
of O
serious O
adverse B-NonOSE_AE
cardiovascular I-NonOSE_AE
reactions I-NonOSE_AE
and O
has O
not O
been O
shown O
to O
provide O
additional O
benefit O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

Use O
caution O
in O
patients O
with O
coexistent O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
and O
stroke B-Not_AE_Candidate
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

Patients O
with O
CKD B-Not_AE_Candidate
and O
an O
insufficient O
hemoglobin O
response O
to O
ESA O
therapy O
may O
be O
at O
even O
greater O
risk O
for O
cardiovascular B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
and O
mortality B-NonOSE_AE
than O
other O
patients O
. O

A O
rate O
of O
hemoglobin B-NonOSE_AE
rise I-NonOSE_AE
of I-NonOSE_AE
greater I-NonOSE_AE
than I-NonOSE_AE
1 I-NonOSE_AE
g I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
over I-NonOSE_AE
2 I-NonOSE_AE
weeks I-NonOSE_AE
may O
contribute O
to O
these O
risks O
. O

* O
In O
controlled O
clinical O
trials O
of O
patients O
with O
cancer B-Not_AE_Candidate
, O
Aranesp O
and O
other O
ESAs O
increased O
the O
risks O
for O
death B-NonOSE_AE
and O
serious O
adverse B-OSE_Labeled_AE
cardiovascular I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

These O
adverse O
reactions O
included O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
and O
stroke B-OSE_Labeled_AE
. O

* O
In O
controlled O
clinical O
trials O
, O
ESAs O
increased O
the O
risk O
of O
death B-NonOSE_AE
in O
patients O
undergoing O
coronary O
artery O
bypass O
graft O
surgery O
( O
CABG O
) O
and O
the O
risk O
of O
deep B-OSE_Labeled_AE
venous I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
( O
DVT O
) O
in O
patients O
undergoing O
orthopedic O
procedures O
. O

The O
design O
and O
overall O
results O
of O
the O
3 O
large O
trials O
comparing O
higher B-NonOSE_AE
and I-NonOSE_AE
lower I-NonOSE_AE
hemoglobin I-NonOSE_AE
targets I-NonOSE_AE
are O
shown O
in O
Table O
3 O
. O

Table O
3 O
: O
Randomized O
Controlled O
Trials O
Showing O
Adverse O
Cardiovascular O
Outcomes O
in O
Patients O
with O
CKD O
Normal O
Hematocrit O
Study O
( O
NHS O
) O
( O
N O
= O
12 O
65 O
) O
CHOIR O
( O
N O
= O
1432 O
) O
TREAT O
( O
N O
= O
4038 O
) O
Time O
Period O
of O
Trial O
1993 O
to O
1996 O
2003 O
to O
2006 O
2004 O
to O
2009 O
Population O
Adult O
patients O
with O
CKD O
on O
hemodialysis O
with O
coexisting O
CHF O
or O
CAD O
, O
hematocrit O
30 O
+/- O
3 O
% O
on O
epoetin O
alfa O
Adult O
patients O
with O
CKD O
not O
on O
dialysis O
with O
hemoglobin O
< O
11 O
g/dL O
not O
previously O
administered O
epoetin O
alfa O
Adult O
patients O
with O
CKD O
not O
on O
dialysis O
with O
type O
II O
diabetes O
, O
hemoglobin O
< O
= O
11 O
g/dL O
Hemoglobin O
Target O
; O
Higher O
vs O
. O
Lower O
( O
g/dL O
) O
14.0 O
vs O
. O
10.0 O
13.5 O
vs O
. O
11.3 O
13.0 O
vs O
. O
> O
= O
9.0 O
Median O
( O
Q1 O
, O
Q3 O
) O
Achieved O
Hemoglobin O
level O
( O
g/dL O
) O
12.6 O
( O
11.6 O
, O
13.3 O
) O
vs O
. O
10.3 O
( O
10.0 O
, O
10.7 O
) O
13.0 O
( O
12.2 O
, O
13.4 O
) O
vs O
. O
11.4 O
( O
11.1 O
, O
11.6 O
) O
12.5 O
( O
12.0 O
, O
12.8 O
) O
vs O
. O
10.6 O
( O
9.9 O
, O
11.3 O
) O
Primary O
Endpoint O
All-cause O
mortality O
or O
non-fatal O
MI O
All-cause O
mortality O
, O
MI O
, O
hospitalization O
for O
CHF O
, O
or O
stroke O
All-cause O
mortality O
, O
MI O
, O
myocardial O
ischemia O
, O
heart O
failure O
, O
and O
stroke O
Hazard O
Ratio O
or O
Relative O
Risk O
( O
95 O
% O
CI O
) O
1.28 O
( O
1.06 O
- O
1.56 O
) O
1.34 O
( O
1.03 O
- O
1.74 O
) O
1.05 O
( O
0.94 O
- O
1.17 O
) O
Adverse O
Outcome O
for O
Higher O
Target O
Group O
All-cause O
mortality O
All-cause O
mortality O
Stroke O
Hazard O
Ratio O
or O
Relative O
Risk O
( O
95 O
% O
CI O
) O
1.27 O
( O
1.04 O
- O
1.54 O
) O
1.48 O
( O
0.97 O
- O
2.27 O
) O
1.92 O
( O
1.38 O
- O
2.68 O
) O
Patients O
with O
Chronic O
Kidney O
Disease O
Normal O
Hematocrit O
Study O
( O
NHS O
) O
: O
A O
prospective O
, O
randomized O
, O
open-label O
study O
of O
1265 O
patients O
with O
chronic B-Not_AE_Candidate
kidney I-Not_AE_Candidate
disease I-Not_AE_Candidate
on O
dialysis O
with O
documented O
evidence O
of O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
or O
ischemic B-Not_AE_Candidate
heart I-Not_AE_Candidate
disease I-Not_AE_Candidate
was O
designed O
to O
test O
the O
hypothesis O
that O
a O
higher O
target O
hematocrit O
( O
Hct O
) O
would O
result O
in O
improved O
outcomes O
compared O
with O
a O
lower O
target O
Hct O
. O

In O
this O
study O
, O
patients O
were O
randomized O
to O
epoetin O
alfa O
treatment O
targeted O
to O
a O
maintenance O
hemoglobin O
of O
either O
14 O
+/- O
1 O
g/dL O
or O
10 O
+/- O
1 O
g/dL O
. O

The O
trial O
was O
terminated O
early O
with O
adverse O
safety O
findings O
of O
higher O
mortality B-NonOSE_AE
in O
the O
high O
hematocrit O
target O
group O
. O

Higher O
mortality B-NonOSE_AE
( O
35 O
% O
vs O
. O
29 O
% O
) O
was O
observed O
for O
the O
patients O
randomized O
to O
a O
target O
hemoglobin O
of O
14 O
g/dL O
than O
for O
the O
patients O
randomized O
to O
a O
target O
hemoglobin O
of O
10 O
g/dL O
. O

For O
all-cause O
mortality B-NonOSE_AE
, O
the O
HR O
= O
1.27 O
; O
95 O
% O
CI O
( O
1.04 O
, O
1.54 O
) O
; O
p=0.018 O
. O

The O
incidence O
of O
nonfatal B-NonOSE_AE
myocardial B-NonOSE_AE
infarction I-NonOSE_AE
, O
vascular B-NonOSE_AE
access I-NonOSE_AE
thrombosis I-NonOSE_AE
, O
and O
other O
thrombotic B-NonOSE_AE
events I-NonOSE_AE
was O
also O
higher O
in O
the O
group O
randomized O
to O
a O
target O
hemoglobin O
of O
14 O
g/dL O
. O

CHOIR O
: O
A O
randomized O
, O
prospective O
trial O
, O
1432 O
patients O
with O
anemia B-Not_AE_Candidate
due I-Not_AE_Candidate
to I-Not_AE_Candidate
CKD I-Not_AE_Candidate
who O
were O
not O
undergoing O
dialysis O
and O
who O
had O
not O
previously O
received O
epoetin O
alfa O
therapy O
were O
randomized O
to O
epoetin O
alfa O
treatment O
targeting O
a O
maintenance O
hemoglobin O
concentration O
of O
either O
13.5 O
g/dL O
or O
11.3 O
g/dL O
. O

The O
trial O
was O
terminated O
early O
with O
adverse O
safety O
findings O
. O

A O
major B-NonOSE_AE
cardiovascular I-NonOSE_AE
event I-NonOSE_AE
( O
death B-NonOSE_AE
, O
myocardial B-NonOSE_AE
infarction I-NonOSE_AE
, O
stroke B-NonOSE_AE
, O
or O
hospitalization O
for O
congestive B-NonOSE_AE
heart I-NonOSE_AE
failure I-NonOSE_AE
) O
occurred O
in O
125 O
of O
the O
715 O
patients O
( O
18 O
% O
) O
in O
the O
higher O
hemoglobin O
group O
compared O
to O
97 O
of O
the O
717 O
patients O
( O
14 O
% O
) O
in O
the O
lower O
hemoglobin O
group O
[ O
hazard O
ratio O
( O
HR O
) O
1.34 O
, O
95 O
% O
CI O
: O
1.03 O
, O
1.74 O
; O
p O
= O
0.03 O
] O
. O

TREAT O
: O
A O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
prospective O
trial O
of O
4038 O
patients O
with O
CKD B-Not_AE_Candidate
not O
on O
dialysis O
( O
eGFR O
of O
20 O
- O
60 O
mL/min O
) O
, O
anemia B-Not_AE_Candidate
( O
hemoglobin B-NonOSE_AE
levels I-NonOSE_AE
< I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
1 I-NonOSE_AE
g I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
) O
, O
and O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
, O
patients O
were O
randomized O
to O
receive O
either O
Aranesp O
treatment O
or O
a O
matching O
placebo O
. O

Placebo O
group O
patients O
also O
received O
Aranesp O
when O
their O
hemoglobin O
levels O
were O
below O
9 O
g/dL O
. O

The O
trial O
objectives O
were O
to O
demonstrate O
the O
benefit O
of O
Aranesp O
treatment O
of O
the O
anemia B-Not_AE_Candidate
to O
a O
target O
hemoglobin O
level O
of O
13 O
g/dL O
, O
when O
compared O
to O
a O
`` O
placebo O
'' O
group O
, O
by O
reducing O
the O
occurrence O
of O
either O
of O
two O
primary O
endpoints O
: O
( O
1 O
) O
a O
composite O
cardiovascular O
endpoint O
of O
all-cause O
mortality B-NonOSE_AE
or O
a O
specified O
cardiovascular B-NonOSE_AE
event I-NonOSE_AE
( O
myocardial B-NonOSE_AE
ischemia I-NonOSE_AE
, O
CHF B-NonOSE_AE
, O
MI B-NonOSE_AE
, O
and O
CVA B-NonOSE_AE
) O
or O
( O
2 O
) O
a O
composite O
renal O
endpoint O
of O
all-cause O
mortality B-NonOSE_AE
or O
progression O
to O
end B-NonOSE_AE
stage I-NonOSE_AE
renal I-NonOSE_AE
disease I-NonOSE_AE
. O

The O
overall O
risks O
for O
each O
of O
the O
two O
primary O
endpoints O
( O
the O
cardiovascular O
composite O
and O
the O
renal O
composite O
) O
were O
not O
reduced O
with O
Aranesp O
treatment O
( O
see O
Table3 O
) O
, O
but O
the O
risk O
of O
stroke B-NonOSE_AE
was O
increased O
nearly O
two-fold O
in O
the O
Aranesp-treated O
group O
versus O
the O
placebo O
group O
: O
annualized O
stroke B-NonOSE_AE
rate O
2.1 O
% O
vs O
. O
1.1 O
% O
, O
respectively O
, O
HR O
1.92 O
; O
95 O
% O
CI O
: O
1.38 O
, O
2.68 O
; O
p O
< O
0.001 O
. O

The O
relative O
risk O
of O
stroke B-NonOSE_AE
was O
particularly O
high O
in O
patients O
with O
a O
prior O
stroke B-Not_AE_Candidate
: O
annualized O
stroke B-NonOSE_AE
rate O
5.2 O
% O
in O
the O
Aranesp O
treated O
group O
and O
1.9 O
% O
in O
the O
placebo O
group O
, O
HR O
3.07 O
; O
95 O
% O
CI O
: O
1.44 O
, O
6.54 O
. O

Also O
, O
among O
Aranesp-treated O
subjects O
with O
a O
past O
history O
of O
cancer B-Not_AE_Candidate
, O
there O
were O
more O
deaths B-NonOSE_AE
due O
to O
all O
causes O
and O
more O
deaths B-NonOSE_AE
adjudicated O
as O
due O
to O
cancer B-NonOSE_AE
, O
in O
comparison O
with O
the O
control O
group O
. O

Patients O
with O
Cancer O
An O
increased O
incidence O
of O
thromboembolic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
some O
serious O
and O
life-threatening O
, O
occurred O
in O
patients O
with O
cancer B-Not_AE_Candidate
treated O
with O
ESAs O
. O

In O
a O
randomized O
, O
placebo-controlled O
study O
( O
Study O
2 O
in O
Table O
4 O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
) O
of O
939 O
women O
with O
metastatic B-Not_AE_Candidate
breast I-Not_AE_Candidate
cancer I-Not_AE_Candidate
receiving O
chemotherapy O
, O
patients O
received O
either O
weekly O
epoetin O
alfa O
or O
placebo O
for O
up O
to O
a O
year O
. O

This O
study O
was O
designed O
to O
show O
that O
survival O
was O
superior O
when O
epoetin O
alfa O
was O
administered O
to O
prevent O
anemia B-NonOSE_AE
( O
maintain O
hemoglobin O
levels O
between O
12 O
and O
14 O
g/dL O
or O
hematocrit O
between O
36 O
% O
and O
42 O
% O
) O
. O

This O
study O
was O
terminated O
prematurely O
when O
interim O
results O
demonstrated O
a O
higher O
mortality B-NonOSE_AE
at O
4 O
months O
( O
8.7 O
% O
vs O
. O
3.4 O
% O
) O
and O
a O
higher O
rate O
of O
fatal B-NonOSE_AE
thrombotic B-NonOSE_AE
reactions I-NonOSE_AE
( O
1.1 O
% O
vs O
. O
0.2 O
% O
) O
in O
the O
first O
4 O
months O
of O
the O
study O
among O
patients O
treated O
with O
epoetin O
alfa O
. O

Based O
on O
Kaplan-Meier O
estimates O
, O
at O
the O
time O
of O
study O
termination O
, O
the O
12-month O
survival O
was O
lower O
in O
the O
epoetin O
alfa O
group O
than O
in O
the O
placebo O
group O
( O
70 O
% O
vs O
. O
76 O
% O
; O
HR O
1.37 O
, O
95 O
% O
CI O
: O
1.07 O
, O
1.75 O
; O
p O
= O
0.012 O
) O
. O

Patients O
Having O
Surgery O
Aranesp O
is O
not O
approved O
for O
reduction O
of O
RBC O
transfusions O
in O
patients O
scheduled O
for O
surgical O
procedures O
. O

An O
increased O
incidence O
of O
DVT B-OSE_Labeled_AE
in O
patients O
receiving O
epoetin O
alfa O
undergoing O
surgical O
orthopedic O
procedures O
was O
demonstrated O
. O

In O
a O
randomized O
, O
controlled O
study O
, O
680 O
adult O
patients O
, O
not O
receiving O
prophylactic O
anticoagulation O
and O
undergoing O
spinal O
surgery O
, O
received O
epoetin O
alfa O
and O
standard O
of O
care O
( O
SOC O
) O
treatment O
( O
n O
= O
340 O
) O
or O
SOC O
treatment O
alone O
( O
n O
= O
340 O
) O
. O

A O
higher O
incidence O
of O
DVTs B-OSE_Labeled_AE
, O
determined O
by O
either O
color O
flow O
duplex O
imaging O
or O
by O
clinical O
symptoms O
, O
was O
observed O
in O
the O
epoetin O
alfa O
group O
( O
16 O
[ O
4.7 O
% O
] O
patients O
) O
compared O
with O
the O
SOC O
group O
( O
7 O
[ O
2.1 O
% O
] O
patients O
) O
. O

In O
addition O
to O
the O
23 O
patients O
with O
DVTs B-OSE_Labeled_AE
included O
in O
the O
primary O
analysis O
, O
19 O
[ O
2.8 O
% O
] O
patients O
experienced O
1 O
other O
thrombovascular B-OSE_Labeled_AE
event I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TVE I-OSE_Labeled_AE
) O
each O
( O
12 O
[ O
3.5 O
% O
] O
in O
the O
epoetin O
alfa O
group O
and O
7 O
[ O
2.1 O
% O
] O
in O
the O
SOC O
group O
) O
. O

Increased O
mortality B-NonOSE_AE
was O
observed O
in O
a O
randomized O
, O
placebo-controlled O
study O
of O
epoetin O
alfa O
in O
adult O
patients O
who O
were O
undergoing O
CABG O
surgery O
( O
7 O
deaths B-NonOSE_AE
in O
126 O
patients O
randomized O
to O
epoetin O
alfa O
versus O
no O
deaths B-NonOSE_AE
among O
56 O
patients O
receiving O
placebo O
) O
. O

Four O
of O
these O
deaths B-NonOSE_AE
occurred O
during O
the O
period O
of O
study O
drug O
administration O
and O
all O
4 O
deaths B-NonOSE_AE
were O
associated O
with O
thrombotic B-NonOSE_AE
events I-NonOSE_AE
. O

5.2 O
Increased O
Mortality O
and/or O
Increased O
Risk O
of O
Tumor B-OSE_Labeled_AE
Progression I-OSE_Labeled_AE
or O
Recurrence O
in O
Patients O
with O
Cancer O
ESAs O
resulted O
in O
decreased O
locoregional O
control/progression-free O
survival O
( O
PFS O
) O
and/or O
overall O
survival O
( O
OS O
) O
( O
see O
Table O
4 O
) O
. O

Adverse O
effects O
on O
PFS O
and/or O
OS O
were O
observed O
in O
studies O
of O
patients O
receiving O
chemotherapy O
for O
breast B-Not_AE_Candidate
cancer I-Not_AE_Candidate
( O
Studies O
1 O
, O
2 O
, O
and O
4 O
) O
, O
lymphoid B-Not_AE_Candidate
malignancy I-Not_AE_Candidate
( O
Study O
3 O
) O
, O
and O
cervical B-Not_AE_Candidate
cancer I-Not_AE_Candidate
( O
Study O
5 O
) O
; O
in O
patients O
with O
advanced O
head B-Not_AE_Candidate
and I-Not_AE_Candidate
neck I-Not_AE_Candidate
cancer I-Not_AE_Candidate
receiving O
radiation O
therapy O
( O
Studies O
6 O
and O
7 O
) O
, O
and O
in O
patients O
with O
non B-Not_AE_Candidate
- I-Not_AE_Candidate
small I-Not_AE_Candidate
cell I-Not_AE_Candidate
lung I-Not_AE_Candidate
cancer I-Not_AE_Candidate
or O
various O
malignancies O
who O
were O
not O
receiving O
chemotherapy O
or O
radiotherapy O
( O
Studies O
8 O
and O
9 O
) O
. O

Table O
4 O
. O

Randomized O
, O
Controlled O
Studies O
with O
Decreased O
Survival O
and/or O
Decreased O
Locoregional O
Control O
Study/Tumor/ O
( O
n O
) O
Hemoglobin O
Target O
Hemoglobin O
( O
Median O
; O
Q1 O
, O
Q3* O
) O
Primary O
Efficacy O
Outcome O
Adverse O
Outcome O
for O
ESA O
- O
containing O
Arm O
Chemotherapy O
Study O
1 O
Metastatic B-Not_AE_Candidate
breast I-Not_AE_Candidate
cancer I-Not_AE_Candidate
( O
n O
= O
2098 O
) O
< O
=12 O
g/dL O
11.6 O
g/dL O
; O
10.7 O
, O
12.1 O
g/dL O
Progression-freesurvival O
( O
PFS O
) O
Decreased O
progression-free O
and O
overall O
survival O
Study O
2 O
Metastatic B-Not_AE_Candidate
breast I-Not_AE_Candidate
cancer I-Not_AE_Candidate
( O
n O
= O
939 O
) O
12-14 O
g/dL O
12.9 O
g/dL O
; O
12.2 O
, O
13.3 O
g/dL O
12-month O
overall O
survival O
Decreased O
12-month O
survival O
Study O
3 O
Lymphoid B-Not_AE_Candidate
malignancy I-Not_AE_Candidate
( O
n O
= O
344 O
) O
13-15 O
g/dL O
( O
M O
) O
13-14 O
g/dL O
( O
F O
) O
11 O
g/dL O
; O
9.8 O
, O
12.1 O
g/dL O
Proportion O
of O
patients O
achieving O
a O
hemoglobin O
response O
Decreased O
overall O
survival O
Study O
4 O
Early O
breast B-Not_AE_Candidate
cancer I-Not_AE_Candidate
( O
n O
= O
733 O
) O
12.5-13 O
g/dL O
13.1 O
g/dL O
; O
12.5 O
, O
13.7 O
g/dL O
Relapse-free O
and O
overall O
survival O
Decreased O
3-year O
relapse-free O
and O
overall O
survival O
Study O
5 O
Cervical B-Not_AE_Candidate
cancer I-Not_AE_Candidate
( O
n O
= O
114 O
) O
12-14 O
g/dL O
12.7 O
g/dL O
; O
12.1 O
, O
13.3 O
g/dL O
Progression-free O
and O
overall O
survival O
and O
locoregional O
control O
Decreased O
3-year O
progression-free O
and O
overall O
survival O
and O
locoregional O
control O
Radiotherapy O
Alone O
Study O
6 O
Head B-Not_AE_Candidate
and I-Not_AE_Candidate
neck I-Not_AE_Candidate
cancer I-Not_AE_Candidate
( O
n O
= O
351 O
) O
> O
= O
15 O
g/dL O
( O
M O
) O
> O
= O
14 O
g/dL O
( O
F O
) O
Not O
available O
Locoregional O
progression-free O
survival O
Decreased O
5-year O
locoregional O
progression-free O
and O
overall O
survival O
Study O
7 O
Head B-Not_AE_Candidate
and I-Not_AE_Candidate
neck I-Not_AE_Candidate
cancer I-Not_AE_Candidate
( O
n O
= O
522 O
) O
14-15.5 O
g/dL O
Not O
available O
Locoregional O
disease O
control O
Decreased O
locoregional O
disease O
control O
No O
Chemotherapy O
or O
Radiotherapy O
Study O
8 O
Non B-Not_AE_Candidate
- I-Not_AE_Candidate
small I-Not_AE_Candidate
cell I-Not_AE_Candidate
lung I-Not_AE_Candidate
cancer I-Not_AE_Candidate
( O
n O
= O
70 O
) O
12-14 O
g/dL O
Not O
available O
Quality O
of O
life O
Decreased O
overall O
survival O
Study O
9 O
Non B-Not_AE_Candidate
- I-Not_AE_Candidate
myeloid I-Not_AE_Candidate
malignancy I-Not_AE_Candidate
( O
n O
= O
989 O
) O
12-13 O
g/dL O
10.6 O
g/dL O
; O
9.4 O
, O
11.8 O
g/dL O
RBC O
transfusions O
Decreased O
overall O
survival O
*Q1 O
= O
25th O
percentile O
Q3 O
= O
75th O
percentile O
This O
study O
did O
not O
include O
a O
defined O
hemoglobin O
target O
. O

Doses O
were O
titrated O
to O
achieve O
and O
maintain O
the O
lowest O
hemoglobin O
level O
sufficient O
to O
avoid O
transfusion O
and O
not O
to O
exceed O
12 O
g/dL O
. O

Decreased O
Overall O
Survival O
Study O
2 O
was O
described O
in O
the O
previous O
section O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Mortality B-NonOSE_AE
at O
4 O
months O
( O
8.7 O
% O
vs O
. O
3.4 O
% O
) O
was O
significantly O
higher O
in O
the O
epoetin O
alfa O
arm O
. O

The O
most O
common O
investigator-attributed O
cause O
of O
death B-NonOSE_AE
within O
the O
first O
4 O
months O
was O
disease O
progression O
; O
28 O
of O
41 O
deaths B-NonOSE_AE
in O
the O
epoetin O
alfa O
arm O
and O
13 O
of O
16 O
deaths B-NonOSE_AE
in O
the O
placebo O
arm O
were O
attributed O
to O
disease O
progression O
. O

Investigator-assessed O
time O
to O
tumor B-NonOSE_AE
progression I-NonOSE_AE
was O
not O
different O
between O
the O
2 O
groups O
. O

Survival O
at O
12 O
months O
was O
significantly O
lower O
in O
the O
epoetin O
alfa O
arm O
( O
70 O
% O
vs O
. O
76 O
% O
; O
HR O
1.37 O
, O
95 O
% O
CI O
: O
1.07 O
, O
1.75 O
; O
p O
= O
0.012 O
) O
. O

Study O
3 O
was O
a O
randomized O
, O
double-blind O
study O
( O
darbepoetin O
alfa O
vs O
. O
placebo O
) O
conducted O
in O
344 O
anemic B-Not_AE_Candidate
patients O
with O
lymphoid B-Not_AE_Candidate
malignancy I-Not_AE_Candidate
receiving O
chemotherapy O
. O

With O
a O
median O
follow-up O
of O
29 O
months O
, O
overall O
mortality B-NonOSE_AE
rates O
were O
significantly O
higher O
among O
patients O
randomized O
to O
darbepoetin O
alfa O
as O
compared O
to O
placebo O
( O
HR O
1.36 O
, O
95 O
% O
CI O
: O
1.02 O
, O
1.82 O
) O
. O

Study O
8 O
was O
a O
multicenter O
, O
randomized O
, O
double-blind O
study O
( O
epoetin O
alfa O
vs O
. O
placebo O
) O
in O
which O
patients O
with O
advanced B-Not_AE_Candidate
non I-Not_AE_Candidate
- I-Not_AE_Candidate
small I-Not_AE_Candidate
cell I-Not_AE_Candidate
lung I-Not_AE_Candidate
cancer I-Not_AE_Candidate
receiving O
only O
palliative O
radiotherapy O
or O
no O
active O
therapy O
were O
treated O
with O
epoetin O
alfa O
to O
achieve O
and O
maintain O
hemoglobin O
levels O
between O
12 O
and O
14 O
g/dL O
. O

Following O
an O
interim O
analysis O
of O
70 O
patients O
( O
planned O
accrual O
300 O
patients O
) O
, O
a O
significant O
difference O
in O
survival O
in O
favor O
of O
the O
patients O
in O
the O
placebo O
arm O
of O
the O
study O
was O
observed O
( O
median O
survival O
63 O
vs O
. O
129 O
days O
; O
HR O
1.84 O
; O
p O
= O
0.04 O
) O
. O

Study O
9 O
was O
a O
randomized O
, O
double-blind O
study O
( O
darbepoetin O
alfa O
vs O
. O
placebo O
) O
in O
989 O
anemic B-Not_AE_Candidate
patients O
with O
active B-Not_AE_Candidate
malignant I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
neither O
receiving O
nor O
planning O
to O
receive O
chemotherapy O
or O
radiation O
therapy O
. O

There O
was O
no O
evidence O
of O
a O
statistically O
significant O
reduction O
in O
proportion O
of O
patients O
receiving O
RBC O
transfusions O
. O

The O
median O
survival O
was O
shorter O
in O
the O
darbepoetin O
alfa O
treatment O
group O
than O
in O
the O
placebo O
group O
( O
8 O
months O
vs O
. O
10.8 O
months O
; O
HR O
1.30 O
, O
95 O
% O
CI O
: O
1.07 O
, O
1.57 O
) O
. O

Decreased O
Progression O
- O
free O
Survival O
and O
Overall O
Survival O
Study O
1 O
was O
a O
randomized O
, O
open-label O
, O
multicenter O
study O
in O
2,098 O
anemic B-Not_AE_Candidate
women O
with O
metastatic B-Not_AE_Candidate
breast I-Not_AE_Candidate
cancer I-Not_AE_Candidate
, O
who O
received O
first O
line O
or O
second O
line O
chemotherapy O
. O

This O
was O
a O
non O
inferiority O
study O
designed O
to O
rule O
out O
a O
15 O
% O
risk O
increase O
in O
tumor B-NonOSE_AE
progression I-NonOSE_AE
or O
death B-NonOSE_AE
of O
epoetin O
alfa O
plus O
standard O
of O
care O
( O
SOC O
) O
as O
compared O
with O
SOC O
alone O
. O

The O
median O
progression O
free O
survival O
( O
PFS O
) O
per O
investigator O
assessment O
of O
disease O
progression O
was O
7.4 O
months O
in O
each O
arm O
( O
HR O
1.09 O
, O
95 O
% O
CI O
: O
0.99 O
, O
1.20 O
) O
, O
indicating O
the O
study O
objective O
was O
not O
met O
. O

At O
the O
time O
of O
clinical O
data O
cutoff O
, O
1337 O
deaths B-NonOSE_AE
were O
reported O
. O

Median O
overall O
survival O
in O
the O
epoetin O
alfa O
plus O
SOC O
group O
was O
17.2 O
months O
compared O
with O
17.4 O
months O
in O
the O
SOC O
alone O
group O
( O
HR O
1.06 O
, O
95 O
% O
CI O
: O
0.95 O
, O
1.18 O
) O
. O

There O
were O
more O
deaths B-NonOSE_AE
from O
disease O
progression O
in O
the O
epoetin O
alfa O
plus O
SOC O
arm O
( O
59 O
% O
vs O
. O
56 O
% O
) O
and O
more O
thrombotic B-OSE_Labeled_AE
vascular I-OSE_Labeled_AE
events I-OSE_Labeled_AE
in O
the O
epoetin O
alfa O
plus O
SOC O
arm O
( O
3 O
% O
vs O
. O
1 O
% O
) O
. O

Study O
4 O
was O
a O
randomized O
, O
open-label O
, O
controlled O
, O
factorial O
design O
study O
in O
which O
darbepoetin O
alfa O
was O
administered O
to O
prevent O
anemia B-Not_AE_Candidate
in O
733 O
women O
receiving O
neo-adjuvant O
breast B-Not_AE_Candidate
cancer I-Not_AE_Candidate
treatment O
. O

A O
final O
analysis O
was O
performed O
after O
a O
median O
follow-up O
of O
approximately O
3 O
years O
. O

The O
3-year O
survival O
rate O
was O
lower O
( O
86 O
% O
vs O
. O
90 O
% O
; O
HR O
1.42 O
, O
95 O
% O
CI O
: O
0.93 O
, O
2.18 O
) O
and O
the O
3-year O
relapse-free O
survival O
rate O
was O
lower O
( O
72 O
% O
vs O
. O
78 O
% O
; O
HR O
1.33 O
, O
95 O
% O
CI O
: O
0.99 O
, O
1.79 O
) O
in O
the O
darbepoetin O
alfa-treated O
arm O
compared O
to O
the O
control O
arm O
. O

Study O
5 O
was O
a O
randomized O
, O
open-label O
, O
controlled O
study O
that O
enrolled O
114 O
of O
a O
planned O
460 O
patients O
with O
cervical B-Not_AE_Candidate
cancer I-Not_AE_Candidate
receiving O
chemotherapy O
and O
radiotherapy O
. O

Patients O
were O
randomized O
to O
receive O
epoetin O
alfa O
to O
maintain O
hemoglobin O
between O
12 O
and O
14 O
g/dL O
or O
to O
RBC O
transfusion O
support O
as O
needed O
. O

The O
study O
was O
terminated O
prematurely O
due O
to O
an O
increase O
in O
thromboembolic B-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
in O
epoetin O
alfa-treated O
patients O
compared O
to O
control O
( O
19 O
% O
vs O
. O
9 O
% O
) O
. O

Both O
local O
recurrence O
( O
21 O
% O
vs O
. O
20 O
% O
) O
and O
distant O
recurrence O
( O
12 O
% O
vs O
. O
7 O
% O
) O
were O
more O
frequent O
in O
epoetin O
alfa-treated O
patients O
compared O
to O
control O
. O

Progression-free O
survival O
at O
3 O
years O
was O
lower O
in O
the O
epoetin O
alfa-treated O
group O
compared O
to O
control O
( O
59 O
% O
vs O
. O
62 O
% O
; O
HR O
1.06 O
, O
95 O
% O
CI O
: O
0.58 O
, O
1.91 O
) O
. O

Overall O
survival O
at O
3 O
years O
was O
lower O
in O
the O
epoetin O
alfa-treated O
group O
compared O
to O
control O
( O
61 O
% O
vs O
. O
71 O
% O
; O
HR O
1.28 O
, O
95 O
% O
CI O
: O
0.68 O
, O
2.42 O
) O
. O

Study O
6 O
was O
a O
randomized O
, O
placebo-controlled O
study O
in O
351 O
patients O
with O
head B-Not_AE_Candidate
and I-Not_AE_Candidate
neck I-Not_AE_Candidate
cancer I-Not_AE_Candidate
where O
epoetin O
beta O
or O
placebo O
was O
administered O
to O
achieve O
target O
hemoglobins O
> O
= O
14 O
and O
> O
= O
15 O
g/dL O
for O
women O
and O
men O
, O
respectively O
. O

Locoregional O
progression-free O
survival O
was O
significantly O
shorter O
in O
patients O
receiving O
epoetin O
beta O
( O
HR O
1.62 O
, O
95 O
% O
CI O
: O
1.22 O
, O
2.14 O
; O
p O
= O
0.0008 O
) O
with O
medians O
of O
406 O
days O
and O
745 O
days O
in O
the O
epoetin O
beta O
and O
placebo O
arms O
respectively O
. O

Overall O
survival O
was O
significantly O
shorter O
in O
patients O
receiving O
epoetin O
beta O
( O
HR O
1.39 O
, O
95 O
% O
CI O
: O
1.05 O
, O
1.84 O
; O
p O
= O
0.02 O
) O
. O

Decreased O
Locoregional O
C O
ontrol O
Study O
7 O
was O
a O
randomized O
, O
open-label O
, O
controlled O
study O
conducted O
in O
522 O
patients O
with O
primary B-Not_AE_Candidate
squamous I-Not_AE_Candidate
cell I-Not_AE_Candidate
carcinoma I-Not_AE_Candidate
of O
the O
head O
and O
neck O
receiving O
radiation O
therapy O
alone O
( O
no O
chemotherapy O
) O
who O
were O
randomized O
to O
receive O
darbepoetin O
alfa O
to O
maintain O
hemoglobin O
levels O
of O
14 O
to15.5 O
g/dL O
or O
no O
darbepoetin O
alfa O
. O

An O
interim O
analysis O
performed O
on O
484 O
patients O
demonstrated O
that O
locoregional O
control O
at O
5 O
years O
was O
significantly O
shorter O
in O
patients O
receiving O
darbepoetin O
alfa O
( O
RR O
1.44 O
, O
95 O
% O
CI O
: O
1.06 O
, O
1.96 O
; O
p O
= O
0.02 O
) O
. O

Overall O
survival O
was O
shorter O
in O
patients O
receiving O
darbepoetin O
alfa O
( O
RR O
1.28 O
, O
95 O
% O
CI O
: O
0.98 O
, O
1.68 O
; O
p O
= O
0.08 O
) O
. O

5.3 O
Hypertension B-OSE_Labeled_AE
Aranesp O
is O
contraindicated O
in O
patients O
with O
uncontrolled B-Not_AE_Candidate
hypertension I-Not_AE_Candidate
. O

In O
Aranesp O
clinical O
studies O
, O
approximately O
40 O
% O
of O
patients O
with O
CKD B-Not_AE_Candidate
required O
initiation O
or O
intensification O
of O
antihypertensive O
therapy O
during O
the O
early O
phase O
of O
treatment O
. O

Hypertensive B-OSE_Labeled_AE
encephalopathy I-OSE_Labeled_AE
and O
seizures B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
with O
CKD B-Not_AE_Candidate
receiving O
Aranesp O
. O

Appropriately O
control O
hypertension B-Not_AE_Candidate
prior O
to O
initiation O
of O
and O
during O
treatment O
with O
Aranesp O
. O

Reduce O
or O
withhold O
Aranesp O
if O
blood O
pressure O
becomes O
difficult O
to O
control O
. O

Advise O
patients O
of O
the O
importance O
of O
compliance O
with O
antihypertensive O
therapy O
and O
dietary O
restrictions O
[ O
see O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.4 O
Seizures O
Aranesp O
increases O
the O
risk O
of O
seizures B-OSE_Labeled_AE
in O
patients O
with O
CKD B-Not_AE_Candidate
. O

During O
the O
first O
several O
months O
following O
initiation O
of O
Aranesp O
, O
monitor O
patients O
closely O
for O
premonitory B-NonOSE_AE
neurologic I-NonOSE_AE
symptoms I-NonOSE_AE
. O

Advise O
patients O
to O
contact O
their O
healthcare O
practitioner O
for O
new-onset O
seizures B-NonOSE_AE
, O
premonitory B-NonOSE_AE
symptoms I-NonOSE_AE
, O
or O
change O
in O
seizure B-NonOSE_AE
frequency O
. O

5.5 O
Lack O
or O
Loss O
of O
Hemoglobin O
Response O
to O
Aranesp O
For O
lack O
or O
loss O
of O
hemoglobin O
response O
to O
Aranesp O
, O
initiate O
a O
search O
for O
causative O
factors O
( O
e.g. O
, O
iron B-NonOSE_AE
deficiency I-NonOSE_AE
, O
infection B-NonOSE_AE
, O
inflammation B-NonOSE_AE
, O
bleeding B-NonOSE_AE
) O
. O

If O
typical O
causes O
of O
lack O
or O
loss O
of O
hemoglobin O
response O
are O
excluded O
, O
evaluate O
for O
PRCA B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
. O

In O
the O
absence O
of O
PRCA B-NonOSE_AE
, O
follow O
dosing O
recommendations O
for O
management O
of O
patients O
with O
an O
insufficient O
hemoglobin O
response O
to O
Aranesp O
therapy O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.6 O
Pure B-OSE_Labeled_AE
Red I-OSE_Labeled_AE
Cell I-OSE_Labeled_AE
Aplasia I-OSE_Labeled_AE
Cases O
of O
PRCA B-OSE_Labeled_AE
and O
of O
severe O
anemia B-OSE_Labeled_AE
, O
with O
or O
without O
other O
cytopenias B-OSE_Labeled_AE
that O
arise O
following O
the O
development O
of O
neutralizing B-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
to I-OSE_Labeled_AE
erythropoietin I-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
treated O
with O
Aranesp O
. O

This O
has O
been O
reported O
predominantly O
in O
patients O
with O
CKD B-Not_AE_Candidate
receiving O
ESAs O
by O
subcutaneous O
administration O
. O

PRCA B-NonOSE_AE
has O
also O
been O
reported O
in O
patients O
receiving O
ESAs O
for O
anemia B-Not_AE_Candidate
related O
to O
hepatitis B-Not_AE_Candidate
C I-Not_AE_Candidate
treatment O
( O
an O
indication O
for O
which O
Aranesp O
is O
not O
approved O
) O
. O

If O
severe O
anemia B-NonOSE_AE
and O
low B-NonOSE_AE
reticulocyte I-NonOSE_AE
count I-NonOSE_AE
develop O
during O
treatment O
with O
Aranesp O
, O
withhold O
Aranesp O
and O
evaluate O
patients O
for O
neutralizing B-NonOSE_AE
antibodies I-NonOSE_AE
to I-NonOSE_AE
erythropoietin I-NonOSE_AE
. O

Contact O
Amgen O
( O
1-800-77-AMGEN O
) O
to O
perform O
assays O
for O
binding O
and O
neutralizing B-NonOSE_AE
antibodies I-NonOSE_AE
. O

Permanently O
discontinue O
Aranesp O
in O
patients O
who O
develop O
PRCA B-NonOSE_AE
following O
treatment O
with O
Aranesp O
or O
other O
erythropoietin O
protein O
drugs O
. O

Do O
not O
switch O
patients O
to O
other O
ESAs O
. O

5.7 O
Serious O
Allergic O
Reactions O
Serious O
allergic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
anaphylactic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
bronchospasm B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
and O
urticaria B-OSE_Labeled_AE
may O
occur O
with O
Aranesp O
. O

Immediately O
and O
permanently O
discontinue O
Aranesp O
and O
administer O
appropriate O
therapy O
if O
a O
serious O
allergic B-NonOSE_AE
or O
anaphylactic B-NonOSE_AE
reaction I-NonOSE_AE
occurs O
. O

5.8 O
Severe O
Cutaneous B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
Blistering B-OSE_Labeled_AE
and O
skin B-OSE_Labeled_AE
exfoliation I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
Erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
and O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
SJS I-OSE_Labeled_AE
) O
/ O
Toxic B-OSE_Labeled_AE
Epidermal I-OSE_Labeled_AE
Necrolysis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TEN I-OSE_Labeled_AE
) O
, O
have O
been O
reported O
in O
patients O
treated O
with O
ESAs O
( O
including O
Aranesp O
) O
in O
the O
post-marketing O
setting O
. O

Discontinue O
Aranesp O
therapy O
immediately O
if O
a O
severe O
cutaneous B-NonOSE_AE
reaction I-NonOSE_AE
, O
such O
as O
SJS B-NonOSE_AE
/ O
TEN B-NonOSE_AE
, O
is O
suspected O
. O

5.9 O
Dialysis O
Management O
Patients O
may O
require O
adjustments O
in O
their O
dialysis O
prescriptions O
after O
initiation O
of O
Aranesp O
. O

Patients O
receiving O
Aranesp O
may O
require O
increased O
anticoagulation O
with O
heparin O
to O
prevent O
clotting B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
extracorporeal I-OSE_Labeled_AE
circuit I-OSE_Labeled_AE
during O
hemodialysis O
. O

6 O
ADVERSE O
REACTIONS O
Six O
serious O
adverse O
reactions O
were O
reported O
by O
four O
patients O
during O
the O
clinical O
program O
. O

These O
serious O
adverse O
reactions O
were O
Mycobacterium B-OSE_Labeled_AE
intracellulare I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
; O
gastrointestinal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
and O
colitis B-OSE_Labeled_AE
; O
sinusitis B-OSE_Labeled_AE
and O
bronchitis B-OSE_Labeled_AE
; O
and O
Streptococcus B-OSE_Labeled_AE
pneumoniae I-OSE_Labeled_AE
meningitis I-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.3 O
) O
] O
. O

The O
most O
commonly O
reported O
adverse O
reaction O
associated O
with O
ARCALYST O
was O
injection B-OSE_Labeled_AE
- I-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
( O
ISR O
) O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

The O
next O
most O
commonly O
reported O
adverse O
reaction O
was O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.3 O
) O
] O
. O

Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
data O
described O
herein O
reflect O
exposure O
to O
ARCALYST O
in O
600 O
patients O
, O
including O
85 O
exposed O
for O
at O
least O
6 O
months O
and O
65 O
exposed O
for O
at O
least O
one O
year O
. O

These O
included O
patients O
with O
CAPS B-Not_AE_Candidate
, O
patients O
with O
other O
diseases O
, O
and O
healthy O
volunteers O
. O

Approximately O
60 O
patients O
with O
CAPS B-Not_AE_Candidate
have O
been O
treated O
weekly O
with O
160 O
mg O
of O
ARCALYST O
. O

The O
pivotal O
trial O
population O
included O
47 O
patients O
with O
CAPS B-Not_AE_Candidate
. O

These O
patients O
were O
between O
the O
ages O
of O
22 O
and O
78 O
years O
( O
average O
51 O
years O
) O
. O

Thirty-one O
patients O
were O
female O
and O
16 O
were O
male O
. O

All O
of O
the O
patients O
were O
White/Caucasian O
. O

Six O
pediatric O
patients O
( O
12-17 O
years O
) O
were O
enrolled O
directly O
into O
the O
open-label O
extension O
phase O
. O

EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
reported O
by O
patients O
with O
CAPS O
treated O
with O
ARCALYST O
are O
injection-site O
reactions O
and O
upper O
respiratory O
tract O
infections O
. O

( O
6.2 O
, O
6.3 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Regeneron O
at O
1-877-REGN-777 O
( O
1-877-734-6777 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trial O
Experience O
Part O
A O
of O
the O
clinical O
trial O
was O
conducted O
in O
patients O
with O
CAPS B-Not_AE_Candidate
who O
were O
naive O
to O
treatment O
with O
ARCALYST O
. O

Part O
A O
of O
the O
study O
was O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
six-week O
study O
comparing O
ARCALYST O
to O
placebo O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

Table O
1 O
reflects O
the O
frequency O
of O
adverse O
events O
reported O
by O
at O
least O
two O
patients O
during O
Part O
A O
. O

Table O
1 O
: O
Most O
Frequent O
Adverse O
Reactions O
( O
Part O
A O
, O
Reported O
by O
at O
Least O
Two O
Patients O
) O
Adverse O
Event O
ARCALYST160 O
mg O
( O
n O
= O
23 O
) O
Placebo O
( O
n= O
24 O
) O
Any O
AE O
17 O
( O
74 O
% O
) O
13 O
( O
54 O
% O
) O
Injection B-OSE_Labeled_AE
- I-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
11 O
( O
48 O
% O
) O
3 O
( O
13 O
% O
) O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
6 O
( O
26 O
% O
) O
1 O
( O
4 O
% O
) O
Nausea B-NonOSE_AE
1 O
( O
4 O
% O
) O
3 O
( O
13 O
% O
) O
Diarrhea B-NonOSE_AE
1 O
( O
4 O
% O
) O
3 O
( O
13 O
% O
) O
Sinusitis B-OSE_Labeled_AE
2 O
( O
9 O
% O
) O
1 O
( O
4 O
% O
) O
Abdominal B-NonOSE_AE
pain I-NonOSE_AE
upper I-NonOSE_AE
0 O
2 O
( O
8 O
% O
) O
Cough B-OSE_Labeled_AE
2 O
( O
9 O
% O
) O
0 O
Hypoesthesia B-OSE_Labeled_AE
2 O
( O
9 O
% O
) O
0 O
Stomach B-NonOSE_AE
discomfort I-NonOSE_AE
1 O
( O
4 O
% O
) O
1 O
( O
4 O
% O
) O
Urinary B-NonOSE_AE
tract I-NonOSE_AE
infection I-NonOSE_AE
1 O
( O
4 O
% O
) O
1 O
( O
4 O
% O
) O
6.2 O
Injection-Site O
Reactions O
In O
patients O
with O
CAPS B-Not_AE_Candidate
, O
the O
most O
common O
and O
consistently O
reported O
adverse O
event O
associated O
with O
ARCALYST O
was O
injection B-OSE_Labeled_AE
- I-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
( O
ISR O
) O
. O

The O
ISRs B-OSE_Labeled_AE
included O
erythema O
, O
swelling O
, O
pruritis O
, O
mass O
, O
bruising O
, O
inflammation O
, O
pain O
, O
edema O
, O
dermatitis O
, O
discomfort O
, O
urticaria O
, O
vesicles O
, O
warmth O
and O
hemorrhage O
. O

Most O
injection B-OSE_Labeled_AE
- I-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
lasted O
for O
one O
to O
two O
days O
. O

No O
ISRs B-NonOSE_AE
were O
assessed O
as O
severe O
, O
and O
no O
patient O
discontinued O
study O
participation O
due O
to O
an O
ISR B-NonOSE_AE
. O

6.3 O
Infections O
During O
Part O
A O
, O
the O
incidence O
of O
patients O
reporting O
infections B-OSE_Labeled_AE
was O
greater O
with O
ARCALYST O
( O
48 O
% O
) O
than O
with O
placebo O
( O
17 O
% O
) O
. O

In O
Part O
B O
, O
randomized O
withdrawal O
, O
the O
incidence O
of O
infections B-NonOSE_AE
were O
similar O
in O
the O
ARCALYST O
( O
18 O
% O
) O
and O
the O
placebo O
patients O
( O
22 O
% O
) O
. O

Part O
A O
of O
the O
trial O
was O
initiated O
in O
the O
winter O
months O
, O
while O
Part O
B O
was O
predominantly O
performed O
in O
the O
summer O
months O
. O

In O
placebo-controlled O
studies O
across O
a O
variety O
of O
patient O
populations O
encompassing O
360 O
patients O
treated O
with O
rilonacept O
and O
179 O
treated O
with O
placebo O
, O
the O
incidence O
of O
infections B-OSE_Labeled_AE
was O
34 O
% O
and O
27 O
% O
( O
2.15 O
per O
patient-exposure O
year O
and O
1.81 O
per O
patient-exposure O
year O
) O
, O
respectively O
, O
for O
rilonacept O
and O
placebo O
. O

Serious O
Infections B-NonOSE_AE
: O
One O
patient O
receiving O
ARCALYST O
for O
an O
unapproved O
indication O
in O
another O
study O
developed O
an O
infection B-NonOSE_AE
in I-NonOSE_AE
his I-NonOSE_AE
olecranon I-NonOSE_AE
bursa I-NonOSE_AE
with I-NonOSE_AE
Mycobacterium I-NonOSE_AE
intracellulare I-NonOSE_AE
. O

The O
patient O
was O
on O
chronic O
glucocorticoid O
treatment O
. O

The O
infection B-NonOSE_AE
occurred O
after O
an O
intraarticular O
glucocorticoid O
injection O
into O
the O
bursa O
with O
subsequent O
local O
exposure O
to O
a O
suspected O
source O
of O
mycobacteria O
. O

The O
patient O
recovered O
after O
the O
administration O
of O
the O
appropriate O
antimicrobial O
therapy O
. O

One O
patient O
treated O
for O
another O
unapproved O
indication O
developed O
bronchitis B-NonOSE_AE
/ O
sinusitis B-NonOSE_AE
, O
which O
resulted O
in O
hospitalization O
. O

One O
patient O
died B-NonOSE_AE
in O
an O
open-label O
study O
of O
CAPS B-Not_AE_Candidate
from O
Streptococcus B-NonOSE_AE
pneumoniae I-NonOSE_AE
meningitis I-NonOSE_AE
. O

6.4 O
Malignancies O
[ O
s O
ee O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

6.5 O
Hematologic O
Events O
One O
patient O
in O
a O
study O
in O
an O
unapproved O
indication O
developed O
transient O
neutropenia B-NonOSE_AE
( O
ANC B-NonOSE_AE
< I-NonOSE_AE
1 I-NonOSE_AE
x I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
9 I-NonOSE_AE
/ I-NonOSE_AE
L I-NonOSE_AE
) O
after O
receiving O
a O
large O
dose O
( O
2000 O
mg O
intravenously O
) O
of O
ARCALYST O
. O

The O
patient O
did O
not O
experience O
any O
infection B-NonOSE_AE
associated I-NonOSE_AE
with I-NonOSE_AE
the I-NonOSE_AE
neutropenia I-NonOSE_AE
. O

6.6 O
Immunogenicity O
Antibodies B-OSE_Labeled_AE
directed O
against I-OSE_Labeled_AE
the O
receptor O
domains O
of O
rilonacept I-OSE_Labeled_AE
were O
detected I-OSE_Labeled_AE
by O
an O
ELISA O
assay O
in O
patients O
with O
CAPS B-Not_AE_Candidate
after O
treatment O
with O
ARCALYST O
. O

Nineteen O
of O
55 O
patients O
( O
35 O
% O
) O
who O
had O
received O
ARCALYST O
for O
at O
least O
6 O
weeks O
tested O
positive O
for O
treatment B-OSE_Labeled_AE
- I-OSE_Labeled_AE
emergent I-OSE_Labeled_AE
binding I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
on O
at O
least O
one O
occasion O
. O

Of O
the O
19 O
, O
seven O
tested O
positive O
at O
the O
last O
assessment O
( O
Week O
18 O
or O
24 O
of O
the O
open-label O
extension O
period O
) O
, O
and O
five O
patients O
tested O
positive B-OSE_Labeled_AE
for O
neutralizing I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
on O
at O
least O
one O
occasion O
. O

There O
was O
no O
correlation O
of O
antibody O
activity O
and O
either O
clinical O
effectiveness O
or O
safety O
. O

The O
data O
reflect O
the O
percentage O
of O
patients O
whose O
test O
results O
were O
positive B-NonOSE_AE
for I-NonOSE_AE
antibodies I-NonOSE_AE
to O
the O
rilonacept O
receptor O
domains O
in O
specific O
assays O
, O
and O
are O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assays O
. O

The O
observed O
incidence O
of O
antibody B-NonOSE_AE
( O
including O
neutralizing O
antibody O
) O
positivity I-NonOSE_AE
in O
an O
assay O
is O
highly O
dependent O
on O
several O
factors O
including O
assay O
sensitivity O
and O
specificity O
, O
assay O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies O
to O
rilonacept O
with O
the O
incidence O
of O
antibodies O
to O
other O
products O
may O
be O
misleading O
. O

6.7 O
Lipid O
profiles O
Cholesterol B-Not_AE_Candidate
and O
lipid O
levels O
may I-Not_AE_Candidate
be I-Not_AE_Candidate
reduced I-Not_AE_Candidate
in O
patients O
with O
chronic B-Not_AE_Candidate
inflammation I-Not_AE_Candidate
. O

Patients O
with O
CAPS B-Not_AE_Candidate
treated O
with O
ARCALYST O
experienced O
increases B-OSE_Labeled_AE
in O
their O
mean O
total I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
, O
HDL O
cholesterol O
, O
LDL O
cholesterol O
, O
and O
triglycerides O
. O

The O
mean O
increases B-OSE_Labeled_AE
from O
baseline O
for O
total I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
, O
HDL O
cholesterol O
, O
LDL O
cholesterol O
, O
and O
triglycerides O
were O
19 O
mg/dL O
, O
2 O
mg/dL O
, O
10 O
mg/dL O
, O
and O
57 O
mg/dL O
respectively O
after O
6 O
weeks O
of O
open-label O
therapy O
. O

Physicians O
should O
monitor O
the O
lipid O
profiles O
of O
their O
patients O
( O
for O
example O
after O
2-3 O
months O
) O
and O
consider O
lipid-lowering O
therapies O
as O
needed O
based O
upon O
cardiovascular O
risk O
factors O
and O
current O
guidelines O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Interleukin-1 O
blockade O
may O
interfere O
with O
immune O
response O
to O
infections O
. O

Serious O
, O
life-threatening O
infections O
have O
been O
reported O
in O
patients O
taking O
ARCALYST O
. O

Discontinue O
treatment O
with O
ARCALYST O
if O
a O
patient O
develops O
a O
serious O
infection O
. O

Do O
not O
initiate O
treatment O
with O
ARCALYST O
in O
patients O
with O
active O
or O
chronic O
infections O
. O

( O
5.1 O
) O
* O
Hypersensitivity O
reactions O
associated O
with O
ARCALYST O
administration O
have O
been O
rare O
. O

If O
a O
hypersensitivity O
reaction O
occurs O
, O
discontinue O
administration O
of O
ARCALYST O
and O
initiate O
appropriate O
therapy O
. O

( O
5.5 O
) O
* O
Live O
vaccines O
should O
not O
be O
given O
concurrently O
with O
ARCALYST O
. O

Prior O
to O
initiation O
of O
therapy O
with O
ARCALYST O
, O
patients O
should O
receive O
all O
recommended O
vaccinations O
. O

( O
5.3 O
) O
5.1 O
Infections O
Interleukin O
-1 O
( O
IL-1 O
) O
blockade O
may O
interfere O
with O
the O
immune O
response O
to O
infections B-OSE_Labeled_AE
. O

Treatment O
with O
another O
medication O
that O
works O
through O
inhibition O
of O
IL-1 O
has O
been O
associated O
with O
an O
increased O
risk O
of O
serious O
infections B-NonOSE_AE
, O
and O
serious O
infections B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
taking O
ARCALYST O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

There O
was O
a O
greater O
incidence O
of O
infections B-OSE_Labeled_AE
in O
patients O
on O
ARCALYST O
compared O
with O
placebo O
. O

In O
the O
controlled O
portion O
of O
the O
study O
, O
one O
infection B-OSE_Labeled_AE
was O
reported O
as O
severe O
, O
which O
was O
bronchitis B-OSE_Labeled_AE
in O
a O
patient O
on O
ARCALYST O
. O

In O
an O
open-label O
extension O
study O
, O
one O
patient O
developed O
bacterial B-OSE_Labeled_AE
meningitis I-OSE_Labeled_AE
and O
died B-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.3 O
) O
] O
. O

ARCALYST O
should O
be O
discontinued O
if O
a O
patient O
develops O
a O
serious O
infection B-NonOSE_AE
. O

Treatment O
with O
ARCALYST O
should O
not O
be O
initiated O
in O
patients O
with O
an O
active O
or O
chronic O
infection B-NonOSE_AE
. O

In O
clinical O
studies O
, O
ARCALYST O
has O
not O
been O
administered O
concomitantly O
with O
tumor O
necrosis O
factor O
( O
TNF O
) O
inhibitors O
. O

An O
increased O
incidence O
of O
serious O
infections B-NonOSE_AE
has O
been O
associated O
with O
administration O
of O
an O
IL-1 O
blocker O
in O
combination O
with O
TNF O
inhibitors O
. O

Taking O
ARCALYST O
with O
TNF O
inhibitors O
is O
not O
recommended O
because O
this O
may O
increase O
the O
risk O
of O
serious O
infections B-NonOSE_AE
. O

Drugs O
that O
affect O
the O
immune O
system O
by O
blocking O
TNF O
have O
been O
associated O
with O
an O
increased O
risk O
of O
reactivation B-NonOSE_AE
of I-NonOSE_AE
latent I-NonOSE_AE
tuberculosis I-NonOSE_AE
( I-NonOSE_AE
TB I-NonOSE_AE
) O
. O

It O
is O
possible O
that O
taking O
drugs O
such O
as O
ARCALYST O
that O
block O
IL-1 O
increases O
the O
risk O
of O
TB B-NonOSE_AE
or O
other O
atypical O
or O
opportunistic B-NonOSE_AE
infections I-NonOSE_AE
. O

Healthcare O
providers O
should O
follow O
current O
CDC O
guidelines O
both O
to O
evaluate O
for O
and O
to O
treat O
possible O
latent B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
infections I-Not_AE_Candidate
before O
initiating O
therapy O
with O
ARCALYST O
. O

5.2 O
Immunosuppression O
The O
impact O
of O
treatment O
with O
ARCALYST O
on O
active B-Not_AE_Candidate
and/or O
chronic O
infections I-Not_AE_Candidate
and O
the O
development O
of O
malignancies B-NonOSE_AE
is O
not O
known O
[ O
see O
Adverse O
Reactions O
( O
6.3 O
) O
] O
. O

However O
, O
treatment O
with O
immunosuppressants O
, O
including O
ARCALYST O
, O
may O
result O
in O
an O
increase O
in O
the O
risk O
of O
malignancies B-OSE_Labeled_AE
. O

5.3 O
Immunizations O
Since O
no O
data O
are O
available O
on O
either O
the O
efficacy O
of O
live O
vaccines O
or O
on O
the O
risks O
of O
secondary B-NonOSE_AE
transmission I-NonOSE_AE
of I-NonOSE_AE
infection I-NonOSE_AE
by O
live O
vaccines O
in O
patients O
receiving O
ARCALYST O
, O
live O
vaccines O
should O
not O
be O
given O
concurrently O
with O
ARCALYST O
. O

In O
addition O
, O
because O
ARCALYST O
may O
interfere B-NonOSE_AE
with I-NonOSE_AE
normal I-NonOSE_AE
immune I-NonOSE_AE
response I-NonOSE_AE
to I-NonOSE_AE
new I-NonOSE_AE
antigens I-NonOSE_AE
, O
vaccinations O
may O
not O
be O
effective O
in O
patients O
receiving O
ARCALYST O
. O

No O
data O
are O
available O
on O
the O
effectiveness O
of O
vaccination O
with O
inactivated O
( O
killed O
) O
antigens O
in O
patients O
receiving O
ARCALYST O
. O

Because O
IL-1 O
blockade O
may O
interfere B-NonOSE_AE
with I-NonOSE_AE
immune I-NonOSE_AE
response I-NonOSE_AE
to I-NonOSE_AE
infections I-NonOSE_AE
, O
it O
is O
recommended O
that O
prior O
to O
initiation O
of O
therapy O
with O
ARCALYST O
adult O
and O
pediatric O
patients O
receive O
all O
recommended O
vaccinations O
, O
as O
appropriate O
, O
including O
pneumococcal O
vaccine O
and O
inactivated O
influenza O
vaccine O
. O

( O
See O
current O
Recommended O
Immunizations O
schedules O
at O
the O
website O
of O
the O
Centers O
for O
Disease O
Control O
. O

http O
: O
//www.cdc.gov/vaccines/recs/schedules/ O
) O
. O

5.4 O
Lipid O
Profile O
Changes O
Patients O
should O
be O
monitored O
for O
changes B-NonOSE_AE
in I-NonOSE_AE
their I-NonOSE_AE
lipid I-NonOSE_AE
profiles I-NonOSE_AE
and O
provided O
with O
medical O
treatment O
if O
warranted O
[ O
see O
Adverse O
Reactions O
( O
6.7 O
) O
] O
. O

5.5 O
Hypersensitivity O
Hypersensitivity B-OSE_Labeled_AE
reactions O
associated O
with O
ARCALYST O
administration O
in O
the O
clinical O
studies O
were O
rare O
. O

If O
a O
hypersensitivity B-NonOSE_AE
reaction I-NonOSE_AE
occurs O
, O
administration O
of O
ARCALYST O
should O
be O
discontinued O
and O
appropriate O
therapy O
initiated O
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
occurring O
at O
least O
3 O
% O
more O
frequently O
than O
on O
placebo O
are O
mild O
local O
reactions O
at O
the O
site O
of O
injection O
. O

( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Merz O
North O
America O
, O
Inc O
. O
at O
1-866-862-1211 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Study O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

In O
5 O
controlled O
randomized O
clinical O
trials O
, O
Asclera O
has O
been O
administered O
to O
401 O
patients O
with O
small O
or O
very O
small O
varicose B-Not_AE_Candidate
veins I-Not_AE_Candidate
( O
reticular B-Not_AE_Candidate
and O
spider O
veins I-Not_AE_Candidate
) O
and O
compared O
with O
another O
sclerosing O
agent O
and O
with O
placebo O
. O

Patients O
were O
18 O
to O
70 O
years O
old O
. O

The O
patient O
population O
was O
predominately O
female O
and O
consisted O
of O
Caucasian O
and O
Asian O
patients O
. O

Table O
1 O
shows O
adverse O
events O
more O
common O
with O
Asclera O
or O
sodium O
tetradecyl O
sulfate O
( O
STS O
) O
1 O
% O
than O
with O
placebo O
by O
at O
least O
3 O
% O
in O
the O
placebo- O
controlled O
EASI O
study O
( O
see O
Clinical O
Studies O
[ O
14 O
] O
) O
. O

All O
of O
these O
were O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
and O
most O
were O
mild O
. O

Table O
1 O
: O
Adverse O
Reactions O
in O
EASI-study O
ASCLERA O
( O
180 O
patients O
) O
STS O
1 O
% O
( O
105 O
patients O
) O
Placebo O
( O
53 O
patients O
) O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
haematoma I-OSE_Labeled_AE
42 O
% O
65 O
% O
19 O
% O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
irritation I-OSE_Labeled_AE
41 O
% O
73 O
% O
30 O
% O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
38 O
% O
74 O
% O
4 O
% O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
24 O
% O
31 O
% O
9 O
% O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
pruritus I-OSE_Labeled_AE
19 O
% O
27 O
% O
4 O
% O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
warmth I-OSE_Labeled_AE
16 O
% O
21 O
% O
6 O
% O
Neovascularisation B-OSE_Labeled_AE
8 O
% O
20 O
% O
4 O
% O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
6 O
% O
1 O
% O
0 O
% O
Ultrasound O
examinations O
at O
one O
week O
( O
+/-3 O
days O
) O
and O
12 O
weeks O
( O
+/-2 O
weeks O
) O
after O
treatment O
did O
not O
reveal O
deep B-NonOSE_AE
vein I-NonOSE_AE
thrombosis I-NonOSE_AE
in O
any O
treatment O
group O
. O

6.2 O
Post-marketing O
Safety O
Experience O
The O
following O
adverse O
reactions O
have O
been O
reported O
during O
use O
of O
polidocanol O
in O
world-wide O
experience O
; O
in O
some O
of O
these O
cases O
these O
adverse O
events O
have O
been O
serious O
or O
troublesome O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
and O
without O
a O
control O
group O
, O
it O
is O
not O
possible O
to O
estimate O
their O
frequency O
reliably O
or O
to O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Immune B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
Anaphylactic B-OSE_Labeled_AE
shock I-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
generalized O
, O
asthma B-OSE_Labeled_AE
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
Cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
migraine B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
( O
local O
) O
, O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
, O
confusional B-OSE_Labeled_AE
state I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
Cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
palpitations B-OSE_Labeled_AE
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
: O
Deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
vasovagal I-OSE_Labeled_AE
, O
circulatory B-OSE_Labeled_AE
collapse I-OSE_Labeled_AE
, O
vasculitis B-OSE_Labeled_AE
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
: O
Dyspnea B-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
Skin B-OSE_Labeled_AE
hyperpigmentation I-OSE_Labeled_AE
, O
dermatitis B-OSE_Labeled_AE
allergic I-OSE_Labeled_AE
, O
hypertrichosis B-OSE_Labeled_AE
( O
in O
the O
area O
of O
sclerotherapy O
) O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
injection I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
: O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
, O
hot B-OSE_Labeled_AE
flush I-OSE_Labeled_AE
Injury B-NonOSE_AE
, I-NonOSE_AE
poisoning I-NonOSE_AE
and I-NonOSE_AE
procedural I-NonOSE_AE
complications I-NonOSE_AE
: O
Nerve B-OSE_Labeled_AE
injury I-OSE_Labeled_AE

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Be O
prepared O
to O
treat O
anaphylaxis O
. O

( O
5.1 O
) O
* O
Do O
not O
inject O
intra-arterially O
. O

( O
5.2 O
) O
* O
Do O
not O
inject O
intra-perivascularily O
. O

( O
5.3 O
) O
5.1 O
Anaphylaxis O
Severe O
allergic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
have O
been O
reported O
following O
polidocanol O
use O
, O
including O
anaphylactic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
some O
of O
them O
fatal B-NonOSE_AE
. O

Severe O
reactions O
are O
more O
frequent O
with O
use O
of O
larger O
volumes O
( O
> O
3 O
mL O
) O
. O

The O
dose O
of O
polidocanol O
should O
therefore O
be O
minimized O
. O

Be O
prepared O
to O
treat O
anaphylaxis B-NonOSE_AE
appropriately O
. O

Severe O
adverse B-NonOSE_AE
local I-NonOSE_AE
effects I-NonOSE_AE
, O
including O
tissue B-NonOSE_AE
necrosis I-NonOSE_AE
, O
may O
occur O
following O
extravasation B-NonOSE_AE
; O
therefore O
, O
care O
should O
be O
taken O
in O
intravenous O
needle O
placement O
and O
the O
smallest O
effective O
volume O
at O
each O
injection O
site O
should O
be O
used O
. O

After O
the O
injection O
session O
is O
completed O
, O
apply O
compression O
with O
a O
stocking O
or O
bandage O
, O
and O
have O
the O
patient O
walk O
for O
15-20 O
minutes O
. O

Keep O
the O
patient O
under O
supervision O
during O
this O
period O
to O
treat O
any O
anaphylactic B-NonOSE_AE
or O
allergic B-NonOSE_AE
reaction I-NonOSE_AE
( O
see O
Dosage O
and O
Administration O
[ O
2 O
] O
) O
. O

5.2 O
Accidental O
Intra-arterial O
Injection O
Intra B-OSE_Labeled_AE
- I-OSE_Labeled_AE
arterial I-OSE_Labeled_AE
injection I-OSE_Labeled_AE
can O
cause O
severe O
necrosis B-NonOSE_AE
, O
ischemia B-NonOSE_AE
or O
gangrene B-NonOSE_AE
. O

If O
this O
occurs O
consult O
a O
vascular O
surgeon O
immediately O
. O

5.3 O
Inadvertent O
Perivascular O
Injection O
Inadvertent B-OSE_Labeled_AE
perivascular I-OSE_Labeled_AE
injection I-OSE_Labeled_AE
of O
Asclera O
can O
cause O
pain B-NonOSE_AE
. O

If O
pain B-NonOSE_AE
is O
severe O
, O
a O
local O
anesthetic O
( O
without O
adrenaline O
) O
may O
be O
injected O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
described O
elsewhere O
in O
the O
prescribing O
information O
: O
* O
Hepatotoxicity B-OSE_Labeled_AE
[ O
see O
Contraindications O
( O
4.1 O
) O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Bone B-OSE_Labeled_AE
Marrow I-OSE_Labeled_AE
Effects I-OSE_Labeled_AE
/ O
Immunosuppression B-OSE_Labeled_AE
Potential/ O
Infections B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Peripheral B-OSE_Labeled_AE
Neuropathy I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Skin B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Increased B-OSE_Labeled_AE
Blood I-OSE_Labeled_AE
Pressure I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Respiratory B-OSE_Labeled_AE
Effects I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
> O
=10 O
% O
and O
> O
=2 O
% O
greater O
than O
placebo O
) O
: O
headache O
, O
diarrhea O
, O
nausea O
, O
alopecia O
, O
increase O
in O
ALT O
( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Genzyme O
Corporation O
at O
1-800-745-4447 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

A O
total O
of O
2047 O
patients O
receiving O
AUBAGIO O
( O
7 O
mg O
or O
14 O
mg O
once O
daily O
) O
constituted O
the O
safety O
population O
in O
the O
pooled O
analysis O
of O
placebo O
controlled O
studies O
in O
patients O
with O
relapsing B-Not_AE_Candidate
forms O
of O
multiple I-Not_AE_Candidate
sclerosis I-Not_AE_Candidate
; O
of O
these O
, O
71 O
% O
were O
female O
. O

The O
average O
age O
was O
37 O
years O
. O

Table O
1 O
lists O
adverse O
reactions O
in O
placebo-controlled O
trials O
with O
rates O
that O
were O
at O
least O
2 O
% O
for O
AUBAGIO O
patients O
and O
also O
at O
least O
2 O
% O
above O
the O
rate O
in O
placebo O
patients O
. O

The O
most O
common O
were O
headache B-OSE_Labeled_AE
, O
an O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
alopecia B-OSE_Labeled_AE
, O
and O
nausea B-OSE_Labeled_AE
. O

The O
adverse O
reaction O
most O
commonly O
associated O
with O
discontinuation O
was O
an O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
( O
3.3 O
% O
, O
2.6 O
% O
, O
and O
2.3 O
% O
of O
all O
patients O
in O
the O
AUBAGIO O
7 O
mg O
, O
AUBAGIO O
14 O
mg O
, O
and O
placebo O
treatment O
arms O
, O
respectively O
) O
. O

Table O
1 O
. O

Adverse O
Reactions O
in O
Pooled O
Placebo-Controlled O
Studies O
in O
Patients O
with O
Relapsing O
Forms O
of O
Multiple O
Sclerosis O
Adverse O
Reaction O
AUBAGIO O
7 O
mg O
( O
N=1045 O
) O
AUBAGIO O
14 O
mg O
( O
N=1002 O
) O
Placebo O
( O
N=997 O
) O
Headache B-OSE_Labeled_AE
18 O
% O
16 O
% O
15 O
% O
Increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Alanine I-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
13 O
% O
15 O
% O
9 O
% O
Diarrhea B-OSE_Labeled_AE
13 O
% O
14 O
% O
8 O
% O
Alopecia B-OSE_Labeled_AE
10 O
% O
13 O
% O
5 O
% O
Nausea B-OSE_Labeled_AE
8 O
% O
11 O
% O
7 O
% O
Paresthesia B-OSE_Labeled_AE
8 O
% O
9 O
% O
7 O
% O
Arthralgia B-OSE_Labeled_AE
8 O
% O
6 O
% O
5 O
% O
Neutropenia B-OSE_Labeled_AE
4 O
% O
6 O
% O
2 O
% O
Hypertension B-OSE_Labeled_AE
3 O
% O
4 O
% O
2 O
% O
Cardiovascular O
deaths O
Four O
cardiovascular B-NonOSE_AE
deaths B-NonOSE_AE
, O
including O
three O
sudden B-NonOSE_AE
deaths I-NonOSE_AE
, O
and O
one O
myocardial B-NonOSE_AE
infarction I-NonOSE_AE
in O
a O
patient O
with O
a O
history O
of O
hyperlipidemia B-Not_AE_Candidate
and O
hypertension B-Not_AE_Candidate
were O
reported O
among O
approximately O
2600 O
patients O
exposed O
to O
AUBAGIO O
in O
the O
premarketing O
database O
. O

These O
cardiovascular B-NonOSE_AE
deaths B-NonOSE_AE
occurred O
during O
uncontrolled O
extension O
studies O
, O
one O
to O
nine O
years O
after O
initiation O
of O
treatment O
. O

A O
relationship O
between O
AUBAGIO O
and O
cardiovascular B-NonOSE_AE
death B-NonOSE_AE
has O
not O
been O
established O
. O

Acute O
Renal O
Failure O
In O
placebo-controlled O
studies O
, O
creatinine B-OSE_Labeled_AE
values I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
more O
than O
100 O
% O
over O
baseline O
in O
8/1045 O
( O
0.8 O
% O
) O
patients O
in O
the O
7 O
mg O
AUBAGIO O
group O
and O
6/1002 O
( O
0.6 O
% O
) O
patients O
in O
the O
14 O
mg O
AUBAGIO O
group O
versus O
4/997 O
( O
0.4 O
% O
) O
patients O
in O
the O
placebo O
group O
. O

These O
elevations O
were O
transient O
. O

Some O
elevations O
were O
accompanied O
by O
hyperkalemia B-OSE_Labeled_AE
. O

AUBAGIO O
may O
cause O
acute B-OSE_Labeled_AE
uric I-OSE_Labeled_AE
acid I-OSE_Labeled_AE
nephropathy I-OSE_Labeled_AE
with O
transient O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
because O
AUBAGIO O
increases B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
uric I-OSE_Labeled_AE
acid I-OSE_Labeled_AE
clearance I-OSE_Labeled_AE
. O

Hypophosphatemia O
In O
clinical O
trials O
, O
18 O
% O
of O
AUBAGIO-treated O
patients O
had O
hypophosphatemia B-OSE_Labeled_AE
with O
serum B-OSE_Labeled_AE
phosphorus I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
of I-OSE_Labeled_AE
at I-OSE_Labeled_AE
least I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
mmol I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
, O
compared O
to O
7 O
% O
of O
placebo-treated O
patients O
; O
4 O
% O
of O
AUBAGIO-treated O
patients O
had O
hypophosphatemia B-OSE_Labeled_AE
with O
serum B-OSE_Labeled_AE
phosphorus I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
at I-OSE_Labeled_AE
least I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
mmol I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
but I-OSE_Labeled_AE
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
mmol I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
, O
compared O
to O
0.8 O
% O
of O
placebo-treated O
patients O
. O

No O
patient O
in O
any O
treatment O
group O
had O
a O
serum B-NonOSE_AE
phosphorus I-NonOSE_AE
below I-NonOSE_AE
0 I-NonOSE_AE
. I-NonOSE_AE
3 I-NonOSE_AE
mmol I-NonOSE_AE
/ I-NonOSE_AE
L I-NonOSE_AE
. O

BOXED O
WARNING O
: O
WARNING O
: O
HEPATOTOXICITY B-OSE_Labeled_AE
and O
RISK O
OF O
TERATOGENICITY O
WARNING O
: O
HEPATOTOXICITY O
and O
RISK O
OF O
TERATOGENICITY O
EXCERPT O
: O
WARNING O
: O
HEPATOTOXICITY O
and O
RISK O
OF O
TERATOGENICITY O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
Hepatotoxicity O
Severe O
liver O
injury O
including O
fatal O
liver O
failure O
has O
been O
reported O
in O
patients O
treated O
with O
leflunomide O
, O
which O
is O
indicated O
for O
rheumatoid O
arthritis O
. O

A O
similar O
risk O
would O
be O
expected O
for O
teriflunomide O
because O
recommended O
doses O
of O
teriflunomide O
and O
leflunomide O
result O
in O
a O
similar O
range O
of O
plasma O
concentrations O
of O
teriflunomide O
. O

Obtain O
transaminase O
and O
bilirubin O
levels O
within O
6 O
months O
before O
initiation O
of O
AUBAGIO O
and O
monitor O
ALT O
levels O
at O
least O
monthly O
for O
six O
months O
( O
5.1 O
) O
. O

If O
drug O
induced O
liver O
injury O
is O
suspected O
, O
discontinue O
AUBAGIO O
and O
start O
accelerated O
elimination O
procedure O
( O
5.3 O
) O
. O

Risk O
of O
Teratogenicity O
Based O
on O
animal O
data O
, O
AUBAGIO O
may O
cause O
major O
birth O
defects O
if O
used O
during O
pregnancy O
. O

AUBAGIO O
is O
contraindicated O
in O
pregnant O
women O
or O
women O
of O
childbearing O
potential O
who O
are O
not O
using O
reliable O
contraception O
. O

Pregnancy O
must O
be O
avoided O
during O
AUBAGIO O
treatment O
. O

( O
4.2 O
, O
5.2 O
) O
Hepatotoxicity O
Severe O
liver B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
including O
fatal O
liver B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
has O
been O
reported O
in O
patients O
treated O
with O
leflunomide O
, O
which O
is O
indicated O
for O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
. O

A O
similar O
risk O
would O
be O
expected O
for O
teriflunomide O
because O
recommended O
doses O
of O
teriflunomide O
and O
leflunomide O
result O
in O
a O
similar O
range O
of O
plasma O
concentrations O
of O
teriflunomide O
. O

Concomitant O
use O
of O
AUBAGIO O
with O
other O
potentially O
hepatotoxic B-NonOSE_AE
drugs O
may O
increase O
the O
risk O
of O
severe O
liver B-NonOSE_AE
injury I-NonOSE_AE
. O

Obtain O
transaminase O
and O
bilirubin O
levels O
within O
6 O
months O
before O
initiation O
of O
AUBAGIO O
therapy O
. O

Monitor O
ALT O
levels O
at O
least O
monthly O
for O
six O
months O
after O
starting O
AUBAGIO O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

If O
drug B-NonOSE_AE
induced I-NonOSE_AE
liver I-NonOSE_AE
injury I-NonOSE_AE
is O
suspected O
, O
discontinue O
AUBAGIO O
and O
start O
an O
accelerated O
elimination O
procedure O
with O
cholestyramine O
or O
charcoal O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

AUBAGIO O
is O
contraindicated O
in O
patients O
with O
severe O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4.1 O
) O
] O
. O

Patients O
with O
pre-existing O
liver B-Not_AE_Candidate
disease I-Not_AE_Candidate
may O
be O
at O
increased O
risk O
of O
developing O
elevated B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
when O
taking O
AUBAGIO O
. O

Risk O
of O
Teratogenicity B-OSE_Labeled_AE
Based O
on O
animal O
data O
, O
AUBAGIO O
may B-OSE_Labeled_AE
cause I-OSE_Labeled_AE
major I-OSE_Labeled_AE
birth I-OSE_Labeled_AE
defects I-OSE_Labeled_AE
if O
used O
during O
pregnancy B-Not_AE_Candidate
. O

Pregnancy B-NonOSE_AE
must O
be O
excluded O
before O
starting O
AUBAGIO O
. O

AUBAGIO O
is O
contraindicated O
in O
pregnant B-Not_AE_Candidate
women I-Not_AE_Candidate
or O
women O
of O
childbearing O
potential O
who O
are O
not O
using O
reliable O
contraception O
. O

Pregnancy B-NonOSE_AE
must O
be O
avoided O
during O
AUBAGIO O
treatment O
or O
prior O
to O
the O
completion O
of O
an O
accelerated O
elimination O
procedure O
after O
AUBAGIO O
treatment O
[ O
see O
Contraindications O
( O
4.2 O
) O
, O
Warnings O
and O
Precautions O
( O
5.2 O
) O
, O
and O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Elimination O
of O
AUBAGIO O
can O
be O
accelerated O
by O
administration O
of O
cholestyramine O
or O
activated O
charcoal O
for O
11 O
days O
( O
5.3 O
) O
* O
AUBAGIO O
may O
decrease O
WBC O
. O

A O
recent O
CBC O
should O
be O
available O
before O
starting O
AUBAGIO O
. O

Monitor O
for O
signs O
and O
symptoms O
of O
infection O
. O

Consider O
suspending O
treatment O
with O
AUBAGIO O
in O
case O
of O
serious O
infection O
. O

Do O
not O
start O
AUBAGIO O
in O
patients O
with O
active O
infections O
( O
5.4 O
) O
* O
If O
patient O
develops O
symptoms O
consistent O
with O
peripheral O
neuropathy O
, O
evaluate O
patient O
and O
consider O
discontinuing O
AUBAGIO O
( O
5.5 O
) O
* O
Stop O
AUBAGIO O
if O
patient O
develops O
Stevens-Johnson O
syndrome O
or O
toxic O
epidermal O
necrolysis O
( O
5.6 O
) O
* O
AUBAGIO O
may O
increase O
blood O
pressure O
. O

Measure O
blood O
pressure O
at O
treatment O
initiation O
and O
monitor O
blood O
pressure O
during O
treatment O
( O
5.7 O
) O
5.1 O
Hepatotoxicity O
Severe O
liver B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
including O
fatal O
liver B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
and O
dysfunction O
has O
been O
reported O
in O
some O
patients O
treated O
with O
leflunomide O
, O
which O
is O
indicated O
for O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
. O

A O
similar O
risk O
would O
be O
expected O
for O
teriflunomide O
because O
recommended O
doses O
of O
teriflunomide O
and O
leflunomide O
result O
in O
a O
similar O
range O
of O
plasma O
concentrations O
of O
teriflunomide O
. O

Patients O
with O
pre-existing O
liver B-Not_AE_Candidate
disease I-Not_AE_Candidate
may O
be O
at O
increased O
risk O
of O
developing O
elevated B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
when O
taking O
AUBAGIO O
. O

Patients O
with O
pre-existing O
acute B-Not_AE_Candidate
or I-Not_AE_Candidate
chronic I-Not_AE_Candidate
liver I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
or O
those O
with O
serum B-Not_AE_Candidate
alanine I-Not_AE_Candidate
aminotransferase I-Not_AE_Candidate
( I-Not_AE_Candidate
ALT I-Not_AE_Candidate
) I-Not_AE_Candidate
greater I-Not_AE_Candidate
than I-Not_AE_Candidate
two I-Not_AE_Candidate
times I-Not_AE_Candidate
the I-Not_AE_Candidate
upper I-Not_AE_Candidate
limit I-Not_AE_Candidate
of I-Not_AE_Candidate
normal I-Not_AE_Candidate
( I-Not_AE_Candidate
ULN I-Not_AE_Candidate
) O
before O
initiating O
treatment O
, O
should O
not O
normally O
be O
treated O
with O
AUBAGIO O
. O

AUBAGIO O
is O
contraindicated O
in O
patients O
with O
severe O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4.1 O
) O
] O
. O

In O
placebo-controlled O
trials O
, O
ALT B-OSE_Labeled_AE
greater I-OSE_Labeled_AE
than I-OSE_Labeled_AE
three I-OSE_Labeled_AE
times I-OSE_Labeled_AE
the I-OSE_Labeled_AE
ULN I-OSE_Labeled_AE
occurred O
in O
61/1045 O
( O
5.8 O
% O
) O
and O
62/1002 O
( O
6.2 O
% O
) O
of O
patients O
receiving O
AUBAGIO O
7 O
mg O
and O
14 O
mg O
, O
respectively O
, O
and O
38/997 O
( O
3.8 O
% O
) O
of O
patients O
receiving O
placebo O
, O
during O
the O
treatment O
period O
. O

These O
elevations O
occurred O
mostly O
within O
the O
first O
year O
of O
treatment O
. O

Half O
of O
the O
cases O
returned O
to O
normal O
without O
drug O
discontinuation O
. O

In O
clinical O
trials O
, O
if O
ALT B-NonOSE_AE
elevation I-NonOSE_AE
was O
greater O
than O
three O
times O
the O
ULN O
on O
two O
consecutive O
tests O
, O
AUBAGIO O
was O
discontinued O
and O
patients O
underwent O
an O
accelerated O
elimination O
procedure O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

Of O
the O
patients O
who O
underwent O
discontinuation O
and O
accelerated O
elimination O
in O
controlled O
trials O
, O
half O
returned O
to O
normal O
or O
near O
normal O
values O
within O
2 O
months O
. O

One O
patient O
in O
the O
controlled O
trials O
developed O
ALT B-OSE_Labeled_AE
3 I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
times I-OSE_Labeled_AE
the I-OSE_Labeled_AE
ULN I-OSE_Labeled_AE
and O
jaundice B-OSE_Labeled_AE
5 O
months O
after O
initiation O
of O
AUBAGIO O
14 O
mg O
treatment O
. O

The O
patient O
was O
hospitalized O
for O
5 O
weeks O
and O
recovered O
after O
plasmapheresis O
and O
cholestyramine O
accelerated O
elimination O
procedure O
. O

AUBAGIO B-NonOSE_AE
- I-NonOSE_AE
induced I-NonOSE_AE
liver I-NonOSE_AE
injury I-NonOSE_AE
in O
this O
patient O
could O
not O
be O
ruled O
out O
. O

Obtain O
serum O
transaminase O
and O
bilirubin O
levels O
within O
6 O
months O
before O
initiation O
of O
AUBAGIO O
therapy O
. O

Monitor O
ALT O
levels O
at O
least O
monthly O
for O
six O
months O
after O
starting O
AUBAGIO O
. O

Consider O
additional O
monitoring O
when O
AUBAGIO O
is O
given O
with O
other O
potentially O
hepatotoxic B-NonOSE_AE
drugs I-NonOSE_AE
. O

Consider O
discontinuing O
AUBAGIO O
if O
serum O
transaminase B-NonOSE_AE
increase I-NonOSE_AE
( O
greater O
than O
three O
times O
the O
ULN O
) O
is O
confirmed O
. O

Monitor O
serum O
transaminase O
and O
bilirubin O
on O
AUBAGIO O
therapy O
, O
particularly O
in O
patients O
who O
develop O
symptoms O
suggestive O
of O
hepatic B-NonOSE_AE
dysfunction I-NonOSE_AE
, O
such O
as O
unexplained O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
fatigue B-NonOSE_AE
, O
anorexia B-NonOSE_AE
, O
or O
jaundice B-NonOSE_AE
and/or O
dark B-NonOSE_AE
urine I-NonOSE_AE
. O

If O
liver B-NonOSE_AE
injury I-NonOSE_AE
is O
suspected O
to O
be O
AUBAGIO-induced O
, O
discontinue O
AUBAGIO O
and O
start O
an O
accelerated O
elimination O
procedure O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
and O
monitor O
liver O
tests O
weekly O
until O
normalized O
. O

If O
AUBAGIO B-NonOSE_AE
- I-NonOSE_AE
induced I-NonOSE_AE
liver I-NonOSE_AE
injury I-NonOSE_AE
is O
unlikely O
because O
some O
other O
probable O
cause O
has O
been O
found O
, O
resumption O
of O
AUBAGIO O
therapy O
may O
be O
considered O
. O

5.2 O
Use O
in O
Women O
of O
Childbearing O
Potential O
There O
are O
no O
adequate O
and O
well-controlled O
studies O
evaluating O
AUBAGIO O
in O
pregnant B-Not_AE_Candidate
women O
. O

However O
, O
based O
on O
animal O
studies O
, O
teriflunomide O
may O
increase B-OSE_Labeled_AE
the I-OSE_Labeled_AE
risk I-OSE_Labeled_AE
of I-OSE_Labeled_AE
teratogenic I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
or O
fetal B-NonOSE_AE
death I-NonOSE_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
[ O
see O
Contraindications O
( O
4.2 O
) O
] O
. O

Women O
of O
childbearing O
potential O
must O
not O
be O
started O
on O
AUBAGIO O
until O
pregnancy B-Not_AE_Candidate
is O
excluded O
and O
it O
has O
been O
confirmed O
that O
they O
are O
using O
reliable O
contraception O
. O

Before O
starting O
treatment O
with O
AUBAGIO O
, O
patients O
must O
be O
fully O
counseled O
on O
the O
potential O
for O
serious O
risk O
to O
the O
fetus O
. O

The O
patient O
must O
be O
advised O
that O
if O
there O
is O
any O
delay O
in O
onset O
of O
menses O
or O
any O
other O
reason O
to O
suspect O
pregnancy B-NonOSE_AE
, O
they O
must O
notify O
the O
physician O
immediately O
for O
pregnancy O
testing O
and O
, O
if O
positive O
, O
the O
physician O
and O
patient O
must O
discuss O
the O
risk O
to O
the O
fetus O
. O

It O
is O
possible O
that O
rapidly O
lowering O
the O
plasma O
concentration O
of O
teriflunomide O
by O
instituting O
an O
accelerated O
elimination O
procedure O
may O
decrease O
the O
risk O
to O
the O
fetus O
from O
AUBAGIO O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

Upon O
discontinuing O
AUBAGIO O
, O
it O
is O
recommended O
that O
all O
women O
of O
childbearing O
potential O
undergo O
an O
accelerated O
elimination O
procedure O
. O

Women O
receiving O
AUBAGIO O
treatment O
who O
wish O
to O
become O
pregnant B-NonOSE_AE
must O
discontinue O
AUBAGIO O
and O
undergo O
an O
accelerated O
elimination O
procedure O
, O
which O
includes O
verification O
of O
teriflunomide O
plasma O
concentrations O
less O
than O
0.02 O
mg/L O
( O
0.02 O
mcg/mL O
) O
. O

Human O
plasma O
concentrations O
of O
teriflunomide O
less O
than O
0.02 O
mg/L O
( O
0.02 O
mcg/mL O
) O
are O
expected O
to O
have O
minimal O
risk O
[ O
see O
Contraindications O
( O
4.2 O
) O
, O
Warnings O
and O
Precautions O
( O
5.3 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

5.3 O
Procedure O
for O
Accelerated O
Elimination O
of O
Teriflunomide O
Teriflunomide O
is O
eliminated O
slowly O
from O
the O
plasma O
. O

Without O
an O
accelerated O
elimination O
procedure O
, O
it O
takes O
on O
average O
8 O
months O
to O
reach O
plasma O
concentrations O
less O
than O
0.02 O
mg/L O
, O
although O
because O
of O
individual O
variations O
in O
drug O
clearance O
it O
may O
take O
as O
long O
as O
2 O
years O
. O

An O
accelerated O
elimination O
procedure O
could O
be O
used O
at O
any O
time O
after O
discontinuation O
of O
AUBAGIO O
. O

Elimination O
can O
be O
accelerated O
by O
either O
of O
the O
following O
procedures O
: O
* O
Administration O
of O
cholestyramine O
8 O
g O
every O
8 O
hours O
for O
11 O
days O
. O

If O
cholestyramine O
8 O
g O
three O
times O
a O
day O
is O
not O
well O
tolerated O
, O
cholestyramine O
4 O
g O
three O
times O
a O
day O
can O
be O
used O
. O

* O
Administration O
of O
50 O
g O
oral O
activated O
charcoal O
powder O
every O
12 O
hours O
for O
11 O
days O
. O

If O
either O
elimination O
procedure O
is O
poorly O
tolerated O
, O
treatment O
days O
do O
not O
need O
to O
be O
consecutive O
unless O
there O
is O
a O
need O
to O
lower O
teriflunomide O
plasma O
concentration O
rapidly O
. O

At O
the O
end O
of O
11 O
days O
, O
both O
regimens O
successfully O
accelerated O
teriflunomide O
elimination O
, O
leading O
to O
more O
than O
98 O
% O
decrease O
in O
teriflunomide O
plasma O
concentrations O
. O

Use O
of O
the O
accelerated O
elimination O
procedure O
may O
potentially O
result O
in O
return O
of O
disease O
activity O
if O
the O
patient O
had O
been O
responding O
to O
AUBAGIO O
treatment O
. O

5.4 O
Bone O
Marrow O
Effects/Immunosuppression O
Potential/Infections O
White O
Blood O
Cell O
( O
WBC O
) O
count O
decrease O
A O
mean O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
white I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
( I-OSE_Labeled_AE
WBC I-OSE_Labeled_AE
) O
count O
of O
approximately O
15 O
% O
( O
mainly O
neutrophils O
and O
lymphocytes O
) O
and O
in O
platelet O
count O
of O
approximately O
10 O
% O
was O
observed O
in O
placebo-controlled O
trials O
with O
7 O
mg O
and O
14 O
mg O
of O
AUBAGIO O
compared O
to O
baseline O
. O

The O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
mean I-OSE_Labeled_AE
WBC I-OSE_Labeled_AE
count I-OSE_Labeled_AE
occurred O
during O
the O
first O
6 O
weeks O
and O
WBC O
count O
remained O
low O
during O
treatment O
. O

In O
placebo-controlled O
studies O
, O
neutrophil B-OSE_Labeled_AE
count I-OSE_Labeled_AE
< I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
* I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
9 I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
was O
observed O
in O
12 O
% O
and O
16 O
% O
of O
patients O
receiving O
AUBAGIO O
7 O
mg O
and O
14 O
mg O
, O
respectively O
, O
compared O
with O
7 O
% O
of O
patients O
receiving O
placebo O
; O
lymphocyte B-OSE_Labeled_AE
count I-OSE_Labeled_AE
< I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
8 I-OSE_Labeled_AE
* I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
9 I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
was O
observed O
in O
10 O
% O
and O
12 O
% O
of O
patients O
receiving O
AUBAGIO O
7 O
mg O
and O
14 O
mg O
, O
respectively O
, O
compared O
with O
6 O
% O
of O
patients O
receiving O
placebo O
. O

No O
cases O
of O
serious O
pancytopenia B-NonOSE_AE
were O
reported O
in O
premarketing O
clinical O
trials O
of O
AUBAGIO O
but O
rare O
cases O
of O
pancytopenia B-OSE_Labeled_AE
, O
agranulocytosis B-OSE_Labeled_AE
, O
and O
thrombocytopenia B-OSE_Labeled_AE
have O
been O
reported O
in O
the O
postmarketing O
setting O
with O
leflunomide O
. O

A O
similar O
risk O
would O
be O
expected O
for O
AUBAGIO O
[ O
see O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

Obtain O
a O
complete O
blood O
cell O
count O
( O
CBC O
) O
within O
6 O
months O
before O
the O
initiation O
of O
treatment O
with O
AUBAGIO O
. O

Further O
monitoring O
should O
be O
based O
on O
signs O
and O
symptoms O
suggestive O
of O
bone B-NonOSE_AE
marrow I-NonOSE_AE
suppression I-NonOSE_AE
. O

Risk O
of O
Infection O
/ O
Tuberculosis O
Screening O
Patients O
with O
active O
acute B-Not_AE_Candidate
or O
chronic O
infections I-Not_AE_Candidate
should O
not O
start O
treatment O
until O
the O
infection O
( O
s O
) O
is O
resolved O
. O

If O
a O
patient O
develops O
a O
serious O
infection B-NonOSE_AE
consider O
suspending O
treatment O
with O
AUBAGIO O
and O
using O
an O
accelerated O
elimination O
procedure O
. O

Reassess O
the O
benefits O
and O
risks O
prior O
to O
resumption O
of O
therapy O
. O

Instruct O
patients O
receiving O
AUBAGIO O
to O
report O
symptoms O
of O
infections B-NonOSE_AE
to O
a O
physician O
. O

AUBAGIO O
is O
not O
recommended O
for O
patients O
with O
severe O
immunodeficiency B-Not_AE_Candidate
, O
bone B-Not_AE_Candidate
marrow I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
or O
severe O
, O
uncontrolled O
infections B-Not_AE_Candidate
. O

Medications O
like O
AUBAGIO O
that O
have O
immunosuppression B-OSE_Labeled_AE
potential O
may O
cause O
patients O
to O
be O
more B-NonOSE_AE
susceptible I-NonOSE_AE
to I-NonOSE_AE
infections I-NonOSE_AE
, O
including O
opportunistic B-NonOSE_AE
infections I-NonOSE_AE
. O

In O
placebo-controlled O
studies O
of O
AUBAGIO O
, O
no O
overall O
increase O
in O
the O
risk O
of O
serious O
infections B-NonOSE_AE
was O
observed O
with O
AUBAGIO O
7 O
mg O
( O
2.2 O
% O
) O
or O
14 O
mg O
( O
2.7 O
% O
) O
compared O
to O
placebo O
( O
2.2 O
% O
) O
. O

However O
, O
one O
fatal O
case O
of O
klebsiella B-OSE_Labeled_AE
pneumonia I-OSE_Labeled_AE
sepsis I-OSE_Labeled_AE
occurred O
in O
a O
patient O
taking O
AUBAGIO O
14 O
mg O
for O
1.7 O
years O
. O

Fatal O
infections B-OSE_Labeled_AE
have O
been O
reported O
in O
the O
post-marketing O
setting O
in O
patients O
receiving O
leflunomide O
, O
especially O
Pneumocystis B-OSE_Labeled_AE
jiroveci I-OSE_Labeled_AE
pneumonia I-OSE_Labeled_AE
and O
aspergillosis B-OSE_Labeled_AE
. O

Most O
of O
the O
reports O
were O
confounded O
by O
concomitant O
immunosuppressant O
therapy O
and/or O
comorbid O
illness O
which O
, O
in O
addition O
to O
rheumatoid B-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
may O
predispose O
patients O
to O
infection B-NonOSE_AE
. O

In O
clinical O
studies O
with O
AUBAGIO O
, O
cytomegalovirus B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
has O
been O
observed O
. O

In O
clinical O
studies O
with O
AUBAGIO O
, O
cases O
of O
tuberculosis B-OSE_Labeled_AE
have O
been O
observed O
. O

Prior O
to O
initiating O
AUBAGIO O
, O
screen O
patients O
for O
latent B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
infection I-Not_AE_Candidate
with O
a O
tuberculin O
skin O
test O
or O
with O
a O
blood O
test O
for O
mycobacterium B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
infection I-Not_AE_Candidate
. O

AUBAGIO O
has O
not O
been O
studied O
in O
patients O
with O
a O
positive B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
screen I-Not_AE_Candidate
, O
and O
the O
safety O
of O
AUBAGIO O
in O
individuals O
with O
latent B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
infection I-Not_AE_Candidate
is O
unknown O
. O

For O
patients O
testing B-Not_AE_Candidate
positive I-Not_AE_Candidate
in I-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
screening I-Not_AE_Candidate
, O
treat O
by O
standard O
medical O
practice O
prior O
to O
therapy O
with O
AUBAGIO O
. O

Vaccination O
No O
clinical O
data O
are O
available O
on O
the O
efficacy O
and O
safety O
of O
live O
vaccinations O
in O
patients O
taking O
AUBAGIO O
. O

Vaccination O
with O
live O
vaccines O
is O
not O
recommended O
. O

The O
long O
half-life O
of O
AUBAGIO O
should O
be O
considered O
when O
contemplating O
administration O
of O
a O
live O
vaccine O
after O
stopping O
AUBAGIO O
. O

Malignancy O
The O
risk O
of O
malignancy B-OSE_Labeled_AE
, O
particularly O
lymphoproliferative B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
is O
increased O
with O
the O
use O
of O
some O
immunosuppressive B-NonOSE_AE
medications O
. O

There O
is O
a O
potential O
for O
immunosuppression B-OSE_Labeled_AE
with O
AUBAGIO O
. O

No O
apparent O
increase O
in O
the O
incidence O
of O
malignancies B-NonOSE_AE
and O
lymphoproliferative B-NonOSE_AE
disorders I-NonOSE_AE
was O
reported O
in O
the O
AUBAGIO O
clinical O
trials O
, O
but O
larger O
and O
longer-term O
studies O
would O
be O
needed O
to O
determine O
whether O
there O
is O
an O
increased O
risk O
of O
malignancy B-NonOSE_AE
or O
lymphoproliferative B-NonOSE_AE
disorders I-NonOSE_AE
with O
AUBAGIO O
. O

5.5 O
Peripheral O
Neuropathy O
In O
placebo-controlled O
studies O
, O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
including O
both O
polyneuropathy B-OSE_Labeled_AE
and O
mononeuropathy B-OSE_Labeled_AE
( O
e.g. O
, O
carpal B-OSE_Labeled_AE
tunnel I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
) O
, O
occurred O
more O
frequently O
in O
patients O
taking O
AUBAGIO O
than O
in O
patients O
taking O
placebo O
. O

The O
incidence O
of O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
confirmed O
by O
nerve O
conduction O
studies O
was O
1.4 O
% O
( O
13 O
patients O
) O
and O
1.9 O
% O
( O
17 O
patients O
) O
of O
patients O
receiving O
7 O
mg O
and O
14 O
mg O
of O
AUBAGIO O
, O
respectively O
, O
compared O
with O
0.4 O
% O
receiving O
placebo O
( O
4 O
patients O
) O
. O

Treatment O
was O
discontinued O
in O
0.7 O
% O
( O
8 O
patients O
) O
with O
confirmed O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
( O
3 O
patients O
receiving O
AUBAGIO O
7 O
mg O
and O
5 O
patients O
receiving O
AUBAGIO O
14 O
mg O
) O
. O

Five O
of O
them O
recovered O
following O
treatment O
discontinuation O
. O

Not O
all O
cases O
of O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
resolved O
with O
continued O
treatment O
. O

Peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
also O
occurred O
in O
patients O
receiving O
leflunomide O
. O

Age O
older O
than O
60 O
years O
, O
concomitant O
neurotoxic B-NonOSE_AE
medications I-NonOSE_AE
, O
and O
diabetes B-Not_AE_Candidate
may O
increase O
the O
risk O
for O
peripheral B-NonOSE_AE
neuropathy I-NonOSE_AE
. O

If O
a O
patient O
taking O
AUBAGIO O
develops O
symptoms O
consistent O
with O
peripheral B-NonOSE_AE
neuropathy I-NonOSE_AE
, O
such O
as O
bilateral B-NonOSE_AE
numbness I-NonOSE_AE
or O
tingling O
of I-NonOSE_AE
hands I-NonOSE_AE
or O
feet O
, O
consider O
discontinuing O
AUBAGIO O
therapy O
and O
performing O
an O
accelerated O
elimination O
procedure O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

5.6 O
Skin O
Reactions O
Rare O
cases O
of O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
and O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
with O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
receiving O
leflunomide O
. O

A O
similar O
risk O
would O
be O
expected O
for O
AUBAGIO O
[ O
see O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

If O
a O
patient O
taking O
AUBAGIO O
develops O
any O
of O
these O
conditions O
, O
stop O
AUBAGIO O
therapy O
and O
perform O
an O
accelerated O
elimination O
procedure O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

5.7 O
Increased O
Blood O
Pressure O
In O
placebo-controlled O
studies O
, O
the O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
from O
basel O
in I-OSE_Labeled_AE
e O
to O
the O
end O
of O
study O
in O
systolic I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
was O
+2.3 O
mmHg O
and O
+2.7 O
mmHg O
for O
AUBAGIO O
7 O
mg O
and O
14 O
mg O
, O
respectively O
, O
and O
-0.6 O
mmHg O
for O
placebo O
. O

The O
change B-OSE_Labeled_AE
from O
basel O
in I-OSE_Labeled_AE
e O
in O
diastolic I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
was O
+1.4 O
mmHg O
and O
+1.9 O
mmHg O
for O
AUBAGIO O
7 O
mg O
and O
14 O
mg O
, O
respectively O
, O
and O
-0.3 O
mmHg O
for O
placebo O
. O

Hypertension B-OSE_Labeled_AE
was O
an O
adverse O
reaction O
in O
3.1 O
% O
and O
4.3 O
% O
of O
patients O
treated O
with O
7 O
mg O
or O
14 O
mg O
of O
AUBAGIO O
compared O
with O
1.8 O
% O
for O
placebo O
. O

Check O
blood O
pressure O
before O
start O
of O
AUBAGIO O
treatment O
and O
periodically O
thereafter O
. O

Elevated B-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
should O
be O
appropriately O
managed O
during O
treatment O
with O
AUBAGIO O
. O

5.8 O
Respiratory B-OSE_Labeled_AE
Effects I-OSE_Labeled_AE
Interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
and O
worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
pre I-OSE_Labeled_AE
- I-OSE_Labeled_AE
existing I-OSE_Labeled_AE
interstitial I-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
have O
been O
reported O
during O
treatment O
with O
leflunomide O
. O

A O
similar O
risk O
would O
be O
expected O
for O
AUBAGIO O
[ O
see O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

Interstitial B-NonOSE_AE
lung I-NonOSE_AE
disease I-NonOSE_AE
may O
be O
fatal O
. O

Interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
may O
occur O
acutely O
at O
any O
time O
during O
therapy O
and O
has O
a O
variable O
clinical O
presentation O
. O

New O
onset O
or O
worsening B-NonOSE_AE
pulmonary I-NonOSE_AE
symptoms I-NonOSE_AE
, O
such O
as O
cough B-NonOSE_AE
and O
dyspnea B-NonOSE_AE
, O
with O
or O
without O
associated O
fever B-NonOSE_AE
, O
may O
be O
a O
reason O
for O
discontinuation O
of O
the O
therapy O
and O
for O
further O
investigation O
as O
appropriate O
. O

If O
discontinuation O
of O
the O
drug O
is O
necessary O
, O
consider O
initiation O
of O
an O
accelerated O
elimination O
procedure O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

5.9 O
Concomitant O
Use O
with O
Immunosuppressive O
or O
Immunomodulating O
Therapies O
Co-administration O
with O
antineoplastic O
, O
or O
immunosuppressive O
therapies O
used O
for O
treatment O
of O
multiple B-Not_AE_Candidate
sclerosis I-Not_AE_Candidate
has O
not O
been O
evaluated O
. O

Safety O
studies O
in O
which O
AUBAGIO O
was O
concomitantly O
administered O
with O
other O
immune O
modulating O
therapies O
for O
up O
to O
one O
year O
( O
interferon O
beta O
, O
glatiramer O
acetate O
) O
did O
not O
reveal O
any O
specific O
safety O
concerns O
. O

The O
long O
term O
safety O
of O
these O
combinations O
in O
the O
treatment O
of O
multiple B-Not_AE_Candidate
sclerosis I-Not_AE_Candidate
has O
not O
been O
established O
. O

In O
any O
situation O
in O
which O
the O
decision O
is O
made O
to O
switch O
from O
AUBAGIO O
to O
another O
agent O
with O
a O
known O
potential O
for O
hematologic B-NonOSE_AE
suppression I-NonOSE_AE
, O
it O
would O
be O
prudent O
to O
monitor O
for O
hematologic B-NonOSE_AE
toxicity I-NonOSE_AE
, O
because O
there O
will O
be O
overlap O
of O
systemic O
exposure O
to O
both O
compounds O
. O

Use O
of O
an O
accelerated O
elimination O
procedure O
may O
decrease O
this O
risk O
, O
but O
may O
also O
potentially O
result O
in O
return O
of O
disease O
activity O
if O
the O
patient O
had O
been O
responding O
to O
AUBAGIO O
treatment O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Gastrointestinal B-OSE_Labeled_AE
Perforations I-OSE_Labeled_AE
and O
Fistulae O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
Surgery O
and O
Wound B-OSE_Labeled_AE
Healing I-OSE_Labeled_AE
Complications I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Hemorrhage B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

* O
Arterial B-OSE_Labeled_AE
Thromboembolic I-OSE_Labeled_AE
Events I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

* O
Venous B-OSE_Labeled_AE
Thromboembolic I-OSE_Labeled_AE
Events I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

* O
Hypertension B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
. O

* O
Posterior B-OSE_Labeled_AE
Reversible I-OSE_Labeled_AE
Encephalopathy I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
. O

* O
Renal B-OSE_Labeled_AE
Injury I-OSE_Labeled_AE
and O
Proteinuria B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
. O

* O
Infusion B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
. O

* O
Ovarian B-OSE_Labeled_AE
Failure I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
. O

* O
Congestive B-NonOSE_AE
Heart I-NonOSE_AE
Failure I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.12 O
) O
. O

] O
. O

EXCERPT O
: O
Most O
common O
adverse O
reactions O
incidence O
( O
incidence O
> O
10 O
% O
) O
are O
epistaxis O
, O
headache O
, O
hypertension O
, O
rhinitis O
, O
proteinuria O
, O
taste O
alteration O
, O
dry O
skin O
, O
rectal O
hemorrhage O
, O
lacrimation O
disorder O
, O
back O
pain O
and O
exfoliative O
dermatitis O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Genentech O
, O
Inc O
. O
at O
1-888-835-2555 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trial O
Experience O
Because O
clinical O
studies O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
studies O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
studies O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
most O
common O
adverse O
reactions O
observed O
in O
patients O
receiving O
Avastin O
as O
a O
single O
agent O
or O
in O
combination O
with O
chemotherapy O
at O
a O
rate O
> O
10 O
% O
, O
are O
epistaxis B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
rhinitis B-OSE_Labeled_AE
, O
proteinuria B-OSE_Labeled_AE
, O
taste B-OSE_Labeled_AE
alteration I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
, O
rectal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
lacrimation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
and O
exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
. O

The O
safety O
data O
below O
reflect O
exposure O
to O
Avastin O
in O
2919 O
patients O
with O
mCRC B-Not_AE_Candidate
, O
non-squamous O
NSCLC B-Not_AE_Candidate
, O
glioblastoma B-Not_AE_Candidate
, O
mRCC B-Not_AE_Candidate
, O
cervical B-Not_AE_Candidate
cancer I-Not_AE_Candidate
, O
platinum-resistant O
or O
platinum-sensitive O
recurrent B-Not_AE_Candidate
epithelial I-Not_AE_Candidate
ovarian I-Not_AE_Candidate
, O
fallopian O
tube O
, O
or O
primary O
peritoneal O
cancer I-Not_AE_Candidate
, O
including O
controlled O
studies O
( O
AVF2107g O
, O
E3200 O
, O
E4599 O
, O
EORTC O
26101 O
, O
BO17705 O
, O
GOG-0240 O
, O
MO22224 O
, O
AVF4095 O
, O
GOG-0213 O
) O
at O
the O
recommended O
dose O
and O
schedule O
for O
a O
median O
of O
6 O
to O
23 O
doses O
. O

Across O
clinical O
studies O
, O
Avastin O
was O
discontinued O
in O
8 O
% O
to O
22 O
% O
of O
patients O
because O
of O
adverse O
reactions O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

Platinum O
- O
Resistant O
Recurrent O
Epithelia O
Ovarian O
, O
Fallopian O
Tube O
, O
or O
Primary O
Peritoneal O
Cancer O
The O
safety O
of O
Avastin O
was O
evaluated O
in O
179 O
patients O
who O
received O
at O
least O
one O
dose O
of O
Avastin O
in O
a O
multicenter O
, O
open-label O
study O
( O
MO22224 O
) O
in O
which O
patients O
were O
randomized O
( O
1:1 O
) O
to O
Avastin O
with O
chemotherapy O
or O
chemotherapy O
alone O
in O
patients O
with O
platinum O
resistant O
, O
recurrent B-Not_AE_Candidate
epithelial I-Not_AE_Candidate
ovarian I-Not_AE_Candidate
, O
fallopian O
tube O
, O
or O
primary O
peritoneal O
cancer I-Not_AE_Candidate
that O
recurred O
within O
< O
6 O
months O
from O
the O
most O
recent O
platinum O
based O
therapy O
. O

Patients O
were O
randomized O
to O
receive O
Avastin O
( O
10 O
mg/kg O
every O
2 O
weeks O
or O
15 O
mg/kg O
every O
3 O
weeks O
) O
. O

Patients O
had O
received O
no O
more O
than O
2 O
prior O
chemotherapy O
regimens O
. O

The O
trial O
excluded O
patients O
with O
evidence O
of O
recto B-Not_AE_Candidate
- I-Not_AE_Candidate
sigmoid I-Not_AE_Candidate
involvement I-Not_AE_Candidate
by O
pelvic O
examination O
or O
bowel B-Not_AE_Candidate
involvement I-Not_AE_Candidate
on O
CT O
scan O
or O
clinical O
symptoms O
of O
bowel B-Not_AE_Candidate
obstruction I-Not_AE_Candidate
. O

Patients O
were O
treated O
until O
disease O
progression O
or O
unacceptable O
toxicity O
. O

Forty O
percent O
of O
patients O
on O
the O
chemotherapy O
alone O
arm O
received O
Avastin O
alone O
upon O
progression O
. O

The O
demographics O
of O
the O
safety O
population O
were O
similar O
to O
the O
demographics O
of O
the O
efficacy O
population O
. O

Adverse O
reactions O
are O
presented O
in O
Table O
2 O
. O

Table O
2 O
: O
Grade O
2-4 O
Adverse O
Reactions O
Occurring O
at O
Higher O
Incidence O
( O
> O
= O
5 O
% O
) O
in O
Patients O
Receiving O
Avastin O
with O
Chemotherapy O
vs O
. O

Chemotherapy O
Alone O
in O
Study O
MO22224 O
Adverse O
Reaction O
[ O
note O
: O
NCI-CTC O
version O
3 O
] O
Avastin O
with O
Chemotherapy O
( O
N=179 O
) O
Chemotherapy O
( O
N=181 O
) O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
31 O
% O
25 O
% O
General B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
Mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
13 O
% O
6 O
% O
Infections B-NonOSE_AE
Infection B-OSE_Labeled_AE
11 O
% O
4 O
% O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Peripheral B-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
18 O
% O
7 O
% O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
Proteinuria B-OSE_Labeled_AE
12 O
% O
0.6 O
% O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Epistaxis B-OSE_Labeled_AE
5 O
% O
0 O
% O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
erythrodysaesthesia I-OSE_Labeled_AE
11 O
% O
5 O
% O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
19 O
% O
6 O
% O
Grade O
3-4 O
adverse O
reactions O
occurring O
at O
a O
higher O
incidence O
( O
> O
= O
2 O
% O
) O
in O
179 O
patients O
receiving O
Avastin O
with O
chemotherapy O
compared O
to O
181 O
patients O
receiving O
chemotherapy O
alone O
were O
hypertension B-OSE_Labeled_AE
( O
6.7 O
% O
vs O
. O
1.1 O
% O
) O
and O
palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
erythrodysaesthesia I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( O
4.5 O
% O
vs O
. O
1.7 O
% O
) O
. O

Platinum-Sensitive O
Recurrent O
Epithelial O
Ovarian O
, O
Fallopian O
Tube O
, O
or O
Primary O
Peritoneal O
Cancer O
The O
safety O
of O
Avastin O
was O
evaluated O
in O
247 O
patients O
who O
received O
at O
least O
one O
dose O
of O
Avastin O
in O
a O
double-blind O
study O
( O
AVF4095g O
) O
in O
patients O
with O
platinum O
sensitive O
recurrent B-Not_AE_Candidate
epithelial I-Not_AE_Candidate
ovarian I-Not_AE_Candidate
, O
fallopian O
tube O
or O
primary O
peritoneal O
cancer I-Not_AE_Candidate
. O

Patients O
were O
randomized O
( O
1:1 O
) O
to O
receive O
Avastin O
( O
15 O
mg/kg O
) O
or O
placebo O
every O
3 O
weeks O
with O
carboplatin O
and O
gemcitabine O
for O
6 O
to O
10 O
cycles O
followed O
by O
Avastin O
or O
placebo O
alone O
until O
disease O
progression O
or O
unacceptable O
toxicity O
. O

The O
demographics O
of O
the O
safety O
population O
were O
similar O
to O
the O
demographics O
of O
the O
efficacy O
population O
. O

Adverse O
reactions O
are O
presented O
in O
Table O
3 O
. O

Table O
3 O
: O
Grade O
1-5 O
Adverse O
Reactions O
Occurring O
at O
a O
Higher O
Incidence O
( O
> O
= O
5 O
% O
) O
in O
Patients O
Receiving O
Avastin O
with O
Chemotherapy O
vs O
. O

Placebo O
with O
Chemotherapy O
in O
Study O
AVF4095g O
Adverse O
Reaction O
[ O
note O
: O
NCI-CTC O
version O
3 O
] O
Avastin O
with O
Carboplatin O
and O
Gemcitabine O
( O
N=247 O
) O
Placebo O
with O
Carboplatin O
and O
Gemcitabine O
( O
N=233 O
) O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Thrombocytopenia B-OSE_Labeled_AE
58 O
% O
51 O
% O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
72 O
% O
66 O
% O
Diarrhea B-OSE_Labeled_AE
38 O
% O
29 O
% O
Stomatitis B-OSE_Labeled_AE
15 O
% O
7 O
% O
Hemorrhoids B-OSE_Labeled_AE
8 O
% O
3 O
% O
Gingival B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
7 O
% O
0 O
% O
General B-NonOSE_AE
disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
82 O
% O
75 O
% O
Mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
15 O
% O
10 O
% O
Infections B-NonOSE_AE
Sinusitis B-OSE_Labeled_AE
15 O
% O
9 O
% O
Injury B-NonOSE_AE
and I-NonOSE_AE
procedural I-NonOSE_AE
complications I-NonOSE_AE
Contusion B-OSE_Labeled_AE
17 O
% O
9 O
% O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
28 O
% O
19 O
% O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
21 O
% O
13 O
% O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
49 O
% O
30 O
% O
Dizziness B-OSE_Labeled_AE
23 O
% O
17 O
% O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
21 O
% O
15 O
% O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
Proteinuria B-OSE_Labeled_AE
20 O
% O
3 O
% O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Epistaxis B-OSE_Labeled_AE
55 O
% O
14 O
% O
Dyspnea B-OSE_Labeled_AE
30 O
% O
24 O
% O
Cough B-OSE_Labeled_AE
26 O
% O
18 O
% O
Oropharyngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
16 O
% O
10 O
% O
Dysphonia B-OSE_Labeled_AE
13 O
% O
3 O
% O
Rhinorrhea B-OSE_Labeled_AE
10 O
% O
4 O
% O
Sinus B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
8 O
% O
2 O
% O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
42 O
% O
9 O
% O
Grade O
3-4 O
adverse O
reactions O
occurring O
at O
a O
higher O
incidence O
( O
> O
= O
2 O
% O
) O
in O
patients O
receiving O
Avastin O
with O
chemotherapy O
compared O
to O
placebo O
with O
chemotherapy O
were O
: O
thrombocytopenia B-OSE_Labeled_AE
( O
40 O
% O
vs O
. O
34 O
% O
) O
, O
nausea B-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
1.3 O
% O
) O
, O
fatigue B-OSE_Labeled_AE
( O
6 O
% O
vs O
. O
4 O
% O
) O
, O
headache B-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
0.9 O
% O
) O
, O
proteinuria B-OSE_Labeled_AE
( O
10 O
% O
vs O
. O
0.4 O
% O
) O
, O
dyspnea B-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
1.7 O
% O
) O
, O
epistaxis B-OSE_Labeled_AE
( O
5 O
% O
vs O
. O
0.4 O
% O
) O
, O
and O
hypertension B-OSE_Labeled_AE
( O
17 O
% O
vs O
. O
0.9 O
% O
) O
. O

The O
safety O
of O
Avastin O
was O
evaluated O
in O
an O
open-label O
, O
controlled O
study O
, O
GOG-0213 O
, O
in O
325 O
patients O
with O
platinum-sensitive O
recurrent B-Not_AE_Candidate
epithelial I-Not_AE_Candidate
ovarian I-Not_AE_Candidate
, O
fallopian O
tube O
, O
or O
primary O
peritoneal O
cancer I-Not_AE_Candidate
, O
who O
have O
not O
received O
more O
than O
one O
previous O
regimen O
of O
chemotherapy O
. O

Patients O
were O
randomized O
( O
1:1 O
) O
to O
receive O
carboplatin O
and O
paclitaxel O
for O
6 O
to O
8 O
cycles O
or O
Avastin O
( O
15 O
mg/kg O
every O
3 O
weeks O
) O
with O
carboplatin O
and O
paclitaxel O
for O
6 O
to O
8 O
cycles O
followed O
by O
Avastin O
as O
a O
single O
agent O
until O
disease O
progression O
or O
unacceptable O
toxicity O
. O

The O
demographics O
of O
the O
safety O
population O
were O
similar O
to O
the O
demographics O
of O
the O
efficacy O
population O
. O

Adverse O
reactions O
are O
presented O
in O
Table O
4 O
. O

Table O
4 O
: O
Grade O
1-5 O
Adverse O
Reactions O
Occurring O
at O
Higher O
Incidence O
( O
> O
= O
5 O
% O
) O
in O
Patients O
Receiving O
Avastin O
with O
Chemotherapy O
vs O
. O

Chemotherapy O
Alone O
in O
Study O
GOG-0213 O
Adverse O
Reaction O
[ O
note O
: O
NCI-CTC O
version O
3 O
] O
Avastin O
with O
Carboplatin O
and O
Paclitaxel O
( O
N=325 O
) O
Carboplatin O
and O
Paclitaxel O
( O
N=332 O
) O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
39 O
% O
32 O
% O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
33 O
% O
28 O
% O
Vomiting B-OSE_Labeled_AE
33 O
% O
25 O
% O
Stomatitis B-OSE_Labeled_AE
33 O
% O
16 O
% O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
35 O
% O
25 O
% O
Hyperglycemia B-OSE_Labeled_AE
31 O
% O
24 O
% O
Hypomagnesemia B-OSE_Labeled_AE
27 O
% O
17 O
% O
Hyponatremia B-OSE_Labeled_AE
17 O
% O
6 O
% O
Weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
15 O
% O
4 O
% O
Hypocalcemia B-OSE_Labeled_AE
12 O
% O
5 O
% O
Hypoalbuminemia B-OSE_Labeled_AE
11 O
% O
6 O
% O
Hyperkalemia B-OSE_Labeled_AE
9 O
% O
3 O
% O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
45 O
% O
30 O
% O
Myalgia B-OSE_Labeled_AE
29 O
% O
18 O
% O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
25 O
% O
14 O
% O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
17 O
% O
10 O
% O
Muscular B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
13 O
% O
8 O
% O
Neck B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
9 O
% O
0 O
% O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Epistaxis B-OSE_Labeled_AE
33 O
% O
2 O
% O
Dyspnea B-OSE_Labeled_AE
30 O
% O
25 O
% O
Cough B-OSE_Labeled_AE
30 O
% O
17 O
% O
Rhinitis B-OSE_Labeled_AE
allergic I-OSE_Labeled_AE
17 O
% O
4 O
% O
Nasal B-OSE_Labeled_AE
mucosal I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
14 O
% O
3 O
% O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
38 O
% O
20 O
% O
Dysarthria B-OSE_Labeled_AE
14 O
% O
2 O
% O
Dizziness B-OSE_Labeled_AE
13 O
% O
8 O
% O
Hepatic B-NonOSE_AE
Disorders I-NonOSE_AE
Aspartate B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
15 O
% O
9 O
% O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Exfoliative B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
23 O
% O
16 O
% O
Nail B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
10 O
% O
2 O
% O
Dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
7 O
% O
2 O
% O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
42 O
% O
3 O
% O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
Proteinuria B-OSE_Labeled_AE
17 O
% O
1 O
% O
Blood B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
13 O
% O
5 O
% O
General B-NonOSE_AE
disorders I-NonOSE_AE
Chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
8 O
% O
2 O
% O
Infections B-NonOSE_AE
Sinusitis B-OSE_Labeled_AE
7 O
% O
2 O
% O
Grade O
3-4 O
adverse O
reactions O
occurring O
at O
a O
higher O
incidence O
( O
> O
= O
2 O
% O
) O
in O
patients O
receiving O
Avastin O
with O
chemotherapy O
compared O
to O
chemotherapy O
alone O
were O
: O
hypertension B-OSE_Labeled_AE
( O
11 O
% O
vs O
. O
0.6 O
% O
) O
, O
fatigue B-OSE_Labeled_AE
( O
8 O
% O
vs O
. O
3 O
% O
) O
, O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
( O
6 O
% O
vs O
. O
3 O
% O
) O
, O
proteinuria B-OSE_Labeled_AE
( O
8 O
% O
vs O
. O
0 O
% O
) O
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
6 O
% O
vs O
. O
0.9 O
% O
) O
, O
hyponatremia B-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
0.9 O
% O
) O
, O
headache B-OSE_Labeled_AE
( O
3 O
% O
vs O
. O
0.9 O
% O
) O
, O
and O
pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
( O
3 O
% O
vs O
. O
0 O
% O
) O
. O

Metastatic O
Renal O
Cell O
Carcinoma O
( O
mRCC O
) O
The O
safety O
of O
Avastin O
was O
evaluated O
in O
337 O
patients O
who O
received O
at O
least O
one O
dose O
of O
Avastin O
in O
a O
multicenter O
, O
double-blind O
study O
( O
BO17705 O
) O
in O
patients O
with O
metastatic B-Not_AE_Candidate
renal I-Not_AE_Candidate
cell I-Not_AE_Candidate
carcinoma I-Not_AE_Candidate
. O

Patients O
who O
had O
undergone O
a O
nephrectomy O
were O
randomized O
( O
1:1 O
) O
to O
receive O
either O
Avastin O
( O
10 O
mg/kg O
every O
2 O
weeks O
) O
or O
placebo O
with O
interferon O
alfa O
. O

Patients O
were O
treated O
until O
disease O
progression O
or O
unacceptable O
toxicity O
. O

The O
demographics O
of O
the O
safety O
population O
were O
similar O
to O
the O
demographics O
of O
the O
efficacy O
population O
. O

Grade O
3-5 O
adverse O
reactions O
occurring O
at O
a O
higher O
incidence O
( O
> O
2 O
% O
) O
were O
fatigue B-OSE_Labeled_AE
( O
13 O
% O
vs O
. O
8 O
% O
) O
, O
asthenia B-OSE_Labeled_AE
( O
10 O
% O
vs O
. O
7 O
% O
) O
, O
proteinuria B-OSE_Labeled_AE
( O
7 O
% O
vs O
. O
0 O
% O
) O
, O
hypertension B-OSE_Labeled_AE
( O
6 O
% O
vs O
. O
1 O
% O
; O
including O
hypertension B-OSE_Labeled_AE
and O
hypertensive B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
) O
, O
and O
hemorrhage B-OSE_Labeled_AE
( O
3 O
% O
vs O
. O
0.3 O
% O
; O
including O
epistaxis B-OSE_Labeled_AE
, O
small O
intestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
aneurysm B-OSE_Labeled_AE
ruptured I-OSE_Labeled_AE
, O
gastric B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
gingival B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
, O
hemoptysis B-OSE_Labeled_AE
, O
hemorrhage B-OSE_Labeled_AE
intracranial I-OSE_Labeled_AE
, O
large O
intestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
and O
traumatic B-OSE_Labeled_AE
hematoma I-OSE_Labeled_AE
) O
. O

Adverse O
reactions O
are O
presented O
in O
Table O
5 O
. O

Table O
5 O
: O
Grades O
1-5 O
Adverse O
Reactions O
Occurring O
at O
Higher O
Incidence O
( O
> O
= O
5 O
% O
) O
of O
Patients O
Receiving O
Avastin O
vs O
. O

Placebo O
with O
Interferon O
Alfa O
in O
Study O
BO17705 O
Adverse O
Reaction O
[ O
note O
: O
NCI-CTC O
version O
3 O
] O
Avastin O
with O
Interferon O
Alfa O
( O
N=337 O
) O
Placebo O
with O
Interferon O
Alfa O
( O
N=304 O
) O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
21 O
% O
16 O
% O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
33 O
% O
27 O
% O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
36 O
% O
31 O
% O
Weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
20 O
% O
15 O
% O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Myalgia B-OSE_Labeled_AE
19 O
% O
14 O
% O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
12 O
% O
6 O
% O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
24 O
% O
16 O
% O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
Proteinuria B-OSE_Labeled_AE
20 O
% O
3 O
% O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Epistaxis B-OSE_Labeled_AE
27 O
% O
4 O
% O
Dysphonia B-OSE_Labeled_AE
5 O
% O
0 O
% O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
28 O
% O
9 O
% O
The O
following O
adverse O
reactions O
were O
reported O
at O
a O
5-fold O
greater O
incidence O
in O
patients O
receiving O
Avastin O
with O
interferon-alfa O
compared O
to O
patients O
receiving O
placebo O
with O
interferon-alfa O
and O
not O
represented O
in O
Table O
3 O
: O
gingival B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
( O
13 O
patients O
vs O
. O
1 O
patient O
) O
; O
rhinitis B-OSE_Labeled_AE
( O
9 O
vs O
. O
0 O
) O
; O
blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
( O
8 O
vs O
. O
0 O
) O
; O
gingivitis B-OSE_Labeled_AE
( O
8 O
vs O
. O
1 O
) O
; O
gastroesophageal B-OSE_Labeled_AE
reflux I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
( O
8 O
vs O
. O
1 O
) O
; O
tinnitus B-OSE_Labeled_AE
( O
7 O
vs O
. O
1 O
) O
; O
tooth B-OSE_Labeled_AE
abscess I-OSE_Labeled_AE
( O
7 O
vs O
. O
0 O
) O
; O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
( O
6 O
vs O
. O
0 O
) O
; O
acne B-OSE_Labeled_AE
( O
5 O
vs O
. O
0 O
) O
; O
deafness B-OSE_Labeled_AE
( O
5 O
vs O
. O
0 O
) O
; O
gastritis B-OSE_Labeled_AE
( O
5 O
vs O
. O
0 O
) O
; O
gingival B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
5 O
vs O
. O
0 O
) O
and O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
( O
5 O
vs O
. O
1 O
) O
. O

Persistent O
, O
Recurrent O
, O
or O
Metastatic O
Cervical O
Cancer O
The O
safety O
of O
Avastin O
was O
evaluated O
in O
218 O
patients O
who O
received O
at O
least O
one O
dose O
of O
Avastin O
in O
a O
multicenter O
study O
( O
GOG-0240 O
) O
in O
patients O
with O
persistent O
, O
recurrent B-Not_AE_Candidate
, O
or O
metastatic O
cervical I-Not_AE_Candidate
cancer I-Not_AE_Candidate
. O

Patients O
were O
randomized O
( O
1:1:1:1 O
) O
to O
receive O
paclitaxel O
and O
cisplatin O
with O
or O
without O
Avastin O
( O
15 O
mg/kg O
every O
3 O
weeks O
) O
, O
or O
paclitaxel O
and O
topotecan O
with O
or O
without O
Avastin O
( O
15 O
mg/kg O
every O
3 O
weeks O
) O
. O

The O
demographics O
of O
the O
safety O
population O
were O
similar O
to O
the O
demographics O
of O
the O
efficacy O
population O
. O

Adverse O
reactions O
are O
presented O
in O
Table O
6 O
. O

Table O
6 O
: O
Grades O
1-4 O
Adverse O
Reactions O
Occurring O
at O
Higher O
Incidence O
( O
> O
= O
5 O
% O
) O
in O
Patients O
Receiving O
Avastin O
with O
Chemotherapy O
vs O
. O

Chemotherapy O
Alone O
in O
Study O
GOG-0240 O
Adverse O
Reaction O
[ O
note O
: O
NCI-CTC O
version O
3 O
] O
Avastin O
with O
Chemotherapy O
( O
N=218 O
) O
Chemotherapy O
( O
N=222 O
) O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
34 O
% O
26 O
% O
Hyperglycemia B-OSE_Labeled_AE
26 O
% O
19 O
% O
Hypomagnesemia B-OSE_Labeled_AE
24 O
% O
15 O
% O
Weight B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
21 O
% O
7 O
% O
Hyponatremia B-OSE_Labeled_AE
19 O
% O
10 O
% O
Hypoalbuminemia B-OSE_Labeled_AE
16 O
% O
11 O
% O
General B-NonOSE_AE
disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
80 O
% O
75 O
% O
Edema B-OSE_Labeled_AE
Peripheral I-OSE_Labeled_AE
15 O
% O
22 O
% O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
22 O
% O
14 O
% O
Infection B-OSE_Labeled_AE
10 O
% O
5 O
% O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
29 O
% O
6 O
% O
Thrombosis B-OSE_Labeled_AE
10 O
% O
3 O
% O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
22 O
% O
13 O
% O
Dysarthria B-OSE_Labeled_AE
8 O
% O
1 O
% O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Stomatitis B-OSE_Labeled_AE
15 O
% O
10 O
% O
Proctalgia B-OSE_Labeled_AE
6 O
% O
1 O
% O
Anal B-OSE_Labeled_AE
fistula I-OSE_Labeled_AE
6 O
% O
0.0 O
% O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
12 O
% O
6 O
% O
Lymphopenia B-OSE_Labeled_AE
12 O
% O
5 O
% O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
Anxiety B-OSE_Labeled_AE
17 O
% O
10 O
% O
Reproductive B-NonOSE_AE
system I-NonOSE_AE
and I-NonOSE_AE
breast I-NonOSE_AE
disorders I-NonOSE_AE
Pelvic B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
14 O
% O
8 O
% O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Epistaxis B-OSE_Labeled_AE
17 O
% O
1 O
% O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
Blood B-OSE_Labeled_AE
Creatinine I-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
16 O
% O
10 O
% O
Proteinuria B-OSE_Labeled_AE
10 O
% O
3 O
% O
Grade O
3-4 O
adverse O
reactions O
occurring O
at O
a O
higher O
incidence O
( O
> O
= O
2 O
% O
) O
in O
218 O
patients O
receiving O
Avastin O
with O
chemotherapy O
compared O
to O
222 O
patients O
receiving O
chemotherapy O
alone O
were O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
12 O
% O
vs O
. O
10 O
% O
) O
, O
hypertension B-OSE_Labeled_AE
( O
11 O
% O
vs O
. O
0.5 O
% O
) O
, O
thrombosis B-OSE_Labeled_AE
( O
8 O
% O
vs O
. O
3 O
% O
) O
, O
diarrhea B-OSE_Labeled_AE
( O
6 O
% O
vs O
. O
3 O
% O
) O
, O
anal B-OSE_Labeled_AE
fistula I-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
0 O
% O
) O
, O
proctalgia B-OSE_Labeled_AE
( O
3 O
% O
vs O
. O
0 O
% O
) O
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
8 O
% O
vs O
. O
6 O
% O
) O
, O
cellulitis B-OSE_Labeled_AE
( O
3 O
% O
vs O
. O
0.5 O
% O
) O
, O
fatigue B-OSE_Labeled_AE
( O
14 O
% O
vs O
. O
10 O
% O
) O
, O
hypokalemia B-OSE_Labeled_AE
( O
7 O
% O
vs O
. O
4 O
% O
) O
, O
hyponatremia B-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
1 O
% O
) O
, O
dehydration B-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
0.5 O
% O
) O
, O
neutropenia B-OSE_Labeled_AE
( O
8 O
% O
vs O
. O
4 O
% O
) O
, O
lymphopenia B-OSE_Labeled_AE
( O
6 O
% O
vs O
. O
3 O
% O
) O
, O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
6 O
% O
vs O
. O
3 O
% O
) O
, O
and O
pelvic B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
6 O
% O
vs O
. O
1 O
% O
) O
. O

Metastatic O
Colorectal O
Cancer O
( O
mCRC O
) O
The O
safety O
of O
Avastin O
was O
evaluated O
in O
392 O
patients O
who O
received O
at O
least O
one O
dose O
of O
Avastin O
in O
a O
double-blind O
, O
active-controlled O
study O
( O
AVF2107g O
) O
, O
which O
compared O
Avastin O
( O
5 O
mg/kg O
every O
2 O
weeks O
) O
with O
bolus-IFL O
to O
placebo O
with O
bolus O
IFL O
in O
patients O
with O
mCRC O
. O

Patients O
were O
randomized O
( O
1:1:1 O
) O
to O
placebo O
with O
bolus O
IFL O
, O
Avastin O
with O
bolus O
IFL O
, O
or O
Avastin O
with O
5 O
fluorouracil O
and O
leucovorin O
. O

The O
demographics O
of O
the O
safety O
population O
were O
similar O
to O
the O
demographics O
of O
the O
efficacy O
population O
. O

All O
Grade O
3-4 O
adverse O
reactions O
and O
selected O
Grade O
1-2 O
adverse O
reactions O
( O
i.e. O
, O
hypertension B-NonOSE_AE
, O
proteinuria B-NonOSE_AE
, O
thromboembolic B-NonOSE_AE
events I-NonOSE_AE
) O
were O
collected O
in O
the O
entire O
study O
population O
. O

Adverse O
reactions O
are O
presented O
in O
Table O
7 O
. O

Table O
7 O
: O
Grade O
3-4 O
Adverse O
Reactions O
Occurring O
at O
Higher O
Incidence O
( O
> O
= O
2 O
% O
) O
in O
Patients O
Receiving O
Avastin O
vs O
. O

Placebo O
in O
Study O
AVF2107g O
Adverse O
Reaction O
[ O
note O
: O
NCI-CTC O
version O
3 O
] O
Avastin O
with O
IFL O
( O
N=392 O
) O
Placebo O
with O
IFL O
( O
N=396 O
) O
General B-NonOSE_AE
disorders I-NonOSE_AE
Asthenia B-OSE_Labeled_AE
10 O
% O
7 O
% O
Pain B-OSE_Labeled_AE
8 O
% O
5 O
% O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
12 O
% O
2 O
% O
Deep B-OSE_Labeled_AE
Vein I-OSE_Labeled_AE
Thrombosis I-OSE_Labeled_AE
9 O
% O
5 O
% O
Intra B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Abdominal I-OSE_Labeled_AE
Thrombosis I-OSE_Labeled_AE
3 O
% O
1 O
% O
Syncope B-OSE_Labeled_AE
3 O
% O
1 O
% O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
34 O
% O
25 O
% O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
8 O
% O
5 O
% O
Constipation B-OSE_Labeled_AE
4 O
% O
2 O
% O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
disorders I-NonOSE_AE
Leukopenia B-OSE_Labeled_AE
37 O
% O
31 O
% O
Neutropenia B-OSE_Labeled_AE
21 O
% O
14 O
% O
The O
safety O
of O
Avastin O
was O
evaluated O
in O
521 O
patients O
in O
an O
open-label O
, O
active-controlled O
study O
( O
E3200 O
) O
. O

Patients O
who O
were O
previously O
treated O
with O
irinotecan O
and O
fluorouracil O
for O
initial O
therapy O
for O
metastatic B-Not_AE_Candidate
colorectal I-Not_AE_Candidate
cancer I-Not_AE_Candidate
. O

Patients O
were O
randomized O
( O
1:1:1 O
) O
to O
FOLFOX4 O
, O
Avastin O
( O
10 O
mg/kg O
every O
2 O
weeks O
prior O
to O
FOLFOX4 O
on O
Day O
1 O
) O
with O
FOLFOX4 O
, O
or O
Avastin O
alone O
( O
10 O
mg/kg O
every O
2 O
weeks O
) O
. O

Avastin O
was O
continued O
until O
disease O
progression O
or O
unacceptable O
toxicity O
. O

The O
demographics O
of O
the O
safety O
population O
were O
similar O
to O
the O
demographics O
of O
the O
efficacy O
population O
. O

The O
most O
frequent O
adverse O
reactions O
( O
selected O
Grade O
3-5 O
non-hematologic O
and O
Grade O
4-5 O
hematologic O
) O
occurring O
at O
a O
higher O
incidence O
( O
> O
= O
2 O
% O
) O
in O
patients O
receiving O
Avastin O
with O
FOLFOX4 O
compared O
to O
FOLFOX4 O
alone O
were O
fatigue B-OSE_Labeled_AE
( O
19 O
% O
vs O
. O
13 O
% O
) O
, O
diarrhea B-OSE_Labeled_AE
( O
18 O
% O
vs O
. O
13 O
% O
) O
, O
sensory B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
( O
17 O
% O
vs O
. O
9 O
% O
) O
, O
nausea B-OSE_Labeled_AE
( O
12 O
% O
vs O
. O
5 O
% O
) O
, O
vomiting B-OSE_Labeled_AE
( O
11 O
% O
vs O
. O
4 O
% O
) O
, O
dehydration B-OSE_Labeled_AE
( O
10 O
% O
vs O
. O
5 O
% O
) O
, O
hypertension B-OSE_Labeled_AE
( O
9 O
% O
vs O
. O
2 O
% O
) O
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
8 O
% O
vs O
. O
5 O
% O
) O
, O
hemorrhage B-OSE_Labeled_AE
( O
5 O
% O
vs O
. O
1 O
% O
) O
, O
other B-OSE_Labeled_AE
neurological I-OSE_Labeled_AE
( O
5 O
% O
vs O
. O
3 O
% O
) O
, O
ileus B-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
1 O
% O
) O
and O
headache B-OSE_Labeled_AE
( O
3 O
% O
vs O
. O
0 O
% O
) O
. O

These O
data O
are O
likely O
to O
under-estimate O
the O
true O
adverse O
event O
rates O
due O
to O
the O
reporting O
mechanisms O
. O

First-Line O
Non O
Squamous O
Non O
Small O
Cell O
Lung O
Cancer O
( O
NSCLC O
) O
The O
safety O
of O
Avastin O
was O
evaluated O
as O
first-line O
treatment O
in O
422 O
patients O
with O
unresectable O
NSCLC B-Not_AE_Candidate
who O
received O
at O
least O
one O
dose O
of O
Avastin O
in O
an O
active-controlled O
, O
open-label O
, O
multicenter O
trial O
( O
E4599 O
) O
. O

Chemotherapy O
naive O
patients O
with O
locally O
advanced O
, O
metastatic O
or O
recurrent O
non-squamous O
NSCLC B-Not_AE_Candidate
were O
randomized O
( O
1:1 O
) O
to O
receive O
six O
21 O
day O
cycles O
of O
paclitaxel O
and O
carboplatin O
with O
or O
without O
Avastin O
( O
15 O
mg/kg O
every O
3 O
weeks O
) O
. O

After O
completion O
or O
upon O
discontinuation O
of O
chemotherapy O
, O
patients O
randomized O
to O
receive O
Avastin O
continued O
to O
receive O
Avastin O
alone O
until O
disease O
progression O
or O
until O
unacceptable O
toxicity O
. O

The O
trial O
excluded O
patients O
with O
predominant O
squamous O
histology O
( O
mixed O
cell O
type O
tumors O
only O
) O
, O
CNS B-Not_AE_Candidate
metastasis I-Not_AE_Candidate
, O
gross B-Not_AE_Candidate
hemoptysis I-Not_AE_Candidate
( O
1/2 O
teaspoon O
or O
more O
of O
red O
blood O
) O
, O
unstable B-Not_AE_Candidate
angina I-Not_AE_Candidate
, O
or O
receiving O
therapeutic O
anticoagulation O
. O

The O
demographics O
of O
the O
safety O
population O
were O
similar O
to O
the O
demographics O
of O
the O
efficacy O
population O
. O

Only O
Grade O
3-5 O
non O
hematologic O
and O
Grade O
4-5 O
hematologic B-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
were O
collected O
. O

Grade O
3-5 O
non B-NonOSE_AE
hematologic I-NonOSE_AE
and O
Grade O
4-5 O
hematologic O
adverse I-NonOSE_AE
reactions I-NonOSE_AE
occurring O
at O
a O
higher O
incidence O
( O
> O
= O
2 O
% O
) O
in O
patients O
receiving O
Avastin O
with O
paclitaxel O
and O
carboplatin O
compared O
with O
patients O
receiving O
chemotherapy O
alone O
were O
neutropenia B-OSE_Labeled_AE
( O
27 O
% O
vs O
. O
17 O
% O
) O
, O
fatigue B-OSE_Labeled_AE
( O
16 O
% O
vs O
. O
13 O
% O
) O
, O
hypertension B-OSE_Labeled_AE
( O
8 O
% O
vs O
. O
0.7 O
% O
) O
, O
infection O
without O
neutropenia B-OSE_Labeled_AE
( O
7 O
% O
vs O
. O
3 O
% O
) O
, O
venous B-OSE_Labeled_AE
thromboembolism I-OSE_Labeled_AE
( O
5 O
% O
vs O
. O
3 O
% O
) O
, O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
( O
5 O
% O
vs O
. O
2 O
% O
) O
, O
pneumonitis B-OSE_Labeled_AE
/ O
pulmonary B-OSE_Labeled_AE
infiltrates I-OSE_Labeled_AE
( O
5 O
% O
vs O
. O
3 O
% O
) O
, O
infection O
with O
Grade O
3 O
or O
4 O
neutropenia B-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
2 O
% O
) O
, O
hyponatremia B-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
1 O
% O
) O
, O
headache B-OSE_Labeled_AE
( O
3 O
% O
vs O
. O
1 O
% O
) O
and O
proteinuria B-OSE_Labeled_AE
( O
3 O
% O
vs O
. O
0 O
% O
) O
. O

Recurrent O
Glioblastoma O
EORTC O
26101 O
was O
a O
multicenter O
, O
randomized O
, O
open-label O
study O
in O
patients O
with O
recurrent B-Not_AE_Candidate
GBM I-Not_AE_Candidate
following O
radiotherapy O
and O
temozolomide O
of O
whom O
278 O
patients O
received O
at O
least O
one O
dose O
of O
Avastin O
and O
are O
considered O
safety O
evaluable O
. O

Patients O
were O
randomized O
( O
2:1 O
) O
to O
receive O
Avastin O
( O
10 O
mg/kg O
every O
2 O
weeks O
) O
with O
lomustine O
or O
lomustine O
alone O
until O
disease O
progression O
or O
unacceptable O
toxicity O
. O

The O
demographics O
of O
the O
safety O
population O
were O
similar O
to O
the O
demographics O
of O
the O
efficacy O
population O
. O

In O
the O
Avastin O
with O
lomustine O
arm O
, O
22 O
% O
of O
patients O
discontinued O
treatment O
due O
to O
adverse O
reactions O
compared O
with O
10 O
% O
of O
patients O
in O
the O
lomustine O
arm O
. O

In O
patients O
receiving O
Avastin O
with O
lomustine O
, O
the O
adverse O
reaction O
profile O
was O
similar O
to O
that O
observed O
in O
other O
approved O
indications O
. O

6.2 O
Immunogenicity O
As O
with O
all O
therapeutic O
proteins O
, O
there O
is O
a O
potential O
for O
immunogenicity B-OSE_Labeled_AE
. O

The O
detection O
of O
antibody B-NonOSE_AE
formation I-NonOSE_AE
is O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
. O

Additionally O
, O
the O
observed O
incidence O
of O
antibody B-NonOSE_AE
( O
including O
neutralizing O
antibody O
) O
positivity I-NonOSE_AE
in O
an O
assay O
may O
be O
influenced O
by O
several O
factors O
, O
including O
assay O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
bevacizumab I-NonOSE_AE
in O
the O
studies O
described O
below O
with O
the O
incidence O
of O
antibodies B-NonOSE_AE
in O
other O
studies O
or O
to I-NonOSE_AE
other I-NonOSE_AE
products I-NonOSE_AE
may O
be O
misleading O
. O

In O
clinical O
studies O
for O
adjuvant O
treatment O
of O
a O
solid O
tumor B-NonOSE_AE
, O
0.6 O
% O
( O
14/2323 O
) O
of O
patients O
tested O
positive O
for O
treatment-emergent O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
bevacizumab I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
as O
detected O
by O
an O
electrochemiluminescent O
( O
ECL O
) O
based O
assay O
. O

Among O
these O
14 O
patients O
, O
three O
tested O
positive B-OSE_Labeled_AE
for I-OSE_Labeled_AE
neutralizing I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
against O
bevacizumab O
using O
an O
enzyme-linked O
immunosorbent O
assay O
( O
ELISA O
) O
. O

The O
clinical O
significance O
of O
these O
anti B-NonOSE_AE
- I-NonOSE_AE
bevacizumab I-NonOSE_AE
antibodies I-NonOSE_AE
is O
not O
known O
. O

6.3 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
Avastin O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
: O
Polyserositis B-OSE_Labeled_AE
Cardiovascular B-NonOSE_AE
: O
Pulmonary B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
, O
Mesenteric B-OSE_Labeled_AE
venous I-OSE_Labeled_AE
occlusion I-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
: O
Gastrointestinal B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
, O
Intestinal B-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
, O
Anastomotic B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
Hemic B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
: O
Pancytopenia B-OSE_Labeled_AE
Hepatobiliary B-NonOSE_AE
disorders I-NonOSE_AE
: O
Gallbladder B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Osteonecrosis B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
jaw I-OSE_Labeled_AE
Renal O
: O
Renal B-OSE_Labeled_AE
thrombotic I-OSE_Labeled_AE
microangiopathy I-OSE_Labeled_AE
( O
manifested O
as O
severe O
proteinuria B-NonOSE_AE
) O
Respiratory B-NonOSE_AE
: O
Nasal B-OSE_Labeled_AE
septum I-OSE_Labeled_AE
perforation I-OSE_Labeled_AE

BOXED O
WARNING O
: O
WARNING O
: O
GASTROINTESTINAL O
PERFORATIONS O
, O
SURGERY O
AND O
WOUND O
HEALING O
COMPLICATIONS O
, O
and O
HEMORRHAGE O
WARNING O
: O
GASTROINTESTINAL O
PERFORATIONS O
, O
SURGERY O
AND O
WOUND O
HEALING O
COMPLICATIONS O
, O
and O
HEMORRHAGE O
EXCERPT O
: O
WARNING O
: O
GASTROINTESTINAL O
PERFORATIONS O
, O
SURGERY O
AND O
WOUND O
HEALING O
COMPLICATIONS O
, O
and O
HEMORRHAGE O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Gastrointestinal O
Perforations O
: O
Discontinue O
for O
gastrointestinal O
perforation O
. O

( O
5.1 O
) O
* O
Surgery O
and O
Wound O
Healing O
Complications O
: O
Discontinue O
in O
patients O
who O
develop O
wound O
healing O
complications O
that O
require O
medical O
intervention O
. O

Withhold O
for O
at O
least O
28 O
days O
prior O
to O
elective O
surgery O
. O

Do O
not O
administer O
Avastin O
for O
at O
least O
28 O
days O
after O
surgery O
and O
until O
the O
wound O
is O
fully O
healed O
. O

( O
5.2 O
) O
* O
Hemorrhage O
: O
Severe O
or O
fatal O
hemorrhages O
have O
occurred O
. O

Do O
not O
administer O
for O
recent O
hemoptysis O
. O

Discontinue O
for O
Grade O
3-4 O
hemorrhage O
( O
5.3 O
) O
Gastrointestinal B-OSE_Labeled_AE
Perforations I-OSE_Labeled_AE
: O
The O
incidence O
of O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
, O
some O
fatal B-NonOSE_AE
, O
in O
patients O
receiving O
Avastin O
ranges O
from O
0.3 O
% O
to O
3 O
% O
. O

Discontinue O
Avastin O
in O
patients O
who O
develop O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Surgery O
and O
Wound B-OSE_Labeled_AE
Healing I-OSE_Labeled_AE
Complications I-OSE_Labeled_AE
: O
The O
incidence O
of O
wound B-OSE_Labeled_AE
healing I-OSE_Labeled_AE
and O
surgical O
complications I-OSE_Labeled_AE
, O
including O
serious O
and O
fatal B-NonOSE_AE
complications O
, O
is O
increased O
in O
patients O
receiving O
Avastin O
. O

Discontinue O
Avastin O
in O
patients O
who O
develop O
wound B-NonOSE_AE
healing I-NonOSE_AE
complications I-NonOSE_AE
that O
require O
medical O
intervention O
. O

Withhold O
Avastin O
at O
least O
28 O
days O
prior O
to O
elective O
surgery O
. O

Do O
not O
administer O
Avastin O
for O
at O
least O
28 O
days O
after O
surgery O
, O
and O
until O
the O
wound O
is O
fully O
healed O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Hemorrhages B-NonOSE_AE
: O
Severe O
or O
fatal B-NonOSE_AE
hemorrhage B-OSE_Labeled_AE
, O
including O
hemoptysis B-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
, O
hematemesis B-OSE_Labeled_AE
, O
CNS B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
and O
vaginal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
occur O
up O
to O
5-fold O
more O
frequently O
in O
patients O
receiving O
Avastin O
. O

Do O
not O
administer O
Avastin O
to O
patients O
with O
a O
recent O
history O
of O
hemoptysis B-Not_AE_Candidate
. O

Discontinue O
in O
patients O
who O
develop O
Grade O
3-4 O
hemorrhage B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Perforation O
or O
Fistula O
: O
Discontinue O
for O
tracheoesophageal O
fistula O
, O
grade O
4 O
fistula O
, O
or O
necrotizing O
fasciitis O
. O

( O
5.1 O
) O
* O
Arterial O
Thromboembolic O
Events O
( O
ATE O
) O
: O
Discontinue O
for O
severe O
ATE O
. O

( O
5.4 O
) O
* O
Venous O
Thromboembolic O
Events O
( O
VTE O
) O
: O
Discontinue O
for O
Grade O
4 O
VTE O
. O

( O
5.5 O
) O
* O
Hypertension O
: O
Monitor O
blood O
pressure O
and O
treat O
hypertension O
. O

Withhold O
if O
not O
medically O
controlled O
; O
resume O
once O
controlled O
. O

Discontinue O
for O
hypertensive O
crisis O
or O
hypertensive O
encephalopathy O
. O

( O
5.6 O
) O
* O
Posterior O
Reversible O
Encephalopathy O
Syndrome O
( O
PRES O
) O
: O
Discontinue O
. O

( O
5.7 O
) O
* O
Renal O
Injury O
and O
Proteinuria O
: O
Monitor O
urine O
protein O
. O

Discontinue O
for O
nephrotic O
syndrome O
. O

Withhold O
until O
less O
than O
2 O
grams O
of O
protein O
in O
urine O
. O

( O
5.8 O
) O
* O
Infusion O
Reactions O
: O
Decrease O
rate O
for O
infusion O
reactions O
. O

Discontinue O
for O
severe O
infusion O
reactions O
and O
administer O
medical O
therapy O
. O

( O
5.9 O
) O
* O
Embryo-fetal O
Toxicity O
: O
Advise O
females O
of O
potential O
risk O
to O
fetus O
and O
need O
for O
use O
of O
effective O
contraception O
. O

( O
5.10 O
, O
8.1 O
, O
8.3 O
) O
* O
Ovarian O
Failure O
: O
Advise O
females O
of O
the O
potential O
risk O
. O

( O
5.11 O
, O
8.3 O
) O
* O
Congestive O
Heart O
Failure O
( O
CHF O
) O
: O
Discontinue O
if O
CHF O
( O
5.12 O
) O
. O

5.1 O
Gastrointestinal O
Perforations O
and O
Fistulae O
Serious O
and O
sometimes O
fatal B-NonOSE_AE
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
occur O
at O
a O
higher O
incidence O
in O
patients O
receiving O
Avastin O
compared O
to O
patients O
receiving O
chemotherapy O
. O

The O
incidence O
ranged O
from O
0.3 O
% O
to O
3 O
% O
across O
clinical O
studies O
, O
with O
the O
highest O
incidence O
in O
patients O
with O
a O
history O
of O
prior O
pelvic O
radiation O
. O

Perforation O
can O
be O
complicated O
by O
intra B-OSE_Labeled_AE
- I-OSE_Labeled_AE
abdominal I-OSE_Labeled_AE
abscess I-OSE_Labeled_AE
, O
fistula B-OSE_Labeled_AE
formation I-OSE_Labeled_AE
, O
and O
the O
need O
for O
diverting O
ostomies O
. O

The O
majority O
of O
perforations O
occurred O
within O
50 O
days O
of O
the O
first O
dose O
. O

Serious O
fistulae B-OSE_Labeled_AE
( O
including O
, O
tracheoesophageal O
, O
bronchopleural O
, O
biliary O
, O
vaginal O
, O
renal O
and O
bladder O
sites O
) O
occur O
at O
a O
higher O
incidence O
in O
patients O
receiving O
Avastin O
compared O
to O
patients O
receiving O
chemotherapy O
. O

The O
incidence O
ranged O
from O
< O
1 O
% O
to O
1.8 O
% O
across O
clinical O
studies O
, O
with O
the O
highest O
incidence O
in O
patients O
with O
cervical B-Not_AE_Candidate
cancer I-Not_AE_Candidate
. O

The O
majority O
of O
fistulae B-OSE_Labeled_AE
occurred O
within O
6 O
months O
of O
the O
first O
dose O
. O

Patients O
who O
develop O
a O
gastrointestinal B-OSE_Labeled_AE
vaginal I-OSE_Labeled_AE
fistula I-OSE_Labeled_AE
may O
also O
have O
a O
bowel B-NonOSE_AE
obstruction I-NonOSE_AE
and O
require O
surgical O
intervention O
, O
as O
well O
as O
a O
diverting O
ostomy O
. O

Avoid O
Avastin O
in O
patients O
with O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
who O
have O
evidence O
of O
recto B-Not_AE_Candidate
- I-Not_AE_Candidate
sigmoid I-Not_AE_Candidate
involvement I-Not_AE_Candidate
by O
pelvic O
examination O
or O
bowel B-Not_AE_Candidate
involvement I-Not_AE_Candidate
on O
CT O
scan O
or O
clinical O
symptoms O
of O
bowel B-Not_AE_Candidate
obstruction I-Not_AE_Candidate
. O

Discontinue O
in O
patients O
who O
develop O
gastrointestinal B-NonOSE_AE
perforation I-NonOSE_AE
, O
tracheoesophageal B-NonOSE_AE
fistula I-NonOSE_AE
or O
any O
Grade O
4 O
fistula B-NonOSE_AE
. O

Discontinue O
in O
patients O
with O
fistula B-NonOSE_AE
formation I-NonOSE_AE
involving I-NonOSE_AE
any I-NonOSE_AE
internal I-NonOSE_AE
organ I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.2 O
Surgery O
and O
Wound O
Healing O
Complications O
In O
a O
controlled O
clinical O
study O
in O
which O
Avastin O
was O
not O
administered O
within O
28 O
days O
of O
major O
surgical O
procedures O
, O
the O
incidence O
of O
wound B-OSE_Labeled_AE
healing I-OSE_Labeled_AE
complications I-OSE_Labeled_AE
, O
including O
serious O
and O
fatal B-NonOSE_AE
complications O
, O
was O
15 O
% O
in O
patients O
with O
mCRC B-Not_AE_Candidate
who O
underwent O
surgery O
while O
receiving O
Avastin O
and O
4 O
% O
in O
patients O
who O
did O
not O
receive O
Avastin O
. O

In O
a O
controlled O
clinical O
study O
in O
patients O
with O
relapsed O
or O
recurrent O
GBM B-Not_AE_Candidate
, O
the O
incidence O
of O
wound B-OSE_Labeled_AE
healing I-OSE_Labeled_AE
events I-OSE_Labeled_AE
was O
5 O
% O
in O
patients O
who O
received O
Avastin O
and O
0.7 O
% O
in O
patients O
who O
did O
not O
receive O
Avastin O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Discontinue O
Avastin O
in O
patients O
with O
wound B-NonOSE_AE
healing I-NonOSE_AE
complications I-NonOSE_AE
requiring O
medical O
intervention O
. O

Withhold O
for O
at O
least O
28 O
days O
prior O
to O
elective O
surgery O
. O

Do O
not O
administer O
for O
at O
least O
28 O
days O
following O
surgery O
and O
until O
the O
wound O
is O
fully O
healed O
. O

Necrotizing B-OSE_Labeled_AE
fasciitis I-OSE_Labeled_AE
including O
fatal B-NonOSE_AE
cases O
, O
has O
been O
reported O
in O
patients O
receiving O
Avastin O
, O
usually O
secondary O
to O
wound B-OSE_Labeled_AE
healing I-OSE_Labeled_AE
complications I-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
or O
fistula B-OSE_Labeled_AE
formation O
. O

Discontinue O
in O
patients O
who O
develop O
necrotizing B-NonOSE_AE
fasciitis I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.3 O
) O
] O
. O

5.3 O
Hemorrhage O
Avastin O
can O
result O
in O
two O
distinct O
patterns O
of O
bleeding B-OSE_Labeled_AE
: O
minor O
hemorrhage B-OSE_Labeled_AE
, O
most O
commonly O
Grade O
1 O
epistaxis B-OSE_Labeled_AE
; O
and O
serious O
, O
and O
in O
some O
cases O
fatal B-NonOSE_AE
, O
hemorrhage B-OSE_Labeled_AE
. O

Severe O
or O
fatal B-NonOSE_AE
hemorrhage B-OSE_Labeled_AE
, O
including O
hemoptysis B-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
, O
hematemesis B-OSE_Labeled_AE
, O
CNS B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
and O
vaginal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
, O
occurred O
up O
to O
5-fold O
more O
frequently O
in O
patients O
receiving O
Avastin O
compared O
to O
patients O
receiving O
chemotherapy O
alone O
. O

Across O
clinical O
studies O
, O
the O
incidence O
of O
Grades O
3-5 O
hemorrhagic B-OSE_Labeled_AE
events O
ranged O
from O
0.4 O
% O
to O
7 O
% O
in O
patients O
receiving O
Avastin O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Serious O
or O
fatal B-NonOSE_AE
pulmonary B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
occurred O
in O
31 O
% O
of O
patients O
with O
squamous O
NSCLC B-Not_AE_Candidate
and O
4 O
% O
of O
patients O
with O
non-squamous O
NSCLC B-Not_AE_Candidate
receiving O
Avastin O
with O
chemotherapy O
compared O
to O
none O
of O
the O
patients O
receiving O
chemotherapy O
alone O
. O

Do O
not O
administer O
Avastin O
to O
patients O
with O
recent O
history O
of O
hemoptysis B-Not_AE_Candidate
of O
1/2 O
teaspoon O
or O
more O
of O
red O
blood O
. O

Discontinue O
in O
patients O
who O
develop O
a O
Grade O
3-4 O
hemorrhage B-NonOSE_AE
. O

5.4 O
Arterial O
Thromboembolic O
Events O
Serious O
, O
sometimes O
fatal B-NonOSE_AE
, O
arterial B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ATE I-OSE_Labeled_AE
) O
including O
cerebral B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
transient B-OSE_Labeled_AE
ischemic I-OSE_Labeled_AE
attacks I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
and O
angina B-OSE_Labeled_AE
, O
occurred O
at O
a O
higher O
incidence O
in O
patients O
receiving O
Avastin O
compared O
to O
patients O
receiving O
chemotherapy O
. O

Across O
clinical O
studies O
, O
the O
incidence O
of O
Grades O
3-5 O
ATE O
was O
5 O
% O
in O
patients O
receiving O
Avastin O
with O
chemotherapy O
compared O
to O
< O
= O
2 O
% O
in O
patients O
receiving O
chemotherapy O
alone O
; O
the O
highest O
incidence O
occurred O
in O
patients O
with O
GBM B-Not_AE_Candidate
. O

The O
risk O
of O
developing O
ATE B-NonOSE_AE
was O
increased O
in O
patients O
with O
a O
history O
of O
arterial B-Not_AE_Candidate
thromboembolism I-Not_AE_Candidate
, O
diabetes B-Not_AE_Candidate
, O
or O
greater O
than O
65 O
years O
old O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
] O
. O

Discontinue O
in O
patients O
who O
develop O
a O
severe O
ATE B-NonOSE_AE
. O

The O
safety O
of O
reinitiating O
Avastin O
after O
an O
ATE B-NonOSE_AE
is O
resolved O
is O
not O
known O
. O

5.5 O
Venous O
Thromboembolic O
Events O
An O
increased O
risk O
of O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
( I-OSE_Labeled_AE
VTE I-OSE_Labeled_AE
) O
was O
observed O
across O
clinical O
studies O
. O

In O
Study O
GOG-0240 O
, O
Grade O
3-4 O
VTE B-OSE_Labeled_AE
was O
reported O
in O
11 O
% O
of O
patients O
receiving O
Avastin O
with O
chemotherapy O
compared O
with O
5 O
% O
of O
patients O
receiving O
chemotherapy O
alone O
. O

In O
EORTC O
26101 O
, O
the O
incidence O
of O
Grade O
3-4 O
VTE B-OSE_Labeled_AE
was O
5 O
% O
in O
patients O
receiving O
Avastin O
with O
chemotherapy O
compared O
to O
2 O
% O
in O
patients O
receiving O
chemotherapy O
alone O
. O

Discontinue O
Avastin O
in O
patients O
with O
a O
Grade O
4 O
VTE B-NonOSE_AE
, O
including O
pulmonary B-NonOSE_AE
embolism I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.6 O
Hypertension O
The O
incidence O
of O
severe O
hypertension B-OSE_Labeled_AE
is O
increased O
in O
patients O
receiving O
Avastin O
as O
compared O
to O
patients O
receiving O
chemotherapy O
alone O
. O

Across O
clinical O
studies O
, O
the O
incidence O
of O
Grade O
3-4 O
hypertension B-OSE_Labeled_AE
ranged O
from O
5 O
% O
to O
18 O
% O
. O

Monitor O
blood O
pressure O
every O
two O
to O
three O
weeks O
during O
treatment O
with O
Avastin O
. O

Treat O
with O
appropriate O
anti B-NonOSE_AE
- I-NonOSE_AE
hypertensive I-NonOSE_AE
therapy I-NonOSE_AE
and O
monitor O
blood O
pressure O
regularly O
. O

Continue O
to O
monitor O
blood O
pressure O
at O
regular O
intervals O
in O
patients O
with O
Avastin-induced O
or O
-exacerbated O
hypertension B-NonOSE_AE
after O
discontinuing O
Avastin O
. O

Withhold O
Avastin O
in O
patients O
with O
severe O
hypertension B-NonOSE_AE
that O
is O
not O
controlled O
with O
medical O
management O
; O
resume O
once O
controlled O
with O
medical O
management O
. O

Discontinue O
in O
patients O
who O
develop O
hypertensive B-NonOSE_AE
crisis I-NonOSE_AE
or O
hypertensive B-NonOSE_AE
encephalopathy I-NonOSE_AE
. O

5.7 O
Posterior B-OSE_Labeled_AE
Reversible I-OSE_Labeled_AE
Encephalopathy I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PRES I-OSE_Labeled_AE
) O
PRES B-OSE_Labeled_AE
was O
reported O
in O
< O
0.5 O
% O
of O
patients O
across O
clinical O
studies O
. O

The O
onset O
of O
symptoms O
occurred O
from O
16 O
hours O
to O
1 O
year O
after O
the O
first O
dose O
. O

PRES B-NonOSE_AE
is O
a O
neurological B-NonOSE_AE
disorder I-NonOSE_AE
which O
can O
present O
with O
headache B-NonOSE_AE
, O
seizure B-NonOSE_AE
, O
lethargy B-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
blindness B-NonOSE_AE
and O
other O
visual B-NonOSE_AE
and O
neurologic O
disturbances I-NonOSE_AE
. O

Mild O
to O
severe O
hypertension B-NonOSE_AE
may O
be O
present O
. O

Magnetic O
resonance O
imaging O
is O
necessary O
to O
confirm O
the O
diagnosis O
of O
PRES B-NonOSE_AE
. O

Discontinue O
Avastin O
in O
patients O
who O
develop O
PRES B-NonOSE_AE
. O

Symptoms O
usually O
resolve O
or O
improve O
within O
days O
after O
discontinuing O
Avastin O
, O
although O
some O
patients O
have O
experienced O
ongoing O
neurologic B-NonOSE_AE
sequelae I-NonOSE_AE
. O

The O
safety O
of O
reinitiating O
Avastin O
in O
patients O
who O
developed O
PRES B-NonOSE_AE
is O
not O
known O
. O

5.8 O
Renal B-OSE_Labeled_AE
Injury I-OSE_Labeled_AE
and O
Proteinuria O
The O
incidence O
and O
severity O
of O
proteinuria B-OSE_Labeled_AE
is O
higher O
in O
patients O
receiving O
Avastin O
as O
compared O
to O
patients O
receiving O
chemotherapy O
. O

Grade O
3 O
( O
defined O
as O
urine B-OSE_Labeled_AE
dipstick I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
+ I-OSE_Labeled_AE
or I-OSE_Labeled_AE
> I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
grams I-OSE_Labeled_AE
of I-OSE_Labeled_AE
protein I-OSE_Labeled_AE
per I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
hours I-OSE_Labeled_AE
) O
to O
Grade O
4 O
( O
defined O
as O
nephrotic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
) O
ranged O
from O
0.7 O
% O
to O
7 O
% O
in O
clinical O
studies O
. O

The O
overall O
incidence O
of O
proteinuria B-OSE_Labeled_AE
( O
all O
grades O
) O
was O
only O
adequately O
assessed O
in O
Study O
BO17705 O
, O
in O
which O
the O
incidence O
was O
20 O
% O
. O

Median O
onset O
of O
proteinuria B-OSE_Labeled_AE
was O
5.6 O
months O
( O
15 O
days O
to O
37 O
months O
) O
after O
initiating O
Avastin O
. O

Median O
time O
to O
resolution O
was O
6.1 O
months O
( O
95 O
% O
CI O
: O
2.8 O
, O
11.3 O
) O
. O

Proteinuria B-OSE_Labeled_AE
did O
not O
resolve O
in O
40 O
% O
of O
patients O
after O
median O
follow-up O
of O
11.2 O
months O
and O
required O
discontinuation O
of O
Avastin O
in O
30 O
% O
of O
the O
patients O
who O
developed O
proteinuria B-OSE_Labeled_AE
. O

In O
an O
exploratory O
, O
pooled O
analysis O
of O
patients O
from O
seven O
randomized O
clinical O
studies O
, O
5 O
% O
of O
patients O
receiving O
Avastin O
with O
chemotherapy O
experienced O
Grades O
2-4 O
( O
defined O
as O
urine B-OSE_Labeled_AE
dipstick I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
+ I-OSE_Labeled_AE
or I-OSE_Labeled_AE
greater I-OSE_Labeled_AE
or I-OSE_Labeled_AE
> I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
gram I-OSE_Labeled_AE
of I-OSE_Labeled_AE
protein I-OSE_Labeled_AE
per I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
hours I-OSE_Labeled_AE
or O
nephrotic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
) O
proteinuria B-OSE_Labeled_AE
. O

Grades O
2-4 O
proteinuria B-OSE_Labeled_AE
resolved O
in O
74 O
% O
of O
patients O
. O

Avastin O
was O
reinitiated O
in O
42 O
% O
of O
patients O
. O

Of O
the O
113 O
patients O
who O
reinitiated O
Avastin O
, O
48 O
% O
experienced O
a O
second O
episode O
of O
Grade O
2-4 O
proteinuria B-OSE_Labeled_AE
. O

Nephrotic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
occurred O
in O
< O
1 O
% O
of O
patients O
receiving O
Avastin O
across O
clinical O
studies O
, O
in O
some O
instances O
with O
fatal B-NonOSE_AE
outcome O
. O

In O
a O
published O
case O
series O
, O
kidney O
biopsy O
of O
6 O
patients O
with O
proteinuria B-OSE_Labeled_AE
showed O
findings O
consistent O
with O
thrombotic B-OSE_Labeled_AE
microangiopathy I-OSE_Labeled_AE
. O

Results O
of O
a O
retrospective O
analysis O
of O
5805 O
patients O
who O
received O
Avastin O
with O
chemotherapy O
and O
3713 O
patients O
who O
received O
chemotherapy O
alone O
, O
showed O
higher O
rates O
of O
elevated B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
( O
between O
1.5 O
to O
1.9 O
times O
baseline O
levels O
) O
in O
patients O
who O
received O
Avastin O
. O

Serum O
creatinine O
levels O
did O
not O
return O
to O
baseline O
in O
approximately O
one-third O
of O
patients O
who O
received O
Avastin O
. O

Monitor O
proteinuria B-NonOSE_AE
by O
dipstick O
urine O
analysis O
for O
the O
development O
or O
worsening O
of O
proteinuria B-NonOSE_AE
with O
serial O
urinalyses O
during O
Avastin O
therapy O
. O

Patients O
with O
a O
2+ O
or O
greater O
urine O
dipstick O
reading O
should O
undergo O
further O
assessment O
with O
a O
24-hour O
urine O
collection O
. O

Withhold O
for O
proteinuria B-NonOSE_AE
greater O
than O
or O
equal O
to O
2 O
grams O
per O
24 O
hours O
and O
resume O
when O
less O
than O
2 O
grams O
per O
24 O
hours O
. O

Discontinue O
in O
patients O
who O
develop O
nephrotic B-NonOSE_AE
syndrome I-NonOSE_AE
. O

Data O
from O
a O
postmarketing O
safety O
study O
showed O
poor O
correlation O
between O
UPCR O
( O
Urine O
Protein/Creatinine O
Ratio O
) O
and O
24-hour O
urine O
protein O
[ O
Pearson O
Correlation O
0.39 O
( O
95 O
% O
CI O
: O
0.17 O
, O
0.57 O
) O
] O
. O

5.9 O
Infusion O
Reactions O
Infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
reported O
across O
clinical O
studies O
and O
post-marketing O
experience O
include O
hypertension B-OSE_Labeled_AE
, O
hypertensive B-OSE_Labeled_AE
crises I-OSE_Labeled_AE
associated O
with O
neurologic B-OSE_Labeled_AE
signs I-OSE_Labeled_AE
and I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
, O
wheezing B-OSE_Labeled_AE
, O
oxygen B-OSE_Labeled_AE
desaturation I-OSE_Labeled_AE
, O
Grade O
3 O
hypersensitivity B-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
headaches B-OSE_Labeled_AE
, O
rigors B-OSE_Labeled_AE
, O
and O
diaphoresis B-OSE_Labeled_AE
. O

In O
clinical O
studies O
, O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
with O
the O
first O
dose O
occurred O
in O
< O
3 O
% O
of O
patients O
and O
severe O
reactions O
occurred O
in O
0.2 O
% O
of O
patients O
. O

Decrease O
the O
rate O
of O
infusion O
for O
mild O
, O
clinically O
insignificant O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
. O

Interrupt O
the O
infusion O
in O
patients O
with O
clinically O
significant O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
and O
consider O
resuming O
at O
a O
slower O
rate O
following O
resolution O
. O

Discontinue O
in O
patients O
who O
develop O
a O
severe O
infusion B-NonOSE_AE
reaction I-NonOSE_AE
and O
administer O
appropriate O
medical O
therapy O
( O
e.g. O
, O
epinephrine O
, O
corticosteroids O
, O
intravenous O
antihistamines O
, O
bronchodilators O
and/or O
oxygen O
) O
. O

5.10 O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Avastin O
may O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
based O
on O
its O
mechanism O
of O
action O
and O
findings O
from O
animal O
studies O
. O

Congenital B-NonOSE_AE
malformations I-NonOSE_AE
were O
observed O
with O
the O
administration O
of O
bevacizumab O
to O
pregnant B-NonOSE_AE
rabbits O
during O
organogenesis O
every O
3 O
days O
at O
a O
dose O
as O
low O
as O
a O
clinical O
dose O
of O
10 O
mg/kg O
. O

Furthermore O
, O
animal O
models O
link O
angiogenesis O
and O
VEGF O
and O
VEGFR O
2 O
to O
critical O
aspects O
of O
female O
reproduction O
, O
embryo-fetal O
development O
, O
and O
postnatal O
development O
. O

Advise O
pregnant B-Not_AE_Candidate
women O
of O
the O
potential O
risk B-OSE_Labeled_AE
to I-OSE_Labeled_AE
a I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

Advise O
females O
of O
reproductive O
potential O
to O
use O
effective O
contraception O
during O
treatment O
with O
and O
for O
6 O
months O
after O
the O
last O
dose O
of O
Avastin O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
, O
8.3 O
) O
, O
Clinical O
Pharmacology O
( O
12.1 O
) O
] O
. O

5.11 O
Ovarian O
Failure O
The O
incidence O
of O
ovarian B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
was O
34 O
% O
vs O
. O
2 O
% O
in O
premenopausal B-Not_AE_Candidate
women O
receiving O
Avastin O
with O
chemotherapy O
as O
compared O
to O
those O
receiving O
chemotherapy O
alone O
for O
adjuvant O
treatment O
of O
a O
solid O
tumor B-Not_AE_Candidate
. O

After O
discontinuing O
Avastin O
, O
recovery O
of O
ovarian O
function O
at O
all O
time O
points O
during O
the O
post-treatment O
period O
was O
demonstrated O
in O
22 O
% O
of O
women O
receiving O
Avastin O
. O

Recovery O
of O
ovarian O
function O
is O
defined O
as O
resumption O
of O
menses O
, O
a O
positive B-NonOSE_AE
serum I-NonOSE_AE
beta I-NonOSE_AE
- I-NonOSE_AE
HCG I-NonOSE_AE
pregnancy I-NonOSE_AE
test I-NonOSE_AE
, O
or O
a O
FSH O
level O
< O
30 O
mIU/mL O
during O
the O
post-treatment O
period O
. O

Long-term O
effects O
of O
Avastin O
on O
fertility O
are O
unknown O
. O

Inform O
females O
of O
reproductive O
potential O
of O
the O
risk O
of O
ovarian B-NonOSE_AE
failure I-NonOSE_AE
prior O
to O
initiating O
Avastin O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.3 O
) O
] O
. O

5.12 O
Congestive O
Heart O
Failure O
( O
CHF O
) O
Avastin O
is O
not O
indicated O
for O
use O
with O
anthracycline-based O
chemotherapy O
. O

The O
incidence O
of O
Grade O
> O
= O
3 O
left B-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
was O
1 O
% O
in O
patients O
receiving O
Avastin O
compared O
to O
0.6 O
% O
of O
patients O
receiving O
chemotherapy O
alone O
. O

Among O
patients O
who O
received O
prior O
anthracycline O
treatment O
, O
the O
rate O
of O
CHF B-NonOSE_AE
was O
4 O
% O
for O
patients O
receiving O
Avastin O
with O
chemotherapy O
as O
compared O
to O
0.6 O
% O
for O
patients O
receiving O
chemotherapy O
alone O
. O

In O
previously O
untreated O
patients O
with O
a O
hematological B-Not_AE_Candidate
malignancy I-Not_AE_Candidate
, O
the O
incidence O
of O
CHF B-NonOSE_AE
and O
decline B-NonOSE_AE
in I-NonOSE_AE
left I-NonOSE_AE
ventricular I-NonOSE_AE
ejection I-NonOSE_AE
fraction I-NonOSE_AE
( I-NonOSE_AE
LVEF I-NonOSE_AE
) O
were O
increased O
in O
patients O
receiving O
Avastin O
with O
anthracycline-based O
chemotherapy O
compared O
to O
patients O
receiving O
placebo O
with O
the O
same O
chemotherapy O
regimen O
. O

The O
proportion O
of O
patients O
with O
a O
decline B-NonOSE_AE
in I-NonOSE_AE
LVEF I-NonOSE_AE
from O
baseline O
of O
> O
= O
20 O
% O
or O
a O
decline O
from O
baseline O
of O
10 O
% O
to O
< O
50 O
% O
, O
was O
10 O
% O
in O
patients O
receiving O
Avastin O
with O
chemotherapy O
compared O
to O
5 O
% O
in O
patients O
receiving O
chemotherapy O
alone O
. O

Time O
to O
onset O
of O
left B-NonOSE_AE
- I-NonOSE_AE
ventricular I-NonOSE_AE
dysfunction I-NonOSE_AE
or O
CHF B-NonOSE_AE
was O
1 O
to O
6 O
months O
after O
the O
first O
dose O
in O
at O
least O
85 O
% O
of O
the O
patients O
and O
was O
resolved O
in O
62 O
% O
of O
the O
patients O
who O
developed O
CHF B-NonOSE_AE
in O
the O
Avastin O
arm O
compared O
to O
82 O
% O
in O
the O
placebo O
arm O
. O

Discontinue O
Avastin O
in O
patients O
who O
develop O
CHF B-NonOSE_AE
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
: O
* O
CNS B-OSE_Labeled_AE
depressant I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
and O
daytime B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Abnormal B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
and O
behavioral B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Depression I-OSE_Labeled_AE
/ O
Suicidal B-OSE_Labeled_AE
ideation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Sleep B-OSE_Labeled_AE
paralysis I-OSE_Labeled_AE
, O
hypnagogic B-OSE_Labeled_AE
/hypnopompic O
hallucinations I-OSE_Labeled_AE
, O
cataplexy B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
EXCERPT O
: O
The O
most O
common O
adverse O
reaction O
( O
reported O
in O
5 O
% O
or O
more O
of O
patients O
treated O
with O
BELSOMRA O
and O
at O
least O
twice O
the O
placebo O
rate O
) O
with O
BELSOMRA O
was O
somnolence O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Merck O
Sharp O
& O
Dohme O
Corp. O
, O
a O
subsidiary O
of O
Merck O
& O
Co. O
, O
Inc. O
, O
at O
1-877-888-4231 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

In O
3-month O
controlled O
efficacy O
trials O
( O
Study O
1 O
and O
Study O
2 O
) O
, O
1263 O
patients O
were O
exposed O
to O
BELSOMRA O
including O
493 O
patients O
who O
received O
BELSOMRA O
15 O
mg O
or O
20 O
mg O
( O
see O
Table O
1 O
) O
. O

In O
a O
long-term O
study O
, O
additional O
patients O
( O
n=521 O
) O
were O
treated O
with O
BELSOMRA O
at O
higher O
than O
recommended O
doses O
, O
including O
a O
total O
of O
160 O
patients O
who O
received O
BELSOMRA O
for O
at O
least O
one O
year O
. O

Table O
1 O
: O
Patient O
Exposure O
to O
BELSOMRA O
15 O
mg O
or O
20 O
mg O
in O
Study O
1 O
and O
Study O
2 O
Patients O
Treated O
BELSOMRA15 O
mg O
BELSOMRA20 O
mg O
For O
> O
= O
1 O
Day O
( O
n O
) O
202 O
291 O
Men O
( O
n O
) O
69 O
105 O
Women O
( O
n O
) O
133 O
186 O
Mean O
Age O
( O
years O
) O
70 O
45 O
For O
> O
= O
3 O
Months O
( O
n O
) O
118 O
172 O
The O
pooled O
safety O
data O
described O
below O
( O
see O
Table O
2 O
) O
reflect O
the O
adverse O
reaction O
profile O
during O
the O
first O
3 O
months O
of O
treatment O
. O

Adverse O
Reactions O
Resulting O
in O
Discontinuation O
of O
Treatment O
The O
incidence O
of O
discontinuation O
due O
to O
adverse O
reactions O
for O
patients O
treated O
with O
15 O
mg O
or O
20 O
mg O
of O
BELSOMRA O
was O
3 O
% O
compared O
to O
5 O
% O
for O
placebo O
. O

No O
individual O
adverse O
reaction O
led O
to O
discontinuation O
at O
an O
incidence O
> O
=1 O
% O
. O

Most O
Common O
Adverse O
Reactions O
In O
clinical O
trials O
of O
patients O
with O
insomnia B-Not_AE_Candidate
treated O
with O
BELSOMRA O
15 O
mg O
or O
20 O
mg O
, O
the O
most O
common O
adverse O
reaction O
( O
reported O
in O
5 O
% O
or O
more O
of O
patients O
treated O
with O
BELSOMRA O
and O
at O
least O
twice O
the O
placebo O
rate O
) O
was O
somnolence B-OSE_Labeled_AE
( O
BELSOMRA O
7 O
% O
; O
placebo O
3 O
% O
) O
. O

Table O
2 O
shows O
the O
percentage O
of O
patients O
with O
adverse O
reactions O
during O
the O
first O
three O
months O
of O
treatment O
, O
based O
on O
the O
pooled O
data O
from O
3-month O
controlled O
efficacy O
trials O
( O
Study O
1 O
and O
Study O
2 O
) O
. O

At O
doses O
of O
15 O
or O
20 O
mg O
, O
the O
incidence O
of O
somnolence B-OSE_Labeled_AE
was O
higher O
in O
females O
( O
8 O
% O
) O
than O
in O
males O
( O
3 O
% O
) O
. O

Of O
the O
adverse O
reactions O
reported O
in O
Table O
2 O
, O
the O
following O
occurred O
in O
women O
at O
an O
incidence O
of O
at O
least O
twice O
that O
in O
men O
: O
headache B-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
dreams I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
and O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
. O

The O
adverse O
reaction O
profile O
in O
elderly O
patients O
was O
generally O
consistent O
with O
non-elderly O
patients O
. O

The O
adverse O
reactions O
reported O
during O
long-term O
treatment O
up O
to O
1 O
year O
were O
generally O
consistent O
with O
those O
observed O
during O
the O
first O
3 O
months O
of O
treatment O
. O

Table O
2 O
: O
Percentage O
of O
Patients O
with O
Adverse O
Reactions O
Incidence O
> O
=2 O
% O
and O
Greater O
than O
Placebo O
in O
3-Month O
Controlled O
Efficacy O
Trials O
( O
Study O
1 O
and O
Study O
2 O
) O
Placebo O
BELSOMRA O
( O
20 O
mg O
in O
non-elderly O
or O
15 O
mg O
in O
elderly O
patients O
) O
n=767 O
n=493 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
1 O
2 O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
1 O
2 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
1 O
2 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
6 O
7 O
Somnolence B-OSE_Labeled_AE
3 O
7 O
Dizziness B-OSE_Labeled_AE
2 O
3 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Abnormal B-OSE_Labeled_AE
dreams I-OSE_Labeled_AE
1 O
2 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
1 O
2 O
Dose O
Relationship O
for O
Adverse O
Reactions O
There O
is O
evidence O
of O
a O
dose O
relationship O
for O
many O
of O
the O
adverse O
reactions O
associated O
with O
BELSOMRA O
use O
, O
particularly O
for O
certain O
CNS B-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
. O

In O
a O
placebo-controlled O
crossover O
study O
( O
Study O
3 O
) O
, O
non-elderly O
adult O
patients O
were O
treated O
for O
up O
to O
one O
month O
with O
BELSOMRA O
at O
doses O
of O
10 O
mg O
, O
20 O
mg O
, O
40 O
mg O
( O
2 O
times O
the O
maximum O
recommended O
dose O
) O
or O
80 O
mg O
( O
4 O
times O
the O
maximum O
recommended O
dose O
) O
. O

In O
patients O
treated O
with O
BELSOMRA O
10 O
mg O
( O
n=62 O
) O
, O
although O
no O
adverse O
reactions O
were O
reported O
at O
an O
incidence O
of O
> O
=2 O
% O
, O
the O
types O
of O
adverse O
reactions O
observed O
were O
similar O
to O
those O
observed O
in O
patients O
treated O
with O
BELSOMRA O
20 O
mg O
. O
BELSOMRA O
was O
associated O
with O
a O
dose-related O
increase O
in O
somnolence B-OSE_Labeled_AE
: O
2 O
% O
at O
the O
10 O
mg O
dose O
, O
5 O
% O
at O
the O
20 O
mg O
dose O
, O
12 O
% O
at O
the O
40 O
mg O
dose O
, O
and O
11 O
% O
at O
the O
80 O
mg O
dose O
, O
compared O
to O
< O
1 O
% O
for O
placebo O
. O

BELSOMRA O
was O
also O
associated O
with O
a O
dose-related O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
: O
1 O
mg/dL O
at O
the O
10 O
mg O
dose O
, O
2 O
mg/dL O
at O
the O
20 O
mg O
dose O
, O
3 O
mg/dL O
at O
the O
40 O
mg O
dose O
, O
and O
6 O
mg/dL O
at O
the O
80 O
mg O
dose O
after O
4 O
weeks O
of O
treatment O
, O
compared O
to O
a O
4 O
mg/dL O
decrease O
for O
placebo O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Daytime O
somnolence O
: O
Risk O
of O
impaired O
alertness O
and O
motor O
coordination O
, O
including O
impaired O
driving O
; O
risk O
increases O
with O
dose O
; O
caution O
patients O
taking O
20 O
mg O
against O
next-day O
driving O
and O
other O
activities O
requiring O
complete O
mental O
alertness O
( O
5.1 O
) O
. O

* O
Need O
to O
evaluate O
for O
co-morbid O
diagnoses O
: O
Reevaluate O
if O
insomnia O
persists O
after O
7 O
to O
10 O
days O
of O
treatment O
( O
5.2 O
) O
. O

* O
Nighttime O
`` O
sleep-driving O
'' O
and O
other O
complex O
behaviors O
while O
out O
of O
bed O
and O
not O
fully O
awake O
. O

Risk O
increases O
with O
dose O
, O
with O
use O
of O
CNS O
depressants O
, O
and O
with O
alcohol O
( O
5.3 O
) O
. O

* O
Depression O
: O
Worsening O
of O
depression O
or O
suicidal O
thinking O
may O
occur O
. O

Risk O
increases O
with O
dose O
. O

Immediately O
evaluate O
any O
new O
behavioral O
changes O
( O
5.4 O
) O
. O

* O
Compromised O
respiratory O
function O
: O
Effect O
on O
respiratory O
function O
should O
be O
considered O
( O
5.5 O
, O
8.6 O
) O
. O

* O
Sleep O
paralysis O
, O
hypnagogic/hypnopompic O
hallucinations O
, O
and O
cataplexy-like O
symptoms O
: O
Risk O
increases O
with O
dose O
( O
5.6 O
) O
. O

5.1 O
CNS O
Depressant O
Effects O
and O
Daytime O
Impairment O
BELSOMRA O
is O
a O
central O
nervous O
system O
( O
CNS O
) O
depressant O
that O
can O
impair B-OSE_Labeled_AE
daytime I-OSE_Labeled_AE
wakefulness I-OSE_Labeled_AE
even O
when O
used O
as O
prescribed O
. O

Prescribers O
should O
monitor O
for O
somnolence B-NonOSE_AE
and O
CNS B-NonOSE_AE
depressant I-NonOSE_AE
effects I-NonOSE_AE
, O
but O
impairment O
can O
occur O
in O
the O
absence O
of O
symptoms O
, O
and O
may O
not O
be O
reliably O
detected O
by O
ordinary O
clinical O
exam O
( O
i.e. O
, O
less O
than O
formal O
testing O
of O
daytime O
wakefulness O
and/or O
psychomotor O
performance O
) O
. O

CNS B-OSE_Labeled_AE
depressant I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
may O
persist O
in O
some O
patients O
for O
up O
to O
several O
days O
after O
discontinuing O
BELSOMRA O
. O

BELSOMRA O
can O
impair B-OSE_Labeled_AE
driving I-OSE_Labeled_AE
skills I-OSE_Labeled_AE
and O
may O
increase B-OSE_Labeled_AE
the I-OSE_Labeled_AE
risk I-OSE_Labeled_AE
of I-OSE_Labeled_AE
falling I-OSE_Labeled_AE
asleep I-OSE_Labeled_AE
while I-OSE_Labeled_AE
driving I-OSE_Labeled_AE
. O

Discontinue O
or O
decrease O
the O
dose O
in O
patients O
who O
drive O
if O
daytime B-NonOSE_AE
somnolence I-NonOSE_AE
develops O
. O

In O
a O
study O
of O
healthy O
adults O
, O
driving B-OSE_Labeled_AE
ability I-OSE_Labeled_AE
was I-OSE_Labeled_AE
impaired I-OSE_Labeled_AE
in O
some O
individuals O
taking O
20 O
mg O
BELSOMRA O
[ O
see O
Clinical O
Studies O
( O
14.2 O
) O
] O
. O

Although O
pharmacodynamic O
tolerance O
or O
adaptation O
to O
some O
adverse O
depressant O
effects O
of O
BELSOMRA O
may O
develop O
with O
daily O
use O
, O
patients O
using O
the O
20 O
mg O
dose O
of O
BELSOMRA O
should O
be O
cautioned O
against O
next-day O
driving O
and O
other O
activities O
requiring O
full O
mental O
alertness O
. O

Patients O
taking O
lower O
doses O
of O
BELSOMRA O
should O
also O
be O
cautioned O
about O
the O
potential O
for O
driving B-NonOSE_AE
impairment I-NonOSE_AE
because O
there O
is O
individual O
variation O
in O
sensitivity O
to O
BELSOMRA O
. O

Co-administration O
with O
other O
CNS O
depressants O
( O
e.g. O
, O
benzodiazepines O
, O
opioids O
, O
tricyclic O
antidepressants O
, O
alcohol O
) O
increases B-NonOSE_AE
the I-NonOSE_AE
risk I-NonOSE_AE
of I-NonOSE_AE
CNS I-NonOSE_AE
depression I-NonOSE_AE
. O

Patients O
should O
be O
advised O
not O
to O
consume O
alcohol O
in O
combination O
with O
BELSOMRA O
because O
of O
additive O
effects O
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

Dosage O
adjustments O
of O
BELSOMRA O
and O
of O
concomitant O
CNS O
depressants O
may O
be O
necessary O
when O
administered O
together O
because O
of O
potentially O
additive O
effects O
. O

The O
use O
of O
BELSOMRA O
with O
other O
drugs O
to O
treat O
insomnia B-Not_AE_Candidate
is O
not O
recommended O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

The O
risk O
of O
next B-NonOSE_AE
- I-NonOSE_AE
day I-NonOSE_AE
impairment I-NonOSE_AE
, O
including O
impaired B-NonOSE_AE
driving I-NonOSE_AE
, O
is O
increased O
if O
BELSOMRA O
is O
taken O
with O
less O
than O
a O
full O
night O
of O
sleep O
remaining O
, O
if O
a O
higher O
than O
the O
recommended O
dose O
is O
taken O
, O
if O
co-administered O
with O
other O
CNS O
depressants O
, O
or O
if O
co-administered O
with O
other O
drugs O
that O
increase O
blood O
levels O
of O
BELSOMRA O
. O

Patients O
should O
be O
cautioned O
against O
driving O
and O
other O
activities O
requiring O
complete O
mental O
alertness O
if O
BELSOMRA O
is O
taken O
in O
these O
circumstances O
. O

5.2 O
Need O
to O
Evaluate O
for O
Co-morbid O
Diagnoses O
Because O
sleep B-Not_AE_Candidate
disturbances I-Not_AE_Candidate
may O
be O
the O
presenting O
manifestation O
of O
a O
physical B-Not_AE_Candidate
and/or O
psychiatric O
disorder I-Not_AE_Candidate
, O
treatment O
of O
insomnia B-Not_AE_Candidate
should O
be O
initiated O
only O
after O
careful O
evaluation O
of O
the O
patient O
. O

The O
failure O
of O
insomnia B-Not_AE_Candidate
to O
remit O
after O
7 O
to O
10 O
days O
of O
treatment O
may O
indicate O
the O
presence O
of O
a O
primary O
psychiatric B-Not_AE_Candidate
and/or O
medical O
illness I-Not_AE_Candidate
that O
should O
be O
evaluated O
. O

Worsening B-Not_AE_Candidate
of I-Not_AE_Candidate
insomnia I-Not_AE_Candidate
or O
the O
emergence O
of O
new O
cognitive B-Not_AE_Candidate
or O
behavioral O
abnormalities I-Not_AE_Candidate
may O
be O
the O
result O
of O
an O
unrecognized O
underlying O
psychiatric B-Not_AE_Candidate
or O
physical O
disorder I-Not_AE_Candidate
, O
and O
can O
emerge O
during O
the O
course O
of O
treatment O
with O
hypnotic O
drugs O
such O
as O
BELSOMRA O
. O

5.3 O
Abnormal O
Thinking O
and O
Behavioral O
Changes O
A O
variety O
of O
cognitive B-OSE_Labeled_AE
and O
behavioral O
changes I-OSE_Labeled_AE
( O
e.g. O
, O
amnesia B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
and O
other O
neuro B-OSE_Labeled_AE
- I-OSE_Labeled_AE
psychiatric I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
) O
have O
been O
reported O
to O
occur O
in O
association O
with O
the O
use O
of O
hypnotics O
such O
as O
BELSOMRA O
. O

Complex B-OSE_Labeled_AE
behaviors I-OSE_Labeled_AE
such O
as O
" B-OSE_Labeled_AE
sleep I-OSE_Labeled_AE
- I-OSE_Labeled_AE
driving I-OSE_Labeled_AE
" I-OSE_Labeled_AE
( O
i.e. O
, O
driving B-OSE_Labeled_AE
while I-OSE_Labeled_AE
not I-OSE_Labeled_AE
fully I-OSE_Labeled_AE
awake I-OSE_Labeled_AE
after O
taking O
a O
hypnotic O
) O
and O
other O
complex B-OSE_Labeled_AE
behaviors I-OSE_Labeled_AE
( O
e.g. O
, O
preparing B-OSE_Labeled_AE
and I-OSE_Labeled_AE
eating I-OSE_Labeled_AE
food I-OSE_Labeled_AE
, O
making O
phone O
calls O
, O
or O
having O
sex O
) O
, O
with I-OSE_Labeled_AE
amnesia I-OSE_Labeled_AE
for I-OSE_Labeled_AE
the I-OSE_Labeled_AE
event I-OSE_Labeled_AE
, O
have O
been O
reported O
in O
association O
with O
the O
use O
of O
hypnotics O
. O

These O
events O
can O
occur O
in O
hypnotic-naive O
as O
well O
as O
in O
hypnotic-experienced O
persons O
. O

The O
use O
of O
alcohol O
and O
other O
CNS O
depressants O
may O
increase O
the O
risk O
of O
such O
behaviors O
. O

Discontinuation O
of O
BELSOMRA O
should O
be O
strongly O
considered O
for O
patients O
who O
report O
any O
complex B-NonOSE_AE
sleep I-NonOSE_AE
behavior I-NonOSE_AE
. O

5.4 O
Worsening O
of O
Depression/Suicidal O
Ideation O
In O
clinical O
studies O
, O
a O
dose-dependent O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
suicidal I-OSE_Labeled_AE
ideation I-OSE_Labeled_AE
was O
observed O
in O
patients O
taking O
BELSOMRA O
as O
assessed O
by O
questionnaire O
. O

Immediately O
evaluate O
patients O
with O
suicidal B-NonOSE_AE
ideation I-NonOSE_AE
or O
any O
new O
behavioral O
sign O
or O
symptom O
. O

In O
primarily O
depressed B-Not_AE_Candidate
patients O
treated O
with O
sedative-hypnotics O
, O
worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
depression I-OSE_Labeled_AE
, O
and O
suicidal B-OSE_Labeled_AE
thoughts I-OSE_Labeled_AE
and O
actions O
( O
including O
completed B-OSE_Labeled_AE
suicides I-OSE_Labeled_AE
) O
have O
been O
reported O
. O

Suicidal B-NonOSE_AE
tendencies I-NonOSE_AE
may O
be O
present O
in O
such O
patients O
and O
protective O
measures O
may O
be O
required O
. O

Intentional B-NonOSE_AE
overdose I-NonOSE_AE
is O
more O
common O
in O
this O
group O
of O
patients O
; O
therefore O
, O
the O
lowest O
number O
of O
tablets O
that O
is O
feasible O
should O
be O
prescribed O
for O
the O
patient O
at O
any O
one O
time O
. O

The O
emergence O
of O
any O
new O
behavioral B-NonOSE_AE
sign I-NonOSE_AE
or I-NonOSE_AE
symptom I-NonOSE_AE
of O
concern O
requires O
careful O
and O
immediate O
evaluation O
. O

5.5 O
Patients O
with O
Compromised O
Respiratory O
Function O
Effect O
of O
BELSOMRA O
on O
respiratory O
function O
should O
be O
considered O
if O
prescribed O
to O
patients O
with O
compromised B-Not_AE_Candidate
respiratory I-Not_AE_Candidate
function I-Not_AE_Candidate
. O

BELSOMRA O
has O
not O
been O
studied O
in O
patients O
with O
severe O
obstructive B-Not_AE_Candidate
sleep I-Not_AE_Candidate
apnea I-Not_AE_Candidate
( O
OSA O
) O
or O
severe O
chronic B-Not_AE_Candidate
obstructive I-Not_AE_Candidate
pulmonary I-Not_AE_Candidate
disease I-Not_AE_Candidate
( O
COPD O
) O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
] O
. O

5.6 O
Sleep O
Paralysis O
, O
Hypnagogic/Hypnopompic O
Hallucinations O
, O
Cataplexy-like O
Symptoms O
Sleep B-OSE_Labeled_AE
paralysis I-OSE_Labeled_AE
, O
an O
inability B-NonOSE_AE
to I-NonOSE_AE
move I-NonOSE_AE
or I-NonOSE_AE
speak I-NonOSE_AE
for I-NonOSE_AE
up I-NonOSE_AE
to I-NonOSE_AE
several I-NonOSE_AE
minutes I-NonOSE_AE
during I-NonOSE_AE
sleep I-NonOSE_AE
- I-NonOSE_AE
wake I-NonOSE_AE
transitions I-NonOSE_AE
, O
and O
hypnagogic B-OSE_Labeled_AE
/hypnopompic O
hallucinations I-OSE_Labeled_AE
, O
including O
vivid B-NonOSE_AE
and O
disturbing O
perceptions I-NonOSE_AE
by O
the O
patient O
, O
can O
occur O
with O
the O
use O
of O
BELSOMRA O
. O

Prescribers O
should O
explain O
the O
nature O
of O
these O
events O
to O
patients O
when O
prescribing O
BELSOMRA O
. O

Symptoms B-OSE_Labeled_AE
similar I-OSE_Labeled_AE
to I-OSE_Labeled_AE
mild I-OSE_Labeled_AE
cataplexy I-OSE_Labeled_AE
can O
occur O
, O
with O
risk O
increasing O
with O
the O
dose O
of O
BELSOMRA O
. O

Such O
symptoms O
can O
include O
periods O
of O
leg B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
lasting O
from O
seconds O
to O
a O
few O
minutes O
, O
can O
occur O
both O
at O
night O
and O
during O
the O
day O
, O
and O
may O
not O
be O
associated O
with O
an O
identified O
triggering O
event O
( O
e.g. O
, O
laughter O
or O
surprise O
) O
. O

ADVERSE O
REACTIONS O
The O
majority O
of O
side O
effects O
observed O
in O
clinical O
trials O
were O
of O
a O
mild O
and O
transient O
nature O
. O

Fewer O
than O
3 O
% O
of O
adult O
patients O
without O
mycobacterial B-Not_AE_Candidate
infections I-Not_AE_Candidate
and O
fewer O
than O
2 O
% O
of O
pediatric O
patients O
without O
mycobacterial B-Not_AE_Candidate
infections I-Not_AE_Candidate
discontinued O
therapy O
because O
of O
drug-related O
side O
effects O
. O

Fewer O
than O
2 O
% O
of O
adult O
patients O
taking O
BIAXIN O
XL O
tablets O
discontinued O
therapy O
because O
of O
drug-related O
side O
effects O
. O

The O
most O
frequently O
reported O
events O
in O
adults O
taking O
BIAXIN O
tablets O
( O
clarithromycin O
tablets O
, O
USP O
) O
were O
diarrhea B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
nausea B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
abnormal B-OSE_Labeled_AE
taste I-OSE_Labeled_AE
( O
3 O
% O
) O
, O
dyspepsia B-OSE_Labeled_AE
( O
2 O
% O
) O
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
/discomfort O
( O
2 O
% O
) O
, O
and O
headache B-OSE_Labeled_AE
( O
2 O
% O
) O
. O

In O
pediatric O
patients O
, O
the O
most O
frequently O
reported O
events O
were O
diarrhea B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
vomiting B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
3 O
% O
) O
, O
rash B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
and O
headache B-OSE_Labeled_AE
( O
2 O
% O
) O
. O

Most O
of O
these O
events O
were O
described O
as O
mild O
or O
moderate O
in O
severity O
. O

Of O
the O
reported O
adverse O
events O
, O
only O
1 O
% O
was O
described O
as O
severe O
. O

The O
most O
frequently O
reported O
events O
in O
adults O
taking O
BIAXIN O
XL O
( O
Clarithromycin O
extended-release O
tablets O
) O
were O
diarrhea B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
abnormal B-OSE_Labeled_AE
taste I-OSE_Labeled_AE
( O
7 O
% O
) O
, O
and O
nausea B-OSE_Labeled_AE
( O
3 O
% O
) O
. O

Most O
of O
these O
events O
were O
described O
as O
mild O
or O
moderate O
in O
severity O
. O

Of O
the O
reported O
adverse O
events O
, O
less O
than O
1 O
% O
were O
described O
as O
severe O
. O

In O
the O
acute B-Not_AE_Candidate
exacerbation I-Not_AE_Candidate
of I-Not_AE_Candidate
chronic I-Not_AE_Candidate
bronchitis I-Not_AE_Candidate
and O
acute B-Not_AE_Candidate
maxillary I-Not_AE_Candidate
sinusitis I-Not_AE_Candidate
studies O
overall O
gastrointestinal B-NonOSE_AE
adverse I-NonOSE_AE
events I-NonOSE_AE
were O
reported O
by O
a O
similar O
proportion O
of O
patients O
taking O
either O
BIAXIN O
tablets O
or O
BIAXIN O
XL O
tablets O
; O
however O
, O
patients O
taking O
BIAXIN O
XL O
tablets O
reported O
significantly O
less O
severe O
gastrointestinal B-NonOSE_AE
symptoms I-NonOSE_AE
compared O
to O
patients O
taking O
BIAXIN O
tablets O
. O

In O
addition O
, O
patients O
taking O
BIAXIN O
XL O
tablets O
had O
significantly O
fewer O
premature O
discontinuations O
for O
drug-related O
gastrointestinal B-NonOSE_AE
or O
abnormal O
taste O
adverse I-No
nOSE B-OSE_Labeled_AE
_ I-OSE_Labeled_AE
AE I-OSE_Labeled_AE
even I-OSE_Labeled_AE
ts I-NonOSE_AE
compared O
to O
BIAXIN O
tablets O
. O

In O
community B-Not_AE_Candidate
- I-Not_AE_Candidate
acquired I-Not_AE_Candidate
pneumonia I-Not_AE_Candidate
studies O
conducted O
in O
adults O
comparing O
clarithromycin O
to O
erythromycin O
base O
or O
erythromycin O
stearate O
, O
there O
were O
fewer O
adverse O
events O
involving O
the O
digestive O
system O
in O
clarithromycin-treated O
patients O
compared O
to O
erythromycin-treated O
patients O
( O
13 O
% O
vs O
32 O
% O
; O
p O
< O
0.01 O
) O
. O

Twenty O
percent O
of O
erythromycin-treated O
patients O
discontinued O
therapy O
due O
to O
adverse O
events O
compared O
to O
4 O
% O
of O
clarithromycin-treated O
patients O
. O

In O
two O
U.S O
. O
studies O
of O
acute B-Not_AE_Candidate
otitis I-Not_AE_Candidate
media I-Not_AE_Candidate
comparing O
clarithromycin O
to O
amoxicillin/potassium O
clavulanate O
in O
pediatric O
patients O
, O
there O
were O
fewer O
adverse O
events O
involving O
the O
digestive O
system O
in O
clarithromycin-treated O
patients O
compared O
to O
amoxicillin/potassium O
clavulanate-treated O
patients O
( O
21 O
% O
vs O
. O
40 O
% O
, O
p O
< O
0.001 O
) O
. O

One-third O
as O
many O
clarithromycin-treated O
patients O
reported O
diarrhea B-OSE_Labeled_AE
as O
did O
amoxicillin/potassium O
clavulanate-treated O
patients O
. O

Post-Marketing O
Experience O
Allergic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
ranging O
from O
urticaria B-OSE_Labeled_AE
and O
mild O
skin B-OSE_Labeled_AE
eruptions I-OSE_Labeled_AE
to O
rare O
cases O
of O
anaphylaxis B-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
drug B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
with I-OSE_Labeled_AE
eosinophilia I-OSE_Labeled_AE
and I-OSE_Labeled_AE
systemic I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
( I-OSE_Labeled_AE
DRESS I-OSE_Labeled_AE
) O
, O
Henoch B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Schonlein I-OSE_Labeled_AE
Purpura I-OSE_Labeled_AE
and O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
have O
occurred O
. O

Other O
spontaneously O
reported O
adverse O
events O
include O
glossitis B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
oral B-OSE_Labeled_AE
moniliasis I-OSE_Labeled_AE
, O
anorexia B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
and O
hemorrhage B-OSE_Labeled_AE
. O

There O
have O
been O
reports O
of O
tooth B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
in O
patients O
treated O
with O
BIAXIN O
. O

Tooth B-NonOSE_AE
discoloration I-NonOSE_AE
is O
usually O
reversible O
with O
professional O
dental O
cleaning O
. O

There O
have O
been O
isolated O
reports O
of O
hearing B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
which O
is O
usually O
reversible O
, O
occurring O
chiefly O
in O
elderly O
women O
. O

Reports O
of O
alterations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
sense I-OSE_Labeled_AE
of I-OSE_Labeled_AE
smell I-OSE_Labeled_AE
including O
smell B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
usually O
in O
conjunction O
with O
taste B-OSE_Labeled_AE
perversion I-OSE_Labeled_AE
or O
taste B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
have O
also O
been O
reported O
. O

Transient B-NonOSE_AE
CNS I-NonOSE_AE
events I-NonOSE_AE
including O
anxiety B-OSE_Labeled_AE
, O
behavioral B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
, O
confusional B-OSE_Labeled_AE
states I-OSE_Labeled_AE
, O
convulsions B-OSE_Labeled_AE
, O
depersonalization B-OSE_Labeled_AE
, O
disorientation B-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
manic B-OSE_Labeled_AE
behavior I-OSE_Labeled_AE
, O
nightmares B-OSE_Labeled_AE
, O
psychosis B-OSE_Labeled_AE
, O
tinnitus B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
and O
vertigo B-OSE_Labeled_AE
have O
been O
reported O
during O
post-marketing O
surveillance O
. O

Events O
usually O
resolve O
with O
discontinuation O
of O
the O
drug O
. O

Adverse O
reactions O
related O
to O
hepatic B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
have O
been O
reported O
in O
postmarketing O
experience O
with O
clarithromycin O
. O

( O
See O
WARNINGS O
- O
Hepatotoxicity B-OSE_Labeled_AE
) O
. O

There O
have O
been O
rare O
reports O
of O
hypoglycemia B-OSE_Labeled_AE
, O
some O
of O
which O
have O
occurred O
in O
patients O
taking O
oral O
hypoglycemic O
agents O
or O
insulin O
. O

There O
have O
been O
post-marketing O
reports O
of O
BIAXIN O
XL O
tablets B-OSE_Labeled_AE
in I-OSE_Labeled_AE
the I-OSE_Labeled_AE
stool I-OSE_Labeled_AE
, O
many O
of O
which O
have O
occurred O
in O
patients O
with O
anatomic O
( O
including O
ileostomy B-Not_AE_Candidate
or O
colostomy B-Not_AE_Candidate
) O
or O
functional O
gastrointestinal B-Not_AE_Candidate
disorders I-Not_AE_Candidate
with I-Not_AE_Candidate
shortened I-Not_AE_Candidate
GI I-Not_AE_Candidate
transit I-Not_AE_Candidate
times I-Not_AE_Candidate
. O

As O
with O
other O
macrolides O
, O
clarithromycin O
has O
been O
associated O
with O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
and O
ventricular B-OSE_Labeled_AE
arrhythmias I-OSE_Labeled_AE
, O
including O
ventricular B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
and O
torsades B-OSE_Labeled_AE
de I-OSE_Labeled_AE
pointes I-OSE_Labeled_AE
. O

There O
have O
been O
reports O
of O
interstitial B-OSE_Labeled_AE
nephritis I-OSE_Labeled_AE
coincident O
with O
clarithromycin O
use O
. O

There O
have O
been O
post-marketing O
reports O
of O
colchicine B-NonOSE_AE
toxicity I-NonOSE_AE
with O
concomitant O
use O
of O
clarithromycin O
and O
colchicine O
, O
especially O
in O
the O
elderly O
, O
some O
of O
which O
occurred O
in O
patients O
with O
renal B-Not_AE_Candidate
insufficiency I-Not_AE_Candidate
. O

Deaths B-NonOSE_AE
have O
been O
reported O
in O
some O
such O
patients O
. O

( O
See O
WARNINGS O
and O
PRECAUTIONS O
. O
) O

There O
have O
been O
reports O
of O
rhabdomyolysis B-OSE_Labeled_AE
coincident O
with O
clarithromycin O
use O
. O

In O
some O
reports O
, O
clarithromycin O
was O
administered O
concomitantly O
with O
statins O
, O
fibrates O
, O
colchicine O
or O
allopurinol O
. O

Changes O
in O
Laboratory O
Values O
Changes O
in O
laboratory O
values O
with O
possible O
clinical O
significance O
were O
as O
follows O
: O
Hepatic O
Elevated B-OSE_Labeled_AE
SGPT I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
) O
< O
1 O
% O
; O
SGOT O
( O
AST O
) O
< O
1 O
% O
; O
GGT O
< O
1 O
% O
; O
alkaline O
phosphatase O
< O
1 O
% O
; O
LDH O
< O
1 O
% O
; O
total O
bilirubin O
< O
1 O
% O
Hematologic O
Decreased B-OSE_Labeled_AE
WBC I-OSE_Labeled_AE
< O
1 O
% O
; O
elevated B-OSE_Labeled_AE
prothrombin I-OSE_Labeled_AE
time I-OSE_Labeled_AE
1 O
% O
Renal O
Elevated B-OSE_Labeled_AE
BUN I-OSE_Labeled_AE
4 O
% O
; O
elevated B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
< O
1 O
% O
GGT O
, O
alkaline O
phosphatase O
, O
and O
prothrombin O
time O
data O
are O
from O
adult O
studies O
only O
. O

PRECAUTIONS O
General O
Prescribing O
BIAXIN O
in O
the O
absence O
of O
a O
proven O
or O
strongly O
suspected O
bacterial B-Not_AE_Candidate
infection I-Not_AE_Candidate
or O
a O
prophylactic O
indication O
is O
unlikely O
to O
provide O
benefit O
to O
the O
patient O
and O
increases O
the O
risk O
of O
the O
development O
of O
drug-resistant O
bacteria O
. O

Clarithromycin O
is O
principally O
excreted O
via O
the O
liver O
and O
kidney O
. O

Clarithromycin O
may O
be O
administered O
without O
dosage O
adjustment O
to O
patients O
with O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
and O
normal O
renal O
function O
. O

However O
, O
in O
the O
presence O
of O
severe O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
with O
or O
without O
coexisting O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
decreased O
dosage O
or O
prolonged O
dosing O
intervals O
may O
be O
appropriate O
. O

Clarithromycin O
in O
combination O
with O
ranitidine O
bismuth O
citrate O
therapy O
is O
not O
recommended O
in O
patients O
with O
creatinine B-Not_AE_Candidate
clearance I-Not_AE_Candidate
less I-Not_AE_Candidate
than I-Not_AE_Candidate
2 I-Not_AE_Candidate
5 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
. O

( O
See O
DOSAGE O
AND O
ADMINISTRATION O
. O
) O

Clarithromycin O
in O
combination O
with O
ranitidine O
bismuth O
citrate O
should O
not O
be O
used O
in O
patients O
with O
a O
history O
of O
acute B-Not_AE_Candidate
porphyria I-Not_AE_Candidate
. O

Exacerbation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
of I-OSE_Labeled_AE
myasthenia I-OSE_Labeled_AE
gravis I-OSE_Labeled_AE
and O
new O
onset O
of O
symptoms O
of O
myasthenic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
has O
been O
reported O
in O
patients O
receiving O
clarithromycin O
therapy O
. O

For O
information O
about O
precautions O
of O
other O
drugs O
indicated O
in O
combination O
with O
BIAXIN O
, O
refer O
to O
the O
PRECAUTIONS O
section O
of O
their O
package O
inserts O
. O

Information O
to O
Patients O
Patients O
should O
be O
counseled O
that O
antibacterial O
drugs O
including O
BIAXIN O
should O
only O
be O
used O
to O
treat O
bacterial B-Not_AE_Candidate
infections I-Not_AE_Candidate
. O

They O
do O
not O
treat O
viral B-Not_AE_Candidate
infections I-Not_AE_Candidate
( O
e.g. O
, O
the O
common B-Not_AE_Candidate
cold I-Not_AE_Candidate
) O
. O

When O
BIAXIN O
is O
prescribed O
to O
treat O
a O
bacterial B-Not_AE_Candidate
infection I-Not_AE_Candidate
, O
patients O
should O
be O
told O
that O
although O
it O
is O
common O
to O
feel O
better O
early O
in O
the O
course O
of O
therapy O
, O
the O
medication O
should O
be O
taken O
exactly O
as O
directed O
. O

Skipping O
doses O
or O
not O
completing O
the O
full O
course O
of O
therapy O
may O
( O
1 O
) O
decrease O
the O
effectiveness O
of O
the O
immediate O
treatment O
and O
( O
2 O
) O
increase O
the O
likelihood O
that O
bacteria O
will O
develop O
resistance O
and O
will O
not O
be O
treatable O
by O
BIAXIN O
or O
other O
antibacterial O
drugs O
in O
the O
future O
. O

Diarrhea B-OSE_Labeled_AE
is O
a O
common O
problem O
caused O
by O
antibiotics O
which O
usually O
ends O
when O
the O
antibiotic O
is O
discontinued O
. O

Sometimes O
after O
starting O
treatment O
with O
antibiotics O
, O
patients O
can O
develop B-OSE_Labeled_AE
watery I-OSE_Labeled_AE
and I-OSE_Labeled_AE
bloody I-OSE_Labeled_AE
stools I-OSE_Labeled_AE
( O
with O
or O
without O
stomach B-OSE_Labeled_AE
cramps I-OSE_Labeled_AE
and O
fever B-OSE_Labeled_AE
) O
even O
as O
late O
as O
two O
or O
more O
months O
after O
having O
taken O
the O
last O
dose O
of O
the O
antibiotic O
. O

If O
this O
occurs O
, O
patients O
should O
contact O
their O
physician O
as O
soon O
as O
possible O
. O

BIAXIN O
may O
interact O
with O
some O
drugs O
; O
therefore O
patients O
should O
be O
advised O
to O
report O
to O
their O
doctor O
the O
use O
of O
any O
other O
medications O
. O

BIAXIN O
tablets O
and O
oral O
suspension O
can O
be O
taken O
with O
or O
without O
food O
and O
can O
be O
taken O
with O
milk O
; O
however O
, O
BIAXIN O
XL O
tablets O
should O
be O
taken O
with O
food O
. O

Do O
NOT O
refrigerate O
the O
suspension O
. O

Drug O
Interactions O
Clarithromycin O
use O
in O
patients O
who O
are O
receiving O
theophylline O
may O
be O
associated O
with O
an O
increase O
of O
serum O
theophylline O
concentrations O
. O

Monitoring O
of O
serum O
theophylline O
concentrations O
should O
be O
considered O
for O
patients O
receiving O
high O
doses O
of O
theophylline O
or O
with O
baseline O
concentrations O
in O
the O
upper O
therapeutic O
range O
. O

In O
two O
studies O
in O
which O
theophylline O
was O
administered O
with O
clarithromycin O
( O
a O
theophylline O
sustained-release O
formulation O
was O
dosed O
at O
either O
6.5 O
mg/kg O
or O
12 O
mg/kg O
together O
with O
250 O
or O
500 O
mg O
q12h O
clarithromycin O
) O
, O
the O
steady-state O
levels O
of O
Cmax O
, O
Cmin O
, O
and O
the O
area O
under O
the O
serum O
concentration O
time O
curve O
( O
AUC O
) O
of O
theophylline O
increased O
about O
20 O
% O
. O

Hypotension B-NonOSE_AE
, O
bradyarrhythmias B-NonOSE_AE
, O
and O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
have O
been O
observed O
in O
patients O
receiving O
concurrent O
verapamil O
, O
belonging O
to O
the O
calcium O
channel O
blockers O
drug O
class O
. O

Concomitant O
administration O
of O
single O
doses O
of O
clarithromycin O
and O
carbamazepine O
has O
been O
shown O
to O
result O
in O
increased O
plasma O
concentrations O
of O
carbamazepine O
. O

Blood O
level O
monitoring O
of O
carbamazepine O
may O
be O
considered O
. O

When O
clarithromycin O
and O
terfenadine O
were O
coadministered O
, O
plasma O
concentrations O
of O
the O
active O
acid O
metabolite O
of O
terfenadine O
were O
threefold O
higher O
, O
on O
average O
, O
than O
the O
values O
observed O
when O
terfenadine O
was O
administered O
alone O
. O

The O
pharmacokinetics O
of O
clarithromycin O
and O
the O
14-OH-clarithromycin O
were O
not O
significantly O
affected O
by O
coadministration O
of O
terfenadine O
once O
clarithromycin O
reached O
steady-state O
conditions O
. O

Concomitant O
administration O
of O
clarithromycin O
with O
terfenadine O
is O
contraindicated O
. O

( O
See O
CONTRAINDICATIONS O
. O
) O

Clarithromycin O
500 O
mg O
every O
8 O
hours O
was O
given O
in O
combination O
with O
omeprazole O
40 O
mg O
daily O
to O
healthy O
adult O
subjects O
. O

The O
steady-state O
plasma O
concentrations O
of O
omeprazole O
were O
increased O
( O
Cmax O
, O
AUC0-24 O
, O
and O
t1/2increases O
of O
30 O
% O
, O
89 O
% O
, O
and O
34 O
% O
, O
respectively O
) O
, O
by O
the O
concomitant O
administration O
of O
clarithromycin O
. O

The O
mean O
24-hour O
gastric O
pH O
value O
was O
5.2 O
when O
omeprazole O
was O
administered O
alone O
and O
5.7 O
when O
coadministered O
with O
clarithromycin O
. O

Coadministration O
of O
clarithromycin O
with O
ranitidine O
bismuth O
citrate O
resulted O
in O
increased O
plasma O
ranitidine O
concentrations O
( O
57 O
% O
) O
, O
increased O
plasma O
bismuth O
trough O
concentrations O
( O
48 O
% O
) O
, O
and O
increased O
14-hydroxy-clarithromycin O
plasma O
concentrations O
( O
31 O
% O
) O
. O

These O
effects O
are O
clinically O
insignificant O
. O

Simultaneous O
oral O
administration O
of O
BIAXIN O
tablets O
and O
zidovudine O
to O
HIV-infected O
adult O
patients O
may O
result O
in O
decreased O
steady-state O
zidovudine O
concentrations O
. O

Following O
administration O
of O
clarithromycin O
500 O
mg O
tablets O
twice O
daily O
with O
zidovudine O
100 O
mg O
every O
4 O
hours O
, O
the O
steady-state O
zidovudine O
AUC O
decreased O
12 O
% O
compared O
to O
administration O
of O
zidovudine O
alone O
( O
n=4 O
) O
. O

Individual O
values O
ranged O
from O
a O
decrease O
of O
34 O
% O
to O
an O
increase O
of O
14 O
% O
. O

When O
clarithromycin O
tablets O
were O
administered O
two O
to O
four O
hours O
prior O
to O
zidovudine O
, O
the O
steady-state O
zidovudine O
Cmaxincreased O
100 O
% O
whereas O
the O
AUC O
was O
unaffected O
( O
n=24 O
) O
. O

Administration O
of O
clarithromycin O
and O
zidovudine O
should O
be O
separated O
by O
at O
least O
two O
hours O
. O

The O
impact O
of O
co-administration O
of O
clarithromycin O
extended-release O
tablets O
and O
zidovudine O
has O
not O
been O
evaluated O
. O

Simultaneous O
administration O
of O
BIAXIN O
tablets O
and O
didanosine O
to O
12 O
HIV-infected O
adult O
patients O
resulted O
in O
no O
statistically O
significant O
change O
in O
didanosine O
pharmacokinetics O
. O

Following O
administration O
of O
fluconazole O
200 O
mg O
daily O
and O
clarithromycin O
500 O
mg O
twice O
daily O
to O
21 O
healthy O
volunteers O
, O
the O
steady-state O
clarithromycin O
Cminand O
AUC O
increased O
33 O
% O
and O
18 O
% O
, O
respectively O
. O

Steady-state O
concentrations O
of O
14-OH O
clarithromycin O
were O
not O
significantly O
affected O
by O
concomitant O
administration O
of O
fluconazole O
. O

No O
dosage O
adjustment O
of O
clarithromycin O
is O
necessary O
when O
co-administered O
with O
fluconazole O
. O

Ritonavir O
Concomitant O
administration O
of O
clarithromycin O
and O
ritonavir O
( O
n O
= O
22 O
) O
resulted O
in O
a O
77 O
% O
increase O
in O
clarithromycin O
AUC O
and O
a O
100 O
% O
decrease O
in O
the O
AUC O
of O
14-OH O
clarithromycin O
. O

Clarithromycin O
may O
be O
administered O
without O
dosage O
adjustment O
to O
patients O
with O
normal O
renal O
function O
taking O
ritonavir O
. O

Since O
concentrations O
of O
14-OH O
clarithromycin O
are O
significantly O
reduced O
when O
clarithromycin O
is O
co-administered O
with O
ritonavir O
, O
alternative O
antibacterial O
therapy O
should O
be O
considered O
for O
indications O
other O
than O
infections O
due O
to O
Mycobacterium B-Not_AE_Candidate
avium I-Not_AE_Candidate
complex I-Not_AE_Candidate
( O
see O
PRECAUTIONS O
- O
Drug O
Interactions O
) O
. O

Doses O
of O
clarithromycin O
greater O
than O
1000 O
mg O
per O
day O
should O
not O
be O
co-administered O
with O
protease O
inhibitors O
. O

Spontaneous O
reports O
in O
the O
post-marketing O
period O
suggest O
that O
concomitant O
administration O
of O
clarithromycin O
and O
oral O
anticoagulants O
may O
potentiate O
the O
effects O
of O
the O
oral O
anticoagulants O
. O

Prothrombin O
times O
should O
be O
carefully O
monitored O
while O
patients O
are O
receiving O
clarithromycin O
and O
oral O
anticoagulants O
simultaneously O
. O

Digoxin O
is O
a O
substrate O
for O
P-glycoprotein O
( O
Pgp O
) O
and O
clarithromycin O
is O
known O
to O
inhibit O
Pgp O
. O

When O
clarithromycin O
and O
digoxin O
are O
co-administered O
, O
inhibition O
of O
Pgp O
by O
clarithromycin O
may O
lead O
to O
increased O
exposure O
of O
digoxin O
. O

Elevated O
digoxin O
serum O
concentrations O
in O
patients O
receiving O
clarithromycin O
and O
digoxin O
concomitantly O
have O
been O
reported O
in O
post-marketing O
surveillance O
. O

Some O
patients O
have O
shown O
clinical O
signs O
consistent O
with O
digoxin B-NonOSE_AE
toxicity I-NonOSE_AE
, O
including O
potentially O
fatal B-NonOSE_AE
arrhythmias B-NonOSE_AE
. O

Monitoring O
of O
serum O
digoxin O
concentrations O
should O
be O
considered O
, O
especially O
for O
patients O
with O
digoxin O
concentrations O
in O
the O
upper O
therapeutic O
range O
. O

Co-administration O
of O
clarithromycin O
, O
known O
to O
inhibit O
CYP3A O
, O
and O
a O
drug O
primarily O
metabolized O
by O
CYP3A O
may O
be O
associated O
with O
elevations O
in O
drug O
concentrations O
that O
could O
increase O
or O
prolong O
both O
therapeutic O
and O
adverse O
effects O
of O
the O
concomitant O
drug O
. O

Clarithromycin O
should O
be O
used O
with O
caution O
in O
patients O
receiving O
treatment O
with O
other O
drugs O
known O
to O
be O
CYP3A O
enzyme O
substrates O
, O
especially O
if O
the O
CYP3A O
substrate O
has O
a O
narrow O
safety O
margin O
( O
e.g. O
, O
carbamazepine O
) O
and/or O
the O
substrate O
is O
extensively O
metabolized O
by O
this O
enzyme O
. O

Dosage O
adjustments O
may O
be O
considered O
, O
and O
when O
possible O
, O
serum O
concentrations O
of O
drugs O
primarily O
metabolized O
by O
CYP3A O
should O
be O
monitored O
closely O
in O
patients O
concurrently O
receiving O
clarithromycin O
. O

The O
following O
are O
examples O
of O
some O
clinically O
significant O
CYP3A O
based O
drug O
interactions O
. O

Interactions O
with O
other O
drugs O
metabolized O
by O
the O
CYP3A O
isoform O
are O
also O
possible O
. O

Carbamazepine O
and O
Terfenadine O
Increased O
serum O
concentrations O
of O
carbamazepine O
and O
the O
active O
acid O
metabolite O
of O
terfenadine O
were O
observed O
in O
clinical O
trials O
with O
clarithromycin O
. O

Colchicine O
Colchicine O
is O
a O
substrate O
for O
both O
CYP3A O
and O
the O
efflux O
transporter O
, O
P-glycoprotein O
( O
Pgp O
) O
. O

Clarithromycin O
and O
other O
macrolides O
are O
known O
to O
inhibit O
CYP3A O
and O
Pgp O
. O

When O
a O
single O
dose O
of O
colchicine O
0.6 O
mg O
was O
administered O
with O
clarithromycin O
250 O
mg O
BID O
for O
7 O
days O
, O
the O
colchicine O
Cmaxincreased O
197 O
% O
and O
the O
AUC0-increased O
239 O
% O
compared O
to O
administration O
of O
colchicine O
alone O
. O

The O
dose O
of O
colchicine O
should O
be O
reduced O
when O
co-administered O
with O
clarithromycin O
in O
patients O
with O
normal O
renal O
and O
hepatic O
function O
. O

Concomitant O
use O
of O
clarithromycin O
and O
colchicine O
is O
contraindicated O
in O
patients O
with O
renal B-Not_AE_Candidate
or O
hepatic O
impairment I-Not_AE_Candidate
. O

( O
See O
WARNINGS O
) O
. O

Efavirenz O
, O
Nevirapine O
, O
Rifampicin O
, O
Rifabutin O
, O
and O
Rifapentine O
Inducers O
of O
CYP3A O
enzymes O
, O
such O
as O
efavirenz O
, O
nevirapine O
, O
rifampicin O
, O
rifabutin O
, O
and O
rifapentine O
will O
increase O
the O
metabolism O
of O
clarithromycin O
, O
thus O
decreasing O
plasma O
concentrations O
of O
clarithromycin O
, O
while O
increasing O
those O
of O
14-OH-clarithromycin O
. O

Since O
the O
microbiological O
activities O
of O
clarithromycin O
and O
14-OH-clarithromycin O
are O
different O
for O
different O
bacteria O
, O
the O
intended O
therapeutic O
effect O
could O
be O
impaired O
during O
concomitant O
administration O
of O
clarithromycin O
and O
enzyme O
inducers O
. O

Alternative O
antibacterial O
treatment O
should O
be O
considered O
when O
treating O
patients O
receiving O
inducers O
of O
CYP3A O
. O

Sildenafil O
, O
Tadalafil O
, O
and O
Vardenafil O
Each O
of O
these O
phosphodiesterase O
inhibitors O
is O
primarily O
metabolized O
by O
CYP3A O
, O
and O
CYP3A O
will O
be O
inhibited O
by O
concomitant O
administration O
of O
clarithromycin O
. O

Co-administration O
of O
clarithromycin O
with O
sildenafil O
, O
tadalafil O
, O
or O
vardenafil O
will O
result O
in O
increased O
exposure O
of O
these O
phosphodiesterase O
inhibitors O
. O

Co-administration O
of O
these O
phosphodiesterase O
inhibitors O
with O
clarithromycin O
is O
not O
recommended O
. O

Tolterodine O
The O
primary O
route O
of O
metabolism O
for O
tolterodine O
is O
via O
CYP2D6 O
. O

However O
, O
in O
a O
subset O
of O
the O
population O
devoid O
of O
CYP2D6 O
, O
the O
identified O
pathway O
of O
metabolism O
is O
via O
CYP3A O
. O

In O
this O
population O
subset O
, O
inhibition O
of O
CYP3A O
results O
in O
significantly O
higher O
serum O
concentrations O
of O
tolterodine O
. O

Tolterodine O
1 O
mg O
twice O
daily O
is O
recommended O
in O
patients O
deficient O
in O
CYP2D6 O
activity O
( O
poor O
metabolizers O
) O
when O
co-administered O
with O
clarithromycin O
. O

Triazolobenzodiazepines O
( O
e.g. O
, O
alprazolam O
, O
midazolam O
, O
triazolam O
) O
When O
a O
single O
dose O
of O
midazolam O
was O
co-administered O
with O
clarithromycin O
tablets O
( O
500 O
mg O
twice O
daily O
for O
7 O
days O
) O
, O
midazolam O
AUC O
increased O
174 O
% O
after O
intravenous O
administration O
of O
midazolam O
and O
600 O
% O
after O
oral O
administration O
. O

When O
oral O
midazolam O
is O
co-administered O
with O
clarithromycin O
, O
dose O
adjustments O
may O
be O
necessary O
and O
possible O
prolongation O
and O
intensity O
of O
effect O
should O
be O
anticipated O
. O

Caution O
and O
appropriate O
dose O
adjustments O
should O
be O
considered O
when O
triazolam O
or O
alprazolam O
is O
co-administered O
with O
clarithromycin O
. O

For O
benzodiazepines O
which O
are O
not O
metabolized O
by O
CYP3A O
( O
e.g. O
, O
temazepam O
, O
nitrazepam O
, O
lorazepam O
) O
, O
a O
clinically O
important O
interaction O
with O
clarithromycin O
is O
unlikely O
. O

There O
have O
been O
post-marketing O
reports O
of O
drug O
interactions O
and O
central B-NonOSE_AE
nervous I-NonOSE_AE
system I-NonOSE_AE
( I-NonOSE_AE
CNS I-NonOSE_AE
) I-NonOSE_AE
effects I-NonOSE_AE
( O
e.g. O
, O
somnolence B-NonOSE_AE
and O
confusion B-NonOSE_AE
) O
with O
the O
concomitant O
use O
of O
clarithromycin O
and O
triazolam O
. O

Monitoring O
the O
patient O
for O
increased O
CNS O
pharmacological O
effects O
is O
suggested O
. O

Atazanavir O
Both O
clarithromycin O
and O
atazanavir O
are O
substrates O
and O
inhibitors O
of O
CYP3A O
, O
and O
there O
is O
evidence O
of O
a O
bi-directional O
drug O
interaction O
. O

Following O
administration O
of O
clarithromycin O
( O
500 O
mg O
twice O
daily O
) O
with O
atazanavir O
( O
400 O
mg O
once O
daily O
) O
, O
the O
clarithromycin O
AUC O
increased O
94 O
% O
, O
the O
14-OH O
clarithromycin O
AUC O
decreased O
70 O
% O
and O
the O
atazanavir O
AUC O
increased O
28 O
% O
. O

When O
clarithromycin O
is O
co-administered O
with O
atazanavir O
, O
the O
dose O
of O
clarithromycin O
should O
be O
decreased O
by O
50 O
% O
. O

Since O
concentrations O
of O
14-OH O
clarithromycin O
are O
significantly O
reduced O
when O
clarithromycin O
is O
co-administered O
with O
atazanavir O
, O
alternative O
antibacterial O
therapy O
should O
be O
considered O
for O
indications O
other O
than O
infections O
due O
to O
Mycobacterium B-Not_AE_Candidate
avium I-Not_AE_Candidate
complex I-Not_AE_Candidate
( O
see O
PRECAUTIONS O
- O
Drug O
Interactions O
) O
. O

Doses O
of O
clarithromycin O
greater O
than O
1000 O
mg O
per O
day O
should O
not O
be O
co-administered O
with O
protease O
inhibitors O
. O

Itraconazole O
Both O
clarithromycin O
and O
itraconazole O
are O
substrates O
and O
inhibitors O
of O
CYP3A O
, O
potentially O
leading O
to O
a O
bi-directional O
drug O
interaction O
when O
administered O
concomitantly O
. O

Clarithromycin O
may O
increase O
the O
plasma O
concentrations O
of O
itraconazole O
, O
while O
itraconazole O
may O
increase O
the O
plasma O
concentrations O
of O
clarithromycin O
. O

Patients O
taking O
itraconazole O
and O
clarithromycin O
concomitantly O
should O
be O
monitored O
closely O
for O
signs O
or O
symptoms O
of O
increased O
or O
prolonged O
adverse O
reactions O
. O

Saquinavir O
Both O
clarithromycin O
and O
saquinavir O
are O
substrates O
and O
inhibitors O
of O
CYP3A O
and O
there O
is O
evidence O
of O
a O
bi-directional O
drug O
interaction O
. O

Following O
administration O
of O
clarithromycin O
( O
500 O
mg O
bid O
) O
and O
saquinavir O
( O
soft O
gelatin O
capsules O
, O
1200 O
mg O
tid O
) O
to O
12 O
healthy O
volunteers O
, O
the O
steady-state O
saquinavir O
AUC O
and O
Cmaxincreased O
177 O
% O
and O
187 O
% O
respectively O
compared O
to O
administration O
of O
saquinavir O
alone O
. O

Clarithromycin O
AUC O
and O
Cmaxincreased O
45 O
% O
and O
39 O
% O
respectively O
, O
whereas O
the O
14-OH O
clarithromycin O
AUC O
and O
Cmaxdecreased O
24 O
% O
and O
34 O
% O
respectively O
, O
compared O
to O
administration O
with O
clarithromycin O
alone O
. O

No O
dose O
adjustment O
of O
clarithromycin O
is O
necessary O
when O
clarithromycin O
is O
co-administered O
with O
saquinavir O
in O
patients O
with O
normal O
renal O
function O
. O

When O
saquinavir O
is O
co-administered O
with O
ritonavir O
, O
consideration O
should O
be O
given O
to O
the O
potential O
effects O
of O
ritonavir O
on O
clarithromycin O
( O
refer O
to O
interaction O
between O
clarithromycin O
and O
ritonavir O
) O
( O
see O
PRECAUTIONS O
- O
Drug O
Interactions O
) O
. O

The O
following O
CYP3A O
based O
drug O
interactions O
have O
been O
observed O
with O
erythromycin O
products O
and/or O
with O
clarithromycin O
in O
post-marketing O
experience O
: O
Antiarrhythmics O
There O
have O
been O
post-marketing O
reports O
of O
torsades B-NonOSE_AE
de I-NonOSE_AE
pointes I-NonOSE_AE
occurring O
with O
concurrent O
use O
of O
clarithromycin O
and O
quinidine O
or O
disopyramide O
. O

Electrocardiograms O
should O
be O
monitored O
for O
QTc B-NonOSE_AE
prolongation I-NonOSE_AE
during O
coadministration O
of O
clarithromycin O
with O
these O
drugs O
. O

Serum O
concentrations O
of O
these O
medications O
should O
also O
be O
monitored O
. O

Ergotamine/Dihydroergotamine O
Post-marketing O
reports O
indicate O
that O
coadministration O
of O
clarithromycin O
with O
ergotamine O
or O
dihydroergotamine O
has O
been O
associated O
with O
acute B-NonOSE_AE
ergot I-NonOSE_AE
toxicity I-NonOSE_AE
characterized O
by O
vasospasm B-NonOSE_AE
and O
ischemia B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
extremities I-NonOSE_AE
and O
other O
tissues O
including O
the O
central O
nervous O
system O
. O

Concomitant O
administration O
of O
clarithromycin O
with O
ergotamine O
or O
dihydroergotamine O
is O
contraindicated O
( O
see O
CONTRAINDICATIONS O
) O
. O

Triazolobenziodidiazepines O
( O
Such O
as O
Triazolam O
and O
Alprazolam O
) O
and O
Related O
Benzodiazepines O
( O
Such O
as O
Midazolam O
) O
Erythromycin O
has O
been O
reported O
to O
decrease O
the O
clearance O
of O
triazolam O
and O
midazolam O
, O
and O
thus O
, O
may O
increase O
the O
pharmacologic O
effect O
of O
these O
benzodiazepines O
. O

There O
have O
been O
post-marketing O
reports O
of O
drug O
interactions O
and O
CNS B-NonOSE_AE
effects I-NonOSE_AE
( O
e.g. O
, O
somnolence B-NonOSE_AE
and O
confusion B-NonOSE_AE
) O
with O
the O
concomitant O
use O
of O
clarithromycin O
and O
triazolam O
. O

Sildenafil O
( O
Viagra O
) O
Erythromycin O
has O
been O
reported O
to O
increase O
the O
systemic O
exposure O
( O
AUC O
) O
of O
sildenafil O
. O

A O
similar O
interaction O
may O
occur O
with O
clarithromycin O
; O
reduction O
of O
sildenafil O
dosage O
should O
be O
considered O
. O

( O
See O
Viagra O
package O
insert O
. O
) O

There O
have O
been O
spontaneous O
or O
published O
reports O
of O
CYP3A O
based O
interactions O
of O
erythromycin O
and/or O
clarithromycin O
with O
cyclosporine O
, O
carbamazepine O
, O
tacrolimus O
, O
alfentanil O
, O
disopyramide O
, O
rifabutin O
, O
quinidine O
, O
methylprednisolone O
, O
cilostazol O
, O
bromocriptine O
and O
vinblastine O
. O

Concomitant O
administration O
of O
clarithromycin O
with O
cisapride O
, O
pimozide O
, O
astemizole O
, O
or O
terfenadine O
is O
contraindicated O
( O
see O
CONTRAINDICATIONS O
. O
) O

In O
addition O
, O
there O
have O
been O
reports O
of O
interactions O
of O
erythromycin O
or O
clarithromycin O
with O
drugs O
not O
thought O
to O
be O
metabolized O
by O
CYP3A O
, O
including O
hexobarbital O
, O
phenytoin O
, O
and O
valproate O
. O

Carcinogenesis O
, O
Mutagenesis O
, O
Impairment O
of O
Fertility O
The O
following O
in O
vitro O
mutagenicity O
tests O
have O
been O
conducted O
with O
clarithromycin O
: O
Salmonella O
/Mammalian O
Microsomes O
Test O
Bacterial O
Induced O
Mutation O
Frequency O
Test O
In O
Vitro O
Chromosome O
Aberration O
Test O
Rat O
Hepatocyte O
DNA O
Synthesis O
Assay O
Mouse O
Lymphoma O
Assay O
Mouse O
Dominant O
Lethal O
Study O
Mouse O
Micronucleus O
Test O
All O
tests O
had O
negative O
results O
except O
the O
In O
Vitro O
Chromosome O
Aberration O
Test O
which O
was O
weakly O
positive O
in O
one O
test O
and O
negative O
in O
another O
. O

In O
addition O
, O
a O
Bacterial O
Reverse-Mutation O
Test O
( O
Ames O
Test O
) O
has O
been O
performed O
on O
clarithromycin O
metabolites O
with O
negative O
results O
. O

Fertility O
and O
reproduction O
studies O
have O
shown O
that O
daily O
doses O
of O
up O
to O
160 O
mg/kg/day O
( O
1.3 O
times O
the O
recommended O
maximum O
human O
dose O
based O
on O
mg/m O
2 O
) O
to O
male O
and O
female O
rats O
caused O
no O
adverse O
effects O
on O
the O
estrous O
cycle O
, O
fertility O
, O
parturition O
, O
or O
number O
and O
viability O
of O
offspring O
. O

Plasma O
levels O
in O
rats O
after O
150 O
mg/kg/day O
were O
2 O
times O
the O
human O
serum O
levels O
. O

In O
the O
150 O
mg/kg/day O
monkey O
studies O
, O
plasma O
levels O
were O
3 O
times O
the O
human O
serum O
levels O
. O

When O
given O
orally O
at O
150 O
mg/kg/day O
( O
2.4 O
times O
the O
recommended O
maximum O
human O
dose O
based O
on O
mg/m O
2 O
) O
, O
clarithromycin O
was O
shown O
to O
produce O
embryonic B-NonOSE_AE
loss I-NonOSE_AE
in O
monkeys O
. O

This O
effect O
has O
been O
attributed O
to O
marked O
maternal B-NonOSE_AE
toxicity I-NonOSE_AE
of O
the O
drug O
at O
this O
high O
dose O
. O

In O
rabbits O
, O
in O
utero O
fetal B-NonOSE_AE
loss I-NonOSE_AE
occurred O
at O
an O
intravenous O
dose O
of O
33 O
mg/m O
2 O
, O
which O
is O
17 O
times O
less O
than O
the O
maximum O
proposed O
human O
oral O
daily O
dose O
of O
618 O
mg/m O
2 O
. O

Long-term O
studies O
in O
animals O
have O
not O
been O
performed O
to O
evaluate O
the O
carcinogenic O
potential O
of O
clarithromycin O
. O

Pregnancy O
Teratogenic O
Effects O
Pregnancy O
Category O
C O
Four O
teratogenicity B-NonOSE_AE
studies O
in O
rats O
( O
three O
with O
oral O
doses O
and O
one O
with O
intravenous O
doses O
up O
to O
160 O
mg/kg/day O
administered O
during O
the O
period O
of O
major O
organogenesis O
) O
and O
two O
in O
rabbits O
at O
oral O
doses O
up O
to O
125 O
mg/kg/day O
( O
approximately O
2 O
times O
the O
recommended O
maximum O
human O
dose O
based O
on O
mg/m O
2 O
) O
or O
intravenous O
doses O
of O
30 O
mg/kg/day O
administered O
during O
gestation O
days O
6 O
to O
18 O
failed O
to O
demonstrate O
any O
teratogenicity B-NonOSE_AE
from O
clarithromycin O
. O

Two O
additional O
oral O
studies O
in O
a O
different O
rat O
strain O
at O
similar O
doses O
and O
similar O
conditions O
demonstrated O
a O
low O
incidence O
of O
cardiovascular B-NonOSE_AE
anomalies I-NonOSE_AE
at O
doses O
of O
150 O
mg/kg/day O
administered O
during O
gestation O
days O
6 O
to O
15 O
. O

Plasma O
levels O
after O
150 O
mg/kg/day O
were O
2 O
times O
the O
human O
serum O
levels O
. O

Four O
studies O
in O
mice O
revealed O
a O
variable O
incidence O
of O
cleft B-NonOSE_AE
palate I-NonOSE_AE
following O
oral O
doses O
of O
1000 O
mg/kg/day O
( O
2 O
and O
4 O
times O
the O
recommended O
maximum O
human O
dose O
based O
on O
mg/m O
2 O
, O
respectively O
) O
during O
gestation O
days O
6 O
to O
15 O
. O

Cleft B-NonOSE_AE
palate I-NonOSE_AE
was O
also O
seen O
at O
500 O
mg/kg/day O
. O

The O
1000 O
mg/kg/day O
exposure O
resulted O
in O
plasma O
levels O
17 O
times O
the O
human O
serum O
levels O
. O

In O
monkeys O
, O
an O
oral O
dose O
of O
70 O
mg/kg/day O
( O
an O
approximate O
equidose O
of O
the O
recommended O
maximum O
human O
dose O
based O
on O
mg/m O
2 O
) O
produced O
fetal B-NonOSE_AE
growth I-NonOSE_AE
retardation I-NonOSE_AE
at O
plasma O
levels O
that O
were O
2 O
times O
the O
human O
serum O
levels O
. O

There O
are O
no O
adequate O
and O
well-controlled O
studies O
in O
pregnant B-Not_AE_Candidate
women O
. O

Clarithromycin O
should O
be O
used O
during O
pregnancy B-NonOSE_AE
only O
if O
the O
potential O
benefit O
justifies O
the O
potential O
risk B-NonOSE_AE
to I-NonOSE_AE
the I-NonOSE_AE
fetus I-NonOSE_AE
. O

( O
See O
WARNINGS O
. O
) O

Nursing O
Mothers O
It O
is O
not O
known O
whether O
clarithromycin O
is O
excreted O
in O
human O
milk O
. O

Because O
many O
drugs O
are O
excreted O
in O
human O
milk O
, O
caution O
should O
be O
exercised O
when O
clarithromycin O
is O
administered O
to O
a O
nursing O
woman O
. O

It O
is O
known O
that O
clarithromycin O
is O
excreted O
in O
the O
milk O
of O
lactating O
animals O
and O
that O
other O
drugs O
of O
this O
class O
are O
excreted O
in O
human O
milk O
. O

Preweaned O
rats O
, O
exposed O
indirectly O
via O
consumption O
of O
milk O
from O
dams O
treated O
with O
150 O
mg/kg/day O
for O
3 O
weeks O
, O
were O
not O
adversely O
affected O
, O
despite O
data O
indicating O
higher O
drug O
levels O
in O
milk O
than O
in O
plasma O
. O

Pediatric O
Use O
Safety O
and O
effectiveness O
of O
clarithromycin O
in O
pediatric O
patients O
under O
6 O
months O
of O
age O
have O
not O
been O
established O
. O

The O
safety O
of O
clarithromycin O
has O
not O
been O
studied O
in O
MAC B-Not_AE_Candidate
patients O
under O
the O
age O
of O
20 O
months O
. O

Neonatal O
and O
juvenile O
animals O
tolerated O
clarithromycin O
in O
a O
manner O
similar O
to O
adult O
animals O
. O

Young O
animals O
were O
slightly O
more O
intolerant O
to O
acute O
overdosage O
and O
to O
subtle O
reductions B-NonOSE_AE
in I-NonOSE_AE
erythrocytes I-NonOSE_AE
, O
platelets O
and O
leukocytes O
but O
were O
less O
sensitive O
to O
toxicity O
in O
the O
liver O
, O
kidney O
, O
thymus O
, O
and O
genitalia O
. O

Geriatric O
Use O
In O
a O
steady-state O
study O
in O
which O
healthy O
elderly O
subjects O
( O
age O
65 O
to O
81 O
years O
old O
) O
were O
given O
500 O
mg O
every O
12 O
hours O
, O
the O
maximum O
serum O
concentrations O
and O
area O
under O
the O
curves O
of O
clarithromycin O
and O
14-OH O
clarithromycin O
were O
increased O
compared O
to O
those O
achieved O
in O
healthy O
young O
adults O
. O

These O
changes O
in O
pharmacokinetics O
parallel O
known O
age-related O
decreases B-NonOSE_AE
in I-NonOSE_AE
renal I-NonOSE_AE
function I-NonOSE_AE
. O

In O
clinical O
trials O
, O
elderly O
patients O
did O
not O
have O
an O
increased O
incidence O
of O
adverse O
events O
when O
compared O
to O
younger O
patients O
. O

Dosage O
adjustment O
should O
be O
considered O
in O
elderly O
patients O
with O
severe B-Not_AE_Candidate
renal I-Not_AE_Candidate
impairment I-Not_AE_Candidate
. O

( O
See O
WARNINGS O
and O
PRECAUTIONS O
. O
) O

WARNINGS O
Use B-OSE_Labeled_AE
In I-OSE_Labeled_AE
Pregnancy I-OSE_Labeled_AE
CLARITHROMYCIN O
SHOULD O
NOT O
BE O
USED O
IN O
PREGNANT B-Not_AE_Candidate
WOMEN O
EXCEPT O
IN O
CLINICAL O
CIRCUMSTANCES O
WHERE O
NO O
ALTERNATIVE O
THERAPY O
IS O
APPROPRIATE O
. O

IF O
PREGNANCY B-NonOSE_AE
OCCURS O
WHILE O
TAKING O
THIS O
DRUG O
, O
THE O
PATIENT O
SHOULD O
BE O
APPRISED O
OF O
THE O
POTENTIAL O
HAZARD B-OSE_Labeled_AE
TO I-OSE_Labeled_AE
THE I-OSE_Labeled_AE
FETUS I-OSE_Labeled_AE
. O

CLARITHROMYCIN O
HAS O
DEMONSTRATED O
ADVERSE B-NonOSE_AE
EFFECTS I-NonOSE_AE
OF I-NonOSE_AE
PREGNANCY I-NonOSE_AE
OUTCOME I-NonOSE_AE
AND/OR O
EMBRYO B-NonOSE_AE
- I-NonOSE_AE
FETAL I-NonOSE_AE
DEVELOPMENT I-NonOSE_AE
IN O
MONKEYS O
, O
RATS O
, O
MICE O
, O
AND O
RABBITS O
AT O
DOSES O
THAT O
PRODUCED O
PLASMA O
LEVELS O
2 O
TO O
17 O
TIMES O
THE O
SERUM O
LEVELS O
ACHIEVED O
IN O
HUMANS O
TREATED O
AT O
THE O
MAXIMUM O
RECOMMENDED O
HUMAN O
DOSES O
. O

( O
See O
PRECAUTIONS O
- O
Pregnancy O
. O
) O

Hepatotoxicity B-OSE_Labeled_AE
Hepatic B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
, O
including O
increased B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
enzymes I-OSE_Labeled_AE
, O
and O
hepatocellular B-OSE_Labeled_AE
and/or O
cholestatic O
hepatitis I-OSE_Labeled_AE
, O
with O
or O
without O
jaundice B-NonOSE_AE
, O
has O
been O
reported O
with O
clarithromycin O
. O

This O
hepatic B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
may O
be O
severe O
and O
is O
usually O
reversible O
. O

In O
some O
instances O
, O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
with O
fatal B-NonOSE_AE
outcome O
has O
been O
reported O
and O
generally O
has O
been O
associated O
with O
serious O
underlying O
diseases O
and/or O
concomitant O
medications O
. O

Discontinue O
clarithromycin O
immediately O
if O
signs O
and O
symptoms O
of O
hepatitis B-NonOSE_AE
occur O
. O

Drug O
Interactions O
Serious O
adverse O
reactions O
have O
been O
reported O
in O
patients O
taking O
clarithromycin O
concomitantly O
with O
CYP3A4 O
substrates O
. O

These O
include O
colchicine B-NonOSE_AE
toxicity I-NonOSE_AE
with O
colchicine O
; O
rhabdomyolysis B-NonOSE_AE
with O
simvastatin O
, O
lovastatin O
, O
and O
atorvastatin O
; O
and O
hypotension B-NonOSE_AE
with O
calcium O
channel O
blockers O
metabolized O
by O
CYP3A4 O
( O
e.g. O
, O
verapamil O
, O
amlodipine O
, O
diltiazem O
) O
( O
see O
CONTRAINDICATIONS O
and O
PRECAUTIONS O
- O
Drug O
Interactions O
) O
. O

Life-threatening O
and O
fatal B-NonOSE_AE
drug B-NonOSE_AE
interactions I-NonOSE_AE
have O
been O
reported O
in O
patients O
treated O
with O
clarithromycin O
and O
colchicine O
. O

Clarithromycin O
is O
a O
strong O
CYP3A4 O
inhibitor O
and O
this O
interaction O
may O
occur O
while O
using O
both O
drugs O
at O
their O
recommended O
doses O
. O

If O
co-administration O
of O
clarithromycin O
and O
colchicine O
is O
necessary O
in O
patients O
with O
normal O
renal O
and O
hepatic O
function O
, O
the O
dose O
of O
colchicine O
should O
be O
reduced O
. O

Patients O
should O
be O
monitored O
for O
clinical O
symptoms O
of O
colchicine B-NonOSE_AE
toxicity I-NonOSE_AE
. O

Concomitant O
administration O
of O
clarithromycin O
and O
colchicine O
is O
contraindicated O
in O
patients O
with O
renal B-Not_AE_Candidate
or O
hepatic O
impairment I-Not_AE_Candidate
( O
see O
CONTRAINDICATIONS O
and O
PRECAUTIONS O
- O
Drug O
Interactions O
) O
. O

Clostridium O
difficile O
Associated O
Diarrhea O
Clostridium B-OSE_Labeled_AE
difficile I-OSE_Labeled_AE
associated I-OSE_Labeled_AE
diarrhea I-OSE_Labeled_AE
( I-OSE_Labeled_AE
CDAD I-OSE_Labeled_AE
) O
has O
been O
reported O
with O
use O
of O
nearly O
all O
antibacterial O
agents O
, O
including O
BIAXIN O
, O
and O
may O
range O
in O
severity O
from O
mild O
diarrhea B-OSE_Labeled_AE
to O
fatal B-NonOSE_AE
colitis B-OSE_Labeled_AE
. O

Treatment O
with O
antibacterial O
agents O
alters O
the O
normal O
flora O
of O
the O
colon O
leading O
to O
overgrowth O
of O
C B-NonOSE_AE
. I-NonOSE_AE
difficile I-NonOSE_AE
. O

C B-NonOSE_AE
. I-NonOSE_AE
difficile I-NonOSE_AE
produces O
toxins O
A O
and O
B O
which O
contribute O
to O
the O
development O
of O
CDAD B-NonOSE_AE
. O

Hypertoxin O
producing O
strains O
of O
C B-NonOSE_AE
. I-NonOSE_AE
difficile I-NonOSE_AE
cause O
increased O
morbidity O
and O
mortality O
, O
as O
these O
infections O
can O
be O
refractory O
to O
antimicrobial O
therapy O
and O
may O
require O
colectomy O
. O

CDAD B-NonOSE_AE
must O
be O
considered O
in O
all O
patients O
who O
present O
with O
diarrhea B-NonOSE_AE
following O
antibiotic O
use O
. O

Careful O
medical O
history O
is O
necessary O
since O
CDAD B-OSE_Labeled_AE
has O
been O
reported O
to O
occur O
over O
two O
months O
after O
the O
administration O
of O
antibacterial O
agents O
. O

If O
CDAD B-NonOSE_AE
is O
suspected O
or O
confirmed O
, O
ongoing O
antibiotic O
use O
not O
directed O
against O
C B-NonOSE_AE
. I-NonOSE_AE
difficile I-NonOSE_AE
may O
need O
to O
be O
discontinued O
. O

Appropriate O
fluid O
and O
electrolyte O
management O
, O
protein O
supplementation O
, O
antibiotic O
treatment O
of O
C B-NonOSE_AE
. I-NonOSE_AE
difficile I-NonOSE_AE
, O
and O
surgical O
evaluation O
should O
be O
instituted O
as O
clinically O
indicated O
. O

For O
information O
about O
warnings O
of O
other O
drugs O
indicated O
in O
combination O
with O
BIAXIN O
, O
refer O
to O
the O
WARNINGS O
section O
of O
their O
package O
inserts O
. O

Due O
to O
the O
risk O
for O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
clarithromycin O
should O
be O
used O
with O
caution O
in O
patients O
with O
a O
medical O
condition O
associated O
with O
an O
increased O
tendency O
toward O
QT B-Not_AE_Candidate
prolongation I-Not_AE_Candidate
and O
torsades B-Not_AE_Candidate
de I-Not_AE_Candidate
pointes I-Not_AE_Candidate
. O

In O
the O
event O
of O
severe O
acute O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
such O
as O
anaphylaxis B-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
drug B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
with I-OSE_Labeled_AE
eosinophilia I-OSE_Labeled_AE
and I-OSE_Labeled_AE
systemic I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
( I-OSE_Labeled_AE
DRESS I-OSE_Labeled_AE
) O
, O
and O
Henoch B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Schonlein I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
clarithromycin O
therapy O
should O
be O
discontinued O
immediately O
and O
appropriate O
treatment O
should O
be O
urgently O
initiated O
. O

Oral O
Hypoglycemic O
Agents/Insulin O
The O
concomitant O
use O
of O
clarithromycin O
and O
oral O
hypoglycemic O
agents O
and/or O
insulin O
can O
result O
in O
significant O
hypoglycemia B-NonOSE_AE
. O

With O
certain O
hypoglycemic B-NonOSE_AE
drugs O
such O
as O
nateglinide O
, O
pioglitazone O
, O
repaglinide O
and O
rosiglitazone O
, O
inhibition O
of O
CYP3A O
enzyme O
by O
clarithromycin O
may O
be O
involved O
and O
could O
cause O
hypolgycemia B-NonOSE_AE
when O
used O
concomitantly O
. O

Careful O
monitoring O
of O
glucose O
is O
recommended O
. O

Oral O
Anticoagulants O
There O
is O
a O
risk O
of O
serious O
hemorrhage B-NonOSE_AE
and O
significant O
elevations B-NonOSE_AE
in I-NonOSE_AE
INR I-NonOSE_AE
and O
prothrombin O
time O
when O
clarithromycin O
is O
co-administered O
with O
warfarin O
. O

INR O
and O
prothrombin O
times O
should O
be O
frequently O
monitored O
while O
patients O
are O
receiving O
clarithromycin O
and O
oral O
anticoagulants O
concurrently O
. O

HMG-CoA O
Reductase O
Inhibitors O
Concomitant O
use O
of O
clarithromycin O
with O
lovastatin O
or O
simvastatin O
is O
contraindicated O
( O
see O
CONTRAINDICATIONS O
) O
. O

As O
with O
other O
macrolides O
, O
clarithromycin O
has O
been O
reported O
to O
increase O
concentrations O
of O
HMG-CoA O
reductase O
inhibitors O
. O

Rare O
reports O
of O
rhabdomyolysis B-NonOSE_AE
have O
been O
reported O
in O
patients O
taking O
these O
drugs O
concomitantly O
. O

Patients O
should O
be O
monitored O
for O
signs O
and O
symptoms O
of O
myopathy B-NonOSE_AE
. O

Rare O
reports O
of O
rhabdomyolysis B-NonOSE_AE
have O
also O
been O
reported O
in O
patients O
taking O
atorvastatin O
or O
rosuvastatin O
concomitantly O
with O
clarithromycin O
. O

When O
used O
with O
clarithromycin O
, O
atorvastatin O
or O
rosuvastatin O
should O
be O
administered O
in O
the O
lowest O
possible O
doses O
. O

Adjustment O
of O
the O
statin O
dose O
or O
use O
of O
a O
statin O
that O
is O
not O
dependent O
on O
CYP3A O
metabolism O
( O
e.g.fluvastatin O
or O
pravastatin O
) O
should O
be O
considered O
. O

ADVERSE O
REACTIONS O
The O
following O
were O
adverse O
events O
considered O
to O
be O
drug O
related O
and O
occurring O
with O
a O
frequency O
of O
> O
=1 O
% O
with O
Carac O
: O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
( O
94.6 O
% O
) O
, O
and O
eye B-OSE_Labeled_AE
irritation I-OSE_Labeled_AE
( O
5.4 O
% O
) O
. O

The O
signs O
and O
symptoms O
of O
facial B-OSE_Labeled_AE
irritation I-OSE_Labeled_AE
( O
i.e. O
, O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
) O
are O
presented O
below O
. O

Summary O
of O
Facial B-OSE_Labeled_AE
Irritation O
Signs O
and O
Symptoms O
- O
Pooled O
Phase O
3 O
Studies O
Clinical O
Sign O
or O
Symptom O
Active O
1 O
Week O
N=85 O
Active O
2 O
Week O
N=87 O
Active O
4 O
Week O
N=85 O
ALL O
Active O
Treatments O
N=257 O
Vehicle O
Treatments O
N=127 O
n O
( O
% O
) O
n O
( O
% O
) O
n O
( O
% O
) O
n O
( O
% O
) O
n O
( O
% O
) O
Erythema I-OSE_Labeled_AE
76 O
( O
89.4 O
) O
82 O
( O
94.3 O
) O
82 O
( O
96.5 O
) O
240 O
( O
93.4 O
) O
76 O
( O
59.8 O
) O
Dryness O
59 O
( O
69.4 O
) O
76 O
( O
87.4 O
) O
79 O
( O
92.9 O
) O
214 O
( O
83.3 O
) O
60 O
( O
47.2 O
) O
Burning O
51 O
( O
60.0 O
) O
70 O
( O
80.5 O
) O
71 O
( O
83.5 O
) O
192 O
( O
74.7 O
) O
28 O
( O
22.0 O
) O
Erosion O
21 O
( O
24.7 O
) O
38 O
( O
43.7 O
) O
54 O
( O
63.5 O
) O
113 O
( O
44.0 O
) O
17 O
( O
13.4 O
) O
Pain O
26 O
( O
30.6 O
) O
34 O
( O
39.1 O
) O
52 O
( O
61.2 O
) O
112 O
( O
43.6 O
) O
7 O
( O
5.5 O
) O
Edema O
12 O
( O
14.1 O
) O
28 O
( O
32.2 O
) O
51 O
( O
60.0 O
) O
91 O
( O
35.4 O
) O
6 O
( O
4.7 O
) O
During O
clinical O
trials O
, O
irritation B-OSE_Labeled_AE
generally O
began O
on O
Day O
4 O
and O
persisted O
for O
the O
remainder O
of O
treatment O
. O

Severity O
of O
facial I-OSE_Labeled_AE
irritation O
at O
the O
last O
treatment O
visit O
was O
slightly O
below O
baseline O
for O
the O
vehicle O
group O
, O
mild O
to O
moderate O
for O
the O
1-week O
active O
treatment O
group O
, O
and O
moderate O
for O
the O
2- O
and O
4-week O
active O
treatment O
groups O
. O

Mean O
severity O
declined O
rapidly O
for O
each O
active O
group O
after O
completion O
of O
treatment O
and O
was O
below O
baseline O
for O
each O
group O
at O
the O
Week O
2 O
post-treatment O
follow-up O
visit O
. O

Thirty-one O
patients O
( O
12 O
% O
of O
those O
treated O
with O
Carac O
in O
the O
Phase O
3 O
clinical O
studies O
) O
discontinued O
study O
treatment O
early O
due O
to O
facial B-OSE_Labeled_AE
irritation I-OSE_Labeled_AE
. O

Except O
for O
three O
patients O
, O
discontinuation O
of O
treatment O
occurred O
on O
or O
after O
Day O
11 O
of O
treatment O
. O

Eye B-OSE_Labeled_AE
irritation I-OSE_Labeled_AE
adverse O
events O
, O
described O
as O
mild O
to O
moderate O
in O
intensity O
, O
were O
characterized O
as O
burning O
, O
watering O
, O
sensitivity O
, O
stinging O
, O
and O
itching O
. O

These O
adverse O
events O
occurred O
across O
all O
treatment O
arms O
in O
one O
of O
the O
two O
Phase O
3 O
studies O
. O

Summary O
of O
All O
Adverse O
Events O
Reported O
in O
> O
=1 O
% O
of O
Patients O
in O
the O
Combined O
Active O
Treatment O
and O
Vehicle O
Groups O
- O
Pooled O
Phase O
3 O
Studies O
9721 O
and O
9722 O
Combined O
Adverse O
Event O
Active O
1 O
Week O
N= O
85 O
Active O
2Week O
N= O
87 O
Active O
4Week O
N= O
85 O
ALL O
Active O
Treatments O
N=257 O
Vehicle O
Treatments O
N=127 O
n O
( O
% O
) O
n O
( O
% O
) O
n O
( O
% O
) O
n O
( O
% O
) O
n O
( O
% O
) O
BODY B-NonOSE_AE
AS I-NonOSE_AE
A I-NonOSE_AE
WHOLE I-NonOSE_AE
7 O
( O
8.2 O
) O
6 O
( O
6.9 O
) O
12 O
( O
14.1 O
) O
25 O
( O
9.7 O
) O
15 O
( O
11.8 O
) O
Headache B-OSE_Labeled_AE
3 O
( O
3.5 O
) O
2 O
( O
2.3 O
) O
3 O
( O
3.5 O
) O
8 O
( O
3.1 O
) O
3 O
( O
2.4 O
) O
Common B-OSE_Labeled_AE
Cold I-OSE_Labeled_AE
4 O
( O
4.7 O
) O
0 O
2 O
( O
2.4 O
) O
6 O
( O
2.3 O
) O
3 O
( O
2.4 O
) O
Allergy B-OSE_Labeled_AE
0 O
2 O
( O
2.3 O
) O
1 O
( O
1.2 O
) O
3 O
( O
1.2 O
) O
2 O
( O
1.6 O
) O
Infection B-OSE_Labeled_AE
UpperRespiratory I-OSE_Labeled_AE
0 O
0 O
0 O
0 O
2 O
( O
1.6 O
) O
MUSCULOSKELETAL B-NonOSE_AE
1 O
( O
1.2 O
) O
1 O
( O
1.1 O
) O
1 O
( O
1.2 O
) O
3 O
( O
1.2 O
) O
5 O
( O
3.9 O
) O
Muscle B-OSE_Labeled_AE
Soreness I-OSE_Labeled_AE
0 O
0 O
0 O
0 O
2 O
( O
1.6 O
) O
RESPIRATORY B-NonOSE_AE
5 O
( O
5.9 O
) O
0 O
1 O
( O
1.2 O
) O
6 O
( O
2.3 O
) O
6 O
( O
4.7 O
) O
Sinusitis B-OSE_Labeled_AE
4 O
( O
4.7 O
) O
0 O
0 O
4 O
( O
1.6 O
) O
2 O
( O
1.6 O
) O
SKIN B-NonOSE_AE
& I-NonOSE_AE
APPENDAGES I-NonOSE_AE
78 O
( O
91.8 O
) O
83 O
( O
95.4 O
) O
82 O
( O
96.5 O
) O
243 O
( O
94.6 O
) O
85 O
( O
66.9 O
) O
Application B-OSE_Labeled_AE
SiteReaction I-OSE_Labeled_AE
78 O
( O
91.8 O
) O
83 O
( O
95.4 O
) O
82 O
( O
96.5 O
) O
243 O
( O
94.6 O
) O
83 O
( O
65.4 O
) O
Irritation B-OSE_Labeled_AE
Skin I-OSE_Labeled_AE
1 O
( O
1.2 O
) O
0 O
2 O
( O
2.4 O
) O
3 O
( O
1.2 O
) O
0 O
SPECIAL B-NonOSE_AE
SENSES I-NonOSE_AE
6 O
( O
7.1 O
) O
4 O
( O
4.6 O
) O
6 O
( O
7.1 O
) O
16 O
( O
6.2 O
) O
6 O
( O
4.7 O
) O
Eye B-OSE_Labeled_AE
Irritation I-OSE_Labeled_AE
5 O
( O
5.9 O
) O
3 O
( O
3.4 O
) O
6 O
( O
7.1 O
) O
14 O
( O
5.4 O
) O
3 O
( O
2.4 O
) O
Adverse O
Experiences O
Reported O
by O
Body O
System O
: O
In O
the O
Phase O
3 O
studies O
, O
no O
serious O
adverse O
event O
was O
considered O
related O
to O
study O
drug O
. O

A O
total O
of O
five O
patients O
, O
three O
in O
the O
active O
treatment O
groups O
and O
two O
in O
the O
vehicle O
group O
, O
experienced O
at O
least O
one O
serious O
adverse O
event O
. O

Three O
patients O
died B-NonOSE_AE
as O
a O
result O
of O
adverse O
event O
( O
s O
) O
considered O
unrelated O
to O
study O
drug O
( O
stomach B-NonOSE_AE
cancer I-NonOSE_AE
, O
myocardial B-NonOSE_AE
infarction I-NonOSE_AE
, O
and O
cardiac B-NonOSE_AE
failure I-NonOSE_AE
) O
. O

Post-treatment O
clinical O
laboratory O
tests O
other O
than O
pregnancy B-NonOSE_AE
tests O
were O
not O
performed O
during O
the O
Phase O
3 O
clinical O
studies O
. O

Clinical O
laboratory O
tests O
were O
performed O
during O
conduct O
of O
a O
Phase O
2 O
study O
of O
104 O
patients O
and O
21 O
patients O
in O
a O
Phase O
1 O
study O
. O

No O
abnormal O
serum O
chemistry O
, O
hematology O
, O
or O
urinalysis O
results O
in O
these O
studies O
were O
considered O
clinically O
significant O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Valeant O
Pharmaceuticals O
North O
America O
LLC O
at O
1-800-321-4576 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

PRECAUTIONS O
General O
: O
There O
is O
a O
possibility O
of O
increased O
absorption O
through O
ulcerated B-Not_AE_Candidate
or O
inflamed B-Not_AE_Candidate
skin I-Not_AE_Candidate
. O

Information O
for O
the O
Patient O
: O
Patients O
using O
Carac O
should O
receive O
the O
following O
information O
and O
instructions O
: O
* O
1 O
. O

This O
medication O
is O
to O
be O
used O
as O
directed O
. O

* O
2 O
. O

This O
medication O
should O
not O
be O
used O
for O
any O
disorder O
other O
than O
that O
for O
which O
it O
was O
prescribed O
. O

* O
3 O
. O

It O
is O
for O
topical O
use O
only O
. O

* O
4 O
. O

Avoid O
contact O
with O
the O
eyes O
, O
eyelids O
, O
nostrils O
, O
and O
mouth O
. O

* O
5 O
. O

Cleanse O
affected O
area O
and O
wait O
10 O
minutes O
before O
applying O
Carac O
. O

* O
6 O
. O

Wash O
hands O
immediately O
after O
applying O
Carac O
. O

* O
7 O
. O

Avoid O
prolonged O
exposure O
to O
sunlight O
or O
other O
forms O
of O
ultraviolet O
irradiation O
during O
treatment O
, O
as O
the O
intensity O
of O
the O
reaction O
may O
be O
increased O
. O

* O
8 O
. O

Most O
patients O
using O
Carac O
get O
skin B-NonOSE_AE
reactions I-NonOSE_AE
where O
the O
medicine O
is O
used O
. O

These O
reactions O
include O
redness O
, O
dryness O
, O
burning O
, O
pain O
, O
erosion O
( O
loss B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
upper I-NonOSE_AE
layer I-NonOSE_AE
of I-NonOSE_AE
skin I-NonOSE_AE
) O
, O
and O
swelling O
. O

Irritation B-NonOSE_AE
at I-NonOSE_AE
the I-NonOSE_AE
application I-NonOSE_AE
site I-NonOSE_AE
may O
persist O
for O
two O
or O
more O
weeks O
after O
therapy O
is O
discontinued O
. O

Treated O
areas O
may O
be O
unsightly O
during O
and O
after O
therapy O
. O

* O
9 O
. O

If O
you O
develop O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
bloody B-NonOSE_AE
diarrhea I-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
fever B-NonOSE_AE
, O
or O
chills B-NonOSE_AE
while O
on O
Carac O
therapy O
, O
stop O
the O
medication O
and O
contact O
your O
physician O
and/or O
pharmacist O
. O

* O
10 O
. O

Report O
any O
side O
effects O
to O
the O
physician O
and/or O
pharmacist O
. O

Laboratory O
Tests O
: O
To O
rule O
out O
the O
presence O
of O
a O
frank O
neoplasm B-NonOSE_AE
, O
a O
biopsy O
may O
be O
considered O
for O
those O
areas O
failing O
to O
respond O
to O
treatment O
or O
recurring O
after O
treatment O
. O

Carcinogenesis O
, O
Mutagenesis O
, O
and O
Impairment O
of O
Fertility O
: O
Adequate O
long-term O
studies O
in O
animals O
to O
evaluate O
carcinogenic B-NonOSE_AE
potential O
have O
not O
been O
conducted O
with O
fluorouracil O
. O

Studies O
with O
the O
active O
ingredient O
of O
Carac O
, O
fluorouracil O
, O
have O
shown O
positive O
effects O
in O
in O
vitro O
and O
in O
vivo O
tests O
for O
mutagenicity B-NonOSE_AE
and O
on O
impairment B-NonOSE_AE
of I-NonOSE_AE
fertility I-NonOSE_AE
in O
in O
vivo O
animal O
studies O
. O

Fluorouracil O
produced O
morphological O
transformation O
of O
cells O
in O
in O
vitro O
cell O
transformation O
assays O
. O

Morphological O
transformation O
was O
also O
produced O
in O
an O
in O
vitro O
assay O
by O
a O
metabolite O
of O
fluorouracil O
, O
and O
the O
transformed O
cells O
produced O
malignant B-NonOSE_AE
tumors I-NonOSE_AE
when O
injected O
into O
immunosuppressed B-Not_AE_Candidate
syngeneic O
mice O
. O

Fluorouracil O
has O
been O
shown O
to O
exert O
mutagenic B-NonOSE_AE
activity O
in O
yeast O
cells O
, O
Bacillus O
subtilis O
, O
and O
Drosophila O
assays O
. O

In O
addition O
, O
fluorouracil O
has O
produced O
chromosome B-NonOSE_AE
damage I-NonOSE_AE
at O
concentrations O
of O
1.0 O
and O
2.0 O
mcg/mL O
in O
an O
in O
vitro O
hamster O
fibroblast O
assay O
, O
was O
positive O
in O
a O
microwell O
mouse O
lymphoma B-NonOSE_AE
assay O
, O
and O
was O
positive O
in O
in O
vivo O
micronucleus O
assays O
in O
rats O
and O
mice O
following O
intraperitoneal O
administration O
. O

Some O
patients O
receiving O
cumulative O
doses O
of O
0.24 O
to O
1.0 O
g O
of O
fluorouracil O
parenterally O
have O
shown O
an O
increase O
in O
numerical O
and O
structural O
chromosome B-NonOSE_AE
aberrations I-NonOSE_AE
in O
peripheral O
blood O
lymphocytes O
. O

Fluorouracil O
has O
been O
shown O
to O
impair B-NonOSE_AE
fertility I-NonOSE_AE
after O
parenteral O
administration O
in O
rats O
. O

Fluorouracil O
administered O
at O
intraperitoneal O
doses O
of O
125 O
and O
250 O
mg/kg O
has O
been O
shown O
to O
induce O
chromosomal B-NonOSE_AE
aberrations I-NonOSE_AE
and O
changes B-NonOSE_AE
in I-NonOSE_AE
chromosome I-NonOSE_AE
organization I-NonOSE_AE
of I-NonOSE_AE
spermatogonia I-NonOSE_AE
in O
rats O
. O

In O
mice O
, O
single-dose O
intravenous O
and O
intraperitoneal O
injections O
of O
fluorouracil O
have O
been O
reported O
to O
kill B-NonOSE_AE
differentiated I-NonOSE_AE
spermatogonia I-NonOSE_AE
and O
spermatocytes O
at O
a O
dose O
of O
500 O
mg/kg O
and O
produce O
abnormalities B-NonOSE_AE
in I-NonOSE_AE
spermatids I-NonOSE_AE
at O
50 O
mg/kg O
. O

Pediatric O
Use O
: O
Actinic B-Not_AE_Candidate
keratosis I-Not_AE_Candidate
is O
not O
a O
condition O
seen O
within O
the O
pediatric O
population O
, O
except O
in O
association O
with O
rare O
genetic O
diseases O
. O

Carac O
should O
not O
be O
used O
in O
children O
. O

The O
safety O
and O
effectiveness O
of O
Carac O
have O
not O
been O
established O
in O
patients O
less O
than O
18 O
years O
old O
. O

Geriatric O
Use O
: O
No O
significant O
differences O
in O
safety O
and O
efficacy O
measures O
were O
demonstrated O
in O
patients O
age O
65 O
and O
older O
compared O
to O
all O
other O
patients O
. O

Pregnancy O
: O
See O
CONTRAINDICATIONS O
. O

Nursing O
Women O
: O
It O
is O
not O
known O
whether O
fluorouracil O
is O
excreted O
in O
human O
milk O
. O

Because O
many O
drugs O
are O
excreted O
in O
human O
milk O
and O
because O
of O
the O
potential O
for O
serious O
adverse O
reactions O
in O
nursing O
infants O
from O
fluorouracil O
, O
a O
decision O
should O
be O
made O
whether O
to O
discontinue O
nursing O
or O
to O
discontinue O
the O
drug O
, O
taking O
into O
account O
the O
importance O
of O
the O
drug O
to O
the O
mother O
. O

WARNINGS O
The O
potential O
for O
a O
delayed B-OSE_Labeled_AE
hypersensitivity I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
to O
fluorouracil O
exists O
. O

Patch O
testing O
to O
prove O
hypersensitivity B-NonOSE_AE
may O
be O
inconclusive O
. O

Patients O
should O
discontinue O
therapy O
with O
Carac O
if O
symptoms O
of O
DPD B-NonOSE_AE
enzyme I-NonOSE_AE
deficiency I-NonOSE_AE
develop O
. O

Rarely O
, O
unexpected O
systemic O
toxicity O
( O
e.g. O
, O
stomatitis B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
, O
neutropenia B-NonOSE_AE
, O
neurotoxicity B-NonOSE_AE
) O
associated O
with O
parenteral O
administration O
of O
fluorouracil O
has O
been O
attributed O
to O
deficiency B-Not_AE_Candidate
of I-Not_AE_Candidate
dihydropyrimidine I-Not_AE_Candidate
dehydrogenase I-Not_AE_Candidate
" B-Not_AE_Candidate
DPD I-Not_AE_Candidate
" I-Not_AE_Candidate
activity O
. O

One O
case O
of O
life-threatening O
systemic O
toxicity O
has O
been O
reported O
with O
the O
topical O
use O
of O
5 O
% O
fluorouracil O
in O
a O
patient O
with O
a O
complete O
absence B-Not_AE_Candidate
of I-Not_AE_Candidate
DPD I-Not_AE_Candidate
enzyme I-Not_AE_Candidate
activity I-Not_AE_Candidate
. O

Symptoms O
included O
severe O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
bloody B-NonOSE_AE
diarrhea I-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
fever B-NonOSE_AE
, O
and O
chills B-NonOSE_AE
. O

Physical O
examination O
revealed O
stomatitis B-NonOSE_AE
, O
erythematous B-NonOSE_AE
skin I-NonOSE_AE
rash I-NonOSE_AE
, O
neutropenia B-NonOSE_AE
, O
thrombocytopenia B-NonOSE_AE
, O
inflammation B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
esophagus I-NonOSE_AE
, O
stomach O
, O
and O
small O
bowel O
. O

Although O
this O
case O
was O
observed O
with O
5 O
% O
fluorouracil O
cream O
, O
it O
is O
unknown O
whether O
patients O
with O
profound O
DPD B-Not_AE_Candidate
enzyme I-Not_AE_Candidate
deficiency I-Not_AE_Candidate
would O
develop O
systemic B-NonOSE_AE
toxicity I-NonOSE_AE
with O
lower O
concentrations O
of O
topically O
applied O
fluorouracil O
. O

Applications O
to O
mucous B-NonOSE_AE
membranes I-NonOSE_AE
should O
be O
avoided O
due O
to O
the O
possibility O
of O
local O
inflammation I-NonOSE_AE
and O
ulceration O
. O

ADVERSE O
REACTIONS O
For O
a O
comparison O
of O
toxicities O
when O
carboplatin O
or O
cisplatin O
was O
given O
in O
combination O
with O
cyclophosphamide O
, O
see O
CLINICAL O
STUDIES O
, O
Use O
with O
Cyclophosphamide O
for O
Initial O
Treatment O
of O
Ovarian B-Not_AE_Candidate
Cancer I-Not_AE_Candidate
, O
Comparative O
Toxicity O
. O

ADVERSE O
EXPERIENCES O
IN O
PATIENTS O
WITH O
OVARIAN O
CANCER O
First O
Line O
Combination O
Therapy O
[ O
note O
: O
Use O
with O
Cyclophosphamide O
for O
Initial O
Treatment O
of O
Ovarian B-Not_AE_Candidate
Cancer I-Not_AE_Candidate
: O
Data O
are O
based O
on O
the O
experience O
of O
393 O
patients O
with O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
( O
regardless O
of O
baseline O
status O
) O
who O
received O
initial O
combination O
therapy O
with O
carboplatin O
and O
cyclophosphamide O
in O
two O
randomized O
controlled O
studies O
conducted O
by O
SWOG O
and O
NCIC O
( O
see O
CLINICAL O
STUDIES O
) O
.Combination O
with O
cyclophosphamide O
as O
well O
as O
duration O
of O
treatment O
may O
be O
responsible O
for O
the O
differences O
that O
can O
be O
noted O
in O
the O
adverse O
experience O
table O
. O
] O

Percent O
Second O
Line O
Single O
Agent O
Therapy O
[ O
note O
: O
Single O
Agent O
Use O
for O
the O
Secondary O
Treatment O
of O
Ovarian O
Cancer O
: O
Data O
are O
based O
on O
the O
experience O
of O
553 O
patients O
with O
previously O
treated O
ovarian O
carcinoma O
( O
regardless O
of O
baseline O
status O
) O
who O
received O
single O
agent O
carboplatin O
. O
] O

Percent O
Bone B-NonOSE_AE
Marrow I-NonOSE_AE
Thrombocytopenia B-OSE_Labeled_AE
< O
100,000/mm3 O
66 O
62 O
< O
50,000/mm3 O
33 O
35 O
Neutropenia B-OSE_Labeled_AE
< O
2,000 O
cells/mm3 O
96 O
67 O
< O
1,000 O
cells/mm3 O
82 O
21 O
Leukopenia B-OSE_Labeled_AE
< O
4,000 O
cells/mm3 O
97 O
85 O
< O
2,000 O
cells/mm3 O
71 O
26 O
Anemia B-OSE_Labeled_AE
< O
11 O
g/dL O
90 O
90 O
< O
8g/dL O
14 O
21 O
Infections B-OSE_Labeled_AE
16 O
5 O
Bleeding B-OSE_Labeled_AE
8 O
5 O
Transfusions B-OSE_Labeled_AE
35 O
44 O
Gastrointestinal B-NonOSE_AE
Nausea B-OSE_Labeled_AE
and O
vomiting B-OSE_Labeled_AE
93 O
92 O
Vomiting B-OSE_Labeled_AE
83 O
81 O
Other O
GI B-OSE_Labeled_AE
side I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
46 O
21 O
Neurologic B-NonOSE_AE
Peripheral B-OSE_Labeled_AE
neuropathies I-OSE_Labeled_AE
15 O
6 O
Ototoxicity B-OSE_Labeled_AE
12 O
1 O
Other O
sensory B-OSE_Labeled_AE
side I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
5 O
1 O
Central B-OSE_Labeled_AE
neurotoxicity I-OSE_Labeled_AE
26 O
5 O
Renal B-NonOSE_AE
Serum B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
6 O
10 O
Blood B-OSE_Labeled_AE
urea I-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
17 O
22 O
Hepatic B-NonOSE_AE
Bilirubin B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
5 O
5 O
SGOT B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
20 O
19 O
Alkaline B-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
29 O
37 O
Electrolytes B-NonOSE_AE
loss I-NonOSE_AE
Sodium O
10 O
47 O
Potassium O
16 O
28 O
Calcium O
16 O
31 O
Magnesium O
61 O
43 O
Other B-NonOSE_AE
side I-NonOSE_AE
effects I-NonOSE_AE
Pain B-OSE_Labeled_AE
44 O
23 O
Asthenia B-OSE_Labeled_AE
41 O
11 O
Cardiovascular O
19 O
6 O
Respiratory O
10 O
6 O
Allergic B-OSE_Labeled_AE
11 O
2 O
Genitourinary O
10 O
2 O
Alopecia B-OSE_Labeled_AE
49 O
2 O
Mucositis B-OSE_Labeled_AE
8 O
1 O
In O
the O
narrative O
section O
that O
follows O
, O
the O
incidences O
of O
adverse O
events O
are O
based O
on O
data O
from O
1,893 O
patients O
with O
various O
types O
of O
tumors O
who O
received O
carboplatin O
as O
single O
agent O
therapy O
. O

Hematologic B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Bone B-OSE_Labeled_AE
marrow I-OSE_Labeled_AE
suppression I-OSE_Labeled_AE
is O
the O
dose-limiting O
toxicity O
of O
carboplatin O
. O

Thrombocytopenia B-OSE_Labeled_AE
with O
platelet B-OSE_Labeled_AE
counts I-OSE_Labeled_AE
below I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
, I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mm I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
occurs O
in O
25 O
% O
of O
the O
patients O
( O
35 O
% O
of O
pretreated O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
patients O
) O
; O
neutropenia B-OSE_Labeled_AE
with O
granulocyte B-OSE_Labeled_AE
counts I-OSE_Labeled_AE
below I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
, I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mm I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
occurs O
in O
16 O
% O
of O
the O
patients O
( O
21 O
% O
of O
pretreated O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
patients O
) O
; O
leukopenia B-OSE_Labeled_AE
with O
WBC B-OSE_Labeled_AE
counts I-OSE_Labeled_AE
below I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
, I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mm I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
occurs O
in O
15 O
% O
of O
the O
patients O
( O
26 O
% O
of O
pretreated O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
patients O
) O
. O

The O
nadir O
usually O
occurs O
about O
day O
21 O
in O
patients O
receiving O
single O
agent O
therapy O
. O

By O
day O
28 O
, O
90 O
% O
of O
patients O
have O
platelet B-NonOSE_AE
counts I-NonOSE_AE
above I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
, I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
/ I-NonOSE_AE
mm I-NonOSE_AE
3 I-NonOSE_AE
; O
74 O
% O
have O
neutrophil B-NonOSE_AE
counts I-NonOSE_AE
above I-NonOSE_AE
2 I-NonOSE_AE
, I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
/ I-NonOSE_AE
mm I-NonOSE_AE
3 I-NonOSE_AE
; O
67 O
% O
have O
leukocyte B-NonOSE_AE
counts I-NonOSE_AE
above I-NonOSE_AE
4 I-NonOSE_AE
, I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
/ I-NonOSE_AE
mm I-NonOSE_AE
3 I-NonOSE_AE
. O

Marrow B-NonOSE_AE
suppression I-NonOSE_AE
is O
usually O
more O
severe O
in O
patients O
with O
impaired B-Not_AE_Candidate
kidney I-Not_AE_Candidate
function I-Not_AE_Candidate
. O

Patients O
with O
poor O
performance O
status O
have O
also O
experienced O
a O
higher O
incidence O
of O
severe O
leukopenia B-NonOSE_AE
and O
thrombocytopenia B-NonOSE_AE
. O

The O
hematologic B-OSE_Labeled_AE
effects I-OSE_Labeled_AE
, O
although O
usually O
reversible O
, O
have O
resulted O
in O
infectious B-OSE_Labeled_AE
or O
hemorrhagic O
complications I-OSE_Labeled_AE
in O
5 O
% O
of O
the O
patients O
treated O
with O
carboplatin O
, O
with O
drug O
related O
death B-NonOSE_AE
occurring O
in O
less O
than O
1 O
% O
of O
the O
patients O
. O

Fever B-OSE_Labeled_AE
has I-OSE_Labeled_AE
also I-OSE_Labeled_AE
been I-OSE_Labeled_AE
reported I-OSE_Labeled_AE
in I-OSE_Labeled_AE
patients I-OSE_Labeled_AE
with I-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
. O

Anemia B-OSE_Labeled_AE
with O
hemoglobin B-OSE_Labeled_AE
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
g I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
has O
been O
observed O
in O
71 O
% O
of O
the O
patients O
who O
started O
therapy O
with O
a O
baseline O
above O
that O
value O
. O

The O
incidence O
of O
anemia B-OSE_Labeled_AE
increases O
with O
increasing O
exposure O
to O
carboplatin O
. O

Transfusions O
have O
been O
administered O
to O
26 O
% O
of O
the O
patients O
treated O
with O
carboplatin O
( O
44 O
% O
of O
previously O
treated O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
patients O
) O
. O

Bone B-OSE_Labeled_AE
marrow I-OSE_Labeled_AE
depression I-OSE_Labeled_AE
may O
be O
more O
severe O
when O
carboplatin O
is O
combined O
with O
other O
bone B-NonOSE_AE
marrow I-NonOSE_AE
suppressing I-NonOSE_AE
drugs O
or O
with O
radiotherapy O
. O

Gastrointestinal B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Vomiting B-OSE_Labeled_AE
occurs O
in O
65 O
% O
of O
the O
patients O
( O
81 O
% O
of O
previously O
treated O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
patients O
) O
and O
in O
about O
one-third O
of O
these O
patients O
it O
is O
severe O
. O

Carboplatin O
, O
as O
a O
single O
agent O
or O
in O
combination O
, O
is O
significantly O
less O
emetogenic B-OSE_Labeled_AE
than O
cisplatin O
; O
however O
, O
patients O
previously O
treated O
with O
emetogenic B-NonOSE_AE
agents I-NonOSE_AE
, O
especially O
cisplatin O
, O
appear O
to O
be O
more O
prone O
to O
vomiting B-NonOSE_AE
. O

Nausea B-OSE_Labeled_AE
alone O
occurs O
in O
an O
additional O
10 O
% O
to O
15 O
% O
of O
patients O
. O

Both O
nausea B-OSE_Labeled_AE
and O
vomiting B-OSE_Labeled_AE
usually O
cease O
within O
24 O
hours O
of O
treatment O
and O
are O
often O
responsive O
to O
antiemetic O
measures O
. O

Although O
no O
conclusive O
efficacy O
data O
exist O
with O
the O
following O
schedules O
, O
prolonged O
administration O
of O
carboplatin O
, O
either O
by O
continuous O
24-hour O
infusion O
or O
by O
daily O
pulse O
doses O
given O
for O
5 O
consecutive O
days O
, O
was O
associated O
with O
less O
severe O
vomiting B-OSE_Labeled_AE
than O
the O
single-dose O
intermittent O
schedule O
. O

Emesis B-NonOSE_AE
was O
increased O
when O
carboplatin O
was O
used O
in O
combination O
with O
other O
emetogenic O
compounds O
. O

Other O
gastrointestinal B-OSE_Labeled_AE
effects O
observed O
frequently O
were O
pain I-OSE_Labeled_AE
, O
in O
17 O
% O
of O
the O
patients O
; O
diarrhea B-OSE_Labeled_AE
, O
in O
6 O
% O
; O
and O
constipation B-OSE_Labeled_AE
, O
also O
in O
6 O
% O
. O

Neurologic B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Peripheral B-OSE_Labeled_AE
neuropathies I-OSE_Labeled_AE
have O
been O
observed O
in O
4 O
% O
of O
the O
patients O
receiving O
carboplatin O
( O
6 O
% O
of O
pretreated O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
patients O
) O
with O
mild O
paresthesias B-OSE_Labeled_AE
occurring O
most O
frequently O
. O

Carboplatin O
therapy O
produces O
significantly O
fewer O
and O
less O
severe O
neurologic B-OSE_Labeled_AE
side I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
than O
does O
therapy O
with O
cisplatin O
. O

However O
, O
patients O
older O
than O
65 O
years O
and/or O
previously O
treated O
with O
cisplatin O
appear O
to O
have O
an O
increased O
risk O
( O
10 O
% O
) O
for O
peripheral B-OSE_Labeled_AE
neuropathies I-OSE_Labeled_AE
. O

In O
70 O
% O
of O
the O
patients O
with O
pre-existing O
cisplatin-induced O
peripheral B-Not_AE_Candidate
neurotoxicity I-Not_AE_Candidate
, O
there O
was O
no O
worsening O
of O
symptoms O
during O
therapy O
with O
carboplatin O
. O

Clinical O
ototoxicity B-OSE_Labeled_AE
and O
other O
sensory B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
such O
as O
visual B-OSE_Labeled_AE
disturbances I-OSE_Labeled_AE
and O
change B-OSE_Labeled_AE
in I-OSE_Labeled_AE
taste I-OSE_Labeled_AE
have O
been O
reported O
in O
only O
1 O
% O
of O
the O
patients O
. O

Central B-OSE_Labeled_AE
nervous I-OSE_Labeled_AE
system I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
have O
been O
reported O
in O
5 O
% O
of O
the O
patients O
and O
appear O
to O
be O
most O
often O
related O
to O
the O
use O
of O
antiemetics O
. O

Although O
the O
overall O
incidence O
of O
peripheral B-OSE_Labeled_AE
neurologic I-OSE_Labeled_AE
side I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
induced O
by O
carboplatin O
is O
low O
, O
prolonged O
treatment O
, O
particularly O
in O
cisplatin O
pretreated O
patients O
, O
may O
result O
in O
cumulative O
neurotoxicity B-OSE_Labeled_AE
. O

Nephrotoxicity B-OSE_Labeled_AE
Development O
of O
abnormal B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
function I-OSE_Labeled_AE
test I-OSE_Labeled_AE
results O
is O
uncommon O
, O
despite O
the O
fact O
that O
carboplatin O
, O
unlike O
cisplatin O
, O
has O
usually O
been O
administered O
without O
high-volume O
fluid O
hydration O
and/or O
forced O
diuresis B-NonOSE_AE
. O

The O
incidences O
of O
abnormal B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
reported O
are O
6 O
% O
for O
serum O
creatinine O
and O
14 O
% O
for O
blood O
urea O
nitrogen O
( O
10 O
% O
and O
22 O
% O
, O
respectively O
, O
in O
pretreated O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
patients O
) O
. O

Most O
of O
these O
reported O
abnormalities O
have O
been O
mild O
and O
about O
one-half O
of O
them O
were O
reversible O
. O

Creatinine O
clearance O
has O
proven O
to O
be O
the O
most O
sensitive O
measure O
of O
kidney O
function O
in O
patients O
receiving O
carboplatin O
, O
and O
it O
appears O
to O
be O
the O
most O
useful O
test O
for O
correlating O
drug O
clearance O
and O
bone B-NonOSE_AE
marrow I-NonOSE_AE
suppression I-NonOSE_AE
. O

Twenty-seven O
percent O
of O
the O
patients O
who O
had O
a O
baseline O
value O
of O
60 O
mL/min O
or O
more O
demonstrated O
a O
reduction O
below O
this O
value O
during O
carboplatin O
therapy O
. O

Hepatic B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
The O
incidences O
of O
abnormal B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
in O
patients O
with O
normal O
baseline O
values O
were O
reported O
as O
follows O
: O
total O
bilirubin O
, O
5 O
% O
; O
SGOT O
, O
15 O
% O
; O
and O
alkaline O
phosphatase O
, O
24 O
% O
; O
( O
5 O
% O
, O
19 O
% O
, O
and O
37 O
% O
, O
respectively O
, O
in O
pretreated O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
patients O
) O
. O

These O
abnormalities O
have O
generally O
been O
mild O
and O
reversible O
in O
about O
one-half O
of O
the O
cases O
, O
although O
the O
role O
of O
metastatic B-Not_AE_Candidate
tumor I-Not_AE_Candidate
in I-Not_AE_Candidate
the I-Not_AE_Candidate
liver I-Not_AE_Candidate
may O
complicate O
the O
assessment O
in O
many O
patients O
. O

In O
a O
limited O
series O
of O
patients O
receiving O
very O
high O
dosages O
of O
carboplatin O
and O
autologous B-Not_AE_Candidate
bone I-Not_AE_Candidate
marrow I-Not_AE_Candidate
transplantation I-Not_AE_Candidate
, O
severe O
abnormalities B-OSE_Labeled_AE
of I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
were O
reported O
. O

Electrolyte B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
The O
incidences O
of O
abnormally O
decreased B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
electrolyte I-OSE_Labeled_AE
values I-OSE_Labeled_AE
reported O
were O
as O
follows O
: O
sodium O
, O
29 O
% O
; O
potassium O
, O
20 O
% O
; O
calcium O
, O
22 O
% O
; O
and O
magnesium O
, O
29 O
% O
; O
( O
47 O
% O
, O
28 O
% O
, O
31 O
% O
, O
and O
43 O
% O
, O
respectively O
, O
in O
pretreated O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
patients O
) O
. O

Electrolyte O
supplementation O
was O
not O
routinely O
administered O
concomitantly O
with O
carboplatin O
, O
and O
these O
electrolyte B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
were O
rarely O
associated O
with O
symptoms O
. O

Allergic O
Reactions O
Hypersensitivity B-OSE_Labeled_AE
to O
carboplatin O
has O
been O
reported O
in O
2 O
% O
of O
the O
patients O
. O

These O
allergic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
have O
been O
similar O
in O
nature O
and O
severity O
to O
those O
reported O
with O
other O
platinum-containing O
compounds O
, O
i.e. O
, O
rash B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
and O
rarely O
bronchospasm B-OSE_Labeled_AE
and O
hypotension B-OSE_Labeled_AE
. O

Anaphylactic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
have O
been O
reported O
as O
part O
of O
postmarketing O
surveillance O
( O
see O
WARNINGS O
) O
. O

These O
reactions O
have O
been O
successfully O
managed O
with O
standard O
epinephrine O
, O
corticosteroid O
, O
and O
antihistamine O
therapy O
. O

Injection O
Site O
Reactions O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
redness O
, O
swelling O
, O
and O
pain O
, O
have O
been O
reported O
during O
postmarketing O
surveillance O
. O

Necrosis B-OSE_Labeled_AE
associated I-OSE_Labeled_AE
with I-OSE_Labeled_AE
extravasation I-OSE_Labeled_AE
has O
also O
been O
reported O
. O

Other O
Events O
Pain B-OSE_Labeled_AE
and O
asthenia B-OSE_Labeled_AE
were O
the O
most O
frequently O
reported O
miscellaneous O
adverse O
effects O
; O
their O
relationship O
to O
the O
tumor B-NonOSE_AE
and O
to O
anemia B-NonOSE_AE
was O
likely O
. O

Alopecia B-OSE_Labeled_AE
was O
reported O
( O
3 O
% O
) O
. O

Cardiovascular B-OSE_Labeled_AE
, O
respiratory O
, O
genitourinary O
, O
and O
mucosal O
side I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
have O
occurred O
in O
6 O
% O
or O
less O
of O
the O
patients O
. O

Cardiovascular B-OSE_Labeled_AE
events I-OSE_Labeled_AE
( O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
embolism B-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
accidents I-OSE_Labeled_AE
) O
were O
fatal B-NonOSE_AE
in O
less O
than O
1 O
% O
of O
the O
patients O
and O
did O
not O
appear O
to O
be O
related O
to O
chemotherapy O
. O

Cancer B-Not_AE_Candidate
-associated O
hemolytic B-Not_AE_Candidate
uremic I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
has O
been O
reported O
rarely O
. O

Malaise B-OSE_Labeled_AE
, O
anorexia B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
, O
and O
stomatitis B-OSE_Labeled_AE
have O
been O
reported O
as O
part O
of O
postmarketing O
surveillance O
. O

BOXED O
WARNING O
: O
WARNING O
WARNING O
Carboplatin O
injection O
10 O
mg/mL O
should O
be O
administered O
under O
the O
supervision O
of O
a O
qualified O
physician O
experienced O
in O
the O
use O
of O
cancer O
chemotherapeutic O
agents O
. O

Appropriate O
management O
of O
therapy O
and O
complications O
is O
possible O
only O
when O
adequate O
treatment O
facilities O
are O
readily O
available O
. O

Bone B-OSE_Labeled_AE
marrow I-OSE_Labeled_AE
suppression I-OSE_Labeled_AE
is O
dose O
related O
and O
may O
be O
severe O
, O
resulting O
in O
infection B-NonOSE_AE
and/or O
bleeding B-NonOSE_AE
. O

Anemia B-OSE_Labeled_AE
may O
be O
cumulative O
and O
may O
require O
transfusion O
support O
. O

Vomiting B-OSE_Labeled_AE
is O
another O
frequent O
drug O
related O
side O
effect O
. O

Anaphylactic B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
to O
carboplatin O
have O
been O
reported O
and O
may O
occur O
within O
minutes O
of O
carboplatin O
injection O
administration O
. O

Epinephrine O
, O
corticosteroids O
, O
and O
antihistamines O
have O
been O
employed O
to O
alleviate O
symptoms O
. O

PRECAUTIONS O
General O
Needles O
or O
intravenous O
administration O
sets O
containing O
aluminum O
parts O
that O
may O
come O
in O
contact O
with O
carboplatin O
injection O
should O
not O
be O
used O
for O
the O
preparation O
or O
administration O
of O
the O
drug O
. O

Aluminum O
can O
react O
with O
carboplatin O
causing O
precipitate O
formation O
and O
loss O
of O
potency O
. O

Drug O
Interactions O
The O
renal O
effects O
of O
nephrotoxic B-NonOSE_AE
compounds O
may O
be O
potentiated O
by O
carboplatin O
. O

Carcinogenesis O
, O
Mutagenesis O
, O
Impairment O
of O
Fertility O
The O
carcinogenic O
potential O
of O
carboplatin O
has O
not O
been O
studied O
, O
but O
compounds O
with O
similar O
mechanisms O
of O
action O
and O
mutagenicity O
profiles O
have O
been O
reported O
to O
be O
carcinogenic B-NonOSE_AE
. O

Carboplatin O
has O
been O
shown O
to O
be O
mutagenic B-OSE_Labeled_AE
both O
in O
vitro O
and O
in O
vivo O
. O

It O
has O
also O
been O
shown O
to O
be O
embryotoxic B-NonOSE_AE
and O
teratogenic B-NonOSE_AE
in O
rats O
receiving O
the O
drug O
during O
organogenesis O
. O

Secondary B-NonOSE_AE
malignancies I-NonOSE_AE
have O
been O
reported O
in O
association O
with O
multi-drug O
therapy O
. O

Pregnancy O
Pregnancy O
Category O
D O
See O
WARNINGS O
. O

Nursing O
Mothers O
It O
is O
not O
known O
whether O
carboplatin O
is O
excreted O
in O
human O
milk O
. O

Because O
there O
is O
a O
possibility O
of O
toxicity O
in O
nursing O
infants O
secondary O
to O
carboplatin O
treatment O
of O
the O
mother O
, O
it O
is O
recommended O
that O
breastfeeding O
be O
discontinued O
if O
the O
mother O
is O
treated O
with O
carboplatin O
injection O
. O

Pediatric O
Use O
Safety O
and O
effectiveness O
in O
pediatric O
patients O
have O
not O
been O
established O
( O
see O
WARNINGS O
, O
" B-NonOSE_AE
audiologic I-NonOSE_AE
toxicity I-NonOSE_AE
" I-NonOSE_AE
) O
. O

Geriatric O
Use O
Of O
the O
789 O
patients O
in O
initial O
treatment O
combination O
therapy O
studies O
( O
NCIC O
and O
SWOG O
) O
, O
395 O
patients O
were O
treated O
with O
carboplatin O
in O
combination O
with O
cyclophosphamide O
. O

Of O
these O
, O
141 O
were O
over O
65 O
years O
of O
age O
and O
22 O
were O
75 O
years O
or O
older O
. O

In O
these O
trials O
, O
age O
was O
not O
a O
prognostic O
factor O
for O
survival O
. O

In O
terms O
of O
safety O
, O
elderly O
patients O
treated O
with O
carboplatin O
were O
more O
likely O
to O
develop O
severe O
thrombocytopenia B-OSE_Labeled_AE
than O
younger O
patients O
. O

In O
a O
combined O
database O
of O
1,942 O
patients O
( O
414 O
were O
> O
= O
65 O
years O
of O
age O
) O
that O
received O
single O
agent O
carboplatin O
for O
different O
tumor B-Not_AE_Candidate
types O
, O
a O
similar O
incidence O
of O
adverse O
events O
was O
seen O
in O
patients O
65 O
years O
and O
older O
and O
in O
patients O
less O
than O
65 O
. O

Other O
reported O
clinical O
experience O
has O
not O
identified O
differences O
in O
responses O
between O
elderly O
and O
younger O
patients O
, O
but O
greater O
sensitivity O
of O
some O
older O
individuals O
can O
not O
be O
ruled O
out O
. O

Because O
renal B-NonOSE_AE
function I-NonOSE_AE
is I-NonOSE_AE
often I-NonOSE_AE
decreased I-NonOSE_AE
in O
the O
elderly O
, O
renal O
function O
should O
be O
considered O
in O
the O
selection O
of O
carboplatin O
injection O
dosage O
( O
see O
DOSAGE O
AND O
ADMINISTRATION O
) O
. O

WARNINGS O
Bone B-OSE_Labeled_AE
marrow I-OSE_Labeled_AE
suppression I-OSE_Labeled_AE
( O
leukopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
and O
thrombocytopenia B-OSE_Labeled_AE
) O
is O
dose-dependent O
and O
is O
also O
the O
dose-limiting O
toxicity O
. O

Peripheral O
blood O
counts O
should O
be O
frequently O
monitored O
during O
carboplatin O
injection O
treatment O
and O
, O
when O
appropriate O
, O
until O
recovery O
is O
achieved O
. O

Median O
nadir O
occurs O
at O
day O
21 O
in O
patients O
receiving O
single O
agent O
carboplatin O
. O

In O
general O
, O
single O
intermittent O
courses O
of O
carboplatin O
should O
not O
be O
repeated O
until O
leukocyte O
, O
neutrophil O
, O
and O
platelet O
counts O
have O
recovered O
. O

Since O
anemia B-OSE_Labeled_AE
is O
cumulative O
, O
transfusions O
may O
be O
needed O
during O
treatment O
with O
carboplatin O
, O
particularly O
in O
patients O
receiving O
prolonged O
therapy O
. O

Bone B-NonOSE_AE
marrow I-NonOSE_AE
suppression I-NonOSE_AE
is O
increased O
in O
patients O
who O
have O
received O
prior O
therapy O
, O
especially O
regimens O
including O
cisplatin O
. O

Marrow B-NonOSE_AE
suppression I-NonOSE_AE
is O
also O
increased O
in O
patients O
with O
impaired B-Not_AE_Candidate
kidney I-Not_AE_Candidate
function I-Not_AE_Candidate
. O

Initial O
carboplatin O
injection O
dosages O
in O
these O
patients O
should O
be O
appropriately O
reduced O
( O
see O
DOSAGE O
AND O
ADMINISTRATION O
) O
and O
blood O
counts O
should O
be O
carefully O
monitored O
between O
courses O
. O

The O
use O
of O
carboplatin O
in O
combination O
with O
other O
bone B-NonOSE_AE
marrow I-NonOSE_AE
suppressing I-NonOSE_AE
therapies O
must O
be O
carefully O
managed O
with O
respect O
to O
dosage O
and O
timing O
in O
order O
to O
minimize O
additive O
effects O
. O

Carboplatin O
has O
limited O
nephrotoxic B-OSE_Labeled_AE
potential O
, O
but O
concomitant O
treatment O
with O
aminoglycosides O
has O
resulted O
in O
increased B-NonOSE_AE
renal I-NonOSE_AE
and/or O
audiologic O
toxicity I-NonOSE_AE
, O
and O
caution O
must O
be O
exercised O
when O
a O
patient O
receives O
both O
drugs O
. O

Clinically O
significant O
hearing B-NonOSE_AE
loss I-NonOSE_AE
has O
been O
reported O
to O
occur O
in O
pediatric O
patients O
when O
carboplatin O
was O
administered O
at O
higher O
than O
recommended O
doses O
in O
combination O
with O
other O
ototoxic B-NonOSE_AE
agents O
. O

Carboplatin O
can O
induce O
emesis B-OSE_Labeled_AE
, O
which O
can O
be O
more O
severe O
in O
patients O
previously O
receiving O
emetogenic B-NonOSE_AE
therapy O
. O

The O
incidence O
and O
intensity O
of O
emesis B-NonOSE_AE
have O
been O
reduced O
by O
using O
premedication O
with O
antiemetics O
. O

Although O
no O
conclusive O
efficacy O
data O
exist O
with O
the O
following O
schedules O
of O
carboplatin O
, O
lengthening O
the O
duration O
of O
single O
intravenous O
administration O
to O
24 O
hours O
or O
dividing O
the O
total O
dose O
over O
five O
consecutive O
daily O
pulse O
doses O
has O
resulted O
in O
reduced O
emesis B-NonOSE_AE
. O

Although O
peripheral B-NonOSE_AE
neurotoxicity I-NonOSE_AE
is O
infrequent O
, O
its O
incidence O
is O
increased O
in O
patients O
older O
than O
65 O
years O
and O
in O
patients O
previously O
treated O
with O
cisplatin O
. O

Pre-existing O
cisplatin-induced O
neurotoxicity B-Not_AE_Candidate
does O
not O
worsen O
in O
about O
70 O
% O
of O
the O
patients O
receiving O
carboplatin O
as O
secondary O
treatment O
. O

Loss B-NonOSE_AE
of I-NonOSE_AE
vision I-NonOSE_AE
, O
which O
can O
be O
complete O
for O
light O
and O
colors O
, O
has O
been O
reported O
after O
the O
use O
of O
carboplatin O
with O
doses O
higher O
than O
those O
recommended O
in O
the O
package O
insert O
. O

Vision O
appears O
to O
recover O
totally O
or O
to O
a O
significant O
extent O
within O
weeks O
of O
stopping O
these O
high O
doses O
. O

As O
in O
the O
case O
of O
other O
platinum-coordination O
compounds O
, O
allergic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
to O
carboplatin O
have O
been O
reported O
. O

These O
may O
occur O
within O
minutes O
of O
administration O
and O
should O
be O
managed O
with O
appropriate O
supportive O
therapy O
. O

There O
is O
increased O
risk O
of O
allergic B-NonOSE_AE
reactions I-NonOSE_AE
including O
anaphylaxis B-NonOSE_AE
in O
patients O
previously O
exposed O
to O
platinum O
therapy O
( O
see O
CONTRAINDICATIONS O
and O
ADVERSE O
REACTIONS O
, O
Allergic O
Reactions O
) O
. O

High O
dosages O
of O
carboplatin O
( O
more O
than O
4 O
times O
the O
recommended O
dose O
) O
have O
resulted O
in O
severe O
abnormalities B-NonOSE_AE
of I-NonOSE_AE
liver I-NonOSE_AE
function I-NonOSE_AE
tests I-NonOSE_AE
. O

Carboplatin O
injection O
may O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
. O

Carboplatin O
has O
been O
shown O
to O
be O
embryotoxic B-NonOSE_AE
and O
teratogenic B-NonOSE_AE
in O
rats O
. O

There O
are O
no O
adequate O
and O
well-controlled O
studies O
in O
pregnant B-Not_AE_Candidate
women O
. O

If O
this O
drug O
is O
used O
during O
pregnancy B-Not_AE_Candidate
, O
or O
if O
the O
patient O
becomes O
pregnant B-NonOSE_AE
while O
receiving O
this O
drug O
, O
the O
patient O
should O
be O
apprised O
of O
the O
potential O
hazard B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

Women O
of O
childbearing O
potential O
should O
be O
advised O
to O
avoid O
becoming O
pregnant B-NonOSE_AE
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
more O
detail O
in O
other O
sections O
of O
the O
labeling O
. O

* O
Hypersensitivity B-OSE_Labeled_AE
[ O
see O
Contraindications O
( O
4 O
) O
] O
* O
Myelosuppression B-OSE_Labeled_AE
, O
Immunosuppression B-OSE_Labeled_AE
, O
Bone B-OSE_Labeled_AE
Marrow I-OSE_Labeled_AE
Failure I-OSE_Labeled_AE
, O
and O
Infections B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
and O
Renal O
Toxicity I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Cardiotoxicity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Pulmonary B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Secondary B-OSE_Labeled_AE
Malignancies I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Veno B-OSE_Labeled_AE
- I-OSE_Labeled_AE
occlusive I-OSE_Labeled_AE
Liver I-OSE_Labeled_AE
Disease I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Reproductive B-OSE_Labeled_AE
System I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.4 O
and O
8.6 O
) O
] O
* O
Impaired B-OSE_Labeled_AE
Wound I-OSE_Labeled_AE
Healing I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Hyponatremia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
EXCERPT O
: O
Adverse O
reactions O
reported O
most O
often O
include O
neutropenia O
, O
febrile O
neutropenia O
, O
fever O
, O
alopecia O
, O
nausea O
, O
vomiting O
, O
and O
diarrhea O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Baxter O
Healthcare O
at O
1-866-888-2472 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Common O
Adverse O
Reactions O
Hematopoietic O
system O
: O
Neutropenia B-OSE_Labeled_AE
occurs O
in O
patients O
treated O
with O
cyclophosphamide O
. O

The O
degree O
of O
neutropenia B-NonOSE_AE
is O
particularly O
important O
because O
it O
correlates O
with O
a O
reduction B-NonOSE_AE
in I-NonOSE_AE
resistance I-NonOSE_AE
to I-NonOSE_AE
infections I-NonOSE_AE
. O

Fever B-NonOSE_AE
without O
documented O
infection B-NonOSE_AE
has O
been O
reported O
in O
neutropenic B-NonOSE_AE
patients O
. O

Gastrointestinal O
system O
: O
Nausea B-OSE_Labeled_AE
and O
vomiting B-OSE_Labeled_AE
occur O
with O
cyclophosphamide O
therapy O
. O

Anorexia B-OSE_Labeled_AE
and O
, O
less O
frequently O
, O
abdominal B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
or O
pain O
and O
diarrhea B-OSE_Labeled_AE
may O
occur O
. O

There O
are O
isolated O
reports O
of O
hemorrhagic B-OSE_Labeled_AE
colitis I-OSE_Labeled_AE
, O
oral B-OSE_Labeled_AE
mucosal I-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
and O
jaundice B-OSE_Labeled_AE
occurring O
during O
therapy O
. O

Skin O
and O
its O
structures O
: O
Alopecia B-OSE_Labeled_AE
occurs O
in O
patients O
treated O
with O
cyclophosphamide O
. O

Skin B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
occurs O
occasionally O
in O
patients O
receiving O
the O
drug O
. O

Pigmentation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
skin I-OSE_Labeled_AE
and O
changes O
in O
nails O
can O
occur O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
from O
clinical O
trials O
or O
post-marketing O
surveillance O
. O

Because O
they O
are O
reported O
from O
a O
population O
from O
unknown O
size O
, O
precise O
estimates O
of O
frequency O
can O
not O
be O
made O
. O

Cardiac B-NonOSE_AE
: O
cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
, O
cardiogenic B-OSE_Labeled_AE
shock I-OSE_Labeled_AE
, O
pericardial B-OSE_Labeled_AE
effusion I-OSE_Labeled_AE
( O
progressing O
to O
cardiac B-OSE_Labeled_AE
tamponade I-OSE_Labeled_AE
) O
, O
myocardial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
including O
fatal B-NonOSE_AE
outcomes O
) O
, O
cardiomyopathy B-OSE_Labeled_AE
, O
myocarditis B-OSE_Labeled_AE
, O
pericarditis B-OSE_Labeled_AE
, O
carditis B-OSE_Labeled_AE
, O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
supraventricular B-OSE_Labeled_AE
arrhythmia I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
arrhythmia I-OSE_Labeled_AE
, O
bradycardia B-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
, O
palpitations B-OSE_Labeled_AE
, O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
. O

Congenital B-NonOSE_AE
, I-NonOSE_AE
Familial I-NonOSE_AE
and I-NonOSE_AE
Genetic I-NonOSE_AE
: O
intra B-OSE_Labeled_AE
- I-OSE_Labeled_AE
uterine I-OSE_Labeled_AE
death I-OSE_Labeled_AE
, O
fetal B-OSE_Labeled_AE
malformation I-OSE_Labeled_AE
, O
fetal B-OSE_Labeled_AE
growth I-OSE_Labeled_AE
retardation I-OSE_Labeled_AE
, O
fetal B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
( O
including O
myelosuppression B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
) O
. O

Ear B-NonOSE_AE
and I-NonOSE_AE
Labyrinth I-NonOSE_AE
: O
deafness B-OSE_Labeled_AE
, O
hearing B-OSE_Labeled_AE
impaired I-OSE_Labeled_AE
, O
tinnitus B-OSE_Labeled_AE
. O

Endocrine B-NonOSE_AE
: O
water B-OSE_Labeled_AE
intoxication I-OSE_Labeled_AE
. O

Eye B-NonOSE_AE
: O
visual B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
conjunctivitis B-OSE_Labeled_AE
, O
lacrimation B-OSE_Labeled_AE
. O

Gastrointestinal B-NonOSE_AE
: O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
, O
colitis B-OSE_Labeled_AE
, O
enteritis B-OSE_Labeled_AE
, O
cecitis B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
parotid B-OSE_Labeled_AE
gland I-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
. O

General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administrative I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
: O
multiorgan B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
general B-OSE_Labeled_AE
physical I-OSE_Labeled_AE
deterioration I-OSE_Labeled_AE
, O
influenza B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
illness I-OSE_Labeled_AE
, O
injection B-OSE_Labeled_AE
/infusion O
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
thrombosis O
, O
necrosis O
, O
phlebitis O
, O
inflammation O
, O
pain O
, O
swelling O
, O
erythema O
) O
, O
pyrexia B-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
malaise B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
. O

Hematologic B-NonOSE_AE
: O
myelosuppression B-OSE_Labeled_AE
, O
bone B-OSE_Labeled_AE
marrow I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
disseminated B-OSE_Labeled_AE
intravascular I-OSE_Labeled_AE
coagulation I-OSE_Labeled_AE
and O
hemolytic B-OSE_Labeled_AE
uremic I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( O
with O
thrombotic B-OSE_Labeled_AE
microangiopathy I-OSE_Labeled_AE
) O
. O

Hepatic B-NonOSE_AE
: O
veno B-OSE_Labeled_AE
- I-OSE_Labeled_AE
occlusive I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
cholestatic B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
, O
cytolytic B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
, O
cholestasis B-OSE_Labeled_AE
; O
hepatotoxicity B-OSE_Labeled_AE
with O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
encephalopathy I-OSE_Labeled_AE
, O
ascites B-OSE_Labeled_AE
, O
hepatomegaly B-OSE_Labeled_AE
, O
blood B-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
function I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
enzymes I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
. O

Immune B-NonOSE_AE
: O
immunosuppression B-OSE_Labeled_AE
, O
anaphylactic B-OSE_Labeled_AE
shock I-OSE_Labeled_AE
and O
hypersensitivity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
. O

Infections B-NonOSE_AE
: O
The O
following O
manifestations O
have O
been O
associated O
with O
myelosuppression B-OSE_Labeled_AE
and O
immunosuppression B-OSE_Labeled_AE
caused O
by O
cyclophosphamide O
: O
increased O
risk O
for O
and O
severity O
of O
pneumonias B-NonOSE_AE
( O
including O
fatal B-NonOSE_AE
outcomes O
) O
, O
other O
bacterial B-NonOSE_AE
, O
fungal O
, O
viral O
, O
protozoal O
and O
, O
parasitic O
infections I-NonOSE_AE
; O
reactivation B-NonOSE_AE
of O
latent O
infections O
, O
( O
including O
viral I-NonOSE_AE
hepatitis I-NonOSE_AE
, O
tuberculosis O
) O
, O
Pneumocystis B-NonOSE_AE
jiroveci I-NonOSE_AE
, O
herpes B-NonOSE_AE
zoster I-NonOSE_AE
, O
Strongyloides B-NonOSE_AE
, O
sepsis B-NonOSE_AE
and O
septic B-NonOSE_AE
shock I-NonOSE_AE
. O

Investigations B-NonOSE_AE
: O
blood B-OSE_Labeled_AE
lactate I-OSE_Labeled_AE
dehydrogenase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
C B-OSE_Labeled_AE
- I-OSE_Labeled_AE
reactive I-OSE_Labeled_AE
protein I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
. O

Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
: O
hyponatremia B-OSE_Labeled_AE
, O
fluid B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
, O
blood B-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
blood B-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
. O

Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
: O
rhabdomyolysis B-OSE_Labeled_AE
, O
scleroderma B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
. O

Neoplasms B-NonOSE_AE
: O
acute B-OSE_Labeled_AE
leukemia I-OSE_Labeled_AE
, O
myelodysplastic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
lymphoma B-OSE_Labeled_AE
, O
sarcomas B-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
cell I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
pelvis I-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
, O
bladder B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
, O
ureteric B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
, O
thyroid B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
. O

Nervous B-NonOSE_AE
System I-NonOSE_AE
: O
encephalopathy B-OSE_Labeled_AE
, O
convulsion B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
neurotoxicity B-OSE_Labeled_AE
has O
been O
reported O
and O
manifested O
as O
reversible B-OSE_Labeled_AE
posterior I-OSE_Labeled_AE
leukoencephalopathy I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
myelopathy B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
polyneuropathy B-OSE_Labeled_AE
, O
neuralgia B-OSE_Labeled_AE
, O
dysesthesia B-OSE_Labeled_AE
, O
hypoesthesia B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
dysgeusia B-OSE_Labeled_AE
, O
hypogeusia B-OSE_Labeled_AE
, O
parosmia B-OSE_Labeled_AE
. O

Pregnancy B-NonOSE_AE
: O
premature B-OSE_Labeled_AE
labor I-OSE_Labeled_AE
. O

Psychiatric B-NonOSE_AE
: O
confusional B-OSE_Labeled_AE
state I-OSE_Labeled_AE
. O

Renal B-NonOSE_AE
and I-NonOSE_AE
Urinary I-NonOSE_AE
: O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
tubular I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
nephropathy B-OSE_Labeled_AE
toxic I-OSE_Labeled_AE
, O
hemorrhagic B-OSE_Labeled_AE
cystitis I-OSE_Labeled_AE
, O
bladder B-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
, O
cystitis B-OSE_Labeled_AE
ulcerative I-OSE_Labeled_AE
, O
bladder B-OSE_Labeled_AE
contracture I-OSE_Labeled_AE
, O
hematuria B-OSE_Labeled_AE
, O
nephrogenic B-OSE_Labeled_AE
diabetes I-OSE_Labeled_AE
insipidus I-OSE_Labeled_AE
, O
atypical B-OSE_Labeled_AE
urinary I-OSE_Labeled_AE
bladder I-OSE_Labeled_AE
epithelial I-OSE_Labeled_AE
cells I-OSE_Labeled_AE
. O

Reproductive B-NonOSE_AE
System I-NonOSE_AE
: O
infertility B-OSE_Labeled_AE
, O
ovarian B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
ovarian B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
amenorrhea B-OSE_Labeled_AE
, O
oligomenorrhea B-OSE_Labeled_AE
, O
testicular B-OSE_Labeled_AE
atrophy I-OSE_Labeled_AE
, O
azoospermia B-OSE_Labeled_AE
, O
oligospermia B-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
: O
pulmonary B-OSE_Labeled_AE
veno I-OSE_Labeled_AE
- I-OSE_Labeled_AE
occlusive I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
acute B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
distress I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
as O
manifested O
by O
respiratory B-NonOSE_AE
failure I-NonOSE_AE
( O
including O
fatal B-NonOSE_AE
outcomes O
) O
, O
obliterative B-OSE_Labeled_AE
bronchiolitis I-OSE_Labeled_AE
, O
organizing B-OSE_Labeled_AE
pneumonia I-OSE_Labeled_AE
, O
alveolitis B-OSE_Labeled_AE
allergic I-OSE_Labeled_AE
, O
pneumonitis B-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
; O
respiratory B-OSE_Labeled_AE
distress I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
pleural B-OSE_Labeled_AE
effusion I-OSE_Labeled_AE
, O
bronchospasm B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
hypoxia B-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
nasal B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
, O
nasal B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
, O
oropharyngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
rhinorrhea B-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
: O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
erythrodysesthesia I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
radiation B-OSE_Labeled_AE
recall I-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
eruption I-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
dermatitis B-OSE_Labeled_AE
, O
blister B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
, O
nail B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
facial B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
, O
hyperhidrosis B-OSE_Labeled_AE
. O

Tumor B-NonOSE_AE
lysis I-NonOSE_AE
syndrome I-NonOSE_AE
: O
like O
other O
cytotoxic O
drugs O
, O
cyclophosphamide O
may O
induce O
tumor B-OSE_Labeled_AE
- I-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
and O
hyperuricemia B-OSE_Labeled_AE
in O
patients O
with O
rapidly O
growing O
tumors B-Not_AE_Candidate
. O

Vascular B-NonOSE_AE
: O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
venous B-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
, O
vasculitis B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
flushing B-OSE_Labeled_AE
, O
hot B-OSE_Labeled_AE
flush I-OSE_Labeled_AE
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Myelosuppression O
, O
Immunosuppression O
, O
Bone O
Marrow O
Failure O
and O
Infections O
- O
Severe O
immunosuppression O
may O
lead O
to O
serious O
and O
sometimes O
fatal O
infections O
. O

Close O
hematological O
monitoring O
is O
required O
. O

( O
5.1 O
) O
* O
Urinary O
Tract O
and O
Renal O
Toxicity O
- O
Hemorrhagic O
cystitis O
, O
pyelitis O
, O
ureteritis O
, O
and O
hematuria O
can O
occur O
. O

Exclude O
or O
correct O
any O
urinary O
tract O
obstructions O
prior O
to O
treatment O
. O

( O
5.2 O
) O
* O
Cardiotoxicity O
- O
Myocarditis O
, O
myopericarditis O
, O
pericardial O
effusion O
, O
arrythmias O
and O
congestive O
heart O
failure O
, O
which O
may O
be O
fatal O
, O
have O
been O
reported O
. O

Monitor O
patients O
, O
especially O
those O
with O
risk O
factors O
for O
cardiotoxicity O
or O
pre-existing O
cardiac O
disease O
. O

( O
5.3 O
) O
* O
Pulmonary O
Toxicity O
- O
Pneumonitis O
, O
pulmonary O
fibrosis O
and O
pulmonary O
veno-occlusive O
disease O
leading O
to O
respiratory O
failure O
may O
occur O
. O

Monitor O
patients O
for O
signs O
and O
symptoms O
of O
pulmonary O
toxicity O
. O

( O
5.4 O
) O
* O
Secondary O
malignancies O
( O
5.5 O
) O
* O
Veno-occlusive O
Liver O
Disease O
- O
Fatal O
outcome O
can O
occur O
. O

( O
5.6 O
) O
* O
Embryo-Fetal O
Toxicity O
- O
Can O
cause O
fetal O
harm O
. O

Advise O
female O
patients O
of O
reproductive O
potential O
to O
avoid O
pregnancy O
. O

( O
5.7 O
, O
8.1 O
, O
8.6 O
) O
5.1 O
Myelosuppression O
, O
Immunosuppression O
, O
Bone O
Marrow O
Failure O
and O
Infections O
Cyclophosphamide O
can O
cause O
myelosuppression B-OSE_Labeled_AE
( O
leukopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
and O
anemia B-OSE_Labeled_AE
) O
, O
bone B-OSE_Labeled_AE
marrow I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
and O
severe O
immunosuppression B-OSE_Labeled_AE
which O
may O
lead O
to O
serious O
and O
sometimes O
fatal B-NonOSE_AE
infections B-NonOSE_AE
, O
including O
sepsis B-NonOSE_AE
and O
septic B-NonOSE_AE
shock I-NonOSE_AE
. O

Latent B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
can I-OSE_Labeled_AE
be I-OSE_Labeled_AE
reactivated I-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

Antimicrobial O
prophylaxis O
may O
be O
indicated O
in O
certain O
cases O
of O
neutropenia B-NonOSE_AE
at O
the O
discretion O
of O
the O
managing O
physician O
. O

In O
case O
of O
neutropenic B-NonOSE_AE
fever I-NonOSE_AE
, O
antibiotic O
therapy O
is O
indicated O
. O

Antimycotics O
and/or O
antivirals O
may O
also O
be O
indicated O
. O

Monitoring O
of O
complete O
blood O
counts O
is O
essential O
during O
cyclophosphamide O
treatment O
so O
that O
the O
dose O
can O
be O
adjusted O
, O
if O
needed O
. O

Cyclophosphamide O
should O
not O
be O
administered O
to O
patients O
with O
neutrophils B-Not_AE_Candidate
< I-Not_AE_Candidate
= I-Not_AE_Candidate
1 I-Not_AE_Candidate
, I-Not_AE_Candidate
5 I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
/ I-Not_AE_Candidate
mm I-Not_AE_Candidate
3 I-Not_AE_Candidate
and O
platelets B-Not_AE_Candidate
< I-Not_AE_Candidate
5 I-Not_AE_Candidate
0 I-Not_AE_Candidate
, I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
/ I-Not_AE_Candidate
mm I-Not_AE_Candidate
3 I-Not_AE_Candidate
. O

Cyclophosphamide O
treatment O
may O
not O
be O
indicated O
, O
or O
should O
be O
interrupted O
, O
or O
the O
dose O
reduced O
, O
in O
patients O
who O
have O
or O
who O
develop O
a O
serious O
infection B-NonOSE_AE
. O

G-CSF O
may O
be O
administered O
to O
reduce O
the O
risks O
of O
neutropenia B-NonOSE_AE
complications O
associated O
with O
cyclophosphamide O
use O
. O

Primary O
and O
secondary O
prophylaxis O
with O
G-CSF O
should O
be O
considered O
in O
all O
patients O
considered O
to O
be O
at O
increased O
risk O
for O
neutropenia B-NonOSE_AE
complications O
. O

The O
nadirs O
of O
the O
reduction B-NonOSE_AE
in I-NonOSE_AE
leukocyte I-NonOSE_AE
count I-NonOSE_AE
and O
thrombocyte O
count O
are O
usually O
reached O
in O
weeks O
1 O
and O
2 O
of O
treatment O
. O

Peripheral O
blood O
cell O
counts O
are O
expected O
to O
normalize O
after O
approximately O
20 O
days O
. O

Bone B-OSE_Labeled_AE
marrow I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
has O
been O
reported O
. O

Severe O
myelosuppression B-NonOSE_AE
may O
be O
expected O
particularly O
in O
patients O
pretreated O
with O
and/or O
receiving O
concomitant O
chemotherapy O
and/or O
radiation O
therapy O
. O

5.2 O
Urinary O
Tract O
and O
Renal O
Toxicity O
Hemorrhagic B-OSE_Labeled_AE
cystitis I-OSE_Labeled_AE
, O
pyelitis B-OSE_Labeled_AE
, O
ureteritis B-OSE_Labeled_AE
, O
and O
hematuria B-OSE_Labeled_AE
have O
been O
reported O
with O
cyclophosphamide O
. O

Medical O
and/or O
surgical O
supportive O
treatment O
may O
be O
required O
to O
treat O
protracted O
cases O
of O
severe O
hemorrhagic B-NonOSE_AE
cystitis I-NonOSE_AE
. O

Discontinue O
cyclophosphamide O
therapy O
in O
case O
of O
severe O
hemorrhagic B-NonOSE_AE
cystitis I-NonOSE_AE
. O

Urotoxicity B-NonOSE_AE
( O
bladder B-NonOSE_AE
ulceration I-NonOSE_AE
, O
necrosis O
, O
fibrosis O
, O
contracture O
and O
secondary O
cancer O
) O
may O
require O
interruption O
of O
cyclophosphamide O
treatment O
or O
cystectomy O
. O

Urotoxicity B-NonOSE_AE
can O
be O
fatal B-NonOSE_AE
. O

Urotoxicity B-OSE_Labeled_AE
can O
occur O
with O
short-term O
or O
long-term O
use O
of O
cyclophosphamide O
. O

Before O
starting O
treatment O
, O
exclude O
or O
correct O
any O
urinary B-Not_AE_Candidate
tract I-Not_AE_Candidate
obstructions I-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

Urinary O
sediment O
should O
be O
checked O
regularly O
for O
the O
presence O
of O
erythrocytes O
and O
other O
signs O
of O
urotoxicity B-NonOSE_AE
and/or O
nephrotoxicity B-NonOSE_AE
. O

Cyclophosphamide O
should O
be O
used O
with O
caution O
, O
if O
at O
all O
, O
in O
patients O
with O
active O
urinary B-Not_AE_Candidate
tract I-Not_AE_Candidate
infections I-Not_AE_Candidate
. O

Aggressive O
hydration O
with O
forced O
diuresis B-NonOSE_AE
and O
frequent O
bladder B-NonOSE_AE
emptying I-NonOSE_AE
can O
reduce O
the O
frequency O
and O
severity O
of O
bladder B-NonOSE_AE
toxicity I-NonOSE_AE
. O

Mesna O
has O
been O
used O
to O
prevent O
severe O
bladder B-NonOSE_AE
toxicity I-NonOSE_AE
. O

5.3 O
Cardiotoxicity O
Myocarditis B-OSE_Labeled_AE
, O
myopericarditis B-OSE_Labeled_AE
, O
pericardial B-OSE_Labeled_AE
effusion I-OSE_Labeled_AE
including O
cardiac B-OSE_Labeled_AE
tamponade I-OSE_Labeled_AE
, O
and O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
which O
may O
be O
fatal B-NonOSE_AE
, O
have O
been O
reported O
with O
cyclophosphamide O
therapy O
Supraventricular B-OSE_Labeled_AE
arrhythmias I-OSE_Labeled_AE
( O
including O
atrial B-OSE_Labeled_AE
fibrillation O
and O
flutter I-OSE_Labeled_AE
) O
and O
ventricular B-OSE_Labeled_AE
arrhythmias I-OSE_Labeled_AE
( O
including O
severe O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
associated O
with O
ventricular B-OSE_Labeled_AE
tachyarrhythmia I-OSE_Labeled_AE
) O
have O
been O
reported O
after O
treatment O
with O
regimens O
that O
included O
cyclophosphamide O
. O

The O
risk O
of O
cardiotoxicity B-OSE_Labeled_AE
may O
be O
increased O
with O
high O
doses O
of O
cyclophosphamide O
, O
in O
patients O
with O
advanced O
age O
, O
and O
in O
patients O
with O
previous O
radiation O
treatment O
to O
the O
cardiac O
region O
and/or O
previous O
or O
concomitant O
treatment O
with O
other O
cardiotoxic B-NonOSE_AE
agents I-NonOSE_AE
. O

Particular O
caution O
is O
necessary O
in O
patients O
with O
risk O
factors O
for O
cardiotoxicity B-NonOSE_AE
and O
in O
patients O
with O
pre-existing O
cardiac B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Monitor O
patients O
with O
risk O
factors O
for O
cardiotoxicity B-NonOSE_AE
and O
with O
pre-existing O
cardiac B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

5.4 O
Pulmonary O
Toxicity O
Pneumonitis B-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
fibrosis I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
veno I-OSE_Labeled_AE
- I-OSE_Labeled_AE
occlusive I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
and O
other O
forms O
of O
pulmonary B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
leading O
to O
respiratory B-NonOSE_AE
failure I-NonOSE_AE
have O
been O
reported O
during O
and O
following O
treatment O
with O
cyclophosphamide O
. O

Late O
onset O
pneumonitis B-NonOSE_AE
( O
greater O
than O
6 O
months O
after O
start O
of O
cyclophosphamide O
) O
appears O
to O
be O
associated O
with O
increased O
mortality B-NonOSE_AE
. O

Pneumonitis B-OSE_Labeled_AE
may O
develop O
years O
after O
treatment O
with O
cyclophosphamide O
. O

Monitor O
patients O
for O
signs O
and O
symptoms O
of O
pulmonary B-NonOSE_AE
toxicity I-NonOSE_AE
. O

5.5 O
Secondary O
Malignancies O
Cyclophosphamide O
is O
genotoxic B-OSE_Labeled_AE
[ O
see O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
. O

Secondary B-OSE_Labeled_AE
malignancies I-OSE_Labeled_AE
( O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
, O
myelodysplasia B-OSE_Labeled_AE
, O
acute B-OSE_Labeled_AE
leukemias I-OSE_Labeled_AE
, O
lymphomas B-OSE_Labeled_AE
, O
thyroid B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
, O
and O
sarcomas B-OSE_Labeled_AE
) O
have O
been O
reported O
in O
patients O
treated O
with O
cyclophosphamide-containing O
regimens O
. O

The O
risk O
of O
bladder B-NonOSE_AE
cancer I-NonOSE_AE
may O
be O
reduced O
by O
prevention O
of O
hemorrhagic B-NonOSE_AE
cystitis I-NonOSE_AE
. O

5.6 O
Veno-occlusive O
Liver O
Disease O
Veno B-OSE_Labeled_AE
- I-OSE_Labeled_AE
occlusive I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
( I-OSE_Labeled_AE
VOD I-OSE_Labeled_AE
) O
including O
fatal B-NonOSE_AE
outcome O
has O
been O
reported O
in O
patients O
receiving O
cyclophosphamide-containing O
regimens O
. O

A O
cytoreductive O
regimen O
in O
preparation O
for O
bone B-Not_AE_Candidate
marrow I-Not_AE_Candidate
transplantation I-Not_AE_Candidate
that O
consists O
of O
cyclophosphamide O
in O
combination O
with O
whole-body O
irradiation O
, O
busulfan O
, O
or O
other O
agents O
has O
been O
identified O
as O
a O
major O
risk O
factor O
. O

VOD B-OSE_Labeled_AE
has O
also O
been O
reported O
to O
develop O
gradually O
in O
patients O
receiving O
long-term O
low-dose O
immunosuppressive B-NonOSE_AE
doses O
of O
cyclophosphamide O
. O

Other O
risk O
factors O
predisposing O
to O
the O
development O
of O
VOD B-NonOSE_AE
include O
preexisting O
disturbances B-Not_AE_Candidate
of I-Not_AE_Candidate
hepatic I-Not_AE_Candidate
function I-Not_AE_Candidate
, O
previous O
radiation O
therapy O
of O
the O
abdomen O
, O
and O
a O
low O
performance O
status O
. O

5.7 O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Cyclophosphamide O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

Exposure O
to O
cyclophosphamide O
during O
pregnancy B-Not_AE_Candidate
may O
cause O
birth B-OSE_Labeled_AE
defects I-OSE_Labeled_AE
, O
miscarriage B-OSE_Labeled_AE
, O
fetal B-OSE_Labeled_AE
growth I-OSE_Labeled_AE
retardation I-OSE_Labeled_AE
, O
and O
fetotoxic B-OSE_Labeled_AE
effects I-OSE_Labeled_AE
in O
the O
newborn O
. O

Cyclophosphamide O
is O
teratogenic B-NonOSE_AE
and O
embryo B-NonOSE_AE
- I-NonOSE_AE
fetal I-NonOSE_AE
toxic I-NonOSE_AE
in O
mice O
, O
rats O
, O
rabbits O
and O
monkeys O
. O

Advise O
female O
patients O
of O
reproductive O
potential O
to O
avoid O
becoming O
pregnant B-NonOSE_AE
and O
to O
use O
highly O
effective O
contraception O
during O
treatment O
and O
for O
up O
to O
1 O
year O
after O
completion O
of O
therapy O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
] O
. O

5.8 O
Infertility O
Male B-OSE_Labeled_AE
and O
female O
reproductive I-OSE_Labeled_AE
function I-OSE_Labeled_AE
and O
fertility O
may O
be O
impaired I-OSE_Labeled_AE
in O
patients O
being O
treated O
with O
cyclophosphamide O
. O

Cyclophosphamide O
interferes B-OSE_Labeled_AE
with I-OSE_Labeled_AE
oogenesis I-OSE_Labeled_AE
and O
spermatogenesis O
. O

It O
may O
cause O
sterility B-OSE_Labeled_AE
in O
both O
sexes O
. O

Development O
of O
sterility B-NonOSE_AE
appears O
to O
depend O
on O
the O
dose O
of O
cyclophosphamide O
, O
duration O
of O
therapy O
, O
and O
the O
state O
of O
gonadal O
function O
at O
the O
time O
of O
treatment O
. O

Cyclophosphamide B-NonOSE_AE
- I-NonOSE_AE
induced I-NonOSE_AE
sterility I-NonOSE_AE
may O
be O
irreversible O
in O
some O
patients O
. O

Advise O
patients O
on O
the O
potential O
risks O
for O
infertility B-NonOSE_AE
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.4 O
and O
8.6 O
) O
] O
. O

5.9 O
Impairment O
of O
Wound O
Healing O
Cyclophosphamide O
may O
interfere B-OSE_Labeled_AE
with I-OSE_Labeled_AE
normal I-OSE_Labeled_AE
wound I-OSE_Labeled_AE
healing I-OSE_Labeled_AE
. O

5.10 O
Hyponatremia O
Hyponatremia B-OSE_Labeled_AE
associated O
with O
increased B-OSE_Labeled_AE
total I-OSE_Labeled_AE
body I-OSE_Labeled_AE
water I-OSE_Labeled_AE
, O
acute B-OSE_Labeled_AE
water I-OSE_Labeled_AE
intoxication I-OSE_Labeled_AE
, O
and O
a O
syndrome B-OSE_Labeled_AE
resembling I-OSE_Labeled_AE
SIADH I-OSE_Labeled_AE
( I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
of I-OSE_Labeled_AE
inappropriate I-OSE_Labeled_AE
secretion I-OSE_Labeled_AE
of I-OSE_Labeled_AE
antidiuretic I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
) O
, O
which O
may O
be O
fatal B-NonOSE_AE
, O
has O
been O
reported O
. O

6 O
ADVERSE O
REACTIONS O
Detailed O
information O
on O
serious O
and O
adverse O
reactions O
of O
particular O
importance O
is O
provided O
in O
the O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5 O
) O
sections O
: O
* O
Drug B-OSE_Labeled_AE
dependence I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
] O
* O
Hypersensitivity B-Not_AE_Candidate
to O
Methylphenidate O
[ O
see O
Contraindications O
( O
4.1 O
) O
] O
* O
Marked O
anxiety B-Not_AE_Candidate
, O
tension B-Not_AE_Candidate
, O
or O
agitation B-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4.2 O
) O
] O
* O
Glaucoma B-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4.3 O
) O
] O
* O
Tics B-Not_AE_Candidate
or O
a O
family O
history O
of O
Tourette B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4.4 O
) O
] O
* O
Monoamine O
Oxidase O
Inhibitors O
[ O
see O
Contraindications O
( O
4.5 O
) O
and O
Drug O
Interactions O
( O
7.1 O
) O
] O
* O
Serious O
Cardiovascular B-OSE_Labeled_AE
Events I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Blood I-OSE_Labeled_AE
Pressure I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Psychiatric B-OSE_Labeled_AE
Adverse I-OSE_Labeled_AE
Events I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Seizures B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Priapism B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Peripheral B-OSE_Labeled_AE
Vasculopathy I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Long-Term O
Suppression B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Growth I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Chemical B-OSE_Labeled_AE
Leukoderma I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Contact B-OSE_Labeled_AE
Sensitization I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Visual B-OSE_Labeled_AE
Disturbance I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
External B-NonOSE_AE
Heat I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
* O
Hematologic B-NonOSE_AE
Monitoring O
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
The O
most O
commonly O
reported O
( O
frequency O
> O
= O
5 O
% O
and O
twice O
the O
rate O
of O
placebo O
) O
adverse O
reactions O
in O
a O
controlled O
trial O
in O
children O
aged O
6-12 O
included O
appetite B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
tic B-OSE_Labeled_AE
, O
affect B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
, O
and O
anorexia B-OSE_Labeled_AE
. O

The O
most O
commonly O
reported O
( O
frequency O
> O
= O
5 O
% O
and O
twice O
the O
rate O
of O
placebo O
) O
adverse O
reactions O
in O
a O
controlled O
trial O
in O
adolescents O
aged O
13-17 O
were O
appetite B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
and O
anorexia B-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

The O
most O
common O
( O
> O
= O
2 O
% O
of O
subjects O
) O
adverse O
reaction O
associated O
with O
discontinuations O
in O
double-blind O
clinical O
trials O
in O
children O
or O
adolescents O
was O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

The O
overall O
Daytrana O
development O
program O
included O
exposure O
to O
Daytrana O
in O
a O
total O
of O
2,152 O
participants O
in O
clinical O
trials O
, O
including O
1,529 O
children O
aged O
6-12 O
, O
223 O
adolescents O
aged O
13-17 O
, O
and O
400 O
adults O
. O

The O
1,752 O
child O
and O
adolescent O
subjects O
aged O
6-17 O
years O
were O
evaluated O
in O
10 O
controlled O
clinical O
studies O
, O
7 O
open-label O
clinical O
studies O
, O
and O
5 O
clinical O
pharmacology O
studies O
. O

In O
a O
combined O
studies O
pool O
of O
children O
using O
Daytrana O
with O
a O
wear O
time O
of O
9 O
hours O
, O
212 O
subjects O
were O
exposed O
for O
> O
= O
6 O
months O
and O
115 O
were O
exposed O
for O
> O
= O
1 O
year O
; O
85 O
adolescents O
have O
been O
exposed O
for O
> O
= O
6 O
months O
. O

Most O
patients O
studied O
were O
exposed O
to O
Daytrana O
patch O
sizes O
of O
12.5 O
cm O
2 O
, O
18.75 O
cm O
2 O
, O
25 O
cm O
2 O
or O
37.5 O
cm O
2 O
, O
with O
a O
wear O
time O
of O
9 O
hours O
. O

In O
the O
data O
presented O
below O
, O
the O
adverse O
reactions O
reported O
during O
exposure O
were O
obtained O
primarily O
by O
general O
inquiry O
at O
each O
visit O
, O
and O
were O
recorded O
by O
the O
clinical O
investigators O
using O
terminology O
of O
their O
own O
choosing O
. O

Consequently O
, O
it O
is O
not O
possible O
to O
provide O
a O
meaningful O
estimate O
of O
the O
proportion O
of O
individuals O
experiencing O
adverse O
reactions O
without O
first O
grouping O
similar O
types O
of O
events O
into O
a O
smaller O
number O
of O
standardized O
event O
categories O
. O

Throughout O
this O
section O
adverse O
reactions O
reported O
are O
events O
that O
were O
considered O
to O
be O
reasonably O
associated O
with O
the O
use O
of O
Daytrana O
based O
on O
comprehensive O
assessment O
of O
the O
available O
adverse O
event O
information O
. O

A O
causal O
association O
for O
Daytrana O
often O
can O
not O
be O
reliably O
established O
in O
individual O
cases O
. O

Further O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

EXCERPT O
: O
* O
Children O
( O
ages O
6-12 O
) O
: O
The O
most O
commonly O
( O
> O
=5 O
% O
and O
twice O
the O
rate O
of O
placebo O
) O
reported O
adverse O
reactions O
in O
a O
placebo-controlled O
trial O
in O
children O
aged O
6-12 O
included O
appetite O
decreased O
, O
insomnia O
, O
nausea O
, O
vomiting O
, O
weight O
decreased O
, O
tic O
, O
affect O
lability O
, O
and O
anorexia O
( O
6.1 O
) O
. O

* O
Adolescents O
( O
ages O
13-17 O
) O
: O
The O
most O
commonly O
( O
> O
=5 O
% O
and O
twice O
the O
rate O
of O
placebo O
) O
reported O
adverse O
reactions O
in O
a O
placebo-controlled O
trial O
in O
adolescents O
aged O
13-17 O
included O
appetite O
decreased O
, O
nausea O
, O
insomnia O
, O
weight O
decreased O
, O
dizziness O
, O
abdominal O
pain O
, O
and O
anorexia O
. O

The O
majority O
of O
subjects O
in O
these O
trials O
had O
erythema O
at O
the O
application O
site O
( O
6.1 O
) O
. O

* O
The O
most O
common O
( O
> O
=2 O
% O
of O
subjects O
) O
adverse O
reaction O
associated O
with O
discontinuations O
in O
controlled O
clinical O
trials O
in O
children O
or O
adolescents O
was O
application O
site O
reactions O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Noven O
Therapeutics O
, O
LLC O
at O
1-877-567-7857 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Adverse O
Reactions O
Associated O
With O
Discontinuation O
of O
Treatment O
In O
a O
7-week O
double-blind O
, O
parallel-group O
, O
placebo-controlled O
study O
in O
children O
with O
ADHD B-Not_AE_Candidate
conducted O
in O
the O
outpatient O
setting O
, O
7.1 O
% O
( O
7/98 O
) O
of O
patients O
treated O
with O
Daytrana O
discontinued O
due O
to O
adverse O
events O
compared O
with O
1.2 O
% O
( O
1/85 O
) O
receiving O
placebo O
. O

The O
most O
commonly O
reported O
( O
> O
= O
1 O
% O
and O
twice O
the O
rate O
of O
placebo O
) O
adverse O
reactions O
leading O
to O
discontinuation O
in O
the O
Daytrana O
group O
were O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
( O
2 O
% O
) O
, O
tics B-OSE_Labeled_AE
( O
1 O
% O
) O
, O
headache B-OSE_Labeled_AE
( O
1 O
% O
) O
, O
and O
irritability B-OSE_Labeled_AE
( O
1 O
% O
) O
. O

In O
a O
7-week O
double-blind O
, O
parallel-group O
, O
placebo-controlled O
study O
in O
adolescents O
with O
ADHD B-Not_AE_Candidate
conducted O
in O
the O
outpatient O
setting O
, O
5.5 O
% O
( O
8/145 O
) O
of O
patients O
treated O
with O
Daytrana O
discontinued O
due O
to O
adverse O
reactions O
compared O
with O
2.8 O
% O
( O
2/72 O
) O
receiving O
placebo O
. O

The O
most O
commonly O
reported O
adverse O
reactions O
leading O
to O
discontinuation O
in O
the O
Daytrana O
group O
were O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
( O
2 O
% O
) O
and O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
/ O
anorexia B-OSE_Labeled_AE
( O
1.4 O
% O
) O
. O

Commonly O
Observed O
Adverse O
Reactions O
in O
Double-Blind O
, O
Placebo-Controlled O
Trials O
Skin B-OSE_Labeled_AE
Irritation I-OSE_Labeled_AE
and O
Application B-OSE_Labeled_AE
Site I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
Daytrana O
is O
a O
dermal B-OSE_Labeled_AE
irritant I-OSE_Labeled_AE
. O

In O
addition O
to O
the O
most O
commonly O
reported O
adverse O
reactions O
presented O
in O
Table O
2 O
, O
the O
majority O
of O
subjects O
in O
those O
studies O
had O
minimal O
to O
definite O
skin B-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
at I-OSE_Labeled_AE
the I-OSE_Labeled_AE
patch I-OSE_Labeled_AE
application I-OSE_Labeled_AE
site I-OSE_Labeled_AE
. O

This O
erythema B-NonOSE_AE
generally O
caused O
no O
or O
minimal O
discomfort O
and O
did O
not O
usually O
interfere O
with O
therapy O
or O
result O
in O
discontinuation O
from O
treatment O
. O

Erythema B-NonOSE_AE
is O
not O
by O
itself O
a O
manifestation O
of O
contact B-NonOSE_AE
sensitization I-NonOSE_AE
. O

However O
, O
contact B-NonOSE_AE
sensitization I-NonOSE_AE
should O
be O
suspected O
if O
erythema B-NonOSE_AE
is O
accompanied O
by O
evidence O
of O
a O
more O
intense O
local B-NonOSE_AE
reaction I-NonOSE_AE
( O
edema I-NonOSE_AE
, O
papules O
, O
vesicles O
) O
that O
does O
not O
significantly O
improve O
within O
48 O
hours O
or O
spreads O
beyond O
the O
patch O
site O
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
. O

Most O
Commonly O
Reported O
Adverse O
Reactions O
Table O
2 O
lists O
treatment-emergent O
adverse O
reactions O
reported O
in O
> O
= O
1 O
% O
Daytrana-treated O
children O
or O
adolescents O
with O
ADHD O
in O
two O
7 O
week O
double-blind O
, O
parallel-group O
, O
placebo-controlled O
studies O
conducted O
in O
the O
outpatient O
setting O
. O

Overall O
, O
in O
these O
studies O
, O
75.5 O
% O
of O
children O
and O
78.6 O
% O
of O
adolescents O
experienced O
at O
least O
1 O
adverse O
event O
. O

* O
Six O
subjects O
had O
affect B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
, O
all O
judged O
as O
mild O
and O
described O
as O
increased B-OSE_Labeled_AE
emotionally I-OSE_Labeled_AE
sensitive I-OSE_Labeled_AE
, O
emotionality B-OSE_Labeled_AE
, O
emotional B-OSE_Labeled_AE
instability I-OSE_Labeled_AE
, O
emotional B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
, O
and O
intermittent B-OSE_Labeled_AE
emotional I-OSE_Labeled_AE
Table O
2 O
Number O
( O
% O
) O
of O
Subjects O
with O
Commonly O
Reported O
Adverse O
Reactions O
( O
> O
= O
1 O
% O
in O
the O
Daytrana O
Group O
) O
in O
7-Week O
Placebo-controlled O
Studies O
in O
Either O
Children O
or O
Adolescents O
- O
Safety O
Population O
Adolescents O
Children O
System O
Organ O
Class O
Preferred O
term O
PlaceboN O
= O
72 O
DaytranaN O
= O
145 O
PlaceboN O
= O
85 O
DaytranaN O
= O
98 O
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
Tachycardia B-OSE_Labeled_AE
0 O
( O
0 O
) O
1 O
( O
0.7 O
) O
0 O
( O
0 O
) O
1 O
( O
1.0 O
) O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
0 O
( O
0 O
) O
7 O
( O
4.8 O
) O
5 O
( O
5.9 O
) O
7 O
( O
7.1 O
) O
Nausea B-OSE_Labeled_AE
2 O
( O
2.8 O
) O
14 O
( O
9.7 O
) O
2 O
( O
2.4 O
) O
12 O
( O
12.2 O
) O
Vomiting B-OSE_Labeled_AE
1 O
( O
1.4 O
) O
5 O
( O
3.4 O
) O
4 O
( O
4.7 O
) O
10 O
( O
10.2 O
) O
Investigations B-NonOSE_AE
Weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
1 O
( O
1.4 O
) O
8 O
( O
5.5 O
) O
0 O
( O
0 O
) O
9 O
( O
9.2 O
) O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
Anorexia B-OSE_Labeled_AE
1 O
( O
1.4 O
) O
7 O
( O
4.8 O
) O
1 O
( O
1.2 O
) O
5 O
( O
5.1 O
) O
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
1 O
( O
1.4 O
) O
37 O
( O
25.5 O
) O
4 O
( O
4.7 O
) O
25 O
( O
25.5 O
) O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
1 O
( O
1.4 O
) O
8 O
( O
5.5 O
) O
1 O
( O
1.2 O
) O
0 O
( O
0 O
) O
Headache B-OSE_Labeled_AE
9 O
( O
12.5 O
) O
18 O
( O
12.4 O
) O
10 O
( O
11.8 O
) O
15 O
( O
15.3 O
) O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
Affect B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
1 O
( O
1.4 O
) O
0 O
( O
0 O
) O
0 O
( O
0 O
) O
6 O
( O
6.1 O
) O
* O
Insomnia B-OSE_Labeled_AE
2 O
( O
2.8 O
) O
9 O
( O
6.2 O
) O
4 O
( O
4.7 O
) O
13 O
( O
13.3 O
) O
Irritability B-OSE_Labeled_AE
5 O
( O
6.9 O
) O
16 O
( O
11 O
) O
4 O
( O
4.7 O
) O
7 O
( O
7.1 O
) O
Tic B-OSE_Labeled_AE
0 O
( O
0 O
) O
0 O
( O
0 O
) O
0 O
( O
0 O
) O
7 O
( O
7.1 O
) O
Adverse O
Reactions O
With O
the O
Long-Term O
Use O
of O
Daytrana O
In O
a O
long-term O
open-label O
study O
of O
up O
to O
12 O
months O
duration O
in O
326 O
children O
wearing O
Daytrana O
9 O
hours O
daily O
, O
the O
most O
common O
( O
> O
= O
10 O
% O
) O
adverse O
reactions O
were O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
and O
weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
. O

A O
total O
of O
30 O
subjects O
( O
9.2 O
% O
) O
were O
withdrawn O
from O
the O
study O
due O
to O
adverse O
events O
and O
22 O
additional O
subjects O
( O
6.7 O
% O
) O
discontinued O
treatment O
as O
the O
result O
of O
an O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
. O

Other O
than O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
affect B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
( O
5 O
subjects O
, O
1.5 O
% O
) O
was O
the O
only O
additional O
adverse O
reaction O
leading O
to O
discontinuation O
reported O
with O
a O
frequency O
of O
greater O
than O
1 O
% O
. O

In O
a O
long-term O
open-label O
study O
of O
up O
to O
6 O
months O
duration O
in O
162 O
adolescents O
wearing O
Daytrana O
9 O
hours O
daily O
, O
the O
most O
common O
( O
> O
= O
10 O
% O
) O
adverse O
reactions O
were O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
and O
headache B-OSE_Labeled_AE
. O

A O
total O
of O
9 O
subjects O
( O
5.5 O
% O
) O
were O
withdrawn O
from O
the O
study O
due O
to O
adverse O
events O
and O
3 O
additional O
subjects O
( O
1.9 O
% O
) O
discontinued O
treatment O
as O
the O
result O
of O
an O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
. O

Other O
adverse O
reactions O
leading O
to O
discontinuation O
that O
occurred O
with O
a O
frequency O
of O
greater O
than O
1 O
% O
included O
affect O
lability O
and O
irritability O
( O
2 O
subjects O
each O
, O
1.2 O
% O
) O
. O

6.2 O
Postmarketing O
Experience O
In O
addition O
, O
the O
following O
adverse O
reactions O
have O
been O
identified O
during O
the O
postapproval O
use O
of O
Daytrana O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
Daytrana O
exposure O
. O

Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
: O
palpitations B-OSE_Labeled_AE
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
: O
visual B-OSE_Labeled_AE
disturbances I-OSE_Labeled_AE
, O
blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
mydriasis B-OSE_Labeled_AE
, O
accommodation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Disorders I-NonOSE_AE
: O
fatigue B-OSE_Labeled_AE
, O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
such O
as O
bleeding O
, O
bruising O
, O
burn O
, O
burning O
, O
dermatitis O
, O
discharge O
, O
discoloration O
, O
discomfort O
, O
dryness O
, O
eczema O
, O
edema O
, O
erosion O
, O
erythema O
, O
excoriation O
, O
exfoliation O
, O
fissure O
, O
hyperpigmentation O
, O
hypopigmentation O
, O
induration O
, O
infection O
, O
inflammation O
, O
irritation O
, O
pain O
, O
papules O
, O
paresthesia O
, O
pruritus O
, O
rash O
, O
scab O
, O
swelling O
, O
ulcer O
, O
urticaria O
, O
vesicles O
, O
and O
warmth O
. O

Immune B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
generalized B-OSE_Labeled_AE
erythematous I-OSE_Labeled_AE
and O
urticarial B-OSE_Labeled_AE
rashes I-OSE_Labeled_AE
, O
allergic B-OSE_Labeled_AE
contact I-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
and O
anaphylaxis B-OSE_Labeled_AE
Investigations B-NonOSE_AE
: O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
convulsion B-OSE_Labeled_AE
, O
dyskinesia B-OSE_Labeled_AE
, O
lethargy B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
in O
combination O
with O
serotonergic O
drugs O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
: O
depression B-OSE_Labeled_AE
, O
hallucination B-OSE_Labeled_AE
, O
nervousness B-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
alopecia B-OSE_Labeled_AE
6.3 O
Adverse O
Reactions O
With O
Oral O
Methylphenidate O
Products O
Nervousness B-OSE_Labeled_AE
and O
insomnia B-OSE_Labeled_AE
are O
the O
most O
common O
adverse O
reactions O
reported O
with O
other O
methylphenidate O
products O
. O

In O
children O
, O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
during O
prolonged O
therapy O
, O
insomnia B-OSE_Labeled_AE
, O
and O
tachycardia B-OSE_Labeled_AE
may O
occur O
more O
frequently O
; O
however O
, O
any O
of O
the O
other O
adverse O
reactions O
listed O
below O
may O
also O
occur O
. O

Other O
reactions O
include O
: O
Cardiac B-NonOSE_AE
: O
angina B-OSE_Labeled_AE
, O
arrhythmia B-OSE_Labeled_AE
, O
pulse B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
or I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
Immune B-NonOSE_AE
: O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
skin B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
, O
exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
with O
histopathological O
findings O
of O
necrotizing B-OSE_Labeled_AE
vasculitis I-OSE_Labeled_AE
, O
and O
thrombocytopenic B-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
Metabolism B-NonOSE_AE
/ I-NonOSE_AE
Nutrition I-NonOSE_AE
: O
anorexia B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
during O
prolonged O
therapy O
Nervous B-NonOSE_AE
System I-NonOSE_AE
: O
drowsiness B-OSE_Labeled_AE
, O
rare O
reports O
of O
Tourette B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
psychosis I-OSE_Labeled_AE
Vascular B-NonOSE_AE
: O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
increased O
or O
decreased I-OSE_Labeled_AE
, O
cerebral B-OSE_Labeled_AE
arteritis I-OSE_Labeled_AE
and/or O
occlusion O
Although O
a O
definite O
causal O
relationship O
has O
not O
been O
established O
, O
the O
following O
have O
been O
reported O
in O
patients O
taking O
methylphenidate O
: O
Blood B-NonOSE_AE
/ I-NonOSE_AE
lymphatic I-NonOSE_AE
: O
leukopenia B-OSE_Labeled_AE
and/or O
anemia B-OSE_Labeled_AE
Hepatobiliary B-NonOSE_AE
: O
abnormal B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
, O
ranging O
from O
transaminase B-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
to O
severe O
hepatic B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
Psychiatric B-NonOSE_AE
: O
transient B-OSE_Labeled_AE
depressed I-OSE_Labeled_AE
mood I-OSE_Labeled_AE
Skin B-NonOSE_AE
/ I-NonOSE_AE
Subcutaneous I-NonOSE_AE
: O
scalp B-OSE_Labeled_AE
hair I-OSE_Labeled_AE
loss I-OSE_Labeled_AE
Neuroleptic B-OSE_Labeled_AE
Malignant I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
: O
Very O
rare O
reports O
of O
neuroleptic B-OSE_Labeled_AE
malignant I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
NMS I-OSE_Labeled_AE
) O
have O
been O
received O
, O
and O
, O
in O
most O
of O
these O
, O
patients O
were O
concurrently O
receiving O
therapies O
associated O
with O
NMS B-NonOSE_AE
. O

In O
a O
single O
report O
, O
a O
ten-year-old O
boy O
who O
had O
been O
taking O
methylphenidate O
for O
approximately O
18 O
months O
experienced O
an O
NMS B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
event I-OSE_Labeled_AE
within O
45 O
minutes O
of O
ingesting O
his O
first O
dose O
of O
venlafaxine O
. O

It O
is O
uncertain O
whether O
this O
case O
represented O
a O
drug-drug O
interaction O
, O
a O
response O
to O
either O
drug O
alone O
, O
or O
some O
other O
cause O
. O

Musculoskeletal B-NonOSE_AE
: O
rhabdomyolysis B-OSE_Labeled_AE

BOXED O
WARNING O
: O
WARNING O
: O
DRUG B-OSE_Labeled_AE
DEPENDENCE I-OSE_Labeled_AE
Daytrana O
should O
be O
given O
cautiously O
to O
patients O
with O
a O
history O
of O
drug B-Not_AE_Candidate
dependence I-Not_AE_Candidate
or O
alcoholism O
. O

Chronic O
abusive B-OSE_Labeled_AE
use I-OSE_Labeled_AE
can O
lead O
to O
marked O
tolerance B-NonOSE_AE
and O
psychological B-NonOSE_AE
dependence I-NonOSE_AE
with O
varying O
degrees O
of O
abnormal B-NonOSE_AE
behavior I-NonOSE_AE
. O

Frank O
psychotic B-NonOSE_AE
episodes I-NonOSE_AE
can O
occur O
, O
especially O
with O
parenteral O
abuse B-NonOSE_AE
. O

Careful O
supervision O
is O
required O
during O
withdrawal O
from O
abusive B-NonOSE_AE
use I-NonOSE_AE
, O
since O
severe O
depression B-NonOSE_AE
may O
occur O
. O

Withdrawal O
following O
chronic O
therapeutic O
use O
may O
unmask O
symptoms O
of O
the O
underlying O
disorder O
that O
may O
require O
follow-up O
. O

EXCERPT O
: O
WARNING O
: O
DRUG O
DEPENDENCE O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
Daytrana O
should O
be O
given O
cautiously O
to O
patients O
with O
a O
history O
of O
drug O
dependence O
or O
alcoholism O
. O

Chronic O
abusive O
use O
can O
lead O
to O
marked O
tolerance O
and O
psychological O
dependence O
with O
varying O
degrees O
of O
abnormal O
behavior O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Serious O
Cardiovascular O
Events O
: O
Sudden O
death O
has O
been O
reported O
in O
association O
with O
CNS O
stimulant O
treatment O
at O
usual O
doses O
in O
children O
and O
adolescents O
with O
structural O
cardiac O
abnormalities O
or O
other O
serious O
heart O
problems O
. O

Sudden O
death O
, O
stroke O
, O
and O
myocardial O
infarction O
have O
been O
reported O
in O
adults O
taking O
stimulant O
drugs O
at O
usual O
doses O
for O
ADHD O
. O

Stimulant O
products O
generally O
should O
not O
be O
used O
in O
patients O
with O
known O
structural O
cardiac O
abnormalities O
, O
cardiomyopathy O
, O
serious O
heart O
rhythm O
abnormalities O
, O
coronary O
artery O
disease O
, O
or O
other O
serious O
heart O
problems O
. O

( O
5.1 O
) O
* O
Increase O
in O
Blood O
Pressure O
: O
Monitor O
patients O
for O
changes O
in O
heart O
rate O
and O
blood O
pressure O
and O
use O
with O
caution O
in O
patients O
for O
whom O
an O
increase O
in O
blood O
pressure O
or O
heart O
rate O
would O
be O
problematic O
. O

( O
5.1 O
) O
* O
Psychiatric O
Adverse O
Events O
: O
Use O
of O
stimulants O
may O
cause O
treatment-emergent O
psychotic O
or O
manic O
symptoms O
in O
patients O
with O
no O
prior O
history O
, O
or O
exacerbation O
of O
symptoms O
in O
patients O
with O
pre-existing O
psychiatric O
illness O
. O

Clinical O
evaluation O
for O
Bipolar O
Disorder O
is O
recommended O
prior O
to O
stimulant O
use O
. O

Monitor O
for O
aggressive O
behavior O
. O

( O
5.2 O
) O
* O
Seizures O
: O
Stimulants O
may O
lower O
the O
convulsive O
threshold O
. O

Discontinue O
in O
the O
presence O
of O
seizures O
. O

( O
5.3 O
) O
* O
Priapism O
: O
Cases O
of O
painful O
and O
prolonged O
penile O
erections O
and O
priapism O
have O
been O
reported O
with O
methylphenidate O
products O
. O

Immediate O
medical O
attention O
should O
be O
sought O
if O
signs O
or O
symptoms O
of O
prolonged O
penile O
erections O
or O
priapism O
are O
observed O
( O
5.4 O
) O
* O
Peripheral O
Vasculopathy O
, O
including O
Raynaud O
's O
phenomenon O
: O
Stimulants O
used O
to O
treat O
ADHD O
are O
associated O
with O
peripheral O
vasculopathy O
, O
including O
Raynaud O
's O
phenomenon O
. O

Careful O
observation O
for O
digital O
changes O
is O
necessary O
during O
treatment O
with O
ADHD O
stimulants O
. O

( O
5.5 O
) O
* O
Long-Term O
Suppression O
of O
Growth O
: O
Monitor O
height O
and O
weight O
at O
appropriate O
intervals O
in O
pediatric O
patients O
. O

( O
5.6 O
) O
* O
Chemical O
Leukoderma O
: O
Daytrana O
use O
may O
result O
in O
a O
persistent O
loss O
of O
skin O
pigmentation O
at O
and O
around O
the O
application O
site O
. O

Loss O
of O
pigmentation O
, O
in O
some O
cases O
, O
has O
been O
reported O
at O
other O
sites O
distant O
from O
the O
application O
site O
. O

Monitor O
for O
signs O
of O
skin O
depigmentation O
. O

Discontinue O
Daytrana O
if O
it O
occurs O
. O

( O
5.7 O
) O
* O
Contact O
Sensitization O
: O
Use O
of O
Daytrana O
may O
lead O
to O
contact O
sensitization O
. O

Treatment O
should O
be O
discontinued O
if O
contact O
sensitization O
is O
suspected O
. O

Erythema O
is O
commonly O
seen O
with O
use O
of O
Daytrana O
and O
is O
not O
by O
itself O
an O
indication O
of O
sensitization O
. O

However O
, O
contact O
sensitization O
should O
be O
suspected O
if O
erythema O
is O
accompanied O
by O
evidence O
of O
a O
more O
intense O
local O
reaction O
( O
edema O
, O
papules O
, O
vesicles O
) O
that O
does O
not O
significantly O
improve O
within O
48 O
hours O
or O
spreads O
beyond O
the O
patch O
site O
. O

( O
5.8 O
) O
* O
Visual O
Disturbance O
: O
Difficulties O
with O
accommodation O
and O
blurring O
of O
vision O
have O
been O
reported O
with O
stimulant O
treatment O
. O

( O
5.9 O
) O
* O
External O
Heat O
: O
Patients O
should O
be O
advised O
to O
avoid O
exposing O
the O
Daytrana O
application O
site O
to O
direct O
external O
heat O
sources O
. O

When O
heat O
is O
applied O
to O
Daytrana O
after O
patch O
application O
, O
both O
the O
rate O
and O
extent O
of O
absorption O
are O
significantly O
increased O
. O

( O
5.10 O
) O
* O
Hematologic O
monitoring O
: O
Periodic O
CBC O
, O
differential O
, O
and O
platelet O
counts O
are O
advised O
during O
prolonged O
therapy O
. O

( O
5.11 O
) O
5.1 O
Serious O
Cardiovascular O
Events O
Sudden O
Death O
and O
Pre-existing O
Structural O
Cardiac O
Abnormalities O
or O
Other O
Serious O
Heart O
Problems O
Children O
and O
Adolescents O
Sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
has O
been O
reported O
in O
association O
with O
CNS O
stimulant O
treatment O
at O
usual O
doses O
in O
children O
and O
adolescents O
with O
structural B-Not_AE_Candidate
cardiac I-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
or O
other O
serious O
heart B-Not_AE_Candidate
problems I-Not_AE_Candidate
. O

Although O
some O
serious O
heart B-Not_AE_Candidate
problems I-Not_AE_Candidate
alone O
carry O
an O
increased O
risk O
of O
sudden B-NonOSE_AE
death I-NonOSE_AE
, O
stimulant O
products O
generally O
should O
not O
be O
used O
in O
children O
or O
adolescents O
with O
known O
serious O
structural B-Not_AE_Candidate
cardiac I-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
, O
cardiomyopathy B-Not_AE_Candidate
, O
serious O
heart B-Not_AE_Candidate
rhythm I-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
, O
or O
other O
serious O
cardiac B-Not_AE_Candidate
problems I-Not_AE_Candidate
that O
may O
place O
them O
at O
increased O
vulnerability O
to O
the O
sympathomimetic O
effects O
of O
a O
stimulant O
drug O
. O

Adults O
Sudden B-OSE_Labeled_AE
deaths I-OSE_Labeled_AE
, O
stroke B-OSE_Labeled_AE
, O
and O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
have O
been O
reported O
in O
adults O
taking O
stimulant O
drugs O
at O
usual O
doses O
for O
ADHD B-Not_AE_Candidate
. O

Although O
the O
role O
of O
stimulants O
in O
these O
adult O
cases O
is O
also O
unknown O
, O
adults O
have O
a O
greater O
likelihood O
than O
children O
of O
having O
serious O
structural B-Not_AE_Candidate
cardiac I-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
, O
cardiomyopathy B-Not_AE_Candidate
, O
serious O
heart B-Not_AE_Candidate
rhythm I-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
, O
coronary B-Not_AE_Candidate
artery I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
or O
other O
serious O
cardiac B-Not_AE_Candidate
problems I-Not_AE_Candidate
. O

Adults O
with O
such O
abnormalities O
should O
also O
generally O
not O
be O
treated O
with O
stimulant O
drugs O
. O

Hypertension O
and O
Other O
Cardiovascular O
Conditions O
Stimulant O
medications O
cause O
a O
modest O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
average O
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
( O
about O
2-4 O
mmHg O
) O
and O
average O
heart O
rate O
( O
about O
3-6 O
bpm O
) O
, O
and O
individuals O
may O
have O
larger O
increases O
. O

While O
the O
mean O
changes O
alone O
would O
not O
be O
expected O
to O
have O
short-term O
consequences O
, O
all O
patients O
should O
be O
monitored O
for O
larger O
changes B-NonOSE_AE
in I-NonOSE_AE
heart I-NonOSE_AE
rate I-NonOSE_AE
and O
blood O
pressure O
. O

Caution O
is O
indicated O
in O
treating O
patients O
whose O
underlying O
medical O
conditions O
might O
be O
compromised O
by O
increases B-NonOSE_AE
in I-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
or O
heart O
rate O
, O
e.g. O
, O
those O
with O
pre-existing O
hypertension B-Not_AE_Candidate
, O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
recent O
myocardial B-Not_AE_Candidate
infarction I-Not_AE_Candidate
, O
or O
ventricular B-Not_AE_Candidate
arrhythmia I-Not_AE_Candidate
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Assessing O
Cardiovascular O
Status O
in O
Patients O
Being O
Treated O
With O
Stimulant O
Medications O
Children O
, O
adolescents O
, O
or O
adults O
who O
are O
being O
considered O
for O
treatment O
with O
stimulant O
medications O
should O
have O
a O
careful O
history O
( O
including O
assessment O
for O
a O
family O
history O
of O
sudden B-Not_AE_Candidate
death I-Not_AE_Candidate
or O
ventricular B-Not_AE_Candidate
arrhythmia I-Not_AE_Candidate
) O
and O
physical O
exam O
to O
assess O
for O
the O
presence O
of O
cardiac B-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
and O
should O
receive O
further O
cardiac O
evaluation O
if O
findings O
suggest O
such O
disease O
( O
e.g. O
, O
electrocardiogram O
and O
echocardiogram O
) O
. O

Patients O
who O
develop O
symptoms O
such O
as O
exertional B-NonOSE_AE
chest I-NonOSE_AE
pain I-NonOSE_AE
, O
unexplained O
syncope B-NonOSE_AE
, O
or O
other O
symptoms O
suggestive O
of O
cardiac B-NonOSE_AE
disease I-NonOSE_AE
during O
stimulant O
treatment O
should O
undergo O
a O
prompt O
cardiac O
evaluation O
. O

5.2 O
Psychiatric O
Adverse O
Events O
Pre-Existing O
Psychosis O
Administration O
of O
stimulants O
may O
exacerbate B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
of I-OSE_Labeled_AE
behavior O
disturbance O
and O
thought I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
in O
patients O
with O
a O
pre-existing O
psychotic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

Bipolar O
Illness O
Particular O
care O
should O
be O
taken O
in O
using O
stimulants O
to O
treat O
ADHD B-Not_AE_Candidate
in O
patients O
with O
comorbid O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
because O
of O
concern O
for O
possible O
induction B-OSE_Labeled_AE
of I-OSE_Labeled_AE
a I-OSE_Labeled_AE
mixed/ O
manic I-OSE_Labeled_AE
episode I-OSE_Labeled_AE
in O
such O
patients O
. O

Prior O
to O
initiating O
treatment O
with O
a O
stimulant O
, O
patients O
with O
comorbid O
depressive B-Not_AE_Candidate
symptoms I-Not_AE_Candidate
should O
be O
adequately O
screened O
to O
determine O
if O
they O
are O
at O
risk O
for O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
; O
such O
screening O
should O
include O
a O
detailed O
psychiatric B-NonOSE_AE
history O
, O
including O
a O
family O
history O
of O
suicide B-Not_AE_Candidate
, O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
and O
depression B-Not_AE_Candidate
. O

Emergence O
of O
New O
Psychotic O
or O
Manic O
Symptoms O
Treatment O
emergent O
psychotic B-OSE_Labeled_AE
or O
manic O
symptoms I-OSE_Labeled_AE
, O
e.g. O
, O
hallucinations B-OSE_Labeled_AE
, O
delusional B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
, O
or O
mania B-OSE_Labeled_AE
in O
children O
and O
adolescents O
without O
a O
prior O
history O
of O
psychotic B-NonOSE_AE
illness I-NonOSE_AE
or O
mania B-NonOSE_AE
can O
be O
caused O
by O
stimulants O
at O
usual O
doses O
. O

If O
such O
symptoms O
occur O
, O
consideration O
should O
be O
given O
to O
a O
possible O
causal O
role O
of O
the O
stimulant O
, O
and O
discontinuation O
of O
treatment O
may O
be O
appropriate O
. O

In O
a O
pooled O
analysis O
of O
multiple O
short O
term O
, O
placebo-controlled O
studies O
, O
such O
symptoms O
occurred O
in O
about O
0.1 O
% O
( O
4 O
patients O
with O
events O
out O
of O
3,482 O
exposed O
to O
methylphenidate O
or O
amphetamine O
for O
several O
weeks O
at O
usual O
doses O
) O
of O
stimulant-treated O
patients O
compared O
to O
none O
in O
placebo-treated O
patients O
. O

Aggression O
Aggressive B-NonOSE_AE
behavior I-NonOSE_AE
or O
hostility B-NonOSE_AE
is O
often O
observed O
in O
children O
and O
adolescents O
with O
ADHD B-Not_AE_Candidate
, O
and O
has O
been O
reported O
in O
clinical O
trials O
and O
the O
postmarketing O
experience O
of O
some O
medications O
indicated O
for O
the O
treatment O
of O
ADHD B-Not_AE_Candidate
. O

Although O
there O
is O
no O
systematic O
evidence O
that O
stimulants O
cause O
aggressive B-NonOSE_AE
behavior I-NonOSE_AE
or O
hostility B-NonOSE_AE
, O
patients O
beginning O
treatment O
for O
ADHD B-Not_AE_Candidate
should O
be O
monitored O
for O
the O
appearance O
of O
or O
worsening B-NonOSE_AE
of I-NonOSE_AE
aggressive I-NonOSE_AE
behavior I-NonOSE_AE
or O
hostility B-NonOSE_AE
. O

5.3 O
Seizures B-OSE_Labeled_AE
There O
is O
some O
clinical O
evidence O
that O
stimulants O
may O
lower B-OSE_Labeled_AE
the I-OSE_Labeled_AE
convulsive I-OSE_Labeled_AE
threshold I-OSE_Labeled_AE
in O
patients O
with O
prior O
history O
of O
seizures B-Not_AE_Candidate
, O
in O
patients O
with O
prior O
EEG B-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
in O
absence O
of O
seizures B-NonOSE_AE
, O
and O
, O
very O
rarely O
, O
in O
patients O
without O
a O
history O
of O
seizures B-NonOSE_AE
and O
no O
prior O
EEG O
evidence O
of O
seizures B-NonOSE_AE
. O

In O
the O
presence O
of O
seizures B-NonOSE_AE
, O
the O
drug O
should O
be O
discontinued O
. O

5.4 O
Priapism O
Prolonged B-OSE_Labeled_AE
and O
painful O
erections I-OSE_Labeled_AE
, O
sometimes O
requiring O
surgical O
intervention O
, O
have O
been O
reported O
with O
methylphenidate O
products O
in O
both O
pediatric O
and O
adult O
patients O
. O

Priapism B-OSE_Labeled_AE
was O
not O
reported O
with O
drug O
initiation O
but O
developed O
after O
some O
time O
on O
the O
drug O
, O
often O
subsequent O
to O
an O
increase O
in O
dose O
. O

Priapism B-NonOSE_AE
has O
also O
appeared O
during O
a O
period O
of O
drug O
withdrawal O
( O
drug O
holidays O
or O
during O
discontinuation O
) O
. O

Patients O
who O
develop O
abnormally B-NonOSE_AE
sustained I-NonOSE_AE
or O
frequent O
and O
painful O
erections I-NonOSE_AE
should O
seek O
immediate O
medical O
attention O
. O

5.5 O
Peripheral O
Vasculopathy O
, O
including O
Raynaud O
's O
phenomenon O
Stimulants O
, O
including O
Daytrana O
, O
used O
to O
treat O
ADHD B-Not_AE_Candidate
are O
associated O
with O
peripheral B-OSE_Labeled_AE
vasculopathy I-OSE_Labeled_AE
, O
including O
Raynaud B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
phenomenon I-OSE_Labeled_AE
. O

Signs O
and O
symptoms O
are O
usually O
intermittent O
and O
mild O
; O
however O
, O
very O
rare O
sequelae O
include O
digital B-NonOSE_AE
ulceration I-NonOSE_AE
and/or O
soft B-NonOSE_AE
tissue I-NonOSE_AE
breakdown I-NonOSE_AE
. O

Effects O
of O
peripheral B-OSE_Labeled_AE
vasculopathy I-OSE_Labeled_AE
, O
including O
Raynaud B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
phenomenon I-OSE_Labeled_AE
, O
were O
observed O
in O
post-marketing O
reports O
at O
different O
times O
and O
at O
therapeutic O
doses O
in O
all O
age O
groups O
throughout O
the O
course O
of O
treatment O
. O

Signs O
and O
symptoms O
generally O
improve O
after O
reduction O
in O
dose O
or O
discontinuation O
of O
drug O
. O

Careful O
observation O
for O
digital B-NonOSE_AE
changes I-NonOSE_AE
is O
necessary O
during O
treatment O
with O
ADHD B-Not_AE_Candidate
stimulants O
. O

Further O
clinical O
evaluation O
( O
e.g. O
, O
rheumatology O
referral O
) O
may O
be O
appropriate O
for O
certain O
patients O
5.6 O
Long-Term O
Suppression O
of O
Growth O
Careful O
follow-up O
of O
weight O
and O
height O
in O
children O
ages O
7 O
to O
10 O
years O
who O
were O
randomized O
to O
either O
methylphenidate O
or O
non-medication O
treatment O
groups O
over O
14 O
months O
, O
as O
well O
as O
in O
naturalistic O
subgroups O
of O
newly O
methylphenidate-treated O
and O
non-medication O
treated O
children O
over O
36 O
months O
( O
to O
the O
ages O
of O
10 O
to O
13 O
years O
) O
, O
suggests O
that O
consistently O
medicated O
children O
( O
i.e. O
, O
treatment O
for O
7 O
days O
per O
week O
throughout O
the O
year O
) O
have O
a O
temporary O
slowing B-OSE_Labeled_AE
in I-OSE_Labeled_AE
growth I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
( O
on O
average O
, O
a O
total O
of O
about O
2 O
cm O
less B-OSE_Labeled_AE
growth I-OSE_Labeled_AE
in I-OSE_Labeled_AE
height I-OSE_Labeled_AE
and O
2.7 O
kg O
less B-OSE_Labeled_AE
growth I-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
over O
3 O
years O
) O
, O
without O
evidence O
of O
growth O
rebound O
during O
this O
period O
of O
development O
. O

Published O
data O
are O
inadequate O
to O
determine O
whether O
chronic O
use O
of O
amphetamines O
may O
cause O
a O
similar O
suppression B-NonOSE_AE
of I-NonOSE_AE
growth I-NonOSE_AE
, O
however O
, O
it O
is O
anticipated O
that O
they O
likely O
have O
this O
effect O
as O
well O
. O

Therefore O
, O
growth O
should O
be O
monitored O
during O
treatment O
with O
stimulants O
, O
and O
patients O
who O
are O
not B-NonOSE_AE
growing I-NonOSE_AE
or O
gaining O
height O
or O
weight O
as O
expected O
may O
need O
to O
have O
their O
treatment O
interrupted O
. O

5.7 O
Chemical B-OSE_Labeled_AE
Leukoderma I-OSE_Labeled_AE
Daytrana O
use O
may O
result O
in O
a O
persistent O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
skin I-OSE_Labeled_AE
pigmentation I-OSE_Labeled_AE
at I-OSE_Labeled_AE
and I-OSE_Labeled_AE
around I-OSE_Labeled_AE
the I-OSE_Labeled_AE
application I-OSE_Labeled_AE
site I-OSE_Labeled_AE
. O

Loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
pigmentation I-OSE_Labeled_AE
, O
in O
some O
cases O
, O
has O
been O
reported O
at O
other O
sites O
distant O
from O
the O
application O
site O
. O

Chemical B-NonOSE_AE
leukoderma I-NonOSE_AE
can O
mimic O
the O
appearance O
of O
vitiligo B-NonOSE_AE
, O
particularly O
when O
the O
loss B-NonOSE_AE
of I-NonOSE_AE
skin I-NonOSE_AE
pigmentation I-NonOSE_AE
involves I-NonOSE_AE
areas I-NonOSE_AE
distant I-NonOSE_AE
from I-NonOSE_AE
the I-NonOSE_AE
application I-NonOSE_AE
site I-NonOSE_AE
. O

Individuals O
with O
a O
history O
of O
vitiligo B-Not_AE_Candidate
and/or O
a O
family O
history O
of O
vitiligo B-Not_AE_Candidate
may O
be O
more O
at O
risk O
. O

Skin B-NonOSE_AE
depigmentation I-NonOSE_AE
may O
persist O
even O
after O
Daytrana O
use O
is O
discontinued O
. O

Monitor O
for O
signs O
of O
skin B-NonOSE_AE
depigmentation I-NonOSE_AE
, O
and O
advise O
patients O
to O
immediately O
inform O
their O
healthcare O
provider O
if O
changes B-NonOSE_AE
in I-NonOSE_AE
skin I-NonOSE_AE
pigmentation I-NonOSE_AE
occur O
. O

Discontinue O
the O
Daytrana O
patch O
in O
patients O
with O
chemical B-NonOSE_AE
leukoderma I-NonOSE_AE
. O

5.8 O
Contact O
Sensitization O
In O
an O
open-label O
study O
of O
305 O
subjects O
conducted O
to O
characterize O
dermal B-NonOSE_AE
reactions I-NonOSE_AE
in O
children O
with O
ADHD B-Not_AE_Candidate
treated O
with O
Daytrana O
using O
a O
9-hour O
wear O
time O
, O
one O
subject O
( O
0.3 O
% O
) O
was O
confirmed O
by O
patch O
testing O
to O
be O
sensitized B-OSE_Labeled_AE
to I-OSE_Labeled_AE
methylphenidate I-OSE_Labeled_AE
( O
allergic B-OSE_Labeled_AE
contact I-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
) O
. O

This O
subject O
experienced O
erythema B-OSE_Labeled_AE
and O
edema O
at I-OSE_Labeled_AE
Daytrana I-OSE_Labeled_AE
application I-OSE_L
abeled B-OSE_Labeled_AE
_ I-OSE_Labeled_AE
AE I-OSE_Labeled_AE
sites I-OSE_Labeled_AE
  I-OSE_Labeled_AE
I I-OSE_Labeled_AE
- I-OSE_Labeled_AE
OSE I-OSE_Labeled_AE
_ I-OSE_Labeled_AE
Labeled I-OSE_Labeled_AE
_ I-OSE_Labeled_AE
AE I-OSE_Labeled_AE
with I-OSE_Labeled_AE
concurrent O
urticarial B-OSE_Labeled_AE
lesions I-OSE_Labeled_AE
on I-OSE_Labeled_AE
the I-OSE_Labeled_AE
abdomen I-OSE_Labeled_AE
and O
legs O
resulting O
in O
treatment O
discontinuation O
. O

This O
subject O
was O
not O
transitioned O
to O
oral O
methylphenidate O
. O

Use O
of O
Daytrana O
may O
lead O
to O
contact B-OSE_Labeled_AE
sensitization I-OSE_Labeled_AE
. O

Daytrana O
should O
be O
discontinued O
if O
contact B-NonOSE_AE
sensitization I-NonOSE_AE
is O
suspected O
. O

Erythema B-OSE_Labeled_AE
is O
commonly O
seen O
with O
use O
of O
Daytrana O
and O
is O
not O
by O
itself O
an O
indication O
of O
sensitization B-NonOSE_AE
. O

However O
, O
contact B-NonOSE_AE
sensitization I-NonOSE_AE
should O
be O
suspected O
if O
erythema B-NonOSE_AE
is O
accompanied O
by O
evidence O
of O
a O
more O
intense O
local B-NonOSE_AE
reaction I-NonOSE_AE
( O
edema O
, O
papules O
, O
vesicles O
) O
that O
does O
not O
significantly O
improve O
within O
48 O
hours O
or O
spreads O
beyond O
the O
patch O
site O
. O

Confirmation O
of O
a O
diagnosis O
of O
contact B-NonOSE_AE
sensitization I-NonOSE_AE
( O
allergic B-NonOSE_AE
contact I-NonOSE_AE
dermatitis I-NonOSE_AE
) O
may O
require O
further O
diagnostic O
testing O
. O

Patients O
sensitized B-OSE_Labeled_AE
from I-OSE_Labeled_AE
use I-OSE_Labeled_AE
of I-OSE_Labeled_AE
Daytrana I-OSE_Labeled_AE
, O
as O
evidenced O
by O
development O
of O
an O
allergic B-OSE_Labeled_AE
contact I-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
may O
develop O
systemic B-OSE_Labeled_AE
sensitization I-OSE_Labeled_AE
or O
other O
systemic O
reactions O
if O
methylphenidate-containing O
products O
are O
taken O
via O
other O
routes O
, O
e.g. O
, O
orally O
. O

Manifestations O
of O
systemic B-NonOSE_AE
sensitization I-NonOSE_AE
may O
include O
a O
flare B-NonOSE_AE
- I-NonOSE_AE
up I-NonOSE_AE
of I-NonOSE_AE
previous I-NonOSE_AE
dermatitis I-NonOSE_AE
or O
of O
prior O
positive O
patch-test O
sites O
, O
or O
generalized B-NonOSE_AE
skin I-NonOSE_AE
eruptions I-NonOSE_AE
in O
previously O
unaffected O
skin O
. O

Other O
systemic O
reactions O
may O
include O
headache B-NonOSE_AE
, O
fever B-NonOSE_AE
, O
malaise B-NonOSE_AE
, O
arthralgia B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
, O
or O
vomiting B-NonOSE_AE
. O

No O
cases O
of O
systemic B-NonOSE_AE
sensitization I-NonOSE_AE
have O
been O
observed O
in O
clinical O
trials O
of O
Daytrana O
. O

Patients O
who O
develop O
contact B-NonOSE_AE
sensitization I-NonOSE_AE
to O
Daytrana O
and O
require O
oral O
treatment O
with O
methylphenidate O
should O
be O
initiated O
on O
oral O
medication O
under O
close O
medical O
supervision O
. O

It O
is O
possible O
that O
some O
patients O
sensitized B-NonOSE_AE
to I-NonOSE_AE
methylphenidate I-NonOSE_AE
by O
exposure O
to O
Daytrana O
may O
not O
be O
able O
to O
take O
methylphenidate O
in O
any O
form O
. O

5.9 O
Visual B-OSE_Labeled_AE
Disturbance I-OSE_Labeled_AE
Difficulties B-OSE_Labeled_AE
with I-OSE_Labeled_AE
accommodation I-OSE_Labeled_AE
and O
blurring B-OSE_Labeled_AE
of I-OSE_Labeled_AE
vision I-OSE_Labeled_AE
have O
been O
reported O
with O
stimulant O
treatment O
. O

5.10 O
Patients O
Using O
External O
Heat O
Patients O
should O
be O
advised O
to O
avoid O
exposing O
the O
Daytrana O
application O
site O
to O
direct B-NonOSE_AE
external I-NonOSE_AE
heat I-NonOSE_AE
sources I-NonOSE_AE
, O
such O
as O
hair O
dryers O
, O
heating O
pads O
, O
electric O
blankets O
, O
heated O
water O
beds O
, O
etc. O
, O
while O
wearing O
the O
patch O
. O

When O
heat O
is O
applied O
to O
Daytrana O
after O
patch O
application O
, O
both O
the O
rate O
and O
extent O
of O
absorption O
are O
significantly O
increased O
. O

The O
temperature-dependent O
increase O
in O
methylphenidate O
absorption O
can O
be O
greater O
than O
2-fold O
[ O
see O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

This O
increased O
absorption O
can O
be O
clinically O
significant O
and O
can O
result O
in O
overdose O
of O
methylphenidate O
[ O
see O
Overdosage O
( O
10 O
) O
] O
. O

5.11 O
Hematologic O
Monitoring O
Periodic O
CBC O
, O
differential O
, O
and O
platelet O
counts O
are O
advised O
during O
prolonged O
therapy O
. O

ADVERSE O
REACTIONS O
( O
Listed O
alphabetically O
, O
under O
each O
subsection O
) O
The O
following O
adverse O
reactions O
have O
been O
reported O
with O
dexamethasone O
or O
other O
corticosteroids O
: O
Allergic O
Reactions O
Anaphylactoid B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
anaphylaxis B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
. O

Cardiovascular O
Bradycardia B-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
arrhythmias I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
enlargement I-OSE_Labeled_AE
, O
circulatory B-OSE_Labeled_AE
collapse I-OSE_Labeled_AE
, O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
fat B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
hypertrophic B-OSE_Labeled_AE
cardiomyopathy I-OSE_Labeled_AE
in I-OSE_Labeled_AE
premature I-OSE_Labeled_AE
infants I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
following O
recent O
myocardial B-Not_AE_Candidate
infarction I-Not_AE_Candidate
( O
see O
WARNINGS O
: O
Cardio-Renal O
) O
, O
edema B-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
, O
thromboembolism B-OSE_Labeled_AE
, O
thrombophlebitis B-OSE_Labeled_AE
, O
vasculitis B-OSE_Labeled_AE
. O

Dermatologic O
Acne B-OSE_Labeled_AE
, O
allergic B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
scaly O
skin I-OSE_Labeled_AE
, O
ecchymoses B-OSE_Labeled_AE
and O
petechiae B-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
, O
impaired B-OSE_Labeled_AE
wound I-OSE_Labeled_AE
healing I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
sweating I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
striae B-OSE_Labeled_AE
, O
suppression B-OSE_Labeled_AE
of I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
to I-OSE_Labeled_AE
skin I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
, O
thin B-OSE_Labeled_AE
fragile I-OSE_Labeled_AE
skin I-OSE_Labeled_AE
, O
thinning B-OSE_Labeled_AE
scalp I-OSE_Labeled_AE
hair I-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
. O

Endocrine O
Decreased B-OSE_Labeled_AE
carbohydrate I-OSE_Labeled_AE
and O
glucose O
tolerance I-OSE_Labeled_AE
, O
development O
of O
cushingoid B-OSE_Labeled_AE
state I-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
glycosuria B-OSE_Labeled_AE
, O
hirsutism B-OSE_Labeled_AE
, O
hypertrichosis B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
requirements I-OSE_Labeled_AE
for I-OSE_Labeled_AE
insulin I-OSE_Labeled_AE
or O
oral O
hypoglycemic O
agents O
in I-OSE_Labeled_AE
diabetes I-OSE_Labeled_AE
, O
manifestations O
of O
latent B-OSE_Labeled_AE
diabetes I-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
, O
menstrual B-OSE_Labeled_AE
irregularities I-OSE_Labeled_AE
, O
secondary B-OSE_Labeled_AE
adrenocortical I-OSE_Labeled_AE
and O
pituitary O
unresponsiveness I-OSE_Labeled_AE
( O
particularly O
in O
times O
of O
stress B-Not_AE_Candidate
, O
as O
in O
trauma O
, O
surgery O
, O
or O
illness B-Not_AE_Candidate
) O
, O
suppression B-OSE_Labeled_AE
of I-OSE_Labeled_AE
growth I-OSE_Labeled_AE
in I-OSE_Labeled_AE
pediatric I-OSE_Labeled_AE
patients I-OSE_Labeled_AE
. O

Fluid O
and O
Electrolyte O
Disturbances O
Congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
in O
susceptible O
patients O
, O
fluid B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
, O
hypokalemic B-OSE_Labeled_AE
alkalosis I-OSE_Labeled_AE
, O
potassium B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
sodium B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
. O

Gastrointestinal O
Abdominal B-OSE_Labeled_AE
distention I-OSE_Labeled_AE
, O
elevation B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
enzyme I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
( O
usually O
reversible O
upon O
discontinuation O
) O
, O
hepatomegaly B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
, O
peptic B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
with O
possible O
perforation O
and O
hemorrhage O
, O
perforation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
small I-OSE_Labeled_AE
and O
large O
intestine I-OSE_Labeled_AE
( O
particularly O
in O
patients O
with O
inflammatory B-Not_AE_Candidate
bowel I-Not_AE_Candidate
disease I-Not_AE_Candidate
) O
, O
ulcerative B-OSE_Labeled_AE
esophagitis I-OSE_Labeled_AE
. O

Metabolic O
Negative B-NonOSE_AE
nitrogen I-NonOSE_AE
balance I-NonOSE_AE
due O
to O
protein B-OSE_Labeled_AE
catabolism I-OSE_Labeled_AE
. O

Musculoskeletal O
Aseptic B-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
of I-OSE_Labeled_AE
femoral I-OSE_Labeled_AE
and O
humeral O
heads I-OSE_Labeled_AE
, O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
muscle I-OSE_Labeled_AE
mass I-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
, O
osteoporosis B-OSE_Labeled_AE
, O
pathologic B-OSE_Labeled_AE
fracture I-OSE_Labeled_AE
of I-OSE_Labeled_AE
long I-OSE_Labeled_AE
bones I-OSE_Labeled_AE
, O
steroid B-OSE_Labeled_AE
myopathy I-OSE_Labeled_AE
, O
tendon B-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
, O
vertebral B-OSE_Labeled_AE
compression I-OSE_Labeled_AE
fractures I-OSE_Labeled_AE
. O

Neurological/Psychiatric O
Convulsions B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
emotional B-OSE_Labeled_AE
instability I-OSE_Labeled_AE
, O
euphoria B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
intracranial I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
with O
papilledema B-OSE_Labeled_AE
( O
pseudotumor B-OSE_Labeled_AE
cerebri I-OSE_Labeled_AE
) O
usually O
following O
discontinuation O
of O
treatment O
, O
insomnia B-OSE_Labeled_AE
, O
mood B-OSE_Labeled_AE
swings I-OSE_Labeled_AE
, O
neuritis B-OSE_Labeled_AE
, O
neuropathy B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
personality B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
, O
psychic B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
vertigo B-OSE_Labeled_AE
. O

Ophthalmic O
Exophthalmos B-OSE_Labeled_AE
, O
glaucoma B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
intraocular I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
, O
posterior B-OSE_Labeled_AE
subcapsular I-OSE_Labeled_AE
cataracts I-OSE_Labeled_AE
. O

Other O
Abnormal B-OSE_Labeled_AE
fat I-OSE_Labeled_AE
deposits I-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
resistance I-OSE_Labeled_AE
to I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
hiccups B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
or O
decreased O
motility I-OSE_Labeled_AE
and O
number O
of I-OSE_Labeled_AE
spermatozoa I-OSE_Labeled_AE
, O
malaise B-OSE_Labeled_AE
, O
moon B-OSE_Labeled_AE
face I-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
. O

PRECAUTIONS O
General O
The O
lowest O
possible O
dose O
of O
corticosteroids O
should O
be O
used O
to O
control O
the O
condition O
under O
treatment O
. O

When O
reduction O
in O
dosage O
is O
possible O
, O
the O
reduction O
should O
be O
gradual O
. O

Since O
complications O
of O
treatment O
with O
corticosteroids O
are O
dependent O
on O
the O
size O
of O
the O
dose O
and O
the O
duration O
of O
treatment O
, O
a O
risk/benefit O
decision O
must O
be O
made O
in O
each O
individual O
case O
as O
to O
dose O
and O
duration O
of O
treatment O
and O
as O
to O
whether O
daily O
or O
intermittent O
therapy O
should O
be O
used O
. O

Kaposi B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
sarcoma I-OSE_Labeled_AE
has O
been O
reported O
to O
occur O
in O
patients O
receiving O
corticosteroid O
therapy O
, O
most O
often O
for O
chronic O
conditions O
. O

Discontinuation O
of O
corticosteroids O
may O
result O
in O
clinical O
improvement O
. O

Cardio-Renal O
As O
sodium B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
with O
resultant O
edema B-NonOSE_AE
and O
potassium B-NonOSE_AE
loss I-NonOSE_AE
may O
occur O
in O
patients O
receiving O
corticosteroids O
, O
these O
agents O
should O
be O
used O
with O
caution O
in O
patients O
with O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
hypertension B-Not_AE_Candidate
, O
or O
renal B-Not_AE_Candidate
insufficiency I-Not_AE_Candidate
Endocrine O
Drug B-OSE_Labeled_AE
- I-OSE_Labeled_AE
induced I-OSE_Labeled_AE
secondary I-OSE_Labeled_AE
adrenocortical I-OSE_Labeled_AE
insufficiency I-OSE_Labeled_AE
may O
be O
minimized O
by O
gradual O
reduction O
of O
dosage O
. O

This O
type O
of O
relative O
insufficiency O
may O
persist O
for O
months O
after O
discontinuation O
of O
therapy O
; O
therefore O
, O
in O
any O
situation O
of O
stress B-Not_AE_Candidate
occurring O
during O
that O
period O
, O
hormone O
therapy O
should O
be O
reinstituted O
. O

Since O
mineralocorticoid B-NonOSE_AE
secretion I-NonOSE_AE
may O
be O
impaired I-NonOSE_AE
, O
salt O
and/or O
a O
mineralocorticoid O
should O
be O
administered O
concurrently O
. O

Gastrointestinal O
Steroids O
should O
be O
used O
with O
caution O
in O
active O
or O
latent O
peptic B-Not_AE_Candidate
ulcers I-Not_AE_Candidate
, O
diverticulitis B-Not_AE_Candidate
, O
fresh B-Not_AE_Candidate
intestinal I-Not_AE_Candidate
anastomoses I-Not_AE_Candidate
, O
and O
nonspecific O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
, O
since O
they O
may O
increase O
the O
risk O
of O
a O
perforation B-NonOSE_AE
. O

Signs O
of O
peritoneal B-NonOSE_AE
irritation I-NonOSE_AE
following O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
in O
patients O
receiving O
corticosteroids O
may O
be O
minimal O
or O
absent O
. O

There O
is O
an O
enhanced O
effect O
due O
to O
decreased O
metabolism O
of O
corticosteroids O
in O
patients O
with O
cirrhosis B-Not_AE_Candidate
. O

Musculoskeletal O
Corticosteroids O
decrease B-OSE_Labeled_AE
bone I-OSE_Labeled_AE
formation I-OSE_Labeled_AE
and O
increase B-OSE_Labeled_AE
bone I-OSE_Labeled_AE
resorption I-OSE_Labeled_AE
both O
through O
their O
effect B-OSE_Labeled_AE
on I-OSE_Labeled_AE
calcium I-OSE_Labeled_AE
regulation I-OSE_Labeled_AE
( O
i.e. O
, O
decreasing O
absorption O
and O
increasing O
excretion O
) O
and O
inhibition B-OSE_Labeled_AE
of I-OSE_Labeled_AE
osteoblast I-OSE_Labeled_AE
function I-OSE_Labeled_AE
. O

This O
, O
together O
with O
a O
decrease B-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
protein I-NonOSE_AE
matrix I-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
bone I-NonOSE_AE
secondary O
to O
an O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
protein I-OSE_Labeled_AE
catabolism I-OSE_Labeled_AE
, O
and O
reduced B-OSE_Labeled_AE
sex I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
production I-OSE_Labeled_AE
, O
may O
lead O
to O
inhibition B-OSE_Labeled_AE
of I-OSE_Labeled_AE
bone I-OSE_Labeled_AE
growth I-OSE_Labeled_AE
in O
pediatric O
patients O
and O
the O
development O
of O
osteoporosis B-OSE_Labeled_AE
at O
any O
age O
. O

Special O
consideration O
should O
be O
given O
to O
patients O
at O
increased O
risk O
of O
osteoporosis B-Not_AE_Candidate
( O
e.g. O
, O
postmenopausal B-Not_AE_Candidate
women O
) O
before O
initiating O
corticosteroid O
therapy O
. O

Neuro-Psychiatric O
Although O
controlled O
clinical O
trials O
have O
shown O
corticosteroids O
to O
be O
effective O
in O
speeding O
the O
resolution O
of O
acute B-Not_AE_Candidate
exacerbations I-Not_AE_Candidate
of I-Not_AE_Candidate
multiple I-Not_AE_Candidate
sclerosis I-Not_AE_Candidate
, O
they O
do O
not O
show O
that O
they O
affect O
the O
ultimate O
outcome O
or O
natural O
history O
of O
the O
disease O
. O

The O
studies O
do O
show O
that O
relatively O
high O
doses O
of O
corticosteroids O
are O
necessary O
to O
demonstrate O
a O
significant O
effect O
( O
see O
DOSAGE O
AND O
ADMINISTRATION O
) O
. O

An O
acute B-OSE_Labeled_AE
myopathy I-OSE_Labeled_AE
has O
been O
observed O
with O
the O
use O
of O
high O
doses O
of O
corticosteroids O
, O
most O
often O
occurring O
in O
patients O
with O
disorders B-Not_AE_Candidate
of I-Not_AE_Candidate
neuromuscular I-Not_AE_Candidate
transmission I-Not_AE_Candidate
( O
e.g. O
, O
myasthenia B-Not_AE_Candidate
gravis I-Not_AE_Candidate
) O
, O
or O
in O
patients O
receiving O
concomitant O
therapy O
with O
neuromuscular O
blocking O
drugs O
( O
e.g. O
, O
pancuronium O
) O
. O

This O
acute B-NonOSE_AE
myopathy I-NonOSE_AE
is O
generalized O
, O
may O
involve O
ocular O
and O
respiratory O
muscles O
, O
and O
may O
result O
in O
quadriparesis B-NonOSE_AE
. O

Elevation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
kinase I-OSE_Labeled_AE
may O
occur O
. O

Clinical O
improvement O
or O
recovery O
after O
stopping O
corticosteroids O
may O
require O
weeks O
to O
years O
. O

Psychic B-OSE_Labeled_AE
derangements I-OSE_Labeled_AE
may O
appear O
when O
corticosteroids O
are O
used O
, O
ranging O
from O
euphoria B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
mood B-OSE_Labeled_AE
swings I-OSE_Labeled_AE
, O
personality B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
, O
and O
severe B-OSE_Labeled_AE
depression I-OSE_Labeled_AE
, O
to O
frank O
psychotic B-OSE_Labeled_AE
manifestations I-OSE_Labeled_AE
. O

Also O
, O
existing O
emotional B-OSE_Labeled_AE
instability I-OSE_Labeled_AE
or O
psychotic O
tendencies O
may O
be O
aggravated I-OSE_Labeled_AE
by O
corticosteroids O
. O

Ophthalmic O
lntraocular B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
may O
become O
elevated I-OSE_Labeled_AE
in O
some O
individuals O
. O

If O
steroid O
therapy O
is O
continued O
for O
more O
than O
6 O
weeks O
, O
intraocular O
pressure O
should O
be O
monitored O
. O

Information O
for O
Patients O
Patients O
should O
be O
warned O
not O
to O
discontinue O
the O
use O
of O
corticosteroids O
abruptly O
or O
without O
medical O
supervision O
. O

As O
prolonged O
use O
may O
cause O
adrenal B-NonOSE_AE
insufficiency I-NonOSE_AE
and O
make O
patients O
dependent B-NonOSE_AE
on O
corticosteroids O
, O
they O
should O
advise O
any O
medical O
attendants O
that O
they O
are O
taking O
corticosteroids O
and O
they O
should O
seek O
medical O
advice O
at O
once O
should O
they O
develop O
an O
acute B-NonOSE_AE
illness I-NonOSE_AE
including O
fever B-NonOSE_AE
or O
other O
signs O
of O
infection B-NonOSE_AE
. O

Following O
prolonged O
therapy O
, O
withdrawal O
of O
corticosteroids O
may O
result O
in O
symptoms O
of O
the O
corticosteroid B-NonOSE_AE
withdrawal I-NonOSE_AE
syndrome I-NonOSE_AE
including O
, O
myalgia B-NonOSE_AE
, O
arthralgia B-NonOSE_AE
, O
and O
malaise B-NonOSE_AE
. O

Persons O
who O
are O
on O
corticosteroids O
should O
be O
warned O
to O
avoid O
exposure O
to O
chickenpox B-NonOSE_AE
or O
measles B-NonOSE_AE
. O

Patients O
should O
also O
be O
advised O
that O
if O
they O
are O
exposed O
, O
medical O
advice O
should O
be O
sought O
without O
delay O
. O

Drug O
Interactions O
Aminoglutethimide O
: O
Aminoglutethimide O
may O
diminish B-NonOSE_AE
adrenal I-NonOSE_AE
suppression I-NonOSE_AE
by O
corticosteroids O
. O

Amphotericin O
B O
Injection O
and O
Potassium-depleting O
agents O
: O
When O
corticosteroids O
are O
administered O
concomitantly O
with O
potassium-depleting O
agents O
( O
e.g. O
, O
amphotericin O
B O
, O
diuretics O
) O
, O
patients O
should O
be O
observed O
closely O
for O
development O
of O
hypokalemia B-NonOSE_AE
. O

In O
addition O
, O
there O
have O
been O
cases O
reported O
in O
which O
concomitant O
use O
of O
amphotericin O
B O
and O
hydrocortisone O
was O
followed O
by O
cardiac B-NonOSE_AE
enlargement I-NonOSE_AE
and O
congestive B-NonOSE_AE
heart I-NonOSE_AE
failure I-NonOSE_AE
. O

Antibiotics O
: O
Macrolide O
antibiotics O
have O
been O
reported O
to O
cause O
a O
significant O
decrease O
in O
corticosteroid O
clearance O
( O
see O
Drug O
Interactions O
: O
Hepatic O
Enzyme O
Inducers O
, O
Inhibitors O
and O
Substrates O
) O
. O

Anticholinesterases O
: O
Concomitant O
use O
of O
anticholinesterase O
agents O
and O
corticosteroids O
may O
produce O
severe B-NonOSE_AE
weakness I-NonOSE_AE
in O
patients O
with O
myasthenia B-Not_AE_Candidate
gravis I-Not_AE_Candidate
. O

If O
possible O
, O
anticholinesterase O
agents O
should O
be O
withdrawn O
at O
least O
24 O
hours O
before O
initiating O
corticosteroid O
therapy O
. O

Anticoagulants O
, O
Oral O
: O
Co-administration O
of O
corticosteroids O
and O
warfarin O
usually O
results O
in O
inhibition O
of O
response O
to O
warfarin O
, O
although O
there O
have O
been O
some O
conflicting O
reports O
. O

Therefore O
, O
coagulation O
indices O
should O
be O
monitored O
frequently O
to O
maintain O
the O
desired O
anticoagulant B-NonOSE_AE
effect I-NonOSE_AE
. O

Antidiabetics O
: O
Because O
corticosteroids O
may O
increase B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
concentrations I-OSE_Labeled_AE
, O
dosage O
adjustments O
of O
antidiabetic O
agents O
may O
be O
required O
. O

Antitubercular O
Drugs O
: O
Serum O
concentrations O
of O
isoniazid O
may O
be O
decreased O
. O

Cholestyramine O
: O
Cholestyramine O
may O
increase O
the O
clearance O
of O
corticosteroids O
. O

Cyclosporine O
: O
Increased O
activity O
of O
both O
cyclosporine O
and O
corticosteroids O
may O
occur O
when O
the O
two O
are O
used O
concurrently O
. O

Convulsions B-NonOSE_AE
have O
been O
reported O
with O
this O
concurrent O
use O
. O

Dexamethasone O
Suppression O
Test O
( O
DST O
) O
: O
False B-NonOSE_AE
- I-NonOSE_AE
negative I-NonOSE_AE
results I-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
dexamethasone I-NonOSE_AE
suppression I-NonOSE_AE
test I-NonOSE_AE
( I-NonOSE_AE
DST I-NonOSE_AE
) O
in O
patients O
being O
treated O
with O
indomethacin O
have O
been O
reported O
. O

Thus O
, O
results O
of O
the O
DST O
should O
be O
interpreted O
with O
caution O
in O
these O
patients O
. O

Digitalis O
Glycosides O
: O
Patients O
on O
digitalis O
glycosides O
may O
be O
at O
increased O
risk O
of O
arrhythmias B-NonOSE_AE
due O
to O
hypokalemia B-NonOSE_AE
. O

Ephedrine O
: O
Ephedrine O
may O
enhance O
the O
metabolic O
clearance O
of O
corticosteroids O
, O
resulting O
in O
decreased O
blood O
levels O
and O
lessened O
physiologic O
activity O
, O
thus O
requiring O
an O
increase O
in O
corticosteroid O
dosage O
. O

Estrogens O
, O
Including O
Oral O
Contraceptives O
: O
Estrogens O
may O
decrease O
the O
hepatic O
metabolism O
of O
certain O
corticosteroids O
, O
thereby O
increasing O
their O
effect O
. O

Hepatic O
Enzyme O
Inducers O
, O
Inhibitors O
and O
Substrates O
: O
Drugs O
which O
induce O
cytochrome O
P450 O
3A4 O
( O
CYP O
3A4 O
) O
enzyme O
activity O
( O
e.g. O
, O
barbiturates O
, O
phenytoin O
, O
carbamazepine O
, O
rifampin O
) O
may O
enhance O
the O
metabolism O
of O
corticosteroids O
and O
require O
that O
the O
dosage O
of O
the O
corticosteroid O
be O
increased O
. O

Drugs O
which O
inhibit O
CYP O
3A4 O
( O
e.g. O
, O
ketoconazole O
, O
macrolide O
antibiotics O
such O
as O
erythromycin O
) O
have O
the O
potential O
to O
result O
in O
increased O
plasma O
concentrations O
of O
corticosteroids O
. O

Dexamethasone O
is O
a O
moderate O
inducer O
of O
CYP O
3A4 O
. O

Co-adminstration O
with O
other O
drugs O
that O
are O
metabolized O
by O
CYP O
3A4 O
( O
e.g. O
, O
indinavir O
, O
erythromycin O
) O
may O
increase O
their O
clearance O
, O
resulting O
in O
decreased O
plasma O
concentration O
. O

Ketoconazole O
: O
Ketoconazole O
has O
been O
reported O
to O
decrease O
the O
metabolism O
of O
certain O
corticosteroids O
by O
up O
to O
60 O
% O
, O
leading O
to O
increased O
risk O
of O
corticosteroid O
side O
effects O
. O

In O
addition O
, O
ketoconazole O
alone O
can O
inhibit B-NonOSE_AE
adrenal I-NonOSE_AE
corticosteroid I-NonOSE_AE
synthesis I-NonOSE_AE
and O
may O
cause O
adrenal B-NonOSE_AE
insufficiency I-NonOSE_AE
during O
corticosteroid O
withdrawal O
. O

Nonsteroidal O
Anti-Inflammatory O
Agents O
( O
NSAIDS O
) O
: O
Concomitant O
use O
of O
aspirin O
( O
or O
other O
nonsteroidal O
antiinflammatory O
agents O
) O
and O
corticosteroids O
increases O
the O
risk O
of O
gastrointestinal B-NonOSE_AE
side I-NonOSE_AE
effects I-NonOSE_AE
. O

Aspirin O
should O
be O
used O
cautiously O
in O
conjunction O
with O
corticosteroids O
in O
hypoprothrombinemia B-Not_AE_Candidate
. O

The O
clearance O
of O
salicylates O
may O
be O
increased O
with O
concurrent O
use O
of O
corticosteroids O
. O

Phenytoin O
: O
In O
post-marketing O
experience O
, O
there O
have O
been O
reports O
of O
both O
increases O
and O
decreases O
in O
phenytoin O
levels O
with O
dexamethasone O
co-administration O
, O
leading O
to O
alterations O
in O
seizure B-NonOSE_AE
control O
. O

Skin O
Tests O
: O
Corticosteroids O
may O
suppress B-NonOSE_AE
reactions I-NonOSE_AE
to I-NonOSE_AE
skin I-NonOSE_AE
tests I-NonOSE_AE
. O

Thalidomide O
: O
Co-administration O
with O
thalidomide O
should O
be O
employed O
cautiously O
, O
as O
toxic B-NonOSE_AE
epidermal I-NonOSE_AE
necrolysis I-NonOSE_AE
has O
been O
reported O
with O
concomitant O
use O
. O

Vaccines O
: O
Patients O
on O
corticosteroid O
therapy O
may O
exhibit O
a O
diminished O
response O
to O
toxoids O
and O
live O
or O
inactivated O
vaccines O
due O
to O
inhibition B-NonOSE_AE
of I-NonOSE_AE
antibody I-NonOSE_AE
response I-NonOSE_AE
. O

Corticosteroids O
may O
also O
potentiate B-NonOSE_AE
the I-NonOSE_AE
replication I-NonOSE_AE
of I-NonOSE_AE
some I-NonOSE_AE
organisms I-NonOSE_AE
contained I-NonOSE_AE
in I-NonOSE_AE
live I-NonOSE_AE
attenuated I-NonOSE_AE
vaccines I-NonOSE_AE
. O

Routine O
administration O
of O
vaccines O
or O
toxoids O
should O
be O
deferred O
until O
corticosteroid O
therapy O
is O
discontinued O
if O
possible O
( O
see O
WARNINGS O
: O
Infections O
: O
Vaccination O
) O
. O

Carcinogenesis O
, O
Mutagenesis O
, O
Impairment O
of O
Fertility O
No O
adequate O
studies O
have O
been O
conducted O
in O
animals O
to O
determine O
whether O
corticosteroids O
have O
a O
potential O
for O
carcinogenesis B-NonOSE_AE
or O
mutagenesis B-NonOSE_AE
. O

Steroids O
may O
increase B-OSE_Labeled_AE
or O
decrease O
motility I-OSE_Labeled_AE
and O
number O
of I-OSE_Labeled_AE
spermatozoa I-OSE_Labeled_AE
in O
some O
patients O
. O

Pregnancy O
Teratogenic O
Effects O
: O
Pregnancy B-NonOSE_AE
Category O
C O
: O
Corticosteroids O
have O
been O
shown O
to O
be O
teratogenic B-NonOSE_AE
in O
many O
species O
when O
given O
in O
doses O
equivalent O
to O
the O
human O
dose O
. O

Animal O
studies O
in O
which O
corticosteroids O
have O
been O
given O
to O
pregnant B-NonOSE_AE
mice O
, O
rats O
, O
and O
rabbits O
have O
yielded O
an O
increased O
incidence O
of O
cleft B-NonOSE_AE
palate I-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
offspring I-NonOSE_AE
. O

There O
are O
no O
adequate O
and O
well-controlled O
studies O
in O
pregnant B-Not_AE_Candidate
women O
. O

Corticosteroids O
should O
be O
used O
during O
pregnancy B-Not_AE_Candidate
only O
if O
the O
potential O
benefit O
justifies O
the O
potential O
risk B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

Infants B-NonOSE_AE
born O
to O
mothers O
who O
have O
received O
substantial O
doses O
of O
corticosteroids O
during O
pregnancy O
shou O
ld B-Not_AE_Candidate
be I-Not_AE_Candidate
car I-Not_AE_Candidate
efully O
observed O
for O
signs O
of O
hypoadrenalism I-NonOSE_AE
. O

Nursing O
Mothers O
Systemically O
administered O
corticosteroids O
appear O
in O
human O
milk O
and O
could O
suppress B-OSE_Labeled_AE
growth I-OSE_Labeled_AE
, O
interfere B-OSE_Labeled_AE
with I-OSE_Labeled_AE
endogenous I-OSE_Labeled_AE
corticosteroid I-OSE_Labeled_AE
production I-OSE_Labeled_AE
, O
or O
cause O
other O
untoward O
effects O
. O

Because O
of O
the O
potential O
for O
serious O
adverse B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
in I-OSE_Labeled_AE
nursing I-OSE_Labeled_AE
infants I-OSE_Labeled_AE
from I-OSE_Labeled_AE
corticosteroids I-OSE_Labeled_AE
, O
a O
decision O
should O
be O
made O
whether O
to O
discontinue O
nursing O
or O
to O
discontinue O
the O
drug O
, O
taking O
into O
account O
the O
importance O
of O
the O
drug O
to O
the O
mother O
. O

Pediatric O
Use O
The O
efficacy O
and O
safety O
of O
corticosteroids O
in O
the O
pediatric O
population O
are O
based O
on O
the O
well-established O
course O
of O
effect O
of O
corticosteroids O
, O
which O
is O
similar O
in O
pediatric O
and O
adult O
populations O
. O

Published O
studies O
provide O
evidence O
of O
efficacy O
and O
safety O
in O
pediatric O
patients O
for O
the O
treatment O
of O
nephrotic B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
( O
patients O
> O
2 O
years O
of O
age O
) O
, O
and O
aggressive O
lymphomas B-Not_AE_Candidate
and O
leukemias B-Not_AE_Candidate
( O
patients O
> O
1 O
month O
of O
age O
) O
. O

Other O
indications O
for O
pediatric O
use O
of O
corticosteroids O
, O
e.g. O
, O
severe O
asthma B-Not_AE_Candidate
and O
wheezing B-Not_AE_Candidate
, O
are O
based O
on O
adequate O
and O
well-controlled O
trials O
conducted O
in O
adults O
, O
on O
the O
premises O
that O
the O
course O
of O
the O
diseases O
and O
their O
pathophysiology O
are O
considered O
to O
be O
substantially O
similar O
in O
both O
populations O
. O

The O
adverse O
effects O
of O
corticosteroids O
in O
pediatric O
patients O
are O
similar O
to O
those O
in O
adults O
( O
see O
ADVERSE O
REACTIONS O
) O
. O

Like O
adults O
, O
pediatric O
patients O
should O
be O
carefully O
observed O
with O
frequent O
measurements O
of O
blood O
pressure O
, O
weight O
, O
height O
, O
intraocular O
pressure O
, O
and O
clinical O
evaluation O
for O
the O
presence O
of O
infection B-NonOSE_AE
, O
psychosocial B-NonOSE_AE
disturbances I-NonOSE_AE
, O
thromboembolism B-NonOSE_AE
, O
peptic B-NonOSE_AE
ulcers I-NonOSE_AE
, O
cataracts B-NonOSE_AE
, O
and O
osteoporosis B-NonOSE_AE
. O

Pediatric O
patients O
who O
are O
treated O
with O
corticosteroids O
by O
any O
route O
, O
including O
systemically O
administered O
corticosteroids O
, O
may O
experience O
a O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
their I-OSE_Labeled_AE
growth I-OSE_Labeled_AE
velocity I-OSE_Labeled_AE
. O

This O
negative B-OSE_Labeled_AE
impact I-OSE_Labeled_AE
of O
corticosteroids O
on I-OSE_Labeled_AE
growth I-OSE_Labeled_AE
has O
been O
observed O
at O
low O
systemic O
doses O
and O
in O
the O
absence O
of O
laboratory O
evidence O
of O
hypothalamic B-NonOSE_AE
- I-NonOSE_AE
pituitary I-NonOSE_AE
- I-NonOSE_AE
adrenal I-NonOSE_AE
( I-NonOSE_AE
HPA I-NonOSE_AE
) I-NonOSE_AE
axis I-NonOSE_AE
suppression I-NonOSE_AE
( O
i.e. O
, O
cosyntropin O
stimulation O
and O
basal O
cortisol O
plasma O
levels O
) O
. O

Growth O
velocity O
may O
therefore O
be O
a O
more O
sensitive O
indicator O
of O
systemic O
corticosteroid O
exposure O
in O
pediatric O
patients O
than O
some O
commonly O
used O
tests O
of O
HPA O
axis O
function O
. O

The O
linear O
growth O
of O
pediatric O
patients O
treated O
with O
corticosteroids O
should O
be O
monitored O
, O
and O
the O
potential O
growth B-NonOSE_AE
effects I-NonOSE_AE
of O
prolonged O
treatment O
should O
be O
weighed O
against O
clinical O
benefits O
obtained O
and O
the O
availability O
of O
treatment O
alternatives O
. O

In O
order O
to O
minimize O
the O
potential O
growth B-NonOSE_AE
effects I-NonOSE_AE
of O
corticosteroids O
, O
pediatric O
patients O
should O
be O
titrated O
to O
the O
lowest O
effective O
dose O
. O

Geriatric O
Use O
Clinical O
studies O
did O
not O
include O
sufficient O
numbers O
of O
subjects O
aged O
65 O
and O
over O
to O
determine O
whether O
they O
respond O
differently O
from O
younger O
subjects O
. O

Other O
reported O
clinical O
experience O
has O
not O
identified O
differences O
in O
responses O
between O
the O
elderly O
and O
younger O
patients O
. O

In O
general O
, O
dose O
selection O
for O
an O
elderly O
patient O
should O
be O
cautious O
, O
usually O
starting O
at O
the O
low O
end O
of O
the O
dosing O
range O
, O
reflecting O
the O
greater O
frequency O
of O
decreased B-Not_AE_Candidate
hepatic I-Not_AE_Candidate
, O
renal O
, O
or O
cardiac O
function I-Not_AE_Candidate
, O
and O
of O
concomitant O
disease O
or O
other O
drug O
therapy O
. O

In O
particular O
, O
the O
increased O
risk O
of O
diabetes B-NonOSE_AE
mellitus I-NonOSE_AE
, O
fluid B-NonOSE_AE
retention I-NonOSE_AE
and O
hypertension B-NonOSE_AE
in O
elderly O
patients O
treated O
with O
corticosteroids O
should O
be O
considered O
. O

WARNINGS O
General O
Rare O
instances O
of O
anaphylactoid B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
have O
occurred O
in O
patients O
receiving O
corticosteroid O
therapy O
( O
see O
ADVERSE O
REACTIONS O
) O
. O

Increased O
dosage O
of O
rapidly O
acting O
corticosteroids O
is O
indicated O
in O
patients O
on O
corticosteroid O
therapy O
subjected O
to O
any O
unusual O
stress B-Not_AE_Candidate
before O
, O
during O
, O
and O
after O
the O
stressful B-Not_AE_Candidate
situation O
. O

Cardio-Renal O
Average O
and O
large O
doses O
of O
corticosteroids O
can O
cause O
elevation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
, O
sodium B-OSE_Labeled_AE
and O
water O
retention I-OSE_Labeled_AE
, O
and O
increased B-OSE_Labeled_AE
excretion I-OSE_Labeled_AE
of I-OSE_Labeled_AE
potassium I-OSE_Labeled_AE
. O

These O
effects O
are O
less O
likely O
to O
occur O
with O
the O
synthetic O
derivatives O
except O
when O
used O
in O
large O
doses O
. O

Dietary O
salt O
restriction O
and O
potassium O
supplementation O
may O
be O
necessary O
. O

All O
corticosteroids O
increase B-OSE_Labeled_AE
calcium I-OSE_Labeled_AE
excretion I-OSE_Labeled_AE
. O

Literature O
reports O
suggest O
an O
apparent O
association O
between O
use O
of O
corticosteroids O
and O
left B-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
free I-OSE_Labeled_AE
wall I-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
after O
a O
recent O
myocardial B-Not_AE_Candidate
infarction I-Not_AE_Candidate
; O
therefore O
, O
therapy O
with O
corticosteroids O
should O
be O
used O
with O
great O
caution O
in O
these O
patients O
. O

Endocrine O
Corticosteroids O
can O
produce O
reversible O
hypothalamic B-OSE_Labeled_AE
- I-OSE_Labeled_AE
pituitary I-OSE_Labeled_AE
adrenal I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HPA I-OSE_Labeled_AE
) I-OSE_Labeled_AE
axis I-OSE_Labeled_AE
suppression I-OSE_Labeled_AE
with O
the O
potential O
for O
corticosteroid B-NonOSE_AE
insufficiency I-NonOSE_AE
after O
withdrawal O
of O
treatment O
. O

Adrenocortical B-NonOSE_AE
insufficiency I-NonOSE_AE
may O
result O
from O
too O
rapid O
withdrawal O
of O
corticosteroids O
and O
may O
be O
minimized O
by O
gradual O
reduction O
of O
dosage O
. O

This O
type O
of O
relative O
insufficiency O
may O
persist O
for O
months O
after O
discontinuation O
of O
therapy O
; O
therefore O
, O
in O
any O
situation O
of O
stress B-Not_AE_Candidate
occurring O
during O
that O
period O
, O
hormone O
therapy O
should O
be O
reinstituted O
. O

If O
the O
patient O
is O
receiving O
steroids O
already O
, O
dosage O
may O
have O
to O
be O
increased O
. O

Metabolic O
clearance O
of O
corticosteroids O
is O
decreased O
in O
hypothyroid B-Not_AE_Candidate
patients O
and O
increased O
in O
hyperthyroid B-Not_AE_Candidate
patients O
. O

Changes B-NonOSE_AE
in I-NonOSE_AE
thyroid I-NonOSE_AE
status I-NonOSE_AE
of O
the O
patient O
may O
necessitate O
adjustment O
in O
dosage O
. O

Infections O
General O
Patients O
who O
are O
on O
corticosteroids O
are O
more O
susceptible B-OSE_Labeled_AE
to I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
than O
are O
healthy O
individuals O
. O

There O
may O
be O
decreased O
resistance O
and O
inability O
to O
localize O
infection B-NonOSE_AE
when O
corticosteroids O
are O
used O
. O

Infection B-OSE_Labeled_AE
with O
any O
pathogen O
( O
viral O
, O
bacterial O
, O
fungal O
, O
protozoan O
or O
helminthic O
) O
in O
any O
location O
of O
the O
body O
may O
be O
associated O
with O
the O
use O
of O
corticosteroids O
alone O
or O
in O
combination O
with O
other O
immunosuppressive B-NonOSE_AE
agents I-NonOSE_AE
. O

These O
infections B-NonOSE_AE
may O
be O
mild O
to O
severe O
. O

With O
increasing O
doses O
of O
corticosteroids O
, O
the O
rate O
of O
occurrence O
of O
infectious B-NonOSE_AE
complications I-NonOSE_AE
increases I-NonOSE_AE
. O

Corticosteroids O
may O
also O
mask B-OSE_Labeled_AE
some O
signs O
of O
current O
infection I-OSE_Labeled_AE
. O

Fungal B-NonOSE_AE
Infections I-NonOSE_AE
: O
Corticosteroids O
may O
exacerbate B-OSE_Labeled_AE
systemic I-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
and O
therefore O
should O
not O
be O
used O
in O
the O
presence O
of O
such O
infections B-NonOSE_AE
unless O
they O
are O
needed O
to O
control O
life B-NonOSE_AE
- I-NonOSE_AE
threatening I-NonOSE_AE
drug I-NonOSE_AE
reactions I-NonOSE_AE
. O

There O
have O
been O
cases O
reported O
in O
which O
concomitant O
use O
of O
amphotericin O
B O
and O
hydrocortisone O
was O
followed O
by O
cardiac B-NonOSE_AE
enlargement I-NonOSE_AE
and O
congestive B-NonOSE_AE
heart I-NonOSE_AE
failure I-NonOSE_AE
( O
see O
PRECAUTIONS O
: O
Drug O
Interactions O
: O
Amphotericin O
B O
injection O
and O
potassium-depleting O
agents O
) O
. O

Special O
Pathogens O
: O
Latent O
disease O
may O
be O
activated O
or O
there O
may O
be O
an O
exacerbation O
of O
intercurrent O
infections B-OSE_Labeled_AE
due O
to O
pathogens O
, O
including O
those O
caused O
by O
Amoeba I-OSE_Labeled_AE
, O
Candida O
, O
Cryptococcus O
, O
Mycobacterium O
, O
Nocardia O
, O
Pneumocystis O
, O
Toxoplasma O
. O

It O
is O
recommended O
that O
latent B-Not_AE_Candidate
amebiasis I-Not_AE_Candidate
or O
active B-Not_AE_Candidate
amebiasis I-Not_AE_Candidate
be O
ruled O
out O
before O
initiating O
corticosteroid O
therapy O
in O
any O
patient O
who O
has O
spent O
time O
in O
the O
tropics O
or O
any O
patient O
with O
unexplained O
diarrhea B-Not_AE_Candidate
. O

Similarly O
, O
corticosteroids O
should O
be O
used O
with O
great O
care O
in O
patients O
with O
known O
or O
suspected O
Strongyloides B-Not_AE_Candidate
( I-Not_AE_Candidate
threadworm I-Not_AE_Candidate
) I-Not_AE_Candidate
infestation I-Not_AE_Candidate
. O

In O
such O
patients O
, O
corticosteroid B-OSE_Labeled_AE
- I-OSE_Labeled_AE
induced I-OSE_Labeled_AE
immunosuppression I-OSE_Labeled_AE
may O
lead O
to O
Strongyloides B-OSE_Labeled_AE
hyperinfection I-OSE_Labeled_AE
and O
dissemination O
with O
widespread O
larval O
migration O
, O
often O
accompanied O
by O
severe O
enterocolitis B-NonOSE_AE
and O
potentially O
fatal B-NonOSE_AE
gram B-NonOSE_AE
- I-NonOSE_AE
negative I-NonOSE_AE
septicemia I-NonOSE_AE
. O

Corticosteroids O
should O
not O
be O
used O
in O
cerebral B-Not_AE_Candidate
malaria I-Not_AE_Candidate
. O

Tuberculosis B-NonOSE_AE
: O
The O
use O
of O
corticosteroids O
in O
active B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
should O
be O
restricted O
to O
those O
cases O
of O
fulminating B-Not_AE_Candidate
or O
disseminated O
tuberculosis I-Not_AE_Candidate
in O
which O
the O
corticosteroid O
is O
used O
for O
the O
management O
of O
the O
disease O
in O
conjunction O
with O
an O
appropriate O
antituberculous B-NonOSE_AE
regimen O
. O

If O
corticosteroids O
are O
indicated O
in O
patients O
with O
latent B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
or O
tuberculin B-Not_AE_Candidate
reactivity I-Not_AE_Candidate
, O
close O
observation O
is O
necessary O
as O
reactivation O
of O
the O
disease O
may O
occur O
. O

During O
prolonged O
corticosteroid O
therapy O
, O
these O
patients O
should O
receive O
chemoprophylaxis O
. O

Vaccination O
: O
Administration O
of O
live O
or O
live O
, O
attenuated O
vaccines O
is O
contraindicated O
in O
patients O
receiving O
immunosuppressive B-NonOSE_AE
doses O
of O
corticosteroids O
. O

Killed O
or O
inactivated O
vaccines O
may O
be O
administered O
. O

However O
, O
the O
response O
to O
such O
vaccines O
can O
not O
be O
predicted O
. O

Immunization O
procedures O
may O
be O
undertaken O
in O
patients O
who O
are O
receiving O
corticosteroids O
as O
replacement O
therapy O
, O
e.g. O
, O
for O
Addison B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Viral B-NonOSE_AE
Infections I-NonOSE_AE
: O
Chickenpox B-NonOSE_AE
and O
measles B-NonOSE_AE
can O
have O
a O
more O
serious O
or O
even O
fatal B-NonOSE_AE
course O
in O
pediatric O
and O
adult O
patients O
on O
corticosteroids O
. O

In O
pediatric O
and O
adult O
patients O
who O
have O
not O
had O
these O
diseases O
, O
particular O
care O
should O
be O
taken O
to O
avoid O
exposure O
. O

The O
contribution O
of O
the O
underlying O
disease O
and/or O
prior O
corticosteroid O
treatment O
to O
the O
risk O
is O
also O
not O
known O
. O

If O
exposed O
to O
chickenpox B-NonOSE_AE
, O
prophylaxis O
with O
varicella B-NonOSE_AE
zoster I-NonOSE_AE
immune I-NonOSE_AE
globulin I-NonOSE_AE
( I-NonOSE_AE
VZIG I-NonOSE_AE
) O
may O
be O
indicated O
. O

If O
exposed O
to O
measles B-NonOSE_AE
, O
prophylaxis O
with O
immune O
globulin O
( O
IG O
) O
may O
be O
indicated O
. O

( O
See O
the O
respective O
package O
inserts O
for O
VZIG O
and O
IG O
for O
complete O
prescribing O
information O
. O
) O

If O
chickenpox B-NonOSE_AE
develops O
, O
treatment O
with O
antiviral O
agents O
should O
be O
considered O
. O

Ophthalmic O
Use O
of O
corticosteroids O
may O
produce O
posterior B-OSE_Labeled_AE
subcapsular I-OSE_Labeled_AE
cataracts I-OSE_Labeled_AE
, O
glaucoma B-OSE_Labeled_AE
with O
possible O
damage B-NonOSE_AE
to I-NonOSE_AE
the I-NonOSE_AE
optic I-NonOSE_AE
nerves I-NonOSE_AE
, O
and O
may O
enhance O
the O
establishment O
of O
secondary O
ocular B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
due O
to O
bacteria O
, O
fungi O
, O
or O
viruses O
. O

The O
use O
of O
oral O
corticosteroids O
is O
not O
recommended O
in O
the O
treatment O
of O
optic B-Not_AE_Candidate
neuritis I-Not_AE_Candidate
and O
may O
lead O
to O
an O
increase O
in O
the O
risk O
of O
new O
episodes O
. O

Corticosteroids O
should O
not O
be O
used O
in O
active O
ocular B-Not_AE_Candidate
herpes I-Not_AE_Candidate
simplex I-Not_AE_Candidate
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
more O
detail O
in O
other O
sections O
of O
the O
labeling O
. O

* O
Cardiomyopathy B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Related I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Foot I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Secondary B-OSE_Labeled_AE
Oral I-OSE_Labeled_AE
Neoplasms I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
The O
most O
common O
adverse O
reactions O
( O
> O
20 O
% O
) O
observed O
with O
DOXIL O
are O
asthenia B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
anorexia B-OSE_Labeled_AE
, O
hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
foot I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
and O
neutropenia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
and O
anemia B-OSE_Labeled_AE
. O

EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
> O
20 O
% O
) O
are O
asthenia O
, O
fatigue O
, O
fever O
, O
anorexia O
, O
nausea O
, O
vomiting O
, O
stomatitis O
, O
diarrhea O
, O
constipation O
, O
hand-foot O
syndrome O
, O
rash O
, O
neutropenia O
, O
thrombocytopenia O
, O
and O
anemia O
( O
6 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
contact O
Janssen O
Products O
, O
LP O
at O
1-800-JANSSEN O
( O
1-800-526-7736 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Adverse O
Reactions O
in O
Clinical O
Trials O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
the O
adverse O
reaction O
rates O
observed O
can O
not O
be O
directly O
compared O
to O
rates O
on O
other O
clinical O
trials O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

The O
safety O
data O
reflect O
exposure O
to O
DOXIL O
in O
1310 O
patients O
including O
: O
239 O
patients O
with O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
, O
753 O
patients O
with O
AIDS B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
Kaposi I-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
sarcoma I-Not_AE_Candidate
, O
and O
318 O
patients O
with O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
. O

The O
following O
tables O
present O
adverse O
reactions O
from O
clinical O
trials O
of O
single-agent O
DOXIL O
in O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
and O
AIDS B-Not_AE_Candidate
- I-Not_AE_Candidate
Related I-Not_AE_Candidate
Kaposi I-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
sarcoma I-Not_AE_Candidate
. O

Patients O
With O
Ovarian O
Cancer O
The O
safety O
data O
described O
below O
are O
from O
Trial O
4 O
, O
which O
included O
239 O
patients O
with O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
treated O
with O
DOXIL O
50 O
mg/m O
2 O
once O
every O
4 O
weeks O
for O
a O
minimum O
of O
four O
courses O
in O
a O
randomized O
, O
multicenter O
, O
open-label O
study O
. O

In O
this O
trial O
, O
patients O
received O
DOXIL O
for O
a O
median O
number O
of O
3.2 O
months O
( O
range O
1 O
day O
to O
25.8 O
months O
) O
. O

The O
median O
age O
of O
the O
patients O
is O
60 O
years O
( O
range O
27 O
to O
87 O
) O
, O
with O
91 O
% O
Caucasian O
, O
6 O
% O
Black O
, O
and O
3 O
% O
Hispanic O
or O
Other O
. O

Table O
3 O
presents O
the O
hematologic B-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
from O
Trial O
4 O
. O

Table O
3 O
: O
Hematologic O
Adverse O
Reactions O
in O
Trial O
4 O
DOXIL O
Patients O
( O
n=239 O
) O
Topotecan O
Patients O
( O
n=235 O
) O
Neutropenia B-OSE_Labeled_AE
500 O
- O
< O
1000/mm O
3 O
8 O
% O
14 O
% O
< O
500/mm O
3 O
4.2 O
% O
62 O
% O
Anemia B-OSE_Labeled_AE
6.5 O
- O
< O
8 O
g/dL O
5 O
% O
25 O
% O
< O
6.5 O
g/dL O
0.4 O
% O
4.3 O
% O
Thrombocytopenia B-OSE_Labeled_AE
10,000 O
- O
< O
50,000/mm O
3 O
1.3 O
% O
17 O
% O
< O
10,000/mm O
3 O
0.0 O
% O
17 O
% O
Table O
4 O
presents O
the O
non B-NonOSE_AE
- I-NonOSE_AE
hematologic I-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
from O
Trial O
4 O
. O

Table O
4 O
: O
Non-Hematologic O
Adverse O
Reactions O
in O
Trial O
4 O
Non-Hematologic O
Adverse O
Reaction O
10 O
% O
or O
Greater O
DOXIL O
( O
% O
) O
treated O
( O
n=239 O
) O
Topotecan O
( O
% O
) O
treated O
( O
n=235 O
) O
All O
grades O
Grades O
3-4 O
All O
grades O
Grades O
3-4 O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
Asthenia B-OSE_Labeled_AE
40 O
7 O
52 O
8 O
Fever B-OSE_Labeled_AE
21 O
0.8 O
31 O
6 O
Mucous B-OSE_Labeled_AE
Membrane I-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
14 O
3.8 O
3.4 O
0 O
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
12 O
1.7 O
10 O
0.9 O
Infection B-OSE_Labeled_AE
12 O
2.1 O
6 O
0.9 O
Headache B-OSE_Labeled_AE
11 O
0.8 O
15 O
0 O
Digestive B-NonOSE_AE
Nausea B-OSE_Labeled_AE
46 O
5 O
63 O
8 O
Stomatitis B-OSE_Labeled_AE
41 O
8 O
15 O
0.4 O
Vomiting B-OSE_Labeled_AE
33 O
8 O
44 O
10 O
Diarrhea B-OSE_Labeled_AE
21 O
2.5 O
35 O
4.2 O
Anorexia B-OSE_Labeled_AE
20 O
2.5 O
22 O
1.3 O
Dyspepsia B-OSE_Labeled_AE
12 O
0.8 O
14 O
0 O
Nervous B-NonOSE_AE
Dizziness B-OSE_Labeled_AE
4.2 O
0 O
10 O
0 O
Respiratory B-NonOSE_AE
Pharyngitis B-OSE_Labeled_AE
16 O
0 O
18 O
0.4 O
Dyspnea B-OSE_Labeled_AE
15 O
4.1 O
23 O
4.3 O
Cough B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
10 O
0 O
12 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
Hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
foot I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
51 O
24 O
0.9 O
0 O
Rash B-OSE_Labeled_AE
29 O
4.2 O
12 O
0.4 O
Alopecia B-OSE_Labeled_AE
19 O
N/A O
52 O
N/A O
The O
following O
additional O
adverse O
reactions O
were O
observed O
in O
patients O
with O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
with O
doses O
administered O
every O
four O
weeks O
( O
Trial O
4 O
) O
. O

Incidence O
1 O
% O
to O
10 O
% O
Cardiovascular B-NonOSE_AE
: O
vasodilation B-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
, O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
. O

Digestive B-NonOSE_AE
: O
oral B-OSE_Labeled_AE
moniliasis I-OSE_Labeled_AE
, O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
esophagitis B-OSE_Labeled_AE
, O
dysphagia B-OSE_Labeled_AE
, O
rectal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
, O
ileus B-OSE_Labeled_AE
. O

Hematologic B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
: O
ecchymosis B-OSE_Labeled_AE
. O

Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
: O
dehydration B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
hyperbilirubinemia B-OSE_Labeled_AE
, O
hypokalemia B-OSE_Labeled_AE
, O
hypercalcemia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
. O

Nervous B-NonOSE_AE
: O
somnolence B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
: O
rhinitis B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
: O
pruritus B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
, O
vesiculobullous B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
maculopapular B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
simplex I-OSE_Labeled_AE
, O
fungal B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
furunculosis B-OSE_Labeled_AE
, O
acne B-OSE_Labeled_AE
. O

Special B-NonOSE_AE
Senses I-NonOSE_AE
: O
conjunctivitis B-OSE_Labeled_AE
, O
taste B-OSE_Labeled_AE
perversion I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
eyes I-OSE_Labeled_AE
. O

Urinary B-NonOSE_AE
: O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
hematuria B-OSE_Labeled_AE
, O
vaginal B-OSE_Labeled_AE
moniliasis I-OSE_Labeled_AE
. O

Patients O
With O
AIDS-Related O
Kaposi O
's O
Sarcoma O
The O
safety O
data O
described O
is O
based O
on O
the O
experience O
reported O
in O
753 O
patients O
with O
AIDS B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
Kaposi I-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
sarcoma I-Not_AE_Candidate
( I-Not_AE_Candidate
KS I-Not_AE_Candidate
) O
enrolled O
in O
four O
open-label O
, O
uncontrolled O
trials O
of O
DOXIL O
administered O
at O
doses O
ranging O
from O
10 O
to O
40 O
mg/m O
2 O
every O
2 O
to O
3 O
weeks O
. O

Demographics O
of O
the O
population O
were O
: O
median O
age O
38.7 O
years O
( O
range O
24-70 O
) O
; O
99 O
% O
male O
; O
88 O
% O
Caucasian O
, O
6 O
% O
Hispanic O
, O
4 O
% O
Black O
, O
and O
2 O
% O
Asian/other/unknown O
. O

The O
majority O
of O
patients O
were O
treated O
with O
20 O
mg/m O
2 O
of O
DOXIL O
every O
2 O
to O
3 O
weeks O
with O
a O
median O
exposure O
of O
4.2 O
months O
( O
range O
1 O
day O
to O
26.6 O
months O
) O
. O

The O
median O
cumulative O
dose O
was O
120 O
mg/m O
2 O
( O
range O
3.3 O
to O
798.6 O
mg/m O
2 O
) O
; O
3 O
% O
received O
cumulative O
doses O
of O
greater O
than O
450 O
mg/m O
2 O
. O

Disease O
characteristics O
were O
: O
61 O
% O
poor O
risk O
for O
KS B-Not_AE_Candidate
tumor I-Not_AE_Candidate
burden I-Not_AE_Candidate
, O
91 O
% O
poor O
risk O
for O
immune O
system O
, O
and O
47 O
% O
poor O
risk O
for O
systemic B-Not_AE_Candidate
illness I-Not_AE_Candidate
; O
36 O
% O
were O
poor O
risk O
for O
all O
three O
categories O
; O
median O
CD4 O
count O
21 O
cells/mm O
3 O
( O
51 O
% O
less O
than O
50 O
cells/mm O
3 O
) O
; O
mean O
absolute O
neutrophil O
count O
at O
study O
entry O
approximately O
3,000 O
cells/mm O
3 O
. O

Of O
the O
693 O
patients O
with O
concomitant O
medication O
information O
, O
59 O
% O
were O
on O
one O
or O
more O
antiretroviral O
medications O
[ O
35 O
% O
zidovudine O
( O
AZT O
) O
, O
21 O
% O
didanosine O
( O
ddI O
) O
, O
16 O
% O
zalcitabine O
( O
ddC O
) O
, O
and O
10 O
% O
stavudine O
( O
D4T O
) O
] O
; O
85 O
% O
received O
PCP B-NonOSE_AE
prophylaxis I-NonOSE_AE
( O
54 O
% O
sulfamethoxazole/trimethoprim O
) O
; O
85 O
% O
received O
antifungal O
medications O
( O
76 O
% O
fluconazole O
) O
; O
72 O
% O
received O
antivirals O
( O
56 O
% O
acyclovir O
, O
29 O
% O
ganciclovir O
, O
and O
16 O
% O
foscarnet O
) O
and O
48 O
% O
patients O
received O
colony-stimulating O
factors O
( O
sargramostim/filgrastim O
) O
during O
their O
course O
of O
treatment O
. O

Adverse O
reactions O
led O
to O
discontinuation O
of O
treatment O
in O
5 O
% O
of O
patients O
with O
AIDS B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
Kaposi I-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
sarcoma I-Not_AE_Candidate
and O
included O
myelosuppression B-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
toxoplasmosis B-OSE_Labeled_AE
, O
HFS B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
/ O
dyspnea B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
optic B-OSE_Labeled_AE
neuritis I-OSE_Labeled_AE
, O
progression B-OSE_Labeled_AE
of I-OSE_Labeled_AE
a I-OSE_Labeled_AE
non I-OSE_Labeled_AE
- I-OSE_Labeled_AE
KS I-OSE_Labeled_AE
tumor I-OSE_Labeled_AE
, O
allergy B-Not_AE_Candidate
to I-Not_AE_Candidate
penicillin I-Not_AE_Candidate
, O
and O
unspecified O
reasons O
. O

Tables O
5 O
and O
6 O
summarize O
adverse O
reactions O
reported O
in O
patients O
treated O
with O
DOXIL O
for O
AIDS-related O
Kaposi O
's O
sarcoma O
in O
a O
pooled O
analysis O
of O
the O
four O
trials O
. O

Table O
5 O
: O
Hematologic O
Adverse O
Reactions O
Reported O
in O
Patients O
With O
AIDS-Related O
Kaposi O
's O
Sarcoma O
Patients O
With O
Refractory O
or O
Intolerant O
AIDS-Related O
Kaposi O
's O
Sarcoma O
( O
n=74 O
[ O
note O
: O
This O
includes O
a O
subset O
of O
subjects O
who O
were O
retrospectively O
identified O
as O
having O
disease O
progression O
on O
prior O
systemic O
combination O
chemotherapy O
( O
at O
least O
2 O
cycles O
of O
a O
regimen O
containing O
at O
least O
2 O
of O
3 O
treatments O
: O
bleomycin O
, O
vincristine O
or O
vinblastine O
, O
or O
doxorubicin O
) O
or O
as O
being O
intolerant O
to O
such O
therapy O
. O
] O

) O
Total O
Patients O
With O
AIDS B-Not_AE_Candidate
- I-Not_AE_Candidate
Related I-Not_AE_Candidate
Kaposi I-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
Sarcoma I-Not_AE_Candidate
( O
n=720 O
[ O
note O
: O
This O
includes O
only O
subjects O
with O
AIDS B-Not_AE_Candidate
- I-Not_AE_Candidate
KS I-Not_AE_Candidate
who O
had O
available O
data O
from O
the O
4 O
pooled O
trials O
. O
] O

) O
Neutropenia B-OSE_Labeled_AE
< O
1000/mm O
3 O
46 O
% O
49 O
% O
< O
500/mm O
3 O
11 O
% O
13 O
% O
Anemia B-OSE_Labeled_AE
< O
10 O
g/dL O
58 O
% O
55 O
% O
< O
8 O
g/dL O
16 O
% O
18 O
% O
Thrombocytopenia B-OSE_Labeled_AE
< O
150,000/mm O
3 O
61 O
% O
61 O
% O
< O
25,000/mm O
3 O
1.4 O
% O
4.2 O
% O
Table O
6 O
: O
Non-Hematologic O
Adverse O
Reactions O
Reported O
in O
> O
= O
5 O
% O
of O
Patients O
With O
AIDS-Related O
Kaposi O
's O
Sarcoma O
Adverse O
Reactions O
Patients O
With O
Refractory O
or O
Intolerant O
AIDS-Related O
Kaposi O
's O
Sarcoma O
( O
n=77 O
[ O
note O
: O
This O
includes O
a O
subset O
of O
subjects O
who O
were O
retrospectively O
identified O
as O
having O
disease O
progression O
on O
prior O
systemic O
combination O
chemotherapy O
( O
at O
least O
2 O
cycles O
of O
a O
regimen O
containing O
at O
least O
2 O
of O
3 O
treatments O
: O
bleomycin O
, O
vincristine O
or O
vinblastine O
, O
or O
doxorubicin O
) O
or O
as O
being O
intolerant O
to O
such O
therapy O
. O
] O

) O
Total O
Patients O
With O
AIDS-Related O
Kaposi O
's O
Sarcoma O
( O
n=705 O
[ O
note O
: O
This O
includes O
only O
subjects O
with O
AIDS B-Not_AE_Candidate
- I-Not_AE_Candidate
KS I-Not_AE_Candidate
who O
had O
available O
adverse O
event O
data O
from O
the O
4 O
pooled O
trials O
. O
] O

) O
Nausea B-OSE_Labeled_AE
18 O
% O
17 O
% O
Asthenia B-OSE_Labeled_AE
7 O
% O
10 O
% O
Fever B-OSE_Labeled_AE
8 O
% O
9 O
% O
Alopecia B-OSE_Labeled_AE
9 O
% O
9 O
% O
Alkaline B-OSE_Labeled_AE
Phosphatase I-OSE_Labeled_AE
Increase I-OSE_Labeled_AE
1.3 O
% O
8 O
% O
Vomiting B-OSE_Labeled_AE
8 O
% O
8 O
% O
Diarrhea B-OSE_Labeled_AE
5 O
% O
8 O
% O
Stomatitis B-OSE_Labeled_AE
5 O
% O
7 O
% O
Oral B-OSE_Labeled_AE
Moniliasis I-OSE_Labeled_AE
1.3 O
% O
6 O
% O
The O
following O
additional O
adverse O
reactions O
were O
observed O
in O
705 O
patients O
with O
AIDS B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
Kaposi I-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
sarcoma I-Not_AE_Candidate
. O

Incidence O
1 O
% O
to O
5 O
% O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
: O
headache B-OSE_Labeled_AE
, O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
infection B-OSE_Labeled_AE
, O
allergic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
. O

Cardiovascular B-NonOSE_AE
: O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
. O

Cutaneous B-NonOSE_AE
: O
herpes B-OSE_Labeled_AE
simplex I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
itching B-OSE_Labeled_AE
. O

Digestive B-NonOSE_AE
: O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
anorexia B-OSE_Labeled_AE
, O
dysphagia B-OSE_Labeled_AE
. O

Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
: O
SGPT B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
hyperbilirubinemia B-OSE_Labeled_AE
. O

Other O
: O
dyspnea B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
. O

Incidence O
Less O
Than O
1 O
% O
Body B-NonOSE_AE
As I-NonOSE_AE
A I-NonOSE_AE
Whole I-NonOSE_AE
: O
sepsis B-OSE_Labeled_AE
, O
moniliasis B-OSE_Labeled_AE
, O
cryptococcosis B-OSE_Labeled_AE
. O

Cardiovascular B-NonOSE_AE
: O
thrombophlebitis B-OSE_Labeled_AE
, O
cardiomyopathy B-OSE_Labeled_AE
, O
palpitation B-OSE_Labeled_AE
, O
bundle B-OSE_Labeled_AE
branch I-OSE_Labeled_AE
block I-OSE_Labeled_AE
, O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
heart B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
thrombosis B-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
arrhythmia I-OSE_Labeled_AE
. O

Digestive B-NonOSE_AE
: O
hepatitis B-OSE_Labeled_AE
. O

Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
Disorders I-NonOSE_AE
: O
dehydration B-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
: O
cough B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
, O
pharyngitis B-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
: O
maculopapular B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
. O

Special B-NonOSE_AE
Senses I-NonOSE_AE
: O
taste B-OSE_Labeled_AE
perversion I-OSE_Labeled_AE
, O
conjunctivitis B-OSE_Labeled_AE
. O

Patients O
With O
Multiple O
Myeloma O
The O
safety O
data O
described O
are O
from O
318 O
patients O
treated O
with O
DOXIL O
( O
30 O
mg/m O
2 O
) O
administered O
on O
day O
4 O
following O
bortezomib O
( O
1.3 O
mg/m O
2 O
i.v O
. O

bolus O
on O
days O
1 O
, O
4 O
, O
8 O
and O
11 O
) O
every O
3 O
weeks O
, O
in O
a O
randomized O
, O
open-label O
, O
multicenter O
study O
( O
Trial O
6 O
) O
. O

In O
this O
trial O
, O
patients O
in O
the O
DOXIL O
+ O
bortezomib O
combination O
group O
were O
treated O
for O
a O
median O
number O
of O
4.5 O
months O
( O
range O
21 O
days O
to O
13.5 O
months O
) O
. O

The O
population O
was O
28 O
to O
85 O
years O
of O
age O
( O
median O
age O
61 O
) O
, O
58 O
% O
male O
, O
90 O
% O
Caucasian O
, O
6 O
% O
Black O
, O
and O
4 O
% O
Asian O
and O
Other O
. O

Table O
7 O
lists O
adverse O
reactions O
reported O
in O
10 O
% O
or O
more O
of O
patients O
treated O
with O
DOXIL O
in O
combination O
with O
bortezomib O
for O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
. O

Table O
7 O
: O
Frequency O
of O
Treatment-Emergent O
Adverse O
Reactions O
Reported O
in O
> O
=10 O
% O
Patients O
Treated O
for O
Multiple O
Myeloma O
With O
DOXIL O
in O
Combination O
With O
Bortezomib O
Adverse O
Reaction O
DOXIL O
+ O
bortezomib O
( O
n=318 O
) O
Bortezomib O
( O
n=318 O
) O
Any O
( O
% O
) O
Grade O
3-4 O
Any O
( O
% O
) O
Grade O
3-4 O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
36 O
32 O
22 O
16 O
Thrombocytopenia B-OSE_Labeled_AE
33 O
24 O
28 O
17 O
Anemia B-OSE_Labeled_AE
25 O
9 O
21 O
9 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
36 O
7 O
28 O
3 O
Pyrexia B-OSE_Labeled_AE
31 O
1 O
22 O
1 O
Asthenia B-OSE_Labeled_AE
22 O
6 O
18 O
4 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
48 O
3 O
40 O
1 O
Diarrhea B-OSE_Labeled_AE
46 O
7 O
39 O
5 O
Vomiting B-OSE_Labeled_AE
32 O
4 O
22 O
1 O
Constipation B-OSE_Labeled_AE
31 O
1 O
31 O
1 O
Mucositis B-OSE_Labeled_AE
/ O
Stomatitis B-OSE_Labeled_AE
20 O
2 O
5 O
< O
1 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
11 O
1 O
8 O
1 O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
11 O
2 O
9 O
2 O
Herpes B-OSE_Labeled_AE
simplex I-OSE_Labeled_AE
10 O
0 O
6 O
1 O
Investigations B-NonOSE_AE
Weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
12 O
0 O
4 O
0 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
disorders I-NonOSE_AE
Anorexia B-OSE_Labeled_AE
19 O
2 O
14 O
< O
1 O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Peripheral B-OSE_Labeled_AE
Neuropathy I-OSE_Labeled_AE
[ O
note O
: O
Peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
includes O
the O
following O
adverse O
reactions O
: O
peripheral B-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
neuropathy B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
, O
polyneuropathy B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
motor I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
and O
neuropathy B-OSE_Labeled_AE
NOS O
. O
] O

42 O
7 O
45 O
11 O
Neuralgia B-OSE_Labeled_AE
17 O
3 O
20 O
4 O
Paresthesia B-OSE_Labeled_AE
/ O
dysesthesia B-OSE_Labeled_AE
13 O
< O
1 O
10 O
0 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
18 O
0 O
12 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
[ O
note O
: O
Rash B-OSE_Labeled_AE
includes O
the O
following O
adverse O
reactions O
: O
rash B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
erythematous I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
macular I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
maculo I-OSE_Labeled_AE
- I-OSE_Labeled_AE
papular I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
pruritic I-OSE_Labeled_AE
, O
exfoliative B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
and O
rash B-OSE_Labeled_AE
generalized O
. O
] O

22 O
1 O
18 O
1 O
Hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
foot I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
19 O
6 O
< O
1 O
0 O
6.2 O
Postmarketing O
Experience O
The O
following O
additional O
adverse O
reactions O
have O
been O
identified O
during O
post O
approval O
use O
of O
DOXIL O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
: O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
( O
in O
some O
cases O
fatal B-NonOSE_AE
) O
Hematologic B-NonOSE_AE
disorders I-NonOSE_AE
: O
Secondary B-OSE_Labeled_AE
acute I-OSE_Labeled_AE
myelogenous I-OSE_Labeled_AE
leukemia I-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
Secondary B-OSE_Labeled_AE
oral I-OSE_Labeled_AE
neoplasms I-OSE_Labeled_AE
: O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

BOXED O
WARNING O
: O
WARNING O
: O
CARDIOMYOPATHY O
and O
INFUSION-RELATED O
REACTIONS O
WARNING O
: O
CARDIOMYOPATHY O
and O
INFUSION-RELATED O
REACTIONS O
* O
DOXIL O
( O
doxorubicin O
HCl O
liposome O
injection O
) O
can O
cause O
myocardial B-OSE_Labeled_AE
damage I-OSE_Labeled_AE
, O
including O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
as O
the O
total O
cumulative O
dose O
of O
doxorubicin O
HCl O
approaches O
550 O
mg/m2 O
. O

In O
a O
clinical O
study O
of O
250 O
patients O
with O
advanced O
cancer B-Not_AE_Candidate
who O
were O
treated O
with O
DOXIL O
, O
the O
risk O
of O
cardiotoxicity B-OSE_Labeled_AE
was O
11 O
% O
when O
the O
cumulative O
anthracycline O
dose O
was O
between O
450-550 O
mg/m2 O
. O

Prior O
use O
of O
other O
anthracyclines O
or O
anthracenediones O
should O
be O
included O
in O
calculations O
of O
total O
cumulative O
dosage O
. O

The O
risk O
of O
cardiomyopathy B-OSE_Labeled_AE
may O
be O
increased O
at O
lower O
cumulative O
doses O
in O
patients O
with O
prior O
mediastinal O
irradiation O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
Acute B-OSE_Labeled_AE
infusion I-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
consisting O
of O
, O
but O
not O
limited O
to O
, O
flushing B-OSE_Labeled_AE
, O
shortness B-OSE_Labeled_AE
of I-OSE_Labeled_AE
breath I-OSE_Labeled_AE
, O
facial B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
tightness B-OSE_Labeled_AE
in I-OSE_Labeled_AE
the I-OSE_Labeled_AE
chest O
or O
throat I-OSE_Labeled_AE
, O
and/or O
hypotension B-OSE_Labeled_AE
occurred O
in O
11 O
% O
of O
patients O
with O
solid B-Not_AE_Candidate
tumors I-Not_AE_Candidate
treated O
with O
DOXIL O
. O

Serious O
, O
life-threatening O
and O
fatal B-NonOSE_AE
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
have O
been O
reported O
[ O
see O
Dosage O
and O
Administration O
( O
2.6 O
) O
and O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
CARDIOMYOPATHY O
and O
INFUSION-RELATED O
REACTIONS O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Myocardial O
damage O
may O
lead O
to O
congestive O
heart O
failure O
and O
may O
occur O
as O
the O
total O
cumulative O
dose O
of O
doxorubicin O
HCl O
approaches O
550 O
mg/m2 O
. O

The O
risk O
of O
cardiomyopathy O
may O
be O
increased O
at O
lower O
cumulative O
doses O
with O
mediastinal O
irradiation O
( O
5.1 O
) O
. O

* O
Acute O
infusion-related O
reactions O
occurred O
in O
11 O
% O
of O
patients O
with O
solid O
tumors O
. O

Serious O
, O
life-threatening O
, O
and O
fatal O
infusion O
reactions O
have O
been O
reported O
. O

Medications/emergency O
equipment O
to O
treat O
such O
reactions O
should O
be O
available O
for O
immediate O
use O
( O
5.2 O
) O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Hand-Foot O
Syndrome O
may O
occur O
. O

Dose O
modification O
or O
discontinuation O
may O
be O
required O
( O
5.3 O
) O
* O
Embryofetal O
Toxicity O
: O
Can O
cause O
fetal O
harm O
. O

Advise O
of O
potential O
risk O
to O
a O
fetus O
. O

Use O
effective O
contraception O
( O
5.5 O
, O
8.1 O
, O
8.3 O
) O
5.1 O
Cardiomyopathy O
Doxorubicin O
HCl O
can O
result O
in O
myocardial B-OSE_Labeled_AE
damage I-OSE_Labeled_AE
, O
including O
acute B-OSE_Labeled_AE
left I-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
. O

The O
risk O
of O
cardiomyopathy B-OSE_Labeled_AE
with O
doxorubicin O
HCl O
is O
generally O
proportional O
to O
the O
cumulative O
exposure O
. O

The O
relationship O
between O
cumulative O
DOXIL O
dose O
and O
the O
risk O
of O
cardiac B-NonOSE_AE
toxicity I-NonOSE_AE
has O
not O
been O
determined O
. O

In O
a O
clinical O
study O
in O
250 O
patients O
with O
advanced O
cancer B-Not_AE_Candidate
who O
were O
treated O
with O
DOXIL O
, O
the O
risk O
of O
cardiotoxicity B-OSE_Labeled_AE
was O
11 O
% O
when O
the O
cumulative O
anthracycline O
dose O
was O
between O
450-550 O
mg/m O
2 O
. O

Cardiotoxicity B-NonOSE_AE
was O
defined O
as O
> B-NonOSE_AE
2 I-NonOSE_AE
0 I-NonOSE_AE
% I-NonOSE_AE
decrease I-NonOSE_AE
in I-NonOSE_AE
resting I-NonOSE_AE
left I-NonOSE_AE
ventricular I-NonOSE_AE
ejection I-NonOSE_AE
fraction I-NonOSE_AE
( I-NonOSE_AE
LVEF I-NonOSE_AE
) O
from O
baseline O
where O
LVEF O
remained O
in O
the O
normal O
range O
or O
a O
> O
10 O
% O
decrease B-NonOSE_AE
in I-NonOSE_AE
LVEF I-NonOSE_AE
from O
baseline O
where O
LVEF O
was O
less O
than O
the O
institutional O
lower O
limit O
of O
normal O
. O

Two O
percent O
of O
patients O
developed O
signs O
and O
symptoms O
of O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
without O
documented O
evidence O
of O
cardiotoxicity B-NonOSE_AE
. O

Assess O
left O
ventricular O
cardiac O
function O
( O
e.g O
. O

MUGA O
or O
echocardiogram O
) O
prior O
to O
initiation O
of O
DOXIL O
, O
during O
treatment O
to O
detect O
acute O
changes O
, O
and O
after O
treatment O
to O
detect O
delayed O
cardiotoxicity B-NonOSE_AE
. O

Administer O
DOXIL O
to O
patients O
with O
a O
history O
of O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
only O
when O
the O
potential O
benefit O
of O
treatment O
outweighs O
the O
risk O
. O

5.2 O
Infusion-Related O
Reactions O
Serious O
and O
sometimes O
life-threatening O
infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
characterized O
by O
one O
or O
more O
of O
the O
following O
symptoms O
can O
occur O
with O
DOXIL O
: O
flushing B-NonOSE_AE
, O
shortness B-NonOSE_AE
of I-NonOSE_AE
breath I-NonOSE_AE
, O
facial B-NonOSE_AE
swelling I-NonOSE_AE
, O
headache B-NonOSE_AE
, O
chills B-NonOSE_AE
, O
chest B-NonOSE_AE
pain I-NonOSE_AE
, O
back B-NonOSE_AE
pain I-NonOSE_AE
, O
tightness B-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
chest O
and O
throat I-NonOSE_AE
, O
fever B-NonOSE_AE
, O
tachycardia B-NonOSE_AE
, O
pruritus B-NonOSE_AE
, O
rash B-NonOSE_AE
, O
cyanosis B-NonOSE_AE
, O
syncope B-NonOSE_AE
, O
bronchospasm B-NonOSE_AE
, O
asthma B-NonOSE_AE
, O
apnea B-NonOSE_AE
, O
and O
hypotension B-NonOSE_AE
. O

The O
majority O
of O
infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
events I-OSE_Labeled_AE
occurred O
during O
the O
first O
infusion O
. O

Of O
239 O
patients O
with O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
treated O
with O
DOXIL O
in O
Trial O
4 O
, O
7 O
% O
of O
patients O
experienced O
acute O
infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
resulting O
in O
dose O
interruption O
. O

All O
occurred O
during O
cycle O
1 O
and O
none O
during O
subsequent O
cycles O
. O

Across O
multiple O
studies O
of O
DOXIL O
monotherapy O
including O
this O
and O
other O
studies O
enrolling O
760 O
patients O
with O
various O
solid B-Not_AE_Candidate
tumors I-Not_AE_Candidate
, O
11 O
% O
of O
patients O
had O
infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

Ensure O
that O
medications O
to O
treat O
infusion B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
reactions I-NonOSE_AE
and O
cardiopulmonary O
resuscitative O
equipment O
are O
available O
for O
immediate O
use O
prior O
to O
initiation O
of O
DOXIL O
. O

Initiate O
DOXIL O
infusions O
at O
a O
rate O
of O
1 O
mg/min O
and O
increase O
rate O
as O
tolerated O
[ O
see O
Dosage O
and O
Administration O
( O
2.6 O
) O
] O
. O

In O
the O
event O
of O
an O
infusion B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
reaction I-NonOSE_AE
, O
temporarily O
stop O
the O
drug O
until O
resolution O
then O
resume O
at O
a O
reduced O
infusion O
rate O
. O

Discontinue O
DOXIL O
infusion O
for O
serious O
or O
life-threatening O
infusion B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
reactions I-NonOSE_AE
. O

5.3 O
Hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Foot I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HFS I-OSE_Labeled_AE
) O
In O
Trial O
4 O
, O
the O
incidence O
of O
HFS B-OSE_Labeled_AE
was O
51 O
% O
of O
patients O
in O
the O
DOXIL O
arm O
and O
0.9 O
% O
of O
patients O
in O
the O
topotecan O
arm O
, O
including O
24 O
% O
Grade O
3 O
or O
4 O
cases O
of O
HFS B-OSE_Labeled_AE
in O
DOXIL-treated O
patients O
and O
no O
Grade O
3 O
or O
4 O
cases O
in O
topotecan-treated O
patients O
. O

HFS B-OSE_Labeled_AE
or O
other O
skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
required O
discontinuation O
of O
DOXIL O
in O
4.2 O
% O
of O
patients O
. O

HFS B-OSE_Labeled_AE
was O
generally O
observed O
after O
2 O
or O
3 O
cycles O
of O
treatment O
but O
may O
occur O
earlier O
. O

Delay O
DOXIL O
for O
the O
first O
episode O
of O
Grade O
2 O
or O
greater O
HFS B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.5 O
) O
] O
. O

Discontinue O
DOXIL O
if O
HFS B-NonOSE_AE
is O
severe O
and O
debilitating O
. O

5.4 O
Secondary O
Oral O
Neoplasms O
Secondary B-OSE_Labeled_AE
oral I-OSE_Labeled_AE
cancers I-OSE_Labeled_AE
, O
primarily O
squamous B-OSE_Labeled_AE
cell I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
, O
have O
been O
reported O
from O
post-marketing O
experience O
in O
patients O
with O
long-term O
( O
more O
than O
one O
year O
) O
exposure O
to O
DOXIL O
. O

These O
malignancies B-OSE_Labeled_AE
were O
diagnosed O
both O
during O
treatment O
with O
DOXIL O
and O
up O
to O
6 O
years O
after O
the O
last O
dose O
. O

Examine O
patients O
at O
regular O
intervals O
for O
the O
presence O
of O
oral B-NonOSE_AE
ulceration I-NonOSE_AE
or O
with O
any O
oral B-NonOSE_AE
discomfort I-NonOSE_AE
that O
may O
be O
indicative O
of O
secondary O
oral B-NonOSE_AE
cancer I-NonOSE_AE
. O

The O
altered O
pharmacokinetics O
and O
preferential O
tissue O
distribution O
of O
liposomal O
doxorubicin O
that O
contributes O
to O
enhanced O
skin B-NonOSE_AE
toxicity I-NonOSE_AE
and O
mucositis B-NonOSE_AE
compared O
to O
free O
doxorubicin O
may O
play O
a O
role O
in O
the O
development O
of O
oral B-NonOSE_AE
secondary I-NonOSE_AE
malignancies I-NonOSE_AE
with O
long-term O
use O
. O

5.5 O
Embryofetal B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Based O
on O
animal O
data O
, O
DOXIL O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
. O

At O
doses O
approximately O
0.12 O
times O
the O
recommended O
clinical O
dose O
, O
DOXIL O
was O
embryotoxic B-NonOSE_AE
and O
abortifacient B-NonOSE_AE
in O
rabbits O
. O

Advise O
pregnant B-Not_AE_Candidate
women O
of O
the O
potential O
risk B-OSE_Labeled_AE
to I-OSE_Labeled_AE
a I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

Advise O
females O
and O
males O
of O
reproductive O
potential O
to O
use O
effective O
contraception O
during O
and O
for O
6 O
months O
after O
treatment O
with O
DOXIL O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
and O
( O
8.3 O
) O
] O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
label O
: O
* O
Hypersensitivity B-OSE_Labeled_AE
[ O
see O
Contraindications O
( O
4.1 O
) O
] O
* O
Suicidal B-OSE_Labeled_AE
Thoughts O
and O
Behaviors I-OSE_Labeled_AE
in O
Children O
, O
Adolescents O
, O
and O
Adults O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Serotonin B-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Blood I-OSE_Labeled_AE
Pressure I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Abnormal B-OSE_Labeled_AE
Bleeding I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Angle B-OSE_Labeled_AE
Closure I-OSE_Labeled_AE
Glaucoma I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Activation O
of O
Mania B-OSE_Labeled_AE
/ O
Hypomania B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Discontinuation B-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Seizure B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Hyponatremia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Weight B-OSE_Labeled_AE
and O
Height O
changes I-OSE_Labeled_AE
in O
Pediatric O
Patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
* O
Appetite B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
in O
Pediatric O
Patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
* O
Interstitial B-OSE_Labeled_AE
Lung I-OSE_Labeled_AE
Disease I-OSE_Labeled_AE
and O
Eosinophilic B-OSE_Labeled_AE
Pneumonia I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.12 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
5 O
% O
and O
at O
least O
twice O
the O
rate O
of O
placebo O
) O
: O
nausea O
, O
somnolence O
, O
dry O
mouth O
, O
sweating O
, O
abnormal O
ejaculation O
, O
anorexia O
, O
constipation O
, O
erectile O
dysfunction O
, O
and O
libido O
decreased O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Wyeth O
Pharmaceuticals O
Inc O
. O
at O
1-800-438-1985 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Studies O
Experience O
Because O
clinical O
studies O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
studies O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
studies O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Most O
Common O
Adverse O
Reactions O
The O
most O
commonly O
observed O
adverse O
reactions O
in O
the O
clinical O
study O
database O
in O
Effexor O
XR O
treated O
patients O
in O
MDD B-Not_AE_Candidate
, O
GAD B-Not_AE_Candidate
, O
SAD B-Not_AE_Candidate
, O
and O
PD B-Not_AE_Candidate
( O
incidence O
> O
= O
5 O
% O
and O
at O
least O
twice O
the O
rate O
of O
placebo O
) O
were O
: O
nausea B-OSE_Labeled_AE
( O
30.0 O
% O
) O
, O
somnolence B-OSE_Labeled_AE
( O
15.3 O
% O
) O
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
( O
14.8 O
% O
) O
, O
sweating B-OSE_Labeled_AE
( O
11.4 O
% O
) O
, O
abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
( O
9.9 O
% O
) O
, O
anorexia B-OSE_Labeled_AE
( O
9.8 O
% O
) O
, O
constipation B-OSE_Labeled_AE
( O
9.3 O
% O
) O
, O
impotence B-OSE_Labeled_AE
( O
5.3 O
% O
) O
and O
decreased B-OSE_Labeled_AE
libido I-OSE_Labeled_AE
( O
5.1 O
% O
) O
. O

Adverse O
Reactions O
Reported O
as O
Reasons O
for O
Discontinuation O
of O
Treatment O
Combined O
across O
short-term O
, O
placebo-controlled O
premarketing O
studies O
for O
all O
indications O
, O
12 O
% O
of O
the O
3,558 O
patients O
who O
received O
Effexor O
XR O
( O
37.5-225 O
mg O
) O
discontinued O
treatment O
due O
to O
an O
adverse O
experience O
, O
compared O
with O
4 O
% O
of O
the O
2,197 O
placebo-treated O
patients O
in O
those O
studies O
. O

The O
most O
common O
adverse O
reactions O
leading O
to O
discontinuation O
in O
> O
= O
1 O
% O
of O
the O
Effexor O
XR O
treated O
patients O
in O
the O
short-term O
studies O
( O
up O
to O
12 O
weeks O
) O
across O
indications O
are O
shown O
in O
Table O
7 O
. O

Table O
7 O
: O
Incidence O
( O
% O
) O
of O
Patients O
Reporting O
Adverse O
Reactions O
Leading O
to O
Discontinuation O
in O
Placebo-controlled O
Clinical O
Studies O
( O
up O
to O
12 O
Weeks O
Duration O
) O
Body O
SystemAdverse O
Reaction O
Effexor O
XRn O
= O
3,558 O
Placebon O
= O
2,197 O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
whole I-NonOSE_AE
Asthenia B-OSE_Labeled_AE
1.7 O
0.5 O
Headache B-OSE_Labeled_AE
1.5 O
0.8 O
Digestive B-NonOSE_AE
system I-NonOSE_AE
Nausea B-OSE_Labeled_AE
4.3 O
0.4 O
Nervous B-NonOSE_AE
system I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
2.2 O
0.8 O
Insomnia B-OSE_Labeled_AE
2.1 O
0.6 O
Somnolence B-OSE_Labeled_AE
1.7 O
0.3 O
Skin B-NonOSE_AE
and I-NonOSE_AE
appendages I-NonOSE_AE
1.5 O
0.6 O
Sweating B-OSE_Labeled_AE
1.0 O
0.2 O
Common O
Adverse O
Reactions O
in O
Placebo-controlled O
Studies O
The O
number O
of O
patients O
receiving O
multiple O
doses O
of O
Effexor O
XR O
during O
the O
premarketing O
assessment O
for O
each O
approved O
indication O
is O
shown O
in O
Table O
8 O
. O

The O
conditions O
and O
duration O
of O
exposure O
to O
venlafaxine O
in O
all O
development O
programs O
varied O
greatly O
, O
and O
included O
( O
in O
overlapping O
categories O
) O
open O
and O
double-blind O
studies O
, O
uncontrolled O
and O
controlled O
studies O
, O
inpatient O
( O
Effexor O
only O
) O
and O
outpatient O
studies O
, O
fixed-dose O
, O
and O
titration O
studies O
. O

Table O
8 O
: O
Patients O
Receiving O
Effexor O
XR O
in O
Premarketing O
Clinical O
Studies O
Indication O
Effexor O
XR O
MDD B-Not_AE_Candidate
705 O
[ O
note O
: O
In O
addition O
, O
in O
the O
premarketing O
assessment O
of O
Effexor O
, O
multiple O
doses O
were O
administered O
to O
2,897 O
patients O
in O
studies O
for O
MDD B-Not_AE_Candidate
. O
] O

GAD B-Not_AE_Candidate
1,381 O
SAD B-Not_AE_Candidate
819 O
PD B-Not_AE_Candidate
1,314 O
The O
incidences O
of O
common O
adverse O
reactions O
( O
those O
that O
occurred O
in O
> O
= O
2 O
% O
of O
Effexor O
XR O
treated O
patients O
[ O
357 O
MDD B-Not_AE_Candidate
patients O
, O
1,381 O
GAD B-Not_AE_Candidate
patients O
, O
819 O
SAD B-Not_AE_Candidate
patients O
, O
and O
1,001 O
PD B-Not_AE_Candidate
patients O
] O
and O
more O
frequently O
than O
placebo O
) O
in O
Effexor O
XR O
treated O
patients O
in O
short-term O
, O
placebo-controlled O
, O
fixed- O
and O
flexible-dose O
clinical O
studies O
( O
doses O
37.5 O
to O
225 O
mg O
per O
day O
) O
are O
shown O
in O
Table O
9 O
. O

The O
adverse O
reaction O
profile O
did O
not O
differ O
substantially O
between O
the O
different O
patient O
populations O
. O

Table O
9 O
: O
Common O
Adverse O
Reactions O
: O
Percentage O
of O
Patients O
Reporting O
Adverse O
Reactions O
( O
> O
= O
2 O
% O
and O
> O
placebo O
) O
in O
Placebo-controlled O
Studies O
( O
up O
to O
12 O
Weeks O
Duration O
) O
across O
All O
Indications O
Body O
SystemAdverse O
Reaction O
Effexor O
XRn O
= O
3,558 O
Placebon O
= O
2,197 O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
whole I-NonOSE_AE
Asthenia B-OSE_Labeled_AE
12.6 O
7.8 O
Cardiovascular B-NonOSE_AE
system I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
3.4 O
2.6 O
Palpitation B-OSE_Labeled_AE
2.2 O
2.0 O
Vasodilatation B-OSE_Labeled_AE
3.7 O
1.9 O
Digestive B-NonOSE_AE
system I-NonOSE_AE
Anorexia B-OSE_Labeled_AE
9.8 O
2.6 O
Constipation B-OSE_Labeled_AE
9.3 O
3.4 O
Diarrhea B-OSE_Labeled_AE
7.7 O
7.2 O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
14.8 O
5.3 O
Nausea B-OSE_Labeled_AE
30.0 O
11.8 O
Vomiting B-OSE_Labeled_AE
4.3 O
2.7 O
Nervous B-NonOSE_AE
system I-NonOSE_AE
Abnormal B-OSE_Labeled_AE
dreams I-OSE_Labeled_AE
2.9 O
1.4 O
Dizziness B-OSE_Labeled_AE
15.8 O
9.5 O
Insomnia B-OSE_Labeled_AE
17.8 O
9.5 O
Libido B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
5.1 O
1.6 O
Nervousness B-OSE_Labeled_AE
7.1 O
5.0 O
Paresthesia B-OSE_Labeled_AE
2.4 O
1.4 O
Somnolence B-OSE_Labeled_AE
15.3 O
7.5 O
Tremor B-OSE_Labeled_AE
4.7 O
1.6 O
Respiratory B-NonOSE_AE
system I-NonOSE_AE
Yawn B-OSE_Labeled_AE
3.7 O
0.2 O
Skin B-NonOSE_AE
and I-NonOSE_AE
appendages I-NonOSE_AE
Sweating B-OSE_Labeled_AE
( O
including O
night B-OSE_Labeled_AE
sweats I-OSE_Labeled_AE
) O
11.4 O
2.9 O
Special B-NonOSE_AE
senses I-NonOSE_AE
Abnormal B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
4.2 O
1.6 O
Urogenital B-NonOSE_AE
system I-NonOSE_AE
Abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
/orgasm O
( O
men O
) O
[ O
note O
: O
Percentages O
based O
on O
the O
number O
of O
men O
( O
Effexor O
XR O
, O
n O
= O
1,440 O
; O
placebo O
, O
n O
= O
923 O
) O
] O
9.9 O
0.5 O
Anorgasmia B-OSE_Labeled_AE
( O
men O
) O
3.6 O
0.1 O
Anorgasmia B-OSE_Labeled_AE
( O
women O
) O
[ O
note O
: O
Percentages O
based O
on O
the O
number O
of O
women O
( O
Effexor O
XR O
, O
n O
= O
2,118 O
; O
placebo O
, O
n O
= O
1,274 O
) O
] O
2.0 O
0.2 O
Impotence O
( O
men O
) O
5.3 O
1.0 O
Other O
Adverse O
Reactions O
Observed O
in O
Clinical O
Studies O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
whole I-NonOSE_AE
- O
Photosensitivity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
Cardiovascular B-NonOSE_AE
system I-NonOSE_AE
- O
Postural B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
Digestive B-NonOSE_AE
system I-NonOSE_AE
- O
Gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
, O
bruxism B-OSE_Labeled_AE
Hemic B-NonOSE_AE
/ I-NonOSE_AE
Lymphatic I-NonOSE_AE
system I-NonOSE_AE
- O
Ecchymosis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
Metabolic B-NonOSE_AE
/ I-NonOSE_AE
Nutritional I-NonOSE_AE
- O
Hypercholesterolemia B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
, O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
Nervous B-NonOSE_AE
system I-NonOSE_AE
- O
Seizures B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
, O
manic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
, O
agitation B-OSE_Labeled_AE
, O
confusion B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
, O
hypertonia B-OSE_Labeled_AE
, O
myoclonus B-OSE_Labeled_AE
, O
depersonalization B-OSE_Labeled_AE
, O
apathy B-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
appendages I-NonOSE_AE
- O
Urticaria B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
alopecia B-OSE_Labeled_AE
Special B-NonOSE_AE
senses I-NonOSE_AE
- O
Mydriasis B-OSE_Labeled_AE
, O
abnormality B-OSE_Labeled_AE
of I-OSE_Labeled_AE
accommodation I-OSE_Labeled_AE
, O
tinnitus B-OSE_Labeled_AE
, O
taste B-OSE_Labeled_AE
perversion I-OSE_Labeled_AE
Urogenital B-NonOSE_AE
system I-NonOSE_AE
- O
Urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
, O
urination B-OSE_Labeled_AE
impaired I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
frequency I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
menstrual B-OSE_Labeled_AE
disorders O
associated O
with O
increased I-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
or O
increased O
irregular O
bleeding O
( O
e.g. O
, O
menorrhagia B-OSE_Labeled_AE
, O
metrorrhagia B-OSE_Labeled_AE
) O
6.2 O
Vital O
Sign O
Changes O
In O
placebo-controlled O
premarketing O
studies O
, O
there O
were O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
mean I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
( O
see O
Table O
10 O
) O
. O

Across O
most O
indications O
, O
a O
dose-related O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
mean I-OSE_Labeled_AE
supine I-OSE_Labeled_AE
systolic O
and O
diastolic I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
was O
evident O
in O
patients O
treated O
with O
Effexor O
XRs O
. O

Across O
all O
clinical O
studies O
in O
MDD B-Not_AE_Candidate
, O
GAD B-Not_AE_Candidate
, O
SAD B-Not_AE_Candidate
and O
PD B-Not_AE_Candidate
, O
1.4 O
% O
of O
patients O
in O
the O
Effexor O
XR O
groups O
experienced O
an O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
SDBP I-OSE_Labeled_AE
of O
> O
=15 O
mm O
Hg O
along O
with O
a O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
mm I-OSE_Labeled_AE
Hg O
, O
compared O
to O
0.9 O
% O
of O
patients O
in O
the O
placebo O
groups O
. O

Similarly O
, O
1 O
% O
of O
patients O
in O
the O
Effexor O
XR O
groups O
experienced O
an O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
SSBP I-OSE_Labeled_AE
of O
> O
= O
20 O
mm O
Hg O
with O
a O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
8 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mm I-OSE_Labeled_AE
Hg I-OSE_Labeled_AE
, O
compared O
to O
0.3 O
% O
of O
patients O
in O
the O
placebo O
groups O
. O

Table O
10 O
: O
Final O
On-therapy O
Mean B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
From I-OSE_Labeled_AE
Baseline I-OSE_Labeled_AE
in I-OSE_Labeled_AE
Supine I-OSE_Labeled_AE
Systolic I-OSE_Labeled_AE
( I-OSE_Labeled_AE
SSBP I-OSE_Labeled_AE
) O
and O
Diastolic O
( O
SDBP O
) O
Blood O
Pressure O
( O
mm O
Hg O
) O
in O
Placebo-controlled O
Studies O
Effexor O
XR O
Placebo O
Indication O
< O
= O
75 O
mg O
per O
day O
> O
75 O
mg O
per O
day O
( O
Duration O
) O
SSBP O
SDBP O
SSBP O
SDBP O
SSBP O
SDBP O
MDD B-Not_AE_Candidate
( O
8-12 O
weeks O
) O
-0.28 O
0.37 O
2.93 O
3.56 O
-1.08 O
-0.10 O
GAD B-Not_AE_Candidate
( O
8 O
weeks O
) O
-0.28 O
0.02 O
2.40 O
1.68 O
-1.26 O
-0.92 O
( O
6 O
months O
) O
1.27 O
-0.69 O
2.06 O
1.28 O
-1.29 O
-0.74 O
SAD B-Not_AE_Candidate
( O
12 O
weeks O
) O
-0.29 O
-1.26 O
1.18 O
1.34 O
-1.96 O
-1.22 O
( O
6 O
months O
) O
-0.98 O
-0.49 O
2.51 O
1.96 O
-1.84 O
-0.65 O
PD B-Not_AE_Candidate
( O
10-12 O
weeks O
) O
-1.15 O
0.97 O
-0.36 O
0.16 O
-1.29 O
-0.99 O
Effexor O
XR O
treatment O
was O
associated O
with O
sustained O
hypertension B-OSE_Labeled_AE
( O
defined O
as O
treatment-emergent O
Supine B-NonOSE_AE
Diastolic I-NonOSE_AE
Blood I-NonOSE_AE
Pressure I-NonOSE_AE
[ I-NonOSE_AE
SDBP I-NonOSE_AE
] I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
9 I-NonOSE_AE
0 I-NonOSE_AE
mm I-NonOSE_AE
Hg I-NonOSE_AE
and O
> O
= O
10 O
mm O
Hg O
above O
baseline O
for O
three O
consecutive O
on-therapy O
visits O
( O
see O
Table O
11 O
) O
. O

An O
insufficient O
number O
of O
patients O
received O
mean O
doses O
of O
Effexor O
XR O
over O
300 O
mg O
per O
day O
in O
clinical O
studies O
to O
fully O
evaluate O
the O
incidence O
of O
sustained O
increases B-NonOSE_AE
in I-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
at O
these O
higher O
doses O
. O

Table O
11 O
: O
Sustained O
Elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
SDBP I-OSE_Labeled_AE
in O
Effexor O
XR O
Premarketing O
Studies O
Indication O
Dose O
Range O
( O
mg O
per O
day O
) O
Incidence O
( O
% O
) O
MDD B-Not_AE_Candidate
75-375 O
19/705 O
( O
3 O
) O
GAD B-Not_AE_Candidate
37.5-225 O
5/1011 O
( O
0.5 O
) O
SAD B-Not_AE_Candidate
75-225 O
5/771 O
( O
0.6 O
) O
PD B-Not_AE_Candidate
75-225 O
9/973 O
( O
0.9 O
) O
Effexor O
XR O
was O
associated O
with O
mean O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
pulse I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
compared O
with O
placebo O
in O
premarketing O
placebo-controlled O
studies O
( O
see O
Table O
12 O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
, O
5.4 O
) O
] O
. O

Table O
12 O
: O
Approximate O
Mean O
Final O
On-therapy O
Increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Pulse I-OSE_Labeled_AE
Rate I-OSE_Labeled_AE
( O
beats/min O
) O
in O
Effexor O
XR O
Premarketing O
Placebo-controlled O
Studies O
( O
up O
to O
12 O
Weeks O
Duration O
) O
Indication O
( O
Duration O
) O
Effexor O
XR O
Placebo O
MDD B-Not_AE_Candidate
( O
12 O
weeks O
) O
2 O
1 O
GAD B-Not_AE_Candidate
( O
8 O
weeks O
) O
2 O
< O
1 O
SAD B-Not_AE_Candidate
( O
12 O
weeks O
) O
3 O
1 O
PD B-Not_AE_Candidate
( O
12 O
weeks O
) O
1 O
< O
1 O
6.3 O
Laboratory O
Changes O
Serum O
Cholesterol O
Effexor O
XR O
was O
associated O
with O
mean O
final O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
concentrations I-OSE_Labeled_AE
compared O
with O
mean O
final O
decreases O
for O
placebo O
in O
premarketing O
MDD B-Not_AE_Candidate
, O
GAD B-Not_AE_Candidate
, O
SAD B-Not_AE_Candidate
and O
PD B-Not_AE_Candidate
clinical O
studies O
( O
Table O
13 O
) O
. O

Table O
13 O
: O
Mean B-OSE_Labeled_AE
Final O
On-therapy O
Changes I-OSE_Labeled_AE
in I-OSE_Labeled_AE
Cholesterol I-OSE_Labeled_AE
Concentrations O
( O
mg/dL O
) O
in O
Effexor O
XR O
Premarketing O
Studies O
Indication O
( O
Duration O
) O
Effexor O
XR O
Placebo O
MDD B-Not_AE_Candidate
( O
12 O
weeks O
) O
+1.5 O
-7.4 O
GAD B-Not_AE_Candidate
( O
8 O
weeks O
) O
+1.0 O
-4.9 O
( O
6 O
months O
) O
+2.3 O
-7.7 O
SAD B-Not_AE_Candidate
( O
12 O
weeks O
) O
+7.9 O
-2.9 O
( O
6 O
months O
) O
+5.6 O
-4.2 O
PD B-Not_AE_Candidate
( O
12 O
weeks O
) O
5.8 O
-3.7 O
Effexor O
XR O
( O
venlafaxine O
hydrochloride O
) O
extended-release O
capsules O
treatment O
for O
up O
to O
12 O
weeks O
in O
premarketing O
placebo-controlled O
trials O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
was O
associated O
with O
a O
mean O
final O
on-therapy O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
concentration O
of O
approximately O
1.5 O
mg/dL O
compared O
with O
a O
mean O
final O
decrease O
of O
7.4 O
mg/dL O
for O
placebo O
. O

Effexor O
XR O
treatment O
for O
up O
to O
8 O
weeks O
and O
up O
to O
6 O
months O
in O
premarketing O
placebo-controlled O
GAD B-Not_AE_Candidate
trials O
was O
associated O
with O
mean O
final O
on-therapy O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
concentration I-OSE_Labeled_AE
of O
approximately O
1.0 O
mg/dL O
and O
2.3 O
mg/dL O
, O
respectively O
while O
placebo O
subjects O
experienced O
mean O
final O
decreases O
of O
4.9 O
mg/dL O
and O
7.7 O
mg/dL O
, O
respectively O
. O

Effexor O
XR O
treatment O
for O
up O
to O
12 O
weeks O
and O
up O
to O
6 O
months O
in O
premarketing O
placebo-controlled O
Social B-Not_AE_Candidate
Anxiety I-Not_AE_Candidate
Disorder I-Not_AE_Candidate
trials O
was O
associated O
with O
mean O
final O
on-therapy O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
concentration I-OSE_Labeled_AE
of O
approximately O
7.9 O
mg/dL O
and O
5.6 O
mg/dL O
, O
respectively O
, O
compared O
with O
mean O
final O
decreases O
of O
2.9 O
and O
4.2 O
mg/dL O
, O
respectively O
, O
for O
placebo O
. O

Effexor O
XR O
treatment O
for O
up O
to O
12 O
weeks O
in O
premarketing O
placebo-controlled O
panic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
trials O
was O
associated O
with O
mean O
final O
on-therapy O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
concentration I-OSE_Labeled_AE
of O
approximately O
5.8 O
mg/dL O
compared O
with O
a O
mean O
final O
decrease O
of O
3.7 O
mg/dL O
for O
placebo O
. O

Patients O
treated O
with O
Effexor O
( O
immediate O
release O
) O
for O
at O
least O
3 O
months O
in O
placebo-controlled O
12-month O
extension O
trials O
had O
a O
mean O
final O
on-therapy O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
total I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
of O
9.1 O
mg/dL O
compared O
with O
a O
decrease O
of O
7.1 O
mg/dL O
among O
placebo-treated O
patients O
. O

This O
increase O
was O
duration O
dependent O
over O
the O
study O
period O
and O
tended O
to O
be O
greater O
with O
higher O
doses O
. O

Clinically O
relevant O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
, O
defined O
as O
1 O
) O
a O
final O
on-therapy O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
> O
=50 O
mg/dL O
from O
baseline O
and O
to O
a O
value O
> O
=261 O
mg/dL O
, O
or O
2 O
) O
an O
average O
on-therapy O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
> O
=50 O
mg/dL O
from O
baseline O
and O
to O
a O
value O
> O
=261 O
mg/dL O
, O
were O
recorded O
in O
5.3 O
% O
of O
venlafaxine-treated O
patients O
and O
0.0 O
% O
of O
placebo-treated O
patients O
. O

Serum O
Triglycerides O
Effexor O
XR O
was O
associated O
with O
mean O
final O
on-therapy O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
fasting I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
triglycerides I-OSE_Labeled_AE
compared O
with O
placebo O
in O
premarketing O
clinical O
studies O
of O
SAD B-Not_AE_Candidate
and O
PD B-Not_AE_Candidate
up O
to O
12 O
weeks O
( O
pooled O
data O
) O
and O
6 O
months O
duration O
( O
Table O
14 O
) O
. O

Table O
14 O
: O
Mean O
Final O
On-therapy O
Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Triglyceride I-OSE_Labeled_AE
Concentrations O
( O
mg/dL O
) O
in O
Effexor O
XR O
Premarketing O
Studies O
Indication O
( O
Duration O
) O
Effexor O
XR O
Placebo O
SAD B-Not_AE_Candidate
( O
12 O
weeks O
) O
8.2 O
0.4 O
SAD B-Not_AE_Candidate
( O
6 O
months O
) O
11.8 O
1.8 O
PD B-Not_AE_Candidate
( O
12 O
weeks O
) O
5.9 O
0.9 O
PD B-Not_AE_Candidate
( O
6 O
months O
) O
9.3 O
0.3 O
6.4 O
Pediatric O
Patients O
In O
general O
, O
the O
adverse O
reaction O
profile O
of O
venlafaxine O
( O
in O
placebo-controlled O
clinical O
studies O
) O
in O
children O
and O
adolescents O
( O
ages O
6 O
to O
17 O
) O
was O
similar O
to O
that O
seen O
for O
adults O
. O

As O
with O
adults O
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
, O
and O
increased B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
were O
observed O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
, O
5.10 O
, O
5.11 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.4 O
) O
] O
. O

In O
pediatric O
clinical O
studies O
, O
the O
adverse O
reaction O
, O
suicidal B-OSE_Labeled_AE
ideation I-OSE_Labeled_AE
, O
was O
observed O
. O

Particularly O
, O
the O
following O
adverse O
reactions O
were O
observed O
in O
pediatric O
patients O
: O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
ecchymosis B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
and O
myalgia B-OSE_Labeled_AE
. O

6.5 O
Adverse O
Reactions O
Identified O
During O
Postapproval O
Use O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
postapproval O
use O
of O
Effexor O
XR O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
: O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
whole I-NonOSE_AE
- O
Anaphylaxis B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
Cardiovascular B-NonOSE_AE
system I-NonOSE_AE
- O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
( O
including O
torsade B-OSE_Labeled_AE
de I-OSE_Labeled_AE
pointes I-OSE_Labeled_AE
) O
, O
takotsubo B-OSE_Labeled_AE
cardiomyopathy I-OSE_Labeled_AE
Digestive B-NonOSE_AE
system I-NonOSE_AE
- O
Pancreatitis B-OSE_Labeled_AE
Hemic B-NonOSE_AE
/ I-NonOSE_AE
Lymphatic I-NonOSE_AE
system I-NonOSE_AE
- O
Mucous B-OSE_Labeled_AE
membrane I-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
, O
blood B-OSE_Labeled_AE
dyscrasias I-OSE_Labeled_AE
( O
including O
agranulocytosis B-OSE_Labeled_AE
, O
aplastic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
and O
pancytopenia B-OSE_Labeled_AE
) O
, O
prolonged B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
time I-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
Metabolic B-NonOSE_AE
/ I-NonOSE_AE
Nutritional I-NonOSE_AE
- O
Hyponatremia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
, O
Syndrome B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Inappropriate I-OSE_Labeled_AE
Antidiuretic I-OSE_Labeled_AE
Hormone I-OSE_Labeled_AE
( I-OSE_Labeled_AE
SIADH I-OSE_Labeled_AE
) I-OSE_Labeled_AE
secretion I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
, O
abnormal B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
, O
prolactin B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
Musculoskeletal B-NonOSE_AE
- O
Rhabdomyolysis B-OSE_Labeled_AE
Nervous B-NonOSE_AE
system I-NonOSE_AE
- O
Neuroleptic B-OSE_Labeled_AE
Malignant I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
NMS I-OSE_Labeled_AE
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
, O
serotonergic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
, O
delirium B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
including O
dystonia B-OSE_Labeled_AE
and O
dyskinesia B-OSE_Labeled_AE
) O
, O
impaired B-OSE_Labeled_AE
coordination O
and O
balance I-OSE_Labeled_AE
, O
tardive B-OSE_Labeled_AE
dyskinesia I-OSE_Labeled_AE
Respiratory B-NonOSE_AE
system I-NonOSE_AE
- O
Dyspnea B-OSE_Labeled_AE
, O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
eosinophilia I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.12 O
) O
] O
Skin B-NonOSE_AE
and I-NonOSE_AE
appendages I-NonOSE_AE
- O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
Special B-NonOSE_AE
senses I-NonOSE_AE
- O
Angle B-OSE_Labeled_AE
- I-OSE_Labeled_AE
closure I-OSE_Labeled_AE
glaucoma I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O

BOXED O
WARNING O
: O
WARNING O
: O
SUICIDAL O
THOUGHTS O
AND O
BEHAVIORS O
WARNING O
: O
SUICIDAL O
THOUGHTS O
AND O
BEHAVIORS O
Antidepressants O
increased O
the O
risk O
of O
suicidal B-OSE_Labeled_AE
thoughts O
and O
behavior I-OSE_Labeled_AE
in O
children O
, O
adolescents O
, O
and O
young O
adults O
in O
short-term O
studies O
. O

These O
studies O
did O
not O
show O
an O
increase O
in O
the O
risk O
of O
suicidal B-NonOSE_AE
thoughts O
and O
behavior I-NonOSE_AE
with O
antidepressant O
use O
in O
patients O
over O
age O
24 O
; O
there O
was O
a O
reduction O
in O
risk O
with O
antidepressant O
use O
in O
patients O
aged O
65 O
and O
older O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

In O
patients O
of O
all O
ages O
who O
are O
started O
on O
antidepressant O
therapy O
monitor O
closely O
for O
clinical O
worsening O
and O
emergence O
of O
suicidal B-NonOSE_AE
thoughts O
and O
behaviors I-NonOSE_AE
. O

Advise O
families O
and O
caregivers O
of O
the O
need O
for O
close O
observation O
and O
communication O
with O
the O
prescriber O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
and O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
SUICIDAL O
THOUGHTS O
AND O
BEHAVIORS O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Increased O
risk O
of O
suicidal O
thinking O
and O
behavior O
in O
children O
, O
adolescents O
and O
young O
adults O
taking O
antidepressants O
( O
5.1 O
) O
* O
Monitor O
for O
worsening O
and O
emergence O
of O
suicidal O
thoughts O
and O
behaviors O
( O
5.1 O
) O
* O
Effexor O
XR O
is O
not O
approved O
for O
use O
in O
pediatric O
patients O
( O
8.4 O
) O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Clinical O
Worsening/Suicide O
Risk O
: O
Monitor O
for O
clinical O
worsening O
and O
suicide O
risk O
( O
5.1 O
) O
. O

* O
Serotonin O
Syndrome O
: O
Risk O
increases O
with O
concomitant O
use O
of O
other O
serotonergic O
drugs O
. O

Discontinue O
Effexor O
XR O
and O
initiate O
supportive O
treatment O
if O
serotonin O
syndrome O
occurs O
( O
4.2 O
, O
5.2 O
, O
7.3 O
) O
. O

* O
Elevations O
in O
Blood O
Pressure O
: O
Control O
hypertension O
before O
initiating O
treatment O
. O

Monitor O
blood O
pressure O
regularly O
during O
treatment O
( O
5.3 O
) O
. O

* O
Abnormal O
Bleeding O
: O
Effexor O
XR O
may O
increase O
risk O
of O
bleeding O
events O
. O

Caution O
patients O
about O
the O
risk O
of O
bleeding O
associated O
with O
the O
concomitant O
use O
of O
Effexor O
XR O
and O
NSAIDs O
, O
aspirin O
, O
or O
other O
drugs O
that O
affect O
coagulation O
( O
5.4 O
) O
. O

* O
Angle O
Closure O
Glaucoma O
: O
Angle O
closure O
glaucoma O
has O
occurred O
in O
patients O
with O
untreated O
anatomically O
narrow O
angles O
treated O
with O
antidepressants O
. O

( O
5.5 O
) O
. O

* O
Activation O
of O
Mania/Hypomania O
: O
Use O
cautiously O
in O
patients O
with O
bipolar O
disorder O
. O

Caution O
patients O
about O
the O
risk O
of O
activation O
of O
mania/hypomania O
( O
5.6 O
) O
. O

5.1 O
Suicidal O
Thoughts O
and O
Behaviors O
in O
Children O
, O
Adolescents O
, O
and O
Young O
Adults O
Patients O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
, O
both O
adult O
and O
pediatric O
, O
may O
experience O
worsening B-NonOSE_AE
of I-NonOSE_AE
their I-NonOSE_AE
depression I-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
ideation I-NonOSE_AE
and O
behavior O
( O
suicidality B-NonOSE_AE
) O
or O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
whether O
or O
not O
they O
are O
taking O
antidepressant O
medications O
, O
and O
this O
risk O
may O
persist O
until O
significant O
remission O
occurs O
. O

Suicide B-NonOSE_AE
is O
a O
known O
risk O
of O
depression B-NonOSE_AE
and O
certain O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
, O
and O
these O
disorders O
themselves O
are O
the O
strongest O
predictors O
of O
suicide B-NonOSE_AE
. O

There O
has O
been O
a O
long-standing O
concern O
, O
however O
, O
that O
antidepressants O
may O
have O
a O
role O
in O
inducing O
worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
depression I-OSE_Labeled_AE
and O
the O
emergence O
of O
suicidality B-OSE_Labeled_AE
in O
certain O
patients O
during O
the O
early O
phases O
of O
treatment O
. O

Pooled O
analyses O
of O
short-term O
placebo-controlled O
studies O
of O
antidepressant O
drugs O
( O
SSRIs O
and O
others O
) O
showed O
that O
these O
drugs O
increase O
the O
risk O
of O
suicidal B-OSE_Labeled_AE
thinking O
and O
behavior I-OSE_Labeled_AE
( O
suicidality B-OSE_Labeled_AE
) O
in O
children O
, O
adolescents O
, O
and O
young O
adults O
( O
ages O
18-24 O
) O
with O
MDD B-Not_AE_Candidate
and O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Short-term O
studies O
did O
not O
show O
an O
increase O
in O
the O
risk O
of O
suicidality B-NonOSE_AE
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
beyond O
age O
24 O
; O
there O
was O
a O
reduction O
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
aged O
65 O
and O
older O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
studies O
in O
children O
and O
adolescents O
with O
MDD B-Not_AE_Candidate
, O
Obsessive B-Not_AE_Candidate
Compulsive I-Not_AE_Candidate
Disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
OCD I-Not_AE_Candidate
) O
, O
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
24 O
short-term O
studies O
of O
9 O
antidepressant O
drugs O
in O
over O
4,400 O
patients O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
studies O
in O
adults O
with O
MDD B-Not_AE_Candidate
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
295 O
short-term O
studies O
( O
median O
duration O
of O
2 O
months O
) O
of O
11 O
antidepressant O
drugs O
in O
over O
77,000 O
patients O
. O

There O
was O
considerable O
variation O
in O
risk O
of O
suicidality B-OSE_Labeled_AE
among O
drugs O
, O
but O
a O
tendency O
toward O
an O
increase O
in O
the O
younger O
patients O
for O
almost O
all O
drugs O
studied O
. O

There O
were O
differences O
in O
absolute O
risk O
of O
suicidality B-NonOSE_AE
across O
the O
different O
indications O
, O
with O
the O
highest O
incidence O
in O
MDD B-Not_AE_Candidate
. O

The O
risk O
differences O
( O
drug O
versus O
placebo O
) O
, O
however O
, O
were O
relatively O
stable O
within O
age O
strata O
and O
across O
indications O
. O

These O
risk O
differences O
( O
drug-placebo O
difference O
in O
the O
number O
of O
cases O
of O
suicidality B-NonOSE_AE
per O
1,000 O
patients O
treated O
) O
are O
provided O
in O
Table O
1 O
. O

Table O
1 O
: O
Difference O
in O
the O
Number O
of O
Cases O
of O
Suicidality B-OSE_Labeled_AE
per O
1,000 O
Patients O
Treated O
versus O
Placebo O
Age O
Range O
Increases O
Compared O
to O
Placebo O
< O
18 O
14 O
additional O
cases O
18-24 O
5 O
additional O
cases O
Decreases O
Compared O
to O
Placebo O
25-64 O
1 O
fewer O
case O
> O
= O
65 O
6 O
fewer O
cases O
No O
suicides B-NonOSE_AE
occurred O
in O
any O
of O
the O
pediatric O
studies O
. O

There O
were O
suicides B-NonOSE_AE
in O
the O
adult O
studies O
, O
but O
the O
number O
was O
not O
sufficient O
to O
reach O
any O
conclusion O
about O
drug O
effect O
on O
suicide B-NonOSE_AE
. O

It O
is O
unknown O
whether O
the O
suicidality B-NonOSE_AE
risk O
extends O
to O
longer O
term O
use O
, O
i.e. O
, O
beyond O
several O
months O
. O

However O
, O
there O
is O
substantial O
evidence O
from O
placebo-controlled O
maintenance O
studies O
in O
adults O
with O
depression B-Not_AE_Candidate
that O
the O
use O
of O
antidepressants O
can O
delay O
the O
recurrence O
of O
depression B-NonOSE_AE
. O

All O
patients O
being O
treated O
with O
antidepressants O
for O
any O
indication O
should O
be O
monitored O
appropriately O
and O
observed O
closely O
for O
clinical O
worsening O
, O
suicidality B-NonOSE_AE
, O
and O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
especially O
during O
the O
initial O
few O
months O
of O
a O
course O
of O
drug O
therapy O
, O
or O
at O
times O
of O
dose O
changes O
, O
either O
increases O
or O
decreases O
. O

The O
following O
symptoms O
, O
anxiety B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
panic B-OSE_Labeled_AE
attacks I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
hostility B-OSE_Labeled_AE
, O
aggressiveness B-OSE_Labeled_AE
, O
impulsivity B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
( O
psychomotor B-OSE_Labeled_AE
restlessness I-OSE_Labeled_AE
) O
, O
hypomania B-OSE_Labeled_AE
, O
and O
mania B-OSE_Labeled_AE
, O
have O
been O
reported O
in O
adult O
and O
pediatric O
patients O
being O
treated O
with O
antidepressants O
for O
MDD B-Not_AE_Candidate
, O
as O
well O
as O
for O
other O
indications O
, O
both O
psychiatric O
and O
nonpsychiatric O
. O

Although O
a O
causal O
link O
between O
the O
emergence O
of O
such O
symptoms O
and O
either O
the O
worsening O
of O
depression B-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
impulses I-NonOSE_AE
has O
not O
been O
established O
, O
there O
is O
concern O
that O
such O
symptoms O
may O
represent O
precursors O
to O
emerging O
suicidality B-NonOSE_AE
. O

Consideration O
should O
be O
given O
to O
changing O
the O
therapeutic O
regimen O
, O
including O
possibly O
discontinuing O
the O
medication O
, O
in O
patients O
whose O
depression B-Not_AE_Candidate
is O
persistently O
worse O
, O
or O
who O
are O
experiencing O
emergent O
suicidality B-NonOSE_AE
or O
symptoms O
that O
might O
be O
precursors O
to O
worsening B-NonOSE_AE
depression I-NonOSE_AE
or O
suicidality B-NonOSE_AE
, O
especially O
if O
these O
symptoms O
are O
severe O
, O
abrupt O
in O
onset O
, O
or O
were O
not O
part O
of O
the O
patient O
's O
presenting O
symptoms O
. O

If O
the O
decision O
has O
been O
made O
to O
discontinue O
treatment O
, O
medication O
should O
be O
tapered O
, O
as O
rapidly O
as O
is O
feasible O
, O
but O
with O
recognition O
that O
abrupt O
discontinuation B-NonOSE_AE
can I-NonOSE_AE
be I-NonOSE_AE
associated I-NonOSE_AE
with I-NonOSE_AE
certain I-NonOSE_AE
symptoms I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
and O
Dosage O
and O
Administration O
( O
2.8 O
) O
] O
. O

Families O
and O
caregivers O
of O
patients O
being O
treated O
with O
antidepressants O
for O
MDD B-Not_AE_Candidate
or O
other O
indications O
, O
both O
psychiatric B-Not_AE_Candidate
and O
nonpsychiatric O
, O
should O
be O
alerted O
about O
the O
need O
to O
monitor O
patients O
for O
the O
emergence O
of O
agitation B-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
and O
the O
other O
symptoms O
described O
above O
, O
as O
well O
as O
the O
emergence O
of O
suicidality B-NonOSE_AE
, O
and O
to O
report O
such O
symptoms O
immediately O
to O
healthcare O
providers O
. O

Such O
monitoring O
should O
include O
daily O
observation O
by O
families O
and O
caregivers O
. O

Prescriptions O
for O
Effexor O
XR O
should O
be O
written O
for O
the O
smallest O
quantity O
of O
capsules O
consistent O
with O
good O
patient O
management O
, O
in O
order O
to O
reduce O
the O
risk O
of O
overdose B-NonOSE_AE
. O

Screening O
Patients O
for O
Bipolar O
Disorder O
A O
major B-NonOSE_AE
depressive I-NonOSE_AE
episode I-NonOSE_AE
may O
be O
the O
initial O
presentation O
of O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

It O
is O
generally O
believed O
( O
though O
not O
established O
in O
controlled O
studies O
) O
that O
treating O
such O
an O
episode O
with O
an O
antidepressant O
alone O
may O
increase O
the O
likelihood O
of O
precipitation B-NonOSE_AE
of I-NonOSE_AE
a I-NonOSE_AE
mixed I-NonOSE_AE
/ I-NonOSE_AE
manic I-NonOSE_AE
episode I-NonOSE_AE
in O
patients O
at O
risk O
for O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

Whether O
any O
of O
the O
symptoms O
described O
above O
represent O
such O
a O
conversion O
is O
unknown O
. O

However O
, O
prior O
to O
initiating O
treatment O
with O
an O
antidepressant O
, O
patients O
with O
depressive B-Not_AE_Candidate
symptoms I-Not_AE_Candidate
should O
be O
adequately O
screened O
to O
determine O
if O
they O
are O
at O
risk O
for O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
; O
such O
screening O
should O
include O
a O
detailed O
psychiatric B-Not_AE_Candidate
history O
, O
including O
a O
family B-Not_AE_Candidate
history I-Not_AE_Candidate
of I-Not_AE_Candidate
suicide I-Not_AE_Candidate
, O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
and O
depression B-Not_AE_Candidate
. O

It O
should O
be O
noted O
that O
Effexor O
XR O
is O
not O
approved O
for O
use O
in O
treating O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
. O

5.2 O
Serotonin O
Syndrome O
The O
development O
of O
a O
potentially O
life-threatening O
serotonin B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
has O
been O
reported O
with O
SNRIs O
and O
SSRIs O
, O
including O
Effexor O
XR O
alone O
, O
but O
particularly O
with O
concomitant O
use O
of O
other O
serotonergic O
drugs O
( O
including O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
tryptophan O
, O
buspirone O
, O
amphetamines O
, O
and O
St O
. O
John O
's O
wort O
) O
and O
with O
drugs O
that O
impair O
metabolism O
of O
serotonin O
in O
particular O
, O
MAOIs O
, O
both O
those O
intended O
to O
treat O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
and O
others O
, O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
) O
. O

Serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
symptoms O
may O
include O
mental B-NonOSE_AE
status I-NonOSE_AE
changes I-NonOSE_AE
( O
e.g. O
, O
agitation B-NonOSE_AE
, O
hallucinations B-NonOSE_AE
, O
delirium B-NonOSE_AE
, O
coma B-NonOSE_AE
) O
autonomic B-NonOSE_AE
instability I-NonOSE_AE
( O
e.g. O
, O
tachycardia B-NonOSE_AE
, O
labile B-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
, O
hyperthermia B-NonOSE_AE
, O
diaphoresis B-NonOSE_AE
, O
flushing B-NonOSE_AE
, O
and O
dizziness B-NonOSE_AE
) O
, O
neuromuscular B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
tremor B-NonOSE_AE
, O
rigidity B-NonOSE_AE
, O
myoclonus B-NonOSE_AE
, O
hyperreflexia B-NonOSE_AE
, O
incoordination B-NonOSE_AE
) O
; O
seizures B-NonOSE_AE
and O
gastrointestinal B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
) O
. O

Patients O
should O
be O
monitored O
for O
the O
emergence O
of O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
. O

The O
concomitant O
use O
of O
Effexor O
XR O
with O
MAOIs O
( O
intended O
to O
treat O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
) O
is O
contraindicated O
. O

Effexor O
XR O
should O
also O
not O
be O
started O
in O
a O
patient O
who O
is O
being O
treated O
with O
MAOIs O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
. O

All O
reports O
with O
methylene O
blue O
that O
provided O
information O
on O
the O
route O
of O
administration O
involved O
intravenous O
administration O
in O
the O
dose O
range O
of O
1 O
mg/kg O
to O
8 O
mg/kg O
. O

No O
reports O
involved O
the O
administration O
of O
methylene O
blue O
by O
other O
routes O
( O
such O
as O
oral O
tablets O
or O
local O
tissue O
injection O
) O
or O
at O
lower O
doses O
. O

There O
may O
be O
circumstances O
when O
it O
is O
necessary O
to O
initiate O
treatment O
with O
a O
MAOI O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
in O
a O
patient O
taking O
Effexor O
XR O
. O

Effexor O
XR O
should O
be O
discontinued O
before O
initiating O
treatment O
with O
the O
MAOI O
[ O
see O
Contraindications O
( O
4.2 O
) O
, O
Dosage O
and O
Administration O
( O
2.6 O
) O
, O
and O
Drug O
Interactions O
( O
7.3 O
) O
] O
. O

If O
concomitant O
use O
of O
Effexor O
XR O
with O
other O
serotonergic O
drugs O
( O
e.g. O
, O
triptans O
, O
tricyclic O
antidepressants O
, O
mirtazapine O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
buspirone O
, O
amphetamines O
, O
tryptophan O
, O
or O
St O
. O
John O
's O
wort O
) O
is O
clinically O
warranted O
, O
careful O
observation O
of O
the O
patient O
is O
advised O
, O
particularly O
during O
treatment O
initiation O
and O
dose O
increases O
[ O
see O
Drug O
Interactions O
( O
7.3 O
) O
] O
. O

Patients O
should O
be O
made O
aware O
of O
the O
potential O
risk O
of O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
. O

Treatment O
with O
Effexor O
XR O
and O
any O
concomitant O
serotonergic O
agents O
should O
be O
discontinued O
immediately O
if O
the O
above O
events O
occur O
, O
and O
supportive O
symptomatic O
treatment O
should O
be O
initiated O
. O

5.3 O
Elevations O
in O
Blood O
Pressure O
In O
controlled O
trials O
, O
there O
were O
dose-related O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
systolic O
and O
diastolic I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
, O
as O
well O
as O
cases O
of O
sustained O
hypertension B-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

Monitor O
blood O
pressure O
before O
initiating O
treatment O
with O
Effexor O
XR O
and O
regularly O
during O
treatment O
. O

Control O
pre-existing O
hypertension B-Not_AE_Candidate
before O
initiating O
treatment O
with O
Effexor O
XR O
. O

Use O
caution O
in O
treating O
patients O
with O
pre-existing O
hypertension B-Not_AE_Candidate
or O
cardiovascular B-Not_AE_Candidate
or O
cerebrovascular O
conditions I-Not_AE_Candidate
that O
might O
be O
compromised O
by O
increases B-NonOSE_AE
in I-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
. O

Sustained O
blood B-NonOSE_AE
pressure I-NonOSE_AE
elevation I-NonOSE_AE
can O
lead O
to O
adverse O
outcomes O
. O

Cases O
of O
elevated B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
requiring O
immediate O
treatment O
have O
been O
reported O
with O
Effexor O
XR O
. O

Consider O
dose O
reduction O
or O
discontinuation O
of O
treatment O
for O
patients O
who O
experience O
a O
sustained O
increase B-NonOSE_AE
in I-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
. O

Across O
all O
clinical O
studies O
with O
Effexor O
, O
1.4 O
% O
of O
patients O
in O
the O
Effexor O
XR O
treated O
groups O
experienced O
a O
> O
=15 O
mm O
Hg O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
supine I-OSE_Labeled_AE
diastolic I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
( O
SDBP O
) O
> O
= O
105 O
mm O
Hg O
, O
compared O
to O
0.9 O
% O
of O
patients O
in O
the O
placebo O
groups O
. O

Similarly O
, O
1 O
% O
of O
patients O
in O
the O
Effexor O
XR O
treated O
groups O
experienced O
a O
> O
= O
20 O
mm O
Hg O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
supine I-OSE_Labeled_AE
systolic I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
( O
SSBP O
) O
with O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
8 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mm I-OSE_Labeled_AE
Hg I-OSE_Labeled_AE
, O
compared O
to O
0.3 O
% O
of O
patients O
in O
the O
placebo O
groups O
[ O
see O
Table O
10 O
in O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

Effexor O
XR O
treatment O
was O
associated O
with O
sustained B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
( O
defined O
as O
treatment-emergent O
SDBP B-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
9 I-NonOSE_AE
0 I-NonOSE_AE
mm I-NonOSE_AE
Hg I-NonOSE_AE
and O
> O
= O
10 O
mm O
Hg O
above O
baseline O
for O
three O
consecutive O
on-therapy O
visits O
[ O
see O
Table O
11 O
in O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

An O
insufficient O
number O
of O
patients O
received O
mean O
doses O
of O
Effexor O
XR O
over O
300 O
mg O
per O
day O
in O
clinical O
studies O
to O
fully O
evaluate O
the O
incidence O
of O
sustained O
increases B-NonOSE_AE
in I-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
at O
these O
higher O
doses O
. O

5.4 O
Abnormal O
Bleeding O
SSRIs O
and O
SNRIs O
, O
including O
Effexor O
XR O
, O
may O
increase O
the O
risk O
of O
bleeding B-OSE_Labeled_AE
events O
, O
ranging O
from O
ecchymoses B-OSE_Labeled_AE
, O
hematomas B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
petechiae B-OSE_Labeled_AE
, O
and O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
to O
life-threatening O
hemorrhage B-OSE_Labeled_AE
. O

Concomitant O
use O
of O
aspirin O
, O
Nonsteroidal O
Anti-Inflammatory O
Drugs O
( O
NSAIDs O
) O
, O
warfarin O
, O
and O
other O
anti-coagulants O
or O
other O
drugs O
known O
to O
affect O
platelet O
function O
may O
add O
to O
this O
risk O
. O

Case O
reports O
and O
epidemiological O
studies O
( O
case-control O
and O
cohort O
design O
) O
have O
demonstrated O
an O
association O
between O
use O
of O
drugs O
that O
interfere O
with O
serotonin O
reuptake O
and O
the O
occurrence O
of O
gastrointestinal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
. O

Caution O
patients O
about O
the O
risk O
of O
bleeding B-NonOSE_AE
associated O
with O
the O
concomitant O
use O
of O
Effexor O
XR O
and O
NSAIDs O
, O
aspirin O
, O
or O
other O
drugs O
that O
affect O
coagulation O
. O

5.5 O
Angle-Closure O
Glaucoma O
The O
pupillary B-OSE_Labeled_AE
dilation I-OSE_Labeled_AE
that O
occurs O
following O
use O
of O
many O
antidepressant O
drugs O
including O
Effexor O
XR O
may O
trigger O
an O
angle B-OSE_Labeled_AE
closure I-OSE_Labeled_AE
attack I-OSE_Labeled_AE
in O
a O
patient O
with O
anatomically B-Not_AE_Candidate
narrow I-Not_AE_Candidate
angles I-Not_AE_Candidate
who O
does O
not O
have O
a O
patent O
iridectomy O
. O

5.6 O
Activation O
of O
Mania/Hypomania O
Mania B-OSE_Labeled_AE
or O
hypomania B-OSE_Labeled_AE
was O
reported O
in O
Effexor O
XR O
treated O
patients O
in O
the O
premarketing O
studies O
in O
MDD B-Not_AE_Candidate
, O
SAD B-Not_AE_Candidate
, O
and O
PD B-Not_AE_Candidate
( O
see O
Table O
2 O
) O
. O

Mania B-NonOSE_AE
/ O
hypomania B-NonOSE_AE
has O
also O
been O
reported O
in O
a O
small O
proportion O
of O
patients O
with O
mood B-Not_AE_Candidate
disorders I-Not_AE_Candidate
who O
were O
treated O
with O
other O
marketed O
drugs O
to O
treat O
MDD B-Not_AE_Candidate
. O

Effexor O
XR O
should O
be O
used O
cautiously O
in O
patients O
with O
a O
history O
of O
mania B-Not_AE_Candidate
or O
hypomania B-Not_AE_Candidate
. O

Table O
2 O
: O
Incidence O
( O
% O
) O
of O
Mania B-OSE_Labeled_AE
or O
Hypomania B-OSE_Labeled_AE
Reported O
in O
Effexor O
XR O
Treated O
Patients O
in O
the O
Premarketing O
Studies O
Indication O
Effexor O
XR O
Placebo O
MDD B-Not_AE_Candidate
0.3 O
0.0 O
GAD B-Not_AE_Candidate
0.0 O
0.2 O
SAD B-Not_AE_Candidate
0.2 O
0.0 O
PD B-Not_AE_Candidate
0.1 O
0.0 O
5.7 O
Discontinuation O
Syndrome O
Discontinuation B-NonOSE_AE
symptoms I-NonOSE_AE
have O
been O
systematically O
evaluated O
in O
patients O
taking O
venlafaxine O
, O
including O
prospective O
analyses O
of O
clinical O
studies O
in O
GAD B-Not_AE_Candidate
and O
retrospective O
surveys O
of O
studies O
in O
MDD B-Not_AE_Candidate
and O
SAD B-Not_AE_Candidate
. O

Abrupt O
discontinuation B-OSE_Labeled_AE
or I-OSE_Labeled_AE
dose I-OSE_Labeled_AE
reduction I-OSE_Labeled_AE
of I-OSE_Labeled_AE
venlafaxine I-OSE_Labeled_AE
at I-OSE_Labeled_AE
various I-OSE_Labeled_AE
doses I-OSE_Labeled_AE
has I-OSE_Labeled_AE
been I-OSE_Labeled_AE
found I-OSE_Labeled_AE
to I-OSE_Labeled_AE
be I-OSE_Labeled_AE
associated I-OSE_Labeled_AE
with I-OSE_Labeled_AE
the I-OSE_Labeled_AE
appearance I-OSE_Labeled_AE
of I-OSE_Labeled_AE
new I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
, O
the O
frequency O
of O
which O
increased O
with O
increased O
dose O
level O
and O
with O
longer O
duration O
of O
treatment O
. O

Reported O
symptoms O
include O
agitation B-NonOSE_AE
, O
anorexia B-NonOSE_AE
, O
anxiety B-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
impaired B-NonOSE_AE
coordination O
and O
balance I-NonOSE_AE
, O
diarrhea B-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
dry B-NonOSE_AE
mouth I-NonOSE_AE
, O
dysphoric B-NonOSE_AE
mood I-NonOSE_AE
, O
fasciculation B-NonOSE_AE
, O
fatigue B-NonOSE_AE
, O
flu B-NonOSE_AE
- I-NonOSE_AE
like I-NonOSE_AE
symptoms I-NonOSE_AE
, O
headaches B-NonOSE_AE
, O
hypomania B-NonOSE_AE
, O
insomnia B-NonOSE_AE
, O
nausea B-NonOSE_AE
, O
nervousness B-NonOSE_AE
, O
nightmares B-NonOSE_AE
, O
sensory B-NonOSE_AE
disturbances I-NonOSE_AE
( O
including O
shock B-NonOSE_AE
- I-NonOSE_AE
like I-NonOSE_AE
electrical I-NonOSE_AE
sensations I-NonOSE_AE
) O
, O
somnolence B-NonOSE_AE
, O
sweating B-NonOSE_AE
, O
tremor B-NonOSE_AE
, O
vertigo B-NonOSE_AE
, O
and O
vomiting B-NonOSE_AE
. O

During O
marketing O
of O
Effexor O
XR O
, O
other O
SNRIs O
, O
and O
SSRIs O
, O
there O
have O
been O
spontaneous O
reports O
of O
adverse B-OSE_Labeled_AE
events I-OSE_Labeled_AE
occurring I-OSE_Labeled_AE
upon I-OSE_Labeled_AE
discontinuation I-OSE_Labeled_AE
of O
these O
drugs O
, O
particularly O
when O
abrupt O
, O
including O
the O
following O
: O
dysphoric B-NonOSE_AE
mood I-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
agitation B-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
sensory B-NonOSE_AE
disturbances I-NonOSE_AE
( O
e.g. O
, O
paresthesia B-NonOSE_AE
, O
such O
as O
electric B-NonOSE_AE
shock I-NonOSE_AE
sensations I-NonOSE_AE
) O
, O
anxiety B-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
lethargy B-NonOSE_AE
, O
emotional B-NonOSE_AE
lability I-NonOSE_AE
, O
insomnia B-NonOSE_AE
, O
hypomania B-NonOSE_AE
, O
tinnitus B-NonOSE_AE
, O
and O
seizures B-NonOSE_AE
. O

While O
these O
events O
are O
generally O
self-limiting O
, O
there O
have O
been O
reports O
of O
serious O
discontinuation B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
. O

Patients O
should O
be O
monitored O
for O
these O
symptoms O
when O
discontinuing O
treatment O
with O
Effexor O
XR O
. O

A O
gradual O
reduction O
in O
the O
dose O
, O
rather O
than O
abrupt O
cessation O
, O
is O
recommended O
whenever O
possible O
. O

If O
intolerable O
symptoms B-NonOSE_AE
occur I-NonOSE_AE
following I-NonOSE_AE
a I-NonOSE_AE
decrease I-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
dose I-NonOSE_AE
or I-NonOSE_AE
upon I-NonOSE_AE
discontinuation I-NonOSE_AE
of I-NonOSE_AE
treatment I-NonOSE_AE
, O
then O
resuming O
the O
previously O
prescribed O
dose O
may O
be O
considered O
. O

Subsequently O
, O
the O
physician O
may O
continue O
decreasing O
the O
dose O
, O
but O
at O
a O
more O
gradual O
rate O
[ O
see O
Dosage O
and O
Administration O
( O
2.8 O
) O
] O
. O

5.8 O
Seizures O
Seizures B-OSE_Labeled_AE
have O
occurred O
with O
venlafaxine O
therapy O
. O

Effexor O
XR O
, O
like O
many O
antidepressants O
, O
should O
be O
used O
cautiously O
in O
patients O
with O
a O
history O
of O
seizures B-Not_AE_Candidate
and O
should O
be O
discontinued O
in O
any O
patient O
who O
develops O
seizures B-NonOSE_AE
. O

[ O
Must O
mitigate O
the O
risk O
: O
Risk O
factors O
, O
concomitant O
meds O
that O
lower B-NonOSE_AE
the I-NonOSE_AE
seizure I-NonOSE_AE
threshold I-NonOSE_AE
. O
] O

5.9 O
Hyponatremia O
Hyponatremia B-OSE_Labeled_AE
can O
occur O
as O
a O
result O
of O
treatment O
with O
SSRIs O
and O
SNRIs O
, O
including O
Effexor O
XR O
. O

In O
many O
cases O
, O
the O
hyponatremia B-OSE_Labeled_AE
appears O
to O
be O
the O
result O
of O
the O
Syndrome B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Inappropriate I-OSE_Labeled_AE
Antidiuretic I-OSE_Labeled_AE
Hormone I-OSE_Labeled_AE
( I-OSE_Labeled_AE
SIADH I-OSE_Labeled_AE
) O
secretion O
. O

Cases O
with O
serum B-OSE_Labeled_AE
sodium I-OSE_Labeled_AE
lower I-OSE_Labeled_AE
than I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mmol I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
have O
been O
reported O
. O

Elderly O
patients O
may O
be O
at O
greater O
risk O
of O
developing O
hyponatremia B-OSE_Labeled_AE
with O
SSRIs O
and O
SNRIs O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
] O
. O

Also O
, O
patients O
taking O
diuretics O
, O
or O
those O
who O
are O
otherwise O
volume-depleted O
, O
may O
be O
at O
greater O
risk O
. O

Consider O
discontinuation O
of O
Effexor O
XR O
in O
patients O
with O
symptomatic O
hyponatremia B-NonOSE_AE
, O
and O
institute O
appropriate O
medical O
intervention O
. O

Signs O
and O
symptoms O
of O
hyponatremia B-NonOSE_AE
include O
headache B-NonOSE_AE
, O
difficulty B-NonOSE_AE
concentrating I-NonOSE_AE
, O
memory B-NonOSE_AE
impairment I-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
weakness B-NonOSE_AE
, O
and O
unsteadiness B-NonOSE_AE
, O
which O
may O
lead O
to O
falls B-NonOSE_AE
. O

Signs O
and O
symptoms O
associated O
with O
more O
severe O
and/or O
acute O
cases O
have O
included O
hallucination B-NonOSE_AE
, O
syncope B-NonOSE_AE
, O
seizure B-NonOSE_AE
, O
coma B-NonOSE_AE
, O
respiratory B-NonOSE_AE
arrest I-NonOSE_AE
, O
and O
death B-NonOSE_AE
. O

5.10 O
Weight O
and O
Height B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
in O
Pediatric O
Patients O
Weight O
Changes O
The O
average O
change B-OSE_Labeled_AE
in I-OSE_Labeled_AE
body I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
and O
incidence O
of O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
( O
percentage O
of O
patients O
who O
lost O
3.5 O
% O
or O
more O
) O
in O
the O
placebo-controlled O
pediatric O
studies O
in O
MDD B-Not_AE_Candidate
, O
GAD B-Not_AE_Candidate
, O
and O
SAD B-Not_AE_Candidate
are O
shown O
in O
Tables O
3 O
and O
4 O
. O

Table O
3 O
: O
Average O
Change O
in O
Body O
Weight O
( O
kg O
) O
From O
Beginning O
of O
Treatment O
in O
Pediatric O
Patients O
in O
Double-blind O
, O
Placebo-controlled O
Studies O
of O
Effexor O
XR O
Indication O
( O
Duration O
) O
Effexor O
XR O
Placebo O
MDD B-Not_AE_Candidate
and O
GAD B-Not_AE_Candidate
( O
4 O
pooled O
studies O
, O
8 O
weeks O
) O
-0.45 O
( O
n O
= O
333 O
) O
+0.77 O
( O
n O
= O
333 O
) O
SAD B-Not_AE_Candidate
( O
16 O
weeks O
) O
-0.75 O
( O
n O
= O
137 O
) O
+0.76 O
( O
n O
= O
148 O
) O
Table O
4 O
: O
Incidence O
( O
% O
) O
of O
Pediatric O
Patients O
Experiencing O
Weight O
Loss O
( O
3.5 O
% O
or O
more O
) O
in O
Double-blind O
, O
Placebo-controlled O
Studies O
of O
Effexor O
XR O
Indication O
( O
Duration O
) O
Effexor O
XR O
Placebo O
MDD B-Not_AE_Candidate
and O
GAD B-Not_AE_Candidate
( O
4 O
pooled O
studies O
, O
8 O
weeks O
) O
18 O
[ O
note O
: O
p O
< O
0.001 O
versus O
placebo O
] O
( O
n O
= O
333 O
) O
3.6 O
( O
n O
= O
333 O
) O
SAD B-Not_AE_Candidate
( O
16 O
weeks O
) O
47 O
( O
n O
= O
137 O
) O
14 O
( O
n O
= O
148 O
) O
Weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
was O
not O
limited O
to O
patients O
with O
treatment-emergent O
anorexia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
. O

The O
risks O
associated O
with O
longer O
term O
Effexor O
XR O
use O
were O
assessed O
in O
an O
open-label O
MDD B-Not_AE_Candidate
study O
of O
children O
and O
adolescents O
who O
received O
Effexor O
XR O
for O
up O
to O
six O
months O
. O

The O
children O
and O
adolescents O
in O
the O
study O
had O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
that I-OSE_Labeled_AE
were I-OSE_Labeled_AE
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
expected I-OSE_Labeled_AE
, O
based O
on O
data O
from O
age- O
and O
sex-matched O
peers O
. O

The O
difference B-OSE_Labeled_AE
between I-OSE_Labeled_AE
observed I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
gain I-OSE_Labeled_AE
and I-OSE_Labeled_AE
expected I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
gain I-OSE_Labeled_AE
was O
larger O
for O
children O
( O
< O
12 O
years O
old O
) O
than O
for O
adolescents O
( O
> O
= O
12 O
years O
old O
) O
. O

Height O
Changes O
Table O
5 O
shows O
the O
average O
height B-NonOSE_AE
increase I-NonOSE_AE
in O
pediatric O
patients O
in O
the O
short-term O
, O
placebo-controlled O
MDD B-Not_AE_Candidate
, O
GAD B-Not_AE_Candidate
, O
and O
SAD B-Not_AE_Candidate
studies O
. O

The O
differences O
in O
height O
increases O
in O
GAD B-Not_AE_Candidate
and O
MDD B-Not_AE_Candidate
studies O
were O
most O
notable O
in O
patients O
younger O
than O
twelve O
. O

Table O
5 O
: O
Average O
Height O
Increases O
( O
cm O
) O
in O
Pediatric O
Patients O
in O
Placebo-controlled O
Studies O
of O
Effexor O
XR O
Indication O
( O
Duration O
) O
Effexor O
XR O
Placebo O
MDD B-Not_AE_Candidate
( O
8 O
weeks O
) O
0.8 O
( O
n O
= O
146 O
) O
0.7 O
( O
n O
= O
147 O
) O
GAD B-Not_AE_Candidate
( O
8 O
weeks O
) O
0.3 O
[ O
note O
: O
p O
= O
0.041 O
] O
( O
n O
= O
122 O
) O
1.0 O
( O
n O
= O
132 O
) O
SAD B-Not_AE_Candidate
( O
16 O
weeks O
) O
1.0 O
( O
n O
= O
109 O
) O
1.0 O
( O
n O
= O
112 O
) O
In O
the O
six-month O
, O
open-label O
MDD B-Not_AE_Candidate
study O
, O
children O
and O
adolescents O
had O
height B-OSE_Labeled_AE
increases I-OSE_Labeled_AE
that O
were O
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
expected I-OSE_Labeled_AE
, O
based O
on O
data O
from O
age- O
and O
sex-matched O
peers O
. O

The O
difference O
between O
observed O
and O
expected O
growth O
rates O
was O
larger O
for O
children O
( O
< O
12 O
years O
old O
) O
than O
for O
adolescents O
( O
> O
= O
12 O
years O
old O
) O
. O

5.11 O
Appetite B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
in O
Pediatric O
Patients O
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
( O
reported O
as O
treatment B-OSE_Labeled_AE
- I-OSE_Labeled_AE
emergent I-OSE_Labeled_AE
anorexia I-OSE_Labeled_AE
) O
was O
more O
commonly O
observed O
in O
Effexor O
XR O
treated O
patients O
versus O
placebo-treated O
patients O
in O
the O
premarketing O
evaluation O
of O
Effexor O
XR O
for O
MDD B-Not_AE_Candidate
, O
GAD B-Not_AE_Candidate
, O
and O
SAD B-Not_AE_Candidate
( O
see O
Table O
6 O
) O
. O

Table O
6 O
: O
Incidence O
( O
% O
) O
of O
Decreased O
Appetite O
and O
Associated O
Discontinuation O
RatesThe O
discontinuation O
rates O
for O
weight O
loss O
were O
0.7 O
% O
for O
patients O
receiving O
either O
Effexor O
XR O
or O
placebo O
. O

( O
% O
) O
in O
Pediatric O
Patients O
in O
Placebo-controlled O
Studies O
of O
Effexor O
XR O
Indication O
( O
Duration O
) O
Effexor O
XR O
Incidence O
Discontinuation O
Placebo O
Incidence O
Discontinuation O
MDD B-Not_AE_Candidate
and O
GAD B-Not_AE_Candidate
( O
pooled O
, O
8 O
weeks O
) O
10 O
0.0 O
3 O
- O
SAD B-Not_AE_Candidate
( O
16 O
weeks O
) O
22 O
0.7 O
3 O
0.0 O
5.12 O
Interstitial O
Lung O
Disease O
and O
Eosinophilic O
Pneumonia O
Interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
and O
eosinophilic B-OSE_Labeled_AE
pneumonia I-OSE_Labeled_AE
associated O
with O
venlafaxine O
therapy O
have O
been O
rarely O
reported O
. O

The O
possibility O
of O
these O
adverse O
events O
should O
be O
considered O
in O
venlafaxine-treated O
patients O
who O
present O
with O
progressive O
dyspnea B-NonOSE_AE
, O
cough B-NonOSE_AE
or O
chest B-NonOSE_AE
discomfort I-NonOSE_AE
. O

Such O
patients O
should O
undergo O
a O
prompt O
medical O
evaluation O
, O
and O
discontinuation O
of O
venlafaxine O
therapy O
should O
be O
considered O
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
Bleeding O
, O
including O
life-threatening O
and O
fatal O
bleeding O
, O
is O
the O
most O
commonly O
reported O
adverse O
reaction O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Eli O
Lilly O
and O
Company O
at O
1-800-545-5979 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Trials O
Experience O
The O
following O
serious O
adverse O
reactions O
are O
also O
discussed O
elsewhere O
in O
the O
labeling O
: O
* O
Bleeding B-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.1 O
, O
5.2 O
) O
] O
* O
Thrombotic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
Safety O
in O
patients O
with O
ACS B-Not_AE_Candidate
undergoing O
PCI O
was O
evaluated O
in O
a O
clopidogrel-controlled O
study O
, O
TRITON-TIMI O
38 O
, O
in O
which O
6741 O
patients O
were O
treated O
with O
Effient O
( O
60-mg O
loading O
dose O
and O
10-mg O
once O
daily O
) O
for O
a O
median O
of O
14.5 O
months O
( O
5802 O
patients O
were O
treated O
for O
over O
6 O
months O
; O
4136 O
patients O
were O
treated O
for O
more O
than O
1 O
year O
) O
. O

The O
population O
treated O
with O
Effient O
was O
27 O
to O
96 O
years O
of O
age O
, O
25 O
% O
female O
, O
and O
92 O
% O
Caucasian O
. O

All O
patients O
in O
the O
TRITON-TIMI O
38 O
study O
were O
to O
receive O
aspirin O
. O

The O
dose O
of O
clopidogrel O
in O
this O
study O
was O
a O
300-mg O
loading O
dose O
and O
75-mg O
once O
daily O
. O

Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
can O
not O
be O
directly O
compared O
with O
the O
rates O
observed O
in O
other O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Drug O
Discontinuation O
The O
rate O
of O
study O
drug O
discontinuation O
because O
of O
adverse O
reactions O
was O
7.2 O
% O
for O
Effient O
and O
6.3 O
% O
for O
clopidogrel O
. O

Bleeding B-OSE_Labeled_AE
was O
the O
most O
common O
adverse O
reaction O
leading O
to O
study O
drug O
discontinuation O
for O
both O
drugs O
( O
2.5 O
% O
for O
Effient O
and O
1.4 O
% O
for O
clopidogrel O
) O
. O

Bleeding O
Bleeding B-NonOSE_AE
Unrelated O
to O
CABG O
Surgery O
- O
In O
TRITON-TIMI O
38 O
, O
overall O
rates O
of O
TIMI O
Major O
or O
Minor O
bleeding B-OSE_Labeled_AE
adverse O
reactions O
unrelated O
to O
coronary O
artery O
bypass O
graft O
surgery O
( O
CABG O
) O
were O
significantly O
higher O
on O
Effient O
than O
on O
clopidogrel O
, O
as O
shown O
in O
Table O
1 O
. O

Table O
1 O
: O
Non-CABG-Related O
Bleedinga O
( O
TRITON-TIMI O
38 O
) O
a O
Patients O
may O
be O
counted O
in O
more O
than O
one O
row O
. O

b O
See O
5.1 O
for O
definition O
. O

Effient O
( O
% O
) O
( O
N=6741 O
) O
Clopidogrel O
( O
% O
) O
( O
N=6716 O
) O
TIMI O
Major O
or O
Minor O
bleeding B-OSE_Labeled_AE
4.5 O
3.4 O
TIMI O
Major O
bleeding B-OSE_Labeled_AE
b O
2.2 O
1.7 O
Life-threatening O
1.3 O
0.8 O
Fatal B-NonOSE_AE
0.3 O
0.1 O
Symptomatic O
intracranial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ICH I-OSE_Labeled_AE
) O
0.3 O
0.3 O
Requiring O
inotropes O
0.3 O
0.1 O
Requiring O
surgical O
intervention O
0.3 O
0.3 O
Requiring O
transfusion O
( O
> O
=4 O
units O
) O
0.7 O
0.5 O
TIMI O
Minor O
bleeding B-OSE_Labeled_AE
b O
2.4 O
1.9 O
Figure O
1 O
demonstrates O
non-CABG O
related O
TIMI O
Major O
or O
Minor O
bleeding B-NonOSE_AE
. O

The O
bleeding B-NonOSE_AE
rate O
is O
highest O
initially O
, O
as O
shown O
in O
Figure O
1 O
( O
inset O
: O
Days O
0 O
to O
7 O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Bleeding B-NonOSE_AE
by O
Weight O
and O
Age O
- O
In O
TRITON-TIMI O
38 O
, O
non-CABG-related O
TIMI O
Major O
or O
Minor O
bleeding B-NonOSE_AE
rates O
in O
patients O
with O
the O
risk O
factors O
of O
age O
> O
=75 O
years O
and O
weight O
< O
60 O
kg O
are O
shown O
in O
Table O
2 O
. O

Table O
2 O
: O
Bleeding B-OSE_Labeled_AE
Rates O
for O
Non-CABG-Related O
Bleeding O
by O
Weight O
and O
Age O
( O
TRITON-TIMI O
38 O
) O
a O
10-mg O
Effient O
maintenance O
dose O
b O
75-mg O
clopidogrel O
maintenance O
dose O
Major/Minor O
Fatal O
Effienta O
( O
% O
) O
Clopidogrelb O
( O
% O
) O
Effienta O
( O
% O
) O
Clopidogrelb O
( O
% O
) O
Weight O
< O
60 O
kg O
( O
N=308 O
Effient O
, O
N=356 O
clopidogrel O
) O
10.1 O
6.5 O
0.0 O
0.3 O
Weight O
> O
=60 O
kg O
( O
N=6373 O
Effient O
, O
N=6299 O
clopidogrel O
) O
4.2 O
3.3 O
0.3 O
0.1 O
Age O
< O
75 O
years O
( O
N=5850 O
Effient O
, O
N=5822 O
clopidogrel O
) O
3.8 O
2.9 O
0.2 O
0.1 O
Age O
> O
=75 O
years O
( O
N=891 O
Effient O
, O
N=894 O
clopidogrel O
) O
9.0 O
6.9 O
1.0 O
0.1 O
Bleeding B-NonOSE_AE
Related O
to O
CABG O
- O
In O
TRITON-TIMI O
38 O
, O
437 O
patients O
who O
received O
a O
thienopyridine O
underwent O
CABG O
during O
the O
course O
of O
the O
study O
. O

The O
rate O
of O
CABG-related O
TIMI O
Major O
or O
Minor O
bleeding B-OSE_Labeled_AE
was O
14.1 O
% O
for O
the O
Effient O
group O
and O
4.5 O
% O
in O
the O
clopidogrel O
group O
( O
see O
Table O
3 O
) O
. O

The O
higher O
risk O
for O
bleeding B-OSE_Labeled_AE
adverse O
reactions O
in O
patients O
treated O
with O
Effient O
persisted O
up O
to O
7 O
days O
from O
the O
most O
recent O
dose O
of O
study O
drug O
. O

Table O
3 O
: O
CABG-Related O
Bleedinga O
( O
TRITON-TIMI O
38 O
) O
a O
Patients O
may O
be O
counted O
in O
more O
than O
one O
row O
. O

Effient O
( O
% O
) O
( O
N=213 O
) O
Clopidogrel O
( O
% O
) O
( O
N=224 O
) O
TIMI O
Major O
or O
Minor O
bleeding B-OSE_Labeled_AE
14.1 O
4.5 O
TIMI O
Major O
bleeding B-OSE_Labeled_AE
11.3 O
3.6 O
Fatal B-NonOSE_AE
0.9 O
0 O
Reoperation O
3.8 O
0.5 O
Transfusion O
of O
> O
=5 O
units O
6.6 O
2.2 O
Intracranial B-NonOSE_AE
hemorrhage I-NonOSE_AE
0 O
0 O
TIMI O
Minor O
bleeding B-OSE_Labeled_AE
2.8 O
0.9 O
Bleeding B-NonOSE_AE
Reported O
as O
Adverse O
Reactions O
- O
Hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
reported O
as O
adverse O
reactions O
in O
TRITON-TIMI O
38 O
were O
, O
for O
Effient O
and O
clopidogrel O
, O
respectively O
: O
epistaxis B-OSE_Labeled_AE
( O
6.2 O
% O
, O
3.3 O
% O
) O
, O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
( O
1.5 O
% O
, O
1.0 O
% O
) O
, O
hemoptysis B-OSE_Labeled_AE
( O
0.6 O
% O
, O
0.5 O
% O
) O
, O
subcutaneous B-OSE_Labeled_AE
hematoma I-OSE_Labeled_AE
( O
0.5 O
% O
, O
0.2 O
% O
) O
, O
post B-OSE_Labeled_AE
- I-OSE_Labeled_AE
procedural I-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
( O
0.5 O
% O
, O
0.2 O
% O
) O
, O
retroperitoneal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
( O
0.3 O
% O
, O
0.2 O
% O
) O
, O
pericardial B-OSE_Labeled_AE
effusion I-OSE_Labeled_AE
/ O
hemorrhage B-OSE_Labeled_AE
/tamponade O
( O
0.3 O
% O
, O
0.2 O
% O
) O
, O
and O
retinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
( O
0.0 O
% O
, O
0.1 O
% O
) O
. O

Malignancies O
During O
TRITON-TIMI O
38 O
, O
newly-diagnosed O
malignancies B-OSE_Labeled_AE
were O
reported O
in O
1.6 O
% O
and O
1.2 O
% O
of O
patients O
treated O
with O
prasugrel O
and O
clopidogrel O
, O
respectively O
. O

The O
sites O
contributing O
to O
the O
differences O
were O
primarily O
colon I-OSE_Labeled_AE
and O
lung O
. O

In O
another O
Phase O
3 O
clinical O
study O
of O
ACS B-Not_AE_Candidate
patients O
not O
undergoing O
PCI O
, O
in O
which O
data O
for O
malignancies B-NonOSE_AE
were O
prospectively O
collected O
, O
newly-diagnosed O
malignancies B-NonOSE_AE
were O
reported O
in O
1.8 O
% O
and O
1.7 O
% O
of O
patients O
treated O
with O
prasugrel O
and O
clopidogrel O
, O
respectively O
. O

The O
site O
of O
malignancies B-NonOSE_AE
was O
balanced O
between O
treatment O
groups O
except O
for O
colorectal B-NonOSE_AE
malignancies I-NonOSE_AE
. O

The O
rates O
of O
colorectal B-OSE_Labeled_AE
malignancies I-OSE_Labeled_AE
were O
0.3 O
% O
prasugrel O
, O
0.1 O
% O
clopidogrel O
and O
most O
were O
detected O
during O
investigation O
of O
GI B-Not_AE_Candidate
bleed I-Not_AE_Candidate
or O
anemia B-Not_AE_Candidate
. O

It O
is O
unclear O
if O
these O
observations O
are O
causally-related O
, O
are O
the O
result O
of O
increased O
detection O
because O
of O
bleeding B-NonOSE_AE
, O
or O
are O
random O
occurrences O
. O

Other O
Adverse O
Events O
In O
TRITON-TIMI O
38 O
, O
common O
and O
other O
important O
non B-NonOSE_AE
- I-NonOSE_AE
hemorrhagic I-NonOSE_AE
adverse I-NonOSE_AE
events I-NonOSE_AE
were O
, O
for O
Effient O
and O
clopidogrel O
, O
respectively O
: O
severe O
thrombocytopenia B-OSE_Labeled_AE
( O
0.06 O
% O
, O
0.04 O
% O
) O
, O
anemia B-OSE_Labeled_AE
( O
2.2 O
% O
, O
2.0 O
% O
) O
, O
abnormal B-OSE_Labeled_AE
hepatic I-OSE_Labeled_AE
function I-OSE_Labeled_AE
( O
0.22 O
% O
, O
0.27 O
% O
) O
, O
allergic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
0.36 O
% O
, O
0.36 O
% O
) O
, O
and O
angioedema B-OSE_Labeled_AE
( O
0.06 O
% O
, O
0.04 O
% O
) O
. O

Table O
4 O
summarizes O
the O
adverse O
events O
reported O
by O
at O
least O
2.5 O
% O
of O
patients O
. O

Table O
4 O
: O
Non-Hemorrhagic O
Treatment O
Emergent O
Adverse O
Events O
Reported O
by O
at O
Least O
2.5 O
% O
of O
Patients O
in O
Either O
Group O
Effient O
( O
% O
) O
( O
N=6741 O
) O
Clopidogrel O
( O
% O
) O
( O
N=6716 O
) O
Hypertension B-OSE_Labeled_AE
7.5 O
7.1 O
Hypercholesterolemia B-OSE_Labeled_AE
/ O
Hyperlipidemia B-OSE_Labeled_AE
7.0 O
7.4 O
Headache B-OSE_Labeled_AE
5.5 O
5.3 O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
5.0 O
4.5 O
Dyspnea B-OSE_Labeled_AE
4.9 O
4.5 O
Nausea B-OSE_Labeled_AE
4.6 O
4.3 O
Dizziness B-OSE_Labeled_AE
4.1 O
4.6 O
Cough B-OSE_Labeled_AE
3.9 O
4.1 O
Hypotension B-OSE_Labeled_AE
3.9 O
3.8 O
Fatigue B-OSE_Labeled_AE
3.7 O
4.8 O
Non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
cardiac I-OSE_Labeled_AE
chest I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
3.1 O
3.5 O
Atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
2.9 O
3.1 O
Bradycardia B-OSE_Labeled_AE
2.9 O
2.4 O
Leukopenia B-OSE_Labeled_AE
( O
< B-OSE_Labeled_AE
4 I-OSE_Labeled_AE
x I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
9 I-OSE_Labeled_AE
WBC I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
) O
2.8 O
3.5 O
Rash B-OSE_Labeled_AE
2.8 O
2.4 O
Pyrexia B-OSE_Labeled_AE
2.7 O
2.2 O
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
2.7 O
3.0 O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
2.6 O
2.6 O
Diarrhea B-OSE_Labeled_AE
2.3 O
2.6 O
6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post O
approval O
use O
of O
Effient O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
- O
Thrombocytopenia B-OSE_Labeled_AE
, O
Thrombotic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
( O
TTP O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
and O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
Immune B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
- O
Hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
anaphylaxis B-OSE_Labeled_AE
[ O
see O
Contraindications O
( O
4.3 O
) O
] O

BOXED O
WARNING O
: O
WARNING O
: O
BLEEDING O
RISK O
WARNING O
: O
BLEEDING O
RISK O
* O
Effient O
can O
cause O
significant O
, O
sometimes O
fatal B-NonOSE_AE
, O
bleeding B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
, O
5.2 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

* O
Do O
not O
use O
Effient O
in O
patients O
with O
active O
pathological O
bleeding B-Not_AE_Candidate
or O
a O
history O
of O
transient B-Not_AE_Candidate
ischemic I-Not_AE_Candidate
attack I-Not_AE_Candidate
or O
stroke B-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4.1 O
, O
4.2 O
) O
] O
. O

* O
In O
patients O
> O
=75 O
years O
of O
age O
, O
Effient O
is O
generally O
not O
recommended O
, O
because O
of O
the O
increased O
risk O
of O
fatal B-NonOSE_AE
and O
intracranial B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
and O
uncertain O
benefit O
, O
except O
in O
high-risk O
situations O
( O
patients O
with O
diabetes B-Not_AE_Candidate
or O
a O
history O
of O
prior O
MI B-Not_AE_Candidate
) O
where O
its O
effect O
appears O
to O
be O
greater O
and O
its O
use O
may O
be O
considered O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
] O
. O

* O
Do O
not O
start O
Effient O
in O
patients O
likely O
to O
undergo O
urgent O
coronary O
artery O
bypass O
graft O
surgery O
( O
CABG O
) O
. O

When O
possible O
, O
discontinue O
Effient O
at O
least O
7 O
days O
prior O
to O
any O
surgery O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

* O
Additional O
risk O
factors O
for O
bleeding B-NonOSE_AE
include O
: O
body O
weight O
< O
60 O
kg O
; O
propensity B-Not_AE_Candidate
to I-Not_AE_Candidate
bleed I-Not_AE_Candidate
; O
concomitant O
use O
of O
medications O
that O
increase O
the O
risk B-NonOSE_AE
of I-NonOSE_AE
bleeding I-NonOSE_AE
( O
e.g. O
, O
warfarin O
, O
heparin O
, O
fibrinolytic O
therapy O
, O
chronic O
use O
of O
non-steroidal O
anti-inflammatory O
drugs O
[ O
NSAIDs O
] O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
Suspect O
bleeding B-NonOSE_AE
in O
any O
patient O
who O
is O
hypotensive B-NonOSE_AE
and O
has O
recently O
undergone O
coronary O
angiography O
, O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
, O
CABG O
, O
or O
other O
surgical O
procedures O
in O
the O
setting O
of O
Effient O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
If O
possible O
, O
manage O
bleeding B-NonOSE_AE
without O
discontinuing O
Effient O
. O

Discontinuing O
Effient O
, O
particularly O
in O
the O
first O
few O
weeks O
after O
acute B-Not_AE_Candidate
coronary I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
, O
increases O
the O
risk O
of O
subsequent O
cardiovascular B-NonOSE_AE
events I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
BLEEDING O
RISK O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Effient O
can O
cause O
significant O
, O
sometimes O
fatal O
, O
bleeding O
( O
5.1 O
, O
5.2 O
, O
6.1 O
) O
. O

* O
Do O
not O
use O
Effient O
in O
patients O
with O
active O
pathological O
bleeding O
or O
a O
history O
of O
transient O
ischemic O
attack O
or O
stroke O
( O
4.1 O
, O
4.2 O
) O
. O

* O
In O
patients O
> O
=75 O
years O
of O
age O
, O
Effient O
is O
generally O
not O
recommended O
, O
except O
in O
high-risk O
patients O
( O
diabetes O
or O
prior O
MI O
) O
, O
where O
its O
use O
may O
be O
considered O
( O
8.5 O
) O
. O

* O
Do O
not O
start O
Effient O
in O
patients O
likely O
to O
undergo O
urgent O
coronary O
artery O
bypass O
graft O
surgery O
( O
CABG O
) O
. O

When O
possible O
, O
discontinue O
Effient O
at O
least O
7 O
days O
prior O
to O
any O
surgery O
( O
5.2 O
) O
. O

* O
Additional O
risk O
factors O
for O
bleeding O
include O
: O
body O
weight O
< O
60 O
kg O
; O
propensity O
to O
bleed O
; O
concomitant O
use O
of O
medications O
that O
increase O
the O
risk O
of O
bleeding O
( O
5.1 O
) O
. O

* O
Suspect O
bleeding O
in O
any O
patient O
who O
is O
hypotensive O
and O
has O
recently O
undergone O
coronary O
angiography O
, O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
, O
CABG O
, O
or O
other O
surgical O
procedures O
in O
the O
setting O
of O
Effient O
( O
5.1 O
) O
. O

* O
If O
possible O
, O
manage O
bleeding O
without O
discontinuing O
Effient O
. O

Stopping O
Effient O
increases O
the O
risk O
of O
subsequent O
cardiovascular O
events O
( O
5.3 O
) O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
CABG-related O
bleeding O
: O
Risk O
increases O
in O
patients O
receiving O
Effient O
who O
undergo O
CABG O
( O
5.2 O
) O
. O

* O
Discontinuation O
of O
Effient O
: O
Premature O
discontinuation O
increases O
risk O
of O
stent O
thrombosis O
, O
MI O
, O
and O
death O
( O
5.3 O
) O
. O

* O
Thrombotic O
thrombocytopenic O
purpura O
( O
TTP O
) O
: O
TTP O
has O
been O
reported O
with O
Effient O
( O
5.4 O
) O
. O

* O
Hypersensitivity O
: O
Hypersensitivity O
including O
angioedema O
has O
been O
reported O
with O
Effient O
including O
in O
patients O
with O
a O
history O
of O
hypersensitivity O
reaction O
to O
other O
thienopyridines O
( O
5.5 O
) O
. O

5.1 O
General O
Risk O
of O
Bleeding O
Thienopyridines O
, O
including O
Effient O
, O
increase O
the O
risk O
of O
bleeding B-OSE_Labeled_AE
. O

With O
the O
dosing O
regimens O
used O
in O
TRITON-TIMI O
38 O
, O
TIMI O
( O
Thrombolysis O
in O
Myocardial B-NonOSE_AE
Infarction I-NonOSE_AE
) O
Major O
( O
clinically O
overt O
bleeding B-NonOSE_AE
associated O
with O
a O
fall B-NonOSE_AE
in I-NonOSE_AE
hemoglobin I-NonOSE_AE
> O
=5 O
g/dL O
, O
or O
intracranial B-NonOSE_AE
hemorrhage I-NonOSE_AE
) O
and O
TIMI O
Minor O
( O
overt O
bleeding B-NonOSE_AE
associated O
with O
a O
fall B-NonOSE_AE
in I-NonOSE_AE
hemoglobin I-NonOSE_AE
of O
> O
=3 O
g/dL O
but O
< O
5 O
g/dL O
) O
bleeding B-OSE_Labeled_AE
events O
were O
more O
common O
on O
Effient O
than O
on O
clopidogrel O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

The O
bleeding B-OSE_Labeled_AE
risk O
is O
highest O
initially O
, O
as O
shown O
in O
Figure O
1 O
( O
events O
through O
450 O
days O
; O
inset O
shows O
events O
through O
7 O
days O
) O
. O

Figure O
1 O
: O
Non-CABG-Related O
TIMI O
Major O
or O
Minor O
Bleeding O
Events O
. O

Figure O
1 O
: O
Non-CABG-Related O
TIMI O
Major O
or O
Minor O
Bleeding O
Events O
. O

Suspect O
bleeding B-NonOSE_AE
in O
any O
patient O
who O
is O
hypotensive B-NonOSE_AE
and O
has O
recently O
undergone O
coronary O
angiography O
, O
PCI O
, O
CABG O
, O
or O
other O
surgical O
procedures O
even O
if O
the O
patient O
does O
not O
have O
overt O
signs O
of O
bleeding B-NonOSE_AE
. O

Do O
not O
use O
Effient O
in O
patients O
with O
active B-Not_AE_Candidate
bleeding I-Not_AE_Candidate
, O
prior O
TIA B-Not_AE_Candidate
or O
stroke B-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4.1 O
, O
4.2 O
) O
] O
. O

Other O
risk O
factors O
for O
bleeding B-NonOSE_AE
are O
: O
* O
Age O
> O
=75 O
years O
. O

Because O
of O
the O
risk O
of O
bleeding B-OSE_Labeled_AE
( O
including O
fatal B-NonOSE_AE
bleeding B-OSE_Labeled_AE
) O
and O
uncertain O
effectiveness O
in O
patients O
> O
=75 O
years O
of O
age O
, O
use O
of O
Effient O
is O
generally O
not O
recommended O
in O
these O
patients O
, O
except O
in O
high-risk O
situations O
( O
patients O
with O
diabetes B-Not_AE_Candidate
or O
history B-Not_AE_Candidate
of I-Not_AE_Candidate
myocardial I-Not_AE_Candidate
infarction I-Not_AE_Candidate
) O
where O
its O
effect O
appears O
to O
be O
greater O
and O
its O
use O
may O
be O
considered O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
, O
Clinical O
Pharmacology O
( O
12.3 O
) O
, O
and O
Clinical O
Trials O
( O
14 O
) O
] O
. O

* O
CABG O
or O
other O
surgical O
procedure O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

* O
Body O
weight O
< O
60 O
kg O
. O

Consider O
a O
lower O
( O
5-mg O
) O
maintenance O
dose O
[ O
see O
Dosage O
and O
Administration O
( O
2 O
) O
, O
Adverse O
Reactions O
( O
6.1 O
) O
, O
and O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
] O
. O

* O
Propensity B-Not_AE_Candidate
to I-Not_AE_Candidate
bleed I-Not_AE_Candidate
( O
e.g. O
, O
recent O
trauma O
, O
recent O
surgery O
, O
recent O
or O
recurrent O
gastrointestinal B-Not_AE_Candidate
( I-Not_AE_Candidate
GI I-Not_AE_Candidate
) I-Not_AE_Candidate
bleeding I-Not_AE_Candidate
, O
active O
peptic B-Not_AE_Candidate
ulcer I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
severe O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
or O
moderate O
to O
severe O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
) O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.7 O
, O
8.8 O
) O
] O
. O

* O
Medications O
that O
increase O
the O
risk O
of O
bleeding B-NonOSE_AE
( O
e.g. O
, O
oral O
anticoagulants O
, O
chronic O
use O
of O
non-steroidal O
anti-inflammatory O
drugs O
[ O
NSAIDs O
] O
, O
and O
fibrinolytic O
agents O
) O
. O

Aspirin O
and O
heparin O
were O
commonly O
used O
in O
TRITON-TIMI O
38 O
[ O
see O
Drug O
Interactions O
( O
7.1 O
, O
7.2 O
. O

7.3 O
) O
, O
and O
Clinical O
Studies O
( O
14 O
) O
] O
. O

Thienopyridines O
inhibit O
platelet O
aggregation O
for O
the O
lifetime O
of O
the O
platelet O
( O
7-10 O
days O
) O
, O
so O
withholding O
a O
dose O
will O
not O
be O
useful O
in O
managing O
a O
bleeding B-NonOSE_AE
event O
or O
the O
risk O
of O
bleeding B-NonOSE_AE
associated O
with O
an O
invasive O
procedure O
. O

Because O
the O
half-life O
of O
prasugrel O
's O
active O
metabolite O
is O
short O
relative O
to O
the O
lifetime O
of O
the O
platelet O
, O
it O
may O
be O
possible O
to O
restore O
hemostasis O
by O
administering O
exogenous O
platelets O
; O
however O
, O
platelet O
transfusions O
within O
6 O
hours O
of O
the O
loading O
dose O
or O
4 O
hours O
of O
the O
maintenance O
dose O
may O
be O
less O
effective O
. O

Figure O
1 O
5.2 O
Coronary O
Artery O
Bypass O
Graft O
Surgery-Related O
Bleeding O
The O
risk O
of O
bleeding B-OSE_Labeled_AE
is O
increased O
in O
patients O
receiving O
Effient O
who O
undergo O
CABG O
. O

If O
possible O
, O
Effient O
should O
be O
discontinued O
at O
least O
7 O
days O
prior O
to O
CABG O
. O

Of O
the O
437 O
patients O
who O
underwent O
CABG O
during O
TRITON-TIMI O
38 O
, O
the O
rates O
of O
CABG-related O
TIMI O
Major O
or O
Minor O
bleeding B-OSE_Labeled_AE
were O
14.1 O
% O
in O
the O
Effient O
group O
and O
4.5 O
% O
in O
the O
clopidogrel O
group O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

The O
higher O
risk O
for O
bleeding B-OSE_Labeled_AE
events O
in O
patients O
treated O
with O
Effient O
persisted O
up O
to O
7 O
days O
from O
the O
most O
recent O
dose O
of O
study O
drug O
. O

For O
patients O
receiving O
a O
thienopyridine O
within O
3 O
days O
prior O
to O
CABG O
, O
the O
frequencies O
of O
TIMI O
Major O
or O
Minor O
bleeding B-OSE_Labeled_AE
were O
26.7 O
% O
( O
12 O
of O
45 O
patients O
) O
in O
the O
Effient O
group O
, O
compared O
with O
5.0 O
% O
( O
3 O
of O
60 O
patients O
) O
in O
the O
clopidogrel O
group O
. O

For O
patients O
who O
received O
their O
last O
dose O
of O
thienopyridine O
within O
4 O
to O
7 O
days O
prior O
to O
CABG O
, O
the O
frequencies O
decreased O
to O
11.3 O
% O
( O
9 O
of O
80 O
patients O
) O
in O
the O
prasugrel O
group O
and O
3.4 O
% O
( O
3 O
of O
89 O
patients O
) O
in O
the O
clopidogrel O
group O
. O

Do O
not O
start O
Effient O
in O
patients O
likely O
to O
undergo O
urgent O
CABG O
. O

CABG B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
bleeding I-NonOSE_AE
may O
be O
treated O
with O
transfusion O
of O
blood O
products O
, O
including O
packed O
red O
blood O
cells O
and O
platelets O
; O
however O
, O
platelet O
transfusions O
within O
6 O
hours O
of O
the O
loading O
dose O
or O
4 O
hours O
of O
the O
maintenance O
dose O
may O
be O
less O
effective O
. O

5.3 O
Discontinuation O
of O
Effient O
Discontinue O
thienopyridines O
, O
including O
Effient O
, O
for O
active B-NonOSE_AE
bleeding I-NonOSE_AE
, O
elective B-NonOSE_AE
surgery I-NonOSE_AE
, O
stroke B-NonOSE_AE
, O
or O
TIA B-NonOSE_AE
. O

The O
optimal O
duration O
of O
thienopyridine O
therapy O
is O
unknown O
. O

In O
patients O
who O
are O
managed O
with O
PCI O
and O
stent O
placement O
, O
premature O
discontinuation O
of O
any O
antiplatelet O
medication O
, O
including O
thienopyridines O
, O
conveys O
an O
increased O
risk O
of O
stent B-NonOSE_AE
thrombosis I-NonOSE_AE
, O
myocardial B-NonOSE_AE
infarction I-NonOSE_AE
, O
and O
death B-NonOSE_AE
. O

Patients O
who O
require O
premature O
discontinuation O
of O
a O
thienopyridine O
will O
be O
at O
increased O
risk O
for O
cardiac B-NonOSE_AE
events I-NonOSE_AE
. O

Lapses O
in O
therapy O
should O
be O
avoided O
, O
and O
if O
thienopyridines O
must O
be O
temporarily O
discontinued O
because O
of O
an O
adverse O
event O
( O
s O
) O
, O
they O
should O
be O
restarted O
as O
soon O
as O
possible O
[ O
see O
Contraindications O
( O
4.1 O
, O
4.2 O
) O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

5.4 O
Thrombotic O
Thrombocytopenic O
Purpura O
Thrombotic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TTP I-OSE_Labeled_AE
) O
has O
been O
reported O
with O
the O
use O
of O
Effient O
. O

TTP B-OSE_Labeled_AE
can O
occur O
after O
a O
brief O
exposure O
( O
< O
2 O
weeks O
) O
. O

TTP B-NonOSE_AE
is O
a O
serious O
condition O
that O
can O
be O
fatal B-NonOSE_AE
and O
requires O
urgent O
treatment O
, O
including O
plasmapheresis O
( O
plasma O
exchange O
) O
. O

TTP B-NonOSE_AE
is O
characterized O
by O
thrombocytopenia B-NonOSE_AE
, O
microangiopathic B-NonOSE_AE
hemolytic I-NonOSE_AE
anemia I-NonOSE_AE
( O
schistocytes B-NonOSE_AE
[ O
fragment B-NonOSE_AE
red I-NonOSE_AE
blood I-NonOSE_AE
cells I-NonOSE_AE
] O
seen O
on O
peripheral O
smear O
) O
, O
neurological B-NonOSE_AE
findings I-NonOSE_AE
, O
renal B-NonOSE_AE
dysfunction I-NonOSE_AE
, O
and O
fever B-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

5.5 O
Hypersensitivity O
Including O
Angioedema O
Hypersensitivity B-OSE_Labeled_AE
including O
angioedema B-OSE_Labeled_AE
has O
been O
reported O
in O
patients O
receiving O
Effient O
, O
including O
patients O
with O
a O
history O
of O
hypersensitivity B-Not_AE_Candidate
reaction I-Not_AE_Candidate
to O
other O
thienopyridines O
[ O
see O
Contraindications O
( O
4.3 O
) O
and O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

6 O
ADVERSE O
REACTIONS O
The O
most O
commonly O
reported O
adverse O
reactions O
are O
hypersensitivity B-OSE_Labeled_AE
( O
e.g. O
, O
rash B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
) O
reactions O
due O
to O
the O
effect O
of O
GH O
( O
e.g. O
, O
arthralgia B-OSE_Labeled_AE
, O
extremity B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
carpal B-OSE_Labeled_AE
tunnel I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
) O
, O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
, O
pruritus O
, O
pain O
, O
urticaria O
, O
irritation O
, O
swelling O
, O
hemorrhage O
) O
. O

During O
the O
first O
26 O
weeks O
of O
treatment O
( O
main O
phase O
) O
, O
discontinuations O
as O
a O
result O
of O
adverse O
reactions O
occurred O
in O
9.6 O
% O
of O
patients O
receiving O
EGRIFTA O
( O
r O
) O
and O
6.8 O
% O
of O
patients O
receiving O
placebo O
. O

Apart O
from O
patients O
with O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
identified O
during O
the O
studies O
and O
who O
were O
discontinued O
per O
protocol O
( O
2.2 O
% O
) O
, O
the O
most O
common O
reasons O
for O
discontinuation O
of O
EGRIFTA O
( O
r O
) O
treatment O
were O
adverse O
reactions O
due O
to O
the O
effect O
of O
GH O
( O
4.2 O
% O
) O
and O
local O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
4.6 O
% O
) O
. O

During O
the O
following O
26 O
weeks O
of O
treatment O
( O
extension O
phase O
) O
, O
discontinuations O
as O
a O
result O
of O
adverse O
events O
occurred O
in O
2.4 O
% O
of O
patients O
in O
the O
T-T O
group O
( O
patients O
treated O
with O
tesamorelin O
for O
Week O
0-26 O
and O
with O
tesamorelin O
for O
Week O
26-52 O
) O
and O
5.2 O
% O
of O
patients O
in O
the O
T-P O
group O
( O
patients O
treated O
with O
tesamorelin O
for O
Week O
0-26 O
and O
with O
placebo O
for O
Week O
26-52 O
) O
. O

EXCERPT O
: O
Most O
commonly O
reported O
adverse O
reactions O
( O
> O
5 O
% O
and O
more O
frequent O
than O
placebo O
) O
: O
Arthralgia O
, O
injection O
site O
erythema O
, O
injection O
site O
pruritus O
, O
pain O
in O
extremity O
, O
peripheral O
edema O
, O
and O
myalgia O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
EGRIFTA O
ASSIST O
TM O
toll O
free O
at O
1-844-EGRIFTA O
( O
1-844-347-4382 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Trial O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Seven O
hundred O
and O
forty O
HIV B-Not_AE_Candidate
- I-Not_AE_Candidate
infected I-Not_AE_Candidate
patients I-Not_AE_Candidate
with I-Not_AE_Candidate
lipodystrophy I-Not_AE_Candidate
and O
excess B-Not_AE_Candidate
abdominal I-Not_AE_Candidate
fat I-Not_AE_Candidate
were O
exposed O
to O
EGRIFTA O
( O
r O
) O
in O
the O
Phase O
3 O
clinical O
trials O
; O
of O
these O
543 O
received O
EGRIFTA O
( O
r O
) O
during O
the O
initial O
26-week O
placebo-controlled O
phase O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

Adverse O
reactions O
that O
occurred O
more O
frequently O
with O
EGRIFTA O
( O
r O
) O
relative O
to O
placebo O
and O
had O
an O
incidence O
> O
=1 O
% O
during O
the O
first O
26 O
weeks O
across O
all O
studies O
are O
presented O
in O
Table O
1 O
. O

Table O
1 O
. O

Adverse O
Reactions O
Reported O
in O
> O
= O
1 O
% O
and O
More O
Frequent O
in O
EGRIFTA O
( O
r O
) O
-treated O
than O
Placebo O
Patients O
during O
the O
26-Week O
Main O
Phase O
( O
Combined O
Studies O
) O
Incidence O
of O
patients O
( O
% O
) O
with O
adverse O
drug O
reactions O
System O
Organ O
Class O
Preferred O
Term O
EGRIFTA O
( O
r O
) O
( O
N=543 O
) O
Placebo O
( O
N=263 O
) O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
Myalgia B-OSE_Labeled_AE
Musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
Musculoskeletal B-OSE_Labeled_AE
stiffness I-OSE_Labeled_AE
Joint B-OSE_Labeled_AE
stiffness I-OSE_Labeled_AE
Muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
Joint B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
13.36.15.51.81.71.51.11.1 O
11.04.61.90.80.40.80.80.0 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
pruritus I-OSE_Labeled_AE
Edema B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
irritation I-OSE_Labeled_AE
Pain B-OSE_Labeled_AE
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
urticaria I-OSE_Labeled_AE
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
Chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
rash I-OSE_Labeled_AE
8.57.66.14.12.91.71.71.71.51.31.11.1 O
2.70.82.33.01.11.10.40.40.40.80.80.0 O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Paresthesia B-OSE_Labeled_AE
Hypoesthesia B-OSE_Labeled_AE
Carpal B-OSE_Labeled_AE
tunnel I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
4.84.21.5 O
2.31.50.0 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
Vomiting B-OSE_Labeled_AE
Dyspepsia B-OSE_Labeled_AE
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
4.42.61.71.1 O
3.80.00.80.8 O
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
Palpitations B-OSE_Labeled_AE
1.1 O
0.4 O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
Depression B-OSE_Labeled_AE
2.0 O
1.5 O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
Pruritus B-OSE_Labeled_AE
Night B-OSE_Labeled_AE
sweats I-OSE_Labeled_AE
3.72.41.1 O
1.51.10.4 O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
1.3 O
0.8 O
Injury B-NonOSE_AE
, I-NonOSE_AE
poisoning I-NonOSE_AE
and I-NonOSE_AE
procedural I-NonOSE_AE
complications I-NonOSE_AE
Muscle B-OSE_Labeled_AE
strain I-OSE_Labeled_AE
1.1 O
0.0 O
Investigations B-NonOSE_AE
Blood B-OSE_Labeled_AE
creatine I-OSE_Labeled_AE
phosphokinase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
1.5 O
0.4 O
Mean O
levels O
of O
fasting O
blood O
glucose O
and O
fasting O
insulin O
were O
not O
significantly O
different O
between O
EGRIFTA O
( O
r O
) O
-treated O
and O
placebo-treated O
patients O
after O
26 O
weeks O
of O
treatment O
. O

In O
the O
EGRIFTA O
( O
r O
) O
Phase O
3 O
clinical O
trials O
, O
mean O
baseline O
( O
Week O
0 O
) O
HbA1cwas O
5.26 O
% O
among O
patients O
in O
the O
EGRIFTA O
( O
r O
) O
group O
and O
5.28 O
% O
among O
those O
in O
the O
placebo O
group O
. O

At O
Week O
26 O
, O
mean O
HbA B-OSE_Labeled_AE
1 I-OSE_Labeled_AE
cwas I-OSE_Labeled_AE
higher I-OSE_Labeled_AE
among O
patients O
treated O
with O
EGRIFTA O
( O
r O
) O
compared O
with O
placebo O
( O
5.39 O
% O
vs O
. O
5.28 O
% O
for O
the O
EGRIFTA O
( O
r O
) O
and O
placebo O
groups O
, O
respectively O
, O
mean O
treatment O
difference O
of O
0.12 O
% O
, O
p=0.0004 O
) O
. O

Patients O
receiving O
EGRIFTA O
( O
r O
) O
had O
an O
increased O
risk O
of O
developing O
diabetes B-OSE_Labeled_AE
( O
HbA B-OSE_Labeled_AE
1 I-OSE_Labeled_AE
clevel I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
% I-OSE_Labeled_AE
) O
compared O
with O
placebo O
( O
4.5 O
% O
vs O
. O
1.3 O
% O
) O
, O
with O
a O
hazard O
ratio O
of O
3.3 O
( O
CI O
1.4 O
, O
9.6 O
) O
. O

Adverse O
reactions O
observed O
during O
Week O
26 O
to O
52 O
of O
the O
Phase O
3 O
clinical O
trials O
which O
had O
an O
incidence O
of O
> O
=1 O
% O
and O
were O
seen O
more O
frequently O
with O
EGRIFTA O
( O
r O
) O
relative O
to O
placebo O
are O
presented O
in O
Table O
2 O
: O
Table O
2 O
. O

Adverse O
Reactions O
Reported O
in O
> O
= O
1 O
% O
and O
More O
Frequent O
in O
EGRIFTA O
( O
r O
) O
-treated O
than O
Placebo O
Patients O
during O
the O
26-Week O
Extension O
Phase O
of O
the O
Combined O
Studies O
( O
Week O
26 O
to O
Week O
52 O
of O
the O
studies O
) O
1T-T O
= O
tesamorelin O
for O
Week O
0-26 O
and O
tesamorelin O
for O
Week O
26-52 O
2T-P O
= O
tesamorelin O
for O
Week O
0-26 O
and O
placebo O
for O
Week O
26-52 O
For O
patients O
who O
continued O
from O
Week O
26-52 O
, O
mean O
levels O
of O
fasting B-NonOSE_AE
blood I-NonOSE_AE
glucose I-NonOSE_AE
, O
fasting B-NonOSE_AE
insulin I-NonOSE_AE
, O
and O
HbA B-NonOSE_AE
1 I-NonOSE_AE
c I-NonOSE_AE
were O
not O
different O
between O
the O
T-T O
and O
T-P O
groups O
. O

Incidence O
of O
patients O
( O
% O
) O
with O
adverse O
drug O
reactions O
System O
Organ O
Class O
Preferred O
Term O
T-T O
1 O
( O
Week O
26-52 O
) O
( O
N=246 O
) O
T-P O
2 O
( O
Week O
26-52 O
) O
( O
N=135 O
) O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
Myalgia B-OSE_Labeled_AE
3.31.2 O
0.70.0 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
pruritus I-OSE_Labeled_AE
Edema B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
2.02.01.2 O
0.00.00.0 O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Paresthesia B-OSE_Labeled_AE
Hypoesthesia B-OSE_Labeled_AE
Neuropathy B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
1.61.61.6 O
1.50.71.5 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Vomiting B-OSE_Labeled_AE
2.0 O
0.7 O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
Depression B-OSE_Labeled_AE
Insomnia B-OSE_Labeled_AE
1.61.2 O
0.70.0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Pruritus B-OSE_Labeled_AE
Urticaria B-OSE_Labeled_AE
Night B-OSE_Labeled_AE
sweats I-OSE_Labeled_AE
1.21.21.2 O
0.70.00.0 O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
Hot B-OSE_Labeled_AE
flush I-OSE_Labeled_AE
1.61.2 O
1.50.7 O
6.2 O
Immunogenicity O
As O
with O
all O
therapeutic O
proteins O
and O
peptides O
, O
there O
is O
a O
potential O
for O
in O
vivo O
development B-OSE_Labeled_AE
of I-OSE_Labeled_AE
anti I-OSE_Labeled_AE
- I-OSE_Labeled_AE
EGRIFTA I-OSE_Labeled_AE
( I-OSE_Labeled_AE
r I-OSE_Labeled_AE
) I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
. O

In O
the O
combined O
Phase O
3 O
clinical O
trials O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
tesamorelin I-OSE_Labeled_AE
IgG I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
were O
detected O
in O
49.5 O
% O
of O
patients O
treated O
with O
EGRIFTA O
( O
r O
) O
for O
26 O
weeks O
and O
47.4 O
% O
of O
patients O
who O
received O
EGRIFTA O
( O
r O
) O
for O
52 O
weeks O
. O

In O
the O
subset O
of O
patients O
with O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
tesamorelin I-OSE_Labeled_AE
IgG I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
were I-OSE_Labeled_AE
detected I-OSE_Labeled_AE
in O
85.2 O
% O
. O

Cross B-OSE_Labeled_AE
- I-OSE_Labeled_AE
reactivity I-OSE_Labeled_AE
to I-OSE_Labeled_AE
endogenous I-OSE_Labeled_AE
growth I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
- I-OSE_Labeled_AE
releasing I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
( I-OSE_Labeled_AE
GHRH I-OSE_Labeled_AE
) O
was O
observed O
in O
approximately O
60 O
% O
of O
patients O
who O
developed O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
tesamorelin I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
. O

Patients O
with O
and O
without O
anti B-NonOSE_AE
- I-NonOSE_AE
tesamorelin I-NonOSE_AE
IgG I-NonOSE_AE
antibodies I-NonOSE_AE
had O
similar O
mean O
reductions B-NonOSE_AE
in I-NonOSE_AE
visceral I-NonOSE_AE
adipose I-NonOSE_AE
tissue I-NonOSE_AE
( I-NonOSE_AE
VAT I-NonOSE_AE
) O
and O
IGF B-NonOSE_AE
- I-NonOSE_AE
1 I-NonOSE_AE
response I-NonOSE_AE
suggesting O
that O
the O
presence B-NonOSE_AE
of I-NonOSE_AE
antibodies I-NonOSE_AE
did O
not O
alter O
the O
efficacy O
of O
EGRIFTA O
( O
r O
) O
. O

In O
a O
group O
of O
patients O
who O
had O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
tesamorelin I-OSE_Labeled_AE
after O
26 O
weeks O
of O
treatment O
( O
56 O
% O
) O
and O
were O
re-assessed O
6 O
months O
later O
, O
after O
stopping O
EGRIFTA O
( O
r O
) O
treatment O
, O
18 O
% O
were O
still O
antibody B-OSE_Labeled_AE
positive I-OSE_Labeled_AE
. O

Neutralizing B-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
to I-OSE_Labeled_AE
tesamorelin I-OSE_Labeled_AE
and O
hGHRH O
were O
detected O
in O
vitro O
at O
Week O
52 O
in O
10 O
% O
and O
5 O
% O
of O
EGRIFTA O
( O
r O
) O
-treated O
patients O
, O
respectively O
. O

They O
did O
not O
appear O
to O
have O
an O
impact O
on O
efficacy O
, O
as O
evidenced O
by O
comparable O
changes O
in O
VAT O
and O
IGF-1 O
level O
in O
patients O
with O
or O
without O
in O
vitro O
neutralizing B-NonOSE_AE
antibodies I-NonOSE_AE
. O

The O
observed O
incidence O
of O
antibody B-NonOSE_AE
positivity I-NonOSE_AE
in O
an O
assay O
is O
highly O
dependent O
on O
several O
factors O
including O
assay O
sensitivity O
and O
specificity O
, O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medication O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
EGRIFTA I-NonOSE_AE
( O
r O
) O
with O
the O
incidence O
of O
antibodies O
to O
other O
products O
may O
be O
misleading O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Neoplasms O
: O
Preexisting O
malignancy O
should O
be O
inactive O
and O
its O
treatment O
complete O
prior O
to O
starting O
EGRIFTA O
( O
r O
) O
therapy O
. O

( O
5.1 O
) O
* O
Elevated O
IGF-1 O
: O
Monitor O
regularly O
in O
all O
patients O
. O

Consider O
discontinuation O
in O
patients O
with O
persistent O
elevations O
. O

( O
5.2 O
) O
* O
Fluid O
retention O
: O
May O
include O
edema O
, O
arthralgia O
, O
and O
carpal O
tunnel O
syndrome O
. O

( O
5.3 O
) O
* O
Glucose O
intolerance O
: O
May O
develop O
with O
EGRIFTA O
( O
r O
) O
use O
. O

Evaluate O
glucose O
status O
prior O
to O
and O
during O
therapy O
with O
EGRIFTA O
( O
r O
) O
. O

( O
5.4 O
) O
* O
Hypersensitivity O
reactions O
( O
e.g. O
, O
rash O
, O
urticaria O
) O
: O
Advise O
patients O
to O
seek O
immediate O
medical O
attention O
if O
suspected O
. O

( O
5.5 O
) O
* O
Injection O
site O
reactions O
: O
Advise O
patients O
to O
rotate O
sites O
. O

( O
5.6 O
) O
* O
Acute O
critical O
illness O
: O
Consider O
discontinuation O
. O

( O
5.7 O
) O
5.1 O
Neoplasms O
EGRIFTA O
( O
r O
) O
induces O
the O
release O
of O
endogenous O
growth O
hormone O
( O
GH O
) O
, O
a O
known O
growth O
factor O
. O

Thus O
, O
patients O
with O
active O
malignancy B-Not_AE_Candidate
should O
not O
be O
treated O
with O
EGRIFTA O
( O
r O
) O
[ O
see O
Contraindications O
( O
4.2 O
) O
] O
. O

For O
patients O
with O
a O
history O
of O
non B-Not_AE_Candidate
- I-Not_AE_Candidate
malignant I-Not_AE_Candidate
neoplasms I-Not_AE_Candidate
, O
EGRIFTA O
( O
r O
) O
therapy O
should O
be O
initiated O
after O
careful O
evaluation O
of O
the O
potential O
benefit O
of O
treatment O
. O

For O
patients O
with O
a O
history O
of O
treated O
and O
stable O
malignancies B-Not_AE_Candidate
, O
EGRIFTA O
( O
r O
) O
therapy O
should O
be O
initiated O
only O
after O
careful O
evaluation O
of O
the O
potential O
benefit O
of O
treatment O
relative O
to O
the O
risk O
of O
re B-NonOSE_AE
- I-NonOSE_AE
activation I-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
underlying I-NonOSE_AE
malignancy I-NonOSE_AE
. O

In O
addition O
, O
the O
decision O
to O
start O
treatment O
with O
EGRIFTA O
( O
r O
) O
should O
be O
considered O
carefully O
based O
on O
the O
increased O
background O
risk O
of O
malignancies B-Not_AE_Candidate
in O
HIV B-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
patients O
. O

5.2 O
Elevated O
IGF-1 O
EGRIFTA O
( O
r O
) O
stimulates O
GH O
production O
and O
increases B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
IGF I-OSE_Labeled_AE
- I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
. O

Given O
that O
IGF-1 O
is O
a O
growth O
factor O
and O
the O
effect O
of O
prolonged O
elevations B-NonOSE_AE
in I-NonOSE_AE
IGF I-NonOSE_AE
- I-NonOSE_AE
1 I-NonOSE_AE
levels O
on O
the O
development O
or O
progression B-NonOSE_AE
of I-NonOSE_AE
malignancies I-NonOSE_AE
is O
unknown O
, O
IGF-1 O
levels O
should O
be O
monitored O
closely O
during O
EGRIFTA O
( O
r O
) O
therapy O
. O

Careful O
consideration O
should O
be O
given O
to O
discontinuing O
EGRIFTA O
( O
r O
) O
in O
patients O
with O
persistent B-NonOSE_AE
elevations I-NonOSE_AE
of I-NonOSE_AE
IGF I-NonOSE_AE
- I-NonOSE_AE
1 I-NonOSE_AE
levels I-NonOSE_AE
( O
e.g. O
, O
> O
3 O
SDS O
) O
, O
particularly O
if O
the O
efficacy O
response O
is O
not O
robust O
( O
e.g. O
, O
based O
on O
visceral O
adipose O
tissue O
changes O
measured O
by O
waist O
circumference O
or O
CT O
scan O
) O
. O

During O
the O
clinical O
trials O
, O
patients O
were O
monitored O
every O
three O
months O
. O

Among O
patients O
who O
received O
EGRIFTA O
( O
r O
) O
for O
26 O
weeks O
, O
47.4 O
% O
had O
IGF B-OSE_Labeled_AE
- I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
greater I-OSE_Labeled_AE
than I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
standard I-OSE_Labeled_AE
deviation I-OSE_Labeled_AE
scores I-OSE_Labeled_AE
( O
SDS O
) O
, O
and O
35.6 O
% O
had O
SDS O
> O
3 O
, O
with O
this O
effect O
seen O
as O
early O
as O
13 O
weeks O
of O
treatment O
. O

Among O
those O
patients O
who O
remained O
on O
EGRIFTA O
( O
r O
) O
for O
a O
total O
of O
52 O
weeks O
, O
at O
the O
end O
of O
treatment O
33.7 O
% O
had O
IGF B-OSE_Labeled_AE
- I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
SDS I-OSE_Labeled_AE
> I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
and O
22.6 O
% O
had O
IGF B-OSE_Labeled_AE
- I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
SDS I-OSE_Labeled_AE
> I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
. O

5.3 O
Fluid O
Retention O
Fluid B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
may O
occur O
during O
EGRIFTA O
( O
r O
) O
therapy O
and O
is O
thought O
to O
be O
related O
to O
the O
induction O
of O
GH O
secretion O
. O

It O
manifests O
as O
increased B-NonOSE_AE
tissue I-NonOSE_AE
turgor I-NonOSE_AE
and O
musculoskeletal B-NonOSE_AE
discomfort I-NonOSE_AE
resulting O
in O
a O
variety O
of O
adverse O
reactions O
( O
e.g O
. O

edema B-NonOSE_AE
, O
arthralgia B-NonOSE_AE
, O
carpal B-NonOSE_AE
tunnel I-NonOSE_AE
syndrome I-NonOSE_AE
) O
which O
are O
either O
transient O
or O
resolve O
with O
discontinuation O
of O
treatment O
. O

5.4 O
Glucose O
Intolerance O
EGRIFTA O
( O
r O
) O
treatment O
may O
result O
in O
glucose B-OSE_Labeled_AE
intolerance I-OSE_Labeled_AE
. O

During O
the O
Phase O
3 O
clinical O
trials O
, O
the O
percentages O
of O
patients O
with O
elevated B-OSE_Labeled_AE
HbA I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
c I-OSE_Labeled_AE
( O
> O
= O
6.5 O
% O
) O
from O
baseline O
to O
Week O
26 O
were O
4.5 O
% O
and O
1.3 O
% O
in O
the O
EGRIFTA O
( O
r O
) O
and O
placebo O
groups O
, O
respectively O
. O

An O
increased O
risk O
of O
developing O
diabetes B-OSE_Labeled_AE
with O
EGRIFTA O
( O
r O
) O
( O
HbA B-OSE_Labeled_AE
1 I-OSE_Labeled_AE
clevel I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
% I-OSE_Labeled_AE
) O
relative O
to O
placebo O
was O
observed O
[ O
intent-to-treat O
hazard O
odds O
ratio O
of O
3.3 O
( O
CI O
1.4 O
, O
9.6 O
) O
] O
. O

Therefore O
, O
glucose O
status O
should O
be O
carefully O
evaluated O
prior O
to O
initiating O
EGRIFTA O
( O
r O
) O
treatment O
. O

In O
addition O
, O
all O
patients O
treated O
with O
EGRIFTA O
( O
r O
) O
should O
be O
monitored O
periodically O
for O
changes O
in O
glucose O
metabolism O
to O
diagnose O
those O
who O
develop O
impaired B-NonOSE_AE
glucose I-NonOSE_AE
tolerance I-NonOSE_AE
or O
diabetes B-NonOSE_AE
. O

Diabetes B-NonOSE_AE
is O
a O
known O
cardiovascular O
risk O
factor O
and O
patients O
who O
develop O
glucose B-NonOSE_AE
intolerance I-NonOSE_AE
have O
an O
elevated O
risk O
for O
developing O
diabetes B-NonOSE_AE
. O

Caution O
should O
be O
exercised O
in O
treating O
HIV B-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
patients I-Not_AE_Candidate
with I-Not_AE_Candidate
lipodystrophy I-Not_AE_Candidate
with O
EGRIFTA O
( O
r O
) O
if O
they O
develop O
glucose B-NonOSE_AE
intolerance I-NonOSE_AE
or O
diabetes B-NonOSE_AE
, O
and O
careful O
consideration O
should O
be O
given O
to O
discontinuing O
EGRIFTA O
( O
r O
) O
treatment O
in O
patients O
who O
do O
not O
show O
a O
clear O
efficacy O
response O
as O
judged O
by O
the O
degree O
of O
reduction O
in O
visceral O
adipose O
tissue O
by O
waist O
circumference O
or O
CT O
scan O
measurements O
. O

Since O
EGRIFTA O
( O
r O
) O
increases B-OSE_Labeled_AE
IGF I-OSE_Labeled_AE
- I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
, O
patients O
with O
diabetes B-Not_AE_Candidate
who O
are O
receiving O
ongoing O
treatment O
with O
EGRIFTA O
( O
r O
) O
should O
be O
monitored O
at O
regular O
intervals O
for O
potential O
development O
or O
worsening O
of O
retinopathy O
. O

5.5 O
Hypersensitivity O
Reactions O
Hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
may O
occur O
in O
patients O
treated O
with O
EGRIFTA O
( O
r O
) O
. O

Hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
occurred O
in O
3.6 O
% O
of O
patients O
with O
HIV B-Not_AE_Candidate
- I-Not_AE_Candidate
associated I-Not_AE_Candidate
lipodystrophy I-Not_AE_Candidate
treated O
with O
EGRIFTA O
( O
r O
) O
in O
the O
Phase O
3 O
clinical O
trials O
. O

These O
reactions O
included O
pruritus B-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
, O
flushing B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
and O
other O
rash B-OSE_Labeled_AE
. O

In O
cases O
of O
suspected O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
, O
patients O
should O
be O
advised O
to O
seek O
prompt O
medical O
attention O
and O
treatment O
with O
EGRIFTA O
( O
r O
) O
should O
be O
discontinued O
immediately O
. O

5.6 O
Injection O
Site O
Reactions O
EGRIFTA O
( O
r O
) O
treatment O
may O
cause O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
, O
pruritus O
, O
pain O
, O
irritation O
, O
and O
bruising O
. O

The O
incidence O
of O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
was O
24.5 O
% O
in O
EGRIFTA O
( O
r O
) O
-treated O
patients O
and O
14.4 O
% O
in O
placebo-treated O
patients O
during O
the O
first O
26 O
weeks O
of O
treatment O
in O
the O
Phase O
3 O
clinical O
trials O
. O

For O
patients O
who O
continued O
EGRIFTA O
( O
r O
) O
for O
an O
additional O
26 O
weeks O
, O
the O
incidence O
of O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
was O
6.1 O
% O
. O

In O
order O
to O
reduce O
the O
incidence O
of O
injection B-NonOSE_AE
site I-NonOSE_AE
reactions I-NonOSE_AE
, O
it O
is O
recommended O
to O
rotate O
the O
site O
of O
injection O
to O
different O
areas O
of O
the O
abdomen O
. O

5.7 O
Acute O
Critical O
Illness O
Increased B-NonOSE_AE
mortality I-NonOSE_AE
in O
patients O
with O
acute B-Not_AE_Candidate
critical I-Not_AE_Candidate
illness I-Not_AE_Candidate
due O
to O
complications O
following O
open B-Not_AE_Candidate
heart I-Not_AE_Candidate
surgery I-Not_AE_Candidate
, O
abdominal B-Not_AE_Candidate
surgery I-Not_AE_Candidate
or O
multiple B-Not_AE_Candidate
accidental I-Not_AE_Candidate
trauma I-Not_AE_Candidate
, O
or O
those O
with O
acute B-Not_AE_Candidate
respiratory I-Not_AE_Candidate
failure I-Not_AE_Candidate
has O
been O
reported O
after O
treatment O
with O
pharmacologic O
amounts O
of O
growth O
hormone O
. O

EGRIFTA O
( O
r O
) O
has O
not O
been O
studied O
in O
patients O
with O
acute B-Not_AE_Candidate
critical I-Not_AE_Candidate
illness I-Not_AE_Candidate
. O

Since O
EGRIFTA O
( O
r O
) O
stimulates B-NonOSE_AE
growth I-NonOSE_AE
hormone I-NonOSE_AE
production I-NonOSE_AE
, O
careful O
consideration O
should O
be O
given O
to O
discontinuing O
EGRIFTA O
( O
r O
) O
in O
critically O
ill O
patients O
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
( O
> O
= O
5 O
% O
) O
in O
the O
clinical O
trials O
were O
headache O
( O
18 O
% O
) O
, O
abdominal O
pain O
( O
12 O
% O
) O
, O
nausea O
( O
12 O
% O
) O
, O
dysmenorrhea O
( O
9 O
% O
) O
, O
fatigue O
( O
6 O
% O
) O
and O
dizziness O
( O
5 O
% O
) O
. O

( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Afaxys O
, O
Inc O
. O
at O
1-855-888-2467 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

ella O
was O
studied O
in O
an O
open-label O
multicenter O
trial O
( O
Open-Label O
Study O
) O
and O
in O
a O
comparative O
, O
randomized O
, O
single-blind O
, O
multicenter O
trial O
( O
Single-Blind O
Comparative O
Study O
) O
. O

In O
these O
studies O
, O
a O
total O
of O
2,637 O
( O
1,533 O
+ O
1,104 O
) O
women O
in O
the O
30 O
mg O
ulipristal O
acetate O
groups O
were O
included O
in O
the O
safety O
analysis O
. O

The O
mean O
age O
of O
women O
who O
received O
ulipristal O
acetate O
was O
24.5 O
years O
and O
the O
mean O
body O
mass O
index O
( O
BMI O
) O
was O
25.3 O
. O

The O
racial O
demographics O
of O
those O
enrolled O
were O
67 O
% O
Caucasian O
, O
20 O
% O
Black O
or O
African O
American O
, O
2 O
% O
Asian O
, O
and O
12 O
% O
other O
. O

The O
most O
common O
adverse O
reactions O
( O
> O
= O
10 O
% O
) O
in O
the O
clinical O
trials O
for O
women O
receiving O
ella O
were O
headache B-OSE_Labeled_AE
( O
18 O
% O
overall O
) O
and O
nausea B-OSE_Labeled_AE
( O
12 O
% O
overall O
) O
and O
abdominal B-OSE_Labeled_AE
and O
upper O
abdominal O
pain I-OSE_Labeled_AE
( O
12 O
% O
overall O
) O
. O

Table O
1 O
lists O
those O
adverse O
reactions O
that O
were O
reported O
in O
> O
= O
5 O
% O
of O
subjects O
in O
the O
clinical O
studies O
( O
14 O
) O
. O

Table O
1 O
: O
Adverse O
Reactions O
in O
> O
= O
5 O
% O
of O
Women O
( O
% O
) O
Receiving O
a O
Single O
Dose O
of O
ella O
( O
30 O
mg O
Ulipristal O
Acetate O
) O
Most O
Common O
Adverse O
Reactions O
Open-Label O
Study O
Single-Blind O
Comparative O
Study O
N O
= O
1,533 O
N O
= O
1,104 O
Headache B-OSE_Labeled_AE
18 O
19 O
Nausea B-OSE_Labeled_AE
12 O
13 O
Abdominal B-OSE_Labeled_AE
and O
upper O
abdominal O
pain I-OSE_Labeled_AE
15 O
8 O
Dysmenorrhea B-OSE_Labeled_AE
7 O
13 O
Fatigue B-OSE_Labeled_AE
6 O
6 O
Dizziness B-OSE_Labeled_AE
5 O
5 O
6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
ella O
: O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Acne B-OSE_Labeled_AE
Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
ella O
is O
not O
indicated O
for O
termination O
of O
an O
existing O
pregnancy O
. O

Exclude O
pregnancy O
before O
administering O
. O

( O
5.1 O
) O
* O
Ectopic O
pregnancy O
: O
Women O
who O
become O
pregnant O
or O
complain O
of O
lower O
abdominal O
pain O
after O
taking O
ella O
should O
be O
evaluated O
for O
ectopic O
pregnancy O
. O

( O
5.2 O
) O
* O
Effect O
on O
menstrual O
cycle O
: O
ella O
may O
alter O
the O
next O
expected O
menses O
. O

If O
menses O
is O
delayed O
beyond O
1 O
week O
, O
pregnancy O
should O
be O
ruled O
out O
. O

( O
5.5 O
) O
* O
ella O
does O
not O
protect O
against O
STI/HIV O
. O

( O
5.6 O
) O
5.1 O
Existing O
Pregnancy O
ella O
is O
not O
indicated O
for O
termination O
of O
an O
existing O
pregnancy B-Not_AE_Candidate
. O

Pregnancy B-Not_AE_Candidate
should O
be O
excluded O
before O
prescribing O
ella O
. O

If O
pregnancy B-Not_AE_Candidate
can O
not O
be O
excluded O
on O
the O
basis O
of O
history O
and/or O
physical O
examination O
, O
pregnancy B-NonOSE_AE
testing I-NonOSE_AE
should O
be O
performed O
. O

A O
follow-up O
physical O
or O
pelvic O
examination O
is O
recommended O
if O
there O
is O
any O
doubt O
concerning O
the O
general O
health O
or O
pregnancy B-NonOSE_AE
status O
of O
any O
woman O
after O
taking O
ella O
. O

5.2 O
Ectopic O
Pregnancy O
A O
history O
of O
ectopic B-Not_AE_Candidate
pregnancy I-Not_AE_Candidate
is O
not O
a O
contraindication O
to O
use O
of O
this O
emergency O
contraceptive O
method O
. O

Healthcare O
providers O
, O
however O
, O
should O
consider O
the O
possibility O
of O
ectopic B-NonOSE_AE
pregnancy I-NonOSE_AE
in O
women O
who O
become O
pregnant B-NonOSE_AE
or O
complain O
of O
lower B-NonOSE_AE
abdominal I-NonOSE_AE
pain I-NonOSE_AE
after O
taking O
ella O
. O

A O
follow-up O
physical O
or O
pelvic O
examination O
is O
recommended O
if O
there O
is O
any O
doubt O
concerning O
the O
general O
health O
or O
pregnancy B-NonOSE_AE
status O
of O
any O
woman O
after O
taking O
ella O
. O

5.3 O
Repeated O
Use O
ella O
is O
for O
occasional O
use O
as O
an O
emergency B-Not_AE_Candidate
contraceptive I-Not_AE_Candidate
. O

It O
should O
not O
replace O
a O
regular O
method O
of O
contraception O
. O

Repeated O
use O
of O
ella O
within O
the O
same O
menstrual O
cycle O
is O
not O
recommended O
, O
as O
safety O
and O
efficacy O
of O
repeat O
use O
within O
the O
same O
cycle O
has O
not O
been O
evaluated O
. O

5.4 O
CYP3A4 O
Inducers O
A O
CYP3A4 O
inducer O
, O
rifampin O
, O
decreases O
the O
plasma O
concentration O
of O
ella O
significantly O
. O

Ella O
should O
not O
be O
administered O
with O
CYP3A4 O
inducers O
[ O
see O
Drug O
interactions O
( O
7.1 O
) O
and O
Pharmacokinetics O
( O
12.3 O
) O
] O
. O

5.5 O
Fertility O
Following O
Use O
A O
rapid O
return O
of O
fertility O
is O
likely O
following O
treatment O
with O
ella O
for O
emergency O
contraception O
; O
therefore O
, O
routine O
contraception O
should O
be O
continued O
or O
initiated O
as O
soon O
as O
possible O
following O
use O
of O
ella O
to O
ensure O
ongoing O
prevention O
of O
pregnancy B-NonOSE_AE
. O

While O
there O
are O
no O
data O
about O
use O
of O
ella O
with O
regular O
hormonal O
contraceptives O
, O
due O
to O
its O
high O
affinity O
binding O
to O
the O
progesterone O
receptor O
, O
use O
of O
ella O
may O
reduce O
the O
contraceptive O
action O
of O
regular O
hormonal O
contraceptive O
methods O
. O

Therefore O
, O
after O
use O
of O
ella O
, O
a O
reliable O
barrier O
method O
of O
contraception O
should O
be O
used O
with O
subsequent O
acts O
of O
intercourse O
that O
occur O
in O
that O
same O
menstrual O
cycle O
. O

5.6 O
Effect O
on O
Menstrual O
Cycle O
After O
ella O
intake O
, O
menses B-OSE_Labeled_AE
sometimes O
occur I-OSE_Labeled_AE
earlier O
or O
later I-OSE_Labeled_AE
than O
expected O
by O
a O
few O
days O
. O

In O
clinical O
trials O
, O
cycle O
length O
was O
increased O
by O
a O
mean O
of O
2.5 O
days O
but O
returned O
to O
normal O
in O
the O
subsequent O
cycle O
. O

Seven O
percent O
of O
subjects O
reported O
menses B-OSE_Labeled_AE
occurring O
more O
than O
7 O
days O
earlier I-OSE_Labeled_AE
than O
expected O
, O
and O
19 O
% O
reported O
a O
delay O
of O
more O
than O
7 O
days O
. O

If O
there O
is O
a O
delay B-NonOSE_AE
in O
the O
onset O
of O
expected O
menses I-NonOSE_AE
beyond O
1 O
week O
, O
rule O
out O
pregnancy B-Not_AE_Candidate
. O

Nine O
percent O
of O
women O
studied O
reported O
intermenstrual B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
after O
use O
of O
ella O
. O

5.7 O
Sexually O
Transmitted O
Infections/HIV O
ella O
does O
not O
protect O
against O
HIV B-Not_AE_Candidate
infection I-Not_AE_Candidate
( I-Not_AE_Candidate
AIDS I-Not_AE_Candidate
) O
or O
other O
sexually B-Not_AE_Candidate
transmitted I-Not_AE_Candidate
infections I-Not_AE_Candidate
( I-Not_AE_Candidate
STIs I-Not_AE_Candidate
) O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Serious O
Infections B-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Neurologic B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Malignancies B-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Patients O
with O
Heart B-Not_AE_Candidate
Failure I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Hematologic B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Hepatitis B-OSE_Labeled_AE
B I-OSE_Labeled_AE
Reactivation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Allergic B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Autoimmunity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Immunosuppression B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
5 O
% O
) O
: O
infections O
and O
injection O
site O
reactions O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Amgen O
Inc O
. O
at O
1-800-77-AMGEN O
( O
1-800-772-6436 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Across O
clinical O
studies O
and O
postmarketing O
experience O
, O
the O
most O
serious O
adverse O
reactions O
with O
Enbrel O
were O
infections B-OSE_Labeled_AE
, O
neurologic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
CHF B-OSE_Labeled_AE
, O
and O
hematologic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5 O
) O
] O
. O

The O
most O
common O
adverse O
reactions O
with O
Enbrel O
were O
infections B-OSE_Labeled_AE
and O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reactions O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
predict O
the O
rates O
observed O
in O
clinical O
practice O
. O

Adverse O
Reactions O
in O
Adult O
Patients O
w O
ith O
R O
heumatoid O
A O
rthritis O
, O
Psoriatic O
Arthritis O
, O
Ankylosing O
Spondylitis O
, O
or O
Plaque O
Psoriasis O
The O
data O
described O
below O
reflect O
exposure O
to O
Enbrel O
in O
2219 O
adult O
patients O
with O
RA B-Not_AE_Candidate
followed O
for O
up O
to O
80 O
months O
, O
in O
182 O
patients O
with O
PsA B-Not_AE_Candidate
for O
up O
to O
24 O
months O
, O
in O
138 O
patients O
with O
AS B-Not_AE_Candidate
for O
up O
to O
6 O
months O
, O
and O
in O
1204 O
adult O
patients O
with O
PsO B-Not_AE_Candidate
for O
up O
to O
18 O
months O
. O

In O
controlled O
trials O
, O
the O
proportion O
of O
Enbrel-treated O
patients O
who O
discontinued O
treatment O
due O
to O
adverse O
events O
was O
approximately O
4 O
% O
in O
the O
indications O
studied O
. O

Adverse O
Reactions O
in O
Pediatric O
Patients O
In O
general O
, O
the O
adverse O
reactions O
in O
pediatric O
patients O
were O
similar O
in O
frequency O
and O
type O
as O
those O
seen O
in O
adult O
patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.4 O
) O
, O
and O
Clinical O
Studies O
( O
14.2 O
and O
14.6 O
) O
] O
. O

In O
a O
48-week O
clinical O
study O
in O
211 O
children O
aged O
4 O
to O
17 O
years O
with O
pediatric O
PsO B-Not_AE_Candidate
, O
the O
adverse O
reactions O
reported O
were O
similar O
to O
those O
seen O
in O
previous O
studies O
in O
adults O
with O
PsO B-Not_AE_Candidate
. O

Long-term O
safety O
profile O
for O
up O
to O
264 O
additional O
weeks O
was O
assessed O
in O
an O
open-label O
extension O
study O
and O
no O
new O
safety O
signals O
were O
identified O
. O

In O
open-label O
clinical O
studies O
of O
children O
with O
JIA B-Not_AE_Candidate
, O
adverse O
reactions O
reported O
in O
those O
ages O
2 O
to O
4 O
years O
were O
similar O
to O
adverse O
reactions O
reported O
in O
older O
children O
. O

Infections O
Infections B-OSE_Labeled_AE
, O
including O
viral B-OSE_Labeled_AE
, O
bacterial O
, O
and O
fungal O
infections I-OSE_Labeled_AE
, O
have O
been O
observed O
in O
adult O
and O
pediatric O
patients O
. O

Infections B-OSE_Labeled_AE
have O
been O
noted O
in O
all O
body O
systems O
and O
have O
been O
reported O
in O
patients O
receiving O
Enbrel O
alone O
or O
in O
combination O
with O
other O
immunosuppressive B-NonOSE_AE
agents I-NonOSE_AE
. O

In O
controlled O
portions O
of O
trials O
, O
the O
types O
and O
severity O
of O
infection B-OSE_Labeled_AE
were O
similar O
between O
Enbrel O
and O
the O
respective O
control O
group O
( O
placebo O
or O
MTX O
for O
RA B-Not_AE_Candidate
and O
PsA B-Not_AE_Candidate
patients O
) O
in O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
AS B-Not_AE_Candidate
and O
PsO B-Not_AE_Candidate
patients O
. O

Rates O
of O
infections B-NonOSE_AE
in O
RA B-Not_AE_Candidate
and O
adult O
PsO B-Not_AE_Candidate
patients O
are O
provided O
in O
Table O
3 O
and O
Table O
4 O
, O
respectively O
. O

Infections B-OSE_Labeled_AE
consisted O
primarily O
of O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
and O
influenza B-OSE_Labeled_AE
. O

In O
controlled O
portions O
of O
trials O
in O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
AS B-Not_AE_Candidate
and O
PsO B-Not_AE_Candidate
, O
the O
rates O
of O
serious O
infection B-OSE_Labeled_AE
were O
similar O
( O
0.8 O
% O
in O
placebo O
, O
3.6 O
% O
in O
MTX O
, O
and O
1.4 O
% O
in O
Enbrel/Enbrel O
+ O
MTX-treated O
groups O
) O
. O

In O
clinical O
trials O
in O
rheumatologic O
indications O
, O
serious O
infections B-OSE_Labeled_AE
experienced O
by O
patients O
have O
included O
, O
but O
are O
not O
limited O
to O
, O
pneumonia B-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
septic B-OSE_Labeled_AE
arthritis I-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
pyelonephritis B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
abscess B-OSE_Labeled_AE
and O
osteomyelitis B-OSE_Labeled_AE
. O

In O
clinical O
trials O
in O
adult O
PsO B-Not_AE_Candidate
patients O
, O
serious O
infections B-OSE_Labeled_AE
experienced O
by O
patients O
have O
included O
, O
but O
are O
not O
limited O
to O
, O
pneumonia B-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
abscess B-OSE_Labeled_AE
and O
osteomyelitis B-OSE_Labeled_AE
. O

The O
rate O
of O
serious O
infections B-NonOSE_AE
was O
not O
increased O
in O
open-label O
extension O
trials O
and O
was O
similar O
to O
that O
observed O
in O
Enbrel- O
and O
placebo-treated O
patients O
from O
controlled O
trials O
. O

In O
66 O
global O
clinical O
trials O
of O
17,505 O
patients O
( O
21,015 O
patient-years O
of O
therapy O
) O
, O
tuberculosis B-OSE_Labeled_AE
was O
observed O
in O
approximately O
0.02 O
% O
of O
patients O
. O

In O
17,696 O
patients O
( O
27,169 O
patient-years O
of O
therapy O
) O
from O
38 O
clinical O
trials O
and O
4 O
cohort O
studies O
in O
the O
U.S O
. O
and O
Canada O
, O
tuberculosis B-OSE_Labeled_AE
was O
observed O
in O
approximately O
0.006 O
% O
of O
patients O
. O

These O
studies O
include O
reports O
of O
pulmonary B-OSE_Labeled_AE
and O
extrapulmonary O
tuberculosis I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

The O
types O
of O
infections B-OSE_Labeled_AE
reported O
in O
pediatric O
patients O
with O
PsO B-Not_AE_Candidate
and O
JIA B-Not_AE_Candidate
were O
generally O
mild O
and O
consistent O
with O
those O
commonly O
seen O
in O
the O
general O
pediatric O
population O
. O

Two O
JIA B-Not_AE_Candidate
patients O
developed O
varicella B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
and O
signs O
and O
symptoms O
of O
aseptic B-OSE_Labeled_AE
meningitis I-OSE_Labeled_AE
, O
which O
resolved O
without O
sequelae O
. O

Injection O
Site O
Reactions O
In O
placebo-controlled O
trials O
in O
rheumatologic O
indications O
, O
approximately O
37 O
% O
of O
patients O
treated O
with O
Enbrel O
developed O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

In O
controlled O
trials O
in O
patients O
with O
PsO B-Not_AE_Candidate
, O
15 O
% O
of O
adult O
patients O
and O
7 O
% O
of O
pediatric O
patients O
treated O
with O
Enbrel O
developed O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
during O
the O
first O
3 O
months O
of O
treatment O
. O

All O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
were O
described O
as O
mild O
to O
moderate O
( O
erythema O
, O
itching O
, O
pain O
, O
swelling O
, O
bleeding O
, O
bruising O
) O
and O
generally O
did O
not O
necessitate O
drug O
discontinuation O
. O

Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
generally O
occurred O
in O
the O
first O
month O
and O
subsequently O
decreased O
in O
frequency O
. O

The O
mean O
duration O
of O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
was O
3 O
to O
5 O
days O
. O

Seven O
percent O
of O
patients O
experienced O
redness B-OSE_Labeled_AE
at I-OSE_Labeled_AE
a I-OSE_Labeled_AE
previous I-OSE_Labeled_AE
injection I-OSE_Labeled_AE
site I-OSE_Labeled_AE
when O
subsequent O
injections O
were O
given O
. O

Other O
Adverse O
Reactions O
Table O
3 O
summarizes O
adverse O
reactions O
reported O
in O
adult O
RA B-Not_AE_Candidate
patients O
. O

The O
types O
of O
adverse O
reactions O
seen O
in O
patients O
with O
PsA B-Not_AE_Candidate
or O
AS B-Not_AE_Candidate
were O
similar O
to O
the O
types O
of O
adverse O
reactions O
seen O
in O
patients O
with O
RA B-Not_AE_Candidate
. O

Table O
3 O
. O

Percent O
of O
Adult O
RA O
Patients O
Experiencing O
Adverse O
Reactions O
in O
Controlled O
Clinical O
Trials O
Placebo O
Controlled O
a O
( O
Studies O
I O
, O
II O
, O
and O
a O
Phase O
2 O
S O
tudy O
) O
Active O
Controlled O
b O
( O
Study O
III O
) O
Placebo O
( O
N O
= O
152 O
) O
E O
nbrel O
c O
( O
N O
= O
349 O
) O
MTX O
( O
N O
= O
217 O
) O
E O
nbrel O
c O
( O
N O
= O
415 O
) O
Reaction O
Percent O
of O
Patients O
Percent O
of O
Patients O
Infection B-OSE_Labeled_AE
d O
( O
total O
) O
39 O
50 O
86 O
81 O
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Infections I-OSE_Labeled_AE
e O
30 O
38 O
70 O
65 O
Non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Infections I-OSE_Labeled_AE
15 O
21 O
59 O
54 O
Injection B-OSE_Labeled_AE
Site I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
11 O
37 O
18 O
43 O
Diarrhea B-OSE_Labeled_AE
9 O
8 O
16 O
16 O
Rash B-OSE_Labeled_AE
2 O
3 O
19 O
13 O
Pruritus B-OSE_Labeled_AE
1 O
2 O
5 O
5 O
Pyrexia B-OSE_Labeled_AE
- O
3 O
4 O
2 O
Urticaria B-OSE_Labeled_AE
1 O
- O
4 O
2 O
Hypersensitivity B-OSE_Labeled_AE
- O
- O
1 O
1 O
a O
Includes O
data O
from O
the O
6-month O
study O
in O
which O
patients O
received O
concurrent O
MTX O
therapy O
in O
both O
arms O
. O

b O
Study O
duration O
of O
2 O
years O
. O

c O
Any O
dose O
. O

d O
Includes O
bacterial B-OSE_Labeled_AE
, O
viral O
and O
fungal O
infections I-OSE_Labeled_AE
. O

e O
Most O
frequent O
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Infections I-OSE_Labeled_AE
were O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
and O
influenza B-OSE_Labeled_AE
. O

In O
placebo-controlled O
adult O
PsO B-Not_AE_Candidate
trials O
, O
the O
percentages O
of O
patients O
reporting O
adverse O
reactions O
in O
the O
50 O
mg O
twice O
a O
week O
dose O
group O
were O
similar O
to O
those O
observed O
in O
the O
25 O
mg O
twice O
a O
week O
dose O
group O
or O
placebo O
group O
. O

Table O
4 O
summarizes O
adverse O
reactions O
reported O
in O
adult O
PsO B-Not_AE_Candidate
patients O
from O
Studies O
I O
and O
II O
. O

Table O
4 O
. O

Percent O
of O
Adult O
PsO O
Patients O
Experiencing O
Adverse O
Reactions O
in O
Placebo-Controlled O
Portions O
of O
Clinical O
Trials O
( O
Studies O
I O
& O
II O
) O
Placebo O
( O
N O
= O
359 O
) O
Enbrel O
a O
( O
N O
= O
876 O
) O
Reaction O
Percent O
of O
Patients O
Infection B-NonOSE_AE
b O
( O
total O
) O
28 O
27 O
Non B-NonOSE_AE
- I-NonOSE_AE
upper I-NonOSE_AE
Respiratory I-NonOSE_AE
Infections I-NonOSE_AE
14 O
12 O
Upper B-NonOSE_AE
Respiratory I-NonOSE_AE
Infections I-NonOSE_AE
c O
17 O
17 O
Injection B-OSE_Labeled_AE
Site I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
6 O
15 O
Diarrhea B-OSE_Labeled_AE
2 O
3 O
Rash B-NonOSE_AE
1 O
1 O
Pruritus B-NonOSE_AE
2 O
1 O
Urticaria B-OSE_Labeled_AE
- O
1 O
Hypersensitivity B-OSE_Labeled_AE
- O
1 O
Pyrexia B-NonOSE_AE
1 O
- O
a O
Includes O
25 O
mg O
subcutaneous O
( O
SC O
) O
once O
weekly O
( O
QW O
) O
, O
25 O
mg O
SC O
twice O
weekly O
( O
BIW O
) O
, O
50 O
mg O
SC O
QW O
, O
and O
50 O
mg O
SC O
BIW O
doses O
. O

b O
Includes O
bacterial B-NonOSE_AE
, O
viral O
and O
fungal O
infections I-NonOSE_AE
. O

c O
Most O
frequent O
Upper B-NonOSE_AE
Respiratory I-NonOSE_AE
Infections I-NonOSE_AE
were O
upper B-NonOSE_AE
respiratory I-NonOSE_AE
tract I-NonOSE_AE
infection I-NonOSE_AE
, O
nasopharyngitis B-NonOSE_AE
and O
sinusitis B-NonOSE_AE
. O

6.2 O
Immunogenicity O
As O
with O
all O
therapeutic O
proteins O
, O
there O
is O
potential O
for O
immunogenicity B-OSE_Labeled_AE
. O

The O
detection O
of O
antibody B-NonOSE_AE
formation I-NonOSE_AE
is O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
. O

Additionally O
, O
the O
observed O
incidence O
of O
antibody B-NonOSE_AE
( I-NonOSE_AE
including I-NonOSE_AE
neutralizing I-NonOSE_AE
antibody I-NonOSE_AE
) I-NonOSE_AE
positivity I-NonOSE_AE
in O
an O
assay O
may O
be O
influenced O
by O
several O
factors O
including O
assay O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
etanercept I-NonOSE_AE
in O
the O
studies O
described O
below O
with O
the O
incidence O
of O
antibodies B-NonOSE_AE
in O
other O
studies O
or O
to I-NonOSE_AE
other I-NonOSE_AE
products I-NonOSE_AE
may O
be O
misleading O
. O

Immunogenicity O
Patients O
with O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
AS B-Not_AE_Candidate
or O
PsO B-Not_AE_Candidate
were O
tested O
at O
multiple O
time O
points O
for O
antibodies B-NonOSE_AE
to I-NonOSE_AE
etanercept I-NonOSE_AE
. O

Antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
TNF I-OSE_Labeled_AE
receptor I-OSE_Labeled_AE
portion I-OSE_Labeled_AE
or I-OSE_Labeled_AE
other I-OSE_Labeled_AE
protein I-OSE_Labeled_AE
components I-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
Enbrel I-OSE_Labeled_AE
drug O
product O
were O
detected O
at O
least O
once O
in O
sera O
of O
approximately O
6 O
% O
of O
adult O
patients O
with O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
AS B-Not_AE_Candidate
or O
PsO B-Not_AE_Candidate
. O

These O
antibodies B-OSE_Labeled_AE
were I-OSE_Labeled_AE
all I-OSE_Labeled_AE
non I-OSE_Labeled_AE
- I-OSE_Labeled_AE
neutralizing I-OSE_Labeled_AE
. O

Results O
from O
JIA B-Not_AE_Candidate
patients O
were O
similar O
to O
those O
seen O
in O
adult O
RA B-Not_AE_Candidate
patients O
treated O
with O
Enbrel O
. O

In O
adult O
PsO B-Not_AE_Candidate
studies O
that O
evaluated O
the O
exposure O
of O
etanercept O
for O
up O
to O
120 O
weeks O
, O
the O
percentage O
of O
patients O
testing B-OSE_Labeled_AE
positive I-OSE_Labeled_AE
at O
the O
assessed O
time O
points O
of O
24 O
, O
48 O
, O
72 O
and O
96 O
weeks O
ranged O
from O
3.6 O
% O
-8.7 O
% O
and O
were O
all O
non I-OSE_Labeled_AE
- I-OSE_Labeled_AE
neutralizing I-OSE_Labeled_AE
. O

The O
percentage O
of O
patients O
testing O
positive O
increased O
with O
an O
increase O
in O
the O
duration O
of O
study O
; O
however O
, O
the O
clinical O
significance O
of O
this O
finding O
is O
unknown O
. O

No O
apparent O
correlation O
of O
antibody B-NonOSE_AE
development I-NonOSE_AE
to O
clinical O
response O
or O
adverse O
events O
was O
observed O
. O

The O
immunogenicity B-NonOSE_AE
data O
of O
Enbrel O
beyond O
120 O
weeks O
of O
exposure O
are O
unknown O
. O

In O
pediatric O
PsO B-Not_AE_Candidate
studies O
, O
approximately O
10 O
% O
of O
subjects O
developed O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
etanercept I-OSE_Labeled_AE
by O
Week O
48 O
and O
approximately O
16 O
% O
of O
subjects O
developed O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
etanercept I-OSE_Labeled_AE
by O
Week O
264 O
. O

All O
of O
these O
antibodies B-OSE_Labeled_AE
were I-OSE_Labeled_AE
non I-OSE_Labeled_AE
- I-OSE_Labeled_AE
neutralizing I-OSE_Labeled_AE
. O

However O
, O
because O
of O
the O
limitations O
of O
the O
immunogenicity B-NonOSE_AE
assays O
, O
the O
incidence O
of O
binding O
and O
neutralizing B-NonOSE_AE
antibodies I-NonOSE_AE
may O
not O
have O
been O
reliably O
determined O
. O

The O
data O
reflect O
the O
percentage O
of O
patients O
whose O
test O
results O
were O
considered O
positive B-NonOSE_AE
for I-NonOSE_AE
antibodies I-NonOSE_AE
to I-NonOSE_AE
etanercept I-NonOSE_AE
in O
an O
ELISA O
assay O
, O
and O
are O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
. O

Autoantibodies O
Patients O
with O
RA B-Not_AE_Candidate
had O
serum O
samples O
tested O
for O
autoantibodies B-NonOSE_AE
at O
multiple O
time O
points O
. O

In O
RA B-Not_AE_Candidate
Studies O
I O
and O
II O
, O
the O
percentage O
of O
patients O
evaluated O
for O
antinuclear B-NonOSE_AE
antibodies I-NonOSE_AE
( I-NonOSE_AE
ANA I-NonOSE_AE
) O
who O
developed O
new B-OSE_Labeled_AE
positive I-OSE_Labeled_AE
ANA I-OSE_Labeled_AE
( O
titer O
> O
= O
1:40 O
) O
was O
higher O
in O
patients O
treated O
with O
Enbrel O
( O
11 O
% O
) O
than O
in O
placebo-treated O
patients O
( O
5 O
% O
) O
. O

The O
percentage O
of O
patients O
who O
developed O
new O
positive B-OSE_Labeled_AE
anti I-OSE_Labeled_AE
- I-OSE_Labeled_AE
double I-OSE_Labeled_AE
- I-OSE_Labeled_AE
stranded I-OSE_Labeled_AE
DNA I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
was O
also O
higher O
by O
radioimmunoassay O
( O
15 O
% O
of O
patients O
treated O
with O
Enbrel O
compared O
to O
4 O
% O
of O
placebo-treated O
patients O
) O
and O
by O
Crithidia O
luciliae O
assay O
( O
3 O
% O
of O
patients O
treated O
with O
Enbrel O
compared O
to O
none O
of O
placebo-treated O
patients O
) O
. O

The O
proportion O
of O
patients O
treated O
with O
Enbrel O
who O
developed O
anticardiolipin B-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
was O
similarly O
increased O
compared O
to O
placebo-treated O
patients O
. O

In O
RA B-Not_AE_Candidate
Study O
III O
, O
no O
pattern O
of O
increased O
autoantibody B-NonOSE_AE
development O
was O
seen O
in O
Enbrel O
patients O
compared O
to O
MTX O
patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
. O

6.3 O
Postmarketing O
Experience O
Adverse O
reactions O
have O
been O
reported O
during O
post O
approval O
use O
of O
Enbrel O
in O
adults O
and O
pediatric O
patients O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
Enbrel O
exposure O
. O

Adverse O
reactions O
are O
listed O
by O
body O
system O
below O
: O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
pancytopenia B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
lymphadenopathy B-OSE_Labeled_AE
, O
aplastic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
inflammatory B-OSE_Labeled_AE
bowel I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
( O
IBD O
) O
General B-NonOSE_AE
disorders I-NonOSE_AE
: O
angioedema B-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
Hepatobiliary B-NonOSE_AE
disorders I-NonOSE_AE
: O
autoimmune B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
B I-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
Immune B-NonOSE_AE
disorders I-NonOSE_AE
: O
macrophage B-OSE_Labeled_AE
activation I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
systemic B-OSE_Labeled_AE
vasculitis I-OSE_Labeled_AE
, O
sarcoidosis B-OSE_Labeled_AE
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
lupus B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
Neoplasms B-NonOSE_AE
benign I-NonOSE_AE
, I-NonOSE_AE
malignant I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
unspecified I-NonOSE_AE
: O
melanoma B-OSE_Labeled_AE
and O
non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
melanoma I-OSE_Labeled_AE
skin I-OSE_Labeled_AE
cancers I-OSE_Labeled_AE
, O
Merkel B-OSE_Labeled_AE
cell I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
convulsions B-OSE_Labeled_AE
, O
multiple B-OSE_Labeled_AE
sclerosis I-OSE_Labeled_AE
, O
demyelination B-OSE_Labeled_AE
, O
optic B-OSE_Labeled_AE
neuritis I-OSE_Labeled_AE
, O
transverse B-OSE_Labeled_AE
myelitis I-OSE_Labeled_AE
, O
paresthesias B-OSE_Labeled_AE
[ O
see O
Warning O
s O
and O
Precaution O
s O
( O
5.2 O
) O
] O
Ocular B-NonOSE_AE
disorders I-NonOSE_AE
: O
uveitis B-OSE_Labeled_AE
, O
scleritis B-OSE_Labeled_AE
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
: O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
cutaneous B-OSE_Labeled_AE
lupus I-OSE_Labeled_AE
erythematosus I-OSE_Labeled_AE
, O
cutaneous B-OSE_Labeled_AE
vasculitis I-OSE_Labeled_AE
( O
including O
leukocytoclastic B-OSE_Labeled_AE
vasculitis I-OSE_Labeled_AE
) O
, O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
subcutaneous B-OSE_Labeled_AE
nodule I-OSE_Labeled_AE
, O
new O
or O
worsening O
psoriasis B-OSE_Labeled_AE
( O
all O
sub-types O
including O
pustular O
and O
palmoplantar O
) O
Opportunistic B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
including O
atypical B-OSE_Labeled_AE
mycobacterial I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
, O
aspergillosis B-OSE_Labeled_AE
and O
Pneumocystis B-OSE_Labeled_AE
jiroveci I-OSE_Labeled_AE
pneumonia I-OSE_Labeled_AE
, O
and O
protozoal B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
have O
also O
been O
reported O
in O
postmarketing O
use O
. O

Rare O
( O
< O
0.1 O
% O
) O
cases O
of O
IBD B-OSE_Labeled_AE
have O
been O
reported O
in O
JIA B-Not_AE_Candidate
patients O
receiving O
Enbrel O
, O
which O
is O
not O
effective O
for O
the O
treatment O
of O
IBD B-Not_AE_Candidate
. O

BOXED O
WARNING O
: O
WARNING O
: O
SERIOUS O
INFECTIONS O
and O
MALIGNANCIES O
WARNING O
: O
SERIOUS O
INFECTIONS O
and O
MALIGNANCIES O
SERIOUS O
INFECTIONS O
Patients O
treated O
with O
Enbrel O
are O
at O
increased O
risk O
for O
developing O
serious O
infections B-OSE_Labeled_AE
that O
may O
lead O
to O
hospitalization O
or O
death B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
and O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

Most O
patients O
who O
developed O
these O
infections B-NonOSE_AE
were O
taking O
concomitant O
immunosuppressants B-NonOSE_AE
such O
as O
methotrexate O
or O
corticosteroids O
. O

Enbrel O
should O
be O
discontinued O
if O
a O
patient O
develops O
a O
serious O
infection B-NonOSE_AE
or O
sepsis B-NonOSE_AE
. O

Reported O
infections B-OSE_Labeled_AE
include O
: O
* O
Active B-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
, O
including O
reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
latent I-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
. O

Patients O
with O
tuberculosis B-OSE_Labeled_AE
have O
frequently O
presented O
with O
disseminated O
or O
extrapulmonary O
disease O
. O

Patients O
should O
be O
tested O
for O
latent B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
before O
Enbrel O
use O
and O
during O
therapy O
. O

Treatment O
for O
latent B-Not_AE_Candidate
infection I-Not_AE_Candidate
should O
be O
initiated O
prior O
to O
Enbrel O
use O
. O

* O
Invasive B-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
including O
histoplasmosis B-OSE_Labeled_AE
, O
coccidioidomycosis B-OSE_Labeled_AE
, O
candidiasis B-OSE_Labeled_AE
, O
aspergillosis B-OSE_Labeled_AE
, O
blastomycosis B-OSE_Labeled_AE
, O
and O
pneumocystosis B-OSE_Labeled_AE
. O

Patients O
with O
histoplasmosis B-OSE_Labeled_AE
or O
other O
invasive B-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
may O
present O
with O
disseminated O
, O
rather O
than O
localized O
, O
disease O
. O

Antigen B-NonOSE_AE
and O
antibody O
testing I-NonOSE_AE
for I-NonOSE_AE
histoplasmosis I-NonOSE_AE
may I-NonOSE_AE
be I-NonOSE_AE
negative I-NonOSE_AE
in O
some O
patients O
with O
active O
infection B-NonOSE_AE
. O

Empiric O
anti-fungal O
therapy O
should O
be O
considered O
in O
patients O
at O
risk O
for O
invasive B-NonOSE_AE
fungal I-NonOSE_AE
infections I-NonOSE_AE
who O
develop O
severe O
systemic O
illness O
. O

* O
Bacterial B-OSE_Labeled_AE
, O
viral O
, O
and O
other O
infections I-OSE_Labeled_AE
due I-OSE_Labeled_AE
to I-OSE_Labeled_AE
opportunistic I-OSE_Labeled_AE
pathogens I-OSE_Labeled_AE
, O
including O
Legionella B-OSE_Labeled_AE
and O
Listeria O
. O

The O
risks O
and O
benefits O
of O
treatment O
with O
Enbrel O
should O
be O
carefully O
considered O
prior O
to O
initiating O
therapy O
in O
patients O
with O
chronic O
or O
recurrent O
infection I-OSE_Labeled_AE
. O

Patients O
should O
be O
closely O
monitored O
for O
the O
development O
of O
signs O
and O
symptoms O
of O
infection B-NonOSE_AE
during O
and O
after O
treatment O
with O
Enbrel O
, O
including O
the O
possible O
development O
of O
tuberculosis B-NonOSE_AE
in O
patients O
who O
tested O
negative O
for O
latent B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
infection I-Not_AE_Candidate
prior O
to O
initiating O
therapy O
. O

MALIGNANCIES O
Lymphoma B-OSE_Labeled_AE
and O
other O
malignancies B-OSE_Labeled_AE
, O
some O
fatal B-NonOSE_AE
, O
have O
been O
reported O
in O
children O
and O
adolescent O
patients O
treated O
with O
TNF O
blockers O
, O
including O
Enbrel O
. O

EXCERPT O
: O
WARNING O
: O
SERIOUS O
INFECTIONS O
and O
MALIGNANCIES O
See O
f O
ull O
p O
rescribing O
i O
nformation O
for O
complete O
b O
oxed O
w O
arning O
. O

SERIOUS O
INFECTIONS O
* O
Increased O
risk O
of O
serious O
infections O
leading O
to O
hospitalization O
or O
death O
, O
including O
tuberculosis O
( O
TB O
) O
, O
bacterial O
sepsis O
, O
invasive O
fungal O
infections O
( O
such O
as O
histoplasmosis O
) O
, O
and O
infections O
due O
to O
other O
opportunistic O
pathogens O
. O

( O
5.1 O
) O
* O
Enbrel O
should O
be O
discontinued O
if O
a O
patient O
develops O
a O
serious O
infection O
or O
sepsis O
during O
treatment O
. O

( O
5.1 O
) O
* O
Perform O
test O
for O
latent O
TB O
; O
if O
positive O
, O
start O
treatment O
for O
TB O
prior O
to O
starting O
Enbrel O
. O

( O
5.1 O
) O
* O
Monitor O
all O
patients O
for O
active O
TB O
during O
treatment O
, O
even O
if O
initial O
latent O
TB O
test O
is O
negative O
. O

( O
5.1 O
) O
MALIGNANCIES O
* O
Lymphoma O
and O
other O
malignancies O
, O
some O
fatal O
, O
have O
been O
reported O
in O
children O
and O
adolescent O
patients O
treated O
with O
TNF O
blockers O
, O
including O
Enbrel O
. O

( O
5.3 O
) O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Do O
not O
start O
Enbrel O
during O
an O
active O
infection O
. O

If O
an O
infection O
develops O
, O
monitor O
carefully O
and O
stop O
Enbrel O
if O
infection O
becomes O
serious O
. O

( O
5.1 O
) O
* O
Consider O
empiric O
anti-fungal O
therapy O
for O
patients O
at O
risk O
for O
invasive O
fungal O
infections O
who O
develop O
a O
severe O
systemic O
illness O
on O
Enbrel O
( O
those O
who O
reside O
or O
travel O
to O
regions O
where O
mycoses O
are O
endemic O
) O
. O

( O
5.1 O
) O
* O
Demyelinating O
disease O
, O
exacerbation O
or O
new O
onset O
, O
may O
occur O
. O

( O
5.2 O
) O
* O
Cases O
of O
lymphoma O
have O
been O
observed O
in O
patients O
receiving O
TNF-blocking O
agents O
. O

( O
5.3 O
) O
* O
Congestive O
heart O
failure O
, O
worsening O
or O
new O
onset O
, O
may O
occur O
. O

( O
5.4 O
) O
* O
Advise O
patients O
to O
seek O
immediate O
medical O
attention O
if O
symptoms O
of O
pancytopenia O
or O
aplastic O
anemia O
develop O
, O
and O
consider O
stopping O
Enbrel O
. O

( O
5.5 O
) O
* O
Monitor O
patients O
previously O
infected O
with O
hepatitis O
B O
virus O
for O
reactivation O
during O
and O
several O
months O
after O
therapy O
. O

If O
reactivation O
occurs O
, O
consider O
stopping O
Enbrel O
and O
beginning O
anti-viral O
therapy O
. O

( O
5.6 O
) O
* O
Anaphylaxis O
or O
serious O
allergic O
reactions O
may O
occur O
. O

( O
5.7 O
) O
* O
Stop O
Enbrel O
if O
lupus-like O
syndrome O
or O
autoimmune O
hepatitis O
develops O
. O

( O
5.9 O
) O
5.1 O
Serious O
Infections O
Patients O
treated O
with O
Enbrel O
are O
at O
increased O
risk O
for O
developing O
serious O
infections B-OSE_Labeled_AE
involving O
various O
organ O
systems O
and O
sites O
that O
may O
lead O
to O
hospitalization O
or O
death B-NonOSE_AE
. O

Opportunistic B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
due O
to O
bacterial O
, O
mycobacterial O
, O
invasive O
fungal O
, O
viral O
, O
parasitic O
, O
or O
other O
opportunistic O
pathogens O
including O
aspergillosis B-OSE_Labeled_AE
, O
blastomycosis B-OSE_Labeled_AE
, O
candidiasis B-OSE_Labeled_AE
, O
coccidioidomycosis B-OSE_Labeled_AE
, O
histoplasmosis B-OSE_Labeled_AE
, O
legionellosis B-OSE_Labeled_AE
, O
listeriosis B-OSE_Labeled_AE
, O
pneumocystosis B-OSE_Labeled_AE
, O
and O
tuberculosis B-OSE_Labeled_AE
have O
been O
reported O
with O
TNF O
blockers O
. O

Patients O
have O
frequently O
presented O
with O
disseminated O
rather O
than O
localized O
disease O
. O

Treatment O
with O
Enbrel O
should O
not O
be O
initiated O
in O
patients O
with O
an O
active O
infection B-Not_AE_Candidate
, O
including O
clinically O
important O
localized B-Not_AE_Candidate
infections I-Not_AE_Candidate
. O

Patients O
greater O
than O
65 O
years O
of O
age O
, O
patients O
with O
co-morbid O
conditions O
, O
and/or O
patients O
taking O
concomitant O
immunosuppressants B-NonOSE_AE
( O
such O
as O
corticosteroids O
or O
methotrexate O
) O
, O
may O
be O
at O
greater O
risk O
of O
infection B-NonOSE_AE
. O

The O
risks O
and O
benefits O
of O
treatment O
should O
be O
considered O
prior O
to O
initiating O
therapy O
in O
patients O
: O
* O
With O
chronic O
or O
recurrent O
infection B-Not_AE_Candidate
; O
* O
Who O
have O
been O
exposed O
to O
tuberculosis B-Not_AE_Candidate
; O
* O
With O
a O
history O
of O
an O
opportunistic B-Not_AE_Candidate
infection I-Not_AE_Candidate
; O
* O
Who O
have O
resided O
or O
traveled O
in O
areas O
of O
endemic O
tuberculosis B-NonOSE_AE
or O
endemic O
mycoses B-NonOSE_AE
, O
such O
as O
histoplasmosis B-NonOSE_AE
, O
coccidioidomycosis B-NonOSE_AE
, O
or O
blastomycosis B-NonOSE_AE
; O
or O
* O
With O
underlying O
conditions O
that O
may O
predispose B-Not_AE_Candidate
them I-Not_AE_Candidate
to I-Not_AE_Candidate
infection I-Not_AE_Candidate
, O
such O
as O
advanced O
or O
poorly O
controlled O
diabetes B-Not_AE_Candidate
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Patients O
should O
be O
closely O
monitored O
for O
the O
development O
of O
signs O
and O
symptoms O
of O
infection B-NonOSE_AE
during O
and O
after O
treatment O
with O
Enbrel O
. O

Enbrel O
should O
be O
discontinued O
if O
a O
patient O
develops O
a O
serious O
infection B-NonOSE_AE
or O
sepsis B-NonOSE_AE
. O

A O
patient O
who O
develops O
a O
new O
infection B-OSE_Labeled_AE
during O
treatment O
with O
Enbrel O
should O
be O
closely O
monitored O
, O
undergo O
a O
prompt O
and O
complete O
diagnostic O
workup O
appropriate O
for O
an O
immunocompromised B-NonOSE_AE
patient O
, O
and O
appropriate O
antimicrobial O
therapy O
should O
be O
initiated O
. O

Tuberculosis O
Cases O
of O
reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
or O
new O
tuberculosis B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
have O
been O
observed O
in O
patients O
receiving O
Enbrel O
, O
including O
patients O
who O
have O
previously O
received O
treatment O
for O
latent B-NonOSE_AE
or O
active O
tuberculosis I-NonOSE_AE
. O

Data O
from O
clinical O
trials O
and O
preclinical O
studies O
suggest O
that O
the O
risk O
of O
reactivation B-NonOSE_AE
of I-NonOSE_AE
latent I-NonOSE_AE
tuberculosis I-NonOSE_AE
infection I-NonOSE_AE
is O
lower O
with O
Enbrel O
than O
with O
TNF-blocking O
monoclonal O
antibodies O
. O

Nonetheless O
, O
postmarketing O
cases O
of O
tuberculosis B-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
have O
been O
reported O
for O
TNF O
blockers O
, O
including O
Enbrel O
. O

Tuberculosis B-OSE_Labeled_AE
has O
developed O
in O
patients O
who O
tested O
negative B-Not_AE_Candidate
for I-Not_AE_Candidate
latent I-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
prior O
to O
initiation O
of O
therapy O
. O

Patients O
should O
be O
evaluated O
for O
tuberculosis B-NonOSE_AE
risk O
factors O
and O
tested O
for O
latent B-Not_AE_Candidate
infection I-Not_AE_Candidate
prior O
to O
initiating O
Enbrel O
and O
periodically O
during O
therapy O
. O

Tests B-NonOSE_AE
for I-NonOSE_AE
latent I-NonOSE_AE
tuberculosis I-NonOSE_AE
infection I-NonOSE_AE
may I-NonOSE_AE
be I-NonOSE_AE
falsely I-NonOSE_AE
negative I-NonOSE_AE
while O
on O
therapy O
with O
Enbrel O
. O

Treatment O
of O
latent B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
infection I-Not_AE_Candidate
prior O
to O
therapy O
with O
TNF-blocking O
agents O
has O
been O
shown O
to O
reduce O
the O
risk O
of O
tuberculosis B-NonOSE_AE
reactivation I-NonOSE_AE
during O
therapy O
. O

Induration B-NonOSE_AE
of I-NonOSE_AE
5 I-NonOSE_AE
mm I-NonOSE_AE
or I-NonOSE_AE
greater I-NonOSE_AE
with I-NonOSE_AE
tuberculin I-NonOSE_AE
skin I-NonOSE_AE
testing I-NonOSE_AE
should I-NonOSE_AE
be I-NonOSE_AE
considered I-NonOSE_AE
a I-NonOSE_AE
positive I-NonOSE_AE
test I-NonOSE_AE
result O
when O
assessing O
if O
treatment O
for O
latent B-NonOSE_AE
tuberculosis I-NonOSE_AE
is O
needed O
prior O
to O
initiating O
Enbrel O
, O
even O
for O
patients O
previously O
vaccinated O
with O
Bacille B-NonOSE_AE
Calmette I-NonOSE_AE
- I-NonOSE_AE
Guerin I-NonOSE_AE
( I-NonOSE_AE
BCG I-NonOSE_AE
) O
. O

Anti B-NonOSE_AE
- I-NonOSE_AE
tuberculosis I-NonOSE_AE
therapy I-NonOSE_AE
should O
also O
be O
considered O
prior O
to O
initiation O
of O
Enbrel O
in O
patients O
with O
a O
past O
history O
of O
latent B-Not_AE_Candidate
or O
active O
tuberculosis I-Not_AE_Candidate
in O
whom O
an O
adequate O
course O
of O
treatment O
can O
not O
be O
confirmed O
, O
and O
for O
patients O
with O
a O
negative B-Not_AE_Candidate
test I-Not_AE_Candidate
for I-Not_AE_Candidate
latent I-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
but O
having O
risk O
factors O
for O
tuberculosis B-Not_AE_Candidate
infection I-Not_AE_Candidate
. O

Consultation O
with O
a O
physician O
with O
expertise O
in O
the O
treatment O
of O
tuberculosis B-NonOSE_AE
is O
recommended O
to O
aid O
in O
the O
decision O
whether O
initiating O
anti B-NonOSE_AE
- I-NonOSE_AE
tuberculosis I-NonOSE_AE
therapy I-NonOSE_AE
is O
appropriate O
for O
an O
individual O
patient O
. O

Tuberculosis B-NonOSE_AE
should O
be O
strongly O
considered O
in O
patients O
who O
develop O
a O
new O
infection B-NonOSE_AE
during O
Enbrel O
treatment O
, O
especially O
in O
patients O
who O
have O
previously O
or O
recently O
traveled O
to O
countries O
with O
a O
high O
prevalence O
of O
tuberculosis B-NonOSE_AE
, O
or O
who O
have O
had O
close O
contact O
with O
a O
person O
with O
active B-NonOSE_AE
tuberculosis I-NonOSE_AE
. O

Invasive O
Fungal O
Infections O
Cases O
of O
serious O
and O
sometimes O
fatal B-NonOSE_AE
fungal B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
including O
histoplasmosis B-OSE_Labeled_AE
, O
have O
been O
reported O
with O
TNF O
blockers O
, O
including O
Enbrel O
. O

For O
patients O
who O
reside O
or O
travel O
in O
regions O
where O
mycoses B-NonOSE_AE
are O
endemic O
, O
invasive B-NonOSE_AE
fungal I-NonOSE_AE
infection I-NonOSE_AE
should O
be O
suspected O
if O
they O
develop O
a O
serious O
systemic B-NonOSE_AE
illness I-NonOSE_AE
. O

Appropriate O
empiric O
anti-fungal O
therapy O
should O
be O
considered O
while O
a O
diagnostic O
workup O
is O
being O
performed O
. O

Antigen B-NonOSE_AE
and O
antibody O
testing I-NonOSE_AE
for I-NonOSE_AE
histoplasmosis I-NonOSE_AE
may I-NonOSE_AE
be I-NonOSE_AE
negative I-NonOSE_AE
in O
some O
patients O
with O
active O
infection B-NonOSE_AE
. O

When O
feasible O
, O
the O
decision O
to O
administer O
empiric O
anti-fungal O
therapy O
in O
these O
patients O
should O
be O
made O
in O
consultation O
with O
a O
physician O
with O
expertise O
in O
the O
diagnosis O
and O
treatment O
of O
invasive O
fungal B-NonOSE_AE
infections I-NonOSE_AE
and O
should O
take O
into O
account O
both O
the O
risk O
for O
severe O
fungal B-NonOSE_AE
infection I-NonOSE_AE
and O
the O
risks O
of O
anti-fungal O
therapy O
. O

In O
38 O
Enbrel O
clinical O
trials O
and O
4 O
cohort O
studies O
in O
all O
approved O
indications O
representing O
27,169 O
patient-years O
of O
exposure O
( O
17,696 O
patients O
) O
from O
the O
United O
States O
and O
Canada O
, O
no O
histoplasmosis B-NonOSE_AE
infections I-NonOSE_AE
were O
reported O
among O
patients O
treated O
with O
Enbrel O
. O

5.2 O
Neurologic B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
Treatment O
with O
TNF-blocking O
agents O
, O
including O
Enbrel O
, O
has O
been O
associated O
with O
rare O
( O
< O
0.1 O
% O
) O
cases O
of O
new O
onset O
or O
exacerbation O
of O
central B-OSE_Labeled_AE
nervous I-OSE_Labeled_AE
system I-OSE_Labeled_AE
demyelinating I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
some O
presenting O
with O
mental B-OSE_Labeled_AE
status I-OSE_Labeled_AE
changes I-OSE_Labeled_AE
and O
some O
associated O
with O
permanent O
disability O
, O
and O
with O
peripheral B-OSE_Labeled_AE
nervous I-OSE_Labeled_AE
system I-OSE_Labeled_AE
demyelinating I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
. O

Cases O
of O
transverse B-OSE_Labeled_AE
myelitis I-OSE_Labeled_AE
, O
optic B-OSE_Labeled_AE
neuritis I-OSE_Labeled_AE
, O
multiple B-OSE_Labeled_AE
sclerosis I-OSE_Labeled_AE
, O
Guillain B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Barre I-OSE_Labeled_AE
syndromes I-OSE_Labeled_AE
, O
other O
peripheral B-OSE_Labeled_AE
demyelinating I-OSE_Labeled_AE
neuropathies I-OSE_Labeled_AE
, O
and O
new O
onset O
or O
exacerbation O
of O
seizure B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
have O
been O
reported O
in O
postmarketing O
experience O
with O
Enbrel O
therapy O
. O

Prescribers O
should O
exercise O
caution O
in O
considering O
the O
use O
of O
Enbrel O
in O
patients O
with O
preexisting O
or O
recent-onset O
central O
or O
peripheral O
nervous O
system O
demyelinating B-Not_AE_Candidate
disorders I-Not_AE_Candidate
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

5.3 O
Malignancies O
Lymphomas O
In O
the O
controlled O
portions O
of O
clinical O
trials O
of O
TNF-blocking O
agents O
, O
more O
cases O
of O
lymphoma B-OSE_Labeled_AE
have O
been O
observed O
among O
patients O
receiving O
a O
TNF O
blocker O
compared O
to O
control O
patients O
. O

During O
the O
controlled O
portions O
of O
Enbrel O
trials O
in O
adult O
patients O
with O
RA B-Not_AE_Candidate
, O
AS B-Not_AE_Candidate
, O
and O
PsA B-Not_AE_Candidate
, O
2 O
lymphomas B-OSE_Labeled_AE
were O
observed O
among O
3306 O
Enbrel-treated O
patients O
versus O
0 O
among O
1521 O
control O
patients O
( O
duration O
of O
controlled O
treatment O
ranged O
from O
3 O
to O
36 O
months O
) O
. O

Among O
6543 O
adult O
rheumatology O
( O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
AS B-Not_AE_Candidate
) O
patients O
treated O
with O
Enbrel O
in O
controlled O
and O
uncontrolled O
portions O
of O
clinical O
trials O
, O
representing O
approximately O
12,845 O
patient-years O
of O
therapy O
, O
the O
observed O
rate O
of O
lymphoma B-OSE_Labeled_AE
was O
0.10 O
cases O
per O
100 O
patient-years O
. O

This O
was O
3-fold O
higher O
than O
the O
rate O
of O
lymphoma B-NonOSE_AE
expected O
in O
the O
general O
U.S O
. O
population O
based O
on O
the O
Surveillance O
, O
Epidemiology O
, O
and O
End O
Results O
( O
SEER O
) O
Database O
. O

An O
increased O
rate O
of O
lymphoma B-NonOSE_AE
up O
to O
several-fold O
has O
been O
reported O
in O
the O
RA B-Not_AE_Candidate
patient O
population O
, O
and O
may O
be O
further O
increased O
in O
patients O
with O
more O
severe O
disease O
activity O
. O

Among O
4410 O
adult O
PsO B-Not_AE_Candidate
patients O
treated O
with O
Enbrel O
in O
clinical O
trials O
up O
to O
36 O
months O
, O
representing O
approximately O
4278 O
patient-years O
of O
therapy O
, O
the O
observed O
rate O
of O
lymphoma B-NonOSE_AE
was O
0.05 O
cases O
per O
100 O
patient-years O
, O
which O
is O
comparable O
to O
the O
rate O
in O
the O
general O
population O
. O

No O
cases O
were O
observed O
in O
Enbrel- O
or O
placebo-treated O
patients O
during O
the O
controlled O
portions O
of O
these O
trials O
. O

Leukemia O
Cases O
of O
acute B-OSE_Labeled_AE
and O
chronic O
leukemia I-OSE_Labeled_AE
have O
been O
reported O
in O
association O
with O
postmarketing O
TNF-blocker O
use O
in O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
and O
other O
indications O
. O

Even O
in O
the O
absence O
of O
TNF-blocker O
therapy O
, O
patients O
with O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
may O
be O
at O
higher O
risk O
( O
approximately O
2-fold O
) O
than O
the O
general O
population O
for O
the O
development O
of O
leukemia B-NonOSE_AE
. O

During O
the O
controlled O
portions O
of O
Enbrel O
trials O
, O
2 O
cases O
of O
leukemia B-OSE_Labeled_AE
were O
observed O
among O
5445 O
( O
0.06 O
cases O
per O
100 O
patient-years O
) O
Enbrel-treated O
patients O
versus O
0 O
among O
2890 O
( O
0 O
% O
) O
control O
patients O
( O
duration O
of O
controlled O
treatment O
ranged O
from O
3 O
to O
48 O
months O
) O
. O

Among O
15,401 O
patients O
treated O
with O
Enbrel O
in O
controlled O
and O
open O
portions O
of O
clinical O
trials O
representing O
approximately O
23,325 O
patient-years O
of O
therapy O
, O
the O
observed O
rate O
of O
leukemia B-OSE_Labeled_AE
was O
0.03 O
cases O
per O
100 O
patient-years O
. O

Other O
Malignancies O
Information O
is O
available O
from O
10,953 O
adult O
patients O
with O
17,123 O
patient-years O
and O
696 O
pediatric O
patients O
with O
1282 O
patient-years O
of O
experience O
across O
45 O
Enbrel O
clinical O
studies O
. O

For O
malignancies B-NonOSE_AE
other O
than O
lymphoma B-NonOSE_AE
and O
non B-NonOSE_AE
- I-NonOSE_AE
melanoma I-NonOSE_AE
skin I-NonOSE_AE
cancer I-NonOSE_AE
, O
there O
was O
no O
difference O
in O
exposure-adjusted O
rates O
between O
the O
Enbrel O
and O
control O
arms O
in O
the O
controlled O
portions O
of O
clinical O
studies O
for O
all O
indications O
. O

Analysis O
of O
the O
malignancy B-NonOSE_AE
rate O
in O
combined O
controlled O
and O
uncontrolled O
portions O
of O
studies O
has O
demonstrated O
that O
types O
and O
rates O
are O
similar O
to O
what O
is O
expected O
in O
the O
general O
U.S O
. O
population O
based O
on O
the O
SEER O
database O
and O
suggests O
no O
increase O
in O
rates O
over O
time O
. O

Whether O
treatment O
with O
Enbrel O
might O
influence O
the O
development O
and O
course O
of O
malignancies B-NonOSE_AE
in O
adults O
is O
unknown O
. O

Melanoma O
and O
Non O
- O
M O
elanoma O
S O
kin O
C O
ancer O
( O
NMSC O
) O
Melanoma B-OSE_Labeled_AE
and O
non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
melanoma I-OSE_Labeled_AE
skin I-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
has O
been O
reported O
in O
patients O
treated O
with O
TNF O
antagonists O
including O
etanercept O
. O

Among O
15,401 O
patients O
treated O
with O
Enbrel O
in O
controlled O
and O
open O
portions O
of O
clinical O
trials O
representing O
approximately O
23,325 O
patient-years O
of O
therapy O
, O
the O
observed O
rate O
of O
melanoma B-OSE_Labeled_AE
was O
0.043 O
cases O
per O
100 O
patient-years O
. O

Among O
3306 O
adult O
rheumatology O
( O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
AS B-Not_AE_Candidate
) O
patients O
treated O
with O
Enbrel O
in O
controlled O
clinical O
trials O
representing O
approximately O
2669 O
patient-years O
of O
therapy O
, O
the O
observed O
rate O
of O
NMSC B-OSE_Labeled_AE
was O
0.41 O
cases O
per O
100 O
patient-years O
vs O
0.37 O
cases O
per O
100 O
patient-years O
among O
1521 O
control-treated O
patients O
representing O
1077 O
patient-years O
. O

Among O
1245 O
adult O
PsO B-Not_AE_Candidate
patients O
treated O
with O
Enbrel O
in O
controlled O
clinical O
trials O
, O
representing O
approximately O
283 O
patient-years O
of O
therapy O
, O
the O
observed O
rate O
of O
NMSC B-OSE_Labeled_AE
was O
3.54 O
cases O
per O
100 O
patient-years O
vs O
1.28 O
cases O
per O
100 O
patient-years O
among O
720 O
control-treated O
patients O
representing O
156 O
patient-years O
. O

Postmarketing O
cases O
of O
Merkel B-OSE_Labeled_AE
cell I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
have O
been O
reported O
very O
infrequently O
in O
patients O
treated O
with O
Enbrel O
. O

Periodic O
skin O
examinations O
should O
be O
considered O
for O
all O
patients O
at O
increased O
risk O
for O
skin B-NonOSE_AE
cancer I-NonOSE_AE
. O

Pediatric O
Patients O
Malignancies B-OSE_Labeled_AE
, O
some O
fatal B-NonOSE_AE
, O
have O
been O
reported O
among O
children O
, O
adolescents O
, O
and O
young O
adults O
who O
received O
treatment O
with O
TNF-blocking O
agents O
( O
initiation O
of O
therapy O
at O
< O
= O
18 O
years O
of O
age O
) O
, O
including O
Enbrel O
. O

Approximately O
half O
the O
cases O
were O
lymphomas B-OSE_Labeled_AE
, O
including O
Hodgkin B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
and O
non-Hodgkin O
's O
lymphoma I-OSE_Labeled_AE
. O

The O
other O
cases O
represented O
a O
variety O
of O
different O
malignancies B-OSE_Labeled_AE
and O
included O
rare O
malignancies B-OSE_Labeled_AE
usually O
associated O
with O
immunosuppression B-NonOSE_AE
and O
malignancies B-OSE_Labeled_AE
that O
are O
not O
usually O
observed O
in O
children O
and O
adolescents O
. O

The O
malignancies B-OSE_Labeled_AE
occurred O
after O
a O
median O
of O
30 O
months O
of O
therapy O
( O
range O
1 O
to O
84 O
months O
) O
. O

Most O
of O
the O
patients O
were O
receiving O
concomitant O
immunosuppressants B-NonOSE_AE
. O

These O
cases O
were O
reported O
postmarketing O
and O
are O
derived O
from O
a O
variety O
of O
sources O
, O
including O
registries O
and O
spontaneous O
postmarketing O
reports O
. O

In O
clinical O
trials O
of O
1140 O
pediatric O
patients O
representing O
1927.2 O
patient-years O
of O
therapy O
, O
no O
malignancies B-NonOSE_AE
, O
including O
lymphoma B-NonOSE_AE
or O
NMSC B-NonOSE_AE
, O
have O
been O
reported O
. O

Post O
m O
arketing O
Use O
In O
global O
postmarketing O
adult O
and O
pediatric O
use O
, O
lymphoma B-OSE_Labeled_AE
and O
other O
malignancies B-OSE_Labeled_AE
have O
been O
reported O
. O

5.4 O
Patients O
With O
Heart O
Failure O
Two O
clinical O
trials O
evaluating O
the O
use O
of O
Enbrel O
in O
the O
treatment O
of O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
were O
terminated O
early O
due O
to O
lack O
of O
efficacy O
. O

One O
of O
these O
studies O
suggested O
higher O
mortality B-NonOSE_AE
in O
Enbrel-treated O
patients O
compared O
to O
placebo O
[ O
see O
Adverse O
React O
ion O
s O
( O
6.2 O
) O
] O
. O

There O
have O
been O
postmarketing O
reports O
of O
worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
congestive I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( I-OSE_Labeled_AE
CHF I-OSE_Labeled_AE
) O
, O
with O
and O
without O
identifiable O
precipitating O
factors O
, O
in O
patients O
taking O
Enbrel O
. O

There O
have O
also O
been O
rare O
( O
< O
0.1 O
% O
) O
reports O
of O
new B-OSE_Labeled_AE
onset I-OSE_Labeled_AE
CHF I-OSE_Labeled_AE
, O
including O
CHF B-OSE_Labeled_AE
in O
patients O
without O
known O
preexisting O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Some O
of O
these O
patients O
have O
been O
under O
50 O
years O
of O
age O
. O

Physicians O
should O
exercise O
caution O
when O
using O
Enbrel O
in O
patients O
who O
also O
have O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
and O
monitor O
patients O
carefully O
. O

5.5 O
Hematologic B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
Rare O
( O
< O
0.1 O
% O
) O
reports O
of O
pancytopenia B-OSE_Labeled_AE
, O
including O
very O
rare O
( O
< O
0.01 O
% O
) O
reports O
of O
aplastic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
some O
with O
a O
fatal B-NonOSE_AE
outcome O
, O
have O
been O
reported O
in O
patients O
treated O
with O
Enbrel O
. O

The O
causal O
relationship O
to O
Enbrel O
therapy O
remains O
unclear O
. O

Although O
no O
high-risk O
group O
has O
been O
identified O
, O
caution O
should O
be O
exercised O
in O
patients O
being O
treated O
with O
Enbrel O
who O
have O
a O
previous O
history O
of O
significant O
hematologic B-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
. O

All O
patients O
should O
be O
advised O
to O
seek O
immediate O
medical O
attention O
if O
they O
develop O
signs O
and O
symptoms O
suggestive O
of O
blood B-NonOSE_AE
dyscrasias I-NonOSE_AE
or O
infection B-NonOSE_AE
( O
eg O
, O
persistent B-NonOSE_AE
fever I-NonOSE_AE
, O
bruising B-NonOSE_AE
, O
bleeding B-NonOSE_AE
, O
pallor B-NonOSE_AE
) O
while O
on O
Enbrel O
. O

Discontinuation O
of O
Enbrel O
therapy O
should O
be O
considered O
in O
patients O
with O
confirmed O
significant O
hematologic B-NonOSE_AE
abnormalities I-NonOSE_AE
. O

Two O
percent O
of O
patients O
treated O
concurrently O
with O
Enbrel O
and O
anakinra O
developed O
neutropenia B-NonOSE_AE
( O
ANC B-NonOSE_AE
< I-NonOSE_AE
1 I-NonOSE_AE
x I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
9 I-NonOSE_AE
/ I-NonOSE_AE
L I-NonOSE_AE
) O
. O

While O
neutropenic B-NonOSE_AE
, O
one O
patient O
developed O
cellulitis B-NonOSE_AE
that O
resolved O
with O
antibiotic O
therapy O
. O

5.6 O
Hepatitis O
B O
Reactivation O
Reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
B I-OSE_Labeled_AE
in O
patients O
who O
were O
previously O
infected B-Not_AE_Candidate
with I-Not_AE_Candidate
the I-Not_AE_Candidate
hepatitis I-Not_AE_Candidate
B I-Not_AE_Candidate
virus I-Not_AE_Candidate
( I-Not_AE_Candidate
HBV I-Not_AE_Candidate
) O
and O
had O
received O
concomitant O
TNF-blocking O
agents O
, O
including O
very O
rare O
cases O
( O
< O
0.01 O
% O
) O
with O
Enbrel O
, O
has O
been O
reported O
. O

In O
some O
instances O
, O
hepatitis B-OSE_Labeled_AE
B I-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
occurring O
in O
conjunction O
with O
TNF-blocker O
therapy O
has O
been O
fatal B-NonOSE_AE
. O

The O
majority O
of O
these O
reports O
have O
occurred O
in O
patients O
concomitantly O
receiving O
other O
medications B-NonOSE_AE
that I-NonOSE_AE
suppress I-NonOSE_AE
the I-NonOSE_AE
immune I-NonOSE_AE
system I-NonOSE_AE
, O
which O
may O
also O
contribute O
to O
hepatitis B-NonOSE_AE
B I-NonOSE_AE
reactivation I-NonOSE_AE
. O

Patients O
at O
risk O
for O
HBV B-NonOSE_AE
infection I-NonOSE_AE
should O
be O
evaluated O
for O
prior O
evidence O
of O
HBV B-NonOSE_AE
infection I-NonOSE_AE
before O
initiating O
TNF-blocker O
therapy O
. O

Prescribers O
should O
exercise O
caution O
in O
prescribing O
TNF O
blockers O
in O
patients O
previously O
infected O
with O
HBV B-Not_AE_Candidate
. O

Adequate O
data O
are O
not O
available O
on O
the O
safety O
or O
efficacy O
of O
treating O
patients O
who O
are O
carriers O
of O
HBV B-NonOSE_AE
with O
anti-viral O
therapy O
in O
conjunction O
with O
TNF-blocker O
therapy O
to O
prevent O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
. O

Patients O
previously O
infected O
with O
HBV B-Not_AE_Candidate
and O
requiring O
treatment O
with O
Enbrel O
should O
be O
closely O
monitored O
for O
clinical O
and O
laboratory O
signs O
of O
active B-NonOSE_AE
HBV I-NonOSE_AE
infection I-NonOSE_AE
throughout O
therapy O
and O
for O
several O
months O
following O
termination O
of O
therapy O
. O

In O
patients O
who O
develop O
HBV B-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
, O
consideration O
should O
be O
given O
to O
stopping O
Enbrel O
and O
initiating O
anti-viral O
therapy O
with O
appropriate O
supportive O
treatment O
. O

The O
safety O
of O
resuming O
Enbrel O
therapy O
after O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
is O
controlled O
is O
not O
known O
. O

Therefore O
, O
prescribers O
should O
weigh O
the O
risks O
and O
benefits O
when O
considering O
resumption O
of O
therapy O
in O
this O
situation O
. O

5.7 O
Allergic O
Reactions O
Allergic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
associated O
with O
administration O
of O
Enbrel O
during O
clinical O
trials O
have O
been O
reported O
in O
< O
2 O
% O
of O
patients O
. O

If O
an O
anaphylactic B-NonOSE_AE
reaction I-NonOSE_AE
or O
other O
serious O
allergic B-NonOSE_AE
reaction I-NonOSE_AE
occurs O
, O
administration O
of O
Enbrel O
should O
be O
discontinued O
immediately O
and O
appropriate O
therapy O
initiated O
. O

Caution O
: O
The O
following O
components O
contain O
dry O
natural O
rubber O
( O
a O
derivative O
of O
latex O
) O
, O
which O
may O
cause O
allergic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
in O
individuals O
sensitive O
to O
latex I-OSE_Labeled_AE
: O
the O
needle O
cover O
of O
the O
prefilled O
syringe O
, O
the O
needle O
cover O
within O
the O
white O
cap O
of O
the O
SureClick O
autoinjector O
, O
and O
the O
needle O
cover O
within O
the O
purple O
cap O
of O
the O
Enbrel O
Mini O
cartridge O
. O

5.8 O
Immunizations O
Live O
vaccines O
should O
not O
be O
given O
concurrently O
with O
Enbrel O
. O

It O
is O
recommended O
that O
pediatric O
patients O
, O
if O
possible O
, O
be O
brought O
up-to-date O
with O
all O
immunizations O
in O
agreement O
with O
current O
immunization O
guidelines O
prior O
to O
initiating O
Enbrel O
therapy O
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.4 O
) O
] O
. O

5.9 O
Autoimmunity O
Treatment O
with O
Enbrel O
may O
result O
in O
the O
formation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
autoantibodies I-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
and O
, O
rarely O
( O
< O
0.1 O
% O
) O
, O
in O
the O
development O
of O
a O
lupus B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
or O
autoimmune B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
, O
which O
may O
resolve O
following O
withdrawal O
of O
Enbrel O
. O

If O
a O
patient O
develops O
symptoms O
and O
findings O
suggestive O
of O
a O
lupus B-NonOSE_AE
- I-NonOSE_AE
like I-NonOSE_AE
syndrome I-NonOSE_AE
or O
autoimmune B-NonOSE_AE
hepatitis I-NonOSE_AE
following O
treatment O
with O
Enbrel O
, O
treatment O
should O
be O
discontinued O
and O
the O
patient O
should O
be O
carefully O
evaluated O
. O

5.10 O
Immunosuppression O
TNF O
mediates O
inflammation B-NonOSE_AE
and O
modulates B-NonOSE_AE
cellular I-NonOSE_AE
immune I-NonOSE_AE
responses O
. O

TNF-blocking O
agents O
, O
including O
Enbrel O
, O
affect O
host O
defenses O
against O
infections B-NonOSE_AE
. O

The O
effect O
of O
TNF O
inhibition O
on O
the O
development O
and O
course O
of O
malignancies B-NonOSE_AE
is O
not O
fully O
understood O
. O

In O
a O
study O
of O
49 O
patients O
with O
RA B-Not_AE_Candidate
treated O
with O
Enbrel O
, O
there O
was O
no O
evidence O
of O
depression B-NonOSE_AE
of I-NonOSE_AE
delayed I-NonOSE_AE
- I-NonOSE_AE
type I-NonOSE_AE
hypersensitivity I-NonOSE_AE
, O
depression B-NonOSE_AE
of I-NonOSE_AE
immunoglobulin I-NonOSE_AE
levels I-NonOSE_AE
, O
or O
change B-NonOSE_AE
in I-NonOSE_AE
enumeration I-NonOSE_AE
of I-NonOSE_AE
effector I-NonOSE_AE
cell I-NonOSE_AE
populations I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
, O
5.3 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.11 O
Use O
in O
Wegener O
's O
Granulomatosis O
Patients O
The O
use O
of O
Enbrel O
in O
patients O
with O
Wegener B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
granulomatosis I-Not_AE_Candidate
receiving O
immunosuppressive B-NonOSE_AE
agents I-NonOSE_AE
is O
not O
recommended O
. O

In O
a O
study O
of O
patients O
with O
Wegener B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
granulomatosis I-Not_AE_Candidate
, O
the O
addition O
of O
Enbrel O
to O
standard O
therapy O
( O
including O
cyclophosphamide O
) O
was O
associated O
with O
a O
higher O
incidence O
of O
non B-NonOSE_AE
- I-NonOSE_AE
cutaneous I-NonOSE_AE
solid I-NonOSE_AE
malignancies I-NonOSE_AE
and O
was O
not O
associated O
with O
improved O
clinical O
outcomes O
when O
compared O
with O
standard O
therapy O
alone O
[ O
see O
Drug O
Interactions O
( O
7.3 O
) O
] O
. O

5.12 O
Use O
with O
Anakinra O
or O
Abatacept O
Use O
of O
Enbrel O
with O
anakinra O
or O
abatacept O
is O
not O
recommended O
[ O
see O
Drug O
Interactions O
( O
7.2 O
) O
] O
. O

5.13 O
Use O
in O
Patients O
with O
Moderate O
to O
Severe O
Alcoholic O
Hepatitis O
In O
a O
study O
of O
48 O
hospitalized O
patients O
treated O
with O
Enbrel O
or O
placebo O
for O
moderate O
to O
severe O
alcoholic B-Not_AE_Candidate
hepatitis I-Not_AE_Candidate
, O
the O
mortality B-NonOSE_AE
rate O
in O
patients O
treated O
with O
Enbrel O
was O
similar O
to O
patients O
treated O
with O
placebo O
at O
1 O
month O
but O
significantly O
higher O
after O
6 O
months O
. O

Physicians O
should O
use O
caution O
when O
using O
Enbrel O
in O
patients O
with O
moderate O
to O
severe O
alcoholic B-Not_AE_Candidate
hepatitis I-Not_AE_Candidate
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
label O
: O
* O
Infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
[ O
See O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
. O
] O

* O
Cardiopulmonary B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
[ O
See O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.2 O
) O
. O
] O

* O
Pulmonary B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.3 O
) O
. O
] O

* O
Dermatologic B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.4 O
) O
. O
] O

* O
Hypomagnesemia B-OSE_Labeled_AE
and O
Electrolyte B-OSE_Labeled_AE
Abnormalities I-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.6 O
) O
. O
] O

The O
most O
common O
adverse O
reactions O
in O
Erbitux O
clinical O
trials O
( O
incidence O
> O
=25 O
% O
) O
include O
cutaneous B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
including O
rash B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
and O
nail B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
) O
, O
headache B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
and O
infection B-OSE_Labeled_AE
. O

The O
most O
serious O
adverse O
reactions O
with O
Erbitux O
are O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
cardiopulmonary B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
dermatologic B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
and O
radiation B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
and O
pulmonary B-OSE_Labeled_AE
embolus I-OSE_Labeled_AE
. O

Across O
Studies O
1 O
, O
3 O
, O
5 O
, O
and O
6 O
, O
Erbitux O
was O
discontinued O
in O
3-10 O
% O
of O
patients O
because O
of O
adverse O
reactions O
. O

EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
=25 O
% O
) O
are O
: O
cutaneous O
adverse O
reactions O
( O
including O
rash O
, O
pruritus O
, O
and O
nail O
changes O
) O
, O
headache O
, O
diarrhea O
, O
and O
infection O
. O

( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Eli O
Lilly O
and O
Company O
at O
1-800-LillyRx O
( O
1-800-545-5979 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
data O
below O
reflect O
exposure O
to O
Erbitux O
in O
1373 O
patients O
with O
SCCHN B-Not_AE_Candidate
or O
colorectal B-Not_AE_Candidate
cancer I-Not_AE_Candidate
in O
randomized O
Phase O
3 O
( O
Studies O
1 O
and O
5 O
) O
or O
Phase O
2 O
( O
Studies O
3 O
and O
6 O
) O
trials O
treated O
at O
the O
recommended O
dose O
and O
schedule O
for O
medians O
of O
7 O
to O
14 O
weeks O
. O

[ O
See O
Clinical O
Studies O
( O
14 O
) O
. O
] O

Infusion B-NonOSE_AE
reactions I-NonOSE_AE
: O
Infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
which O
included O
pyrexia B-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
rigors B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
bronchospasm B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
and O
hypotension B-OSE_Labeled_AE
occurred O
in O
15-21 O
% O
of O
patients O
across O
studies O
. O

Grades O
3 O
and O
4 O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
occurred O
in O
2-5 O
% O
of O
patients O
; O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
were O
fatal B-NonOSE_AE
in O
1 O
patient O
. O

Infections B-NonOSE_AE
: O
The O
incidence O
of O
infection B-OSE_Labeled_AE
was O
variable O
across O
studies O
, O
ranging O
from O
13-35 O
% O
. O

Sepsis B-OSE_Labeled_AE
occurred O
in O
1-4 O
% O
of O
patients O
. O

Renal B-NonOSE_AE
: O
Renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
occurred O
in O
1 O
% O
of O
patients O
with O
colorectal B-Not_AE_Candidate
cancer I-Not_AE_Candidate
. O

Squamous O
Cell O
Carcinoma O
of O
the O
Head O
and O
Neck O
Erbitux O
in O
Combination O
with O
Radiation O
Therapy O
Table O
2 O
contains O
selected O
adverse O
reactions O
in O
420 O
patients O
receiving O
radiation O
therapy O
either O
alone O
or O
with O
Erbitux O
for O
locally O
or O
regionally O
advanced O
SCCHN B-Not_AE_Candidate
in O
Study O
1 O
. O

Erbitux O
was O
administered O
at O
the O
recommended O
dose O
and O
schedule O
( O
400 O
mg/m O
2 O
initial O
dose O
, O
followed O
by O
250 O
mg/m O
2 O
weekly O
) O
. O

Patients O
received O
a O
median O
of O
8 O
infusions O
( O
range O
1-11 O
) O
. O

Table O
2 O
: O
Incidence O
of O
Selected O
Adverse O
Reactions O
( O
> O
=10 O
% O
) O
in O
Patients O
with O
Locoregionally O
Advanced O
SCCHN O
Body O
System O
Preferred O
Term O
Erbitux O
plus O
Radiation O
( O
n=208 O
) O
Radiation O
Therapy O
Alone O
( O
n=212 O
) O
Grades O
1-4 O
Grades O
3 O
and O
4 O
Grades O
1-4 O
Grades O
3 O
and O
4 O
% O
of O
Patients O
a O
Includes O
cases O
also O
reported O
as O
infusion B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
. O

b O
Infusion B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
is O
defined O
as O
any O
event O
described O
at O
any O
time O
during O
the O
clinical O
study O
as O
`` O
allergic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
`` O
or O
`` O
anaphylactoid B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
`` O
, O
or O
any O
event O
occurring O
on O
the O
first O
day O
of O
dosing O
described O
as O
`` O
allergic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
`` O
, O
`` O
anaphylactoid B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
`` O
, O
`` O
fever B-OSE_Labeled_AE
`` O
, O
`` O
chills B-OSE_Labeled_AE
`` O
, O
`` O
chills B-OSE_Labeled_AE
and I-OSE_Labeled_AE
fever I-OSE_Labeled_AE
`` O
, O
or O
`` O
dyspnea B-OSE_Labeled_AE
`` O
. O

c O
Based O
on O
laboratory O
measurements O
, O
not O
on O
reported O
adverse O
reactions O
, O
the O
number O
of O
subjects O
with O
tested O
samples O
varied O
from O
205-206 O
for O
Erbitux O
plus O
Radiation O
arm O
; O
209-210 O
for O
Radiation O
alone O
. O

d O
Acneiform B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
is O
defined O
as O
any O
event O
described O
as O
`` O
acne B-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
`` O
, O
`` O
maculopapular B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
`` O
, O
`` O
pustular B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
`` O
, O
`` O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
`` O
, O
or O
`` O
exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
`` O
. O

Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
Asthenia B-OSE_Labeled_AE
56 O
4 O
49 O
5 O
Fever B-OSE_Labeled_AE
a O
29 O
1 O
13 O
1 O
Headache B-OSE_Labeled_AE
19 O
< O
1 O
8 O
< O
1 O
Infusion B-OSE_Labeled_AE
Reaction I-OSE_Labeled_AE
b O
15 O
3 O
2 O
0 O
Infection B-OSE_Labeled_AE
13 O
1 O
9 O
1 O
Chills B-OSE_Labeled_AE
a O
16 O
0 O
5 O
0 O
Digestive B-NonOSE_AE
Nausea B-OSE_Labeled_AE
49 O
2 O
37 O
2 O
Emesis B-OSE_Labeled_AE
29 O
2 O
23 O
4 O
Diarrhea B-OSE_Labeled_AE
19 O
2 O
13 O
1 O
Dyspepsia B-OSE_Labeled_AE
14 O
0 O
9 O
1 O
Metabolic B-NonOSE_AE
/ I-NonOSE_AE
Nutritional I-NonOSE_AE
Weight B-OSE_Labeled_AE
Loss I-OSE_Labeled_AE
84 O
11 O
72 O
7 O
Dehydration B-OSE_Labeled_AE
25 O
6 O
19 O
8 O
Alanine B-OSE_Labeled_AE
Transaminase I-OSE_Labeled_AE
, I-OSE_Labeled_AE
high I-OSE_Labeled_AE
c O
43 O
2 O
21 O
1 O
Aspartate B-OSE_Labeled_AE
Transaminase I-OSE_Labeled_AE
, I-OSE_Labeled_AE
high I-OSE_Labeled_AE
c O
38 O
1 O
24 O
1 O
Alkaline B-OSE_Labeled_AE
Phosphatase I-OSE_Labeled_AE
, I-OSE_Labeled_AE
high I-OSE_Labeled_AE
c O
33 O
< O
1 O
24 O
0 O
Respiratory B-NonOSE_AE
Pharyngitis B-OSE_Labeled_AE
26 O
3 O
19 O
4 O
Skin B-NonOSE_AE
/ I-NonOSE_AE
Appendages I-NonOSE_AE
Acneiform B-OSE_Labeled_AE
Rash I-OSE_Labeled_AE
d O
87 O
17 O
10 O
1 O
Radiation B-OSE_Labeled_AE
Dermatitis I-OSE_Labeled_AE
86 O
23 O
90 O
18 O
Application B-OSE_Labeled_AE
Site I-OSE_Labeled_AE
Reaction I-OSE_Labeled_AE
18 O
0 O
12 O
1 O
Pruritus B-OSE_Labeled_AE
16 O
0 O
4 O
0 O
The O
incidence O
and O
severity O
of O
mucositis B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
and O
xerostomia B-OSE_Labeled_AE
were O
similar O
in O
both O
arms O
of O
the O
study O
. O

Late O
Radiation O
Toxicity O
The O
overall O
incidence O
of O
late B-OSE_Labeled_AE
radiation I-OSE_Labeled_AE
toxicities I-OSE_Labeled_AE
( O
any O
grade O
) O
was O
higher O
in O
Erbitux O
in O
combination O
with O
radiation O
therapy O
compared O
with O
radiation O
therapy O
alone O
. O

The O
following O
sites O
were O
affected O
: O
salivary O
glands O
( O
65 O
% O
versus O
56 O
% O
) O
, O
larynx O
( O
52 O
% O
versus O
36 O
% O
) O
, O
subcutaneous O
tissue O
( O
49 O
% O
versus O
45 O
% O
) O
, O
mucous O
membrane O
( O
48 O
% O
versus O
39 O
% O
) O
, O
esophagus O
( O
44 O
% O
versus O
35 O
% O
) O
, O
skin O
( O
42 O
% O
versus O
33 O
% O
) O
. O

The O
incidence O
of O
Grade O
3 O
or O
4 O
late B-NonOSE_AE
radiation I-NonOSE_AE
toxicities I-NonOSE_AE
was O
similar O
between O
the O
radiation O
therapy O
alone O
and O
the O
Erbitux O
plus O
radiation O
treatment O
groups O
. O

Study O
2 O
: O
EU-Approved O
Cetuximab O
in O
Combination O
with O
Platinum-based O
Therapy O
with O
5-Fluorouracil O
Study O
2 O
used O
EU-approved O
cetuximab O
. O

Since O
U.S.-licensed O
Erbitux O
provides O
approximately O
22 O
% O
higher O
exposure O
relative O
to O
the O
EU-approved O
cetuximab O
, O
the O
data O
provided O
below O
may O
underestimate O
the O
incidence O
and O
severity O
of O
adverse O
reactions O
anticipated O
with O
Erbitux O
for O
this O
indication O
. O

However O
, O
the O
tolerability O
of O
the O
recommended O
dose O
is O
supported O
by O
safety O
data O
from O
additional O
studies O
of O
Erbitux O
[ O
see O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

Table O
3 O
contains O
selected O
adverse O
reactions O
in O
434 O
patients O
with O
recurrent O
locoregional O
disease O
or O
metastatic O
SCCHN B-Not_AE_Candidate
receiving O
EU-approved O
cetuximab O
in O
combination O
with O
platinum-based O
therapy O
with O
5-FU O
or O
platinum-based O
therapy O
with O
5-FU O
alone O
in O
Study O
2 O
. O

Cetuximab O
was O
administered O
at O
400 O
mg/m O
2 O
for O
the O
initial O
dose O
, O
followed O
by O
250 O
mg/m O
2 O
weekly O
. O

Patients O
received O
a O
median O
of O
17 O
infusions O
( O
range O
1-89 O
) O
. O

Table O
3 O
: O
Incidence O
of O
Selected O
Adverse O
Reactions O
( O
> O
=10 O
% O
) O
in O
Patients O
with O
Recurrent O
Locoregional O
Disease O
or O
Metastatic O
SCCHN O
System O
Organ O
Class O
Preferred O
Term O
EU-Approved O
Cetuximab O
plus O
Platinum-based O
Therapy O
with O
5-FU O
( O
n=219 O
) O
Platinum-based O
Therapy O
with O
5-FU O
Alone O
( O
n=215 O
) O
Grades O
1-4 O
Grades O
3 O
and O
4 O
Grades O
1-4 O
Grades O
3 O
and O
4 O
% O
of O
Patients O
a O
Infusion B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
defined O
as O
any O
event O
of O
`` O
anaphylactic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
`` O
, O
`` O
hypersensitivity B-OSE_Labeled_AE
`` O
, O
`` O
fever B-OSE_Labeled_AE
and/or O
chills B-OSE_Labeled_AE
`` O
, O
`` O
dyspnea B-OSE_Labeled_AE
`` O
, O
or O
`` O
pyrexia B-OSE_Labeled_AE
`` O
on O
the O
first O
day O
of O
dosing O
. O

b O
Infection B-OSE_Labeled_AE
- O
this O
term O
excludes O
sepsis B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
events O
which O
are O
presented O
separately O
. O

c O
Acneiform B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
defined O
as O
any O
event O
described O
as O
`` O
acne B-OSE_Labeled_AE
`` O
, O
`` O
dermatitis B-OSE_Labeled_AE
acneiform I-OSE_Labeled_AE
`` O
, O
`` O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
`` O
, O
`` O
exfoliative B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
erythematous I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
macular I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
papular I-OSE_Labeled_AE
`` O
, O
or O
`` O
rash B-OSE_Labeled_AE
pustular I-OSE_Labeled_AE
`` O
.Chemotherapy O
= O
cisplatin O
+ O
5-fluorouracil O
or O
carboplatin O
+ O
5-fluorouracil O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Conjunctivitis B-OSE_Labeled_AE
10 O
0 O
0 O
0 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
54 O
4 O
47 O
4 O
Diarrhea B-OSE_Labeled_AE
26 O
5 O
16 O
1 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
Pyrexia B-OSE_Labeled_AE
22 O
0 O
13 O
1 O
Infusion B-OSE_Labeled_AE
Reactiona I-OSE_Labeled_AE
10 O
2 O
< O
1 O
0 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Infection B-OSE_Labeled_AE
b O
44 O
11 O
27 O
8 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Anorexia B-OSE_Labeled_AE
25 O
5 O
14 O
1 O
Hypocalcemia B-OSE_Labeled_AE
12 O
4 O
5 O
1 O
Hypokalemia B-OSE_Labeled_AE
12 O
7 O
7 O
5 O
Hypomagnesemia B-OSE_Labeled_AE
11 O
5 O
5 O
1 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Acneiform B-OSE_Labeled_AE
Rash I-OSE_Labeled_AE
c O
70 O
9 O
2 O
0 O
Rash B-OSE_Labeled_AE
28 O
5 O
2 O
0 O
Acne B-OSE_Labeled_AE
22 O
2 O
0 O
0 O
Dermatitis B-OSE_Labeled_AE
Acneiform I-OSE_Labeled_AE
15 O
2 O
0 O
0 O
Dry B-OSE_Labeled_AE
Skin I-OSE_Labeled_AE
14 O
0 O
< O
1 O
0 O
Alopecia B-OSE_Labeled_AE
12 O
0 O
7 O
0 O
For O
cardiac B-NonOSE_AE
disorders I-NonOSE_AE
, O
approximately O
9 O
% O
of O
subjects O
in O
both O
the O
EU-approved O
cetuximab O
plus O
chemotherapy O
and O
chemotherapy-only O
treatment O
arms O
in O
Study O
2 O
experienced O
a O
cardiac B-OSE_Labeled_AE
event I-OSE_Labeled_AE
. O

The O
majority O
of O
these O
events O
occurred O
in O
patients O
who O
received O
cisplatin/5-FU O
, O
with O
or O
without O
cetuximab O
as O
follows O
: O
11 O
% O
and O
12 O
% O
in O
patients O
who O
received O
cisplatin/5-FU O
with O
or O
without O
cetuximab O
, O
respectively O
, O
and O
6 O
% O
or O
4 O
% O
in O
patients O
who O
received O
carboplatin/5-FU O
with O
or O
without O
cetuximab O
, O
respectively O
. O

In O
both O
arms O
, O
the O
incidence O
of O
cardiovascular B-OSE_Labeled_AE
events I-OSE_Labeled_AE
was O
higher O
in O
the O
cisplatin O
with O
5-FU O
containing O
subgroup O
. O

Death B-NonOSE_AE
attributed O
to O
cardiovascular B-NonOSE_AE
event I-NonOSE_AE
or O
sudden B-NonOSE_AE
death I-NonOSE_AE
was O
reported O
in O
3 O
% O
of O
the O
patients O
in O
the O
cetuximab O
plus O
platinum-based O
therapy O
with O
5-FU O
arm O
and O
2 O
% O
in O
the O
platinum-based O
chemotherapy O
with O
5-FU O
alone O
arm O
. O

Colorectal O
Cancer O
Study O
4 O
: O
EU-Approved O
Cetuximab O
in O
Combination O
with O
FOLFIRI O
Study O
4 O
used O
EU-approved O
cetuximab O
. O

U.S.-licensed O
Erbitux O
provides O
approximately O
22 O
% O
higher O
exposure O
to O
cetuximab O
relative O
to O
the O
EU-approved O
cetuximab O
. O

The O
data O
provided O
below O
for O
Study O
4 O
is O
consistent O
in O
incidence O
and O
severity O
of O
adverse O
reactions O
with O
those O
seen O
for O
Erbitux O
in O
this O
indication O
. O

The O
tolerability O
of O
the O
recommended O
dose O
is O
supported O
by O
safety O
data O
from O
additional O
studies O
of O
Erbitux O
[ O
see O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

Table O
4 O
contains O
selected O
adverse O
reactions O
in O
667 O
patients O
with O
K-Ras O
wild-type O
, O
EGFR-expressing O
, O
metastatic B-Not_AE_Candidate
colorectal I-Not_AE_Candidate
cancer I-Not_AE_Candidate
receiving O
EU-approved O
cetuximab O
plus O
FOLFIRI O
or O
FOLFIRI O
alone O
in O
Study O
4 O
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
. O

Cetuximab O
was O
administered O
at O
the O
recommended O
dose O
and O
schedule O
( O
400 O
mg/m O
2 O
initial O
dose O
, O
followed O
by O
250 O
mg/m O
2 O
weekly O
) O
. O

Patients O
received O
a O
median O
of O
26 O
infusions O
( O
range O
1-224 O
) O
. O

Table O
4 O
: O
Incidence O
of O
Selected O
Adverse O
Reactions O
Occurring O
in O
> O
=10 O
% O
of O
Patients O
with O
K-Ras O
Wild-type O
and O
EGFR-expressing O
, O
Metastatic O
Colorectal O
Cancera O
Body O
System O
Preferred O
Term O
EU-Approved O
Cetuximab O
plus O
FOLFIRI O
( O
n=317 O
) O
FOLFIRI O
Alone O
( O
n=350 O
) O
Grades O
1-4 O
b O
Grades O
3 O
and O
4 O
Grades O
1-4 O
Grades O
3 O
and O
4 O
% O
of O
Patients O
a O
Adverse O
reactions O
occurring O
in O
at O
least O
10 O
% O
of O
Erbitux O
combination O
arm O
with O
a O
frequency O
at O
least O
5 O
% O
greater O
than O
that O
seen O
in O
the O
FOLFIRI O
arm O
. O

b O
Adverse O
reactions O
were O
graded O
using O
the O
NCI O
CTC O
, O
V O
2.0 O
. O
c O
Infusion B-OSE_Labeled_AE
related I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
is O
defined O
as O
any O
event O
meeting O
the O
medical O
concepts O
of O
allergy B-OSE_Labeled_AE
/ O
anaphylaxis B-OSE_Labeled_AE
at O
any O
time O
during O
the O
clinical O
study O
or O
any O
event O
occurring O
on O
the O
first O
day O
of O
dosing O
and O
meeting O
the O
medical O
concepts O
of O
dyspnea B-OSE_Labeled_AE
and O
fever B-OSE_Labeled_AE
or O
by O
the O
following O
events O
using O
MedDRA O
preferred O
terms O
: O
`` O
acute B-OSE_Labeled_AE
myocardial I-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
`` O
, O
`` O
angina B-OSE_Labeled_AE
pectoris I-OSE_Labeled_AE
`` O
, O
`` O
angioedema B-OSE_Labeled_AE
`` O
, O
`` O
autonomic B-OSE_Labeled_AE
seizure I-OSE_Labeled_AE
`` O
, O
`` O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
`` O
, O
`` O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
`` O
, O
`` O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
`` O
, O
`` O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
`` O
, O
`` O
cardiopulmonary B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
`` O
, O
`` O
cardiovascular B-OSE_Labeled_AE
insufficiency I-OSE_Labeled_AE
`` O
, O
`` O
clonus B-OSE_Labeled_AE
`` O
, O
`` O
convulsion B-OSE_Labeled_AE
`` O
, O
`` O
coronary B-OSE_Labeled_AE
no I-OSE_Labeled_AE
- I-OSE_Labeled_AE
reflow I-OSE_Labeled_AE
phenomenon I-OSE_Labeled_AE
`` O
, O
`` O
epilepsy O
'' O
, O
`` O
hypertension B-OSE_Labeled_AE
`` O
, O
`` O
hypertensive B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
`` O
, O
`` O
hypertensive B-OSE_Labeled_AE
emergency I-OSE_Labeled_AE
`` O
, O
`` O
hypotension B-OSE_Labeled_AE
`` O
, O
`` O
infusion B-OSE_Labeled_AE
related I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
`` O
, O
`` O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
`` O
, O
`` O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
`` O
, O
`` O
myocardial B-OSE_Labeled_AE
ischaemia I-OSE_Labeled_AE
`` O
, O
" B-OSE_Labeled_AE
prinzmetal I-OSE_Labeled_AE
angina I-OSE_Labeled_AE
" I-OSE_Labeled_AE
, O
`` O
shock B-OSE_Labeled_AE
`` O
, O
`` O
sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
`` O
, O
`` O
syncope B-OSE_Labeled_AE
`` O
, O
or O
`` O
systolic B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
`` O
. O

d O
Acne B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
rash I-OSE_Labeled_AE
is O
defined O
by O
the O
events O
using O
MedDRA O
preferred O
terms O
and O
included O
`` O
acne B-OSE_Labeled_AE
`` O
, O
`` O
acne B-OSE_Labeled_AE
pustular I-OSE_Labeled_AE
`` O
, O
`` O
butterfly B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
`` O
, O
`` O
dermatitis B-OSE_Labeled_AE
acneiform I-OSE_Labeled_AE
`` O
, O
`` O
drug B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
with I-OSE_Labeled_AE
eosinophilia I-OSE_Labeled_AE
and I-OSE_Labeled_AE
systemic I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
`` O
, O
`` O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
`` O
, O
`` O
erythema B-OSE_Labeled_AE
`` O
, O
`` O
exfoliative B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
`` O
, O
`` O
folliculitis B-OSE_Labeled_AE
`` O
, O
`` O
genital B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
`` O
, O
`` O
mucocutaneous B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
`` O
, O
`` O
pruritus B-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
erythematous I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
follicular I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
generalized I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
macular I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
maculopapular I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
maculovesicular I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
morbilliform I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
papular I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
papulosquamous I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
pruritic I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
pustular I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
rubelliform I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
scarlatiniform I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
vesicular I-OSE_Labeled_AE
`` O
, O
`` O
skin B-OSE_Labeled_AE
exfoliation I-OSE_Labeled_AE
`` O
, O
`` O
skin B-OSE_Labeled_AE
hyperpigmentation I-OSE_Labeled_AE
`` O
, O
`` O
skin B-OSE_Labeled_AE
plaque I-OSE_Labeled_AE
`` O
, O
`` O
telangiectasia B-OSE_Labeled_AE
`` O
, O
or O
`` O
xerosis B-OSE_Labeled_AE
`` O
. O

Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
49 O
31 O
42 O
24 O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Conjunctivitis B-OSE_Labeled_AE
18 O
< O
1 O
3 O
0 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
66 O
16 O
60 O
10 O
Stomatitis B-OSE_Labeled_AE
31 O
3 O
19 O
1 O
Dyspepsia B-OSE_Labeled_AE
16 O
0 O
9 O
0 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
Infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
Reaction I-OSE_Labeled_AE
c O
14 O
2 O
< O
1 O
0 O
Pyrexia B-OSE_Labeled_AE
26 O
1 O
14 O
1 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Paronychia B-OSE_Labeled_AE
20 O
4 O
< O
1 O
0 O
Investigations B-NonOSE_AE
Weight B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
15 O
1 O
9 O
1 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Anorexia B-OSE_Labeled_AE
30 O
3 O
23 O
2 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Acne B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
Rash I-OSE_Labeled_AE
d O
86 O
18 O
13 O
< O
1 O
Rash B-OSE_Labeled_AE
44 O
9 O
4 O
0 O
Dermatitis B-OSE_Labeled_AE
Acneiform I-OSE_Labeled_AE
26 O
5 O
< O
1 O
0 O
Dry B-OSE_Labeled_AE
Skin I-OSE_Labeled_AE
22 O
0 O
4 O
0 O
Acne B-OSE_Labeled_AE
14 O
2 O
0 O
0 O
Pruritus B-OSE_Labeled_AE
14 O
0 O
3 O
0 O
Palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
Erythrodysesthesia I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
19 O
4 O
4 O
< O
1 O
Skin B-OSE_Labeled_AE
Fissures I-OSE_Labeled_AE
19 O
2 O
1 O
0 O
Erbitux O
Monotherapy O
Table O
5 O
contains O
selected O
adverse O
reactions O
in O
242 O
patients O
with O
K-Ras O
wild-type O
, O
EGFR-expressing O
, O
metastatic B-Not_AE_Candidate
colorectal I-Not_AE_Candidate
cancer I-Not_AE_Candidate
who O
received O
best O
supportive O
care O
( O
BSC O
) O
alone O
or O
with O
Erbitux O
in O
Study O
5 O
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
. O

Erbitux O
was O
administered O
at O
the O
recommended O
dose O
and O
schedule O
( O
400 O
mg/m O
2 O
initial O
dose O
, O
followed O
by O
250 O
mg/m O
2 O
weekly O
) O
. O

Patients O
received O
a O
median O
of O
17 O
infusions O
( O
range O
1-51 O
) O
. O

Table O
5 O
: O
Incidence O
of O
Selected O
Adverse O
Reactions O
Occurring O
in O
> O
=10 O
% O
of O
Patients O
with O
K-Ras O
Wild-type O
, O
EGFR-expressing O
, O
Metastatic O
Colorectal O
Cancer O
Treated O
with O
Erbitux O
Monotherapya O
Body O
System O
Preferred O
Term O
Erbitux O
plus O
BSC O
( O
n=118 O
) O
BSC O
alone O
( O
n=124 O
) O
Grades O
1-4 O
b O
Grades O
3 O
and O
4 O
Grades O
1-4 O
Grades O
3 O
and O
4 O
% O
of O
Patients O
a O
Adverse O
reactions O
occurring O
in O
at O
least O
10 O
% O
of O
Erbitux O
plus O
BSC O
arm O
with O
a O
frequency O
at O
least O
5 O
% O
greater O
than O
that O
seen O
in O
the O
BSC O
alone O
arm O
. O

b O
Adverse O
reactions O
were O
graded O
using O
the O
NCI O
CTC O
, O
V O
2.0 O
. O
c O
Infusion B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
is O
defined O
as O
any O
event O
( O
chills B-OSE_Labeled_AE
, O
rigors B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
, O
bronchospasm B-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
tightness I-OSE_Labeled_AE
, O
swelling B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
flushing B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
, O
tremors B-OSE_Labeled_AE
, O
shaking B-OSE_Labeled_AE
, O
drug B-OSE_Labeled_AE
fever I-OSE_Labeled_AE
, O
or O
other O
hypersensitivity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
) O
recorded O
by O
the O
investigator O
as O
infusion-related O
. O

Dermatology B-NonOSE_AE
/ I-NonOSE_AE
Skin I-NonOSE_AE
Rash B-OSE_Labeled_AE
/ O
Desquamation B-OSE_Labeled_AE
95 O
16 O
21 O
1 O
Dry B-OSE_Labeled_AE
Skin I-OSE_Labeled_AE
57 O
0 O
15 O
0 O
Pruritus B-OSE_Labeled_AE
47 O
2 O
11 O
0 O
Other B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Dermatology I-OSE_Labeled_AE
35 O
0 O
7 O
2 O
Nail B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
31 O
0 O
4 O
0 O
Constitutional B-NonOSE_AE
Symptoms I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
91 O
31 O
79 O
29 O
Fever B-OSE_Labeled_AE
25 O
3 O
16 O
0 O
Infusion B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
c O
18 O
3 O
0 O
0 O
Rigors B-OSE_Labeled_AE
, O
Chills B-OSE_Labeled_AE
16 O
1 O
3 O
0 O
Pain B-OSE_Labeled_AE
Pain B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Other I-OSE_Labeled_AE
59 O
18 O
37 O
10 O
Headache B-OSE_Labeled_AE
38 O
2 O
11 O
0 O
Bone B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
15 O
4 O
8 O
2 O
Pulmonary B-NonOSE_AE
Dyspnea B-OSE_Labeled_AE
49 O
16 O
44 O
13 O
Cough B-OSE_Labeled_AE
30 O
2 O
19 O
2 O
Gastrointestinal B-NonOSE_AE
Nausea B-OSE_Labeled_AE
64 O
6 O
50 O
6 O
Constipation B-OSE_Labeled_AE
53 O
3 O
38 O
3 O
Diarrhea B-OSE_Labeled_AE
42 O
2 O
23 O
2 O
Vomiting B-OSE_Labeled_AE
40 O
5 O
26 O
5 O
Stomatitis B-OSE_Labeled_AE
32 O
1 O
10 O
0 O
Other B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Gastrointestinal I-OSE_Labeled_AE
22 O
12 O
16 O
5 O
Dehydration B-OSE_Labeled_AE
13 O
5 O
3 O
0 O
Mouth B-OSE_Labeled_AE
Dryness I-OSE_Labeled_AE
12 O
0 O
6 O
0 O
Taste B-OSE_Labeled_AE
Disturbance I-OSE_Labeled_AE
10 O
0 O
5 O
0 O
Infection B-NonOSE_AE
Infection B-OSE_Labeled_AE
without I-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
38 O
11 O
19 O
5 O
Musculoskeletal B-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
14 O
3 O
6 O
0 O
Neurology B-NonOSE_AE
Neuropathy B-OSE_Labeled_AE
- I-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
45 O
1 O
38 O
2 O
Insomnia B-OSE_Labeled_AE
27 O
0 O
13 O
0 O
Confusion B-OSE_Labeled_AE
18 O
6 O
10 O
2 O
Anxiety B-OSE_Labeled_AE
14 O
1 O
5 O
1 O
Depression B-OSE_Labeled_AE
14 O
0 O
5 O
0 O
Erbitux O
in O
Combination O
with O
Irinotecan O
The O
most O
frequently O
reported O
adverse O
reactions O
in O
354 O
patients O
treated O
with O
Erbitux O
plus O
irinotecan O
in O
clinical O
trials O
were O
acneiform B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
( O
88 O
% O
) O
, O
asthenia B-OSE_Labeled_AE
/ O
malaise B-OSE_Labeled_AE
( O
73 O
% O
) O
, O
diarrhea B-OSE_Labeled_AE
( O
72 O
% O
) O
, O
and O
nausea B-OSE_Labeled_AE
( O
55 O
% O
) O
. O

The O
most O
common O
Grades O
3-4 O
adverse O
reactions O
included O
diarrhea B-OSE_Labeled_AE
( O
22 O
% O
) O
, O
leukopenia B-OSE_Labeled_AE
( O
17 O
% O
) O
, O
asthenia B-OSE_Labeled_AE
/ O
malaise B-OSE_Labeled_AE
( O
16 O
% O
) O
, O
and O
acneiform B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
( O
14 O
% O
) O
. O

6.2 O
Immunogenicity O
As O
with O
all O
therapeutic O
proteins O
, O
there O
is O
potential O
for O
immunogenicity B-OSE_Labeled_AE
. O

An O
ELISA O
methodology O
was O
used O
to O
characterize O
the O
incidence O
of O
anti B-NonOSE_AE
- I-NonOSE_AE
cetuximab I-NonOSE_AE
antibodies I-NonOSE_AE
. O

In O
total O
, O
105 O
Erbitux-treated O
patients O
with O
at O
least O
one O
post-baseline O
blood O
sample O
( O
> O
=4 O
weeks O
post O
first O
administration O
) O
were O
assessed O
for O
the O
development O
of O
anti B-NonOSE_AE
- I-NonOSE_AE
cetuximab I-NonOSE_AE
binding I-NonOSE_AE
antibodies I-NonOSE_AE
and O
the O
incidence O
of O
treatment-emergent O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
cetuximab I-OSE_Labeled_AE
binding I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
was O
< O
5 O
% O
. O

The O
incidence O
of O
antibody B-NonOSE_AE
formation I-NonOSE_AE
is O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
. O

Additionally O
, O
the O
observed O
incidence O
of O
antibody B-NonOSE_AE
( O
including O
neutralizing O
a O
ntibody B-NonOSE_AE
) I-NonOSE_AE
positivity I-NonOSE_AE
  I-NonOSE_AE
I-NonOSE_AE O
in O
an O
assay O
may O
be O
influenced O
by O
several O
factors O
including O
assay O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
Erbitux I-NonOSE_AE
with O
the O
incidence B-NonOSE_AE
of I-NonOSE_AE
antibodies I-NonOSE_AE
to I-NonOSE_AE
other I-NonOSE_AE
products I-NonOSE_AE
may O
be O
misleading O
. O

6.3 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
Erbitux O
. O

Because O
these O
reactions O
are O
reported O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

* O
Aseptic B-OSE_Labeled_AE
meningitis I-OSE_Labeled_AE
* O
Mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
* O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
life-threatening O
and O
fatal B-NonOSE_AE
bullous B-OSE_Labeled_AE
mucocutaneous I-OSE_Labeled_AE
disease I-OSE_Labeled_AE

BOXED O
WARNING O
: O
WARNING O
: O
SERIOUS O
INFUSION O
REACTIONS O
and O
CARDIOPULMONARY O
ARREST O
WARNING O
: O
SERIOUS O
INFUSION O
REACTIONS O
and O
CARDIOPULMONARY O
ARREST O
Infusion B-NonOSE_AE
Reactions I-NonOSE_AE
: O
Serious O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
occurred O
with O
the O
administration O
of O
Erbitux O
in O
approximately O
3 O
% O
of O
patients O
in O
clinical O
trials O
, O
with O
fatal B-NonOSE_AE
outcome O
reported O
in O
less O
than O
1 O
in O
1000 O
. O

[ O
See O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
Adverse O
Reactions O
( O
6 O
) O
. O
] O

Immediately O
interrupt O
and O
permanently O
discontinue O
Erbitux O
infusion O
for O
serious O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
. O

[ O
See O
Dosage O
and O
Administration O
( O
2.4 O
) O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
. O
] O

Cardiopulmonary B-NonOSE_AE
Arrest I-NonOSE_AE
: O
Cardiopulmonary B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
and/or O
sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
occurred O
in O
2 O
% O
of O
patients O
with O
squamous B-Not_AE_Candidate
cell I-Not_AE_Candidate
carcinoma I-Not_AE_Candidate
of I-Not_AE_Candidate
the I-Not_AE_Candidate
head I-Not_AE_Candidate
and I-Not_AE_Candidate
neck I-Not_AE_Candidate
treated O
with O
Erbitux O
and O
radiation O
therapy O
in O
Study O
1 O
and O
in O
3 O
% O
of O
patients O
with O
squamous B-Not_AE_Candidate
cell I-Not_AE_Candidate
carcinoma I-Not_AE_Candidate
of I-Not_AE_Candidate
the I-Not_AE_Candidate
head I-Not_AE_Candidate
and I-Not_AE_Candidate
neck I-Not_AE_Candidate
treated O
with O
European O
Union O
( O
EU O
) O
-approved O
cetuximab O
in O
combination O
with O
platinum-based O
therapy O
with O
5-fluorouracil O
( O
5-FU O
) O
in O
Study O
2 O
. O

Closely O
monitor O
serum O
electrolytes O
, O
including O
serum O
magnesium O
, O
potassium O
, O
and O
calcium O
, O
during O
and O
after O
Erbitux O
administration O
. O

[ O
See O
Warnings O
and O
Precautions O
( O
5.2 O
, O
5.6 O
) O
, O
Clinical O
Studies O
( O
14.1 O
) O
. O
] O

EXCERPT O
: O
WARNING O
: O
SERIOUS O
INFUSION O
REACTIONSand O
CARDIOPULMONARY O
ARREST O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Serious O
infusion O
reactions O
, O
some O
fatal O
, O
occurred O
in O
approximately O
3 O
% O
of O
patients O
. O

( O
5.1 O
) O
* O
Cardiopulmonary O
arrest O
and/or O
sudden O
death O
occurred O
in O
2 O
% O
of O
patients O
with O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
treated O
with O
Erbitux O
and O
radiation O
therapy O
and O
in O
3 O
% O
of O
patients O
with O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
treated O
with O
cetuximab O
in O
combination O
with O
platinum-based O
therapy O
with O
5-fluorouracil O
( O
5-FU O
) O
. O

Closely O
monitor O
serum O
electrolytes O
, O
including O
serum O
magnesium O
, O
potassium O
, O
and O
calcium O
, O
during O
and O
after O
Erbitux O
administration O
. O

( O
5.2 O
, O
5.6 O
) O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Infusion O
Reactions O
: O
Immediately O
stop O
and O
permanently O
discontinue O
Erbitux O
for O
serious O
infusion O
reactions O
. O

Monitor O
patients O
following O
infusion O
. O

( O
5.1 O
) O
* O
Cardiopulmonary O
Arrest O
: O
Closely O
monitor O
serum O
electrolytes O
during O
and O
after O
Erbitux O
. O

( O
5.2 O
, O
5.6 O
) O
* O
Pulmonary O
Toxicity O
: O
Interrupt O
therapy O
for O
acute O
onset O
or O
worsening O
of O
pulmonary O
symptoms O
. O

( O
5.3 O
) O
* O
Dermatologic O
Toxicity O
: O
Mucocutaneous O
adverse O
reactions O
. O

Limit O
sun O
exposure O
. O

Monitor O
for O
inflammatory O
or O
infectious O
sequelae O
. O

( O
2.4 O
, O
5.4 O
) O
* O
Hypomagnesemia O
: O
Periodically O
monitor O
during O
and O
for O
at O
least O
8 O
weeks O
following O
the O
completion O
of O
Erbitux O
. O

Replete O
electrolytes O
as O
necessary O
. O

( O
5.6 O
) O
* O
Increased O
tumor O
progression O
, O
increased O
mortality O
, O
or O
lack O
of O
benefit O
in O
patients O
with O
Ras O
-mutant O
mCRC O
. O

( O
5.7 O
) O
5.1 O
Infusion O
Reactions O
Serious O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
requiring O
medical O
intervention O
and O
immediate O
, O
permanent O
discontinuation O
of O
Erbitux O
included O
rapid O
onset O
of O
airway B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
( O
bronchospasm B-OSE_Labeled_AE
, O
stridor B-OSE_Labeled_AE
, O
hoarseness B-OSE_Labeled_AE
) O
, O
hypotension B-OSE_Labeled_AE
, O
shock B-OSE_Labeled_AE
, O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
and/or O
cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
. O

Severe O
( O
NCI O
CTC O
Grades O
3 O
and O
4 O
) O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
occurred O
in O
2-5 O
% O
of O
1373 O
patients O
in O
Studies O
1 O
, O
3 O
, O
5 O
, O
and O
6 O
receiving O
Erbitux O
, O
with O
fatal B-NonOSE_AE
outcome O
in O
1 O
patient O
. O

[ O
See O
Clinical O
Studies O
( O
14.1 O
, O
14.2 O
) O
. O
] O

Approximately O
90 O
% O
of O
severe O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
occurred O
with O
the O
first O
infusion O
despite O
premedication O
with O
antihistamines O
. O

Monitor O
patients O
for O
1 O
hour O
following O
Erbitux O
infusions O
in O
a O
setting O
with O
resuscitation O
equipment O
and O
other O
agents O
necessary O
to O
treat O
anaphylaxis B-NonOSE_AE
( O
eg O
, O
epinephrine O
, O
corticosteroids O
, O
intravenous O
antihistamines O
, O
bronchodilators O
, O
and O
oxygen O
) O
. O

Monitor O
longer O
to O
confirm O
resolution O
of O
the O
event O
in O
patients O
requiring O
treatment O
for O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
. O

Immediately O
and O
permanently O
discontinue O
Erbitux O
in O
patients O
with O
serious O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
. O

[ O
See O
Boxed O
Warning O
, O
Dosage O
and O
Administration O
( O
2.4 O
) O
. O
] O

5.2 O
Cardiopulmonary O
Arrest O
Cardiopulmonary B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
and/or O
sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
occurred O
in O
4 O
( O
2 O
% O
) O
of O
208 O
patients O
treated O
with O
radiation O
therapy O
and O
Erbitux O
as O
compared O
to O
none O
of O
212 O
patients O
treated O
with O
radiation O
therapy O
alone O
in O
Study O
1 O
. O

Three O
patients O
with O
prior O
history O
of O
coronary B-Not_AE_Candidate
artery I-Not_AE_Candidate
disease I-Not_AE_Candidate
died B-NonOSE_AE
at O
home O
, O
with O
myocardial B-NonOSE_AE
infarction I-NonOSE_AE
as O
the O
presumed O
cause O
of O
death B-NonOSE_AE
. O

One O
of O
these O
patients O
had O
arrhythmia B-Not_AE_Candidate
and O
one O
had O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
. O

Death B-NonOSE_AE
occurred O
27 O
, O
32 O
, O
and O
43 O
days O
after O
the O
last O
dose O
of O
Erbitux O
. O

One O
patient O
with O
no O
prior O
history O
of O
coronary B-NonOSE_AE
artery I-NonOSE_AE
disease I-NonOSE_AE
died B-NonOSE_AE
one O
day O
after O
the O
last O
dose O
of O
Erbitux O
. O

In O
Study O
2 O
, O
fatal B-NonOSE_AE
cardiac B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
and/or O
sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
occurred O
in O
7 O
( O
3 O
% O
) O
of O
219 O
patients O
treated O
with O
EU-approved O
cetuximab O
and O
platinum-based O
therapy O
with O
5-FU O
as O
compared O
to O
4 O
( O
2 O
% O
) O
of O
215 O
patients O
treated O
with O
chemotherapy O
alone O
. O

Five O
of O
these O
7 O
patients O
in O
the O
chemotherapy O
plus O
cetuximab O
arm O
received O
concomitant O
cisplatin O
and O
2 O
patients O
received O
concomitant O
carboplatin O
. O

All O
4 O
patients O
in O
the O
chemotherapy-alone O
arm O
received O
cisplatin O
. O

Carefully O
consider O
use O
of O
Erbitux O
in O
combination O
with O
radiation O
therapy O
or O
platinum-based O
therapy O
with O
5-FU O
in O
head B-Not_AE_Candidate
and I-Not_AE_Candidate
neck I-Not_AE_Candidate
cancer I-Not_AE_Candidate
patients O
with O
a O
history O
of O
coronary B-Not_AE_Candidate
artery I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
or O
arrhythmias B-Not_AE_Candidate
in O
light O
of O
these O
risks O
. O

Closely O
monitor O
serum O
electrolytes O
, O
including O
serum O
magnesium O
, O
potassium O
, O
and O
calcium O
, O
during O
and O
after O
Erbitux O
. O

[ O
See O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.6 O
) O
. O
] O

5.3 O
Pulmonary B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ILD I-OSE_Labeled_AE
) O
, O
including O
1 O
fatality B-NonOSE_AE
, O
occurred O
in O
4 O
of O
1570 O
( O
< O
0.5 O
% O
) O
patients O
receiving O
Erbitux O
in O
Studies O
1 O
, O
3 O
, O
and O
6 O
, O
as O
well O
as O
other O
studies O
, O
in O
colorectal B-Not_AE_Candidate
cancer I-Not_AE_Candidate
and O
head B-Not_AE_Candidate
and I-Not_AE_Candidate
neck I-Not_AE_Candidate
cancer I-Not_AE_Candidate
. O

Interrupt O
Erbitux O
for O
acute O
onset O
or O
worsening B-NonOSE_AE
of I-NonOSE_AE
pulmonary I-NonOSE_AE
symptoms I-NonOSE_AE
. O

Permanently O
discontinue O
Erbitux O
for O
confirmed O
ILD B-NonOSE_AE
. O

5.4 O
Dermatologic O
Toxicity O
Dermatologic B-OSE_Labeled_AE
toxicities I-OSE_Labeled_AE
, O
including O
acneiform B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
drying I-OSE_Labeled_AE
and O
fissuring O
, O
paronychial B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
, O
infectious B-OSE_Labeled_AE
sequelae I-OSE_Labeled_AE
( O
for O
example O
, O
S B-OSE_Labeled_AE
. I-OSE_Labeled_AE
aureus I-OSE_Labeled_AE
sepsis I-OSE_Labeled_AE
, O
abscess B-OSE_Labeled_AE
formation I-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
blepharitis B-OSE_Labeled_AE
, O
conjunctivitis B-OSE_Labeled_AE
, O
keratitis B-OSE_Labeled_AE
/ O
ulcerative B-OSE_Labeled_AE
keratitis I-OSE_Labeled_AE
with O
decreased B-OSE_Labeled_AE
visual I-OSE_Labeled_AE
acuity I-OSE_Labeled_AE
, O
cheilitis B-OSE_Labeled_AE
) O
, O
and O
hypertrichosis B-OSE_Labeled_AE
occurred O
in O
patients O
receiving O
Erbitux O
therapy O
. O

Acneiform B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
occurred O
in O
76-88 O
% O
of O
1373 O
patients O
receiving O
Erbitux O
in O
Studies O
1 O
, O
3 O
, O
5 O
, O
and O
6 O
. O

Severe O
acneiform B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
occurred O
in O
1-17 O
% O
of O
patients O
. O

Acneiform B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
usually O
developed O
within O
the O
first O
two O
weeks O
of O
therapy O
and O
resolved O
in O
a O
majority O
of O
the O
patients O
after O
cessation O
of O
treatment O
, O
although O
in O
nearly O
half O
, O
the O
event O
continued O
beyond O
28 O
days O
. O

Life-threatening O
and O
fatal B-NonOSE_AE
bullous B-OSE_Labeled_AE
mucocutaneous I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
with O
blisters O
, O
erosions O
, O
and O
skin O
sloughing O
has O
also O
been O
observed O
in O
patients O
treated O
with O
Erbitux O
. O

It O
could O
not O
be O
determined O
whether O
these O
mucocutaneous B-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
were O
directly O
related O
to O
EGFR B-NonOSE_AE
inhibition I-NonOSE_AE
or O
to O
idiosyncratic O
immune B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
effects I-NonOSE_AE
( O
eg O
, O
Stevens B-NonOSE_AE
- I-NonOSE_AE
Johnson I-NonOSE_AE
syndrome I-NonOSE_AE
or O
toxic B-NonOSE_AE
epidermal I-NonOSE_AE
necrolysis I-NonOSE_AE
) O
. O

Monitor O
patients O
receiving O
Erbitux O
for O
dermatologic B-NonOSE_AE
toxicities I-NonOSE_AE
and O
infectious B-NonOSE_AE
sequelae I-NonOSE_AE
. O

Instruct O
patients O
to O
limit O
sun O
exposure O
during O
Erbitux O
therapy O
. O

[ O
See O
Dosage O
and O
Administration O
( O
2.4 O
) O
. O
] O

5.5 O
Use O
of O
Erbitux O
in O
Combination O
With O
Radiation O
and O
Cisplatin O
In O
a O
controlled O
study O
, O
940 O
patients O
with O
locally O
advanced O
SCCHN B-Not_AE_Candidate
were O
randomized O
1:1 O
to O
receive O
either O
Erbitux O
in O
combination O
with O
radiation O
therapy O
and O
cisplatin O
or O
radiation O
therapy O
and O
cisplatin O
alone O
. O

The O
addition O
of O
Erbitux O
resulted O
in O
an O
increase O
in O
the O
incidence O
of O
Grade O
3-4 O
mucositis B-OSE_Labeled_AE
, O
radiation B-OSE_Labeled_AE
recall I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
acneiform B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
and O
electrolyte B-OSE_Labeled_AE
disturbances I-OSE_Labeled_AE
compared O
to O
radiation O
and O
cisplatin O
alone O
. O

Adverse O
reactions O
with O
fatal B-NonOSE_AE
outcome O
were O
reported O
in O
20 O
patients O
( O
4.4 O
% O
) O
in O
the O
Erbitux O
combination O
arm O
and O
14 O
patients O
( O
3.0 O
% O
) O
in O
the O
control O
arm O
. O

Nine O
patients O
in O
the O
Erbitux O
arm O
( O
2.0 O
% O
) O
experienced O
myocardial B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
compared O
to O
4 O
patients O
( O
0.9 O
% O
) O
in O
the O
control O
arm O
. O

The O
main O
efficacy O
outcome O
of O
the O
study O
was O
progression-free O
survival O
( O
PFS O
) O
. O

The O
addition O
of O
Erbitux O
to O
radiation O
and O
cisplatin O
did O
not O
improve O
PFS O
. O

5.6 O
Hypomagnesemia O
and O
Electrolyte O
Abnormalities O
In O
patients O
evaluated O
during O
clinical O
trials O
, O
hypomagnesemia B-OSE_Labeled_AE
occurred O
in O
55 O
% O
of O
365 O
patients O
receiving O
Erbitux O
in O
Study O
5 O
and O
two O
other O
clinical O
trials O
in O
colorectal B-Not_AE_Candidate
cancer I-Not_AE_Candidate
and O
head B-Not_AE_Candidate
and I-Not_AE_Candidate
neck I-Not_AE_Candidate
cancer I-Not_AE_Candidate
, O
respectively O
, O
and O
was O
severe O
( O
NCI O
CTC O
Grades O
3 O
and O
4 O
) O
in O
6-17 O
% O
. O

In O
Study O
2 O
, O
where O
EU-approved O
cetuximab O
was O
administered O
in O
combination O
with O
platinum-based O
therapy O
, O
the O
addition O
of O
cetuximab O
to O
cisplatin O
and O
5-FU O
resulted O
in O
an O
increased O
incidence O
of O
hypomagnesemia B-OSE_Labeled_AE
( O
14 O
% O
vs O
. O
6 O
% O
) O
and O
of O
Grade O
3-4 O
hypomagnesemia B-OSE_Labeled_AE
( O
7 O
% O
vs O
. O
2 O
% O
) O
compared O
to O
cisplatin O
and O
5-FU O
alone O
. O

In O
contrast O
, O
the O
incidences O
of O
hypomagnesemia B-NonOSE_AE
were O
similar O
for O
those O
who O
received O
cetuximab O
, O
carboplatin O
, O
and O
5-FU O
compared O
to O
carboplatin O
and O
5-FU O
( O
4 O
% O
vs O
. O
4 O
% O
) O
. O

No O
patient O
experienced O
Grade O
3-4 O
hypomagnesemia B-NonOSE_AE
in O
either O
arm O
in O
the O
carboplatin O
subgroup O
. O

The O
onset O
of O
hypomagnesemia B-OSE_Labeled_AE
and O
accompanying O
electrolyte B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
occurred O
days O
to O
months O
after O
initiation O
of O
Erbitux O
. O

Periodically O
monitor O
patients O
for O
hypomagnesemia B-NonOSE_AE
, O
hypocalcemia B-NonOSE_AE
, O
and O
hypokalemia B-NonOSE_AE
, O
during O
and O
for O
at O
least O
8 O
weeks O
following O
the O
completion O
of O
Erbitux O
. O

Replete O
electrolytes O
as O
necessary O
. O

5.7 O
Increased O
Tumor O
Progression O
, O
Increased O
Mortality O
, O
or O
Lack O
of O
Benefit O
in O
Patients O
with O
Ras O
-Mutant O
mCRC O
Erbitux O
is O
not O
indicated O
for O
the O
treatment O
of O
patients O
with O
colorectal B-Not_AE_Candidate
cancer I-Not_AE_Candidate
that O
harbor O
somatic O
mutations O
in O
exon O
2 O
( O
codons O
12 O
and O
13 O
) O
, O
exon O
3 O
( O
codons O
59 O
and O
61 O
) O
, O
and O
exon O
4 O
( O
codons O
117 O
and O
146 O
) O
of O
either O
K-Ras O
or O
N-Ras O
and O
hereafter O
is O
referred O
to O
as O
`` O
Ras O
. O
'' O

Retrospective O
subset O
analyses O
of O
Ras O
-mutant O
and O
wild-type O
populations O
across O
several O
randomized O
clinical O
trials O
including O
Study O
4 O
were O
conducted O
to O
investigate O
the O
role O
of O
Ras O
mutations O
on O
the O
clinical O
effects O
of O
anti-EGFR-directed O
monoclonal O
antibodies O
. O

Use O
of O
cetuximab O
in O
patients O
with O
Ras O
mutations O
resulted O
in O
no O
clinical O
benefit O
with O
treatment O
related O
toxicity O
. O

[ O
See O
Indications O
and O
Usage O
( O
1.2 O
) O
, O
Clinical O
Pharmacology O
( O
12.1 O
) O
, O
Clinical O
Studies O
( O
14.2 O
) O
. O
] O

5.8 O
Epidermal O
Growth O
Factor O
Receptor O
( O
EGFR O
) O
Expression O
and O
Response O
Because O
expression O
of O
EGFR O
has O
been O
detected O
in O
nearly O
all O
SCCHN B-NonOSE_AE
tumor I-NonOSE_AE
specimens O
, O
patients O
enrolled O
in O
the O
head B-Not_AE_Candidate
and I-Not_AE_Candidate
neck I-Not_AE_Candidate
cancer I-Not_AE_Candidate
clinical O
studies O
were O
not O
required O
to O
have O
immunohistochemical O
evidence O
of O
EGFR B-NonOSE_AE
tumor I-NonOSE_AE
expression I-NonOSE_AE
prior O
to O
study O
entry O
. O

Patients O
enrolled O
in O
the O
colorectal B-Not_AE_Candidate
cancer I-Not_AE_Candidate
clinical O
studies O
were O
required O
to O
have O
immunohistochemical O
evidence O
of O
EGFR B-NonOSE_AE
tumor I-NonOSE_AE
expression I-NonOSE_AE
. O

Primary B-NonOSE_AE
tumor I-NonOSE_AE
or O
tumor B-NonOSE_AE
from I-NonOSE_AE
a I-NonOSE_AE
metastatic I-NonOSE_AE
site I-NonOSE_AE
was O
tested O
with O
the O
DakoCytomation O
EGFR O
pharmDxTM O
test O
kit O
. O

Specimens O
were O
scored O
based O
on O
the O
percentage O
of O
cells O
expressing O
EGFR O
and O
intensity O
( O
barely/faint O
, O
weak-to-moderate O
, O
and O
strong O
) O
. O

Response O
rate O
did O
not O
correlate O
with O
either O
the O
percentage O
of O
positive O
cells O
or O
the O
intensity O
of O
EGFR O
expression O
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
( O
> O
= O
10 O
% O
) O
across O
all O
studies O
with O
GATTEX O
are O
abdominal O
pain O
, O
injection O
site O
reactions O
, O
nausea O
, O
headaches O
, O
abdominal O
distension O
, O
upper O
respiratory O
tract O
infection O
. O

In O
addition O
, O
vomiting O
and O
fluid O
overload O
were O
reported O
in O
the O
SBS O
studies O
( O
1 O
and O
3 O
) O
at O
rates O
> O
= O
10 O
% O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
NPS O
Pharmaceuticals O
at O
1-855-5GATTEX O
( O
1-855-542-8839 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
the O
adverse O
reaction O
rates O
observed O
can O
not O
be O
directly O
compared O
to O
rates O
in O
other O
clinical O
trials O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

Across O
all O
clinical O
studies O
, O
566 O
subjects O
were O
exposed O
to O
at O
least O
one O
dose O
of O
GATTEX O
( O
190 O
patient-years O
of O
exposure O
; O
mean O
duration O
of O
exposure O
was O
17 O
weeks O
) O
. O

Of O
the O
566 O
subjects O
, O
173 O
subjects O
were O
treated O
in O
Phase O
3 O
SBS B-Not_AE_Candidate
studies O
( O
134/173 O
[ O
77 O
% O
] O
at O
the O
dose O
of O
0.05 O
mg/kg/day O
and O
39/173 O
[ O
23 O
% O
] O
at O
the O
dose O
of O
0.10 O
mg/kg/day O
) O
. O

The O
most O
commonly O
reported O
( O
> O
= O
10 O
% O
) O
adverse O
reactions O
in O
patients O
treated O
with O
GATTEX O
across O
all O
clinical O
studies O
( O
n O
= O
566 O
) O
were O
: O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
30.0 O
% O
) O
; O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
22.4 O
% O
) O
; O
nausea B-OSE_Labeled_AE
( O
18.2 O
% O
) O
; O
headaches B-OSE_Labeled_AE
( O
15.9 O
% O
) O
; O
abdominal B-OSE_Labeled_AE
distension I-OSE_Labeled_AE
( O
13.8 O
% O
) O
; O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
11.8 O
% O
) O
. O

The O
rates O
of O
adverse O
reactions O
in O
subjects O
with O
SBS B-Not_AE_Candidate
participating O
in O
two O
randomized O
, O
placebo-controlled O
, O
24-week O
, O
double-blind O
clinical O
studies O
( O
Study O
1 O
and O
Study O
3 O
) O
are O
summarized O
in O
Table O
1 O
. O

Only O
those O
reactions O
with O
a O
rate O
of O
at O
least O
5 O
% O
in O
the O
GATTEX O
group O
, O
and O
greater O
than O
placebo O
group O
, O
are O
summarized O
in O
Table O
1 O
. O

The O
majority O
of O
these O
reactions O
were O
mild O
or O
moderate O
. O

Of O
subjects O
receiving O
GATTEX O
at O
the O
recommended O
dose O
of O
0.05 O
mg/kg/day O
, O
88.3 O
% O
( O
N=68/77 O
) O
experienced O
an O
adverse O
reaction O
, O
as O
compared O
to O
83.1 O
% O
( O
49/59 O
) O
for O
placebo O
. O

Many O
of O
these O
adverse O
reactions O
have O
been O
reported O
in O
association O
with O
the O
underlying O
disease O
and/or O
parenteral O
nutrition O
. O

Table O
1 O
: O
Adverse O
reactions O
in O
> O
=5 O
% O
of O
GATTEX-treated O
SBS O
subjects O
and O
more O
frequent O
than O
placebo O
: O
Studies O
1 O
and O
3 O
Adverse O
Reaction O
Placebo O
( O
N=59 O
) O
n O
( O
% O
) O
GATTEX0.05mg/kg/day O
( O
N=77 O
) O
n O
( O
% O
) O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
16 O
( O
27.1 O
) O
29 O
( O
37.7 O
) O
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
8 O
( O
13.6 O
) O
20 O
( O
26.0 O
) O
Nausea B-OSE_Labeled_AE
12 O
( O
20.3 O
) O
19 O
( O
24.7 O
) O
Abdominal B-OSE_Labeled_AE
Distension I-OSE_Labeled_AE
1 O
( O
1.7 O
) O
15 O
( O
19.5 O
) O
Vomiting B-OSE_Labeled_AE
6 O
( O
10.2 O
) O
9 O
( O
11.7 O
) O
Fluid B-OSE_Labeled_AE
Overload I-OSE_Labeled_AE
4 O
( O
6.8 O
) O
9 O
( O
11.7 O
) O
Flatulence B-OSE_Labeled_AE
4 O
( O
6.8 O
) O
7 O
( O
9.1 O
) O
Hypersensitivity B-OSE_Labeled_AE
3 O
( O
5.1 O
) O
6 O
( O
7.8 O
) O
Appetite B-OSE_Labeled_AE
Disorders I-OSE_Labeled_AE
2 O
( O
3.4 O
) O
5 O
( O
6.5 O
) O
Sleep B-OSE_Labeled_AE
Disturbances I-OSE_Labeled_AE
0 O
4 O
( O
5.2 O
) O
Cough B-OSE_Labeled_AE
0 O
4 O
( O
5.2 O
) O
Skin B-OSE_Labeled_AE
Hemorrhage I-OSE_Labeled_AE
1 O
( O
1.7 O
) O
4 O
( O
5.2 O
) O
Subjects O
with O
Stoma B-Not_AE_Candidate
Gastrointestin I-Not_AE_Candidate
al O
Stoma O
Complication O
3 O
( O
13.6 O
) O
13 O
( O
41.9 O
) O
In O
placebo-controlled O
Studies O
1 O
and O
3 O
, O
12 O
% O
of O
patients O
in O
each O
of O
the O
placebo O
and O
GATTEX O
study O
groups O
experienced O
an O
injection B-NonOSE_AE
site I-NonOSE_AE
reaction I-NonOSE_AE
. O

Adverse O
Reactions O
of O
Special O
Interest O
Malignancy B-NonOSE_AE
. O

Three O
subjects O
were O
diagnosed O
with O
malignancy B-OSE_Labeled_AE
in O
the O
clinical O
studies O
, O
all O
of O
whom O
were O
male O
and O
had O
received O
GATTEX O
0.05 O
mg/kg/day O
in O
Study O
2 O
. O

One O
subject O
had O
a O
history O
of O
abdominal O
radiation O
for O
Hodgkin B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
two O
decades O
prior O
to O
receiving O
GATTEX O
and O
prior O
liver B-Not_AE_Candidate
lesion I-Not_AE_Candidate
on O
CT O
scan O
, O
and O
was O
diagnosed O
with O
metastatic B-OSE_Labeled_AE
adenocarcinoma I-OSE_Labeled_AE
of O
unconfirmed O
origin O
after O
11 O
months O
of O
exposure O
to O
GATTEX O
. O

Two O
subjects O
had O
extensive O
smoking O
histories O
, O
and O
were O
diagnosed O
with O
lung B-OSE_Labeled_AE
cancers I-OSE_Labeled_AE
( O
squamous I-OSE_Labeled_AE
and O
non-small O
cell I-OSE_Labeled_AE
) O
after O
12 O
months O
and O
3 O
months O
of O
GATTEX O
exposure O
, O
respectively O
. O

Colorectal B-OSE_Labeled_AE
Polyps I-OSE_Labeled_AE
. O

In O
the O
clinical O
studies O
, O
6 O
subjects O
were O
diagnosed O
with O
polyps B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
G I-OSE_Labeled_AE
. I-OSE_Labeled_AE
I I-OSE_Labeled_AE
. I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
after O
initiation O
of O
study O
treatment O
. O

In O
the O
SBS B-Not_AE_Candidate
placebo-controlled O
studies O
, O
1/59 O
( O
1.7 O
% O
) O
of O
subjects O
on O
placebo O
and O
1/109 O
( O
0.9 O
% O
) O
of O
subjects O
on O
GATTEX O
0.05 O
mg/kg/day O
were O
diagnosed O
with O
intestinal B-NonOSE_AE
polyps I-NonOSE_AE
( I-NonOSE_AE
inflammatory I-NonOSE_AE
stomal I-NonOSE_AE
and O
hyperplastic O
sigmoidal O
after O
3 O
and O
5 O
months O
, O
respectively O
) O
. O

The O
remaining O
4 O
polyp B-NonOSE_AE
cases O
occurred O
in O
the O
extension O
studies O
- O
two O
colorectal B-OSE_Labeled_AE
villous I-OSE_Labeled_AE
adenomas I-OSE_Labeled_AE
( O
onset O
at O
6 O
and O
7 O
months O
in O
GATTEX O
0.10 O
and O
0.05 O
mg/kg/day O
dose O
groups O
, O
respectively O
) O
, O
one O
hyperplastic B-OSE_Labeled_AE
polyp I-OSE_Labeled_AE
( O
onset O
6 O
months O
in O
GATTEX O
0.10 O
mg/kg/day O
dose O
group O
) O
, O
and O
one O
small O
duodenal B-OSE_Labeled_AE
polyp I-OSE_Labeled_AE
( O
onset O
at O
3 O
months O
in O
GATTEX O
0.05 O
mg/kg/day O
dose O
group O
) O
. O

Gastrointestinal B-OSE_Labeled_AE
Obstruction I-OSE_Labeled_AE
. O

Overall O
, O
12 O
subjects O
experienced O
one O
or O
more O
episodes O
of O
intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
/stenosis O
: O
6 O
in O
SBS B-Not_AE_Candidate
placebo-controlled O
studies O
and O
6 O
in O
the O
extension O
studies O
. O

The O
6 O
subjects O
in O
the O
placebo-controlled O
trials O
were O
all O
on O
GATTEX O
: O
3/77 O
( O
3.9 O
% O
) O
on O
GATTEX O
0.05 O
mg/kg/day O
and O
3/32 O
( O
9.4 O
% O
) O
on O
GATTEX O
0.10 O
mg/kg/day O
. O

No O
cases O
of O
intestinal B-NonOSE_AE
obstruction I-NonOSE_AE
occurred O
in O
the O
placebo O
group O
. O

Onsets O
ranged O
from O
1 O
day O
to O
6 O
months O
. O

In O
the O
extension O
studies O
, O
6 O
additional O
subjects O
( O
all O
on O
GATTEX O
0.05 O
mg/kg/day O
) O
were O
diagnosed O
with O
intestinal B-OSE_Labeled_AE
obstruction/ O
stenosis I-OSE_Labeled_AE
with O
onsets O
ranging O
from O
6 O
days O
to O
7 O
months O
. O

Two O
of O
the O
6 O
subjects O
from O
the O
placebo-controlled O
trials O
experienced O
recurrence O
of O
obstruction O
in O
the O
extension O
studies O
. O

Of O
all O
8 O
subjects O
with O
an O
episode O
of O
intestinal B-OSE_Labeled_AE
obstruction/ O
stenosis I-OSE_Labeled_AE
in O
these O
extension O
studies O
, O
1 O
subject O
required O
endoscopic O
dilation O
and O
none O
required O
surgical O
intervention O
. O

Gallbladder B-NonOSE_AE
, O
Biliary O
and O
Pancreatic O
Disease I-NonOSE_AE
. O

For O
gallbladder B-NonOSE_AE
and O
biliary O
disease I-NonOSE_AE
in O
the O
placebo-controlled O
studies O
, O
3 O
subjects O
were O
diagnosed O
with O
cholecystitis B-OSE_Labeled_AE
, O
all O
of O
whom O
had O
a O
prior O
history O
of O
gallbladder B-Not_AE_Candidate
disease I-Not_AE_Candidate
and O
were O
in O
the O
GATTEX O
0.05 O
mg/kg/day O
dose O
group O
. O

No O
cases O
were O
reported O
in O
the O
placebo O
group O
. O

One O
of O
these O
3 O
cases O
had O
gallbladder B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
and O
underwent O
cholecystectomy O
the O
next O
day O
. O

The O
remaining O
2 O
cases O
underwent O
elective O
cholecystectomy O
at O
a O
later O
date O
. O

In O
the O
extension O
studies O
, O
3 O
subjects O
had O
an O
episode O
of O
acute B-OSE_Labeled_AE
cholecystitis I-OSE_Labeled_AE
; O
2 O
subjects O
had O
new-onset O
cholelithiasis B-OSE_Labeled_AE
; O
and O
1 O
subject O
experienced O
cholestasis B-NonOSE_AE
secondary O
to O
an O
obstructed B-Not_AE_Candidate
biliary I-Not_AE_Candidate
stent I-Not_AE_Candidate
. O

For O
pancreatic B-NonOSE_AE
disease I-NonOSE_AE
in O
the O
placebo-controlled O
studies O
, O
1 O
subject O
( O
GATTEX O
0.05 O
mg/kg/day O
dose O
group O
) O
had O
a O
pancreatic B-OSE_Labeled_AE
pseudocyst I-OSE_Labeled_AE
diagnosed O
after O
4 O
months O
of O
GATTEX O
. O

In O
the O
extension O
studies O
, O
1 O
subject O
was O
diagnosed O
with O
chronic B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
; O
and O
1 O
subject O
was O
diagnosed O
with O
acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
. O

Fluid B-NonOSE_AE
Overload I-NonOSE_AE
. O

In O
the O
placebo-controlled O
trials O
, O
fluid B-OSE_Labeled_AE
overload I-OSE_Labeled_AE
was O
reported O
in O
4/59 O
( O
6.8 O
% O
) O
of O
subjects O
on O
placebo O
and O
9/77 O
( O
11.7 O
% O
) O
subjects O
on O
GATTEX O
0.05 O
mg/kg/day O
. O

Of O
the O
9 O
cases O
in O
the O
GATTEX O
group O
, O
there O
were O
2 O
cases O
of O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
CHF O
) O
, O
1 O
of O
whom O
was O
reported O
as O
a O
serious O
adverse O
event O
and O
the O
other O
as O
non-serious O
. O

The O
serious O
case O
had O
onset O
at O
6 O
months O
, O
and O
was O
possibly O
associated O
with O
previously O
undiagnosed O
hypothyroidism B-Not_AE_Candidate
and/or O
cardiac B-Not_AE_Candidate
dysfunction I-Not_AE_Candidate
. O

Concomitant O
Oral O
Medication O
. O

GATTEX O
can O
increase O
the O
absorption O
of O
concomitant O
oral O
medications O
such O
as O
benzodiazepines O
and O
psychotropic O
agents O
. O

In O
the O
placebo-controlled O
trials O
, O
an O
analysis O
of O
episodes O
of O
cognition B-NonOSE_AE
and O
attention O
disturbances I-NonOSE_AE
was O
performed O
for O
subjects O
on O
benzodiazepines O
. O

One O
of O
the O
subjects O
in O
the O
GATTEX O
0.05 O
mg/kg/day O
group O
( O
on O
prazepam O
) O
experienced O
dramatic O
deterioration B-NonOSE_AE
in I-NonOSE_AE
mental I-NonOSE_AE
status I-NonOSE_AE
progressing O
to O
coma B-NonOSE_AE
during O
her O
first O
week O
of O
GATTEX O
therapy O
. O

She O
was O
admitted O
to O
the O
ICU O
where O
her O
benzodiazepine O
level O
was O
> O
300 O
mcg/L O
. O

GATTEX O
and O
prazepam O
were O
discontinued O
, O
and O
coma B-NonOSE_AE
resolved O
5 O
days O
later O
. O

6.2 O
Immunogenicity O
Consistent O
with O
the O
potentially O
immunogenic B-NonOSE_AE
properties O
of O
medicinal O
products O
containing O
peptides O
, O
administration O
of O
GATTEX O
may O
trigger O
the O
development B-OSE_Labeled_AE
of I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
. O

In O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
parallel-group O
, O
multi-national O
, O
multi-center O
, O
clinical O
trial O
( O
Study O
1 O
) O
in O
adults O
with O
SBS O
, O
the O
incidence O
of O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
GATTEX I-OSE_Labeled_AE
antibody I-OSE_Labeled_AE
was O
0 O
% O
( O
0/16 O
) O
at O
Week O
12 O
and O
18 O
% O
( O
6/34 O
) O
at O
Week O
24 O
in O
subjects O
who O
received O
subcutaneous O
administration O
of O
0.05 O
mg/kg O
GATTEX O
once O
daily O
. O

The O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
GATTEX I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
were O
cross-reactive O
to O
native O
glucagon-like O
peptide O
( O
GLP-2 O
) O
in O
five O
of O
the O
six O
subjects O
( O
83 O
% O
) O
who O
had O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
GATTEX I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
. O

In O
the O
extension O
study O
( O
Study O
2 O
) O
, O
the O
immunogenicity B-OSE_Labeled_AE
incidence O
rate O
increased O
over O
time O
to O
27 O
% O
( O
14/51 O
) O
at O
12 O
months O
and O
38 O
% O
( O
13/34 O
) O
at O
18 O
months O
. O

Anti B-NonOSE_AE
- I-NonOSE_AE
GATTEX I-NonOSE_AE
antibodies I-NonOSE_AE
appear O
to O
have O
no O
impact O
on O
short O
term O
( O
up O
to O
1.5 O
years O
) O
efficacy O
and O
safety O
although O
the O
long-term O
impact O
is O
unknown O
. O

A O
total O
of O
40 O
subjects O
were O
tested O
for O
neutralizing B-NonOSE_AE
antibodies I-NonOSE_AE
- O
20 O
of O
these O
subjects O
had O
no O
neutralizing B-NonOSE_AE
antibodies I-NonOSE_AE
, O
and O
the O
remaining O
20 O
subjects O
had O
no O
detectable O
neutralizing B-NonOSE_AE
antibodies I-NonOSE_AE
although O
, O
the O
presence O
of O
teduglutide O
at O
low O
levels O
in O
these O
study O
samples O
could O
have O
resulted O
in O
false O
negatives O
( O
no O
neutralizing B-NonOSE_AE
antibody I-NonOSE_AE
detected I-NonOSE_AE
although O
present O
) O
. O

Immunogenicity B-NonOSE_AE
assay O
results O
are O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
and O
may O
be O
influenced O
by O
several O
factors O
such O
as O
: O
assay O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medication O
, O
and O
underlying O
diseases O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
GATTEX I-NonOSE_AE
with O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
other I-NonOSE_AE
products I-NonOSE_AE
may O
be O
misleading O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Neoplastic O
growth O
. O

There O
is O
a O
risk O
for O
acceleration O
of O
neoplastic O
growth O
. O

Colonoscopy O
of O
the O
entire O
colon O
with O
removal O
of O
polyps O
should O
be O
done O
before O
initiating O
treatment O
with O
GATTEX O
and O
is O
recommended O
after O
1 O
year O
. O

Subsequent O
colonoscopies O
should O
be O
done O
as O
needed O
, O
but O
no O
less O
frequently O
than O
every O
5 O
years O
. O

In O
case O
of O
intestinal O
malignancy O
discontinue O
GATTEX O
. O

The O
clinical O
decision O
to O
continue O
GATTEX O
in O
patients O
with O
non-gastrointestinal O
malignancy O
should O
be O
made O
based O
on O
risk O
and O
benefit O
considerations O
. O

( O
5.1 O
) O
* O
Intestinal O
obstruction O
. O

In O
patients O
who O
develop O
obstruction O
, O
GATTEX O
should O
be O
temporarily O
discontinued O
pending O
further O
clinical O
evaluation O
and O
management O
. O

( O
5.2 O
) O
* O
Biliary O
and O
pancreatic O
disease O
. O

Patients O
should O
undergo O
laboratory O
assessment O
( O
bilirubin O
, O
alkaline O
phosphatase O
, O
lipase O
, O
amylase O
) O
before O
starting O
GATTEX O
. O

Subsequent O
laboratory O
tests O
should O
be O
done O
every O
6 O
months O
. O

If O
clinically O
meaningful O
changes O
are O
seen O
, O
further O
evaluation O
is O
recommended O
including O
imaging O
, O
and O
continued O
treatment O
with O
GATTEX O
should O
be O
reassessed O
. O

( O
5.3 O
) O
* O
Fluid O
overload O
. O

There O
is O
a O
potential O
for O
fluid O
overload O
while O
on O
GATTEX O
. O

If O
fluid O
overload O
occurs O
, O
especially O
in O
patients O
with O
cardiovascular O
disease O
, O
parenteral O
support O
should O
be O
appropriately O
adjusted O
, O
and O
GATTEX O
treatment O
reassessed O
. O

( O
5.4 O
) O
5.1 O
Acceleration O
of O
Neoplastic O
Growth O
Based O
on O
the O
pharmacologic O
activity O
and O
findings O
in O
animals O
, O
GATTEX O
has O
the O
potential O
to O
cause O
hyperplastic B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
including O
neoplasia B-OSE_Labeled_AE
. O

In O
patients O
at O
increased O
risk O
for O
malignancy B-NonOSE_AE
, O
the O
clinical O
decision O
to O
use O
GATTEX O
should O
be O
considered O
only O
if O
the O
benefits O
outweigh O
the O
risks O
. O

In O
patients O
with O
active O
gastrointestinal B-Not_AE_Candidate
malignancy I-Not_AE_Candidate
( O
GI O
tract O
, O
hepatobiliary O
, O
pancreatic O
) O
, O
GATTEX O
therapy O
should O
be O
discontinued O
. O

In O
patients O
with O
active O
non B-NonOSE_AE
- I-NonOSE_AE
gastrointestinal I-NonOSE_AE
malignancy I-NonOSE_AE
, O
the O
clinical O
decision O
to O
continue O
GATTEX O
should O
be O
made O
based O
on O
risk-benefit O
considerations O
. O

[ O
see O
Clinical O
Pharmacology O
( O
12.1 O
) O
and O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
Colorectal O
Polyps O
Colorectal B-OSE_Labeled_AE
polyps I-OSE_Labeled_AE
were O
identified O
during O
the O
clinical O
trials O
. O

Colonoscopy O
of O
the O
entire O
colon O
with O
removal O
of O
polyps B-NonOSE_AE
should O
be O
done O
within O
6 O
months O
prior O
to O
starting O
treatment O
with O
GATTEX O
. O

A O
follow-up O
colonoscopy O
( O
or O
alternate O
imaging O
) O
is O
recommended O
at O
the O
end O
of O
1 O
year O
of O
GATTEX O
. O

Subsequent O
colonoscopies O
should O
be O
done O
every O
5 O
years O
or O
more O
often O
as O
needed O
. O

If O
a O
polyp B-NonOSE_AE
is O
found O
, O
adherence O
to O
current O
polyp B-NonOSE_AE
follow-up O
guidelines O
is O
recommended O
. O

In O
case O
of O
diagnosis O
of O
colorectal B-NonOSE_AE
cancer I-NonOSE_AE
, O
GATTEX O
therapy O
should O
be O
discontinued O
. O

[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
Small B-OSE_Labeled_AE
Bowel I-OSE_Labeled_AE
Neoplasia I-OSE_Labeled_AE
Based O
on O
benign B-NonOSE_AE
tumor I-NonOSE_AE
findings O
in O
the O
rat O
carcinogenicity B-NonOSE_AE
study O
, O
patients O
should O
be O
monitored O
clinically O
for O
small B-NonOSE_AE
bowel I-NonOSE_AE
neoplasia I-NonOSE_AE
. O

If O
a O
benign B-NonOSE_AE
neoplasm I-NonOSE_AE
is O
found O
, O
it O
should O
be O
removed O
. O

In O
case O
of O
small B-NonOSE_AE
bowel I-NonOSE_AE
cancer I-NonOSE_AE
, O
GATTEX O
therapy O
should O
be O
discontinued O
. O

[ O
see O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
5.2 O
Intestinal O
Obstruction O
Intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
has O
been O
reported O
in O
clinical O
trials O
. O

In O
patients O
who O
develop O
intestinal B-NonOSE_AE
or O
stomal O
obstruction I-NonOSE_AE
, O
GATTEX O
should O
be O
temporarily O
discontinued O
while O
the O
patient O
is O
clinically O
managed O
. O

GATTEX O
may O
be O
restarted O
when O
the O
obstructive O
presentation O
resolves O
, O
if O
clinically O
indicated O
. O

[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
5.3 O
Biliary O
and O
Pancreatic O
Disease O
Gallbladder O
and O
Biliary O
Tract O
Disease O
Cholecystitis B-OSE_Labeled_AE
, O
cholangitis B-OSE_Labeled_AE
, O
and O
cholelithiasis B-OSE_Labeled_AE
, O
have O
been O
reported O
in O
clinical O
studies O
. O

For O
identification O
of O
the O
onset O
or O
worsening O
of O
gallbladder B-NonOSE_AE
/biliary O
disease I-NonOSE_AE
, O
patients O
should O
undergo O
laboratory O
assessment O
of O
bilirubin O
and O
alkaline O
phosphatase O
within O
6 O
months O
prior O
to O
starting O
GATTEX O
, O
and O
at O
least O
every O
6 O
months O
while O
on O
GATTEX O
; O
or O
more O
frequently O
if O
needed O
. O

If O
clinically O
meaningful O
changes O
are O
seen O
, O
further O
evaluation O
including O
imaging O
of O
the O
gallbladder O
and/or O
biliary O
tract O
is O
recommended O
; O
and O
the O
need O
for O
continued O
GATTEX O
treatment O
should O
be O
reassessed O
. O

[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
Pancreatic O
Disease O
Pancreatitis B-OSE_Labeled_AE
has O
been O
reported O
in O
clinical O
studies O
. O

For O
identification O
of O
onset O
or O
worsening O
of O
pancreatic B-NonOSE_AE
disease I-NonOSE_AE
, O
patients O
should O
undergo O
laboratory O
assessment O
of O
lipase O
and O
amylase O
within O
6 O
months O
prior O
to O
starting O
GATTEX O
, O
and O
at O
least O
every O
6 O
months O
while O
on O
GATTEX O
; O
or O
more O
frequently O
if O
needed O
. O

If O
clinically O
meaningful O
changes O
are O
seen O
, O
further O
evaluation O
such O
as O
imaging O
of O
the O
pancreas O
is O
recommended O
; O
and O
the O
need O
for O
continued O
GATTEX O
treatment O
should O
be O
reassessed O
. O

[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
and O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
5.4 O
Fluid O
Overload O
Fluid B-OSE_Labeled_AE
overload I-OSE_Labeled_AE
and O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
have O
been O
observed O
in O
clinical O
trials O
, O
which O
were O
felt O
to O
be O
related O
to O
enhanced O
fluid O
absorption O
associated O
with O
GATTEX O
. O

If O
fluid B-NonOSE_AE
overload I-NonOSE_AE
occurs O
, O
parenteral O
support O
should O
be O
adjusted O
and O
GATTEX O
treatment O
should O
be O
reassessed O
, O
especially O
in O
patients O
with O
underlying O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

If O
significant O
cardiac B-NonOSE_AE
deterioration I-NonOSE_AE
develops O
while O
on O
GATTEX O
, O
the O
need O
for O
continued O
GATTEX O
treatment O
should O
be O
reassessed O
. O

[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
5.5 O
Increased O
Absorption O
of O
Concomitant O
Oral O
Medication O
Altered B-NonOSE_AE
mental I-NonOSE_AE
status I-NonOSE_AE
in O
association O
with O
GATTEX O
has O
been O
observed O
in O
patients O
on O
benzodiazepines O
in O
clinical O
trials O
. O

Patients O
on O
concomitant O
oral O
drugs O
( O
e.g. O
, O
benzodiazepines O
, O
phenothiazines O
) O
requiring O
titration O
or O
with O
a O
narrow O
therapeutic O
index O
may O
require O
dose O
adjustment O
while O
on O
GATTEX O
. O

[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O

6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
label O
: O
* O
Hepatitis B-OSE_Labeled_AE
B I-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Progressive B-OSE_Labeled_AE
multifocal I-OSE_Labeled_AE
leukoencephalopathy I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Tumor B-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Infections B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Neutropenia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Thrombocytopenia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
10 O
% O
) O
were O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
and O
diarrhea B-OSE_Labeled_AE
. O

EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
10 O
% O
) O
were O
infusion O
reactions O
, O
neutropenia O
, O
thrombocytopenia O
, O
anemia O
, O
pyrexia O
, O
cough O
, O
nausea O
, O
and O
diarrhea O
. O

( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Genentech O
at O
1-888-835-2555 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trial O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
data O
described O
in O
Tables O
3-6 O
below O
are O
based O
on O
a O
safety O
population O
of O
773 O
previously O
untreated O
patients O
with O
CLL B-Not_AE_Candidate
. O

Patients O
were O
treated O
with O
chlorambucil O
alone O
, O
GAZYVA O
in O
combination O
with O
chlorambucil O
, O
or O
rituximab O
in O
combination O
with O
chlorambucil O
. O

The O
Stage O
1 O
analysis O
compared O
GAZYVA O
in O
combination O
with O
chlorambucil O
vs O
. O
chlorambucil O
alone O
, O
and O
Stage O
2 O
compared O
GAZYVA O
in O
combination O
with O
chlorambucil O
vs O
. O
rituximab O
in O
combination O
with O
chlorambucil O
. O

Patients O
received O
three O
1000 O
mg O
doses O
of O
GAZYVA O
on O
the O
first O
cycle O
and O
a O
single O
dose O
of O
1000 O
mg O
once O
every O
28 O
days O
for O
5 O
additional O
cycles O
in O
combination O
with O
chlorambucil O
( O
6 O
cycles O
of O
28 O
days O
each O
in O
total O
) O
. O

In O
the O
last O
140 O
patients O
enrolled O
, O
the O
first O
dose O
of O
GAZYVA O
was O
split O
between O
day O
1 O
( O
100 O
mg O
) O
and O
day O
2 O
( O
900 O
mg O
) O
[ O
see O
Dosage O
and O
Administration O
( O
2.1 O
) O
] O
. O

In O
total O
, O
81 O
% O
of O
patients O
received O
all O
6 O
cycles O
( O
of O
28 O
days O
each O
) O
of O
GAZYVA-based O
therapy O
. O

Table O
3 O
Summary O
of O
Adverse O
Reactions O
Reported O
in O
> O
= O
5 O
% O
of O
Patients O
and O
at O
Least O
2 O
% O
Greater O
in O
the O
GAZYVA O
Treated O
Arm O
( O
Stage O
1 O
) O
Adverse O
Reactions O
( O
MedDRA O
) O
System O
Organ O
Class O
GAZYVA O
+ O
Chlorambuciln O
= O
241 O
Chlorambuciln O
= O
116 O
All O
Grades O
% O
Grades O
3-4 O
% O
All O
Grades O
% O
Grades O
3-4 O
% O
Injury B-NonOSE_AE
, I-NonOSE_AE
poisoning I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
procedural I-NonOSE_AE
complications I-NonOSE_AE
Infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
69 O
21 O
0 O
0 O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
41 O
35 O
18 O
16 O
Thrombocytopenia B-OSE_Labeled_AE
15 O
11 O
8 O
4 O
Anemia B-OSE_Labeled_AE
12 O
5 O
10 O
4 O
Leukopenia B-OSE_Labeled_AE
7 O
5 O
0 O
0 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Pyrexia B-OSE_Labeled_AE
10 O
< O
1 O
7 O
0 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
10 O
0 O
7 O
< O
1 O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
6 O
2 O
3 O
< O
1 O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorder I-NonOSE_AE
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
5 O
< O
1 O
2 O
0 O
Table O
4 O
Summary O
of O
Adverse O
Reactions O
Reported O
in O
> O
= O
5 O
% O
of O
Patients O
and O
at O
Least O
2 O
% O
Greater O
in O
the O
GAZYVA O
Treated O
Arm O
( O
Stage O
2 O
) O
Adverse O
Reactions O
( O
MedDRA O
) O
System O
Organ O
Class O
GAZYVA O
+ O
Chlorambuciln O
= O
336 O
Rituximab O
+ O
Chlorambuciln O
= O
321 O
All O
Grades O
% O
Grades O
3-4 O
% O
All O
Grades O
% O
Grades O
3-4 O
% O
Injury B-NonOSE_AE
, I-NonOSE_AE
poisoning I-NonOSE_AE
and I-NonOSE_AE
procedural I-NonOSE_AE
complications I-NonOSE_AE
Infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
66 O
20 O
38 O
4 O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
38 O
33 O
32 O
28 O
Thrombocytopenia B-OSE_Labeled_AE
14 O
10 O
7 O
3 O
Leukopenia B-OSE_Labeled_AE
6 O
4 O
2 O
< O
1 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Pyrexia B-OSE_Labeled_AE
9 O
< O
1 O
7 O
< O
1 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
10 O
2 O
8 O
< O
1 O
Constipation B-OSE_Labeled_AE
8 O
0 O
5 O
0 O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Nasopharyngitis B-OSE_Labeled_AE
6 O
< O
1 O
3 O
0 O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
5 O
1 O
2 O
< O
1 O
Table O
5 O
Post-Baseline O
Laboratory O
Abnormalities O
by O
CTCAE O
Grade O
in O
> O
= O
5 O
% O
of O
Patients O
and O
at O
Least O
2 O
% O
Greater O
in O
the O
GAZYVA O
Treated O
Arm O
( O
Stage O
1 O
) O
Investigations O
GAZYVA O
+ O
Chlorambuciln O
= O
241 O
Chlorambuciln O
= O
116 O
All O
Grades O
% O
Grades O
3-4 O
% O
All O
Grades O
% O
Grades O
3-4 O
% O
Hematology B-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
78 O
48 O
53 O
27 O
Lymphopenia B-OSE_Labeled_AE
80 O
40 O
9 O
3 O
Leukopenia B-OSE_Labeled_AE
84 O
37 O
12 O
< O
1 O
Chemistry B-NonOSE_AE
Hypocalcemia B-OSE_Labeled_AE
38 O
3 O
33 O
2 O
Hyperkalemia B-OSE_Labeled_AE
33 O
5 O
18 O
3 O
Hyponatremia B-OSE_Labeled_AE
30 O
8 O
12 O
3 O
AST B-OSE_Labeled_AE
( I-OSE_Labeled_AE
SGOT I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
) O
29 O
1 O
16 O
0 O
Creatinine B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
30 O
< O
1 O
20 O
2 O
ALT B-OSE_Labeled_AE
( I-OSE_Labeled_AE
SGPT I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
) O
27 O
2 O
16 O
0 O
Hypoalbuminemia B-OSE_Labeled_AE
23 O
< O
1 O
15 O
< O
1 O
Alkaline B-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
18 O
0 O
11 O
0 O
Hypokalemia B-OSE_Labeled_AE
15 O
1 O
5 O
< O
1 O
Table O
6 O
Post-Baseline O
Laboratory O
Abnormalities O
by O
CTCAE O
Grade O
in O
> O
= O
5 O
% O
of O
Patients O
and O
at O
Least O
2 O
% O
Greater O
in O
the O
GAZYVA O
Treated O
Arm O
( O
Stage O
2 O
) O
Investigations O
GAZYVA O
+ O
Chlorambuciln O
= O
336 O
Rituximab O
+ O
Chlorambuciln O
= O
321 O
All O
Grades O
% O
Grades O
3-4 O
% O
All O
Grades O
% O
Grades O
3-4 O
% O
Hematology B-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
76 O
46 O
69 O
41 O
Lymphopenia B-OSE_Labeled_AE
80 O
39 O
50 O
16 O
Leukopenia B-OSE_Labeled_AE
84 O
35 O
62 O
16 O
Thrombocytopenia B-OSE_Labeled_AE
48 O
13 O
40 O
8 O
Anemia B-OSE_Labeled_AE
39 O
10 O
37 O
10 O
Chemistry B-NonOSE_AE
Hypocalcemia B-OSE_Labeled_AE
37 O
3 O
32 O
< O
1 O
Hyperkalemia B-OSE_Labeled_AE
14 O
1 O
10 O
< O
1 O
Hyponatremia B-OSE_Labeled_AE
26 O
7 O
18 O
2 O
AST B-OSE_Labeled_AE
( I-OSE_Labeled_AE
SGOT I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
) O
27 O
2 O
21 O
< O
1 O
ALT B-OSE_Labeled_AE
( I-OSE_Labeled_AE
SGPT I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
) O
28 O
2 O
21 O
1 O
Hypoalbuminemia B-OSE_Labeled_AE
23 O
< O
1 O
16 O
< O
1 O
Infusion B-NonOSE_AE
Reactions I-NonOSE_AE
: O
The O
incidence O
of O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
was O
65 O
% O
with O
the O
first O
infusion O
of O
GAZYVA O
. O

The O
incidence O
of O
Grade O
3 O
or O
4 O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
was O
20 O
% O
with O
7 O
% O
of O
patients O
discontinuing O
therapy O
. O

The O
incidence O
of O
reactions O
with O
subsequent O
infusions O
was O
3 O
% O
with O
the O
second O
1000 O
mg O
and O
< O
1 O
% O
thereafter O
. O

No O
Grade O
3 O
or O
4 O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
were O
reported O
beyond O
the O
first O
1000 O
mg O
infused O
. O

Of O
the O
first O
53 O
patients O
receiving O
GAZYVA O
on O
the O
trial O
, O
47 O
( O
89 O
% O
) O
experienced O
an O
infusion B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
. O

After O
this O
experience O
, O
study O
protocol O
modifications O
were O
made O
to O
require O
pre-medication O
with O
a O
corticosteroid O
, O
antihistamine O
, O
and O
acetaminophen O
. O

The O
first O
dose O
was O
also O
divided O
into O
two O
infusions O
( O
100 O
mg O
on O
day O
1 O
and O
900 O
mg O
on O
day O
2 O
) O
. O

For O
the O
140 O
patients O
for O
whom O
these O
mitigation O
measures O
were O
implemented O
, O
74 O
patients O
( O
53 O
% O
) O
experienced O
a O
reaction O
with O
the O
first O
1000 O
mg O
( O
64 O
patients O
on O
day O
1 O
, O
3 O
patients O
on O
day O
2 O
, O
and O
7 O
patients O
on O
both O
days O
) O
and O
< O
3 O
% O
thereafter O
[ O
see O
Dosage O
and O
Administration O
( O
2 O
) O
] O
. O

Neutropenia B-NonOSE_AE
: O
The O
incidence O
of O
neutropenia B-OSE_Labeled_AE
reported O
as O
an O
adverse O
reaction O
was O
38 O
% O
in O
the O
GAZYVA O
treated O
arm O
and O
32 O
% O
in O
the O
rituximab O
treated O
arm O
, O
with O
the O
incidence O
of O
serious O
adverse O
events O
being O
1 O
% O
and O
< O
1 O
% O
, O
respectively O
( O
Table O
4 O
) O
. O

Cases O
of O
late B-OSE_Labeled_AE
- I-OSE_Labeled_AE
onset I-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
( O
occurring O
28 O
days O
after O
completion O
of O
treatment O
or O
later O
) O
were O
16 O
% O
in O
the O
GAZYVA O
treated O
arm O
and O
12 O
% O
in O
the O
rituximab O
treated O
arm O
. O

Infection B-NonOSE_AE
: O
The O
incidence O
of O
infections B-OSE_Labeled_AE
was O
similar O
between O
GAZYVA O
and O
rituximab O
treated O
arms O
. O

Thirty-eight O
percent O
of O
patients O
in O
the O
GAZYVA O
treated O
arm O
and O
37 O
% O
in O
the O
rituximab O
treated O
arm O
experienced O
an O
infection B-OSE_Labeled_AE
, O
with O
Grade O
3-4 O
rates O
being O
11 O
% O
and O
13 O
% O
, O
respectively O
. O

Fatal O
events O
were O
reported O
in O
1 O
% O
of O
patients O
in O
both O
arms O
. O

Thrombocytopenia B-NonOSE_AE
: O
The O
overall O
incidence O
of O
thrombocytopenia B-OSE_Labeled_AE
reported O
as O
an O
adverse O
reaction O
was O
higher O
in O
the O
GAZYVA O
treated O
arm O
( O
14 O
% O
) O
compared O
to O
the O
rituximab O
treated O
arm O
( O
7 O
% O
) O
, O
with O
the O
incidence O
of O
Grade O
3-4 O
events O
being O
10 O
% O
and O
3 O
% O
, O
respectively O
( O
Table O
4 O
) O
. O

The O
difference O
in O
incidences O
between O
the O
treatment O
arms O
is O
driven O
by O
events O
occurring O
during O
the O
first O
cycle O
. O

The O
incidence O
of O
thrombocytopenia B-OSE_Labeled_AE
( O
all O
grades O
) O
in O
the O
first O
cycle O
were O
11 O
% O
in O
the O
GAZYVA O
and O
3 O
% O
in O
the O
rituximab O
treated O
arms O
, O
with O
Grade O
3-4 O
rates O
being O
8 O
% O
and O
2 O
% O
, O
respectively O
. O

Four O
percent O
of O
patients O
in O
the O
GAZYVA O
treated O
arm O
experienced O
acute O
thrombocytopenia B-OSE_Labeled_AE
( O
occurring O
within O
24 O
hours O
after O
the O
GAZYVA O
infusion O
) O
. O

The O
overall O
incidence O
of O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
and O
the O
number O
of O
fatal O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
similar O
between O
the O
treatment O
arms O
, O
with O
3 O
in O
the O
rituximab O
and O
4 O
in O
the O
GAZYVA O
treated O
arms O
. O

However O
, O
all O
fatal O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
in O
patients O
treated O
with O
GAZYVA O
occurred O
in O
Cycle O
1 O
. O

Tumor B-NonOSE_AE
Lysis I-NonOSE_AE
Syndrome I-NonOSE_AE
: O
The O
incidence O
of O
Grade O
3 O
or O
4 O
tumor B-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
was O
2 O
% O
in O
the O
GAZYVA O
treated O
arm O
versus O
0 O
% O
in O
the O
rituximab O
treated O
arm O
. O

Musculoskeletal B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Adverse O
events O
related O
to O
musculoskeletal B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
( O
all O
events O
from O
the O
System O
Organ O
Class O
) O
, O
including O
pain B-OSE_Labeled_AE
, O
have O
been O
reported O
in O
the O
GAZYVA O
treated O
arm O
with O
higher O
incidence O
than O
in O
the O
rituximab O
treated O
arm O
( O
18 O
% O
vs O
. O
15 O
% O
) O
. O

Liver B-NonOSE_AE
Enzyme I-NonOSE_AE
Elevations I-NonOSE_AE
: O
Hepatic B-OSE_Labeled_AE
enzyme I-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
have O
occurred O
in O
patients O
who O
received O
GAZYVA O
in O
clinical O
trials O
and O
had O
normal O
baseline O
hepatic O
enzyme O
levels O
( O
AST O
, O
ALT O
, O
and O
ALP O
) O
. O

The O
events O
occurred O
most O
frequently O
within O
24-48 O
hours O
of O
the O
first O
infusion O
. O

In O
some O
patients O
, O
elevations B-OSE_Labeled_AE
in O
liver I-OSE_Labeled_AE
enzymes I-OSE_Labeled_AE
were O
observed O
concurrently O
with O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
or O
tumor B-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
. O

In O
the O
pivotal O
study O
, O
there O
was O
no O
clinically O
meaningful O
difference O
in O
overall O
hepatotoxicity B-OSE_Labeled_AE
adverse O
events O
between O
all O
arms O
( O
4 O
% O
of O
patients O
in O
the O
GAZYVA O
treated O
arm O
) O
. O

Medications O
commonly O
used O
to O
prevent O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
( O
e.g. O
, O
acetaminophen O
) O
may O
also O
be O
implicated O
in O
these O
events O
. O

Monitor O
liver O
function O
tests O
during O
treatment O
, O
especially O
during O
the O
first O
cycle O
. O

Consider O
treatment O
interruption O
or O
discontinuation O
for O
hepatotoxicity B-NonOSE_AE
. O

6.2 O
Immunogenicity O
Serum O
samples O
from O
patients O
with O
previously O
untreated O
CLL B-Not_AE_Candidate
were O
tested O
during O
and O
after O
treatment O
for O
antibodies B-NonOSE_AE
to I-NonOSE_AE
GAZYVA I-NonOSE_AE
. O

Of O
the O
GAZYVA O
treated O
patients O
, O
7 O
% O
( O
18/271 O
) O
tested O
positive B-OSE_Labeled_AE
for I-OSE_Labeled_AE
anti I-OSE_Labeled_AE
- I-OSE_Labeled_AE
GAZYVA I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
at O
one O
or O
more O
time O
points O
. O

Neutralizing B-NonOSE_AE
activity I-NonOSE_AE
of I-NonOSE_AE
anti I-NonOSE_AE
- I-NonOSE_AE
GAZYVA I-NonOSE_AE
antibodies I-NonOSE_AE
has O
not O
been O
assessed O
. O

Immunogenicity O
data O
are O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
test O
methods O
used O
. O

Additionally O
, O
the O
observed O
incidence O
of O
a O
positive O
result O
in O
a O
test O
method O
may O
be O
influenced O
by O
several O
factors O
, O
including O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
drug O
interference O
, O
concomitant O
medication O
, O
and O
the O
underlying O
disease O
. O

Therefore O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
GAZYVA I-NonOSE_AE
with O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
other I-NonOSE_AE
products I-NonOSE_AE
may O
be O
misleading O
. O

Clinical O
significance O
of O
anti B-NonOSE_AE
- I-NonOSE_AE
GAZYVA I-NonOSE_AE
antibodies I-NonOSE_AE
is O
not O
known O
. O

6.3 O
Additional O
Clinical O
Trial O
Experience O
Worsening B-NonOSE_AE
of I-NonOSE_AE
Pre I-NonOSE_AE
- I-NonOSE_AE
existing I-NonOSE_AE
Cardiac I-NonOSE_AE
Conditions I-NonOSE_AE
: O
Fatal B-NonOSE_AE
cardiac B-OSE_Labeled_AE
events I-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
treated O
with O
GAZYVA O
. O

BOXED O
WARNING O
: O
WARNING O
: O
HEPATITIS O
B O
VIRUS O
REACTIVATION O
and O
PROGRESSIVE O
MULTIFOCAL O
LEUKOENCEPHALOPATHY O
WARNING O
: O
HEPATITIS O
B O
VIRUS O
REACTIVATION O
and O
PROGRESSIVE O
MULTIFOCAL O
LEUKOENCEPHALOPATHY O
* O
Hepatitis B-OSE_Labeled_AE
B I-OSE_Labeled_AE
Virus I-OSE_Labeled_AE
( O
HBV O
) O
reactivation I-OSE_Labeled_AE
, O
in O
some O
cases O
resulting O
in O
fulminant B-NonOSE_AE
hepatitis I-NonOSE_AE
, O
hepatic B-NonOSE_AE
failure I-NonOSE_AE
, O
and O
death B-NonOSE_AE
, O
can O
occur O
in O
patients O
receiving O
CD20-directed O
cytolytic O
antibodies O
, O
including O
GAZYVA O
. O

Screen O
all O
patients O
for O
HBV B-Not_AE_Candidate
infection I-Not_AE_Candidate
before O
treatment O
initiation O
. O

Monitor O
HBV B-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
patients I-Not_AE_Candidate
during O
and O
after O
treatment O
with O
GAZYVA O
. O

Discontinue O
GAZYVA O
and O
concomitant O
medications O
in O
the O
event O
of O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
Progressive B-OSE_Labeled_AE
Multifocal I-OSE_Labeled_AE
Leukoencephalopathy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PML I-OSE_Labeled_AE
) O
including O
fatal O
PML B-OSE_Labeled_AE
, O
can O
occur O
in O
patients O
receiving O
GAZYVA O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
HEPATITIS O
B O
VIRUS O
REACTIVATION O
and O
PROGRESSIVE O
MULTIFOCAL O
LEUKOENCEPHALOPATHY O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Hepatitis O
B O
Virus O
( O
HBV O
) O
reactivation O
, O
in O
some O
cases O
resulting O
in O
fulminant O
hepatitis O
, O
hepatic O
failure O
, O
and O
death O
. O

( O
5.1 O
) O
* O
Progressive O
Multifocal O
Leukoencephalopathy O
( O
PML O
) O
resulting O
in O
death O
. O

( O
5.2 O
) O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Infusion O
reactions O
: O
Premedicate O
patients O
with O
glucocorticoid O
, O
acetaminophen O
, O
and O
anti-histamine O
. O

Monitor O
patients O
closely O
during O
infusions O
. O

Interrupt O
or O
discontinue O
infusion O
for O
reactions O
. O

( O
2.2 O
, O
5.3 O
) O
* O
Tumor O
Lysis O
Syndrome O
: O
Anticipate O
tumor O
lysis O
syndrome O
; O
premedicate O
with O
anti-hyperuricemics O
and O
adequate O
hydration O
especially O
for O
patients O
with O
high O
tumor O
burden O
and/or O
high O
circulating O
lymphocyte O
count O
. O

Correct O
electrolyte O
abnormalities O
, O
provide O
supportive O
care O
, O
and O
monitor O
renal O
function O
and O
fluid O
balance O
. O

( O
5.4 O
) O
* O
Neutropenia O
: O
Monitor O
for O
infection O
. O

( O
5.6 O
) O
* O
Thrombocytopenia O
: O
Monitor O
platelet O
counts O
and O
for O
bleeding O
. O

Management O
of O
hemorrhage O
may O
require O
blood O
product O
support O
. O

( O
5.7 O
) O
* O
Immunization O
: O
Do O
not O
administer O
live O
virus O
vaccines O
prior O
to O
or O
during O
GAZYVA O
treatment O
. O

( O
5.8 O
) O
5.1 O
Hepatitis O
B O
Virus O
Reactivation O
Hepatitis B-OSE_Labeled_AE
B I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HBV I-OSE_Labeled_AE
) I-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
, O
in O
some O
cases O
resulting O
in O
fulminant B-NonOSE_AE
hepatitis I-NonOSE_AE
, O
hepatic B-NonOSE_AE
failure I-NonOSE_AE
, O
and O
death B-NonOSE_AE
, O
can O
occur O
in O
patients O
treated O
with O
anti-CD20 O
antibodies O
such O
as O
GAZYVA O
. O

HBV B-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
has O
been O
reported O
in O
patients O
who O
are O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
surface I-Not_AE_Candidate
antigen I-Not_AE_Candidate
( I-Not_AE_Candidate
HBsAg I-Not_AE_Candidate
) I-Not_AE_Candidate
positive I-Not_AE_Candidate
and O
also O
in O
patients O
who O
are O
HBsAg O
negative O
but O
are O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
core I-Not_AE_Candidate
antibody I-Not_AE_Candidate
( I-Not_AE_Candidate
anti I-Not_AE_Candidate
- I-Not_AE_Candidate
HBc I-Not_AE_Candidate
) I-Not_AE_Candidate
positive I-Not_AE_Candidate
. O

Reactivation O
has O
also O
occurred O
in O
patients O
who O
appear O
to O
have O
resolved O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
infection I-Not_AE_Candidate
( O
i.e. O
, O
HBsAg B-Not_AE_Candidate
negative I-Not_AE_Candidate
, O
anti B-Not_AE_Candidate
- I-Not_AE_Candidate
HBc I-Not_AE_Candidate
positive I-Not_AE_Candidate
, O
and O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
surface I-Not_AE_Candidate
antibody I-Not_AE_Candidate
[ I-Not_AE_Candidate
anti I-Not_AE_Candidate
- I-Not_AE_Candidate
HBs I-Not_AE_Candidate
] I-Not_AE_Candidate
positive I-Not_AE_Candidate
) O
. O

HBV B-NonOSE_AE
reactivation I-NonOSE_AE
is O
defined O
as O
an O
abrupt O
increase O
in O
HBV O
replication O
manifesting O
as O
a O
rapid O
increase O
in O
serum O
HBV O
DNA O
level O
or O
detection O
of O
HBsAg O
in O
a O
person O
who O
was O
previously O
HBsAg B-Not_AE_Candidate
negative I-Not_AE_Candidate
and O
anti B-Not_AE_Candidate
- I-Not_AE_Candidate
HBc I-Not_AE_Candidate
positive I-Not_AE_Candidate
. O

Reactivation B-NonOSE_AE
of I-NonOSE_AE
HBV I-NonOSE_AE
replication I-NonOSE_AE
is O
often O
followed O
by O
hepatitis B-NonOSE_AE
, O
i.e. O
, O
increase B-NonOSE_AE
in I-NonOSE_AE
transaminase I-NonOSE_AE
levels I-NonOSE_AE
and O
, O
in O
severe O
cases O
, O
increase B-NonOSE_AE
in I-NonOSE_AE
bilirubin I-NonOSE_AE
levels O
, O
liver B-NonOSE_AE
failure I-NonOSE_AE
, O
and O
death B-NonOSE_AE
. O

Screen O
all O
patients O
for O
HBV B-Not_AE_Candidate
infection I-Not_AE_Candidate
by O
measuring O
HBsAg O
and O
anti-HBc O
before O
initiating O
treatment O
with O
GAZYVA O
. O

For O
patients O
who O
show O
evidence O
of O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
infection I-Not_AE_Candidate
( O
HBsAg B-Not_AE_Candidate
positive I-Not_AE_Candidate
[ O
regardless O
of O
antibody O
status O
] O
or O
HBsAg B-Not_AE_Candidate
negative I-Not_AE_Candidate
but O
anti B-Not_AE_Candidate
- I-Not_AE_Candidate
HBc I-Not_AE_Candidate
positive I-Not_AE_Candidate
) O
, O
consult O
physicians O
with O
expertise O
in O
managing O
hepatitis B-NonOSE_AE
B I-NonOSE_AE
regarding O
monitoring O
and O
consideration O
for O
HBV O
antiviral O
therapy O
. O

Monitor O
patients O
with O
evidence O
of O
current O
or O
prior O
HBV B-Not_AE_Candidate
infection I-Not_AE_Candidate
for O
clinical O
and O
laboratory O
signs O
of O
hepatitis B-NonOSE_AE
or O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
during O
and O
for O
several O
months O
following O
treatment O
with O
GAZYVA O
. O

HBV B-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
has O
been O
reported O
for O
other O
CD20-directed O
cytolytic O
antibodies O
following O
completion O
of O
therapy O
. O

In O
patients O
who O
develop O
reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
HBV I-OSE_Labeled_AE
while O
receiving O
GAZYVA O
, O
immediately O
discontinue O
GAZYVA O
and O
any O
concomitant O
chemotherapy O
and O
institute O
appropriate O
treatment O
. O

Resumption O
of O
GAZYVA O
in O
patients O
whose O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
resolves O
should O
be O
discussed O
with O
physicians O
with O
expertise O
in O
managing O
hepatitis B-NonOSE_AE
B I-NonOSE_AE
. O

Insufficient O
data O
exist O
regarding O
the O
safety O
of O
resuming O
GAZYVA O
in O
patients O
who O
develop O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
. O

5.2 O
Progressive O
Multifocal O
Leukoencephalopathy O
JC B-OSE_Labeled_AE
virus I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
resulting O
in O
progressive B-OSE_Labeled_AE
multifocal I-OSE_Labeled_AE
leukoencephalopathy I-OSE_Labeled_AE
( O
PML O
) O
, O
which O
can O
be O
fatal O
, O
was O
observed O
in O
patients O
treated O
with O
GAZYVA O
. O

Consider O
the O
diagnosis O
of O
PML B-NonOSE_AE
in O
any O
patient O
presenting O
with O
new O
onset O
or O
changes B-NonOSE_AE
to I-NonOSE_AE
preexisting I-NonOSE_AE
neurologic I-NonOSE_AE
manifestations I-NonOSE_AE
. O

Evaluation O
of O
PML B-NonOSE_AE
includes O
, O
but O
is O
not O
limited O
to O
, O
consultation O
with O
a O
neurologist O
, O
brain O
MRI O
, O
and O
lumbar O
puncture O
. O

Discontinue O
GAZYVA O
therapy O
and O
consider O
discontinuation O
or O
reduction O
of O
any O
concomitant O
chemotherapy O
or O
immunosuppressive O
therapy O
in O
patients O
who O
develop O
PML B-NonOSE_AE
. O

5.3 O
Infusion O
Reactions O
GAZYVA O
can O
cause O
severe O
and O
life-threatening O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

Two O
thirds O
of O
patients O
experienced O
a O
reaction O
to O
the O
first O
1000 O
mg O
infused O
of O
GAZYVA O
. O

Infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
can O
also O
occur O
with O
subsequent O
infusions O
. O

Symptoms O
may O
include O
hypotension B-NonOSE_AE
, O
tachycardia B-NonOSE_AE
, O
dyspnea B-NonOSE_AE
, O
and O
respiratory B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
bronchospasm B-NonOSE_AE
, O
larynx B-NonOSE_AE
and O
throat O
irritation I-NonOSE_AE
, O
wheezing B-NonOSE_AE
, O
laryngeal B-NonOSE_AE
edema I-NonOSE_AE
) O
. O

Other O
common O
symptoms O
include O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
, O
hypertension B-NonOSE_AE
, O
flushing B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
pyrexia B-NonOSE_AE
, O
and O
chills B-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Premedicate O
patients O
with O
acetaminophen O
, O
antihistamine O
, O
and O
a O
glucocorticoid O
. O

Institute O
medical O
management O
( O
e.g. O
, O
glucocorticoids O
, O
epinephrine O
, O
bronchodilators O
, O
and/or O
oxygen O
) O
for O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
as O
needed O
. O

Closely O
monitor O
patients O
during O
the O
entire O
infusion O
. O

Infusion B-NonOSE_AE
reactions I-NonOSE_AE
within O
24 O
hours O
of O
receiving O
GAZYVA O
have O
occurred O
[ O
see O
Dosage O
and O
Administration O
( O
2 O
) O
] O
. O

For O
patients O
with O
any O
Grade O
4 O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
, O
including O
but O
not O
limited O
to O
anaphylaxis B-NonOSE_AE
, O
acute O
life B-NonOSE_AE
- I-NonOSE_AE
threatening I-NonOSE_AE
respiratory I-NonOSE_AE
symptoms I-NonOSE_AE
, O
or O
other O
life-threatening O
infusion B-NonOSE_AE
reaction I-NonOSE_AE
: O
Stop O
the O
GAZYVA O
infusion O
. O

Permanently O
discontinue O
GAZYVA O
therapy O
. O

For O
patients O
with O
Grade O
1 O
, O
2 O
, O
or O
3 O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
: O
Interrupt O
GAZYVA O
for O
Grade O
3 O
reactions O
until O
resolution O
of O
symptoms O
. O

Interrupt O
or O
reduce O
the O
rate O
of O
the O
infusion O
for O
Grade O
1 O
or O
2 O
reactions O
and O
manage O
symptoms O
[ O
see O
Dosage O
and O
Administration O
( O
2 O
) O
] O
. O

For O
patients O
with O
preexisting O
cardiac B-Not_AE_Candidate
or O
pulmonary B-Not_AE_Candidate
conditions I-Not_AE_Candidate
, O
monitor O
more O
frequently O
throughout O
the O
infusion O
and O
the O
post-infusion O
period O
since O
they O
may O
be O
at O
greater O
risk O
of O
experiencing O
more O
severe O
reactions O
. O

Hypotension B-NonOSE_AE
may O
occur O
as O
part O
of O
the O
GAZYVA O
infusion B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
. O

Consider O
withholding O
antihypertensive O
treatments O
for O
12 O
hours O
prior O
to O
, O
during O
each O
GAZYVA O
infusion O
, O
and O
for O
the O
first O
hour O
after O
administration O
until O
blood O
pressure O
is O
stable O
. O

For O
patients O
at O
increased O
risk O
of O
hypertensive B-Not_AE_Candidate
crisis I-Not_AE_Candidate
, O
consider O
the O
benefits O
versus O
the O
risks O
of O
withholding O
their O
antihypertensive O
medication O
as O
is O
suggested O
here O
. O

5.4 O
Tumor O
Lysis O
Syndrome O
Acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
, O
hyperkalemia B-NonOSE_AE
, O
hypocalcemia B-NonOSE_AE
, O
hyperuricemia B-NonOSE_AE
, O
and/or O
hyperphosphatemia B-NonOSE_AE
from O
Tumor B-OSE_Labeled_AE
Lysis I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( O
TLS O
) O
can O
occur O
within O
12-24 O
hours O
after O
the O
first O
infusion O
. O

Patients O
with O
high B-Not_AE_Candidate
tumor I-Not_AE_Candidate
burden I-Not_AE_Candidate
and/or O
high B-Not_AE_Candidate
circulating O
lymphocyte I-Not_AE_Candidate
count I-Not_AE_Candidate
( O
> O
25 O
* O
10 O
9 O
/L O
) O
are O
at O
greater O
risk O
for O
TLS B-NonOSE_AE
and O
should O
receive O
appropriate O
tumor O
lysis O
prophylaxis O
with O
anti-hyperuricemics O
( O
e.g. O
, O
allopurinol O
) O
and O
hydration O
beginning O
12-24 O
hours O
prior O
to O
the O
infusion O
of O
GAZYVA O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

For O
treatment O
of O
TLS B-NonOSE_AE
, O
correct O
electrolyte B-NonOSE_AE
abnormalities I-NonOSE_AE
, O
monitor O
renal O
function O
and O
fluid O
balance O
, O
and O
administer O
supportive O
care O
, O
including O
dialysis O
as O
indicated O
. O

5.5 O
Infections O
Serious O
bacterial B-OSE_Labeled_AE
, O
fungal O
, O
and O
new O
or O
reactivated O
viral O
infections I-OSE_Labeled_AE
can O
occur O
during O
and O
following O
GAZYVA O
therapy O
. O

Fatal O
infections B-OSE_Labeled_AE
have O
been O
reported O
with O
GAZYVA O
. O

Do O
not O
administer O
GAZYVA O
to O
patients O
with O
an O
active B-Not_AE_Candidate
infection I-Not_AE_Candidate
. O

Patients O
with O
a O
history O
of O
recurring O
or O
chronic B-Not_AE_Candidate
infections I-Not_AE_Candidate
may O
be O
at O
increased O
risk O
of O
infection B-NonOSE_AE
. O

5.6 O
Neutropenia O
GAZYVA O
in O
combination O
with O
chlorambucil O
caused O
Grade O
3 O
or O
4 O
neutropenia B-OSE_Labeled_AE
in O
33 O
% O
of O
patients O
in O
the O
trial O
. O

Patients O
with O
Grade O
3 O
to O
4 O
neutropenia B-NonOSE_AE
should O
be O
monitored O
frequently O
with O
regular O
laboratory O
tests O
until O
resolution O
. O

Anticipate O
, O
evaluate O
, O
and O
treat O
any O
symptoms O
or O
signs O
of O
developing O
infection B-NonOSE_AE
. O

Neutropenia B-OSE_Labeled_AE
can O
also O
be O
of O
late O
onset O
( O
occurring O
more O
than O
28 O
days O
after O
completion O
of O
treatment O
) O
and/or O
prolonged O
( O
lasting O
longer O
than O
28 O
days O
) O
. O

Patients O
with O
neutropenia B-NonOSE_AE
are O
strongly O
recommended O
to O
receive O
antimicrobial O
prophylaxis O
throughout O
the O
treatment O
period O
. O

Antiviral O
and O
antifungal O
prophylaxis O
should O
be O
considered O
. O

5.7 O
Thrombocytopenia O
GAZYVA O
in O
combination O
with O
chlorambucil O
caused O
Grade O
3 O
or O
4 O
thrombocytopenia B-OSE_Labeled_AE
in O
10 O
% O
of O
patients O
in O
the O
trial O
. O

In O
4 O
% O
of O
patients O
, O
GAZYVA O
caused O
acute O
thrombocytopenia B-OSE_Labeled_AE
occurring O
within O
24 O
hours O
after O
the O
GAZYVA O
infusion O
. O

Fatal O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
during O
Cycle O
1 O
have O
also O
been O
reported O
in O
patients O
treated O
with O
GAZYVA O
. O

Monitor O
all O
patients O
frequently O
for O
thrombocytopenia B-NonOSE_AE
and O
hemorrhagic B-NonOSE_AE
events I-NonOSE_AE
, O
especially O
during O
the O
first O
cycle O
. O

In O
patients O
with O
Grade O
3 O
or O
4 O
thrombocytopenia B-NonOSE_AE
, O
monitor O
platelet O
counts O
more O
frequently O
until O
resolution O
and O
consider O
subsequent O
dose O
delays O
of O
GAZYVA O
and O
chlorambucil O
or O
dose O
reductions O
of O
chlorambucil O
. O

Transfusion O
of O
blood O
products O
( O
i.e. O
, O
platelet O
transfusion O
) O
may O
be O
necessary O
. O

Consider O
withholding O
concomitant O
medications O
which O
may O
increase B-NonOSE_AE
bleeding I-NonOSE_AE
risk I-NonOSE_AE
( O
platelet O
inhibitors O
, O
anticoagulants O
) O
, O
especially O
during O
the O
first O
cycle O
. O

5.8 O
Immunization O
The O
safety O
and O
efficacy O
of O
immunization O
with O
live O
or O
attenuated O
viral O
vaccines O
during O
or O
following O
GAZYVA O
therapy O
has O
not O
been O
studied O
. O

Immunization O
with O
live O
virus O
vaccines O
is O
not O
recommended O
during O
treatment O
and O
until O
B-cell O
recovery O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
important O
adverse O
reactions O
are O
also O
described O
elsewhere O
in O
the O
labeling O
: O
* O
Increased O
mortality O
in O
patients O
with O
acute O
critical O
illness O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Fatalities O
in O
children O
with O
Prader B-Not_AE_Candidate
- I-Not_AE_Candidate
Willi I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Neoplasms B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Glucose B-OSE_Labeled_AE
intolerance I-OSE_Labeled_AE
and O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Intracranial B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Severe O
hypersensitivity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Fluid B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Hypoadrenalism B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Hypothyroidism B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Slipped B-OSE_Labeled_AE
capital I-OSE_Labeled_AE
femoral I-OSE_Labeled_AE
epiphysis I-OSE_Labeled_AE
in O
pediatric O
patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
* O
Progression B-OSE_Labeled_AE
of I-OSE_Labeled_AE
preexisting I-OSE_Labeled_AE
scoliosis I-OSE_Labeled_AE
in O
pediatric O
patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
* O
Otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
and O
cardiovascular B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
in O
patients O
with O
Turner B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.12 O
) O
] O
* O
Lipoatrophy B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.13 O
) O
] O
* O
Pancreatitis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.15 O
) O
] O
EXCERPT O
: O
Other O
common O
somatropin-related O
adverse O
reactions O
include O
injection O
site O
reactions/rashes O
and O
lipoatrophy O
( O
6.1 O
) O
and O
headaches O
( O
6.3 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Pfizer O
Inc O
. O
at O
1-800-438-1985 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
during O
the O
clinical O
trials O
performed O
with O
one O
somatropin O
formulation O
can O
not O
always O
be O
directly O
compared O
to O
the O
rates O
observed O
during O
the O
clinical O
trials O
performed O
with O
a O
second O
somatropin O
formulation O
, O
and O
may O
not O
reflect O
the O
adverse O
reaction O
rates O
observed O
in O
practice O
. O

Clinical O
Trials O
in O
children O
with O
GHD O
In O
clinical O
studies O
with O
GENOTROPIN O
in O
pediatric O
GHD B-Not_AE_Candidate
patients O
, O
the O
following O
events O
were O
reported O
infrequently O
: O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
pain B-OSE_Labeled_AE
or O
burning O
associated O
with I-OSE_Labeled_AE
the I-OSE_Labeled_AE
injection I-OSE_Labeled_AE
, O
fibrosis O
, O
nodules O
, O
rash O
, O
inflammation O
, O
pigmentation O
, O
or O
bleeding O
; O
lipoatrophy B-OSE_Labeled_AE
; O
headache B-OSE_Labeled_AE
; O
hematuria B-OSE_Labeled_AE
; O
hypothyroidism B-OSE_Labeled_AE
; O
and O
mild O
hyperglycemia B-OSE_Labeled_AE
. O

Clinical O
Trials O
in O
PWS O
In O
two O
clinical O
studies O
with O
GENOTROPIN O
in O
pediatric O
patients O
with O
Prader B-Not_AE_Candidate
- I-Not_AE_Candidate
Willi I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
, O
the O
following O
drug-related O
events O
were O
reported O
: O
edema B-OSE_Labeled_AE
, O
aggressiveness B-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
, O
benign B-OSE_Labeled_AE
intracranial I-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
, O
hair B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
and O
myalgia B-OSE_Labeled_AE
. O

Clinical O
Trials O
in O
children O
with O
SGA O
In O
clinical O
studies O
of O
273 O
pediatric O
patients O
born O
small B-Not_AE_Candidate
for I-Not_AE_Candidate
gestational I-Not_AE_Candidate
age I-Not_AE_Candidate
treated O
with O
GENOTROPIN O
, O
the O
following O
clinically O
significant O
events O
were O
reported O
: O
mild O
transient O
hyperglycemia B-OSE_Labeled_AE
, O
one O
patient O
with O
benign B-OSE_Labeled_AE
intracranial I-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
, O
two O
patients O
with O
central B-OSE_Labeled_AE
precocious I-OSE_Labeled_AE
puberty I-OSE_Labeled_AE
, O
two O
patients O
with O
jaw B-OSE_Labeled_AE
prominence I-OSE_Labeled_AE
, O
and O
several O
patients O
with O
aggravation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
preexisting I-OSE_Labeled_AE
scoliosis I-OSE_Labeled_AE
, O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
and O
self-limited O
progression B-OSE_Labeled_AE
of I-OSE_Labeled_AE
pigmented I-OSE_Labeled_AE
nevi I-OSE_Labeled_AE
. O

Anti B-NonOSE_AE
- I-NonOSE_AE
hGH I-NonOSE_AE
antibodies I-NonOSE_AE
were O
not O
detected O
in O
any O
of O
the O
patients O
treated O
with O
GENOTROPIN O
. O

Clinical O
Trials O
in O
children O
with O
Turner O
Syndrome O
In O
two O
clinical O
studies O
with O
GENOTROPIN O
in O
pediatric O
patients O
with O
Turner B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
, O
the O
most O
frequently O
reported O
adverse O
events O
were O
respiratory B-OSE_Labeled_AE
illnesses I-OSE_Labeled_AE
( O
influenza B-OSE_Labeled_AE
, O
tonsillitis B-OSE_Labeled_AE
, O
otitis B-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
) O
, O
joint B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
and O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
. O

The O
only O
treatment-related O
adverse O
event O
that O
occurred O
in O
more O
than O
1 O
patient O
was O
joint B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
. O

Clinical O
Trials O
in O
children O
with O
Idiopathic O
Short O
Stature O
In O
two O
open-label O
clinical O
studies O
with O
GENOTROPIN O
in O
pediatric O
patients O
with O
ISS B-Not_AE_Candidate
, O
the O
most O
commonly O
encountered O
adverse O
events O
include O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
influenza B-OSE_Labeled_AE
, O
tonsillitis B-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
headaches B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
, O
fracture B-OSE_Labeled_AE
, O
altered B-OSE_Labeled_AE
mood I-OSE_Labeled_AE
, O
and O
arthralgia B-OSE_Labeled_AE
. O

In O
one O
of O
the O
two O
studies O
, O
during O
GENOTROPIN O
treatment O
, O
the O
mean O
IGF-1 O
standard O
deviation O
( O
SD O
) O
scores O
were O
maintained O
in O
the O
normal O
range O
. O

IGF-1 O
SD O
scores O
above O
+2 O
SD O
were O
observed O
as O
follows O
: O
1 O
subject O
( O
3 O
% O
) O
, O
10 O
subjects O
( O
30 O
% O
) O
and O
16 O
subjects O
( O
38 O
% O
) O
in O
the O
untreated O
control O
, O
0 O
. O

23 O
and O
the O
0.47 O
mg/kg/week O
groups O
, O
respectively O
, O
had O
at O
least O
one O
measurement O
; O
while O
0 O
subjects O
( O
0 O
% O
) O
, O
2 O
subjects O
( O
7 O
% O
) O
and O
6 O
subjects O
( O
14 O
% O
) O
had O
two O
or O
more O
consecutive O
IGF-1 O
measurements O
above O
+2 O
SD O
. O

Clinical O
Trials O
in O
adults O
with O
GHD O
In O
clinical O
trials O
with O
GENOTROPIN O
in O
1,145 O
GHD B-Not_AE_Candidate
adults O
, O
the O
majority O
of O
the O
adverse O
events O
consisted O
of O
mild O
to O
moderate O
symptoms O
of O
fluid B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
, O
including O
peripheral B-NonOSE_AE
swelling I-NonOSE_AE
, O
arthralgia B-NonOSE_AE
, O
pain B-NonOSE_AE
and O
stiffness B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
extremities I-NonOSE_AE
, O
peripheral B-NonOSE_AE
edema I-NonOSE_AE
, O
myalgia B-NonOSE_AE
, O
paresthesia B-NonOSE_AE
, O
and O
hypoesthesia B-NonOSE_AE
. O

These O
events O
were O
reported O
early O
during O
therapy O
, O
and O
tended O
to O
be O
transient O
and/or O
responsive O
to O
dosage O
reduction O
. O

Table O
1 O
displays O
the O
adverse O
events O
reported O
by O
5 O
% O
or O
more O
of O
adult O
GHD B-Not_AE_Candidate
patients O
in O
clinical O
trials O
after O
various O
durations O
of O
treatment O
with O
GENOTROPIN O
. O

Also O
presented O
are O
the O
corresponding O
incidence O
rates O
of O
these O
adverse O
events O
in O
placebo O
patients O
during O
the O
6-month O
double-blind O
portion O
of O
the O
clinical O
trials O
. O

Table O
1 O
Adverse O
Events O
Reported O
by O
> O
= O
5 O
% O
of O
1,145 O
Adult O
GHD O
Patients O
During O
Clinical O
Trials O
of O
GENOTROPIN O
and O
Placebo O
, O
Grouped O
by O
Duration O
of O
Treatment O
Double O
Blind O
Phase O
Open O
Label O
PhaseGENOTROPIN O
Adverse O
Event O
Placebo0-6 O
mo.n O
= O
572 O
% O
Patients O
GENOTROPIN0-6 O
mo.n O
= O
573 O
% O
Patients O
6-12 O
mo.n O
= O
504 O
% O
Patients O
12-18 O
mo.n O
= O
63 O
% O
Patients O
18-24 O
mo.n O
= O
60 O
% O
Patients O
n O
= O
number O
of O
patients O
receiving O
treatment O
during O
the O
indicated O
period. O
% O
= O
percentage O
of O
patients O
who O
reported O
the O
event O
during O
the O
indicated O
period O
. O

Swelling B-OSE_Labeled_AE
, I-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
5.1 O
17.5 O
[ O
note O
: O
Increased O
significantly O
when O
compared O
to O
placebo O
, O
P O
< O
=.025 O
: O
Fisher O
's O
Exact O
Test O
( O
one-sided O
) O
] O
5.6 O
0 O
1.7 O
Arthralgia B-OSE_Labeled_AE
4.2 O
17.3 O
6.9 O
6.3 O
3.3 O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
14.5 O
15.5 O
13.1 O
15.9 O
13.3 O
Pain B-OSE_Labeled_AE
, I-OSE_Labeled_AE
extremities I-OSE_Labeled_AE
5.9 O
14.7 O
6.7 O
1.6 O
3.3 O
Edema B-OSE_Labeled_AE
, I-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
2.6 O
10.8 O
3.0 O
0 O
0 O
Paresthesia B-OSE_Labeled_AE
1.9 O
9.6 O
2.2 O
3.2 O
0 O
Headache B-OSE_Labeled_AE
7.7 O
9.9 O
6.2 O
0 O
0 O
Stiffness B-OSE_Labeled_AE
of I-OSE_Labeled_AE
extremities I-OSE_Labeled_AE
1.6 O
7.9 O
2.4 O
1.6 O
0 O
Fatigue B-OSE_Labeled_AE
3.8 O
5.8 O
4.6 O
6.3 O
1.7 O
Myalgia B-OSE_Labeled_AE
1.6 O
4.9 O
2.0 O
4.8 O
6.7 O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
4.4 O
2.8 O
3.4 O
4.8 O
5.0 O
Post-Trial O
Extension O
Studies O
in O
Adults O
In O
expanded O
post-trial O
extension O
studies O
, O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
developed O
in O
12 O
of O
3,031 O
patients O
( O
0.4 O
% O
) O
during O
treatment O
with O
GENOTROPIN O
. O

All O
12 O
patients O
had O
predisposing O
factors O
, O
e.g. O
, O
elevated B-Not_AE_Candidate
glycated I-Not_AE_Candidate
hemoglobin I-Not_AE_Candidate
levels I-Not_AE_Candidate
and/or O
marked O
obesity B-Not_AE_Candidate
, O
prior O
to O
receiving O
GENOTROPIN O
. O

Of O
the O
3,031 O
patients O
receiving O
GENOTROPIN O
, O
61 O
( O
2 O
% O
) O
developed O
symptoms O
of O
carpal B-OSE_Labeled_AE
tunnel I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
which O
lessened O
after O
dosage O
reduction O
or O
treatment O
interruption O
( O
52 O
) O
or O
surgery O
( O
9 O
) O
. O

Other O
adverse O
events O
that O
have O
been O
reported O
include O
generalized B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
and O
hypoesthesia B-OSE_Labeled_AE
. O

Anti-hGH O
Antibodies O
As O
with O
all O
therapeutic O
proteins O
, O
there O
is O
potential O
for O
immunogenicity B-NonOSE_AE
. O

The O
detection O
of O
antibody B-NonOSE_AE
formation I-NonOSE_AE
is O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
. O

Additionally O
, O
the O
observed O
incidence O
of O
antibody B-NonOSE_AE
( O
including O
neutralizing O
a O
ntibody B-NonOSE_AE
) I-NonOSE_AE
positivity I-NonOSE_AE
  I-NonOSE_AE
I-NonOSE_AE O
in O
an O
assay O
may O
be O
influenced O
by O
several O
factors O
including O
assay O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
GENOTROPIN I-NonOSE_AE
with O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
other I-NonOSE_AE
products I-NonOSE_AE
may O
be O
misleading O
. O

In O
the O
case O
of O
growth O
hormone O
, O
antibodies B-NonOSE_AE
with O
binding O
capacities O
lower O
than O
2 O
mg/mL O
have O
not O
been O
associated O
with O
growth B-NonOSE_AE
attenuation I-NonOSE_AE
. O

In O
a O
very O
small O
number O
of O
patients O
treated O
with O
somatropin O
, O
when O
binding O
capacity O
was O
greater O
than O
2 O
mg/mL O
, O
interference B-NonOSE_AE
with I-NonOSE_AE
the I-NonOSE_AE
growth I-NonOSE_AE
response I-NonOSE_AE
was O
observed O
. O

In O
419 O
pediatric O
patients O
evaluated O
in O
clinical O
studies O
with O
GENOTROPIN O
lyophilized O
powder O
, O
244 O
had O
been O
treated O
previously O
with O
GENOTROPIN O
or O
other O
growth O
hormone O
preparations O
and O
175 O
had O
received O
no O
previous O
growth O
hormone O
therapy O
. O

Antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
growth I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
( O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
hGH I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
) O
were O
present O
in O
six O
previously O
treated O
patients O
at O
baseline O
. O

Three O
of O
the O
six O
became O
negative B-OSE_Labeled_AE
for I-OSE_Labeled_AE
anti I-OSE_Labeled_AE
- I-OSE_Labeled_AE
hGH I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
during O
6 O
to O
12 O
months O
of O
treatment O
with O
GENOTROPIN O
. O

Of O
the O
remaining O
413 O
patients O
, O
eight O
( O
1.9 O
% O
) O
developed O
detectable O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
hGH I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
during O
treatment O
with O
GENOTROPIN O
; O
none O
had O
an O
antibody B-NonOSE_AE
binding O
capacity O
> O
2 O
mg/L O
. O

There O
was O
no O
evidence O
that O
the O
growth O
response O
to O
GENOTROPIN O
was O
affected O
in O
these O
antibody B-NonOSE_AE
- I-NonOSE_AE
positive I-NonOSE_AE
patients O
. O

Periplasmic O
Escherichia O
coli O
Peptides O
Preparations O
of O
GENOTROPIN O
contain O
a O
small O
amount O
of O
periplasmic O
Escherichia O
coli O
peptides O
( O
PECP O
) O
. O

Anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
PECP I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
are O
found O
in O
a O
small O
number O
of O
patients O
treated O
with O
GENOTROPIN O
, O
but O
these O
appear O
to O
be O
of O
no O
clinical O
significance O
. O

6.2 O
Post-Marketing O
Experience O
Because O
these O
adverse O
events O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Serious O
systemic B-OSE_Labeled_AE
hypersensitivity I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
anaphylactic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
and O
angioedema B-OSE_Labeled_AE
have O
been O
reported O
with O
post-marketing O
use O
of O
somatropin O
products O
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
. O

Leukemia B-NonOSE_AE
has O
been O
reported O
in O
a O
small O
number O
of O
GHD B-Not_AE_Candidate
children O
treated O
with O
somatropin O
, O
somatrem O
( O
methionylated O
rhGH O
) O
and O
GH O
of O
pituitary O
origin O
. O

It O
is O
uncertain O
whether O
these O
cases O
of O
leukemia B-NonOSE_AE
are O
related O
to O
GH O
therapy O
, O
the O
pathology O
of O
GHD B-Not_AE_Candidate
itself O
, O
or O
other O
associated O
treatments O
such O
as O
radiation O
therapy O
. O

On O
the O
basis O
of O
current O
evidence O
, O
experts O
have O
not O
been O
able O
to O
conclude O
that O
GH O
therapy O
per O
se O
was O
responsible O
for O
these O
cases O
of O
leukemia B-NonOSE_AE
. O

The O
risk O
for O
children O
with O
GHD B-Not_AE_Candidate
, O
if O
any O
, O
remains O
to O
be O
established O
[ O
see O
Contraindications O
( O
4 O
) O
and O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

The O
following O
serious O
adverse O
reactions O
have O
been O
observed O
with O
use O
of O
somatropin O
( O
including O
events O
observed O
in O
patients O
who O
received O
brands O
of O
somatropin O
other O
than O
GENOTROPIN O
) O
: O
acute B-OSE_Labeled_AE
critical I-OSE_Labeled_AE
illness I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
, O
sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
, O
intracranial B-OSE_Labeled_AE
tumors I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
, O
central B-OSE_Labeled_AE
hypothyroidism I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
, O
cardiovascular B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
and O
pancreatitis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.15 O
) O
] O
. O

Slipped B-OSE_Labeled_AE
capital I-OSE_Labeled_AE
femoral I-OSE_Labeled_AE
epiphysis I-OSE_Labeled_AE
and O
Legg B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Calve I-OSE_Labeled_AE
- I-OSE_Labeled_AE
Perthes I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
( O
osteonecrosis B-OSE_Labeled_AE
/ O
avascular B-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
; O
occasionally O
associated O
with O
slipped B-OSE_Labeled_AE
capital I-OSE_Labeled_AE
femoral I-OSE_Labeled_AE
epiphysis I-OSE_Labeled_AE
) O
have O
been O
reported O
in O
children O
treated O
with O
growth O
hormone O
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
. O

Cases O
have O
been O
reported O
with O
GENOTROPIN O
. O

The O
following O
additional O
adverse O
reactions O
have O
been O
observed O
during O
the O
appropriate O
use O
of O
somatropin O
: O
headaches B-OSE_Labeled_AE
( O
children O
and O
adults O
) O
, O
gynecomastia B-OSE_Labeled_AE
( O
children O
) O
, O
and O
significant B-OSE_Labeled_AE
diabetic I-OSE_Labeled_AE
retinopathy I-OSE_Labeled_AE
. O

New-onset O
type B-OSE_Labeled_AE
2 I-OSE_Labeled_AE
diabetes I-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
has O
been O
reported O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Acute O
Critical O
Illness O
: O
Potential O
benefit O
of O
treatment O
continuation O
should O
be O
weighed O
against O
the O
potential O
risk O
( O
5.1 O
) O
* O
Prader-Willi O
syndrome O
in O
Children O
: O
Evaluate O
for O
signs O
of O
upper O
airway O
obstruction O
and O
sleep O
apnea O
before O
initiation O
of O
treatmentDiscontinue O
treatment O
if O
these O
signs O
occur O
( O
5.2 O
) O
* O
Neoplasm O
: O
Monitor O
patients O
with O
preexisting O
tumors O
for O
progression O
or O
recurrence O
. O

Increased O
risk O
of O
a O
second O
neoplasm O
in O
childhood O
cancer O
survivors O
treated O
with O
somatropin O
in O
particular O
meningiomas O
in O
patients O
treated O
with O
radiation O
to O
the O
head O
for O
their O
first O
neoplasm O
( O
5.3 O
) O
* O
Impaired O
Glucose O
Tolerance O
and O
Diabetes O
Mellitus O
: O
May O
be O
unmaskedPeriodically O
monitor O
glucose O
levels O
in O
all O
patients O
. O

Doses O
of O
concurrent O
antihyperglycemic O
drugs O
in O
diabetics O
may O
require O
adjustment O
( O
5.4 O
) O
* O
Intracranial O
Hypertension O
: O
Exclude O
preexisting O
papilledema O
. O

May O
develop O
and O
is O
usually O
reversible O
after O
discontinuation O
or O
dose O
reduction O
( O
5.5 O
) O
* O
Hypersensitivity O
: O
Serious O
hypersensitivity O
reactions O
may O
occur O
. O

In O
the O
event O
of O
an O
allergic O
reaction O
, O
seek O
prompt O
medical O
attention O
( O
5.6 O
) O
* O
Fluid O
Retention O
( O
i.e. O
, O
edema O
, O
arthralgia O
, O
carpal O
tunnel O
syndrome O
- O
especially O
in O
adults O
) O
: O
May O
occur O
frequently O
. O

Reduce O
dose O
as O
necessary O
( O
5.7 O
) O
* O
Hypoadrenalism O
: O
Monitor O
patients O
for O
reduced O
serum O
cortisol O
levels O
and/or O
need O
for O
glucocorticoid O
dose O
increases O
in O
those O
with O
known O
hypoadrenalism O
( O
5.8 O
) O
* O
Hypothyroidism O
: O
May O
first O
become O
evident O
or O
worsen O
. O

Monitor O
thyroid O
function O
periodically O
( O
5.9 O
) O
* O
Slipped O
Capital O
Femoral O
Epiphysis O
: O
May O
develop O
. O

Evaluate O
children O
with O
the O
onset O
of O
a O
limp O
or O
hip/knee O
pain O
( O
5.10 O
) O
* O
Progression O
of O
Preexisting O
Scoliosis O
: O
Monitor O
any O
child O
with O
scoliosis O
for O
progression O
of O
the O
curve O
( O
5.11 O
) O
* O
Pancreatitis O
: O
Consider O
pancreatitis O
in O
patients O
with O
persistent O
severe O
abdominal O
pain O
( O
5.15 O
) O
5.1 O
Acute O
Critical O
Illness O
Increased O
mortality B-NonOSE_AE
in O
patients O
with O
acute B-Not_AE_Candidate
critical I-Not_AE_Candidate
illness I-Not_AE_Candidate
due O
to O
complications O
following O
open O
heart O
surgery O
, O
abdominal O
surgery O
or O
multiple O
accidental O
trauma O
, O
or O
those O
with O
acute B-Not_AE_Candidate
respiratory I-Not_AE_Candidate
failure I-Not_AE_Candidate
has O
been O
reported O
after O
treatment O
with O
pharmacologic O
amounts O
of O
somatropin O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

Two O
placebo-controlled O
clinical O
trials O
in O
non B-Not_AE_Candidate
- I-Not_AE_Candidate
growth I-Not_AE_Candidate
hormone I-Not_AE_Candidate
deficient I-Not_AE_Candidate
adult O
patients O
( O
n=522 O
) O
with O
these O
conditions O
in O
intensive O
care O
units O
revealed O
a O
significant O
increase O
in O
mortality B-NonOSE_AE
( O
42 O
% O
vs O
. O
19 O
% O
) O
among O
somatropin-treated O
patients O
( O
doses O
5.3-8 O
mg/day O
) O
compared O
to O
those O
receiving O
placebo O
. O

The O
safety O
of O
continuing O
somatropin O
treatment O
in O
patients O
receiving O
replacement O
doses O
for O
approved O
indications O
who O
concurrently O
develop O
these O
illnesses O
has O
not O
been O
established O
. O

Therefore O
, O
the O
potential O
benefit O
of O
treatment O
continuation O
with O
somatropin O
in O
patients O
having O
acute B-Not_AE_Candidate
critical I-Not_AE_Candidate
illnesses I-Not_AE_Candidate
should O
be O
weighed O
against O
the O
potential O
risk O
. O

5.2 O
Prader-Willi O
Syndrome O
in O
Children O
There O
have O
been O
reports O
of O
fatalities B-NonOSE_AE
after O
initiating O
therapy O
with O
somatropin O
in O
pediatric O
patients O
with O
Prader B-Not_AE_Candidate
- I-Not_AE_Candidate
Willi I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
who O
had O
one O
or O
more O
of O
the O
following O
risk O
factors O
: O
severe B-Not_AE_Candidate
obesity I-Not_AE_Candidate
, O
history O
of O
upper B-Not_AE_Candidate
airway I-Not_AE_Candidate
obstruction I-Not_AE_Candidate
or O
sleep B-Not_AE_Candidate
apnea I-Not_AE_Candidate
, O
or O
unidentified O
respiratory B-Not_AE_Candidate
infection I-Not_AE_Candidate
. O

Male O
patients O
with O
one O
or O
more O
of O
these O
factors O
may O
be O
at O
greater O
risk O
than O
females O
. O

Patients O
with O
Prader B-Not_AE_Candidate
- I-Not_AE_Candidate
Willi I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
should O
be O
evaluated O
for O
signs O
of O
upper B-NonOSE_AE
airway I-NonOSE_AE
obstruction I-NonOSE_AE
and O
sleep B-NonOSE_AE
apnea I-NonOSE_AE
before O
initiation O
of O
treatment O
with O
somatropin O
. O

If O
during O
treatment O
with O
somatropin O
, O
patients O
show O
signs O
of O
upper B-NonOSE_AE
airway I-NonOSE_AE
obstruction I-NonOSE_AE
( O
including O
onset O
of O
or O
increased B-NonOSE_AE
snoring I-NonOSE_AE
) O
and/or O
new O
onset O
sleep B-NonOSE_AE
apnea I-NonOSE_AE
, O
treatment O
should O
be O
interrupted O
. O

All O
patients O
with O
Prader B-Not_AE_Candidate
- I-Not_AE_Candidate
Willi I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
treated O
with O
somatropin O
should O
also O
have O
effective O
weight O
control O
and O
be O
monitored O
for O
signs O
of O
respiratory B-NonOSE_AE
infection I-NonOSE_AE
, O
which O
should O
be O
diagnosed O
as O
early O
as O
possible O
and O
treated O
aggressively O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

5.3 O
Neoplasms O
In O
childhood O
cancer B-Not_AE_Candidate
survivors O
who O
were O
treated O
with O
radiation O
to O
the O
brain/head O
for O
their O
first O
neoplasm B-Not_AE_Candidate
and O
who O
developed O
subsequent O
GHD B-Not_AE_Candidate
and O
were O
treated O
with O
somatropin O
, O
an O
increased O
risk O
of O
a O
second B-OSE_Labeled_AE
neoplasm I-OSE_Labeled_AE
has O
been O
reported O
. O

Intracranial B-OSE_Labeled_AE
tumors I-OSE_Labeled_AE
, O
in O
particular O
meningiomas B-OSE_Labeled_AE
, O
were O
the O
most O
common O
of O
these O
second O
neoplasms B-NonOSE_AE
. O

In O
adults O
, O
it O
is O
unknown O
whether O
there O
is O
any O
relationship O
between O
somatropin O
replacement O
therapy O
and O
CNS B-NonOSE_AE
tumor I-NonOSE_AE
recurrence I-NonOSE_AE
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

Monitor O
all O
patients O
with O
a O
history O
of O
GHD B-Not_AE_Candidate
secondary O
to O
an O
intracranial B-Not_AE_Candidate
neoplasm I-Not_AE_Candidate
routinely O
while O
on O
somatropin O
therapy O
for O
progression O
or O
recurrence B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
tumor I-NonOSE_AE
. O

Because O
children O
with O
certain O
rare O
genetic O
causes O
of O
short B-Not_AE_Candidate
stature I-Not_AE_Candidate
have O
an O
increased O
risk O
of O
developing O
malignancies B-NonOSE_AE
, O
practitioners O
should O
thoroughly O
consider O
the O
risks O
and O
benefits O
of O
starting O
somatropin O
in O
these O
patients O
. O

If O
treatment O
with O
somatropin O
is O
initiated O
, O
these O
patients O
should O
be O
carefully O
monitored O
for O
development O
of O
neoplasms B-NonOSE_AE
. O

Monitor O
patients O
on O
somatropin O
therapy O
carefully O
for O
increased B-NonOSE_AE
growth I-NonOSE_AE
, O
or O
potential O
malignant O
changes O
, O
of I-NonOSE_AE
preexisting I-NonOSE_AE
nevi I-NonOSE_AE
. O

5.4 O
Impaired B-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
Tolerance I-OSE_Labeled_AE
and O
Diabetes O
Mellitus O
Treatment O
with O
somatropin O
may O
decrease B-OSE_Labeled_AE
insulin I-OSE_Labeled_AE
sensitivity I-OSE_Labeled_AE
, O
particularly O
at O
higher O
doses O
in O
susceptible O
patients O
. O

As O
a O
result O
, O
previously O
undiagnosed O
impaired B-Not_AE_Candidate
glucose I-Not_AE_Candidate
tolerance I-Not_AE_Candidate
and O
overt O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
may O
be O
unmasked O
during O
somatropin O
treatment O
. O

New B-OSE_Labeled_AE
- I-OSE_Labeled_AE
onset I-OSE_Labeled_AE
Type I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
diabetes I-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
has O
been O
reported O
. O

Therefore O
, O
glucose O
levels O
should O
be O
monitored O
periodically O
in O
all O
patients O
treated O
with O
somatropin O
, O
especially O
in O
those O
with O
risk O
factors O
for O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
, O
such O
as O
obesity B-Not_AE_Candidate
, O
Turner B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
, O
or O
a O
family O
history O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
. O

Patients O
with O
preexisting O
type B-Not_AE_Candidate
1 I-Not_AE_Candidate
or O
type O
2 O
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
or O
impaired B-Not_AE_Candidate
glucose I-Not_AE_Candidate
tolerance I-Not_AE_Candidate
should O
be O
monitored O
closely O
during O
somatropin O
therapy O
. O

The O
doses O
of O
antihyperglycemic O
drugs O
( O
i.e. O
, O
insulin O
or O
oral/injectable O
agents O
) O
may O
require O
adjustment O
when O
somatropin O
therapy O
is O
instituted O
in O
these O
patients O
. O

5.5 O
Intracranial O
Hypertension O
Intracranial B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
( I-OSE_Labeled_AE
IH I-OSE_Labeled_AE
) O
with O
papilledema B-NonOSE_AE
, O
visual B-NonOSE_AE
changes I-NonOSE_AE
, O
headache B-NonOSE_AE
, O
nausea B-NonOSE_AE
and/or O
vomiting B-NonOSE_AE
has O
been O
reported O
in O
a O
small O
number O
of O
patients O
treated O
with O
somatropin O
products O
. O

Symptoms O
usually O
occurred O
within O
the O
first O
eight O
( O
8 O
) O
weeks O
after O
the O
initiation O
of O
somatropin O
therapy O
. O

In O
all O
reported O
cases O
, O
IH B-NonOSE_AE
- I-NonOSE_AE
associated I-NonOSE_AE
signs O
and O
symptoms O
rapidly O
resolved O
after O
cessation O
of O
therapy O
or O
a O
reduction O
of O
the O
somatropin O
dose O
. O

Funduscopic O
examination O
should O
be O
performed O
routinely O
before O
initiating O
treatment O
with O
somatropin O
to O
exclude O
preexisting O
papilledema O
, O
and O
periodically O
during O
the O
course O
of O
somatropin O
therapy O
. O

If O
papilledema B-NonOSE_AE
is O
observed O
by O
funduscopy O
during O
somatropin O
treatment O
, O
treatment O
should O
be O
stopped O
. O

If O
somatropin B-NonOSE_AE
- I-NonOSE_AE
induced I-NonOSE_AE
IH I-NonOSE_AE
is O
diagnosed O
, O
treatment O
with O
somatropin O
can O
be O
restarted O
at O
a O
lower O
dose O
after O
IH B-NonOSE_AE
- I-NonOSE_AE
associated I-NonOSE_AE
signs O
and O
symptoms O
have O
resolved O
. O

Patients O
with O
Turner B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
and O
Prader B-Not_AE_Candidate
- I-Not_AE_Candidate
Willi I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
may O
be O
at O
increased O
risk O
for O
the O
development O
of O
IH B-OSE_Labeled_AE
. O

5.6 O
Severe O
Hypersensitivity O
Serious O
systemic B-OSE_Labeled_AE
hypersensitivity I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
anaphylactic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
and O
angioedema B-OSE_Labeled_AE
have O
been O
reported O
with O
post-marketing O
use O
of O
somatropin O
products O
. O

Patients O
and O
caregivers O
should O
be O
informed O
that O
such O
reactions O
are O
possible O
and O
that O
prompt O
medical O
attention O
should O
be O
sought O
if O
an O
allergic O
reaction O
occurs O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

5.7 O
Fluid O
Retention O
Fluid B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
during O
somatropin O
replacement O
therapy O
in O
adults O
may O
occur O
. O

Clinical O
manifestations O
of O
fluid B-NonOSE_AE
retention I-NonOSE_AE
( O
e.g. O
, O
edema B-NonOSE_AE
, O
arthralgia B-NonOSE_AE
, O
myalgia B-NonOSE_AE
, O
nerve B-NonOSE_AE
compression I-NonOSE_AE
syndromes I-NonOSE_AE
including O
carpal B-NonOSE_AE
tunnel I-NonOSE_AE
syndrome I-NonOSE_AE
/ O
paraesthesias B-NonOSE_AE
) O
are O
usually O
transient O
and O
dose O
dependent O
. O

5.8 O
Hypoadrenalism O
Patients O
receiving O
somatropin O
therapy O
who O
have O
or O
are O
at O
risk O
for O
pituitary B-Not_AE_Candidate
hormone I-Not_AE_Candidate
deficiency I-Not_AE_Candidate
( O
s O
) O
may O
be O
at O
risk O
for O
reduced B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
cortisol I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
and/or O
unmasking O
of O
central B-OSE_Labeled_AE
( I-OSE_Labeled_AE
secondary I-OSE_Labeled_AE
) I-OSE_Labeled_AE
hypoadrenalism I-OSE_Labeled_AE
. O

In O
addition O
, O
patients O
treated O
with O
glucocorticoid O
replacement O
for O
previously O
diagnosed O
hypoadrenalism B-Not_AE_Candidate
may O
require O
an O
increase O
in O
their O
maintenance O
or O
stress B-NonOSE_AE
doses I-NonOSE_AE
following O
initiation O
of O
somatropin O
treatment O
[ O
see O
Section O
7.1 O
, O
11-beta O
Hydroxysteroid O
Dehydrogenase O
Type O
1 O
] O
. O

5.9 O
Hypothyroidism O
Undiagnosed/untreated O
hypothyroidism B-Not_AE_Candidate
may O
prevent O
an O
optimal O
response O
to O
somatropin O
, O
in O
particular O
, O
the O
growth O
response O
in O
children O
. O

Patients O
with O
Turner B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
have O
an O
inherently O
increased O
risk O
of O
developing O
autoimmune B-NonOSE_AE
thyroid I-NonOSE_AE
disease O
and O
primary B-NonOSE_AE
hypothyroidism I-NonOSE_AE
. O

In O
patients O
with O
growth B-Not_AE_Candidate
hormone I-Not_AE_Candidate
deficiency I-Not_AE_Candidate
, O
central B-OSE_Labeled_AE
( I-OSE_Labeled_AE
secondary I-OSE_Labeled_AE
) I-OSE_Labeled_AE
hypothyroidism I-OSE_Labeled_AE
may O
first O
become O
evident O
or O
worsen O
during O
somatropin O
treatment O
. O

Therefore O
, O
patients O
treated O
with O
somatropin O
should O
have O
periodic O
thyroid O
function O
tests O
and O
thyroid O
hormone O
replacement O
therapy O
should O
be O
initiated O
or O
appropriately O
adjusted O
when O
indicated O
. O

5.10 O
Slipped O
Capital O
Femoral O
Epiphyses O
in O
Pediatric O
Patients O
Slipped B-OSE_Labeled_AE
capital I-OSE_Labeled_AE
femoral I-OSE_Labeled_AE
epiphyses I-OSE_Labeled_AE
may O
occur O
more O
frequently O
in O
patients O
with O
endocrine O
disorders O
( O
including O
GHD B-Not_AE_Candidate
and O
Turner B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
) O
or O
in O
patients O
undergoing O
rapid B-NonOSE_AE
growth I-NonOSE_AE
. O

Any O
pediatric O
patient O
with O
the O
onset O
of O
a O
limp B-NonOSE_AE
or O
complaints O
of O
hip B-NonOSE_AE
or O
knee O
pain I-NonOSE_AE
during O
somatropin O
therapy O
should O
be O
carefully O
evaluated O
. O

5.11 O
Progression O
of O
Preexisting O
Scoliosis O
in O
Pediatric O
Patients O
Progression B-OSE_Labeled_AE
of I-OSE_Labeled_AE
scoliosis I-OSE_Labeled_AE
can O
occur O
in O
patients O
who O
experience O
rapid B-NonOSE_AE
growth I-NonOSE_AE
. O

Because O
somatropin O
increases B-NonOSE_AE
growth I-NonOSE_AE
rate I-NonOSE_AE
, O
patients O
with O
a O
history O
of O
scoliosis B-Not_AE_Candidate
who O
are O
treated O
with O
somatropin O
should O
be O
monitored O
for O
progression O
of O
scoliosis B-NonOSE_AE
. O

However O
, O
somatropin O
has O
not O
been O
shown O
to O
increase O
the O
occurrence O
of O
scoliosis B-NonOSE_AE
. O

Skeletal B-NonOSE_AE
abnormalities I-NonOSE_AE
including O
scoliosis B-NonOSE_AE
are O
commonly O
seen O
in O
untreated O
Turner B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
patients O
. O

Scoliosis B-NonOSE_AE
is O
also O
commonly O
seen O
in O
untreated O
patients O
with O
Prader B-Not_AE_Candidate
- I-Not_AE_Candidate
Willi I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
. O

Physicians O
should O
be O
alert O
to O
these O
abnormalities O
, O
which O
may O
manifest O
during O
somatropin O
therapy O
. O

5.12 O
Otitis O
Media O
and O
Cardiovascular B-OSE_Labeled_AE
Disorders I-OSE_Labeled_AE
in O
Turner O
Syndrome O
Patients O
with O
Turner B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
should O
be O
evaluated O
carefully O
for O
otitis B-NonOSE_AE
media I-NonOSE_AE
and O
other O
ear B-NonOSE_AE
disorders I-NonOSE_AE
since O
these O
patients O
have O
an O
increased O
risk O
of O
ear B-NonOSE_AE
and O
hearing O
disorders I-NonOSE_AE
. O

Somatropin O
treatment O
may O
increase O
the O
occurrence O
of O
otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
in O
patients O
with O
Turner B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
. O

In O
addition O
, O
patients O
with O
Turner B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
should O
be O
monitored O
closely O
for O
cardiovascular B-NonOSE_AE
disorders I-NonOSE_AE
( O
e.g. O
, O
stroke B-NonOSE_AE
, O
aortic B-NonOSE_AE
aneurysm I-NonOSE_AE
/dissection O
, O
hypertension B-NonOSE_AE
) O
as O
these O
patients O
are O
also O
at O
risk O
for O
these O
conditions O
. O

5.13 O
Lipoatrophy O
When O
somatropin O
is O
administered O
subcutaneously O
at O
the O
same O
site O
over O
a O
long O
period O
of O
time O
, O
tissue B-NonOSE_AE
atrophy I-NonOSE_AE
may O
result O
. O

This O
can O
be O
avoided O
by O
rotating O
the O
injection O
site O
[ O
see O
Dosage O
and O
Administration O
. O

( O
2.3 O
) O
] O
. O

5.14 O
Laboratory O
Tests O
Serum O
levels O
of O
inorganic B-OSE_Labeled_AE
phosphorus I-OSE_Labeled_AE
, O
alkaline O
phosphatase O
, O
parathyroid O
hormone O
( O
PTH O
) O
and O
IGF-I O
may O
increase I-OSE_Labeled_AE
during O
somatropin O
therapy O
. O

5.15 O
Pancreatitis O
Cases O
of O
pancreatitis B-OSE_Labeled_AE
have O
been O
reported O
rarely O
in O
children O
and O
adults O
receiving O
somatropin O
treatment O
, O
with O
some O
evidence O
supporting O
a O
greater O
risk O
in O
children O
compared O
with O
adults O
. O

Published O
literature O
indicates O
that O
girls O
who O
have O
Turner B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
may O
be O
at O
greater O
risk O
than O
other O
somatropin-treated O
children O
. O

Pancreatitis B-NonOSE_AE
should O
be O
considered O
in O
any O
somatropin-treated O
patient O
, O
especially O
a O
child O
, O
who O
develops O
persistent O
severe O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
( O
incidence O
greater O
than O
or O
equal O
to O
10 O
% O
, O
all O
grades O
) O
observed O
with O
treatment O
with O
HARVONI O
for O
8 O
, O
12 O
, O
or O
24 O
weeks O
are O
fatigue O
and O
headache O
( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Gilead O
Sciences O
, O
Inc O
. O
at O
1-800-GILEAD-5 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
safety O
assessment O
of O
HARVONI O
was O
based O
on O
pooled O
data O
from O
three O
Phase O
3 O
clinical O
trials O
of O
subjects O
with O
genotype B-Not_AE_Candidate
1 I-Not_AE_Candidate
chronic I-Not_AE_Candidate
hepatitis I-Not_AE_Candidate
C I-Not_AE_Candidate
( I-Not_AE_Candidate
CHC I-Not_AE_Candidate
) O
with O
compensated B-Not_AE_Candidate
liver I-Not_AE_Candidate
disease I-Not_AE_Candidate
( I-Not_AE_Candidate
with I-Not_AE_Candidate
and I-Not_AE_Candidate
without I-Not_AE_Candidate
cirrhosis I-Not_AE_Candidate
) O
including O
215 O
, O
539 O
, O
and O
326 O
subjects O
who O
received O
HARVONI O
for O
8 O
, O
12 O
and O
24 O
weeks O
, O
respectively O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

The O
proportion O
of O
subjects O
who O
permanently O
discontinued O
treatment O
due O
to O
adverse O
events O
was O
0 O
% O
, O
< O
1 O
% O
, O
and O
1 O
% O
for O
subjects O
receiving O
HARVONI O
for O
8 O
, O
12 O
, O
and O
24 O
weeks O
, O
respectively O
. O

The O
most O
common O
adverse O
reactions O
( O
> O
=10 O
% O
) O
were O
fatigue B-OSE_Labeled_AE
and O
headache B-OSE_Labeled_AE
in O
subjects O
treated O
with O
8 O
, O
12 O
, O
or O
24 O
weeks O
of O
HARVONI O
. O

Table O
2 O
lists O
adverse O
reactions O
( O
adverse O
events O
assessed O
as O
causally O
related O
by O
the O
investigator O
, O
all O
grades O
) O
observed O
in O
> O
=5 O
% O
of O
subjects O
receiving O
8 O
, O
12 O
, O
or O
24 O
weeks O
treatment O
with O
HARVONI O
in O
clinical O
trials O
. O

The O
majority O
of O
adverse O
reactions O
presented O
in O
Table O
2 O
occurred O
at O
severity O
of O
grade O
1 O
. O

The O
side-by-side O
tabulation O
is O
to O
simplify O
presentation O
; O
direct O
comparison O
across O
trials O
should O
not O
be O
made O
due O
to O
differing O
trial O
designs O
. O

Table O
2 O
Adverse O
Reactions O
( O
All O
Grades O
) O
Reported O
in O
> O
=5 O
% O
of O
Subjects O
Receiving O
8 O
, O
12 O
, O
or O
24 O
Weeks O
of O
Treatment O
with O
HARVONI O
HARVONI8 O
weeks O
HARVONI12 O
weeks O
HARVONI24 O
weeks O
N=215 O
N=539 O
N=326 O
Fatigue B-OSE_Labeled_AE
16 O
% O
13 O
% O
18 O
% O
Headache B-OSE_Labeled_AE
11 O
% O
14 O
% O
17 O
% O
Nausea B-OSE_Labeled_AE
6 O
% O
7 O
% O
9 O
% O
Diarrhea B-OSE_Labeled_AE
4 O
% O
3 O
% O
7 O
% O
Insomnia B-OSE_Labeled_AE
3 O
% O
5 O
% O
6 O
% O
Laboratory O
Abnormalities O
Bilirubin B-NonOSE_AE
Elevations I-NonOSE_AE
: O
Bilirubin B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
of O
greater O
than O
1.5*ULN O
were O
observed O
in O
3 O
% O
, O
< O
1 O
% O
, O
and O
2 O
% O
of O
subjects O
treated O
with O
HARVONI O
for O
8 O
, O
12 O
, O
and O
24 O
weeks O
, O
respectively O
. O

Lipase B-NonOSE_AE
Elevations I-NonOSE_AE
: O
Transient O
, O
asymptomatic O
lipase B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
of O
greater O
than O
3*ULN O
were O
observed O
in O
< O
1 O
% O
, O
2 O
% O
, O
and O
3 O
% O
of O
subjects O
treated O
with O
HARVONI O
for O
8 O
, O
12 O
, O
and O
24 O
weeks O
, O
respectively O
. O

Creatine B-NonOSE_AE
Kinase I-NonOSE_AE
: O
Creatine B-NonOSE_AE
kinase I-NonOSE_AE
was O
not O
assessed O
in O
Phase O
3 O
trials O
of O
HARVONI O
. O

Isolated O
, O
asymptomatic O
creatine B-NonOSE_AE
kinase I-NonOSE_AE
elevations I-NonOSE_AE
( O
Grade O
3 O
or O
4 O
) O
have O
been O
previously O
reported O
in O
subjects O
treated O
with O
sofosbuvir O
in O
combination O
with O
ribavirin O
or O
peginterferon/ribavirin O
in O
other O
clinical O
trials O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post O
approval O
use O
of O
HARVONI O
. O

Because O
postmarketing O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
Serious O
symptomatic O
bradycardia B-NonOSE_AE
has O
been O
reported O
in O
patients O
taking O
amiodarone O
who O
initiate O
treatment O
with O
HARVONI O
[ O
See O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
Drug O
Interactions O
( O
7.2 O
) O
] O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Bradycardia O
with O
amiodarone O
coadministration O
: O
Serious O
symptomatic O
bradycardia O
may O
occur O
in O
patients O
taking O
amiodarone O
, O
particularly O
in O
patients O
also O
receiving O
beta O
blockers O
, O
or O
those O
with O
underlying O
cardiac O
comorbidities O
and/or O
advanced O
liver O
disease O
. O

Coadministration O
of O
amiodarone O
with O
HARVONI O
is O
not O
recommended O
. O

In O
patients O
without O
alternative O
, O
viable O
treatment O
options O
, O
cardiac O
monitoring O
is O
recommended O
. O

( O
5.1 O
, O
6.2 O
, O
7.2 O
) O
* O
Use O
with O
other O
drugs O
containing O
sofosbuvir O
, O
including O
SOVALDI O
, O
is O
not O
recommended O
( O
5.3 O
) O
5.1 O
Serious O
Symptomatic O
Bradycardia O
When O
Coadministered O
with O
Amiodarone O
Postmarketing O
cases O
of O
symptomatic O
bradycardia B-NonOSE_AE
, O
as O
well O
as O
fatal O
cardiac B-NonOSE_AE
arrest I-NonOSE_AE
and O
cases O
requiring O
pacemaker O
intervention O
, O
have O
been O
reported O
when O
amiodarone O
is O
coadministered O
with O
HARVONI O
. O

Bradycardia B-NonOSE_AE
has O
generally O
occurred O
within O
hours O
to O
days O
, O
but O
cases O
have O
been O
observed O
up O
to O
2 O
weeks O
after O
initiating O
HCV B-Not_AE_Candidate
treatment O
. O

Patients O
also O
taking O
beta O
blockers O
, O
or O
those O
with O
underlying O
cardiac B-Not_AE_Candidate
comorbidities I-Not_AE_Candidate
and/or O
advanced O
liver B-Not_AE_Candidate
disease I-Not_AE_Candidate
may O
be O
at O
increased O
risk O
for O
symptomatic B-NonOSE_AE
bradycardia I-NonOSE_AE
with O
coadministration O
of O
amiodarone O
. O

Bradycardia B-NonOSE_AE
generally O
resolved O
after O
discontinuation O
of O
HCV B-Not_AE_Candidate
treatment O
. O

The O
mechanism O
for O
this O
effect O
is O
unknown O
. O

Coadministration O
of O
amiodarone O
with O
HARVONI O
is O
not O
recommended O
. O

For O
patients O
taking O
amiodarone O
who O
have O
no O
other O
alternative O
, O
viable O
treatment O
options O
and O
who O
will O
be O
coadministered O
HARVONI O
: O
* O
Counsel O
patients O
about O
the O
risk O
of O
serious O
symptomatic O
bradycardia B-NonOSE_AE
* O
Cardiac O
monitoring O
in O
an O
in-patient O
setting O
for O
the O
first O
48 O
hours O
of O
coadministration O
is O
recommended O
, O
after O
which O
outpatient O
or O
self-monitoring O
of O
the O
heart O
rate O
should O
occur O
on O
a O
daily O
basis O
through O
at O
least O
the O
first O
2 O
weeks O
of O
treatment O
. O

Patients O
who O
are O
taking O
HARVONI O
who O
need O
to O
start O
amiodarone O
therapy O
due O
to O
no O
other O
alternative O
, O
viable O
treatment O
options O
should O
undergo O
similar O
cardiac O
monitoring O
as O
outlined O
above O
. O

Due O
to O
amiodarone O
's O
long O
half-life O
, O
patients O
discontinuing O
amiodarone O
just O
prior O
to O
starting O
HARVONI O
should O
also O
undergo O
similar O
cardiac O
monitoring O
as O
outlined O
above O
. O

Patients O
who O
develop O
signs O
or O
symptoms O
of O
bradycardia B-NonOSE_AE
should O
seek O
medical O
evaluation O
immediately O
. O

Symptoms O
may O
include O
near B-NonOSE_AE
- I-NonOSE_AE
fainting I-NonOSE_AE
or O
fainting B-NonOSE_AE
, O
dizziness B-NonOSE_AE
or O
lightheadedness B-NonOSE_AE
, O
malaise B-NonOSE_AE
, O
weakness B-NonOSE_AE
, O
excessive B-NonOSE_AE
tiredness I-NonOSE_AE
, O
shortness B-NonOSE_AE
of I-NonOSE_AE
breath I-NonOSE_AE
, O
chest B-NonOSE_AE
pains I-NonOSE_AE
, O
confusion B-NonOSE_AE
or O
memory B-NonOSE_AE
problems I-NonOSE_AE
[ O
See O
Adverse O
Reactions O
( O
6.2 O
) O
, O
Drug O
Interactions O
( O
7.2 O
) O
] O
. O

5.2 O
Risk O
of O
Reduced O
Therapeutic O
Effect O
Due O
to O
P-gp O
Inducers O
The O
concomitant O
use O
of O
HARVONI O
and O
P-gp O
inducers O
( O
e.g. O
, O
rifampin O
, O
St O
. O
John O
's O
wort O
) O
may O
significantly O
decrease O
ledipasvir O
and O
sofosbuvir O
plasma O
concentrations O
and O
may O
lead O
to O
a O
reduced O
therapeutic O
effect O
of O
HARVONI O
. O

Therefore O
, O
the O
use O
of O
HARVONI O
with O
P-gp O
inducers O
( O
e.g. O
, O
rifampin O
or O
St O
. O
John O
's O
wort O
) O
is O
not O
recommended O
[ O
see O
Drug O
Interactions O
( O
7.2 O
) O
] O
. O

5.3 O
Related O
Products O
Not O
Recommended O
The O
use O
of O
HARVONI O
with O
other O
products O
containing O
sofosbuvir O
( O
SOVALDI O
( O
r O
) O
) O
is O
not O
recommended O
. O

6 O
ADVERSE O
REACTIONS O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

EXCERPT O
: O
* O
Adverse O
reactions O
occurring O
in O
> O
=2 O
% O
of O
patients O
include O
nausea O
, O
vomiting O
, O
diarrhea O
, O
headache O
, O
decreased O
appetite O
, O
dizziness O
, O
abdominal O
pain O
, O
pruritus O
, O
somnolence O
, O
elevated O
transaminases O
, O
and O
elevated O
creatinine O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Paladin O
Therapeutics O
Inc O
. O
at O
1-888-550-6060 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Visceral O
Leishmaniasis O
One O
Phase O
3 O
trial O
was O
conducted O
in O
patients O
> O
= O
12 O
years O
of O
age O
in O
India O
. O

Two-hundred O
and O
ninety-nine O
( O
299 O
) O
patients O
( O
211 O
men O
and O
88 O
women O
) O
received O
oral O
IMPAVIDO O
at O
a O
target O
dose O
of O
2.5 O
mg/kg/day O
for O
28 O
days O
( O
50 O
mg O
capsule O
once O
daily O
if O
weight O
was O
less O
than O
25 O
kg O
and O
50 O
mg O
capsule O
twice O
daily O
if O
weight O
was O
25 O
kg O
or O
greater O
) O
. O

Patients O
ranged O
between O
12 O
and O
64 O
years O
of O
age O
. O

Weight O
ranged O
between O
15 O
and O
67 O
kg O
( O
mean O
weight O
38.6 O
kg O
) O
and O
BMI O
ranged O
between O
8.2 O
and O
24 O
( O
mean O
16.1 O
) O
. O

Ninety-nine O
( O
99 O
) O
patients O
received O
1 O
mg/kg/day O
amphotericin O
B O
deoxycholate O
intravenously O
every O
other O
day O
for O
15 O
doses O
. O

A O
statistically O
significant O
higher O
percentage O
of O
men O
received O
IMPAVIDO O
compared O
to O
amphotericin O
B O
. O

Less O
than O
1 O
% O
of O
patients O
who O
received O
IMPAVIDO O
died B-NonOSE_AE
( O
2/299 O
) O
and O
no O
patient O
who O
received O
amphotericin O
B O
died B-NonOSE_AE
. O

Serious O
adverse O
reactions O
were O
reported O
in O
2 O
% O
of O
IMPAVIDO O
recipients O
( O
6/299 O
) O
and O
1 O
% O
of O
amphotericin O
B O
recipients O
( O
1/99 O
) O
. O

Approximately O
3 O
% O
of O
patients O
discontinued O
treatment O
in O
each O
treatment O
arm O
due O
to O
an O
adverse O
reaction O
. O

Serious O
adverse O
reactions O
and O
adverse O
reactions O
leading O
to O
drug O
discontinuation O
that O
were O
thought O
to O
be O
related O
or O
possibly O
related O
to O
IMPAVIDO O
included O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
melena B-OSE_Labeled_AE
and O
thrombocytopenia B-OSE_Labeled_AE
, O
arthritis B-OSE_Labeled_AE
and O
skin B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
CTCAE O
( O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
) O
Grade O
4 O
diarrhea B-OSE_Labeled_AE
( O
> O
=10 O
stools O
per O
day O
) O
and O
CTCAE O
Grade O
4 O
hyperbilirubinemia B-OSE_Labeled_AE
( O
> O
=10x O
upper O
limit O
of O
normal O
ULN O
) O
. O

Table O
2 O
: O
Treatment O
Emergent O
Adverse O
Reactions O
Occurring O
in O
> O
=2 O
% O
of O
Visceral O
Leishmaniasis O
Patients O
Receiving O
IMPAVIDO O
System O
Organ O
ClassPreferred O
Term O
IMPAVIDON O
= O
299 O
Amphotericin O
B O
DeoxycholateN O
= O
99 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
61 O
( O
20.4 O
% O
) O
6 O
( O
6.1 O
% O
) O
Vomiting B-OSE_Labeled_AE
113 O
( O
37.8 O
% O
) O
20 O
( O
20.0 O
% O
) O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Asthenia B-OSE_Labeled_AE
19 O
( O
6.3 O
% O
) O
4 O
( O
4.0 O
% O
) O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
69 O
( O
23.1 O
% O
) O
22 O
( O
22.2 O
% O
) O
In O
this O
study O
, O
creatinine B-OSE_Labeled_AE
( O
Cr O
) O
elevations I-OSE_Labeled_AE
> O
= O
1.5 O
times O
above O
baseline O
occurred O
in O
approximately O
10 O
% O
of O
IMPAVIDO O
recipients O
and O
in O
40 O
% O
of O
amphotericin O
B O
recipients O
at O
the O
end O
of O
therapy O
. O

Ten O
percent O
of O
subjects O
in O
each O
arm O
had O
Cr B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
> O
=1.5 O
times O
above O
baseline O
at O
6 O
months O
follow O
up O
. O

No O
IMPAVIDO O
recipient O
discontinued O
therapy O
due O
to O
Cr B-NonOSE_AE
elevation I-NonOSE_AE
. O

Elevations B-OSE_Labeled_AE
of O
transaminases I-OSE_Labeled_AE
during O
therapy O
occurred O
in O
up O
to O
half O
of O
IMPAVIDO O
recipients O
and O
up O
to O
a O
third O
of O
amphotericin O
B O
recipients O
. O

The O
elevations O
were O
mild O
( O
< O
3x O
ULN O
) O
or O
moderate O
( O
3-5x O
ULN O
) O
in O
94 O
% O
and O
6 O
% O
respectively O
of O
IMPAVIDO-treated O
patients O
who O
experienced O
an O
elevation O
. O

No O
patient O
discontinued O
therapy O
due O
to O
elevations B-NonOSE_AE
in I-NonOSE_AE
transaminases I-NonOSE_AE
. O

At O
the O
end O
of O
therapy O
, O
62 O
% O
and O
2.4 O
% O
of O
IMPAVIDO O
recipients O
and O
54 O
% O
and O
2 O
% O
of O
amphotericin O
B O
recipients O
had O
platelet B-OSE_Labeled_AE
count I-OSE_Labeled_AE
< I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
, I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
and O
< O
50,000 O
respectively O
. O

Cutaneous O
Leishmaniasis O
The O
efficacy O
of O
IMPAVIDO O
in O
the O
treatment O
of O
cutaneous B-Not_AE_Candidate
leishmaniasis I-Not_AE_Candidate
was O
evaluated O
in O
one O
placebo-controlled O
trial O
conducted O
in O
Colombia O
and O
Guatemala O
and O
in O
two O
comparative O
trials O
conducted O
in O
Bolivia O
and O
Brazil O
respectively O
. O

In O
the O
placebo-controlled O
trial O
, O
eighty-nine O
( O
89 O
) O
patients O
> O
=12 O
years O
of O
age O
received O
a O
target O
IMPAVIDO O
dose O
of O
2.5 O
mg/kg/day O
for O
28 O
days O
and O
forty-four O
( O
44 O
) O
received O
placebo O
. O

In O
the O
comparative O
trials O
, O
one O
hundred O
and O
twenty O
( O
120 O
) O
patients O
> O
=12 O
years O
of O
age O
received O
a O
target O
IMPAVIDO O
dose O
of O
2.5 O
mg/kg/day O
for O
28 O
days O
and O
fifty O
eight O
( O
58 O
) O
patients O
received O
20 O
mg/kg/day O
pentavalent O
antimony O
( O
meglumine O
) O
parenterally O
for O
20 O
days O
. O

Table O
3 O
: O
Adverse O
Reactions O
Occurring O
in O
> O
=2 O
% O
of O
IMPAVIDO-Treated O
Patients O
> O
=12 O
Years O
of O
Age O
with O
Cutaneous O
Leishmaniasis O
in O
the O
Placebo-Controlled O
Trial O
System O
Organ O
ClassPreferred O
Term O
IMPAVIDON O
= O
89 O
PlaceboN O
= O
44 O
Ear B-NonOSE_AE
and I-NonOSE_AE
Labyrinth I-NonOSE_AE
Disorders I-NonOSE_AE
Motion B-OSE_Labeled_AE
Sickness I-OSE_Labeled_AE
26 O
( O
29.2 O
% O
) O
10 O
( O
22.7 O
% O
) O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
10 O
( O
11.2 O
% O
) O
3 O
( O
6.8 O
% O
) O
Diarrhea B-OSE_Labeled_AE
7 O
( O
7.9 O
% O
) O
2 O
( O
4.5 O
% O
) O
Nausea B-OSE_Labeled_AE
32 O
( O
35.9 O
% O
) O
5 O
( O
11.1 O
% O
) O
Vomiting B-OSE_Labeled_AE
4 O
( O
4.5 O
% O
) O
0 O
General B-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Disorders I-NonOSE_AE
Malaise B-OSE_Labeled_AE
3 O
( O
3.4 O
% O
) O
1 O
( O
2.3 O
% O
) O
Pyrexia B-OSE_Labeled_AE
5 O
( O
5.6 O
% O
) O
2 O
( O
4.5 O
% O
) O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
4 O
( O
4.5 O
% O
) O
0 O
Headache B-OSE_Labeled_AE
25 O
( O
28.1 O
% O
) O
10 O
( O
22.7 O
% O
) O
Somnolence B-OSE_Labeled_AE
3 O
( O
3.4 O
% O
) O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Pruritus B-OSE_Labeled_AE
4 O
( O
4.5 O
% O
) O
0 O
Table O
4 O
: O
Adverse O
Reactions O
Occurring O
in O
> O
=2 O
% O
of O
IMPAVIDO-Treated O
Patients O
> O
= O
12 O
Years O
of O
Age O
with O
Cutaneous O
Leishmaniasis O
in O
Two O
Comparative O
Trials O
System O
Organ O
ClassPreferred O
Term O
IMPAVIDON O
= O
120 O
MeglumineN O
= O
58 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
9 O
( O
7.5 O
% O
) O
3 O
( O
5.2 O
% O
) O
Diarrhea B-OSE_Labeled_AE
18 O
( O
15.0 O
% O
) O
3 O
( O
5.2 O
% O
) O
Nausea B-OSE_Labeled_AE
50 O
( O
41.7 O
% O
) O
3 O
( O
5.2 O
% O
) O
Vomiting B-OSE_Labeled_AE
33 O
( O
27.5 O
% O
) O
0 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Lymphangitis B-OSE_Labeled_AE
7 O
( O
5.8 O
% O
) O
0 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
13 O
( O
10.8 O
% O
) O
4 O
( O
5.8 O
% O
) O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
15 O
( O
12.5 O
% O
) O
4 O
( O
6.9 O
% O
) O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Pruritus B-OSE_Labeled_AE
7 O
( O
5.8 O
% O
) O
0 O
In O
the O
placebo O
controlled O
trial O
, O
12/89 O
( O
13.4 O
% O
) O
IMPAVIDO O
subjects O
had O
Cr B-OSE_Labeled_AE
increases I-OSE_Labeled_AE
of O
1.5-3 O
times O
above O
baseline O
, O
compared O
to O
2/44 O
( O
4.5 O
% O
) O
placebo O
subjects O
at O
end O
of O
therapy O
. O

In O
the O
comparative O
trial O
, O
a O
similar O
percentage O
of O
subjects O
who O
received O
IMPAVIDO O
or O
pentavalent O
antimony O
had O
Cr B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
above O
baseline O
at O
3 O
and O
6 O
months O
after O
therapy O
( O
approximately O
5 O
% O
) O
. O

Approximately O
25 O
% O
of O
IMPAVIDO O
subjects O
and O
11 O
% O
of O
pentavalent O
antimony O
subjects O
had O
Cr B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
1.5-3 O
times O
above O
baseline O
at O
the O
end O
of O
therapy O
in O
the O
two O
active O
controlled O
trials O
. O

The O
frequency O
of O
AST B-NonOSE_AE
and O
ALT O
increase I-NonOSE_AE
above O
upper O
limit O
of O
normal O
at O
end O
of O
therapy O
was O
similar O
in O
IMPAVIDO O
and O
placebo O
recipients O
( O
approximately O
5 O
% O
) O
. O

Other O
adverse O
events O
seen O
at O
< O
2 O
% O
incidence O
in O
the O
IMPAVIDO O
group O
included O
anemia B-OSE_Labeled_AE
, O
lymphadenopathy B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
distension I-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
dysphagia B-OSE_Labeled_AE
, O
flatulence B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
malaise B-OSE_Labeled_AE
, O
abscess B-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
ecthyma B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
testicular B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
testicular B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
pyoderma B-OSE_Labeled_AE
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
use O
of O
IMPAVIDO O
worldwide O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatics I-NonOSE_AE
Disorders I-NonOSE_AE
: O
thrombocytopenia B-OSE_Labeled_AE
, O
agranulocytosis B-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
: O
melena B-OSE_Labeled_AE
General B-NonOSE_AE
Disorders I-NonOSE_AE
: O
generalized B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
Hepatobiliary B-NonOSE_AE
Disorders I-NonOSE_AE
: O
jaundice B-OSE_Labeled_AE
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
seizure B-OSE_Labeled_AE
Reproductive B-NonOSE_AE
System I-NonOSE_AE
and I-NonOSE_AE
Breast I-NonOSE_AE
Disorders I-NonOSE_AE
: O
scrotal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
ejaculate I-OSE_Labeled_AE
volume I-OSE_Labeled_AE
, O
absent B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
. O

Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
: O
epistaxis B-OSE_Labeled_AE

BOXED O
WARNING O
: O
WARNING O
: O
EMBRYO B-OSE_Labeled_AE
- I-OSE_Labeled_AE
FETAL I-OSE_Labeled_AE
TOXICITY I-OSE_Labeled_AE
WARNING O
: O
EMBRYO-FETAL O
TOXICITY O
IMPAVIDO O
may O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
. O

Fetal B-NonOSE_AE
death I-NonOSE_AE
and O
teratogenicity B-NonOSE_AE
occurred O
in O
animals O
administered O
miltefosine O
at O
doses O
lower O
than O
the O
recommended O
human O
dose O
. O

Do O
not O
administer O
IMPAVIDO O
to O
pregnant B-Not_AE_Candidate
women O
. O

Obtain O
a O
serum O
or O
urine O
pregnancy B-NonOSE_AE
test O
in O
females O
of O
reproductive O
potential O
prior O
to O
prescribing O
IMPAVIDO O
. O

Females O
of O
reproductive O
potential O
should O
be O
advised O
to O
use O
effective O
contraception O
during O
IMPAVIDO O
therapy O
and O
for O
5 O
months O
after O
therapy O
[ O
see O
Contraindications O
( O
4.1 O
) O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.1 O
, O
8.8 O
) O
and O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
EMBRYO-FETAL O
TOXICITY O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

IMPAVIDO O
may O
cause O
fetal O
harm O
. O

Fetal O
death O
and O
teratogenicity O
, O
occurred O
in O
animals O
administered O
miltefosine O
at O
doses O
lower O
than O
the O
recommended O
human O
dose O
. O

Do O
not O
administer O
IMPAVIDO O
to O
pregnant O
women O
. O

Obtain O
a O
serum O
or O
urine O
pregnancy O
test O
in O
females O
of O
reproductive O
potential O
prior O
to O
prescribing O
IMPAVIDO O
. O

Advise O
females O
of O
reproductive O
potential O
to O
use O
effective O
contraception O
during O
therapy O
and O
for O
5 O
months O
after O
therapy O
( O
4.1 O
, O
5.1 O
, O
8.1 O
, O
8.8 O
, O
13.1 O
) O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Embryo-Fetal O
Toxicity O
. O

Do O
not O
use O
in O
pregnant O
women O
. O

Obtain O
a O
urine O
or O
serum O
pregnancy O
test O
prior O
to O
initiation O
of O
therapy O
. O

Advise O
use O
of O
effective O
contraception O
in O
females O
of O
reproductive O
potential O
( O
Boxed O
Warning O
, O
5.1 O
, O
8.1 O
, O
8.8 O
, O
13.1 O
) O
. O

* O
Reproductive O
effects O
. O

Miltefosine O
caused O
testicular O
atrophy O
and O
impaired O
fertility O
in O
male O
rats O
and O
impaired O
fertility O
in O
female O
rats O
. O

Advise O
patients O
of O
reproductive O
toxicities O
in O
animal O
studies O
and O
that O
the O
potential O
effects O
on O
human O
fertility O
have O
not O
been O
adequately O
evaluated O
( O
13.1 O
) O
. O

* O
Renal O
Effects O
. O

Monitor O
serum O
creatinine O
during O
therapy O
and O
for O
4 O
weeks O
after O
end O
of O
therapy O
( O
5.3 O
, O
6.1 O
) O
. O

* O
Hepatic O
Effects O
. O

Monitor O
transaminases O
and O
bilirubin O
during O
therapy O
( O
5.4 O
, O
6.1 O
) O
. O

* O
Gastrointestinal O
Effects O
. O

Encourage O
fluid O
intake O
( O
5.5 O
) O
. O

* O
Thrombocytopenia O
. O

Monitor O
platelet O
count O
during O
therapy O
for O
visceral O
leishmaniasis O
( O
5.6 O
, O
6.1 O
) O
. O

* O
Absorption O
of O
Oral O
Contraceptives O
. O

Advise O
use O
of O
alternative O
method O
of O
contraception O
if O
vomiting O
and/or O
diarrhea O
occur O
( O
5.7 O
) O
. O

* O
Stevens-Johnson O
syndrome O
. O

Discontinue O
IMPAVIDO O
( O
5.8 O
) O
. O

5.1 O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Miltefosine O
may O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
. O

Embryo B-NonOSE_AE
- I-NonOSE_AE
fetal I-NonOSE_AE
toxicity I-NonOSE_AE
, O
including O
death O
and O
teratogenicity B-NonOSE_AE
, O
was O
observed O
in O
animals O
administered O
miltefosine O
prior O
to O
mating O
, O
during O
early O
pregnancy B-NonOSE_AE
, O
and O
during O
organogenesis O
at O
doses O
lower O
than O
the O
maximum O
recommended O
human O
dose O
( O
MRHD O
) O
. O

Do O
not O
use O
IMPAVIDO O
in O
pregnant B-Not_AE_Candidate
women O
. O

Obtain O
a O
urine O
or O
serum O
pregnancy B-NonOSE_AE
test O
prior O
to O
prescribing O
IMPAVIDO O
to O
females O
of O
reproductive O
potential O
. O

Advise O
females O
of O
reproductive O
potential O
to O
use O
effective O
contraception O
during O
IMPAVIDO O
therapy O
and O
for O
5 O
months O
after O
completion O
of O
therapy O
[ O
see O
Boxed O
Warning O
, O
Contraindications O
( O
4.1 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.1 O
, O
8.8 O
) O
] O
. O

5.2 O
Reproductive O
Effects O
Females O
Miltefosine O
caused O
impaired B-NonOSE_AE
fertility I-NonOSE_AE
in O
rats O
and O
reversible B-NonOSE_AE
follicular I-NonOSE_AE
atresia I-NonOSE_AE
and O
diestrus B-NonOSE_AE
in O
dogs O
at O
doses O
approximately O
1.0 O
and O
0.2 O
times O
respectively O
the O
MRHD O
based O
on O
body O
surface O
area O
comparisons O
[ O
see O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
. O

Effects O
on O
human O
female O
fertility O
have O
not O
been O
formally O
studied O
. O

Males O
Miltefosine O
caused O
reduced B-NonOSE_AE
viable O
sperm I-NonOSE_AE
counts I-NonOSE_AE
and O
impaired B-NonOSE_AE
fertility I-NonOSE_AE
in O
rats O
at O
doses O
approximately O
0.4 O
times O
the O
MRHD O
[ O
see O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
. O

A O
higher O
dose O
in O
rats O
, O
approximately O
1.0 O
times O
the O
MRHD O
, O
caused O
testicular B-NonOSE_AE
atrophy I-NonOSE_AE
and O
impaired B-NonOSE_AE
fertility I-NonOSE_AE
that O
did O
not O
fully O
reverse O
10 O
weeks O
after O
drug O
administration O
ended O
. O

Scrotal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
and O
decreased B-OSE_Labeled_AE
or O
absent O
ejaculation I-OSE_Labeled_AE
during O
therapy O
have O
been O
reported O
during O
IMPAVIDO O
therapy O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

The O
effects O
of O
IMPAVIDO O
on O
human O
male O
fertility O
have O
not O
been O
adequately O
studied O
. O

Advise O
women O
and O
men O
of O
the O
animal O
fertility O
findings O
, O
and O
that O
the O
potential O
for O
impaired B-NonOSE_AE
fertility I-NonOSE_AE
with O
IMPAVIDO O
therapy O
in O
humans O
has O
not O
been O
adequately O
evaluated O
. O

5.3 O
Renal O
Effects O
Elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
( I-OSE_Labeled_AE
Cr I-OSE_Labeled_AE
) O
were O
noted O
in O
clinical O
trials O
evaluating O
IMPAVIDO O
in O
the O
treatment O
of O
cutaneous B-Not_AE_Candidate
, I-Not_AE_Candidate
mucosal I-Not_AE_Candidate
and I-Not_AE_Candidate
visceral I-Not_AE_Candidate
leishmaniasis I-Not_AE_Candidate
. O

Monitor O
renal O
function O
weekly O
in O
patients O
receiving O
IMPAVIDO O
during O
therapy O
and O
for O
4 O
weeks O
after O
end O
of O
therapy O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.4 O
Hepatic O
Effects O
Elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
( O
ALT O
, O
AST O
) O
and O
bilirubin O
were O
noted O
in O
clinical O
trials O
evaluating O
IMPAVIDO O
in O
the O
treatment O
of O
visceral B-Not_AE_Candidate
leishmaniasis I-Not_AE_Candidate
. O

Monitor O
liver O
transaminases O
( O
ALT O
, O
AST O
) O
and O
bilirubin O
during O
therapy O
in O
patients O
receiving O
IMPAVIDO O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.5 O
Gastrointestinal O
Effects O
Vomiting B-OSE_Labeled_AE
and/or O
diarrhea B-OSE_Labeled_AE
commonly O
occur O
during O
IMPAVIDO O
administration O
and O
may O
result O
in O
volume B-NonOSE_AE
depletion I-NonOSE_AE
. O

Encourage O
fluid O
intake O
to O
avoid O
volume B-NonOSE_AE
depletion I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.6 O
Thrombocytopenia O
Thrombocytopenia B-OSE_Labeled_AE
during O
therapy O
has O
been O
reported O
in O
patients O
treated O
for O
visceral B-Not_AE_Candidate
leishmaniasis I-Not_AE_Candidate
. O

Monitor O
platelet O
count O
during O
therapy O
for O
visceral B-Not_AE_Candidate
leishmaniasis I-Not_AE_Candidate
[ O
see O
Adverse O
Reactions O
( O
6.1 O
, O
6.2 O
) O
] O
. O

5.7 O
Absorption O
of O
Oral O
Contraceptives O
Vomiting B-NonOSE_AE
and/or O
diarrhea B-NonOSE_AE
occurring O
during O
IMPAVIDO O
therapy O
may O
affect O
the O
absorption O
of O
oral O
contraceptives O
, O
and O
therefore O
compromise O
their O
efficacy O
. O

If O
vomiting B-NonOSE_AE
and/or O
diarrhea B-NonOSE_AE
occur O
during O
IMPAVIDO O
therapy O
, O
advise O
females O
to O
use O
additional O
non-hormonal O
or O
alternative O
method O
( O
s O
) O
of O
effective O
contraception O
. O

5.8 O
Stevens-Johnson O
Syndrome O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
has O
been O
reported O
during O
IMPAVIDO O
therapy O
. O

Discontinue O
IMPAVIDO O
if O
an O
exfoliative B-NonOSE_AE
or O
bullous O
rash I-NonOSE_AE
is O
noted O
during O
therapy O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

6 O
ADVERSE O
REACTIONS O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

The O
safety O
of O
INLYTA O
has O
been O
evaluated O
in O
715 O
patients O
in O
monotherapy O
studies O
, O
which O
included O
537 O
patients O
with O
advanced O
RCC B-Not_AE_Candidate
. O

The O
data O
described O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
reflect O
exposure O
to O
INLYTA O
in O
359 O
patients O
with O
advanced O
RCC B-Not_AE_Candidate
who O
participated O
in O
a O
randomized O
clinical O
study O
versus O
sorafenib O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

The O
following O
risks O
, O
including O
appropriate O
action O
to O
be O
taken O
, O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
label O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1-5.13 O
) O
] O
: O
hypertension B-OSE_Labeled_AE
, O
arterial B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
hemorrhage B-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
and O
fistula O
formation O
, O
thyroid B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
, O
wound B-OSE_Labeled_AE
healing I-OSE_Labeled_AE
complications I-OSE_Labeled_AE
, O
RPLS B-OSE_Labeled_AE
, O
proteinuria B-OSE_Labeled_AE
, O
elevation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
enzymes I-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
and O
fetal B-OSE_Labeled_AE
development I-OSE_Labeled_AE
. O

EXCERPT O
: O
The O
most O
common O
( O
> O
=20 O
% O
) O
adverse O
reactions O
are O
diarrhea O
, O
hypertension O
, O
fatigue O
, O
decreased O
appetite O
, O
nausea O
, O
dysphonia O
, O
palmar-plantar O
erythrodysesthesia O
( O
hand-foot O
) O
syndrome O
, O
weight O
decreased O
, O
vomiting O
, O
asthenia O
, O
and O
constipation O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Pfizer O
, O
Inc O
at O
1-800-438-1985 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
The O
median O
duration O
of O
treatment O
was O
6.4 O
months O
( O
range O
0.03 O
to O
22.0 O
) O
for O
patients O
who O
received O
INLYTA O
and O
5.0 O
months O
( O
range O
0.03 O
to O
20.1 O
) O
for O
patients O
who O
received O
sorafenib O
. O

Dose O
modifications O
or O
temporary O
delay O
of O
treatment O
due O
to O
an O
adverse O
reaction O
occurred O
in O
199/359 O
patients O
( O
55 O
% O
) O
receiving O
INLYTA O
and O
220/355 O
patients O
( O
62 O
% O
) O
receiving O
sorafenib O
. O

Permanent O
discontinuation O
due O
to O
an O
adverse O
reaction O
occurred O
in O
34/359 O
patients O
( O
9 O
% O
) O
receiving O
INLYTA O
and O
46/355 O
patients O
( O
13 O
% O
) O
receiving O
sorafenib O
. O

The O
most O
common O
( O
> O
=20 O
% O
) O
adverse O
reactions O
observed O
following O
treatment O
with O
INLYTA O
were O
diarrhea B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
dysphonia B-OSE_Labeled_AE
, O
palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
erythrodysesthesia I-OSE_Labeled_AE
( I-OSE_Labeled_AE
hand I-OSE_Labeled_AE
- I-OSE_Labeled_AE
foot I-OSE_Labeled_AE
) I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
and O
constipation B-OSE_Labeled_AE
. O

Table O
1 O
presents O
adverse O
reactions O
reported O
in O
> O
=10 O
% O
patients O
who O
received O
INLYTA O
or O
sorafenib O
. O

Table O
1 O
. O

Adverse O
Reactions O
Occurring O
in O
> O
=10 O
% O
of O
Patients O
Who O
Received O
INLYTA O
or O
Sorafenib O
Adverse O
Reaction O
[ O
note O
: O
Percentages O
are O
treatment-emergent O
, O
all-causality O
events O
] O
INLYTA O
Sorafenib O
( O
N=359 O
) O
( O
N=355 O
) O
All O
Grades O
[ O
note O
: O
National O
Cancer O
Institute O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
, O
Version O
3.0 O
] O
Grade O
3/4 O
All O
Grades O
Grade O
3/4 O
% O
% O
% O
% O
Diarrhea B-OSE_Labeled_AE
55 O
11 O
53 O
7 O
Hypertension B-OSE_Labeled_AE
40 O
16 O
29 O
11 O
Fatigue B-OSE_Labeled_AE
39 O
11 O
32 O
5 O
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
34 O
5 O
29 O
4 O
Nausea B-OSE_Labeled_AE
32 O
3 O
22 O
1 O
Dysphonia B-OSE_Labeled_AE
31 O
0 O
14 O
0 O
Palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
erythrodysesthesia I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
27 O
5 O
51 O
16 O
Weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
25 O
2 O
21 O
1 O
Vomiting B-OSE_Labeled_AE
24 O
3 O
17 O
1 O
Asthenia B-OSE_Labeled_AE
21 O
5 O
14 O
3 O
Constipation B-OSE_Labeled_AE
20 O
1 O
20 O
1 O
Hypothyroidism B-OSE_Labeled_AE
19 O
< O
1 O
8 O
0 O
Cough B-OSE_Labeled_AE
15 O
1 O
17 O
1 O
Mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
15 O
1 O
12 O
1 O
Arthralgia B-OSE_Labeled_AE
15 O
2 O
11 O
1 O
Stomatitis B-OSE_Labeled_AE
15 O
1 O
12 O
< O
1 O
Dyspnea B-OSE_Labeled_AE
15 O
3 O
12 O
3 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
14 O
2 O
11 O
1 O
Headache B-OSE_Labeled_AE
14 O
1 O
11 O
0 O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
13 O
1 O
14 O
1 O
Rash B-OSE_Labeled_AE
13 O
< O
1 O
32 O
4 O
Proteinuria B-OSE_Labeled_AE
11 O
3 O
7 O
2 O
Dysgeusia B-OSE_Labeled_AE
11 O
0 O
8 O
0 O
Dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
10 O
0 O
11 O
0 O
Dyspepsia B-OSE_Labeled_AE
10 O
0 O
2 O
0 O
Pruritus B-OSE_Labeled_AE
7 O
0 O
12 O
0 O
Alopecia B-OSE_Labeled_AE
4 O
0 O
32 O
0 O
Erythema B-OSE_Labeled_AE
2 O
0 O
10 O
< O
1 O
Selected O
adverse O
reactions O
( O
all O
grades O
) O
that O
were O
reported O
in O
< O
10 O
% O
of O
patients O
treated O
with O
INLYTA O
included O
dizziness B-OSE_Labeled_AE
( O
9 O
% O
) O
, O
upper B-OSE_Labeled_AE
abdominal I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
8 O
% O
) O
, O
myalgia B-OSE_Labeled_AE
( O
7 O
% O
) O
, O
dehydration B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
epistaxis B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
anemia B-OSE_Labeled_AE
( O
4 O
% O
) O
, O
hemorrhoids B-OSE_Labeled_AE
( O
4 O
% O
) O
, O
hematuria B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
tinnitus B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
lipase B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
3 O
% O
) O
, O
glossodynia B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
( O
2 O
% O
) O
, O
rectal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
( O
2 O
% O
) O
, O
hemoptysis B-OSE_Labeled_AE
( O
2 O
% O
) O
, O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
( O
1 O
% O
) O
, O
retinal B-OSE_Labeled_AE
- I-OSE_Labeled_AE
vein I-OSE_Labeled_AE
occlusion I-OSE_Labeled_AE
/thrombosis O
( O
1 O
% O
) O
, O
polycythemia B-OSE_Labeled_AE
( O
1 O
% O
) O
, O
and O
transient B-OSE_Labeled_AE
ischemic I-OSE_Labeled_AE
attack I-OSE_Labeled_AE
( O
1 O
% O
) O
. O

Table O
2 O
presents O
the O
most O
common O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
reported O
in O
> O
=10 O
% O
patients O
who O
received O
INLYTA O
or O
sorafenib O
. O

Table O
2 O
. O

Laboratory O
Abnormalities O
Occurring O
in O
> O
=10 O
% O
of O
Patients O
Who O
Received O
INLYTA O
or O
Sorafenib O
Laboratory O
Abnormality O
N O
INLYTA O
N O
Sorafenib O
All O
Grades O
[ O
note O
: O
National O
Cancer O
Institute O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
, O
Version O
3.0 O
] O
Grade O
3/4 O
All O
Grades O
Grade O
3/4 O
% O
% O
% O
% O
ALP O
: O
alkaline O
phosphatase O
; O
ALT O
: O
alanine O
aminotransferase O
; O
AST O
: O
aspartate O
aminotransferase O
Hematology O
Hemoglobin B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
320 O
35 O
< O
1 O
316 O
52 O
4 O
Lymphocytes B-OSE_Labeled_AE
( I-OSE_Labeled_AE
absolute I-OSE_Labeled_AE
) I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
317 O
33 O
3 O
309 O
36 O
4 O
Platelets B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
312 O
15 O
< O
1 O
310 O
14 O
0 O
White B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cells I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
320 O
11 O
0 O
315 O
16 O
< O
1 O
Chemistry B-NonOSE_AE
Creatinine B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
336 O
55 O
0 O
318 O
41 O
< O
1 O
Bicarbonate B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
314 O
44 O
< O
1 O
291 O
43 O
0 O
Hypocalcemia B-OSE_Labeled_AE
336 O
39 O
1 O
319 O
59 O
2 O
ALP B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
336 O
30 O
1 O
319 O
34 O
1 O
Hyperglycemia B-OSE_Labeled_AE
336 O
28 O
2 O
319 O
23 O
2 O
Lipase B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
338 O
27 O
5 O
319 O
46 O
15 O
Amylase B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
338 O
25 O
2 O
319 O
33 O
2 O
ALT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
331 O
22 O
< O
1 O
313 O
22 O
2 O
AST B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
331 O
20 O
< O
1 O
311 O
25 O
1 O
Hypernatremia B-OSE_Labeled_AE
338 O
17 O
1 O
319 O
13 O
1 O
Hypoalbuminemia B-OSE_Labeled_AE
337 O
15 O
< O
1 O
319 O
18 O
1 O
Hyperkalemia B-OSE_Labeled_AE
333 O
15 O
3 O
314 O
10 O
3 O
Hypoglycemia B-OSE_Labeled_AE
336 O
11 O
< O
1 O
319 O
8 O
< O
1 O
Hyponatremia B-OSE_Labeled_AE
338 O
13 O
4 O
319 O
11 O
2 O
Hypophosphatemia B-OSE_Labeled_AE
336 O
13 O
2 O
318 O
49 O
16 O
Selected O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
( O
all O
grades O
) O
that O
were O
reported O
in O
< O
10 O
% O
of O
patients O
treated O
with O
INLYTA O
included O
hemoglobin B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
above O
the O
upper O
limit O
of O
normal O
) O
( O
9 O
% O
for O
INLYTA O
versus O
1 O
% O
for O
sorafenib O
) O
and O
hypercalcemia B-OSE_Labeled_AE
( O
6 O
% O
for O
INLYTA O
versus O
2 O
% O
for O
sorafenib O
) O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Hypertension O
including O
hypertensive O
crisis O
has O
been O
observed O
. O

Blood O
pressure O
should O
be O
well-controlled O
prior O
to O
initiating O
INLYTA O
. O

Monitor O
for O
hypertension O
and O
treat O
as O
needed O
. O

For O
persistent O
hypertension O
despite O
use O
of O
anti-hypertensive O
medications O
, O
reduce O
the O
INLYTA O
dose O
. O

( O
5.1 O
) O
* O
Arterial O
and O
venous O
thrombotic O
events O
have O
been O
observed O
and O
can O
be O
fatal O
. O

Use O
with O
caution O
in O
patients O
who O
are O
at O
increased O
risk O
for O
these O
events O
. O

( O
5.2 O
, O
5.3 O
) O
* O
Hemorrhagic O
events O
, O
including O
fatal O
events O
, O
have O
been O
reported O
. O

INLYTA O
has O
not O
been O
studied O
in O
patients O
with O
evidence O
of O
untreated O
brain O
metastasis O
or O
recent O
active O
gastrointestinal O
bleeding O
and O
should O
not O
be O
used O
in O
those O
patients O
. O

( O
5.4 O
) O
* O
Cardiac O
failure O
has O
been O
observed O
and O
can O
be O
fatal O
. O

Monitor O
for O
signs O
or O
symptoms O
of O
cardiac O
failure O
throughout O
treatment O
with O
INLYTA O
. O

( O
5.5 O
) O
* O
Gastrointestinal O
perforation O
and O
fistula O
, O
including O
death O
, O
have O
occurred O
. O

Use O
with O
caution O
in O
patients O
at O
risk O
for O
gastrointestinal O
perforation O
or O
fistula O
. O

( O
5.6 O
) O
* O
Hypothyroidism O
requiring O
thyroid O
hormone O
replacement O
has O
been O
reported O
. O

Monitor O
thyroid O
function O
before O
initiation O
of O
, O
and O
periodically O
throughout O
, O
treatment O
with O
INLYTA O
. O

( O
5.7 O
) O
* O
Stop O
INLYTA O
at O
least O
24 O
hours O
prior O
to O
scheduled O
surgery O
. O

( O
5.8 O
) O
* O
Reversible O
Posterior O
Leukoencephalopathy O
Syndrome O
( O
RPLS O
) O
has O
been O
observed O
. O

Permanently O
discontinue O
INLYTA O
if O
signs O
or O
symptoms O
of O
RPLS O
occur O
. O

( O
5.9 O
) O
* O
Monitor O
for O
proteinuria O
before O
initiation O
of O
, O
and O
periodically O
throughout O
, O
treatment O
with O
INLYTA O
. O

For O
moderate O
to O
severe O
proteinuria O
, O
reduce O
the O
dose O
or O
temporarily O
interrupt O
treatment O
with O
INLYTA O
. O

( O
5.10 O
) O
* O
Liver O
enzyme O
elevation O
has O
been O
observed O
during O
treatment O
with O
INLYTA O
. O

Monitor O
ALT O
, O
AST O
and O
bilirubin O
before O
initiation O
of O
, O
and O
periodically O
throughout O
, O
treatment O
with O
INLYTA O
. O

( O
5.11 O
) O
* O
The O
starting O
dose O
of O
INLYTA O
should O
be O
decreased O
if O
used O
in O
patients O
with O
moderate O
hepatic O
impairment O
. O

INLYTA O
has O
not O
been O
studied O
in O
patients O
with O
severe O
hepatic O
impairment O
. O

( O
2.2 O
, O
5.12 O
) O
* O
INLYTA O
can O
cause O
fetal O
harm O
when O
administered O
to O
a O
pregnant O
woman O
based O
on O
its O
mechanism O
of O
action O
. O

Women O
of O
childbearing O
potential O
should O
be O
advised O
of O
the O
potential O
hazard O
to O
the O
fetus O
and O
to O
avoid O
becoming O
pregnant O
while O
receiving O
INLYTA O
. O

( O
5.13 O
, O
8.1 O
) O
5.1 O
Hypertension O
and O
Hypertensive O
Crisis O
In O
a O
controlled O
clinical O
study O
with O
INLYTA O
for O
the O
treatment O
of O
patients O
with O
RCC B-Not_AE_Candidate
, O
hypertension B-OSE_Labeled_AE
was O
reported O
in O
145/359 O
patients O
( O
40 O
% O
) O
receiving O
INLYTA O
and O
103/355 O
patients O
( O
29 O
% O
) O
receiving O
sorafenib O
. O

Grade O
3/4 O
hypertension B-OSE_Labeled_AE
was O
observed O
in O
56/359 O
patients O
( O
16 O
% O
) O
receiving O
INLYTA O
and O
39/355 O
patients O
( O
11 O
% O
) O
receiving O
sorafenib O
. O

Hypertensive B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
was O
reported O
in O
2/359 O
patients O
( O
< O
1 O
% O
) O
receiving O
INLYTA O
and O
none O
of O
the O
patients O
receiving O
sorafenib O
. O

The O
median O
onset O
time O
for O
hypertension B-OSE_Labeled_AE
( O
systolic B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
> I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mmHg I-OSE_Labeled_AE
or O
diastolic B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
> I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mmHg I-OSE_Labeled_AE
) O
was O
within O
the O
first O
month O
of O
the O
start O
of O
INLYTA O
treatment O
and O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
increases I-OSE_Labeled_AE
have O
been O
observed O
as O
early O
as O
4 O
days O
after O
starting O
INLYTA O
. O

Hypertension B-NonOSE_AE
was O
managed O
with O
standard O
antihypertensive O
therapy O
. O

Discontinuation O
of O
INLYTA O
treatment O
due O
to O
hypertension B-OSE_Labeled_AE
occurred O
in O
1/359 O
patients O
( O
< O
1 O
% O
) O
receiving O
INLYTA O
and O
none O
of O
the O
patients O
receiving O
sorafenib O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Blood O
pressure O
should O
be O
well-controlled O
prior O
to O
initiating O
INLYTA O
. O

Patients O
should O
be O
monitored O
for O
hypertension B-NonOSE_AE
and O
treated O
as O
needed O
with O
standard O
anti B-NonOSE_AE
- I-NonOSE_AE
hypertensive I-NonOSE_AE
therapy I-NonOSE_AE
. O

In O
the O
case O
of O
persistent O
hypertension B-NonOSE_AE
despite O
use O
of O
anti B-NonOSE_AE
- I-NonOSE_AE
hypertensive I-NonOSE_AE
medications I-NonOSE_AE
, O
reduce O
the O
INLYTA O
dose O
. O

Discontinue O
INLYTA O
if O
hypertension B-NonOSE_AE
is O
severe O
and O
persistent O
despite O
anti B-NonOSE_AE
- I-NonOSE_AE
hypertensive I-NonOSE_AE
therapy I-NonOSE_AE
and O
dose O
reduction O
of O
INLYTA O
, O
and O
discontinuation O
should O
be O
considered O
if O
there O
is O
evidence O
of O
hypertensive B-NonOSE_AE
crisis I-NonOSE_AE
. O

If O
INLYTA O
is O
interrupted O
, O
patients O
receiving O
antihypertensive O
medications O
should O
be O
monitored O
for O
hypotension B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.2 O
Arterial O
Thromboembolic O
Events O
In O
clinical O
trials O
, O
arterial B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
have O
been O
reported O
, O
including O
deaths B-NonOSE_AE
. O

In O
a O
controlled O
clinical O
study O
with O
INLYTA O
for O
the O
treatment O
of O
patients O
with O
RCC B-Not_AE_Candidate
, O
Grade O
3/4 O
arterial B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
reported O
in O
4/359 O
patients O
( O
1 O
% O
) O
receiving O
INLYTA O
and O
4/355 O
patients O
( O
1 O
% O
) O
receiving O
sorafenib O
. O

Fatal B-NonOSE_AE
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
was O
reported O
in O
1/359 O
patients O
( O
< O
1 O
% O
) O
receiving O
INLYTA O
and O
none O
of O
the O
patients O
receiving O
sorafenib O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

In O
clinical O
trials O
with O
INLYTA O
, O
arterial B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
( O
including O
transient B-OSE_Labeled_AE
ischemic I-OSE_Labeled_AE
attack I-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
and O
retinal B-OSE_Labeled_AE
artery I-OSE_Labeled_AE
occlusion I-OSE_Labeled_AE
) O
were O
reported O
in O
17/715 O
patients O
( O
2 O
% O
) O
, O
with O
two O
deaths B-NonOSE_AE
secondary O
to O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
. O

Use O
INLYTA O
with O
caution O
in O
patients O
who O
are O
at O
risk O
for O
, O
or O
who O
have O
a O
history O
of O
, O
these O
events O
. O

INLYTA O
has O
not O
been O
studied O
in O
patients O
who O
had O
an O
arterial B-Not_AE_Candidate
thromboembolic I-Not_AE_Candidate
event I-Not_AE_Candidate
within O
the O
previous O
12 O
months O
. O

5.3 O
Venous O
Thromboembolic O
Events O
In O
clinical O
trials O
, O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
have O
been O
reported O
, O
including O
deaths B-NonOSE_AE
. O

In O
a O
controlled O
clinical O
study O
with O
INLYTA O
for O
the O
treatment O
of O
patients O
with O
RCC B-Not_AE_Candidate
, O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
reported O
in O
11/359 O
patients O
( O
3 O
% O
) O
receiving O
INLYTA O
and O
2/355 O
patients O
( O
1 O
% O
) O
receiving O
sorafenib O
. O

Grade O
3/4 O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
reported O
in O
9/359 O
patients O
( O
3 O
% O
) O
receiving O
INLYTA O
( O
including O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
, O
retinal B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
occlusion I-OSE_Labeled_AE
and O
retinal B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
) O
and O
2/355 O
patients O
( O
1 O
% O
) O
receiving O
sorafenib O
. O

Fatal B-NonOSE_AE
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
was O
reported O
in O
1/359 O
patients O
( O
< O
1 O
% O
) O
receiving O
INLYTA O
and O
none O
of O
the O
patients O
receiving O
sorafenib O
. O

In O
clinical O
trials O
with O
INLYTA O
, O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
reported O
in O
22/715 O
patients O
( O
3 O
% O
) O
, O
with O
two O
deaths B-NonOSE_AE
secondary O
to O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
. O

Use O
INLYTA O
with O
caution O
in O
patients O
who O
are O
at O
risk O
for O
, O
or O
who O
have O
a O
history O
of O
, O
these O
events O
. O

INLYTA O
has O
not O
been O
studied O
in O
patients O
who O
had O
a O
venous B-Not_AE_Candidate
thromboembolic I-Not_AE_Candidate
event I-Not_AE_Candidate
within O
the O
previous O
6 O
months O
. O

5.4 O
Hemorrhage O
In O
a O
controlled O
clinical O
study O
with O
INLYTA O
for O
the O
treatment O
of O
patients O
with O
RCC B-Not_AE_Candidate
, O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
reported O
in O
58/359 O
patients O
( O
16 O
% O
) O
receiving O
INLYTA O
and O
64/355 O
patients O
( O
18 O
% O
) O
receiving O
sorafenib O
. O

Grade O
3/4 O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
reported O
in O
5/359 O
( O
1 O
% O
) O
patients O
receiving O
INLYTA O
( O
including O
cerebral B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
hematuria B-OSE_Labeled_AE
, O
hemoptysis B-OSE_Labeled_AE
, O
lower B-OSE_Labeled_AE
gastrointestinal I-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
and O
melena B-OSE_Labeled_AE
) O
and O
11/355 O
( O
3 O
% O
) O
patients O
receiving O
sorafenib O
. O

Fatal B-NonOSE_AE
hemorrhage B-OSE_Labeled_AE
was O
reported O
in O
1/359 O
patients O
( O
< O
1 O
% O
) O
receiving O
INLYTA O
( O
gastric B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
) O
and O
3/355 O
patients O
( O
1 O
% O
) O
receiving O
sorafenib O
. O

INLYTA O
has O
not O
been O
studied O
in O
patients O
who O
have O
evidence O
of O
untreated O
brain B-Not_AE_Candidate
metastasis I-Not_AE_Candidate
or O
recent O
active B-Not_AE_Candidate
gastrointestinal I-Not_AE_Candidate
bleeding I-Not_AE_Candidate
and O
should O
not O
be O
used O
in O
those O
patients O
. O

If O
any O
bleeding B-NonOSE_AE
requires O
medical O
intervention O
, O
temporarily O
interrupt O
the O
INLYTA O
dose O
. O

5.5 O
Cardiac O
Failure O
In O
a O
controlled O
clinical O
study O
with O
INLYTA O
for O
the O
treatment O
of O
patients O
with O
RCC B-Not_AE_Candidate
, O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
was O
reported O
in O
6/359 O
patients O
( O
2 O
% O
) O
receiving O
INLYTA O
and O
3/355 O
patients O
( O
1 O
% O
) O
receiving O
sorafenib O
. O

Grade O
3/4 O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
was O
observed O
in O
2/359 O
patients O
( O
1 O
% O
) O
receiving O
INLYTA O
and O
1/355 O
patients O
( O
< O
1 O
% O
) O
receiving O
sorafenib O
. O

Fatal B-NonOSE_AE
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
was O
reported O
in O
2/359 O
patients O
( O
1 O
% O
) O
receiving O
INLYTA O
and O
1/355 O
patients O
( O
< O
1 O
% O
) O
receiving O
sorafenib O
. O

Monitor O
for O
signs O
or O
symptoms O
of O
cardiac B-NonOSE_AE
failure I-NonOSE_AE
throughout O
treatment O
with O
INLYTA O
. O

Management O
of O
cardiac B-NonOSE_AE
failure I-NonOSE_AE
may O
require O
permanent O
discontinuation O
of O
INLYTA O
. O

5.6 O
Gastrointestinal O
Perforation O
and O
Fistula O
Formation O
In O
a O
controlled O
clinical O
study O
with O
INLYTA O
for O
the O
treatment O
of O
patients O
with O
RCC O
, O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
was O
reported O
in O
1/359 O
patients O
( O
< O
1 O
% O
) O
receiving O
INLYTA O
and O
none O
of O
the O
patients O
receiving O
sorafenib O
. O

In O
clinical O
trials O
with O
INLYTA O
, O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
was O
reported O
in O
5/715 O
patients O
( O
1 O
% O
) O
, O
including O
one O
death B-NonOSE_AE
. O

In O
addition O
to O
cases O
of O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
, O
fistulas O
were O
reported O
in O
4/715 O
patients O
( O
1 O
% O
) O
. O

Monitor O
for O
symptoms O
of O
gastrointestinal B-NonOSE_AE
perforation I-NonOSE_AE
or O
fistula O
periodically O
throughout O
treatment O
with O
INLYTA O
. O

5.7 O
Thyroid O
Dysfunction O
In O
a O
controlled O
clinical O
study O
with O
INLYTA O
for O
the O
treatment O
of O
patients O
with O
RCC B-Not_AE_Candidate
, O
hypothyroidism B-OSE_Labeled_AE
was O
reported O
in O
69/359 O
patients O
( O
19 O
% O
) O
receiving O
INLYTA O
and O
29/355 O
patients O
( O
8 O
% O
) O
receiving O
sorafenib O
. O

Hyperthyroidism B-OSE_Labeled_AE
was O
reported O
in O
4/359 O
patients O
( O
1 O
% O
) O
receiving O
INLYTA O
and O
4/355 O
patients O
( O
1 O
% O
) O
receiving O
sorafenib O
. O

In O
patients O
who O
had O
thyroid B-Not_AE_Candidate
stimulating I-Not_AE_Candidate
hormone I-Not_AE_Candidate
( I-Not_AE_Candidate
TSH I-Not_AE_Candidate
) I-Not_AE_Candidate
< I-Not_AE_Candidate
5 I-Not_AE_Candidate
muU I-Not_AE_Candidate
/ I-Not_AE_Candidate
mL I-Not_AE_Candidate
before O
treatment O
, O
elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
TSH I-OSE_Labeled_AE
to O
> O
=10 O
muU/mL O
occurred O
in O
79/245 O
patients O
( O
32 O
% O
) O
receiving O
INLYTA O
and O
25/232 O
patients O
( O
11 O
% O
) O
receiving O
sorafenib O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Monitor O
thyroid O
function O
before O
initiation O
of O
, O
and O
periodically O
throughout O
, O
treatment O
with O
INLYTA O
. O

Treat O
hypothyroidism B-NonOSE_AE
and O
hyperthyroidism B-NonOSE_AE
according O
to O
standard O
medical O
practice O
to O
maintain O
euthyroid O
state O
. O

5.8 O
Wound O
Healing O
Complications O
No O
formal O
studies O
of O
the O
effect O
of O
INLYTA O
on O
wound B-Not_AE_Candidate
healing I-Not_AE_Candidate
have O
been O
conducted O
. O

Stop O
treatment O
with O
INLYTA O
at O
least O
24 O
hours O
prior O
to O
scheduled O
surgery O
. O

The O
decision O
to O
resume O
INLYTA O
therapy O
after O
surgery O
should O
be O
based O
on O
clinical O
judgment O
of O
adequate O
wound O
healing O
. O

5.9 O
Reversible O
Posterior O
Leukoencephalopathy O
Syndrome O
In O
a O
controlled O
clinical O
study O
with O
INLYTA O
for O
the O
treatment O
of O
patients O
with O
RCC B-Not_AE_Candidate
, O
reversible B-OSE_Labeled_AE
posterior I-OSE_Labeled_AE
leukoencephalopathy I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
RPLS I-OSE_Labeled_AE
) O
was O
reported O
in O
1/359 O
patients O
( O
< O
1 O
% O
) O
receiving O
INLYTA O
and O
none O
of O
the O
patients O
receiving O
sorafenib O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

There O
were O
two O
additional O
reports O
of O
RPLS B-OSE_Labeled_AE
in O
other O
clinical O
trials O
with O
INLYTA O
. O

RPLS B-NonOSE_AE
is O
a O
neurological O
disorder O
which O
can O
present O
with O
headache B-NonOSE_AE
, O
seizure B-NonOSE_AE
, O
lethargy B-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
blindness B-NonOSE_AE
and O
other O
visual B-NonOSE_AE
and O
neurologic O
disturbances I-NonOSE_AE
. O

Mild O
to O
severe O
hypertension B-NonOSE_AE
may O
be O
present O
. O

Magnetic O
resonance O
imaging O
is O
necessary O
to O
confirm O
the O
diagnosis O
of O
RPLS B-NonOSE_AE
. O

Discontinue O
INLYTA O
in O
patients O
developing O
RPLS B-NonOSE_AE
. O

The O
safety O
of O
reinitiating O
INLYTA O
therapy O
in O
patients O
previously O
experiencing O
RPLS B-Not_AE_Candidate
is O
not O
known O
. O

5.10 O
Proteinuria O
In O
a O
controlled O
clinical O
study O
with O
INLYTA O
for O
the O
treatment O
of O
patients O
with O
RCC B-Not_AE_Candidate
, O
proteinuria B-OSE_Labeled_AE
was O
reported O
in O
39/359 O
patients O
( O
11 O
% O
) O
receiving O
INLYTA O
and O
26/355 O
patients O
( O
7 O
% O
) O
receiving O
sorafenib O
. O

Grade O
3 O
proteinuria B-OSE_Labeled_AE
was O
reported O
in O
11/359 O
patients O
( O
3 O
% O
) O
receiving O
INLYTA O
and O
6/355 O
patients O
( O
2 O
% O
) O
receiving O
sorafenib O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Monitoring O
for O
proteinuria B-NonOSE_AE
before O
initiation O
of O
, O
and O
periodically O
throughout O
, O
treatment O
with O
INLYTA O
is O
recommended O
. O

For O
patients O
who O
develop O
moderate O
to O
severe O
proteinuria B-NonOSE_AE
, O
reduce O
the O
dose O
or O
temporarily O
interrupt O
INLYTA O
treatment O
. O

5.11 O
Elevation O
of O
Liver O
Enzymes O
In O
a O
controlled O
clinical O
study O
with O
INLYTA O
for O
the O
treatment O
of O
patients O
with O
RCC B-Not_AE_Candidate
, O
alanine B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
) I-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
of O
all O
grades O
occurred O
in O
22 O
% O
of O
patients O
on O
both O
arms O
, O
with O
Grade O
3/4 O
events O
in O
< O
1 O
% O
of O
patients O
on O
the O
INLYTA O
arm O
and O
2 O
% O
of O
patients O
on O
the O
sorafenib O
arm O
. O

Monitor O
ALT O
, O
aspartate O
aminotransferase O
( O
AST O
) O
and O
bilirubin O
before O
initiation O
of O
and O
periodically O
throughout O
treatment O
with O
INLYTA O
. O

5.12 O
Hepatic O
Impairment O
The O
systemic O
exposure O
to O
axitinib O
was O
higher O
in O
subjects O
with O
moderate O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
( O
Child B-Not_AE_Candidate
- I-Not_AE_Candidate
Pugh I-Not_AE_Candidate
class I-Not_AE_Candidate
B I-Not_AE_Candidate
) O
compared O
to O
subjects O
with O
normal O
hepatic O
function O
. O

A O
dose O
decrease O
is O
recommended O
when O
administering O
INLYTA O
to O
patients O
with O
moderate O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
( O
Child B-Not_AE_Candidate
- I-Not_AE_Candidate
Pugh I-Not_AE_Candidate
class I-Not_AE_Candidate
B I-Not_AE_Candidate
) O
. O

INLYTA O
has O
not O
been O
studied O
in O
patients O
with O
severe O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
( O
Child B-Not_AE_Candidate
- I-Not_AE_Candidate
Pugh I-Not_AE_Candidate
class I-Not_AE_Candidate
C I-Not_AE_Candidate
) O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
, O
and O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

5.13 O
Pregnancy O
INLYTA O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
based O
on O
its O
mechanism O
of O
action O
. O

There O
are O
no O
adequate O
and O
well-controlled O
studies O
in O
pregnant B-Not_AE_Candidate
women O
using O
INLYTA O
. O

In O
developmental B-NonOSE_AE
toxicity I-NonOSE_AE
studies O
in O
mice O
, O
axitinib O
was O
teratogenic B-NonOSE_AE
, O
embryotoxic B-NonOSE_AE
and O
fetotoxic B-NonOSE_AE
at O
maternal O
exposures O
that O
were O
lower O
than O
human O
exposures O
at O
the O
recommended O
clinical O
dose O
. O

Women O
of O
childbearing O
potential O
should O
be O
advised O
to O
avoid O
becoming O
pregnant B-NonOSE_AE
while O
receiving O
INLYTA O
. O

If O
this O
drug O
is O
used O
during O
pregnancy B-Not_AE_Candidate
, O
or O
if O
a O
patient O
becomes O
pregnant B-NonOSE_AE
while O
receiving O
this O
drug O
, O
the O
patient O
should O
be O
apprised O
of O
the O
potential O
hazard B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
important O
adverse O
reactions O
are O
described O
below O
and O
elsewhere O
in O
the O
labeling O
: O
* O
Lower B-OSE_Labeled_AE
Limb I-OSE_Labeled_AE
Amputation I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Hypotension B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Ketoacidosis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Acute B-OSE_Labeled_AE
Kidney I-OSE_Labeled_AE
Injury I-OSE_Labeled_AE
and O
Impairment B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Renal I-OSE_Labeled_AE
Function I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Hyperkalemia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Urosepsis B-OSE_Labeled_AE
and O
Pyelonephritis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Hypoglycemia B-NonOSE_AE
with O
Concomitant O
Use O
with O
Insulin O
and O
Insulin O
Secretagogues O
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Genital B-OSE_Labeled_AE
Mycotic I-OSE_Labeled_AE
Infections I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Hypersensitivity B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Bone B-OSE_Labeled_AE
Fracture I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
* O
Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Low I-OSE_Labeled_AE
- I-OSE_Labeled_AE
Density I-OSE_Labeled_AE
Lipoprotein I-OSE_Labeled_AE
( O
LDL-C O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
* O
Most O
common O
adverse O
reactions O
associated O
with O
INVOKANA O
( O
5 O
% O
or O
greater O
incidence O
) O
: O
female B-OSE_Labeled_AE
genital I-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
and O
increased B-OSE_Labeled_AE
urination I-OSE_Labeled_AE
( O
6.1 O
) O
EXCERPT O
: O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Janssen O
Pharmaceuticals O
, O
Inc O
. O
at O
1-800-526-7736 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Studies O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
the O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

Pool O
of O
Placebo-Controlled O
Trials O
The O
data O
in O
Table O
1 O
is O
derived O
from O
four O
26-week O
placebo-controlled O
trials O
. O

In O
one O
trial O
INVOKANA O
was O
used O
as O
monotherapy O
and O
in O
three O
trials O
INVOKANA O
was O
used O
as O
add-on O
therapy O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

These O
data O
reflect O
exposure O
of O
1667 O
patients O
to O
INVOKANA O
and O
a O
mean O
duration O
of O
exposure O
to O
INVOKANA O
of O
24 O
weeks O
. O

Patients O
received O
INVOKANA O
100 O
mg O
( O
N=833 O
) O
, O
INVOKANA O
300 O
mg O
( O
N=834 O
) O
or O
placebo O
( O
N=646 O
) O
once O
daily O
. O

The O
mean O
age O
of O
the O
population O
was O
56 O
years O
and O
2 O
% O
were O
older O
than O
75 O
years O
of O
age O
. O

Fifty O
percent O
( O
50 O
% O
) O
of O
the O
population O
was O
male O
and O
72 O
% O
were O
Caucasian O
, O
12 O
% O
were O
Asian O
, O
and O
5 O
% O
were O
Black O
or O
African O
American O
. O

At O
baseline O
the O
population O
had O
diabetes B-Not_AE_Candidate
for O
an O
average O
of O
7.3 O
years O
, O
had O
a O
mean O
HbA1Cof O
8.0 O
% O
and O
20 O
% O
had O
established O
microvascular B-Not_AE_Candidate
complications I-Not_AE_Candidate
of I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
. O

Baseline O
renal B-Not_AE_Candidate
function I-Not_AE_Candidate
was O
normal O
or O
mildly I-Not_AE_Candidate
impaired I-Not_AE_Candidate
( O
mean O
eGFR B-Not_AE_Candidate
8 I-Not_AE_Candidate
8 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
) O
. O

Table O
1 O
shows O
common O
adverse O
reactions O
associated O
with O
the O
use O
of O
INVOKANA O
. O

These O
adverse O
reactions O
were O
not O
present O
at O
baseline O
, O
occurred O
more O
commonly O
on O
INVOKANA O
than O
on O
placebo O
, O
and O
occurred O
in O
at O
least O
2 O
% O
of O
patients O
treated O
with O
either O
INVOKANA O
100 O
mg O
or O
INVOKANA O
300 O
mg O
. O
Table O
1 O
: O
Adverse O
Reactions O
From O
Pool O
of O
Four O
26-Week O
Placebo-Controlled O
Studies O
Reported O
in O
> O
= O
2 O
% O
of O
INVOKANA-Treated O
PatientsThe O
four O
placebo-controlled O
trials O
included O
one O
monotherapy O
trial O
and O
three O
add-on O
combination O
trials O
with O
metformin O
, O
metformin O
and O
sulfonylurea O
, O
or O
metformin O
and O
pioglitazone O
. O

Note O
: O
Percentages O
were O
weighted O
by O
studies O
. O

Study O
weights O
were O
proportional O
to O
the O
harmonic O
mean O
of O
the O
three O
treatment O
sample O
sizes O
. O

Adverse O
Reaction O
PlaceboN=646 O
INVOKANA O
100 O
mgN=833 O
INVOKANA O
300 O
mgN=834 O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
[ O
note O
: O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
include O
the O
following O
adverse O
reactions O
: O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
Cystitis B-OSE_Labeled_AE
, O
Kidney B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
and O
Urosepsis B-OSE_Labeled_AE
. O
] O

3.8 O
% O
5.9 O
% O
4.4 O
% O
Increased B-OSE_Labeled_AE
urination I-OSE_Labeled_AE
[ O
note O
: O
Increased B-OSE_Labeled_AE
urination I-OSE_Labeled_AE
includes O
the O
following O
adverse O
reactions O
: O
Polyuria B-OSE_Labeled_AE
, O
Pollakiuria B-OSE_Labeled_AE
, O
Urine B-OSE_Labeled_AE
output I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
Micturition B-OSE_Labeled_AE
urgency I-OSE_Labeled_AE
, O
and O
Nocturia B-OSE_Labeled_AE
. O
] O

0.7 O
% O
5.1 O
% O
4.6 O
% O
Thirst B-OSE_Labeled_AE
[ O
note O
: O
Thirst O
includes O
the O
following O
adverse O
reactions O
: O
Thirst B-OSE_Labeled_AE
, O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
and O
Polydipsia B-OSE_Labeled_AE
. O
] O

0.1 O
% O
2.8 O
% O
2.4 O
% O
Constipation B-OSE_Labeled_AE
0.9 O
% O
1.8 O
% O
2.4 O
% O
Nausea B-OSE_Labeled_AE
1.6 O
% O
2.1 O
% O
2.3 O
% O
N=312 O
N=425 O
N=430 O
Female B-OSE_Labeled_AE
genital I-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
[ O
note O
: O
Female B-OSE_Labeled_AE
genital I-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
include O
the O
following O
adverse O
reactions O
: O
Vulvovaginal B-OSE_Labeled_AE
candidiasis I-OSE_Labeled_AE
, O
Vulvovaginal B-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
Vulvovaginitis B-OSE_Labeled_AE
, O
Vaginal B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
Vulvitis B-OSE_Labeled_AE
, O
and O
Genital B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
. O
] O

2.8 O
% O
10.6 O
% O
11.6 O
% O
Vulvovaginal B-OSE_Labeled_AE
pruritus I-OSE_Labeled_AE
0.0 O
% O
1.6 O
% O
3.2 O
% O
N=334 O
N=408 O
N=404 O
Male B-OSE_Labeled_AE
genital I-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
[ O
note O
: O
Male B-OSE_Labeled_AE
genital I-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
s O
include O
the O
following O
adverse O
reactions O
: O
Balanitis B-OSE_Labeled_AE
or O
Balanoposthitis B-OSE_Labeled_AE
, O
Balanitis B-OSE_Labeled_AE
candida I-OSE_Labeled_AE
, O
and O
Genital B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
. O
] O

0.7 O
% O
4.2 O
% O
3.8 O
% O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
was O
also O
more O
commonly O
reported O
in O
patients O
taking O
INVOKANA O
100 O
mg O
( O
1.8 O
% O
) O
, O
300 O
mg O
( O
1.7 O
% O
) O
than O
in O
patients O
taking O
placebo O
( O
0.8 O
% O
) O
. O

Pool O
of O
Placebo- O
and O
Active-Controlled O
Trials O
The O
occurrence O
of O
adverse O
reactions O
for O
canagliflozin O
was O
evaluated O
in O
a O
larger O
pool O
of O
patients O
participating O
in O
placebo- O
and O
active-controlled O
trials O
. O

The O
data O
combined O
eight O
clinical O
trials O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
and O
reflect O
exposure O
of O
6177 O
patients O
to O
INVOKANA O
. O

The O
mean O
duration O
of O
exposure O
to O
INVOKANA O
was O
38 O
weeks O
with O
1832 O
individuals O
exposed O
to O
INVOKANA O
for O
greater O
than O
50 O
weeks O
. O

Patients O
received O
INVOKANA O
100 O
mg O
( O
N=3092 O
) O
, O
INVOKANA O
300 O
mg O
( O
N=3085 O
) O
or O
comparator O
( O
N=3262 O
) O
once O
daily O
. O

The O
mean O
age O
of O
the O
population O
was O
60 O
years O
and O
5 O
% O
were O
older O
than O
75 O
years O
of O
age O
. O

Fifty-eight O
percent O
( O
58 O
% O
) O
of O
the O
population O
was O
male O
and O
73 O
% O
were O
Caucasian O
, O
16 O
% O
were O
Asian O
, O
and O
4 O
% O
were O
Black O
or O
African O
American O
. O

At O
baseline O
, O
the O
population O
had O
diabetes B-Not_AE_Candidate
for O
an O
average O
of O
11 O
years O
, O
had O
a O
mean O
HbA1Cof O
8.0 O
% O
and O
33 O
% O
had O
established O
microvascular B-Not_AE_Candidate
complications I-Not_AE_Candidate
of I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
. O

Baseline O
renal B-Not_AE_Candidate
function I-Not_AE_Candidate
was I-Not_AE_Candidate
normal I-Not_AE_Candidate
or I-Not_AE_Candidate
mildly I-Not_AE_Candidate
impaired I-Not_AE_Candidate
( O
mean O
eGFR B-Not_AE_Candidate
8 I-Not_AE_Candidate
1 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
) O
. O

The O
types O
and O
frequency O
of O
common O
adverse O
reactions O
observed O
in O
the O
pool O
of O
eight O
clinical O
trials O
were O
consistent O
with O
those O
listed O
in O
Table O
1 O
. O

Percentages O
were O
weighted O
by O
studies O
. O

Study O
weights O
were O
proportional O
to O
the O
harmonic O
mean O
of O
the O
three O
treatment O
sample O
sizes O
. O

In O
this O
pool O
, O
INVOKANA O
was O
also O
associated O
with O
the O
adverse O
reactions O
of O
fatigue B-OSE_Labeled_AE
( O
1.8 O
% O
with O
comparator O
, O
2.2 O
% O
with O
INVOKANA O
100 O
mg O
, O
and O
2.0 O
% O
with O
INVOKANA O
300 O
mg O
) O
and O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
strength I-OSE_Labeled_AE
or I-OSE_Labeled_AE
energy I-OSE_Labeled_AE
( O
i.e. O
, O
asthenia B-OSE_Labeled_AE
) O
( O
0.6 O
% O
with O
comparator O
, O
0.7 O
% O
with O
INVOKANA O
100 O
mg O
, O
and O
1.1 O
% O
with O
INVOKANA O
300 O
mg O
) O
. O

In O
the O
pool O
of O
eight O
clinical O
trials O
, O
the O
incidence O
rate O
of O
pancreatitis B-OSE_Labeled_AE
( O
acute O
or O
chronic I-OSE_Labeled_AE
) O
was O
0.1 O
% O
, O
0.2 O
% O
, O
and O
0.1 O
% O
receiving O
comparator O
, O
INVOKANA O
100 O
mg O
, O
and O
INVOKANA O
300 O
mg O
, O
respectively O
. O

In O
the O
pool O
of O
eight O
clinical O
trials O
, O
hypersensitivity B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
including O
erythema B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
and O
angioedema B-OSE_Labeled_AE
) O
occurred O
in O
3.0 O
% O
, O
3.8 O
% O
, O
and O
4.2 O
% O
of O
patients O
receiving O
comparator O
, O
INVOKANA O
100 O
mg O
, O
and O
INVOKANA O
300 O
mg O
, O
respectively O
. O

Five O
patients O
experienced O
serious O
adverse O
reactions O
of O
hypersensitivity B-OSE_Labeled_AE
with O
INVOKANA O
, O
which O
included O
4 O
patients O
with O
urticaria B-OSE_Labeled_AE
and O
1 O
patient O
with O
a O
diffuse B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
and O
urticaria B-OSE_Labeled_AE
occurring O
within O
hours O
of O
exposure O
to O
INVOKANA O
. O

Among O
these O
patients O
, O
2 O
patients O
discontinued O
INVOKANA O
. O

One O
patient O
with O
urticaria B-OSE_Labeled_AE
had O
recurrence O
when O
INVOKANA O
was O
re-initiated O
. O

Photosensitivity B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
including O
photosensitivity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
polymorphic B-OSE_Labeled_AE
light I-OSE_Labeled_AE
eruption I-OSE_Labeled_AE
, O
and O
sunburn B-OSE_Labeled_AE
) O
occurred O
in O
0.1 O
% O
, O
0.2 O
% O
, O
and O
0.2 O
% O
of O
patients O
receiving O
comparator O
, O
INVOKANA O
100 O
mg O
, O
and O
INVOKANA O
300 O
mg O
, O
respectively O
. O

Other O
adverse O
reactions O
occurring O
more O
frequently O
on O
INVOKANA O
than O
on O
comparator O
were O
: O
Lower O
Limb O
Amputation O
An O
approximately O
2-fold O
increased O
risk O
of O
lower B-OSE_Labeled_AE
limb I-OSE_Labeled_AE
amputations I-OSE_Labeled_AE
associated O
with O
INVOKANA O
use O
was O
observed O
in O
CANVAS O
and O
CANVAS-R O
, O
two O
large O
, O
randomized O
, O
placebo-controlled O
trials O
evaluating O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
who O
had O
either O
established O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
were O
at O
risk O
for O
cardiovascular B-NonOSE_AE
disease I-NonOSE_AE
. O

Patients O
in O
CANVAS O
and O
CANVAS-R O
were O
followed O
for O
an O
average O
of O
5.7 O
and O
2.1 O
years O
, O
respectively O
. O

The O
amputation B-NonOSE_AE
data O
for O
CANVAS O
and O
CANVAS-R O
are O
shown O
in O
Tables O
2 O
and O
3 O
, O
respectively O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Table O
2 O
: O
CANVAS O
Amputations O
PlaceboN=1441 O
INVOKANA O
100 O
mgN=1445 O
INVOKANA O
300 O
mgN=1441 O
INVOKANA O
( O
Pooled O
) O
N=2886 O
Note O
: O
Incidence O
is O
based O
on O
the O
number O
of O
patients O
with O
at O
least O
one O
amputation B-NonOSE_AE
, O
and O
not O
the O
total O
number O
of O
amputation B-NonOSE_AE
events O
. O

A O
patient O
's O
follow-up O
is O
calculated O
from O
Day O
1 O
to O
the O
first O
amputation B-NonOSE_AE
event O
date O
. O

Some O
patients O
had O
more O
than O
one O
amputation B-NonOSE_AE
. O

Patients O
with O
an O
amputation B-OSE_Labeled_AE
, O
n O
( O
% O
) O
22 O
( O
1.5 O
) O
50 O
( O
3.5 O
) O
45 O
( O
3.1 O
) O
95 O
( O
3.3 O
) O
Total O
amputations B-OSE_Labeled_AE
33 O
83 O
79 O
162 O
Amputation B-OSE_Labeled_AE
incidence O
rate O
( O
per O
1000 O
patient-years O
) O
2.8 O
6.2 O
5.5 O
5.9 O
Hazard O
Ratio O
( O
95 O
% O
CI O
) O
-- O
2.24 O
( O
1.36 O
, O
3.69 O
) O
2.01 O
( O
1.20 O
, O
3.34 O
) O
2.12 O
( O
1.34 O
, O
3.38 O
) O
Table O
3 O
: O
CANVAS-R O
Amputations O
PlaceboN=2903 O
INVOKANA O
100 O
mg O
( O
with O
up-titration O
to O
300 O
mg O
) O
N=2904 O
Note O
: O
Incidence O
is O
based O
on O
the O
number O
of O
patients O
with O
at O
least O
one O
amputation B-NonOSE_AE
, O
and O
not O
the O
total O
number O
of O
amputation B-NonOSE_AE
events I-NonOSE_AE
. O

A O
patient O
's O
follow-up O
is O
calculated O
from O
Day O
1 O
to O
the O
first O
amputation B-NonOSE_AE
event O
date O
. O

Some O
patients O
had O
more O
than O
one O
amputation B-NonOSE_AE
. O

Patients O
with O
an O
amputation B-OSE_Labeled_AE
, O
n O
( O
% O
) O
25 O
( O
0.9 O
) O
45 O
( O
1.5 O
) O
Total O
amputations B-OSE_Labeled_AE
36 O
59 O
Amputation B-OSE_Labeled_AE
incidence O
rate O
( O
per O
1000 O
patient-years O
) O
4.2 O
7.5 O
Hazard O
Ratio O
( O
95 O
% O
CI O
) O
-- O
1.80 O
( O
1.10 O
, O
2.93 O
) O
Volume O
Depletion-Related O
Adverse O
Reactions O
INVOKANA O
results O
in O
an O
osmotic O
diuresis O
, O
which O
may O
lead O
to O
reductions B-OSE_Labeled_AE
in I-OSE_Labeled_AE
intravascular I-OSE_Labeled_AE
volume I-OSE_Labeled_AE
. O

In O
clinical O
studies O
, O
treatment O
with O
INVOKANA O
was O
associated O
with O
a O
dose-dependent O
increase O
in O
the O
incidence O
of O
volume B-OSE_Labeled_AE
depletion I-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
e.g. O
, O
hypotension B-OSE_Labeled_AE
, O
postural B-OSE_Labeled_AE
dizziness I-OSE_Labeled_AE
, O
orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
, O
and O
dehydration B-OSE_Labeled_AE
) O
. O

An O
increased O
incidence O
was O
observed O
in O
patients O
on O
the O
300 O
mg O
dose O
. O

The O
three O
factors O
associated O
with O
the O
largest O
increase O
in O
volume B-NonOSE_AE
depletion I-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
were O
the O
use O
of O
loop O
diuretics O
, O
moderate B-Not_AE_Candidate
renal I-Not_AE_Candidate
impairment I-Not_AE_Candidate
( O
eGFR B-Not_AE_Candidate
3 I-Not_AE_Candidate
0 I-Not_AE_Candidate
to I-Not_AE_Candidate
less I-Not_AE_Candidate
than I-Not_AE_Candidate
6 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
) O
, O
and O
age O
75 O
years O
and O
older O
( O
Table O
4 O
) O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
, O
Warnings O
and O
Precautions O
( O
5.2 O
) O
, O
and O
Use O
in O
Specific O
Populations O
( O
8.5 O
and O
8.6 O
) O
] O
. O

Table O
4 O
: O
Proportion O
of O
Patients O
With O
at O
Least O
One O
Volume B-OSE_Labeled_AE
Depletion I-OSE_Labeled_AE
- I-OSE_Labeled_AE
Related I-OSE_Labeled_AE
Adverse I-OSE_Labeled_AE
Reaction I-OSE_Labeled_AE
( O
Pooled O
Results O
from O
8 O
Clinical O
Trials O
) O
Baseline O
Characteristic O
Comparator O
Group O
[ O
note O
: O
Includes O
placebo O
and O
active-comparator O
groups O
] O
% O
INVOKANA O
100 O
mg O
% O
INVOKANA O
300 O
mg O
% O
Overall O
population O
1.5 O
% O
2.3 O
% O
3.4 O
% O
75 O
years O
of O
age O
and O
older O
[ O
note O
: O
Patients O
could O
have O
more O
than O
1 O
of O
the O
listed O
risk O
factors O
] O
2.6 O
% O
4.9 O
% O
8.7 O
% O
eGFR B-Not_AE_Candidate
less I-Not_AE_Candidate
than I-Not_AE_Candidate
6 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
2.5 O
% O
4.7 O
% O
8.1 O
% O
Use O
of O
loop O
diuretic O
4.7 O
% O
3.2 O
% O
8.8 O
% O
Falls O
In O
a O
pool O
of O
nine O
clinical O
trials O
with O
mean O
duration O
of O
exposure O
to O
INVOKANA O
of O
85 O
weeks O
, O
the O
proportion O
of O
patients O
who O
experienced O
falls B-OSE_Labeled_AE
was O
1.3 O
% O
, O
1.5 O
% O
, O
and O
2.1 O
% O
with O
comparator O
, O
INVOKANA O
100 O
mg O
, O
and O
INVOKANA O
300 O
mg O
, O
respectively O
. O

The O
higher O
risk O
of O
falls B-OSE_Labeled_AE
for O
patients O
treated O
with O
INVOKANA O
was O
observed O
within O
the O
first O
few O
weeks O
of O
treatment O
. O

Impairment O
in O
Renal O
Function O
INVOKANA O
is O
associated O
with O
a O
dose-dependent O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
and O
a O
concomitant O
fall B-OSE_Labeled_AE
in I-OSE_Labeled_AE
estimated I-OSE_Labeled_AE
GFR I-OSE_Labeled_AE
( O
Table O
5 O
) O
. O

Patients O
with O
moderate O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
at O
baseline O
had O
larger O
mean O
changes O
. O

Table O
5 O
: O
Changes B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Serum O
Creatinine O
and O
eGFR I-OSE_Labeled_AE
Associated O
with O
INVOKANA O
in O
the O
Pool O
of O
Four O
Placebo-Controlled O
Trials O
and O
Moderate O
Renal O
Impairment O
Trial O
PlaceboN=646 O
INVOKANA O
100 O
mgN=833 O
INVOKANA O
300 O
mgN=834 O
Pool O
of O
Four O
Placebo-Controlled O
Trials O
Baseline O
Creatinine O
( O
mg/dL O
) O
0.84 O
0.82 O
0.82 O
eGFR O
( O
mL/min/1.73 O
m O
2 O
) O
87.0 O
88.3 O
88.8 O
Week O
6 O
Change O
Creatinine O
( O
mg/dL O
) O
0.01 O
0.03 O
0.05 O
eGFR O
( O
mL/min/1.73 O
m O
2 O
) O
-1.6 O
-3.8 O
-5.0 O
End O
of O
Treatment O
Change O
[ O
note O
: O
Week O
26 O
in O
mITT O
LOCF O
population O
] O
Creatinine O
( O
mg/dL O
) O
0.01 O
0.02 O
0.03 O
eGFR O
( O
mL/min/1.73 O
m O
2 O
) O
-1.6 O
-2.3 O
-3.4 O
PlaceboN=90 O
INVOKANA O
100 O
mgN=90 O
INVOKANA O
300 O
mgN=89 O
Moderate B-Not_AE_Candidate
Renal I-Not_AE_Candidate
Impairment I-Not_AE_Candidate
Trial O
Baseline O
Creatinine O
( O
mg/dL O
) O
1.61 O
1.62 O
1.63 O
eGFR O
( O
mL/min/1.73 O
m O
2 O
) O
40.1 O
39.7 O
38.5 O
Week O
3 O
Change O
Creatinine O
( O
mg/dL O
) O
0.03 O
0.18 O
0.28 O
eGFR O
( O
mL/min/1.73 O
m O
2 O
) O
-0.7 O
-4.6 O
-6.2 O
End O
of O
Treatment O
Change O
Creatinine O
( O
mg/dL O
) O
0.07 O
0.16 O
0.18 O
eGFR O
( O
mL/min/1.73 O
m O
2 O
) O
-1.5 O
-3.6 O
-4.0 O
In O
the O
pool O
of O
four O
placebo-controlled O
trials O
where O
patients O
had O
normal O
or O
mildly O
impaired B-Not_AE_Candidate
baseline I-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
, O
the O
proportion O
of O
patients O
who O
experienced O
at O
least O
one O
event O
of O
significant O
renal B-OSE_Labeled_AE
function I-OSE_Labeled_AE
decline I-OSE_Labeled_AE
, O
defined O
as O
an O
eGFR B-NonOSE_AE
below I-NonOSE_AE
8 I-NonOSE_AE
0 I-NonOSE_AE
mL I-NonOSE_AE
/ I-NonOSE_AE
min I-NonOSE_AE
/ I-NonOSE_AE
1 I-NonOSE_AE
. I-NonOSE_AE
7 I-NonOSE_AE
3 I-NonOSE_AE
m I-NonOSE_AE
2 I-NonOSE_AE
and O
30 O
% O
lower O
than O
baseline O
, O
was O
2.1 O
% O
with O
placebo O
, O
2.0 O
% O
with O
INVOKANA O
100 O
mg O
, O
and O
4.1 O
% O
with O
INVOKANA O
300 O
mg O
. O
At O
the O
end O
of O
treatment O
, O
0.5 O
% O
with O
placebo O
, O
0.7 O
% O
with O
INVOKANA O
100 O
mg O
, O
and O
1.4 O
% O
with O
INVOKANA O
300 O
mg O
had O
a O
significant O
renal B-OSE_Labeled_AE
function I-OSE_Labeled_AE
decline I-OSE_Labeled_AE
. O

In O
a O
trial O
carried O
out O
in O
patients O
with O
moderate O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
with O
a O
baseline O
eGFR B-Not_AE_Candidate
of I-Not_AE_Candidate
3 I-Not_AE_Candidate
0 I-Not_AE_Candidate
to I-Not_AE_Candidate
less I-Not_AE_Candidate
than I-Not_AE_Candidate
5 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
( O
mean O
baseline O
eGFR B-Not_AE_Candidate
3 I-Not_AE_Candidate
9 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
) O
[ O
see O
Clinical O
Studies O
( O
14.3 O
) O
] O
, O
the O
proportion O
of O
patients O
who O
experienced O
at O
least O
one O
event O
of O
significant O
renal B-OSE_Labeled_AE
function I-OSE_Labeled_AE
decline I-OSE_Labeled_AE
, O
defined O
as O
an O
eGFR B-OSE_Labeled_AE
3 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
% I-OSE_Labeled_AE
lower I-OSE_Labeled_AE
than I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
, O
was O
6.9 O
% O
with O
placebo O
, O
18 O
% O
with O
INVOKANA O
100 O
mg O
, O
and O
22.5 O
% O
with O
INVOKANA O
300 O
mg O
. O
At O
the O
end O
of O
treatment O
, O
4.6 O
% O
with O
placebo O
, O
3.4 O
% O
with O
INVOKANA O
100 O
mg O
, O
and O
2.2 O
% O
with O
INVOKANA O
300 O
mg O
had O
a O
significant O
renal B-OSE_Labeled_AE
function I-OSE_Labeled_AE
decline I-OSE_Labeled_AE
. O

In O
a O
pooled O
population O
of O
patients O
with O
moderate O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
( O
N=1085 O
) O
with O
baseline O
eGFR B-Not_AE_Candidate
of I-Not_AE_Candidate
3 I-Not_AE_Candidate
0 I-Not_AE_Candidate
to I-Not_AE_Candidate
less I-Not_AE_Candidate
than I-Not_AE_Candidate
6 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 O
( O
mean O
baseline O
eGFR B-Not_AE_Candidate
4 I-Not_AE_Candidate
8 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
) O
, O
the O
overall O
incidence O
of O
these O
events O
was O
lower O
than O
in O
the O
dedicated O
trial O
but O
a O
dose-dependent O
increase O
in O
incident O
episodes O
of O
significant O
renal B-OSE_Labeled_AE
function I-OSE_Labeled_AE
decline I-OSE_Labeled_AE
compared O
to O
placebo O
was O
still O
observed O
. O

Use O
of O
INVOKANA O
has O
been O
associated O
with O
an O
increased O
incidence O
of O
renal B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
e.g. O
, O
increased B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
glomerular I-OSE_Labeled_AE
filtration I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
and O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
) O
, O
particularly O
in O
patients O
with O
moderate O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
. O

In O
the O
pooled O
analysis O
of O
patients O
with O
moderate O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
the O
incidence O
of O
renal B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
was O
3.7 O
% O
with O
placebo O
, O
8.9 O
% O
with O
INVOKANA O
100 O
mg O
, O
and O
9.3 O
% O
with O
INVOKANA O
300 O
mg O
. O
Discontinuations O
due O
to O
renal B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
events I-OSE_Labeled_AE
occurred O
in O
1.0 O
% O
with O
placebo O
, O
1.2 O
% O
with O
INVOKANA O
100 O
mg O
, O
and O
1.6 O
% O
with O
INVOKANA O
300 O
mg O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

Genital O
Mycotic O
Infections O
In O
the O
pool O
of O
four O
placebo-controlled O
clinical O
trials O
, O
female B-OSE_Labeled_AE
genital I-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
( O
e.g. O
, O
vulvovaginal B-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
vulvovaginal B-OSE_Labeled_AE
candidiasis I-OSE_Labeled_AE
, O
and O
vulvovaginitis B-OSE_Labeled_AE
) O
occurred O
in O
2.8 O
% O
, O
10.6 O
% O
, O
and O
11.6 O
% O
of O
females O
treated O
with O
placebo O
, O
INVOKANA O
100 O
mg O
, O
and O
INVOKANA O
300 O
mg O
, O
respectively O
. O

Patients O
with O
a O
history O
of O
genital B-Not_AE_Candidate
mycotic I-Not_AE_Candidate
infections I-Not_AE_Candidate
were O
more O
likely O
to O
develop O
genital B-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
on O
INVOKANA O
. O

Female B-NonOSE_AE
patients O
who O
developed O
genital I-NonOSE_AE
mycotic I-NonOSE_AE
infections I-NonOSE_AE
on O
INVOKANA O
were O
more O
likely O
to O
experience O
recurrence O
and O
require O
treatment O
with O
oral O
or O
topical O
antifungal O
agents O
and O
anti-microbial O
agents O
. O

In O
females B-OSE_Labeled_AE
, O
discontinuation O
due O
to O
genital I-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
occurred O
in O
0 O
% O
and O
0.7 O
% O
of O
patients O
treated O
with O
placebo O
and O
INVOKANA O
, O
respectively O
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
. O

In O
the O
pool O
of O
four O
placebo-controlled O
clinical O
trials O
, O
male B-OSE_Labeled_AE
genital I-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
( O
e.g. O
, O
candidal B-OSE_Labeled_AE
balanitis I-OSE_Labeled_AE
, O
balanoposthitis B-OSE_Labeled_AE
) O
occurred O
in O
0.7 O
% O
, O
4.2 O
% O
, O
and O
3.8 O
% O
of O
males O
treated O
with O
placebo O
, O
INVOKANA O
100 O
mg O
, O
and O
INVOKANA O
300 O
mg O
, O
respectively O
. O

Male B-OSE_Labeled_AE
genital I-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
occurred O
more O
commonly O
in O
uncircumcised O
males O
and O
in O
males O
with O
a O
prior O
history O
of O
balanitis B-Not_AE_Candidate
or O
balanoposthitis B-Not_AE_Candidate
. O

Male O
patients O
who O
developed O
genital B-NonOSE_AE
mycotic I-NonOSE_AE
infections I-NonOSE_AE
on O
INVOKANA O
were O
more O
likely O
to O
experience O
recurrent O
infections O
( O
22 O
% O
on O
INVOKANA O
versus O
none O
on O
placebo O
) O
, O
and O
require O
treatment O
with O
oral O
or O
topical O
antifungal O
agents O
and O
anti-microbial O
agents O
than O
patients O
on O
comparators O
. O

In O
males O
, O
discontinuations O
due O
to O
genital B-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
occurred O
in O
0 O
% O
and O
0.5 O
% O
of O
patients O
treated O
with O
placebo O
and O
INVOKANA O
, O
respectively O
. O

In O
the O
pooled O
analysis O
of O
8 O
controlled O
trials O
, O
phimosis B-OSE_Labeled_AE
was O
reported O
in O
0.3 O
% O
of O
uncircumcised O
male O
patients O
treated O
with O
INVOKANA O
and O
0.2 O
% O
required O
circumcision O
to O
treat O
the O
phimosis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
. O

Hypoglycemia O
In O
all O
clinical O
trials O
, O
hypoglycemia B-NonOSE_AE
was O
defined O
as O
any O
event O
regardless O
of O
symptoms O
, O
where O
biochemical O
hypoglycemia B-NonOSE_AE
was O
documented O
( O
any O
glucose B-NonOSE_AE
value I-NonOSE_AE
below I-NonOSE_AE
or I-NonOSE_AE
equal I-NonOSE_AE
to I-NonOSE_AE
7 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
) O
. O

Severe O
hypoglycemia B-NonOSE_AE
was O
defined O
as O
an O
event O
consistent O
with O
hypoglycemia B-NonOSE_AE
where O
the O
patient O
required O
the O
assistance O
of O
another O
person O
to O
recover O
, O
lost B-NonOSE_AE
consciousness I-NonOSE_AE
, O
or O
experienced O
a O
seizure B-NonOSE_AE
( O
regardless O
of O
whether O
biochemical O
documentation O
of O
a O
low B-NonOSE_AE
glucose I-NonOSE_AE
value I-NonOSE_AE
was O
obtained O
) O
. O

In O
individual O
clinical O
trials O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
, O
episodes O
of O
hypoglycemia B-NonOSE_AE
occurred O
at O
a O
higher O
rate O
when O
INVOKANA O
was O
co-administered O
with O
insulin O
or O
sulfonylureas O
( O
Table O
6 O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
. O

Table O
6 O
: O
Incidence O
of O
Hypoglycemia B-OSE_Labeled_AE
Number O
of O
patients O
experiencing O
at O
least O
one O
event O
of O
hypoglycemia B-OSE_Labeled_AE
based O
on O
either O
biochemically O
documented O
episodes O
or O
severe O
hypoglycemic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
in O
the O
intent-to-treat O
population O
in O
Controlled O
Clinical O
Studies O
Monotherapy O
( O
26 O
weeks O
) O
Placebo O
( O
N=192 O
) O
INVOKANA O
100 O
mg O
( O
N=195 O
) O
INVOKANA O
300 O
mg O
( O
N=197 O
) O
Overall O
[ O
N O
( O
% O
) O
] O
5 O
( O
2.6 O
) O
7 O
( O
3.6 O
) O
6 O
( O
3.0 O
) O
In O
Combination O
with O
Metformin O
( O
26 O
weeks O
) O
Placebo O
+ O
Metformin O
( O
N=183 O
) O
INVOKANA O
100 O
mg O
+ O
Metformin O
( O
N=368 O
) O
INVOKANA O
300 O
mg O
+ O
Metformin O
( O
N=367 O
) O
Overall O
[ O
N O
( O
% O
) O
] O
3 O
( O
1.6 O
) O
16 O
( O
4.3 O
) O
17 O
( O
4.6 O
) O
Severe O
[ O
N O
( O
% O
) O
] O
[ O
note O
: O
Severe O
episodes O
of O
hypoglycemia B-NonOSE_AE
were O
defined O
as O
those O
where O
the O
patient O
required O
the O
assistance O
of O
another O
person O
to O
recover O
, O
lost O
consciousness O
, O
or O
experienced O
a O
seizure O
( O
regardless O
of O
whether O
biochemical O
documentation O
of O
a O
low O
glucose O
value O
was O
obtained O
) O
] O
0 O
( O
0 O
) O
1 O
( O
0.3 O
) O
1 O
( O
0.3 O
) O
In O
Combination O
with O
Metformin O
( O
52 O
weeks O
) O
Glimepiride O
+ O
Metformin O
( O
N=482 O
) O
INVOKANA O
100 O
mg O
+ O
Metformin O
( O
N=483 O
) O
INVOKANA O
300 O
mg O
+ O
Metformin O
( O
N=485 O
) O
Overall O
[ O
N O
( O
% O
) O
] O
165 O
( O
34.2 O
) O
27 O
( O
5.6 O
) O
24 O
( O
4.9 O
) O
Severe O
[ O
N O
( O
% O
) O
] O
15 O
( O
3.1 O
) O
2 O
( O
0.4 O
) O
3 O
( O
0.6 O
) O
In O
Combination O
with O
Sulfonylurea O
( O
18 O
weeks O
) O
Placebo O
+ O
Sulfonylurea O
( O
N=69 O
) O
INVOKANA O
100 O
mg O
+ O
Sulfonylurea O
( O
N=74 O
) O
INVOKANA O
300 O
mg O
+ O
Sulfonylurea O
( O
N=72 O
) O
Overall O
[ O
N O
( O
% O
) O
] O
4 O
( O
5.8 O
) O
3 O
( O
4.1 O
) O
9 O
( O
12.5 O
) O
In O
Combination O
with O
Metformin O
+ O
Sulfonylurea O
( O
26 O
weeks O
) O
Placebo O
+ O
Metformin O
+ O
Sulfonylurea O
( O
N=156 O
) O
INVOKANA O
100 O
mg O
+ O
Metformin O
+ O
Sulfonylurea O
( O
N=157 O
) O
INVOKANA O
300 O
mg O
+ O
Metformin O
+ O
Sulfonylurea O
( O
N=156 O
) O
Overall O
[ O
N O
( O
% O
) O
] O
24 O
( O
15.4 O
) O
43 O
( O
27.4 O
) O
47 O
( O
30.1 O
) O
Severe O
[ O
N O
( O
% O
) O
] O
1 O
( O
0.6 O
) O
1 O
( O
0.6 O
) O
0 O
In O
Combination O
with O
Metformin O
+ O
Sulfonylurea O
( O
52 O
weeks O
) O
Sitagliptin O
+ O
Metformin O
+ O
Sulfonylurea O
( O
N=378 O
) O
INVOKANA O
300 O
mg O
+ O
Metformin O
+ O
Sulfonylurea O
( O
N=377 O
) O
Overall O
[ O
N O
( O
% O
) O
] O
154 O
( O
40.7 O
) O
163 O
( O
43.2 O
) O
Severe O
[ O
N O
( O
% O
) O
] O
13 O
( O
3.4 O
) O
15 O
( O
4.0 O
) O
In O
Combination O
with O
Metformin O
+ O
Pioglitazone O
( O
26 O
weeks O
) O
Placebo O
+ O
Metformin O
+ O
Pioglitazone O
( O
N=115 O
) O
INVOKANA O
100 O
mg O
+ O
Metformin O
+ O
Pioglitazone O
( O
N=113 O
) O
INVOKANA O
300 O
mg O
+ O
Metformin O
+ O
Pioglitazone O
( O
N=114 O
) O
Overall O
[ O
N O
( O
% O
) O
] O
3 O
( O
2.6 O
) O
3 O
( O
2.7 O
) O
6 O
( O
5.3 O
) O
In O
Combination O
with O
Insulin O
( O
18 O
weeks O
) O
Placebo O
( O
N=565 O
) O
INVOKANA O
100 O
mg O
( O
N=566 O
) O
INVOKANA O
300 O
mg O
( O
N=587 O
) O
Overall O
[ O
N O
( O
% O
) O
] O
208 O
( O
36.8 O
) O
279 O
( O
49.3 O
) O
285 O
( O
48.6 O
) O
Severe O
[ O
N O
( O
% O
) O
] O
14 O
( O
2.5 O
) O
10 O
( O
1.8 O
) O
16 O
( O
2.7 O
) O
Bone O
Fracture O
The O
occurrence O
of O
bone B-NonOSE_AE
fractures I-NonOSE_AE
was O
evaluated O
in O
a O
pool O
of O
nine O
clinical O
trials O
with O
a O
mean O
duration O
of O
exposure O
to O
INVOKANA O
of O
85 O
weeks O
. O

The O
incidence O
rates O
of O
adjudicated O
bone B-OSE_Labeled_AE
fractures I-OSE_Labeled_AE
were O
1.1 O
, O
1.4 O
, O
and O
1.5 O
per O
100 O
patient-years O
of O
exposure O
in O
the O
comparator O
, O
INVOKANA O
100 O
mg O
, O
and O
INVOKANA O
300 O
mg O
groups O
, O
respectively O
. O

Fractures B-OSE_Labeled_AE
were O
observed O
as O
early O
as O
12 O
weeks O
after O
treatment O
initiation O
and O
were O
more O
likely O
to O
be O
low O
trauma O
( O
e.g. O
, O
fall B-NonOSE_AE
from O
no O
more O
than O
standing O
height O
) O
, O
and O
affect O
the O
upper O
extremities O
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
. O

Laboratory O
and O
Imaging O
Tests O
Increases O
in O
Serum O
Potassium O
In O
a O
pooled O
population O
of O
patients O
( O
N=723 O
) O
with O
moderate O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
( O
eGFR B-Not_AE_Candidate
4 I-Not_AE_Candidate
5 I-Not_AE_Candidate
to I-Not_AE_Candidate
less I-Not_AE_Candidate
than I-Not_AE_Candidate
6 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
) O
, O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
potassium I-OSE_Labeled_AE
to O
greater O
than O
5.4 O
mEq/L O
and O
15 O
% O
above O
baseline O
occurred O
in O
5.3 O
% O
, O
5.0 O
% O
, O
and O
8.8 O
% O
of O
patients O
treated O
with O
placebo O
, O
INVOKANA O
100 O
mg O
, O
and O
INVOKANA O
300 O
mg O
, O
respectively O
. O

Severe O
elevations O
( O
greater O
than O
or O
equal O
to O
6.5 O
mEq/L O
) O
occurred O
in O
0.4 O
% O
of O
patients O
treated O
with O
placebo O
, O
no O
patients O
treated O
with O
INVOKANA O
100 O
mg O
, O
and O
1.3 O
% O
of O
patients O
treated O
with O
INVOKANA O
300 O
mg O
. O

In O
these O
patients O
, O
increases B-NonOSE_AE
in I-NonOSE_AE
potassium I-NonOSE_AE
were O
more O
commonly O
seen O
in O
those O
with O
elevated B-Not_AE_Candidate
potassium I-Not_AE_Candidate
at O
baseline O
. O

Among O
patients O
with O
moderate O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
approximately O
84 O
% O
were O
taking O
medications O
that O
interfere O
with O
potassium O
excretion O
, O
such O
as O
potassium-sparing O
diuretics O
, O
angiotensin-converting-enzyme O
inhibitors O
, O
and O
angiotensin-receptor O
blockers O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
and O
5.5 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
] O
. O

Increases O
in O
Serum O
Magnesium O
Dose-related O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
magnesium I-OSE_Labeled_AE
were O
observed O
early O
after O
initiation O
of O
INVOKANA O
( O
within O
6 O
weeks O
) O
and O
remained O
elevated O
throughout O
treatment O
. O

In O
the O
pool O
of O
four O
placebo-controlled O
trials O
, O
the O
mean B-OSE_Labeled_AE
percent I-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
magnesium I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
was O
8.1 O
% O
and O
9.3 O
% O
with O
INVOKANA O
100 O
mg O
and O
INVOKANA O
300 O
mg O
, O
respectively O
, O
compared O
to O
-0.6 O
% O
with O
placebo O
. O

In O
a O
trial O
of O
patients O
with O
moderate O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
[ O
see O
Clinical O
Studies O
( O
14.3 O
) O
] O
, O
serum B-OSE_Labeled_AE
magnesium I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
by O
0.2 O
% O
, O
9.2 O
% O
, O
and O
14.8 O
% O
with O
placebo O
, O
INVOKANA O
100 O
mg O
, O
and O
INVOKANA O
300 O
mg O
, O
respectively O
. O

Increases O
in O
Serum O
Phosphate O
Dose-related O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
phosphate I-OSE_Labeled_AE
levels O
were O
observed O
with O
INVOKANA O
. O

In O
the O
pool O
of O
four O
placebo O
controlled O
trials O
, O
the O
mean O
percent O
change B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
phosphate I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
were O
3.6 O
% O
and O
5.1 O
% O
with O
INVOKANA O
100 O
mg O
and O
INVOKANA O
300 O
mg O
, O
respectively O
, O
compared O
to O
1.5 O
% O
with O
placebo O
. O

In O
a O
trial O
of O
patients O
with O
moderate O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
[ O
see O
Clinical O
Studies O
( O
14.3 O
) O
] O
, O
the O
mean O
serum B-OSE_Labeled_AE
phosphate I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
by O
1.2 O
% O
, O
5.0 O
% O
, O
and O
9.3 O
% O
with O
placebo O
, O
INVOKANA O
100 O
mg O
, O
and O
INVOKANA O
300 O
mg O
, O
respectively O
. O

Increases O
in O
Low-Density O
Lipoprotein O
Cholesterol O
( O
LDL-C O
) O
and O
non-High-Density O
Lipoprotein O
Cholesterol O
( O
non-HDL-C O
) O
In O
the O
pool O
of O
four O
placebo-controlled O
trials O
, O
dose-related O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
LDL I-OSE_Labeled_AE
- I-OSE_Labeled_AE
C I-OSE_Labeled_AE
with O
INVOKANA O
were O
observed O
. O

Mean B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
( I-OSE_Labeled_AE
percent I-OSE_Labeled_AE
changes I-OSE_Labeled_AE
) I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
in I-OSE_Labeled_AE
LDL I-OSE_Labeled_AE
- I-OSE_Labeled_AE
C I-OSE_Labeled_AE
relative O
to O
placebo O
were O
4.4 O
mg/dL O
( O
4.5 O
% O
) O
and O
8.2 O
mg/dL O
( O
8.0 O
% O
) O
with O
INVOKANA O
100 O
mg O
and O
INVOKANA O
300 O
mg O
, O
respectively O
. O

The O
mean O
baseline O
LDL-C O
levels O
were O
104 O
to O
110 O
mg/dL O
across O
treatment O
groups O
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
. O

Dose-related O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
non I-OSE_Labeled_AE
- I-OSE_Labeled_AE
HDL I-OSE_Labeled_AE
- I-OSE_Labeled_AE
C I-OSE_Labeled_AE
with O
INVOKANA O
were O
observed O
. O

Mean O
changes B-OSE_Labeled_AE
( I-OSE_Labeled_AE
percent I-OSE_Labeled_AE
changes I-OSE_Labeled_AE
) I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
in I-OSE_Labeled_AE
non I-OSE_Labeled_AE
- I-OSE_Labeled_AE
HDL I-OSE_Labeled_AE
- I-OSE_Labeled_AE
C I-OSE_Labeled_AE
relative O
to O
placebo O
were O
2.1 O
mg/dL O
( O
1.5 O
% O
) O
and O
5.1 O
mg/dL O
( O
3.6 O
% O
) O
with O
INVOKANA O
100 O
mg O
and O
300 O
mg O
, O
respectively O
. O

The O
mean O
baseline O
non-HDL-C O
levels O
were O
140 O
to O
147 O
mg/dL O
across O
treatment O
groups O
. O

Increases O
in O
Hemoglobin O
In O
the O
pool O
of O
four O
placebo-controlled O
trials O
, O
mean O
changes B-OSE_Labeled_AE
( I-OSE_Labeled_AE
percent I-OSE_Labeled_AE
changes I-OSE_Labeled_AE
) I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
were O
-0.18 O
g/dL O
( O
-1.1 O
% O
) O
with O
placebo O
, O
0.47 O
g/dL O
( O
3.5 O
% O
) O
with O
INVOKANA O
100 O
mg O
, O
and O
0.51 O
g/dL O
( O
3.8 O
% O
) O
with O
INVOKANA O
300 O
mg O
. O

The O
mean O
baseline O
hemoglobin O
value O
was O
approximately O
14.1 O
g/dL O
across O
treatment O
groups O
. O

At O
the O
end O
of O
treatment O
, O
0.8 O
% O
, O
4.0 O
% O
, O
and O
2.7 O
% O
of O
patients O
treated O
with O
placebo O
, O
INVOKANA O
100 O
mg O
, O
and O
INVOKANA O
300 O
mg O
, O
respectively O
, O
had O
hemoglobin B-OSE_Labeled_AE
above I-OSE_Labeled_AE
the I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
limit I-OSE_Labeled_AE
of I-OSE_Labeled_AE
normal I-OSE_Labeled_AE
. O

Decreases O
in O
Bone O
Mineral O
Density O
Bone O
mineral O
density O
( O
BMD O
) O
was O
measured O
by O
dual-energy O
X-ray O
absorptiometry O
in O
a O
clinical O
trial O
of O
714 O
older O
adults O
( O
mean O
age O
64 O
years O
) O
[ O
see O
Clinical O
Studies O
( O
14.3 O
) O
] O
. O

At O
2 O
years O
, O
patients O
randomized O
to O
INVOKANA O
100 O
mg O
and O
INVOKANA O
300 O
mg O
had O
placebo-corrected O
declines B-OSE_Labeled_AE
in I-OSE_Labeled_AE
BMD I-OSE_Labeled_AE
at I-OSE_Labeled_AE
the O
total O
hip O
of O
0.9 O
% O
and O
1.2 O
% O
, O
respectively O
, O
and O
at O
the O
lumbar I-OSE_Labeled_AE
spine I-OSE_Labeled_AE
of O
0.3 O
% O
and O
0.7 O
% O
, O
respectively O
. O

Additionally O
, O
placebo-adjusted O
BMD B-OSE_Labeled_AE
declines I-OSE_Labeled_AE
were O
0.1 O
% O
at I-OSE_Labeled_AE
the I-OSE_Labeled_AE
femoral O
neck O
for O
both O
INVOKANA O
doses O
and O
0.4 O
% O
at O
the O
distal I-OSE_Labeled_AE
forearm I-OSE_Labeled_AE
for O
patients O
randomized O
to O
INVOKANA O
300 O
mg O
. O

The O
placebo-adjusted O
change O
at O
the O
distal O
forearm O
for O
patients O
randomized O
to O
INVOKANA O
100 O
mg O
was O
0 O
% O
. O

6.2 O
Postmarketing O
Experience O
Additional O
adverse O
reactions O
have O
been O
identified O
during O
postapproval O
use O
of O
INVOKANA O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
generally O
not O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Ketoacidosis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
Acute B-OSE_Labeled_AE
Kidney I-OSE_Labeled_AE
Injury I-OSE_Labeled_AE
and O
Impairment B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Renal I-OSE_Labeled_AE
Function I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
Anaphylaxis B-OSE_Labeled_AE
, O
Angioedema B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
Urosepsis B-OSE_Labeled_AE
and O
Pyelonephritis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O

BOXED O
WARNING O
: O
WARNING O
: O
LOWER O
LIMB O
AMPUTATION O
WARNING O
: O
LOWER O
LIMB O
AMPUTATION O
* O
An O
approximately O
2-fold O
increased O
risk O
of O
lower B-OSE_Labeled_AE
limb I-OSE_Labeled_AE
amputations I-OSE_Labeled_AE
associated O
with O
INVOKANA O
use O
was O
observed O
in O
CANVAS O
and O
CANVAS-R O
, O
two O
large O
, O
randomized O
, O
placebo-controlled O
trials O
in O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
who O
had O
established O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
( I-Not_AE_Candidate
CVD I-Not_AE_Candidate
) O
or O
were O
at O
risk O
for O
CVD B-Not_AE_Candidate
. O

* O
Amputations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
toe I-OSE_Labeled_AE
and O
midfoot O
were O
most O
frequent O
; O
however O
, O
amputations B-OSE_Labeled_AE
involving I-OSE_Labeled_AE
the I-OSE_Labeled_AE
leg I-OSE_Labeled_AE
were O
also O
observed O
. O

Some O
patients O
had O
multiple O
amputations B-OSE_Labeled_AE
, O
some O
involving O
both O
limbs O
. O

* O
Before O
initiating O
, O
consider O
factors O
that O
may O
increase O
the O
risk O
of O
amputation B-NonOSE_AE
, O
such O
as O
a O
history O
of O
prior O
amputation B-Not_AE_Candidate
, O
peripheral B-Not_AE_Candidate
vascular I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
neuropathy B-Not_AE_Candidate
, O
and O
diabetic B-Not_AE_Candidate
foot I-Not_AE_Candidate
ulcers I-Not_AE_Candidate
. O

* O
Monitor O
patients O
receiving O
INVOKANA O
for O
infection B-NonOSE_AE
, O
new O
pain B-NonOSE_AE
or O
tenderness B-NonOSE_AE
, O
sores B-NonOSE_AE
or O
ulcers O
involving I-NonOSE_AE
the I-NonOSE_AE
lower I-NonOSE_AE
limbs I-NonOSE_AE
, O
and O
discontinue O
if O
these O
complications O
occur O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
LOWER O
LIMB O
AMPUTATION O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
In O
patients O
with O
type O
2 O
diabetes O
who O
have O
established O
cardiovascular O
disease O
( O
CVD O
) O
or O
at O
risk O
for O
CVD O
, O
INVOKANA O
has O
been O
associated O
with O
lower O
limb O
amputations O
, O
most O
frequently O
of O
the O
toe O
and O
midfoot O
; O
some O
also O
involved O
the O
leg O
( O
5.1 O
) O
* O
Before O
initiating O
, O
consider O
factors O
that O
may O
increase O
the O
risk O
of O
amputation O
. O

Monitor O
patients O
receiving O
INVOKANA O
for O
infections O
or O
ulcers O
of O
the O
lower O
limbs O
, O
and O
discontinue O
if O
these O
occur O
. O

( O
5.1 O
) O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Lower O
limb O
amputation O
: O
See O
boxed O
warning O
( O
5.1 O
) O
* O
Hypotension O
: O
Before O
initiating O
INVOKANA O
, O
assess O
volume O
status O
and O
correct O
hypovolemia O
in O
patients O
with O
renal O
impairment O
, O
the O
elderly O
, O
in O
patients O
with O
low O
systolic O
blood O
pressure O
, O
or O
if O
on O
diuretics O
, O
ACEi O
, O
or O
ARB O
. O

Monitor O
for O
signs O
and O
symptoms O
during O
therapy O
( O
5.2 O
) O
* O
Ketoacidosis O
: O
Assess O
patients O
who O
present O
with O
signs O
and O
symptoms O
of O
metabolic O
acidosis O
for O
ketoacidosis O
, O
regardless O
of O
blood O
glucose O
level O
. O

If O
suspected O
, O
discontinue O
INVOKANA O
, O
evaluate O
and O
treat O
promptly O
. O

Before O
initiating O
INVOKANA O
, O
consider O
risk O
factors O
for O
ketoacidosis O
. O

Patients O
on O
INVOKANA O
may O
require O
monitoring O
and O
temporary O
discontinuation O
of O
therapy O
in O
clinical O
situations O
known O
to O
predispose O
to O
ketoacidosis O
( O
5.3 O
) O
* O
Acute O
kidney O
injury O
and O
impairment O
in O
renal O
function O
: O
Consider O
temporarily O
discontinuing O
in O
settings O
of O
reduced O
oral O
intake O
or O
fluid O
losses O
. O

If O
acute O
kidney O
injury O
occurs O
, O
discontinue O
and O
promptly O
treat O
. O

Monitor O
renal O
function O
during O
therapy O
( O
5.4 O
) O
* O
Hyperkalemia O
: O
Monitor O
potassium O
levels O
in O
patients O
with O
impaired O
renal O
function O
and O
in O
patients O
predisposed O
to O
hyperkalemia O
( O
2.2 O
, O
5.5 O
, O
6.1 O
, O
8.6 O
) O
* O
Urosepsis O
and O
pyelonephritis O
: O
Evaluate O
patients O
for O
signs O
and O
symptoms O
of O
urinary O
tract O
infections O
and O
treat O
promptly O
, O
if O
indicated O
( O
5.6 O
) O
* O
Hypoglycemia O
: O
Consider O
a O
lower O
dose O
of O
insulin O
or O
the O
insulin O
secretagogue O
to O
reduce O
the O
risk O
of O
hypoglycemia O
when O
used O
in O
combination O
with O
INVOKANA O
( O
5.7 O
) O
* O
Genital O
mycotic O
infections O
: O
Monitor O
and O
treat O
if O
indicated O
( O
5.8 O
) O
* O
Hypersensitivity O
reactions O
: O
Discontinue O
INVOKANA O
and O
monitor O
until O
signs O
and O
symptoms O
resolve O
( O
5.9 O
) O
* O
Bone O
fracture O
: O
Consider O
factors O
that O
contribute O
to O
fracture O
risk O
before O
initiating O
INVOKANA O
( O
5.10 O
) O
* O
Increased O
LDL-C O
: O
Monitor O
LDL-C O
and O
treat O
if O
appropriate O
( O
5.11 O
) O
5.1 O
Lower O
Limb O
Amputation O
An O
approximately O
2-fold O
increased O
risk O
of O
lower B-OSE_Labeled_AE
limb I-OSE_Labeled_AE
amputations I-OSE_Labeled_AE
associated O
with O
INVOKANA O
use O
was O
observed O
in O
CANVAS O
and O
CANVAS-R O
, O
two O
large O
, O
randomized O
, O
placebo-controlled O
trials O
evaluating O
patients O
with O
type O
2 O
diabetes O
who O
had O
either O
established O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
were O
at O
risk O
for O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

In O
CANVAS O
, O
INVOKANA-treated O
patients O
and O
placebo-treated O
patients O
had O
5.9 O
and O
2.8 O
amputations B-OSE_Labeled_AE
per O
1000 O
patients O
per O
year O
, O
respectively O
. O

In O
CANVAS-R O
, O
INVOKANA-treated O
patients O
and O
placebo-treated O
patients O
had O
7.5 O
and O
4.2 O
amputations B-OSE_Labeled_AE
per O
1000 O
patients O
per O
year O
, O
respectively O
. O

The O
risk O
of O
lower B-OSE_Labeled_AE
limb I-OSE_Labeled_AE
amputations I-OSE_Labeled_AE
was O
observed O
at O
both O
the O
100 O
mg O
and O
300 O
mg O
once O
daily O
dosage O
regimens O
. O

The O
amputation B-NonOSE_AE
data O
for O
CANVAS O
and O
CANVAS-R O
are O
shown O
in O
Tables O
2 O
and O
3 O
, O
respectively O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Amputations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the O
toe O
and O
midfoot I-OSE_Labeled_AE
( O
99 O
out O
of O
140 O
patients O
with O
amputations B-OSE_Labeled_AE
receiving O
INVOKANA O
in O
the O
two O
trials O
) O
were O
the O
most O
frequent O
; O
however O
, O
amputations B-OSE_Labeled_AE
involving I-OSE_Labeled_AE
the I-OSE_Labeled_AE
leg I-OSE_Labeled_AE
, O
below O
and O
above O
the O
knee O
, O
were O
also O
observed O
( O
41 O
out O
of O
140 O
patients O
with O
amputations B-OSE_Labeled_AE
receiving O
INVOKANA O
in O
the O
two O
trials O
) O
. O

Some O
patients O
had O
multiple O
amputations B-OSE_Labeled_AE
, O
some O
involving O
both O
lower O
limbs O
. O

Lower B-NonOSE_AE
limb I-NonOSE_AE
infections I-NonOSE_AE
, O
gangrene B-NonOSE_AE
, O
and O
diabetic B-NonOSE_AE
foot I-NonOSE_AE
ulcers I-NonOSE_AE
were O
the O
most O
common O
precipitating O
medical O
events O
leading O
to O
the O
need O
for O
an O
amputation B-NonOSE_AE
. O

The O
risk O
of O
amputation B-NonOSE_AE
was O
highest O
in O
patients O
with O
a O
baseline O
history O
of O
prior O
amputation B-Not_AE_Candidate
, O
peripheral B-Not_AE_Candidate
vascular I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
and O
neuropathy B-Not_AE_Candidate
. O

Before O
initiating O
INVOKANA O
, O
consider O
factors O
in O
the O
patient O
history O
that O
may O
predispose O
to O
the O
need O
for O
amputations B-NonOSE_AE
, O
such O
as O
a O
history O
of O
prior O
amputation B-Not_AE_Candidate
, O
peripheral B-Not_AE_Candidate
vascular I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
neuropathy B-Not_AE_Candidate
and O
diabetic B-Not_AE_Candidate
foot I-Not_AE_Candidate
ulcers I-Not_AE_Candidate
. O

Counsel O
patients O
about O
the O
importance O
of O
routine O
preventative O
foot O
care O
. O

Monitor O
patients O
receiving O
INVOKANA O
for O
signs O
and O
symptoms O
of O
infection B-NonOSE_AE
( O
including O
osteomyelitis B-NonOSE_AE
) O
, O
new O
pain B-NonOSE_AE
or O
tenderness O
, O
sores O
or O
ulcers O
involving O
the O
lower I-NonOSE_AE
limbs I-NonOSE_AE
, O
and O
discontinue O
INVOKANA O
if O
these O
complications O
occur O
. O

5.2 O
Hypotension O
INVOKANA O
causes O
intravascular B-OSE_Labeled_AE
volume I-OSE_Labeled_AE
contraction I-OSE_Labeled_AE
. O

Symptomatic O
hypotension B-OSE_Labeled_AE
can O
occur O
after O
initiating O
INVOKANA O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
particularly O
in O
patients O
with O
impaired B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
( O
eGFR B-Not_AE_Candidate
less I-Not_AE_Candidate
than I-Not_AE_Candidate
6 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
) O
, O
elderly O
patients O
, O
patients O
on O
either O
diuretics O
or O
medications O
that O
interfere O
with O
the O
renin-angiotensin-aldosterone O
system O
( O
e.g. O
, O
angiotensin-converting-enzyme O
[ O
ACE O
] O
inhibitors O
, O
angiotensin O
receptor O
blockers O
[ O
ARBs O
] O
) O
, O
or O
patients O
with O
low B-Not_AE_Candidate
systolic I-Not_AE_Candidate
blood I-Not_AE_Candidate
pressure I-Not_AE_Candidate
. O

Before O
initiating O
INVOKANA O
in O
patients O
with O
one O
or O
more O
of O
these O
characteristics O
, O
volume O
status O
should O
be O
assessed O
and O
corrected O
. O

Monitor O
for O
signs O
and O
symptoms O
after O
initiating O
therapy O
. O

5.3 O
Ketoacidosis O
Reports O
of O
ketoacidosis B-OSE_Labeled_AE
, O
a O
serious O
life-threatening O
condition O
requiring O
urgent O
hospitalization O
have O
been O
identified O
in O
postmarketing O
surveillance O
in O
patients O
with O
type B-Not_AE_Candidate
1 I-Not_AE_Candidate
and O
type O
2 O
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
receiving O
sodium O
glucose O
co-transporter-2 O
( O
SGLT2 O
) O
inhibitors O
, O
including O
INVOKANA O
. O

Fatal B-NonOSE_AE
cases O
of O
ketoacidosis B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
taking O
INVOKANA O
. O

INVOKANA O
is O
not O
indicated O
for O
the O
treatment O
of O
patients O
with O
type B-Not_AE_Candidate
1 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
[ O
see O
Indications O
and O
Usage O
( O
1 O
) O
] O
. O

Patients O
treated O
with O
INVOKANA O
who O
present O
with O
signs O
and O
symptoms O
consistent O
with O
severe O
metabolic B-NonOSE_AE
acidosis I-NonOSE_AE
should O
be O
assessed O
for O
ketoacidosis B-NonOSE_AE
regardless O
of O
presenting O
blood O
glucose O
levels O
, O
as O
ketoacidosis B-OSE_Labeled_AE
associated O
with O
INVOKANA O
may O
be O
present O
even O
if O
blood B-NonOSE_AE
glucose I-NonOSE_AE
levels I-NonOSE_AE
are I-NonOSE_AE
less I-NonOSE_AE
than I-NonOSE_AE
2 I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
. O

If O
ketoacidosis B-NonOSE_AE
is O
suspected O
, O
INVOKANA O
should O
be O
discontinued O
, O
patient O
should O
be O
evaluated O
, O
and O
prompt O
treatment O
should O
be O
instituted O
. O

Treatment O
of O
ketoacidosis B-NonOSE_AE
may O
require O
insulin O
, O
fluid O
and O
carbohydrate O
replacement O
. O

In O
many O
of O
the O
postmarketing O
reports O
, O
and O
particularly O
in O
patients O
with O
type B-Not_AE_Candidate
1 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
, O
the O
presence O
of O
ketoacidosis B-NonOSE_AE
was O
not O
immediately O
recognized O
and O
institution O
of O
treatment O
was O
delayed O
because O
presenting O
blood B-NonOSE_AE
glucose I-NonOSE_AE
levels I-NonOSE_AE
were I-NonOSE_AE
below I-NonOSE_AE
those O
typically O
expected O
for O
diabetic B-NonOSE_AE
ketoacidosis I-NonOSE_AE
( O
often O
less O
than O
250 O
mg/dL O
) O
. O

Signs O
and O
symptoms O
at O
presentation O
were O
consistent O
with O
dehydration B-NonOSE_AE
and O
severe O
metabolic B-NonOSE_AE
acidosis I-NonOSE_AE
and O
included O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
generalized B-NonOSE_AE
malaise I-NonOSE_AE
, O
and O
shortness B-NonOSE_AE
of I-NonOSE_AE
breath I-NonOSE_AE
. O

In O
some O
but O
not O
all O
cases O
, O
factors O
predisposing O
to O
ketoacidosis B-NonOSE_AE
such O
as O
insulin O
dose O
reduction O
, O
acute B-Not_AE_Candidate
febrile I-Not_AE_Candidate
illness I-Not_AE_Candidate
, O
reduced O
caloric O
intake O
due O
to O
illness O
or O
surgery O
, O
pancreatic B-Not_AE_Candidate
disorders I-Not_AE_Candidate
suggesting O
insulin B-Not_AE_Candidate
deficiency I-Not_AE_Candidate
( O
e.g. O
, O
type B-Not_AE_Candidate
1 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
, O
history O
of O
pancreatitis B-Not_AE_Candidate
or O
pancreatic O
surgery O
) O
, O
and O
alcohol O
abuse O
were O
identified O
. O

Before O
initiating O
INVOKANA O
, O
consider O
factors O
in O
the O
patient O
history O
that O
may O
predispose O
to O
ketoacidosis B-NonOSE_AE
including O
pancreatic B-Not_AE_Candidate
insulin I-Not_AE_Candidate
deficiency I-Not_AE_Candidate
from O
any O
cause O
, O
caloric O
restriction O
, O
and O
alcohol O
abuse O
. O

In O
patients O
treated O
with O
INVOKANA O
consider O
monitoring O
for O
ketoacidosis B-NonOSE_AE
and O
temporarily O
discontinuing O
INVOKANA O
in O
clinical O
situations O
known O
to O
predispose O
to O
ketoacidosis B-NonOSE_AE
( O
e.g. O
, O
prolonged O
fasting O
due O
to O
acute B-NonOSE_AE
illness I-NonOSE_AE
or O
surgery O
) O
. O

5.4 O
Acute O
Kidney O
Injury O
and O
Impairment O
in O
Renal O
Function O
INVOKANA O
causes O
intravascular B-OSE_Labeled_AE
volume I-OSE_Labeled_AE
contraction I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
and O
can O
cause O
renal B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

There O
have O
been O
postmarketing O
reports O
of O
acute B-OSE_Labeled_AE
kidney I-OSE_Labeled_AE
injury I-OSE_Labeled_AE
, O
some O
requiring O
hospitalization O
and O
dialysis B-NonOSE_AE
, O
in O
patients O
receiving O
INVOKANA O
; O
some O
reports O
involved O
patients O
younger O
than O
65 O
years O
of O
age O
. O

Before O
initiating O
INVOKANA O
, O
consider O
factors O
that O
may O
predispose O
patients O
to O
acute B-NonOSE_AE
kidney I-NonOSE_AE
injury I-NonOSE_AE
including O
hypovolemia B-Not_AE_Candidate
, O
chronic B-Not_AE_Candidate
renal I-Not_AE_Candidate
insufficiency I-Not_AE_Candidate
, O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
and O
concomitant O
medications O
( O
diuretics O
, O
ACE O
inhibitors O
, O
ARBs O
, O
NSAIDs O
) O
. O

Consider O
temporarily O
discontinuing O
INVOKANA O
in O
any O
setting O
of O
reduced O
oral O
intake O
( O
such O
as O
acute B-NonOSE_AE
illness I-NonOSE_AE
or O
fasting O
) O
or O
fluid B-NonOSE_AE
losses I-NonOSE_AE
( O
such O
as O
gastrointestinal B-NonOSE_AE
illness I-NonOSE_AE
or O
excessive O
heat O
exposure O
) O
; O
monitor O
patients O
for O
signs O
and O
symptoms O
of O
acute B-NonOSE_AE
kidney I-NonOSE_AE
injury I-NonOSE_AE
. O

If O
acute B-NonOSE_AE
kidney I-NonOSE_AE
injury I-NonOSE_AE
occurs O
, O
discontinue O
INVOKANA O
promptly O
and O
institute O
treatment O
. O

INVOKANA O
increases B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
and O
decreases B-OSE_Labeled_AE
eGFR I-OSE_Labeled_AE
. O

Patients O
with O
hypovolemia B-Not_AE_Candidate
may O
be O
more O
susceptible O
to O
these O
changes O
. O

Renal B-OSE_Labeled_AE
function I-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
can O
occur O
after O
initiating O
INVOKANA O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Renal O
function O
should O
be O
evaluated O
prior O
to O
initiation O
of O
INVOKANA O
and O
monitored O
periodically O
thereafter O
. O

Dosage O
adjustment O
and O
more O
frequent O
renal O
function O
monitoring O
are O
recommended O
in O
patients O
with O
an B-Not_AE_Candidate
eGFR I-Not_AE_Candidate
below I-Not_AE_Candidate
6 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 O
. O

Use O
of O
INVOKANA O
is O
not O
recommended O
when O
eGFR B-Not_AE_Candidate
is I-Not_AE_Candidate
persistently I-Not_AE_Candidate
less I-Not_AE_Candidate
than I-Not_AE_Candidate
4 I-Not_AE_Candidate
5 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
and O
is O
contraindicated O
in O
patients O
with O
an O
eGFR B-Not_AE_Candidate
less I-Not_AE_Candidate
than I-Not_AE_Candidate
3 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
, O
Contraindications O
( O
4 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
] O
. O

5.5 O
Hyperkalemia O
INVOKANA O
can O
lead O
to O
hyperkalemia B-OSE_Labeled_AE
. O

Patients O
with O
moderate B-Not_AE_Candidate
renal I-Not_AE_Candidate
impairment I-Not_AE_Candidate
who O
are O
taking O
medications O
that O
interfere O
with O
potassium O
excretion O
, O
such O
as O
potassium-sparing O
diuretics O
, O
or O
medications O
that O
interfere O
with O
the O
renin-angiotensin-aldosterone O
system O
are O
at O
an O
increased O
risk O
of O
developing O
hyperkalemia B-OSE_Labeled_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Monitor O
serum O
potassium O
levels O
periodically O
after O
initiating O
INVOKANA O
in O
patients O
with O
impaired B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
and O
in O
patients O
predisposed O
to O
hyperkalemia B-NonOSE_AE
due O
to O
medications O
or O
other O
medical O
conditions O
. O

5.6 O
Urosepsis O
and O
Pyelonephritis O
There O
have O
been O
postmarketing O
reports O
of O
serious O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
including O
urosepsis B-OSE_Labeled_AE
and O
pyelonephritis B-OSE_Labeled_AE
requiring O
hospitalization O
in O
patients O
receiving O
SGLT2 O
inhibitors O
, O
including O
INVOKANA O
. O

Treatment O
with O
SGLT2 O
inhibitors O
increases O
the O
risk O
for O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
. O

Evaluate O
patients O
for O
signs O
and O
symptoms O
of O
urinary B-NonOSE_AE
tract I-NonOSE_AE
infections I-NonOSE_AE
and O
treat O
promptly O
, O
if O
indicated O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

5.7 O
Hypoglycemia O
with O
Concomitant O
Use O
with O
Insulin O
and O
Insulin O
Secretagogues O
Insulin O
and O
insulin O
secretagogues O
are O
known O
to O
cause O
hypoglycemia B-NonOSE_AE
. O

INVOKANA O
can O
increase O
the O
risk O
of O
hypoglycemia B-NonOSE_AE
when O
combined O
with O
insulin O
or O
an O
insulin O
secretagogue O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Therefore O
, O
a O
lower O
dose O
of O
insulin O
or O
insulin O
secretagogue O
may O
be O
required O
to O
minimize O
the O
risk O
of O
hypoglycemia B-NonOSE_AE
when O
used O
in O
combination O
with O
INVOKANA O
. O

5.8 O
Genital O
Mycotic O
Infections O
INVOKANA O
increases O
the O
risk O
of O
genital B-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
. O

Patients O
with O
a O
history O
of O
genital B-Not_AE_Candidate
mycotic I-Not_AE_Candidate
infections I-Not_AE_Candidate
and O
uncircumcised O
males O
were O
more O
likely O
to O
develop O
genital B-OSE_Labeled_AE
mycotic I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Monitor O
and O
treat O
appropriately O
. O

5.9 O
Hypersensitivity O
Reactions O
Hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
angioedema B-OSE_Labeled_AE
and O
anaphylaxis B-OSE_Labeled_AE
, O
have O
been O
reported O
with O
INVOKANA O
. O

These O
reactions O
generally O
occurred O
within O
hours O
to O
days O
after O
initiating O
INVOKANA O
. O

If O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
occur O
, O
discontinue O
use O
of O
INVOKANA O
; O
treat O
and O
monitor O
until O
signs O
and O
symptoms O
resolve O
[ O
see O
Contraindications O
( O
4 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
, O
6.2 O
) O
] O
. O

5.10 O
Bone O
Fracture O
An O
increased O
risk O
of O
bone B-OSE_Labeled_AE
fracture I-OSE_Labeled_AE
, O
occurring O
as O
early O
as O
12 O
weeks O
after O
treatment O
initiation O
, O
was O
observed O
in O
patients O
using O
INVOKANA O
. O

Consider O
factors O
that O
contribute O
to O
fracture O
risk O
prior O
to O
initiating O
INVOKANA O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.11 O
Increases O
in O
Low-Density O
Lipoprotein O
( O
LDL-C O
) O
Dose-related O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
LDL I-OSE_Labeled_AE
- I-OSE_Labeled_AE
C I-OSE_Labeled_AE
occur O
with O
INVOKANA O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Monitor O
LDL-C O
and O
treat O
if O
appropriate O
after O
initiating O
INVOKANA O
. O

5.12 O
Macrovascular O
Outcomes O
There O
have O
been O
no O
clinical O
studies O
establishing O
conclusive O
evidence O
of O
macrovascular B-NonOSE_AE
risk O
reduction O
with O
INVOKANA O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
described O
in O
more O
detail O
in O
other O
sections O
of O
the O
prescribing O
information O
. O

* O
Myelosuppression B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Infection B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Electrocardiographic B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Tumor B-OSE_Labeled_AE
Lysis I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
were O
neutropenia O
, O
lymphopenia O
, O
thrombocytopenia O
, O
infections O
, O
nausea O
, O
fatigue O
, O
vomiting O
, O
anorexia O
, O
anemia O
, O
and O
ECG O
T-wave O
changes O
( O
6 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Celgene O
Corporation O
at O
1-888-423-5436 O
or O
the O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Cutaneous B-Not_AE_Candidate
T I-Not_AE_Candidate
- I-Not_AE_Candidate
Cell I-Not_AE_Candidate
Lymphoma I-Not_AE_Candidate
The O
safety O
of O
ISTODAX O
was O
evaluated O
in O
185 O
patients O
with O
CTCL B-Not_AE_Candidate
in O
2 O
single O
arm O
clinical O
studies O
in O
which O
patients O
received O
a O
starting O
dose O
of O
14 O
mg/m O
2 O
. O

The O
mean O
duration O
of O
treatment O
in O
these O
studies O
was O
5.6 O
months O
( O
range O
: O
< O
1 O
to O
83.4 O
months O
) O
. O

Common O
Adverse O
Reactions O
Table O
1 O
summarizes O
the O
most O
frequent O
adverse O
reactions O
( O
> O
20 O
% O
) O
regardless O
of O
causality O
using O
the O
National O
Cancer O
Institute-Common O
Terminology O
Criteria O
for O
Adverse O
Events O
( O
NCI-CTCAE O
, O
Version O
3.0 O
) O
. O

Due O
to O
methodological O
differences O
between O
the O
studies O
, O
the O
AE O
data O
are O
presented O
separately O
for O
Study O
1 O
and O
Study O
2 O
. O

Adverse O
reactions O
are O
ranked O
by O
their O
incidence O
in O
Study O
1 O
. O

Laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
commonly O
reported O
( O
> O
20 O
% O
) O
as O
adverse O
reactions O
are O
included O
in O
Table O
1 O
. O

Table O
1 O
. O

Adverse O
Reactions O
Occurring O
in O
> O
20 O
% O
of O
Patients O
in O
Either O
CTCL O
Study O
( O
N=185 O
) O
Adverse O
Reactions O
n O
( O
% O
) O
Study O
1 O
( O
n=102 O
) O
Study O
2 O
( O
n=83 O
) O
All O
grades O
Grade O
3 O
or O
4 O
All O
grades O
Grade O
3 O
or O
4 O
Any O
adverse O
reaction O
99 O
( O
97 O
) O
36 O
( O
35 O
) O
83 O
( O
100 O
) O
68 O
( O
82 O
) O
Nausea B-OSE_Labeled_AE
57 O
( O
56 O
) O
3 O
( O
3 O
) O
71 O
( O
86 O
) O
5 O
( O
6 O
) O
Asthenia B-OSE_Labeled_AE
/ O
Fatigue B-OSE_Labeled_AE
54 O
( O
53 O
) O
8 O
( O
8 O
) O
64 O
( O
77 O
) O
12 O
( O
14 O
) O
Infections B-OSE_Labeled_AE
47 O
( O
46 O
) O
11 O
( O
11 O
) O
45 O
( O
54 O
) O
27 O
( O
33 O
) O
Vomiting B-OSE_Labeled_AE
35 O
( O
34 O
) O
1 O
( O
< O
1 O
) O
43 O
( O
52 O
) O
8 O
( O
10 O
) O
Anorexia B-OSE_Labeled_AE
23 O
( O
23 O
) O
1 O
( O
< O
1 O
) O
45 O
( O
54 O
) O
3 O
( O
4 O
) O
Hypomagnesemia B-OSE_Labeled_AE
22 O
( O
22 O
) O
1 O
( O
< O
1 O
) O
23 O
( O
28 O
) O
0 O
Diarrhea B-OSE_Labeled_AE
20 O
( O
20 O
) O
1 O
( O
< O
1 O
) O
22 O
( O
27 O
) O
1 O
( O
1 O
) O
Pyrexia B-OSE_Labeled_AE
20 O
( O
20 O
) O
4 O
( O
4 O
) O
19 O
( O
23 O
) O
1 O
( O
1 O
) O
Anemia B-OSE_Labeled_AE
19 O
( O
19 O
) O
3 O
( O
3 O
) O
60 O
( O
72 O
) O
13 O
( O
16 O
) O
Thrombocytopenia B-OSE_Labeled_AE
17 O
( O
17 O
) O
0 O
54 O
( O
65 O
) O
12 O
( O
14 O
) O
Dysgeusia B-OSE_Labeled_AE
15 O
( O
15 O
) O
0 O
33 O
( O
40 O
) O
0 O
Constipation B-OSE_Labeled_AE
12 O
( O
12 O
) O
2 O
( O
2 O
) O
32 O
( O
39 O
) O
1 O
( O
1 O
) O
Neutropenia B-OSE_Labeled_AE
11 O
( O
11 O
) O
4 O
( O
4 O
) O
47 O
( O
57 O
) O
22 O
( O
27 O
) O
Hypotension B-OSE_Labeled_AE
7 O
( O
7 O
) O
3 O
( O
3 O
) O
19 O
( O
23 O
) O
3 O
( O
4 O
) O
Pruritus B-OSE_Labeled_AE
7 O
( O
7 O
) O
0 O
26 O
( O
31 O
) O
5 O
( O
6 O
) O
Hypokalemia B-OSE_Labeled_AE
6 O
( O
6 O
) O
0 O
17 O
( O
20 O
) O
2 O
( O
2 O
) O
Dermatitis B-OSE_Labeled_AE
/ O
Exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
4 O
( O
4 O
) O
1 O
( O
< O
1 O
) O
22 O
( O
27 O
) O
7 O
( O
8 O
) O
Hypocalcemia B-OSE_Labeled_AE
4 O
( O
4 O
) O
0 O
43 O
( O
52 O
) O
5 O
( O
6 O
) O
Leukopenia B-OSE_Labeled_AE
4 O
( O
4 O
) O
0 O
38 O
( O
46 O
) O
18 O
( O
22 O
) O
Lymphopenia B-OSE_Labeled_AE
4 O
( O
4 O
) O
0 O
47 O
( O
57 O
) O
31 O
( O
37 O
) O
Alanine B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
3 O
( O
3 O
) O
0 O
18 O
( O
22 O
) O
2 O
( O
2 O
) O
Aspartate B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
3 O
( O
3 O
) O
0 O
23 O
( O
28 O
) O
3 O
( O
4 O
) O
Hypoalbuminemia B-OSE_Labeled_AE
3 O
( O
3 O
) O
1 O
( O
< O
1 O
) O
40 O
( O
48 O
) O
3 O
( O
4 O
) O
Electrocardiogram B-OSE_Labeled_AE
ST I-OSE_Labeled_AE
- I-OSE_Labeled_AE
T I-OSE_Labeled_AE
wave I-OSE_Labeled_AE
changes I-OSE_Labeled_AE
2 O
( O
2 O
) O
0 O
52 O
( O
63 O
) O
0 O
Hyperglycemia B-OSE_Labeled_AE
2 O
( O
2 O
) O
2 O
( O
2 O
) O
42 O
( O
51 O
) O
1 O
( O
1 O
) O
Hyponatremia B-OSE_Labeled_AE
1 O
( O
< O
1 O
) O
1 O
( O
< O
1 O
) O
17 O
( O
20 O
) O
2 O
( O
2 O
) O
Hypermagnesemia B-OSE_Labeled_AE
0 O
0 O
22 O
( O
27 O
) O
7 O
( O
8 O
) O
Hypophosphatemia B-OSE_Labeled_AE
0 O
0 O
22 O
( O
27 O
) O
8 O
( O
10 O
) O
Hyperuricemia B-OSE_Labeled_AE
0 O
0 O
27 O
( O
33 O
) O
7 O
( O
8 O
) O
Serious O
Adverse O
Reactions O
Infections B-OSE_Labeled_AE
were O
the O
most O
common O
type O
of O
SAE O
reported O
in O
both O
studies O
with O
8 O
patients O
( O
8 O
% O
) O
in O
Study O
1 O
and O
26 O
patients O
( O
31 O
% O
) O
in O
Study O
2 O
experiencing O
a O
serious O
infection B-OSE_Labeled_AE
. O

Serious O
adverse O
reactions O
reported O
in O
> O
2 O
% O
of O
patients O
in O
Study O
1 O
were O
sepsis B-OSE_Labeled_AE
and O
pyrexia B-OSE_Labeled_AE
( O
3 O
% O
) O
. O

In O
Study O
2 O
, O
serious O
adverse O
reactions O
in O
> O
2 O
% O
of O
patients O
were O
fatigue B-OSE_Labeled_AE
( O
7 O
% O
) O
, O
supraventricular B-OSE_Labeled_AE
arrhythmia I-OSE_Labeled_AE
, O
central B-OSE_Labeled_AE
line I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
hypotension B-OSE_Labeled_AE
, O
hyperuricemia B-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
( O
5 O
% O
) O
, O
ventricular B-OSE_Labeled_AE
arrhythmia I-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
, O
aspartate B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
catheter B-OSE_Labeled_AE
related I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
hypophosphatemia B-OSE_Labeled_AE
and O
dyspnea B-OSE_Labeled_AE
( O
4 O
% O
) O
. O

Most O
deaths B-NonOSE_AE
were O
due O
to O
disease O
progression O
. O

In O
Study O
1 O
, O
there O
were O
two O
deaths B-NonOSE_AE
due O
to O
cardiopulmonary B-NonOSE_AE
failure I-NonOSE_AE
and O
acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
. O

In O
Study O
2 O
, O
there O
were O
six O
deaths B-NonOSE_AE
due O
to O
infection B-NonOSE_AE
( O
4 O
) O
, O
myocardial B-NonOSE_AE
ischemia I-NonOSE_AE
, O
and O
acute B-NonOSE_AE
respiratory I-NonOSE_AE
distress I-NonOSE_AE
syndrome I-NonOSE_AE
. O

Discontinuations O
Discontinuation O
due O
to O
an O
adverse O
event O
occurred O
in O
21 O
% O
of O
patients O
in O
Study O
1 O
and O
11 O
% O
in O
Study O
2 O
. O

Discontinuations O
occurring O
in O
at O
least O
2 O
% O
of O
patients O
in O
either O
study O
included O
infection B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
, O
and O
hypomagnesemia B-OSE_Labeled_AE
. O

Peripheral O
T-Cell O
Lymphoma O
The O
safety O
of O
ISTODAX O
was O
evaluated O
in O
178 O
patients O
with O
PTCL B-Not_AE_Candidate
in O
a O
sponsor-conducted O
pivotal O
study O
( O
Study O
3 O
) O
and O
a O
secondary O
NCI-sponsored O
study O
( O
Study O
4 O
) O
in O
which O
patients O
received O
a O
starting O
dose O
of O
14 O
mg/m O
2 O
. O

The O
mean O
duration O
of O
treatment O
and O
number O
of O
cycles O
were O
5.6 O
months O
and O
6 O
cycles O
in O
Study O
3 O
and O
9.6 O
months O
and O
8 O
cycles O
in O
Study O
4 O
. O

Common O
Adverse O
Reactions O
Table O
2 O
summarizes O
the O
most O
frequent O
adverse O
reactions O
( O
> O
= O
10 O
% O
) O
regardless O
of O
causality O
, O
using O
the O
NCI-CTCAE O
, O
Version O
3.0 O
. O

The O
AE O
data O
are O
presented O
separately O
for O
Study O
3 O
and O
Study O
4 O
. O

Laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
commonly O
reported O
( O
> O
= O
10 O
% O
) O
as O
adverse O
reactions O
are O
included O
in O
Table O
2 O
. O

Table O
2 O
. O

Adverse O
Reactions O
Occurring O
in O
> O
=10 O
% O
of O
Patients O
with O
PTCL O
in O
Study O
3 O
and O
Corresponding O
Incidence O
in O
Study O
4 O
( O
N=178 O
) O
Adverse O
Reactions O
n O
( O
% O
) O
Study O
3 O
( O
N=131 O
) O
Study O
4 O
( O
N=47 O
) O
All O
grades O
Grade O
3 O
or O
4 O
All O
grades O
Grade O
3 O
or O
4 O
Any O
adverse O
reactions O
128 O
( O
97 O
) O
88 O
( O
67 O
) O
47 O
( O
100 O
) O
40 O
( O
85 O
) O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
77 O
( O
59 O
) O
3 O
( O
2 O
) O
35 O
( O
75 O
) O
3 O
( O
6 O
) O
Vomiting B-OSE_Labeled_AE
51 O
( O
39 O
) O
6 O
( O
5 O
) O
19 O
( O
40 O
) O
4 O
( O
9 O
) O
Diarrhea B-OSE_Labeled_AE
47 O
( O
36 O
) O
3 O
( O
2 O
) O
17 O
( O
36 O
) O
1 O
( O
2 O
) O
Constipation B-OSE_Labeled_AE
39 O
( O
30 O
) O
1 O
( O
< O
1 O
) O
19 O
( O
40 O
) O
1 O
( O
2 O
) O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
18 O
( O
14 O
) O
3 O
( O
2 O
) O
6 O
( O
13 O
) O
1 O
( O
2 O
) O
Stomatitis B-OSE_Labeled_AE
14 O
( O
11 O
) O
0 O
3 O
( O
6 O
) O
0 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Asthenia B-OSE_Labeled_AE
/ O
Fatigue B-OSE_Labeled_AE
72 O
( O
55 O
) O
11 O
( O
8 O
) O
36 O
( O
77 O
) O
9 O
( O
19 O
) O
Pyrexia B-OSE_Labeled_AE
46 O
( O
35 O
) O
8 O
( O
6 O
) O
22 O
( O
47 O
) O
8 O
( O
17 O
) O
Chills B-OSE_Labeled_AE
14 O
( O
11 O
) O
1 O
( O
< O
1 O
) O
8 O
( O
17 O
) O
0 O
Edema B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
13 O
( O
10 O
) O
1 O
( O
< O
1 O
) O
3 O
( O
6 O
) O
0 O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Thrombocytopenia B-OSE_Labeled_AE
53 O
( O
41 O
) O
32 O
( O
24 O
) O
34 O
( O
72 O
) O
17 O
( O
36 O
) O
Neutropenia B-OSE_Labeled_AE
39 O
( O
30 O
) O
26 O
( O
20 O
) O
31 O
( O
66 O
) O
22 O
( O
47 O
) O
Anemia B-OSE_Labeled_AE
33 O
( O
25 O
) O
14 O
( O
11 O
) O
29 O
( O
62 O
) O
13 O
( O
28 O
) O
Leukopenia B-OSE_Labeled_AE
16 O
( O
12 O
) O
8 O
( O
6 O
) O
26 O
( O
55 O
) O
21 O
( O
45 O
) O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
Anorexia B-OSE_Labeled_AE
37 O
( O
28 O
) O
2 O
( O
2 O
) O
21 O
( O
45 O
) O
1 O
( O
2 O
) O
Hypokalemia B-OSE_Labeled_AE
14 O
( O
11 O
) O
3 O
( O
2 O
) O
8 O
( O
17 O
) O
1 O
( O
2 O
) O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Dysgeusia B-OSE_Labeled_AE
27 O
( O
21 O
) O
0 O
13 O
( O
28 O
) O
0 O
Headache B-OSE_Labeled_AE
19 O
( O
15 O
) O
0 O
16 O
( O
34 O
) O
1 O
( O
2 O
) O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
23 O
( O
18 O
) O
0 O
10 O
( O
21 O
) O
0 O
Dyspnea B-OSE_Labeled_AE
17 O
( O
13 O
) O
3 O
( O
2 O
) O
10 O
( O
21 O
) O
2 O
( O
4 O
) O
Investigations B-NonOSE_AE
Weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
14 O
( O
11 O
) O
0 O
7 O
( O
15 O
) O
0 O
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
Tachycardia B-OSE_Labeled_AE
13 O
( O
10 O
) O
0 O
0 O
0 O
Serious O
Adverse O
Reactions O
Infections B-OSE_Labeled_AE
were O
the O
most O
common O
type O
of O
SAE O
reported O
. O

In O
Study O
3 O
, O
26 O
patients O
( O
20 O
% O
) O
experienced O
a O
serious O
infection B-OSE_Labeled_AE
, O
including O
6 O
patients O
( O
5 O
% O
) O
with O
serious O
treatment-related O
infections B-OSE_Labeled_AE
. O

In O
Study O
4 O
, O
11 O
patients O
( O
23 O
% O
) O
experienced O
a O
serious O
infection B-OSE_Labeled_AE
, O
including O
8 O
patients O
( O
17 O
% O
) O
with O
serious O
treatment-related O
infections B-OSE_Labeled_AE
. O

Serious O
adverse O
reactions O
reported O
in O
> O
= O
2 O
% O
of O
patients O
in O
Study O
3 O
were O
pyrexia B-OSE_Labeled_AE
( O
8 O
% O
) O
, O
pneumonia B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
( O
5 O
% O
) O
, O
cellulitis B-OSE_Labeled_AE
, O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
, O
( O
4 O
% O
) O
, O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
3 O
% O
) O
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
and O
dehydration B-OSE_Labeled_AE
( O
2 O
% O
) O
. O

In O
Study O
4 O
, O
serious O
adverse O
reactions O
in O
> O
= O
2 O
patients O
were O
pyrexia B-OSE_Labeled_AE
( O
17 O
% O
) O
, O
aspartate B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
( O
13 O
% O
) O
, O
anemia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
alanine B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
11 O
% O
) O
, O
infection B-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
( O
9 O
% O
) O
, O
lymphopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
hyperbilirubinemia B-OSE_Labeled_AE
, O
hypocalcemia B-OSE_Labeled_AE
, O
hypoxia B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
arrhythmia I-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
hypersensitivity B-OSE_Labeled_AE
, O
catheter B-OSE_Labeled_AE
related I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
hyperuricemia B-OSE_Labeled_AE
, O
hypoalbuminemia B-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
, O
pneumonitis B-OSE_Labeled_AE
, O
packed O
red O
blood O
cell O
transfusion O
, O
and O
platelet O
transfusion O
( O
4 O
% O
) O
. O

Reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
B I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
has O
occurred O
in O
1 O
% O
of O
patients O
with O
PTCL B-Not_AE_Candidate
patients O
in O
clinical O
trials O
in O
Western O
population O
enrolled O
in O
Study O
3 O
and O
Study O
4 O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Deaths B-NonOSE_AE
due O
to O
all O
causes O
within O
30 O
days O
of O
the O
last O
dose O
of O
ISTODAX O
occurred O
in O
7 O
% O
of O
patients O
in O
Study O
3 O
and O
17 O
% O
of O
patients O
in O
Study O
4 O
. O

In O
Study O
3 O
, O
there O
were O
5 O
deaths B-NonOSE_AE
unrelated O
to O
disease O
progression O
that O
were O
due O
to O
infections B-NonOSE_AE
, O
including O
multi B-NonOSE_AE
- I-NonOSE_AE
organ I-NonOSE_AE
failure I-NonOSE_AE
/ O
sepsis B-NonOSE_AE
, O
pneumonia B-NonOSE_AE
, O
septic B-NonOSE_AE
shock I-NonOSE_AE
, O
candida B-NonOSE_AE
sepsis I-NonOSE_AE
, O
and O
sepsis B-OSE_Labeled_AE
/ O
cardiogenic B-NonOSE_AE
shock I-NonOSE_AE
. O

In O
Study O
4 O
, O
there O
were O
3 O
deaths B-NonOSE_AE
unrelated O
to O
disease O
progression O
that O
were O
due O
to O
sepsis B-OSE_Labeled_AE
, O
aspartate B-NonOSE_AE
aminotransferase I-NonOSE_AE
elevation I-NonOSE_AE
in O
the O
setting O
of O
Epstein B-NonOSE_AE
Barr I-NonOSE_AE
virus I-NonOSE_AE
reactivation I-NonOSE_AE
, O
and O
death B-NonOSE_AE
of O
unknown O
cause O
. O

Discontinuations O
Discontinuation O
due O
to O
an O
adverse O
event O
occurred O
in O
19 O
% O
of O
patients O
in O
Study O
3 O
and O
in O
28 O
% O
of O
patients O
in O
Study O
4 O
. O

In O
Study O
3 O
, O
thrombocytopenia B-OSE_Labeled_AE
and O
pneumonia B-OSE_Labeled_AE
were O
the O
only O
events O
leading O
to O
treatment O
discontinuation O
in O
at O
least O
2 O
% O
of O
patients O
. O

In O
Study O
4 O
, O
events O
leading O
to O
treatment O
discontinuation O
in O
> O
= O
2 O
patients O
were O
thrombocytopenia B-OSE_Labeled_AE
( O
11 O
% O
) O
, O
anemia B-OSE_Labeled_AE
, O
infection B-OSE_Labeled_AE
, O
and O
alanine B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
4 O
% O
) O
. O

6.2 O
Postmarketing O
Experience O
No O
additional O
safety O
signals O
have O
been O
observed O
from O
postmarketing O
experience O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Myelosuppression O
: O
ISTODAX O
can O
cause O
thrombocytopenia O
, O
leukopenia O
( O
neutropenia O
and O
lymphopenia O
) O
, O
and O
anemia O
; O
monitor O
blood O
counts O
during O
treatment O
with O
ISTODAX O
; O
interrupt O
and/or O
modify O
the O
dose O
as O
necessary O
( O
2.2 O
) O
. O

* O
Infections O
: O
Fatal O
and O
serious O
infections O
. O

Reactivation O
of O
DNA O
viruses O
( O
Epstein O
Barr O
and O
hepatitis O
B O
) O
. O

Consider O
monitoring O
and O
prophylaxis O
in O
patients O
with O
evidence O
of O
prior O
hepatitis O
B O
( O
5.2 O
) O
. O

* O
Electrocardiographic O
( O
ECG O
) O
changes O
: O
Consider O
cardiovascular O
monitoring O
in O
patients O
with O
congenital O
long O
QT O
syndrome O
, O
a O
history O
of O
significant O
cardiovascular O
disease O
, O
and O
patients O
taking O
medicinal O
products O
that O
lead O
to O
significant O
QT O
prolongation O
. O

Ensure O
that O
potassium O
and O
magnesium O
are O
within O
the O
normal O
range O
before O
administration O
of O
ISTODAX O
( O
5.3 O
) O
. O

* O
Tumor O
lysis O
syndrome O
: O
Patients O
with O
advanced O
stage O
disease O
and/or O
high O
tumor O
burden O
are O
at O
greater O
risk O
and O
should O
be O
closely O
monitored O
and O
appropriate O
precautions O
taken O
( O
5.4 O
) O
. O

* O
Embryo-fetal O
toxicity O
: O
ISTODAX O
may O
cause O
fetal O
harm O
when O
administered O
to O
a O
pregnant O
woman O
. O

Advise O
women O
of O
potential O
hazard O
to O
the O
fetus O
and O
to O
avoid O
pregnancy O
while O
receiving O
ISTODAX O
( O
5.5 O
, O
8.1 O
) O
. O

5.1 O
Myelosuppression B-OSE_Labeled_AE
Treatment O
with O
ISTODAX O
can O
cause O
thrombocytopenia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
( O
neutropenia B-OSE_Labeled_AE
and O
lymphopenia B-OSE_Labeled_AE
) O
, O
and O
anemia B-OSE_Labeled_AE
. O

Monitor O
blood O
counts O
regularly O
during O
treatment O
with O
ISTODAX O
, O
and O
modify O
the O
dose O
as O
necessary O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
and O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

5.2 O
Infections O
Fatal B-NonOSE_AE
and O
serious O
infections B-OSE_Labeled_AE
, O
including O
pneumonia B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
and O
viral B-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
, O
including O
Epstein O
Barr O
and O
hepatitis O
B O
viruses O
, O
have O
been O
reported O
in O
clinical O
trials O
with O
ISTODAX O
. O

These O
can O
occur O
during O
treatment O
and O
within O
30 O
days O
after O
treatment O
. O

The O
risk O
of O
life O
threatening O
infections O
may O
be O
greater O
in O
patients O
with O
a O
history O
of O
prior O
treatment O
with O
monoclonal O
antibodies O
directed O
against O
lymphocyte O
antigens O
and O
in O
patients O
with O
disease B-Not_AE_Candidate
involvement I-Not_AE_Candidate
of I-Not_AE_Candidate
the I-Not_AE_Candidate
bone I-Not_AE_Candidate
marrow I-Not_AE_Candidate
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

Reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
B I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
has O
occurred O
in O
1 O
% O
of O
PTCL B-Not_AE_Candidate
patients O
in O
clinical O
trials O
in O
Western O
populations O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

In O
patients O
with O
evidence O
of O
prior O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
infection I-Not_AE_Candidate
, O
consider O
monitoring O
for O
reactivation O
, O
and O
consider O
antiviral O
prophylaxis O
. O

Reactivation B-OSE_Labeled_AE
of O
Epstein I-OSE_Labeled_AE
Barr I-OSE_Labeled_AE
viral I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
leading O
to O
liver B-NonOSE_AE
failure I-NonOSE_AE
has O
occurred O
in O
a O
trial O
of O
patients O
with O
relapsed O
or O
refractory O
extranodal O
NK/ O
T B-Not_AE_Candidate
- I-Not_AE_Candidate
cell I-Not_AE_Candidate
lymphoma I-Not_AE_Candidate
. O

In O
one O
case O
, O
ganciclovir O
prophylaxis O
failed O
to O
prevent O
Epstein B-NonOSE_AE
Barr I-NonOSE_AE
viral I-NonOSE_AE
reactivation I-NonOSE_AE
. O

5.3 O
Electrocardiographic O
Changes O
Several O
treatment-emergent O
morphological O
changes B-OSE_Labeled_AE
in I-OSE_Labeled_AE
ECGs I-OSE_Labeled_AE
( O
including O
T B-OSE_Labeled_AE
- I-OSE_Labeled_AE
wave I-OSE_Labeled_AE
and O
ST-segment O
changes I-OSE_Labeled_AE
) O
have O
been O
reported O
in O
clinical O
studies O
. O

The O
clinical O
significance O
of O
these O
changes O
is O
unknown O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

In O
patients O
with O
congenital B-Not_AE_Candidate
long I-Not_AE_Candidate
QT I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
, O
patients O
with O
a O
history O
of O
significant O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
and O
patients O
taking O
anti-arrhythmic O
medicines O
or O
medicinal O
products O
that O
lead O
to O
significant O
QT B-NonOSE_AE
prolongation I-NonOSE_AE
, O
consider O
cardiovascular O
monitoring O
of O
ECGs O
at O
baseline O
and O
periodically O
during O
treatment O
. O

Confirm O
that O
potassium O
and O
magnesium O
levels O
are O
within O
normal O
range O
before O
administration O
of O
ISTODAX O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

5.4 O
Tumor O
Lysis O
Syndrome O
Tumor B-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TLS I-OSE_Labeled_AE
) O
has O
been O
reported O
to O
occur O
in O
1 O
% O
of O
patients O
with O
tumor B-Not_AE_Candidate
stage O
CTCL B-Not_AE_Candidate
and O
2 O
% O
of O
patients O
with O
Stage O
III/IV O
PTCL B-Not_AE_Candidate
. O

Patients O
with O
advanced O
stage O
disease O
and/or O
high O
tumor B-Not_AE_Candidate
burden O
may O
be O
at O
greater O
risk O
, O
should O
be O
closely O
monitored O
, O
and O
managed O
as O
appropriate O
. O

5.5 O
Use O
in O
Pregnancy O
There O
are O
no O
adequate O
and O
well-controlled O
studies O
of O
ISTODAX O
in O
pregnant B-Not_AE_Candidate
women O
. O

However O
, O
based O
on O
its O
mechanism O
of O
action O
and O
findings O
in O
animals O
, O
ISTODAX O
may O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
. O

In O
an O
animal O
reproductive O
study O
, O
romidepsin O
was O
embryocidal B-NonOSE_AE
and O
resulted O
in O
adverse O
effects B-NonOSE_AE
on I-NonOSE_AE
the I-NonOSE_AE
developing I-NonOSE_AE
fetus I-NonOSE_AE
at O
exposures O
below O
those O
in O
patients O
at O
the O
recommended O
dose O
of O
14 O
mg/m O
2 O
/week O
. O

If O
this O
drug O
is O
used O
during O
pregnancy B-Not_AE_Candidate
, O
or O
if O
the O
patient O
becomes O
pregnant B-NonOSE_AE
while O
taking O
ISTODAX O
, O
the O
patient O
should O
be O
apprised O
of O
the O
potential O
hazard B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
label O
: O
* O
Hepatotoxicity B-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Left B-OSE_Labeled_AE
Ventricular I-OSE_Labeled_AE
Dysfunction I-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Pulmonary B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Related I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
, O
Hypersensitivity B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Hemorrhage B-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Thrombocytopenia B-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Neurotoxicity B-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
EXCERPT O
: O
The O
most O
common O
adverse O
drug O
reactions O
( O
frequency O
> O
25 O
% O
) O
with O
KADCYLA O
( O
n=884 O
treated O
patients O
) O
were O
fatigue O
, O
nausea O
, O
musculoskeletal O
pain O
, O
hemorrhage O
, O
thrombocytopenia O
, O
headache O
, O
increased O
transaminases O
, O
constipation O
and O
epistaxis O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Genentech O
at O
1-888-835-2555 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

In O
clinical O
trials O
, O
KADCYLA O
has O
been O
evaluated O
as O
single-agent O
in O
884 O
patients O
with O
HER B-Not_AE_Candidate
2 I-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
metastatic O
breast I-Not_AE_Candidate
cancer I-Not_AE_Candidate
. O

The O
most O
common O
( O
frequency O
> O
= O
25 O
% O
) O
adverse O
drug O
reactions O
( O
ADRs O
) O
seen O
in O
884 O
patients O
treated O
with O
KADCYLA O
were O
fatigue B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
hemorrhage B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
and O
epistaxis B-OSE_Labeled_AE
. O

The O
ADRs O
described O
in O
Table O
6 O
were O
identified O
in O
patients O
with O
HER B-Not_AE_Candidate
2 I-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
metastatic O
breast I-Not_AE_Candidate
cancer I-Not_AE_Candidate
treated O
in O
a O
randomized O
trial O
( O
Study O
1 O
) O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

Patients O
were O
randomized O
to O
receive O
KADCYLA O
or O
lapatinib O
plus O
capecitabine O
. O

The O
median O
duration O
of O
study O
treatment O
was O
7.6 O
months O
for O
patients O
in O
the O
KADCYLA-treated O
group O
and O
5.5 O
months O
and O
5.3 O
months O
for O
patients O
treated O
with O
lapatinib O
and O
capecitabine O
, O
respectively O
. O

Two O
hundred O
and O
eleven O
( O
43.1 O
% O
) O
patients O
experienced O
> O
= O
Grade O
3 O
adverse O
events O
in O
the O
KADCYLA-treated O
group O
compared O
with O
289 O
( O
59.2 O
% O
) O
patients O
in O
the O
lapatinib O
plus O
capecitabine-treated O
group O
. O

Dose O
adjustments O
for O
KADCYLA O
were O
permitted O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

Thirty-two O
patients O
( O
6.5 O
% O
) O
discontinued O
KADCYLA O
due O
to O
an O
adverse O
event O
, O
compared O
with O
41 O
patients O
( O
8.4 O
% O
) O
who O
discontinued O
lapatinib O
, O
and O
51 O
patients O
( O
10.5 O
% O
) O
who O
discontinued O
capecitabine O
due O
to O
an O
adverse O
event O
. O

The O
most O
common O
adverse O
events O
leading O
to O
KADCYLA O
withdrawal O
were O
thrombocytopenia B-OSE_Labeled_AE
and O
increased B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
. O

Eighty O
patients O
( O
16.3 O
% O
) O
treated O
with O
KADCYLA O
had O
adverse O
events O
leading O
to O
dose O
reductions O
. O

The O
most O
frequent O
adverse O
events O
leading O
to O
dose O
reduction O
of O
KADCYLA O
( O
in O
> O
= O
1 O
% O
of O
patients O
) O
included O
thrombocytopenia B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
, O
and O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
. O

Adverse O
events O
that O
led O
to O
dose O
delays O
occurred O
in O
116 O
( O
23.7 O
% O
) O
of O
KADCYLA O
treated O
patients O
. O

The O
most O
frequent O
adverse O
events O
leading O
to O
a O
dose O
delay O
of O
KADCYLA O
( O
in O
> O
= O
1 O
% O
of O
patients O
) O
were O
neutropenia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
and O
pyrexia B-OSE_Labeled_AE
. O

Table O
6 O
reports O
the O
ADRs O
that O
occurred O
in O
patients O
in O
the O
KADCYLA-treated O
group O
( O
n=490 O
) O
of O
the O
randomized O
trial O
( O
Study O
1 O
) O
. O

Selected O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
are O
shown O
in O
Table O
7 O
. O

The O
most O
common O
ADRs O
seen O
with O
KADCYLA O
in O
the O
randomized O
trial O
( O
frequency O
> O
25 O
% O
) O
were O
nausea B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
hemorrhage B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
and O
constipation B-OSE_Labeled_AE
. O

The O
most O
common O
NCI-CTCAE O
( O
version O
3 O
) O
> O
= O
Grade O
3 O
ADRs O
( O
frequency O
> O
2 O
% O
) O
were O
thrombocytopenia B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
, O
hypokalemia B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
and O
fatigue B-OSE_Labeled_AE
. O

Table O
6 O
Summary O
of O
Adverse O
Drug O
Reactions O
Occurring O
in O
Patients O
on O
the O
KADCYLA O
Treatment O
Arm O
in O
the O
Randomized O
Trial O
( O
Study O
1 O
) O
Adverse O
Drug O
Reactions O
( O
MedDRA O
) O
System O
Organ O
Class O
KADCYLA O
( O
3.6 O
mg/kg O
) O
n=490Frequency O
rate O
% O
Lapatinib O
( O
1250 O
mg O
) O
+ O
Capecitabine O
( O
2000 O
mg/m O
2 O
) O
n=488Frequency O
rate O
% O
All O
grades O
( O
% O
) O
Grade O
3 O
- O
4 O
( O
% O
) O
All O
grades O
( O
% O
) O
Grade O
3 O
- O
4 O
( O
% O
) O
ND O
= O
Not O
determined O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
6.7 O
2.0 O
9.0 O
4.3 O
Anemia B-OSE_Labeled_AE
14.3 O
4.1 O
10.5 O
2.5 O
Thrombocytopenia B-OSE_Labeled_AE
31.2 O
14.5 O
3.3 O
0.4 O
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
Left B-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
1.8 O
0.2 O
3.3 O
0.4 O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Lacrimation B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
3.3 O
0 O
2.5 O
0 O
Dry B-OSE_Labeled_AE
eye I-OSE_Labeled_AE
3.9 O
0 O
3.1 O
0 O
Vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
4.5 O
0 O
0.8 O
0 O
Conjunctivitis B-OSE_Labeled_AE
3.9 O
0 O
2.3 O
0 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Dyspepsia B-OSE_Labeled_AE
9.2 O
0 O
11.5 O
0.4 O
Stomatitis B-OSE_Labeled_AE
14.1 O
0.2 O
32.6 O
2.5 O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
16.7 O
0 O
4.9 O
0.2 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
18.6 O
0.8 O
17.6 O
1.6 O
Vomiting B-OSE_Labeled_AE
19.2 O
0.8 O
29.9 O
4.5 O
Diarrhea B-OSE_Labeled_AE
24.1 O
1.6 O
79.7 O
20.7 O
Constipation B-OSE_Labeled_AE
26.5 O
0.4 O
11.1 O
0 O
Nausea B-OSE_Labeled_AE
39.8 O
0.8 O
45.1 O
2.5 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
7.1 O
0 O
8.2 O
0.2 O
Chills B-OSE_Labeled_AE
7.6 O
0 O
3.1 O
0 O
Pyrexia B-OSE_Labeled_AE
18.6 O
0.2 O
8.4 O
0.4 O
Asthenia B-OSE_Labeled_AE
17.8 O
0.4 O
17.6 O
1.6 O
Fatigue B-OSE_Labeled_AE
36.3 O
2.5 O
28.3 O
3.5 O
Hepatobiliary B-NonOSE_AE
Disorders I-NonOSE_AE
Nodular B-OSE_Labeled_AE
regenerative I-OSE_Labeled_AE
hyperplasia I-OSE_Labeled_AE
0.4 O
ND O
0 O
0 O
Portal B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
0.4 O
0.2 O
0 O
0 O
Immune B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Drug B-OSE_Labeled_AE
hypersensitivity I-OSE_Labeled_AE
2.2 O
0 O
0.8 O
0 O
Injury B-NonOSE_AE
, I-NonOSE_AE
Poisoning I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
Procedural I-NonOSE_AE
Infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
1.4 O
0 O
0.2 O
0 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
9.4 O
0.6 O
3.9 O
0 O
Investigations B-NonOSE_AE
Blood B-OSE_Labeled_AE
alkaline I-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
4.7 O
0.4 O
3.7 O
0.4 O
Increased B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
28.8 O
8.0 O
14.3 O
2.5 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Hypokalemia B-OSE_Labeled_AE
10.2 O
2.7 O
9.4 O
4.7 O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Myalgia B-OSE_Labeled_AE
14.1 O
0.6 O
3.7 O
0 O
Arthralgia B-OSE_Labeled_AE
19.2 O
0.6 O
8.4 O
0 O
Musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
36.1 O
1.8 O
30.5 O
1.4 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Dysgeusia B-OSE_Labeled_AE
8.0 O
0 O
4.1 O
0.2 O
Dizziness B-OSE_Labeled_AE
10.2 O
0.4 O
10.7 O
0.2 O
Peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
21.2 O
2.2 O
13.5 O
0.2 O
Headache B-OSE_Labeled_AE
28.2 O
0.8 O
14.5 O
0.8 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
12.0 O
0.4 O
8.6 O
0.2 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Pneumonitis B-OSE_Labeled_AE
1.2 O
0 O
0 O
0 O
Dyspnea B-OSE_Labeled_AE
12.0 O
0.8 O
8.0 O
0.4 O
Cough B-OSE_Labeled_AE
18.2 O
0.2 O
13.1 O
0.2 O
Epistaxis B-OSE_Labeled_AE
22.5 O
0.2 O
8.4 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Pruritus B-OSE_Labeled_AE
5.5 O
0.2 O
9.2 O
0 O
Rash B-OSE_Labeled_AE
11.6 O
0 O
27.5 O
1.8 O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
Hemorrhage B-OSE_Labeled_AE
32.2 O
1.8 O
16.4 O
0.8 O
Hypertension B-OSE_Labeled_AE
5.1 O
1.2 O
2.3 O
0.4 O
Table O
7 O
Selected O
Laboratory O
Abnormalities O
Parameter O
KADCYLA O
( O
3.6 O
mg/kg O
) O
Lapatinib O
( O
1250 O
mg O
) O
+ O
Capecitabine O
( O
2000 O
mg/m O
2 O
) O
All O
Grade O
% O
Grade O
3 O
% O
Grade O
4 O
% O
All O
Grade O
% O
Grade O
3 O
% O
Grade O
4 O
% O
Increased B-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
17 O
< O
1 O
0 O
57 O
2 O
0 O
Increased B-OSE_Labeled_AE
AST I-OSE_Labeled_AE
98 O
7 O
< O
1 O
65 O
3 O
0 O
Increased B-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
82 O
5 O
< O
1 O
54 O
3 O
0 O
Decreased B-OSE_Labeled_AE
platelet I-OSE_Labeled_AE
count I-OSE_Labeled_AE
83 O
14 O
3 O
21 O
< O
1 O
< O
1 O
Decreased B-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
60 O
4 O
1 O
64 O
3 O
< O
1 O
Decreased B-OSE_Labeled_AE
neutrophils I-OSE_Labeled_AE
39 O
3 O
< O
1 O
38 O
6 O
2 O
Decreased B-OSE_Labeled_AE
potassium I-OSE_Labeled_AE
33 O
3 O
0 O
31 O
6 O
< O
1 O
Hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
has O
been O
observed O
in O
two O
patients O
( O
0.2 O
% O
) O
with O
HER B-Not_AE_Candidate
2 I-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
metastatic O
breast I-Not_AE_Candidate
cancer I-Not_AE_Candidate
in O
clinical O
trials O
( O
n=884 O
) O
with O
KADCYLA O
as O
single-agent O
. O

6.2 O
Immunogenicity O
As O
with O
all O
therapeutic O
proteins O
, O
there O
is O
the O
potential O
for O
an O
immune B-OSE_Labeled_AE
response I-OSE_Labeled_AE
to I-OSE_Labeled_AE
KADCYLA I-OSE_Labeled_AE
. O

A O
total O
of O
836 O
patients O
from O
six O
clinical O
studies O
were O
tested O
at O
multiple O
time O
points O
for O
anti B-NonOSE_AE
- I-NonOSE_AE
therapeutic I-NonOSE_AE
antibody I-NonOSE_AE
( I-NonOSE_AE
ATA I-NonOSE_AE
) O
responses O
to O
KADCYLA O
. O

Following O
KADCYLA O
dosing O
, O
5.3 O
% O
( O
44/836 O
) O
of O
patients O
tested O
positive B-OSE_Labeled_AE
for I-OSE_Labeled_AE
anti I-OSE_Labeled_AE
- I-OSE_Labeled_AE
KADCYLA I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
at O
one O
or O
more O
post-dose O
time O
points O
. O

The O
presence O
of O
KADCYLA O
in O
patient O
serum O
at O
the O
time O
of O
ATA B-NonOSE_AE
sampling O
may O
interfere O
with O
the O
ability O
of O
this O
assay O
to O
detect O
anti B-NonOSE_AE
- I-NonOSE_AE
KADCYLA I-NonOSE_AE
antibodies I-NonOSE_AE
. O

As O
a O
result O
, O
data O
may O
not O
accurately O
reflect O
the O
true O
incidence O
of O
anti B-NonOSE_AE
- I-NonOSE_AE
KADCYLA I-NonOSE_AE
antibody I-NonOSE_AE
development O
. O

In O
addition O
, O
neutralizing B-NonOSE_AE
activity I-NonOSE_AE
of I-NonOSE_AE
anti I-NonOSE_AE
- I-NonOSE_AE
KADCYLA I-NonOSE_AE
antibodies I-NonOSE_AE
has O
not O
been O
assessed O
. O

Immunogenicity B-NonOSE_AE
data O
are O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
test O
methods O
used O
. O

Additionally O
, O
the O
observed O
incidence O
of O
a O
positive O
result O
in O
a O
test O
method O
may O
be O
influenced O
by O
several O
factors O
, O
including O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
drug O
interference O
, O
concomitant O
medication O
and O
the O
underlying O
disease O
. O

Therefore O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
KADCYLA I-NonOSE_AE
with O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
other I-NonOSE_AE
products I-NonOSE_AE
may O
be O
misleading O
. O

Clinical O
significance O
of O
anti B-NonOSE_AE
- I-NonOSE_AE
KADCYLA I-NonOSE_AE
antibodies I-NonOSE_AE
is O
not O
yet O
known O
. O

BOXED O
WARNING O
: O
Do O
Not O
Substitute O
KADCYLA O
for O
or O
with O
Trastuzumab O
WARNING O
: O
HEPATOTOXICITY O
, O
CARDIAC O
TOXICITY O
, O
EMBRYO-FETAL O
TOXICITY O
* O
Hepatotoxicity B-NonOSE_AE
: O
Serious O
hepatotoxicity B-OSE_Labeled_AE
has O
been O
reported O
, O
including O
liver B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
and O
death B-NonOSE_AE
in O
patients O
treated O
with O
KADCYLA O
. O

Monitor O
serum O
transaminases O
and O
bilirubin O
prior O
to O
initiation O
of O
KADCYLA O
treatment O
and O
prior O
to O
each O
KADCYLA O
dose O
. O

Reduce O
dose O
or O
discontinue O
KADCYLA O
as O
appropriate O
in O
cases O
of O
increased B-NonOSE_AE
serum I-NonOSE_AE
transaminases I-NonOSE_AE
or O
total O
bilirubin O
. O

( O
2.2 O
, O
5.1 O
) O
* O
Cardiac B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
: O
KADCYLA O
administration O
may O
lead O
to O
reductions B-OSE_Labeled_AE
in I-OSE_Labeled_AE
left I-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
ejection I-OSE_Labeled_AE
fraction I-OSE_Labeled_AE
( I-OSE_Labeled_AE
LVEF I-OSE_Labeled_AE
) O
. O

Evaluate O
left O
ventricular O
function O
in O
all O
patients O
prior O
to O
and O
during O
treatment O
with O
KADCYLA O
. O

Withhold O
treatment O
for O
clinically O
significant O
decrease B-NonOSE_AE
in I-NonOSE_AE
left I-NonOSE_AE
ventricular I-NonOSE_AE
function I-NonOSE_AE
. O

( O
2.2 O
, O
5.2 O
) O
* O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
: O
Exposure O
to O
KADCYLA O
can O
result O
in O
embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
fetal I-OSE_Labeled_AE
death I-OSE_Labeled_AE
or O
birth B-OSE_Labeled_AE
defects I-OSE_Labeled_AE
. O

Advise O
patients O
of O
these O
risks O
and O
the O
need O
for O
effective O
contraception O
. O

( O
5.3 O
, O
8.1 O
, O
8.6 O
) O
EXCERPT O
: O
WARNING O
: O
HEPATOTOXICITY O
, O
CARDIAC O
TOXICITY O
, O
EMBRYO-FETAL O
TOXICITY O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
* O
Do O
not O
substitute O
KADCYLA O
for O
or O
with O
trastuzumab O
. O

( O
2.1 O
) O
* O
Hepatotoxicity O
, O
liver O
failure O
and O
death O
have O
occurred O
in O
KADCYLA-treated O
patients O
. O

Monitor O
hepatic O
function O
prior O
to O
initiation O
and O
prior O
to O
each O
dose O
. O

Institute O
dose O
modifications O
or O
permanently O
discontinue O
as O
appropriate O
. O

( O
2.2 O
, O
5.1 O
) O
* O
KADCYLA O
may O
lead O
to O
reductions O
in O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
. O

Assess O
LVEF O
prior O
to O
initiation O
. O

Monitor O
and O
withhold O
dosing O
or O
discontinue O
as O
appropriate O
. O

( O
2.2 O
, O
5.2 O
) O
* O
Can O
cause O
fetal O
harm O
. O

Advise O
women O
of O
potential O
risk O
to O
the O
fetus O
. O

( O
5.3 O
, O
8.1 O
, O
8.6 O
) O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Pulmonary O
Toxicity O
: O
Permanently O
discontinue O
KADCYLA O
in O
patients O
diagnosed O
with O
interstitial O
lung O
disease O
or O
pneumonitis O
. O

( O
2.2 O
, O
5.4 O
) O
* O
Infusion-Related O
Reactions O
, O
Hypersensitivity O
Reactions O
: O
Monitor O
for O
signs O
and O
symptoms O
during O
and O
after O
infusion O
. O

If O
significant O
infusion-related O
reactions O
or O
hypersensitivity O
reactions O
occur O
, O
slow O
or O
interrupt O
the O
infusion O
and O
administer O
appropriate O
medical O
therapies O
. O

Permanently O
discontinue O
KADCYLA O
for O
life O
threatening O
infusion-related O
reaction O
. O

( O
2.1 O
, O
2.2 O
, O
5.5 O
) O
* O
Hemorrhage O
: O
Fatal O
cases O
of O
hemorrhage O
occurred O
in O
clinical O
trials O
among O
patients O
with O
no O
known O
identified O
risk O
factors O
, O
as O
well O
as O
among O
patients O
with O
thrombocytopenia O
and O
those O
receiving O
anti-coagulation O
and O
antiplatelet O
therapy O
. O

Use O
caution O
with O
these O
agents O
and O
consider O
additional O
monitoring O
when O
concomitant O
use O
is O
medically O
necessary O
. O

( O
5.6 O
) O
* O
Thrombocytopenia O
: O
Monitor O
platelet O
counts O
prior O
to O
each O
KADCYLA O
dose O
. O

Institute O
dose O
modifications O
as O
appropriate O
. O

( O
2.2 O
, O
5.7 O
) O
* O
Neurotoxicity O
: O
Monitor O
for O
signs O
or O
symptoms O
. O

Withhold O
dosing O
temporarily O
for O
patients O
experiencing O
Grade O
3 O
or O
4 O
peripheral O
neuropathy O
. O

( O
2.2 O
, O
5.8 O
, O
13.2 O
) O
* O
HER2 O
Testing O
: O
Perform O
using O
FDA-approved O
tests O
by O
laboratories O
with O
demonstrated O
proficiency O
. O

( O
5.9 O
) O
5.1 O
Hepatotoxicity O
Hepatotoxicity B-OSE_Labeled_AE
, O
predominantly O
in O
the O
form O
of O
asymptomatic O
, O
transient O
increases B-OSE_Labeled_AE
in O
the O
concentrations O
of O
serum O
transaminases I-OSE_Labeled_AE
, O
has O
been O
observed O
in O
clinical O
trials O
with O
KADCYLA O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Serious O
hepatobiliary B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
including O
at O
least O
two O
fatal B-NonOSE_AE
cases O
of O
severe O
drug B-OSE_Labeled_AE
- I-OSE_Labeled_AE
induced I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
injury I-OSE_Labeled_AE
and O
associated O
hepatic B-OSE_Labeled_AE
encephalopathy I-OSE_Labeled_AE
, O
have O
been O
reported O
in O
clinical O
trials O
with O
KADCYLA O
. O

Some O
of O
the O
observed O
cases O
may O
have O
been O
confounded O
by O
comorbidities O
and/or O
concomitant O
medications O
with O
known O
hepatotoxic B-NonOSE_AE
potential O
. O

Monitor O
serum O
transaminases O
and O
bilirubin O
prior O
to O
initiation O
of O
KADCYLA O
treatment O
and O
prior O
to O
each O
KADCYLA O
dose O
. O

Patients O
with O
known O
active O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
virus I-Not_AE_Candidate
or O
hepatitis B-Not_AE_Candidate
C I-Not_AE_Candidate
virus I-Not_AE_Candidate
were O
excluded O
from O
Study O
1 O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

Reduce O
the O
dose O
or O
discontinue O
KADCYLA O
as O
appropriate O
in O
cases O
of O
increased B-NonOSE_AE
serum I-NonOSE_AE
transaminases I-NonOSE_AE
and/or O
total O
bilirubin O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

Permanently O
discontinue O
KADCYLA O
treatment O
in O
patients O
with O
serum B-NonOSE_AE
transaminases I-NonOSE_AE
> I-NonOSE_AE
3 I-NonOSE_AE
* I-NonOSE_AE
ULN I-NonOSE_AE
and O
concomitant O
total B-NonOSE_AE
bilirubin I-NonOSE_AE
> I-NonOSE_AE
2 I-NonOSE_AE
* I-NonOSE_AE
ULN I-NonOSE_AE
. O

KADCYLA O
has O
not O
been O
studied O
in O
patients O
with O
serum O
transaminases B-NonOSE_AE
> I-NonOSE_AE
2 I-NonOSE_AE
. I-NonOSE_AE
5 I-NonOSE_AE
* I-NonOSE_AE
ULN I-NonOSE_AE
or O
bilirubin B-NonOSE_AE
> I-NonOSE_AE
1 I-NonOSE_AE
. I-NonOSE_AE
5 I-NonOSE_AE
* I-NonOSE_AE
ULN I-NonOSE_AE
prior O
to O
the O
initiation O
of O
treatment O
. O

In O
clinical O
trials O
of O
KADCYLA O
, O
cases O
of O
nodular B-OSE_Labeled_AE
regenerative I-OSE_Labeled_AE
hyperplasia I-OSE_Labeled_AE
( I-OSE_Labeled_AE
NRH I-OSE_Labeled_AE
) O
of O
the O
liver O
have O
been O
identified O
from O
liver O
biopsies O
( O
3 O
cases O
out O
of O
884 O
treated O
patients O
, O
one O
of O
which O
was O
fatal B-NonOSE_AE
) O
. O

Two O
of O
these O
three O
cases O
of O
NRH B-OSE_Labeled_AE
were O
observed O
in O
the O
randomized O
trial O
( O
Study O
1 O
) O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

NRH B-NonOSE_AE
is O
a O
rare O
liver B-NonOSE_AE
condition I-NonOSE_AE
characterized I-NonOSE_AE
by I-NonOSE_AE
widespread I-NonOSE_AE
benign I-NonOSE_AE
transformation I-NonOSE_AE
of I-NonOSE_AE
hepatic I-NonOSE_AE
parenchyma I-NonOSE_AE
into I-NonOSE_AE
small I-NonOSE_AE
regenerative I-NonOSE_AE
nodules I-NonOSE_AE
; O
NRH B-NonOSE_AE
may O
lead O
to O
non B-NonOSE_AE
- I-NonOSE_AE
cirrhotic I-NonOSE_AE
portal I-NonOSE_AE
hypertension I-NonOSE_AE
. O

The O
diagnosis O
of O
NRH B-NonOSE_AE
can O
be O
confirmed O
only O
by O
histopathology O
. O

NRH B-NonOSE_AE
should O
be O
considered O
in O
all O
patients O
with O
clinical O
symptoms O
of O
portal B-NonOSE_AE
hypertension I-NonOSE_AE
and/or O
cirrhosis B-NonOSE_AE
- I-NonOSE_AE
like I-NonOSE_AE
pattern I-NonOSE_AE
seen O
on O
the O
computed O
tomography O
( O
CT O
) O
scan O
of O
the O
liver O
but O
with O
normal O
transaminases O
and O
no O
other O
manifestations O
of O
cirrhosis B-NonOSE_AE
. O

Upon O
diagnosis O
of O
NRH B-NonOSE_AE
, O
KADCYLA O
treatment O
must O
be O
permanently O
discontinued O
. O

5.2 O
Left O
Ventricular O
Dysfunction O
Patients O
treated O
with O
KADCYLA O
are O
at O
increased O
risk O
of O
developing O
left B-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
. O

A O
decrease B-OSE_Labeled_AE
of I-OSE_Labeled_AE
LVEF I-OSE_Labeled_AE
to I-OSE_Labeled_AE
< I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
% I-OSE_Labeled_AE
has O
been O
observed O
in O
patients O
treated O
with O
KADCYLA O
. O

In O
the O
randomized O
trial O
( O
Study O
1 O
) O
, O
left B-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
occurred O
in O
1.8 O
% O
of O
patients O
in O
the O
KADCYLA-treated O
group O
and O
3.3 O
% O
of O
patients O
in O
the O
lapatinib O
plus O
capecitabine-treated O
group O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Assess O
LVEF O
prior O
to O
initiation O
of O
KADCYLA O
and O
at O
regular O
intervals O
( O
e.g O
. O

every O
three O
months O
) O
during O
treatment O
to O
ensure O
the O
LVEF O
is O
within O
the O
institution O
's O
normal O
limits O
. O

Treatment O
with O
KADCYLA O
has O
not O
been O
studied O
in O
patients O
with O
LVEF B-Not_AE_Candidate
< I-Not_AE_Candidate
5 I-Not_AE_Candidate
0 I-Not_AE_Candidate
% I-Not_AE_Candidate
prior O
to O
initiation O
of O
treatment O
. O

If O
, O
at O
routine O
monitoring O
, O
LVEF B-NonOSE_AE
is O
< O
40 O
% O
, O
or O
is O
40 O
% O
to O
45 O
% O
with O
a O
10 O
% O
or O
greater O
absolute O
decrease I-NonOSE_AE
below O
the O
pretreatment O
value O
, O
withhold O
KADCYLA O
and O
repeat O
LVEF O
assessment O
within O
approximately O
3 O
weeks O
. O

Permanently O
discontinue O
KADCYLA O
if O
the O
LVEF O
has O
not O
improved O
or O
has O
declined O
further O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

Patients O
with O
a O
history O
of O
symptomatic B-Not_AE_Candidate
congestive I-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
( I-Not_AE_Candidate
CHF I-Not_AE_Candidate
) O
, O
serious O
cardiac B-Not_AE_Candidate
arrhythmia I-Not_AE_Candidate
, O
or O
history B-Not_AE_Candidate
of I-Not_AE_Candidate
myocardial I-Not_AE_Candidate
infarction I-Not_AE_Candidate
or O
unstable B-Not_AE_Candidate
angina I-Not_AE_Candidate
within O
6 O
months O
were O
excluded O
from O
Study O
1 O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

5.3 O
Embryo-Fetal O
Toxicity O
KADCYLA O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
. O

There O
are O
no O
adequate O
and O
well-controlled O
studies O
of O
KADCYLA O
in O
pregnant B-Not_AE_Candidate
women O
and O
no O
reproductive O
and O
developmental O
toxicology O
studies O
have O
been O
conducted O
with O
ado-trastuzumab O
emtansine O
. O

Nevertheless O
, O
treatment O
with O
trastuzumab O
, O
the O
antibody O
component O
of O
KADCYLA O
, O
during O
pregnancy B-Not_AE_Candidate
in O
the O
postmarketing O
setting O
has O
resulted O
in O
oligohydramnios B-OSE_Labeled_AE
, O
some O
associated O
with O
fatal B-NonOSE_AE
pulmonary B-OSE_Labeled_AE
hypoplasia I-OSE_Labeled_AE
, O
skeletal B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
and O
neonatal B-OSE_Labeled_AE
death I-OSE_Labeled_AE
. O

DM1 O
, O
the O
cytotoxic B-NonOSE_AE
component O
of O
KADCYLA O
, O
can O
be O
expected O
to O
cause O
embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
fetal I-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
based O
on O
its O
mechanism O
of O
action O
. O

If O
KADCYLA O
is O
used O
during O
pregnancy B-Not_AE_Candidate
, O
or O
if O
the O
patient O
becomes O
pregnant B-NonOSE_AE
while O
receiving O
KADCYLA O
or O
within O
7 O
months O
following O
the O
last O
dose O
of O
KADCYLA O
, O
apprise O
the O
patient O
of O
the O
potential O
hazard B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

Verify O
pregnancy B-NonOSE_AE
status O
prior O
to O
the O
initiation O
of O
KADCYLA O
. O

Advise O
patients O
of O
the O
risks O
of O
embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
fetal I-OSE_Labeled_AE
death I-OSE_Labeled_AE
and O
birth B-OSE_Labeled_AE
defects I-OSE_Labeled_AE
and O
the O
need O
for O
contraception O
during O
and O
after O
treatment O
. O

Advise O
patients O
to O
contact O
their O
healthcare O
provider O
immediately O
if O
they O
suspect O
they O
may O
be O
pregnant B-NonOSE_AE
. O

If O
KADCYLA O
is O
administered O
during O
pregnancy B-Not_AE_Candidate
or O
if O
a O
patient O
becomes O
pregnant B-NonOSE_AE
while O
receiving O
KADCYLA O
or O
within O
7 O
months O
following O
the O
last O
dose O
of O
KADCYLA O
, O
immediately O
report O
exposure O
to O
the O
Genentech O
Adverse O
Event O
Line O
at O
1-888-835-2555 O
. O

Encourage O
women O
who O
may O
be O
exposed O
during O
pregnancy B-NonOSE_AE
or O
within O
7 O
months O
prior O
to O
conception O
, O
to O
enroll O
in O
the O
MotHER O
Pregnancy B-NonOSE_AE
Registry O
by O
contacting O
1-800-690-6720 O
[ O
see O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.4 O
Pulmonary B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Cases O
of O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ILD I-OSE_Labeled_AE
) O
, O
including O
pneumonitis B-OSE_Labeled_AE
, O
some O
leading O
to O
acute B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
distress I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
or O
fatal B-NonOSE_AE
outcome O
have O
been O
reported O
in O
clinical O
trials O
with O
KADCYLA O
. O

Pneumonitis B-OSE_Labeled_AE
at O
an O
incidence O
of O
0.8 O
% O
( O
7 O
out O
of O
884 O
treated O
patients O
) O
has O
been O
reported O
, O
with O
one O
case O
of O
grade O
3 O
pneumonitis B-OSE_Labeled_AE
. O

Signs O
and O
symptoms O
include O
dyspnea B-NonOSE_AE
, O
cough B-NonOSE_AE
, O
fatigue B-NonOSE_AE
, O
and O
pulmonary B-NonOSE_AE
infiltrates I-NonOSE_AE
. O

These O
events O
may O
or O
may O
not O
occur O
as O
sequelae O
of O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
. O

In O
the O
randomized O
trial O
( O
Study O
1 O
) O
, O
the O
overall O
frequency O
of O
pneumonitis B-OSE_Labeled_AE
was O
1.2 O
% O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Permanently O
discontinue O
treatment O
with O
KADCYLA O
in O
patients O
diagnosed O
with O
ILD B-NonOSE_AE
or O
pneumonitis B-NonOSE_AE
. O

Patients O
with O
dyspnea B-Not_AE_Candidate
at I-Not_AE_Candidate
rest I-Not_AE_Candidate
due O
to O
complications O
of O
advanced B-Not_AE_Candidate
malignancy I-Not_AE_Candidate
and O
co-morbidities O
may O
be O
at O
increased O
risk O
of O
pulmonary B-NonOSE_AE
toxicity I-NonOSE_AE
. O

5.5 O
Infusion-Related O
Reactions O
, O
Hypersensitivity O
Reactions O
Treatment O
with O
KADCYLA O
has O
not O
been O
studied O
in O
patients O
who O
had O
trastuzumab O
permanently O
discontinued O
due O
to O
infusion B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
reactions I-NonOSE_AE
( I-NonOSE_AE
IRR I-NonOSE_AE
) O
and/or O
hypersensitivity B-NonOSE_AE
; O
treatment O
with O
KADCYLA O
is O
not O
recommended O
for O
these O
patients O
. O

Infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
characterized O
by O
one O
or O
more O
of O
the O
following O
symptoms O
- O
flushing B-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
wheezing B-OSE_Labeled_AE
, O
bronchospasm B-OSE_Labeled_AE
, O
and O
tachycardia B-OSE_Labeled_AE
have O
been O
reported O
in O
clinical O
trials O
of O
KADCYLA O
. O

In O
the O
randomized O
trial O
( O
Study O
1 O
) O
, O
the O
overall O
frequency O
of O
IRRs B-OSE_Labeled_AE
in O
patients O
treated O
with O
KADCYLA O
was O
1.4 O
% O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

In O
most O
patients O
, O
these O
reactions O
resolved O
over O
the O
course O
of O
several O
hours O
to O
a O
day O
after O
the O
infusion O
was O
terminated O
. O

KADCYLA O
treatment O
should O
be O
interrupted O
in O
patients O
with O
severe O
IRR B-NonOSE_AE
. O

KADCYLA O
treatment O
should O
be O
permanently O
discontinued O
in O
the O
event O
of O
a O
life-threatening O
IRR B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

Patients O
should O
be O
observed O
closely O
for O
IRR B-NonOSE_AE
reactions O
, O
especially O
during O
the O
first O
infusion O
. O

One O
case O
of O
a O
serious O
, O
allergic B-OSE_Labeled_AE
/anaphylactic-like O
reaction I-OSE_Labeled_AE
has O
been O
observed O
in O
clinical O
trials O
of O
single-agent O
KADCYLA O
. O

Medications O
to O
treat O
such O
reactions O
, O
as O
well O
as O
emergency O
equipment O
, O
should O
be O
available O
for O
immediate O
use O
. O

5.6 O
Hemorrhage O
Cases O
of O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
including O
central B-OSE_Labeled_AE
nervous I-OSE_Labeled_AE
system I-OSE_Labeled_AE
, O
respiratory O
, O
and O
gastrointestinal O
hemorrhage I-OSE_Labeled_AE
, O
have O
been O
reported O
in O
clinical O
trials O
with O
Kadcyla O
. O

Some O
of O
these O
bleeding B-OSE_Labeled_AE
events O
resulted O
in O
fatal B-NonOSE_AE
outcomes O
. O

In O
the O
randomized O
trial O
( O
Study O
1 O
) O
, O
the O
overall O
frequency O
of O
hemorrhage B-OSE_Labeled_AE
was O
32.2 O
% O
in O
the O
KADCYLA-treated O
group O
and O
16.4 O
% O
in O
the O
lapatinib O
plus O
capecitabine-treated O
group O
. O

The O
incidence O
of O
> O
= O
Grade O
3 O
hemorrhage B-OSE_Labeled_AE
was O
1.8 O
% O
in O
the O
KADCYLA-treated O
group O
and O
0.8 O
% O
in O
the O
lapatinib O
plus O
capecitabine-treated O
group O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Although O
, O
in O
some O
of O
the O
observed O
cases O
the O
patients O
were O
also O
receiving O
anti-coagulation O
therapy O
, O
antiplatelet O
therapy O
, O
or O
had O
thrombocytopenia B-Not_AE_Candidate
, O
in O
others O
there O
were O
no O
known O
additional O
risk O
factors O
. O

Use O
caution O
with O
these O
agents O
and O
consider O
additional O
monitoring O
when O
concomitant O
use O
is O
medically O
necessary O
. O

5.7 O
Thrombocytopenia O
Thrombocytopenia B-OSE_Labeled_AE
, O
or O
decreased B-OSE_Labeled_AE
platelet I-OSE_Labeled_AE
count I-OSE_Labeled_AE
, O
was O
reported O
in O
clinical O
trials O
of O
KADCYLA O
( O
103 O
of O
884 O
treated O
patients O
with O
> O
= O
Grade O
3 O
; O
283 O
of O
884 O
treated O
patients O
with O
any O
Grade O
) O
. O

The O
majority O
of O
these O
patients O
had O
Grade O
1 O
or O
2 O
events O
( O
< O
LLN O
to O
> O
= O
50,000/mm O
3 O
) O
with O
the O
nadir O
occurring O
by O
day O
8 O
and O
generally O
improving O
to O
Grade O
0 O
or O
1 O
( O
> O
= O
75,000 O
/mm O
3 O
) O
by O
the O
next O
scheduled O
dose O
. O

In O
clinical O
trials O
of O
KADCYLA O
, O
the O
incidence O
and O
severity O
of O
thrombocytopenia B-NonOSE_AE
were O
higher O
in O
Asian O
patients O
. O

In O
the O
randomized O
trial O
( O
Study O
1 O
) O
, O
the O
overall O
frequency O
of O
thrombocytopenia B-OSE_Labeled_AE
was O
31.2 O
% O
in O
the O
KADCYLA-treated O
group O
and O
3.3 O
% O
in O
the O
lapatinib O
plus O
capecitabine-treated O
group O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

The O
incidence O
of O
> O
= O
Grade O
3 O
thrombocytopenia B-OSE_Labeled_AE
was O
14.5 O
% O
in O
the O
KADCYLA-treated O
group O
and O
0.4 O
% O
in O
the O
lapatinib O
plus O
capecitabine-treated O
group O
. O

In O
Asian O
patients O
, O
the O
incidence O
of O
> O
= O
Grade O
3 O
thrombocytopenia B-OSE_Labeled_AE
was O
45.1 O
% O
in O
the O
KADCYLA-treated O
group O
and O
1.3 O
% O
in O
the O
lapatinib O
plus O
capecitabine-treated O
group O
. O

Monitor O
platelet O
counts O
prior O
to O
initiation O
of O
KADCYLA O
and O
prior O
to O
each O
KADCYLA O
dose O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

KADCYLA O
has O
not O
been O
studied O
in O
patients O
with O
platelet B-Not_AE_Candidate
counts I-Not_AE_Candidate
< I-Not_AE_Candidate
1 I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
, I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
/mm O
3 O
prior O
to O
initiation O
of O
treatment O
. O

In O
the O
event O
of O
decreased B-NonOSE_AE
platelet I-NonOSE_AE
count I-NonOSE_AE
to O
Grade O
3 O
or O
greater O
( O
< O
50,000/mm O
3 O
) O
do O
not O
administer O
KADCYLA O
until O
platelet O
counts O
recover O
to O
Grade O
1 O
( O
> O
= O
75,000/mm O
3 O
) O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

Patients O
with O
thrombocytopenia B-Not_AE_Candidate
( O
< O
100,000/mm O
3 O
) O
and O
patients O
on O
anti-coagulant O
treatment O
should O
be O
closely O
monitored O
during O
treatment O
with O
KADCYLA O
. O

5.8 O
Neurotoxicity B-OSE_Labeled_AE
Peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
mainly O
as O
Grade O
1 O
and O
predominantly O
sensory O
, O
was O
reported O
in O
clinical O
trials O
of O
KADCYLA O
( O
14 O
of O
884 O
treated O
patients O
with O
> O
= O
Grade O
3 O
; O
196 O
of O
884 O
treated O
patients O
with O
any O
Grade O
) O
. O

In O
the O
randomized O
trial O
( O
Study O
1 O
) O
, O
the O
overall O
frequency O
of O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
was O
21.2 O
% O
in O
the O
KADCYLA-treated O
group O
and O
13.5 O
% O
in O
the O
lapatinib O
plus O
capecitabine-treated O
group O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

The O
incidence O
of O
> O
= O
Grade O
3 O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
was O
2.2 O
% O
in O
the O
KADCYLA-treated O
group O
and O
0.2 O
% O
in O
the O
lapatinib O
plus O
capecitabine-treated O
group O
. O

KADCYLA O
should O
be O
temporarily O
discontinued O
in O
patients O
experiencing O
Grade O
3 O
or O
4 O
peripheral B-NonOSE_AE
neuropathy I-NonOSE_AE
until O
resolution O
to O
< O
= O
Grade O
2 O
. O

Patients O
should O
be O
clinically O
monitored O
on O
an O
ongoing O
basis O
for O
signs O
or O
symptoms O
of O
neurotoxicity B-NonOSE_AE
[ O
see O
Nonclinical O
Toxicology O
( O
13.2 O
) O
] O
. O

5.9 O
HER2 O
Testing O
Detection O
of O
HER B-Not_AE_Candidate
2 I-Not_AE_Candidate
protein I-Not_AE_Candidate
overexpression I-Not_AE_Candidate
or I-Not_AE_Candidate
gene I-Not_AE_Candidate
amplification I-Not_AE_Candidate
is O
necessary O
for O
selection O
of O
patients O
appropriate O
for O
KADCYLA O
therapy O
because O
these O
are O
the O
only O
patients O
studied O
for O
whom O
benefit O
has O
been O
shown O
[ O
see O
Indications O
and O
Usage O
( O
1 O
) O
, O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

In O
the O
randomized O
study O
( O
Study O
1 O
) O
, O
patients O
with O
breast B-Not_AE_Candidate
cancer I-Not_AE_Candidate
were O
required O
to O
have O
evidence O
of O
HER B-Not_AE_Candidate
2 I-Not_AE_Candidate
overexpression I-Not_AE_Candidate
defined O
as O
3+ O
IHC O
by O
Dako O
HerceptestTM O
or O
evidence O
of O
overexpression O
defined O
as O
FISH O
amplification O
ratio O
> O
= O
2.0 O
by O
Dako O
HER2 O
FISH O
PharmDxTM O
test O
kit O
. O

Only O
limited O
data O
were O
available O
for O
patients O
whose O
breast B-Not_AE_Candidate
cancer I-Not_AE_Candidate
was O
positive O
by O
FISH O
and O
0 O
or O
1+ O
by O
IHC O
. O

Assessment O
of O
HER2 O
status O
should O
be O
performed O
by O
laboratories O
with O
demonstrated O
proficiency O
in O
the O
specific O
technology O
being O
utilized O
. O

Improper O
assay O
performance O
, O
including O
use O
of O
sub- O
optimally O
fixed O
tissue O
, O
failure O
to O
utilize O
specified O
reagents O
, O
deviation O
from O
specific O
assay O
instructions O
, O
and O
failure O
to O
include O
appropriate O
controls O
for O
assay O
validation O
, O
can O
lead O
to O
unreliable O
results O
. O

5.10 O
Extravasation O
In O
KADCYLA O
clinical O
studies O
, O
reactions O
secondary O
to O
extravasation B-OSE_Labeled_AE
have O
been O
observed O
. O

These O
reactions O
, O
observed O
more O
frequently O
within O
24 O
hours O
of O
infusion O
, O
were O
usually O
mild O
and O
comprised O
erythema B-OSE_Labeled_AE
, O
tenderness O
, O
skin O
irrit O
at I-OSE_Labeled_AE
ion O
, O
pain O
, O
or O
swelling O
at O
the I-OSE_Labeled_AE
infusion I-OSE_Labeled_AE
site I-OSE_Labeled_AE
. O

Specific O
treatment O
for O
KADCYLA O
extravasation B-NonOSE_AE
is O
unknown O
. O

The O
infusion B-NonOSE_AE
site I-NonOSE_AE
should I-NonOSE_AE
be I-NonOSE_AE
closely I-NonOSE_AE
monitored I-NonOSE_AE
for I-NonOSE_AE
possible I-NonOSE_AE
subcutaneous I-NonOSE_AE
infiltration I-NonOSE_AE
during I-NonOSE_AE
drug I-NonOSE_AE
administration I-NonOSE_AE
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
Common O
adverse O
reactions O
occurring O
in O
> O
=1 O
% O
in O
subjects O
treated O
with O
KERYDIN O
included O
application O
site O
exfoliation O
, O
ingrown O
toenail O
, O
application O
site O
erythema O
, O
and O
application O
site O
dermatitis O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Anacor O
Pharmaceuticals O
at O
1-844-4ANACOR O
[ O
1-844-426-2267 O
] O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

In O
two O
clinical O
trials O
, O
791 O
subjects O
were O
treated O
with O
KERYDIN O
. O

The O
most O
commonly O
reported O
adverse O
reactions O
are O
listed O
below O
( O
Table O
1 O
) O
. O

Table O
1 O
: O
Adverse O
Reactions O
Occurring O
in O
> O
=1 O
% O
of O
KERYDIN O
Topical O
Solution O
, O
5 O
% O
-Treated O
Subjects O
and O
at O
a O
Greater O
Frequency O
than O
Observed O
with O
Vehicle O
Preferred O
Term O
KERYDINN=791 O
n O
( O
% O
) O
VehicleN=395 O
n O
( O
% O
) O
Application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
exfoliation I-OSE_Labeled_AE
21 O
( O
2.7 O
% O
) O
1 O
( O
0.3 O
% O
) O
Ingrown B-OSE_Labeled_AE
toenail I-OSE_Labeled_AE
20 O
( O
2.5 O
% O
) O
1 O
( O
0.3 O
% O
) O
Application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
13 O
( O
1.6 O
% O
) O
0 O
( O
0 O
% O
) O
Application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
10 O
( O
1.3 O
% O
) O
0 O
( O
0 O
% O
) O
A O
cumulative O
irritancy O
study O
revealed O
the O
potential O
for O
KERYDIN O
to O
cause O
skin B-OSE_Labeled_AE
irritation I-OSE_Labeled_AE
. O

There O
was O
no O
evidence O
that O
KERYDIN O
causes O
contact O
sensitization O
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
( O
incidence O
< O
1 O
% O
) O
are O
injection O
site O
irritation O
and/or O
pain O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Navidea O
Biopharmaceuticals O
, O
Inc O
. O
at O
1-800-476-5270 O
or O
www.lymphoseek.com O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

In O
open O
label O
, O
single O
arm O
clinical O
trials O
, O
553 O
patients O
with O
either O
breast B-Not_AE_Candidate
cancer I-Not_AE_Candidate
, O
malanoma B-Not_AE_Candidate
, O
or O
squamous B-Not_AE_Candidate
cell I-Not_AE_Candidate
carcinoma I-Not_AE_Candidate
of I-Not_AE_Candidate
the I-Not_AE_Candidate
oral I-Not_AE_Candidate
cavity I-Not_AE_Candidate
, O
skin O
, O
and O
lip O
received O
Lymphoseek O
. O

No O
patients O
experienced O
serious O
adverse O
reactions O
. O

Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
irritation I-OSE_Labeled_AE
( O
4 O
patients O
; O
0.7 O
% O
) O
and O
pain O
( O
1 O
patient O
; O
0.2 O
% O
) O
were O
reported O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
Hypersensitivity O
: O
Ask O
patients O
about O
prior O
reactions O
to O
drugs O
, O
especially O
dextran O
or O
modified O
forms O
of O
dextran O
. O

Observe O
for O
hypersensitivity O
signs O
and O
symptoms O
following O
Lymphoseek O
injection O
. O

Have O
resuscitation O
equipment O
and O
trained O
personnel O
immediately O
available O
. O

( O
5.1 O
) O
5.1 O
Hypersensitivity O
Reactions O
Lymphoseek O
may O
pose O
a O
risk O
of O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
due I-OSE_Labeled_AE
to I-OSE_Labeled_AE
its I-OSE_Labeled_AE
chemical I-OSE_Labeled_AE
similarity I-OSE_Labeled_AE
to O
dextran O
[ O
see O
Description O
( O
11 O
) O
] O
. O

Serious O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
have O
been O
associated O
with O
dextran O
and O
modified O
forms O
of O
dextran O
( O
such O
as O
iron O
dextran O
drugs O
) O
. O

Before O
administering O
Lymphoseek O
, O
ask O
patients O
about O
prior O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
to O
drugs O
, O
especially O
to O
dextran O
and O
modified O
forms O
of O
dextran O
. O

Have O
resuscitation O
equipment O
and O
trained O
personnel O
immediately O
available O
at O
the O
time O
of O
Lymphoseek O
administration O
. O

5.2 O
Radiation O
Risks O
Any O
radiation-emitting O
product O
may O
increase O
the O
risk B-NonOSE_AE
for I-NonOSE_AE
cancer I-NonOSE_AE
, O
especially O
in O
pediatric O
patients O
. O

Adhere O
to O
the O
dose O
recommendations O
and O
ensure O
safe O
handling O
to O
minimize O
the O
risk O
for O
excessive O
radiation B-NonOSE_AE
exposure I-NonOSE_AE
to O
either O
patients O
or O
health O
care O
workers O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Cardiac B-OSE_Labeled_AE
Toxicities I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Acute B-OSE_Labeled_AE
Renal I-OSE_Labeled_AE
Failure I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Tumor B-OSE_Labeled_AE
Lysis I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Pulmonary B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Pulmonary B-OSE_Labeled_AE
Hypertension I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Dyspnea B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Hypertension B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Venous B-OSE_Labeled_AE
Thrombosis I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Infusion B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Hemorrhage B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
* O
Thrombocytopenia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
* O
Hepatic B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
and O
Hepatic B-OSE_Labeled_AE
Failure I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.12 O
) O
] O
* O
Thrombotic B-OSE_Labeled_AE
Microangiopathy I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.13 O
) O
] O
* O
Posterior B-OSE_Labeled_AE
Reversible I-OSE_Labeled_AE
Encephalopathy I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.14 O
) O
] O
* O
Increased O
Fatal B-NonOSE_AE
and O
Serious O
Toxicities O
in O
Combintaion O
with O
Melphalan O
and O
Prednisone O
in O
Newly O
Diagnosed O
Transplant-Ineligible O
Patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.15 O
) O
] O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
occurring O
in O
at O
least O
20 O
% O
of O
patients O
treated O
with O
Kyprolis O
in O
monotherapy O
trials O
: O
anemia O
, O
fatigue O
, O
thrombocytopenia O
, O
nausea O
, O
pyrexia O
, O
dyspnea O
, O
diarrhea O
, O
headache O
, O
cough O
, O
edema O
peripheral O
. O

( O
6 O
) O
The O
most O
common O
adverse O
reactions O
occurring O
in O
at O
least O
20 O
% O
of O
patients O
treated O
with O
Kyprolis O
in O
the O
combination O
therapy O
trials O
: O
anemia O
, O
neutropenia O
, O
diarrhea O
, O
dyspnea O
, O
fatigue O
, O
thrombocytopenia O
, O
pyrexia O
, O
insomnia O
, O
muscle O
spasm O
, O
cough O
, O
upper O
respiratory O
tract O
infection O
, O
hypokalemia O
. O

( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Amgen O
Medical O
Information O
at O
1-800-77-AMGEN O
( O
1-800-772-6436 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
with O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
, O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
medical O
practice O
. O

Safety O
Experience O
with O
Kyprolis O
in O
Combination O
with O
Lenalidomide O
and O
Dexamethasone O
in O
Patients O
with O
Multiple O
Myeloma O
The O
safety O
of O
Kyprolis O
in O
combination O
with O
lenalidomide O
and O
dexamethasone O
( O
KRd O
) O
was O
evaluated O
in O
an O
open-label O
randomized O
study O
in O
patients O
with O
relapsed O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
. O

Details O
of O
the O
study O
treatment O
are O
described O
in O
Section O
14.1 O
. O

The O
median O
number O
of O
cycles O
initiated O
was O
22 O
cycles O
for O
the O
KRd O
arm O
and O
14 O
cycles O
for O
the O
Rd O
arm O
. O

Deaths B-NonOSE_AE
due O
to O
adverse O
reactions O
within O
30 O
days O
of O
the O
last O
dose O
of O
any O
therapy O
in O
the O
KRd O
arm O
occurred O
in O
27/392 O
( O
7 O
% O
) O
patients O
compared O
with O
27/389 O
( O
7 O
% O
) O
patients O
who O
died B-NonOSE_AE
due O
to O
adverse O
events O
within O
30 O
days O
of O
the O
last O
dose O
of O
any O
Rd O
therapy O
. O

The O
most O
common O
cause O
of O
deaths B-NonOSE_AE
occurring O
in O
patients O
( O
% O
) O
in O
the O
two O
arms O
( O
KRd O
versus O
Rd O
) O
included O
cardiac B-NonOSE_AE
10 O
( O
3 O
% O
) O
versus O
7 O
( O
2 O
% O
) O
, O
infection B-NonOSE_AE
9 O
( O
2 O
% O
) O
versu O
s O
10 O
( O
3 O
% O
) O
, O
renal B-NonOSE_AE
0 O
( O
0 O
% O
) O
versus O
1 O
( O
< O
1 O
% O
) O
, O
and O
other O
adverse O
reactions O
9 O
( O
2 O
% O
) O
versus O
10 O
( O
3 O
% O
) O
. O

Serious O
adverse O
reactions O
were O
reported O
in O
60 O
% O
of O
the O
patients O
in O
the O
KRd O
arm O
and O
54 O
% O
of O
the O
patients O
in O
the O
Rd O
arm O
. O

The O
most O
common O
serious O
adverse O
reactions O
reported O
in O
the O
KRd O
arm O
as O
compared O
with O
the O
Rd O
arm O
were O
pneumonia B-OSE_Labeled_AE
( O
14 O
% O
versus O
11 O
% O
) O
, O
respiratory B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
4 O
% O
versus O
1.5 O
% O
) O
, O
pyrexia B-OSE_Labeled_AE
( O
4 O
% O
versus O
2 O
% O
) O
, O
and O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
( O
3 O
% O
versus O
2 O
% O
) O
. O

Discontinuation O
due O
to O
any O
adverse O
reaction O
occurred O
in O
26 O
% O
in O
the O
KRd O
arm O
versus O
25 O
% O
in O
the O
Rd O
arm O
. O

Adverse O
reactions O
leading O
to O
discontinuation O
of O
Kyprolis O
occurred O
in O
12 O
% O
of O
patients O
and O
the O
most O
common O
reactions O
included O
pneumonia B-OSE_Labeled_AE
( O
1 O
% O
) O
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
( O
0.8 O
% O
) O
, O
and O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
0.8 O
% O
) O
. O

Common O
Adverse O
Reactions O
( O
> O
= O
10 O
% O
) O
The O
adverse O
reactions O
in O
the O
first O
12 O
cycles O
of O
therapy O
that O
occurred O
at O
a O
rate O
of O
10 O
% O
or O
greater O
in O
the O
KRd O
arm O
are O
presented O
in O
Table O
8 O
. O

Table O
8 O
: O
Most O
Common O
Adverse O
Reactions O
( O
> O
= O
10 O
% O
in O
the O
KRd O
Arm O
) O
Occurring O
in O
Cycles O
1-12 O
( O
20/27 O
mg/m2 O
Regimen O
In O
Combination O
with O
Lenalidomide O
and O
Dexamethasone O
) O
KRd O
Arm O
( O
N O
= O
392 O
) O
n O
( O
% O
) O
Rd O
Arm O
( O
N O
= O
389 O
) O
n O
( O
% O
) O
Adverse O
Reactions O
by O
Body O
System O
Any O
Grade O
> O
= O
Grade O
3 O
Any O
Grade O
> O
= O
Grade O
3 O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Anemia B-OSE_Labeled_AE
138 O
( O
35 O
) O
53 O
( O
14 O
) O
127 O
( O
33 O
) O
47 O
( O
12 O
) O
Neutropenia B-OSE_Labeled_AE
124 O
( O
32 O
) O
104 O
( O
27 O
) O
115 O
( O
30 O
) O
89 O
( O
23 O
) O
Thrombocytopenia B-OSE_Labeled_AE
100 O
( O
26 O
) O
58 O
( O
15 O
) O
75 O
( O
19 O
) O
39 O
( O
10 O
) O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
115 O
( O
29 O
) O
7 O
( O
2 O
) O
105 O
( O
27 O
) O
12 O
( O
3 O
) O
Constipation B-OSE_Labeled_AE
68 O
( O
17 O
) O
0 O
53 O
( O
14 O
) O
1 O
( O
0 O
) O
Nausea B-OSE_Labeled_AE
60 O
( O
15 O
) O
1 O
( O
0 O
) O
39 O
( O
10 O
) O
3 O
( O
1 O
) O
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
109 O
( O
28 O
) O
21 O
( O
5 O
) O
104 O
( O
27 O
) O
20 O
( O
5 O
) O
Pyrexia B-OSE_Labeled_AE
93 O
( O
24 O
) O
5 O
( O
1 O
) O
64 O
( O
17 O
) O
1 O
( O
0 O
) O
Edema B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
63 O
( O
16 O
) O
2 O
( O
1 O
) O
57 O
( O
15 O
) O
2 O
( O
1 O
) O
Asthenia B-OSE_Labeled_AE
53 O
( O
14 O
) O
11 O
( O
3 O
) O
46 O
( O
12 O
) O
7 O
( O
2 O
) O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
85 O
( O
22 O
) O
7 O
( O
2 O
) O
52 O
( O
13 O
) O
3 O
( O
1 O
) O
Nasopharyngitis B-OSE_Labeled_AE
63 O
( O
16 O
) O
0 O
43 O
( O
11 O
) O
0 O
Bronchitis B-OSE_Labeled_AE
54 O
( O
14 O
) O
5 O
( O
1 O
) O
39 O
( O
10 O
) O
2 O
( O
1 O
) O
Pneumonia B-OSE_Labeled_AE
a O
54 O
( O
14 O
) O
35 O
( O
9 O
) O
43 O
( O
11 O
) O
27 O
( O
7 O
) O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Hypokalemia B-OSE_Labeled_AE
78 O
( O
20 O
) O
22 O
( O
6 O
) O
35 O
( O
9 O
) O
12 O
( O
3 O
) O
Hypocalcemia B-OSE_Labeled_AE
55 O
( O
14 O
) O
10 O
( O
3 O
) O
39 O
( O
10 O
) O
5 O
( O
1 O
) O
Hyperglycemia B-OSE_Labeled_AE
43 O
( O
11 O
) O
18 O
( O
5 O
) O
33 O
( O
9 O
) O
15 O
( O
4 O
) O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
88 O
( O
22 O
) O
3 O
( O
1 O
) O
73 O
( O
19 O
) O
3 O
( O
1 O
) O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Peripheral B-OSE_Labeled_AE
neuropathies I-OSE_Labeled_AE
b O
43 O
( O
11 O
) O
7 O
( O
2 O
) O
37 O
( O
10 O
) O
4 O
( O
1 O
) O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
63 O
( O
16 O
) O
6 O
( O
2 O
) O
50 O
( O
13 O
) O
8 O
( O
2 O
) O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
c O
91 O
( O
23 O
) O
2 O
( O
1 O
) O
52 O
( O
13 O
) O
0 O
Dyspnea B-OSE_Labeled_AE
d O
70 O
( O
18 O
) O
9 O
( O
2 O
) O
58 O
( O
15 O
) O
6 O
( O
2 O
) O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
45 O
( O
12 O
) O
5 O
( O
1 O
) O
53 O
( O
14 O
) O
5 O
( O
1 O
) O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
Embolic B-OSE_Labeled_AE
and O
thrombotic O
events I-OSE_Labeled_AE
venous I-OSE_Labeled_AE
e O
49 O
( O
13 O
) O
16 O
( O
4 O
) O
22 O
( O
6 O
) O
9 O
( O
2 O
) O
Hypertension B-OSE_Labeled_AE
f O
41 O
( O
11 O
) O
12 O
( O
3 O
) O
15 O
( O
4 O
) O
4 O
( O
1 O
) O
KRd O
= O
Kyprolis O
, O
lenalidomide O
, O
and O
dexamethasone O
; O
Rd O
= O
lenalidomide O
and O
dexamethasone O
a O
Pneumonia B-OSE_Labeled_AE
includes O
pneumonia B-OSE_Labeled_AE
and O
bronchopneumonia B-OSE_Labeled_AE
. O

b O
Peripheral B-OSE_Labeled_AE
neuropathies I-OSE_Labeled_AE
includes O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
and O
peripheral B-OSE_Labeled_AE
motor I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
. O

c O
Cough B-OSE_Labeled_AE
includes O
cough B-OSE_Labeled_AE
and O
productive B-OSE_Labeled_AE
cough I-OSE_Labeled_AE
. O

d O
Dyspnea B-OSE_Labeled_AE
includes O
dyspnea B-OSE_Labeled_AE
and O
dyspnea B-OSE_Labeled_AE
exertional I-OSE_Labeled_AE
. O

e O
Embolic B-OSE_Labeled_AE
and O
thrombotic O
events I-OSE_Labeled_AE
, O
venous I-OSE_Labeled_AE
include O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
thrombophlebitis B-OSE_Labeled_AE
superficial I-OSE_Labeled_AE
, O
thrombophlebitis B-OSE_Labeled_AE
, O
venous B-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
limb I-OSE_Labeled_AE
, O
post B-OSE_Labeled_AE
thrombotic I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
venous B-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
. O

f O
Hypertension B-OSE_Labeled_AE
includes O
hypertension B-OSE_Labeled_AE
, O
hypertensive B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
. O

There O
were O
274 O
( O
70 O
% O
) O
patients O
in O
the O
KRd O
arm O
who O
received O
treatment O
beyond O
Cycle O
12 O
. O

There O
were O
no O
new O
clinically O
relevant O
adverse O
reactions O
that O
emerged O
in O
the O
later O
treatment O
cycles O
. O

Adverse O
Reactions O
Occurring O
at O
a O
Frequency O
of O
< O
10 O
% O
* O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
, O
lymphopenia B-OSE_Labeled_AE
* O
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
congestive I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
, O
pericardial B-OSE_Labeled_AE
effusion I-OSE_Labeled_AE
* O
Eye B-NonOSE_AE
disorders I-NonOSE_AE
: O
cataract B-OSE_Labeled_AE
, O
vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
* O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
toothache B-OSE_Labeled_AE
* O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
: O
chills B-OSE_Labeled_AE
, O
infusion B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
multi B-OSE_Labeled_AE
- I-OSE_Labeled_AE
organ I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
* O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
: O
influenza B-OSE_Labeled_AE
, O
lung B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
rhinitis B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
viral B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
* O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
: O
dehydration B-OSE_Labeled_AE
, O
hyperkalemia B-OSE_Labeled_AE
, O
hyperuricemia B-OSE_Labeled_AE
, O
hypoalbuminemia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
, O
tumor B-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
* O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
muscular B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
* O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
hypoesthesia B-OSE_Labeled_AE
, O
intracranial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
deafness B-OSE_Labeled_AE
* O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
: O
anxiety B-OSE_Labeled_AE
, O
delirium B-OSE_Labeled_AE
* O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
: O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
acute I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
* O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
: O
dysphonia B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
oropharyngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
* O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
erythema B-OSE_Labeled_AE
, O
hyperhidrosis B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
* O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
: O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
, O
hemorrhage B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
Grade O
3 O
and O
higher O
adverse O
reactions O
that O
occurred O
during O
Cycles O
1-12 O
with O
a O
substantial O
difference O
( O
> O
= O
2 O
% O
) O
between O
the O
two O
arms O
were O
neutropenia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
hypokalemia B-OSE_Labeled_AE
, O
and O
hypophosphatemia B-OSE_Labeled_AE
. O

Laboratory O
Abnormalities O
Table O
9 O
describes O
Grade O
3-4 O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
reported O
at O
a O
rate O
of O
> O
= O
10 O
% O
in O
the O
KRd O
arm O
for O
patients O
who O
received O
combination O
therapy O
. O

Table O
9 O
: O
Grade O
3-4 O
Laboratory O
Abnormalities O
( O
> O
= O
10 O
% O
in O
the O
KRd O
Arm O
) O
in O
Cycles O
1-12 O
( O
20/27 O
mg/m2 O
Regimen O
In O
Combination O
with O
Lenalidomide O
and O
Dexamethasone O
) O
Laboratory B-NonOSE_AE
Abnormality I-NonOSE_AE
KRd O
( O
N O
= O
392 O
) O
n O
( O
% O
) O
Rd O
( O
N O
= O
389 O
) O
n O
( O
% O
) O
Decreased B-OSE_Labeled_AE
lymphocytes I-OSE_Labeled_AE
182 O
( O
46 O
) O
119 O
( O
31 O
) O
Decreased B-OSE_Labeled_AE
absolute I-OSE_Labeled_AE
neutrophil I-OSE_Labeled_AE
count I-OSE_Labeled_AE
152 O
( O
39 O
) O
140 O
( O
36 O
) O
Decreased B-OSE_Labeled_AE
phosphorus I-OSE_Labeled_AE
122 O
( O
31 O
) O
106 O
( O
27 O
) O
Decreased B-OSE_Labeled_AE
platelets I-OSE_Labeled_AE
101 O
( O
26 O
) O
59 O
( O
15 O
) O
Decreased B-OSE_Labeled_AE
total I-OSE_Labeled_AE
white I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
count I-OSE_Labeled_AE
97 O
( O
25 O
) O
71 O
( O
18 O
) O
Decreased B-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
58 O
( O
15 O
) O
68 O
( O
18 O
) O
Decreased B-OSE_Labeled_AE
potassium I-OSE_Labeled_AE
41 O
( O
11 O
) O
23 O
( O
6 O
) O
KRd O
= O
Kyprolis O
, O
lenalidomide O
, O
and O
dexamethasone O
; O
Rd O
= O
lenalidomide O
and O
dexamethasone O
Safety O
Experience O
with O
Kyprolis O
in O
Combination O
with O
Dexamethasone O
in O
Patients O
with O
Multiple O
Myeloma O
The O
safety O
of O
Kyprolis O
in O
combination O
with O
dexamethasone O
was O
evaluated O
in O
an O
open-label O
, O
randomized O
trial O
of O
patients O
with O
relapsed O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
. O

The O
study O
treatment O
is O
described O
in O
Section O
14.2 O
. O

Patients O
received O
treatment O
for O
a O
median O
duration O
of O
40 O
weeks O
in O
the O
Kyprolis/dexamethasone O
( O
Kd O
) O
arm O
and O
27 O
weeks O
in O
the O
bortezomib/dexamethasone O
( O
Vd O
) O
arm O
. O

Deaths B-NonOSE_AE
due O
to O
adverse O
reactions O
within O
30 O
days O
of O
last O
study O
treatment O
occurred O
in O
22/463 O
( O
5 O
% O
) O
patients O
in O
the O
Kd O
arm O
and O
21/456 O
( O
5 O
% O
) O
patients O
in O
the O
Vd O
arm O
. O

The O
causes O
of O
death B-NonOSE_AE
occurring O
in O
patients O
( O
% O
) O
in O
the O
two O
arms O
( O
Kd O
versus O
Vd O
) O
included O
cardiac B-NonOSE_AE
7 O
( O
2 O
% O
) O
versus O
5 O
( O
1 O
% O
) O
, O
infections B-NonOSE_AE
5 O
( O
1 O
% O
) O
versus O
8 O
( O
2 O
% O
) O
, O
disease O
progression O
6 O
( O
1 O
% O
) O
versus O
4 O
( O
1 O
% O
) O
, O
pulmonary B-NonOSE_AE
3 O
( O
1 O
% O
) O
versus O
2 O
( O
< O
1 O
% O
) O
, O
renal B-NonOSE_AE
1 O
( O
< O
1 O
% O
) O
versus O
0 O
( O
0 O
% O
) O
, O
and O
other O
adverse O
events O
2 O
( O
< O
1 O
% O
) O
versus O
2 O
( O
< O
1 O
% O
) O
. O

Serious O
adverse O
reactions O
were O
reported O
in O
48 O
% O
of O
the O
patients O
in O
the O
Kd O
arm O
and O
36 O
% O
of O
the O
patients O
in O
the O
Vd O
arm O
. O

In O
both O
treatment O
arms O
, O
pneumonia B-OSE_Labeled_AE
was O
the O
most O
commonly O
reported O
serious O
adverse O
reaction O
( O
6 O
% O
versus O
9 O
% O
) O
. O

Discontinuation O
due O
to O
any O
adverse O
reaction O
occurred O
in O
20 O
% O
in O
the O
Kd O
arm O
versus O
21 O
% O
in O
the O
Vd O
arm O
. O

The O
most O
common O
reaction O
leading O
to O
discontinuation O
was O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
in O
the O
Kd O
arm O
( O
n O
= O
6 O
, O
1.3 O
% O
) O
and O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
in O
the O
Vd O
arm O
( O
n O
= O
19 O
, O
4.2 O
% O
) O
. O

Common O
Adverse O
Reactions O
( O
> O
= O
10 O
% O
) O
Adverse O
reactions O
in O
the O
first O
6 O
months O
of O
therapy O
that O
occurred O
at O
a O
rate O
of O
10 O
% O
or O
greater O
in O
the O
Kd O
arm O
are O
presented O
in O
Table O
10 O
. O

Table O
10 O
: O
Most O
Common O
Adverse O
Reactions O
( O
> O
= O
10 O
% O
in O
the O
Kd O
Arm O
) O
Occurring O
in O
Months O
1-6 O
( O
20/56 O
mg/m2 O
Regimen O
In O
Combination O
with O
Dexamethasone O
) O
Kd O
( O
N O
= O
463 O
) O
n O
( O
% O
) O
Vd O
( O
N O
= O
456 O
) O
n O
( O
% O
) O
Adverse O
Reaction O
by O
Body O
System O
Any O
Grade O
> O
= O
Grade O
3 O
Any O
Grade O
> O
= O
Grade O
3 O
Blood B-NonOSE_AE
and I-NonOSE_AE
L I-NonOSE_AE
ymphatic I-NonOSE_AE
S I-NonOSE_AE
ystem I-NonOSE_AE
D I-NonOSE_AE
isorders I-NonOSE_AE
Anemia B-OSE_Labeled_AE
160 O
( O
35 O
) O
57 O
( O
12 O
) O
112 O
( O
25 O
) O
43 O
( O
9 O
) O
Thrombocytopenia B-OSE_Labeled_AE
a O
127 O
( O
27 O
) O
46 O
( O
10 O
) O
112 O
( O
25 O
) O
65 O
( O
14 O
) O
Gastrointestinal B-NonOSE_AE
D I-NonOSE_AE
isorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
111 O
( O
24 O
) O
14 O
( O
3 O
) O
150 O
( O
33 O
) O
26 O
( O
6 O
) O
Nausea B-OSE_Labeled_AE
69 O
( O
15 O
) O
4 O
( O
1 O
) O
66 O
( O
15 O
) O
3 O
( O
1 O
) O
Constipation B-OSE_Labeled_AE
58 O
( O
13 O
) O
1 O
( O
0 O
) O
109 O
( O
24 O
) O
6 O
( O
1 O
) O
Vomiting B-OSE_Labeled_AE
45 O
( O
10 O
) O
5 O
( O
1 O
) O
32 O
( O
7 O
) O
3 O
( O
1 O
) O
General B-NonOSE_AE
D I-NonOSE_AE
isorders I-NonOSE_AE
and I-NonOSE_AE
A I-NonOSE_AE
dministration I-NonOSE_AE
S I-NonOSE_AE
ite I-NonOSE_AE
C I-NonOSE_AE
onditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
112 O
( O
24 O
) O
13 O
( O
3 O
) O
124 O
( O
27 O
) O
25 O
( O
6 O
) O
Pyrexia B-OSE_Labeled_AE
102 O
( O
22 O
) O
9 O
( O
2 O
) O
52 O
( O
11 O
) O
3 O
( O
1 O
) O
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
75 O
( O
16 O
) O
3 O
( O
1 O
) O
73 O
( O
16 O
) O
3 O
( O
1 O
) O
Asthenia B-OSE_Labeled_AE
71 O
( O
15 O
) O
9 O
( O
2 O
) O
66 O
( O
14 O
) O
13 O
( O
3 O
) O
Infections B-NonOSE_AE
and I-NonOSE_AE
I I-NonOSE_AE
nfestations I-NonOSE_AE
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
66 O
( O
14 O
) O
4 O
( O
1 O
) O
54 O
( O
12 O
) O
3 O
( O
1 O
) O
Bronchitis B-OSE_Labeled_AE
54 O
( O
12 O
) O
5 O
( O
1 O
) O
26 O
( O
6 O
) O
2 O
( O
0 O
) O
Nasopharyngitis B-OSE_Labeled_AE
45 O
( O
10 O
) O
0 O
( O
0 O
) O
42 O
( O
9 O
) O
1 O
( O
0 O
) O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
C I-NonOSE_AE
onnective I-NonOSE_AE
T I-NonOSE_AE
issue I-NonOSE_AE
D I-NonOSE_AE
isorders I-NonOSE_AE
Muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
66 O
( O
14 O
) O
1 O
( O
0 O
) O
22 O
( O
5 O
) O
3 O
( O
1 O
) O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
58 O
( O
13 O
) O
7 O
( O
2 O
) O
60 O
( O
13 O
) O
8 O
( O
2 O
) O
Nervous B-NonOSE_AE
S I-NonOSE_AE
ystem I-NonOSE_AE
D I-NonOSE_AE
isorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
68 O
( O
15 O
) O
4 O
( O
1 O
) O
38 O
( O
8 O
) O
2 O
( O
0 O
) O
Peripheral B-OSE_Labeled_AE
neuropathies I-OSE_Labeled_AE
b O
, O
c O
54 O
( O
12 O
) O
7 O
( O
2 O
) O
167 O
( O
37 O
) O
23 O
( O
5 O
) O
Psychiatric B-NonOSE_AE
D I-NonOSE_AE
isorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
103 O
( O
22 O
) O
5 O
( O
1 O
) O
113 O
( O
25 O
) O
10 O
( O
2 O
) O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
T I-NonOSE_AE
horacic I-NonOSE_AE
and I-NonOSE_AE
M I-NonOSE_AE
ediastinal I-NonOSE_AE
D I-NonOSE_AE
isorders I-NonOSE_AE
Dyspnea B-OSE_Labeled_AE
d O
123 O
( O
27 O
) O
23 O
( O
5 O
) O
66 O
( O
15 O
) O
8 O
( O
2 O
) O
Cough B-OSE_Labeled_AE
e O
91 O
( O
20 O
) O
0 O
( O
0 O
) O
61 O
( O
13 O
) O
2 O
( O
0 O
) O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
f O
80 O
( O
17 O
) O
29 O
( O
6 O
) O
33 O
( O
7 O
) O
12 O
( O
3 O
) O
Kd O
= O
Kyprolis O
and O
dexamethasone O
; O
Vd O
= O
bortezomib O
and O
dexamethasone O
a O
Thrombocytopenia B-OSE_Labeled_AE
includes O
platelet B-OSE_Labeled_AE
count I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
and O
thrombocytopenia B-OSE_Labeled_AE
. O

b O
Peripheral B-OSE_Labeled_AE
neuropathies I-OSE_Labeled_AE
include O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
and O
peripheral B-OSE_Labeled_AE
motor I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
. O

c O
See O
Clinical O
Studies O
( O
14.2 O
) O
. O

d O
Dyspnea B-OSE_Labeled_AE
includes O
dyspnea B-OSE_Labeled_AE
and O
dyspnea B-OSE_Labeled_AE
exertional I-OSE_Labeled_AE
. O

e O
Cough B-OSE_Labeled_AE
includes O
cough B-OSE_Labeled_AE
and O
productive B-OSE_Labeled_AE
cough I-OSE_Labeled_AE
. O

f O
Hypertension B-OSE_Labeled_AE
includes O
hypertension B-OSE_Labeled_AE
, O
hypertensive B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
, O
and O
hypertensive B-OSE_Labeled_AE
emergency I-OSE_Labeled_AE
. O

The O
event O
rate O
of O
> O
= O
Grade O
2 O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
in O
the O
Kd O
arm O
was O
6 O
% O
( O
95 O
% O
CI O
: O
4 O
, O
8 O
) O
versus O
32 O
% O
( O
95 O
% O
CI O
: O
28 O
, O
36 O
) O
in O
the O
Vd O
arm O
. O

Adverse O
Reactions O
Occurring O
at O
a O
Frequency O
of O
< O
10 O
% O
* O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
lymphopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
thrombotic B-OSE_Labeled_AE
microangiopathy I-OSE_Labeled_AE
, O
thrombotic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
* O
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
congestive I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
, O
palpitations B-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
* O
Eye B-NonOSE_AE
disorders I-NonOSE_AE
: O
cataract B-OSE_Labeled_AE
, O
vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
* O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
toothache B-OSE_Labeled_AE
* O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
: O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
infusion B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
including O
inflammation B-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
, O
and O
erythema B-OSE_Labeled_AE
) O
, O
pain B-OSE_Labeled_AE
* O
Hepatobiliary B-NonOSE_AE
disorders I-NonOSE_AE
: O
cholestasis B-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
hyperbilirubinemia B-OSE_Labeled_AE
* O
Immune B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
drug B-OSE_Labeled_AE
hypersensitivity I-OSE_Labeled_AE
* O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
: O
bronchopneumonia B-OSE_Labeled_AE
, O
influenza B-OSE_Labeled_AE
, O
lung B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
rhinitis B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
viral B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
* O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
: O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
, O
hypercalcemia B-OSE_Labeled_AE
, O
hyperkalemia B-OSE_Labeled_AE
, O
hyperuricemia B-OSE_Labeled_AE
, O
hypoalbuminemia B-OSE_Labeled_AE
, O
hypocalcemia B-OSE_Labeled_AE
, O
hypomagnesemia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
, O
hypophosphatemia B-OSE_Labeled_AE
, O
tumor B-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
* O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
muscular B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
chest I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
* O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
hypoesthesia B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
posterior B-OSE_Labeled_AE
reversible I-OSE_Labeled_AE
encephalopathy I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
* O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
: O
anxiety B-OSE_Labeled_AE
* O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
: O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
acute I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
* O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
: O
acute B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
distress I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
dysphonia B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
oropharyngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
pneumonitis B-OSE_Labeled_AE
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
, O
wheezing B-OSE_Labeled_AE
* O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
erythema B-OSE_Labeled_AE
, O
hyperhidrosis B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
* O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
: O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
, O
flushing B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
Laboratory O
Abnormalities O
Table O
11 O
describes O
Grades O
3-4 O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
reported O
at O
a O
rate O
of O
> O
= O
10 O
% O
in O
the O
Kd O
arm O
. O

Table O
11 O
: O
Grades O
3-4 O
Laboratory O
Abnormalities O
( O
> O
= O
10 O
% O
) O
in O
Months O
1-6 O
( O
20/56 O
mg/m2 O
Regimen O
In O
Combination O
with O
Dexamethasone O
) O
Laboratory B-NonOSE_AE
Abnormality I-NonOSE_AE
Kd O
( O
N O
= O
463 O
) O
n O
( O
% O
) O
Vd O
( O
N O
= O
456 O
) O
n O
( O
% O
) O
Decreased B-OSE_Labeled_AE
lymphocytes I-OSE_Labeled_AE
248 O
( O
54 O
) O
180 O
( O
40 O
) O
Increase B-OSE_Labeled_AE
uric I-OSE_Labeled_AE
acid I-OSE_Labeled_AE
243 O
( O
53 O
) O
198 O
( O
43 O
) O
Decreased B-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
79 O
( O
17 O
) O
68 O
( O
15 O
) O
Decreased B-OSE_Labeled_AE
platelets I-OSE_Labeled_AE
85 O
( O
18 O
) O
77 O
( O
17 O
) O
Decreased B-OSE_Labeled_AE
phosphorus I-OSE_Labeled_AE
73 O
( O
16 O
) O
61 O
( O
13 O
) O
Decreased B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
clearance I-OSE_Labeled_AE
a O
65 O
( O
14 O
) O
49 O
( O
11 O
) O
Increased B-OSE_Labeled_AE
potassium I-OSE_Labeled_AE
55 O
( O
12 O
) O
21 O
( O
5 O
) O
Kd O
= O
Kyprolis O
and O
dexamethasone O
; O
Vd O
= O
bortezomib O
and O
dexamethasone O
a O
Calculated O
using O
the O
Cockcroft-Gault O
formula O
. O

Safety O
Experience O
with O
Kyprolis O
in O
Patients O
with O
Multiple O
Myeloma O
who O
Received O
Monotherapy O
The O
safety O
of O
Kyprolis O
, O
dosed O
at O
20/27 O
mg/m O
2 O
by O
up O
to O
10-minute O
infusion O
, O
was O
evaluated O
in O
clinical O
trials O
in O
which O
598 O
patients O
with O
relapsed O
and/or O
refractory O
myeloma B-Not_AE_Candidate
received O
Kyprolis O
monotherapy O
starting O
with O
the O
20 O
mg/m O
2 O
dose O
in O
Cycle O
1 O
, O
Day O
1 O
and O
escalating O
to O
27 O
mg/m O
2 O
on O
Cycle O
1 O
, O
Day O
8 O
or O
Cycle O
2 O
, O
Day O
1 O
. O

Premedication O
with O
dexamethasone O
4 O
mg O
was O
required O
before O
each O
dose O
in O
Cycle O
1 O
and O
was O
optional O
for O
subsequent O
cycles O
. O

The O
median O
age O
was O
64 O
years O
( O
range O
32-87 O
) O
, O
and O
approximately O
57 O
% O
were O
male O
. O

The O
patients O
received O
a O
median O
of O
5 O
( O
range O
1-20 O
) O
prior O
regimens O
. O

The O
median O
number O
of O
cycles O
initiated O
was O
4 O
( O
range O
1-35 O
) O
. O

Serious O
adverse O
reactions O
, O
regardless O
of O
causality O
, O
were O
reported O
in O
50 O
% O
of O
patients O
in O
the O
pooled O
Kyprolis O
monotherapy O
studies O
( O
N O
= O
598 O
) O
. O

The O
most O
common O
serious O
adverse O
reactions O
were O
: O
pneumonia B-OSE_Labeled_AE
( O
8 O
% O
) O
, O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
5 O
% O
) O
, O
disease B-OSE_Labeled_AE
progression I-OSE_Labeled_AE
( O
4 O
% O
) O
, O
pyrexia B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
hypercalcemia B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
3 O
% O
) O
, O
multiple B-OSE_Labeled_AE
myeloma I-OSE_Labeled_AE
( O
3 O
% O
) O
, O
anemia B-OSE_Labeled_AE
( O
2 O
% O
) O
, O
and O
dyspnea B-OSE_Labeled_AE
( O
2 O
% O
) O
. O

In O
patients O
treated O
with O
Kyprolis O
, O
the O
incidence O
of O
serious O
adverse O
reactions O
was O
higher O
in O
those O
> O
= O
65 O
years O
old O
and O
those O
> O
= O
75 O
years O
old O
[ O
see O
Geriatric O
Use O
( O
8.5 O
) O
] O
. O

Deaths B-NonOSE_AE
due O
to O
adverse O
reactions O
within O
30 O
days O
of O
the O
last O
dose O
of O
Kyprolis O
occurred O
in O
30/598 O
( O
5 O
% O
) O
patients O
receiving O
Kyprolis O
monotherapy O
. O

These O
adverse O
reactions O
were O
related O
to O
cardiac B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
in O
10 O
( O
2 O
% O
) O
patients O
, O
infections B-OSE_Labeled_AE
in O
8 O
( O
1 O
% O
) O
patients O
, O
renal B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
in O
4 O
( O
< O
1 O
% O
) O
patients O
, O
and O
other O
adverse O
reactions O
in O
8 O
( O
1 O
% O
) O
patients O
. O

In O
a O
randomized O
trial O
comparing O
Kyprolis O
as O
a O
single O
agent O
versus O
corticosteroids O
with O
optional O
oral O
cyclophosphamide O
for O
patients O
with O
relapsed O
and O
refractory O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
, O
mortality B-NonOSE_AE
was O
higher O
in O
the O
patients O
treated O
with O
Kyprolis O
in O
comparison O
to O
the O
control O
arm O
in O
the O
subgroup O
of O
48 O
patients O
> O
= O
75 O
years O
of O
age O
. O

The O
most O
common O
cause O
of O
discontinuation O
due O
to O
an O
adverse O
reaction O
was O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
2 O
% O
) O
. O

Safety O
of O
Kyprolis O
monotherapy O
dosed O
at O
20/56 O
mg/m O
2 O
by O
30-minute O
infusion O
was O
evaluated O
in O
a O
multicenter O
, O
open-label O
study O
in O
patients O
with O
relapsed O
and/or O
refractory O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
. O

The O
study O
treatment O
is O
described O
in O
Section O
14.3 O
. O

The O
patients O
received O
a O
median O
of O
4 O
( O
range O
1-10 O
) O
prior O
regimens O
. O

The O
common O
adverse O
reactions O
occurring O
at O
a O
rate O
of O
20 O
% O
or O
greater O
with O
Kyprolis O
monotherapy O
are O
presented O
in O
Table O
12 O
. O

Table O
12 O
: O
Most O
Common O
Adverse O
Reactions O
( O
> O
= O
20 O
% O
) O
with O
Kyprolis O
Monotherapy O
20/56 O
mg/m O
2 O
by O
30 O
- O
minute O
infusion O
( O
N O
= O
24 O
) O
20/27 O
mg/m O
2 O
by O
2 O
- O
to O
10 O
- O
minute O
infusion O
( O
N O
= O
598 O
) O
Adverse O
Reaction O
Any O
Grade O
n O
( O
% O
) O
Grades O
3 O
- O
5 O
n O
( O
% O
) O
Any O
Grade O
n O
( O
% O
) O
Grades O
3 O
- O
5 O
n O
( O
% O
) O
Fatigue B-OSE_Labeled_AE
14 O
( O
58 O
) O
2 O
( O
8 O
) O
238 O
( O
40 O
) O
25 O
( O
4 O
) O
Dyspnea B-OSE_Labeled_AE
a O
14 O
( O
58 O
) O
2 O
( O
8 O
) O
202 O
( O
34 O
) O
21 O
( O
4 O
) O
Pyrexia B-OSE_Labeled_AE
14 O
( O
58 O
) O
0 O
177 O
( O
30 O
) O
11 O
( O
2 O
) O
Thrombocytopenia B-OSE_Labeled_AE
13 O
( O
54 O
) O
13 O
( O
54 O
) O
220 O
( O
37 O
) O
152 O
( O
25 O
) O
Nausea B-OSE_Labeled_AE
13 O
( O
54 O
) O
0 O
211 O
( O
35 O
) O
7 O
( O
1 O
) O
Anemia B-OSE_Labeled_AE
10 O
( O
42 O
) O
7 O
( O
29 O
) O
291 O
( O
49 O
) O
141 O
( O
24 O
) O
Hypertension B-OSE_Labeled_AE
b O
10 O
( O
42 O
) O
3 O
( O
13 O
) O
90 O
( O
15 O
) O
22 O
( O
4 O
) O
Chills B-OSE_Labeled_AE
9 O
( O
38 O
) O
0 O
73 O
( O
12 O
) O
1 O
( O
< O
1 O
) O
Headache B-OSE_Labeled_AE
8 O
( O
33 O
) O
0 O
141 O
( O
24 O
) O
7 O
( O
1 O
) O
Cough B-OSE_Labeled_AE
c O
8 O
( O
33 O
) O
0 O
134 O
( O
22 O
) O
2 O
( O
< O
1 O
) O
Vomiting B-OSE_Labeled_AE
8 O
( O
33 O
) O
0 O
104 O
( O
17 O
) O
4 O
( O
1 O
) O
Lymphopenia B-OSE_Labeled_AE
8 O
( O
33 O
) O
8 O
( O
33 O
) O
85 O
( O
14 O
) O
73 O
( O
12 O
) O
Insomnia B-OSE_Labeled_AE
7 O
( O
29 O
) O
0 O
75 O
( O
13 O
) O
0 O
Dizziness B-OSE_Labeled_AE
7 O
( O
29 O
) O
0 O
64 O
( O
11 O
) O
5 O
( O
1 O
) O
Diarrhea B-OSE_Labeled_AE
6 O
( O
25 O
) O
1 O
( O
4 O
) O
160 O
( O
27 O
) O
8 O
( O
1 O
) O
Blood B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
6 O
( O
25 O
) O
1 O
( O
4 O
) O
103 O
( O
17 O
) O
15 O
( O
3 O
) O
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
5 O
( O
21 O
) O
0 O
118 O
( O
20 O
) O
1 O
( O
< O
1 O
) O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
5 O
( O
21 O
) O
1 O
( O
4 O
) O
115 O
( O
19 O
) O
19 O
( O
3 O
) O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
5 O
( O
21 O
) O
1 O
( O
4 O
) O
112 O
( O
19 O
) O
15 O
( O
3 O
) O
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
5 O
( O
21 O
) O
0 O
89 O
( O
15 O
) O
2 O
( O
< O
1 O
) O
Muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
5 O
( O
21 O
) O
0 O
62 O
( O
10 O
) O
2 O
( O
< O
1 O
) O
Chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
5 O
( O
21 O
) O
0 O
20 O
( O
3 O
) O
1 O
( O
< O
1 O
) O
a O
Dyspnea B-OSE_Labeled_AE
includes O
preferred O
terms O
of O
dyspnea B-OSE_Labeled_AE
and O
dyspnea B-OSE_Labeled_AE
exertional I-OSE_Labeled_AE
. O

b O
Hypertension B-OSE_Labeled_AE
includes O
hypertension B-OSE_Labeled_AE
, O
hypertensive B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
, O
and O
hypertensive B-OSE_Labeled_AE
emergency I-OSE_Labeled_AE
. O

c O
Cough B-OSE_Labeled_AE
includes O
cough B-OSE_Labeled_AE
and O
productive B-OSE_Labeled_AE
cough I-OSE_Labeled_AE
. O

Adverse O
Reactions O
Occurring O
at O
a O
Frequency O
of O
< O
20 O
% O
* O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
* O
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
congestive I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
* O
Eye B-NonOSE_AE
disorders I-NonOSE_AE
: O
cataract B-OSE_Labeled_AE
, O
blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
* O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
toothache B-OSE_Labeled_AE
* O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
: O
asthenia B-OSE_Labeled_AE
, O
infusion B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
multi B-OSE_Labeled_AE
- I-OSE_Labeled_AE
organ I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
* O
Hepatobiliary B-NonOSE_AE
disorders I-NonOSE_AE
: O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
* O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
: O
bronchitis B-OSE_Labeled_AE
, O
bronchopneumonia B-OSE_Labeled_AE
, O
influenza B-OSE_Labeled_AE
, O
lung B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
rhinitis B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
* O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
: O
hypercalcemia B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
hyperkalemia B-OSE_Labeled_AE
, O
hyperuricemia B-OSE_Labeled_AE
, O
hypoalbuminemia B-OSE_Labeled_AE
, O
hypocalcemia B-OSE_Labeled_AE
, O
hypokalemia B-OSE_Labeled_AE
, O
hypomagnesemia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
, O
hypophosphatemia B-OSE_Labeled_AE
, O
tumor B-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
* O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
arthralgia B-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
chest I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
* O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
hypoesthesia B-OSE_Labeled_AE
, O
intracranial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
motor I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
* O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
: O
anxiety B-OSE_Labeled_AE
* O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
: O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
* O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
: O
dysphonia B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
oropharyngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
* O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
erythema B-OSE_Labeled_AE
, O
hyperhidrosis B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
* O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
: O
embolic B-OSE_Labeled_AE
and O
thrombotic O
events I-OSE_Labeled_AE
, O
venous I-OSE_Labeled_AE
( O
including O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
and O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
) O
, O
hemorrhage B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
Grade O
3 O
and O
higher O
adverse O
reactions O
occurring O
at O
an O
incidence O
of O
> O
1 O
% O
include O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
congestive I-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
hyperkalemia B-OSE_Labeled_AE
, O
hyperuricemia B-OSE_Labeled_AE
, O
hypoalbuminemia B-OSE_Labeled_AE
, O
hypocalcemia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
, O
hypophosphatemia B-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
acute I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
and O
hypotension B-OSE_Labeled_AE
. O

Laboratory O
Abnormalities O
Table O
13 O
describes O
Grade O
3-4 O
laboratory O
abnormalities O
reported O
at O
a O
rate O
of O
> O
10 O
% O
for O
patients O
who O
received O
Kyprolis O
monotherapy O
. O

Table O
13 O
: O
Grade O
3-4 O
Laboratory O
Abnormalities O
( O
> O
10 O
% O
) O
with O
Kyprolis O
Monotherapy O
Laboratory B-NonOSE_AE
Abnormality I-NonOSE_AE
Kyprolis O
20/56 O
mg/m O
2 O
( O
N O
= O
24 O
) O
Kyprolis O
20/27 O
mg/m O
2 O
( O
N O
= O
598 O
) O
Decreased B-OSE_Labeled_AE
lymphocytes I-OSE_Labeled_AE
15 O
( O
63 O
) O
151 O
( O
25 O
) O
Decreased B-OSE_Labeled_AE
platelets I-OSE_Labeled_AE
11 O
( O
46 O
) O
184 O
( O
31 O
) O
Decreased B-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
7 O
( O
29 O
) O
132 O
( O
22 O
) O
Decreased B-OSE_Labeled_AE
total I-OSE_Labeled_AE
white I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
count I-OSE_Labeled_AE
3 O
( O
13 O
) O
71 O
( O
12 O
) O
Decreased B-OSE_Labeled_AE
sodium I-OSE_Labeled_AE
2 O
( O
8 O
) O
69 O
( O
12 O
) O
Decreased B-OSE_Labeled_AE
absolute I-OSE_Labeled_AE
neutrophil I-OSE_Labeled_AE
count I-OSE_Labeled_AE
2 O
( O
8 O
) O
67 O
( O
11 O
) O
6.2 O
Postmarketing O
Experience O
The O
following O
additional O
adverse O
reactions O
were O
reported O
in O
the O
postmarketing O
experience O
with O
Kyprolis O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
: O
hemolytic B-OSE_Labeled_AE
uremic I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HUS I-OSE_Labeled_AE
) O
, O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
, O
pericarditis B-OSE_Labeled_AE
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Cardiac O
Toxicities O
: O
Monitor O
for O
signs O
and O
symptoms O
of O
cardiac O
failure O
or O
ischemia O
. O

Withhold O
Kyprolis O
and O
evaluate O
promptly O
. O

( O
5.1 O
) O
* O
Acute O
Renal O
Failure O
: O
Monitor O
serum O
creatinine O
regularly O
. O

( O
5.2 O
) O
* O
Tumor O
Lysis O
Syndrome O
( O
TLS O
) O
: O
Administer O
pre-treatment O
hydration O
. O

( O
2.1 O
) O
Monitor O
for O
TLS O
, O
including O
uric O
acid O
levels O
and O
treat O
promptly O
. O

( O
5.3 O
) O
* O
Pulmonary O
Toxicity O
, O
including O
Acute O
Respiratory O
Distress O
Syndrome O
, O
Acute O
Respiratory O
Failure O
, O
and O
Acute O
Diffuse O
Infiltrative O
Pulmonary O
Disease O
: O
Withhold O
Kyprolis O
and O
evaluate O
promptly O
. O

( O
5.4 O
) O
* O
Pulmonary O
Hypertension O
: O
Withhold O
Kyprolis O
and O
evaluate O
. O

( O
5.5 O
) O
* O
Dyspnea O
: O
For O
severe O
or O
life O
threatening O
dyspnea O
, O
withhold O
Kyprolis O
and O
evaluate O
. O

( O
5.6 O
) O
* O
Hypertension O
Including O
Hypertensive O
Crisis O
: O
Monitor O
blood O
pressure O
regularly O
. O

If O
hypertension O
can O
not O
be O
controlled O
, O
interrupt O
treatment O
with O
Kyprolis O
. O

( O
5.7 O
) O
* O
Venous O
Thrombosis O
: O
Thromboprophylaxis O
is O
recommended O
. O

( O
5.8 O
) O
* O
Infusion O
Reactions O
: O
Premedicate O
with O
dexamethasone O
. O

( O
2.1 O
, O
5.9 O
) O
* O
Hemorrhage O
: O
Fatal O
or O
serious O
cases O
of O
hemorrhage O
may O
occur O
, O
including O
gastrointestinal O
, O
pulmonary O
, O
and O
intracranial O
hemorrhage O
. O

Promptly O
evaluate O
signs O
and O
symptoms O
of O
blood O
loss O
. O

( O
5.10 O
) O
* O
Thrombocytopenia O
: O
Monitor O
platelet O
counts O
; O
interrupt O
or O
reduce O
Kyprolis O
dosing O
as O
clinically O
indicated O
. O

( O
2.3 O
, O
5.11 O
) O
* O
Hepatic O
Toxicity O
and O
Hepatic O
Failure O
: O
Monitor O
liver O
enzymes O
regularly O
. O

Withhold O
Kyprolis O
if O
suspected O
. O

( O
5.12 O
) O
* O
Thrombotic O
Microangiopathy O
: O
Monitor O
for O
signs O
and O
symptoms O
. O

Discontinue O
Kyprolis O
if O
suspected O
. O

( O
5.13 O
) O
* O
Posterior O
Reversible O
Encephalopathy O
Syndrome O
( O
PRES O
) O
: O
Consider O
neuro-radiological O
imaging O
( O
MRI O
) O
for O
onset O
of O
visual O
or O
neurological O
symptoms O
; O
discontinue O
Kyprolis O
if O
suspected O
. O

( O
5.14 O
) O
* O
Increased O
Fatal O
and O
Serious O
Toxicites O
in O
Combination O
with O
Melphalan O
and O
Prednisone O
in O
Newly O
Diagnosed O
Transplant-Ineligible O
Patients O
( O
5.15 O
) O
* O
Embryo-Fetal O
Toxicity O
: O
Kyprolis O
can O
cause O
fetal O
harm O
. O

Females O
of O
reproductive O
potential O
should O
avoid O
becoming O
pregnant O
while O
being O
treated O
. O

( O
5.16 O
, O
8.1 O
) O
5.1 O
Cardiac B-OSE_Labeled_AE
Toxicities I-OSE_Labeled_AE
New O
onset O
or O
worsening O
of O
pre-existing O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
e.g. O
, O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
ejection I-OSE_Labeled_AE
fraction I-OSE_Labeled_AE
) O
, O
restrictive B-OSE_Labeled_AE
cardiomyopathy I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
, O
and O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
including O
fatalities B-NonOSE_AE
have O
occurred O
following O
administration O
of O
Kyprolis O
. O

Some O
events O
occurred O
in O
patients O
with O
normal O
baseline O
ventricular O
function O
. O

In O
clinical O
studies O
with O
Kyprolis O
, O
these O
events O
occurred O
throughout O
the O
course O
of O
Kyprolis O
therapy O
. O

Death B-NonOSE_AE
due O
to O
cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
has O
occurred O
within O
one O
day O
of O
Kyprolis O
administration O
. O

In O
a O
randomized O
, O
open-label O
, O
multicenter O
trial O
evaluating O
Kyprolis O
in O
combination O
with O
lenalidomide O
and O
dexamethasone O
( O
KRd O
) O
versus O
lenalidomide/dexamethasone O
( O
Rd O
) O
, O
the O
incidence O
of O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
events I-OSE_Labeled_AE
was O
6 O
% O
in O
the O
KRd O
arm O
versus O
4 O
% O
in O
the O
Rd O
arm O
. O

In O
a O
randomized O
, O
open-label O
, O
multicenter O
trial O
of O
Kyprolis O
plus O
dexamethasone O
( O
Kd O
) O
versus O
bortezomib O
plus O
dexamethasone O
( O
Vd O
) O
, O
the O
incidence O
of O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
events I-OSE_Labeled_AE
was O
8 O
% O
in O
the O
Kd O
arm O
versus O
3 O
% O
in O
the O
Vd O
arm O
. O

Monitor O
patients O
for O
clinical O
signs O
or O
symptoms O
of O
cardiac B-NonOSE_AE
failure I-NonOSE_AE
or O
cardiac B-NonOSE_AE
ischemia I-NonOSE_AE
. O

Evaluate O
promptly O
if O
cardiac B-NonOSE_AE
toxicity I-NonOSE_AE
is O
suspected O
. O

Withhold O
Kyprolis O
for O
Grade O
3 O
or O
4 O
cardiac B-NonOSE_AE
adverse I-NonOSE_AE
events I-NonOSE_AE
until O
recovery O
, O
and O
consider O
whether O
to O
restart O
Kyprolis O
at O
1 O
dose O
level O
reduction O
based O
on O
a O
benefit/risk O
assessment O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

While O
adequate O
hydration O
is O
required O
prior O
to O
each O
dose O
in O
Cycle O
1 O
, O
all O
patients O
should O
also O
be O
monitored O
for O
evidence O
of O
volume B-NonOSE_AE
overload I-NonOSE_AE
, O
especially O
patients O
at O
risk O
for O
cardiac B-NonOSE_AE
failure I-NonOSE_AE
. O

Adjust O
total O
fluid O
intake O
as O
clinically O
appropriate O
in O
patients O
with O
baseline O
cardiac B-Not_AE_Candidate
failure I-Not_AE_Candidate
or O
who O
are O
at O
risk O
for O
cardiac B-NonOSE_AE
failure I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.1 O
) O
] O
. O

In O
patients O
> O
= O
75 O
years O
of O
age O
, O
the O
risk O
of O
cardiac B-NonOSE_AE
failure I-NonOSE_AE
is O
increased O
compared O
to O
patients O
 O
75 O
years O
of O
age O
. O

Patients O
with O
New B-Not_AE_Candidate
York I-Not_AE_Candidate
Heart I-Not_AE_Candidate
Association I-Not_AE_Candidate
Class I-Not_AE_Candidate
III I-Not_AE_Candidate
and O
IV O
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
recent O
myocardial B-Not_AE_Candidate
infarction I-Not_AE_Candidate
, O
conduction B-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
, O
angina B-Not_AE_Candidate
, O
or O
arrhythmias B-Not_AE_Candidate
uncontrolled O
by O
medications O
were O
not O
eligible O
for O
the O
clinical O
trials O
. O

These O
patients O
may O
be O
at O
greater O
risk O
for O
cardiac B-NonOSE_AE
complications I-NonOSE_AE
and O
should O
have O
a O
comprehensive O
medical O
assessment O
( O
including O
blood O
pressure O
and O
fluid O
management O
) O
prior O
to O
starting O
treatment O
with O
Kyprolis O
and O
remain O
under O
close O
follow-up O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
] O
. O

5.2 O
Acute O
Renal O
Failure O
Cases O
of O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
have O
occurred O
in O
patients O
receiving O
Kyprolis O
. O

Renal B-OSE_Labeled_AE
insufficiency I-OSE_Labeled_AE
adverse O
events O
( O
including O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
) O
have O
occurred O
in O
approximately O
10 O
% O
of O
patients O
treated O
with O
Kyprolis O
. O

Acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
was O
reported O
more O
frequently O
in O
patients O
with O
advanced O
relapsed O
and O
refractory O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
who O
received O
Kyprolis O
monotherapy O
. O

This O
risk O
was O
greater O
in O
patients O
with O
a O
baseline O
reduced B-Not_AE_Candidate
estimated I-Not_AE_Candidate
creatinine I-Not_AE_Candidate
clearance I-Not_AE_Candidate
( O
calculated O
using O
Cockcroft O
and O
Gault O
equation O
) O
. O

Monitor O
renal O
function O
with O
regular O
measurement O
of O
the O
serum O
creatinine O
and/or O
estimated O
creatinine O
clearance O
. O

Reduce O
or O
withhold O
dose O
as O
appropriate O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.3 O
Tumor O
Lysis O
Syndrome O
Cases O
of O
tumor B-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TLS I-OSE_Labeled_AE
) O
, O
including O
fatal B-NonOSE_AE
outcomes O
, O
have O
been O
reported O
in O
patients O
who O
received O
Kyprolis O
. O

Patients O
with O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
and O
a O
high O
tumor B-Not_AE_Candidate
burden I-Not_AE_Candidate
should O
be O
considered O
to O
be O
at O
greater O
risk O
for O
TLS B-OSE_Labeled_AE
. O

Ensure O
that O
patients O
are O
well O
hydrated O
before O
administration O
of O
Kyprolis O
in O
Cycle O
1 O
, O
and O
in O
subsequent O
cycles O
as O
needed O
[ O
see O
Dosage O
and O
Administration O
( O
2.1 O
) O
] O
. O

Consider O
uric O
acid-lowering O
drugs O
in O
patients O
at O
risk O
for O
TLS B-NonOSE_AE
. O

Monitor O
for O
evidence O
of O
TLS O
during O
treatment O
and O
manage O
promptly O
, O
including O
interruption O
of O
Kyprolis O
until O
TLS O
is O
resolved O
[ O
see O
Dosage O
and O
Administration O
( O
2.1 O
) O
] O
. O

5.4 O
Pulmonary O
Toxicity O
Acute B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Distress I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ARDS I-OSE_Labeled_AE
) O
, O
acute B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
and O
acute B-OSE_Labeled_AE
diffuse I-OSE_Labeled_AE
infiltrative I-OSE_Labeled_AE
pulmonary I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
such O
as O
pneumonitis B-OSE_Labeled_AE
and O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
have O
occurred O
in O
less O
than O
1 O
% O
of O
patients O
receiving O
Kyprolis O
. O

Some O
events O
have O
been O
fatal B-NonOSE_AE
. O

In O
the O
event O
of O
drug-induced O
pulmonary B-NonOSE_AE
toxicity I-NonOSE_AE
, O
discontinue O
Kyprolis O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.5 O
Pulmonary O
Hypertension O
Pulmonary B-OSE_Labeled_AE
arterial I-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
was O
reported O
in O
approximately O
1 O
% O
of O
patients O
treated O
with O
Kyprolis O
and O
was O
Grade O
3 O
or O
greater O
in O
less O
than O
1 O
% O
of O
patients O
. O

Evaluate O
with O
cardiac O
imaging O
and/or O
other O
tests O
as O
indicated O
. O

Withhold O
Kyprolis O
for O
pulmonary B-NonOSE_AE
hypertension I-NonOSE_AE
until O
resolved O
or O
returned O
to O
baseline O
, O
and O
consider O
whether O
to O
restart O
Kyprolis O
based O
on O
a O
benefit/risk O
assessment O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.6 O
Dyspnea O
Dyspnea B-OSE_Labeled_AE
was O
reported O
in O
28 O
% O
of O
patients O
treated O
with O
Kyprolis O
and O
was O
Grade O
3 O
or O
greater O
in O
4 O
% O
of O
patients O
. O

Evaluate O
dyspnea B-NonOSE_AE
to O
exclude O
cardiopulmonary B-NonOSE_AE
conditions I-NonOSE_AE
including O
cardiac B-NonOSE_AE
failure I-NonOSE_AE
and O
pulmonary B-NonOSE_AE
syndromes I-NonOSE_AE
. O

Stop O
Kyprolis O
for O
Grade O
3 O
or O
4 O
dyspnea B-NonOSE_AE
until O
resolved O
or O
returned O
to O
baseline O
. O

Consider O
whether O
to O
restart O
Kyprolis O
based O
on O
a O
benefit/risk O
assessment O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
, O
Warnings O
and O
Precautions O
( O
5.1 O
and O
5.4 O
) O
, O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.7 O
Hypertension O
Hypertension B-OSE_Labeled_AE
, O
including O
hypertensive B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
and O
hypertensive B-OSE_Labeled_AE
emergency I-OSE_Labeled_AE
, O
has O
been O
observed O
with O
Kyprolis O
. O

In O
a O
randomized O
, O
open-label O
, O
multicenter O
trial O
evaluating O
Kyprolis O
in O
combination O
with O
KRd O
versus O
Rd O
, O
the O
incidence O
of O
hypertension B-OSE_Labeled_AE
events O
was O
16 O
% O
in O
the O
KRd O
arm O
versus O
8 O
% O
in O
the O
Rd O
arm O
. O

In O
a O
randomized O
, O
open-label O
, O
multicenter O
trial O
of O
Kd O
versus O
Vd O
, O
the O
incidence O
of O
hypertension B-OSE_Labeled_AE
events O
was O
26 O
% O
in O
the O
Kd O
arm O
versus O
10 O
% O
in O
the O
Vd O
arm O
. O

Some O
of O
these O
events O
have O
been O
fatal B-NonOSE_AE
. O

Monitor O
blood O
pressure O
regularly O
in O
all O
patients O
. O

If O
hypertension B-NonOSE_AE
can O
not O
be O
adequately O
controlled O
, O
withhold O
Kyprolis O
and O
evaluate O
. O

Consider O
whether O
to O
restart O
Kyprolis O
based O
on O
a O
benefit/risk O
assessment O
[ O
see O
Dosage O
and O
Administration O
( O
2 O
) O
] O
. O

5.8 O
Venous O
Thrombosis O
Venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
( O
including O
deep B-OSE_Labeled_AE
venous I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
and O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
) O
have O
been O
observed O
with O
Kyprolis O
. O

In O
a O
randomized O
, O
open-label O
, O
multicenter O
trial O
evaluating O
KRd O
versus O
Rd O
( O
with O
thromboprophylaxis O
used O
in O
both O
arms O
) O
, O
the O
incidence O
of O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
in O
the O
first O
12 O
cycles O
was O
13 O
% O
in O
the O
KRd O
arm O
versus O
6 O
% O
in O
the O
Rd O
arm O
. O

In O
a O
randomized O
, O
open-label O
, O
multicenter O
trial O
of O
Kd O
versus O
Vd O
, O
the O
incidence O
of O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
in O
months O
1-6 O
was O
9 O
% O
in O
the O
Kd O
arm O
versus O
2 O
% O
in O
the O
Vd O
arm O
. O

With O
Kyprolis O
monotherapy O
, O
the O
incidence O
of O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
was O
2 O
% O
. O

Thromboprophylaxis O
is O
recommended O
for O
patients O
being O
treated O
with O
the O
combination O
of O
Kyprolis O
with O
dexamethasone O
or O
with O
lenalidomide O
plus O
dexamethasone O
. O

The O
thromboprophylaxis O
regimen O
should O
be O
based O
on O
an O
assessment O
of O
the O
patient O
's O
underlying O
risks O
. O

Patients O
using O
oral O
contraceptives O
or O
a O
hormonal O
method O
of O
contraception O
associated O
with O
a O
risk O
of O
thrombosis B-NonOSE_AE
should O
consider O
an O
alternative O
method O
of O
effective O
contraception O
during O
treatment O
with O
Kyprolis O
in O
combination O
with O
dexamethasone O
or O
lenalidomide O
plus O
dexamethasone O
[ O
see O
Use O
in O
Specific O
Population O
( O
8.3 O
) O
] O
. O

5.9 O
Infusion O
Reactions O
Infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
life-threatening O
reactions O
, O
have O
occurred O
in O
patients O
receiving O
Kyprolis O
. O

Symptoms O
include O
fever B-NonOSE_AE
, O
chills B-NonOSE_AE
, O
arthralgia B-NonOSE_AE
, O
myalgia B-NonOSE_AE
, O
facial B-NonOSE_AE
flushing I-NonOSE_AE
, O
facial B-NonOSE_AE
edema I-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
weakness B-NonOSE_AE
, O
shortness B-NonOSE_AE
of I-NonOSE_AE
breath I-NonOSE_AE
, O
hypotension B-NonOSE_AE
, O
syncope B-NonOSE_AE
, O
chest B-NonOSE_AE
tightness I-NonOSE_AE
, O
or O
angina B-NonOSE_AE
. O

These O
reactions O
can O
occur O
immediately O
following O
or O
up O
to O
24 O
hours O
after O
administration O
of O
Kyprolis O
. O

Administer O
dexamethasone O
prior O
to O
Kyprolis O
to O
reduce O
the O
incidence O
and O
severity O
of O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2 O
) O
] O
. O

Inform O
patients O
of O
the O
risk O
and O
of O
symptoms O
and O
to O
contact O
a O
physician O
immediately O
if O
symptoms O
of O
an O
infusion B-NonOSE_AE
reaction I-NonOSE_AE
occur O
. O

5.10 O
Hemorrhage O
Fatal B-NonOSE_AE
or O
serious O
cases O
of O
hemorrhage B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
treated O
with O
Kyprolis O
. O

Hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
have O
included O
gastrointestinal B-OSE_Labeled_AE
, O
pulmonary O
, O
and O
intracranial O
hemorrhage I-OSE_Labeled_AE
and O
epistaxis B-OSE_Labeled_AE
. O

The O
bleeding B-OSE_Labeled_AE
can O
be O
spontaneous O
, O
and O
intracranial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
has O
occurred O
without O
trauma O
. O

Hemorrhage B-OSE_Labeled_AE
has O
been O
reported O
in O
patients O
having O
either O
low B-Not_AE_Candidate
or O
normal O
platelet I-Not_AE_Candidate
counts I-Not_AE_Candidate
. O

Hemorrhage B-OSE_Labeled_AE
has O
also O
been O
reported O
in O
patients O
who O
were O
not O
on O
antiplatelet O
therapy O
or O
anticoagulation O
. O

Promptly O
evaluate O
signs O
and O
symptoms O
of O
blood B-NonOSE_AE
loss I-NonOSE_AE
. O

Reduce O
or O
withhold O
dose O
as O
appropriate O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.11 O
Thrombocytopenia O
Kyprolis O
causes O
thrombocytopenia B-OSE_Labeled_AE
with O
platelet O
nadirs O
observed O
between O
Day O
8 O
and O
Day O
15 O
of O
each O
28-day O
cycle O
, O
with O
recovery O
to O
baseline O
platelet O
count O
usually O
by O
the O
start O
of O
the O
next O
cycle O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Thrombocytopenia B-OSE_Labeled_AE
was O
reported O
in O
approximately O
40 O
% O
of O
patients O
in O
clinical O
trials O
with O
Kyprolis O
. O

Monitor O
platelet O
counts O
frequently O
during O
treatment O
with O
Kyprolis O
. O

Reduce O
or O
withhold O
dose O
as O
appropriate O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

Hemorrhage B-OSE_Labeled_AE
may O
occur O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
and O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
. O

5.12 O
Hepatic O
Toxicity O
and O
Hepatic O
Failure O
Cases O
of O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
including O
fatal B-NonOSE_AE
cases O
, O
have O
been O
reported O
( O
< O
1 O
% O
) O
during O
treatment O
with O
Kyprolis O
. O

Kyprolis O
can O
cause O
increased B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
. O

Monitor O
liver O
enzymes O
regularly O
, O
regardless O
of O
baseline O
values O
. O

Reduce O
or O
withhold O
dose O
as O
appropriate O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.13 O
Thrombotic O
Microangiopathy O
Cases O
of O
thrombotic B-OSE_Labeled_AE
microangiopathy I-OSE_Labeled_AE
, O
including O
thrombotic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
/ O
hemolytic B-OSE_Labeled_AE
uremic I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( O
TTP B-OSE_Labeled_AE
/ O
HUS B-OSE_Labeled_AE
) O
, O
have O
been O
reported O
in O
patients O
who O
received O
Kyprolis O
. O

Some O
of O
these O
events O
have O
been O
fatal B-NonOSE_AE
. O

Monitor O
for O
signs O
and O
symptoms O
of O
TTP B-NonOSE_AE
/ O
HUS B-NonOSE_AE
. O

If O
the O
diagnosis O
is O
suspected O
, O
stop O
Kyprolis O
and O
evaluate O
. O

If O
the O
diagnosis O
of O
TTP B-NonOSE_AE
/ O
HUS B-NonOSE_AE
is O
excluded O
, O
Kyprolis O
may O
be O
restarted O
. O

The O
safety O
of O
reinitiating O
Kyprolis O
therapy O
in O
patients O
previously O
experiencing O
TTP B-NonOSE_AE
/ O
HUS B-NonOSE_AE
is O
not O
known O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.14 O
Posterior O
Reversible O
Encephalopathy O
Syndrome O
Cases O
of O
posterior B-OSE_Labeled_AE
reversible I-OSE_Labeled_AE
encephalopathy I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PRES I-OSE_Labeled_AE
) O
have O
been O
reported O
in O
patients O
receiving O
Kyprolis O
. O

PRES B-NonOSE_AE
, O
formerly O
termed O
Reversible B-NonOSE_AE
Posterior I-NonOSE_AE
Leukoencephalopathy I-NonOSE_AE
Syndrome I-NonOSE_AE
( I-NonOSE_AE
RPLS I-NonOSE_AE
) O
, O
is O
a O
neurological B-NonOSE_AE
disorder I-NonOSE_AE
which O
can O
present O
with O
seizure B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
lethargy B-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
blindness B-NonOSE_AE
, O
altered B-NonOSE_AE
consciousness I-NonOSE_AE
, O
and O
other O
visual B-NonOSE_AE
and O
neurological O
disturbances I-NonOSE_AE
, O
along O
with O
hypertension B-NonOSE_AE
, O
and O
the O
diagnosis O
is O
confirmed O
by O
neuro-radiological O
imaging O
( O
MRI O
) O
. O

Discontinue O
Kyprolis O
if O
PRES B-NonOSE_AE
is O
suspected O
and O
evaluate O
. O

The O
safety O
of O
reinitiating O
Kyprolis O
therapy O
in O
patients O
previously O
experiencing O
PRES B-NonOSE_AE
is O
not O
known O
. O

5.15 O
Increased O
Fatal O
and O
Serious O
Toxicities O
in O
Combination O
with O
Melphalan O
and O
Prednisone O
in O
Newly O
Diagnosed O
Transplant-Ineligible O
Patients O
In O
a O
clinical O
trial O
of O
955 O
transplant-ineligible O
patients O
with O
newly O
diagnosed O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
randomized O
to O
Kyprolis O
( O
20/36 O
mg/m O
2 O
by O
30-minute O
infusion O
twice O
weekly O
for O
four O
of O
each O
six-week O
cycle O
) O
, O
melphalan O
and O
prednisone O
( O
KMP O
) O
or O
bortezomib O
, O
melphalan O
and O
prednisone O
( O
VMP O
) O
, O
a O
higher O
incidence O
of O
fatal B-NonOSE_AE
adverse O
reactions O
( O
7 O
% O
versus O
4 O
% O
) O
and O
serious O
adverse O
reactions O
( O
50 O
% O
versus O
42 O
% O
) O
were O
observed O
in O
the O
KMP O
arm O
compared O
to O
patients O
in O
the O
VMP O
arm O
, O
respectively O
. O

Patients O
in O
the O
KMP O
arm O
were O
observed O
to O
have O
a O
higher O
incidence O
of O
any O
grade O
adverse O
reactions O
involving O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
11 O
% O
versus O
4 O
% O
) O
, O
hypertension B-OSE_Labeled_AE
( O
25 O
% O
versus O
8 O
% O
) O
, O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
14 O
% O
versus O
6 O
% O
) O
, O
and O
dyspnea B-OSE_Labeled_AE
( O
18 O
% O
versus O
9 O
% O
) O
. O

This O
study O
did O
not O
meet O
its O
primary O
outcome O
measure O
of O
superiority O
in O
progression-free O
survival O
for O
the O
KMP O
arm O
. O

Kyprolis O
in O
combination O
with O
melphalan O
and O
prednisone O
is O
not O
indicated O
for O
transplant-ineligible O
patients O
with O
newly O
diagnosed O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
. O

5.16 O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Kyprolis O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
based O
on O
its O
mechanism O
of O
action O
and O
findings O
in O
animals O
. O

There O
are O
no O
adequate O
and O
well-controlled O
studies O
in O
pregnant B-Not_AE_Candidate
women O
using O
Kyprolis O
. O

Advise O
females O
of O
reproductive O
potential O
to O
avoid O
becoming O
pregnant B-NonOSE_AE
while O
being O
treated O
with O
Kyprolis O
. O

Advise O
males O
of O
reproductive O
potential O
to O
avoid O
fathering O
a O
child O
while O
being O
treated O
with O
Kyprolis O
. O

Advise O
women O
who O
use O
Kyprolis O
during O
pregnancy B-Not_AE_Candidate
or O
become O
pregnant B-Not_AE_Candidate
during O
treatment O
with O
Kyprolis O
of O
the O
potential O
hazard B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
, O
8.3 O
) O
] O
. O

6 O
ADVERSE O
REACTIONS O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

EXCERPT O
: O
The O
most O
common O
ocular O
adverse O
reactions O
, O
occurring O
in O
less O
than O
4 O
% O
of O
eyes O
treated O
with O
LASTACAFT O
( O
r O
) O
, O
were O
eye O
irritation O
, O
burning O
and/or O
stinging O
on O
instillation O
, O
eye O
redness O
, O
and O
eye O
pruritus O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Allergan O
at O
1-800-433-8871 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Studies O
Experience O
The O
most O
frequent O
ocular B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
occurring O
in O
less O
than O
4 O
% O
of O
eyes O
treated O
with O
LASTACAFT O
( O
r O
) O
, O
were O
eye B-OSE_Labeled_AE
irritation I-OSE_Labeled_AE
, O
burning O
and/or O
stinging O
upon O
instillation O
, O
eye B-OSE_Labeled_AE
redness I-OSE_Labeled_AE
and O
eye B-OSE_Labeled_AE
pruritus I-OSE_Labeled_AE
. O

6.2 O
Non-ocular O
Adverse O
Reactions O
The O
most O
frequent O
non-ocular O
adverse O
reactions O
, O
occurring O
in O
less O
than O
3 O
% O
of O
subjects O
with O
eyes O
treated O
with O
LASTACAFT O
( O
r O
) O
, O
were O
nasopharyngitis B-OSE_Labeled_AE
and O
headache B-OSE_Labeled_AE
. O

Some O
of O
these O
events O
were O
similar O
to O
the O
underlying O
disease O
being O
studied O
. O

6.3 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
postmarketing O
use O
of O
LASTACAFT O
( O
r O
) O
in O
clinical O
practice O
. O

Because O
they O
are O
reported O
voluntarily O
from O
a O
population O
of O
unknown O
size O
, O
estimates O
of O
frequency O
can O
not O
be O
made O
. O

These O
reactions O
include O
: O
eye B-OSE_Labeled_AE
discharge I-OSE_Labeled_AE
, O
eye B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
of I-OSE_Labeled_AE
eyelid I-OSE_Labeled_AE
, O
eyelid B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
hypersensitivity B-OSE_Labeled_AE
, O
and O
somnolence B-OSE_Labeled_AE
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
To O
minimize O
the O
risk O
of O
eye O
injury O
and O
contamination O
, O
do O
not O
touch O
dropper O
tip O
to O
eyelids O
and O
surrounding O
areas O
, O
or O
any O
other O
surface O
. O

Keep O
bottle O
tightly O
closed O
when O
not O
in O
use O
. O

( O
5.1 O
) O
* O
LASTACAFT O
( O
r O
) O
should O
not O
be O
used O
to O
treat O
contact O
lens-related O
irritation O
. O

( O
5.2 O
) O
* O
Remove O
contact O
lenses O
prior O
to O
instillation O
of O
LASTACAFT O
( O
r O
) O
. O

( O
5.2 O
) O
5.1 O
Potential O
for O
Eye O
Injury O
and O
Contamination O
To O
minimize O
eye B-NonOSE_AE
injury I-NonOSE_AE
and O
contamination O
of O
the O
dropper O
tip O
and O
solution O
, O
care O
should O
be O
taken O
not O
to O
touch O
the O
eyelids O
or O
surrounding O
areas O
with O
the O
dropper O
tip O
of O
the O
bottle O
. O

Keep O
bottle O
tightly O
closed O
when O
not O
in O
use O
. O

5.2 O
Contact O
Lens O
Use O
Patients O
should O
be O
advised O
not O
to O
wear O
a O
contact O
lens O
if O
their O
eye O
is O
red O
. O

LASTACAFT O
( O
r O
) O
should O
not O
be O
used O
to O
treat O
contact B-Not_AE_Candidate
lens I-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
irritation I-Not_AE_Candidate
. O

LASTACAFT O
( O
r O
) O
should O
not O
be O
instilled O
while O
wearing O
contact O
lenses O
. O

Remove O
contact O
lenses O
prior O
to O
instillation O
of O
LASTACAFT O
( O
r O
) O
. O

The O
preservative O
in O
LASTACAFT O
( O
r O
) O
, O
benzalkonium O
chloride O
, O
may O
be O
absorbed O
by O
soft O
contact O
lenses O
. O

Lenses O
may O
be O
reinserted O
after O
10 O
minutes O
following O
administration O
of O
LASTACAFT O
( O
r O
) O
. O

5.3 O
Topical O
Ophthalmic O
Use O
Only O
LASTACAFT O
( O
r O
) O
is O
for O
topical O
ophthalmic O
use O
only O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
more O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Increased O
Mortality B-NonOSE_AE
in O
Elderly O
Patients O
with O
Dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
Related I-Not_AE_Candidate
Psychosis I-Not_AE_Candidate
[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Suicidal B-OSE_Labeled_AE
Thoughts I-OSE_Labeled_AE
and O
Behaviors O
[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Cerebrovascular B-NonOSE_AE
Adverse I-NonOSE_AE
Reactions I-NonOSE_AE
, O
Including O
Stroke B-NonOSE_AE
, O
in O
Elderly O
Patients O
with O
Dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
Psychosis I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.23 O
) O
] O
* O
Neuroleptic B-OSE_Labeled_AE
Malignant I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Tardive B-OSE_Labeled_AE
Dyskinesia I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Metabolic B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
( O
Hyperglycemia B-OSE_Labeled_AE
and O
Diabetes B-Not_AE_Candidate
Mellitus I-Not_AE_Candidate
, O
Dyslipidemia B-OSE_Labeled_AE
, O
and O
Weight B-OSE_Labeled_AE
Gain I-OSE_Labeled_AE
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Hyperprolactinemia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Leukopenia B-OSE_Labeled_AE
, O
Neutropenia B-OSE_Labeled_AE
, O
and O
Agranulocytosis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Orthostatic B-OSE_Labeled_AE
Hypotension I-OSE_Labeled_AE
and O
Syncope B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Seizures B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
* O
Potential O
for O
Cognitive B-OSE_Labeled_AE
and O
Motor O
Impairment I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
* O
Body B-OSE_Labeled_AE
Temperature I-OSE_Labeled_AE
Dysregulation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.12 O
) O
] O
* O
Suicide B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.13 O
) O
] O
* O
Activation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Mania/ O
Hypomania I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.14 O
) O
] O
* O
Dysphagia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.15 O
) O
] O
* O
Neurological B-OSE_Labeled_AE
Adverse I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
in O
Patients O
with O
Parkinson B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
Disease I-Not_AE_Candidate
or O
Dementia B-Not_AE_Candidate
with I-Not_AE_Candidate
Lewy I-Not_AE_Candidate
Bodies I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.16 O
) O
] O
EXCERPT O
: O
Commonly O
observed O
adverse O
reactions O
( O
incidence O
> O
= O
5 O
% O
and O
at O
least O
twice O
the O
rate O
for O
placebo O
) O
were O
( O
6.1 O
) O
: O
* O
Schizophrenia O
: O
somnolence O
, O
akathisia O
, O
extrapyramidal O
symptoms O
, O
and O
nausea O
* O
Bipolar O
depression O
: O
akathisia O
, O
extrapyramidal O
symptoms O
, O
and O
somnolence O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Sunovion O
Pharmaceuticals O
Inc O
. O
at O
1-877-737-7226 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

The O
information O
below O
is O
derived O
from O
an O
integrated O
clinical O
study O
database O
for O
LATUDA O
consisting O
of O
3799 O
patients O
exposed O
to O
one O
or O
more O
doses O
of O
LATUDA O
for O
the O
treatment O
of O
schizophrenia B-Not_AE_Candidate
and O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
in O
placebo-controlled O
studies O
. O

This O
experience O
corresponds O
with O
a O
total O
experience O
of O
1250.9 O
patient-years O
. O

A O
total O
of O
1106 O
LATUDA-treated O
patients O
had O
at O
least O
24 O
weeks O
and O
371 O
LATUDA-treated O
patients O
had O
at O
least O
52 O
weeks O
of O
exposure O
. O

Adverse O
events O
during O
exposure O
to O
study O
treatment O
were O
obtained O
by O
general O
inquiry O
and O
voluntarily O
reported O
adverse O
experiences O
, O
as O
well O
as O
results O
from O
physical O
examinations O
, O
vital O
signs O
, O
ECGs O
, O
weights O
and O
laboratory O
investigations O
. O

Adverse O
experiences O
were O
recorded O
by O
clinical O
investigators O
using O
their O
own O
terminology O
. O

In O
order O
to O
provide O
a O
meaningful O
estimate O
of O
the O
proportion O
of O
individuals O
experiencing O
adverse O
events O
, O
events O
were O
grouped O
in O
standardized O
categories O
using O
MedDRA O
terminology O
. O

Schizophrenia O
The O
following O
findings O
are O
based O
on O
the O
short-term O
, O
placebo-controlled O
premarketing O
studies O
for O
schizophrenia B-Not_AE_Candidate
in O
which O
LATUDA O
was O
administered O
at O
daily O
doses O
ranging O
from O
20 O
to O
160 O
mg O
( O
n=1508 O
) O
. O

Commonly O
Observed O
Adverse O
Reactions O
: O
The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
5 O
% O
and O
at O
least O
twice O
the O
rate O
of O
placebo O
) O
in O
patients O
treated O
with O
LATUDA O
were O
somnolence B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
, O
and O
nausea B-OSE_Labeled_AE
. O

Adverse O
Reactions O
Associated O
with O
Discontinuation O
of O
Treatment O
: O
A O
total O
of O
9.5 O
% O
( O
143/1508 O
) O
LATUDA-treated O
patients O
and O
9.3 O
% O
( O
66/708 O
) O
of O
placebo-treated O
patients O
discontinued O
due O
to O
adverse O
reactions O
. O

There O
were O
no O
adverse O
reactions O
associated O
with O
discontinuation O
in O
subjects O
treated O
with O
LATUDA O
that O
were O
at O
least O
2 O
% O
and O
at O
least O
twice O
the O
placebo O
rate O
. O

Adverse O
Reactions O
Occurring O
at O
an O
Incidence O
of O
2 O
% O
or O
More O
in O
LATUDA-Treated O
Patients O
: O
Adverse O
reactions O
associated O
with O
the O
use O
of O
LATUDA O
( O
incidence O
of O
2 O
% O
or O
greater O
, O
rounded O
to O
the O
nearest O
percent O
and O
LATUDA O
incidence O
greater O
than O
placebo O
) O
that O
occurred O
during O
acute O
therapy O
( O
up O
to O
6 O
weeks O
in O
patients O
with O
schizophrenia O
) O
are O
shown O
in O
Table O
15 O
. O

Table O
15 O
: O
Adverse O
Reactions O
in O
2 O
% O
or O
More O
of O
LATUDA-Treated O
Patients O
and O
That O
Occurred O
at O
Greater O
Incidence O
than O
in O
the O
Placebo-Treated O
Patients O
in O
Short-term O
Schizophrenia O
Studies O
Note O
: O
Figures O
rounded O
to O
the O
nearest O
integer O
* O
Somnolence B-OSE_Labeled_AE
includes O
adverse O
event O
terms O
: O
hypersomnia B-OSE_Labeled_AE
, O
hypersomnolence B-OSE_Labeled_AE
, O
sedation B-OSE_Labeled_AE
, O
and O
somnolence B-OSE_Labeled_AE
** O
Extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
includes O
adverse O
event O
terms O
: O
bradykinesia B-OSE_Labeled_AE
, O
cogwheel B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
drooling B-OSE_Labeled_AE
, O
dystonia B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
hypokinesia B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
oculogyric B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
, O
oromandibular B-OSE_Labeled_AE
dystonia I-OSE_Labeled_AE
, O
parkinsonism B-OSE_Labeled_AE
, O
psychomotor B-OSE_Labeled_AE
retardation I-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
, O
torticollis B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
and O
trismus B-OSE_Labeled_AE
Percentage O
of O
Patients O
Reporting O
Reaction O
LATUDA O
Body O
System O
or O
Organ O
Class O
Placebo O
( O
N=708 O
) O
( O
% O
) O
20 O
mg/day O
( O
N=71 O
) O
( O
% O
) O
40 O
mg/day O
( O
N=487 O
) O
( O
% O
) O
80 O
mg/day O
( O
N=538 O
) O
( O
% O
) O
120 O
mg/day O
( O
N=291 O
) O
( O
% O
) O
160 O
mg/day O
( O
N=121 O
) O
( O
% O
) O
All O
LATUDA O
( O
N=1508 O
) O
( O
% O
) O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
5 O
11 O
10 O
9 O
13 O
7 O
10 O
Vomiting B-OSE_Labeled_AE
6 O
7 O
6 O
9 O
9 O
7 O
8 O
Dyspepsia B-OSE_Labeled_AE
5 O
11 O
6 O
5 O
8 O
6 O
6 O
Salivary B-OSE_Labeled_AE
Hypersecretion I-OSE_Labeled_AE
< O
1 O
1 O
1 O
2 O
4 O
2 O
2 O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
2 O
0 O
4 O
3 O
4 O
0 O
3 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Somnolence B-OSE_Labeled_AE
* O
7 O
15 O
16 O
15 O
26 O
8 O
17 O
Akathisia B-OSE_Labeled_AE
3 O
6 O
11 O
12 O
22 O
7 O
13 O
Extrapyramidal B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
** O
6 O
6 O
11 O
12 O
22 O
13 O
14 O
Dizziness B-OSE_Labeled_AE
2 O
6 O
4 O
4 O
5 O
6 O
4 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
8 O
8 O
10 O
11 O
9 O
7 O
10 O
Agitation B-OSE_Labeled_AE
4 O
10 O
7 O
3 O
6 O
5 O
5 O
Anxiety B-OSE_Labeled_AE
4 O
3 O
6 O
4 O
7 O
3 O
5 O
Restlessness B-OSE_Labeled_AE
1 O
1 O
3 O
1 O
3 O
2 O
2 O
Dose-Related O
Adverse O
Reactions O
in O
the O
Schizophrenia O
Studies O
Akathisia B-OSE_Labeled_AE
and O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
were O
dose-related O
. O

The O
frequency O
of O
akathisia B-OSE_Labeled_AE
increased O
with O
dose O
up O
to O
120 O
mg/day O
( O
5.6 O
% O
for O
LATUDA O
20 O
mg O
, O
10.7 O
% O
for O
LATUDA O
40 O
mg O
, O
12.3 O
% O
for O
LATUDA O
80 O
mg O
, O
and O
22.0 O
% O
for O
LATUDA O
120 O
mg O
) O
. O

Akathisia B-OSE_Labeled_AE
was O
reported O
by O
7.4 O
% O
( O
9/121 O
) O
of O
patients O
receiving O
160 O
mg/day O
. O

Akathisia B-NonOSE_AE
occurred O
in O
3.0 O
% O
of O
subjects O
receiving O
placebo O
. O

The O
frequency O
of O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
increased O
with O
dose O
up O
to O
120 O
mg/day O
( O
5.6 O
% O
for O
LATUDA O
20 O
mg O
, O
11.5 O
% O
for O
LATUDA O
40 O
mg O
, O
11.9 O
% O
for O
LATUDA O
80 O
mg O
, O
and O
22.0 O
% O
for O
LATUDA O
120 O
mg O
) O
. O

Bipolar O
Depression O
( O
Monotherapy O
) O
The O
following O
findings O
are O
based O
on O
the O
short-term O
, O
placebo-controlled O
premarketing O
study O
for O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
in O
which O
LATUDA O
was O
administered O
at O
daily O
doses O
ranging O
from O
20 O
to O
120 O
mg O
( O
n=331 O
) O
. O

Commonly O
Observed O
Adverse O
Reactions O
: O
The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
5 O
% O
, O
in O
either O
dose O
group O
, O
and O
at O
least O
twice O
the O
rate O
of O
placebo O
) O
in O
patients O
treated O
with O
LATUDA O
were O
akathisia B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
and O
anxiety B-OSE_Labeled_AE
. O

Adverse O
Reactions O
Associated O
with O
Discontinuation O
of O
Treatment O
: O
A O
total O
of O
6.0 O
% O
( O
20/331 O
) O
LATUDA-treated O
patients O
and O
5.4 O
% O
( O
9/168 O
) O
of O
placebo-treated O
patients O
discontinued O
due O
to O
adverse O
reactions O
. O

There O
were O
no O
adverse O
reactions O
associated O
with O
discontinuation O
in O
subjects O
treated O
with O
LATUDA O
that O
were O
at O
least O
2 O
% O
and O
at O
least O
twice O
the O
placebo O
rate O
. O

Adverse O
Reactions O
Occurring O
at O
an O
Incidence O
of O
2 O
% O
or O
More O
in O
LATUDA-Treated O
Patients O
: O
Adverse O
reactions O
associated O
with O
the O
use O
of O
LATUDA O
( O
incidence O
of O
2 O
% O
or O
greater O
, O
rounded O
to O
the O
nearest O
percent O
and O
LATUDA O
incidence O
greater O
than O
placebo O
) O
that O
occurred O
during O
acute O
therapy O
( O
up O
to O
6 O
weeks O
in O
patients O
with O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
) O
are O
shown O
in O
Table O
16 O
. O

Table O
16 O
: O
Adverse O
Reactions O
in O
2 O
% O
or O
More O
of O
LATUDA-Treated O
Patients O
and O
That O
Occurred O
at O
Greater O
Incidence O
than O
in O
the O
Placebo-Treated O
Patients O
in O
a O
Short-term O
Monotherapy O
Bipolar B-Not_AE_Candidate
Depression I-Not_AE_Candidate
Study O
Note O
: O
Figures O
rounded O
to O
the O
nearest O
integer O
* O
Extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
includes O
adverse O
event O
terms O
: O
bradykinesia B-OSE_Labeled_AE
, O
cogwheel B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
drooling B-OSE_Labeled_AE
, O
dystonia B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
glabellar B-OSE_Labeled_AE
reflex I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
hypokinesia B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
oculogyric B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
, O
oromandibular B-OSE_Labeled_AE
dystonia I-OSE_Labeled_AE
, O
parkinsonism B-OSE_Labeled_AE
, O
psychomotor B-OSE_Labeled_AE
retardation I-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
, O
torticollis B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
and O
trismus B-OSE_Labeled_AE
** O
Somnolence B-OSE_Labeled_AE
includes O
adverse O
event O
terms O
: O
hypersomnia B-OSE_Labeled_AE
, O
hypersomnolence B-OSE_Labeled_AE
, O
sedation B-OSE_Labeled_AE
, O
and O
somnolence B-OSE_Labeled_AE
Percentage O
of O
Patients O
Reporting O
Reaction O
Body O
System O
or O
Organ O
Class O
Dictionary-derived O
Term O
Placebo O
( O
N=168 O
) O
( O
% O
) O
LATUDA O
20-60 O
mg/day O
( O
N=164 O
) O
( O
% O
) O
LATUDA O
80-120 O
mg/day O
( O
N=167 O
) O
( O
% O
) O
All O
LATUDA O
( O
N=331 O
) O
( O
% O
) O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
8 O
10 O
17 O
14 O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
4 O
6 O
4 O
5 O
Vomiting B-OSE_Labeled_AE
2 O
2 O
6 O
4 O
Diarrhea B-OSE_Labeled_AE
2 O
5 O
3 O
4 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Nasopharyngitis B-OSE_Labeled_AE
1 O
4 O
4 O
4 O
Influenza B-OSE_Labeled_AE
1 O
< O
1 O
2 O
2 O
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
< O
1 O
2 O
1 O
2 O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
< O
1 O
3 O
< O
1 O
2 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Extrapyramidal B-OSE_Labeled_AE
Symptoms I-OSE_Labeled_AE
* O
2 O
5 O
9 O
7 O
Akathisia B-OSE_Labeled_AE
2 O
8 O
11 O
9 O
Somnolence B-OSE_Labeled_AE
** O
7 O
7 O
14 O
11 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Anxiety B-OSE_Labeled_AE
1 O
4 O
5 O
4 O
Dose-Related O
Adverse O
Reactions O
in O
the O
Monotherapy O
Study O
: O
In O
the O
short-term O
, O
placebo-controlled O
study O
( O
involving O
lower O
and O
higher O
LATUDA O
dose O
ranges O
) O
[ O
see O
Clinical O
Studies O
( O
14.2 O
) O
] O
the O
adverse O
reactions O
that O
occurred O
with O
a O
greater O
than O
5 O
% O
incidence O
in O
the O
patients O
treated O
with O
LATUDA O
in O
any O
dose O
group O
and O
greater O
than O
placebo O
in O
both O
groups O
were O
nausea B-OSE_Labeled_AE
( O
10.4 O
% O
, O
17.4 O
% O
) O
, O
somnolence B-OSE_Labeled_AE
( O
7.3 O
% O
, O
13.8 O
% O
) O
, O
akathisia B-OSE_Labeled_AE
( O
7.9 O
% O
, O
10.8 O
% O
) O
, O
and O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
( O
4.9 O
% O
, O
9.0 O
% O
) O
for O
LATUDA O
20 O
to O
60 O
mg/day O
and O
LATUDA O
80 O
to O
120 O
mg/day O
, O
respectively O
. O

Bipolar O
Depression O
Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
The O
following O
findings O
are O
based O
on O
two O
short-term O
, O
placebo-controlled O
premarketing O
studies O
for O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
in O
which O
LATUDA O
was O
administered O
at O
daily O
doses O
ranging O
from O
20 O
to O
120 O
mg O
as O
adjunctive O
therapy O
with O
lithium O
or O
valproate O
( O
n=360 O
) O
. O

Commonly O
Observed O
Adverse O
Reactions O
: O
The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
5 O
% O
and O
at O
least O
twice O
the O
rate O
of O
placebo O
) O
in O
subjects O
treated O
with O
LATUDA O
were O
akathisia B-OSE_Labeled_AE
and O
somnolence B-OSE_Labeled_AE
. O

Adverse O
Reactions O
Associated O
with O
Discontinuation O
of O
Treatment O
: O
A O
total O
of O
5.8 O
% O
( O
21/360 O
) O
LATUDA-treated O
patients O
and O
4.8 O
% O
( O
16/334 O
) O
of O
placebo-treated O
patients O
discontinued O
due O
to O
adverse O
reactions O
. O

There O
were O
no O
adverse O
reactions O
associated O
with O
discontinuation O
in O
subjects O
treated O
with O
LATUDA O
that O
were O
at O
least O
2 O
% O
and O
at O
least O
twice O
the O
placebo O
rate O
. O

Adverse O
Reactions O
Occurring O
at O
an O
Incidence O
of O
2 O
% O
or O
More O
in O
LATUDA-Treated O
Patients O
: O
Adverse O
reactions O
associated O
with O
the O
use O
of O
LATUDA O
( O
incidence O
of O
2 O
% O
or O
greater O
, O
rounded O
to O
the O
nearest O
percent O
and O
LATUDA O
incidence O
greater O
than O
placebo O
) O
that O
occurred O
during O
acute O
therapy O
( O
up O
to O
6 O
weeks O
in O
patients O
with O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
) O
are O
shown O
in O
Table O
17 O
. O

Table O
17 O
: O
Adverse O
Reactions O
in O
2 O
% O
or O
More O
of O
LATUDA-Treated O
Patients O
and O
That O
Occurred O
at O
Greater O
Incidence O
than O
in O
the O
Placebo-Treated O
Patients O
in O
the O
Short-term O
Adjunctive O
Therapy O
Bipolar O
Depression O
Studies O
Note O
: O
Figures O
rounded O
to O
the O
nearest O
integer O
* O
Extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
includes O
adverse O
event O
terms O
: O
bradykinesia B-OSE_Labeled_AE
, O
cogwheel B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
drooling B-OSE_Labeled_AE
, O
dystonia B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
glabellar B-OSE_Labeled_AE
reflex I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
hypokinesia B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
oculogyric B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
, O
oromandibular B-OSE_Labeled_AE
dystonia I-OSE_Labeled_AE
, O
parkinsonism B-OSE_Labeled_AE
, O
psychomotor B-OSE_Labeled_AE
retardation I-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
, O
torticollis B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
and O
trismus B-OSE_Labeled_AE
** O
Somnolence B-OSE_Labeled_AE
includes O
adverse O
event O
terms O
: O
hypersomnia B-OSE_Labeled_AE
, O
hypersomnolence B-OSE_Labeled_AE
, O
sedation B-OSE_Labeled_AE
, O
and O
somnolence B-OSE_Labeled_AE
Percentage O
of O
Patients O
Reporting O
Reaction O
Body O
System O
or O
Organ O
Class O
Dictionary-derived O
Term O
Placebo O
( O
N=334 O
) O
( O
% O
) O
LATUDA O
20 O
to O
120 O
mg/day O
( O
N=360 O
) O
( O
% O
) O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
10 O
14 O
Vomiting B-OSE_Labeled_AE
1 O
4 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
1 O
3 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Nasopharyngitis B-OSE_Labeled_AE
2 O
4 O
Investigations B-NonOSE_AE
Weight B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
< O
1 O
3 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Increased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
1 O
3 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Extrapyramidal B-OSE_Labeled_AE
Symptoms I-OSE_Labeled_AE
* O
9 O
14 O
Somnolence B-OSE_Labeled_AE
** O
5 O
11 O
Akathisia B-OSE_Labeled_AE
5 O
11 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Restlessness B-OSE_Labeled_AE
< O
1 O
4 O
Extrapyramidal O
Symptoms O
Schizophrenia O
In O
the O
short-term O
, O
placebo-controlled O
schizophrenia B-Not_AE_Candidate
studies O
, O
for O
LATUDA-treated O
patients O
, O
the O
incidence O
of O
reported O
events O
related O
to O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
( I-OSE_Labeled_AE
EPS I-OSE_Labeled_AE
) O
, O
excluding O
akathisia B-NonOSE_AE
and O
restlessness B-NonOSE_AE
, O
was O
13.5 O
% O
versus O
5.8 O
% O
for O
placebo-treated O
patients O
. O

The O
incidence O
of O
akathisia B-OSE_Labeled_AE
for O
LATUDA-treated O
patients O
was O
12.9 O
% O
versus O
3.0 O
% O
for O
placebo-treated O
patients O
. O

Incidence O
of O
EPS B-OSE_Labeled_AE
by O
dose O
is O
provided O
in O
Table O
18 O
. O

Table O
18 O
: O
Incidence O
of O
EPS O
Compared O
to O
Placebo O
in O
Schizophrenia O
Studies O
Note O
: O
Figures O
rounded O
to O
the O
nearest O
integer O
* O
Dystonia B-OSE_Labeled_AE
includes O
adverse O
event O
terms O
: O
dystonia B-OSE_Labeled_AE
, O
oculogyric B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
, O
oromandibular B-OSE_Labeled_AE
dystonia I-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
, O
torticollis B-OSE_Labeled_AE
, O
and O
trismus B-OSE_Labeled_AE
** O
Parkinsonism B-OSE_Labeled_AE
includes O
adverse O
event O
terms O
: O
bradykinesia B-OSE_Labeled_AE
, O
cogwheel B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
drooling B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
hypokinesia B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
parkinsonism B-OSE_Labeled_AE
, O
psychomotor B-OSE_Labeled_AE
retardation I-OSE_Labeled_AE
, O
and O
tremor B-OSE_Labeled_AE
LATUDA O
Adverse O
Event O
Term O
Placebo O
( O
N=708 O
) O
( O
% O
) O
20 O
mg/day O
( O
N=71 O
) O
( O
% O
) O
40 O
mg/day O
( O
N=487 O
) O
( O
% O
) O
80 O
mg/day O
( O
N=538 O
) O
( O
% O
) O
120 O
mg/day O
( O
N=291 O
) O
( O
% O
) O
160 O
mg/day O
( O
N=121 O
) O
( O
% O
) O
All O
EPS B-OSE_Labeled_AE
events O
9 O
10 O
21 O
23 O
39 O
20 O
All O
EPS B-OSE_Labeled_AE
events O
, O
excluding O
Akathisia B-NonOSE_AE
/ O
Restlessness B-NonOSE_AE
6 O
6 O
11 O
12 O
22 O
13 O
Akathisia B-OSE_Labeled_AE
3 O
6 O
11 O
12 O
22 O
7 O
Dystonia B-OSE_Labeled_AE
* O
< O
1 O
0 O
4 O
5 O
7 O
2 O
Parkinsonism B-OSE_Labeled_AE
** O
5 O
6 O
9 O
8 O
17 O
11 O
Restlessness B-OSE_Labeled_AE
1 O
1 O
3 O
1 O
3 O
2 O
Bipolar O
Depression O
Monotherapy O
In O
the O
short-term O
, O
placebo-controlled O
monotherapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
for O
LATUDA-treated O
patients O
, O
the O
incidence O
of O
reported O
events O
related O
to O
EPS B-OSE_Labeled_AE
, O
excluding O
akathisia B-NonOSE_AE
and O
restlessness B-NonOSE_AE
was O
6.9 O
% O
versus O
2.4 O
% O
for O
placebo-treated O
patients O
. O

The O
incidence O
of O
akathisia B-NonOSE_AE
for O
LATUDA-treated O
patients O
was O
9.4 O
% O
versus O
2.4 O
% O
for O
placebo-treated O
patients O
. O

Incidence O
of O
EPS B-OSE_Labeled_AE
by O
dose O
groups O
is O
provided O
in O
Table O
19 O
. O

Table O
19 O
: O
Incidence O
of O
EPS O
Compared O
to O
Placebo O
in O
the O
Monotherapy O
Bipolar O
Depression O
Study O
LATUDA O
Adverse O
Event O
Term O
Placebo O
( O
N=168 O
) O
( O
% O
) O
20 O
to O
60 O
mg/day O
( O
N=164 O
) O
( O
% O
) O
80 O
to O
120 O
mg/day O
( O
N=167 O
) O
( O
% O
) O
All O
EPS B-OSE_Labeled_AE
events O
5 O
12 O
20 O
All O
EPS B-OSE_Labeled_AE
events O
, O
excluding O
Akathisia B-NonOSE_AE
/ O
Restlessness B-NonOSE_AE
2 O
5 O
9 O
Note O
: O
Figures O
rounded O
to O
the O
nearest O
integer O
* O
Dystonia B-OSE_Labeled_AE
includes O
adverse O
event O
terms O
: O
dystonia B-OSE_Labeled_AE
, O
oculogyric B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
, O
oromandibular B-OSE_Labeled_AE
dystonia I-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
, O
torticollis B-OSE_Labeled_AE
, O
and O
trismus B-OSE_Labeled_AE
** O
Parkinsonism B-OSE_Labeled_AE
includes O
adverse O
event O
terms O
: O
bradykinesia B-OSE_Labeled_AE
, O
cogwheel B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
drooling B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
glabellar B-OSE_Labeled_AE
reflex I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
hypokinesia B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
parkinsonism B-OSE_Labeled_AE
, O
psychomotor B-OSE_Labeled_AE
retardation I-OSE_Labeled_AE
, O
and O
tremor B-OSE_Labeled_AE
Akathisia B-OSE_Labeled_AE
2 O
8 O
11 O
Dystonia B-OSE_Labeled_AE
* O
0 O
0 O
2 O
Parkinsonism B-OSE_Labeled_AE
** O
2 O
5 O
8 O
Restlessness B-OSE_Labeled_AE
< O
1 O
0 O
3 O
Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
In O
the O
short-term O
, O
placebo-controlled O
adjunctive O
therapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
studies O
, O
for O
LATUDA-treated O
patients O
, O
the O
incidence O
of O
EPS B-OSE_Labeled_AE
, O
excluding O
akathisia B-NonOSE_AE
and O
restlessness B-NonOSE_AE
, O
was O
13.9 O
% O
versus O
8.7 O
% O
for O
placebo O
. O

The O
incidence O
of O
akathisia B-OSE_Labeled_AE
for O
LATUDA-treated O
patients O
was O
10.8 O
% O
versus O
4.8 O
% O
for O
placebo-treated O
patients O
. O

Incidence O
of O
EPS B-OSE_Labeled_AE
is O
provided O
in O
Table O
20 O
. O

Table O
20 O
: O
Incidence O
of O
EPS O
Compared O
to O
Placebo O
in O
the O
Adjunctive O
Therapy O
Bipolar O
Depression O
Studies O
Adverse O
Event O
Term O
Placebo O
( O
N=334 O
) O
( O
% O
) O
LATUDA O
20 O
to O
120 O
mg/day O
( O
N=360 O
) O
( O
% O
) O
All O
EPS B-OSE_Labeled_AE
events O
13 O
24 O
All O
EPS B-OSE_Labeled_AE
events O
, O
excluding O
Akathisia B-NonOSE_AE
/ O
Restlessness B-NonOSE_AE
9 O
14 O
Note O
: O
Figures O
rounded O
to O
the O
nearest O
integer O
* O
Dystonia B-OSE_Labeled_AE
includes O
adverse O
event O
terms O
: O
dystonia B-OSE_Labeled_AE
, O
oculogyric B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
, O
oromandibular B-OSE_Labeled_AE
dystonia I-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
, O
torticollis B-OSE_Labeled_AE
, O
and O
trismus B-OSE_Labeled_AE
** O
Parkinsonism B-OSE_Labeled_AE
includes O
adverse O
event O
terms O
: O
bradykinesia B-OSE_Labeled_AE
, O
cogwheel B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
drooling B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
glabellar B-OSE_Labeled_AE
reflex I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
hypokinesia B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
parkinsonism B-OSE_Labeled_AE
, O
psychomotor B-OSE_Labeled_AE
retardation I-OSE_Labeled_AE
, O
and O
tremor B-OSE_Labeled_AE
Akathisia B-OSE_Labeled_AE
5 O
11 O
Dystonia B-OSE_Labeled_AE
* O
< O
1 O
1 O
Parkinsonism B-OSE_Labeled_AE
** O
8 O
13 O
Restlessness B-OSE_Labeled_AE
< O
1 O
4 O
In O
the O
short-term O
, O
placebo-controlled O
schizophrenia B-Not_AE_Candidate
and O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
studies O
, O
data O
was O
objectively O
collected O
on O
the O
Simpson O
Angus O
Rating O
Scale O
( O
SAS O
) O
for O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
( I-OSE_Labeled_AE
EPS I-OSE_Labeled_AE
) O
, O
the O
Barnes O
Akathisia O
Scale O
( O
BAS O
) O
for O
akathisia B-NonOSE_AE
and O
the O
Abnormal B-NonOSE_AE
Involuntary I-NonOSE_AE
Movement O
Scale O
( O
AIMS O
) O
for O
dyskinesias B-NonOSE_AE
. O

Schizophrenia O
The O
mean O
change O
from O
baseline O
for O
LATUDA-treated O
patients O
for O
the O
SAS O
, O
BAS O
and O
AIMS O
was O
comparable O
to O
placebo-treated O
patients O
, O
with O
the O
exception O
of O
the O
Barnes O
Akathisia B-NonOSE_AE
Scale O
global O
score O
( O
LATUDA O
, O
0.1 O
; O
placebo O
, O
0.0 O
) O
. O

The O
percentage O
of O
patients O
who O
shifted O
from O
normal O
to O
abnormal O
was O
greater O
in O
LATUDA-treated O
patients O
versus O
placebo O
for O
the O
BAS O
( O
LATUDA O
, O
14.4 O
% O
; O
placebo O
, O
7.1 O
% O
) O
, O
the O
SAS O
( O
LATUDA O
, O
5.0 O
% O
; O
placebo O
, O
2.3 O
% O
) O
and O
the O
AIMS O
( O
LATUDA O
, O
7.4 O
% O
; O
placebo O
, O
5.8 O
% O
) O
. O

Bipolar O
Depression O
Monotherapy O
The O
mean O
change O
from O
baseline O
for O
LATUDA-treated O
patients O
for O
the O
SAS O
, O
BAS O
and O
AIMS O
was O
comparable O
to O
placebo-treated O
patients O
. O

The O
percentage O
of O
patients O
who O
shifted O
from O
normal O
to O
abnormal O
was O
greater O
in O
LATUDA-treated O
patients O
versus O
placebo O
for O
the O
BAS O
( O
LATUDA O
, O
8.4 O
% O
; O
placebo O
, O
5.6 O
% O
) O
, O
the O
SAS O
( O
LATUDA O
, O
3.7 O
% O
; O
placebo O
, O
1.9 O
% O
) O
and O
the O
AIMS O
( O
LATUDA O
, O
3.4 O
% O
; O
placebo O
, O
1.2 O
% O
) O
. O

Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
The O
mean O
change O
from O
baseline O
for O
LATUDA-treated O
patients O
for O
the O
SAS O
, O
BAS O
and O
AIMS O
was O
comparable O
to O
placebo-treated O
patients O
. O

The O
percentage O
of O
patients O
who O
shifted O
from O
normal O
to O
abnormal O
was O
greater O
in O
LATUDA-treated O
patients O
versus O
placebo O
for O
the O
BAS O
( O
LATUDA O
, O
8.7 O
% O
; O
placebo O
, O
2.1 O
% O
) O
, O
the O
SAS O
( O
LATUDA O
, O
2.8 O
% O
; O
placebo O
, O
2.1 O
% O
) O
and O
the O
AIMS O
( O
LATUDA O
, O
2.8 O
% O
; O
placebo O
, O
0.6 O
% O
) O
. O

Dystonia O
Class O
Effect O
: O
Symptoms O
of O
dystonia B-OSE_Labeled_AE
, O
prolonged O
abnormal B-OSE_Labeled_AE
contractions I-OSE_Labeled_AE
of I-OSE_Labeled_AE
muscle I-OSE_Labeled_AE
groups I-OSE_Labeled_AE
, O
may O
occur O
in O
susceptible O
individuals O
during O
the O
first O
few O
days O
of O
treatment O
. O

Dystonic B-NonOSE_AE
symptoms I-NonOSE_AE
include O
: O
spasm B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
neck I-NonOSE_AE
muscles I-NonOSE_AE
, O
sometimes O
progressing O
to O
tightness B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
throat I-NonOSE_AE
, O
swallowing B-NonOSE_AE
difficulty I-NonOSE_AE
, O
difficulty B-NonOSE_AE
breathing I-NonOSE_AE
, O
and/or O
protrusion B-NonOSE_AE
of I-NonOSE_AE
the O
tongue I-NonOSE_AE
. O

While O
these O
symptoms O
can O
occur O
at O
low O
doses O
, O
they O
occur O
more O
frequently O
and O
with O
greater O
severity O
with O
high O
potency O
and O
at O
higher O
doses O
of O
first-generation O
antipsychotic O
drugs O
. O

An O
elevated O
risk O
of O
acute B-NonOSE_AE
dystonia I-NonOSE_AE
is O
observed O
in O
males O
and O
younger O
age O
groups O
. O

Schizophrenia O
In O
the O
short-term O
, O
placebo-controlled O
schizophrenia B-Not_AE_Candidate
clinical O
studies O
, O
dystonia B-OSE_Labeled_AE
occurred O
in O
4.2 O
% O
of O
LATUDA-treated O
subjects O
( O
0.0 O
% O
LATUDA O
20 O
mg O
, O
3.5 O
% O
LATUDA O
40 O
mg O
, O
4.5 O
% O
LATUDA O
80 O
mg O
, O
6.5 O
% O
LATUDA O
120 O
mg O
and O
2.5 O
% O
LATUDA O
160 O
mg O
) O
compared O
to O
0.8 O
% O
of O
subjects O
receiving O
placebo O
. O

Seven O
subjects O
( O
0.5 O
% O
, O
7/1508 O
) O
discontinued O
clinical O
trials O
due O
to O
dystonic O
events O
- O
four O
were O
receiving O
LATUDA O
80 O
mg/day O
and O
three O
were O
receiving O
LATUDA O
120 O
mg/day O
. O

Bipolar O
Depression O
Monotherapy O
In O
the O
short-term O
, O
flexible-dose O
, O
placebo-controlled O
monotherapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
dystonia B-OSE_Labeled_AE
occurred O
in O
0.9 O
% O
of O
LATUDA-treated O
subjects O
( O
0.0 O
% O
and O
1.8 O
% O
for O
LATUDA O
20 O
to O
60 O
mg/day O
and O
LATUDA O
80 O
to O
120 O
mg/day O
, O
respectively O
) O
compared O
to O
0.0 O
% O
of O
subjects O
receiving O
placebo O
. O

No O
subject O
discontinued O
the O
clinical O
study O
due O
to O
dystonic B-NonOSE_AE
events I-NonOSE_AE
. O

Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
In O
the O
short-term O
, O
flexible-dose O
, O
placebo-controlled O
adjunctive O
therapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
studies O
, O
dystonia B-OSE_Labeled_AE
occurred O
in O
1.1 O
% O
of O
LATUDA-treated O
subjects O
( O
20 O
to O
120 O
mg O
) O
compared O
to O
0.6 O
% O
of O
subjects O
receiving O
placebo O
. O

No O
subject O
discontinued O
the O
clinical O
study O
due O
to O
dystonic B-NonOSE_AE
events I-NonOSE_AE
. O

Other O
Adverse O
Reactions O
Observed O
During O
the O
Premarketing O
Evaluation O
of O
LATUDA O
Following O
is O
a O
list O
of O
adverse O
reactions O
reported O
by O
patients O
treated O
with O
LATUDA O
at O
multiple O
doses O
of O
> O
= O
20 O
mg O
once O
daily O
within O
the O
premarketing O
database O
of O
2905 O
patients O
with O
schizophrenia B-Not_AE_Candidate
. O

The O
reactions O
listed O
are O
those O
that O
could O
be O
of O
clinical O
importance O
, O
as O
well O
as O
reactions O
that O
are O
plausibly O
drug-related O
on O
pharmacologic O
or O
other O
grounds O
. O

Reactions O
listed O
in O
Table O
15 O
or O
those O
that O
appear O
elsewhere O
in O
the O
LATUDA O
label O
are O
not O
included O
. O

Although O
the O
reactions O
reported O
occurred O
during O
treatment O
with O
LATUDA O
, O
they O
were O
not O
necessarily O
caused O
by O
it O
. O

Reactions O
are O
further O
categorized O
by O
organ O
class O
and O
listed O
in O
order O
of O
decreasing O
frequency O
according O
to O
the O
following O
definitions O
: O
those O
occurring O
in O
at O
least O
1/100 O
patients O
( O
frequent O
) O
( O
only O
those O
not O
already O
listed O
in O
the O
tabulated O
results O
from O
placebo-controlled O
studies O
appear O
in O
this O
listing O
) O
; O
those O
occurring O
in O
1/100 O
to O
1/1000 O
patients O
( O
infrequent O
) O
; O
and O
those O
occurring O
in O
fewer O
than O
1/1000 O
patients O
( O
rare O
) O
. O

Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Infrequent O
: O
anemia B-OSE_Labeled_AE
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Frequent O
: O
tachycardia B-OSE_Labeled_AE
; O
Infrequent O
: O
AV B-OSE_Labeled_AE
block I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
st I-OSE_Labeled_AE
degree I-OSE_Labeled_AE
, O
angina B-OSE_Labeled_AE
pectoris I-OSE_Labeled_AE
, O
bradycardia B-OSE_Labeled_AE
Ear B-NonOSE_AE
and I-NonOSE_AE
Labyrinth I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Infrequent O
: O
vertigo B-OSE_Labeled_AE
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Frequent O
: O
blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Frequent O
: O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
; O
Infrequent O
: O
gastritis B-OSE_Labeled_AE
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administrative I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
: O
Rare O
: O
sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
Investigations B-NonOSE_AE
: O
Frequent O
: O
CPK B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Frequent O
: O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Rare O
: O
rhabdomyolysis B-OSE_Labeled_AE
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Infrequent O
: O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
dysarthria B-OSE_Labeled_AE
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Infrequent O
: O
abnormal B-OSE_Labeled_AE
dreams I-OSE_Labeled_AE
, O
panic B-OSE_Labeled_AE
attack I-OSE_Labeled_AE
, O
sleep B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
Renal B-NonOSE_AE
and I-NonOSE_AE
Urinary I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Infrequent O
: O
dysuria B-OSE_Labeled_AE
; O
Rare O
: O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
Reproductive B-NonOSE_AE
System I-NonOSE_AE
and I-NonOSE_AE
Breast I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Infrequent O
: O
amenorrhea B-OSE_Labeled_AE
, O
dysmenorrhea B-OSE_Labeled_AE
; O
Rare O
: O
breast B-OSE_Labeled_AE
enlargement I-OSE_Labeled_AE
, O
breast B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
galactorrhea B-OSE_Labeled_AE
, O
erectile B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Frequent O
: O
rash B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
; O
Rare O
: O
angioedema B-OSE_Labeled_AE
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Frequent O
: O
hypertension B-OSE_Labeled_AE
Clinical O
Laboratory O
Changes O
Schizophrenia O
Serum O
Creatinine O
: O
In O
short-term O
, O
placebo-controlled O
trials O
, O
the O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
Baseline I-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
was O
+0.05 O
mg/dL O
for O
LATUDA-treated O
patients O
compared O
to O
+0.02 O
mg/dL O
for O
placebo-treated O
patients O
. O

A O
creatinine B-OSE_Labeled_AE
shift O
from O
normal O
to O
high I-OSE_Labeled_AE
occurred O
in O
3.0 O
% O
( O
43/1453 O
) O
of O
LATUDA-treated O
patients O
and O
1.6 O
% O
( O
11/681 O
) O
on O
placebo O
. O

The O
threshold O
for O
high B-NonOSE_AE
creatinine I-NonOSE_AE
value O
varied O
from O
> O
0.79 O
to O
> O
1.3 O
mg/dL O
based O
on O
the O
centralized O
laboratory O
definition O
for O
each O
study O
( O
Table O
21 O
) O
. O

Table O
21 O
: O
Serum O
Creatinine O
Shifts O
from O
Normal O
at O
Baseline O
to O
High O
at O
Study O
End-Point O
in O
Schizophrenia O
Studies O
Laboratory O
Parameter O
Placebo O
( O
N=708 O
) O
LATUDA O
20mg/day O
( O
N=71 O
) O
LATUDA O
40mg/day O
( O
N=487 O
) O
LATUDA O
80mg/day O
( O
N=538 O
) O
LATUDA O
120 O
mg/day O
( O
N=291 O
) O
LATUDA O
160mg/day O
( O
N=121 O
) O
Serum B-OSE_Labeled_AE
Creatinine I-OSE_Labeled_AE
Elevated I-OSE_Labeled_AE
2 O
% O
1 O
% O
2 O
% O
2 O
% O
5 O
% O
7 O
% O
Bipolar O
Depression O
Monotherapy O
Serum O
Creatinine O
: O
In O
the O
short-term O
, O
flexible-dose O
, O
placebo-controlled O
monotherapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
the O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
Baseline I-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
was O
+0.01 O
mg/dL O
for O
LATUDA-treated O
patients O
compared O
to O
-0.02 O
mg/dL O
for O
placebo-treated O
patients O
. O

A O
creatinine B-OSE_Labeled_AE
shift O
from O
normal O
to O
high I-OSE_Labeled_AE
occurred O
in O
2.8 O
% O
( O
9/322 O
) O
of O
LATUDA-treated O
patients O
and O
0.6 O
% O
( O
1/162 O
) O
on O
placebo O
( O
Table O
22 O
) O
. O

Table O
22 O
: O
Serum O
Creatinine O
Shifts O
from O
Normal O
at O
Baseline O
to O
High O
at O
Study O
End-Point O
in O
a O
Monotherapy O
Bipolar O
Depression O
Study O
Laboratory O
Parameter O
Placebo O
( O
N=168 O
) O
LATUDA20 O
to O
60 O
mg/day O
( O
N=164 O
) O
LATUDA80 O
to O
120 O
mg/day O
( O
N=167 O
) O
Serum B-OSE_Labeled_AE
Creatinine I-OSE_Labeled_AE
Elevated I-OSE_Labeled_AE
< O
1 O
% O
2 O
% O
4 O
% O
Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
Serum O
Creatinine O
: O
In O
short-term O
, O
placebo-controlled O
premarketing O
adjunctive O
studies O
for O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
, O
the O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
Baseline I-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
was O
+0.04 O
mg/dL O
for O
LATUDA-treated O
patients O
compared O
to O
-0.01 O
mg/dL O
for O
placebo-treated O
patients O
. O

A O
creatinine B-OSE_Labeled_AE
shift O
from O
normal O
to O
high I-OSE_Labeled_AE
occurred O
in O
4.3 O
% O
( O
15/360 O
) O
of O
LATUDA-treated O
patients O
and O
1.6 O
% O
( O
5/334 O
) O
on O
placebo O
( O
Table O
23 O
) O
. O

Table O
23 O
: O
Serum O
Creatinine O
Shifts O
from O
Normal O
at O
Baseline O
to O
High O
at O
Study O
End-Point O
in O
the O
Adjunctive O
Therapy O
Bipolar B-Not_AE_Candidate
Depression I-Not_AE_Candidate
Studies O
Laboratory O
Parameter O
Placebo O
( O
N=334 O
) O
LATUDA O
20 O
to O
120 O
mg/day O
( O
N=360 O
) O
Serum B-OSE_Labeled_AE
Creatinine I-OSE_Labeled_AE
Elevated I-OSE_Labeled_AE
2 O
% O
4 O
% O

BOXED O
WARNING O
: O
WARNINGS O
: O
INCREASED O
MORTALITY O
IN O
ELDERLY O
PATIENTS O
WITH O
DEMENTIA-RELATED O
PSYCHOSIS O
; O
AND O
SUICIDAL O
THOUGHTS O
AND O
BEHAVIORS O
WARNINGS O
: O
INCREASED O
MORTALITY O
IN O
ELDERLY O
PATIENTS O
WITH O
DEMENTIA-RELATED O
PSYCHOSIS O
; O
AND O
SUICIDAL O
THOUGHTS O
AND O
BEHAVIORS O
* O
Elderly O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
treated O
with O
antipsychotic O
drugs O
are O
at O
an O
increased O
risk O
of O
death B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
LATUDA O
is O
not O
approved O
for O
use O
in O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
Antidepressants O
increased O
the O
risk O
of O
suicidal B-OSE_Labeled_AE
thoughts I-OSE_Labeled_AE
and O
behavior O
in O
children O
, O
adolescents O
, O
and O
young O
adults O
in O
short-term O
studies O
. O

These O
studies O
did O
not O
show O
an O
increase O
in O
the O
risk O
of O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
and O
behavior O
with O
antidepressant O
use O
in O
patients O
over O
age O
24 O
; O
there O
was O
a O
reduction O
in O
risk O
with O
antidepressant O
use O
in O
patients O
aged O
65 O
and O
older O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

* O
In O
patients O
of O
all O
ages O
who O
are O
started O
on O
antidepressant O
therapy O
, O
monitor O
closely O
for O
worsening O
, O
and O
for O
emergence O
of O
suicidal B-NonOSE_AE
thoughts O
and O
behaviors I-NonOSE_AE
. O

Advise O
families O
and O
caregivers O
of O
the O
need O
for O
close O
observation O
and O
communication O
with O
the O
prescriber O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

EXCERPT O
: O
WARNINGS O
: O
INCREASED O
MORTALITY O
IN O
ELDERLY O
PATIENTS O
WITH O
DEMENTIA-RELATED O
PSYCHOSIS O
; O
AND O
SUICIDAL O
THOUGHTS O
AND O
BEHAVIORS O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Elderly O
patients O
with O
dementia-related O
psychosis O
treated O
with O
antipsychotic O
drugs O
are O
at O
an O
increased O
risk O
of O
death O
. O

* O
LATUDA O
is O
not O
approved O
for O
the O
treatment O
of O
patients O
with O
dementia-related O
psychosis O
( O
5.1 O
) O
. O

* O
Increased O
risk O
of O
suicidal O
thinking O
and O
behavior O
in O
children O
, O
adolescents O
, O
and O
young O
adults O
taking O
antidepressants O
( O
5.2 O
) O
* O
Monitor O
for O
worsening O
and O
emergence O
of O
suicidal O
thoughts O
and O
behaviors O
( O
5.2 O
) O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Cerebrovascular O
Adverse O
Reactions O
in O
Elderly O
Patients O
with O
Dementia-Related O
Psychosis O
: O
Increased O
incidence O
of O
cerebrovascular O
adverse O
events O
( O
e.g. O
, O
stroke O
, O
transient O
ischemic O
attack O
) O
( O
5.2 O
) O
. O

* O
Neuroleptic O
Malignant O
Syndrome O
: O
Manage O
with O
immediate O
discontinuation O
and O
close O
monitoring O
( O
5.4 O
) O
. O

* O
Tardive O
Dyskinesia O
: O
Discontinue O
if O
clinically O
appropriate O
( O
5.5 O
) O
. O

* O
* O
- O
Hyperglycemia O
and O
Diabetes O
Mellitus O
: O
Monitor O
patients O
for O
symptoms O
of O
hyperglycemia O
including O
polydipsia O
, O
polyuria O
, O
polyphagia O
, O
and O
weakness O
. O

Monitor O
glucose O
regularly O
in O
patients O
with O
diabetes O
or O
at O
risk O
for O
diabetes O
. O

* O
- O
Dyslipidemia O
: O
Undesirable O
alterations O
have O
been O
observed O
in O
patients O
treated O
with O
atypical O
antipsychotics O
. O

* O
- O
Weight O
Gain O
: O
Gain O
in O
body O
weight O
has O
been O
observed O
. O

Monitor O
weight O
. O

Metabolic O
Changes O
: O
Atypical O
antipsychotic O
drugs O
have O
been O
associated O
with O
metabolic O
changes O
that O
may O
increase O
cardiovascular/cerebrovascular O
risk O
. O

These O
metabolic O
changes O
include O
hyperglycemia O
, O
dyslipidemia O
, O
and O
weight O
gain O
( O
5.6 O
) O
. O

* O
Hyperprolactinemia O
: O
Prolactin O
elevations O
may O
occur O
( O
5.7 O
) O
. O

* O
Leukopenia O
, O
Neutropenia O
, O
and O
Agranulocytosis O
: O
Perform O
complete O
blood O
counts O
( O
CBC O
) O
in O
patients O
with O
a O
pre-existing O
low O
white O
blood O
cell O
count O
( O
WBC O
) O
or O
a O
history O
of O
leukopenia O
or O
neutropenia O
. O

Consider O
discontinuing O
LATUDA O
if O
a O
clinically O
significant O
decline O
in O
WBC O
occurs O
in O
the O
absence O
of O
other O
causative O
factors O
( O
5.8 O
) O
. O

* O
Orthostatic O
Hypotension O
and O
Syncope O
: O
Dizziness O
, O
tachycardia O
or O
bradycardia O
, O
and O
syncope O
may O
occur O
, O
especially O
early O
in O
treatment O
. O

In O
patients O
with O
known O
cardiovascular O
or O
cerebrovascular O
disease O
, O
and O
in O
antipsychotic-naive O
patients O
, O
consider O
a O
lower O
starting O
dose O
and O
slower O
titration O
( O
5.9 O
) O
. O

5.1 O
Increased O
Mortality O
in O
Elderly O
Patients O
with O
Dementia-Related O
Psychosis O
Elderly O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
treated O
with O
antipsychotic O
drugs O
are O
at O
an O
increased O
risk O
of O
death B-NonOSE_AE
. O

Analyses O
of O
17 O
placebo-controlled O
trials O
( O
modal O
duration O
of O
10 O
weeks O
) O
, O
largely O
in O
patients O
taking O
atypical O
antipsychotic O
drugs O
, O
revealed O
a O
risk O
of O
death B-NonOSE_AE
in O
drug-treated O
patients O
of O
between O
1.6- O
to O
1.7-times O
the O
risk O
of O
death B-NonOSE_AE
in O
placebo-treated O
patients O
. O

Over O
the O
course O
of O
a O
typical O
10-week O
controlled O
trial O
, O
the O
rate O
of O
death B-NonOSE_AE
in O
drug-treated O
patients O
was O
about O
4.5 O
% O
, O
compared O
to O
a O
rate O
of O
about O
2.6 O
% O
in O
the O
placebo O
group O
. O

Although O
the O
causes O
of O
death B-NonOSE_AE
were O
varied O
, O
most O
of O
the O
deaths B-NonOSE_AE
appeared O
to O
be O
either O
cardiovascular O
( O
e.g. O
, O
heart B-NonOSE_AE
failure I-NonOSE_AE
, O
sudden B-NonOSE_AE
death I-NonOSE_AE
) O
or O
infectious B-NonOSE_AE
( O
e.g. O
, O
pneumonia B-NonOSE_AE
) O
in O
nature O
. O

Observational O
studies O
suggest O
that O
, O
similar O
to O
atypical O
antipsychotic O
drugs O
, O
treatment O
with O
conventional O
antipsychotic O
drugs O
may O
increase B-NonOSE_AE
mortality I-NonOSE_AE
. O

The O
extent O
to O
which O
the O
findings O
of O
increased B-NonOSE_AE
mortality I-NonOSE_AE
in O
observational O
studies O
may O
be O
attributed O
to O
the O
antipsychotic O
drug O
as O
opposed O
to O
some O
characteristic O
( O
s O
) O
of O
the O
patients O
is O
not O
clear O
. O

LATUDA O
is O
not O
approved O
for O
the O
treatment O
of O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
[ O
see O
Boxed O
Warning O
] O
. O

5.2 O
Suicidal O
Thoughts O
and O
Behaviors O
in O
Adolescents O
and O
Young O
Adults O
Patients O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
, O
both O
adult O
and O
pediatric O
, O
may O
experience O
worsening B-NonOSE_AE
of I-NonOSE_AE
their I-NonOSE_AE
depression I-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
ideation I-NonOSE_AE
and O
behavior O
( O
suicidality O
) O
or O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
whether O
or O
not O
they O
are O
taking O
antidepressant O
medications O
, O
and O
this O
risk O
may O
persist O
until O
significant O
remission O
occurs O
. O

Suicide B-NonOSE_AE
is O
a O
known O
risk O
of O
depression B-NonOSE_AE
and O
certain O
other O
psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
, O
and O
these O
disorders O
themselves O
are O
the O
strongest O
predictors O
of O
suicide B-NonOSE_AE
. O

There O
has O
been O
a O
long-standing O
concern O
, O
however O
, O
that O
antidepressants O
may O
have O
a O
role O
in O
inducing O
worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
depression I-OSE_Labeled_AE
and O
the O
emergence B-OSE_Labeled_AE
of I-OSE_Labeled_AE
suicidality I-OSE_Labeled_AE
in O
certain O
patients O
during O
the O
early O
phases O
of O
treatment O
. O

Pooled O
analyses O
of O
short-term O
placebo-controlled O
trials O
of O
antidepressant O
drugs O
( O
SSRIs O
and O
others O
) O
showed O
that O
these O
drugs O
increase O
the O
risk O
of O
suicidal B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
and O
behavior O
( O
suicidality O
) O
in O
children O
, O
adolescents O
, O
and O
young O
adults O
( O
ages O
18-24 O
) O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
and O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Short-term O
studies O
did O
not O
show O
an O
increase B-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
risk I-NonOSE_AE
of I-NonOSE_AE
suicidality I-NonOSE_AE
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
beyond O
age O
24 O
; O
there O
was O
a O
reduction O
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
aged O
65 O
and O
older O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
trials O
in O
children O
and O
adolescents O
with O
MDD B-Not_AE_Candidate
, O
obsessive B-Not_AE_Candidate
compulsive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
OCD I-Not_AE_Candidate
) O
, O
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
24 O
short-term O
trials O
of O
9 O
antidepressant O
drugs O
in O
over O
4400 O
patients O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
trials O
in O
adults O
with O
MDD B-Not_AE_Candidate
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
295 O
short-term O
trials O
( O
median O
duration O
of O
2 O
months O
) O
of O
11 O
antidepressant O
drugs O
in O
over O
77,000 O
patients O
. O

There O
was O
considerable O
variation O
in O
risk O
of O
suicidality B-NonOSE_AE
among O
drugs O
, O
but O
a O
tendency O
toward O
an O
increase O
in O
the O
younger O
patients O
for O
almost O
all O
drugs O
studied O
. O

There O
were O
differences O
in O
absolute O
risk O
of O
suicidality B-NonOSE_AE
across O
the O
different O
indications O
, O
with O
the O
highest O
incidence O
in O
MDD B-Not_AE_Candidate
. O

The O
risk O
of O
differences O
( O
drug O
vs O
. O
placebo O
) O
, O
however O
, O
were O
relatively O
stable O
within O
age O
strata O
and O
across O
indications O
. O

These O
risk O
differences O
( O
drug-placebo O
difference O
in O
the O
number O
of O
cases O
of O
suicidality O
per O
1000 O
patients O
treated O
) O
are O
provided O
in O
Table O
2 O
. O

Table O
2 O
Age O
Range O
Drug-Placebo O
Difference O
in O
Number O
of O
Cases O
of O
Suicidality B-OSE_Labeled_AE
per O
1000 O
Patients O
Treated O
Increases I-OSE_Labeled_AE
Compared O
to O
Placebo O
< O
18 O
14 O
additional O
cases O
18-24 O
5 O
additional O
cases O
Decreases O
Compared O
to O
Placebo O
25-64 O
1 O
fewer O
case O
> O
=65 O
6 O
fewer O
cases O
No O
suicides B-NonOSE_AE
occurred O
in O
any O
of O
the O
pediatric O
trials O
. O

There O
were O
suicides B-NonOSE_AE
in O
the O
adult O
trials O
, O
but O
the O
number O
was O
not O
sufficient O
to O
reach O
any O
conclusion O
about O
drug O
effect O
on O
suicide B-NonOSE_AE
. O

It O
is O
unknown O
whether O
the O
suicidality B-NonOSE_AE
risk I-NonOSE_AE
extends O
to O
longer-term O
use O
, O
i.e. O
, O
beyond O
several O
months O
. O

However O
, O
there O
is O
substantial O
evidence O
from O
placebo-controlled O
maintenance O
trials O
in O
adults O
with O
depression B-Not_AE_Candidate
that O
the O
use O
of O
antidepressants O
can O
delay O
the O
recurrence O
of O
depression B-Not_AE_Candidate
. O

All O
patients O
being O
treated O
with O
antidepressants O
for O
any O
indication O
should O
be O
monitored O
appropriately O
and O
observed O
closely O
for O
clinical O
worsening O
, O
suicidality B-NonOSE_AE
, O
and O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
especially O
during O
the O
initial O
few O
months O
of O
a O
course O
of O
drug O
therapy O
, O
or O
at O
times O
of O
dose O
changes O
, O
either O
increases O
or O
decreases O
. O

The O
following O
symptoms O
, O
anxiety B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
panic B-OSE_Labeled_AE
attacks I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
hostility B-OSE_Labeled_AE
, O
aggressiveness B-OSE_Labeled_AE
, O
impulsivity B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
( O
psychomotor B-OSE_Labeled_AE
restlessness I-OSE_Labeled_AE
) O
, O
hypomania B-OSE_Labeled_AE
, O
and O
mania B-OSE_Labeled_AE
, O
have O
been O
reported O
in O
adult O
and O
pediatric O
patients O
being O
treated O
with O
antidepressants O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
as O
well O
as O
for O
other O
indications O
, O
both O
psychiatric B-Not_AE_Candidate
and O
nonpsychiatric O
. O

Although O
a O
causal O
link O
between O
the O
emergence O
of O
such O
symptoms O
and O
either O
the O
worsening B-NonOSE_AE
of I-NonOSE_AE
depression I-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
impulses I-NonOSE_AE
has O
not O
been O
established O
, O
there O
is O
concern O
that O
such O
symptoms O
may O
represent O
precursors O
to O
emerging O
suicidality B-NonOSE_AE
. O

Consideration O
should O
be O
given O
to O
changing O
the O
therapeutic O
regimen O
, O
including O
possibly O
discontinuing O
the O
medication O
, O
in O
patients O
whose O
depression B-Not_AE_Candidate
is O
persistently O
worse O
, O
or O
who O
are O
experiencing O
emergent B-NonOSE_AE
suicidality I-NonOSE_AE
or O
symptoms O
that O
might O
be O
precursors O
to O
worsening O
depression B-NonOSE_AE
or O
suicidality B-NonOSE_AE
, O
especially O
if O
these O
symptoms O
are O
severe O
, O
abrupt O
in O
onset O
, O
or O
were O
not O
part O
of O
the O
patient O
's O
presenting O
symptoms O
. O

Families O
and O
caregivers O
of O
patients O
being O
treated O
with O
antidepressants O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
or O
other O
indications O
, O
both O
psychiatric B-Not_AE_Candidate
and O
nonpsychiatric O
, O
should O
be O
alerted O
about O
the O
need O
to O
monitor O
patients O
for O
the O
emergence O
of O
agitation B-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
and O
the O
other O
symptoms O
described O
above O
, O
as O
well O
as O
the O
emergence O
of O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
and O
behaviors O
, O
and O
to O
report O
such O
symptoms O
immediately O
to O
health O
care O
providers O
. O

Such O
monitoring O
should O
include O
daily O
observation O
by O
families O
and O
caregivers O
. O

Prescriptions O
for O
LATUDA O
should O
be O
written O
for O
the O
smallest O
quantity O
of O
capsules O
consistent O
with O
good O
patient O
management O
, O
in O
order O
to O
reduce O
the O
risk O
of O
overdose O
. O

5.3 O
Cerebrovascular O
Adverse O
Reactions O
, O
Including O
Stroke O
in O
Elderly O
Patients O
with O
Dementia-Related O
Psychosis O
In O
placebo-controlled O
trials O
with O
risperidone O
, O
aripiprazole O
, O
and O
olanzapine O
in O
elderly O
subjects O
with O
dementia B-Not_AE_Candidate
, O
there O
was O
a O
higher O
incidence O
of O
cerebrovascular B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
cerebrovascular B-OSE_Labeled_AE
accidents I-OSE_Labeled_AE
and O
transient B-OSE_Labeled_AE
ischemic I-OSE_Labeled_AE
attacks I-OSE_Labeled_AE
) O
, O
including O
fatalities B-NonOSE_AE
, O
compared O
to O
placebo-treated O
subjects O
. O

LATUDA O
is O
not O
approved O
for O
the O
treatment O
of O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
[ O
see O
also O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

5.4 O
Neuroleptic O
Malignant O
Syndrome O
A O
potentially O
fatal B-NonOSE_AE
symptom O
complex O
sometimes O
referred O
to O
as O
Neuroleptic B-OSE_Labeled_AE
Malignant I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
NMS I-OSE_Labeled_AE
) O
has O
been O
reported O
in O
association O
with O
administration O
of O
antipsychotic O
drugs O
, O
including O
LATUDA O
. O

Clinical O
manifestations O
of O
NMS B-NonOSE_AE
are O
hyperpyrexia B-NonOSE_AE
, O
muscle B-NonOSE_AE
rigidity I-NonOSE_AE
, O
altered B-NonOSE_AE
mental I-NonOSE_AE
status I-NonOSE_AE
, O
and O
evidence O
of O
autonomic B-NonOSE_AE
instability I-NonOSE_AE
( O
irregular B-NonOSE_AE
pulse I-NonOSE_AE
or O
blood O
pressure O
, O
tachycardia B-NonOSE_AE
, O
diaphoresis B-NonOSE_AE
, O
and O
cardiac B-NonOSE_AE
dysrhythmia I-NonOSE_AE
) O
. O

Additional O
signs O
may O
include O
elevated B-NonOSE_AE
creatine I-NonOSE_AE
phosphokinase I-NonOSE_AE
, O
myoglobinuria B-NonOSE_AE
( O
rhabdomyolysis B-NonOSE_AE
) O
, O
and O
acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
. O

The O
diagnostic O
evaluation O
of O
patients O
with O
this O
syndrome O
is O
complicated O
. O

It O
is O
important O
to O
exclude O
cases O
where O
the O
clinical O
presentation O
includes O
both O
serious O
medical O
illness O
( O
e.g. O
, O
pneumonia B-NonOSE_AE
, O
systemic B-NonOSE_AE
infection I-NonOSE_AE
) O
and O
untreated O
or O
inadequately O
treated O
extrapyramidal B-NonOSE_AE
signs I-NonOSE_AE
and I-NonOSE_AE
symptoms I-NonOSE_AE
( I-NonOSE_AE
EPS I-NonOSE_AE
) O
. O

Other O
important O
considerations O
in O
the O
differential O
diagnosis O
include O
central B-NonOSE_AE
anticholinergic I-NonOSE_AE
toxicity I-NonOSE_AE
, O
heat B-NonOSE_AE
stroke I-NonOSE_AE
, O
drug B-NonOSE_AE
fever I-NonOSE_AE
, O
and O
primary O
central O
nervous O
system O
pathology O
. O

The O
management O
of O
NMS B-NonOSE_AE
should O
include O
: O
1 O
) O
immediate O
discontinuation O
of O
antipsychotic O
drugs O
and O
other O
drugs O
not O
essential O
to O
concurrent O
therapy O
; O
2 O
) O
intensive O
symptomatic O
treatment O
and O
medical O
monitoring O
; O
and O
3 O
) O
treatment O
of O
any O
concomitant O
serious O
medical O
problems O
for O
which O
specific O
treatments O
are O
available O
. O

There O
is O
no O
general O
agreement O
about O
specific O
pharmacological O
treatment O
regimens O
for O
NMS B-NonOSE_AE
. O

If O
a O
patient O
requires O
antipsychotic O
drug O
treatment O
after O
recovery O
from O
NMS B-NonOSE_AE
, O
the O
potential O
reintroduction O
of O
drug O
therapy O
should O
be O
carefully O
considered O
. O

If O
reintroduced O
, O
the O
patient O
should O
be O
carefully O
monitored O
, O
since O
recurrences O
of O
NMS B-NonOSE_AE
have O
been O
reported O
. O

5.5 O
Tardive O
Dyskinesia O
Tardive B-OSE_Labeled_AE
dyskinesia I-OSE_Labeled_AE
is O
a O
syndrome O
consisting O
of O
potentially O
irreversible O
, O
involuntary O
, O
dyskinetic B-NonOSE_AE
movements I-NonOSE_AE
that O
can O
develop O
in O
patients O
treated O
with O
antipsychotic O
drugs O
. O

Although O
the O
prevalence O
of O
the O
syndrome O
appears O
to O
be O
highest O
among O
the O
elderly O
, O
especially O
elderly O
women O
, O
it O
is O
impossible O
to O
rely O
upon O
prevalence O
estimates O
to O
predict O
, O
at O
the O
inception O
of O
antipsychotic O
treatment O
, O
which O
patients O
are O
likely O
to O
develop O
the O
syndrome O
. O

Whether O
antipsychotic O
drug O
products O
differ O
in O
their O
potential O
to O
cause O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
is O
unknown O
. O

The O
risk O
of O
developing O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
and O
the O
likelihood O
that O
it O
will O
become O
irreversible O
are O
believed O
to O
increase O
as O
the O
duration O
of O
treatment O
and O
the O
total O
cumulative O
dose O
of O
antipsychotic O
drugs O
administered O
to O
the O
patient O
increase O
. O

However O
, O
the O
syndrome O
can O
develop O
, O
although O
much O
less O
commonly O
, O
after O
relatively O
brief O
treatment O
periods O
at O
low O
doses O
. O

There O
is O
no O
known O
treatment O
for O
established O
cases O
of O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
, O
although O
the O
syndrome O
may O
remit O
, O
partially O
or O
completely O
, O
if O
antipsychotic O
treatment O
is O
withdrawn O
. O

Antipsychotic O
treatment O
, O
itself O
, O
however O
, O
may O
suppress O
( O
or O
partially O
suppress O
) O
the O
signs O
and O
symptoms O
of O
the O
syndrome O
and O
thereby O
may O
possibly O
mask O
the O
underlying O
process O
. O

The O
effect O
that O
symptomatic O
suppression O
has O
upon O
the O
long-term O
course O
of O
the O
syndrome O
is O
unknown O
. O

Given O
these O
considerations O
, O
LATUDA O
should O
be O
prescribed O
in O
a O
manner O
that O
is O
most O
likely O
to O
minimize O
the O
occurrence O
of O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
. O

Chronic O
antipsychotic O
treatment O
should O
generally O
be O
reserved O
for O
patients O
who O
suffer O
from O
a O
chronic O
illness O
that O
( O
1 O
) O
is O
known O
to O
respond O
to O
antipsychotic O
drugs O
, O
and O
( O
2 O
) O
for O
whom O
alternative O
, O
equally O
effective O
, O
but O
potentially O
less O
harmful O
treatments O
are O
not O
available O
or O
appropriate O
. O

In O
patients O
who O
do O
require O
chronic O
treatment O
, O
the O
smallest O
dose O
and O
the O
shortest O
duration O
of O
treatment O
producing O
a O
satisfactory O
clinical O
response O
should O
be O
sought O
. O

The O
need O
for O
continued O
treatment O
should O
be O
reassessed O
periodically O
. O

If O
signs O
and O
symptoms O
of O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
appear O
in O
a O
patient O
on O
LATUDA O
, O
drug O
discontinuation O
should O
be O
considered O
. O

However O
, O
some O
patients O
may O
require O
treatment O
with O
LATUDA O
despite O
the O
presence O
of O
the O
syndrome O
. O

5.6 O
Metabolic O
Changes O
Atypical O
antipsychotic O
drugs O
have O
been O
associated O
with O
metabolic B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
that O
may O
increase O
cardiovascular/cerebrovascular O
risk O
. O

These O
metabolic O
changes O
include O
hyperglycemia B-OSE_Labeled_AE
, O
dyslipidemia B-OSE_Labeled_AE
, O
and O
body B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
gain I-OSE_Labeled_AE
. O

While O
all O
of O
the O
drugs O
in O
the O
class O
have O
been O
shown O
to O
produce O
some O
metabolic B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
, O
each O
drug O
has O
its O
own O
specific O
risk O
profile O
. O

Hyperglycemia O
and O
Diabetes O
Mellitus O
Hyperglycemia B-OSE_Labeled_AE
, O
in O
some O
cases O
extreme O
and O
associated O
with O
ketoacidosis B-OSE_Labeled_AE
or O
hyperosmolar B-OSE_Labeled_AE
coma I-OSE_Labeled_AE
or O
death B-NonOSE_AE
, O
has O
been O
reported O
in O
patients O
treated O
with O
atypical O
antipsychotics O
. O

Assessment O
of O
the O
relationship O
between O
atypical O
antipsychotic O
use O
and O
glucose B-NonOSE_AE
abnormalities I-NonOSE_AE
is O
complicated O
by O
the O
possibility O
of O
an O
increased O
background O
risk O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
in O
patients O
with O
schizophrenia B-Not_AE_Candidate
and O
the O
increasing O
incidence O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
in O
the O
general O
population O
. O

Given O
these O
confounders O
, O
the O
relationship O
between O
atypical O
antipsychotic O
use O
and O
hyperglycemia B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
adverse I-NonOSE_AE
events I-NonOSE_AE
is O
not O
completely O
understood O
. O

However O
, O
epidemiological O
studies O
suggest O
an O
increased O
risk O
of O
treatment-emergent O
hyperglycemia B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
events I-OSE_Labeled_AE
in O
patients O
treated O
with O
the O
atypical O
antipsychotics O
. O

Because O
LATUDA O
was O
not O
marketed O
at O
the O
time O
these O
studies O
were O
performed O
, O
it O
is O
not O
known O
if O
LATUDA O
is O
associated O
with O
this O
increased O
risk O
. O

Patients O
with O
an O
established O
diagnosis O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
who O
are O
started O
on O
atypical O
antipsychotics O
should O
be O
monitored O
regularly O
for O
worsening B-NonOSE_AE
of I-NonOSE_AE
glucose I-NonOSE_AE
control I-NonOSE_AE
. O

Patients O
with O
risk O
factors O
for O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
( O
e.g. O
, O
obesity B-Not_AE_Candidate
, O
family B-Not_AE_Candidate
history I-Not_AE_Candidate
of I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
) O
who O
are O
starting O
treatment O
with O
atypical O
antipsychotics O
should O
undergo O
fasting O
blood O
glucose O
testing O
at O
the O
beginning O
of O
treatment O
and O
periodically O
during O
treatment O
. O

Any O
patient O
treated O
with O
atypical O
antipsychotics O
should O
be O
monitored O
for O
symptoms O
of O
hyperglycemia B-NonOSE_AE
including O
polydipsia B-NonOSE_AE
, O
polyuria B-NonOSE_AE
, O
polyphagia B-NonOSE_AE
, O
and O
weakness B-NonOSE_AE
. O

Patients O
who O
develop O
symptoms O
of O
hyperglycemia B-NonOSE_AE
during O
treatment O
with O
atypical O
antipsychotics O
should O
undergo O
fasting O
blood O
glucose O
testing O
. O

In O
some O
cases O
, O
hyperglycemia B-NonOSE_AE
has O
resolved O
when O
the O
atypical O
antipsychotic O
was O
discontinued O
; O
however O
, O
some O
patients O
required O
continuation O
of O
anti-diabetic O
treatment O
despite O
discontinuation O
of O
the O
suspect O
drug O
. O

Schizophrenia O
Pooled O
data O
from O
short-term O
, O
placebo-controlled O
schizophrenia B-Not_AE_Candidate
studies O
are O
presented O
in O
Table O
3 O
. O

Table O
3 O
: O
Change O
in O
Fasting O
Glucose O
in O
Schizophrenia O
Studies O
LATUDA O
Placebo O
20 O
mg/day O
40 O
mg/day O
80 O
mg/day O
120 O
mg/day O
160 O
mg/day O
Mean B-OSE_Labeled_AE
Change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
Baseline I-OSE_Labeled_AE
( O
mg/dL O
) O
n=680 O
n=71 O
n=478 O
n=508 O
n=283 O
n=113 O
Serum I-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
-0.0 O
-0.6 O
+2.6 O
-0.4 O
+2.5 O
+ O
2.5 O
Proportion O
of O
Patients O
with O
Shifts O
to O
> O
= O
126 O
mg/dL O
Serum B-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
8.3 O
% O
( O
52/628 O
) O
11.7 O
% O
( O
7/60 O
) O
12.7 O
% O
( O
57/449 O
) O
6.8 O
% O
( O
32/472 O
) O
10.0 O
% O
( O
26/260 O
) O
5.6 O
% O
( O
6/108 O
) O
In O
the O
uncontrolled O
, O
longer-term O
schizophrenia B-Not_AE_Candidate
studies O
( O
primarily O
open-label O
extension O
studies O
) O
, O
LATUDA O
was O
associated O
with O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
of O
+1.8 O
mg/dL O
at O
week O
24 O
( O
n=355 O
) O
, O
+0.8 O
mg/dL O
at O
week O
36 O
( O
n=299 O
) O
and O
+2.3 O
mg/dL O
at O
week O
52 O
( O
n=307 O
) O
. O

Bipolar O
Depression O
Monotherapy O
Data O
from O
the O
short-term O
, O
flexible-dose O
, O
placebo-controlled O
monotherapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
are O
presented O
in O
Table O
4 O
. O

Table O
4 O
: O
Change O
in O
Fasting O
Glucose O
in O
the O
Monotherapy O
Bipolar O
Depression O
Study O
LATUDA O
Placebo O
20 O
to O
60 O
mg/day O
80 O
to O
120 O
mg/day O
Mean B-OSE_Labeled_AE
Change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
Baseline I-OSE_Labeled_AE
( O
mg/dL O
) O
Patients O
were O
randomized O
to O
flexibly O
dosed O
LATUDA O
20 O
to O
60 O
mg/day O
, O
LATUDA O
80 O
to O
120 O
mg/day O
, O
or O
placebo O
n=148 O
n=140 O
n=143 O
Serum I-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
+1.8 O
-0.8 O
+1.8 O
Proportion O
of O
Patients O
with O
Shifts O
to O
> O
= O
126 O
mg/dL O
Serum B-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
4.3 O
% O
( O
6/141 O
) O
2.2 O
% O
( O
3/138 O
) O
6.4 O
% O
( O
9/141 O
) O
In O
the O
uncontrolled O
, O
open-label O
, O
longer-term O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
patients O
who O
received O
LATUDA O
as O
monotherapy O
in O
the O
short-term O
study O
and O
continued O
in O
the O
longer-term O
study O
, O
had O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
of O
+1.2 O
mg/dL O
at O
week O
24 O
( O
n=129 O
) O
. O

Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
Data O
from O
the O
short-term O
, O
flexible-dosed O
, O
placebo-controlled O
adjunctive O
therapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
studies O
are O
presented O
in O
Table O
5 O
. O

Table O
5 O
: O
Change O
in O
Fasting O
Glucose O
in O
the O
Adjunctive O
Therapy O
Bipolar O
Depression O
Studies O
LATUDA O
Placebo O
20 O
to O
120 O
mg/day O
Mean B-OSE_Labeled_AE
Change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
Baseline I-OSE_Labeled_AE
( O
mg/dL O
) O
Patients O
were O
randomized O
to O
flexibly O
dosed O
LATUDA O
20 O
to O
120 O
mg/day O
or O
placebo O
as O
adjunctive O
therapy O
with O
lithium O
or O
valproate O
. O

n=302 O
n=319 O
Serum I-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
-0.9 O
+1.2 O
Proportion O
of O
Patients O
with O
Shifts O
to O
> O
= O
126 O
mg/dL O
Serum B-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
1.0 O
% O
( O
3/290 O
) O
1.3 O
% O
( O
4/316 O
) O
In O
the O
uncontrolled O
, O
open-label O
, O
longer-term O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
patients O
who O
received O
LATUDA O
as O
adjunctive O
therapy O
with O
either O
lithium O
or O
valproate O
in O
the O
short-term O
study O
and O
continued O
in O
the O
longer-term O
study O
, O
had O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
of I-OSE_Labeled_AE
+ I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
7 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
at I-OSE_Labeled_AE
week I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
( O
n=88 O
) O
. O

Dyslipidemia B-OSE_Labeled_AE
Undesirable B-OSE_Labeled_AE
alterations I-OSE_Labeled_AE
in I-OSE_Labeled_AE
lipids I-OSE_Labeled_AE
have O
been O
observed O
in O
patients O
treated O
with O
atypical O
antipsychotics O
. O

Schizophrenia O
Pooled O
data O
from O
short-term O
, O
placebo-controlled O
schizophrenia B-Not_AE_Candidate
studies O
are O
presented O
in O
Table O
6 O
. O

Table O
6 O
: O
Change O
in O
Fasting O
Lipids O
in O
Schizophrenia O
Studies O
LATUDA O
Placebo O
20 O
mg/day O
40 O
mg/day O
80 O
mg/day O
120 O
mg/day O
160 O
mg/day O
Mean B-OSE_Labeled_AE
Change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
Baseline I-OSE_Labeled_AE
( O
mg/dL O
) O
n=660 O
n=71 O
n=466 O
n=499 O
n=268 O
n=115 O
Total I-OSE_Labeled_AE
Cholesterol I-OSE_Labeled_AE
-5.8 O
-12.3 O
-5.7 O
-6.2 O
-3.8 O
-6.9 O
Triglycerides O
-13.4 O
-29.1 O
-5.1 O
-13.0 O
-3.1 O
-10.6 O
Proportion O
of O
Patients O
with O
Shifts O
Total B-OSE_Labeled_AE
Cholesterol I-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
5.3 O
% O
( O
30/571 O
) O
13.8 O
% O
( O
8/58 O
) O
6.2 O
% O
( O
25/402 O
) O
5.3 O
% O
( O
23/434 O
) O
3.8 O
% O
( O
9/238 O
) O
4.0 O
% O
( O
4/101 O
) O
Triglycerides B-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
10.1 O
% O
( O
53/526 O
) O
14.3 O
% O
( O
7/49 O
) O
10.8 O
% O
( O
41/379 O
) O
6.3 O
% O
( O
25/400 O
) O
10.5 O
% O
( O
22/209 O
) O
7.0 O
% O
( O
7/100 O
) O
In O
the O
uncontrolled O
, O
longer-term O
schizophrenia B-Not_AE_Candidate
studies O
( O
primarily O
open-label O
extension O
studies O
) O
, O
LATUDA O
was O
associated O
with O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
total I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
and O
triglycerides O
of O
-3.8 O
( O
n=356 O
) O
and O
-15.1 O
( O
n=357 O
) O
mg/dL O
at O
week O
24 O
, O
-3.1 O
( O
n=303 O
) O
and O
-4.8 O
( O
n=303 O
) O
mg/dL O
at O
week O
36 O
and O
-2.5 O
( O
n=307 O
) O
and O
-6.9 O
( O
n=307 O
) O
mg/dL O
at O
week O
52 O
, O
respectively O
. O

Bipolar O
Depression O
Monotherapy O
Data O
from O
the O
short-term O
, O
flexible-dosed O
, O
placebo-controlled O
, O
monotherapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
are O
presented O
in O
Table O
7 O
. O

Table O
7 O
: O
Change O
in O
Fasting O
Lipids O
in O
the O
Monotherapy O
Bipolar O
Depression O
Study O
LATUDA O
Placebo O
20 O
to O
60 O
mg/day O
80 O
to O
120 O
mg/day O
Mean B-OSE_Labeled_AE
Change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
Baseline I-OSE_Labeled_AE
( O
mg/dL O
) O
Patients O
were O
randomized O
to O
flexibly O
dosed O
LATUDA O
20 O
to O
60 O
mg/day O
, O
LATUDA O
80 O
to O
120 O
mg/day O
, O
or O
placebo O
n=147 O
n=140 O
n=144 O
Total I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
-3.2 O
+1.2 O
-4.6 O
Triglycerides O
+6.0 O
+5.6 O
+0.4 O
Proportion O
of O
Patients O
with O
Shifts O
Total B-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
4.2 O
% O
( O
5/118 O
) O
4.4 O
% O
( O
5/113 O
) O
4.4 O
% O
( O
5/114 O
) O
Triglycerides B-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
4.8 O
% O
( O
6/126 O
) O
10.1 O
% O
( O
12/119 O
) O
9.8 O
% O
( O
12/122 O
) O
In O
the O
uncontrolled O
, O
open-label O
, O
longer-term O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
patients O
who O
received O
LATUDA O
as O
monotherapy O
in O
the O
short-term O
and O
continued O
in O
the O
longer-term O
study O
had O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
total I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
and O
triglycerides O
of O
-0.5 O
( O
n=130 O
) O
and O
-1.0 O
( O
n=130 O
) O
mg/dL O
at O
week O
24 O
, O
respectively O
. O

Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
Data O
from O
the O
short-term O
, O
flexible-dosed O
, O
placebo-controlled O
, O
adjunctive O
therapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
studies O
are O
presented O
in O
Table O
8 O
. O

Table O
8 O
: O
Change O
in O
Fasting O
Lipids O
in O
the O
Adjunctive O
Therapy O
Bipolar O
Depression O
Studies O
LATUDA O
Placebo O
20 O
to O
120 O
mg/day O
Mean B-OSE_Labeled_AE
Change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
Baseline I-OSE_Labeled_AE
( O
mg/dL O
) O
Patients O
were O
randomized O
to O
flexibly O
dosed O
LATUDA O
20 O
to O
120 O
mg/day O
or O
placebo O
as O
adjunctive O
therapy O
with O
lithium O
or O
valproate O
. O

n=303 O
n=321 O
Total I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
-2.9 O
-3.1 O
Triglycerides O
-4.6 O
+4.6 O
Proportion O
of O
Patients O
with O
Shifts O
Total B-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
5.7 O
% O
( O
15/263 O
) O
5.4 O
% O
( O
15/276 O
) O
Triglycerides B-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
8.6 O
% O
( O
21/243 O
) O
10.8 O
% O
( O
28/260 O
) O
In O
the O
uncontrolled O
, O
open-label O
, O
longer-term O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
patients O
who O
received O
LATUDA O
, O
as O
adjunctive O
therapy O
with O
either O
lithium O
or O
valproate O
in O
the O
short-term O
study O
and O
continued O
in O
the O
longer-term O
study O
, O
had O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
total I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
and O
triglycerides O
of O
-0.9 O
( O
n=88 O
) O
and O
+5.3 O
( O
n=88 O
) O
mg/dL O
at O
week O
24 O
, O
respectively O
. O

Weight O
Gain O
Weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
has O
been O
observed O
with O
atypical O
antipsychotic O
use O
. O

Clinical O
monitoring O
of O
weight O
is O
recommended O
. O

Schizophrenia O
Pooled O
data O
from O
short-term O
, O
placebo-controlled O
schizophrenia O
studies O
are O
presented O
in O
Table O
9 O
. O

The O
mean O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
was O
+0.43 O
kg O
for O
LATUDA-treated O
patients O
compared O
to O
-0.02 O
kg O
for O
placebo-treated O
patients O
. O

Change B-NonOSE_AE
in I-NonOSE_AE
weight I-NonOSE_AE
from I-NonOSE_AE
baseline I-NonOSE_AE
for O
olanzapine O
was O
+4.15 O
kg O
and O
for O
quetiapine O
extended-release O
was O
+2.09 O
kg O
in O
Studies O
3 O
and O
5 O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
, O
respectively O
. O

The O
proportion O
of O
patients O
with O
a O
> O
= O
7 O
% O
increase B-OSE_Labeled_AE
in O
body I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
( O
at O
Endpoint O
) O
was O
4.8 O
% O
for O
LATUDA-treated O
patients O
versus O
3.3 O
% O
for O
placebo-treated O
patients O
. O

Table O
9 O
: O
Mean B-OSE_Labeled_AE
Change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
Weight I-OSE_Labeled_AE
( O
kg O
) O
from O
Baseline O
in O
Schizophrenia O
Studies O
LATUDA O
Placebo O
( O
n=696 O
) O
20 O
mg/day O
( O
n=71 O
) O
40 O
mg/day O
( O
n=484 O
) O
80 O
mg/day O
( O
n=526 O
) O
120 O
mg/day O
( O
n=291 O
) O
160 O
mg/day O
( O
n=114 O
) O
All O
Patients O
-0.02 O
-0.15 O
+0.22 O
+0.54 O
+0.68 O
+0.60 O
In O
the O
uncontrolled O
, O
longer-term O
schizophrenia B-Not_AE_Candidate
studies O
( O
primarily O
open-label O
extension O
studies O
) O
, O
LATUDA O
was O
associated O
with O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
of O
-0.69 O
kg O
at O
week O
24 O
( O
n=755 O
) O
, O
-0.59 O
kg O
at O
week O
36 O
( O
n=443 O
) O
and O
-0.73 O
kg O
at O
week O
52 O
( O
n=377 O
) O
. O

Bipolar O
Depression O
Monotherapy O
Data O
from O
the O
short-term O
, O
flexible-dosed O
, O
placebo-controlled O
monotherapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
are O
presented O
in O
Table O
10 O
. O

The O
mean O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
was O
+0.29 O
kg O
for O
LATUDA-treated O
patients O
compared O
to O
-0.04 O
kg O
for O
placebo-treated O
patients O
. O

The O
proportion O
of O
patients O
with O
a O
> O
= O
7 O
% O
increase B-OSE_Labeled_AE
in O
body I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
( O
at O
Endpoint O
) O
was O
2.4 O
% O
for O
LATUDA-treated O
patients O
versus O
0.7 O
% O
for O
placebo-treated O
patients O
. O

Table O
10 O
: O
Mean B-OSE_Labeled_AE
Change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
Weight I-OSE_Labeled_AE
( O
kg O
) O
from O
Baseline O
in O
the O
Monotherapy O
Bipolar O
Depression O
Study O
LATUDA O
Placebo O
( O
n=151 O
) O
20 O
to O
60 O
mg/day O
( O
n=143 O
) O
80 O
to O
120 O
mg/day O
( O
n=147 O
) O
Patients O
were O
randomized O
to O
flexibly O
dosed O
LATUDA O
20 O
to O
60 O
mg/day O
, O
LATUDA O
80 O
to O
120 O
mg/day O
, O
or O
placebo O
All O
Patients O
-0.04 O
+0.56 O
+0.02 O
In O
the O
uncontrolled O
, O
open-label O
, O
longer-term O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
patients O
who O
received O
LATUDA O
as O
monotherapy O
in O
the O
short-term O
and O
continued O
in O
the O
longer-term O
study O
had O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
of I-OSE_Labeled_AE
- I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
kg I-OSE_Labeled_AE
at O
week O
24 O
( O
n=130 O
) O
. O

Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
Data O
from O
the O
short-term O
, O
flexible-dosed O
, O
placebo-controlled O
adjunctive O
therapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
studies O
are O
presented O
in O
Table O
11 O
. O

The O
mean O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
was O
+0.11 O
kg O
for O
LATUDA-treated O
patients O
compared O
to O
+0.16 O
kg O
for O
placebo-treated O
patients O
. O

The O
proportion O
of O
patients O
with O
a O
> O
= O
7 O
% O
increase B-OSE_Labeled_AE
in O
body I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
( O
at O
Endpoint O
) O
was O
3.1 O
% O
for O
LATUDA-treated O
patients O
versus O
0.3 O
% O
for O
placebo-treated O
patients O
. O

Table O
11 O
: O
Mean B-OSE_Labeled_AE
Change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
Weight I-OSE_Labeled_AE
( O
kg O
) O
from O
Baseline O
in O
the O
Adjunctive O
Therapy O
Bipolar O
Depression O
Studies O
LATUDA O
Placebo O
( O
n=307 O
) O
20 O
to O
120 O
mg/day O
( O
n=327 O
) O
Patients O
were O
randomized O
to O
flexibly O
dosed O
LATUDA O
20 O
to O
120 O
mg/day O
or O
placebo O
as O
adjunctive O
therapy O
with O
lithium O
or O
valproate O
. O

All O
Patients O
+0.16 O
+0.11 O
In O
the O
uncontrolled O
, O
open-label O
, O
longer-term O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
patients O
who O
were O
treated O
with O
LATUDA O
, O
as O
adjunctive O
therapy O
with O
either O
lithium O
or O
valproate O
in O
the O
short-term O
and O
continued O
in O
the O
longer-term O
study O
, O
had O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
of O
+1.28 O
kg O
at O
week O
24 O
( O
n=86 O
) O
. O

5.7 O
Hyperprolactinemia B-OSE_Labeled_AE
As O
with O
other O
drugs O
that O
antagonize O
dopamine O
D2receptors O
, O
LATUDA O
elevates B-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
. O

Hyperprolactinemia B-NonOSE_AE
may O
suppress B-NonOSE_AE
hypothalamic I-NonOSE_AE
GnRH I-NonOSE_AE
, O
resulting O
in O
reduced B-NonOSE_AE
pituitary I-NonOSE_AE
gonadotrophin I-NonOSE_AE
secretion I-NonOSE_AE
. O

This O
, O
in O
turn O
, O
may O
inhibit B-NonOSE_AE
reproductive I-NonOSE_AE
function I-NonOSE_AE
by I-NonOSE_AE
impairing I-NonOSE_AE
gonadal I-NonOSE_AE
steroidogenesis I-NonOSE_AE
in O
both O
female O
and O
male O
patients O
. O

Galactorrhea B-OSE_Labeled_AE
, O
amenorrhea B-OSE_Labeled_AE
, O
gynecomastia B-OSE_Labeled_AE
, O
and O
impotence B-OSE_Labeled_AE
have O
been O
reported O
with O
prolactin-elevating O
compounds O
. O

Long-standing O
hyperprolactinemia B-NonOSE_AE
, O
when O
associated O
with O
hypogonadism B-NonOSE_AE
, O
may O
lead O
to O
decreased B-NonOSE_AE
bone I-NonOSE_AE
density I-NonOSE_AE
in O
both O
female O
and O
male O
patients O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

Tissue O
culture O
experiments O
indicate O
that O
approximately O
one-third O
of O
human O
breast B-NonOSE_AE
cancers I-NonOSE_AE
are O
prolactin-dependent O
in O
vitro O
, O
a O
factor O
of O
potential O
importance O
if O
the O
prescription O
of O
these O
drugs O
is O
considered O
in O
a O
patient O
with O
previously O
detected O
breast B-Not_AE_Candidate
cancer I-Not_AE_Candidate
. O

As O
is O
common O
with O
compounds O
which O
increase B-NonOSE_AE
prolactin I-NonOSE_AE
release I-NonOSE_AE
, O
an O
increase B-NonOSE_AE
in I-NonOSE_AE
mammary I-NonOSE_AE
gland I-NonOSE_AE
neoplasia I-NonOSE_AE
was O
observed O
in O
a O
LATUDA O
carcinogenicity B-NonOSE_AE
study O
conducted O
in O
rats O
and O
mice O
[ O
see O
Nonclinical O
Toxicology O
( O
13 O
) O
] O
. O

Neither O
clinical O
studies O
nor O
epidemiologic O
studies O
conducted O
to O
date O
have O
shown O
an O
association O
between O
chronic O
administration O
of O
this O
class O
of O
drugs O
and O
tumorigenesis B-NonOSE_AE
in O
humans O
, O
but O
the O
available O
evidence O
is O
too O
limited O
to O
be O
conclusive O
. O

Schizophrenia O
In O
short-term O
, O
placebo-controlled O
schizophrenia B-Not_AE_Candidate
studies O
, O
the O
median B-OSE_Labeled_AE
change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
to I-OSE_Labeled_AE
endpoint I-OSE_Labeled_AE
in I-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
for O
LATUDA-treated O
patients O
was O
+0.4 O
ng/mL O
and O
was O
-1.9 O
ng/mL O
in O
the O
placebo-treated O
patients O
. O

The O
median O
change O
from O
baseline O
to O
endpoint O
for O
males O
was O
+0.5 O
ng/mL O
and O
for O
females O
was O
-0.2 O
ng/mL O
. O

Median B-NonOSE_AE
changes I-NonOSE_AE
for I-NonOSE_AE
prolactin I-NonOSE_AE
by O
dose O
are O
shown O
in O
Table O
12 O
. O

Table O
12 O
: O
Median B-OSE_Labeled_AE
Change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
Prolactin I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ng I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mL I-OSE_Labeled_AE
) I-OSE_Labeled_AE
from I-OSE_Labeled_AE
Baseline I-OSE_Labeled_AE
in O
Schizophrenia O
Studies O
LATUDA O
Placebo O
20 O
mg/day O
40 O
mg/day O
80 O
mg/day O
120 O
mg/day O
160 O
mg/day O
All O
Patients O
-1.9 O
( O
n=672 O
) O
-1.1 O
( O
n=70 O
) O
-1.4 O
( O
n=476 O
) O
-0.2 O
( O
n=495 O
) O
+3.3 O
( O
n=284 O
) O
+3.3 O
( O
n=115 O
) O
Females O
-5.1 O
( O
n=200 O
) O
-0.7 O
( O
n=19 O
) O
-4.0 O
( O
n=149 O
) O
-0.2 O
( O
n=150 O
) O
+6.7 O
( O
n=70 O
) O
+7.1 O
( O
n=36 O
) O
Males O
-1.3 O
( O
n=472 O
) O
-1.2 O
( O
n=51 O
) O
-0.7 O
( O
n=327 O
) O
-0.2 O
( O
n=345 O
) O
+3.1 O
( O
n=214 O
) O
+2.4 O
( O
n=79 O
) O
The O
proportion O
of O
patients O
with O
prolactin B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
> O
= O
5* O
upper O
limit O
of O
normal O
( O
ULN O
) O
was O
2.8 O
% O
for O
LATUDA-treated O
patients O
versus O
1.0 O
% O
for O
placebo-treated O
patients O
. O

The O
proportion O
of O
female O
patients O
with O
prolactin B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
> O
= O
5x O
ULN O
was O
5.7 O
% O
for O
LATUDA-treated O
patients O
versus O
2.0 O
% O
for O
placebo-treated O
female O
patients O
. O

The O
proportion O
of O
male O
patients O
with O
prolactin B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
> O
= O
5x O
ULN O
was O
1.6 O
% O
versus O
0.6 O
% O
for O
placebo-treated O
male O
patients O
. O

In O
the O
uncontrolled O
longer-term O
schizophrenia B-Not_AE_Candidate
studies O
( O
primarily O
open-label O
extension O
studies O
) O
, O
LATUDA O
was O
associated O
with O
a O
median B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
of O
-0.9 O
ng/mL O
at O
week O
24 O
( O
n=357 O
) O
, O
-5.3ng/mL O
at O
week O
36 O
( O
n=190 O
) O
and O
-2.2 O
ng/mL O
at O
week O
52 O
( O
n=307 O
) O
. O

Bipolar O
Depression O
Monotherapy O
The O
median B-OSE_Labeled_AE
change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
to O
endpoint O
in O
prolactin I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
, O
in O
the O
short-term O
, O
flexible-dosed O
, O
placebo-controlled O
monotherapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
was O
+1.7 O
ng/mL O
and O
+3.5 O
ng/mL O
with O
LATUDA O
20 O
to O
60 O
mg/day O
and O
80 O
to O
120 O
mg/day O
, O
respectively O
compared O
to O
+0.3 O
ng/mL O
with O
placebo-treated O
patients O
. O

The O
median O
change O
from O
baseline O
to O
endpoint O
for O
males O
was O
+1.5 O
ng/mL O
and O
for O
females O
was O
+3.1 O
ng/mL O
. O

Median B-NonOSE_AE
changes I-NonOSE_AE
for I-NonOSE_AE
prolactin I-NonOSE_AE
by O
dose O
range O
are O
shown O
in O
Table O
13 O
. O

Table O
13 O
: O
Median B-OSE_Labeled_AE
Change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
Prolactin I-OSE_Labeled_AE
( O
ng/mL O
) O
from O
Baseline O
in O
the O
Monotherapy O
Bipolar O
Depression O
Study O
LATUDA O
Placebo O
20 O
to O
60 O
mg/day O
80 O
to O
120 O
mg/day O
Patients O
were O
randomized O
to O
flexibly O
dosed O
LATUDA O
20 O
to O
60 O
mg/day O
, O
LATUDA O
80 O
to O
120 O
mg/day O
, O
or O
placebo O
All O
Patients O
+0.3 O
( O
n=147 O
) O
+1.7 O
( O
n=140 O
) O
+3.5 O
( O
n=144 O
) O
Females O
0.0 O
( O
n=82 O
) O
+1.8 O
( O
n=78 O
) O
+5.3 O
( O
n=88 O
) O
Males O
+0.4 O
( O
n=65 O
) O
+1.2 O
( O
n=62 O
) O
+1.9 O
( O
n=56 O
) O
The O
proportion O
of O
patients O
with O
prolactin B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
> O
= O
5x O
upper O
limit O
of O
normal O
( O
ULN O
) O
was O
0.4 O
% O
for O
LATUDA-treated O
patients O
versus O
0.0 O
% O
for O
placebo-treated O
patients O
. O

The O
proportion O
of O
female O
patients O
with O
prolactin B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
> O
= O
5x O
ULN O
was O
0.6 O
% O
for O
LATUDA-treated O
patients O
versus O
0 O
% O
for O
placebo-treated O
female O
patients O
. O

The O
proportion O
of O
male O
patients O
with O
prolactin B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
> O
= O
5x O
ULN O
was O
0 O
% O
versus O
0 O
% O
for O
placebo-treated O
male O
patients O
. O

In O
the O
uncontrolled O
, O
open-label O
, O
longer-term O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
patients O
who O
were O
treated O
with O
LATUDA O
as O
monotherapy O
in O
the O
short-term O
and O
continued O
in O
the O
longer-term O
study O
, O
had O
a O
median B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
of O
-1.15 O
ng/mL O
at O
week O
24 O
( O
n=130 O
) O
. O

Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
The O
median B-OSE_Labeled_AE
change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
to O
endpoint O
in O
prolactin I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
, O
in O
the O
short-term O
, O
flexible-dosed O
, O
placebo-controlled O
adjunctive O
therapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
studies O
was O
+2.8 O
ng/mL O
with O
LATUDA O
20 O
to O
120 O
mg/day O
compared O
to O
0.0 O
ng/mL O
with O
placebo-treated O
patients O
. O

The O
median O
change O
from O
baseline O
to O
endpoint O
for O
males O
was O
+2.4 O
ng/mL O
and O
for O
females O
was O
+3.2 O
ng/mL O
. O

Median O
changes O
for O
prolactin O
across O
the O
dose O
range O
are O
shown O
in O
Table O
14 O
. O

Table O
14 O
: O
Median B-OSE_Labeled_AE
Change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
Prolactin I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ng I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mL I-OSE_Labeled_AE
) I-OSE_Labeled_AE
from I-OSE_Labeled_AE
Baseline I-OSE_Labeled_AE
in O
the O
Adjunctive O
Therapy O
Bipolar O
Depression O
Studies O
LATUDA O
Placebo O
20 O
to O
120 O
mg/day O
Patients O
were O
randomized O
to O
flexibly O
dosed O
LATUDA O
20 O
to O
120 O
mg/day O
or O
placebo O
as O
adjunctive O
therapy O
with O
lithium O
or O
valproate O
. O

All O
Patients O
0.0 O
( O
n=301 O
) O
+2.8 O
( O
n=321 O
) O
Females O
+0.4 O
( O
n=156 O
) O
+3.2 O
( O
n=162 O
) O
Males O
-0.1 O
( O
n=145 O
) O
+2.4 O
( O
n=159 O
) O
The O
proportion O
of O
patients O
with O
prolactin B-NonOSE_AE
elevations I-NonOSE_AE
> O
= O
5x O
upper O
limit O
of O
normal O
( O
ULN O
) O
was O
0.0 O
% O
for O
LATUDA-treated O
patients O
versus O
0.0 O
% O
for O
placebo-treated O
patients O
. O

The O
proportion O
of O
female O
patients O
with O
prolactin B-NonOSE_AE
elevations I-NonOSE_AE
> O
= O
5x O
ULN O
was O
0 O
% O
for O
LATUDA-treated O
patients O
versus O
0 O
% O
for O
placebo-treated O
female O
patients O
. O

The O
proportion O
of O
male O
patients O
with O
prolactin B-NonOSE_AE
elevations I-NonOSE_AE
> O
= O
5x O
ULN O
was O
0 O
% O
versus O
0 O
% O
for O
placebo-treated O
male O
patients O
. O

In O
the O
uncontrolled O
, O
open-label O
, O
longer-term O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
patients O
who O
were O
treated O
with O
LATUDA O
, O
as O
adjunctive O
therapy O
with O
either O
lithium O
or O
valproate O
, O
in O
the O
short-term O
and O
continued O
in O
the O
longer-term O
study O
, O
had O
a O
median B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
of O
-2.9 O
ng/mL O
at O
week O
24 O
( O
n=88 O
) O
. O

5.8 O
Leukopenia O
, O
Neutropenia O
and O
Agranulocytosis O
Leukopenia B-OSE_Labeled_AE
/ O
neutropenia B-OSE_Labeled_AE
has O
been O
reported O
during O
treatment O
with O
antipsychotic O
agents O
. O

Agranulocytosis B-NonOSE_AE
( O
including O
fatal B-NonOSE_AE
cases O
) O
has O
been O
reported O
with O
other O
agents O
in O
the O
class O
. O

Possible O
risk O
factors O
for O
leukopenia B-NonOSE_AE
/ O
neutropenia B-NonOSE_AE
include O
pre-existing O
low B-Not_AE_Candidate
white I-Not_AE_Candidate
blood I-Not_AE_Candidate
cell I-Not_AE_Candidate
count I-Not_AE_Candidate
( I-Not_AE_Candidate
WBC I-Not_AE_Candidate
) O
and O
history O
of O
drug B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
leukopenia I-Not_AE_Candidate
/neutropenia O
. O

Patients O
with O
a O
pre-existing O
low B-Not_AE_Candidate
WBC I-Not_AE_Candidate
or O
a O
history O
of O
drug B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
leukopenia I-Not_AE_Candidate
/neutropenia O
should O
have O
their O
complete O
blood O
count O
( O
CBC O
) O
monitored O
frequently O
during O
the O
first O
few O
months O
of O
therapy O
and O
LATUDA O
should O
be O
discontinued O
at O
the O
first O
sign O
of O
decline B-NonOSE_AE
in I-NonOSE_AE
WBC I-NonOSE_AE
, O
in O
the O
absence O
of O
other O
causative O
factors O
. O

Patients O
with O
neutropenia B-NonOSE_AE
should O
be O
carefully O
monitored O
for O
fever B-NonOSE_AE
or O
other O
symptoms O
or O
signs O
of O
infection B-NonOSE_AE
and O
treated O
promptly O
if O
such O
symptoms O
or O
signs O
occur O
. O

Patients O
with O
severe O
neutropenia B-NonOSE_AE
( O
absolute B-NonOSE_AE
neutrophil I-NonOSE_AE
count I-NonOSE_AE
< I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
/ I-NonOSE_AE
mm I-NonOSE_AE
3 I-NonOSE_AE
) O
should O
discontinue O
LATUDA O
and O
have O
their O
WBC O
followed O
until O
recovery O
. O

5.9 O
Orthostatic O
Hypotension O
and O
Syncope O
LATUDA O
may O
cause O
orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
and O
syncope B-OSE_Labeled_AE
, O
perhaps O
due O
to O
its O
alpha1-adrenergic O
receptor O
antagonism O
. O

Associated O
adverse O
reactions O
can O
include O
dizziness B-OSE_Labeled_AE
, O
lightheadedness B-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
, O
and O
bradycardia B-OSE_Labeled_AE
. O

Generally O
, O
these O
risks O
are O
greatest O
at O
the O
beginning O
of O
treatment O
and O
during O
dose O
escalation O
. O

Patients O
at O
increased O
risk O
of O
these O
adverse O
reactions O
or O
at O
increased O
risk O
of O
developing O
complications O
from O
hypotension B-NonOSE_AE
include O
those O
with O
dehydration B-Not_AE_Candidate
, O
hypovolemia B-Not_AE_Candidate
, O
treatment O
with O
antihypertensive B-NonOSE_AE
medication I-NonOSE_AE
, O
history O
of O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
( O
e.g. O
, O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
myocardial B-Not_AE_Candidate
infarction I-Not_AE_Candidate
, O
ischemia B-Not_AE_Candidate
, O
or O
conduction B-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
) O
, O
history O
of O
cerebrovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
as O
well O
as O
patients O
who O
are O
antipsychotic-naive O
. O

In O
such O
patients O
, O
consider O
using O
a O
lower O
starting O
dose O
and O
slower O
titration O
, O
and O
monitor O
orthostatic O
vital O
signs O
. O

Orthostatic B-NonOSE_AE
hypotension I-NonOSE_AE
, O
as O
assessed O
by O
vital O
sign O
measurement O
, O
was O
defined O
by O
the O
following O
vital O
sign O
changes O
: O
> O
= O
20 O
mm O
Hg O
decrease B-NonOSE_AE
in I-NonOSE_AE
systolic O
blood I-NonOSE_AE
pressure I-NonOSE_AE
and O
> O
= O
10 O
bpm O
increase B-NonOSE_AE
in I-NonOSE_AE
pulse I-NonOSE_AE
from O
sitting O
to O
standing O
or O
supine O
to O
standing O
position O
. O

Schizophrenia O
The O
incidence O
of O
orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
and O
syncope B-OSE_Labeled_AE
reported O
as O
adverse O
events O
from O
short-term O
, O
placebo-controlled O
schizophrenia B-Not_AE_Candidate
studies O
was O
( O
LATUDA O
incidence O
, O
placebo O
incidence O
) O
: O
orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
[ O
0.3 O
% O
( O
5/1508 O
) O
, O
0.1 O
% O
( O
1/708 O
) O
] O
and O
syncope B-OSE_Labeled_AE
[ O
0.1 O
% O
( O
2/1508 O
) O
, O
0 O
% O
( O
0/708 O
) O
] O
. O

In O
short-term O
schizophrenia B-Not_AE_Candidate
clinical O
studies O
, O
orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
, O
as O
assessed O
by O
vital O
signs O
, O
occurred O
with O
a O
frequency O
of O
0.8 O
% O
with O
LATUDA O
40 O
mg O
, O
2.1 O
% O
with O
LATUDA O
80 O
mg O
, O
1.7 O
% O
with O
LATUDA O
120 O
mg O
and O
0.8 O
% O
with O
LATUDA O
160 O
mg O
compared O
to O
0.7 O
% O
with O
placebo O
. O

Bipolar O
Depression O
Monotherapy O
In O
the O
short-term O
, O
flexible-dose O
, O
placebo-controlled O
monotherapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
there O
were O
no O
reported O
adverse O
events O
of O
orthostatic B-NonOSE_AE
hypotension I-NonOSE_AE
and O
syncope B-NonOSE_AE
. O

Orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
, O
as O
assessed O
by O
vital O
signs O
, O
occurred O
with O
a O
frequency O
of O
0.6 O
% O
with O
LATUDA O
20 O
to O
60 O
mg O
and O
0.6 O
% O
with O
LATUDA O
80 O
to O
120 O
mg O
compared O
to O
0 O
% O
with O
placebo O
. O

Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
In O
the O
short-term O
, O
flexible-dose O
, O
placebo-controlled O
adjunctive O
therapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
therapy O
studies O
, O
there O
were O
no O
reported O
adverse O
events O
of O
orthostatic B-NonOSE_AE
hypotension I-NonOSE_AE
and O
syncope B-NonOSE_AE
. O

Orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
, O
as O
assessed O
by O
vital O
signs O
, O
occurred O
with O
a O
frequency O
of O
1.1 O
% O
with O
LATUDA O
20 O
to O
120 O
mg O
compared O
to O
0.9 O
% O
with O
placebo O
. O

5.10 O
Seizures O
As O
with O
other O
antipsychotic O
drugs O
, O
LATUDA O
should O
be O
used O
cautiously O
in O
patients O
with O
a O
history B-Not_AE_Candidate
of I-Not_AE_Candidate
seizures I-Not_AE_Candidate
or O
with O
conditions O
that O
lower B-NonOSE_AE
the I-NonOSE_AE
seizure I-NonOSE_AE
threshold I-NonOSE_AE
, O
e.g. O
, O
Alzheimer B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
dementia I-Not_AE_Candidate
. O

Conditions O
that O
lower B-NonOSE_AE
the I-NonOSE_AE
seizure I-NonOSE_AE
threshold I-NonOSE_AE
may O
be O
more O
prevalent O
in O
patients O
65 O
years O
or O
older O
. O

Schizophrenia O
In O
short-term O
, O
placebo-controlled O
schizophrenia B-Not_AE_Candidate
studies O
, O
seizures B-NonOSE_AE
/ O
convulsions B-NonOSE_AE
occurred O
in O
0.1 O
% O
( O
2/1508 O
) O
of O
patients O
treated O
with O
LATUDA O
compared O
to O
0.1 O
% O
( O
1/708 O
) O
placebo-treated O
patients O
. O

Bipolar O
Depression O
Monotherapy O
In O
the O
short-term O
, O
flexible-dose O
, O
placebo-controlled O
monotherapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
no O
patient O
experienced O
seizures B-NonOSE_AE
/ O
convulsions B-NonOSE_AE
. O

Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
In O
the O
short-term O
, O
flexible-dose O
, O
placebo-controlled O
adjunctive O
therapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
studies O
, O
no O
patient O
experienced O
seizures B-NonOSE_AE
/ O
convulsions B-NonOSE_AE
. O

5.11 O
Potential O
for O
Cognitive B-OSE_Labeled_AE
and O
Motor O
Impairment I-OSE_Labeled_AE
LATUDA O
, O
like O
other O
antipsychotics O
, O
has O
the O
potential O
to O
impair B-OSE_Labeled_AE
judgment I-OSE_Labeled_AE
, O
thinking O
or O
motor O
skills O
. O

Caution O
patients O
about O
operating O
hazardous O
machinery O
, O
including O
motor O
vehicles O
, O
until O
they O
are O
reasonably O
certain O
that O
therapy O
with O
LATUDA O
does O
not O
affect O
them O
adversely O
. O

In O
clinical O
studies O
with O
LATUDA O
, O
somnolence B-OSE_Labeled_AE
included O
: O
hypersomnia B-OSE_Labeled_AE
, O
hypersomnolence B-OSE_Labeled_AE
, O
sedation B-OSE_Labeled_AE
and O
somnolence B-OSE_Labeled_AE
. O

Schizophrenia O
In O
short-term O
, O
placebo-controlled O
schizophrenia B-Not_AE_Candidate
studies O
, O
somnolence B-OSE_Labeled_AE
was O
reported O
by O
17.0 O
% O
( O
256/1508 O
) O
of O
patients O
treated O
with O
LATUDA O
( O
15.5 O
% O
LATUDA O
20 O
mg O
, O
15.6 O
% O
LATUDA O
40 O
mg O
, O
15.2 O
% O
LATUDA O
80 O
mg O
, O
26.5 O
% O
LATUDA O
120 O
mg O
and O
8.3 O
% O
LATUDA O
160 O
mg/day O
) O
compared O
to O
7.1 O
% O
( O
50/708 O
) O
of O
placebo O
patients O
. O

Bipolar O
Depression O
Monotherapy O
In O
the O
short-term O
, O
flexible-dosed O
, O
placebo-controlled O
monotherapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
somnolence B-OSE_Labeled_AE
was O
reported O
by O
7.3 O
% O
( O
12/164 O
) O
and O
13.8 O
% O
( O
23/167 O
) O
with O
LATUDA O
20 O
to O
60 O
mg O
and O
80 O
to120 O
mg O
, O
respectively O
compared O
to O
6.5 O
% O
( O
11/168 O
) O
of O
placebo O
patients O
. O

Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
In O
the O
short-term O
, O
flexible-dosed O
, O
placebo-controlled O
adjunctive O
therapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
studies O
, O
somnolence B-OSE_Labeled_AE
was O
reported O
by O
11.4 O
% O
( O
41/360 O
) O
of O
patients O
treated O
with O
LATUDA O
20-120 O
mg O
compared O
to O
5.1 O
% O
( O
17/334 O
) O
of O
placebo O
patients O
. O

5.12 O
Body O
Temperature O
Dysregulation O
Disruption B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
body I-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
ability I-OSE_Labeled_AE
to I-OSE_Labeled_AE
reduce I-OSE_Labeled_AE
core I-OSE_Labeled_AE
body I-OSE_Labeled_AE
temperature I-OSE_Labeled_AE
has O
been O
attributed O
to O
antipsychotic O
agents O
. O

Appropriate O
care O
is O
advised O
when O
prescribing O
LATUDA O
for O
patients O
who O
will O
be O
experiencing O
conditions O
that O
may O
contribute O
to O
an O
elevation B-NonOSE_AE
in I-NonOSE_AE
core I-NonOSE_AE
body I-NonOSE_AE
temperature I-NonOSE_AE
, O
e.g. O
, O
exercising O
strenuously O
, O
exposure O
to O
extreme O
heat O
, O
receiving O
concomitant O
medication O
with O
anticholinergic O
activity O
, O
or O
being O
subject O
to O
dehydration B-NonOSE_AE
[ O
see O
Patient O
Counseling O
Information O
( O
17.9 O
) O
] O
. O

5.13 O
Suicide O
The O
possibility O
of O
a O
suicide B-NonOSE_AE
attempt I-NonOSE_AE
is O
inherent O
in O
psychotic O
illness O
and O
close O
supervision O
of O
high-risk O
patients O
should O
accompany O
drug O
therapy O
. O

Prescriptions O
for O
LATUDA O
should O
be O
written O
for O
the O
smallest O
quantity O
of O
tablets O
consistent O
with O
good O
patient O
management O
in O
order O
to O
reduce O
the O
risk O
of O
overdose B-NonOSE_AE
. O

Schizophrenia O
In O
short-term O
, O
placebo-controlled O
schizophrenia B-Not_AE_Candidate
studies O
, O
the O
incidence O
of O
treatment-emergent O
suicidal B-NonOSE_AE
ideation I-NonOSE_AE
was O
0.4 O
% O
( O
6/1508 O
) O
for O
LATUDA-treated O
patients O
compared O
to O
0.8 O
% O
( O
6/708 O
) O
on O
placebo O
. O

No O
suicide B-NonOSE_AE
attempts I-NonOSE_AE
or O
completed B-NonOSE_AE
suicides I-NonOSE_AE
were O
reported O
in O
these O
studies O
. O

Bipolar O
Depression O
Monotherapy O
In O
the O
short-term O
, O
flexible-dose O
, O
placebo-controlled O
monotherapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
the O
incidence O
of O
treatment-emergent O
suicidal B-NonOSE_AE
ideation I-NonOSE_AE
was O
0.0 O
% O
( O
0/331 O
) O
with O
LATUDA-treated O
patients O
compared O
to O
0.0 O
% O
( O
0/168 O
) O
with O
placebo-treated O
patients O
. O

No O
suicide B-NonOSE_AE
attempts I-NonOSE_AE
or O
completed B-NonOSE_AE
suicides I-NonOSE_AE
were O
reported O
in O
this O
study O
. O

Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
In O
the O
short-term O
, O
flexible-dose O
, O
placebo-controlled O
adjunctive O
therapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
studies O
, O
the O
incidence O
of O
treatment-emergent O
suicidal B-OSE_Labeled_AE
ideation I-OSE_Labeled_AE
was O
1.1 O
% O
( O
4/360 O
) O
for O
LATUDA-treated O
patients O
compared O
to O
0.3 O
% O
( O
1/334 O
) O
on O
placebo O
. O

No O
suicide B-NonOSE_AE
attempts I-NonOSE_AE
or O
completed B-NonOSE_AE
suicides I-NonOSE_AE
were O
reported O
in O
these O
studies O
. O

5.14 O
Activation O
of O
Mania/Hypomania O
Antidepressant O
treatment O
can O
increase O
the O
risk O
of O
developing O
a O
manic B-OSE_Labeled_AE
or O
hypomanic B-OSE_Labeled_AE
episode I-OSE_Labeled_AE
, O
particularly O
in O
patients O
with O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

Monitor O
patients O
for O
the O
emergence O
of O
such O
episodes O
. O

In O
the O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
monotherapy O
and O
adjunctive O
therapy O
( O
with O
lithium O
or O
valproate O
) O
studies O
, O
less O
than O
1 O
% O
of O
subjects O
in O
the O
LATUDA O
and O
placebo O
groups O
developed O
manic B-NonOSE_AE
or O
hypomanic B-NonOSE_AE
episodes I-NonOSE_AE
. O

5.15 O
Dysphagia B-OSE_Labeled_AE
Esophageal B-OSE_Labeled_AE
dysmotility I-OSE_Labeled_AE
and O
aspiration B-OSE_Labeled_AE
have O
been O
associated O
with O
antipsychotic O
drug O
use O
. O

Aspiration B-NonOSE_AE
pneumonia I-NonOSE_AE
is O
a O
common O
cause O
of O
morbidity O
and O
mortality O
in O
elderly O
patients O
, O
in O
particular O
those O
with O
advanced O
Alzheimer B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
dementia I-Not_AE_Candidate
. O

LATUDA O
and O
other O
antipsychotic O
drugs O
should O
be O
used O
cautiously O
in O
patients O
at O
risk O
for O
aspiration B-Not_AE_Candidate
pneumonia I-Not_AE_Candidate
. O

5.16 O
Neurological B-OSE_Labeled_AE
Adverse I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
in O
Patients O
with O
Parkinson O
's O
Disease O
or O
Dementia O
with O
Lewy O
Bodies O
Patients O
with O
Parkinson B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
Disease I-Not_AE_Candidate
or O
Dementia B-Not_AE_Candidate
with I-Not_AE_Candidate
Lewy I-Not_AE_Candidate
Bodies I-Not_AE_Candidate
are O
reported O
to O
have O
an O
increased O
sensitivity O
to O
antipsychotic O
medication O
. O

Manifestations O
of O
this O
increased O
sensitivity O
include O
confusion B-OSE_Labeled_AE
, O
obtundation B-OSE_Labeled_AE
, O
postural B-OSE_Labeled_AE
instability I-OSE_Labeled_AE
with O
frequent B-NonOSE_AE
falls I-NonOSE_AE
, O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
, O
and O
clinical O
features O
consistent O
with O
the O
neuroleptic B-OSE_Labeled_AE
malignant I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
The O
most O
common O
reactions O
( O
> O
=3 O
% O
) O
were O
nausea O
, O
headache O
, O
diarrhea O
, O
insomnia O
, O
constipation O
and O
dizziness O
( O
6.2 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Janssen O
Pharmaceuticals O
, O
Inc O
. O
at O
1-800-526-7736 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Serious O
and O
Otherwise O
Important O
Adverse O
Reactions O
The O
following O
serious O
and O
otherwise O
important O
adverse O
drug O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
labeling O
: O
* O
Disabling B-OSE_Labeled_AE
and I-OSE_Labeled_AE
Potentially I-OSE_Labeled_AE
Irreversible I-OSE_Labeled_AE
Serious I-OSE_Labeled_AE
Adverse I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Tendinitis B-OSE_Labeled_AE
and O
Tendon B-OSE_Labeled_AE
Rupture I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Peripheral B-OSE_Labeled_AE
Neuropathy I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Central B-OSE_Labeled_AE
Nervous I-OSE_Labeled_AE
System I-OSE_Labeled_AE
Effects I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Exacerbation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Myasthenia I-OSE_Labeled_AE
Gravis I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Other O
Serious O
and O
Sometimes O
Fatal B-NonOSE_AE
Reactions O
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Hypersensitivity B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Hepatotoxicity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Clostridium B-OSE_Labeled_AE
difficile I-OSE_Labeled_AE
- I-OSE_Labeled_AE
Associated I-OSE_Labeled_AE
Diarrhea I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Prolongation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
QT I-OSE_Labeled_AE
Interval I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
* O
Musculoskeletal B-OSE_Labeled_AE
Disorders I-OSE_Labeled_AE
in O
Pediatric O
Patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
* O
Blood B-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
Disturbances I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.12 O
) O
] O
* O
Photosensitivity B-OSE_Labeled_AE
/ O
Phototoxicity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.13 O
) O
] O
* O
Development B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Drug I-OSE_Labeled_AE
Resistant I-OSE_Labeled_AE
Bacteria I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.14 O
) O
] O
Hypotension O
has O
been O
associated O
with O
rapid O
or O
bolus O
intravenous O
infusion O
of O
LEVAQUIN O
( O
r O
) O
. O

LEVAQUIN O
( O
r O
) O
should O
be O
infused O
slowly O
over O
60 O
to O
90 O
minutes O
, O
depending O
on O
dosage O
[ O
see O
Dosage O
and O
Administration O
( O
2.5 O
) O
] O
. O

Crystalluria B-OSE_Labeled_AE
and O
cylindruria B-OSE_Labeled_AE
have O
been O
reported O
with O
quinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
. O

Therefore O
, O
adequate O
hydration O
of O
patients O
receiving O
LEVAQUIN O
( O
r O
) O
should O
be O
maintained O
to O
prevent O
the O
formation B-NonOSE_AE
of I-NonOSE_AE
a I-NonOSE_AE
highly I-NonOSE_AE
concentrated I-NonOSE_AE
urine I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.5 O
) O
] O
. O

6.2 O
Clinical O
Trial O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
data O
described O
below O
reflect O
exposure O
to O
LEVAQUIN O
( O
r O
) O
in O
7537 O
patients O
in O
29 O
pooled O
Phase O
3 O
clinical O
trials O
. O

The O
population O
studied O
had O
a O
mean O
age O
of O
50 O
years O
( O
approximately O
74 O
% O
of O
the O
population O
was O
< O
65 O
years O
of O
age O
) O
, O
50 O
% O
were O
male O
, O
71 O
% O
were O
Caucasian O
, O
19 O
% O
were O
Black O
. O

Patients O
were O
treated O
with O
LEVAQUIN O
( O
r O
) O
for O
a O
wide O
variety O
of O
infectious O
diseases O
[ O
see O
Indications O
and O
Usage O
( O
1 O
) O
] O
. O

Patients O
received O
LEVAQUIN O
( O
r O
) O
doses O
of O
750 O
mg O
once O
daily O
, O
250 O
mg O
once O
daily O
, O
or O
500 O
mg O
once O
or O
twice O
daily O
. O

Treatment O
duration O
was O
usually O
3-14 O
days O
, O
and O
the O
mean O
number O
of O
days O
on O
therapy O
was O
10 O
days O
. O

The O
overall O
incidence O
, O
type O
and O
distribution O
of O
adverse O
reactions O
was O
similar O
in O
patients O
receiving O
LEVAQUIN O
( O
r O
) O
doses O
of O
750 O
mg O
once O
daily O
, O
250 O
mg O
once O
daily O
, O
and O
500 O
mg O
once O
or O
twice O
daily O
. O

Discontinuation O
of O
LEVAQUIN O
( O
r O
) O
due O
to O
adverse O
drug O
reactions O
occurred O
in O
4.3 O
% O
of O
patients O
overall O
, O
3.8 O
% O
of O
patients O
treated O
with O
the O
250 O
mg O
and O
500 O
mg O
doses O
and O
5.4 O
% O
of O
patients O
treated O
with O
the O
750 O
mg O
dose O
. O

The O
most O
common O
adverse O
drug O
reactions O
leading O
to O
discontinuation O
with O
the O
250 O
and O
500 O
mg O
doses O
were O
gastrointestinal O
( O
1.4 O
% O
) O
, O
primarily O
nausea B-OSE_Labeled_AE
( O
0.6 O
% O
) O
; O
vomiting B-OSE_Labeled_AE
( O
0.4 O
% O
) O
; O
dizziness B-OSE_Labeled_AE
( O
0.3 O
% O
) O
; O
and O
headache B-OSE_Labeled_AE
( O
0.2 O
% O
) O
. O

The O
most O
common O
adverse O
drug O
reactions O
leading O
to O
discontinuation O
with O
the O
750 O
mg O
dose O
were O
gastrointestinal O
( O
1.2 O
% O
) O
, O
primarily O
nausea B-OSE_Labeled_AE
( O
0.6 O
% O
) O
, O
vomiting B-OSE_Labeled_AE
( O
0.5 O
% O
) O
; O
dizziness B-OSE_Labeled_AE
( O
0.3 O
% O
) O
; O
and O
headache B-OSE_Labeled_AE
( O
0.3 O
% O
) O
. O

Adverse O
reactions O
occurring O
in O
> O
=1 O
% O
of O
LEVAQUIN O
( O
r O
) O
-treated O
patients O
and O
less O
common O
adverse O
reactions O
, O
occurring O
in O
0.1 O
to O
< O
1 O
% O
of O
LEVAQUIN O
( O
r O
) O
-treated O
patients O
, O
are O
shown O
in O
Table O
4 O
and O
Table O
5 O
, O
respectively O
. O

The O
most O
common O
adverse O
drug O
reactions O
( O
> O
=3 O
% O
) O
are O
nausea B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
and O
dizziness B-OSE_Labeled_AE
. O

Table O
4 O
: O
Common O
( O
> O
=1 O
% O
) O
Adverse O
Reactions O
Reported O
in O
Clinical O
Trials O
with O
LEVAQUIN O
( O
r O
) O
System/Organ O
Class O
Adverse O
Reaction O
% O
( O
N O
= O
7537 O
) O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
moniliasis B-OSE_Labeled_AE
1 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
insomnia B-OSE_Labeled_AE
[ O
note O
: O
N O
= O
7274 O
] O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
4 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
headache B-OSE_Labeled_AE
dizziness O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
63 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
dyspnea B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
1 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
nausea B-OSE_Labeled_AE
7 O
diarrhea B-OSE_Labeled_AE
5 O
constipation B-OSE_Labeled_AE
3 O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
2 O
vomiting B-OSE_Labeled_AE
2 O
dyspepsia B-OSE_Labeled_AE
2 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
rash B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
pruritus B-OSE_Labeled_AE
21 O
Reproductive B-NonOSE_AE
System I-NonOSE_AE
and I-NonOSE_AE
Breast I-NonOSE_AE
Disorders I-NonOSE_AE
vaginitis B-OSE_Labeled_AE
1 O
[ O
note O
: O
N O
= O
3758 O
( O
women O
) O
] O
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
edema B-OSE_Labeled_AE
1 O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
1 O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
1 O
Table O
5 O
: O
Less O
Common O
( O
0.1 O
to O
1 O
% O
) O
Adverse O
Reactions O
Reported O
in O
Clinical O
Trials O
with O
LEVAQUIN O
( O
r O
) O
( O
N O
= O
7537 O
) O
System/Organ O
Class O
Adverse O
Reaction O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
genital B-OSE_Labeled_AE
moniliasis I-OSE_Labeled_AE
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
anemia B-OSE_Labeled_AE
thrombocytopeniagranulocytopenia O
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
Immune B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
allergic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
, O
5.7 O
) O
] O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
hyperglycemia B-OSE_Labeled_AE
hypoglycemia O
[ O
see O
Warnings O
and O
Precautions O
( O
5.12 O
) O
] O
hyperkalemia B-OSE_Labeled_AE
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
anxiety B-OSE_Labeled_AE
agitationconfusiondepressionhallucinationnightmare O
[ O
note O
: O
N O
= O
7274 O
] O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
sleep B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
anorexiaabnormal O
dreaming O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
tremor B-OSE_Labeled_AE
convulsions O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
paresthesia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
vertigo B-OSE_Labeled_AE
hypertoniahyperkinesiasabnormal O
gaitsomnolencesyncope O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
epistaxis B-OSE_Labeled_AE
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
palpitationventricular O
tachycardiaventricular O
arrhythmia O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
phlebitis B-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
gastritis B-OSE_Labeled_AE
stomatitispancreatitisesophagitisgastroenteritisglossitispseudomembranous/ O
C B-OSE_Labeled_AE
. I-OSE_Labeled_AE
difficile I-OSE_Labeled_AE
colitis I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
Hepatobiliary B-NonOSE_AE
Disorders I-NonOSE_AE
abnormal B-OSE_Labeled_AE
hepatic I-OSE_Labeled_AE
function I-OSE_Labeled_AE
increased O
hepatic O
enzymesincreased O
alkaline O
phosphatase O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
urticaria B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
arthralgia B-OSE_Labeled_AE
tendinitis O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
myalgia B-OSE_Labeled_AE
skeletal O
pain O
Renal B-NonOSE_AE
and I-NonOSE_AE
Urinary I-NonOSE_AE
Disorders I-NonOSE_AE
abnormal B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
function I-OSE_Labeled_AE
acute O
renal O
failure O
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
In O
clinical O
trials O
using O
multiple-dose O
therapy O
, O
ophthalmologic B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
, O
including O
cataracts B-OSE_Labeled_AE
and O
multiple B-OSE_Labeled_AE
punctate I-OSE_Labeled_AE
lenticular I-OSE_Labeled_AE
opacities I-OSE_Labeled_AE
, O
have O
been O
noted O
in O
patients O
undergoing O
treatment O
with O
quinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
. O

The O
relationship O
of O
the O
drugs O
to O
these O
events O
is O
not O
presently O
established O
. O

6.3 O
Postmarketing O
Experience O
Table O
6 O
lists O
adverse O
reactions O
that O
have O
been O
identified O
during O
post-approval O
use O
of O
LEVAQUIN O
( O
r O
) O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Table O
6 O
: O
Postmarketing O
Reports O
Of O
Adverse O
Drug O
Reactions O
System/Organ O
Class O
Adverse O
Reaction O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
pancytopenia B-OSE_Labeled_AE
aplastic O
anemialeukopeniahemolytic O
anemia O
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
eosinophilia B-OSE_Labeled_AE
Immune B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
sometimes O
fatal B-NonOSE_AE
including O
: O
anaphylactic B-OSE_Labeled_AE
/anaphylactoid O
reactions I-OSE_Labeled_AE
anaphylactic B-OSE_Labeled_AE
shock I-OSE_Labeled_AE
angioneurotic B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
serum B-OSE_Labeled_AE
sickness I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
, O
5.7 O
) O
] O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
psychosis B-OSE_Labeled_AE
paranoiaisolated O
reports O
of O
suicidal B-OSE_Labeled_AE
ideation I-OSE_Labeled_AE
, O
suicide B-OSE_Labeled_AE
attempt I-OSE_Labeled_AE
and O
completed B-OSE_Labeled_AE
suicide I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
exacerbation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
myasthenia I-OSE_Labeled_AE
gravis I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
anosmia B-OSE_Labeled_AE
ageusiaparosmiadysgeusiaperipheral O
neuropathy O
( O
may O
be O
irreversible O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
isolated O
reports O
of O
encephalopathy B-OSE_Labeled_AE
abnormal O
electroencephalogram O
( O
EEG O
) O
dysphonia B-OSE_Labeled_AE
pseudotumor O
cerebri O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
uveitis B-OSE_Labeled_AE
vision O
disturbance O
, O
including O
diplopia B-OSE_Labeled_AE
visual O
acuity B-OSE_Labeled_AE
reduced I-OSE_Labeled_AE
vision O
blurredscotoma O
Ear B-NonOSE_AE
and I-NonOSE_AE
Labyrinth I-NonOSE_AE
Disorders I-NonOSE_AE
hypoacusis B-OSE_Labeled_AE
tinnitus O
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
isolated O
reports O
of O
torsade B-OSE_Labeled_AE
de I-OSE_Labeled_AE
pointes I-OSE_Labeled_AE
electrocardiogram O
QT O
prolonged O
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
tachycardia B-OSE_Labeled_AE
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
vasodilatation B-OSE_Labeled_AE
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
isolated O
reports O
of O
allergic B-OSE_Labeled_AE
pneumonitis I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
Hepatobiliary B-NonOSE_AE
Disorders I-NonOSE_AE
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
including O
fatal B-NonOSE_AE
cases O
) O
hepatitis B-OSE_Labeled_AE
jaundice O
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
, O
( O
5.8 O
) O
] O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
bullous B-OSE_Labeled_AE
eruptions I-OSE_Labeled_AE
to O
include O
: O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
Acute O
Generalized O
Exanthematous O
Pustulosis O
( O
AGEP O
) O
fixed B-OSE_Labeled_AE
drug I-OSE_Labeled_AE
eruptions I-OSE_Labeled_AE
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
photosensitivity B-OSE_Labeled_AE
/ O
phototoxicity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.13 O
) O
] O
leukocytoclastic B-OSE_Labeled_AE
vasculitis I-OSE_Labeled_AE
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
tendon B-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
muscle B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
, O
including O
rupture O
rhabdomyolysis B-OSE_Labeled_AE
Renal B-NonOSE_AE
and I-NonOSE_AE
Urinary I-NonOSE_AE
Disorders I-NonOSE_AE
interstitial B-OSE_Labeled_AE
nephritis I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
multi B-OSE_Labeled_AE
- I-OSE_Labeled_AE
organ I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
pyrexia O
Investigations B-NonOSE_AE
prothrombin B-OSE_Labeled_AE
time I-OSE_Labeled_AE
prolonged I-OSE_Labeled_AE
international O
normalized O
ratio O
prolongedmuscle O
enzymes O
increased O

BOXED O
WARNING O
: O
WARNING O
: O
SERIOUS O
ADVERSE O
REACTIONS O
INCLUDING O
TENDINITIS O
, O
TENDON O
RUPTURE O
, O
PERIPHERAL O
NEUROPATHY O
, O
CENTRAL O
NERVOUS O
SYSTEM O
EFFECTS O
AND O
EXACERBATION O
OF O
MYASTHENIA O
GRAVIS O
WARNING O
: O
SERIOUS O
ADVERSE O
REACTIONS O
INCLUDING O
TENDINITIS O
, O
TENDON O
RUPTURE O
, O
PERIPHERAL O
NEUROPATHY O
, O
CENTRAL O
NERVOUS O
SYSTEM O
EFFECTS O
AND O
EXACERBATION B-OSE_Labeled_AE
OF I-OSE_Labeled_AE
MYASTHENIA I-OSE_Labeled_AE
GRAVIS I-OSE_Labeled_AE
* O
Fluoroquinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
, O
have O
been O
associated O
with O
disabling O
and O
potentially O
irreversible O
serious O
adverse O
reactions O
that O
have O
occurred O
together O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
, O
including O
: O
Tendinitis B-OSE_Labeled_AE
and O
tendon B-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
Peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
Central B-OSE_Labeled_AE
nervous I-OSE_Labeled_AE
system I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
Discontinue O
LEVAQUIN O
immediately O
and O
avoid O
the O
use O
of O
fluoroquinolones O
, O
including O
LEVAQUIN O
, O
in O
patients O
who O
experience O
any O
of O
these O
serious O
adverse O
reactions O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Fluoroquinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
, O
may O
exacerbate B-OSE_Labeled_AE
muscle I-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
in O
patients O
with O
myasthenia B-Not_AE_Candidate
gravis I-Not_AE_Candidate
. O

Avoid O
LEVAQUIN O
( O
r O
) O
in O
patients O
with O
a O
known O
history O
of O
myasthenia B-Not_AE_Candidate
gravis I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

* O
Because O
fluoroquinolones O
, O
including O
LEVAQUIN O
, O
have O
been O
associated O
with O
serious O
adverse O
reactions O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1-5.14 O
) O
] O
, O
reserve O
LEVAQUIN O
for O
use O
in O
patients O
who O
have O
no O
alternative O
treatment O
options O
for O
the O
following O
indications O
: O
Uncomplicated O
urinary B-Not_AE_Candidate
tract I-Not_AE_Candidate
infection I-Not_AE_Candidate
[ O
see O
Indications O
and O
Usage O
( O
1.12 O
) O
] O
Acute B-Not_AE_Candidate
bacterial I-Not_AE_Candidate
exacerbation I-Not_AE_Candidate
of I-Not_AE_Candidate
chronic I-Not_AE_Candidate
bronchitis I-Not_AE_Candidate
[ O
see O
Indications O
and O
Usage O
( O
1.13 O
) O
] O
Acute B-Not_AE_Candidate
bacterial I-Not_AE_Candidate
sinusitis I-Not_AE_Candidate
[ O
see O
Indications O
and O
Usage O
( O
1.14 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
SERIOUS O
ADVERSE O
REACTIONS O
INCLUDING O
TENDINITIS O
, O
TENDON O
RUPTURE O
, O
PERIPHERAL O
NEUROPATHY O
, O
CENTRAL O
NERVOUS O
SYSTEM O
EFFECTS O
AND O
EXACERBATION O
OF O
MYASTHENIA O
GRAVIS O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

Fluoroquinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
, O
have O
been O
associated O
with O
disabling O
and O
potentially O
irreversible O
serious O
adverse O
reactions O
that O
have O
occurred O
together O
( O
5.1 O
) O
, O
including O
: O
* O
Tendinitis O
and O
tendon O
rupture O
( O
5.2 O
) O
* O
Peripheral O
neuropathy O
( O
5.3 O
) O
* O
Central O
nervous O
system O
effects O
( O
5.4 O
) O
Discontinue O
LEVAQUIN O
immediately O
and O
avoid O
the O
use O
of O
fluoroquinolones O
, O
including O
LEVAQUIN O
, O
in O
patients O
who O
experience O
any O
of O
these O
serious O
adverse O
reactions O
( O
5.1 O
) O
Fluoroquinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
, O
may O
exacerbate O
muscle O
weakness O
in O
patients O
with O
myasthenia O
gravis O
. O

Avoid O
LEVAQUIN O
( O
r O
) O
in O
patients O
with O
a O
known O
history O
of O
myasthenia O
gravis O
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

Because O
fluoroquinolones O
, O
including O
LEVAQUIN O
, O
have O
been O
associated O
with O
serious O
adverse O
reactions O
( O
5.1-5.14 O
) O
, O
reserve O
LEVAQUIN O
for O
use O
in O
patients O
who O
have O
no O
alternative O
treatment O
options O
for O
the O
following O
indications O
: O
* O
Uncomplicated O
urinary O
tract O
infection O
( O
1.12 O
) O
* O
Acute O
bacterial O
exacerbation O
of O
chronic O
bronchitis O
( O
1.13 O
) O
* O
Acute O
bacterial O
sinusitis O
( O
1.14 O
) O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Anaphylactic O
reactions O
and O
allergic O
skin O
reactions O
, O
serious O
, O
occasionally O
fatal O
, O
may O
occur O
after O
first O
dose O
( O
4 O
, O
5.7 O
) O
* O
Hematologic O
( O
including O
agranulocytosis O
, O
thrombocytopenia O
) O
, O
and O
renal O
toxicities O
may O
occur O
after O
multiple O
doses O
( O
5.6 O
) O
* O
Hepatotoxicity O
: O
Severe O
, O
and O
sometimes O
fatal O
, O
hepatotoxicity O
has O
been O
reported O
. O

Discontinue O
immediately O
if O
signs O
and O
symptoms O
of O
hepatitis O
occur O
( O
5.8 O
) O
* O
Clostridium O
difficile O
-associated O
colitis O
: O
evaluate O
if O
diarrhea O
occurs O
( O
5.9 O
) O
* O
Prolongation O
of O
the O
QT O
interval O
and O
isolated O
cases O
of O
torsade O
de O
pointes O
have O
been O
reported O
. O

Avoid O
use O
in O
patients O
with O
known O
prolongation O
, O
those O
with O
hypokalemia O
, O
and O
with O
other O
drugs O
that O
prolong O
the O
QT O
interval O
( O
5.10 O
, O
8.5 O
) O
5.1 O
Disabling O
and O
Potentially O
Irreversible O
Serious O
Adverse O
Reactions O
Including O
Tendinitis O
and O
Tendon O
Rupture O
, O
Peripheral O
Neuropathy O
, O
and O
Central O
Nervous O
System O
Effects O
Fluoroquinolones O
, O
including O
LEVAQUIN O
, O
have O
been O
associated O
with O
disabling O
and O
potentially O
irreversible O
serious O
adverse O
reactions O
from O
different O
body O
systems O
that O
can O
occur O
together O
in O
the O
same O
patient O
. O

Commonly O
seen O
adverse O
reactions O
include O
tendinitis B-OSE_Labeled_AE
, O
tendon B-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
and O
central B-OSE_Labeled_AE
nervous I-OSE_Labeled_AE
system I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
( O
hallucinations B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
severe O
headaches B-OSE_Labeled_AE
, O
and O
confusion B-OSE_Labeled_AE
) O
. O

These O
reactions O
can O
occur O
within O
hours O
to O
weeks O
after O
starting O
LEVAQUIN O
. O

Patients O
of O
any O
age O
or O
without O
pre-existing O
risk O
factors O
have O
experienced O
these O
adverse O
reactions O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
, O
5.3 O
, O
5.4 O
) O
] O
. O

Discontinue O
LEVAQUIN O
immediately O
at O
the O
first O
signs O
or O
symptoms O
of O
any O
serious O
adverse O
reaction O
. O

In O
addition O
, O
avoid O
the O
use O
of O
fluoroquinolones O
, O
including O
LEVAQUIN O
, O
in O
patients O
who O
have O
experienced O
any O
of O
these O
serious O
adverse O
reactions O
associated O
with O
fluoroquinolones O
. O

5.2 O
Tendinitis O
and O
Tendon O
Rupture O
Fluoroquinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
, O
have O
been O
associated O
with O
an O
increased O
risk O
of O
tendinitis B-OSE_Labeled_AE
and O
tendon B-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
in O
all O
ages O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
and O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

This O
adverse O
reaction O
most O
frequently O
involves O
the O
Achilles O
tendon O
And O
has O
also O
been O
reported O
with O
the O
rotator O
cuff O
( O
the O
shoulder O
) O
, O
the O
hand O
, O
the O
biceps O
, O
the O
thumb O
, O
and O
other O
tendon O
sites O
. O

Tendinitis B-OSE_Labeled_AE
or O
tendon B-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
can O
occur O
within O
hours O
or O
days O
of O
starting O
LEVAQUIN O
or O
as O
long O
as O
several O
months O
after O
completion O
of O
fluoroquinolone O
therapy O
. O

Tendinitis B-OSE_Labeled_AE
and O
tendon B-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
can O
occur O
bilaterally O
. O

The O
risk O
of O
developing O
fluoroquinolone B-OSE_Labeled_AE
- I-OSE_Labeled_AE
associated I-OSE_Labeled_AE
tendinitis I-OSE_Labeled_AE
and O
tendon B-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
is O
increased O
in O
patients O
over O
60 O
years O
of O
age O
, O
in O
those O
taking O
corticosteroid O
drugs O
, O
and O
in O
patients O
with O
kidney O
, O
heart O
or O
lung O
transplants O
. O

Other O
factors O
that O
may O
independently O
increase O
the O
risk O
of O
tendon B-NonOSE_AE
rupture I-NonOSE_AE
include O
strenuous O
physical O
activity O
, O
renal B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
and O
previous O
tendon B-Not_AE_Candidate
disorders I-Not_AE_Candidate
such O
as O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
. O

Tendinitis B-OSE_Labeled_AE
and O
tendon B-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
taking O
fluoroquinolones O
who O
do O
not O
have O
the O
above O
risk O
factors O
. O

Discontinue O
LEVAQUIN O
( O
r O
) O
immediately O
if O
the O
patient O
experiences O
pain B-NonOSE_AE
, O
swelling O
, O
inflammation O
or O
rupture O
of I-NonOSE_AE
a I-NonOSE_AE
tendon I-NonOSE_AE
. O

Patients O
should O
be O
advised O
to O
rest O
at O
the O
first O
sign O
of O
tendinitis B-NonOSE_AE
or O
tendon B-NonOSE_AE
rupture I-NonOSE_AE
, O
and O
to O
contact O
their O
healthcare O
provider O
regarding O
changing O
to O
a O
non-quinolone O
antimicrobial O
drug O
. O

Avoid O
LEVAQUIN O
in O
patients O
who O
have O
a O
history O
of O
tendon B-Not_AE_Candidate
disorders I-Not_AE_Candidate
or O
tendon B-Not_AE_Candidate
rupture I-Not_AE_Candidate
[ O
see O
Adverse O
Reactions O
( O
6.3 O
) O
; O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.3 O
Peripheral O
Neuropathy O
Fluoroquinolones O
, O
including O
LEVAQUIN O
, O
have O
been O
associated O
with O
an O
increased O
risk O
of O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
. O

Cases O
of O
sensory B-OSE_Labeled_AE
or O
sensorimotor O
axonal I-OSE_Labeled_AE
polyneuropathy I-OSE_Labeled_AE
affecting O
small O
and/or O
large O
axons O
resulting O
in O
paresthesias B-NonOSE_AE
, O
hypoesthesias B-NonOSE_AE
, O
dysesthesias B-NonOSE_AE
and O
weakness B-NonOSE_AE
have O
been O
reported O
in O
patients O
receiving O
fluoroquinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
. O

Symptoms O
may O
occur O
soon O
after O
initiation O
of O
LEVAQUIN O
( O
r O
) O
and O
may O
be O
irreversible O
in O
some O
patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
, O
6.2 O
) O
] O
. O

Discontinue O
LEVAQUIN O
( O
r O
) O
immediately O
if O
the O
patient O
experiences O
symptoms O
of O
neuropathy B-NonOSE_AE
including O
pain B-NonOSE_AE
, O
burning B-NonOSE_AE
, O
tingling B-NonOSE_AE
, O
numbness B-NonOSE_AE
, O
and/or O
weakness B-NonOSE_AE
or O
other O
alterations B-NonOSE_AE
of I-NonOSE_AE
sensation I-NonOSE_AE
including O
light O
touch O
, O
pain O
, O
temperature O
, O
position O
sense O
, O
and O
vibratory B-NonOSE_AE
sensation I-NonOSE_AE
. O

Avoid O
fluoroquinolones O
, O
including O
LEVAQUIN O
, O
in O
patients O
who O
have O
previously O
experienced O
peripheral B-Not_AE_Candidate
neuropathy I-Not_AE_Candidate
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
, O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.4 O
Central O
Nervous O
System O
Effects O
Fluoroquinolones O
, O
including O
LEVAQUIN O
, O
have O
been O
associated O
with O
an O
increased O
risk O
of O
central B-OSE_Labeled_AE
nervous I-OSE_Labeled_AE
system I-OSE_Labeled_AE
( I-OSE_Labeled_AE
CNS I-OSE_Labeled_AE
) I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
, O
including O
convulsions B-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
psychoses I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
intracranial I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
( O
including O
pseudotumor B-OSE_Labeled_AE
cerebri I-OSE_Labeled_AE
) O
. O

Fluoroquinolones O
may O
also O
cause O
central B-OSE_Labeled_AE
nervous I-OSE_Labeled_AE
system I-OSE_Labeled_AE
stimulation I-OSE_Labeled_AE
which O
may O
lead O
to O
tremors B-OSE_Labeled_AE
, O
restlessness B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
lightheadedness B-OSE_Labeled_AE
, O
confusion B-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
, O
paranoia B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
nightmares B-OSE_Labeled_AE
, O
and O
insomnia B-OSE_Labeled_AE
. O

Suicidal B-OSE_Labeled_AE
thoughts I-OSE_Labeled_AE
, O
and O
attempted B-OSE_Labeled_AE
or I-OSE_Labeled_AE
completed I-OSE_Labeled_AE
suicide I-OSE_Labeled_AE
may O
also O
occur O
, O
especially O
in O
patients O
with O
a O
medical O
history O
of O
depression B-Not_AE_Candidate
, O
or O
an O
underlying O
risk O
factor O
for O
depression B-Not_AE_Candidate
. O

These O
reactions O
may O
occur O
following O
the O
first O
dose O
. O

If O
these O
reactions O
occur O
in O
patients O
receiving O
LEVAQUIN O
( O
r O
) O
, O
discontinue O
LEVAQUIN O
and O
institute O
appropriate O
measures O
. O

As O
with O
other O
fluoroquinolones O
, O
LEVAQUIN O
( O
r O
) O
should O
be O
used O
with O
caution O
in O
patients O
with O
a O
known O
or O
suspected O
central B-Not_AE_Candidate
nervous I-Not_AE_Candidate
system I-Not_AE_Candidate
( I-Not_AE_Candidate
CNS I-Not_AE_Candidate
) I-Not_AE_Candidate
disorder I-Not_AE_Candidate
that O
may O
predispose O
them O
to O
seizures B-NonOSE_AE
or O
lower B-NonOSE_AE
the I-NonOSE_AE
seizure I-NonOSE_AE
threshold I-NonOSE_AE
( O
e.g. O
, O
severe O
cerebral B-Not_AE_Candidate
arteriosclerosis I-Not_AE_Candidate
, O
epilepsy B-Not_AE_Candidate
) O
or O
in O
the O
presence O
of O
other O
risk O
factors O
that O
may O
predispose O
them O
to O
seizures B-Not_AE_Candidate
or O
lower B-Not_AE_Candidate
the I-Not_AE_Candidate
seizure I-Not_AE_Candidate
threshold I-Not_AE_Candidate
( O
e.g. O
, O
certain O
drug O
therapy O
, O
renal B-Not_AE_Candidate
dysfunction I-Not_AE_Candidate
) O
. O

[ O
see O
Adverse O
Reactions O
( O
6 O
) O
; O
Drug O
Interactions O
( O
7.4 O
, O
7.5 O
) O
; O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.5 O
Exacerbation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Myasthenia I-OSE_Labeled_AE
Gravis I-OSE_Labeled_AE
Fluoroquinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
, O
have O
neuromuscular O
blocking O
activity O
and O
may O
exacerbate B-OSE_Labeled_AE
muscle I-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
in O
patients O
with O
myasthenia B-Not_AE_Candidate
gravis I-Not_AE_Candidate
. O

Postmarketing O
serious O
adverse O
reactions O
including O
deaths B-NonOSE_AE
and O
requirement O
for O
ventilatory O
support O
, O
have O
been O
associated O
with O
fluoroquinolone O
use O
in O
patients O
with O
myasthenia B-Not_AE_Candidate
gravis I-Not_AE_Candidate
. O

Avoid O
LEVAQUIN O
( O
r O
) O
in O
patients O
with O
a O
known O
history O
of O
myasthenia B-Not_AE_Candidate
gravis I-Not_AE_Candidate
[ O
see O
Adverse O
Reactions O
( O
6.3 O
) O
; O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.6 O
Other O
Serious O
and O
Sometimes O
Fatal O
Adverse O
Reactions O
Other O
serious O
and O
sometimes O
fatal B-NonOSE_AE
adverse O
reactions O
, O
some O
due O
to O
hypersensitivity B-OSE_Labeled_AE
, O
and O
some O
due O
to O
uncertain O
etiology O
, O
have O
been O
reported O
rarely O
in O
patients O
receiving O
therapy O
with O
fluoroquinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
. O

These O
events O
may O
be O
severe O
and O
generally O
occur O
following O
the O
administration O
of O
multiple O
doses O
. O

Clinical O
manifestations O
may O
include O
one O
or O
more O
of O
the O
following O
: O
* O
fever B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
or O
severe O
dermatologic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
e.g. O
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
) O
; O
* O
vasculitis B-OSE_Labeled_AE
; O
arthralgia B-OSE_Labeled_AE
; O
myalgia B-OSE_Labeled_AE
; O
serum B-OSE_Labeled_AE
sickness I-OSE_Labeled_AE
; O
* O
allergic B-OSE_Labeled_AE
pneumonitis I-OSE_Labeled_AE
; O
* O
interstitial B-OSE_Labeled_AE
nephritis I-OSE_Labeled_AE
; O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
insufficiency O
or O
failure I-OSE_Labeled_AE
; O
* O
hepatitis B-OSE_Labeled_AE
; O
jaundice B-OSE_Labeled_AE
; O
acute B-OSE_Labeled_AE
hepatic I-OSE_Labeled_AE
necrosis O
or O
failure I-OSE_Labeled_AE
; O
* O
anemia B-OSE_Labeled_AE
, O
including O
hemolytic B-OSE_Labeled_AE
and O
aplastic B-OSE_Labeled_AE
; O
thrombocytopenia B-OSE_Labeled_AE
, O
including O
thrombotic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
; O
leukopenia B-OSE_Labeled_AE
; O
agranulocytosis B-OSE_Labeled_AE
; O
pancytopenia B-OSE_Labeled_AE
; O
and/or O
other O
hematologic B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
. O

Discontinue O
LEVAQUIN O
immediately O
at O
the O
first O
appearance O
of O
skin B-NonOSE_AE
rash I-NonOSE_AE
, O
jaundice B-NonOSE_AE
, O
or O
any O
other O
sign O
of O
hypersensitivity B-NonOSE_AE
and O
institute O
supportive O
measures O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
; O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.7 O
Hypersensitivity O
Reactions O
Serious O
and O
occasionally O
fatal B-NonOSE_AE
hypersensitivity B-OSE_Labeled_AE
and/or O
anaphylactic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
receiving O
therapy O
with O
fluoroquinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
. O

These O
reactions O
often O
occur O
following O
the O
first O
dose O
. O

Some O
reactions O
have O
been O
accompanied O
by O
cardiovascular B-NonOSE_AE
collapse I-NonOSE_AE
, O
hypotension B-NonOSE_AE
/ O
shock B-NonOSE_AE
, O
seizure B-NonOSE_AE
, O
loss B-NonOSE_AE
of I-NonOSE_AE
consciousness I-NonOSE_AE
, O
tingling B-NonOSE_AE
, O
angioedema B-NonOSE_AE
( O
including O
tongue B-NonOSE_AE
, O
laryngeal O
, O
throat O
, O
or O
facial O
edema/ O
swelling I-NonOSE_AE
) O
, O
airway B-NonOSE_AE
obstruction I-NonOSE_AE
( O
including O
bronchospasm B-NonOSE_AE
, O
shortness B-NonOSE_AE
of I-NonOSE_AE
breath I-NonOSE_AE
, O
and O
acute B-NonOSE_AE
respiratory I-NonOSE_AE
distress I-NonOSE_AE
) O
, O
dyspnea B-NonOSE_AE
, O
urticaria B-NonOSE_AE
, O
itching B-NonOSE_AE
, O
and O
other O
serious O
skin B-NonOSE_AE
reactions I-NonOSE_AE
. O

LEVAQUIN O
( O
r O
) O
should O
be O
discontinued O
immediately O
at O
the O
first O
appearance O
of O
a O
skin B-NonOSE_AE
rash I-NonOSE_AE
or O
any O
other O
sign O
of O
hypersensitivity B-NonOSE_AE
. O

Serious O
acute O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
may O
require O
treatment O
with O
epinephrine O
and O
other O
resuscitative O
measures O
, O
including O
oxygen O
, O
intravenous O
fluids O
, O
antihistamines O
, O
corticosteroids O
, O
pressor O
amines O
, O
and O
airway O
management O
, O
as O
clinically O
indicated O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
; O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.8 O
Hepatotoxicity O
Post-marketing O
reports O
of O
severe O
hepatotoxicity B-OSE_Labeled_AE
( O
including O
acute B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
and O
fatal B-NonOSE_AE
events O
) O
have O
been O
received O
for O
patients O
treated O
with O
LEVAQUIN O
( O
r O
) O
. O

No O
evidence O
of O
serious O
drug B-NonOSE_AE
- I-NonOSE_AE
associated I-NonOSE_AE
hepatotoxicity I-NonOSE_AE
was O
detected O
in O
clinical O
trials O
of O
over O
7,000 O
patients O
. O

Severe O
hepatotoxicity B-OSE_Labeled_AE
generally O
occurred O
within O
14 O
days O
of O
initiation O
of O
therapy O
and O
most O
cases O
occurred O
within O
6 O
days O
. O

Most O
cases O
of O
severe O
hepatotoxicity B-NonOSE_AE
were O
not O
associated O
with O
hypersensitivity B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
. O

The O
majority O
of O
fatal B-NonOSE_AE
hepatotoxicity B-NonOSE_AE
reports O
occurred O
in O
patients O
65 O
years O
of O
age O
or O
older O
and O
most O
were O
not O
associated O
with O
hypersensitivity B-NonOSE_AE
. O

LEVAQUIN O
( O
r O
) O
should O
be O
discontinued O
immediately O
if O
the O
patient O
develops O
signs O
and O
symptoms O
of O
hepatitis B-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
; O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.9 O
Clostridium O
difficile-Associated O
Diarrhea O
Clostridium B-OSE_Labeled_AE
difficile I-OSE_Labeled_AE
- I-OSE_Labeled_AE
associated I-OSE_Labeled_AE
diarrhea I-OSE_Labeled_AE
( I-OSE_Labeled_AE
CDAD I-OSE_Labeled_AE
) O
has O
been O
reported O
with O
use O
of O
nearly O
all O
antibacterial O
agents O
, O
including O
LEVAQUIN O
( O
r O
) O
, O
and O
may O
range O
in O
severity O
from O
mild O
diarrhea B-OSE_Labeled_AE
to O
fatal B-NonOSE_AE
colitis B-OSE_Labeled_AE
. O

Treatment O
with O
antibacterial O
agents O
alters B-NonOSE_AE
the I-NonOSE_AE
normal I-NonOSE_AE
flora I-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
colon I-NonOSE_AE
leading O
to O
overgrowth B-NonOSE_AE
of I-NonOSE_AE
C I-NonOSE_AE
. I-NonOSE_AE
difficile I-NonOSE_AE
. O

C B-NonOSE_AE
. I-NonOSE_AE
difficile I-NonOSE_AE
produces O
toxins O
A O
and O
B O
which O
contribute O
to O
the O
development O
of O
CDAD B-NonOSE_AE
. O

Hypertoxin O
producing O
strains O
of O
C B-NonOSE_AE
. I-NonOSE_AE
difficile I-NonOSE_AE
cause O
increased O
morbidity O
and O
mortality B-NonOSE_AE
, O
as O
these O
infections B-NonOSE_AE
can O
be O
refractory O
to O
antimicrobial O
therapy O
and O
may O
require O
colectomy O
. O

CDAD B-NonOSE_AE
must O
be O
considered O
in O
all O
patients O
who O
present O
with O
diarrhea B-NonOSE_AE
following O
antibiotic O
use O
. O

Careful O
medical O
history O
is O
necessary O
since O
CDAD B-NonOSE_AE
has O
been O
reported O
to O
occur O
over O
two O
months O
after O
the O
administration O
of O
antibacterial O
agents O
. O

If O
CDAD B-NonOSE_AE
is O
suspected O
or O
confirmed O
, O
ongoing O
antibiotic O
use O
not O
directed O
against O
C B-NonOSE_AE
. I-NonOSE_AE
difficile I-NonOSE_AE
may O
need O
to O
be O
discontinued O
. O

Appropriate O
fluid O
and O
electrolyte O
management O
, O
protein O
supplementation O
, O
antibiotic O
treatment O
of O
C B-NonOSE_AE
. I-NonOSE_AE
difficile I-NonOSE_AE
, O
and O
surgical O
evaluation O
should O
be O
instituted O
as O
clinically O
indicated O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
, O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.10 O
Prolongation O
of O
the O
QT O
Interval O
Some O
fluoroquinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
, O
have O
been O
associated O
with O
prolongation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
QT I-OSE_Labeled_AE
interval I-OSE_Labeled_AE
on O
the O
electrocardiogram O
and O
infrequent O
cases O
of O
arrhythmia B-OSE_Labeled_AE
. O

Rare O
cases O
of O
torsade B-OSE_Labeled_AE
de I-OSE_Labeled_AE
pointes I-OSE_Labeled_AE
have O
been O
spontaneously O
reported O
during O
postmarketing O
surveillance O
in O
patients O
receiving O
fluoroquinolones O
, O
including O
LEVAQUIN O
( O
r O
) O
. O

LEVAQUIN O
( O
r O
) O
should O
be O
avoided O
in O
patients O
with O
known O
prolongation B-Not_AE_Candidate
of I-Not_AE_Candidate
the I-Not_AE_Candidate
QT I-Not_AE_Candidate
interval I-Not_AE_Candidate
, O
patients O
with O
uncorrected O
hypokalemia B-Not_AE_Candidate
, O
and O
patients O
receiving O
Class O
IA O
( O
quinidine O
, O
procainamide O
) O
, O
or O
Class O
III O
( O
amiodarone O
, O
sotalol O
) O
antiarrhythmic O
agents O
. O

Elderly O
patients O
may O
be O
more O
susceptible O
to O
drug B-NonOSE_AE
- I-NonOSE_AE
associated I-NonOSE_AE
effects I-NonOSE_AE
on I-NonOSE_AE
the I-NonOSE_AE
QT I-NonOSE_AE
interval I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.3 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
, O
and O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.11 O
Musculoskeletal O
Disorders O
in O
Pediatric O
Patients O
and O
Arthropathic O
Effects O
in O
Animals O
LEVAQUIN O
( O
r O
) O
is O
indicated O
in O
pediatric O
patients O
( O
6 O
months O
of O
age O
and O
older O
) O
only O
for O
the O
prevention O
of O
inhalational B-Not_AE_Candidate
anthrax I-Not_AE_Candidate
( O
post-exposure O
) O
and O
for O
plague B-Not_AE_Candidate
[ O
see O
Indications O
and O
Usage O
( O
1.7 O
, O
1.8 O
) O
] O
. O

An O
increased O
incidence O
of O
musculoskeletal B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
( O
arthralgia B-OSE_Labeled_AE
, O
arthritis B-OSE_Labeled_AE
, O
tendinopathy B-OSE_Labeled_AE
, O
and O
gait B-OSE_Labeled_AE
abnormality I-OSE_Labeled_AE
) O
compared O
to O
controls O
has O
been O
observed O
in O
pediatric O
patients O
receiving O
LEVAQUIN O
( O
r O
) O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.4 O
) O
] O
. O

In O
immature O
rats O
and O
dogs O
, O
the O
oral O
and O
intravenous O
administration O
of O
levofloxacin O
resulted O
in O
increased O
osteochondrosis B-NonOSE_AE
. O

Histopathological O
examination O
of O
the O
weight-bearing O
joints O
of O
immature O
dogs O
dosed O
with O
levofloxacin O
revealed O
persistent O
lesions B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
cartilage I-NonOSE_AE
. O

Other O
fluoroquinolones O
also O
produce O
similar O
erosions B-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
weight I-NonOSE_AE
- I-NonOSE_AE
bearing I-NonOSE_AE
joints I-NonOSE_AE
and O
other O
signs O
of O
arthropathy B-NonOSE_AE
in O
immature O
animals O
of O
various O
species O
[ O
see O
Animal O
Toxicology O
and/or O
Pharmacology O
( O
13.2 O
) O
] O
. O

5.12 O
Blood O
Glucose O
Disturbances O
As O
with O
other O
fluoroquinolones O
, O
disturbances B-OSE_Labeled_AE
of I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
, O
including O
symptomatic O
hyper B-OSE_Labeled_AE
- O
and O
hypo O
glycemia I-OSE_Labeled_AE
, O
have O
been O
reported O
with O
LEVAQUIN O
( O
r O
) O
, O
usually O
in O
diabetic O
patients O
receiving O
concomitant O
treatment O
with O
an O
oral O
hypoglycemic B-NonOSE_AE
agent I-NonOSE_AE
( O
e.g. O
, O
glyburide O
) O
or O
with O
insulin O
. O

In O
these O
patients O
, O
careful O
monitoring O
of O
blood O
glucose O
is O
recommended O
. O

If O
a O
hypoglycemic B-NonOSE_AE
reaction O
occurs O
in O
a O
patient O
being O
treated O
with O
LEVAQUIN O
( O
r O
) O
, O
LEVAQUIN O
( O
r O
) O
should O
be O
discontinued O
and O
appropriate O
therapy O
should O
be O
initiated O
immediately O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
; O
Drug O
Interactions O
( O
7.3 O
) O
; O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.13 O
Photosensitivity/Phototoxicity O
Moderate O
to O
severe O
photosensitivity B-OSE_Labeled_AE
/phototoxicity O
reactions I-OSE_Labeled_AE
, O
the O
latter O
of O
which O
may O
manifest O
as O
exaggerated O
sunburn B-NonOSE_AE
reactions I-NonOSE_AE
( O
e.g. O
, O
burning B-NonOSE_AE
, O
erythema B-NonOSE_AE
, O
exudation B-NonOSE_AE
, O
vesicles B-NonOSE_AE
, O
blistering B-NonOSE_AE
, O
edema B-NonOSE_AE
) O
involving O
areas O
exposed O
to O
light O
( O
typically O
the O
face O
, O
`` O
V O
'' O
area O
of O
the O
neck O
, O
extensor O
surfaces O
of O
the O
forearms O
, O
dorsa O
of O
the O
hands O
) O
, O
can O
be O
associated O
with O
the O
use O
of O
fluoroquinolones O
after O
sun O
or O
UV O
light O
exposure O
. O

Therefore O
, O
excessive O
exposure O
to O
these O
sources O
of O
light O
should O
be O
avoided O
. O

Drug O
therapy O
should O
be O
discontinued O
if O
photosensitivity B-NonOSE_AE
/ O
phototoxicity B-NonOSE_AE
occurs O
[ O
see O
Adverse O
Reactions O
( O
6.3 O
) O
; O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.14 O
Development O
of O
Drug O
Resistant O
Bacteria O
Prescribing O
LEVAQUIN O
( O
r O
) O
in O
the O
absence O
of O
a O
proven O
or O
strongly O
suspected O
bacterial B-NonOSE_AE
infection I-NonOSE_AE
or O
a O
prophylactic O
indication O
is O
unlikely O
to O
provide O
benefit O
to O
the O
patient O
and O
increases O
the O
risk O
of O
the O
development B-OSE_Labeled_AE
of I-OSE_Labeled_AE
drug I-OSE_Labeled_AE
- I-OSE_Labeled_AE
resistant I-OSE_Labeled_AE
bacteria I-OSE_Labeled_AE
[ O
see O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
Most O
commonly O
observed O
adverse O
reactions O
( O
incidence O
> O
= O
5 O
% O
and O
at O
least O
twice O
the O
incidence O
of O
placebo O
patients O
) O
are O
: O
insomnia O
, O
ejaculation O
disorder O
( O
primarily O
ejaculatory O
delay O
) O
, O
nausea O
, O
sweating O
increased O
, O
fatigue O
and O
somnolence O
, O
decreased O
libido O
, O
and O
anorgasmia O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Allergan O
at O
1-800- O
433-8871 O
, O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
studies O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
studies O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
studies O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Clinical O
Trial O
Data O
Sources O
Pediatrics O
( O
6 O
-17 O
years O
) O
Adverse O
events O
were O
collected O
in O
576 O
pediatric O
patients O
( O
286 O
Lexapro O
, O
290 O
placebo O
) O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
in O
double-blind O
placebo-controlled O
studies O
. O

Safety O
and O
effectiveness O
of O
Lexapro O
in O
pediatric O
patients O
less O
than O
12 O
years O
of O
age O
has O
not O
been O
established O
. O

Adults O
Adverse O
events O
information O
for O
Lexapro O
was O
collected O
from O
715 O
patients O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
who O
were O
exposed O
to O
escitalopram O
and O
from O
592 O
patients O
who O
were O
exposed O
to O
placebo O
in O
double-blind O
, O
placebo-controlled O
trials O
. O

An O
additional O
284 O
patients O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
were O
newly O
exposed O
to O
escitalopram O
in O
open-label O
trials O
. O

The O
adverse O
event O
information O
for O
Lexapro O
in O
patients O
with O
GAD B-Not_AE_Candidate
was O
collected O
from O
429 O
patients O
exposed O
to O
escitalopram O
and O
from O
427 O
patients O
exposed O
to O
placebo O
in O
double-blind O
, O
placebo-controlled O
trials O
. O

Adverse O
events O
during O
exposure O
were O
obtained O
primarily O
by O
general O
inquiry O
and O
recorded O
by O
clinical O
investigators O
using O
terminology O
of O
their O
own O
choosing O
. O

Consequently O
, O
it O
is O
not O
possible O
to O
provide O
a O
meaningful O
estimate O
of O
the O
proportion O
of O
individuals O
experiencing O
adverse O
events O
without O
first O
grouping O
similar O
types O
of O
events O
into O
a O
smaller O
number O
of O
standardized O
event O
categories O
. O

In O
the O
tables O
and O
tabulations O
that O
follow O
, O
standard O
World O
Health O
Organization O
( O
WHO O
) O
terminology O
has O
been O
used O
to O
classify O
reported O
adverse O
events O
. O

The O
stated O
frequencies O
of O
adverse O
reactions O
represent O
the O
proportion O
of O
individuals O
who O
experienced O
, O
at O
least O
once O
, O
a O
treatment-emergent O
adverse O
event O
of O
the O
type O
listed O
. O

An O
event O
was O
considered O
treatment-emergent O
if O
it O
occurred O
for O
the O
first O
time O
or O
worsened O
while O
receiving O
therapy O
following O
baseline O
evaluation O
. O

Adverse O
Events O
Associated O
with O
Discontinuation O
of O
Treatment O
Major B-Not_AE_Candidate
Depressive I-Not_AE_Candidate
Disorder I-Not_AE_Candidate
Pediatrics O
( O
6 O
-17 O
years O
) O
Adverse O
events O
were O
associated O
with O
discontinuation O
of O
3.5 O
% O
of O
286 O
patients O
receiving O
Lexapro O
and O
1 O
% O
of O
290 O
patients O
receiving O
placebo O
. O

The O
most O
common O
adverse O
event O
( O
incidence O
at O
least O
1 O
% O
for O
Lexapro O
and O
greater O
than O
placebo O
) O
associated O
with O
discontinuation O
was O
insomnia B-OSE_Labeled_AE
( O
1 O
% O
Lexapro O
, O
0 O
% O
placebo O
) O
. O

Adults O
Among O
the O
715 O
depressed B-Not_AE_Candidate
patients O
who O
received O
Lexapro O
in O
placebo-controlled O
trials O
, O
6 O
% O
discontinued O
treatment O
due O
to O
an O
adverse O
event O
, O
as O
compared O
to O
2 O
% O
of O
592 O
patients O
receiving O
placebo O
. O

In O
two O
fixed-dose O
studies O
, O
the O
rate O
of O
discontinuation O
for O
adverse O
events O
in O
patients O
receiving O
10 O
mg/day O
Lexapro O
was O
not O
significantly O
different O
from O
the O
rate O
of O
discontinuation O
for O
adverse O
events O
in O
patients O
receiving O
placebo O
. O

The O
rate O
of O
discontinuation O
for O
adverse O
events O
in O
patients O
assigned O
to O
a O
fixed O
dose O
of O
20 O
mg/day O
Lexapro O
was O
10 O
% O
, O
which O
was O
significantly O
different O
from O
the O
rate O
of O
discontinuation O
for O
adverse O
events O
in O
patients O
receiving O
10 O
mg/day O
Lexapro O
( O
4 O
% O
) O
and O
placebo O
( O
3 O
% O
) O
. O

Adverse O
events O
that O
were O
associated O
with O
the O
discontinuation O
of O
at O
least O
1 O
% O
of O
patients O
treated O
with O
Lexapro O
, O
and O
for O
which O
the O
rate O
was O
at O
least O
twice O
that O
of O
placebo O
, O
were O
nausea B-OSE_Labeled_AE
( O
2 O
% O
) O
and O
ejaculation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
( O
2 O
% O
of O
male O
patients O
) O
. O

Generalized B-Not_AE_Candidate
Anxiety I-Not_AE_Candidate
Disorder I-Not_AE_Candidate
Adults O
Among O
the O
429 O
GAD B-Not_AE_Candidate
patients O
who O
received O
Lexapro O
10-20 O
mg/day O
in O
placebo-controlled O
trials O
, O
8 O
% O
discontinued O
treatment O
due O
to O
an O
adverse O
event O
, O
as O
compared O
to O
4 O
% O
of O
427 O
patients O
receiving O
placebo O
. O

Adverse O
events O
that O
were O
associated O
with O
the O
discontinuation O
of O
at O
least O
1 O
% O
of O
patients O
treated O
with O
Lexapro O
, O
and O
for O
which O
the O
rate O
was O
at O
least O
twice O
the O
placebo O
rate O
, O
were O
nausea B-OSE_Labeled_AE
( O
2 O
% O
) O
, O
insomnia B-OSE_Labeled_AE
( O
1 O
% O
) O
, O
and O
fatigue B-OSE_Labeled_AE
( O
1 O
% O
) O
. O

Incidence O
of O
Adverse O
Reactions O
in O
Placebo-Controlled O
Clinical O
Trials O
Major B-Not_AE_Candidate
Depressive I-Not_AE_Candidate
Disorder I-Not_AE_Candidate
Pediatrics O
( O
6 O
-17 O
years O
) O
The O
overall O
profile O
of O
adverse O
reactions O
in O
pediatric O
patients O
was O
generally O
similar O
to O
that O
seen O
in O
adult O
studies O
, O
as O
shown O
in O
Table O
2 O
. O

However O
, O
the O
following O
adverse O
reactions O
( O
excluding O
those O
which O
appear O
in O
Table O
2 O
and O
those O
for O
which O
the O
coded O
terms O
were O
uninformative O
or O
misleading O
) O
were O
reported O
at O
an O
incidence O
of O
at O
least O
2 O
% O
for O
Lexapro O
and O
greater O
than O
placebo O
: O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
and O
nasal B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
. O

Adults O
The O
most O
commonly O
observed O
adverse O
reactions O
in O
Lexapro O
patients O
( O
incidence O
of O
approximately O
5 O
% O
or O
greater O
and O
approximately O
twice O
the O
incidence O
in O
placebo O
patients O
) O
were O
insomnia B-OSE_Labeled_AE
, O
ejaculation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
( O
primarily O
ejaculatory B-OSE_Labeled_AE
delay I-OSE_Labeled_AE
) O
, O
nausea B-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
and O
somnolence B-OSE_Labeled_AE
. O

Table O
2 O
enumerates O
the O
incidence O
, O
rounded O
to O
the O
nearest O
percent O
, O
of O
treatment-emergent O
adverse O
events O
that O
occurred O
among O
715 O
depressed B-Not_AE_Candidate
patients O
who O
received O
Lexapro O
at O
doses O
ranging O
from O
10 O
to O
20 O
mg/day O
in O
placebo-controlled O
trials O
. O

Events O
included O
are O
those O
occurring O
in O
2 O
% O
or O
more O
of O
patients O
treated O
with O
Lexapro O
and O
for O
which O
the O
incidence O
in O
patients O
treated O
with O
Lexapro O
was O
greater O
than O
the O
incidence O
in O
placebo-treated O
patients O
. O

TABLE O
2 O
Treatment-Emergent O
Adverse O
Reactions O
observed O
with O
a O
frequency O
of O
> O
= O
2 O
% O
and O
greater O
than O
placebo O
for O
Major O
Depressive O
Disorder O
1Primarily O
ejaculatory B-OSE_Labeled_AE
delay I-OSE_Labeled_AE
. O

2Denominator O
used O
was O
for O
males O
only O
( O
N=225 O
Lexapro O
; O
N=188 O
placebo O
) O
. O

3Denominator O
used O
was O
for O
females O
only O
( O
N=490 O
Lexapro O
; O
N=404 O
placebo O
) O
. O

Adverse O
Reaction O
Lexapro O
Placebo O
( O
N=715 O
) O
% O
( O
N=592 O
) O
% O
Autonomic B-NonOSE_AE
Nervous I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
6 O
% O
5 O
% O
Sweating B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
5 O
% O
2 O
% O
Central B-NonOSE_AE
& I-NonOSE_AE
Peripheral I-NonOSE_AE
Nervous I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
5 O
% O
3 O
% O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
15 O
% O
7 O
% O
Diarrhea B-OSE_Labeled_AE
8 O
% O
5 O
% O
Constipation B-OSE_Labeled_AE
3 O
% O
1 O
% O
Indigestion B-OSE_Labeled_AE
3 O
% O
1 O
% O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
2 O
% O
1 O
% O
General B-NonOSE_AE
Influenza B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
Symptoms I-OSE_Labeled_AE
5 O
% O
4 O
% O
Fatigue B-OSE_Labeled_AE
5 O
% O
2 O
% O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
9 O
% O
4 O
% O
Somnolence B-OSE_Labeled_AE
6 O
% O
2 O
% O
Appetite B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
3 O
% O
1 O
% O
Libido B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
3 O
% O
1 O
% O
Respiratory B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Rhinitis B-OSE_Labeled_AE
5 O
% O
4 O
% O
Sinusitis B-OSE_Labeled_AE
3 O
% O
2 O
% O
Urogenital B-NonOSE_AE
Ejaculation B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
1,2 O
9 O
% O
< O
1 O
% O
Impotence B-OSE_Labeled_AE
2 O
3 O
% O
< O
1 O
% O
Anorgasmia B-OSE_Labeled_AE
3 O
2 O
% O
< O
1 O
% O
Generalized O
Anxiety O
Disorder O
Adults O
The O
most O
commonly O
observed O
adverse O
reactions O
in O
Lexapro O
patients O
( O
incidence O
of O
approximately O
5 O
% O
or O
greater O
and O
approximately O
twice O
the O
incidence O
in O
placebo O
patients O
) O
were O
nausea B-OSE_Labeled_AE
, O
ejaculation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
( O
primarily O
ejaculatory B-OSE_Labeled_AE
delay I-OSE_Labeled_AE
) O
, O
insomnia B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
libido I-OSE_Labeled_AE
, O
and O
anorgasmia B-OSE_Labeled_AE
. O

Table O
3 O
enumerates O
the O
incidence O
, O
rounded O
to O
the O
nearest O
percent O
of O
treatment-emergent O
adverse O
events O
that O
occurred O
among O
429 O
GAD B-Not_AE_Candidate
patients O
who O
received O
Lexapro O
10 O
to O
20 O
mg/day O
in O
placebo-controlled O
trials O
. O

Events O
included O
are O
those O
occurring O
in O
2 O
% O
or O
more O
of O
patients O
treated O
with O
Lexapro O
and O
for O
which O
the O
incidence O
in O
patients O
treated O
with O
Lexapro O
was O
greater O
than O
the O
incidence O
in O
placebo-treated O
patients O
. O

TABLE O
3 O
Treatment-Emergent O
Adverse O
Reactions O
observed O
with O
a O
frequency O
of O
> O
= O
2 O
% O
and O
greater O
than O
placebo O
for O
Generalized O
Anxiety O
Disorder O
1Primarily O
ejaculatory B-OSE_Labeled_AE
delay I-OSE_Labeled_AE
. O

2Denominator O
used O
was O
for O
males O
only O
( O
N=182 O
Lexapro O
; O
N=195 O
placebo O
) O
. O

3Denominator O
used O
was O
for O
females O
only O
( O
N=247 O
Lexapro O
; O
N=232 O
placebo O
) O
. O

Adverse O
Reactions O
Lexapro O
Placebo O
( O
N=429 O
) O
% O
( O
N=427 O
) O
% O
Autonomic B-NonOSE_AE
Nervous I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
9 O
% O
5 O
% O
Sweating B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
4 O
% O
1 O
% O
Central B-NonOSE_AE
& I-NonOSE_AE
Peripheral I-NonOSE_AE
Nervous I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
24 O
% O
17 O
% O
Paresthesia B-OSE_Labeled_AE
2 O
% O
1 O
% O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
18 O
% O
8 O
% O
Diarrhea B-OSE_Labeled_AE
8 O
% O
6 O
% O
Constipation B-OSE_Labeled_AE
5 O
% O
4 O
% O
Indigestion B-OSE_Labeled_AE
3 O
% O
2 O
% O
Vomiting B-OSE_Labeled_AE
3 O
% O
1 O
% O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
2 O
% O
1 O
% O
Flatulence B-OSE_Labeled_AE
2 O
% O
1 O
% O
Toothache B-OSE_Labeled_AE
2 O
% O
0 O
% O
General B-NonOSE_AE
Fatigue B-OSE_Labeled_AE
8 O
% O
2 O
% O
Influenza B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
Symptoms I-OSE_Labeled_AE
5 O
% O
4 O
% O
Musculoskeletal B-NonOSE_AE
System I-NonOSE_AE
Disorder I-NonOSE_AE
Neck B-OSE_Labeled_AE
/Shoulder O
Pain I-OSE_Labeled_AE
3 O
% O
1 O
% O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Somnolence B-OSE_Labeled_AE
13 O
% O
7 O
% O
Insomnia B-OSE_Labeled_AE
12 O
% O
6 O
% O
Libido B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
7 O
% O
2 O
% O
Dreaming B-OSE_Labeled_AE
Abnormal I-OSE_Labeled_AE
3 O
% O
2 O
% O
Appetite B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
3 O
% O
1 O
% O
Lethargy B-OSE_Labeled_AE
3 O
% O
1 O
% O
Respiratory B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Yawning B-OSE_Labeled_AE
2 O
% O
1 O
% O
Urogenital B-NonOSE_AE
Ejaculation B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
1,2 O
14 O
% O
2 O
% O
Anorgasmia B-OSE_Labeled_AE
3 O
6 O
% O
< O
1 O
% O
Menstrual B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
2 O
% O
1 O
% O
Dose O
Dependency O
of O
Adverse O
Reactions O
The O
potential O
dose O
dependency O
of O
common O
adverse O
reactions O
( O
defined O
as O
an O
incidence O
rate O
of O
> O
=5 O
% O
in O
either O
the O
10 O
mg O
or O
20 O
mg O
Lexapro O
groups O
) O
was O
examined O
on O
the O
basis O
of O
the O
combined O
incidence O
of O
adverse O
reactions O
in O
two O
fixed-dose O
trials O
. O

The O
overall O
incidence O
rates O
of O
adverse O
events O
in O
10 O
mg O
Lexapro-treated O
patients O
( O
66 O
% O
) O
was O
similar O
to O
that O
of O
the O
placebo-treated O
patients O
( O
61 O
% O
) O
, O
while O
the O
incidence O
rate O
in O
20 O
mg/day O
Lexapro-treated O
patients O
was O
greater O
( O
86 O
% O
) O
. O

Table O
4 O
shows O
common O
adverse O
reactions O
that O
occurred O
in O
the O
20 O
mg/day O
Lexapro O
group O
with O
an O
incidence O
that O
was O
approximately O
twice O
that O
of O
the O
10 O
mg/day O
Lexapro O
group O
and O
approximately O
twice O
that O
of O
the O
placebo O
group O
. O

TABLE O
4 O
Incidence O
of O
Common O
Adverse O
Reactions O
in O
Patients O
with O
Major O
Depressive O
Disorder O
Adverse O
Reaction O
Placebo O
10 O
mg/day O
20 O
mg/day O
( O
N=311 O
) O
Lexapro O
Lexapro O
( O
N=310 O
) O
( O
N=125 O
) O
Insomnia B-OSE_Labeled_AE
4 O
% O
7 O
% O
14 O
% O
Diarrhea B-OSE_Labeled_AE
5 O
% O
6 O
% O
14 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
3 O
% O
4 O
% O
9 O
% O
Somnolence B-OSE_Labeled_AE
1 O
% O
4 O
% O
9 O
% O
Dizziness B-OSE_Labeled_AE
2 O
% O
4 O
% O
7 O
% O
Sweating B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
< O
1 O
% O
3 O
% O
8 O
% O
Constipation B-OSE_Labeled_AE
1 O
% O
3 O
% O
6 O
% O
Fatigue B-OSE_Labeled_AE
2 O
% O
2 O
% O
6 O
% O
Indigestion B-OSE_Labeled_AE
1 O
% O
2 O
% O
6 O
% O
Male O
and O
Female O
Sexual O
Dysfunction O
with O
SSRIs O
Although O
changes B-NonOSE_AE
in I-NonOSE_AE
sexual I-NonOSE_AE
desire I-NonOSE_AE
, O
sexual B-NonOSE_AE
performance I-NonOSE_AE
, O
and O
sexual B-NonOSE_AE
satisfaction I-NonOSE_AE
often O
occur O
as O
manifestations O
of O
a O
psychiatric B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
they O
may O
also O
be O
a O
consequence O
of O
pharmacologic O
treatment O
. O

In O
particular O
, O
some O
evidence O
suggests O
that O
SSRIs O
can O
cause O
such O
untoward B-OSE_Labeled_AE
sexual I-OSE_Labeled_AE
experiences I-OSE_Labeled_AE
. O

Reliable O
estimates O
of O
the O
incidence O
and O
severity O
of O
untoward B-NonOSE_AE
experiences I-NonOSE_AE
involving I-NonOSE_AE
sexual I-NonOSE_AE
desire O
, O
performance O
, O
and O
satisfaction I-NonOSE_AE
are O
difficult O
to O
obtain O
, O
however O
, O
in O
part O
because O
patients O
and O
physicians O
may O
be O
reluctant O
to O
discuss O
them O
. O

Accordingly O
, O
estimates O
of O
the O
incidence O
of O
untoward B-NonOSE_AE
sexual I-NonOSE_AE
experience O
and O
performance I-NonOSE_AE
cited O
in O
product O
labeling O
are O
likely O
to O
underestimate O
their O
actual O
incidence O
. O

TABLE O
5 O
Incidence O
of O
Sexual O
Side O
Effects O
in O
Placebo-Controlled O
Clinical O
Trials O
Adverse O
Event O
Lexapro O
Placebo O
In O
Males O
Only O
( O
N=407 O
) O
( O
N=383 O
) O
Ejaculation B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
( O
primarily O
ejaculatory B-OSE_Labeled_AE
delay I-OSE_Labeled_AE
) O
12 O
% O
1 O
% O
Libido B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
6 O
% O
2 O
% O
Impotence B-OSE_Labeled_AE
2 O
% O
< O
1 O
% O
In O
Females O
Only O
( O
N=737 O
) O
( O
N=636 O
) O
Libido B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
3 O
% O
1 O
% O
Anorgasmia B-OSE_Labeled_AE
3 O
% O
< O
1 O
% O
There O
are O
no O
adequately O
designed O
studies O
examining O
sexual B-NonOSE_AE
dysfunction I-NonOSE_AE
with O
escitalopram O
treatment O
. O

Priapism B-OSE_Labeled_AE
has O
been O
reported O
with O
all O
SSRIs O
. O

While O
it O
is O
difficult O
to O
know O
the O
precise O
risk O
of O
sexual B-NonOSE_AE
dysfunction I-NonOSE_AE
associated O
with O
the O
use O
of O
SSRIs O
, O
physicians O
should O
routinely O
inquire O
about O
such O
possible O
side O
effects O
. O

Vital O
Sign O
Changes O
Lexapro O
and O
placebo O
groups O
were O
compared O
with O
respect O
to O
( O
1 O
) O
mean O
change O
from O
baseline O
in O
vital O
signs O
( O
pulse O
, O
systolic O
blood O
pressure O
, O
and O
diastolic O
blood O
pressure O
) O
and O
( O
2 O
) O
the O
incidence O
of O
patients O
meeting O
criteria O
for O
potentially O
clinically O
significant O
changes O
from O
baseline O
in O
these O
variables O
. O

These O
analyses O
did O
not O
reveal O
any O
clinically O
important O
changes O
in O
vital O
signs O
associated O
with O
Lexapro O
treatment O
. O

In O
addition O
, O
a O
comparison O
of O
supine O
and O
standing O
vital O
sign O
measures O
in O
subjects O
receiving O
Lexapro O
indicated O
that O
Lexapro O
treatment O
is O
not O
associated O
with O
orthostatic B-NonOSE_AE
changes I-NonOSE_AE
. O

Weight O
Changes O
Patients O
treated O
with O
Lexapro O
in O
controlled O
trials O
did O
not O
differ O
from O
placebo-treated O
patients O
with O
regard O
to O
clinically O
important O
change B-NonOSE_AE
in I-NonOSE_AE
body I-NonOSE_AE
weight I-NonOSE_AE
. O

Laboratory O
Changes O
Lexapro O
and O
placebo O
groups O
were O
compared O
with O
respect O
to O
( O
1 O
) O
mean O
change O
from O
baseline O
in O
various O
serum O
chemistry O
, O
hematology O
, O
and O
urinalysis O
variables O
, O
and O
( O
2 O
) O
the O
incidence O
of O
patients O
meeting O
criteria O
for O
potentially O
clinically O
significant O
changes O
from O
baseline O
in O
these O
variables O
. O

These O
analyses O
revealed O
no O
clinically O
important O
changes B-NonOSE_AE
in I-NonOSE_AE
laboratory I-NonOSE_AE
test I-NonOSE_AE
parameters O
associated O
with O
Lexapro O
treatment O
. O

ECG B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
Electrocardiograms O
from O
Lexapro O
( O
N=625 O
) O
and O
placebo O
( O
N=527 O
) O
groups O
were O
compared O
with O
respect O
to O
outliers O
defined O
as O
subjects O
with O
QTc B-NonOSE_AE
changes I-NonOSE_AE
over I-NonOSE_AE
6 I-NonOSE_AE
0 I-NonOSE_AE
msec I-NonOSE_AE
from I-NonOSE_AE
baseline I-NonOSE_AE
or O
absolute O
values O
over O
500 O
msec O
post-dose O
, O
and O
subjects O
with O
heart B-NonOSE_AE
rate I-NonOSE_AE
increases I-NonOSE_AE
to O
over O
100 O
bpm O
or O
decreases O
to O
less O
than O
50 O
bpm O
with O
a O
25 O
% O
change O
from O
baseline O
( O
tachycardic B-NonOSE_AE
or O
bradycardic B-NonOSE_AE
outliers O
, O
respectively O
) O
. O

None O
of O
the O
patients O
in O
the O
Lexapro O
group O
had O
a O
QTcF B-NonOSE_AE
interval I-NonOSE_AE
> I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
msec I-NonOSE_AE
or O
a O
prolongation O
> O
60 O
msec O
compared O
to O
0.2 O
% O
of O
patients O
in O
the O
placebo O
group O
. O

The O
incidence O
of O
tachycardic B-NonOSE_AE
outliers O
was O
0.2 O
% O
in O
the O
Lexapro O
and O
the O
placebo O
group O
. O

The O
incidence O
of O
bradycardic B-OSE_Labeled_AE
outliers O
was O
0.5 O
% O
in O
the O
Lexapro O
group O
and O
0.2 O
% O
in O
the O
placebo O
group O
. O

QTcF O
interval O
was O
evaluated O
in O
a O
randomized O
, O
placebo O
and O
active O
( O
moxifloxacin O
400 O
mg O
) O
controlled O
cross-over O
, O
escalating O
multiple-dose O
study O
in O
113 O
healthy O
subjects O
. O

The O
maximum O
mean O
( O
95 O
% O
upper O
confidence O
bound O
) O
difference O
from O
placebo O
arm O
were O
4.5 O
( O
6.4 O
) O
and O
10.7 O
( O
12.7 O
) O
msec O
for O
10 O
mg O
and O
supratherapeutic O
30 O
mg O
escitalopram O
given O
once O
daily O
, O
respectively O
. O

Based O
on O
the O
established O
exposure-response O
relationship O
, O
the O
predicted B-OSE_Labeled_AE
QTcF I-OSE_Labeled_AE
change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
placebo I-OSE_Labeled_AE
arm I-OSE_Labeled_AE
( I-OSE_Labeled_AE
9 I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
% I-OSE_Labeled_AE
confidence I-OSE_Labeled_AE
interval I-OSE_Labeled_AE
) I-OSE_Labeled_AE
under I-OSE_Labeled_AE
the I-OSE_Labeled_AE
Cmaxfor I-OSE_Labeled_AE
the I-OSE_Labeled_AE
dose I-OSE_Labeled_AE
of I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
is I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
( I-OSE_Labeled_AE
7 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
9 I-OSE_Labeled_AE
) I-OSE_Labeled_AE
msec I-OSE_Labeled_AE
. O

Escitalopram O
30 O
mg O
given O
once O
daily O
resulted O
in O
mean O
Cmaxof O
1.7-fold O
higher O
than O
the O
mean O
Cmaxfor O
the O
maximum O
recommended O
therapeutic O
dose O
at O
steady O
state O
( O
20 O
mg O
) O
. O

The O
exposure O
under O
supratherapeutic O
30 O
mg O
dose O
is O
similar O
to O
the O
steady O
state O
concentrations O
expected O
in O
CYP2C19 O
poor O
metabolizers O
following O
a O
therapeutic O
dose O
of O
20 O
mg O
. O
Other O
Reactions O
Observed O
During O
the O
Premarketing O
Evaluation O
of O
Lexapro O
Following O
is O
a O
list O
of O
treatment-emergent O
adverse O
events O
, O
as O
defined O
in O
the O
introduction O
to O
the O
ADVERSE O
REACTIONS O
section O
, O
reported O
by O
the O
1428 O
patients O
treated O
with O
Lexapro O
for O
periods O
of O
up O
to O
one O
year O
in O
double-blind O
or O
open-label O
clinical O
trials O
during O
its O
premarketing O
evaluation O
. O

The O
listing O
does O
not O
include O
those O
events O
already O
listed O
in O
Tables O
2 O
& O
3 O
, O
those O
events O
for O
which O
a O
drug O
cause O
was O
remote O
and O
at O
a O
rate O
less O
than O
1 O
% O
or O
lower O
than O
placebo O
, O
those O
events O
which O
were O
so O
general O
as O
to O
be O
uninformative O
, O
and O
those O
events O
reported O
only O
once O
which O
did O
not O
have O
a O
substantial O
probability O
of O
being O
acutely O
life O
threatening O
. O

Events O
are O
categorized O
by O
body O
system O
. O

Events O
of O
major O
clinical O
importance O
are O
described O
in O
the O
Warnings O
and O
Precautions O
section O
( O
5 O
) O
. O

Cardiovascular B-NonOSE_AE
- O
hypertension B-OSE_Labeled_AE
, O
palpitation B-OSE_Labeled_AE
. O

Central B-NonOSE_AE
and I-NonOSE_AE
Peripheral I-NonOSE_AE
Nervous I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
- O
light B-OSE_Labeled_AE
- I-OSE_Labeled_AE
headed I-OSE_Labeled_AE
feeling I-OSE_Labeled_AE
, O
migraine B-OSE_Labeled_AE
. O

Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
- O
abdominal B-OSE_Labeled_AE
cramp I-OSE_Labeled_AE
, O
heartburn B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
. O

General B-NonOSE_AE
- O
allergy B-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
hot B-OSE_Labeled_AE
flushes I-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
limb I-OSE_Labeled_AE
. O

Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
Disorders I-NonOSE_AE
- O
increased B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
. O

Musculoskeletal B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
- O
arthralgia B-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
jaw B-OSE_Labeled_AE
stiffness I-OSE_Labeled_AE
. O

Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
- O
appetite B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
concentration B-OSE_Labeled_AE
impaired I-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
. O

Reproductive B-NonOSE_AE
Disorders I-NonOSE_AE
/ I-NonOSE_AE
Female I-NonOSE_AE
- O
menstrual B-OSE_Labeled_AE
cramps I-OSE_Labeled_AE
, O
menstrual B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
- O
bronchitis B-OSE_Labeled_AE
, O
coughing B-OSE_Labeled_AE
, O
nasal B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
, O
sinus B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
, O
sinus B-OSE_Labeled_AE
headache I-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
Disorders I-NonOSE_AE
- O
rash B-OSE_Labeled_AE
. O

Special B-NonOSE_AE
Senses I-NonOSE_AE
- O
vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
, O
tinnitus B-OSE_Labeled_AE
. O

Urinary B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
- O
urinary B-OSE_Labeled_AE
frequency I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
. O

6.2 O
Post-Marketing O
Experience O
Adverse O
Reactions O
Reported O
Subsequent O
to O
the O
Marketing O
of O
Escitalopram O
The O
following O
additional O
adverse O
reactions O
have O
been O
identified O
from O
spontaneous O
reports O
of O
escitalopram O
received O
worldwide O
. O

These O
adverse O
reactions O
have O
been O
chosen O
for O
inclusion O
because O
of O
a O
combination O
of O
seriousness O
, O
frequency O
of O
reporting O
, O
or O
potential O
causal O
connection O
to O
escitalopram O
and O
have O
not O
been O
listed O
elsewhere O
in O
labeling O
. O

However O
, O
because O
these O
adverse O
reactions O
were O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

These O
events O
include O
: O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
anemia B-OSE_Labeled_AE
, O
agranulocytis B-OSE_Labeled_AE
, O
aplastic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
hemolytic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
idiopathic B-OSE_Labeled_AE
thrombocytopenia I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
. O

Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
: O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
bradycardia B-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
, O
torsade B-OSE_Labeled_AE
de I-OSE_Labeled_AE
pointes I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
arrhythmia I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
. O

Ear B-NonOSE_AE
and I-NonOSE_AE
labyrinth I-NonOSE_AE
disorders I-NonOSE_AE
: O
vertigo B-OSE_Labeled_AE
Endocrine B-NonOSE_AE
Disorders I-NonOSE_AE
: O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
, O
hyperprolactinemia B-OSE_Labeled_AE
, O
SIADH B-OSE_Labeled_AE
. O

Eye B-NonOSE_AE
Disorders I-NonOSE_AE
: O
angle B-OSE_Labeled_AE
closure I-OSE_Labeled_AE
glaucoma I-OSE_Labeled_AE
, O
diplopia B-OSE_Labeled_AE
, O
mydriasis B-OSE_Labeled_AE
, O
visual B-OSE_Labeled_AE
disturbance I-OSE_Labeled_AE
. O

Gastrointestinal B-NonOSE_AE
Disorder I-NonOSE_AE
: O
dysphagia B-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
gastroesophageal B-OSE_Labeled_AE
reflux I-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
, O
rectal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
. O

General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
: O
abnormal B-OSE_Labeled_AE
gait I-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
fall B-OSE_Labeled_AE
, O
feeling B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
malaise B-OSE_Labeled_AE
. O

Hepatobiliary B-NonOSE_AE
Disorders I-NonOSE_AE
: O
fulminant B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
. O

Immune B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
allergic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
anaphylaxis B-OSE_Labeled_AE
. O

Investigations B-NonOSE_AE
: O
bilirubin B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
, O
electrocardiogram B-OSE_Labeled_AE
QT I-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
enzymes I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
hypercholesterolemia B-OSE_Labeled_AE
, O
INR B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
prothrombin B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
. O

Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
: O
hyperglycemia B-OSE_Labeled_AE
, O
hypoglycemia B-OSE_Labeled_AE
, O
hypokalemia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
. O

Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
muscle B-OSE_Labeled_AE
cramp I-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
stiffness I-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
, O
rhabdomyolysis B-OSE_Labeled_AE
. O

Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
akathisia B-OSE_Labeled_AE
, O
amnesia B-OSE_Labeled_AE
, O
ataxia B-OSE_Labeled_AE
, O
choreoathetosis B-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
dysarthria B-OSE_Labeled_AE
, O
dyskinesia B-OSE_Labeled_AE
, O
dystonia B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
grand B-OSE_Labeled_AE
mal I-OSE_Labeled_AE
seizures I-OSE_Labeled_AE
( O
or O
convulsions B-OSE_Labeled_AE
) O
, O
hypoaesthesia B-OSE_Labeled_AE
, O
myoclonus B-OSE_Labeled_AE
, O
nystagmus B-OSE_Labeled_AE
, O
Parkinsonism B-OSE_Labeled_AE
, O
restless B-OSE_Labeled_AE
legs I-OSE_Labeled_AE
, O
seizures B-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
, O
tardive B-OSE_Labeled_AE
dyskinesia I-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
. O

Pregnancy B-NonOSE_AE
, I-NonOSE_AE
Puerperium I-NonOSE_AE
and I-NonOSE_AE
Perinatal I-NonOSE_AE
Conditions I-NonOSE_AE
: O
spontaneous B-OSE_Labeled_AE
abortion I-OSE_Labeled_AE
. O

Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
: O
acute B-OSE_Labeled_AE
psychosis I-OSE_Labeled_AE
, O
aggression B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
anger B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
apathy B-OSE_Labeled_AE
, O
completed B-OSE_Labeled_AE
suicide I-OSE_Labeled_AE
, O
confusion B-OSE_Labeled_AE
, O
depersonalization B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
aggravated I-OSE_Labeled_AE
, O
delirium B-OSE_Labeled_AE
, O
delusion B-OSE_Labeled_AE
, O
disorientation B-OSE_Labeled_AE
, O
feeling B-OSE_Labeled_AE
unreal I-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
( I-OSE_Labeled_AE
visual O
and O
auditory I-OSE_Labeled_AE
) O
, O
mood B-OSE_Labeled_AE
swings I-OSE_Labeled_AE
, O
nervousness B-OSE_Labeled_AE
, O
nightmare B-OSE_Labeled_AE
, O
panic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
paranoia B-OSE_Labeled_AE
, O
restlessness B-OSE_Labeled_AE
, O
self B-OSE_Labeled_AE
- I-OSE_Labeled_AE
harm I-OSE_Labeled_AE
or O
thoughts B-OSE_Labeled_AE
of I-OSE_Labeled_AE
self I-OSE_Labeled_AE
- I-OSE_Labeled_AE
harm I-OSE_Labeled_AE
, O
suicide B-OSE_Labeled_AE
attempt I-OSE_Labeled_AE
, O
suicidal B-OSE_Labeled_AE
ideation I-OSE_Labeled_AE
, O
suicidal B-OSE_Labeled_AE
tendency I-OSE_Labeled_AE
. O

Renal B-NonOSE_AE
and I-NonOSE_AE
Urinary I-NonOSE_AE
Disorders I-NonOSE_AE
: O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
dysuria B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
. O

Reproductive B-NonOSE_AE
System I-NonOSE_AE
and I-NonOSE_AE
Breast I-NonOSE_AE
Disorders I-NonOSE_AE
: O
menorrhagia B-OSE_Labeled_AE
, O
priapism B-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
: O
dyspnea B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
newborn I-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
alopecia B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
dermatitis B-OSE_Labeled_AE
, O
ecchymosis B-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
photosensitivity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
. O

Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
: O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
, O
flushing B-OSE_Labeled_AE
, O
hypertensive B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
, O
phlebitis B-OSE_Labeled_AE
, O
thrombosis B-OSE_Labeled_AE
. O

BOXED O
WARNING O
: O
WARNINGS O
: O
SUICIDALITY O
AND O
ANTIDEPRESSANT O
DRUGS O
WARNINGS O
: O
SUICIDALITY O
AND O
ANTIDEPRESSANT O
DRUGS O
Antidepressants O
increased O
the O
risk O
compared O
to O
placebo O
of O
suicidal B-OSE_Labeled_AE
thinking O
and O
behavior I-OSE_Labeled_AE
( O
suicidality B-OSE_Labeled_AE
) O
in O
children O
, O
adolescents O
, O
and O
young O
adults O
in O
short-term O
studies O
of O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
and O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Anyone O
considering O
the O
use O
of O
Lexapro O
or O
any O
other O
antidepressant O
in O
a O
child O
, O
adolescent O
, O
or O
young O
adult O
must O
balance O
this O
risk O
with O
the O
clinical O
need O
. O

Short-term O
studies O
did O
not O
show O
an O
increase O
in O
the O
risk O
of O
suicidality B-NonOSE_AE
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
beyond O
age O
24 O
; O
there O
was O
a O
reduction O
in O
risk O
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
aged O
65 O
and O
older O
. O

Depression B-Not_AE_Candidate
and O
certain O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
are O
themselves O
associated O
with O
increases O
in O
the O
risk O
of O
suicide B-NonOSE_AE
. O

Patients O
of O
all O
ages O
who O
are O
started O
on O
antidepressant O
therapy O
should O
be O
monitored O
appropriately O
and O
observed O
closely O
for O
clinical O
worsening O
, O
suicidality B-NonOSE_AE
, O
or O
unusual O
changes B-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
. O

Families O
and O
caregivers O
should O
be O
advised O
of O
the O
need O
for O
close O
observation O
and O
communication O
with O
the O
prescriber O
. O

Lexapro O
is O
not O
approved O
for O
use O
in O
pediatric O
patients O
less O
than O
12 O
years O
of O
age O
. O

[ O
See O
Warnings O
and O
Precautions O
: O
Clinical O
Worsening O
and O
Suicide B-NonOSE_AE
Risk O
( O
5.1 O
) O
, O
Patient O
Counseling O
Information O
: O
Information O
for O
Patients O
( O
17.1 O
) O
, O
and O
Use O
in O
Specific O
Populations O
: O
Pediatric O
Use O
( O
8.4 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
Suicidality O
and O
Antidepressant O
Drugs O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

Increased O
risk O
of O
suicidal O
thinking O
and O
behavior O
in O
children O
, O
adolescents O
and O
young O
adults O
taking O
antidepressants O
for O
major O
depressive O
disorder O
( O
MDD O
) O
and O
other O
psychiatric O
disorders O
. O

Lexapro O
is O
not O
approved O
for O
use O
in O
pediatric O
patients O
less O
than O
12 O
years O
of O
age O
( O
5.1 O
) O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Clinical O
Worsening/Suicide O
Risk O
: O
Monitor O
for O
clinical O
worsening O
, O
suicidality O
and O
unusual O
change O
in O
behavior O
, O
especially O
, O
during O
the O
initial O
few O
months O
of O
therapy O
or O
at O
times O
of O
dose O
changes O
( O
5.1 O
) O
. O

* O
Serotonin O
Syndrome O
: O
Serotonin O
syndrome O
has O
been O
reported O
with O
SSRIs O
and O
SNRIs O
, O
including O
Lexapro O
, O
both O
when O
taken O
alone O
, O
but O
especially O
when O
co-administered O
with O
other O
serotonergic O
agents O
( O
including O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
tryptophan O
, O
buspirone O
, O
amphetamines O
, O
and O
St O
. O
John O
's O
Wort O
) O
. O

If O
such O
symptoms O
occur O
, O
discontinue O
Lexapro O
and O
initiate O
supportive O
treatment O
. O

If O
concomitant O
use O
of O
Lexapro O
with O
other O
serotonergic O
drugs O
is O
clinically O
warranted O
, O
patients O
should O
be O
made O
aware O
of O
a O
potential O
increased O
risk O
for O
serotonin O
syndrome O
, O
particularly O
during O
treatment O
initiation O
and O
dose O
increases O
( O
5.2 O
) O
. O

* O
Discontinuation O
of O
Treatment O
with O
Lexapro O
: O
A O
gradual O
reduction O
in O
dose O
rather O
than O
abrupt O
cessation O
is O
recommended O
whenever O
possible O
( O
5.3 O
) O
. O

* O
Seizures O
: O
Prescribe O
with O
care O
in O
patients O
with O
a O
history O
of O
seizure O
( O
5.4 O
) O
. O

* O
Activation O
of O
Mania/Hypomania O
: O
Use O
cautiously O
in O
patients O
with O
a O
history O
of O
mania O
( O
5.5 O
) O
. O

* O
Hyponatremia O
: O
Can O
occur O
in O
association O
with O
SIADH O
( O
5.6 O
) O
. O

* O
Abnormal O
Bleeding O
: O
Use O
caution O
in O
concomitant O
use O
with O
NSAIDs O
, O
aspirin O
, O
warfarin O
or O
other O
drugs O
that O
affect O
coagulation O
( O
5.7 O
) O
. O

* O
Interference O
with O
Cognitive O
and O
Motor O
Performance O
: O
Use O
caution O
when O
operating O
machinery O
( O
5.8 O
) O
. O

* O
Angle O
Closure O
Glaucoma O
: O
Angle O
closure O
glaucoma O
has O
occurred O
in O
patients O
with O
untreated O
anatomically O
narrow O
angles O
treated O
with O
antidepressants O
. O

( O
5.9 O
) O
* O
Use O
in O
Patients O
with O
Concomitant O
Illness O
: O
Use O
caution O
in O
patients O
with O
diseases O
or O
conditions O
that O
produce O
altered O
metabolism O
or O
hemodynamic O
responses O
( O
5.10 O
) O
. O

5.1 O
Clinical O
Worsening O
and O
Suicide O
Risk O
Patients O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
, O
both O
adult O
and O
pediatric O
, O
may O
experience O
worsening B-NonOSE_AE
of I-NonOSE_AE
their I-NonOSE_AE
depression I-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
ideation I-NonOSE_AE
and O
behavior O
( O
suicidality B-NonOSE_AE
) O
or O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
whether O
or O
not O
they O
are O
taking O
antidepressant O
medications O
, O
and O
this O
risk O
may O
persist O
until O
significant O
remission O
occurs O
. O

Suicide B-NonOSE_AE
is O
a O
known O
risk O
of O
depression B-Not_AE_Candidate
and O
certain O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
, O
and O
these O
disorders O
themselves O
are O
the O
strongest O
predictors O
of O
suicide B-NonOSE_AE
. O

There O
has O
been O
a O
long-standing O
concern O
, O
however O
, O
that O
antidepressants O
may O
have O
a O
role O
in O
inducing O
worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
depression I-OSE_Labeled_AE
and O
the O
emergence O
of O
suicidality B-OSE_Labeled_AE
in O
certain O
patients O
during O
the O
early O
phases O
of O
treatment O
. O

Pooled O
analyses O
of O
short-term O
placebo-controlled O
trials O
of O
antidepressant O
drugs O
( O
SSRIs O
and O
others O
) O
showed O
that O
these O
drugs O
increase O
the O
risk O
of O
suicidal B-OSE_Labeled_AE
thinking O
and O
behavior I-OSE_Labeled_AE
( O
suicidality B-OSE_Labeled_AE
) O
in O
children O
, O
adolescents O
, O
and O
young O
adults O
( O
ages O
18-24 O
) O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
and O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Short-term O
studies O
did O
not O
show O
an O
increase O
in O
the O
risk O
of O
suicidality B-NonOSE_AE
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
beyond O
age O
24 O
; O
there O
was O
a O
reduction O
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
aged O
65 O
and O
older O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
trials O
in O
children O
and O
adolescents O
with O
MDD B-Not_AE_Candidate
, O
obsessive B-Not_AE_Candidate
compulsive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
OCD I-Not_AE_Candidate
) O
, O
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
24 O
short-term O
trials O
of O
9 O
antidepressant O
drugs O
in O
over O
4400 O
patients O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
trials O
in O
adults O
with O
MDD B-Not_AE_Candidate
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
295 O
short-term O
trials O
( O
median O
duration O
of O
2 O
months O
) O
of O
11 O
antidepressant O
drugs O
in O
over O
77,000 O
patients O
. O

There O
was O
considerable O
variation O
in O
risk O
of O
suicidality B-OSE_Labeled_AE
among O
drugs O
, O
but O
a O
tendency O
toward O
an O
increase O
in O
the O
younger O
patients O
for O
almost O
all O
drugs O
studied O
. O

There O
were O
differences O
in O
absolute O
risk O
of O
suicidality B-NonOSE_AE
across O
the O
different O
indications O
, O
with O
the O
highest O
incidence O
in O
MDD B-Not_AE_Candidate
. O

The O
risk O
differences O
( O
drug O
vs O
. O
placebo O
) O
, O
however O
, O
were O
relatively O
stable O
within O
age O
strata O
and O
across O
indications O
. O

These O
risk O
differences O
( O
drug-placebo O
difference O
in O
the O
number O
of O
cases O
of O
suicidality B-NonOSE_AE
per O
1000 O
patients O
treated O
) O
are O
provided O
in O
Table O
1 O
. O

TABLE O
1 O
Age O
Range O
Drug-Placebo O
Difference O
in O
Number O
of O
Cases O
of O
Suicidality B-OSE_Labeled_AE
per O
1000 O
Patients O
Treated O
Increases O
Compared O
to O
Placebo O
< O
18 O
14 O
additional O
cases O
18-24 O
5 O
additional O
cases O
Decreases O
Compared O
to O
Placebo O
25-64 O
1 O
fewer O
case O
> O
=65 O
6 O
fewer O
cases O
No O
suicides B-NonOSE_AE
occurred O
in O
any O
of O
the O
pediatric O
trials O
. O

There O
were O
suicides B-NonOSE_AE
in O
the O
adult O
trials O
, O
but O
the O
number O
was O
not O
sufficient O
to O
reach O
any O
conclusion O
about O
drug O
effect O
on O
suicide B-NonOSE_AE
. O

It O
is O
unknown O
whether O
the O
suicidality B-NonOSE_AE
risk O
extends O
to O
longer-term O
use O
, O
i.e. O
, O
beyond O
several O
months O
. O

However O
, O
there O
is O
substantial O
evidence O
from O
placebo-controlled O
maintenance O
trials O
in O
adults O
with O
depression B-Not_AE_Candidate
that O
the O
use O
of O
antidepressants O
can O
delay O
the O
recurrence O
of O
depression B-NonOSE_AE
. O

All O
patients O
being O
treated O
with O
antidepressants O
for O
any O
indication O
should O
be O
monitored O
appropriately O
and O
observed O
closely O
for O
clinical O
worsening O
, O
suicidality B-NonOSE_AE
, O
and O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
especially O
during O
the O
initial O
few O
months O
of O
a O
course O
of O
drug O
therapy O
, O
or O
at O
times O
of O
dose O
changes O
, O
either O
increases O
or O
decreases O
. O

The O
following O
symptoms O
, O
anxiety B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
panic B-OSE_Labeled_AE
attacks I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
hostility B-OSE_Labeled_AE
, O
aggressiveness B-OSE_Labeled_AE
, O
impulsivity B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
( O
psychomotor B-OSE_Labeled_AE
restlessness I-OSE_Labeled_AE
) O
, O
hypomania B-OSE_Labeled_AE
, O
and O
mania B-OSE_Labeled_AE
, O
have O
been O
reported O
in O
adult O
and O
pediatric O
patients O
being O
treated O
with O
antidepressants O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
as O
well O
as O
for O
other O
indications O
, O
both O
psychiatric B-Not_AE_Candidate
and O
nonpsychiatric O
. O

Although O
a O
causal O
link O
between O
the O
emergence O
of O
such O
symptoms O
and O
either O
the O
worsening B-NonOSE_AE
of I-NonOSE_AE
depression I-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
impulses I-NonOSE_AE
has O
not O
been O
established O
, O
there O
is O
concern O
that O
such O
symptoms O
may O
represent O
precursors O
to O
emerging O
suicidality B-NonOSE_AE
. O

Consideration O
should O
be O
given O
to O
changing O
the O
therapeutic O
regimen O
, O
including O
possibly O
discontinuing O
the O
medication O
, O
in O
patients O
whose O
depression B-Not_AE_Candidate
is O
persistently O
worse O
, O
or O
who O
are O
experiencing O
emergent O
suicidality B-NonOSE_AE
or O
symptoms O
that O
might O
be O
precursors O
to O
worsening B-NonOSE_AE
depression I-NonOSE_AE
or O
suicidality B-NonOSE_AE
, O
especially O
if O
these O
symptoms O
are O
severe O
, O
abrupt O
in O
onset O
, O
or O
were O
not O
part O
of O
the O
patient O
's O
presenting O
symptoms O
. O

If O
the O
decision O
has O
been O
made O
to O
discontinue O
treatment O
, O
medication O
should O
be O
tapered O
, O
as O
rapidly O
as O
is O
feasible O
, O
but O
with O
recognition O
that O
abrupt O
discontinuation B-NonOSE_AE
can I-NonOSE_AE
be I-NonOSE_AE
associated I-NonOSE_AE
with I-NonOSE_AE
certain I-NonOSE_AE
symptoms I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.4 O
) O
] O
. O

Families O
and O
caregivers O
of O
patients O
being O
treated O
with O
antidepressants O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
or O
other O
indications O
, O
both O
psychiatric B-Not_AE_Candidate
and O
nonpsychiatric O
, O
should O
be O
alerted O
about O
the O
need O
to O
monitor O
patients O
for O
the O
emergence O
of O
agitation B-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
and O
the O
other O
symptoms O
described O
above O
, O
as O
well O
as O
the O
emergence O
of O
suicidality B-NonOSE_AE
, O
and O
to O
report O
such O
symptoms O
immediately O
to O
health O
care O
providers O
. O

Such O
monitoring O
should O
include O
daily O
observation O
by O
families O
and O
caregivers O
[ O
see O
also O
Patient O
Counseling O
Information O
( O
17.1 O
) O
] O
. O

Prescriptions O
for O
Lexapro O
should O
be O
written O
for O
the O
smallest O
quantity O
of O
tablets O
consistent O
with O
good O
patient O
management O
, O
in O
order O
to O
reduce O
the O
risk O
of O
overdose B-NonOSE_AE
. O

Screening O
Patients O
for O
Bipolar O
Disorder O
A O
major B-NonOSE_AE
depressive I-NonOSE_AE
episode I-NonOSE_AE
may O
be O
the O
initial O
presentation O
of O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

It O
is O
generally O
believed O
( O
though O
not O
established O
in O
controlled O
trials O
) O
that O
treating O
such O
an O
episode O
with O
an O
antidepressant O
alone O
may O
increase O
the O
likelihood O
of O
precipitation B-NonOSE_AE
of I-NonOSE_AE
a I-NonOSE_AE
mixed I-NonOSE_AE
/ I-NonOSE_AE
manic I-NonOSE_AE
episode I-NonOSE_AE
in O
patients O
at O
risk O
for O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

Whether O
any O
of O
the O
symptoms O
described O
above O
represent O
such O
a O
conversion O
is O
unknown O
. O

However O
, O
prior O
to O
initiating O
treatment O
with O
an O
antidepressant O
, O
patients O
with O
depressive B-Not_AE_Candidate
symptoms I-Not_AE_Candidate
should O
be O
adequately O
screened O
to O
determine O
if O
they O
are O
at O
risk O
for O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
; O
such O
screening O
should O
include O
a O
detailed O
psychiatric B-Not_AE_Candidate
history O
, O
including O
a O
family B-Not_AE_Candidate
history I-Not_AE_Candidate
of I-Not_AE_Candidate
suicide I-Not_AE_Candidate
, O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
and O
depression B-Not_AE_Candidate
. O

It O
should O
be O
noted O
that O
Lexapro O
is O
not O
approved O
for O
use O
in O
treating O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
. O

5.2 O
Serotonin O
Syndrome O
The O
development O
of O
a O
potentially O
life-threatening O
serotonin B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
has O
been O
reported O
with O
SNRIs O
and O
SSRIs O
, O
including O
Lexapro O
, O
alone O
but O
particularly O
with O
concomitant O
use O
of O
other O
serotonergic O
drugs O
( O
including O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
tryptophan O
, O
buspirone O
, O
amphetamines O
, O
and O
St O
. O
John O
's O
Wort O
) O
and O
with O
drugs O
that O
impair O
metabolism O
of O
serotonin O
( O
in O
particular O
, O
MAOIs O
, O
both O
those O
intended O
to O
treat O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
and O
also O
others O
, O
such O
as O
linezolid O
and O
intravenous O
methylene O
blue O
) O
. O

Serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
symptoms O
may O
include O
mental B-NonOSE_AE
status I-NonOSE_AE
changes I-NonOSE_AE
( O
e.g. O
, O
agitation B-NonOSE_AE
, O
hallucinations B-NonOSE_AE
, O
delirium B-NonOSE_AE
, O
and O
coma B-NonOSE_AE
) O
, O
autonomic B-NonOSE_AE
instability I-NonOSE_AE
( O
e.g. O
, O
tachycardia B-NonOSE_AE
, O
labile B-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
diaphoresis B-NonOSE_AE
, O
flushing B-NonOSE_AE
, O
hyperthermia B-NonOSE_AE
) O
, O
neuromuscular B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
tremor B-NonOSE_AE
, O
rigidity B-NonOSE_AE
, O
myoclonus B-NonOSE_AE
, O
hyperreflexia B-NonOSE_AE
, O
incoordination B-NonOSE_AE
) O
seizures B-NonOSE_AE
, O
and/or O
gastrointestinal B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
) O
. O

Patients O
should O
be O
monitored O
for O
the O
emergence O
of O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
. O

The O
concomitant O
use O
of O
Lexapro O
with O
MAOIs O
intended O
to O
treat O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
is O
contraindicated O
. O

Lexapro O
should O
also O
not O
be O
started O
in O
a O
patient O
who O
is O
being O
treated O
with O
MAOIs O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
. O

All O
reports O
with O
methylene O
blue O
that O
provided O
information O
on O
the O
route O
of O
administration O
involved O
intravenous O
administration O
in O
the O
dose O
range O
of O
1 O
mg/kg O
to O
8 O
mg/kg O
. O

No O
reports O
involved O
the O
administration O
of O
methylene O
blue O
by O
other O
routes O
( O
such O
as O
oral O
tablets O
or O
local O
tissue O
injection O
) O
or O
at O
lower O
doses O
. O

There O
may O
be O
circumstances O
when O
it O
is O
necessary O
to O
initiate O
treatment O
with O
an O
MAOI O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
in O
a O
patient O
taking O
Lexapro O
. O

Lexapro O
should O
be O
discontinued O
before O
initiating O
treatment O
with O
the O
MAOI O
[ O
see O
Contraindications O
( O
4.1 O
) O
and O
Dosage O
and O
Administration O
( O
2.5 O
and O
2.6 O
) O
] O
. O

If O
concomitant O
use O
of O
Lexapro O
with O
other O
serotonergic O
drugs O
including O
, O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
buspirone O
, O
tryptophan O
, O
amphetamine O
and O
St O
. O
John O
's O
Wort O
is O
clinically O
warranted O
, O
patients O
should O
be O
made O
aware O
of O
a O
potential O
increased O
risk O
for O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
, O
particularly O
during O
treatment O
initiation O
and O
dose O
increases O
. O

Treatment O
with O
Lexapro O
and O
any O
concomitant O
serotonergic O
agents O
, O
should O
be O
discontinued O
immediately O
if O
the O
above O
events O
occur O
and O
supportive O
symptomatic O
treatment O
should O
be O
initiated O
. O

5.3 O
Discontinuation O
of O
Treatment O
with O
Lexapro O
During O
marketing O
of O
Lexapro O
and O
other O
SSRIs O
and O
SNRIs O
( O
serotonin O
and O
norepinephrine O
reuptake O
inhibitors O
) O
, O
there O
have O
been O
spontaneous O
reports O
of O
adverse B-OSE_Labeled_AE
events I-OSE_Labeled_AE
occurring I-OSE_Labeled_AE
upon I-OSE_Labeled_AE
discontinuation I-OSE_Labeled_AE
of O
these O
drugs O
, O
particularly O
when O
abrupt O
, O
including O
the O
following O
: O
dysphoric B-NonOSE_AE
mood I-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
agitation B-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
sensory B-NonOSE_AE
disturbances I-NonOSE_AE
( O
e.g. O
, O
paresthesias B-NonOSE_AE
such O
as O
electric B-NonOSE_AE
shock I-NonOSE_AE
sensations I-NonOSE_AE
) O
, O
anxiety B-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
lethargy B-NonOSE_AE
, O
emotional B-NonOSE_AE
lability I-NonOSE_AE
, O
insomnia B-NonOSE_AE
, O
and O
hypomania B-NonOSE_AE
. O

While O
these O
events O
are O
generally O
self-limiting O
, O
there O
have O
been O
reports O
of O
serious O
discontinuation B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
. O

Patients O
should O
be O
monitored O
for O
these O
symptoms O
when O
discontinuing O
treatment O
with O
Lexapro O
. O

A O
gradual O
reduction O
in O
the O
dose O
rather O
than O
abrupt O
cessation O
is O
recommended O
whenever O
possible O
. O

If O
intolerable O
symptoms O
occur O
following O
a O
decrease O
in O
the O
dose O
or O
upon O
discontinuation O
of O
treatment O
, O
then O
resuming O
the O
previously O
prescribed O
dose O
may O
be O
considered O
. O

Subsequently O
, O
the O
physician O
may O
continue O
decreasing O
the O
dose O
but O
at O
a O
more O
gradual O
rate O
[ O
see O
Dosage O
and O
Administration O
( O
2.4 O
) O
] O
. O

5.4 O
Seizures O
Although O
anticonvulsant O
effects O
of O
racemic O
citalopram O
have O
been O
observed O
in O
animal O
studies O
, O
Lexapro O
has O
not O
been O
systematically O
evaluated O
in O
patients O
with O
a O
seizure B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

These O
patients O
were O
excluded O
from O
clinical O
studies O
during O
the O
product O
's O
premarketing O
testing O
. O

In O
clinical O
trials O
of O
Lexapro O
, O
cases O
of O
convulsion B-OSE_Labeled_AE
have O
been O
reported O
in O
association O
with O
Lexapro O
treatment O
. O

Like O
other O
drugs O
effective O
in O
the O
treatment O
of O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
Lexapro O
should O
be O
introduced O
with O
care O
in O
patients O
with O
a O
history O
of O
seizure B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

5.5 O
Activation O
of O
Mania/Hypomania O
In O
placebo-controlled O
trials O
of O
Lexapro O
in O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
activation O
of O
mania B-OSE_Labeled_AE
/ O
hypomania B-OSE_Labeled_AE
was O
reported O
in O
one O
( O
0.1 O
% O
) O
of O
715 O
patients O
treated O
with O
Lexapro O
and O
in O
none O
of O
the O
592 O
patients O
treated O
with O
placebo O
. O

One O
additional O
case O
of O
hypomania B-OSE_Labeled_AE
has O
been O
reported O
in O
association O
with O
Lexapro O
treatment O
. O

Activation O
of O
mania B-OSE_Labeled_AE
/ O
hypomania B-OSE_Labeled_AE
has O
also O
been O
reported O
in O
a O
small O
proportion O
of O
patients O
with O
major B-Not_AE_Candidate
affective I-Not_AE_Candidate
disorders I-Not_AE_Candidate
treated O
with O
racemic O
citalopram O
and O
other O
marketed O
drugs O
effective O
in O
the O
treatment O
of O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

As O
with O
all O
drugs O
effective O
in O
the O
treatment O
of O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
Lexapro O
should O
be O
used O
cautiously O
in O
patients O
with O
a O
history O
of O
mania B-Not_AE_Candidate
. O

5.6 O
Hyponatremia O
Hyponatremia B-OSE_Labeled_AE
may O
occur O
as O
a O
result O
of O
treatment O
with O
SSRIs O
and O
SNRIs O
, O
including O
Lexapro O
. O

In O
many O
cases O
, O
this O
hyponatremia B-OSE_Labeled_AE
appears O
to O
be O
the O
result O
of O
the O
syndrome B-OSE_Labeled_AE
of I-OSE_Labeled_AE
inappropriate I-OSE_Labeled_AE
antidiuretic I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
secretion I-OSE_Labeled_AE
( I-OSE_Labeled_AE
SIADH I-OSE_Labeled_AE
) O
, O
and O
was O
reversible O
when O
Lexapro O
was O
discontinued O
. O

Cases O
with O
serum B-OSE_Labeled_AE
sodium I-OSE_Labeled_AE
lower I-OSE_Labeled_AE
than I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mmol I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
have O
been O
reported O
. O

Elderly O
patients O
may O
be O
at O
greater O
risk O
of O
developing O
hyponatremia B-OSE_Labeled_AE
with O
SSRIs O
and O
SNRIs O
. O

Also O
, O
patients O
taking O
diuretics O
or O
who O
are O
otherwise O
volume B-Not_AE_Candidate
depleted I-Not_AE_Candidate
may O
be O
at O
greater O
risk O
[ O
see O
Geriatric O
Use O
( O
8.5 O
) O
] O
. O

Discontinuation O
of O
Lexapro O
should O
be O
considered O
in O
patients O
with O
symptomatic O
hyponatremia B-NonOSE_AE
and O
appropriate O
medical O
intervention O
should O
be O
instituted O
. O

Signs O
and O
symptoms O
of O
hyponatremia B-NonOSE_AE
include O
headache B-NonOSE_AE
, O
difficulty B-NonOSE_AE
concentrating I-NonOSE_AE
, O
memory B-NonOSE_AE
impairment I-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
weakness B-NonOSE_AE
, O
and O
unsteadiness B-NonOSE_AE
, O
which O
may O
lead O
to O
falls B-NonOSE_AE
. O

Signs O
and O
symptoms O
associated O
with O
more O
severe O
and/or O
acute O
cases O
have O
included O
hallucination B-NonOSE_AE
, O
syncope B-NonOSE_AE
, O
seizure B-NonOSE_AE
, O
coma B-NonOSE_AE
, O
respiratory B-NonOSE_AE
arrest I-NonOSE_AE
, O
and O
death B-NonOSE_AE
. O

5.7 O
Abnormal O
Bleeding O
SSRIs O
and O
SNRIs O
, O
including O
Lexapro O
, O
may O
increase O
the O
risk O
of O
bleeding B-OSE_Labeled_AE
events O
. O

Concomitant O
use O
of O
aspirin O
, O
nonsteroidal O
anti-inflammatory O
drugs O
, O
warfarin O
, O
and O
other O
anticoagulants O
may O
add O
to O
the O
risk O
. O

Case O
reports O
and O
epidemiological O
studies O
( O
case-control O
and O
cohort O
design O
) O
have O
demonstrated O
an O
association O
between O
use O
of O
drugs O
that O
interfere O
with O
serotonin O
reuptake O
and O
the O
occurrence O
of O
gastrointestinal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
. O

Bleeding B-OSE_Labeled_AE
events O
related O
to O
SSRIs O
and O
SNRIs O
use O
have O
ranged O
from O
ecchymoses B-OSE_Labeled_AE
, O
hematomas B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
and O
petechiae B-OSE_Labeled_AE
to O
life-threatening O
hemorrhages B-OSE_Labeled_AE
. O

Patients O
should O
be O
cautioned O
about O
the O
risk O
of O
bleeding B-NonOSE_AE
associated O
with O
the O
concomitant O
use O
of O
Lexapro O
and O
NSAIDs O
, O
aspirin O
, O
or O
other O
drugs O
that O
affect O
coagulation O
. O

5.8 O
Interference O
with O
Cognitive O
and O
Motor O
Performance O
In O
a O
study O
in O
normal O
volunteers O
, O
Lexapro O
10 O
mg/day O
did O
not O
produce O
impairment B-NonOSE_AE
of I-NonOSE_AE
intellectual I-NonOSE_AE
function I-NonOSE_AE
or O
psychomotor O
performance O
. O

Because O
any O
psychoactive O
drug O
may O
impair B-OSE_Labeled_AE
judgment O
, O
thinking O
, O
or O
motor I-OSE_Labeled_AE
skills I-OSE_Labeled_AE
, O
however O
, O
patients O
should O
be O
cautioned O
about O
operating O
hazardous O
machinery O
, O
including O
automobiles O
, O
until O
they O
are O
reasonably O
certain O
that O
Lexapro O
therapy O
does O
not O
affect O
their O
ability O
to O
engage O
in O
such O
activities O
. O

5.9 O
Angle O
Closure O
Glaucoma O
Angle O
Closure O
Glaucoma O
: O
The O
pupillary B-OSE_Labeled_AE
dilation I-OSE_Labeled_AE
that O
occurs O
following O
use O
of O
many O
antidepressant O
drugs O
including O
Lexapro O
may O
trigger O
an O
angle B-OSE_Labeled_AE
closure I-OSE_Labeled_AE
attack I-OSE_Labeled_AE
in O
a O
patient O
with O
anatomically B-Not_AE_Candidate
narrow I-Not_AE_Candidate
angles I-Not_AE_Candidate
who I-Not_AE_Candidate
does I-Not_AE_Candidate
not I-Not_AE_Candidate
have I-Not_AE_Candidate
a I-Not_AE_Candidate
patent I-Not_AE_Candidate
iridectomy I-Not_AE_Candidate
. O

5.10 O
Use O
in O
Patients O
with O
Concomitant O
Illness O
Clinical O
experience O
with O
Lexapro O
in O
patients O
with O
certain O
concomitant O
systemic O
illnesses O
is O
limited O
. O

Caution O
is O
advisable O
in O
using O
Lexapro O
in O
patients O
with O
diseases O
or O
conditions O
that O
produce O
altered B-NonOSE_AE
metabolism I-NonOSE_AE
or O
hemodynamic B-NonOSE_AE
responses I-NonOSE_AE
. O

Lexapro O
has O
not O
been O
systematically O
evaluated O
in O
patients O
with O
a O
recent O
history O
of O
myocardial B-Not_AE_Candidate
infarction I-Not_AE_Candidate
or O
unstable B-Not_AE_Candidate
heart I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Patients O
with O
these O
diagnoses O
were O
generally O
excluded O
from O
clinical O
studies O
during O
the O
product O
's O
premarketing O
testing O
. O

In O
subjects O
with O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
clearance O
of O
racemic O
citalopram O
was O
decreased O
and O
plasma O
concentrations O
were O
increased O
. O

The O
recommended O
dose O
of O
Lexapro O
in O
hepatically B-Not_AE_Candidate
impaired I-Not_AE_Candidate
patients O
is O
10 O
mg/day O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

Because O
escitalopram O
is O
extensively O
metabolized O
, O
excretion O
of O
unchanged O
drug O
in O
urine O
is O
a O
minor O
route O
of O
elimination O
. O

Until O
adequate O
numbers O
of O
patients O
with O
severe O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
have O
been O
evaluated O
during O
chronic O
treatment O
with O
Lexapro O
, O
however O
, O
it O
should O
be O
used O
with O
caution O
in O
such O
patients O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
> O
=2 O
% O
) O
reported O
in O
IBS-C O
or O
CIC O
patients O
are O
: O
diarrhea O
, O
abdominal O
pain O
, O
flatulence O
and O
abdominal O
distension O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Allergan O
at O
1-800-678-1605 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
with O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Exposure O
in O
clinical O
development O
included O
approximately O
2570 O
, O
2040 O
, O
and O
1220 O
patients O
with O
either O
IBS-C O
or O
CIC O
treated O
with O
LINZESS O
for O
6 O
months O
or O
longer O
, O
1 O
year O
or O
longer O
, O
and O
18 O
months O
or O
longer O
, O
respectively O
( O
not O
mutually O
exclusive O
) O
. O

Demographic O
characteristics O
were O
comparable O
between O
treatment O
groups O
in O
all O
studies O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

Irritable O
Bowel O
Syndrome O
with O
Constipation O
( O
IBS-C O
) O
Most O
Common O
Adverse O
Reactions O
The O
data O
described O
below O
reflect O
exposure O
to O
LINZESS O
in O
the O
two O
placebo-controlled O
clinical O
trials O
involving O
1605 O
adult O
patients O
with O
IBS B-Not_AE_Candidate
- I-Not_AE_Candidate
C I-Not_AE_Candidate
( O
Trials O
1 O
and O
2 O
) O
. O

Patients O
were O
randomized O
to O
receive O
placebo O
or O
290 O
mcg O
LINZESS O
once O
daily O
on O
an O
empty O
stomach O
for O
up O
to O
26 O
weeks O
. O

Table O
1 O
provides O
the O
incidence O
of O
adverse O
reactions O
reported O
in O
at O
least O
2 O
% O
of O
IBS-C O
patients O
in O
the O
LINZESS O
treatment O
group O
and O
at O
an O
incidence O
that O
was O
greater O
than O
in O
the O
placebo O
group O
. O

Table O
1 O
: O
Most O
Common O
Adverse O
Reactionsa O
in O
Two O
Placebo-Controlled O
Trials O
( O
1 O
and O
2 O
) O
in O
Patients O
with O
IBS-C O
a O
: O
Reported O
in O
at O
least O
2 O
% O
of O
LINZESS-treated O
patients O
and O
at O
an O
incidence O
greater O
than O
placebo O
b O
: O
`` O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
`` O
term O
includes O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
abdominal I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
and O
lower B-OSE_Labeled_AE
abdominal I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
. O

Adverse O
Reactions O
LINZESS O
290 O
mcg O
[ O
N=807 O
] O
% O
Placebo O
[ O
N=798 O
] O
% O
Gastrointestinal B-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
b O
Flatulence B-OSE_Labeled_AE
Abdominal B-OSE_Labeled_AE
distension I-OSE_Labeled_AE
20742 O
3521 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Viral B-OSE_Labeled_AE
Gastroenteritis I-OSE_Labeled_AE
3 O
1 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
4 O
3 O
Diarrhea O
Diarrhea B-OSE_Labeled_AE
was O
the O
most O
commonly O
reported O
adverse O
reaction O
of O
the O
LINZESS-treated O
patients O
in O
the O
pooled O
IBS B-Not_AE_Candidate
- I-Not_AE_Candidate
C I-Not_AE_Candidate
pivotal O
placebo-controlled O
trials O
. O

In O
these O
trials O
, O
20 O
% O
of O
LINZESS-treated O
patients O
reported O
diarrhea B-OSE_Labeled_AE
compared O
to O
3 O
% O
of O
placebo-treated O
patients O
. O

Severe O
diarrhea B-OSE_Labeled_AE
was O
reported O
in O
2 O
% O
of O
the O
LINZESS-treated O
patients O
versus O
less O
than O
1 O
% O
of O
the O
placebo-treated O
patients O
, O
and O
5 O
% O
of O
LINZESS-treated O
patients O
discontinued O
due O
to O
diarrhea B-OSE_Labeled_AE
vs O
less O
than O
1 O
% O
of O
placebo-treated O
patients O
. O

The O
majority O
of O
reported O
cases O
of O
diarrhea B-OSE_Labeled_AE
started O
within O
the O
first O
2 O
weeks O
of O
LINZESS O
treatment O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Adverse O
Reactions O
Leading O
to O
Discontinuation O
In O
placebo-controlled O
trials O
in O
patients O
with O
IBS B-Not_AE_Candidate
- I-Not_AE_Candidate
C I-Not_AE_Candidate
, O
9 O
% O
of O
patients O
treated O
with O
LINZESS O
and O
3 O
% O
of O
patients O
treated O
with O
placebo O
discontinued O
prematurely O
due O
to O
adverse O
reactions O
. O

In O
the O
LINZESS O
treatment O
group O
, O
the O
most O
common O
reasons O
for O
discontinuation O
due O
to O
adverse O
reactions O
were O
diarrhea B-OSE_Labeled_AE
( O
5 O
% O
) O
and O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
1 O
% O
) O
. O

In O
comparison O
, O
less O
than O
1 O
% O
of O
patients O
in O
the O
placebo O
group O
withdrew O
due O
to O
diarrhea B-NonOSE_AE
or O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
. O

Adverse O
Reactions O
Leading O
to O
Dose O
Reductions O
In O
the O
open-label O
, O
long-term O
trials O
, O
2147 O
patients O
with O
IBS B-Not_AE_Candidate
- I-Not_AE_Candidate
C I-Not_AE_Candidate
received O
290 O
mcg O
of O
LINZESS O
daily O
for O
up O
to O
18 O
months O
. O

In O
these O
trials O
, O
29 O
% O
of O
patients O
had O
their O
dose O
reduced O
or O
suspended O
secondary O
to O
adverse O
reactions O
, O
the O
majority O
of O
which O
were O
diarrhea B-OSE_Labeled_AE
or O
other O
GI B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

Less O
Common O
Adverse O
Reactions O
Defecation B-OSE_Labeled_AE
urgency I-OSE_Labeled_AE
, O
fecal B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
and O
gastroesophagal B-OSE_Labeled_AE
reflux I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
were O
reported O
in O
< O
2 O
% O
of O
patients O
in O
the O
LINZESS O
treatment O
group O
and O
at O
an O
incidence O
greater O
than O
in O
the O
placebo O
treatment O
group O
. O

Chronic O
Idiopathic O
Constipation O
( O
CIC O
) O
Most O
Common O
Adverse O
Reactions O
The O
data O
described O
below O
reflect O
exposure O
to O
LINZESS O
in O
the O
two O
double-blind O
placebo-controlled O
clinical O
trials O
of O
1275 O
adult O
patients O
with O
CIC B-Not_AE_Candidate
( O
Trials O
3 O
and O
4 O
) O
. O

Patients O
were O
randomized O
to O
receive O
placebo O
or O
145 O
mcg O
LINZESS O
or O
290 O
mcg O
LINZESS O
once O
daily O
on O
an O
empty O
stomach O
, O
for O
at O
least O
12 O
weeks O
. O

Table O
2 O
provides O
the O
incidence O
of O
adverse O
reactions O
reported O
in O
at O
least O
2 O
% O
of O
CIC O
patients O
in O
the O
145 O
mcg O
LINZESS O
treatment O
group O
and O
at O
an O
incidence O
that O
was O
greater O
than O
in O
the O
placebo O
treatment O
group O
. O

Table O
2 O
: O
Most O
Common O
Adverse O
Reactionsa O
in O
the O
Two O
Placebo-controlled O
Trials O
( O
3 O
and O
4 O
) O
in O
Patients O
with O
CIC O
a O
: O
Reported O
in O
at O
least O
2 O
% O
of O
LINZESS-treated O
patients O
and O
at O
an O
incidence O
greater O
than O
placebo O
b O
: O
`` O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
`` O
term O
includes O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
abdominal I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
and O
lower B-OSE_Labeled_AE
abdominal I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
. O

Adverse O
Reactions O
LINZESS O
145 O
mcg O
[ O
N=430 O
] O
% O
Placebo O
[ O
N=423 O
] O
% O
Gastrointestinal B-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
b O
Flatulence B-OSE_Labeled_AE
Abdominal B-OSE_Labeled_AE
distension I-OSE_Labeled_AE
16763 O
5652 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
Sinusitis B-OSE_Labeled_AE
53 O
42 O
The O
safety O
of O
a O
72 O
mcg O
dose O
was O
evaluated O
in O
an O
additional O
placebo-controlled O
trial O
in O
which O
1223 O
patients O
were O
randomized O
to O
LINZESS O
72 O
mcg O
, O
145 O
mcg O
, O
or O
placebo O
once O
daily O
for O
12 O
weeks O
( O
Trial O
5 O
) O
. O

In O
Trial O
5 O
, O
adverse O
reactions O
that O
occurred O
at O
a O
frequency O
of O
> O
= O
2 O
% O
in O
LINZESS-treated O
patients O
( O
n=411 O
in O
each O
LINZESS O
72 O
mcg O
and O
145 O
mcg O
group O
) O
and O
at O
a O
higher O
rate O
than O
placebo O
( O
n=401 O
) O
were O
: O
* O
Diarrhea B-OSE_Labeled_AE
( O
LINZESS O
72 O
mcg O
19 O
% O
; O
LINZESS O
145 O
mcg O
22 O
% O
; O
placebo O
7 O
% O
) O
* O
Abdominal B-OSE_Labeled_AE
distension I-OSE_Labeled_AE
( O
LINZESS O
72 O
mcg O
2 O
% O
; O
LINZESS O
145 O
mcg O
1 O
% O
; O
placebo O
< O
1 O
% O
) O
Diarrhea B-OSE_Labeled_AE
This O
section O
summarizes O
information O
from O
Trials O
3 O
and O
4 O
( O
pooled O
) O
and O
Trial O
5 O
regarding O
diarrhea B-OSE_Labeled_AE
, O
the O
most O
commonly O
reported O
adverse O
reaction O
reported O
in O
LINZESS-treated O
patients O
in O
CIC B-Not_AE_Candidate
placebo-controlled O
studies O
. O

In O
all O
trials O
, O
the O
majority O
of O
reported O
cases O
of O
diarrhea B-OSE_Labeled_AE
started O
within O
the O
first O
2 O
weeks O
of O
LINZESS O
treatment O
. O

Severe O
diarrhea B-OSE_Labeled_AE
was O
reported O
in O
less O
than O
1 O
% O
of O
the O
72 O
mcg O
LINZESS-treated O
patients O
( O
Trial O
5 O
) O
, O
in O
2 O
% O
of O
the O
145 O
mcg O
LINZESS-treated O
patients O
( O
Trials O
3 O
and O
4 O
; O
Trial O
5 O
) O
, O
and O
less O
than O
1 O
% O
of O
the O
placebo-treated O
patients O
( O
Trials O
3 O
, O
4 O
, O
and O
5 O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Adverse O
Reactions O
Leading O
to O
Discontinuation O
In O
placebo-controlled O
trials O
in O
patients O
with O
CIC B-Not_AE_Candidate
, O
3 O
% O
of O
patients O
treated O
with O
72 O
mcg O
( O
Trial O
5 O
) O
and O
between O
5 O
% O
( O
Trial O
5 O
) O
and O
8 O
% O
( O
Trials O
3 O
and O
4 O
) O
of O
patients O
treated O
with O
145 O
mcg O
of O
LINZESS O
discontinued O
prematurely O
due O
to O
adverse O
reactions O
compared O
to O
between O
less O
than O
1 O
% O
( O
Trial O
5 O
) O
and O
4 O
% O
( O
Trials O
3 O
and O
4 O
) O
of O
patients O
treated O
with O
placebo O
. O

In O
patients O
treated O
with O
72 O
mcg O
LINZESS O
the O
most O
common O
reason O
for O
discontinuation O
due O
to O
adverse O
reactions O
was O
diarrhea B-OSE_Labeled_AE
( O
2 O
% O
in O
Trial O
5 O
) O
and O
in O
patients O
treated O
with O
145 O
mcg O
LINZESS O
, O
the O
most O
common O
reasons O
for O
discontinuation O
due O
to O
adverse O
reactions O
were O
diarrhea B-OSE_Labeled_AE
( O
3 O
% O
in O
Trial O
5 O
and O
5 O
% O
in O
Trials O
3 O
and O
4 O
) O
and O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
1 O
% O
in O
Trials O
3 O
and O
4 O
) O
. O

In O
comparison O
, O
less O
than O
1 O
% O
of O
patients O
in O
the O
placebo O
group O
withdrew O
due O
to O
diarrhea B-NonOSE_AE
or O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
( O
Trials O
3 O
and O
4 O
; O
Trial O
5 O
) O
. O

Adverse O
Reactions O
Leading O
to O
Dose O
Reductions O
In O
the O
open-label O
, O
long-term O
trials O
, O
1129 O
patients O
with O
CIC B-Not_AE_Candidate
received O
290 O
mcg O
of O
LINZESS O
daily O
for O
up O
to O
18 O
months O
. O

In O
these O
trials O
, O
27 O
% O
of O
patients O
had O
their O
dose O
reduced O
or O
suspended O
secondary O
to O
adverse O
reactions O
, O
the O
majority O
of O
which O
were O
diarrhea B-OSE_Labeled_AE
or O
other O
GI B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

Less O
Common O
Adverse O
Reactions O
Defecation B-OSE_Labeled_AE
urgency I-OSE_Labeled_AE
, O
fecal B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
and O
viral B-OSE_Labeled_AE
gastroenteritis I-OSE_Labeled_AE
, O
were O
reported O
in O
less O
than O
2 O
% O
of O
patients O
in O
the O
LINZESS O
treatment O
group O
and O
at O
an O
incidence O
greater O
than O
placebo O
treatment O
group O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post O
approval O
use O
of O
LINZESS O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Hematochezia B-OSE_Labeled_AE
, O
rectal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
and O
allergic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
or O
hives B-OSE_Labeled_AE
. O

BOXED O
WARNING O
: O
WARNING O
: O
RISK O
OF O
SERIOUS O
DEHYDRATION O
IN O
PEDIATRIC O
PATIENTS O
WARNING O
: O
RISK O
OF O
SERIOUS O
DEHYDRATION O
IN O
PEDIATRIC O
PATIENTS O
* O
LINZESS O
is O
contraindicated O
in O
patients O
less O
than O
6 O
years O
of O
age O
; O
in O
nonclinical O
studies O
in O
neonatal O
mice O
, O
administration O
of O
a O
single O
, O
clinically O
relevant O
adult O
oral O
dose O
of O
linaclotide O
caused O
deaths B-NonOSE_AE
due O
to O
dehydration B-NonOSE_AE
[ O
see O
Contraindications O
( O
4 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.4 O
) O
] O
. O

* O
Avoid O
use O
of O
LINZESS O
in O
patients O
6 O
years O
to O
less O
than O
18 O
years O
of O
age O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.4 O
) O
] O
. O

* O
The O
safety O
and O
effectiveness O
of O
LINZESS O
have O
not O
been O
established O
in O
patients O
less O
than O
18 O
years O
of O
age O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.4 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
RISK O
OF O
SERIOUS O
DEHYDRATION O
IN O
PEDIATRIC O
PATIENTS O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
LINZESS O
is O
contraindicated O
in O
patients O
less O
than O
6 O
years O
of O
age O
; O
in O
neonatal O
mice O
, O
linaclotide O
caused O
deaths O
due O
to O
dehydration O
. O

( O
4 O
, O
8.4 O
) O
* O
Avoid O
use O
of O
LINZESS O
in O
patients O
6 O
years O
to O
less O
than O
18 O
years O
of O
age O
. O

( O
5.1 O
, O
8.4 O
) O
* O
The O
safety O
and O
effectiveness O
of O
LINZESS O
have O
not O
been O
established O
in O
patients O
less O
than O
18 O
years O
of O
age O
( O
8.4 O
) O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Diarrhea O
: O
Patients O
may O
experience O
severe O
diarrhea O
. O

If O
severe O
diarrhea O
occurs O
, O
suspend O
dosing O
and O
rehydrate O
the O
patient O
. O

( O
5.2 O
) O
5.1 O
Risk O
of O
Serious O
Dehydration O
in O
Pediatric O
Patients O
LINZESS O
is O
contraindicated O
in O
patients O
less O
than O
6 O
years O
of O
age O
. O

The O
safety O
and O
effectiveness O
of O
LINZESS O
in O
patients O
less O
than O
18 O
years O
of O
age O
have O
not O
been O
established O
. O

In O
neonatal O
mice O
( O
human O
age O
equivalent O
of O
approximately O
0 O
to O
28 O
days O
) O
, O
linaclotide O
increased B-NonOSE_AE
fluid I-NonOSE_AE
secretion I-NonOSE_AE
as O
a O
consequence O
of O
GC-C O
agonism O
resulting O
in O
mortality B-NonOSE_AE
within O
the O
first O
24 O
hours O
due O
to O
dehydration B-NonOSE_AE
. O

Due O
to O
increased O
intestinal O
expression O
of O
GC-C O
, O
patients O
less O
than O
6 O
years O
of O
age O
may O
be O
more O
likely O
than O
patients O
6 O
years O
of O
age O
and O
older O
to O
develop O
severe O
diarrhea B-NonOSE_AE
and O
its O
potentially O
serious O
consequences O
. O

Avoid O
use O
of O
LINZESS O
in O
pediatric O
patients O
6 O
years O
to O
less O
than O
18 O
years O
of O
age O
. O

Although O
there O
were O
no O
deaths B-NonOSE_AE
in O
older O
juvenile O
mice O
, O
given O
the O
deaths B-NonOSE_AE
in O
young O
juvenile O
mice O
and O
the O
lack O
of O
clinical O
safety O
and O
efficacy O
data O
in O
pediatric O
patients O
, O
avoid O
the O
use O
of O
LINZESS O
in O
pediatric O
patients O
6 O
years O
to O
less O
than O
18 O
years O
of O
age O
[ O
see O
Contraindications O
( O
4 O
) O
, O
Warnings O
and O
Precautions O
( O
5.2 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.4 O
) O
] O
. O

5.2 O
Diarrhea O
Diarrhea B-OSE_Labeled_AE
was O
the O
most O
common O
adverse O
reaction O
of O
LINZESS-treated O
patients O
in O
the O
pooled O
IBS-C O
and O
CIC O
double-blind O
placebo-controlled O
trials O
. O

The O
incidence O
of O
diarrhea B-OSE_Labeled_AE
was O
similar O
between O
the O
IBS B-Not_AE_Candidate
- I-Not_AE_Candidate
C I-Not_AE_Candidate
and O
CIC B-Not_AE_Candidate
populations O
. O

Severe O
diarrhea B-OSE_Labeled_AE
was O
reported O
in O
2 O
% O
of O
145 O
mcg O
and O
290 O
mcg O
LINZESS-treated O
patients O
, O
and O
in O
< O
1 O
% O
of O
72 O
mcg O
LINZESS-treated O
CIC O
patients O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

In O
post-marketing O
experience O
, O
severe O
diarrhea B-OSE_Labeled_AE
associated O
with O
dizziness B-NonOSE_AE
, O
syncope B-NonOSE_AE
, O
hypotension B-NonOSE_AE
and O
electrolyte B-NonOSE_AE
abnormalities I-NonOSE_AE
( O
hypokalemia B-NonOSE_AE
and O
hyponatremia B-NonOSE_AE
) O
requiring O
hospitalization O
or O
intravenous O
fluid O
administration O
have O
been O
reported O
in O
patients O
treated O
with O
LINZESS O
. O

If O
severe O
diarrhea B-NonOSE_AE
occurs O
, O
suspend O
dosing O
and O
rehydrate O
the O
patient O
. O

ADVERSE O
REACTIONS O
Spasticity O
of O
Spinal O
Cord O
Origin O
Clinical O
Studies O
Commonly O
Observed O
in O
Patients O
with O
Spasticity O
of O
Spinal O
Origin O
In O
pre- O
and O
post- O
marketing O
clinical O
trials O
, O
the O
most O
commonly O
observed O
adverse O
events O
associated O
with O
use O
of O
LIORESAL O
INTRATHECAL O
( O
baclofen O
injection O
) O
which O
were O
not O
seen O
at O
an O
equivalent O
incidence O
among O
placebo-treated O
patients O
were O
: O
somnolence B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
convulsions B-OSE_Labeled_AE
and O
hypotonia B-OSE_Labeled_AE
. O

Associated O
with O
Discontinuation O
of O
Treatment O
8/474 O
patients O
with O
spasticity B-Not_AE_Candidate
of I-Not_AE_Candidate
spinal I-Not_AE_Candidate
cord I-Not_AE_Candidate
origin I-Not_AE_Candidate
receiving O
long O
term O
infusion O
of O
LIORESAL O
INTRATHECAL O
in O
pre- O
and O
post- O
marketing O
clinical O
studies O
in O
the O
U O
. O
S O
. O
discontinued O
treatment O
due O
to O
adverse O
events O
. O

These O
include O
: O
pump B-OSE_Labeled_AE
pocket I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
( O
3 O
) O
, O
meningitis B-OSE_Labeled_AE
( O
2 O
) O
, O
wound B-OSE_Labeled_AE
dehiscence I-OSE_Labeled_AE
( O
1 O
) O
, O
gynecological B-OSE_Labeled_AE
fibroids I-OSE_Labeled_AE
( O
1 O
) O
and O
pump B-OSE_Labeled_AE
overpressurization I-OSE_Labeled_AE
( O
1 O
) O
with O
unknown O
, O
if O
any O
, O
sequela O
. O

Eleven O
patients O
who O
developed O
coma B-NonOSE_AE
secondary O
to O
overdose B-NonOSE_AE
had O
their O
treatment O
temporarily O
suspended O
, O
but O
all O
were O
subsequently O
re-started O
and O
were O
not O
, O
therefore O
, O
considered O
to O
be O
true O
discontinuations O
. O

Fatalities B-NonOSE_AE
See O
Warnings O
. O

Incidence O
in O
Controlled O
Trials O
Experience O
with O
LIORESAL O
INTRATHECAL O
( O
baclofen O
injection O
) O
obtained O
in O
parallel O
, O
placebo-controlled O
, O
randomized O
studies O
provides O
only O
a O
limited O
basis O
for O
estimating O
the O
incidence O
of O
adverse O
events O
because O
the O
studies O
were O
of O
very O
brief O
duration O
( O
up O
to O
three O
days O
of O
infusion O
) O
and O
involved O
only O
a O
total O
of O
63 O
patients O
. O

The O
following O
events O
occurred O
among O
the O
31 O
patients O
receiving O
LIORESAL O
INTRATHECAL O
( O
baclofen O
injection O
) O
in O
two O
randomized O
, O
placebo-controlled O
trials O
: O
hypotension B-OSE_Labeled_AE
( O
2 O
) O
, O
dizziness B-OSE_Labeled_AE
( O
2 O
) O
, O
headache B-OSE_Labeled_AE
( O
2 O
) O
, O
dyspnea B-OSE_Labeled_AE
( O
1 O
) O
. O

No O
adverse O
events O
were O
reported O
among O
the O
32 O
patients O
receiving O
placebo O
in O
these O
studies O
. O

Events O
Observed O
during O
the O
Pre- O
and O
Post-marketing O
Evaluation O
of O
LIORESAL O
INTRATHECAL O
Adverse O
events O
associated O
with O
the O
use O
of O
LIORESAL O
INTRATHECAL O
reflect O
experience O
gained O
with O
576 O
patients O
followed O
prospectively O
in O
the O
United O
States O
. O

They O
received O
LIORESAL O
INTRATHECAL O
for O
periods O
of O
one O
day O
( O
screening O
) O
( O
N O
= O
576 O
) O
to O
over O
eight O
years O
( O
maintenance O
) O
( O
N O
= O
10 O
) O
. O

The O
usual O
screening O
bolus O
dose O
administered O
prior O
to O
pump O
implantation O
in O
these O
studies O
was O
typically O
50 O
mcg O
. O

The O
maintenance O
dose O
ranged O
from O
12 O
mcg O
to O
2003 O
mcg O
per O
day O
. O

Because O
of O
the O
open O
, O
uncontrolled O
nature O
of O
the O
experience O
, O
a O
causal O
linkage O
between O
events O
observed O
and O
the O
administration O
of O
LIORESAL O
INTRATHECAL O
can O
not O
be O
reliably O
assessed O
in O
many O
cases O
and O
many O
of O
the O
adverse O
events O
reported O
are O
known O
to O
occur O
in O
association O
with O
the O
underlying O
conditions O
being O
treated O
. O

Nonetheless O
, O
many O
of O
the O
more O
commonly O
reported O
reactions- O
hypotonia B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
/ O
vomiting B-OSE_Labeled_AE
and O
headache B-OSE_Labeled_AE
- I-OSE_Labeled_AE
appear O
clearly O
drug-related O
. O

Adverse O
experiences O
reported O
during O
all O
U.S O
. O
studies O
( O
both O
controlled O
and O
uncontrolled O
) O
are O
shown O
in O
the O
following O
table O
. O

Eight O
of O
474 O
patients O
who O
received O
chronic O
infusion O
via O
implanted O
pumps O
had O
adverse O
experiences O
which O
led O
to O
a O
discontinuation O
of O
long O
term O
treatment O
in O
the O
pre- O
and O
post-marketing O
studies O
. O

INCIDENCE O
OF O
MOST O
FREQUENT O
( O
> O
=1 O
% O
) O
ADVERSE O
EVENTS O
IN O
PATIENTS O
WITH O
SPASTICITY O
OF O
SPINAL O
ORIGIN O
IN O
PROSPECTIVELY O
MONITORED O
CLINICAL O
TRIALS O
Percent O
of O
Patients O
Reporting O
Events O
N O
= O
576Screening O
[ O
note O
: O
Following O
administration O
of O
test O
bolus O
] O
Percent O
N O
= O
474Titration O
[ O
note O
: O
Two O
month O
period O
following O
implant O
] O
Percent O
N O
= O
430Maintenance O
[ O
note O
: O
Beyond O
two O
months O
following O
implant O
] O
Percent O
Adverse O
Event O
N= O
total O
number O
of O
patients O
entering O
each O
period O
% O
= O
% O
of O
patients O
evaluated O
Hypotonia B-OSE_Labeled_AE
5.4 O
13.5 O
25.3 O
Somnolence B-OSE_Labeled_AE
5.7 O
5.9 O
20.9 O
Dizziness B-OSE_Labeled_AE
1.7 O
1.9 O
7.9 O
Paresthesia B-OSE_Labeled_AE
2.4 O
2.1 O
6.7 O
Nausea B-OSE_Labeled_AE
and O
Vomiting B-OSE_Labeled_AE
1.6 O
2.3 O
5.6 O
Headache B-OSE_Labeled_AE
1.6 O
2.5 O
5.1 O
Constipation B-OSE_Labeled_AE
0.2 O
1.5 O
5.1 O
Convulsion B-OSE_Labeled_AE
0.5 O
1.3 O
4.7 O
Urinary B-OSE_Labeled_AE
Retention I-OSE_Labeled_AE
0.7 O
1.7 O
1.9 O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
0.2 O
0.4 O
3.3 O
Accidental B-OSE_Labeled_AE
Injury I-OSE_Labeled_AE
0.0 O
0.2 O
3.5 O
Asthenia B-OSE_Labeled_AE
0.7 O
1.3 O
1.4 O
Confusion B-OSE_Labeled_AE
0.5 O
0.6 O
2.3 O
Death B-NonOSE_AE
0.2 O
0.4 O
3.0 O
Pain B-OSE_Labeled_AE
0.0 O
0.6 O
3.0 O
Speech B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
0.0 O
0.2 O
3.5 O
Hypotension B-OSE_Labeled_AE
1.0 O
0.2 O
1.9 O
Ambylopia B-OSE_Labeled_AE
0.5 O
0.2 O
2.3 O
Diarrhea B-OSE_Labeled_AE
0.0 O
0.8 O
2.3 O
Hypoventilation B-OSE_Labeled_AE
0.2 O
0.8 O
2.1 O
Coma B-OSE_Labeled_AE
0.0 O
1.5 O
0.9 O
Impotence B-OSE_Labeled_AE
0.2 O
0.4 O
1.6 O
Peripheral B-OSE_Labeled_AE
Edema I-OSE_Labeled_AE
0.0 O
0.0 O
2.3 O
Urinary B-OSE_Labeled_AE
Incontinence I-OSE_Labeled_AE
0.0 O
0.8 O
1.4 O
Insomnia B-OSE_Labeled_AE
0.0 O
0.4 O
1.6 O
Anxiety B-OSE_Labeled_AE
0.2 O
0.4 O
0.9 O
Depression B-OSE_Labeled_AE
0.0 O
0.0 O
1.6 O
Dyspnea B-OSE_Labeled_AE
0.3 O
0.0 O
1.2 O
Fever B-OSE_Labeled_AE
0.5 O
0.2 O
0.7 O
Pneumonia B-OSE_Labeled_AE
0.2 O
0.2 O
1.2 O
Urinary B-OSE_Labeled_AE
Frequency I-OSE_Labeled_AE
0.0 O
0.6 O
0.9 O
Urticaria B-OSE_Labeled_AE
0.2 O
0.2 O
1.2 O
Anorexia B-OSE_Labeled_AE
0.0 O
0.4 O
0.9 O
Diplopia B-OSE_Labeled_AE
0.0 O
0.4 O
0.9 O
Dysautonomia B-OSE_Labeled_AE
0.2 O
0.2 O
0.9 O
Hallucinations B-OSE_Labeled_AE
0.3 O
0.4 O
0.5 O
Hypertension B-OSE_Labeled_AE
0.2 O
0.6 O
0.5 O
In O
addition O
to O
the O
more O
common O
( O
1 O
% O
or O
more O
) O
adverse O
events O
reported O
in O
the O
prospectively O
followed O
576 O
domestic O
patients O
in O
pre- O
and O
post-marketing O
studies O
, O
experience O
from O
an O
additional O
194 O
patients O
exposed O
to O
LIORESAL O
INTRATHECAL O
( O
baclofen O
injection O
) O
from O
foreign O
studies O
has O
been O
reported O
. O

The O
following O
adverse O
events O
, O
not O
described O
in O
the O
table O
, O
and O
arranged O
in O
decreasing O
order O
of O
frequency O
, O
and O
classified O
by O
body O
system O
, O
were O
reported O
: O
Nervous B-NonOSE_AE
System I-NonOSE_AE
: O
Abnormal B-OSE_Labeled_AE
gait I-OSE_Labeled_AE
, O
thinking B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
amnesia B-OSE_Labeled_AE
, O
twitching B-OSE_Labeled_AE
, O
vasodilitation B-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
nystagmus B-OSE_Labeled_AE
, O
personality B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
psychotic B-OSE_Labeled_AE
depression I-OSE_Labeled_AE
, O
cerebral B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
, O
emotional B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
, O
euphoria B-OSE_Labeled_AE
, O
hypertonia B-OSE_Labeled_AE
, O
ileus B-OSE_Labeled_AE
, O
drug B-OSE_Labeled_AE
dependence I-OSE_Labeled_AE
, O
incoordination B-OSE_Labeled_AE
, O
paranoid B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
and O
ptosis B-OSE_Labeled_AE
. O

Digestive B-NonOSE_AE
System I-NonOSE_AE
: O
Flatulence B-OSE_Labeled_AE
, O
dysphagia B-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
and O
gastroenteritis B-OSE_Labeled_AE
. O

Cardiovascular B-NonOSE_AE
: O
Postural B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
, O
bradycardia B-OSE_Labeled_AE
, O
palpitations B-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
, O
arrhythmia B-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
, O
deep B-OSE_Labeled_AE
thrombophlebitis I-OSE_Labeled_AE
, O
pallor B-OSE_Labeled_AE
and O
tachycardia B-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
: O
Respiratory B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
aspiration B-OSE_Labeled_AE
pneumonia I-OSE_Labeled_AE
, O
hyperventilation B-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolus I-OSE_Labeled_AE
and O
rhinitis B-OSE_Labeled_AE
. O

Urogenital B-NonOSE_AE
: O
Hematuria B-OSE_Labeled_AE
and O
kidney B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
: O
Alopecia B-OSE_Labeled_AE
and O
sweating B-OSE_Labeled_AE
. O

Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
albuminuria B-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
and O
hyperglycemia B-OSE_Labeled_AE
. O

Special B-NonOSE_AE
Senses I-NonOSE_AE
: O
Abnormal B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
abnormality B-OSE_Labeled_AE
of I-OSE_Labeled_AE
accommodation I-OSE_Labeled_AE
, O
photophobia B-OSE_Labeled_AE
, O
taste B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
and O
tinnitus B-OSE_Labeled_AE
. O

Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
: O
Suicide B-OSE_Labeled_AE
, O
lack B-OSE_Labeled_AE
of I-OSE_Labeled_AE
drug I-OSE_Labeled_AE
effect I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
hypothermia B-OSE_Labeled_AE
, O
neck B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
face B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
flu B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
and O
overdose B-OSE_Labeled_AE
. O

Hemic B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
: O
Anemia B-OSE_Labeled_AE
. O

Spasticity O
of O
Cerebral O
Origin O
Clinical O
Studies O
Commonly O
Observed O
In O
pre-marketing O
clinical O
trials O
, O
the O
most O
commonly O
observed O
adverse O
events O
associated O
with O
use O
of O
LIORESAL O
INTRATHECAL O
( O
baclofen O
injection O
) O
which O
were O
not O
seen O
at O
an O
equivalent O
incidence O
among O
placebo-treated O
patients O
included O
: O
agitation B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
leukocytosis B-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
and O
hypotonia B-OSE_Labeled_AE
. O

Associated O
with O
Discontinuation O
of O
Treatment O
Nine O
of O
211 O
patients O
receiving O
LIORESAL O
INTRATHECAL O
in O
pre-marketing O
clinical O
studies O
in O
the O
U.S O
. O
discontinued O
long O
term O
infusion O
due O
to O
adverse O
events O
associated O
with O
intrathecal O
therapy O
. O

The O
nine O
adverse O
events O
leading O
to O
discontinuation O
were O
: O
infection B-OSE_Labeled_AE
( O
3 O
) O
, O
CSF B-OSE_Labeled_AE
leaks I-OSE_Labeled_AE
( O
2 O
) O
, O
meningitis B-OSE_Labeled_AE
( O
2 O
) O
, O
drainage B-OSE_Labeled_AE
( O
1 O
) O
, O
and O
unmanageable B-OSE_Labeled_AE
trunk I-OSE_Labeled_AE
control I-OSE_Labeled_AE
( O
1 O
) O
. O

Fatalities B-NonOSE_AE
Three O
deaths B-NonOSE_AE
, O
none O
of O
which O
were O
attributed O
to O
LIORESAL O
INTRATHECAL O
, O
were O
reported O
in O
patients O
in O
clinical O
trials O
involving O
patients O
with O
spasticity B-Not_AE_Candidate
of I-Not_AE_Candidate
cerebral I-Not_AE_Candidate
origin I-Not_AE_Candidate
. O

See O
Warnings O
on O
other O
deaths B-NonOSE_AE
reported O
in O
spinal B-Not_AE_Candidate
spasticity I-Not_AE_Candidate
patients O
. O

Incidence O
in O
Controlled O
Trials O
Experience O
with O
LIORESAL O
INTRATHECAL O
( O
baclofen O
injection O
) O
obtained O
in O
parallel O
, O
placebo-controlled O
, O
randomized O
studies O
provides O
only O
a O
limited O
basis O
for O
estimating O
the O
incidence O
of O
adverse O
events O
because O
the O
studies O
involved O
a O
total O
of O
62 O
patients O
exposed O
to O
a O
single O
50 O
mcg O
intrathecal O
bolus O
. O

The O
following O
events O
occurred O
among O
the O
62 O
patients O
receiving O
LIORESAL O
INTRATHECAL O
in O
two O
randomized O
, O
placebo-controlled O
trials O
involving O
cerebral B-Not_AE_Candidate
palsy I-Not_AE_Candidate
and O
head B-Not_AE_Candidate
injury I-Not_AE_Candidate
patients O
, O
respectively O
: O
agitation B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
leukocytosis B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
nystagmus B-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
, O
and O
hypotonia B-OSE_Labeled_AE
. O

Events O
Observed O
during O
the O
Pre-marketing O
Evaluation O
of O
LIORESAL O
INTRATHECAL O
Adverse O
events O
associated O
with O
the O
use O
of O
LIORESAL O
INTRATHECAL O
reflect O
experience O
gained O
with O
a O
total O
of O
211 O
U O
. O
S O
. O
patients O
with O
spasticity B-Not_AE_Candidate
of I-Not_AE_Candidate
cerebral I-Not_AE_Candidate
origin I-Not_AE_Candidate
, O
of O
whom O
112 O
were O
pediatric O
patients O
( O
under O
age O
16 O
at O
enrollment O
) O
. O

They O
received O
LIORESAL O
INTRATHECAL O
for O
periods O
of O
one O
day O
( O
screening O
) O
( O
N= O
211 O
) O
to O
84 O
months O
( O
maintenance O
) O
( O
N= O
1 O
) O
. O

The O
usual O
screening O
bolus O
dose O
administered O
prior O
to O
pump O
implantation O
in O
these O
studies O
was O
50-75 O
mcg O
. O

The O
maintenance O
dose O
ranged O
from O
22 O
mcg O
to O
1400 O
mcg O
per O
day O
. O

Doses O
used O
in O
this O
patient O
population O
for O
long O
term O
infusion O
are O
generally O
lower O
than O
those O
required O
for O
patients O
with O
spasticity B-Not_AE_Candidate
of I-Not_AE_Candidate
spinal I-Not_AE_Candidate
cord I-Not_AE_Candidate
origin I-Not_AE_Candidate
. O

Because O
of O
the O
open O
, O
uncontrolled O
nature O
of O
the O
experience O
, O
a O
causal O
linkage O
between O
events O
observed O
and O
the O
administration O
of O
LIORESAL O
INTRATHECAL O
can O
not O
be O
reliably O
assessed O
in O
many O
cases O
. O

Nonetheless O
, O
many O
of O
the O
more O
commonly O
reported O
reactions- O
somnolence B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
hypotonia B-OSE_Labeled_AE
and O
coma B-OSE_Labeled_AE
- I-OSE_Labeled_AE
appear O
clearly O
drug-related O
. O

The O
most O
frequent O
( O
> O
=1 O
% O
) O
adverse O
events O
reported O
during O
all O
clinical O
trials O
are O
shown O
in O
the O
following O
table O
. O

Nine O
patients O
discontinued O
long O
term O
treatment O
due O
to O
adverse O
events O
. O

INCIDENCE O
OF O
MOST O
FREQUENT O
( O
> O
= O
1 O
% O
) O
ADVERSE O
EVENTS O
IN O
PATIENTS O
WITH O
SPASTICITY O
OF O
CEREBRAL O
ORIGIN O
IN O
PROSPECTIVELY O
MONITORED O
CLINICAL O
TRIALS O
Percent O
of O
Patients O
Reporting O
Events O
N O
= O
211Screening O
[ O
note O
: O
Following O
administration O
of O
test O
bolus O
] O
Percent O
N O
= O
153Titration O
[ O
note O
: O
Two O
month O
period O
following O
implant O
] O
Percent O
N O
= O
150Maintenance O
[ O
note O
: O
Beyond O
two O
months O
following O
implant O
] O
Percent O
Adverse O
Event O
N= O
Total O
number O
of O
patients O
entering O
each O
period O
. O

211 O
patients O
received O
drug O
; O
( O
1 O
of O
212 O
) O
received O
placebo O
only O
. O

Hypotonia B-OSE_Labeled_AE
2.4 O
14.4 O
34.7 O
Somnolence B-OSE_Labeled_AE
7.6 O
10.5 O
18.7 O
Headache B-OSE_Labeled_AE
6.6 O
7.8 O
10.7 O
Nausea B-OSE_Labeled_AE
and O
Vomiting B-OSE_Labeled_AE
6.6 O
10.5 O
4.0 O
Vomiting B-OSE_Labeled_AE
6.2 O
8.5 O
4.0 O
Urinary B-OSE_Labeled_AE
Retention I-OSE_Labeled_AE
0.9 O
6.5 O
8.0 O
Convulsion B-OSE_Labeled_AE
0.9 O
3.3 O
10.0 O
Dizziness B-OSE_Labeled_AE
2.4 O
2.6 O
8.0 O
Nausea B-OSE_Labeled_AE
1.4 O
3.3 O
7.3 O
Hypoventilation B-OSE_Labeled_AE
1.4 O
1.3 O
4.0 O
Hypertonia B-OSE_Labeled_AE
0.0 O
0.7 O
6.0 O
Paresthesia B-OSE_Labeled_AE
1.9 O
0.7 O
3.3 O
Hypotension B-OSE_Labeled_AE
1.9 O
0.7 O
2.0 O
Increased B-OSE_Labeled_AE
Salivation I-OSE_Labeled_AE
0.0 O
2.6 O
2.7 O
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
0.9 O
0.7 O
2.0 O
Constipation B-OSE_Labeled_AE
0.5 O
1.3 O
2.0 O
Pain B-OSE_Labeled_AE
0.0 O
0.0 O
4.0 O
Pruritus B-OSE_Labeled_AE
0.0 O
0.0 O
4.0 O
Diarrhea B-OSE_Labeled_AE
0.5 O
0.7 O
2.0 O
Peripheral B-OSE_Labeled_AE
Edema I-OSE_Labeled_AE
0.0 O
0.0 O
3.3 O
Thinking B-OSE_Labeled_AE
Abnormal I-OSE_Labeled_AE
0.5 O
1.3 O
0.7 O
Agitation B-OSE_Labeled_AE
0.5 O
0.0 O
1.3 O
Asthenia B-OSE_Labeled_AE
0.0 O
0.0 O
2.0 O
Chills B-OSE_Labeled_AE
0.5 O
0.0 O
1.3 O
Coma B-OSE_Labeled_AE
0.5 O
0.0 O
1.3 O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
0.5 O
0.0 O
1.3 O
Pneumonia B-OSE_Labeled_AE
0.0 O
0.0 O
2.0 O
Speech B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
0.5 O
0.7 O
0.7 O
Tremor B-OSE_Labeled_AE
0.5 O
0.0 O
1.3 O
Urinary B-OSE_Labeled_AE
Incontinence I-OSE_Labeled_AE
0.0 O
0.0 O
2.0 O
Urination B-OSE_Labeled_AE
Impaired I-OSE_Labeled_AE
0.0 O
0.0 O
2.0 O
The O
more O
common O
( O
1 O
% O
or O
more O
) O
adverse O
events O
reported O
in O
the O
prospectively O
followed O
211 O
patients O
exposed O
to O
LIORESAL O
INTRATHECAL O
( O
baclofen O
injection O
) O
have O
been O
reported O
. O

In O
the O
total O
cohort O
, O
the O
following O
adverse O
events O
, O
not O
described O
in O
the O
table O
, O
and O
arranged O
in O
decreasing O
order O
of O
frequency O
, O
and O
classified O
by O
body O
system O
, O
were O
reported O
: O
Nervous B-NonOSE_AE
System I-NonOSE_AE
: O
Akathisia B-OSE_Labeled_AE
, O
ataxia B-OSE_Labeled_AE
, O
confusion B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
opisthotonos B-OSE_Labeled_AE
, O
amnesia B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
, O
hysteria B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
nystagmus B-OSE_Labeled_AE
, O
personality B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
reflexes B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
and O
vasodilitation B-OSE_Labeled_AE
. O

Digestive B-NonOSE_AE
System I-NonOSE_AE
: O
Dysphagia B-OSE_Labeled_AE
, O
fecal B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
and O
tongue B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
. O

Cardiovascular B-NonOSE_AE
: O
Bradycardia B-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
: O
Apnea B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
and O
hyperventilation B-OSE_Labeled_AE
. O

Urogenital B-NonOSE_AE
: O
Abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
, O
kidney B-OSE_Labeled_AE
calculus I-OSE_Labeled_AE
, O
oliguria B-OSE_Labeled_AE
and O
vaginitis B-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
: O
Rash B-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
, O
alopecia B-OSE_Labeled_AE
, O
contact B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
and O
skin B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
. O

Special B-NonOSE_AE
Senses I-NonOSE_AE
: O
Abnormality B-OSE_Labeled_AE
of I-OSE_Labeled_AE
accommodation I-OSE_Labeled_AE
. O

Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
: O
Death B-NonOSE_AE
, O
fever B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
carcinoma B-OSE_Labeled_AE
, O
malaise B-OSE_Labeled_AE
and O
hypothermia B-OSE_Labeled_AE
. O

Hemic B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
: O
Leukocytosis B-OSE_Labeled_AE
and O
petechial B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
. O

Postmarketing O
Experience O
The O
following O
adverse O
events O
have O
been O
reported O
during O
post-approval O
use O
of O
LIORESAL O
INTRATHECAL O
. O

Because O
these O
events O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
possible O
to O
reliably O
estimate O
their O
frequency O
. O

Musculoskeletal O
The O
onset O
of O
scoliosis B-OSE_Labeled_AE
or O
worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
a I-OSE_Labeled_AE
pre I-OSE_Labeled_AE
- I-OSE_Labeled_AE
existing I-OSE_Labeled_AE
scoliosis I-OSE_Labeled_AE
has O
been O
reported O
. O

Urogenital O
Sexual B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
in O
men O
and O
women O
, O
including O
decreased B-OSE_Labeled_AE
libido I-OSE_Labeled_AE
and O
orgasm B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
, O
have O
been O
reported O
. O

Erectile B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
in O
men O
has O
also O
been O
reported O
. O

Priapism B-NonOSE_AE
has O
been O
reported O
following O
baclofen O
withdrawal B-NonOSE_AE
. O

BOXED O
WARNING O
: O
Abrupt B-OSE_Labeled_AE
discontinuation I-OSE_Labeled_AE
of I-OSE_Labeled_AE
intrathecal I-OSE_Labeled_AE
baclofen I-OSE_Labeled_AE
, O
regardless O
of O
the O
cause O
, O
has O
resulted O
in O
sequelae O
that O
include O
high B-NonOSE_AE
fever I-NonOSE_AE
, O
altered B-NonOSE_AE
mental I-NonOSE_AE
status I-NonOSE_AE
, O
exaggerated B-NonOSE_AE
rebound I-NonOSE_AE
spasticity I-NonOSE_AE
, O
and O
muscle B-NonOSE_AE
rigidity I-NonOSE_AE
, O
that O
in O
rare O
cases O
has O
advanced O
to O
rhabdomyolysis B-NonOSE_AE
, O
multiple B-NonOSE_AE
organ I-NonOSE_AE
- I-NonOSE_AE
system I-NonOSE_AE
failure I-NonOSE_AE
and O
death B-NonOSE_AE
. O

Prevention O
of O
abrupt O
discontinuation O
of O
intrathecal O
baclofen O
requires O
careful O
attention O
to O
programming O
and O
monitoring O
of O
the O
infusion O
system O
, O
refill O
scheduling O
and O
procedures O
, O
and O
pump O
alarms O
. O

Patients O
and O
caregivers O
should O
be O
advised O
of O
the O
importance O
of O
keeping O
scheduled O
refill O
visits O
and O
should O
be O
educated O
on O
the O
early O
symptoms O
of O
baclofen B-NonOSE_AE
withdrawal I-NonOSE_AE
. O

Special O
attention O
should O
be O
given O
to O
patients O
at O
apparent O
risk O
( O
e.g O
. O

spinal B-Not_AE_Candidate
cord I-Not_AE_Candidate
injuries I-Not_AE_Candidate
at I-Not_AE_Candidate
T I-Not_AE_Candidate
- I-Not_AE_Candidate
6 I-Not_AE_Candidate
or I-Not_AE_Candidate
above I-Not_AE_Candidate
, O
communication B-Not_AE_Candidate
difficulties I-Not_AE_Candidate
, O
history O
of O
withdrawal B-Not_AE_Candidate
symptoms I-Not_AE_Candidate
from I-Not_AE_Candidate
oral I-Not_AE_Candidate
or I-Not_AE_Candidate
intrathecal I-Not_AE_Candidate
baclofen I-Not_AE_Candidate
) O
. O

Consult O
the O
technical O
manual O
of O
the O
implantable O
infusion O
system O
for O
additional O
postimplant O
clinician O
and O
patient O
information O
( O
see O
WARNINGS O
) O
. O

PRECAUTIONS O
Children O
should O
be O
of O
sufficient O
body O
mass O
to O
accommodate O
the O
implantable O
pump O
for O
chronic O
infusion O
. O

Please O
consult O
pump O
manufacturer O
's O
manual O
for O
specific O
recommendations O
. O

Safety O
and O
effectiveness O
in O
pediatric O
patients O
below O
the O
age O
of O
4 O
have O
not O
been O
established O
. O

Screening O
Patients O
should O
be O
infection B-Not_AE_Candidate
-free O
prior O
to O
the O
screening O
trial O
with O
LIORESAL O
INTRATHECAL O
( O
baclofen O
injection O
) O
because O
the O
presence O
of O
a O
systemic O
infection B-NonOSE_AE
may O
interfere O
with O
an O
assessment O
of O
the O
patient O
's O
response O
to O
bolus O
LIORESAL O
INTRATHECAL O
. O

Pump O
Implantation O
Patients O
should O
be O
infection B-Not_AE_Candidate
-free O
prior O
to O
pump O
implantation O
because O
the O
presence O
of O
infection B-NonOSE_AE
may O
increase O
the O
risk O
of O
surgical O
complications O
. O

Moreover O
, O
a O
systemic O
infection B-NonOSE_AE
may O
complicate O
dosing O
. O

Pump O
Dose O
Adjustment O
and O
Titration O
In O
most O
patients O
, O
it O
will O
be O
necessary O
to O
increase O
the O
dose O
gradually O
over O
time O
to O
maintain O
effectiveness O
; O
a O
sudden O
requirement O
for O
substantial O
dose O
escalation O
typically O
indicates O
a O
catheter O
complication O
( O
i O
. O
e. O
, O
catheter O
kink O
or O
dislodgement O
) O
. O

Reservoir O
refilling O
must O
be O
performed O
by O
fully O
trained O
and O
qualified O
personnel O
following O
the O
directions O
provided O
by O
the O
pump O
manufacturer O
. O

Inadvertent B-OSE_Labeled_AE
injection I-OSE_Labeled_AE
into I-OSE_Labeled_AE
the I-OSE_Labeled_AE
subcutaneous I-OSE_Labeled_AE
tissue I-OSE_Labeled_AE
can O
occur O
if O
the O
reservoir O
refill O
septum O
is O
not O
properly O
accessed O
. O

Subcutaneous O
injection O
may O
result O
in O
symptoms O
of O
a O
systemic O
overdose B-NonOSE_AE
or O
early O
depletion O
of O
the O
reservoir O
. O

Refill O
intervals O
should O
be O
carefully O
calculated O
to O
prevent O
depletion O
of O
the O
reservoir O
, O
as O
this O
would O
result O
in O
the O
return O
of O
severe O
spasticity B-NonOSE_AE
and O
possibly O
symptoms O
of O
withdrawal B-NonOSE_AE
. O

Strict O
aseptic O
technique O
in O
filling O
is O
required O
to O
avoid O
bacterial O
contamination O
and O
serious O
infection B-NonOSE_AE
. O

A O
period O
of O
observation O
appropriate O
to O
the O
clinical O
situation O
should O
follow O
each O
refill O
or O
manipulation O
of O
the O
drug O
reservoir O
. O

Extreme O
caution O
must O
be O
used O
when O
filling O
an O
FDA O
approved O
implantable O
pump O
equipped O
with O
an O
injection O
port O
that O
allows O
direct O
access O
to O
the O
intrathecal O
catheter O
. O

Direct B-OSE_Labeled_AE
injection I-OSE_Labeled_AE
into I-OSE_Labeled_AE
the I-OSE_Labeled_AE
catheter I-OSE_Labeled_AE
through O
the O
catheter O
access O
port O
may O
cause O
a O
life-threatening O
overdose B-NonOSE_AE
. O

Additional O
considerations O
pertaining O
to O
dosage O
adjustment O
It O
may O
be O
important O
to O
titrate O
the O
dose O
to O
maintain O
some O
degree O
of O
muscle O
tone O
and O
allow O
occasional O
spasms B-NonOSE_AE
to O
: O
1 O
) O
help O
support O
circulatory O
function O
, O
2 O
) O
possibly O
prevent O
the O
formation O
of O
deep B-NonOSE_AE
vein I-NonOSE_AE
thrombosis I-NonOSE_AE
, O
3 O
) O
optimize O
activities O
of O
daily O
living O
and O
ease O
of O
care O
. O

Except O
in O
overdose B-NonOSE_AE
related O
emergencies O
, O
the O
dose O
of O
LIORESAL O
INTRATHECAL O
should O
ordinarily O
be O
reduced O
slowly O
if O
the O
drug O
is O
discontinued O
for O
any O
reason O
. O

An O
attempt O
should O
be O
made O
to O
discontinue O
concomitant O
oral O
antispasticity O
medication O
to O
avoid O
possible O
overdose B-NonOSE_AE
or O
adverse O
drug O
interactions O
, O
either O
prior O
to O
screening O
or O
following O
implant O
and O
initiation O
of O
chronic O
LIORESAL O
INTRATHECAL O
infusion O
. O

Reduction O
and O
discontinuation O
of O
oral O
anti-spasmotics O
should O
be O
done O
slowly O
and O
with O
careful O
monitoring O
by O
the O
physician O
. O

Abrupt O
reduction O
or O
discontinuation O
of O
concomitant O
antispastics O
should O
be O
avoided O
. O

Drowsiness O
Drowsiness B-OSE_Labeled_AE
has O
been O
reported O
in O
patients O
on O
LIORESAL O
INTRATHECAL O
. O

Patients O
should O
be O
cautioned B-NonOSE_AE
regarding I-NonOSE_AE
the I-NonOSE_AE
operation I-NonOSE_AE
of I-NonOSE_AE
automobiles I-NonOSE_AE
or O
other O
dangerous O
machinery O
, O
and O
activities O
made O
hazardous O
by O
decreased B-NonOSE_AE
alertness I-NonOSE_AE
. O

Patients O
should O
also O
be O
cautioned O
that O
the O
central B-NonOSE_AE
nervous I-NonOSE_AE
system I-NonOSE_AE
depressant I-NonOSE_AE
effects I-NonOSE_AE
of O
LIORESAL O
INTRATHECAL O
( O
baclofen O
injection O
) O
may O
be O
additive O
to O
those O
of O
alcohol O
and O
other O
CNS O
depressants O
. O

Intrathecal O
mass O
Cases O
of O
intrathecal B-OSE_Labeled_AE
mass I-OSE_Labeled_AE
at I-OSE_Labeled_AE
the I-OSE_Labeled_AE
tip I-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
implanted I-OSE_Labeled_AE
catheter I-OSE_Labeled_AE
have O
been O
reported O
, O
most O
of O
them O
involving O
pharmacy O
compounded O
analgesic O
admixtures O
. O

The O
most O
frequent O
symptoms O
associated O
with O
intrathecal B-NonOSE_AE
mass I-NonOSE_AE
are O
: O
1 O
) O
decreased B-NonOSE_AE
therapeutic I-NonOSE_AE
response I-NonOSE_AE
( O
worsening B-NonOSE_AE
spasticity I-NonOSE_AE
, O
return B-NonOSE_AE
of I-NonOSE_AE
spasticity I-NonOSE_AE
when O
previously O
well O
controlled O
, O
withdrawal B-NonOSE_AE
symptoms I-NonOSE_AE
, O
poor O
response O
to O
escalating O
doses O
, O
or O
frequent O
or O
large O
dosage O
increases O
) O
, O
2 O
) O
pain B-NonOSE_AE
, O
3 O
) O
neurological B-NonOSE_AE
deficit/ O
dysfunction I-NonOSE_AE
. O

Clinicians O
should O
monitor O
patients O
on O
intraspinal O
therapy O
carefully O
for O
any O
new O
neurological B-NonOSE_AE
signs I-NonOSE_AE
or I-NonOSE_AE
symptoms I-NonOSE_AE
. O

In O
patients O
with O
new O
neurological O
signs O
or O
symptoms O
suggestive O
of O
an O
intrathecal B-NonOSE_AE
mass I-NonOSE_AE
, O
consider O
a O
neurosurgical O
consultation O
, O
since O
many O
of O
the O
symptoms O
of O
inflammatory B-NonOSE_AE
mass I-NonOSE_AE
are O
not O
unlike O
the O
symptoms O
experienced O
by O
patients O
with O
severe O
spasticity B-Not_AE_Candidate
from O
their O
disease O
. O

In O
some O
cases O
, O
performance O
of O
an O
imaging O
procedure O
may O
be O
appropriate O
to O
confirm O
or O
rule-out O
the O
diagnosis O
of O
an O
intrathecal B-NonOSE_AE
mass I-NonOSE_AE
. O

Precautions O
in O
special O
patient O
populations O
Careful O
dose O
titration O
of O
LIORESAL O
INTRATHECAL O
is O
needed O
when O
spasticity B-NonOSE_AE
is O
necessary O
to O
sustain O
upright O
posture O
and O
balance O
in O
locomotion O
or O
whenever O
spasticity B-NonOSE_AE
is O
used O
to O
obtain O
optimal O
function O
and O
care O
. O

Patients O
suffering O
from O
psychotic B-Not_AE_Candidate
disorders I-Not_AE_Candidate
, O
schizophrenia B-Not_AE_Candidate
, O
or O
confusional B-Not_AE_Candidate
states I-Not_AE_Candidate
should O
be O
treated O
cautiously O
with O
LIORESAL O
INTRATHECAL O
and O
kept O
under O
careful O
surveillance O
, O
because O
exacerbations O
of O
these O
conditions O
have O
been O
observed O
with O
oral O
administration O
. O

LIORESAL O
INTRATHECAL O
should O
be O
used O
with O
caution O
in O
patients O
with O
a O
history O
of O
autonomic B-Not_AE_Candidate
dysreflexia I-Not_AE_Candidate
. O

The O
presence O
of O
nociceptive O
stimuli O
or O
abrupt O
withdrawal B-NonOSE_AE
of O
LIORESAL O
INTRATHECAL O
( O
baclofen O
injection O
) O
may O
cause O
an O
autonomic B-NonOSE_AE
dysreflexic I-NonOSE_AE
episode I-NonOSE_AE
. O

Because O
LIORESAL O
is O
primarily O
excreted O
unchanged O
by O
the O
kidneys O
, O
it O
should O
be O
given O
with O
caution O
in O
patients O
with O
impaired B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
and O
it O
may O
be O
necessary O
to O
reduce O
the O
dosage O
. O

LABORATORY O
TESTS O
No O
specific O
laboratory O
tests O
are O
deemed O
essential O
for O
the O
management O
of O
patients O
on O
LIORESAL O
INTRATHECAL O
. O

DRUG O
INTERACTIONS O
There O
is O
inadequate O
systematic O
experience O
with O
the O
use O
of O
LIORESAL O
INTRATHECAL O
in O
combination O
with O
other O
medications O
to O
predict O
specific O
drug-drug O
interactions O
. O

Interactions O
attributed O
to O
the O
combined O
use O
of O
LIORESAL O
INTRATHECAL O
and O
epidural O
morphine O
include O
hypotension B-NonOSE_AE
and O
dyspnea B-NonOSE_AE
. O

CARCINOGENESIS O
, O
MUTAGENESIS O
, O
AND O
IMPAIRMENT O
OF O
FERTILITY O
No O
increase O
in O
tumors B-NonOSE_AE
was O
seen O
in O
rats O
receiving O
baclofen O
orally O
for O
two O
years O
. O

Adequate O
genotoxicity B-NonOSE_AE
assays O
of O
baclofen O
have O
not O
been O
performed O
. O

PREGNANCY O
There O
are O
no O
adequate O
and O
well-controlled O
studies O
in O
pregnant B-Not_AE_Candidate
women O
. O

In O
animal O
studies O
, O
baclofen O
had O
adverse O
effects O
on O
embryofetal B-NonOSE_AE
development I-NonOSE_AE
when O
administered O
orally O
to O
pregnant B-NonOSE_AE
rats O
. O

LIORESAL O
INTRATHECAL O
should O
be O
used O
during O
pregnancy B-Not_AE_Candidate
only O
if O
the O
potential O
benefit O
justifies O
the O
potential O
risk B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

Baclofen O
given O
orally O
increased O
the O
incidence O
of O
fetal B-NonOSE_AE
structural I-NonOSE_AE
abnormalities I-NonOSE_AE
( O
omphaloceles B-NonOSE_AE
) O
in O
rats O
. O

Reductions B-NonOSE_AE
in I-NonOSE_AE
food I-NonOSE_AE
intake I-NonOSE_AE
and O
body B-NonOSE_AE
weight I-NonOSE_AE
gain I-NonOSE_AE
were O
observed O
in O
the O
dams O
. O

Fetal B-NonOSE_AE
structural I-NonOSE_AE
abnormalities I-NonOSE_AE
were O
not O
observed O
in O
mice O
or O
rabbits O
NURSING O
MOTHERS O
In O
mothers O
treated O
with O
oral O
LIORESAL O
( O
baclofen O
USP O
) O
in O
therapeutic O
doses O
, O
the O
active O
substance O
passes O
into O
the O
milk O
. O

It O
is O
not O
known O
whether O
detectable O
levels O
of O
drug O
are O
present O
in O
milk O
of O
nursing O
mothers O
receiving O
LIORESAL O
INTRATHECAL O
. O

As O
a O
general O
rule O
, O
nursing O
should O
be O
undertaken O
while O
a O
patient O
is O
receiving O
LIORESAL O
INTRATHECAL O
only O
if O
the O
potential O
benefit O
justifies O
the O
potential O
risks O
to O
the O
infant O
. O

PEDIATRIC O
USE O
Children O
should O
be O
of O
sufficient O
body O
mass O
to O
accommodate O
the O
implantable O
pump O
for O
chronic O
infusion O
. O

Please O
consult O
pump O
manufacturer O
's O
manual O
for O
specific O
recommendations O
. O

Safety O
and O
effectiveness O
in O
pediatric O
patients O
below O
the O
age O
of O
4 O
have O
not O
been O
established O
. O

Considerations O
based O
on O
experience O
with O
oral O
LIORESAL O
( O
baclofen O
USP O
) O
A O
dose-related O
increase O
in O
incidence O
of O
ovarian B-NonOSE_AE
cysts I-NonOSE_AE
was O
observed O
in O
female O
rats O
treated O
chronically O
with O
oral O
LIORESAL O
. O

Ovarian B-OSE_Labeled_AE
cysts I-OSE_Labeled_AE
have O
been O
found O
by O
palpation O
in O
about O
4 O
% O
of O
the O
multiple B-Not_AE_Candidate
sclerosis I-Not_AE_Candidate
patients O
who O
were O
treated O
with O
oral O
LIORESAL O
for O
up O
to O
one O
year O
. O

In O
most O
cases O
these O
cysts O
disappeared O
spontaneously O
while O
patients O
continued O
to O
receive O
the O
drug O
. O

Ovarian B-NonOSE_AE
cysts I-NonOSE_AE
are O
estimated O
to O
occur O
spontaneously O
in O
approximately O
1 O
% O
to O
5 O
% O
of O
the O
normal O
female O
population O
. O

WARNINGS O
LIORESAL O
INTRATHECAL O
is O
for O
use O
in O
single O
bolus O
intrathecal O
injections O
( O
via O
a O
catheter O
placed O
in O
the O
lumbar O
intrathecal O
space O
or O
injection O
by O
lumbar O
puncture O
) O
and O
in O
implantable O
pumps O
approved O
by O
the O
FDA O
specifically O
for O
the O
intrathecal O
administration O
of O
baclofen O
. O

Because O
of O
the O
possibility O
of O
potentially O
life-threatening O
CNS B-OSE_Labeled_AE
depression I-OSE_Labeled_AE
, O
cardiovascular B-OSE_Labeled_AE
collapse I-OSE_Labeled_AE
, O
and/or O
respiratory B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
physicians O
must O
be O
adequately O
trained O
and O
educated O
in O
chronic O
intrathecal O
infusion O
therapy O
. O

The O
pump O
system O
should O
not O
be O
implanted O
until O
the O
patient O
's O
response O
to O
bolus O
LIORESAL O
INTRATHECAL O
injection O
is O
adequately O
evaluated O
. O

Evaluation O
( O
consisting O
of O
a O
screening O
procedure O
: O
see O
Dosage O
and O
Administration O
) O
requires O
that O
LIORESAL O
INTRATHECAL O
be O
administered O
into O
the O
intrathecal O
space O
via O
a O
catheter O
or O
lumbar O
puncture O
. O

Because O
of O
the O
risks O
associated O
with O
the O
screening O
procedure O
and O
the O
adjustment O
of O
dosage O
following O
pump O
implantation O
, O
these O
phases O
must O
be O
conducted O
in O
a O
medically O
supervised O
and O
adequately O
equipped O
environment O
following O
the O
instructions O
outlined O
in O
the O
Dosage O
and O
Administration O
section O
. O

Resuscitative O
equipment O
should O
be O
available O
. O

Following O
surgical O
implantation O
of O
the O
pump O
, O
particularly O
during O
the O
initial O
phases O
of O
pump O
use O
, O
the O
patient O
should O
be O
monitored O
closely O
until O
it O
is O
certain O
that O
the O
patient O
's O
response O
to O
the O
infusion O
is O
acceptable O
and O
reasonably O
stable O
. O

On O
each O
occasion O
that O
the O
dosing O
rate O
of O
the O
pump O
and/or O
the O
concentration O
of O
LIORESAL O
INTRATHECAL O
( O
baclofen O
injection O
) O
in O
the O
reservoir O
is O
adjusted O
, O
close O
medical O
monitoring O
is O
required O
until O
it O
is O
certain O
that O
the O
patient O
's O
response O
to O
the O
infusion O
is O
acceptable O
and O
reasonably O
stable O
. O

It O
is O
mandatory O
that O
the O
patient O
, O
all O
patient O
caregivers O
, O
and O
the O
physicians O
responsible O
for O
the O
patient O
receive O
adequate O
information O
regarding O
the O
risks O
of O
this O
mode O
of O
treatment O
. O

All O
medical O
personnel O
and O
caregivers O
should O
be O
instructed O
in O
1 O
) O
the O
signs O
and O
symptoms O
of O
overdose B-NonOSE_AE
, O
2 O
) O
procedures O
to O
be O
followed O
in O
the O
event O
of O
overdose B-NonOSE_AE
and O
3 O
) O
proper O
home O
care O
of O
the O
pump O
and O
insertion O
site O
. O

Overdose O
Signs O
of O
overdose B-OSE_Labeled_AE
may O
appear O
suddenly O
or O
insidiously O
. O

Acute O
massive O
overdose B-OSE_Labeled_AE
may O
present O
as O
coma B-NonOSE_AE
. O

Less O
sudden O
and/or O
less O
severe O
forms O
of O
overdose B-OSE_Labeled_AE
may O
present O
with O
signs O
of O
drowsiness B-NonOSE_AE
, O
lightheadedness B-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
somnolence B-NonOSE_AE
, O
respiratory B-NonOSE_AE
depression I-NonOSE_AE
, O
seizures B-NonOSE_AE
, O
rostral O
progression O
of O
hypotonia B-NonOSE_AE
and O
loss B-NonOSE_AE
of I-NonOSE_AE
consciousness I-NonOSE_AE
progressing O
to O
coma B-NonOSE_AE
. O

Should O
overdose B-NonOSE_AE
appear O
likely O
, O
the O
patient O
should O
be O
taken O
immediately O
to O
a O
hospital O
for O
assessment O
and O
emptying O
of O
the O
pump O
reservoir O
. O

In O
cases O
reported O
to O
date O
, O
overdose B-NonOSE_AE
has O
generally O
been O
related O
to O
pump B-NonOSE_AE
malfunction I-NonOSE_AE
, O
inadvertent B-OSE_Labeled_AE
subcutaneous I-OSE_Labeled_AE
injection I-OSE_Labeled_AE
, O
or O
dosing B-OSE_Labeled_AE
error I-OSE_Labeled_AE
. O

( O
See O
Drug B-NonOSE_AE
Overdose I-NonOSE_AE
Symptoms O
and O
Treatment O
. O
) O

Extreme O
caution O
must O
be O
used O
when O
filling O
an O
FDA O
approved O
implantable O
pump O
. O

Such O
pumps O
should O
only O
be O
refilled O
through O
the O
reservoir O
refill O
septum O
. O

Inadvertent B-OSE_Labeled_AE
injection I-OSE_Labeled_AE
into I-OSE_Labeled_AE
the I-OSE_Labeled_AE
subcutaneous I-OSE_Labeled_AE
tissue I-OSE_Labeled_AE
can O
occur O
if O
the O
reservoir O
refill O
septum O
is O
not O
properly O
accessed O
. O

Some O
pumps O
are O
also O
equipped O
with O
a O
catheter O
access O
port O
that O
allows O
direct O
access O
to O
the O
intrathecal O
catheter O
. O

Direct B-OSE_Labeled_AE
injection I-OSE_Labeled_AE
into I-OSE_Labeled_AE
this O
catheter I-OSE_Labeled_AE
access I-OSE_Labeled_AE
port I-OSE_Labeled_AE
or O
inadvertent B-OSE_Labeled_AE
injection I-OSE_Labeled_AE
into I-OSE_Labeled_AE
the I-OSE_Labeled_AE
subcutaneous I-OSE_Labeled_AE
tissue I-OSE_Labeled_AE
may O
cause O
a O
life-threatening O
overdose B-NonOSE_AE
. O

Withdrawal O
Abrupt O
withdrawal B-OSE_Labeled_AE
of O
intrathecal O
baclofen O
, O
regardless O
of O
the O
cause O
, O
has O
resulted O
in O
sequelae O
that O
included O
high B-NonOSE_AE
fever I-NonOSE_AE
, O
altered B-NonOSE_AE
mental I-NonOSE_AE
status I-NonOSE_AE
, O
exaggerated O
rebound B-NonOSE_AE
spasticity I-NonOSE_AE
and O
muscle B-NonOSE_AE
rigidity I-NonOSE_AE
that O
in O
rare O
cases O
progressed O
to O
rhabdomyolysis B-NonOSE_AE
, O
multiple B-NonOSE_AE
organ I-NonOSE_AE
- I-NonOSE_AE
system I-NonOSE_AE
failure I-NonOSE_AE
, O
and O
death B-NonOSE_AE
. O

In O
the O
first O
9 O
years O
of O
post-marketing O
experience O
, O
27 O
cases O
of O
withdrawal B-OSE_Labeled_AE
temporally O
related O
to O
the O
cessation O
of O
baclofen O
therapy O
were O
reported O
; O
six O
patients O
died B-NonOSE_AE
. O

In O
most O
cases O
, O
symptoms O
of O
withdrawal B-OSE_Labeled_AE
appeared O
within O
hours O
to O
a O
few O
days O
following O
interruption O
of O
baclofen O
therapy O
. O

Common O
reasons O
for O
abrupt O
interruption O
of O
intrathecal O
baclofen O
therapy O
included O
malfunction B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
catheter I-NonOSE_AE
( O
especially O
disconnection O
) O
, O
low B-NonOSE_AE
volume I-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
pump I-NonOSE_AE
reservoir I-NonOSE_AE
, O
and O
end B-NonOSE_AE
of I-NonOSE_AE
pump I-NonOSE_AE
battery I-NonOSE_AE
life I-NonOSE_AE
; O
human O
error O
may O
have O
played O
a O
causal O
or O
contributing O
role O
in O
some O
cases O
. O

Cases O
of O
intrathecal B-OSE_Labeled_AE
mass I-OSE_Labeled_AE
at I-OSE_Labeled_AE
the I-OSE_Labeled_AE
tip I-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
implanted I-OSE_Labeled_AE
catheter I-OSE_Labeled_AE
leading O
to O
withdrawal B-NonOSE_AE
symptoms O
have O
also O
been O
reported O
, O
most O
of O
them O
involving O
pharmacy O
compounded O
analgesic O
admixtures O
( O
see O
PRECAUTIONS O
) O
. O

Prevention O
of O
abrupt O
discontinuation O
of O
intrathecal O
baclofen O
requires O
careful O
attention O
to O
programming O
and O
monitoring O
of O
the O
infusion O
system O
, O
refill O
scheduling O
and O
procedures O
, O
and O
pump O
alarms O
. O

Patients O
and O
caregivers O
should O
be O
advised O
of O
the O
importance O
of O
keeping O
scheduled O
refill O
visits O
and O
should O
be O
educated O
on O
the O
early O
symptoms O
of O
baclofen B-NonOSE_AE
withdrawal I-NonOSE_AE
. O

All O
patients O
receiving O
intrathecal O
baclofen O
therapy O
are O
potentially O
at O
risk O
for O
withdrawal B-OSE_Labeled_AE
. O

Early O
symptoms O
of O
baclofen B-OSE_Labeled_AE
withdrawal I-OSE_Labeled_AE
may O
include O
return O
of O
baseline O
spasticity B-NonOSE_AE
, O
pruritus B-NonOSE_AE
, O
hypotension B-NonOSE_AE
, O
and O
paresthesias B-NonOSE_AE
. O

Priapism B-NonOSE_AE
may O
develop O
or O
recur O
if O
treatment O
with O
intrathecal O
baclofen O
is O
interrupted O
. O

Some O
clinical O
characteristics O
of O
the O
advanced O
intrathecal B-NonOSE_AE
baclofen I-NonOSE_AE
withdrawal I-NonOSE_AE
syndrome I-NonOSE_AE
may O
resemble O
autonomic B-NonOSE_AE
dysreflexia I-NonOSE_AE
, O
infection B-NonOSE_AE
( O
sepsis B-NonOSE_AE
) O
, O
malignant B-NonOSE_AE
hyperthermia I-NonOSE_AE
, O
neuroleptic B-NonOSE_AE
- I-NonOSE_AE
malignant I-NonOSE_AE
syndrome I-NonOSE_AE
, O
or O
other O
conditions O
associated O
with O
a O
hypermetabolic B-NonOSE_AE
state I-NonOSE_AE
or O
widespread O
rhabdomyolysis B-NonOSE_AE
. O

Rapid O
, O
accurate O
diagnosis O
and O
treatment O
in O
an O
emergency-room O
or O
intensive-care O
setting O
are O
important O
in O
order O
to O
prevent O
the O
potentially O
life-threatening O
central B-NonOSE_AE
nervous I-NonOSE_AE
system I-NonOSE_AE
and O
systemic O
effects I-NonOSE_AE
of O
intrathecal B-NonOSE_AE
baclofen I-NonOSE_AE
withdrawal I-NonOSE_AE
. O

The O
suggested O
treatment O
for O
intrathecal B-NonOSE_AE
baclofen I-NonOSE_AE
withdrawal I-NonOSE_AE
is O
the O
restoration O
of O
intrathecal O
baclofen O
at O
or O
near O
the O
same O
dosage O
as O
before O
therapy O
was O
interrupted O
. O

However O
, O
if O
restoration O
of O
intrathecal O
delivery O
is O
delayed O
, O
treatment O
with O
GABA-ergic O
agonist O
drugs O
such O
as O
oral O
or O
enteral O
baclofen O
, O
or O
oral O
, O
enteral O
, O
or O
intravenous O
benzodiazepines O
may O
prevent O
potentially O
fatal B-NonOSE_AE
sequelae O
. O

Oral O
or O
enteral O
baclofen O
alone O
should O
not O
be O
relied O
upon O
to O
halt O
the O
progression O
of O
intrathecal B-NonOSE_AE
baclofen I-NonOSE_AE
withdrawal I-NonOSE_AE
. O

Seizures B-NonOSE_AE
have O
been O
reported O
during I-NonOSE_AE
overdose O
and O
w O
ith B-NonOSE_AE
wit I-NonOSE_AE
hdrawal I-NonOSE_AE
from O
LIORESAL O
INTRATHECAL O
as O
well O
as O
in O
patients O
maintained O
on O
therapeutic O
doses O
of O
LIORESAL O
INTRATHECAL O
. O

Fatalities O
Spasticity O
of O
Spinal O
Cord O
Origin O
There O
were O
16 O
deaths B-NonOSE_AE
reported O
among O
the O
576 O
U.S O
. O
patients O
treated O
with O
LIORESAL O
INTRATHECAL O
( O
baclofen O
injection O
) O
in O
pre- O
and O
post- O
marketing O
studies O
evaluated O
as O
of O
December O
1992 O
. O

Because O
these O
patients O
were O
treated O
under O
uncontrolled O
clinical O
settings O
, O
it O
is O
impossible O
to O
determine O
definitively O
what O
role O
, O
if O
any O
, O
LIORESAL O
INTRATHECAL O
played O
in O
their O
deaths B-NonOSE_AE
. O

As O
a O
group O
, O
the O
patients O
who O
died B-NonOSE_AE
were O
relatively O
young O
( O
mean O
age O
was O
47 O
with O
a O
range O
from O
25 O
to O
63 O
) O
, O
but O
the O
majority O
suffered O
from O
severe O
spasticity B-Not_AE_Candidate
of O
many O
years O
duration O
, O
were O
nonambulatory O
, O
had O
various O
medical O
complications O
such O
as O
pneumonia B-Not_AE_Candidate
, O
urinary B-Not_AE_Candidate
tract I-Not_AE_Candidate
infections I-Not_AE_Candidate
, O
and O
decubiti B-Not_AE_Candidate
, O
and/or O
had O
received O
multiple O
concomitant O
medications O
. O

A O
case-by-case O
review O
of O
the O
clinical O
course O
of O
the O
16 O
patients O
who O
died B-NonOSE_AE
failed O
to O
reveal O
any O
unique O
signs O
, O
symptoms O
, O
or O
laboratory O
results O
that O
would O
suggest O
that O
treatment O
with O
LIORESAL O
INTRATHECAL O
caused O
their O
deaths B-NonOSE_AE
. O

Two O
patients O
, O
however O
, O
did O
suffer O
sudden B-NonOSE_AE
and I-NonOSE_AE
unexpected I-NonOSE_AE
death I-NonOSE_AE
within O
2 O
weeks O
of O
pump O
implantation O
and O
one O
patient O
died B-NonOSE_AE
unexpectedly O
after O
screening O
. O

One O
patient O
, O
a O
44 O
year O
old O
male O
with O
MS B-Not_AE_Candidate
, O
died B-NonOSE_AE
in O
hospital O
on O
the O
second O
day O
following O
pump O
implantation O
. O

An O
autopsy O
demonstrated O
severe O
fibrosis B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
coronary I-NonOSE_AE
conduction I-NonOSE_AE
system I-NonOSE_AE
. O

A O
second O
patient O
, O
a O
52 O
year O
old O
woman O
with O
MS B-Not_AE_Candidate
and O
a O
history O
of O
an O
inferior B-Not_AE_Candidate
wall I-Not_AE_Candidate
myocardial I-Not_AE_Candidate
infarction I-Not_AE_Candidate
, O
was O
found O
dead O
in O
bed O
12 O
days O
after O
pump O
implantation O
, O
2 O
hours O
after O
having O
had O
documented O
normal O
vital O
signs O
. O

An O
autopsy O
revealed O
pulmonary B-NonOSE_AE
congestion I-NonOSE_AE
and O
bilateral B-NonOSE_AE
pleural I-NonOSE_AE
effusions I-NonOSE_AE
. O

It O
is O
impossible O
to O
determine O
whether O
LIORESAL O
INTRATHECAL O
contributed O
to O
these O
deaths B-NonOSE_AE
. O

The O
third O
patient O
underwent O
three O
baclofen O
screening O
trials O
. O

His O
medical O
history O
included O
SCI B-Not_AE_Candidate
, O
aspiration B-Not_AE_Candidate
pneumonia I-Not_AE_Candidate
, O
septic B-Not_AE_Candidate
shock I-Not_AE_Candidate
, O
disseminated B-Not_AE_Candidate
intravascular I-Not_AE_Candidate
coagulopathy I-Not_AE_Candidate
, O
severe O
metabolic B-Not_AE_Candidate
acidosis I-Not_AE_Candidate
, O
hepatic B-Not_AE_Candidate
toxicity I-Not_AE_Candidate
, O
and O
status B-Not_AE_Candidate
epilepticus I-Not_AE_Candidate
. O

Twelve O
days O
after O
screening O
( O
he O
was O
not O
implanted O
) O
, O
he O
again O
experienced O
status B-NonOSE_AE
epilepticus I-NonOSE_AE
with O
subsequent O
significant O
neurological B-NonOSE_AE
deterioration I-NonOSE_AE
. O

Based O
upon O
prior O
instruction O
, O
extraordinary O
resuscitative O
measures O
were O
not O
pursued O
and O
the O
patient O
died B-NonOSE_AE
. O

Spasticity O
of O
Cerebral O
Origin O
There O
were O
three O
deaths B-NonOSE_AE
occurring O
among O
the O
211 O
patients O
treated O
with O
LIORESAL O
INTRATHECAL O
in O
pre- O
marketing O
studies O
as O
of O
March O
1996 O
. O

These O
deaths B-NonOSE_AE
were O
not O
attributed O
to O
the O
therapy O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
label O
: O
Rhabdomyolysis B-OSE_Labeled_AE
and O
myopathy B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
Liver B-OSE_Labeled_AE
enzyme I-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
EXCERPT O
: O
The O
most O
commonly O
reported O
adverse O
reactions O
( O
incidence O
> O
= O
2 O
% O
) O
in O
patients O
treated O
with O
LIPITOR O
in O
placebo-controlled O
trials O
regardless O
of O
causality O
were O
: O
nasopharyngitis O
, O
arthralgia O
, O
diarrhea O
, O
pain O
in O
extremity O
, O
and O
urinary O
tract O
infection O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Pfizer O
at O
( O
1-800-438-1985 O
and O
www.pfizer.com O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
the O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

In O
the O
LIPITOR O
placebo-controlled O
clinical O
trial O
database O
of O
16,066 O
patients O
( O
8755 O
LIPITOR O
vs O
. O
7311 O
placebo O
; O
age O
range O
10-93 O
years O
, O
39 O
% O
women O
, O
91 O
% O
Caucasians O
, O
3 O
% O
Blacks O
, O
2 O
% O
Asians O
, O
4 O
% O
other O
) O
with O
a O
median O
treatment O
duration O
of O
53 O
weeks O
, O
9.7 O
% O
of O
patients O
on O
LIPITOR O
and O
9.5 O
% O
of O
the O
patients O
on O
placebo O
discontinued O
due O
to O
adverse O
reactions O
regardless O
of O
causality O
. O

The O
five O
most O
common O
adverse O
reactions O
in O
patients O
treated O
with O
LIPITOR O
that O
led O
to O
treatment O
discontinuation O
and O
occurred O
at O
a O
rate O
greater O
than O
placebo O
were O
: O
myalgia B-OSE_Labeled_AE
( O
0.7 O
% O
) O
, O
diarrhea B-OSE_Labeled_AE
( O
0.5 O
% O
) O
, O
nausea B-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
alanine B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increase I-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
and O
hepatic B-OSE_Labeled_AE
enzyme I-OSE_Labeled_AE
increase I-OSE_Labeled_AE
( O
0.4 O
% O
) O
. O

The O
most O
commonly O
reported O
adverse O
reactions O
( O
incidence O
> O
= O
2 O
% O
and O
greater O
than O
placebo O
) O
regardless O
of O
causality O
, O
in O
patients O
treated O
with O
LIPITOR O
in O
placebo O
controlled O
trials O
( O
n=8755 O
) O
were O
: O
nasopharyngitis B-OSE_Labeled_AE
( O
8.3 O
% O
) O
, O
arthralgia B-OSE_Labeled_AE
( O
6.9 O
% O
) O
, O
diarrhea B-OSE_Labeled_AE
( O
6.8 O
% O
) O
, O
pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
( O
6.0 O
% O
) O
, O
and O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
5.7 O
% O
) O
. O

Table O
3 O
summarizes O
the O
frequency O
of O
clinical O
adverse O
reactions O
, O
regardless O
of O
causality O
, O
reported O
in O
> O
= O
2 O
% O
and O
at O
a O
rate O
greater O
than O
placebo O
in O
patients O
treated O
with O
LIPITOR O
( O
n=8755 O
) O
, O
from O
seventeen O
placebo-controlled O
trials O
. O

Table O
3 O
. O

Clinical O
adverse O
reactions O
occurring O
in O
> O
= O
2 O
% O
in O
patients O
treated O
with O
any O
dose O
of O
LIPITOR O
and O
at O
an O
incidence O
greater O
than O
placebo O
regardless O
of O
causality O
( O
% O
of O
patients O
) O
. O

Adverse O
Reaction O
[ O
note O
: O
Adverse O
Reaction O
> O
= O
2 O
% O
in O
any O
dose O
greater O
than O
placebo O
] O
Any O
doseN=8755 O
10 O
mgN=3908 O
20 O
mgN=188 O
40 O
mgN=604 O
80 O
mgN=4055 O
PlaceboN=7311 O
Nasopharyngitis B-OSE_Labeled_AE
8.3 O
12.9 O
5.3 O
7.0 O
4.2 O
8.2 O
Arthralgia B-OSE_Labeled_AE
6.9 O
8.9 O
11.7 O
10.6 O
4.3 O
6.5 O
Diarrhea B-OSE_Labeled_AE
6.8 O
7.3 O
6.4 O
14.1 O
5.2 O
6.3 O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
6.0 O
8.5 O
3.7 O
9.3 O
3.1 O
5.9 O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
5.7 O
6.9 O
6.4 O
8.0 O
4.1 O
5.6 O
Dyspepsia B-OSE_Labeled_AE
4.7 O
5.9 O
3.2 O
6.0 O
3.3 O
4.3 O
Nausea B-OSE_Labeled_AE
4.0 O
3.7 O
3.7 O
7.1 O
3.8 O
3.5 O
Musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
3.8 O
5.2 O
3.2 O
5.1 O
2.3 O
3.6 O
Muscle B-OSE_Labeled_AE
Spasms I-OSE_Labeled_AE
3.6 O
4.6 O
4.8 O
5.1 O
2.4 O
3.0 O
Myalgia B-OSE_Labeled_AE
3.5 O
3.6 O
5.9 O
8.4 O
2.7 O
3.1 O
Insomnia B-OSE_Labeled_AE
3.0 O
2.8 O
1.1 O
5.3 O
2.8 O
2.9 O
Pharyngolaryngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
2.3 O
3.9 O
1.6 O
2.8 O
0.7 O
2.1 O
Other O
adverse O
reactions O
reported O
in O
placebo-controlled O
studies O
include O
: O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
whole I-NonOSE_AE
: O
malaise B-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
; O
Digestive B-NonOSE_AE
system I-NonOSE_AE
: O
abdominal B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
, O
eructation B-OSE_Labeled_AE
, O
flatulence B-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
, O
cholestasis B-OSE_Labeled_AE
; O
Musculoskeletal B-NonOSE_AE
system I-NonOSE_AE
: O
musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
fatigue I-OSE_Labeled_AE
, O
neck B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
joint B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
; O
Metabolic B-NonOSE_AE
and I-NonOSE_AE
nutritional I-NonOSE_AE
system I-NonOSE_AE
: O
transaminases B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
, O
liver B-OSE_Labeled_AE
function I-OSE_Labeled_AE
test I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
blood B-OSE_Labeled_AE
alkaline I-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
increase I-OSE_Labeled_AE
, O
creatine B-OSE_Labeled_AE
phosphokinase I-OSE_Labeled_AE
increase I-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
; O
Nervous B-NonOSE_AE
system I-NonOSE_AE
: O
nightmare B-OSE_Labeled_AE
; O
Respiratory B-NonOSE_AE
system I-NonOSE_AE
: O
epistaxis B-OSE_Labeled_AE
; O
Skin B-NonOSE_AE
and I-NonOSE_AE
appendages I-NonOSE_AE
: O
urticaria B-OSE_Labeled_AE
; O
Special B-NonOSE_AE
senses I-NonOSE_AE
: O
vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
, O
tinnitus B-OSE_Labeled_AE
; O
Urogenital B-NonOSE_AE
system I-NonOSE_AE
: O
white B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cells I-OSE_Labeled_AE
urine I-OSE_Labeled_AE
positive I-OSE_Labeled_AE
. O

Anglo-Scandinavian O
Cardiac O
Outcomes O
Trial O
( O
ASCOT O
) O
In O
ASCOT O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
involving O
10,305 O
participants O
( O
age O
range O
40-80 O
years O
, O
19 O
% O
women O
; O
94.6 O
% O
Caucasians O
, O
2.6 O
% O
Africans O
, O
1.5 O
% O
South O
Asians O
, O
1.3 O
% O
mixed/other O
) O
treated O
with O
LIPITOR O
10 O
mg O
daily O
( O
n=5,168 O
) O
or O
placebo O
( O
n=5,137 O
) O
, O
the O
safety O
and O
tolerability O
profile O
of O
the O
group O
treated O
with O
LIPITOR O
was O
comparable O
to O
that O
of O
the O
group O
treated O
with O
placebo O
during O
a O
median O
of O
3.3 O
years O
of O
follow-up O
. O

Collaborative O
Atorvastatin O
Diabetes O
Study O
( O
CARDS O
) O
In O
CARDS O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
involving O
2,838 O
subjects O
( O
age O
range O
39-77 O
years O
, O
32 O
% O
women O
; O
94.3 O
% O
Caucasians O
, O
2.4 O
% O
South O
Asians O
, O
2.3 O
% O
Afro-Caribbean O
, O
1.0 O
% O
other O
) O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
treated O
with O
LIPITOR O
10 O
mg O
daily O
( O
n=1,428 O
) O
or O
placebo O
( O
n=1,410 O
) O
, O
there O
was O
no O
difference O
in O
the O
overall O
frequency O
of O
adverse O
reactions O
or O
serious O
adverse O
reactions O
between O
the O
treatment O
groups O
during O
a O
median O
follow-up O
of O
3.9 O
years O
. O

No O
cases O
of O
rhabdomyolysis B-NonOSE_AE
were O
reported O
. O

Treating O
to O
New O
Targets O
Study O
( O
TNT O
) O
In O
TNT O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
involving O
10,001 O
subjects O
( O
age O
range O
29-78 O
years O
, O
19 O
% O
women O
; O
94.1 O
% O
Caucasians O
, O
2.9 O
% O
Blacks O
, O
1.0 O
% O
Asians O
, O
2.0 O
% O
other O
) O
with O
clinically O
evident O
CHD B-Not_AE_Candidate
treated O
with O
LIPITOR O
10 O
mg O
daily O
( O
n=5006 O
) O
or O
LIPITOR O
80 O
mg O
daily O
( O
n=4995 O
) O
, O
there O
were O
more O
serious O
adverse O
reactions O
and O
discontinuations O
due O
to O
adverse O
reactions O
in O
the O
high-dose O
atorvastatin O
group O
( O
92 O
, O
1.8 O
% O
; O
497 O
, O
9.9 O
% O
, O
respectively O
) O
as O
compared O
to O
the O
low-dose O
group O
( O
69 O
, O
1.4 O
% O
; O
404 O
, O
8.1 O
% O
, O
respectively O
) O
during O
a O
median O
follow-up O
of O
4.9 O
years O
. O

Persistent O
transaminase B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
( O
> O
=3 O
* O
ULN O
twice O
within O
4-10 O
days O
) O
occurred O
in O
62 O
( O
1.3 O
% O
) O
individuals O
with O
atorvastatin O
80 O
mg O
and O
in O
nine O
( O
0.2 O
% O
) O
individuals O
with O
atorvastatin O
10 O
mg O
. O
Elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
CK I-OSE_Labeled_AE
( O
> O
= O
10 O
* O
ULN O
) O
were O
low O
overall O
, O
but O
were O
higher O
in O
the O
high-dose O
atorvastatin O
treatment O
group O
( O
13 O
, O
0.3 O
% O
) O
compared O
to O
the O
low-dose O
atorvastatin O
group O
( O
6 O
, O
0.1 O
% O
) O
. O

Incremental O
Decrease O
in O
Endpoints O
through O
Aggressive O
Lipid O
Lowering O
Study O
( O
IDEAL O
) O
In O
IDEAL O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
involving O
8,888 O
subjects O
( O
age O
range O
26-80 O
years O
, O
19 O
% O
women O
; O
99.3 O
% O
Caucasians O
, O
0.4 O
% O
Asians O
, O
0.3 O
% O
Blacks O
, O
0.04 O
% O
other O
) O
treated O
with O
LIPITOR O
80 O
mg/day O
( O
n=4439 O
) O
or O
simvastatin O
20-40 O
mg O
daily O
( O
n=4449 O
) O
, O
there O
was O
no O
difference O
in O
the O
overall O
frequency O
of O
adverse O
reactions O
or O
serious O
adverse O
reactions O
between O
the O
treatment O
groups O
during O
a O
median O
follow-up O
of O
4.8 O
years O
. O

Stroke O
Prevention O
by O
Aggressive O
Reduction O
in O
Cholesterol O
Levels O
( O
SPARCL O
) O
In O
SPARCL O
involving O
4731 O
subjects O
( O
age O
range O
21-92 O
years O
, O
40 O
% O
women O
; O
93.3 O
% O
Caucasians O
, O
3.0 O
% O
Blacks O
, O
0.6 O
% O
Asians O
, O
3.1 O
% O
other O
) O
without O
clinically O
evident O
CHD B-Not_AE_Candidate
but O
with O
a O
stroke B-Not_AE_Candidate
or O
transient B-Not_AE_Candidate
ischemic I-Not_AE_Candidate
attack I-Not_AE_Candidate
( O
TIA O
) O
within O
the O
previous O
6 O
months O
treated O
with O
LIPITOR O
80 O
mg O
( O
n=2365 O
) O
or O
placebo O
( O
n=2366 O
) O
for O
a O
median O
follow-up O
of O
4.9 O
years O
, O
there O
was O
a O
higher O
incidence O
of O
persistent O
hepatic B-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
( O
> O
= O
3 O
* O
ULN O
twice O
within O
4-10 O
days O
) O
in O
the O
atorvastatin O
group O
( O
0.9 O
% O
) O
compared O
to O
placebo O
( O
0.1 O
% O
) O
. O

Elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
CK I-OSE_Labeled_AE
( O
> O
10 O
* O
ULN O
) O
were O
rare O
, O
but O
were O
higher O
in O
the O
atorvastatin O
group O
( O
0.1 O
% O
) O
compared O
to O
placebo O
( O
0.0 O
% O
) O
. O

Diabetes B-OSE_Labeled_AE
was O
reported O
as O
an O
adverse O
reaction O
in O
144 O
subjects O
( O
6.1 O
% O
) O
in O
the O
atorvastatin O
group O
and O
89 O
subjects O
( O
3.8 O
% O
) O
in O
the O
placebo O
group O
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

In O
a O
post-hoc O
analysis O
, O
LIPITOR O
80 O
mg O
reduced O
the O
incidence O
of O
ischemic B-Not_AE_Candidate
stroke I-Not_AE_Candidate
( O
218/2365 O
, O
9.2 O
% O
vs O
. O
274/2366 O
, O
11.6 O
% O
) O
and O
increased O
the O
incidence O
of O
hemorrhagic B-OSE_Labeled_AE
stroke I-OSE_Labeled_AE
( O
55/2365 O
, O
2.3 O
% O
vs O
. O
33/2366 O
, O
1.4 O
% O
) O
compared O
to O
placebo O
. O

The O
incidence O
of O
fatal B-NonOSE_AE
hemorrhagic B-NonOSE_AE
stroke I-NonOSE_AE
was O
similar O
between O
groups O
( O
17 O
LIPITOR O
vs O
. O
18 O
placebo O
) O
. O

The O
incidence O
of O
non-fatal O
hemorrhagic B-OSE_Labeled_AE
strokes I-OSE_Labeled_AE
was O
significantly O
greater O
in O
the O
atorvastatin O
group O
( O
38 O
non-fatal O
hemorrhagic B-OSE_Labeled_AE
strokes I-OSE_Labeled_AE
) O
as O
compared O
to O
the O
placebo O
group O
( O
16 O
non-fatal O
hemorrhagic B-NonOSE_AE
strokes I-NonOSE_AE
) O
. O

Subjects O
who O
entered O
the O
study O
with O
a O
hemorrhagic B-Not_AE_Candidate
stroke I-Not_AE_Candidate
appeared O
to O
be O
at O
increased O
risk O
for O
hemorrhagic B-OSE_Labeled_AE
stroke I-OSE_Labeled_AE
[ O
7 O
( O
16 O
% O
) O
LIPITOR O
vs O
. O
2 O
( O
4 O
% O
) O
placebo O
] O
. O

There O
were O
no O
significant O
differences O
between O
the O
treatment O
groups O
for O
all-cause O
mortality B-NonOSE_AE
: O
216 O
( O
9.1 O
% O
) O
in O
the O
LIPITOR O
80 O
mg/day O
group O
vs O
. O
211 O
( O
8.9 O
% O
) O
in O
the O
placebo O
group O
. O

The O
proportions O
of O
subjects O
who O
experienced O
cardiovascular B-NonOSE_AE
death I-NonOSE_AE
were O
numerically O
smaller O
in O
the O
LIPITOR O
80 O
mg O
group O
( O
3.3 O
% O
) O
than O
in O
the O
placebo O
group O
( O
4.1 O
% O
) O
. O

The O
proportions O
of O
subjects O
who O
experienced O
non-cardiovascular O
death B-NonOSE_AE
were O
numerically O
larger O
in O
the O
LIPITOR O
80 O
mg O
group O
( O
5.0 O
% O
) O
than O
in O
the O
placebo O
group O
( O
4.0 O
% O
) O
. O

Adverse O
Reactions O
from O
Clinical O
Studies O
of O
LIPITOR O
in O
Pediatric O
Patients O
In O
a O
26-week O
controlled O
study O
in O
boys O
and O
postmenarchal O
girls O
with O
HeFH O
( O
ages O
10 O
years O
to O
17 O
years O
) O
( O
n=140 O
, O
31 O
% O
female O
; O
92 O
% O
Caucasians O
, O
1.6 O
% O
Blacks O
, O
1.6 O
% O
Asians O
, O
4.8 O
% O
other O
) O
, O
the O
safety O
and O
tolerability O
profile O
of O
LIPITOR O
10 O
to O
20 O
mg O
daily O
, O
as O
an O
adjunct O
to O
diet O
to O
reduce B-Not_AE_Candidate
total I-Not_AE_Candidate
cholesterol I-Not_AE_Candidate
, O
LDL-C O
, O
and O
apo O
B O
levels O
, O
was O
generally O
similar O
to O
that O
of O
placebo O
[ O
see O
Use O
in O
Special O
Populations O
( O
8.4 O
) O
and O
Clinical O
Studies O
( O
14.6 O
) O
] O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
LIPITOR O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Adverse O
reactions O
associated O
with O
LIPITOR O
therapy O
reported O
since O
market O
introduction O
, O
that O
are O
not O
listed O
above O
, O
regardless O
of O
causality O
assessment O
, O
include O
the O
following O
: O
anaphylaxis B-OSE_Labeled_AE
, O
angioneurotic B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
bullous B-OSE_Labeled_AE
rashes I-OSE_Labeled_AE
( O
including O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
and O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
) O
, O
rhabdomyolysis B-OSE_Labeled_AE
, O
myositis B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
tendon B-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
, O
fatal B-NonOSE_AE
and O
non-fatal O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
and O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
. O

There O
have O
been O
rare O
reports O
of O
immune B-OSE_Labeled_AE
- I-OSE_Labeled_AE
mediated I-OSE_Labeled_AE
necrotizing I-OSE_Labeled_AE
myopathy I-OSE_Labeled_AE
associated O
with O
statin O
use O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

There O
have O
been O
rare O
postmarketing O
reports O
of O
cognitive B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
( O
e.g. O
, O
memory B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
forgetfulness B-OSE_Labeled_AE
, O
amnesia B-OSE_Labeled_AE
, O
memory B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
confusion B-OSE_Labeled_AE
) O
associated O
with O
statin O
use O
. O

These O
cognitive B-OSE_Labeled_AE
issues I-OSE_Labeled_AE
have O
been O
reported O
for O
all O
statins O
. O

The O
reports O
are O
generally O
nonserious O
, O
and O
reversible O
upon O
statin O
discontinuation O
, O
with O
variable O
times O
to O
symptom O
onset O
( O
1 O
day O
to O
years O
) O
and O
symptom O
resolution O
( O
median O
of O
3 O
weeks O
) O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Skeletal O
muscle O
effects O
( O
e.g. O
, O
myopathy O
and O
rhabdomyolysis O
) O
: O
Risks O
increase O
when O
higher O
doses O
are O
used O
concomitantly O
with O
cyclosporine O
and O
strong O
CYP3A4 O
inhibitors O
( O
e.g. O
, O
clarithromycin O
, O
itraconazole O
, O
HIV O
protease O
inhibitors O
) O
. O

Predisposing O
factors O
include O
advanced O
age O
( O
> O
65 O
) O
, O
uncontrolled O
hypothyroidism O
, O
and O
renal O
impairment O
. O

Rare O
cases O
of O
rhabdomyolysis O
with O
acute O
renal O
failure O
secondary O
to O
myoglobinuria O
have O
been O
reported O
. O

Advise O
patients O
to O
promptly O
report O
to O
their O
physician O
unexplained O
and/or O
persistent O
muscle O
pain O
, O
tenderness O
, O
or O
weakness O
. O

LIPITOR O
therapy O
should O
be O
discontinued O
if O
myopathy O
is O
diagnosed O
or O
suspected O
( O
5.1 O
, O
8.5 O
) O
. O

* O
Liver O
enzyme O
abnormalities O
: O
Persistent O
elevations O
in O
hepatic O
transaminases O
can O
occur O
. O

Check O
liver O
enzyme O
tests O
before O
initiating O
therapy O
and O
as O
clinically O
indicated O
thereafter O
( O
5.2 O
) O
. O

* O
A O
higher O
incidence O
of O
hemorrhagic O
stroke O
was O
seen O
in O
patients O
without O
CHD O
but O
with O
stroke O
or O
TIA O
within O
the O
previous O
6 O
months O
in O
the O
LIPITOR O
80 O
mg O
group O
vs O
. O
placebo O
( O
5.5 O
) O
. O

5.1 O
Skeletal O
Muscle O
Rare O
cases O
of O
rhabdomyolysis B-OSE_Labeled_AE
with O
acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
secondary O
to O
myoglobinuria B-OSE_Labeled_AE
have O
been O
reported O
with O
LIPITOR O
and O
with O
other O
drugs O
in O
this O
class O
. O

A O
history O
of O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
may O
be O
a O
risk O
factor O
for O
the O
development O
of O
rhabdomyolysis B-NonOSE_AE
. O

Such O
patients O
merit O
closer O
monitoring O
for O
skeletal O
muscle O
effects O
. O

Atorvastatin O
, O
like O
other O
statins O
, O
occasionally O
causes O
myopathy B-OSE_Labeled_AE
, O
defined O
as O
muscle B-NonOSE_AE
aches I-NonOSE_AE
or O
muscle B-NonOSE_AE
weakness I-NonOSE_AE
in O
conjunction O
with O
increases B-NonOSE_AE
in I-NonOSE_AE
creatine I-NonOSE_AE
phosphokinase I-NonOSE_AE
( I-NonOSE_AE
CPK I-NonOSE_AE
) O
values O
> O
10 O
times O
ULN O
. O

The O
concomitant O
use O
of O
higher O
doses O
of O
atorvastatin O
with O
certain O
drugs O
such O
as O
cyclosporine O
and O
strong O
CYP3A4 O
inhibitors O
( O
e.g. O
, O
clarithromycin O
, O
itraconazole O
, O
and O
HIV O
protease O
inhibitors O
) O
increases O
the O
risk O
of O
myopathy B-NonOSE_AE
/ O
rhabdomyolysis B-NonOSE_AE
. O

There O
have O
been O
rare O
reports O
of O
immune B-OSE_Labeled_AE
- I-OSE_Labeled_AE
mediated I-OSE_Labeled_AE
necrotizing I-OSE_Labeled_AE
myopathy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
IMNM I-OSE_Labeled_AE
) O
, O
an O
autoimmune B-OSE_Labeled_AE
myopathy I-OSE_Labeled_AE
, O
associated O
with O
statin O
use O
. O

IMNM B-NonOSE_AE
is O
characterized O
by O
: O
proximal B-NonOSE_AE
muscle I-NonOSE_AE
weakness I-NonOSE_AE
and O
elevated B-NonOSE_AE
serum I-NonOSE_AE
creatine I-NonOSE_AE
kinase I-NonOSE_AE
, O
which O
persist O
despite O
discontinuation O
of O
statin O
treatment O
; O
muscle O
biopsy O
showing O
necrotizing B-NonOSE_AE
myopathy I-NonOSE_AE
without O
significant O
inflammation B-NonOSE_AE
; O
improvement O
with O
immunosuppressive B-NonOSE_AE
agents I-NonOSE_AE
. O

Myopathy B-NonOSE_AE
should O
be O
considered O
in O
any O
patient O
with O
diffuse O
myalgias B-NonOSE_AE
, O
muscle B-NonOSE_AE
tenderness O
or O
weakness I-NonOSE_AE
, O
and/or O
marked O
elevation B-NonOSE_AE
of I-NonOSE_AE
CPK I-NonOSE_AE
. O

Patients O
should O
be O
advised O
to O
report O
promptly O
unexplained O
muscle B-NonOSE_AE
pain I-NonOSE_AE
, O
tenderness O
, O
or O
weakness O
, O
particularly O
if O
accompanied O
by O
malaise B-NonOSE_AE
or O
fever B-NonOSE_AE
or O
if O
muscle B-NonOSE_AE
signs I-NonOSE_AE
and I-NonOSE_AE
symptoms I-NonOSE_AE
persist O
after O
discontinuing O
LIPITOR O
. O

LIPITOR O
therapy O
should O
be O
discontinued O
if O
markedly O
elevated B-NonOSE_AE
CPK I-NonOSE_AE
levels I-NonOSE_AE
occur O
or O
myopathy B-NonOSE_AE
is O
diagnosed O
or O
suspected O
. O

The O
risk O
of O
myopathy B-NonOSE_AE
during O
treatment O
with O
drugs O
in O
this O
class O
is O
increased O
with O
concurrent O
administration O
of O
cyclosporine O
, O
fibric O
acid O
derivatives O
, O
erythromycin O
, O
clarithromycin O
, O
the O
hepatitis O
C O
protease O
inhibitor O
telaprevir O
, O
combinations O
of O
HIV O
protease O
inhibitors O
, O
including O
saquinavir O
plus O
ritonavir O
, O
lopinavir O
plus O
ritonavir O
, O
tipranavir O
plus O
ritonavir O
, O
darunavir O
plus O
ritonavir O
, O
fosamprenavir O
, O
and O
fosamprenavir O
plus O
ritonavir O
, O
niacin O
, O
or O
azole O
antifungals O
. O

Physicians O
considering O
combined O
therapy O
with O
LIPITOR O
and O
fibric O
acid O
derivatives O
, O
erythromycin O
, O
clarithromycin O
, O
a O
combination O
of O
saquinavir O
plus O
ritonavir O
, O
lopinavir O
plus O
ritonavir O
, O
darunavir O
plus O
ritonavir O
, O
fosamprenavir O
, O
or O
fosamprenavir O
plus O
ritonavir O
, O
azole O
antifungals O
, O
or O
lipid-modifying O
doses O
of O
niacin O
should O
carefully O
weigh O
the O
potential O
benefits O
and O
risks O
and O
should O
carefully O
monitor O
patients O
for O
any O
signs O
or O
symptoms O
of O
muscle B-NonOSE_AE
pain I-NonOSE_AE
, O
tenderness B-NonOSE_AE
, O
or O
weakness B-NonOSE_AE
, O
particularly O
during O
the O
initial O
months O
of O
therapy O
and O
during O
any O
periods O
of O
upward O
dosage O
titration O
of O
either O
drug O
. O

Lower O
starting O
and O
maintenance O
doses O
of O
atorvastatin O
should O
be O
considered O
when O
taken O
concomitantly O
with O
the O
aforementioned O
drugs O
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

Periodic O
creatine O
phosphokinase O
( O
CPK O
) O
determinations O
may O
be O
considered O
in O
such O
situations O
, O
but O
there O
is O
no O
assurance O
that O
such O
monitoring O
will O
prevent O
the O
occurrence O
of O
severe O
myopathy B-NonOSE_AE
. O

Prescribing O
recommendations O
for O
interacting O
agents O
are O
summarized O
in O
Table O
2 O
[ O
see O
Dosage O
and O
Administration O
( O
2.6 O
) O
, O
Drug O
Interactions O
( O
7 O
) O
, O
and O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

Table O
2 O
. O

Drug O
Interactions O
Associated O
with O
Increased O
Risk O
of O
Myopathy/Rhabdomyolysis O
Interacting O
Agents O
Prescribing O
Recommendations O
Cyclosporine O
, O
HIV O
protease O
inhibitors O
( O
tipranavir O
plus O
ritonavir O
) O
, O
hepatitis O
C O
protease O
inhibitor O
( O
telaprevir O
) O
Avoid O
atorvastatin O
HIV O
protease O
inhibitor O
( O
lopinavir O
plus O
ritonavir O
) O
Use O
with O
caution O
and O
lowest O
dose O
necessary O
Clarithromycin O
, O
itraconazole O
, O
HIV O
protease O
inhibitors O
( O
saquinavir O
plus O
ritonavir O
[ O
note O
: O
Use O
with O
caution O
and O
with O
the O
lowest O
dose O
necessary O
( O
12.3 O
) O
] O
, O
darunavir O
plus O
ritonavir O
, O
fosamprenavir O
, O
fosamprenavir O
plus O
ritonavir O
) O
Do O
not O
exceed O
20 O
mg O
atorvastatin O
daily O
HIV O
protease O
inhibitor O
( O
nelfinavir O
) O
Hepatitis O
C O
protease O
inhibitor O
( O
boceprevir O
) O
Do O
not O
exceed O
40 O
mg O
atorvastatin O
daily O
Cases O
of O
myopathy B-NonOSE_AE
, O
including O
rhabdomyolysis B-NonOSE_AE
, O
have O
been O
reported O
with O
atorvastatin O
co-administered O
with O
colchicine O
, O
and O
caution O
should O
be O
exercised O
when O
prescribing O
atorvastatin O
with O
colchicine O
[ O
see O
Drug O
Interactions O
( O
7.11 O
) O
] O
. O

LIPITOR O
therapy O
should O
be O
temporarily O
withheld O
or O
discontinued O
in O
any O
patient O
with O
an O
acute O
, O
serious O
condition O
suggestive O
of O
a O
myopathy B-NonOSE_AE
or O
having O
a O
risk O
factor O
predisposing O
to O
the O
development O
of O
renal B-NonOSE_AE
failure I-NonOSE_AE
secondary O
to O
rhabdomyolysis B-NonOSE_AE
( O
e.g. O
, O
severe O
acute B-Not_AE_Candidate
infection I-Not_AE_Candidate
, O
hypotension B-Not_AE_Candidate
, O
major O
surgery O
, O
trauma O
, O
severe O
metabolic B-Not_AE_Candidate
, O
endocrine O
and O
electrolyte O
disorders I-Not_AE_Candidate
, O
and O
uncontrolled B-Not_AE_Candidate
seizures I-Not_AE_Candidate
) O
. O

5.2 O
Liver B-OSE_Labeled_AE
Dysfunction I-OSE_Labeled_AE
Statins O
, O
like O
some O
other O
lipid-lowering O
therapies O
, O
have O
been O
associated O
with O
biochemical O
abnormalities B-OSE_Labeled_AE
of I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
. O

Persistent O
elevations B-OSE_Labeled_AE
( O
> O
3 O
times O
the O
upper O
limit O
of O
normal O
[ O
ULN O
] O
occurr O
in I-OSE_Labeled_AE
g O
on O
2 O
or O
more O
occasions O
) O
in O
serum I-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
occurred O
in O
0.7 O
% O
of O
patients O
who O
received O
LIPITOR O
in O
clinical O
trials O
. O

The O
incidence O
of O
these O
abnormalities O
was O
0.2 O
% O
, O
0.2 O
% O
, O
0.6 O
% O
, O
and O
2.3 O
% O
for O
10 O
, O
20 O
, O
40 O
, O
and O
80 O
mg O
, O
respectively O
. O

One O
patient O
in O
clinical O
trials O
developed O
jaundice B-OSE_Labeled_AE
. O

Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
( O
LFT O
) O
in O
other O
patients O
were O
not O
associated O
with O
jaundice B-NonOSE_AE
or O
other O
clinical O
signs O
or O
symptoms O
. O

Upon O
dose O
reduction O
, O
drug O
interruption O
, O
or O
discontinuation O
, O
transaminase O
levels O
returned O
to O
or O
near O
pretreatment O
levels O
without O
sequelae O
. O

Eighteen O
of O
30 O
patients O
with O
persistent B-NonOSE_AE
LFT I-NonOSE_AE
elevations I-NonOSE_AE
continued O
treatment O
with O
a O
reduced O
dose O
of O
LIPITOR O
. O

It O
is O
recommended O
that O
liver O
enzyme O
tests O
be O
obtained O
prior O
to O
initiating O
therapy O
with O
LIPITOR O
and O
repeated O
as O
clinically O
indicated O
. O

There O
have O
been O
rare O
postmarketing O
reports O
of O
fatal B-NonOSE_AE
and O
non-fatal O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
in O
patients O
taking O
statins O
, O
including O
atorvastatin O
. O

If O
serious O
liver B-NonOSE_AE
injury I-NonOSE_AE
with O
clinical O
symptoms O
and/or O
hyperbilirubinemia B-NonOSE_AE
or O
jaundice B-NonOSE_AE
occurs O
during O
treatment O
with O
LIPITOR O
, O
promptly O
interrupt O
therapy O
. O

If O
an O
alternate O
etiology O
is O
not O
found O
, O
do O
not O
restart O
LIPITOR O
. O

LIPITOR O
should O
be O
used O
with O
caution O
in O
patients O
who O
consume O
substantial O
quantities O
of O
alcohol O
and/or O
have O
a O
history O
of O
liver B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Active B-Not_AE_Candidate
liver I-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
unexplained B-Not_AE_Candidate
persistent I-Not_AE_Candidate
transaminase I-Not_AE_Candidate
elevations I-Not_AE_Candidate
are O
contraindications O
to O
the O
use O
of O
LIPITOR O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

5.3 O
Endocrine O
Function O
Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
HbA I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
c I-OSE_Labeled_AE
and O
fasting O
serum O
glucose O
levels O
have O
been O
reported O
with O
HMG-CoA O
reductase O
inhibitors O
, O
including O
LIPITOR O
. O

Statins O
interfere O
with O
cholesterol O
synthesis O
and O
theoretically O
might O
blunt O
adrenal O
and/or O
gonadal O
steroid O
production O
. O

Clinical O
studies O
have O
shown O
that O
LIPITOR O
does O
not O
reduce B-NonOSE_AE
basal I-NonOSE_AE
plasma I-NonOSE_AE
cortisol I-NonOSE_AE
concentration I-NonOSE_AE
or O
impair B-NonOSE_AE
adrenal I-NonOSE_AE
reserve I-NonOSE_AE
. O

The O
effects O
of O
statins O
on O
male O
fertility O
have O
not O
been O
studied O
in O
adequate O
numbers O
of O
patients O
. O

The O
effects O
, O
if O
any O
, O
on O
the O
pituitary-gonadal O
axis O
in O
premenopausal O
women O
are O
unknown O
. O

Caution O
should O
be O
exercised O
if O
a O
statin O
is O
administered O
concomitantly O
with O
drugs O
that O
may O
decrease B-NonOSE_AE
the I-NonOSE_AE
levels I-NonOSE_AE
or I-NonOSE_AE
activity I-NonOSE_AE
of I-NonOSE_AE
endogenous I-NonOSE_AE
steroid I-NonOSE_AE
hormones I-NonOSE_AE
, O
such O
as O
ketoconazole O
, O
spironolactone O
, O
and O
cimetidine O
. O

5.4 O
CNS O
Toxicity O
Brain B-NonOSE_AE
hemorrhage I-NonOSE_AE
was O
seen O
in O
a O
female O
dog O
treated O
for O
3 O
months O
at O
120 O
mg/kg/day O
. O

Brain B-NonOSE_AE
hemorrhage I-NonOSE_AE
and O
optic B-NonOSE_AE
nerve I-NonOSE_AE
vacuolation I-NonOSE_AE
were O
seen O
in O
another O
female O
dog O
that O
was O
sacrificed O
in O
moribund O
condition O
after O
11 O
weeks O
of O
escalating O
doses O
up O
to O
280 O
mg/kg/day O
. O

The O
120 O
mg/kg O
dose O
resulted O
in O
a O
systemic O
exposure O
approximately O
16 O
times O
the O
human O
plasma O
area-under-the-curve O
( O
AUC O
, O
0-24 O
hours O
) O
based O
on O
the O
maximum O
human O
dose O
of O
80 O
mg/day O
. O

A O
single O
tonic B-NonOSE_AE
convulsion I-NonOSE_AE
was O
seen O
in O
each O
of O
2 O
male O
dogs O
( O
one O
treated O
at O
10 O
mg/kg/day O
and O
one O
at O
120 O
mg/kg/day O
) O
in O
a O
2-year O
study O
. O

No O
CNS B-NonOSE_AE
lesions I-NonOSE_AE
have O
been O
observed O
in O
mice O
after O
chronic O
treatment O
for O
up O
to O
2 O
years O
at O
doses O
up O
to O
400 O
mg/kg/day O
or O
in O
rats O
at O
doses O
up O
to O
100 O
mg/kg/day O
. O

These O
doses O
were O
6 O
to O
11 O
times O
( O
mouse O
) O
and O
8 O
to O
16 O
times O
( O
rat O
) O
the O
human O
AUC O
( O
0-24 O
) O
based O
on O
the O
maximum O
recommended O
human O
dose O
of O
80 O
mg/day O
. O

CNS B-NonOSE_AE
vascular I-NonOSE_AE
lesions I-NonOSE_AE
, O
characterized O
by O
perivascular B-NonOSE_AE
hemorrhages I-NonOSE_AE
, O
edema B-NonOSE_AE
, O
and O
mononuclear B-NonOSE_AE
cell I-NonOSE_AE
infiltration I-NonOSE_AE
of I-NonOSE_AE
perivascular I-NonOSE_AE
spaces I-NonOSE_AE
, O
have O
been O
observed O
in O
dogs O
treated O
with O
other O
members O
of O
this O
class O
. O

A O
chemically O
similar O
drug O
in O
this O
class O
produced O
optic B-NonOSE_AE
nerve I-NonOSE_AE
degeneration I-NonOSE_AE
( O
Wallerian B-NonOSE_AE
degeneration I-NonOSE_AE
of I-NonOSE_AE
retinogeniculate I-NonOSE_AE
fibers I-NonOSE_AE
) O
in O
clinically O
normal O
dogs O
in O
a O
dose-dependent O
fashion O
at O
a O
dose O
that O
produced O
plasma O
drug O
levels O
about O
30 O
times O
higher O
than O
the O
mean O
drug O
level O
in O
humans O
taking O
the O
highest O
recommended O
dose O
. O

5.5 O
Use O
in O
Patients O
with O
Recent O
Stroke O
or O
TIA O
In O
a O
post-hoc O
analysis O
of O
the O
Stroke B-NonOSE_AE
Prevention O
by O
Aggressive O
Reduction O
in O
Cholesterol O
Levels O
( O
SPARCL O
) O
study O
where O
LIPITOR O
80 O
mg O
vs O
. O
placebo O
was O
administered O
in O
4,731 O
subjects O
without O
CHD B-NonOSE_AE
who O
had O
a O
stroke B-Not_AE_Candidate
or O
TIA B-Not_AE_Candidate
within O
the O
preceding O
6 O
months O
, O
a O
higher O
incidence O
of O
hemorrhagic B-OSE_Labeled_AE
stroke I-OSE_Labeled_AE
was O
seen O
in O
the O
LIPITOR O
80 O
mg O
group O
compared O
to O
placebo O
( O
55 O
, O
2.3 O
% O
atorvastatin O
vs O
. O
33 O
, O
1.4 O
% O
placebo O
; O
HR O
: O
1.68 O
, O
95 O
% O
CI O
: O
1.09 O
, O
2.59 O
; O
p=0.0168 O
) O
. O

The O
incidence O
of O
fatal B-NonOSE_AE
hemorrhagic B-NonOSE_AE
stroke I-NonOSE_AE
was O
similar O
across O
treatment O
groups O
( O
17 O
vs O
. O
18 O
for O
the O
atorvastatin O
and O
placebo O
groups O
, O
respectively O
) O
. O

The O
incidence O
of O
nonfatal O
hemorrhagic B-OSE_Labeled_AE
stroke I-OSE_Labeled_AE
was O
significantly O
higher O
in O
the O
atorvastatin O
group O
( O
38 O
, O
1.6 O
% O
) O
as O
compared O
to O
the O
placebo O
group O
( O
16 O
, O
0.7 O
% O
) O
. O

Some O
baseline O
characteristics O
, O
including O
hemorrhagic B-Not_AE_Candidate
and O
lacunar O
stroke I-Not_AE_Candidate
on O
study O
entry O
, O
were O
associated O
with O
a O
higher O
incidence O
of O
hemorrhagic B-OSE_Labeled_AE
stroke I-OSE_Labeled_AE
in O
the O
atorvastatin O
group O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
observed O
in O
clinical O
trials O
were O
application O
site O
reactions O
, O
which O
occurred O
in O
less O
than O
1 O
% O
of O
subjects O
. O

( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Valeant O
Pharmaceuticals O
North O
America O
LLC O
at O
1-800-321-4576 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
, O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

In O
three O
Phase O
3 O
clinical O
trials O
, O
616 O
subjects O
were O
exposed O
to O
LUZU O
Cream O
, O
1 O
% O
: O
305 O
with O
interdigital B-Not_AE_Candidate
tinea I-Not_AE_Candidate
pedis I-Not_AE_Candidate
and O
311 O
subjects O
with O
tinea B-Not_AE_Candidate
cruris I-Not_AE_Candidate
. O

Subjects O
with O
interdigital B-Not_AE_Candidate
tinea I-Not_AE_Candidate
pedis I-Not_AE_Candidate
or O
tinea B-Not_AE_Candidate
cruris I-Not_AE_Candidate
applied O
LUZU O
Cream O
, O
1 O
% O
or O
vehicle O
cream O
once O
daily O
for O
14 O
days O
or O
7 O
days O
, O
respectively O
, O
to O
affected O
and O
adjacent O
areas O
. O

During O
clinical O
trials O
with O
LUZU O
Cream O
, O
1 O
% O
, O
the O
most O
common O
adverse O
reactions O
were O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
which O
occurred O
in O
less O
than O
1 O
% O
of O
subjects O
in O
both O
the O
LUZU O
and O
vehicle O
arms O
. O

Most O
adverse O
reactions O
were O
mild O
in O
severity O
. O

6.2 O
Post-Marketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
postmarketing O
use O
of O
luliconazole O
cream O
, O
1 O
% O
: O
contact B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
and O
cellulitis B-OSE_Labeled_AE
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
another O
section O
of O
the O
label O
: O
* O
New B-OSE_Labeled_AE
Primary I-OSE_Labeled_AE
Malignancies I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Hemorrhage B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Venous B-OSE_Labeled_AE
Thromboembolism I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Cardiomyopathy B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Ocular B-OSE_Labeled_AE
Toxicities I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Interstitial B-OSE_Labeled_AE
Lung I-OSE_Labeled_AE
Disease I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Serious O
Febrile B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Serious O
Skin B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Hyperglycemia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Most O
common O
adverse O
reactions O
( O
> O
=20 O
% O
) O
for O
MEKINIST O
as O
a O
single O
agent O
include O
rash O
, O
diarrhea O
, O
and O
lymphedema O
. O

( O
6.1 O
) O
* O
Most O
common O
adverse O
reactions O
( O
> O
=20 O
% O
) O
for O
MEKINIST O
in O
combination O
with O
dabrafenib O
include O
pyrexia O
, O
chills O
, O
fatigue O
, O
rash O
, O
nausea O
, O
vomiting O
, O
diarrhea O
, O
abdominal O
pain O
, O
peripheral O
edema O
, O
cough O
, O
headache O
, O
arthralgia O
, O
night O
sweats O
, O
decreased O
appetite O
, O
constipation O
, O
and O
myalgia O
. O

( O
6.1 O
) O
EXCERPT O
: O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
GlaxoSmithKline O
at O
1-888-825-5249 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
with O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
data O
described O
in O
the O
Warnings O
and O
Precautions O
section O
and O
below O
reflect O
exposure O
to O
MEKINIST O
as O
a O
single O
agent O
and O
in O
combination O
with O
dabrafenib O
. O

MEKINIST O
as O
a O
single O
agent O
was O
evaluated O
in O
329 O
patients O
including O
107 O
( O
33 O
% O
) O
exposed O
for O
greater O
than O
or O
equal O
to O
6 O
months O
and O
30 O
( O
9 O
% O
) O
exposed O
for O
greater O
than O
or O
equal O
to O
one O
year O
. O

MEKINIST O
as O
a O
single O
agent O
was O
studied O
in O
open-label O
, O
single-arm O
trials O
( O
N O
= O
118 O
) O
or O
in O
an O
open-label O
, O
randomized O
, O
active-controlled O
trial O
( O
N O
= O
211 O
) O
. O

The O
median O
age O
was O
54 O
years O
, O
60 O
% O
were O
male O
, O
> O
99 O
% O
were O
white O
, O
and O
all O
patients O
had O
metastatic B-Not_AE_Candidate
melanoma I-Not_AE_Candidate
. O

All O
patients O
received O
2 O
mg O
once-daily O
doses O
of O
MEKINIST O
. O

The O
incidence O
of O
RPED O
and O
RVO O
are O
obtained O
from O
the O
1,749 O
patients O
from O
all O
clinical O
trials O
with O
MEKINIST O
. O

The O
safety O
of O
MEKINIST O
in O
combination O
with O
dabrafenib O
was O
evaluated O
in O
Trial O
2 O
and O
other O
trials O
consisting O
of O
202 O
patients O
with O
BRAF O
V600 O
mutation-positive O
unresectable O
or O
metastatic B-Not_AE_Candidate
melanoma I-Not_AE_Candidate
who O
received O
MEKINIST O
2 O
mg O
orally O
once O
daily O
in O
combination O
with O
dabrafenib O
150 O
mg O
orally O
twice O
daily O
until O
disease O
progression O
or O
unacceptable O
toxicity O
. O

Among O
these O
202 O
patients O
, O
68 O
( O
34 O
% O
) O
were O
exposed O
to O
MEKINIST O
and O
66 O
( O
33 O
% O
) O
were O
exposed O
to O
dabrafenib O
for O
greater O
than O
6 O
to O
12 O
months O
while O
36 O
( O
18 O
% O
) O
were O
exposed O
to O
MEKINIST O
and O
40 O
( O
20 O
% O
) O
were O
exposed O
to O
dabrafenib O
for O
greater O
than O
one O
year O
. O

The O
median O
age O
was O
54 O
years O
, O
57 O
% O
were O
male O
and O
> O
99 O
% O
were O
white O
. O

Table O
3 O
presents O
adverse O
reactions O
identified O
from O
analyses O
of O
Trial O
1 O
, O
a O
randomized O
, O
open-label O
trial O
of O
patients O
with O
BRAF O
V600E O
or O
V600K O
mutation-positive O
melanoma B-Not_AE_Candidate
receiving O
MEKINIST O
( O
N O
= O
211 O
) O
2 O
mg O
orally O
once O
daily O
or O
chemotherapy O
( O
N O
= O
99 O
) O
( O
either O
dacarbazine O
1,000 O
mg/m O
2 O
every O
3 O
weeks O
or O
paclitaxel O
175 O
mg/m O
2 O
every O
3 O
weeks O
) O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

Patients O
with O
abnormal B-Not_AE_Candidate
LVEF I-Not_AE_Candidate
, O
history O
of O
acute B-Not_AE_Candidate
coronary I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
within O
6 O
months O
, O
or O
current O
evidence O
of O
Class O
II O
or O
greater O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
( O
New O
York O
Heart O
Association O
) O
were O
excluded O
from O
Trial O
1 O
. O

The O
median O
duration O
of O
treatment O
with O
MEKINIST O
was O
4.3 O
months O
. O

In O
Trial O
1 O
, O
9 O
% O
of O
patients O
receiving O
MEKINIST O
experienced O
adverse O
reactions O
resulting O
in O
permanent O
discontinuation O
of O
trial O
medication O
. O

The O
most O
common O
adverse O
reactions O
resulting O
in O
permanent O
discontinuation O
of O
MEKINIST O
were O
decreased B-OSE_Labeled_AE
left I-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
ejection I-OSE_Labeled_AE
fraction I-OSE_Labeled_AE
( I-OSE_Labeled_AE
LVEF I-OSE_Labeled_AE
) O
, O
pneumonitis B-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
and O
rash B-OSE_Labeled_AE
. O

Adverse O
reactions O
led O
to O
dose O
reductions O
in O
27 O
% O
of O
patients O
treated O
with O
MEKINIST O
. O

Rash B-OSE_Labeled_AE
and O
decreased B-OSE_Labeled_AE
LVEF I-OSE_Labeled_AE
were O
the O
most O
common O
reasons O
cited O
for O
dose O
reductions O
of O
MEKINIST O
. O

Table O
3 O
. O

Selected O
Adverse O
Reactions O
Occurring O
in O
> O
=10 O
% O
of O
Patients O
Receiving O
MEKINIST O
and O
at O
a O
Higher O
Incidence O
( O
> O
=5 O
% O
) O
Than O
in O
the O
Chemotherapy O
Arm O
or O
> O
=2 O
% O
( O
Grades O
3 O
or O
4 O
) O
Adverse O
Reactions O
Adverse O
Reactions O
MEKINIST O
Chemotherapy O
N O
= O
211 O
N O
= O
99 O
All O
Gradesa O
Grades O
3 O
and O
4b O
All O
Gradesa O
Grades O
3 O
and O
4b O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
57 O
8 O
10 O
0 O
Dermatitis B-OSE_Labeled_AE
acneiform I-OSE_Labeled_AE
19 O
< O
1 O
1 O
0 O
Dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
11 O
0 O
0 O
0 O
Pruritus B-OSE_Labeled_AE
10 O
2 O
1 O
0 O
Paronychia B-OSE_Labeled_AE
10 O
0 O
1 O
0 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
43 O
0 O
16 O
2 O
Stomatitis B-OSE_Labeled_AE
c O
15 O
2 O
2 O
0 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
d O
13 O
1 O
5 O
1 O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Lymphedema B-OSE_Labeled_AE
e O
32 O
1 O
4 O
0 O
Hypertension B-OSE_Labeled_AE
15 O
12 O
7 O
3 O
Hemorrhage B-OSE_Labeled_AE
f O
13 O
< O
1 O
0 O
0 O
a O
National O
Cancer O
Institute O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
, O
version O
4.0 O
. O
b O
Grade O
4 O
adverse O
reactions O
limited O
to O
rash B-OSE_Labeled_AE
( O
n O
= O
1 O
) O
in O
trametinib O
arm O
and O
diarrhea B-NonOSE_AE
( O
n O
= O
1 O
) O
in O
chemotherapy O
arm O
. O

c O
Includes O
the O
following O
terms O
: O
stomatitis B-OSE_Labeled_AE
, O
aphthous B-OSE_Labeled_AE
stomatitis I-OSE_Labeled_AE
, O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
and O
mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
. O

d O
Includes O
the O
following O
terms O
: O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
lower I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
, O
and O
abdominal B-OSE_Labeled_AE
tenderness I-OSE_Labeled_AE
. O

e O
Includes O
the O
following O
terms O
: O
lymphedema B-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
and O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
. O

f O
Includes O
the O
following O
terms O
: O
epistaxis B-OSE_Labeled_AE
, O
gingival B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
, O
hematochezia B-OSE_Labeled_AE
, O
rectal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
melena B-OSE_Labeled_AE
, O
vaginal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
hemorrhoidal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
hematuria B-OSE_Labeled_AE
, O
and O
conjunctival B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
. O

Other O
clinically O
important O
adverse O
reactions O
observed O
in O
< O
=10 O
% O
of O
patients O
( O
N O
= O
329 O
) O
treated O
with O
MEKINIST O
were O
: O
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Bradycardia B-OSE_Labeled_AE
. O

Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Xerostomia B-OSE_Labeled_AE
. O

Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
: O
Folliculitis B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
pustular I-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
. O

Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Rhabdomyolysis B-OSE_Labeled_AE
. O

Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Dizziness B-OSE_Labeled_AE
, O
dysgeusia B-OSE_Labeled_AE
. O

Ocular B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
eye I-OSE_Labeled_AE
. O

Table O
4 O
. O

Percent-Patient O
Incidence O
of O
Laboratory O
Abnormalities O
Occurring O
at O
a O
Higher O
Incidence O
in O
Patients O
Treated O
With O
MEKINIST O
in O
Trial O
1 O
( O
Between-Arm O
Difference O
of O
> O
=5 O
% O
[ O
All O
Grades O
] O
or O
> O
=2 O
% O
[ O
Grades O
3 O
or O
4 O
] O
a O
) O
Test O
MEKINIST O
Chemotherapy O
N O
= O
211 O
N O
= O
99 O
All O
Grades O
Grades O
3 O
and O
4 O
All O
Grades O
Grades O
3 O
and O
4 O
Increased B-OSE_Labeled_AE
aspartate O
aminotransferase I-OSE_Labeled_AE
( O
AST O
) O
60 O
2 O
16 O
1 O
Increased B-OSE_Labeled_AE
alanine I-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
( O
ALT O
) O
39 O
3 O
20 O
3 O
Hypoalbuminemia B-OSE_Labeled_AE
42 O
2 O
23 O
1 O
Anemia B-OSE_Labeled_AE
38 O
2 O
26 O
3 O
Increased B-OSE_Labeled_AE
alkaline I-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
24 O
2 O
18 O
3 O
* O
a O
No O
Grade O
4 O
events O
were O
reported O
in O
either O
treatment O
arm O
. O

Table O
5 O
presents O
adverse O
reactions O
from O
Trial O
2 O
, O
a O
multicenter O
, O
open-label O
, O
randomized O
trial O
of O
162 O
patients O
with O
BRAF O
V600E O
or O
V600K O
mutation-positive O
melanoma B-Not_AE_Candidate
receiving O
MEKINIST O
2 O
mg O
once O
daily O
in O
combination O
with O
dabrafenib O
150 O
mg O
twice O
daily O
( O
N O
= O
55 O
) O
, O
MEKINIST O
1 O
mg O
once O
daily O
in O
combination O
with O
dabrafenib O
150 O
mg O
twice O
daily O
( O
N O
= O
54 O
) O
, O
and O
dabrafenib O
as O
a O
single O
agent O
150 O
mg O
twice O
daily O
( O
N O
= O
53 O
) O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

Patients O
with O
abnormal B-Not_AE_Candidate
LVEF I-Not_AE_Candidate
, O
history O
of O
acute B-Not_AE_Candidate
coronary I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
within O
6 O
months O
, O
current O
evidence O
of O
Class O
II O
or O
greater O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
( O
New O
York O
Heart O
Association O
) O
, O
history O
of O
RVO B-Not_AE_Candidate
, O
or O
RPED B-Not_AE_Candidate
, O
QTc B-Not_AE_Candidate
interval I-Not_AE_Candidate
> I-Not_AE_Candidate
= I-Not_AE_Candidate
4 I-Not_AE_Candidate
8 I-Not_AE_Candidate
0 I-Not_AE_Candidate
msec I-Not_AE_Candidate
, O
treatment O
refractory B-Not_AE_Candidate
hypertension I-Not_AE_Candidate
, O
uncontrolled O
arrhythmias B-Not_AE_Candidate
, O
history O
of O
pneumonitis B-Not_AE_Candidate
or O
interstitial B-Not_AE_Candidate
lung I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
or O
a O
known O
history O
of O
G B-Not_AE_Candidate
6 I-Not_AE_Candidate
PD I-Not_AE_Candidate
deficiency I-Not_AE_Candidate
were O
excluded O
. O

The O
median O
duration O
of O
treatment O
was O
10.9 O
months O
for O
both O
MEKINIST O
( O
2-mg O
once-daily O
treatment O
group O
) O
and O
dabrafenib O
when O
used O
in O
combination O
, O
10.6 O
months O
for O
both O
MEKINIST O
( O
1-mg O
once-daily O
treatment O
group O
) O
and O
dabrafenib O
when O
used O
in O
combination O
, O
and O
6.1 O
months O
for O
dabrafenib O
as O
a O
single O
agent O
. O

In O
Trial O
2 O
, O
13 O
% O
of O
patients O
receiving O
MEKINIST O
in O
combination O
with O
dabrafenib O
at O
the O
recommended O
dose O
experienced O
adverse O
reactions O
resulting O
in O
permanent O
discontinuation O
of O
trial O
medication O
( O
s O
) O
. O

The O
most O
common O
adverse O
reaction O
resulting O
in O
permanent O
discontinuation O
was O
pyrexia B-OSE_Labeled_AE
( O
4 O
% O
) O
. O

Adverse O
reactions O
led O
to O
dose O
reductions O
in O
49 O
% O
and O
dose O
interruptions O
in O
67 O
% O
of O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
. O

Pyrexia B-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
and O
nausea B-OSE_Labeled_AE
were O
the O
most O
common O
reasons O
cited O
for O
dose O
reductions O
, O
and O
pyrexia B-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
and O
decreased B-OSE_Labeled_AE
ejection I-OSE_Labeled_AE
fraction I-OSE_Labeled_AE
were O
the O
most O
common O
reasons O
cited O
for O
dose O
interruptions O
of O
MEKINIST O
and O
dabrafenib O
when O
used O
in O
combination O
. O

Table O
5 O
. O

Common O
Adverse O
Drug O
Reactions O
Occurring O
in O
> O
10 O
% O
( O
All O
Grades O
) O
or O
> O
=5 O
% O
( O
Grades O
3 O
or O
4 O
) O
of O
Patients O
Treated O
With O
MEKINIST O
in O
Combination O
With O
Dabrafenib O
in O
Trial O
2 O
Adverse O
Reactions O
MEKINIST O
2 O
mg O
plus O
Dabrafenib O
N O
= O
55 O
MEKINIST O
1 O
mg O
plus O
Dabrafenib O
N O
= O
54 O
Dabrafenib O
N O
= O
53 O
All O
Grades O
a O
Grades O
3 O
and O
4 O
All O
Grades O
a O
Grades O
3 O
and O
4 O
All O
Grades O
a O
Grades O
3 O
and O
4 O
General O
disorders O
and O
administrative O
site O
conditions O
Pyrexia B-OSE_Labeled_AE
71 O
5 O
69 O
9 O
26 O
0 O
Chills B-OSE_Labeled_AE
58 O
2 O
50 O
2 O
17 O
0 O
Fatigue B-OSE_Labeled_AE
53 O
4 O
57 O
2 O
40 O
6 O
Edema B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
b O
31 O
0 O
28 O
0 O
17 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
c O
45 O
0 O
43 O
2 O
53 O
0 O
Night B-OSE_Labeled_AE
sweats I-OSE_Labeled_AE
24 O
0 O
15 O
0 O
6 O
0 O
Dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
18 O
0 O
9 O
0 O
6 O
0 O
Dermatitis B-OSE_Labeled_AE
acneiform I-OSE_Labeled_AE
16 O
0 O
11 O
0 O
4 O
0 O
Actinic B-OSE_Labeled_AE
keratosis I-OSE_Labeled_AE
15 O
0 O
7 O
0 O
9 O
0 O
Erythema B-OSE_Labeled_AE
15 O
0 O
6 O
0 O
2 O
0 O
Pruritus B-OSE_Labeled_AE
11 O
0 O
11 O
0 O
13 O
0 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
44 O
2 O
46 O
6 O
21 O
0 O
Vomiting B-OSE_Labeled_AE
40 O
2 O
43 O
4 O
15 O
0 O
Diarrhea B-OSE_Labeled_AE
36 O
2 O
26 O
0 O
28 O
0 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
d O
33 O
2 O
24 O
2 O
21 O
2 O
Constipation B-OSE_Labeled_AE
22 O
0 O
17 O
2 O
11 O
0 O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
11 O
0 O
11 O
0 O
6 O
0 O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
29 O
0 O
37 O
2 O
28 O
0 O
Dizziness B-OSE_Labeled_AE
16 O
0 O
13 O
0 O
9 O
0 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
29 O
0 O
11 O
0 O
21 O
0 O
Oropharyngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
13 O
0 O
7 O
0 O
0 O
0 O
Musculoskeletal B-NonOSE_AE
, I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
bone I-NonOSE_AE
disorders I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
27 O
0 O
44 O
0 O
34 O
0 O
Myalgia B-OSE_Labeled_AE
22 O
2 O
24 O
0 O
23 O
2 O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
18 O
5 O
11 O
0 O
11 O
2 O
Muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
16 O
0 O
2 O
0 O
4 O
0 O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
16 O
0 O
11 O
2 O
19 O
0 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutritional I-NonOSE_AE
disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
22 O
0 O
30 O
0 O
19 O
0 O
Dehydration B-OSE_Labeled_AE
11 O
0 O
6 O
2 O
2 O
0 O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
18 O
0 O
11 O
0 O
8 O
2 O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hemorrhage B-OSE_Labeled_AE
e O
16 O
5 O
11 O
0 O
2 O
0 O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
13 O
2 O
6 O
0 O
9 O
2 O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
Renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
f O
7 O
7 O
2 O
0 O
0 O
0 O
* O
a O
National O
Cancer O
Institute O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
, O
version O
4 O
. O

* O
b O
Includes O
the O
following O
terms O
: O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
and O
lymphedema B-OSE_Labeled_AE
. O

* O
c O
Includes O
the O
following O
terms O
: O
rash B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
generalized I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
pruritic I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
erythematous I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
papular I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
vesicular I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
macular I-OSE_Labeled_AE
, O
and O
rash B-OSE_Labeled_AE
maculo I-OSE_Labeled_AE
- I-OSE_Labeled_AE
papular I-OSE_Labeled_AE
. O

* O
d O
Includes O
the O
following O
terms O
: O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
lower I-OSE_Labeled_AE
, O
and O
abdominal B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
. O

* O
e O
Includes O
the O
following O
terms O
: O
brain B-OSE_Labeled_AE
stem I-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
cerebral B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
gastric B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
gingival B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
hematuria B-OSE_Labeled_AE
, O
vaginal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
hemorrhage B-OSE_Labeled_AE
intracranial I-OSE_Labeled_AE
, O
eye B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
and O
vitreous B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
. O

* O
f O
Includes O
the O
following O
terms O
: O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
and O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
acute I-OSE_Labeled_AE
. O

Other O
clinically O
important O
adverse O
reactions O
( O
N O
= O
202 O
) O
observed O
in O
< O
10 O
% O
of O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
were O
: O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
, O
transient B-OSE_Labeled_AE
blindness I-OSE_Labeled_AE
. O

Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Stomatitis B-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
. O

General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
: O
Asthenia B-OSE_Labeled_AE
. O

Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
: O
Cellulitis B-OSE_Labeled_AE
, O
folliculitis B-OSE_Labeled_AE
, O
paronychia B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
pustular I-OSE_Labeled_AE
. O

Neoplasms B-NonOSE_AE
Benign O
, O
Malignant I-NonOSE_AE
, O
and O
Unspecified O
( O
including O
cysts O
and O
polyps O
) O
: O
Skin B-OSE_Labeled_AE
papilloma I-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
erythrodysesthesia I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
hyperkeratosis B-OSE_Labeled_AE
, O
hyperhidrosis B-OSE_Labeled_AE
. O

Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Hypertension B-OSE_Labeled_AE
. O

Table O
6 O
. O

Treatment-Emergent O
Laboratory O
Abnormalities O
Occurring O
at O
> O
=10 O
% O
( O
All O
Grades O
) O
or O
> O
=2 O
% O
( O
Grades O
3 O
or O
4 O
) O
of O
Patients O
Treated O
With O
MEKINIST O
in O
Combination O
With O
Dabrafenib O
in O
Trial O
2 O
Test O
MEKINIST O
2 O
mg O
plus O
Dabrafenib O
N O
= O
55 O
MEKINIST O
1 O
mg O
plus O
Dabrafenib O
N O
= O
54 O
Dabrafenib O
N O
= O
53 O
All O
Grades O
Grades O
3 O
and O
4 O
All O
Grades O
Grades O
3 O
and O
4 O
All O
Grades O
Grades O
3 O
and O
4a O
Hematology B-NonOSE_AE
Leukopenia B-OSE_Labeled_AE
62 O
5 O
46 O
4 O
21 O
0 O
Lymphopenia B-OSE_Labeled_AE
55 O
22 O
59 O
19 O
40 O
6 O
Neutropenia B-OSE_Labeled_AE
55 O
13 O
37 O
2 O
9 O
2 O
Anemia B-OSE_Labeled_AE
55 O
4 O
46 O
7 O
28 O
0 O
Thrombocytopenia B-OSE_Labeled_AE
31 O
4 O
31 O
2 O
8 O
0 O
Liver B-NonOSE_AE
Function I-NonOSE_AE
Tests I-NonOSE_AE
Increased B-OSE_Labeled_AE
AST I-OSE_Labeled_AE
60 O
5 O
54 O
0 O
15 O
0 O
Increased B-OSE_Labeled_AE
alkaline I-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
60 O
2 O
67 O
6 O
26 O
2 O
Increased B-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
42 O
4 O
35 O
4 O
11 O
0 O
Hyperbilirubinemia B-OSE_Labeled_AE
15 O
0 O
7 O
4 O
0 O
0 O
Chemistry B-NonOSE_AE
Hyperglycemia B-OSE_Labeled_AE
58 O
5 O
67 O
6 O
49 O
2 O
Increased B-OSE_Labeled_AE
GGT I-OSE_Labeled_AE
56 O
11 O
54 O
17 O
38 O
2 O
Hyponatremia B-OSE_Labeled_AE
55 O
11 O
48 O
15 O
36 O
2 O
Hypoalbuminemia B-OSE_Labeled_AE
53 O
0 O
43 O
2 O
23 O
0 O
Hypophosphatemia B-OSE_Labeled_AE
47 O
5 O
41 O
11 O
40 O
0 O
Hypokalemia B-OSE_Labeled_AE
29 O
2 O
15 O
2 O
23 O
6 O
Increased B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
24 O
5 O
20 O
2 O
9 O
0 O
Hypomagnesemia B-OSE_Labeled_AE
18 O
2 O
2 O
0 O
6 O
0 O
Hyperkalemia B-OSE_Labeled_AE
18 O
0 O
22 O
0 O
15 O
4 O
Hypercalcemia B-OSE_Labeled_AE
15 O
0 O
19 O
2 O
4 O
0 O
Hypocalcemia B-OSE_Labeled_AE
13 O
0 O
20 O
0 O
9 O
0 O
* O
a O
No O
Grade O
4 O
events O
were O
reported O
in O
dabrafenib O
arm O
. O

* O
ALT O
= O
Alanine O
aminotransferase O
; O
AST O
= O
Aspartate O
aminotransferase O
; O
GGT O
= O
Gamma O
glutamyltransferase O
. O

QT B-OSE_Labeled_AE
Prolongation I-OSE_Labeled_AE
: O
In O
Trial O
2 O
, O
QTcF B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
to O
> O
500 O
msec O
occurred O
in O
4 O
% O
( O
2/55 O
) O
of O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
and O
in O
2 O
% O
( O
1/53 O
) O
of O
patients O
treated O
with O
dabrafenib O
as O
a O
single O
agent O
. O

The O
QTcF B-OSE_Labeled_AE
was O
increased I-OSE_Labeled_AE
more O
than O
60 O
msec O
from O
baseline O
in O
13 O
% O
( O
7/55 O
) O
of O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
and O
2 O
% O
( O
1/53 O
) O
of O
patients O
treated O
with O
dabrafenib O
as O
a O
single O
agent O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
Review O
the O
Full O
Prescribing O
Information O
for O
dabrafenib O
prior O
to O
initiation O
of O
MEKINIST O
in O
combination O
with O
dabrafenib O
. O

The O
following O
serious O
adverse O
reactions O
of O
dabrafenib O
as O
a O
single O
agent O
, O
which O
may O
occur O
when O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
, O
are O
not O
described O
in O
the O
Full O
Prescribing O
Information O
for O
MEKINIST O
: O
* O
Tumor B-NonOSE_AE
promotion I-NonOSE_AE
in O
patients O
with O
BRAF B-Not_AE_Candidate
wild I-Not_AE_Candidate
- I-Not_AE_Candidate
type I-Not_AE_Candidate
melanoma I-Not_AE_Candidate
* O
Hemolytic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
in I-OSE_Labeled_AE
patients I-OSE_Labeled_AE
with I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
- I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
- I-OSE_Labeled_AE
phosphate I-OSE_Labeled_AE
dehydrogenase I-OSE_Labeled_AE
deficiency I-OSE_Labeled_AE
* O
New O
primary O
malignancies O
, O
cutaneous O
and O
non-cutaneous O
, O
can O
occur O
when O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
. O

Monitor O
patients O
for O
new O
malignancies O
prior O
to O
initiation O
of O
therapy O
while O
on O
therapy O
, O
and O
following O
discontinuation O
of O
the O
combination O
treatment O
. O

( O
5.1 O
, O
2.3 O
) O
* O
Hemorrhage O
: O
Major O
hemorrhagic O
events O
can O
occur O
in O
patients O
receiving O
MEKINIST O
in O
combination O
with O
dabrafenib O
. O

Monitor O
for O
signs O
and O
symptoms O
of O
bleeding O
( O
5.2 O
, O
2.3 O
) O
* O
Venous O
Thromboembolism O
: O
Deep O
vein O
thrombosis O
and O
pulmonary O
embolism O
can O
occur O
in O
patients O
receiving O
MEKINIST O
in O
combination O
with O
dabrafenib O
. O

( O
5.3 O
, O
2.3 O
) O
. O

* O
Cardiomyopathy O
: O
Assess O
LVEF O
before O
treatment O
, O
after O
one O
month O
of O
treatment O
, O
then O
every O
2 O
to O
3 O
months O
thereafter O
. O

( O
5.4 O
, O
2.3 O
) O
* O
Ocular O
Toxicities O
: O
Perform O
ophthalmologic O
evaluation O
for O
any O
visual O
disturbances O
. O

For O
Retinal O
Vein O
Occlusion O
( O
RVO O
) O
, O
permanently O
discontinue O
MEKINIST O
. O

( O
5.5 O
, O
2.3 O
) O
* O
Interstitial O
Lung O
Disease O
( O
ILD O
) O
: O
Withhold O
MEKINIST O
for O
new O
or O
progressive O
unexplained O
pulmonary O
symptoms O
. O

Permanently O
discontinue O
MEKINIST O
for O
treatment-related O
ILD O
or O
pneumonitis O
. O

( O
5.6 O
, O
2.3 O
) O
* O
Serious O
Febrile O
Reactions O
can O
occur O
when O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
. O

( O
5.7 O
, O
2.3 O
) O
* O
Serious O
Skin O
Toxicity O
: O
Monitor O
for O
skin O
toxicities O
and O
for O
secondary O
infections O
. O

Discontinue O
for O
intolerable O
Grade O
2 O
, O
or O
Grade O
3 O
or O
4 O
rash O
not O
improving O
within O
3 O
weeks O
despite O
interruption O
of O
MEKINIST O
. O

( O
5.8 O
, O
2.3 O
) O
* O
Hyperglycemia O
: O
Monitor O
serum O
glucose O
levels O
in O
patients O
with O
pre-existing O
diabetes O
or O
hyperglycemia O
. O

( O
5.9 O
, O
2.3 O
) O
* O
Embryofetal O
Toxicity O
: O
Can O
cause O
fetal O
harm O
. O

Advise O
females O
of O
reproductive O
potential O
of O
potential O
risk O
to O
the O
fetus O
. O

( O
5.10 O
, O
8.1 O
, O
8.6 O
) O
EXCERPT O
: O
5.1 O
New O
Primary O
Malignancies O
New O
primary O
malignancies B-OSE_Labeled_AE
, I-OSE_Labeled_AE
cutaneous I-OSE_Labeled_AE
and O
non-cutaneous O
, O
can O
occur O
when O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
and O
with O
dabrafenib O
as O
a O
single O
agent O
[ O
refer O
to O
Full O
Prescribing O
Information O
for O
dabrafenib O
] O
. O

Cutaneous O
Malignancies O
: O
In O
Trial O
2 O
, O
the O
incidence O
of O
basal B-OSE_Labeled_AE
cell I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
was O
increased O
in O
patients O
receiving O
MEKINIST O
in O
combination O
with O
dabrafenib O
, O
with O
an O
incidence O
of O
9 O
% O
( O
5/55 O
) O
in O
patients O
receiving O
MEKINIST O
in O
combination O
with O
dabrafenib O
compared O
with O
2 O
% O
( O
1/53 O
) O
in O
patients O
receiving O
dabrafenib O
as O
a O
single O
agent O
. O

The O
range O
of O
time O
to O
diagnosis O
of O
basal B-OSE_Labeled_AE
cell I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
was O
28 O
to O
249 O
days O
in O
patients O
receiving O
MEKINIST O
in O
combination O
with O
dabrafenib O
and O
was O
197 O
days O
for O
the O
patient O
receiving O
dabrafenib O
as O
a O
single O
agent O
. O

Cutaneous B-OSE_Labeled_AE
squamous I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
carcinomas I-OSE_Labeled_AE
( O
SCC O
) O
, O
including O
keratoacanthoma B-OSE_Labeled_AE
, O
occurred O
in O
7 O
% O
of O
patients O
receiving O
MEKINIST O
in O
combination O
with O
dabrafenib O
and O
19 O
% O
of O
patients O
receiving O
dabrafenib O
as O
a O
single O
agent O
. O

The O
range O
of O
time O
to O
diagnosis O
of O
cuSCC B-OSE_Labeled_AE
was O
136 O
to O
197 O
days O
in O
the O
combination O
arm O
and O
was O
9 O
to O
197 O
days O
in O
the O
arm O
receiving O
dabrafenib O
as O
a O
single O
agent O
. O

New B-NonOSE_AE
primary I-NonOSE_AE
melanoma I-NonOSE_AE
occurred O
in O
2 O
% O
( O
1/53 O
) O
of O
patients O
receiving O
dabrafenib O
and O
in O
none O
of O
the O
55 O
patients O
receiving O
MEKINIST O
in O
combination O
with O
dabrafenib O
. O

Perform O
dermatologic O
evaluations O
prior O
to O
initiation O
of O
MEKINIST O
in O
combination O
with O
dabrafenib O
, O
every O
2 O
months O
while O
on O
therapy O
, O
and O
for O
up O
to O
6 O
months O
following O
discontinuation O
of O
the O
combination O
. O

No O
dose O
modifications O
of O
MEKINIST O
or O
dabrafenib O
are O
recommended O
in O
patients O
who O
develop O
new O
primary O
cutaneous B-NonOSE_AE
malignancies I-NonOSE_AE
. O

Non-Cutaneous O
Malignancies O
: O
Based O
on O
its O
mechanism O
of O
action O
, O
dabrafenib O
may O
promote O
growth O
and O
development O
of O
malignancies B-NonOSE_AE
with O
activation O
of O
RAS O
through O
mutation O
or O
other O
mechanisms O
[ O
refer O
to O
the O
Full O
Prescribing O
Information O
for O
dabrafenib O
] O
. O

In O
patients O
receiving O
MEKINIST O
in O
combination O
with O
dabrafenib O
, O
four O
cases O
of O
non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
cutaneous I-OSE_Labeled_AE
malignancies I-OSE_Labeled_AE
were O
identified O
: O
KRAS B-OSE_Labeled_AE
mutation I-OSE_Labeled_AE
- I-OSE_Labeled_AE
positive I-OSE_Labeled_AE
pancreatic I-OSE_Labeled_AE
adenocarcinoma I-OSE_Labeled_AE
( O
n O
= O
1 O
) O
, O
recurrent B-OSE_Labeled_AE
NRAS I-OSE_Labeled_AE
mutation I-OSE_Labeled_AE
- I-OSE_Labeled_AE
positive I-OSE_Labeled_AE
colorectal I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
( O
n O
= O
1 O
) O
, O
head B-OSE_Labeled_AE
and I-OSE_Labeled_AE
neck I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
( O
n O
= O
1 O
) O
, O
and O
glioblastoma B-OSE_Labeled_AE
( O
n O
= O
1 O
) O
. O

Monitor O
patients O
receiving O
the O
combination O
closely O
for O
signs O
or O
symptoms O
of O
non B-NonOSE_AE
- I-NonOSE_AE
cutaneous I-NonOSE_AE
malignancies I-NonOSE_AE
. O

If O
used O
in O
combination O
with O
dabrafenib O
, O
no O
dose O
modification O
is O
required O
for O
MEKINIST O
in O
patients O
who O
develop O
non B-NonOSE_AE
- I-NonOSE_AE
cutaneous I-NonOSE_AE
malignancies I-NonOSE_AE
. O

Permanently O
discontinue O
dabrafenib O
in O
patients O
who O
develop O
RAS B-NonOSE_AE
mutation I-NonOSE_AE
- I-NonOSE_AE
positive I-NonOSE_AE
non I-NonOSE_AE
- I-NonOSE_AE
cutaneous I-NonOSE_AE
malignancies I-NonOSE_AE
. O

5.2 O
Hemorrhage O
Hemorrhages B-OSE_Labeled_AE
, O
including O
major B-OSE_Labeled_AE
hemorrhages I-OSE_Labeled_AE
defined O
as O
symptomatic O
bleeding B-OSE_Labeled_AE
in O
a O
critical O
area O
or O
organ O
, O
can O
occur O
when O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
. O

In O
Trial O
2 O
, O
treatment O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
resulted O
in O
an O
increased O
incidence O
and O
severity O
of O
any O
hemorrhagic B-OSE_Labeled_AE
event I-OSE_Labeled_AE
: O
16 O
% O
( O
9/55 O
) O
of O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
compared O
with O
2 O
% O
( O
1/53 O
) O
of O
patients O
treated O
with O
dabrafenib O
as O
a O
single O
agent O
. O

The O
major O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
of O
intracranial B-OSE_Labeled_AE
or O
gastric O
hemorrhage I-OSE_Labeled_AE
occurred O
in O
5 O
% O
( O
3/55 O
) O
of O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
compared O
with O
none O
of O
the O
53 O
patients O
treated O
with O
dabrafenib O
as O
a O
single O
agent O
. O

Intracranial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
was O
fatal O
in O
two O
( O
4 O
% O
) O
patients O
receiving O
the O
combination O
of O
MEKINIST O
and O
dabrafenib O
. O

Permanently O
discontinue O
MEKINIST O
, O
and O
also O
permanently O
discontinue O
dabrafenib O
if O
administered O
in O
combination O
, O
for O
all O
Grade O
4 O
hemorrhagic B-NonOSE_AE
events I-NonOSE_AE
and O
for O
any O
Grade O
3 O
hemorrhagic O
events O
that O
do O
not O
improve O
. O

Withhold O
MEKINIST O
for O
up O
to O
3 O
weeks O
for O
Grade O
3 O
hemorrhagic B-NonOSE_AE
events I-NonOSE_AE
; O
if O
improved O
resume O
at O
a O
lower O
dose O
level O
. O

Withhold O
dabrafenib O
for O
Grade O
3 O
hemorrhagic B-NonOSE_AE
events I-NonOSE_AE
; O
if O
improved O
resume O
at O
a O
lower O
dose O
level O
. O

5.3 O
Venous O
Thromboembolism O
Venous B-OSE_Labeled_AE
thromboembolism I-OSE_Labeled_AE
can O
occur O
when O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
. O

In O
Trial O
2 O
, O
treatment O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
resulted O
in O
an O
increased O
incidence O
of O
deep B-OSE_Labeled_AE
venous I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
DVT I-OSE_Labeled_AE
) O
and O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PE I-OSE_Labeled_AE
) O
: O
7 O
% O
( O
4/55 O
) O
of O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
compared O
with O
none O
of O
the O
53 O
patients O
treated O
with O
dabrafenib O
as O
a O
single O
agent O
. O

Pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
was O
fatal B-NonOSE_AE
in O
one O
( O
2 O
% O
) O
patient O
receiving O
the O
combination O
of O
MEKINIST O
and O
dabrafenib O
. O

Advise O
patients O
to O
immediately O
seek O
medical O
care O
if O
they O
develop O
symptoms O
of O
DVT B-NonOSE_AE
or O
PE B-NonOSE_AE
, O
such O
as O
shortness B-NonOSE_AE
of I-NonOSE_AE
breath I-NonOSE_AE
, O
chest B-NonOSE_AE
pain I-NonOSE_AE
, O
or O
arm B-NonOSE_AE
or O
leg O
swelling I-NonOSE_AE
. O

Permanently O
discontinue O
MEKINIST O
and O
dabrafenib O
for O
life O
threatening O
PE B-NonOSE_AE
. O

Withhold O
MEKINIST O
for O
uncomplicated O
DVT B-NonOSE_AE
and O
PE B-NonOSE_AE
for O
up O
to O
3 O
weeks O
; O
if O
improved O
, O
MEKINIST O
may O
be O
resumed O
at O
a O
lower O
dose O
level O
. O

Do O
not O
modify O
the O
dose O
of O
dabrafenib O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.4 O
Cardiomyopathy O
Cardiomyopathy B-OSE_Labeled_AE
can O
occur O
when O
MEKINIST O
is O
administered O
as O
a O
single O
agent O
or O
when O
used O
in O
combination O
with O
dabrafenib O
. O

In O
Trial O
1 O
, O
cardiomyopathy B-OSE_Labeled_AE
( O
defined O
as O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
left B-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
, O
or O
decreased B-OSE_Labeled_AE
left I-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
ejection I-OSE_Labeled_AE
fraction I-OSE_Labeled_AE
[ O
LVEF O
] O
) O
occurred O
in O
7 O
% O
( O
14/211 O
) O
of O
patients O
treated O
with O
MEKINIST O
; O
no O
chemotherapy-treated O
patients O
in O
Trial O
1 O
developed O
cardiomyopathy B-NonOSE_AE
. O

In O
Trial O
2 O
, O
cardiomyopathy B-OSE_Labeled_AE
occurred O
in O
9 O
% O
( O
5/55 O
) O
of O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
and O
in O
none O
of O
patients O
treated O
with O
dabrafenib O
as O
a O
single O
agent O
. O

The O
median O
time O
to O
onset O
of O
cardiomyopathy B-OSE_Labeled_AE
in O
patients O
treated O
with O
MEKINIST O
was O
63 O
days O
( O
range O
: O
16 O
to O
156 O
days O
) O
for O
Trial O
1 O
and O
86 O
days O
( O
range O
: O
27 O
to O
253 O
days O
) O
for O
Trial O
2 O
. O

Cardiomyopathy B-OSE_Labeled_AE
was O
identified O
within O
the O
first O
month O
of O
treatment O
with O
MEKINIST O
in O
5 O
of O
14 O
patients O
in O
Trial O
1 O
and O
in O
2 O
of O
5 O
patients O
in O
Trial O
2 O
. O

Development O
of O
cardiomyopathy B-NonOSE_AE
resulted O
in O
dose O
reduction O
( O
7/211 O
) O
and/or O
discontinuation O
( O
4/211 O
) O
of O
study O
drug O
in O
Trial O
1 O
, O
and O
resulted O
in O
dose O
reduction O
( O
4/55 O
) O
and/or O
dose O
interruption O
( O
1/55 O
) O
in O
Trial O
2 O
. O

Cardiomyopathy B-NonOSE_AE
resolved O
in O
10 O
of O
14 O
( O
71 O
% O
) O
patients O
in O
Trial O
1 O
and O
in O
all O
5 O
patients O
in O
Trial O
2 O
. O

Across O
clinical O
trials O
of O
MEKINIST O
administered O
either O
as O
a O
single O
agent O
( O
N O
= O
329 O
) O
, O
or O
in O
combination O
with O
dabrafenib O
( O
N O
= O
202 O
) O
, O
11 O
% O
and O
8 O
% O
of O
patients O
, O
respectively O
, O
developed O
evidence O
of O
cardiomyopathy B-OSE_Labeled_AE
( O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
LVEF I-OSE_Labeled_AE
below O
institutional O
lower O
limits O
of O
normal O
with O
an O
absolute O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
LVEF I-OSE_Labeled_AE
> O
=10 O
% O
below O
baseline O
) O
. O

Five O
percent O
and O
2 O
% O
in O
single-agent O
and O
in O
combination O
trials O
, O
respectively O
, O
demonstrated O
a O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
LVEF I-OSE_Labeled_AE
below O
institutional O
lower O
limits O
of O
normal O
with O
an O
absolute O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
LVEF I-OSE_Labeled_AE
of O
> O
=20 O
% O
below O
baseline O
. O

Assess O
LVEF O
by O
echocardiogram O
or O
multigated O
acquisition O
( O
MUGA O
) O
scan O
before O
initiation O
of O
MEKINIST O
as O
a O
single O
agent O
and O
in O
combination O
with O
dabrafenib O
, O
one O
month O
after O
initiation O
, O
and O
then O
at O
2- O
to O
3-month O
intervals O
while O
on O
treatment O
. O

Withhold O
treatment O
with O
MEKINIST O
for O
up O
to O
4 O
weeks O
if O
absolute O
LVEF B-NonOSE_AE
value I-NonOSE_AE
decreases I-NonOSE_AE
by O
10 O
% O
from O
pretreatment O
values O
and O
is O
less O
than O
the O
lower O
limit O
of O
normal O
. O

For O
symptomatic O
cardiomyopathy B-NonOSE_AE
or O
persistent O
, O
asymptomatic O
LV B-NonOSE_AE
dysfunction I-NonOSE_AE
that O
does O
not O
resolve O
within O
4 O
weeks O
, O
permanently O
discontinue O
MEKINIST O
and O
withhold O
dabrafenib O
. O

Resume O
dabrafenib O
at O
the O
same O
dose O
upon O
recovery O
of O
cardiac O
function O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.5 O
Ocular O
Toxicities O
Retinal B-OSE_Labeled_AE
Vein I-OSE_Labeled_AE
Occlusion I-OSE_Labeled_AE
( O
RVO O
) O
: O
Across O
all O
clinical O
trials O
of O
MEKINIST O
, O
the O
incidence O
of O
RVO B-OSE_Labeled_AE
was O
0.2 O
% O
( O
4/1,749 O
) O
. O

RVO B-NonOSE_AE
may O
lead O
to O
macular B-NonOSE_AE
edema I-NonOSE_AE
, O
decreased B-NonOSE_AE
visual I-NonOSE_AE
function I-NonOSE_AE
, O
neovascularization B-NonOSE_AE
, O
and O
glaucoma B-NonOSE_AE
. O

Urgently O
( O
within O
24 O
hours O
) O
perform O
ophthalmological O
evaluation O
for O
patient-reported O
loss B-NonOSE_AE
of I-NonOSE_AE
vision I-NonOSE_AE
or O
other O
visual B-NonOSE_AE
disturbances I-NonOSE_AE
. O

Permanently O
discontinue O
MEKINIST O
in O
patients O
with O
documented O
RVO B-NonOSE_AE
. O

If O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
, O
do O
not O
modify O
dabrafenib O
dose O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

Retinal O
Pigment O
Epithelial O
Detachment O
( O
RPED O
) O
: O
Retinal B-OSE_Labeled_AE
pigment I-OSE_Labeled_AE
epithelial I-OSE_Labeled_AE
detachment I-OSE_Labeled_AE
( I-OSE_Labeled_AE
RPED I-OSE_Labeled_AE
) O
can O
occur O
when O
MEKINIST O
is O
administered O
as O
a O
single O
agent O
or O
when O
used O
in O
combination O
with O
dabrafenib O
. O

In O
Trial O
1 O
and O
Trial O
2 O
, O
ophthalmologic O
examinations O
including O
retinal O
evaluation O
were O
performed O
pretreatment O
and O
at O
regular O
intervals O
during O
treatment O
. O

In O
Trial O
1 O
, O
one O
patient O
( O
0.5 O
% O
) O
receiving O
MEKINIST O
developed O
RPED B-OSE_Labeled_AE
and O
no O
cases O
of O
RPED O
were O
identified O
in O
chemotherapy-treated O
patients O
. O

Across O
all O
clinical O
trials O
of O
MEKINIST O
, O
the O
incidence O
of O
RPED B-OSE_Labeled_AE
was O
0.8 O
% O
( O
14/1,749 O
) O
. O

Retinal B-OSE_Labeled_AE
detachments I-OSE_Labeled_AE
were O
often O
bilateral O
and O
multifocal O
, O
occurring O
in O
the O
macular O
region O
of O
the O
retina O
. O

RPED B-OSE_Labeled_AE
led O
to O
reduction B-NonOSE_AE
in I-NonOSE_AE
visual I-NonOSE_AE
acuity I-NonOSE_AE
that O
resolved O
after O
a O
median O
of O
11.5 O
days O
( O
range O
: O
3 O
to O
71 O
days O
) O
following O
the O
interruption O
of O
dosing O
with O
MEKINIST O
, O
although O
Ocular B-NonOSE_AE
Coherence I-NonOSE_AE
Tomography I-NonOSE_AE
( I-NonOSE_AE
OCT I-NonOSE_AE
) I-NonOSE_AE
abnormalities I-NonOSE_AE
persisted O
beyond O
a O
month O
in O
at O
least O
several O
cases O
. O

In O
Trial O
2 O
, O
one O
patient O
( O
2 O
% O
) O
receiving O
MEKINIST O
in O
combination O
with O
dabrafenib O
developed O
RPED B-OSE_Labeled_AE
. O

Perform O
ophthalmological O
evaluation O
at O
any O
time O
a O
patient O
reports O
visual B-NonOSE_AE
disturbances I-NonOSE_AE
and O
compare O
with O
baseline O
, O
if O
available O
. O

Withhold O
MEKINIST O
if O
RPED O
is O
diagnosed O
. O

If O
resolution O
of O
the O
RPED B-NonOSE_AE
is O
documented O
on O
repeat O
ophthalmological O
evaluation O
within O
3 O
weeks O
, O
resume O
MEKINIST O
at O
a O
lower O
dose O
level O
. O

Discontinue O
MEKINIST O
if O
no O
improvement O
after O
3 O
weeks O
. O

If O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
, O
do O
not O
modify O
the O
dose O
of O
dabrafenib O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

Uveitis O
and O
Iritis O
: O
Uveitis B-OSE_Labeled_AE
and O
iritis B-OSE_Labeled_AE
can O
occur O
when O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
and O
with O
dabrafenib O
as O
a O
single O
agent O
[ O
refer O
to O
Full O
Prescribing O
Information O
for O
dabrafenib O
] O
. O

Uveitis B-OSE_Labeled_AE
occurred O
in O
1 O
% O
( O
2/202 O
) O
of O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
. O

Symptomatic O
treatment O
employed O
in O
clinical O
trials O
included O
steroid O
and O
mydriatic O
ophthalmic O
drops O
. O

Monitor O
patients O
for O
visual O
signs O
and O
symptoms O
of O
uveitis B-NonOSE_AE
( O
e.g. O
, O
change B-NonOSE_AE
in I-NonOSE_AE
vision I-NonOSE_AE
, O
photophobia B-NonOSE_AE
, O
eye B-NonOSE_AE
pain I-NonOSE_AE
) O
. O

If O
diagnosed O
, O
withhold O
dabrafenib O
for O
up O
to O
6 O
weeks O
until O
uveitis B-NonOSE_AE
/ O
iritis B-NonOSE_AE
resolves O
to O
Grade O
0-1 O
. O

If O
not O
improved O
, O
permanently O
discontinue O
dabrafenib O
. O

If O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
, O
do O
not O
modify O
the O
dose O
of O
MEKINIST O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.6 O
Interstitial O
Lung O
Disease O
In O
clinical O
trials O
of O
MEKINIST O
( O
N O
= O
329 O
) O
as O
a O
single O
agent O
, O
ILD B-OSE_Labeled_AE
or O
pneumonitis B-OSE_Labeled_AE
occurred O
in O
2 O
% O
of O
patients O
. O

In O
Trial O
1 O
, O
2 O
% O
( O
5/211 O
) O
of O
patients O
treated O
with O
MEKINIST O
developed O
ILD B-OSE_Labeled_AE
or O
pneumonitis B-OSE_Labeled_AE
; O
all O
five O
patients O
required O
hospitalization O
. O

The O
median O
time O
to O
first O
presentation O
of O
ILD B-OSE_Labeled_AE
or O
pneumonitis B-OSE_Labeled_AE
was O
160 O
days O
( O
range O
: O
60 O
to O
172 O
days O
) O
. O

Withhold O
MEKINIST O
in O
patients O
presenting O
with O
new O
or O
progressive O
pulmonary O
symptoms O
and O
findings O
including O
cough B-NonOSE_AE
, O
dyspnea B-NonOSE_AE
, O
hypoxia B-NonOSE_AE
, O
pleural B-NonOSE_AE
effusion I-NonOSE_AE
, O
or O
infiltrates B-NonOSE_AE
, O
pending O
clinical O
investigations O
. O

Permanently O
discontinue O
MEKINIST O
for O
patients O
diagnosed O
with O
treatment-related O
ILD B-NonOSE_AE
or O
pneumonitis B-NonOSE_AE
. O

If O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
, O
do O
not O
modify O
the O
dose O
of O
dabrafenib O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.7 O
Serious O
Febrile O
Reactions O
Serious O
febrile B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
and O
fever B-OSE_Labeled_AE
of O
any O
severity O
accompanied O
by O
hypotension B-OSE_Labeled_AE
, O
rigors B-OSE_Labeled_AE
or O
chills B-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
, O
or O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
can O
occur O
when O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
and O
with O
dabrafenib O
as O
a O
single O
agent O
[ O
refer O
to O
Full O
Prescribing O
Information O
for O
dabrafenib O
] O
. O

The O
incidence O
and O
severity O
of O
pyrexia B-OSE_Labeled_AE
are O
increased O
when O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
compared O
with O
dabrafenib O
as O
a O
single O
agent O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

In O
Trial O
2 O
, O
the O
incidence O
of O
fever B-OSE_Labeled_AE
( O
serious O
and O
non-serious O
) O
was O
71 O
% O
( O
39/55 O
) O
in O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
and O
26 O
% O
( O
14/53 O
) O
in O
patients O
treated O
with O
dabrafenib O
as O
a O
single O
agent O
. O

Serious O
febrile B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
and O
fever B-OSE_Labeled_AE
of O
any O
severity O
accompanied O
by O
hypotension B-OSE_Labeled_AE
, O
rigors B-OSE_Labeled_AE
, O
or O
chills B-OSE_Labeled_AE
occurred O
in O
25 O
% O
( O
14/55 O
) O
of O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
compared O
with O
2 O
% O
( O
1/53 O
) O
of O
patients O
treated O
with O
dabrafenib O
as O
a O
single O
agent O
. O

Fever B-OSE_Labeled_AE
was O
complicated O
with O
chills B-OSE_Labeled_AE
/ O
rigors B-OSE_Labeled_AE
in O
51 O
% O
( O
28/55 O
) O
, O
dehydration B-OSE_Labeled_AE
in O
9 O
% O
( O
5/55 O
) O
, O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
in O
4 O
% O
( O
2/55 O
) O
, O
and O
syncope B-OSE_Labeled_AE
in O
4 O
% O
( O
2/55 O
) O
of O
patients O
in O
Trial O
2 O
. O

In O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
, O
the O
median O
time O
to O
initial O
onset O
of O
fever B-OSE_Labeled_AE
was O
30 O
days O
compared O
with O
19 O
days O
in O
patients O
treated O
with O
dabrafenib O
as O
a O
single O
agent O
; O
the O
median O
duration O
of O
fever B-OSE_Labeled_AE
was O
6 O
days O
with O
the O
combination O
compared O
with O
4 O
days O
with O
dabrafenib O
as O
a O
single O
agent O
. O

Across O
clinical O
trials O
of O
MEKINIST O
administered O
in O
combination O
with O
dabrafenib O
( O
N O
= O
202 O
) O
, O
the O
incidence O
of O
pyrexia B-OSE_Labeled_AE
was O
57 O
% O
( O
116/202 O
) O
. O

Withhold O
dabrafenib O
for O
fever B-NonOSE_AE
of O
101.3oF O
or O
higher O
. O

Withhold O
MEKINIST O
for O
fever B-NonOSE_AE
higher O
than O
104oF O
. O

Withhold O
dabrafenib O
and O
MEKINIST O
for O
any O
serious O
febrile B-NonOSE_AE
reaction I-NonOSE_AE
or O
fever B-NonOSE_AE
accompanied O
by O
hypotension B-NonOSE_AE
, O
rigors B-NonOSE_AE
or O
chills B-NonOSE_AE
, O
dehydration B-NonOSE_AE
, O
or O
renal B-NonOSE_AE
failure I-NonOSE_AE
, O
and O
evaluate O
for O
signs O
and O
symptoms O
of O
infection B-NonOSE_AE
. O

Refer O
to O
Table O
2 O
for O
recommended O
dose O
modifications O
for O
adverse O
reactions O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

Prophylaxis O
with O
antipyretics O
may O
be O
required O
when O
resuming O
MEKINIST O
or O
dabrafenib O
. O

5.8 O
Serious O
Skin O
Toxicity O
Serious O
skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
can O
occur O
when O
MEKINIST O
is O
administered O
as O
a O
single O
agent O
or O
when O
used O
in O
combination O
with O
dabrafenib O
. O

Serious O
skin B-NonOSE_AE
toxicity I-NonOSE_AE
can O
also O
occur O
with O
dabrafenib O
as O
a O
single O
agent O
[ O
refer O
to O
Full O
Prescribing O
Information O
for O
dabrafenib O
] O
. O

In O
Trial O
1 O
, O
the O
overall O
incidence O
of O
any O
skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
, O
the O
most O
common O
of O
which O
were O
rash B-OSE_Labeled_AE
, O
dermatitis B-OSE_Labeled_AE
acneiform I-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
erythrodysesthesia I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
and O
erythema B-OSE_Labeled_AE
, O
was O
87 O
% O
in O
patients O
treated O
with O
MEKINIST O
and O
13 O
% O
in O
chemotherapy-treated O
patients O
. O

Severe O
skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
occurred O
in O
12 O
% O
of O
patients O
treated O
with O
MEKINIST O
. O

Skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
requiring O
hospitalization O
occurred O
in O
6 O
% O
of O
patients O
treated O
with O
MEKINIST O
, O
most O
commonly O
for O
secondary O
infections B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
skin I-NonOSE_AE
requiring O
intravenous O
antibiotics O
or O
severe O
skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
without O
secondary B-NonOSE_AE
infection I-NonOSE_AE
. O

In O
comparison O
, O
no O
patients O
treated O
with O
chemotherapy O
required O
hospitalization O
for O
severe O
skin B-NonOSE_AE
toxicity I-NonOSE_AE
or O
infections B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
skin I-NonOSE_AE
. O

The O
median O
time O
to O
onset O
of O
skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
in O
patients O
treated O
with O
MEKINIST O
was O
15 O
days O
( O
range O
: O
1 O
to O
221 O
days O
) O
and O
median O
time O
to O
resolution O
of O
skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
was O
48 O
days O
( O
range O
: O
1 O
to O
282 O
days O
) O
. O

Reductions O
in O
the O
dose O
of O
MEKINIST O
were O
required O
in O
12 O
% O
and O
permanent O
discontinuation O
of O
MEKINIST O
was O
required O
in O
1 O
% O
of O
patients O
with O
skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
. O

In O
Trial O
2 O
, O
the O
incidence O
of O
any O
skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
was O
similar O
for O
patients O
receiving O
MEKINIST O
in O
combination O
with O
dabrafenib O
( O
65 O
% O
[ O
36/55 O
] O
) O
compared O
with O
patients O
receiving O
dabrafenib O
as O
a O
single O
agent O
( O
68 O
% O
[ O
36/53 O
] O
) O
. O

The O
median O
time O
to O
onset O
of O
skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
in O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
was O
37 O
days O
( O
range O
: O
1 O
to O
225 O
days O
) O
and O
median O
time O
to O
resolution O
of O
skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
was O
33 O
days O
( O
range O
: O
3 O
to O
421 O
days O
) O
. O

No O
patient O
required O
dose O
reduction O
or O
permanent O
discontinuation O
of O
MEKINIST O
or O
dabrafenib O
for O
skin B-NonOSE_AE
toxicity I-NonOSE_AE
. O

Across O
clinical O
trials O
of O
MEKINIST O
administered O
in O
combination O
with O
dabrafenib O
( O
n O
= O
202 O
) O
, O
severe O
skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
and O
secondary O
infection B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
skin I-NonOSE_AE
requiring O
hospitalization O
occurred O
in O
2.5 O
% O
( O
5/202 O
) O
of O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
. O

Withhold O
MEKINIST O
, O
and O
dabrafenib O
if O
used O
in O
combination O
, O
for O
intolerable O
or O
severe O
skin B-NonOSE_AE
toxicity I-NonOSE_AE
. O

MEKINIST O
and O
dabrafenib O
may O
be O
resumed O
at O
lower O
dose O
levels O
in O
patients O
with O
improvement O
or O
recovery O
from O
skin B-NonOSE_AE
toxicity I-NonOSE_AE
within O
3 O
weeks O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.9 O
Hyperglycemia O
Hyperglycemia B-OSE_Labeled_AE
can O
occur O
when O
MEKINIST O
is O
used O
in O
combination O
with O
dabrafenib O
and O
with O
dabrafenib O
as O
a O
single O
agent O
. O

Hyperglycemia B-NonOSE_AE
requiring O
an O
increase O
in O
the O
dose O
of O
, O
or O
initiation O
of O
insulin O
or O
oral O
hypoglycemic O
agent O
therapy O
occurred O
with O
dabrafenib O
as O
a O
single O
agent O
[ O
refer O
to O
Full O
Prescribing O
Information O
for O
dabrafenib O
] O
. O

In O
Trial O
2 O
, O
the O
incidence O
of O
Grade O
3 O
hyperglycemia B-OSE_Labeled_AE
based O
on O
laboratory O
values O
was O
5 O
% O
( O
3/55 O
) O
in O
patients O
treated O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
compared O
with O
2 O
% O
( O
1/53 O
) O
in O
patients O
treated O
with O
dabrafenib O
as O
a O
single O
agent O
. O

Monitor O
serum O
glucose O
levels O
as O
clinically O
appropriate O
during O
treatment O
with O
MEKINIST O
in O
combination O
with O
dabrafenib O
in O
patients O
with O
pre-existing O
diabetes B-Not_AE_Candidate
or O
hyperglycemia B-Not_AE_Candidate
. O

Advise O
patients O
to O
report O
symptoms O
of O
severe O
hyperglycemia B-NonOSE_AE
. O

5.10 O
Embryofetal B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Based O
on O
its O
mechanism O
of O
action O
, O
MEKINIST O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
. O

MEKINIST O
was O
embryotoxic B-NonOSE_AE
and O
abortifacient B-NonOSE_AE
in O
rabbits O
at O
doses O
greater O
than O
or O
equal O
to O
those O
resulting O
in O
exposures O
approximately O
0.3 O
times O
the O
human O
exposure O
at O
the O
recommended O
clinical O
dose O
. O

If O
this O
drug O
is O
used O
during O
pregnancy B-Not_AE_Candidate
, O
or O
if O
the O
patient O
becomes O
pregnant B-NonOSE_AE
while O
taking O
this O
drug O
, O
the O
patient O
should O
be O
apprised O
of O
the O
potential O
hazard B-OSE_Labeled_AE
to I-OSE_Labeled_AE
a I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

Advise O
female O
patients O
of O
reproductive O
potential O
to O
use O
highly O
effective O
contraception O
during O
treatment O
with O
MEKINIST O
and O
for O
4 O
months O
after O
treatment O
. O

Advise O
patients O
to O
use O
a O
highly O
effective O
non-hormonal O
method O
of O
contraception O
when O
MEKINIST O
is O
administered O
in O
combination O
with O
dabrafenib O
, O
since O
dabrafenib O
can O
render O
hormonal O
contraceptives O
ineffective O
. O

Advise O
patients O
to O
contact O
their O
healthcare O
provider O
if O
they O
become O
pregnant B-NonOSE_AE
, O
or O
if O
pregnancy B-Not_AE_Candidate
is O
suspected O
, O
while O
taking O
MEKINIST O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
, O
8.6 O
) O
] O
. O

6 O
ADVERSE O
REACTIONS O
Serious O
and O
important O
adverse O
reactions O
described O
elsewhere O
in O
labeling O
include O
: O
* O
Gastrointestinal B-NonOSE_AE
perforation I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Opioid B-OSE_Labeled_AE
withdrawal I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
in O
clinical O
trials O
( O
> O
= O
3 O
% O
) O
are O
: O
abdominal O
pain O
, O
diarrhea O
, O
nausea O
, O
flatulence O
, O
vomiting O
, O
and O
headache O
( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
AstraZeneca O
at O
1-800-236-9933 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
data O
described O
below O
reflect O
exposure O
to O
MOVANTIK O
in O
1497 O
patients O
in O
clinical O
trials O
, O
including O
537 O
patients O
exposed O
for O
greater O
than O
six O
months O
, O
and O
320 O
patients O
exposed O
for O
12 O
months O
. O

The O
safety O
data O
described O
in O
Table O
1 O
are O
derived O
from O
two O
double-blind O
, O
placebo-controlled O
trials O
( O
Studies O
1 O
and O
2 O
) O
in O
patients O
with O
OIC B-Not_AE_Candidate
and O
non B-Not_AE_Candidate
- I-Not_AE_Candidate
cancer I-Not_AE_Candidate
related I-Not_AE_Candidate
pain I-Not_AE_Candidate
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

Study O
3 O
( O
n=302 O
) O
was O
a O
safety O
extension O
study O
that O
allowed O
patients O
from O
Study O
1 O
to O
continue O
the O
same O
blinded O
treatment O
for O
an O
additional O
12 O
weeks O
. O

Safety O
data O
for O
patients O
in O
Study O
3 O
are O
similar O
to O
those O
listed O
in O
Table O
1 O
. O

Study O
4 O
( O
n=844 O
) O
was O
a O
Phase O
3 O
, O
52-week O
, O
multi-center O
, O
open-label O
, O
randomized O
, O
parallel O
group O
, O
safety O
and O
tolerability O
study O
of O
naloxegol O
versus O
usual O
care O
treatment O
for O
OIC O
( O
as O
determined O
by O
the O
investigator O
and O
excluding O
peripheral O
opioid O
antagonists O
) O
in O
patients O
with O
non B-Not_AE_Candidate
- I-Not_AE_Candidate
cancer I-Not_AE_Candidate
related I-Not_AE_Candidate
pain I-Not_AE_Candidate
. O

The O
population O
enrolled O
in O
Study O
4 O
was O
similar O
to O
that O
of O
the O
other O
studies O
. O

Eligible O
patients O
were O
randomized O
in O
a O
2:1 O
ratio O
to O
receive O
either O
naloxegol O
25 O
mg O
once O
daily O
or O
usual O
care O
treatment O
for O
OIC B-Not_AE_Candidate
. O

The O
most O
commonly O
used O
laxatives O
in O
the O
usual O
care O
group O
were O
rectal O
stimulants O
( O
e.g. O
, O
bisacodyl O
) O
, O
oral O
stimulants O
( O
e.g. O
, O
senna O
) O
, O
and O
oral O
osmotics O
( O
e.g. O
, O
macrogol O
, O
magnesium O
) O
. O

Safety O
data O
for O
patients O
in O
Study O
4 O
are O
similar O
to O
those O
listed O
in O
Table O
1 O
. O

Table O
1 O
lists O
adverse O
reactions O
in O
pooled O
Studies O
1 O
and O
2 O
occurring O
in O
> O
= O
3 O
% O
of O
patients O
receiving O
MOVANTIK O
12.5 O
mg O
or O
25 O
mg O
and O
at O
an O
incidence O
greater O
than O
placebo O
. O

Table O
1 O
. O

Adverse O
ReactionsAdverse O
reactions O
occurring O
in O
> O
=3 O
% O
of O
patients O
receiving O
MOVANTIK O
12.5 O
mg O
or O
25 O
mg O
and O
at O
an O
incidence O
greater O
than O
placebo O
. O

in O
Patients O
with O
OIC B-Not_AE_Candidate
and O
Non B-Not_AE_Candidate
- I-Not_AE_Candidate
Cancer I-Not_AE_Candidate
Pain I-Not_AE_Candidate
( O
Studies O
1 O
and O
2 O
) O
Adverse O
Reaction O
MOVANTIK O
25 O
mg O
( O
n=446 O
) O
MOVANTIK O
12.5 O
mg O
( O
n=441 O
) O
Placebo O
( O
n=444 O
) O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
21 O
% O
12 O
% O
7 O
% O
Diarrhea B-OSE_Labeled_AE
9 O
% O
6 O
% O
5 O
% O
Nausea B-OSE_Labeled_AE
8 O
% O
7 O
% O
5 O
% O
Flatulence B-OSE_Labeled_AE
6 O
% O
3 O
% O
3 O
% O
Vomiting B-OSE_Labeled_AE
5 O
% O
3 O
% O
4 O
% O
Headache B-OSE_Labeled_AE
4 O
% O
4 O
% O
3 O
% O
Hyperhidrosis B-OSE_Labeled_AE
3 O
% O
< O
1 O
% O
< O
1 O
% O
Opioid B-OSE_Labeled_AE
Withdrawal I-OSE_Labeled_AE
Possible O
opioid B-OSE_Labeled_AE
withdrawal I-OSE_Labeled_AE
, O
defined O
as O
at O
least O
three O
adverse O
reactions O
potentially O
related O
to O
opioid B-OSE_Labeled_AE
withdrawal I-OSE_Labeled_AE
that O
occurred O
on O
the O
same O
day O
and O
were O
not O
all O
related O
to O
the O
gastrointestinal O
system O
, O
occurred O
in O
less O
than O
1 O
% O
( O
1/444 O
) O
of O
placebo O
subjects O
, O
1 O
% O
( O
5/441 O
) O
receiving O
MOVANTIK O
12.5 O
mg O
, O
and O
3 O
% O
( O
14/446 O
) O
receiving O
MOVANTIK O
25 O
mg O
in O
Studies O
1 O
and O
2 O
regardless O
of O
maintenance O
opioid O
treatment O
. O

Symptoms O
included O
but O
were O
not O
limited O
to O
hyperhidrosis B-NonOSE_AE
, O
chills B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
, O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
anxiety B-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
and O
yawning B-NonOSE_AE
. O

Patients O
receiving O
methadone O
as O
therapy O
for O
their O
pain O
condition O
were O
observed O
in O
Studies O
1 O
and O
2 O
to O
have O
a O
higher O
frequency O
of O
gastrointestinal B-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
than O
patients O
receiving O
other O
opioids O
[ O
39 O
% O
( O
7/18 O
) O
vs O
. O
26 O
% O
( O
110/423 O
) O
in O
the O
12.5 O
mg O
group O
; O
75 O
% O
( O
24/32 O
) O
vs O
. O
34 O
% O
( O
142/414 O
) O
in O
the O
25 O
mg O
group O
] O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Gastrointestinal O
perforation O
: O
Consider O
the O
overall O
risk O
benefit O
in O
patients O
with O
known O
or O
suspected O
lesions O
of O
the O
GI O
tract O
. O

Monitor O
for O
severe O
, O
persistent O
or O
worsening O
abdominal O
pain O
; O
discontinue O
if O
development O
of O
symptoms O
( O
5.1 O
) O
* O
Opioid O
withdrawal O
: O
Consider O
the O
overall O
risk O
benefit O
in O
patients O
with O
disruptions O
to O
the O
blood-brain O
barrier O
. O

Monitor O
for O
symptoms O
of O
opioid O
withdrawal O
( O
5.2 O
) O
5.1 O
Gastrointestinal O
Perforation O
Cases O
of O
gastrointestinal B-NonOSE_AE
perforation I-NonOSE_AE
have O
been O
reported O
with O
use O
of O
another O
peripherally O
acting O
opioid O
antagonist O
in O
patients O
with O
conditions O
that O
may O
be O
associated O
with O
localized O
or O
diffuse O
reduction B-Not_AE_Candidate
of I-Not_AE_Candidate
structural I-Not_AE_Candidate
integrity I-Not_AE_Candidate
in I-Not_AE_Candidate
the I-Not_AE_Candidate
wall I-Not_AE_Candidate
of I-Not_AE_Candidate
the I-Not_AE_Candidate
gastrointestinal I-Not_AE_Candidate
tract I-Not_AE_Candidate
( O
e.g. O
, O
peptic B-Not_AE_Candidate
ulcer I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
Ogilvie B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
, O
diverticular B-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
infiltrative B-Not_AE_Candidate
gastrointestinal I-Not_AE_Candidate
tract I-Not_AE_Candidate
malignancies I-Not_AE_Candidate
or O
peritoneal B-Not_AE_Candidate
metastases I-Not_AE_Candidate
) O
. O

Take O
into O
account O
the O
overall O
risk-benefit O
profile O
when O
using O
MOVANTIK O
in O
patients O
with O
these O
conditions O
or O
other O
conditions O
which O
might O
result O
in O
impaired B-NonOSE_AE
integrity I-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
gastrointestinal I-NonOSE_AE
tract I-NonOSE_AE
wall I-NonOSE_AE
( O
e.g. O
, O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
) O
. O

Monitor O
for O
the O
development O
of O
severe O
, O
persistent O
or O
worsening O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
; O
discontinue O
MOVANTIK O
in O
patients O
who O
develop O
this O
symptom O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

5.2 O
Opioid O
Withdrawal O
Clusters O
of O
symptoms O
consistent O
with O
opioid B-OSE_Labeled_AE
withdrawal I-OSE_Labeled_AE
, O
including O
hyperhidrosis B-NonOSE_AE
, O
chills B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
, O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
anxiety B-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
and O
yawning B-NonOSE_AE
have O
occurred O
in O
patients O
treated O
with O
MOVANTIK O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

In O
addition O
, O
patients O
receiving O
methadone O
as O
therapy O
for O
their O
pain B-Not_AE_Candidate
condition O
were O
observed O
in O
clinical O
trials O
to O
have O
a O
higher O
frequency O
of O
gastrointestinal B-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
that O
may O
have O
been O
related O
to O
opioid B-NonOSE_AE
withdrawal I-NonOSE_AE
than O
patients O
receiving O
other O
opioids O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Patients O
having O
disruptions B-Not_AE_Candidate
to I-Not_AE_Candidate
the I-Not_AE_Candidate
blood I-Not_AE_Candidate
- I-Not_AE_Candidate
brain I-Not_AE_Candidate
barrier I-Not_AE_Candidate
may O
be O
at O
increased O
risk O
for O
opioid B-NonOSE_AE
withdrawal I-NonOSE_AE
or O
reduced B-NonOSE_AE
analgesia I-NonOSE_AE
. O

Take O
into O
account O
the O
overall O
risk-benefit O
profile O
when O
using O
MOVANTIK O
in O
such O
patients O
. O

Monitor O
for O
symptoms O
of O
opioid B-NonOSE_AE
withdrawal I-NonOSE_AE
in O
such O
patients O
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
Most O
commonly O
reported O
adverse O
reactions O
( O
> O
2 O
% O
and O
> O
placebo O
) O
were O
hypertension O
, O
nasopharyngitis O
, O
urinary O
tract O
infection O
and O
headache O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Astellas O
Pharma O
US O
, O
Inc O
. O
at O
1-800-727-7003 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

In O
three O
, O
12 O
week O
, O
double-blind O
, O
placebo-controlled O
, O
safety O
and O
efficacy O
studies O
in O
patients O
with O
overactive B-Not_AE_Candidate
bladder I-Not_AE_Candidate
( O
Studies O
1 O
, O
2 O
, O
and O
3 O
) O
, O
MYRBETRIQ O
( O
r O
) O
was O
evaluated O
for O
safety O
in O
2736 O
patients O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

Study O
1 O
also O
included O
an O
active O
control O
. O

For O
the O
combined O
Studies O
1 O
, O
2 O
, O
and O
3 O
, O
432 O
patients O
received O
MYRBETRIQ O
( O
r O
) O
25 O
mg O
, O
1375 O
received O
MYRBETRIQ O
( O
r O
) O
50 O
mg O
, O
and O
929 O
received O
MYRBETRIQ O
( O
r O
) O
100 O
mg O
once O
daily O
. O

In O
these O
studies O
, O
the O
majority O
of O
the O
patients O
were O
Caucasian O
( O
94 O
% O
) O
, O
and O
female O
( O
72 O
% O
) O
with O
a O
mean O
age O
of O
59 O
years O
( O
range O
18 O
to O
95 O
years O
) O
. O

MYRBETRIQ O
( O
r O
) O
was O
also O
evaluated O
for O
safety O
in O
1632 O
patients O
who O
received O
MYRBETRIQ O
( O
r O
) O
50 O
mg O
once O
daily O
( O
n=812 O
patients O
) O
or O
MYRBETRIQ O
( O
r O
) O
100 O
mg O
( O
n=820 O
patients O
) O
in O
a O
1 O
year O
, O
randomized O
, O
fixed O
dose O
, O
double-blind O
, O
active O
controlled O
, O
safety O
study O
in O
patients O
with O
overactive B-Not_AE_Candidate
bladder I-Not_AE_Candidate
( O
Study O
4 O
) O
. O

Of O
these O
patients O
, O
731 O
received O
MYRBETRIQ O
( O
r O
) O
in O
a O
previous O
12 O
week O
study O
. O

In O
Study O
4 O
, O
1385 O
patients O
received O
MYRBETRIQ O
( O
r O
) O
continuously O
for O
at O
least O
6 O
months O
, O
1311 O
patients O
received O
MYRBETRIQ O
( O
r O
) O
for O
at O
least O
9 O
months O
, O
and O
564 O
patients O
received O
MYRBETRIQ O
( O
r O
) O
for O
at O
least O
1 O
year O
. O

The O
most O
frequent O
adverse O
events O
( O
0.2 O
% O
) O
leading O
to O
discontinuation O
in O
Studies O
1 O
, O
2 O
and O
3 O
for O
the O
25 O
mg O
or O
50 O
mg O
dose O
were O
nausea B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
and O
tachycardia B-OSE_Labeled_AE
. O

Atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
( O
0.2 O
% O
) O
and O
prostate B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
( O
0.1 O
% O
) O
were O
reported O
as O
serious O
adverse O
events O
by O
more O
than O
1 O
patient O
and O
at O
a O
rate O
greater O
than O
placebo O
. O

Table O
1 O
lists O
adverse O
reactions O
, O
derived O
from O
all O
adverse O
events O
, O
that O
were O
reported O
in O
Studies O
1 O
, O
2 O
and O
3 O
at O
an O
incidence O
greater O
than O
placebo O
and O
in O
1 O
% O
or O
more O
of O
patients O
treated O
with O
MYRBETRIQ O
( O
r O
) O
25 O
mg O
or O
50 O
mg O
once O
daily O
for O
up O
to O
12 O
weeks O
. O

The O
most O
commonly O
reported O
adverse O
reactions O
( O
greater O
than O
2 O
% O
of O
MYRBETRIQ O
( O
r O
) O
patients O
and O
greater O
than O
placebo O
) O
were O
hypertension B-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
and O
headache B-OSE_Labeled_AE
. O

Table O
1 O
: O
Percentages O
of O
Patients O
with O
Adverse O
Reactions O
, O
Derived O
from O
All O
Adverse O
Events O
, O
Exceeding O
Placebo O
Rate O
and O
Reported O
by O
1 O
% O
or O
More O
Patients O
Treated O
With O
MYRBETRIQ O
( O
r O
) O
25 O
mg O
or O
50 O
mg O
Once O
Daily O
in O
Studies O
1 O
, O
2 O
, O
and O
3 O
Placebo O
( O
% O
) O
MYRBETRIQ O
( O
r O
) O
25 O
mg O
( O
% O
) O
MYRBETRIQ O
( O
r O
) O
50 O
mg O
( O
% O
) O
Number O
of O
Patients O
1380 O
432 O
1375 O
Hypertension B-OSE_Labeled_AE
Includes O
reports O
of O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
above I-OSE_Labeled_AE
the I-OSE_Labeled_AE
normal I-OSE_Labeled_AE
range I-OSE_Labeled_AE
, O
and O
BP B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
, O
occurring O
predominantly O
in O
subjects O
with O
baseline O
hypertension B-Not_AE_Candidate
. O

7.6 O
11.3 O
7.5 O
Nasopharyngitis B-OSE_Labeled_AE
2.5 O
3.5 O
3.9 O
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
1.8 O
4.2 O
2.9 O
Headache B-OSE_Labeled_AE
3.0 O
2.1 O
3.2 O
Constipation B-OSE_Labeled_AE
1.4 O
1.6 O
1.6 O
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
1.7 O
2.1 O
1.5 O
Arthralgia B-OSE_Labeled_AE
1.1 O
1.6 O
1.3 O
Diarrhea B-OSE_Labeled_AE
1.3 O
1.2 O
1.5 O
Tachycardia B-OSE_Labeled_AE
0.6 O
1.6 O
1.2 O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
0.7 O
1.4 O
0.6 O
Fatigue B-OSE_Labeled_AE
1.0 O
1.4 O
1.2 O
Other O
adverse O
reactions O
reported O
by O
less O
than O
1 O
% O
of O
patients O
treated O
with O
MYRBETRIQ O
( O
r O
) O
in O
Studies O
1 O
, O
2 O
, O
or O
3 O
included O
: O
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
palpitations B-OSE_Labeled_AE
, O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
[ O
see O
Clinical O
Pharmacology O
( O
12.2 O
) O
] O
Eye B-NonOSE_AE
disorders I-NonOSE_AE
: O
glaucoma B-OSE_Labeled_AE
[ O
see O
Clinical O
Pharmacology O
( O
12.2 O
) O
] O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
dyspepsia B-OSE_Labeled_AE
, O
gastritis B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
distension I-OSE_Labeled_AE
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
: O
sinusitis B-OSE_Labeled_AE
, O
rhinitis B-OSE_Labeled_AE
Investigations B-NonOSE_AE
: O
GGT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
AST B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
ALT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
LDH B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
: O
nephrolithiasis B-OSE_Labeled_AE
, O
bladder B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
Reproductive B-NonOSE_AE
system I-NonOSE_AE
and I-NonOSE_AE
breast I-NonOSE_AE
disorders I-NonOSE_AE
: O
vulvovaginal B-OSE_Labeled_AE
pruritus I-OSE_Labeled_AE
, O
vaginal B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
urticaria B-OSE_Labeled_AE
, O
leukocytoclastic B-OSE_Labeled_AE
vasculitis I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
purpura B-OSE_Labeled_AE
, O
lip B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
Table O
2 O
lists O
the O
rates O
of O
the O
most O
commonly O
reported O
adverse O
reactions O
, O
derived O
from O
all O
adverse O
events O
in O
patients O
treated O
with O
MYRBETRIQ O
( O
r O
) O
50 O
mg O
for O
up O
to O
52 O
weeks O
in O
Study O
4 O
. O

The O
most O
commonly O
reported O
adverse O
reactions O
( O
> O
3 O
% O
of O
MYRBETRIQ O
( O
r O
) O
patients O
) O
were O
hypertension B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
and O
nasopharyngitis B-OSE_Labeled_AE
. O

Table O
2 O
: O
Percentages O
of O
Patients O
with O
Adverse O
Reactions O
, O
Derived O
from O
all O
Adverse O
Events O
, O
Reported O
by O
Greater O
Than O
2 O
% O
of O
Patients O
Treated O
With O
MYRBETRIQ O
( O
r O
) O
50 O
mg O
Once O
Daily O
in O
Study O
4 O
MYRBETRIQ O
( O
r O
) O
50 O
mg O
( O
% O
) O
Active O
Control O
( O
% O
) O
Number O
of O
Patients O
812 O
812 O
Hypertension B-OSE_Labeled_AE
9.2 O
9.6 O
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
5.9 O
6.4 O
Headache B-OSE_Labeled_AE
4.1 O
2.5 O
Nasopharyngitis B-OSE_Labeled_AE
3.9 O
3.1 O
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
2.8 O
1.6 O
Constipation B-OSE_Labeled_AE
2.8 O
2.7 O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
2.8 O
8.6 O
Dizziness B-OSE_Labeled_AE
2.7 O
2.6 O
Sinusitis B-OSE_Labeled_AE
2.7 O
1.5 O
Influenza B-OSE_Labeled_AE
2.6 O
3.4 O
Arthralgia B-OSE_Labeled_AE
2.1 O
2.0 O
Cystitis B-OSE_Labeled_AE
2.1 O
2.3 O
In O
Study O
4 O
, O
in O
patients O
treated O
with O
MYRBETRIQ O
( O
r O
) O
50 O
mg O
once O
daily O
, O
adverse O
reactions O
leading O
to O
discontinuation O
reported O
by O
more O
than O
2 O
patients O
and O
at O
a O
rate O
greater O
than O
active O
control O
included O
: O
constipation B-OSE_Labeled_AE
( O
0.9 O
% O
) O
, O
headache B-OSE_Labeled_AE
( O
0.6 O
% O
) O
, O
dizziness B-OSE_Labeled_AE
( O
0.5 O
% O
) O
, O
hypertension B-OSE_Labeled_AE
( O
0.5 O
% O
) O
, O
dry B-OSE_Labeled_AE
eyes I-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
nausea B-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
and O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
0.4 O
% O
) O
. O

Serious O
adverse O
events O
reported O
by O
at O
least O
2 O
patients O
and O
exceeding O
active O
control O
included O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
( O
0.4 O
% O
) O
and O
osteoarthritis B-OSE_Labeled_AE
( O
0.2 O
% O
) O
. O

Serum O
ALT B-OSE_Labeled_AE
/AST O
increased I-OSE_Labeled_AE
from O
baseline O
by O
greater O
than O
10-fold O
in O
2 O
patients O
( O
0.3 O
% O
) O
taking O
MYRBETRIQ O
( O
r O
) O
50 O
mg O
, O
and O
these O
markers O
subsequently O
returned O
to O
baseline O
while O
both O
patients O
continued O
MYRBETRIQ O
( O
r O
) O
. O

In O
Study O
4 O
, O
serious O
adverse O
events O
of O
neoplasm O
were O
reported O
by O
0.1 O
% O
, O
1.3 O
% O
, O
and O
0.5 O
% O
of O
patients O
treated O
with O
MYRBETRIQ O
( O
r O
) O
50 O
mg O
, O
MYRBETRIQ O
( O
r O
) O
100 O
mg O
and O
active O
control O
once O
daily O
, O
respectively O
. O

Neoplasms B-OSE_Labeled_AE
reported O
by O
2 O
patients O
treated O
with O
MYRBETRIQ O
( O
r O
) O
100 O
mg O
included O
breast B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
, O
lung B-OSE_Labeled_AE
neoplasm I-OSE_Labeled_AE
malignant I-OSE_Labeled_AE
and O
prostate B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
. O

In O
a O
separate O
clinical O
study O
in O
Japan O
, O
a O
single O
case O
was O
reported O
as O
Stevens B-NonOSE_AE
- I-NonOSE_AE
Johnson I-NonOSE_AE
syndrome I-NonOSE_AE
with O
increased B-NonOSE_AE
serum I-NonOSE_AE
ALT I-NonOSE_AE
, O
AST O
and O
bilirubin O
in O
a O
patient O
taking O
MYRBETRIQ O
( O
r O
) O
100 O
mg O
as O
well O
as O
an O
herbal O
medication O
( O
Kyufu O
Gold O
) O
. O

6.2 O
Postmarketing O
Experience O
Because O
these O
spontaneously O
reported O
events O
are O
from O
the O
worldwide O
postmarketing O
experience O
, O
from O
a O
population O
of O
uncertain O
size O
, O
the O
frequency O
of O
events O
and O
the O
role O
of O
mirabegron O
in O
their O
causation O
can O
not O
be O
reliably O
determined O
. O

The O
following O
events O
have O
been O
reported O
in O
association O
with O
mirabegron O
use O
in O
worldwide O
postmarketing O
experience O
: O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
: O
angioedema B-OSE_Labeled_AE
of O
the O
face O
, O
lips O
, O
tongue O
, O
and O
larynx O
, O
with O
or O
without O
respiratory B-NonOSE_AE
symptoms I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
Urologic B-NonOSE_AE
: O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Increases O
in O
Blood O
Pressure O
: O
MYRBETRIQ O
( O
r O
) O
can O
increase O
blood O
pressure O
. O

Periodic O
blood O
pressure O
determinations O
are O
recommended O
, O
especially O
in O
hypertensive O
patients O
. O

MYRBETRIQ O
( O
r O
) O
is O
not O
recommended O
for O
use O
in O
severe O
uncontrolled O
hypertensive O
patients O
( O
5.1 O
) O
. O

* O
Urinary O
Retention O
in O
Patients O
With O
Bladder O
Outlet O
Obstruction O
and O
in O
Patients O
Taking O
Antimuscarinic O
Drugs O
for O
Overactive O
Bladder O
: O
Administer O
with O
caution O
in O
these O
patients O
because O
of O
risk O
of O
urinary O
retention O
( O
5.2 O
) O
. O

* O
Angioedema O
: O
Angioedema O
of O
the O
face O
, O
lips O
, O
tongue O
and/or O
larynx O
has O
been O
reported O
with O
MYRBETRIQ O
( O
r O
) O
( O
5.3 O
, O
6.2 O
) O
. O

* O
Patients O
Taking O
Drugs O
Metabolized O
by O
CYP2D6 O
: O
MYRBETRIQ O
( O
r O
) O
is O
a O
moderate O
inhibitor O
of O
CYP2D6 O
. O

Appropriate O
monitoring O
is O
recommended O
and O
dose O
adjustment O
may O
be O
necessary O
for O
narrow O
therapeutic O
index O
CYP2D6 O
substrates O
( O
5.4 O
, O
7.1 O
, O
12.3 O
) O
. O

5.1 O
Increases O
in O
Blood O
Pressure O
MYRBETRIQ O
( O
r O
) O
can O
increase B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
. O

Periodic O
blood O
pressure O
determinations O
are O
recommended O
, O
especially O
in O
hypertensive B-Not_AE_Candidate
patients O
. O

MYRBETRIQ O
( O
r O
) O
is O
not O
recommended O
for O
use O
in O
patients O
with O
severe O
uncontrolled B-Not_AE_Candidate
hypertension I-Not_AE_Candidate
( O
defined O
as O
systolic B-Not_AE_Candidate
blood I-Not_AE_Candidate
pressure I-Not_AE_Candidate
greater I-Not_AE_Candidate
than I-Not_AE_Candidate
or I-Not_AE_Candidate
equal I-Not_AE_Candidate
to I-Not_AE_Candidate
1 I-Not_AE_Candidate
8 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mm I-Not_AE_Candidate
Hg I-Not_AE_Candidate
and/or O
diastolic B-Not_AE_Candidate
blood I-Not_AE_Candidate
pressure I-Not_AE_Candidate
greater I-Not_AE_Candidate
than I-Not_AE_Candidate
or I-Not_AE_Candidate
equal I-Not_AE_Candidate
to I-Not_AE_Candidate
1 I-Not_AE_Candidate
1 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mm I-Not_AE_Candidate
Hg I-Not_AE_Candidate
) O
[ O
see O
Clinical O
Pharmacology O
( O
12.2 O
) O
] O
. O

In O
two O
, O
randomized O
, O
placebo-controlled O
, O
healthy O
volunteer O
studies O
, O
MYRBETRIQ O
( O
r O
) O
was O
associated O
with O
dose-related O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
supine I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
. O

In O
these O
studies O
, O
at O
the O
maximum O
recommended O
dose O
of O
50 O
mg O
, O
the O
mean O
maximum O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
systolic I-OSE_Labeled_AE
/diastolic O
blood O
pressure O
was O
approximately O
3.5/1.5 O
mm O
Hg O
greater O
than O
placebo O
. O

In O
contrast O
, O
in O
OAB B-Not_AE_Candidate
patients O
in O
clinical O
trials O
, O
the O
mean O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
systolic I-OSE_Labeled_AE
and O
diastolic O
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
at O
the O
maximum O
recommended O
dose O
of O
50 O
mg O
was O
approximately O
0.5 O
- O
1 O
mm O
Hg O
greater O
than O
placebo O
. O

Worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
pre I-OSE_Labeled_AE
- I-OSE_Labeled_AE
existing I-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
was O
reported O
infrequently O
in O
MYRBETRIQ O
( O
r O
) O
patients O
. O

5.2 O
Urinary O
Retention O
in O
Patients O
with O
Bladder O
Outlet O
Obstruction O
and O
in O
Patients O
Taking O
Antimuscarinic O
Medications O
for O
OAB O
Urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
in O
patients O
with O
bladder B-Not_AE_Candidate
outlet I-Not_AE_Candidate
obstruction I-Not_AE_Candidate
( O
BOO O
) O
and O
in O
patients O
taking O
antimuscarinic O
medications O
for O
the O
treatment O
of O
OAB B-Not_AE_Candidate
has O
been O
reported O
in O
postmarketing O
experience O
in O
patients O
taking O
mirabegron O
. O

A O
controlled O
clinical O
safety O
study O
in O
patients O
with O
BOO B-Not_AE_Candidate
did O
not O
demonstrate O
increased B-NonOSE_AE
urinary I-NonOSE_AE
retention I-NonOSE_AE
in O
MYRBETRIQ O
( O
r O
) O
patients O
; O
however O
, O
MYRBETRIQ O
( O
r O
) O
should O
be O
administered O
with O
caution O
to O
patients O
with O
clinically O
significant O
BOO B-Not_AE_Candidate
. O

MYRBETRIQ O
( O
r O
) O
should O
also O
be O
administered O
with O
caution O
to O
patients O
taking O
antimuscarinic O
medications O
for O
the O
treatment O
of O
OAB B-Not_AE_Candidate
[ O
see O
Clinical O
Pharmacology O
( O
12.2 O
) O
] O
. O

5.3 O
Angioedema O
Angioedema B-OSE_Labeled_AE
of O
the O
face O
, O
lips O
, O
tongue O
, O
and/or O
larynx O
has O
been O
reported O
with O
MYRBETRIQ O
( O
r O
) O
. O

In O
some O
cases O
angioedema B-OSE_Labeled_AE
occurred O
after O
the O
first O
dose O
. O

Cases O
of O
angioedema B-OSE_Labeled_AE
have O
been O
reported O
to O
occur O
hours O
after O
the O
first O
dose O
or O
after O
multiple O
doses O
. O

Angioedema B-NonOSE_AE
associated O
with O
upper B-NonOSE_AE
airway I-NonOSE_AE
swelling I-NonOSE_AE
may O
be O
life O
threatening O
. O

If O
involvement O
of O
the O
tongue O
, O
hypopharynx O
, O
or O
larynx O
occurs O
, O
promptly O
discontinue O
MYRBETRIQ O
( O
r O
) O
and O
initiate O
appropriate O
therapy O
and/or O
measures O
necessary O
to O
ensure O
a O
patent O
airway O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

5.4 O
Patients O
Taking O
Drugs O
Metabolized O
by O
CYP2D6 O
Since O
mirabegron O
is O
a O
moderate O
CYP2D6 O
inhibitor O
, O
the O
systemic O
exposure O
to O
CYP2D6 O
substrates O
such O
as O
metoprolol O
and O
desipramine O
is O
increased O
when O
co-administered O
with O
mirabegron O
. O

Therefore O
, O
appropriate O
monitoring O
and O
dose O
adjustment O
may O
be O
necessary O
, O
especially O
with O
narrow O
therapeutic O
index O
drugs O
metabolized O
by O
CYP2D6 O
, O
such O
as O
thioridazine O
, O
flecainide O
, O
and O
propafenone O
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
and O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
Most O
common O
adverse O
events O
( O
> O
1 O
% O
) O
were O
application O
site O
erythema O
and O
ocular O
erythema O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
ParaPRO O
, O
LLC O
at O
1-855-628-7622 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Studies O
Experience O
Because O
clinical O
studies O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
studies O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
studies O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

NATROBA O
Topical O
Suspension O
was O
studied O
in O
two O
randomized O
, O
active-controlled O
trials O
( O
N=552 O
) O
in O
subjects O
with O
head O
lice O
; O
the O
results O
are O
presented O
in O
Table O
1 O
. O

Table O
1 O
: O
Selected O
Adverse O
Events O
Occurring O
in O
at O
least O
1 O
% O
of O
Subjects O
Signs O
Spinosad O
( O
N=552 O
) O
Permethrin O
1 O
% O
( O
N=457 O
) O
Application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
17 O
( O
3 O
% O
) O
31 O
( O
7 O
% O
) O
Ocular B-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
12 O
( O
2 O
% O
) O
15 O
( O
3 O
% O
) O
Application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
irritation I-OSE_Labeled_AE
5 O
( O
1 O
% O
) O
7 O
( O
2 O
% O
) O
Other O
less O
common O
reactions O
( O
less O
than O
1 O
% O
but O
more O
than O
0.1 O
% O
) O
were O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
dryness I-OSE_Labeled_AE
, O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
exfoliation I-OSE_Labeled_AE
, O
alopecia B-OSE_Labeled_AE
, O
and O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
.Systemic O
safety O
was O
not O
assessed O
in O
pediatric O
subjects O
under O
6 O
months O
of O
age O
as O
laboratory O
parameters O
were O
not O
monitored O
in O
these O
controlled O
studies O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Benzyl O
alcohol O
toxicity O
: O
Not O
recommended O
in O
infants O
below O
the O
age O
of O
6 O
months O
; O
potential O
for O
increased O
systemic O
absorption O
. O

( O
5.1 O
) O
5.1 O
Benzyl B-OSE_Labeled_AE
Alcohol I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
NATROBA O
Topical O
Suspension O
contains O
benzyl O
alcohol O
and O
is O
not O
recommended O
for O
use O
in O
neonates O
and O
infants O
below O
the O
age O
of O
6 O
months O
. O

Systemic O
exposure O
to O
benzyl O
alcohol O
has O
been O
associated O
with O
serious O
adverse O
reactions O
and O
death B-OSE_Labeled_AE
in I-OSE_Labeled_AE
neonates I-OSE_Labeled_AE
and O
low B-OSE_Labeled_AE
birth I-OSE_Labeled_AE
- I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
infants I-OSE_Labeled_AE
[ O
See O
Use O
in O
Specific O
Populations O
( O
8.4 O
) O
] O
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
* O
Adverse O
reactions O
reported O
in O
> O
=5 O
% O
of O
patients O
treated O
with O
ONGLYZA O
and O
more O
commonly O
than O
in O
patients O
treated O
with O
placebo O
are O
upper O
respiratory O
tract O
infection O
, O
urinary O
tract O
infection O
, O
and O
headache O
. O

( O
6.1 O
) O
* O
Peripheral O
edema O
was O
reported O
more O
commonly O
in O
patients O
treated O
with O
the O
combination O
of O
ONGLYZA O
and O
a O
thiazolidinedione O
( O
TZD O
) O
than O
in O
patients O
treated O
with O
the O
combination O
of O
placebo O
and O
TZD O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
AstraZeneca O
at O
1-800-236-9933 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Adverse O
Reactions O
with O
Monotherapy O
and O
with O
Add-On O
Combination O
Therapy O
In O
two O
placebo-controlled O
monotherapy O
trials O
of O
24-weeks O
duration O
, O
patients O
were O
treated O
with O
ONGLYZA O
2.5 O
mg O
daily O
, O
ONGLYZA O
5 O
mg O
daily O
, O
and O
placebo O
. O

Three O
24-week O
, O
placebo-controlled O
, O
add-on O
combination O
therapy O
trials O
were O
also O
conducted O
: O
one O
with O
metformin O
, O
one O
with O
a O
thiazolidinedione O
( O
pioglitazone O
or O
rosiglitazone O
) O
, O
and O
one O
with O
glyburide O
. O

In O
these O
three O
trials O
, O
patients O
were O
randomized O
to O
add-on O
therapy O
with O
ONGLYZA O
2.5 O
mg O
daily O
, O
ONGLYZA O
5 O
mg O
daily O
, O
or O
placebo O
. O

A O
saxagliptin O
10 O
mg O
treatment O
arm O
was O
included O
in O
one O
of O
the O
monotherapy O
trials O
and O
in O
the O
add-on O
combination O
trial O
with O
metformin O
. O

The O
10 O
mg O
dosage O
is O
not O
an O
approved O
dosage O
. O

In O
a O
prespecified O
pooled O
analysis O
of O
the O
24-week O
data O
( O
regardless O
of O
glycemic O
rescue O
) O
from O
the O
two O
monotherapy O
trials O
, O
the O
add-on O
to O
metformin O
trial O
, O
the O
add-on O
to O
thiazolidinedione O
( O
TZD O
) O
trial O
, O
and O
the O
add-on O
to O
glyburide O
trial O
, O
the O
overall O
incidence O
of O
adverse O
events O
in O
patients O
treated O
with O
ONGLYZA O
2.5 O
mg O
and O
ONGLYZA O
5 O
mg O
was O
similar O
to O
placebo O
( O
72 O
% O
and O
72.2 O
% O
versus O
70.6 O
% O
, O
respectively O
) O
. O

Discontinuation O
of O
therapy O
due O
to O
adverse O
events O
occurred O
in O
2.2 O
% O
, O
3.3 O
% O
, O
and O
1.8 O
% O
of O
patients O
receiving O
ONGLYZA O
2.5 O
mg O
, O
ONGLYZA O
5 O
mg O
, O
and O
placebo O
, O
respectively O
. O

The O
most O
common O
adverse O
events O
( O
reported O
in O
at O
least O
2 O
patients O
treated O
with O
ONGLYZA O
2.5 O
mg O
or O
at O
least O
2 O
patients O
treated O
with O
ONGLYZA O
5 O
mg O
) O
associated O
with O
premature O
discontinuation O
of O
therapy O
included O
lymphopenia B-OSE_Labeled_AE
( O
0.1 O
% O
and O
0.5 O
% O
versus O
0 O
% O
, O
respectively O
) O
, O
rash B-OSE_Labeled_AE
( O
0.2 O
% O
and O
0.3 O
% O
versus O
0.3 O
% O
) O
, O
blood B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
0.3 O
% O
and O
0 O
% O
versus O
0 O
% O
) O
, O
and O
blood B-OSE_Labeled_AE
creatine I-OSE_Labeled_AE
phosphokinase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
0.1 O
% O
and O
0.2 O
% O
versus O
0 O
% O
) O
. O

The O
adverse O
reactions O
in O
this O
pooled O
analysis O
reported O
( O
regardless O
of O
investigator O
assessment O
of O
causality O
) O
in O
> O
=5 O
% O
of O
patients O
treated O
with O
ONGLYZA O
5 O
mg O
, O
and O
more O
commonly O
than O
in O
patients O
treated O
with O
placebo O
are O
shown O
in O
Table O
1 O
. O

Table O
1 O
: O
Adverse O
Reactions O
in O
Placebo-Controlled O
TrialsThe O
5 O
placebo-controlled O
trials O
include O
two O
monotherapy O
trials O
and O
one O
add-on O
combination O
therapy O
trial O
with O
each O
of O
the O
following O
: O
metformin O
, O
thiazolidinedione O
, O
or O
glyburide O
. O

Table O
shows O
24-week O
data O
regardless O
of O
glycemic O
rescue O
. O

Reported O
in O
> O
=5 O
% O
of O
Patients O
Treated O
with O
ONGLYZA O
5 O
mg O
and O
More O
Commonly O
than O
in O
Patients O
Treated O
with O
Placebo O
Number O
( O
% O
) O
of O
Patients O
ONGLYZA O
5 O
mg O
N=882 O
Placebo O
N=799 O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
68 O
( O
7.7 O
) O
61 O
( O
7.6 O
) O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
60 O
( O
6.8 O
) O
49 O
( O
6.1 O
) O
Headache B-OSE_Labeled_AE
57 O
( O
6.5 O
) O
47 O
( O
5.9 O
) O
In O
patients O
treated O
with O
ONGLYZA O
2.5 O
mg O
, O
headache B-OSE_Labeled_AE
( O
6.5 O
% O
) O
was O
the O
only O
adverse O
reaction O
reported O
at O
a O
rate O
> O
=5 O
% O
and O
more O
commonly O
than O
in O
patients O
treated O
with O
placebo O
. O

In O
this O
pooled O
analysis O
, O
adverse O
reactions O
that O
were O
reported O
in O
> O
=2 O
% O
of O
patients O
treated O
with O
ONGLYZA O
2.5 O
mg O
or O
ONGLYZA O
5 O
mg O
and O
> O
=1 O
% O
more O
frequently O
compared O
to O
placebo O
included O
: O
sinusitis B-OSE_Labeled_AE
( O
2.9 O
% O
and O
2.6 O
% O
versus O
1.6 O
% O
, O
respectively O
) O
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
2.4 O
% O
and O
1.7 O
% O
versus O
0.5 O
% O
) O
, O
gastroenteritis B-OSE_Labeled_AE
( O
1.9 O
% O
and O
2.3 O
% O
versus O
0.9 O
% O
) O
, O
and O
vomiting B-OSE_Labeled_AE
( O
2.2 O
% O
and O
2.3 O
% O
versus O
1.3 O
% O
) O
. O

In O
the O
add-on O
to O
TZD O
trial O
, O
the O
incidence O
of O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
was O
higher O
for O
ONGLYZA O
5 O
mg O
versus O
placebo O
( O
8.1 O
% O
and O
4.3 O
% O
, O
respectively O
) O
. O

The O
incidence O
of O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
for O
ONGLYZA O
2.5 O
mg O
was O
3.1 O
% O
. O

None O
of O
the O
reported O
adverse O
reactions O
of O
peripheral B-NonOSE_AE
edema I-NonOSE_AE
resulted O
in O
study O
drug O
discontinuation O
. O

Rates O
of O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
for O
ONGLYZA O
2.5 O
mg O
and O
ONGLYZA O
5 O
mg O
versus O
placebo O
were O
3.6 O
% O
and O
2 O
% O
versus O
3 O
% O
given O
as O
monotherapy O
, O
2.1 O
% O
and O
2.1 O
% O
versus O
2.2 O
% O
given O
as O
add-on O
therapy O
to O
metformin O
, O
and O
2.4 O
% O
and O
1.2 O
% O
versus O
2.2 O
% O
given O
as O
add-on O
therapy O
to O
glyburide O
. O

The O
incidence O
rate O
of O
fractures B-OSE_Labeled_AE
was O
1.0 O
and O
0.6 O
per O
100 O
patient-years O
, O
respectively O
, O
for O
ONGLYZA O
( O
pooled O
analysis O
of O
2.5 O
mg O
, O
5 O
mg O
, O
and O
10 O
mg O
) O
and O
placebo O
. O

The O
10 O
mg O
dosage O
is O
not O
an O
approved O
dosage O
. O

The O
incidence O
rate O
of O
fracture B-NonOSE_AE
events O
in O
patients O
who O
received O
ONGLYZA O
did O
not O
increase O
over O
time O
. O

Causality O
has O
not O
been O
established O
and O
nonclinical O
studies O
have O
not O
demonstrated O
adverse O
effects O
of O
ONGLYZA O
on O
bone O
. O

An O
event O
of O
thrombocytopenia B-NonOSE_AE
, O
consistent O
with O
a O
diagnosis O
of O
idiopathic B-NonOSE_AE
thrombocytopenic I-NonOSE_AE
purpura I-NonOSE_AE
, O
was O
observed O
in O
the O
clinical O
program O
. O

The O
relationship O
of O
this O
event O
to O
ONGLYZA O
is O
not O
known O
. O

Adverse O
Reactions O
in O
Patients O
with O
Renal O
Impairment O
ONGLYZA O
2.5 O
mg O
was O
compared O
to O
placebo O
in O
a O
12-week O
trial O
in O
170 O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
and O
moderate O
or O
severe B-Not_AE_Candidate
renal I-Not_AE_Candidate
impairment I-Not_AE_Candidate
or O
end B-Not_AE_Candidate
- I-Not_AE_Candidate
stage I-Not_AE_Candidate
renal I-Not_AE_Candidate
disease I-Not_AE_Candidate
( O
ESRD O
) O
. O

The O
incidence O
of O
adverse O
events O
, O
including O
serious O
adverse O
events O
and O
discontinuations O
due O
to O
adverse O
events O
, O
was O
similar O
between O
ONGLYZA O
and O
placebo O
. O

Adverse O
Reactions O
with O
Concomitant O
Use O
with O
Insulin O
In O
the O
add-on O
to O
insulin O
trial O
[ O
see O
Clinical O
Studies O
( O
14.2 O
) O
] O
, O
the O
incidence O
of O
adverse O
events O
, O
including O
serious O
adverse O
events O
and O
discontinuations O
due O
to O
adverse O
events O
, O
was O
similar O
between O
ONGLYZA O
and O
placebo O
, O
except O
for O
confirmed O
hypoglycemia B-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Adverse O
Reactions O
with O
Concomitant O
Use O
with O
Metformin O
in O
Treatment-Naive O
Patients O
with O
Type O
2 O
Diabetes O
Table O
2 O
shows O
the O
adverse O
reactions O
reported O
( O
regardless O
of O
investigator O
assessment O
of O
causality O
) O
in O
> O
=5 O
% O
of O
patients O
participating O
in O
an O
additional O
24-week O
, O
active-controlled O
trial O
of O
coadministered O
ONGLYZA O
and O
metformin O
in O
treatment-naive O
patients O
. O

Table O
2 O
: O
Initial O
Therapy O
with O
Combination O
of O
ONGLYZA O
and O
Metformin O
in O
Treatment-Naive O
Patients O
: O
Adverse O
Reactions O
Reported O
in O
> O
=5 O
% O
of O
Patients O
Treated O
with O
Combination O
Therapy O
of O
ONGLYZA O
5 O
mg O
Plus O
Metformin O
( O
and O
More O
Commonly O
than O
in O
Patients O
Treated O
with O
Metformin O
Alone O
) O
Number O
( O
% O
) O
of O
Patients O
ONGLYZA O
5 O
mg O
+ O
Metformin O
N=320 O
Metformin O
N=328 O
Headache B-OSE_Labeled_AE
24 O
( O
7.5 O
) O
17 O
( O
5.2 O
) O
Nasopharyngitis B-OSE_Labeled_AE
22 O
( O
6.9 O
) O
13 O
( O
4.0 O
) O
Hypoglycemia O
Adverse O
reactions O
of O
hypoglycemia B-NonOSE_AE
were O
based O
on O
all O
reports O
of O
hypoglycemia B-NonOSE_AE
. O

A O
concurrent O
glucose O
measurement O
was O
not O
required O
or O
was O
normal O
in O
some O
patients O
. O

Therefore O
, O
it O
is O
not O
possible O
to O
conclusively O
determine O
that O
all O
these O
reports O
reflect O
true O
hypoglycemia B-NonOSE_AE
. O

In O
the O
add-on O
to O
glyburide O
study O
, O
the O
overall O
incidence O
of O
reported O
hypoglycemia B-OSE_Labeled_AE
was O
higher O
for O
ONGLYZA O
2.5 O
mg O
and O
ONGLYZA O
5 O
mg O
( O
13.3 O
% O
and O
14.6 O
% O
) O
versus O
placebo O
( O
10.1 O
% O
) O
. O

The O
incidence O
of O
confirmed O
hypoglycemia B-OSE_Labeled_AE
in O
this O
study O
, O
defined O
as O
symptoms O
of O
hypoglycemia B-NonOSE_AE
accompanied O
by O
a O
fingerstick O
glucose B-NonOSE_AE
value I-NonOSE_AE
of I-NonOSE_AE
< I-NonOSE_AE
= I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
, O
was O
2.4 O
% O
and O
0.8 O
% O
for O
ONGLYZA O
2.5 O
mg O
and O
ONGLYZA O
5 O
mg O
and O
0.7 O
% O
for O
placebo O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

The O
incidence O
of O
reported O
hypoglycemia B-OSE_Labeled_AE
for O
ONGLYZA O
2.5 O
mg O
and O
ONGLYZA O
5 O
mg O
versus O
placebo O
given O
as O
monotherapy O
was O
4 O
% O
and O
5.6 O
% O
versus O
4.1 O
% O
, O
respectively O
, O
7.8 O
% O
and O
5.8 O
% O
versus O
5 O
% O
given O
as O
add-on O
therapy O
to O
metformin O
, O
and O
4.1 O
% O
and O
2.7 O
% O
versus O
3.8 O
% O
given O
as O
add-on O
therapy O
to O
TZD O
. O

The O
incidence O
of O
reported O
hypoglycemia B-NonOSE_AE
was O
3.4 O
% O
in O
treatment-naive O
patients O
given O
ONGLYZA O
5 O
mg O
plus O
metformin O
and O
4 O
% O
in O
patients O
given O
metformin O
alone O
. O

In O
the O
active-controlled O
trial O
comparing O
add-on O
therapy O
with O
ONGLYZA O
5 O
mg O
to O
glipizide O
in O
patients O
inadequately O
controlled O
on O
metformin O
alone O
, O
the O
incidence O
of O
reported O
hypoglycemia B-NonOSE_AE
was O
3 O
% O
( O
19 O
events O
in O
13 O
patients O
) O
with O
ONGLYZA O
5 O
mg O
versus O
36.3 O
% O
( O
750 O
events O
in O
156 O
patients O
) O
with O
glipizide O
. O

Confirmed O
symptomatic O
hypoglycemia B-NonOSE_AE
( O
accompanying O
fingerstick O
blood B-NonOSE_AE
glucose I-NonOSE_AE
< I-NonOSE_AE
= I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
) O
was O
reported O
in O
none O
of O
the O
ONGLYZA-treated O
patients O
and O
in O
35 O
glipizide-treated O
patients O
( O
8.1 O
% O
) O
( O
p O
< O
0.0001 O
) O
. O

During O
12 O
weeks O
of O
treatment O
in O
patients O
with O
moderate O
or O
severe B-Not_AE_Candidate
renal I-Not_AE_Candidate
impairment I-Not_AE_Candidate
or O
ESRD B-Not_AE_Candidate
, O
the O
overall O
incidence O
of O
reported O
hypoglycemia B-NonOSE_AE
was O
20 O
% O
among O
patients O
treated O
with O
ONGLYZA O
2.5 O
mg O
and O
22 O
% O
among O
patients O
treated O
with O
placebo O
. O

Four O
ONGLYZA-treated O
patients O
( O
4.7 O
% O
) O
and O
three O
placebo-treated O
patients O
( O
3.5 O
% O
) O
reported O
at O
least O
one O
episode O
of O
confirmed O
symptomatic O
hypoglycemia B-OSE_Labeled_AE
( O
accompanying O
fingerstick O
glucose B-NonOSE_AE
< I-NonOSE_AE
= I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
) O
. O

In O
the O
add-on O
to O
insulin O
trial O
, O
the O
overall O
incidence O
of O
reported O
hypoglycemia B-NonOSE_AE
was O
18.4 O
% O
for O
ONGLYZA O
5 O
mg O
and O
19.9 O
% O
for O
placebo O
. O

However O
, O
the O
incidence O
of O
confirmed O
symptomatic O
hypoglycemia B-OSE_Labeled_AE
( O
accompanying O
fingerstick O
blood B-NonOSE_AE
glucose I-NonOSE_AE
< I-NonOSE_AE
= I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
) O
was O
higher O
with O
ONGLYZA O
5 O
mg O
( O
5.3 O
% O
) O
versus O
placebo O
( O
3.3 O
% O
) O
. O

In O
the O
add-on O
to O
metformin O
plus O
sulfonylurea O
trial O
, O
the O
overall O
incidence O
of O
reported O
hypoglycemia B-NonOSE_AE
was O
10.1 O
% O
for O
ONGLYZA O
5 O
mg O
and O
6.3 O
% O
for O
placebo O
. O

Confirmed O
hypoglycemia B-OSE_Labeled_AE
was O
reported O
in O
1.6 O
% O
of O
the O
ONGLYZA-treated O
patients O
and O
in O
none O
of O
the O
placebo-treated O
patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Hypersensitivity O
Reactions O
Hypersensitivity B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
such O
as O
urticaria B-OSE_Labeled_AE
and O
facial B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
in O
the O
5-study O
pooled O
analysis O
up O
to O
Week O
24 O
were O
reported O
in O
1.5 O
% O
, O
1.5 O
% O
, O
and O
0.4 O
% O
of O
patients O
who O
received O
ONGLYZA O
2.5 O
mg O
, O
ONGLYZA O
5 O
mg O
, O
and O
placebo O
, O
respectively O
. O

None O
of O
these O
events O
in O
patients O
who O
received O
ONGLYZA O
required O
hospitalization O
or O
were O
reported O
as O
life-threatening O
by O
the O
investigators O
. O

One O
ONGLYZA-treated O
patient O
in O
this O
pooled O
analysis O
discontinued O
due O
to O
generalized B-OSE_Labeled_AE
urticaria I-OSE_Labeled_AE
and O
facial B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
. O

Infections O
In O
the O
unblinded O
, O
controlled O
, O
clinical O
trial O
database O
for O
ONGLYZA O
to O
date O
, O
there O
have O
been O
6 O
( O
0.12 O
% O
) O
reports O
of O
tuberculosis B-OSE_Labeled_AE
among O
the O
4959 O
ONGLYZA-treated O
patients O
( O
1.1 O
per O
1000 O
patient-years O
) O
compared O
to O
no O
reports O
of O
tuberculosis B-NonOSE_AE
among O
the O
2868 O
comparator-treated O
patients O
. O

Two O
of O
these O
six O
cases O
were O
confirmed O
with O
laboratory O
testing O
. O

The O
remaining O
cases O
had O
limited O
information O
or O
had O
presumptive O
diagnoses O
of O
tuberculosis B-NonOSE_AE
. O

None O
of O
the O
six O
cases O
occurred O
in O
the O
United O
States O
or O
in O
Western O
Europe O
. O

One O
case O
occurred O
in O
Canada O
in O
a O
patient O
originally O
from O
Indonesia O
who O
had O
recently O
visited O
Indonesia O
. O

The O
duration O
of O
treatment O
with O
ONGLYZA O
until O
report O
of O
tuberculosis B-OSE_Labeled_AE
ranged O
from O
144 O
to O
929 O
days O
. O

Post-treatment O
lymphocyte O
counts O
were O
consistently O
within O
the O
reference O
range O
for O
four O
cases O
. O

One O
patient O
had O
lymphopenia B-Not_AE_Candidate
prior O
to O
initiation O
of O
ONGLYZA O
that O
remained O
stable O
throughout O
ONGLYZA O
treatment O
. O

The O
final O
patient O
had O
an O
isolated O
lymphocyte B-OSE_Labeled_AE
count I-OSE_Labeled_AE
below I-OSE_Labeled_AE
normal I-OSE_Labeled_AE
approximately O
four O
months O
prior O
to O
the O
report O
of O
tuberculosis B-OSE_Labeled_AE
. O

There O
have O
been O
no O
spontaneous O
reports O
of O
tuberculosis B-NonOSE_AE
associated O
with O
ONGLYZA O
use O
. O

Causality O
has O
not O
been O
estimated O
and O
there O
are O
too O
few O
cases O
to O
date O
to O
determine O
whether O
tuberculosis B-NonOSE_AE
is O
related O
to O
ONGLYZA O
use O
. O

There O
has O
been O
one O
case O
of O
a O
potential O
opportunistic B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
in O
the O
unblinded O
, O
controlled O
clinical O
trial O
database O
to O
date O
in O
an O
ONGLYZA-treated O
patient O
who O
developed O
suspected O
foodborne O
fatal B-NonOSE_AE
salmonella B-OSE_Labeled_AE
sepsis I-OSE_Labeled_AE
after O
approximately O
600 O
days O
of O
ONGLYZA O
therapy O
. O

There O
have O
been O
no O
spontaneous O
reports O
of O
opportunistic B-NonOSE_AE
infections I-NonOSE_AE
associated O
with O
ONGLYZA O
use O
. O

Vital O
Signs O
No O
clinically O
meaningful O
changes O
in O
vital O
signs O
have O
been O
observed O
in O
patients O
treated O
with O
ONGLYZA O
. O

Laboratory O
Tests O
Absolute O
Lymphocyte O
Counts O
There O
was O
a O
dose-related O
mean O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
absolute I-OSE_Labeled_AE
lymphocyte I-OSE_Labeled_AE
count I-OSE_Labeled_AE
observed O
with O
ONGLYZA O
. O

From O
a O
baseline O
mean O
absolute O
lymphocyte B-OSE_Labeled_AE
count I-OSE_Labeled_AE
of O
approximately O
2200 O
cells/microL O
, O
mean I-OSE_Labeled_AE
decreases I-OSE_Labeled_AE
of O
approximately O
100 O
and O
120 O
cells/microL O
with O
ONGLYZA O
5 O
mg O
and O
10 O
mg O
, O
respectively O
, O
relative O
to O
placebo O
were O
observed O
at O
24 O
weeks O
in O
a O
pooled O
analysis O
of O
five O
placebo-controlled O
clinical O
studies O
. O

Similar O
effects O
were O
observed O
when O
ONGLYZA O
5 O
mg O
was O
given O
in O
initial O
combination O
with O
metformin O
compared O
to O
metformin O
alone O
. O

There O
was O
no O
difference O
observed O
for O
ONGLYZA O
2.5 O
mg O
relative O
to O
placebo O
. O

The O
proportion O
of O
patients O
who O
were O
reported O
to O
have O
a O
lymphocyte B-OSE_Labeled_AE
count I-OSE_Labeled_AE
< I-OSE_Labeled_AE
= I-OSE_Labeled_AE
7 I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
cells I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
microL I-OSE_Labeled_AE
was O
0.5 O
% O
, O
1.5 O
% O
, O
1.4 O
% O
, O
and O
0.4 O
% O
in O
the O
ONGLYZA O
2.5 O
mg O
, O
5 O
mg O
, O
10 O
mg O
, O
and O
placebo O
groups O
, O
respectively O
. O

In O
most O
patients O
, O
recurrence O
was O
not O
observed O
with O
repeated O
exposure O
to O
ONGLYZA O
although O
some O
patients O
had O
recurrent O
decreases O
upon O
rechallenge O
that O
led O
to O
discontinuation O
of O
ONGLYZA O
. O

The O
decreases B-NonOSE_AE
in I-NonOSE_AE
lymphocyte I-NonOSE_AE
count I-NonOSE_AE
were O
not O
associated O
with O
clinically O
relevant O
adverse O
reactions O
. O

The O
10 O
mg O
dosage O
is O
not O
an O
approved O
dosage O
. O

The O
clinical O
significance O
of O
this O
decrease B-NonOSE_AE
in I-NonOSE_AE
lymphocyte I-NonOSE_AE
count I-NonOSE_AE
relative O
to O
placebo O
is O
not O
known O
. O

When O
clinically O
indicated O
, O
such O
as O
in O
settings O
of O
unusual O
or O
prolonged O
infection B-NonOSE_AE
, O
lymphocyte O
count O
should O
be O
measured O
. O

The O
effect O
of O
ONGLYZA O
on O
lymphocyte O
counts O
in O
patients O
with O
lymphocyte B-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
( O
e.g. O
, O
human B-Not_AE_Candidate
immunodeficiency I-Not_AE_Candidate
virus I-Not_AE_Candidate
) O
is O
unknown O
. O

6.2 O
Postmarketing O
Experience O
Additional O
adverse O
reactions O
have O
been O
identified O
during O
postapproval O
use O
of O
ONGLYZA O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
generally O
not O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

* O
Hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
anaphylaxis B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
and O
exfoliative B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
conditions I-OSE_Labeled_AE
[ O
see O
Contraindications O
( O
4 O
) O
and O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

* O
Acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
[ O
see O
Indications O
and O
Usage O
( O
1.2 O
) O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
Severe O
and O
disabling O
arthralgia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Acute O
Pancreatitis O
( O
postmarketing O
reports O
) O
: O
If O
pancreatitis O
is O
suspected O
, O
promptly O
discontinue O
ONGLYZA O
. O

( O
5.1 O
) O
* O
Hypoglycemia O
: O
In O
add-on O
to O
sulfonylurea O
, O
add-on O
to O
insulin O
, O
and O
add-on O
to O
metformin O
plus O
sulfonylurea O
trials O
, O
confirmed O
hypoglycemia O
was O
more O
common O
in O
patients O
treated O
with O
ONGLYZA O
compared O
to O
placebo O
. O

When O
used O
with O
an O
insulin O
secretagogue O
( O
e.g. O
, O
sulfonylurea O
) O
or O
insulin O
, O
a O
lower O
dose O
of O
the O
insulin O
secretagogue O
or O
insulin O
may O
be O
required O
to O
minimize O
the O
risk O
of O
hypoglycemia O
. O

( O
5.2 O
, O
6.1 O
) O
* O
Hypersensitivity-Related O
Events O
( O
e.g. O
, O
urticaria O
, O
facial O
edema O
) O
: O
More O
common O
in O
patients O
treated O
with O
ONGLYZA O
than O
in O
patients O
treated O
with O
placebo O
; O
and O
postmarketing O
reports O
of O
serious O
hypersensitivity O
reactions O
such O
as O
anaphylaxis O
, O
angioedema O
, O
and O
exfoliative O
skin O
conditions O
. O

Promptly O
discontinue O
ONGLYZA O
, O
assess O
for O
other O
potential O
causes O
, O
institute O
appropriate O
monitoring O
and O
treatment O
, O
and O
initiate O
alternative O
treatment O
for O
diabetes O
. O

( O
5.3 O
, O
6.1 O
, O
6.2 O
) O
* O
Arthralgia O
: O
Severe O
and O
disabling O
arthralgia O
has O
been O
reported O
in O
patients O
taking O
DPP4 O
inhibitors O
. O

Consider O
as O
a O
possible O
cause O
for O
severe O
joint O
pain O
and O
discontinue O
drug O
if O
appropriate O
. O

( O
5.4 O
) O
* O
There O
have O
been O
no O
clinical O
studies O
establishing O
conclusive O
evidence O
of O
macrovascular O
risk O
reduction O
with O
ONGLYZA O
or O
any O
other O
antidiabetic O
drug O
. O

( O
5.5 O
) O
5.1 O
Pancreatitis O
There O
have O
been O
postmarketing O
reports O
of O
acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
in O
patients O
taking O
ONGLYZA O
. O

After O
initiation O
of O
ONGLYZA O
, O
patients O
should O
be O
observed O
carefully O
for O
signs O
and O
symptoms O
of O
pancreatitis B-NonOSE_AE
. O

If O
pancreatitis B-NonOSE_AE
is O
suspected O
, O
ONGLYZA O
should O
promptly O
be O
discontinued O
and O
appropriate O
management O
should O
be O
initiated O
. O

It O
is O
unknown O
whether O
patients O
with O
a O
history B-Not_AE_Candidate
of I-Not_AE_Candidate
pancreatitis I-Not_AE_Candidate
are O
at O
increased O
risk O
for O
the O
development O
of O
pancreatitis B-NonOSE_AE
while O
using O
ONGLYZA O
. O

5.2 O
Hypoglycemia O
with O
Concomitant O
Use O
of O
Sulfonylurea O
or O
Insulin O
When O
ONGLYZA O
was O
used O
in O
combination O
with O
a O
sulfonylurea O
or O
with O
insulin O
, O
medications O
known O
to O
cause O
hypoglycemia B-NonOSE_AE
, O
the O
incidence O
of O
confirmed O
hypoglycemia B-NonOSE_AE
was O
increased O
over O
that O
of O
placebo O
used O
in O
combination O
with O
a O
sulfonylurea O
or O
with O
insulin O
. O

[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Therefore O
, O
a O
lower O
dose O
of O
the O
insulin O
secretagogue O
or O
insulin O
may O
be O
required O
to O
minimize O
the O
risk O
of O
hypoglycemia B-NonOSE_AE
when O
used O
in O
combination O
with O
ONGLYZA O
[ O
see O
Dosage O
and O
Administration O
( O
2.4 O
) O
] O
. O

5.3 O
Hypersensitivity O
Reactions O
There O
have O
been O
postmarketing O
reports O
of O
serious O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
in O
patients O
treated O
with O
ONGLYZA O
. O

These O
reactions O
include O
anaphylaxis B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
and O
exfoliative B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
conditions I-OSE_Labeled_AE
. O

Onset O
of O
these O
reactions O
occurred O
within O
the O
first O
3 O
months O
after O
initiation O
of O
treatment O
with O
ONGLYZA O
, O
with O
some O
reports O
occurring O
after O
the O
first O
dose O
. O

If O
a O
serious O
hypersensitivity B-NonOSE_AE
reaction I-NonOSE_AE
is O
suspected O
, O
discontinue O
ONGLYZA O
, O
assess O
for O
other O
potential O
causes O
for O
the O
event O
, O
and O
institute O
alternative O
treatment O
for O
diabetes B-Not_AE_Candidate
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

Use O
caution O
in O
a O
patient O
with O
a O
history O
of O
angioedema B-Not_AE_Candidate
to O
another O
dipeptidyl O
peptidase-4 O
( O
DPP4 O
) O
inhibitor O
because O
it O
is O
unknown O
whether O
such O
patients O
will O
be O
predisposed O
to O
angioedema B-NonOSE_AE
with O
ONGLYZA O
. O

5.4 O
Severe O
and O
Disabling O
Arthralgia O
There O
have O
been O
postmarketing O
reports O
of O
severe O
and O
disabling O
arthralgia B-OSE_Labeled_AE
in O
patients O
taking O
DPP4 O
inhibitors O
. O

The O
time O
to O
onset O
of O
symptoms O
following O
initiation O
of O
drug O
therapy O
varied O
from O
one O
day O
to O
years O
. O

Patients O
experienced O
relief O
of O
symptoms O
upon O
discontinuation O
of O
the O
medication O
. O

A O
subset O
of O
patients O
experienced O
a O
recurrence O
of O
symptoms O
when O
restarting O
the O
same O
drug O
or O
a O
different O
DPP4 O
inhibitor O
. O

Consider O
DPP4 O
inhibitors O
as O
a O
possible O
cause O
for O
severe O
joint B-NonOSE_AE
pain I-NonOSE_AE
and O
discontinue O
drug O
if O
appropriate O
. O

5.5 O
Macrovascular O
Outcomes O
There O
have O
been O
no O
clinical O
studies O
establishing O
conclusive O
evidence O
of O
macrovascular B-NonOSE_AE
risk I-NonOSE_AE
reduction O
with O
ONGLYZA O
or O
any O
other O
antidiabetic O
drug O
. O

6 O
ADVERSE O
REACTIONS O
Clinically O
significant O
adverse O
reactions O
that O
appear O
in O
other O
sections O
of O
the O
labeling O
include O
: O
* O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Hepatotoxicity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Hemoglobin I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
more O
frequent O
than O
placebo O
by O
> O
=3 O
% O
) O
are O
anemia O
, O
nasopharyngitis/pharyngitis O
, O
bronchitis O
, O
headache O
, O
influenza O
, O
and O
urinary O
tract O
infection O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Actelion O
at O
1-866-228-3546 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trial O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

Safety O
data O
for O
OPSUMIT O
were O
obtained O
primarily O
from O
one O
placebo-controlled O
clinical O
study O
in O
742 O
patients O
with O
PAH B-Not_AE_Candidate
( O
SERAPHIN O
study O
) O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

The O
exposure O
to O
OPSUMIT O
in O
this O
trial O
was O
up O
to O
3.6 O
years O
with O
a O
median O
exposure O
of O
about O
2 O
years O
( O
N=542 O
for O
1 O
year O
; O
N=429 O
for O
2 O
years O
; O
and O
N=98 O
for O
more O
than O
3 O
years O
) O
. O

The O
overall O
incidence O
of O
treatment O
discontinuations O
because O
of O
adverse O
events O
was O
similar O
across O
OPSUMIT O
10 O
mg O
and O
placebo O
treatment O
groups O
( O
approximately O
11 O
% O
) O
. O

Table O
2 O
presents O
adverse O
reactions O
more O
frequent O
on O
OPSUMIT O
than O
on O
placebo O
by O
> O
=3 O
% O
. O

Table O
2 O
Adverse O
Reactions O
Adverse O
Reaction O
OPSUMIT O
10 O
mg O
( O
N=242 O
) O
( O
% O
) O
Placebo O
( O
N=249 O
) O
( O
% O
) O
Anemia B-OSE_Labeled_AE
13 O
3 O
Nasopharyngitis B-OSE_Labeled_AE
/ O
pharyngitis B-OSE_Labeled_AE
20 O
13 O
Bronchitis B-OSE_Labeled_AE
12 O
6 O
Headache B-OSE_Labeled_AE
14 O
9 O
Influenza B-OSE_Labeled_AE
6 O
2 O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
9 O
6 O
6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
OPSUMIT O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Immune B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
angioedema B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
and O
rash B-OSE_Labeled_AE
) O
Respiratory B-NonOSE_AE
, O
thoracic O
and O
mediastinal O
disorders I-NonOSE_AE
: O
nasal B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE

BOXED O
WARNING O
: O
WARNING O
: O
EMBRYO B-OSE_Labeled_AE
- I-OSE_Labeled_AE
FETAL I-OSE_Labeled_AE
TOXICITY I-OSE_Labeled_AE
WARNING O
: O
EMBRYO-FETAL O
TOXICITY O
* O
Do O
not O
administer O
OPSUMIT O
to O
a O
pregnant B-Not_AE_Candidate
female O
because O
it O
may O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
[ O
see O
Contraindications O
( O
4.1 O
) O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

* O
Females O
of O
reproductive O
potential O
: O
Exclude O
pregnancy B-Not_AE_Candidate
before O
the O
start O
of O
treatment O
, O
monthly O
during O
treatment O
, O
and O
1 O
month O
after O
stopping O
treatment O
. O

Prevent O
pregnancy B-Not_AE_Candidate
during O
treatment O
and O
for O
one O
month O
after O
stopping O
treatment O
by O
using O
acceptable O
methods O
of O
contraception O
[ O
see O
Use O
in O
Special O
Populations O
( O
8.6 O
) O
] O
. O

* O
For O
all O
female O
patients O
, O
OPSUMIT O
is O
available O
only O
through O
a O
restricted O
program O
called O
the O
OPSUMIT O
Risk O
Evaluation O
and O
Mitigation O
Strategy O
( O
REMS O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
EMBRYO-FETAL O
TOXICITY O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
* O
Do O
not O
administer O
OPSUMIT O
to O
a O
pregnant O
female O
because O
it O
may O
cause O
fetal O
harm O
( O
4.1 O
, O
5.1 O
, O
8.1 O
) O
. O

* O
Females O
of O
reproductive O
potential O
: O
exclude O
pregnancy O
before O
start O
of O
treatment O
, O
monthly O
during O
treatment O
, O
and O
1 O
month O
after O
stopping O
treatment O
. O

Prevent O
pregnancy O
during O
treatment O
and O
for O
one O
month O
after O
treatment O
by O
using O
acceptable O
methods O
of O
contraception O
( O
2.2 O
, O
8.6 O
) O
. O

* O
For O
all O
female O
patients O
, O
OPSUMIT O
is O
available O
only O
through O
a O
restricted O
program O
called O
the O
OPSUMIT O
Risk O
Evaluation O
and O
Mitigation O
Strategy O
( O
REMS O
) O
( O
5.2 O
) O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Other O
ERAs O
cause O
hepatotoxicity O
and O
liver O
failure O
. O

Obtain O
baseline O
liver O
enzymes O
and O
monitor O
as O
clinically O
indicated O
( O
5.3 O
) O
. O

* O
Decreases O
in O
hemoglobin O
( O
5.4 O
) O
. O

* O
Pulmonary O
edema O
in O
patients O
with O
pulmonary O
veno-occlusive O
disease O
. O

If O
confirmed O
, O
discontinue O
treatment O
( O
5.5 O
) O
. O

* O
Decreases O
in O
sperm O
count O
have O
been O
observed O
in O
patients O
taking O
ERAs O
( O
5.6 O
) O
. O

5.1 O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
OPSUMIT O
may O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
during O
pregnancy B-Not_AE_Candidate
and O
is O
contraindicated O
for O
use O
in O
females O
who O
are O
pregnant B-Not_AE_Candidate
. O

In O
females O
of O
reproductive O
potential O
, O
exclude O
pregnancy B-Not_AE_Candidate
prior O
to O
initiation O
of O
therapy O
, O
ensure O
use O
of O
acceptable O
contraceptive O
methods O
and O
obtain O
monthly O
pregnancy O
tests O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.1 O
, O
8.6 O
) O
] O
. O

OPSUMIT O
is O
available O
for O
females O
through O
the O
OPSUMIT O
REMS O
Program O
, O
a O
restricted O
distribution O
program O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

5.2 O
OPSUMIT O
REMS O
Program O
For O
all O
females O
, O
OPSUMIT O
is O
available O
only O
through O
a O
restricted O
program O
called O
the O
OPSUMIT O
REMS O
Program O
, O
because O
of O
the O
risk O
of O
embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
fetal I-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
[ O
see O
Contraindications O
( O
4.1 O
) O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
and O
Use O
in O
Specific O
Populations O
( O
8.1 O
, O
8.6 O
) O
] O
. O

Notable O
requirements O
of O
the O
OPSUMIT O
REMS O
Program O
include O
the O
following O
: O
* O
Prescribers O
must O
be O
certified O
with O
the O
program O
by O
enrolling O
and O
completing O
training O
. O

* O
All O
females O
, O
regardless O
of O
reproductive O
potential O
, O
must O
enroll O
in O
the O
OPSUMIT O
REMS O
Program O
prior O
to O
initiating O
OPSUMIT O
. O

Male O
patients O
are O
not O
enrolled O
in O
the O
REMS O
. O

* O
Females O
of O
reproductive O
potential O
must O
comply O
with O
the O
pregnancy O
testing O
and O
contraception O
requirements O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
] O
. O

* O
Pharmacies O
must O
be O
certified O
with O
the O
program O
and O
must O
only O
dispense O
to O
patients O
who O
are O
authorized O
to O
receive O
OPSUMIT O
. O

Further O
information O
is O
available O
at O
www.OPSUMITREMS.com O
or O
1-866-228-3546 O
. O

Information O
on O
OPSUMIT O
certified O
pharmacies O
or O
wholesale O
distributors O
is O
available O
through O
Actelion O
Pathways O
at O
1-866-228-3546 O
. O

5.3 O
Hepatotoxicity O
Other O
ERAs O
have O
caused O
elevations B-NonOSE_AE
of I-NonOSE_AE
aminotransferases I-NonOSE_AE
, O
hepatotoxicity B-NonOSE_AE
, O
and O
liver B-NonOSE_AE
failure I-NonOSE_AE
. O

The O
incidence O
of O
elevated B-NonOSE_AE
aminotransferases I-NonOSE_AE
in O
the O
study O
of O
OPSUMIT O
in O
PAH B-Not_AE_Candidate
is O
shown O
in O
Table O
1 O
. O

Table O
1 O
Incidence O
of O
Elevated B-OSE_Labeled_AE
Aminotransferases I-OSE_Labeled_AE
in O
the O
SERAPHIN O
Study O
OPSUMIT O
10 O
mg O
( O
N=242 O
) O
Placebo O
( O
N=249 O
) O
> I-OSE_Labeled_AE
3 O
* O
ULN O
3.4 O
% O
4.5 O
% O
> O
8 I-OSE_Labeled_AE
* I-OSE_Labeled_AE
ULN I-OSE_Labeled_AE
2.1 O
% O
0.4 O
% O
In O
the O
placebo-controlled O
study O
of O
OPSUMIT O
, O
discontinuations O
for O
hepatic B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
3.3 O
% O
in O
the O
OPSUMIT O
10 O
mg O
group O
vs O
. O
1.6 O
% O
for O
placebo O
. O

Obtain O
liver O
enzyme O
tests O
prior O
to O
initiation O
of O
OPSUMIT O
and O
repeat O
during O
treatment O
as O
clinically O
indicated O
. O

Advise O
patients O
to O
report O
symptoms O
suggesting O
hepatic B-NonOSE_AE
injury I-NonOSE_AE
( O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
right B-NonOSE_AE
upper I-NonOSE_AE
quadrant I-NonOSE_AE
pain I-NonOSE_AE
, O
fatigue B-NonOSE_AE
, O
anorexia B-NonOSE_AE
, O
jaundice B-NonOSE_AE
, O
dark B-NonOSE_AE
urine I-NonOSE_AE
, O
fever B-NonOSE_AE
, O
or O
itching B-NonOSE_AE
) O
. O

If O
clinically O
relevant O
aminotransferase B-NonOSE_AE
elevations I-NonOSE_AE
occur O
, O
or O
if O
elevations O
are O
accompanied O
by O
an O
increase B-NonOSE_AE
in I-NonOSE_AE
bilirubin I-NonOSE_AE
> I-NonOSE_AE
2 I-NonOSE_AE
* I-NonOSE_AE
ULN I-NonOSE_AE
, O
or O
by O
clinical O
symptoms O
of O
hepatotoxicity B-NonOSE_AE
, O
discontinue O
OPSUMIT O
. O

Consider O
re-initiation O
of O
OPSUMIT O
when O
hepatic O
enzyme O
levels O
normalize O
in O
patients O
who O
have O
not O
experienced O
clinical O
symptoms O
of O
hepatotoxicity B-NonOSE_AE
. O

5.4 O
Hemoglobin O
Decrease O
Decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
concentration I-OSE_Labeled_AE
and O
hematocrit O
have O
occurred O
following O
administration O
of O
other O
ERAs O
and O
were O
observed O
in O
clinical O
studies O
with O
OPSUMIT O
. O

These O
decreases O
occurred O
early O
and O
stabilized O
thereafter O
. O

In O
the O
placebo-controlled O
study O
of O
OPSUMIT O
in O
PAH B-Not_AE_Candidate
, O
OPSUMIT O
10 O
mg O
caused O
a O
mean O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
from O
baseline O
to O
up O
to O
18 O
months O
of O
about O
1.0 O
g/dL O
compared O
to O
no O
change O
in O
the O
placebo O
group O
. O

A O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
to O
below O
10.0 O
g/dL O
was O
reported O
in O
8.7 O
% O
of O
the O
OPSUMIT O
10 O
mg O
group O
and O
in O
3.4 O
% O
of O
the O
placebo O
group O
. O

Decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
seldom O
require O
transfusion O
. O

Initiation O
of O
OPSUMIT O
is O
not O
recommended O
in O
patients O
with O
severe B-Not_AE_Candidate
anemia I-Not_AE_Candidate
. O

Measure O
hemoglobin O
prior O
to O
initiation O
of O
treatment O
and O
repeat O
during O
treatment O
as O
clinically O
indicated O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.5 O
Pulmonary O
Edema O
with O
Pulmonary O
Veno-occlusive O
Disease O
( O
PVOD O
) O
Should O
signs O
of O
pulmonary B-NonOSE_AE
edema I-NonOSE_AE
occur O
, O
consider O
the O
possibility O
of O
associated O
PVOD B-OSE_Labeled_AE
. O

If O
confirmed O
, O
discontinue O
OPSUMIT O
. O

5.6 O
Decreased O
Sperm O
Counts O
Other O
ERAs O
have O
caused O
adverse B-NonOSE_AE
effects I-NonOSE_AE
on I-NonOSE_AE
spermatogenesis I-NonOSE_AE
. O

Counsel O
men O
about O
potential O
effects O
on O
fertility O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
and O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
. O

ADVERSE O
REACTIONS O
Associated O
With O
Discontinuation O
of O
Treatment O
: O
Twenty O
percent O
( O
1,199/6,145 O
) O
of O
patients O
treated O
with O
PAXIL O
in O
worldwide O
clinical O
trials O
in O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
and O
16.1 O
% O
( O
84/522 O
) O
, O
11.8 O
% O
( O
64/542 O
) O
, O
9.4 O
% O
( O
44/469 O
) O
, O
10.7 O
% O
( O
79/735 O
) O
, O
and O
11.7 O
% O
( O
79/676 O
) O
of O
patients O
treated O
with O
PAXIL O
in O
worldwide O
trials O
in O
social B-Not_AE_Candidate
anxiety I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
OCD B-Not_AE_Candidate
, O
panic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
GAD B-Not_AE_Candidate
, O
and O
PTSD B-Not_AE_Candidate
, O
respectively O
, O
discontinued O
treatment O
due O
to O
an O
adverse O
event O
. O

The O
most O
common O
events O
( O
> O
=1 O
% O
) O
associated O
with O
discontinuation O
and O
considered O
to O
be O
drug O
related O
( O
i.e. O
, O
those O
events O
associated O
with O
dropout O
at O
a O
rate O
approximately O
twice O
or O
greater O
for O
PAXIL O
compared O
to O
placebo O
) O
included O
the O
following O
: O
Major O
Depressive O
Disorder O
OCD O
Panic O
Disorder O
Social O
Anxiety O
Disorder O
Generalized O
Anxiety O
Disorder O
PTSD O
PAXIL O
Placebo O
PAXIL O
Placebo O
PAXIL O
Placebo O
PAXIL O
Placebo O
PAXIL O
Placebo O
PAXIL O
Placebo O
CNS B-NonOSE_AE
Somnolence B-OSE_Labeled_AE
2.3 O
% O
0.7 O
% O
- O
1.9 O
% O
0.3 O
% O
3.4 O
% O
0.3 O
% O
2.0 O
% O
0.2 O
% O
2.8 O
% O
0.6 O
% O
Insomnia B-OSE_Labeled_AE
- O
- O
1.7 O
% O
0 O
% O
1.3 O
% O
0.3 O
% O
3.1 O
% O
0 O
% O
- O
- O
Agitation B-OSE_Labeled_AE
1.1 O
% O
0.5 O
% O
- O
- O
- O
Tremor B-OSE_Labeled_AE
1.1 O
% O
0.3 O
% O
- O
1.7 O
% O
0 O
% O
1.0 O
% O
0.2 O
% O
Anxiety B-OSE_Labeled_AE
- O
- O
- O
1.1 O
% O
0 O
% O
- O
- O
Dizziness B-OSE_Labeled_AE
- O
- O
1.5 O
% O
0 O
% O
1.9 O
% O
0 O
% O
1.0 O
% O
0.2 O
% O
- O
- O
Gastrointestinal B-NonOSE_AE
Constipation B-OSE_Labeled_AE
- O
1.1 O
% O
0 O
% O
- O
- O
Nausea B-OSE_Labeled_AE
3.2 O
% O
1.1 O
% O
1.9 O
% O
0 O
% O
3.2 O
% O
1.2 O
% O
4.0 O
% O
0.3 O
% O
2.0 O
% O
0.2 O
% O
2.2 O
% O
0.6 O
% O
Diarrhea B-OSE_Labeled_AE
1.0 O
% O
0.3 O
% O
- O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
1.0 O
% O
0.3 O
% O
- O
- O
- O
Vomiting B-OSE_Labeled_AE
1.0 O
% O
0.3 O
% O
- O
1.0 O
% O
0 O
% O
- O
- O
Flatulence B-OSE_Labeled_AE
1.0 O
% O
0.3 O
% O
- O
- O
Other O
Asthenia B-OSE_Labeled_AE
1.6 O
% O
0.4 O
% O
1.9 O
% O
0.4 O
% O
2.5 O
% O
0.6 O
% O
1.8 O
% O
0.2 O
% O
1.6 O
% O
0.2 O
% O
Abnormal B-OSE_Labeled_AE
Ejaculationa I-OSE_Labeled_AE
1.6 O
% O
0 O
% O
2.1 O
% O
0 O
% O
4.9 O
% O
0.6 O
% O
2.5 O
% O
0.5 O
% O
- O
- O
Sweating B-OSE_Labeled_AE
1.0 O
% O
0.3 O
% O
- O
1.1 O
% O
0 O
% O
1.1 O
% O
0.2 O
% O
- O
- O
Impotencea B-OSE_Labeled_AE
- O
1.5 O
% O
0 O
% O
- O
- O
Libido B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
1.0 O
% O
0 O
% O
- O
- O
Where O
numbers O
are O
not O
provided O
the O
incidence O
of O
the O
adverse O
events O
in O
patients O
treated O
with O
PAXIL O
was O
not O
> O
1 O
% O
or O
was O
not O
greater O
than O
or O
equal O
to O
2 O
times O
the O
incidence O
of O
placebo O
. O

a O
. O

Incidence O
corrected O
for O
gender O
. O

Commonly O
Observed O
Adverse O
Events O
: O
Major O
Depressive O
Disorder O
: O
The O
most O
commonly O
observed O
adverse O
events O
associated O
with O
the O
use O
of O
paroxetine O
( O
incidence O
of O
5 O
% O
or O
greater O
and O
incidence O
for O
PAXIL O
at O
least O
twice O
that O
for O
placebo O
, O
derived O
from O
Table O
2 O
) O
were O
: O
Asthenia B-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
nervousness B-OSE_Labeled_AE
, O
ejaculatory B-OSE_Labeled_AE
disturbance I-OSE_Labeled_AE
, O
and O
other O
male B-OSE_Labeled_AE
genital I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
. O

Obsessive O
Compulsive O
Disorder O
: O
The O
most O
commonly O
observed O
adverse O
events O
associated O
with O
the O
use O
of O
paroxetine O
( O
incidence O
of O
5 O
% O
or O
greater O
and O
incidence O
for O
PAXIL O
at O
least O
twice O
that O
of O
placebo O
, O
derived O
from O
Table O
3 O
) O
were O
: O
Nausea B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
, O
impotence B-OSE_Labeled_AE
, O
and O
abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
. O

Panic O
Disorder O
: O
The O
most O
commonly O
observed O
adverse O
events O
associated O
with O
the O
use O
of O
paroxetine O
( O
incidence O
of O
5 O
% O
or O
greater O
and O
incidence O
for O
PAXIL O
at O
least O
twice O
that O
for O
placebo O
, O
derived O
from O
Table O
3 O
) O
were O
: O
Asthenia B-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
, O
female B-OSE_Labeled_AE
genital I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
and O
impotence B-OSE_Labeled_AE
. O

Social O
Anxiety O
Disorder O
: O
The O
most O
commonly O
observed O
adverse O
events O
associated O
with O
the O
use O
of O
paroxetine O
( O
incidence O
of O
5 O
% O
or O
greater O
and O
incidence O
for O
PAXIL O
at O
least O
twice O
that O
for O
placebo O
, O
derived O
from O
Table O
3 O
) O
were O
: O
Sweating B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
yawn B-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
, O
female B-OSE_Labeled_AE
genital I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
and O
impotence B-OSE_Labeled_AE
. O

Generalized O
Anxiety O
Disorder O
: O
The O
most O
commonly O
observed O
adverse O
events O
associated O
with O
the O
use O
of O
paroxetine O
( O
incidence O
of O
5 O
% O
or O
greater O
and O
incidence O
for O
PAXIL O
at O
least O
twice O
that O
for O
placebo O
, O
derived O
from O
Table O
4 O
) O
were O
: O
Asthenia B-OSE_Labeled_AE
, O
infection B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
, O
and O
abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
. O

Posttraumatic O
Stress O
Disorder O
: O
The O
most O
commonly O
observed O
adverse O
events O
associated O
with O
the O
use O
of O
paroxetine O
( O
incidence O
of O
5 O
% O
or O
greater O
and O
incidence O
for O
PAXIL O
at O
least O
twice O
that O
for O
placebo O
, O
derived O
from O
Table O
4 O
) O
were O
: O
Asthenia B-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
, O
female B-OSE_Labeled_AE
genital I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
and O
impotence B-OSE_Labeled_AE
. O

Incidence O
in O
Controlled O
Clinical O
Trials O
: O
The O
prescriber O
should O
be O
aware O
that O
the O
figures O
in O
the O
tables O
following O
can O
not O
be O
used O
to O
predict O
the O
incidence O
of O
side O
effects O
in O
the O
course O
of O
usual O
medical O
practice O
where O
patient O
characteristics O
and O
other O
factors O
differ O
from O
those O
that O
prevailed O
in O
the O
clinical O
trials O
. O

Similarly O
, O
the O
cited O
frequencies O
can O
not O
be O
compared O
with O
figures O
obtained O
from O
other O
clinical O
investigations O
involving O
different O
treatments O
, O
uses O
, O
and O
investigators O
. O

The O
cited O
figures O
, O
however O
, O
do O
provide O
the O
prescribing O
physician O
with O
some O
basis O
for O
estimating O
the O
relative O
contribution O
of O
drug O
and O
nondrug O
factors O
to O
the O
side O
effect O
incidence O
rate O
in O
the O
populations O
studied O
. O

Major O
Depressive O
Disorder O
: O
Table O
2 O
enumerates O
adverse O
events O
that O
occurred O
at O
an O
incidence O
of O
1 O
% O
or O
more O
among O
paroxetine-treated O
patients O
who O
participated O
in O
short-term O
( O
6-week O
) O
placebo-controlled O
trials O
in O
which O
patients O
were O
dosed O
in O
a O
range O
of O
20 O
mg O
to O
50 O
mg/day O
. O

Reported O
adverse O
events O
were O
classified O
using O
a O
standard O
COSTART-based O
Dictionary O
terminology O
. O

Table O
2 O
. O

Treatment-Emergent O
Adverse O
Experience O
Incidence O
in O
Placebo-Controlled O
Clinical O
Trials O
for O
Major O
Depressive O
Disordera O
Body O
System O
Preferred O
Term O
PAXIL O
( O
n O
= O
421 O
) O
Placebo O
( O
n O
= O
421 O
) O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
Headache B-OSE_Labeled_AE
18 O
% O
17 O
% O
Asthenia B-OSE_Labeled_AE
15 O
% O
6 O
% O
Cardiovascular B-NonOSE_AE
Palpitation B-OSE_Labeled_AE
3 O
% O
1 O
% O
Vasodilation B-OSE_Labeled_AE
3 O
% O
1 O
% O
Dermatologic B-NonOSE_AE
Sweating B-OSE_Labeled_AE
11 O
% O
2 O
% O
Rash B-OSE_Labeled_AE
2 O
% O
1 O
% O
Gastrointestinal B-NonOSE_AE
Nausea B-OSE_Labeled_AE
26 O
% O
9 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
18 O
% O
12 O
% O
Constipation B-OSE_Labeled_AE
14 O
% O
9 O
% O
Diarrhea B-OSE_Labeled_AE
12 O
% O
8 O
% O
Decreased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
6 O
% O
2 O
% O
Flatulence B-OSE_Labeled_AE
4 O
% O
2 O
% O
Oropharynx B-OSE_Labeled_AE
Disorderb I-OSE_Labeled_AE
2 O
% O
0 O
% O
Dyspepsia B-OSE_Labeled_AE
2 O
% O
1 O
% O
Musculoskeletal B-NonOSE_AE
Myopathy B-OSE_Labeled_AE
2 O
% O
1 O
% O
Myalgia B-OSE_Labeled_AE
2 O
% O
1 O
% O
Myasthenia B-OSE_Labeled_AE
1 O
% O
0 O
% O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Somnolence B-OSE_Labeled_AE
23 O
% O
9 O
% O
Dizziness B-OSE_Labeled_AE
13 O
% O
6 O
% O
Insomnia B-OSE_Labeled_AE
13 O
% O
6 O
% O
Tremor B-OSE_Labeled_AE
8 O
% O
2 O
% O
Nervousness B-OSE_Labeled_AE
5 O
% O
3 O
% O
Anxiety B-OSE_Labeled_AE
5 O
% O
3 O
% O
Paresthesia B-OSE_Labeled_AE
4 O
% O
2 O
% O
Libido B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
3 O
% O
0 O
% O
Drugged B-OSE_Labeled_AE
Feeling I-OSE_Labeled_AE
2 O
% O
1 O
% O
Confusion B-OSE_Labeled_AE
1 O
% O
0 O
% O
Respiration B-NonOSE_AE
Yawn B-OSE_Labeled_AE
4 O
% O
0 O
% O
Special B-NonOSE_AE
Senses I-NonOSE_AE
Blurred B-OSE_Labeled_AE
Vision I-OSE_Labeled_AE
4 O
% O
1 O
% O
Taste B-OSE_Labeled_AE
Perversion I-OSE_Labeled_AE
2 O
% O
0 O
% O
Urogenital B-NonOSE_AE
System I-NonOSE_AE
Ejaculatory B-OSE_Labeled_AE
Disturbancec I-OSE_Labeled_AE
, O
d O
13 O
% O
0 O
% O
Other O
Male B-OSE_Labeled_AE
Genital I-OSE_Labeled_AE
Disordersc I-OSE_Labeled_AE
, O
e O
10 O
% O
0 O
% O
Urinary B-OSE_Labeled_AE
Frequency I-OSE_Labeled_AE
3 O
% O
1 O
% O
Urination B-OSE_Labeled_AE
Disorderf I-OSE_Labeled_AE
3 O
% O
0 O
% O
Female B-OSE_Labeled_AE
Genital I-OSE_Labeled_AE
Disordersc I-OSE_Labeled_AE
, O
g O
2 O
% O
0 O
% O
a O
. O

Events O
reported O
by O
at O
least O
1 O
% O
of O
patients O
treated O
with O
PAXIL O
are O
included O
, O
except O
the O
following O
events O
which O
had O
an O
incidence O
on O
placebo O
> O
= O
PAXIL O
: O
Abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
agitation B-NonOSE_AE
, O
back B-NonOSE_AE
pain I-NonOSE_AE
, O
chest B-NonOSE_AE
pain I-NonOSE_AE
, O
CNS B-NonOSE_AE
stimulation I-NonOSE_AE
, O
fever B-NonOSE_AE
, O
increased B-NonOSE_AE
appetite I-NonOSE_AE
, O
myoclonus B-NonOSE_AE
, O
pharyngitis B-NonOSE_AE
, O
postural B-NonOSE_AE
hypotension I-NonOSE_AE
, O
respiratory B-NonOSE_AE
disorder I-NonOSE_AE
( O
includes O
mostly O
`` O
cold B-NonOSE_AE
symptoms I-NonOSE_AE
`` O
or O
`` O
URI B-NonOSE_AE
`` O
) O
, O
trauma B-NonOSE_AE
, O
and O
vomiting B-NonOSE_AE
. O

b O
. O

Includes O
mostly O
`` O
lump B-OSE_Labeled_AE
in I-OSE_Labeled_AE
throat I-OSE_Labeled_AE
`` O
and O
`` O
tightness B-OSE_Labeled_AE
in I-OSE_Labeled_AE
throat I-OSE_Labeled_AE
. O
'' O

c O
. O
Percentage O
corrected O
for O
gender O
. O

d O
. O
Mostly O
`` O
ejaculatory B-OSE_Labeled_AE
delay I-OSE_Labeled_AE
. O
'' O

e O
. O
Includes O
`` O
anorgasmia B-OSE_Labeled_AE
, O
'' O
`` O
erectile B-OSE_Labeled_AE
difficulties I-OSE_Labeled_AE
, O
'' O
`` O
delayed B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
/orgasm O
, O
'' O
and O
`` O
sexual B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
, O
'' O
and O
`` O
impotence B-OSE_Labeled_AE
. O
'' O

f O
. O
Includes O
mostly O
`` O
difficulty B-OSE_Labeled_AE
with I-OSE_Labeled_AE
micturition I-OSE_Labeled_AE
`` O
and O
`` O
urinary B-OSE_Labeled_AE
hesitancy I-OSE_Labeled_AE
. O
'' O

g O
. O
Includes O
mostly O
`` O
anorgasmia B-OSE_Labeled_AE
`` O
and O
`` O
difficulty B-OSE_Labeled_AE
reaching I-OSE_Labeled_AE
climax I-OSE_Labeled_AE
/orgasm O
. O
'' O

Obsessive O
Compulsive O
Disorder O
, O
Panic O
Disorder O
, O
and O
Social O
Anxiety O
Disorder O
: O
Table O
3 O
enumerates O
adverse O
events O
that O
occurred O
at O
a O
frequency O
of O
2 O
% O
or O
more O
among O
OCD B-Not_AE_Candidate
patients O
on O
PAXIL O
who O
participated O
in O
placebo-controlled O
trials O
of O
12-weeks O
duration O
in O
which O
patients O
were O
dosed O
in O
a O
range O
of O
20 O
mg O
to O
60 O
mg/day O
or O
among O
patients O
with O
panic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
on O
PAXIL O
who O
participated O
in O
placebo-controlled O
trials O
of O
10- O
to O
12-weeks O
duration O
in O
which O
patients O
were O
dosed O
in O
a O
range O
of O
10 O
mg O
to O
60 O
mg/day O
or O
among O
patients O
with O
social B-Not_AE_Candidate
anxiety I-Not_AE_Candidate
disorder I-Not_AE_Candidate
on O
PAXIL O
who O
participated O
in O
placebo-controlled O
trials O
of O
12-weeks O
duration O
in O
which O
patients O
were O
dosed O
in O
a O
range O
of O
20 O
mg O
to O
50 O
mg/day O
. O

Table O
3 O
. O

Treatment-Emergent O
Adverse O
Experience O
Incidence O
in O
Placebo-Controlled O
Clinical O
Trials O
for O
Obsessive O
Compulsive O
Disorder O
, O
Panic O
Disorder O
, O
and O
Social O
Anxiety O
Disordera O
Body O
System O
Preferred O
Term O
Obsessive O
Compulsive O
Disorder O
Panic O
Disorder O
Social O
Anxiety O
Disorder O
PAXIL O
( O
n O
= O
542 O
) O
Placebo O
( O
n O
= O
265 O
) O
PAXIL O
( O
n O
= O
469 O
) O
Placebo O
( O
n O
= O
324 O
) O
PAXIL O
( O
n O
= O
425 O
) O
Placebo O
( O
n O
= O
339 O
) O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
Asthenia B-OSE_Labeled_AE
22 O
% O
14 O
% O
14 O
% O
5 O
% O
22 O
% O
14 O
% O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
- O
- O
4 O
% O
3 O
% O
- O
- O
Chest B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
3 O
% O
2 O
% O
- O
- O
- O
- O
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
- O
- O
3 O
% O
2 O
% O
- O
- O
Chills B-OSE_Labeled_AE
2 O
% O
1 O
% O
2 O
% O
1 O
% O
- O
- O
Trauma B-OSE_Labeled_AE
- O
- O
- O
- O
3 O
% O
1 O
% O
Cardiovascular B-NonOSE_AE
Vasodilation B-OSE_Labeled_AE
4 O
% O
1 O
% O
- O
- O
- O
- O
Palpitation B-OSE_Labeled_AE
2 O
% O
0 O
% O
- O
- O
- O
- O
Dermatologic B-NonOSE_AE
Sweating B-OSE_Labeled_AE
9 O
% O
3 O
% O
14 O
% O
6 O
% O
9 O
% O
2 O
% O
Rash B-OSE_Labeled_AE
3 O
% O
2 O
% O
- O
- O
- O
- O
Gastrointestinal B-NonOSE_AE
Nausea B-OSE_Labeled_AE
23 O
% O
10 O
% O
23 O
% O
17 O
% O
25 O
% O
7 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
18 O
% O
9 O
% O
18 O
% O
11 O
% O
9 O
% O
3 O
% O
Constipation B-OSE_Labeled_AE
16 O
% O
6 O
% O
8 O
% O
5 O
% O
5 O
% O
2 O
% O
Diarrhea B-OSE_Labeled_AE
10 O
% O
10 O
% O
12 O
% O
7 O
% O
9 O
% O
6 O
% O
Decreased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
9 O
% O
3 O
% O
7 O
% O
3 O
% O
8 O
% O
2 O
% O
Dyspepsia B-OSE_Labeled_AE
- O
- O
- O
- O
4 O
% O
2 O
% O
Flatulence B-OSE_Labeled_AE
- O
- O
- O
- O
4 O
% O
2 O
% O
Increased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
4 O
% O
3 O
% O
2 O
% O
1 O
% O
- O
- O
Vomiting B-OSE_Labeled_AE
- O
- O
- O
- O
2 O
% O
1 O
% O
Musculoskeletal B-NonOSE_AE
Myalgia B-OSE_Labeled_AE
- O
- O
- O
- O
4 O
% O
3 O
% O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
24 O
% O
13 O
% O
18 O
% O
10 O
% O
21 O
% O
16 O
% O
Somnolence B-OSE_Labeled_AE
24 O
% O
7 O
% O
19 O
% O
11 O
% O
22 O
% O
5 O
% O
Dizziness B-OSE_Labeled_AE
12 O
% O
6 O
% O
14 O
% O
10 O
% O
11 O
% O
7 O
% O
Tremor B-OSE_Labeled_AE
11 O
% O
1 O
% O
9 O
% O
1 O
% O
9 O
% O
1 O
% O
Nervousness B-OSE_Labeled_AE
9 O
% O
8 O
% O
- O
- O
8 O
% O
7 O
% O
Libido B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
7 O
% O
4 O
% O
9 O
% O
1 O
% O
12 O
% O
1 O
% O
Agitation B-OSE_Labeled_AE
- O
- O
5 O
% O
4 O
% O
3 O
% O
1 O
% O
Anxiety B-OSE_Labeled_AE
- O
- O
5 O
% O
4 O
% O
5 O
% O
4 O
% O
Abnormal B-OSE_Labeled_AE
Dreams I-OSE_Labeled_AE
4 O
% O
1 O
% O
- O
- O
- O
- O
ConcentrationImpaired B-OSE_Labeled_AE
3 O
% O
2 O
% O
- O
- O
4 O
% O
1 O
% O
Depersonalization B-OSE_Labeled_AE
3 O
% O
0 O
% O
- O
- O
- O
- O
Myoclonus B-OSE_Labeled_AE
3 O
% O
0 O
% O
3 O
% O
2 O
% O
2 O
% O
1 O
% O
Amnesia B-OSE_Labeled_AE
2 O
% O
1 O
% O
- O
- O
- O
- O
Respiratory B-NonOSE_AE
System I-NonOSE_AE
Rhinitis B-OSE_Labeled_AE
- O
- O
3 O
% O
0 O
% O
- O
- O
Pharyngitis B-OSE_Labeled_AE
- O
- O
- O
- O
4 O
% O
2 O
% O
Yawn B-OSE_Labeled_AE
- O
- O
- O
- O
5 O
% O
1 O
% O
Special B-NonOSE_AE
Senses I-NonOSE_AE
Abnormal B-OSE_Labeled_AE
Vision I-OSE_Labeled_AE
4 O
% O
2 O
% O
- O
- O
4 O
% O
1 O
% O
Taste B-OSE_Labeled_AE
Perversion I-OSE_Labeled_AE
2 O
% O
0 O
% O
- O
- O
- O
- O
Urogenital B-NonOSE_AE
System I-NonOSE_AE
Abnormal B-OSE_Labeled_AE
Ejaculationb I-OSE_Labeled_AE
23 O
% O
1 O
% O
21 O
% O
1 O
% O
28 O
% O
1 O
% O
Dysmenorrhea B-OSE_Labeled_AE
- O
- O
- O
- O
5 O
% O
4 O
% O
Female B-OSE_Labeled_AE
GenitalDisorderb I-OSE_Labeled_AE
3 O
% O
0 O
% O
9 O
% O
1 O
% O
9 O
% O
1 O
% O
Impotenceb B-OSE_Labeled_AE
8 O
% O
1 O
% O
5 O
% O
0 O
% O
5 O
% O
1 O
% O
Urinary B-OSE_Labeled_AE
Frequency I-OSE_Labeled_AE
3 O
% O
1 O
% O
2 O
% O
0 O
% O
- O
- O
Urination B-OSE_Labeled_AE
Impaired I-OSE_Labeled_AE
3 O
% O
0 O
% O
- O
- O
- O
- O
Urinary B-OSE_Labeled_AE
TractInfection I-OSE_Labeled_AE
2 O
% O
1 O
% O
2 O
% O
1 O
% O
- O
- O
a O
. O

Events O
reported O
by O
at O
least O
2 O
% O
of O
OCD B-Not_AE_Candidate
, O
panic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
and O
social B-Not_AE_Candidate
anxiety I-Not_AE_Candidate
disorder I-Not_AE_Candidate
in O
patients O
treated O
with O
PAXIL O
are O
included O
, O
except O
the O
following O
events O
which O
had O
an O
incidence O
on O
placebo O
> O
= O
PAXIL O
: O
[ O
OCD B-Not_AE_Candidate
] O
: O
Abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
agitation B-NonOSE_AE
, O
anxiety B-NonOSE_AE
, O
back B-NonOSE_AE
pain I-NonOSE_AE
, O
cough B-NonOSE_AE
increased I-NonOSE_AE
, O
depression B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
hyperkinesia B-NonOSE_AE
, O
infection B-NonOSE_AE
, O
paresthesia B-NonOSE_AE
, O
pharyngitis B-NonOSE_AE
, O
respiratory B-NonOSE_AE
disorder I-NonOSE_AE
, O
rhinitis B-NonOSE_AE
, O
and O
sinusitis B-NonOSE_AE
. O

[ O
panic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
] O
: O
Abnormal B-NonOSE_AE
dreams I-NonOSE_AE
, O
abnormal B-NonOSE_AE
vision I-NonOSE_AE
, O
chest B-NonOSE_AE
pain I-NonOSE_AE
, O
cough B-NonOSE_AE
increased I-NonOSE_AE
, O
depersonalization B-NonOSE_AE
, O
depression B-NonOSE_AE
, O
dysmenorrhea B-NonOSE_AE
, O
dyspepsia B-NonOSE_AE
, O
flu B-NonOSE_AE
syndrome I-NonOSE_AE
, O
headache B-NonOSE_AE
, O
infection B-NonOSE_AE
, O
myalgia B-NonOSE_AE
, O
nervousness B-NonOSE_AE
, O
palpitation B-NonOSE_AE
, O
paresthesia B-NonOSE_AE
, O
pharyngitis B-NonOSE_AE
, O
rash B-NonOSE_AE
, O
respiratory B-NonOSE_AE
disorder I-NonOSE_AE
, O
sinusitis B-NonOSE_AE
, O
taste B-NonOSE_AE
perversion I-NonOSE_AE
, O
trauma B-NonOSE_AE
, O
urination B-NonOSE_AE
impaired I-NonOSE_AE
, O
and O
vasodilation B-NonOSE_AE
. O

[ O
social B-Not_AE_Candidate
anxiety I-Not_AE_Candidate
disorder I-Not_AE_Candidate
] O
: O
Abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
depression B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
infection B-NonOSE_AE
, O
respiratory B-NonOSE_AE
disorder I-NonOSE_AE
, O
and O
sinusitis B-NonOSE_AE
. O

b O
. O

Percentage O
corrected O
for O
gender O
. O

Generalized O
Anxiety O
Disorder O
and O
Posttraumatic O
Stress O
Disorder O
: O
Table O
4 O
enumerates O
adverse O
events O
that O
occurred O
at O
a O
frequency O
of O
2 O
% O
or O
more O
among O
GAD B-Not_AE_Candidate
patients O
on O
PAXIL O
who O
participated O
in O
placebo-controlled O
trials O
of O
8-weeks O
duration O
in O
which O
patients O
were O
dosed O
in O
a O
range O
of O
10 O
mg/day O
to O
50 O
mg/day O
or O
among O
PTSD B-Not_AE_Candidate
patients O
on O
PAXIL O
who O
participated O
in O
placebo-controlled O
trials O
of O
12-weeks O
duration O
in O
which O
patients O
were O
dosed O
in O
a O
range O
of O
20 O
mg/day O
to O
50 O
mg/day O
. O

Table O
4 O
. O

Treatment-Emergent O
Adverse O
Experience O
Incidence O
in O
Placebo-Controlled O
Clinical O
Trials O
for O
Generalized O
Anxiety O
Disorder O
and O
Posttraumatic O
Stress O
Disordera O
Body O
System O
Preferred O
Term O
Generalized O
Anxiety O
Disorder O
Posttraumatic O
Stress O
Disorder O
PAXIL O
( O
n O
= O
735 O
) O
Placebo O
( O
n O
= O
529 O
) O
PAXIL O
( O
n O
= O
676 O
) O
Placebo O
( O
n O
= O
504 O
) O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
Asthenia B-OSE_Labeled_AE
14 O
% O
6 O
% O
12 O
% O
4 O
% O
Headache B-OSE_Labeled_AE
17 O
% O
14 O
% O
- O
- O
Infection B-OSE_Labeled_AE
6 O
% O
3 O
% O
5 O
% O
4 O
% O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
4 O
% O
3 O
% O
Trauma B-OSE_Labeled_AE
6 O
% O
5 O
% O
Cardiovascular B-NonOSE_AE
Vasodilation B-OSE_Labeled_AE
3 O
% O
1 O
% O
2 O
% O
1 O
% O
Dermatologic B-NonOSE_AE
Sweating B-OSE_Labeled_AE
6 O
% O
2 O
% O
5 O
% O
1 O
% O
Gastrointestinal B-NonOSE_AE
Nausea B-OSE_Labeled_AE
20 O
% O
5 O
% O
19 O
% O
8 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
11 O
% O
5 O
% O
10 O
% O
5 O
% O
Constipation B-OSE_Labeled_AE
10 O
% O
2 O
% O
5 O
% O
3 O
% O
Diarrhea B-OSE_Labeled_AE
9 O
% O
7 O
% O
11 O
% O
5 O
% O
Decreased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
5 O
% O
1 O
% O
6 O
% O
3 O
% O
Vomiting B-OSE_Labeled_AE
3 O
% O
2 O
% O
3 O
% O
2 O
% O
Dyspepsia B-OSE_Labeled_AE
- O
- O
5 O
% O
3 O
% O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
11 O
% O
8 O
% O
12 O
% O
11 O
% O
Somnolence B-OSE_Labeled_AE
15 O
% O
5 O
% O
16 O
% O
5 O
% O
Dizziness B-OSE_Labeled_AE
6 O
% O
5 O
% O
6 O
% O
5 O
% O
Tremor B-OSE_Labeled_AE
5 O
% O
1 O
% O
4 O
% O
1 O
% O
Nervousness B-OSE_Labeled_AE
4 O
% O
3 O
% O
- O
- O
Libido B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
9 O
% O
2 O
% O
5 O
% O
2 O
% O
Abnormal B-OSE_Labeled_AE
Dreams I-OSE_Labeled_AE
3 O
% O
2 O
% O
Respiratory B-NonOSE_AE
System I-NonOSE_AE
Respiratory B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
7 O
% O
5 O
% O
- O
- O
Sinusitis B-OSE_Labeled_AE
4 O
% O
3 O
% O
- O
- O
Yawn B-OSE_Labeled_AE
4 O
% O
- O
2 O
% O
< O
1 O
% O
Special B-NonOSE_AE
Senses I-NonOSE_AE
Abnormal B-OSE_Labeled_AE
Vision I-OSE_Labeled_AE
2 O
% O
1 O
% O
3 O
% O
1 O
% O
Urogenital B-NonOSE_AE
System I-NonOSE_AE
Abnormal B-OSE_Labeled_AE
Ejaculationb I-OSE_Labeled_AE
25 O
% O
2 O
% O
13 O
% O
2 O
% O
Female B-OSE_Labeled_AE
Genital I-OSE_Labeled_AE
Disorderb I-OSE_Labeled_AE
4 O
% O
1 O
% O
5 O
% O
1 O
% O
Impotenceb B-OSE_Labeled_AE
4 O
% O
3 O
% O
9 O
% O
1 O
% O
a O
. O

Events O
reported O
by O
at O
least O
2 O
% O
of O
GAD B-Not_AE_Candidate
and O
PTSD B-Not_AE_Candidate
in O
patients O
treated O
with O
PAXIL O
are O
included O
, O
except O
the O
following O
events O
which O
had O
an O
incidence O
on O
placebo O
> O
= O
PAXIL O
[ O
GAD B-Not_AE_Candidate
] O
: O
Abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
back B-NonOSE_AE
pain I-NonOSE_AE
, O
trauma B-NonOSE_AE
, O
dyspepsia B-NonOSE_AE
, O
myalgia B-NonOSE_AE
, O
and O
pharyngitis B-NonOSE_AE
. O

[ O
PTSD B-Not_AE_Candidate
] O
: O
Back B-NonOSE_AE
pain I-NonOSE_AE
, O
headache B-NonOSE_AE
, O
anxiety B-NonOSE_AE
, O
depression B-NonOSE_AE
, O
nervousness B-NonOSE_AE
, O
respiratory B-NonOSE_AE
disorder I-NonOSE_AE
, O
pharyngitis B-NonOSE_AE
, O
and O
sinusitis B-NonOSE_AE
. O

b O
. O

Percentage O
corrected O
for O
gender O
. O

Dose O
Dependency O
of O
Adverse O
Events O
: O
A O
comparison O
of O
adverse O
event O
rates O
in O
a O
fixed-dose O
study O
comparing O
10 O
, O
20 O
, O
30 O
, O
and O
40 O
mg/day O
of O
PAXIL O
with O
placebo O
in O
the O
treatment O
of O
major O
depressive O
disorder O
revealed O
a O
clear O
dose O
dependency O
for O
some O
of O
the O
more O
common O
adverse O
events O
associated O
with O
use O
of O
PAXIL O
, O
as O
shown O
in O
Table O
5 O
: O
Table O
5 O
. O

Treatment-Emergent O
Adverse O
Experience O
Incidence O
in O
a O
Dose-Comparison O
Trial O
in O
the O
Treatment O
of O
Major O
Depressive O
Disordera O
Body O
System/Preferred O
Term O
Placebo O
PAXIL O
n O
= O
51 O
10 O
mg O
n O
= O
102 O
20 O
mg O
n O
= O
104 O
30 O
mg O
n O
= O
101 O
40 O
mg O
n O
= O
102 O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
Asthenia B-OSE_Labeled_AE
0.0 O
% O
2.9 O
% O
10.6 O
% O
13.9 O
% O
12.7 O
% O
Dermatology B-NonOSE_AE
Sweating B-OSE_Labeled_AE
2.0 O
% O
1.0 O
% O
6.7 O
% O
8.9 O
% O
11.8 O
% O
Gastrointestinal B-NonOSE_AE
Constipation B-OSE_Labeled_AE
5.9 O
% O
4.9 O
% O
7.7 O
% O
9.9 O
% O
12.7 O
% O
Decreased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
2.0 O
% O
2.0 O
% O
5.8 O
% O
4.0 O
% O
4.9 O
% O
Diarrhea B-OSE_Labeled_AE
7.8 O
% O
9.8 O
% O
19.2 O
% O
7.9 O
% O
14.7 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
2.0 O
% O
10.8 O
% O
18.3 O
% O
15.8 O
% O
20.6 O
% O
Nausea B-OSE_Labeled_AE
13.7 O
% O
14.7 O
% O
26.9 O
% O
34.7 O
% O
36.3 O
% O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Anxiety B-OSE_Labeled_AE
0.0 O
% O
2.0 O
% O
5.8 O
% O
5.9 O
% O
5.9 O
% O
Dizziness B-OSE_Labeled_AE
3.9 O
% O
6.9 O
% O
6.7 O
% O
8.9 O
% O
12.7 O
% O
Nervousness B-OSE_Labeled_AE
0.0 O
% O
5.9 O
% O
5.8 O
% O
4.0 O
% O
2.9 O
% O
Paresthesia B-OSE_Labeled_AE
0.0 O
% O
2.9 O
% O
1.0 O
% O
5.0 O
% O
5.9 O
% O
Somnolence B-OSE_Labeled_AE
7.8 O
% O
12.7 O
% O
18.3 O
% O
20.8 O
% O
21.6 O
% O
Tremor B-OSE_Labeled_AE
0.0 O
% O
0.0 O
% O
7.7 O
% O
7.9 O
% O
14.7 O
% O
Special B-NonOSE_AE
Senses I-NonOSE_AE
Blurred B-OSE_Labeled_AE
Vision I-OSE_Labeled_AE
2.0 O
% O
2.9 O
% O
2.9 O
% O
2.0 O
% O
7.8 O
% O
Urogenital B-NonOSE_AE
System I-NonOSE_AE
Abnormal B-OSE_Labeled_AE
Ejaculation I-OSE_Labeled_AE
0.0 O
% O
5.8 O
% O
6.5 O
% O
10.6 O
% O
13.0 O
% O
Impotence B-OSE_Labeled_AE
0.0 O
% O
1.9 O
% O
4.3 O
% O
6.4 O
% O
1.9 O
% O
Male B-OSE_Labeled_AE
Genital I-OSE_Labeled_AE
Disorders I-OSE_Labeled_AE
0.0 O
% O
3.8 O
% O
8.7 O
% O
6.4 O
% O
3.7 O
% O
a O
. O

Rule O
for O
including O
adverse O
events O
in O
table O
: O
Incidence O
at O
least O
5 O
% O
for O
1 O
of O
paroxetine O
groups O
and O
> O
= O
twice O
the O
placebo O
incidence O
for O
at O
least O
1 O
paroxetine O
group O
. O

In O
a O
fixed-dose O
study O
comparing O
placebo O
and O
20 O
, O
40 O
, O
and O
60 O
mg O
of O
PAXIL O
in O
the O
treatment O
of O
OCD B-Not_AE_Candidate
, O
there O
was O
no O
clear O
relationship O
between O
adverse O
events O
and O
the O
dose O
of O
PAXIL O
to O
which O
patients O
were O
assigned O
. O

No O
new O
adverse O
events O
were O
observed O
in O
the O
group O
treated O
with O
60 O
mg O
of O
PAXIL O
compared O
to O
any O
of O
the O
other O
treatment O
groups O
. O

In O
a O
fixed-dose O
study O
comparing O
placebo O
and O
10 O
, O
20 O
, O
and O
40 O
mg O
of O
PAXIL O
in O
the O
treatment O
of O
panic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
there O
was O
no O
clear O
relationship O
between O
adverse O
events O
and O
the O
dose O
of O
PAXIL O
to O
which O
patients O
were O
assigned O
, O
except O
for O
asthenia B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
and O
abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
. O

In O
flexible-dose O
studies O
, O
no O
new O
adverse O
events O
were O
observed O
in O
patients O
receiving O
60 O
mg O
of O
PAXIL O
compared O
to O
any O
of O
the O
other O
treatment O
groups O
. O

In O
a O
fixed-dose O
study O
comparing O
placebo O
and O
20 O
, O
40 O
, O
and O
60 O
mg O
of O
PAXIL O
in O
the O
treatment O
of O
social O
anxiety B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
for O
most O
of O
the O
adverse O
events O
, O
there O
was O
no O
clear O
relationship O
between O
adverse O
events O
and O
the O
dose O
of O
PAXIL O
to O
which O
patients O
were O
assigned O
. O

In O
a O
fixed-dose O
study O
comparing O
placebo O
and O
20 O
and O
40 O
mg O
of O
PAXIL O
in O
the O
treatment O
of O
generalized O
anxiety B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
for O
most O
of O
the O
adverse O
events O
, O
there O
was O
no O
clear O
relationship O
between O
adverse O
events O
and O
the O
dose O
of O
PAXIL O
to O
which O
patients O
were O
assigned O
, O
except O
for O
the O
following O
adverse O
events O
: O
Asthenia B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
and O
abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
. O

In O
a O
fixed-dose O
study O
comparing O
placebo O
and O
20 O
and O
40 O
mg O
of O
PAXIL O
in O
the O
treatment O
of O
posttraumatic B-Not_AE_Candidate
stress I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
for O
most O
of O
the O
adverse O
events O
, O
there O
was O
no O
clear O
relationship O
between O
adverse O
events O
and O
the O
dose O
of O
PAXIL O
to O
which O
patients O
were O
assigned O
, O
except O
for O
impotence B-OSE_Labeled_AE
and O
abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
. O

Adaptation O
to O
Certain O
Adverse O
Events O
: O
Over O
a O
4- O
to O
6-week O
period O
, O
there O
was O
evidence O
of O
adaptation O
to O
some O
adverse O
events O
with O
continued O
therapy O
( O
e.g. O
, O
nausea B-OSE_Labeled_AE
and O
dizziness B-OSE_Labeled_AE
) O
, O
but O
less O
to O
other O
effects O
( O
e.g. O
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
and O
asthenia B-OSE_Labeled_AE
) O
. O

Male O
and O
Female O
Sexual O
Dysfunction O
With O
SSRIs O
: O
Although O
changes B-NonOSE_AE
in I-NonOSE_AE
sexual I-NonOSE_AE
desire I-NonOSE_AE
, O
sexual O
performance O
, O
and O
sexual O
satisfaction O
often O
occur O
as O
manifestations O
of O
a O
psychiatric B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
they O
may O
also O
be O
a O
consequence O
of O
pharmacologic O
treatment O
. O

In O
particular O
, O
some O
evidence O
suggests O
that O
selective O
serotonin O
reuptake O
inhibitors O
( O
SSRIs O
) O
can O
cause O
such O
untoward B-OSE_Labeled_AE
sexual I-OSE_Labeled_AE
experiences I-OSE_Labeled_AE
. O

Reliable O
estimates O
of O
the O
incidence O
and O
severity O
of O
untoward B-NonOSE_AE
experiences I-NonOSE_AE
involving I-NonOSE_AE
sexual I-NonOSE_AE
desire I-NonOSE_AE
, O
performance O
, O
and O
satisfaction O
are O
difficult O
to O
obtain O
, O
however O
, O
in O
part O
because O
patients O
and O
physicians O
may O
be O
reluctant O
to O
discuss O
them O
. O

Accordingly O
, O
estimates O
of O
the O
incidence O
of O
untoward B-NonOSE_AE
sexual I-NonOSE_AE
experience I-NonOSE_AE
and O
performance O
cited O
in O
product O
labeling O
, O
are O
likely O
to O
underestimate O
their O
actual O
incidence O
. O

In O
placebo-controlled O
clinical O
trials O
involving O
more O
than O
3,200 O
patients O
, O
the O
ranges O
for O
the O
reported O
incidence O
of O
sexual B-NonOSE_AE
side I-NonOSE_AE
effects I-NonOSE_AE
in O
males O
and O
females O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
OCD B-Not_AE_Candidate
, O
panic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
social B-Not_AE_Candidate
anxiety I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
GAD B-Not_AE_Candidate
, O
and O
PTSD B-Not_AE_Candidate
are O
displayed O
in O
Table O
6 O
. O

Table O
6 O
. O

Incidence O
of O
Sexual O
Adverse O
Events O
in O
Controlled O
Clinical O
Trials O
PAXIL O
Placebo O
n O
( O
males O
) O
1446 O
1042 O
Decreased B-OSE_Labeled_AE
Libido I-OSE_Labeled_AE
6-15 O
% O
0-5 O
% O
Ejaculatory B-OSE_Labeled_AE
Disturbance I-OSE_Labeled_AE
13-28 O
% O
0-2 O
% O
Impotence B-OSE_Labeled_AE
2-9 O
% O
0-3 O
% O
n O
( O
females O
) O
1822 O
1340 O
Decreased B-OSE_Labeled_AE
Libido I-OSE_Labeled_AE
0-9 O
% O
0-2 O
% O
Orgasmic B-OSE_Labeled_AE
Disturbance I-OSE_Labeled_AE
2-9 O
% O
0-1 O
% O
There O
are O
no O
adequate O
and O
well-controlled O
studies O
examining O
sexual B-NonOSE_AE
dysfunction I-NonOSE_AE
with O
paroxetine O
treatment O
. O

Paroxetine O
treatment O
has O
been O
associated O
with O
several O
cases O
of O
priapism B-OSE_Labeled_AE
. O

In O
those O
cases O
with O
a O
known O
outcome O
, O
patients O
recovered O
without O
sequelae O
. O

While O
it O
is O
difficult O
to O
know O
the O
precise O
risk O
of O
sexual B-NonOSE_AE
dysfunction I-NonOSE_AE
associated O
with O
the O
use O
of O
SSRIs O
, O
physicians O
should O
routinely O
inquire O
about O
such O
possible O
side O
effects O
. O

Weight O
and O
Vital O
Sign O
Changes O
: O
Significant O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
may O
be O
an O
undesirable O
result O
of O
treatment O
with O
PAXIL O
for O
some O
patients O
but O
, O
on O
average O
, O
patients O
in O
controlled O
trials O
had O
minimal O
( O
about O
1 O
pound O
) O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
versus O
smaller O
changes O
on O
placebo O
and O
active O
control O
. O

No O
significant O
changes B-NonOSE_AE
in I-NonOSE_AE
vital I-NonOSE_AE
signs I-NonOSE_AE
( O
systolic O
and O
diastolic O
blood O
pressure O
, O
pulse O
and O
temperature O
) O
were O
observed O
in O
patients O
treated O
with O
PAXIL O
in O
controlled O
clinical O
trials O
. O

ECG O
Changes O
: O
In O
an O
analysis O
of O
ECGs O
obtained O
in O
682 O
patients O
treated O
with O
PAXIL O
and O
415 O
patients O
treated O
with O
placebo O
in O
controlled O
clinical O
trials O
, O
no O
clinically O
significant O
changes B-NonOSE_AE
were I-NonOSE_AE
seen I-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
ECGs I-NonOSE_AE
of O
either O
group O
. O

Liver O
Function O
Tests O
: O
In O
placebo-controlled O
clinical O
trials O
, O
patients O
treated O
with O
PAXIL O
exhibited O
abnormal B-NonOSE_AE
values I-NonOSE_AE
on I-NonOSE_AE
liver I-NonOSE_AE
function I-NonOSE_AE
tests I-NonOSE_AE
at O
no O
greater O
rate O
than O
that O
seen O
in O
placebo-treated O
patients O
. O

In O
particular O
, O
the O
PAXIL-versus-placebo O
comparisons O
for O
alkaline B-NonOSE_AE
phosphatase I-NonOSE_AE
, O
SGOT O
, O
SGPT O
, O
and O
bilirubin O
revealed O
no O
differences O
in O
the O
percentage O
of O
patients O
with O
marked O
abnormalities I-NonOSE_AE
. O

Hallucinations O
: O
In O
pooled O
clinical O
trials O
of O
immediate-release O
paroxetine O
hydrochloride O
, O
hallucinations B-OSE_Labeled_AE
were O
observed O
in O
22 O
of O
9089 O
patients O
receiving O
drug O
and O
4 O
of O
3187 O
patients O
receiving O
placebo O
. O

Other O
Events O
Observed O
During O
the O
Premarketing O
Evaluation O
of O
PAXIL O
: O
During O
its O
premarketing O
assessment O
in O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
multiple O
doses O
of O
PAXIL O
were O
administered O
to O
6,145 O
patients O
in O
phase O
2 O
and O
3 O
studies O
. O

The O
conditions O
and O
duration O
of O
exposure O
to O
PAXIL O
varied O
greatly O
and O
included O
( O
in O
overlapping O
categories O
) O
open O
and O
double-blind O
studies O
, O
uncontrolled O
and O
controlled O
studies O
, O
inpatient O
and O
outpatient O
studies O
, O
and O
fixed-dose O
, O
and O
titration O
studies O
. O

During O
premarketing O
clinical O
trials O
in O
OCD B-Not_AE_Candidate
, O
panic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
social B-Not_AE_Candidate
anxiety I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
generalized B-Not_AE_Candidate
anxiety I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
and O
posttraumatic B-Not_AE_Candidate
stress I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
542 O
, O
469 O
, O
522 O
, O
735 O
, O
and O
676 O
patients O
, O
respectively O
, O
received O
multiple O
doses O
of O
PAXIL O
. O

Untoward O
events O
associated O
with O
this O
exposure O
were O
recorded O
by O
clinical O
investigators O
using O
terminology O
of O
their O
own O
choosing O
. O

Consequently O
, O
it O
is O
not O
possible O
to O
provide O
a O
meaningful O
estimate O
of O
the O
proportion O
of O
individuals O
experiencing O
adverse O
events O
without O
first O
grouping O
similar O
types O
of O
untoward O
events O
into O
a O
smaller O
number O
of O
standardized O
event O
categories O
. O

In O
the O
tabulations O
that O
follow O
, O
reported O
adverse O
events O
were O
classified O
using O
a O
standard O
COSTART-based O
Dictionary O
terminology O
. O

The O
frequencies O
presented O
, O
therefore O
, O
represent O
the O
proportion O
of O
the O
9,089 O
patients O
exposed O
to O
multiple O
doses O
of O
PAXIL O
who O
experienced O
an O
event O
of O
the O
type O
cited O
on O
at O
least O
1 O
occasion O
while O
receiving O
PAXIL O
. O

All O
reported O
events O
are O
included O
except O
those O
already O
listed O
in O
Tables O
2 O
to O
5 O
, O
those O
reported O
in O
terms O
so O
general O
as O
to O
be O
uninformative O
and O
those O
events O
where O
a O
drug O
cause O
was O
remote O
. O

It O
is O
important O
to O
emphasize O
that O
although O
the O
events O
reported O
occurred O
during O
treatment O
with O
paroxetine O
, O
they O
were O
not O
necessarily O
caused O
by O
it O
. O

Events O
are O
further O
categorized O
by O
body O
system O
and O
listed O
in O
order O
of O
decreasing O
frequency O
according O
to O
the O
following O
definitions O
: O
Frequent O
adverse O
events O
are O
those O
occurring O
on O
1 O
or O
more O
occasions O
in O
at O
least O
1/100 O
patients O
( O
only O
those O
not O
already O
listed O
in O
the O
tabulated O
results O
from O
placebo-controlled O
trials O
appear O
in O
this O
listing O
) O
; O
infrequent O
adverse O
events O
are O
those O
occurring O
in O
1/100 O
to O
1/1,000 O
patients O
; O
rare O
events O
are O
those O
occurring O
in O
fewer O
than O
1/1,000 O
patients O
. O

Events O
of O
major O
clinical O
importance O
are O
also O
described O
in O
the O
PRECAUTIONS O
section O
. O

Body O
as O
a O
Whole O
: O
Infrequent O
: O
Allergic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
face B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
malaise B-OSE_Labeled_AE
, O
neck B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
; O
rare O
: O
Adrenergic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
moniliasis B-OSE_Labeled_AE
, O
neck B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
pelvic B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
peritonitis B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
ulcer B-OSE_Labeled_AE
. O

Cardiovascular O
System O
: O
Frequent O
: O
Hypertension B-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
; O
infrequent O
: O
Bradycardia B-OSE_Labeled_AE
, O
hematoma B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
migraine B-OSE_Labeled_AE
, O
postural B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
; O
rare O
: O
Angina B-OSE_Labeled_AE
pectoris I-OSE_Labeled_AE
, O
arrhythmia B-OSE_Labeled_AE
nodal I-OSE_Labeled_AE
, O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
bundle B-OSE_Labeled_AE
branch I-OSE_Labeled_AE
block I-OSE_Labeled_AE
, O
cerebral B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
heart B-OSE_Labeled_AE
block I-OSE_Labeled_AE
, O
low B-OSE_Labeled_AE
cardiac I-OSE_Labeled_AE
output I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarct I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
, O
pallor B-OSE_Labeled_AE
, O
phlebitis B-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolus I-OSE_Labeled_AE
, O
supraventricular B-OSE_Labeled_AE
extrasystoles I-OSE_Labeled_AE
, O
thrombophlebitis B-OSE_Labeled_AE
, O
thrombosis B-OSE_Labeled_AE
, O
varicose B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
, O
vascular B-OSE_Labeled_AE
headache I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
extrasystoles I-OSE_Labeled_AE
. O

Digestive O
System O
: O
Infrequent O
: O
Bruxism B-OSE_Labeled_AE
, O
colitis B-OSE_Labeled_AE
, O
dysphagia B-OSE_Labeled_AE
, O
eructation B-OSE_Labeled_AE
, O
gastritis B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
gingivitis B-OSE_Labeled_AE
, O
glossitis B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
salivation I-OSE_Labeled_AE
, O
liver B-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
rectal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
ulcerative B-OSE_Labeled_AE
stomatitis I-OSE_Labeled_AE
; O
rare O
: O
Aphthous B-OSE_Labeled_AE
stomatitis I-OSE_Labeled_AE
, O
bloody B-OSE_Labeled_AE
diarrhea I-OSE_Labeled_AE
, O
bulimia B-OSE_Labeled_AE
, O
cardiospasm B-OSE_Labeled_AE
, O
cholelithiasis B-OSE_Labeled_AE
, O
duodenitis B-OSE_Labeled_AE
, O
enteritis B-OSE_Labeled_AE
, O
esophagitis B-OSE_Labeled_AE
, O
fecal B-OSE_Labeled_AE
impactions I-OSE_Labeled_AE
, O
fecal B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
gum B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
hematemesis B-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
, O
ileitis B-OSE_Labeled_AE
, O
ileus B-OSE_Labeled_AE
, O
intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
, O
jaundice B-OSE_Labeled_AE
, O
melena B-OSE_Labeled_AE
, O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
peptic B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
, O
salivary B-OSE_Labeled_AE
gland I-OSE_Labeled_AE
enlargement I-OSE_Labeled_AE
, O
sialadenitis B-OSE_Labeled_AE
, O
stomach B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
tooth B-OSE_Labeled_AE
caries I-OSE_Labeled_AE
. O

Endocrine O
System O
: O
Rare O
: O
Diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
, O
goiter B-OSE_Labeled_AE
, O
hyperthyroidism B-OSE_Labeled_AE
, O
hypothyroidism B-OSE_Labeled_AE
, O
thyroiditis B-OSE_Labeled_AE
. O

Hemic O
and O
Lymphatic O
Systems O
: O
Infrequent O
: O
Anemia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
lymphadenopathy B-OSE_Labeled_AE
, O
purpura B-OSE_Labeled_AE
; O
rare O
: O
Abnormal B-OSE_Labeled_AE
erythrocytes I-OSE_Labeled_AE
, O
basophilia B-OSE_Labeled_AE
, O
bleeding B-OSE_Labeled_AE
time I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
eosinophilia B-OSE_Labeled_AE
, O
hypochromic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
iron B-OSE_Labeled_AE
deficiency I-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
leukocytosis B-OSE_Labeled_AE
, O
lymphedema B-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
lymphocytes I-OSE_Labeled_AE
, O
lymphocytosis B-OSE_Labeled_AE
, O
microcytic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
monocytosis B-OSE_Labeled_AE
, O
normocytic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
thrombocythemia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
. O

Metabolic O
and O
Nutritional O
: O
Frequent O
: O
Weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
; O
infrequent O
: O
Edema B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
SGOT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
SGPT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
thirst B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
; O
rare O
: O
Alkaline B-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
bilirubinemia B-OSE_Labeled_AE
, O
BUN B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
creatinine B-OSE_Labeled_AE
phosphokinase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
, O
gamma B-OSE_Labeled_AE
globulins I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
gout B-OSE_Labeled_AE
, O
hypercalcemia B-OSE_Labeled_AE
, O
hypercholesteremia B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
hyperkalemia B-OSE_Labeled_AE
, O
hyperphosphatemia B-OSE_Labeled_AE
, O
hypocalcemia B-OSE_Labeled_AE
, O
hypoglycemia B-OSE_Labeled_AE
, O
hypokalemia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
, O
ketosis B-OSE_Labeled_AE
, O
lactic B-OSE_Labeled_AE
dehydrogenase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
protein I-OSE_Labeled_AE
nitrogen I-OSE_Labeled_AE
( I-OSE_Labeled_AE
NPN I-OSE_Labeled_AE
) I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
. O

Musculoskeletal O
System O
: O
Frequent O
: O
Arthralgia B-OSE_Labeled_AE
; O
infrequent O
: O
Arthritis B-OSE_Labeled_AE
, O
arthrosis B-OSE_Labeled_AE
; O
rare O
: O
Bursitis B-OSE_Labeled_AE
, O
myositis B-OSE_Labeled_AE
, O
osteoporosis B-OSE_Labeled_AE
, O
generalized B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
, O
tenosynovitis B-OSE_Labeled_AE
, O
tetany B-OSE_Labeled_AE
. O

Nervous O
System O
: O
Frequent O
: O
Emotional B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
, O
vertigo B-OSE_Labeled_AE
; O
infrequent O
: O
Abnormal B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
, O
alcohol B-OSE_Labeled_AE
abuse I-OSE_Labeled_AE
, O
ataxia B-OSE_Labeled_AE
, O
dystonia B-OSE_Labeled_AE
, O
dyskinesia B-OSE_Labeled_AE
, O
euphoria B-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
, O
hostility B-OSE_Labeled_AE
, O
hypertonia B-OSE_Labeled_AE
, O
hypesthesia B-OSE_Labeled_AE
, O
hypokinesia B-OSE_Labeled_AE
, O
incoordination B-OSE_Labeled_AE
, O
lack B-OSE_Labeled_AE
of I-OSE_Labeled_AE
emotion I-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
manic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
neurosis B-OSE_Labeled_AE
, O
paralysis B-OSE_Labeled_AE
, O
paranoid B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
; O
rare O
: O
Abnormal B-OSE_Labeled_AE
gait I-OSE_Labeled_AE
, O
akinesia B-OSE_Labeled_AE
, O
antisocial B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
aphasia B-OSE_Labeled_AE
, O
choreoathetosis B-OSE_Labeled_AE
, O
circumoral B-OSE_Labeled_AE
paresthesias I-OSE_Labeled_AE
, O
convulsion B-OSE_Labeled_AE
, O
delirium B-OSE_Labeled_AE
, O
delusions B-OSE_Labeled_AE
, O
diplopia B-OSE_Labeled_AE
, O
drug B-OSE_Labeled_AE
dependence I-OSE_Labeled_AE
, O
dysarthria B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
fasciculations B-OSE_Labeled_AE
, O
grand B-OSE_Labeled_AE
mal I-OSE_Labeled_AE
convulsion I-OSE_Labeled_AE
, O
hyperalgesia B-OSE_Labeled_AE
, O
hysteria B-OSE_Labeled_AE
, O
manic B-OSE_Labeled_AE
- I-OSE_Labeled_AE
depressive I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
meningitis B-OSE_Labeled_AE
, O
myelitis B-OSE_Labeled_AE
, O
neuralgia B-OSE_Labeled_AE
, O
neuropathy B-OSE_Labeled_AE
, O
nystagmus B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
neuritis I-OSE_Labeled_AE
, O
psychotic B-OSE_Labeled_AE
depression I-OSE_Labeled_AE
, O
psychosis B-OSE_Labeled_AE
, O
reflexes B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
reflexes B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
stupor B-OSE_Labeled_AE
, O
torticollis B-OSE_Labeled_AE
, O
trismus B-OSE_Labeled_AE
, O
withdrawal B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
. O

Respiratory O
System O
: O
Infrequent O
: O
Asthma B-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
hyperventilation B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
flu I-OSE_Labeled_AE
; O
rare O
: O
Emphysema B-OSE_Labeled_AE
, O
hemoptysis B-OSE_Labeled_AE
, O
hiccups B-OSE_Labeled_AE
, O
lung B-OSE_Labeled_AE
fibrosis I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
sputum B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
stridor B-OSE_Labeled_AE
, O
voice B-OSE_Labeled_AE
alteration I-OSE_Labeled_AE
. O

Skin O
and O
Appendages O
: O
Frequent O
: O
Pruritus B-OSE_Labeled_AE
; O
infrequent O
: O
Acne B-OSE_Labeled_AE
, O
alopecia B-OSE_Labeled_AE
, O
contact B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
, O
ecchymosis B-OSE_Labeled_AE
, O
eczema B-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
simplex I-OSE_Labeled_AE
, O
photosensitivity B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
; O
rare O
: O
Angioedema B-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
nodosum I-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
fungal B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
furunculosis B-OSE_Labeled_AE
; O
herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
, O
hirsutism B-OSE_Labeled_AE
, O
maculopapular B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
seborrhea B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
hypertrophy I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
vesiculobullous B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
. O

Special O
Senses O
: O
Frequent O
: O
Tinnitus B-OSE_Labeled_AE
; O
infrequent O
: O
Abnormality B-OSE_Labeled_AE
of I-OSE_Labeled_AE
accommodation I-OSE_Labeled_AE
, O
conjunctivitis B-OSE_Labeled_AE
, O
ear B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
eye B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
keratoconjunctivitis B-OSE_Labeled_AE
, O
mydriasis B-OSE_Labeled_AE
, O
otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
; O
rare O
: O
Amblyopia B-OSE_Labeled_AE
, O
anisocoria B-OSE_Labeled_AE
, O
blepharitis B-OSE_Labeled_AE
, O
cataract B-OSE_Labeled_AE
, O
conjunctival B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
corneal B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
, O
deafness B-OSE_Labeled_AE
, O
exophthalmos B-OSE_Labeled_AE
, O
eye B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
glaucoma B-OSE_Labeled_AE
, O
hyperacusis B-OSE_Labeled_AE
, O
night B-OSE_Labeled_AE
blindness I-OSE_Labeled_AE
, O
otitis B-OSE_Labeled_AE
externa I-OSE_Labeled_AE
, O
parosmia B-OSE_Labeled_AE
, O
photophobia B-OSE_Labeled_AE
, O
ptosis B-OSE_Labeled_AE
, O
retinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
taste B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
visual B-OSE_Labeled_AE
field I-OSE_Labeled_AE
defect I-OSE_Labeled_AE
. O

Urogenital O
System O
: O
Infrequent O
: O
Amenorrhea B-OSE_Labeled_AE
, O
breast B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
cystitis B-OSE_Labeled_AE
, O
dysuria B-OSE_Labeled_AE
, O
hematuria B-OSE_Labeled_AE
, O
menorrhagia B-OSE_Labeled_AE
, O
nocturia B-OSE_Labeled_AE
, O
polyuria B-OSE_Labeled_AE
, O
pyuria B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
urgency I-OSE_Labeled_AE
, O
vaginitis B-OSE_Labeled_AE
; O
rare O
: O
Abortion B-OSE_Labeled_AE
, O
breast B-OSE_Labeled_AE
atrophy I-OSE_Labeled_AE
, O
breast B-OSE_Labeled_AE
enlargement I-OSE_Labeled_AE
, O
endometrial B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
epididymitis B-OSE_Labeled_AE
, O
female B-OSE_Labeled_AE
lactation I-OSE_Labeled_AE
, O
fibrocystic B-OSE_Labeled_AE
breast I-OSE_Labeled_AE
, O
kidney B-OSE_Labeled_AE
calculus I-OSE_Labeled_AE
, O
kidney B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
leukorrhea B-OSE_Labeled_AE
, O
mastitis B-OSE_Labeled_AE
, O
metrorrhagia B-OSE_Labeled_AE
, O
nephritis B-OSE_Labeled_AE
, O
oliguria B-OSE_Labeled_AE
, O
salpingitis B-OSE_Labeled_AE
, O
urethritis B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
casts I-OSE_Labeled_AE
, O
uterine B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
, O
urolith B-OSE_Labeled_AE
, O
vaginal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
vaginal B-OSE_Labeled_AE
moniliasis I-OSE_Labeled_AE
. O

Postmarketing O
Reports O
: O
Voluntary O
reports O
of O
adverse O
events O
in O
patients O
taking O
PAXIL O
that O
have O
been O
received O
since O
market O
introduction O
and O
not O
listed O
above O
that O
may O
have O
no O
causal O
relationship O
with O
the O
drug O
include O
acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
( O
the O
most O
severe O
cases O
were O
deaths B-NonOSE_AE
due O
to O
liver B-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
, O
and O
grossly O
elevated B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
associated O
with O
severe O
liver B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
) O
, O
Guillain B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Barre I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
priapism B-OSE_Labeled_AE
, O
syndrome B-OSE_Labeled_AE
of I-OSE_Labeled_AE
inappropriate I-OSE_Labeled_AE
ADH I-OSE_Labeled_AE
secretion I-OSE_Labeled_AE
, O
symptoms O
suggestive O
of O
prolactinemia B-OSE_Labeled_AE
and O
galactorrhea B-OSE_Labeled_AE
; O
extrapyramidal B-NonOSE_AE
symptoms I-NonOSE_AE
which O
have O
included O
akathisia B-NonOSE_AE
, O
bradykinesia B-NonOSE_AE
, O
cogwheel B-NonOSE_AE
rigidity I-NonOSE_AE
, O
dystonia B-NonOSE_AE
, O
hypertonia B-NonOSE_AE
, O
oculogyric B-NonOSE_AE
crisis I-NonOSE_AE
which O
has O
been O
associated O
with O
concomitant O
use O
of O
pimozide O
; O
tremor B-OSE_Labeled_AE
and O
trismus B-OSE_Labeled_AE
; O
status B-OSE_Labeled_AE
epilepticus I-OSE_Labeled_AE
, O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
, O
allergic B-OSE_Labeled_AE
alveolitis I-OSE_Labeled_AE
, O
anaphylaxis B-OSE_Labeled_AE
, O
eclampsia B-OSE_Labeled_AE
, O
laryngismus B-OSE_Labeled_AE
, O
optic B-OSE_Labeled_AE
neuritis I-OSE_Labeled_AE
, O
porphyria B-OSE_Labeled_AE
, O
restless B-OSE_Labeled_AE
legs I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
RLS I-OSE_Labeled_AE
) O
, O
ventricular B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
( O
including O
torsade B-OSE_Labeled_AE
de I-OSE_Labeled_AE
pointes I-OSE_Labeled_AE
) O
, O
thrombocytopenia B-OSE_Labeled_AE
, O
hemolytic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
events O
related O
to O
impaired B-OSE_Labeled_AE
hematopoiesis I-OSE_Labeled_AE
( O
including O
aplastic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
pancytopenia B-OSE_Labeled_AE
, O
bone B-OSE_Labeled_AE
marrow I-OSE_Labeled_AE
aplasia I-OSE_Labeled_AE
, O
and O
agranulocytosis B-OSE_Labeled_AE
) O
, O
vasculitic B-OSE_Labeled_AE
syndromes I-OSE_Labeled_AE
( O
such O
as O
Henoch B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Schonlein I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
) O
, O
and O
premature B-OSE_Labeled_AE
births I-OSE_Labeled_AE
in O
pregnant B-Not_AE_Candidate
women O
. O

There O
has O
been O
a O
case O
report O
of O
an O
elevated O
phenytoin O
level O
after O
4 O
weeks O
of O
PAXIL O
and O
phenytoin O
coadministration O
. O

There O
has O
been O
a O
case O
report O
of O
severe O
hypotension B-NonOSE_AE
when O
PAXIL O
was O
added O
to O
chronic O
metoprolol O
treatment O
. O

BOXED O
WARNING O
: O
Suicidality O
and O
Antidepressant O
Drugs O
Suicidality O
and O
Antidepressant O
Drugs O
Antidepressants O
increased O
the O
risk O
compared O
to O
placebo O
of O
suicidal B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
and O
behavior O
( O
suicidality B-OSE_Labeled_AE
) O
in O
children O
, O
adolescents O
, O
and O
young O
adults O
in O
short-term O
studies O
of O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
and O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Anyone O
considering O
the O
use O
of O
PAXIL O
or O
any O
other O
antidepressant O
in O
a O
child O
, O
adolescent O
, O
or O
young O
adult O
must O
balance O
this O
risk O
with O
the O
clinical O
need O
. O

Short-term O
studies O
did O
not O
show O
an O
increase O
in O
the O
risk O
of O
suicidality B-NonOSE_AE
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
beyond O
age O
24 O
; O
there O
was O
a O
reduction O
in O
risk O
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
aged O
65 O
and O
older O
. O

Depression B-Not_AE_Candidate
and O
certain O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
are O
themselves O
associated O
with O
increases O
in O
the O
risk O
of O
suicide B-NonOSE_AE
. O

Patients O
of O
all O
ages O
who O
are O
started O
on O
antidepressant O
therapy O
should O
be O
monitored O
appropriately O
and O
observed O
closely O
for O
clinical O
worsening O
, O
suicidality B-NonOSE_AE
, O
or O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
. O

Families O
and O
caregivers O
should O
be O
advised O
of O
the O
need O
for O
close O
observation O
and O
communication O
with O
the O
prescriber O
. O

PAXIL O
is O
not O
approved O
for O
use O
in O
pediatric O
patients O
. O

( O
See O
WARNINGS O
: O
Clinical O
Worsening O
and O
Suicide B-NonOSE_AE
Risk O
, O
PRECAUTIONS O
: O
Information O
for O
Patients O
, O
and O
PRECAUTIONS O
: O
Pediatric O
Use O
. O
) O

PRECAUTIONS O
General O
: O
Activation O
of O
Mania/Hypomania O
: O
During O
premarketing O
testing O
, O
hypomania B-OSE_Labeled_AE
or O
mania B-OSE_Labeled_AE
occurred O
in O
approximately O
1.0 O
% O
of O
unipolar B-Not_AE_Candidate
patients O
treated O
with O
PAXIL O
compared O
to O
1.1 O
% O
of O
active-control O
and O
0.3 O
% O
of O
placebo-treated O
unipolar B-Not_AE_Candidate
patients O
. O

In O
a O
subset O
of O
patients O
classified O
as O
bipolar B-Not_AE_Candidate
, O
the O
rate O
of O
manic B-OSE_Labeled_AE
episodes O
was O
2.2 O
% O
for O
PAXIL O
and O
11.6 O
% O
for O
the O
combined O
active-control O
groups O
. O

As O
with O
all O
drugs O
effective O
in O
the O
treatment O
of O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
PAXIL O
should O
be O
used O
cautiously O
in O
patients O
with O
a O
history O
of O
mania B-Not_AE_Candidate
. O

Seizures O
: O
During O
premarketing O
testing O
, O
seizures B-OSE_Labeled_AE
occurred O
in O
0.1 O
% O
of O
patients O
treated O
with O
PAXIL O
, O
a O
rate O
similar O
to O
that O
associated O
with O
other O
drugs O
effective O
in O
the O
treatment O
of O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

PAXIL O
should O
be O
used O
cautiously O
in O
patients O
with O
a O
history O
of O
seizures B-Not_AE_Candidate
. O

It O
should O
be O
discontinued O
in O
any O
patient O
who O
develops O
seizures B-NonOSE_AE
. O

Discontinuation O
of O
Treatment O
With O
PAXIL O
: O
Recent O
clinical O
trials O
supporting O
the O
various O
approved O
indications O
for O
PAXIL O
employed O
a O
taper-phase O
regimen O
, O
rather O
than O
an O
abrupt O
discontinuation O
of O
treatment O
. O

The O
taper-phase O
regimen O
used O
in O
GAD B-Not_AE_Candidate
and O
PTSD B-Not_AE_Candidate
clinical O
trials O
involved O
an O
incremental O
decrease O
in O
the O
daily O
dose O
by O
10 O
mg/day O
at O
weekly O
intervals O
. O

When O
a O
daily O
dose O
of O
20 O
mg/day O
was O
reached O
, O
patients O
were O
continued O
on O
this O
dose O
for O
1 O
week O
before O
treatment O
was O
stopped O
. O

With O
this O
regimen O
in O
those O
studies O
, O
the O
following O
adverse O
events O
were O
reported O
at O
an O
incidence O
of O
2 O
% O
or O
greater O
for O
PAXIL O
and O
were O
at O
least O
twice O
that O
reported O
for O
placebo O
: O
Abnormal B-NonOSE_AE
dreams I-NonOSE_AE
, O
paresthesia B-NonOSE_AE
, O
and O
dizziness B-NonOSE_AE
. O

In O
the O
majority O
of O
patients O
, O
these O
events O
were O
mild O
to O
moderate O
and O
were O
self-limiting O
and O
did O
not O
require O
medical O
intervention O
. O

During O
marketing O
of O
PAXIL O
and O
other O
SSRIs O
and O
SNRIs O
, O
there O
have O
been O
spontaneous O
reports O
of O
adverse B-OSE_Labeled_AE
events I-OSE_Labeled_AE
occurring I-OSE_Labeled_AE
upon I-OSE_Labeled_AE
the I-OSE_Labeled_AE
discontinuation I-OSE_Labeled_AE
of O
these O
drugs O
( O
particularly O
when O
abrupt O
) O
, O
including O
the O
following O
: O
Dysphoric B-NonOSE_AE
mood I-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
agitation B-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
sensory B-NonOSE_AE
disturbances I-NonOSE_AE
( O
e.g. O
, O
paresthesias B-NonOSE_AE
such O
as O
electric B-NonOSE_AE
shock I-NonOSE_AE
sensations I-NonOSE_AE
and O
tinnitus B-NonOSE_AE
) O
, O
anxiety B-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
lethargy B-NonOSE_AE
, O
emotional B-NonOSE_AE
lability I-NonOSE_AE
, O
insomnia B-NonOSE_AE
, O
and O
hypomania B-NonOSE_AE
. O

While O
these O
events O
are O
generally O
self-limiting O
, O
there O
have O
been O
reports O
of O
serious O
discontinuation B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
. O

Patients O
should O
be O
monitored O
for O
these O
symptoms B-NonOSE_AE
when I-NonOSE_AE
discontinuing I-NonOSE_AE
treatment I-NonOSE_AE
with O
PAXIL O
. O

A O
gradual O
reduction O
in O
the O
dose O
rather O
than O
abrupt O
cessation O
is O
recommended O
whenever O
possible O
. O

If O
intolerable O
symptoms O
occur O
following O
a O
decrease O
in O
the O
dose O
or O
upon O
discontinuation O
of O
treatment O
, O
then O
resuming O
the O
previously O
prescribed O
dose O
may O
be O
considered O
. O

Subsequently O
, O
the O
physician O
may O
continue O
decreasing O
the O
dose O
but O
at O
a O
more O
gradual O
rate O
( O
see O
DOSAGE O
AND O
ADMINISTRATION O
) O
. O

See O
also O
PRECAUTIONS O
: O
Pediatric O
Use O
, O
for O
adverse O
events O
reported O
upon O
discontinuation O
of O
treatment O
with O
PAXIL O
in O
pediatric O
patients O
. O

Tamoxifen O
: O
Some O
studies O
have O
shown O
that O
the O
efficacy O
of O
tamoxifen O
, O
as O
measured O
by O
the O
risk O
of O
breast B-NonOSE_AE
cancer I-NonOSE_AE
relapse/ O
mortality B-NonOSE_AE
, O
may O
be O
reduced O
when O
co-prescribed O
with O
paroxetine O
as O
a O
result O
of O
paroxetine O
's O
irreversible O
inhibition O
of O
CYP2D6 O
( O
see O
Drug O
Interactions O
) O
. O

However O
, O
other O
studies O
have O
failed O
to O
demonstrate O
such O
a O
risk O
. O

It O
is O
uncertain O
whether O
the O
coadministration O
of O
paroxetine O
and O
tamoxifen O
has O
a O
significant O
adverse O
effect O
on O
the O
efficacy O
of O
tamoxifen O
. O

One O
study O
suggests O
that O
the O
risk O
may O
increase O
with O
longer O
duration O
of O
coadministration O
. O

When O
tamoxifen O
is O
used O
for O
the O
treatment O
or O
prevention O
of O
breast B-Not_AE_Candidate
cancer I-Not_AE_Candidate
, O
prescribers O
should O
consider O
using O
an O
alternative O
antidepressant O
with O
little O
or O
no O
CYP2D6 O
inhibition O
. O

Akathisia O
: O
The O
use O
of O
paroxetine O
or O
other O
SSRIs O
has O
been O
associated O
with O
the O
development O
of O
akathisia B-OSE_Labeled_AE
, O
which O
is O
characterized O
by O
an O
inner O
sense O
of O
restlessness B-NonOSE_AE
and O
psychomotor B-NonOSE_AE
agitation I-NonOSE_AE
such O
as O
an O
inability B-NonOSE_AE
to I-NonOSE_AE
sit I-NonOSE_AE
or I-NonOSE_AE
stand I-NonOSE_AE
still I-NonOSE_AE
usually O
associated O
with O
subjective O
distress B-NonOSE_AE
. O

This O
is O
most O
likely O
to O
occur O
within O
the O
first O
few O
weeks O
of O
treatment O
. O

Hyponatremia O
: O
Hyponatremia B-OSE_Labeled_AE
may O
occur O
as O
a O
result O
of O
treatment O
with O
SSRIs O
and O
SNRIs O
, O
including O
PAXIL O
. O

In O
many O
cases O
, O
this O
hyponatremia B-OSE_Labeled_AE
appears O
to O
be O
the O
result O
of O
the O
syndrome B-OSE_Labeled_AE
of I-OSE_Labeled_AE
inappropriate I-OSE_Labeled_AE
antidiuretic I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
secretion I-OSE_Labeled_AE
( I-OSE_Labeled_AE
SIADH I-OSE_Labeled_AE
) O
. O

Cases O
with O
serum B-OSE_Labeled_AE
sodium I-OSE_Labeled_AE
lower I-OSE_Labeled_AE
than I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mmol I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
have O
been O
reported O
. O

Elderly O
patients O
may O
be O
at O
greater O
risk O
of O
developing O
hyponatremia B-OSE_Labeled_AE
with O
SSRIs O
and O
SNRIs O
. O

Also O
, O
patients O
taking O
diuretics O
or O
who O
are O
otherwise O
volume B-Not_AE_Candidate
depleted I-Not_AE_Candidate
may O
be O
at O
greater O
risk O
( O
see O
PRECAUTIONS O
: O
Geriatric O
Use O
) O
. O

Discontinuation O
of O
PAXIL O
should O
be O
considered O
in O
patients O
with O
symptomatic O
hyponatremia B-NonOSE_AE
and O
appropriate O
medical O
intervention O
should O
be O
instituted O
. O

Signs O
and O
symptoms O
of O
hyponatremia B-NonOSE_AE
include O
headache B-NonOSE_AE
, O
difficulty B-NonOSE_AE
concentrating I-NonOSE_AE
, O
memory B-NonOSE_AE
impairment I-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
weakness B-NonOSE_AE
, O
and O
unsteadiness B-NonOSE_AE
, O
which O
may O
lead O
to O
falls B-NonOSE_AE
. O

Signs O
and O
symptoms O
associated O
with O
more O
severe O
and/or O
acute O
cases O
have O
included O
hallucination B-NonOSE_AE
, O
syncope B-NonOSE_AE
, O
seizure B-NonOSE_AE
, O
coma B-NonOSE_AE
, O
respiratory B-NonOSE_AE
arrest I-NonOSE_AE
, O
and O
death B-NonOSE_AE
. O

Abnormal O
Bleeding O
: O
SSRIs O
and O
SNRIs O
, O
including O
paroxetine O
, O
may O
increase O
the O
risk O
of O
bleeding B-OSE_Labeled_AE
events O
. O

Concomitant O
use O
of O
aspirin O
, O
nonsteroidal O
anti-inflammatory O
drugs O
, O
warfarin O
, O
and O
other O
anticoagulants O
may O
add O
to O
this O
risk O
. O

Case O
reports O
and O
epidemiological O
studies O
( O
case-control O
and O
cohort O
design O
) O
have O
demonstrated O
an O
association O
between O
use O
of O
drugs O
that O
interfere O
with O
serotonin O
reuptake O
and O
the O
occurrence O
of O
gastrointestinal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
. O

Bleeding B-OSE_Labeled_AE
events O
related O
to O
SSRIs O
and O
SNRIs O
use O
have O
ranged O
from O
ecchymoses B-OSE_Labeled_AE
, O
hematomas B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
and O
petechiae B-OSE_Labeled_AE
to O
life-threatening O
hemorrhages B-OSE_Labeled_AE
. O

Patients O
should O
be O
cautioned O
about O
the O
risk O
of O
bleeding B-NonOSE_AE
associated O
with O
the O
concomitant O
use O
of O
paroxetine O
and O
NSAIDs O
, O
aspirin O
, O
or O
other O
drugs O
that O
affect O
coagulation O
. O

Bone O
Fracture O
: O
Epidemiological O
studies O
on O
bone B-OSE_Labeled_AE
fracture I-OSE_Labeled_AE
risk O
following O
exposure O
to O
some O
antidepressants O
, O
including O
SSRIs O
, O
have O
reported O
an O
association O
between O
antidepressant O
treatment O
and O
fractures B-OSE_Labeled_AE
. O

There O
are O
multiple O
possible O
causes O
for O
this O
observation O
and O
it O
is O
unknown O
to O
what O
extent O
fracture B-NonOSE_AE
risk O
is O
directly O
attributable O
to O
SSRI O
treatment O
. O

The O
possibility O
of O
a O
pathological B-NonOSE_AE
fracture I-NonOSE_AE
, O
that O
is O
, O
a O
fracture B-NonOSE_AE
produced I-NonOSE_AE
by I-NonOSE_AE
minimal I-NonOSE_AE
trauma I-NonOSE_AE
in O
a O
patient O
with O
decreased B-Not_AE_Candidate
bone I-Not_AE_Candidate
mineral I-Not_AE_Candidate
density I-Not_AE_Candidate
, O
should O
be O
considered O
in O
patients O
treated O
with O
paroxetine O
who O
present O
with O
unexplained O
bone B-NonOSE_AE
pain I-NonOSE_AE
, O
point B-NonOSE_AE
tenderness I-NonOSE_AE
, O
swelling B-NonOSE_AE
, O
or O
bruising B-NonOSE_AE
. O

Use O
in O
Patients O
With O
Concomitant O
Illness O
: O
Clinical O
experience O
with O
PAXIL O
in O
patients O
with O
certain O
concomitant O
systemic O
illness O
is O
limited O
. O

Caution O
is O
advisable O
in O
using O
PAXIL O
in O
patients O
with O
diseases O
or O
conditions O
that O
could O
affect O
metabolism O
or O
hemodynamic O
responses O
. O

As O
with O
other O
SSRIs O
, O
mydriasis B-OSE_Labeled_AE
has O
been O
infrequently O
reported O
in O
premarketing O
studies O
with O
PAXIL O
. O

A O
few O
cases O
of O
acute B-OSE_Labeled_AE
angle I-OSE_Labeled_AE
closure I-OSE_Labeled_AE
glaucoma I-OSE_Labeled_AE
associated O
with O
paroxetine O
therapy O
have O
been O
reported O
in O
the O
literature O
. O

As O
mydriasis B-NonOSE_AE
can O
cause O
acute B-NonOSE_AE
angle I-NonOSE_AE
closure I-NonOSE_AE
in O
patients O
with O
narrow B-Not_AE_Candidate
angle I-Not_AE_Candidate
glaucoma I-Not_AE_Candidate
, O
caution O
should O
be O
used O
when O
PAXIL O
is O
prescribed O
for O
patients O
with O
narrow B-Not_AE_Candidate
angle I-Not_AE_Candidate
glaucoma I-Not_AE_Candidate
. O

PAXIL O
has O
not O
been O
evaluated O
or O
used O
to O
any O
appreciable O
extent O
in O
patients O
with O
a O
recent O
history O
of O
myocardial B-Not_AE_Candidate
infarction I-Not_AE_Candidate
or O
unstable B-Not_AE_Candidate
heart I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Patients O
with O
these O
diagnoses O
were O
excluded O
from O
clinical O
studies O
during O
the O
product O
's O
premarket O
testing O
. O

Evaluation O
of O
electrocardiograms O
of O
682 O
patients O
who O
received O
PAXIL O
in O
double-blind O
, O
placebo-controlled O
trials O
, O
however O
, O
did O
not O
indicate O
that O
PAXIL O
is O
associated O
with O
the O
development O
of O
significant O
ECG B-NonOSE_AE
abnormalities I-NonOSE_AE
. O

Similarly O
, O
PAXIL O
does O
not O
cause O
any O
clinically O
important O
changes B-NonOSE_AE
in I-NonOSE_AE
heart I-NonOSE_AE
rate I-NonOSE_AE
or O
blood O
pressure O
. O

Increased O
plasma O
concentrations O
of O
paroxetine O
occur O
in O
patients O
with O
severe O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
( O
creatinine B-Not_AE_Candidate
clearance I-Not_AE_Candidate
< I-Not_AE_Candidate
3 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
. O
) O

or O
severe O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
. O

A O
lower O
starting O
dose O
should O
be O
used O
in O
such O
patients O
( O
see O
DOSAGE O
AND O
ADMINISTRATION O
) O
. O

Information O
for O
Patients O
: O
PAXIL O
should O
not O
be O
chewed O
or O
crushed O
, O
and O
should O
be O
swallowed O
whole O
. O

Patients O
should O
be O
cautioned O
about O
the O
risk O
of O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
with O
the O
concomitant O
use O
of O
PAXIL O
and O
triptans O
, O
tramadol O
, O
or O
other O
serotonergic O
agents O
. O

Patients O
should O
be O
advised O
that O
taking O
Paxil O
can O
cause O
mild O
pupillary B-NonOSE_AE
dilation I-NonOSE_AE
, O
which O
in O
susceptible O
individuals O
, O
can O
lead O
to O
an O
episode O
of O
angle B-NonOSE_AE
closure I-NonOSE_AE
glaucoma I-NonOSE_AE
. O

Pre-existing O
glaucoma B-Not_AE_Candidate
is O
almost O
always O
open B-Not_AE_Candidate
- I-Not_AE_Candidate
angle I-Not_AE_Candidate
glaucoma I-Not_AE_Candidate
because O
angle B-Not_AE_Candidate
closure I-Not_AE_Candidate
glaucoma I-Not_AE_Candidate
, O
when O
diagnosed O
, O
can O
be O
treated O
definitively O
with O
iridectomy O
. O

Open B-NonOSE_AE
- I-NonOSE_AE
angle I-NonOSE_AE
glaucoma I-NonOSE_AE
is O
not O
a O
risk O
factor O
for O
angle B-NonOSE_AE
closure I-NonOSE_AE
glaucoma I-NonOSE_AE
. O

Patients O
may O
wish O
to O
be O
examined O
to O
determine O
whether O
they O
are O
susceptible O
to O
angle B-NonOSE_AE
closure I-NonOSE_AE
, O
and O
have O
a O
prophylactic O
procedure O
( O
e.g. O
, O
iridectomy O
) O
, O
if O
they O
are O
susceptible O
. O

Prescribers O
or O
other O
health O
professionals O
should O
inform O
patients O
, O
their O
families O
, O
and O
their O
caregivers O
about O
the O
benefits O
and O
risks O
associated O
with O
treatment O
with O
PAXIL O
and O
should O
counsel O
them O
in O
its O
appropriate O
use O
. O

A O
patient O
Medication O
Guide O
is O
available O
for O
PAXIL O
. O

The O
prescriber O
or O
health O
professional O
should O
instruct O
patients O
, O
their O
families O
, O
and O
their O
caregivers O
to O
read O
the O
Medication O
Guide O
and O
should O
assist O
them O
in O
understanding O
its O
contents O
. O

Patients O
should O
be O
given O
the O
opportunity O
to O
discuss O
the O
contents O
of O
the O
Medication O
Guide O
and O
to O
obtain O
answers O
to O
any O
questions O
they O
may O
have O
. O

The O
complete O
text O
of O
the O
Medication O
Guide O
is O
reprinted O
at O
the O
end O
of O
this O
document O
. O

Patients O
should O
be O
advised O
of O
the O
following O
issues O
and O
asked O
to O
alert O
their O
prescriber O
if O
these O
occur O
while O
taking O
PAXIL O
. O

Clinical O
Worsening O
and O
Suicide O
Risk O
: O
Patients O
, O
their O
families O
, O
and O
their O
caregivers O
should O
be O
encouraged O
to O
be O
alert O
to O
the O
emergence O
of O
anxiety B-NonOSE_AE
, O
agitation B-NonOSE_AE
, O
panic B-NonOSE_AE
attacks I-NonOSE_AE
, O
insomnia B-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
hostility B-NonOSE_AE
, O
aggressiveness B-NonOSE_AE
, O
impulsivity B-NonOSE_AE
, O
akathisia B-NonOSE_AE
( O
psychomotor B-NonOSE_AE
restlessness I-NonOSE_AE
) O
, O
hypomania B-NonOSE_AE
, O
mania B-NonOSE_AE
, O
other O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
worsening B-NonOSE_AE
of I-NonOSE_AE
depression I-NonOSE_AE
, O
and O
suicidal B-NonOSE_AE
ideation I-NonOSE_AE
, O
especially O
early O
during O
antidepressant O
treatment O
and O
when O
the O
dose O
is O
adjusted O
up O
or O
down O
. O

Families O
and O
caregivers O
of O
patients O
should O
be O
advised O
to O
look O
for O
the O
emergence O
of O
such O
symptoms O
on O
a O
day-to-day O
basis O
, O
since O
changes O
may O
be O
abrupt O
. O

Such O
symptoms O
should O
be O
reported O
to O
the O
patient O
's O
prescriber O
or O
health O
professional O
, O
especially O
if O
they O
are O
severe O
, O
abrupt O
in O
onset O
, O
or O
were O
not O
part O
of O
the O
patient O
's O
presenting O
symptoms O
. O

Symptoms O
such O
as O
these O
may O
be O
associated O
with O
an O
increased O
risk O
for O
suicidal B-NonOSE_AE
thinking I-NonOSE_AE
and O
behavior O
and O
indicate O
a O
need O
for O
very O
close O
monitoring O
and O
possibly O
changes O
in O
the O
medication O
. O

Drugs O
That O
Interfere O
With O
Hemostasis O
( O
e.g. O
, O
NSAIDs O
, O
Aspirin O
, O
and O
Warfarin O
) O
: O
Patients O
should O
be O
cautioned O
about O
the O
concomitant O
use O
of O
paroxetine O
and O
NSAIDs O
, O
aspirin O
, O
warfarin O
, O
or O
other O
drugs O
that O
affect O
coagulation O
since O
combined O
use O
of O
psychotropic O
drugs O
that O
interfere O
with O
serotonin O
reuptake O
and O
these O
agents O
has O
been O
associated O
with O
an O
increased O
risk O
of O
bleeding B-NonOSE_AE
. O

Interference O
With O
Cognitive O
and O
Motor O
Performance O
: O
Any O
psychoactive O
drug O
may O
impair B-NonOSE_AE
judgment I-NonOSE_AE
, O
thinking O
, O
or O
motor O
skills O
. O

Although O
in O
controlled O
studies O
PAXIL O
has O
not O
been O
shown O
to O
impair B-NonOSE_AE
psychomotor I-NonOSE_AE
performance I-NonOSE_AE
, O
patients O
should O
be O
cautioned O
about O
operating O
hazardous O
machinery O
, O
including O
automobiles O
, O
until O
they O
are O
reasonably O
certain O
that O
therapy O
with O
PAXIL O
does O
not O
affect O
their O
ability O
to O
engage O
in O
such O
activities O
. O

Completing O
Course O
of O
Therapy O
: O
While O
patients O
may O
notice O
improvement O
with O
treatment O
with O
PAXIL O
in O
1 O
to O
4 O
weeks O
, O
they O
should O
be O
advised O
to O
continue O
therapy O
as O
directed O
. O

Concomitant O
Medication O
: O
Patients O
should O
be O
advised O
to O
inform O
their O
physician O
if O
they O
are O
taking O
, O
or O
plan O
to O
take O
, O
any O
prescription O
or O
over-the-counter O
drugs O
, O
since O
there O
is O
a O
potential O
for O
interactions O
. O

Alcohol O
: O
Although O
PAXIL O
has O
not O
been O
shown O
to O
increase O
the O
impairment B-NonOSE_AE
of I-NonOSE_AE
mental I-NonOSE_AE
and O
motor O
skills I-NonOSE_AE
caused O
by O
alcohol O
, O
patients O
should O
be O
advised O
to O
avoid O
alcohol O
while O
taking O
PAXIL O
. O

Pregnancy O
: O
Patients O
should O
be O
advised O
to O
notify O
their O
physician O
if O
they O
become O
pregnant B-NonOSE_AE
or O
intend O
to O
become O
pregnant B-NonOSE_AE
during O
therapy O
( O
see O
WARNINGS O
: O
Usage O
in O
Pregnancy B-NonOSE_AE
: O
Teratogenic B-NonOSE_AE
Effects I-NonOSE_AE
and O
Nonteratogenic B-NonOSE_AE
Effects I-NonOSE_AE
) O
. O

Nursing O
: O
Patients O
should O
be O
advised O
to O
notify O
their O
physician O
if O
they O
are O
breastfeeding O
an O
infant O
( O
see O
PRECAUTIONS O
: O
Nursing O
Mothers O
) O
. O

Laboratory O
Tests O
: O
There O
are O
no O
specific O
laboratory O
tests O
recommended O
. O

Drug O
Interactions O
: O
Tryptophan O
: O
As O
with O
other O
serotonin O
reuptake O
inhibitors O
, O
an O
interaction O
between O
paroxetine O
and O
tryptophan O
may O
occur O
when O
they O
are O
coadministered O
. O

Adverse O
experiences O
, O
consisting O
primarily O
of O
headache B-NonOSE_AE
, O
nausea B-NonOSE_AE
, O
sweating B-NonOSE_AE
, O
and O
dizziness B-NonOSE_AE
, O
have O
been O
reported O
when O
tryptophan O
was O
administered O
to O
patients O
taking O
PAXIL O
. O

Consequently O
, O
concomitant O
use O
of O
PAXIL O
with O
tryptophan O
is O
not O
recommended O
( O
see O
WARNINGS O
: O
Serotonin O
Syndrome O
) O
. O

Monoamine O
Oxidase O
Inhibitors O
: O
See O
CONTRAINDICATIONS O
and O
WARNINGS O
. O

Pimozide O
: O
In O
a O
controlled O
study O
of O
healthy O
volunteers O
, O
after O
PAXIL O
was O
titrated O
to O
60 O
mg O
daily O
, O
co-administration O
of O
a O
single O
dose O
of O
2 O
mg O
pimozide O
was O
associated O
with O
mean O
increases O
in O
pimozide O
AUC O
of O
151 O
% O
and O
Cmaxof O
62 O
% O
, O
compared O
to O
pimozide O
administered O
alone O
. O

The O
increase O
in O
pimozide O
AUC O
and O
Cmaxis O
due O
to O
the O
CYP2D6 O
inhibitory O
properties O
of O
paroxetine O
. O

Due O
to O
the O
narrow O
therapeutic O
index O
of O
pimozide O
and O
its O
known O
ability O
to O
prolong B-NonOSE_AE
the I-NonOSE_AE
QT I-NonOSE_AE
interval I-NonOSE_AE
, O
concomitant O
use O
of O
pimozide O
and O
PAXIL O
is O
contraindicated O
( O
see O
CONTRAINDICATIONS O
) O
. O

Serotonergic O
Drugs O
: O
Based O
on O
the O
mechanism O
of O
action O
of O
SNRIs O
and O
SSRIs O
, O
including O
paroxetine O
hydrochloride O
, O
and O
the O
potential O
for O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
, O
caution O
is O
advised O
when O
PAXIL O
is O
coadministered O
with O
other O
drugs O
that O
may O
affect O
the O
serotonergic O
neurotransmitter O
systems O
, O
such O
as O
triptans O
, O
lithium O
, O
fentanyl O
, O
tramadol O
, O
amphetamines O
, O
or O
St O
. O
John O
's O
Wort O
( O
see O
WARNINGS O
: O
Serotonin B-NonOSE_AE
Syndrome I-NonOSE_AE
) O
. O

The O
concomitant O
use O
of O
PAXIL O
with O
MAOIs O
( O
including O
linezolid O
and O
intravenous O
methylene O
blue O
) O
is O
contraindicated O
( O
see O
CONTRAINDICATIONS O
) O
. O

The O
concomitant O
use O
of O
PAXIL O
with O
other O
SSRIs O
, O
SNRIs O
or O
tryptophan O
is O
not O
recommended O
( O
see O
PRECAUTIONS O
: O
Drug O
Interactions O
: O
Tryptophan O
) O
. O

Thioridazine O
: O
See O
CONTRAINDICATIONS O
and O
WARNINGS O
. O

Warfarin O
: O
Preliminary O
data O
suggest O
that O
there O
may O
be O
a O
pharmacodynamic O
interaction O
( O
that O
causes O
an O
increased B-NonOSE_AE
bleeding I-NonOSE_AE
diathesis O
in O
the O
face O
of O
unaltered O
prothrombin O
time O
) O
between O
paroxetine O
and O
warfarin O
. O

Since O
there O
is O
little O
clinical O
experience O
, O
the O
concomitant O
administration O
of O
PAXIL O
and O
warfarin O
should O
be O
undertaken O
with O
caution O
( O
see O
PRECAUTIONS O
: O
Drugs O
That O
Interfere O
With O
Hemostasis O
) O
. O

Triptans O
: O
There O
have O
been O
rare O
postmarketing O
reports O
of O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
with O
the O
use O
of O
an O
SSRI O
and O
a O
triptan O
. O

If O
concomitant O
use O
of O
PAXIL O
with O
a O
triptan O
is O
clinically O
warranted O
, O
careful O
observation O
of O
the O
patient O
is O
advised O
, O
particularly O
during O
treatment O
initiation O
and O
dose O
increases O
( O
see O
WARNINGS O
: O
Serotonin O
Syndrome O
) O
. O

Drugs O
Affecting O
Hepatic O
Metabolism O
: O
The O
metabolism O
and O
pharmacokinetics O
of O
paroxetine O
may O
be O
affected O
by O
the O
induction O
or O
inhibition O
of O
drug-metabolizing O
enzymes O
. O

Cimetidine O
: O
Cimetidine O
inhibits O
many O
cytochrome O
P450 O
( O
oxidative O
) O
enzymes O
. O

In O
a O
study O
where O
PAXIL O
( O
30 O
mg O
once O
daily O
) O
was O
dosed O
orally O
for O
4 O
weeks O
, O
steady-state O
plasma O
concentrations O
of O
paroxetine O
were O
increased O
by O
approximately O
50 O
% O
during O
coadministration O
with O
oral O
cimetidine O
( O
300 O
mg O
three O
times O
daily O
) O
for O
the O
final O
week O
. O

Therefore O
, O
when O
these O
drugs O
are O
administered O
concurrently O
, O
dosage O
adjustment O
of O
PAXIL O
after O
the O
20-mg O
starting O
dose O
should O
be O
guided O
by O
clinical O
effect O
. O

The O
effect O
of O
paroxetine O
on O
cimetidine O
's O
pharmacokinetics O
was O
not O
studied O
. O

Phenobarbital O
: O
Phenobarbital O
induces O
many O
cytochrome O
P450 O
( O
oxidative O
) O
enzymes O
. O

When O
a O
single O
oral O
30-mg O
dose O
of O
PAXIL O
was O
administered O
at O
phenobarbital O
steady O
state O
( O
100 O
mg O
once O
daily O
for O
14 O
days O
) O
, O
paroxetine O
AUC O
and O
T1/2were O
reduced O
( O
by O
an O
average O
of O
25 O
% O
and O
38 O
% O
, O
respectively O
) O
compared O
to O
paroxetine O
administered O
alone O
. O

The O
effect O
of O
paroxetine O
on O
phenobarbital O
pharmacokinetics O
was O
not O
studied O
. O

Since O
PAXIL O
exhibits O
nonlinear O
pharmacokinetics O
, O
the O
results O
of O
this O
study O
may O
not O
address O
the O
case O
where O
the O
2 O
drugs O
are O
both O
being O
chronically O
dosed O
. O

No O
initial O
dosage O
adjustment O
of O
PAXIL O
is O
considered O
necessary O
when O
coadministered O
with O
phenobarbital O
; O
any O
subsequent O
adjustment O
should O
be O
guided O
by O
clinical O
effect O
. O

Phenytoin O
: O
When O
a O
single O
oral O
30-mg O
dose O
of O
PAXIL O
was O
administered O
at O
phenytoin O
steady O
state O
( O
300 O
mg O
once O
daily O
for O
14 O
days O
) O
, O
paroxetine O
AUC O
and O
T1/2 O
were O
reduced O
( O
by O
an O
average O
of O
50 O
% O
and O
35 O
% O
, O
respectively O
) O
compared O
to O
PAXIL O
administered O
alone O
. O

In O
a O
separate O
study O
, O
when O
a O
single O
oral O
300-mg O
dose O
of O
phenytoin O
was O
administered O
at O
paroxetine O
steady O
state O
( O
30 O
mg O
once O
daily O
for O
14 O
days O
) O
, O
phenytoin O
AUC O
was O
slightly O
reduced O
( O
12 O
% O
on O
average O
) O
compared O
to O
phenytoin O
administered O
alone O
. O

Since O
both O
drugs O
exhibit O
nonlinear O
pharmacokinetics O
, O
the O
above O
studies O
may O
not O
address O
the O
case O
where O
the O
2 O
drugs O
are O
both O
being O
chronically O
dosed O
. O

No O
initial O
dosage O
adjustments O
are O
considered O
necessary O
when O
these O
drugs O
are O
coadministered O
; O
any O
subsequent O
adjustments O
should O
be O
guided O
by O
clinical O
effect O
( O
see O
ADVERSE O
REACTIONS O
: O
Postmarketing O
Reports O
) O
. O

Drugs O
Metabolized O
by O
CYP2D6 O
: O
Many O
drugs O
, O
including O
most O
drugs O
effective O
in O
the O
treatment O
of O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( O
paroxetine O
, O
other O
SSRIs O
and O
many O
tricyclics O
) O
, O
are O
metabolized O
by O
the O
cytochrome O
P450isozyme O
CYP2D6 O
. O

Like O
other O
agents O
that O
are O
metabolized O
by O
CYP2D6 O
, O
paroxetine O
may O
significantly O
inhibit O
the O
activity O
of O
this O
isozyme O
. O

In O
most O
patients O
( O
> O
90 O
% O
) O
, O
this O
CYP2D6 O
isozyme O
is O
saturated O
early O
during O
dosing O
with O
PAXIL O
. O

In O
1 O
study O
, O
daily O
dosing O
of O
PAXIL O
( O
20 O
mg O
once O
daily O
) O
under O
steady-state O
conditions O
increased O
single O
dose O
desipramine O
( O
100 O
mg O
) O
Cmax O
, O
AUC O
, O
and O
T1/2 O
by O
an O
average O
of O
approximately O
2- O
, O
5- O
, O
and O
3-fold O
, O
respectively O
. O

Concomitant O
use O
of O
paroxetine O
with O
risperidone O
, O
a O
CYP2D6 O
substrate O
has O
also O
been O
evaluated O
. O

In O
1 O
study O
, O
daily O
dosing O
of O
paroxetine O
20 O
mg O
in O
patients O
stabilized O
on O
risperidone O
( O
4 O
to O
8 O
mg/day O
) O
increased O
mean O
plasma O
concentrations O
of O
risperidone O
approximately O
4-fold O
, O
decreased O
9-hydroxyrisperidone O
concentrations O
approximately O
10 O
% O
, O
and O
increased O
concentrations O
of O
the O
active O
moiety O
( O
the O
sum O
of O
risperidone O
plus O
9-hydroxyrisperidone O
) O
approximately O
1.4-fold O
. O

The O
effect O
of O
paroxetine O
on O
the O
pharmacokinetics O
of O
atomoxetine O
has O
been O
evaluated O
when O
both O
drugs O
were O
at O
steady O
state O
. O

In O
healthy O
volunteers O
who O
were O
extensive O
metabolizers O
of O
CYP2D6 O
, O
paroxetine O
20 O
mg O
daily O
was O
given O
in O
combination O
with O
20 O
mg O
atomoxetine O
every O
12 O
hours O
. O

This O
resulted O
in O
increases O
in O
steady O
state O
atomoxetine O
AUC O
values O
that O
were O
6- O
to O
8-fold O
greater O
and O
in O
atomoxetine O
Cmaxvalues O
that O
were O
3- O
to O
4-fold O
greater O
than O
when O
atomoxetine O
was O
given O
alone O
. O

Dosage O
adjustment O
of O
atomoxetine O
may O
be O
necessary O
and O
it O
is O
recommended O
that O
atomoxetine O
be O
initiated O
at O
a O
reduced O
dose O
when O
it O
is O
given O
with O
paroxetine O
. O

Concomitant O
use O
of O
PAXIL O
with O
other O
drugs O
metabolized O
by O
cytochrome O
CYP2D6 O
has O
not O
been O
formally O
studied O
but O
may O
require O
lower O
doses O
than O
usually O
prescribed O
for O
either O
PAXIL O
or O
the O
other O
drug O
. O

Therefore O
, O
coadministration O
of O
PAXIL O
with O
other O
drugs O
that O
are O
metabolized O
by O
this O
isozyme O
, O
including O
certain O
drugs O
effective O
in O
the O
treatment O
of O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( O
e.g. O
, O
nortriptyline O
, O
amitriptyline O
, O
imipramine O
, O
desipramine O
, O
and O
fluoxetine O
) O
, O
phenothiazines O
, O
risperidone O
, O
and O
Type O
1C O
antiarrhythmics O
( O
e.g. O
, O
propafenone O
, O
flecainide O
, O
and O
encainide O
) O
, O
or O
that O
inhibit O
this O
enzyme O
( O
e.g. O
, O
quinidine O
) O
, O
should O
be O
approached O
with O
caution O
. O

However O
, O
due O
to O
the O
risk O
of O
serious O
ventricular B-NonOSE_AE
arrhythmias I-NonOSE_AE
and O
sudden B-NonOSE_AE
death I-NonOSE_AE
potentially O
associated O
with O
elevated O
plasma O
levels O
of O
thioridazine O
, O
paroxetine O
and O
thioridazine O
should O
not O
be O
coadministered O
( O
see O
CONTRAINDICATIONS O
and O
WARNINGS O
) O
. O

Tamoxifen O
is O
a O
pro-drug O
requiring O
metabolic O
activation O
by O
CYP2D6 O
. O

Inhibition O
of O
CYP2D6 O
by O
paroxetine O
may O
lead O
to O
reduced O
plasma O
concentrations O
of O
an O
active O
metabolite O
( O
endoxifen O
) O
and O
hence O
reduced O
efficacy O
of O
tamoxifen O
( O
see O
PRECAUTIONS O
) O
. O

At O
steady O
state O
, O
when O
the O
CYP2D6 O
pathway O
is O
essentially O
saturated O
, O
paroxetine O
clearance O
is O
governed O
by O
alternative O
P450isozymes O
that O
, O
unlike O
CYP2D6 O
, O
show O
no O
evidence O
of O
saturation O
( O
see O
PRECAUTIONS O
: O
Tricyclic O
Antidepressants O
[ O
TCAs O
] O
) O
. O

Drugs O
Metabolized O
by O
Cytochrome O
CYP3A4 O
: O
An O
in O
vivo O
interaction O
study O
involving O
the O
coadministration O
under O
steady-state O
conditions O
of O
paroxetine O
and O
terfenadine O
, O
a O
substrate O
for O
cytochrome O
CYP3A4 O
, O
revealed O
no O
effect O
of O
paroxetine O
on O
terfenadine O
pharmacokinetics O
. O

In O
addition O
, O
in O
vitro O
studies O
have O
shown O
ketoconazole O
, O
a O
potent O
inhibitor O
of O
CYP3A4 O
activity O
, O
to O
be O
at O
least O
100 O
times O
more O
potent O
than O
paroxetine O
as O
an O
inhibitor O
of O
the O
metabolism O
of O
several O
substrates O
for O
this O
enzyme O
, O
including O
terfenadine O
, O
astemizole O
, O
cisapride O
, O
triazolam O
, O
and O
cyclosporine O
. O

Based O
on O
the O
assumption O
that O
the O
relationship O
between O
paroxetine O
's O
in O
vitro O
Kiand O
its O
lack O
of O
effect O
on O
terfenadine O
's O
in O
vivo O
clearance O
predicts O
its O
effect O
on O
other O
CYP3A4 O
substrates O
, O
paroxetine O
's O
extent O
of O
inhibition O
of O
CYP3A4 O
activity O
is O
not O
likely O
to O
be O
of O
clinical O
significance O
. O

Tricyclic O
Antidepressants O
( O
TCAs O
) O
: O
Caution O
is O
indicated O
in O
the O
coadministration O
of O
tricyclic O
antidepressants O
( O
TCAs O
) O
with O
PAXIL O
, O
because O
paroxetine O
may O
inhibit O
TCA O
metabolism O
. O

Plasma O
TCA O
concentrations O
may O
need O
to O
be O
monitored O
, O
and O
the O
dose O
of O
TCA O
may O
need O
to O
be O
reduced O
, O
if O
a O
TCA O
is O
coadministered O
with O
PAXIL O
( O
see O
PRECAUTIONS O
: O
Drugs O
Metabolized O
by O
Cytochrome O
CYP2D6 O
) O
. O

Drugs O
Highly O
Bound O
to O
Plasma O
Protein O
: O
Because O
paroxetine O
is O
highly O
bound O
to O
plasma O
protein O
, O
administration O
of O
PAXIL O
to O
a O
patient O
taking O
another O
drug O
that O
is O
highly O
protein O
bound O
may O
cause O
increased O
free O
concentrations O
of O
the O
other O
drug O
, O
potentially O
resulting O
in O
adverse O
events O
. O

Conversely O
, O
adverse O
effects O
could O
result O
from O
displacement O
of O
paroxetine O
by O
other O
highly O
bound O
drugs O
. O

Drugs O
That O
Interfere O
With O
Hemostasis O
( O
e.g. O
, O
NSAIDs O
, O
Aspirin O
, O
and O
Warfarin O
) O
: O
Serotonin O
release O
by O
platelets O
plays O
an O
important O
role O
in O
hemostasis O
. O

Epidemiological O
studies O
of O
the O
case-control O
and O
cohort O
design O
that O
have O
demonstrated O
an O
association O
between O
use O
of O
psychotropic O
drugs O
that O
interfere O
with O
serotonin O
reuptake O
and O
the O
occurrence O
of O
upper O
gastrointestinal B-NonOSE_AE
bleeding I-NonOSE_AE
have O
also O
shown O
that O
concurrent O
use O
of O
an O
NSAID O
or O
aspirin O
may O
potentiate O
this O
risk O
of O
bleeding B-NonOSE_AE
. O

Altered O
anticoagulant O
effects O
, O
including O
increased B-NonOSE_AE
bleeding I-NonOSE_AE
, O
have O
been O
reported O
when O
SSRIs O
or O
SNRIs O
are O
coadministered O
with O
warfarin O
. O

Patients O
receiving O
warfarin O
therapy O
should O
be O
carefully O
monitored O
when O
paroxetine O
is O
initiated O
or O
discontinued O
. O

Alcohol O
: O
Although O
PAXIL O
does O
not O
increase O
the O
impairment B-NonOSE_AE
of I-NonOSE_AE
mental I-NonOSE_AE
and O
motor O
skills I-NonOSE_AE
caused O
by O
alcohol O
, O
patients O
should O
be O
advised O
to O
avoid O
alcohol O
while O
taking O
PAXIL O
. O

Lithium O
: O
A O
multiple-dose O
study O
has O
shown O
that O
there O
is O
no O
pharmacokinetic O
interaction O
between O
PAXIL O
and O
lithium O
carbonate O
. O

However O
, O
due O
to O
the O
potential O
for O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
, O
caution O
is O
advised O
when O
PAXIL O
is O
coadministered O
with O
lithium O
. O

Digoxin O
: O
The O
steady-state O
pharmacokinetics O
of O
paroxetine O
was O
not O
altered O
when O
administered O
with O
digoxin O
at O
steady O
state O
. O

Mean O
digoxin O
AUC O
at O
steady O
state O
decreased O
by O
15 O
% O
in O
the O
presence O
of O
paroxetine O
. O

Since O
there O
is O
little O
clinical O
experience O
, O
the O
concurrent O
administration O
of O
paroxetine O
and O
digoxin O
should O
be O
undertaken O
with O
caution O
. O

Diazepam O
: O
Under O
steady-state O
conditions O
, O
diazepam O
does O
not O
appear O
to O
affect O
paroxetine O
kinetics O
. O

The O
effects O
of O
paroxetine O
on O
diazepam O
were O
not O
evaluated O
. O

Procyclidine O
: O
Daily O
oral O
dosing O
of O
PAXIL O
( O
30 O
mg O
once O
daily O
) O
increased O
steady-state O
AUC0-24 O
, O
Cmax O
, O
and O
Cminvalues O
of O
procyclidine O
( O
5 O
mg O
oral O
once O
daily O
) O
by O
35 O
% O
, O
37 O
% O
, O
and O
67 O
% O
, O
respectively O
, O
compared O
to O
procyclidine O
alone O
at O
steady O
state O
. O

If O
anticholinergic O
effects O
are O
seen O
, O
the O
dose O
of O
procyclidine O
should O
be O
reduced O
. O

Beta-Blockers O
: O
In O
a O
study O
where O
propranolol O
( O
80 O
mg O
twice O
daily O
) O
was O
dosed O
orally O
for O
18 O
days O
, O
the O
established O
steady-state O
plasma O
concentrations O
of O
propranolol O
were O
unaltered O
during O
coadministration O
with O
PAXIL O
( O
30 O
mg O
once O
daily O
) O
for O
the O
final O
10 O
days O
. O

The O
effects O
of O
propranolol O
on O
paroxetine O
have O
not O
been O
evaluated O
( O
see O
ADVERSE O
REACTIONS O
: O
Postmarketing O
Reports O
) O
. O

Theophylline O
: O
Reports O
of O
elevated O
theophylline O
levels O
associated O
with O
treatment O
with O
PAXIL O
have O
been O
reported O
. O

While O
this O
interaction O
has O
not O
been O
formally O
studied O
, O
it O
is O
recommended O
that O
theophylline O
levels O
be O
monitored O
when O
these O
drugs O
are O
concurrently O
administered O
. O

Fosamprenavir/Ritonavir O
: O
Co-administration O
of O
fosamprenavir/ritonavir O
with O
paroxetine O
significantly O
decreased O
plasma O
levels O
of O
paroxetine O
. O

Any O
dose O
adjustment O
should O
be O
guided O
by O
clinical O
effect O
( O
tolerability O
and O
efficacy O
) O
. O

Electroconvulsive O
Therapy O
( O
ECT O
) O
: O
There O
are O
no O
clinical O
studies O
of O
the O
combined O
use O
of O
ECT O
and O
PAXIL O
. O

Carcinogenesis O
, O
Mutagenesis O
, O
Impairment O
of O
Fertility O
: O
Carcinogenesis O
: O
Two-year O
carcinogenicity O
studies O
were O
conducted O
in O
rodents O
given O
paroxetine O
in O
the O
diet O
at O
1 O
, O
5 O
, O
and O
25 O
mg/kg/day O
( O
mice O
) O
and O
1 O
, O
5 O
, O
and O
20 O
mg/kg/day O
( O
rats O
) O
. O

These O
doses O
are O
up O
to O
2.4 O
( O
mouse O
) O
and O
3.9 O
( O
rat O
) O
times O
the O
MRHD O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
social B-Not_AE_Candidate
anxiety I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
GAD B-Not_AE_Candidate
, O
and O
PTSD B-Not_AE_Candidate
on O
a O
mg/m O
2 O
basis O
. O

Because O
the O
MRHD O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
is O
slightly O
less O
than O
that O
for O
OCD B-Not_AE_Candidate
( O
50 O
mg O
versus O
60 O
mg O
) O
, O
the O
doses O
used O
in O
these O
carcinogenicity O
studies O
were O
only O
2.0 O
( O
mouse O
) O
and O
3.2 O
( O
rat O
) O
times O
the O
MRHD O
for O
OCD B-Not_AE_Candidate
. O

There O
was O
a O
significantly O
greater O
number O
of O
male O
rats O
in O
the O
high-dose O
group O
with O
reticulum B-NonOSE_AE
cell I-NonOSE_AE
sarcomas I-NonOSE_AE
( O
1/100 O
, O
0/50 O
, O
0/50 O
, O
and O
4/50 O
for O
control O
, O
low- O
, O
middle- O
, O
and O
high-dose O
groups O
, O
respectively O
) O
and O
a O
significantly O
increased O
linear O
trend O
across O
dose O
groups O
for O
the O
occurrence O
of O
lymphoreticular B-NonOSE_AE
tumors I-NonOSE_AE
in O
male O
rats O
. O

Female O
rats O
were O
not O
affected O
. O

Although O
there O
was O
a O
dose-related O
increase O
in O
the O
number O
of O
tumors B-NonOSE_AE
in O
mice O
, O
there O
was O
no O
drug-related O
increase O
in O
the O
number O
of O
mice O
with O
tumors B-NonOSE_AE
. O

The O
relevance O
of O
these O
findings O
to O
humans O
is O
unknown O
. O

Mutagenesis O
: O
Paroxetine O
produced O
no O
genotoxic B-NonOSE_AE
effects I-NonOSE_AE
in O
a O
battery O
of O
5 O
in O
vitro O
and O
2 O
in O
vivo O
assays O
that O
included O
the O
following O
: O
Bacterial O
mutation O
assay O
, O
mouse O
lymphoma B-NonOSE_AE
mutation O
assay O
, O
unscheduled O
DNA O
synthesis O
assay O
, O
and O
tests O
for O
cytogenetic B-NonOSE_AE
aberrations I-NonOSE_AE
in O
vivo O
in O
mouse O
bone O
marrow O
and O
in O
vitro O
in O
human O
lymphocytes O
and O
in O
a O
dominant O
lethal O
test O
in O
rats O
. O

Impairment O
of O
Fertility O
: O
Some O
clinical O
studies O
have O
shown O
that O
SSRIs O
( O
including O
paroxetine O
) O
may O
affect B-OSE_Labeled_AE
sperm I-OSE_Labeled_AE
quality I-OSE_Labeled_AE
during O
SSRI O
treatment O
, O
which O
may O
affect B-NonOSE_AE
fertility I-NonOSE_AE
in I-NonOSE_AE
some I-NonOSE_AE
men I-NonOSE_AE
. O

A O
reduced O
pregnancy B-NonOSE_AE
rate O
was O
found O
in O
reproduction O
studies O
in O
rats O
at O
a O
dose O
of O
paroxetine O
of O
15 O
mg/kg/day O
, O
which O
is O
2.9 O
times O
the O
MRHD O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
social B-Not_AE_Candidate
anxiety I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
GAD B-Not_AE_Candidate
, O
and O
PTSD B-Not_AE_Candidate
or O
2.4 O
times O
the O
MRHD O
for O
OCD B-Not_AE_Candidate
on O
a O
mg/m O
2 O
basis O
. O

Irreversible B-NonOSE_AE
lesions I-NonOSE_AE
occurred I-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
reproductive I-NonOSE_AE
tract I-NonOSE_AE
of O
male O
rats O
after O
dosing O
in O
toxicity O
studies O
for O
2 O
to O
52 O
weeks O
. O

These O
lesions O
consisted O
of O
vacuolation B-NonOSE_AE
of I-NonOSE_AE
epididymal I-NonOSE_AE
tubular I-NonOSE_AE
epithelium I-NonOSE_AE
at O
50 O
mg/kg/day O
and O
atrophic B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
seminiferous I-NonOSE_AE
tubules I-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
testes I-NonOSE_AE
with O
arrested B-NonOSE_AE
spermatogenesis I-NonOSE_AE
at O
25 O
mg/kg/day O
( O
9.8 O
and O
4.9 O
times O
the O
MRHD O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
social B-Not_AE_Candidate
anxiety I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
and O
GAD B-Not_AE_Candidate
; O
8.2 O
and O
4.1 O
times O
the O
MRHD O
for O
OCD B-Not_AE_Candidate
and O
PD O
on O
a O
mg/m O
2 O
basis O
) O
. O

Pregnancy O
: O
Pregnancy B-NonOSE_AE
Category O
D O
. O
See O
WARNINGS O
: O
Usage O
in O
Pregnancy B-NonOSE_AE
: O
Teratogenic B-NonOSE_AE
Effects I-NonOSE_AE
and O
Nonteratogenic B-NonOSE_AE
Effects I-NonOSE_AE
. O

Labor O
and O
Delivery O
: O
The O
effect O
of O
paroxetine O
on O
labor O
and O
delivery O
in O
humans O
is O
unknown O
. O

Nursing O
Mothers O
: O
Like O
many O
other O
drugs O
, O
paroxetine O
is O
secreted O
in O
human O
milk O
, O
and O
caution O
should O
be O
exercised O
when O
PAXIL O
is O
administered O
to O
a O
nursing O
woman O
. O

Pediatric O
Use O
: O
Safety O
and O
effectiveness O
in O
the O
pediatric O
population O
have O
not O
been O
established O
( O
see O
BOX O
WARNING O
and O
WARNINGS O
: O
Clinical O
Worsening O
and O
Suicide O
Risk O
) O
. O

Three O
placebo-controlled O
trials O
in O
752 O
pediatric O
patients O
with O
MDD B-Not_AE_Candidate
have O
been O
conducted O
with O
PAXIL O
, O
and O
the O
data O
were O
not O
sufficient O
to O
support O
a O
claim O
for O
use O
in O
pediatric O
patients O
. O

Anyone O
considering O
the O
use O
of O
PAXIL O
in O
a O
child O
or O
adolescent O
must O
balance O
the O
potential O
risks O
with O
the O
clinical O
need O
. O

Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
and O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
have O
been O
observed O
in O
association O
with O
the O
use O
of O
SSRIs O
. O

Consequently O
, O
regular O
monitoring O
of O
weight O
and O
growth O
should O
be O
performed O
in O
children O
and O
adolescents O
treated O
with O
an O
SSRI O
such O
as O
PAXIL O
. O

In O
placebo-controlled O
clinical O
trials O
conducted O
with O
pediatric O
patients O
, O
the O
following O
adverse O
events O
were O
reported O
in O
at O
least O
2 O
% O
of O
pediatric O
patients O
treated O
with O
PAXIL O
and O
occurred O
at O
a O
rate O
at O
least O
twice O
that O
for O
pediatric O
patients O
receiving O
placebo O
: O
emotional B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
( O
including O
self B-OSE_Labeled_AE
- I-OSE_Labeled_AE
harm I-OSE_Labeled_AE
, O
suicidal B-OSE_Labeled_AE
thoughts I-OSE_Labeled_AE
, O
attempted B-OSE_Labeled_AE
suicide I-OSE_Labeled_AE
, O
crying B-OSE_Labeled_AE
, O
and O
mood B-OSE_Labeled_AE
fluctuations I-OSE_Labeled_AE
) O
, O
hostility B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
, O
hyperkinesia B-OSE_Labeled_AE
, O
and O
agitation B-OSE_Labeled_AE
. O

Events B-OSE_Labeled_AE
reported I-OSE_Labeled_AE
upon I-OSE_Labeled_AE
discontinuation I-OSE_Labeled_AE
of I-OSE_Labeled_AE
treatment I-OSE_Labeled_AE
with O
PAXIL O
in O
the O
pediatric O
clinical O
trials O
that O
included O
a O
taper O
phase O
regimen O
, O
which O
occurred O
in O
at O
least O
2 O
% O
of O
patients O
who O
received O
PAXIL O
and O
which O
occurred O
at O
a O
rate O
at O
least O
twice O
that O
of O
placebo O
, O
were O
: O
emotional B-NonOSE_AE
lability I-NonOSE_AE
( O
including O
suicidal B-NonOSE_AE
ideation I-NonOSE_AE
, O
suicide B-NonOSE_AE
attempt I-NonOSE_AE
, O
mood B-NonOSE_AE
changes I-NonOSE_AE
, O
and O
tearfulness B-NonOSE_AE
) O
, O
nervousness B-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
nausea B-NonOSE_AE
, O
and O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
( O
see O
DOSAGE O
AND O
ADMINISTRATION O
: O
Discontinuation O
of O
Treatment O
With O
PAXIL O
) O
. O

Geriatric O
Use O
: O
SSRIs O
and O
SNRIs O
, O
including O
PAXIL O
, O
have O
been O
associated O
with O
cases O
of O
clinically O
significant O
hyponatremia B-OSE_Labeled_AE
in O
elderly O
patients O
, O
who O
may O
be O
at O
greater O
risk O
for O
this O
adverse O
event O
( O
see O
PRECAUTIONS O
: O
Hyponatremia B-NonOSE_AE
) O
. O

In O
worldwide O
premarketing O
clinical O
trials O
with O
PAXIL O
, O
17 O
% O
of O
patients O
treated O
with O
PAXIL O
( O
approximately O
700 O
) O
were O
65 O
years O
of O
age O
or O
older O
. O

Pharmacokinetic O
studies O
revealed O
a O
decreased O
clearance O
in O
the O
elderly O
, O
and O
a O
lower O
starting O
dose O
is O
recommended O
; O
there O
were O
, O
however O
, O
no O
overall O
differences O
in O
the O
adverse O
event O
profile O
between O
elderly O
and O
younger O
patients O
, O
and O
effectiveness O
was O
similar O
in O
younger O
and O
older O
patients O
( O
see O
CLINICAL O
PHARMACOLOGY O
and O
DOSAGE O
AND O
ADMINISTRATION O
) O
. O

WARNINGS O
Clinical O
Worsening O
and O
Suicide O
Risk O
: O
Patients O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
, O
both O
adult O
and O
pediatric O
, O
may O
experience O
worsening O
of O
their O
depression B-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
ideation I-NonOSE_AE
and O
behavior O
( O
suicidality B-NonOSE_AE
) O
or O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
whether O
or O
not O
they O
are O
taking O
antidepressant O
medications O
, O
and O
this O
risk O
may O
persist O
until O
significant O
remission O
occurs O
. O

Suicide B-NonOSE_AE
is O
a O
known O
risk O
of O
depression B-Not_AE_Candidate
and O
certain O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
, O
and O
these O
disorders O
themselves O
are O
the O
strongest O
predictors O
of O
suicide B-NonOSE_AE
. O

There O
has O
been O
a O
long-standing O
concern O
, O
however O
, O
that O
antidepressants O
may O
have O
a O
role O
in O
inducing O
worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
depression I-OSE_Labeled_AE
and O
the O
emergence O
of O
suicidality B-OSE_Labeled_AE
in O
certain O
patients O
during O
the O
early O
phases O
of O
treatment O
. O

Pooled O
analyses O
of O
short-term O
placebo-controlled O
trials O
of O
antidepressant O
drugs O
( O
SSRIs O
and O
others O
) O
showed O
that O
these O
drugs O
increase O
the O
risk O
of O
suicidal B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
and O
behavior O
( O
suicidality B-OSE_Labeled_AE
) O
in O
children O
, O
adolescents O
, O
and O
young O
adults O
( O
ages O
18-24 O
) O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
and O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Short-term O
studies O
did O
not O
show O
an O
increase O
in O
the O
risk O
of O
suicidality B-NonOSE_AE
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
beyond O
age O
24 O
; O
there O
was O
a O
reduction O
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
aged O
65 O
and O
older O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
trials O
in O
children O
and O
adolescents O
with O
MDD B-Not_AE_Candidate
, O
obsessive B-Not_AE_Candidate
compulsive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
OCD I-Not_AE_Candidate
) O
, O
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
24 O
short-term O
trials O
of O
9 O
antidepressant O
drugs O
in O
over O
4,400 O
patients O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
trials O
in O
adults O
with O
MDD B-Not_AE_Candidate
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
295 O
short-term O
trials O
( O
median O
duration O
of O
2 O
months O
) O
of O
11 O
antidepressant O
drugs O
in O
over O
77,000 O
patients O
. O

There O
was O
considerable O
variation O
in O
risk O
of O
suicidality B-OSE_Labeled_AE
among O
drugs O
, O
but O
a O
tendency O
toward O
an O
increase O
in O
the O
younger O
patients O
for O
almost O
all O
drugs O
studied O
. O

There O
were O
differences O
in O
absolute O
risk O
of O
suicidality B-NonOSE_AE
across O
the O
different O
indications O
, O
with O
the O
highest O
incidence O
in O
MDD B-Not_AE_Candidate
. O

The O
risk O
differences O
( O
drug O
vs O
placebo O
) O
, O
however O
, O
were O
relatively O
stable O
within O
age O
strata O
and O
across O
indications O
. O

These O
risk O
differences O
( O
drug-placebo O
difference O
in O
the O
number O
of O
cases O
of O
suicidality B-NonOSE_AE
per O
1,000 O
patients O
treated O
) O
are O
provided O
in O
Table O
1 O
. O

Table O
1 O
Age O
Range O
Drug-Placebo O
Difference O
in O
Number O
of O
Cases O
of O
Suicidality B-OSE_Labeled_AE
per O
1,000 O
Patients O
Treated O
Increases O
Compared O
to O
Placebo O
< O
18 O
14 O
additional O
cases O
18-24 O
5 O
additional O
cases O
Decreases O
Compared O
to O
Placebo O
25-64 O
1 O
fewer O
case O
> O
=65 O
6 O
fewer O
cases O
No O
suicides B-NonOSE_AE
occurred O
in O
any O
of O
the O
pediatric O
trials O
. O

There O
were O
suicides B-NonOSE_AE
in O
the O
adult O
trials O
, O
but O
the O
number O
was O
not O
sufficient O
to O
reach O
any O
conclusion O
about O
drug O
effect O
on O
suicide B-NonOSE_AE
. O

It O
is O
unknown O
whether O
the O
suicidality B-NonOSE_AE
risk O
extends O
to O
longer-term O
use O
, O
i.e. O
, O
beyond O
several O
months O
. O

However O
, O
there O
is O
substantial O
evidence O
from O
placebo-controlled O
maintenance O
trials O
in O
adults O
with O
depression B-Not_AE_Candidate
that O
the O
use O
of O
antidepressants O
can O
delay O
the O
recurrence O
of O
depression B-NonOSE_AE
. O

All O
patients O
being O
treated O
with O
antidepressants O
for O
any O
indication O
should O
be O
monitored O
appropriately O
and O
observed O
closely O
for O
clinical O
worsening O
, O
suicidality B-NonOSE_AE
, O
and O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
especially O
during O
the O
initial O
few O
months O
of O
a O
course O
of O
drug O
therapy O
, O
or O
at O
times O
of O
dose O
changes O
, O
either O
increases O
or O
decreases O
. O

The O
following O
symptoms O
, O
anxiety B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
panic B-OSE_Labeled_AE
attacks I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
hostility B-OSE_Labeled_AE
, O
aggressiveness B-OSE_Labeled_AE
, O
impulsivity B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
( O
psychomotor B-OSE_Labeled_AE
restlessness I-OSE_Labeled_AE
) O
, O
hypomania B-OSE_Labeled_AE
, O
and O
mania B-OSE_Labeled_AE
, O
have O
been O
reported O
in O
adult O
and O
pediatric O
patients O
being O
treated O
with O
antidepressants O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
as O
well O
as O
for O
other O
indications O
, O
both O
psychiatric O
and O
nonpsychiatric O
. O

Although O
a O
causal O
link O
between O
the O
emergence O
of O
such O
symptoms O
and O
either O
the O
worsening B-NonOSE_AE
of I-NonOSE_AE
depression I-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
impulses I-NonOSE_AE
has O
not O
been O
established O
, O
there O
is O
concern O
that O
such O
symptoms O
may O
represent O
precursors O
to O
emerging O
suicidality B-NonOSE_AE
. O

Consideration O
should O
be O
given O
to O
changing O
the O
therapeutic O
regimen O
, O
including O
possibly O
discontinuing O
the O
medication O
, O
in O
patients O
whose O
depression B-Not_AE_Candidate
is O
persistently O
worse O
, O
or O
who O
are O
experiencing O
emergent O
suicidality B-NonOSE_AE
or O
symptoms O
that O
might O
be O
precursors O
to O
worsening O
depression B-NonOSE_AE
or O
suicidality B-NonOSE_AE
, O
especially O
if O
these O
symptoms O
are O
severe O
, O
abrupt O
in O
onset O
, O
or O
were O
not O
part O
of O
the O
patient O
's O
presenting O
symptoms O
. O

If O
the O
decision O
has O
been O
made O
to O
discontinue O
treatment O
, O
medication O
should O
be O
tapered O
, O
as O
rapidly O
as O
is O
feasible O
, O
but O
with O
recognition O
that O
abrupt O
discontinuation O
can O
be O
associated O
with O
certain O
symptoms O
( O
see O
PRECAUTIONS O
and O
DOSAGE O
AND O
ADMINISTRATION O
: O
Discontinuation O
of O
Treatment O
With O
PAXIL O
, O
for O
a O
description O
of O
the O
risks O
of O
discontinuation O
of O
PAXIL O
) O
. O

Families O
and O
caregivers O
of O
patients O
being O
treated O
with O
antidepressants O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
or O
other O
indications O
, O
both O
psychiatric O
and O
nonpsychiatric O
, O
should O
be O
alerted O
about O
the O
need O
to O
monitor O
patients O
for O
the O
emergence O
of O
agitation B-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
and O
the O
other O
symptoms O
described O
above O
, O
as O
well O
as O
the O
emergence O
of O
suicidality B-NonOSE_AE
, O
and O
to O
report O
such O
symptoms O
immediately O
to O
healthcare O
providers O
. O

Such O
monitoring O
should O
include O
daily O
observation O
by O
families O
and O
caregivers O
. O

Prescriptions O
for O
PAXIL O
should O
be O
written O
for O
the O
smallest O
quantity O
of O
tablets O
consistent O
with O
good O
patient O
management O
, O
in O
order O
to O
reduce O
the O
risk O
of O
overdose B-NonOSE_AE
. O

Screening O
Patients O
for O
Bipolar O
Disorder O
: O
A O
major B-NonOSE_AE
depressive I-NonOSE_AE
episode I-NonOSE_AE
may O
be O
the O
initial O
presentation O
of O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

It O
is O
generally O
believed O
( O
though O
not O
established O
in O
controlled O
trials O
) O
that O
treating O
such O
an O
episode O
with O
an O
antidepressant O
alone O
may O
increase O
the O
likelihood O
of O
precipitation B-NonOSE_AE
of I-NonOSE_AE
a I-NonOSE_AE
mixed I-NonOSE_AE
/ I-NonOSE_AE
manic I-NonOSE_AE
episode I-NonOSE_AE
in O
patients O
at O
risk O
for O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

Whether O
any O
of O
the O
symptoms O
described O
above O
represent O
such O
a O
conversion O
is O
unknown O
. O

However O
, O
prior O
to O
initiating O
treatment O
with O
an O
antidepressant O
, O
patients O
with O
depressive B-Not_AE_Candidate
symptoms I-Not_AE_Candidate
should O
be O
adequately O
screened O
to O
determine O
if O
they O
are O
at O
risk O
for O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
; O
such O
screening O
should O
include O
a O
detailed O
psychiatric B-Not_AE_Candidate
history O
, O
including O
a O
family B-Not_AE_Candidate
history I-Not_AE_Candidate
of I-Not_AE_Candidate
suicide I-Not_AE_Candidate
, O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
and O
depression B-Not_AE_Candidate
. O

It O
should O
be O
noted O
that O
PAXIL O
is O
not O
approved O
for O
use O
in O
treating O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
. O

Serotonin O
Syndrome O
: O
The O
development O
of O
a O
potentially O
life-threatening O
serotonin B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
has O
been O
reported O
with O
SNRIs O
and O
SSRIs O
, O
including O
PAXIL O
, O
alone O
but O
particularly O
with O
concomitant O
use O
of O
other O
serotonergic O
drugs O
( O
including O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
tryptophan O
, O
buspirone O
, O
amphetamines O
, O
and O
St O
. O
John O
's O
Wort O
) O
and O
with O
drugs O
that O
impair O
metabolism O
of O
serotonin O
( O
in O
particular O
, O
MAOIs O
, O
both O
those O
intended O
to O
treat O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
and O
also O
others O
, O
such O
as O
linezolid O
and O
intravenous O
methylene O
blue O
) O
. O

Serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
symptoms O
may O
include O
mental B-NonOSE_AE
status I-NonOSE_AE
changes I-NonOSE_AE
( O
e.g. O
, O
agitation B-NonOSE_AE
, O
hallucinations B-NonOSE_AE
, O
delirium B-NonOSE_AE
, O
and O
coma B-NonOSE_AE
) O
, O
autonomic B-NonOSE_AE
instability I-NonOSE_AE
( O
e.g. O
, O
tachycardia B-NonOSE_AE
, O
labile B-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
diaphoresis B-NonOSE_AE
, O
flushing B-NonOSE_AE
, O
hyperthermia B-NonOSE_AE
) O
, O
neuromuscular B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
tremor B-NonOSE_AE
, O
rigidity B-NonOSE_AE
, O
myoclonus B-NonOSE_AE
, O
hyperreflexia B-NonOSE_AE
, O
incoordination B-NonOSE_AE
) O
, O
seizures B-NonOSE_AE
, O
and/or O
gastrointestinal B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
) O
. O

Patients O
should O
be O
monitored O
for O
the O
emergence O
of O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
. O

The O
concomitant O
use O
of O
PAXIL O
with O
MAOIs O
intended O
to O
treat O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
is O
contraindicated O
. O

PAXIL O
should O
also O
not O
be O
started O
in O
a O
patient O
who O
is O
being O
treated O
with O
MAOIs O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
. O

All O
reports O
with O
methylene O
blue O
that O
provided O
information O
on O
the O
route O
of O
administration O
involved O
intravenous O
administration O
in O
the O
dose O
range O
of O
1 O
mg/kg O
to O
8 O
mg/kg O
. O

No O
reports O
involved O
the O
administration O
of O
methylene O
blue O
by O
other O
routes O
( O
such O
as O
oral O
tablets O
or O
local O
tissue O
injection O
) O
or O
at O
lower O
doses O
. O

There O
may O
be O
circumstances O
when O
it O
is O
necessary O
to O
initiate O
treatment O
with O
an O
MAOI O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
in O
a O
patient O
taking O
PAXIL O
. O

PAXIL O
should O
be O
discontinued O
before O
initiating O
treatment O
with O
the O
MAOI O
( O
see O
CONTRAINDICATIONS O
and O
DOSAGE O
AND O
ADMINISTRATION O
) O
. O

If O
concomitant O
use O
of O
PAXIL O
with O
certain O
other O
serotonergic O
drugs O
, O
i.e. O
, O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
buspirone O
, O
tryptophan O
, O
amphetamines O
, O
and O
St O
. O
John O
's O
Wort O
is O
clinically O
warranted O
, O
be O
aware O
of O
a O
potential O
increased O
risk O
for O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
, O
particularly O
during O
treatment O
initiation O
and O
dose O
increases O
. O

Treatment O
with O
PAXIL O
and O
any O
concomitant O
serotonergic O
agents O
should O
be O
discontinued O
immediately O
if O
the O
above O
events O
occur O
and O
supportive O
symptomatic O
treatment O
should O
be O
initiated O
. O

Angle-Closure O
Glaucoma O
: O
The O
pupillary B-OSE_Labeled_AE
dilation I-OSE_Labeled_AE
that O
occurs O
following O
use O
of O
many O
antidepressant O
drugs O
including O
Paxil O
may O
trigger O
an O
angle B-OSE_Labeled_AE
closure I-OSE_Labeled_AE
attack I-OSE_Labeled_AE
in O
a O
patient O
with O
anatomically B-Not_AE_Candidate
narrow I-Not_AE_Candidate
angles I-Not_AE_Candidate
who O
does O
not O
have O
a O
patent O
iridectomy O
. O

Potential O
Interaction O
With O
Thioridazine O
: O
Thioridazine O
administration O
alone O
produces O
prolongation B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
QTc I-NonOSE_AE
interval I-NonOSE_AE
, O
which O
is O
associated O
with O
serious O
ventricular B-NonOSE_AE
arrhythmias I-NonOSE_AE
, O
such O
as O
torsade B-NonOSE_AE
de I-NonOSE_AE
pointes I-NonOSE_AE
- O
type O
arrhythmias B-NonOSE_AE
, O
and O
sudden B-NonOSE_AE
death I-NonOSE_AE
. O

This O
effect O
appears O
to O
be O
dose O
related O
. O

An O
in O
vivo O
study O
suggests O
that O
drugs O
which O
inhibit O
CYP2D6 O
, O
such O
as O
paroxetine O
, O
will O
elevate O
plasma O
levels O
of O
thioridazine O
. O

Therefore O
, O
it O
is O
recommended O
that O
paroxetine O
not O
be O
used O
in O
combination O
with O
thioridazine O
( O
see O
CONTRAINDICATIONS O
and O
PRECAUTIONS O
) O
. O

Usage O
in O
Pregnancy O
: O
Teratogenic B-OSE_Labeled_AE
Effects I-OSE_Labeled_AE
: O
Epidemiological O
studies O
have O
shown O
that O
infants B-OSE_Labeled_AE
exposed I-OSE_Labeled_AE
to I-OSE_Labeled_AE
paroxetine I-OSE_Labeled_AE
in I-OSE_Labeled_AE
the I-OSE_Labeled_AE
first I-OSE_Labeled_AE
trimester I-OSE_Labeled_AE
of I-OSE_Labeled_AE
pregnancy I-OSE_Labeled_AE
have O
an O
increased O
risk O
of O
congenital B-OSE_Labeled_AE
malformations I-OSE_Labeled_AE
, O
particularly O
cardiovascular O
malformations O
. O

The O
findings O
from O
these O
studies O
are O
summarized O
below O
: O
* O
A O
study O
based O
on O
Swedish O
national O
registry O
data O
demonstrated O
that O
infants B-OSE_Labeled_AE
exposed I-OSE_Labeled_AE
to I-OSE_Labeled_AE
paroxetine I-OSE_Labeled_AE
during I-OSE_Labeled_AE
pregnancy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
n I-OSE_Labeled_AE
= I-OSE_Labeled_AE
8 I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
) I-OSE_Labeled_AE
had I-OSE_Labeled_AE
an I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
risk I-OSE_Labeled_AE
of I-OSE_Labeled_AE
cardiovascular I-OSE_Labeled_AE
malformations I-OSE_Labeled_AE
( O
2 O
% O
risk O
in O
paroxetine-exposed O
infants O
) O
compared O
to O
the O
entire O
registry O
population O
( O
1 O
% O
risk O
) O
, O
for O
an O
odds O
ratio O
( O
OR O
) O
of O
1.8 O
( O
95 O
% O
confidence O
interval O
1.1 O
to O
2.8 O
) O
. O

No O
increase O
in O
the O
risk O
of O
overall B-NonOSE_AE
congenital I-NonOSE_AE
malformations I-NonOSE_AE
was O
seen O
in O
the O
paroxetine-exposed O
infants O
. O

The O
cardiac B-OSE_Labeled_AE
malformations I-OSE_Labeled_AE
in I-OSE_Labeled_AE
the I-OSE_Labeled_AE
paroxetine I-OSE_Labeled_AE
- I-OSE_Labeled_AE
exposed I-OSE_Labeled_AE
infants I-OSE_Labeled_AE
were O
primarily O
ventricular B-OSE_Labeled_AE
septal I-OSE_Labeled_AE
defects I-OSE_Labeled_AE
( I-OSE_Labeled_AE
VSDs I-OSE_Labeled_AE
) O
and O
atrial B-OSE_Labeled_AE
septal I-OSE_Labeled_AE
defects I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ASDs I-OSE_Labeled_AE
) O
. O

Septal B-NonOSE_AE
defects I-NonOSE_AE
range O
in O
severity O
from O
those O
that O
resolve O
spontaneously O
to O
those O
which O
require O
surgery O
. O

* O
A O
separate O
retrospective O
cohort O
study O
from O
the O
United O
States O
( O
United O
Healthcare O
data O
) O
evaluated O
5,956 O
infants O
of O
mothers O
dispensed O
antidepressants O
during O
the O
first O
trimester O
( O
n O
= O
815 O
for O
paroxetine O
) O
. O

This O
study O
showed O
a O
trend O
towards O
an O
increased O
risk O
for O
cardiovascular B-OSE_Labeled_AE
malformations I-OSE_Labeled_AE
for O
paroxetine O
( O
risk O
of O
1.5 O
% O
) O
compared O
to O
other O
antidepressants O
( O
risk O
of O
1 O
% O
) O
, O
for O
an O
OR O
of O
1.5 O
( O
95 O
% O
confidence O
interval O
0.8 O
to O
2.9 O
) O
. O

Of O
the O
12 O
paroxetine B-OSE_Labeled_AE
- I-OSE_Labeled_AE
exposed I-OSE_Labeled_AE
infants I-OSE_Labeled_AE
with I-OSE_Labeled_AE
cardiovascular I-OSE_Labeled_AE
malformations I-OSE_Labeled_AE
, O
9 O
had O
VSDs B-OSE_Labeled_AE
. O

This O
study O
also O
suggested O
an O
increased O
risk O
of O
overall O
major O
congenital B-OSE_Labeled_AE
malformations I-OSE_Labeled_AE
including O
cardiovascular O
defects O
for O
paroxetine O
( O
4 O
% O
risk O
) O
compared O
to O
other O
( O
2 O
% O
risk O
) O
antidepressants O
( O
OR O
1.8 O
; O
95 O
% O
confidence O
interval O
1.2 O
to O
2.8 O
) O
. O

* O
Two O
large O
case-control O
studies O
using O
separate O
databases O
, O
each O
with O
> O
9,000 O
birth B-NonOSE_AE
defect I-NonOSE_AE
cases O
and O
> O
4,000 O
controls O
, O
found O
that O
maternal O
use O
of O
paroxetine O
during O
the O
first O
trimester O
of O
pregnancy O
was O
associated O
with O
a O
2- O
to O
3-fold O
increased O
risk O
of O
right B-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
outflow I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
obstructions I-OSE_Labeled_AE
. O

In O
one O
study O
the O
odds O
ratio O
was O
2.5 O
( O
95 O
% O
confidence O
interval O
, O
1.0 O
to O
6.0 O
, O
7 O
exposed O
infants O
) O
and O
in O
the O
other O
study O
the O
odds O
ratio O
was O
3.3 O
( O
95 O
% O
confidence O
interval O
, O
1.3 O
to O
8.8 O
, O
6 O
exposed O
infants O
) O
. O

Other O
studies O
have O
found O
varying O
results O
as O
to O
whether O
there O
was O
an O
increased O
risk O
of O
overall O
, O
cardiovascular B-NonOSE_AE
, O
or O
specific O
congenital I-NonOSE_AE
malformations I-NonOSE_AE
. O

A O
meta-analysis O
of O
epidemiological O
data O
over O
a O
16-year O
period O
( O
1992 O
to O
2008 O
) O
on O
first O
trimester O
paroxetine O
use O
in O
pregnancy B-Not_AE_Candidate
and O
congenital B-NonOSE_AE
malformations I-NonOSE_AE
included O
the O
above-noted O
studies O
in O
addition O
to O
others O
( O
n O
= O
17 O
studies O
that O
included O
overall O
malformations B-NonOSE_AE
and O
n O
= O
14 O
studies O
that O
included O
cardiovascular B-NonOSE_AE
malformations I-NonOSE_AE
; O
n O
= O
20 O
distinct O
studies O
) O
. O

While O
subject O
to O
limitations O
, O
this O
meta-analysis O
suggested O
an O
increased O
occurrence O
of O
cardiovascular B-OSE_Labeled_AE
malformations I-OSE_Labeled_AE
( O
prevalence O
odds O
ratio O
[ O
POR O
] O
1.5 O
; O
95 O
% O
confidence O
interval O
1.2 O
to O
1.9 O
) O
and O
overall O
malformations B-OSE_Labeled_AE
( O
POR O
1.2 O
; O
95 O
% O
confidence O
interval O
1.1 O
to O
1.4 O
) O
with O
paroxetine O
use O
during O
the O
first O
trimester O
. O

It O
was O
not O
possible O
in O
this O
meta-analysis O
to O
determine O
the O
extent O
to O
which O
the O
observed O
prevalence O
of O
cardiovascular B-NonOSE_AE
malformations I-NonOSE_AE
might O
have O
contributed O
to O
that O
of O
overall O
malformations B-NonOSE_AE
, O
nor O
was O
it O
possible O
to O
determine O
whether O
any O
specific O
types O
of O
cardiovascular B-NonOSE_AE
malformations I-NonOSE_AE
might O
have O
contributed O
to O
the O
observed O
prevalence O
of O
all O
cardiovascular B-NonOSE_AE
malformations I-NonOSE_AE
. O

If O
a O
patient O
becomes O
pregnant B-NonOSE_AE
while O
taking O
paroxetine O
, O
she O
should O
be O
advised O
of O
the O
potential O
harm B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

Unless O
the O
benefits O
of O
paroxetine O
to O
the O
mother O
justify O
continuing O
treatment O
, O
consideration O
should O
be O
given O
to O
either O
discontinuing O
paroxetine O
therapy O
or O
switching O
to O
another O
antidepressant O
( O
see O
PRECAUTIONS O
: O
Discontinuation O
of O
Treatment O
With O
PAXIL O
) O
. O

For O
women O
who O
intend O
to O
become O
pregnant B-NonOSE_AE
or O
are O
in O
their O
first O
trimester O
of O
pregnancy B-Not_AE_Candidate
, O
paroxetine O
should O
only O
be O
initiated O
after O
consideration O
of O
the O
other O
available O
treatment O
options O
. O

Animal O
Findings O
: O
Reproduction O
studies O
were O
performed O
at O
doses O
up O
to O
50 O
mg/kg/day O
in O
rats O
and O
6 O
mg/kg/day O
in O
rabbits O
administered O
during O
organogenesis O
. O

These O
doses O
are O
approximately O
8 O
( O
rat O
) O
and O
2 O
( O
rabbit O
) O
times O
the O
maximum O
recommended O
human O
dose O
( O
MRHD O
) O
on O
an O
mg/m O
2 O
basis O
. O

These O
studies O
have O
revealed O
no O
evidence O
of O
teratogenic B-NonOSE_AE
effects I-NonOSE_AE
. O

However O
, O
in O
rats O
, O
there O
was O
an O
increase O
in O
pup O
deaths O
during O
the O
first O
4 O
days O
of O
lactation O
when O
dosing O
occurred O
during O
the O
last O
trimester O
of O
gestation O
and O
continued O
throughout O
lactation O
. O

This O
effect O
occurred O
at O
a O
dose O
of O
1 O
mg/kg/day O
or O
approximately O
one-sixth O
of O
the O
MRHD O
on O
an O
mg/m O
2 O
basis O
. O

The O
no-effect O
dose O
for O
rat O
pup O
mortality O
was O
not O
determined O
. O

The O
cause O
of O
these O
deaths B-NonOSE_AE
is O
not O
known O
. O

Nonteratogenic O
Effects O
: O
Neonates B-OSE_Labeled_AE
exposed O
to O
PAXIL O
and O
other O
SSRIs O
or O
serotonin O
and O
norepinephrine O
reuptake O
inhibitors O
( O
SNRIs O
) O
, O
late O
in O
the O
third O
trimester O
have O
developed O
complications O
requiring O
prolonged O
hospitalization O
, O
respiratory I-OSE_Labeled_AE
support O
, O
and O
tube O
feeding O
. O

Such O
complications O
can O
arise O
immediately O
upon O
delivery O
. O

Reported O
clinical O
findings O
have O
included O
respiratory O
distress I-OSE_Labeled_AE
, O
cyanosis O
, O
apnea O
, O
seizures O
, O
temperature O
instability O
, O
feeding O
difficulty O
, O
vomiting O
, O
hypoglycemia O
, O
hypotonia O
, O
hypertonia O
, O
hyperreflexia O
, O
tremor O
, O
jitteriness O
, O
irritability O
, O
and O
constant O
crying O
. O

These O
features O
are O
consistent O
with O
either O
a O
direct O
toxic O
effect O
of O
SSRIs O
and O
SNRIs O
or O
, O
possibly O
, O
a O
drug B-OSE_Labeled_AE
discontinuation I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
. O

It O
should O
be O
noted O
that O
, O
in O
some O
cases O
, O
the O
clinical O
picture O
is O
consistent O
with O
serotonin B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( O
see O
WARNINGS O
: O
Serotonin B-NonOSE_AE
Syndrome I-NonOSE_AE
) O
. O

Infants O
exposed O
to O
SSRIs O
in O
pregnancy O
may O
have O
an O
increased O
risk O
for O
persistent O
pulmonary B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
newborn I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PPHN I-OSE_Labeled_AE
) O
. O

PPHN B-OSE_Labeled_AE
occurs O
in O
1 O
- O
2 O
per O
1,000 O
live O
births O
in O
the O
general O
population O
and O
is O
associated O
with O
substantial O
neonatal O
morbidity O
and O
mortality B-NonOSE_AE
. O

Several O
recent O
epidemiologic O
studies O
suggest O
a O
positive O
statistical O
association O
between O
SSRI O
use O
( O
including O
PAXIL O
) O
in O
pregnancy B-Not_AE_Candidate
and O
PPHN B-OSE_Labeled_AE
. O

Other O
studies O
do O
not O
show O
a O
significant O
statistical O
association O
. O

Physicians O
should O
also O
note O
the O
results O
of O
a O
prospective O
longitudinal O
study O
of O
201 O
pregnant B-Not_AE_Candidate
women O
with O
a O
history O
of O
major B-Not_AE_Candidate
depression I-Not_AE_Candidate
, O
who O
were O
either O
on O
antidepressants O
or O
had O
received O
antidepressants O
less O
than O
12 O
weeks O
prior O
to O
their O
last O
menstrual O
period O
, O
and O
were O
in O
remission O
. O

Women O
who O
discontinued O
antidepressant O
medication O
during O
pregnancy B-Not_AE_Candidate
showed O
a O
significant O
increase O
in O
relapse O
of O
their O
major O
depression B-Not_AE_Candidate
compared O
to O
those O
women O
who O
remained O
on O
antidepressant O
medication O
throughout O
pregnancy B-Not_AE_Candidate
. O

When O
treating O
a O
pregnant B-Not_AE_Candidate
woman O
with O
PAXIL O
, O
the O
physician O
should O
carefully O
consider O
both O
the O
potential O
risks O
of O
taking O
an O
SSRI O
, O
along O
with O
the O
established O
benefits O
of O
treating O
depression B-Not_AE_Candidate
with O
an O
antidepressant O
. O

This O
decision O
can O
only O
be O
made O
on O
a O
case O
by O
case O
basis O
( O
see O
DOSAGE O
AND O
ADMINISTRATION O
and O
ADVERSE O
REACTIONS O
: O
Postmarketing O
Reports O
) O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Cardiovascular B-OSE_Labeled_AE
Thrombotic I-OSE_Labeled_AE
Events I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
GI B-OSE_Labeled_AE
Bleeding I-OSE_Labeled_AE
, O
Ulceration O
and O
Perforation O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Hepatotoxicity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Hypertension B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Heart B-OSE_Labeled_AE
Failure I-OSE_Labeled_AE
and O
Edema B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Renal B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
and O
Hyperkalemia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Anaphylactic B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Serious O
Skin B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Hematologic B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
with O
PENNSAID O
are O
application O
site O
reactions O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Horizon O
Pharma O
USA O
Inc O
. O
at O
1-866-479-6742 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
data O
described O
below O
reflect O
exposure O
to O
PENNSAID O
of O
130 O
patients O
treated O
for O
4 O
weeks O
( O
mean O
duration O
of O
28 O
days O
) O
in O
one O
Phase O
2 O
controlled O
trial O
. O

This O
population O
's O
mean O
age O
was O
approximately O
60 O
years O
, O
85 O
% O
of O
patients O
were O
Caucasian O
, O
65 O
% O
were O
females O
, O
and O
all O
patients O
had O
primary O
osteoarthritis B-Not_AE_Candidate
. O

The O
most O
common O
adverse O
events O
with O
PENNSAID O
were O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
skin I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

These O
events O
were O
the O
most O
common O
reason O
for O
withdrawing O
from O
the O
study O
. O

Application O
Site O
Reactions O
: O
In O
this O
controlled O
trial O
, O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
were O
characterized O
by O
one O
or O
more O
of O
the O
following O
: O
dryness O
( O
22 O
% O
) O
, O
exfoliation O
( O
7 O
% O
) O
, O
erythema O
( O
4 O
% O
) O
, O
pruritus O
( O
2 O
% O
) O
, O
pain O
( O
2 O
% O
) O
, O
induration O
( O
2 O
% O
) O
, O
rash O
( O
2 O
% O
) O
, O
and O
scabbing O
( O
< O
1 O
% O
) O
. O

Other O
Common O
Adverse O
Reactions O
: O
Table O
1 O
lists O
all O
adverse O
reactions O
occurring O
in O
> O
1 O
% O
of O
patients O
receiving O
PENNSAID O
, O
where O
the O
rate O
in O
the O
PENNSAID O
group O
exceeded O
vehicle O
, O
from O
a O
controlled O
study O
conducted O
in O
patients O
with O
osteoarthritis B-Not_AE_Candidate
. O

Table O
1 O
: O
Incidence O
of O
Adverse O
Reactions O
Occurring O
in O
> O
1 O
% O
of O
Subjects O
with O
Osteoarthritis O
Using O
PENNSAID O
and O
More O
Often O
than O
in O
Subjects O
with O
OA O
Using O
Vehicle O
Control O
( O
Pooled O
) O
Adverse O
Reaction O
PENNSAIDN=130n O
( O
% O
) O
Vehicle O
ControlN=129n O
( O
% O
) O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
4 O
( O
3 O
% O
) O
1 O
( O
< O
1 O
% O
) O
Application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
induration I-OSE_Labeled_AE
2 O
( O
2 O
% O
) O
1 O
( O
< O
1 O
% O
) O
Contusion B-OSE_Labeled_AE
2 O
( O
2 O
% O
) O
1 O
( O
< O
1 O
% O
) O
Sinus B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
2 O
( O
2 O
% O
) O
1 O
( O
< O
1 O
% O
) O
Nausea B-OSE_Labeled_AE
2 O
( O
2 O
% O
) O
0 O
PENNSAID O
1.5 O
% O
The O
safety O
of O
PENNSAID O
2 O
% O
is O
based O
in O
part O
, O
on O
prior O
experience O
with O
PENNSAID O
1.5 O
% O
. O

The O
data O
described O
below O
reflect O
exposure O
to O
PENNSAID O
1.5 O
% O
of O
911 O
patients O
treated O
between O
4 O
and O
12 O
weeks O
( O
mean O
duration O
of O
49 O
days O
) O
in O
seven O
Phase O
3 O
controlled O
trials O
, O
as O
well O
as O
exposure O
of O
793 O
patients O
treated O
in O
an O
open-label O
study O
, O
including O
463 O
patients O
treated O
for O
at O
least O
6 O
months O
, O
and O
144 O
patients O
treated O
for O
at O
least O
12 O
months O
. O

The O
population O
mean O
age O
was O
approximately O
60 O
years O
, O
89 O
% O
of O
patients O
were O
Caucasian O
, O
64 O
% O
were O
females O
, O
and O
all O
patients O
had O
primary O
osteoarthritis B-Not_AE_Candidate
. O

The O
most O
common O
adverse O
events O
with O
PENNSAID O
1.5 O
% O
were O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
skin I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

These O
events O
were O
the O
most O
common O
reason O
for O
withdrawing O
from O
the O
studies O
. O

Application O
Site O
Reactions O
: O
In O
controlled O
trials O
, O
application B-NonOSE_AE
site I-NonOSE_AE
reactions I-NonOSE_AE
were O
characterized O
by O
one O
or O
more O
of O
the O
following O
: O
dryness O
, O
erythema O
, O
induration O
, O
vesicles O
, O
paresthesia O
, O
pruritus O
, O
vasodilation O
, O
acne O
, O
and O
urticaria O
. O

The O
most O
frequent O
of O
these O
reactions O
were O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
( O
32 O
% O
) O
, O
contact B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
characterized O
by O
skin B-NonOSE_AE
erythema I-NonOSE_AE
and O
induration B-NonOSE_AE
( O
9 O
% O
) O
, O
contact B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
with I-OSE_Labeled_AE
vesicles I-OSE_Labeled_AE
( O
2 O
% O
) O
and O
pruritus O
( O
4 O
% O
) O
. O

In O
one O
controlled O
trial O
, O
a O
higher O
rate O
of O
contact B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
with I-OSE_Labeled_AE
vesicles I-OSE_Labeled_AE
( O
4 O
% O
) O
was O
observed O
after O
treatment O
of O
152 O
subjects O
with O
the O
combination O
of O
PENNSAID O
1.5 O
% O
and O
oral O
diclofenac O
. O

In O
the O
open-label O
uncontrolled O
long-term O
safety O
study O
, O
contact B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
occurred O
in O
13 O
% O
and O
contact B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
with I-OSE_Labeled_AE
vesicles I-OSE_Labeled_AE
in O
10 O
% O
of O
patients O
, O
generally O
within O
the O
first O
6 O
months O
of O
exposure O
, O
leading O
to O
a O
withdrawal O
rate O
for O
an O
application O
site O
event O
of O
14 O
% O
. O

Other O
Common O
Adverse O
Reactions O
: O
In O
controlled O
trials O
, O
subjects O
treated O
with O
PENNSAID O
1.5 O
% O
experienced O
some O
adverse O
events O
associated O
with O
the O
NSAID O
class O
more O
frequently O
than O
subjects O
using O
placebo O
( O
constipation B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
flatulence B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
; O
see O
Table O
2 O
) O
. O

The O
combination O
of O
PENNSAID O
1.5 O
% O
and O
oral O
diclofenac O
, O
compared O
to O
oral O
diclofenac O
alone O
, O
resulted O
in O
a O
higher O
rate O
of O
rectal B-NonOSE_AE
hemorrhage I-NonOSE_AE
( O
3 O
% O
vs O
. O
less O
than O
1 O
% O
) O
, O
and O
more O
frequent O
abnormal B-NonOSE_AE
creatinine I-NonOSE_AE
( O
12 O
% O
vs O
. O
7 O
% O
) O
, O
urea O
( O
20 O
% O
vs O
. O
12 O
% O
) O
, O
and O
hemoglobin O
( O
13 O
% O
vs O
. O
9 O
% O
) O
, O
but O
no O
difference O
in O
elevation B-NonOSE_AE
of I-NonOSE_AE
liver I-NonOSE_AE
transaminases I-NonOSE_AE
. O

Table O
2 O
lists O
all O
adverse O
reactions O
occurring O
in O
> O
=1 O
% O
of O
patients O
receiving O
PENNSAID O
1.5 O
% O
, O
where O
the O
rate O
in O
the O
PENNSAID O
1.5 O
% O
group O
exceeded O
placebo O
, O
from O
seven O
controlled O
studies O
conducted O
in O
patients O
with O
osteoarthritis B-Not_AE_Candidate
. O

Since O
these O
trials O
were O
of O
different O
durations O
, O
these O
percentages O
do O
not O
capture O
cumulative O
rates O
of O
occurrence O
. O

Table O
2 O
: O
Adverse O
Reactions O
Occurring O
in O
> O
=1 O
% O
of O
Patients O
Treated O
with O
PENNSAID O
1.5 O
% O
Topical O
Solution O
in O
Placebo O
and O
Oral O
Diclofenac-Controlled O
Trials O
Treatment O
Group O
: O
PENNSAID O
1.5 O
% O
N=911 O
Topical O
PlaceboN=332 O
Adverse O
Reaction O
N O
( O
% O
) O
N O
( O
% O
) O
Dry B-OSE_Labeled_AE
Skin I-OSE_Labeled_AE
( I-OSE_Labeled_AE
Application I-OSE_Labeled_AE
Site I-OSE_Labeled_AE
) O
292 O
( O
32 O
) O
17 O
( O
5 O
) O
Contact B-OSE_Labeled_AE
Dermatitis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
Application I-OSE_Labeled_AE
Site I-OSE_Labeled_AE
) O
83 O
( O
9 O
) O
6 O
( O
2 O
) O
Dyspepsia B-OSE_Labeled_AE
72 O
( O
8 O
) O
13 O
( O
4 O
) O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
54 O
( O
6 O
) O
10 O
( O
3 O
) O
Flatulence B-OSE_Labeled_AE
35 O
( O
4 O
) O
1 O
( O
< O
1 O
) O
Pruritus B-OSE_Labeled_AE
( I-OSE_Labeled_AE
Application I-OSE_Labeled_AE
Site I-OSE_Labeled_AE
) O
34 O
( O
4 O
) O
7 O
( O
2 O
) O
Diarrhea B-OSE_Labeled_AE
33 O
( O
4 O
) O
7 O
( O
2 O
) O
Nausea B-OSE_Labeled_AE
33 O
( O
4 O
) O
3 O
( O
1 O
) O
Pharyngitis B-OSE_Labeled_AE
40 O
( O
4 O
) O
13 O
( O
4 O
) O
Constipation B-OSE_Labeled_AE
29 O
( O
3 O
) O
1 O
( O
< O
1 O
) O
Edema B-OSE_Labeled_AE
26 O
( O
3 O
) O
0 O
Rash B-OSE_Labeled_AE
( O
Non-Application O
Site O
) O
25 O
( O
3 O
) O
5 O
( O
2 O
) O
Infection B-OSE_Labeled_AE
25 O
( O
3 O
) O
8 O
( O
2 O
) O
Ecchymosis B-OSE_Labeled_AE
19 O
( O
2 O
) O
1 O
( O
< O
1 O
) O
Dry B-OSE_Labeled_AE
Skin I-OSE_Labeled_AE
( O
Non-Application O
Site O
) O
19 O
( O
2 O
) O
1 O
( O
< O
1 O
) O
Contact B-OSE_Labeled_AE
Dermatitis I-OSE_Labeled_AE
, O
vesicles O
( I-OSE_Labeled_AE
Application I-OSE_Labeled_AE
Site I-OSE_Labeled_AE
) O
18 O
( O
2 O
) O
0 O
Paresthesia B-OSE_Labeled_AE
( O
Non-Application O
Site O
) O
14 O
( O
2 O
) O
3 O
( O
< O
1 O
) O
Accidental B-NonOSE_AE
Injury I-NonOSE_AE
22 O
( O
2 O
) O
7 O
( O
2 O
) O
Pruritus B-OSE_Labeled_AE
( O
Non-Application O
Site O
) O
15 O
( O
2 O
) O
2 O
( O
< O
1 O
) O
Sinusitis B-OSE_Labeled_AE
10 O
( O
1 O
) O
2 O
( O
< O
1 O
) O
Halitosis B-OSE_Labeled_AE
11 O
( O
1 O
) O
1 O
( O
< O
1 O
) O
Application B-OSE_Labeled_AE
Site I-OSE_Labeled_AE
Reaction I-OSE_Labeled_AE
( O
not O
otherwise O
specified O
) O
11 O
( O
1 O
) O
3 O
( O
< O
1 O
) O
6.2 O
Postmarketing O
Experience O
In O
postmarketing O
surveillance O
, O
the O
following O
adverse O
reactions O
have O
been O
reported O
during O
post- O
approval O
use O
of O
PENNSAID O
1.5 O
% O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
: O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
accidental B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
, O
allergic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
body B-OSE_Labeled_AE
odor I-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
face B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
halitosis B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
neck B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
Cardiovascular B-NonOSE_AE
: O
palpitation B-OSE_Labeled_AE
, O
cardiovascular B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
: O
diarrhea B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
lip B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
, O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
rectal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
ulcerative B-OSE_Labeled_AE
stomatitis I-OSE_Labeled_AE
, O
swollen B-OSE_Labeled_AE
tongue I-OSE_Labeled_AE
Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
: O
creatinine B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
Musculoskeletal B-NonOSE_AE
: O
leg B-OSE_Labeled_AE
cramps I-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
Nervous B-NonOSE_AE
: O
depression B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
drowsiness B-OSE_Labeled_AE
, O
lethargy B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
at I-OSE_Labeled_AE
application I-OSE_Labeled_AE
site I-OSE_Labeled_AE
Respiratory B-NonOSE_AE
: O
asthma B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
laryngismus B-OSE_Labeled_AE
, O
laryngitis B-OSE_Labeled_AE
, O
pharyngitis B-OSE_Labeled_AE
, O
throat B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
: O
At O
the O
Application B-OSE_Labeled_AE
Site I-OSE_Labeled_AE
: O
rash I-OSE_Labeled_AE
, O
skin O
burning O
sensation O
; O
Other B-NonOSE_AE
Skin I-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
Adverse I-NonOSE_AE
Reactions I-NonOSE_AE
: O
eczema B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
Special B-NonOSE_AE
Senses I-NonOSE_AE
: O
abnormal B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
cataract B-OSE_Labeled_AE
, O
ear B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
eye B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
eye B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
taste B-OSE_Labeled_AE
perversion I-OSE_Labeled_AE
Vascular B-NonOSE_AE
: O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE

BOXED O
WARNING O
: O
WARNING O
: O
RISK O
OF O
SERIOUS O
CARDIOVASCULAR O
AND O
GASTROINTESTINAL O
EVENTS O
WARNING O
: O
RISK O
OF O
SERIOUS O
CARDIOVASCULAR O
AND O
GASTROINTESTINAL O
EVENTS O
EXCERPT O
: O
WARNING O
: O
RISK O
OF O
SERIOUS O
CARDIOVASCULAR O
AND O
GASTROINTESTINAL O
EVENTS O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Nonsteroidal O
anti-inflammatory O
drugs O
( O
NSAIDs O
) O
cause O
an O
increased O
risk O
of O
serious O
cardiovascular O
thrombotic O
events O
, O
including O
myocardial O
infarction O
, O
and O
stroke O
, O
which O
can O
be O
fatal O
This O
risk O
may O
occur O
early O
in O
treatment O
and O
may O
increase O
with O
duration O
of O
use O
( O
5.1 O
) O
* O
PENNSAID O
is O
contraindicated O
in O
the O
setting O
of O
coronary O
artery O
bypass O
graft O
( O
CABG O
) O
surgery O
( O
4 O
, O
5.1 O
) O
* O
NSAIDs O
cause O
an O
increased O
risk O
of O
serious O
gastrointestinal O
( O
GI O
) O
adverse O
events O
including O
bleeding O
, O
ulceration O
, O
and O
perforation O
of O
the O
stomach O
or O
intestines O
, O
which O
can O
be O
fatal O
. O

These O
events O
can O
occur O
at O
any O
time O
during O
use O
and O
without O
warning O
symptoms O
. O

Elderly O
patients O
and O
patients O
with O
a O
prior O
history O
of O
peptic O
ulcer O
disease O
and/or O
GI O
bleeding O
are O
at O
greater O
risk O
for O
serious O
GI O
events O
( O
5.2 O
) O
Cardiovascular O
Thrombotic O
Events O
* O
Nonsteroidal O
anti-inflammatory O
drugs O
( O
NSAIDs O
) O
cause O
an O
increased O
risk O
of O
serious O
cardiovascular B-OSE_Labeled_AE
thrombotic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
including O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
and O
stroke B-OSE_Labeled_AE
, O
which O
can O
be O
fatal B-NonOSE_AE
. O

This O
risk O
may O
occur O
early O
in O
treatment O
and O
may O
increase O
with O
duration O
of O
use O
. O

[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
PENNSAID O
is O
contraindicated O
in O
the O
setting O
of O
coronary O
artery O
bypass O
graft O
( O
CABG O
) O
surgery O
[ O
see O
Contraindications O
( O
4 O
) O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Gastrointestinal O
Bleeding O
, O
Ulceration O
, O
and O
Perforation O
* O
NSAIDs O
cause O
an O
increased O
risk O
of O
serious O
gastrointestinal B-OSE_Labeled_AE
( I-OSE_Labeled_AE
GI I-OSE_Labeled_AE
) I-OSE_Labeled_AE
adverse O
events O
including O
bleeding I-OSE_Labeled_AE
, O
ulceration O
, O
and O
perforation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
stomach O
or O
intestines I-OSE_Labeled_AE
, O
which O
can O
be O
fatal B-NonOSE_AE
. O

These O
events O
can O
occur O
at O
any O
time O
during O
use O
and O
without O
warning O
symptoms O
. O

Elderly O
patients O
and O
patients O
with O
a O
prior O
history O
of O
peptic B-Not_AE_Candidate
ulcer I-Not_AE_Candidate
disease I-Not_AE_Candidate
and/or O
GI B-Not_AE_Candidate
bleeding I-Not_AE_Candidate
are O
at O
greater O
risk O
for O
serious O
GI B-NonOSE_AE
events I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Hepatotoxicity O
: O
Inform O
patients O
of O
warning O
signs O
and O
symptoms O
of O
hepatotoxicity O
. O

Discontinue O
if O
abnormal O
liver O
tests O
persist O
or O
worsen O
or O
if O
clinical O
signs O
and O
symptoms O
of O
liver O
disease O
develop O
( O
5.3 O
) O
* O
Hypertension O
: O
Patients O
taking O
some O
antihypertensive O
medications O
may O
have O
impaired O
response O
to O
these O
therapies O
when O
taking O
NSAIDs O
. O

Monitor O
blood O
pressure O
( O
5.4 O
, O
7 O
) O
* O
Heart O
Failure O
and O
Edema O
: O
Avoid O
use O
of O
PENNSAID O
in O
patients O
with O
severe O
heart O
failure O
unless O
benefits O
are O
expected O
to O
outweigh O
risk O
of O
worsening O
heart O
failure O
( O
5.5 O
) O
* O
Renal O
Toxicity O
: O
Monitor O
renal O
function O
in O
patients O
with O
renal O
or O
hepatic O
impairment O
, O
heart O
failure O
, O
dehydration O
, O
or O
hypovolemia O
. O

Avoid O
use O
of O
PENNSAID O
in O
patients O
with O
advanced O
renal O
disease O
unless O
benefits O
are O
expected O
to O
outweigh O
risk O
of O
worsening O
renal O
function O
( O
5.6 O
) O
* O
Anaphylactic O
Reactions O
: O
Seek O
emergency O
help O
if O
an O
anaphylactic O
reaction O
occurs O
( O
5.7 O
) O
* O
Exacerbation O
of O
Asthma O
Related O
to O
Aspirin O
Sensitivity O
: O
PENNSAID O
is O
contraindicated O
in O
patients O
with O
aspirin-sensitive O
asthma O
. O

Monitor O
patients O
with O
preexisting O
asthma O
( O
without O
aspirin O
sensitivity O
) O
( O
5.8 O
) O
* O
Serious O
Skin O
Reactions O
: O
Discontinue O
PENNSAID O
at O
first O
appearance O
of O
skin O
rash O
or O
other O
signs O
of O
hypersensitivity O
. O

( O
5.9 O
, O
5.14 O
) O
* O
Premature O
Closure O
of O
Fetal O
Ductus O
Arteriosus O
: O
Avoid O
use O
in O
pregnant O
women O
starting O
at O
30 O
weeks O
gestation O
( O
5.10 O
, O
8.1 O
) O
* O
Hematologic O
Toxicity O
: O
Monitor O
hemoglobin O
or O
hematocrit O
in O
patients O
with O
any O
signs O
or O
symptoms O
of O
anemia O
( O
5.11 O
, O
7 O
) O
. O

* O
Exposure O
to O
light O
: O
Avoid O
exposure O
of O
treated O
knee O
( O
s O
) O
to O
natural O
or O
artificial O
sunlight O
. O

( O
5.11 O
) O
* O
Eye O
Contact O
: O
Avoid O
contact O
of O
PENNSAID O
with O
eyes O
and O
mucosa O
. O

( O
5.15 O
) O
* O
Oral O
Nonsteroidal O
Anti-inflammatory O
Drugs O
: O
Avoid O
concurrent O
use O
with O
oral O
NSAIDs O
. O

( O
5.16 O
) O
5.1 O
Cardiovascular O
Thrombotic O
Events O
Clinical O
trials O
of O
several O
COX-2 O
selective O
and O
nonselective O
NSAIDs O
of O
up O
to O
three O
years O
duration O
have O
shown O
an O
increased O
risk O
of O
serious O
cardiovascular B-OSE_Labeled_AE
( I-OSE_Labeled_AE
CV I-OSE_Labeled_AE
) I-OSE_Labeled_AE
thrombotic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
including O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
( I-OSE_Labeled_AE
MI I-OSE_Labeled_AE
) O
, O
and O
stroke B-OSE_Labeled_AE
, O
which O
can O
be O
fatal B-NonOSE_AE
. O

Based O
on O
available O
data O
, O
it O
is O
unclear O
that O
the O
risk O
for O
CV B-NonOSE_AE
thrombotic I-NonOSE_AE
events I-NonOSE_AE
is O
similar O
for O
all O
NSAIDs O
. O

The O
relative O
increase O
in O
serious O
CV B-NonOSE_AE
thrombotic I-NonOSE_AE
events I-NonOSE_AE
over O
baseline O
conferred O
by O
NSAID O
use O
appears O
to O
be O
similar O
in O
those O
with O
and O
without O
known O
CV B-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
risk O
factors O
for O
CV B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

However O
, O
patients O
with O
known O
CV B-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
risk O
factors O
had O
a O
higher O
absolute O
incidence O
of O
excess O
serious O
CV B-NonOSE_AE
thrombotic I-NonOSE_AE
events I-NonOSE_AE
, O
due O
to O
their O
increased O
baseline O
rate O
. O

Some O
observational O
studies O
found O
that O
this O
increased O
risk O
of O
serious O
CV B-OSE_Labeled_AE
thrombotic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
began O
as O
early O
as O
the O
first O
weeks O
of O
treatment O
. O

The O
increase O
in O
CV B-NonOSE_AE
thrombotic I-NonOSE_AE
risk I-NonOSE_AE
has O
been O
observed O
most O
consistently O
at O
higher O
doses O
. O

To O
minimize O
the O
potential O
risk O
for O
an O
adverse O
CV B-NonOSE_AE
event I-NonOSE_AE
in O
NSAID-treated O
patients O
, O
use O
the O
lowest O
effective O
dose O
for O
the O
shortest O
duration O
possible O
. O

Physicians O
and O
patients O
should O
remain O
alert O
for O
the O
development O
of O
such O
events O
, O
throughout O
the O
entire O
treatment O
course O
, O
even O
in O
the O
absence O
of O
previous O
CV B-NonOSE_AE
symptoms I-NonOSE_AE
. O

Patients O
should O
be O
informed O
about O
the O
symptoms O
of O
serious O
CV B-NonOSE_AE
events I-NonOSE_AE
and O
the O
steps O
to O
take O
if O
they O
occur O
. O

There O
is O
no O
consistent O
evidence O
that O
concurrent O
use O
of O
aspirin O
mitigates O
the O
increased O
risk O
of O
serious O
CV B-NonOSE_AE
thrombotic I-NonOSE_AE
events I-NonOSE_AE
associated O
with O
NSAID O
use O
. O

The O
concurrent O
use O
of O
aspirin O
and O
an O
NSAID O
, O
such O
as O
diclofenac O
, O
increases O
the O
risk O
of O
serious O
gastrointestinal B-NonOSE_AE
( I-NonOSE_AE
GI I-NonOSE_AE
) I-NonOSE_AE
events I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Status O
Post O
Coronary O
Artery O
Bypass O
Graft O
( O
CABG O
) O
Surgery O
Two O
large O
, O
controlled O
, O
clinical O
trials O
of O
a O
COX-2 O
selective O
NSAID O
for O
the O
treatment O
of O
pain B-Not_AE_Candidate
in O
the O
first O
10-14 O
days O
following O
CABG O
surgery O
found O
an O
increased O
incidence O
of O
myocardial B-NonOSE_AE
infarction I-NonOSE_AE
and O
stroke B-NonOSE_AE
. O

NSAIDs O
are O
contraindicated O
in O
the O
setting O
of O
CABG O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

Post-MI O
Patients O
Observational O
studies O
conducted O
in O
the O
Danish O
National O
Registry O
have O
demonstrated O
that O
patients O
treated O
with O
NSAIDs O
in O
the O
post B-Not_AE_Candidate
- I-Not_AE_Candidate
MI I-Not_AE_Candidate
period O
were O
at O
increased O
risk O
of O
reinfarction B-OSE_Labeled_AE
, O
CV B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
death I-OSE_Labeled_AE
, O
and O
all-cause O
mortality B-NonOSE_AE
beginning O
in O
the O
first O
week O
of O
treatment O
. O

In O
this O
same O
cohort O
, O
the O
incidence O
of O
death B-NonOSE_AE
in O
the O
first O
year O
post-MI O
was O
20 O
per O
100 O
person O
years O
in O
NSAID-treated O
patients O
compared O
to O
12 O
per O
100 O
person O
years O
in O
non-NSAID O
exposed O
patients O
. O

Although O
the O
absolute O
rate O
of O
death B-NonOSE_AE
declined O
somewhat O
after O
the O
first O
year O
post B-Not_AE_Candidate
- I-Not_AE_Candidate
MI I-Not_AE_Candidate
, O
the O
increased O
relative O
risk O
of O
death B-NonOSE_AE
in O
NSAID O
users O
persisted O
over O
at O
least O
the O
next O
four O
years O
of O
follow-up O
. O

Avoid O
the O
use O
of O
PENNSAID O
in O
patients O
with O
a O
recent O
MI B-Not_AE_Candidate
unless O
the O
benefits O
are O
expected O
to O
outweigh O
the O
risk O
of O
recurrent O
CV B-NonOSE_AE
thrombotic I-NonOSE_AE
events I-NonOSE_AE
. O

If O
PENNSAID O
is O
used O
in O
patients O
with O
a O
recent O
MI B-Not_AE_Candidate
, O
monitor O
patients O
for O
signs O
of O
cardiac B-NonOSE_AE
ischemia I-NonOSE_AE
. O

5.2 O
Gastrointestinal O
Bleeding O
, O
Ulceration O
, O
and O
Perforation O
NSAIDs O
, O
including O
diclofenac O
, O
cause O
serious O
gastrointestinal B-OSE_Labeled_AE
( I-OSE_Labeled_AE
GI I-OSE_Labeled_AE
) I-OSE_Labeled_AE
adverse O
events O
including O
inflammation I-OSE_Labeled_AE
, O
bleeding O
, O
ulceration O
, O
and O
perforation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
esophagus O
, O
stomach O
, O
small I-OSE_Labeled_AE
intestine I-OSE_Labeled_AE
, O
or O
large O
intestine O
, O
which O
can O
be O
fatal B-NonOSE_AE
. O

These O
serious O
adverse O
events O
can O
occur O
at O
any O
time O
, O
with O
or O
without O
warning O
symptoms O
, O
in O
patients O
treated O
with O
NSAIDs O
. O

Only O
one O
in O
five O
patients O
who O
develop O
a O
serious O
upper B-NonOSE_AE
GI I-NonOSE_AE
adverse I-NonOSE_AE
event I-NonOSE_AE
on O
NSAID O
therapy O
is O
symptomatic O
. O

Upper B-OSE_Labeled_AE
GI I-OSE_Labeled_AE
ulcers I-OSE_Labeled_AE
, O
gross O
bleeding O
, O
or O
perforation O
caused O
by O
NSAIDs O
occurred O
in O
approximately O
1 O
% O
of O
patients O
treated O
for O
3-6 O
months O
, O
and O
in O
about O
2 O
% O
-4 O
% O
of O
patients O
treated O
for O
one O
year O
. O

However O
, O
even O
short-term O
NSAID O
therapy O
is O
not O
without O
risk O
. O

Risk O
Factors O
for O
GI O
Bleeding O
, O
Ulceration O
, O
and O
Perforation O
Patients O
with O
a O
prior O
history O
of O
peptic B-Not_AE_Candidate
ulcer I-Not_AE_Candidate
disease I-Not_AE_Candidate
and/or O
GI B-Not_AE_Candidate
bleeding I-Not_AE_Candidate
who O
used O
NSAIDs O
had O
a O
greater O
than O
10-fold O
increased O
risk O
for O
developing O
a O
GI B-OSE_Labeled_AE
bleed I-OSE_Labeled_AE
compared O
to O
patients O
without O
these O
risk O
factors O
. O

Other O
factors O
that O
increase O
the O
risk O
of O
GI B-NonOSE_AE
bleeding I-NonOSE_AE
in O
patients O
treated O
with O
NSAIDs O
include O
longer O
duration O
of O
NSAID O
therapy O
; O
concomitant O
use O
of O
oral O
corticosteroids O
, O
aspirin O
, O
anticoagulants O
, O
or O
selective O
serotonin O
reuptake O
inhibitors O
( O
SSRIs O
) O
; O
smoking O
; O
use O
of O
alcohol O
; O
older O
age O
; O
and O
poor O
general O
health O
status O
. O

Most O
postmarketing O
reports O
of O
fatal B-NonOSE_AE
GI B-OSE_Labeled_AE
events I-OSE_Labeled_AE
occurred O
in O
elderly O
or O
debilitated O
patients O
. O

Additionally O
, O
patients O
with O
advanced O
liver B-Not_AE_Candidate
disease I-Not_AE_Candidate
and/or O
coagulopathy B-Not_AE_Candidate
are O
at O
increased O
risk O
for O
GI B-NonOSE_AE
bleeding I-NonOSE_AE
. O

Strategies O
to O
Minimize O
the O
GI O
Risks O
in O
NSAID-treated O
patients O
: O
* O
Use O
the O
lowest O
effective O
dosage O
for O
the O
shortest O
possible O
duration O
. O

* O
Avoid O
administration O
of O
more O
than O
one O
NSAID O
at O
a O
time O
. O

* O
Avoid O
use O
in O
patients O
at O
higher O
risk O
unless O
benefits O
are O
expected O
to O
outweigh O
the O
increased O
risk O
of O
bleeding B-NonOSE_AE
. O

For O
such O
patients O
, O
as O
well O
as O
those O
with O
active O
GI B-Not_AE_Candidate
bleeding I-Not_AE_Candidate
, O
consider O
alternate O
therapies O
other O
than O
NSAIDs O
. O

* O
Remain O
alert O
for O
signs O
and O
symptoms O
of O
GI B-NonOSE_AE
ulceration I-NonOSE_AE
and O
bleeding O
during O
NSAID O
therapy O
. O

* O
If O
a O
serious O
GI B-NonOSE_AE
adverse I-NonOSE_AE
event I-NonOSE_AE
is O
suspected O
, O
promptly O
initiate O
evaluation O
and O
treatment O
, O
and O
discontinue O
PENNSAID O
until O
a O
serious O
GI B-NonOSE_AE
adverse I-NonOSE_AE
event I-NonOSE_AE
is O
ruled O
out O
. O

* O
In O
the O
setting O
of O
concomitant O
use O
of O
low-dose O
aspirin O
for O
cardiac O
prophylaxis O
, O
monitor O
patients O
more O
closely O
for O
evidence O
of O
GI B-NonOSE_AE
bleeding I-NonOSE_AE
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

5.3 O
Hepatotoxicity O
In O
clinical O
trials O
of O
oral O
diclofenac O
containing O
products O
, O
meaningful O
elevations B-OSE_Labeled_AE
( O
i.e. O
, O
more O
than O
3 O
times O
the O
ULN O
) O
of I-OSE_Labeled_AE
AST I-OSE_Labeled_AE
( I-OSE_Labeled_AE
SGOT I-OSE_Labeled_AE
) O
occurred O
in O
about O
2 O
% O
of O
approximately O
5,700 O
patients O
at O
some O
time O
during O
diclofenac O
treatment O
( O
ALT O
was O
not O
measured O
in O
all O
studies O
) O
. O

In O
a O
large O
, O
open-label O
, O
controlled O
trial O
of O
3,700 O
patients O
treated O
with O
oral O
diclofenac O
for O
2 O
- O
6 O
months O
, O
patients O
were O
monitored O
first O
at O
8 O
weeks O
and O
1,200 O
patients O
were O
monitored O
again O
at O
24 O
weeks O
. O

Meaningful O
elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
ALT O
and/or O
AST I-OSE_Labeled_AE
occurred O
in O
about O
4 O
% O
of O
3,700 O
patients O
and O
included O
marked O
elevations O
( O
greater O
than O
8 O
times O
the O
ULN O
) O
in O
about O
1 O
% O
of O
the O
3,700 O
patients O
. O

In O
that O
open-label O
study O
, O
a O
higher O
incidence O
of O
borderline O
( O
less O
than O
3 O
times O
the O
ULN O
) O
, O
moderate O
( O
3 O
to O
8 O
times O
the O
ULN O
) O
, O
and O
marked O
( O
greater O
than O
8 O
times O
the O
ULN O
) O
elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
ALT O
or O
AST I-OSE_Labeled_AE
was O
observed O
in O
patients O
receiving O
diclofenac O
when O
compared O
to O
other O
NSAIDs O
. O

Elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
were O
seen O
more O
frequently O
in O
patients O
with O
osteoarthritis B-Not_AE_Candidate
than O
in O
those O
with O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
. O

Almost O
all O
meaningful O
elevations B-NonOSE_AE
in I-NonOSE_AE
transaminases I-NonOSE_AE
were O
detected O
before O
patients O
became O
symptomatic O
. O

Abnormal O
tests O
occurred O
during O
the O
first O
2 O
months O
of O
therapy O
with O
oral O
diclofenac O
in O
42 O
of O
the O
51 O
patients O
in O
all O
trials O
who O
developed O
marked O
transaminase B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
. O

In O
postmarketing O
reports O
, O
cases O
of O
drug B-OSE_Labeled_AE
- I-OSE_Labeled_AE
induced I-OSE_Labeled_AE
hepatotoxicity I-OSE_Labeled_AE
have O
been O
reported O
in O
the O
first O
month O
, O
and O
in O
some O
cases O
, O
the O
first O
2 O
months O
of O
NSAID O
therapy O
, O
but O
can O
occur O
at O
any O
time O
during O
treatment O
with O
diclofenac O
. O

Postmarketing O
surveillance O
has O
reported O
cases O
of O
severe O
hepatic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
liver B-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
, O
jaundice B-OSE_Labeled_AE
, O
fulminant B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
with O
and O
without O
jaundice B-NonOSE_AE
, O
and O
liver B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
. O

Some O
of O
these O
reported O
cases O
resulted O
in O
fatalities B-NonOSE_AE
or O
liver O
transplantation O
. O

In O
a O
European O
retrospective O
population-based O
, O
case-controlled O
study O
, O
10 O
cases O
of O
oral O
diclofenac O
associated O
drug B-OSE_Labeled_AE
- I-OSE_Labeled_AE
induced I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
injury I-OSE_Labeled_AE
with O
current O
use O
compared O
with O
non-use O
of O
diclofenac O
were O
associated O
with O
a O
statistically O
significant O
4-fold O
adjusted O
odds O
ratio O
of O
liver B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
. O

In O
this O
particular O
study O
, O
based O
on O
an O
overall O
number O
of O
10 O
cases O
of O
liver B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
associated O
with O
diclofenac O
, O
the O
adjusted O
odds O
ratio O
increased O
further O
with O
female O
gender O
, O
doses O
of O
150 O
mg O
or O
more O
, O
and O
duration O
of O
use O
for O
more O
than O
90 O
days O
. O

Physicians O
should O
measure O
transaminases O
at O
baseline O
and O
periodically O
in O
patients O
receiving O
long-term O
therapy O
with O
diclofenac O
, O
because O
severe O
hepatotoxicity B-NonOSE_AE
may O
develop O
without O
a O
prodrome O
of O
distinguishing O
symptoms O
. O

The O
optimum O
times O
for O
making O
the O
first O
and O
subsequent O
transaminase O
measurements O
are O
not O
known O
. O

Based O
on O
clinical O
trial O
data O
and O
postmarketing O
experiences O
, O
transaminases O
should O
be O
monitored O
within O
4 O
to O
8 O
weeks O
after O
initiating O
treatment O
with O
diclofenac O
. O

However O
, O
severe O
hepatic B-NonOSE_AE
reactions I-NonOSE_AE
can O
occur O
at O
any O
time O
during O
treatment O
with O
diclofenac O
. O

If O
abnormal B-NonOSE_AE
liver I-NonOSE_AE
tests I-NonOSE_AE
persist O
or O
worsen O
, O
if O
clinical O
signs O
and/or O
symptoms O
consistent O
with O
liver B-NonOSE_AE
disease I-NonOSE_AE
develop O
, O
or O
if O
systemic O
manifestations O
occur O
( O
e.g. O
, O
eosinophilia B-NonOSE_AE
, O
rash B-NonOSE_AE
, O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
diarrhea B-NonOSE_AE
, O
dark B-NonOSE_AE
urine I-NonOSE_AE
, O
etc O
. O

) O
, O
PENNSAID O
should O
be O
discontinued O
immediately O
. O

Inform O
patients O
of O
the O
warning O
signs O
and O
symptoms O
of O
hepatotoxicity B-NonOSE_AE
( O
e.g. O
, O
nausea B-NonOSE_AE
, O
fatigue B-NonOSE_AE
, O
lethargy B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
, O
pruritus B-NonOSE_AE
, O
jaundice B-NonOSE_AE
, O
right B-NonOSE_AE
upper I-NonOSE_AE
quadrant I-NonOSE_AE
tenderness I-NonOSE_AE
, O
and O
" B-NonOSE_AE
flu I-NonOSE_AE
- I-NonOSE_AE
like I-NonOSE_AE
" I-NonOSE_AE
symptoms I-NonOSE_AE
) O
. O

If O
clinical O
signs O
and O
symptoms O
consistent O
with O
liver B-NonOSE_AE
disease I-NonOSE_AE
develop O
, O
or O
if O
systemic O
manifestations O
occur O
( O
e.g. O
, O
eosinophilia B-NonOSE_AE
, O
rash B-NonOSE_AE
, O
etc O
. O

) O
, O
discontinue O
PENNSAID O
immediately O
, O
and O
perform O
a O
clinical O
evaluation O
of O
the O
patient O
. O

To O
minimize O
the O
potential O
risk O
for O
an O
adverse O
liver B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
event I-NonOSE_AE
in O
patients O
treated O
with O
PENNSAID O
, O
use O
the O
lowest O
effective O
dose O
for O
the O
shortest O
duration O
possible O
. O

Exercise O
caution O
when O
prescribing O
PENNSAID O
with O
concomitant O
drugs O
that O
are O
known O
to O
be O
potentially O
hepatotoxic O
( O
e.g. O
, O
acetaminophen O
, O
antibiotics O
, O
antiepileptics O
) O
. O

5.4 O
Hypertension O
NSAIDs O
, O
including O
PENNSAID O
, O
can O
lead O
to O
new O
onset O
of O
hypertension B-OSE_Labeled_AE
or O
worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
preexisting I-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
, O
either O
of O
which O
may O
contribute O
to O
the O
increased O
incidence O
of O
CV B-NonOSE_AE
events I-NonOSE_AE
. O

Patients O
taking O
angiotensin O
converting O
enzyme O
( O
ACE O
) O
inhibitors O
, O
thiazide O
diuretics O
, O
or O
loop O
diuretics O
may O
have O
impaired O
response O
to O
these O
therapies O
when O
taking O
NSAIDs O
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

Monitor O
blood O
pressure O
( O
BP O
) O
during O
the O
initiation O
of O
NSAID O
treatment O
and O
throughout O
the O
course O
of O
therapy O
. O

5.5 O
Heart O
Failure O
and O
Edema O
The O
Coxib O
and O
traditional O
NSAID O
Trialists O
' O
Collaboration O
meta-analysis O
of O
randomized O
controlled O
trials O
demonstrated O
an O
approximately O
two-fold O
increase O
in O
hospitalizations O
for O
heart B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
in O
COX-2 O
selective O
treated O
patients O
and O
nonselective O
NSAID-treated O
patients O
compared O
to O
placebo-treated O
patients O
. O

In O
a O
Danish O
National O
Registry O
study O
of O
patients O
with O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
NSAID O
use O
increased O
the O
risk O
of O
MI B-OSE_Labeled_AE
, O
hospitalization O
for O
heart B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
and O
death B-NonOSE_AE
. O

Additionally O
, O
fluid B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
and O
edema B-OSE_Labeled_AE
have O
been O
observed O
in O
some O
patients O
treated O
with O
NSAIDs O
. O

Use O
of O
diclofenac O
may O
blunt O
the O
CV B-NonOSE_AE
effects I-NonOSE_AE
of O
several O
therapeutic O
agents O
used O
to O
treat O
these O
medical O
conditions O
( O
e.g. O
, O
diuretics O
, O
ACE O
inhibitors O
, O
or O
angiotensin O
receptor O
blockers O
[ O
ARBs O
] O
) O
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

Avoid O
the O
use O
of O
PENNSAID O
in O
patients O
with O
severe O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
unless O
the O
benefits O
are O
expected O
to O
outweigh O
the O
risk O
of O
worsening B-NonOSE_AE
heart I-NonOSE_AE
failure I-NonOSE_AE
. O

If O
PENNSAID O
is O
used O
in O
patients O
with O
severe O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
monitor O
patients O
for O
signs O
of O
worsening B-NonOSE_AE
heart I-NonOSE_AE
failure I-NonOSE_AE
. O

5.6 O
Renal O
Toxicity O
and O
Hyperkalemia O
Renal O
Toxicity O
Long-term O
administration O
of O
NSAIDs O
has O
resulted O
in O
renal B-OSE_Labeled_AE
papillary I-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
and O
other O
renal B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
. O

Renal B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
has O
also O
been O
seen O
in O
patients O
in O
whom O
renal O
prostaglandins O
have O
a O
compensatory O
role O
in O
the O
maintenance O
of O
renal O
perfusion O
. O

In O
these O
patients O
, O
administration O
of O
an O
NSAID O
may O
cause O
a O
dose-dependent O
reduction B-NonOSE_AE
in I-NonOSE_AE
prostaglandin O
formation O
and O
, O
secondarily O
, O
in O
renal I-NonOSE_AE
blood I-NonOSE_AE
flow I-NonOSE_AE
, O
which O
may O
precipitate O
overt O
renal B-NonOSE_AE
decompensation I-NonOSE_AE
. O

Patients O
at O
greatest O
risk O
of O
this O
reaction O
are O
those O
with O
impaired B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
, O
dehydration B-Not_AE_Candidate
, O
hypovolemia B-Not_AE_Candidate
, O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
liver B-Not_AE_Candidate
dysfunction I-Not_AE_Candidate
, O
those O
taking O
diuretics O
and O
ACE-inhibitors O
or O
ARBs O
, O
and O
the O
elderly O
. O

Discontinuation O
of O
NSAID O
therapy O
is O
usually O
followed O
by O
recovery O
to O
the O
pretreatment O
state O
. O

No O
information O
is O
available O
from O
controlled O
clinical O
studies O
regarding O
the O
use O
of O
PENNSAID O
in O
patients O
with O
advanced O
renal B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

The O
renal B-OSE_Labeled_AE
effects I-OSE_Labeled_AE
of O
PENNSAID O
may O
hasten O
the O
progression B-OSE_Labeled_AE
of I-OSE_Labeled_AE
renal I-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
in O
patients O
with O
preexisting O
renal B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Correct O
volume O
status O
in O
dehydrated B-Not_AE_Candidate
or O
hypovolemic B-Not_AE_Candidate
patients O
prior O
to O
initiating O
PENNSAID O
. O

Monitor O
renal O
function O
in O
patients O
with O
renal B-Not_AE_Candidate
or O
hepatic O
impairment I-Not_AE_Candidate
, O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
dehydration B-Not_AE_Candidate
, O
or O
hypovolemia B-Not_AE_Candidate
during O
use O
of O
PENNSAID O
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

Avoid O
the O
use O
of O
PENNSAID O
in O
patients O
with O
advanced O
renal B-Not_AE_Candidate
disease I-Not_AE_Candidate
unless O
the O
benefits O
are O
expected O
to O
outweigh O
the O
risk O
of O
worsening B-NonOSE_AE
renal I-NonOSE_AE
function I-NonOSE_AE
. O

If O
PENNSAID O
is O
used O
in O
patients O
with O
advanced O
renal B-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
monitor O
patients O
for O
signs O
of O
worsening B-NonOSE_AE
renal I-NonOSE_AE
function I-NonOSE_AE
. O

Hyperkalemia O
Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
potassium I-OSE_Labeled_AE
concentration I-OSE_Labeled_AE
, O
including O
hyperkalemia B-OSE_Labeled_AE
, O
have O
been O
reported O
with O
use O
of O
NSAIDs O
, O
even O
in O
some O
patients O
without O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
. O

In O
patients O
with O
normal O
renal O
function O
, O
these O
effects O
have O
been O
attributed O
to O
a O
hyporeninemic B-Not_AE_Candidate
- I-Not_AE_Candidate
hypoaldosteronism I-Not_AE_Candidate
state I-Not_AE_Candidate
. O

5.7 O
Anaphylactic O
Reactions O
Diclofenac O
has O
been O
associated O
with O
anaphylactic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
in O
patients O
with O
and O
without O
known O
hypersensitivity B-Not_AE_Candidate
to I-Not_AE_Candidate
diclofenac I-Not_AE_Candidate
and O
in O
patients O
with O
aspirin B-Not_AE_Candidate
- I-Not_AE_Candidate
sensitive I-Not_AE_Candidate
asthma I-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4 O
) O
and O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
. O

Seek O
emergency O
help O
if O
an O
anaphylactic B-NonOSE_AE
reaction I-NonOSE_AE
occurs O
. O

5.8 O
Exacerbation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Asthma I-OSE_Labeled_AE
Related I-OSE_Labeled_AE
to I-OSE_Labeled_AE
Aspirin I-OSE_Labeled_AE
Sensitivity I-OSE_Labeled_AE
A O
subpopulation O
of O
patients O
with O
asthma B-Not_AE_Candidate
may O
have O
aspirin B-Not_AE_Candidate
- I-Not_AE_Candidate
sensitive I-Not_AE_Candidate
asthma I-Not_AE_Candidate
which O
may O
include O
chronic O
rhinosinusitis B-Not_AE_Candidate
complicated O
by O
nasal B-Not_AE_Candidate
polyps I-Not_AE_Candidate
; O
severe O
, O
potentially O
fatal B-NonOSE_AE
bronchospasm B-Not_AE_Candidate
; O
and/or O
intolerance B-Not_AE_Candidate
to I-Not_AE_Candidate
aspirin I-Not_AE_Candidate
and O
other O
NSAIDs O
. O

Because O
cross B-OSE_Labeled_AE
- I-OSE_Labeled_AE
reactivity I-OSE_Labeled_AE
between I-OSE_Labeled_AE
aspirin I-OSE_Labeled_AE
and I-OSE_Labeled_AE
other I-OSE_Labeled_AE
NSAIDs I-OSE_Labeled_AE
has O
been O
reported O
in O
such O
aspirin-sensitive O
patients O
, O
PENNSAID O
is O
contraindicated O
in O
patients O
with O
this O
form O
of O
aspirin O
sensitivity O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

When O
PENNSAID O
is O
used O
in O
patients O
with O
preexisting O
asthma B-Not_AE_Candidate
( O
without O
known O
aspirin O
sensitivity O
) O
, O
monitor O
patients O
for O
changes O
in O
the O
signs O
and O
symptoms O
of O
asthma B-NonOSE_AE
. O

5.9 O
Serious O
Skin O
Reactions O
NSAIDs O
, O
including O
diclofenac O
, O
can O
cause O
serious O
skin B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
such O
as O
exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( O
SJS O
) O
, O
and O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
( O
TEN O
) O
, O
which O
can O
be O
fatal B-NonOSE_AE
. O

These O
serious O
events O
may O
occur O
without O
warning O
. O

Inform O
patients O
about O
the O
signs O
and O
symptoms O
of O
serious O
skin B-NonOSE_AE
reactions I-NonOSE_AE
, O
and O
to O
discontinue O
the O
use O
of O
PENNSAID O
at O
the O
first O
appearance O
of O
skin B-NonOSE_AE
rash I-NonOSE_AE
or O
any O
other O
sign O
of O
hypersensitivity B-NonOSE_AE
. O

PENNSAID O
is O
contraindicated O
in O
patients O
with O
previous O
serious O
skin B-Not_AE_Candidate
reactions I-Not_AE_Candidate
to I-Not_AE_Candidate
NSAIDs I-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

Do O
not O
apply O
PENNSAID O
to O
open O
skin B-NonOSE_AE
wounds I-NonOSE_AE
, O
infections B-NonOSE_AE
, O
inflammations B-NonOSE_AE
, O
or O
exfoliative B-NonOSE_AE
dermatitis I-NonOSE_AE
, O
as O
it O
may O
affect O
absorption O
and O
tolerability O
of O
the O
drug O
. O

5.10 O
Premature O
Closure O
of O
Fetal O
Ductus O
Arteriosus O
Diclofenac O
may O
cause O
premature B-OSE_Labeled_AE
closure I-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetal I-OSE_Labeled_AE
ductus I-OSE_Labeled_AE
arteriosus I-OSE_Labeled_AE
. O

Avoid O
use O
of O
NSAIDs O
, O
including O
PENNSAID O
, O
in O
pregnant B-Not_AE_Candidate
women O
starting O
at O
30 O
weeks O
of O
gestation O
( O
third O
trimester O
) O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

5.11 O
Hematologic B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Anemia B-OSE_Labeled_AE
has O
occurred O
in O
NSAID-treated O
patients O
. O

This O
may O
be O
due O
to O
occult O
or O
gross O
blood B-Not_AE_Candidate
loss I-Not_AE_Candidate
, O
fluid B-Not_AE_Candidate
retention I-Not_AE_Candidate
, O
or O
an O
incompletely O
described O
effect B-Not_AE_Candidate
on I-Not_AE_Candidate
erythropoiesis I-Not_AE_Candidate
. O

If O
a O
patient O
treated O
with O
PENNSAID O
has O
any O
signs O
or O
symptoms O
of O
anemia B-NonOSE_AE
, O
monitor O
hemoglobin O
or O
hematocrit O
. O

NSAIDs O
, O
including O
PENNSAID O
, O
may O
increase O
the O
risk O
of O
bleeding B-OSE_Labeled_AE
events O
. O

Co-morbid O
conditions O
such O
as O
coagulation B-Not_AE_Candidate
disorders I-Not_AE_Candidate
or O
concomitant O
use O
of O
warfarin O
, O
other O
anticoagulants O
, O
antiplatelet O
agents O
( O
e.g. O
, O
aspirin O
) O
, O
serotonin O
reuptake O
inhibitors O
( O
SSRIs O
) O
and O
serotonin O
norepinephrine O
reuptake O
inhibitors O
( O
SNRIs O
) O
may O
increase O
this O
risk O
. O

Monitor O
these O
patients O
for O
signs O
of O
bleeding B-NonOSE_AE
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

5.12 O
Masking B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Inflammation I-OSE_Labeled_AE
and O
Fever O
The O
pharmacological O
activity O
of O
PENNSAID O
in O
reducing B-NonOSE_AE
inflammation I-NonOSE_AE
, O
and O
possibly O
fever O
, O
may O
diminish O
the O
utility O
of O
diagnostic O
signs O
in O
detecting O
infections B-NonOSE_AE
. O

5.13 O
Laboratory O
Monitoring O
Because O
serious O
GI B-NonOSE_AE
bleeding I-NonOSE_AE
, O
hepatotoxicity B-NonOSE_AE
, O
and O
renal B-NonOSE_AE
injury I-NonOSE_AE
can O
occur O
without O
warning O
symptoms O
or O
signs O
, O
consider O
monitoring O
patients O
on O
long-term O
NSAID O
treatment O
with O
a O
CBC O
and O
a O
chemistry O
profile O
periodically O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
, O
5.3 O
, O
5.6 O
) O
] O
. O

5.14 O
Sun O
Exposure O
Instruct O
patients O
to O
avoid O
exposure O
to O
natural O
or O
artificial O
sunlight O
on O
treated O
knee O
( O
s O
) O
because O
studies O
in O
animals O
indicated O
topical O
diclofenac O
treatment O
resulted O
in O
an O
earlier O
onset O
of O
ultraviolet B-NonOSE_AE
light I-NonOSE_AE
- I-NonOSE_AE
induced I-NonOSE_AE
skin I-NonOSE_AE
tumors I-NonOSE_AE
. O

The O
potential O
effects O
of O
PENNSAID O
on O
skin B-NonOSE_AE
response I-NonOSE_AE
to I-NonOSE_AE
ultraviolet I-NonOSE_AE
damage I-NonOSE_AE
in O
humans O
are O
not O
known O
. O

5.15 O
Eye O
Exposure O
Avoid O
contact O
of O
PENNSAID O
with O
eyes O
and O
mucosa O
. O

Advise O
patients O
that O
if O
eye O
contact O
occurs O
, O
immediately O
wash O
out O
the O
eye B-NonOSE_AE
with O
water O
or O
saline O
and O
consult O
a O
physician O
if O
irritation I-NonOSE_AE
persists O
for O
more O
than O
an O
hour O
. O

5.16 O
Oral O
Nonsteroidal O
Anti-Inflammatory O
Drugs O
Concomitant O
use O
of O
oral O
NSAIDs O
with O
PENNSAID O
1.5 O
% O
resulted O
in O
a O
higher O
rate O
of O
rectal B-NonOSE_AE
hemorrhage I-NonOSE_AE
, O
more O
frequent O
abnormal B-NonOSE_AE
creatinine I-NonOSE_AE
, O
urea O
and O
hemoglobin O
. O

Therefore O
, O
do O
not O
use O
combination O
therapy O
with O
PENNSAID O
and O
an O
oral O
NSAID O
unless O
the O
benefit O
outweighs O
the O
risk O
and O
conduct O
periodic O
laboratory O
evaluations O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
below O
and O
elsewhere O
in O
the O
labeling O
: O
* O
Bleeding B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Thrombotic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
EXCERPT O
: O
Bleeding O
, O
including O
life-threatening O
and O
fatal O
bleeding O
, O
is O
the O
most O
commonly O
reported O
adverse O
reaction O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Bristol-Myers O
Squibb/Sanofi O
Pharmaceuticals O
Partnership O
at O
1-800-633-1610 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
and O
durations O
of O
follow-up O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Plavix O
has O
been O
evaluated O
for O
safety O
in O
more O
than O
54,000 O
patients O
, O
including O
over O
21,000 O
patients O
treated O
for O
one O
year O
or O
more O
. O

The O
clinically O
important O
adverse O
reactions O
observed O
in O
trials O
comparing O
Plavix O
plus O
aspirin O
to O
placebo O
plus O
aspirin O
and O
trials O
comparing O
Plavix O
alone O
to O
aspirin O
alone O
are O
discussed O
below O
. O

Bleeding O
CURE O
In O
CURE O
, O
Plavix O
use O
with O
aspirin O
was O
associated O
with O
an O
increase O
in O
major O
bleeding B-OSE_Labeled_AE
( I-OSE_Labeled_AE
primarily I-OSE_Labeled_AE
gastrointestinal I-OSE_Labeled_AE
and O
at O
puncture O
sites O
) O
compared O
to O
placebo O
with O
aspirin O
( O
see O
Table O
1 O
) O
. O

The O
incidence O
of O
intracranial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
( O
0.1 O
% O
) O
and O
fatal B-NonOSE_AE
bleeding B-OSE_Labeled_AE
( O
0.2 O
% O
) O
were O
the O
same O
in O
both O
groups O
. O

Other O
bleeding B-OSE_Labeled_AE
events O
that O
were O
reported O
more O
frequently O
in O
the O
clopidogrel O
group O
were O
epistaxis B-OSE_Labeled_AE
, O
hematuria B-OSE_Labeled_AE
, O
and O
bruise B-OSE_Labeled_AE
. O

The O
overall O
incidence O
of O
bleeding B-NonOSE_AE
is O
described O
in O
Table O
1 O
. O

Table O
1 O
: O
CURE O
Incidence O
of O
Bleeding B-OSE_Labeled_AE
Complications O
( O
% O
patients O
) O
Event O
Plavix O
( O
+ O
aspirin O
) O
( O
n=6259 O
) O
Placebo O
( O
+ O
aspirin O
) O
( O
n=6303 O
) O
Major O
bleeding B-OSE_Labeled_AE
[ O
note O
: O
Life-threatening O
and O
other O
major O
bleeding B-OSE_Labeled_AE
. O
] O

3.7 O
2.7 O
Life-threatening O
bleeding B-OSE_Labeled_AE
2.2 O
1.8 O
Fatal B-NonOSE_AE
0.2 O
0.2 O
5 O
g/dL O
hemoglobin B-OSE_Labeled_AE
drop I-OSE_Labeled_AE
0.9 O
0.9 O
Requiring O
surgical O
intervention O
0.7 O
0.7 O
Hemorrhagic B-OSE_Labeled_AE
strokes I-OSE_Labeled_AE
0.1 O
0.1 O
Requiring O
inotropes O
0.5 O
0.5 O
Requiring O
transfusion O
( O
> O
=4 O
units O
) O
1.2 O
1.0 O
Other O
major O
bleeding B-OSE_Labeled_AE
1.6 O
1.0 O
Significantly O
disabling O
0.4 O
0.3 O
Intraocular B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
with O
significant O
loss B-NonOSE_AE
of I-NonOSE_AE
vision I-NonOSE_AE
0.05 O
0.03 O
Requiring O
2-3 O
units O
of O
blood O
1.3 O
0.9 O
Minor O
bleeding B-OSE_Labeled_AE
[ O
note O
: O
Led O
to O
interruption O
of O
study O
medication O
. O
] O

5.1 O
2.4 O
COMMIT O
In O
COMMIT O
, O
similar O
rates O
of O
major O
bleeding B-OSE_Labeled_AE
were O
observed O
in O
the O
Plavix O
and O
placebo O
groups O
, O
both O
of O
which O
also O
received O
aspirin O
( O
see O
Table O
2 O
) O
. O

Table O
2 O
: O
Incidence O
of O
Bleeding O
Events O
in O
COMMIT O
( O
% O
patients O
) O
Type O
of O
Bleeding B-OSE_Labeled_AE
Plavix O
( O
+ O
aspirin O
) O
( O
n=22961 O
) O
Placebo O
( O
+ O
aspirin O
) O
( O
n=22891 O
) O
p-value O
Major O
[ O
note O
: O
Major O
bleeds O
were O
cerebral O
bleeds O
or O
noncerebra B-OSE_Labeled_AE
l I-OSE_Labeled_AE
  I-OSE_Labeled_AE
I I-OSE_Labeled_AE
-OSE_ O
Labeled B-OSE_Labeled_AE
_ I-OSE_Labeled_AE
AE I-OSE_Labeled_AE
bleeds I-OSE_Labeled_AE
thought O
to O
have O
caused O
death B-NonOSE_AE
or O
that O
required O
transfusion O
. O
] O

noncerebral B-OSE_Labeled_AE
or O
cerebral O
bleeding I-OSE_Labeled_AE
0.6 O
0.5 O
0.59 O
Major O
noncerebral O
0.4 O
0.3 O
0.48 O
Fatal B-NonOSE_AE
0.2 O
0.2 O
0.90 O
Hemorrhagic B-OSE_Labeled_AE
stroke I-OSE_Labeled_AE
0.2 O
0.2 O
0.91 O
Fatal B-NonOSE_AE
0.2 O
0.2 O
0.81 O
Other O
noncerebral B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
( O
nonmajor O
) O
3.6 O
3.1 O
0.005 O
Any O
noncerebral B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
3.9 O
3.4 O
0.004 O
CAPRIE O
( O
Plavix O
vs O
Aspirin O
) O
In O
CAPRIE O
, O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
occurred O
at O
a O
rate O
of O
2.0 O
% O
in O
those O
taking O
Plavix O
versus O
2.7 O
% O
in O
those O
taking O
aspirin O
; O
bleeding B-OSE_Labeled_AE
requiring O
hospitalization O
occurred O
in O
0.7 O
% O
and O
1.1 O
% O
, O
respectively O
. O

The O
incidence O
of O
intracranial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
was O
0.4 O
% O
for O
Plavix O
compared O
to O
0.5 O
% O
for O
aspirin O
. O

Other O
bleeding B-OSE_Labeled_AE
events O
that O
were O
reported O
more O
frequently O
in O
the O
Plavix O
group O
were O
epistaxis B-OSE_Labeled_AE
and O
hematoma B-OSE_Labeled_AE
. O

Other O
Adverse O
Events O
In O
CURE O
and O
CHARISMA O
, O
which O
compared O
Plavix O
plus O
aspirin O
to O
aspirin O
alone O
, O
there O
was O
no O
difference O
in O
the O
rate O
of O
adverse O
events O
( O
other O
than O
bleeding B-NonOSE_AE
) O
between O
Plavix O
and O
placebo O
. O

In O
CAPRIE O
, O
which O
compared O
Plavix O
to O
aspirin O
, O
pruritus B-OSE_Labeled_AE
was O
more O
frequently O
reported O
in O
those O
taking O
Plavix O
. O

No O
other O
difference O
in O
the O
rate O
of O
adverse O
events O
( O
other O
than O
bleeding B-NonOSE_AE
) O
was O
reported O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
postapproval O
use O
of O
Plavix O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
an O
unknown O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Hemorrhages B-OSE_Labeled_AE
, O
including O
those O
with O
fatal B-NonOSE_AE
outcome O
, O
have O
been O
reported O
in O
patients O
treated O
with O
Plavix O
. O

* O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
Agranulocytosis B-OSE_Labeled_AE
, O
aplastic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
/ O
pancytopenia B-OSE_Labeled_AE
, O
thrombotic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
( O
TTP O
) O
, O
acquired B-OSE_Labeled_AE
hemophilia I-OSE_Labeled_AE
A I-OSE_Labeled_AE
* O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
Colitis B-OSE_Labeled_AE
( O
including O
ulcerative B-OSE_Labeled_AE
or O
lymphocytic O
colitis I-OSE_Labeled_AE
) O
, O
pancreatitis B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
gastric B-OSE_Labeled_AE
/duodenal O
ulcer I-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
* O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
condition I-NonOSE_AE
: O
Fever B-OSE_Labeled_AE
* O
Hepatobiliary B-NonOSE_AE
disorders I-NonOSE_AE
: O
Acute B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
( O
noninfectious I-OSE_Labeled_AE
) O
, O
abnormal B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
test I-OSE_Labeled_AE
* O
Immune B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
Hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
anaphylactoid B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
serum B-OSE_Labeled_AE
sickness I-OSE_Labeled_AE
* O
Musculoskeletal B-NonOSE_AE
, I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
and I-NonOSE_AE
bone I-NonOSE_AE
disorders I-NonOSE_AE
: O
Myalgia B-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
, O
arthritis B-OSE_Labeled_AE
* O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
Taste B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
ageusia B-OSE_Labeled_AE
* O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
: O
Confusion B-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
* O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
: O
Bronchospasm B-OSE_Labeled_AE
, O
interstitial B-OSE_Labeled_AE
pneumonitis I-OSE_Labeled_AE
, O
eosinophilic B-OSE_Labeled_AE
pneumonia I-OSE_Labeled_AE
* O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
: O
Increased B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
* O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
Maculopapular B-OSE_Labeled_AE
, O
erythematous O
or O
exfoliative O
rash I-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
bullous B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
eczema B-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
acute B-OSE_Labeled_AE
generalized I-OSE_Labeled_AE
exanthematous I-OSE_Labeled_AE
pustulosis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
AGEP I-OSE_Labeled_AE
) I-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
drug B-OSE_Labeled_AE
- I-OSE_Labeled_AE
induced I-OSE_Labeled_AE
hypersensitivity I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
drug B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
with I-OSE_Labeled_AE
eosinophilia I-OSE_Labeled_AE
and I-OSE_Labeled_AE
systemic I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
( O
DRESS B-OSE_Labeled_AE
) O
, O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
lichen B-OSE_Labeled_AE
planus I-OSE_Labeled_AE
, O
generalized B-OSE_Labeled_AE
pruritus I-OSE_Labeled_AE
* O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
: O
Vasculitis B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE

BOXED O
WARNING O
: O
WARNING O
: O
DIMINISHED O
ANTIPLATELET O
EFFECT O
IN O
PATIENTS O
WITH O
TWO O
LOSS-OF-FUNCTION O
ALLELES O
OF O
THE O
CYP2C19 O
GENE O
WARNING O
: O
DIMINISHED O
ANTIPLATELET O
EFFECT O
IN O
PATIENTS O
WITH O
TWO O
LOSS-OF-FUNCTION O
ALLELES O
OF O
THE O
CYP2C19 O
GENE O
EXCERPT O
: O
WARNING O
: O
DIMINISHED O
ANTIPLATELET O
EFFECT O
IN O
PATIENTS O
WITH O
TWO O
LOSS-OF-FUNCTION O
ALLELES O
OF O
THE O
CYP2C19 O
GENE O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Effectiveness O
of O
Plavix O
depends O
on O
conversion O
to O
an O
active O
metabolite O
by O
the O
cytochrome O
P450 O
( O
CYP O
) O
system O
, O
principally O
CYP2C19 O
. O

( O
5.1 O
, O
12.3 O
) O
* O
Tests O
are O
available O
to O
identify O
patients O
who O
are O
CYP2C19 O
poor O
metabolizers O
. O

( O
12.5 O
) O
* O
Consider O
use O
of O
another O
platelet O
P2Y12 O
inhibitor O
in O
patients O
identified O
as O
CYP2C19 O
poor O
metabolizers O
. O

( O
5.1 O
) O
The O
effectiveness O
of O
Plavix O
results O
from O
its O
antiplatelet O
activity O
, O
which O
is O
dependent O
on O
its O
conversion O
to O
an O
active O
metabolite O
by O
the O
cytochrome O
P450 O
( O
CYP O
) O
system O
, O
principally O
CYP2C19 O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

Plavix O
at O
recommended O
doses O
forms O
less O
of O
the O
active O
metabolite O
and O
so O
has O
a O
reduced B-NonOSE_AE
effect I-NonOSE_AE
on I-NonOSE_AE
platelet I-NonOSE_AE
activity I-NonOSE_AE
in O
patients O
who O
are O
homozygous B-Not_AE_Candidate
for I-Not_AE_Candidate
nonfunctional I-Not_AE_Candidate
alleles I-Not_AE_Candidate
of I-Not_AE_Candidate
the I-Not_AE_Candidate
CYP I-Not_AE_Candidate
2 I-Not_AE_Candidate
C I-Not_AE_Candidate
1 I-Not_AE_Candidate
9 I-Not_AE_Candidate
gene I-Not_AE_Candidate
, O
( O
termed O
" B-Not_AE_Candidate
CYP I-Not_AE_Candidate
2 I-Not_AE_Candidate
C I-Not_AE_Candidate
1 I-Not_AE_Candidate
9 I-Not_AE_Candidate
poor I-Not_AE_Candidate
metabolizers I-Not_AE_Candidate
" I-Not_AE_Candidate
) O
. O

Tests O
are O
available O
to O
identify O
patients O
who O
are O
CYP2C19 O
poor O
metabolizers O
[ O
see O
Clinical O
Pharmacology O
( O
12.5 O
) O
] O
. O

Consider O
use O
of O
another O
platelet O
P2Y12 O
inhibitor O
in O
patients O
identified O
as O
CYP2C19 O
poor O
metabolizers O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
CYP2C19 O
inhibitors O
: O
Avoid O
concomitant O
use O
of O
omeprazole O
or O
esomeprazole O
. O

( O
5.1 O
) O
* O
Bleeding O
: O
Plavix O
increases O
risk O
of O
bleeding O
. O

( O
5.2 O
) O
* O
Discontinuation O
: O
Premature O
discontinuation O
increases O
risk O
of O
cardiovascular O
events O
. O

Discontinue O
5 O
days O
prior O
to O
elective O
surgery O
that O
has O
a O
major O
risk O
of O
bleeding O
. O

( O
5.3 O
) O
* O
Thrombotic O
thrombocytopenic O
purpura O
( O
TTP O
) O
has O
been O
reported O
. O

( O
5.4 O
) O
* O
Cross-reactivity O
among O
thienopyridines O
has O
been O
reported O
. O

( O
5.5 O
) O
5.1 O
Diminished O
Antiplatelet O
Activity O
in O
Patients O
with O
Impaired O
CYP2C19 O
Function O
Clopidogrel O
is O
a O
prodrug O
. O

Inhibition B-NonOSE_AE
of I-NonOSE_AE
platelet I-NonOSE_AE
aggregation I-NonOSE_AE
by O
clopidogrel O
is O
achieved O
through O
an O
active O
metabolite O
. O

The O
metabolism O
of O
clopidogrel O
to O
its O
active O
metabolite O
can O
be O
impaired O
by O
genetic B-Not_AE_Candidate
variations I-Not_AE_Candidate
in I-Not_AE_Candidate
CYP I-Not_AE_Candidate
2 I-Not_AE_Candidate
C I-Not_AE_Candidate
1 I-Not_AE_Candidate
9 I-Not_AE_Candidate
[ O
see O
Boxed O
Warning O
] O
. O

The O
metabolism O
of O
clopidogrel O
can O
also O
be O
impaired O
by O
drugs O
that O
inhibit O
CYP2C19 O
, O
such O
as O
omeprazole O
or O
esomeprazole O
. O

Avoid O
concomitant O
use O
of O
Plavix O
with O
omeprazole O
or O
esomeprazole O
because O
both O
significantly O
reduce B-NonOSE_AE
the I-NonOSE_AE
antiplatelet I-NonOSE_AE
activity I-NonOSE_AE
of O
Plavix O
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

5.2 O
General O
Risk O
of O
Bleeding O
Thienopyridines O
, O
including O
Plavix O
, O
increase O
the O
risk O
of O
bleeding B-OSE_Labeled_AE
. O

Thienopyridines O
inhibit B-NonOSE_AE
platelet I-NonOSE_AE
aggregation I-NonOSE_AE
for O
the O
lifetime O
of O
the O
platelet O
( O
7-10 O
days O
) O
. O

Because O
the O
half-life O
of O
clopidogrel O
's O
active O
metabolite O
is O
short O
, O
it O
may O
be O
possible O
to O
restore O
hemostasis O
by O
administering O
exogenous O
platelets O
; O
however O
, O
platelet O
transfusions O
within O
4 O
hours O
of O
the O
loading O
dose O
or O
2 O
hours O
of O
the O
maintenance O
dose O
may O
be O
less O
effective O
. O

5.3 O
Discontinuation O
of O
Plavix O
Discontinuation O
of O
Plavix O
increases O
the O
risk O
of O
cardiovascular B-NonOSE_AE
events I-NonOSE_AE
. O

If O
Plavix O
must O
be O
temporarily O
discontinued O
( O
e.g. O
, O
to O
treat O
bleeding B-Not_AE_Candidate
or O
for O
surgery O
with O
a O
major O
risk O
of O
bleeding B-Not_AE_Candidate
) O
, O
restart O
it O
as O
soon O
as O
possible O
. O

When O
possible O
, O
interrupt O
therapy O
with O
Plavix O
for O
five O
days O
prior O
to O
such O
surgery O
. O

Resume O
Plavix O
as O
soon O
as O
hemostasis O
is O
achieved O
. O

5.4 O
Thrombotic B-OSE_Labeled_AE
Thrombocytopenic I-OSE_Labeled_AE
Purpura I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TTP I-OSE_Labeled_AE
) O
TTP B-OSE_Labeled_AE
, O
sometimes O
fatal O
, O
has O
been O
reported O
following O
use O
of O
Plavix O
, O
sometimes O
after O
a O
short O
exposure O
( O
< O
2 O
weeks O
) O
. O

TTP B-NonOSE_AE
is O
a O
serious O
condition O
that O
requires O
urgent O
treatment O
including O
plasmapheresis O
( O
plasma O
exchange O
) O
. O

It O
is O
characterized O
by O
thrombocytopenia B-NonOSE_AE
, O
microangiopathic B-NonOSE_AE
hemolytic I-NonOSE_AE
anemia I-NonOSE_AE
( O
schistocytes B-NonOSE_AE
[ O
fragmented O
RBCs O
] O
seen O
on O
peripheral O
smear O
) O
, O
neurological B-NonOSE_AE
findings I-NonOSE_AE
, O
renal B-NonOSE_AE
dysfunction I-NonOSE_AE
, O
and O
fever B-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

5.5 O
Cross-Reactivity O
among O
Thienopyridines O
Hypersensitivity B-OSE_Labeled_AE
including O
rash B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
or O
hematologic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
has O
been O
reported O
in O
patients O
receiving O
Plavix O
, O
including O
patients O
with O
a O
history B-Not_AE_Candidate
of I-Not_AE_Candidate
hypersensitivity O
or O
hematologic I-Not_AE_
Candidate B-Not_AE_Candidate
reac I-Not_AE_Candidate
tion I-Not_AE_Candidate
to O
other O
thienopyridines O
[ O
see O
Contraindications O
( O
4.2 O
) O
and O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
> O
1 O
% O
) O
are O
nausea O
, O
headache O
and O
vomiting O
( O
abdominal O
bloating O
, O
distension O
, O
pain/cramping O
, O
and O
watery O
diarrhea O
not O
requiring O
an O
intervention O
were O
not O
collected O
) O
( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Ferring O
at O
1-888-FERRING O
( O
1-888-337-7464 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

In O
randomized O
, O
multicenter O
, O
controlled O
clinical O
trials O
, O
nausea B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
and O
vomiting B-OSE_Labeled_AE
were O
the O
most O
common O
adverse O
reactions O
( O
> O
1 O
% O
) O
following O
Prepopik O
( O
r O
) O
administration O
. O

The O
patients O
were O
not O
blinded O
to O
the O
study O
drug O
. O

Since O
abdominal B-OSE_Labeled_AE
bloating I-OSE_Labeled_AE
, O
distension B-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
/ O
cramping B-OSE_Labeled_AE
, O
and O
watery B-OSE_Labeled_AE
diarrhea I-OSE_Labeled_AE
are O
known O
to O
occur O
in O
response O
to O
colon O
cleansing O
preparations O
, O
these O
effects O
were O
documented O
as O
adverse O
events O
in O
the O
clinical O
trials O
only O
if O
they O
required O
medical O
intervention O
( O
such O
as O
a O
change O
in O
study O
drug O
or O
led O
to O
study O
discontinuation O
, O
therapeutic O
or O
diagnostic O
procedures O
, O
met O
the O
criteria O
for O
a O
serious O
adverse O
event O
) O
, O
or O
showed O
clinically O
significant O
worsening O
during O
the O
study O
that O
was O
not O
in O
the O
frame O
of O
the O
usual O
clinical O
course O
, O
as O
determined O
by O
the O
investigator O
. O

Prepopik O
( O
r O
) O
was O
compared O
for O
colon O
cleansing O
effectiveness O
with O
a O
preparation O
containing O
two O
liters O
( O
2L O
) O
of O
polyethylene O
glycol O
plus O
electrolytes O
solution O
( O
PEG O
+ O
E O
) O
and O
two O
5-mg O
bisacodyl O
tablets O
, O
all O
administered O
the O
day O
before O
the O
procedure O
. O

Table O
1 O
displays O
the O
most O
common O
adverse O
reactions O
in O
Study O
1 O
and O
Study O
2 O
for O
the O
Prepopik O
( O
r O
) O
Split-Dose O
and O
Day-Before O
dosing O
regimens O
, O
respectively O
, O
each O
as O
compared O
to O
the O
comparator O
preparation O
. O

Table O
1 O
: O
Treatment-Emergent O
Adverse O
Reactions O
observed O
in O
at O
Least O
( O
> O
1 O
% O
) O
of O
Patients O
using O
the O
Split-Dose O
Regimen O
and O
Day-Before O
Regimen O
abdominal B-NonOSE_AE
bloating I-NonOSE_AE
, O
distension B-NonOSE_AE
, O
pain B-NonOSE_AE
/cramping O
, O
and O
watery B-NonOSE_AE
diarrhea I-NonOSE_AE
not O
requiring O
an O
intervention O
were O
not O
collected O
Adverse O
Reaction O
Study O
1 O
: O
Split-Dose O
Regimen O
Study O
2 O
: O
Day-Before O
Regimen O
PREPOPIK O
( O
r O
) O
( O
N=305 O
) O
n O
( O
% O
= O
n/N O
) O
2L O
PEG+Ewith O
2 O
* O
5-mg O
bisacodyl O
tablets O
( O
N=298 O
) O
n O
( O
% O
= O
n/N O
) O
PREPOPIK O
( O
r O
) O
( O
N=296 O
) O
n O
( O
% O
= O
n/N O
) O
2L O
PEG+Ewith O
2 O
* O
5-mg O
bisacodyl O
tablets O
( O
N=302 O
) O
n O
( O
% O
= O
n/N O
) O
Nausea B-OSE_Labeled_AE
8 O
( O
2.6 O
) O
11 O
( O
3.7 O
) O
9 O
( O
3.0 O
) O
13 O
( O
4.3 O
) O
Headache B-OSE_Labeled_AE
5 O
( O
1.6 O
) O
5 O
( O
1.7 O
) O
8 O
( O
2.7 O
) O
5 O
( O
1.7 O
) O
Vomiting B-OSE_Labeled_AE
3 O
( O
1.0 O
) O
10 O
( O
3.4 O
) O
4 O
( O
1.4 O
) O
6 O
( O
2.0 O
) O
Electrolyte O
Abnormalities O
In O
general O
, O
Prepopik O
( O
r O
) O
was O
associated O
with O
numerically O
higher O
rates O
of O
abnormal B-OSE_Labeled_AE
electrolyte I-OSE_Labeled_AE
shifts O
on O
the O
day O
of O
colonoscopy O
compared O
to O
the O
preparation O
containing O
2L O
of O
PEG O
+ O
E O
plus O
two O
* O
5-mg O
bisacodyl O
tablets O
( O
Table O
2 O
) O
. O

These O
shifts O
were O
transient O
in O
nature O
and O
numerically O
similar O
between O
treatment O
arms O
at O
the O
Day O
30 O
visit O
. O

Table O
2 O
: O
Shifts O
from O
Normal O
Baseline O
to O
Outside O
the O
Normal O
Range O
at O
Day O
7 O
and O
Day O
30 O
Laboratory O
Parameter O
( O
direction O
of O
change O
) O
Visit O
Study O
1 O
: O
Split-Dose O
Regimen O
Study O
2 O
: O
Day-Before O
Regimen O
PREPOPIK O
( O
r O
) O
2L O
PEG+E O
with O
2* O
5 O
mg O
bisacodyl O
tablets O
PREPOPIK O
( O
r O
) O
2L O
PEG+E O
with O
2* O
5 O
mg O
bisacodyl O
tablets O
n/N O
( O
% O
) O
n/N O
( O
% O
) O
Potassium B-OSE_Labeled_AE
( I-OSE_Labeled_AE
low I-OSE_Labeled_AE
) O
Day O
of O
Colonoscopy O
19/260 O
( O
7.3 O
) O
11/268 O
( O
4.1 O
) O
13/274 O
( O
4.7 O
) O
13/271 O
( O
4.8 O
) O
24-48 O
hours O
3/302 O
( O
1.0 O
) O
2/294 O
( O
0.7 O
) O
3/287 O
( O
1.0 O
) O
5/292 O
( O
1.7 O
) O
Day O
7 O
11/285 O
( O
3.9 O
) O
8/279 O
( O
2.9 O
) O
6/276 O
( O
2.2 O
) O
14/278 O
( O
5.0 O
) O
Day O
30 O
11/284 O
( O
3.9 O
) O
8/278 O
( O
2.9 O
) O
7/275 O
( O
2.5 O
) O
8/284 O
( O
2.8 O
) O
Sodium B-OSE_Labeled_AE
( I-OSE_Labeled_AE
low I-OSE_Labeled_AE
) O
Day O
of O
Colonoscopy O
11/298 O
( O
3.7 O
) O
3/295 O
( O
1.0 O
) O
3/286 O
( O
1.0 O
) O
3/295 O
( O
1.0 O
) O
24-48 O
hours O
1/303 O
( O
0.3 O
) O
1/295 O
( O
0.3 O
) O
1/288 O
( O
0.3 O
) O
1/293 O
( O
0.3 O
) O
Day O
7 O
2/300 O
( O
0.7 O
) O
1/292 O
( O
0.3 O
) O
1/285 O
( O
0.4 O
) O
1/291 O
( O
0.3 O
) O
Day O
30 O
2/299 O
( O
0.7 O
) O
3/291 O
( O
1.0 O
) O
1/284 O
( O
0.4 O
) O
1/296 O
( O
0.3 O
) O
Chloride B-OSE_Labeled_AE
( I-OSE_Labeled_AE
low I-OSE_Labeled_AE
) O
Day O
of O
Colonoscopy O
11/301 O
( O
3.7 O
) O
1/298 O
( O
0.3 O
) O
3/287 O
( O
1.0 O
) O
0/297 O
( O
0.0 O
) O
24-48 O
hours O
1/303 O
( O
0.3 O
) O
0/295 O
( O
0.0 O
) O
2/288 O
( O
0.7 O
) O
0/293 O
( O
0.0 O
) O
Day O
7 O
1/303 O
( O
0.3 O
) O
3/295 O
( O
1.0 O
) O
0/285 O
( O
0.0 O
) O
0/293 O
( O
0.0 O
) O
Day O
30 O
2/302 O
( O
0.7 O
) O
3/294 O
( O
1.0 O
) O
0/285 O
( O
0.0 O
) O
0/298 O
( O
0.0 O
) O
Magnesium B-OSE_Labeled_AE
( I-OSE_Labeled_AE
high I-OSE_Labeled_AE
) O
Day O
of O
Colonoscopy O
34/294 O
( O
11.6 O
) O
0/294 O
( O
0.0 O
) O
25/288 O
( O
8.7 O
) O
1/289 O
( O
0.3 O
) O
24-48 O
hours O
0/303 O
( O
0.0 O
) O
0/295 O
( O
0.0 O
) O
0/288 O
( O
0.0 O
) O
0/293 O
( O
0.0 O
) O
Day O
7 O
0/297 O
( O
0.0 O
) O
1/291 O
( O
0.3 O
) O
1/286 O
( O
0.3 O
) O
1/285 O
( O
0.4 O
) O
Day O
30 O
1/296 O
( O
0.3 O
) O
2/290 O
( O
0.7 O
) O
0/286 O
( O
0.0 O
) O
0/290 O
( O
0.0 O
) O
Calcium B-OSE_Labeled_AE
( I-OSE_Labeled_AE
low I-OSE_Labeled_AE
) O
Day O
of O
Colonoscopy O
2/292 O
( O
0.7 O
) O
1/286 O
( O
0.3 O
) O
0/276 O
( O
0.0 O
) O
2/282 O
( O
0.7 O
) O
24-48 O
hours O
0/303 O
( O
0.0 O
) O
0/295 O
( O
0.0 O
) O
0/288 O
( O
0.0 O
) O
0/293 O
( O
0.0 O
) O
Day O
7 O
0/293 O
( O
0.0 O
) O
1/283 O
( O
0.4 O
) O
0/274 O
( O
0.0 O
) O
0/278 O
( O
0.0 O
) O
Day O
30 O
0/292 O
( O
0.0 O
) O
1/282 O
( O
0.4 O
) O
0/274 O
( O
0.0 O
) O
1/283 O
( O
0.4 O
) O
Creatinine B-OSE_Labeled_AE
( I-OSE_Labeled_AE
high I-OSE_Labeled_AE
) O
Day O
of O
Colonoscopy O
5/260 O
( O
1.9 O
) O
13/268 O
( O
4.9 O
) O
12/266 O
( O
4.5 O
) O
16/270 O
( O
5.9 O
) O
24-48 O
hours O
1/303 O
( O
0.3 O
) O
0/295 O
( O
0.0 O
) O
0/288 O
( O
0.0 O
) O
0/293 O
( O
0.0 O
) O
Day O
7 O
10/264 O
( O
0.4 O
) O
13/267 O
( O
4.8 O
) O
10/264 O
( O
3.8 O
) O
10/265 O
( O
3.8 O
) O
Day O
30 O
11/264 O
( O
4.2 O
) O
14/265 O
( O
5.3 O
) O
18/264 O
( O
6.8 O
) O
10/272 O
( O
3.7 O
) O
eGFR B-OSE_Labeled_AE
( I-OSE_Labeled_AE
low I-OSE_Labeled_AE
) O
Day O
of O
Colonoscopy O
22/221 O
( O
10.0 O
) O
17/214 O
( O
7.9 O
) O
26/199 O
( O
13.1 O
) O
25/224 O
( O
11.2 O
) O
24-48 O
hours O
76/303 O
( O
25.1 O
) O
72/295 O
( O
24.4 O
) O
82/288 O
( O
28.5 O
) O
62/293 O
( O
21.2 O
) O
Day O
7 O
22/223 O
( O
10.0 O
) O
17/213 O
( O
8.0 O
) O
11/198 O
( O
5.6 O
) O
28/219 O
( O
12.8 O
) O
Day O
30 O
24/223 O
( O
10.8 O
) O
21/211 O
( O
10.0 O
) O
21/199 O
( O
10.6 O
) O
24/224 O
( O
10.7 O
) O
6.2 O
Postmarketing O
Experience O
The O
following O
foreign O
spontaneous O
reports O
have O
been O
identified O
during O
use O
of O
formulations O
similar O
to O
Prepopik O
( O
r O
) O
. O

Because O
these O
events O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Allergic O
reactions O
Cases O
of O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
rash B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
and O
purpura B-OSE_Labeled_AE
have O
been O
reported O
. O

Electrolyte O
abnormalities O
There O
have O
been O
reports O
of O
hypokalemia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
and O
hypermagnesemia B-OSE_Labeled_AE
with O
the O
use O
of O
Prepopik O
( O
r O
) O
for O
colon O
preparation O
prior O
to O
colonoscopy O
. O

Gastrointestinal O
: O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
fecal B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
and O
proctalgia B-OSE_Labeled_AE
have O
been O
reported O
with O
the O
use O
of O
Prepopik O
( O
r O
) O
for O
colon O
preparation O
prior O
to O
colonoscopy O
. O

There O
have O
been O
isolated O
reports O
of O
reversible O
aphthoid O
ileal B-OSE_Labeled_AE
ulcers I-OSE_Labeled_AE
. O

Ischemic B-OSE_Labeled_AE
colitis I-OSE_Labeled_AE
has O
been O
reported O
with O
the O
use O
of O
Prepopik O
( O
r O
) O
for O
colon O
preparation O
prior O
to O
colonoscopy O
. O

However O
, O
a O
causal O
relationship O
between O
these O
ischemic B-NonOSE_AE
colitis I-NonOSE_AE
cases O
and O
the O
use O
of O
Prepopik O
( O
r O
) O
has O
not O
been O
established O
. O

Neurologic O
, O
There O
have O
been O
reports O
of O
generalized B-OSE_Labeled_AE
tonic I-OSE_Labeled_AE
- I-OSE_Labeled_AE
clonic I-OSE_Labeled_AE
seizures I-OSE_Labeled_AE
associated O
with O
and O
without O
hyponatremia B-OSE_Labeled_AE
in O
epileptic B-Not_AE_Candidate
patients I-Not_AE_Candidate
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Risk O
of O
fluid O
and O
electrolyte O
abnormalities O
, O
arrhythmia O
, O
seizures O
, O
and O
renal O
impairment O
: O
Encourage O
adequate O
hydration O
, O
assess O
concurrent O
medications O
, O
and O
consider O
laboratory O
assessments O
prior O
to O
and O
after O
use O
( O
5.1 O
, O
5.2 O
, O
5.3 O
, O
5.4 O
) O
* O
Risks O
in O
patients O
with O
renal O
insufficiency O
or O
patients O
taking O
concomitant O
medications O
that O
affect O
renal O
function O
: O
Use O
caution O
, O
ensure O
adequate O
hydration O
and O
consider O
testing O
( O
5.3 O
) O
* O
Mucosal O
ulcerations O
: O
Consider O
potential O
for O
mucosal O
ulcerations O
when O
interpreting O
colonoscopy O
findings O
in O
patients O
with O
known O
or O
suspected O
inflammatory O
bowel O
disease O
( O
5.5 O
) O
* O
Suspected O
GI O
obstruction O
or O
perforation O
: O
Rule O
out O
diagnosis O
before O
administration O
( O
4 O
, O
5.6 O
) O
* O
Patients O
at O
risk O
for O
aspiration O
: O
Observe O
during O
administration O
( O
5.7 O
) O
* O
Not O
for O
direct O
ingestion O
: O
Dissolve O
and O
take O
with O
additional O
water O
( O
5.8 O
) O
5.1 O
Serious O
Fluid O
and O
Serum O
Chemistry O
Abnormalities O
Advise O
patients O
to O
hydrate O
adequately O
before O
, O
during O
, O
and O
after O
the O
use O
of O
Prepopik O
( O
r O
) O
. O

Use O
caution O
in O
patients O
with O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
when O
replacing O
fluids O
. O

If O
a O
patient O
develops O
significant O
vomiting B-NonOSE_AE
or O
signs O
of O
dehydration B-NonOSE_AE
including O
signs O
of O
orthostatic B-NonOSE_AE
hypotension I-NonOSE_AE
after O
taking O
Prepopik O
( O
r O
) O
, O
consider O
performing O
post-colonoscopy O
lab O
tests O
( O
electrolytes O
, O
creatinine O
, O
and O
BUN O
) O
and O
treat O
accordingly O
. O

Approximately O
20 O
% O
of O
patients O
in O
both O
arms O
( O
Prepopik O
( O
r O
) O
, O
2L O
of O
PEG O
+ O
E O
plus O
two O
* O
5-mg O
bisacodyl O
tablets O
) O
of O
clinical O
trials O
of O
Prepopik O
( O
r O
) O
had O
orthostatic B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
( O
changes O
in I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
and/or O
heart O
rate O
) O
on O
the O
day O
of O
colonoscopy O
. O

In O
clinical O
trials O
orthostatic B-NonOSE_AE
changes I-NonOSE_AE
were O
documented O
out O
to O
seven O
days O
post O
colonoscopy O
. O

[ O
see O
Adverse O
Reactions O
( O
6.1 O
, O
6.2 O
) O
] O
Fluid B-OSE_Labeled_AE
and I-OSE_Labeled_AE
electrolyte I-OSE_Labeled_AE
disturbances I-OSE_Labeled_AE
can O
lead O
to O
serious O
adverse O
events O
including O
cardiac B-OSE_Labeled_AE
arrhythmias I-OSE_Labeled_AE
or O
seizures B-OSE_Labeled_AE
and O
renal B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
. O

Fluid B-NonOSE_AE
and O
electrolyte O
abnormalities I-NonOSE_AE
should O
be O
corrected O
before O
treatment O
with O
Prepopik O
( O
r O
) O
. O

In O
addition O
, O
use O
caution O
when O
prescribing O
Prepopik O
( O
r O
) O
for O
patients O
who O
have O
conditions O
or O
who O
are O
using O
medications O
that O
increase O
the O
risk O
for O
fluid B-NonOSE_AE
and O
electrolyte O
disturbances I-NonOSE_AE
or O
that O
may O
increase O
the O
risk O
of O
adverse O
events O
of O
seizure B-NonOSE_AE
, O
arrhythmia B-NonOSE_AE
, O
and O
renal B-NonOSE_AE
impairment I-NonOSE_AE
. O

5.2 O
Seizures O
There O
have O
been O
reports O
of O
generalized B-OSE_Labeled_AE
tonic I-OSE_Labeled_AE
- I-OSE_Labeled_AE
clonic I-OSE_Labeled_AE
seizures I-OSE_Labeled_AE
with O
the O
use O
of O
bowel O
preparation O
products O
in O
patients O
with O
no O
prior O
history O
of O
seizures B-Not_AE_Candidate
. O

The O
seizure B-OSE_Labeled_AE
cases O
were O
associated O
with O
electrolyte B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
( O
e.g. O
, O
hyponatremia B-OSE_Labeled_AE
, O
hypokalemia B-OSE_Labeled_AE
, O
hypocalcemia B-OSE_Labeled_AE
, O
and O
hypomagnesemia B-OSE_Labeled_AE
) O
and O
low B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
osmolality I-OSE_Labeled_AE
. O

The O
neurologic B-NonOSE_AE
abnormalities I-NonOSE_AE
resolved O
with O
correction O
of O
fluid B-NonOSE_AE
and O
electrolyte O
abnormalities I-NonOSE_AE
. O

Use O
caution O
when O
prescribing O
Prepopik O
( O
r O
) O
for O
patients O
with O
a O
history O
of O
seizures B-Not_AE_Candidate
and O
in O
patients O
at O
risk O
of O
seizure B-NonOSE_AE
, O
such O
as O
patients O
taking O
medications O
that O
lower B-NonOSE_AE
the I-NonOSE_AE
seizure I-NonOSE_AE
threshold I-NonOSE_AE
( O
e.g. O
, O
tricyclic O
antidepressants O
) O
, O
patients O
withdrawing O
from O
alcohol O
or O
benzodiazepines O
, O
patients O
with O
known O
or O
suspected O
hyponatremia B-Not_AE_Candidate
. O

[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
5.3 O
Use O
in O
Patients O
with O
Renal O
Impairment O
As O
in O
other O
magnesium O
containing O
bowel O
preparations O
, O
use O
caution O
when O
prescribing O
Prepopik O
( O
r O
) O
for O
patients O
with O
impaired B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
or O
patients O
taking O
concomitant O
medications O
that O
may O
affect O
renal O
function O
( O
such O
as O
diuretics O
, O
angiotensin O
converting O
enzyme O
inhibitors O
, O
angiotensin O
receptor O
blockers O
, O
or O
non-steroidal O
anti-inflammatory O
drugs O
) O
. O

These O
patients O
may O
be O
at O
increased O
risk O
for O
renal B-NonOSE_AE
injury I-NonOSE_AE
. O

Advise O
these O
patients O
of O
the O
importance O
of O
adequate O
hydration O
before O
, O
during O
and O
after O
the O
use O
of O
Prepopik O
( O
r O
) O
. O

Consider O
performing O
baseline O
and O
post-colonoscopy O
laboratory O
tests O
( O
electrolytes O
, O
creatinine O
, O
and O
BUN O
) O
in O
these O
patients O
. O

In O
patients O
with O
severely O
reduced B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
( I-Not_AE_Candidate
creatinine I-Not_AE_Candidate
clearance I-Not_AE_Candidate
< I-Not_AE_Candidate
3 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
) O
, O
accumulation B-NonOSE_AE
of I-NonOSE_AE
magnesium I-NonOSE_AE
in I-NonOSE_AE
plasma I-NonOSE_AE
may O
occur O
. O

5.4 O
Cardiac O
Arrhythmias O
There O
have O
been O
rare O
reports O
of O
serious O
arrhythmias B-OSE_Labeled_AE
associated O
with O
the O
use O
of O
ionic O
osmotic O
laxative O
products O
for O
bowel O
preparation O
. O

Use O
caution O
when O
prescribing O
Prepopik O
( O
r O
) O
for O
patients O
at O
increased O
risk O
of O
arrhythmias B-NonOSE_AE
( O
e.g. O
, O
patients O
with O
a O
history O
of O
prolonged B-Not_AE_Candidate
QT I-Not_AE_Candidate
, O
uncontrolled O
arrhythmias B-Not_AE_Candidate
, O
recent O
myocardial B-Not_AE_Candidate
infarction I-Not_AE_Candidate
, O
unstable B-Not_AE_Candidate
angina I-Not_AE_Candidate
, O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
or O
cardiomyopathy B-Not_AE_Candidate
) O
. O

Pre-dose O
and O
post-colonoscopy O
ECGs O
should O
be O
considered O
in O
patients O
at O
increased O
risk O
of O
serious O
cardiac B-NonOSE_AE
arrhythmias I-NonOSE_AE
. O

5.5 O
Colonic O
Mucosal O
Ulceration O
, O
Ischemic O
Colitis O
and O
Ulcerative O
Colitis O
Osmotic O
laxatives O
may O
produce O
colonic B-OSE_Labeled_AE
mucosal I-OSE_Labeled_AE
aphthous I-OSE_Labeled_AE
ulcerations I-OSE_Labeled_AE
and O
there O
have O
been O
reports O
of O
more O
serious O
cases O
of O
ischemic B-OSE_Labeled_AE
colitis I-OSE_Labeled_AE
requiring O
hospitalization O
. O

Concurrent O
use O
of O
additional O
stimulant O
laxatives O
with O
Prepopik O
( O
r O
) O
may O
increase O
this O
risk O
. O

The O
potential O
for O
mucosal B-NonOSE_AE
ulcerations I-NonOSE_AE
should O
be O
considered O
when O
interpreting O
colonoscopy O
findings O
in O
patients O
with O
known O
or O
suspected O
inflammatory B-Not_AE_Candidate
bowel I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
5.6 O
Use O
in O
Patients O
with O
Significant O
Gastrointestinal O
Disease O
If O
gastrointestinal B-Not_AE_Candidate
obstruction I-Not_AE_Candidate
or O
perforation O
is O
suspected O
, O
perform O
appropriate O
diagnostic O
studies O
to O
rule O
out O
these O
conditions O
before O
administering O
Prepopik O
( O
r O
) O
. O

Use O
with O
caution O
in O
patients O
with O
severe O
active O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
. O

5.7 O
Aspiration O
Patients O
with O
impaired B-Not_AE_Candidate
gag I-Not_AE_Candidate
reflex I-Not_AE_Candidate
and O
patients O
prone O
to O
regurgitation B-Not_AE_Candidate
or O
aspiration B-Not_AE_Candidate
should O
be O
observed O
during O
the O
administration O
of O
Prepopik O
( O
r O
) O
. O

Use O
with O
caution O
in O
these O
patients O
. O

5.8 O
Not O
for O
Direct O
Ingestion O
Each O
packet O
must O
be O
dissolved O
in O
5 O
ounces O
of O
cold O
water O
and O
administered O
at O
separate O
times O
according O
to O
the O
dosing O
regimen O
. O

Ingestion O
of O
additional O
water O
is O
important O
to O
patient O
tolerance O
. O

Direct O
ingestion O
of O
the O
undissolved O
powder O
may O
increase O
the O
risk O
of O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
dehydration B-NonOSE_AE
, O
and O
electrolyte B-NonOSE_AE
disturbances I-NonOSE_AE
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
and O
otherwise O
important O
adverse O
drug O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
labeling O
: O
* O
Lymphoma B-OSE_Labeled_AE
and O
Other O
Malignancies B-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Serious O
Infections B-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Polyoma B-OSE_Labeled_AE
Virus I-OSE_Labeled_AE
Infections I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
CMV B-OSE_Labeled_AE
Infections I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
New O
Onset O
Diabetes B-OSE_Labeled_AE
After O
Transplant O
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Nephrotoxicity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Neurotoxicity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Hyperkalemia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Hypertension B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
* O
Anaphylaxis B-OSE_Labeled_AE
with O
Prograf O
Injection O
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
* O
Myocardial B-OSE_Labeled_AE
Hypertrophy I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.15 O
) O
] O
* O
Pure B-OSE_Labeled_AE
Red I-OSE_Labeled_AE
Cell I-OSE_Labeled_AE
Aplasia I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.17 O
) O
] O
* O
Gastrointestinal B-OSE_Labeled_AE
Perforation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.18 O
) O
] O
* O
Kidney B-Not_AE_Candidate
Transplant I-Not_AE_Candidate
: O
The O
most O
common O
adverse O
reactions O
( O
> O
= O
30 O
% O
) O
were O
infection B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
function I-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
hypomagnesemia B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
hypophosphatemia B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
, O
hyperlipidemia B-OSE_Labeled_AE
, O
hyperkalemia B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
( O
6.1 O
) O
* O
Liver B-Not_AE_Candidate
Transplant I-Not_AE_Candidate
: O
The O
most O
common O
adverse O
reactions O
( O
> O
= O
40 O
% O
) O
were O
tremor B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
function I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
hyperkalemia B-OSE_Labeled_AE
, O
hypomagnesemia B-OSE_Labeled_AE
, O
and O
hyperglycemia B-OSE_Labeled_AE
( O
6.1 O
) O
* O
Heart B-Not_AE_Candidate
Transplant I-Not_AE_Candidate
: O
The O
most O
common O
adverse O
reactions O
( O
> O
= O
15 O
% O
) O
were O
abnormal B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
function I-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
, O
CMV B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
infection B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
, O
pericardial B-OSE_Labeled_AE
effusion I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
and O
hyperlipemia B-OSE_Labeled_AE
( O
6.1 O
) O
EXCERPT O
: O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Astellas O
Pharma O
US O
, O
Inc O
at O
1-800-727-7003 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Studies O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

In O
addition O
, O
the O
clinical O
trials O
were O
not O
designed O
to O
establish O
comparative O
differences O
across O
study O
arms O
with O
regards O
to O
the O
adverse O
reactions O
discussed O
below O
. O

Kidney O
Transplant O
The O
incidence O
of O
adverse O
reactions O
was O
determined O
in O
three O
randomized O
kidney B-Not_AE_Candidate
transplant I-Not_AE_Candidate
trials O
. O

One O
of O
the O
trials O
used O
azathioprine O
( O
AZA O
) O
and O
corticosteroids O
and O
two O
of O
the O
trials O
used O
mycophenolate O
mofetil O
( O
MMF O
) O
and O
corticosteroids O
concomitantly O
for O
maintenance O
immunosuppression B-NonOSE_AE
. O

Prograf-based O
immunosuppression B-NonOSE_AE
in O
conjunction O
with O
azathioprine O
and O
corticosteroids O
following O
kidney B-Not_AE_Candidate
transplantation I-Not_AE_Candidate
was O
assessed O
in O
trial O
where O
205 O
patients O
received O
Prograf O
based O
immunosuppression B-NonOSE_AE
and O
207 O
patients O
received O
cyclosporine O
based O
immunosuppression B-NonOSE_AE
. O

The O
trial O
population O
had O
a O
mean O
age O
of O
43 O
years O
( O
mean+/-sd O
was O
43+/-13 O
years O
on O
Prograf O
and O
44+/-12 O
years O
on O
cyclosporine O
arm O
) O
, O
the O
distribution O
was O
61 O
% O
male O
, O
and O
the O
composition O
was O
White O
( O
58 O
% O
) O
, O
Black O
( O
25 O
% O
) O
, O
Hispanic O
( O
12 O
% O
) O
and O
Other O
( O
5 O
% O
) O
. O

The O
12 O
month O
post B-NonOSE_AE
- I-NonOSE_AE
transplant I-NonOSE_AE
information O
from O
this O
trial O
is O
presented O
below O
. O

The O
most O
common O
adverse O
reactions O
( O
> O
= O
30 O
% O
) O
observed O
in O
Prograf-treated O
kidney B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
are O
: O
infection B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
function I-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
hypomagnesemia B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
hypophosphatemia B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
, O
hyperlipidemia B-OSE_Labeled_AE
, O
hyperkalemia B-OSE_Labeled_AE
and O
anemia B-OSE_Labeled_AE
. O

Adverse O
reactions O
that O
occurred O
in O
> O
= O
15 O
% O
of O
kidney B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
treated O
with O
Prograf O
in O
conjunction O
with O
azathioprine O
are O
presented O
below O
: O
Table O
4 O
. O

Kidney O
Transplantation O
: O
Adverse O
Reactions O
Occurring O
in O
> O
= O
15 O
% O
of O
Patients O
Treated O
with O
Prograf O
in O
Conjunction O
with O
Azathioprine O
( O
AZA O
) O
Prograf/AZA O
( O
N=205 O
) O
Cyclosporine/AZA O
( O
N=207 O
) O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Tremor B-OSE_Labeled_AE
Headache B-OSE_Labeled_AE
Insomnia B-OSE_Labeled_AE
Paresthesia B-OSE_Labeled_AE
Dizziness B-OSE_Labeled_AE
54 O
% O
44 O
% O
32 O
% O
23 O
% O
19 O
% O
34 O
% O
38 O
% O
30 O
% O
16 O
% O
16 O
% O
Gastrointestinal B-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
Nausea B-OSE_Labeled_AE
Constipation B-OSE_Labeled_AE
Vomiting B-OSE_Labeled_AE
Dyspepsia B-OSE_Labeled_AE
44 O
% O
38 O
% O
35 O
% O
29 O
% O
28 O
% O
41 O
% O
36 O
% O
43 O
% O
23 O
% O
20 O
% O
Cardiovascular B-NonOSE_AE
Hypertension B-OSE_Labeled_AE
Chest B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
50 O
% O
19 O
% O
52 O
% O
13 O
% O
Urogenital B-NonOSE_AE
Creatinine B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
45 O
% O
34 O
% O
42 O
% O
35 O
% O
Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
Hypophosphatemia B-OSE_Labeled_AE
Hypomagnesemia B-OSE_Labeled_AE
Hyperlipemia B-OSE_Labeled_AE
Hyperkalemia B-OSE_Labeled_AE
Diabetes B-OSE_Labeled_AE
Mellitus I-OSE_Labeled_AE
Hypokalemia B-OSE_Labeled_AE
Hyperglycemia B-OSE_Labeled_AE
Edema B-OSE_Labeled_AE
49 O
% O
34 O
% O
31 O
% O
31 O
% O
24 O
% O
22 O
% O
22 O
% O
18 O
% O
53 O
% O
17 O
% O
38 O
% O
32 O
% O
9 O
% O
25 O
% O
16 O
% O
19 O
% O
Hemic B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
Anemia B-OSE_Labeled_AE
Leukopenia B-OSE_Labeled_AE
30 O
% O
15 O
% O
24 O
% O
17 O
% O
Miscellaneous B-NonOSE_AE
Infection B-OSE_Labeled_AE
Peripheral B-OSE_Labeled_AE
Edema I-OSE_Labeled_AE
Asthenia B-OSE_Labeled_AE
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
Pain B-OSE_Labeled_AE
Fever B-OSE_Labeled_AE
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
45 O
% O
36 O
% O
34 O
% O
33 O
% O
32 O
% O
29 O
% O
24 O
% O
49 O
% O
48 O
% O
30 O
% O
31 O
% O
30 O
% O
29 O
% O
20 O
% O
Respiratory B-NonOSE_AE
System I-NonOSE_AE
Dyspnea B-OSE_Labeled_AE
Cough B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
22 O
% O
18 O
% O
18 O
% O
15 O
% O
Musculoskeletal B-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
25 O
% O
24 O
% O
Skin B-NonOSE_AE
Rash B-OSE_Labeled_AE
Pruritus B-OSE_Labeled_AE
17 O
% O
15 O
% O
12 O
% O
7 O
% O
Two O
trials O
were O
conducted O
for O
Prograf-based O
immunosuppression B-NonOSE_AE
in O
conjunction O
with O
MMF O
and O
corticosteroids O
. O

In O
the O
non-US O
trial O
( O
Study O
1 O
) O
, O
the O
incidence O
of O
adverse O
reactions O
was O
based O
on O
1195 O
kidney B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
that O
received O
Prograf O
( O
Group O
C O
, O
n=403 O
) O
, O
or O
one O
of O
two O
cyclosporine O
( O
CsA O
) O
regimens O
( O
Group O
A O
, O
n=384 O
and O
Group O
B O
, O
n=408 O
) O
in O
combination O
with O
MMF O
and O
corticosteroids O
; O
all O
patients O
, O
except O
those O
in O
one O
of O
the O
two O
cyclosporine O
groups O
, O
also O
received O
induction O
with O
daclizumab O
. O

The O
trial O
population O
had O
a O
mean O
age O
of O
46 O
years O
( O
range O
17 O
to O
76 O
) O
, O
the O
distribution O
was O
65 O
% O
male O
, O
and O
the O
composition O
was O
93 O
% O
Caucasian O
. O

The O
12 O
month O
post-transplant O
information O
from O
this O
trial O
is O
presented O
below O
. O

Adverse O
reactions O
that O
occurred O
in O
> O
= O
10 O
% O
of O
kidney B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
treated O
with O
Prograf O
in O
conjunction O
with O
MMF O
in O
Study O
1 O
[ O
Note O
: O
This O
trial O
was O
conducted O
entirely O
outside O
of O
the O
United O
States O
. O

Such O
trials O
often O
report O
a O
lower O
incidence O
of O
adverse O
reactions O
in O
comparison O
to O
U.S O
. O
trials O
] O
are O
presented O
below O
: O
Table O
5 O
. O

Kidney O
Transplantation O
: O
Adverse O
Reactions O
Occurring O
in O
> O
= O
10 O
% O
of O
Patients O
Treated O
with O
Prograf O
in O
Conjunction O
with O
MMF O
( O
Study O
1 O
) O
Key O
: O
Group O
A O
= O
CsA/MMF/CS O
, O
B O
= O
CsA/MMF/CS/Daclizumab O
, O
C= O
Tac/MMF/CS/DaclizumabCsA= O
Cyclosporine O
, O
CS O
= O
Corticosteroids O
, O
Tac O
= O
Tacrolimus O
, O
MMF O
= O
mycophenolate O
mofetil O
Prograf O
( O
Group O
C O
) O
Cyclosporine O
( O
Group O
A O
) O
Cyclosporine O
( O
Group O
B O
) O
( O
N=403 O
) O
( O
N=384 O
) O
( O
N=408 O
) O
Diarrhea B-OSE_Labeled_AE
25 O
% O
16 O
% O
13 O
% O
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
24 O
% O
28 O
% O
24 O
% O
Anemia B-OSE_Labeled_AE
17 O
% O
19 O
% O
17 O
% O
Hypertension B-OSE_Labeled_AE
13 O
% O
14 O
% O
12 O
% O
Leukopenia B-OSE_Labeled_AE
13 O
% O
10 O
% O
10 O
% O
Edema B-OSE_Labeled_AE
Peripheral I-OSE_Labeled_AE
11 O
% O
12 O
% O
13 O
% O
Hyperlipidemia B-OSE_Labeled_AE
10 O
% O
15 O
% O
13 O
% O
In O
the O
U.S O
. O
trial O
( O
Study O
2 O
) O
with O
Prograf-based O
immunosuppression B-NonOSE_AE
in O
conjunction O
with O
MMF O
and O
corticosteroids O
, O
424 O
kidney B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
received O
Prograf O
( O
n=212 O
) O
or O
cyclosporine O
( O
n=212 O
) O
in O
combination O
with O
MMF O
1 O
gram O
twice O
daily O
, O
basiliximab O
induction O
, O
and O
corticosteroids O
. O

The O
trial O
population O
had O
a O
mean O
age O
of O
48 O
years O
( O
range O
17 O
to O
77 O
) O
, O
the O
distribution O
was O
63 O
% O
male O
, O
and O
the O
composition O
was O
White O
( O
74 O
% O
) O
, O
Black O
( O
20 O
% O
) O
, O
Asian O
( O
3 O
% O
) O
and O
other O
( O
3 O
% O
) O
. O

The O
12 O
month O
post B-NonOSE_AE
- I-NonOSE_AE
transplant I-NonOSE_AE
information O
from O
this O
trial O
is O
presented O
below O
. O

Adverse O
reactions O
that O
occurred O
in O
> O
=15 O
% O
of O
kidney B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
treated O
with O
Prograf O
in O
conjunction O
with O
MMF O
in O
Study O
2 O
are O
presented O
below O
: O
Table O
6 O
. O

Kidney O
Transplantation O
: O
Adverse O
Reactions O
Occurring O
in O
> O
= O
15 O
% O
of O
Patients O
Treated O
with O
Prograf O
in O
Conjunction O
with O
MMF O
( O
Study O
2 O
) O
Prograf/MMF O
Cyclosporine/MMF O
( O
N=212 O
) O
( O
N=212 O
) O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
44 O
% O
26 O
% O
Nausea B-OSE_Labeled_AE
39 O
% O
47 O
% O
Constipation B-OSE_Labeled_AE
36 O
% O
41 O
% O
Vomiting B-OSE_Labeled_AE
26 O
% O
25 O
% O
Dyspepsia B-OSE_Labeled_AE
18 O
% O
15 O
% O
Injury B-NonOSE_AE
, I-NonOSE_AE
Poisoning I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
Procedural I-NonOSE_AE
Complications I-NonOSE_AE
Post B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Procedural I-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
29 O
% O
27 O
% O
Incision B-OSE_Labeled_AE
Site I-OSE_Labeled_AE
Complication I-OSE_Labeled_AE
28 O
% O
23 O
% O
Graft B-OSE_Labeled_AE
Dysfunction I-OSE_Labeled_AE
24 O
% O
18 O
% O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Hypomagnesemia B-OSE_Labeled_AE
28 O
% O
22 O
% O
Hypophosphatemia B-OSE_Labeled_AE
28 O
% O
21 O
% O
Hyperkalemia B-OSE_Labeled_AE
26 O
% O
19 O
% O
Hyperglycemia B-OSE_Labeled_AE
21 O
% O
15 O
% O
Hyperlipidemia B-OSE_Labeled_AE
18 O
% O
25 O
% O
Hypokalemia B-OSE_Labeled_AE
16 O
% O
18 O
% O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Tremor B-OSE_Labeled_AE
34 O
% O
20 O
% O
Headache B-OSE_Labeled_AE
24 O
% O
25 O
% O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Anemia B-OSE_Labeled_AE
30 O
% O
28 O
% O
Leukopenia B-OSE_Labeled_AE
16 O
% O
12 O
% O
Miscellaneous B-NonOSE_AE
Edema B-OSE_Labeled_AE
Peripheral I-OSE_Labeled_AE
35 O
% O
46 O
% O
Hypertension B-OSE_Labeled_AE
32 O
% O
35 O
% O
Insomnia B-OSE_Labeled_AE
30 O
% O
21 O
% O
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
26 O
% O
22 O
% O
Blood B-OSE_Labeled_AE
Creatinine I-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
23 O
% O
23 O
% O
Less O
frequently O
observed O
adverse O
reactions O
in O
both O
liver B-Not_AE_Candidate
transplantation I-Not_AE_Candidate
and O
kidney B-Not_AE_Candidate
transplantation I-Not_AE_Candidate
patients O
are O
described O
under O
the O
subsection O
Less O
Frequently O
Reported O
Adverse O
Reactions O
. O

Liver O
Transplantation O
There O
were O
two O
randomized O
comparative O
liver B-Not_AE_Candidate
transplant I-Not_AE_Candidate
trials O
. O

In O
the O
U.S O
. O
trial O
, O
263 O
adult O
and O
pediatric O
patients O
received O
tacrolimus O
and O
steroids O
and O
266 O
patients O
received O
cyclosporine-based O
immunosuppressive O
regimen O
( O
CsA/AZA O
) O
. O

The O
trial O
population O
had O
a O
mean O
age O
of O
44 O
years O
( O
range O
0.4 O
to70 O
) O
, O
the O
distribution O
was O
52 O
% O
male O
, O
and O
the O
composition O
was O
White O
( O
78 O
% O
) O
, O
Black O
( O
5 O
% O
) O
, O
Asian O
( O
2 O
% O
) O
, O
Hispanic O
( O
13 O
% O
) O
and O
Other O
( O
2 O
% O
) O
. O

In O
the O
European O
trial O
, O
270 O
patients O
received O
tacrolimus O
and O
steroids O
and O
275 O
patients O
received O
CsA/AZA O
. O

The O
trial O
population O
had O
a O
mean O
age O
of O
46 O
years O
( O
range O
15 O
to O
68 O
) O
, O
the O
distribution O
was O
59 O
% O
male O
, O
and O
the O
composition O
was O
White O
( O
95.4 O
% O
) O
, O
Black O
( O
1 O
% O
) O
, O
Asian O
( O
2 O
% O
) O
and O
Other O
( O
2 O
% O
) O
. O

The O
proportion O
of O
patients O
reporting O
more O
than O
one O
adverse O
event O
was O
> O
99 O
% O
in O
both O
the O
tacrolimus O
group O
and O
the O
CsA/AZA O
group O
. O

Precautions O
must O
be O
taken O
when O
comparing O
the O
incidence O
of O
adverse O
reactions O
in O
the O
U.S O
. O
trial O
to O
that O
in O
the O
European O
trial O
. O

The O
12-month O
post-transplant O
information O
from O
the O
U.S O
. O
trial O
and O
from O
the O
European O
trial O
is O
presented O
below O
. O

The O
two O
trials O
also O
included O
different O
patient O
populations O
and O
patients O
were O
treated O
with O
immunosuppressive O
regimens O
of O
differing O
intensities O
. O

Adverse O
reactions O
reported O
in O
> O
=15 O
% O
in O
tacrolimus O
patients O
( O
combined O
trial O
results O
) O
are O
presented O
below O
for O
the O
two O
controlled O
trials O
in O
liver B-Not_AE_Candidate
transplantation I-Not_AE_Candidate
. O

The O
most O
common O
adverse O
reactions O
( O
> O
= O
40 O
% O
) O
observed O
in O
Prograf-treated O
liver B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
are O
: O
tremor B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
function I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
hyperkalemia B-OSE_Labeled_AE
, O
hypomagnesemia B-OSE_Labeled_AE
, O
and O
hyperglycemia B-OSE_Labeled_AE
. O

These O
all O
occur O
with O
oral O
and O
IV O
administration O
of O
Prograf O
and O
some O
may O
respond O
to O
a O
reduction O
in O
dosing O
( O
e.g. O
, O
tremor B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
) O
. O

Diarrhea B-OSE_Labeled_AE
was O
sometimes O
associated O
with O
other O
gastrointestinal B-OSE_Labeled_AE
complaints I-OSE_Labeled_AE
such O
as O
nausea B-OSE_Labeled_AE
and O
vomiting B-OSE_Labeled_AE
. O

Table O
7 O
. O

Liver O
Transplantation O
: O
Adverse O
Reactions O
Occurring O
in O
> O
= O
15 O
% O
of O
Patients O
Treated O
with O
Prograf O
U.S O
. O
TRIAL O
EUROPEAN O
TRIAL O
Prograf O
( O
N=250 O
) O
Cyclosporine/AZA O
( O
N=250 O
) O
Prograf O
( O
N=264 O
) O
Cyclosporine/AZA O
( O
N=265 O
) O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Headache B-OSE_Labeled_AE
Insomnia B-OSE_Labeled_AE
Tremor B-OSE_Labeled_AE
Paresthesia B-OSE_Labeled_AE
64 O
% O
64 O
% O
56 O
% O
40 O
% O
60 O
% O
68 O
% O
46 O
% O
30 O
% O
37 O
% O
32 O
% O
48 O
% O
17 O
% O
26 O
% O
23 O
% O
32 O
% O
17 O
% O
Gastrointestinal B-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
Nausea B-OSE_Labeled_AE
LFT B-OSE_Labeled_AE
Abnormal I-OSE_Labeled_AE
Anorexia B-OSE_Labeled_AE
Vomiting B-OSE_Labeled_AE
Constipation B-OSE_Labeled_AE
72 O
% O
46 O
% O
36 O
% O
34 O
% O
27 O
% O
24 O
% O
47 O
% O
37 O
% O
30 O
% O
24 O
% O
15 O
% O
27 O
% O
37 O
% O
32 O
% O
6 O
% O
7 O
% O
14 O
% O
23 O
% O
27 O
% O
27 O
% O
5 O
% O
5 O
% O
11 O
% O
21 O
% O
Cardiovascular B-NonOSE_AE
Hypertension B-OSE_Labeled_AE
47 O
% O
56 O
% O
38 O
% O
43 O
% O
Urogenital B-NonOSE_AE
Kidney B-OSE_Labeled_AE
Function I-OSE_Labeled_AE
Abnormal I-OSE_Labeled_AE
40 O
% O
27 O
% O
36 O
% O
23 O
% O
Creatinine B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
39 O
% O
25 O
% O
24 O
% O
19 O
% O
BUN B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
30 O
% O
22 O
% O
12 O
% O
9 O
% O
Oliguria B-OSE_Labeled_AE
18 O
% O
15 O
% O
19 O
% O
12 O
% O
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
16 O
% O
18 O
% O
21 O
% O
19 O
% O
Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
Hypomagnesemia B-OSE_Labeled_AE
Hyperglycemia B-OSE_Labeled_AE
Hyperkalemia B-OSE_Labeled_AE
Hypokalemia B-OSE_Labeled_AE
48 O
% O
47 O
% O
45 O
% O
29 O
% O
45 O
% O
38 O
% O
26 O
% O
34 O
% O
16 O
% O
33 O
% O
13 O
% O
13 O
% O
9 O
% O
22 O
% O
9 O
% O
16 O
% O
Hemic B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
Anemia B-OSE_Labeled_AE
Leukocytosis B-OSE_Labeled_AE
Thrombocytopenia B-OSE_Labeled_AE
47 O
% O
32 O
% O
24 O
% O
38 O
% O
26 O
% O
20 O
% O
5 O
% O
8 O
% O
14 O
% O
1 O
% O
8 O
% O
19 O
% O
Miscellaneous B-NonOSE_AE
Pain B-OSE_Labeled_AE
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
Asthenia B-OSE_Labeled_AE
Fever B-OSE_Labeled_AE
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
Ascites B-OSE_Labeled_AE
Peripheral B-OSE_Labeled_AE
Edema I-OSE_Labeled_AE
63 O
% O
59 O
% O
52 O
% O
48 O
% O
30 O
% O
27 O
% O
26 O
% O
57 O
% O
54 O
% O
48 O
% O
56 O
% O
29 O
% O
22 O
% O
26 O
% O
24 O
% O
29 O
% O
11 O
% O
19 O
% O
17 O
% O
7 O
% O
12 O
% O
22 O
% O
22 O
% O
7 O
% O
22 O
% O
17 O
% O
8 O
% O
14 O
% O
Respiratory B-NonOSE_AE
System I-NonOSE_AE
Pleural B-OSE_Labeled_AE
Effusion I-OSE_Labeled_AE
Dyspnea B-OSE_Labeled_AE
Atelectasis B-OSE_Labeled_AE
30 O
% O
29 O
% O
28 O
% O
32 O
% O
23 O
% O
30 O
% O
36 O
% O
5 O
% O
5 O
% O
35 O
% O
4 O
% O
4 O
% O
Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
Pruritus B-OSE_Labeled_AE
Rash B-OSE_Labeled_AE
36 O
% O
24 O
% O
20 O
% O
19 O
% O
15 O
% O
10 O
% O
7 O
% O
4 O
% O
Less O
frequently O
observed O
adverse O
reactions O
in O
both O
liver B-Not_AE_Candidate
transplantation I-Not_AE_Candidate
and O
kidney B-Not_AE_Candidate
transplantation I-Not_AE_Candidate
patients O
are O
described O
under O
the O
subsection O
Less O
Frequently O
Reported O
Adverse O
Reactions O
. O

Heart B-Not_AE_Candidate
Transplantation I-Not_AE_Candidate
The O
incidence O
of O
adverse O
reactions O
was O
determined O
based O
on O
two O
trials O
in O
primary O
orthotopic O
heart B-Not_AE_Candidate
transplantation I-Not_AE_Candidate
. O

In O
a O
trial O
conducted O
in O
Europe O
, O
314 O
patients O
received O
a O
regimen O
of O
antibody O
induction O
, O
corticosteroids O
and O
azathioprine O
( O
AZA O
) O
in O
combination O
with O
Prograf O
( O
n=157 O
) O
or O
cyclosporine O
( O
n=157 O
) O
for O
18 O
months O
. O

The O
trial O
population O
had O
a O
mean O
age O
of O
51 O
years O
( O
range O
18 O
to O
65 O
) O
, O
the O
distribution O
was O
82 O
% O
male O
, O
and O
the O
composition O
was O
White O
( O
96 O
% O
) O
, O
Black O
( O
3 O
% O
) O
and O
other O
( O
1 O
% O
) O
. O

The O
most O
common O
adverse O
reactions O
( O
> O
= O
15 O
% O
) O
observed O
in O
Prograf-treated O
heart B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
are O
: O
abnormal B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
function I-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
, O
CMV B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
infection B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
, O
pericardial B-OSE_Labeled_AE
effusion I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
and O
hyperlipemia B-OSE_Labeled_AE
. O

Adverse O
reactions O
in O
heart B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
in O
the O
European O
trial O
are O
presented O
below O
: O
Table O
8 O
. O

Heart O
Transplantation O
: O
Adverse O
Reactions O
Occurring O
in O
> O
= O
15 O
% O
of O
Patients O
Treated O
with O
Prograf O
in O
Conjunction O
with O
Azathioprine O
( O
AZA O
) O
Prograf/AZA O
( O
n=157 O
) O
Cyclosporine/AZA O
( O
n=157 O
) O
Cardiovascular B-NonOSE_AE
System I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
62 O
% O
69 O
% O
Pericardial B-OSE_Labeled_AE
Effusion I-OSE_Labeled_AE
15 O
% O
14 O
% O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
CMV B-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
32 O
% O
30 O
% O
Infection B-OSE_Labeled_AE
24 O
% O
21 O
% O
Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
Disorders I-NonOSE_AE
Diabetes B-OSE_Labeled_AE
Mellitus I-OSE_Labeled_AE
26 O
% O
16 O
% O
Hyperglycemia B-OSE_Labeled_AE
23 O
% O
17 O
% O
Hyperlipemia B-OSE_Labeled_AE
18 O
% O
27 O
% O
Hemic B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Anemia B-OSE_Labeled_AE
50 O
% O
36 O
% O
Leukopenia B-OSE_Labeled_AE
48 O
% O
39 O
% O
Urogenital B-NonOSE_AE
System I-NonOSE_AE
Kidney B-OSE_Labeled_AE
Function I-OSE_Labeled_AE
Abnormal I-OSE_Labeled_AE
56 O
% O
57 O
% O
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
16 O
% O
12 O
% O
Respiratory B-NonOSE_AE
System I-NonOSE_AE
Bronchitis B-OSE_Labeled_AE
17 O
% O
18 O
% O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Tremor B-OSE_Labeled_AE
15 O
% O
6 O
% O
In O
the O
European O
trial O
, O
the O
cyclosporine O
trough O
concentrations O
were O
above O
the O
pre-defined O
target O
range O
( O
i.e. O
, O
100 O
to O
200 O
ng/mL O
) O
at O
Day O
122 O
and O
beyond O
in O
32 O
to O
68 O
% O
of O
the O
patients O
in O
the O
cyclosporine O
treatment O
arm O
, O
whereas O
the O
tacrolimus O
trough O
concentrations O
were O
within O
the O
pre-defined O
target O
range O
( O
i.e. O
, O
5 O
to O
15 O
ng/mL O
) O
in O
74 O
to O
86 O
% O
of O
the O
patients O
in O
the O
tacrolimus O
treatment O
arm O
. O

In O
a O
U.S O
. O
trial O
, O
the O
incidence O
of O
adverse O
reactions O
was O
based O
on O
331 O
heart B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
that O
received O
corticosteroids O
and O
Prograf O
in O
combination O
with O
sirolimus O
( O
n=109 O
) O
, O
Prograf O
in O
combination O
with O
MMF O
( O
n=107 O
) O
or O
cyclosporine O
modified O
in O
combination O
with O
MMF O
( O
n=115 O
) O
for O
1 O
year O
. O

The O
trial O
population O
had O
a O
mean O
age O
of O
53 O
years O
( O
range O
18 O
to O
75 O
) O
, O
the O
distribution O
was O
78 O
% O
male O
, O
and O
the O
composition O
was O
White O
( O
83 O
% O
) O
, O
Black O
( O
13 O
% O
) O
and O
other O
( O
4 O
% O
) O
. O

Only O
selected O
targeted O
treatment-emergent O
adverse O
reactions O
were O
collected O
in O
the O
U.S O
. O
heart B-Not_AE_Candidate
transplantation I-Not_AE_Candidate
trial O
. O

Those O
reactions O
that O
were O
reported O
at O
a O
rate O
of O
15 O
% O
or O
greater O
in O
patients O
treated O
with O
Prograf O
and O
MMF O
include O
the O
following O
: O
any O
target O
adverse O
reactions O
( O
99 O
% O
) O
, O
hypertension B-OSE_Labeled_AE
( O
89 O
% O
) O
, O
hyperglycemia B-OSE_Labeled_AE
requiring O
antihyperglycemic O
therapy O
( O
70 O
% O
) O
, O
hypertriglyceridemia B-OSE_Labeled_AE
( O
65 O
% O
) O
, O
anemia B-OSE_Labeled_AE
( O
hemoglobin B-OSE_Labeled_AE
< I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
g I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
( O
65 O
% O
) O
, O
fasting B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
> I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
( O
on O
two O
separate O
occasions O
) O
( O
61 O
% O
) O
, O
hypercholesterolemia B-OSE_Labeled_AE
( O
57 O
% O
) O
, O
hyperlipidemia B-OSE_Labeled_AE
( O
34 O
% O
) O
, O
WBCs B-OSE_Labeled_AE
< I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
cells I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mcL I-OSE_Labeled_AE
( O
34 O
% O
) O
, O
serious O
bacterial B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
( O
30 O
% O
) O
, O
magnesium B-OSE_Labeled_AE
< I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
mEq I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
( O
24 O
% O
) O
, O
platelet B-OSE_Labeled_AE
count I-OSE_Labeled_AE
< I-OSE_Labeled_AE
7 I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
, I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
cells I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mcL I-OSE_Labeled_AE
( O
19 O
% O
) O
, O
and O
other O
opportunistic B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
( O
15 O
% O
) O
. O

Other O
targeted O
treatment-emergent O
adverse O
reactions O
in O
Prograf-treated O
patients O
occurred O
at O
a O
rate O
of O
less O
than O
15 O
% O
, O
and O
include O
the O
following O
: O
Cushingoid B-OSE_Labeled_AE
features I-OSE_Labeled_AE
, O
impaired B-OSE_Labeled_AE
wound I-OSE_Labeled_AE
healing I-OSE_Labeled_AE
, O
hyperkalemia B-OSE_Labeled_AE
, O
Candida B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
and O
CMV B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
. O

New O
Onset O
Diabetes O
After O
Transplant O
Kidney O
Transplant O
New B-NonOSE_AE
Onset I-NonOSE_AE
Diabetes I-NonOSE_AE
After I-NonOSE_AE
Transplant I-NonOSE_AE
( I-NonOSE_AE
NODAT I-NonOSE_AE
) O
is O
defined O
as O
a O
composite O
of O
fasting B-NonOSE_AE
plasma I-NonOSE_AE
glucose I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
2 I-NonOSE_AE
6 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
, O
HbA B-NonOSE_AE
1 I-NonOSE_AE
C I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
6 I-NonOSE_AE
% I-NonOSE_AE
, O
insulin O
use O
> O
= O
30 O
days O
or O
oral O
hypoglycemic B-NonOSE_AE
use I-NonOSE_AE
. O

In O
a O
trial O
in O
kidney B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
( O
Study O
2 O
) O
, O
NODAT B-OSE_Labeled_AE
was O
observed O
in O
75 O
% O
in O
the O
Prograf-treated O
and O
61 O
% O
in O
the O
Neoral-treated O
patients O
without O
pre-transplant O
history O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
( O
Table O
9 O
) O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

Table O
9 O
. O

Incidence O
of O
New O
Onset O
Diabetes O
After O
Transplant O
at O
1 O
year O
in O
Kidney O
Transplant O
Recipients O
in O
a O
Phase O
3 O
Trial O
( O
Study O
2 O
) O
Parameter O
Treatment O
Group O
Prograf/MMF O
( O
n O
= O
212 O
) O
Neoral/MMF O
( O
n O
= O
212 O
) O
NODAT B-OSE_Labeled_AE
112/150 O
( O
75 O
% O
) O
93/152 O
( O
61 O
% O
) O
Fasting B-OSE_Labeled_AE
Plasma I-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
96/150 O
( O
64 O
% O
) O
80/152 O
( O
53 O
% O
) O
HbA B-OSE_Labeled_AE
1 I-OSE_Labeled_AE
C I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
% I-OSE_Labeled_AE
59/150 O
( O
39 O
% O
) O
28/152 O
( O
18 O
% O
) O
Insulin O
Use O
> O
= O
30 O
days O
9/150 O
( O
6 O
% O
) O
4/152 O
( O
3 O
% O
) O
Oral O
Hypoglycemic B-NonOSE_AE
Use I-NonOSE_AE
15/150 O
( O
10 O
% O
) O
5/152 O
( O
3 O
% O
) O
In O
early O
trials O
of O
Prograf O
, O
Post B-NonOSE_AE
- I-NonOSE_AE
Transplant I-NonOSE_AE
Diabetes I-NonOSE_AE
Mellitus I-NonOSE_AE
( I-NonOSE_AE
PTDM I-NonOSE_AE
) O
was O
evaluated O
with O
a O
more O
limited O
criteria O
of O
`` O
use O
of O
insulin O
for O
30 O
or O
more O
consecutive O
days O
with O
< O
5 O
day O
gap O
'' O
in O
patients O
without O
a O
prior O
history O
of O
insulin B-NonOSE_AE
- I-NonOSE_AE
dependent I-NonOSE_AE
diabetes I-NonOSE_AE
mellitus I-NonOSE_AE
or O
non B-NonOSE_AE
- I-NonOSE_AE
insulin I-NonOSE_AE
dependent I-NonOSE_AE
diabetes I-NonOSE_AE
mellitus I-NonOSE_AE
. O

Data O
are O
presented O
in O
Tables O
10 O
to O
13 O
. O

PTDM B-OSE_Labeled_AE
was O
reported O
in O
20 O
% O
of O
Prograf/Azathioprine O
( O
AZA O
) O
-treated O
kidney B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
without O
pre-transplant O
history O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
in O
a O
Phase O
3 O
trial O
( O
Table O
10 O
) O
. O

The O
median O
time O
to O
onset O
of O
PTDM B-OSE_Labeled_AE
was O
68 O
days O
. O

Insulin O
dependence O
was O
reversible O
in O
15 O
% O
of O
these O
PTDM B-OSE_Labeled_AE
patients O
at O
one O
year O
and O
in O
50 O
% O
at O
2 O
years O
post B-NonOSE_AE
- I-NonOSE_AE
transplant I-NonOSE_AE
. O

Black O
and O
Hispanic O
kidney B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
were O
at O
an O
increased O
risk O
of O
development O
of O
PTDM B-OSE_Labeled_AE
( O
Table O
11 O
) O
. O

Table O
10 O
. O

Incidence O
of O
Post-Transplant O
Diabetes O
Mellitus O
and O
Insulin O
Use O
at O
2 O
Years O
in O
Kidney O
Transplant O
Recipients O
in O
a O
Phase O
3 O
Trial O
using O
Azathioprine O
( O
AZA O
) O
Status O
of O
PTDM B-NonOSE_AE
Use O
of O
insulin O
for O
30 O
or O
more O
consecutive O
days O
, O
with O
< O
5 O
day O
gap O
, O
without O
a O
prior O
history O
of O
insulin B-Not_AE_Candidate
- I-Not_AE_Candidate
dependent I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
or O
non B-Not_AE_Candidate
- I-Not_AE_Candidate
insulin I-Not_AE_Candidate
dependent I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
. O

Prograf/AZA O
CsA/AZA O
Patients O
without O
pre-transplant O
history O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
151 O
151 O
New O
onset O
PTDM B-OSE_Labeled_AE
, O
1st O
Year O
30/151 O
( O
20 O
% O
) O
6/151 O
( O
4 O
% O
) O
Still O
insulin B-OSE_Labeled_AE
- I-OSE_Labeled_AE
dependent I-OSE_Labeled_AE
at O
one O
year O
in O
those O
without O
prior O
history O
of O
diabetes B-Not_AE_Candidate
25/151 O
( O
17 O
% O
) O
5/151 O
( O
3 O
% O
) O
New O
onset O
PTDM B-OSE_Labeled_AE
post O
1 O
year O
1 O
0 O
Patients O
with O
PTDM B-OSE_Labeled_AE
at O
2 O
years O
16/151 O
( O
11 O
% O
) O
5/151 O
( O
3 O
% O
) O
Table O
11 O
. O

Development O
of O
Post-Transplant O
Diabetes O
Mellitus O
by O
Race O
or O
Ethnicity O
and O
by O
Treatment O
Group O
During O
First O
Year O
Post O
Kidney O
Transplantation O
in O
a O
Phase O
3 O
Trial O
Patient O
Race O
Patients O
Who O
Developed O
PTDM B-NonOSE_AE
Use O
of O
insulin O
for O
30 O
or O
more O
consecutive O
days O
, O
with O
< O
5 O
day O
gap O
, O
without O
a O
prior O
history O
of O
insulin B-Not_AE_Candidate
- I-Not_AE_Candidate
dependent I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
or O
non B-Not_AE_Candidate
- I-Not_AE_Candidate
insulin I-Not_AE_Candidate
dependent I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
. O

Prograf O
Cyclosporine O
Black O
15/41 O
( O
37 O
% O
) O
3 O
( O
8 O
% O
) O
Hispanic O
5/17 O
( O
29 O
% O
) O
1 O
( O
6 O
% O
) O
Caucasian O
10/82 O
( O
12 O
% O
) O
1 O
( O
1 O
% O
) O
Other O
0/11 O
( O
0 O
% O
) O
1 O
( O
10 O
% O
) O
Total O
30/151 O
( O
20 O
% O
) O
6 O
( O
4 O
% O
) O
Liver O
Transplant O
Insulin B-OSE_Labeled_AE
- I-OSE_Labeled_AE
dependent I-OSE_Labeled_AE
PTDM I-OSE_Labeled_AE
was O
reported O
in O
18 O
% O
and O
11 O
% O
of O
Prograf-treated O
liver B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
and O
was O
reversible O
in O
45 O
% O
and O
31 O
% O
of O
these O
patients O
at O
1 O
year O
post B-NonOSE_AE
- I-NonOSE_AE
transplant I-NonOSE_AE
, O
in O
the O
U.S O
. O
and O
European O
randomized O
trials O
, O
respectively O
, O
( O
Table O
12 O
) O
. O

Hyperglycemia B-OSE_Labeled_AE
was O
associated O
with O
the O
use O
of O
Prograf O
in O
47 O
% O
and O
33 O
% O
of O
liver B-Not_AE_Candidate
transplant I-Not_AE_Candidate
recipients O
in O
the O
U.S O
. O
and O
European O
randomized O
trials O
, O
respectively O
, O
and O
may O
require O
treatment O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Table O
12 O
. O

Incidence O
of O
Post-Transplant O
Diabetes O
Mellitus O
and O
Insulin O
Use O
at O
1 O
Year O
in O
Liver O
Transplant O
Recipients O
Status O
of O
PTDM B-NonOSE_AE
Use O
of O
insulin O
for O
30 O
or O
more O
consecutive O
days O
, O
with O
< O
5 O
day O
gap O
, O
without O
a O
prior O
history O
of O
insulin B-Not_AE_Candidate
- I-Not_AE_Candidate
dependent I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
or O
non B-Not_AE_Candidate
- I-Not_AE_Candidate
insulin I-Not_AE_Candidate
dependent I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
. O

US O
Trial O
European O
Trial O
Prograf O
Cyclosporine O
Prograf O
Cyclosporine O
Patients O
at O
riskPatients O
without O
pre-transplant O
history O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
. O

239 O
236 O
239 O
249 O
New O
Onset O
PTDM B-OSE_Labeled_AE
42 O
( O
18 O
% O
) O
30 O
( O
13 O
% O
) O
26 O
( O
11 O
% O
) O
12 O
( O
5 O
% O
) O
Patients O
still O
on O
insulin O
at O
1 O
year O
23 O
( O
10 O
% O
) O
19 O
( O
8 O
% O
) O
18 O
( O
8 O
% O
) O
6 O
( O
2 O
% O
) O
Heart O
Transplant O
Insulin B-OSE_Labeled_AE
- I-OSE_Labeled_AE
dependent I-OSE_Labeled_AE
PTDM I-OSE_Labeled_AE
was O
reported O
in O
13 O
% O
and O
22 O
% O
of O
Prograf-treated O
heart B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
receiving O
mycophenolate O
mofetil O
( O
MMF O
) O
or O
azathioprine O
( O
AZA O
) O
and O
was O
reversible O
in O
30 O
% O
and O
17 O
% O
of O
these O
patients O
at O
one O
year O
post B-NonOSE_AE
- I-NonOSE_AE
transplant I-NonOSE_AE
, O
in O
the O
U.S O
. O
and O
European O
randomized O
trials O
, O
respectively O
( O
Table O
13 O
) O
. O

Hyperglycemia B-OSE_Labeled_AE
defined O
as O
two O
fasting B-OSE_Labeled_AE
plasma I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
was O
reported O
with O
the O
use O
of O
Prograf O
plus O
MMF O
or O
AZA O
in O
32 O
% O
and O
35 O
% O
of O
heart B-Not_AE_Candidate
transplant I-Not_AE_Candidate
recipients O
in O
the O
U.S O
. O
and O
European O
randomized O
trials O
, O
respectively O
, O
and O
may O
require O
treatment O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Table O
13 O
. O

Incidence O
of O
Post-Transplant O
Diabetes O
Mellitus O
and O
Insulin O
Use O
at O
1 O
Year O
in O
Heart O
Transplant O
Recipients O
Status O
of O
PTDM B-NonOSE_AE
Use O
of O
insulin O
for O
30 O
or O
more O
consecutive O
days O
without O
a O
prior O
history O
of O
insulin B-Not_AE_Candidate
- I-Not_AE_Candidate
dependent I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
or O
non B-Not_AE_Candidate
- I-Not_AE_Candidate
insulin I-Not_AE_Candidate
dependent I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
. O

US O
Trial O
European O
Trial O
Prograf/MMF O
Cyclosporine/MMF O
Prograf/AZA O
Cyclosporine/AZA O
Patients O
at O
riskPatients O
without O
pre-transplant O
history O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
. O

75 O
83 O
132 O
138 O
New O
Onset O
PTDM B-OSE_Labeled_AE
10 O
( O
13 O
% O
) O
6 O
( O
7 O
% O
) O
29 O
( O
22 O
% O
) O
5 O
( O
4 O
% O
) O
Patients O
still O
on O
insulin O
at O
1 O
year O
7-12 O
months O
for O
the O
U.S O
. O
trial O
. O

7 O
( O
9 O
% O
) O
1 O
( O
1 O
% O
) O
24 O
( O
18 O
% O
) O
4 O
( O
3 O
% O
) O
Less O
Frequently O
Reported O
Adverse O
Reactions O
( O
> O
3 O
% O
and O
< O
15 O
% O
) O
The O
following O
adverse O
reactions O
were O
reported O
in O
either O
liver B-Not_AE_Candidate
, O
kidney O
, O
and/or O
heart O
transplant I-Not_AE_Candidate
recipients O
who O
were O
treated O
with O
tacrolimus O
in O
clinical O
trials O
. O

Nervous B-NonOSE_AE
System I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
Abnormal B-OSE_Labeled_AE
dreams I-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
amnesia B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
confusion B-OSE_Labeled_AE
, O
convulsion B-OSE_Labeled_AE
, O
crying B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
mood I-OSE_Labeled_AE
, O
emotional B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
, O
encephalopathy B-OSE_Labeled_AE
, O
haemorrhagic B-OSE_Labeled_AE
stroke I-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
, O
hypertonia B-OSE_Labeled_AE
, O
incoordination B-OSE_Labeled_AE
, O
monoparesis B-OSE_Labeled_AE
, O
myoclonus B-OSE_Labeled_AE
, O
nerve B-OSE_Labeled_AE
compression I-OSE_Labeled_AE
, O
nervousness B-OSE_Labeled_AE
, O
neuralgia B-OSE_Labeled_AE
, O
neuropathy B-OSE_Labeled_AE
, O
paralysis B-OSE_Labeled_AE
flaccid I-OSE_Labeled_AE
, O
psychomotor B-OSE_Labeled_AE
skills I-OSE_Labeled_AE
impaired I-OSE_Labeled_AE
, O
psychosis B-OSE_Labeled_AE
, O
quadriparesis B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
thinking B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
vertigo B-OSE_Labeled_AE
, O
writing B-OSE_Labeled_AE
impaired I-OSE_Labeled_AE
Special B-NonOSE_AE
Senses I-NonOSE_AE
Abnormal B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
amblyopia B-OSE_Labeled_AE
, O
ear B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
, O
tinnitus B-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
Cholangitis B-OSE_Labeled_AE
, O
cholestatic B-OSE_Labeled_AE
jaundice I-OSE_Labeled_AE
, O
duodenitis B-OSE_Labeled_AE
, O
dysphagia B-OSE_Labeled_AE
, O
esophagitis B-OSE_Labeled_AE
, O
flatulence B-OSE_Labeled_AE
, O
gastritis B-OSE_Labeled_AE
, O
gastroesophagitis B-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
GGT B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
, O
GI B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
GI B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
granulomatous I-OSE_Labeled_AE
, O
ileus B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
jaundice B-OSE_Labeled_AE
, O
liver B-OSE_Labeled_AE
damage I-OSE_Labeled_AE
, O
oesophagitis B-OSE_Labeled_AE
ulcerative I-OSE_Labeled_AE
, O
oral B-OSE_Labeled_AE
moniliasis I-OSE_Labeled_AE
, O
pancreatic B-OSE_Labeled_AE
pseudocyst I-OSE_Labeled_AE
, O
rectal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
Cardiovascular B-NonOSE_AE
Abnormal B-OSE_Labeled_AE
ECG I-OSE_Labeled_AE
, O
angina B-OSE_Labeled_AE
pectoris I-OSE_Labeled_AE
, O
arrhythmia B-OSE_Labeled_AE
, O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
atrial B-OSE_Labeled_AE
flutter I-OSE_Labeled_AE
, O
bradycardia B-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
cardiopulmonary B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
cardiovascular B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
deep B-OSE_Labeled_AE
thrombophlebitis I-OSE_Labeled_AE
, O
echocardiogram B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
electrocardiogram B-OSE_Labeled_AE
QRS I-OSE_Labeled_AE
complex I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
electrocardiogram B-OSE_Labeled_AE
ST I-OSE_Labeled_AE
segment I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
heart B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
heart B-OSE_Labeled_AE
rate I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
hemorrhage B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
vascular I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
phlebitis B-OSE_Labeled_AE
, O
postural B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
, O
thrombosis B-OSE_Labeled_AE
, O
vasodilatation B-OSE_Labeled_AE
Urogenital B-NonOSE_AE
Acute B-OSE_Labeled_AE
kidney I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
, O
albuminuria B-OSE_Labeled_AE
, O
BK B-OSE_Labeled_AE
nephropathy I-OSE_Labeled_AE
, O
bladder B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
, O
cystitis B-OSE_Labeled_AE
, O
dysuria B-OSE_Labeled_AE
, O
hematuria B-OSE_Labeled_AE
, O
hydronephrosis B-OSE_Labeled_AE
, O
kidney B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
kidney B-OSE_Labeled_AE
tubular I-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
, O
nocturia B-OSE_Labeled_AE
, O
pyuria B-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
nephropathy I-OSE_Labeled_AE
, O
urge B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
frequency I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
, O
vaginitis B-OSE_Labeled_AE
Metabolic B-NonOSE_AE
/ I-NonOSE_AE
Nutritional I-NonOSE_AE
Acidosis B-OSE_Labeled_AE
, O
alkaline B-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
alkalosis B-OSE_Labeled_AE
, O
ALT B-OSE_Labeled_AE
( I-OSE_Labeled_AE
SGPT I-OSE_Labeled_AE
) I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
AST B-OSE_Labeled_AE
( I-OSE_Labeled_AE
SGOT I-OSE_Labeled_AE
) I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
bicarbonate B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
bilirubinemia B-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
, O
GGT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
gout B-OSE_Labeled_AE
, O
healing B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
hypercalcemia B-OSE_Labeled_AE
, O
hypercholesterolemia B-OSE_Labeled_AE
, O
hyperphosphatemia B-OSE_Labeled_AE
, O
hyperuricemia B-OSE_Labeled_AE
, O
hypervolemia B-OSE_Labeled_AE
, O
hypocalcemia B-OSE_Labeled_AE
, O
hypoglycemia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
, O
hypoproteinemia B-OSE_Labeled_AE
, O
lactic B-OSE_Labeled_AE
dehydrogenase I-OSE_Labeled_AE
increase I-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
Endocrine B-NonOSE_AE
Cushing B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
Hemic B-NonOSE_AE
/ I-NonOSE_AE
Lymphatic I-NonOSE_AE
Coagulation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
ecchymosis B-OSE_Labeled_AE
, O
haematocrit B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
haemoglobin B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
hypochromic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
leukocytosis B-OSE_Labeled_AE
, O
polycythemia B-OSE_Labeled_AE
, O
prothrombin B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
serum B-OSE_Labeled_AE
iron I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
Miscellaneous B-NonOSE_AE
Abdomen B-OSE_Labeled_AE
enlarged I-OSE_Labeled_AE
, O
abscess B-OSE_Labeled_AE
, O
accidental B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
, O
allergic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
fall B-OSE_Labeled_AE
, O
feeling B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
flu B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
generalized B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
hernia B-OSE_Labeled_AE
, O
mobility B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
peritonitis B-OSE_Labeled_AE
, O
photosensitivity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
temperature B-OSE_Labeled_AE
intolerance I-OSE_Labeled_AE
, O
ulcer B-OSE_Labeled_AE
Musculoskeletal B-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
, O
cramps B-OSE_Labeled_AE
, O
generalized B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
, O
joint B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
leg B-OSE_Labeled_AE
cramps I-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
, O
myasthenia B-OSE_Labeled_AE
, O
osteoporosis B-OSE_Labeled_AE
Respiratory B-NonOSE_AE
Asthma B-OSE_Labeled_AE
, O
emphysema B-OSE_Labeled_AE
, O
hiccups B-OSE_Labeled_AE
, O
lung B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
lung B-OSE_Labeled_AE
function I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
pharyngitis B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
pneumothorax B-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
rhinitis B-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
, O
voice B-OSE_Labeled_AE
alteration I-OSE_Labeled_AE
Skin B-NonOSE_AE
Acne B-OSE_Labeled_AE
, O
alopecia B-OSE_Labeled_AE
, O
exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
fungal B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
simplex I-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
, O
hirsutism B-OSE_Labeled_AE
, O
neoplasm B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
benign I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
6.2 O
Postmarketing O
Adverse O
Reactions O
The O
following O
adverse O
reactions O
have O
been O
reported O
from O
worldwide O
marketing O
experience O
with O
Prograf O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Decisions O
to O
include O
these O
reactions O
in O
labeling O
are O
typically O
based O
on O
one O
or O
more O
of O
the O
following O
factors O
: O
( O
1 O
) O
seriousness O
of O
the O
reaction O
, O
( O
2 O
) O
frequency O
of O
the O
reporting O
, O
or O
( O
3 O
) O
strength O
of O
causal O
connection O
to O
the O
drug O
. O

Other O
reactions O
include O
: O
Cardiovascular B-NonOSE_AE
Atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
atrial B-OSE_Labeled_AE
flutter I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
arrhythmia I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
electrocardiogram B-OSE_Labeled_AE
T I-OSE_Labeled_AE
wave I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
flushing B-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
ischaemia I-OSE_Labeled_AE
, O
pericardial B-OSE_Labeled_AE
effusion I-OSE_Labeled_AE
, O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
, O
Torsade B-OSE_Labeled_AE
de I-OSE_Labeled_AE
Pointes I-OSE_Labeled_AE
, O
venous B-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
deep I-OSE_Labeled_AE
limb I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
extrasystoles I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
hypertrophy I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.15 O
) O
] O
. O

Gastrointestinal B-NonOSE_AE
Bile B-OSE_Labeled_AE
duct I-OSE_Labeled_AE
stenosis I-OSE_Labeled_AE
, O
colitis B-OSE_Labeled_AE
, O
enterocolitis B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
gastrooesophageal B-OSE_Labeled_AE
reflux I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
cytolysis I-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
, O
hepatotoxicity B-OSE_Labeled_AE
, O
impaired B-OSE_Labeled_AE
gastric I-OSE_Labeled_AE
emptying I-OSE_Labeled_AE
, O
liver B-OSE_Labeled_AE
fatty I-OSE_Labeled_AE
, O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
haemorrhagic I-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
necrotizing I-OSE_Labeled_AE
, O
stomach B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
, O
venoocclusive B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
Hemic B-NonOSE_AE
/ I-NonOSE_AE
Lymphatic I-NonOSE_AE
Agranulocytosis B-OSE_Labeled_AE
, O
disseminated B-OSE_Labeled_AE
intravascular I-OSE_Labeled_AE
coagulation I-OSE_Labeled_AE
, O
hemolytic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
pancytopenia B-OSE_Labeled_AE
, O
thrombocytopenic B-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
, O
thrombotic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
, O
pure B-OSE_Labeled_AE
red I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
aplasia I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.17 O
) O
] O
Infections B-NonOSE_AE
Cases O
of O
progressive B-OSE_Labeled_AE
multifocal I-OSE_Labeled_AE
leukoencephalopathy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PML I-OSE_Labeled_AE
) O
, O
sometimes O
fatal B-NonOSE_AE
; O
- O
polyoma B-OSE_Labeled_AE
virus I-OSE_Labeled_AE
- I-OSE_Labeled_AE
associated I-OSE_Labeled_AE
nephropathy I-OSE_Labeled_AE
, I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PVAN I-OSE_Labeled_AE
) O
including O
graft B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
Metabolic B-NonOSE_AE
/ I-NonOSE_AE
Nutritional I-NonOSE_AE
Glycosuria B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
amylase I-OSE_Labeled_AE
including O
pancreatitis B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
Miscellaneous B-NonOSE_AE
Feeling B-OSE_Labeled_AE
hot I-OSE_Labeled_AE
and O
cold O
, O
feeling B-OSE_Labeled_AE
jittery I-OSE_Labeled_AE
, O
hot B-OSE_Labeled_AE
flushes I-OSE_Labeled_AE
, O
multi B-OSE_Labeled_AE
- I-OSE_Labeled_AE
organ I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
primary B-OSE_Labeled_AE
graft I-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
Nervous B-NonOSE_AE
System I-NonOSE_AE
Carpal B-OSE_Labeled_AE
tunnel I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
cerebral B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
hemiparesis B-OSE_Labeled_AE
, O
leukoencephalopathy B-OSE_Labeled_AE
, O
mental B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
mutism B-OSE_Labeled_AE
, O
posterior B-OSE_Labeled_AE
reversible I-OSE_Labeled_AE
encephalopathy I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PRES I-OSE_Labeled_AE
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
, O
progressive B-OSE_Labeled_AE
multifocal I-OSE_Labeled_AE
leukoencephalopathy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PML I-OSE_Labeled_AE
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
, O
quadriplegia B-OSE_Labeled_AE
, O
speech B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
Respiratory B-NonOSE_AE
Acute B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
distress I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
lung B-OSE_Labeled_AE
infiltration I-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
distress I-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
Skin B-NonOSE_AE
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
Special B-NonOSE_AE
Senses I-NonOSE_AE
Blindness B-OSE_Labeled_AE
, O
blindness B-OSE_Labeled_AE
cortical I-OSE_Labeled_AE
, O
hearing B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
including O
deafness B-OSE_Labeled_AE
, O
photophobia B-OSE_Labeled_AE
Urogenital B-NonOSE_AE
Acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
cystitis B-OSE_Labeled_AE
haemorrhagic I-OSE_Labeled_AE
, O
hemolytic B-OSE_Labeled_AE
- I-OSE_Labeled_AE
uremic I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
micturition B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE

BOXED O
WARNING O
: O
BOXED O
WARNING O
- O
MALIGNANCIES O
AND O
SERIOUS O
INFECTIONS B-OSE_Labeled_AE
BOXED O
WARNING O
- O
MALIGNANCIES O
AND O
SERIOUS O
INFECTIONS O
* O
Increased O
risk O
of O
development O
of O
lymphoma B-OSE_Labeled_AE
and O
other O
malignancies B-OSE_Labeled_AE
, O
particularly O
of O
the O
skin I-OSE_Labeled_AE
, O
due O
to O
immunosuppression B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

* O
Increased B-OSE_Labeled_AE
susceptibility I-OSE_Labeled_AE
to O
bacterial B-OSE_Labeled_AE
, O
viral O
, O
fungal O
, O
and O
protozoal O
infections I-OSE_Labeled_AE
, O
including O
opportunistic B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
, O
5.4 O
, O
5.5 O
) O
] O
. O

* O
Only O
physicians O
experienced O
in O
immunosuppressive B-NonOSE_AE
therapy I-NonOSE_AE
and O
management O
of O
organ B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
should O
prescribe O
Prograf O
. O

Patients O
receiving O
the O
drug O
should O
be O
managed O
in O
facilities O
equipped O
and O
staffed O
with O
adequate O
laboratory O
and O
supportive O
medical O
resources O
. O

The O
physician O
responsible O
for O
maintenance O
therapy O
should O
have O
complete O
information O
requisite O
for O
the O
follow-up O
of O
the O
patient O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
MALIGNANCIES O
AND O
SERIOUS O
INFECTIONS O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
* O
Increased O
risk O
of O
development O
of O
lymphoma O
and O
other O
malignancies O
, O
particularly O
of O
the O
skin O
, O
due O
to O
immunosuppression O
( O
5.2 O
) O
* O
Increased O
susceptibility O
to O
bacterial O
, O
viral O
, O
fungal O
, O
and O
protozoal O
infections O
, O
including O
opportunistic O
infections O
( O
5.3 O
, O
5.4 O
, O
5.5 O
) O
* O
Only O
physicians O
experienced O
in O
immunosuppressive O
therapy O
and O
management O
of O
organ O
transplant O
patients O
should O
prescribe O
Prograf O
( O
5.1 O
) O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Lymphoma O
and O
Other O
Malignancies O
: O
Risk O
of O
lymphomas O
, O
including O
post O
transplant O
lymphoproliferative O
disorder O
( O
PLTD O
) O
; O
appears O
related O
to O
intensity O
and O
duration O
of O
use O
. O

Avoid O
prolonged O
exposure O
to O
UV O
light O
and O
sunlight O
( O
5.2 O
) O
* O
Serious O
infections O
: O
Increased O
risk O
of O
bacterial O
, O
viral O
, O
fungal O
and O
protozoal O
infections O
, O
including O
opportunistic O
infections O
: O
combination O
immunosuppression O
should O
be O
used O
with O
caution O
( O
5.3 O
) O
* O
Polyoma O
Virus O
Infections O
: O
Serious O
, O
sometimes O
fatal O
outcomes O
, O
including O
polyoma O
virus-associated O
nephropathy O
( O
PVAN O
) O
, O
mostly O
due O
to O
BK O
virus O
, O
and O
JC O
virus-associated O
progressive O
multifocal O
leukoencephalopathy O
( O
PML O
) O
; O
consider O
reducing O
immunosuppression O
( O
5.4 O
) O
* O
Cytomegalovirus O
( O
CMV O
) O
Infections O
: O
Increased O
risk O
of O
CMV O
viremia O
and O
disease O
; O
consider O
reducing O
immunosuppression O
( O
5.5 O
) O
* O
New O
Onset O
Diabetes O
After O
Transplant O
: O
Monitor O
blood O
glucose O
( O
5.6 O
) O
* O
Nephrotoxicity O
: O
Acute O
and/or O
chronic O
; O
reduce O
the O
dose O
; O
use O
caution O
with O
other O
nephrotoxic O
drugs O
( O
5.7 O
) O
* O
Neurotoxicity O
: O
Risk O
of O
Posterior O
Reversible O
Encephalopathy O
Syndrome O
, O
monitor O
for O
neurologic O
abnormalities O
; O
reduce O
or O
discontinue O
Prograf O
and O
other O
immunosuppressants O
( O
5.8 O
) O
* O
Hyperkalemia O
: O
Monitor O
serum O
potassium O
levels O
. O

Careful O
consideration O
should O
be O
given O
prior O
to O
use O
of O
other O
agents O
also O
associated O
with O
hyperkalemia O
( O
5.9 O
) O
* O
Hypertension O
: O
May O
require O
antihypertensive O
therapy O
. O

Monitor O
relevant O
drug-drug O
interactions O
( O
5.10 O
) O
* O
Anaphylactic O
Reactions O
with O
IV O
formulation O
: O
Observe O
patients O
receiving O
Prograf O
injection O
for O
signs O
and O
symptoms O
of O
anaphylaxis O
( O
5.11 O
) O
* O
Use O
with O
Sirolimus O
: O
Not O
recommended O
in O
liver O
and O
heart O
transplant O
due O
to O
increased O
risk O
of O
serious O
adverse O
reactions O
( O
5.12 O
) O
* O
Myocardial O
Hypertrophy O
: O
Consider O
dosage O
reduction O
or O
discontinuation O
( O
5.15 O
) O
* O
Immunizations O
: O
Use O
of O
live O
vaccines O
should O
be O
avoided O
( O
5.16 O
) O
* O
Pure O
Red O
Cell O
Aplasia O
: O
Discontinuation O
should O
be O
considered O
( O
5.17 O
) O
5.1 O
Management O
of O
Immunosuppression O
Only O
physicians O
experienced O
in O
immunosuppressive B-NonOSE_AE
therapy I-NonOSE_AE
and O
management O
of O
organ B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
should O
use O
Prograf O
. O

Patients O
receiving O
the O
drug O
should O
be O
managed O
in O
facilities O
equipped O
and O
staffed O
with O
adequate O
laboratory O
and O
supportive O
medical O
resources O
. O

The O
physicians O
responsible O
for O
maintenance O
therapy O
should O
have O
complete O
information O
requisite O
for O
the O
follow O
up O
of O
the O
patient O
[ O
see O
Boxed O
Warning O
] O
. O

5.2 O
Lymphoma O
and O
Other O
Malignancies O
Patients O
receiving O
immunosuppressants O
, O
including O
Prograf O
, O
are O
at O
increased O
risk O
of O
developing O
lymphomas B-OSE_Labeled_AE
and O
other O
malignancies B-OSE_Labeled_AE
, O
particularly O
of O
the O
skin I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
] O
. O

The O
risk O
appears O
to O
be O
related O
to O
the O
intensity O
and O
duration O
of O
immunosuppression B-NonOSE_AE
rather O
than O
to O
the O
use O
of O
any O
specific O
agent O
. O

As O
usual O
for O
patients O
with O
increased O
risk O
for O
skin B-NonOSE_AE
cancer I-NonOSE_AE
, O
exposure O
to O
sunlight O
and O
UV O
light O
should O
be O
limited O
by O
wearing O
protective O
clothing O
and O
using O
a O
sunscreen O
with O
a O
high O
protection O
factor O
. O

Post B-OSE_Labeled_AE
transplant I-OSE_Labeled_AE
lymphoproliferative I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PTLD I-OSE_Labeled_AE
) O
has O
been O
reported O
in O
immunosuppressed B-Not_AE_Candidate
organ B-Not_AE_Candidate
transplant I-Not_AE_Candidate
recipients O
. O

The O
majority O
of O
PTLD B-OSE_Labeled_AE
events O
appear O
related O
to O
Epstein B-OSE_Labeled_AE
Barr I-OSE_Labeled_AE
Virus I-OSE_Labeled_AE
( I-OSE_Labeled_AE
EBV I-OSE_Labeled_AE
) I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
. O

The O
risk O
of O
PTLD B-NonOSE_AE
appears O
greatest O
in O
those O
individuals O
who O
are O
EBV B-Not_AE_Candidate
seronegative I-Not_AE_Candidate
, O
a O
population O
which O
includes O
many O
young O
children O
. O

5.3 O
Serious O
Infections O
Patients O
receiving O
immunosuppressants O
, O
including O
Prograf O
, O
are O
at O
increased O
risk O
of O
developing O
bacterial B-OSE_Labeled_AE
, O
viral O
, O
fungal O
, O
and O
protozoal O
infections I-OSE_Labeled_AE
, O
including O
opportunistic B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.4 O
, O
5.5 O
) O
] O
. O

These O
infections B-OSE_Labeled_AE
may O
lead O
to O
serious O
, O
including O
fatal B-NonOSE_AE
, O
outcomes O
. O

Because O
of O
the O
danger O
of O
oversuppression B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
immune I-NonOSE_AE
system I-NonOSE_AE
which O
can O
increase O
susceptibility B-NonOSE_AE
to I-NonOSE_AE
infection I-NonOSE_AE
, O
combination O
immunosuppressant B-NonOSE_AE
therapy I-NonOSE_AE
should O
be O
used O
with O
caution O
. O

5.4 O
Polyoma O
Virus O
Infections O
Patients O
receiving O
immunosuppressants O
, O
including O
Prograf O
, O
are O
at O
increased O
risk O
for O
opportunistic B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
including O
polyoma B-OSE_Labeled_AE
virus I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
. O

Polyoma B-NonOSE_AE
virus I-NonOSE_AE
infections I-NonOSE_AE
in O
transplant B-Not_AE_Candidate
patients O
may O
have O
serious O
, O
and O
sometimes O
fatal B-NonOSE_AE
, O
outcomes O
. O

These O
include O
polyoma B-OSE_Labeled_AE
virus I-OSE_Labeled_AE
- I-OSE_Labeled_AE
associated I-OSE_Labeled_AE
nephropathy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PVAN I-OSE_Labeled_AE
) O
, O
mostly O
due O
to O
BK B-OSE_Labeled_AE
virus I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
and O
JC B-OSE_Labeled_AE
virus I-OSE_Labeled_AE
- I-OSE_Labeled_AE
associated I-OSE_Labeled_AE
progressive I-OSE_Labeled_AE
multifocal I-OSE_Labeled_AE
leukoencephalopathy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PML I-OSE_Labeled_AE
) O
which O
have O
been O
observed O
in O
patients O
receiving O
tacrolimus O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

PVAN B-NonOSE_AE
is O
associated O
with O
serious O
outcomes O
, O
including O
deteriorating B-NonOSE_AE
renal I-NonOSE_AE
function I-NonOSE_AE
and O
kidney B-NonOSE_AE
graft I-NonOSE_AE
loss I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

Patient O
monitoring O
may O
help O
detect O
patients O
at O
risk O
for O
PVAN B-NonOSE_AE
. O

Cases O
of O
PML B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
treated O
with O
Prograf O
. O

PML B-NonOSE_AE
, O
which O
is O
sometimes O
fatal B-NonOSE_AE
, O
commonly O
presents O
with O
hemiparesis B-NonOSE_AE
, O
apathy B-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
cognitive B-NonOSE_AE
deficiencies I-NonOSE_AE
and O
ataxia B-NonOSE_AE
. O

Risk O
factors O
for O
PML B-NonOSE_AE
include O
treatment O
with O
immunosuppressant B-NonOSE_AE
therapies I-NonOSE_AE
and O
impairment B-Not_AE_Candidate
of I-Not_AE_Candidate
immune I-Not_AE_Candidate
function I-Not_AE_Candidate
. O

In O
immunosuppressed B-Not_AE_Candidate
patients O
, O
physicians O
should O
consider O
PML B-NonOSE_AE
in O
the O
differential O
diagnosis O
in O
patients O
reporting O
neurological B-NonOSE_AE
symptoms I-NonOSE_AE
and O
consultation O
with O
a O
neurologist O
should O
be O
considered O
as O
clinically O
indicated O
. O

Reductions O
in O
immunosuppression B-NonOSE_AE
should O
be O
considered O
for O
patients O
who O
develop O
evidence O
of O
PVAN B-NonOSE_AE
or O
PML B-NonOSE_AE
. O

Physicians O
should O
also O
consider O
the O
risk O
that O
reduced O
immunosuppression B-NonOSE_AE
represents O
to O
the O
functioning O
allograft O
. O

5.5 O
Cytomegalovirus O
( O
CMV O
) O
Infections O
Patients O
receiving O
immunosuppressants O
, O
including O
Prograf O
, O
are O
at O
increased O
risk O
of O
developing O
CMV B-OSE_Labeled_AE
viremia I-OSE_Labeled_AE
and O
CMV B-OSE_Labeled_AE
disease I-OSE_Labeled_AE
. O

The O
risk O
of O
CMV B-OSE_Labeled_AE
disease I-OSE_Labeled_AE
is O
highest O
among O
transplant B-Not_AE_Candidate
recipients O
seronegative B-Not_AE_Candidate
for I-Not_AE_Candidate
CMV I-Not_AE_Candidate
at O
time O
of O
transplant B-NonOSE_AE
who O
receive O
a O
graft O
from O
a O
CMV B-Not_AE_Candidate
seropositive I-Not_AE_Candidate
donor I-Not_AE_Candidate
. O

Therapeutic O
approaches O
to O
limiting O
CMV B-NonOSE_AE
disease I-NonOSE_AE
exist O
and O
should O
be O
routinely O
provided O
. O

Patient O
monitoring O
may O
help O
detect O
patients O
at O
risk O
for O
CMV B-NonOSE_AE
disease I-NonOSE_AE
. O

Consideration O
should O
be O
given O
to O
reducing O
the O
amount O
of O
immunosuppression B-NonOSE_AE
in O
patients O
who O
develop O
CMV B-NonOSE_AE
viremia I-NonOSE_AE
and/or O
CMV B-NonOSE_AE
disease I-NonOSE_AE
. O

5.6 O
New O
Onset O
Diabetes O
After O
Transplant O
Prograf O
was O
shown O
to O
cause O
new O
onset O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
in O
clinical O
trials O
of O
kidney B-Not_AE_Candidate
, O
liver O
, O
and O
heart O
transplantation I-Not_AE_Candidate
. O

New O
onset O
diabetes B-OSE_Labeled_AE
after O
transplantation B-Not_AE_Candidate
may O
be O
reversible O
in O
some O
patients O
. O

Black O
and O
Hispanic O
kidney B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
are O
at O
an O
increased O
risk O
. O

Blood O
glucose O
concentrations O
should O
be O
monitored O
closely O
in O
patients O
using O
Prograf O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.7 O
Nephrotoxicity O
Prograf O
, O
like O
other O
calcineurin-inhibitors O
, O
can O
cause O
acute O
or O
chronic O
nephrotoxicity B-OSE_Labeled_AE
, O
particularly O
when O
used O
in O
high O
doses O
. O

Acute O
nephrotoxicity B-OSE_Labeled_AE
is O
most O
often O
related O
to O
vasoconstriction B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
afferent I-NonOSE_AE
renal I-NonOSE_AE
arteriole I-NonOSE_AE
, O
is O
characterized O
by O
increasing B-NonOSE_AE
serum I-NonOSE_AE
creatinine I-NonOSE_AE
, O
hyperkalemia B-NonOSE_AE
, O
and/or O
a O
decrease B-NonOSE_AE
in I-NonOSE_AE
urine I-NonOSE_AE
output I-NonOSE_AE
, O
and O
is O
typically O
reversible O
. O

Chronic O
calcineurin B-OSE_Labeled_AE
- I-OSE_Labeled_AE
inhibitor I-OSE_Labeled_AE
nephrotoxicity I-OSE_Labeled_AE
is O
associated O
with O
increased B-NonOSE_AE
serum I-NonOSE_AE
creatinine I-NonOSE_AE
, O
decreased B-NonOSE_AE
kidney I-NonOSE_AE
graft I-NonOSE_AE
life I-NonOSE_AE
, O
and O
characteristic O
histologic O
changes B-NonOSE_AE
observed I-NonOSE_AE
on I-NonOSE_AE
renal I-NonOSE_AE
biopsy I-NonOSE_AE
; O
the O
changes O
associated O
with O
chronic O
calcineurin B-OSE_Labeled_AE
- I-OSE_Labeled_AE
inhibitor I-OSE_Labeled_AE
nephrotoxicity I-OSE_Labeled_AE
are O
typically O
progressive O
. O

Patients O
with O
impaired B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
should O
be O
monitored O
closely O
as O
the O
dosage O
of O
Prograf O
may O
need O
to O
be O
reduced O
. O

In O
patients O
with O
persistent O
elevations B-Not_AE_Candidate
of I-Not_AE_Candidate
serum I-Not_AE_Candidate
creatinine I-Not_AE_Candidate
who O
are O
unresponsive O
to O
dosage O
adjustments O
, O
consideration O
should O
be O
given O
to O
changing O
to O
another O
immunosuppressive B-NonOSE_AE
therapy I-NonOSE_AE
. O

Based O
on O
reported O
adverse O
reactions O
terms O
related O
to O
decreased B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
function I-OSE_Labeled_AE
, O
nephrotoxicity B-OSE_Labeled_AE
was O
reported O
in O
approximately O
52 O
% O
of O
kidney B-Not_AE_Candidate
transplantation I-Not_AE_Candidate
patients O
and O
in O
40 O
% O
and O
36 O
% O
of O
liver B-Not_AE_Candidate
transplantation I-Not_AE_Candidate
patients O
receiving O
Prograf O
in O
the O
U.S O
. O
and O
European O
randomized O
trials O
, O
respectively O
, O
and O
in O
59 O
% O
of O
heart B-Not_AE_Candidate
transplantation I-Not_AE_Candidate
patients O
in O
a O
European O
randomized O
trial O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Due O
to O
the O
potential O
for O
additive O
or O
synergistic O
impairment B-NonOSE_AE
of I-NonOSE_AE
renal I-NonOSE_AE
function I-NonOSE_AE
, O
care O
should O
be O
taken O
when O
administering O
Prograf O
with O
drugs O
that O
may O
be O
associated O
with O
renal B-NonOSE_AE
dysfunction I-NonOSE_AE
. O

These O
include O
, O
but O
are O
not O
limited O
to O
, O
aminoglycosides O
, O
ganciclovir O
, O
amphotericin O
B O
, O
cisplatin O
, O
nucleotide O
reverse O
transcriptase O
inhibitors O
( O
e.g. O
, O
tenofovir O
) O
and O
protease O
inhibitors O
( O
e.g. O
, O
ritonavir O
, O
indinavir O
) O
. O

Similarly O
, O
care O
should O
be O
exercised O
when O
administering O
with O
CYP3A4 O
inhibitors O
such O
as O
antifungal O
drugs O
( O
e.g. O
, O
ketoconazole O
) O
, O
calcium O
channel O
blockers O
( O
e.g. O
, O
diltiazem O
, O
verapamil O
) O
, O
and O
macrolide O
antibiotics O
( O
e.g. O
, O
clarithromycin O
, O
erythromycin O
, O
troleandomycin O
) O
which O
will O
result O
in O
increased O
tacrolimus O
whole O
blood O
concentrations O
due O
to O
inhibition O
of O
tacrolimus O
metabolism O
[ O
see O
Drug O
Interactions O
( O
7.3 O
, O
7.4 O
, O
7.5 O
, O
7.6 O
) O
] O
. O

5.8 O
Neurotoxicity O
Prograf O
may O
cause O
a O
spectrum O
of O
neurotoxicities B-OSE_Labeled_AE
, O
particularly O
when O
used O
in O
high O
doses O
. O

The O
most O
severe O
neurotoxicities B-OSE_Labeled_AE
include O
posterior B-OSE_Labeled_AE
reversible I-OSE_Labeled_AE
encephalopathy I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PRES I-OSE_Labeled_AE
) O
, O
delirium B-OSE_Labeled_AE
, O
and O
coma B-OSE_Labeled_AE
. O

Patients O
treated O
with O
tacrolimus O
have O
been O
reported O
to O
develop O
PRES B-OSE_Labeled_AE
. O

Symptoms O
indicating O
PRES B-NonOSE_AE
include O
headache B-NonOSE_AE
, O
altered B-NonOSE_AE
mental I-NonOSE_AE
status I-NonOSE_AE
, O
seizures B-NonOSE_AE
, O
visual B-NonOSE_AE
disturbances I-NonOSE_AE
and O
hypertension B-NonOSE_AE
. O

Diagnosis O
may O
be O
confirmed O
by O
radiological O
procedure O
. O

If O
PRES B-NonOSE_AE
is O
suspected O
or O
diagnosed O
, O
blood O
pressure O
control O
should O
be O
maintained O
and O
immediate O
reduction O
of O
immunosuppression B-NonOSE_AE
is O
advised O
. O

This O
syndrome O
is O
characterized O
by O
reversal O
of O
symptoms O
upon O
reduction O
or O
discontinuation O
of O
immunosuppression B-NonOSE_AE
. O

Coma B-OSE_Labeled_AE
and O
delirium B-OSE_Labeled_AE
, O
in O
the O
absence O
of O
PRES B-NonOSE_AE
, O
have O
also O
been O
associated O
with O
high O
plasma O
concentrations O
of O
tacrolimus O
. O

Seizures B-OSE_Labeled_AE
have O
occurred O
in O
adult O
and O
pediatric O
patients O
receiving O
Prograf O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Less O
severe O
neurotoxicities B-OSE_Labeled_AE
, O
include O
tremors B-OSE_Labeled_AE
, O
paresthesias B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
and O
other O
changes B-OSE_Labeled_AE
in I-OSE_Labeled_AE
motor I-OSE_Labeled_AE
function I-OSE_Labeled_AE
, O
mental O
status O
, O
and O
sensory O
function O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Tremor B-OSE_Labeled_AE
and O
headache B-OSE_Labeled_AE
have O
been O
associated O
with O
high O
whole-blood O
concentrations O
of O
tacrolimus O
and O
may O
respond O
to O
dosage O
adjustment O
. O

5.9 O
Hyperkalemia O
Hyperkalemia B-OSE_Labeled_AE
has O
been O
reported O
with O
Prograf O
use O
. O

Serum O
potassium O
levels O
should O
be O
monitored O
. O

Careful O
consideration O
should O
be O
given O
prior O
to O
use O
of O
other O
agents O
also O
associated O
with O
hyperkalemia B-NonOSE_AE
( O
e.g. O
, O
potassium-sparing O
diuretics O
, O
ACE O
inhibitors O
, O
angiotensin O
receptor O
blockers O
) O
during O
Prograf O
therapy O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.10 O
Hypertension O
Hypertension B-OSE_Labeled_AE
is O
a O
common O
adverse O
effect O
of O
Prograf O
therapy O
and O
may O
require O
antihypertensive O
therapy O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

The O
control O
of O
blood O
pressure O
can O
be O
accomplished O
with O
any O
of O
the O
common O
antihypertensive O
agents O
, O
though O
careful O
consideration O
should O
be O
given O
prior O
to O
use O
of O
antihypertensive O
agents O
associated O
with O
hyperkalemia B-NonOSE_AE
( O
e.g. O
, O
potassium-sparing O
diuretics O
, O
ACE O
inhibitors O
, O
angiotensin O
receptor O
blockers O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
. O

Calcium-channel O
blocking O
agents O
may O
increase O
tacrolimus O
blood O
concentrations O
and O
therefore O
require O
dosage O
reduction O
of O
Prograf O
[ O
see O
Drug O
Interactions O
( O
7.5 O
) O
] O
. O

5.11 O
Anaphylactic O
Reactions O
with O
Prograf O
Injection O
Anaphylactic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
have O
occurred O
with O
injectables O
containing O
castor O
oil O
derivatives O
, O
including O
Prograf O
, O
in O
a O
small O
percentage O
of O
patients O
( O
0.6 O
% O
) O
. O

The O
exact O
cause O
of O
these O
reactions O
is O
not O
known O
. O

Prograf O
injection O
should O
be O
reserved O
for O
patients O
who O
are O
unable O
to O
take O
Prograf O
capsules O
[ O
see O
Indications O
and O
Usage O
( O
1.4 O
) O
] O
. O

Patients O
receiving O
Prograf O
injection O
should O
be O
under O
continuous O
observation O
for O
at O
least O
the O
first O
30 O
minutes O
following O
the O
start O
of O
the O
infusion O
and O
at O
frequent O
intervals O
thereafter O
. O

If O
signs O
or O
symptoms O
of O
anaphylaxis B-NonOSE_AE
occur O
, O
the O
infusion O
should O
be O
stopped O
. O

An O
aqueous O
solution O
of O
epinephrine O
should O
be O
available O
at O
the O
bedside O
as O
well O
as O
a O
source O
of O
oxygen O
. O

5.12 O
Use O
with O
Sirolimus O
The O
safety O
and O
efficacy O
of O
Prograf O
with O
sirolimus O
has O
not O
been O
established O
in O
kidney B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
. O

Use O
of O
sirolimus O
with O
Prograf O
in O
studies O
of O
de O
novo O
liver B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
was O
associated O
with O
an O
excess O
mortality B-NonOSE_AE
, O
graft B-NonOSE_AE
loss I-NonOSE_AE
, O
and O
hepatic B-NonOSE_AE
artery I-NonOSE_AE
thrombosis I-NonOSE_AE
( I-NonOSE_AE
HAT I-NonOSE_AE
) O
and O
is O
not O
recommended O
[ O
see O
Indications O
and O
Usage O
( O
1.4 O
) O
] O
. O

Use O
of O
sirolimus O
( O
2 O
mg O
per O
day O
) O
with O
Prograf O
in O
heart B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
in O
a O
U.S O
. O
trial O
was O
associated O
with O
increased O
risk O
of O
renal B-NonOSE_AE
function I-NonOSE_AE
impairment I-NonOSE_AE
, O
wound B-NonOSE_AE
healing I-NonOSE_AE
complications I-NonOSE_AE
, O
and O
insulin B-NonOSE_AE
- I-NonOSE_AE
dependent I-NonOSE_AE
post I-NonOSE_AE
- I-NonOSE_AE
transplant I-NonOSE_AE
diabetes I-NonOSE_AE
mellitus I-NonOSE_AE
, O
and O
is O
not O
recommended O
[ O
see O
Clinical O
Studies O
( O
14.3 O
) O
] O
. O

5.13 O
Use O
with O
CYP3A4 O
Inhibitors O
and O
Inducers O
When O
coadministering O
Prograf O
with O
strong O
CYP3A4-inhibitors O
( O
e.g. O
, O
telaprevir O
, O
boceprevir O
, O
ritonavir O
, O
ketoconazole O
, O
itraconazole O
, O
voriconazole O
, O
clarithromycin O
) O
and O
strong O
inducers O
( O
e.g. O
, O
rifampin O
, O
rifabutin O
) O
adjustments O
in O
the O
dosing O
regimen O
of O
Prograf O
and O
subsequent O
frequent O
monitoring O
of O
tacrolimus O
whole O
blood O
trough O
concentrations O
and O
tacrolimus-associated O
adverse O
reactions O
are O
recommended O
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

5.14 O
QT O
Prolongation O
Prograf O
may O
prolong B-OSE_Labeled_AE
the I-OSE_Labeled_AE
QT I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
QTc I-OSE_Labeled_AE
interval I-OSE_Labeled_AE
and O
may O
cause O
Torsade B-OSE_Labeled_AE
de I-OSE_Labeled_AE
Pointes I-OSE_Labeled_AE
. O

Avoid O
Prograf O
in O
patients O
with O
congenital B-Not_AE_Candidate
long I-Not_AE_Candidate
QT I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
. O

In O
patients O
with O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
bradyarrhythmias B-Not_AE_Candidate
, O
those O
taking O
certain O
antiarrhythmic O
medications O
or O
other O
medicinal O
products O
that O
lead O
to O
QT B-NonOSE_AE
prolongation I-NonOSE_AE
, O
and O
those O
with O
electrolyte B-Not_AE_Candidate
disturbances I-Not_AE_Candidate
such O
as O
hypokalemia B-Not_AE_Candidate
, O
hypocalcemia B-Not_AE_Candidate
, O
or O
hypomagnesemia B-Not_AE_Candidate
, O
consider O
obtaining O
electrocardiograms O
and O
monitoring O
electrolytes O
( O
magnesium O
, O
potassium O
, O
calcium O
) O
periodically O
during O
treatment O
. O

When O
coadministering O
Prograf O
with O
other O
substrates O
and/or O
inhibitors O
of O
CYP3A4 O
that O
also O
have O
the O
potential O
to O
prolong B-NonOSE_AE
the I-NonOSE_AE
QT I-NonOSE_AE
interval I-NonOSE_AE
, O
a O
reduction O
in O
Prograf O
dose O
, O
frequent O
monitoring O
of O
tacrolimus O
whole O
blood O
concentrations O
, O
and O
monitoring O
for O
QT B-NonOSE_AE
prolongation I-NonOSE_AE
is O
recommended O
. O

Use O
of O
Prograf O
with O
amiodarone O
has O
been O
reported O
to O
result O
in O
increased O
tacrolimus O
whole O
blood O
concentrations O
with O
or O
without O
concurrent O
QT B-NonOSE_AE
prolongation I-NonOSE_AE
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

5.15 O
Myocardial O
Hypertrophy O
Myocardial B-OSE_Labeled_AE
hypertrophy I-OSE_Labeled_AE
has O
been O
reported O
in O
infants O
, O
children O
, O
and O
adults O
, O
particularly O
those O
with O
high O
tacrolimus O
trough O
concentrations O
, O
and O
is O
generally O
manifested O
by O
echocardiographically O
demonstrated O
concentric O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
left I-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
posterior I-OSE_Labeled_AE
wall I-OSE_Labeled_AE
and O
interventricular O
septum O
thickness I-OSE_Labeled_AE
. O

This O
condition O
appears O
reversible O
in O
most O
cases O
following O
dose O
reduction O
or O
discontinuance O
of O
therapy O
. O

In O
patients O
who O
develop O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
or O
clinical O
manifestations O
of O
ventricular B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
while O
receiving O
Prograf O
therapy O
, O
echocardiographic O
evaluation O
should O
be O
considered O
. O

If O
myocardial B-NonOSE_AE
hypertrophy I-NonOSE_AE
is O
diagnosed O
, O
dosage O
reduction O
or O
discontinuation O
of O
Prograf O
should O
be O
considered O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

5.16 O
Immunizations O
The O
use O
of O
live O
vaccines O
should O
be O
avoided O
during O
treatment O
with O
tacrolimus O
; O
examples O
include O
( O
not O
limited O
to O
) O
the O
following O
: O
intranasal O
influenza O
, O
measles O
, O
mumps O
, O
rubella O
, O
oral O
polio O
, O
BCG O
, O
yellow O
fever O
, O
varicella O
, O
and O
TY21a O
typhoid O
vaccines O
. O

5.17 O
Pure O
Red O
Cell O
Aplasia O
Cases O
of O
pure B-OSE_Labeled_AE
red I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
aplasia I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PRCA I-OSE_Labeled_AE
) O
have O
been O
reported O
in O
patients O
treated O
with O
tacrolimus O
. O

A O
mechanism O
for O
tacrolimus B-OSE_Labeled_AE
- I-OSE_Labeled_AE
induced I-OSE_Labeled_AE
PRCA I-OSE_Labeled_AE
has O
not O
been O
elucidated O
. O

All O
patients O
reported O
risk O
factors O
for O
PRCA B-NonOSE_AE
such O
as O
parvovirus B-Not_AE_Candidate
B I-Not_AE_Candidate
1 I-Not_AE_Candidate
9 I-Not_AE_Candidate
infection I-Not_AE_Candidate
, O
underlying O
disease O
, O
or O
concomitant O
medications O
associated O
with O
PRCA B-NonOSE_AE
. O

If O
PRCA B-NonOSE_AE
is O
diagnosed O
, O
discontinuation O
of O
Prograf O
should O
be O
considered O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

5.18 O
Gastrointestinal O
Perforation O
Gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
has O
been O
reported O
in O
patients O
treated O
with O
Prograf O
; O
all O
reported O
cases O
were O
considered O
to O
be O
a O
complication O
of O
transplant B-Not_AE_Candidate
surgery O
or O
accompanied O
by O
infection B-Not_AE_Candidate
, O
diverticulum B-Not_AE_Candidate
, O
or O
malignant B-Not_AE_Candidate
neoplasm I-Not_AE_Candidate
. O

As O
gastrointestinal B-NonOSE_AE
perforation I-NonOSE_AE
may O
be O
serious O
or O
life-threatening O
, O
appropriate O
medical/surgical O
management O
should O
be O
instituted O
promptly O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Serious O
skin B-OSE_Labeled_AE
and O
hypersensitivity O
reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Neuropsychiatric B-OSE_Labeled_AE
Events I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reaction O
( O
incidence O
> O
2 O
% O
) O
is O
diarrhea O
( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
BioCryst O
Pharmaceuticals O
, O
Inc O
. O
at O
1-844-273-2327 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

In O
five O
randomized O
, O
double-blind O
, O
controlled O
trials O
, O
1,399 O
subjects O
with O
acute O
uncomplicated O
influenza B-Not_AE_Candidate
received O
a O
single O
dose O
of O
RAPIVAB O
, O
administered O
intravenously O
or O
intramuscularly O
, O
at O
doses O
up O
to O
600 O
mg O
. O

Among O
the O
664 O
subjects O
receiving O
RAPIVAB O
600 O
mg O
( O
intravenous O
or O
intramuscular O
) O
, O
the O
most O
commonly O
observed O
adverse O
reaction O
was O
diarrhea B-OSE_Labeled_AE
, O
occurring O
at O
a O
rate O
of O
8 O
% O
versus O
7 O
% O
in O
subjects O
receiving O
placebo O
. O

No O
subject O
receiving O
RAPIVAB O
600 O
mg O
experienced O
a O
serious O
adverse O
event O
and O
less O
than O
1 O
% O
discontinued O
study O
because O
of O
an O
adverse O
reaction O
. O

Clinically O
significant O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
( O
DAIDS O
Grade O
2-4 O
) O
listed O
in O
Table O
2 O
occurred O
more O
frequently O
in O
subjects O
treated O
with O
RAPIVAB O
600 O
mg O
( O
intravenous O
or O
intramuscular O
) O
than O
placebo O
. O

Only O
events O
occurring O
at O
> O
=2 O
% O
are O
included O
. O

Table O
2 O
: O
Laboratory O
Abnormalities O
Occurring O
in O
> O
=2 O
% O
of O
Subjects O
Treated O
with O
RAPIVAB O
600 O
mg O
Laboratory O
Parameter O
Abnormality O
RAPIVAB O
600 O
mg O
Placebo O
Alanine B-OSE_Labeled_AE
Aminotransferase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
* I-OSE_Labeled_AE
ULN I-OSE_Labeled_AE
) O
( O
N=654 O
) O
3 O
% O
( O
N=430 O
) O
2 O
% O
Serum B-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
( O
N=660 O
) O
5 O
% O
( O
N=433 O
) O
3 O
% O
Creatine B-OSE_Labeled_AE
Phosphokinase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
* I-OSE_Labeled_AE
ULN I-OSE_Labeled_AE
) O
( O
N=654 O
) O
4 O
% O
( O
N=431 O
) O
2 O
% O
Neutrophils B-OSE_Labeled_AE
( I-OSE_Labeled_AE
< I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
* I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
9 I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
) O
( O
N=654 O
) O
8 O
% O
( O
N=430 O
) O
6 O
% O
In O
a O
subset O
of O
subjects O
with O
serious O
influenza B-Not_AE_Candidate
requiring O
hospitalization O
treated O
with O
RAPIVAB O
600 O
mg O
as O
monotherapy O
( O
N=101 O
) O
the O
following O
adverse O
reactions O
were O
also O
reported O
more O
frequently O
with O
RAPIVAB O
as O
compared O
to O
placebo O
: O
constipation B-OSE_Labeled_AE
( O
4 O
% O
versus O
2 O
% O
) O
, O
insomnia B-OSE_Labeled_AE
( O
3 O
% O
versus O
0 O
% O
) O
, O
AST B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
3 O
% O
versus O
2 O
% O
) O
, O
and O
hypertension B-OSE_Labeled_AE
( O
2 O
% O
versus O
0 O
% O
) O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
additional O
adverse O
reactions O
have O
been O
identified O
during O
postapproval O
use O
of O
RAPIVAB O
in O
Japan O
. O

Because O
postmarketing O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Dermatologic B-NonOSE_AE
: O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
, O
exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
Psychiatric B-NonOSE_AE
: O
abnormal B-OSE_Labeled_AE
behavior I-OSE_Labeled_AE
, O
hallucination B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Serious O
skin/hypersensitivity O
reactions O
such O
as O
Stevens-Johnson O
syndrome O
and O
erythema O
multiforme O
have O
occurred O
with O
RAPIVAB O
. O

( O
5.1 O
) O
* O
Neuropsychiatric O
events O
: O
Patients O
with O
influenza O
may O
be O
at O
an O
increased O
risk O
of O
hallucinations O
, O
delirium O
and O
abnormal O
behavior O
early O
in O
their O
illness O
. O

Monitor O
for O
signs O
of O
abnormal O
behavior O
. O

( O
5.2 O
) O
5.1 O
Serious O
Skin/ O
Hypersensitivity B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
Rare O
cases O
of O
serious O
skin B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
have O
been O
reported O
with O
RAPIVAB O
in O
clinical O
studies O
and O
in O
postmarketing O
experience O
; O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
has O
been O
reported O
with O
RAPIVAB O
in O
postmarketing O
experience O
. O

Appropriate O
treatment O
should O
be O
instituted O
if O
a O
serious O
skin B-NonOSE_AE
reaction I-NonOSE_AE
occurs O
or O
is O
suspected O
. O

5.2 O
Neuropsychiatric B-OSE_Labeled_AE
Events I-OSE_Labeled_AE
Influenza B-Not_AE_Candidate
can O
be O
associated O
with O
a O
variety O
of O
neurologic B-NonOSE_AE
and O
behavioral O
symptoms I-NonOSE_AE
that O
can O
include O
events O
such O
as O
hallucinations B-NonOSE_AE
, O
delirium B-NonOSE_AE
, O
and O
abnormal B-NonOSE_AE
behavior I-NonOSE_AE
, O
in O
some O
cases O
resulting O
in O
fatal B-NonOSE_AE
outcomes O
. O

These O
events O
may O
occur O
in O
the O
setting O
of O
encephalitis B-Not_AE_Candidate
or O
encephalopathy B-Not_AE_Candidate
but O
can O
occur O
in O
uncomplicated O
influenza B-Not_AE_Candidate
as O
well O
. O

There O
have O
been O
postmarketing O
reports O
( O
from O
Japan O
) O
of O
delirium B-OSE_Labeled_AE
and O
abnormal B-OSE_Labeled_AE
behavior I-OSE_Labeled_AE
leading O
to O
injury B-NonOSE_AE
in O
patients O
with O
influenza B-Not_AE_Candidate
who O
were O
receiving O
neuraminidase O
inhibitors O
, O
including O
RAPIVAB O
. O

Because O
these O
events O
were O
reported O
voluntarily O
during O
clinical O
practice O
, O
estimates O
of O
frequency O
can O
not O
be O
made O
, O
but O
they O
appear O
to O
be O
uncommon O
. O

These O
events O
were O
reported O
primarily O
among O
pediatric O
patients O
and O
often O
had O
an O
abrupt O
onset O
and O
rapid O
resolution O
. O

The O
contribution O
of O
RAPIVAB O
to O
these O
events O
has O
not O
been O
established O
. O

Patients O
with O
influenza B-Not_AE_Candidate
should O
be O
closely O
monitored O
for O
signs O
of O
abnormal B-NonOSE_AE
behavior I-NonOSE_AE
. O

5.3 O
Risk O
of O
Bacterial O
Infections O
There O
is O
no O
evidence O
for O
efficacy O
of O
RAPIVAB O
in O
any O
illness O
caused O
by O
agents O
other O
than O
influenza B-Not_AE_Candidate
viruses O
. O

Serious O
bacterial B-NonOSE_AE
infections I-NonOSE_AE
may O
begin O
with O
influenza B-NonOSE_AE
- I-NonOSE_AE
like I-NonOSE_AE
symptoms I-NonOSE_AE
or O
may O
coexist O
with O
or O
occur O
as O
complications O
during O
the O
course O
of O
influenza B-Not_AE_Candidate
. O

RAPIVAB O
has O
not O
been O
shown O
to O
prevent O
such O
complications O
. O

Prescribers O
should O
be O
alert O
to O
the O
potential O
for O
secondary B-NonOSE_AE
bacterial O
infections I-NonOSE_AE
and O
treat O
with O
antibiotics O
as O
appropriate O
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
Common O
adverse O
reactions O
in O
healthy O
adult O
subjects O
( O
> O
=1.5 O
% O
) O
were O
: O
rash O
, O
pain O
in O
extremity O
, O
pruritus O
, O
and O
somnolence O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
GlaxoSmithKline O
at O
1-888-825-5249 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
with O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
safety O
of O
raxibacumab O
has O
been O
studied O
only O
in O
healthy O
volunteers O
. O

It O
has O
not O
been O
studied O
in O
patients O
with O
inhalational O
anthrax O
. O

The O
safety O
of O
raxibacumab O
has O
been O
evaluated O
in O
326 O
healthy O
subjects O
treated O
with O
a O
dose O
of O
40 O
mg/kg O
in O
3 O
clinical O
trials O
: O
a O
drug O
interaction O
trial O
with O
ciprofloxacin O
( O
Study O
1 O
) O
, O
a O
repeat-dose O
trial O
of O
20 O
subjects O
with O
the O
second O
raxibacumab O
dose O
administered O
> O
=4 O
months O
after O
the O
first O
dose O
( O
Study O
2 O
) O
, O
and O
a O
placebo-controlled O
trial O
evaluating O
single O
doses O
with O
a O
subset O
of O
subjects O
receiving O
2 O
raxibacumab O
doses O
14 O
days O
apart O
( O
Study O
3 O
) O
. O

Raxibacumab O
was O
administered O
to O
86 O
healthy O
subjects O
in O
Study O
1 O
. O

In O
Study O
3 O
, O
240 O
healthy O
subjects O
received O
raxibacumab O
( O
217 O
received O
1 O
dose O
and O
23 O
received O
2 O
doses O
) O
and O
80 O
subjects O
received O
placebo O
. O

The O
overall O
safety O
of O
raxibacumab O
was O
evaluated O
as O
an O
integrated O
summary O
of O
these O
3 O
clinical O
trials O
. O

Of O
326 O
raxibacumab O
subjects O
, O
283 O
received O
single O
doses O
, O
23 O
received O
2 O
doses O
14 O
days O
apart O
, O
and O
20 O
received O
2 O
doses O
more O
than O
4 O
months O
apart O
. O

The O
subjects O
were O
18 O
to O
88 O
years O
of O
age O
, O
53 O
% O
female O
, O
74 O
% O
white O
, O
17 O
% O
black/African O
American O
, O
6 O
% O
Asian O
, O
and O
15 O
% O
Hispanic O
. O

Adverse O
Reactions O
Leading O
to O
Discontinuation O
of O
Raxibacumab O
Infusion O
Four O
subjects O
( O
1.2 O
% O
) O
had O
their O
infusion O
of O
raxibacumab O
discontinued O
for O
adverse O
reactions O
: O
2 O
subjects O
( O
neither O
of O
whom O
received O
diphenhydramine O
premedication O
) O
due O
to O
urticaria B-OSE_Labeled_AE
( O
mild O
) O
, O
and O
1 O
subject O
each O
discontinued O
for O
clonus B-OSE_Labeled_AE
( O
mild O
) O
and O
dyspnea B-OSE_Labeled_AE
( O
moderate O
) O
. O

Most O
Frequently O
Reported O
Adverse O
Reactions O
The O
most O
frequently O
reported O
adverse O
reactions O
were O
rash B-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
and O
somnolence B-OSE_Labeled_AE
. O

Table O
3 O
. O

Adverse O
Reactions O
Reported O
in O
> O
=1.5 O
% O
of O
Healthy O
Adult O
Subjects O
Exposed O
to O
Raxibacumab O
40 O
mg/kg O
IV O
Preferred O
Term O
Placebo O
N O
= O
80 O
( O
% O
) O
Single-dose O
Raxibacumab O
N O
= O
283 O
( O
% O
) O
Double-dose O
Raxibacumab O
> O
=4 O
Months O
Apart O
N O
= O
20 O
( O
% O
) O
Double-dose O
Raxibacumab O
2 O
Weeks O
Apart O
N O
= O
23 O
( O
% O
) O
Total O
Raxibacumab O
Subjects O
N O
= O
326 O
( O
% O
) O
Rash B-OSE_Labeled_AE
/ O
Rash B-OSE_Labeled_AE
erythematous I-OSE_Labeled_AE
/ O
Rash B-OSE_Labeled_AE
papular I-OSE_Labeled_AE
1 O
( O
1.3 O
) O
9 O
( O
3.2 O
) O
0 O
0 O
9 O
( O
2.8 O
) O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
1 O
( O
1.3 O
) O
7 O
( O
2.5 O
) O
0 O
0 O
7 O
( O
2.1 O
) O
Pruritus B-OSE_Labeled_AE
0 O
7 O
( O
2.5 O
) O
0 O
0 O
7 O
( O
2.1 O
) O
Somnolence B-OSE_Labeled_AE
0 O
4 O
( O
1.4 O
) O
0 O
1 O
( O
4.3 O
) O
5 O
( O
1.5 O
) O
Rashes O
For O
all O
subjects O
exposed O
to O
raxibacumab O
in O
clinical O
trials O
, O
the O
rate O
of O
rash B-OSE_Labeled_AE
was O
2.8 O
% O
( O
9/326 O
) O
compared O
with O
1.3 O
% O
( O
1/80 O
) O
of O
placebo O
subjects O
. O

Mild O
to O
moderate O
infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
rashes I-OSE_Labeled_AE
were O
reported O
in O
22.2 O
% O
( O
6/27 O
) O
of O
subjects O
who O
did O
not O
receive O
diphenhydramine O
premedication O
compared O
to O
3.3 O
% O
( O
2/61 O
) O
of O
subjects O
who O
were O
premedicated O
with O
diphenhydramine O
in O
the O
ciprofloxacin/raxibacumab O
combination O
trial O
( O
Study O
1 O
) O
. O

In O
the O
placebo-controlled O
raxibacumab O
study O
where O
all O
subjects O
received O
diphenhydramine O
( O
Study O
3 O
) O
, O
the O
rate O
of O
rash B-NonOSE_AE
was O
2.5 O
% O
in O
both O
placebo- O
and O
raxibacumab-treated O
subjects O
. O

Less O
Common O
Adverse O
Reactions O
Clinically O
significant O
adverse O
reactions O
that O
were O
reported O
in O
< O
1.5 O
% O
of O
subjects O
exposed O
to O
raxibacumab O
and O
at O
rates O
higher O
than O
in O
placebo O
subjects O
are O
listed O
below O
: O
* O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
: O
anemia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
lymphadenopathy B-OSE_Labeled_AE
* O
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
palpitations B-OSE_Labeled_AE
* O
Ear B-NonOSE_AE
and I-NonOSE_AE
labyrinth I-NonOSE_AE
: O
vertigo B-OSE_Labeled_AE
* O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
: O
fatigue B-OSE_Labeled_AE
, O
infusion B-OSE_Labeled_AE
site I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
* O
Investigations B-NonOSE_AE
: O
blood B-OSE_Labeled_AE
amylase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
blood B-OSE_Labeled_AE
creatine I-OSE_Labeled_AE
phosphokinase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
prothrombin B-OSE_Labeled_AE
time I-OSE_Labeled_AE
prolonged I-OSE_Labeled_AE
* O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
: O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
* O
Nervous B-NonOSE_AE
system I-NonOSE_AE
: O
syncope B-OSE_Labeled_AE
vasovagal I-OSE_Labeled_AE
* O
Psychiatric B-NonOSE_AE
: O
insomnia B-OSE_Labeled_AE
* O
Vascular B-NonOSE_AE
: O
flushing B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
Immunogenicity O
The O
development O
of O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
raxibacumab I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
was O
evaluated O
in O
all O
subjects O
receiving O
single O
and O
double O
doses O
of O
raxibacumab O
in O
Studies O
1 O
, O
2 O
, O
and O
3 O
. O

Immunogenic B-NonOSE_AE
responses I-NonOSE_AE
against I-NonOSE_AE
raxibacumab I-NonOSE_AE
were I-NonOSE_AE
not I-NonOSE_AE
detected I-NonOSE_AE
in O
any O
raxibacumab-treated O
human O
subjects O
following O
single O
or O
repeat O
doses O
of O
raxibacumab O
. O

The O
incidence O
of O
antibody B-NonOSE_AE
formation I-NonOSE_AE
is O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
immunogenicity O
assay O
. O

Additionally O
, O
the O
observed O
incidence O
of O
any O
antibody B-NonOSE_AE
positivity I-NonOSE_AE
in O
an O
assay O
is O
highly O
dependent O
on O
several O
factors O
, O
including O
assay O
sensitivity O
and O
specificity O
, O
assay O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
raxibacumab I-NonOSE_AE
with O
the O
incidence O
of O
antibodies O
to O
other O
products O
may O
be O
misleading O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
Infusion O
reactions O
may O
occur O
. O

Premedicate O
with O
diphenhydramine O
. O

Slow O
or O
interrupt O
infusion O
and O
administer O
treatment O
based O
on O
severity O
of O
the O
reaction O
. O

( O
5.1 O
) O
5.1 O
Infusion O
Reactions O
Infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
were O
reported O
during O
administration O
of O
raxibacumab O
in O
clinical O
trials O
including O
reports O
of O
rash B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
and O
pruritus B-OSE_Labeled_AE
. O

If O
these O
reactions O
occur O
, O
slow O
or O
interrupt O
raxibacumab O
infusion O
and O
administer O
appropriate O
treatment O
based O
on O
severity O
of O
the O
reaction O
. O

Premedicate O
with O
diphenhydramine O
within O
1 O
hour O
prior O
to O
administering O
raxibacumab O
to O
reduce O
the O
risk O
of O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.1 O
) O
, O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

6 O
ADVERSE O
REACTIONS O
Serious O
and O
important O
adverse O
reactions O
described O
elsewhere O
in O
labeling O
include O
: O
* O
Gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Severe O
or O
persistent O
diarrhea B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Opioid B-OSE_Labeled_AE
withdrawal I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
The O
most O
common O
adverse O
reactions O
( O
> O
= O
1 O
% O
) O
in O
adult O
patients O
with O
opioid B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
constipation I-Not_AE_Candidate
and O
chronic B-Not_AE_Candidate
non I-Not_AE_Candidate
- I-Not_AE_Candidate
cancer I-Not_AE_Candidate
pain I-Not_AE_Candidate
are O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
hyperhidrosis B-OSE_Labeled_AE
, O
hot B-OSE_Labeled_AE
flush I-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
and O
chills B-OSE_Labeled_AE
( O
6.1 O
) O
* O
The O
most O
common O
adverse O
reactions O
( O
> O
= O
5 O
% O
) O
in O
adult O
patients O
with O
opioid B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
constipation I-Not_AE_Candidate
and O
advanced O
illness O
are O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
flatulence B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
and O
diarrhea B-OSE_Labeled_AE
( O
6.1 O
) O
EXCERPT O
: O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Salix O
Pharmaceuticals O
Inc O
. O
at O
1-800-508-0024 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

Opioid-Induced O
Constipation O
in O
Adult O
Patients O
with O
Chronic O
Non-Cancer O
Pain O
The O
safety O
of O
RELISTOR O
was O
evaluated O
in O
a O
double-blind O
, O
placebo-controlled O
trial O
in O
adult O
patients O
with O
opioid B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
constipation I-Not_AE_Candidate
and O
chronic B-Not_AE_Candidate
non I-Not_AE_Candidate
- I-Not_AE_Candidate
cancer I-Not_AE_Candidate
pain I-Not_AE_Candidate
receiving O
opioid O
analgesia O
. O

This O
study O
( O
Study O
1 O
) O
included O
a O
4-week O
, O
double-blind O
, O
placebo-controlled O
period O
in O
which O
adult O
patients O
were O
randomized O
to O
receive O
RELISTOR O
12 O
mg O
once O
daily O
( O
150 O
patients O
) O
or O
placebo O
( O
162 O
patients O
) O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

After O
4 O
weeks O
of O
double-blind O
treatment O
, O
patients O
began O
an O
8-week O
open-label O
treatment O
period O
during O
which O
RELISTOR O
12 O
mg O
was O
administered O
less O
frequently O
than O
the O
recommended O
dosage O
regimen O
of O
12 O
mg O
once O
daily O
. O

Adverse O
reactions O
in O
adult O
patients O
with O
opioid B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
constipation I-Not_AE_Candidate
and O
chronic B-Not_AE_Candidate
non I-Not_AE_Candidate
- I-Not_AE_Candidate
cancer I-Not_AE_Candidate
pain I-Not_AE_Candidate
receiving O
RELISTOR O
are O
shown O
in O
Table O
2 O
. O

The O
adverse O
reactions O
in O
the O
table O
below O
may O
reflect O
symptoms O
of O
opioid B-NonOSE_AE
withdrawal I-NonOSE_AE
. O

Table O
2 O
: O
Adverse O
Reactions* O
in O
4-Week O
Double-Blind O
, O
Placebo-Controlled O
Period O
of O
Clinical O
Study O
of O
RELISTOR O
in O
Adult O
Patients O
with O
Opioid-InducedConstipation O
and O
Chronic O
Non-Cancer O
Pain O
Adverse O
Reaction O
RELISTOR O
12 O
mg O
once O
dailyn O
= O
150 O
Placebo O
n O
= O
162 O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
21 O
% O
6 O
% O
Nausea B-OSE_Labeled_AE
9 O
% O
6 O
% O
Diarrhea B-OSE_Labeled_AE
6 O
% O
4 O
% O
Hyperhidrosis B-OSE_Labeled_AE
6 O
% O
1 O
% O
Hot B-OSE_Labeled_AE
Flush I-OSE_Labeled_AE
3 O
% O
2 O
% O
Tremor B-OSE_Labeled_AE
1 O
% O
< O
1 O
% O
Chills B-OSE_Labeled_AE
1 O
% O
0 O
% O
*Adverse O
reactions O
occuring O
in O
> O
= O
1 O
% O
of O
patients O
receiving O
RELISTOR O
12 O
mg O
once O
daily O
and O
at O
an O
incidence O
greater O
than O
placebo O
. O

. O

During O
the O
4-week O
double-blind O
period O
, O
in O
patients O
with O
opioid B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
constipation I-Not_AE_Candidate
and O
chronic B-Not_AE_Candidate
non I-Not_AE_Candidate
- I-Not_AE_Candidate
cancer I-Not_AE_Candidate
pain I-Not_AE_Candidate
that O
received O
RELISTOR O
12 O
mg O
every O
other O
day O
, O
there O
was O
a O
higher O
incidence O
of O
adverse O
reactions O
, O
including O
nausea B-OSE_Labeled_AE
( O
12 O
% O
) O
, O
diarrhea B-OSE_Labeled_AE
( O
12 O
% O
) O
, O
vomiting B-OSE_Labeled_AE
( O
7 O
% O
) O
, O
tremor B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
feeling B-OSE_Labeled_AE
of I-OSE_Labeled_AE
body I-OSE_Labeled_AE
temperature I-OSE_Labeled_AE
change I-OSE_Labeled_AE
( O
3 O
% O
) O
, O
piloerection B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
and O
chills B-OSE_Labeled_AE
( O
2 O
% O
) O
as O
compared O
to O
daily O
Relistor O
dosing O
. O

Use O
of O
RELISTOR O
12 O
mg O
every O
other O
day O
is O
not O
recommended O
in O
patients O
with O
OIC B-Not_AE_Candidate
and O
chronic B-Not_AE_Candidate
non I-Not_AE_Candidate
- I-Not_AE_Candidate
cancer I-Not_AE_Candidate
pain I-Not_AE_Candidate
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

The O
rates O
of O
discontinuation O
due O
to O
adverse O
reactions O
during O
the O
double-blind O
period O
( O
Study O
1 O
) O
were O
higher O
in O
the O
RELISTOR O
once O
daily O
( O
7 O
% O
) O
than O
the O
placebo O
group O
( O
3 O
% O
) O
. O

Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
was O
the O
most O
common O
adverse O
reaction O
resulting O
in O
discontinuation O
from O
the O
double-blind O
period O
in O
the O
RELISTOR O
once O
daily O
group O
( O
2 O
% O
) O
. O

The O
safety O
of O
RELISTOR O
was O
also O
evaluated O
in O
a O
48-week O
, O
open-label O
, O
uncontrolled O
trial O
in O
1034 O
adult O
patients O
with O
opioid B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
constipation I-Not_AE_Candidate
and O
chronic B-Not_AE_Candidate
non I-Not_AE_Candidate
- I-Not_AE_Candidate
cancer I-Not_AE_Candidate
pain I-Not_AE_Candidate
( O
Study O
2 O
) O
. O

Patients O
were O
allowed O
to O
administer O
RELISTOR O
12 O
mg O
less O
frequently O
than O
the O
recommended O
dosage O
regimen O
of O
12 O
mg O
once O
daily O
, O
and O
took O
a O
median O
of O
6 O
doses O
per O
week O
. O

A O
total O
of O
624 O
patients O
( O
60 O
% O
) O
completed O
at O
least O
24 O
weeks O
of O
treatment O
and O
477 O
( O
46 O
% O
) O
completed O
the O
48-week O
study O
. O

The O
adverse O
reactions O
seen O
in O
this O
study O
were O
similar O
to O
those O
observed O
during O
the O
4-week O
double-blind O
period O
of O
Study O
1 O
. O

Additionally O
, O
in O
Study O
2 O
, O
investigators O
reported O
4 O
myocardial B-NonOSE_AE
infarctions I-NonOSE_AE
( O
1 O
fatal B-NonOSE_AE
) O
, O
1 O
stroke B-NonOSE_AE
( O
fatal B-NonOSE_AE
) O
, O
1 O
fatal B-NonOSE_AE
cardiac B-NonOSE_AE
arrest I-NonOSE_AE
and O
1 O
sudden B-NonOSE_AE
death I-NonOSE_AE
. O

It O
is O
not O
possible O
to O
establish O
a O
relationship O
between O
these O
events O
and O
RELISTOR O
. O

Opioid-Induced O
Constipation O
in O
Adult O
Patients O
with O
Advanced O
Illness O
The O
safety O
of O
RELISTOR O
was O
evaluated O
in O
two O
, O
double-blind O
, O
placebo-controlled O
trials O
in O
adult O
patients O
with O
opioid B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
constipation I-Not_AE_Candidate
and O
advanced O
illness O
receiving O
palliative O
care O
: O
Study O
3 O
included O
a O
single-dose O
, O
double-blind O
, O
placebo-controlled O
period O
, O
whereas O
Study O
4 O
included O
a O
14-day O
multiple O
dose O
, O
double-blind O
, O
placebo-controlled O
period O
[ O
see O
Clinical O
Studies O
( O
14 O
.2 O
) O
] O
. O

The O
most O
common O
( O
> O
= O
5 O
% O
) O
adverse O
reactions O
in O
adult O
patients O
with O
opioid B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
constipation I-Not_AE_Candidate
and O
advanced O
illness O
receiving O
RELISTOR O
are O
shown O
in O
Table O
3 O
below O
. O

Table O
3 O
: O
Adverse O
Reactions O
from O
all O
Doses O
in O
Double-Blind O
, O
Placebo-Controlled O
Clinical O
Studies O
of O
RELISTOR O
in O
Adult O
Patients O
with O
Opioid-Induced O
Constipation O
and O
Advanced O
Illness* O
Adverse O
Reaction O
RELISTORn O
= O
165 O
Placebon O
= O
123 O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
29 O
% O
10 O
% O
Flatulence B-OSE_Labeled_AE
13 O
% O
6 O
% O
Nausea B-OSE_Labeled_AE
12 O
% O
5 O
% O
Dizziness B-OSE_Labeled_AE
7 O
% O
2 O
% O
Diarrhea B-OSE_Labeled_AE
6 O
% O
2 O
% O
* O
Adverse O
reactions O
occuring O
in O
> O
= O
5 O
% O
of O
patients O
receiving O
all O
doses O
of O
RELISTOR O
( O
0.075 O
, O
0.15 O
, O
and O
0.30 O
mg/kg/dose O
) O
and O
at O
an O
incidence O
greater O
than O
placebo O
. O

The O
rates O
of O
discontinuation O
due O
to O
adverse O
events O
during O
the O
double-blind O
placebo O
controlled O
clinical O
trials O
( O
Study O
3 O
and O
Study O
4 O
) O
were O
comparable O
between O
RELISTOR O
( O
1 O
% O
) O
and O
placebo O
( O
2 O
% O
) O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
RELISTOR O
. O

Because O
they O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Gastrointestinal B-NonOSE_AE
Perforation O
, O
cramping O
, O
vomiting B-OSE_Labeled_AE
Gen B-NonOSE_AE
eral I-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administrative I-NonOSE_AE
Site I-NonOSE_AE
Disorders I-NonOSE_AE
Diaphoresis B-OSE_Labeled_AE
, O
flushing B-OSE_Labeled_AE
, O
malaise B-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
. O

Cases O
of O
opioid B-OSE_Labeled_AE
withdrawal I-OSE_Labeled_AE
have O
been O
reported O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Gastrointestinal O
perforation O
: O
Consider O
the O
overall O
risk O
benefit O
in O
patients O
with O
known O
or O
suspected O
lesions O
of O
the O
GI O
tract O
. O

Monitor O
for O
severe O
, O
persistent O
or O
worsening O
abdominal O
pain O
; O
discontinue O
if O
development O
of O
symptoms O
( O
5.1 O
) O
* O
Severe O
or O
persistent O
diarrhea O
: O
Discontinue O
if O
severe O
or O
persistent O
diarrhea O
occurs O
during O
treatment O
( O
5.2 O
) O
* O
Opioid O
withdrawal O
: O
Consider O
the O
overall O
risk O
benefit O
in O
patients O
with O
disruptions O
to O
the O
blood-brain O
barrier O
. O

Monitor O
closely O
for O
symptoms O
of O
opioid O
withdrawal O
( O
5.3 O
) O
5.1 O
Gastrointestinal O
Perforation O
Cases O
of O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
have O
been O
reported O
in O
adult O
patients O
with O
opioid B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
constipation I-Not_AE_Candidate
and O
advanced O
illness O
with O
conditions O
that O
may O
be O
associated O
with O
localized O
or O
diffuse O
reduction B-Not_AE_Candidate
of I-Not_AE_Candidate
structural I-Not_AE_Candidate
integrity I-Not_AE_Candidate
in I-Not_AE_Candidate
the I-Not_AE_Candidate
wall I-Not_AE_Candidate
of I-Not_AE_Candidate
the I-Not_AE_Candidate
gastrointestinal I-Not_AE_Candidate
tract I-Not_AE_Candidate
( O
e.g. O
, O
peptic B-Not_AE_Candidate
ulcer I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
Ogilvie B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
, O
diverticular B-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
infiltrative B-Not_AE_Candidate
gastrointestinal I-Not_AE_Candidate
tract I-Not_AE_Candidate
malignancies I-Not_AE_Candidate
or O
peritoneal B-Not_AE_Candidate
metastases I-Not_AE_Candidate
) O
. O

Take O
into O
account O
the O
overall O
risk-benefit O
profile O
when O
using O
RELISTOR O
in O
patients O
with O
these O
conditions O
or O
other O
conditions O
which O
might O
result O
in O
impaired B-NonOSE_AE
integrity I-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
gastrointestinal I-NonOSE_AE
tract I-NonOSE_AE
wall I-NonOSE_AE
( O
e.g. O
, O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
) O
. O

Monitor O
for O
the O
development O
of O
severe O
, O
persistent O
, O
or O
worsening O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
; O
discontinue O
RELISTOR O
in O
patients O
who O
develop O
this O
symptom O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

5.2 O
Severe O
or O
Persistent O
Diarrhea B-OSE_Labeled_AE
If O
severe O
or O
persistent O
diarrhea B-NonOSE_AE
occurs O
during O
treatment O
, O
advise O
patients O
to O
discontinue O
therapy O
with O
RELISTOR O
and O
consult O
their O
healthcare O
provider O
. O

5.3 O
Opioid O
Withdrawal O
Symptoms O
consistent O
with O
opioid B-OSE_Labeled_AE
withdrawal I-OSE_Labeled_AE
, O
including O
hyperhidrosis B-NonOSE_AE
, O
chills B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
, O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
anxiety B-NonOSE_AE
, O
and O
yawning B-NonOSE_AE
have O
occurred O
in O
patients O
treated O
with O
RELISTOR O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Patients O
having O
disruptions B-Not_AE_Candidate
to I-Not_AE_Candidate
the I-Not_AE_Candidate
blood I-Not_AE_Candidate
- I-Not_AE_Candidate
brain I-Not_AE_Candidate
barrier I-Not_AE_Candidate
may O
be O
at O
increased O
risk O
for O
opioid B-NonOSE_AE
withdrawal I-NonOSE_AE
and/or O
reduced B-NonOSE_AE
analgesia I-NonOSE_AE
. O

Take O
into O
account O
the O
overall O
risk-benefit O
profile O
when O
using O
RELISTOR O
in O
such O
patients O
. O

Monitor O
for O
adequacy O
of O
analgesia O
and O
symptoms O
of O
opioid B-NonOSE_AE
withdrawal I-NonOSE_AE
in O
such O
patients O
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
> O
10 O
% O
) O
- O
infections O
( O
e.g O
. O

upper O
respiratory O
, O
sinusitis O
, O
and O
pharyngitis O
) O
, O
infusion-related O
reactions O
, O
headache O
, O
and O
abdominal O
pain O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Janssen O
Biotech O
, O
Inc O
. O
at O
1-800-JANSSEN O
( O
1-800-526-7736 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Adverse O
Reactions O
in O
Adults O
The O
data O
described O
herein O
reflect O
exposure O
to O
REMICADE O
in O
4779 O
adult O
patients O
( O
1304 O
patients O
with O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
1106 O
patients O
with O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
202 O
with O
ankylosing B-Not_AE_Candidate
spondylitis I-Not_AE_Candidate
, O
293 O
with O
psoriatic B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
484 O
with O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
, O
1373 O
with O
plaque B-Not_AE_Candidate
psoriasis I-Not_AE_Candidate
, O
and O
17 O
patients O
with O
other O
conditions O
) O
, O
including O
2625 O
patients O
exposed O
beyond O
30 O
weeks O
and O
374 O
exposed O
beyond O
1 O
year O
. O

[ O
For O
information O
on O
adverse O
reactions O
in O
pediatric O
patients O
see O
Adverse O
Reactions O
( O
6.1 O
) O
. O
] O

One O
of O
the O
most-common O
reasons O
for O
discontinuation O
of O
treatment O
was O
infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
e.g. O
, O
dyspnea B-OSE_Labeled_AE
, O
flushing B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
and O
rash B-OSE_Labeled_AE
) O
. O

Infusion-related O
Reactions O
An O
infusion O
reaction O
was O
defined O
in O
clinical O
trials O
as O
any O
adverse O
event O
occurring O
during O
an O
infusion O
or O
within O
1 O
hour O
after O
an O
infusion O
. O

In O
Phase O
3 O
clinical O
studies O
, O
18 O
% O
of O
REMICADE-treated O
patients O
experienced O
an O
infusion B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
compared O
to O
5 O
% O
of O
placebo-treated O
patients O
. O

Of O
infliximab-treated O
patients O
who O
had O
an O
infusion B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
during O
the O
induction O
period O
, O
27 O
% O
experienced O
an O
infusion B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
during O
the O
maintenance O
period O
. O

Of O
patients O
who O
did O
not O
have O
an O
infusion O
reaction O
during O
the O
induction O
period O
, O
9 O
% O
experienced O
an O
infusion B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
during O
the O
maintenance O
period O
. O

Among O
all O
REMICADE O
infusions O
, O
3 O
% O
were O
accompanied O
by O
nonspecific O
symptoms O
such O
as O
fever B-OSE_Labeled_AE
or O
chills B-OSE_Labeled_AE
, O
1 O
% O
were O
accompanied O
by O
cardiopulmonary B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
primarily O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
or O
dyspnea B-OSE_Labeled_AE
) O
, O
and O
< O
1 O
% O
were O
accompanied O
by O
pruritus B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
or O
the O
combined O
symptoms O
of O
pruritus B-OSE_Labeled_AE
/ O
urticaria B-OSE_Labeled_AE
and O
cardiopulmonary B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

Serious O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
occurred O
in O
< O
1 O
% O
of O
patients O
and O
included O
anaphylaxis B-OSE_Labeled_AE
, O
convulsions B-OSE_Labeled_AE
, O
erythematous B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
and O
hypotension B-OSE_Labeled_AE
. O

Approximately O
3 O
% O
of O
patients O
discontinued O
REMICADE O
because O
of O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
and O
all O
patients O
recovered O
with O
treatment O
and/or O
discontinuation O
of O
the O
infusion O
. O

REMICADE O
infusions O
beyond O
the O
initial O
infusion O
were O
not O
associated O
with O
a O
higher O
incidence O
of O
reactions O
. O

The O
infusion B-NonOSE_AE
reaction I-NonOSE_AE
rates O
remained O
stable O
in O
psoriasis B-Not_AE_Candidate
through O
1 O
year O
in O
psoriasis B-Not_AE_Candidate
Study O
I O
. O

In O
psoriasis B-Not_AE_Candidate
Study O
II O
, O
the O
rates O
were O
variable O
over O
time O
and O
somewhat O
higher O
following O
the O
final O
infusion O
than O
after O
the O
initial O
infusion O
. O

Across O
the O
3 O
psoriasis B-Not_AE_Candidate
studies O
, O
the O
percent O
of O
total O
infusions O
resulting O
in O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
i.e. O
, O
an O
adverse O
event O
occurring O
within O
1 O
hour O
) O
was O
7 O
% O
in O
the O
3 O
mg/kg O
group O
, O
4 O
% O
in O
the O
5 O
mg/kg O
group O
, O
and O
1 O
% O
in O
the O
placebo O
group O
. O

Patients O
who O
became O
positive B-OSE_Labeled_AE
for I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
to I-OSE_Labeled_AE
infliximab I-OSE_Labeled_AE
were O
more O
likely O
( O
approximately O
two-to O
three-fold O
) O
to O
have O
an O
infusion B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
than O
were O
those O
who O
were O
negative O
. O

Use O
of O
concomitant O
immunosuppressant B-NonOSE_AE
agents I-NonOSE_AE
appeared O
to O
reduce O
the O
frequency O
of O
both O
antibodies B-NonOSE_AE
to I-NonOSE_AE
infliximab I-NonOSE_AE
and O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
and O
Drug O
Interactions O
( O
7.4 O
) O
] O
. O

Infusion O
Reactions O
Following O
Re-administration O
In O
a O
clinical O
trial O
of O
patients O
with O
moderate O
to O
severe O
psoriasis B-Not_AE_Candidate
designed O
to O
assess O
the O
efficacy O
of O
long-term O
maintenance O
therapy O
versus O
re-treatment O
with O
an O
induction O
regimen O
of O
REMICADE O
following O
disease O
flare O
, O
4 O
% O
( O
8/219 O
) O
of O
patients O
in O
the O
re-treatment O
therapy O
arm O
experienced O
serious O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
versus O
< O
1 O
% O
( O
1/222 O
) O
in O
the O
maintenance O
therapy O
arm O
. O

Patients O
enrolled O
in O
this O
trial O
did O
not O
receive O
any O
concomitant O
immunosuppressant B-NonOSE_AE
therapy I-NonOSE_AE
. O

In O
this O
study O
, O
the O
majority O
of O
serious O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
occurred O
during O
the O
second O
infusion O
at O
Week O
2 O
. O

Symptoms O
included O
, O
but O
were O
not O
limited O
to O
, O
dyspnea B-NonOSE_AE
, O
urticaria B-NonOSE_AE
, O
facial B-NonOSE_AE
edema I-NonOSE_AE
, O
and O
hypotension B-NonOSE_AE
. O

In O
all O
cases O
, O
REMICADE O
treatment O
was O
discontinued O
and/or O
other O
treatment O
instituted O
with O
complete O
resolution O
of O
signs O
and O
symptoms O
. O

Delayed O
Reactions/Reactions O
Following O
Re-administration O
In O
psoriasis B-Not_AE_Candidate
studies O
, O
approximately O
1 O
% O
of O
REMICADE-treated O
patients O
experienced O
a O
possible O
delayed B-OSE_Labeled_AE
hypersensitivity I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
generally O
reported O
as O
serum B-OSE_Labeled_AE
sickness I-OSE_Labeled_AE
or O
a O
combination O
of O
arthralgia B-OSE_Labeled_AE
and/or O
myalgia B-OSE_Labeled_AE
with O
fever B-OSE_Labeled_AE
and/or O
rash B-OSE_Labeled_AE
. O

These O
reactions O
generally O
occurred O
within O
2 O
weeks O
after O
repeat O
infusion O
. O

Infections O
In O
REMICADE O
clinical O
studies O
, O
treated O
infections B-OSE_Labeled_AE
were O
reported O
in O
36 O
% O
of O
REMICADE-treated O
patients O
( O
average O
of O
51 O
weeks O
of O
follow-up O
) O
and O
in O
25 O
% O
of O
placebo-treated O
patients O
( O
average O
of O
37 O
weeks O
of O
follow-up O
) O
. O

The O
infections B-OSE_Labeled_AE
most O
frequently O
reported O
were O
respiratory B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
( O
including O
sinusitis B-OSE_Labeled_AE
, O
pharyngitis B-OSE_Labeled_AE
, O
and O
bronchitis B-OSE_Labeled_AE
) O
and O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
. O

Among O
REMICADE-treated O
patients O
, O
serious O
infections B-OSE_Labeled_AE
included O
pneumonia B-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
abscess B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
and O
bacterial B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
. O

In O
clinical O
trials O
, O
7 O
opportunistic B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
were O
reported O
; O
2 O
cases O
each O
of O
coccidioidomycosis B-OSE_Labeled_AE
( O
1 O
case O
was O
fatal B-NonOSE_AE
) O
and O
histoplasmosis B-OSE_Labeled_AE
( O
1 O
case O
was O
fatal B-NonOSE_AE
) O
, O
and O
1 O
case O
each O
of O
pneumocystosis B-OSE_Labeled_AE
, O
nocardiosis B-OSE_Labeled_AE
and O
cytomegalovirus B-OSE_Labeled_AE
. O

Tuberculosis B-OSE_Labeled_AE
was O
reported O
in O
14 O
patients O
, O
4 O
of O
whom O
died B-NonOSE_AE
due O
to O
miliary B-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
. O

Other O
cases O
of O
tuberculosis B-OSE_Labeled_AE
, O
including O
disseminated B-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
, O
also O
have O
been O
reported O
post-marketing O
. O

Most O
of O
these O
cases O
of O
tuberculosis B-OSE_Labeled_AE
occurred O
within O
the O
first O
2 O
months O
after O
initiation O
of O
therapy O
with O
REMICADE O
and O
may O
reflect O
recrudescence B-NonOSE_AE
of I-NonOSE_AE
latent I-NonOSE_AE
disease I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

In O
the O
1-year O
placebo-controlled O
studies O
RA B-Not_AE_Candidate
I O
and O
RA B-Not_AE_Candidate
II O
, O
5.3 O
% O
of O
patients O
receiving O
REMICADE O
every O
8 O
weeks O
with O
MTX O
developed O
serious O
infections B-OSE_Labeled_AE
as O
compared O
to O
3.4 O
% O
of O
placebo O
patients O
receiving O
MTX O
. O

Of O
924 O
patients O
receiving O
REMICADE O
, O
1.7 O
% O
developed O
pneumonia B-OSE_Labeled_AE
and O
0.4 O
% O
developed O
TB B-OSE_Labeled_AE
, O
when O
compared O
to O
0.3 O
% O
and O
0.0 O
% O
in O
the O
placebo O
arm O
respectively O
. O

In O
a O
shorter O
( O
22-week O
) O
placebo-controlled O
study O
of O
1082 O
RA B-Not_AE_Candidate
patients O
randomized O
to O
receive O
placebo O
, O
3 O
mg/kg O
or O
10 O
mg/kg O
REMICADE O
infusions O
at O
0 O
, O
2 O
, O
and O
6 O
weeks O
, O
followed O
by O
every O
8 O
weeks O
with O
MTX O
, O
serious O
infections B-OSE_Labeled_AE
were O
more O
frequent O
in O
the O
10 O
mg/kg O
REMICADE O
group O
( O
5.3 O
% O
) O
than O
the O
3 O
mg/kg O
or O
placebo O
groups O
( O
1.7 O
% O
in O
both O
) O
. O

During O
the O
54-week O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
II O
Study O
, O
15 O
% O
of O
patients O
with O
fistulizing B-Not_AE_Candidate
Crohn I-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
developed O
a O
new O
fistula B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
abscess I-OSE_Labeled_AE
. O

In O
REMICADE O
clinical O
studies O
in O
patients O
with O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
, O
infections B-OSE_Labeled_AE
treated O
with O
antimicrobials O
were O
reported O
in O
27 O
% O
of O
REMICADE-treated O
patients O
( O
average O
of O
41 O
weeks O
of O
follow-up O
) O
and O
in O
18 O
% O
of O
placebo-treated O
patients O
( O
average O
32 O
weeks O
of O
follow-up O
) O
. O

The O
types O
of O
infections B-NonOSE_AE
, O
including O
serious O
infections B-NonOSE_AE
, O
reported O
in O
patients O
with O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
were O
similar O
to O
those O
reported O
in O
other O
clinical O
studies O
. O

The O
onset O
of O
serious O
infections B-NonOSE_AE
may O
be O
preceded O
by O
constitutional O
symptoms O
such O
as O
fever B-NonOSE_AE
, O
chills B-NonOSE_AE
, O
weight B-NonOSE_AE
loss I-NonOSE_AE
, O
and O
fatigue B-NonOSE_AE
. O

The O
majority O
of O
serious O
infections B-NonOSE_AE
, O
however O
, O
may O
also O
be O
preceded O
by O
signs O
or O
symptoms O
localized O
to O
the O
site O
of O
the O
infection B-NonOSE_AE
. O

Autoantibodies/Lupus-like O
Syndrome O
Approximately O
half O
of O
REMICADE-treated O
patients O
in O
clinical O
trials O
who O
were O
antinuclear B-Not_AE_Candidate
antibody I-Not_AE_Candidate
( I-Not_AE_Candidate
ANA I-Not_AE_Candidate
) I-Not_AE_Candidate
negative I-Not_AE_Candidate
at O
baseline O
developed O
a O
positive B-OSE_Labeled_AE
ANA I-OSE_Labeled_AE
during O
the O
trial O
compared O
with O
approximately O
one-fifth O
of O
placebo-treated O
patients O
. O

Anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
dsDNA I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
were O
newly O
detected O
in O
approximately O
one-fifth O
of O
REMICADE-treated O
patients O
compared O
with O
0 O
% O
of O
placebo-treated O
patients O
. O

Reports O
of O
lupus B-OSE_Labeled_AE
and O
lupus B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
syndromes I-OSE_Labeled_AE
, O
however O
, O
remain O
uncommon O
. O

Malignancies O
In O
controlled O
trials O
, O
more O
REMICADE-treated O
patients O
developed O
malignancies B-OSE_Labeled_AE
than O
placebo-treated O
patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

In O
a O
randomized O
controlled O
clinical O
trial O
exploring O
the O
use O
of O
REMICADE O
in O
patients O
with O
moderate O
to O
severe O
COPD B-Not_AE_Candidate
who O
were O
either O
current O
smokers O
or O
ex-smokers O
, O
157 O
patients O
were O
treated O
with O
REMICADE O
at O
doses O
similar O
to O
those O
used O
in O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
and O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Of O
these O
REMICADE-treated O
patients O
, O
9 O
developed O
a O
malignancy B-OSE_Labeled_AE
, O
including O
1 O
lymphoma B-OSE_Labeled_AE
, O
for O
a O
rate O
of O
7.67 O
cases O
per O
100 O
patient-years O
of O
follow-up O
( O
median O
duration O
of O
follow-up O
0.8 O
years O
; O
95 O
% O
CI O
3.51 O
- O
14.56 O
) O
. O

There O
was O
1 O
reported O
malignancy B-OSE_Labeled_AE
among O
77 O
control O
patients O
for O
a O
rate O
of O
1.63 O
cases O
per O
100 O
patient-years O
of O
follow-up O
( O
median O
duration O
of O
follow-up O
0.8 O
years O
; O
95 O
% O
CI O
0.04 O
- O
9.10 O
) O
. O

The O
majority O
of O
the O
malignancies B-OSE_Labeled_AE
developed I-OSE_Labeled_AE
in I-OSE_Labeled_AE
the I-OSE_Labeled_AE
lung I-OSE_Labeled_AE
or O
head O
and O
neck O
. O

Patients O
with O
Heart O
Failure O
In O
a O
randomized O
study O
evaluating O
REMICADE O
in O
moderate O
to O
severe O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
( I-Not_AE_Candidate
NYHA I-Not_AE_Candidate
Class I-Not_AE_Candidate
III I-Not_AE_Candidate
/IV O
; O
left B-Not_AE_Candidate
ventricular I-Not_AE_Candidate
ejection I-Not_AE_Candidate
fraction I-Not_AE_Candidate
< I-Not_AE_Candidate
= I-Not_AE_Candidate
3 I-Not_AE_Candidate
5 I-Not_AE_Candidate
% I-Not_AE_Candidate
) O
, O
150 O
patients O
were O
randomized O
to O
receive O
treatment O
with O
3 O
infusions O
of O
REMICADE O
10 O
mg/kg O
, O
5 O
mg/kg O
, O
or O
placebo O
, O
at O
0 O
, O
2 O
, O
and O
6 O
weeks O
. O

Higher O
incidences O
of O
mortality B-NonOSE_AE
and O
hospitalization O
due O
to O
worsening B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
were O
observed O
in O
patients O
receiving O
the O
10 O
mg/kg O
REMICADE O
dose O
. O

At O
1 O
year O
, O
8 O
patients O
in O
the O
10 O
mg/kg O
REMICADE O
group O
had O
died B-NonOSE_AE
compared O
with O
4 O
deaths B-NonOSE_AE
each O
in O
the O
5 O
mg/kg O
REMICADE O
and O
the O
placebo O
groups O
. O

There O
were O
trends O
toward O
increased O
dyspnea B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
angina B-OSE_Labeled_AE
, O
and O
dizziness B-OSE_Labeled_AE
in O
both O
the O
10 O
mg/kg O
and O
5 O
mg/kg O
REMICADE O
treatment O
groups O
, O
versus O
placebo O
. O

REMICADE O
has O
not O
been O
studied O
in O
patients O
with O
mild O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
( I-Not_AE_Candidate
NYHA I-Not_AE_Candidate
Class I-Not_AE_Candidate
I I-Not_AE_Candidate
/II O
) O
[ O
see O
Contraindications O
( O
4 O
) O
and O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

Immunogenicity O
Treatment O
with O
REMICADE O
can O
be O
associated O
with O
the O
development O
of O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
infliximab I-OSE_Labeled_AE
. O

An O
enzyme O
immunoassay O
( O
EIA O
) O
method O
was O
originally O
used O
to O
measure O
anti B-NonOSE_AE
- I-NonOSE_AE
infliximab I-NonOSE_AE
antibodies I-NonOSE_AE
in O
clinical O
studies O
of O
REMICADE O
. O

The O
EIA O
method O
is O
subject O
to O
interference O
by O
serum O
infliximab O
, O
possibly O
resulting O
in O
an O
underestimation O
of O
the O
rate O
of O
patient O
antibody B-NonOSE_AE
formation I-NonOSE_AE
. O

A O
separate O
, O
drug-tolerant O
electrochemiluminescence O
immunoassay O
( O
ECLIA O
) O
method O
for O
detecting O
antibodies B-NonOSE_AE
to I-NonOSE_AE
infliximab I-NonOSE_AE
was O
subsequently O
developed O
and O
validated O
. O

This O
method O
is O
60-fold O
more O
sensitive O
than O
the O
original O
EIA O
. O

With O
the O
ECLIA O
method O
, O
all O
clinical O
samples O
can O
be O
classified O
as O
either O
positive O
or O
negative O
for O
antibodies B-NonOSE_AE
to I-NonOSE_AE
infliximab I-NonOSE_AE
without O
the O
need O
for O
the O
inconclusive O
category O
. O

The O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
infliximab I-NonOSE_AE
was O
based O
on O
the O
original O
EIA O
method O
in O
all O
clinical O
studies O
of O
REMICADE O
except O
for O
the O
Phase O
3 O
study O
in O
pediatric O
patients O
with O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
where O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
infliximab I-NonOSE_AE
was O
detected O
using O
both O
the O
EIA O
and O
ECLIA O
methods O
[ O
see O
Adverse O
Reactions O
, O
Pediatric O
Ulcerative B-Not_AE_Candidate
Colitis I-Not_AE_Candidate
( O
6.1 O
) O
] O
. O

The O
incidence O
of O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
infliximab I-OSE_Labeled_AE
in O
patients O
given O
a O
3-dose O
induction O
regimen O
followed O
by O
maintenance O
dosing O
was O
approximately O
10 O
% O
as O
assessed O
through O
1 O
to O
2 O
years O
of O
REMICADE O
treatment O
. O

A O
higher O
incidence O
of O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
infliximab I-OSE_Labeled_AE
was O
observed O
in O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
patients O
receiving O
REMICADE O
after O
drug-free O
intervals O
> O
16 O
weeks O
. O

In O
a O
study O
of O
psoriatic B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
in O
which O
191 O
patients O
received O
5 O
mg/kg O
with O
or O
without O
MTX O
, O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
infliximab I-OSE_Labeled_AE
occurred O
in O
15 O
% O
of O
patients O
. O

The O
majority O
of O
antibody B-NonOSE_AE
- I-NonOSE_AE
positive I-NonOSE_AE
patients O
had O
low O
titers O
. O

Patients O
who O
were O
antibody B-NonOSE_AE
- I-NonOSE_AE
positive I-NonOSE_AE
were O
more O
likely O
to O
have O
higher O
rates O
of O
clearance O
, O
reduced O
efficacy O
and O
to O
experience O
an O
infusion B-NonOSE_AE
reaction I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
than O
were O
patients O
who O
were O
antibody B-NonOSE_AE
negative I-NonOSE_AE
. O

Antibody B-OSE_Labeled_AE
development O
was O
lower O
among O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
and O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
patients O
receiving O
immunosuppressant B-NonOSE_AE
therapies I-NonOSE_AE
such O
as O
6-MP/AZA O
or O
MTX O
. O

In O
the O
psoriasis B-Not_AE_Candidate
Study O
II O
, O
which O
included O
both O
the O
5 O
mg/kg O
and O
3 O
mg/kg O
doses O
, O
antibodies B-OSE_Labeled_AE
were O
observed O
in O
36 O
% O
of O
patients O
treated O
with O
5 O
mg/kg O
every O
8 O
weeks O
for O
1 O
year O
, O
and O
in O
51 O
% O
of O
patients O
treated O
with O
3 O
mg/kg O
every O
8 O
weeks O
for O
1 O
year O
. O

In O
the O
psoriasis B-Not_AE_Candidate
Study O
III O
, O
which O
also O
included O
both O
the O
5 O
mg/kg O
and O
3 O
mg/kg O
doses O
, O
antibodies B-OSE_Labeled_AE
were O
observed O
in O
20 O
% O
of O
patients O
treated O
with O
5 O
mg/kg O
induction O
( O
weeks O
0 O
, O
2 O
and O
6 O
) O
, O
and O
in O
27 O
% O
of O
patients O
treated O
with O
3 O
mg/kg O
induction O
. O

Despite O
the O
increase B-NonOSE_AE
in I-NonOSE_AE
antibody I-NonOSE_AE
formation O
, O
the O
infusion B-NonOSE_AE
reaction I-NonOSE_AE
rates I-NonOSE_AE
in O
Studies O
I O
and O
II O
in O
patients O
treated O
with O
5 O
mg/kg O
induction O
followed O
by O
every O
8 O
week O
maintenance O
for O
1 O
year O
and O
in O
Study O
III O
in O
patients O
treated O
with O
5 O
mg/kg O
induction O
( O
14.1 O
% O
-23.0 O
% O
) O
and O
serious O
infusion B-NonOSE_AE
reaction I-NonOSE_AE
rates O
( O
< O
1 O
% O
) O
were O
similar O
to O
those O
observed O
in O
other O
study O
populations O
. O

The O
clinical O
significance O
of O
apparent O
increased O
immunogenicity B-NonOSE_AE
on O
efficacy O
and O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
in O
psoriasis B-Not_AE_Candidate
patients O
as O
compared O
to O
patients O
with O
other O
diseases O
treated O
with O
REMICADE O
over O
the O
long O
term O
is O
not O
known O
. O

The O
data O
reflect O
the O
percentage O
of O
patients O
whose O
test O
results O
were O
positive B-NonOSE_AE
for I-NonOSE_AE
antibodies I-NonOSE_AE
to I-NonOSE_AE
infliximab I-NonOSE_AE
in O
an O
immunoassay O
, O
and O
they O
are O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
. O

Additionally O
, O
the O
observed O
incidence O
of O
antibody B-NonOSE_AE
positivity I-NonOSE_AE
in O
an O
assay O
may O
be O
influenced O
by O
several O
factors O
including O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medication O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
infliximab I-NonOSE_AE
with O
the O
incidence O
of O
antibodies O
to O
other O
products O
may O
be O
misleading O
. O

Hepatotoxicity B-OSE_Labeled_AE
Severe O
liver B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
, O
including O
acute B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
and O
autoimmune B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
, O
has O
been O
reported O
in O
patients O
receiving O
REMICADE O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

Reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
B I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
has O
occurred O
in O
patients O
receiving O
TNF-blocking O
agents O
, O
including O
REMICADE O
, O
who O
are O
chronic O
carriers O
of O
this O
virus O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

In O
clinical O
trials O
in O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
, O
ankylosing B-Not_AE_Candidate
spondylitis I-Not_AE_Candidate
, O
plaque B-Not_AE_Candidate
psoriasis I-Not_AE_Candidate
, O
and O
psoriatic B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
aminotransferases I-OSE_Labeled_AE
were O
observed O
( O
ALT O
more O
common O
than O
AST O
) O
in O
a O
greater O
proportion O
of O
patients O
receiving O
REMICADE O
than O
in O
controls O
( O
Table O
1 O
) O
, O
both O
when O
REMICADE O
was O
given O
as O
monotherapy O
and O
when O
it O
was O
used O
in O
combination O
with O
other O
immunosuppressive B-NonOSE_AE
agents I-NonOSE_AE
. O

In O
general O
, O
patients O
who O
developed O
ALT B-OSE_Labeled_AE
and O
AST O
elevations I-OSE_Labeled_AE
were O
asymptomatic O
, O
and O
the O
abnormalities O
decreased O
or O
resolved O
with O
either O
continuation O
or O
discontinuation O
of O
REMICADE O
, O
or O
modification O
of O
concomitant O
medications O
. O

Table O
1 O
: O
Proportion O
of O
patients O
with O
elevated B-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
in O
clinical O
trials O
Proportion O
of O
patients O
with O
elevated B-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
> O
1 O
to O
< O
3 O
* O
ULN O
> O
=3 O
* O
ULN O
> O
=5 O
* O
ULN O
Placebo O
REMICADE O
Placebo O
REMICADE O
Placebo O
REMICADE O
Rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
[ O
note O
: O
Placebo O
patients O
received O
methotrexate O
while O
REMICADE O
patients O
received O
both O
REMICADE O
and O
methotrexate O
. O

Median O
follow-up O
was O
58 O
weeks O
. O
] O

24 O
% O
34 O
% O
3 O
% O
4 O
% O
< O
1 O
% O
< O
1 O
% O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
[ O
note O
: O
Placebo O
patients O
in O
the O
2 O
Phase O
3 O
trials O
in O
Crohn O
's O
disease O
received O
an O
initial O
dose O
of O
5 O
mg/kg O
REMICADE O
at O
study O
start O
and O
were O
on O
placebo O
in O
the O
maintenance O
phase O
. O

Patients O
who O
were O
randomized O
to O
the O
placebo O
maintenance O
group O
and O
then O
later O
crossed O
over O
to O
REMICADE O
are O
included O
in O
the O
REMICADE O
group O
in O
ALT O
analysis O
. O

Median O
follow-up O
was O
54 O
weeks O
. O
] O

34 O
% O
39 O
% O
4 O
% O
5 O
% O
0 O
% O
2 O
% O
Ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
[ O
note O
: O
Median O
follow-up O
was O
30 O
weeks O
. O

Specifically O
, O
the O
median O
duration O
of O
follow-up O
was O
30 O
weeks O
for O
placebo O
and O
31 O
weeks O
for O
REMICADE O
. O
] O

12 O
% O
17 O
% O
1 O
% O
2 O
% O
< O
1 O
% O
< O
1 O
% O
Ankylosing B-Not_AE_Candidate
spondylitis I-Not_AE_Candidate
[ O
note O
: O
Median O
follow-up O
was O
24 O
weeks O
for O
the O
placebo O
group O
and O
102 O
weeks O
for O
the O
REMICADE O
group O
. O
] O

15 O
% O
51 O
% O
0 O
% O
10 O
% O
0 O
% O
4 O
% O
Psoriatic B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
[ O
note O
: O
Median O
follow-up O
was O
39 O
weeks O
for O
the O
REMICADE O
group O
and O
18 O
weeks O
for O
the O
placebo O
group O
. O
] O

16 O
% O
50 O
% O
0 O
% O
7 O
% O
0 O
% O
2 O
% O
Plaque B-Not_AE_Candidate
psoriasis I-Not_AE_Candidate
[ O
note O
: O
ALT O
values O
are O
obtained O
in O
2 O
Phase O
3 O
psoriasis O
studies O
with O
median O
follow-up O
of O
50 O
weeks O
for O
REMICADE O
and O
16 O
weeks O
for O
placebo O
. O
] O

24 O
% O
49 O
% O
< O
1 O
% O
8 O
% O
0 O
% O
3 O
% O
Adverse O
Reactions O
in O
Psoriasis O
Studies O
During O
the O
placebo-controlled O
portion O
across O
the O
3 O
clinical O
trials O
up O
to O
Week O
16 O
, O
the O
proportion O
of O
patients O
who O
experienced O
at O
least O
1 O
serious O
adverse O
reaction O
( O
SAE O
; O
defined O
as O
resulting O
in O
death B-NonOSE_AE
, O
life O
threatening O
, O
requires O
hospitalization O
, O
or O
persistent O
or O
significant O
disability/incapacity O
) O
was O
0.5 O
% O
in O
the O
3 O
mg/kg O
REMICADE O
group O
, O
1.9 O
% O
in O
the O
placebo O
group O
, O
and O
1.6 O
% O
in O
the O
5 O
mg/kg O
REMICADE O
group O
. O

Among O
patients O
in O
the O
2 O
Phase O
3 O
studies O
, O
12.4 O
% O
of O
patients O
receiving O
REMICADE O
5 O
mg/kg O
every O
8 O
weeks O
through O
1 O
year O
of O
maintenance O
treatment O
experienced O
at O
least O
1 O
SAE O
in O
Study O
I O
. O

In O
Study O
II O
, O
4.1 O
% O
and O
4.7 O
% O
of O
patients O
receiving O
REMICADE O
3 O
mg/kg O
and O
5 O
mg/kg O
every O
8 O
weeks O
, O
respectively O
, O
through O
1 O
year O
of O
maintenance O
treatment O
experienced O
at O
least O
1 O
SAE O
. O

One O
death B-NonOSE_AE
due O
to O
bacterial B-NonOSE_AE
sepsis I-NonOSE_AE
occurred O
25 O
days O
after O
the O
second O
infusion O
of O
5 O
mg/kg O
REMICADE O
. O

Serious O
infections B-OSE_Labeled_AE
included O
sepsis B-OSE_Labeled_AE
, O
and O
abscesses B-OSE_Labeled_AE
. O

In O
Study O
I O
, O
2.7 O
% O
of O
patients O
receiving O
REMICADE O
5 O
mg/kg O
every O
8 O
weeks O
through O
1 O
year O
of O
maintenance O
treatment O
experienced O
at O
least O
1 O
serious O
infection B-OSE_Labeled_AE
. O

In O
Study O
II O
, O
1.0 O
% O
and O
1.3 O
% O
of O
patients O
receiving O
REMICADE O
3 O
mg/kg O
and O
5 O
mg/kg O
, O
respectively O
, O
through O
1 O
year O
of O
treatment O
experienced O
at O
least O
1 O
serious O
infection B-OSE_Labeled_AE
. O

The O
most O
common O
serious O
infection B-NonOSE_AE
( O
requiring O
hospitalization O
) O
was O
abscess B-OSE_Labeled_AE
( O
skin O
, O
throat O
, O
and O
peri-rectal O
) O
reported O
by O
5 O
( O
0.7 O
% O
) O
patients O
in O
the O
5 O
mg/kg O
REMICADE O
group O
. O

Two O
active O
cases O
of O
tuberculosis B-OSE_Labeled_AE
were O
reported O
: O
6 O
weeks O
and O
34 O
weeks O
after O
starting O
REMICADE O
. O

In O
the O
placebo-controlled O
portion O
of O
the O
psoriasis B-Not_AE_Candidate
studies O
, O
7 O
of O
1123 O
patients O
who O
received O
REMICADE O
at O
any O
dose O
were O
diagnosed O
with O
at O
least O
one O
NMSC B-OSE_Labeled_AE
compared O
to O
0 O
of O
334 O
patients O
who O
received O
placebo O
. O

In O
the O
psoriasis B-Not_AE_Candidate
studies O
, O
1 O
% O
( O
15/1373 O
) O
of O
patients O
experienced O
serum B-OSE_Labeled_AE
sickness I-OSE_Labeled_AE
or O
a O
combination O
of O
arthralgia B-OSE_Labeled_AE
and/or O
myalgia B-OSE_Labeled_AE
with O
fever B-OSE_Labeled_AE
, O
and/or O
rash B-OSE_Labeled_AE
, O
usually O
early O
in O
the O
treatment O
course O
. O

Of O
these O
patients O
, O
6 O
required O
hospitalization O
due O
to O
fever B-OSE_Labeled_AE
, O
severe O
myalgia B-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
, O
swollen B-OSE_Labeled_AE
joints I-OSE_Labeled_AE
, O
and O
immobility B-OSE_Labeled_AE
. O

Other O
Adverse O
Reactions O
Safety O
data O
are O
available O
from O
4779 O
REMICADE-treated O
adult O
patients O
, O
including O
1304 O
with O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
1106 O
with O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
484 O
with O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
, O
202 O
with O
ankylosing B-Not_AE_Candidate
spondylitis I-Not_AE_Candidate
, O
293 O
with O
psoriatic B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
1373 O
with O
plaque B-Not_AE_Candidate
psoriasis I-Not_AE_Candidate
and O
17 O
with O
other O
conditions O
. O

[ O
For O
information O
on O
other O
adverse O
reactions O
in O
pediatric O
patients O
, O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Adverse O
reactions O
reported O
in O
> O
=5 O
% O
of O
all O
patients O
with O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
receiving O
4 O
or O
more O
infusions O
are O
in O
Table O
2 O
. O

The O
types O
and O
frequencies O
of O
adverse O
reactions O
observed O
were O
similar O
in O
REMICADE-treated O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
ankylosing B-Not_AE_Candidate
spondylitis I-Not_AE_Candidate
, O
psoriatic B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
plaque B-Not_AE_Candidate
psoriasis I-Not_AE_Candidate
and O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
patients O
except O
for O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
which O
occurred O
in O
26 O
% O
of O
REMICADE-treated O
patients O
with O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

In O
the O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
studies O
, O
there O
were O
insufficient O
numbers O
and O
duration O
of O
follow-up O
for O
patients O
who O
never O
received O
REMICADE O
to O
provide O
meaningful O
comparisons O
. O

Table O
2 O
: O
Adverse O
reactions O
occurring O
in O
5 O
% O
or O
more O
of O
patients O
receiving O
4 O
or O
more O
infusions O
for O
rheumatoid O
arthritis O
Placebo O
REMICADE O
( O
n=350 O
) O
( O
n=1129 O
) O
Average O
weeks O
of O
follow-up O
59 O
66 O
Gastrointestinal B-NonOSE_AE
Nausea B-OSE_Labeled_AE
20 O
% O
21 O
% O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
8 O
% O
12 O
% O
Diarrhea B-NonOSE_AE
12 O
% O
12 O
% O
Dyspepsia B-OSE_Labeled_AE
7 O
% O
10 O
% O
Respiratory B-NonOSE_AE
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
25 O
% O
32 O
% O
Sinusitis B-OSE_Labeled_AE
8 O
% O
14 O
% O
Pharyngitis B-OSE_Labeled_AE
8 O
% O
12 O
% O
Coughing B-OSE_Labeled_AE
8 O
% O
12 O
% O
Bronchitis B-OSE_Labeled_AE
9 O
% O
10 O
% O
Skin B-NonOSE_AE
and I-NonOSE_AE
appendages I-NonOSE_AE
disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
5 O
% O
10 O
% O
Pruritus B-OSE_Labeled_AE
2 O
% O
7 O
% O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
whole I-NonOSE_AE
- I-NonOSE_AE
general I-NonOSE_AE
disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
7 O
% O
9 O
% O
Pain B-OSE_Labeled_AE
7 O
% O
8 O
% O
Resistance B-NonOSE_AE
mechanism I-NonOSE_AE
disorders I-NonOSE_AE
Fever B-OSE_Labeled_AE
4 O
% O
7 O
% O
Moniliasis B-OSE_Labeled_AE
3 O
% O
5 O
% O
Central B-NonOSE_AE
and I-NonOSE_AE
peripheral I-NonOSE_AE
nervous I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
14 O
% O
18 O
% O
Musculoskeletal B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
7 O
% O
8 O
% O
Urinary B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
6 O
% O
8 O
% O
Cardiovascular B-NonOSE_AE
disorders I-NonOSE_AE
, I-NonOSE_AE
general I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
5 O
% O
7 O
% O
The O
most O
common O
serious O
adverse O
reactions O
observed O
in O
clinical O
trials O
were O
infections B-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Other O
serious O
, O
medically O
relevant O
adverse O
reactions O
> O
=0.2 O
% O
or O
clinically O
significant O
adverse O
reactions O
by O
body O
system O
were O
as O
follows O
: O
* O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
whole I-NonOSE_AE
: O
allergic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
* O
Blood B-NonOSE_AE
: O
pancytopenia B-OSE_Labeled_AE
* O
Cardiovascular B-NonOSE_AE
: O
hypotension B-OSE_Labeled_AE
* O
Gastrointestinal B-NonOSE_AE
: O
constipation B-OSE_Labeled_AE
, O
intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
* O
Central B-NonOSE_AE
and I-NonOSE_AE
Peripheral I-NonOSE_AE
Nervous I-NonOSE_AE
: O
dizziness B-OSE_Labeled_AE
* O
Heart B-NonOSE_AE
Rate I-NonOSE_AE
and I-NonOSE_AE
Rhythm I-NonOSE_AE
: O
bradycardia B-OSE_Labeled_AE
* O
Liver B-NonOSE_AE
and I-NonOSE_AE
Biliary I-NonOSE_AE
: O
hepatitis B-OSE_Labeled_AE
* O
Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
: O
dehydration B-OSE_Labeled_AE
* O
Platelet B-NonOSE_AE
, I-NonOSE_AE
Bleeding I-NonOSE_AE
and I-NonOSE_AE
Clotting I-NonOSE_AE
: O
thrombocytopenia B-OSE_Labeled_AE
* O
Neoplasms B-NonOSE_AE
: O
lymphoma B-OSE_Labeled_AE
* O
Red B-NonOSE_AE
Blood I-NonOSE_AE
Cell I-NonOSE_AE
: O
anemia B-OSE_Labeled_AE
, O
hemolytic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
* O
Resistance B-NonOSE_AE
Mechanism I-NonOSE_AE
: O
cellulitis B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
serum B-OSE_Labeled_AE
sickness I-OSE_Labeled_AE
, O
sarcoidosis B-OSE_Labeled_AE
* O
Respiratory B-NonOSE_AE
: O
lower B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
including O
pneumonia B-OSE_Labeled_AE
) O
, O
pleurisy B-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
* O
Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
: O
increased B-OSE_Labeled_AE
sweating I-OSE_Labeled_AE
* O
Vascular B-NonOSE_AE
( I-NonOSE_AE
Extracardiac I-NonOSE_AE
) O
: O
thrombophlebitis B-OSE_Labeled_AE
* O
White B-NonOSE_AE
Cell I-NonOSE_AE
and I-NonOSE_AE
Reticuloendothelial I-NonOSE_AE
: O
leukopenia B-OSE_Labeled_AE
, O
lymphadenopathy B-OSE_Labeled_AE
Adverse O
Reactions O
in O
Pediatric O
Patients O
Pediatric O
Crohn O
's O
Disease O
There O
were O
some O
differences O
in O
the O
adverse O
reactions O
observed O
in O
the O
pediatric O
patients O
receiving O
REMICADE O
compared O
to O
those O
observed O
in O
adults O
with O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

These O
differences O
are O
discussed O
in O
the O
following O
paragraphs O
. O

The O
following O
adverse O
reactions O
were O
reported O
more O
commonly O
in O
103 O
randomized O
pediatric O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
patients O
administered O
5 O
mg/kg O
REMICADE O
through O
54 O
weeks O
than O
in O
385 O
adult O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
patients O
receiving O
a O
similar O
treatment O
regimen O
: O
anemia B-OSE_Labeled_AE
( O
11 O
% O
) O
, O
leukopenia B-OSE_Labeled_AE
( O
9 O
% O
) O
, O
flushing B-OSE_Labeled_AE
( O
9 O
% O
) O
, O
viral B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
8 O
% O
) O
, O
neutropenia B-OSE_Labeled_AE
( O
7 O
% O
) O
, O
bone B-OSE_Labeled_AE
fracture I-OSE_Labeled_AE
( O
7 O
% O
) O
, O
bacterial B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
6 O
% O
) O
, O
and O
respiratory B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
allergic I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
( O
6 O
% O
) O
. O

Infections B-OSE_Labeled_AE
were O
reported O
in O
56 O
% O
of O
randomized O
pediatric O
patients O
in O
Study O
Peds O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
and O
in O
50 O
% O
of O
adult O
patients O
in O
Study O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
I O
. O

In O
Study O
Peds O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
, O
infections B-OSE_Labeled_AE
were O
reported O
more O
frequently O
for O
patients O
who O
received O
every O
8-week O
as O
opposed O
to O
every O
12-week O
infusions O
( O
74 O
% O
and O
38 O
% O
, O
respectively O
) O
, O
while O
serious O
infections B-OSE_Labeled_AE
were O
reported O
for O
3 O
patients O
in O
the O
every O
8-week O
and O
4 O
patients O
in O
the O
every O
12-week O
maintenance O
treatment O
group O
. O

The O
most O
commonly O
reported O
infections B-NonOSE_AE
were O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
and O
pharyngitis B-OSE_Labeled_AE
, O
and O
the O
most O
commonly O
reported O
serious O
infection B-NonOSE_AE
was O
abscess B-OSE_Labeled_AE
. O

Pneumonia B-OSE_Labeled_AE
was O
reported O
for O
3 O
patients O
, O
( O
2 O
in O
the O
every O
8-week O
and O
1 O
in O
the O
every O
12-week O
maintenance O
treatment O
groups O
) O
. O

Herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
was O
reported O
for O
2 O
patients O
in O
the O
every O
8-week O
maintenance O
treatment O
group O
. O

In O
Study O
Peds O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
, O
18 O
% O
of O
randomized O
patients O
experienced O
1 O
or O
more O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
, O
with O
no O
notable O
difference O
between O
treatment O
groups O
. O

Of O
the O
112 O
patients O
in O
Study O
Peds O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
, O
there O
were O
no O
serious O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
, O
and O
2 O
patients O
had O
non-serious O
anaphylactoid B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

In O
Study O
Peds O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
, O
in O
which O
all O
patients O
received O
stable O
doses O
of O
6-MP O
, O
AZA O
, O
or O
MTX O
, O
excluding O
inconclusive O
samples O
, O
3 O
of O
24 O
patients O
had O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
infliximab I-OSE_Labeled_AE
. O

Although O
105 O
patients O
were O
tested O
for O
antibodies B-NonOSE_AE
to I-NonOSE_AE
infliximab I-NonOSE_AE
, O
81 O
patients O
were O
classified O
as O
inconclusive O
because O
they O
could O
not O
be O
ruled O
as O
negative O
due O
to O
assay O
interference O
by O
the O
presence O
of O
infliximab O
in O
the O
sample O
. O

Elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
up O
to O
3 O
times O
the O
upper O
limit O
of O
normal O
( O
ULN O
) O
were O
seen O
in O
18 O
% O
of O
pediatric O
patients O
in O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
clinical O
trials O
; O
4 O
% O
had O
ALT B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
> O
=3 O
* O
ULN O
, O
and O
1 O
% O
had O
elevations O
> O
=5 O
* O
ULN O
. O

( O
Median O
follow-up O
was O
53 O
weeks O
. O
) O

Pediatric O
Ulcerative O
Colitis O
Overall O
, O
the O
adverse O
reactions O
reported O
in O
the O
pediatric O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
trial O
and O
adult O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
( O
Study O
UC O
I O
and O
Study O
UC O
II O
) O
studies O
were O
generally O
consistent O
. O

In O
a O
pediatric O
UC O
trial O
, O
the O
most O
common O
adverse O
reactions O
were O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
pharyngitis B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
and O
headache B-OSE_Labeled_AE
. O

Infections B-OSE_Labeled_AE
were O
reported O
in O
31 O
( O
52 O
% O
) O
of O
60 O
treated O
patients O
in O
the O
pediatric O
UC B-Not_AE_Candidate
trial O
and O
22 O
( O
37 O
% O
) O
required O
oral O
or O
parenteral O
antimicrobial O
treatment O
. O

The O
proportion O
of O
patients O
with O
infections B-OSE_Labeled_AE
in O
the O
pediatric O
UC B-Not_AE_Candidate
trial O
was O
similar O
to O
that O
in O
the O
pediatric O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
study O
( O
Study O
Peds O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
) O
but O
higher O
than O
the O
proportion O
in O
the O
adults O
' O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
studies O
( O
Study O
UC B-Not_AE_Candidate
I O
and O
Study O
UC B-Not_AE_Candidate
II O
) O
. O

The O
overall O
incidence O
of O
infections B-OSE_Labeled_AE
in O
the O
pediatric O
UC B-Not_AE_Candidate
trial O
was O
13/22 O
( O
59 O
% O
) O
in O
the O
every O
8 O
week O
maintenance O
treatment O
group O
. O

Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
7/60 O
[ O
12 O
% O
] O
) O
and O
pharyngitis B-OSE_Labeled_AE
( O
5/60 O
[ O
8 O
% O
] O
) O
were O
the O
most O
frequently O
reported O
respiratory B-NonOSE_AE
system I-NonOSE_AE
infections I-NonOSE_AE
. O

Serious O
infections B-OSE_Labeled_AE
were O
reported O
in O
12 O
% O
( O
7/60 O
) O
of O
all O
treated O
patients O
. O

In O
the O
pediatric O
UC B-Not_AE_Candidate
trial O
, O
58 O
patients O
were O
evaluated O
for O
antibodies B-NonOSE_AE
to I-NonOSE_AE
infliximab I-NonOSE_AE
using O
the O
EIA O
as O
well O
as O
the O
drug-tolerant O
ECLIA O
. O

With O
the O
EIA O
, O
4 O
of O
58 O
( O
7 O
% O
) O
patients O
had O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
infliximab I-OSE_Labeled_AE
. O

With O
the O
ECLIA O
, O
30 O
of O
58 O
( O
52 O
% O
) O
patients O
had O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
infliximab I-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
, O
Immunogenicity B-NonOSE_AE
( O
6.1 O
) O
] O
. O

The O
higher O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
infliximab I-NonOSE_AE
by O
the O
ECLIA O
method O
was O
due O
to O
the O
60-fold O
higher O
sensitivity O
compared O
to O
the O
EIA O
method O
. O

While O
EIA-positive O
patients O
generally O
had O
undetectable O
trough O
infliximab O
concentrations O
, O
ECLIA-positive O
patients O
could O
have O
detectable O
trough O
concentrations O
of O
infliximab O
because O
the O
ECLIA O
assay O
is O
more O
sensitive O
and O
drug-tolerant O
. O

Elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
up O
to O
3 O
times O
the O
upper O
limit O
of O
normal O
( O
ULN O
) O
were O
seen O
in O
17 O
% O
( O
10/60 O
) O
of O
pediatric O
patients O
in O
the O
pediatric O
UC B-Not_AE_Candidate
trial O
; O
7 O
% O
( O
4/60 O
) O
had O
ALT B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
> O
=3 O
* O
ULN O
, O
and O
2 O
% O
( O
1/60 O
) O
had O
elevations O
> O
=5 O
* O
ULN O
( O
median O
follow-up O
was O
49 O
weeks O
) O
. O

Overall O
, O
8 O
of O
60 O
( O
13 O
% O
) O
treated O
patients O
experienced O
one O
or O
more O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
4 O
of O
22 O
( O
18 O
% O
) O
patients O
in O
the O
every O
8-week O
treatment O
maintenance O
group O
. O

No O
serious O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
were O
reported O
. O

In O
the O
pediatric O
UC B-Not_AE_Candidate
trial O
, O
45 O
patients O
were O
in O
the O
12 O
to O
17 O
year O
age O
group O
and O
15 O
in O
the O
6 O
to O
11 O
year O
age O
group O
. O

The O
numbers O
of O
patients O
in O
each O
subgroup O
are O
too O
small O
to O
make O
any O
definitive O
conclusions O
about O
the O
effect O
of O
age O
on O
safety O
events O
. O

There O
were O
higher O
proportions O
of O
patients O
with O
serious O
adverse O
events O
( O
40 O
% O
vs O
. O
18 O
% O
) O
and O
discontinuation O
due O
to O
adverse O
events O
( O
40 O
% O
vs O
. O
16 O
% O
) O
in O
the O
younger O
age O
group O
than O
in O
the O
older O
age O
group O
. O

While O
the O
proportion O
of O
patients O
with O
infections B-OSE_Labeled_AE
was O
also O
higher O
in O
the O
younger O
age O
group O
( O
60 O
% O
vs O
. O
49 O
% O
) O
, O
for O
serious O
infections B-OSE_Labeled_AE
, O
the O
proportions O
were O
similar O
in O
the O
two O
age O
groups O
( O
13 O
% O
in O
the O
6 O
to O
11 O
year O
age O
group O
vs O
. O
11 O
% O
in O
the O
12 O
to O
17 O
year O
age O
group O
) O
. O

Overall O
proportions O
of O
adverse O
reactions O
, O
including O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
were O
similar O
between O
the O
6 O
to O
11 O
and O
12 O
to O
17 O
year O
age O
groups O
( O
13 O
% O
) O
. O

6.2 O
Postmarketing O
Experience O
Adverse O
reactions O
have O
been O
identified O
during O
post O
approval O
use O
of O
REMICADE O
in O
adult O
and O
pediatric O
patients O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

The O
following O
adverse O
reactions O
, O
some O
with O
fatal B-NonOSE_AE
outcome O
, O
have O
been O
reported O
during O
post-approval O
use O
of O
REMICADE O
: O
neutropenia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
, O
agranulocytosis B-OSE_Labeled_AE
( O
including O
infants O
exposed O
in O
utero O
to O
infliximab O
) O
, O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
( O
including O
pulmonary B-OSE_Labeled_AE
fibrosis I-OSE_Labeled_AE
/ O
interstitial B-OSE_Labeled_AE
pneumonitis I-OSE_Labeled_AE
and O
rapidly O
progressive O
disease O
) O
, O
idiopathic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
, O
thrombotic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
, O
pericardial B-OSE_Labeled_AE
effusion I-OSE_Labeled_AE
, O
systemic B-OSE_Labeled_AE
and O
cutaneous O
vasculitis I-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
demyelinating I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
( O
such O
as O
Guillain B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Barre I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
chronic B-OSE_Labeled_AE
inflammatory I-OSE_Labeled_AE
demyelinating I-OSE_Labeled_AE
polyneuropathy I-OSE_Labeled_AE
, O
and O
multifocal B-OSE_Labeled_AE
motor I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
) O
, O
new O
onset O
and O
worsening B-OSE_Labeled_AE
psoriasis I-OSE_Labeled_AE
( O
all O
subtypes O
including O
pustular O
, O
primarily O
palmoplantar O
) O
, O
transverse B-OSE_Labeled_AE
myelitis I-OSE_Labeled_AE
, O
and O
neuropathies B-OSE_Labeled_AE
( O
additional O
neurologic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
have O
also O
been O
observed O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
, O
acute B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
jaundice B-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
, O
and O
cholestasis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
, O
serious O
infections B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
, O
malignancies B-OSE_Labeled_AE
, O
including O
melanoma B-OSE_Labeled_AE
, O
Merkel B-OSE_Labeled_AE
cell I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
, O
and O
cervical B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
and O
vaccine B-NonOSE_AE
breakthrough I-NonOSE_AE
infection I-NonOSE_AE
including O
bovine B-NonOSE_AE
tuberculosis I-NonOSE_AE
( O
disseminated B-NonOSE_AE
BCG I-NonOSE_AE
infection I-NonOSE_AE
) O
following O
vaccination O
in O
an O
infant B-OSE_Labeled_AE
exposed I-OSE_Labeled_AE
in I-OSE_Labeled_AE
utero I-OSE_Labeled_AE
to I-OSE_Labeled_AE
infliximab I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.15 O
) O
] O
. O

Infusion-related O
Reactions O
In O
post-marketing O
experience O
, O
cases O
of O
anaphylactic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
laryngeal B-OSE_Labeled_AE
/pharyngeal O
edema I-OSE_Labeled_AE
and O
severe O
bronchospasm B-OSE_Labeled_AE
, O
and O
seizure B-OSE_Labeled_AE
have O
been O
associated O
with O
REMICADE O
administration O
. O

Cases O
of O
transient B-OSE_Labeled_AE
visual I-OSE_Labeled_AE
loss I-OSE_Labeled_AE
have O
been O
reported O
in O
association O
with O
REMICADE O
during O
or O
within O
2 O
hours O
of O
infusion O
. O

Cerebrovascular B-OSE_Labeled_AE
accidents I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
ischemia/ O
infarction I-OSE_Labeled_AE
( O
some O
fatal B-NonOSE_AE
) O
, O
and O
arrhythmia B-OSE_Labeled_AE
occurring O
within O
24 O
hours O
of O
initiation O
of O
infusion O
have O
also O
been O
reported O
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
. O

Adverse O
Reactions O
in O
Pediatric O
Patients O
The O
following O
serious O
adverse O
reactions O
have O
been O
reported O
in O
the O
post-marketing O
experience O
in O
children O
: O
infections B-OSE_Labeled_AE
( O
some O
fatal B-NonOSE_AE
) O
including O
opportunistic B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
and O
tuberculosis B-OSE_Labeled_AE
, O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
and O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

Serious O
adverse O
reactions O
in O
the O
post-marketing O
experience O
with O
REMICADE O
in O
the O
pediatric O
population O
have O
also O
included O
malignancies B-OSE_Labeled_AE
, O
including O
hepatosplenic B-OSE_Labeled_AE
T I-OSE_Labeled_AE
- I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
lymphomas I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
, O
transient O
hepatic B-OSE_Labeled_AE
enzyme I-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
, O
lupus B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
syndromes I-OSE_Labeled_AE
, O
and O
the O
development O
of O
autoantibodies B-OSE_Labeled_AE
. O

BOXED O
WARNING O
: O
WARNING O
: O
SERIOUS O
INFECTIONS O
and O
MALIGNANCY O
WARNING O
: O
SERIOUS O
INFECTIONS O
and O
MALIGNANCY O
EXCERPT O
: O
WARNING O
: O
SERIOUS O
INFECTIONS O
and O
MALIGNANCY O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Increased O
risk O
of O
serious O
infections O
leading O
to O
hospitalization O
or O
death O
, O
including O
tuberculosis O
( O
TB O
) O
, O
bacterial O
sepsis O
, O
invasive O
fungal O
infections O
( O
such O
as O
histoplasmosis O
) O
and O
infections O
due O
to O
other O
opportunistic O
pathogens O
. O

* O
Discontinue O
REMICADE O
if O
a O
patient O
develops O
a O
serious O
infection O
. O

* O
Perform O
test O
for O
latent O
TB O
; O
if O
positive O
, O
start O
treatment O
for O
TB O
prior O
to O
starting O
REMICADE O
. O

Monitor O
all O
patients O
for O
active O
TB O
during O
treatment O
, O
even O
if O
initial O
latent O
TB O
test O
is O
negative O
. O

( O
5.1 O
) O
* O
Lymphoma O
and O
other O
malignancies O
, O
some O
fatal O
, O
have O
been O
reported O
in O
children O
and O
adolescent O
patients O
treated O
with O
tumor O
necrosis O
factor O
( O
TNF O
) O
blockers O
, O
including O
REMICADE O
. O

* O
Postmarketing O
cases O
of O
fatal O
hepatosplenic O
T-cell O
lymphoma O
( O
HSTCL O
) O
have O
been O
reported O
in O
patients O
treated O
with O
TNF O
blockers O
including O
REMICADE O
. O

Almost O
all O
had O
received O
azathioprine O
or O
6-mercaptopurine O
concomitantly O
with O
a O
TNF-blocker O
at O
or O
prior O
to O
diagnosis O
. O

The O
majority O
of O
REMICADE O
cases O
were O
reported O
in O
patients O
with O
Crohn O
's O
disease O
or O
ulcerative O
colitis O
, O
most O
of O
whom O
were O
adolescent O
or O
young O
adult O
males O
. O

( O
5.2 O
) O
SERIOUS O
INFECTIONS O
Patients O
treated O
with O
REMICADE O
( O
r O
) O
are O
at O
increased O
risk O
for O
developing O
serious O
infections B-OSE_Labeled_AE
that O
may O
lead O
to O
hospitalization O
or O
death B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Most O
patients O
who O
developed O
these O
infections B-NonOSE_AE
were O
taking O
concomitant O
immunosuppressants B-NonOSE_AE
such O
as O
methotrexate O
or O
corticosteroids O
. O

REMICADE O
should O
be O
discontinued O
if O
a O
patient O
develops O
a O
serious O
infection B-NonOSE_AE
or O
sepsis B-NonOSE_AE
. O

Reported O
infections B-OSE_Labeled_AE
include O
: O
* O
Active B-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
, O
including O
reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
latent I-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
. O

Patients O
with O
tuberculosis B-OSE_Labeled_AE
have O
frequently O
presented O
with O
disseminated O
or O
extrapulmonary I-OSE_Labeled_AE
disease O
. O

Patients O
should O
be O
tested O
for O
latent B-NonOSE_AE
tuberculosis I-NonOSE_AE
before O
REMICADE O
use O
and O
during O
therapy.1,2 O
Treatment O
for O
latent B-Not_AE_Candidate
infection I-Not_AE_Candidate
should O
be O
initiated O
prior O
to O
REMICADE O
use O
. O

* O
Invasive B-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
including O
histoplasmosis B-OSE_Labeled_AE
, O
coccidioidomycosis B-OSE_Labeled_AE
, O
candidiasis B-OSE_Labeled_AE
, O
aspergillosis B-OSE_Labeled_AE
, O
blastomycosis B-OSE_Labeled_AE
, O
and O
pneumocystosis B-OSE_Labeled_AE
. O

Patients O
with O
histoplasmosis B-OSE_Labeled_AE
or O
other O
invasive O
fungal B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
may O
present O
with O
disseminated O
, O
rather O
than O
localized O
, O
disease O
. O

Antigen B-NonOSE_AE
and O
antibody O
testing I-NonOSE_AE
for I-NonOSE_AE
histoplasmosis I-NonOSE_AE
may I-NonOSE_AE
be I-NonOSE_AE
negative I-NonOSE_AE
in O
some O
patients O
with O
active O
infection B-NonOSE_AE
. O

Empiric O
anti-fungal O
therapy O
should O
be O
considered O
in O
patients O
at O
risk O
for O
invasive B-NonOSE_AE
fungal I-NonOSE_AE
infections I-NonOSE_AE
who O
develop O
severe O
systemic O
illness B-NonOSE_AE
. O

* O
Bacterial B-OSE_Labeled_AE
, O
viral O
and O
other O
infections I-OSE_Labeled_AE
due I-OSE_Labeled_AE
to I-OSE_Labeled_AE
opportunistic I-OSE_Labeled_AE
pathogens I-OSE_Labeled_AE
, O
including O
Legionella B-OSE_Labeled_AE
and O
Listeria B-OSE_Labeled_AE
. O

The O
risks O
and O
benefits O
of O
treatment O
with O
REMICADE O
should O
be O
carefully O
considered O
prior O
to O
initiating O
therapy O
in O
patients O
with O
chronic O
or O
recurrent O
infection B-Not_AE_Candidate
. O

Patients O
should O
be O
closely O
monitored O
for O
the O
development O
of O
signs O
and O
symptoms O
of O
infection B-NonOSE_AE
during O
and O
after O
treatment O
with O
REMICADE O
, O
including O
the O
possible O
development O
of O
tuberculosis B-NonOSE_AE
in O
patients O
who O
tested B-Not_AE_Candidate
negative I-Not_AE_Candidate
for I-Not_AE_Candidate
latent I-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
infection I-Not_AE_Candidate
prior O
to O
initiating O
therapy O
. O

MALIGNANCY O
Lymphoma B-OSE_Labeled_AE
and O
other O
malignancies B-OSE_Labeled_AE
, O
some O
fatal B-NonOSE_AE
, O
have O
been O
reported O
in O
children O
and O
adolescent O
patients O
treated O
with O
TNF O
blockers O
, O
including O
REMICADE O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Postmarketing O
cases O
of O
hepatosplenic B-OSE_Labeled_AE
T I-OSE_Labeled_AE
- I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
lymphoma I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HSTCL I-OSE_Labeled_AE
) O
, O
a O
rare O
type O
of O
T B-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
lymphoma I-NonOSE_AE
, O
have O
been O
reported O
in O
patients O
treated O
with O
TNF O
blockers O
including O
REMICADE O
. O

These O
cases O
have O
had O
a O
very O
aggressive O
disease O
course O
and O
have O
been O
fatal B-NonOSE_AE
. O

Almost O
all O
patients O
had O
received O
treatment O
with O
azathioprine O
or O
6-mercaptopurine O
concomitantly O
with O
a O
TNF-blocker O
at O
or O
prior O
to O
diagnosis O
. O

The O
majority O
of O
reported O
REMICADE O
cases O
have O
occurred O
in O
patients O
with O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
and O
most O
were O
in O
adolescent O
and O
young O
adult O
males O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Serious O
infections O
- O
do O
not O
give O
REMICADE O
during O
an O
active O
infection O
. O

If O
an O
infection O
develops O
, O
monitor O
carefully O
and O
stop O
REMICADE O
if O
infection O
becomes O
serious O
. O

( O
5.1 O
) O
* O
Invasive O
fungal O
infections O
- O
for O
patients O
who O
develop O
a O
systemic O
illness O
on O
REMICADE O
, O
consider O
empiric O
antifungal O
therapy O
for O
those O
who O
reside O
or O
travel O
to O
regions O
where O
mycoses O
are O
endemic O
( O
5.1 O
) O
* O
Malignancies O
- O
the O
incidence O
of O
malignancies O
, O
including O
invasive O
cervical O
cancer O
and O
lymphoma O
, O
was O
greater O
in O
REMICADE O
treated O
patients O
than O
in O
controls O
. O

Due O
to O
the O
risk O
of O
HSTCL O
carefully O
assess O
the O
risk/benefit O
especially O
if O
the O
patient O
has O
Crohn O
's O
disease O
or O
ulcerative O
colitis O
, O
is O
male O
, O
and O
is O
receiving O
azathioprine O
or O
6-mercaptopurine O
treatment O
. O

( O
5.2 O
) O
* O
Hepatitis O
B O
virus O
reactivation O
- O
test O
for O
HBV O
infection O
before O
starting O
REMICADE O
. O

Monitor O
HBV O
carriers O
during O
and O
several O
months O
after O
therapy O
. O

If O
reactivation O
occurs O
, O
stop O
REMICADE O
and O
begin O
anti-viral O
therapy O
. O

( O
5.3 O
) O
* O
Hepatotoxicity O
- O
severe O
hepatic O
reactions O
, O
some O
fatal O
or O
necessitating O
liver O
transplantation O
. O

Stop O
REMICADE O
in O
cases O
of O
jaundice O
and/or O
marked O
liver O
enzyme O
elevations O
. O

( O
5.4 O
) O
* O
Heart O
failure O
- O
new O
onset O
or O
worsening O
symptoms O
may O
occur O
. O

( O
4 O
, O
5.5 O
) O
* O
Cytopenias O
- O
advise O
patients O
to O
seek O
immediate O
medical O
attention O
if O
signs O
and O
symptoms O
develop O
, O
and O
consider O
stopping O
REMICADE O
. O

( O
5.6 O
) O
* O
Hypersensitivity O
- O
serious O
infusion O
reactions O
including O
anaphylaxis O
or O
serum O
sickness-like O
reactions O
may O
occur O
. O

( O
5.7 O
) O
* O
Cardiovascular O
and O
Cerebrovascular O
Reactions O
- O
Cerebrovascular O
accidents O
, O
myocardial O
infarctions O
( O
some O
fatal O
) O
, O
and O
arrhythmias O
have O
been O
reported O
during O
and O
within O
24 O
hours O
of O
initiation O
of O
REMICADE O
infusion O
. O

Monitor O
patients O
during O
REMICADE O
infusion O
and O
if O
serious O
reaction O
occurs O
, O
discontinue O
infusion O
. O

( O
5.8 O
) O
* O
Demyelinating O
disease O
- O
exacerbation O
or O
new O
onset O
may O
occur O
. O

( O
5.9 O
) O
* O
Lupus-like O
syndrome O
- O
stop O
REMICADE O
if O
syndrome O
develops O
. O

( O
5.14 O
) O
* O
Live O
vaccines O
or O
therapeutic O
infectious O
agents O
- O
should O
not O
be O
given O
with O
REMICADE O
. O

Bring O
pediatric O
patients O
up O
to O
date O
with O
all O
vaccinations O
prior O
to O
initiating O
REMICADE O
. O

At O
least O
a O
six O
month O
waiting O
period O
following O
birth O
is O
recommended O
before O
the O
administration O
of O
live O
vaccines O
to O
infants O
exposed O
in O
utero O
to O
infliximab O
( O
5.15 O
) O
5.1 O
Serious O
Infections O
Patients O
treated O
with O
REMICADE O
are O
at O
increased O
risk O
for O
developing O
serious O
infections B-OSE_Labeled_AE
involving O
various O
organ O
systems O
and O
sites O
that O
may O
lead O
to O
hospitalization O
or O
death B-NonOSE_AE
. O

Opportunistic B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
due O
to O
bacterial O
, O
mycobacterial O
, O
invasive O
fungal O
, O
viral O
, O
or O
parasitic O
organisms O
including O
aspergillosis B-OSE_Labeled_AE
, O
blastomycosis B-OSE_Labeled_AE
, O
candidiasis B-OSE_Labeled_AE
, O
coccidioidomycosis B-OSE_Labeled_AE
, O
histoplasmosis B-OSE_Labeled_AE
, O
legionellosis B-OSE_Labeled_AE
, O
listeriosis B-OSE_Labeled_AE
, O
pneumocystosis B-OSE_Labeled_AE
and O
tuberculosis B-OSE_Labeled_AE
have O
been O
reported O
with O
TNF-blockers O
. O

Patients O
have O
frequently O
presented O
with O
disseminated O
rather O
than O
localized O
disease O
. O

Treatment O
with O
REMICADE O
should O
not O
be O
initiated O
in O
patients O
with O
an O
active O
infection B-Not_AE_Candidate
, O
including O
clinically O
important O
localized B-Not_AE_Candidate
infections I-Not_AE_Candidate
. O

Patients O
greater O
than O
65 O
years O
of O
age O
, O
patients O
with O
co-morbid O
conditions O
and/or O
patients O
taking O
concomitant O
immunosuppressants O
such O
as O
corticosteroids O
or O
methotrexate O
may O
be O
at O
greater O
risk O
of O
infection B-NonOSE_AE
. O

The O
risks O
and O
benefits O
of O
treatment O
should O
be O
considered O
prior O
to O
initiating O
therapy O
in O
patients O
: O
* O
with O
chronic O
or O
recurrent O
infection B-Not_AE_Candidate
; O
* O
who O
have O
been O
exposed B-Not_AE_Candidate
to I-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
; O
* O
with O
a O
history O
of O
an O
opportunistic B-Not_AE_Candidate
infection I-Not_AE_Candidate
; O
* O
who O
have O
resided O
or O
traveled O
in O
areas O
of O
endemic O
tuberculosis B-NonOSE_AE
or O
endemic B-NonOSE_AE
mycoses I-NonOSE_AE
, O
such O
as O
histoplasmosis B-NonOSE_AE
, O
coccidioidomycosis B-NonOSE_AE
, O
or O
blastomycosis B-NonOSE_AE
; O
or O
* O
with O
underlying O
conditions O
that O
may O
predispose B-Not_AE_Candidate
them I-Not_AE_Candidate
to I-Not_AE_Candidate
infection I-Not_AE_Candidate
. O

Tuberculosis O
Cases O
of O
reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
or O
new O
tuberculosis B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
have O
been O
observed O
in O
patients O
receiving O
REMICADE O
, O
including O
patients O
who O
have O
previously O
received O
treatment O
for O
latent B-Not_AE_Candidate
or O
active O
tuberculosis I-Not_AE_Candidate
. O

Cases O
of O
active B-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
have O
also O
occurred O
in O
patients O
being O
treated O
with O
REMICADE O
during O
treatment O
for O
latent B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
. O

Patients O
should O
be O
evaluated O
for O
tuberculosis B-NonOSE_AE
risk O
factors O
and O
tested O
for O
latent B-Not_AE_Candidate
infection I-Not_AE_Candidate
prior O
to O
initiating O
REMICADE O
and O
periodically O
during O
therapy O
. O

Treatment O
of O
latent B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
infection I-Not_AE_Candidate
prior O
to O
therapy O
with O
TNF O
blocking O
agents O
has O
been O
shown O
to O
reduce O
the O
risk O
of O
tuberculosis B-NonOSE_AE
reactivation I-NonOSE_AE
during O
therapy O
. O

Induration O
of O
5 O
mm O
or O
greater O
with O
tuberculin B-NonOSE_AE
skin I-NonOSE_AE
testing I-NonOSE_AE
should O
be O
considered O
a O
positive I-NonOSE_AE
test O
result O
when O
assessing O
if O
treatment O
for O
latent B-NonOSE_AE
tuberculosis I-NonOSE_AE
is O
needed O
prior O
to O
initiating O
REMICADE O
, O
even O
for O
patients O
previously O
vaccinated O
with O
Bacille B-NonOSE_AE
Calmette I-NonOSE_AE
- I-NonOSE_AE
Guerin I-NonOSE_AE
( I-NonOSE_AE
BCG I-NonOSE_AE
) O
. O

Anti B-NonOSE_AE
- I-NonOSE_AE
tuberculosis I-NonOSE_AE
therapy O
should O
also O
be O
considered O
prior O
to O
initiation O
of O
REMICADE O
in O
patients O
with O
a O
past O
history O
of O
latent B-Not_AE_Candidate
or O
active O
tuberculosis I-Not_AE_Candidate
in O
whom O
an O
adequate O
course O
of O
treatment O
can O
not O
be O
confirmed O
, O
and O
for O
patients O
with O
a O
negative B-Not_AE_Candidate
test I-Not_AE_Candidate
for I-Not_AE_Candidate
latent I-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
but O
having O
risk O
factors O
for O
tuberculosis B-NonOSE_AE
infection I-NonOSE_AE
. O

Consultation O
with O
a O
physician O
with O
expertise O
in O
the O
treatment O
of O
tuberculosis B-NonOSE_AE
is O
recommended O
to O
aid O
in O
the O
decision O
whether O
initiating O
anti B-NonOSE_AE
- I-NonOSE_AE
tuberculosis I-NonOSE_AE
therapy O
is O
appropriate O
for O
an O
individual O
patient O
. O

Tuberculosis B-NonOSE_AE
should O
be O
strongly O
considered O
in O
patients O
who O
develop O
a O
new O
infection B-NonOSE_AE
during O
REMICADE O
treatment O
, O
especially O
in O
patients O
who O
have O
previously O
or O
recently O
traveled O
to O
countries O
with O
a O
high O
prevalence O
of O
tuberculosis B-NonOSE_AE
, O
or O
who O
have O
had O
close O
contact O
with O
a O
person O
with O
active B-NonOSE_AE
tuberculosis I-NonOSE_AE
. O

Monitoring O
Patients O
should O
be O
closely O
monitored O
for O
the O
development O
of O
signs O
and O
symptoms O
of O
infection B-NonOSE_AE
during O
and O
after O
treatment O
with O
REMICADE O
, O
including O
the O
development O
of O
tuberculosis B-NonOSE_AE
in O
patients O
who O
tested B-Not_AE_Candidate
negative I-Not_AE_Candidate
for I-Not_AE_Candidate
latent I-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
infection I-Not_AE_Candidate
prior O
to O
initiating O
therapy O
. O

Tests B-NonOSE_AE
for I-NonOSE_AE
latent I-NonOSE_AE
tuberculosis I-NonOSE_AE
infection I-NonOSE_AE
may O
also O
be O
falsely I-NonOSE_AE
negative I-NonOSE_AE
while O
on O
therapy O
with O
REMICADE O
. O

REMICADE O
should O
be O
discontinued O
if O
a O
patient O
develops O
a O
serious O
infection B-NonOSE_AE
or O
sepsis B-NonOSE_AE
. O

A O
patient O
who O
develops O
a O
new O
infection B-NonOSE_AE
during O
treatment O
with O
REMICADE O
should O
be O
closely O
monitored O
, O
undergo O
a O
prompt O
and O
complete O
diagnostic O
workup O
appropriate O
for O
an O
immunocompromised B-Not_AE_Candidate
patient O
, O
and O
appropriate O
antimicrobial O
therapy O
should O
be O
initiated O
. O

Invasive O
Fungal O
Infections O
For O
patients O
who O
reside O
or O
travel O
in O
regions O
where O
mycoses B-NonOSE_AE
are O
endemic O
, O
invasive B-NonOSE_AE
fungal I-NonOSE_AE
infection I-NonOSE_AE
should O
be O
suspected O
if O
they O
develop O
a O
serious O
systemic O
illness B-NonOSE_AE
. O

Appropriate O
empiric O
antifungal O
therapy O
should O
be O
considered O
while O
a O
diagnostic O
workup O
is O
being O
performed O
. O

Antigen B-NonOSE_AE
and I-NonOSE_AE
antibody I-NonOSE_AE
testing I-NonOSE_AE
for I-NonOSE_AE
histoplasmosis I-NonOSE_AE
may I-NonOSE_AE
be I-NonOSE_AE
negative I-NonOSE_AE
in O
some O
patients O
with O
active O
infection B-NonOSE_AE
. O

When O
feasible O
, O
the O
decision O
to O
administer O
empiric O
antifungal O
therapy O
in O
these O
patients O
should O
be O
made O
in O
consultation O
with O
a O
physician O
with O
expertise O
in O
the O
diagnosis O
and O
treatment O
of O
invasive O
fungal B-NonOSE_AE
infections I-NonOSE_AE
and O
should O
take O
into O
account O
both O
the O
risk O
for O
severe O
fungal B-NonOSE_AE
infection I-NonOSE_AE
and O
the O
risks O
of O
antifungal O
therapy O
. O

5.2 O
Malignancies O
Malignancies B-OSE_Labeled_AE
, O
some O
fatal B-NonOSE_AE
, O
have O
been O
reported O
among O
children O
, O
adolescents O
and O
young O
adults O
who O
received O
treatment O
with O
TNF-blocking O
agents O
( O
initiation O
of O
therapy O
< O
=18 O
years O
of O
age O
) O
, O
including O
REMICADE O
. O

Approximately O
half O
of O
these O
cases O
were O
lymphomas B-OSE_Labeled_AE
, O
including O
Hodgkin B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
and O
non-Hodgkin O
's O
lymphoma I-OSE_Labeled_AE
. O

The O
other O
cases O
represented O
a O
variety O
of O
malignancies B-OSE_Labeled_AE
, O
including O
rare O
malignancies B-OSE_Labeled_AE
that O
are O
usually O
associated O
with O
immunosuppression B-NonOSE_AE
and O
malignancies B-OSE_Labeled_AE
that O
are O
not O
usually O
observed O
in O
children O
and O
adolescents O
. O

The O
malignancies B-OSE_Labeled_AE
occurred O
after O
a O
median O
of O
30 O
months O
( O
range O
1 O
to O
84 O
months O
) O
after O
the O
first O
dose O
of O
TNF O
blocker O
therapy O
. O

Most O
of O
the O
patients O
were O
receiving O
concomitant O
immunosuppressants O
. O

These O
cases O
were O
reported O
post-marketing O
and O
are O
derived O
from O
a O
variety O
of O
sources O
, O
including O
registries O
and O
spontaneous O
postmarketing O
reports O
. O

Lymphomas O
In O
the O
controlled O
portions O
of O
clinical O
trials O
of O
all O
the O
TNF-blocking O
agents O
, O
more O
cases O
of O
lymphoma B-OSE_Labeled_AE
have O
been O
observed O
among O
patients O
receiving O
a O
TNF O
blocker O
compared O
with O
control O
patients O
. O

In O
the O
controlled O
and O
open-label O
portions O
of O
REMICADE O
clinical O
trials O
, O
5 O
patients O
developed O
lymphomas B-OSE_Labeled_AE
among O
5707 O
patients O
treated O
with O
REMICADE O
( O
median O
duration O
of O
follow-up O
1.0 O
years O
) O
vs O
. O
0 O
lymphomas B-NonOSE_AE
in O
1600 O
control O
patients O
( O
median O
duration O
of O
follow-up O
0.4 O
years O
) O
. O

In O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
patients O
, O
2 O
lymphomas B-OSE_Labeled_AE
were O
observed O
for O
a O
rate O
of O
0.08 O
cases O
per O
100 O
patient-years O
of O
follow-up O
, O
which O
is O
approximately O
three-fold O
higher O
than O
expected O
in O
the O
general O
population O
. O

In O
the O
combined O
clinical O
trial O
population O
for O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
psoriatic B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
ankylosing B-Not_AE_Candidate
spondylitis I-Not_AE_Candidate
, O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
, O
and O
plaque B-Not_AE_Candidate
psoriasis I-Not_AE_Candidate
, O
5 O
lymphomas B-OSE_Labeled_AE
were O
observed O
for O
a O
rate O
of O
0.10 O
cases O
per O
100 O
patient-years O
of O
follow-up O
, O
which O
is O
approximately O
four-fold O
higher O
than O
expected O
in O
the O
general O
population O
. O

Patients O
with O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
or O
plaque B-Not_AE_Candidate
psoriasis I-Not_AE_Candidate
, O
particularly O
patients O
with O
highly O
active O
disease O
and/or O
chronic O
exposure O
to O
immunosuppressant B-NonOSE_AE
therapies I-NonOSE_AE
, O
may O
be O
at O
a O
higher O
risk O
( O
up O
to O
several O
fold O
) O
than O
the O
general O
population O
for O
the O
development O
of O
lymphoma B-NonOSE_AE
, O
even O
in O
the O
absence O
of O
TNF-blocking O
therapy O
. O

Cases O
of O
acute B-OSE_Labeled_AE
and O
chronic O
leukemia I-OSE_Labeled_AE
have O
been O
reported O
with O
postmarketing O
TNF-blocker O
use O
in O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
and O
other O
indications O
. O

Even O
in O
the O
absence O
of O
TNF O
blocker O
therapy O
, O
patients O
with O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
may O
be O
at O
a O
higher O
risk O
( O
approximately O
2-fold O
) O
than O
the O
general O
population O
for O
the O
development O
of O
leukemia B-NonOSE_AE
. O

Hepatosplenic O
T-cell O
Lymphoma O
( O
HSTCL O
) O
Postmarketing O
cases O
of O
hepatosplenic B-OSE_Labeled_AE
T I-OSE_Labeled_AE
- I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
lymphoma I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HSTCL I-OSE_Labeled_AE
) O
, O
a O
rare O
type O
of O
T B-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
lymphoma I-NonOSE_AE
, O
have O
been O
reported O
in O
patients O
treated O
with O
TNF O
blockers O
including O
REMICADE O
. O

These O
cases O
have O
had O
a O
very O
aggressive O
disease O
course O
and O
have O
been O
fatal B-NonOSE_AE
. O

Almost O
all O
patients O
had O
received O
treatment O
with O
the O
immunosuppressants O
azathioprine O
or O
6-mercaptopurine O
concomitantly O
with O
a O
TNF-blocker O
at O
or O
prior O
to O
diagnosis O
. O

The O
majority O
of O
reported O
REMICADE O
cases O
have O
occurred O
in O
patients O
with O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
and O
most O
were O
in O
adolescent O
and O
young O
adult O
males O
. O

It O
is O
uncertain O
whether O
the O
occurrence O
of O
HSTCL B-NonOSE_AE
is O
related O
to O
TNF-blockers O
or O
TNF-blockers O
in O
combination O
with O
these O
other O
immunosuppressants O
. O

When O
treating O
patients O
, O
consideration O
of O
whether O
to O
use O
REMICADE O
alone O
or O
in O
combination O
with O
other O
immunosuppressants O
such O
as O
azathioprine O
or O
6-mercaptopurine O
should O
take O
into O
account O
a O
possibility O
that O
there O
is O
a O
higher O
risk O
of O
HSTCL B-NonOSE_AE
with O
combination O
therapy O
versus O
an O
observed O
increased O
risk O
of O
immunogenicity B-NonOSE_AE
and O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
with O
REMICADE O
monotherapy O
from O
the O
clinical O
trial O
data O
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Skin B-OSE_Labeled_AE
Cancer I-OSE_Labeled_AE
Melanoma B-OSE_Labeled_AE
and O
Merkel B-OSE_Labeled_AE
cell I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
treated O
with O
TNF O
blocker O
therapy O
, O
including O
REMICADE O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

Periodic O
skin O
examination O
is O
recommended O
for O
all O
patients O
, O
particularly O
those O
with O
risk O
factors O
for O
skin B-NonOSE_AE
cancer I-NonOSE_AE
. O

Cervical O
Cancer O
A O
population-based O
retrospective O
cohort O
study O
using O
data O
from O
Swedish O
national O
health O
registries O
found O
a O
2 O
to O
3 O
fold O
increase O
in O
the O
incidence O
of O
invasive O
cervical B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
in O
women O
with O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
treated O
with O
infliximab O
compared O
to O
biologics-naive O
patients O
or O
the O
general O
population O
, O
particularly O
those O
over O
60 O
years O
of O
age O
. O

A O
causal O
relationship O
between O
infliximab O
and O
cervical B-NonOSE_AE
cancer I-NonOSE_AE
can O
not O
be O
excluded O
. O

Periodic O
screening O
should O
continue O
in O
women O
treated O
with O
REMICADE O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

Other O
Malignancies O
In O
the O
controlled O
portions O
of O
clinical O
trials O
of O
some O
TNF-blocking O
agents O
including O
REMICADE O
, O
more O
malignancies B-OSE_Labeled_AE
( O
excluding O
lymphoma B-NonOSE_AE
and O
nonmelanoma B-NonOSE_AE
skin I-NonOSE_AE
cancer I-NonOSE_AE
[ I-NonOSE_AE
NMSC I-NonOSE_AE
] O
) O
have O
been O
observed O
in O
patients O
receiving O
those O
TNF-blockers O
compared O
with O
control O
patients O
. O

During O
the O
controlled O
portions O
of O
REMICADE O
trials O
in O
patients O
with O
moderately O
to O
severely O
active O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
psoriatic B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
ankylosing B-Not_AE_Candidate
spondylitis I-Not_AE_Candidate
, O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
, O
and O
plaque B-Not_AE_Candidate
psoriasis I-Not_AE_Candidate
, O
14 O
patients O
were O
diagnosed O
with O
malignancies B-OSE_Labeled_AE
( O
excluding O
lymphoma B-NonOSE_AE
and O
NMSC B-NonOSE_AE
) O
among O
4019 O
REMICADE-treated O
patients O
vs O
. O
1 O
among O
1597 O
control O
patients O
( O
at O
a O
rate O
of O
0.52/100 O
patient-years O
among O
REMICADE-treated O
patients O
vs O
. O
a O
rate O
of O
0.11/100 O
patient-years O
among O
control O
patients O
) O
, O
with O
median O
duration O
of O
follow-up O
0.5 O
years O
for O
REMICADE-treated O
patients O
and O
0.4 O
years O
for O
control O
patients O
. O

Of O
these O
, O
the O
most O
common O
malignancies B-OSE_Labeled_AE
were O
breast I-OSE_Labeled_AE
, O
colorectal O
, O
and O
melanoma B-OSE_Labeled_AE
. O

The O
rate O
of O
malignancies B-NonOSE_AE
among O
REMICADE-treated O
patients O
was O
similar O
to O
that O
expected O
in O
the O
general O
population O
whereas O
the O
rate O
in O
control O
patients O
was O
lower O
than O
expected O
. O

In O
a O
clinical O
trial O
exploring O
the O
use O
of O
REMICADE O
in O
patients O
with O
moderate O
to O
severe O
chronic B-Not_AE_Candidate
obstructive I-Not_AE_Candidate
pulmonary I-Not_AE_Candidate
disease I-Not_AE_Candidate
( I-Not_AE_Candidate
COPD I-Not_AE_Candidate
) O
, O
more O
malignancies B-OSE_Labeled_AE
, O
the O
majority O
of O
lung O
or O
head O
and O
neck O
origin O
, O
were O
reported O
in O
REMICADE-treated O
patients O
compared O
with O
control O
patients O
. O

All O
patients O
had O
a O
history O
of O
heavy O
smoking O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Prescribers O
should O
exercise O
caution O
when O
considering O
the O
use O
of O
REMICADE O
in O
patients O
with O
moderate O
to O
severe O
COPD B-Not_AE_Candidate
. O

Psoriasis B-Not_AE_Candidate
patients O
should O
be O
monitored O
for O
nonmelanoma B-NonOSE_AE
skin I-NonOSE_AE
cancers I-NonOSE_AE
( I-NonOSE_AE
NMSCs I-NonOSE_AE
) O
, O
particularly O
those O
patients O
who O
have O
had O
prior O
prolonged O
phototherapy O
treatment O
. O

In O
the O
maintenance O
portion O
of O
clinical O
trials O
for O
REMICADE O
, O
NMSCs B-OSE_Labeled_AE
were O
more O
common O
in O
patients O
with O
previous O
phototherapy O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

The O
potential O
role O
of O
TNF-blocking O
therapy O
in O
the O
development O
of O
malignancies B-NonOSE_AE
is O
not O
known O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Rates O
in O
clinical O
trials O
for O
REMICADE O
can O
not O
be O
compared O
to O
rates O
in O
clinical O
trials O
of O
other O
TNF-blockers O
and O
may O
not O
predict O
rates O
observed O
in O
a O
broader O
patient O
population O
. O

Caution O
should O
be O
exercised O
in O
considering O
REMICADE O
treatment O
in O
patients O
with O
a O
history O
of O
malignancy B-Not_AE_Candidate
or O
in O
continuing O
treatment O
in O
patients O
who O
develop O
malignancy B-NonOSE_AE
while O
receiving O
REMICADE O
. O

5.3 O
Hepatitis O
B O
Virus O
Reactivation O
Use O
of O
TNF O
blockers O
, O
including O
REMICADE O
, O
has O
been O
associated O
with O
reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
B I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HBV I-OSE_Labeled_AE
) O
in O
patients O
who O
are O
chronic O
carriers O
of O
this O
virus O
. O

In O
some O
instances O
, O
HBV B-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
occurring O
in O
conjunction O
with O
TNF O
blocker O
therapy O
has O
been O
fatal B-NonOSE_AE
. O

The O
majority O
of O
these O
reports O
have O
occurred O
in O
patients O
concomitantly O
receiving O
other O
medications B-NonOSE_AE
that I-NonOSE_AE
suppress I-NonOSE_AE
the I-NonOSE_AE
immune I-NonOSE_AE
system I-NonOSE_AE
, O
which O
may O
also O
contribute O
to O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
. O

Patients O
should O
be O
tested O
for O
HBV B-Not_AE_Candidate
infection I-Not_AE_Candidate
before O
initiating O
TNF O
blocker O
therapy O
, O
including O
REMICADE O
. O

For O
patients O
who O
test B-Not_AE_Candidate
positive I-Not_AE_Candidate
for I-Not_AE_Candidate
hepatitis I-Not_AE_Candidate
B I-Not_AE_Candidate
surface I-Not_AE_Candidate
antigen I-Not_AE_Candidate
, O
consultation O
with O
a O
physician O
with O
expertise O
in O
the O
treatment O
of O
hepatitis B-NonOSE_AE
B I-NonOSE_AE
is O
recommended O
. O

Adequate O
data O
are O
not O
available O
on O
the O
safety O
or O
efficacy O
of O
treating O
patients O
who O
are O
carriers B-Not_AE_Candidate
of I-Not_AE_Candidate
HBV I-Not_AE_Candidate
with O
anti-viral O
therapy O
in O
conjunction O
with O
TNF O
blocker O
therapy O
to O
prevent O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
. O

Patients O
who O
are O
carriers B-Not_AE_Candidate
of I-Not_AE_Candidate
HBV I-Not_AE_Candidate
and O
require O
treatment O
with O
TNF O
blockers O
should O
be O
closely O
monitored O
for O
clinical O
and O
laboratory O
signs O
of O
active O
HBV B-NonOSE_AE
infection I-NonOSE_AE
throughout O
therapy O
and O
for O
several O
months O
following O
termination O
of O
therapy O
. O

In O
patients O
who O
develop O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
, O
TNF O
blockers O
should O
be O
stopped O
and O
antiviral O
therapy O
with O
appropriate O
supportive O
treatment O
should O
be O
initiated O
. O

The O
safety O
of O
resuming O
TNF O
blocker O
therapy O
after O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
is O
controlled O
is O
not O
known O
. O

Therefore O
, O
prescribers O
should O
exercise O
caution O
when O
considering O
resumption O
of O
TNF O
blocker O
therapy O
in O
this O
situation O
and O
monitor O
patients O
closely O
. O

5.4 O
Hepatotoxicity B-OSE_Labeled_AE
Severe O
hepatic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
acute B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
jaundice B-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
and O
cholestasis B-OSE_Labeled_AE
, O
have O
been O
reported O
in O
postmarketing O
data O
in O
patients O
receiving O
REMICADE O
. O

Autoimmune B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
has O
been O
diagnosed O
in O
some O
of O
these O
cases O
. O

Severe O
hepatic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
occurred O
between O
2 O
weeks O
to O
more O
than O
1 O
year O
after O
initiation O
of O
REMICADE O
; O
elevations B-NonOSE_AE
in I-NonOSE_AE
hepatic I-NonOSE_AE
aminotransferase I-NonOSE_AE
levels I-NonOSE_AE
were O
not O
noted O
prior O
to O
discovery O
of O
the O
liver B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
in O
many O
of O
these O
cases O
. O

Some O
of O
these O
cases O
were O
fatal B-NonOSE_AE
or O
necessitated O
liver B-NonOSE_AE
transplantation I-NonOSE_AE
. O

Patients O
with O
symptoms O
or O
signs O
of O
liver B-NonOSE_AE
dysfunction I-NonOSE_AE
should O
be O
evaluated O
for O
evidence O
of O
liver B-NonOSE_AE
injury I-NonOSE_AE
. O

If O
jaundice B-NonOSE_AE
and/or O
marked O
liver B-NonOSE_AE
enzyme I-NonOSE_AE
elevations I-NonOSE_AE
( O
e.g. O
, O
> O
=5 O
times O
the O
upper O
limit O
of O
normal O
) O
develop O
, O
REMICADE O
should O
be O
discontinued O
, O
and O
a O
thorough O
investigation O
of O
the O
abnormality O
should O
be O
undertaken O
. O

In O
clinical O
trials O
, O
mild O
or O
moderate O
elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
ALT O
and O
AST I-OSE_Labeled_AE
have O
been O
observed O
in O
patients O
receiving O
REMICADE O
without O
progression O
to O
severe O
hepatic B-NonOSE_AE
injury I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.5 O
Patients O
with O
Heart O
Failure O
REMICADE O
has O
been O
associated O
with O
adverse O
outcomes O
in O
patients O
with O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
and O
should O
be O
used O
in O
patients O
with O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
only O
after O
consideration O
of O
other O
treatment O
options O
. O

The O
results O
of O
a O
randomized O
study O
evaluating O
the O
use O
of O
REMICADE O
in O
patients O
with O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
( I-Not_AE_Candidate
NYHA I-Not_AE_Candidate
Functional I-Not_AE_Candidate
Class I-Not_AE_Candidate
III I-Not_AE_Candidate
/IV O
) O
suggested O
higher O
mortality B-NonOSE_AE
in O
patients O
who O
received O
10 O
mg/kg O
REMICADE O
, O
and O
higher O
rates O
of O
cardiovascular B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
events I-OSE_Labeled_AE
at O
doses O
of O
5 O
mg/kg O
and O
10 O
mg/kg O
. O

There O
have O
been O
post-marketing O
reports O
of O
worsening B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
with O
and O
without O
identifiable O
precipitating O
factors O
, O
in O
patients O
taking O
REMICADE O
. O

There O
have O
also O
been O
post-marketing O
reports O
of O
new O
onset O
heart B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
including O
heart B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
in O
patients O
without O
known O
pre-existing O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Some O
of O
these O
patients O
have O
been O
under O
50 O
years O
of O
age O
. O

If O
a O
decision O
is O
made O
to O
administer O
REMICADE O
to O
patients O
with O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
they O
should O
be O
closely O
monitored O
during O
therapy O
, O
and O
REMICADE O
should O
be O
discontinued O
if O
new O
or O
worsening O
symptoms O
of O
heart B-NonOSE_AE
failure I-NonOSE_AE
appear O
[ O
see O
Contraindications O
( O
4 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.6 O
Hematologic O
Reactions O
Cases O
of O
leukopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
and O
pancytopenia B-OSE_Labeled_AE
, O
some O
with O
a O
fatal B-NonOSE_AE
outcome O
, O
have O
been O
reported O
in O
patients O
receiving O
REMICADE O
. O

The O
causal O
relationship O
to O
REMICADE O
therapy O
remains O
unclear O
. O

Although O
no O
high-risk O
group O
( O
s O
) O
has O
been O
identified O
, O
caution O
should O
be O
exercised O
in O
patients O
being O
treated O
with O
REMICADE O
who O
have O
ongoing O
or O
a O
history O
of O
significant O
hematologic B-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
. O

All O
patients O
should O
be O
advised O
to O
seek O
immediate O
medical O
attention O
if O
they O
develop O
signs O
and O
symptoms O
suggestive O
of O
blood B-NonOSE_AE
dyscrasias I-NonOSE_AE
or O
infection B-NonOSE_AE
( O
e.g. O
, O
persistent O
fever B-NonOSE_AE
) O
while O
on O
REMICADE O
. O

Discontinuation O
of O
REMICADE O
therapy O
should O
be O
considered O
in O
patients O
who O
develop O
significant O
hematologic B-NonOSE_AE
abnormalities I-NonOSE_AE
. O

5.7 O
Hypersensitivity O
REMICADE O
has O
been O
associated O
with O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
that O
vary O
in O
their O
time O
of O
onset O
and O
required O
hospitalization O
in O
some O
cases O
. O

Most O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
which O
include O
anaphylaxis B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
and/or O
hypotension B-OSE_Labeled_AE
, O
have O
occurred O
during O
or O
within O
2 O
hours O
of O
REMICADE O
infusion O
. O

However O
, O
in O
some O
cases O
, O
serum B-OSE_Labeled_AE
sickness I-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
have O
been O
observed O
in O
patients O
after O
initial O
REMICADE O
therapy O
( O
i.e. O
, O
as O
early O
as O
after O
the O
second O
dose O
) O
, O
and O
when O
REMICADE O
therapy O
was O
reinstituted O
following O
an O
extended O
period O
without O
REMICADE O
treatment O
. O

Symptoms O
associated O
with O
these O
reactions O
include O
fever B-NonOSE_AE
, O
rash B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
sore B-NonOSE_AE
throat I-NonOSE_AE
, O
myalgias B-NonOSE_AE
, O
polyarthralgias B-NonOSE_AE
, O
hand B-NonOSE_AE
and O
facial O
edema I-NonOSE_AE
and/or O
dysphagia B-NonOSE_AE
. O

These O
reactions O
were O
associated O
with O
a O
marked O
increase O
in O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
infliximab I-OSE_Labeled_AE
, O
loss O
of O
detectable O
serum O
concentrations O
of O
infliximab O
, O
and O
possible O
loss O
of O
drug O
efficacy O
. O

REMICADE O
should O
be O
discontinued O
for O
severe O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
. O

Medications O
for O
the O
treatment O
of O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
( O
e.g. O
, O
acetaminophen O
, O
antihistamines O
, O
corticosteroids O
and/or O
epinephrine O
) O
should O
be O
available O
for O
immediate O
use O
in O
the O
event O
of O
a O
reaction O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

In O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
and O
psoriasis B-Not_AE_Candidate
clinical O
trials O
, O
re-administration O
of O
REMICADE O
after O
a O
period O
of O
no O
treatment O
resulted O
in O
a O
higher O
incidence O
of O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
relative O
to O
regular O
maintenance O
treatment O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

In O
general O
, O
the O
benefit-risk O
of O
re-administration O
of O
REMICADE O
after O
a O
period O
of O
no-treatment O
, O
especially O
as O
a O
re-induction O
regimen O
given O
at O
weeks O
0 O
, O
2 O
and O
6 O
, O
should O
be O
carefully O
considered O
. O

In O
the O
case O
where O
REMICADE O
maintenance O
therapy O
for O
psoriasis B-Not_AE_Candidate
is O
interrupted O
, O
REMICADE O
should O
be O
reinitiated O
as O
a O
single O
dose O
followed O
by O
maintenance O
therapy O
. O

5.8 O
Cardiovascular O
and O
Cerebrovascular O
Reactions O
During O
and O
After O
Infusion O
Serious O
cerebrovascular B-OSE_Labeled_AE
accidents I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
ischemia/ O
infarction I-OSE_Labeled_AE
( O
some O
fatal B-NonOSE_AE
) O
, O
hypotension B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
and O
arrhythmias B-OSE_Labeled_AE
have O
been O
reported O
during O
and O
within O
24 O
hours O
of O
initiation O
of O
REMICADE O
infusion O
. O

Cases O
of O
transient B-OSE_Labeled_AE
visual I-OSE_Labeled_AE
loss I-OSE_Labeled_AE
have O
been O
reported O
during O
or O
within O
2 O
hours O
of O
infusion O
of O
REMICADE O
. O

Monitor O
patients O
during O
infusion O
and O
if O
serious O
reaction O
occurs O
, O
discontinue O
infusion O
. O

Further O
management O
of O
reactions O
should O
be O
dictated O
by O
signs O
and O
symptoms O
[ O
See O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

5.9 O
Neurologic O
Reactions O
REMICADE O
and O
other O
agents O
that O
inhibit O
TNF O
have O
been O
associated O
with O
CNS O
manifestation O
of O
systemic B-OSE_Labeled_AE
vasculitis I-OSE_Labeled_AE
, O
seizure B-OSE_Labeled_AE
and O
new O
onset O
or O
exacerbation O
of O
clinical O
symptoms O
and/or O
radiographic O
evidence O
of O
central B-OSE_Labeled_AE
nervous I-OSE_Labeled_AE
system I-OSE_Labeled_AE
demyelinating I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
including O
multiple B-OSE_Labeled_AE
sclerosis I-OSE_Labeled_AE
and O
optic B-OSE_Labeled_AE
neuritis I-OSE_Labeled_AE
, O
and O
peripheral B-OSE_Labeled_AE
demyelinating I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
including O
Guillain B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Barre I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
. O

Prescribers O
should O
exercise O
caution O
in O
considering O
the O
use O
of O
REMICADE O
in O
patients O
with O
these O
neurologic B-NonOSE_AE
disorders I-NonOSE_AE
and O
should O
consider O
discontinuation O
of O
REMICADE O
if O
these O
disorders O
develop O
. O

5.10 O
Use O
with O
Anakinra O
Serious O
infections B-NonOSE_AE
and O
neutropenia B-NonOSE_AE
were O
seen O
in O
clinical O
studies O
with O
concurrent O
use O
of O
anakinra O
and O
another O
TNFalpha-blocking O
agent O
, O
etanercept O
, O
with O
no O
added O
clinical O
benefit O
compared O
to O
etanercept O
alone O
. O

Because O
of O
the O
nature O
of O
the O
adverse O
reactions O
seen O
with O
the O
combination O
of O
etanercept O
and O
anakinra O
therapy O
, O
similar O
toxicities O
may O
also O
result O
from O
the O
combination O
of O
anakinra O
and O
other O
TNFalpha-blocking O
agents O
. O

Therefore O
, O
the O
combination O
of O
REMICADE O
and O
anakinra O
is O
not O
recommended O
. O

5.11 O
Use O
with O
Abatacept O
In O
clinical O
studies O
, O
concurrent O
administration O
of O
TNF-blocking O
agents O
and O
abatacept O
have O
been O
associated O
with O
an O
increased O
risk O
of O
infections B-NonOSE_AE
including O
serious O
infections B-NonOSE_AE
compared O
with O
TNF O
- O
blocking O
agents O
alone O
, O
without O
increased O
clinical O
benefit O
. O

Therefore O
, O
the O
combination O
of O
REMICADE O
and O
abatacept O
is O
not O
recommended O
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

5.12 O
Concurrent O
Administration O
with O
Other O
Biological O
Therapeutics O
There O
is O
insufficient O
information O
regarding O
the O
concomitant O
use O
of O
REMICADE O
with O
other O
biological O
therapeutics O
used O
to O
treat O
the O
same O
conditions O
as O
REMICADE O
. O

The O
concomitant O
use O
of O
REMICADE O
with O
these O
biologics O
is O
not O
recommended O
because O
of O
the O
possibility O
of O
an O
increased O
risk O
of O
infection B-NonOSE_AE
[ O
see O
Drug O
Interactions O
( O
7.3 O
) O
] O
. O

5.13 O
Switching O
Between O
Biological O
Disease-Modifying O
Antirheumatic O
Drugs O
( O
DMARDs O
) O
Care O
should O
be O
taken O
when O
switching O
from O
one O
biologic O
to O
another O
, O
since O
overlapping O
biological O
activity O
may O
further O
increase O
the O
risk O
of O
infection B-NonOSE_AE
. O

5.14 O
Autoimmunity O
Treatment O
with O
REMICADE O
may O
result O
in O
the O
formation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
autoantibodies I-OSE_Labeled_AE
and O
in O
the O
development O
of O
a O
lupus B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
. O

If O
a O
patient O
develops O
symptoms O
suggestive O
of O
a O
lupus B-NonOSE_AE
- I-NonOSE_AE
like I-NonOSE_AE
syndrome I-NonOSE_AE
following O
treatment O
with O
REMICADE O
, O
treatment O
should O
be O
discontinued O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.15 O
Live O
Vaccines/Therapeutic O
Infectious O
Agents O
In O
patients O
receiving O
anti-TNF O
therapy O
, O
limited O
data O
are O
available O
on O
the O
response O
to O
vaccination O
with O
live O
vaccines O
or O
on O
the O
secondary B-NonOSE_AE
transmission I-NonOSE_AE
of I-NonOSE_AE
infection I-NonOSE_AE
by I-NonOSE_AE
live I-NonOSE_AE
vaccines I-NonOSE_AE
. O

Use O
of O
live O
vaccines O
can O
result O
in O
clinical O
infections B-NonOSE_AE
, O
including O
disseminated B-NonOSE_AE
infections I-NonOSE_AE
. O

The O
concurrent O
administration O
of O
live O
vaccines O
with O
REMICADE O
is O
not O
recommended O
. O

Fatal B-NonOSE_AE
outcome O
due O
to O
disseminated B-NonOSE_AE
BCG I-NonOSE_AE
infection I-NonOSE_AE
has O
been O
reported O
in O
an O
infant O
who O
received O
a O
BCG O
vaccine O
after O
in B-OSE_Labeled_AE
utero I-OSE_Labeled_AE
exposure I-OSE_Labeled_AE
to I-OSE_Labeled_AE
infliximab I-OSE_Labeled_AE
. O

Infliximab O
is O
known O
to O
cross O
the O
placenta O
and O
has O
been O
detected O
up O
to O
6 O
months O
following O
birth O
. O

At O
least O
a O
six O
month O
waiting O
period O
following O
birth O
is O
recommended O
before O
the O
administration O
of O
any O
live O
vaccine O
to O
infants O
exposed O
in O
utero O
to O
infliximab O
. O

Other O
uses O
of O
therapeutic O
infectious O
agents O
such O
as O
live O
attenuated O
bacteria O
( O
e.g. O
, O
BCG O
bladder O
instillation O
for O
the O
treatment O
of O
cancer B-Not_AE_Candidate
) O
could O
result O
in O
clinical O
infections B-NonOSE_AE
, O
including O
disseminated B-NonOSE_AE
infections I-NonOSE_AE
. O

It O
is O
recommended O
that O
therapeutic B-NonOSE_AE
infectious I-NonOSE_AE
agents I-NonOSE_AE
not O
be O
given O
concurrently O
with O
REMICADE O
. O

It O
is O
recommended O
that O
all O
pediatric O
patients O
be O
brought O
up O
to O
date O
with O
all O
vaccinations O
prior O
to O
initiating O
REMICADE O
therapy O
. O

The O
interval O
between O
vaccination O
and O
initiation O
of O
REMICADE O
therapy O
should O
be O
in O
accordance O
with O
current O
vaccination O
guidelines O
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
* O
Most O
of O
the O
safety O
experience O
is O
with O
sevelamer O
tablets O
and O
sevelamer O
hydrochloride O
. O

In O
long-term O
studies O
with O
sevelamer O
hydrochloride O
, O
which O
contains O
the O
same O
active O
moiety O
as O
sevelamer O
carbonate O
, O
the O
most O
common O
adverse O
events O
included O
: O
vomiting O
( O
22 O
% O
) O
, O
nausea O
( O
20 O
% O
) O
, O
diarrhea O
( O
19 O
% O
) O
, O
dyspepsia O
( O
16 O
% O
) O
, O
abdominal O
pain O
( O
9 O
% O
) O
, O
flatulence O
( O
8 O
% O
) O
, O
and O
constipation O
( O
8 O
% O
) O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Genzyme O
Corporation O
at O
1-800-847-0069 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

There O
are O
limited O
clinical O
trial O
data O
on O
the O
safety O
of O
Renvela O
. O

However O
, O
because O
it O
contains O
the O
same O
active O
ingredient O
as O
the O
hydrochloride O
salt O
, O
the O
adverse O
event O
profiles O
of O
the O
two O
salts O
are O
expected O
to O
be O
similar O
. O

In O
a O
cross-over O
study O
in O
hemodialysis O
patients O
with O
treatment O
durations O
of O
eight O
weeks O
each O
and O
no O
washout O
, O
and O
another O
cross-over O
study O
in O
hemodialysis O
patients O
with O
treatment O
durations O
of O
four O
weeks O
each O
and O
no O
washout O
between O
treatment O
periods O
, O
the O
adverse O
reactions O
on O
sevelamer O
carbonate O
powder O
were O
similar O
to O
those O
reported O
for O
sevelamer O
hydrochloride O
. O

In O
a O
parallel O
design O
study O
of O
sevelamer O
hydrochloride O
with O
treatment O
duration O
of O
52 O
weeks O
, O
adverse O
reactions O
reported O
for O
sevelamer O
hydrochloride O
( O
n=99 O
) O
were O
similar O
to O
those O
reported O
for O
the O
active-comparator O
group O
( O
n=101 O
) O
. O

Overall O
adverse O
reactions O
among O
those O
treated O
with O
sevelamer O
hydrochloride O
occurring O
in O
> O
5 O
% O
of O
patients O
included O
: O
vomiting B-OSE_Labeled_AE
( O
22 O
% O
) O
, O
nausea B-OSE_Labeled_AE
( O
20 O
% O
) O
, O
diarrhea B-OSE_Labeled_AE
( O
19 O
% O
) O
, O
dyspepsia B-OSE_Labeled_AE
( O
16 O
% O
) O
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
9 O
% O
) O
, O
flatulence B-OSE_Labeled_AE
( O
8 O
% O
) O
, O
and O
constipation B-OSE_Labeled_AE
( O
8 O
% O
) O
. O

A O
total O
of O
27 O
patients O
treated O
with O
sevelamer O
and O
10 O
patients O
treated O
with O
comparator O
withdrew O
from O
the O
study O
due O
to O
adverse O
reactions O
. O

Based O
on O
studies O
of O
8-52 O
weeks O
, O
the O
most O
common O
reason O
for O
withdrawal O
from O
sevelamer O
hydrochloride O
was O
gastrointestinal B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
3 O
% O
-16 O
% O
) O
. O

In O
143 O
peritoneal O
dialysis O
patients O
studied O
for O
12 O
weeks O
using O
sevelamer O
hydrochloride O
, O
most O
common O
adverse O
reactions O
were O
similar O
to O
adverse O
reactions O
observed O
in O
hemodialysis O
patients O
. O

The O
most O
frequently O
occurring O
treatment O
emergent O
serious O
adverse O
reaction O
was O
peritonitis B-OSE_Labeled_AE
( O
8 O
reactions O
in O
8 O
patients O
[ O
8 O
% O
] O
in O
the O
sevelamer O
group O
and O
2 O
reactions O
in O
2 O
patients O
[ O
4 O
% O
] O
on O
active O
control O
) O
. O

Thirteen O
patients O
( O
14 O
% O
) O
in O
the O
sevelamer O
group O
and O
9 O
patients O
( O
20 O
% O
) O
in O
the O
active-control O
group O
discontinued O
, O
mostly O
for O
gastrointestinal B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

6.2 O
Postmarketing O
Experience O
Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
to O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

The O
following O
adverse O
reactions O
have O
been O
identified O
during O
postapproval O
use O
of O
sevelamer O
hydrochloride O
or O
sevelamer O
carbonate O
: O
hypersensitivity B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
fecal B-OSE_Labeled_AE
impaction I-OSE_Labeled_AE
, O
and O
uncommon O
cases O
of O
ileus B-OSE_Labeled_AE
, O
intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
, O
and O
intestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
. O

Appropriate O
medical O
management O
should O
be O
given O
to O
patients O
who O
develop O
constipation B-NonOSE_AE
or O
have O
worsening O
of O
existing O
constipation B-NonOSE_AE
to O
avoid O
severe O
complications O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Serious O
cases O
of O
dysphagia O
, O
bowel O
obstruction O
, O
and O
perforation O
have O
been O
associated O
with O
sevelamer O
use O
, O
some O
requiring O
hospitalization O
and O
surgery O
. O

( O
5.1 O
) O
5.1 O
Gastrointestinal B-OSE_Labeled_AE
Adverse I-OSE_Labeled_AE
Events I-OSE_Labeled_AE
Cases O
of O
dysphagia B-OSE_Labeled_AE
and O
esophageal B-OSE_Labeled_AE
tablet I-OSE_Labeled_AE
retention I-OSE_Labeled_AE
have O
been O
reported O
in O
association O
with O
use O
of O
the O
tablet O
formulation O
of O
sevelamer O
, O
some O
requiring O
hospitalization O
and O
intervention O
. O

Consider O
using O
sevelamer O
suspension O
in O
patients O
with O
a O
history O
of O
swallowing B-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Cases O
of O
bowel B-OSE_Labeled_AE
obstruction O
and O
perforation I-OSE_Labeled_AE
have O
also O
been O
reported O
with O
sevelamer O
use O
. O

Patients O
with O
dysphagia B-Not_AE_Candidate
, O
swallowing B-Not_AE_Candidate
disorders I-Not_AE_Candidate
, O
severe O
gastrointestinal B-Not_AE_Candidate
( I-Not_AE_Candidate
GI I-Not_AE_Candidate
) I-Not_AE_Candidate
motility I-Not_AE_Candidate
disorders I-Not_AE_Candidate
, O
including O
severe O
constipation B-Not_AE_Candidate
, O
or O
major O
GI O
tract O
surgery O
were O
not O
included O
in O
the O
Renvela O
clinical O
studies O
. O

5.2 O
Reductions O
in O
Vitamins O
D O
, O
E O
, O
K O
( O
clotting O
factors O
) O
and O
Folic O
Acid O
Levels O
In O
preclinical O
studies O
in O
rats O
and O
dogs O
, O
sevelamer O
hydrochloride O
, O
which O
contains O
the O
same O
active O
moiety O
as O
sevelamer O
carbonate O
, O
reduced B-NonOSE_AE
vitamins O
D O
, O
E O
, O
and O
K O
( O
coagulation O
parameters O
) O
and O
folic I-NonOSE_AE
acid I-NonOSE_AE
levels I-NonOSE_AE
at O
doses O
of O
6-10 O
times O
the O
recommended O
human O
dose O
. O

In O
short-term O
clinical O
trials O
, O
there O
was O
no O
evidence O
of O
reduction B-NonOSE_AE
in I-NonOSE_AE
serum I-NonOSE_AE
levels I-NonOSE_AE
of I-NonOSE_AE
vitamins I-NonOSE_AE
. O

However O
, O
in O
a O
one-year O
clinical O
trial O
, O
2 B-OSE_Labeled_AE
5 I-OSE_Labeled_AE
- I-OSE_Labeled_AE
hydroxyvitamin I-OSE_Labeled_AE
D I-OSE_Labeled_AE
( O
normal O
range O
10 O
to O
55 O
ng/mL O
) O
fell I-OSE_Labeled_AE
from O
39 O
+/- O
22 O
ng/mL O
to O
34 O
+/- O
22 O
ng/mL O
( O
p O
< O
0.01 O
) O
with O
sevelamer O
hydrochloride O
treatment O
. O

Most O
( O
approximately O
75 O
% O
) O
patients O
in O
sevelamer O
hydrochloride O
clinical O
trials O
were O
receiving O
vitamin O
supplements O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
are O
discussed O
in O
more O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Increased O
mortality O
in O
elderly O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Cerebrovascular B-NonOSE_AE
adverse I-NonOSE_AE
events I-NonOSE_AE
, O
including O
stroke B-NonOSE_AE
, O
in O
elderly O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Neuroleptic B-OSE_Labeled_AE
malignant I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Tardive B-OSE_Labeled_AE
dyskinesia I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Metabolic B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
( O
Hyperglycemia B-OSE_Labeled_AE
and O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
, O
Dyslipidemia B-OSE_Labeled_AE
, O
and O
Weight B-OSE_Labeled_AE
Gain I-OSE_Labeled_AE
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Hyperprolactinemia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Falls B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Leukopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
and O
agranulocytosis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Potential O
for O
cognitive B-OSE_Labeled_AE
and O
motor O
impairment I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
* O
Seizures B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
* O
Dysphagia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.12 O
) O
] O
* O
Priapism B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.13 O
) O
] O
* O
Disruption B-OSE_Labeled_AE
of I-OSE_Labeled_AE
body I-OSE_Labeled_AE
temperature I-OSE_Labeled_AE
regulation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.14 O
) O
] O
* O
Patients O
with O
Phenylketonuria B-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.15 O
) O
] O
. O

The O
most O
common O
adverse O
reactions O
in O
clinical O
trials O
( O
> O
5 O
% O
and O
twice O
placebo O
) O
were O
parkinsonism B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
, O
dystonia B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
sedation B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
abdominal I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
stomach B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
salivary B-OSE_Labeled_AE
hypersecretion I-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
nasal B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
, O
and O
pharyngolaryngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
. O

The O
most O
common O
adverse O
reactions O
that O
were O
associated O
with O
discontinuation O
from O
clinical O
trials O
( O
causing O
discontinuation O
in O
> O
1 O
% O
of O
adults O
and/or O
> O
2 O
% O
of O
pediatrics O
) O
were O
nausea B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
sedation B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
and O
akathisia B-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
, O
Discontinuations O
Due O
to O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

The O
data O
described O
in O
this O
section O
are O
derived O
from O
a O
clinical O
trial O
database O
consisting O
of O
9803 O
adult O
and O
pediatric O
patients O
exposed O
to O
one O
or O
more O
doses O
of O
RISPERDAL O
( O
r O
) O
for O
the O
treatment O
of O
schizophrenia B-Not_AE_Candidate
, O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
, O
autistic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
and O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
in O
pediatrics O
and O
elderly B-Not_AE_Candidate
patients O
with O
dementia I-Not_AE_Candidate
. O

Of O
these O
9803 O
patients O
, O
2687 O
were O
patients O
who O
received O
RISPERDAL O
( O
r O
) O
while O
participating O
in O
double-blind O
, O
placebo-controlled O
trials O
. O

The O
conditions O
and O
duration O
of O
treatment O
with O
RISPERDAL O
( O
r O
) O
varied O
greatly O
and O
included O
( O
in O
overlapping O
categories O
) O
double-blind O
, O
fixed- O
and O
flexible-dose O
, O
placebo- O
or O
active-controlled O
studies O
and O
open-label O
phases O
of O
studies O
, O
inpatients O
and O
outpatients O
, O
and O
short-term O
( O
up O
to O
12 O
weeks O
) O
and O
longer-term O
( O
up O
to O
3 O
years O
) O
exposures O
. O

Safety O
was O
assessed O
by O
collecting O
adverse O
events O
and O
performing O
physical O
examinations O
, O
vital O
signs O
, O
body O
weights O
, O
laboratory O
analyses O
, O
and O
ECGs O
. O

EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
in O
clinical O
trials O
( O
> O
=5 O
% O
and O
twice O
placebo O
) O
were O
parkinsonism O
, O
akathisia O
, O
dystonia O
, O
tremor O
, O
sedation O
, O
dizziness O
, O
anxiety O
, O
blurred O
vision O
, O
nausea O
, O
vomiting O
, O
upper O
abdominal O
pain O
, O
stomach O
discomfort O
, O
dyspepsia O
, O
diarrhea O
, O
salivary O
hypersecretion O
, O
constipation O
, O
dry O
mouth O
, O
increased O
appetite O
, O
increased O
weight O
, O
fatigue O
, O
rash O
, O
nasal O
congestion O
, O
upper O
respiratory O
tract O
infection O
, O
nasopharyngitis O
, O
and O
pharyngolaryngeal O
pain O
. O

( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Janssen O
Pharmaceuticals O
, O
Inc O
. O
at O
1-800-JANSSEN O
( O
1-800-526-7736 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

Commonly-Observed O
Adverse O
Reactions O
in O
Double-Blind O
, O
Placebo-Controlled O
Clinical O
Trials O
- O
Schizophrenia O
Adult O
Patients O
with O
Schizophrenia O
Table O
8 O
lists O
the O
adverse O
reactions O
reported O
in O
2 O
% O
or O
more O
of O
RISPERDAL O
( O
r O
) O
-treated O
adult O
patients O
with O
schizophrenia B-Not_AE_Candidate
in O
three O
4- O
to O
8-week O
, O
double-blind O
, O
placebo-controlled O
trials O
. O

Table O
8 O
. O

Adverse O
Reactions O
in O
> O
=2 O
% O
of O
RISPERDAL O
( O
r O
) O
-Treated O
Adult O
Patients O
( O
and O
greater O
than O
placebo O
) O
with O
Schizophrenia O
in O
Double-Blind O
, O
Placebo-Controlled O
Trials O
Percentage O
of O
Patients O
Reporting O
Reaction O
RISPERDAL O
( O
r O
) O
System/Organ O
Class O
Adverse O
Reaction O
2-8 O
mg O
per O
day O
( O
N=366 O
) O
> O
8-16 O
mg O
per O
day O
( O
N=198 O
) O
Placebo O
( O
N=225 O
) O
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
Tachycardia B-OSE_Labeled_AE
1 O
3 O
0 O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
3 O
1 O
1 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
9 O
4 O
4 O
Constipation B-OSE_Labeled_AE
8 O
9 O
6 O
Dyspepsia B-OSE_Labeled_AE
8 O
6 O
5 O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
4 O
0 O
1 O
Abdominal B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
3 O
1 O
1 O
Salivary B-OSE_Labeled_AE
hypersecretion I-OSE_Labeled_AE
2 O
1 O
< O
1 O
Diarrhea B-OSE_Labeled_AE
2 O
1 O
1 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
3 O
1 O
0 O
Chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
2 O
2 O
1 O
Asthenia B-OSE_Labeled_AE
2 O
1 O
< O
1 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Nasopharyngitis B-OSE_Labeled_AE
3 O
4 O
3 O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
2 O
3 O
1 O
Sinusitis B-OSE_Labeled_AE
1 O
2 O
1 O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
1 O
3 O
0 O
Investigations B-NonOSE_AE
Blood B-OSE_Labeled_AE
creatine I-OSE_Labeled_AE
phosphokinase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
1 O
2 O
< O
1 O
Heart B-OSE_Labeled_AE
rate I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
< O
1 O
2 O
0 O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
4 O
1 O
1 O
Arthralgia B-OSE_Labeled_AE
2 O
3 O
< O
1 O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
2 O
1 O
1 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Parkinsonism B-OSE_Labeled_AE
[ O
note O
: O
Parkinsonism B-OSE_Labeled_AE
includes O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
stiffness I-OSE_Labeled_AE
, O
parkinsonism B-OSE_Labeled_AE
, O
cogwheel B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
akinesia B-OSE_Labeled_AE
, O
bradykinesia B-OSE_Labeled_AE
, O
hypokinesia B-OSE_Labeled_AE
, O
masked B-OSE_Labeled_AE
facies I-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
and O
Parkinson B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
. O

Akathisia B-OSE_Labeled_AE
includes O
akathisia B-OSE_Labeled_AE
and O
restlessness B-OSE_Labeled_AE
. O

Dystonia B-OSE_Labeled_AE
includes O
dystonia B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
contractions I-OSE_Labeled_AE
involuntary I-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
contracture I-OSE_Labeled_AE
, O
oculogyration B-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
paralysis I-OSE_Labeled_AE
. O

Tremor B-OSE_Labeled_AE
includes O
tremor B-OSE_Labeled_AE
and O
parkinsonian B-OSE_Labeled_AE
rest I-OSE_Labeled_AE
tremor I-OSE_Labeled_AE
. O
] O

14 O
17 O
8 O
Akathisia B-OSE_Labeled_AE
10 O
10 O
3 O
Sedation B-OSE_Labeled_AE
10 O
5 O
2 O
Dizziness B-OSE_Labeled_AE
7 O
4 O
2 O
Dystonia B-OSE_Labeled_AE
3 O
4 O
2 O
Tremor B-OSE_Labeled_AE
2 O
3 O
1 O
Dizziness B-OSE_Labeled_AE
postural I-OSE_Labeled_AE
2 O
0 O
0 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
32 O
25 O
27 O
Anxiety B-OSE_Labeled_AE
16 O
11 O
11 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Nasal B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
4 O
6 O
2 O
Dyspnea B-OSE_Labeled_AE
1 O
2 O
0 O
Epistaxis B-OSE_Labeled_AE
< O
1 O
2 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
1 O
4 O
1 O
Dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
1 O
3 O
0 O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
Orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
2 O
1 O
0 O
Pediatric O
Patients O
with O
Schizophrenia O
Table O
9 O
lists O
the O
adverse O
reactions O
reported O
in O
5 O
% O
or O
more O
of O
RISPERDAL O
( O
r O
) O
-treated O
pediatric O
patients O
with O
schizophrenia B-Not_AE_Candidate
in O
a O
6-week O
double-blind O
, O
placebo-controlled O
trial O
. O

Table O
9 O
. O

Adverse O
Reactions O
in O
> O
=5 O
% O
of O
RISPERDAL O
( O
r O
) O
-Treated O
Pediatric O
Patients O
( O
and O
greater O
than O
placebo O
) O
with O
Schizophrenia O
in O
a O
Double-Blind O
Trial O
Percentage O
of O
Patients O
Reporting O
Reaction O
RISPERDAL O
( O
r O
) O
System/Organ O
Class O
Adverse O
Reaction O
1-3 O
mg O
per O
day O
( O
N=55 O
) O
4-6 O
mg O
per O
day O
( O
N=51 O
) O
Placebo O
( O
N=54 O
) O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Salivary B-OSE_Labeled_AE
hypersecretion I-OSE_Labeled_AE
0 O
10 O
2 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Sedation B-OSE_Labeled_AE
24 O
12 O
4 O
Parkinsonism B-OSE_Labeled_AE
[ O
note O
: O
Parkinsonism B-OSE_Labeled_AE
includes O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
stiffness I-OSE_Labeled_AE
, O
and O
hypokinesia B-OSE_Labeled_AE
. O

Akathisia B-OSE_Labeled_AE
includes O
akathisia B-OSE_Labeled_AE
and O
restlessness B-OSE_Labeled_AE
. O

Dystonia B-OSE_Labeled_AE
includes O
dystonia B-OSE_Labeled_AE
and O
oculogyration B-OSE_Labeled_AE
. O
] O

16 O
28 O
11 O
Tremor B-OSE_Labeled_AE
11 O
10 O
6 O
Akathisia B-OSE_Labeled_AE
9 O
10 O
4 O
Dizziness B-OSE_Labeled_AE
7 O
14 O
2 O
Dystonia B-OSE_Labeled_AE
2 O
6 O
0 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Anxiety B-OSE_Labeled_AE
7 O
6 O
0 O
Commonly-Observed O
Adverse O
Reactions O
in O
Double-Blind O
, O
Placebo-Controlled O
Clinical O
Trials O
- O
Bipolar B-Not_AE_Candidate
Mania I-Not_AE_Candidate
Adult O
Patients O
with O
Bipolar O
Mania O
Table O
10 O
lists O
the O
adverse O
reactions O
reported O
in O
2 O
% O
or O
more O
of O
RISPERDAL O
( O
r O
) O
-treated O
adult O
patients O
with O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
in O
four O
3-week O
, O
double-blind O
, O
placebo-controlled O
monotherapy O
trials O
. O

Table O
10 O
. O

Adverse O
Reactions O
in O
> O
=2 O
% O
of O
RISPERDAL O
( O
r O
) O
-Treated O
Adult O
Patients O
( O
and O
greater O
than O
placebo O
) O
with O
Bipolar O
Mania O
in O
Double-Blind O
, O
Placebo-Controlled O
Monotherapy O
Trials O
Percentage O
of O
Patients O
Reporting O
Reaction O
System/Organ O
Class O
Adverse O
Reaction O
RISPERDAL O
( O
r O
) O
1-6 O
mg O
per O
day O
( O
N=448 O
) O
Placebo O
( O
N=424 O
) O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
2 O
1 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
5 O
2 O
Diarrhea B-OSE_Labeled_AE
3 O
2 O
Salivary B-OSE_Labeled_AE
hypersecretion I-OSE_Labeled_AE
3 O
1 O
Stomach B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
2 O
< O
1 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
2 O
1 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Parkinsonism B-OSE_Labeled_AE
[ O
note O
: O
Parkinsonism B-OSE_Labeled_AE
includes O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
parkinsonism B-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
stiffness I-OSE_Labeled_AE
, O
hypokinesia B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
tightness I-OSE_Labeled_AE
, O
bradykinesia B-OSE_Labeled_AE
, O
cogwheel B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
. O

Akathisia B-OSE_Labeled_AE
includes O
akathisia B-OSE_Labeled_AE
and O
restlessness B-OSE_Labeled_AE
. O

Tremor B-OSE_Labeled_AE
includes O
tremor B-OSE_Labeled_AE
and O
parkinsonian B-OSE_Labeled_AE
rest I-OSE_Labeled_AE
tremor I-OSE_Labeled_AE
. O

Dystonia B-OSE_Labeled_AE
includes O
dystonia B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
, O
oculogyration B-OSE_Labeled_AE
, O
torticollis B-OSE_Labeled_AE
. O
] O

25 O
9 O
Sedation B-OSE_Labeled_AE
11 O
4 O
Akathisia B-OSE_Labeled_AE
9 O
3 O
Tremor B-OSE_Labeled_AE
6 O
3 O
Dizziness B-OSE_Labeled_AE
6 O
5 O
Dystonia B-OSE_Labeled_AE
5 O
1 O
Lethargy B-OSE_Labeled_AE
2 O
1 O
Table O
11 O
lists O
the O
adverse O
reactions O
reported O
in O
2 O
% O
or O
more O
of O
RISPERDAL O
( O
r O
) O
-treated O
adult O
patients O
with O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
in O
two O
3-week O
, O
double-blind O
, O
placebo-controlled O
adjuvant O
therapy O
trials O
. O

Table O
11 O
. O

Adverse O
Reactions O
in O
> O
=2 O
% O
of O
RISPERDAL O
( O
r O
) O
-Treated O
Adult O
Patients O
( O
and O
greater O
than O
placebo O
) O
with O
Bipolar O
Mania O
in O
Double-Blind O
, O
Placebo-Controlled O
Adjunctive O
Therapy O
Trials O
Percentage O
of O
Patients O
Reporting O
Reaction O
System/Organ O
Class O
RISPERDAL O
( O
r O
) O
+ O
Mood O
Stabilizer O
Placebo O
+ O
Mood O
Stabilizer O
Adverse O
Reaction O
( O
N=127 O
) O
( O
N=126 O
) O
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
Palpitations B-OSE_Labeled_AE
2 O
0 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Dyspepsia B-OSE_Labeled_AE
9 O
8 O
Nausea B-OSE_Labeled_AE
6 O
4 O
Diarrhea B-OSE_Labeled_AE
6 O
4 O
Salivary B-OSE_Labeled_AE
hypersecretion I-OSE_Labeled_AE
2 O
0 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
2 O
1 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
2 O
1 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Parkinsonism B-OSE_Labeled_AE
[ O
note O
: O
Parkinsonism B-OSE_Labeled_AE
includes O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
hypokinesia B-OSE_Labeled_AE
and O
bradykinesia B-OSE_Labeled_AE
. O

Akathisia B-OSE_Labeled_AE
includes O
hyperkinesia B-OSE_Labeled_AE
and O
akathisia B-OSE_Labeled_AE
. O
] O

14 O
4 O
Sedation B-OSE_Labeled_AE
9 O
4 O
Akathisia B-OSE_Labeled_AE
8 O
0 O
Dizziness B-OSE_Labeled_AE
7 O
2 O
Tremor B-OSE_Labeled_AE
6 O
2 O
Lethargy B-OSE_Labeled_AE
2 O
1 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Anxiety B-OSE_Labeled_AE
3 O
2 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Pharyngolaryngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
5 O
2 O
Cough B-OSE_Labeled_AE
2 O
0 O
Pediatric O
Patients O
with O
Bipolar B-Not_AE_Candidate
Mania I-Not_AE_Candidate
Table O
12 O
lists O
the O
adverse O
reactions O
reported O
in O
5 O
% O
or O
more O
of O
RISPERDAL O
( O
r O
) O
-treated O
pediatric O
patients O
with O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
in O
a O
3-week O
double-blind O
, O
placebo-controlled O
trial O
. O

Table O
12 O
. O

Adverse O
Reactions O
in O
> O
=5 O
% O
of O
RISPERDAL O
( O
r O
) O
-Treated O
Pediatric O
Patients O
( O
and O
greater O
than O
placebo O
) O
with O
Bipolar O
Mania O
in O
Double-Blind O
, O
Placebo-Controlled O
Trials O
Percentage O
of O
Patients O
Reporting O
Reaction O
RISPERDAL O
( O
r O
) O
System/Organ O
Class O
Adverse O
Reaction O
0.5-2.5 O
mg O
per O
day O
( O
N=50 O
) O
3-6 O
mg O
per O
day O
( O
N=61 O
) O
Placebo O
( O
N=58 O
) O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
4 O
7 O
0 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
16 O
13 O
5 O
Nausea B-OSE_Labeled_AE
16 O
13 O
7 O
Vomiting B-OSE_Labeled_AE
10 O
10 O
5 O
Diarrhea B-OSE_Labeled_AE
8 O
7 O
2 O
Dyspepsia B-OSE_Labeled_AE
10 O
3 O
2 O
Stomach B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
6 O
0 O
2 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
18 O
30 O
3 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Increased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
4 O
7 O
2 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Sedation B-OSE_Labeled_AE
42 O
56 O
19 O
Dizziness B-OSE_Labeled_AE
16 O
13 O
5 O
Parkinsonism B-OSE_Labeled_AE
[ O
note O
: O
Parkinsonism B-OSE_Labeled_AE
includes O
musculoskeletal B-OSE_Labeled_AE
stiffness I-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
bradykinesia B-OSE_Labeled_AE
, O
and O
nuchal B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
. O

Dystonia B-OSE_Labeled_AE
includes O
dystonia B-OSE_Labeled_AE
, O
laryngospasm B-OSE_Labeled_AE
, O
and O
muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
. O

Akathisia B-OSE_Labeled_AE
includes O
restlessness B-OSE_Labeled_AE
and O
akathisia B-OSE_Labeled_AE
. O
] O

6 O
12 O
3 O
Dystonia B-OSE_Labeled_AE
6 O
5 O
0 O
Akathisia B-OSE_Labeled_AE
0 O
8 O
2 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Anxiety B-OSE_Labeled_AE
0 O
8 O
3 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Pharyngolaryngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
10 O
3 O
5 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
0 O
7 O
2 O
Commonly-Observed O
Adverse O
Reactions O
in O
Double-Blind O
, O
Placebo-Controlled O
Clinical O
Trials O
- O
Autistic O
Disorder O
Table O
13 O
lists O
the O
adverse O
reactions O
reported O
in O
5 O
% O
or O
more O
of O
RISPERDAL O
( O
r O
) O
-treated O
pediatric O
patients O
treated O
for O
irritability B-Not_AE_Candidate
associated I-Not_AE_Candidate
with I-Not_AE_Candidate
autistic I-Not_AE_Candidate
disorder I-Not_AE_Candidate
in O
two O
8-week O
, O
double-blind O
, O
placebo-controlled O
trials O
and O
one O
6-week O
double-blind O
, O
placebo-controlled O
study O
. O

Table O
13 O
. O

Adverse O
Reactions O
in O
> O
=5 O
% O
of O
RISPERDAL O
( O
r O
) O
-Treated O
Pediatric O
Patients O
( O
and O
greater O
than O
placebo O
) O
Treated O
for O
Irritability O
Associated O
with O
Autistic O
Disorder O
in O
Double-Blind O
, O
Placebo-Controlled O
Trials O
Percentage O
of O
Patients O
Reporting O
Reaction O
System/Organ O
Class O
RISPERDAL O
( O
r O
) O
0.5-4.0 O
mg/day O
Placebo O
Adverse O
Reaction O
( O
N=107 O
) O
( O
N=115 O
) O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Vomiting B-OSE_Labeled_AE
20 O
17 O
Constipation B-OSE_Labeled_AE
17 O
6 O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
10 O
4 O
Nausea B-OSE_Labeled_AE
8 O
5 O
Salivary B-OSE_Labeled_AE
hypersecretion I-OSE_Labeled_AE
7 O
1 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
31 O
9 O
Pyrexia B-OSE_Labeled_AE
16 O
13 O
Thirst B-OSE_Labeled_AE
7 O
4 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Nasopharyngitis B-OSE_Labeled_AE
19 O
9 O
Rhinitis B-OSE_Labeled_AE
9 O
7 O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
8 O
3 O
Investigations B-NonOSE_AE
Weight B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
8 O
2 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Increased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
44 O
15 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Sedation B-OSE_Labeled_AE
63 O
15 O
Drooling B-OSE_Labeled_AE
12 O
4 O
Headache B-OSE_Labeled_AE
12 O
10 O
Tremor B-OSE_Labeled_AE
8 O
1 O
Dizziness B-OSE_Labeled_AE
8 O
2 O
Parkinsonism B-OSE_Labeled_AE
[ O
note O
: O
Parkinsonism B-OSE_Labeled_AE
includes O
musculoskeletal B-OSE_Labeled_AE
stiffness I-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
cogwheel B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
and O
muscle B-OSE_Labeled_AE
tightness I-OSE_Labeled_AE
. O
] O

8 O
1 O
Renal B-NonOSE_AE
and I-NonOSE_AE
Urinary I-NonOSE_AE
Disorders I-NonOSE_AE
Enuresis B-OSE_Labeled_AE
16 O
10 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
17 O
12 O
Rhinorrhea B-OSE_Labeled_AE
12 O
10 O
Nasal B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
10 O
4 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
8 O
5 O
Other O
Adverse O
Reactions O
Observed O
During O
the O
Clinical O
Trial O
Evaluation O
of O
Risperidone O
The O
following O
additional O
adverse O
reactions O
occurred O
across O
all O
placebo-controlled O
, O
active-controlled O
, O
and O
open-label O
studies O
of O
RISPERDAL O
( O
r O
) O
in O
adults O
and O
pediatric O
patients O
. O

Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
anemia B-OSE_Labeled_AE
, O
granulocytopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
: O
sinus B-OSE_Labeled_AE
bradycardia I-OSE_Labeled_AE
, O
sinus B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
, O
atrioventricular B-OSE_Labeled_AE
block I-OSE_Labeled_AE
first I-OSE_Labeled_AE
degree I-OSE_Labeled_AE
, O
bundle B-OSE_Labeled_AE
branch I-OSE_Labeled_AE
block I-OSE_Labeled_AE
left I-OSE_Labeled_AE
, O
bundle B-OSE_Labeled_AE
branch I-OSE_Labeled_AE
block I-OSE_Labeled_AE
right I-OSE_Labeled_AE
, O
atrioventricular B-OSE_Labeled_AE
block I-OSE_Labeled_AE
Ear B-NonOSE_AE
and I-NonOSE_AE
Labyrinth I-NonOSE_AE
Disorders I-NonOSE_AE
: O
ear B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
tinnitus B-OSE_Labeled_AE
Endocrine B-NonOSE_AE
Disorders I-NonOSE_AE
: O
hyperprolactinemia B-OSE_Labeled_AE
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
: O
ocular B-OSE_Labeled_AE
hyperemia I-OSE_Labeled_AE
, O
eye B-OSE_Labeled_AE
discharge I-OSE_Labeled_AE
, O
conjunctivitis B-OSE_Labeled_AE
, O
eye B-OSE_Labeled_AE
rolling I-OSE_Labeled_AE
, O
eyelid B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
eye B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
, O
eyelid B-OSE_Labeled_AE
margin I-OSE_Labeled_AE
crusting I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
eye I-OSE_Labeled_AE
, O
lacrimation B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
photophobia B-OSE_Labeled_AE
, O
glaucoma B-OSE_Labeled_AE
, O
visual B-OSE_Labeled_AE
acuity I-OSE_Labeled_AE
reduced I-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
: O
dysphagia B-OSE_Labeled_AE
, O
fecaloma B-OSE_Labeled_AE
, O
fecal B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
gastritis B-OSE_Labeled_AE
, O
lip B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
, O
cheilitis B-OSE_Labeled_AE
, O
aptyalism B-OSE_Labeled_AE
General B-NonOSE_AE
Disorders I-NonOSE_AE
: O
edema B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
, O
thirst B-OSE_Labeled_AE
, O
gait B-OSE_Labeled_AE
disturbance I-OSE_Labeled_AE
, O
influenza B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
illness I-OSE_Labeled_AE
, O
pitting B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
sluggishness B-OSE_Labeled_AE
, O
malaise B-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
, O
face B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
discomfort B-OSE_Labeled_AE
, O
generalized B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
drug B-OSE_Labeled_AE
withdrawal I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
coldness I-OSE_Labeled_AE
, O
feeling B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
Immune B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
drug B-OSE_Labeled_AE
hypersensitivity I-OSE_Labeled_AE
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
: O
pneumonia B-OSE_Labeled_AE
, O
influenza B-OSE_Labeled_AE
, O
ear B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
viral B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
pharyngitis B-OSE_Labeled_AE
, O
tonsillitis B-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
, O
eye B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
localized B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
cystitis B-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
, O
onychomycosis B-OSE_Labeled_AE
, O
acarodermatitis B-OSE_Labeled_AE
, O
bronchopneumonia B-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
tracheobronchitis B-OSE_Labeled_AE
, O
otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
chronic I-OSE_Labeled_AE
Investigations B-NonOSE_AE
: O
body B-OSE_Labeled_AE
temperature I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
blood B-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
alanine B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
electrocardiogram B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
eosinophil B-OSE_Labeled_AE
count I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
white B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
count I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
blood B-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
hemoglobin B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
hematocrit B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
body B-OSE_Labeled_AE
temperature I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
transaminases B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
: O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
polydipsia B-OSE_Labeled_AE
, O
anorexia B-OSE_Labeled_AE
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
joint B-OSE_Labeled_AE
stiffness I-OSE_Labeled_AE
, O
joint B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
chest I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
posture B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
, O
neck B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
muscular B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
, O
rhabdomyolysis B-OSE_Labeled_AE
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
balance B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
disturbance B-OSE_Labeled_AE
in I-OSE_Labeled_AE
attention I-OSE_Labeled_AE
, O
dysarthria B-OSE_Labeled_AE
, O
unresponsive B-OSE_Labeled_AE
to I-OSE_Labeled_AE
stimuli I-OSE_Labeled_AE
, O
depressed B-OSE_Labeled_AE
level I-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
, O
movement B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
transient B-OSE_Labeled_AE
ischemic I-OSE_Labeled_AE
attack I-OSE_Labeled_AE
, O
coordination B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
speech B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
, O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
, O
hypoesthesia B-OSE_Labeled_AE
, O
tardive B-OSE_Labeled_AE
dyskinesia I-OSE_Labeled_AE
, O
dyskinesia B-OSE_Labeled_AE
, O
cerebral B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
neuroleptic B-OSE_Labeled_AE
malignant I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
diabetic B-OSE_Labeled_AE
coma I-OSE_Labeled_AE
, O
head B-OSE_Labeled_AE
titubation I-OSE_Labeled_AE
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
: O
agitation B-OSE_Labeled_AE
, O
blunted B-OSE_Labeled_AE
affect I-OSE_Labeled_AE
, O
confusional B-OSE_Labeled_AE
state I-OSE_Labeled_AE
, O
middle B-OSE_Labeled_AE
insomnia I-OSE_Labeled_AE
, O
nervousness B-OSE_Labeled_AE
, O
sleep B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
listlessness B-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
and O
anorgasmia B-OSE_Labeled_AE
Renal B-NonOSE_AE
and I-NonOSE_AE
Urinary I-NonOSE_AE
Disorders I-NonOSE_AE
: O
enuresis B-OSE_Labeled_AE
, O
dysuria B-OSE_Labeled_AE
, O
pollakiuria B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
Reproductive B-NonOSE_AE
System I-NonOSE_AE
and I-NonOSE_AE
Breast I-NonOSE_AE
Disorders I-NonOSE_AE
: O
menstruation B-OSE_Labeled_AE
irregular I-OSE_Labeled_AE
, O
amenorrhea B-OSE_Labeled_AE
, O
gynecomastia B-OSE_Labeled_AE
, O
galactorrhea B-OSE_Labeled_AE
, O
vaginal B-OSE_Labeled_AE
discharge I-OSE_Labeled_AE
, O
menstrual B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
erectile B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
, O
retrograde B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
, O
ejaculation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
sexual B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
, O
breast B-OSE_Labeled_AE
enlargement I-OSE_Labeled_AE
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
: O
wheezing B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
aspiration I-OSE_Labeled_AE
, O
sinus B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
, O
dysphonia B-OSE_Labeled_AE
, O
productive B-OSE_Labeled_AE
cough I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
, O
rales B-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
hyperventilation B-OSE_Labeled_AE
, O
nasal B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
erythema B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
lesion I-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
erythematous I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
papular I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
generalized I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
maculopapular I-OSE_Labeled_AE
, O
acne B-OSE_Labeled_AE
, O
hyperkeratosis B-OSE_Labeled_AE
, O
seborrheic B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
: O
hypotension B-OSE_Labeled_AE
, O
flushing B-OSE_Labeled_AE
Additional O
Adverse O
Reactions O
Reported O
with O
RISPERDAL O
CONSTA O
( O
r O
) O
The O
following O
is O
a O
list O
of O
additional O
adverse O
reactions O
that O
have O
been O
reported O
during O
the O
premarketing O
evaluation O
of O
RISPERDAL O
CONSTA O
( O
r O
) O
, O
regardless O
of O
frequency O
of O
occurrence O
: O
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
: O
bradycardia B-OSE_Labeled_AE
Ear B-NonOSE_AE
and I-NonOSE_AE
Labyrinth I-NonOSE_AE
Disorders I-NonOSE_AE
: O
vertigo B-OSE_Labeled_AE
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
: O
blepharospasm B-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
: O
toothache B-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
: O
pain B-OSE_Labeled_AE
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
: O
lower B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
infection B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
subcutaneous B-OSE_Labeled_AE
abscess I-OSE_Labeled_AE
Injury B-NonOSE_AE
and I-NonOSE_AE
Poisoning I-NonOSE_AE
: O
fall B-OSE_Labeled_AE
Investigations B-NonOSE_AE
: O
weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
gamma B-OSE_Labeled_AE
- I-OSE_Labeled_AE
glutamyltransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
enzyme I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
Musculoskeletal B-NonOSE_AE
, I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
Bone I-NonOSE_AE
Disorders I-NonOSE_AE
: O
buttock B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
convulsion B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
: O
depression B-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
eczema B-OSE_Labeled_AE
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
: O
hypertension B-OSE_Labeled_AE
Discontinuations O
Due O
to O
Adverse O
Reactions O
Schizophrenia B-Not_AE_Candidate
- O
Adults O
Approximately O
7 O
% O
( O
39/564 O
) O
of O
RISPERDAL O
( O
r O
) O
-treated O
patients O
in O
double-blind O
, O
placebo-controlled O
trials O
discontinued O
treatment O
due O
to O
an O
adverse O
reaction O
, O
compared O
with O
4 O
% O
( O
10/225 O
) O
who O
were O
receiving O
placebo O
. O

The O
adverse O
reactions O
associated O
with O
discontinuation O
in O
2 O
or O
more O
RISPERDAL O
( O
r O
) O
-treated O
patients O
were O
: O
Table O
14 O
. O

Adverse O
Reactions O
Associated O
With O
Discontinuation O
in O
2 O
or O
More O
RISPERDAL O
( O
r O
) O
-Treated O
Adult O
Patients O
in O
Schizophrenia O
Trials O
RISPERDAL O
( O
r O
) O
Adverse O
Reaction O
2-8 O
mg/day O
( O
N=366 O
) O
> O
8-16 O
mg/day O
( O
N=198 O
) O
Placebo O
( O
N=225 O
) O
Dizziness B-OSE_Labeled_AE
1.4 O
% O
1.0 O
% O
0 O
% O
Nausea B-OSE_Labeled_AE
1.4 O
% O
0 O
% O
0 O
% O
Vomiting B-OSE_Labeled_AE
0.8 O
% O
0 O
% O
0 O
% O
Parkinsonism B-OSE_Labeled_AE
0.8 O
% O
0 O
% O
0 O
% O
Somnolence B-OSE_Labeled_AE
0.8 O
% O
0 O
% O
0 O
% O
Dystonia B-OSE_Labeled_AE
0.5 O
% O
0 O
% O
0 O
% O
Agitation B-OSE_Labeled_AE
0.5 O
% O
0 O
% O
0 O
% O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
0.5 O
% O
0 O
% O
0 O
% O
Orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
0.3 O
% O
0.5 O
% O
0 O
% O
Akathisia B-OSE_Labeled_AE
0.3 O
% O
2.0 O
% O
0 O
% O
Discontinuation O
for O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
( O
including O
Parkinsonism B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
, O
dystonia B-OSE_Labeled_AE
, O
and O
tardive B-OSE_Labeled_AE
dyskinesia I-OSE_Labeled_AE
) O
was O
1 O
% O
in O
placebo-treated O
patients O
, O
and O
3.4 O
% O
in O
active O
control-treated O
patients O
in O
a O
double-blind O
, O
placebo- O
and O
active-controlled O
trial O
. O

Schizophrenia O
- O
Pediatrics O
Approximately O
7 O
% O
( O
7/106 O
) O
, O
of O
RISPERDAL O
( O
r O
) O
-treated O
patients O
discontinued O
treatment O
due O
to O
an O
adverse O
reaction O
in O
a O
double-blind O
, O
placebo-controlled O
trial O
, O
compared O
with O
4 O
% O
( O
2/54 O
) O
placebo-treated O
patients O
. O

The O
adverse O
reactions O
associated O
with O
discontinuation O
for O
at O
least O
one O
RISPERDAL O
( O
r O
) O
-treated O
patient O
were O
dizziness B-OSE_Labeled_AE
( O
2 O
% O
) O
, O
somnolence B-OSE_Labeled_AE
( O
1 O
% O
) O
, O
sedation B-OSE_Labeled_AE
( O
1 O
% O
) O
, O
lethargy B-OSE_Labeled_AE
( O
1 O
% O
) O
, O
anxiety B-OSE_Labeled_AE
( O
1 O
% O
) O
, O
balance B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
( O
1 O
% O
) O
, O
hypotension B-OSE_Labeled_AE
( O
1 O
% O
) O
, O
and O
palpitation B-OSE_Labeled_AE
( O
1 O
% O
) O
. O

Bipolar O
Mania O
- O
Adults O
In O
double-blind O
, O
placebo-controlled O
trials O
with O
RISPERDAL O
( O
r O
) O
as O
monotherapy O
, O
approximately O
6 O
% O
( O
25/448 O
) O
of O
RISPERDAL O
( O
r O
) O
-treated O
patients O
discontinued O
treatment O
due O
to O
an O
adverse O
event O
, O
compared O
with O
approximately O
5 O
% O
( O
19/424 O
) O
of O
placebo-treated O
patients O
. O

The O
adverse O
reactions O
associated O
with O
discontinuation O
in O
RISPERDAL O
( O
r O
) O
-treated O
patients O
were O
: O
Table O
15 O
. O

Adverse O
Reactions O
Associated O
With O
Discontinuation O
in O
2 O
or O
More O
RISPERDAL O
( O
r O
) O
-Treated O
Adult O
Patients O
in O
Bipolar O
Mania O
Clinical O
Trials O
Adverse O
Reaction O
RISPERDAL O
( O
r O
) O
1-6 O
mg/day O
( O
N=448 O
) O
Placebo O
( O
N=424 O
) O
Parkinsonism B-OSE_Labeled_AE
0.4 O
% O
0 O
% O
Lethargy B-OSE_Labeled_AE
0.2 O
% O
0 O
% O
Dizziness B-OSE_Labeled_AE
0.2 O
% O
0 O
% O
Alanine B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
0.2 O
% O
0.2 O
% O
Aspartate B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
0.2 O
% O
0.2 O
% O
Bipolar O
Mania O
- O
Pediatrics O
In O
a O
double-blind O
, O
placebo-controlled O
trial O
12 O
% O
( O
13/111 O
) O
of O
RISPERDAL O
( O
r O
) O
-treated O
patients O
discontinued O
due O
to O
an O
adverse O
reaction O
, O
compared O
with O
7 O
% O
( O
4/58 O
) O
of O
placebo-treated O
patients O
. O

The O
adverse O
reactions O
associated O
with O
discontinuation O
in O
more O
than O
one O
RISPERDAL O
( O
r O
) O
-treated O
pediatric O
patient O
were O
nausea B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
somnolence B-OSE_Labeled_AE
( O
2 O
% O
) O
, O
sedation B-OSE_Labeled_AE
( O
2 O
% O
) O
, O
and O
vomiting B-OSE_Labeled_AE
( O
2 O
% O
) O
. O

Autistic O
Disorder O
- O
Pediatrics O
In O
the O
two O
8-week O
, O
placebo-controlled O
trials O
in O
pediatric O
patients O
treated O
for O
irritability B-Not_AE_Candidate
associated I-Not_AE_Candidate
with I-Not_AE_Candidate
autistic I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( O
n=156 O
) O
, O
one O
RISPERDAL O
( O
r O
) O
-treated O
patient O
discontinued O
due O
to O
an O
adverse O
reaction O
( O
Parkinsonism B-OSE_Labeled_AE
) O
, O
and O
one O
placebo-treated O
patient O
discontinued O
due O
to O
an O
adverse O
event O
. O

Dose O
Dependency O
of O
Adverse O
Reactions O
in O
Clinical O
Trials O
Extrapyramidal O
Symptoms O
Data O
from O
two O
fixed-dose O
trials O
in O
adults O
with O
schizophrenia B-Not_AE_Candidate
provided O
evidence O
of O
dose-relatedness O
for O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
associated O
with O
RISPERDAL O
( O
r O
) O
treatment O
. O

Two O
methods O
were O
used O
to O
measure O
extrapyramidal B-NonOSE_AE
symptoms I-NonOSE_AE
( I-NonOSE_AE
EPS I-NonOSE_AE
) O
in O
an O
8-week O
trial O
comparing O
4 O
fixed O
doses O
of O
RISPERDAL O
( O
r O
) O
( O
2 O
, O
6 O
, O
10 O
, O
and O
16 O
mg/day O
) O
, O
including O
( O
1 O
) O
a O
Parkinsonism B-NonOSE_AE
score O
( O
mean O
change O
from O
baseline O
) O
from O
the O
Extrapyramidal B-NonOSE_AE
Symptom I-NonOSE_AE
Rating O
Scale O
, O
and O
( O
2 O
) O
incidence O
of O
spontaneous O
complaints O
of O
EPS B-NonOSE_AE
: O
Table O
16 O
. O

Dose O
Groups O
Placebo O
RISPERDAL O
( O
r O
) O
2 O
mg O
RISPERDAL O
( O
r O
) O
6 O
mg O
RISPERDAL O
( O
r O
) O
10 O
mg O
RISPERDAL O
( O
r O
) O
16 O
mg O
Parkinsonism B-OSE_Labeled_AE
1.2 O
0.9 O
1.8 O
2.4 O
2.6 O
EPS B-OSE_Labeled_AE
Incidence O
13 O
% O
17 O
% O
21 O
% O
21 O
% O
35 O
% O
Similar O
methods O
were O
used O
to O
measure O
extrapyramidal B-NonOSE_AE
symptoms I-NonOSE_AE
( O
EPS O
) O
in O
an O
8-week O
trial O
comparing O
5 O
fixed O
doses O
of O
RISPERDAL O
( O
r O
) O
( O
1 O
, O
4 O
, O
8 O
, O
12 O
, O
and O
16 O
mg/day O
) O
: O
Table O
17 O
. O

Dose O
Groups O
RISPERDAL O
( O
r O
) O
1 O
mg O
RISPERDAL O
( O
r O
) O
4 O
mg O
RISPERDAL O
( O
r O
) O
8 O
mg O
RISPERDAL O
( O
r O
) O
12 O
mg O
RISPERDAL O
( O
r O
) O
16 O
mg O
Parkinsonism B-OSE_Labeled_AE
0.6 O
1.7 O
2.4 O
2.9 O
4.1 O
EPS B-OSE_Labeled_AE
Incidence O
7 O
% O
12 O
% O
17 O
% O
18 O
% O
20 O
% O
Dystonia O
Class O
Effect O
: O
Symptoms O
of O
dystonia B-OSE_Labeled_AE
, O
prolonged B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
contractions I-OSE_Labeled_AE
of I-OSE_Labeled_AE
muscle I-OSE_Labeled_AE
groups I-OSE_Labeled_AE
, O
may O
occur O
in O
susceptible O
individuals O
during O
the O
first O
few O
days O
of O
treatment O
. O

Dystonic B-NonOSE_AE
symptoms I-NonOSE_AE
include O
: O
spasm B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
neck I-NonOSE_AE
muscles I-NonOSE_AE
, O
sometimes O
progressing O
to O
tightness B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
throat I-NonOSE_AE
, O
swallowing B-NonOSE_AE
difficulty I-NonOSE_AE
, O
difficulty B-NonOSE_AE
breathing I-NonOSE_AE
, O
and/or O
protrusion B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
tongue I-NonOSE_AE
. O

While O
these O
symptoms O
can O
occur O
at O
low O
doses O
, O
they O
occur O
more O
frequently O
and O
with O
greater O
severity O
with O
high O
potency O
and O
at O
higher O
doses O
of O
first O
generation O
antipsychotic O
drugs O
. O

An O
elevated O
risk O
of O
acute B-NonOSE_AE
dystonia I-NonOSE_AE
is O
observed O
in O
males O
and O
younger O
age O
groups O
. O

Other O
Adverse O
Reactions O
Adverse O
event O
data O
elicited O
by O
a O
checklist O
for O
side O
effects O
from O
a O
large O
study O
comparing O
5 O
fixed O
doses O
of O
RISPERDAL O
( O
r O
) O
( O
1 O
, O
4 O
, O
8 O
, O
12 O
, O
and O
16 O
mg/day O
) O
were O
explored O
for O
dose-relatedness O
of O
adverse O
events O
. O

A O
Cochran-Armitage O
Test O
for O
trend O
in O
these O
data O
revealed O
a O
positive O
trend O
( O
p O
< O
0.05 O
) O
for O
the O
following O
adverse O
reactions O
: O
somnolence B-OSE_Labeled_AE
, O
vision B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
palpitations B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
, O
erectile B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
, O
ejaculation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
sexual B-OSE_Labeled_AE
function I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
and O
skin B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
. O

Changes B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Body I-OSE_Labeled_AE
Weight I-OSE_Labeled_AE
Weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
was O
observed O
in O
short-term O
, O
controlled O
trials O
and O
longer-term O
uncontrolled O
studies O
in O
adult O
and O
pediatric O
patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
, O
Adverse O
Reactions O
( O
6 O
) O
, O
and O
Use O
in O
Specific O
Populations O
( O
8.4 O
) O
] O
. O

Changes O
in O
ECG O
Parameters O
Between-group O
comparisons O
for O
pooled O
placebo-controlled O
trials O
in O
adults O
revealed O
no O
statistically O
significant O
differences O
between O
risperidone O
and O
placebo O
in O
mean O
changes B-NonOSE_AE
from I-NonOSE_AE
baseline I-NonOSE_AE
in I-NonOSE_AE
ECG I-NonOSE_AE
parameters I-NonOSE_AE
, O
including O
QT O
, O
QTc O
, O
and O
PR O
intervals O
, O
and O
heart O
rate O
. O

When O
all O
RISPERDAL O
( O
r O
) O
doses O
were O
pooled O
from O
randomized O
controlled O
trials O
in O
several O
indications O
, O
there O
was O
a O
mean O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
of O
1 O
beat O
per O
minute O
compared O
to O
no O
change O
for O
placebo O
patients O
. O

In O
short-term O
schizophrenia B-Not_AE_Candidate
trials O
, O
higher O
doses O
of O
risperidone O
( O
8-16 O
mg/day O
) O
were O
associated O
with O
a O
higher O
mean O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
compared O
to O
placebo O
( O
4-6 O
beats O
per O
minute O
) O
. O

In O
pooled O
placebo-controlled O
acute B-Not_AE_Candidate
mania I-Not_AE_Candidate
trials O
in O
adults O
, O
there O
were O
small O
decreases B-NonOSE_AE
in I-NonOSE_AE
mean I-NonOSE_AE
heart I-NonOSE_AE
rate I-NonOSE_AE
, O
similar O
among O
all O
treatment O
groups O
. O

In O
the O
two O
placebo-controlled O
trials O
in O
children O
and O
adolescents O
with O
autistic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
( O
aged O
5 O
- O
16 O
years O
) O
mean O
changes O
in O
heart B-OSE_Labeled_AE
rate I-OSE_Labeled_AE
were O
an O
increase I-OSE_Labeled_AE
of O
8.4 O
beats O
per O
minute O
in O
the O
RISPERDAL O
( O
r O
) O
groups O
and O
6.5 O
beats O
per O
minute O
in O
the O
placebo O
group O
. O

There O
were O
no O
other O
notable O
ECG B-NonOSE_AE
changes I-NonOSE_AE
. O

In O
a O
placebo-controlled O
acute B-Not_AE_Candidate
mania I-Not_AE_Candidate
trial O
in O
children O
and O
adolescents O
( O
aged O
10 O
- O
17 O
years O
) O
, O
there O
were O
no O
significant O
changes B-NonOSE_AE
in I-NonOSE_AE
ECG I-NonOSE_AE
parameters I-NonOSE_AE
, O
other O
than O
the O
effect O
of O
RISPERDAL O
( O
r O
) O
to O
transiently O
increase B-OSE_Labeled_AE
pulse I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
( O
< O
6 O
beats O
per O
minute O
) O
. O

In O
two O
controlled O
schizophrenia B-Not_AE_Candidate
trials O
in O
adolescents O
( O
aged O
13 O
- O
17 O
years O
) O
, O
there O
were O
no O
clinically O
meaningful O
changes B-NonOSE_AE
in I-NonOSE_AE
ECG I-NonOSE_AE
parameters I-NonOSE_AE
including O
corrected O
QT O
intervals O
between O
treatment O
groups O
or O
within O
treatment O
groups O
over O
time O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
postapproval O
use O
of O
risperidone O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

These O
adverse O
reactions O
include O
: O
alopecia B-OSE_Labeled_AE
, O
anaphylactic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
cardiopulmonary B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
diabetic B-OSE_Labeled_AE
ketoacidosis I-OSE_Labeled_AE
in O
patients O
with O
impaired B-Not_AE_Candidate
glucose I-Not_AE_Candidate
metabolism I-Not_AE_Candidate
, O
dysgeusia B-OSE_Labeled_AE
, O
hypoglycemia B-OSE_Labeled_AE
, O
hypothermia B-OSE_Labeled_AE
, O
ileus B-OSE_Labeled_AE
, O
inappropriate B-OSE_Labeled_AE
antidiuretic I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
secretion I-OSE_Labeled_AE
, O
intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
, O
jaundice B-OSE_Labeled_AE
, O
mania B-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
, O
pituitary B-OSE_Labeled_AE
adenoma I-OSE_Labeled_AE
, O
precocious B-OSE_Labeled_AE
puberty I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
, O
sleep B-OSE_Labeled_AE
apnea I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
thrombotic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
, O
and O
water B-OSE_Labeled_AE
intoxication I-OSE_Labeled_AE
. O

BOXED O
WARNING O
: O
WARNING O
: O
INCREASED O
MORTALITY O
IN O
ELDERLY O
PATIENTS O
WITH O
DEMENTIA-RELATED O
PSYCHOSIS O
WARNING O
: O
INCREASED O
MORTALITY O
IN O
ELDERLY O
PATIENTS O
WITH O
DEMENTIA-RELATED O
PSYCHOSIS O
Elderly O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
treated O
with O
antipsychotic O
drugs O
are O
at O
an O
increased O
risk O
of O
death B-NonOSE_AE
. O

RISPERDAL O
( O
r O
) O
( O
risperidone O
) O
is O
not O
approved O
for O
the O
treatment O
of O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
. O

[ O
See O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
EXCERPT O
: O
WARNING O
: O
INCREASED O
MORTALITY O
IN O
ELDERLY O
PATIENTS O
WITH O
DEMENTIA-RELATED O
PSYCHOSIS O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Elderly O
patients O
with O
dementia-related O
psychosis O
treated O
with O
antipsychotic O
drugs O
are O
at O
an O
increased O
risk O
of O
death O
. O

* O
RISPERDAL O
( O
r O
) O
is O
not O
approved O
for O
use O
in O
patients O
with O
dementia-related O
psychosis O
. O

( O
5.1 O
) O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Cerebrovascular O
events O
, O
including O
stroke O
, O
in O
elderly O
patients O
with O
dementia-related O
psychosis O
: O
RISPERDAL O
( O
r O
) O
is O
not O
approved O
for O
use O
in O
patients O
with O
dementia-related O
psychosis O
. O

( O
5.2 O
) O
* O
Neuroleptic O
Malignant O
Syndrome O
: O
Manage O
with O
immediate O
discontinuation O
of O
RISPERDAL O
( O
r O
) O
and O
close O
monitoring O
. O

( O
5.3 O
) O
* O
Tardive O
dyskinesia O
: O
Consider O
discontinuing O
RISPERDAL O
( O
r O
) O
if O
clinically O
indicated O
. O

( O
5.4 O
) O
* O
* O
Hyperglycemia O
and O
Diabetes O
Mellitus O
: O
Monitor O
patients O
for O
symptoms O
of O
hyperglycemia O
including O
polydipsia O
, O
polyuria O
, O
polyphagia O
, O
and O
weakness O
. O

Monitor O
glucose O
regularly O
in O
patients O
with O
diabetes O
or O
at O
risk O
for O
diabetes O
. O

( O
5.5 O
) O
* O
Dyslipidemia O
: O
Undesirable O
alterations O
have O
been O
observed O
in O
patients O
treated O
with O
atypical O
antipsychotics O
. O

( O
5.5 O
) O
* O
Weight O
Gain O
: O
Significant O
weight O
gain O
has O
been O
reported O
. O

Monitor O
weight O
gain O
. O

( O
5.5 O
) O
Metabolic O
Changes O
: O
Atypical O
antipsychotic O
drugs O
have O
been O
associated O
with O
metabolic O
changes O
that O
may O
increase O
cardiovascular/ O
cerebrovascular O
risk O
. O

These O
metabolic O
changes O
include O
hyperglycemia O
, O
dyslipidemia O
, O
and O
weight O
gain O
. O

( O
5.5 O
) O
* O
Hyperprolactinemia O
: O
Prolactin O
elevations O
occur O
and O
persist O
during O
chronic O
administration O
. O

( O
5.6 O
) O
* O
Orthostatic O
hypotension O
: O
For O
patients O
at O
risk O
, O
consider O
a O
lower O
starting O
dose O
and O
slower O
titration O
. O

( O
5.7 O
) O
* O
Leukopenia O
, O
Neutropenia O
, O
and O
Agranulocytosis O
: O
Perform O
complete O
blood O
counts O
in O
patients O
with O
a O
history O
of O
clinically O
significant O
low O
white O
blood O
cell O
count O
( O
WBC O
) O
. O

Consider O
discontinuing O
RISPERDAL O
( O
r O
) O
if O
a O
clinically O
significant O
decline O
in O
WBC O
occurs O
in O
the O
absence O
of O
other O
causative O
factors O
. O

( O
5.9 O
) O
* O
Potential O
for O
cognitive O
and O
motor O
impairment O
: O
Use O
caution O
when O
operating O
machinery O
. O

( O
5.10 O
) O
* O
Seizures O
: O
Use O
cautiously O
in O
patients O
with O
a O
history O
of O
seizures O
or O
with O
conditions O
that O
lower O
the O
seizure O
threshold O
. O

( O
5.11 O
) O
5.1 O
Increased O
Mortality O
in O
Elderly O
Patients O
with O
Dementia-Related O
Psychosis O
Elderly O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
treated O
with O
antipsychotic O
drugs O
are O
at O
an O
increased O
risk O
of O
death B-NonOSE_AE
. O

Analyses O
of O
17 O
placebo-controlled O
trials O
( O
modal O
duration O
of O
10 O
weeks O
) O
, O
largely O
in O
patients O
taking O
atypical O
antipsychotic O
drugs O
, O
revealed O
a O
risk O
of O
death B-NonOSE_AE
in O
drug-treated O
patients O
of O
between O
1.6 O
to O
1.7 O
times O
the O
risk O
of O
death B-NonOSE_AE
in O
placebo-treated O
patients O
. O

Over O
the O
course O
of O
a O
typical O
10-week O
controlled O
trial O
, O
the O
rate O
of O
death B-NonOSE_AE
in O
drug-treated O
patients O
was O
about O
4.5 O
% O
, O
compared O
to O
a O
rate O
of O
about O
2.6 O
% O
in O
the O
placebo O
group O
. O

Although O
the O
causes O
of O
death B-NonOSE_AE
were O
varied O
, O
most O
of O
the O
deaths B-NonOSE_AE
appeared O
to O
be O
either O
cardiovascular I-NonOSE_AE
( O
e.g. O
, O
heart B-NonOSE_AE
failure I-NonOSE_AE
, O
sudden B-NonOSE_AE
death I-NonOSE_AE
) O
or O
infectious B-NonOSE_AE
( O
e.g. O
, O
pneumonia B-NonOSE_AE
) O
in O
nature O
. O

Observational O
studies O
suggest O
that O
, O
similar O
to O
atypical O
antipsychotic O
drugs O
, O
treatment O
with O
conventional O
antipsychotic O
drugs O
may O
increase O
mortality B-NonOSE_AE
. O

The O
extent O
to O
which O
the O
findings O
of O
increased O
mortality O
in O
observational O
studies O
may O
be O
attributed O
to O
the O
antipsychotic O
drug O
as O
opposed O
to O
some O
characteristic O
( O
s O
) O
of O
the O
patients O
is O
not O
clear O
. O

In O
two O
of O
four O
placebo-controlled O
trials O
in O
elderly B-Not_AE_Candidate
patients O
with O
dementia I-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
, O
a O
higher O
incidence O
of O
mortality O
was O
observed O
in O
patients O
treated O
with O
furosemide O
plus O
RISPERDAL O
( O
r O
) O
when O
compared O
to O
patients O
treated O
with O
RISPERDAL O
( O
r O
) O
alone O
or O
with O
placebo O
plus O
furosemide O
. O

No O
pathological O
mechanism O
has O
been O
identified O
to O
explain O
this O
finding O
, O
and O
no O
consistent O
pattern O
for O
cause O
of O
death B-NonOSE_AE
was O
observed O
. O

RISPERDAL O
( O
r O
) O
( O
risperidone O
) O
is O
not O
approved O
for O
the O
treatment O
of O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
[ O
see O
Boxed O
Warning O
] O
. O

5.2 O
Cerebrovascular O
Adverse O
Reactions O
, O
Including O
Stroke O
, O
in O
Elderly O
Patients O
with O
Dementia-Related O
Psychosis O
Cerebrovascular B-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
( O
e.g. O
, O
stroke B-NonOSE_AE
, O
transient B-NonOSE_AE
ischemic I-NonOSE_AE
attack I-NonOSE_AE
) O
, O
including O
fatalities B-NonOSE_AE
, O
were O
reported O
in O
patients O
( O
mean O
age O
85 O
years O
; O
range O
73-97 O
) O
in O
trials O
of O
risperidone O
in O
elderly O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
. O

In O
placebo-controlled O
trials O
, O
there O
was O
a O
significantly O
higher O
incidence O
of O
cerebrovascular B-NonOSE_AE
adverse I-NonOSE_AE
events I-NonOSE_AE
in O
patients O
treated O
with O
risperidone O
compared O
to O
patients O
treated O
with O
placebo O
. O

RISPERDAL O
( O
r O
) O
is O
not O
approved O
for O
the O
treatment O
of O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
. O

[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
5.3 O
Neuroleptic O
Malignant O
Syndrome O
Antipsychotic O
drugs O
including O
RISPERDAL O
( O
r O
) O
can O
cause O
a O
potentially O
fatal B-NonOSE_AE
symptom O
complex O
referred O
to O
as O
Neuroleptic B-OSE_Labeled_AE
Malignant I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
NMS I-OSE_Labeled_AE
) O
. O

Clinical O
manifestations O
of O
NMS B-NonOSE_AE
include O
hyperpyrexia B-NonOSE_AE
, O
muscle B-NonOSE_AE
rigidity I-NonOSE_AE
, O
altered B-NonOSE_AE
mental I-NonOSE_AE
status I-NonOSE_AE
, O
and O
autonomic B-NonOSE_AE
instability I-NonOSE_AE
( O
irregular B-NonOSE_AE
pulse I-NonOSE_AE
or O
blood O
pressure O
, O
tachycardia B-NonOSE_AE
, O
diaphoresis B-NonOSE_AE
, O
and O
cardiac B-NonOSE_AE
dysrhythmia I-NonOSE_AE
) O
. O

Additional O
signs O
may O
include O
elevated B-NonOSE_AE
creatine I-NonOSE_AE
phosphokinase I-NonOSE_AE
( I-NonOSE_AE
CPK I-NonOSE_AE
) O
, O
myoglobinuria B-NonOSE_AE
, O
rhabdomyolysis B-NonOSE_AE
, O
and O
acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
. O

The O
diagnostic O
evaluation O
of O
patients O
with O
this O
syndrome O
is O
complicated O
. O

In O
arriving O
at O
a O
diagnosis O
, O
it O
is O
important O
to O
identify O
cases O
in O
which O
the O
clinical O
presentation O
includes O
both O
serious O
medical O
illness O
( O
e.g. O
, O
pneumonia B-NonOSE_AE
, O
systemic B-NonOSE_AE
infection I-NonOSE_AE
, O
etc O
. O
) O

and O
untreated O
or O
inadequately O
treated O
extrapyramidal B-NonOSE_AE
signs I-NonOSE_AE
and I-NonOSE_AE
symptoms I-NonOSE_AE
( I-NonOSE_AE
EPS I-NonOSE_AE
) O
. O

Other O
important O
considerations O
in O
the O
differential O
diagnosis O
include O
central B-NonOSE_AE
anticholinergic I-NonOSE_AE
toxicity I-NonOSE_AE
, O
heat B-NonOSE_AE
stroke I-NonOSE_AE
, O
drug B-NonOSE_AE
fever I-NonOSE_AE
, O
and O
primary B-NonOSE_AE
central I-NonOSE_AE
nervous I-NonOSE_AE
system I-NonOSE_AE
pathology I-NonOSE_AE
. O

The O
management O
of O
NMS B-NonOSE_AE
should O
include O
: O
( O
1 O
) O
immediate O
discontinuation O
of O
antipsychotic O
drugs O
and O
other O
drugs O
not O
essential O
to O
concurrent O
therapy O
; O
( O
2 O
) O
intensive O
symptomatic O
treatment O
and O
medical O
monitoring O
; O
and O
( O
3 O
) O
treatment O
of O
any O
concomitant O
serious O
medical O
problems O
for O
which O
specific O
treatments O
are O
available O
. O

There O
is O
no O
general O
agreement O
about O
specific O
pharmacological O
treatment O
regimens O
for O
uncomplicated O
NMS B-NonOSE_AE
. O

If O
a O
patient O
requires O
antipsychotic O
drug O
treatment O
after O
recovery O
from O
NMS B-NonOSE_AE
, O
the O
potential O
reintroduction O
of O
drug O
therapy O
should O
be O
carefully O
considered O
. O

The O
patient O
should O
be O
carefully O
monitored O
, O
since O
recurrences O
of O
NMS B-NonOSE_AE
have O
been O
reported O
. O

5.4 O
Tardive B-OSE_Labeled_AE
Dyskinesia I-OSE_Labeled_AE
A O
syndrome O
of O
potentially O
irreversible O
, O
involuntary O
, O
dyskinetic B-OSE_Labeled_AE
movements I-OSE_Labeled_AE
may O
develop O
in O
patients O
treated O
with O
antipsychotic O
drugs O
. O

The O
risk O
of O
developing O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
and O
the O
likelihood O
that O
it O
will O
become O
irreversible O
are O
believed O
to O
increase O
as O
the O
duration O
of O
treatment O
and O
the O
total O
cumulative O
dose O
of O
antipsychotic O
drugs O
administered O
to O
the O
patient O
increase O
. O

However O
, O
the O
syndrome O
can O
develop O
, O
although O
much O
less O
commonly O
, O
after O
relatively O
brief O
treatment O
periods O
at O
low O
doses O
. O

There O
is O
no O
known O
treatment O
for O
established O
cases O
of O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
, O
although O
the O
syndrome O
may O
remit O
, O
partially O
or O
completely O
, O
if O
antipsychotic O
treatment O
is O
withdrawn O
. O

Antipsychotic O
treatment O
, O
itself O
, O
however O
, O
may O
suppress O
( O
or O
partially O
suppress O
) O
the O
signs O
and O
symptoms O
of O
the O
syndrome O
and O
thereby O
may O
possibly O
mask O
the O
underlying O
process O
. O

The O
effect O
that O
symptomatic O
suppression O
has O
upon O
the O
long-term O
course O
of O
the O
syndrome O
is O
unknown O
. O

Given O
these O
considerations O
, O
prescribe O
RISPERDAL O
( O
r O
) O
in O
a O
manner O
that O
is O
most O
likely O
to O
minimize O
the O
occurrence O
of O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
. O

Chronic O
antipsychotic O
treatment O
should O
generally O
be O
reserved O
for O
patients O
who O
suffer O
from O
a O
chronic O
illness O
that O
: O
( O
1 O
) O
is O
known O
to O
respond O
to O
antipsychotic O
drugs O
, O
and O
( O
2 O
) O
for O
whom O
alternative O
, O
equally O
effective O
, O
but O
potentially O
less O
harmful O
treatments O
are O
not O
available O
or O
appropriate O
. O

In O
patients O
who O
do O
require O
chronic O
treatment O
, O
the O
smallest O
dose O
and O
the O
shortest O
duration O
of O
treatment O
producing O
a O
satisfactory O
clinical O
response O
should O
be O
sought O
. O

The O
need O
for O
continued O
treatment O
should O
be O
reassessed O
periodically O
. O

If O
signs O
and O
symptoms O
of O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
appear O
in O
a O
patient O
treated O
with O
RISPERDAL O
( O
r O
) O
, O
consider O
drug O
discontinuation O
. O

However O
, O
some O
patients O
may O
require O
treatment O
with O
RISPERDAL O
( O
r O
) O
despite O
the O
presence O
of O
the O
syndrome O
. O

5.5 O
Metabolic O
Changes O
Atypical O
antipsychotic O
drugs O
have O
been O
associated O
with O
metabolic B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
that O
may O
increase O
cardiovascular/cerebrovascular O
risk O
. O

These O
metabolic B-NonOSE_AE
changes I-NonOSE_AE
include O
hyperglycemia B-OSE_Labeled_AE
, O
dyslipidemia B-OSE_Labeled_AE
, O
and O
body B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
gain I-OSE_Labeled_AE
. O

While O
all O
of O
the O
drugs O
in O
the O
class O
have O
been O
shown O
to O
produce O
some O
metabolic B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
, O
each O
drug O
has O
its O
own O
specific O
risk O
profile O
. O

Hyperglycemia O
and O
Diabetes O
Mellitus O
Hyperglycemia B-OSE_Labeled_AE
and O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
, O
in O
some O
cases O
extreme O
and O
associated O
with O
ketoacidosis B-OSE_Labeled_AE
or O
hyperosmolar B-OSE_Labeled_AE
coma I-OSE_Labeled_AE
or O
death B-NonOSE_AE
, O
have O
been O
reported O
in O
patients O
treated O
with O
atypical O
antipsychotics O
including O
RISPERDAL O
( O
r O
) O
. O

Assessment O
of O
the O
relationship O
between O
atypical O
antipsychotic O
use O
and O
glucose B-NonOSE_AE
abnormalities I-NonOSE_AE
is O
complicated O
by O
the O
possibility O
of O
an O
increased O
background O
risk O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
in O
patients O
with O
schizophrenia B-Not_AE_Candidate
and O
the O
increasing O
incidence O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
in O
the O
general O
population O
. O

Given O
these O
confounders O
, O
the O
relationship O
between O
atypical O
antipsychotic O
use O
and O
hyperglycemia B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
adverse I-NonOSE_AE
events I-NonOSE_AE
is O
not O
completely O
understood O
. O

However O
, O
epidemiological O
studies O
suggest O
an O
increased O
risk O
of O
treatment-emergent O
hyperglycemia B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
events I-OSE_Labeled_AE
in O
patients O
treated O
with O
the O
atypical O
antipsychotics O
. O

Precise O
risk O
estimates O
for O
hyperglycemia B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
adverse I-NonOSE_AE
events I-NonOSE_AE
in O
patients O
treated O
with O
atypical O
antipsychotics O
are O
not O
available O
. O

Patients O
with O
an O
established O
diagnosis O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
who O
are O
started O
on O
atypical O
antipsychotics O
, O
including O
RISPERDAL O
( O
r O
) O
, O
should O
be O
monitored O
regularly O
for O
worsening B-NonOSE_AE
of I-NonOSE_AE
glucose I-NonOSE_AE
control I-NonOSE_AE
. O

Patients O
with O
risk O
factors O
for O
diabetes B-NonOSE_AE
mellitus I-NonOSE_AE
( O
e.g. O
, O
obesity B-Not_AE_Candidate
, O
family B-Not_AE_Candidate
history I-Not_AE_Candidate
of I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
) O
who O
are O
starting O
treatment O
with O
atypical O
antipsychotics O
, O
including O
RISPERDAL O
( O
r O
) O
, O
should O
undergo O
fasting O
blood O
glucose O
testing O
at O
the O
beginning O
of O
treatment O
and O
periodically O
during O
treatment O
. O

Any O
patient O
treated O
with O
atypical O
antipsychotics O
, O
including O
RISPERDAL O
( O
r O
) O
, O
should O
be O
monitored O
for O
symptoms O
of O
hyperglycemia B-NonOSE_AE
including O
polydipsia B-NonOSE_AE
, O
polyuria B-NonOSE_AE
, O
polyphagia B-NonOSE_AE
, O
and O
weakness B-NonOSE_AE
. O

Patients O
who O
develop O
symptoms O
of O
hyperglycemia B-NonOSE_AE
during O
treatment O
with O
atypical O
antipsychotics O
, O
including O
RISPERDAL O
( O
r O
) O
, O
should O
undergo O
fasting O
blood O
glucose O
testing O
. O

In O
some O
cases O
, O
hyperglycemia B-NonOSE_AE
has O
resolved O
when O
the O
atypical O
antipsychotic O
, O
including O
RISPERDAL O
( O
r O
) O
, O
was O
discontinued O
; O
however O
, O
some O
patients O
required O
continuation O
of O
anti-diabetic O
treatment O
despite O
discontinuation O
of O
RISPERDAL O
( O
r O
) O
. O

Pooled O
data O
from O
three O
double-blind O
, O
placebo-controlled O
schizophrenia B-Not_AE_Candidate
studies O
and O
four O
double-blind O
, O
placebo-controlled O
bipolar B-Not_AE_Candidate
monotherapy O
studies O
are O
presented O
in O
Table O
2 O
. O

Table O
2 O
. O

Change O
in O
Random O
Glucose O
from O
Seven O
Placebo-Controlled O
, O
3- O
to O
8-Week O
, O
Fixed- O
or O
Flexible-Dose O
Studies O
in O
Adult O
Subjects O
with O
Schizophrenia O
or O
Bipolar O
Mania O
RISPERDAL O
( O
r O
) O
Placebo O
1-8 O
mg/day O
> O
8-16 O
mg/day O
Mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
( O
mg/dL O
) O
n=555 O
n=748 O
n=164 O
Serum I-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
-1.4 O
0.8 O
0.6 O
Proportion O
of O
patients O
with O
shifts O
Serum B-NonOSE_AE
Glucose I-NonOSE_AE
( I-NonOSE_AE
< I-NonOSE_AE
1 I-NonOSE_AE
4 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
to I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
2 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
) O
0.6 O
% O
( O
3/525 O
) O
0.4 O
% O
( O
3/702 O
) O
0 O
% O
( O
0/158 O
) O
In O
longer-term O
, O
controlled O
and O
uncontrolled O
studies O
, O
RISPERDAL O
( O
r O
) O
was O
associated O
with O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
of O
+2.8 O
mg/dL O
at O
Week O
24 O
( O
n=151 O
) O
and O
+4.1 O
mg/dL O
at O
Week O
48 O
( O
n=50 O
) O
. O

Data O
from O
the O
placebo-controlled O
3- O
to O
6-week O
study O
in O
children O
and O
adolescents O
with O
schizophrenia B-Not_AE_Candidate
( O
13-17 O
years O
of O
age O
) O
, O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
10-17 O
years O
of O
age O
) O
, O
or O
autistic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
( O
5 O
to O
17 O
years O
of O
age O
) O
are O
presented O
in O
Table O
3 O
. O

Table O
3 O
. O

Change O
in O
Fasting O
Glucose O
from O
Three O
Placebo-Controlled O
, O
3- O
to O
6-Week O
, O
Fixed-Dose O
Studies O
in O
Children O
and O
Adolescents O
with O
Schizophrenia O
( O
13-17 O
years O
of O
age O
) O
, O
Bipolar O
Mania O
( O
10-17 O
years O
of O
age O
) O
, O
or O
Autistic O
Disorder O
( O
5 O
to O
17 O
years O
of O
age O
) O
RISPERDAL O
( O
r O
) O
Placebo O
0.5-6 O
mg/day O
Mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
( O
mg/dL O
) O
n=76 O
n=135 O
Serum I-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
-1.3 O
2.6 O
Proportion O
of O
patients O
with O
shifts O
Serum B-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
( I-OSE_Labeled_AE
< I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
to I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
0 O
% O
( O
0/64 O
) O
0.8 O
% O
( O
1/120 O
) O
In O
longer-term O
, O
uncontrolled O
, O
open-label O
extension O
pediatric O
studies O
, O
RISPERDAL O
( O
r O
) O
was O
associated O
with O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
fasting I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
of O
+5.2 O
mg/dL O
at O
Week O
24 O
( O
n=119 O
) O
. O

Dyslipidemia B-OSE_Labeled_AE
Undesirable B-OSE_Labeled_AE
alterations I-OSE_Labeled_AE
in I-OSE_Labeled_AE
lipids I-OSE_Labeled_AE
have O
been O
observed O
in O
patients O
treated O
with O
atypical O
antipsychotics O
. O

Pooled O
data O
from O
7 O
placebo-controlled O
, O
3- O
to O
8- O
week O
, O
fixed- O
or O
flexible-dose O
studies O
in O
adult O
subjects O
with O
schizophrenia B-Not_AE_Candidate
or O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
are O
presented O
in O
Table O
4 O
. O

Table O
4 O
. O

Change O
in O
Random O
Lipids O
from O
Seven O
Placebo-Controlled O
, O
3- O
to O
8-Week O
, O
Fixed- O
or O
Flexible-Dose O
Studies O
in O
Adult O
Subjects O
with O
Schizophrenia O
or O
Bipolar O
Mania O
RISPERDAL O
( O
r O
) O
Placebo O
1-8 O
mg/day O
> O
8-16 O
mg/day O
Mean O
change O
from O
baseline O
( O
mg/dL O
) O
Cholesterol B-OSE_Labeled_AE
n=559 O
n=742 O
n=156 O
Change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
0.6 O
6.9 O
1.8 O
Triglycerides B-OSE_Labeled_AE
n=183 O
n=307 O
n=123 O
Change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
-17.4 O
-4.9 O
-8.3 O
Proportion O
of O
patients O
With O
Shifts O
Cholesterol B-OSE_Labeled_AE
( I-OSE_Labeled_AE
< I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
to I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
2.7 O
% O
4.3 O
% O
6.3 O
% O
( O
10/368 O
) O
( O
22/516 O
) O
( O
6/96 O
) O
Triglycerides B-OSE_Labeled_AE
( I-OSE_Labeled_AE
< I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
to I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
1.1 O
% O
( O
2/180 O
) O
2.7 O
% O
( O
8/301 O
) O
2.5 O
% O
( O
3/121 O
) O
In O
longer-term O
, O
controlled O
and O
uncontrolled O
studies O
, O
RISPERDAL O
( O
r O
) O
was O
associated O
with O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
( I-OSE_Labeled_AE
a I-OSE_Labeled_AE
) I-OSE_Labeled_AE
non I-OSE_Labeled_AE
- I-OSE_Labeled_AE
fasting I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
of O
+4.4 O
mg/dL O
at O
Week O
24 O
( O
n=231 O
) O
and O
+5.5 O
mg/dL O
at O
Week O
48 O
( O
n=86 O
) O
; O
and O
( O
b O
) O
non-fasting O
triglycerides O
of O
+19.9 O
mg/dL O
at O
Week O
24 O
( O
n=52 O
) O
. O

Pooled O
data O
from O
3 O
placebo-controlled O
, O
3- O
to O
6-week O
, O
fixed-dose O
studies O
in O
children O
and O
adolescents O
with O
schizophrenia B-Not_AE_Candidate
( O
13-17 O
years O
of O
age O
) O
, O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
10-17 O
years O
of O
age O
) O
, O
or O
autistic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
( O
5-17 O
years O
of O
age O
) O
are O
presented O
in O
Table O
5 O
. O

Table O
5 O
. O

Change O
in O
Fasting O
Lipids O
from O
Three O
Placebo-Controlled O
, O
3- O
to O
6-Week O
, O
Fixed-Dose O
Studies O
in O
Children O
and O
Adolescents O
with O
Schizophrenia O
( O
13-17 O
Years O
of O
Age O
) O
, O
Bipolar O
Mania O
( O
10-17 O
Years O
of O
Age O
) O
, O
or O
Autistic O
Disorder O
( O
5 O
to O
17 O
Years O
of O
Age O
) O
RISPERDAL O
( O
r O
) O
Placebo O
0.5-6 O
mg/day O
Mean O
change O
from O
baseline O
( O
mg/dL O
) O
Cholesterol B-OSE_Labeled_AE
n=74 O
n=133 O
Change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
0.3 O
-0.3 O
LDL B-OSE_Labeled_AE
n=22 O
n=22 O
Change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
3.7 O
0.5 O
HDL B-OSE_Labeled_AE
n=22 O
n=22 O
Change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
1.6 O
-1.9 O
Triglycerides B-OSE_Labeled_AE
n=77 O
n=138 O
Change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
-9.0 O
-2.6 O
Proportion O
of O
patients O
with O
shifts O
Cholesterol B-OSE_Labeled_AE
( I-OSE_Labeled_AE
< I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
7 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
to I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
2.4 O
% O
( O
1/42 O
) O
3.8 O
% O
( O
3/80 O
) O
LDL B-OSE_Labeled_AE
( I-OSE_Labeled_AE
< I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
to I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
0 O
% O
( O
0/16 O
) O
0 O
% O
( O
0/16 O
) O
HDL B-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
to I-OSE_Labeled_AE
< I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
0 O
% O
( O
0/19 O
) O
10 O
% O
( O
2/20 O
) O
Triglycerides B-OSE_Labeled_AE
( I-OSE_Labeled_AE
< I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
to I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
1.5 O
% O
( O
1/65 O
) O
7.1 O
% O
( O
8/113 O
) O
In O
longer-term O
, O
uncontrolled O
, O
open-label O
extension O
pediatric O
studies O
, O
RISPERDAL O
( O
r O
) O
was O
associated O
with O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
( I-OSE_Labeled_AE
a I-OSE_Labeled_AE
) I-OSE_Labeled_AE
fasting I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
of O
+2.1 O
mg/dL O
at O
Week O
24 O
( O
n=114 O
) O
; O
( O
b O
) O
fasting O
LDL O
of O
-0.2 O
mg/dL O
at O
Week O
24 O
( O
n=103 O
) O
; O
( O
c O
) O
fasting O
HDL O
of O
+0.4 O
mg/dL O
at O
Week O
24 O
( O
n=103 O
) O
; O
and O
( O
d O
) O
fasting O
triglycerides O
of O
+6.8 O
mg/dL O
at O
Week O
24 O
( O
n=120 O
) O
. O

Weight O
Gain O
Weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
has O
been O
observed O
with O
atypical O
antipsychotic O
use O
. O

Clinical O
monitoring O
of O
weight O
is O
recommended O
. O

Data O
on O
mean O
changes B-NonOSE_AE
in I-NonOSE_AE
body I-NonOSE_AE
weight I-NonOSE_AE
and O
the O
proportion O
of O
subjects O
meeting O
a O
weight B-NonOSE_AE
gain I-NonOSE_AE
criterion O
of O
7 O
% O
or O
greater O
of O
body O
weight O
from O
7 O
placebo-controlled O
, O
3- O
to O
8- O
week O
, O
fixed- O
or O
flexible-dose O
studies O
in O
adult O
subjects O
with O
schizophrenia B-Not_AE_Candidate
or O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
are O
presented O
in O
Table O
6 O
. O

Table O
6 O
. O

Mean O
Change O
in O
Body O
Weight O
( O
kg O
) O
and O
the O
Proportion O
of O
Subjects O
with O
> O
=7 O
% O
Gain O
in O
Body O
Weight O
From O
Seven O
Placebo-Controlled O
, O
3- O
to O
8-Week O
, O
Fixed- O
or O
Flexible-Dose O
Studies O
in O
Adult O
Subjects O
With O
Schizophrenia O
or O
Bipolar O
Mania O
RISPERDAL O
( O
r O
) O
Placebo O
( O
n=597 O
) O
1-8 O
mg/day O
( O
n=769 O
) O
> O
8-16 O
mg/day O
( O
n=158 O
) O
Weight B-OSE_Labeled_AE
( I-OSE_Labeled_AE
kg I-OSE_Labeled_AE
) I-OSE_Labeled_AE
Chan I-OSE_Labeled_AE
ge O
f I-OSE_Labeled_AE
rom O
base I-OSE_Labeled_AE
line O
-0.3 O
0.7 O
2.2 O
Weight B-OSE_Labeled_AE
Gain I-OSE_Labeled_AE
> O
=7 O
% O
increase O
from O
baseline O
2.9 O
% O
8.7 O
% O
20.9 O
% O
In O
longer-term O
, O
controlled O
and O
uncontrolled O
studies O
, O
RISPERDAL O
( O
r O
) O
was O
associated O
with O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
of O
+4.3 O
kg O
at O
Week O
24 O
( O
n=395 O
) O
and O
+5.3 O
kg O
at O
Week O
48 O
( O
n=203 O
) O
. O

Data O
on O
mean B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
body I-NonOSE_AE
weight I-NonOSE_AE
and O
the O
proportion O
of O
subjects O
meeting O
the O
criterion O
of O
> O
=7 O
% O
gain B-NonOSE_AE
in I-NonOSE_AE
body I-NonOSE_AE
weight I-NonOSE_AE
from O
nine O
placebo-controlled O
, O
3- O
to O
8-week O
, O
fixed-dose O
studies O
in O
children O
and O
adolescents O
with O
schizophrenia B-Not_AE_Candidate
( O
13-17 O
years O
of O
age O
) O
, O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
10-17 O
years O
of O
age O
) O
, O
autistic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
( O
5-17 O
years O
of O
age O
) O
, O
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
( O
5-17 O
years O
of O
age O
) O
are O
presented O
in O
Table O
7 O
. O

Table O
7 O
. O

Mean O
Change O
in O
Body O
Weight O
( O
kg O
) O
and O
the O
Proportion O
of O
Subjects O
With O
> O
=7 O
% O
Gain O
in O
Body O
Weight O
From O
Nine O
Placebo-Controlled O
, O
3- O
to O
8-Week O
, O
Fixed-Dose O
Studies O
in O
Children O
and O
Adolescents O
With O
Schizophrenia O
( O
13-17 O
Years O
of O
Age O
) O
, O
Bipolar O
Mania O
( O
10-17 O
Years O
of O
Age O
) O
, O
Autistic O
Disorder O
( O
5 O
to O
17 O
Years O
of O
Age O
) O
or O
Other O
Psychiatric O
Disorders O
( O
5-17 O
Years O
of O
Age O
) O
Placebo O
( O
n=375 O
) O
RISPERDAL O
( O
r O
) O
0.5-6 O
mg/day O
( O
n=448 O
) O
Weight B-OSE_Labeled_AE
( I-OSE_Labeled_AE
kg I-OSE_Labeled_AE
) I-OSE_Labeled_AE
Chan I-OSE_Labeled_AE
ge O
f I-OSE_Labeled_AE
rom O
base I-OSE_Labeled_AE
line O
0.6 O
2.0 O
Weight B-OSE_Labeled_AE
Gain I-OSE_Labeled_AE
> O
=7 O
% O
increase O
from O
baseline O
6.9 O
% O
32.6 O
% O
In O
longer-term O
, O
uncontrolled O
, O
open-label O
extension O
pediatric O
studies O
, O
RISPERDAL O
( O
r O
) O
was O
associated O
with O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
of O
+5.5 O
kg O
at O
Week O
24 O
( O
n=748 O
) O
and O
+8.0 O
kg O
at O
Week O
48 O
( O
n=242 O
) O
. O

In O
a O
long-term O
, O
open-label O
extension O
study O
in O
adolescent O
patients O
with O
schizophrenia B-Not_AE_Candidate
, O
weight B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
was O
reported O
as O
a O
treatment-emergent O
adverse O
event O
in O
14 O
% O
of O
patients O
. O

In O
103 O
adolescent O
patients O
with O
schizophrenia B-Not_AE_Candidate
, O
a O
mean B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
of I-OSE_Labeled_AE
9 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
kg I-OSE_Labeled_AE
was O
observed O
after O
8 O
months O
of O
RISPERDAL O
( O
r O
) O
treatment O
. O

The O
majority O
of O
that O
increase O
was O
observed O
within O
the O
first O
6 O
months O
. O

The O
average O
percentiles O
at O
baseline O
and O
8 O
months O
, O
respectively O
, O
were O
56 O
and O
72 O
for O
weight O
, O
55 O
and O
58 O
for O
height O
, O
and O
51 O
and O
71 O
for O
body O
mass O
index O
. O

In O
long-term O
, O
open-label O
trials O
( O
studies O
in O
patients O
with O
autistic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
) O
, O
a O
mean B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
of I-OSE_Labeled_AE
7 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
kg I-OSE_Labeled_AE
after O
12 O
months O
of O
RISPERDAL O
( O
r O
) O
treatment O
was O
observed O
, O
which O
was O
higher O
than O
the O
expected O
normal O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
( O
approximately O
3 O
to O
3.5 O
kg O
per O
year O
adjusted O
for O
age O
, O
based O
on O
Centers O
for O
Disease O
Control O
and O
Prevention O
normative O
data O
) O
. O

The O
majority O
of O
that O
increase O
occurred O
within O
the O
first O
6 O
months O
of O
exposure O
to O
RISPERDAL O
( O
r O
) O
. O

The O
average O
percentiles O
at O
baseline O
and O
12 O
months O
, O
respectively O
, O
were O
49 O
and O
60 O
for O
weight O
, O
48 O
and O
53 O
for O
height O
, O
and O
50 O
and O
62 O
for O
body O
mass O
index O
. O

In O
one O
3-week O
, O
placebo-controlled O
trial O
in O
children O
and O
adolescent O
patients O
with O
acute B-Not_AE_Candidate
manic I-Not_AE_Candidate
or I-Not_AE_Candidate
mixed I-Not_AE_Candidate
episodes I-Not_AE_Candidate
of I-Not_AE_Candidate
bipolar I-Not_AE_Candidate
I I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
body I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
were O
higher O
in O
the O
RISPERDAL O
( O
r O
) O
groups O
than O
the O
placebo O
group O
, O
but O
not O
dose O
related O
( O
1.90 O
kg O
in O
the O
RISPERDAL O
( O
r O
) O
0.5-2.5 O
mg O
group O
, O
1.44 O
kg O
in O
the O
RISPERDAL O
( O
r O
) O
3-6 O
mg O
group O
, O
and O
0.65 O
kg O
in O
the O
placebo O
group O
) O
. O

A O
similar O
trend O
was O
observed O
in O
the O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
in I-OSE_Labeled_AE
body I-OSE_Labeled_AE
mass I-OSE_Labeled_AE
index I-OSE_Labeled_AE
. O

When O
treating O
pediatric O
patients O
with O
RISPERDAL O
( O
r O
) O
for O
any O
indication O
, O
weight B-NonOSE_AE
gain I-NonOSE_AE
should O
be O
assessed O
against O
that O
expected O
with O
normal O
growth O
. O

5.6 O
Hyperprolactinemia B-OSE_Labeled_AE
As O
with O
other O
drugs O
that O
antagonize O
dopamine O
D2receptors O
, O
RISPERDAL O
( O
r O
) O
elevates B-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
and O
the O
elevation O
persists O
during O
chronic O
administration O
. O

RISPERDAL O
( O
r O
) O
is O
associated O
with O
higher O
levels O
of O
prolactin B-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
than O
other O
antipsychotic O
agents O
. O

Hyperprolactinemia B-NonOSE_AE
may O
suppress B-NonOSE_AE
hypothalamic I-NonOSE_AE
GnRH I-NonOSE_AE
, O
resulting O
in O
reduced B-NonOSE_AE
pituitary I-NonOSE_AE
gonadotropin I-NonOSE_AE
secretion I-NonOSE_AE
. O

This O
, O
in O
turn O
, O
may O
inhibit B-NonOSE_AE
reproductive I-NonOSE_AE
function I-NonOSE_AE
by O
impairing B-NonOSE_AE
gonadal I-NonOSE_AE
steroidogenesis I-NonOSE_AE
in O
both O
female O
and O
male O
patients O
. O

Galactorrhea B-OSE_Labeled_AE
, O
amenorrhea B-OSE_Labeled_AE
, O
gynecomastia B-OSE_Labeled_AE
, O
and O
impotence B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
receiving O
prolactin-elevating O
compounds O
. O

Long-standing O
hyperprolactinemia B-NonOSE_AE
when O
associated O
with O
hypogonadism B-NonOSE_AE
may O
lead O
to O
decreased B-NonOSE_AE
bone I-NonOSE_AE
density I-NonOSE_AE
in O
both O
female O
and O
male O
subjects O
. O

Tissue O
culture O
experiments O
indicate O
that O
approximately O
one-third O
of O
human O
breast B-NonOSE_AE
cancers I-NonOSE_AE
are O
prolactin O
dependent O
in O
vitro O
, O
a O
factor O
of O
potential O
importance O
if O
the O
prescription O
of O
these O
drugs O
is O
contemplated O
in O
a O
patient O
with O
previously O
detected O
breast B-Not_AE_Candidate
cancer I-Not_AE_Candidate
. O

An O
increase O
in O
pituitary B-NonOSE_AE
gland I-NonOSE_AE
, O
mammary O
gland O
, O
and O
pancreatic O
islet O
cell O
neoplasia I-NonOSE_AE
( O
mammary B-NonOSE_AE
adenocarcinomas I-NonOSE_AE
, O
pituitary B-NonOSE_AE
and O
pancreatic O
adenomas I-NonOSE_AE
) O
was O
observed O
in O
the O
risperidone O
carcinogenicity O
studies O
conducted O
in O
mice O
and O
rats O
[ O
see O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
. O

Neither O
clinical O
studies O
nor O
epidemiologic O
studies O
conducted O
to O
date O
have O
shown O
an O
association O
between O
chronic O
administration O
of O
this O
class O
of O
drugs O
and O
tumorigenesis B-NonOSE_AE
in O
humans O
; O
the O
available O
evidence O
is O
considered O
too O
limited O
to O
be O
conclusive O
at O
this O
time O
. O

5.7 O
Orthostatic O
Hypotension O
RISPERDAL O
( O
r O
) O
may O
induce O
orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
associated O
with O
dizziness B-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
, O
and O
in O
some O
patients O
, O
syncope B-OSE_Labeled_AE
, O
especially O
during O
the O
initial O
dose-titration O
period O
, O
probably O
reflecting O
its O
alpha-adrenergic O
antagonistic O
properties O
. O

Syncope B-OSE_Labeled_AE
was O
reported O
in O
0.2 O
% O
( O
6/2607 O
) O
of O
RISPERDAL O
( O
r O
) O
-treated O
patients O
in O
Phase O
2 O
and O
3 O
studies O
in O
adults O
with O
schizophrenia B-Not_AE_Candidate
. O

The O
risk O
of O
orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
and O
syncope B-OSE_Labeled_AE
may O
be O
minimized O
by O
limiting O
the O
initial O
dose O
to O
2 O
mg O
total O
( O
either O
once O
daily O
or O
1 O
mg O
twice O
daily O
) O
in O
normal O
adults O
and O
0.5 O
mg O
twice O
daily O
in O
the O
elderly O
and O
patients O
with O
renal B-Not_AE_Candidate
or O
hepatic O
impairment I-Not_AE_Candidate
[ O
see O
Dosage O
and O
Administration O
( O
2.1 O
, O
2.4 O
) O
] O
. O

Monitoring O
of O
orthostatic O
vital O
signs O
should O
be O
considered O
in O
patients O
for O
whom O
this O
is O
of O
concern O
. O

A O
dose O
reduction O
should O
be O
considered O
if O
hypotension B-NonOSE_AE
occurs O
. O

RISPERDAL O
( O
r O
) O
should O
be O
used O
with O
particular O
caution O
in O
patients O
with O
known O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
( O
history O
of O
myocardial B-Not_AE_Candidate
infarction I-Not_AE_Candidate
or O
ischemia B-Not_AE_Candidate
, O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
or O
conduction B-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
) O
, O
cerebrovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
and O
conditions O
which O
would O
predispose O
patients O
to O
hypotension B-NonOSE_AE
, O
e.g. O
, O
dehydration B-Not_AE_Candidate
and O
hypovolemia B-Not_AE_Candidate
. O

Clinically O
significant O
hypotension B-NonOSE_AE
has O
been O
observed O
with O
concomitant O
use O
of O
RISPERDAL O
( O
r O
) O
and O
antihypertensive B-NonOSE_AE
medication I-NonOSE_AE
. O

5.8 O
Falls O
Somnolence B-OSE_Labeled_AE
, O
postural B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
, O
motor B-OSE_Labeled_AE
and O
sensory O
instability I-OSE_Labeled_AE
have O
been O
reported O
with O
the O
use O
of O
antipsychotics O
, O
including O
RISPERDAL O
( O
r O
) O
, O
which O
may O
lead O
to O
falls B-NonOSE_AE
and O
, O
consequently O
, O
fractures B-NonOSE_AE
or O
other O
fall B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
injuries I-NonOSE_AE
. O

For O
patients O
, O
particularly O
the O
elderly O
, O
with O
diseases O
, O
conditions O
, O
or O
medications O
that O
could O
exacerbate O
these O
effects O
, O
assess O
the O
risk O
of O
falls B-NonOSE_AE
when O
initiating O
antipsychotic O
treatment O
and O
recurrently O
for O
patients O
on O
long-term O
antipsychotic O
therapy O
. O

5.9 O
Leukopenia O
, O
Neutropenia O
, O
and O
Agranulocytosis O
Class O
Effect O
: O
In O
clinical O
trial O
and/or O
postmarketing O
experience O
, O
events O
of O
leukopenia B-OSE_Labeled_AE
/ O
neutropenia B-OSE_Labeled_AE
have O
been O
reported O
temporally O
related O
to O
antipsychotic O
agents O
, O
including O
RISPERDAL O
( O
r O
) O
. O

Agranulocytosis B-OSE_Labeled_AE
has O
also O
been O
reported O
. O

Possible O
risk O
factors O
for O
leukopenia B-NonOSE_AE
/ O
neutropenia B-NonOSE_AE
include O
pre-existing O
low B-Not_AE_Candidate
white I-Not_AE_Candidate
blood I-Not_AE_Candidate
cell I-Not_AE_Candidate
count I-Not_AE_Candidate
( I-Not_AE_Candidate
WBC I-Not_AE_Candidate
) O
and O
history O
of O
drug B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
leukopenia/ O
neutropenia I-Not_AE_Candidate
. O

Patients O
with O
a O
history O
of O
a O
clinically O
significant O
low B-Not_AE_Candidate
WBC I-Not_AE_Candidate
or O
a O
drug B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
leukopenia I-Not_AE_Candidate
/neutropenia O
should O
have O
their O
complete O
blood O
count O
( O
CBC O
) O
monitored O
frequently O
during O
the O
first O
few O
months O
of O
therapy O
and O
discontinuation O
of O
RISPERDAL O
( O
r O
) O
should O
be O
considered O
at O
the O
first O
sign O
of O
a O
clinically O
significant O
decline B-NonOSE_AE
in I-NonOSE_AE
WBC I-NonOSE_AE
in O
the O
absence O
of O
other O
causative O
factors O
. O

Patients O
with O
clinically O
significant O
neutropenia B-NonOSE_AE
should O
be O
carefully O
monitored O
for O
fever B-NonOSE_AE
or O
other O
symptoms O
or O
signs O
of O
infection B-NonOSE_AE
and O
treated O
promptly O
if O
such O
symptoms O
or O
signs O
occur O
. O

Patients O
with O
severe O
neutropenia B-NonOSE_AE
( O
absolute B-NonOSE_AE
neutrophil I-NonOSE_AE
count I-NonOSE_AE
< I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
/ I-NonOSE_AE
mm I-NonOSE_AE
3 I-NonOSE_AE
) O
should O
discontinue O
RISPERDAL O
( O
r O
) O
and O
have O
their O
WBC O
followed O
until O
recovery O
. O

5.10 O
Potential O
for O
Cognitive B-OSE_Labeled_AE
and O
Motor O
Impairment I-OSE_Labeled_AE
Somnolence B-OSE_Labeled_AE
was O
a O
commonly O
reported O
adverse O
reaction O
associated O
with O
RISPERDAL O
( O
r O
) O
treatment O
, O
especially O
when O
ascertained O
by O
direct O
questioning O
of O
patients O
. O

This O
adverse O
reaction O
is O
dose-related O
, O
and O
in O
a O
study O
utilizing O
a O
checklist O
to O
detect O
adverse O
events O
, O
41 O
% O
of O
the O
high-dose O
patients O
( O
RISPERDAL O
( O
r O
) O
16 O
mg/day O
) O
reported O
somnolence B-OSE_Labeled_AE
compared O
to O
16 O
% O
of O
placebo O
patients O
. O

Direct O
questioning O
is O
more O
sensitive O
for O
detecting O
adverse O
events O
than O
spontaneous O
reporting O
, O
by O
which O
8 O
% O
of O
RISPERDAL O
( O
r O
) O
16 O
mg/day O
patients O
and O
1 O
% O
of O
placebo O
patients O
reported O
somnolence B-OSE_Labeled_AE
as O
an O
adverse O
reaction O
. O

Since O
RISPERDAL O
( O
r O
) O
has O
the O
potential O
to O
impair B-OSE_Labeled_AE
judgment I-OSE_Labeled_AE
, O
thinking O
, O
or O
motor O
skills O
, O
patients O
should O
be O
cautioned O
about O
operating O
hazardous O
machinery O
, O
including O
automobiles O
, O
until O
they O
are O
reasonably O
certain O
that O
RISPERDAL O
( O
r O
) O
therapy O
does O
not O
affect O
them O
adversely O
. O

5.11 O
Seizures O
During O
premarketing O
testing O
in O
adult O
patients O
with O
schizophrenia B-Not_AE_Candidate
, O
seizures B-OSE_Labeled_AE
occurred O
in O
0.3 O
% O
( O
9/2607 O
) O
of O
RISPERDAL O
( O
r O
) O
-treated O
patients O
, O
two O
in O
association O
with O
hyponatremia B-NonOSE_AE
. O

RISPERDAL O
( O
r O
) O
should O
be O
used O
cautiously O
in O
patients O
with O
a O
history O
of O
seizures B-Not_AE_Candidate
. O

5.12 O
Dysphagia B-OSE_Labeled_AE
Esophageal B-OSE_Labeled_AE
dysmotility I-OSE_Labeled_AE
and O
aspiration B-OSE_Labeled_AE
have O
been O
associated O
with O
antipsychotic O
drug O
use O
. O

Aspiration B-NonOSE_AE
pneumonia I-NonOSE_AE
is O
a O
common O
cause O
of O
morbidity O
and O
mortality O
in O
patients O
with O
advanced O
Alzheimer B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
dementia I-Not_AE_Candidate
. O

RISPERDAL O
( O
r O
) O
and O
other O
antipsychotic O
drugs O
should O
be O
used O
cautiously O
in O
patients O
at O
risk O
for O
aspiration B-NonOSE_AE
pneumonia I-NonOSE_AE
. O

[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
5.13 O
Priapism O
Priapism B-OSE_Labeled_AE
has O
been O
reported O
during O
postmarketing O
surveillance O
. O

Severe O
priapism B-NonOSE_AE
may O
require O
surgical O
intervention O
. O

5.14 O
Body O
Temperature O
Regulation O
Disruption B-OSE_Labeled_AE
of I-OSE_Labeled_AE
body I-OSE_Labeled_AE
temperature I-OSE_Labeled_AE
regulation I-OSE_Labeled_AE
has O
been O
attributed O
to O
antipsychotic O
agents O
. O

Both O
hyperthermia B-OSE_Labeled_AE
and O
hypothermia B-OSE_Labeled_AE
have O
been O
reported O
in O
association O
with O
oral O
RISPERDAL O
( O
r O
) O
use O
. O

Caution O
is O
advised O
when O
prescribing O
for O
patients O
who O
will O
be O
exposed O
to O
temperature O
extremes O
. O

5.15 O
Patients O
with O
Phenylketonuria O
Inform O
patients O
that O
RISPERDAL O
( O
r O
) O
M-TAB O
( O
r O
) O
Orally O
Disintegrating O
Tablets O
contain O
phenylalanine O
. O

Phenylalanine O
is O
a O
component O
of O
aspartame O
. O

Each O
4 O
mg O
RISPERDAL O
( O
r O
) O
M-TAB O
( O
r O
) O
Orally O
Disintegrating O
Tablet O
contains O
0.84 O
mg O
phenylalanine O
; O
each O
3 O
mg O
RISPERDAL O
( O
r O
) O
M-TAB O
( O
r O
) O
Orally O
Disintegrating O
Tablet O
contains O
0.63 O
mg O
phenylalanine O
; O
each O
2 O
mg O
RISPERDAL O
( O
r O
) O
M-TAB O
( O
r O
) O
Orally O
Disintegrating O
Tablet O
contains O
0.42 O
mg O
phenylalanine O
; O
each O
1 O
mg O
RISPERDAL O
( O
r O
) O
M-TAB O
( O
r O
) O
Orally O
Disintegrating O
Tablet O
contains O
0.28 O
mg O
phenylalanine O
; O
and O
each O
0.5 O
mg O
RISPERDAL O
( O
r O
) O
M-TAB O
( O
r O
) O
Orally O
Disintegrating O
Tablet O
contains O
0.14 O
mg O
phenylalanine O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
more O
detail O
in O
other O
sections O
of O
the O
prescribing O
information O
: O
* O
Vision B-OSE_Labeled_AE
Loss I-OSE_Labeled_AE
[ O
see O
BOXED O
WARNING O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Magnetic B-OSE_Labeled_AE
Resonance I-OSE_Labeled_AE
Imaging I-OSE_Labeled_AE
( I-OSE_Labeled_AE
MRI I-OSE_Labeled_AE
) I-OSE_Labeled_AE
Abnormalities I-OSE_Labeled_AE
in O
Infants O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Neurotoxicity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Suicidal B-OSE_Labeled_AE
Behavior I-OSE_Labeled_AE
and O
Ideation O
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Withdrawal B-NonOSE_AE
of O
Antiepileptic O
Drugs O
( O
AEDs O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Anemia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Somnolence B-OSE_Labeled_AE
and O
Fatigue B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Peripheral B-OSE_Labeled_AE
Neuropathy I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Weight B-OSE_Labeled_AE
Gain I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
* O
Edema B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
EXCERPT O
: O
Refractory O
Complex O
Partial O
Seizures O
Most O
common O
adverse O
reactions O
in O
controlled O
studies O
include O
: O
* O
Adults O
> O
16 O
years O
of O
age O
( O
change O
of O
> O
=5 O
% O
over O
placebo O
) O
: O
in O
addition O
to O
permanent O
vision O
loss O
, O
fatigue O
, O
somnolence O
, O
nystagmus O
, O
tremor O
, O
vision O
blurred O
, O
memory O
impairment O
, O
weight O
gain O
, O
arthralgia O
, O
abnormal O
coordination O
, O
and O
confusional O
state O
( O
6.1 O
) O
* O
Pediatrics O
10 O
to O
16 O
years O
of O
age O
( O
change O
of O
> O
=5 O
% O
over O
placebo O
) O
: O
increased O
weight O
, O
upper O
respiratory O
tract O
infection O
, O
tremor O
, O
fatigue O
, O
aggression O
and O
diplopia O
( O
6.1 O
) O
Infantile O
Spasms O
( O
incidence O
> O
5 O
% O
) O
* O
Somnolence O
, O
bronchitis O
, O
ear O
infection O
, O
and O
otitis O
media O
acute O
( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Lundbeck O
at O
1-800-455-1141 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trial O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Adverse O
Reactions O
in O
U O
. O

S O
. O

and O
Primary O
Non-U O
. O

S O
. O

Clinical O
Studies O
In O
U.S O
. O
and O
primary O
non-U.S O
. O
clinical O
studies O
of O
4,079 O
SABRIL O
treated O
patients O
, O
the O
most O
commonly O
observed O
( O
> O
=5 O
% O
) O
adverse O
reactions O
associated O
with O
the O
use O
of O
SABRIL O
in O
combination O
with O
other O
AEDs O
were O
headache B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
convulsion B-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
visual B-OSE_Labeled_AE
field I-OSE_Labeled_AE
defect I-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
nystagmus B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
memory B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
coordination B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
, O
diplopia B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
influenza B-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
, O
and O
rash B-OSE_Labeled_AE
. O

The O
adverse O
reactions O
most O
commonly O
associated O
with O
SABRIL O
treatment O
discontinuation O
in O
> O
=1 O
% O
of O
patients O
were O
convulsion B-OSE_Labeled_AE
and O
depression B-OSE_Labeled_AE
. O

In O
patients O
with O
infantile B-Not_AE_Candidate
spasms I-Not_AE_Candidate
, O
the O
adverse O
reactions O
most O
commonly O
associated O
with O
SABRIL O
treatment O
discontinuation O
in O
> O
=1 O
% O
of O
patients O
were O
infections B-OSE_Labeled_AE
, O
status B-OSE_Labeled_AE
epilepticus I-OSE_Labeled_AE
, O
developmental B-OSE_Labeled_AE
coordination I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
dystonia B-OSE_Labeled_AE
, O
hypotonia B-OSE_Labeled_AE
, O
hypertonia B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
and O
insomnia B-OSE_Labeled_AE
. O

Most O
Common O
Adverse O
Reactions O
in O
Controlled O
Clinical O
Trials O
Refractory B-Not_AE_Candidate
C I-Not_AE_Candidate
omplex I-Not_AE_Candidate
Partial I-Not_AE_Candidate
Seizures I-Not_AE_Candidate
Adults O
Table O
5 O
lists O
the O
treatment O
emergent O
adverse O
reactions O
that O
occurred O
in O
> O
=2 O
% O
and O
more O
than O
one O
patient O
per O
SABRIL O
treated O
group O
and O
that O
occurred O
more O
frequently O
than O
in O
placebo O
patients O
from O
2 O
U.S O
. O
add-on O
clinical O
studies O
of O
refractory B-Not_AE_Candidate
CPS I-Not_AE_Candidate
in O
adults O
. O

Table O
5 O
. O

Treatment O
Emergent O
Adverse O
Reactions O
Occurring O
in O
> O
=2 O
% O
and O
More O
than O
One O
Patient O
per O
SABRIL-Treated O
Group O
and O
More O
Frequently O
than O
in O
Placebo O
Patients O
( O
Studies O
024 O
and O
025 O
) O
SABRIL O
dosage O
( O
mg/day O
) O
Body O
System O
Adverse O
Reaction O
3000 O
[ O
N=134 O
] O
% O
6000 O
[ O
N=43 O
] O
% O
Placebo O
[ O
N=135 O
] O
% O
Ear B-NonOSE_AE
Disorders I-NonOSE_AE
Tinnitus B-OSE_Labeled_AE
2 O
0 O
1 O
Vertigo B-OSE_Labeled_AE
2 O
5 O
1 O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
13 O
16 O
5 O
Diplopia B-OSE_Labeled_AE
7 O
16 O
3 O
Asthenopia B-OSE_Labeled_AE
2 O
2 O
0 O
Eye B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
0 O
5 O
0 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Diarrhoea B-OSE_Labeled_AE
10 O
16 O
7 O
Nausea B-OSE_Labeled_AE
10 O
2 O
8 O
Vomiting B-OSE_Labeled_AE
7 O
9 O
6 O
Constipation B-OSE_Labeled_AE
8 O
5 O
3 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
5 O
5 O
1 O
Dyspepsia B-OSE_Labeled_AE
4 O
5 O
3 O
Stomach B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
4 O
2 O
1 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
3 O
2 O
1 O
Toothache B-OSE_Labeled_AE
2 O
5 O
2 O
Abdominal B-OSE_Labeled_AE
distension I-OSE_Labeled_AE
2 O
0 O
1 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
23 O
40 O
16 O
Gait B-OSE_Labeled_AE
disturbance I-OSE_Labeled_AE
6 O
12 O
7 O
Asthenia B-OSE_Labeled_AE
5 O
7 O
1 O
Oedema B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
5 O
7 O
1 O
Fever B-OSE_Labeled_AE
4 O
7 O
3 O
Chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
1 O
5 O
1 O
Thirst B-OSE_Labeled_AE
2 O
0 O
0 O
Malaise B-OSE_Labeled_AE
0 O
5 O
0 O
Infections B-NonOSE_AE
Nasopharyngitis B-OSE_Labeled_AE
14 O
9 O
10 O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
7 O
9 O
6 O
Influenza B-OSE_Labeled_AE
5 O
7 O
4 O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
4 O
5 O
0 O
Bronchitis B-OSE_Labeled_AE
0 O
5 O
1 O
Injury B-NonOSE_AE
Contusion B-OSE_Labeled_AE
3 O
5 O
2 O
Joint B-OSE_Labeled_AE
sprain I-OSE_Labeled_AE
1 O
2 O
1 O
Muscle B-OSE_Labeled_AE
strain I-OSE_Labeled_AE
1 O
2 O
1 O
Wound B-OSE_Labeled_AE
secretion I-OSE_Labeled_AE
0 O
2 O
0 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Increased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
1 O
5 O
1 O
Weight B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
6 O
14 O
3 O
Musculoskeletal B-NonOSE_AE
Disorders I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
10 O
5 O
3 O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
4 O
7 O
2 O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
6 O
2 O
4 O
Myalgia B-OSE_Labeled_AE
3 O
5 O
1 O
Muscle B-OSE_Labeled_AE
twitching I-OSE_Labeled_AE
1 O
9 O
1 O
Muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
3 O
0 O
1 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
33 O
26 O
31 O
Somnolence B-OSE_Labeled_AE
22 O
26 O
13 O
Dizziness B-OSE_Labeled_AE
24 O
26 O
17 O
Nystagmus B-OSE_Labeled_AE
13 O
19 O
9 O
Tremor B-OSE_Labeled_AE
15 O
16 O
8 O
Memory B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
7 O
16 O
3 O
Coordination B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
7 O
16 O
2 O
Disturbance B-OSE_Labeled_AE
in I-OSE_Labeled_AE
attention I-OSE_Labeled_AE
9 O
0 O
1 O
Sensory B-OSE_Labeled_AE
disturbance I-OSE_Labeled_AE
4 O
7 O
2 O
Hyporeflexia B-OSE_Labeled_AE
4 O
5 O
1 O
Paraesthesia B-OSE_Labeled_AE
7 O
2 O
1 O
Lethargy B-OSE_Labeled_AE
4 O
7 O
2 O
Hyperreflexia B-OSE_Labeled_AE
4 O
2 O
3 O
Hypoaesthesia B-OSE_Labeled_AE
4 O
5 O
1 O
Sedation B-OSE_Labeled_AE
4 O
0 O
0 O
Status B-OSE_Labeled_AE
epilepticus I-OSE_Labeled_AE
2 O
5 O
0 O
Dysarthria B-OSE_Labeled_AE
2 O
2 O
1 O
Postictal B-OSE_Labeled_AE
state I-OSE_Labeled_AE
2 O
0 O
1 O
Sensory B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
0 O
5 O
0 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Irritability B-OSE_Labeled_AE
7 O
23 O
7 O
Depression B-OSE_Labeled_AE
6 O
14 O
3 O
Confusional B-OSE_Labeled_AE
state I-OSE_Labeled_AE
4 O
14 O
1 O
Anxiety B-OSE_Labeled_AE
4 O
0 O
3 O
Depressed B-OSE_Labeled_AE
mood I-OSE_Labeled_AE
5 O
0 O
1 O
Thinking B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
3 O
7 O
0 O
Abnormal B-OSE_Labeled_AE
behaviour I-OSE_Labeled_AE
3 O
5 O
1 O
Expressive B-OSE_Labeled_AE
language I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
1 O
7 O
1 O
Nervousness B-OSE_Labeled_AE
2 O
5 O
2 O
Abnormal B-OSE_Labeled_AE
dreams I-OSE_Labeled_AE
1 O
5 O
1 O
Reproductive B-NonOSE_AE
System I-NonOSE_AE
Dysmenorrhoea B-OSE_Labeled_AE
9 O
5 O
3 O
Erectile B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
0 O
5 O
0 O
Respiratory B-NonOSE_AE
and I-NonOSE_AE
Thoracic I-NonOSE_AE
Disorders I-NonOSE_AE
Pharyngolaryngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
7 O
14 O
5 O
Cough B-OSE_Labeled_AE
2 O
14 O
7 O
Pulmonary B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
0 O
5 O
1 O
Sinus B-OSE_Labeled_AE
headache I-OSE_Labeled_AE
6 O
2 O
1 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
4 O
5 O
4 O
Pediatrics O
10 O
to O
16 O
years O
of O
age O
Table O
6 O
lists O
adverse O
reactions O
from O
controlled O
clinical O
studies O
of O
pediatric O
patients O
receiving O
SABRIL O
or O
placebo O
as O
add-on O
therapy O
for O
refractory O
complex B-Not_AE_Candidate
partial I-Not_AE_Candidate
seizures I-Not_AE_Candidate
. O

Adverse O
reactions O
that O
are O
listed O
occurred O
in O
at O
least O
2 O
% O
of O
SABRIL O
treated O
patients O
and O
more O
frequently O
than O
placebo O
. O

The O
median O
SABRIL O
dose O
was O
49.4 O
mg/kg O
, O
( O
range O
of O
8.0 O
- O
105.9 O
mg/kg O
) O
. O

Table O
6 O
. O

Treatment-Emergent O
Adverse O
Reactions O
Reported O
by O
> O
=2 O
% O
of O
Pediatric O
CPS O
Patients O
( O
10 O
to O
16 O
years O
of O
age O
) O
Treated O
with O
SABRIL O
and O
Higher O
than O
Placebo O
Body O
System O
Adverse O
Reaction O
All O
SABRIL O
[ O
N=109 O
] O
% O
Placebo O
[ O
N=46 O
] O
% O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Diplopia B-OSE_Labeled_AE
5 O
0 O
Vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
3 O
0 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Diarrhoea B-OSE_Labeled_AE
6 O
2 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
3 O
0 O
Constipation B-OSE_Labeled_AE
3 O
2 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
9 O
4 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
10 O
4 O
Influenza B-OSE_Labeled_AE
6 O
2 O
Otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
6 O
2 O
Investigations B-NonOSE_AE
Weight B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
17 O
2 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Somnolence B-OSE_Labeled_AE
6 O
2 O
Tremor B-OSE_Labeled_AE
6 O
0 O
Nystagmus B-OSE_Labeled_AE
5 O
2 O
Psychomotor B-OSE_Labeled_AE
hyperactivity I-OSE_Labeled_AE
4 O
2 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Abnormal B-OSE_Labeled_AE
behavior I-OSE_Labeled_AE
6 O
2 O
Aggression B-OSE_Labeled_AE
5 O
0 O
Disorientation B-OSE_Labeled_AE
4 O
0 O
Reproduction B-NonOSE_AE
and I-NonOSE_AE
Breast I-NonOSE_AE
Disorders I-NonOSE_AE
Dysmenorrhea B-OSE_Labeled_AE
3 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Acne B-OSE_Labeled_AE
3 O
0 O
Infantile B-Not_AE_Candidate
Spasms I-Not_AE_Candidate
In O
a O
randomized O
, O
placebo-controlled O
IS O
study O
with O
a O
5 O
day O
double-blind O
treatment O
phase O
( O
n=40 O
) O
, O
the O
adverse O
events O
reported O
by O
> O
5 O
% O
of O
patients O
receiving O
SABRIL O
and O
that O
occurred O
more O
frequently O
than O
in O
placebo O
patients O
, O
were O
somnolence B-OSE_Labeled_AE
( O
SABRIL O
45 O
% O
, O
placebo O
30 O
% O
) O
, O
bronchitis B-OSE_Labeled_AE
( O
SABRIL O
30 O
% O
, O
placebo O
15 O
% O
) O
, O
ear B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
SABRIL O
10 O
% O
, O
placebo O
5 O
% O
) O
, O
and O
otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
acute I-OSE_Labeled_AE
SABRIL O
10 O
% O
, O
placebo O
0 O
% O
) O
. O

In O
a O
dose O
response O
study O
of O
low-dose O
( O
18-36 O
mg/kg/day O
) O
versus O
high-dose O
( O
100-148 O
mg/kg/day O
) O
vigabatrin O
, O
no O
clear O
correlation O
between O
dose O
and O
incidence O
of O
adverse O
events O
was O
observed O
. O

The O
treatment O
emergent O
adverse O
reactions O
( O
> O
=5 O
% O
in O
either O
dose O
group O
) O
are O
summarized O
in O
Table O
7 O
. O

Table O
7 O
. O

Treatment O
Emergent O
Adverse O
Reactions O
Occurring O
in O
> O
=5 O
% O
of O
Infantile O
Spasms O
Patients O
SABRILLow O
Dose O
SABRIL O
High O
Dose O
Body O
System O
Adverse O
Reaction O
[ O
N=114 O
] O
% O
[ O
N=108 O
] O
% O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
( O
other O
than O
field O
or O
acuity O
changes O
) O
Strabismus B-OSE_Labeled_AE
5 O
5 O
Conjunctivitis B-OSE_Labeled_AE
5 O
2 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Vomiting B-OSE_Labeled_AE
14 O
20 O
Constipation B-OSE_Labeled_AE
14 O
12 O
Diarrhea B-OSE_Labeled_AE
13 O
12 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Fever B-OSE_Labeled_AE
29 O
19 O
Infections B-NonOSE_AE
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
51 O
46 O
Otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
44 O
30 O
Viral B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
20 O
19 O
Pneumonia B-OSE_Labeled_AE
13 O
11 O
Candidiasis B-OSE_Labeled_AE
8 O
3 O
Ear B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
7 O
14 O
Gastroenteritis B-OSE_Labeled_AE
viral I-OSE_Labeled_AE
6 O
5 O
Sinusitis B-OSE_Labeled_AE
5 O
9 O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
5 O
6 O
Influenza B-OSE_Labeled_AE
5 O
3 O
Croup B-OSE_Labeled_AE
infectious I-OSE_Labeled_AE
5 O
1 O
Metabolism B-NonOSE_AE
& I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
9 O
7 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Sedation B-OSE_Labeled_AE
19 O
17 O
Somnolence B-OSE_Labeled_AE
17 O
19 O
Status B-OSE_Labeled_AE
epilepticus I-OSE_Labeled_AE
6 O
4 O
Lethargy B-OSE_Labeled_AE
5 O
7 O
Convulsion B-OSE_Labeled_AE
4 O
7 O
Hypotonia B-OSE_Labeled_AE
4 O
6 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Irritability B-OSE_Labeled_AE
16 O
23 O
Insomnia B-OSE_Labeled_AE
10 O
12 O
Respiratory B-NonOSE_AE
Disorders I-NonOSE_AE
Nasal B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
13 O
4 O
Cough B-OSE_Labeled_AE
3 O
8 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
8 O
11 O
6.2 O
Post O
Marketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
reported O
during O
post O
approval O
use O
of O
SABRIL O
worldwide O
. O

All O
adverse O
reactions O
that O
are O
not O
listed O
above O
as O
adverse O
reactions O
reported O
in O
clinical O
trials O
, O
that O
are O
not O
relatively O
common O
in O
the O
population O
and O
are O
not O
too O
vague O
to O
be O
useful O
are O
listed O
in O
this O
section O
. O

These O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
; O
therefore O
, O
it O
is O
not O
possible O
to O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Adverse O
reactions O
are O
categorized O
by O
system O
organ O
class O
. O

Birth B-NonOSE_AE
Defects I-NonOSE_AE
: O
Congenital B-OSE_Labeled_AE
cardiac I-OSE_Labeled_AE
defects I-OSE_Labeled_AE
, O
congenital B-OSE_Labeled_AE
external I-OSE_Labeled_AE
ear I-OSE_Labeled_AE
anomaly I-OSE_Labeled_AE
, O
congenital B-OSE_Labeled_AE
hemangioma I-OSE_Labeled_AE
, O
congenital B-OSE_Labeled_AE
hydronephrosis I-OSE_Labeled_AE
, O
congenital B-OSE_Labeled_AE
male I-OSE_Labeled_AE
genital I-OSE_Labeled_AE
malformation I-OSE_Labeled_AE
, O
congenital B-OSE_Labeled_AE
oral I-OSE_Labeled_AE
malformation I-OSE_Labeled_AE
, O
congenital B-OSE_Labeled_AE
vesicoureteric I-OSE_Labeled_AE
reflux I-OSE_Labeled_AE
, O
dentofacial O
anomaly O
, O
dysmorphism O
, O
fetal O
anticonvulsant O
syndrome O
, O
hamartomas O
, O
hip O
dysplasia O
, O
limb O
malformation O
, O
limb O
reduction O
defect O
, O
low O
set O
ears O
, O
renal O
aplasia O
, O
retinitis O
pigmentosa O
, O
supernumerary O
nipple O
, O
talipes O
Ear B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Deafness B-OSE_Labeled_AE
Endocrine B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Delayed B-OSE_Labeled_AE
puberty I-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
esophagitis B-OSE_Labeled_AE
General B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Developmental B-OSE_Labeled_AE
delay I-OSE_Labeled_AE
, O
facial B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
malignant B-OSE_Labeled_AE
hyperthermia I-OSE_Labeled_AE
, O
multi B-OSE_Labeled_AE
- I-OSE_Labeled_AE
organ I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
Hepatobiliary B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Cholestasis B-OSE_Labeled_AE
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Dystonia B-OSE_Labeled_AE
, O
encephalopathy B-OSE_Labeled_AE
, O
hypertonia B-OSE_Labeled_AE
, O
hypotonia B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
spasticity I-OSE_Labeled_AE
, O
myoclonus B-OSE_Labeled_AE
, O
optic B-OSE_Labeled_AE
neuritis I-OSE_Labeled_AE
, O
dyskinesia B-OSE_Labeled_AE
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Acute B-OSE_Labeled_AE
psychosis I-OSE_Labeled_AE
, O
apathy B-OSE_Labeled_AE
, O
delirium B-OSE_Labeled_AE
, O
hypomania B-OSE_Labeled_AE
, O
neonatal B-OSE_Labeled_AE
agitation I-OSE_Labeled_AE
, O
psychotic B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
Respiratory B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Laryngeal B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
stridor B-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Angioedema B-OSE_Labeled_AE
, O
maculo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
papular I-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( O
SJS O
) O
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
( O
TEN O
) O

BOXED O
WARNING O
: O
WARNING O
: O
VISION O
LOSS O
WARNING O
: O
VISION O
LOSS O
* O
SABRIL O
causes O
permanent B-OSE_Labeled_AE
bilateral O
concentric O
visual I-OSE_Labeled_AE
field I-OSE_Labeled_AE
constriction I-OSE_Labeled_AE
. O

Because O
assessing O
vision O
may O
be O
difficult O
in O
infants O
and O
children O
, O
the O
frequency O
and O
extent O
of O
vision B-NonOSE_AE
loss I-NonOSE_AE
is O
poorly O
characterized O
in O
these O
patients O
. O

For O
this O
reason O
, O
the O
risk O
described O
below O
is O
primarily O
based O
on O
the O
adult O
experience O
. O

* O
Based O
upon O
adult O
studies O
, O
30 O
percent O
or O
more O
of O
patients O
can O
be O
affected O
, O
ranging O
in O
severity O
from O
mild O
to O
severe O
, O
including O
tunnel B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
to O
within B-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
degrees I-OSE_Labeled_AE
of I-OSE_Labeled_AE
visual I-OSE_Labeled_AE
fixation I-OSE_Labeled_AE
, O
and O
can O
result O
in O
disability O
. O

In O
some O
cases O
, O
SABRIL O
also O
can O
damage B-OSE_Labeled_AE
the I-OSE_Labeled_AE
central I-OSE_Labeled_AE
retina I-OSE_Labeled_AE
and O
may O
decrease B-OSE_Labeled_AE
visual I-OSE_Labeled_AE
acuity I-OSE_Labeled_AE
. O

* O
The O
onset O
of O
vision B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
from O
SABRIL O
is O
unpredictable O
, O
and O
can O
occur O
within O
weeks O
of O
starting O
treatment O
or O
sooner O
, O
or O
at O
any O
time O
after O
starting O
treatment O
, O
even O
after O
months O
or O
years O
. O

* O
Symptoms O
of O
vision B-NonOSE_AE
loss I-NonOSE_AE
from O
SABRIL O
are O
unlikely O
to O
be O
recognized O
by O
patients O
or O
caregivers O
before O
vision B-NonOSE_AE
loss I-NonOSE_AE
is O
severe O
. O

Vision B-NonOSE_AE
loss I-NonOSE_AE
of O
milder O
severity O
, O
while O
often O
unrecognized O
by O
the O
patient O
or O
caregiver O
, O
can O
still O
adversely O
affect O
function O
. O

* O
The O
risk O
of O
vision B-NonOSE_AE
loss I-NonOSE_AE
increases O
with O
increasing O
dose O
and O
cumulative O
exposure O
, O
but O
there O
is O
no O
dose O
or O
exposure O
known O
to O
be O
free O
of O
risk O
of O
vision B-NonOSE_AE
loss I-NonOSE_AE
. O

* O
Unless O
a O
patient O
is O
formally O
exempted O
from O
periodic O
ophthalmologic O
assessment O
as O
documented O
in O
the O
SHARE O
program O
, O
vision O
should O
be O
assessed O
to O
the O
extent O
possible O
at O
baseline O
( O
no O
later O
than O
4 O
weeks O
after O
starting O
SABRIL O
) O
and O
at O
least O
every O
3 O
months O
during O
therapy O
. O

Vision O
assessment O
is O
also O
required O
about O
3 O
to O
6 O
months O
after O
the O
discontinuation O
of O
SABRIL O
therapy O
. O

* O
Once O
detected O
, O
vision B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
due O
to O
SABRIL O
is O
not O
reversible O
. O

It O
is O
expected O
that O
, O
even O
with O
frequent O
monitoring O
, O
some O
patients O
will O
develop O
severe O
vision B-NonOSE_AE
loss I-NonOSE_AE
. O

* O
Drug O
discontinuation O
should O
be O
considered O
, O
balancing O
benefit O
and O
risk O
, O
if O
visual B-NonOSE_AE
loss I-NonOSE_AE
is O
documented O
. O

* O
It O
is O
possible O
that O
vision B-NonOSE_AE
loss I-NonOSE_AE
can O
worsen O
despite O
discontinuation O
of O
SABRIL O
. O

* O
Because O
of O
the O
risk O
of O
visual B-NonOSE_AE
loss I-NonOSE_AE
, O
SABRIL O
should O
be O
withdrawn O
from O
patients O
with O
refractory O
complex B-Not_AE_Candidate
partial I-Not_AE_Candidate
seizures I-Not_AE_Candidate
who O
fail O
to O
show O
substantial O
clinical O
benefit O
within O
3 O
months O
of O
initiation O
and O
within O
2-4 O
weeks O
of O
initiation O
for O
patients O
with O
infantile B-Not_AE_Candidate
spasms I-Not_AE_Candidate
, O
or O
sooner O
if O
treatment O
failure O
becomes O
obvious O
. O

Patient O
response O
to O
and O
continued O
need O
for O
SABRIL O
should O
be O
periodically O
reassessed O
. O

* O
SABRIL O
should O
not O
be O
used O
in O
patients O
with O
, O
or O
at O
high O
risk O
of O
, O
other O
types O
of O
irreversible B-Not_AE_Candidate
vision I-Not_AE_Candidate
loss I-Not_AE_Candidate
unless O
the O
benefits O
of O
treatment O
clearly O
outweigh O
the O
risks O
. O

The O
interaction O
of O
other O
types O
of O
irreversible B-Not_AE_Candidate
vision I-Not_AE_Candidate
damage I-Not_AE_Candidate
with O
vision B-NonOSE_AE
damage I-NonOSE_AE
from O
SABRIL O
has O
not O
been O
well-characterized O
, O
but O
is O
likely O
adverse O
. O

* O
SABRIL O
should O
not O
be O
used O
with O
other O
drugs O
associated O
with O
serious O
adverse B-NonOSE_AE
ophthalmic I-NonOSE_AE
effects I-NonOSE_AE
such O
as O
retinopathy B-NonOSE_AE
or O
glaucoma B-NonOSE_AE
unless O
the O
benefits O
clearly O
outweigh O
the O
risks O
. O

* O
The O
possibility O
that O
vision B-NonOSE_AE
loss I-NonOSE_AE
from O
SABRIL O
may O
be O
more O
common O
, O
more O
severe O
or O
have O
more O
severe O
functional O
consequences O
in O
infants O
and O
children O
than O
in O
adults O
can O
not O
be O
excluded O
. O

* O
The O
lowest O
dose O
and O
shortest O
exposure O
to O
SABRIL O
consistent O
with O
clinical O
objectives O
should O
be O
used O
. O

Because O
of O
the O
risk O
of O
permanent B-NonOSE_AE
vision I-NonOSE_AE
loss I-NonOSE_AE
, O
SABRIL O
is O
available O
only O
through O
a O
restricted O
program O
under O
a O
Risk O
Evaluation O
and O
Mitigation O
Strategy O
( O
REMS O
) O
called O
the O
SHARE O
Program O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Further O
information O
is O
available O
at O
[ O
www.sabril.net O
or O
1-888-45-SHARE O
] O
. O

EXCERPT O
: O
WARNING O
: O
VISION O
LOSS O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
SABRIL O
causes O
progressive O
and O
permanent O
bilateral O
concentric O
visual O
field O
constriction O
in O
a O
high O
percentage O
of O
patients O
. O

In O
some O
cases O
, O
SABRIL O
may O
also O
reduce O
visual O
acuity O
( O
5.1 O
) O
. O

* O
Risk O
increases O
with O
total O
dose O
and O
duration O
of O
use O
, O
but O
no O
exposure O
to O
SABRIL O
is O
known O
that O
is O
free O
of O
risk O
of O
vision O
loss O
( O
5.1 O
) O
. O

* O
Risk O
of O
new O
and O
worsening O
vision O
loss O
continues O
as O
long O
as O
SABRIL O
is O
used O
, O
and O
possibly O
after O
discontinuing O
SABRIL O
( O
5.1 O
) O
. O

* O
Unless O
a O
patient O
is O
formally O
exempted O
, O
periodic O
vision O
assessment O
is O
required O
for O
patients O
on O
SABRIL O
. O

However O
, O
this O
assessment O
can O
not O
always O
prevent O
vision O
damage O
( O
5.1 O
) O
. O

* O
SABRIL O
can O
cause O
permanent O
vision O
loss O
. O

SABRIL O
is O
available O
only O
through O
a O
restricted O
program O
called O
the O
SHARE O
Program O
( O
5.2 O
) O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Permanent O
vision O
loss O
: O
Baseline O
and O
periodic O
vision O
assessment O
is O
required O
( O
5.1 O
) O
* O
Abnormal O
MRI O
signal O
changes O
have O
been O
reported O
in O
some O
infants O
with O
IS O
receiving O
SABRIL O
( O
5.3 O
) O
* O
Suicidal O
behavior O
and O
ideation O
: O
Antiepileptic O
drugs O
, O
including O
SABRIL O
increase O
the O
risk O
of O
suicidal O
thoughts O
and O
behavior O
( O
5.5 O
) O
* O
Withdrawal O
of O
AEDs O
: O
Dose O
should O
be O
tapered O
gradually O
to O
avoid O
withdrawal O
seizures O
( O
5.6 O
) O
* O
Anemia O
: O
Monitor O
for O
symptoms O
of O
anemia O
( O
5.7 O
) O
* O
Somnolence O
and O
fatigue O
: O
Advise O
patients O
not O
to O
drive O
or O
operate O
machinery O
until O
they O
have O
gained O
sufficient O
experience O
on O
SABRIL O
( O
5.8 O
) O
5.1 O
Vision O
Loss O
Because O
of O
the O
risk O
of O
vision B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
and O
because O
, O
when O
it O
is O
effective O
, O
SABRIL O
provides O
an O
observable O
symptomatic O
benefit O
, O
patient O
response O
and O
continued O
need O
for O
treatment O
should O
be O
periodically O
assessed O
. O

In O
patients O
with O
refractory O
complex B-Not_AE_Candidate
partial I-Not_AE_Candidate
seizures I-Not_AE_Candidate
, O
SABRIL O
should O
be O
withdrawn O
if O
a O
substantial O
clinical O
benefit O
is O
not O
observed O
within O
3 O
months O
of O
initiating O
treatment O
. O

If O
, O
in O
the O
clinical O
judgment O
of O
the O
prescriber O
, O
evidence O
of O
treatment O
failure O
becomes O
obvious O
earlier O
than O
3 O
months O
, O
treatment O
should O
be O
discontinued O
at O
that O
time O
. O

In O
patients O
with O
infantile B-Not_AE_Candidate
spasms I-Not_AE_Candidate
, O
SABRIL O
should O
be O
withdrawn O
if O
a O
substantial O
clinical O
benefit O
is O
not O
observed O
within O
2 O
to O
4 O
weeks O
. O

If O
, O
in O
the O
clinical O
judgment O
of O
the O
prescriber O
, O
evidence O
of O
treatment O
failure O
becomes O
obvious O
earlier O
than O
2 O
to O
4 O
weeks O
, O
treatment O
should O
be O
discontinued O
at O
that O
time O
[ O
see O
BOXED O
WARNING O
] O
. O

Monitoring O
of O
Vision O
Monitoring O
of O
vision O
by O
an O
ophthalmic O
professional O
with O
expertise O
in O
visual O
field O
interpretation O
and O
the O
ability O
to O
perform O
dilated O
indirect O
ophthalmoscopy O
of O
the O
retina O
is O
required O
, O
unless O
a O
patient O
is O
formally O
exempted O
from O
periodic O
ophthalmologic O
assessment O
as O
documented O
in O
the O
Support O
, O
Help O
And O
Resources O
for O
Epilepsy B-NonOSE_AE
( O
SHARE O
) O
program O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Because O
vision O
testing O
in O
infants O
is O
difficult O
, O
vision B-NonOSE_AE
loss I-NonOSE_AE
may O
not O
be O
detected O
until O
it O
is O
severe O
. O

For O
patients O
receiving O
SABRIL O
who O
are O
not O
exempted O
, O
vision O
assessment O
is O
required O
at O
baseline O
( O
no O
later O
than O
4 O
weeks O
after O
starting O
SABRIL O
) O
and O
at O
least O
every O
3 O
months O
while O
on O
therapy O
and O
about O
3-6 O
months O
after O
the O
discontinuation O
of O
therapy O
. O

The O
diagnostic O
approach O
should O
be O
individualized O
for O
the O
patient O
and O
clinical O
situation O
. O

For O
all O
patients O
, O
attempts O
to O
monitor O
vision O
periodically O
and/or O
formal O
exemptions O
must O
be O
documented O
under O
the O
SHARE O
program O
. O

In O
adults O
and O
cooperative O
pediatric O
patients O
, O
perimetry O
is O
recommended O
, O
preferably O
by O
automated O
threshold O
visual O
field O
testing O
. O

Additional O
testing O
may O
also O
include O
electrophysiology O
( O
e.g. O
, O
electroretinography O
[ O
ERG O
] O
) O
, O
retinal O
imaging O
( O
e.g. O
, O
optical O
coherence O
tomography O
[ O
OCT O
] O
) O
, O
and/or O
other O
methods O
appropriate O
for O
the O
patient O
, O
but O
this O
additional O
testing O
is O
not O
required O
. O

In O
patients O
exempted O
from O
vision O
testing O
, O
treatment O
may O
continue O
according O
to O
clinical O
judgment O
, O
with O
appropriate O
patient O
counseling O
and O
with O
documentation O
in O
the O
SHARE O
program O
of O
the O
exemption O
. O

Because O
of O
variability O
, O
results O
from O
ophthalmic O
monitoring O
must O
be O
interpreted O
with O
caution O
, O
and O
repeat O
assessment O
is O
recommended O
if O
results O
are O
abnormal O
or O
uninterpretable O
. O

Repeat O
assessment O
in O
the O
first O
few O
weeks O
of O
treatment O
is O
recommended O
to O
establish O
if O
, O
and O
to O
what O
degree O
, O
reproducible O
results O
can O
be O
obtained O
, O
and O
to O
guide O
selection O
of O
appropriate O
ongoing O
monitoring O
for O
the O
patient O
. O

The O
onset O
and O
progression O
of O
vision B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
from O
SABRIL O
is O
unpredictable O
, O
and O
it O
may O
occur O
or O
worsen O
precipitously O
between O
assessments O
. O

Once O
detected O
, O
vision B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
due O
to O
SABRIL O
is O
not O
reversible O
. O

It O
is O
expected O
that O
even O
with O
frequent O
monitoring O
, O
some O
SABRIL O
patients O
will O
develop O
severe O
vision B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
. O

Drug O
discontinuation O
should O
be O
considered O
, O
balancing O
benefit O
and O
risk O
, O
if O
visual B-NonOSE_AE
loss I-NonOSE_AE
is O
documented O
. O

5.2 O
SABRIL O
SHARE O
Program O
SABRIL O
is O
available O
only O
through O
a O
restricted O
distribution O
program O
called O
the O
SHARE O
program O
, O
because O
of O
the O
risk O
of O
vision B-NonOSE_AE
loss I-NonOSE_AE
. O

Notable O
requirements O
components O
of O
the O
SHARE O
Program O
include O
the O
following O
: O
* O
* O
Assess O
vision O
prior O
to O
initiating O
therapy O
and O
then O
every O
3 O
months O
during O
therapy O
. O

* O
Remove O
patients O
from O
SABRIL O
therapy O
if O
the O
patients O
do O
not O
experience O
a O
meaningful O
reduction O
in O
seizures B-Not_AE_Candidate
. O

* O
* O
The O
patient O
is O
blind B-Not_AE_Candidate
( O
subsequent O
Ophthalmologic O
Assessment O
Forms O
do O
not O
need O
to O
be O
submitted O
to O
the O
REMS O
coordinating O
center O
) O
* O
The O
patient O
's O
general O
neurological B-Not_AE_Candidate
and I-Not_AE_Candidate
/ I-Not_AE_Candidate
or I-Not_AE_Candidate
mental I-Not_AE_Candidate
condition I-Not_AE_Candidate
permanently O
precludes O
the O
need O
for O
visual O
assessment O
( O
subsequent O
Ophthalmologic O
Assessment O
Forms O
do O
not O
need O
to O
be O
submitted O
to O
the O
REMS O
coordinating O
center O
) O
* O
The O
patient O
's O
general O
neurological B-Not_AE_Candidate
condition I-Not_AE_Candidate
temporarily O
precludes O
the O
ability O
to O
assess O
visual O
function O
. O

The O
evaluation O
, O
however O
, O
may O
be O
performed O
at O
a O
later O
time O
as O
clinically O
appropriate O
. O

* O
The O
patient O
's O
medical O
condition O
prevents O
visual O
assessment O
being O
performed O
safely O
* O
For O
other O
reasons O
specified O
by O
the O
prescriber O
The O
prescriber O
may O
, O
with O
appropriate O
documentation O
and O
caregiver O
counseling O
, O
exempt O
certain O
patients O
from O
vision O
assessment O
, O
using O
the O
Ophthalmologic O
Assessment O
Form O
, O
if O
: O
Prescribers O
must O
be O
certified O
with O
the O
program O
by O
enrolling O
and O
reviewing O
educational O
materials O
and O
comply O
with O
the O
following O
: O
* O
Patient/parent/legal O
guardian O
must O
understand O
the O
risks O
and O
benefits O
and O
sign O
a O
Patient-Prescriber O
Agreement O
. O

* O
Pharmacies O
that O
dispense O
SABRIL O
must O
be O
certified O
and O
agree O
to O
comply O
with O
the O
REMS O
requirements O
. O

Certified O
pharmacies O
must O
only O
dispense O
SABRIL O
to O
patients O
who O
are O
enrolled O
in O
the O
program O
. O

5.3 O
Magnetic O
Resonance O
Imaging O
( O
MRI O
) O
Abnormalities O
in O
Infants O
Abnormal B-OSE_Labeled_AE
MRI I-OSE_Labeled_AE
signal I-OSE_Labeled_AE
changes I-OSE_Labeled_AE
characterized O
by O
increased B-OSE_Labeled_AE
T I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
signal I-OSE_Labeled_AE
and O
restricted B-OSE_Labeled_AE
diffusion I-OSE_Labeled_AE
in I-OSE_Labeled_AE
a O
symmetric O
pattern O
involving O
the O
thalamus O
, O
basal O
ganglia O
, O
brain O
stem O
, O
and O
cerebellum I-OSE_Labeled_AE
have O
been O
observed O
in O
some O
infants O
treated O
with O
vigabatrin O
for O
infantile B-Not_AE_Candidate
spasms I-Not_AE_Candidate
. O

In O
a O
retrospective O
epidemiologic O
study O
in O
infants O
with O
IS B-Not_AE_Candidate
( O
N=205 O
) O
, O
the O
prevalence O
of O
these O
changes O
was O
22 O
% O
in O
vigabatrin O
treated O
patients O
versus O
4 O
% O
in O
patients O
treated O
with O
other O
therapies O
. O

In O
the O
study O
above O
, O
in O
post O
marketing O
experience O
, O
and O
in O
published O
literature O
reports O
, O
these O
changes O
generally O
resolved O
with O
discontinuation O
of O
treatment O
. O

In O
a O
few O
patients O
, O
the O
lesion O
resolved O
despite O
continued O
use O
. O

It O
has O
been O
reported O
that O
some O
infants O
exhibited O
coincident O
motor B-NonOSE_AE
abnormalities I-NonOSE_AE
, O
but O
no O
causal O
relationship O
has O
been O
established O
and O
the O
potential O
for O
long-term O
clinical O
sequelae O
has O
not O
been O
adequately O
studied O
. O

Neurotoxicity B-NonOSE_AE
( O
brain B-NonOSE_AE
histopathology I-NonOSE_AE
and O
neurobehavioral O
abnormalities I-NonOSE_AE
) O
was O
observed O
in O
rats O
exposed O
to O
vigabatrin O
during O
late O
gestation O
and O
the O
neonatal O
and O
juvenile O
periods O
of O
development O
. O

The O
relationship O
between O
these O
findings O
and O
the O
abnormal B-NonOSE_AE
MRI I-NonOSE_AE
findings I-NonOSE_AE
in O
infants O
treated O
with O
vigabatrin O
for O
infantile B-Not_AE_Candidate
spasms I-Not_AE_Candidate
is O
unknown O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

The O
specific O
pattern O
of O
signal O
changes O
observed O
in O
IS B-Not_AE_Candidate
patients O
was O
not O
observed O
in O
older O
pediatric O
and O
adult O
patients O
treated O
with O
vigabatrin O
for O
refractory B-Not_AE_Candidate
CPS I-Not_AE_Candidate
. O

In O
a O
blinded O
review O
of O
MRI O
images O
obtained O
in O
prospective O
clinical O
trials O
in O
patients O
with O
refractory B-Not_AE_Candidate
CPS I-Not_AE_Candidate
3 O
years O
and O
older O
( O
N=656 O
) O
, O
no O
difference O
was O
observed O
in O
anatomic O
distribution O
or O
prevalence O
of O
MRI B-NonOSE_AE
signal I-NonOSE_AE
changes I-NonOSE_AE
between O
vigabatrin O
treated O
and O
placebo O
treated O
patients O
. O

For O
adults O
treated O
with O
SABRIL O
, O
routine O
MRI O
surveillance O
is O
unnecessary O
as O
there O
is O
no O
evidence O
that O
vigabatrin O
causes O
MRI B-NonOSE_AE
changes I-NonOSE_AE
in O
this O
population O
. O

5.4 O
Neurotoxicity O
Vacuolation B-NonOSE_AE
, O
characterized O
by O
fluid O
accumulation O
and O
separation O
of I-NonOSE_AE
the I-NonOSE_AE
outer I-NonOSE_AE
layers I-NonOSE_AE
of I-NonOSE_AE
myelin I-NonOSE_AE
, O
has O
been O
observed O
in I-NonOSE_AE
brain I-NonOSE_AE
white I-NonOSE_AE
matter I-NonOSE_AE
tracts I-NonOSE_AE
in O
adult O
and O
juvenile O
rats O
and O
adult O
mice O
, O
dogs O
, O
and O
possibly O
monkeys O
following O
administration O
of O
vigabatrin O
. O

This O
lesion O
, O
referred O
to O
as O
intramyelinic B-NonOSE_AE
edema I-NonOSE_AE
( O
IME O
) O
, O
was O
seen O
in O
animals O
at O
doses O
within O
the O
human O
therapeutic O
range O
. O

A O
no-effect O
dose O
was O
not O
established O
in O
rodents O
or O
dogs O
. O

In O
the O
rat O
and O
dog O
, O
vacuolation B-NonOSE_AE
was O
reversible O
following O
discontinuation O
of O
vigabatrin O
treatment O
, O
but O
, O
in O
the O
rat O
, O
pathologic O
changes O
consisting O
of O
swollen B-NonOSE_AE
or O
degenerating O
axons I-NonOSE_AE
, O
m O
in I-NonOSE_AE
eralization O
, O
and O
gliosis O
were O
seen O
in O
brain I-NonOSE_AE
areas O
in O
which O
vacuolation B-NonOSE_AE
had O
been O
previously O
observed O
. O

Vacuolation B-NonOSE_AE
in O
adult O
animals O
was O
correlated O
with O
alterations B-NonOSE_AE
in I-NonOSE_AE
MRI I-NonOSE_AE
and O
changes B-NonOSE_AE
in O
visual O
and O
somatosensory I-NonOSE_AE
evoked I-NonOSE_AE
potentials I-NonOSE_AE
( O
EP O
) O
. O

Administration O
of O
vigabatrin O
to O
rats O
during O
the O
neonatal O
and O
juvenile O
periods O
of O
development O
produced O
vacuolar B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
the O
brain O
gray O
matter O
( O
areas O
including O
the O
thalamus O
, O
midbrain O
, O
deep O
cerebellar O
nuclei O
, O
substantia O
nigra O
, O
hippocampus O
, O
and O
forebrain I-NonOSE_AE
) O
which O
are O
considered O
distinct O
from O
the O
IME O
observed O
in O
vigabatrin O
treated O
adult O
animals O
. O

Decreased B-NonOSE_AE
myelination I-NonOSE_AE
and O
evidence O
of O
oligodendrocyte O
in I-NonOSE_AE
jury O
were O
additional O
findings O
in O
the I-NonOSE_AE
brains I-NonOSE_AE
of O
vigabatrin-treated O
rats O
. O

An O
increase B-NonOSE_AE
in I-NonOSE_AE
apoptosis I-NonOSE_AE
was O
seen O
in I-NonOSE_AE
some O
brain I-NonOSE_AE
regions O
following O
vigabatrin O
exposure O
during O
the O
early O
postnatal O
period O
. O

Long-term O
neurobehavioral B-NonOSE_AE
abnormalities I-NonOSE_AE
( O
convulsions B-NonOSE_AE
, O
neuromotor B-NonOSE_AE
impairment I-NonOSE_AE
, O
learning B-NonOSE_AE
deficits I-NonOSE_AE
) O
were O
also O
observed O
following O
vigabatrin O
treatment O
of O
young O
rats O
. O

These O
effects O
in O
young O
animals O
occurred O
at O
doses O
lower O
than O
those O
producing O
neurotoxicity B-NonOSE_AE
in O
adult O
animals O
and O
were O
associated O
with O
plasma O
vigabatrin O
levels O
substantially O
lower O
than O
those O
achieved O
clinically O
in O
infants O
and O
children O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

In O
a O
published O
study O
, O
vigabatrin O
( O
200 O
, O
400 O
mg/kg/day O
) O
induced O
apoptotic B-NonOSE_AE
neurodegeneration I-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
brain I-NonOSE_AE
of O
young O
rats O
when O
administered O
by O
intraperitoneal O
injection O
on O
postnatal O
days O
5-7 O
. O

Administration O
of O
vigabatrin O
to O
female O
rats O
during O
pregnancy B-NonOSE_AE
and O
lactation O
at O
doses O
below O
those O
used O
clinically O
resulted O
in O
hippocampal B-NonOSE_AE
vacuolation I-NonOSE_AE
and O
convulsions O
in I-NonOSE_AE
the O
mature O
offspring I-NonOSE_AE
. O

Abnormal B-OSE_Labeled_AE
MRI I-OSE_Labeled_AE
signal I-OSE_Labeled_AE
changes O
characterized O
by O
in I-OSE_Labeled_AE
creased O
T2 O
signal O
and O
restricted O
diffusio O
n B-OSE_Labeled_AE
in I-OSE_Labeled_AE
a I-OSE_Labeled_AE
symmetric I-OSE_Labeled_AE
patter I-OSE_Labeled_AE
n O
involving O
the O
thalamus I-OSE_Labeled_AE
, O
basal O
ganglia O
, O
brain O
stem O
, O
and O
cerebellum I-OSE_Labeled_AE
have O
been O
observed O
in O
some O
infants O
treated O
for O
IS B-Not_AE_Candidate
with O
vigabatrin O
. O

Studies O
of O
the O
effects O
of O
vigabatrin O
on O
MRI O
and O
EP O
in O
adult O
epilepsy B-Not_AE_Candidate
patients O
have O
demonstrated O
no O
clear-cut O
abnormalities O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

5.5 O
Suicidal O
Behavior O
and O
Ideation O
Antiepileptic O
drugs O
( O
AEDs O
) O
, O
including O
SABRIL O
, O
increase O
the O
risk O
of O
suicidal B-OSE_Labeled_AE
thoughts I-OSE_Labeled_AE
or O
behavior O
in O
patients O
taking O
these O
drugs O
for O
any O
indication O
. O

Patients O
treated O
with O
any O
AED O
for O
any O
indication O
should O
be O
monitored O
for O
the O
emergence O
or O
worsening B-NonOSE_AE
of I-NonOSE_AE
depression I-NonOSE_AE
, O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
or O
behavior O
, O
and/or O
any O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
mood I-NonOSE_AE
or O
behavior O
. O

Pooled O
analyses O
of O
199 O
placebo-controlled O
clinical O
trials O
( O
mono- O
and O
adjunctive O
therapy O
) O
of O
11 O
different O
AEDs O
showed O
that O
patients O
randomized O
to O
one O
of O
the O
AEDs O
had O
approximately O
twice O
the O
risk O
( O
adjusted O
Relative O
Risk O
1.8 O
, O
95 O
% O
CI O
: O
1.2 O
, O
2.7 O
) O
of O
suicidal B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
or O
behavior O
compared O
to O
patients O
randomized O
to O
placebo O
. O

In O
these O
trials O
, O
which O
had O
a O
median O
treatment O
duration O
of O
12 O
weeks O
, O
the O
estimated O
incidence O
rate O
of O
suicidal B-OSE_Labeled_AE
behavior I-OSE_Labeled_AE
or O
ideation O
among O
27,863 O
AED O
treated O
patients O
was O
0.43 O
% O
, O
compared O
to O
0.24 O
% O
among O
16,029 O
placebo O
treated O
patients O
, O
representing O
an O
increase O
of O
approximately O
one O
case O
of O
suicidal B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
or O
behavior O
for O
every O
530 O
patients O
treated O
. O

There O
were O
four O
suicides B-OSE_Labeled_AE
in O
drug O
treated O
patients O
in O
the O
trials O
and O
none O
in O
placebo O
treated O
patients O
, O
but O
the O
number O
is O
too O
small O
to O
allow O
any O
conclusion O
about O
drug O
effect O
on O
suicide B-NonOSE_AE
. O

The O
increased O
risk O
of O
suicidal B-OSE_Labeled_AE
thoughts I-OSE_Labeled_AE
or O
behavior O
with O
AEDs O
was O
observed O
as O
early O
as O
one O
week O
after O
starting O
drug O
treatment O
with O
AEDs O
and O
persisted O
for O
the O
duration O
of O
treatment O
assessed O
. O

Because O
most O
trials O
included O
in O
the O
analysis O
did O
not O
extend O
beyond O
24 O
weeks O
, O
the O
risk O
of O
suicidal B-NonOSE_AE
thoughts O
or O
behavior I-NonOSE_AE
beyond O
24 O
weeks O
could O
not O
be O
assessed O
. O

The O
risk O
of O
suicidal B-NonOSE_AE
thoughts O
or O
behavior I-NonOSE_AE
was O
generally O
consistent O
among O
drugs O
in O
the O
data O
analyzed O
. O

The O
finding O
of O
increased O
risk O
with O
AEDs O
of O
varying O
mechanisms O
of O
action O
and O
across O
a O
range O
of O
indications O
suggests O
that O
the O
risk O
applies O
to O
all O
AEDs O
used O
for O
any O
indication O
. O

The O
risk O
did O
not O
vary O
substantially O
by O
age O
( O
5-100 O
years O
) O
in O
the O
clinical O
trials O
analyzed O
. O

Table O
4 O
shows O
absolute O
and O
relative O
risk O
by O
indication O
for O
all O
evaluated O
AEDs O
. O

Table O
4 O
. O

Risk O
by O
Indication O
for O
Antiepileptic O
Drugs O
in O
the O
Pooled O
Analysis O
Indication O
Placebo O
Patients O
with O
Events O
per O
1000 O
Patients O
Drug O
Patients O
with O
Events O
per O
1000 O
Patients O
Relative O
Risk O
: O
Incidence O
of O
Drug O
Events O
in O
Drug O
Patients/Incidence O
in O
Placebo O
Patients O
Risk O
Difference O
: O
Additional O
Drug O
Patients O
with O
Events O
per O
1000 O
Patients O
Epilepsy B-Not_AE_Candidate
1.0 O
3.4 O
3.5 O
2.4 O
Psychiatric B-Not_AE_Candidate
5.7 O
8.5 O
1.5 O
2.9 O
Other O
1.0 O
1.8 O
1.9 O
0.9 O
Total O
2.4 O
4.3 O
1.8 O
1.9 O
The O
relative O
risk O
for O
suicidal B-OSE_Labeled_AE
thoughts I-OSE_Labeled_AE
or O
behavior O
was O
higher O
in O
clinical O
trials O
for O
epilepsy B-Not_AE_Candidate
than O
in O
clinical O
trials O
for O
psychiatric O
or O
other O
conditions O
, O
but O
the O
absolute O
risk O
differences O
were O
similar O
for O
the O
epilepsy B-Not_AE_Candidate
and O
psychiatric B-Not_AE_Candidate
indications O
. O

Anyone O
considering O
prescribing O
SABRIL O
or O
any O
other O
AED O
must O
balance O
the O
risk O
of O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
or O
behavior O
with O
the O
risk O
of O
untreated O
illness O
. O

Epilepsy B-Not_AE_Candidate
and O
many O
other O
illnesses O
for O
which O
AEDs O
are O
prescribed O
are O
themselves O
associated O
with O
morbidity O
and O
mortality B-NonOSE_AE
and O
an O
increased O
risk O
of O
suicidal B-Not_AE_Candidate
thoughts I-Not_AE_Candidate
and O
behavior O
. O

Should O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
and O
behavior O
emerge O
during O
treatment O
, O
the O
prescriber O
needs O
to O
consider O
whether O
the O
emergence O
of O
these O
symptoms O
in O
any O
given O
patient O
may O
be O
related O
to O
the O
illness O
being O
treated O
. O

Patients O
, O
their O
caregivers O
, O
and O
families O
should O
be O
informed O
that O
AEDs O
increase O
the O
risk O
of O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
and O
behavior O
and O
should O
be O
advised O
of O
the O
need O
to O
be O
alert O
for O
the O
emergence O
or O
worsening B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
signs I-NonOSE_AE
and I-NonOSE_AE
symptoms I-NonOSE_AE
of I-NonOSE_AE
depression I-NonOSE_AE
, O
any O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
mood I-NonOSE_AE
or O
behavior O
, O
or O
the O
emergence O
of O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
, O
behavior O
, O
or O
thoughts B-NonOSE_AE
about I-NonOSE_AE
self I-NonOSE_AE
- I-NonOSE_AE
harm I-NonOSE_AE
. O

Behaviors O
of O
concern O
should O
be O
reported O
immediately O
to O
healthcare O
providers O
. O

5.6 O
Withdrawal O
of O
Antiepileptic O
Drugs O
( O
AEDs O
) O
As O
with O
all O
AEDs O
, O
SABRIL O
should O
be O
withdrawn O
gradually O
. O

Patients O
and O
caregivers O
should O
be O
told O
not O
to O
suddenly O
discontinue O
SABRIL O
therapy O
. O

In O
controlled O
clinical O
studies O
in O
adults O
with O
complex B-Not_AE_Candidate
partial I-Not_AE_Candidate
seizures I-Not_AE_Candidate
, O
SABRIL O
was O
tapered O
by O
decreasing O
the O
daily O
dose O
1000 O
mg/day O
on O
a O
weekly O
basis O
until O
discontinued O
. O

In O
a O
controlled O
study O
in O
pediatric O
patients O
with O
complex B-Not_AE_Candidate
partial I-Not_AE_Candidate
seizures I-Not_AE_Candidate
, O
SABRIL O
was O
tapered O
by O
decreasing O
the O
daily O
dose O
by O
one O
third O
every O
week O
for O
three O
weeks O
. O

In O
a O
controlled O
clinical O
study O
in O
patients O
with O
infantile B-Not_AE_Candidate
spasms I-Not_AE_Candidate
, O
SABRIL O
was O
tapered O
by O
decreasing O
the O
daily O
dose O
at O
a O
rate O
of O
25-50 O
mg/kg O
every O
3-4 O
days O
[ O
see O
Dosage O
and O
Administration O
( O
2.1 O
) O
] O
. O

5.7 O
Anemia O
In O
North O
American O
controlled O
trials O
in O
adults O
, O
6 O
% O
of O
patients O
( O
16/280 O
) O
receiving O
SABRIL O
and O
2 O
% O
of O
patients O
( O
3/188 O
) O
receiving O
placebo O
had O
adverse O
events O
of O
anemia B-OSE_Labeled_AE
and/or O
met O
criteria O
for O
potentially O
clinically O
important O
hematology B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
involving O
hemoglobin O
, O
hematocrit O
, O
and/or O
RBC O
indices O
. O

Across O
U.S O
. O
controlled O
trials O
, O
there O
were O
mean O
decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
of O
about O
3 O
% O
and O
0 O
% O
in O
SABRIL O
and O
placebo O
treated O
patients O
, O
respectively O
, O
and O
a O
mean O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hematocrit I-OSE_Labeled_AE
of O
about O
1 O
% O
in O
SABRIL O
treated O
patients O
compared O
to O
a O
mean O
gain O
of O
about O
1 O
% O
in O
patients O
treated O
with O
placebo O
. O

In O
controlled O
and O
open O
label O
epilepsy B-Not_AE_Candidate
trials O
in O
adults O
and O
pediatric O
patients O
, O
3 O
SABRIL O
patients O
( O
0.06 O
% O
, O
3/4855 O
) O
discontinued O
for O
anemia B-OSE_Labeled_AE
and O
2 O
SABRIL O
patients O
experienced O
unexplained O
declines B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
to O
below O
8 O
g/dL O
and/or O
hematocrit O
below O
24 O
% O
. O

5.8 O
Somnolence O
and O
Fatigue O
SABRIL O
causes O
somnolence B-OSE_Labeled_AE
and O
fatigue B-OSE_Labeled_AE
. O

Patients O
should O
be O
advised O
not O
to O
drive O
a O
car O
or O
operate O
other O
complex O
machinery O
until O
they O
are O
familiar O
with O
the O
effects O
of O
SABRIL O
on O
their O
ability O
to O
perform O
such O
activities O
. O

Pooled O
data O
from O
two O
SABRIL O
controlled O
trials O
in O
adults O
demonstrated O
that O
24 O
% O
( O
54/222 O
) O
of O
SABRIL O
patients O
experienced O
somnolence B-OSE_Labeled_AE
compared O
to O
10 O
% O
( O
14/135 O
) O
of O
placebo O
patients O
. O

In O
those O
same O
studies O
, O
28 O
% O
of O
SABRIL O
patients O
experienced O
fatigue B-OSE_Labeled_AE
compared O
to O
15 O
% O
( O
20/135 O
) O
of O
placebo O
patients O
. O

Almost O
1 O
% O
of O
SABRIL O
patients O
discontinued O
from O
clinical O
trials O
for O
somnolence B-OSE_Labeled_AE
and O
almost O
1 O
% O
discontinued O
for O
fatigue B-OSE_Labeled_AE
. O

Pooled O
data O
from O
three O
SABRIL O
controlled O
trials O
in O
pediatric O
patients O
demonstrated O
that O
6 O
% O
( O
10/165 O
) O
of O
SABRIL O
patients O
experienced O
somnolence B-OSE_Labeled_AE
compared O
to O
5 O
% O
( O
5/104 O
) O
of O
placebo O
patients O
. O

In O
those O
same O
studies O
, O
10 O
% O
( O
17/165 O
) O
of O
SABRIL O
patients O
experienced O
fatigue B-OSE_Labeled_AE
compared O
to O
7 O
% O
( O
7/104 O
) O
of O
placebo O
patients O
. O

No O
SABRIL O
patients O
discontinued O
from O
clinical O
trials O
due O
to O
somnolence B-NonOSE_AE
or O
fatigue B-NonOSE_AE
. O

5.9 O
Peripheral O
Neuropathy O
SABRIL O
causes O
symptoms O
of O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
in O
adults O
. O

Pediatric O
clinical O
trials O
were O
not O
designed O
to O
assess O
symptoms O
of O
peripheral B-NonOSE_AE
neuropathy I-NonOSE_AE
, O
but O
observed O
incidence O
of O
symptoms O
based O
on O
pooled O
data O
from O
controlled O
pediatric O
studies O
appeared O
similar O
for O
pediatric O
patients O
on O
vigabatrin O
and O
placebo O
. O

In O
a O
pool O
of O
North O
American O
controlled O
and O
uncontrolled O
epilepsy B-Not_AE_Candidate
studies O
, O
4.2 O
% O
( O
19/457 O
) O
of O
SABRIL O
patients O
developed O
signs O
and/or O
symptoms O
of O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
. O

In O
the O
subset O
of O
North O
American O
placebo-controlled O
epilepsy O
trials O
, O
1.4 O
% O
( O
4/280 O
) O
of O
SABRIL O
treated O
patients O
and O
no O
( O
0/188 O
) O
placebo O
patients O
developed O
signs O
and/or O
symptoms O
of O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
. O

Initial O
manifestations O
of O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
in O
these O
trials O
included O
, O
in O
some O
combination O
, O
symptoms O
of O
numbness B-NonOSE_AE
or O
tingling O
in O
the O
toes I-NonOSE_AE
or O
feet O
, O
signs O
of O
reduced B-NonOSE_AE
distal I-NonOSE_AE
lower I-NonOSE_AE
limb I-NonOSE_AE
vibration I-NonOSE_AE
or O
position O
sensation O
, O
or O
progressive B-NonOSE_AE
loss I-NonOSE_AE
of I-NonOSE_AE
reflexes I-NonOSE_AE
, O
starting O
at O
the O
ankles O
. O

Clinical O
studies O
in O
the O
development O
program O
were O
not O
designed O
to O
investigate O
peripheral B-NonOSE_AE
neuropathy I-NonOSE_AE
systematically O
and O
did O
not O
include O
nerve O
conduction O
studies O
, O
quantitative O
sensory O
testing O
, O
or O
skin O
or O
nerve O
biopsy O
. O

There O
is O
insufficient O
evidence O
to O
determine O
if O
development O
of O
these O
signs O
and O
symptoms O
were O
related O
to O
duration O
of O
SABRIL O
treatment O
, O
cumulative O
dose O
, O
or O
if O
the O
findings O
of O
peripheral B-NonOSE_AE
neuropathy I-NonOSE_AE
were O
completely O
reversible O
upon O
discontinuation O
of O
SABRIL O
. O

5.10 O
Weight O
Gain O
SABRIL O
causes O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
in O
adult O
and O
pediatric O
patients O
. O

Data O
pooled O
from O
randomized O
controlled O
trials O
in O
adults O
found O
that O
17 O
% O
( O
77/443 O
) O
of O
SABRIL O
patients O
versus O
8 O
% O
( O
22/275 O
) O
of O
placebo O
patients O
gained B-OSE_Labeled_AE
> O
=7 O
% O
of O
baseline O
body O
weight I-OSE_Labeled_AE
. O

In O
these O
same O
trials O
, O
the O
mean O
weight O
change O
among O
SABRIL O
patients O
was O
3.5 O
kg O
compared O
to O
1.6 O
kg O
for O
placebo O
patients O
. O

Data O
pooled O
from O
randomized O
controlled O
trials O
in O
pediatric O
patients O
with O
refractory O
complex B-Not_AE_Candidate
partial I-Not_AE_Candidate
seizures I-Not_AE_Candidate
found O
that O
47 O
% O
( O
77/163 O
) O
of O
SABRIL O
patients O
versus O
19 O
% O
( O
19/102 O
) O
of O
placebo O
patients O
gained B-OSE_Labeled_AE
> O
=7 O
% O
of O
baseline O
body O
weight I-OSE_Labeled_AE
. O

In O
all O
epilepsy B-Not_AE_Candidate
trials O
, O
0.6 O
% O
( O
31/4855 O
) O
of O
SABRIL O
patients O
discontinued O
for O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
. O

The O
long O
term O
effects O
of O
SABRIL O
related O
weight B-NonOSE_AE
gain I-NonOSE_AE
are O
not O
known O
. O

Weight B-NonOSE_AE
gain I-NonOSE_AE
was O
not O
related O
to O
the O
occurrence O
of O
edema B-NonOSE_AE
. O

5.11 O
Edema O
SABRIL O
causes O
edema B-OSE_Labeled_AE
in O
adults O
. O

Pediatric O
clinical O
trials O
were O
not O
designed O
to O
assess O
edema B-NonOSE_AE
, O
but O
observed O
incidence O
of O
edema B-NonOSE_AE
based O
pooled O
data O
from O
controlled O
pediatric O
studies O
appeared O
similar O
for O
pediatric O
patients O
on O
vigabatrin O
and O
placebo O
. O

Pooled O
data O
from O
controlled O
trials O
demonstrated O
increased O
risk O
among O
SABRIL O
patients O
compared O
to O
placebo O
patients O
for O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
( O
SABRIL O
2 O
% O
, O
placebo O
1 O
% O
) O
, O
and O
edema B-OSE_Labeled_AE
( O
SABRIL O
1 O
% O
, O
placebo O
0 O
% O
) O
. O

In O
these O
studies O
, O
one O
SABRIL O
and O
no O
placebo O
patients O
discontinued O
for O
an O
edema B-OSE_Labeled_AE
related O
AE O
. O

In O
adults O
, O
there O
was O
no O
apparent O
association O
between O
edema B-NonOSE_AE
and O
cardiovascular B-NonOSE_AE
adverse I-NonOSE_AE
events I-NonOSE_AE
such O
as O
hypertension B-NonOSE_AE
or O
congestive B-NonOSE_AE
heart I-NonOSE_AE
failure I-NonOSE_AE
. O

Edema B-NonOSE_AE
was O
not O
associated O
with O
laboratory B-NonOSE_AE
changes I-NonOSE_AE
suggestive O
of O
deterioration B-NonOSE_AE
in I-NonOSE_AE
renal O
or O
hepatic I-NonOSE_AE
function I-NonOSE_AE
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
The O
most O
frequently O
occurring O
adverse O
reactions O
( O
> O
= O
5 O
% O
and O
greater O
than O
placebo O
) O
were O
nausea O
, O
headache O
, O
constipation O
, O
dizziness O
, O
insomnia O
, O
hot O
flush O
, O
hyperhidrosis O
, O
vomiting O
, O
palpitations O
, O
heart O
rate O
increased O
, O
dry O
mouth O
, O
and O
hypertension O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Forest O
Laboratories O
, O
LLC. O
, O
at O
( O
800 O
) O
678-1605 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Patient O
Exposure O
Savella O
was O
evaluated O
in O
three O
double-blind O
placebo-controlled O
trials O
involving O
2209 O
fibromyalgia B-Not_AE_Candidate
patients O
( O
1557 O
patients O
treated O
with O
Savella O
and O
652 O
patients O
treated O
with O
placebo O
) O
for O
a O
treatment O
period O
up O
to O
29 O
weeks O
. O

The O
stated O
frequencies O
of O
adverse O
reactions O
represent O
the O
proportion O
of O
individuals O
who O
experienced O
, O
at O
least O
once O
, O
a O
treatment-emergent O
adverse O
reaction O
of O
the O
type O
listed O
. O

A O
reaction O
was O
considered O
treatment O
emergent O
if O
it O
occurred O
for O
the O
first O
time O
or O
worsened O
while O
receiving O
therapy O
following O
baseline O
evaluation O
. O

Adverse O
Reactions O
Leading O
to O
Discontinuation O
In O
placebo-controlled O
trials O
in O
patients O
with O
fibromyalgia B-Not_AE_Candidate
, O
23 O
% O
of O
patients O
treated O
with O
Savella O
100 O
mg/day O
, O
26 O
% O
of O
patients O
treated O
with O
Savella O
200 O
mg/day O
discontinued O
prematurely O
due O
to O
adverse O
reactions O
, O
compared O
to O
12 O
% O
of O
patients O
treated O
with O
placebo O
. O

The O
adverse O
reactions O
that O
led O
to O
withdrawal B-NonOSE_AE
in O
> O
= O
1 O
% O
of O
patients O
in O
the O
Savella O
treatment O
group O
and O
with O
an O
incidence O
rate O
greater O
than O
that O
in O
the O
placebo O
treatment O
group O
were O
nausea B-OSE_Labeled_AE
( O
milnacipran O
6 O
% O
, O
placebo O
1 O
% O
) O
, O
palpitations B-OSE_Labeled_AE
( O
milnacipran O
3 O
% O
, O
placebo O
1 O
% O
) O
, O
headache B-OSE_Labeled_AE
( O
milnacipran O
2 O
% O
, O
placebo O
0 O
% O
) O
, O
constipation B-OSE_Labeled_AE
( O
milnacipran O
1 O
% O
, O
placebo O
0 O
% O
) O
, O
heart B-OSE_Labeled_AE
rate I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
milnacipran O
1 O
% O
, O
placebo O
0 O
% O
) O
, O
hyperhidrosis B-OSE_Labeled_AE
( O
milnacipran O
1 O
% O
, O
placebo O
0 O
% O
) O
, O
vomiting B-OSE_Labeled_AE
( O
milnacipran O
1 O
% O
, O
placebo O
0 O
% O
) O
, O
and O
dizziness B-OSE_Labeled_AE
( O
milnacipran O
1 O
% O
and O
placebo O
0.5 O
% O
) O
. O

Discontinuation O
due O
to O
adverse O
reactions O
was O
generally O
more O
common O
among O
patients O
treated O
with O
Savella O
200 O
mg/day O
compared O
to O
Savella O
100 O
mg/day O
. O

Most O
Common O
Adverse O
Reactions O
in O
Placebo O
Controlled O
Trials O
In O
the O
placebo-controlled O
fibromyalgia O
patient O
trials O
, O
the O
most O
frequently O
occurring O
adverse O
reaction O
in O
clinical O
trials O
was O
nausea B-OSE_Labeled_AE
. O

The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
5 O
% O
and O
twice O
placebo O
) O
in O
patients O
treated O
with O
Savella O
were O
constipation B-OSE_Labeled_AE
, O
hot B-OSE_Labeled_AE
flush I-OSE_Labeled_AE
, O
hyperhidrosis B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
palpitations B-OSE_Labeled_AE
, O
heart B-OSE_Labeled_AE
rate I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
and O
hypertension B-OSE_Labeled_AE
. O

Table O
4 O
lists O
all O
adverse O
reactions O
that O
occurred O
in O
at O
least O
2 O
% O
of O
patients O
treated O
with O
Savella O
at O
either O
100 O
or O
200 O
mg/day O
and O
at O
an O
incidence O
greater O
than O
that O
of O
placebo O
. O

Table O
4 O
: O
Treatment-Emergent O
Adverse O
Reaction O
Incidence O
in O
Placebo O
Controlled O
Trials O
in O
Fibromyalgia O
Patients O
( O
Events O
Occurring O
in O
at O
Least O
2 O
% O
of O
All O
Savella-Treated O
Patients O
and O
Occurring O
More O
Frequently O
in O
Either O
Savella O
Treatment O
Group O
Than O
in O
the O
Placebo O
Treatment O
Group O
) O
System O
Organ O
Class-Preferred O
Term O
Savella100 O
mg/day O
( O
n O
= O
623 O
) O
% O
Savella200 O
mg/day O
( O
n O
= O
934 O
) O
% O
All O
Savella O
( O
n O
= O
1557 O
) O
% O
Placebo O
( O
n O
= O
652 O
) O
% O
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
Palpitations B-OSE_Labeled_AE
8 O
7 O
7 O
2 O
Tachycardia B-OSE_Labeled_AE
3 O
2 O
2 O
1 O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
1 O
2 O
2 O
1 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
35 O
39 O
37 O
20 O
Constipation B-OSE_Labeled_AE
16 O
15 O
16 O
4 O
Vomiting B-OSE_Labeled_AE
6 O
7 O
7 O
2 O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
5 O
5 O
5 O
2 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
3 O
3 O
3 O
2 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
3 O
2 O
2 O
2 O
Chills B-OSE_Labeled_AE
1 O
2 O
2 O
0 O
Chest B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
2 O
1 O
1 O
1 O
Infections B-NonOSE_AE
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
7 O
6 O
6 O
6 O
Investigations B-NonOSE_AE
Heart B-OSE_Labeled_AE
rate I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
5 O
6 O
6 O
1 O
Blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
3 O
3 O
3 O
1 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
1 O
2 O
2 O
0 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
19 O
17 O
18 O
14 O
Dizziness B-OSE_Labeled_AE
11 O
10 O
10 O
6 O
Migraine B-OSE_Labeled_AE
6 O
4 O
5 O
3 O
Paresthesia B-OSE_Labeled_AE
2 O
3 O
2 O
2 O
Tremor B-OSE_Labeled_AE
2 O
2 O
2 O
1 O
Hypoesthesia B-OSE_Labeled_AE
1 O
2 O
1 O
1 O
Tension B-OSE_Labeled_AE
headache I-OSE_Labeled_AE
2 O
1 O
1 O
1 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
12 O
12 O
12 O
10 O
Anxiety B-OSE_Labeled_AE
5 O
3 O
4 O
4 O
Respiratory B-NonOSE_AE
Disorders I-NonOSE_AE
Dyspnea B-OSE_Labeled_AE
2 O
2 O
2 O
1 O
Skin B-NonOSE_AE
Disorders I-NonOSE_AE
Hyperhidrosis B-OSE_Labeled_AE
8 O
9 O
9 O
2 O
Rash B-OSE_Labeled_AE
3 O
4 O
3 O
2 O
Pruritus B-OSE_Labeled_AE
3 O
2 O
2 O
2 O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
Hot B-OSE_Labeled_AE
flush I-OSE_Labeled_AE
11 O
12 O
12 O
2 O
Hypertension B-OSE_Labeled_AE
7 O
4 O
5 O
2 O
Flushing B-OSE_Labeled_AE
2 O
3 O
3 O
1 O
Weight B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
In O
placebo-controlled O
fibromyalgia O
clinical O
trials O
, O
patients O
treated O
with O
Savella O
for O
up O
to O
3 O
months O
experienced O
a O
mean O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
of O
approximately O
0.8 O
kg O
in O
both O
the O
Savella O
100 O
mg/day O
and O
the O
Savella O
200 O
mg/day O
treatment O
groups O
, O
compared O
with O
a O
mean O
weight B-NonOSE_AE
loss I-NonOSE_AE
of O
approximately O
0.2 O
kg O
in O
placebo-treated O
patients O
. O

Genitourinary O
Adverse O
Reactions O
in O
Males O
In O
the O
placebo-controlled O
fibromyalgia B-Not_AE_Candidate
studies O
, O
the O
following O
treatment-emergent O
adverse O
reactions O
related O
to O
the O
genitourinary O
system O
were O
observed O
in O
at O
least O
2 O
% O
of O
male O
patients O
treated O
with O
Savella O
, O
and O
occurred O
at O
a O
rate O
greater O
than O
in O
placebo-treated O
male O
patients O
: O
dysuria B-OSE_Labeled_AE
, O
ejaculation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
erectile B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
, O
ejaculation B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
prostatitis B-OSE_Labeled_AE
, O
scrotal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
testicular B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
testicular B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
hesitation I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
, O
urethral B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
and O
urine B-OSE_Labeled_AE
flow I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
. O

Other O
Adverse O
Reactions O
Observed O
During O
Clinical O
Trials O
of O
Savella O
in O
Fibromyalgia O
Following O
is O
a O
list O
of O
frequent O
( O
those O
occurring O
on O
one O
or O
more O
occasions O
in O
at O
least O
1/100 O
patients O
) O
treatment-emergent O
adverse O
reactions O
reported O
from O
1824 O
fibromyalgia B-Not_AE_Candidate
patients O
treated O
with O
Savella O
for O
periods O
up O
to O
68 O
weeks O
. O

The O
listing O
does O
not O
include O
those O
events O
already O
listed O
in O
Table O
4 O
, O
those O
events O
for O
which O
a O
drug O
cause O
was O
remote O
, O
those O
events O
which O
were O
so O
general O
as O
to O
be O
uninformative O
, O
and O
those O
events O
reported O
only O
once O
which O
did O
not O
have O
a O
substantial O
probability O
of O
being O
acutely O
life O
threatening O
. O

Adverse O
reactions O
are O
categorized O
by O
body O
system O
and O
listed O
in O
order O
of O
decreasing O
frequency O
. O

Adverse O
reactions O
of O
major O
clinical O
importance O
are O
described O
in O
the O
Warnings O
and O
Precautions O
section O
( O
5 O
) O
. O

Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
- O
diarrhea B-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
gastroesophageal B-OSE_Labeled_AE
reflux I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
flatulence B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
distension I-OSE_Labeled_AE
General B-NonOSE_AE
Disorders I-NonOSE_AE
- O
fatigue B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
Infections B-NonOSE_AE
- O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
cystitis B-OSE_Labeled_AE
Injury B-NonOSE_AE
, I-NonOSE_AE
Poisoning I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
Procedural I-NonOSE_AE
Complications I-NonOSE_AE
- O
contusion B-OSE_Labeled_AE
, O
fall B-OSE_Labeled_AE
Investigations B-NonOSE_AE
- O
weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
or O
increased O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
- O
hypercholesterolemia B-OSE_Labeled_AE
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
- O
somnolence B-OSE_Labeled_AE
, O
dysgeusia B-OSE_Labeled_AE
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
- O
depression B-OSE_Labeled_AE
, O
stress B-OSE_Labeled_AE
Skin B-NonOSE_AE
Disorders I-NonOSE_AE
- O
night B-OSE_Labeled_AE
sweats I-OSE_Labeled_AE
6.2 O
Postmarketing O
Experience O
The O
following O
additional O
adverse O
reactions O
have O
been O
identified O
from O
spontaneous O
reports O
of O
Savella O
received O
worldwide O
. O

These O
adverse O
reactions O
have O
been O
chosen O
for O
inclusion O
because O
of O
a O
combination O
of O
seriousness O
, O
frequency O
of O
reporting O
, O
or O
potential O
causal O
connection O
to O
Savella O
. O

However O
, O
because O
these O
adverse O
reactions O
were O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

These O
events O
include O
: O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
- O
leukopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
- O
supraventricular B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
- O
accommodation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
Endocrine B-NonOSE_AE
Disorders I-NonOSE_AE
- O
hyperprolactinemia B-OSE_Labeled_AE
Hepatobiliary B-NonOSE_AE
Disorders I-NonOSE_AE
- O
hepatitis B-OSE_Labeled_AE
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
- O
anorexia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
- O
rhabdomyolysis B-OSE_Labeled_AE
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
- O
convulsions B-OSE_Labeled_AE
( O
including O
grand O
mal O
) O
, O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
, O
Parkinsonism B-OSE_Labeled_AE
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
- O
aggression B-OSE_Labeled_AE
, O
anger B-OSE_Labeled_AE
, O
delirium B-OSE_Labeled_AE
, O
hallucination B-OSE_Labeled_AE
, O
homicidal B-OSE_Labeled_AE
ideation I-OSE_Labeled_AE
Renal B-NonOSE_AE
and I-NonOSE_AE
Urinary I-NonOSE_AE
Disorders I-NonOSE_AE
- O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
Reproductive B-NonOSE_AE
System I-NonOSE_AE
and I-NonOSE_AE
Breast I-NonOSE_AE
Disorders I-NonOSE_AE
- O
galactorrhea B-OSE_Labeled_AE
Skin B-NonOSE_AE
Disorders I-NonOSE_AE
- O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
- O
hypertensive B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE

BOXED O
WARNING O
: O
WARNING O
: O
SUICIDALITY O
AND O
ANTIDEPRESSANT O
DRUGS O
WARNING O
: O
SUICIDALITY O
AND O
ANTIDEPRESSANT O
DRUGS O
Savella O
is O
a O
selective O
serotonin O
and O
norepinephrine O
reuptake O
inhibitor O
( O
SNRI O
) O
, O
similar O
to O
some O
drugs O
used O
for O
the O
treatment O
of O
depression B-Not_AE_Candidate
and O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Antidepressants O
increased O
the O
risk O
compared O
to O
placebo O
of O
suicidal B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
and O
behavior O
( O
suicidality B-OSE_Labeled_AE
) O
in O
children O
, O
adolescents O
, O
and O
young O
adults O
in O
short-term O
studies O
of O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
and O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Anyone O
considering O
the O
use O
of O
such O
drugs O
in O
a O
child O
, O
adolescent O
, O
or O
young O
adult O
must O
balance O
this O
risk O
with O
the O
clinical O
need O
. O

Short-term O
studies O
did O
not O
show O
an O
increase O
in O
the O
risk O
of O
suicidality B-NonOSE_AE
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
beyond O
age O
24 O
; O
there O
was O
a O
reduction O
in O
risk O
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
aged O
65 O
and O
older O
. O

Depression B-Not_AE_Candidate
and O
certain O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
are O
themselves O
associated O
with O
increases O
in O
the O
risk O
of O
suicide B-NonOSE_AE
. O

Patients O
of O
all O
ages O
who O
are O
started O
on O
Savella O
should O
be O
monitored O
appropriately O
and O
observed O
closely O
for O
clinical O
worsening O
, O
suicidality B-NonOSE_AE
, O
or O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
. O

Families O
and O
caregivers O
should O
be O
advised O
of O
the O
need O
for O
close O
observation O
and O
communication O
with O
the O
prescriber O
. O

Savella O
is O
not O
approved O
for O
use O
in O
the O
treatment O
of O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

Savella O
is O
not O
approved O
for O
use O
in O
pediatric O
patients O
[ O
see O
Indications O
and O
Usage O
( O
1 O
) O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.4 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
SUICIDALITY O
AND O
ANTIDEPRESSANT O
DRUGS O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Increased O
risk O
of O
suicidal O
ideation O
, O
thinking O
, O
and O
behavior O
in O
children O
, O
adolescents O
, O
and O
young O
adults O
taking O
antidepressants O
for O
major O
depressive O
disorder O
( O
MDD O
) O
and O
other O
psychiatric O
disorders O
( O
5.1 O
) O
. O

* O
Savella O
is O
not O
approved O
for O
use O
in O
pediatric O
patients O
( O
1 O
, O
8.4 O
) O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Suicidality O
: O
Monitor O
for O
worsening O
of O
depressive O
symptoms O
and O
suicide O
risk O
( O
5.1 O
) O
. O

* O
Serotonin O
Syndrome O
: O
Serotonin O
syndrome O
has O
been O
reported O
with O
SSRIs O
and O
SNRIs O
, O
including O
Savella O
, O
both O
when O
taken O
alone O
, O
but O
especially O
when O
co-administered O
with O
other O
serotonergic O
agents O
( O
including O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
tryptophan O
, O
buspirone O
and O
St O
. O
John O
's O
Wort O
) O
. O

If O
such O
symptoms O
occur O
, O
discontinue O
Savella O
and O
initiate O
supportive O
treatment O
. O

If O
concomitant O
use O
of O
Savella O
with O
other O
serotonergic O
drugs O
is O
clinically O
warranted O
, O
patients O
should O
be O
made O
aware O
of O
a O
potential O
increased O
risk O
for O
serotonin O
syndrome O
, O
particularly O
during O
treatment O
and O
dose O
increases O
( O
5.2 O
) O
. O

* O
Elevated O
blood O
pressure O
and O
heart O
rate O
: O
Savella O
may O
increase O
blood O
pressure O
and O
heart O
rate O
. O

In O
an O
ambulatory O
blood O
pressure O
monitoring O
study O
, O
a O
substantially O
higher O
proportion O
of O
Savella-treated O
patients O
experienced O
clinically O
significant O
blood O
pressure O
and O
heart O
rate O
elevations O
as O
compared O
with O
placebo-treated O
patients O
. O

Measure O
blood O
pressure O
and O
heart O
rate O
prior O
to O
initiating O
treatment O
with O
Savella O
and O
monitor O
periodically O
throughout O
treatment O
( O
5.3 O
, O
5.4 O
) O
. O

* O
Seizures O
: O
Cases O
have O
been O
reported O
with O
Savella O
therapy O
. O

Prescribe O
Savella O
with O
care O
in O
patients O
with O
a O
history O
of O
seizure O
disorder O
( O
5.5 O
) O
. O

* O
Hepatotoxicity O
: O
More O
patients O
treated O
with O
Savella O
than O
with O
placebo O
experienced O
mild O
elevations O
of O
ALT O
and O
AST O
. O

Rarely O
, O
fulminant O
hepatitis O
has O
been O
reported O
in O
patients O
treated O
with O
Savella O
. O

Avoid O
concomitant O
use O
of O
Savella O
in O
patients O
with O
substantial O
alcohol O
use O
or O
chronic O
liver O
disease O
( O
5.6 O
) O
. O

* O
Discontinuation O
: O
Withdrawal O
symptoms O
have O
been O
reported O
in O
patients O
when O
discontinuing O
treatment O
with O
Savella O
. O

A O
gradual O
dose O
reduction O
is O
recommended O
( O
5.7 O
) O
. O

* O
Abnormal O
Bleeding O
: O
Savella O
may O
increase O
the O
risk O
of O
bleeding O
events O
. O

Caution O
patients O
about O
the O
risk O
of O
bleeding O
associated O
with O
the O
concomitant O
use O
of O
Savella O
and O
NSAIDs O
, O
aspirin O
, O
or O
other O
drugs O
that O
affect O
coagulation O
( O
5.9 O
) O
. O

* O
Male O
patients O
with O
a O
history O
of O
obstructive O
uropathies O
may O
experience O
higher O
rates O
of O
genitourinary O
adverse O
events O
( O
5.11 O
) O
. O

5.1 O
Suicide O
Risk O
Savella O
is O
a O
selective O
serotonin O
and O
norepinephrine O
re-uptake O
inhibitor O
( O
SNRI O
) O
, O
similar O
to O
some O
drugs O
used O
for O
the O
treatment O
of O
depression B-Not_AE_Candidate
and O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Patients O
, O
both O
adult O
and O
pediatric O
, O
with O
depression B-Not_AE_Candidate
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
may O
experience O
worsening B-NonOSE_AE
of I-NonOSE_AE
their I-NonOSE_AE
depression I-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
ideation I-NonOSE_AE
and O
behavior O
( O
suicidality B-NonOSE_AE
) O
or O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
whether O
or O
not O
they O
are O
taking O
these O
medications O
, O
and O
this O
risk O
may O
persist O
until O
significant O
remission O
occurs O
. O

Suicide B-NonOSE_AE
is O
a O
known O
risk O
of O
depression B-Not_AE_Candidate
and O
certain O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
, O
and O
these O
disorders O
themselves O
are O
the O
strongest O
predictors O
of O
suicide B-NonOSE_AE
. O

There O
has O
been O
a O
long-standing O
concern O
, O
however O
, O
that O
antidepressants O
, O
including O
drugs O
that O
inhibit O
the O
reuptake O
of O
norepinephrine O
and/or O
serotonin O
, O
may O
have O
a O
role O
in O
inducing O
worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
depression I-OSE_Labeled_AE
and O
the O
emergence O
of O
suicidality B-OSE_Labeled_AE
in O
certain O
patients O
during O
the O
early O
phases O
of O
treatment O
. O

In O
the O
placebo-controlled O
clinical O
trials O
of O
adults O
with O
fibromyalgia B-Not_AE_Candidate
, O
among O
the O
patients O
who O
had O
a O
history O
of O
depression B-Not_AE_Candidate
at O
treatment O
initiation O
, O
the O
incidence O
of O
suicidal B-OSE_Labeled_AE
ideation I-OSE_Labeled_AE
was O
0.5 O
% O
in O
patients O
treated O
with O
placebo O
, O
0 O
% O
in O
patients O
treated O
with O
Savella O
100 O
mg/day O
, O
and O
1.3 O
% O
in O
patients O
treated O
with O
Savella O
200 O
mg/day O
. O

No O
suicides B-NonOSE_AE
occurred O
in O
the O
short-term O
or O
longer-term O
( O
up O
to O
1 O
year O
) O
fibromyalgia B-Not_AE_Candidate
trials O
. O

Pooled O
analyses O
of O
short-term O
placebo-controlled O
trials O
of O
drugs O
used O
to O
treat O
depression B-Not_AE_Candidate
( O
SSRIs O
and O
others O
) O
showed O
that O
these O
drugs O
increase O
the O
risk O
of O
suicidal B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
and O
behavior O
( O
suicidality B-OSE_Labeled_AE
) O
in O
children O
, O
adolescents O
, O
and O
young O
adults O
( O
ages O
18-24 O
) O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
and O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Short-term O
studies O
did O
not O
show O
an O
increase O
in O
the O
risk O
of O
suicidality B-NonOSE_AE
with O
these O
drugs O
compared O
to O
placebo O
in O
adults O
beyond O
age O
24 O
; O
there O
was O
a O
reduction O
in O
suicidality B-NonOSE_AE
risk O
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
age O
65 O
and O
older O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
trials O
in O
children O
and O
adolescents O
with O
MDD B-Not_AE_Candidate
, O
obsessive B-Not_AE_Candidate
compulsive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
OCD I-Not_AE_Candidate
) O
, O
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
24 O
short-term O
trials O
of O
9 O
drugs O
used O
to O
treat O
depression B-Not_AE_Candidate
in O
over O
4400 O
patients O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
trials O
in O
adults O
with O
MDD B-Not_AE_Candidate
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
295 O
short-term O
trials O
( O
median O
duration O
of O
2 O
months O
) O
of O
11 O
antidepressant O
drugs O
in O
over O
77,000 O
patients O
. O

There O
was O
considerable O
variation O
in O
risk O
of O
suicidality B-OSE_Labeled_AE
among O
drugs O
, O
but O
a O
tendency O
toward O
an O
increase O
in O
the O
younger O
patients O
for O
almost O
all O
drugs O
studied O
. O

There O
were O
differences O
in O
absolute O
risk O
of O
suicidality B-NonOSE_AE
across O
the O
different O
indications O
, O
with O
the O
highest O
incidence O
in O
MDD B-Not_AE_Candidate
. O

The O
risk O
of O
differences O
( O
drug O
versus O
placebo O
) O
, O
however O
, O
were O
relatively O
stable O
within O
age O
strata O
and O
across O
indications O
. O

These O
risk O
differences O
( O
drug-placebo O
difference O
in O
the O
number O
of O
cases O
of O
suicidality B-NonOSE_AE
per O
1000 O
patients O
treated O
) O
are O
provided O
in O
Table O
1 O
. O

Table O
1 O
: O
Risk O
Differences O
( O
Drug O
- O
Placebo O
) O
in O
the O
number O
of O
Cases O
of O
Suicidality B-OSE_Labeled_AE
, O
per O
1000 O
patients O
treated O
Age O
Range O
Drug-Placebo O
Difference O
in O
Number O
of O
Cases O
of O
Suicidality O
per O
1000 O
Patients O
Treated O
< O
18 O
14 O
additional O
cases O
18-24 O
5 O
additional O
cases O
Decreases O
Compared O
to O
Placebo O
25-64 O
1 O
fewer O
case O
> O
= O
65 O
6 O
fewer O
cases O
No O
suicides B-NonOSE_AE
occurred O
in O
any O
of O
the O
pediatric O
trials O
. O

There O
were O
suicides B-NonOSE_AE
in O
the O
adult O
trials O
, O
but O
the O
number O
was O
not O
sufficient O
to O
reach O
any O
conclusion O
about O
drug O
effect O
on O
suicide B-NonOSE_AE
. O

It O
is O
unknown O
whether O
the O
suicidality B-NonOSE_AE
risk O
extends O
to O
longer-term O
use O
, O
i.e. O
, O
beyond O
several O
months O
. O

However O
, O
there O
is O
substantial O
evidence O
from O
placebo-controlled O
maintenance O
trials O
in O
adults O
with O
depression B-Not_AE_Candidate
that O
the O
use O
of O
antidepressants O
can O
delay O
the O
recurrence O
of O
depression B-NonOSE_AE
. O

All O
patients O
being O
treated O
with O
drugs O
inhibiting O
the O
reuptake O
of O
norepinephrine O
and/or O
serotonin O
for O
any O
indication O
should O
be O
monitored O
appropriately O
and O
observed O
closely O
for O
clinical O
worsening O
, O
suicidality B-NonOSE_AE
, O
and O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
especially O
during O
the O
initial O
few O
months O
of O
a O
course O
of O
drug O
therapy O
, O
or O
at O
times O
of O
dose O
changes O
, O
either O
increases O
or O
decreases O
. O

The O
following O
symptoms O
, O
anxiety B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
panic B-OSE_Labeled_AE
attacks I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
hostility B-OSE_Labeled_AE
, O
aggressiveness B-OSE_Labeled_AE
, O
impulsivity B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
( O
psychomotor B-OSE_Labeled_AE
restlessness I-OSE_Labeled_AE
) O
, O
hypomania B-OSE_Labeled_AE
, O
mania B-OSE_Labeled_AE
, O
have O
been O
reported O
in O
adult O
and O
pediatric O
patients O
being O
treated O
with O
drugs O
inhibiting O
the O
reuptake O
of O
norepinephrine O
and/or O
serotonin O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
as O
well O
as O
for O
other O
indications O
, O
both O
psychiatric B-Not_AE_Candidate
and O
nonpsychiatric O
. O

Although O
a O
causal O
link O
between O
the O
emergence O
of O
such O
symptoms O
and O
either O
the O
worsening B-NonOSE_AE
of I-NonOSE_AE
depression I-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
impulses I-NonOSE_AE
has O
not O
been O
established O
, O
there O
is O
concern O
that O
such O
symptoms O
may O
represent O
precursors O
to O
emerging O
suicidality B-NonOSE_AE
. O

Consideration O
should O
be O
given O
to O
changing O
the O
therapeutic O
regimen O
, O
including O
possibly O
discontinuing O
the O
medication O
, O
in O
patients O
who O
may O
experience O
worsening O
depressive B-NonOSE_AE
symptoms I-NonOSE_AE
, O
or O
who O
are O
experiencing O
emergent O
suicidality B-NonOSE_AE
or O
symptoms O
that O
might O
be O
precursors O
to O
worsening O
depression B-NonOSE_AE
or O
suicidality B-NonOSE_AE
, O
especially O
if O
these O
symptoms O
are O
severe O
or O
abrupt O
in O
onset O
, O
or O
were O
not O
part O
of O
the O
patient O
's O
presenting O
symptoms O
. O

If O
the O
decision O
has O
been O
made O
to O
discontinue O
treatment O
due O
to O
worsening O
depressive B-NonOSE_AE
symptoms I-NonOSE_AE
or O
emergent O
suicidality B-NonOSE_AE
, O
medication O
should O
be O
tapered O
, O
as O
rapidly O
as O
is O
feasible O
, O
but O
with O
recognition O
that O
abrupt O
discontinuation O
can O
produce O
withdrawal B-NonOSE_AE
symptoms I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.1 O
, O
2.4 O
) O
, O
and O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
. O

Families O
and O
caregivers O
of O
patients O
being O
treated O
with O
drugs O
inhibiting O
the O
reuptake O
of O
norepinephrine O
and/or O
serotonin O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
or O
other O
indications O
, O
both O
psychiatric O
and O
nonpsychiatric O
, O
should O
be O
alerted O
about O
the O
need O
to O
monitor O
patients O
for O
the O
emergence O
of O
agitation B-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
and O
the O
other O
symptoms O
described O
above O
, O
as O
well O
as O
the O
emergence O
of O
suicidality B-NonOSE_AE
, O
and O
to O
report O
such O
symptoms O
immediately O
to O
health O
care O
providers O
. O

Such O
monitoring O
should O
include O
daily O
observation O
by O
families O
and O
caregivers O
. O

Prescriptions O
for O
Savella O
should O
be O
written O
for O
the O
smallest O
quantity O
of O
tablets O
consistent O
with O
good O
patient O
management O
, O
in O
order O
to O
reduce O
the O
risk O
of O
overdose B-NonOSE_AE
. O

5.2 O
Serotonin O
Syndrome O
The O
development O
of O
a O
potentially O
life-threatening O
serotonin B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
has O
been O
reported O
with O
SNRIs O
and O
SSRIs O
, O
including O
Savella O
, O
alone O
but O
particularly O
with O
concomitant O
use O
of O
other O
serotonergic O
drugs O
( O
including O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
tryptophan O
, O
buspirone O
, O
and O
St O
. O
John O
's O
Wort O
) O
and O
with O
drugs O
that O
impair O
metabolism O
of O
serotonin O
( O
in O
particular O
MAOIs O
, O
both O
those O
intended O
to O
treat O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
and O
also O
others O
, O
such O
as O
linezolid O
and O
intravenous O
methylene O
blue O
) O
. O

Serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
symptoms O
may O
include O
mental B-NonOSE_AE
status I-NonOSE_AE
changes I-NonOSE_AE
( O
e.g. O
, O
agitation B-NonOSE_AE
, O
hallucinations B-NonOSE_AE
, O
delirium B-NonOSE_AE
, O
and O
coma B-NonOSE_AE
) O
, O
autonomic B-NonOSE_AE
instability I-NonOSE_AE
( O
e.g. O
, O
tachycardia B-NonOSE_AE
, O
labile B-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
diaphoresis B-NonOSE_AE
, O
flushing B-NonOSE_AE
, O
hyperthermia B-NonOSE_AE
) O
, O
neuromuscular B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
tremor B-NonOSE_AE
, O
rigidity B-NonOSE_AE
, O
myoclonus B-NonOSE_AE
, O
hyperreflexia B-NonOSE_AE
, O
incoordination B-NonOSE_AE
) O
, O
seizures B-NonOSE_AE
, O
and/or O
gastrointestinal B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
) O
. O

Patients O
should O
be O
monitored O
for O
the O
emergence O
of O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
. O

The O
concomitant O
use O
of O
Savella O
with O
MAOIs O
intended O
to O
treat O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
is O
contraindicated O
. O

Savella O
should O
also O
not O
be O
started O
in O
a O
patient O
who O
is O
being O
treated O
with O
MAOIs O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
. O

All O
reports O
with O
methylene O
blue O
that O
provided O
information O
on O
the O
route O
of O
administration O
involved O
intravenous O
administration O
in O
the O
dose O
range O
of O
1 O
mg/kg O
to O
8 O
mg/kg O
. O

No O
reports O
involved O
the O
administration O
of O
methylene O
blue O
by O
other O
routes O
( O
such O
as O
oral O
tablets O
or O
local O
tissue O
injection O
) O
or O
at O
lower O
doses O
. O

There O
may O
be O
circumstances O
when O
it O
is O
necessary O
to O
initiate O
treatment O
with O
an O
MAOI O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
in O
a O
patient O
taking O
Savella O
. O

Savella O
should O
be O
discontinued O
before O
initiating O
treatment O
with O
the O
MAOI O
[ O
see O
Contraindications O
( O
4.1 O
) O
, O
Dosage O
and O
Administration O
( O
2.5 O
, O
2.6 O
) O
] O
. O

If O
concomitant O
use O
of O
Savella O
with O
other O
serotonergic O
drugs O
including O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
buspirone O
, O
tryptophan O
and O
St O
. O
John O
's O
Wort O
is O
clinically O
warranted O
, O
patients O
should O
be O
made O
aware O
of O
a O
potential O
increased O
risk O
for O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
, O
particularly O
during O
treatment O
initiation O
and O
dose O
increases O
. O

Treatment O
with O
Savella O
and O
any O
concomitant O
serotonergic O
agents O
should O
be O
discontinued O
immediately O
if O
the O
above O
events O
occur O
, O
and O
supportive O
symptomatic O
treatment O
should O
be O
initiated O
. O

5.3 O
Elevated O
Blood O
Pressure O
A O
double-blind O
, O
placebo-controlled O
ambulatory O
blood O
pressure O
monitoring O
( O
ABPM O
) O
study O
was O
conducted O
to O
evaluate O
the O
effects O
of O
milnacipran O
( O
up O
to O
200 O
mg/day O
) O
on O
blood O
pressure O
in O
321 O
fibromyalgia B-Not_AE_Candidate
patients O
. O

Among O
fibromyalgia B-Not_AE_Candidate
patients O
who O
were O
normotensive O
at O
baseline O
, O
an O
analysis O
of O
the O
blood O
pressure O
findings O
demonstrated O
a O
substantially O
higher O
proportion O
of O
Savella-treated O
patients O
had O
a O
hypertensive B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
measurement O
at O
the O
Week O
4 O
, O
50 O
mg O
BID O
steady O
state O
visit O
( O
17.7 O
% O
[ O
n=21/119 O
] O
) O
and O
the O
Week O
7 O
, O
100 O
mg O
BID O
steady O
state O
visit O
( O
14.3 O
% O
[ O
n=15/105 O
] O
) O
as O
compared O
to O
placebo-treated O
patients O
( O
3.7 O
% O
[ O
n=2/54 O
] O
and O
0 O
% O
[ O
0/49 O
] O
at O
the O
Week O
4 O
and O
Week O
7 O
visits O
, O
respectively O
) O
. O

Hypertension B-NonOSE_AE
was O
defined O
as O
mean B-NonOSE_AE
systolic I-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
( O
SBP O
) O
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
4 I-NonOSE_AE
0 I-NonOSE_AE
mmHg I-NonOSE_AE
and O
change B-NonOSE_AE
from I-NonOSE_AE
baseline I-NonOSE_AE
in I-NonOSE_AE
mean I-NonOSE_AE
SBP I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
mmHg I-NonOSE_AE
or O
mean B-NonOSE_AE
diastolic I-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
( I-NonOSE_AE
DBP I-NonOSE_AE
) I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
9 I-NonOSE_AE
0 I-NonOSE_AE
mmHg I-NonOSE_AE
and O
change B-NonOSE_AE
from I-NonOSE_AE
baseline I-NonOSE_AE
in I-NonOSE_AE
mean I-NonOSE_AE
DBP I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
5 I-NonOSE_AE
mmHg I-NonOSE_AE
for O
the O
12-hour O
period O
post O
AM O
study O
drug O
measurement O
at O
that O
visit O
. O

Furthermore O
, O
1.9 O
% O
( O
4/210 O
) O
of O
Savella-treated O
and O
0.9 O
% O
( O
1/111 O
) O
of O
placebo O
patients O
discontinued O
treatment O
for O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
. O

The O
increased B-OSE_Labeled_AE
risk I-OSE_Labeled_AE
of I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
measurements O
in O
the O
hypertensive B-OSE_Labeled_AE
range O
in O
Savella-treated O
patients O
is O
supported O
by O
substantial O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
mean I-OSE_Labeled_AE
SBP I-OSE_Labeled_AE
and O
DBP O
measurements O
observed O
in O
the O
ABPM O
study O
. O

Table O
2 O
shows O
that O
, O
following O
treatment O
with O
Savella O
50 O
mg O
BID O
for O
three O
weeks O
in O
patients O
who O
were O
normotensive O
at O
baseline O
, O
the O
mean B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
was I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
mmHg I-OSE_Labeled_AE
in I-OSE_Labeled_AE
systolic I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
( I-OSE_Labeled_AE
SBP I-OSE_Labeled_AE
) O
and O
diastolic O
blood O
pressure O
( O
DBP O
) O
. O

After O
further O
treatment O
with O
Savella O
100 O
mg O
BID O
for O
two O
weeks O
, O
the O
mean B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
in I-OSE_Labeled_AE
SBP O
and O
DBP I-OSE_Labeled_AE
was O
6 O
mmHg O
. O

Similar O
elevations O
occurred O
in O
Savella-treated O
patients O
who O
were O
hypertensive B-Not_AE_Candidate
at O
baseline O
. O

Table O
2 O
: O
Mean B-OSE_Labeled_AE
( O
Standard O
Error O
) O
Change I-OSE_Labeled_AE
from O
Baseline O
in O
Mean O
24-hour O
Systolic I-OSE_Labeled_AE
and O
Diastolic O
Blood I-OSE_Labeled_AE
Pressure I-OSE_Labeled_AE
( O
mmHg O
) O
of O
Milnacipran O
or O
Placebo O
following O
4 O
Weeks O
of O
Treatment O
( O
50mg O
BID O
) O
and O
a O
Subsequent O
2 O
Weeks O
of O
Treatment O
( O
100mg O
BID O
) O
*Blood O
pressure O
measurements O
made O
after O
3 O
weeks O
of O
milnacipran O
50mg O
BID O
^Blood O
pressure O
measurements O
made O
after O
2 O
weeks O
of O
milnacipran O
100mg O
BID O
Normotensive O
Hypertensive B-Not_AE_Candidate
n O
Systolic O
Diastolic O
n O
Systolic O
Diastolic O
Placebo O
39 O
0 O
( O
2 O
) O
-1 O
( O
1 O
) O
50 O
0 O
( O
2 O
) O
0 O
( O
2 O
) O
50 O
mg O
BID* O
92 O
5 O
( O
1 O
) O
5 O
( O
1 O
) O
84 O
5 O
( O
2 O
) O
4 O
( O
1 O
) O
Placebo O
37 O
0 O
( O
2 O
) O
-1 O
( O
1 O
) O
47 O
-1 O
( O
2 O
) O
0 O
( O
1 O
) O
100 O
mg O
BID^ O
82 O
6 O
( O
1 O
) O
6 O
( O
1 O
) O
80 O
5 O
( O
2 O
) O
4 O
( O
1 O
) O
Similar O
patterns O
of O
treatment-emergent O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
were O
observed O
in O
Phase O
3 O
and O
clinical O
pharmacology O
studies O
as O
manifested O
by O
an O
increased O
risk O
of O
new O
onset O
hypertension B-OSE_Labeled_AE
or O
substantial O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
end O
of O
study O
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
measurements O
in O
patients O
with O
hypertension B-Not_AE_Candidate
at O
baseline O
( O
Table O
3 O
) O
. O

Table O
3 O
: O
Blood O
pressure O
changes O
in O
Phase O
3 O
randomized O
controlled O
trials O
Milnacipran50 O
mg O
BID O
Milnacipran100 O
mg O
BID O
Placebo O
FM B-Not_AE_Candidate
patients O
normotensive O
at O
baseline O
who O
became O
hypertensive B-OSE_Labeled_AE
( O
defined O
as O
SBP B-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
4 I-NonOSE_AE
0 I-NonOSE_AE
mmHg I-NonOSE_AE
or O
DBP B-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
9 I-NonOSE_AE
0 I-NonOSE_AE
mmHg I-NonOSE_AE
on O
three O
consecutive O
post-baseline O
visits O
) O
20 O
% O
17 O
% O
7 O
% O
FM B-Not_AE_Candidate
patients O
with O
sustained O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
SBP I-OSE_Labeled_AE
( O
increase O
of O
> O
= O
15 O
mmHg O
on O
three O
consecutive O
post-baseline O
visits O
) O
9 O
% O
6 O
% O
2 O
% O
FM B-Not_AE_Candidate
patients O
with O
sustained O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
DBP I-OSE_Labeled_AE
( O
increase O
of O
> O
= O
10 O
mmHg O
on O
three O
consecutive O
post-baseline O
visits O
) O
13 O
% O
10 O
% O
4 O
% O
FM B-Not_AE_Candidate
patients O
hypertensive B-Not_AE_Candidate
at O
baseline O
who O
had O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
SBP I-OSE_Labeled_AE
> O
= O
15 O
mmHg O
at O
end O
of O
study O
10 O
% O
7 O
% O
4 O
% O
FM B-Not_AE_Candidate
patients O
hypertensive B-Not_AE_Candidate
at O
baseline O
who O
had O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
DBP I-OSE_Labeled_AE
> O
= O
10 O
mmHg O
at O
end O
of O
study O
8 O
% O
6 O
% O
3 O
% O
Sustained O
increases B-NonOSE_AE
in I-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
may O
have O
adverse O
consequences O
. O

Cases O
of O
elevated B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
requiring O
immediate O
treatment O
have O
been O
reported O
. O

Concomitant O
use O
of O
Savella O
with O
drugs O
that O
increase B-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
and O
heart B-NonOSE_AE
rate I-NonOSE_AE
has O
not O
been O
evaluated O
and O
such O
combinations O
should O
be O
used O
with O
caution O
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

Effects O
of O
Savella O
on O
blood O
pressure O
in O
patients O
with O
significant O
hypertension B-Not_AE_Candidate
or O
cardiac B-Not_AE_Candidate
disease I-Not_AE_Candidate
have O
not O
been O
systematically O
evaluated O
. O

Savella O
should O
be O
used O
with O
caution O
in O
these O
patients O
. O

Measure O
blood O
pressure O
prior O
to O
initiating O
treatment O
and O
periodically O
monitor O
blood O
pressure O
throughout O
Savella O
treatment O
. O

Treat O
pre-existing O
hypertension B-Not_AE_Candidate
and O
other B-Not_AE_Candidate
cardiovascular I-Not_AE_Candidate
disease I-Not_AE_Candidate
before O
starting O
therapy O
with O
Savella O
. O

For O
patients O
who O
experience O
a O
sustained O
increase B-NonOSE_AE
in I-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
while O
receiving O
Savella O
, O
either O
reduce O
the O
dose O
or O
discontinue O
treatment O
with O
Savella O
if O
clinically O
warranted O
. O

5.4 O
Elevated O
Heart O
Rate O
A O
double-blind O
, O
placebo-controlled O
ABPM O
study O
was O
conducted O
to O
evaluate O
the O
effects O
of O
milnacipran O
( O
up O
to O
200 O
mg/day O
) O
on O
blood O
pressure O
in O
321 O
fibromyalgia B-Not_AE_Candidate
patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

Information O
on O
heart O
rate O
was O
also O
collected O
. O

Following O
treatment O
with O
Savella O
50mg O
BID O
for O
three O
weeks O
in O
patients O
who O
were O
normotensive O
at O
baseline O
, O
the O
mean O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
mean O
24-hour O
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
from O
baseline O
was O
13 O
beats O
per O
minute O
. O

After O
further O
treatment O
with O
Savella O
100 O
mg O
BID O
for O
two O
weeks O
, O
the O
mean O
increase B-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
was O
13 O
beats O
per O
minute O
. O

Similar O
trends O
were O
observed O
in O
the O
clinical O
trials O
where O
Savella O
treatment O
was O
associated O
with O
mean O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
of O
approximately O
7 O
to O
8 O
beats O
per O
minute O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
] O
. O

Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
> O
= O
20 O
beats O
per O
minute O
occurred O
more O
frequently O
in O
Savella-treated O
patients O
when O
compared O
to O
placebo O
( O
8 O
% O
in O
the O
Savella O
50 O
mg O
BID O
and O
100 O
mg O
BID O
treatment O
arms O
versus O
0.3 O
% O
in O
the O
placebo O
arm O
) O
. O

Savella O
has O
not O
been O
systematically O
evaluated O
in O
patients O
with O
a O
cardiac B-Not_AE_Candidate
rhythm I-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

Measure O
heart O
rate O
prior O
to O
initiating O
treatment O
and O
periodically O
monitor O
the O
heart O
rate O
throughout O
Savella O
treatment O
. O

Treat O
pre-existing O
tachyarrhythmias B-Not_AE_Candidate
and O
other O
cardiac B-Not_AE_Candidate
disease I-Not_AE_Candidate
before O
starting O
therapy O
with O
Savella O
. O

For O
patients O
who O
experience O
a O
sustained O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
while O
receiving O
Savella O
, O
either O
reduce O
the O
dose O
or O
discontinue O
treatment O
with O
Savella O
if O
clinically O
warranted O
. O

5.5 O
Seizures O
Savella O
has O
not O
been O
systematically O
evaluated O
in O
patients O
with O
a O
seizure B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

In O
clinical O
trials O
evaluating O
Savella O
in O
patients O
with O
fibromyalgia B-Not_AE_Candidate
, O
seizures B-NonOSE_AE
/ O
convulsions B-NonOSE_AE
have O
not O
been O
reported O
. O

However O
, O
seizures B-NonOSE_AE
have O
been O
reported O
infrequently O
in O
patients O
treated O
with O
Savella O
for O
disorders O
other O
than O
fibromyalgia B-Not_AE_Candidate
. O

Savella O
should O
be O
prescribed O
with O
care O
in O
patients O
with O
a O
history O
of O
a O
seizure B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

5.6 O
Hepatotoxicity O
In O
the O
placebo-controlled O
fibromyalgia B-Not_AE_Candidate
trials O
, O
increases O
in O
the O
number O
of O
patients O
treated O
with O
Savella O
with O
mild O
elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
or O
AST O
( O
1-3 O
times O
the O
upper O
limit O
of O
normal O
, O
ULN O
) O
were O
observed O
. O

Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
were O
more O
frequently O
observed O
in O
the O
patients O
treated O
with O
Savella O
100 O
mg/day O
( O
6 O
% O
) O
and O
Savella O
200 O
mg/day O
( O
7 O
% O
) O
, O
compared O
to O
the O
patients O
treated O
with O
placebo O
( O
3 O
% O
) O
. O

One O
patient O
receiving O
Savella O
100 O
mg/day O
( O
0.2 O
% O
) O
had O
an O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
greater O
than O
5 O
times O
the O
upper O
limit O
of O
normal O
but O
did O
not O
exceed O
10 O
times O
the O
upper O
limit O
of O
normal O
. O

Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
AST I-OSE_Labeled_AE
were O
more O
frequently O
observed O
in O
the O
patients O
treated O
with O
Savella O
100 O
mg/day O
( O
3 O
% O
) O
and O
Savella O
200 O
mg/day O
( O
5 O
% O
) O
compared O
to O
the O
patients O
treated O
with O
placebo O
( O
2 O
% O
) O
. O

The O
increases B-NonOSE_AE
of I-NonOSE_AE
bilirubin I-NonOSE_AE
observed O
in O
the O
fibromyalgia B-Not_AE_Candidate
clinical O
trials O
were O
not O
clinically O
significant O
. O

No O
case O
met O
the O
criteria O
of O
elevated B-NonOSE_AE
ALT I-NonOSE_AE
> I-NonOSE_AE
3 I-NonOSE_AE
x I-NonOSE_AE
ULN I-NonOSE_AE
and O
associated O
with O
an O
increase B-NonOSE_AE
in I-NonOSE_AE
bilirubin I-NonOSE_AE
> O
= O
2x O
ULN O
. O

There O
have O
been O
cases O
of O
increased B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
enzymes I-OSE_Labeled_AE
and O
reports O
of O
severe B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
injury I-OSE_Labeled_AE
, O
including O
fulminant B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
with O
milnacipran O
from O
foreign O
postmarketing O
experience O
. O

In O
the O
cases O
of O
severe B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
injury I-OSE_Labeled_AE
, O
there O
were O
significant O
underlying O
clinical O
conditions O
and/or O
the O
use O
of O
multiple O
concomitant O
medications O
. O

Because O
of O
underreporting O
, O
it O
is O
impossible O
to O
provide O
an O
accurate O
estimate O
of O
the O
true O
incidence O
of O
these O
reactions O
. O

Savella O
should O
be O
discontinued O
in O
patients O
who O
develop O
jaundice B-NonOSE_AE
or O
other O
evidence O
of O
liver B-NonOSE_AE
dysfunction I-NonOSE_AE
. O

Treatment O
with O
Savella O
should O
not O
be O
resumed O
unless O
another O
cause O
can O
be O
established O
. O

Savella O
should O
ordinarily O
not O
be O
prescribed O
to O
patients O
with O
substantial O
alcohol O
use O
or O
evidence O
of O
chronic B-Not_AE_Candidate
liver I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

5.7 O
Discontinuation O
of O
Treatment O
with O
Savella O
Withdrawal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
have O
been O
observed O
in O
clinical O
trials O
following O
discontinuation O
of O
milnacipran O
, O
as O
with O
other O
SNRIs O
and O
SSRIs O
. O

During O
marketing O
of O
milnacipran O
, O
and O
other O
SNRIs O
and O
SSRIs O
, O
there O
have O
been O
spontaneous O
reports O
of O
adverse O
events O
indicative O
of O
withdrawal B-OSE_Labeled_AE
and O
physical B-OSE_Labeled_AE
dependence I-OSE_Labeled_AE
occurring O
upon O
discontinuation O
of O
these O
drugs O
, O
particularly O
when O
discontinuation O
is O
abrupt O
. O

The O
adverse O
events O
include O
the O
following O
: O
dysphoric B-NonOSE_AE
mood I-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
agitation B-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
sensory B-NonOSE_AE
disturbances I-NonOSE_AE
( O
e.g. O
, O
paresthesias B-NonOSE_AE
such O
as O
electric B-NonOSE_AE
shock I-NonOSE_AE
sensations I-NonOSE_AE
) O
, O
anxiety B-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
lethargy B-NonOSE_AE
, O
emotional B-NonOSE_AE
lability I-NonOSE_AE
, O
insomnia B-NonOSE_AE
, O
hypomania B-NonOSE_AE
, O
tinnitus B-NonOSE_AE
, O
and O
seizures B-NonOSE_AE
. O

Although O
these O
events O
are O
generally O
self-limiting O
, O
some O
have O
been O
reported O
to O
be O
severe O
. O

Patients O
should O
be O
monitored O
for O
these O
symptoms B-NonOSE_AE
when I-NonOSE_AE
discontinuing I-NonOSE_AE
treatment I-NonOSE_AE
with O
Savella O
. O

Savella O
should O
be O
tapered O
and O
not O
abruptly O
discontinued O
after O
extended O
use O
. O

If O
intolerable O
symptoms B-NonOSE_AE
occur I-NonOSE_AE
following I-NonOSE_AE
a I-NonOSE_AE
decrease I-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
dose I-NonOSE_AE
or I-NonOSE_AE
upon I-NonOSE_AE
discontinuation I-NonOSE_AE
of I-NonOSE_AE
treatment I-NonOSE_AE
, O
then O
resuming O
the O
previously O
prescribed O
dose O
may O
be O
considered O
. O

Subsequently O
, O
the O
physician O
may O
continue O
decreasing O
the O
dose O
but O
at O
a O
more O
gradual O
rate O
[ O
see O
Dosage O
and O
Administration O
( O
2.4 O
) O
] O
. O

5.8 O
Hyponatremia O
Hyponatremia B-OSE_Labeled_AE
may O
occur O
as O
a O
result O
of O
treatment O
with O
SSRIs O
and O
SNRIs O
, O
including O
Savella O
. O

In O
many O
cases O
, O
this O
hyponatremia B-OSE_Labeled_AE
appears O
to O
be O
the O
result O
of O
the O
syndrome B-OSE_Labeled_AE
of I-OSE_Labeled_AE
inappropriate I-OSE_Labeled_AE
antidiuretic I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
secretion I-OSE_Labeled_AE
( O
SIADH O
) O
. O

Cases O
with O
serum B-OSE_Labeled_AE
sodium I-OSE_Labeled_AE
lower I-OSE_Labeled_AE
than I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mmol I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
have O
been O
reported O
. O

Elderly O
patients O
may O
be O
at O
greater O
risk O
of O
developing O
hyponatremia B-OSE_Labeled_AE
with O
SNRIs O
, O
SSRIs O
, O
or O
Savella O
. O

Also O
, O
patients O
taking O
diuretics O
or O
who O
are O
otherwise O
volume B-Not_AE_Candidate
- I-Not_AE_Candidate
depleted I-Not_AE_Candidate
may O
be O
at O
greater O
risk O
[ O
see O
Geriatric O
Use O
( O
8.5 O
) O
] O
. O

Discontinuation O
of O
Savella O
should O
be O
considered O
in O
patients O
with O
symptomatic O
hyponatremia B-NonOSE_AE
. O

Signs O
and O
symptoms O
of O
hyponatremia B-NonOSE_AE
include O
headache B-NonOSE_AE
, O
difficulty B-NonOSE_AE
concentrating I-NonOSE_AE
, O
memory B-NonOSE_AE
impairment I-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
weakness B-NonOSE_AE
, O
and O
unsteadiness B-NonOSE_AE
, O
which O
may O
lead O
to O
falls B-NonOSE_AE
. O

Signs O
and O
symptoms O
associated O
with O
more O
severe O
and/or O
acute O
cases O
have O
included O
hallucination B-NonOSE_AE
, O
syncope B-NonOSE_AE
, O
seizure B-NonOSE_AE
, O
coma B-NonOSE_AE
, O
respiratory B-NonOSE_AE
arrest I-NonOSE_AE
, O
and O
death B-NonOSE_AE
. O

5.9 O
Abnormal O
Bleeding O
SSRIs O
and O
SNRIs O
, O
including O
Savella O
, O
may O
increase O
the O
risk O
of O
bleeding B-OSE_Labeled_AE
events I-OSE_Labeled_AE
. O

Concomitant O
use O
of O
aspirin O
, O
nonsteroidal O
anti-inflammatory O
drugs O
( O
NSAIDs O
) O
, O
warfarin O
, O
and O
other O
anti-coagulants O
may O
add O
to O
this O
risk O
. O

Case O
reports O
and O
epidemiological O
studies O
( O
case-control O
and O
cohort O
design O
) O
have O
demonstrated O
an O
association O
between O
use O
of O
drugs O
that O
interfere O
with O
serotonin O
reuptake O
and O
the O
occurrence O
of O
gastrointestinal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
. O

Bleeding B-OSE_Labeled_AE
events O
related O
to O
SSRIs O
and O
SNRIs O
use O
have O
ranged O
from O
ecchymoses B-OSE_Labeled_AE
, O
hematomas B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
and O
petechiae B-OSE_Labeled_AE
to O
life-threatening O
hemorrhages I-OSE_Labeled_AE
. O

Patients O
should O
be O
cautioned O
about O
the O
risk O
of O
bleeding B-NonOSE_AE
associated O
with O
the O
concomitant O
use O
of O
Savella O
and O
NSAIDs O
, O
aspirin O
, O
or O
other O
drugs O
that O
affect O
coagulation O
. O

5.10 O
Activation O
of O
Mania O
No O
activation O
of O
mania B-NonOSE_AE
or O
hypomania B-NonOSE_AE
was O
reported O
in O
the O
clinical O
trials O
evaluating O
effects O
of O
Savella O
in O
patients O
with O
fibromyalgia B-Not_AE_Candidate
. O

However O
those O
clinical O
trials O
excluded O
patients O
with O
current O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
episode I-Not_AE_Candidate
. O

Activation O
of O
mania B-NonOSE_AE
and O
hypomania B-NonOSE_AE
have O
been O
reported O
in O
patients O
with O
mood B-Not_AE_Candidate
disorders I-Not_AE_Candidate
who O
were O
treated O
with O
other O
similar O
drugs O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

As O
with O
these O
other O
agents O
, O
Savella O
should O
be O
used O
cautiously O
in O
patients O
with O
a O
history O
of O
mania B-Not_AE_Candidate
. O

5.11 O
Patients O
with O
a O
History O
of O
Dysuria O
Because O
of O
their O
noradrenergic O
effect O
, O
SNRIs O
including O
Savella O
, O
can O
affect O
urethral B-OSE_Labeled_AE
resistance I-OSE_Labeled_AE
and O
micturition O
. O

In O
the O
controlled O
fibromyalgia B-Not_AE_Candidate
trials O
, O
dysuria B-OSE_Labeled_AE
occurred O
more O
frequently O
in O
patients O
treated O
with O
Savella O
( O
1 O
% O
) O
than O
in O
placebo-treated O
patients O
( O
0.5 O
% O
) O
. O

Caution O
is O
advised O
in O
use O
of O
Savella O
in O
patients O
with O
a O
history O
of O
dysuria B-Not_AE_Candidate
, O
notably O
in O
male O
patients O
with O
prostatic B-Not_AE_Candidate
hypertrophy I-Not_AE_Candidate
, O
prostatitis B-Not_AE_Candidate
, O
and O
other O
lower B-Not_AE_Candidate
urinary I-Not_AE_Candidate
tract I-Not_AE_Candidate
obstructive I-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Male O
patients O
are O
more O
prone O
to O
genitourinary B-NonOSE_AE
adverse I-NonOSE_AE
effects I-NonOSE_AE
, O
such O
as O
dysuria B-NonOSE_AE
or O
urinary B-NonOSE_AE
retention I-NonOSE_AE
, O
and O
may O
experience O
testicular B-NonOSE_AE
pain I-NonOSE_AE
or O
ejaculation B-NonOSE_AE
disorders I-NonOSE_AE
. O

5.12 O
Angle O
Closure O
Glaucoma O
The O
pupillary B-OSE_Labeled_AE
dilation I-OSE_Labeled_AE
that O
occurs O
following O
use O
of O
SNRI O
drugs O
including O
Savella O
may O
trigger O
an O
angle B-OSE_Labeled_AE
closure I-OSE_Labeled_AE
attack I-OSE_Labeled_AE
in O
a O
patient O
with O
anatomically O
narrow O
angles O
who O
does O
not O
have O
a O
patent O
iridectomy O
. O

5.13 O
Concomitant O
Use O
with O
Alcohol O
In O
clinical O
trials O
, O
more O
patients O
treated O
with O
Savella O
developed O
elevated B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
than O
did O
placebo O
treated O
patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
. O

Because O
it O
is O
possible O
that O
milnacipran O
may O
aggravate B-OSE_Labeled_AE
pre I-OSE_Labeled_AE
- I-OSE_Labeled_AE
existing I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
Savella O
should O
not O
be O
prescribed O
to O
patients O
with O
substantial O
alcohol O
use O
or O
evidence O
of O
chronic B-Not_AE_Candidate
liver I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
labeling O
: O
* O
Hypocalcemia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Upper B-OSE_Labeled_AE
Gastrointestinal I-OSE_Labeled_AE
Bleeding I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Hypotension B-OSE_Labeled_AE
, O
Worsening B-OSE_Labeled_AE
Heart I-OSE_Labeled_AE
Failure I-OSE_Labeled_AE
and/or O
Arrhythmias B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Adynamic B-OSE_Labeled_AE
Bone I-OSE_Labeled_AE
Disease I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
( O
i.e. O
, O
> O
= O
25 O
% O
) O
associated O
with O
Sensipar O
were O
nausea O
and O
vomiting O
. O

( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Amgen O
Medical O
Information O
at O
1-800-77-AMGEN O
( O
1-800-772-6436 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
with O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

Secondary O
Hyperparathyroidism O
in O
Patients O
with O
Chronic O
Kidney O
Disease O
on O
Dialysis O
In O
three O
double-blind O
, O
placebo-controlled O
clinical O
trials O
, O
1126 O
patients O
with O
CKD B-Not_AE_Candidate
on O
dialysis O
received O
study O
drug O
( O
656 O
Sensipar O
, O
470 O
placebo O
) O
for O
up O
to O
6 O
months O
. O

The O
most O
frequently O
reported O
adverse O
reactions O
are O
listed O
in O
Table O
1 O
. O

Seizures B-OSE_Labeled_AE
were O
observed O
in O
1.4 O
% O
( O
13/910 O
) O
of O
Sensipar-treated O
patients O
and O
0.7 O
% O
( O
5/641 O
) O
of O
placebo-treated O
patients O
across O
all O
completed O
placebo O
controlled O
trials O
. O

Table O
1 O
. O

Adverse O
Reactions O
with O
Frequency O
> O
= O
5 O
% O
in O
Patients O
on O
Dialysis O
in O
Short-Term O
Studies O
for O
up O
to O
6 O
Months O
Placebo O
Sensipar O
( O
n O
= O
470 O
) O
( O
n O
= O
656 O
) O
Event* O
: O
( O
% O
) O
( O
% O
) O
Nausea B-OSE_Labeled_AE
19 O
31 O
Vomiting B-OSE_Labeled_AE
15 O
27 O
Diarrhea B-OSE_Labeled_AE
20 O
21 O
Myalgia B-OSE_Labeled_AE
14 O
15 O
Dizziness B-OSE_Labeled_AE
8 O
10 O
Hypertension B-OSE_Labeled_AE
5 O
7 O
Asthenia B-OSE_Labeled_AE
4 O
7 O
Anorexia B-OSE_Labeled_AE
4 O
6 O
Pain B-OSE_Labeled_AE
Chest I-OSE_Labeled_AE
, I-OSE_Labeled_AE
Non I-OSE_Labeled_AE
- I-OSE_Labeled_AE
Cardiac I-OSE_Labeled_AE
4 O
6 O
Dialysis B-OSE_Labeled_AE
Access I-OSE_Labeled_AE
Site I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
4 O
5 O
*Included O
are O
events O
that O
were O
reported O
at O
a O
greater O
incidence O
in O
the O
Sensipar O
group O
than O
in O
the O
placebo O
group O
. O

In O
a O
randomized O
, O
double-blind O
placebo O
controlled O
study O
of O
3883 O
patients O
with O
secondary B-Not_AE_Candidate
HPT I-Not_AE_Candidate
and O
CKD B-Not_AE_Candidate
receiving O
dialysis O
in O
which O
patients O
were O
treated O
for O
up O
to O
64 O
months O
( O
mean O
duration O
of O
treatment O
was O
21 O
months O
in O
the O
Sensipar O
group O
) O
, O
the O
most O
frequently O
reported O
adverse O
reactions O
( O
incidence O
of O
> O
= O
5 O
% O
in O
the O
Sensipar O
group O
and O
a O
difference O
> O
= O
1 O
% O
compared O
to O
placebo O
) O
are O
listed O
in O
Table O
2 O
. O

Table O
2 O
. O

Frequency O
of O
Adverse O
Reactions O
in O
Dialysis O
Patients O
Treated O
for O
up O
to O
64 O
Months O
in O
a O
Long-Term O
Study1 O
Placebo O
( O
n O
= O
1923 O
) O
Sensipar O
( O
n O
= O
1938 O
) O
3699 O
subject-years O
4044 O
subject-years O
Percent O
of O
subjects O
reporting O
Adverse O
Reactions O
( O
% O
) O
90.9 O
93.2 O
Nausea B-OSE_Labeled_AE
15.5 O
29.1 O
Vomiting B-OSE_Labeled_AE
13.7 O
25.6 O
Diarrhea B-OSE_Labeled_AE
18.7 O
20.5 O
Dyspnea B-OSE_Labeled_AE
11.5 O
13.4 O
Cough B-OSE_Labeled_AE
9.8 O
11.7 O
Hypotension B-OSE_Labeled_AE
10.5 O
11.6 O
Headache B-OSE_Labeled_AE
9.6 O
11.5 O
Hypocalcemia B-OSE_Labeled_AE
1.4 O
11.2 O
Muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
9.2 O
11.1 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
9.6 O
10.9 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
6.3 O
8.2 O
Hyperkalemia B-OSE_Labeled_AE
6.1 O
8.1 O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
6.3 O
7.6 O
Dyspepsia B-OSE_Labeled_AE
4.6 O
7.4 O
Dizziness B-OSE_Labeled_AE
4.7 O
7.3 O
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
3.5 O
5.9 O
Asthenia B-OSE_Labeled_AE
3.8 O
5.4 O
Constipation B-OSE_Labeled_AE
3.8 O
5.0 O
1 O
Adverse O
reactions O
that O
occurred O
in O
> O
= O
5 O
% O
frequency O
in O
the O
Sensipar O
group O
and O
a O
difference O
> O
= O
1 O
% O
compared O
to O
the O
placebo O
group O
( O
Safety O
Analysis O
Set O
) O
Crude O
incidence O
rate O
= O
100 O
* O
Total O
number O
of O
subjects O
with O
event/ O
n O
n O
= O
Number O
of O
subjects O
receiving O
at O
least O
one O
dose O
of O
study O
drug O
Additional O
adverse O
reaction O
rates O
from O
the O
long-term O
, O
randomized O
, O
double-blind O
placebo O
controlled O
study O
for O
Sensipar O
versus O
placebo O
are O
as O
follows O
: O
seizure B-OSE_Labeled_AE
( O
2.5 O
% O
, O
1.6 O
% O
) O
, O
rash B-OSE_Labeled_AE
( O
2.2 O
% O
, O
1.9 O
% O
) O
, O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
9.4 O
% O
, O
8.3 O
% O
) O
. O

Patients O
with O
Parathyroid O
Carcinoma O
and O
Primary O
Hyperparathyroidism O
The O
safety O
profile O
of O
Sensipar O
in O
these O
patient O
populations O
is O
generally O
consistent O
with O
that O
seen O
in O
patients O
with O
CKD B-Not_AE_Candidate
on O
dialysis O
. O

Forty O
six O
patients O
were O
treated O
with O
Sensipar O
in O
a O
single O
arm O
study O
, O
29 O
with O
Parathyroid B-Not_AE_Candidate
Carcinoma I-Not_AE_Candidate
and O
17 O
with O
intractable O
pHPT B-Not_AE_Candidate
. O

Nine O
( O
20 O
% O
) O
of O
the O
patients O
withdrew O
from O
the O
study O
due O
to O
adverse O
events O
. O

The O
most O
frequent O
adverse O
reactions O
and O
the O
most O
frequent O
cause O
of O
withdrawal O
in O
these O
patient O
populations O
were O
nausea B-OSE_Labeled_AE
and O
vomiting B-OSE_Labeled_AE
. O

Severe O
or O
prolonged O
cases O
of O
nausea B-OSE_Labeled_AE
and O
vomiting B-OSE_Labeled_AE
can O
lead O
to O
dehydration B-NonOSE_AE
and O
worsening O
hypercalcemia B-NonOSE_AE
so O
careful O
monitoring O
of O
electrolytes O
is O
recommended O
in O
patients O
with O
these O
symptoms O
. O

Eight O
patients O
died O
during O
treatment O
with O
Sensipar O
in O
this O
study O
, O
7 O
with O
Parathyroid B-Not_AE_Candidate
Carcinoma I-Not_AE_Candidate
( O
24 O
% O
) O
and O
1 O
( O
6 O
% O
) O
with O
intractable O
pHPT B-Not_AE_Candidate
. O

Causes O
of O
death B-NonOSE_AE
were O
cardiovascular B-NonOSE_AE
( O
5 O
patients O
) O
, O
multi B-NonOSE_AE
- I-NonOSE_AE
organ I-NonOSE_AE
failure I-NonOSE_AE
( O
1 O
patient O
) O
, O
gastrointestinal B-NonOSE_AE
hemorrhage I-NonOSE_AE
( O
1 O
patient O
) O
and O
metastatic B-NonOSE_AE
carcinoma I-NonOSE_AE
( O
1 O
patient O
) O
. O

Adverse O
events O
of O
hypocalcemia B-OSE_Labeled_AE
were O
reported O
in O
three O
patients O
( O
7 O
% O
) O
. O

Seizures B-OSE_Labeled_AE
were O
observed O
in O
0.7 O
% O
( O
1/140 O
) O
of O
cinacalcet-treated O
patients O
and O
0.0 O
% O
( O
0/46 O
) O
of O
placebo-treated O
patients O
in O
all O
clinical O
studies O
. O

Table O
3 O
. O

Adverse O
Reactions O
with O
Frequency O
> O
= O
10 O
% O
in O
a O
Single O
Arm O
, O
Open-Label O
Study O
in O
Patients O
with O
Primary O
Hyperparathyroidism O
or O
Parathyroid O
Carcinoma O
Sensipar O
ParathyroidCarcinoma O
( O
n O
= O
29 O
) O
IntractablepHPT O
( O
n O
= O
17 O
) O
Total O
( O
n O
= O
46 O
) O
n O
( O
% O
) O
n O
( O
% O
) O
n O
( O
% O
) O
Number O
of O
Subjects O
Reporting O
Adverse O
Reactions O
28 O
( O
97 O
) O
17 O
( O
100 O
) O
45 O
( O
98 O
) O
Nausea B-OSE_Labeled_AE
19 O
( O
66 O
) O
10 O
( O
59 O
) O
29 O
( O
63 O
) O
Vomiting B-OSE_Labeled_AE
15 O
( O
52 O
) O
6 O
( O
35 O
) O
21 O
( O
46 O
) O
Paresthesia B-OSE_Labeled_AE
4 O
( O
14 O
) O
5 O
( O
29 O
) O
9 O
( O
20 O
) O
Fatigue B-OSE_Labeled_AE
6 O
( O
21 O
) O
2 O
( O
12 O
) O
8 O
( O
17 O
) O
Fracture B-OSE_Labeled_AE
6 O
( O
21 O
) O
2 O
( O
12 O
) O
8 O
( O
17 O
) O
Hypercalcemia B-OSE_Labeled_AE
6 O
( O
21 O
) O
2 O
( O
12 O
) O
8 O
( O
17 O
) O
Anorexia B-OSE_Labeled_AE
6 O
( O
21 O
) O
1 O
( O
6 O
) O
7 O
( O
15 O
) O
Asthenia B-OSE_Labeled_AE
5 O
( O
17 O
) O
2 O
( O
12 O
) O
7 O
( O
15 O
) O
Dehydration B-OSE_Labeled_AE
7 O
( O
24 O
) O
0 O
( O
0 O
) O
7 O
( O
15 O
) O
Anemia B-OSE_Labeled_AE
5 O
( O
17 O
) O
1 O
( O
6 O
) O
6 O
( O
13 O
) O
Arthralgia B-OSE_Labeled_AE
5 O
( O
17 O
) O
1 O
( O
6 O
) O
6 O
( O
13 O
) O
Constipation B-OSE_Labeled_AE
3 O
( O
10 O
) O
3 O
( O
18 O
) O
6 O
( O
13 O
) O
Depression B-OSE_Labeled_AE
3 O
( O
10 O
) O
3 O
( O
18 O
) O
6 O
( O
13 O
) O
Headache B-OSE_Labeled_AE
6 O
( O
21 O
) O
0 O
( O
0 O
) O
6 O
( O
13 O
) O
Infection B-OSE_Labeled_AE
Upper I-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
3 O
( O
10 O
) O
2 O
( O
12 O
) O
5 O
( O
11 O
) O
Pain B-OSE_Labeled_AE
Limb I-OSE_Labeled_AE
3 O
( O
10 O
) O
2 O
( O
12 O
) O
5 O
( O
11 O
) O
n O
= O
Number O
of O
subjects O
receiving O
at O
least O
one O
dose O
of O
study O
drug O
. O

pHPT B-Not_AE_Candidate
= I-Not_AE_Candidate
primary I-Not_AE_Candidate
hyperparathyroidism I-Not_AE_Candidate
In O
a O
randomized O
double-blind O
, O
placebo-controlled O
study O
of O
67 O
patients O
with O
primary B-Not_AE_Candidate
hyperparathyroidism I-Not_AE_Candidate
for O
whom O
parathyroidectomy O
would O
be O
indicated O
on O
the O
basis O
of O
serum O
calcium O
levels O
, O
but O
who O
are O
unable O
to O
undergo O
surgery O
, O
the O
most O
common O
adverse O
reactions O
are O
listed O
in O
Table O
4 O
. O

Table O
4 O
. O

Adverse O
Reactions O
Occurring O
in O
> O
= O
10 O
% O
of O
Subjects O
in O
a O
Double-Blind O
, O
Placebo-Controlled O
Study O
in O
Patients O
with O
Primary O
Hyperparathyroidism O
Adverse O
Reaction O
Placebo O
( O
n O
= O
34 O
) O
n O
( O
% O
) O
Cinacalcet O
( O
n O
= O
33 O
) O
n O
( O
% O
) O
Nausea B-OSE_Labeled_AE
6 O
( O
18 O
) O
10 O
( O
30 O
) O
Muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
0 O
( O
0 O
) O
6 O
( O
18 O
) O
Headache B-OSE_Labeled_AE
2 O
( O
6 O
) O
4 O
( O
12 O
) O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
2 O
( O
6 O
) O
4 O
( O
12 O
) O
n O
= O
Number O
of O
subjects O
receiving O
at O
least O
one O
dose O
of O
study O
drug O
Coded O
using O
MedDRA O
version O
16.0 O
Hypocalcemia O
In O
26-week O
studies O
of O
patients O
with O
secondary B-Not_AE_Candidate
HPT I-Not_AE_Candidate
and O
CKD B-Not_AE_Candidate
on O
dialysis O
66 O
% O
of O
patients O
receiving O
Sensipar O
compared O
with O
25 O
% O
of O
patients O
receiving O
placebo O
developed O
at O
least O
one O
serum O
calcium O
value O
less O
than O
8.4 O
mg/dL O
, O
whereas O
, O
29 O
% O
of O
patients O
receiving O
Sensipar O
compared O
with O
11 O
% O
of O
patients O
receiving O
placebo O
developed O
at O
least O
one O
serum O
calcium O
value O
less O
than O
7.5 O
mg/dL O
. O

Less O
than O
1 O
% O
of O
patients O
in O
each O
group O
permanently O
discontinued O
study O
drug O
due O
to O
hypocalcemia B-OSE_Labeled_AE
. O

In O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
in O
patients O
with O
secondary B-Not_AE_Candidate
HPT I-Not_AE_Candidate
and O
CKD B-Not_AE_Candidate
receiving O
dialysis O
in O
which O
patients O
were O
treated O
for O
up O
to O
64 O
months O
( O
mean O
duration O
of O
treatment O
was O
21 O
months O
in O
the O
cinacalcet O
group O
) O
, O
75 O
% O
of O
patients O
receiving O
Sensipar O
compared O
with O
29 O
% O
of O
patients O
receiving O
placebo O
developed O
at O
least O
one O
serum B-OSE_Labeled_AE
calcium I-OSE_Labeled_AE
value I-OSE_Labeled_AE
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
8 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
and O
33 O
% O
of O
cinacalcet O
patients O
compared O
with O
12 O
% O
of O
patients O
receiving O
placebo O
had O
at O
least O
one O
serum B-OSE_Labeled_AE
calcium I-OSE_Labeled_AE
value I-OSE_Labeled_AE
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
7 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
. O

Most O
of O
the O
cases O
of O
severe O
hypocalcemia B-OSE_Labeled_AE
less O
than O
7.5 O
mg/dL O
( O
21/33=64 O
% O
) O
occurred O
during O
the O
first O
6 O
months O
. O

In O
this O
trial O
, O
1.1 O
% O
of O
patients O
receiving O
Sensipar O
and O
0.1 O
% O
of O
patients O
receiving O
placebo O
permanently O
discontinued O
study O
drug O
due O
to O
hypocalcemia B-OSE_Labeled_AE
. O

During O
a O
placebo-controlled O
part O
of O
a O
52-week O
study O
in O
patients O
with O
primary B-Not_AE_Candidate
HPT I-Not_AE_Candidate
who O
met O
criteria O
for O
parathyroidectomy O
on O
the O
basis O
of O
corrected O
total O
serum O
calcium O
( O
> O
11.3 O
mg/dL O
[ O
2.82 O
mmol/L O
] O
and O
< O
= O
12.5 O
mg/dL O
[ O
3.12 O
mmol/L O
] O
) O
, O
serum B-OSE_Labeled_AE
calcium I-OSE_Labeled_AE
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
8 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
was O
observed O
in O
6.1 O
% O
( O
2/33 O
) O
of O
Sensipar O
treated O
patients O
and O
0 O
% O
( O
0/34 O
) O
of O
placebo O
treated O
patients O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post O
approval O
use O
of O
Sensipar O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

* O
Rash B-OSE_Labeled_AE
and O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
including O
angioedema B-OSE_Labeled_AE
and O
urticaria B-OSE_Labeled_AE
) O
, O
and O
myalgia B-OSE_Labeled_AE
* O
Isolated O
, O
idiosyncratic O
cases O
of O
hypotension B-OSE_Labeled_AE
, O
worsening B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
and/or O
arrhythmia B-OSE_Labeled_AE
have O
been O
* O
reported O
in O
patients O
with O
impaired B-Not_AE_Candidate
cardiac I-Not_AE_Candidate
function I-Not_AE_Candidate
* O
Gastrointestinal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Hypocalcemia O
: O
Life O
threatening O
events O
and O
fatal O
outcomes O
were O
reported O
. O

Hypocalcemia O
can O
prolong O
QT O
interval O
, O
lower O
the O
threshold O
for O
seizures O
, O
and O
cause O
hypotension O
, O
worsening O
heart O
failure O
, O
and/or O
arrhythmia O
. O

Monitor O
serum O
calcium O
carefully O
for O
the O
occurrence O
of O
hypocalcemia O
during O
treatment O
( O
2.4 O
, O
5.1 O
) O
* O
Upper O
Gastrointestinal O
( O
GI O
) O
Bleeding O
: O
Patients O
with O
risk O
factors O
for O
upper O
GI O
bleeding O
may O
be O
at O
increased O
risk O
. O

Monitor O
patients O
and O
promptly O
evaluate O
and O
treat O
any O
suspected O
GI O
bleeding O
. O

( O
5.2 O
) O
* O
Hypotension O
, O
Worsening O
Heart O
Failure O
and/or O
Arrhythmias O
: O
In O
postmarketing O
safety O
surveillance O
, O
isolated O
, O
idiosyncratic O
cases O
of O
hypotension O
, O
worsening O
heart O
failure O
, O
and/or O
arrhythmia O
have O
been O
reported O
in O
patients O
with O
impaired O
cardiac O
function O
. O

( O
5.3 O
) O
* O
Adynamic O
B O
one O
D O
isease O
: O
May O
develop O
if O
iPTH O
levels O
are O
suppressed O
below O
100 O
pg/mL O
. O

( O
5.4 O
) O
5.1 O
Hypocalcemia O
Sensipar O
lowers B-NonOSE_AE
serum I-NonOSE_AE
calcium I-NonOSE_AE
and O
can O
lead O
to O
hypocalcemia B-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Significant O
lowering B-NonOSE_AE
of I-NonOSE_AE
serum I-NonOSE_AE
calcium I-NonOSE_AE
can O
cause O
paresthesias B-NonOSE_AE
, O
myalgias B-NonOSE_AE
, O
muscle B-NonOSE_AE
spasms I-NonOSE_AE
, O
tetany B-NonOSE_AE
, O
seizures B-NonOSE_AE
, O
QT B-NonOSE_AE
interval I-NonOSE_AE
prolongation I-NonOSE_AE
and O
ventricular B-NonOSE_AE
arrhythmia I-NonOSE_AE
. O

Life O
threatening O
events O
and O
fatal B-NonOSE_AE
outcomes O
associated O
with O
hypocalcemia B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
treated O
with O
Sensipar O
, O
including O
in O
pediatric O
patients O
. O

The O
safety O
and O
effectiveness O
of O
Sensipar O
have O
not O
been O
established O
in O
pediatric O
patients O
[ O
see O
Pediatric O
Use O
( O
8.4 O
) O
] O
. O

Sensipar O
is O
not O
indicated O
for O
patients O
with O
CKD B-Not_AE_Candidate
not O
on O
dialysis O
[ O
see O
I O
ndications O
and O
Usage O
( O
1 O
) O
] O
. O

In O
patients O
with O
secondary B-Not_AE_Candidate
HPT I-Not_AE_Candidate
and O
CKD B-Not_AE_Candidate
not O
on O
dialysis O
, O
the O
long O
term O
safety O
and O
efficacy O
of O
Sensipar O
have O
not O
been O
established O
. O

Clinical O
studies O
indicate O
that O
Sensipar-treated O
patients O
with O
CKD B-Not_AE_Candidate
not O
on O
dialysis O
have O
an O
increased O
risk O
for O
hypocalcemia B-NonOSE_AE
compared O
with O
Sensipar-treated O
patients O
with O
CKD B-Not_AE_Candidate
on O
dialysis O
, O
which O
may O
be O
due O
to O
lower O
baseline O
calcium O
levels O
. O

In O
a O
phase O
3 O
study O
of O
32 O
weeks O
duration O
and O
including O
404 O
patients O
with O
CKD B-Not_AE_Candidate
not O
on O
dialysis O
( O
302 O
cinacalcet O
, O
102 O
placebo O
) O
, O
in O
which O
the O
median O
dose O
for O
cinacalcet O
was O
60 O
mg O
per O
day O
at O
the O
completion O
of O
the O
study O
, O
80 O
% O
of O
Sensipar-treated O
patients O
experienced O
at O
least O
one O
serum B-OSE_Labeled_AE
calcium I-OSE_Labeled_AE
value I-OSE_Labeled_AE
< I-OSE_Labeled_AE
8 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
compared O
with O
5 O
% O
of O
patients O
receiving O
placebo O
. O

QT O
Interval O
Prolongation O
and O
Ventricular O
Arrhythmia O
Decreases B-NonOSE_AE
in I-NonOSE_AE
serum I-NonOSE_AE
calcium I-NonOSE_AE
can O
also O
prolong B-NonOSE_AE
the I-NonOSE_AE
QT I-NonOSE_AE
interval I-NonOSE_AE
, O
potentially O
resulting O
in O
ventricular B-NonOSE_AE
arrhythmia I-NonOSE_AE
. O

Cases O
of O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
and O
ventricular B-OSE_Labeled_AE
arrhythmia I-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
treated O
with O
Sensipar O
. O

Patients O
with O
congenital B-Not_AE_Candidate
long I-Not_AE_Candidate
QT I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
, O
history O
of O
QT B-Not_AE_Candidate
interval I-Not_AE_Candidate
prolongation I-Not_AE_Candidate
, O
family O
history O
of O
long B-Not_AE_Candidate
QT I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
or O
sudden B-Not_AE_Candidate
cardiac I-Not_AE_Candidate
death I-Not_AE_Candidate
, O
and O
other O
conditions O
that O
predispose O
to O
QT B-Not_AE_Candidate
interval I-Not_AE_Candidate
prolongation I-Not_AE_Candidate
and O
ventricular B-Not_AE_Candidate
arrhythmia I-Not_AE_Candidate
may O
be O
at O
increased O
risk O
for O
QT B-NonOSE_AE
interval I-NonOSE_AE
prolongation I-NonOSE_AE
and O
ventricular B-NonOSE_AE
arrhythmias I-NonOSE_AE
if O
they O
develop O
hypocalcemia B-NonOSE_AE
due O
to O
Sensipar O
. O

Closely O
monitor O
corrected O
serum O
calcium O
and O
QT O
interval O
in O
patients O
at O
risk O
receiving O
Sensipar O
. O

Seizures O
In O
clinical O
studies O
, O
seizures B-OSE_Labeled_AE
( O
primarily O
generalized O
or O
tonic-clonic O
) O
were O
observed O
in O
1.4 O
% O
( O
43/3049 O
) O
of O
Sensipar-treated O
patients O
and O
0.7 O
% O
( O
5/687 O
) O
of O
placebo-treated O
patients O
. O

While O
the O
basis O
for O
the O
reported O
difference O
in O
seizure B-NonOSE_AE
rate O
is O
not O
clear O
, O
the O
threshold B-NonOSE_AE
for I-NonOSE_AE
seizures I-NonOSE_AE
is I-NonOSE_AE
lowered I-NonOSE_AE
by O
significant O
reductions B-NonOSE_AE
in I-NonOSE_AE
serum I-NonOSE_AE
calcium I-NonOSE_AE
levels I-NonOSE_AE
. O

Monitor O
serum O
calcium O
levels O
in O
patients O
with O
seizure B-Not_AE_Candidate
disorders I-Not_AE_Candidate
receiving O
Sensipar O
. O

Concurrent O
administration O
of O
Sensipar O
with O
calcium B-NonOSE_AE
- I-NonOSE_AE
lowering I-NonOSE_AE
drugs I-NonOSE_AE
including O
other O
calcium-sensing O
receptor O
agonists O
could O
result O
in O
severe B-NonOSE_AE
hypocalcemia I-NonOSE_AE
. O

Closely O
monitor O
serum O
calcium O
in O
patients O
receiving O
Sensipar O
and O
concomitant O
therapies O
known O
to O
lower B-NonOSE_AE
serum I-NonOSE_AE
calcium I-NonOSE_AE
levels I-NonOSE_AE
. O

Educate O
patients O
on O
the O
symptoms O
of O
hypocalcemia B-NonOSE_AE
and O
advise O
them O
to O
contact O
a O
healthcare O
provider O
if O
they O
occur O
. O

If O
corrected B-NonOSE_AE
serum I-NonOSE_AE
calcium I-NonOSE_AE
falls I-NonOSE_AE
below I-NonOSE_AE
the I-NonOSE_AE
lower I-NonOSE_AE
limit I-NonOSE_AE
of I-NonOSE_AE
normal I-NonOSE_AE
or O
symptoms O
of O
hypocalcemia B-NonOSE_AE
develop O
, O
start O
or O
increase B-NonOSE_AE
calcium I-NonOSE_AE
supplementation I-NonOSE_AE
( O
including O
calcium O
, O
calcium-containing O
phosphate O
binders O
, O
and/or O
vitamin O
D O
sterols O
or O
increases O
in O
dialysate O
calcium O
concentration O
) O
. O

Sensipar O
dose O
reduction O
or O
discontinuation O
of O
Sensipar O
may O
be O
necessary O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.2 O
Upper O
Gastrointestinal O
Bleeding O
Cases O
of O
gastrointestinal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
, O
mostly O
upper B-OSE_Labeled_AE
gastrointestinal I-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
, O
have O
occurred O
in O
patients O
using O
calcimimetics O
, O
including O
Sensipar O
, O
from O
postmarketing O
and O
clinical O
trial O
sources O
. O

The O
exact O
cause O
of O
GI O
bleeding O
in O
these O
patients O
is O
unknown O
. O

Patients O
with O
risk O
factors O
for O
upper B-Not_AE_Candidate
GI I-Not_AE_Candidate
bleeding I-Not_AE_Candidate
( O
such O
as O
known O
gastritis B-Not_AE_Candidate
, O
esophagitis B-Not_AE_Candidate
, O
ulcers B-Not_AE_Candidate
or O
severe O
vomiting B-Not_AE_Candidate
) O
may O
be O
at O
increased O
risk O
for O
GI B-NonOSE_AE
bleeding I-NonOSE_AE
when O
receiving O
Sensipar O
treatment O
. O

Monitor O
patients O
for O
worsening O
of O
common O
GI B-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
of O
nausea B-NonOSE_AE
and O
vomiting B-NonOSE_AE
associated O
with O
Sensipar O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
and O
for O
signs O
and O
symptoms O
of O
GI B-NonOSE_AE
bleeding I-NonOSE_AE
and O
ulcerations B-NonOSE_AE
during O
Sensipar O
therapy O
. O

Promptly O
evaluate O
and O
treat O
any O
suspected O
GI B-NonOSE_AE
bleeding I-NonOSE_AE
. O

5.3 O
Hypotension O
, O
Worsening O
Heart O
Failure O
and/or O
Arrhythmias O
In O
postmarketing O
safety O
surveillance O
, O
isolated O
, O
idiosyncratic O
cases O
of O
hypotension B-OSE_Labeled_AE
, O
worsening B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
and/or O
arrhythmia B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
with O
impaired B-Not_AE_Candidate
cardiac I-Not_AE_Candidate
function I-Not_AE_Candidate
, O
in O
which O
a O
causal O
relationship O
to O
Sensipar O
could O
not O
be O
completely O
excluded O
and O
which O
may O
be O
mediated O
by O
reductions B-NonOSE_AE
in I-NonOSE_AE
serum I-NonOSE_AE
calcium I-NonOSE_AE
levels I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

5.4 O
Adynamic O
Bone O
Disease O
Adynamic B-NonOSE_AE
bone I-NonOSE_AE
disease I-NonOSE_AE
may O
develop O
if O
iPTH B-NonOSE_AE
levels I-NonOSE_AE
are I-NonOSE_AE
suppressed I-NonOSE_AE
below I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
pg I-NonOSE_AE
/ I-NonOSE_AE
mL I-NonOSE_AE
. O

One O
clinical O
study O
evaluated O
bone O
histomorphometry O
in O
patients O
treated O
with O
Sensipar O
for O
1 O
year O
. O

Three O
patients O
with O
mild O
hyperparathyroid B-Not_AE_Candidate
bone I-Not_AE_Candidate
disease I-Not_AE_Candidate
at O
the O
beginning O
of O
the O
study O
developed O
adynamic B-OSE_Labeled_AE
bone I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
during O
treatment O
with O
Sensipar O
. O

Two O
of O
these O
patients O
had O
iPTH B-OSE_Labeled_AE
levels I-OSE_Labeled_AE
below I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
pg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mL I-OSE_Labeled_AE
at O
multiple O
time O
points O
during O
the O
study O
. O

In O
three O
6-month O
, O
phase O
3 O
studies O
conducted O
in O
patients O
with O
CKD B-Not_AE_Candidate
on O
dialysis O
, O
11 O
% O
of O
patients O
treated O
with O
Sensipar O
had O
mean O
iPTH B-OSE_Labeled_AE
values I-OSE_Labeled_AE
below I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
pg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mL I-OSE_Labeled_AE
during O
the O
efficacy-assessment O
phase O
. O

If O
iPTH B-NonOSE_AE
levels I-NonOSE_AE
decrease I-NonOSE_AE
below O
150 O
pg/mL O
in O
patients O
treated O
with O
Sensipar O
, O
the O
dose O
of O
Sensipar O
and/or O
vitamin O
D O
sterols O
should O
be O
reduced O
or O
therapy O
discontinued O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
more O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Increased O
mortality B-NonOSE_AE
in O
elderly O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Suicidal B-OSE_Labeled_AE
thoughts O
and O
behaviors I-OSE_Labeled_AE
in O
adolescents O
and O
young O
adults O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Cerebrovascular B-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
, O
including O
stroke B-NonOSE_AE
in O
elderly O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
5.3 O
] O
* O
Neuroleptic B-OSE_Labeled_AE
Malignant I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
NMS I-OSE_Labeled_AE
) O
[ O
see O
Warnings O
and O
Precautions O
5.4 O
] O
* O
Metabolic B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
( O
hyperglycemia B-OSE_Labeled_AE
, O
dyslipidemia B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
) O
[ O
see O
Warnings O
and O
Precautions O
5 O
. O

5 O
] O
* O
Tardive B-OSE_Labeled_AE
dyskinesia I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
5.6 O
] O
* O
Hypotension B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
5.7 O
] O
* O
Falls B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
5.8 O
] O
* O
Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
( O
children O
and O
adolescents O
) O
[ O
see O
Warnings O
and O
Precautions O
5.9 O
] O
* O
Leukopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
and O
agranulocytosis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
5.10 O
] O
* O
Cataracts B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
5.11 O
] O
* O
QT B-NonOSE_AE
Prolongation I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
5.12 O
] O
* O
Seizures B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
5.13 O
] O
* O
Hypothyroidism B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
5.14 O
] O
* O
Hyperprolactinemia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
5.15 O
] O
* O
Potential O
for O
cognitive B-OSE_Labeled_AE
and O
motor O
impairment I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
5.16 O
] O
* O
Body B-NonOSE_AE
temperature I-NonOSE_AE
regulation I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
5.17 O
] O
* O
Dysphagia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
5.18 O
] O
* O
Discontinuation B-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
5.19 O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
=5 O
% O
and O
twice O
placebo O
) O
: O
Adults O
: O
somnolence O
, O
dry O
mouth O
, O
dizziness O
, O
constipation O
, O
asthenia O
, O
abdominal O
pain O
, O
postural O
hypotension O
, O
pharyngitis O
, O
weight O
gain O
, O
lethargy O
, O
ALT O
increased O
, O
dyspepsia O
( O
6.1 O
) O
Children O
and O
Adolescents O
: O
somnolence O
, O
dizziness O
, O
fatigue O
, O
increased O
appetite O
, O
nausea O
, O
vomiting O
, O
dry O
mouth O
, O
tachycardia O
, O
weight O
increased O
( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
AstraZeneca O
at O
1-800-236-9933 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Study O
Experience O
Because O
clinical O
studies O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
studies O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
studies O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Adults O
: O
The O
information O
below O
is O
derived O
from O
a O
clinical O
trial O
database O
for O
SEROQUEL O
consisting O
of O
over O
4300 O
patients O
. O

This O
database O
includes O
698 O
patients O
exposed O
to O
SEROQUEL O
for O
the O
treatment O
of O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
, O
405 O
patients O
exposed O
to O
SEROQUEL O
for O
the O
treatment O
of O
acute O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
monotherapy O
and O
adjunct O
therapy O
) O
, O
646 O
patients O
exposed O
to O
SEROQUEL O
for O
the O
maintenance O
treatment O
of O
bipolar B-Not_AE_Candidate
I I-Not_AE_Candidate
disorder I-Not_AE_Candidate
as O
adjunct O
therapy O
, O
and O
approximately O
2600 O
patients O
and/or O
normal O
subjects O
exposed O
to O
1 O
or O
more O
doses O
of O
SEROQUEL O
for O
the O
treatment O
of O
schizophrenia B-Not_AE_Candidate
. O

Of O
these O
approximately O
4300 O
subjects O
, O
approximately O
4000 O
( O
2300 O
in O
schizophrenia B-Not_AE_Candidate
, O
405 O
in O
acute O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
, O
698 O
in O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
, O
and O
646 O
for O
the O
maintenance O
treatment O
of O
bipolar B-Not_AE_Candidate
I I-Not_AE_Candidate
disorder I-Not_AE_Candidate
) O
were O
patients O
who O
participated O
in O
multiple O
dose O
effectiveness O
trials O
, O
and O
their O
experience O
corresponded O
to O
approximately O
2400 O
patient-years O
. O

The O
conditions O
and O
duration O
of O
treatment O
with O
SEROQUEL O
varied O
greatly O
and O
included O
( O
in O
overlapping O
categories O
) O
open-label O
and O
double-blind O
phases O
of O
studies O
, O
inpatients O
and O
outpatients O
, O
fixed-dose O
and O
dose-titration O
studies O
, O
and O
short-term O
or O
longer-term O
exposure O
. O

Adverse O
reactions O
were O
assessed O
by O
collecting O
adverse O
events O
, O
results O
of O
physical O
examinations O
, O
vital O
signs O
, O
weights O
, O
laboratory O
analyses O
, O
ECGs O
, O
and O
results O
of O
ophthalmologic O
examinations O
. O

The O
stated O
frequencies O
of O
adverse O
reactions O
represent O
the O
proportion O
of O
individuals O
who O
experienced O
, O
at O
least O
once O
, O
a O
treatment-emergent O
adverse O
reaction O
of O
the O
type O
listed O
. O

Adverse O
Reactions O
Associated O
with O
Discontinuation O
of O
Treatment O
in O
Short-Term O
, O
Placebo-Controlled O
Trials O
Schizophrenia B-Not_AE_Candidate
: O
Overall O
, O
there O
was O
little O
difference O
in O
the O
incidence O
of O
discontinuation O
due O
to O
adverse O
reactions O
( O
4 O
% O
for O
SEROQUEL O
vs O
. O
3 O
% O
for O
placebo O
) O
in O
a O
pool O
of O
controlled O
trials O
. O

However O
, O
discontinuations O
due O
to O
somnolence B-OSE_Labeled_AE
( O
0.8 O
% O
SEROQUEL O
vs O
. O
0 O
% O
placebo O
) O
and O
hypotension B-OSE_Labeled_AE
( O
0.4 O
% O
SEROQUEL O
vs O
. O
0 O
% O
placebo O
) O
were O
considered O
to O
be O
drug O
related O
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
and O
5.19 O
) O
] O
. O

Bipolar B-Not_AE_Candidate
Disorder I-Not_AE_Candidate
: O
Mania B-Not_AE_Candidate
: O
Overall O
, O
discontinuations O
due O
to O
adverse O
reactions O
were O
5.7 O
% O
for O
SEROQUEL O
vs O
. O
5.1 O
% O
for O
placebo O
in O
monotherapy O
and O
3.6 O
% O
for O
SEROQUEL O
vs O
. O
5.9 O
% O
for O
placebo O
in O
adjunct O
therapy O
. O

Depression B-Not_AE_Candidate
: O
Overall O
, O
discontinuations O
due O
to O
adverse O
reactions O
were O
12.3 O
% O
for O
SEROQUEL O
300 O
mg O
vs O
. O
19.0 O
% O
for O
SEROQUEL O
600 O
mg O
and O
5.2 O
% O
for O
placebo O
. O

Commonly O
Observed O
Adverse O
Reactions O
in O
Short-Term O
, O
Placebo-Controlled O
Trials O
: O
In O
the O
acute O
therapy O
of O
schizophrenia B-Not_AE_Candidate
( O
up O
to O
6 O
weeks O
) O
and O
bipolar O
mania O
( O
up O
to O
12 O
weeks O
) O
trials O
, O
the O
most O
commonly O
observed O
adverse O
reactions O
associated O
with O
the O
use O
of O
SEROQUEL O
monotherapy O
( O
incidence O
of O
5 O
% O
or O
greater O
) O
and O
observed O
at O
a O
rate O
on O
SEROQUEL O
at O
least O
twice O
that O
of O
placebo O
were O
somnolence B-OSE_Labeled_AE
( O
18 O
% O
) O
, O
dizziness B-OSE_Labeled_AE
( O
11 O
% O
) O
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
( O
9 O
% O
) O
, O
constipation B-OSE_Labeled_AE
( O
8 O
% O
) O
, O
ALT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
5 O
% O
) O
, O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
( O
5 O
% O
) O
, O
and O
dyspepsia B-OSE_Labeled_AE
( O
5 O
% O
) O
. O

Adverse O
Reactions O
Occurring O
at O
an O
Incidence O
of O
2 O
% O
or O
More O
Among O
SEROQUEL O
Treated O
Patients O
in O
Short-Term O
, O
Placebo-Controlled O
Trials O
: O
The O
prescriber O
should O
be O
aware O
that O
the O
figures O
in O
the O
tables O
and O
tabulations O
can O
not O
be O
used O
to O
predict O
the O
incidence O
of O
side O
effects O
in O
the O
course O
of O
usual O
medical O
practice O
where O
patient O
characteristics O
and O
other O
factors O
differ O
from O
those O
that O
prevailed O
in O
the O
clinical O
trials O
. O

Similarly O
, O
the O
cited O
frequencies O
can O
not O
be O
compared O
with O
figures O
obtained O
from O
other O
clinical O
investigations O
involving O
different O
treatments O
, O
uses O
, O
and O
investigators O
. O

The O
cited O
figures O
, O
however O
, O
do O
provide O
the O
prescribing O
physician O
with O
some O
basis O
for O
estimating O
the O
relative O
contribution O
of O
drug O
and O
nondrug O
factors O
to O
the O
side O
effect O
incidence O
in O
the O
population O
studied O
. O

Table O
9 O
enumerates O
the O
incidence O
, O
rounded O
to O
the O
nearest O
percent O
, O
of O
adverse O
reactions O
that O
occurred O
during O
acute O
therapy O
of O
schizophrenia B-Not_AE_Candidate
( O
up O
to O
6 O
weeks O
) O
and O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
up O
to O
12 O
weeks O
) O
in O
2 O
% O
or O
more O
of O
patients O
treated O
with O
SEROQUEL O
( O
doses O
ranging O
from O
75 O
to O
800 O
mg/day O
) O
where O
the O
incidence O
in O
patients O
treated O
with O
SEROQUEL O
was O
greater O
than O
the O
incidence O
in O
placebo-treated O
patients O
. O

Table O
9 O
: O
Adverse O
Reaction O
Incidence O
in O
3- O
to O
12-Week O
Placebo-Controlled O
Clinical O
Trials O
for O
the O
Treatment O
of O
Schizophrenia O
and O
Bipolar O
Mania O
( O
Monotherapy O
) O
Preferred O
Term O
SEROQUEL O
( O
n=719 O
) O
PLACEBO O
( O
n=404 O
) O
Headache B-OSE_Labeled_AE
21 O
% O
14 O
% O
Agitation B-OSE_Labeled_AE
20 O
% O
17 O
% O
Somnolence B-OSE_Labeled_AE
18 O
% O
8 O
% O
Dizziness B-OSE_Labeled_AE
11 O
% O
5 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
9 O
% O
3 O
% O
Constipation B-OSE_Labeled_AE
8 O
% O
3 O
% O
Pain B-OSE_Labeled_AE
7 O
% O
5 O
% O
Tachycardia B-OSE_Labeled_AE
6 O
% O
4 O
% O
Vomiting B-OSE_Labeled_AE
6 O
% O
5 O
% O
Asthenia B-OSE_Labeled_AE
5 O
% O
3 O
% O
Dyspepsia B-OSE_Labeled_AE
5 O
% O
1 O
% O
Weight B-OSE_Labeled_AE
Gain I-OSE_Labeled_AE
5 O
% O
1 O
% O
ALT B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
5 O
% O
1 O
% O
Anxiety B-OSE_Labeled_AE
4 O
% O
3 O
% O
Pharyngitis B-OSE_Labeled_AE
4 O
% O
3 O
% O
Rash B-OSE_Labeled_AE
4 O
% O
2 O
% O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
4 O
% O
1 O
% O
Postural B-OSE_Labeled_AE
Hypotension I-OSE_Labeled_AE
4 O
% O
1 O
% O
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
3 O
% O
1 O
% O
AST B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
3 O
% O
1 O
% O
Rhinitis B-OSE_Labeled_AE
3 O
% O
1 O
% O
Fever B-OSE_Labeled_AE
2 O
% O
1 O
% O
Gastroenteritis B-OSE_Labeled_AE
2 O
% O
0 O
% O
Amblyopia B-OSE_Labeled_AE
2 O
% O
1 O
% O
In O
the O
acute O
adjunct O
therapy O
of O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
up O
to O
3 O
weeks O
) O
studies O
, O
the O
most O
commonly O
observed O
adverse O
reactions O
associated O
with O
the O
use O
of O
SEROQUEL O
( O
incidence O
of O
5 O
% O
or O
greater O
) O
and O
observed O
at O
a O
rate O
on O
SEROQUEL O
at O
least O
twice O
that O
of O
placebo O
were O
somnolence B-OSE_Labeled_AE
( O
34 O
% O
) O
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
( O
19 O
% O
) O
, O
asthenia B-OSE_Labeled_AE
( O
10 O
% O
) O
, O
constipation B-OSE_Labeled_AE
( O
10 O
% O
) O
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
7 O
% O
) O
, O
postural B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
( O
7 O
% O
) O
, O
pharyngitis B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
and O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
( O
6 O
% O
) O
. O

Table O
10 O
enumerates O
the O
incidence O
, O
rounded O
to O
the O
nearest O
percent O
, O
of O
adverse O
reactions O
that O
occurred O
during O
therapy O
( O
up O
to O
3 O
weeks O
) O
of O
acute B-Not_AE_Candidate
mania I-Not_AE_Candidate
in O
2 O
% O
or O
more O
of O
patients O
treated O
with O
SEROQUEL O
( O
doses O
ranging O
from O
100 O
to O
800 O
mg/day O
) O
used O
as O
adjunct O
therapy O
to O
lithium O
and O
divalproex O
where O
the O
incidence O
in O
patients O
treated O
with O
SEROQUEL O
was O
greater O
than O
the O
incidence O
in O
placebo-treated O
patients O
. O

Table O
10 O
: O
Adverse O
Reaction O
Incidence O
in O
3-Week O
Placebo-Controlled O
Clinical O
Trials O
for O
the O
Treatment O
of O
Bipolar O
Mania O
( O
Adjunct O
Therapy O
) O
Preferred O
Term O
SEROQUEL O
( O
n=196 O
) O
PLACEBO O
( O
n=203 O
) O
Somnolence B-OSE_Labeled_AE
34 O
% O
9 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
19 O
% O
3 O
% O
Headache B-OSE_Labeled_AE
17 O
% O
13 O
% O
Asthenia B-OSE_Labeled_AE
10 O
% O
4 O
% O
Constipation B-OSE_Labeled_AE
10 O
% O
5 O
% O
Dizziness B-OSE_Labeled_AE
9 O
% O
6 O
% O
Tremor B-OSE_Labeled_AE
8 O
% O
7 O
% O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
7 O
% O
3 O
% O
Postural B-OSE_Labeled_AE
Hypotension I-OSE_Labeled_AE
7 O
% O
2 O
% O
Agitation B-OSE_Labeled_AE
6 O
% O
4 O
% O
Weight B-OSE_Labeled_AE
Gain I-OSE_Labeled_AE
6 O
% O
3 O
% O
Pharyngitis B-OSE_Labeled_AE
6 O
% O
3 O
% O
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
5 O
% O
3 O
% O
Hypertonia B-OSE_Labeled_AE
4 O
% O
3 O
% O
Rhinitis B-OSE_Labeled_AE
4 O
% O
2 O
% O
Peripheral B-OSE_Labeled_AE
Edema I-OSE_Labeled_AE
4 O
% O
2 O
% O
Twitching B-OSE_Labeled_AE
4 O
% O
1 O
% O
Dyspepsia B-OSE_Labeled_AE
4 O
% O
3 O
% O
Depression B-OSE_Labeled_AE
3 O
% O
2 O
% O
Amblyopia B-OSE_Labeled_AE
3 O
% O
2 O
% O
Speech B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
3 O
% O
1 O
% O
Hypotension B-OSE_Labeled_AE
3 O
% O
1 O
% O
Hormone B-OSE_Labeled_AE
Level I-OSE_Labeled_AE
Altered I-OSE_Labeled_AE
3 O
% O
0 O
% O
Heaviness B-OSE_Labeled_AE
2 O
% O
1 O
% O
Infection B-OSE_Labeled_AE
2 O
% O
1 O
% O
Fever B-OSE_Labeled_AE
2 O
% O
1 O
% O
Hypertension B-OSE_Labeled_AE
2 O
% O
1 O
% O
Tachycardia B-OSE_Labeled_AE
2 O
% O
1 O
% O
Increased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
2 O
% O
1 O
% O
Hypothyroidism B-OSE_Labeled_AE
2 O
% O
1 O
% O
Incoordination B-OSE_Labeled_AE
2 O
% O
1 O
% O
Thinking B-OSE_Labeled_AE
Abnormal I-OSE_Labeled_AE
2 O
% O
0 O
% O
Anxiety B-OSE_Labeled_AE
2 O
% O
0 O
% O
Ataxia B-OSE_Labeled_AE
2 O
% O
0 O
% O
Sinusitis B-OSE_Labeled_AE
2 O
% O
1 O
% O
Sweating B-OSE_Labeled_AE
2 O
% O
1 O
% O
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
2 O
% O
1 O
% O
In O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
studies O
( O
up O
to O
8 O
weeks O
) O
, O
the O
most O
commonly O
observed O
treatment O
emergent O
adverse O
reactions O
associated O
with O
the O
use O
of O
SEROQUEL O
( O
incidence O
of O
5 O
% O
or O
greater O
) O
and O
observed O
at O
a O
rate O
on O
SEROQUEL O
at O
least O
twice O
that O
of O
placebo O
were O
somnolence B-OSE_Labeled_AE
( O
57 O
% O
) O
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
( O
44 O
% O
) O
, O
dizziness B-OSE_Labeled_AE
( O
18 O
% O
) O
, O
constipation B-OSE_Labeled_AE
( O
10 O
% O
) O
, O
and O
lethargy B-OSE_Labeled_AE
( O
5 O
% O
) O
. O

Table O
11 O
enumerates O
the O
incidence O
, O
rounded O
to O
the O
nearest O
percent O
, O
of O
adverse O
reactions O
that O
occurred O
during O
therapy O
( O
up O
to O
8 O
weeks O
) O
of O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
in O
2 O
% O
or O
more O
of O
patients O
treated O
with O
SEROQUEL O
( O
doses O
of O
300 O
and O
600 O
mg/day O
) O
where O
the O
incidence O
in O
patients O
treated O
with O
SEROQUEL O
was O
greater O
than O
the O
incidence O
in O
placebo-treated O
patients O
. O

Table O
11 O
: O
Adverse O
Reaction O
Incidence O
in O
8-Week O
Placebo-Controlled O
Clinical O
Trials O
for O
the O
Treatment O
of O
Bipolar O
Depression O
Preferred O
Term O
SEROQUEL O
( O
n=698 O
) O
PLACEBO O
( O
n=347 O
) O
Somnolence B-OSE_Labeled_AE
Somnolence O
combines O
adverse O
reaction O
terms O
somnolence B-OSE_Labeled_AE
and O
sedation B-OSE_Labeled_AE
57 O
% O
15 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
44 O
% O
13 O
% O
Dizziness B-OSE_Labeled_AE
18 O
% O
7 O
% O
Constipation B-OSE_Labeled_AE
10 O
% O
4 O
% O
Fatigue B-OSE_Labeled_AE
10 O
% O
8 O
% O
Dyspepsia B-OSE_Labeled_AE
7 O
% O
4 O
% O
Vomiting B-OSE_Labeled_AE
5 O
% O
4 O
% O
Increased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
5 O
% O
3 O
% O
Lethargy B-OSE_Labeled_AE
5 O
% O
2 O
% O
Nasal B-OSE_Labeled_AE
Congestion I-OSE_Labeled_AE
5 O
% O
3 O
% O
Orthostatic B-OSE_Labeled_AE
Hypotension I-OSE_Labeled_AE
4 O
% O
3 O
% O
Akathisia B-OSE_Labeled_AE
4 O
% O
1 O
% O
Palpitations B-OSE_Labeled_AE
4 O
% O
1 O
% O
Vision B-OSE_Labeled_AE
Blurred I-OSE_Labeled_AE
4 O
% O
2 O
% O
Weight B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
4 O
% O
1 O
% O
Arthralgia B-OSE_Labeled_AE
3 O
% O
2 O
% O
Paraesthesia B-OSE_Labeled_AE
3 O
% O
2 O
% O
Cough B-OSE_Labeled_AE
3 O
% O
1 O
% O
Extrapyramidal B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
3 O
% O
1 O
% O
Irritability B-OSE_Labeled_AE
3 O
% O
1 O
% O
Dysarthria B-OSE_Labeled_AE
3 O
% O
0 O
% O
Hypersomnia B-OSE_Labeled_AE
3 O
% O
0 O
% O
Sinus B-OSE_Labeled_AE
Congestion I-OSE_Labeled_AE
2 O
% O
1 O
% O
Abnormal B-OSE_Labeled_AE
Dreams I-OSE_Labeled_AE
2 O
% O
1 O
% O
Tremor B-OSE_Labeled_AE
2 O
% O
1 O
% O
Gastroesophageal B-OSE_Labeled_AE
Reflux I-OSE_Labeled_AE
Disease I-OSE_Labeled_AE
2 O
% O
1 O
% O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Extremity I-OSE_Labeled_AE
2 O
% O
1 O
% O
Asthenia B-OSE_Labeled_AE
2 O
% O
1 O
% O
Balance B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
2 O
% O
1 O
% O
Hypoesthesia B-OSE_Labeled_AE
2 O
% O
1 O
% O
Dysphagia B-OSE_Labeled_AE
2 O
% O
0 O
% O
Restless B-OSE_Labeled_AE
Legs I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
2 O
% O
0 O
% O
Explorations O
for O
interactions O
on O
the O
basis O
of O
gender O
, O
age O
, O
and O
race O
did O
not O
reveal O
any O
clinically O
meaningful O
differences O
in O
the O
adverse O
reaction O
occurrence O
on O
the O
basis O
of O
these O
demographic O
factors O
. O

Dose O
Dependency O
of O
Adverse O
Reactions O
in O
Short-Term O
, O
Placebo-Controlled O
Trials O
Dose-related O
Adverse O
Reactions O
: O
Spontaneously O
elicited O
adverse O
reaction O
data O
from O
a O
study O
of O
schizophrenia B-Not_AE_Candidate
comparing O
five O
fixed O
doses O
of O
SEROQUEL O
( O
75 O
mg O
, O
150 O
mg O
, O
300 O
mg O
, O
600 O
mg O
, O
and O
750 O
mg/day O
) O
to O
placebo O
were O
explored O
for O
dose-relatedness O
of O
adverse O
reactions O
. O

Logistic O
regression O
analyses O
revealed O
a O
positive O
dose O
response O
( O
p O
< O
0.05 O
) O
for O
the O
following O
adverse O
reactions O
: O
dyspepsia B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
and O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
. O

Adverse O
Reactions O
in O
clinical O
trials O
with O
quetiapine O
and O
not O
listed O
elsewhere O
in O
the O
label O
: O
The O
following O
adverse O
reactions O
have O
also O
been O
reported O
with O
quetiapine O
: O
nightmares B-OSE_Labeled_AE
, O
hypersensitivity B-OSE_Labeled_AE
and O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatine I-OSE_Labeled_AE
phosphokinase I-OSE_Labeled_AE
( O
not O
associated O
with O
NMS B-NonOSE_AE
) O
, O
galactorrhea B-OSE_Labeled_AE
, O
bradycardia B-OSE_Labeled_AE
( O
which O
may O
occur O
at O
or O
near O
initiation O
of O
treatment O
and O
be O
associated O
with O
hypotension B-OSE_Labeled_AE
and/ O
or O
syncope B-OSE_Labeled_AE
) O
, O
decreased B-OSE_Labeled_AE
platelets I-OSE_Labeled_AE
, O
somnambulism B-OSE_Labeled_AE
( O
and O
other O
related O
events O
) O
, O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
gamma I-OSE_Labeled_AE
- I-OSE_Labeled_AE
GT I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
, O
hypothermia B-OSE_Labeled_AE
, O
and O
priapism B-OSE_Labeled_AE
. O

Extrapyramidal B-OSE_Labeled_AE
Symptoms I-OSE_Labeled_AE
( I-OSE_Labeled_AE
EPS I-OSE_Labeled_AE
) O
: O
Dystonia O
Class O
Effect O
: O
Symptoms O
of O
dystonia B-OSE_Labeled_AE
, O
prolonged B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
contractions I-OSE_Labeled_AE
of I-OSE_Labeled_AE
muscle I-OSE_Labeled_AE
groups I-OSE_Labeled_AE
, O
may O
occur O
in O
susceptible O
individuals O
during O
the O
first O
few O
days O
of O
treatment O
. O

Dystonic B-NonOSE_AE
symptoms I-NonOSE_AE
include O
: O
spasm B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
neck I-NonOSE_AE
muscles I-NonOSE_AE
, O
sometimes O
progressing O
to O
tightness B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
throat I-NonOSE_AE
, O
swallowing B-NonOSE_AE
difficulty I-NonOSE_AE
, O
difficulty B-NonOSE_AE
breathing I-NonOSE_AE
, O
and/or O
protrusion B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
tongue I-NonOSE_AE
. O

While O
these O
symptoms O
can O
occur O
at O
low O
doses O
, O
they O
occur O
more O
frequently O
and O
with O
greater O
severity O
with O
high O
potency O
and O
at O
higher O
doses O
of O
first O
generation O
antipsychotic O
drugs O
. O

An O
elevated O
risk O
of O
acute B-NonOSE_AE
dystonia I-NonOSE_AE
is O
observed O
in O
males O
and O
younger O
age O
groups O
. O

Four O
methods O
were O
used O
to O
measure O
EPS B-NonOSE_AE
: O
( O
1 O
) O
Simpson-Angus O
total O
score O
( O
mean O
change O
from O
baseline O
) O
which O
evaluates O
Parkinsonism B-NonOSE_AE
and O
akathisia B-NonOSE_AE
, O
( O
2 O
) O
Barnes O
Akathisia B-NonOSE_AE
Rating O
Scale O
( O
BARS O
) O
Global O
Assessment O
Score O
, O
( O
3 O
) O
incidence O
of O
spontaneous O
complaints O
of O
EPS B-NonOSE_AE
( O
akathisia B-NonOSE_AE
, O
akinesia B-NonOSE_AE
, O
cogwheel B-NonOSE_AE
rigidity I-NonOSE_AE
, O
extrapyramidal B-NonOSE_AE
syndrome I-NonOSE_AE
, O
hypertonia B-NonOSE_AE
, O
hypokinesia B-NonOSE_AE
, O
neck B-NonOSE_AE
rigidity I-NonOSE_AE
, O
and O
tremor B-NonOSE_AE
) O
, O
and O
( O
4 O
) O
use O
of O
anticholinergic O
medications O
to O
treat O
emergent O
EPS B-NonOSE_AE
. O

Adults O
: O
Data O
from O
one O
6-week O
clinical O
trial O
of O
schizophrenia B-Not_AE_Candidate
comparing O
five O
fixed O
doses O
of O
SEROQUEL O
( O
75 O
, O
150 O
, O
300 O
, O
600 O
, O
750 O
mg/day O
) O
provided O
evidence O
for O
the O
lack O
of O
treatment-emergent O
extrapyramidal B-NonOSE_AE
symptoms I-NonOSE_AE
( I-NonOSE_AE
EPS I-NonOSE_AE
) O
and O
dose-relatedness O
for O
EPS B-NonOSE_AE
associated O
with O
SEROQUEL O
treatment O
. O

Three O
methods O
were O
used O
to O
measure O
EPS B-NonOSE_AE
: O
( O
1 O
) O
Simpson-Angus O
total O
score O
( O
mean O
change O
from O
baseline O
) O
which O
evaluates O
Parkinsonism B-NonOSE_AE
and O
akathisia B-NonOSE_AE
, O
( O
2 O
) O
incidence O
of O
spontaneous O
complaints O
of O
EPS B-NonOSE_AE
( O
akathisia B-NonOSE_AE
, O
akinesia B-NonOSE_AE
, O
cogwheel B-NonOSE_AE
rigidity I-NonOSE_AE
, O
extrapyramidal B-NonOSE_AE
syndrome I-NonOSE_AE
, O
hypertonia B-NonOSE_AE
, O
hypokinesia B-NonOSE_AE
, O
neck B-NonOSE_AE
rigidity I-NonOSE_AE
, O
and O
tremor B-NonOSE_AE
) O
, O
and O
( O
3 O
) O
use O
of O
anticholinergic O
medications O
to O
treat O
emergent O
EPS B-NonOSE_AE
. O

In O
Table O
12 O
, O
dystonic B-NonOSE_AE
event I-NonOSE_AE
included O
nuchal B-NonOSE_AE
rigidity I-NonOSE_AE
, O
hypertonia B-NonOSE_AE
, O
dystonia B-NonOSE_AE
, O
muscle B-NonOSE_AE
rigidity I-NonOSE_AE
, O
oculogyration B-NonOSE_AE
; O
parkinsonism B-NonOSE_AE
included O
cogwheel B-NonOSE_AE
rigidity I-NonOSE_AE
, O
tremor B-NonOSE_AE
, O
drooling B-NonOSE_AE
, O
hypokinesia B-NonOSE_AE
; O
akathisia B-NonOSE_AE
included O
akathisia B-NonOSE_AE
, O
psychomotor B-NonOSE_AE
agitation I-NonOSE_AE
; O
dyskinetic B-NonOSE_AE
event I-NonOSE_AE
included O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
, O
dyskinesia B-NonOSE_AE
, O
choreoathetosis B-NonOSE_AE
; O
and O
other O
extrapyramidal B-NonOSE_AE
event I-NonOSE_AE
included O
restlessness B-NonOSE_AE
, O
extrapyramidal B-NonOSE_AE
disorder I-NonOSE_AE
, O
movement B-NonOSE_AE
disorder I-NonOSE_AE
. O

Table O
12 O
: O
Adverse O
Reactions O
Associated O
with O
EPS O
in O
a O
Short-Term O
, O
Placebo-Controlled O
Multiple O
Fixed-Dose O
Phase O
III O
Schizophrenia O
Trial O
( O
6 O
weeks O
duration O
) O
Preferred O
Term O
SEROQUEL O
75 O
mg/day O
( O
N=53 O
) O
SEROQUEL O
150 O
mg/day O
( O
N=48 O
) O
SEROQUEL O
300 O
mg/day O
( O
N=52 O
) O
SEROQUEL O
600 O
mg/day O
( O
N=51 O
) O
SEROQUEL O
750 O
mg/day O
( O
N=54 O
) O
Placebo O
( O
N=51 O
) O
n O
% O
n O
% O
n O
% O
n O
% O
n O
% O
n O
% O
Dystonic B-NonOSE_AE
event I-NonOSE_AE
2 O
3.8 O
2 O
4.2 O
0 O
0.0 O
2 O
3.9 O
3 O
5.6 O
4 O
7.8 O
Parkinsonism B-NonOSE_AE
2 O
3.8 O
0 O
0.0 O
1 O
1.9 O
1 O
2.0 O
1 O
1.9 O
4 O
7.8 O
Akathisia B-NonOSE_AE
1 O
1.9 O
1 O
2.1 O
0 O
0.0 O
0 O
0.0 O
1 O
1.9 O
4 O
7.8 O
Dyskinetic B-NonOSE_AE
event I-NonOSE_AE
2 O
3.8 O
0 O
0.0 O
0 O
0.0 O
1 O
2.0 O
0 O
0.0 O
0 O
0.0 O
Other O
extrapyramidal B-NonOSE_AE
event I-NonOSE_AE
2 O
3.8 O
0 O
0.0 O
3 O
5.8 O
3 O
5.9 O
1 O
1.9 O
4 O
7.8 O
Parkinsonism B-NonOSE_AE
incidence O
rates O
as O
measured O
by O
the O
Simpson-Angus O
total O
score O
for O
placebo O
and O
the O
five O
fixed O
doses O
( O
75 O
, O
150 O
, O
300 O
, O
600 O
, O
750 O
mg/day O
) O
were O
: O
-0.6 O
; O
-1.0 O
, O
-1.2 O
; O
-1.6 O
; O
-1.8 O
and O
-1.8 O
. O

The O
rate O
of O
anticholinergic O
medication O
use O
to O
treat O
emergent O
EPS B-NonOSE_AE
for O
placebo O
and O
the O
five O
fixed O
doses O
was O
: O
14 O
% O
; O
11 O
% O
; O
10 O
% O
; O
8 O
% O
; O
12 O
% O
and O
11 O
% O
. O

In O
six O
additional O
placebo-controlled O
clinical O
trials O
( O
3 O
in O
acute O
mania B-Not_AE_Candidate
and O
3 O
in O
schizophrenia B-Not_AE_Candidate
) O
using O
variable O
doses O
of O
SEROQUEL O
, O
there O
were O
no O
differences O
between O
the O
SEROQUEL O
and O
placebo O
treatment O
groups O
in O
the O
incidence O
of O
EPS B-NonOSE_AE
, O
as O
assessed O
by O
Simpson-Angus O
total O
scores O
, O
spontaneous O
complaints O
of O
EPS B-NonOSE_AE
and O
the O
use O
of O
concomitant O
anticholinergic O
medications O
to O
treat O
EPS B-NonOSE_AE
. O

In O
two O
placebo-controlled O
clinical O
trials O
for O
the O
treatment O
of O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
using O
300 O
mg O
and O
600 O
mg O
of O
SEROQUEL O
, O
the O
incidence O
of O
adverse O
reactions O
potentially O
related O
to O
EPS B-OSE_Labeled_AE
was O
12 O
% O
in O
both O
dose O
groups O
and O
6 O
% O
in O
the O
placebo O
group O
. O

In O
these O
studies O
, O
the O
incidence O
of O
the O
individual O
adverse O
reactions O
( O
akathisia B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
dyskinesia B-OSE_Labeled_AE
, O
dystonia B-OSE_Labeled_AE
, O
restlessness B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
contractions I-OSE_Labeled_AE
involuntary I-OSE_Labeled_AE
, O
psychomotor B-OSE_Labeled_AE
hyperactivity I-OSE_Labeled_AE
and O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
) O
were O
generally O
low O
and O
did O
not O
exceed O
4 O
% O
in O
any O
treatment O
group O
. O

The O
3 O
treatment O
groups O
were O
similar O
in O
mean O
change O
in O
SAS O
total O
score O
and O
BARS O
Global O
Assessment O
score O
at O
the O
end O
of O
treatment O
. O

The O
use O
of O
concomitant O
anticholinergic O
medications O
was O
infrequent O
and O
similar O
across O
the O
three O
treatment O
groups O
. O

Children O
and O
Adolescents O
The O
information O
below O
is O
derived O
from O
a O
clinical O
trial O
database O
for O
SEROQUEL O
consisting O
of O
over O
1000 O
pediatric O
patients O
. O

This O
database O
includes O
677 O
patients O
exposed O
to O
SEROQUEL O
for O
the O
treatment O
of O
schizophrenia B-Not_AE_Candidate
and O
393 O
children O
and O
adolescents O
( O
10-17 O
years O
old O
) O
exposed O
to O
SEROQUEL O
for O
the O
treatment O
of O
acute O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
. O

Adverse O
Reactions O
Associated O
with O
Discontinuation O
of O
Treatment O
in O
Short-Term O
, O
Placebo-Controlled O
Trials O
Schizophrenia B-Not_AE_Candidate
: O
The O
incidence O
of O
discontinuation O
due O
to O
adverse O
reactions O
for O
quetiapine-treated O
and O
placebo-treated O
patients O
was O
8.2 O
% O
and O
2.7 O
% O
, O
respectively O
. O

The O
adverse O
event O
leading O
to O
discontinuation O
in O
1 O
% O
or O
more O
of O
patients O
on O
SEROQUEL O
and O
at O
a O
greater O
incidence O
than O
placebo O
was O
somnolence B-OSE_Labeled_AE
( O
2.7 O
% O
and O
0 O
% O
for O
placebo O
) O
. O

Bipolar B-Not_AE_Candidate
I I-Not_AE_Candidate
Mania I-Not_AE_Candidate
: O
The O
incidence O
of O
discontinuation O
due O
to O
adverse O
reactions O
for O
quetiapine-treated O
and O
placebo-treated O
patients O
was O
11.4 O
% O
and O
4.4 O
% O
, O
respectively O
. O

The O
adverse O
reactions O
leading O
to O
discontinuation O
in O
2 O
% O
or O
more O
of O
patients O
on O
SEROQUEL O
and O
at O
a O
greater O
incidence O
than O
placebo O
were O
somnolence B-OSE_Labeled_AE
( O
4.1 O
% O
vs O
. O
1.1 O
% O
) O
and O
fatigue B-OSE_Labeled_AE
( O
2.1 O
% O
vs O
. O
0 O
) O
. O

Commonly O
Observed O
Adverse O
Reactions O
in O
Short-Term O
, O
Placebo-Controlled O
Trials O
In O
therapy O
for O
schizophrenia B-Not_AE_Candidate
( O
up O
to O
6 O
weeks O
) O
, O
the O
most O
commonly O
observed O
adverse O
reactions O
associated O
with O
the O
use O
of O
quetiapine O
in O
adolescents O
( O
incidence O
of O
5 O
% O
or O
greater O
and O
quetiapine O
incidence O
at O
least O
twice O
that O
for O
placebo O
) O
were O
somnolence B-OSE_Labeled_AE
( O
34 O
% O
) O
, O
dizziness B-OSE_Labeled_AE
( O
12 O
% O
) O
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
( O
7 O
% O
) O
, O
tachycardia B-OSE_Labeled_AE
( O
7 O
% O
) O
. O

In O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
therapy O
( O
up O
to O
3 O
weeks O
) O
the O
most O
commonly O
observed O
adverse O
reactions O
associated O
with O
the O
use O
of O
quetiapine O
in O
children O
and O
adolescents O
( O
incidence O
of O
5 O
% O
or O
greater O
and O
quetiapine O
incidence O
at O
least O
twice O
that O
for O
placebo O
) O
were O
somnolence B-OSE_Labeled_AE
( O
53 O
% O
) O
, O
dizziness B-OSE_Labeled_AE
( O
18 O
% O
) O
, O
fatigue B-OSE_Labeled_AE
( O
11 O
% O
) O
, O
increased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
( O
9 O
% O
) O
, O
nausea B-OSE_Labeled_AE
( O
8 O
% O
) O
, O
vomiting B-OSE_Labeled_AE
( O
8 O
% O
) O
, O
tachycardia B-OSE_Labeled_AE
( O
7 O
% O
) O
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
( O
7 O
% O
) O
, O
and O
weight B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
6 O
% O
) O
. O

In O
an O
acute O
( O
8-week O
) O
SEROQUEL O
XR O
trial O
in O
children O
and O
adolescents O
( O
10-17 O
years O
of O
age O
) O
with O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
, O
in O
which O
efficacy O
was O
not O
established O
, O
the O
most O
commonly O
observed O
adverse O
reactions O
associated O
with O
the O
use O
of O
SEROQUEL O
XR O
( O
incidence O
of O
5 O
% O
or O
greater O
and O
at O
least O
twice O
that O
for O
placebo O
) O
were O
dizziness B-OSE_Labeled_AE
( O
7 O
% O
) O
, O
diarrhea B-OSE_Labeled_AE
( O
5 O
% O
) O
, O
fatigue B-OSE_Labeled_AE
( O
5 O
% O
) O
and O
nausea B-OSE_Labeled_AE
( O
5 O
% O
) O
. O

Adverse O
Reactions O
Occurring O
at O
an O
Incidence O
of O
> O
= O
2 O
% O
among O
SEROQUEL O
Treated O
Patients O
in O
Short-Term O
, O
Placebo-Controlled O
Trials O
Schizophrenia B-Not_AE_Candidate
( O
Adolescents O
, O
13- O
17 O
years O
old O
) O
The O
following O
findings O
were O
based O
on O
a O
6-week O
placebo-controlled O
trial O
in O
which O
quetiapine O
was O
administered O
in O
either O
doses O
of O
400 O
or O
800 O
mg/day O
. O

Table O
13 O
enumerates O
the O
incidence O
, O
rounded O
to O
the O
nearest O
percent O
, O
of O
treatment-emergent O
adverse O
reactions O
that O
occurred O
during O
therapy O
( O
up O
to O
6 O
weeks O
) O
of O
schizophrenia B-Not_AE_Candidate
in O
2 O
% O
or O
more O
of O
patients O
treated O
with O
SEROQUEL O
( O
doses O
of O
400 O
or O
800 O
mg/day O
) O
where O
the O
incidence O
in O
patients O
treated O
with O
SEROQUEL O
was O
at O
least O
twice O
the O
incidence O
in O
placebo-treated O
patients O
. O

Adverse O
events O
that O
were O
potentially O
dose-related O
with O
higher O
frequency O
in O
the O
800 O
mg O
group O
compared O
to O
the O
400 O
mg O
group O
included O
dizziness B-OSE_Labeled_AE
( O
8 O
% O
vs O
. O
15 O
% O
) O
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
10 O
% O
) O
, O
and O
tachycardia B-OSE_Labeled_AE
( O
6 O
% O
vs O
. O
11 O
% O
) O
. O

Table O
13 O
: O
Adverse O
Reaction O
Incidence O
in O
a O
6-Week O
Placebo-Controlled O
Clinical O
Trial O
for O
the O
Treatment O
of O
Schizophrenia O
in O
Adolescent O
Patients O
Preferred O
Term O
SEROQUEL O
400 O
mg O
( O
n=73 O
) O
SEROQUEL800 O
mg O
( O
n=74 O
) O
Placebo O
( O
n=75 O
) O
Somnolence B-OSE_Labeled_AE
Somnolence O
combines O
adverse O
reaction O
terms O
somnolence B-OSE_Labeled_AE
and O
sedation B-OSE_Labeled_AE
. O

33 O
% O
35 O
% O
11 O
% O
Dizziness B-OSE_Labeled_AE
8 O
% O
15 O
% O
5 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
4 O
% O
10 O
% O
1 O
% O
Tachycardia B-OSE_Labeled_AE
Tachycardia O
combines O
adverse O
reaction O
terms O
tachycardia B-OSE_Labeled_AE
and O
sinus B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
. O

6 O
% O
11 O
% O
0 O
% O
Irritability B-OSE_Labeled_AE
3 O
% O
5 O
% O
0 O
% O
Arthralgia B-OSE_Labeled_AE
1 O
% O
3 O
% O
0 O
% O
Asthenia B-OSE_Labeled_AE
1 O
% O
3 O
% O
1 O
% O
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
1 O
% O
3 O
% O
0 O
% O
Dyspnea B-OSE_Labeled_AE
0 O
% O
3 O
% O
0 O
% O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
3 O
% O
1 O
% O
0 O
% O
Anorexia B-OSE_Labeled_AE
3 O
% O
1 O
% O
0 O
% O
Tooth B-OSE_Labeled_AE
Abscess I-OSE_Labeled_AE
3 O
% O
1 O
% O
0 O
% O
Dyskinesia B-OSE_Labeled_AE
3 O
% O
0 O
% O
0 O
% O
Epistaxis B-OSE_Labeled_AE
3 O
% O
0 O
% O
1 O
% O
Muscle B-OSE_Labeled_AE
Rigidity I-OSE_Labeled_AE
3 O
% O
0 O
% O
0 O
% O
Bipolar O
I O
Mania O
( O
Children O
and O
Adolescents O
10 O
to O
17 O
years O
old O
) O
The O
following O
findings O
were O
based O
on O
a O
3-week O
placebo-controlled O
trial O
in O
which O
quetiapine O
was O
administered O
in O
either O
doses O
of O
400 O
or O
600 O
mg/day O
. O

Commonly O
Observed O
Adverse O
Reactions O
In O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
therapy O
( O
up O
to O
3 O
weeks O
) O
the O
most O
commonly O
observed O
adverse O
reactions O
associated O
with O
the O
use O
of O
quetiapine O
in O
children O
and O
adolescents O
( O
incidence O
of O
5 O
% O
or O
greater O
and O
quetiapine O
incidence O
at O
least O
twice O
that O
for O
placebo O
) O
were O
somnolence B-OSE_Labeled_AE
( O
53 O
% O
) O
, O
dizziness B-OSE_Labeled_AE
( O
18 O
% O
) O
, O
fatigue B-OSE_Labeled_AE
( O
11 O
% O
) O
, O
increased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
( O
9 O
% O
) O
, O
nausea B-OSE_Labeled_AE
( O
8 O
% O
) O
, O
vomiting B-OSE_Labeled_AE
( O
8 O
% O
) O
, O
tachycardia B-OSE_Labeled_AE
( O
7 O
% O
) O
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
( O
7 O
% O
) O
, O
and O
weight B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
6 O
% O
) O
. O

Table O
14 O
enumerates O
the O
incidence O
, O
rounded O
to O
the O
nearest O
percent O
, O
of O
treatment-emergent O
adverse O
reactions O
that O
occurred O
during O
therapy O
( O
up O
to O
3 O
weeks O
) O
of O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
in O
2 O
% O
or O
more O
of O
patients O
treated O
with O
SEROQUEL O
( O
doses O
of O
400 O
or O
600 O
mg/day O
) O
where O
the O
incidence O
in O
patients O
treated O
with O
SEROQUEL O
was O
greater O
than O
the O
incidence O
in O
placebo-treated O
patients O
. O

Adverse O
events O
that O
were O
potentially O
dose-related O
with O
higher O
frequency O
in O
the O
600 O
mg O
group O
compared O
to O
the O
400 O
mg O
group O
included O
somnolence B-OSE_Labeled_AE
( O
50 O
% O
vs O
. O
57 O
% O
) O
, O
nausea B-OSE_Labeled_AE
( O
6 O
% O
vs O
. O
10 O
% O
) O
and O
tachycardia B-OSE_Labeled_AE
( O
6 O
% O
vs O
. O
9 O
% O
) O
. O

Table O
14 O
: O
Adverse O
Reactions O
in O
a O
3-Week O
Placebo-Controlled O
Clinical O
Trial O
for O
the O
Treatment O
of O
Bipolar O
Mania O
in O
Children O
and O
Adolescent O
Patients O
Preferred O
Term O
SEROQUEL O
400 O
mg O
( O
n=95 O
) O
SEROQUEL O
600 O
mg O
( O
n=98 O
) O
Placebo O
( O
n=90 O
) O
Somnolence B-OSE_Labeled_AE
Somnolence O
combines O
adverse O
reactions O
terms O
somnolence B-OSE_Labeled_AE
and O
sedation B-OSE_Labeled_AE
. O

50 O
% O
57 O
% O
14 O
% O
Dizziness B-OSE_Labeled_AE
19 O
% O
17 O
% O
2 O
% O
Nausea B-OSE_Labeled_AE
6 O
% O
10 O
% O
4 O
% O
Fatigue B-OSE_Labeled_AE
14 O
% O
9 O
% O
4 O
% O
Increased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
10 O
% O
9 O
% O
1 O
% O
Tachycardia B-OSE_Labeled_AE
Tachycardia O
combines O
adverse O
reaction O
terms O
tachycardia B-OSE_Labeled_AE
and O
sinus B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
. O

6 O
% O
9 O
% O
1 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
7 O
% O
7 O
% O
0 O
% O
Vomiting B-OSE_Labeled_AE
8 O
% O
7 O
% O
3 O
% O
Nasal B-OSE_Labeled_AE
Congestion I-OSE_Labeled_AE
3 O
% O
6 O
% O
2 O
% O
Weight B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
6 O
% O
6 O
% O
0 O
% O
Irritability B-OSE_Labeled_AE
3 O
% O
5 O
% O
1 O
% O
Pyrexia B-OSE_Labeled_AE
1 O
% O
4 O
% O
1 O
% O
Aggression B-OSE_Labeled_AE
1 O
% O
3 O
% O
0 O
% O
Musculoskeletal B-OSE_Labeled_AE
Stiffness I-OSE_Labeled_AE
1 O
% O
3 O
% O
1 O
% O
Accidental B-OSE_Labeled_AE
Overdose I-OSE_Labeled_AE
0 O
% O
2 O
% O
0 O
% O
Acne B-OSE_Labeled_AE
3 O
% O
2 O
% O
0 O
% O
Arthralgia B-OSE_Labeled_AE
4 O
% O
2 O
% O
1 O
% O
Lethargy B-OSE_Labeled_AE
2 O
% O
2 O
% O
0 O
% O
Pallor B-OSE_Labeled_AE
1 O
% O
2 O
% O
0 O
% O
Stomach B-OSE_Labeled_AE
Discomfort I-OSE_Labeled_AE
4 O
% O
2 O
% O
1 O
% O
Syncope B-OSE_Labeled_AE
2 O
% O
2 O
% O
0 O
% O
Vision B-OSE_Labeled_AE
Blurred I-OSE_Labeled_AE
3 O
% O
2 O
% O
0 O
% O
Constipation B-OSE_Labeled_AE
4 O
% O
2 O
% O
0 O
% O
Ear B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
2 O
% O
0 O
% O
0 O
% O
Paresthesia B-OSE_Labeled_AE
2 O
% O
0 O
% O
0 O
% O
Sinus B-OSE_Labeled_AE
Congestion I-OSE_Labeled_AE
3 O
% O
0 O
% O
0 O
% O
Thirst B-OSE_Labeled_AE
2 O
% O
0 O
% O
0 O
% O
Extrapyramidal O
Symptoms O
: O
In O
a O
short-term O
placebo-controlled O
monotherapy O
trial O
in O
adolescent O
patients O
with O
schizophrenia B-Not_AE_Candidate
( O
6-week O
duration O
) O
, O
the O
aggregated O
incidence O
of O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
was O
12.9 O
% O
( O
19/147 O
) O
for O
SEROQUEL O
and O
5.3 O
% O
( O
4/75 O
) O
for O
placebo O
, O
though O
the O
incidence O
of O
the O
individual O
adverse O
events O
( O
akathisia B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
hypokinesia B-OSE_Labeled_AE
, O
restlessness B-OSE_Labeled_AE
, O
psychomotor B-OSE_Labeled_AE
hyperactivity I-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
dyskinesia B-OSE_Labeled_AE
) O
did O
not O
exceed O
4.1 O
% O
in O
any O
treatment O
group O
. O

In O
a O
short-term O
placebo-controlled O
monotherapy O
trial O
in O
children O
and O
adolescent O
patients O
with O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
3-week O
duration O
) O
, O
the O
aggregated O
incidence O
of O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
was O
3.6 O
% O
( O
7/193 O
) O
or O
SEROQUEL O
and O
1.1 O
% O
( O
1/90 O
) O
for O
placebo O
. O

Table O
15 O
presents O
a O
listing O
of O
patients O
with O
adverse O
reactions O
potentially O
associated O
with O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
in O
the O
short-term O
placebo-controlled O
monotherapy O
trial O
in O
adolescent O
patients O
with O
schizophrenia B-Not_AE_Candidate
( O
6-week O
duration O
) O
. O

In O
Tables O
15 O
- O
16 O
dystonic B-OSE_Labeled_AE
event I-OSE_Labeled_AE
included O
nuchal B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
hypertonia B-OSE_Labeled_AE
, O
and O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
; O
parkinsonism B-OSE_Labeled_AE
included O
cogwheel B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
and O
tremor B-OSE_Labeled_AE
; O
akathisia B-OSE_Labeled_AE
included O
akathisia B-OSE_Labeled_AE
only O
dyskinetic B-OSE_Labeled_AE
event I-OSE_Labeled_AE
included O
tardive B-OSE_Labeled_AE
dyskinesia I-OSE_Labeled_AE
, O
dyskinesia B-OSE_Labeled_AE
; O
and O
choreoathetosis B-OSE_Labeled_AE
; O
and O
other O
extrapyramidal B-OSE_Labeled_AE
event I-OSE_Labeled_AE
included O
restlessness B-OSE_Labeled_AE
and O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
. O

Table O
15 O
: O
Adverse O
Reactions O
Associated O
with O
Extrapyramidal O
Symptoms O
in O
the O
Placebo-Controlled O
Trial O
in O
Adolescent O
Patients O
with O
Schizophrenia O
( O
6-week O
duration O
) O
Preferred O
Term O
SEROQUEL O
400 O
mg/day O
( O
N=73 O
) O
SEROQUEL O
800 O
mg/day O
( O
N=74 O
) O
All O
SEROQUEL O
( O
N=147 O
) O
Placebo O
( O
N=75 O
) O
n O
% O
n O
% O
n O
% O
n O
% O
Dystonic B-OSE_Labeled_AE
event I-OSE_Labeled_AE
2 O
2.7 O
0 O
0.0 O
2 O
1.4 O
0 O
0.0 O
Parkinsonism B-OSE_Labeled_AE
4 O
5.5 O
4 O
5.4 O
8 O
5.4 O
2 O
2.7 O
Akathisia B-OSE_Labeled_AE
3 O
4.1 O
4 O
5.4 O
7 O
4.8 O
3 O
4.0 O
Dyskinetic B-OSE_Labeled_AE
event I-OSE_Labeled_AE
2 O
2.7 O
0 O
0.0 O
2 O
1.4 O
0 O
0.0 O
Other O
Extrapyramidal B-OSE_Labeled_AE
Event I-OSE_Labeled_AE
2 O
2.7 O
2 O
2.7 O
4 O
2.7 O
0 O
0.0 O
Table O
16 O
presents O
a O
listing O
of O
patients O
with O
adverse O
reactions O
associated O
with O
extrapyramidal B-NonOSE_AE
symptoms I-NonOSE_AE
in O
a O
short-term O
placebo-controlled O
monotherapy O
trial O
in O
children O
and O
adolescent O
patients O
with O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
3-week O
duration O
) O
. O

Table O
16 O
: O
Adverse O
Reactions O
Associated O
with O
Extrapyramidal O
Symptoms O
in O
a O
Placebo-Controlled O
Trial O
in O
Children O
and O
Adolescent O
Patients O
with O
Bipolar O
I O
Mania O
( O
3-week O
duration O
) O
Preferred O
TermThere O
were O
no O
adverse O
experiences O
with O
the O
preferred O
term O
of O
dystonic B-NonOSE_AE
or O
dyskinetic B-NonOSE_AE
events I-NonOSE_AE
. O

SEROQUEL O
400 O
mg/day O
( O
N=95 O
) O
SEROQUEL O
600 O
mg/day O
( O
N=98 O
) O
All O
SEROQUEL O
( O
N=193 O
) O
Placebo O
( O
N=90 O
) O
n O
% O
n O
% O
n O
% O
n O
% O
Parkinsonism B-OSE_Labeled_AE
2 O
2.1 O
1 O
1.0 O
3 O
1.6 O
1 O
1.1 O
Akathisia B-OSE_Labeled_AE
1 O
1.0 O
1 O
1.0 O
2 O
1.0 O
0 O
0.0 O
Other O
Extrapyramidal B-OSE_Labeled_AE
Event I-OSE_Labeled_AE
1 O
1.1 O
1 O
1.0 O
2 O
1.0 O
0 O
0.0 O
Other O
Adverse O
Reactions O
Observed O
During O
the O
Pre-Marketing O
Evaluation O
of O
SEROQUEL O
Following O
is O
a O
list O
of O
COSTART O
terms O
that O
reflect O
treatment-emergent O
adverse O
reactions O
as O
defined O
in O
the O
introduction O
to O
the O
ADVERSE O
REACTIONS O
section O
reported O
by O
patients O
treated O
with O
SEROQUEL O
at O
multiple O
doses O
> O
75 O
mg/day O
during O
any O
phase O
of O
a O
trial O
within O
the O
premarketing O
database O
of O
approximately O
2200 O
patients O
treated O
for O
schizophrenia B-Not_AE_Candidate
. O

All O
reported O
reactions O
are O
included O
except O
those O
already O
listed O
in O
the O
tables O
or O
elsewhere O
in O
labeling O
, O
those O
reactions O
for O
which O
a O
drug O
cause O
was O
remote O
, O
and O
those O
reaction O
terms O
which O
were O
so O
general O
as O
to O
be O
uninformative O
. O

It O
is O
important O
to O
emphasize O
that O
, O
although O
the O
reactions O
reported O
occurred O
during O
treatment O
with O
SEROQUEL O
, O
they O
were O
not O
necessarily O
caused O
by O
it O
. O

Reactions O
are O
further O
categorized O
by O
body O
system O
and O
listed O
in O
order O
of O
decreasing O
frequency O
according O
to O
the O
following O
definitions O
: O
frequent O
adverse O
reactions O
are O
those O
occurring O
in O
at O
least O
1/100 O
patients O
( O
only O
those O
not O
already O
listed O
in O
the O
tabulated O
results O
from O
placebo-controlled O
trials O
appear O
in O
this O
listing O
) O
; O
infrequent O
adverse O
reactions O
are O
those O
occurring O
in O
1/100 O
to O
1/1000 O
patients O
; O
rare O
reactions O
are O
those O
occurring O
in O
fewer O
than O
1/1000 O
patients O
. O

Nervous B-NonOSE_AE
System I-NonOSE_AE
: O
Infrequent O
: O
abnormal B-OSE_Labeled_AE
dreams I-OSE_Labeled_AE
, O
dyskinesia B-OSE_Labeled_AE
, O
thinking B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
tardive B-OSE_Labeled_AE
dyskinesia I-OSE_Labeled_AE
, O
vertigo B-OSE_Labeled_AE
, O
involuntary B-OSE_Labeled_AE
movements I-OSE_Labeled_AE
, O
confusion B-OSE_Labeled_AE
, O
amnesia B-OSE_Labeled_AE
, O
psychosis B-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
, O
hyperkinesia B-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
, O
incoordination B-OSE_Labeled_AE
, O
paranoid B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
gait I-OSE_Labeled_AE
, O
myoclonus B-OSE_Labeled_AE
, O
delusions B-OSE_Labeled_AE
, O
manic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
apathy B-OSE_Labeled_AE
, O
ataxia B-OSE_Labeled_AE
, O
depersonalization B-OSE_Labeled_AE
, O
stupor B-OSE_Labeled_AE
, O
bruxism B-OSE_Labeled_AE
, O
catatonic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
hemiplegia B-OSE_Labeled_AE
; O
aphasia B-OSE_Labeled_AE
, O
buccoglossal B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
choreoathetosis B-OSE_Labeled_AE
, O
delirium B-OSE_Labeled_AE
, O
emotional B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
, O
euphoria B-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
neuralgia B-OSE_Labeled_AE
, O
stuttering B-OSE_Labeled_AE
, O
subdural B-OSE_Labeled_AE
hematoma I-OSE_Labeled_AE
. O

Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
: O
Frequent O
: O
flu B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
; O
Infrequent O
: O
neck B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
pelvic B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
suicide O
attempt O
, O
malaise B-OSE_Labeled_AE
, O
photosensitivity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
face B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
moniliasis B-OSE_Labeled_AE
; O
Rare O
: O
abdomen B-OSE_Labeled_AE
enlarged I-OSE_Labeled_AE
. O

Digestive B-NonOSE_AE
System I-NonOSE_AE
: O
Frequent O
: O
anorexia B-OSE_Labeled_AE
; O
Infrequent O
: O
increased B-OSE_Labeled_AE
salivation I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
gamma B-OSE_Labeled_AE
glutamyl I-OSE_Labeled_AE
transpeptidase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
gingivitis B-OSE_Labeled_AE
, O
dysphagia B-OSE_Labeled_AE
, O
flatulence B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
gastritis B-OSE_Labeled_AE
, O
hemorrhoids B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
thirst B-OSE_Labeled_AE
, O
tooth B-OSE_Labeled_AE
caries I-OSE_Labeled_AE
, O
fecal B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
gastroesophageal B-OSE_Labeled_AE
reflux I-OSE_Labeled_AE
, O
gum B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
rectal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
; O
Rare O
: O
glossitis B-OSE_Labeled_AE
, O
hematemesis B-OSE_Labeled_AE
, O
intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
, O
melena B-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
. O

Cardiovascular B-NonOSE_AE
System I-NonOSE_AE
: O
Infrequent O
: O
vasodilatation B-OSE_Labeled_AE
, O
QT B-OSE_Labeled_AE
interval I-OSE_Labeled_AE
prolonged I-OSE_Labeled_AE
, O
migraine B-OSE_Labeled_AE
, O
bradycardia B-OSE_Labeled_AE
, O
cerebral B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
, O
irregular B-OSE_Labeled_AE
pulse I-OSE_Labeled_AE
, O
T B-OSE_Labeled_AE
wave I-OSE_Labeled_AE
abnormality I-OSE_Labeled_AE
, O
bundle B-OSE_Labeled_AE
branch I-OSE_Labeled_AE
block I-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
deep B-OSE_Labeled_AE
thrombophlebitis I-OSE_Labeled_AE
, O
T B-OSE_Labeled_AE
wave I-OSE_Labeled_AE
inversion I-OSE_Labeled_AE
; O
Rare O
: O
angina B-OSE_Labeled_AE
pectoris I-OSE_Labeled_AE
, O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
AV B-OSE_Labeled_AE
block I-OSE_Labeled_AE
first I-OSE_Labeled_AE
degree I-OSE_Labeled_AE
, O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
ST B-OSE_Labeled_AE
elevated I-OSE_Labeled_AE
, O
thrombophlebitis B-OSE_Labeled_AE
, O
T B-OSE_Labeled_AE
wave I-OSE_Labeled_AE
flattening I-OSE_Labeled_AE
, O
ST B-OSE_Labeled_AE
abnormality I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
QRS I-OSE_Labeled_AE
duration I-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
System I-NonOSE_AE
: O
Frequent O
: O
cough B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
; O
Infrequent O
: O
pneumonia B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
asthma B-OSE_Labeled_AE
; O
Rare O
: O
hiccup B-OSE_Labeled_AE
, O
hyperventilation B-OSE_Labeled_AE
. O

Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
System I-NonOSE_AE
: O
Infrequent O
: O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
alkaline B-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
hyperlipidemia B-OSE_Labeled_AE
, O
alcohol B-OSE_Labeled_AE
intolerance I-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
creatinine B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
hypoglycemia B-OSE_Labeled_AE
; O
Rare O
: O
glycosuria B-OSE_Labeled_AE
, O
gout B-OSE_Labeled_AE
, O
hand B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
hypokalemia B-OSE_Labeled_AE
, O
water B-OSE_Labeled_AE
intoxication I-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
System I-NonOSE_AE
: O
Infrequent O
: O
pruritus B-OSE_Labeled_AE
, O
acne B-OSE_Labeled_AE
, O
eczema B-OSE_Labeled_AE
, O
contact B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
maculopapular B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
seborrhea B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
; O
Rare O
: O
exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
psoriasis B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
. O

Urogenital B-NonOSE_AE
System I-NonOSE_AE
: O
Infrequent O
: O
dysmenorrheal B-OSE_Labeled_AE
[ O
note O
: O
Adjusted O
for O
gender O
. O
] O

, O
vaginitis B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
metrorrhagia B-OSE_Labeled_AE
, O
impotence B-OSE_Labeled_AE
, O
dysuria B-OSE_Labeled_AE
, O
vaginal B-OSE_Labeled_AE
moniliasis I-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
, O
cystitis B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
frequency I-OSE_Labeled_AE
, O
amenorrhea B-OSE_Labeled_AE
, O
female B-OSE_Labeled_AE
lactation I-OSE_Labeled_AE
, O
leukorrhea B-OSE_Labeled_AE
, O
vaginal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
vulvovaginitis B-OSE_Labeled_AE
, O
orchitis B-OSE_Labeled_AE
; O
gynecomastia B-OSE_Labeled_AE
, O
nocturia B-OSE_Labeled_AE
, O
polyuria B-OSE_Labeled_AE
, O
acute B-OSE_Labeled_AE
kidney I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
. O

Special B-NonOSE_AE
Senses I-NonOSE_AE
: O
Infrequent O
: O
conjunctivitis B-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
eyes I-OSE_Labeled_AE
, O
tinnitus B-OSE_Labeled_AE
, O
taste B-OSE_Labeled_AE
perversion I-OSE_Labeled_AE
, O
blepharitis B-OSE_Labeled_AE
, O
eye B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
; O
Rare O
: O
abnormality B-OSE_Labeled_AE
of I-OSE_Labeled_AE
accommodation I-OSE_Labeled_AE
, O
deafness B-OSE_Labeled_AE
, O
glaucoma B-OSE_Labeled_AE
. O

Musculoskeletal B-NonOSE_AE
System I-NonOSE_AE
: O
Infrequent O
: O
pathological B-OSE_Labeled_AE
fracture I-OSE_Labeled_AE
, O
myasthenia B-OSE_Labeled_AE
, O
twitching B-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
, O
arthritis B-OSE_Labeled_AE
, O
leg B-OSE_Labeled_AE
cramps I-OSE_Labeled_AE
, O
bone B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
. O

Hemic B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
: O
Infrequent O
: O
leukocytosis B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
, O
ecchymosis B-OSE_Labeled_AE
, O
eosinophilia B-OSE_Labeled_AE
, O
hypochromic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
; O
lymphadenopathy B-OSE_Labeled_AE
, O
cyanosis B-OSE_Labeled_AE
; O
Rare O
: O
hemolysis B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
. O

Endocrine B-NonOSE_AE
System I-NonOSE_AE
: O
Infrequent O
: O
hypothyroidism B-OSE_Labeled_AE
, O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
; O
Rare O
: O
hyperthyroidism B-OSE_Labeled_AE
. O

Laboratory O
, O
ECG O
and O
vital O
sign O
changes O
observed O
in O
clinical O
studies O
Laboratory O
Changes O
: O
Neutrophil O
Counts O
Adults O
: O
In O
placebo-controlled O
monotherapy O
clinical O
trials O
involving O
3368 O
patients O
on O
quetiapine O
fumarate O
and O
1515 O
on O
placebo O
, O
the O
incidence O
of O
at O
least O
one O
occurrence O
of O
neutrophil B-OSE_Labeled_AE
count I-OSE_Labeled_AE
< I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
x I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
9 I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
among O
patients O
with O
a O
normal O
baseline O
neutrophil O
count O
and O
at O
least O
one O
available O
follow O
up O
laboratory O
measurement O
was O
0.3 O
% O
( O
10/2967 O
) O
in O
patients O
treated O
with O
quetiapine O
fumarate O
, O
compared O
to O
0.1 O
% O
( O
2/1349 O
) O
in O
patients O
treated O
with O
placebo O
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
. O

Transaminase O
Elevations O
Adults O
: O
Asymptomatic O
, O
transient O
and O
reversible O
elevations B-OSE_Labeled_AE
in O
serum O
transaminases O
( O
primarily O
ALT I-OSE_Labeled_AE
) O
have O
been O
reported O
. O

In O
schizophrenia B-Not_AE_Candidate
trials O
in O
adults O
, O
the O
proportions O
of O
patients O
with O
transaminase B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
of O
> O
3 O
times O
the O
upper O
limits O
of O
the O
normal O
reference O
range O
in O
a O
pool O
of O
3- O
to O
6-week O
placebo-controlled O
trials O
were O
approximately O
6 O
% O
( O
29/483 O
) O
for O
SEROQUEL O
compared O
to O
1 O
% O
( O
3/194 O
) O
for O
placebo O
. O

In O
acute O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
trials O
in O
adults O
, O
the O
proportions O
of O
patients O
with O
transaminase B-NonOSE_AE
elevations I-NonOSE_AE
of O
> O
3 O
times O
the O
upper O
limits O
of O
the O
normal O
reference O
range O
in O
a O
pool O
of O
3- O
to O
12-week O
placebo-controlled O
trials O
were O
approximately O
1 O
% O
for O
both O
SEROQUEL O
( O
3/560 O
) O
and O
placebo O
( O
3/294 O
) O
. O

These O
hepatic B-OSE_Labeled_AE
enzyme I-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
usually O
occurred O
within O
the O
first O
3 O
weeks O
of O
drug O
treatment O
and O
promptly O
returned O
to O
pre-study O
levels O
with O
ongoing O
treatment O
with O
SEROQUEL O
. O

In O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
trials O
, O
the O
proportions O
of O
patients O
with O
transaminase B-NonOSE_AE
elevations I-NonOSE_AE
of O
> O
3 O
times O
the O
upper O
limits O
of O
the O
normal O
reference O
range O
in O
two O
8-week O
placebo-controlled O
trials O
was O
1 O
% O
( O
5/698 O
) O
for O
SEROQUEL O
and O
2 O
% O
( O
6/347 O
) O
for O
placebo O
. O

Decreased O
Hemoglobin O
Adults O
: O
In O
short-term O
placebo-controlled O
trials O
, O
decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
to O
< O
= O
13 O
g/dL O
males O
, O
< O
= O
12 O
g/dL O
females O
on O
at O
least O
one O
occasion O
occurred O
in O
8.3 O
% O
( O
594/7155 O
) O
of O
quetiapine-treated O
patients O
compared O
to O
6.2 O
% O
( O
219/3536 O
) O
of O
patients O
treated O
with O
placebo O
. O

In O
a O
database O
of O
controlled O
and O
uncontrolled O
clinical O
trials O
, O
decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
to O
< O
= O
13 O
g/dL O
males O
, O
< O
= O
12 O
g/dL O
females O
on O
at O
least O
one O
occasion O
occurred O
in O
11 O
% O
( O
2277/20729 O
) O
of O
quetiapine-treated O
patients O
. O

Interference O
with O
Urine O
Drug O
Screens O
There O
have O
been O
literature O
reports O
suggesting O
false B-OSE_Labeled_AE
positive I-OSE_Labeled_AE
results I-OSE_Labeled_AE
in I-OSE_Labeled_AE
urine I-OSE_Labeled_AE
enzyme I-OSE_Labeled_AE
immunoassays I-OSE_Labeled_AE
for O
methadone O
and O
tricyclic O
antidepressants O
in O
patients O
who O
have O
taken O
quetiapine O
. O

Caution O
should O
be O
exercised O
in O
the O
interpretation O
of O
positive B-OSE_Labeled_AE
urine I-OSE_Labeled_AE
drug I-OSE_Labeled_AE
screen I-OSE_Labeled_AE
results I-OSE_Labeled_AE
for O
these O
drugs O
, O
and O
confirmation O
by O
alternative O
analytical O
technique O
( O
e.g. O
, O
chromatographic O
methods O
) O
should O
be O
considered O
. O

ECG O
Changes O
Adults O
: O
Between-group O
comparisons O
for O
pooled O
placebo-controlled O
trials O
revealed O
no O
statistically O
significant O
SEROQUEL/placebo O
differences O
in O
the O
proportions O
of O
patients O
experiencing O
potentially O
important O
changes B-NonOSE_AE
in I-NonOSE_AE
ECG I-NonOSE_AE
parameters I-NonOSE_AE
, O
including O
QT O
, O
QTc O
, O
and O
PR O
intervals O
. O

However O
, O
the O
proportions O
of O
patients O
meeting O
the O
criteria O
for O
tachycardia B-OSE_Labeled_AE
were O
compared O
in O
four O
3- O
to O
6-week O
placebo-controlled O
clinical O
trials O
for O
the O
treatment O
of O
schizophrenia B-Not_AE_Candidate
revealing O
a O
1 O
% O
( O
4/399 O
) O
incidence O
for O
SEROQUEL O
compared O
to O
0.6 O
% O
( O
1/156 O
) O
incidence O
for O
placebo O
. O

In O
acute O
( O
monotherapy O
) O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
trials O
the O
proportions O
of O
patients O
meeting O
the O
criteria O
for O
tachycardia B-OSE_Labeled_AE
was O
0.5 O
% O
( O
1/192 O
) O
for O
SEROQUEL O
compared O
to O
0 O
% O
( O
0/178 O
) O
incidence O
for O
placebo O
. O

In O
acute O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
adjunct O
) O
trials O
the O
proportions O
of O
patients O
meeting O
the O
same O
criteria O
was O
0.6 O
% O
( O
1/166 O
) O
for O
SEROQUEL O
compared O
to O
0 O
% O
( O
0/171 O
) O
incidence O
for O
placebo O
. O

In O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
trials O
, O
no O
patients O
had O
heart B-NonOSE_AE
rate I-NonOSE_AE
increases I-NonOSE_AE
to O
> O
120 O
beats O
per O
minute O
. O

SEROQUEL O
use O
was O
associated O
with O
a O
mean O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
, O
assessed O
by O
ECG O
, O
of O
7 O
beats O
per O
minute O
compared O
to O
a O
mean O
increase O
of O
1 O
beat O
per O
minute O
among O
placebo O
patients O
. O

This O
slight O
tendency O
to O
tachycardia B-NonOSE_AE
in O
adults O
may O
be O
related O
to O
SEROQUEL O
's O
potential O
for O
inducing O
orthostatic B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
. O

Children O
and O
Adolescents O
: O
In O
the O
acute O
( O
6 O
week O
) O
schizophrenia B-Not_AE_Candidate
trial O
in O
adolescents O
, O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
( O
> O
110 O
bpm O
) O
occurred O
in O
5.2 O
% O
( O
3/73 O
) O
of O
patients O
receiving O
SEROQUEL O
400 O
mg O
and O
8.5 O
% O
( O
5/74 O
) O
of O
patients O
receiving O
SEROQUEL O
800 O
mg O
compared O
to O
0 O
% O
( O
0/75 O
) O
of O
patients O
receiving O
placebo O
. O

Mean O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
were O
3.8 O
bpm O
and O
11.2 O
bpm O
for O
SEROQUEL O
400 O
mg O
and O
800 O
mg O
groups O
, O
respectively O
, O
compared O
to O
a O
decrease O
of O
3.3 O
bpm O
in O
the O
placebo O
group O
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
. O

In O
the O
acute O
( O
3 O
week O
) O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
trial O
in O
children O
and O
adolescents O
, O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
( O
> O
110 O
bpm O
) O
occurred O
in O
1.1 O
% O
( O
1/89 O
) O
of O
patients O
receiving O
SEROQUEL O
400 O
mg O
and O
4.7 O
% O
( O
4/85 O
) O
of O
patients O
receiving O
SEROQUEL O
600 O
mg O
compared O
to O
0 O
% O
( O
0/98 O
) O
of O
patients O
receiving O
placebo O
. O

Mean O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
were O
12.8 O
bpm O
and O
13.4 O
bpm O
for O
SEROQUEL O
400 O
mg O
and O
600 O
mg O
groups O
, O
respectively O
, O
compared O
to O
a O
decrease O
of O
1.7 O
bpm O
in O
the O
placebo O
group O
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
. O

In O
an O
acute O
( O
8-week O
) O
SEROQUEL O
XR O
trial O
in O
children O
and O
adolescents O
( O
10-17 O
years O
of O
age O
) O
with O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
, O
in O
which O
efficacy O
was O
not O
established O
, O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
( O
> O
110 O
bpm O
10-12 O
years O
and O
13-17 O
years O
) O
occurred O
in O
0 O
% O
of O
patients O
receiving O
SEROQUEL O
XR O
and O
1.2 O
% O
of O
patients O
receiving O
placebo O
. O

Mean O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
were O
3.4 O
bpm O
for O
SEROQUEL O
XR O
, O
compared O
to O
0.3 O
bpm O
in O
the O
placebo O
group O
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
were O
identified O
during O
post O
approval O
of O
SEROQUEL O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Adverse O
reactions O
reported O
since O
market O
introduction O
which O
were O
temporally O
related O
to O
quetiapine O
therapy O
include O
anaphylactic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
cardiomyopathy B-OSE_Labeled_AE
, O
drug B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
with I-OSE_Labeled_AE
eosinophilia I-OSE_Labeled_AE
and I-OSE_Labeled_AE
systemic I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
( I-OSE_Labeled_AE
DRESS I-OSE_Labeled_AE
) O
, O
hyponatremia B-OSE_Labeled_AE
, O
myocarditis B-OSE_Labeled_AE
, O
nocturnal B-OSE_Labeled_AE
enuresis I-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
, O
retrograde B-OSE_Labeled_AE
amnesia I-OSE_Labeled_AE
, O
rhabdomyolysis B-OSE_Labeled_AE
, O
syndrome B-OSE_Labeled_AE
of I-OSE_Labeled_AE
inappropriate I-OSE_Labeled_AE
antidiuretic I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
secretion I-OSE_Labeled_AE
( I-OSE_Labeled_AE
SIADH I-OSE_Labeled_AE
) O
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
SJS I-OSE_Labeled_AE
) O
, O
and O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TEN I-OSE_Labeled_AE
) O
. O

BOXED O
WARNING O
: O
WARNING O
: O
INCREASED O
MORTALITY O
IN O
ELDERLY O
PATIENTS O
WITH O
DEMENTIA-RELATED O
PSYCHOSIS O
; O
and O
SUICIDAL O
THOUGHTS O
AND O
BEHAVIORS O
WARNING O
: O
INCREASED O
MORTALITY O
IN O
ELDERLY O
PATIENTS O
WITH O
DEMENTIA-RELATED O
PSYCHOSIS O
; O
and O
SUICIDAL O
THOUGHTS O
AND O
BEHAVIORS O
Increased O
Mortality O
in O
Elderly O
Patients O
with O
Dementia-Related O
Psychosis O
Elderly O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
treated O
with O
antipsychotic O
drugs O
are O
at O
an O
increased O
risk O
of O
death B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

SEROQUEL O
is O
not O
approved O
for O
the O
treatment O
of O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Suicidal O
Thoughts O
and O
Behaviors O
Antidepressants O
increased O
the O
risk O
of O
suicidal B-OSE_Labeled_AE
thoughts O
and O
behavior I-OSE_Labeled_AE
in O
children O
, O
adolescents O
, O
and O
young O
adults O
in O
short-term O
studies O
. O

These O
studies O
did O
not O
show O
an O
increase O
in O
the O
risk O
of O
suicidal B-NonOSE_AE
thoughts O
and O
behavior I-NonOSE_AE
with O
antidepressant O
use O
in O
patients O
over O
age O
24 O
; O
there O
was O
a O
reduction O
in O
risk O
with O
antidepressant O
use O
in O
patients O
aged O
65 O
and O
older O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

In O
patients O
of O
all O
ages O
who O
are O
started O
on O
antidepressant O
therapy O
, O
monitor O
closely O
for O
worsening O
, O
and O
for O
emergence O
of O
suicidal B-NonOSE_AE
thoughts O
and O
behaviors I-NonOSE_AE
. O

Advise O
families O
and O
caregivers O
of O
the O
need O
for O
close O
observation O
and O
communication O
with O
the O
prescriber O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

SEROQUEL O
is O
not O
approved O
for O
use O
in O
pediatric O
patients O
under O
ten O
years O
of O
age O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.4 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
INCREASED O
MORTALITY O
IN O
ELDERLY O
PATIENTS O
WITH O
DEMENTIA-RELATED O
PSYCHOSIS O
; O
and O
SUICIDAL O
THOUGHTS O
AND O
BEHAVIORS O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

Increased O
Mortality O
in O
Elderly O
Patients O
with O
Dementia-Related O
Psychosis O
* O
Elderly O
patients O
with O
dementia-related O
psychosis O
treated O
with O
antipsychotic O
drugs O
are O
at O
an O
increased O
risk O
of O
death O
. O

SEROQUEL O
is O
not O
approved O
for O
elderly O
patients O
with O
dementia-related O
psychosis O
( O
5.1 O
) O
Suicidal O
Thoughts O
and O
Behaviors O
* O
Increased O
risk O
of O
suicidal O
thoughts O
and O
behavior O
in O
children O
, O
adolescents O
and O
young O
adults O
taking O
antidepressants O
( O
5.2 O
) O
* O
Monitor O
for O
worsening O
and O
emergence O
of O
suicidal O
thoughts O
and O
behaviors O
( O
5.2 O
) O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Cerebrovascular O
Adverse O
Reactions O
: O
Increased O
incidence O
of O
cerebrovascular O
adverse O
events O
( O
e.g. O
, O
stroke O
, O
transient O
ischemic O
attack O
) O
has O
been O
seen O
in O
elderly O
patients O
with O
dementia-related O
psychoses O
treated O
with O
atypical O
antipsychotic O
drugs O
( O
5.3 O
) O
* O
Neuroleptic O
Malignant O
Syndrome O
( O
NMS O
) O
: O
Manage O
with O
immediate O
discontinuation O
and O
close O
monitoring O
( O
5.4 O
) O
* O
* O
 O
Hyperglycemia O
and O
Diabetes O
Mellitus O
: O
Monitor O
patients O
for O
symptoms O
of O
hyperglycemia O
including O
polydipsia O
, O
polyuria O
, O
polyphagia O
, O
and O
weakness O
. O

Monitor O
glucose O
regularly O
in O
patients O
with O
diabetes O
or O
at O
risk O
for O
diabetes O
* O
 O
Dyslipidemia O
: O
Undesirable O
alterations O
have O
been O
observed O
in O
patients O
treated O
with O
atypical O
antipsychotics O
. O

Appropriate O
clinical O
monitoring O
is O
recommended O
, O
including O
fasting O
blood O
lipid O
testing O
at O
the O
beginning O
of O
, O
and O
periodically O
, O
during O
treatment O
* O
 O
Weight O
Gain O
: O
Gain O
in O
body O
weight O
has O
been O
observed O
; O
clinical O
monitoring O
of O
weight O
is O
recommended O
Metabolic O
Changes O
: O
Atypical O
antipsychotics O
have O
been O
associated O
with O
metabolic O
changes O
. O

These O
metabolic O
changes O
include O
hyperglycemia O
, O
dyslipidemia O
, O
and O
weight O
gain O
( O
5.5 O
) O
* O
Tardive O
Dyskinesia O
: O
Discontinue O
if O
clinically O
appropriate O
( O
5.6 O
) O
* O
Hypotension O
: O
Use O
with O
caution O
in O
patients O
with O
known O
cardiovascular O
or O
cerebrovascular O
disease O
( O
5.7 O
) O
* O
Increased O
Blood O
Pressure O
in O
Children O
and O
Adolescents O
: O
Monitor O
blood O
pressure O
at O
the O
beginning O
of O
, O
and O
periodically O
during O
treatment O
in O
children O
and O
adolescents O
( O
5.9 O
) O
* O
Leukopenia O
, O
Neutropenia O
and O
Agranulocytosis O
: O
Monitor O
complete O
blood O
count O
frequently O
during O
the O
first O
few O
months O
of O
treatment O
in O
patients O
with O
a O
pre-existing O
low O
white O
cell O
count O
or O
a O
history O
of O
leukopenia/neutropenia O
and O
discontinue O
SEROQUEL O
at O
the O
first O
sign O
of O
a O
decline O
in O
WBC O
in O
absence O
of O
other O
causative O
factors O
( O
5.10 O
) O
* O
Cataracts O
: O
Lens O
changes O
have O
been O
observed O
in O
patients O
during O
long-term O
quetiapine O
treatment O
. O

Lens O
examination O
is O
recommended O
when O
starting O
treatment O
and O
at O
6-month O
intervals O
during O
chronic O
treatment O
( O
5.11 O
) O
5.1 O
Increased O
Mortality O
in O
Elderly O
Patients O
with O
Dementia-Related O
Psychosis O
Elderly O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
treated O
with O
antipsychotic O
drugs O
are O
at O
an O
increased O
risk O
of O
death B-NonOSE_AE
. O

Analysis O
of O
17 O
placebo-controlled O
trials O
( O
modal O
duration O
of O
10 O
weeks O
) O
, O
largely O
in O
patients O
taking O
atypical O
antipsychotic O
drugs O
, O
revealed O
a O
risk O
of O
death B-NonOSE_AE
in O
drug-treated O
patients O
of O
between O
1.6 O
to O
1.7 O
times O
the O
risk O
of O
death B-NonOSE_AE
in O
placebo-treated O
patients O
. O

Over O
the O
course O
of O
a O
typical O
10-week O
controlled O
trial O
, O
the O
rate O
of O
death B-NonOSE_AE
in O
drug-treated O
patients O
was O
about O
4.5 O
% O
, O
compared O
to O
a O
rate O
of O
about O
2.6 O
% O
in O
the O
placebo O
group O
. O

Although O
the O
causes O
of O
death B-NonOSE_AE
were O
varied O
, O
most O
of O
the O
deaths B-NonOSE_AE
appeared O
to O
be O
either O
cardiovascular I-NonOSE_AE
( O
e.g. O
, O
heart B-NonOSE_AE
failure I-NonOSE_AE
, O
sudden B-NonOSE_AE
death I-NonOSE_AE
) O
or O
infectious B-NonOSE_AE
( O
e.g. O
, O
pneumonia B-NonOSE_AE
) O
in O
nature O
. O

Observational O
studies O
suggest O
that O
, O
similar O
to O
atypical O
antipsychotic O
drugs O
, O
treatment O
with O
conventional O
antipsychotic O
drugs O
may O
increase O
mortality B-NonOSE_AE
. O

The O
extent O
to O
which O
the O
findings O
of O
increased O
mortality B-NonOSE_AE
in O
observational O
studies O
may O
be O
attributed O
to O
the O
antipsychotic O
drug O
as O
opposed O
to O
some O
characteristic O
( O
s O
) O
of O
the O
patients O
is O
not O
clear O
. O

SEROQUEL O
is O
not O
approved O
for O
the O
treatment O
of O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
[ O
see O
Boxed O
Warning O
] O
. O

5.2 O
Suicidal O
Thoughts O
and O
Behaviors O
in O
Adolescents O
and O
Young O
Adults O
Patients O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
, O
both O
adult O
and O
pediatric O
, O
may O
experience O
worsening B-NonOSE_AE
of I-NonOSE_AE
their I-NonOSE_AE
depression I-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
ideation I-NonOSE_AE
and O
behavior O
( O
suicidality B-NonOSE_AE
) O
or O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
whether O
or O
not O
they O
are O
taking O
antidepressant O
medications O
, O
and O
this O
risk O
may O
persist O
until O
significant O
remission O
occurs O
. O

Suicide B-NonOSE_AE
is O
a O
known O
risk O
of O
depression B-NonOSE_AE
and O
certain O
other O
psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
, O
and O
these O
disorders O
themselves O
are O
the O
strongest O
predictors O
of O
suicide B-NonOSE_AE
. O

There O
has O
been O
a O
long-standing O
concern O
, O
however O
, O
that O
antidepressants O
may O
have O
a O
role O
in O
inducing O
worsening B-NonOSE_AE
of I-NonOSE_AE
depression I-NonOSE_AE
and O
the O
emergence O
of O
suicidality B-NonOSE_AE
in O
certain O
patients O
during O
the O
early O
phases O
of O
treatment O
. O

Pooled O
analyses O
of O
short-term O
placebo-controlled O
trials O
of O
antidepressant O
drugs O
( O
SSRIs O
and O
others O
) O
showed O
that O
these O
drugs O
increase O
the O
risk O
of O
suicidal B-OSE_Labeled_AE
thinking O
and O
behavior I-OSE_Labeled_AE
( O
suicidality B-OSE_Labeled_AE
) O
in O
children O
, O
adolescents O
, O
and O
young O
adults O
( O
ages O
18-24 O
) O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
and O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Short-term O
studies O
did O
not O
show O
an O
increase O
in O
the O
risk O
of O
suicidality B-NonOSE_AE
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
beyond O
age O
24 O
; O
there O
was O
a O
reduction O
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
aged O
65 O
and O
older O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
trials O
in O
children O
and O
adolescents O
with O
MDD B-Not_AE_Candidate
, O
obsessive B-Not_AE_Candidate
- I-Not_AE_Candidate
compulsive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
OCD I-Not_AE_Candidate
) O
, O
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
24 O
short-term O
trials O
of O
9 O
antidepressant O
drugs O
in O
over O
4400 O
patients O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
trials O
in O
adults O
with O
MDD B-Not_AE_Candidate
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
295 O
short-term O
trials O
( O
median O
duration O
of O
2 O
months O
) O
of O
11 O
antidepressant O
drugs O
in O
over O
77,000 O
patients O
. O

There O
was O
considerable O
variation O
in O
risk O
of O
suicidality B-NonOSE_AE
among O
drugs O
, O
but O
a O
tendency O
toward O
an O
increase O
in O
the O
younger O
patients O
for O
almost O
all O
drugs O
studied O
. O

There O
were O
differences O
in O
absolute O
risk O
of O
suicidality B-NonOSE_AE
across O
the O
different O
indications O
, O
with O
the O
highest O
incidence O
in O
MDD B-Not_AE_Candidate
. O

The O
risk O
differences O
( O
drug O
vs O
. O
placebo O
) O
, O
however O
, O
were O
relatively O
stable O
within O
age O
strata O
and O
across O
indications O
. O

These O
risk O
differences O
( O
drug-placebo O
difference O
in O
the O
number O
of O
cases O
of O
suicidality B-NonOSE_AE
per O
1000 O
patients O
treated O
) O
are O
provided O
in O
Table O
2 O
. O

Table O
2 O
: O
Drug-Placebo O
Difference O
in O
Number O
of O
Cases O
of O
Suicidality O
per O
1000 O
Patients O
Treated O
Age O
Range O
Drug-Placebo O
Difference O
in O
Number O
of O
Cases O
of O
Suicidality B-OSE_Labeled_AE
per O
1000 O
Patients O
Treated O
Increases I-OSE_Labeled_AE
Compared O
to O
Placebo O
< O
18 O
14 O
additional O
cases O
18-24 O
5 O
additional O
cases O
Decreases O
Compared O
to O
Placebo O
25-64 O
1 O
fewer O
case O
> O
=65 O
6 O
fewer O
cases O
No O
suicides B-NonOSE_AE
occurred O
in O
any O
of O
the O
pediatric O
trials O
. O

There O
were O
suicides B-NonOSE_AE
in O
the O
adult O
trials O
, O
but O
the O
number O
was O
not O
sufficient O
to O
reach O
any O
conclusion O
about O
drug O
effect O
on O
suicide B-NonOSE_AE
. O

It O
is O
unknown O
whether O
the O
suicidality B-NonOSE_AE
risk O
extends O
to O
longer-term O
use O
, O
i.e. O
, O
beyond O
several O
months O
. O

However O
, O
there O
is O
substantial O
evidence O
from O
placebo-controlled O
maintenance O
trials O
in O
adults O
with O
depression B-Not_AE_Candidate
that O
the O
use O
of O
antidepressants O
can O
delay O
the O
recurrence O
of O
depression B-NonOSE_AE
. O

All O
patients O
being O
treated O
with O
antidepressants O
for O
any O
indication O
should O
be O
monitored O
appropriately O
and O
observed O
closely O
for O
clinical O
worsening O
, O
suicidality B-NonOSE_AE
, O
and O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
especially O
during O
the O
initial O
few O
months O
of O
a O
course O
of O
drug O
therapy O
, O
or O
at O
times O
of O
dose O
changes O
, O
either O
increases O
or O
decreases O
. O

The O
following O
symptoms O
, O
anxiety B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
panic B-OSE_Labeled_AE
attacks I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
hostility B-OSE_Labeled_AE
, O
aggressiveness B-OSE_Labeled_AE
, O
impulsivity B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
( O
psychomotor B-OSE_Labeled_AE
restlessness I-OSE_Labeled_AE
) O
, O
hypomania B-OSE_Labeled_AE
, O
and O
mania B-OSE_Labeled_AE
, O
have O
been O
reported O
in O
adult O
and O
pediatric O
patients O
being O
treated O
with O
antidepressants O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
as O
well O
as O
for O
other O
indications O
, O
both O
psychiatric O
and O
nonpsychiatric O
. O

Although O
a O
causal O
link O
between O
the O
emergence O
of O
such O
symptoms O
and O
either O
the O
worsening B-NonOSE_AE
of I-NonOSE_AE
depression I-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
impulses I-NonOSE_AE
has O
not O
been O
established O
, O
there O
is O
concern O
that O
such O
symptoms O
may O
represent O
precursors O
to O
emerging O
suicidality B-NonOSE_AE
. O

Consideration O
should O
be O
given O
to O
changing O
the O
therapeutic O
regimen O
, O
including O
possibly O
discontinuing O
the O
medication O
, O
in O
patients O
whose O
depression B-NonOSE_AE
is I-NonOSE_AE
persistently I-NonOSE_AE
worse I-NonOSE_AE
, O
or O
who O
are O
experiencing O
emergent O
suicidality B-NonOSE_AE
or O
symptoms O
that O
might O
be O
precursors O
to O
worsening B-NonOSE_AE
depression I-NonOSE_AE
or O
suicidality B-NonOSE_AE
, O
especially O
if O
these O
symptoms O
are O
severe O
, O
abrupt O
in O
onset O
, O
or O
were O
not O
part O
of O
the O
patient O
's O
presenting O
symptoms O
. O

Families O
and O
caregivers O
of O
patients O
being O
treated O
with O
antidepressants O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
or O
other O
indications O
, O
both O
psychiatric O
and O
nonpsychiatric O
, O
should O
be O
alerted O
about O
the O
need O
to O
monitor O
patients O
for O
the O
emergence O
of O
agitation B-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
and O
the O
other O
symptoms O
described O
above O
, O
as O
well O
as O
the O
emergence O
of O
suicidality B-NonOSE_AE
, O
and O
to O
report O
such O
symptoms O
immediately O
to O
healthcare O
providers O
. O

Such O
monitoring O
should O
include O
daily O
observation O
by O
families O
and O
caregivers O
. O

Prescriptions O
for O
SEROQUEL O
should O
be O
written O
for O
the O
smallest O
quantity O
of O
tablets O
consistent O
with O
good O
patient O
management O
, O
in O
order O
to O
reduce O
the O
risk O
of O
overdose B-NonOSE_AE
. O

Screening O
Patients O
for O
Bipolar B-NonOSE_AE
Disorder I-NonOSE_AE
: O
A O
major B-NonOSE_AE
depressive I-NonOSE_AE
episode I-NonOSE_AE
may O
be O
the O
initial O
presentation O
of O
bipolar B-NonOSE_AE
disorder I-NonOSE_AE
. O

It O
is O
generally O
believed O
( O
though O
not O
established O
in O
controlled O
trials O
) O
that O
treating O
such O
an O
episode O
with O
an O
antidepressant O
alone O
may O
increase O
the O
likelihood O
of O
precipitation B-NonOSE_AE
of I-NonOSE_AE
a I-NonOSE_AE
mixed I-NonOSE_AE
/ I-NonOSE_AE
manic I-NonOSE_AE
episode I-NonOSE_AE
in I-NonOSE_AE
patients I-NonOSE_AE
at I-NonOSE_AE
risk I-NonOSE_AE
for I-NonOSE_AE
bipolar I-NonOSE_AE
disorder I-NonOSE_AE
. O

Whether O
any O
of O
the O
symptoms O
described O
above O
represent O
such O
a O
conversion O
is O
unknown O
. O

However O
, O
prior O
to O
initiating O
treatment O
with O
an O
antidepressant O
, O
including O
SEROQUEL O
, O
patients O
with O
depressive B-Not_AE_Candidate
symptoms I-Not_AE_Candidate
should O
be O
adequately O
screened O
to O
determine O
if O
they O
are O
at O
risk O
for O
bipolar B-NonOSE_AE
disorder I-NonOSE_AE
; O
such O
screening O
should O
include O
a O
detailed O
psychiatric O
history O
, O
including O
a O
family O
history O
of O
suicide B-Not_AE_Candidate
, O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
and O
depression B-Not_AE_Candidate
. O

5.3 O
Cerebrovascular O
Adverse O
Reactions O
, O
Including O
Stroke O
, O
in O
Elderly O
Patients O
with O
Dementia-Related O
Psychosis O
In O
placebo-controlled O
trials O
with O
risperidone O
, O
aripiprazole O
, O
and O
olanzapine O
in O
elderly O
subjects O
with O
dementia B-Not_AE_Candidate
, O
there O
was O
a O
higher O
incidence O
of O
cerebrovascular B-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
( O
cerebrovascular B-NonOSE_AE
accidents I-NonOSE_AE
and O
transient B-NonOSE_AE
ischemic I-NonOSE_AE
attacks I-NonOSE_AE
) O
including O
fatalities B-NonOSE_AE
compared O
to O
placebo-treated O
subjects O
. O

SEROQUEL O
is O
not O
approved O
for O
the O
treatment O
of O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
[ O
see O
also O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

5.4 O
Neuroleptic O
Malignant O
Syndrome O
( O
NMS O
) O
A O
potentially O
fatal B-NonOSE_AE
symptom O
complex O
sometimes O
referred O
to O
as O
Neuroleptic B-OSE_Labeled_AE
Malignant I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
NMS I-OSE_Labeled_AE
) O
has O
been O
reported O
in O
association O
with O
administration O
of O
antipsychotic O
drugs O
, O
including O
SEROQUEL O
. O

Rare O
cases O
of O
NMS B-OSE_Labeled_AE
have O
been O
reported O
with O
SEROQUEL O
. O

Clinical O
manifestations O
of O
NMS B-NonOSE_AE
are O
hyperpyrexia B-NonOSE_AE
, O
muscle B-NonOSE_AE
rigidity I-NonOSE_AE
, O
altered B-NonOSE_AE
mental I-NonOSE_AE
status I-NonOSE_AE
, O
and O
evidence O
of O
autonomic B-NonOSE_AE
instability I-NonOSE_AE
( O
irregular B-NonOSE_AE
pulse O
or O
blood I-NonOSE_AE
pressure I-NonOSE_AE
, O
tachycardia B-NonOSE_AE
, O
diaphoresis B-NonOSE_AE
, O
and O
cardiac B-NonOSE_AE
dysrhythmia I-NonOSE_AE
) O
. O

Additional O
signs O
may O
include O
elevated B-NonOSE_AE
creatinine I-NonOSE_AE
phosphokinase I-NonOSE_AE
, O
myoglobinuria B-NonOSE_AE
( O
rhabdomyolysis B-NonOSE_AE
) O
and O
acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
. O

The O
diagnostic O
evaluation O
of O
patients O
with O
this O
syndrome O
is O
complicated O
. O

In O
arriving O
at O
a O
diagnosis O
, O
it O
is O
important O
to O
exclude O
cases O
where O
the O
clinical O
presentation O
includes O
both O
serious O
medical O
illness O
( O
e.g. O
, O
pneumonia B-NonOSE_AE
, O
systemic B-NonOSE_AE
infection I-NonOSE_AE
, O
etc O
. O
) O

and O
untreated O
or O
inadequately O
treated O
extrapyramidal B-NonOSE_AE
signs I-NonOSE_AE
and I-NonOSE_AE
symptoms I-NonOSE_AE
( I-NonOSE_AE
EPS I-NonOSE_AE
) O
. O

Other O
important O
considerations O
in O
the O
differential O
diagnosis O
include O
central B-NonOSE_AE
anticholinergic I-NonOSE_AE
toxicity I-NonOSE_AE
, O
heat B-NonOSE_AE
stroke I-NonOSE_AE
, O
drug B-NonOSE_AE
fever I-NonOSE_AE
and O
primary B-NonOSE_AE
central I-NonOSE_AE
nervous I-NonOSE_AE
system I-NonOSE_AE
( I-NonOSE_AE
CNS I-NonOSE_AE
) I-NonOSE_AE
pathology I-NonOSE_AE
. O

The O
management O
of O
NMS B-NonOSE_AE
should O
include O
: O
1 O
) O
immediate O
discontinuation O
of O
antipsychotic O
drugs O
and O
other O
drugs O
not O
essential O
to O
concurrent O
therapy O
; O
2 O
) O
intensive O
symptomatic O
treatment O
and O
medical O
monitoring O
; O
and O
3 O
) O
treatment O
of O
any O
concomitant O
serious O
medical O
problems O
for O
which O
specific O
treatments O
are O
available O
. O

There O
is O
no O
general O
agreement O
about O
specific O
pharmacological O
treatment O
regimens O
for O
NMS B-NonOSE_AE
. O

If O
a O
patient O
requires O
antipsychotic O
drug O
treatment O
after O
recovery O
from O
NMS B-NonOSE_AE
, O
the O
potential O
reintroduction O
of O
drug O
therapy O
should O
be O
carefully O
considered O
. O

The O
patient O
should O
be O
carefully O
monitored O
since O
recurrences O
of O
NMS B-NonOSE_AE
have O
been O
reported O
. O

5.5 O
Metabolic O
Changes O
Atypical O
antipsychotic O
drugs O
have O
been O
associated O
with O
metabolic B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
that O
include O
hyperglycemia B-OSE_Labeled_AE
/ O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
, O
dyslipidemia B-OSE_Labeled_AE
, O
and O
body B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
gain I-OSE_Labeled_AE
. O

While O
all O
of O
the O
drugs O
in O
the O
class O
have O
been O
shown O
to O
produce O
some O
metabolic B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
, O
each O
drug O
has O
its O
own O
specific O
risk O
profile O
. O

In O
some O
patients O
, O
a O
worsening B-NonOSE_AE
of I-NonOSE_AE
more O
than O
one O
of O
the O
metabolic O
parameters O
of O
weight I-NonOSE_AE
, O
blood O
glucose O
, O
and O
lipids O
was O
observed O
in O
clinical O
studies O
. O

Changes B-NonOSE_AE
in I-NonOSE_AE
these I-NonOSE_AE
metabolic I-NonOSE_AE
profiles O
should O
be O
managed O
as O
clinically O
appropriate O
. O

Hyperglycemia O
and O
Diabetes O
Mellitus O
Hyperglycemia B-OSE_Labeled_AE
, O
in O
some O
cases O
extreme O
and O
associated O
with O
ketoacidosis B-OSE_Labeled_AE
or O
hyperosmolar B-OSE_Labeled_AE
coma I-OSE_Labeled_AE
or O
death B-NonOSE_AE
, O
has O
been O
reported O
in O
patients O
treated O
with O
atypical O
antipsychotics O
, O
including O
quetiapine O
. O

Assessment O
of O
the O
relationship O
between O
atypical O
antipsychotic O
use O
and O
glucose B-NonOSE_AE
abnormalities I-NonOSE_AE
is O
complicated O
by O
the O
possibility O
of O
an O
increased O
background O
risk O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
in O
patients O
with O
schizophrenia B-Not_AE_Candidate
and O
the O
increasing O
incidence O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
in O
the O
general O
population O
. O

Given O
these O
confounders O
, O
the O
relationship O
between O
atypical O
antipsychotic O
use O
and O
hyperglycemia B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
is O
not O
completely O
understood O
. O

However O
, O
epidemiological O
studies O
suggest O
an O
increased O
risk O
of O
treatment-emergent O
hyperglycemia B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
in O
patients O
treated O
with O
the O
atypical O
antipsychotics O
. O

Precise O
risk O
estimates O
for O
hyperglycemia B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
in O
patients O
treated O
with O
atypical O
antipsychotics O
are O
not O
available O
. O

Patients O
with O
an O
established O
diagnosis O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
who O
are O
started O
on O
atypical O
antipsychotics O
should O
be O
monitored O
regularly O
for O
worsening B-NonOSE_AE
of I-NonOSE_AE
glucose I-NonOSE_AE
control I-NonOSE_AE
. O

Patients O
with O
risk O
factors O
for O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
( O
e.g. O
, O
obesity B-Not_AE_Candidate
, O
family B-Not_AE_Candidate
history I-Not_AE_Candidate
of I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
) O
who O
are O
starting O
treatment O
with O
atypical O
antipsychotics O
should O
undergo O
fasting O
blood O
glucose O
testing O
at O
the O
beginning O
of O
treatment O
and O
periodically O
during O
treatment O
. O

Any O
patient O
treated O
with O
atypical O
antipsychotics O
should O
be O
monitored O
for O
symptoms O
of O
hyperglycemia B-NonOSE_AE
including O
polydipsia B-NonOSE_AE
, O
polyuria B-NonOSE_AE
, O
polyphagia B-NonOSE_AE
, O
and O
weakness B-NonOSE_AE
. O

Patients O
who O
develop O
symptoms O
of O
hyperglycemia B-NonOSE_AE
during O
treatment O
with O
atypical O
antipsychotics O
should O
undergo O
fasting O
blood O
glucose O
testing O
. O

In O
some O
cases O
, O
hyperglycemia B-NonOSE_AE
has O
resolved O
when O
the O
atypical O
antipsychotic O
was O
discontinued O
; O
however O
, O
some O
patients O
required O
continuation O
of O
anti-diabetic O
treatment O
despite O
discontinuation O
of O
the O
suspect O
drug O
. O

Adults O
: O
Table O
3 O
: O
Fasting O
Glucose O
- O
Proportion O
of O
Patients O
Shifting O
to O
> O
=126 O
mg/dL O
in O
Short-Term O
( O
< O
=12 O
weeks O
) O
Placebo-Controlled O
StudiesIncludes O
SEROQUEL O
and O
SEROQUEL O
XR O
data O
. O

Laboratory O
Analyte O
Category O
Change O
( O
At O
Least O
Once O
) O
from O
Baseline O
Treatment O
Arm O
N O
Patients O
n O
( O
% O
) O
Fasting B-NonOSE_AE
Glucose I-NonOSE_AE
Normal O
to O
High O
( O
< O
100 O
mg/dL O
to O
> O
=126 O
mg/dL O
) O
Quetiapine O
2907 O
71 O
( O
2.4 O
% O
) O
Placebo O
1346 O
19 O
( O
1.4 O
% O
) O
Borderline I-NonOSE_AE
to I-NonOSE_AE
High I-NonOSE_AE
( O
> O
= O
100 O
mg/dL O
and O
< O
126 O
mg/dL O
to O
> O
=126 O
mg/dL O
) O
Quetiapine O
572 O
67 O
( O
11.7 O
% O
) O
Placebo O
279 O
33 O
( O
11.8 O
% O
) O
In O
a O
24-week O
trial O
( O
active-controlled O
, O
115 O
patients O
treated O
with O
SEROQUEL O
) O
designed O
to O
evaluate O
glycemic O
status O
with O
oral O
glucose O
tolerance O
testing O
of O
all O
patients O
, O
at O
week O
24 O
the O
incidence O
of O
a O
treatment-emergent O
post-glucose O
challenge O
glucose B-OSE_Labeled_AE
level I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
was O
1.7 O
% O
and O
the O
incidence O
of O
a O
fasting B-OSE_Labeled_AE
treatment-emergent O
blood I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
level I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
was O
2.6 O
% O
. O

The O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
fasting I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
was O
3.2 O
mg/dL O
and O
mean O
change B-OSE_Labeled_AE
in I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
- I-OSE_Labeled_AE
hour I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
was O
-1.8 O
mg/dL O
for O
quetiapine O
. O

In O
2 O
long-term O
placebo-controlled O
randomized O
withdrawal O
clinical O
trials O
for O
bipolar B-Not_AE_Candidate
I I-Not_AE_Candidate
disorder I-Not_AE_Candidate
maintenance O
, O
mean O
exposure O
of O
213 O
days O
for O
SEROQUEL O
( O
646 O
patients O
) O
and O
152 O
days O
for O
placebo O
( O
680 O
patients O
) O
, O
the O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
was O
+5.0 O
mg/dL O
for O
SEROQUEL O
and O
-0.05 O
mg/dL O
for O
placebo O
. O

The O
exposure-adjusted O
rate O
of O
any O
increased B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
level I-OSE_Labeled_AE
( O
> O
= O
126 O
mg/dL O
) O
for O
patients O
more O
than O
8 O
hours O
since O
a O
meal O
( O
however O
, O
some O
patients O
may O
not O
have O
been O
precluded O
from O
calorie O
intake O
from O
fluids O
during O
fasting O
period O
) O
was O
18.0 O
per O
100 O
patient O
years O
for O
SEROQUEL O
( O
10.7 O
% O
of O
patients O
; O
n=556 O
) O
and O
9.5 O
for O
placebo O
per O
100 O
patient O
years O
( O
4.6 O
% O
of O
patients O
; O
n=581 O
) O
. O

Children O
and O
Adolescents O
: O
In O
a O
placebo-controlled O
SEROQUEL O
monotherapy O
study O
of O
adolescent O
patients O
( O
13-17 O
years O
of O
age O
) O
with O
schizophrenia B-Not_AE_Candidate
( O
6 O
weeks O
duration O
) O
, O
the O
mean O
change B-NonOSE_AE
in I-NonOSE_AE
fasting I-NonOSE_AE
glucose I-NonOSE_AE
levels I-NonOSE_AE
for O
SEROQUEL O
( O
n=138 O
) O
compared O
to O
placebo O
( O
n=67 O
) O
was O
-0.75 O
mg/dL O
versus O
-1.70 O
mg/dL O
. O

In O
a O
placebo-controlled O
SEROQUEL O
monotherapy O
study O
of O
children O
and O
adolescent O
patients O
( O
10-17 O
years O
of O
age O
) O
with O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
3 O
weeks O
duration O
) O
, O
the O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
fasting I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
level I-OSE_Labeled_AE
for O
SEROQUEL O
( O
n=170 O
) O
compared O
to O
placebo O
( O
n=81 O
) O
was O
3.62 O
mg/dL O
versus O
-1.17 O
mg/dL O
. O

No O
patient O
in O
either O
study O
with O
a O
baseline O
normal B-Not_AE_Candidate
fasting I-Not_AE_Candidate
glucose I-Not_AE_Candidate
level I-Not_AE_Candidate
( I-Not_AE_Candidate
< I-Not_AE_Candidate
1 I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mg I-Not_AE_Candidate
/ I-Not_AE_Candidate
dL I-Not_AE_Candidate
) O
or O
a O
baseline O
borderline B-Not_AE_Candidate
fasting I-Not_AE_Candidate
glucose I-Not_AE_Candidate
level I-Not_AE_Candidate
( I-Not_AE_Candidate
> I-Not_AE_Candidate
= I-Not_AE_Candidate
1 I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mg I-Not_AE_Candidate
/ I-Not_AE_Candidate
dL I-Not_AE_Candidate
and I-Not_AE_Candidate
< I-Not_AE_Candidate
1 I-Not_AE_Candidate
2 I-Not_AE_Candidate
6 I-Not_AE_Candidate
mg I-Not_AE_Candidate
/ I-Not_AE_Candidate
dL I-Not_AE_Candidate
) O
had O
a O
treatment-emergent O
blood B-NonOSE_AE
glucose I-NonOSE_AE
level I-NonOSE_AE
of I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
2 I-NonOSE_AE
6 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
. O

In O
a O
placebo-controlled O
SEROQUEL O
XR O
monotherapy O
study O
( O
8 O
weeks O
duration O
) O
of O
children O
and O
adolescent O
patients O
( O
10 O
- O
17 O
years O
of O
age O
) O
with O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
, O
in O
which O
efficacy O
was O
not O
established O
, O
the O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
fasting I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
for O
SEROQUEL O
XR O
( O
n O
= O
60 O
) O
compared O
to O
placebo O
( O
n O
= O
62 O
) O
was O
1.8 O
mg/dL O
versus O
1.6 O
mg/dL O
. O

In O
this O
study O
, O
there O
were O
no O
patients O
in O
the O
SEROQUEL O
XR O
or O
placebo-treated O
groups O
with O
a O
baseline O
normal O
fasting O
glucose O
level O
( O
< O
100 O
mg/dL O
) O
that O
had O
an O
increase B-NonOSE_AE
in I-NonOSE_AE
blood I-NonOSE_AE
glucose I-NonOSE_AE
level I-NonOSE_AE
> I-NonOSE_AE
1 I-NonOSE_AE
2 I-NonOSE_AE
6 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
. O

There O
was O
one O
patient O
in O
the O
SEROQUEL O
XR O
group O
with O
a O
baseline O
borderline B-Not_AE_Candidate
fasting I-Not_AE_Candidate
glucose I-Not_AE_Candidate
level I-Not_AE_Candidate
( I-Not_AE_Candidate
> I-Not_AE_Candidate
1 I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mg I-Not_AE_Candidate
/ I-Not_AE_Candidate
dL I-Not_AE_Candidate
and I-Not_AE_Candidate
< I-Not_AE_Candidate
1 I-Not_AE_Candidate
2 I-Not_AE_Candidate
6 I-Not_AE_Candidate
mg I-Not_AE_Candidate
/ I-Not_AE_Candidate
dL I-Not_AE_Candidate
) O
who O
had O
an O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
level O
of O
> O
126 O
mg/dL O
compared O
to O
zero O
patients O
in O
the O
placebo O
group O
. O

Dyslipidemia B-OSE_Labeled_AE
Adults O
: O
Table O
4 O
shows O
the O
percentage O
of O
adult O
patients O
with O
changes B-NonOSE_AE
in I-NonOSE_AE
total I-NonOSE_AE
cholesterol I-NonOSE_AE
, O
triglycerides O
, O
LDL-cholesterol O
and O
HDL-cholesterol O
from O
baseline O
by O
indication O
in O
clinical O
trials O
with O
SEROQUEL O
. O

Table O
4 O
: O
Percentage O
of O
Adult O
Patients O
with O
Shifts O
in O
Total O
Cholesterol O
, O
Triglycerides O
, O
LDL-Cholesterol O
and O
HDL-Cholesterol O
from O
Baseline O
to O
Clinically O
Significant O
Levels O
by O
Indication O
Laboratory O
Analyte O
Indication O
Treatment O
Arm O
N O
Patients O
n O
( O
% O
) O
Total B-OSE_Labeled_AE
Cholesterol I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
Schizophrenia B-Not_AE_Candidate
6 I-Not_AE_Candidate
weeks O
duration O
SEROQUEL O
137 O
24 O
( O
18 O
% O
) O
Placebo O
92 O
6 O
( O
7 O
% O
) O
Bipolar B-Not_AE_Candidate
Depression I-Not_AE_Candidate
8 I-Not_AE_Candidate
weeks O
duration O
SEROQUEL O
463 O
41 O
( O
9 O
% O
) O
Placebo O
250 O
15 O
( O
6 O
% O
) O
Triglycerides B-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
Schizophrenia B-Not_AE_Candidate
SEROQUEL O
120 O
26 O
( O
22 O
% O
) O
Placebo O
70 O
11 O
( O
16 O
% O
) O
Bipolar B-Not_AE_Candidate
Depression I-Not_AE_Candidate
SEROQUEL O
436 O
59 O
( O
14 O
% O
) O
Placebo O
232 O
20 O
( O
9 O
% O
) O
LDL B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Cholesterol I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
Schizophrenia B-Not_AE_Candidate
SEROQUEL O
naParameters O
not O
measured O
in O
the O
SEROQUEL O
registration O
studies O
for O
schizophrenia B-Not_AE_Candidate
. O

Lipid O
parameters O
also O
were O
not O
measured O
in O
the O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
registration O
studies O
. O

na O
Placebo O
na O
na O
Bipolar B-Not_AE_Candidate
Depression I-Not_AE_Candidate
SEROQUEL O
465 O
29 O
( O
6 O
% O
) O
Placebo O
256 O
12 O
( O
5 O
% O
) O
HDL B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Cholesterol I-OSE_Labeled_AE
< I-OSE_Labeled_AE
= I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
Schizophrenia B-Not_AE_Candidate
SEROQUEL O
na O
na O
Placebo O
na O
na O
Bipolar B-Not_AE_Candidate
Depression I-Not_AE_Candidate
SEROQUEL O
393 O
56 O
( O
14 O
% O
) O
Placebo O
214 O
29 O
( O
14 O
% O
) O
Children O
and O
Adolescents O
: O
Table O
5 O
shows O
the O
percentage O
of O
children O
and O
adolescents O
with O
changes B-NonOSE_AE
in I-NonOSE_AE
total I-NonOSE_AE
cholesterol I-NonOSE_AE
, O
triglycerides O
, O
LDL-cholesterol O
and O
HDL-cholesterol O
from O
baseline O
in O
clinical O
trials O
with O
SEROQUEL O
. O

Table O
5 O
: O
Percentage O
of O
Children O
and O
Adolescents O
with O
Shifts O
in O
Total O
Cholesterol O
, O
Triglycerides O
, O
LDL-Cholesterol O
and O
HDL-Cholesterol O
from O
Baseline O
to O
Clinically O
Significant O
Levels O
Laboratory O
Analyte O
Indication O
Treatment O
Arm O
N O
Patients O
n O
( O
% O
) O
Total B-OSE_Labeled_AE
Cholesterol I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
Schizophrenia B-Not_AE_Candidate
1 I-Not_AE_Candidate
3 I-Not_AE_Candidate
- I-Not_AE_Candidate
1 I-Not_AE_Candidate
7 I-Not_AE_Candidate
years O
, O
6 O
weeks O
duration O
SEROQUEL O
107 O
13 O
( O
12 O
% O
) O
Placebo O
56 O
1 O
( O
2 O
% O
) O
Bipolar B-Not_AE_Candidate
Mania I-Not_AE_Candidate
1 I-Not_AE_Candidate
0 I-Not_AE_Candidate
- I-Not_AE_Candidate
1 I-Not_AE_Candidate
7 I-Not_AE_Candidate
years O
, O
3 O
weeks O
duration O
SEROQUEL O
159 O
16 O
( O
10 O
% O
) O
Placebo O
66 O
2 O
( O
3 O
% O
) O
Triglycerides B-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
Schizophrenia B-Not_AE_Candidate
SEROQUEL O
103 O
17 O
( O
17 O
% O
) O
Placebo O
51 O
4 O
( O
8 O
% O
) O
Bipolar B-Not_AE_Candidate
Mania I-Not_AE_Candidate
SEROQUEL O
149 O
32 O
( O
22 O
% O
) O
Placebo O
60 O
8 O
( O
13 O
% O
) O
LDL B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Cholesterol I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
Schizophrenia B-Not_AE_Candidate
SEROQUEL O
112 O
4 O
( O
4 O
% O
) O
Placebo O
60 O
1 O
( O
2 O
% O
) O
Bipolar B-Not_AE_Candidate
Mania I-Not_AE_Candidate
SEROQUEL O
169 O
13 O
( O
8 O
% O
) O
Placebo O
74 O
4 O
( O
5 O
% O
) O
HDL B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Cholesterol I-OSE_Labeled_AE
< I-OSE_Labeled_AE
= I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
Schizophrenia B-Not_AE_Candidate
SEROQUEL O
104 O
16 O
( O
15 O
% O
) O
Placebo O
54 O
10 O
( O
19 O
% O
) O
Bipolar B-Not_AE_Candidate
Mania I-Not_AE_Candidate
SEROQUEL O
154 O
16 O
( O
10 O
% O
) O
Placebo O
61 O
4 O
( O
7 O
% O
) O
In O
a O
placebo-controlled O
SEROQUEL O
XR O
monotherapy O
study O
( O
8 O
weeks O
duration O
) O
of O
children O
and O
adolescent O
patients O
( O
10-17 O
years O
of O
age O
) O
with O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
, O
in O
which O
efficacy O
was O
not O
established O
, O
the O
percentage O
of O
children O
and O
adolescents O
with O
shifts O
in O
total B-NonOSE_AE
cholesterol I-NonOSE_AE
( I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
2 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
) O
, O
triglycerides B-NonOSE_AE
( I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
) O
, O
LDL B-NonOSE_AE
- I-NonOSE_AE
cholesterol I-NonOSE_AE
( I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
3 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
) O
and O
HDL B-NonOSE_AE
- I-NonOSE_AE
cholesterol I-NonOSE_AE
( I-NonOSE_AE
< I-NonOSE_AE
= I-NonOSE_AE
4 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
) O
from B-NonOSE_AE
baseline I-NonOSE_AE
to I-NonOSE_AE
clinically I-NonOSE_AE
significant I-NonOSE_AE
levels I-NonOSE_AE
were O
: O
total O
cholesterol O
8 O
% O
( O
7/83 O
) O
for O
SEROQUEL O
XR O
vs O
. O
6 O
% O
( O
5/84 O
) O
for O
placebo O
; O
triglycerides O
28 O
% O
( O
22/80 O
) O
for O
SEROQUEL O
XR O
vs O
. O
9 O
% O
( O
7/82 O
) O
for O
placebo O
; O
LDL I-NonOSE_AE
- I-NonOSE_AE
cholesterol I-NonOSE_AE
2 O
% O
( O
2/86 O
) O
for O
SEROQUEL O
XR O
vs O
. O
4 O
% O
( O
3/85 O
) O
for O
placebo O
and O
HDL-cholesterol O
20 O
% O
( O
13/65 O
) O
for O
SEROQUEL O
XR O
vs O
. O
15 O
% O
( O
11/74 O
) O
for O
placebo O
. O

Weight O
Gain O
Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
have O
been O
observed O
in O
clinical O
trials O
. O

Patients O
receiving O
quetiapine O
should O
receive O
regular O
monitoring O
of O
weight O
. O

Adults O
: O
In O
clinical O
trials O
with O
SEROQUEL O
the O
following O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
have O
been O
reported O
. O

Table O
6 O
: O
Proportion O
of O
Patients O
with O
Weight O
Gain O
> O
=7 O
% O
of O
Body O
Weight O
( O
Adults O
) O
Vital O
Sign O
Indication O
Treatment O
Arm O
N O
Patients O
n O
( O
% O
) O
Weight B-OSE_Labeled_AE
Gain I-OSE_Labeled_AE
> O
=7 O
% O
of O
Body O
Weight O
Schizophreniaup B-Not_AE_Candidate
to O
6 O
weeks O
duration O
SEROQUEL O
391 O
89 O
( O
23 O
% O
) O
Placebo O
206 O
11 O
( O
6 O
% O
) O
Bipolar B-Not_AE_Candidate
Mania I-Not_AE_Candidate
( O
monotherapy O
) O
up O
to O
12 O
weeks O
duration O
SEROQUEL O
209 O
44 O
( O
21 O
% O
) O
Placebo O
198 O
13 O
( O
7 O
% O
) O
Bipolar B-Not_AE_Candidate
Mania I-Not_AE_Candidate
( O
adjunct O
therapy O
) O
up O
to O
3 O
weeks O
duration O
SEROQUEL O
196 O
25 O
( O
13 O
% O
) O
Placebo O
203 O
8 O
( O
4 O
% O
) O
Bipolar B-Not_AE_Candidate
Depressionup I-Not_AE_Candidate
to O
8 O
weeks O
duration O
SEROQUEL O
554 O
47 O
( O
8 O
% O
) O
Placebo O
295 O
7 O
( O
2 O
% O
) O
Children O
and O
Adolescents O
: O
In O
two O
clinical O
trials O
with O
SEROQUEL O
, O
one O
in O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
and O
one O
in O
schizophrenia B-Not_AE_Candidate
, O
reported O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
are O
included O
in O
table O
7 O
. O

Table O
7 O
: O
Proportion O
of O
Patients O
with O
Weight O
Gain O
> O
=7 O
% O
of O
Body O
Weight O
( O
Children O
and O
Adolescents O
) O
Vital O
Sign O
Indication O
Treatment O
Arm O
N O
Patients O
n O
( O
% O
) O
Weight B-OSE_Labeled_AE
Gain I-OSE_Labeled_AE
> O
=7 O
% O
of O
Body O
Weight O
Schizophrenia B-Not_AE_Candidate
6 O
weeks O
duration O
SEROQUEL O
111 O
23 O
( O
21 O
% O
) O
Placebo O
44 O
3 O
( O
7 O
% O
) O
Bipolar B-Not_AE_Candidate
Mania I-Not_AE_Candidate
3 O
weeks O
duration O
SEROQUEL O
157 O
18 O
( O
12 O
% O
) O
Placebo O
68 O
0 O
( O
0 O
% O
) O
The O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
body I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
in O
the O
schizophrenia B-Not_AE_Candidate
trial O
was O
2.0 O
kg O
in O
the O
SEROQUEL O
group O
and O
-0.4 O
kg O
in O
the O
placebo O
group O
and O
in O
the O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
trial O
, O
it O
was O
1.7 O
kg O
in O
the O
SEROQUEL O
group O
and O
0.4 O
kg O
in O
the O
placebo O
group O
. O

In O
an O
open-label O
study O
that O
enrolled O
patients O
from O
the O
above O
two O
pediatric O
trials O
, O
63 O
% O
of O
patients O
( O
241/380 O
) O
completed O
26 O
weeks O
of O
therapy O
with O
SEROQUEL O
. O

After O
26 O
weeks O
of O
treatment O
, O
the O
mean O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
body I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
was O
4.4 O
kg O
. O

Forty-five O
percent O
of O
the O
patients O
gained B-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
7 I-OSE_Labeled_AE
% I-OSE_Labeled_AE
of I-OSE_Labeled_AE
their I-OSE_Labeled_AE
body I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
, O
not O
adjusted O
for O
normal O
growth O
. O

In O
order O
to O
adjust O
for O
normal O
growth O
over O
26 O
weeks O
an O
increase O
of O
at O
least O
0.5 O
standard O
deviation O
from O
baseline O
in O
BMI O
was O
used O
as O
a O
measure O
of O
a O
clinically O
significant O
change O
; O
18.3 O
% O
of O
patients O
on O
SEROQUEL O
met O
this O
criterion O
after O
26 O
weeks O
of O
treatment O
. O

In O
a O
clinical O
trial O
for O
SEROQUEL O
XR O
in O
children O
and O
adolescents O
( O
10-17 O
years O
of O
age O
) O
with O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
, O
in O
which O
efficacy O
was O
not O
established O
, O
the O
percentage O
of O
patients O
with O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
> O
=7 O
% O
of O
body O
weight O
at O
any O
time O
was O
15 O
% O
( O
14/92 O
) O
for O
SEROQUEL O
XR O
vs O
. O
10 O
% O
( O
10/100 O
) O
for O
placebo O
. O

The O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
body I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
was I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
kg I-OSE_Labeled_AE
in O
the O
SEROQUEL O
XR O
group O
vs O
. O
0.6 O
kg O
in O
the O
placebo O
group O
. O

When O
treating O
pediatric O
patients O
with O
SEROQUEL O
for O
any O
indication O
, O
weight B-NonOSE_AE
gain I-NonOSE_AE
should O
be O
assessed O
against O
that O
expected O
for O
normal O
growth O
. O

5.6 O
Tardive B-OSE_Labeled_AE
Dyskinesia I-OSE_Labeled_AE
A O
syndrome O
of O
potentially O
irreversible O
, O
involuntary O
, O
dyskinetic B-OSE_Labeled_AE
movements I-OSE_Labeled_AE
may O
develop O
in O
patients O
treated O
with O
antipsychotic O
drugs O
, O
including O
quetiapine O
. O

Although O
the O
prevalence O
of O
the O
syndrome O
appears O
to O
be O
highest O
among O
the O
elderly O
, O
especially O
elderly O
women O
, O
it O
is O
impossible O
to O
rely O
upon O
prevalence O
estimates O
to O
predict O
, O
at O
the O
inception O
of O
antipsychotic O
treatment O
, O
which O
patients O
are O
likely O
to O
develop O
the O
syndrome O
. O

Whether O
antipsychotic O
drug O
products O
differ O
in O
their O
potential O
to O
cause O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
is O
unknown O
. O

The O
risk O
of O
developing O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
and O
the O
likelihood O
that O
it O
will O
become O
irreversible O
are O
believed O
to O
increase O
as O
the O
duration O
of O
treatment O
and O
the O
total O
cumulative O
dose O
of O
antipsychotic O
drugs O
administered O
to O
the O
patient O
increase O
. O

However O
, O
the O
syndrome O
can O
develop O
, O
although O
much O
less O
commonly O
, O
after O
relatively O
brief O
treatment O
periods O
at O
low O
doses O
or O
may O
even O
arise O
after O
discontinuation O
of O
treatment O
. O

There O
is O
no O
known O
treatment O
for O
established O
cases O
of O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
, O
although O
the O
syndrome O
may O
remit O
, O
partially O
or O
completely O
, O
if O
antipsychotic O
treatment O
is O
withdrawn O
. O

Antipsychotic O
treatment O
, O
itself O
, O
however O
, O
may O
suppress O
( O
or O
partially O
suppress O
) O
the O
signs O
and O
symptoms O
of O
the O
syndrome O
and O
thereby O
may O
possibly O
mask O
the O
underlying O
process O
. O

The O
effect O
that O
symptomatic O
suppression O
has O
upon O
the O
long-term O
course O
of O
the O
syndrome O
is O
unknown O
. O

Given O
these O
considerations O
, O
SEROQUEL O
should O
be O
prescribed O
in O
a O
manner O
that O
is O
most O
likely O
to O
minimize O
the O
occurrence O
of O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
. O

Chronic O
antipsychotic O
treatment O
should O
generally O
be O
reserved O
for O
patients O
who O
appear O
to O
suffer O
from O
a O
chronic O
illness O
that O
( O
1 O
) O
is O
known O
to O
respond O
to O
antipsychotic O
drugs O
, O
and O
( O
2 O
) O
for O
whom O
alternative O
, O
equally O
effective O
, O
but O
potentially O
less O
harmful O
treatments O
are O
not O
available O
or O
appropriate O
. O

In O
patients O
who O
do O
require O
chronic O
treatment O
, O
the O
smallest O
dose O
and O
the O
shortest O
duration O
of O
treatment O
producing O
a O
satisfactory O
clinical O
response O
should O
be O
sought O
. O

The O
need O
for O
continued O
treatment O
should O
be O
reassessed O
periodically O
. O

If O
signs O
and O
symptoms O
of O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
appear O
in O
a O
patient O
on O
SEROQUEL O
, O
drug O
discontinuation O
should O
be O
considered O
. O

However O
, O
some O
patients O
may O
require O
treatment O
with O
SEROQUEL O
despite O
the O
presence O
of O
the O
syndrome O
. O

5.7 O
Hypotension O
Quetiapine O
may O
induce O
orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
associated O
with O
dizziness B-NonOSE_AE
, O
tachycardia B-NonOSE_AE
and O
, O
in O
some O
patients O
, O
syncope B-NonOSE_AE
, O
especially O
during O
the O
initial O
dose-titration O
period O
, O
probably O
reflecting O
its O
alpha1-adrenergic O
antagonist O
properties O
. O

Syncope B-OSE_Labeled_AE
was O
reported O
in O
1 O
% O
( O
28/3265 O
) O
of O
the O
patients O
treated O
with O
SEROQUEL O
, O
compared O
with O
0.2 O
% O
( O
2/954 O
) O
on O
placebo O
and O
about O
0.4 O
% O
( O
2/527 O
) O
on O
active O
control O
drugs O
. O

Orthostatic B-NonOSE_AE
hypotension I-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
and O
syncope B-NonOSE_AE
may O
lead O
to O
falls B-NonOSE_AE
. O

SEROQUEL O
should O
be O
used O
with O
particular O
caution O
in O
patients O
with O
known O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
( O
history O
of O
myocardial B-Not_AE_Candidate
infarction I-Not_AE_Candidate
or O
ischemic B-Not_AE_Candidate
heart I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
or O
conduction B-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
) O
, O
cerebrovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
conditions O
which O
would O
predispose O
patients O
to O
hypotension B-NonOSE_AE
( O
dehydration B-Not_AE_Candidate
, O
hypovolemia B-Not_AE_Candidate
and O
treatment O
with O
antihypertensive B-NonOSE_AE
medications I-NonOSE_AE
) O
. O

The O
risk O
of O
orthostatic B-NonOSE_AE
hypotension I-NonOSE_AE
and O
syncope B-NonOSE_AE
may O
be O
minimized O
by O
limiting O
the O
initial O
dose O
to O
25 O
mg O
twice O
daily O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

If O
hypotension B-NonOSE_AE
occurs O
during O
titration O
to O
the O
target O
dose O
, O
a O
return O
to O
the O
previous O
dose O
in O
the O
titration O
schedule O
is O
appropriate O
. O

5.8 O
Falls O
Atypical O
antipsychotic O
drugs O
, O
including O
SEROQUEL O
, O
may O
cause O
somnolence B-OSE_Labeled_AE
, O
postural B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
, O
motor B-OSE_Labeled_AE
and O
sensory O
instability I-OSE_Labeled_AE
, O
which O
may O
lead O
to O
falls B-NonOSE_AE
and O
, O
consequently O
, O
fractures B-NonOSE_AE
or O
other O
injuries O
. O

For O
patients O
with O
diseases O
, O
conditions O
, O
or O
medications O
that O
could O
exacerbate O
these O
effects O
, O
complete O
fall B-NonOSE_AE
risk O
assessments O
when O
initiating O
antipsychotic O
treatment O
and O
recurrently O
for O
patients O
on O
long-term O
antipsychotic O
therapy O
. O

5.9 O
Increases O
in O
Blood O
Pressure O
( O
Children O
and O
Adolescents O
) O
In O
placebo-controlled O
trials O
in O
children O
and O
adolescents O
with O
schizophrenia B-Not_AE_Candidate
( O
6-week O
duration O
) O
or O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
3-week O
duration O
) O
, O
the O
incidence O
of O
increases B-OSE_Labeled_AE
at O
any O
time O
in I-OSE_Labeled_AE
systolic I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
( O
> O
=20 O
mmHg O
) O
was O
15.2 O
% O
( O
51/335 O
) O
for O
SEROQUEL O
and O
5.5 O
% O
( O
9/163 O
) O
for O
placebo O
; O
the O
incidence O
of O
increases B-OSE_Labeled_AE
at O
any O
time O
in I-OSE_Labeled_AE
diastolic I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
( O
> O
=10 O
mmHg O
) O
was O
40.6 O
% O
( O
136/335 O
) O
for O
SEROQUEL O
and O
24.5 O
% O
( O
40/163 O
) O
for O
placebo O
. O

In O
the O
26-week O
open-label O
clinical O
trial O
, O
one O
child O
with O
a O
reported O
history O
of O
hypertension B-Not_AE_Candidate
experienced O
a O
hypertensive B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
. O

Blood O
pressure O
in O
children O
and O
adolescents O
should O
be O
measured O
at O
the O
beginning O
of O
, O
and O
periodically O
during O
treatment O
. O

In O
a O
placebo-controlled O
SEROQUEL O
XR O
clinical O
trial O
( O
8 O
weeks O
duration O
) O
in O
children O
and O
adolescents O
( O
10-17 O
years O
of O
age O
) O
with O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
, O
in O
which O
efficacy O
was O
not O
established O
, O
the O
incidence O
of O
increases B-OSE_Labeled_AE
at O
any O
time O
in I-OSE_Labeled_AE
systolic I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
( O
> O
=20 O
mmHg O
) O
was O
6.5 O
% O
( O
6/92 O
) O
for O
SEROQUEL O
XR O
and O
6.0 O
% O
( O
6/100 O
) O
for O
placebo O
; O
the O
incidence O
of O
increases B-OSE_Labeled_AE
at O
any O
time O
in I-OSE_Labeled_AE
diastolic I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
( O
> O
=10 O
mmHg O
) O
was O
46.7 O
% O
( O
43/92 O
) O
for O
SEROQUEL O
XR O
and O
36.0 O
% O
( O
36/100 O
) O
for O
placebo O
. O

5.10 O
Leukopenia O
, O
Neutropenia O
and O
Agranulocytosis O
In O
clinical O
trial O
and O
postmarketing O
experience O
, O
events O
of O
leukopenia B-OSE_Labeled_AE
/ O
neutropenia B-OSE_Labeled_AE
have O
been O
reported O
temporally O
related O
to O
atypical O
antipsychotic O
agents O
, O
including O
SEROQUEL O
. O

Agranulocytosis B-OSE_Labeled_AE
( O
including O
fatal B-NonOSE_AE
cases O
) O
has O
also O
been O
reported O
. O

Possible O
risk O
factors O
for O
leukopenia B-NonOSE_AE
/ O
neutropenia B-NonOSE_AE
include O
pre-existing O
low B-Not_AE_Candidate
white I-Not_AE_Candidate
cell I-Not_AE_Candidate
count I-Not_AE_Candidate
( I-Not_AE_Candidate
WBC I-Not_AE_Candidate
) O
and O
history O
of O
drug B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
leukopenia/ O
neutropenia I-Not_AE_Candidate
. O

Patients O
with O
a O
pre-existing O
low B-Not_AE_Candidate
WBC I-Not_AE_Candidate
or O
a O
history O
of O
drug B-Not_AE_Candidate
induced I-Not_AE_Candidate
leukopenia I-Not_AE_Candidate
/neutropenia O
should O
have O
their O
complete O
blood O
count O
( O
CBC O
) O
monitored O
frequently O
during O
the O
first O
few O
months O
of O
therapy O
and O
should O
discontinue O
SEROQUEL O
at O
the O
first O
sign O
of O
a O
decline B-NonOSE_AE
in I-NonOSE_AE
WBC I-NonOSE_AE
in O
absence O
of O
other O
causative O
factors O
. O

Patients O
with O
neutropenia B-NonOSE_AE
should O
be O
carefully O
monitored O
for O
fever B-NonOSE_AE
or O
other O
symptoms O
or O
signs O
of O
infection B-NonOSE_AE
and O
treated O
promptly O
if O
such O
symptoms O
or O
signs O
occur O
. O

Patients O
with O
severe O
neutropenia B-NonOSE_AE
( O
absolute B-NonOSE_AE
neutrophil I-NonOSE_AE
count I-NonOSE_AE
< I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
/ I-NonOSE_AE
mm I-NonOSE_AE
3 I-NonOSE_AE
) O
should O
discontinue O
SEROQUEL O
and O
have O
their O
WBC O
followed O
until O
recovery O
. O

5.11 O
Cataracts O
The O
development O
of O
cataracts B-NonOSE_AE
was O
observed O
in O
association O
with O
quetiapine O
treatment O
in O
chronic O
dog O
studies O
[ O
see O
Nonclinical O
Toxicology O
( O
13.2 O
) O
] O
. O

Lens B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
have O
also O
been O
observed O
in O
adults O
, O
children O
and O
adolescents O
during O
long-term O
SEROQUEL O
treatment O
, O
but O
a O
causal O
relationship O
to O
SEROQUEL O
use O
has O
not O
been O
established O
. O

Nevertheless O
, O
the O
possibility O
of O
lenticular B-NonOSE_AE
changes I-NonOSE_AE
can O
not O
be O
excluded O
at O
this O
time O
. O

Therefore O
, O
examination O
of O
the O
lens O
by O
methods O
adequate O
to O
detect O
cataract B-NonOSE_AE
formation I-NonOSE_AE
, O
such O
as O
slit O
lamp O
exam O
or O
other O
appropriately O
sensitive O
methods O
, O
is O
recommended O
at O
initiation O
of O
treatment O
or O
shortly O
thereafter O
, O
and O
at O
6-month O
intervals O
during O
chronic O
treatment O
. O

5.12 O
QT O
Prolongation O
In O
clinical O
trials O
, O
quetiapine O
was O
not O
associated O
with O
a O
persistent O
increase B-NonOSE_AE
in I-NonOSE_AE
QT I-NonOSE_AE
intervals I-NonOSE_AE
. O

However O
, O
the O
QT O
effect O
was O
not O
systematically O
evaluated O
in O
a O
thorough O
QT O
study O
. O

In O
post O
marketing O
experience O
, O
there O
were O
cases O
reported O
of O
QT B-NonOSE_AE
prolongation I-NonOSE_AE
in O
patients O
who O
overdosed O
on O
quetiapine O
[ O
see O
Overdosage O
( O
10.1 O
) O
] O
, O
in O
patients O
with O
concomitant O
illness O
, O
and O
in O
patients O
taking O
medicines O
known O
to O
cause O
electrolyte B-Not_AE_Candidate
imbalance I-Not_AE_Candidate
or O
increase B-Not_AE_Candidate
QT I-Not_AE_Candidate
interval I-Not_AE_Candidate
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

The O
use O
of O
quetiapine O
should O
be O
avoided O
in O
combination O
with O
other O
drugs O
that O
are O
known O
to O
prolong B-NonOSE_AE
QTc I-NonOSE_AE
including O
Class O
1A O
antiarrythmics O
( O
e.g. O
, O
quinidine O
, O
procainamide O
) O
or O
Class O
III O
antiarrythmics O
( O
e.g. O
, O
amiodarone O
, O
sotalol O
) O
, O
antipsychotic O
medications O
( O
e.g. O
, O
ziprasidone O
, O
chlorpromazine O
, O
thioridazine O
) O
, O
antibiotics O
( O
e.g. O
, O
gatifloxacin O
, O
moxifloxacin O
) O
, O
or O
any O
other O
class O
of O
medications O
known O
to O
prolong B-NonOSE_AE
the I-NonOSE_AE
QTc I-NonOSE_AE
interval I-NonOSE_AE
( O
e.g. O
, O
pentamidine O
, O
levomethadyl O
acetate O
, O
methadone O
) O
. O

Quetiapine O
should O
also O
be O
avoided O
in O
circumstances O
that O
may O
increase O
the O
risk O
of O
occurrence O
of O
torsade B-NonOSE_AE
de I-NonOSE_AE
pointes I-NonOSE_AE
and/or O
sudden B-NonOSE_AE
death I-NonOSE_AE
including O
( O
1 O
) O
a O
history O
of O
cardiac B-Not_AE_Candidate
arrhythmias I-Not_AE_Candidate
such O
as O
bradycardia B-Not_AE_Candidate
; O
( O
2 O
) O
hypokalemia B-Not_AE_Candidate
or O
hypomagnesemia B-Not_AE_Candidate
; O
( O
3 O
) O
concomitant O
use O
of O
other O
drugs O
that O
prolong B-NonOSE_AE
the I-NonOSE_AE
QTc I-NonOSE_AE
interval I-NonOSE_AE
; O
and O
( O
4 O
) O
presence O
of O
congenital B-Not_AE_Candidate
prolongation I-Not_AE_Candidate
of I-Not_AE_Candidate
the I-Not_AE_Candidate
QT I-Not_AE_Candidate
interval I-Not_AE_Candidate
. O

Caution O
should O
also O
be O
exercised O
when O
quetiapine O
is O
prescribed O
in O
patients O
with O
increased O
risk O
of O
QT B-NonOSE_AE
prolongation I-NonOSE_AE
( O
e.g. O
, O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
family O
history O
of O
QT B-Not_AE_Candidate
prolongation I-Not_AE_Candidate
, O
the O
elderly O
, O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
and O
heart B-Not_AE_Candidate
hypertrophy I-Not_AE_Candidate
) O
. O

5.13 O
Seizures O
During O
clinical O
trials O
, O
seizures B-OSE_Labeled_AE
occurred O
in O
0.5 O
% O
( O
20/3490 O
) O
of O
patients O
treated O
with O
SEROQUEL O
compared O
to O
0.2 O
% O
( O
2/954 O
) O
on O
placebo O
and O
0.7 O
% O
( O
4/527 O
) O
on O
active O
control O
drugs O
. O

As O
with O
other O
antipsychotics O
, O
SEROQUEL O
should O
be O
used O
cautiously O
in O
patients O
with O
a O
history O
of O
seizures B-Not_AE_Candidate
or O
with O
conditions O
that O
potentially O
lower B-NonOSE_AE
the I-NonOSE_AE
seizure I-NonOSE_AE
threshold I-NonOSE_AE
, O
e.g. O
, O
Alzheimer B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
dementia I-Not_AE_Candidate
. O

Conditions O
that O
lower B-NonOSE_AE
the I-NonOSE_AE
seizure I-NonOSE_AE
threshold I-NonOSE_AE
may O
be O
more O
prevalent O
in O
a O
population O
of O
65 O
years O
or O
older O
. O

5.14 O
Hypothyroidism B-OSE_Labeled_AE
Adults O
: O
Clinical O
trials O
with O
quetiapine O
demonstrated O
dose-related O
decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
thyroid I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
. O

The O
reduction B-OSE_Labeled_AE
in O
total O
and O
free I-OSE_Labeled_AE
thyroxine I-OSE_Labeled_AE
( I-OSE_Labeled_AE
T I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
) O
of O
approximately O
20 O
% O
at O
the O
higher O
end O
of O
the O
therapeutic O
dose O
range O
was O
maximal O
in O
the O
first O
six O
weeks O
of O
treatment O
and O
maintained O
without O
adaptation O
or O
progression O
during O
more O
chronic O
therapy O
. O

In O
nearly O
all O
cases O
, O
cessation O
of O
quetiapine O
treatment O
was O
associated O
with O
a O
reversal O
of O
the O
effects O
on O
total O
and O
free O
T4 O
, O
irrespective O
of O
the O
duration O
of O
treatment O
. O

The O
mechanism O
by O
which O
quetiapine O
effects O
the O
thyroid O
axis O
is O
unclear O
. O

If O
there O
is O
an O
effect O
on O
the O
hypothalamic-pituitary O
axis O
, O
measurement O
of O
TSH O
alone O
may O
not O
accurately O
reflect O
a O
patient O
's O
thyroid O
status O
. O

Therefore O
, O
both O
TSH O
and O
free O
T4 O
, O
in O
addition O
to O
clinical O
assessment O
, O
should O
be O
measured O
at O
baseline O
and O
at O
follow-up O
. O

In O
the O
mania B-Not_AE_Candidate
adjunct O
studies O
, O
where O
SEROQUEL O
was O
added O
to O
lithium O
or O
divalproex O
, O
12 O
% O
( O
24/196 O
) O
of O
SEROQUEL O
treated O
patients O
compared O
to O
7 O
% O
( O
15/203 O
) O
of O
placebo-treated O
patients O
had O
elevated B-OSE_Labeled_AE
TSH I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
. O

Of O
the O
SEROQUEL O
treated O
patients O
with O
elevated B-OSE_Labeled_AE
TSH I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
, O
3 O
had O
simultaneous O
low B-OSE_Labeled_AE
free I-OSE_Labeled_AE
T I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
( O
free O
T4 O
< O
0.8 O
LLN O
) O
. O

About O
0.7 O
% O
( O
26/3489 O
) O
of O
SEROQUEL O
patients O
did O
experience O
TSH B-OSE_Labeled_AE
increases I-OSE_Labeled_AE
in O
monotherapy O
studies O
. O

Some O
patients O
with O
TSH B-OSE_Labeled_AE
increases I-OSE_Labeled_AE
needed O
replacement O
thyroid O
treatment O
. O

In O
all O
quetiapine O
trials O
, O
the O
incidence O
of O
significant O
shifts B-NonOSE_AE
in I-NonOSE_AE
thyroid I-NonOSE_AE
hormones I-NonOSE_AE
and O
TSH O
were O
[ O
note O
: O
Based O
on O
shifts O
from O
normal O
baseline O
to O
potentially O
clinically O
important O
value O
at O
any O
time O
post-baseline O
. O

Shifts B-NonOSE_AE
in I-NonOSE_AE
total I-NonOSE_AE
T I-NonOSE_AE
4 I-NonOSE_AE
, O
free O
T4 O
, O
total O
T3and O
free O
T3are O
defined O
as O
M0.8 O
x O
LLN O
( O
pmol/L O
) O
and O
shift B-NonOSE_AE
in I-NonOSE_AE
TSH I-NonOSE_AE
is O
> O
5 O
mlU/L O
at O
any O
time O
. O
] O

: O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
free I-OSE_Labeled_AE
T I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
( O
free O
T4 O
< O
0.8 O
LLN O
) O
, O
2.0 O
% O
( O
357/17513 O
) O
; O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
total I-OSE_Labeled_AE
T I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
, O
4.0 O
% O
( O
75/1861 O
) O
; O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
free I-OSE_Labeled_AE
T I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
, O
0.4 O
% O
( O
53/13766 O
) O
; O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
total I-OSE_Labeled_AE
T I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
, O
2.0 O
% O
( O
26/1312 O
) O
, O
and O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
TSH I-OSE_Labeled_AE
, O
4.9 O
% O
( O
956/19412 O
) O
. O

In O
eight O
patients O
, O
where O
TBG O
was O
measured O
, O
levels O
of O
TBG O
were O
unchanged O
. O

Table O
8 O
shows O
the O
incidence O
of O
these O
shifts O
in O
short-term O
placebo-controlled O
clinical O
trials O
. O

Table O
8 O
: O
Incidence O
of O
Shifts B-OSE_Labeled_AE
in O
Thyroid O
Hormone O
Levels O
and O
TSH O
in O
Short-Term O
Placebo-Controlled O
Clinical O
TrialsBased O
on O
shifts O
from O
normal O
baseline O
to O
potentially O
clinically O
important O
value O
at O
any O
time O
post-baseline O
. O

Shifts O
in O
total I-OSE_Labeled_AE
T I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
, O
free O
T4 O
, O
total O
T3 O
and O
free O
T3 O
are O
defined O
as O
< O
0.8 O
x O
LLN O
( O
pmol/L O
) O
and O
shift B-NonOSE_AE
in I-NonOSE_AE
TSH I-NonOSE_AE
is O
> O
5 O
mlU/L O
at O
any O
time. O
, O
Includes O
SEROQUEL O
and O
SEROQUEL O
XR O
data O
. O

Total O
T4 O
Free O
T4 O
Total O
T3 O
Free O
T3 O
TSH O
Quetiapine O
Placebo O
Quetiapine O
Placebo O
Quetiapine O
Placebo O
Quetiapine O
Placebo O
Quetiapine O
Placebo O
3.4 O
% O
( O
37/1097 O
) O
0.6 O
% O
( O
4/651 O
) O
0.7 O
% O
( O
52/7218 O
) O
0.1 O
% O
( O
4/3668 O
) O
0.5 O
% O
( O
2/369 O
) O
0.0 O
% O
( O
0/113 O
) O
0.2 O
% O
( O
11/5673 O
) O
0.0 O
% O
( O
1/2679 O
) O
3.2 O
% O
( O
240/7587 O
) O
2.7 O
% O
( O
105/3912 O
) O
In O
short-term O
placebo-controlled O
monotherapy O
trials O
, O
the O
incidence O
of O
reciprocal O
, O
shifts O
in O
T3and O
TSH O
was O
0.0 O
% O
for O
both O
quetiapine O
( O
1/4800 O
) O
and O
placebo O
( O
0/2190 O
) O
and O
for O
T4and O
TSH O
the O
shifts O
were O
0.1 O
% O
( O
7/6154 O
) O
for O
quetiapine O
versus O
0.0 O
% O
( O
1/3007 O
) O
for O
placebo O
. O

Children O
and O
Adolescents O
: O
In O
acute O
placebo-controlled O
trials O
in O
children O
and O
adolescent O
patients O
with O
schizophrenia B-Not_AE_Candidate
( O
6-week O
duration O
) O
or O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
3-week O
duration O
) O
, O
the O
incidence O
of O
shifts O
for O
thyroid O
function O
values O
at O
any O
time O
for O
SEROQUEL O
treated O
patients O
and O
placebo-treated O
patients O
for O
elevated B-OSE_Labeled_AE
TSH I-OSE_Labeled_AE
was O
2.9 O
% O
( O
8/280 O
) O
vs O
. O
0.7 O
% O
( O
1/138 O
) O
, O
respectively O
and O
for O
decreased B-OSE_Labeled_AE
total I-OSE_Labeled_AE
thyroxine I-OSE_Labeled_AE
was O
2.8 O
% O
( O
8/289 O
) O
vs O
. O
0 O
% O
( O
0/145 O
, O
respectively O
) O
. O

Of O
the O
SEROQUEL O
treated O
patients O
with O
elevated B-OSE_Labeled_AE
TSH I-OSE_Labeled_AE
levels O
, O
1 O
had O
simultaneous O
low B-OSE_Labeled_AE
free I-OSE_Labeled_AE
T I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
level O
at O
end O
of O
treatment O
. O

5.15 O
Hyperprolactinemia B-OSE_Labeled_AE
Adults O
: O
During O
clinical O
trials O
with O
quetiapine O
, O
the O
incidence O
of O
shifts B-OSE_Labeled_AE
in I-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
to I-OSE_Labeled_AE
a I-OSE_Labeled_AE
clinically I-OSE_Labeled_AE
significant I-OSE_Labeled_AE
value I-OSE_Labeled_AE
occurred O
in O
3.6 O
% O
( O
158/4416 O
) O
of O
patients O
treated O
with O
quetiapine O
compared O
to O
2.6 O
% O
( O
51/1968 O
) O
on O
placebo O
. O

Children O
and O
Adolescents O
: O
In O
acute O
placebo-controlled O
trials O
in O
children O
and O
adolescent O
patients O
with O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
3-week O
duration O
) O
or O
schizophrenia B-Not_AE_Candidate
( O
6-week O
duration O
) O
, O
the O
incidence O
of O
shifts B-OSE_Labeled_AE
in I-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
to I-OSE_Labeled_AE
a I-OSE_Labeled_AE
value I-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
ug I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
males O
; O
> O
26 O
ug/L O
females O
at O
any O
time O
) O
was O
13.4 O
% O
( O
18/134 O
) O
for O
SEROQUEL O
compared O
to O
4 O
% O
( O
3/75 O
) O
for O
placebo O
in O
males O
and O
8.7 O
% O
( O
9/104 O
) O
for O
SEROQUEL O
compared O
to O
0 O
% O
( O
0/39 O
) O
for O
placebo O
in O
females O
. O

Like O
other O
drugs O
that O
antagonize O
dopamine O
D2receptors O
, O
SEROQUEL O
elevates B-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
in O
some O
patients O
and O
the O
elevation O
may O
persist O
during O
chronic O
administration O
. O

Hyperprolactinemia B-NonOSE_AE
, O
regardless O
of O
etiology O
, O
may O
suppress B-NonOSE_AE
hypothalamic I-NonOSE_AE
GnRH I-NonOSE_AE
, O
resulting O
in O
reduced B-NonOSE_AE
pituitary I-NonOSE_AE
gonadotrophin I-NonOSE_AE
secretion I-NonOSE_AE
. O

This O
, O
in O
turn O
, O
may O
inhibit B-NonOSE_AE
reproductive I-NonOSE_AE
function I-NonOSE_AE
by O
impairing B-NonOSE_AE
gonadal I-NonOSE_AE
steroidogenesis I-NonOSE_AE
in O
both O
female O
and O
male O
patients O
. O

Galactorrhea B-OSE_Labeled_AE
, O
amenorrhea B-OSE_Labeled_AE
, O
gynecomastia B-OSE_Labeled_AE
, O
and O
impotence B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
receiving O
prolactin B-NonOSE_AE
- I-NonOSE_AE
elevating I-NonOSE_AE
compounds O
. O

Long-standing O
hyperprolactinemia B-NonOSE_AE
when O
associated O
with O
hypogonadism B-NonOSE_AE
may O
lead O
to O
decreased B-NonOSE_AE
bone I-NonOSE_AE
density I-NonOSE_AE
in O
both O
female O
and O
male O
subjects O
. O

Tissue O
culture O
experiments O
indicate O
that O
approximately O
one-third O
of O
human O
breast B-NonOSE_AE
cancers I-NonOSE_AE
are O
prolactin O
dependent O
in O
vitro O
, O
a O
factor O
of O
potential O
importance O
if O
the O
prescription O
of O
these O
drugs O
is O
considered O
in O
a O
patient O
with O
previously O
detected O
breast B-Not_AE_Candidate
cancer I-Not_AE_Candidate
. O

As O
is O
common O
with O
compounds O
which O
increase B-NonOSE_AE
prolactin I-NonOSE_AE
release O
, O
mammary B-NonOSE_AE
gland I-NonOSE_AE
, O
and O
pancreatic O
islet O
cell O
neoplasia I-NonOSE_AE
( O
mammary B-NonOSE_AE
adenocarcinomas I-NonOSE_AE
, O
pituitary B-NonOSE_AE
and O
pancreatic O
adenomas I-NonOSE_AE
) O
was O
observed O
in O
carcinogenicity B-NonOSE_AE
studies O
conducted O
in O
mice O
and O
rats O
. O

Neither O
clinical O
studies O
nor O
epidemiologic O
studies O
conducted O
to O
date O
have O
shown O
an O
association O
between O
chronic O
administration O
of O
this O
class O
of O
drugs O
and O
tumorigenesis B-NonOSE_AE
in O
humans O
, O
but O
the O
available O
evidence O
is O
too O
limited O
to O
be O
conclusive O
[ O
see O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
. O

5.16 O
Potential O
for O
Cognitive B-OSE_Labeled_AE
and O
Motor O
Impairment I-OSE_Labeled_AE
Somnolence B-OSE_Labeled_AE
was O
a O
commonly O
reported O
adverse O
event O
reported O
in O
patients O
treated O
with O
SEROQUEL O
especially O
during O
the O
3-5 O
day O
period O
of O
initial O
dose-titration O
. O

In O
schizophrenia B-Not_AE_Candidate
trials O
, O
somnolence B-OSE_Labeled_AE
was O
reported O
in O
18 O
% O
( O
89/510 O
) O
of O
patients O
on O
SEROQUEL O
compared O
to O
11 O
% O
( O
22/206 O
) O
of O
placebo O
patients O
. O

In O
acute O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
trials O
using O
SEROQUEL O
as O
monotherapy O
, O
somnolence B-OSE_Labeled_AE
was O
reported O
in O
16 O
% O
( O
34/209 O
) O
of O
patients O
on O
SEROQUEL O
compared O
to O
4 O
% O
of O
placebo O
patients O
. O

In O
acute O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
trials O
using O
SEROQUEL O
as O
adjunct O
therapy O
, O
somnolence B-OSE_Labeled_AE
was O
reported O
in O
34 O
% O
( O
66/196 O
) O
of O
patients O
on O
SEROQUEL O
compared O
to O
9 O
% O
( O
19/203 O
) O
of O
placebo O
patients O
. O

In O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
trials O
, O
somnolence B-OSE_Labeled_AE
was O
reported O
in O
57 O
% O
( O
398/698 O
) O
of O
patients O
on O
SEROQUEL O
compared O
to O
15 O
% O
( O
51/347 O
) O
of O
placebo O
patients O
. O

Since O
SEROQUEL O
has O
the O
potential O
to O
impair B-OSE_Labeled_AE
judgment O
, O
thinking O
, O
or O
motor I-OSE_Labeled_AE
skills I-OSE_Labeled_AE
, O
patients O
should O
be O
cautioned O
about O
performing O
activities O
requiring O
mental O
alertness O
, O
such O
as O
operating O
a O
motor O
vehicle O
( O
including O
automobiles O
) O
or O
operating O
hazardous O
machinery O
until O
they O
are O
reasonably O
certain O
that O
SEROQUEL O
therapy O
does O
not O
affect O
them O
adversely O
. O

Somnolence B-OSE_Labeled_AE
may O
lead O
to O
falls B-NonOSE_AE
. O

5.17 O
Body O
Temperature O
Regulation O
Although O
not O
reported O
with O
SEROQUEL O
, O
disruption B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
body I-NonOSE_AE
' I-NonOSE_AE
s I-NonOSE_AE
ability I-NonOSE_AE
to I-NonOSE_AE
reduce I-NonOSE_AE
core I-NonOSE_AE
body I-NonOSE_AE
temperature I-NonOSE_AE
has O
been O
attributed O
to O
antipsychotic O
agents O
. O

Appropriate O
care O
is O
advised O
when O
prescribing O
SEROQUEL O
for O
patients O
who O
will O
be O
experiencing O
conditions O
which O
may O
contribute O
to O
an O
elevation B-NonOSE_AE
in I-NonOSE_AE
core I-NonOSE_AE
body I-NonOSE_AE
temperature I-NonOSE_AE
, O
e.g. O
, O
exercising O
strenuously O
, O
exposure O
to O
extreme O
heat O
, O
receiving O
concomitant O
medication O
with O
anticholinergic O
activity O
, O
or O
being O
subject O
to O
dehydration B-NonOSE_AE
. O

5.18 O
Dysphagia B-OSE_Labeled_AE
Esophageal B-OSE_Labeled_AE
dysmotility I-OSE_Labeled_AE
and O
aspiration B-OSE_Labeled_AE
have O
been O
associated O
with O
antipsychotic O
drug O
use O
. O

Aspiration B-NonOSE_AE
pneumonia I-NonOSE_AE
is O
a O
common O
cause O
of O
morbidity O
and O
mortality B-NonOSE_AE
in O
elderly O
patients O
, O
in O
particular O
those O
with O
advanced O
Alzheimer B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
dementia I-Not_AE_Candidate
. O

SEROQUEL O
and O
other O
antipsychotic O
drugs O
should O
be O
used O
cautiously O
in O
patients O
at O
risk O
for O
aspiration B-Not_AE_Candidate
pneumonia I-Not_AE_Candidate
. O

5.19 O
Discontinuation O
Syndrome O
Acute B-OSE_Labeled_AE
withdrawal I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
, O
such O
as O
insomnia B-NonOSE_AE
, O
nausea B-NonOSE_AE
, O
and O
vomiting B-NonOSE_AE
have O
been O
described O
after O
abrupt O
cessation O
of O
atypical O
antipsychotic O
drugs O
, O
including O
SEROQUEL O
. O

In O
short-term O
placebo-controlled O
, O
monotherapy O
clinical O
trials O
with O
SEROQUEL O
XR O
that O
included O
a O
discontinuation O
phase O
which O
evaluated O
discontinuation B-NonOSE_AE
symptoms I-NonOSE_AE
, O
the O
aggregated O
incidence O
of O
patients O
experiencing O
one O
or O
more O
discontinuation B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
after O
abrupt O
cessation O
was O
12.1 O
% O
( O
241/1993 O
) O
for O
SEROQUEL O
XR O
and O
6.7 O
% O
( O
71/1065 O
) O
for O
placebo O
. O

The O
incidence O
of O
the O
individual O
adverse O
events O
( O
i.e. O
, O
insomnia B-NonOSE_AE
, O
nausea B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
dizziness B-NonOSE_AE
and O
irritability B-NonOSE_AE
) O
did O
not O
exceed O
5.3 O
% O
in O
any O
treatment O
group O
and O
usually O
resolved O
after O
1 O
week O
post-discontinuation O
. O

Gradual O
withdrawal O
is O
advised O
. O

6 O
ADVERSE O
REACTIONS O
Clinically O
significant O
adverse O
reactions O
that O
appear O
in O
other O
sections O
of O
the O
labeling O
include O
: O
* O
Hypocortisolism B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Hyperglycemia B-OSE_Labeled_AE
and O
Diabetes B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Bradycardia B-OSE_Labeled_AE
and O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Liver B-OSE_Labeled_AE
Test I-OSE_Labeled_AE
Elevations I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Cholelithiasis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Pituitary B-OSE_Labeled_AE
Hormone I-OSE_Labeled_AE
Deficiency I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
occurring O
in O
> O
= O
20 O
% O
of O
patients O
are O
diarrhea O
, O
nausea O
, O
hyperglycemia O
, O
cholelithiasis O
, O
headache O
, O
abdominal O
pain O
, O
fatigue O
, O
and O
diabetes O
mellitus O
( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Novartis O
Pharmaceuticals O
Corporation O
at O
1-888-669-6682 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

A O
total O
of O
162 O
Cushing B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
patients O
were O
exposed O
to O
SIGNIFOR O
in O
the O
Phase O
III O
study O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

At O
study O
entry O
, O
patients O
were O
randomized O
to O
receive O
twice O
a O
day O
( O
b.i.d O
. O
) O

doses O
of O
either O
0.6 O
mg O
or O
0.9 O
mg O
of O
SIGNIFOR O
given O
subcutaneously O
. O

The O
mean O
age O
of O
patients O
was O
approximately O
40 O
years O
old O
with O
a O
predominance O
of O
female O
patients O
( O
78 O
% O
) O
. O

The O
majority O
of O
the O
patients O
had O
persistent O
or O
recurrent O
Cushing B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
( O
83 O
% O
) O
and O
few O
patients O
( O
< O
= O
5 O
% O
) O
in O
either O
treatment O
group O
had O
received O
previous O
pituitary O
irradiation O
. O

The O
median O
exposure O
to O
the O
treatment O
was O
10.4 O
months O
( O
0.03-37.8 O
) O
with O
68 O
% O
of O
patients O
having O
at O
least O
six-months O
exposure O
. O

In O
the O
Phase O
III O
trial O
, O
adverse O
reactions O
were O
reported O
in O
98 O
% O
of O
patients O
. O

The O
most O
common O
adverse O
reactions O
( O
frequency O
> O
= O
20 O
% O
in O
either O
group O
) O
were O
diarrhea B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
cholelithiasis B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
and O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
. O

There O
were O
no O
deaths O
during O
the O
study O
. O

Serious O
adverse O
events O
were O
reported O
in O
25 O
% O
of O
patients O
. O

Adverse O
events O
leading O
to O
study O
discontinuation O
were O
reported O
in O
17 O
% O
of O
patients O
. O

Adverse O
reactions O
with O
an O
overall O
frequency O
higher O
than O
5 O
% O
are O
presented O
in O
Table O
1 O
by O
randomized O
dose O
group O
and O
overall O
. O

Adverse O
reactions O
are O
ranked O
by O
frequency O
, O
with O
the O
most O
frequent O
reactions O
listed O
first O
. O

Table O
1 O
- O
Adverse O
reactions O
[ O
n O
( O
% O
) O
] O
with O
an O
overall O
frequency O
of O
more O
than O
5 O
% O
in O
the O
combined O
dose O
group O
in O
the O
Phase O
III O
study O
in O
Cushing O
's O
disease O
patients O
SIGNIFOR0.6 O
mg O
bidN=82 O
SIGNIFOR0.9 O
mg O
bidN=80 O
OverallN=162 O
Diarrhea B-OSE_Labeled_AE
48 O
( O
59 O
) O
46 O
( O
58 O
) O
94 O
( O
58 O
) O
Nausea B-OSE_Labeled_AE
38 O
( O
46 O
) O
46 O
( O
58 O
) O
84 O
( O
52 O
) O
Hyperglycemia B-OSE_Labeled_AE
31 O
( O
38 O
) O
34 O
( O
43 O
) O
65 O
( O
40 O
) O
Cholelithiasis B-OSE_Labeled_AE
25 O
( O
30 O
) O
24 O
( O
30 O
) O
49 O
( O
30 O
) O
Headache B-OSE_Labeled_AE
23 O
( O
28 O
) O
23 O
( O
29 O
) O
46 O
( O
28 O
) O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
19 O
( O
23 O
) O
20 O
( O
25 O
) O
39 O
( O
24 O
) O
Fatigue B-OSE_Labeled_AE
12 O
( O
15 O
) O
19 O
( O
24 O
) O
31 O
( O
19 O
) O
Diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
13 O
( O
16 O
) O
16 O
( O
20 O
) O
29 O
( O
18 O
) O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
14 O
( O
17 O
) O
14 O
( O
18 O
) O
28 O
( O
17 O
) O
Nasopharyngitis B-OSE_Labeled_AE
10 O
( O
12 O
) O
11 O
( O
14 O
) O
21 O
( O
13 O
) O
Alopecia B-OSE_Labeled_AE
10 O
( O
12 O
) O
10 O
( O
13 O
) O
20 O
( O
12 O
) O
Asthenia B-OSE_Labeled_AE
13 O
( O
16 O
) O
5 O
( O
6 O
) O
18 O
( O
11 O
) O
Glycosylated B-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
10 O
( O
12 O
) O
8 O
( O
10 O
) O
18 O
( O
11 O
) O
Alanine B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
11 O
( O
13 O
) O
6 O
( O
8 O
) O
17 O
( O
10 O
) O
Gamma B-OSE_Labeled_AE
- I-OSE_Labeled_AE
glutamyl I-OSE_Labeled_AE
transferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
10 O
( O
12 O
) O
7 O
( O
9 O
) O
17 O
( O
10 O
) O
Edema B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
9 O
( O
11 O
) O
8 O
( O
10 O
) O
17 O
( O
10 O
) O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
10 O
( O
12 O
) O
6 O
( O
8 O
) O
16 O
( O
10 O
) O
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
7 O
( O
9 O
) O
9 O
( O
11 O
) O
16 O
( O
10 O
) O
Hypercholesterolemia B-OSE_Labeled_AE
7 O
( O
9 O
) O
9 O
( O
11 O
) O
16 O
( O
10 O
) O
Hypertension B-OSE_Labeled_AE
8 O
( O
10 O
) O
8 O
( O
10 O
) O
16 O
( O
10 O
) O
Dizziness B-OSE_Labeled_AE
8 O
( O
10 O
) O
7 O
( O
9 O
) O
15 O
( O
9 O
) O
Hypoglycemia B-OSE_Labeled_AE
12 O
( O
15 O
) O
3 O
( O
4 O
) O
15 O
( O
9 O
) O
Type B-OSE_Labeled_AE
2 I-OSE_Labeled_AE
diabetes I-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
10 O
( O
12 O
) O
5 O
( O
6 O
) O
15 O
( O
9 O
) O
Anxiety B-OSE_Labeled_AE
5 O
( O
6 O
) O
9 O
( O
11 O
) O
14 O
( O
9 O
) O
Influenza B-OSE_Labeled_AE
9 O
( O
11 O
) O
5 O
( O
6 O
) O
14 O
( O
9 O
) O
Insomnia B-OSE_Labeled_AE
3 O
( O
4 O
) O
11 O
( O
14 O
) O
14 O
( O
9 O
) O
Myalgia B-OSE_Labeled_AE
10 O
( O
12 O
) O
4 O
( O
5 O
) O
14 O
( O
9 O
) O
Arthralgia B-OSE_Labeled_AE
5 O
( O
6 O
) O
8 O
( O
10 O
) O
13 O
( O
8 O
) O
Pruritus B-OSE_Labeled_AE
6 O
( O
7 O
) O
7 O
( O
9 O
) O
13 O
( O
8 O
) O
Lipase B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
7 O
( O
9 O
) O
5 O
( O
6 O
) O
12 O
( O
7 O
) O
Constipation B-OSE_Labeled_AE
7 O
( O
9 O
) O
4 O
( O
5 O
) O
11 O
( O
7 O
) O
Hypotension B-OSE_Labeled_AE
5 O
( O
6 O
) O
6 O
( O
8 O
) O
11 O
( O
7 O
) O
Vomiting B-OSE_Labeled_AE
3 O
( O
4 O
) O
8 O
( O
10 O
) O
11 O
( O
7 O
) O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
4 O
( O
5 O
) O
6 O
( O
8 O
) O
10 O
( O
6 O
) O
Dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
5 O
( O
6 O
) O
5 O
( O
6 O
) O
10 O
( O
6 O
) O
Electrocardiogram B-OSE_Labeled_AE
QT I-OSE_Labeled_AE
prolonged I-OSE_Labeled_AE
5 O
( O
6 O
) O
5 O
( O
6 O
) O
10 O
( O
6 O
) O
Hypokalemia B-OSE_Labeled_AE
6 O
( O
7 O
) O
4 O
( O
5 O
) O
10 O
( O
6 O
) O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
6 O
( O
7 O
) O
4 O
( O
5 O
) O
10 O
( O
6 O
) O
Sinus B-OSE_Labeled_AE
bradycardia I-OSE_Labeled_AE
8 O
( O
10 O
) O
2 O
( O
3 O
) O
10 O
( O
6 O
) O
Vertigo B-OSE_Labeled_AE
4 O
( O
5 O
) O
6 O
( O
8 O
) O
10 O
( O
6 O
) O
Abdominal B-OSE_Labeled_AE
distension I-OSE_Labeled_AE
4 O
( O
5 O
) O
5 O
( O
6 O
) O
9 O
( O
6 O
) O
Adrenal B-OSE_Labeled_AE
insufficiency I-OSE_Labeled_AE
4 O
( O
5 O
) O
5 O
( O
6 O
) O
9 O
( O
6 O
) O
Aspartate B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
6 O
( O
7 O
) O
3 O
( O
4 O
) O
9 O
( O
6 O
) O
Blood B-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
6 O
( O
7 O
) O
3 O
( O
4 O
) O
9 O
( O
6 O
) O
Other O
notable O
adverse O
reactions O
which O
occurred O
with O
a O
frequency O
less O
than O
5 O
% O
were O
: O
anemia B-OSE_Labeled_AE
( O
4 O
% O
) O
; O
blood B-OSE_Labeled_AE
amylase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
2 O
% O
) O
and O
prothrombin B-OSE_Labeled_AE
time I-OSE_Labeled_AE
prolonged I-OSE_Labeled_AE
( O
2 O
% O
) O
. O

Gastrointestinal O
Disorders O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
, O
predominantly O
diarrhea B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
and O
vomiting B-OSE_Labeled_AE
were O
reported O
frequently O
in O
the O
Phase O
III O
trial O
( O
see O
Table O
1 O
) O
. O

These O
events O
began O
to O
develop O
primarily O
during O
the O
first O
month O
of O
treatment O
with O
SIGNIFOR O
and O
required O
no O
intervention O
. O

Hyperglycemia O
and O
Diabetes O
Hyperglycemia B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
terms I-OSE_Labeled_AE
were O
reported O
frequently O
in O
the O
Phase O
III O
trial O
. O

For O
all O
patients O
, O
these O
terms O
included O
: O
hyperglycemia B-OSE_Labeled_AE
( O
40 O
% O
) O
, O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
( O
18 O
% O
) O
, O
increased B-OSE_Labeled_AE
HbA I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
c I-OSE_Labeled_AE
( O
11 O
% O
) O
, O
and O
type B-OSE_Labeled_AE
2 I-OSE_Labeled_AE
diabetes I-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
( O
9 O
% O
) O
. O

In O
general O
, O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
fasting I-OSE_Labeled_AE
plasma I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
( I-OSE_Labeled_AE
FPG I-OSE_Labeled_AE
) O
and O
hemoglobin O
A1c O
( O
HbA1c O
) O
were O
seen O
soon O
after O
initiation O
of O
SIGNIFOR O
and O
were O
sustained O
during O
the O
treatment O
period O
. O

In O
the O
SIGNIFOR O
0.6 O
mg O
group O
, O
mean O
fasting B-OSE_Labeled_AE
plasma I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
( I-OSE_Labeled_AE
FPG I-OSE_Labeled_AE
) I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
from O
98.6 O
mg/dL O
at O
baseline O
to O
125.1 O
mg/dL O
at O
Month O
6 O
. O

In O
the O
SIGNIFOR O
0.9 O
mg O
group O
, O
mean O
fasting B-OSE_Labeled_AE
plasma I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
( I-OSE_Labeled_AE
FPG I-OSE_Labeled_AE
) I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
from O
97.0 O
mg/dL O
at O
baseline O
to O
128.0 O
mg/dL O
at O
Month O
6 O
. O

In O
the O
SIGNIFOR O
0.6 O
mg O
group O
, O
HbA B-OSE_Labeled_AE
1 I-OSE_Labeled_AE
c I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
from O
5.8 O
% O
at O
baseline O
to O
7.2 O
% O
at O
Month O
6 O
. O

In O
the O
SIGNIFOR O
0.9 O
mg O
group O
, O
HbA B-OSE_Labeled_AE
1 I-OSE_Labeled_AE
c I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
from O
5.8 O
% O
at O
baseline O
to O
7.3 O
% O
at O
Month O
6 O
[ O
see O
Warning O
and O
Precautions O
( O
5.2 O
) O
] O
. O

At O
one-month O
follow-up O
visits O
following O
discontinuation O
of O
SIGNIFOR O
, O
mean B-NonOSE_AE
FPG I-NonOSE_AE
and O
HbA1c O
levels I-NonOSE_AE
decreased I-NonOSE_AE
but O
remained O
above O
baseline O
values O
. O

Long-term O
follow-up O
data O
are O
not O
available O
. O

Elevated O
Liver O
Tests O
In O
the O
Phase O
III O
trial O
, O
there O
were O
transient O
mean O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
values O
in O
patients O
treated O
with O
SIGNIFOR O
. O

Mean O
values O
returned O
to O
baseline O
levels O
by O
Month O
4 O
of O
treatment O
. O

The O
elevations O
were O
not O
associated O
with O
clinical O
symptoms O
of O
hepatic B-NonOSE_AE
disease I-NonOSE_AE
. O

In O
the O
clinical O
development O
program O
of O
SIGNIFOR O
, O
there O
were O
4 O
patients O
with O
concurrent O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
greater O
than O
3 O
x O
ULN O
and O
bilirubin O
greater O
than O
2 O
x O
ULN O
: O
one O
patient O
with O
Cushing B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
and O
three O
healthy O
volunteers O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

In O
all O
four O
cases O
, O
the O
elevations O
were O
noted O
within O
the O
first O
10 O
days O
of O
treatment O
. O

In O
all O
of O
these O
cases O
, O
total B-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
were O
seen O
either O
concomitantly O
or O
preceding O
the O
transaminase B-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
. O

The O
patient O
with O
Cushing B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
developed O
jaundice B-OSE_Labeled_AE
. O

All O
four O
cases O
had O
resolution O
of O
the O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
with O
discontinuation O
of O
SIGNIFOR O
. O

Hypocortisolism O
Cases O
of O
hypocortisolism B-OSE_Labeled_AE
were O
reported O
in O
the O
Phase O
III O
study O
in O
Cushing B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
patients O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
and O
Clinical O
Studies O
( O
14 O
) O
] O
. O

The O
majority O
of O
cases O
were O
manageable O
by O
reducing O
the O
dose O
of O
SIGNIFOR O
and/or O
adding O
low-dose O
, O
short-term O
glucocorticoid O
therapy O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Injection O
Site O
Reactions O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
were O
reported O
in O
17 O
% O
of O
patients O
enrolled O
in O
the O
Phase O
III O
trial O
in O
Cushing B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

The O
events O
were O
most O
frequently O
reported O
as O
local B-OSE_Labeled_AE
pain O
, O
erythema I-OSE_Labeled_AE
, O
hematoma O
, O
hemorrhage O
, O
and O
pruritus O
. O

These O
events O
resolved O
spontaneously O
and O
required O
no O
intervention O
. O

Thyroid O
Function O
Hypothyroidism B-OSE_Labeled_AE
with O
the O
use O
of O
SIGNIFOR O
was O
reported O
for O
seven O
patients O
participating O
in O
the O
Phase O
III O
study O
in O
Cushing B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

All O
seven O
patients O
presented O
with O
a O
TSH B-Not_AE_Candidate
close I-Not_AE_Candidate
to I-Not_AE_Candidate
or I-Not_AE_Candidate
below I-Not_AE_Candidate
the I-Not_AE_Candidate
lower I-Not_AE_Candidate
limit I-Not_AE_Candidate
at O
study O
entry O
which O
precludes O
establishing O
a O
conclusive O
relationship O
between O
the O
adverse O
event O
and O
the O
use O
of O
SIGNIFOR O
. O

Other O
Abnormal O
Laboratory O
Findings O
Asymptomatic O
and O
reversible O
elevations B-OSE_Labeled_AE
in O
lipase I-OSE_Labeled_AE
and O
amylase O
were O
observed O
in O
patients O
receiving O
SIGNIFOR O
in O
clinical O
studies O
. O

Pancreatitis B-OSE_Labeled_AE
is O
a O
potential O
adverse O
reaction O
associated O
with O
the O
use O
of O
somatostatin O
analogs O
due O
to O
the O
association O
between O
cholelithiasis B-NonOSE_AE
and O
acute B-NonOSE_AE
pancreatitis I-NonOSE_AE
. O

For O
hemoglobin O
levels O
, O
mean O
decreases O
that O
remained O
within O
normal O
range O
were O
observed O
. O

Also O
, O
post-baseline O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
PT I-OSE_Labeled_AE
and O
PTT O
were O
noted O
in O
33 O
% O
and O
47 O
% O
of O
patients O
, O
respectively O
. O

The O
PT B-OSE_Labeled_AE
and O
PTT O
elevations I-OSE_Labeled_AE
were O
minimal O
. O

These O
laboratory O
findings O
are O
of O
unclear O
clinical O
significance O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Hypocortisolism O
: O
Decreases O
in O
circulating O
levels O
of O
cortisol O
may O
occur O
resulting O
in O
biochemical O
and/or O
clinical O
hypocortisolism O
. O

SIGNIFOR O
dose O
reduction O
or O
interruption O
and/or O
adding O
a O
low-dose O
short-term O
glucocorticoid O
may O
be O
necessary O
( O
5.1 O
) O
* O
Hyperglycemia O
and O
Diabetes O
( O
occurs O
with O
initiation O
) O
: O
Intensive O
glucose O
monitoring O
is O
recommended O
and O
may O
require O
initiation O
or O
adjustment O
of O
anti-diabetic O
treatment O
per O
standard O
of O
care O
( O
5.2 O
) O
* O
Bradycardia O
and O
QT O
Prolongation O
: O
Use O
with O
caution O
in O
at-risk O
patients O
; O
ECG O
testing O
prior O
to O
dosing O
and O
on O
treatment O
( O
5.3 O
, O
7.1 O
) O
* O
Liver O
Test O
Elevations O
: O
Evaluate O
liver O
tests O
prior O
to O
and O
during O
treatment O
( O
5.4 O
) O
* O
Cholelithiasis O
: O
Perform O
gallbladder O
ultrasounds O
before O
starting O
treatment O
and O
at O
6-month O
intervals O
( O
5.5 O
) O
5.1 O
Hypocortisolism O
Treatment O
with O
SIGNIFOR O
leads O
to O
suppression B-Not_AE_Candidate
of I-Not_AE_Candidate
adrenocorticotropic I-Not_AE_Candidate
hormone I-Not_AE_Candidate
( I-Not_AE_Candidate
ACTH I-Not_AE_Candidate
) I-Not_AE_Candidate
secretion I-Not_AE_Candidate
in I-Not_AE_Candidate
Cushing I-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Suppression B-Not_AE_Candidate
of I-Not_AE_Candidate
ACTH I-Not_AE_Candidate
may O
lead O
to O
a O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
circulating I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
of I-OSE_Labeled_AE
cortisol I-OSE_Labeled_AE
and O
potentially O
hypocortisolism B-OSE_Labeled_AE
. O

Monitor O
and O
instruct O
patients O
on O
the O
signs O
and O
symptoms O
associated O
with O
hypocortisolism B-NonOSE_AE
( O
e.g. O
, O
weakness B-NonOSE_AE
, O
fatigue B-NonOSE_AE
, O
anorexia B-NonOSE_AE
, O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
hypotension B-NonOSE_AE
, O
hyponatremia B-NonOSE_AE
or O
hypoglycemia B-NonOSE_AE
) O
. O

If O
hypocortisolism B-NonOSE_AE
occurs O
, O
consider O
temporary O
dose O
reduction O
or O
interruption O
of O
treatment O
with O
SIGNIFOR O
, O
as O
well O
as O
temporary O
, O
exogenous O
glucocorticoid O
replacement O
therapy O
. O

5.2 O
Hyperglycemia B-OSE_Labeled_AE
and O
Diabetes O
Elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
have O
been O
seen O
in O
healthy O
volunteers O
and O
patients O
treated O
with O
SIGNIFOR O
. O

In O
the O
Phase O
III O
trial O
, O
the O
development O
of O
pre B-OSE_Labeled_AE
- I-OSE_Labeled_AE
diabetes I-OSE_Labeled_AE
and O
diabetes B-OSE_Labeled_AE
was O
observed O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

In O
this O
trial O
, O
nearly O
all O
patients-including O
those O
with O
normal O
glucose O
status O
at O
baseline O
, O
pre B-Not_AE_Candidate
- I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
, O
and O
diabetes B-Not_AE_Candidate
-developed O
worsening B-OSE_Labeled_AE
glycemia I-OSE_Labeled_AE
in O
the O
first O
two O
weeks O
of O
treatment O
. O

Cushing B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
patients O
with O
poor B-Not_AE_Candidate
glycemic I-Not_AE_Candidate
control I-Not_AE_Candidate
( O
as O
defined O
by O
HbA B-NonOSE_AE
1 I-NonOSE_AE
c I-NonOSE_AE
values I-NonOSE_AE
> I-NonOSE_AE
8 I-NonOSE_AE
% I-NonOSE_AE
while O
receiving O
anti-diabetic O
therapy O
) O
may O
be O
at O
a O
higher O
risk O
of O
developing O
severe O
hyperglycemia B-NonOSE_AE
and O
associated O
complications O
, O
e.g. O
, O
ketoacidosis B-NonOSE_AE
. O

Because O
of O
this O
predictable O
adverse O
reaction O
, O
the O
glycemic O
status O
[ O
fasting O
plasma O
glucose O
( O
FPG O
) O
or O
hemoglobin O
A1c O
( O
HbA1c O
) O
] O
should O
be O
assessed O
prior O
to O
starting O
treatment O
with O
SIGNIFOR O
. O

In O
patients O
with O
uncontrolled B-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
intensive O
anti-diabetic O
therapy O
should O
be O
optimized O
prior O
to O
treatment O
with O
SIGNIFOR O
. O

Self-monitoring O
of O
blood O
glucose O
and/or O
FPG O
assessments O
should O
be O
done O
every O
week O
for O
the O
first O
two O
to O
three O
months O
and O
periodically O
thereafter O
, O
as O
clinically O
appropriate O
, O
as O
well O
as O
over O
the O
first O
two O
to O
four O
weeks O
after O
any O
dose O
increase O
. O

After O
treatment O
discontinuation O
, O
glycemic O
monitoring O
( O
e.g. O
, O
FPG O
or O
HbA1c O
) O
should O
be O
done O
according O
to O
clinical O
practice O
. O

Patients O
who O
were O
initiated O
on O
anti-diabetic O
therapy O
as O
a O
result O
of O
SIGNIFOR O
may O
require O
closer O
monitoring O
after O
discontinuation O
of O
SIGNIFOR O
, O
especially O
if O
the O
anti-diabetic O
therapy O
has O
a O
risk O
of O
causing O
hypoglycemia B-NonOSE_AE
. O

If O
hyperglycemia B-NonOSE_AE
develops O
in O
a O
patient O
treated O
with O
SIGNIFOR O
, O
the O
initiation O
or O
adjustment O
of O
anti-diabetic O
treatment O
per O
standard O
of O
care O
is O
recommended O
. O

The O
optimal O
treatment O
for O
the O
management O
of O
SIGNIFOR-induced O
hyperglycemia B-NonOSE_AE
is O
not O
known O
. O

If O
uncontrolled O
hyperglycemia B-NonOSE_AE
persists O
, O
despite O
appropriate O
medical O
management O
, O
the O
dose O
of O
SIGNIFOR O
should O
be O
reduced O
or O
discontinued O
. O

5.3 O
Bradycardia O
and O
QT O
Prolongation O
Bradycardia O
Bradycardia B-OSE_Labeled_AE
has O
been O
reported O
with O
the O
use O
of O
SIGNIFOR O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

Patients O
with O
cardiac B-Not_AE_Candidate
disease I-Not_AE_Candidate
and/or O
risk O
factors O
for O
bradycardia B-Not_AE_Candidate
, O
such O
as O
history O
of O
clinically O
significant O
bradycardia B-Not_AE_Candidate
, O
high-grade O
heart B-Not_AE_Candidate
block I-Not_AE_Candidate
, O
or O
concomitant O
use O
of O
drugs O
associated O
with O
bradycardia B-Not_AE_Candidate
, O
should O
be O
carefully O
monitored O
. O

Dose O
adjustments O
of O
beta-blockers O
, O
calcium O
channel O
blockers O
, O
or O
correction O
of O
electrolyte B-NonOSE_AE
disturbances I-NonOSE_AE
may O
be O
necessary O
. O

QT O
Prolongation O
SIGNIFOR O
is O
associated O
with O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
. O

In O
two O
thorough O
QT O
studies O
with O
SIGNIFOR O
, O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
occurred O
at O
therapeutic O
and O
supra-therapeutic O
doses O
. O

SIGNIFOR O
should O
be O
used O
with O
caution O
in O
patients O
who O
are O
at O
significant O
risk O
of O
developing O
prolongation B-NonOSE_AE
of I-NonOSE_AE
QTc I-NonOSE_AE
, O
such O
as O
those O
: O
* O
with O
congenital B-Not_AE_Candidate
long I-Not_AE_Candidate
QT I-Not_AE_Candidate
prolongation I-Not_AE_Candidate
. O

* O
with O
uncontrolled O
or O
significant O
cardiac B-Not_AE_Candidate
disease I-Not_AE_Candidate
including O
recent B-Not_AE_Candidate
myocardial I-Not_AE_Candidate
infarction I-Not_AE_Candidate
, O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
unstable B-Not_AE_Candidate
angina I-Not_AE_Candidate
or O
clinically O
significant O
bradycardia B-Not_AE_Candidate
. O

* O
on O
anti-arrhythmic O
therapy O
or O
other O
substances O
that O
are O
known O
to O
lead O
to O
QT B-Not_AE_Candidate
prolongation I-Not_AE_Candidate
. O

* O
with O
hypokalemia B-Not_AE_Candidate
and/or O
hypomagnesemia B-Not_AE_Candidate
. O

A O
baseline O
ECG O
is O
recommended O
prior O
to O
initiating O
therapy O
with O
SIGNIFOR O
and O
monitoring O
for O
an O
effect O
on O
the O
QTc O
interval O
is O
advisable O
. O

Hypokalemia B-NonOSE_AE
and O
hypomagnesemia B-NonOSE_AE
must O
be O
corrected O
prior O
to O
SIGNIFOR O
administration O
and O
should O
be O
monitored O
periodically O
during O
therapy O
. O

5.4 O
Liver O
Test O
Elevations O
In O
the O
Phase O
III O
trial O
, O
5 O
% O
of O
patients O
had O
an O
ALT B-OSE_Labeled_AE
or O
AST O
level O
greater I-OSE_Labeled_AE
than I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
times I-OSE_Labeled_AE
the I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
limit I-OSE_Labeled_AE
of I-OSE_Labeled_AE
normal I-OSE_Labeled_AE
( O
ULN O
) O
. O

In O
the O
entire O
clinical O
development O
program O
of O
SIGNIFOR O
, O
there O
were O
4 O
cases O
of O
concurrent O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
( O
alanine O
aminotransferase O
) O
greater O
than O
3 O
x O
ULN O
and O
bilirubin B-OSE_Labeled_AE
greater I-OSE_Labeled_AE
than O
2 O
x O
ULN O
: O
one O
patient O
with O
Cushing O
's O
disease O
and O
three O
healthy O
volunteers O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

In O
these O
cases O
, O
total B-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
were O
seen O
either O
concomitantly O
or O
preceding O
the O
transaminase B-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
. O

Monitoring O
of O
liver O
tests O
should O
be O
done O
after O
1 O
to O
2 O
weeks O
on O
treatment O
, O
then O
monthly O
for O
3 O
months O
, O
and O
every O
6 O
months O
thereafter O
. O

If O
ALT O
is O
normal O
at O
baseline O
and O
elevations B-NonOSE_AE
of I-NonOSE_AE
ALT I-NonOSE_AE
of O
3-5 O
times O
the O
ULN O
are O
observed O
on O
treatment O
, O
repeat O
the O
test O
within O
a O
week O
or O
within O
48 O
hours O
if O
exceeding O
5 O
times O
ULN O
. O

If O
ALT B-NonOSE_AE
is I-NonOSE_AE
abnormal I-NonOSE_AE
at O
baseline O
and O
elevations B-NonOSE_AE
of I-NonOSE_AE
ALT I-NonOSE_AE
of O
3-5 O
times O
the O
baseline O
values O
are O
observed O
on O
treatment O
, O
repeat O
the O
test O
within O
a O
week O
or O
sooner O
if O
exceeding O
5 O
times O
ULN O
. O

Tests O
should O
be O
done O
in O
a O
laboratory O
that O
can O
provide O
same-day O
results O
. O

If O
the O
values O
are O
confirmed O
or O
rising O
, O
interrupt O
SIGNIFOR O
treatment O
and O
investigate O
for O
probable O
cause O
of O
the O
findings O
, O
which O
may O
or O
may O
not O
be O
SIGNIFOR-related O
. O

Serial O
measures O
of O
ALT O
, O
aspartate O
aminotransferase O
, O
alkaline O
phosphatase O
, O
and O
total O
bilirubin O
, O
should O
be O
done O
weekly O
, O
or O
more O
frequently O
, O
if O
any O
value O
exceeds O
5 O
times O
the O
baseline O
value O
in O
case O
of O
abnormal O
baselines O
or O
5 O
times O
the O
ULN O
in O
case O
of O
normal O
baselines O
. O

If O
resolution O
of O
abnormalities O
to O
normal O
or O
near O
normal O
occurs O
, O
resuming O
treatment O
with O
SIGNIFOR O
may O
be O
done O
cautiously O
, O
with O
close O
observation O
, O
and O
only O
if O
some O
other O
likely O
cause O
has O
been O
found O
. O

5.5 O
Cholelithiasis O
Cholelithiasis B-OSE_Labeled_AE
has O
been O
frequently O
reported O
in O
clinical O
studies O
with O
SIGNIFOR O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

Ultrasonic O
examination O
of O
the O
gallbladder O
before O
, O
and O
at O
6- O
to O
12-month O
intervals O
during O
SIGNIFOR O
therapy O
is O
recommended O
. O

5.6 O
Monitoring O
for O
Deficiency O
of O
Pituitary O
Hormones O
As O
the O
pharmacological O
activity O
of O
SIGNIFOR O
mimics O
that O
of O
somatostatin O
, O
inhibition B-OSE_Labeled_AE
of I-OSE_Labeled_AE
pituitary I-OSE_Labeled_AE
hormones I-OSE_Labeled_AE
, O
other O
than O
ACTH O
, O
may O
occur O
. O

Monitoring O
of O
pituitary O
function O
( O
e.g. O
, O
TSH/free O
T4 O
, O
GH/IGF-1 O
) O
should O
occur O
prior O
to O
initiation O
of O
therapy O
with O
SIGNIFOR O
and O
periodically O
during O
treatment O
should O
be O
considered O
as O
clinically O
appropriate O
. O

Patients O
who O
have O
undergone O
transsphenoidal B-Not_AE_Candidate
surgery I-Not_AE_Candidate
and O
pituitary B-Not_AE_Candidate
irradiation I-Not_AE_Candidate
are O
particularly O
at O
increased O
risk O
for O
deficiency B-NonOSE_AE
of O
pituitary I-NonOSE_AE
hormones I-NonOSE_AE
. O

6 O
ADVERSE O
REACTIONS O
Long-acting O
beta2-adrenergic O
agonists O
, O
such O
as O
STRIVERDI O
RESPIMAT O
, O
increase O
the O
risk O
of O
asthma B-NonOSE_AE
-related O
death B-NonOSE_AE
. O

STRIVERDI O
RESPIMAT O
is O
not O
indicated O
for O
the O
treatment O
of O
asthma B-Not_AE_Candidate
[ O
see O
Boxed O
Warning O
and O
Warning O
and O
Precautions O
( O
5.1 O
) O
] O
. O

EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
=2 O
% O
and O
more O
than O
placebo O
) O
are O
nasopharyngitis O
, O
upper O
respiratory O
tract O
infection O
, O
bronchitis O
, O
urinary O
tract O
infection O
, O
cough O
, O
dizziness O
, O
rash O
, O
diarrhea O
, O
back O
pain O
and O
arthralgia O
( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Boehringer O
Ingelheim O
Pharmaceuticals O
, O
Inc O
. O
at O
( O
800 O
) O
542-6257 O
or O
( O
800 O
) O
459-9906 O
TTY O
, O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
in O
Chronic O
Obstructive O
Pulmonary O
Disease O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
with O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
STRIVERDI O
RESPIMAT O
clinical O
development O
program O
included O
seven O
dose-ranging O
trials O
and O
eight O
confirmatory O
trials O
. O

Four O
of O
the O
confirmatory O
trials O
were O
6-week O
cross-over O
trials O
and O
four O
were O
48-week O
parallel O
group O
trials O
. O

Adverse O
reactions O
observed O
in O
the O
dose-ranging O
trials O
and O
four O
6-week O
cross-over O
trials O
were O
consistent O
with O
those O
observed O
in O
the O
48-week O
parallel O
group O
trials O
, O
which O
formed O
the O
primary O
safety O
database O
. O

The O
primary O
safety O
database O
consisted O
of O
pooled O
data O
from O
the O
four O
48-week O
double-blind O
, O
active O
and O
placebo-controlled O
, O
parallel O
group O
confirmatory O
clinical O
trials O
. O

These O
trials O
included O
3104 O
adult O
COPD B-Not_AE_Candidate
patients O
( O
77 O
% O
males O
and O
23 O
% O
females O
) O
40 O
years O
of O
age O
and O
older O
. O

Of O
these O
patients O
, O
876 O
and O
883 O
patients O
were O
treated O
with O
STRIVERDI O
RESPIMAT O
5 O
mcg O
and O
10 O
mcg O
once-daily O
, O
respectively O
. O

The O
STRIVERDI O
RESPIMAT O
groups O
were O
composed O
of O
mostly O
Caucasians O
( O
66 O
% O
) O
with O
a O
mean O
age O
of O
64 O
years O
and O
a O
mean O
percent O
predicted O
FEV1at O
baseline O
of O
44 O
% O
for O
both O
the O
5 O
mcg O
and O
10 O
mcg O
treatment O
groups O
. O

Control O
arms O
for O
comparison O
included O
placebo O
in O
all O
four O
trials O
plus O
formoterol O
12 O
mcg O
in O
two O
trials O
. O

In O
these O
four O
clinical O
trials O
, O
seventy-two O
percent O
( O
72 O
% O
) O
of O
patients O
exposed O
to O
any O
dose O
of O
STRIVERDI O
RESPIMAT O
reported O
an O
adverse O
reaction O
compared O
to O
71 O
% O
in O
the O
placebo O
group O
. O

The O
proportion O
of O
patients O
who O
discontinued O
due O
to O
an O
adverse O
reaction O
was O
7.2 O
% O
for O
STRIVERDI O
RESPIMAT O
treated O
patients O
compared O
to O
8.8 O
% O
for O
placebo O
treated O
patients O
. O

The O
adverse O
reaction O
most O
commonly O
leading O
to O
discontinuation O
was O
worsening B-OSE_Labeled_AE
COPD I-OSE_Labeled_AE
. O

The O
most O
common O
serious O
adverse O
reactions O
were O
COPD B-OSE_Labeled_AE
exacerbation I-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
and O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
. O

Table O
1 O
shows O
all O
adverse O
drug O
reactions O
reported O
by O
at O
least O
2 O
% O
of O
patients O
( O
and O
higher O
than O
placebo O
) O
who O
received O
STRIVERDI O
RESPIMAT O
5 O
mcg O
during O
the O
48-week O
trials O
. O

Table O
1 O
: O
Number O
and O
frequency O
of O
adverse O
drug O
reactions O
greater O
than O
2 O
% O
( O
and O
higher O
than O
placebo O
) O
in O
COPD O
patients O
exposed O
to O
STRIVERDI O
RESPIMAT O
5 O
mcg O
: O
Pooled O
data O
from O
the O
four O
48-week O
, O
double-blind O
, O
active- O
and O
placebo-controlled O
clinical O
trials O
in O
COPD O
patients O
40 O
years O
of O
age O
and O
older O
* O
Rash B-OSE_Labeled_AE
includes O
a O
grouping O
of O
similar O
terms O
. O

Treatment O
STRIVERDI5 O
mcg O
once-daily O
Placebo O
Body B-NonOSE_AE
system I-NonOSE_AE
( O
adverse O
drug O
reaction O
) O
n=876n O
( O
% O
) O
n=885n O
( O
% O
) O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Nasopharyngitis B-OSE_Labeled_AE
99 O
( O
11.3 O
) O
68 O
( O
7.7 O
) O
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
72 O
( O
8.2 O
) O
66 O
( O
7.5 O
) O
Bronchitis B-OSE_Labeled_AE
41 O
( O
4.7 O
) O
32 O
( O
3.6 O
) O
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
22 O
( O
2.5 O
) O
9 O
( O
1.0 O
) O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
37 O
( O
4.2 O
) O
35 O
( O
4.0 O
) O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
20 O
( O
2.3 O
) O
19 O
( O
2.1 O
) O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
* O
19 O
( O
2.2 O
) O
10 O
( O
1.1 O
) O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
25 O
( O
2.9 O
) O
22 O
( O
2.5 O
) O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
31 O
( O
3.5 O
) O
24 O
( O
2.7 O
) O
Arthralgia B-OSE_Labeled_AE
18 O
( O
2.1 O
) O
7 O
( O
0.8 O
) O
Additional O
adverse O
reactions O
that O
occurred O
in O
greater O
than O
2 O
% O
( O
and O
higher O
than O
placebo O
) O
of O
patients O
exposed O
to O
STRIVERDI O
RESPIMAT O
10 O
mcg O
were O
pneumonia B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
and O
pyrexia B-OSE_Labeled_AE
. O

Lung B-OSE_Labeled_AE
cancers I-OSE_Labeled_AE
were O
reported O
in O
6 O
( O
0.7 O
% O
) O
, O
3 O
( O
0.3 O
% O
) O
, O
and O
2 O
( O
0.2 O
% O
) O
patients O
who O
received O
STRIVERDI O
RESPIMAT O
10 O
mcg O
, O
5 O
mcg O
, O
and O
placebo O
, O
respectively O
. O

BOXED O
WARNING O
: O
WARNING O
: O
ASTHMA-RELATED O
DEATH O
WARNING O
: O
ASTHMA-RELATED O
DEATH O
Long-acting O
beta2-adrenergic O
agonists O
( O
LABA O
) O
increase O
the O
risk O
of O
asthma B-NonOSE_AE
-related O
death B-NonOSE_AE
. O

Data O
from O
a O
large O
, O
placebo-controlled O
US O
study O
that O
compared O
the O
safety O
of O
another O
long-acting O
beta2-adrenergic O
agonist O
( O
salmeterol O
) O
or O
placebo O
added O
to O
usual O
asthma B-Not_AE_Candidate
therapy O
showed O
an O
increase O
in O
asthma B-NonOSE_AE
-related O
deaths B-NonOSE_AE
in O
patients O
receiving O
salmeterol O
. O

This O
finding O
with O
salmeterol O
is O
considered O
a O
class O
effect O
of O
LABA O
, O
including O
olodaterol O
, O
the O
active O
ingredient O
in O
STRIVERDI O
RESPIMAT O
. O

The O
safety O
and O
efficacy O
of O
STRIVERDI O
RESPIMAT O
in O
patients O
with O
asthma B-Not_AE_Candidate
have O
not O
been O
established O
. O

STRIVERDI O
RESPIMAT O
is O
not O
indicated O
for O
the O
treatment O
of O
asthma B-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4 O
) O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
ASTHMA-RELATED O
DEATH O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
* O
Long-acting O
beta2-adrenergic O
agonists O
( O
LABA O
) O
increase O
the O
risk O
of O
asthma-related O
death O
( O
5.1 O
) O
* O
A O
placebo-controlled O
study O
with O
another O
long-acting O
beta2-adrenergic O
agonist O
( O
salmeterol O
) O
showed O
an O
increase O
in O
asthma-related O
deaths O
in O
patients O
receiving O
salmeterol O
( O
5.1 O
) O
* O
This O
finding O
of O
an O
increased O
risk O
of O
asthma-related O
death O
with O
salmeterol O
is O
considered O
a O
class O
effect O
of O
LABA O
, O
including O
olodaterol O
, O
the O
active O
ingredient O
in O
STRIVERDI O
RESPIMAT O
. O

The O
safety O
and O
efficacy O
of O
STRIVERDI O
RESPIMAT O
in O
patients O
with O
asthma O
have O
not O
been O
established O
. O

STRIVERDI O
RESPIMAT O
is O
not O
indicated O
for O
the O
treatment O
of O
asthma O
. O

( O
4 O
, O
5.1 O
) O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Do O
not O
initiate O
STRIVERDI O
RESPIMAT O
in O
acutely O
deteriorating O
COPD O
patients O
( O
5.2 O
) O
* O
Do O
not O
use O
for O
relief O
of O
acute O
symptoms O
. O

Concomitant O
short-acting O
beta2-agonists O
can O
be O
used O
as O
needed O
for O
acute O
relief O
. O

( O
5.2 O
) O
* O
Do O
not O
exceed O
the O
recommended O
dose O
. O

Excessive O
use O
of O
STRIVERDI O
RESPIMAT O
, O
or O
use O
in O
conjunction O
with O
other O
medications O
containing O
LABA O
can O
result O
in O
clinically O
significant O
cardiovascular O
effects O
and O
may O
be O
fatal O
. O

( O
5.3 O
) O
* O
Life-threatening O
paradoxical O
bronchospasm O
can O
occur O
. O

Discontinue O
STRIVERDI O
RESPIMAT O
immediately O
. O

( O
5.4 O
) O
* O
Use O
with O
caution O
in O
patients O
with O
cardiovascular O
or O
convulsive O
disorders O
, O
thyrotoxicosis O
or O
sensitivity O
to O
sympathomimetic O
drugs O
( O
5.5 O
, O
5.6 O
) O
5.1 O
Asthma-Related O
Death O
[ O
see O
Boxed O
Warning O
] O
* O
Data O
from O
a O
large O
placebo-controlled O
study O
in O
asthma B-Not_AE_Candidate
patients O
showed O
that O
long-acting O
beta2-adrenergic O
agonists O
may O
increase O
the O
risk O
of O
asthma B-NonOSE_AE
-related O
death B-NonOSE_AE
. O

Data O
are O
not O
available O
to O
determine O
whether O
the O
rate O
of O
death B-NonOSE_AE
in O
patients O
with O
COPD B-Not_AE_Candidate
is O
increased O
by O
long-acting O
beta2-adrenergic O
agonists O
. O

* O
A O
28-week O
, O
placebo-controlled O
US O
study O
comparing O
the O
safety O
of O
another O
long-acting O
beta2-adrenergic O
agonist O
( O
salmeterol O
) O
with O
placebo O
, O
each O
added O
to O
usual O
asthma B-Not_AE_Candidate
therapy O
, O
showed O
an O
increase O
in O
asthma B-NonOSE_AE
-related O
deaths B-NonOSE_AE
in O
patients O
receiving O
salmeterol O
( O
13/13,176 O
in O
patients O
treated O
with O
salmeterol O
vs O
. O
3/13,179 O
in O
patients O
treated O
with O
placebo O
; O
RR O
4.37 O
, O
95 O
% O
CI O
1.25 O
, O
15.34 O
) O
. O

The O
increased O
risk O
of O
asthma B-NonOSE_AE
-related O
death B-NonOSE_AE
is O
considered O
a O
class O
effect O
of O
long-acting O
beta2-adrenergic O
agonists O
, O
including O
STRIVERDI O
RESPIMAT O
. O

No O
study O
adequate O
to O
determine O
whether O
the O
rate O
of O
asthma B-NonOSE_AE
-related O
death B-NonOSE_AE
is O
increased O
in O
patients O
treated O
with O
STRIVERDI O
RESPIMAT O
has O
been O
conducted O
. O

The O
safety O
and O
efficacy O
of O
STRIVERDI O
RESPIMAT O
in O
patients O
with O
asthma B-Not_AE_Candidate
have O
not O
been O
established O
. O

STRIVERDI O
RESPIMAT O
is O
not O
indicated O
for O
the O
treatment O
of O
asthma B-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

5.2 O
Deterioration O
of O
Disease O
and O
Acute O
Episodes O
STRIVERDI O
RESPIMAT O
should O
not O
be O
initiated O
in O
patients O
with O
acutely B-Not_AE_Candidate
deteriorating I-Not_AE_Candidate
COPD I-Not_AE_Candidate
, O
which O
may O
be O
a O
life-threatening O
condition O
. O

STRIVERDI O
RESPIMAT O
has O
not O
been O
studied O
in O
patients O
with O
acutely B-Not_AE_Candidate
deteriorating I-Not_AE_Candidate
COPD I-Not_AE_Candidate
. O

The O
use O
of O
STRIVERDI O
RESPIMAT O
in O
this O
setting O
is O
inappropriate O
. O

STRIVERDI O
RESPIMAT O
should O
not O
be O
used O
for O
the O
relief O
of O
acute O
symptoms O
, O
i.e. O
, O
as O
rescue O
therapy O
for O
the O
treatment O
of O
acute O
episodes O
of O
bronchospasm B-NonOSE_AE
. O

STRIVERDI O
RESPIMAT O
has O
not O
been O
studied O
in O
the O
relief O
of O
acute O
symptoms O
and O
extra O
doses O
should O
not O
be O
used O
for O
that O
purpose O
. O

Acute O
symptoms O
should O
be O
treated O
with O
an O
inhaled O
short-acting O
beta2-agonist O
. O

When O
beginning O
STRIVERDI O
RESPIMAT O
, O
patients O
who O
have O
been O
taking O
inhaled O
, O
short-acting O
beta2-agonists O
on O
a O
regular O
basis O
( O
e.g. O
, O
four O
times O
a O
day O
) O
should O
be O
instructed O
to O
discontinue O
the O
regular O
use O
of O
these O
drugs O
and O
use O
them O
only O
for O
symptomatic O
relief O
of O
acute O
respiratory B-NonOSE_AE
symptoms I-NonOSE_AE
. O

When O
prescribing O
STRIVERDI O
RESPIMAT O
, O
the O
healthcare O
provider O
should O
also O
prescribe O
an O
inhaled O
, O
short-acting O
beta2-agonist O
and O
instruct O
the O
patient O
on O
how O
it O
should O
be O
used O
. O

Increasing O
inhaled O
beta2-agonist O
use O
is O
a O
signal O
of O
deteriorating O
disease O
for O
which O
prompt O
medical O
attention O
is O
indicated O
. O

COPD B-Not_AE_Candidate
may O
deteriorate O
acutely O
over O
a O
period O
of O
hours O
or O
chronically O
over O
several O
days O
or O
longer O
. O

If O
STRIVERDI O
RESPIMAT O
no O
longer O
controls O
symptoms O
of O
bronchoconstriction B-NonOSE_AE
, O
or O
the O
patient O
's O
inhaled O
, O
short-acting O
beta2-agonist O
becomes O
less O
effective O
or O
the O
patient O
needs O
more O
inhalation O
of O
short-acting O
beta2-agonist O
than O
usual O
, O
these O
may O
be O
markers O
of O
deterioration O
of O
disease O
. O

In O
this O
setting O
, O
a O
re-evaluation O
of O
the O
patient O
and O
the O
COPD B-Not_AE_Candidate
treatment O
regimen O
should O
be O
undertaken O
at O
once O
. O

Increasing O
the O
daily O
dosage O
of O
STRIVERDI O
RESPIMAT O
beyond O
the O
recommended O
dose O
is O
not O
appropriate O
in O
this O
situation O
. O

5.3 O
Excessive O
Use O
of O
STRIVERDI O
RESPIMAT O
and O
Use O
with O
Long-Acting O
Beta2-Agonists O
As O
with O
other O
inhaled O
drugs O
containing O
beta2-adrenergic O
agents O
, O
STRIVERDI O
RESPIMAT O
should O
not O
be O
used O
more O
often O
than O
recommended O
, O
at O
higher O
doses O
than O
recommended O
, O
or O
in O
conjunction O
with O
other O
medications O
containing O
long-acting O
beta2-agonists O
, O
as O
an O
overdose B-NonOSE_AE
may O
result O
. O

Clinically O
significant O
cardiovascular B-NonOSE_AE
effects I-NonOSE_AE
and O
fatalities B-NonOSE_AE
have O
been O
reported O
in O
association O
with O
excessive O
use O
of O
inhaled O
sympathomimetic O
drugs O
. O

5.4 O
Paradoxical O
Bronchospasm O
As O
with O
other O
inhaled O
beta2-agonists O
, O
STRIVERDI O
RESPIMAT O
may O
produce O
paradoxical B-OSE_Labeled_AE
bronchospasm I-OSE_Labeled_AE
that O
may O
be O
life-threatening O
. O

If O
paradoxical B-NonOSE_AE
bronchospasm I-NonOSE_AE
occurs O
, O
STRIVERDI O
RESPIMAT O
should O
be O
discontinued O
immediately O
and O
alternative O
therapy O
instituted O
. O

5.5 O
Cardiovascular O
Effects O
STRIVERDI O
RESPIMAT O
, O
like O
other O
beta2-agonists O
, O
can O
produce O
a O
clinically O
significant O
cardiovascular B-OSE_Labeled_AE
effect I-OSE_Labeled_AE
in O
some O
patients O
as O
measured O
by O
increases B-OSE_Labeled_AE
in O
pulse O
rate O
, O
systolic I-OSE_Labeled_AE
or O
diastolic O
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
, O
and/or O
symptoms O
. O

If O
such O
effects O
occur O
, O
STRIVERDI O
RESPIMAT O
may O
need O
to O
be O
discontinued O
. O

In O
addition O
, O
beta-agonists O
have O
been O
reported O
to O
produce O
ECG B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
, O
such O
as O
flattening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
t I-OSE_Labeled_AE
he O
T O
wave I-OSE_Labeled_AE
, O
prolongation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
QTc I-OSE_Labeled_AE
interval I-OSE_Labeled_AE
, O
and O
ST B-OSE_Labeled_AE
segment I-OSE_Labeled_AE
depression I-OSE_Labeled_AE
. O

The O
clinical O
significance O
of O
these O
findings O
is O
unknown O
. O

Long O
acting O
beta2-adrenergic O
agonists O
should O
be O
administered O
with O
caution O
in O
patients O
with O
cardiovascular B-Not_AE_Candidate
disorders I-Not_AE_Candidate
, O
especially O
coronary B-Not_AE_Candidate
insufficiency I-Not_AE_Candidate
, O
cardiac B-Not_AE_Candidate
arrhythmias I-Not_AE_Candidate
, O
hypertrophic B-Not_AE_Candidate
obstructive I-Not_AE_Candidate
cardiomyopathy I-Not_AE_Candidate
, O
and O
hypertension B-Not_AE_Candidate
. O

5.6 O
Co-existing O
Conditions O
STRIVERDI O
RESPIMAT O
, O
like O
other O
sympathomimetic O
amines O
, O
should O
be O
used O
with O
caution O
in O
patients O
with O
convulsive B-Not_AE_Candidate
disorders I-Not_AE_Candidate
or O
thyrotoxicosis B-Not_AE_Candidate
, O
in O
patients O
with O
known O
or O
suspected O
prolongation B-Not_AE_Candidate
of O
the O
QT I-Not_AE_Candidate
interval I-Not_AE_Candidate
, O
and O
in O
patients O
who O
are O
unusually O
responsive O
to O
sympathomimetic O
amines O
. O

Doses O
of O
the O
related O
beta2-agonist O
albuterol O
, O
when O
administered O
intravenously O
, O
have O
been O
reported O
to O
aggravate B-NonOSE_AE
pre I-NonOSE_AE
- I-NonOSE_AE
existing I-NonOSE_AE
diabetes I-NonOSE_AE
mellitus I-NonOSE_AE
and O
ketoacidosis B-NonOSE_AE
. O

5.7 O
Hypokalemia O
and O
Hyperglycemia O
Beta-adrenergic O
agonists O
may O
produce O
significant O
hypokalemia B-OSE_Labeled_AE
in O
some O
patients O
, O
which O
has O
the O
potential O
to O
produce O
adverse O
cardiovascular B-NonOSE_AE
effects I-NonOSE_AE
[ O
see O
Clinical O
Pharmacology O
( O
12.2 O
) O
] O
. O

The O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
potassium I-OSE_Labeled_AE
is O
usually O
transient O
, O
not O
requiring O
supplementation O
. O

Inhalation O
of O
high O
doses O
of O
beta2-adrenergic O
agonists O
may O
produce O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
plasma I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
. O

In O
patients O
with O
severe O
COPD B-Not_AE_Candidate
, O
hypokalemia B-NonOSE_AE
may O
be O
potentiated O
by O
hypoxia B-Not_AE_Candidate
and O
concomitant O
treatment O
[ O
see O
Drug O
Interactions O
( O
7.2 O
) O
] O
, O
which O
may O
increase O
the O
susceptibility O
for O
cardiac B-NonOSE_AE
arrhythmias I-NonOSE_AE
. O

Clinically O
notable O
decreases B-NonOSE_AE
in I-NonOSE_AE
serum I-NonOSE_AE
potassium I-NonOSE_AE
or O
changes B-NonOSE_AE
in I-NonOSE_AE
blood I-NonOSE_AE
glucose I-NonOSE_AE
were O
infrequent O
during O
clinical O
studies O
with O
long-term O
administration O
of O
STRIVERDI O
RESPIMAT O
with O
the O
rates O
similar O
to O
those O
for O
placebo O
controls O
. O

STRIVERDI O
RESPIMAT O
has O
not O
been O
investigated O
in O
patients O
whose O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
is O
not O
well O
controlled O
. O

5.8 O
Hypersensitivity O
Reactions O
Immediate O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
angioedema B-OSE_Labeled_AE
, O
may O
occur O
after O
administration O
of O
STRIVERDI O
RESPIMAT O
. O

If O
such O
a O
reaction O
occurs O
, O
therapy O
with O
STRIVERDI O
RESPIMAT O
should O
be O
stopped O
at O
once O
and O
alternative O
treatment O
should O
be O
considered O
. O

6 O
ADVERSE O
REACTIONS O
Because O
clinical O
studies O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
studies O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
studies O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

EXCERPT O
: O
Most O
common O
adverse O
reactions O
associated O
with O
the O
use O
of O
SURFAXIN O
are O
endotracheal O
tube O
reflux O
, O
pallor O
, O
endotracheal O
tube O
obstruction O
, O
and O
need O
for O
dose O
interruption O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Discovery O
Laboratories O
, O
Inc O
. O
at O
1-877-SURFAXN O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Studies O
in O
Premature O
Infants O
at O
Risk O
for O
Respiratory O
Distress O
Syndrome O
The O
safety O
data O
described O
below O
reflect O
exposure O
to O
SURFAXIN O
at O
a O
dose O
of O
5.8 O
mL O
per O
kg O
( O
up O
to O
4 O
doses O
) O
administered O
in O
either O
4 O
aliquots O
( O
Study O
1 O
) O
or O
2 O
aliquots O
( O
Study O
2 O
) O
in O
643 O
infants O
32 O
weeks O
gestational O
age O
or O
less O
in O
2 O
randomized O
double-blind O
, O
active-controlled O
clinical O
studies O
in O
which O
infants O
could O
receive O
up O
to O
4 O
doses O
of O
surfactant O
intratracheally O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

Study O
1 O
was O
conducted O
in O
1294 O
premature B-Not_AE_Candidate
infants I-Not_AE_Candidate
who O
weighed O
between O
600 O
g O
and O
1250 O
g O
at O
birth O
and O
were O
32 O
weeks O
or O
less O
in O
gestational O
age O
. O

Infants O
received O
1 O
of O
3 O
surfactants O
, O
SURFAXIN O
( O
N O
= O
524 O
) O
, O
colfosceril O
palmitate O
( O
N O
= O
506 O
) O
, O
or O
beractant O
( O
N O
= O
258 O
) O
. O

Study O
2 O
was O
conducted O
in O
252 O
premature B-Not_AE_Candidate
infants I-Not_AE_Candidate
who O
weighed O
between O
600 O
g O
and O
1250 O
g O
and O
were O
less O
than O
29 O
weeks O
in O
gestational O
age O
. O

Infants O
received O
SURFAXIN O
( O
N O
= O
119 O
) O
or O
poractant O
alfa O
( O
N O
= O
124 O
) O
. O

Comparator O
surfactants O
colfosceril O
palmitate O
and O
beractant O
were O
administered O
at O
the O
recommended O
doses O
( O
5.0 O
and O
4.0 O
mL O
per O
kg O
, O
respectively O
) O
while O
the O
first O
dose O
of O
poractant O
alfa O
administered O
( O
2.2 O
mL O
per O
kg O
) O
was O
less O
than O
the O
recommended O
dose O
of O
2.5 O
mL O
per O
kg O
. O

Any O
subsequent O
doses O
of O
poractant O
alfa O
were O
at O
the O
recommended O
1.25 O
mL O
per O
kg O
dose O
. O

Administration B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
( O
endotracheal B-OSE_Labeled_AE
tube I-OSE_Labeled_AE
reflux I-OSE_Labeled_AE
, O
pallor B-OSE_Labeled_AE
, O
endotracheal B-OSE_Labeled_AE
tube I-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
, O
and O
need O
for O
dose O
interruption O
) O
were O
assessed O
in O
both O
SURFAXIN O
controlled O
clinical O
studies O
. O

Overall O
, O
the O
incidence O
of O
administration B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
was O
higher O
in O
infants O
who O
received O
SURFAXIN O
compared O
to O
other O
surfactants O
( O
Table O
2 O
) O
and O
resulted O
in O
a O
greater O
proportion O
of O
infants O
treated O
with O
SURFAXIN O
who O
experienced O
administration B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
oxygen O
desaturation O
an B-OSE_Labeled_AE
d O
bradycar I-OSE_Labeled_AE
d I-OSE_Labeled_AE
i I-OSE_Labeled_AE
a I-OSE_Labeled_AE
. O

For O
Study O
1 O
, O
oxygen B-OSE_Labeled_AE
desaturation I-OSE_Labeled_AE
was O
reported O
in O
17 O
% O
, O
9 O
% O
, O
and O
13 O
% O
and O
bradycardia B-OSE_Labeled_AE
for O
5 O
% O
, O
2 O
% O
, O
and O
3 O
% O
of O
infants O
treated O
with O
SURFAXIN O
, O
colfosceril O
palmitate O
, O
and O
beractant O
, O
respectively O
. O

For O
Study O
2 O
, O
oxygen B-OSE_Labeled_AE
desaturation I-OSE_Labeled_AE
was O
reported O
in O
8 O
% O
and O
2 O
% O
and O
bradycardia B-OSE_Labeled_AE
in O
3 O
% O
and O
2 O
% O
of O
infants O
treated O
with O
SURFAXIN O
and O
poractant O
alfa O
, O
respectively O
. O

These O
adverse O
reactions O
did O
not O
appear O
to O
be O
associated O
with O
an O
increased O
incidence O
of O
serious O
complications O
or O
mortality O
relative O
to O
the O
comparator O
surfactants O
( O
Table O
3 O
) O
. O

Table O
2 O
. O

Administration-Related O
Adverse O
Reactions O
in O
SURFAXIN O
Controlled O
Clinical O
Studies O
a O
a O
Table O
includes O
only O
infants O
who O
received O
study O
treatment O
. O

b O
In O
Study O
1 O
doses O
were O
administered O
in O
4 O
aliquots O
. O

c O
In O
Study O
2 O
doses O
were O
administered O
in O
2 O
aliquots O
. O

Study O
1 O
b O
Study O
2 O
c O
SURFAXIN O
( O
N O
= O
524 O
) O
Colfoscerilpalmitate O
( O
N O
= O
506 O
) O
Beractant O
( O
N O
= O
258 O
) O
SURFAXIN O
( O
N O
= O
119 O
) O
Poractant O
alfa O
( O
N O
= O
124 O
) O
Total O
DosesAdministered O
994 O
1038 O
444 O
174 O
160 O
Total O
Number O
of O
Events O
( O
Events O
per O
100 O
Doses O
) O
ETT B-OSE_Labeled_AE
Reflux I-OSE_Labeled_AE
183 O
( O
18 O
) O
161 O
( O
16 O
) O
67 O
( O
15 O
) O
47 O
( O
27 O
) O
31 O
( O
19 O
) O
Pallor B-OSE_Labeled_AE
88 O
( O
9 O
) O
46 O
( O
4 O
) O
38 O
( O
9 O
) O
18 O
( O
10 O
) O
7 O
( O
4 O
) O
Dose B-OSE_Labeled_AE
Interruption I-OSE_Labeled_AE
87 O
( O
9 O
) O
46 O
( O
4 O
) O
30 O
( O
7 O
) O
7 O
( O
4 O
) O
2 O
( O
1 O
) O
ETT B-OSE_Labeled_AE
Obstruction I-OSE_Labeled_AE
55 O
( O
6 O
) O
21 O
( O
2 O
) O
19 O
( O
4 O
) O
27 O
( O
16 O
) O
1 O
( O
1 O
) O
Table O
3 O
. O

Common O
Serious O
Complications O
Associated O
with O
Prematurity O
and O
RDS O
in O
SURFAXIN O
Controlled O
Clinical O
Studies O
Through O
36-Weeks O
Post-Conceptual O
Age O
( O
PCA O
) O
Study O
1 O
Study O
2 O
SURFAXIN O
( O
N O
= O
527 O
) O
% O
Colfoscerilpalmitate O
( O
N O
= O
509 O
) O
% O
Beractant O
( O
N O
= O
258 O
) O
% O
SURFAXIN O
( O
N O
= O
119 O
) O
% O
Poractantalfa O
( O
N O
= O
124 O
) O
% O
Apnea B-Not_AE_Candidate
52 O
52 O
46 O
66 O
75 O
Intraventricular B-Not_AE_Candidate
hemorrhage I-Not_AE_Candidate
, O
all O
grades O
52 O
57 O
54 O
39 O
38 O
- O
Grade O
3/4 O
19 O
18 O
21 O
13 O
8 O
Periventricular B-Not_AE_Candidate
leukomalacia I-Not_AE_Candidate
10 O
10 O
12 O
4 O
9 O
Acquired O
sepsis B-Not_AE_Candidate
44 O
44 O
44 O
45 O
52 O
Patent B-Not_AE_Candidate
ductus I-Not_AE_Candidate
arteriosus I-Not_AE_Candidate
37 O
35 O
37 O
43 O
44 O
Retinopathy B-Not_AE_Candidate
of I-Not_AE_Candidate
prematurity I-Not_AE_Candidate
, O
all O
grades O
27 O
26 O
25 O
32 O
31 O
-Grade O
3/4 O
6 O
7 O
6 O
5 O
9 O
Necrotizing B-Not_AE_Candidate
enterocolitis I-Not_AE_Candidate
, O
all O
grades O
17 O
17 O
19 O
13 O
15 O
-Grade O
2/3 O
6 O
8 O
14 O
8 O
8 O
Pulmonary B-Not_AE_Candidate
air I-Not_AE_Candidate
leak I-Not_AE_Candidate
through O
Day O
7 O
, O
all O
types O
15 O
17 O
14 O
9 O
7 O
- O
Pulmonary B-Not_AE_Candidate
interstitial I-Not_AE_Candidate
emphysema I-Not_AE_Candidate
9 O
10 O
10 O
3 O
5 O
- O
Pneumothorax B-Not_AE_Candidate
3 O
4 O
2 O
4 O
1 O
Pulmonary B-Not_AE_Candidate
hemorrhage I-Not_AE_Candidate
10 O
12 O
14 O
6 O
9 O
All-cause O
mortality O
through O
36-weeks O
PCA O
was O
similar O
regardless O
of O
which O
exogenous O
surfactant O
was O
administered O
. O

Adverse O
reactions O
reported O
in O
the O
controlled O
clinical O
studies O
through O
36-weeks O
PCA O
occurring O
in O
at O
least O
10 O
% O
of O
infants O
were O
anemia B-OSE_Labeled_AE
, O
jaundice B-OSE_Labeled_AE
, O
metabolic B-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
, O
oxygen B-OSE_Labeled_AE
desaturation I-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
, O
and O
bradycardia B-OSE_Labeled_AE
. O

These O
reactions O
occurred O
at O
rates O
similar O
to O
the O
comparator O
surfactants O
. O

No O
assessments O
for O
immunogenicity O
to O
SURFAXIN O
were O
performed O
in O
these O
clinical O
studies O
. O

Follow-up O
Evaluations O
Twelve-month O
corrected-age O
follow-up O
of O
1546 O
infants O
enrolled O
in O
the O
2 O
controlled O
clinical O
studies O
demonstrated O
no O
significant O
differences O
in O
mortality O
or O
gross O
neurologic O
findings O
between O
infants O
treated O
with O
SURFAXIN O
and O
those O
treated O
with O
the O
comparator O
surfactants O
( O
colfosceril O
palmitate O
, O
beractant O
, O
or O
poractant O
alfa O
) O
. O

Clinical O
Study O
in O
Adults O
with O
ARDS O
The O
safety O
and O
efficacy O
of O
lucinactant O
administered O
in O
2 O
doses O
separated O
by O
48 O
hours O
via O
segmental O
bronchoscopic O
lavage O
in O
adults O
with O
ARDS B-Not_AE_Candidate
was O
evaluated O
in O
a O
two-part O
clinical O
trial O
in O
124 O
adult O
patients O
. O

Twenty-two O
patients O
were O
studied O
in O
the O
initial O
open-label O
portion O
of O
the O
trial O
( O
Part O
A O
) O
and O
102 O
patients O
participated O
in O
a O
subsequent O
randomized O
controlled O
portion O
( O
Part O
B O
) O
. O

Compared O
to O
standard O
of O
care O
, O
patients O
who O
received O
treatment O
with O
lucinactant O
via O
segmental O
bronchoscopic O
lavage O
at O
doses O
up O
to O
50 O
mL O
per O
lung O
segment O
had O
an O
increased O
incidence O
of O
death B-NonOSE_AE
, O
multi B-NonOSE_AE
- I-NonOSE_AE
organ I-NonOSE_AE
failure I-NonOSE_AE
, O
sepsis B-NonOSE_AE
, O
anoxic B-NonOSE_AE
encephalopathy I-NonOSE_AE
, O
renal B-NonOSE_AE
failure I-NonOSE_AE
, O
hypoxia B-NonOSE_AE
/ O
decreased B-NonOSE_AE
oxygen I-NonOSE_AE
saturation I-NonOSE_AE
, O
pneumothorax B-NonOSE_AE
, O
hypotension B-NonOSE_AE
, O
and O
pulmonary B-NonOSE_AE
embolism I-NonOSE_AE
compared O
to O
those O
patients O
receiving O
standard O
of O
care O
. O

SURFAXIN O
is O
not O
indicated O
for O
use O
in O
the O
treatment O
of O
ARDS B-Not_AE_Candidate
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Acute O
Changes O
in O
Lung O
Compliance O
: O
Infants O
receiving O
SURFAXIN O
should O
receive O
frequent O
clinical O
assessments O
so O
that O
oxygen O
and O
ventilatory O
support O
can O
be O
modified O
to O
respond O
to O
changes O
in O
respiratory O
status O
. O

( O
5.1 O
) O
* O
Administration-Related O
Adverse O
Reactions O
: O
If O
adverse O
reactions O
including O
bradycardia O
, O
oxygen O
desaturation O
, O
reflux O
of O
SURFAXIN O
into O
the O
endotracheal O
tube O
( O
ETT O
) O
, O
and O
airway/ETT O
obstruction O
occur O
during O
administration O
of O
SURFAXIN O
, O
dosing O
should O
be O
interrupted O
and O
the O
infant O
's O
clinical O
condition O
assessed O
and O
stabilized O
. O

Suctioning O
of O
the O
ETT O
or O
reintubation O
may O
be O
required O
if O
airway O
obstruction O
persists O
or O
is O
severe O
. O

( O
5.2 O
) O
* O
Increased O
Serious O
Adverse O
Reactions O
in O
Adults O
with O
Acute O
Respiratory O
Distress O
Syndrome O
( O
ARDS O
) O
: O
Adults O
with O
ARDS O
who O
received O
lucinactant O
via O
segmental O
bronchoscopic O
lavage O
had O
an O
increased O
incidence O
of O
death O
, O
multi-organ O
failure O
, O
sepsis O
, O
anoxic O
encephalopathy O
, O
renal O
failure O
, O
hypoxia O
, O
pneumothorax O
, O
hypotension O
, O
and O
pulmonary O
embolism O
. O

SURFAXIN O
is O
not O
indicated O
for O
use O
in O
ARDS O
. O

( O
5.3 O
) O
5.1 O
Acute O
Changes O
in O
Lung O
Compliance O
Administration O
of O
exogenous O
surfactants O
, O
including O
SURFAXIN O
, O
can O
rapidly O
affect O
lung O
compliance O
and O
oxygenation O
. O

SURFAXIN O
should O
be O
administered O
only O
by O
clinicians O
trained O
and O
experienced O
in O
the O
resuscitation O
, O
intubation O
, O
stabilization O
, O
and O
ventilatory O
management O
of O
premature B-Not_AE_Candidate
infants I-Not_AE_Candidate
in O
a O
clinical O
setting O
with O
the O
capacity O
to O
care O
for O
critically O
ill O
neonates O
. O

Infants O
receiving O
SURFAXIN O
should O
receive O
frequent O
clinical O
assessments O
so O
that O
oxygen O
and O
ventilatory O
support O
can O
be O
modified O
to O
respond O
to O
changes O
in O
respiratory O
status O
. O

5.2 O
Administration B-NonOSE_AE
- I-NonOSE_AE
Related I-NonOSE_AE
Adverse I-NonOSE_AE
Reactions I-NonOSE_AE
Frequently O
occurring O
adverse O
reactions O
related O
to O
the O
administration O
of O
SURFAXIN O
include O
bradycardia B-OSE_Labeled_AE
, O
oxygen B-OSE_Labeled_AE
desaturation I-OSE_Labeled_AE
, O
reflux B-OSE_Labeled_AE
of I-OSE_Labeled_AE
drug I-OSE_Labeled_AE
into I-OSE_Labeled_AE
the I-OSE_Labeled_AE
endotracheal I-OSE_Labeled_AE
tube I-OSE_Labeled_AE
( O
ETT O
) O
, O
and O
airway B-OSE_Labeled_AE
/ETT O
obstruction I-OSE_Labeled_AE
. O

If O
any O
of O
these O
events O
occur O
, O
dosing O
with O
SURFAXIN O
should O
be O
interrupted O
and O
the O
infant O
's O
clinical O
condition O
assessed O
and O
stabilized O
. O

Suctioning O
of O
the O
ETT O
or O
reintubation O
may O
be O
required O
if O
airway B-NonOSE_AE
obstruction I-NonOSE_AE
persists O
or O
is O
severe O
. O

After O
the O
patient O
is O
stable O
, O
dosing O
may O
proceed O
with O
appropriate O
monitoring O
. O

5.3 O
Increased O
Serious O
Adverse O
Reactions O
in O
Adults O
with O
ARDS O
In O
a O
two-part O
clinical O
trial O
in O
adult O
patients O
with O
ARDS B-Not_AE_Candidate
, O
compared O
to O
standard O
of O
care O
, O
patients O
who O
received O
lucinactant O
via O
segmental O
bronchoscopic O
lavage O
had O
an O
increased O
incidence O
of O
death B-NonOSE_AE
, O
multi B-NonOSE_AE
- I-NonOSE_AE
organ I-NonOSE_AE
failure I-NonOSE_AE
, O
sepsis B-NonOSE_AE
, O
anoxic B-NonOSE_AE
encephalopathy I-NonOSE_AE
, O
renal B-NonOSE_AE
failure I-NonOSE_AE
, O
hypoxia B-NonOSE_AE
, O
pneumothorax B-NonOSE_AE
, O
hypotension B-NonOSE_AE
, O
and O
pulmonary B-NonOSE_AE
embolism I-NonOSE_AE
. O

SURFAXIN O
is O
not O
indicated O
for O
use O
in O
the O
treatment O
of O
ARDS O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
described O
in O
detail O
in O
other O
labeling O
sections O
: O
* O
Teratogenicity B-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.1 O
, O
5.2 O
) O
, O
and O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
* O
Venous B-OSE_Labeled_AE
and I-OSE_Labeled_AE
Arterial I-OSE_Labeled_AE
Thromboembolism I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.3 O
) O
, O
and O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
* O
Increased O
Mortality B-NonOSE_AE
in O
Patients O
with O
MM O
When O
Pembrolizumab O
Is O
Added O
to O
a O
Thalidomide O
Analogue O
and O
Dexamethasone O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Drowsiness B-OSE_Labeled_AE
and O
Somnolence B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Peripheral B-OSE_Labeled_AE
Neuropathy I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Dizziness B-OSE_Labeled_AE
and O
Orthostatic B-OSE_Labeled_AE
Hypotension I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Neutropenia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Thrombocytopenia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Increased B-OSE_Labeled_AE
HIV I-OSE_Labeled_AE
Viral I-OSE_Labeled_AE
Load I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
* O
Bradycardia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
* O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
and O
Toxic B-OSE_Labeled_AE
Epidermal I-OSE_Labeled_AE
Necrolysis I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.12 O
) O
] O
* O
Seizures B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.13 O
) O
] O
* O
Tumor B-OSE_Labeled_AE
Lysis I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.14 O
) O
] O
* O
Hypersensitivity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.16 O
) O
] O
* O
MM B-Not_AE_Candidate
: O
The O
most O
common O
adverse O
reactions O
( O
> O
= O
20 O
% O
) O
are O
fatigue B-OSE_Labeled_AE
, O
hypocalcemia B-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
neuropathy B-OSE_Labeled_AE
- I-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
/ O
desquamation B-OSE_Labeled_AE
, O
confusion B-OSE_Labeled_AE
, O
anorexia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
/ O
agitation B-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
thrombosis B-OSE_Labeled_AE
/ O
embolism B-OSE_Labeled_AE
, O
neuropathy B-OSE_Labeled_AE
- I-OSE_Labeled_AE
motor I-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
and O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
. O

( O
6.1 O
) O
* O
ENL B-Not_AE_Candidate
: O
The O
most O
common O
adverse O
reactions O
( O
> O
= O
10 O
% O
) O
are O
somnolence B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
and O
headache B-OSE_Labeled_AE
. O

( O
6.1 O
) O
EXCERPT O
: O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
or O
embryo-fetal O
exposure O
: O
contact O
Celgene O
Corporation O
at O
1-888-423-5436 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Most O
patients O
taking O
thalidomide O
can O
be O
expected O
to O
experience O
adverse O
reactions O
. O

Teratogenicity O
: O
The O
most O
serious O
toxicity O
associated O
with O
thalidomide O
is O
its O
documented O
human B-OSE_Labeled_AE
teratogenicity I-OSE_Labeled_AE
. O

The O
risk O
of O
severe O
birth B-OSE_Labeled_AE
defects I-OSE_Labeled_AE
, O
primarily O
phocomelia B-OSE_Labeled_AE
or O
death B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
, O
is O
extremely O
high O
during O
the O
critical O
period O
of O
pregnancy B-Not_AE_Candidate
. O

The O
critical O
period O
is O
estimated O
, O
depending O
on O
the O
source O
of O
information O
, O
to O
range O
from O
35 O
to O
50 O
days O
after O
the O
last O
menstrual O
period O
. O

The O
risk O
of O
other O
potentially O
severe O
birth B-NonOSE_AE
defects I-NonOSE_AE
outside O
this O
critical O
period O
is O
unknown O
, O
but O
may O
be O
significant O
. O

Based O
on O
present O
knowledge O
, O
thalidomide O
must O
not O
be O
used O
at O
any O
time O
during O
pregnancy B-Not_AE_Candidate
. O

Because O
thalidomide O
is O
present O
in O
the O
semen O
of O
patients O
receiving O
the O
drug O
, O
males O
receiving O
thalidomide O
must O
always O
use O
a O
latex O
or O
synthetic O
condom O
during O
any O
sexual O
contact O
with O
females O
of O
reproductive O
potential O
, O
even O
if O
he O
has O
undergone O
a O
successful O
vasectomy O
. O

Venous O
and O
Arterial B-OSE_Labeled_AE
Thromboembolism I-OSE_Labeled_AE
: O
An O
increased O
risk O
of O
venous B-OSE_Labeled_AE
thromboembolism I-OSE_Labeled_AE
( O
such O
as O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
and O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
) O
, O
ischemic B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
( O
including O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
) O
, O
and O
stroke B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
with O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
treated O
with O
thalidomide O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

Peripheral O
Neuropathy O
: O
Peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
is O
a O
very O
common O
, O
potentially O
severe O
, O
adverse O
reaction O
of O
treatment O
with O
thalidomide O
that O
may O
result O
in O
irreversible O
damage O
. O

Peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
generally O
occurs O
following O
chronic O
use O
over O
a O
period O
of O
months O
. O

However O
, O
reports O
following O
relatively O
short-term O
use O
also O
exist O
. O

Incidence O
of O
neuropathy B-OSE_Labeled_AE
events O
leading O
to O
discontinuation O
, O
dose O
reduction O
or O
interruption O
increases O
with O
cumulative O
dose O
and O
duration O
of O
therapy O
. O

Symptoms O
may O
occur O
some O
time O
after O
thalidomide O
treatment O
has O
been O
stopped O
and O
may O
resolve O
slowly O
or O
not O
at O
all O
. O

Somnolence B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
and O
rash B-OSE_Labeled_AE
are O
the O
most O
commonly O
observed O
adverse O
reactions O
associated O
with O
the O
use O
of O
thalidomide O
. O

Adverse O
event O
profiles O
from O
clinical O
trials O
are O
summarized O
in O
the O
sections O
that O
follow O
. O

Adverse O
Reactions O
in O
Multiple O
Myeloma O
Controlled O
Clinical O
Trials O
The O
safety O
analyses O
were O
conducted O
in O
two O
controlled O
clinical O
studies O
( O
Study O
1 O
and O
Study O
2 O
) O
. O

The O
safety O
analysis O
in O
Study O
1 O
was O
conducted O
on O
204 O
patients O
who O
received O
treatment O
. O

Table O
1 O
lists O
the O
most O
common O
adverse O
drug O
reactions O
( O
> O
= O
10 O
% O
) O
. O

The O
most O
frequently O
reported O
adverse O
reactions O
were O
fatigue B-OSE_Labeled_AE
, O
hypocalcemia B-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
sensory B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
/ O
desquamation B-OSE_Labeled_AE
, O
confusion B-OSE_Labeled_AE
, O
anorexia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
/ O
agitation B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
thrombosis B-OSE_Labeled_AE
/ O
embolism B-OSE_Labeled_AE
, O
neuropathy B-OSE_Labeled_AE
- I-OSE_Labeled_AE
motor I-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
and O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
. O

Twenty-three O
percent O
of O
patients O
( O
47/204 O
) O
discontinued O
due O
to O
adverse O
reactions O
; O
30 O
% O
( O
31/102 O
) O
from O
the O
THALOMID/dexamethasone O
arm O
and O
16 O
% O
( O
16/102 O
) O
from O
the O
dexamethasone O
alone O
arm O
. O

Table O
1 O
: O
Adverse O
Drug O
Reactions O
Reported O
in O
> O
=10 O
% O
of O
Patients O
in O
the O
THALOMID/Dexamethasone O
Arm O
( O
Study O
1 O
- O
Safety O
Population O
; O
N=204 O
) O
*Treatment-emergent O
adverse O
reactions O
reported O
in O
> O
=10 O
% O
of O
patients O
in O
THALOMID/dexamethasone O
arm O
and O
with O
a O
> O
=1 O
% O
difference O
in O
the O
THALOMID/dexamethasone O
arm O
compared O
to O
the O
dexamethasone O
alone O
arm O
. O

Body O
SystemAdverse O
Reaction O
Thal O
+ O
Dex O
* O
( O
N=102 O
) O
Dex O
Alone* O
( O
N=102 O
) O
All O
Gradesn O
( O
% O
) O
Grade O
3/4n O
( O
% O
) O
All O
Gradesn O
( O
% O
) O
Grade O
3/4n O
( O
% O
) O
Metabolic B-NonOSE_AE
/ I-NonOSE_AE
Laboratory I-NonOSE_AE
97 O
( O
95 O
) O
33 O
( O
32 O
) O
96 O
( O
94 O
) O
30 O
( O
29 O
) O
Hypocalcemia B-OSE_Labeled_AE
73 O
( O
72 O
) O
11 O
( O
11 O
) O
60 O
( O
59 O
) O
5 O
( O
5 O
) O
Neurology B-NonOSE_AE
92 O
( O
90 O
) O
30 O
( O
29 O
) O
76 O
( O
74 O
) O
18 O
( O
18 O
) O
Neuropathy B-OSE_Labeled_AE
- I-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
55 O
( O
54 O
) O
4 O
( O
4 O
) O
28 O
( O
28 O
) O
1 O
( O
1 O
) O
Confusion B-OSE_Labeled_AE
29 O
( O
28 O
) O
9 O
( O
9 O
) O
12 O
( O
12 O
) O
3 O
( O
3 O
) O
Anxiety B-OSE_Labeled_AE
/ O
agitation B-OSE_Labeled_AE
26 O
( O
26 O
) O
1 O
( O
1 O
) O
14 O
( O
14 O
) O
3 O
( O
3 O
) O
Tremor B-OSE_Labeled_AE
26 O
( O
26 O
) O
1 O
( O
1 O
) O
6 O
( O
6 O
) O
0 O
( O
0 O
) O
Neuropathy B-OSE_Labeled_AE
- I-OSE_Labeled_AE
motor I-OSE_Labeled_AE
22 O
( O
22 O
) O
8 O
( O
8 O
) O
16 O
( O
16 O
) O
5 O
( O
5 O
) O
Dizziness B-OSE_Labeled_AE
/ O
lightheadedness B-OSE_Labeled_AE
20 O
( O
20 O
) O
1 O
( O
1 O
) O
14 O
( O
14 O
) O
0 O
( O
0 O
) O
Depressed B-OSE_Labeled_AE
level I-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
16 O
( O
16 O
) O
3 O
( O
3 O
) O
3 O
( O
3 O
) O
3 O
( O
3 O
) O
Constitutional B-NonOSE_AE
Symptoms I-NonOSE_AE
91 O
( O
89 O
) O
19 O
( O
19 O
) O
84 O
( O
82 O
) O
16 O
( O
16 O
) O
Fatigue B-OSE_Labeled_AE
81 O
( O
79 O
) O
17 O
( O
17 O
) O
72 O
( O
71 O
) O
13 O
( O
13 O
) O
Fever B-OSE_Labeled_AE
24 O
( O
24 O
) O
1 O
( O
1 O
) O
20 O
( O
20 O
) O
3 O
( O
3 O
) O
Weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
23 O
( O
23 O
) O
1 O
( O
1 O
) O
21 O
( O
21 O
) O
2 O
( O
2 O
) O
Weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
22 O
( O
22 O
) O
1 O
( O
1 O
) O
13 O
( O
13 O
) O
0 O
( O
0 O
) O
Blood B-NonOSE_AE
/ I-NonOSE_AE
Bone I-NonOSE_AE
Marrow I-NonOSE_AE
88 O
( O
86 O
) O
29 O
( O
29 O
) O
96 O
( O
94 O
) O
19 O
( O
19 O
) O
Leukocytes B-OSE_Labeled_AE
( I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
) O
36 O
( O
35 O
) O
6 O
( O
6 O
) O
30 O
( O
29 O
) O
3 O
( O
3 O
) O
Neutrophils B-OSE_Labeled_AE
( I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
) O
32 O
( O
31 O
) O
10 O
( O
10 O
) O
24 O
( O
24 O
) O
10 O
( O
10 O
) O
Gastrointestinal B-NonOSE_AE
83 O
( O
81 O
) O
22 O
( O
22 O
) O
70 O
( O
69 O
) O
8 O
( O
8 O
) O
Constipation B-OSE_Labeled_AE
56 O
( O
55 O
) O
8 O
( O
8 O
) O
29 O
( O
28 O
) O
1 O
( O
1 O
) O
Anorexia B-OSE_Labeled_AE
29 O
( O
28 O
) O
4 O
( O
4 O
) O
25 O
( O
24 O
) O
2 O
( O
2 O
) O
Nausea B-OSE_Labeled_AE
29 O
( O
28 O
) O
5 O
( O
5 O
) O
23 O
( O
22 O
) O
1 O
( O
1 O
) O
Mouth B-OSE_Labeled_AE
dryness I-OSE_Labeled_AE
12 O
( O
12 O
) O
1 O
( O
1 O
) O
6 O
( O
6 O
) O
0 O
( O
0 O
) O
Cardiovascular B-NonOSE_AE
70 O
( O
69 O
) O
37 O
( O
36 O
) O
60 O
( O
59 O
) O
21 O
( O
21 O
) O
Edema B-OSE_Labeled_AE
58 O
( O
56 O
) O
6 O
( O
6 O
) O
47 O
( O
46 O
) O
4 O
( O
4 O
) O
Thrombosis B-OSE_Labeled_AE
/ O
embolism B-OSE_Labeled_AE
23 O
( O
22 O
) O
21 O
( O
21 O
) O
5 O
( O
5 O
) O
5 O
( O
5 O
) O
Pain B-OSE_Labeled_AE
64 O
( O
63 O
) O
10 O
( O
10 O
) O
66 O
( O
65 O
) O
15 O
( O
15 O
) O
Myalgia B-OSE_Labeled_AE
17 O
( O
17 O
) O
0 O
( O
0 O
) O
14 O
( O
14 O
) O
1 O
( O
1 O
) O
Arthralgia B-OSE_Labeled_AE
13 O
( O
13 O
) O
0 O
( O
0 O
) O
10 O
( O
10 O
) O
2 O
( O
2 O
) O
Pulmonary B-NonOSE_AE
52 O
( O
51 O
) O
19 O
( O
19 O
) O
51 O
( O
50 O
) O
20 O
( O
20 O
) O
Dyspnea B-OSE_Labeled_AE
43 O
( O
42 O
) O
13 O
( O
13 O
) O
32 O
( O
31 O
) O
15 O
( O
15 O
) O
Dermatology B-NonOSE_AE
/ I-NonOSE_AE
Skin I-NonOSE_AE
48 O
( O
47 O
) O
5 O
( O
5 O
) O
35 O
( O
34 O
) O
2 O
( O
2 O
) O
Rash B-OSE_Labeled_AE
/ O
desquamation B-OSE_Labeled_AE
31 O
( O
30 O
) O
4 O
( O
4 O
) O
18 O
( O
18 O
) O
2 O
( O
2 O
) O
Dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
21 O
( O
21 O
) O
0 O
( O
0 O
) O
11 O
( O
11 O
) O
0 O
( O
0 O
) O
Hepatic B-NonOSE_AE
47 O
( O
46 O
) O
7 O
( O
7 O
) O
45 O
( O
44 O
) O
4 O
( O
4 O
) O
Bilirubin B-OSE_Labeled_AE
14 O
( O
14 O
) O
2 O
( O
2 O
) O
10 O
( O
10 O
) O
2 O
( O
2 O
) O
Musculoskeletal B-NonOSE_AE
42 O
( O
41 O
) O
9 O
( O
9 O
) O
41 O
( O
40 O
) O
14 O
( O
14 O
) O
Muscle B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
41 O
( O
40 O
) O
6 O
( O
6 O
) O
38 O
( O
37 O
) O
13 O
( O
13 O
) O
The O
safety O
analysis O
in O
Study O
2 O
was O
conducted O
on O
466 O
patients O
who O
received O
treatment O
. O

Table O
2 O
lists O
the O
most O
common O
adverse O
drug O
reactions O
( O
> O
= O
10 O
% O
) O
that O
were O
observed O
. O

Table O
3 O
lists O
the O
most O
common O
Grade O
3/4 O
adverse O
drug O
reactions O
( O
occurring O
at O
> O
2 O
% O
) O
that O
were O
observed O
. O

The O
adverse O
reactions O
most O
often O
reported O
by O
patients O
treated O
with O
THALOMID/dexamethasone O
were O
constipation B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
and O
fatigue B-OSE_Labeled_AE
. O

Adverse O
reactions O
with O
a O
frequency O
at O
least O
2-fold O
higher O
in O
the O
THALOMID/dexamethasone O
group O
than O
in O
the O
placebo/dexamethasone O
group O
include O
constipation B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
and O
peripheral B-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
. O

Twenty-six O
percent O
of O
patients O
( O
121/466 O
) O
discontinued O
due O
to O
adverse O
events O
; O
37 O
% O
( O
86/234 O
) O
from O
the O
THALOMID/dexamethasone O
arm O
and O
15 O
% O
( O
35/232 O
) O
from O
the O
placebo/dexamethasone O
arm O
. O

Table O
2 O
: O
Adverse O
Drug O
Reactions O
Reported O
in O
> O
=10 O
% O
of O
Patients O
in O
the O
THALOMID/Dexamethasone O
Arm O
( O
Study O
2 O
- O
Safety O
Population O
; O
N=466 O
) O
*All O
adverse O
reactions O
reported O
in O
> O
=10 O
% O
of O
patients O
in O
THALOMID/dexamethasone O
arm O
and O
with O
a O
> O
=1 O
% O
difference O
in O
proportion O
of O
patients O
between O
the O
THALOMID/dexamethasone O
arm O
compared O
to O
the O
placebo/dexamethasone O
arm O
. O

NOS O
= O
not O
otherwise O
specified O
. O

Body O
SystemAdverse O
Reaction O
Thal/Dex O
( O
N=234 O
) O
*n O
( O
% O
) O
Placebo/Dex O
( O
N=232 O
) O
*n O
( O
% O
) O
Patients O
with O
at O
least O
1 O
Adverse O
Reaction O
233 O
( O
99 O
) O
230 O
( O
99 O
) O
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
176 O
( O
75 O
) O
149 O
( O
64 O
) O
Edema B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
80 O
( O
34 O
) O
57 O
( O
25 O
) O
Asthenia B-OSE_Labeled_AE
56 O
( O
24 O
) O
47 O
( O
20 O
) O
Fatigue B-OSE_Labeled_AE
50 O
( O
21 O
) O
36 O
( O
16 O
) O
Edema B-OSE_Labeled_AE
NOS O
31 O
( O
13 O
) O
19 O
( O
8 O
) O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
162 O
( O
69 O
) O
149 O
( O
64 O
) O
Constipation B-OSE_Labeled_AE
116 O
( O
50 O
) O
49 O
( O
21 O
) O
Nausea B-OSE_Labeled_AE
30 O
( O
13 O
) O
27 O
( O
12 O
) O
Dyspepsia B-OSE_Labeled_AE
27 O
( O
11 O
) O
21 O
( O
9 O
) O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
161 O
( O
69 O
) O
138 O
( O
60 O
) O
Tremor B-OSE_Labeled_AE
62 O
( O
26 O
) O
29 O
( O
12 O
) O
Dizziness B-OSE_Labeled_AE
51 O
( O
23 O
) O
32 O
( O
14 O
) O
Paresthesia B-OSE_Labeled_AE
27 O
( O
12 O
) O
15 O
( O
6 O
) O
Peripheral B-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
24 O
( O
10 O
) O
12 O
( O
5 O
) O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
139 O
( O
59 O
) O
138 O
( O
60 O
) O
Pneumonia B-OSE_Labeled_AE
NOS O
35 O
( O
15 O
) O
28 O
( O
12 O
) O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
90 O
( O
38 O
) O
97 O
( O
42 O
) O
Anxiety B-OSE_Labeled_AE
27 O
( O
12 O
) O
22 O
( O
10 O
) O
Depression B-OSE_Labeled_AE
24 O
( O
10 O
) O
19 O
( O
8 O
) O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
96 O
( O
41 O
) O
89 O
( O
38 O
) O
Hyperglycemia B-OSE_Labeled_AE
NOS O
36 O
( O
15 O
) O
32 O
( O
14 O
) O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
92 O
( O
39 O
) O
53 O
( O
23 O
) O
Deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
30 O
( O
13 O
) O
4 O
( O
2 O
) O
Table O
3 O
: O
Grade O
3/4 O
Adverse O
Drug O
Reactions O
Reported O
in O
> O
2 O
% O
of O
Patients O
in O
the O
THALOMID/Dexamethasone O
Arm O
( O
Study O
2 O
- O
Safety O
Population O
; O
N=466 O
) O
*All O
Grade O
3/4 O
adverse O
reactions O
with O
> O
2 O
% O
of O
patients O
in O
THALOMID/dexamethasone O
arm O
and O
with O
a O
higher O
frequency O
in O
the O
THALOMID/dexamethasone O
arm O
compared O
to O
the O
placebo/dexamethasone O
arm O
. O

NOS O
= O
not O
otherwise O
specified O
. O

Body O
SystemAdverse O
Reaction O
THALOMID/Dex O
( O
N=234 O
) O
*n O
( O
% O
) O
Placebo/Dex O
( O
N=232 O
) O
*n O
( O
% O
) O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
50 O
( O
21 O
) O
36 O
( O
16 O
) O
Pneumonia B-OSE_Labeled_AE
NOS O
17 O
( O
7 O
) O
14 O
( O
6 O
) O
Bronchopneumonia B-OSE_Labeled_AE
NOS O
7 O
( O
3 O
) O
3 O
( O
1 O
) O
General B-NonOSE_AE
Disorders I-NonOSE_AE
andAdministration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
44 O
( O
19 O
) O
26 O
( O
11 O
) O
Asthenia B-OSE_Labeled_AE
11 O
( O
5 O
) O
4 O
( O
2 O
) O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
NutritionDisorders I-NonOSE_AE
33 O
( O
14 O
) O
34 O
( O
15 O
) O
Hypokalemia B-OSE_Labeled_AE
7 O
( O
3 O
) O
3 O
( O
1 O
) O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
47 O
( O
20 O
) O
20 O
( O
9 O
) O
Syncope B-OSE_Labeled_AE
8 O
( O
3 O
) O
1 O
( O
< O
1 O
) O
Peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
NOS O
8 O
( O
3 O
) O
0 O
( O
0 O
) O
Cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
6 O
( O
3 O
) O
1 O
( O
< O
1 O
) O
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
35 O
( O
15 O
) O
27 O
( O
11 O
) O
Atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
11 O
( O
5 O
) O
8 O
( O
3 O
) O
Myocardial B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
6 O
( O
3 O
) O
2 O
( O
1 O
) O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
42 O
( O
18 O
) O
14 O
( O
6 O
) O
Deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
27 O
( O
12 O
) O
4 O
( O
2 O
) O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
26 O
( O
11 O
) O
22 O
( O
10 O
) O
Constipation B-OSE_Labeled_AE
7 O
( O
3 O
) O
2 O
( O
1 O
) O
Investigations B-NonOSE_AE
21 O
( O
9 O
) O
21 O
( O
9 O
) O
Weight B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
8 O
( O
3 O
) O
4 O
( O
2 O
) O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
SystemDisorders I-NonOSE_AE
24 O
( O
10 O
) O
17 O
( O
7 O
) O
Neutropenia B-OSE_Labeled_AE
8 O
( O
3 O
) O
6 O
( O
3 O
) O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
, I-NonOSE_AE
andMediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
27 O
( O
12 O
) O
13 O
( O
6 O
) O
Pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
16 O
( O
7 O
) O
4 O
( O
2 O
) O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
19 O
( O
8 O
) O
8 O
( O
3 O
) O
Anxiety B-OSE_Labeled_AE
5 O
( O
2 O
) O
3 O
( O
1 O
) O
Confusional B-OSE_Labeled_AE
state I-OSE_Labeled_AE
5 O
( O
2 O
) O
2 O
( O
1 O
) O
Ear B-NonOSE_AE
and I-NonOSE_AE
Labyrinth I-NonOSE_AE
Disorders I-NonOSE_AE
6 O
( O
3 O
) O
0 O
( O
0 O
) O
Vertigo B-OSE_Labeled_AE
5 O
( O
2 O
) O
0 O
( O
0 O
) O
Less O
Common O
Adverse O
Drug O
Reactions O
in O
Multiple O
Myeloma O
Controlled O
Clinical O
Trials O
In O
Study O
2 O
, O
THALOMID O
in O
combination O
with O
dexamethasone O
in O
patients O
with O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
, O
the O
following O
adverse O
drug O
reactions O
not O
described O
above O
were O
reported* O
: O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
Vomiting B-OSE_Labeled_AE
NOS O
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
peritonitis B-OSE_Labeled_AE
, O
diverticular B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
Somnolence B-OSE_Labeled_AE
, O
hypoesthesia B-OSE_Labeled_AE
, O
polyneuropathy B-OSE_Labeled_AE
NOS O
, O
transient B-OSE_Labeled_AE
ischemic I-OSE_Labeled_AE
attack I-OSE_Labeled_AE
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
: O
Bronchitis B-OSE_Labeled_AE
NOS O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
: O
Mood B-OSE_Labeled_AE
alteration I-OSE_Labeled_AE
NOS O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
: O
Hypotension B-OSE_Labeled_AE
NOS O
, O
orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
Bradycardia B-OSE_Labeled_AE
NOS O
Eye B-NonOSE_AE
disorders I-NonOSE_AE
: O
Blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
* O
All O
adverse O
reactions O
with O
> O
=3 O
% O
of O
patients O
in O
THALOMID/dexamethasone O
arm O
and O
with O
a O
> O
=1 O
% O
difference O
in O
proportion O
of O
patients O
between O
the O
THALOMID/dexamethasone O
arm O
compared O
to O
the O
placebo/dexamethasone O
arm O
. O

All O
grade O
3/4 O
and O
serious O
adverse O
reactions O
reported O
> O
2 O
patients O
in O
THALOMID/dexamethasone O
arm O
and O
with O
a O
percentage O
higher O
in O
the O
THALOMID/dexamethasone O
arm O
compared O
to O
the O
placebo/dexamethasone O
arm O
have O
been O
considered O
for O
possible O
inclusion O
. O

In O
any O
cases O
medical O
judgment O
has O
been O
applied O
for O
consideration O
of O
causality O
assessment O
. O

Adverse O
Reactions O
in O
Erythema O
Nodosum O
Leprosum O
( O
ENL O
) O
Clinical O
Trials O
Table O
4 O
lists O
treatment-emergent O
signs O
and O
symptoms O
that O
occurred O
in O
THALOMID-treated O
patients O
in O
clinical O
trials O
in O
ENL B-Not_AE_Candidate
. O

The O
most O
common O
adverse O
reactions O
( O
> O
=10 O
% O
) O
reported O
in O
patients O
with O
ENL O
were O
somnolence B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
. O

Doses O
ranged O
from O
50 O
to O
300 O
mg/day O
. O

All O
adverse O
reactions O
were O
mild O
to O
moderate O
in O
severity O
, O
and O
none O
resulted O
in O
discontinuation O
. O

Table O
4 O
: O
Summary O
of O
Adverse O
Events O
( O
AEs O
) O
Reported O
in O
Celgene-sponsored O
Controlled O
Clinical O
Trials O
Body O
System/Adverse O
Event O
All O
AEs O
Reportedin O
Patients O
with O
ENL O
AEs O
Reported O
in O
> O
=3 O
HIV-seropositive O
Patients O
Thalidomide O
Placebo O
50 O
to O
300 O
mg/day O
( O
N=24 O
) O
100 O
mg/day O
( O
N=36 O
) O
200 O
mg/day O
( O
N=32 O
) O
( O
N=35 O
) O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
0 O
8 O
( O
22.2 O
% O
) O
13 O
( O
40.6 O
% O
) O
10 O
( O
28.6 O
% O
) O
Anemia B-OSE_Labeled_AE
0 O
2 O
( O
5.6 O
% O
) O
4 O
( O
12.5 O
% O
) O
3 O
( O
8.6 O
% O
) O
Leukopenia B-OSE_Labeled_AE
0 O
6 O
( O
16.7 O
% O
) O
8 O
( O
25.0 O
% O
) O
3 O
( O
8.6 O
% O
) O
Lymphadenopathy B-OSE_Labeled_AE
0 O
2 O
( O
5.6 O
% O
) O
4 O
( O
12.5 O
% O
) O
3 O
( O
8.6 O
% O
) O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
16 O
( O
66.7 O
% O
) O
18 O
( O
50.0 O
% O
) O
19 O
( O
59.4 O
% O
) O
13 O
( O
37.1 O
% O
) O
Abdominal B-NonOSE_AE
pain I-NonOSE_AE
1 O
( O
4.2 O
% O
) O
1 O
( O
2.8 O
% O
) O
1 O
( O
3.1 O
% O
) O
4 O
( O
11.4 O
% O
) O
Accidental B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
2 O
( O
5.6 O
% O
) O
0 O
1 O
( O
2.9 O
% O
) O
Asthenia B-OSE_Labeled_AE
2 O
( O
8.3 O
% O
) O
2 O
( O
5.6 O
% O
) O
7 O
( O
21.9 O
% O
) O
1 O
( O
2.9 O
% O
) O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
2 O
( O
5.6 O
% O
) O
0 O
0 O
Chills B-NonOSE_AE
1 O
( O
4.2 O
% O
) O
0 O
3 O
( O
9.4 O
% O
) O
4 O
( O
11.4 O
% O
) O
Facial B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
0 O
0 O
0 O
Fever B-OSE_Labeled_AE
0 O
7 O
( O
19.4 O
% O
) O
7 O
( O
21.9 O
% O
) O
6 O
( O
17.1 O
% O
) O
Headache B-OSE_Labeled_AE
3 O
( O
12.5 O
% O
) O
6 O
( O
16.7 O
% O
) O
6 O
( O
18.7 O
% O
) O
4 O
( O
11.4 O
% O
) O
Infection B-OSE_Labeled_AE
0 O
3 O
( O
8.3 O
% O
) O
2 O
( O
6.3 O
% O
) O
1 O
( O
2.9 O
% O
) O
Malaise B-OSE_Labeled_AE
2 O
( O
8.3 O
% O
) O
0 O
0 O
0 O
Neck B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
0 O
0 O
0 O
Neck B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
0 O
0 O
0 O
Pain B-OSE_Labeled_AE
2 O
( O
8.3 O
% O
) O
0 O
1 O
( O
3.1 O
% O
) O
2 O
( O
5.7 O
% O
) O
Digestive B-NonOSE_AE
System I-NonOSE_AE
5 O
( O
20.8 O
% O
) O
16 O
( O
44.4 O
% O
) O
16 O
( O
50.0 O
% O
) O
15 O
( O
42.9 O
% O
) O
Anorexia B-OSE_Labeled_AE
0 O
1 O
( O
2.8 O
% O
) O
3 O
( O
9.4 O
% O
) O
2 O
( O
5.7 O
% O
) O
Constipation B-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
1 O
( O
2.8 O
% O
) O
3 O
( O
9.4 O
% O
) O
0 O
Diarrhea B-NonOSE_AE
1 O
( O
4.2 O
% O
) O
4 O
( O
11.1 O
% O
) O
6 O
( O
18.7 O
% O
) O
6 O
( O
17.1 O
% O
) O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
0 O
3 O
( O
8.3 O
% O
) O
3 O
( O
9.4 O
% O
) O
2 O
( O
5.7 O
% O
) O
Flatulence B-OSE_Labeled_AE
0 O
3 O
( O
8.3 O
% O
) O
0 O
2 O
( O
5.7 O
% O
) O
Liver B-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
multiple I-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
0 O
0 O
3 O
( O
9.4 O
% O
) O
0 O
Nausea B-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
0 O
4 O
( O
12.5 O
% O
) O
1 O
( O
2.9 O
% O
) O
Oral B-OSE_Labeled_AE
moniliasis I-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
4 O
( O
11.1 O
% O
) O
2 O
( O
6.3 O
% O
) O
0 O
Tooth B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
0 O
0 O
0 O
Metabolic B-NonOSE_AE
and I-NonOSE_AE
Endocrine I-NonOSE_AE
Disorders I-NonOSE_AE
1 O
( O
4.2 O
% O
) O
8 O
( O
22.2 O
% O
) O
12 O
( O
37.5 O
% O
) O
8 O
( O
22.9 O
% O
) O
Edema B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
3 O
( O
8.3 O
% O
) O
1 O
( O
3.1 O
% O
) O
0 O
Hyperlipemia B-OSE_Labeled_AE
0 O
2 O
( O
5.6 O
% O
) O
3 O
( O
9.4 O
% O
) O
1 O
( O
2.9 O
% O
) O
SGOT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
0 O
1 O
( O
2.8 O
% O
) O
4 O
( O
12.5 O
% O
) O
2 O
( O
5.7 O
% O
) O
Nervous B-NonOSE_AE
System I-NonOSE_AE
13 O
( O
54.2 O
% O
) O
19 O
( O
52.8 O
% O
) O
18 O
( O
56.3 O
% O
) O
12 O
( O
34.3 O
% O
) O
Agitation B-OSE_Labeled_AE
0 O
0 O
3 O
( O
9.4 O
% O
) O
0 O
Dizziness B-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
7 O
( O
19.4 O
% O
) O
6 O
( O
18.7 O
% O
) O
0 O
Insomnia B-OSE_Labeled_AE
0 O
0 O
3 O
( O
9.4 O
% O
) O
2 O
( O
5.7 O
% O
) O
Nervousness B-OSE_Labeled_AE
0 O
1 O
( O
2.8 O
% O
) O
3 O
( O
9.4 O
% O
) O
0 O
Neuropathy B-OSE_Labeled_AE
0 O
3 O
( O
8.3 O
% O
) O
0 O
0 O
Paresthesia B-OSE_Labeled_AE
0 O
2 O
( O
5.6 O
% O
) O
5 O
( O
15.6 O
% O
) O
4 O
( O
11.4 O
% O
) O
Somnolence B-OSE_Labeled_AE
9 O
( O
37.5 O
% O
) O
13 O
( O
36.1 O
% O
) O
12 O
( O
37.5 O
% O
) O
4 O
( O
11.4 O
% O
) O
Tremor B-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
0 O
0 O
0 O
Vertigo B-OSE_Labeled_AE
2 O
( O
8.3 O
% O
) O
0 O
0 O
0 O
Respiratory B-NonOSE_AE
System I-NonOSE_AE
3 O
( O
12.5 O
% O
) O
9 O
( O
25.0 O
% O
) O
6 O
( O
18.7 O
% O
) O
9 O
( O
25.7 O
% O
) O
Pharyngitis B-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
3 O
( O
8.3 O
% O
) O
2 O
( O
6.3 O
% O
) O
2 O
( O
5.7 O
% O
) O
Rhinitis B-NonOSE_AE
1 O
( O
4.2 O
% O
) O
0 O
0 O
4 O
( O
11.4 O
% O
) O
Sinusitis B-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
3 O
( O
8.3 O
% O
) O
1 O
( O
3.1 O
% O
) O
2 O
( O
5.7 O
% O
) O
Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
10 O
( O
41.7 O
% O
) O
17 O
( O
47.2 O
% O
) O
18 O
( O
56.3 O
% O
) O
19 O
( O
54.3 O
% O
) O
Acne B-OSE_Labeled_AE
0 O
4 O
( O
11.1 O
% O
) O
1 O
( O
3.1 O
% O
) O
0 O
Dermatitis B-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
2 O
( O
5.6 O
% O
) O
3 O
( O
9.4 O
% O
) O
0 O
Nail B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
0 O
1 O
( O
3.1 O
% O
) O
0 O
Pruritus B-NonOSE_AE
2 O
( O
8.3 O
% O
) O
1 O
( O
2.8 O
% O
) O
2 O
( O
6.3 O
% O
) O
2 O
( O
5.7 O
% O
) O
Rash B-NonOSE_AE
5 O
( O
20.8 O
% O
) O
9 O
( O
25.0 O
% O
) O
8 O
( O
25.0 O
% O
) O
11 O
( O
31.4 O
% O
) O
Rash B-OSE_Labeled_AE
maculopapular I-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
6 O
( O
16.7 O
% O
) O
6 O
( O
18.7 O
% O
) O
2 O
( O
5.7 O
% O
) O
Sweating B-NonOSE_AE
0 O
0 O
4 O
( O
12.5 O
% O
) O
4 O
( O
11.4 O
% O
) O
Urogenital B-NonOSE_AE
System I-NonOSE_AE
2 O
( O
8.3 O
% O
) O
6 O
( O
16.7 O
% O
) O
2 O
( O
6.3 O
% O
) O
4 O
( O
11.4 O
% O
) O
Albuminuria B-OSE_Labeled_AE
0 O
3 O
( O
8.3 O
% O
) O
1 O
( O
3.1 O
% O
) O
2 O
( O
5.7 O
% O
) O
Hematuria B-OSE_Labeled_AE
0 O
4 O
( O
11.1 O
% O
) O
0 O
1 O
( O
2.9 O
% O
) O
Impotence B-OSE_Labeled_AE
2 O
( O
8.3 O
% O
) O
1 O
( O
2.8 O
% O
) O
0 O
0 O
Other O
Adverse O
Events O
Observed O
in O
ENL O
Patients O
THALOMID O
in O
doses O
up O
to O
400 O
mg/day O
has O
been O
administered O
investigationally O
in O
the O
United O
States O
over O
a O
19-year O
period O
in O
1465 O
patients O
with O
ENL B-Not_AE_Candidate
. O

The O
published O
literature O
describes O
the O
treatment O
of O
an O
additional O
1678 O
patients O
. O

To O
provide O
a O
meaningful O
estimate O
of O
the O
proportion O
of O
the O
individuals O
having O
adverse O
events O
, O
similar O
types O
of O
events O
were O
grouped O
into O
a O
smaller O
number O
of O
standardized O
categories O
using O
a O
modified O
COSTART O
dictionary/terminology O
. O

These O
categories O
are O
used O
in O
the O
listing O
below O
. O

All O
reported O
events O
are O
included O
except O
those O
already O
listed O
in O
the O
previous O
table O
. O

Due O
to O
the O
fact O
that O
these O
data O
were O
collected O
from O
uncontrolled O
studies O
, O
the O
incidence O
rate O
can O
not O
be O
determined O
. O

No O
causal O
relationship O
between O
THALOMID O
and O
these O
events O
can O
be O
conclusively O
determined O
at O
this O
time O
. O

These O
are O
reports O
of O
all O
adverse O
events O
noted O
by O
investigators O
in O
patients O
to O
whom O
they O
had O
administered O
thalidomide O
. O

Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
: O
ESR B-OSE_Labeled_AE
decrease I-OSE_Labeled_AE
, O
eosinophilia B-OSE_Labeled_AE
, O
granulocytopenia B-OSE_Labeled_AE
, O
hypochromic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
leukemia B-OSE_Labeled_AE
, O
leukocytosis B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
MCV B-OSE_Labeled_AE
elevated I-OSE_Labeled_AE
, O
RBC B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
spleen B-OSE_Labeled_AE
palpable I-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
. O

Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
: O
Abdomen B-OSE_Labeled_AE
enlarged I-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
photosensitivity B-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
. O

Cardiovascular B-NonOSE_AE
System I-NonOSE_AE
: O
Bradycardia B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
vascular I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
, O
vasodilation B-OSE_Labeled_AE
. O

Digestive B-NonOSE_AE
System I-NonOSE_AE
: O
Anorexia B-OSE_Labeled_AE
, O
appetite B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
/ O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
enlarged B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
, O
eructation B-OSE_Labeled_AE
, O
flatulence B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
, O
intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
. O

Metabolic B-NonOSE_AE
and I-NonOSE_AE
Endocrine I-NonOSE_AE
: O
ADH B-OSE_Labeled_AE
inappropriate I-OSE_Labeled_AE
, O
amyloidosis B-OSE_Labeled_AE
, O
bilirubinemia B-OSE_Labeled_AE
, O
BUN B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
creatinine B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
cyanosis B-OSE_Labeled_AE
, O
diabetes B-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
electrolyte B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
hyperkalemia B-OSE_Labeled_AE
, O
hyperuricemia B-OSE_Labeled_AE
, O
hypocalcemia B-OSE_Labeled_AE
, O
hypoproteinemia B-OSE_Labeled_AE
, O
LDH B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
phosphorus B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
SGPT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
. O

Muscular B-NonOSE_AE
Skeletal I-NonOSE_AE
: O
Arthritis B-OSE_Labeled_AE
, O
bone B-OSE_Labeled_AE
tenderness I-OSE_Labeled_AE
, O
hypertonia B-OSE_Labeled_AE
, O
joint B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
leg B-OSE_Labeled_AE
cramps I-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
, O
myasthenia B-OSE_Labeled_AE
, O
periosteal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
. O

Nervous B-NonOSE_AE
System I-NonOSE_AE
: O
Abnormal B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
amnesia B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
causalgia B-OSE_Labeled_AE
, O
circumoral B-OSE_Labeled_AE
paresthesia I-OSE_Labeled_AE
, O
confusion B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
euphoria B-OSE_Labeled_AE
, O
hyperesthesia B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
nervousness B-OSE_Labeled_AE
, O
neuralgia B-OSE_Labeled_AE
, O
neuritis B-OSE_Labeled_AE
, O
neuropathy B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
neuritis I-OSE_Labeled_AE
, O
psychosis B-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
System I-NonOSE_AE
: O
Cough B-OSE_Labeled_AE
, O
emphysema B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolus I-OSE_Labeled_AE
, O
rales B-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
voice B-OSE_Labeled_AE
alteration I-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
: O
Acne B-OSE_Labeled_AE
, O
alopecia B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
, O
eczematous B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
ichthyosis B-OSE_Labeled_AE
, O
perifollicular B-OSE_Labeled_AE
thickening I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
, O
seborrhea B-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
vesiculobullous B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
. O

Special B-NonOSE_AE
Senses I-NonOSE_AE
: O
Amblyopia B-OSE_Labeled_AE
, O
deafness B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
eye I-OSE_Labeled_AE
, O
eye B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
tinnitus B-OSE_Labeled_AE
. O

Urogenital B-NonOSE_AE
: O
Decreased B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
clearance I-OSE_Labeled_AE
, O
hematuria B-OSE_Labeled_AE
, O
orchitis B-OSE_Labeled_AE
, O
proteinuria B-OSE_Labeled_AE
, O
pyuria B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
frequency I-OSE_Labeled_AE
. O

Other O
Adverse O
Events O
Observed O
in O
HIV-seropositive O
Patients O
In O
addition O
to O
controlled O
clinical O
trials O
, O
THALOMID O
has O
been O
used O
in O
uncontrolled O
studies O
in O
145 O
patients O
. O

Less O
frequent O
adverse O
events O
that O
have O
been O
reported O
in O
these O
HIV B-Not_AE_Candidate
- I-Not_AE_Candidate
seropositive I-Not_AE_Candidate
patients O
treated O
with O
THALOMID O
were O
grouped O
into O
a O
smaller O
number O
of O
standardized O
categories O
using O
modified O
COSTART O
dictionary/terminology O
and O
these O
categories O
are O
used O
in O
the O
listing O
below O
. O

Adverse O
events O
that O
have O
already O
been O
included O
in O
the O
tables O
and O
narrative O
above O
, O
or O
that O
are O
too O
general O
to O
be O
informative O
are O
not O
listed O
. O

Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
: O
Aplastic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
macrocytic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
megaloblastic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
microcytic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
. O

Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
: O
Ascites B-OSE_Labeled_AE
, O
AIDS B-OSE_Labeled_AE
, O
allergic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
and O
fever B-OSE_Labeled_AE
, O
cyst B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
CD I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
count I-OSE_Labeled_AE
, O
facial B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
flu B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
hernia B-OSE_Labeled_AE
, O
thyroid B-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
level I-OSE_Labeled_AE
altered I-OSE_Labeled_AE
, O
moniliasis B-OSE_Labeled_AE
, O
photosensitivity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
sarcoma B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
viral B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
. O

Cardiovascular B-NonOSE_AE
System I-NonOSE_AE
: O
Angina B-OSE_Labeled_AE
pectoris I-OSE_Labeled_AE
, O
arrhythmia B-OSE_Labeled_AE
, O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
bradycardia B-OSE_Labeled_AE
, O
cerebral B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
deep B-OSE_Labeled_AE
thrombophlebitis I-OSE_Labeled_AE
, O
heart B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
heart B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
murmur B-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarct I-OSE_Labeled_AE
, O
palpitation B-OSE_Labeled_AE
, O
pericarditis B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
vascular I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
postural B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
, O
thrombophlebitis B-OSE_Labeled_AE
, O
thrombosis B-OSE_Labeled_AE
. O

Digestive B-NonOSE_AE
System I-NonOSE_AE
: O
Cholangitis B-OSE_Labeled_AE
, O
cholestatic B-OSE_Labeled_AE
jaundice I-OSE_Labeled_AE
, O
colitis B-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
dysphagia B-OSE_Labeled_AE
, O
esophagitis B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
gum B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
, O
parotid B-OSE_Labeled_AE
gland I-OSE_Labeled_AE
enlargement I-OSE_Labeled_AE
, O
periodontitis B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
, O
tooth B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
. O

Metabolic B-NonOSE_AE
and I-NonOSE_AE
Endocrine I-NonOSE_AE
: O
Avitaminosis B-OSE_Labeled_AE
, O
bilirubinemia B-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
, O
hypercholesterolemia B-OSE_Labeled_AE
, O
hypoglycemia B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
alkaline I-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
lipase I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
. O

Muscular B-NonOSE_AE
Skeletal I-NonOSE_AE
: O
Myalgia B-OSE_Labeled_AE
, O
myasthenia B-OSE_Labeled_AE
. O

Nervous B-NonOSE_AE
System I-NonOSE_AE
: O
Abnormal B-OSE_Labeled_AE
gait I-OSE_Labeled_AE
, O
ataxia B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
libido I-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
reflexes I-OSE_Labeled_AE
, O
dementia B-OSE_Labeled_AE
, O
dysesthesia B-OSE_Labeled_AE
, O
dyskinesia B-OSE_Labeled_AE
, O
emotional B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
, O
hostility B-OSE_Labeled_AE
, O
hypalgesia B-OSE_Labeled_AE
, O
hyperkinesia B-OSE_Labeled_AE
, O
incoordination B-OSE_Labeled_AE
, O
meningitis B-OSE_Labeled_AE
, O
neurologic B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
vertigo B-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
System I-NonOSE_AE
: O
Apnea B-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
, O
lung B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
lung B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
( O
including O
Pneumocystis B-OSE_Labeled_AE
carinii I-OSE_Labeled_AE
pneumonia I-OSE_Labeled_AE
) O
, O
rhinitis B-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
: O
Angioedema B-OSE_Labeled_AE
, O
benign B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
neoplasm I-OSE_Labeled_AE
, O
eczema B-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
simplex I-OSE_Labeled_AE
, O
incomplete O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
nail B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
psoriasis B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
. O

Special B-NonOSE_AE
Senses I-NonOSE_AE
: O
Conjunctivitis B-OSE_Labeled_AE
, O
eye B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
lacrimation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
retinitis B-OSE_Labeled_AE
, O
taste B-OSE_Labeled_AE
perversion I-OSE_Labeled_AE
. O

6.2 O
Postmarketing O
Experience O
The O
following O
additional O
adverse O
reactions O
have O
been O
identified O
during O
post O
approval O
use O
of O
THALOMID O
and O
are O
not O
already O
included O
in O
Clinical O
Trials O
Experience O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
: O
Decreased B-OSE_Labeled_AE
white I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
counts I-OSE_Labeled_AE
including O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
, O
changes B-OSE_Labeled_AE
in I-OSE_Labeled_AE
prothrombin I-OSE_Labeled_AE
time I-OSE_Labeled_AE
, O
pancytopenia B-OSE_Labeled_AE
, O
chronic B-OSE_Labeled_AE
myelogenous I-OSE_Labeled_AE
leukemia I-OSE_Labeled_AE
, O
nodular B-OSE_Labeled_AE
sclerosing I-OSE_Labeled_AE
Hodgkin I-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
erythroleukemia B-OSE_Labeled_AE
, O
lymphedema B-OSE_Labeled_AE
, O
lymphopenia B-OSE_Labeled_AE
. O

Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
: O
Hangover B-OSE_Labeled_AE
effect I-OSE_Labeled_AE
Cardiovascular B-NonOSE_AE
System I-NonOSE_AE
: O
Sick B-OSE_Labeled_AE
sinus I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
EKG B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
. O

Digestive B-NonOSE_AE
System I-NonOSE_AE
: O
Intestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
perforations I-OSE_Labeled_AE
, O
bile B-OSE_Labeled_AE
duct I-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
, O
stomach B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
, O
aphthous B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
. O

Ear B-NonOSE_AE
and I-NonOSE_AE
Labyrinthine I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Hearing B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
. O

Immune B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Hypersensitivity B-OSE_Labeled_AE
. O

Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
: O
Severe O
infections B-OSE_Labeled_AE
( O
e.g. O
, O
fatal B-NonOSE_AE
sepsis B-OSE_Labeled_AE
including O
septic B-OSE_Labeled_AE
shock I-OSE_Labeled_AE
) O
and O
viral B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
( O
including O
varicella B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
, O
cytomegalovirus B-OSE_Labeled_AE
, O
and O
hepatitis B-OSE_Labeled_AE
B I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
) O
. O

Metabolic B-NonOSE_AE
and I-NonOSE_AE
Endocrine I-NonOSE_AE
: O
Electrolyte B-OSE_Labeled_AE
imbalance I-OSE_Labeled_AE
including O
hypercalcemia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
and O
hypomagnesemia B-OSE_Labeled_AE
, O
hypothyroidism B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
alkaline I-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
, O
tumor B-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
myxedema B-OSE_Labeled_AE
. O

Nervous B-NonOSE_AE
System I-NonOSE_AE
: O
Changes B-OSE_Labeled_AE
in I-OSE_Labeled_AE
mental I-OSE_Labeled_AE
status I-OSE_Labeled_AE
or O
mood O
including O
suicide B-OSE_Labeled_AE
attempts I-OSE_Labeled_AE
, O
disturbances B-OSE_Labeled_AE
in I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
including O
lethargy B-OSE_Labeled_AE
, O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
or O
stupor B-OSE_Labeled_AE
, O
seizures B-OSE_Labeled_AE
including O
grand B-OSE_Labeled_AE
mal I-OSE_Labeled_AE
convulsions I-OSE_Labeled_AE
and O
status B-OSE_Labeled_AE
epilepticus I-OSE_Labeled_AE
, O
Parkinson B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
stroke B-OSE_Labeled_AE
, O
carpal B-OSE_Labeled_AE
tunnel I-OSE_Labeled_AE
, O
Raynaud B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
migraine B-OSE_Labeled_AE
, O
foot B-OSE_Labeled_AE
drop I-OSE_Labeled_AE
. O

Renal B-NonOSE_AE
and I-NonOSE_AE
Urinary I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
oliguria B-OSE_Labeled_AE
, O
enuresis B-OSE_Labeled_AE
. O

Reproductive B-NonOSE_AE
System I-NonOSE_AE
and I-NonOSE_AE
Breast I-NonOSE_AE
Disorders I-NonOSE_AE
: O
amenorrhea B-OSE_Labeled_AE
, O
sexual B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
, O
galactorrhea B-OSE_Labeled_AE
, O
gynecomastia B-OSE_Labeled_AE
, O
metrorrhagia B-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
System I-NonOSE_AE
: O
Pleural B-OSE_Labeled_AE
effusion I-OSE_Labeled_AE
, O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
: O
Erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
nodosum I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
purpura B-OSE_Labeled_AE
, O
petechiae B-OSE_Labeled_AE
. O

Special B-NonOSE_AE
Senses I-NonOSE_AE
: O
Diplopia B-OSE_Labeled_AE
, O
nystagmus B-OSE_Labeled_AE

BOXED O
WARNING O
: O
WARNING O
: O
EMBRYO-FETAL O
TOXICITY O
AND O
VENOUS O
THROMBOEMBOLISM O
EMBRYO B-OSE_Labeled_AE
- I-OSE_Labeled_AE
FETAL I-OSE_Labeled_AE
TOXICITY I-OSE_Labeled_AE
If O
thalidomide O
is O
taken O
during O
pregnancy B-Not_AE_Candidate
, O
it O
can O
cause O
severe O
birth B-OSE_Labeled_AE
defects I-OSE_Labeled_AE
or O
embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
fetal I-OSE_Labeled_AE
death I-OSE_Labeled_AE
. O

Thalidomide O
should O
never O
be O
used O
by O
females O
who O
are O
pregnant B-Not_AE_Candidate
or O
who O
could O
become O
pregnant B-NonOSE_AE
while O
taking O
the O
drug O
. O

Even O
a O
single O
dose O
[ O
1 O
capsule O
( O
regardless O
of O
strength O
) O
] O
taken O
by O
a O
pregnant B-Not_AE_Candidate
woman O
during O
her O
pregnancy B-Not_AE_Candidate
can O
cause O
severe O
birth B-OSE_Labeled_AE
defects I-OSE_Labeled_AE
. O

Because O
of O
this O
toxicity O
and O
in O
an O
effort O
to O
make O
the O
chance O
of O
embryo B-NonOSE_AE
- I-NonOSE_AE
fetal I-NonOSE_AE
exposure I-NonOSE_AE
to I-NonOSE_AE
THALOMID I-NonOSE_AE
( O
r O
) O
( O
thalidomide O
) O
as O
negligible O
as O
possible O
, O
THALOMID O
( O
r O
) O
( O
thalidomide O
) O
is O
approved O
for O
marketing O
only O
through O
a O
special O
restricted O
distribution O
program O
: O
THALOMID O
REMS O
( O
r O
) O
program O
, O
approved O
by O
the O
Food O
and O
Drug O
Administration O
. O

You O
can O
get O
the O
information O
about O
THALOMID O
and O
the O
THALOMID O
REMS O
program O
on O
the O
Internet O
at O
www.celgeneriskmanagement.com O
or O
by O
calling O
the O
manufacturer O
's O
toll-free O
number O
1-888-423-5436 O
. O

VENOUS O
THROMBOEMBOLISM O
The O
use O
of O
THALOMID O
( O
r O
) O
( O
thalidomide O
) O
in O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
results O
in O
an O
increased O
risk O
of O
venous B-OSE_Labeled_AE
thromboembolism I-OSE_Labeled_AE
, O
such O
as O
deep B-OSE_Labeled_AE
venous I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
and O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
. O

This O
risk O
increases O
significantly O
when O
thalidomide O
is O
used O
in O
combination O
with O
standard O
chemotherapeutic O
agents O
including O
dexamethasone O
. O

In O
one O
controlled O
trial O
, O
the O
rate O
of O
venous B-OSE_Labeled_AE
thromboembolism I-OSE_Labeled_AE
was O
22.5 O
% O
in O
patients O
receiving O
thalidomide O
in O
combination O
with O
dexamethasone O
compared O
to O
4.9 O
% O
in O
patients O
receiving O
dexamethasone O
alone O
( O
p O
= O
0.002 O
) O
. O

Patients O
and O
physicians O
are O
advised O
to O
be O
observant O
for O
the O
signs O
and O
symptoms O
of O
thromboembolism B-NonOSE_AE
. O

Instruct O
patients O
to O
seek O
medical O
care O
if O
they O
develop O
symptoms O
such O
as O
shortness B-NonOSE_AE
of I-NonOSE_AE
breath I-NonOSE_AE
, O
chest B-NonOSE_AE
pain I-NonOSE_AE
, O
or O
arm B-NonOSE_AE
or O
leg O
swelling I-NonOSE_AE
. O

Consider O
thromboprophylaxis O
based O
on O
an O
assessment O
of O
individual O
patients O
' O
underlying O
risk O
factors O
. O

EXCERPT O
: O
WARNING O
: O
EMBRYO-FETAL O
TOXICITY O
AND O
VENOUS O
THROMBOEMBOLISM O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

EMBRYO-FETAL O
TOXICITY O
* O
If O
thalidomide O
is O
taken O
during O
pregnancy O
, O
it O
can O
cause O
severe O
birth O
defects O
or O
embryo-fetal O
death O
. O

Thalidomide O
should O
never O
be O
used O
by O
females O
who O
are O
pregnant O
or O
who O
could O
be O
pregnant O
while O
taking O
the O
drug O
. O

Even O
a O
single O
dose O
[ O
1 O
capsule O
( O
regardless O
of O
strength O
) O
] O
taken O
by O
a O
pregnant O
woman O
during O
her O
pregnancy O
can O
cause O
severe O
birth O
defects O
. O

* O
Pregnancy O
must O
be O
excluded O
before O
start O
of O
treatment O
. O

Prevent O
pregnancy O
thereafter O
by O
the O
use O
of O
two O
reliable O
methods O
of O
contraception O
. O

( O
5.1 O
, O
8.3 O
) O
THALOMID O
( O
r O
) O
( O
thalidomide O
) O
is O
only O
available O
through O
a O
restricted O
distribution O
program O
, O
the O
THALOMID O
REMS O
( O
r O
) O
program O
( O
5.2 O
) O
. O

VENOUS O
THROMBOEMBOLISM O
* O
Significant O
increased O
risk O
of O
deep O
vein O
thrombosis O
( O
DVT O
) O
and O
pulmonary O
embolism O
( O
PE O
) O
in O
patients O
with O
multiple O
myeloma O
receiving O
THALOMID O
( O
r O
) O
( O
thalidomide O
) O
with O
dexamethasone O
( O
5.3 O
) O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Ischemic O
heart O
disease O
( O
including O
myocardial O
infarction O
) O
and O
stroke O
have O
been O
observed O
in O
patients O
treated O
with O
THALOMID O
in O
combination O
with O
dexamethasone O
. O

( O
5.3 O
) O
* O
Increased O
Mortality O
: O
Observed O
in O
patients O
with O
MM O
when O
pembrolizumab O
was O
added O
to O
dexamethasone O
and O
a O
thalidomide O
analogue O
. O

( O
5.4 O
) O
* O
Drowsiness O
and O
Somnolence O
: O
Instruct O
patients O
to O
avoid O
situations O
where O
drowsiness O
may O
be O
a O
problem O
and O
not O
to O
take O
other O
medications O
that O
may O
cause O
drowsiness O
. O

( O
5.5 O
) O
* O
Peripheral O
Neuropathy O
: O
Examine O
patients O
at O
monthly O
intervals O
for O
the O
first O
3 O
months O
of O
thalidomide O
therapy O
and O
periodically O
thereafter O
for O
signs O
or O
symptoms O
of O
peripheral O
neuropathy O
. O

Consider O
electrophysiological O
testing O
, O
consisting O
of O
measurement O
of O
sensory O
nerve O
action O
potential O
( O
SNAP O
) O
amplitudes O
at O
baseline O
and O
thereafter O
every O
6 O
months O
in O
an O
effort O
to O
detect O
asymptomatic O
neuropathy O
. O

( O
5.6 O
) O
* O
Dizziness O
and O
Orthostatic O
Hypotension O
: O
Advise O
patients O
to O
sit O
upright O
for O
a O
few O
minutes O
prior O
to O
standing O
up O
from O
a O
recumbent O
position O
. O

( O
5.7 O
) O
* O
Neutropenia O
: O
Patients O
may O
require O
dose O
interruption O
and/or O
dose O
reduction O
. O

( O
5.8 O
) O
* O
Thrombocytopenia O
: O
Patients O
may O
require O
dose O
interruption O
and/or O
dose O
reduction O
. O

( O
5.9 O
) O
* O
Increased O
HIV O
Viral O
Load O
: O
Measure O
viral O
load O
after O
the O
first O
and O
third O
months O
of O
treatment O
and O
every O
3 O
months O
thereafter O
. O

( O
5.10 O
) O
* O
Bradycardia O
: O
Monitor O
patients O
for O
bradycardia O
and O
possible O
syncope O
. O

Dose O
reduction O
or O
discontinuation O
may O
be O
required O
. O

( O
5.11 O
) O
* O
Stevens-Johnson O
Syndrome O
and O
Toxic O
Epidermal O
Necrolysis O
: O
Do O
not O
resume O
THALOMID O
following O
discontinuation O
for O
these O
reactions O
. O

( O
5.12 O
) O
* O
Seizures O
: O
Monitor O
patients O
with O
a O
history O
of O
seizures O
or O
at O
risk O
for O
the O
development O
of O
seizures O
closely O
for O
clinical O
changes O
that O
could O
precipitate O
acute O
seizure O
activity O
. O

( O
5.13 O
) O
* O
Tumor O
Lysis O
Syndrome O
: O
Monitor O
patients O
at O
risk O
( O
e.g. O
, O
those O
with O
high O
tumor O
burden O
prior O
to O
treatment O
) O
and O
take O
appropriate O
precautions O
. O

( O
5.14 O
) O
* O
Hypersensitivity O
: O
Monitor O
patients O
for O
potential O
hypersensitivity O
to O
the O
drug O
and O
its O
components O
. O

( O
5.16 O
) O
5.1 O
Embryo-Fetal O
Toxicity O
Thalidomide O
is O
a O
powerful O
human B-OSE_Labeled_AE
teratogen I-OSE_Labeled_AE
that O
induces O
a O
high O
frequency O
of O
severe O
and O
life-threatening O
birth B-OSE_Labeled_AE
defects I-OSE_Labeled_AE
, O
even O
after O
a O
single O
dose O
. O

Mortality B-NonOSE_AE
at O
or O
shortly O
after O
birth O
has O
been O
reported O
in O
about O
40 O
% O
of O
infants O
. O

When O
there O
is O
no O
satisfactory O
alternative O
treatment O
, O
females O
of O
reproductive O
potential O
may O
be O
treated O
with O
thalidomide O
provided O
adequate O
precautions O
are O
taken O
to O
avoid O
pregnancy B-NonOSE_AE
. O

THALOMID O
( O
r O
) O
( O
thalidomide O
) O
is O
only O
available O
through O
the O
THALOMID O
REMS O
program O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Oral O
ingestion O
is O
the O
only O
type O
of O
maternal O
thalidomide O
exposure O
known O
to O
result O
in O
drug-associated O
birth B-OSE_Labeled_AE
defects I-OSE_Labeled_AE
. O

There O
are O
no O
specific O
data O
available O
regarding O
the O
reproductive O
risks O
of O
cutaneous O
absorption O
or O
inhalation O
of O
thalidomide O
; O
however O
, O
females O
of O
reproductive O
potential O
should O
avoid O
contact O
with O
THALOMID O
( O
r O
) O
( O
thalidomide O
) O
Capsules O
. O

THALOMID O
Capsules O
should O
be O
stored O
in O
blister O
packs O
until O
ingestion O
. O

If O
there O
is O
contact O
with O
non-intact O
thalidomide O
capsules O
or O
the O
powder O
contents O
, O
the O
exposed O
area O
should O
be O
washed O
with O
soap O
and O
water O
. O

If O
healthcare O
providers O
or O
other O
care O
givers O
are O
exposed O
to O
body O
fluids O
from O
patients O
receiving O
THALOMID O
( O
thalidomide O
) O
the O
exposed O
area O
should O
be O
washed O
with O
soap O
and O
water O
. O

Appropriate O
precautions O
should O
be O
utilized O
, O
such O
as O
wearing O
gloves O
to O
prevent O
the O
potential O
cutaneous O
exposure O
to O
THALOMID O
. O

Females O
of O
Reproductive O
Potential O
Females O
of O
reproductive O
potential O
must O
avoid O
pregnancy B-NonOSE_AE
for O
at O
least O
4 O
weeks O
before O
beginning O
THALOMID O
therapy O
, O
during O
therapy O
, O
during O
dose O
interruptions O
and O
for O
at O
least O
4 O
weeks O
after O
completing O
therapy O
. O

Females O
must O
commit O
either O
to O
abstain O
continuously O
from O
heterosexual O
sexual O
intercourse O
or O
to O
use O
two O
methods O
of O
reliable O
birth O
control O
, O
beginning O
4 O
weeks O
prior O
to O
initiating O
treatment O
with O
THALOMID O
, O
during O
therapy O
, O
during O
dose O
interruptions O
and O
continuing O
for O
4 O
weeks O
following O
discontinuation O
of O
THALOMID O
therapy O
. O

Two O
negative B-NonOSE_AE
pregnancy I-NonOSE_AE
tests I-NonOSE_AE
must O
be O
obtained O
prior O
to O
initiating O
therapy O
. O

The O
first O
test O
should O
be O
performed O
within O
10-14 O
days O
and O
the O
second O
test O
within O
24 O
hours O
prior O
to O
prescribing O
THALOMID O
therapy O
and O
then O
weekly O
during O
the O
first O
month O
, O
then O
monthly O
thereafter O
in O
females O
with O
regular O
menstrual O
cycles O
or O
every O
2 O
weeks O
in O
females O
with O
irregular B-Not_AE_Candidate
menstrual I-Not_AE_Candidate
cycles I-Not_AE_Candidate
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.3 O
) O
] O
. O

Males O
Thalidomide B-NonOSE_AE
is I-NonOSE_AE
present I-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
semen I-NonOSE_AE
of I-NonOSE_AE
patients I-NonOSE_AE
receiving I-NonOSE_AE
the I-NonOSE_AE
drug I-NonOSE_AE
. O

Therefore O
, O
males O
must O
always O
use O
a O
latex O
or O
synthetic O
condom O
during O
any O
sexual O
contact O
with O
females O
of O
reproductive O
potential O
while O
taking O
THALOMID O
and O
for O
up O
to O
4 O
weeks O
after O
discontinuing O
THALOMID O
, O
even O
if O
they O
have O
undergone O
a O
successful O
vasectomy O
. O

Male O
patients O
taking O
THALOMID O
must O
not O
donate O
sperm O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.3 O
) O
] O
. O

Blood O
Donation O
Patients O
must O
not O
donate O
blood O
during O
treatment O
with O
THALOMID O
and O
for O
4 O
weeks O
following O
discontinuation O
of O
the O
drug O
because O
the O
blood O
might O
be O
given O
to O
a O
pregnant O
female O
patient O
whose O
fetus O
must O
not O
be O
exposed O
to O
THALOMID O
. O

5.2 O
THALOMID O
REMS O
Program O
Because O
of O
the O
embryo B-NonOSE_AE
- I-NonOSE_AE
fetal I-NonOSE_AE
risk I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
, O
THALOMID O
is O
available O
only O
through O
a O
restricted O
program O
under O
a O
Risk O
Evaluation O
and O
Mitigation O
Strategy O
( O
REMS O
) O
, O
the O
THALOMID O
REMS O
program O
. O

Required O
components O
of O
the O
THALOMID O
REMS O
program O
include O
the O
following O
: O
* O
Prescribers O
must O
be O
certified O
with O
the O
THALOMID O
REMS O
program O
by O
enrolling O
and O
complying O
with O
the O
REMS O
requirements O
. O

* O
Patients O
must O
sign O
a O
Patient-Physician O
Agreement O
Form O
and O
comply O
with O
the O
REMS O
requirements O
. O

In O
particular O
, O
female O
patients O
of O
reproductive O
potential O
who O
are O
not O
pregnant B-NonOSE_AE
must O
comply O
with O
the O
pregnancy B-NonOSE_AE
testing O
and O
contraception O
requirements O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.3 O
) O
] O
and O
males O
must O
comply O
with O
contraception O
requirements O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.3 O
) O
] O
. O

* O
Pharmacies O
must O
be O
certified O
with O
the O
THALOMID O
REMS O
program O
, O
must O
only O
dispense O
to O
patients O
who O
are O
authorized O
to O
receive O
THALOMID O
and O
comply O
with O
REMS O
requirements O
. O

Further O
information O
about O
the O
THALOMID O
REMS O
program O
is O
available O
at O
www.celgeneriskmanagement.com O
or O
by O
telephone O
at O
1-888-423-5436 O
. O

5.3 O
Venous O
and O
Arterial O
Thromboembolism O
The O
use O
of O
THALOMID O
in O
patients O
with O
MM B-Not_AE_Candidate
results O
in O
an O
increased O
risk O
of O
venous B-OSE_Labeled_AE
thromboembolism I-OSE_Labeled_AE
, O
such O
as O
deep B-OSE_Labeled_AE
venous I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
and O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
. O

This O
risk O
increases O
significantly O
when O
thalidomide O
is O
used O
in O
combination O
with O
standard O
chemotherapeutic O
agents O
including O
dexamethasone O
. O

In O
one O
controlled O
trial O
, O
the O
rate O
of O
venous B-OSE_Labeled_AE
thromboembolism I-OSE_Labeled_AE
was O
22.5 O
% O
in O
patients O
receiving O
thalidomide O
in O
combination O
with O
dexamethasone O
compared O
to O
4.9 O
% O
in O
patients O
receiving O
dexamethasone O
alone O
( O
p O
= O
0.002 O
) O
. O

Ischemic B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
( O
11.1 O
% O
) O
, O
including O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
( O
1.3 O
% O
) O
, O
and O
stroke B-OSE_Labeled_AE
( O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
2.6 O
% O
) O
have O
also O
occurred O
in O
patients O
with O
previously O
untreated O
MM B-Not_AE_Candidate
treated O
with O
THALOMID O
and O
dexamethasone O
compared O
to O
placebo O
and O
dexamethasone O
( O
4.7 O
% O
, O
1.7 O
% O
, O
and O
0.9 O
% O
, O
respectively O
) O
in O
one O
clinical O
trial O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Consider O
thromboprophylaxis O
based O
on O
an O
assessment O
of O
individual O
patients O
' O
underlying O
risk O
factors O
. O

Patients O
and O
physicians O
should O
be O
observant O
for O
the O
signs O
and O
symptoms O
of O
thromboembolism B-NonOSE_AE
. O

Advise O
patients O
to O
seek O
immediate O
medical O
care O
if O
they O
develop O
symptoms O
such O
as O
shortness B-NonOSE_AE
of I-NonOSE_AE
breath I-NonOSE_AE
, O
chest B-NonOSE_AE
pain I-NonOSE_AE
, O
or O
arm B-NonOSE_AE
or O
leg O
swelling I-NonOSE_AE
[ O
see O
Boxed O
Warning O
] O
. O

Agents O
that O
also O
may O
increase O
the O
risk O
of O
thromboembolism B-NonOSE_AE
should O
be O
used O
with O
caution O
in O
patients O
receiving O
THALOMID O
[ O
see O
Drug O
Interactions O
( O
7.7 O
) O
] O
. O

5.4 O
Increased O
Mortality O
in O
Patients O
with O
MM O
When O
Pembrolizumab O
Is O
Added O
to O
a O
Thalidomide O
Analogue O
and O
Dexamethasone O
In O
two O
randomized O
clinical O
trials O
in O
patients O
with O
MM B-Not_AE_Candidate
, O
the O
addition O
of O
pembrolizumab O
to O
a O
thalidomide O
analogue O
plus O
dexamethasone O
, O
a O
use O
for O
which O
no O
PD-1 O
or O
PD-L1 O
blocking O
antibody O
is O
indicated O
, O
resulted O
in O
increased O
mortality B-NonOSE_AE
. O

Treatment O
of O
patients O
with O
MM B-Not_AE_Candidate
with O
a O
PD-1 O
or O
PD-L1 O
blocking O
antibody O
in O
combination O
with O
a O
thalidomide O
analogue O
plus O
dexamethasone O
is O
not O
recommended O
outside O
of O
controlled O
clinical O
trials O
. O

5.5 O
Drowsiness O
and O
Somnolence O
Thalidomide O
frequently O
causes O
drowsiness B-OSE_Labeled_AE
and O
somnolence B-OSE_Labeled_AE
. O

Patients O
should O
be O
instructed O
to O
avoid O
situations O
where O
drowsiness B-NonOSE_AE
may O
be O
a O
problem O
and O
not O
to O
take O
other O
medications O
that O
may O
cause O
drowsiness B-NonOSE_AE
without O
adequate O
medical O
advice O
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

Advise O
patients O
as O
to O
the O
possible O
impairment B-NonOSE_AE
of O
mental O
and/or O
physical O
abilities O
required O
for O
the O
performance O
of O
hazardous O
tasks O
, O
such O
as O
driving I-NonOSE_AE
a I-NonOSE_AE
car I-NonOSE_AE
or O
operating O
other O
complex O
or O
dangerous O
machinery O
. O

Dose O
reductions O
may O
be O
required O
. O

5.6 O
Peripheral O
Neuropathy O
Thalidomide O
is O
known O
to O
cause O
nerve B-OSE_Labeled_AE
damage I-OSE_Labeled_AE
that O
may O
be O
permanent O
. O

Peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
is O
a O
common O
( O
> O
=10 O
% O
) O
and O
potentially O
severe O
adverse O
reaction O
of O
treatment O
with O
thalidomide O
that O
may O
be O
irreversible O
. O

Peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
generally O
occurs O
following O
chronic O
use O
over O
a O
period O
of O
months O
; O
however O
, O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
following O
relatively O
short-term O
use O
has O
been O
reported O
. O

The O
correlation O
with O
cumulative O
dose O
is O
unclear O
. O

Symptoms O
may O
occur O
some O
time O
after O
thalidomide O
treatment O
has O
been O
stopped O
and O
may O
resolve O
slowly O
or O
not O
at O
all O
. O

Few O
reports O
of O
neuropathy B-OSE_Labeled_AE
have O
arisen O
in O
the O
treatment O
of O
ENL B-Not_AE_Candidate
despite O
long-term O
thalidomide O
treatment O
. O

However O
, O
the O
inability O
clinically O
to O
differentiate O
thalidomide B-NonOSE_AE
neuropathy I-NonOSE_AE
from O
the O
neuropathy B-NonOSE_AE
often O
seen O
in O
Hansen B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
makes O
it O
difficult O
to O
determine O
accurately O
the O
incidence O
of O
thalidomide B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
neuropathy I-NonOSE_AE
in O
ENL B-Not_AE_Candidate
patients O
treated O
with O
thalidomide O
. O

Patients O
should O
be O
examined O
at O
monthly O
intervals O
for O
the O
first O
3 O
months O
of O
thalidomide O
therapy O
to O
enable O
the O
clinician O
to O
detect O
early O
signs O
of O
neuropathy B-NonOSE_AE
, O
which O
include O
numbness B-NonOSE_AE
, O
tingling O
or O
pain O
in O
the O
hands I-NonOSE_AE
and O
feet O
. O

Patients O
should O
be O
evaluated O
periodically O
thereafter O
during O
treatment O
. O

Patients O
should O
be O
regularly O
counseled O
, O
questioned O
, O
and O
evaluated O
for O
signs O
or O
symptoms O
of O
peripheral B-NonOSE_AE
neuropathy I-NonOSE_AE
. O

Consideration O
should O
be O
given O
to O
electrophysiological O
testing O
, O
consisting O
of O
measurement O
of O
sensory O
nerve O
action O
potential O
( O
SNAP O
) O
amplitudes O
at O
baseline O
and O
thereafter O
every O
6 O
months O
in O
an O
effort O
to O
detect O
asymptomatic O
neuropathy O
. O

If O
symptoms O
of O
drug B-NonOSE_AE
- I-NonOSE_AE
induced I-NonOSE_AE
neuropathy I-NonOSE_AE
develop O
, O
thalidomide O
should O
be O
discontinued O
immediately O
to O
limit O
further O
damage O
, O
if O
clinically O
appropriate O
. O

Usually O
, O
treatment O
with O
thalidomide O
should O
only O
be O
reinitiated O
if O
the O
neuropathy B-NonOSE_AE
returns O
to O
baseline O
status O
. O

Medications O
known O
to O
be O
associated O
with O
neuropathy B-NonOSE_AE
should O
be O
used O
with O
caution O
in O
patients O
receiving O
thalidomide O
[ O
see O
Drug O
Interactions O
( O
7.3 O
) O
] O
. O

5.7 O
Dizziness O
and O
Orthostatic O
Hypotension O
Patients O
should O
also O
be O
advised O
that O
thalidomide O
may O
cause O
dizziness B-OSE_Labeled_AE
and O
orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
and O
that O
, O
therefore O
, O
they O
should O
sit O
upright O
for O
a O
few O
minutes O
prior O
to O
standing O
up O
from O
a O
recumbent O
position O
. O

5.8 O
Neutropenia O
Decreased B-OSE_Labeled_AE
white I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
counts I-OSE_Labeled_AE
, O
including O
neutropenia B-OSE_Labeled_AE
, O
have O
been O
reported O
in O
association O
with O
the O
clinical O
use O
of O
thalidomide O
. O

Treatment O
should O
not O
be O
initiated O
with O
an O
absolute B-Not_AE_Candidate
neutrophil I-Not_AE_Candidate
count I-Not_AE_Candidate
( I-Not_AE_Candidate
ANC I-Not_AE_Candidate
) I-Not_AE_Candidate
of I-Not_AE_Candidate
< I-Not_AE_Candidate
7 I-Not_AE_Candidate
5 I-Not_AE_Candidate
0 I-Not_AE_Candidate
/ I-Not_AE_Candidate
mm I-Not_AE_Candidate
3 I-Not_AE_Candidate
. O

White O
blood O
cell O
count O
and O
differential O
should O
be O
monitored O
on O
an O
ongoing O
basis O
, O
especially O
in O
patients O
who O
may O
be O
more O
prone O
to O
neutropenia B-Not_AE_Candidate
, O
such O
as O
patients O
who O
are O
HIV B-Not_AE_Candidate
- I-Not_AE_Candidate
seropositive I-Not_AE_Candidate
. O

If O
ANC B-NonOSE_AE
decreases I-NonOSE_AE
to I-NonOSE_AE
below I-NonOSE_AE
7 I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
/ I-NonOSE_AE
mm I-NonOSE_AE
3 I-NonOSE_AE
while O
on O
treatment O
, O
the O
patient O
's O
medication O
regimen O
should O
be O
re-evaluated O
and O
, O
if O
the O
neutropenia B-NonOSE_AE
persists O
, O
consideration O
should O
be O
given O
to O
withholding O
thalidomide O
if O
clinically O
appropriate O
. O

5.9 O
Thrombocytopenia O
Thrombocytopenia B-OSE_Labeled_AE
, O
including O
Grade O
3 O
or O
4 O
occurrences O
, O
has O
been O
reported O
in O
association O
with O
the O
clinical O
use O
of O
thalidomide O
. O

Monitor O
blood O
counts O
, O
including O
platelet O
counts O
. O

Dose O
reduction O
, O
delay O
, O
or O
discontinuation O
may O
be O
required O
. O

Monitor O
for O
signs O
and O
symptoms O
of O
bleeding B-NonOSE_AE
including O
petechiae B-NonOSE_AE
, O
epistaxis B-NonOSE_AE
, O
and O
gastrointestinal B-NonOSE_AE
bleeding I-NonOSE_AE
, O
especially O
if O
concomitant O
medication O
may O
increase O
the O
risk O
of O
bleeding B-NonOSE_AE
. O

5.10 O
Increased O
HIV O
Viral O
Load O
In O
a O
randomized O
, O
placebo-controlled O
trial O
of O
thalidomide O
in O
an O
HIV B-Not_AE_Candidate
- I-Not_AE_Candidate
seropositive I-Not_AE_Candidate
patient O
population O
, O
plasma B-OSE_Labeled_AE
HIV I-OSE_Labeled_AE
RNA I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
were O
found O
to O
increase I-OSE_Labeled_AE
( O
median O
change O
= O
0.42 O
log10copies O
HIV O
RNA/mL O
, O
p O
= O
0.04 O
compared O
to O
placebo O
) O
. O

A O
similar O
trend O
was O
observed O
in O
a O
second O
, O
unpublished O
study O
conducted O
in O
patients O
who O
were O
HIV B-Not_AE_Candidate
- I-Not_AE_Candidate
seropositive I-Not_AE_Candidate
. O

The O
clinical O
significance O
of O
this O
increase O
is O
unknown O
. O

Both O
studies O
were O
conducted O
prior O
to O
availability O
of O
highly O
active O
antiretroviral O
therapy O
. O

Until O
the O
clinical O
significance O
of O
this O
finding O
is O
further O
understood O
, O
in O
HIV B-Not_AE_Candidate
- I-Not_AE_Candidate
seropositive I-Not_AE_Candidate
patients O
, O
viral O
load O
should O
be O
measured O
after O
the O
first O
and O
third O
months O
of O
treatment O
and O
every O
3 O
months O
thereafter O
. O

5.11 O
Bradycardia O
Bradycardia B-OSE_Labeled_AE
in O
association O
with O
thalidomide O
use O
has O
been O
reported O
. O

Cases O
of O
bradycardia B-OSE_Labeled_AE
have O
been O
reported O
, O
some O
required O
medical O
interventions O
. O

The O
clinical O
significance O
and O
underlying O
etiology O
of O
the O
bradycardia B-NonOSE_AE
noted O
in O
some O
thalidomide-treated O
patients O
are O
presently O
unknown O
. O

Monitor O
patients O
for O
bradycardia B-NonOSE_AE
and O
syncope B-NonOSE_AE
. O

Dose O
reduction O
or O
discontinuation O
may O
be O
required O
. O

Medications O
known O
to O
decrease B-NonOSE_AE
heart I-NonOSE_AE
rate I-NonOSE_AE
should O
be O
used O
with O
caution O
in O
patients O
receiving O
thalidomide O
[ O
see O
Drug O
Interactions O
( O
7.2 O
) O
] O
. O

5.12 O
Stevens-Johnson O
Syndrome O
and O
Toxic O
Epidermal O
Necrolysis O
Serious O
dermatologic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
and O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
which O
may O
be O
fatal B-NonOSE_AE
, O
have O
been O
reported O
. O

THALOMID O
should O
be O
discontinued O
if O
a O
skin B-NonOSE_AE
rash I-NonOSE_AE
occurs O
and O
only O
resumed O
following O
appropriate O
clinical O
evaluation O
. O

If O
the O
rash B-NonOSE_AE
is O
exfoliative O
, O
purpuric O
, O
or O
bullous I-NonOSE_AE
or O
if O
Stevens B-NonOSE_AE
- I-NonOSE_AE
Johnson I-NonOSE_AE
syndrome I-NonOSE_AE
or O
toxic B-NonOSE_AE
epidermal I-NonOSE_AE
necrolysis I-NonOSE_AE
is O
suspected O
, O
use O
of O
THALOMID O
should O
not O
be O
resumed O
. O

5.13 O
Seizures O
Although O
not O
reported O
from O
pre-marketing O
controlled O
clinical O
trials O
, O
seizures B-OSE_Labeled_AE
, O
including O
grand B-OSE_Labeled_AE
mal I-OSE_Labeled_AE
convulsions I-OSE_Labeled_AE
, O
have O
been O
reported O
during O
post-approval O
use O
of O
THALOMID O
in O
clinical O
practice O
. O

Because O
these O
events O
are O
reported O
voluntarily O
from O
a O
population O
of O
unknown O
size O
, O
estimates O
of O
frequency O
can O
not O
be O
made O
. O

Most O
patients O
had O
disorders O
that O
may O
have O
predisposed O
them O
to O
seizure B-NonOSE_AE
activity O
, O
and O
it O
is O
not O
currently O
known O
whether O
thalidomide O
has O
any O
epileptogenic B-NonOSE_AE
influence O
. O

During O
therapy O
with O
thalidomide O
, O
patients O
with O
a O
history O
of O
seizures B-Not_AE_Candidate
or O
with O
other O
risk O
factors O
for O
the O
development O
of O
seizures B-NonOSE_AE
should O
be O
monitored O
closely O
for O
clinical O
changes O
that O
could O
precipitate O
acute O
seizure B-NonOSE_AE
activity O
. O

5.14 O
Tumor B-OSE_Labeled_AE
Lysis I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
Monitor O
patients O
at O
risk O
of O
tumor B-NonOSE_AE
lysis I-NonOSE_AE
syndrome I-NonOSE_AE
( O
e.g. O
, O
patients O
with O
high O
tumor B-Not_AE_Candidate
burden O
prior O
to O
treatment O
) O
and O
take O
appropriate O
precautions O
. O

5.15 O
Contraceptive O
Risks O
Some O
contraceptive O
methods O
may O
pose O
a O
higher O
risk O
of O
adverse O
effects O
or O
may O
be O
medically O
contraindicated O
in O
some O
patients O
treated O
with O
THALOMID O
. O

Because O
some O
patients O
may O
develop O
sudden O
, O
severe O
neutropenia B-NonOSE_AE
and/or O
thrombocytopenia B-NonOSE_AE
, O
use O
of O
an O
intrauterine O
device O
( O
IUD O
) O
or O
implantable O
contraception O
in O
these O
patients O
may O
carry O
an O
increased O
risk O
for O
infection B-NonOSE_AE
or O
bleeding B-NonOSE_AE
either O
at O
insertion O
, O
removal O
or O
during O
use O
. O

Treatment O
with O
THALOMID O
, O
the O
presence O
of O
an O
underlying O
malignancy B-Not_AE_Candidate
, O
and/or O
use O
of O
an O
estrogen-containing O
contraceptive O
can O
each O
increase O
the O
risk O
of O
thromboembolism B-OSE_Labeled_AE
. O

It O
is O
not O
known O
if O
these O
risks O
of O
thromboembolism B-NonOSE_AE
are O
additive O
. O

However O
, O
they O
should O
be O
taken O
into O
consideration O
when O
choosing O
contraceptive O
methods O
. O

5.16 O
Hypersensitivity O
Hypersensitivity B-OSE_Labeled_AE
to O
THALOMID O
has O
been O
reported O
. O

Signs O
and O
symptoms O
have O
included O
the O
occurrence O
of O
erythematous B-NonOSE_AE
macular I-NonOSE_AE
rash I-NonOSE_AE
, O
possibly O
associated O
with O
fever B-NonOSE_AE
, O
tachycardia B-NonOSE_AE
, O
and O
hypotension B-NonOSE_AE
, O
and O
if O
severe O
, O
may O
necessitate O
interruption O
of O
therapy O
. O

If O
the O
reaction O
recurs O
when O
dosing O
is O
resumed O
, O
THALOMID O
should O
be O
discontinued O
. O

ADVERSE O
REACTIONS O
TOBI O
was O
generally O
well O
tolerated O
during O
two O
clinical O
studies O
in O
258 O
cystic B-Not_AE_Candidate
fibrosis I-Not_AE_Candidate
patients O
ranging O
in O
age O
from O
6 O
to O
48 O
years O
. O

Patients O
received O
TOBI O
in O
alternating O
periods O
of O
28 O
days O
on O
and O
28 O
days O
off O
drug O
in O
addition O
to O
their O
standard O
cystic B-Not_AE_Candidate
fibrosis I-Not_AE_Candidate
therapy O
for O
a O
total O
of O
24 O
weeks O
. O

Voice B-OSE_Labeled_AE
alteration I-OSE_Labeled_AE
and O
tinnitus B-OSE_Labeled_AE
were O
the O
only O
adverse O
experiences O
reported O
by O
significantly O
more O
TOBI-treated O
patients O
. O

Thirty-three O
patients O
( O
13 O
% O
) O
treated O
with O
TOBI O
complained O
of O
voice B-OSE_Labeled_AE
alteration I-OSE_Labeled_AE
compared O
to O
17 O
( O
7 O
% O
) O
placebo O
patients O
. O

Voice B-OSE_Labeled_AE
alteration I-OSE_Labeled_AE
was O
more O
common O
in O
the O
on-drug O
periods O
. O

Eight O
patients O
from O
the O
TOBI O
group O
( O
3 O
% O
) O
reported O
tinnitus B-OSE_Labeled_AE
compared O
to O
no O
placebo O
patients O
. O

All O
episodes O
were O
transient O
, O
resolved O
without O
discontinuation O
of O
the O
TOBI O
treatment O
regimen O
, O
and O
were O
not O
associated O
with O
loss B-NonOSE_AE
of I-NonOSE_AE
hearing I-NonOSE_AE
in O
audiograms O
. O

Tinnitus B-NonOSE_AE
is O
one O
of O
the O
sentinel O
symptoms O
of O
cochlear B-NonOSE_AE
toxicity I-NonOSE_AE
, O
and O
patients O
with O
this O
symptom O
should O
be O
carefully O
monitored O
for O
high O
frequency O
hearing B-NonOSE_AE
loss I-NonOSE_AE
. O

The O
numbers O
of O
patients O
reporting O
vestibular B-NonOSE_AE
adverse I-NonOSE_AE
experiences I-NonOSE_AE
such O
as O
dizziness B-NonOSE_AE
were O
similar O
in O
the O
TOBI O
and O
placebo O
groups O
. O

Nine O
( O
3 O
% O
) O
patients O
in O
the O
TOBI O
group O
and O
nine O
( O
3 O
% O
) O
patients O
in O
the O
placebo O
group O
had O
increases B-NonOSE_AE
in I-NonOSE_AE
serum I-NonOSE_AE
creatinine I-NonOSE_AE
of O
at O
least O
50 O
% O
over O
baseline O
. O

In O
all O
nine O
patients O
in O
the O
TOBI O
group O
, O
creatinine B-NonOSE_AE
decreased I-NonOSE_AE
at O
the O
next O
visit O
. O

Table O
1 O
lists O
the O
percent O
of O
patients O
with O
treatment-emergent O
adverse O
experiences O
( O
spontaneously O
reported O
and O
solicited O
) O
that O
occurred O
in O
> O
5 O
% O
of O
TOBI O
patients O
during O
the O
two O
Phase O
III O
studies O
. O

Table O
1 O
: O
Percent O
of O
Patients O
With O
Treatment O
Emergent O
Adverse O
Experiences O
Occurring O
in O
> O
5 O
% O
of O
TOBI O
Patients O
1 O
Includes O
subjective O
complaints O
of O
fever B-NonOSE_AE
. O

2 O
Includes O
reported O
decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
pulmonary I-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
or O
decreased B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
volume I-OSE_Labeled_AE
on I-OSE_Labeled_AE
chest I-OSE_Labeled_AE
radiograph I-OSE_Labeled_AE
associated O
with O
intercurrent O
illness O
or O
study O
drug O
administration O
. O

Adverse O
Event O
TOBI O
( O
n=258 O
) O
% O
Placebo O
( O
n=262 O
) O
% O
Cough B-NonOSE_AE
Increased I-NonOSE_AE
46.1 O
47.3 O
Pharyngitis B-NonOSE_AE
38.0 O
39.3 O
Sputum B-NonOSE_AE
Increased I-NonOSE_AE
37.6 O
39.7 O
Asthenia B-NonOSE_AE
35.7 O
39.3 O
Rhinitis B-OSE_Labeled_AE
34.5 O
33.6 O
Dyspnea B-NonOSE_AE
33.7 O
38.5 O
Fever B-NonOSE_AE
1 O
32.9 O
43.5 O
Lung B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
31.4 O
31.3 O
Headache B-NonOSE_AE
26.7 O
32.1 O
Chest B-NonOSE_AE
Pain I-NonOSE_AE
26.0 O
29.8 O
Sputum B-OSE_Labeled_AE
Discoloration I-OSE_Labeled_AE
21.3 O
19.8 O
Hemoptysis B-NonOSE_AE
19.4 O
23.7 O
Anorexia B-NonOSE_AE
18.6 O
27.9 O
Lung B-OSE_Labeled_AE
Function I-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
2 O
16.3 O
15.3 O
Asthma B-NonOSE_AE
15.9 O
20.2 O
Vomiting B-NonOSE_AE
14.0 O
22.1 O
Abdominal B-NonOSE_AE
Pain I-NonOSE_AE
12.8 O
23.7 O
Voice B-OSE_Labeled_AE
Alteration I-OSE_Labeled_AE
12.8 O
6.5 O
Nausea B-NonOSE_AE
11.2 O
16.0 O
Weight B-NonOSE_AE
Loss I-NonOSE_AE
10.1 O
15.3 O
Pain B-NonOSE_AE
8.1 O
12.6 O
Sinusitis B-NonOSE_AE
8.1 O
9.2 O
Ear B-NonOSE_AE
Pain I-NonOSE_AE
7.4 O
8.8 O
Back B-NonOSE_AE
Pain I-NonOSE_AE
7.0 O
8.0 O
Epistaxis B-OSE_Labeled_AE
7.0 O
6.5 O
Taste B-NonOSE_AE
Perversion I-NonOSE_AE
6.6 O
6.9 O
Diarrhea B-NonOSE_AE
6.2 O
10.3 O
Malaise B-OSE_Labeled_AE
6.2 O
5.3 O
Lower B-NonOSE_AE
Respiratory I-NonOSE_AE
Tract I-NonOSE_AE
Infection I-NonOSE_AE
5.8 O
8.0 O
Dizziness B-NonOSE_AE
5.8 O
7.6 O
Hyperventilation B-NonOSE_AE
5.4 O
9.9 O
Rash B-NonOSE_AE
5.4 O
6.1 O
Adverse O
drug O
reactions O
( O
< O
5 O
% O
) O
occurring O
more O
frequently O
with O
TOBI O
in O
the O
placebo-controlled O
studies O
and O
assessed O
as O
drug-related O
in O
> O
=1 O
% O
of O
patients O
: O
Ear B-NonOSE_AE
and I-NonOSE_AE
labyrinth I-NonOSE_AE
disorders I-NonOSE_AE
Tinnitus B-OSE_Labeled_AE
( O
3.1 O
% O
, O
vs O
0 O
% O
for O
placebo O
) O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Myalgia B-OSE_Labeled_AE
( O
4.7 O
% O
, O
vs O
2.7 O
% O
for O
placebo O
) O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Laryngitis B-OSE_Labeled_AE
( O
4.3 O
% O
, O
vs O
3.1 O
% O
for O
placebo O
) O
Adverse O
drug O
reactions O
derived O
from O
spontaneous O
reports O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
postapproval O
use O
of O
TOBI O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Ear B-NonOSE_AE
and I-NonOSE_AE
labyrinth I-NonOSE_AE
disorders I-NonOSE_AE
Hearing B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
( O
see O
WARNINGS O
- O
Ototoxicity O
) O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Hypersensitivity B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Aphonia B-OSE_Labeled_AE
, O
dysgeusia B-OSE_Labeled_AE
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Bronchospasm B-OSE_Labeled_AE
( O
see O
WARNINGS O
- O
Bronchospasm B-OSE_Labeled_AE
) O
, O
oropharyngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE

PRECAUTIONS O
Information O
for O
Patients O
NOTE O
: O
In O
addition O
to O
information O
provided O
below O
, O
a O
Patient O
Medication O
Guide O
providing O
instructions O
for O
proper O
use O
of O
TOBI O
is O
contained O
inside O
the O
package O
. O

Safety O
Information O
TOBI O
is O
in O
a O
class O
of O
antibiotics O
that O
have O
caused O
hearing B-NonOSE_AE
loss I-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
kidney B-NonOSE_AE
damage I-NonOSE_AE
, O
and O
harm B-NonOSE_AE
to I-NonOSE_AE
a I-NonOSE_AE
fetus I-NonOSE_AE
. O

Ringing B-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
ears I-NonOSE_AE
and O
hoarseness B-NonOSE_AE
were O
two O
symptoms O
that O
were O
seen O
in O
more O
patients O
taking O
TOBI O
than O
placebo O
in O
research O
studies O
. O

Patients O
with O
cystic B-Not_AE_Candidate
fibrosis I-Not_AE_Candidate
can O
have O
many O
symptoms O
. O

Some O
of O
these O
symptoms O
may O
be O
related O
to O
your O
medications O
. O

If O
you O
have O
new O
or O
worsening O
symptoms O
, O
you O
should O
tell O
your O
doctor O
. O

Hearing B-NonOSE_AE
: O
You O
should O
tell O
your O
doctor O
if O
you O
have O
ringing B-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
ears I-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
or O
any O
changes B-NonOSE_AE
in I-NonOSE_AE
hearing I-NonOSE_AE
. O

Kidney B-NonOSE_AE
Damage I-NonOSE_AE
: O
Inform O
your O
doctor O
if O
you O
have O
any O
history O
of O
kidney B-Not_AE_Candidate
problems I-Not_AE_Candidate
. O

Pregnancy B-NonOSE_AE
: O
If O
you O
want O
to O
become O
pregnant B-NonOSE_AE
or O
are O
pregnant B-NonOSE_AE
while O
on O
TOBI O
, O
you O
should O
talk O
with O
your O
doctor O
about O
the O
possibility O
of O
TOBI O
causing O
any O
harm O
. O

Nursing O
Mothers O
: O
If O
you O
are O
nursing O
a O
baby O
, O
you O
should O
talk O
with O
your O
doctor O
before O
using O
TOBI O
. O

TOBI O
Packaging O
TOBI O
comes O
in O
a O
single O
dose O
, O
ready-to-use O
ampule O
containing O
300 O
mg O
tobramycin O
. O

Each O
foil O
pouch O
contains O
4 O
ampules O
, O
for O
2 O
days O
of O
TOBI O
therapy O
. O

Dosage O
The O
300 O
mg O
dose O
of O
TOBI O
is O
the O
same O
for O
patients O
regardless O
of O
age O
or O
weight O
. O

TOBI O
has O
not O
been O
studied O
in O
patients O
less O
than O
6 O
years O
old O
. O

Doses O
should O
be O
inhaled O
as O
close O
to O
12 O
hours O
apart O
as O
possible O
and O
not O
less O
than O
6 O
hours O
apart O
. O

You O
should O
not O
mix O
TOBI O
with O
dornase O
alfa O
( O
PULMOZYME O
( O
r O
) O
, O
Genentech O
) O
in O
the O
nebulizer O
. O

If O
you O
are O
taking O
several O
medications O
the O
recommended O
order O
is O
as O
follows O
: O
bronchodilator O
first O
, O
followed O
by O
chest O
physiotherapy O
, O
then O
other O
inhaled O
medications O
and O
, O
finally O
, O
TOBI O
. O

Treatment O
Schedule O
You O
should O
take O
TOBI O
in O
repeated O
cycles O
of O
28 O
days O
on O
drug O
followed O
by O
28 O
days O
off O
drug O
. O

You O
should O
take O
TOBI O
twice O
a O
day O
during O
the O
28-day O
period O
on O
drug O
. O

How O
To O
Administer O
TOBI O
THIS O
INFORMATION O
IS O
NOT O
INTENDED O
TO O
REPLACE O
CONSULTATION O
WITH O
YOUR O
PHYSICIAN O
AND O
CF O
CARE O
TEAM O
ABOUT O
PROPERLY O
TAKING O
MEDICATION O
OR O
USING O
INHALATION O
EQUIPMENT O
. O

TOBI O
is O
specifically O
formulated O
for O
inhalation O
using O
a O
PARI O
LC O
PLUSTM O
Reusable O
Nebulizer O
and O
a O
DeVilbiss O
( O
r O
) O
Pulmo-Aide O
( O
r O
) O
air O
compressor O
. O

TOBI O
can O
be O
taken O
at O
home O
, O
school O
, O
or O
at O
work O
. O

The O
following O
are O
instructions O
on O
how O
to O
use O
the O
DeVilbiss O
Pulmo-Aide O
air O
compressor O
and O
PARI O
LC O
PLUS O
Reusable O
Nebulizer O
to O
administer O
TOBI O
. O

You O
will O
need O
the O
following O
supplies O
: O
* O
TOBI O
plastic O
ampule O
( O
vial O
) O
* O
DeVilbiss O
Pulmo-Aide O
air O
compressor O
* O
PARI O
LC O
PLUS O
Reusable O
Nebulizer O
* O
Tubing O
to O
connect O
the O
nebulizer O
and O
compressor O
* O
Clean O
paper O
or O
cloth O
towels O
* O
Nose O
clips O
( O
optional O
) O
It O
is O
important O
that O
your O
nebulizer O
and O
compressor O
function O
properly O
before O
starting O
your O
TOBI O
therapy O
. O

Note O
: O
Please O
refer O
to O
the O
manufacturers O
' O
care O
and O
use O
instructions O
for O
important O
information O
. O

Preparing O
Your O
TOBI O
for O
Inhalation O
1 O
. O

Wash O
your O
hands O
thoroughly O
with O
soap O
and O
water O
. O

2a O
. O

TOBI O
is O
packaged O
with O
4 O
ampules O
per O
foil O
pouch O
. O

2b O
. O

Separate O
one O
ampule O
by O
gently O
pulling O
apart O
at O
the O
bottom O
tabs O
. O

Store O
all O
remaining O
ampules O
in O
the O
refrigerator O
as O
directed O
. O

3 O
. O

Lay O
out O
the O
contents O
of O
a O
PARI O
LC O
PLUS O
Reusable O
Nebulizer O
package O
on O
a O
clean O
, O
dry O
paper O
or O
cloth O
towel O
. O

You O
should O
have O
the O
following O
parts O
: O
* O
Nebulizer O
Top O
and O
Bottom O
( O
Nebulizer O
Cup O
) O
Assembly O
* O
Inspiratory O
Valve O
Cap O
* O
Mouthpiece O
with O
Valve O
* O
Tubing O
4 O
. O

Remove O
the O
Nebulizer O
Top O
from O
the O
Nebulizer O
Cup O
by O
twisting O
the O
Nebulizer O
Top O
counter-clockwise O
, O
and O
then O
lifting O
off O
. O

Place O
the O
Nebulizer O
Top O
on O
the O
clean O
paper O
or O
cloth O
towel O
. O

Stand O
the O
Nebulizer O
Cup O
upright O
on O
the O
towel O
. O

5 O
. O

Connect O
one O
end O
of O
the O
tubing O
to O
the O
compressor O
air O
outlet O
. O

The O
tubing O
should O
fit O
snugly O
. O

Plug O
in O
your O
compressor O
to O
an O
electrical O
outlet O
. O

6 O
. O

Open O
the O
TOBI O
ampule O
by O
holding O
the O
bottom O
tab O
with O
one O
hand O
and O
twisting O
off O
the O
top O
of O
the O
ampule O
with O
the O
other O
hand O
. O

Be O
careful O
not O
to O
squeeze O
the O
ampule O
until O
you O
are O
ready O
to O
empty O
its O
contents O
into O
the O
Nebulizer O
Cup O
. O

7 O
. O

Squeeze O
all O
the O
contents O
of O
the O
ampule O
into O
the O
Nebulizer O
Cup O
. O

8 O
. O

Replace O
the O
Nebulizer O
Top O
. O

Note O
: O
In O
order O
to O
insert O
the O
Nebulizer O
Top O
into O
the O
Nebulizer O
Cup O
, O
the O
semi-circle O
halfway O
down O
the O
stem O
of O
the O
Nebulizer O
Top O
should O
face O
the O
Nebulizer O
Outlet O
. O

9 O
. O

Attach O
the O
Mouthpiece O
to O
the O
Nebulizer O
Outlet O
. O

Then O
firmly O
push O
the O
Inspiratory O
Valve O
Cap O
in O
place O
on O
the O
Nebulizer O
Top O
. O

Note O
: O
The O
Inspiratory O
Valve O
Cap O
will O
fit O
snugly O
. O

10 O
. O

Connect O
the O
free O
end O
of O
the O
tubing O
from O
the O
compressor O
to O
the O
Air O
Intake O
on O
the O
bottom O
of O
the O
nebulizer O
, O
making O
sure O
to O
keep O
the O
nebulizer O
upright O
. O

Press O
the O
tubing O
on O
the O
Air O
Intake O
firmly O
. O

TOBI O
Treatment O
1 O
. O

Turn O
on O
the O
compressor O
. O

2 O
. O

Check O
for O
a O
steady O
mist O
from O
the O
Mouthpiece O
. O

If O
there O
is O
no O
mist O
, O
check O
all O
tubing O
connections O
and O
confirm O
that O
the O
compressor O
is O
working O
properly O
. O

3 O
. O

Sit O
or O
stand O
in O
an O
upright O
position O
that O
will O
allow O
you O
to O
breathe O
normally O
. O

4 O
. O

Place O
Mouthpiece O
between O
your O
teeth O
and O
on O
top O
of O
your O
tongue O
and O
breathe O
normally O
only O
through O
your O
mouth O
. O

Nose O
clips O
may O
help O
you O
breathe O
through O
your O
mouth O
and O
not O
through O
your O
nose O
. O

Do O
not O
block O
airflow O
with O
your O
tongue O
. O

5 O
. O

Continue O
treatment O
until O
all O
your O
TOBI O
is O
gone O
, O
and O
there O
is O
no O
longer O
any O
mist O
being O
produced O
. O

You O
may O
hear O
a O
sputtering O
sound O
when O
the O
Nebulizer O
Cup O
is O
empty O
. O

The O
entire O
TOBI O
treatment O
should O
take O
approximately O
15 O
minutes O
to O
complete O
. O

Note O
: O
If O
you O
are O
interrupted O
, O
need O
to O
cough O
or O
rest O
during O
your O
TOBI O
treatment O
, O
turn O
off O
the O
compressor O
to O
save O
your O
medication O
. O

Turn O
the O
compressor O
back O
on O
when O
you O
are O
ready O
to O
resume O
your O
therapy O
. O

6 O
. O

Follow O
the O
nebulizer O
cleaning O
and O
disinfecting O
instructions O
after O
completing O
therapy O
. O

Cleaning O
Your O
Nebulizer O
To O
reduce O
the O
risk O
of O
infection O
, O
illness O
or O
injury O
from O
contamination O
, O
you O
must O
thoroughly O
clean O
all O
parts O
of O
the O
nebulizer O
as O
instructed O
after O
each O
treatment O
. O

Never O
use O
a O
nebulizer O
with O
a O
clogged O
nozzle O
. O

If O
the O
nozzle O
is O
clogged O
, O
no O
aerosol O
mist O
is O
produced O
, O
which O
will O
alter O
the O
effectiveness O
of O
the O
treatment O
. O

Replace O
the O
nebulizer O
if O
clogging O
occurs O
. O

1 O
. O

Remove O
tubing O
from O
nebulizer O
and O
disassemble O
nebulizer O
parts O
. O

2 O
. O

Wash O
all O
parts O
( O
except O
tubing O
) O
with O
warm O
water O
and O
liquid O
dish O
soap O
. O

3 O
. O

Rinse O
thoroughly O
with O
warm O
water O
and O
shake O
out O
water O
. O

4 O
. O

Air O
dry O
or O
hand O
dry O
nebulizer O
parts O
on O
a O
clean O
, O
lint-free O
cloth O
. O

Reassemble O
nebulizer O
when O
dry O
, O
and O
store O
. O

5 O
. O

You O
can O
also O
wash O
all O
parts O
of O
the O
nebulizer O
in O
a O
dishwasher O
( O
except O
tubing O
) O
. O

Place O
the O
nebulizer O
parts O
in O
a O
dishwasher O
basket O
, O
then O
place O
on O
the O
top O
rack O
of O
the O
dishwasher O
. O

Remove O
and O
dry O
the O
parts O
when O
the O
cycle O
is O
complete O
. O

Disinfecting O
Your O
Nebulizer O
Your O
nebulizer O
is O
for O
your O
use O
only O
- O
Do O
not O
share O
your O
nebulizer O
with O
other O
people O
. O

You O
must O
regularly O
disinfect O
the O
nebulizer O
. O

Failure O
to O
do O
so O
could O
lead O
to O
serious O
or O
fatal B-NonOSE_AE
illness O
. O

Clean O
the O
nebulizer O
as O
described O
above O
. O

Every O
other O
treatment O
day O
, O
disinfect O
the O
nebulizer O
parts O
( O
except O
tubing O
) O
by O
boiling O
them O
in O
water O
for O
a O
full O
10 O
minutes O
. O

Dry O
parts O
on O
a O
clean O
, O
lint-free O
cloth O
. O

Care O
and O
Use O
of O
Your O
Pulmo-Aide O
Compressor O
Follow O
the O
manufacturer O
's O
instructions O
for O
care O
and O
use O
of O
your O
compressor O
. O

Filter O
Change O
: O
1 O
. O

DeVilbiss O
Compressor O
filters O
should O
be O
changed O
every O
six O
months O
or O
sooner O
if O
filter O
turns O
completely O
gray O
in O
color O
. O

Compressor O
Cleaning O
: O
1 O
. O

With O
power O
switch O
in O
the O
`` O
Off O
'' O
position O
, O
unplug O
power O
cord O
from O
wall O
outlet O
. O

2 O
. O

Wipe O
outside O
of O
the O
compressor O
cabinet O
with O
a O
clean O
, O
damp O
cloth O
every O
few O
days O
to O
keep O
dust O
free O
. O

Caution O
: O
Do O
not O
submerge O
in O
water O
; O
doing O
so O
will O
result O
in O
compressor O
damage O
. O

Storage O
Instructions O
You O
should O
store O
TOBI O
ampules O
in O
a O
refrigerator O
( O
2 O
degrees O
C-8 O
degrees O
C O
or O
36 O
degrees O
F O
-46 O
degrees O
F O
) O
. O

However O
, O
when O
you O
do O
n't O
have O
a O
refrigerator O
available O
( O
e.g. O
, O
transporting O
your O
TOBI O
) O
, O
you O
may O
store O
the O
foil O
pouches O
( O
opened O
or O
unopened O
) O
at O
room O
temperature O
( O
up O
to O
25 O
degrees O
C/77 O
degrees O
F O
) O
for O
up O
to O
28 O
days O
. O

Avoid O
exposing O
TOBI O
ampules O
to O
intense O
light O
. O

Unrefrigerated O
TOBI O
, O
which O
is O
normally O
slightly O
yellow O
, O
may O
darken O
with O
age O
; O
however O
, O
the O
color O
change O
does O
not O
indicate O
any O
change O
in O
the O
quality O
of O
the O
product O
. O

You O
should O
not O
use O
TOBI O
if O
it O
is O
cloudy O
, O
if O
there O
are O
particles O
in O
the O
solution O
, O
or O
if O
it O
has O
been O
stored O
at O
room O
temperature O
for O
more O
than O
28 O
days O
. O

You O
should O
not O
use O
TOBI O
beyond O
the O
expiration O
date O
stamped O
on O
the O
ampule O
. O

Additional O
Information O
Nebulizer O
: O
1-800-327-8632 O
Compressor O
: O
1-800-338-1988 O
TOBI O
: O
1-888-NOW-NOVA O
( O
1-888-669-6682 O
) O
Laboratory O
Tests O
Audiograms O
Clinical O
studies O
of O
TOBI O
did O
not O
identify O
hearing B-NonOSE_AE
loss I-NonOSE_AE
using O
audiometric O
tests O
which O
evaluated O
hearing O
up O
to O
8000 O
Hz O
. O

Physicians O
should O
consider O
an O
audiogram O
for O
patients O
who O
show O
any O
evidence O
of O
auditory B-NonOSE_AE
dysfunction I-NonOSE_AE
, O
or O
who O
are O
at O
increased O
risk O
for O
auditory B-NonOSE_AE
dysfunction I-NonOSE_AE
. O

Tinnitus B-NonOSE_AE
may O
be O
a O
sentinel O
symptom O
of O
ototoxicity B-NonOSE_AE
, O
and O
therefore O
the O
onset O
of O
this O
symptom O
warrants O
caution O
. O

Serum O
Concentrations O
In O
patients O
with O
normal O
renal O
function O
treated O
with O
TOBI O
, O
serum O
tobramycin O
concentrations O
are O
approximately O
1 O
mcg/mL O
1 O
hour O
after O
dose O
administration O
and O
do O
not O
require O
routine O
monitoring O
. O

Serum O
concentrations O
of O
tobramycin O
in O
patients O
with O
renal B-Not_AE_Candidate
dysfunction I-Not_AE_Candidate
or O
patients O
treated O
with O
concomitant O
parenteral O
tobramycin O
should O
be O
monitored O
at O
the O
discretion O
of O
the O
treating O
physician O
. O

The O
serum O
concentration O
of O
tobramycin O
should O
only O
be O
monitored O
through O
venipuncture O
and O
not O
finger O
prick O
blood O
sampling O
. O

Contamination O
of O
the O
skin O
of O
the O
fingers O
with O
tobramycin O
may O
lead O
to O
falsely O
increased O
measurements O
of O
serum O
levels O
of O
the O
drug O
. O

This O
contamination O
can O
not O
be O
completely O
avoided O
by O
hand O
washing O
before O
testing O
. O

Renal O
Function O
The O
clinical O
studies O
of O
TOBI O
did O
not O
reveal O
any O
imbalance O
in O
the O
percentage O
of O
patients O
in O
the O
TOBI O
and O
placebo O
groups O
who O
experienced O
at O
least O
a O
50 O
% O
rise B-NonOSE_AE
in I-NonOSE_AE
serum I-NonOSE_AE
creatinine I-NonOSE_AE
from O
baseline O
( O
see O
ADVERSE O
REACTIONS O
) O
. O

Laboratory O
tests O
of O
urine O
and O
renal O
function O
should O
be O
conducted O
at O
the O
discretion O
of O
the O
treating O
physician O
. O

Drug O
Interactions O
In O
clinical O
studies O
of O
TOBI O
, O
patients O
taking O
TOBI O
concomitantly O
with O
dornase O
alfa O
( O
PULMOZYME O
, O
Genentech O
) O
, O
beta-agonists O
, O
inhaled O
corticosteroids O
, O
other O
anti-pseudomonal O
antibiotics O
, O
or O
parenteral O
aminoglycosides O
demonstrated O
adverse O
experience O
profiles O
similar O
to O
the O
study O
population O
as O
a O
whole O
. O

Concurrent O
and/or O
sequential O
use O
of O
TOBI O
with O
other O
drugs O
with O
neurotoxic B-NonOSE_AE
, O
nephrotoxic B-NonOSE_AE
, O
or O
ototoxic B-NonOSE_AE
potential O
should O
be O
avoided O
. O

Some O
diuretics O
can O
enhance O
aminoglycoside O
toxicity O
by O
altering O
antibiotic O
concentrations O
in O
serum O
and O
tissue O
. O

TOBI O
should O
not O
be O
administered O
concomitantly O
with O
ethacrynic O
acid O
, O
furosemide O
, O
urea O
, O
or O
intravenous O
mannitol O
. O

The O
interaction O
between O
inhaled O
mannitol O
and O
TOBI O
has O
not O
been O
evaluated O
. O

Carcinogenesis O
, O
Mutagenesis O
, O
Impairment O
of O
Fertility O
A O
two-year O
rat O
inhalation O
toxicology O
study O
to O
assess O
carcinogenic B-NonOSE_AE
potential O
of O
TOBI O
has O
been O
completed O
. O

Rats O
were O
exposed O
to O
TOBI O
for O
up O
to O
1.5 O
hours O
per O
day O
for O
95 O
weeks O
. O

The O
clinical O
formulation O
of O
the O
drug O
was O
used O
for O
this O
carcinogenicity O
study O
. O

Serum O
levels O
of O
tobramycin O
of O
up O
to O
35 O
mcg/mL O
were O
measured O
in O
rats O
, O
in O
contrast O
to O
the O
average O
1 O
mcg/mL O
levels O
observed O
in O
cystic B-Not_AE_Candidate
fibrosis I-Not_AE_Candidate
patients O
in O
clinical O
trials O
. O

There O
was O
no O
drug-related O
increase O
in O
the O
incidence O
of O
any O
variety O
of O
tumor B-NonOSE_AE
. O

Additionally O
, O
TOBI O
has O
been O
evaluated O
for O
genotoxicity B-NonOSE_AE
in O
a O
battery O
of O
in O
vitro O
and O
in O
vivo O
tests O
. O

The O
Ames O
bacterial O
reversion O
test O
, O
conducted O
with O
5 O
tester O
strains O
, O
failed O
to O
show O
a O
significant O
increase B-NonOSE_AE
in I-NonOSE_AE
revertants I-NonOSE_AE
with O
or O
without O
metabolic O
activation O
in O
all O
strains O
. O

Tobramycin O
was O
negative O
in O
the O
mouse O
lymphoma B-NonOSE_AE
forward O
mutation O
assay O
, O
did O
not O
induce O
chromosomal B-NonOSE_AE
aberrations I-NonOSE_AE
in O
Chinese O
hamster O
ovary O
cells O
, O
and O
was O
negative O
in O
the O
mouse O
micronucleus O
test O
. O

Subcutaneous O
administration O
of O
up O
to O
100 O
mg/kg O
of O
tobramycin O
did O
not O
affect O
mating B-NonOSE_AE
behavior I-NonOSE_AE
or O
cause O
impairment B-NonOSE_AE
of I-NonOSE_AE
fertility I-NonOSE_AE
in O
male O
or O
female O
rats O
. O

Pregnancy O
Teratogenic O
Effects O
- O
Pregnancy O
Category O
D O
( O
See O
WARNINGS O
) O
No O
reproduction O
toxicology O
studies O
have O
been O
conducted O
with O
TOBI O
. O

However O
, O
subcutaneous O
administration O
of O
tobramycin O
at O
doses O
of O
100 O
or O
20 O
mg/kg/day O
during O
organogenesis O
was O
not O
teratogenic B-NonOSE_AE
in O
rats O
or O
rabbits O
, O
respectively O
. O

Doses O
of O
tobramycin O
> O
=40 O
mg/kg/day O
were O
severely O
maternally B-NonOSE_AE
toxic I-NonOSE_AE
to O
rabbits O
and O
precluded O
the O
evaluation O
of O
teratogenicity B-NonOSE_AE
. O

Aminoglycosides O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
( O
e.g. O
, O
congenital B-OSE_Labeled_AE
deafness I-OSE_Labeled_AE
) O
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
. O

Ototoxicity B-NonOSE_AE
was O
not O
evaluated O
in O
offspring O
during O
nonclinical O
reproduction B-NonOSE_AE
toxicity I-NonOSE_AE
studies O
with O
tobramycin O
. O

If O
TOBI O
is O
used O
during O
pregnancy B-NonOSE_AE
, O
or O
if O
the O
patient O
becomes O
pregnant B-NonOSE_AE
while O
taking O
TOBI O
, O
the O
patient O
should O
be O
apprised O
of O
the O
potential O
hazard B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

Nursing O
Mothers O
It O
is O
not O
known O
if O
TOBI O
will O
reach O
sufficient O
concentrations O
after O
administration O
by O
inhalation O
to O
be O
excreted O
in O
human O
breast O
milk O
. O

Because O
of O
the O
potential O
for O
ototoxicity B-NonOSE_AE
and O
nephrotoxicity B-NonOSE_AE
in O
infants O
, O
a O
decision O
should O
be O
made O
whether O
to O
terminate O
nursing O
or O
discontinue O
TOBI O
. O

Pediatric O
Use O
The O
safety O
and O
efficacy O
of O
TOBI O
have O
not O
been O
studied O
in O
pediatric O
patients O
under O
6 O
years O
of O
age O
. O

Geriatric O
Use O
Clinical O
studies O
of O
TOBI O
did O
not O
include O
patients O
aged O
65 O
years O
and O
over O
. O

Tobramycin O
is O
known O
to O
be O
substantially O
excreted O
by O
the O
kidney O
, O
and O
the O
risk O
of O
adverse O
reactions O
to O
this O
drug O
may O
be O
greater O
in O
patients O
with O
impaired B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
. O

Because O
elderly O
patients O
are O
more O
likely O
to O
have O
decreased B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
, O
it O
may O
be O
useful O
to O
monitor O
renal O
function O
( O
see O
WARNINGS O
- O
Nephrotoxicity O
; O
PRECAUTIONS O
- O
Serum O
Concentrations O
) O
. O

WARNINGS O
Caution O
should O
be O
exercised O
when O
prescribing O
TOBI O
to O
patients O
with O
known O
or O
suspected O
renal B-Not_AE_Candidate
, O
auditory O
, O
vestibular O
, O
or O
neuromuscular O
dysfunction I-Not_AE_Candidate
. O

Patients O
receiving O
concomitant O
parenteral O
aminoglycoside O
therapy O
should O
be O
monitored O
as O
clinically O
appropriate O
. O

Aminoglycosides O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
. O

Aminoglycosides O
cross O
the O
placenta O
, O
and O
streptomycin O
has O
been O
associated O
with O
several O
reports O
of O
total O
, O
irreversible O
, O
bilateral O
congenital B-OSE_Labeled_AE
deafness I-OSE_Labeled_AE
in O
pediatric O
patients B-OSE_Labeled_AE
exposed I-OSE_Labeled_AE
in I-OSE_Labeled_AE
utero I-OSE_Labeled_AE
. O

Patients O
who O
use O
TOBI O
during O
pregnancy B-NonOSE_AE
, O
or O
become O
pregnant B-NonOSE_AE
while O
taking O
TOBI O
should O
be O
apprised O
of O
the O
potential O
hazard B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

Ototoxicity O
Ototoxicity B-NonOSE_AE
, O
as O
measured O
by O
complaints O
of O
hearing B-NonOSE_AE
loss I-NonOSE_AE
or O
by O
audiometric O
evaluations O
, O
did O
not O
occur O
with O
TOBI O
therapy O
during O
clinical O
studies O
. O

However O
, O
transient O
tinnitus B-OSE_Labeled_AE
occurred O
in O
eight O
TOBI-treated O
patients O
versus O
no O
placebo O
patients O
in O
the O
clinical O
studies O
. O

Tinnitus B-NonOSE_AE
may O
be O
a O
sentinel O
symptom O
of O
ototoxicity B-NonOSE_AE
, O
and O
therefore O
the O
onset O
of O
this O
symptom O
warrants O
caution O
( O
see O
ADVERSE O
REACTIONS O
) O
. O

Ototoxicity B-OSE_Labeled_AE
, O
manifested O
as O
both O
auditory B-OSE_Labeled_AE
and O
vestibular O
toxicity I-OSE_Labeled_AE
, O
has O
been O
reported O
with O
parenteral O
aminoglycosides O
. O

Vestibular B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
may O
be O
manifested O
by O
vertigo B-NonOSE_AE
, O
ataxia B-NonOSE_AE
or O
dizziness B-NonOSE_AE
. O

In O
postmarketing O
experience O
, O
patients O
receiving O
TOBI O
have O
reported O
hearing B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
. O

Some O
of O
these O
reports O
occurred O
in O
patients O
with O
previous O
or O
concomitant O
treatment O
with O
systemic O
aminoglycosides O
. O

Patients O
with O
hearing B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
frequently O
reported O
tinnitus B-OSE_Labeled_AE
. O

Nephrotoxicity O
Nephrotoxicity B-OSE_Labeled_AE
was O
not O
seen O
during O
TOBI O
clinical O
studies O
but O
has O
been O
associated O
with O
aminoglycosides O
as O
a O
class O
. O

If O
nephrotoxicity B-NonOSE_AE
occurs O
in O
a O
patient O
receiving O
TOBI O
, O
tobramycin O
therapy O
should O
be O
discontinued O
until O
serum O
concentrations O
fall O
below O
2 O
mcg/mL O
. O

Muscular O
Disorders O
TOBI O
should O
be O
used O
cautiously O
in O
patients O
with O
neuromuscular B-Not_AE_Candidate
disorders I-Not_AE_Candidate
, O
such O
as O
myasthenia B-Not_AE_Candidate
gravis I-Not_AE_Candidate
or O
Parkinson B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
since O
aminoglycosides O
may O
aggravate B-OSE_Labeled_AE
muscle I-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
because O
of O
a O
potential O
curare-like O
effect O
on O
neuromuscular O
function O
. O

Bronchospasm O
Bronchospasm B-OSE_Labeled_AE
has O
been O
reported O
with O
inhalation O
of O
TOBI O
. O

In O
clinical O
studies O
of O
TOBI O
, O
changes B-NonOSE_AE
in I-NonOSE_AE
FEV I-NonOSE_AE
1 I-NonOSE_AE
measured O
after O
the O
inhaled O
dose O
were O
similar O
in O
the O
TOBI O
and O
placebo O
groups O
. O

Bronchospasm B-NonOSE_AE
should O
be O
treated O
as O
medically O
appropriate O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
described O
below O
or O
elsewhere O
in O
the O
prescribing O
information O
: O
* O
Risk O
of O
Thyroid B-NonOSE_AE
C I-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
Tumors I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Pancreatitis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Use O
with O
Medications O
Known O
to O
Cause O
Hypoglycemia B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Renal B-OSE_Labeled_AE
Impairment I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Hypersensitivity B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
The O
most O
common O
adverse O
reactions O
, O
reported O
in O
> O
=5 O
% O
of O
patients O
treated O
with O
VICTOZA O
are O
: O
nausea B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
( O
6.1 O
) O
. O

* O
Immunogenicity B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
including O
urticaria B-OSE_Labeled_AE
, O
were O
more O
common O
among O
VICTOZA-treated O
patients O
( O
0.8 O
% O
) O
than O
among O
comparator-treated O
patients O
( O
0.4 O
% O
) O
in O
clinical O
trials O
( O
6.2 O
) O
. O

EXCERPT O
: O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Novo O
Nordisk O
Inc O
. O
at O
1-877-484-2869 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Common O
Adverse O
Reactions O
The O
data O
in O
Table O
1 O
are O
derived O
from O
5 O
glycemic O
control O
, O
placebo-controlled O
trials O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

These O
data O
reflect O
exposure O
of O
1673 O
patients O
to O
VICTOZA O
and O
a O
mean O
duration O
of O
exposure O
to O
VICTOZA O
of O
37.3 O
weeks O
. O

The O
mean O
age O
of O
patients O
was O
58 O
years O
, O
4 O
% O
were O
75 O
years O
or O
older O
and O
54 O
% O
were O
male O
. O

The O
population O
was O
79 O
% O
White O
, O
6 O
% O
Black O
or O
African O
American O
, O
13 O
% O
Asian O
; O
4 O
% O
were O
of O
Hispanic O
or O
Latino O
ethnicity O
. O

At O
baseline O
the O
population O
had O
diabetes B-Not_AE_Candidate
for O
an O
average O
of O
9.1 O
years O
and O
a O
mean O
HbA1cof O
8.4 O
% O
. O

Baseline O
estimated O
renal B-Not_AE_Candidate
function I-Not_AE_Candidate
was O
normal O
or O
mildly I-Not_AE_Candidate
impaired I-Not_AE_Candidate
in O
88.1 O
% O
and O
moderately O
impaired O
in O
11.9 O
% O
of O
the O
pooled O
population O
. O

Table O
1 O
shows O
common O
adverse O
reactions O
, O
excluding O
hypoglycemia B-NonOSE_AE
, O
associated O
with O
the O
use O
of O
VICTOZA O
. O

These O
adverse O
reactions O
occurred O
more O
commonly O
on O
VICTOZA O
than O
on O
placebo O
and O
occurred O
in O
at O
least O
5 O
% O
of O
patients O
treated O
with O
VICTOZA O
. O

Table O
1 O
Adverse O
reactions O
reported O
in O
> O
= O
5 O
% O
of O
VICTOZA-treated O
patients O
Placebo O
N=661 O
Liraglutide O
1.2 O
mg O
N= O
645 O
Liraglutide O
1.8 O
mg O
N= O
1024 O
Adverse O
Reaction O
( O
% O
) O
( O
% O
) O
( O
% O
) O
Nausea B-OSE_Labeled_AE
5 O
18 O
20 O
Diarrhea B-OSE_Labeled_AE
4 O
10 O
12 O
Headache B-OSE_Labeled_AE
7 O
11 O
10 O
Nasopharyngitis B-OSE_Labeled_AE
8 O
9 O
10 O
Vomiting B-OSE_Labeled_AE
2 O
6 O
9 O
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
1 O
10 O
9 O
Dyspepsia B-OSE_Labeled_AE
1 O
4 O
7 O
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
6 O
7 O
6 O
Constipation B-OSE_Labeled_AE
1 O
5 O
5 O
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
3 O
4 O
5 O
Cumulative O
proportions O
were O
calculated O
combining O
studies O
using O
Cochran-Mantel-Haenszel O
weights O
. O

In O
an O
analysis O
of O
placebo- O
and O
active-controlled O
trials O
, O
the O
types O
and O
frequency O
of O
common O
adverse O
reactions O
, O
excluding O
hypoglycemia B-NonOSE_AE
, O
were O
similar O
to O
those O
listed O
in O
Table O
1 O
. O

Other O
Adverse O
Reactions O
Gastrointestinal O
Adverse O
Reactions O
In O
the O
pool O
of O
5 O
glycemic O
control O
, O
placebo-controlled O
clinical O
trials O
, O
withdrawals O
due O
to O
gastrointestinal B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
occurred O
in O
4.3 O
% O
of O
VICTOZA-treated O
patients O
and O
0.5 O
% O
of O
placebo-treated O
patients O
. O

Withdrawal O
due O
to O
gastrointestinal B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
events I-OSE_Labeled_AE
mainly O
occurred O
during O
the O
first O
2-3 O
months O
of O
the O
trials O
. O

Injection O
site O
reactions O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
e.g. O
, O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
erythema O
) O
were O
reported O
in O
approximately O
2 O
% O
of O
VICTOZA-treated O
patients O
in O
the O
five O
double-blind O
, O
glycemic O
control O
trials O
of O
at O
least O
26 O
weeks O
duration O
. O

Less O
than O
0.2 O
% O
of O
VICTOZA-treated O
patients O
discontinued O
due O
to O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

Hypoglycemia O
Hypoglycemia O
requiring O
the O
assistance O
of O
another O
person O
in O
placebo-controlled O
trials O
In O
5 O
glycemic O
control O
, O
placebo-controlled O
clinical O
trials O
of O
at O
least O
26 O
weeks O
duration O
, O
hypoglycemia B-OSE_Labeled_AE
requiring O
the O
assistance O
of O
another O
person O
for O
treatment O
occurred O
in O
8 O
VICTOZA-treated O
patients O
( O
7.5 O
events O
per O
1000 O
patient-years O
) O
. O

Of O
these O
8 O
VICTOZA-treated O
patients O
, O
7 O
patients O
were O
concomitantly O
using O
a O
sulfonylurea O
. O

Table O
2 O
Incidence O
( O
% O
) O
and O
Rate O
( O
episodes/patient O
year O
) O
of O
Hypoglycemia B-OSE_Labeled_AE
in O
26-Week O
Combination O
Therapy O
Placebo-controlled O
Trials O
Placebo O
Comparator O
VICTOZA O
Treatment O
Add-on O
to O
Metformin O
Placebo O
+ O
Metformin O
( O
N O
= O
121 O
) O
( O
N O
= O
724 O
) O
VICTOZA O
+ O
Metformin O
Patient O
not O
able O
to O
self-treat O
0 O
0.1 O
( O
0.001 O
) O
Patient O
able O
to O
self-treat O
2.5 O
( O
0.06 O
) O
3.6 O
( O
0.05 O
) O
Add-on O
to O
Glimepiride O
Placebo O
+ O
Glimepiride O
( O
N O
= O
114 O
) O
VICTOZA O
+ O
Glimepiride O
( O
N O
= O
695 O
) O
Patient O
not O
able O
to O
self-treat O
0 O
0.1 O
( O
0.003 O
) O
Patient O
able O
to O
self-treat O
2.6 O
( O
0.17 O
) O
7.5 O
( O
0.38 O
) O
Not O
classified O
0 O
0.9 O
( O
0.05 O
) O
Add-on O
to O
Metformin O
+ O
Rosiglitazone O
Placebo O
+ O
Metformin O
+ O
Rosiglitazone O
( O
N O
= O
175 O
) O
( O
N O
= O
355 O
) O
VICTOZA O
+ O
Metformin O
+ O
Rosiglitazone O
Patient O
not O
able O
to O
self-treat O
0 O
0 O
Patient O
able O
to O
self-treat O
4.6 O
( O
0.15 O
) O
7.9 O
( O
0.49 O
) O
Not O
classified O
1.1 O
( O
0.03 O
) O
0.6 O
( O
0.01 O
) O
Add-on O
to O
Metformin O
+ O
Glimepiride O
Placebo O
+ O
Metformin O
+ O
Glimepiride O
( O
N O
= O
114 O
) O
( O
N O
= O
230 O
) O
VICTOZA O
+ O
Metformin O
+ O
Glimepiride O
Patient O
not O
able O
to O
self-treat O
0 O
2.2 O
( O
0.06 O
) O
Patient O
able O
to O
self-treat O
16.7 O
( O
0.95 O
) O
27.4 O
( O
1.16 O
) O
Not O
classified O
0 O
0 O
`` O
Patient O
not O
able O
to O
self-treat O
'' O
is O
defined O
as O
an O
event O
requiring O
the O
assistance O
of O
another O
person O
for O
treatment O
. O

Papillary O
thyroid O
carcinoma O
In O
glycemic O
control O
trials O
of O
VICTOZA O
, O
there O
were O
7 O
reported O
cases O
of O
papillary B-OSE_Labeled_AE
thyroid I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
in O
patients O
treated O
with O
VICTOZA O
and O
1 O
case O
in O
a O
comparator-treated O
patient O
( O
1.5 O
vs O
. O
0.5 O
cases O
per O
1000 O
patient-years O
) O
. O

Most O
of O
these O
papillary B-NonOSE_AE
thyroid I-NonOSE_AE
carcinomas I-NonOSE_AE
were O
< O
1 O
cm O
in O
greatest O
diameter O
and O
were O
diagnosed O
in O
surgical O
pathology O
specimens O
after O
thyroidectomy O
prompted O
by O
findings O
on O
protocol-specified O
screening O
with O
serum O
calcitonin O
or O
thyroid O
ultrasound O
. O

Cholelithiasis O
and O
cholecystitis O
In O
glycemic O
control O
trials O
of O
VICTOZA O
, O
the O
incidence O
of O
cholelithiasis B-NonOSE_AE
was O
0.3 O
% O
in O
both O
VICTOZA-treated O
and O
placebo-treated O
patients O
. O

The O
incidence O
of O
cholecystitis B-NonOSE_AE
was O
0.2 O
% O
in O
both O
VICTOZA-treated O
and O
placebo-treated O
patients O
. O

In O
the O
LEADER O
trial O
[ O
see O
Clinical O
Studies O
( O
14.2 O
) O
] O
, O
the O
incidence O
of O
cholelithiasis B-OSE_Labeled_AE
was O
1.5 O
% O
( O
3.9 O
cases O
per O
1000 O
patient O
years O
of O
observation O
) O
in O
VICTOZA-treated O
and O
1.1 O
% O
( O
2.8 O
cases O
per O
1000 O
patient O
years O
of O
observation O
) O
in O
placebo-treated O
patients O
, O
both O
on O
a O
background O
of O
standard O
of O
care O
. O

The O
incidence O
of O
acute B-OSE_Labeled_AE
cholecystitis I-OSE_Labeled_AE
was O
1.1 O
% O
( O
2.9 O
cases O
per O
1000 O
patient O
years O
of O
observation O
) O
in O
VICTOZA-treated O
and O
0.7 O
% O
( O
1.9 O
cases O
per O
1000 O
patient O
years O
of O
observation O
) O
in O
placebo-treated O
patients O
. O

Laboratory O
Tests O
Bilirubin O
In O
the O
five O
glycemic O
control O
trials O
of O
at O
least O
26 O
weeks O
duration O
, O
mildly O
elevated B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
concentrations O
( O
elevations O
to O
no O
more O
than O
twice O
the O
upper O
limit O
of O
the O
reference O
range O
) O
occurred O
in O
4.0 O
% O
of O
VICTOZA-treated O
patients O
, O
2.1 O
% O
of O
placebo-treated O
patients O
and O
3.5 O
% O
of O
active-comparator-treated O
patients O
. O

This O
finding O
was O
not O
accompanied O
by O
abnormalities B-NonOSE_AE
in I-NonOSE_AE
other I-NonOSE_AE
liver I-NonOSE_AE
tests I-NonOSE_AE
. O

The O
significance O
of O
this O
isolated O
finding O
is O
unknown O
. O

Calcitonin O
Calcitonin O
, O
a O
biological O
marker O
of O
MTC B-NonOSE_AE
, O
was O
measured O
throughout O
the O
clinical O
development O
program O
. O

At O
the O
end O
of O
the O
glycemic O
control O
trials O
, O
adjusted O
mean O
serum O
calcitonin B-OSE_Labeled_AE
concentrations I-OSE_Labeled_AE
were I-OSE_Labeled_AE
higher I-OSE_Labeled_AE
in O
VICTOZA-treated O
patients O
compared O
to O
placebo-treated O
patients O
but O
not O
compared O
to O
patients O
receiving O
active O
comparator O
. O

Between O
group O
differences O
in O
adjusted O
mean O
serum O
calcitonin O
values O
were O
approximately O
0.1 O
ng/L O
or O
less O
. O

Among O
patients O
with O
pretreatment O
calcitonin O
< O
20 O
ng/L O
, O
calcitonin B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
to O
> O
20 O
ng/L O
occurred O
in O
0.7 O
% O
of O
VICTOZA-treated O
patients O
, O
0.3 O
% O
of O
placebo-treated O
patients O
, O
and O
0.5 O
% O
of O
active-comparator-treated O
patients O
. O

The O
clinical O
significance O
of O
these O
findings O
is O
unknown O
. O

Lipase O
and O
Amylase O
In O
one O
glycemic O
control O
trial O
in O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
patients O
, O
a O
mean O
increase B-OSE_Labeled_AE
of O
33 O
% O
for O
lipase I-OSE_Labeled_AE
and O
15 O
% O
for O
amylase O
from O
baseline O
was O
observed O
for O
VICTOZA-treated O
patients O
while O
placebo-treated O
patients O
had O
a O
mean O
decrease B-NonOSE_AE
in I-NonOSE_AE
lipase I-NonOSE_AE
of O
3 O
% O
and O
a O
mean O
increase B-NonOSE_AE
in I-NonOSE_AE
amylase I-NonOSE_AE
of O
1 O
% O
. O

In O
the O
LEADER O
trial O
, O
serum O
lipase O
and O
amylase O
were O
routinely O
measured O
. O

Among O
VICTOZA-treated O
patients O
, O
7.9 O
% O
had O
a O
lipase B-OSE_Labeled_AE
value I-OSE_Labeled_AE
at O
any O
time O
during O
treatment O
of O
greater I-OSE_Labeled_AE
than I-OSE_Labeled_AE
or I-OSE_Labeled_AE
equal I-OSE_Labeled_AE
to I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
times I-OSE_Labeled_AE
the I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
limit I-OSE_Labeled_AE
of I-OSE_Labeled_AE
normal I-OSE_Labeled_AE
compared O
with O
4.5 O
% O
of O
placebo-treated O
patients O
, O
and O
1 O
% O
of O
VICTOZA-treated O
patients O
had O
an O
amylase B-OSE_Labeled_AE
value I-OSE_Labeled_AE
at O
any O
time O
during O
treatment O
of O
greater I-OSE_Labeled_AE
than I-OSE_Labeled_AE
or I-OSE_Labeled_AE
equal I-OSE_Labeled_AE
to I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
times I-OSE_Labeled_AE
the I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
limit I-OSE_Labeled_AE
of I-OSE_Labeled_AE
normal I-OSE_Labeled_AE
versus O
0.7 O
% O
of O
placebo-treated O
patients O
. O

The O
clinical O
significance O
of O
elevations B-NonOSE_AE
in I-NonOSE_AE
lipase I-NonOSE_AE
or O
amylase O
with O
VICTOZA O
is O
unknown O
in O
the O
absence O
of O
other O
signs O
and O
symptoms O
of O
pancreatitis B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Vital O
signs O
VICTOZA O
did O
not O
have O
adverse B-NonOSE_AE
effects I-NonOSE_AE
on I-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
. O

Mean O
increase B-OSE_Labeled_AE
s O
from O
basel O
in I-OSE_Labeled_AE
e O
in O
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
of O
2 O
to O
3 O
beats O
per O
minute O
have O
been O
observed O
with O
VICTOZA O
compared O
to O
placebo O
. O

6.2 O
Immunogenicity O
Consistent O
with O
the O
potentially O
immunogenic B-NonOSE_AE
properties I-NonOSE_AE
of I-NonOSE_AE
protein I-NonOSE_AE
and I-NonOSE_AE
peptide I-NonOSE_AE
pharmaceuticals I-NonOSE_AE
, O
patients O
treated O
with O
VICTOZA O
may O
develop O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
liraglutide I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
. O

The O
detection O
of O
antibody B-NonOSE_AE
formation I-NonOSE_AE
is O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
. O

Additionally O
, O
the O
observed O
incidence O
of O
antibody B-NonOSE_AE
( O
including O
neutralizing O
a O
ntibody B-NonOSE_AE
) I-NonOSE_AE
positivity I-NonOSE_AE
  I-NonOSE_AE
I-NonOSE_AE O
in O
an O
assay O
may O
be O
influenced O
by O
several O
factors O
including O
assay O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
liraglutide I-NonOSE_AE
can O
not O
be O
directly O
compared O
with O
the O
incidence O
of O
antibodies B-NonOSE_AE
of I-NonOSE_AE
other I-NonOSE_AE
products I-NonOSE_AE
. O

Approximately O
50-70 O
% O
of O
VICTOZA-treated O
patients O
in O
five O
double-blind O
clinical O
trials O
of O
26 O
weeks O
duration O
or O
longer O
were O
tested O
for O
the O
presence O
of O
anti B-NonOSE_AE
- I-NonOSE_AE
liraglutide I-NonOSE_AE
antibodies I-NonOSE_AE
at O
the O
end O
of O
treatment O
. O

Low O
titers O
( O
concentrations O
not O
requiring O
dilution O
of O
serum O
) O
of O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
liraglutide I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
were I-OSE_Labeled_AE
detected I-OSE_Labeled_AE
in O
8.6 O
% O
of O
these O
VICTOZA-treated O
patients O
. O

Cross B-OSE_Labeled_AE
- I-OSE_Labeled_AE
reacting I-OSE_Labeled_AE
anti I-OSE_Labeled_AE
- I-OSE_Labeled_AE
liraglutide I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
to I-OSE_Labeled_AE
native I-OSE_Labeled_AE
glucagon I-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
peptide I-OSE_Labeled_AE
- I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
( I-OSE_Labeled_AE
GLP I-OSE_Labeled_AE
- I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
) O
occurred O
in O
6.9 O
% O
of O
the O
VICTOZA-treated O
patients O
in O
the O
double-blind O
52-week O
monotherapy O
trial O
and O
in O
4.8 O
% O
of O
the O
VICTOZA-treated O
patients O
in O
the O
double-blind O
26-week O
add-on O
combination O
therapy O
trials O
. O

These O
cross B-NonOSE_AE
- I-NonOSE_AE
reacting I-NonOSE_AE
antibodies I-NonOSE_AE
were O
not O
tested O
for O
neutralizing B-NonOSE_AE
effect I-NonOSE_AE
against I-NonOSE_AE
native I-NonOSE_AE
GLP I-NonOSE_AE
- I-NonOSE_AE
1 I-NonOSE_AE
, O
and O
thus O
the O
potential O
for O
clinically O
significant O
neutralization B-NonOSE_AE
of I-NonOSE_AE
native I-NonOSE_AE
GLP I-NonOSE_AE
- I-NonOSE_AE
1 I-NonOSE_AE
was O
not O
assessed O
. O

Antibodies B-OSE_Labeled_AE
that I-OSE_Labeled_AE
had I-OSE_Labeled_AE
a I-OSE_Labeled_AE
neutralizing I-OSE_Labeled_AE
effect O
on O
liraglutide O
in O
an O
in O
vitro O
assay O
occurred O
in O
2.3 O
% O
of O
the O
VICTOZA-treated O
patients O
in O
the O
double-blind O
52-week O
monotherapy O
trial O
and O
in O
1.0 O
% O
of O
the O
VICTOZA-treated O
patients O
in O
the O
double-blind O
26-week O
add-on O
combination O
therapy O
trials O
. O

Antibody B-NonOSE_AE
formation I-NonOSE_AE
was O
not O
associated O
with O
reduced O
efficacy O
of O
VICTOZA O
when O
comparing O
mean O
HbA1c O
of O
all O
antibody B-NonOSE_AE
- I-NonOSE_AE
positive I-NonOSE_AE
and O
all O
antibody B-NonOSE_AE
- I-NonOSE_AE
negative I-NonOSE_AE
patients O
. O

However O
, O
the O
3 O
patients O
with O
the O
highest O
titers O
of O
anti B-NonOSE_AE
- I-NonOSE_AE
liraglutide I-NonOSE_AE
antibodies I-NonOSE_AE
had O
no O
reduction O
in O
HbA1c O
with O
VICTOZA O
treatment O
. O

In O
five O
double-blind O
glycemic O
control O
trials O
of O
VICTOZA O
, O
events O
from O
a O
composite O
of O
adverse O
events O
potentially O
related O
to O
immunogenicity B-OSE_Labeled_AE
( O
e.g O
. O

urticaria B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
) O
occurred O
among O
0.8 O
% O
of O
VICTOZA-treated O
patients O
and O
among O
0.4 O
% O
of O
comparator-treated O
patients O
. O

Urticaria B-OSE_Labeled_AE
accounted O
for O
approximately O
one-half O
of O
the O
events O
in O
this O
composite O
for O
VICTOZA-treated O
patients O
. O

Patients O
who O
developed O
anti B-NonOSE_AE
- I-NonOSE_AE
liraglutide I-NonOSE_AE
antibodies I-NonOSE_AE
were O
not O
more O
likely O
to O
develop O
events O
from O
the O
immunogenicity B-NonOSE_AE
events I-NonOSE_AE
composite O
than O
were O
patients O
who O
did O
not O
develop O
anti B-NonOSE_AE
- I-NonOSE_AE
liraglutide I-NonOSE_AE
antibodies I-NonOSE_AE
. O

In O
the O
LEADER O
trial O
[ O
see O
Clinical O
Studies O
( O
14.2 O
) O
] O
, O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
liraglutide I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
were O
detected O
in O
11 O
out O
of O
the O
1247 O
( O
0.9 O
% O
) O
VICTOZA-treated O
patients O
with O
antibody B-NonOSE_AE
measurements O
. O

Of O
the O
11 O
VICTOZA-treated O
patients O
who O
developed O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
liraglutide I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
, O
none O
were O
observed O
to O
develop O
neutralizing B-NonOSE_AE
antibodies I-NonOSE_AE
to I-NonOSE_AE
liraglutide I-NonOSE_AE
, O
and O
5 O
patients O
( O
0.4 O
% O
) O
developed O
cross B-OSE_Labeled_AE
- I-OSE_Labeled_AE
reacting I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
against I-OSE_Labeled_AE
native I-OSE_Labeled_AE
GLP I-OSE_Labeled_AE
- I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
. O

6.3 O
Post-Marketing O
Experience O
The O
following O
additional O
adverse O
reactions O
have O
been O
reported O
during O
post-approval O
use O
of O
VICTOZA O
. O

Because O
these O
events O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
generally O
not O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

* O
Medullary B-OSE_Labeled_AE
thyroid I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Dehydration B-OSE_Labeled_AE
resulting O
from O
nausea B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
and O
diarrhea B-OSE_Labeled_AE
. O

[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
and O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
* O
Increased B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
, O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
or O
worsening O
of O
chronic B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
sometimes O
requiring O
hemodialysis O
. O

[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
and O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
* O
Angioedema B-OSE_Labeled_AE
and O
anaphylactic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

[ O
see O
Contraindications O
( O
4 O
) O
, O
Warnings O
and O
Precautions O
( O
5.6 O
) O
, O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
* O
Allergic B-NonOSE_AE
reactions I-NonOSE_AE
: O
rash B-OSE_Labeled_AE
and O
pruritus B-OSE_Labeled_AE
* O
Acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
, O
hemorrhagic B-OSE_Labeled_AE
and O
necrotizing O
pancreatitis I-OSE_Labeled_AE
sometimes O
resulting O
in O
death O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Hepatobiliary B-NonOSE_AE
disorders I-NonOSE_AE
: O
elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
enzymes I-OSE_Labeled_AE
, O
hyperbilirubinemia B-OSE_Labeled_AE
, O
cholestasis B-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O

BOXED O
WARNING O
: O
WARNING O
: O
RISK O
OF O
THYROID O
C-CELL O
TUMORS O
WARNING O
: O
RISK O
OF O
THYROID O
C-CELL O
TUMORS O
* O
Liraglutide O
causes O
dose-dependent O
and O
treatment-duration-dependent O
thyroid B-NonOSE_AE
C I-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
tumors I-NonOSE_AE
at O
clinically O
relevant O
exposures O
in O
both O
genders O
of O
rats O
and O
mice O
. O

It O
is O
unknown O
whether O
VICTOZA O
causes O
thyroid B-NonOSE_AE
C I-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
tumors I-NonOSE_AE
, O
including O
medullary B-NonOSE_AE
thyroid I-NonOSE_AE
carcinoma I-NonOSE_AE
( I-NonOSE_AE
MTC I-NonOSE_AE
) O
, O
in O
humans O
, O
as O
the O
human O
relevance O
of O
liraglutide-induced O
rodent O
thyroid B-NonOSE_AE
C I-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
tumors I-NonOSE_AE
has O
not O
been O
determined O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
and O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
. O

* O
VICTOZA O
is O
contraindicated O
in O
patients O
with O
a O
personal O
or O
family O
history O
of O
MTC B-Not_AE_Candidate
and O
in O
patients O
with O
Multiple B-Not_AE_Candidate
Endocrine I-Not_AE_Candidate
Neoplasia I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
type I-Not_AE_Candidate
2 I-Not_AE_Candidate
( I-Not_AE_Candidate
MEN I-Not_AE_Candidate
2 I-Not_AE_Candidate
) O
. O

Counsel O
patients O
regarding O
the O
potential O
risk O
for O
MTC B-NonOSE_AE
with O
the O
use O
of O
VICTOZA O
and O
inform O
them O
of O
symptoms O
of O
thyroid B-NonOSE_AE
tumors I-NonOSE_AE
( O
e.g O
. O

a O
mass B-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
neck I-NonOSE_AE
, O
dysphagia B-NonOSE_AE
, O
dyspnea B-NonOSE_AE
, O
persistent B-NonOSE_AE
hoarseness I-NonOSE_AE
) O
. O

Routine O
monitoring O
of O
serum O
calcitonin O
or O
using O
thyroid O
ultrasound O
is O
of O
uncertain O
value O
for O
early O
detection O
of O
MTC B-NonOSE_AE
in O
patients O
treated O
with O
VICTOZA O
[ O
see O
Contraindications O
( O
4 O
) O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
RISK O
OF O
THYROID O
C-CELL O
TUMORS O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Liraglutide O
causes O
thyroid O
C-cell O
tumors O
at O
clinically O
relevant O
exposures O
in O
both O
genders O
of O
rats O
and O
mice O
. O

It O
is O
unknown O
whether O
VICTOZA O
causes O
thyroid O
C-cell O
tumors O
, O
including O
medullary O
thyroid O
carcinoma O
( O
MTC O
) O
, O
in O
humans O
, O
as O
the O
human O
relevance O
of O
liraglutide-induced O
rodent O
thyroid O
C-cell O
tumors O
has O
not O
been O
determined O
( O
5.1 O
, O
13.1 O
) O
. O

* O
VICTOZA O
is O
contraindicated O
in O
patients O
with O
a O
personal O
or O
family O
history O
of O
MTC O
or O
in O
patients O
with O
Multiple O
Endocrine O
Neoplasia O
syndrome O
type O
2 O
( O
MEN O
2 O
) O
. O

Counsel O
patients O
regarding O
the O
potential O
risk O
of O
MTC O
and O
the O
symptoms O
of O
thyroid O
tumors O
( O
4 O
, O
5.1 O
) O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Thyroid O
C-cell O
Tumors O
: O
See O
Boxed O
Warning O
( O
5.1 O
) O
. O

* O
Pancreatitis O
: O
Postmarketing O
reports O
, O
including O
fatal O
and O
non-fatal O
hemorrhagic O
or O
necrotizing O
pancreatitis O
. O

Discontinue O
promptly O
if O
pancreatitis O
is O
suspected O
. O

Do O
not O
restart O
if O
pancreatitis O
is O
confirmed O
( O
5.2 O
) O
. O

* O
Never O
share O
a O
VICTOZA O
pen O
between O
patients O
, O
even O
if O
the O
needle O
is O
changed O
( O
5.3 O
) O
. O

* O
Serious O
Hypoglycemia O
: O
When O
VICTOZA O
is O
used O
with O
an O
insulin O
secretagogue O
( O
e.g O
. O

a O
sulfonylurea O
) O
or O
insulin O
, O
consider O
lowering O
the O
dose O
of O
the O
insulin O
secretagogue O
or O
insulin O
to O
reduce O
the O
risk O
of O
hypoglycemia O
( O
5.4 O
) O
. O

* O
Renal O
Impairment O
: O
Postmarketing O
, O
usually O
in O
association O
with O
nausea O
, O
vomiting O
, O
diarrhea O
, O
or O
dehydration O
which O
may O
sometimes O
require O
hemodialysis O
. O

Use O
caution O
when O
initiating O
or O
escalating O
doses O
of O
VICTOZA O
in O
patients O
with O
renal O
impairment O
( O
5.5 O
) O
. O

* O
Hypersensitivity O
: O
Postmarketing O
reports O
of O
serious O
hypersensitivity O
reactions O
( O
e.g. O
, O
anaphylactic O
reactions O
and O
angioedema O
) O
. O

Discontinue O
VICTOZA O
and O
promptly O
seek O
medical O
advice O
( O
5.6 O
) O
. O

* O
Acute O
Gallbladder O
Disease O
: O
If O
cholelithiasis O
or O
cholecystitis O
are O
suspected O
, O
gallbladder O
studies O
are O
indicated O
( O
5.7 O
) O
. O

5.1 O
Risk O
of O
Thyroid O
C-cell O
Tumors O
Liraglutide O
causes O
dose-dependent O
and O
treatment-duration-dependent O
thyroid B-NonOSE_AE
C I-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
tumors I-NonOSE_AE
( O
adenomas O
and/or O
carcinomas O
) O
at O
clinically O
relevant O
exposures O
in O
both O
genders O
of O
rats O
and O
mice O
[ O
see O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
. O

Malignant B-NonOSE_AE
thyroid I-NonOSE_AE
C I-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
carcinomas I-NonOSE_AE
were O
detected O
in O
rats O
and O
mice O
. O

It O
is O
unknown O
whether O
VICTOZA O
will O
cause O
thyroid B-NonOSE_AE
C I-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
tumors I-NonOSE_AE
, O
including O
medullary B-NonOSE_AE
thyroid I-NonOSE_AE
carcinoma I-NonOSE_AE
( I-NonOSE_AE
MTC I-NonOSE_AE
) O
, O
in O
humans O
, O
as O
the O
human O
relevance O
of O
liraglutide-induced O
rodent O
thyroid B-NonOSE_AE
C I-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
tumors I-NonOSE_AE
has O
not O
been O
determined O
. O

Cases O
of O
MTC B-OSE_Labeled_AE
in O
patients O
treated O
with O
VICTOZA O
have O
been O
reported O
in O
the O
postmarketing O
period O
; O
the O
data O
in O
these O
reports O
are O
insufficient O
to O
establish O
or O
exclude O
a O
causal O
relationship O
between O
MTC B-NonOSE_AE
and O
VICTOZA O
use O
in O
humans O
. O

VICTOZA O
is O
contraindicated O
in O
patients O
with O
a O
personal O
or O
family O
history O
of O
MTC B-Not_AE_Candidate
or O
in O
patients O
with O
MEN B-Not_AE_Candidate
2 I-Not_AE_Candidate
. O

Counsel O
patients O
regarding O
the O
potential O
risk O
for O
MTC B-NonOSE_AE
with O
the O
use O
of O
VICTOZA O
and O
inform O
them O
of O
symptoms O
of O
thyroid B-NonOSE_AE
tumors I-NonOSE_AE
( O
e.g O
. O

a O
mass B-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
neck I-NonOSE_AE
, O
dysphagia B-NonOSE_AE
, O
dyspnea B-NonOSE_AE
, O
persistent B-NonOSE_AE
hoarseness I-NonOSE_AE
) O
. O

Routine O
monitoring O
of O
serum O
calcitonin O
or O
using O
thyroid O
ultrasound O
is O
of O
uncertain O
value O
for O
early O
detection O
of O
MTC B-NonOSE_AE
in O
patients O
treated O
with O
VICTOZA O
. O

Such O
monitoring O
may O
increase O
the O
risk O
of O
unnecessary O
procedures O
, O
due O
to O
low O
test O
specificity O
for O
serum O
calcitonin O
and O
a O
high O
background O
incidence O
of O
thyroid B-NonOSE_AE
disease I-NonOSE_AE
. O

Significantly O
elevated B-NonOSE_AE
serum I-NonOSE_AE
calcitonin I-NonOSE_AE
may O
indicate O
MTC B-NonOSE_AE
and O
patients O
with O
MTC B-NonOSE_AE
usually O
have O
calcitonin B-NonOSE_AE
values I-NonOSE_AE
> I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
ng I-NonOSE_AE
/ I-NonOSE_AE
L I-NonOSE_AE
. O

If O
serum O
calcitonin O
is O
measured O
and O
found O
to O
be O
elevated O
, O
the O
patient O
should O
be O
further O
evaluated O
. O

Patients O
with O
thyroid B-NonOSE_AE
nodules I-NonOSE_AE
noted O
on O
physical O
examination O
or O
neck O
imaging O
should O
also O
be O
further O
evaluated O
. O

5.2 O
Pancreatitis O
Based O
on O
spontaneous O
postmarketing O
reports O
, O
acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
, O
including O
fatal O
and O
non-fatal O
hemorrhagic B-OSE_Labeled_AE
or O
necrotizing O
pancreatitis I-OSE_Labeled_AE
, O
has O
been O
observed O
in O
patients O
treated O
with O
VICTOZA O
. O

After O
initiation O
of O
VICTOZA O
, O
observe O
patients O
carefully O
for O
signs O
and O
symptoms O
of O
pancreatitis B-NonOSE_AE
( O
including O
persistent O
severe O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
sometimes O
radiating O
to O
the O
back O
and O
which O
may O
or O
may O
not O
be O
accompanied O
by O
vomiting B-NonOSE_AE
) O
. O

If O
pancreatitis B-NonOSE_AE
is O
suspected O
, O
VICTOZA O
should O
promptly O
be O
discontinued O
and O
appropriate O
management O
should O
be O
initiated O
. O

If O
pancreatitis B-NonOSE_AE
is O
confirmed O
, O
VICTOZA O
should O
not O
be O
restarted O
. O

In O
glycemic O
control O
trials O
of O
VICTOZA O
, O
there O
have O
been O
13 O
cases O
of O
pancreatitis B-OSE_Labeled_AE
among O
VICTOZA-treated O
patients O
and O
1 O
case O
in O
a O
comparator O
( O
glimepiride O
) O
treated O
patient O
( O
2.7 O
vs O
. O
0.5 O
cases O
per O
1000 O
patient-years O
) O
. O

Nine O
of O
the O
13 O
cases O
with O
VICTOZA O
were O
reported O
as O
acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
and O
four O
were O
reported O
as O
chronic B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
. O

In O
one O
case O
in O
a O
VICTOZA-treated O
patient O
, O
pancreatitis B-OSE_Labeled_AE
, O
with I-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
, O
was O
observed O
and O
led O
to O
death O
; O
however O
clinical O
causality O
could O
not O
be O
established O
. O

Some O
patients O
had O
other O
risk O
factors O
for O
pancreatitis B-NonOSE_AE
, O
such O
as O
a O
history O
of O
cholelithiasis B-Not_AE_Candidate
or O
alcohol B-Not_AE_Candidate
abuse I-Not_AE_Candidate
. O

VICTOZA O
has O
been O
studied O
in O
a O
limited O
number O
of O
patients O
with O
a O
history O
of O
pancreatitis B-Not_AE_Candidate
. O

It O
is O
unknown O
if O
patients O
with O
a O
history O
of O
pancreatitis B-Not_AE_Candidate
are O
at O
higher O
risk O
for O
development O
of O
pancreatitis B-NonOSE_AE
on O
VICTOZA O
. O

5.3 O
Never O
Share O
a O
VICTOZA O
Pen O
Between O
Patients O
VICTOZA O
pens O
must O
never O
be O
shared O
between O
patients O
, O
even O
if O
the O
needle O
is O
changed O
. O

Pen-sharing O
poses O
a O
risk O
for O
transmission B-NonOSE_AE
of I-NonOSE_AE
blood I-NonOSE_AE
- I-NonOSE_AE
borne I-NonOSE_AE
pathogens I-NonOSE_AE
. O

5.4 O
Use O
with O
Medications O
Known O
to O
Cause O
Hypoglycemia O
Patients O
receiving O
VICTOZA O
in O
combination O
with O
an O
insulin O
secretagogue O
( O
e.g. O
, O
sulfonylurea O
) O
or O
insulin O
may O
have O
an O
increased O
risk O
of O
hypoglycemia B-NonOSE_AE
. O

The O
risk O
of O
hypoglycemia B-NonOSE_AE
may O
be O
lowered O
by O
a O
reduction O
in O
the O
dose O
of O
sulfonylurea O
( O
or O
other O
concomitantly O
administered O
insulin O
secretagogues O
) O
or O
insulin O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
, O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.5 O
Renal B-OSE_Labeled_AE
Impairment I-OSE_Labeled_AE
VICTOZA O
has O
not O
been O
found O
to O
be O
directly O
nephrotoxic B-NonOSE_AE
in O
animal O
studies O
or O
clinical O
trials O
. O

There O
have O
been O
postmarketing O
reports O
of O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
and O
worsening O
of O
chronic B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
which O
may O
sometimes O
require O
hemodialysis B-NonOSE_AE
in O
VICTOZA-treated O
patients O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

Some O
of O
these O
events O
were O
reported O
in O
patients O
without O
known O
underlying O
renal B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

A O
majority O
of O
the O
reported O
events O
occurred O
in O
patients O
who O
had O
experienced O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
, O
or O
dehydration B-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Some O
of O
the O
reported O
events O
occurred O
in O
patients O
receiving O
one O
or O
more O
medications O
known O
to O
affect O
renal O
function O
or O
hydration O
status O
. O

Altered B-NonOSE_AE
renal I-NonOSE_AE
function I-NonOSE_AE
has O
been O
reversed O
in O
many O
of O
the O
reported O
cases O
with O
supportive O
treatment O
and O
discontinuation O
of O
potentially O
causative O
agents O
, O
including O
VICTOZA O
. O

Use O
caution O
when O
initiating O
or O
escalating O
doses O
of O
VICTOZA O
in O
patients O
with O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
] O
. O

5.6 O
Hypersensitivity O
Reactions O
There O
have O
been O
postmarketing O
reports O
of O
serious O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
e.g. O
, O
anaphylactic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
and O
angioedema B-OSE_Labeled_AE
) O
in O
patients O
treated O
with O
VICTOZA O
. O

If O
a O
hypersensitivity B-NonOSE_AE
reaction I-NonOSE_AE
occurs O
, O
discontinue O
VICTOZA O
; O
treat O
promptly O
per O
standard O
of O
care O
, O
and O
monitor O
until O
signs O
and O
symptoms O
resolve O
. O

Do O
not O
use O
in O
patients O
with O
a O
previous O
hypersensitivity B-Not_AE_Candidate
reaction I-Not_AE_Candidate
to O
VICTOZA O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

Anaphylaxis B-NonOSE_AE
and O
angioedema B-NonOSE_AE
have O
been O
reported O
with O
other O
GLP-1 O
receptor O
agonists O
. O

Use O
caution O
in O
a O
patient O
with O
a O
history O
of O
anaphylaxis B-Not_AE_Candidate
or O
angioedema B-Not_AE_Candidate
with O
another O
GLP-receptor O
agonist O
because O
it O
is O
unknown O
whether O
such O
patients O
will O
be O
predisposed O
to O
these O
reactions O
with O
VICTOZA O
. O

5.7 O
Acute O
Gallbladder O
Disease O
In O
the O
LEADER O
trial O
[ O
see O
Clinical O
Studies O
( O
14.2 O
) O
] O
, O
3.1 O
% O
of O
Victoza-treated O
patients O
versus O
1.9 O
% O
of O
placebo-treated O
patients O
reported O
an O
acute B-OSE_Labeled_AE
event I-OSE_Labeled_AE
of I-OSE_Labeled_AE
gallbladder I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
such O
as O
cholelithiasis B-OSE_Labeled_AE
or O
cholecystitis B-OSE_Labeled_AE
. O

The O
majority O
of O
events O
required O
hospitalization O
or O
cholecystectomy O
. O

If O
cholelithiasis B-NonOSE_AE
is O
suspected O
, O
gallbladder O
studies O
and O
appropriate O
clinical O
follow-up O
are O
indicated O
. O

6 O
ADVERSE O
REACTIONS O
If O
VIEKIRA O
PAK O
is O
administered O
with O
ribavirin O
( O
RBV O
) O
, O
refer O
to O
the O
prescribing O
information O
for O
ribavirin O
for O
a O
list O
of O
ribavirin-associated O
adverse O
reactions O
. O

The O
following O
adverse O
reaction O
is O
described O
below O
and O
elsewhere O
in O
the O
labeling O
: O
* O
Increased O
Risk O
of O
ALT B-OSE_Labeled_AE
Elevations I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
EXCERPT O
: O
In O
subjects O
receiving O
VIEKIRA O
PAK O
with O
ribavirin O
, O
the O
most O
commonly O
reported O
adverse O
reactions O
( O
greater O
than O
10 O
% O
of O
subjects O
) O
were O
fatigue O
, O
nausea O
, O
pruritus O
, O
other O
skin O
reactions O
, O
insomnia O
and O
asthenia O
. O

In O
subjects O
receiving O
VIEKIRA O
PAK O
without O
ribavirin O
, O
the O
most O
commonly O
reported O
adverse O
reactions O
( O
greater O
than O
or O
equal O
to O
5 O
% O
of O
subjects O
) O
were O
nausea O
, O
pruritus O
and O
insomnia O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
AbbVie O
Inc O
. O
at O
1-800-633-9110 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
clinical O
trials O
of O
VIEKIRA O
PAK O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
safety O
assessment O
was O
based O
on O
data O
from O
six O
Phase O
3 O
clinical O
trials O
in O
more O
than O
2,000 O
subjects O
who O
received O
VIEKIRA O
PAK O
with O
or O
without O
ribavirin O
for O
12 O
or O
24 O
weeks O
. O

VIEKIRA O
PAK O
with O
Ribavirin O
in O
Placebo-Controlled O
Trials O
The O
safety O
of O
VIEKIRA O
PAK O
in O
combination O
with O
ribavirin O
was O
assessed O
in O
770 O
subjects O
with O
chronic O
HCV B-Not_AE_Candidate
infection I-Not_AE_Candidate
in O
two O
placebo-controlled O
trials O
( O
SAPPHIRE-I O
and O
-II O
) O
[ O
see O
Clinical O
Studies O
( O
14.1 O
, O
14.2 O
) O
] O
. O

Adverse O
reactions O
that O
occurred O
more O
often O
in O
subjects O
treated O
with O
VIEKIRA O
PAK O
in O
combination O
with O
ribavirin O
compared O
to O
placebo O
were O
fatigue B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
other O
skin B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
and O
asthenia B-OSE_Labeled_AE
( O
see O
Table O
3 O
) O
. O

The O
majority O
of O
the O
adverse O
reactions O
were O
mild O
in O
severity O
. O

Two O
percent O
of O
subjects O
experienced O
a O
serious O
adverse O
event O
( O
SAE O
) O
. O

The O
proportion O
of O
subjects O
who O
permanently O
discontinued O
treatment O
due O
to O
adverse O
reactions O
was O
less O
than O
1 O
% O
. O

Table O
3 O
. O

Adverse O
Reactions O
with O
> O
=5 O
% O
Greater O
Frequency O
Reported O
in O
Subjects O
with O
Chronic O
HCV O
GT1 O
Infection O
Treated O
with O
VIEKIRA O
PAK O
in O
Combination O
with O
Ribavirin O
Compared O
to O
Placebo O
for O
12 O
Weeks O
SAPPHIRE-I O
and O
-II O
VIEKIRA O
PAK O
+ O
RBV O
12 O
Weeks O
N O
= O
770 O
% O
Placebo O
12 O
Weeks O
N O
= O
255 O
% O
Fatigue B-OSE_Labeled_AE
34 O
26 O
Nausea B-OSE_Labeled_AE
22 O
15 O
Pruritus B-OSE_Labeled_AE
* O
18 O
7 O
Skin B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
$ O
16 O
9 O
Insomnia B-OSE_Labeled_AE
14 O
8 O
Asthenia B-OSE_Labeled_AE
14 O
7 O
*Grouped O
term O
' O
pruritus B-OSE_Labeled_AE
' O
included O
the O
preferred O
terms O
pruritus B-OSE_Labeled_AE
and O
pruritus B-OSE_Labeled_AE
generalized I-OSE_Labeled_AE
. O

$ O
Grouped O
terms O
: O
rash B-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
, O
eczema B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
maculo I-OSE_Labeled_AE
- I-OSE_Labeled_AE
papular I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
macular I-OSE_Labeled_AE
, O
dermatitis B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
papular I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
exfoliation I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
pruritic I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
erythematous I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
generalized I-OSE_Labeled_AE
, O
dermatitis B-OSE_Labeled_AE
allergic I-OSE_Labeled_AE
, O
dermatitis B-OSE_Labeled_AE
contact I-OSE_Labeled_AE
, O
exfoliative B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
photosensitivity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
psoriasis B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
ulcer B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
. O

VIEKIRA O
PAK O
with O
and O
without O
Ribavirin O
in O
Regimen-Controlled O
Trials O
VIEKIRA O
PAK O
with O
and O
without O
ribavirin O
was O
assessed O
in O
401 O
and O
509 O
subjects O
with O
chronic B-Not_AE_Candidate
HCV I-Not_AE_Candidate
infection I-Not_AE_Candidate
, O
respectively O
, O
in O
three O
clinical O
trials O
( O
PEARL-II O
, O
PEARL-III O
and O
PEARL-IV O
) O
[ O
see O
Clinical O
Studies O
( O
14.1 O
, O
14.2 O
) O
] O
. O

Pruritus B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
and O
asthenia B-OSE_Labeled_AE
were O
identified O
as O
adverse O
events O
occurring O
more O
often O
in O
subjects O
treated O
with O
VIEKIRA O
PAK O
in O
combination O
with O
ribavirin O
( O
see O
Table O
4 O
) O
. O

The O
majority O
of O
adverse O
events O
were O
mild O
to O
moderate O
in O
severity O
. O

The O
proportion O
of O
subjects O
who O
permanently O
discontinued O
treatment O
due O
to O
adverse O
events O
was O
less O
than O
1 O
% O
for O
both O
VIEKIRA O
PAK O
in O
combination O
with O
ribavirin O
and O
VIEKIRA O
PAK O
alone O
. O

Table O
4 O
. O

Adverse O
Events O
with O
> O
=5 O
% O
Greater O
Frequency O
Reported O
in O
Subjects O
with O
Chronic O
HCV O
GT1 O
Infection O
Treated O
with O
VIEKIRA O
PAK O
in O
Combination O
with O
Ribavirin O
Compared O
to O
VIEKIRA O
PAK O
for O
12 O
Weeks O
PEARL-II O
, O
-III O
and O
-IV O
VIEKIRA O
PAK O
+ O
RBV O
12 O
Weeks O
N O
= O
401 O
% O
VIEKIRA O
PAK O
12 O
Weeks O
N O
= O
509 O
% O
Nausea B-OSE_Labeled_AE
16 O
8 O
Pruritus B-OSE_Labeled_AE
* O
13 O
7 O
Insomnia B-OSE_Labeled_AE
12 O
5 O
Asthenia B-OSE_Labeled_AE
9 O
4 O
*Grouped O
term O
' O
pruritus B-OSE_Labeled_AE
' O
included O
the O
preferred O
terms O
pruritus B-OSE_Labeled_AE
and O
pruritus B-OSE_Labeled_AE
generalized I-OSE_Labeled_AE
. O

VIEKIRA O
PAK O
with O
Ribavirin O
in O
Subjects O
with O
Compensated O
Cirrhosis O
VIEKIRA O
PAK O
with O
ribavirin O
was O
assessed O
in O
380 O
subjects O
with O
compensated B-Not_AE_Candidate
cirrhosis I-Not_AE_Candidate
who O
were O
treated O
for O
12 O
( O
n=208 O
) O
or O
24 O
( O
n=172 O
) O
weeks O
duration O
( O
TURQUOISE-II O
) O
[ O
see O
Clinical O
Studies O
( O
14.1 O
, O
14.3 O
) O
] O
. O

The O
type O
and O
severity O
of O
adverse O
events O
in O
subjects O
with O
compensated B-Not_AE_Candidate
cirrhosis I-Not_AE_Candidate
was O
comparable O
to O
non B-Not_AE_Candidate
- I-Not_AE_Candidate
cirrhotic I-Not_AE_Candidate
subjects O
in O
other O
phase O
3 O
trials O
. O

Fatigue B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
and O
dyspnea B-OSE_Labeled_AE
occurred O
at O
least O
5 O
% O
more O
often O
in O
subjects O
treated O
for O
24 O
weeks O
. O

The O
majority O
of O
adverse O
events O
occurred O
during O
the O
first O
12 O
weeks O
of O
dosing O
in O
both O
treatment O
arms O
. O

Most O
of O
the O
adverse O
events O
were O
mild O
to O
moderate O
in O
severity O
. O

The O
proportion O
of O
subjects O
treated O
with O
VIEKIRA O
PAK O
for O
12 O
and O
24 O
weeks O
with O
SAEs O
was O
6 O
% O
and O
5 O
% O
, O
respectively O
and O
2 O
% O
of O
subjects O
permanently O
discontinued O
treatment O
due O
to O
adverse O
events O
in O
each O
treatment O
arm O
. O

Skin O
Reactions O
In O
PEARL-II O
, O
-III O
and O
-IV O
, O
7 O
% O
of O
subjects O
receiving O
VIEKIRA O
PAK O
alone O
and O
10 O
% O
of O
subjects O
receiving O
VIEKIRA O
PAK O
with O
ribavirin O
reported O
rash B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
events I-OSE_Labeled_AE
. O

In O
SAPPHIRE-I O
and O
-II O
16 O
% O
of O
subjects O
receiving O
VIEKIRA O
PAK O
with O
ribavirin O
and O
9 O
% O
of O
subjects O
receiving O
placebo O
reported O
skin B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

In O
TURQUOISE-II O
, O
18 O
% O
and O
24 O
% O
of O
subjects O
receiving O
VIEKIRA O
PAK O
with O
ribavirin O
for O
12 O
or O
24 O
weeks O
reported O
skin B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

The O
majority O
of O
events O
were O
graded O
as O
mild O
in O
severity O
. O

There O
were O
no O
serious O
events O
or O
severe B-NonOSE_AE
cutaneous I-NonOSE_AE
reactions I-NonOSE_AE
, O
such O
as O
Stevens B-NonOSE_AE
Johnson I-NonOSE_AE
Syndrome I-NonOSE_AE
( I-NonOSE_AE
SJS I-NonOSE_AE
) O
, O
toxic B-NonOSE_AE
epidermal I-NonOSE_AE
necrolysis I-NonOSE_AE
( I-NonOSE_AE
TEN I-NonOSE_AE
) O
, O
erythema B-NonOSE_AE
multiforme I-NonOSE_AE
( I-NonOSE_AE
EM I-NonOSE_AE
) O
or O
drug B-NonOSE_AE
rash I-NonOSE_AE
with I-NonOSE_AE
eosinophilia I-NonOSE_AE
and I-NonOSE_AE
systemic I-NonOSE_AE
symptoms I-NonOSE_AE
( I-NonOSE_AE
DRESS I-NonOSE_AE
) O
. O

Laboratory O
Abnormalities O
Serum O
ALT O
Elevations O
Approximately O
1 O
% O
of O
subjects O
treated O
with O
VIEKIRA O
PAK O
experienced O
post-baseline O
serum O
ALT B-OSE_Labeled_AE
levels I-OSE_Labeled_AE
greater I-OSE_Labeled_AE
than I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
times I-OSE_Labeled_AE
the I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
limit I-OSE_Labeled_AE
of I-OSE_Labeled_AE
normal I-OSE_Labeled_AE
( O
ULN O
) O
after O
starting O
treatment O
. O

The O
incidence O
increased O
to O
25 O
% O
( O
4/16 O
) O
among O
women O
taking O
a O
concomitant O
ethinyl O
estradiol O
containing O
medication O
[ O
see O
Contraindications O
( O
4 O
) O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

The O
incidence O
of O
clinically O
relevant O
ALT B-NonOSE_AE
elevations I-NonOSE_AE
among O
women O
using O
estrogens O
other O
than O
ethinyl O
estradiol O
, O
such O
as O
estradiol O
and O
conjugated O
estrogens O
used O
in O
hormone O
replacement O
therapy O
was O
3 O
% O
( O
2/59 O
) O
. O

ALT B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
were O
typically O
asymptomatic O
, O
generally O
occurred O
during O
the O
first O
4 O
weeks O
of O
treatment O
( O
mean O
time O
20 O
days O
, O
range O
8-57 O
days O
) O
and O
most O
resolved O
with O
ongoing O
therapy O
. O

The O
majority O
of O
these O
ALT B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
were O
assessed O
as O
drug B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
injury I-OSE_Labeled_AE
. O

Elevations B-NonOSE_AE
in O
ALT I-NonOSE_AE
were O
generally O
not O
associated O
with O
bilirubin B-NonOSE_AE
elevations I-NonOSE_AE
. O

Cirrhosis B-NonOSE_AE
was O
not O
a O
risk O
factor O
for O
elevated B-NonOSE_AE
ALT I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Serum O
Bilirubin O
Elevations O
Post-baseline O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
at O
least O
2 O
x O
ULN O
were O
observed O
in O
15 O
% O
of O
subjects O
receiving O
VIEKIRA O
PAK O
with O
ribavirin O
compared O
to O
2 O
% O
in O
those O
receiving O
VIEKIRA O
PAK O
alone O
. O

These O
bilirubin B-OSE_Labeled_AE
increases I-OSE_Labeled_AE
were I-OSE_Labeled_AE
predominately I-OSE_Labeled_AE
indirect I-OSE_Labeled_AE
and O
related O
to O
the O
inhibition O
of O
the O
bilirubin O
transporters O
OATP1B1/1B3 O
by O
paritaprevir B-OSE_Labeled_AE
and I-OSE_Labeled_AE
ribavirin I-OSE_Labeled_AE
- I-OSE_Labeled_AE
induced I-OSE_Labeled_AE
hemolysis I-OSE_Labeled_AE
. O

Bilirubin B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
occurred O
after O
initiation O
of O
treatment O
, O
peaked O
by O
study O
Week O
1 O
, O
and O
generally O
resolved O
with O
ongoing O
therapy O
. O

Bilirubin B-NonOSE_AE
elevations I-NonOSE_AE
were O
not O
associated O
with O
serum O
ALT B-NonOSE_AE
elevations I-NonOSE_AE
. O

Anemia/Decreased O
Hemoglobin O
Across O
all O
Phase O
3 O
studies O
, O
the O
mean O
change O
from O
baseline O
in O
hemoglobin O
levels O
in O
subjects O
treated O
with O
VIEKIRA O
PAK O
in O
combination O
with O
ribavirin O
was O
-2.4 O
g/dL O
and O
the O
mean O
change O
in O
subjects O
treated O
with O
VIEKIRA O
PAK O
alone O
was O
-0.5 O
g/dL O
. O

Decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
levels O
occurred O
early O
in O
treatment O
( O
Week O
1-2 O
) O
with O
further O
reductions O
through O
Week O
3 O
. O

Hemoglobin B-OSE_Labeled_AE
values I-OSE_Labeled_AE
remained I-OSE_Labeled_AE
low I-OSE_Labeled_AE
during O
the O
remainder O
of O
treatment O
and O
returned O
towards O
baseline O
levels O
by O
post-treatment O
Week O
4 O
. O

Less O
than O
1 O
% O
of O
subjects O
treated O
with O
VIEKIRA O
PAK O
with O
ribavirin O
had O
hemoglobin B-OSE_Labeled_AE
levels I-OSE_Labeled_AE
decrease I-OSE_Labeled_AE
to O
less O
than O
8.0 O
g/dL O
during O
treatment O
. O

Seven O
percent O
of O
subjects O
treated O
with O
VIEKIRA O
PAK O
in O
combination O
with O
ribavirin O
underwent O
a O
ribavirin O
dose O
reduction O
due O
to O
a O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
; O
three O
subjects O
received O
a O
blood O
transfusion O
and O
five O
required O
erythropoietin O
. O

One O
patient O
discontinued O
therapy O
due O
to O
anemia B-OSE_Labeled_AE
. O

No O
subjects O
treated O
with O
VIEKIRA O
PAK O
alone O
had O
a O
hemoglobin B-NonOSE_AE
level I-NonOSE_AE
less I-NonOSE_AE
than I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
g I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
. O

VIEKIRA O
PAK O
in O
HCV/HIV-1 O
Co-infected O
Subjects O
VIEKIRA O
PAK O
with O
ribavirin O
was O
assessed O
in O
63 O
subjects O
with O
HCV B-Not_AE_Candidate
/ I-Not_AE_Candidate
HIV I-Not_AE_Candidate
- I-Not_AE_Candidate
1 I-Not_AE_Candidate
co I-Not_AE_Candidate
- I-Not_AE_Candidate
infection I-Not_AE_Candidate
who O
were O
on O
stable O
antiretroviral O
therapy O
. O

The O
most O
common O
adverse O
events O
occurring O
in O
at O
least O
10 O
% O
of O
subjects O
were O
fatigue B-OSE_Labeled_AE
( O
48 O
% O
) O
, O
insomnia B-OSE_Labeled_AE
( O
19 O
% O
) O
, O
nausea B-OSE_Labeled_AE
( O
17 O
% O
) O
, O
headache B-OSE_Labeled_AE
( O
16 O
% O
) O
, O
pruritus B-OSE_Labeled_AE
( O
13 O
% O
) O
, O
cough B-OSE_Labeled_AE
( O
11 O
% O
) O
, O
irritability B-OSE_Labeled_AE
( O
10 O
% O
) O
, O
and O
ocular B-OSE_Labeled_AE
icterus I-OSE_Labeled_AE
( O
10 O
% O
) O
. O

Elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
total I-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
greater O
than O
2 O
x O
ULN O
( O
mostly O
indirect O
) O
occurred O
in O
34 O
( O
54 O
% O
) O
subjects O
. O

Fifteen O
of O
these O
subjects O
were O
also O
receiving O
atazanavir O
at O
the O
time O
of O
bilirubin B-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
and O
nine O
also O
had O
adverse O
events O
of O
ocular B-OSE_Labeled_AE
icterus I-OSE_Labeled_AE
, O
jaundice B-OSE_Labeled_AE
or O
hyperbilirubinemia B-OSE_Labeled_AE
. O

None O
of O
the O
subjects O
with O
hyperbilirubinemia B-NonOSE_AE
had O
concomitant O
elevations B-NonOSE_AE
of I-NonOSE_AE
aminotransferases I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
, O
Adverse O
Reactions O
( O
6.1 O
) O
and O
Clinical O
Studies O
( O
14.6 O
) O
] O
. O

No O
subject O
experienced O
a O
grade O
3 O
ALT B-NonOSE_AE
elevation I-NonOSE_AE
. O

Seven O
subjects O
( O
11 O
% O
) O
had O
at O
least O
one O
post-baseline O
hemoglobin B-OSE_Labeled_AE
value I-OSE_Labeled_AE
of I-OSE_Labeled_AE
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
g I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
, O
and O
six O
of O
these O
subjects O
had O
a O
ribavirin O
dose O
modification O
; O
no O
subject O
in O
this O
small O
cohort O
required O
a O
blood O
transfusion O
or O
erythropoietin O
. O

Median O
declines B-OSE_Labeled_AE
in I-OSE_Labeled_AE
CD I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
+ I-OSE_Labeled_AE
T I-OSE_Labeled_AE
- I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
counts I-OSE_Labeled_AE
of O
47 O
cells/mm O
3 O
and O
62 O
cells/mm O
3 O
were O
observed O
at O
the O
end O
of O
12 O
and O
24 O
weeks O
of O
treatment O
, O
respectively O
, O
and O
most O
returned O
to O
baseline O
levels O
post-treatment O
. O

Two O
subjects O
had O
CD B-OSE_Labeled_AE
4 I-OSE_Labeled_AE
+ I-OSE_Labeled_AE
T I-OSE_Labeled_AE
- I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
counts I-OSE_Labeled_AE
decrease I-OSE_Labeled_AE
to O
less O
than O
200 O
cells/mm O
3 O
during O
treatment O
without O
a O
decrease B-NonOSE_AE
in I-NonOSE_AE
CD I-NonOSE_AE
4 I-NonOSE_AE
% I-NonOSE_AE
. O

No O
subject O
experienced O
an O
AIDS B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
opportunistic I-NonOSE_AE
infection I-NonOSE_AE
. O

VIEKIRA O
PAK O
in O
Selected O
Liver O
Transplant O
Recipients O
VIEKIRA O
PAK O
with O
ribavirin O
was O
assessed O
in O
34 O
post B-Not_AE_Candidate
- I-Not_AE_Candidate
liver I-Not_AE_Candidate
transplant I-Not_AE_Candidate
subjects O
with O
recurrent B-Not_AE_Candidate
HCV O
infection I-Not_AE_Candidate
. O

Adverse O
events O
occurring O
in O
more O
than O
20 O
% O
of O
subjects O
included O
fatigue B-OSE_Labeled_AE
50 O
% O
, O
headache B-OSE_Labeled_AE
44 O
% O
, O
cough B-OSE_Labeled_AE
32 O
% O
, O
diarrhea B-OSE_Labeled_AE
26 O
% O
, O
insomnia B-OSE_Labeled_AE
26 O
% O
, O
asthenia B-OSE_Labeled_AE
24 O
% O
, O
nausea B-OSE_Labeled_AE
24 O
% O
, O
muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
21 O
% O
and O
rash B-OSE_Labeled_AE
21 O
% O
. O

Ten O
subjects O
( O
29 O
% O
) O
had O
at O
least O
one O
post-baseline O
hemoglobin B-OSE_Labeled_AE
value I-OSE_Labeled_AE
of I-OSE_Labeled_AE
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
g I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
. O

Ten O
subjects O
underwent O
a O
ribavirin O
dose O
modification O
due O
to O
decrease O
in O
hemoglobin O
and O
3 O
% O
( O
1/34 O
) O
had O
an O
interruption O
of O
ribavirin O
. O

Five O
subjects O
received O
erythropoietin O
, O
all O
of O
whom O
initiated O
ribavirin O
at O
the O
starting O
dose O
of O
1000 O
to O
1200 O
mg O
daily O
. O

No O
subject O
received O
a O
blood O
transfusion O
[ O
see O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

6.2 O
Post-Marketing O
Adverse O
Reactions O
Hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
including O
angioedema B-OSE_Labeled_AE
) O
have O
been O
observed O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
ALT O
Elevations O
: O
Discontinue O
ethinyl O
estradiol-containing O
medications O
prior O
to O
starting O
VIEKIRA O
PAK O
( O
alternative O
contraceptive O
methods O
are O
recommended O
) O
. O

Perform O
hepatic O
laboratory O
testing O
on O
all O
patients O
during O
the O
first O
4 O
weeks O
of O
treatment O
. O

For O
ALT O
elevations O
on O
VIEKIRA O
PAK O
, O
monitor O
closely O
and O
follow O
recommendations O
in O
full O
prescribing O
information O
. O

( O
5.1 O
) O
* O
Risks O
Associated O
With O
Ribavirin O
Combination O
Treatment O
: O
If O
VIEKIRA O
PAK O
is O
administered O
with O
ribavirin O
, O
the O
warnings O
and O
precautions O
for O
ribavirin O
also O
apply O
to O
this O
combination O
regimen O
. O

( O
5.2 O
) O
* O
Drug O
Interactions O
: O
The O
concomitant O
use O
of O
VIEKIRA O
PAK O
and O
certain O
other O
drugs O
may O
result O
in O
known O
or O
potentially O
significant O
drug O
interactions O
, O
some O
of O
which O
may O
lead O
to O
loss O
of O
therapeutic O
effect O
of O
VIEKIRA O
PAK O
. O

( O
5.3 O
) O
5.1 O
Increased O
Risk O
of O
ALT O
Elevations O
During O
clinical O
trials O
with O
VIEKIRA O
PAK O
with O
or O
without O
ribavirin O
, O
elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
to O
greater O
than O
5 O
times O
the O
upper O
limit O
of O
normal O
( O
ULN O
) O
occurred O
in O
approximately O
1 O
% O
of O
all O
subjects O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

ALT B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
were O
typically O
asymptomatic O
, O
occurred O
during O
the O
first O
4 O
weeks O
of O
treatment O
, O
and O
declined O
within O
two O
to O
eight O
weeks O
of O
onset O
with O
continued O
dosing O
of O
VIEKIRA O
PAK O
with O
or O
without O
ribavirin O
. O

These O
ALT B-NonOSE_AE
elevations I-NonOSE_AE
were O
significantly O
more O
frequent O
in O
female O
subjects O
who O
were O
using O
ethinyl O
estradiol-containing O
medications O
such O
as O
combined O
oral O
contraceptives O
, O
contraceptive O
patches O
or O
contraceptive O
vaginal O
rings O
. O

Ethinyl O
estradiol-containing O
medications O
must O
be O
discontinued O
prior O
to O
starting O
therapy O
with O
VIEKIRA O
PAK O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

Alternative O
methods O
of O
contraception O
( O
e.g O
, O
progestin O
only O
contraception O
or O
non-hormonal O
methods O
) O
are O
recommended O
during O
VIEKIRA O
PAK O
therapy O
. O

Ethinyl O
estradiol-containing O
medications O
can O
be O
restarted O
approximately O
2 O
weeks O
following O
completion O
of O
treatment O
with O
VIEKIRA O
PAK O
. O

Women O
using O
estrogens O
other O
than O
ethinyl O
estradiol O
, O
such O
as O
estradiol O
and O
conjugated O
estrogens O
used O
in O
hormone O
replacement O
therapy O
had O
a O
rate O
of O
ALT B-NonOSE_AE
elevation I-NonOSE_AE
similar O
to O
those O
not O
receiving O
any O
estrogens O
; O
however O
, O
due O
to O
the O
limited O
number O
of O
subjects O
taking O
these O
other O
estrogens O
, O
caution O
is O
warranted O
for O
co-administration O
with O
VIEKIRA O
PAK O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Hepatic O
laboratory O
testing O
should O
be O
performed O
during O
the O
first O
4 O
weeks O
of O
starting O
treatment O
and O
as O
clinically O
indicated O
thereafter O
. O

If O
ALT B-NonOSE_AE
is I-NonOSE_AE
found I-NonOSE_AE
to I-NonOSE_AE
be I-NonOSE_AE
elevated I-NonOSE_AE
above O
baseline O
levels O
, O
it O
should O
be O
repeated O
and O
monitored O
closely O
: O
* O
Patients O
should O
be O
instructed O
to O
consult O
their O
health O
care O
professional O
without O
delay O
if O
they O
have O
onset O
of O
fatigue B-NonOSE_AE
, O
weakness B-NonOSE_AE
, O
lack B-NonOSE_AE
of I-NonOSE_AE
appetite I-NonOSE_AE
, O
nausea B-NonOSE_AE
and O
vomiting B-NonOSE_AE
, O
jaundice B-NonOSE_AE
or O
discolored B-NonOSE_AE
feces I-NonOSE_AE
. O

* O
Consider O
discontinuing O
VIEKIRA O
PAK O
if O
ALT B-NonOSE_AE
levels I-NonOSE_AE
remain I-NonOSE_AE
persistently I-NonOSE_AE
greater I-NonOSE_AE
than I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
times I-NonOSE_AE
the I-NonOSE_AE
ULN I-NonOSE_AE
. O

* O
Discontinue O
VIEKIRA O
PAK O
if O
ALT B-NonOSE_AE
elevation I-NonOSE_AE
is O
accompanied O
by O
signs O
or O
symptoms O
of O
liver B-NonOSE_AE
inflammation I-NonOSE_AE
or O
increasing B-NonOSE_AE
conjugated I-NonOSE_AE
bilirubin I-NonOSE_AE
, O
alkaline O
phosphatase O
, O
or O
INR O
. O

5.2 O
Risks O
Associated O
With O
Ribavirin O
Combination O
Treatment O
If O
VIEKIRA O
PAK O
is O
administered O
with O
ribavirin O
, O
the O
warnings O
and O
precautions O
for O
ribavirin O
, O
in O
particular O
the O
pregnancy B-NonOSE_AE
avoidance O
warning O
, O
apply O
to O
this O
combination O
regimen O
. O

Refer O
to O
the O
ribavirin O
prescribing O
information O
for O
a O
full O
list O
of O
the O
warnings O
and O
precautions O
for O
ribavirin O
. O

5.3 O
Risk O
of O
Adverse O
Reactions O
or O
Reduced O
Therapeutic O
Effect O
Due O
to O
Drug O
Interactions O
The O
concomitant O
use O
of O
VIEKIRA O
PAK O
and O
certain O
other O
drugs O
may O
result O
in O
known O
or O
potentially O
significant O
drug O
interactions O
, O
some O
of O
which O
may O
lead O
to O
: O
* O
Loss O
of O
therapeutic O
effect O
of O
VIEKIRA O
PAK O
and O
possible O
development B-NonOSE_AE
of I-NonOSE_AE
resistance I-NonOSE_AE
* O
Possible O
clinically O
significant O
adverse O
reactions O
from O
greater O
exposures O
of O
concomitant O
drugs O
or O
components O
of O
VIEKIRA O
PAK O
. O

See O
Table O
5 O
for O
steps O
to O
prevent O
or O
manage O
these O
possible O
and O
known O
significant O
drug O
interactions O
, O
including O
dosing O
recommendations O
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

Consider O
the O
potential O
for O
drug O
interactions O
prior O
to O
and O
during O
VIEKIRA O
PAK O
therapy O
; O
review O
concomitant O
medications O
during O
VIEKIRA O
PAK O
therapy O
; O
and O
monitor O
for O
the O
adverse O
reactions O
associated O
with O
the O
concomitant O
drugs O
[ O
see O
Contraindications O
( O
4 O
) O
and O
Drug O
Interactions O
( O
7 O
) O
] O
. O

5.4 O
Risk O
of O
HIV-1 O
Protease O
Inhibitor O
Drug O
Resistance O
in O
HCV/HIV-1 O
Co-infected O
Patients O
The O
ritonavir O
component O
of O
VIEKIRA O
PAK O
is O
also O
an O
HIV-1 O
protease O
inhibitor O
and O
can O
select B-OSE_Labeled_AE
for I-OSE_Labeled_AE
HIV I-OSE_Labeled_AE
- I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
protease I-OSE_Labeled_AE
inhibitor I-OSE_Labeled_AE
resistance I-OSE_Labeled_AE
- I-OSE_Labeled_AE
associated I-OSE_Labeled_AE
substitutions I-OSE_Labeled_AE
. O

Any O
HCV B-Not_AE_Candidate
/ O
HIV B-Not_AE_Candidate
- I-Not_AE_Candidate
1 I-Not_AE_Candidate
co-infected O
patients O
treated O
with O
VIEKIRA O
PAK O
should O
also O
be O
on O
a O
suppressive O
antiretroviral O
drug O
regimen O
to O
reduce O
the O
risk O
of O
HIV B-NonOSE_AE
- I-NonOSE_AE
1 I-NonOSE_AE
protease I-NonOSE_AE
inhibitor I-NonOSE_AE
drug I-NonOSE_AE
resistance I-NonOSE_AE
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Suicidal B-OSE_Labeled_AE
Thoughts I-OSE_Labeled_AE
and O
Behaviors O
in O
Children O
, O
Adolescents O
, O
and O
Young O
Adults O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
Serotonin B-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

* O
Increased O
Risk O
of O
Bleeding B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

* O
Activation O
of O
Mania B-OSE_Labeled_AE
or O
Hypomania B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

* O
Discontinuation B-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

* O
Seizures B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Angle B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Closure I-OSE_Labeled_AE
Glaucoma I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
. O

* O
Hyponatremia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
. O

EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
5 O
% O
and O
at O
least O
twice O
the O
rate O
of O
placebo O
) O
: O
diarrhea O
, O
nausea O
, O
vomiting O
, O
and O
insomnia O
( O
6 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Forest O
Laboratories O
, O
LLC O
. O

at O
1-800-678-1605 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
and O
varying O
lengths O
of O
time O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
studies O
of O
another O
drug O
and O
may O
not O
reflect O
rates O
observed O
in O
practice O
. O

The O
most O
commonly O
observed O
adverse O
reactions O
in O
VIIBRYD-treated O
patients O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( O
MDD O
) O
in O
placebo-controlled O
studies O
( O
incidence O
> O
= O
5 O
% O
and O
at O
least O
twice O
the O
rate O
of O
placebo O
) O
were O
diarrhea B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
and O
insomnia B-OSE_Labeled_AE
. O

Patient O
Exposure O
The O
safety O
of O
VIIBRYD O
was O
evaluated O
in O
3,007 O
patients O
( O
18-70 O
years O
of O
age O
) O
diagnosed O
with O
MDD B-Not_AE_Candidate
who O
participated O
in O
clinical O
studies O
, O
representing O
676 O
patient-years O
of O
exposure O
. O

In O
an O
open-label O
52 O
week O
study O
at O
40 O
mg O
daily O
, O
599 O
patients O
were O
exposed O
to O
VIIBRYD O
for O
a O
total O
of O
348 O
patient-years O
. O

The O
adverse O
reaction O
information O
presented O
below O
was O
derived O
from O
studies O
of O
VIIBRYD O
20 O
mg O
and O
40 O
mg O
daily O
in O
patients O
with O
MDD O
including O
: O
* O
Four O
placebo-controlled O
8 O
to O
10-week O
studies O
in O
2,233 O
patients O
, O
including O
1,266 O
VIIBRYD-treated O
patients O
; O
and O
* O
An O
open-label O
52-week O
study O
of O
599 O
VIIBRYD-treated O
patients O
. O

These O
studies O
included O
a O
titration O
period O
of O
10 O
mg O
daily O
for O
7 O
days O
, O
followed O
by O
20 O
mg O
daily O
for O
7 O
days O
or O
to O
40 O
mg O
daily O
over O
2 O
weeks O
. O

In O
these O
clinical O
trials O
, O
VIIBRYD O
was O
administered O
with O
food O
. O

Adverse O
reactions O
reported O
as O
reasons O
for O
discontinuation O
of O
treatment O
In O
these O
studies O
, O
7.3 O
% O
of O
the O
VIIBRYD-treated O
patients O
discontinued O
treatment O
due O
to O
an O
adverse O
reaction O
, O
compared O
with O
3.5 O
% O
of O
placebo-treated O
patients O
. O

The O
most O
common O
adverse O
reaction O
leading O
to O
discontinuation O
in O
at O
least O
1 O
% O
of O
the O
VIIBRYD-treated O
patients O
in O
the O
placebo-controlled O
studies O
was O
nausea B-OSE_Labeled_AE
( O
1.4 O
% O
) O
. O

Common O
adverse O
reactions O
in O
placebo-controlled O
MDD O
studies O
Table O
2 O
shows O
the O
incidence O
of O
common O
adverse O
reactions O
occuring O
in O
> O
= O
2 O
% O
of O
VIIBRYD-treated O
patients O
and O
greater O
than O
the O
rate O
of O
placebo-treated O
patients O
in O
MDD O
Studies O
. O

There O
were O
no O
dose-related O
adverse O
reactions O
between O
20 O
mg O
and O
40 O
mg O
reported O
. O

Table O
2 O
: O
Common O
Adverse O
Reactions O
Occurring O
in O
> O
= O
2 O
% O
of O
VIIBRYD-treated O
Patients O
and O
Greater O
than O
the O
Rate O
of O
Placebo-Treated O
Patients O
System O
Organ O
Class O
Preferred O
Term O
Placebo O
N=967 O
VIIBRYD O
20 O
mg/day O
N=288 O
VIIBRYD O
40 O
mg/day O
N=978 O
1 O
Includes O
abdominal B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
, O
and O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
. O

2 O
Includes O
headache B-OSE_Labeled_AE
and O
tension B-OSE_Labeled_AE
headache I-OSE_Labeled_AE
3 O
Includes O
restlessness B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
, O
and O
restless B-OSE_Labeled_AE
legs I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
Sexual O
adverse O
reactions O
are O
presented O
in O
Table O
3 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
10 O
% O
26 O
% O
29 O
% O
Nausea B-OSE_Labeled_AE
7 O
% O
22 O
% O
24 O
% O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
5 O
% O
8 O
% O
7 O
% O
Vomiting B-OSE_Labeled_AE
2 O
% O
4 O
% O
5 O
% O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
1 O
3 O
% O
7 O
% O
4 O
% O
Dyspepsia B-OSE_Labeled_AE
2 O
% O
2 O
% O
3 O
% O
Flatulence B-OSE_Labeled_AE
1 O
% O
3 O
% O
3 O
% O
Gastroenteritis B-OSE_Labeled_AE
1 O
% O
1 O
% O
2 O
% O
Abdominal B-OSE_Labeled_AE
distension I-OSE_Labeled_AE
1 O
% O
2 O
% O
1 O
% O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
2 O
14 O
% O
15 O
% O
14 O
% O
Dizziness B-OSE_Labeled_AE
5 O
% O
6 O
% O
8 O
% O
Somnolence B-OSE_Labeled_AE
2 O
% O
4 O
% O
5 O
% O
Paresthesia B-OSE_Labeled_AE
1 O
% O
1 O
% O
2 O
% O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
2 O
% O
7 O
% O
6 O
% O
Abnormal B-OSE_Labeled_AE
dreams I-OSE_Labeled_AE
2 O
% O
2 O
% O
3 O
% O
Restlessness B-OSE_Labeled_AE
3 O
1 O
% O
2 O
% O
3 O
% O
General B-NonOSE_AE
disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
3 O
% O
4 O
% O
3 O
% O
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
Palpitations B-OSE_Labeled_AE
< O
1 O
% O
1 O
% O
2 O
% O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
Increased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
1 O
% O
1 O
% O
3 O
% O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
1 O
% O
2 O
% O
1 O
% O
Investigations B-NonOSE_AE
Increased B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
1 O
% O
1 O
% O
2 O
% O
Sexual O
adverse O
reactions O
Table O
3 O
displays O
the O
most O
common O
sexual O
adverse O
reactions O
in O
the O
placebo-controlled O
MDD O
studies O
. O

Table O
3 O
: O
Common O
Sexual O
Adverse O
Reactions O
Occurring O
in O
> O
= O
2 O
% O
of O
VIIBRYD-treated O
Patients O
and O
Greater O
than O
the O
Rate O
of O
Placebo-Treated O
Patients O
- O
Not O
applicable*Includes O
abnormal B-OSE_Labeled_AE
orgasm I-OSE_Labeled_AE
and O
anorgasmia B-OSE_Labeled_AE
Preferred O
Term O
Males O
Females O
Placebo O
N=416 O
VIIBRYD O
20 O
mg/day O
N=122 O
VIIBRYD O
40 O
mg/day O
N=417 O
Placebo O
N=551 O
VIIBRYD O
20 O
mg/day O
N=166 O
VIIBRYD O
40 O
mg/day O
N=561 O
Abnormal B-OSE_Labeled_AE
Orgasm I-OSE_Labeled_AE
* I-OSE_Labeled_AE
< O
1 O
% O
2 O
% O
2 O
% O
0 O
% O
1 O
% O
1 O
% O
Erectile B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
1 O
% O
0 O
% O
3 O
% O
- O
- O
- O
Libido B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
< O
1 O
% O
3 O
% O
4 O
% O
< O
1 O
% O
2 O
% O
2 O
% O
Ejaculation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
0 O
% O
1 O
% O
2 O
% O
- O
- O
- O
Other O
adverse O
reactions O
observed O
in O
clinical O
studies O
The O
following O
list O
does O
not O
include O
reactions O
: O
1 O
) O
already O
listed O
in O
previous O
tables O
or O
elsewhere O
in O
labeling O
, O
2 O
) O
for O
which O
a O
drug O
cause O
was O
remote O
, O
3 O
) O
which O
were O
so O
general O
as O
to O
be O
uninformative O
, O
4 O
) O
which O
were O
not O
considered O
to O
have O
significant O
clinical O
implications O
, O
or O
5 O
) O
which O
occurred O
at O
a O
rate O
equal O
to O
or O
less O
than O
placebo O
. O

Reactions O
are O
categorized O
by O
body O
system O
according O
to O
the O
following O
definitions O
: O
frequent O
adverse O
reactions O
are O
those O
occurring O
in O
at O
least O
1/100 O
patients O
; O
infrequent O
adverse O
reactions O
are O
those O
occurring O
in O
1/100 O
to O
1/1000 O
patients O
; O
rare O
reactions O
are O
those O
occurring O
in O
fewer O
than O
1/1000 O
patients O
: O
* O
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
infrequent O
: O
ventricular B-OSE_Labeled_AE
extrasystoles I-OSE_Labeled_AE
* O
Eye B-NonOSE_AE
disorders I-NonOSE_AE
: O
infrequent O
: O
dry B-OSE_Labeled_AE
eye I-OSE_Labeled_AE
, O
vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
, O
rare O
: O
cataracts B-OSE_Labeled_AE
* O
Nervous B-NonOSE_AE
System I-NonOSE_AE
: O
frequent O
: O
sedation B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
; O
infrequent O
: O
migraine B-OSE_Labeled_AE
* O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
: O
infrequent O
: O
panic B-OSE_Labeled_AE
attack I-OSE_Labeled_AE
* O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
infrequent O
: O
hyperhidrosis B-OSE_Labeled_AE
, O
night B-OSE_Labeled_AE
sweats I-OSE_Labeled_AE
6.2 O
Post-marketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
VIIBRYD O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Reports O
of O
adverse O
reactions O
temporally O
associated O
with O
VIIBRYD O
that O
have O
been O
received O
since O
market O
introduction O
and O
that O
are O
not O
listed O
above O
include O
the O
following O
: O
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
: O
irritability B-OSE_Labeled_AE
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
: O
hallucinations B-OSE_Labeled_AE
, O
suicide B-OSE_Labeled_AE
attempt I-OSE_Labeled_AE
, O
suicidal B-OSE_Labeled_AE
ideation I-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
rash B-OSE_Labeled_AE
, O
generalized B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
drug B-OSE_Labeled_AE
eruption I-OSE_Labeled_AE

BOXED O
WARNING O
: O
WARNING O
: O
SUICIDAL O
THOUGHTS O
AND O
BEHAVIORS O
WARNING O
: O
SUICIDAL O
THOUGHTS O
AND O
BEHAVIORS O
Antidepressants O
increased O
the O
risk O
of O
suicidal B-OSE_Labeled_AE
thoughts O
and O
behaviors I-OSE_Labeled_AE
in O
patients O
aged O
24 O
years O
and O
younger O
in O
short-term O
studies O
. O

Monitor O
closely O
for O
clinical O
worsening O
and O
for O
emergence O
of O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
and O
behaviors O
. O

The O
safety O
and O
efficacy O
of O
VIIBRYD O
have O
not O
been O
established O
in O
pediatric O
patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
and O
Use O
in O
Specific O
Populations O
( O
8.4 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
SUICIDAL O
THOUGHTS O
AND O
BEHAVIORS O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Antidepressants O
increase O
the O
risk O
of O
suicidal O
thoughts O
and O
behaviors O
in O
patients O
aged O
24 O
years O
and O
younger O
( O
5.1 O
) O
. O

* O
Monitor O
for O
clinical O
worsening O
and O
emergence O
of O
suicidal O
thoughts O
and O
behaviors O
( O
5.1 O
) O
. O

* O
Safety O
and O
effectiveness O
of O
VIIBRYD O
have O
not O
been O
established O
in O
pediatric O
patients O
( O
8.4 O
) O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Serotonin O
Syndrome O
: O
Increased O
risk O
when O
co-administered O
with O
other O
serotonergic O
agents O
( O
e.g. O
, O
SSRI O
, O
SNRI O
, O
triptans O
) O
, O
but O
also O
when O
taken O
alone O
. O

If O
it O
occurs O
, O
discontinue O
VIIBRYD O
and O
initiate O
supportive O
treatment O
( O
5.2 O
) O
* O
Increased O
Risk O
of O
Bleeding O
: O
Concomitant O
use O
of O
aspirin O
, O
nonsteroidal O
anti-inflammatory O
drugs O
( O
NSAIDs O
) O
, O
other O
antiplatelet O
drugs O
, O
warfarin O
, O
and O
other O
anticoagulants O
may O
increase O
this O
risk O
( O
5.3 O
) O
* O
Activation O
of O
Mania/Hypomania O
: O
Screen O
patients O
for O
bipolar O
disorder O
( O
5.4 O
) O
. O

* O
Seizures O
: O
Can O
occur O
with O
treatment O
. O

Use O
with O
caution O
in O
patients O
with O
a O
seizure O
disorder O
( O
5.6 O
) O
. O

* O
Angle O
Closure O
Glaucoma O
: O
Avoid O
use O
of O
antidepressants O
, O
including O
VIIBRYD O
, O
in O
patients O
with O
untreated O
anatomically O
narrow O
angles O
. O

( O
5.7 O
) O
5.1 O
Suicidal O
Thoughts O
and O
Behavior O
in O
Children O
, O
Adolescents O
and O
Young O
Adults O
In O
pooled O
analyses O
of O
placebo-controlled O
trials O
of O
antidepressant O
drugs O
( O
SSRIs O
and O
other O
antidepressant O
classes O
) O
that O
included O
approximately O
77,000 O
adult O
patients O
, O
and O
over O
4,400 O
pediatric O
patients O
, O
the O
incidence O
of O
suicidal B-OSE_Labeled_AE
thoughts O
and O
behaviors I-OSE_Labeled_AE
in O
patients O
age O
24 O
years O
and O
younger O
was O
greater O
in O
antidepressant-treated O
patients O
than O
in O
placebo-treated O
patients O
. O

The O
drug-placebo O
differences O
in O
the O
number O
of O
cases O
of O
suicidal B-NonOSE_AE
thoughts O
and O
behaviors I-NonOSE_AE
per O
1000 O
patients O
treated O
are O
provided O
in O
Table O
1 O
. O

No O
suicides B-NonOSE_AE
occurred O
in O
any O
of O
the O
pediatric O
studies O
. O

There O
were O
suicides B-NonOSE_AE
in O
the O
adult O
studies O
, O
but O
the O
number O
was O
not O
sufficient O
to O
reach O
any O
conclusion O
about O
antidepressant O
drug O
effect O
on O
suicide B-NonOSE_AE
. O

Table O
1 O
: O
Risk O
Differences O
of O
the O
Number O
of O
Patients O
with O
Suicidal O
Thoughts O
or O
Behaviors O
in O
the O
Pooled O
Placebo-Controlled O
Trials O
of O
Antidepressants O
in O
Pediatric O
and O
Adult O
Patients O
Age O
Range O
( O
years O
) O
Drug-Placebo O
Difference O
in O
Number O
of O
Patients O
with O
Suicidal B-OSE_Labeled_AE
Thoughts I-OSE_Labeled_AE
or O
Behaviors O
per O
1000 O
Patients O
Treated O
Increases O
Compared O
to O
Placebo O
< O
18 O
14 O
additional O
patients O
18-24 O
5 O
additional O
patients O
Decreases O
Compared O
to O
Placebo O
25-64 O
1 O
fewer O
patient O
> O
=65 O
6 O
fewer O
patients O
It O
is O
unknown O
whether O
the O
risk O
of O
suicidal B-NonOSE_AE
thoughts O
and O
behaviors I-NonOSE_AE
in O
children O
, O
adolescents O
, O
and O
young O
adults O
extends O
to O
longer-term O
use O
, O
i.e. O
, O
beyond O
four O
months O
. O

However O
, O
there O
is O
substantial O
evidence O
from O
placebo-controlled O
maintenance O
studies O
in O
adults O
with O
MDD B-Not_AE_Candidate
that O
antidepressants O
delay O
the O
recurrence O
of O
depression B-NonOSE_AE
. O

Monitor O
all O
antidepressant-treated O
patients O
for O
clinical O
worsening O
and O
emergence O
of O
suicidal B-NonOSE_AE
thoughts O
and O
behaviors I-NonOSE_AE
, O
especially O
during O
the O
initial O
few O
months O
of O
drug O
therapy O
and O
at O
times O
of O
dosage O
changes O
. O

Counsel O
family O
members O
or O
caregivers O
of O
patients O
to O
monitor O
for O
changes O
in O
behavior O
and O
to O
alert O
the O
healthcare O
provider O
. O

Consider O
changing O
the O
therapeutic O
regimen O
, O
including O
possibly O
discontinuing O
VIIBRYD O
, O
in O
patients O
whose O
depression B-Not_AE_Candidate
is O
persistently O
worse O
, O
or O
who O
are O
experiencing O
emergent O
suicidal B-NonOSE_AE
thoughts O
or O
behaviors I-NonOSE_AE
. O

5.2 O
Serotonin O
Syndrome O
SNRIs O
and O
SSRIs O
, O
including O
VIIBRYD O
, O
can O
precipitate O
serotonin B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
a O
potentially O
life-threatening O
condition O
. O

The O
risk O
is O
increased O
with O
concomitant O
use O
of O
other O
serotonergic O
drugs O
( O
including O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
tryptophan O
, O
buspirone O
, O
and O
St O
. O
John O
's O
Wort O
) O
and O
with O
drugs O
that O
impair O
metabolism O
of O
serotonin O
, O
i.e. O
, O
MAOIs O
[ O
see O
Contraindications O
( O
4 O
) O
and O
Drug O
Interactions O
( O
7 O
) O
] O
. O

Serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
can O
also O
occur O
when O
these O
drugs O
are O
used O
alone O
. O

Symptoms O
of O
serotonin B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
were O
noted O
in O
0.1 O
% O
of O
MDD B-Not_AE_Candidate
patients O
treated O
with O
VIIBRYD O
in O
premarketing O
clinical O
trials O
. O

Serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
signs O
and O
symptoms O
may O
include O
mental B-NonOSE_AE
status I-NonOSE_AE
changes I-NonOSE_AE
( O
e.g. O
, O
agitation B-NonOSE_AE
, O
hallucinations B-NonOSE_AE
, O
delirium B-NonOSE_AE
, O
and O
coma B-NonOSE_AE
) O
, O
autonomic B-NonOSE_AE
instability I-NonOSE_AE
( O
e.g. O
, O
tachycardia B-NonOSE_AE
, O
labile B-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
diaphoresis B-NonOSE_AE
, O
flushing B-NonOSE_AE
, O
hyperthermia B-NonOSE_AE
) O
, O
neuromuscular B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
tremor B-NonOSE_AE
, O
rigidity B-NonOSE_AE
, O
myoclonus B-NonOSE_AE
, O
hyperreflexia B-NonOSE_AE
, O
incoordination B-NonOSE_AE
) O
, O
seizures B-NonOSE_AE
, O
and O
gastrointestinal B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
) O
. O

The O
concomitant O
use O
of O
VIIBRYD O
with O
MAOIs O
is O
contraindicated O
. O

In O
addition O
, O
do O
not O
initiate O
VIIBRYD O
in O
a O
patient O
being O
treated O
with O
MAOIs O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
. O

No O
reports O
involved O
the O
administration O
of O
methylene O
blue O
by O
other O
routes O
( O
such O
as O
oral O
tablets O
or O
local O
tissue O
injection O
) O
. O

If O
it O
is O
necessary O
to O
initiate O
treatment O
with O
an O
MAOI O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
in O
a O
patient O
taking O
VIIBRYD O
, O
discontinue O
VIIBRYD O
before O
initiating O
treatment O
with O
the O
MAOI O
[ O
see O
Contraindications O
( O
4 O
) O
, O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

Monitor O
all O
patients O
taking O
VIIBRYD O
for O
the O
emergence O
of O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
. O

Discontinue O
treatment O
with O
VIIBRYD O
and O
any O
concomitant O
serotonergic O
agents O
immediately O
if O
the O
above O
symptoms O
occur O
, O
and O
initiate O
supportive O
symptomatic O
treatment O
. O

If O
concomitant O
use O
of O
VIIBRYD O
with O
other O
serotonergic O
drugs O
is O
clinically O
warranted O
, O
inform O
patients O
of O
the O
increased O
risk O
for O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
and O
monitor O
for O
symptoms O
. O

5.3 O
Increased O
Risk O
of O
Bleeding O
Drugs O
that O
interfere O
with O
serotonin O
reuptake O
inhibition O
, O
including O
VIIBRYD O
, O
increase O
the O
risk O
of O
bleeding B-OSE_Labeled_AE
events O
. O

Concomitant O
use O
of O
aspirin O
, O
nonsteroidal O
anti-inflammatory O
drugs O
( O
NSAIDS O
) O
, O
other O
antiplatelet O
drugs O
, O
warfarin O
, O
and O
other O
anticoagulants O
may O
add O
to O
this O
risk O
. O

Case O
reports O
and O
epidemiological O
studies O
( O
case-control O
and O
cohort O
design O
) O
have O
demonstrated O
an O
association O
between O
use O
of O
drugs O
that O
interfere O
with O
serotonin O
reuptake O
and O
the O
occurrence O
of O
gastrointestinal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
. O

Bleeding B-OSE_Labeled_AE
events O
related O
to O
drugs O
that O
interfere O
with O
serotonin O
reuptake O
have O
ranged O
from O
ecchymosis B-OSE_Labeled_AE
, O
hematoma B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
and O
petechiae B-OSE_Labeled_AE
to O
life-threatening O
hemorrhages B-OSE_Labeled_AE
. O

Inform O
patients O
about O
the O
risk O
of O
bleeding B-NonOSE_AE
associated O
with O
the O
concomitant O
use O
of O
VIIBRYD O
and O
antiplatelet O
agents O
or O
anticoagulants O
. O

For O
patients O
taking O
warfarin O
, O
carefully O
monitor O
coagulation O
indices O
when O
initiating O
, O
titrating O
, O
or O
discontinuing O
VIIBRYD O
. O

5.4 O
Activation O
of O
Mania O
or O
Hypomania O
In O
patients O
with O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
treating O
a O
depressive B-Not_AE_Candidate
episode I-Not_AE_Candidate
with O
VIIBRYD O
or O
another O
antidepressant O
may O
precipitate O
a O
mixed B-OSE_Labeled_AE
/manic O
episode I-OSE_Labeled_AE
. O

In O
controlled O
clinical O
trials O
, O
patients O
with O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
were O
excluded O
; O
however O
, O
symptoms O
of O
mania B-OSE_Labeled_AE
or O
hypomania B-OSE_Labeled_AE
were O
reported O
in O
0.1 O
% O
of O
undiagnosed O
patients O
treated O
with O
VIIBRYD O
. O

Prior O
to O
initiating O
treatment O
with O
VIIBRYD O
, O
screen O
patients O
for O
any O
personal O
or O
family O
history O
of O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
mania B-Not_AE_Candidate
, O
or O
hypomania B-Not_AE_Candidate
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.5 O
Discontinuation O
Syndrome O
Adverse B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
after I-OSE_Labeled_AE
discontinuation I-OSE_Labeled_AE
of O
serotonergic O
antidepressants O
, O
particularly O
after O
abrupt O
discontinuation O
, O
include O
: O
nausea B-NonOSE_AE
, O
sweating B-NonOSE_AE
, O
dysphoric B-NonOSE_AE
mood I-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
agitation B-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
sensory B-NonOSE_AE
disturbances I-NonOSE_AE
( O
e.g. O
, O
paresthesia B-NonOSE_AE
, O
such O
as O
electric B-NonOSE_AE
shock I-NonOSE_AE
sensations I-NonOSE_AE
) O
, O
tremor B-NonOSE_AE
, O
anxiety B-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
lethargy B-NonOSE_AE
, O
emotional B-NonOSE_AE
lability I-NonOSE_AE
, O
insomnia B-NonOSE_AE
, O
hypomania B-NonOSE_AE
, O
tinnitus B-NonOSE_AE
, O
and O
seizures B-NonOSE_AE
. O

A O
gradual O
reduction O
in O
dosage O
rather O
than O
abrupt O
cessation O
is O
recommended O
whenever O
possible O
[ O
see O
Dosage O
and O
Administration O
( O
2.5 O
) O
] O
. O

5.6 O
Seizures O
VIIBRYD O
has O
not O
been O
systematically O
evaluated O
in O
patients O
with O
a O
seizure B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

Patients O
with O
a O
history O
of O
seizures B-Not_AE_Candidate
were O
excluded O
from O
clinical O
studies O
. O

VIIBRYD O
should O
be O
prescribed O
with O
caution O
in O
patients O
with O
a O
seizure B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

5.7 O
Angle-Closure O
Glaucoma O
The O
pupillary B-OSE_Labeled_AE
dilation I-OSE_Labeled_AE
that O
occurs O
following O
use O
of O
many O
antidepressant O
drugs O
including O
VIIBRYD O
may O
trigger O
an O
angle B-OSE_Labeled_AE
closure I-OSE_Labeled_AE
attack I-OSE_Labeled_AE
in O
a O
patient O
with O
anatomically B-Not_AE_Candidate
narrow I-Not_AE_Candidate
angles I-Not_AE_Candidate
who O
does O
not O
have O
a O
patent O
iridectomy O
. O

Avoid O
use O
of O
antidepressants O
, O
including O
VIIBRYD O
, O
in O
patients O
with O
untreated O
anatomically B-Not_AE_Candidate
narrow I-Not_AE_Candidate
angles I-Not_AE_Candidate
. O

5.8 O
Hyponatremia O
Hyponatremia B-OSE_Labeled_AE
may O
occur O
as O
a O
result O
of O
treatment O
with O
SNRIs O
and O
SSRIs O
, O
including O
VIIBRYD O
. O

Cases O
of O
serum B-OSE_Labeled_AE
sodium I-OSE_Labeled_AE
lower I-OSE_Labeled_AE
than I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mmol I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
have O
been O
reported O
. O

Signs O
and O
symptoms O
of O
hyponatremia B-NonOSE_AE
include O
headache B-NonOSE_AE
, O
difficulty B-NonOSE_AE
concentrating I-NonOSE_AE
, O
memory B-NonOSE_AE
impairment I-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
weakness B-NonOSE_AE
, O
and O
unsteadiness B-NonOSE_AE
, O
which O
may O
lead O
to O
falls B-NonOSE_AE
. O

Signs O
and O
symptoms O
associated O
with O
more O
severe O
and/or O
acute O
cases O
have O
included O
hallucination B-NonOSE_AE
, O
syncope B-NonOSE_AE
, O
seizure B-NonOSE_AE
, O
coma B-NonOSE_AE
, O
respiratory B-NonOSE_AE
arrest I-NonOSE_AE
, O
and O
death B-NonOSE_AE
. O

In O
many O
cases O
, O
this O
hyponatremia B-OSE_Labeled_AE
appears O
to O
be O
the O
result O
of O
the O
syndrome B-OSE_Labeled_AE
of I-OSE_Labeled_AE
inappropriate I-OSE_Labeled_AE
antidiuretic I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
secretion I-OSE_Labeled_AE
( O
SIADH O
) O
. O

In O
patients O
with O
symptomatic O
hyponatremia B-NonOSE_AE
, O
discontinue O
VIIBRYD O
and O
institute O
appropriate O
medical O
intervention O
. O

Elderly O
patients O
, O
patients O
taking O
diuretics O
, O
and O
those O
who O
are O
volume B-Not_AE_Candidate
- I-Not_AE_Candidate
depleted I-Not_AE_Candidate
may O
be O
at O
greater O
risk O
of O
developing O
hyponatremia B-NonOSE_AE
with O
SSRIs O
and O
SNRIs O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
] O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
described O
below O
and O
elsewhere O
in O
the O
labeling O
: O
* O
Suicidal B-OSE_Labeled_AE
Behavior I-OSE_Labeled_AE
and O
Ideation O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Dizziness B-OSE_Labeled_AE
and O
Ataxia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Cardiac B-OSE_Labeled_AE
Rhythm I-OSE_Labeled_AE
and O
Conduction O
Abnormalities I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Syncope B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Multiorgan B-OSE_Labeled_AE
Hypersensitivity I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Monotherapy O
: O
Most O
common O
adverse O
reactions O
are O
similar O
to O
those O
seen O
in O
adjunctive O
therapy O
studies O
( O
6.1 O
) O
* O
Adjunctive O
therapy O
: O
Most O
common O
adverse O
reactions O
( O
> O
=10 O
% O
and O
greater O
than O
placebo O
) O
are O
diplopia B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
( O
6.1 O
) O
EXCERPT O
: O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
UCB O
, O
Inc O
. O
at O
1-844-599-2273 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

In O
the O
premarketing O
development O
of O
adjunctive O
therapy O
for O
partial B-Not_AE_Candidate
-onset O
seizures I-Not_AE_Candidate
, O
1327 O
patients O
received O
VIMPAT O
in O
controlled O
and O
uncontrolled O
trials O
, O
of O
whom O
1000 O
were O
treated O
for O
longer O
than O
6 O
months O
, O
and O
852 O
for O
longer O
than O
12 O
months O
. O

The O
monotherapy O
development O
program O
included O
425 O
patients O
, O
310 O
of O
whom O
were O
treated O
for O
longer O
than O
6 O
months O
, O
and O
254 O
for O
longer O
than O
12 O
months O
. O

VIMPAT O
Tablet O
and O
Oral O
Solution O
Monotherapy O
Historical-Control O
Trial O
( O
Study O
1 O
) O
* O
In O
the O
monotherapy O
trial O
, O
16 O
% O
of O
patients O
randomized O
to O
receive O
VIMPAT O
at O
the O
recommended O
doses O
of O
300 O
and O
400 O
mg/day O
discontinued O
from O
the O
trial O
as O
a O
result O
of O
an O
adverse O
reaction O
. O

The O
adverse O
reaction O
most O
commonly O
( O
> O
=1 O
% O
on O
VIMPAT O
) O
leading O
to O
discontinuation O
was O
dizziness B-OSE_Labeled_AE
. O

* O
Adverse O
reactions O
that O
occurred O
in O
this O
study O
were O
generally O
similar O
to O
those O
that O
occurred O
in O
adjunctive O
placebo-controlled O
studies O
. O

One O
adverse O
reaction O
, O
insomnia B-OSE_Labeled_AE
, O
occurred O
at O
a O
rate O
of O
> O
=2 O
% O
and O
was O
not O
reported O
at O
a O
similar O
rate O
in O
previous O
studies O
. O

This O
adverse O
reaction O
has O
also O
been O
observed O
in O
postmarketing O
experience O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

Because O
this O
study O
did O
not O
include O
a O
placebo O
control O
group O
, O
causality O
could O
not O
be O
established O
. O

* O
Dizziness B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
and O
fatigue B-OSE_Labeled_AE
all O
occurred O
at O
lower O
incidences O
during O
the O
AED O
Withdrawal O
Phase O
and O
Monotherapy O
Phase O
, O
compared O
with O
the O
Titration O
Phase O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

Adjunctive O
Therapy O
Controlled O
Trials O
( O
Studies O
2 O
, O
3 O
, O
and O
4 O
) O
* O
In O
adjunctive O
therapy O
controlled O
clinical O
trials O
, O
the O
rate O
of O
discontinuation O
as O
a O
result O
of O
an O
adverse O
reaction O
was O
8 O
% O
and O
17 O
% O
in O
patients O
randomized O
to O
receive O
VIMPAT O
at O
the O
recommended O
doses O
of O
200 O
and O
400 O
mg/day O
, O
respectively O
, O
29 O
% O
at O
600 O
mg/day O
, O
and O
5 O
% O
in O
patients O
randomized O
to O
receive O
placebo O
. O

The O
adverse O
reactions O
most O
commonly O
( O
> O
1 O
% O
on O
VIMPAT O
and O
greater O
than O
placebo O
) O
leading O
to O
discontinuation O
were O
dizziness B-OSE_Labeled_AE
, O
ataxia B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
diplopia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
vertigo B-OSE_Labeled_AE
, O
and O
blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
. O

* O
Table O
2 O
gives O
the O
incidence O
of O
adverse O
reactions O
that O
occurred O
in O
> O
=2 O
% O
of O
adult O
patients O
with O
partial B-Not_AE_Candidate
-onset O
seizures I-Not_AE_Candidate
in O
the O
VIMPAT O
total O
group O
and O
for O
which O
the O
incidence O
was O
greater O
than O
placebo O
. O

Table O
2 O
: O
Adverse O
Reactions O
Incidence O
in O
Adjunctive O
Therapy O
Pooled O
, O
Placebo-Controlled O
Trials O
in O
Patients O
with O
Partial-Onset O
Seizures O
( O
Studies O
2 O
, O
3 O
, O
and O
4 O
) O
System O
Organ O
Class/Preferred O
Term O
PlaceboN=364 O
% O
VIMPAT200 O
mg/dayN=270 O
% O
VIMPAT400 O
mg/dayN=471 O
% O
VIMPAT600 O
mg/dayN=203 O
% O
VIMPATTotalN=944 O
% O
Ear B-NonOSE_AE
and I-NonOSE_AE
labyrinth I-NonOSE_AE
disorder I-NonOSE_AE
Vertigo B-OSE_Labeled_AE
1 O
5 O
3 O
4 O
4 O
Eye B-NonOSE_AE
disorders I-NonOSE_AE
Diplopia B-OSE_Labeled_AE
2 O
6 O
10 O
16 O
11 O
Blurred B-OSE_Labeled_AE
Vision I-OSE_Labeled_AE
3 O
2 O
9 O
16 O
8 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
4 O
7 O
11 O
17 O
11 O
Vomiting B-OSE_Labeled_AE
3 O
6 O
9 O
16 O
9 O
Diarrhea B-OSE_Labeled_AE
3 O
3 O
5 O
4 O
4 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
6 O
7 O
7 O
15 O
9 O
Gait B-OSE_Labeled_AE
disturbance I-OSE_Labeled_AE
< O
1 O
< O
1 O
2 O
4 O
2 O
Asthenia B-OSE_Labeled_AE
1 O
2 O
2 O
4 O
2 O
Injury B-NonOSE_AE
, I-NonOSE_AE
poisoning I-NonOSE_AE
and I-NonOSE_AE
procedural I-NonOSE_AE
complications I-NonOSE_AE
Contusion B-OSE_Labeled_AE
3 O
3 O
4 O
2 O
3 O
Skin B-OSE_Labeled_AE
laceration I-OSE_Labeled_AE
2 O
2 O
3 O
3 O
3 O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
8 O
16 O
30 O
53 O
31 O
Headache B-OSE_Labeled_AE
9 O
11 O
14 O
12 O
13 O
Ataxia B-OSE_Labeled_AE
2 O
4 O
7 O
15 O
8 O
Somnolence B-OSE_Labeled_AE
5 O
5 O
8 O
8 O
7 O
Tremor B-OSE_Labeled_AE
4 O
4 O
6 O
12 O
7 O
Nystagmus B-OSE_Labeled_AE
4 O
2 O
5 O
10 O
5 O
Balance B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
0 O
1 O
5 O
6 O
4 O
Memory B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
2 O
1 O
2 O
6 O
2 O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
Depression B-OSE_Labeled_AE
1 O
2 O
2 O
2 O
2 O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
disorders I-NonOSE_AE
Pruritus B-OSE_Labeled_AE
1 O
3 O
2 O
3 O
2 O
The O
overall O
adverse O
reaction O
rate O
was O
similar O
in O
male O
and O
female O
patients O
. O

Although O
there O
were O
few O
non-Caucasian O
patients O
, O
no O
differences O
in O
the O
incidences O
of O
adverse O
events O
compared O
to O
Caucasian O
patients O
were O
observed O
. O

Laboratory O
Abnormalities O
* O
Abnormalities B-OSE_Labeled_AE
in O
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
have O
occurred O
in O
controlled O
trials O
with O
VIMPAT O
in O
adult O
patients O
with O
partial B-Not_AE_Candidate
-onset O
seizures I-Not_AE_Candidate
who O
were O
taking O
1 O
to O
3 O
concomitant O
anti-epileptic O
drugs O
. O

Elevations B-OSE_Labeled_AE
of O
ALT I-OSE_Labeled_AE
to O
> O
=3* O
ULN O
occurred O
in O
0.7 O
% O
( O
7/935 O
) O
of O
VIMPAT O
patients O
and O
0 O
% O
( O
0/356 O
) O
of O
placebo O
patients O
. O

One O
case O
of O
hepatitis B-OSE_Labeled_AE
with O
transaminases B-NonOSE_AE
> I-NonOSE_AE
2 I-NonOSE_AE
0 I-NonOSE_AE
* I-NonOSE_AE
ULN I-NonOSE_AE
occurred O
in O
one O
healthy O
subject O
10 O
days O
after O
VIMPAT O
treatment O
completion O
, O
along O
with O
nephritis B-OSE_Labeled_AE
( O
proteinuria B-NonOSE_AE
and O
urine B-NonOSE_AE
casts I-NonOSE_AE
) O
. O

Serologic O
studies O
were O
negative O
for O
viral B-NonOSE_AE
hepatitis I-NonOSE_AE
. O

Transaminases O
returned O
to O
normal O
within O
one O
month O
without O
specific O
treatment O
. O

At O
the O
time O
of O
this O
event O
, O
bilirubin O
was O
normal O
. O

The O
hepatitis B-NonOSE_AE
/ O
nephritis B-NonOSE_AE
was O
interpreted O
as O
a O
delayed B-OSE_Labeled_AE
hypersensitivity I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
to O
VIMPAT O
. O

Other O
Adverse O
Reactions O
* O
The O
following O
is O
a O
list O
of O
adverse O
reactions O
reported O
by O
patients O
treated O
with O
VIMPAT O
in O
all O
clinical O
trials O
in O
patients O
with O
partial B-Not_AE_Candidate
-onset O
seizures I-Not_AE_Candidate
, O
including O
controlled O
trials O
and O
long-term O
open-label O
extension O
trials O
. O

Adverse O
reactions O
addressed O
in O
other O
tables O
or O
sections O
are O
not O
listed O
here O
. O

* O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
neutropenia B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
* O
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
palpitations B-OSE_Labeled_AE
* O
Ear B-NonOSE_AE
and I-NonOSE_AE
labyrinth I-NonOSE_AE
disorders I-NonOSE_AE
: O
tinnitus B-OSE_Labeled_AE
* O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
constipation B-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
oral B-OSE_Labeled_AE
hypoaesthesia I-OSE_Labeled_AE
* O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
: O
irritability B-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
, O
feeling B-OSE_Labeled_AE
drunk I-OSE_Labeled_AE
* O
Injury B-NonOSE_AE
, I-NonOSE_AE
poisoning I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
procedural I-NonOSE_AE
complications I-NonOSE_AE
: O
fall B-OSE_Labeled_AE
* O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
* O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
paresthesia B-OSE_Labeled_AE
, O
cognitive B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
hypoaesthesia B-OSE_Labeled_AE
, O
dysarthria B-OSE_Labeled_AE
, O
disturbance B-OSE_Labeled_AE
in I-OSE_Labeled_AE
attention I-OSE_Labeled_AE
, O
cerebellar B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
* O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
: O
confusional B-OSE_Labeled_AE
state I-OSE_Labeled_AE
, O
mood B-OSE_Labeled_AE
altered I-OSE_Labeled_AE
, O
depressed B-OSE_Labeled_AE
mood I-OSE_Labeled_AE
VIMPAT O
Injection O
Adverse O
reactions O
with O
intravenous O
administration O
generally O
were O
similar O
to O
those O
that O
occurred O
with O
the O
oral O
formulation O
, O
although O
intravenous O
administration O
was O
associated O
with O
local O
adverse O
reactions O
such O
as O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
or O
discomfort O
( O
2.5 O
% O
) O
, O
irritation O
( O
1 O
% O
) O
, O
and O
erythema O
( O
0.5 O
% O
) O
. O

One O
case O
of O
profound O
bradycardia B-NonOSE_AE
( O
26 O
bpm O
: O
BP O
100/60 O
mmHg O
) O
occurred O
in O
a O
patient O
during O
a O
15-minute O
infusion O
of O
150 O
mg O
VIMPAT O
. O

This O
patient O
was O
on O
a O
beta-blocker O
. O

Infusion O
was O
discontinued O
and O
the O
patient O
experienced O
a O
rapid O
recovery O
. O

The O
safety O
of O
a O
15-minute O
loading O
dose O
administration O
of O
VIMPAT O
Injection O
200 O
mg O
to O
400 O
mg O
followed O
by O
oral O
administration O
of O
VIMPAT O
given O
twice O
daily O
at O
the O
same O
total O
daily O
dose O
as O
the O
initial O
intravenous O
infusion O
was O
assessed O
in O
an O
open-label O
study O
in O
patients O
with O
partial B-Not_AE_Candidate
-onset O
seizures I-Not_AE_Candidate
. O

Patients O
had O
to O
have O
been O
maintained O
on O
a O
stable O
dose O
regimen O
of O
1 O
to O
2 O
marketed O
antiepileptics O
for O
at O
least O
28 O
days O
prior O
to O
treatment O
assignment O
. O

Treatment O
groups O
were O
as O
follows O
: O
* O
Single O
dose O
of O
intravenous O
VIMPAT O
Injection O
200 O
mg O
followed O
by O
oral O
VIMPAT O
200 O
mg/day O
( O
100 O
mg O
every O
12 O
hours O
) O
* O
Single O
dose O
of O
intravenous O
VIMPAT O
Injection O
300 O
mg O
followed O
by O
oral O
VIMPAT O
300 O
mg/day O
( O
150 O
mg O
every O
12 O
hours O
) O
* O
Single O
dose O
of O
intravenous O
VIMPAT O
Injection O
400 O
mg O
followed O
by O
oral O
VIMPAT O
400 O
mg/day O
( O
200 O
mg O
every O
12 O
hours O
) O
. O

Table O
3 O
gives O
the O
incidence O
of O
adverse O
reactions O
that O
occurred O
in O
> O
=5 O
% O
of O
adult O
patients O
in O
any O
VIMPAT O
dosing O
group O
. O

Table O
3 O
: O
Adverse O
Reactions O
in O
a O
15-minute O
Infusion O
Study O
in O
Patients O
with O
Partial-Onset O
Seizures O
System O
Organ O
Class/Preferred O
Term O
VIMPAT O
200 O
mgN=25 O
% O
VIMPAT O
300 O
mgN=50 O
% O
VIMPAT O
400 O
mgN=25 O
% O
VIMPAT O
TotalN=100 O
% O
Eye B-NonOSE_AE
disorders I-NonOSE_AE
Diplopia B-OSE_Labeled_AE
4 O
6 O
20 O
9 O
Blurred B-OSE_Labeled_AE
Vision I-OSE_Labeled_AE
0 O
4 O
12 O
5 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
0 O
16 O
24 O
14 O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
0 O
6 O
12 O
6 O
Vomiting B-OSE_Labeled_AE
0 O
4 O
12 O
5 O
Oral B-OSE_Labeled_AE
Paresthesia I-OSE_Labeled_AE
4 O
4 O
8 O
5 O
Oral B-OSE_Labeled_AE
Hypoesthesia I-OSE_Labeled_AE
0 O
6 O
8 O
5 O
Diarrhea B-OSE_Labeled_AE
0 O
8 O
0 O
4 O
General B-NonOSE_AE
disorders I-NonOSE_AE
/ I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
0 O
18 O
12 O
12 O
Gait B-OSE_Labeled_AE
disturbance I-OSE_Labeled_AE
8 O
2 O
0 O
3 O
Chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
0 O
0 O
12 O
3 O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
20 O
46 O
60 O
43 O
Somnolence B-OSE_Labeled_AE
0 O
34 O
36 O
26 O
Headache B-OSE_Labeled_AE
8 O
4 O
16 O
8 O
Paresthesia B-OSE_Labeled_AE
8 O
6 O
4 O
6 O
Tremor B-OSE_Labeled_AE
0 O
6 O
4 O
4 O
Abnormal B-OSE_Labeled_AE
Coordination I-OSE_Labeled_AE
0 O
6 O
0 O
3 O
Skin B-NonOSE_AE
& I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Pruritus B-OSE_Labeled_AE
0 O
6 O
4 O
4 O
Hyperhidrosis B-OSE_Labeled_AE
0 O
0 O
8 O
2 O
Adverse O
reactions O
that O
occurred O
with O
infusion O
of O
VIMPAT O
200 O
mg O
over O
15-minutes O
followed O
by O
VIMPAT O
100 O
mg O
administered O
orally O
twice O
per O
day O
were O
similar O
in O
frequency O
to O
those O
that O
occurred O
in O
3-month O
adjunctive O
therapy O
controlled O
trials O
. O

Considering O
the O
difference O
in O
period O
of O
observations O
( O
1 O
week O
vs O
. O
3 O
months O
) O
, O
the O
incidence O
of O
CNS O
adverse O
reactions O
, O
such O
as O
dizziness B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
and O
paresthesia B-OSE_Labeled_AE
may O
be O
higher O
with O
15-minute O
administration O
of O
VIMPAT O
Injection O
than O
with O
administration O
over O
a O
30-to O
60-minute O
period O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
VIMPAT O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
Agranulocytosis B-OSE_Labeled_AE
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
: O
Aggression B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
hallucination B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
psychotic B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
Angioedema B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Monitor O
patients O
for O
suicidal O
behavior O
and O
ideation O
( O
5.1 O
) O
* O
VIMPAT O
may O
cause O
dizziness O
and O
ataxia O
( O
5.2 O
) O
* O
Cardiac O
Rhythm O
and O
Conduction O
Abnormalities O
: O
ECG O
before O
beginning O
VIMPAT O
, O
and O
after O
VIMPAT O
is O
titrated O
to O
steady-state O
maintenance O
dose O
is O
recommended O
in O
patients O
with O
known O
cardiac O
conduction O
problems O
, O
taking O
drugs O
known O
to O
induce O
PR O
interval O
prolongation O
, O
or O
with O
severe O
cardiac O
disease O
( O
5.3 O
) O
* O
VIMPAT O
may O
cause O
syncope O
( O
5.4 O
) O
* O
VIMPAT O
should O
be O
gradually O
withdrawn O
to O
minimize O
the O
potential O
of O
increased O
seizure O
frequency O
( O
5.5 O
) O
* O
Multiorgan O
Hypersensitivity O
Reactions O
( O
5.6 O
) O
5.1 O
Suicidal O
Behavior O
and O
Ideation O
Antiepileptic O
drugs O
( O
AEDs O
) O
, O
including O
VIMPAT O
, O
increase O
the O
risk O
of O
suicidal B-OSE_Labeled_AE
thoughts I-OSE_Labeled_AE
or O
behavior O
in O
patients O
taking O
these O
drugs O
for O
any O
indication O
. O

Patients O
treated O
with O
any O
AED O
for O
any O
indication O
should O
be O
monitored O
for O
the O
emergence O
or O
worsening B-NonOSE_AE
of I-NonOSE_AE
depression I-NonOSE_AE
, O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
or O
behavior O
, O
and/or O
any O
unusual O
changes B-NonOSE_AE
in I-NonOSE_AE
mood I-NonOSE_AE
or O
behavior O
. O

Pooled O
analyses O
of O
199 O
placebo-controlled O
clinical O
trials O
( O
mono- O
and O
adjunctive O
therapy O
) O
of O
11 O
different O
AEDs O
showed O
that O
patients O
randomized O
to O
one O
of O
the O
AEDs O
had O
approximately O
twice O
the O
risk O
( O
adjusted O
Relative O
Risk O
1.8 O
, O
95 O
% O
CI:1.2 O
, O
2.7 O
) O
of O
suicidal B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
or O
behavior O
compared O
to O
patients O
randomized O
to O
placebo O
. O

In O
these O
trials O
, O
which O
had O
a O
median O
treatment O
duration O
of O
12 O
weeks O
, O
the O
estimated O
incidence O
of O
suicidal B-OSE_Labeled_AE
behavior I-OSE_Labeled_AE
or O
ideation O
among O
27,863 O
AED-treated O
patients O
was O
0.43 O
% O
, O
compared O
to O
0.24 O
% O
among O
16,029 O
placebo-treated O
patients O
, O
representing O
an O
increase O
of O
approximately O
one O
case O
of O
suicidal B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
or O
behavior O
for O
every O
530 O
patients O
treated O
. O

There O
were O
four O
suicides B-OSE_Labeled_AE
in O
drug-treated O
patients O
in O
the O
trials O
and O
none O
in O
placebo-treated O
patients O
, O
but O
the O
number O
of O
events O
is O
too O
small O
to O
allow O
any O
conclusion O
about O
drug O
effect O
on O
suicide B-NonOSE_AE
. O

The O
increased O
risk O
of O
suicidal B-OSE_Labeled_AE
thoughts I-OSE_Labeled_AE
or O
behavior O
with O
AEDs O
was O
observed O
as O
early O
as O
one O
week O
after O
starting O
treatment O
with O
AEDs O
and O
persisted O
for O
the O
duration O
of O
treatment O
assessed O
. O

Because O
most O
trials O
included O
in O
the O
analysis O
did O
not O
extend O
beyond O
24 O
weeks O
, O
the O
risk O
of O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
or O
behavior O
beyond O
24 O
weeks O
could O
not O
be O
assessed O
. O

The O
risk O
of O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
or O
behavior O
was O
generally O
consistent O
among O
drugs O
in O
the O
data O
analyzed O
. O

The O
finding O
of O
increased O
risk O
with O
AEDs O
of O
varying O
mechanisms O
of O
action O
and O
across O
a O
range O
of O
indications O
suggests O
that O
the O
risk O
applies O
to O
all O
AEDs O
used O
for O
any O
indication O
. O

The O
risk O
did O
not O
vary O
substantially O
by O
age O
( O
5-100 O
years O
) O
in O
the O
clinical O
trials O
analyzed O
. O

Table O
1 O
shows O
absolute O
and O
relative O
risk O
by O
indication O
for O
all O
evaluated O
AEDs O
. O

Table O
1 O
Risk O
by O
Indication O
for O
Antiepileptic O
Drugs O
in O
the O
Pooled O
Analysis O
Indication O
Placebo O
Patients O
with O
Events O
Per O
1000 O
Patients O
Drug O
Patients O
with O
Events O
Per O
1000 O
Patients O
Relative O
Risk O
: O
Incidence O
of O
Events O
in O
Drug O
Patients/Incidence O
in O
Placebo O
Patients O
Risk O
Difference O
: O
Additional O
Drug O
Patients O
with O
Events O
Per O
1000 O
Patients O
Epilepsy B-Not_AE_Candidate
1.0 O
3.4 O
3.5 O
2.4 O
Psychiatric B-Not_AE_Candidate
5.7 O
8.5 O
1.5 O
2.9 O
Other O
1.0 O
1.8 O
1.9 O
0.9 O
Total O
2.4 O
4.3 O
1.8 O
1.9 O
The O
relative O
risk O
for O
suicidal B-OSE_Labeled_AE
thoughts O
or O
behavior I-OSE_Labeled_AE
was O
higher O
in O
clinical O
trials O
for O
epilepsy B-Not_AE_Candidate
than O
in O
clinical O
trials O
for O
psychiatric B-Not_AE_Candidate
or O
other O
conditions O
, O
but O
the O
absolute O
risk O
differences O
were O
similar O
. O

Anyone O
considering O
prescribing O
VIMPAT O
or O
any O
other O
AED O
must O
balance O
this O
risk O
with O
the O
risk O
of O
untreated O
illness O
. O

Epilepsy B-Not_AE_Candidate
and O
many O
other O
illnesses O
for O
which O
antiepileptics O
are O
prescribed O
are O
themselves O
associated O
with O
morbidity O
and O
mortality O
and O
an O
increased O
risk O
of O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
and O
behavior O
. O

Should O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
and O
behavior O
emerge O
during O
treatment O
, O
the O
prescriber O
needs O
to O
consider O
whether O
the O
emergence O
of O
these O
symptoms O
in O
any O
given O
patient O
may O
be O
related O
to O
the O
illness O
being O
treated O
. O

Patients O
, O
their O
caregivers O
, O
and O
families O
should O
be O
informed O
that O
AEDs O
increase O
the O
risk O
of O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
and O
behavior O
and O
should O
be O
advised O
of O
the O
need O
to O
be O
alert O
for O
the O
emergence O
or O
worsening O
of O
the O
signs O
and O
symptoms O
of O
depression B-NonOSE_AE
, O
any O
unusual O
changes B-NonOSE_AE
in I-NonOSE_AE
mood I-NonOSE_AE
or O
behavior O
, O
or O
the O
emergence O
of O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
, O
behavior O
, O
or O
thoughts B-NonOSE_AE
about I-NonOSE_AE
self I-NonOSE_AE
- I-NonOSE_AE
harm I-NonOSE_AE
. O

Behaviors B-NonOSE_AE
of I-NonOSE_AE
concern I-NonOSE_AE
should O
be O
reported O
immediately O
to O
healthcare O
providers O
. O

5.2 O
Dizziness O
and O
Ataxia O
VIMPAT O
may O
cause O
dizziness B-OSE_Labeled_AE
and O
ataxia B-OSE_Labeled_AE
. O

In O
patients O
with O
partial B-Not_AE_Candidate
-onset O
seizures I-Not_AE_Candidate
taking O
1 O
to O
3 O
concomitant O
AEDs O
, O
dizziness B-OSE_Labeled_AE
was O
experienced O
by O
25 O
% O
of O
patients O
randomized O
to O
the O
recommended O
doses O
( O
200 O
to O
400 O
mg/day O
) O
of O
VIMPAT O
( O
compared O
with O
8 O
% O
of O
placebo O
patients O
) O
and O
was O
the O
adverse O
event O
most O
frequently O
leading O
to O
discontinuation O
( O
3 O
% O
) O
. O

Ataxia B-OSE_Labeled_AE
was O
experienced O
by O
6 O
% O
of O
patients O
randomized O
to O
the O
recommended O
doses O
( O
200 O
to O
400 O
mg/day O
) O
of O
VIMPAT O
( O
compared O
to O
2 O
% O
of O
placebo O
patients O
) O
. O

The O
onset O
of O
dizziness B-OSE_Labeled_AE
and O
ataxia B-OSE_Labeled_AE
was O
most O
commonly O
observed O
during O
titration O
. O

There O
was O
a O
substantial O
increase O
in O
these O
adverse O
events O
at O
doses O
higher O
than O
400 O
mg/day O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.3 O
Cardiac O
Rhythm O
and O
Conduction O
Abnormalities O
PR O
interval O
prolongation O
Dose-dependent O
prolongations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
PR I-OSE_Labeled_AE
interval I-OSE_Labeled_AE
with O
VIMPAT O
have O
been O
observed O
in O
clinical O
studies O
in O
patients O
and O
in O
healthy O
volunteers O
[ O
see O
Clinical O
Pharmacology O
( O
12.2 O
) O
] O
. O

In O
adjunctive O
clinical O
trials O
in O
patients O
with O
partial B-Not_AE_Candidate
-onset O
epilepsy I-Not_AE_Candidate
, O
asymptomatic O
first B-OSE_Labeled_AE
- I-OSE_Labeled_AE
degree I-OSE_Labeled_AE
atrioventricular I-OSE_Labeled_AE
( O
AV O
) O
block I-OSE_Labeled_AE
was O
observed O
as O
an O
adverse O
reaction O
in O
0.4 O
% O
( O
4/944 O
) O
of O
patients O
randomized O
to O
receive O
VIMPAT O
and O
0 O
% O
( O
0/364 O
) O
of O
patients O
randomized O
to O
receive O
placebo O
. O

In O
clinical O
trials O
in O
patients O
with O
diabetic B-Not_AE_Candidate
neuropathy I-Not_AE_Candidate
, O
asymptomatic O
first B-OSE_Labeled_AE
- I-OSE_Labeled_AE
degree I-OSE_Labeled_AE
AV I-OSE_Labeled_AE
block I-OSE_Labeled_AE
was O
observed O
as O
an O
adverse O
reaction O
in O
0.5 O
% O
( O
5/1023 O
) O
of O
patients O
receiving O
VIMPAT O
and O
0 O
% O
( O
0/291 O
) O
of O
patients O
receiving O
placebo O
. O

Second B-OSE_Labeled_AE
degree I-OSE_Labeled_AE
and O
complete O
AV I-OSE_Labeled_AE
block I-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
in O
pain B-Not_AE_Candidate
studies O
and O
in O
patients O
with O
seizures B-Not_AE_Candidate
. O

When O
VIMPAT O
is O
given O
with O
other O
drugs O
that O
prolong B-NonOSE_AE
the I-NonOSE_AE
PR I-NonOSE_AE
interval I-NonOSE_AE
, O
further B-NonOSE_AE
PR I-NonOSE_AE
prolongation I-NonOSE_AE
is O
possible O
. O

VIMPAT O
should O
be O
used O
with O
caution O
in O
patients O
with O
known O
conduction O
problems O
( O
e.g. O
, O
marked O
first B-Not_AE_Candidate
- I-Not_AE_Candidate
degree I-Not_AE_Candidate
AV I-Not_AE_Candidate
block I-Not_AE_Candidate
, O
second B-Not_AE_Candidate
- I-Not_AE_Candidate
degree I-Not_AE_Candidate
or I-Not_AE_Candidate
higher I-Not_AE_Candidate
AV I-Not_AE_Candidate
block I-Not_AE_Candidate
and O
sick B-Not_AE_Candidate
sinus I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
without O
pacemaker O
) O
, O
sodium B-Not_AE_Candidate
channelopathies I-Not_AE_Candidate
( O
e.g. O
, O
Brugada B-Not_AE_Candidate
Syndrome I-Not_AE_Candidate
) O
, O
on O
concomitant O
medications O
that O
prolong B-NonOSE_AE
PR I-NonOSE_AE
interval I-NonOSE_AE
, O
or O
with O
severe O
cardiac B-Not_AE_Candidate
disease I-Not_AE_Candidate
such O
as O
myocardial B-Not_AE_Candidate
ischemia I-Not_AE_Candidate
or O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
or O
structural B-Not_AE_Candidate
heart I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

In O
such O
patients O
, O
obtaining O
an O
ECG O
before O
beginning O
VIMPAT O
, O
and O
after O
VIMPAT O
is O
titrated O
to O
steady-state O
maintenance O
dose O
, O
is O
recommended O
. O

In O
addition O
, O
these O
patients O
should O
be O
closely O
monitored O
if O
they O
are O
administered O
VIMPAT O
through O
the O
intravenous O
route O
. O

One O
case O
of O
profound O
bradycardia B-OSE_Labeled_AE
was O
observed O
in O
a O
patient O
during O
a O
15-minute O
infusion O
of O
150 O
mg O
VIMPAT O
. O

There O
were O
two O
postmarketing O
reports O
of O
third B-NonOSE_AE
degree I-NonOSE_AE
AV I-NonOSE_AE
block I-NonOSE_AE
in O
patients O
with O
significant O
cardiac B-Not_AE_Candidate
history I-Not_AE_Candidate
and O
also O
receiving O
metoprolol O
and O
amlodipine O
during O
infusion O
of O
VIMPAT O
injection O
at O
doses O
higher O
than O
recommended O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
, O
Drug O
Interactions O
( O
7.2 O
) O
] O
. O

Atrial O
fibrillation O
and O
Atrial O
flutter O
In O
the O
short-term O
investigational O
trials O
of O
VIMPAT O
in O
epilepsy B-Not_AE_Candidate
patients O
, O
there O
were O
no O
cases O
of O
atrial B-NonOSE_AE
fibrillation I-NonOSE_AE
or O
flutter O
. O

Both O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
and O
atrial B-OSE_Labeled_AE
flutter I-OSE_Labeled_AE
have O
been O
reported O
in O
open O
label O
epilepsy B-Not_AE_Candidate
trials O
and O
in O
postmarketing O
experience O
. O

In O
patients O
with O
diabetic B-Not_AE_Candidate
neuropathy I-Not_AE_Candidate
, O
0.5 O
% O
of O
patients O
treated O
with O
VIMPAT O
experienced O
an O
adverse O
reaction O
of O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
or O
atrial B-OSE_Labeled_AE
flutter I-OSE_Labeled_AE
, O
compared O
to O
0 O
% O
of O
placebo-treated O
patients O
. O

VIMPAT O
administration O
may O
predispose O
to O
atrial B-OSE_Labeled_AE
arrhythmias I-OSE_Labeled_AE
( O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
or O
flutter O
) O
, O
especially O
in O
patients O
with O
diabetic B-Not_AE_Candidate
neuropathy I-Not_AE_Candidate
and/or O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

5.4 O
Syncope O
In O
the O
short-term O
controlled O
trials O
of O
VIMPAT O
in O
epilepsy O
patients O
with O
no O
significant O
system O
illnesses O
, O
there O
was O
no O
increase O
in O
syncope B-NonOSE_AE
compared O
to O
placebo O
. O

In O
the O
short-term O
controlled O
trials O
of O
VIMPAT O
in O
patients O
with O
diabetic B-Not_AE_Candidate
neuropathy I-Not_AE_Candidate
, O
1.2 O
% O
of O
patients O
who O
were O
treated O
with O
VIMPAT O
reported O
an O
adverse O
reaction O
of O
syncope B-OSE_Labeled_AE
or O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
, O
compared O
to O
0 O
% O
of O
placebo-treated O
patients O
with O
diabetic B-Not_AE_Candidate
neuropathy I-Not_AE_Candidate
. O

Most O
of O
the O
cases O
of O
syncope B-OSE_Labeled_AE
were O
observed O
in O
patients O
receiving O
doses O
above O
400 O
mg/day O
. O

The O
cause O
of O
syncope B-NonOSE_AE
was O
not O
determined O
in O
most O
cases O
. O

However O
, O
several O
were O
associated O
with O
either O
changes B-NonOSE_AE
in I-NonOSE_AE
orthostatic O
blood I-NonOSE_AE
pressure I-NonOSE_AE
, O
atrial B-NonOSE_AE
flutter/ O
fibrillation I-NonOSE_AE
( O
and O
associated O
tachycardia B-NonOSE_AE
) O
, O
or O
bradycardia B-OSE_Labeled_AE
. O

Cases O
of O
syncope B-OSE_Labeled_AE
have O
also O
been O
observed O
in O
open-label O
clinical O
epilepsy B-Not_AE_Candidate
studies O
. O

These O
cases O
were O
associated O
with O
a O
history O
of O
risk O
factors O
for O
cardiac B-Not_AE_Candidate
disease I-Not_AE_Candidate
and O
the O
use O
of O
drugs B-Not_AE_Candidate
that I-Not_AE_Candidate
slow I-Not_AE_Candidate
AV I-Not_AE_Candidate
conduction I-Not_AE_Candidate
. O

5.5 O
Withdrawal O
of O
Antiepileptic O
Drugs O
( O
AEDs O
) O
As O
with O
all O
AEDs O
, O
VIMPAT O
should O
be O
withdrawn O
gradually O
( O
over O
a O
minimum O
of O
1 O
week O
) O
to O
minimize O
the O
potential O
of O
increased B-NonOSE_AE
seizure I-NonOSE_AE
frequency I-NonOSE_AE
in O
patients O
with O
seizure B-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

5.6 O
Multiorgan O
Hypersensitivity O
Reactions O
One O
case O
of O
symptomatic O
hepatitis B-OSE_Labeled_AE
and O
nephritis B-OSE_Labeled_AE
was O
observed O
among O
4011 O
subjects O
exposed O
to O
VIMPAT O
during O
clinical O
development O
. O

The O
event O
occurred O
in O
a O
healthy O
volunteer O
, O
10 O
days O
after O
stopping O
VIMPAT O
treatment O
. O

The O
subject O
was O
not O
taking O
any O
concomitant O
medication O
and O
potential O
known O
viral B-NonOSE_AE
etiologies I-NonOSE_AE
for I-NonOSE_AE
hepatitis I-NonOSE_AE
were O
ruled I-NonOSE_AE
out I-NonOSE_AE
. O

The O
subject O
fully O
recovered O
within O
a O
month O
, O
without O
specific O
treatment O
. O

The O
case O
is O
consistent O
with O
a O
delayed O
multiorgan B-OSE_Labeled_AE
hypersensitivity I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
. O

Additional O
potential O
cases O
included O
2 O
with O
rash B-OSE_Labeled_AE
and O
elevated B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
enzymes I-OSE_Labeled_AE
and O
1 O
with O
myocarditis B-OSE_Labeled_AE
and O
hepatitis B-OSE_Labeled_AE
of O
uncertain O
etiology O
. O

Multiorgan B-OSE_Labeled_AE
hypersensitivity I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( I-OSE_Labeled_AE
also I-OSE_Labeled_AE
known I-OSE_Labeled_AE
as I-OSE_Labeled_AE
D I-OSE_Labeled_AE
rug I-OSE_Labeled_AE
R I-OSE_Labeled_AE
eaction I-OSE_Labeled_AE
with I-OSE_Labeled_AE
E I-OSE_Labeled_AE
osinophilia I-OSE_Labeled_AE
and I-OSE_Labeled_AE
S I-OSE_Labeled_AE
ystemic I-OSE_Labeled_AE
S I-OSE_Labeled_AE
ymptoms I-OSE_Labeled_AE
, I-OSE_Labeled_AE
or I-OSE_Labeled_AE
DRESS I-OSE_Labeled_AE
) O
have O
been O
reported O
with O
other O
antiepileptics O
and O
typically O
, O
although O
not O
exclusively O
, O
present O
with O
fever B-NonOSE_AE
and O
rash B-NonOSE_AE
associated O
with O
other O
organ O
system O
involvement O
, O
that O
may O
or O
may O
not O
include O
eosinophilia B-NonOSE_AE
, O
hepatitis B-NonOSE_AE
, O
nephritis B-NonOSE_AE
, O
lymphadenopathy B-NonOSE_AE
, O
and/or O
myocarditis B-NonOSE_AE
. O

Because O
this O
disorder O
is O
variable O
in O
its O
expression O
, O
other O
organ O
system O
signs O
and O
symptoms O
not O
noted O
here O
may O
occur O
. O

If O
this O
reaction O
is O
suspected O
, O
VIMPAT O
should O
be O
discontinued O
and O
alternative O
treatment O
started O
. O

5.7 O
Phenylketonurics O
VIMPAT O
oral O
solution O
contains O
aspartame O
, O
a O
source O
of O
phenylalanine O
. O

A O
200 O
mg O
dose O
of O
VIMPAT O
oral O
solution O
( O
equivalent O
to O
20 O
mL O
) O
contains O
0.32 O
mg O
of O
phenylalanine O
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
in O
patients O
with O
advanced O
renal O
cell O
carcinoma O
( O
> O
=20 O
% O
) O
are O
diarrhea O
, O
hypertension O
, O
hair O
color O
changes O
( O
depigmentation O
) O
, O
nausea O
, O
anorexia O
, O
and O
vomiting O
. O

( O
6.1 O
) O
The O
most O
common O
adverse O
reactions O
in O
patients O
with O
advanced O
soft O
tissue O
sarcoma O
( O
> O
=20 O
% O
) O
are O
fatigue O
, O
diarrhea O
, O
nausea O
, O
decreased O
weight O
, O
hypertension O
, O
decreased O
appetite O
, O
hair O
color O
changes O
, O
vomiting O
, O
tumor O
pain O
, O
dysgeusia O
, O
headache O
, O
musculoskeletal O
pain O
, O
myalgia O
, O
gastrointestinal O
pain O
, O
and O
dyspnea O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
GlaxoSmithKline O
at O
1-888-825-5249 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
with O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Potentially O
serious O
adverse O
reactions O
with O
VOTRIENT O
included O
: O
* O
Hepatotoxicity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
and O
torsades B-OSE_Labeled_AE
de I-OSE_Labeled_AE
pointes I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Cardiac B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Arterial B-OSE_Labeled_AE
and O
venous O
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
and O
5.6 O
) O
] O
* O
Thrombotic B-OSE_Labeled_AE
microangiopathy I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
and O
fistula O
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Interstitial B-OSE_Labeled_AE
Lung I-OSE_Labeled_AE
Disease I-OSE_Labeled_AE
( O
ILD O
) O
/ O
Pneumonitis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Reversible B-OSE_Labeled_AE
Posterior I-OSE_Labeled_AE
Leukoencephalopathy I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( O
RPLS O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
* O
Hypertension B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
* O
Infection B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.15 O
) O
] O
* O
Increased B-NonOSE_AE
toxicity I-NonOSE_AE
with O
other O
cancer O
therapies O
[ O
see O
Warnings O
and O
Precautions O
( O
5.16 O
) O
] O
Renal B-Not_AE_Candidate
Cell I-Not_AE_Candidate
Carcinoma I-Not_AE_Candidate
: O
The O
safety O
of O
VOTRIENT O
has O
been O
evaluated O
in O
977 O
patients O
in O
the O
monotherapy O
trials O
which O
included O
586 O
patients O
with O
RCC B-Not_AE_Candidate
at O
the O
time O
of O
NDA O
submission O
. O

With O
a O
median O
duration O
of O
treatment O
of O
7.4 O
months O
( O
range O
: O
0.1 O
to O
27.6 O
) O
, O
the O
most O
commonly O
observed O
adverse O
reactions O
( O
> O
=20 O
% O
) O
in O
the O
586 O
patients O
were O
diarrhea B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
hair B-OSE_Labeled_AE
color I-OSE_Labeled_AE
change I-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
anorexia B-OSE_Labeled_AE
, O
and O
vomiting B-OSE_Labeled_AE
. O

The O
data O
described O
below O
reflect O
the O
safety O
profile O
of O
VOTRIENT O
in O
290 O
RCC B-Not_AE_Candidate
patients O
who O
participated O
in O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

The O
median O
duration O
of O
treatment O
was O
7.4 O
months O
( O
range O
: O
0 O
to O
23 O
) O
for O
patients O
who O
received O
VOTRIENT O
and O
3.8 O
months O
( O
range O
: O
0 O
to O
22 O
) O
for O
the O
placebo O
arm O
. O

Forty-two O
percent O
of O
patients O
on O
VOTRIENT O
required O
a O
dose O
interruption O
. O

Thirty-six O
percent O
of O
patients O
on O
VOTRIENT O
were O
dose O
reduced O
. O

Table O
1 O
presents O
the O
most O
common O
adverse O
reactions O
occurring O
in O
> O
=10 O
% O
of O
patients O
who O
received O
VOTRIENT O
. O

Table O
1 O
. O

Adverse O
Reactions O
Occurring O
in O
> O
=10 O
% O
of O
Patients O
with O
RCC O
Who O
Received O
VOTRIENT O
VOTRIENT O
Placebo O
( O
N O
= O
290 O
) O
( O
N O
= O
145 O
) O
All O
Gradesa O
Grade O
3 O
Grade O
4 O
All O
Gradesa O
Grade O
3 O
Grade O
4 O
Adverse O
Reactions O
% O
% O
% O
% O
% O
% O
Diarrhea B-OSE_Labeled_AE
52 O
3 O
< O
1 O
9 O
< O
1 O
0 O
Hypertension B-OSE_Labeled_AE
40 O
4 O
0 O
10 O
< O
1 O
0 O
Hair B-OSE_Labeled_AE
color I-OSE_Labeled_AE
changes I-OSE_Labeled_AE
38 O
< O
1 O
0 O
3 O
0 O
0 O
Nausea B-OSE_Labeled_AE
26 O
< O
1 O
0 O
9 O
0 O
0 O
Anorexia B-OSE_Labeled_AE
22 O
2 O
0 O
10 O
< O
1 O
0 O
Vomiting B-OSE_Labeled_AE
21 O
2 O
< O
1 O
8 O
2 O
0 O
Fatigue B-OSE_Labeled_AE
19 O
2 O
0 O
8 O
1 O
1 O
Asthenia B-OSE_Labeled_AE
14 O
3 O
0 O
8 O
0 O
0 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
11 O
2 O
0 O
1 O
0 O
0 O
Headache B-OSE_Labeled_AE
10 O
0 O
0 O
5 O
0 O
0 O
a O
National O
Cancer O
Institute O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
, O
version O
3 O
. O

Other O
adverse O
reactions O
observed O
more O
commonly O
in O
patients O
treated O
with O
VOTRIENT O
than O
placebo O
and O
that O
occurred O
in O
< O
10 O
% O
( O
any O
grade O
) O
were O
alopecia B-OSE_Labeled_AE
( O
8 O
% O
versus O
< O
1 O
% O
) O
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
5 O
% O
versus O
1 O
% O
) O
, O
dysgeusia B-OSE_Labeled_AE
( O
altered B-OSE_Labeled_AE
taste I-OSE_Labeled_AE
) O
( O
8 O
% O
versus O
< O
1 O
% O
) O
, O
dyspepsia B-OSE_Labeled_AE
( O
5 O
% O
versus O
< O
1 O
% O
) O
, O
dysphonia B-OSE_Labeled_AE
( O
4 O
% O
versus O
< O
1 O
% O
) O
, O
facial B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
( O
1 O
% O
versus O
0 O
% O
) O
, O
palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
erythrodysesthesia I-OSE_Labeled_AE
( O
hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
foot I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
) O
( O
6 O
% O
versus O
< O
1 O
% O
) O
, O
proteinuria B-OSE_Labeled_AE
( O
9 O
% O
versus O
0 O
% O
) O
, O
rash B-OSE_Labeled_AE
( O
8 O
% O
versus O
3 O
% O
) O
, O
skin B-OSE_Labeled_AE
depigmentation I-OSE_Labeled_AE
( O
3 O
% O
versus O
0 O
% O
) O
, O
and O
weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
( O
9 O
% O
versus O
3 O
% O
) O
. O

Additional O
adverse O
reactions O
from O
other O
clinical O
trials O
in O
RCC B-Not_AE_Candidate
patients O
treated O
with O
VOTRIENT O
are O
listed O
below O
: O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Arthralgia B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
. O

Table O
2 O
presents O
the O
most O
common O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
occurring O
in O
> O
10 O
% O
of O
patients O
who O
received O
VOTRIENT O
and O
more O
commonly O
( O
> O
=5 O
% O
) O
in O
patients O
who O
received O
VOTRIENT O
versus O
placebo O
. O

Table O
2 O
. O

Selected O
Laboratory O
Abnormalities O
Occurring O
in O
> O
10 O
% O
of O
Patients O
with O
RCC O
Who O
Received O
VOTRIENT O
and O
More O
Commonly O
( O
> O
=5 O
% O
) O
in O
Patients O
Who O
Received O
VOTRIENT O
versus O
Placebo O
VOTRIENT O
Placebo O
( O
N O
= O
290 O
) O
( O
N O
= O
145 O
) O
All O
Gradesa O
Grade O
3 O
Grade O
4 O
All O
Gradesa O
Grade O
3 O
Grade O
4 O
Parameters O
% O
% O
% O
% O
% O
% O
Hematologic B-NonOSE_AE
Leukopenia B-OSE_Labeled_AE
37 O
0 O
0 O
6 O
0 O
0 O
Neutropenia B-OSE_Labeled_AE
34 O
1 O
< O
1 O
6 O
0 O
0 O
Thrombocytopenia B-OSE_Labeled_AE
32 O
< O
1 O
< O
1 O
5 O
0 O
< O
1 O
Lymphocytopenia B-OSE_Labeled_AE
31 O
4 O
< O
1 O
24 O
1 O
0 O
Chemistry B-NonOSE_AE
ALT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
53 O
10 O
2 O
22 O
1 O
0 O
AST B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
53 O
7 O
< O
1 O
19 O
< O
1 O
0 O
Glucose B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
41 O
< O
1 O
0 O
33 O
1 O
0 O
Total B-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
36 O
3 O
< O
1 O
10 O
1 O
< O
1 O
Phosphorus B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
34 O
4 O
0 O
11 O
0 O
0 O
Sodium B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
31 O
4 O
1 O
24 O
4 O
0 O
Magnesium B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
26 O
< O
1 O
1 O
14 O
0 O
0 O
Glucose B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
17 O
0 O
< O
1 O
3 O
0 O
0 O
a O
National O
Cancer O
Institute O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
, O
version O
3 O
. O

Soft B-Not_AE_Candidate
Tissue I-Not_AE_Candidate
Sarcoma I-Not_AE_Candidate
: O
The O
safety O
of O
VOTRIENT O
has O
been O
evaluated O
in O
382 O
patients O
with O
advanced O
soft B-Not_AE_Candidate
tissue I-Not_AE_Candidate
sarcoma I-Not_AE_Candidate
, O
with O
a O
median O
duration O
of O
treatment O
of O
3.6 O
months O
( O
range O
: O
0 O
to O
53 O
) O
. O

The O
most O
commonly O
observed O
adverse O
reactions O
( O
> O
=20 O
% O
) O
in O
the O
382 O
patients O
were O
fatigue B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
tumor B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
hair B-OSE_Labeled_AE
color I-OSE_Labeled_AE
changes I-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
dysgeusia B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
and O
skin B-OSE_Labeled_AE
hypopigmentation I-OSE_Labeled_AE
. O

The O
data O
described O
below O
reflect O
the O
safety O
profile O
of O
VOTRIENT O
in O
240 O
patients O
who O
participated O
in O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
[ O
see O
Clinical O
Studies O
( O
14.2 O
) O
] O
. O

The O
median O
duration O
of O
treatment O
was O
4.5 O
months O
( O
range O
: O
0 O
to O
24 O
) O
for O
patients O
who O
received O
VOTRIENT O
and O
1.9 O
months O
( O
range O
: O
0 O
to O
24 O
) O
for O
the O
placebo O
arm O
. O

Fifty-eight O
percent O
of O
patients O
on O
VOTRIENT O
required O
a O
dose O
interruption O
. O

Thirty-eight O
percent O
of O
patients O
on O
VOTRIENT O
had O
their O
dose O
reduced O
. O

Seventeen O
percent O
of O
patients O
who O
received O
VOTRIENT O
discontinued O
therapy O
due O
to O
adverse O
reactions O
. O

Table O
3 O
presents O
the O
most O
common O
adverse O
reactions O
occurring O
in O
> O
=10 O
% O
of O
patients O
who O
received O
VOTRIENT O
. O

Table O
3 O
. O

Adverse O
Reactions O
Occurring O
in O
> O
=10 O
% O
of O
Patients O
with O
STS O
Who O
Received O
VOTRIENT O
VOTRIENT O
Placebo O
( O
N O
= O
240 O
) O
( O
N O
= O
123 O
) O
All O
Gradesa O
Grade O
3 O
Grade O
4 O
All O
Gradesa O
Grade O
3 O
Grade O
4 O
Adverse O
Reactions O
% O
% O
% O
% O
% O
% O
Fatigue B-OSE_Labeled_AE
65 O
13 O
1 O
48 O
4 O
1 O
Diarrhea B-OSE_Labeled_AE
59 O
5 O
0 O
15 O
1 O
0 O
Nausea B-OSE_Labeled_AE
56 O
3 O
0 O
22 O
2 O
0 O
Weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
48 O
4 O
0 O
15 O
0 O
0 O
Hypertension B-OSE_Labeled_AE
42 O
7 O
0 O
6 O
0 O
0 O
Appetite B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
40 O
6 O
0 O
19 O
0 O
0 O
Hair B-OSE_Labeled_AE
color I-OSE_Labeled_AE
changes I-OSE_Labeled_AE
39 O
0 O
0 O
2 O
0 O
0 O
Vomiting B-OSE_Labeled_AE
33 O
3 O
0 O
11 O
1 O
0 O
Tumor B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
29 O
8 O
0 O
21 O
7 O
2 O
Dysgeusia B-OSE_Labeled_AE
28 O
0 O
0 O
3 O
0 O
0 O
Headache B-OSE_Labeled_AE
23 O
1 O
0 O
8 O
0 O
0 O
Musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
23 O
2 O
0 O
20 O
2 O
0 O
Myalgia B-OSE_Labeled_AE
23 O
2 O
0 O
9 O
0 O
0 O
Gastrointestinal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
23 O
3 O
0 O
9 O
4 O
0 O
Dyspnea B-OSE_Labeled_AE
20 O
5 O
< O
1 O
17 O
5 O
1 O
Exfoliative B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
18 O
< O
1 O
0 O
9 O
0 O
0 O
Cough B-OSE_Labeled_AE
17 O
< O
1 O
0 O
12 O
< O
1 O
0 O
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
14 O
2 O
0 O
9 O
2 O
0 O
Mucositis B-OSE_Labeled_AE
12 O
2 O
0 O
2 O
0 O
0 O
Alopecia B-OSE_Labeled_AE
12 O
0 O
0 O
1 O
0 O
0 O
Dizziness B-OSE_Labeled_AE
11 O
1 O
0 O
4 O
0 O
0 O
Skin B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
b O
11 O
2 O
0 O
1 O
0 O
0 O
Skin B-OSE_Labeled_AE
hypopigmentation I-OSE_Labeled_AE
11 O
0 O
0 O
0 O
0 O
0 O
Stomatitis B-OSE_Labeled_AE
11 O
< O
1 O
0 O
3 O
0 O
0 O
Chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
10 O
2 O
0 O
6 O
0 O
0 O
a O
National O
Cancer O
Institute O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
, O
version O
3 O
. O
b O
27 O
of O
the O
28 O
cases O
of O
skin B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
were O
palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
erythrodysesthesia I-OSE_Labeled_AE
. O

Other O
adverse O
reactions O
observed O
more O
commonly O
in O
patients O
treated O
with O
VOTRIENT O
that O
occurred O
in O
> O
=5 O
% O
of O
patients O
and O
at O
an O
incidence O
of O
more O
than O
2 O
% O
difference O
from O
placebo O
included O
insomnia B-OSE_Labeled_AE
( O
9 O
% O
versus O
6 O
% O
) O
, O
hypothyroidism B-OSE_Labeled_AE
( O
8 O
% O
versus O
0 O
% O
) O
, O
dysphonia B-OSE_Labeled_AE
( O
8 O
% O
versus O
2 O
% O
) O
, O
epistaxis B-OSE_Labeled_AE
( O
8 O
% O
versus O
2 O
% O
) O
, O
left B-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
( O
8 O
% O
versus O
4 O
% O
) O
, O
dyspepsia B-OSE_Labeled_AE
( O
7 O
% O
versus O
2 O
% O
) O
, O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
( O
6 O
% O
versus O
< O
1 O
% O
) O
, O
chills B-OSE_Labeled_AE
( O
5 O
% O
versus O
1 O
% O
) O
, O
vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
( O
5 O
% O
versus O
2 O
% O
) O
, O
and O
nail B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
( O
5 O
% O
versus O
0 O
% O
) O
. O

Table O
4 O
presents O
the O
most O
common O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
occurring O
in O
> O
10 O
% O
of O
patients O
who O
received O
VOTRIENT O
and O
more O
commonly O
( O
> O
=5 O
% O
) O
in O
patients O
who O
received O
VOTRIENT O
versus O
placebo O
. O

Table O
4 O
. O

Selected O
Laboratory O
Abnormalities O
Occurring O
in O
> O
10 O
% O
of O
Patients O
with O
STS O
Who O
Received O
VOTRIENT O
and O
More O
Commonly O
( O
> O
=5 O
% O
) O
in O
Patients O
Who O
Received O
VOTRIENT O
versus O
Placebo O
VOTRIENT O
Placebo O
( O
N O
= O
240 O
) O
( O
N O
= O
123 O
) O
All O
Gradesa O
Grade O
3 O
Grade O
4 O
All O
Gradesa O
Grade O
3 O
Grade O
4 O
Parameters O
% O
% O
% O
% O
% O
% O
Hematologic B-NonOSE_AE
Leukopenia B-OSE_Labeled_AE
44 O
1 O
0 O
15 O
0 O
0 O
Lymphocytopenia B-OSE_Labeled_AE
43 O
10 O
0 O
36 O
9 O
2 O
Thrombocytopenia B-OSE_Labeled_AE
36 O
3 O
1 O
6 O
0 O
0 O
Neutropenia B-OSE_Labeled_AE
33 O
4 O
0 O
7 O
0 O
0 O
Chemistry B-NonOSE_AE
AST B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
51 O
5 O
3 O
22 O
2 O
0 O
ALT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
46 O
8 O
2 O
18 O
2 O
1 O
Glucose B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
45 O
< O
1 O
0 O
35 O
2 O
0 O
Albumin B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
34 O
1 O
0 O
21 O
0 O
0 O
Alkaline B-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
32 O
3 O
0 O
23 O
1 O
0 O
Sodium B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
31 O
4 O
0 O
20 O
3 O
0 O
Total B-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
29 O
1 O
0 O
7 O
2 O
0 O
Potassium B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
16 O
1 O
0 O
11 O
0 O
0 O
a O
National O
Cancer O
Institute O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
, O
version O
3 O
. O

Diarrhea B-NonOSE_AE
: O
Diarrhea B-OSE_Labeled_AE
occurred O
frequently O
and O
was O
predominantly O
mild O
to O
moderate O
in O
severity O
in O
both O
the O
RCC B-Not_AE_Candidate
and O
STS B-Not_AE_Candidate
clinical O
trials O
. O

Patients O
should O
be O
advised O
how O
to O
manage O
mild O
diarrhea B-NonOSE_AE
and O
to O
notify O
their O
healthcare O
provider O
if O
moderate O
to O
severe O
diarrhea B-NonOSE_AE
occurs O
so O
appropriate O
management O
can O
be O
implemented O
to O
minimize O
its O
impact O
. O

Lipase B-NonOSE_AE
Elevations I-NonOSE_AE
: O
In O
a O
single-arm O
RCC B-Not_AE_Candidate
trial O
, O
increases B-OSE_Labeled_AE
in O
lipase I-OSE_Labeled_AE
values O
were O
observed O
for O
27 O
% O
( O
48/181 O
) O
of O
patients O
. O

Elevations B-OSE_Labeled_AE
in O
lipase I-OSE_Labeled_AE
as O
an O
adverse O
reaction O
were O
reported O
for O
4 O
% O
( O
10/225 O
) O
of O
patients O
and O
were O
Grade O
3 O
for O
6 O
patients O
and O
Grade O
4 O
for O
1 O
patient O
. O

In O
the O
RCC B-Not_AE_Candidate
trials O
of O
VOTRIENT O
, O
clinical O
pancreatitis B-OSE_Labeled_AE
was O
observed O
in O
< O
1 O
% O
( O
4/586 O
) O
of O
patients O
. O

Pneumothorax B-NonOSE_AE
: O
Two O
of O
290 O
patients O
treated O
with O
VOTRIENT O
and O
no O
patient O
on O
the O
placebo O
arm O
in O
the O
randomized O
RCC B-Not_AE_Candidate
trial O
developed O
a O
pneumothorax B-OSE_Labeled_AE
. O

In O
the O
randomized O
trial O
of O
VOTRIENT O
for O
the O
treatment O
of O
STS B-Not_AE_Candidate
, O
pneumothorax B-OSE_Labeled_AE
occurred O
in O
3 O
% O
( O
8/240 O
) O
of O
patients O
treated O
with O
VOTRIENT O
and O
in O
no O
patients O
on O
the O
placebo O
arm O
. O

Bradycardia B-NonOSE_AE
: O
In O
the O
randomized O
trial O
of O
VOTRIENT O
for O
the O
treatment O
of O
RCC B-Not_AE_Candidate
, O
bradycardia B-OSE_Labeled_AE
based O
on O
vital O
signs O
( O
< O
60 O
beats O
per O
minute O
) O
was O
observed O
in O
19 O
% O
( O
52/280 O
) O
of O
patients O
treated O
with O
VOTRIENT O
and O
in O
11 O
% O
( O
16/144 O
) O
of O
patients O
on O
the O
placebo O
arm O
. O

Bradycardia B-OSE_Labeled_AE
was O
reported O
as O
an O
adverse O
reaction O
in O
2 O
% O
( O
7/290 O
) O
of O
patients O
treated O
with O
VOTRIENT O
compared O
with O
< O
1 O
% O
( O
1/145 O
) O
of O
patients O
treated O
with O
placebo O
. O

In O
the O
randomized O
trial O
of O
VOTRIENT O
for O
the O
treatment O
of O
STS B-Not_AE_Candidate
, O
bradycardia B-OSE_Labeled_AE
based O
on O
vital O
signs O
( O
< O
60 O
beats O
per O
minute O
) O
was O
observed O
in O
19 O
% O
( O
45/238 O
) O
of O
patients O
treated O
with O
VOTRIENT O
and O
in O
4 O
% O
( O
5/121 O
) O
of O
patients O
on O
the O
placebo O
arm O
. O

Bradycardia B-OSE_Labeled_AE
was O
reported O
as O
an O
adverse O
reaction O
in O
2 O
% O
( O
4/240 O
) O
of O
patients O
treated O
with O
VOTRIENT O
compared O
with O
< O
1 O
% O
( O
1/123 O
) O
of O
patients O
treated O
with O
placebo O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
VOTRIENT O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
the O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Eye B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Retinal B-OSE_Labeled_AE
detachment/ O
tear I-OSE_Labeled_AE
. O

Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Pancreatitis B-OSE_Labeled_AE
. O

BOXED O
WARNING O
: O
WARNING O
: O
HEPATOTOXICITY O
WARNING O
: O
HEPATOTOXICITY O
Severe O
and O
fatal B-NonOSE_AE
hepatotoxicity B-OSE_Labeled_AE
has O
been O
observed O
in O
clinical O
trials O
. O

Monitor O
hepatic O
function O
and O
interrupt O
, O
reduce O
, O
or O
discontinue O
dosing O
as O
recommended O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
HEPATOTOXICITY O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

Severe O
and O
fatal O
hepatotoxicity O
has O
been O
observed O
in O
clinical O
trials O
. O

Monitor O
hepatic O
function O
and O
interrupt O
, O
reduce O
, O
or O
discontinue O
dosing O
as O
recommended O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Increases O
in O
serum O
transaminase O
levels O
and O
bilirubin O
were O
observed O
. O

Severe O
and O
fatal O
hepatotoxicity O
has O
occurred O
. O

Measure O
liver O
chemistries O
before O
the O
initiation O
of O
treatment O
and O
regularly O
during O
treatment O
. O

( O
5.1 O
) O
* O
Prolonged O
QT O
intervals O
and O
torsades O
de O
pointes O
have O
been O
observed O
. O

Use O
with O
caution O
in O
patients O
at O
higher O
risk O
of O
developing O
QT O
interval O
prolongation O
. O

Monitoring O
electrocardiograms O
and O
electrolytes O
should O
be O
considered O
. O

( O
5.2 O
) O
* O
Cardiac O
dysfunction O
such O
as O
congestive O
heart O
failure O
and O
decreased O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
have O
occurred O
. O

Monitor O
blood O
pressure O
and O
manage O
hypertension O
promptly O
. O

Baseline O
and O
periodic O
evaluation O
of O
LVEF O
is O
recommended O
in O
patients O
at O
risk O
of O
cardiac O
dysfunction O
. O

( O
5.3 O
) O
* O
Fatal O
hemorrhagic O
events O
have O
been O
reported O
. O

VOTRIENT O
has O
not O
been O
studied O
in O
patients O
who O
have O
a O
history O
of O
hemoptysis O
, O
cerebral O
, O
or O
clinically O
significant O
gastrointestinal O
hemorrhage O
in O
the O
past O
6 O
months O
and O
should O
not O
be O
used O
in O
those O
patients O
. O

( O
5.4 O
) O
* O
Arterial O
thromboembolic O
events O
have O
been O
observed O
and O
can O
be O
fatal O
. O

Use O
with O
caution O
in O
patients O
who O
are O
at O
increased O
risk O
for O
these O
events O
. O

( O
5.5 O
) O
* O
Venous O
thromboembolic O
events O
( O
VTE O
) O
have O
been O
observed O
, O
including O
fatal O
pulmonary O
emboli O
( O
PE O
) O
. O

Monitor O
for O
signs O
and O
symptoms O
of O
VTE O
and O
PE O
. O

( O
5.6 O
) O
* O
Thrombotic O
microangiopathy O
( O
TMA O
) O
, O
including O
thrombotic O
thrombocytopenic O
purpura O
( O
TTP O
) O
and O
hemolytic O
uremic O
syndrome O
( O
HUS O
) O
has O
been O
observed O
. O

Permanently O
discontinue O
VOTRIENT O
if O
TMA O
occurs O
. O

( O
5.7 O
) O
* O
Gastrointestinal O
perforation O
or O
fistula O
has O
occurred O
. O

Fatal O
perforation O
events O
have O
occurred O
. O

Use O
with O
caution O
in O
patients O
at O
risk O
for O
gastrointestinal O
perforation O
or O
fistula O
. O

( O
5.8 O
) O
* O
Interstitial O
lung O
disease O
( O
ILD O
) O
/pneumonitis O
have O
been O
observed O
and O
can O
be O
fatal O
. O

Discontinue O
VOTRIENT O
in O
patients O
developing O
ILD O
or O
pneumonitis O
. O

( O
5.9 O
) O
* O
Reversible O
Posterior O
Leukoencephalopathy O
Syndrome O
( O
RPLS O
) O
has O
been O
observed O
and O
can O
be O
fatal O
. O

Permanently O
discontinue O
VOTRIENT O
in O
patients O
developing O
RPLS O
. O

( O
5.10 O
) O
* O
Hypertension O
including O
hypertensive O
crisis O
has O
been O
observed O
. O

Blood O
pressure O
should O
be O
well O
controlled O
prior O
to O
initiating O
VOTRIENT O
. O

Monitor O
blood O
pressure O
within O
one O
week O
after O
starting O
VOTRIENT O
and O
frequently O
thereafter O
. O

( O
5.11 O
) O
* O
Interruption O
of O
therapy O
with O
VOTRIENT O
is O
recommended O
in O
patients O
undergoing O
surgical O
procedures O
. O

( O
5.12 O
) O
* O
Hypothyroidism O
may O
occur O
. O

Monitoring O
of O
thyroid O
function O
tests O
is O
recommended O
. O

( O
5.13 O
) O
* O
Proteinuria O
: O
Monitor O
urine O
protein O
. O

Interrupt O
treatment O
for O
24-hour O
urine O
protein O
> O
=3 O
grams O
and O
discontinue O
for O
repeat O
episodes O
despite O
dose O
reductions O
. O

( O
5.14 O
) O
* O
Infection O
: O
Serious O
infections O
( O
with O
or O
without O
neutropenia O
) O
, O
some O
with O
fatal O
outcome O
, O
have O
been O
reported O
. O

Monitor O
for O
signs O
and O
symptoms O
and O
treat O
active O
infection O
promptly O
. O

Interrupt O
or O
discontinue O
VOTRIENT O
. O

( O
5.15 O
) O
* O
Animal O
studies O
have O
demonstrated O
VOTRIENT O
can O
severely O
affect O
organ O
growth O
and O
maturation O
during O
early O
post-natal O
development O
. O

The O
safety O
and O
effectiveness O
in O
pediatric O
patients O
have O
not O
been O
established O
. O

( O
5.17 O
) O
* O
VOTRIENT O
can O
cause O
fetal O
harm O
when O
administered O
to O
a O
pregnant O
woman O
. O

Women O
of O
childbearing O
potential O
should O
be O
advised O
of O
the O
potential O
hazard O
to O
the O
fetus O
and O
to O
avoid O
becoming O
pregnant O
while O
taking O
VOTRIENT O
. O

( O
5.18 O
, O
8.1 O
) O
5.1 O
Hepatic O
Toxicity O
and O
Hepatic O
Impairment O
In O
clinical O
trials O
with O
VOTRIENT O
, O
hepatotoxicity B-OSE_Labeled_AE
, O
manifested O
as O
increases B-OSE_Labeled_AE
in O
serum O
transaminases O
( O
ALT O
, O
AST I-OSE_Labeled_AE
) O
and O
bilirubin O
, O
was O
observed O
. O

This O
hepatotoxicity B-OSE_Labeled_AE
can O
be O
severe O
and O
fatal B-NonOSE_AE
. O

Patients O
older O
than O
65 O
years O
are O
at O
greater O
risk O
for O
hepatotoxicity B-NonOSE_AE
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
] O
. O

Transaminase B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
occur O
early O
in O
the O
course O
of O
treatment O
( O
92.5 O
% O
of O
all O
transaminase B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
of O
any O
grade O
occurred O
in O
the O
first O
18 O
weeks O
) O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

In O
the O
randomized O
RCC B-Not_AE_Candidate
trial O
, O
ALT B-OSE_Labeled_AE
> I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
X I-OSE_Labeled_AE
ULN I-OSE_Labeled_AE
was O
reported O
in O
18 O
% O
and O
3 O
% O
of O
the O
groups O
receiving O
VOTRIENT O
and O
placebo O
, O
respectively O
. O

ALT B-OSE_Labeled_AE
> I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
X I-OSE_Labeled_AE
ULN I-OSE_Labeled_AE
was O
reported O
in O
4 O
% O
of O
patients O
who O
received O
VOTRIENT O
and O
in O
< O
1 O
% O
of O
patients O
who O
received O
placebo O
. O

Concurrent O
elevation B-OSE_Labeled_AE
in O
ALT I-OSE_Labeled_AE
> O
3 O
X O
ULN O
and O
bilirubin B-OSE_Labeled_AE
> I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
X I-OSE_Labeled_AE
ULN I-OSE_Labeled_AE
in O
the O
absence O
of O
significant O
alkaline B-NonOSE_AE
phosphatase I-NonOSE_AE
> I-NonOSE_AE
3 I-NonOSE_AE
X I-NonOSE_AE
ULN I-NonOSE_AE
occurred O
in O
2 O
% O
( O
5/290 O
) O
of O
patients O
on O
VOTRIENT O
and O
1 O
% O
( O
2/145 O
) O
on O
placebo O
. O

In O
the O
randomized O
STS B-Not_AE_Candidate
trial O
, O
ALT B-OSE_Labeled_AE
> I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
X I-OSE_Labeled_AE
ULN I-OSE_Labeled_AE
was O
reported O
in O
18 O
% O
and O
5 O
% O
of O
the O
groups O
receiving O
VOTRIENT O
and O
placebo O
, O
respectively O
. O

ALT B-OSE_Labeled_AE
> I-OSE_Labeled_AE
8 I-OSE_Labeled_AE
X I-OSE_Labeled_AE
ULN I-OSE_Labeled_AE
was O
reported O
in O
5 O
% O
and O
2 O
% O
of O
the O
groups O
receiving O
VOTRIENT O
and O
placebo O
, O
respectively O
. O

Concurrent O
elevation B-OSE_Labeled_AE
in O
ALT I-OSE_Labeled_AE
> O
3 O
X O
ULN O
and O
bilirubin O
> O
2 O
X O
ULN O
in O
the O
absence O
of O
significant O
alkaline B-NonOSE_AE
phosphatase I-NonOSE_AE
> I-NonOSE_AE
3 I-NonOSE_AE
X I-NonOSE_AE
ULN I-NonOSE_AE
occurred O
in O
2 O
% O
( O
4/240 O
) O
of O
patients O
on O
VOTRIENT O
and O
< O
1 O
% O
( O
1/123 O
) O
on O
placebo O
. O

Two-tenths O
percent O
of O
the O
patients O
( O
2/977 O
) O
from O
trials O
that O
supported O
the O
RCC B-Not_AE_Candidate
indication O
died B-NonOSE_AE
with O
disease B-NonOSE_AE
progression I-NonOSE_AE
and O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
and O
0.4 O
% O
of O
patients O
( O
1/240 O
) O
in O
the O
randomized O
STS O
trial O
died B-NonOSE_AE
of O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
. O

* O
Monitor O
serum O
liver O
tests O
before O
initiation O
of O
treatment O
with O
VOTRIENT O
and O
at O
Weeks O
3 O
, O
5 O
, O
7 O
, O
and O
9 O
. O

Thereafter O
, O
monitor O
at O
Month O
3 O
and O
at O
Month O
4 O
, O
and O
as O
clinically O
indicated O
. O

Periodic O
monitoring O
should O
then O
continue O
after O
Month O
4 O
. O

* O
Patients O
with O
isolated O
ALT B-NonOSE_AE
elevations I-NonOSE_AE
between I-NonOSE_AE
3 I-NonOSE_AE
X I-NonOSE_AE
ULN I-NonOSE_AE
and O
8 O
X O
ULN O
may O
be O
continued O
on O
VOTRIENT O
with O
weekly O
monitoring O
of O
liver O
function O
until O
ALT O
returns O
to O
Grade O
1 O
or O
baseline O
. O

* O
Patients O
with O
isolated O
ALT B-NonOSE_AE
elevations I-NonOSE_AE
of O
> O
8 O
X O
ULN O
should O
have O
VOTRIENT O
interrupted O
until O
they O
return O
to O
Grade O
1 O
or O
baseline O
. O

If O
the O
potential O
benefit O
for O
reinitiating O
treatment O
with O
VOTRIENT O
is O
considered O
to O
outweigh O
the O
risk O
for O
hepatotoxicity B-NonOSE_AE
, O
then O
reintroduce O
VOTRIENT O
at O
a O
reduced O
dose O
of O
no O
more O
than O
400 O
mg O
once O
daily O
and O
measure O
serum O
liver O
tests O
weekly O
for O
8 O
weeks O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

Following O
reintroduction O
of O
VOTRIENT O
, O
if O
ALT B-NonOSE_AE
elevations I-NonOSE_AE
> O
3 O
X O
ULN O
recur O
, O
then O
VOTRIENT O
should O
be O
permanently O
discontinued O
. O

* O
If O
ALT B-NonOSE_AE
elevations I-NonOSE_AE
> O
3 O
X O
ULN O
occur O
concurrently O
with O
bilirubin B-NonOSE_AE
elevations I-NonOSE_AE
> O
2 O
X O
ULN O
, O
VOTRIENT O
should O
be O
permanently O
discontinued O
. O

Patients O
should O
be O
monitored O
until O
resolution O
. O

VOTRIENT O
is O
a O
uridine O
diphosphate O
( O
UDP O
) O
-glucuronosyl O
transferase O
1A1 O
( O
UGT1A1 O
) O
inhibitor O
. O

Mild O
, O
indirect O
( O
unconjugated B-OSE_Labeled_AE
) I-OSE_Labeled_AE
hyperbilirubinemia I-OSE_Labeled_AE
may O
occur O
in O
patients O
with O
Gilbert B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
[ O
see O
Clinical O
Pharmacology O
( O
12.5 O
) O
] O
. O

Patients O
with O
only O
a O
mild O
indirect B-NonOSE_AE
hyperbilirubinemia I-NonOSE_AE
, O
known O
Gilbert B-NonOSE_AE
' I-NonOSE_AE
s I-NonOSE_AE
syndrome I-NonOSE_AE
, O
and O
elevation B-NonOSE_AE
in I-NonOSE_AE
ALT I-NonOSE_AE
> O
3 O
X O
ULN O
should O
be O
managed O
as O
per O
the O
recommendations O
outlined O
for O
isolated O
ALT B-NonOSE_AE
elevations I-NonOSE_AE
. O

Concomitant O
use O
of O
VOTRIENT O
and O
simvastatin O
increases O
the O
risk O
of O
ALT B-NonOSE_AE
elevations I-NonOSE_AE
and O
should O
be O
undertaken O
with O
caution O
and O
close O
monitoring O
[ O
see O
Drug O
Interactions O
( O
7.4 O
) O
] O
. O

Insufficient O
data O
are O
available O
to O
assess O
the O
risk O
of O
concomitant O
administration O
of O
alternative O
statins O
and O
VOTRIENT O
. O

In O
patients O
with O
pre-existing O
moderate O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
the O
starting O
dose O
of O
VOTRIENT O
should O
be O
reduced O
or O
alternatives O
to O
VOTRIENT O
should O
be O
considered O
. O

Treatment O
with O
VOTRIENT O
is O
not O
recommended O
in O
patients O
with O
pre-existing O
severe O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
defined O
as O
total O
bilirubin B-Not_AE_Candidate
> I-Not_AE_Candidate
3 I-Not_AE_Candidate
X I-Not_AE_Candidate
ULN I-Not_AE_Candidate
with O
any O
level O
of O
ALT O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
, O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

5.2 O
QT O
Prolongation O
and O
Torsades O
de O
Pointes O
In O
the O
RCC B-Not_AE_Candidate
trials O
of O
VOTRIENT O
, O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
( O
> O
=500 O
msec O
) O
was O
identified O
on O
routine O
electrocardiogram O
monitoring O
in O
2 O
% O
( O
11/558 O
) O
of O
patients O
. O

Torsades B-OSE_Labeled_AE
de I-OSE_Labeled_AE
pointes I-OSE_Labeled_AE
occurred O
in O
< O
1 O
% O
( O
2/977 O
) O
of O
patients O
who O
received O
VOTRIENT O
in O
the O
monotherapy O
trials O
. O

In O
the O
randomized O
RCC B-Not_AE_Candidate
and O
STS B-Not_AE_Candidate
trials O
, O
1 O
% O
( O
3/290 O
) O
of O
patients O
and O
0.4 O
% O
( O
1/240 O
) O
of O
patients O
, O
respectively O
, O
who O
received O
VOTRIENT O
had O
post-baseline O
values O
between O
500 O
to O
549 O
msec O
. O

Post-baseline O
QT O
data O
were O
only O
collected O
in O
the O
STS B-Not_AE_Candidate
trial O
if O
ECG B-NonOSE_AE
abnormalities I-NonOSE_AE
were O
reported O
as O
an O
adverse O
reaction O
. O

None O
of O
the O
268 O
patients O
who O
received O
placebo O
on O
the O
two O
trials O
had O
post-baseline O
QTc B-NonOSE_AE
values I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
msec I-NonOSE_AE
. O

VOTRIENT O
should O
be O
used O
with O
caution O
in O
patients O
with O
a O
history O
of O
QT B-Not_AE_Candidate
interval I-Not_AE_Candidate
prolongation I-Not_AE_Candidate
, O
in O
patients O
taking O
antiarrhythmics O
or O
other O
medications O
that O
may O
prolong B-NonOSE_AE
QT I-NonOSE_AE
interval I-NonOSE_AE
, O
and O
those O
with O
relevant O
pre B-Not_AE_Candidate
- I-Not_AE_Candidate
existing I-Not_AE_Candidate
cardiac O
disease I-Not_AE_Candidate
. O

When O
using O
VOTRIENT O
, O
baseline O
and O
periodic O
monitoring O
of O
electrocardiograms O
and O
maintenance O
of O
electrolytes O
( O
e.g. O
, O
calcium O
, O
magnesium O
, O
potassium O
) O
within O
the O
normal O
range O
should O
be O
performed O
. O

5.3 O
Cardiac O
Dysfunction O
In O
clinical O
trials O
with O
VOTRIENT O
, O
events O
of O
cardiac B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
such O
as O
decreased B-OSE_Labeled_AE
left I-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
ejection I-OSE_Labeled_AE
fraction I-OSE_Labeled_AE
( O
LVEF O
) O
and O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
have O
occurred O
. O

In O
the O
overall O
safety O
population O
for O
RCC B-Not_AE_Candidate
( O
N O
= O
586 O
) O
, O
cardiac B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
was O
observed O
in O
0.6 O
% O
( O
4/586 O
) O
of O
patients O
without O
routine O
on-study O
LVEF O
monitoring O
. O

In O
a O
randomized O
RCC B-Not_AE_Candidate
trial O
of O
VOTRIENT O
compared O
with O
sunitinib O
, O
myocardial B-NonOSE_AE
dysfunction I-NonOSE_AE
was O
defined O
as O
symptoms O
of O
cardiac B-NonOSE_AE
dysfunction I-NonOSE_AE
or O
> O
=15 O
% O
absolute O
decline B-NonOSE_AE
in I-NonOSE_AE
LVEF I-NonOSE_AE
compared O
with O
baseline O
or O
a O
decline B-NonOSE_AE
in I-NonOSE_AE
LVEF I-NonOSE_AE
of I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
% I-NonOSE_AE
compared O
with O
baseline O
that O
is O
also O
below O
the O
lower O
limit O
of O
normal O
. O

In O
patients O
who O
had O
baseline O
and O
follow O
up O
LVEF O
measurements O
, O
myocardial B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
occurred O
in O
13 O
% O
( O
47/362 O
) O
of O
patients O
on O
VOTRIENT O
compared O
with O
11 O
% O
( O
42/369 O
) O
of O
patients O
on O
sunitinib O
. O

Congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
occurred O
in O
0.5 O
% O
of O
patients O
on O
each O
arm O
. O

In O
the O
randomized O
STS B-Not_AE_Candidate
trial O
, O
myocardial B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
occurred O
in O
11 O
% O
( O
16/142 O
) O
of O
patients O
on O
VOTRIENT O
compared O
with O
5 O
% O
( O
2/40 O
) O
of O
patients O
on O
placebo O
. O

One O
percent O
( O
3/240 O
) O
of O
patients O
on O
VOTRIENT O
in O
the O
STS B-Not_AE_Candidate
trial O
had O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
which O
did O
not O
resolve O
in O
one O
patient O
. O

Fourteen O
of O
the O
16 O
patients O
with O
myocardial B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
treated O
with O
VOTRIENT O
in O
the O
STS B-Not_AE_Candidate
trial O
had O
concurrent O
hypertension B-Not_AE_Candidate
which O
may O
have O
exacerbated O
cardiac B-NonOSE_AE
dysfunction I-NonOSE_AE
in O
patients O
at O
risk O
( O
e.g. O
, O
those O
with O
prior O
anthracycline O
therapy O
) O
possibly O
by O
increasing B-NonOSE_AE
cardiac I-NonOSE_AE
afterload I-NonOSE_AE
. O

Blood O
pressure O
should O
be O
monitored O
and O
managed O
promptly O
using O
a O
combination O
of O
anti B-NonOSE_AE
- I-NonOSE_AE
hypertensive I-NonOSE_AE
therapy I-NonOSE_AE
and O
dose O
modification O
of O
VOTRIENT O
( O
interruption O
and O
re-initiation O
at O
a O
reduced O
dose O
based O
on O
clinical O
judgment O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
. O

Patients O
should O
be O
carefully O
monitored O
for O
clinical O
signs O
or O
symptoms O
of O
congestive B-NonOSE_AE
heart I-NonOSE_AE
failure I-NonOSE_AE
. O

Baseline O
and O
periodic O
evaluation O
of O
LVEF O
is O
recommended O
in O
patients O
at O
risk O
of O
cardiac B-NonOSE_AE
dysfunction I-NonOSE_AE
including O
previous O
anthracycline O
exposure O
. O

5.4 O
Hemorrhagic O
Events O
Fatal O
hemorrhage B-OSE_Labeled_AE
occurred O
in O
0.9 O
% O
( O
5/586 O
) O
in O
the O
RCC B-Not_AE_Candidate
trials O
; O
there O
were O
no O
reports O
of O
fatal B-NonOSE_AE
hemorrhage B-NonOSE_AE
in O
the O
STS B-Not_AE_Candidate
trials O
. O

In O
the O
randomized O
RCC B-Not_AE_Candidate
trial O
, O
13 O
% O
( O
37/290 O
) O
of O
patients O
treated O
with O
VOTRIENT O
and O
5 O
% O
( O
7/145 O
) O
of O
patients O
on O
placebo O
experienced O
at O
least O
1 O
hemorrhagic B-OSE_Labeled_AE
event I-OSE_Labeled_AE
. O

The O
most O
common O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
in O
the O
patients O
treated O
with O
VOTRIENT O
were O
hematuria B-OSE_Labeled_AE
( O
4 O
% O
) O
, O
epistaxis B-OSE_Labeled_AE
( O
2 O
% O
) O
, O
hemoptysis B-OSE_Labeled_AE
( O
2 O
% O
) O
, O
and O
rectal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
( O
1 O
% O
) O
. O

Nine O
of O
37 O
patients O
treated O
with O
VOTRIENT O
who O
had O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
experienced O
serious O
events O
including O
pulmonary B-OSE_Labeled_AE
, O
gastrointestinal O
, O
and O
genitourinary O
hemorrhage I-OSE_Labeled_AE
. O

One O
percent O
( O
4/290 O
) O
of O
patients O
treated O
with O
VOTRIENT O
died B-NonOSE_AE
from O
hemorrhage B-OSE_Labeled_AE
compared O
with O
no O
( O
0/145 O
) O
patients O
on O
placebo O
. O

In O
the O
overall O
safety O
population O
in O
RCC B-Not_AE_Candidate
( O
N O
= O
586 O
) O
, O
cerebral B-OSE_Labeled_AE
/intracranial O
hemorrhage I-OSE_Labeled_AE
was O
observed O
in O
< O
1 O
% O
( O
2/586 O
) O
of O
patients O
treated O
with O
VOTRIENT O
. O

In O
the O
randomized O
STS B-Not_AE_Candidate
trial O
, O
22 O
% O
( O
53/240 O
) O
of O
patients O
treated O
with O
VOTRIENT O
compared O
with O
8 O
% O
( O
10/123 O
) O
treated O
with O
placebo O
experienced O
at O
least O
1 O
hemorrhagic B-OSE_Labeled_AE
event I-OSE_Labeled_AE
. O

The O
most O
common O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
epistaxis B-OSE_Labeled_AE
( O
8 O
% O
) O
, O
mouth B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
( O
3 O
% O
) O
, O
and O
anal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
( O
2 O
% O
) O
. O

Grade O
4 O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
in O
the O
STS B-Not_AE_Candidate
population O
occurred O
in O
1 O
% O
( O
3/240 O
) O
of O
patients O
and O
included O
intracranial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
subarachnoid B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
and O
peritoneal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
. O

VOTRIENT O
has O
not O
been O
studied O
in O
patients O
who O
have O
a O
history O
of O
hemoptysis B-Not_AE_Candidate
, O
cerebral B-Not_AE_Candidate
hemorrhage I-Not_AE_Candidate
, O
or O
clinically O
significant O
gastrointestinal B-Not_AE_Candidate
hemorrhage I-Not_AE_Candidate
in O
the O
past O
6 O
months O
and O
should O
not O
be O
used O
in O
those O
patients O
. O

5.5 O
Arterial O
Thromboembolic O
Events O
Fatal O
arterial B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
observed O
in O
0.3 O
% O
( O
2/586 O
) O
of O
patients O
in O
the O
RCC B-Not_AE_Candidate
trials O
and O
in O
no O
patients O
in O
the O
STS B-Not_AE_Candidate
trials O
. O

In O
the O
randomized O
RCC B-Not_AE_Candidate
trial O
, O
2 O
% O
( O
5/290 O
) O
of O
patients O
receiving O
VOTRIENT O
experienced O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
or O
ischemia O
, O
0.3 O
% O
( O
1/290 O
) O
had O
a O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
and O
1 O
% O
( O
4/290 O
) O
had O
an O
event O
of O
transient B-OSE_Labeled_AE
ischemic I-OSE_Labeled_AE
attack I-OSE_Labeled_AE
. O

In O
the O
randomized O
STS B-Not_AE_Candidate
trial O
, O
2 O
% O
( O
4/240 O
) O
of O
patients O
receiving O
VOTRIENT O
experienced O
a O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
or O
ischemia B-OSE_Labeled_AE
, O
0.4 O
% O
( O
1/240 O
) O
had O
a O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
and O
there O
were O
no O
incidents O
of O
transient B-NonOSE_AE
ischemic I-NonOSE_AE
attack I-NonOSE_AE
. O

No O
arterial B-NonOSE_AE
thromboembolic I-NonOSE_AE
events I-NonOSE_AE
were O
reported O
in O
patients O
who O
received O
placebo O
in O
either O
trial O
. O

VOTRIENT O
should O
be O
used O
with O
caution O
in O
patients O
who O
are O
at O
increased O
risk O
for O
these O
events O
or O
who O
have O
had O
a O
history O
of O
these O
events O
. O

VOTRIENT O
has O
not O
been O
studied O
in O
patients O
who O
have O
had O
an O
arterial B-Not_AE_Candidate
thromboembolic I-Not_AE_Candidate
event I-Not_AE_Candidate
within O
the O
previous O
6 O
months O
and O
should O
not O
be O
used O
in O
those O
patients O
. O

5.6 O
Venous O
Thromboembolic O
Events O
In O
RCC B-Not_AE_Candidate
and O
STS B-Not_AE_Candidate
trials O
of O
VOTRIENT O
, O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
( O
VTE O
) O
including O
venous B-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
and O
fatal O
pulmonary B-OSE_Labeled_AE
embolus I-OSE_Labeled_AE
( O
PE O
) O
have O
occurred O
. O

In O
the O
randomized O
STS B-Not_AE_Candidate
trial O
, O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
reported O
in O
5 O
% O
of O
patients O
treated O
with O
VOTRIENT O
compared O
with O
2 O
% O
with O
placebo O
. O

In O
the O
randomized O
RCC B-Not_AE_Candidate
trial O
, O
the O
rate O
was O
1 O
% O
in O
both O
arms O
. O

Fatal B-NonOSE_AE
pulmonary B-OSE_Labeled_AE
embolus I-OSE_Labeled_AE
occurred O
in O
1 O
% O
( O
2/240 O
) O
of O
STS B-Not_AE_Candidate
patients O
receiving O
VOTRIENT O
and O
in O
no O
patients O
receiving O
placebo O
. O

There O
were O
no O
fatal O
pulmonary B-NonOSE_AE
emboli I-NonOSE_AE
in O
the O
RCC B-Not_AE_Candidate
trial O
. O

Monitor O
for O
signs O
and O
symptoms O
of O
VTE B-NonOSE_AE
and O
PE B-NonOSE_AE
. O

5.7 O
Thrombotic O
Microangiopathy O
Thrombotic B-OSE_Labeled_AE
microangiopathy I-OSE_Labeled_AE
( O
TMA O
) O
, O
including O
thrombotic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
( O
TTP O
) O
and O
hemolytic B-OSE_Labeled_AE
uremic I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( O
HUS O
) O
, O
has O
been O
reported O
in O
clinical O
trials O
of O
VOTRIENT O
as O
monotherapy O
, O
in O
combination O
with O
bevacizumab O
, O
and O
in O
combination O
with O
topotecan O
. O

VOTRIENT O
is O
not O
indicated O
for O
use O
in O
combination O
with O
other O
agents O
. O

Six O
of O
the O
7 O
TMA B-OSE_Labeled_AE
cases O
occurred O
within O
90 O
days O
of O
the O
initiation O
of O
VOTRIENT O
. O

Improvement O
of O
TMA B-NonOSE_AE
was O
observed O
after O
treatment O
was O
discontinued O
. O

Monitor O
for O
signs O
and O
symptoms O
of O
TMA B-NonOSE_AE
. O

Permanently O
discontinue O
VOTRIENT O
in O
patients O
developing O
TMA B-NonOSE_AE
. O

Manage O
as O
clinically O
indicated O
. O

5.8 O
Gastrointestinal O
Perforation O
and O
Fistula O
In O
the O
RCC B-Not_AE_Candidate
and O
STS B-Not_AE_Candidate
trials O
, O
gastrointestinal B-NonOSE_AE
perforation O
or O
fistula O
occurred O
in O
0.9 O
% O
( O
5/586 O
) O
of O
patients O
and O
1 O
% O
( O
4/382 O
) O
of O
patients O
receiving O
VOTRIENT O
, O
respectively O
. O

Fatal O
perfora O
tions B-NonOSE_AE
 I-NonOSE_AE
occurred O
in O
0.3 O
% O
( O
2/586 O
) O
of O
these O
patients O
in O
the O
RCC B-Not_AE_Candidate
trials O
and O
in O
0.3 O
% O
( O
1/382 O
) O
of O
these O
patients O
in O
the O
STS B-Not_AE_Candidate
trials O
. O

Monitor O
for O
signs O
and O
symptoms O
of O
gastrointestinal B-NonOSE_AE
perforation I-NonOSE_AE
or O
fistula O
. O

5.9 O
Interstitial B-OSE_Labeled_AE
Lung I-OSE_Labeled_AE
Disease I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ILD I-OSE_Labeled_AE
) O
/Pneumonitis O
ILD B-OSE_Labeled_AE
/ O
pneumonitis B-OSE_Labeled_AE
, O
which O
can O
be O
fatal B-NonOSE_AE
, O
has O
been O
reported O
in O
association O
with O
VOTRIENT O
. O

In O
clinical O
trials O
, O
ILD B-OSE_Labeled_AE
/ O
pneumonitis B-OSE_Labeled_AE
occurred O
in O
0.1 O
% O
of O
patients O
treated O
with O
VOTRIENT O
. O

Monitor O
patients O
for O
pulmonary O
symptoms O
indicative O
of O
ILD B-NonOSE_AE
/ O
pneumonitis B-NonOSE_AE
and O
discontinue O
VOTRIENT O
in O
patients O
developing O
ILD B-NonOSE_AE
or O
pneumonitis B-NonOSE_AE
. O

5.10 O
Reversible O
Posterior O
Leukoencephalopathy O
Syndrome O
Reversible B-OSE_Labeled_AE
Posterior I-OSE_Labeled_AE
Leukoencephalopathy I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( O
RPLS O
) O
has O
been O
reported O
in O
patients O
receiving O
VOTRIENT O
and O
may O
be O
fatal B-NonOSE_AE
. O

RPLS B-NonOSE_AE
is O
a O
neurological B-NonOSE_AE
disorder I-NonOSE_AE
which O
can O
present O
with O
headache B-NonOSE_AE
, O
seizure B-NonOSE_AE
, O
lethargy B-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
blindness B-NonOSE_AE
, O
and O
other O
visual B-NonOSE_AE
and O
neurologic O
disturbances I-NonOSE_AE
. O

Mild O
to O
severe O
hypertension B-NonOSE_AE
may O
be O
present O
. O

The O
diagnosis O
of O
RPLS B-NonOSE_AE
is O
optimally O
confirmed O
by O
magnetic O
resonance O
imaging O
. O

Permanently O
discontinue O
VOTRIENT O
in O
patients O
developing O
RPLS B-NonOSE_AE
. O

5.11 O
Hypertension O
In O
clinical O
trials O
, O
hypertension B-OSE_Labeled_AE
( O
systolic B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
or O
diastolic B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mm I-OSE_Labeled_AE
Hg I-OSE_Labeled_AE
) O
and O
hypertensive B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
were O
observed O
in O
patients O
treated O
with O
VOTRIENT O
. O

Blood O
pressure O
should O
be O
well O
controlled O
prior O
to O
initiating O
VOTRIENT O
. O

Hypertension B-OSE_Labeled_AE
occurs O
early O
in O
the O
course O
of O
treatment O
( O
40 O
% O
of O
cases O
occurred O
by O
Day O
9 O
and O
90 O
% O
of O
cases O
occurred O
in O
the O
first O
18 O
weeks O
) O
. O

Blood O
pressure O
should O
be O
monitored O
early O
after O
starting O
treatment O
( O
no O
longer O
than O
one O
week O
) O
and O
frequently O
thereafter O
to O
ensure O
blood O
pressure O
control O
. O

Approximately O
40 O
% O
of O
patients O
who O
received O
VOTRIENT O
experienced O
hypertension B-OSE_Labeled_AE
. O

Grade O
3 O
hypertension B-OSE_Labeled_AE
was O
reported O
in O
4 O
% O
to O
7 O
% O
of O
patients O
receiving O
VOTRIENT O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Increased B-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
should O
be O
treated O
promptly O
with O
standard O
anti B-NonOSE_AE
- I-NonOSE_AE
hypertensive I-NonOSE_AE
therapy I-NonOSE_AE
and O
dose O
reduction O
or O
interruption O
of O
VOTRIENT O
as O
clinically O
warranted O
. O

VOTRIENT O
should O
be O
discontinued O
if O
there O
is O
evidence O
of O
hypertensive B-NonOSE_AE
crisis I-NonOSE_AE
or O
if O
hypertension B-NonOSE_AE
is O
severe O
and O
persistent O
despite O
anti B-NonOSE_AE
- I-NonOSE_AE
hypertensive I-NonOSE_AE
therapy I-NonOSE_AE
and O
dose O
reduction O
. O

Approximately O
1 O
% O
of O
patients O
required O
permanent O
discontinuation O
of O
VOTRIENT O
because O
of O
hypertension B-OSE_Labeled_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.12 O
Wound O
Healing O
No O
formal O
trials O
on O
the O
effect O
of O
VOTRIENT O
on O
wound B-NonOSE_AE
healing I-NonOSE_AE
have O
been O
conducted O
. O

Since O
vascular O
endothelial O
growth O
factor O
receptor O
( O
VEGFR O
) O
inhibitors O
such O
as O
pazopanib O
may O
impair B-OSE_Labeled_AE
wound I-OSE_Labeled_AE
healing I-OSE_Labeled_AE
, O
treatment O
with O
VOTRIENT O
should O
be O
stopped O
at O
least O
7 O
days O
prior O
to O
scheduled O
surgery O
. O

The O
decision O
to O
resume O
VOTRIENT O
after O
surgery O
should O
be O
based O
on O
clinical O
judgment O
of O
adequate O
wound O
healing O
. O

VOTRIENT O
should O
be O
discontinued O
in O
patients O
with O
wound B-NonOSE_AE
dehiscence I-NonOSE_AE
. O

5.13 O
Hypothyroidism O
Hypothyroidism B-OSE_Labeled_AE
, O
confirmed O
based O
on O
a O
simultaneous O
rise B-OSE_Labeled_AE
of I-OSE_Labeled_AE
TSH I-OSE_Labeled_AE
and O
decline B-OSE_Labeled_AE
of I-OSE_Labeled_AE
T I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
, O
was O
reported O
in O
7 O
% O
( O
19/290 O
) O
of O
patients O
treated O
with O
VOTRIENT O
in O
the O
randomized O
RCC B-Not_AE_Candidate
trial O
and O
in O
5 O
% O
( O
11/240 O
) O
of O
patients O
treated O
with O
VOTRIENT O
in O
the O
randomized O
STS B-Not_AE_Candidate
trial O
. O

No O
patients O
on O
the O
placebo O
arm O
of O
either O
trial O
had O
hypothyroidism B-NonOSE_AE
. O

In O
RCC B-Not_AE_Candidate
and O
STS B-Not_AE_Candidate
trials O
of O
VOTRIENT O
, O
hypothyroidism B-OSE_Labeled_AE
was O
reported O
as O
an O
adverse O
reaction O
in O
4 O
% O
( O
26/586 O
) O
and O
5 O
% O
( O
20/382 O
) O
of O
patients O
, O
respectively O
. O

Proactive O
monitoring O
of O
thyroid O
function O
tests O
is O
recommended O
. O

5.14 O
Proteinuria O
In O
the O
randomized O
RCC B-Not_AE_Candidate
trial O
, O
proteinuria B-OSE_Labeled_AE
was O
reported O
as O
an O
adverse O
reaction O
in O
9 O
% O
( O
27/290 O
) O
of O
patients O
receiving O
VOTRIENT O
and O
in O
no O
patients O
receiving O
placebo O
. O

In O
2 O
patients O
, O
proteinuria B-OSE_Labeled_AE
led O
to O
discontinuation O
of O
treatment O
with O
VOTRIENT O
. O

In O
the O
randomized O
STS B-Not_AE_Candidate
trial O
, O
proteinuria B-OSE_Labeled_AE
was O
reported O
as O
an O
adverse O
reaction O
in O
1 O
% O
( O
2/240 O
) O
of O
patients O
, O
and O
nephrotic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
was O
reported O
in O
1 O
patient O
treated O
with O
VOTRIENT O
compared O
with O
none O
in O
patients O
receiving O
placebo O
. O

Treatment O
was O
withdrawn O
in O
the O
patient O
with O
nephrotic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
. O

Baseline O
and O
periodic O
urinalysis O
during O
treatment O
is O
recommended O
with O
follow O
up O
measurement O
of O
24-hour O
urine O
protein O
as O
clinically O
indicated O
. O

Interrupt O
VOTRIENT O
and O
dose O
reduce O
for O
24-hour O
urine O
protein O
> O
=3 O
grams O
; O
discontinue O
VOTRIENT O
for O
repeat O
episodes O
despite O
dose O
reductions O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.15 O
Infection O
Serious O
infections B-OSE_Labeled_AE
( O
with O
or O
without O
neutropenia O
) O
, O
including O
some O
with O
fatal O
outcome O
, O
have O
been O
reported O
. O

Monitor O
patients O
for O
signs O
and O
symptoms O
of O
infection B-NonOSE_AE
. O

Institute O
appropriate O
anti-infective O
therapy O
promptly O
and O
consider O
interruption O
or O
discontinuation O
of O
VOTRIENT O
for O
serious O
infections B-NonOSE_AE
. O

5.16 O
Increased O
Toxicity O
with O
Other O
Cancer O
Therapy O
VOTRIENT O
is O
not O
indicated O
for O
use O
in O
combination O
with O
other O
agents O
. O

Clinical O
trials O
of O
VOTRIENT O
in O
combination O
with O
pemetrexed O
and O
lapatinib O
were O
terminated O
early O
due O
to O
concerns O
over O
increased O
toxicity O
and O
mortality B-NonOSE_AE
. O

The O
fatal B-NonOSE_AE
toxicities O
observed O
included O
pulmonary B-NonOSE_AE
hemorrhage I-NonOSE_AE
, O
gastrointestinal B-NonOSE_AE
hemorrhage I-NonOSE_AE
, O
and O
sudden B-NonOSE_AE
death I-NonOSE_AE
. O

A O
safe O
and O
effective O
combination O
dose O
has O
not O
been O
established O
with O
these O
regimens O
. O

5.17 O
Increased O
Toxicity O
in O
Developing O
Organs O
The O
safety O
and O
effectiveness O
of O
VOTRIENT O
in O
pediatric O
patients O
have O
not O
been O
established O
. O

VOTRIENT O
is O
not O
indicated O
for O
use O
in O
pediatric O
patients O
. O

Based O
on O
its O
mechanism O
of O
action O
, O
pazopanib O
may O
have O
severe O
effects B-OSE_Labeled_AE
on I-OSE_Labeled_AE
organ I-OSE_Labeled_AE
growth I-OSE_Labeled_AE
and I-OSE_Labeled_AE
maturation I-OSE_Labeled_AE
during O
early O
post-natal O
development O
. O

Administration O
of O
pazopanib O
to O
juvenile O
rats O
less O
than O
21 O
days O
old O
resulted O
in O
toxicity B-NonOSE_AE
to I-NonOSE_AE
the I-NonOSE_AE
lungs I-NonOSE_AE
, O
liver O
, O
heart O
, O
and O
kidney O
and O
in O
death B-NonOSE_AE
at O
doses O
significantly O
lower O
than O
the O
clinically O
recommended O
dose O
or O
doses O
tolerated O
in O
older O
animals O
. O

VOTRIENT O
may O
potentially O
cause O
serious O
adverse B-OSE_Labeled_AE
effects I-OSE_Labeled_AE
on I-OSE_Labeled_AE
organ I-OSE_Labeled_AE
development I-OSE_Labeled_AE
in O
pediatric O
patients O
, O
particularly O
in O
patients O
younger O
than O
2 O
years O
of O
age O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.4 O
) O
] O
. O

5.18 O
Pregnancy O
VOTRIENT O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
. O

Based O
on O
its O
mechanism O
of O
action O
, O
VOTRIENT O
is O
expected O
to O
result O
in O
adverse B-OSE_Labeled_AE
reproductive I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
. O

In O
pre-clinical O
studies O
in O
rats O
and O
rabbits O
, O
pazopanib O
was O
teratogenic B-NonOSE_AE
, O
embryotoxic B-NonOSE_AE
, O
fetotoxic B-NonOSE_AE
, O
and O
abortifacient B-NonOSE_AE
. O

There O
are O
no O
adequate O
and O
well-controlled O
studies O
of O
VOTRIENT O
in O
pregnant B-Not_AE_Candidate
women O
. O

If O
this O
drug O
is O
used O
during O
pregnancy B-Not_AE_Candidate
, O
or O
if O
the O
patient O
becomes O
pregnant B-NonOSE_AE
while O
taking O
this O
drug O
, O
the O
patient O
should O
be O
apprised O
of O
the O
potential O
hazard B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

Women O
of O
childbearing O
potential O
should O
be O
advised O
to O
avoid O
becoming O
pregnant B-NonOSE_AE
while O
taking O
VOTRIENT O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Hepatotoxicity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Interstitial B-OSE_Labeled_AE
Lung I-OSE_Labeled_AE
Disease I-OSE_Labeled_AE
( O
Pneumonitis O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
QT B-OSE_Labeled_AE
Interval I-OSE_Labeled_AE
Prolongation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Bradycardia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Severe O
Visual B-OSE_Labeled_AE
Loss I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
( O
> O
=25 O
% O
) O
are O
vision O
disorders O
, O
nausea O
, O
diarrhea O
, O
vomiting O
, O
edema O
, O
constipation O
, O
elevated O
transaminases O
, O
fatigue O
, O
decreased O
appetite O
, O
upper O
respiratory O
infection O
, O
dizziness O
, O
and O
neuropathy O
. O

( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Pfizer O
Inc O
. O
at O
1-800-438-1985 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

The O
data O
in O
the O
Warnings O
and O
Precautions O
section O
reflect O
exposure O
to O
XALKORI O
in O
1719 O
patients O
who O
received O
XALKORI O
250 O
mg O
twice O
daily O
enrolled O
on O
Studies O
1 O
( O
including O
an O
additional O
109 O
patients O
who O
crossed O
over O
from O
the O
control O
arm O
) O
, O
2 O
, O
3 O
, O
a O
single O
arm O
trial O
( O
n=1063 O
) O
of O
ALK B-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
NSCLC B-Not_AE_Candidate
, O
and O
an O
additional O
ALK B-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
NSCLC B-Not_AE_Candidate
expansion O
cohort O
of O
a O
dose O
finding O
study O
( O
n=154 O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5 O
) O
] O
. O

The O
data O
described O
below O
is O
based O
primarily O
on O
343 O
patients O
with O
ALK B-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
metastatic B-Not_AE_Candidate
NSCLC I-Not_AE_Candidate
who O
received O
XALKORI O
250 O
mg O
twice O
daily O
from O
2 O
open-label O
, O
randomized O
, O
active-controlled O
trials O
( O
Studies O
1 O
and O
2 O
) O
. O

The O
safety O
of O
XALKORI O
was O
also O
evaluated O
in O
50 O
patients O
with O
ROS1-positive O
metastatic B-Not_AE_Candidate
NSCLC I-Not_AE_Candidate
from O
a O
single-arm O
study O
( O
Study O
3 O
) O
. O

The O
most O
common O
adverse O
reactions O
( O
> O
=25 O
% O
) O
of O
XALKORI O
are O
vision B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
and O
neuropathy B-OSE_Labeled_AE
. O

Previously O
Untreated O
ALK-Positive O
Metastatic O
NSCLC O
- O
Study O
1 O
The O
data O
in O
Table O
3 O
are O
derived O
from O
340 O
patients O
with O
ALK B-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
metastatic O
NSCLC B-Not_AE_Candidate
who O
had O
not O
received O
previous O
systemic O
treatment O
for O
advanced O
disease O
who O
received O
treatment O
in O
a O
randomized O
, O
multicenter O
, O
open-label O
, O
active-controlled O
trial O
( O
Study O
1 O
) O
. O

Patients O
in O
the O
XALKORI O
arm O
( O
n=171 O
) O
received O
XALKORI O
250 O
mg O
orally O
twice O
daily O
until O
documented O
disease O
progression O
, O
intolerance O
to O
therapy O
, O
or O
the O
investigator O
determined O
that O
the O
patient O
was O
no O
longer O
experiencing O
clinical O
benefit O
. O

A O
total O
of O
169 O
patients O
in O
the O
chemotherapy O
arm O
received O
pemetrexed O
500 O
mg/m O
2 O
in O
combination O
with O
cisplatin O
75 O
mg/m O
2 O
( O
n=91 O
) O
or O
carboplatin O
at O
a O
dose O
calculated O
to O
produce O
an O
area O
under O
the O
concentration-time O
curve O
( O
AUC O
) O
of O
5 O
or O
6 O
mg O
min/mL O
( O
n=78 O
) O
. O

Chemotherapy O
was O
given O
by O
intravenous O
infusion O
every O
3 O
weeks O
for O
up O
to O
6 O
cycles O
, O
in O
the O
absence O
of O
dose-limiting O
chemotherapy-related O
toxicities O
. O

After O
6 O
cycles O
, O
patients O
remained O
on O
study O
with O
no O
additional O
anticancer O
treatment O
, O
and O
tumor O
assessments O
continued O
until O
documented O
disease O
progression O
. O

The O
median O
duration O
of O
study O
treatment O
was O
10.9 O
months O
for O
patients O
in O
the O
XALKORI O
arm O
and O
4.1 O
months O
for O
patients O
in O
the O
chemotherapy O
arm O
. O

Median O
duration O
of O
treatment O
was O
5.2 O
months O
for O
patients O
who O
received O
XALKORI O
after O
cross O
over O
from O
chemotherapy O
. O

Across O
the O
340 O
patients O
who O
were O
treated O
in O
Study O
1 O
, O
the O
median O
age O
was O
53 O
years O
; O
16 O
% O
of O
patients O
were O
older O
than O
65 O
years O
. O

A O
total O
of O
62 O
% O
of O
patients O
were O
female O
and O
46 O
% O
were O
Asian O
. O

Serious O
adverse O
events O
were O
reported O
in O
58 O
patients O
( O
34 O
% O
) O
treated O
with O
XALKORI O
. O

The O
most O
frequent O
serious O
adverse O
events O
reported O
in O
patients O
treated O
with O
XALKORI O
were O
dyspnea B-OSE_Labeled_AE
( O
4.1 O
% O
) O
and O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
( O
2.9 O
% O
) O
. O

Fatal O
adverse O
events O
in O
XALKORI-treated O
patients O
occurred O
in O
2.3 O
% O
patients O
, O
consisting O
of O
septic B-OSE_Labeled_AE
shock I-OSE_Labeled_AE
, O
acute B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
and O
diabetic B-OSE_Labeled_AE
ketoacidosis I-OSE_Labeled_AE
. O

Dose O
reductions O
due O
to O
adverse O
reactions O
were O
required O
in O
6.4 O
% O
of O
XALKORI-treated O
patients O
. O

The O
most O
frequent O
adverse O
reactions O
that O
led O
to O
dose O
reduction O
in O
these O
patients O
were O
nausea B-OSE_Labeled_AE
( O
1.8 O
% O
) O
and O
elevated B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
( O
1.8 O
% O
) O
. O

Permanent O
discontinuation O
of O
XALKORI O
treatment O
for O
adverse O
reactions O
was O
8.2 O
% O
. O

The O
most O
frequent O
adverse O
reactions O
that O
led O
to O
permanent O
discontinuation O
in O
XALKORI-treated O
patients O
were O
elevated B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
( O
1.2 O
% O
) O
, O
hepatotoxicity B-OSE_Labeled_AE
( O
1.2 O
% O
) O
, O
and O
ILD B-OSE_Labeled_AE
( O
1.2 O
% O
) O
. O

Tables O
3 O
and O
4 O
summarize O
common O
adverse O
reactions O
and O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
in O
XALKORI-treated O
patients O
. O

Table O
3 O
. O

Adverse O
Reactions O
Reported O
at O
a O
Higher O
Incidence O
( O
> O
=5 O
% O
Higher O
for O
All O
Grades O
or O
> O
=2 O
% O
Higher O
for O
Grades O
3-4 O
) O
with O
XALKORI O
than O
Chemotherapy O
in O
Study O
1Adverse O
reactions O
were O
graded O
using O
NCI O
CTCAE O
version O
4.0.Includes O
cases O
reported O
within O
the O
clustered O
terms O
: O
Adverse O
Reaction O
XALKORI O
( O
N=171 O
) O
Chemotherapy O
( O
Pemetrexed/Cisplatin O
or O
Pemetrexed/Carboplatin O
) O
( O
N=169 O
) O
All O
Grades O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
All O
Grades O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
Electrocardiogram B-OSE_Labeled_AE
QT I-OSE_Labeled_AE
prolonged I-OSE_Labeled_AE
6 O
2 O
2 O
0 O
Bradycardia B-OSE_Labeled_AE
[ O
note O
: O
Bradycardia B-OSE_Labeled_AE
( O
Bradycardia B-OSE_Labeled_AE
, O
Sinus B-OSE_Labeled_AE
bradycardia I-OSE_Labeled_AE
) O
. O
] O

14 O
1 O
1 O
0 O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Vision B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
[ O
note O
: O
Vision B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
( O
Diplopia B-OSE_Labeled_AE
, O
Photophobia B-OSE_Labeled_AE
, O
Photopsia B-OSE_Labeled_AE
, O
Reduced B-OSE_Labeled_AE
visual I-OSE_Labeled_AE
acuity I-OSE_Labeled_AE
, O
Blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
Vitreous B-OSE_Labeled_AE
floaters I-OSE_Labeled_AE
, O
Visual B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
) O
. O
] O

71 O
1 O
10 O
0 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Vomiting B-OSE_Labeled_AE
46 O
2 O
36 O
3 O
Diarrhea B-OSE_Labeled_AE
61 O
2 O
13 O
1 O
Constipation B-OSE_Labeled_AE
43 O
2 O
30 O
0 O
Dyspepsia B-OSE_Labeled_AE
14 O
0 O
2 O
0 O
Dysphagia B-OSE_Labeled_AE
10 O
1 O
2 O
1 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
[ O
note O
: O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
Abdominal B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
, O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
Lower B-OSE_Labeled_AE
abdominal I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
Upper B-OSE_Labeled_AE
abdominal I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
Abdominal B-OSE_Labeled_AE
tenderness I-OSE_Labeled_AE
) O
. O
] O

26 O
0 O
12 O
0 O
Esophagitis B-OSE_Labeled_AE
[ O
note O
: O
Esophagitis B-OSE_Labeled_AE
( O
Esophagitis B-OSE_Labeled_AE
, O
Esophageal B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
) O
. O
] O

6 O
2 O
1 O
0 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
Edema B-OSE_Labeled_AE
[ O
note O
: O
Edema B-OSE_Labeled_AE
( O
Edema B-OSE_Labeled_AE
, O
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
Face B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
Generalized B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
Local B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
, O
Periorbital B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
) O
. O
] O

49 O
1 O
12 O
1 O
Pyrexia B-OSE_Labeled_AE
19 O
0 O
11 O
1 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
[ O
note O
: O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
Nasopharyngitis B-OSE_Labeled_AE
, O
Pharyngitis B-OSE_Labeled_AE
, O
Rhinitis B-OSE_Labeled_AE
, O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
) O
. O
] O

32 O
0 O
12 O
1 O
Investigations B-NonOSE_AE
Increased B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
8 O
1 O
2 O
0 O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
16 O
0 O
7 O
0 O
Muscle B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
8 O
0 O
2 O
1 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
[ O
note O
: O
Dizziness B-OSE_Labeled_AE
( O
Balance B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
Dizziness B-OSE_Labeled_AE
, O
Postural B-OSE_Labeled_AE
dizziness I-OSE_Labeled_AE
, O
Presyncope B-OSE_Labeled_AE
) O
. O
] O

18 O
0 O
10 O
1 O
Dysgeusia B-OSE_Labeled_AE
26 O
0 O
5 O
0 O
Headache B-OSE_Labeled_AE
22 O
1 O
15 O
0 O
Additional O
adverse O
reactions O
occurring O
at O
an O
overall O
incidence O
between O
1 O
% O
and O
60 O
% O
in O
patients O
treated O
with O
XALKORI O
included O
nausea B-OSE_Labeled_AE
( O
56 O
% O
) O
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
( O
30 O
% O
) O
, O
fatigue B-OSE_Labeled_AE
( O
29 O
% O
) O
, O
neuropathy B-OSE_Labeled_AE
( O
21 O
% O
; O
gait B-OSE_Labeled_AE
disturbance I-OSE_Labeled_AE
, O
hypoesthesia B-OSE_Labeled_AE
, O
muscular B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
, O
neuralgia B-OSE_Labeled_AE
, O
neuropathy B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
polyneuropathy B-OSE_Labeled_AE
, O
sensory B-OSE_Labeled_AE
disturbance I-OSE_Labeled_AE
) O
, O
rash B-OSE_Labeled_AE
( O
11 O
% O
) O
, O
renal B-OSE_Labeled_AE
cyst I-OSE_Labeled_AE
( O
5 O
% O
) O
, O
ILD B-OSE_Labeled_AE
( O
1 O
% O
; O
ILD B-OSE_Labeled_AE
, O
pneumonitis B-OSE_Labeled_AE
) O
, O
syncope B-OSE_Labeled_AE
( O
1 O
% O
) O
, O
and O
decreased B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
testosterone I-OSE_Labeled_AE
( O
1 O
% O
; O
hypogonadism B-OSE_Labeled_AE
) O
. O

Table O
4 O
. O

Laboratory O
Abnormalities O
with O
Grade O
3 O
or O
4 O
Incidence O
of O
> O
=4 O
% O
in O
XALKORI-Treated O
Patients O
in O
Study O
1 O
Laboratory O
Abnormality O
XALKORI O
Chemotherapy O
Any O
Grade O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
Any O
Grade O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
Additional O
laboratory B-NonOSE_AE
test I-NonOSE_AE
abnormality I-NonOSE_AE
in O
patients O
treated O
with O
XALKORI O
was O
an O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
( O
Any O
Grade O
: O
99 O
% O
; O
Grade O
3 O
: O
2 O
% O
; O
Grade O
4 O
: O
0 O
% O
) O
compared O
to O
the O
chemotherapy O
arm O
( O
Any O
Grade O
: O
92 O
% O
; O
Grade O
3 O
: O
0 O
% O
; O
Grade O
4 O
: O
1 O
% O
) O
. O

Hematology B-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
52 O
11 O
59 O
16 O
Lymphopenia B-OSE_Labeled_AE
48 O
7 O
53 O
13 O
Chemistry B-NonOSE_AE
ALT B-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
79 O
15 O
33 O
2 O
AST B-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
66 O
8 O
28 O
1 O
Hypophosphatemia B-OSE_Labeled_AE
32 O
10 O
21 O
6 O
Previously O
Treated O
ALK-Positive O
Metastatic O
NSCLC O
- O
Study O
2 O
The O
data O
in O
Table O
5 O
are O
derived O
from O
343 O
patients O
with O
ALK B-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
metastatic B-Not_AE_Candidate
NSCLC I-Not_AE_Candidate
enrolled O
in O
a O
randomized O
, O
multicenter O
, O
active-controlled O
, O
open-label O
trial O
( O
Study O
2 O
) O
. O

Patients O
in O
the O
XALKORI O
arm O
( O
n=172 O
) O
received O
XALKORI O
250 O
mg O
orally O
twice O
daily O
until O
documented O
disease O
progression O
, O
intolerance O
to O
therapy O
, O
or O
the O
investigator O
determined O
that O
the O
patient O
was O
no O
longer O
experiencing O
clinical O
benefit O
. O

A O
total O
of O
171 O
patients O
in O
the O
chemotherapy O
arm O
received O
pemetrexed O
500 O
mg/m O
2 O
( O
n=99 O
) O
or O
docetaxel O
75 O
mg/m O
2 O
( O
n=72 O
) O
by O
intravenous O
infusion O
every O
3 O
weeks O
until O
documented O
disease O
progression O
, O
intolerance O
to O
therapy O
, O
or O
the O
investigator O
determined O
that O
the O
patient O
was O
no O
longer O
experiencing O
clinical O
benefit O
. O

Patients O
in O
the O
chemotherapy O
arm O
received O
pemetrexed O
unless O
they O
had O
received O
pemetrexed O
as O
part O
of O
first-line O
or O
maintenance O
treatment O
. O

The O
median O
duration O
of O
study O
treatment O
was O
7.1 O
months O
for O
patients O
who O
received O
XALKORI O
and O
2.8 O
months O
for O
patients O
who O
received O
chemotherapy O
. O

Across O
the O
347 O
patients O
who O
were O
randomized O
to O
study O
treatment O
( O
343 O
received O
at O
least O
1 O
dose O
of O
study O
treatment O
) O
, O
the O
median O
age O
was O
50 O
years O
; O
14 O
% O
of O
patients O
were O
older O
than O
65 O
years O
. O

A O
total O
of O
56 O
% O
of O
patients O
were O
female O
and O
45 O
% O
of O
patients O
were O
Asian O
. O

Serious O
adverse O
reactions O
were O
reported O
in O
64 O
patients O
( O
37.2 O
% O
) O
treated O
with O
XALKORI O
and O
40 O
patients O
( O
23.4 O
% O
) O
in O
the O
chemotherapy O
arm O
. O

The O
most O
frequent O
serious O
adverse O
reactions O
reported O
in O
patients O
treated O
with O
XALKORI O
were O
pneumonia B-OSE_Labeled_AE
( O
4.1 O
% O
) O
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
( O
3.5 O
% O
) O
, O
dyspnea B-OSE_Labeled_AE
( O
2.3 O
% O
) O
, O
and O
ILD B-OSE_Labeled_AE
( O
2.9 O
% O
) O
. O

Fatal B-NonOSE_AE
adverse O
reactions O
in O
XALKORI-treated O
patients O
in O
Study O
2 O
occurred O
in O
9 O
( O
5 O
% O
) O
patients O
, O
consisting O
of O
: O
acute B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
distress I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
arrhythmia B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
pneumonitis B-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
ILD B-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
and O
sepsis B-OSE_Labeled_AE
. O

Dose O
reductions O
due O
to O
adverse O
reactions O
were O
required O
in O
16 O
% O
of O
XALKORI-treated O
patients O
. O

The O
most O
frequent O
adverse O
reactions O
that O
led O
to O
dose O
reduction O
in O
the O
patients O
treated O
with O
XALKORI O
were O
ALT B-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
( O
7.6 O
% O
) O
including O
some O
patients O
with O
concurrent O
AST B-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
, O
QTc B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
( O
2.9 O
% O
) O
, O
and O
neutropenia B-OSE_Labeled_AE
( O
2.3 O
% O
) O
. O

XALKORI O
was O
discontinued O
for O
adverse O
reactions O
in O
15 O
% O
of O
patients O
. O

The O
most O
frequent O
adverse O
reactions O
that O
led O
to O
discontinuation O
of O
XALKORI O
were O
ILD B-OSE_Labeled_AE
( O
1.7 O
% O
) O
, O
ALT B-OSE_Labeled_AE
and O
AST O
elevation I-OSE_Labeled_AE
( O
1.2 O
% O
) O
, O
dyspnea B-OSE_Labeled_AE
( O
1.2 O
% O
) O
, O
and O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
( O
1.2 O
% O
) O
. O

Tables O
5 O
and O
6 O
summarize O
common O
adverse O
reactions O
and O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
in O
XALKORI-treated O
patients O
. O

Table O
5 O
. O

Adverse O
Reactions O
Reported O
at O
a O
Higher O
Incidence O
( O
> O
=5 O
% O
Higher O
for O
All O
Grades O
or O
> O
=2 O
% O
Higher O
for O
Grades O
3/4 O
) O
with O
XALKORI O
than O
Chemotherapy O
in O
Study O
2Adverse O
reactions O
were O
graded O
using O
NCI O
CTCAE O
version O
4.0.Includes O
cases O
reported O
within O
the O
clustered O
terms O
: O
Adverse O
Reaction O
XALKORI O
( O
N=172 O
) O
Chemotherapy O
( O
Pemetrexed O
or O
Docetaxel O
) O
( O
N=171 O
) O
All O
Grades O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
All O
Grades O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
[ O
note O
: O
Dizziness B-OSE_Labeled_AE
( O
Balance B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
Dizziness B-OSE_Labeled_AE
, O
Postural B-OSE_Labeled_AE
dizziness I-OSE_Labeled_AE
) O
. O
] O

22 O
1 O
8 O
0 O
Dysgeusia B-OSE_Labeled_AE
26 O
0 O
9 O
0 O
Syncope B-OSE_Labeled_AE
3 O
3 O
0 O
0 O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Vision B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
[ O
note O
: O
Vision B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
( O
Diplopia B-OSE_Labeled_AE
, O
Photophobia B-OSE_Labeled_AE
, O
Photopsia B-OSE_Labeled_AE
, O
Blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
Reduced B-OSE_Labeled_AE
visual I-OSE_Labeled_AE
acuity I-OSE_Labeled_AE
, O
Visual B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
Vitreous B-OSE_Labeled_AE
floaters I-OSE_Labeled_AE
) O
. O
] O

60 O
0 O
9 O
0 O
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
Electrocardiogram B-OSE_Labeled_AE
QT I-OSE_Labeled_AE
prolonged I-OSE_Labeled_AE
5 O
3 O
0 O
0 O
Bradycardia B-OSE_Labeled_AE
[ O
note O
: O
Bradycardia B-OSE_Labeled_AE
( O
Bradycardia B-OSE_Labeled_AE
, O
Sinus B-OSE_Labeled_AE
bradycardia I-OSE_Labeled_AE
) O
. O
] O

5 O
0 O
0 O
0 O
Investigations B-NonOSE_AE
Decreased B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
10 O
1 O
4 O
0 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Vomiting B-OSE_Labeled_AE
47 O
1 O
18 O
0 O
Nausea B-OSE_Labeled_AE
55 O
1 O
37 O
1 O
Diarrhea B-OSE_Labeled_AE
60 O
0 O
19 O
1 O
Constipation B-OSE_Labeled_AE
42 O
2 O
23 O
0 O
Dyspepsia B-OSE_Labeled_AE
8 O
0 O
3 O
0 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
[ O
note O
: O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
Laryngitis B-OSE_Labeled_AE
, O
Nasopharyngitis B-OSE_Labeled_AE
, O
Pharyngitis B-OSE_Labeled_AE
, O
Rhinitis B-OSE_Labeled_AE
, O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
) O
. O
] O

26 O
0 O
13 O
1 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
[ O
note O
: O
Pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
( O
Pulmonary B-OSE_Labeled_AE
artery I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
, O
Pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
) O
. O
] O

6 O
5 O
2 O
2 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
Edema B-OSE_Labeled_AE
[ O
note O
: O
Edema B-OSE_Labeled_AE
( O
Face B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
Generalized B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
Local B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
, O
Localized B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
Edema B-OSE_Labeled_AE
, O
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
Periorbital B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
) O
. O
] O

31 O
0 O
16 O
0 O
Additional O
adverse O
reactions O
occurring O
at O
an O
overall O
incidence O
between O
1 O
% O
and O
30 O
% O
in O
patients O
treated O
with O
XALKORI O
included O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
( O
27 O
% O
) O
, O
fatigue B-OSE_Labeled_AE
( O
27 O
% O
) O
, O
neuropathy B-OSE_Labeled_AE
( O
19 O
% O
; O
dysesthesia B-OSE_Labeled_AE
, O
gait B-OSE_Labeled_AE
disturbance I-OSE_Labeled_AE
, O
hypoesthesia B-OSE_Labeled_AE
, O
muscular B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
, O
neuralgia B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
polyneuropathy B-OSE_Labeled_AE
, O
burning B-OSE_Labeled_AE
sensation I-OSE_Labeled_AE
in I-OSE_Labeled_AE
skin I-OSE_Labeled_AE
) O
, O
rash B-OSE_Labeled_AE
( O
9 O
% O
) O
, O
ILD B-OSE_Labeled_AE
( O
4 O
% O
; O
acute B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
distress I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
ILD B-OSE_Labeled_AE
, O
pneumonitis B-OSE_Labeled_AE
) O
, O
renal B-OSE_Labeled_AE
cyst I-OSE_Labeled_AE
( O
4 O
% O
) O
, O
esophagitis B-OSE_Labeled_AE
( O
2 O
% O
) O
, O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
1 O
% O
) O
, O
and O
decreased B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
testosterone I-OSE_Labeled_AE
( O
1 O
% O
; O
hypogonadism B-OSE_Labeled_AE
) O
. O

Table O
6 O
. O

Laboratory O
Abnormalities O
with O
Grade O
3 O
or O
4 O
Incidence O
of O
> O
=4 O
% O
in O
XALKORI-Treated O
Patients O
in O
Study O
2 O
Laboratory O
Abnormality O
XALKORI O
Chemotherapy O
Any O
Grade O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
Any O
Grade O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
Additional O
laboratory B-NonOSE_AE
test I-NonOSE_AE
abnormality I-NonOSE_AE
in O
patients O
treated O
with O
XALKORI O
was O
an O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
( O
Any O
Grade O
: O
96 O
% O
; O
Grade O
3 O
: O
1 O
% O
; O
Grade O
4 O
: O
0 O
% O
) O
compared O
to O
the O
chemotherapy O
arm O
( O
Any O
Grade O
: O
72 O
% O
; O
Grade O
3 O
: O
0 O
% O
; O
Grade O
4 O
: O
0 O
% O
) O
. O

Hematology B-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
49 O
12 O
28 O
12 O
Lymphopenia B-OSE_Labeled_AE
51 O
9 O
60 O
25 O
Chemistry B-NonOSE_AE
ALT B-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
76 O
17 O
38 O
4 O
AST B-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
61 O
9 O
33 O
0 O
Hypokalemia B-OSE_Labeled_AE
18 O
4 O
10 O
1 O
Hypophosphatemia B-OSE_Labeled_AE
28 O
5 O
25 O
6 O
ROS1-Positive O
Metastatic O
NSCLC O
- O
Study O
3 O
The O
safety O
profile O
of O
XALKORI O
from O
Study O
3 O
, O
which O
was O
evaluated O
in O
50 O
patients O
with O
ROS1-positive O
metastatic B-Not_AE_Candidate
NSCLC I-Not_AE_Candidate
, O
was O
generally O
consistent O
with O
the O
safety O
profile O
of O
XALKORI O
evaluated O
in O
patients O
with O
ALK B-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
metastatic B-Not_AE_Candidate
NSCLC I-Not_AE_Candidate
( O
n=1669 O
) O
. O

Vision B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
occurred O
in O
92 O
% O
of O
patients O
in O
Study O
3 O
; O
90 O
% O
were O
Grade O
1 O
and O
2 O
% O
were O
Grade O
2 O
. O

The O
median O
duration O
of O
exposure O
to O
XALKORI O
was O
34.4 O
months O
. O

Description O
of O
Selected O
Adverse O
Drug O
Reactions O
Vision O
disorders O
Vision B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
most O
commonly O
visual B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
photopsia B-OSE_Labeled_AE
, O
blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
or O
vitreous B-OSE_Labeled_AE
floaters I-OSE_Labeled_AE
, O
occurred O
in O
1084 O
( O
63.1 O
% O
) O
of O
1719 O
patients O
. O

The O
majority O
( O
95 O
% O
) O
of O
these O
patients O
had O
Grade O
1 O
visual B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

There O
were O
13 O
( O
0.8 O
% O
) O
patients O
with O
Grade O
3 O
and O
4 O
( O
0.2 O
% O
) O
patients O
with O
Grade O
4 O
visual B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
. O

Based O
on O
the O
Visual O
Symptom O
Assessment O
Questionnaire O
( O
VSAQ-ALK O
) O
, O
patients O
treated O
with O
XALKORI O
in O
Studies O
1 O
and O
2 O
reported O
a O
higher O
incidence O
of O
visual B-OSE_Labeled_AE
disturbances I-OSE_Labeled_AE
compared O
to O
patients O
treated O
with O
chemotherapy O
. O

The O
onset O
of O
vision B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
generally O
was O
within O
the O
first O
week O
of O
drug O
administration O
. O

The O
majority O
of O
patients O
on O
the O
XALKORI O
arms O
in O
Studies O
1 O
and O
2 O
( O
> O
50 O
% O
) O
reported O
visual B-OSE_Labeled_AE
disturbances I-OSE_Labeled_AE
which O
occurred O
at O
a O
frequency O
of O
4-7 O
days O
each O
week O
, O
lasted O
up O
to O
1 O
minute O
, O
and O
had O
mild O
or O
no O
impact O
( O
scores O
0 O
to O
3 O
out O
of O
a O
maximum O
score O
of O
10 O
) O
on O
daily O
activities O
as O
captured O
in O
the O
VSAQ-ALK O
questionnaire O
. O

Neuropathy O
Neuropathy B-OSE_Labeled_AE
, O
most O
commonly O
sensory O
in O
nature O
, O
occurred O
in O
435 O
( O
25 O
% O
) O
of O
1719 O
patients O
. O

Most O
events O
( O
95 O
% O
) O
were O
Grade O
1 O
or O
Grade O
2 O
in O
severity O
. O

Renal O
cysts O
Renal B-OSE_Labeled_AE
cysts I-OSE_Labeled_AE
were O
experienced O
by O
52 O
( O
3 O
% O
) O
of O
1719 O
patients O
. O

The O
majority O
of O
renal B-OSE_Labeled_AE
cysts I-OSE_Labeled_AE
in O
XALKORI-treated O
patients O
were O
complex O
. O

Local B-OSE_Labeled_AE
cystic I-OSE_Labeled_AE
invasion I-OSE_Labeled_AE
beyond I-OSE_Labeled_AE
the I-OSE_Labeled_AE
kidney I-OSE_Labeled_AE
occurred O
, O
in O
some O
cases O
with O
imaging O
characteristics O
suggestive O
of O
abscess B-NonOSE_AE
formation O
. O

However O
, O
across O
clinical O
trials O
no O
renal B-NonOSE_AE
abscesses I-NonOSE_AE
were O
confirmed O
by O
microbiology O
tests O
. O

Renal B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
The O
estimated O
glomerular B-OSE_Labeled_AE
filtration I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
( I-OSE_Labeled_AE
eGFR I-OSE_Labeled_AE
) I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
from O
a O
baseline O
median O
of O
96.42 O
mL/min/1.73 O
m O
2 O
( O
n=1681 O
) O
to O
a O
median O
of O
80.23 O
mL/min/1.73 O
m O
2 O
at O
2 O
weeks O
( O
n=1499 O
) O
in O
patients O
with O
ALK B-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
advanced O
NSCLC B-Not_AE_Candidate
who O
received O
XALKORI O
in O
clinical O
trials O
. O

No O
clinically O
relevant O
changes O
occurred O
in O
median O
eGFR O
from O
12 O
to O
104 O
weeks O
of O
treatment O
. O

Median O
eGFR B-NonOSE_AE
slightly I-NonOSE_AE
increased I-NonOSE_AE
( O
83.02 O
mL/min/1.73 O
m O
2 O
) O
4 O
weeks O
after O
the O
last O
dose O
of O
XALKORI O
. O

Overall O
, O
76 O
% O
of O
patients O
had O
a O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
eGFR I-OSE_Labeled_AE
to O
< O
90 O
mL/min/1.73 O
m O
2 O
, O
38 O
% O
had O
a O
decrease B-OSE_Labeled_AE
to O
eGFR I-OSE_Labeled_AE
to O
< O
60 O
mL/min/1.73 O
m O
2 O
, O
and O
3.6 O
% O
had O
a O
decrease B-OSE_Labeled_AE
to O
eGFR I-OSE_Labeled_AE
to O
< O
30 O
mL/min/1.73 O
m O
2 O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Hepatotoxicity O
: O
Fatal O
hepatotoxicity O
occurred O
in O
0.1 O
% O
of O
patients O
. O

Monitor O
with O
periodic O
liver O
testing O
. O

Temporarily O
suspend O
, O
dose O
reduce O
, O
or O
permanently O
discontinue O
XALKORI O
. O

( O
5.1 O
) O
* O
Interstitial O
Lung O
Disease O
( O
ILD O
) O
/Pneumonitis O
: O
Occurred O
in O
2.9 O
% O
of O
patients O
. O

Permanently O
discontinue O
in O
patients O
with O
ILD/pneumonitis O
. O

( O
5.2 O
) O
* O
QT O
Interval O
Prolongation O
: O
Occurred O
in O
2.1 O
% O
of O
patients O
. O

Monitor O
electrocardiograms O
and O
electrolytes O
in O
patients O
who O
have O
a O
history O
of O
or O
predisposition O
for O
QTc O
prolongation O
, O
or O
who O
are O
taking O
medications O
that O
prolong O
QT O
. O

Temporarily O
suspend O
, O
dose O
reduce O
, O
or O
permanently O
discontinue O
XALKORI O
. O

( O
5.3 O
) O
* O
Bradycardia O
: O
XALKORI O
can O
cause O
bradycardia O
. O

Monitor O
heart O
rate O
and O
blood O
pressure O
regularly O
. O

Temporarily O
suspend O
, O
dose O
reduce O
, O
or O
permanently O
discontinue O
XALKORI O
. O

( O
5.4 O
) O
* O
Severe O
Visual O
Loss O
: O
Reported O
in O
0.2 O
% O
of O
patients O
. O

Discontinue O
XALKORI O
in O
patients O
with O
severe O
visual O
loss O
. O

Perform O
an O
ophthalmological O
evaluation O
. O

( O
5.5 O
) O
* O
Embryo-Fetal O
Toxicity O
: O
Can O
cause O
fetal O
harm O
. O

Advise O
females O
of O
reproductive O
potential O
of O
the O
potential O
risk O
to O
a O
fetus O
and O
use O
of O
effective O
contraception O
. O

( O
5.6 O
, O
8.1 O
, O
8.3 O
) O
5.1 O
Hepatotoxicity B-OSE_Labeled_AE
Drug B-OSE_Labeled_AE
- I-OSE_Labeled_AE
induced I-OSE_Labeled_AE
hepatotoxicity I-OSE_Labeled_AE
with O
fatal B-NonOSE_AE
outcome O
occurred O
in O
2 O
( O
0.1 O
% O
) O
of O
the O
1719 O
patients O
treated O
with O
XALKORI O
across O
clinical O
trials O
. O

Concurrent O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
alanine I-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
) I-OSE_Labeled_AE
or O
aspartate O
aminotransferase O
( O
AST O
) O
greater O
than O
or O
equal O
to O
3 O
times O
the O
upper O
limit O
of O
normal O
( O
ULN O
) O
and O
total B-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
greater I-OSE_Labeled_AE
than I-OSE_Labeled_AE
or I-OSE_Labeled_AE
equal I-OSE_Labeled_AE
to I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
times I-OSE_Labeled_AE
the I-OSE_Labeled_AE
ULN I-OSE_Labeled_AE
, O
with O
normal O
alkaline O
phosphatase O
, O
occurred O
in O
10 O
patients O
( O
< O
1 O
% O
) O
treated O
with O
XALKORI O
. O

Elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
ALT O
or O
AST I-OSE_Labeled_AE
greater O
than O
5 O
times O
the O
ULN O
occurred O
in O
187 O
( O
11.2 O
% O
) O
and O
95 O
( O
5.7 O
% O
) O
patients O
, O
respectively O
. O

Seventeen O
patients O
( O
1.0 O
% O
) O
required O
permanent O
discontinuation O
due O
to O
elevated B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
. O

Transaminase B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
generally O
occurred O
within O
the O
first O
2 O
months O
of O
treatment O
. O

Monitor O
liver O
function O
tests O
, O
including O
ALT O
, O
AST O
, O
and O
total O
bilirubin O
, O
every O
2 O
weeks O
during O
the O
first O
2 O
months O
of O
treatment O
, O
then O
once O
a O
month O
, O
and O
as O
clinically O
indicated O
, O
with O
more O
frequent O
repeat O
testing O
for O
increased B-NonOSE_AE
liver I-NonOSE_AE
transaminases I-NonOSE_AE
, O
alkaline O
phosphatase O
, O
or O
total O
bilirubin O
in O
patients O
who O
develop O
transaminase B-NonOSE_AE
elevations I-NonOSE_AE
. O

Temporarily O
suspend O
, O
dose O
reduce O
, O
or O
permanently O
discontinue O
XALKORI O
as O
described O
in O
Table O
2 O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

5.2 O
Interstitial O
Lung O
Disease O
( O
Pneumonitis O
) O
Severe O
, O
life-threatening O
, O
or O
fatal O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ILD I-OSE_Labeled_AE
) O
/ O
pneumonitis B-OSE_Labeled_AE
can O
occur O
in O
patients O
treated O
with O
XALKORI O
. O

Across O
clinical O
trials O
( O
n=1719 O
) O
, O
50 O
XALKORI-treated O
patients O
( O
2.9 O
% O
) O
had O
ILD B-OSE_Labeled_AE
of O
any O
grade O
, O
18 O
patients O
( O
1.0 O
% O
) O
had O
Grade O
3 O
or O
4 O
ILD B-OSE_Labeled_AE
, O
and O
8 O
patients O
( O
0.5 O
% O
) O
had O
fatal B-NonOSE_AE
ILD B-OSE_Labeled_AE
. O

Interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
generally O
occurred O
within O
3 O
months O
after O
the O
initiation O
of O
XALKORI O
. O

Monitor O
patients O
for O
pulmonary B-NonOSE_AE
symptoms I-NonOSE_AE
indicative O
of O
ILD B-NonOSE_AE
/ O
pneumonitis B-NonOSE_AE
. O

Exclude O
other O
potential O
causes O
of O
ILD B-NonOSE_AE
/ O
pneumonitis B-NonOSE_AE
, O
and O
permanently O
discontinue O
XALKORI O
in O
patients O
diagnosed O
with O
drug B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
ILD I-NonOSE_AE
/ O
pneumonitis B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

5.3 O
QT O
Interval O
Prolongation O
QTc B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
can O
occur O
in O
patients O
treated O
with O
XALKORI O
. O

Across O
clinical O
trials O
, O
34 O
of O
1616 O
patients O
( O
2.1 O
% O
) O
had O
QTcF B-OSE_Labeled_AE
( O
corrected O
QT O
for O
heart O
rate O
by O
the O
Fridericia O
method O
) O
greater I-OSE_Labeled_AE
than I-OSE_Labeled_AE
or I-OSE_Labeled_AE
equal I-OSE_Labeled_AE
to I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
ms I-OSE_Labeled_AE
and O
79 O
of O
1582 O
patients O
( O
5.0 O
% O
) O
had O
an O
increase B-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
QTcF I-OSE_Labeled_AE
greater O
than O
or O
equal O
to O
60 O
ms O
by O
automated O
machine-read O
evaluation O
of O
ECGs O
. O

Avoid O
use O
of O
XALKORI O
in O
patients O
with O
congenital B-Not_AE_Candidate
long I-Not_AE_Candidate
QT I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
. O

Monitor O
ECGs O
and O
electrolytes O
in O
patients O
with O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
bradyarrhythmias B-Not_AE_Candidate
, O
electrolyte B-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
, O
or O
who O
are O
taking O
medications O
that O
are O
known O
to O
prolong B-NonOSE_AE
the I-NonOSE_AE
QT I-NonOSE_AE
interval I-NonOSE_AE
. O

Permanently O
discontinue O
XALKORI O
in O
patients O
who O
develop O
QTc B-NonOSE_AE
greater I-NonOSE_AE
than I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
ms I-NonOSE_AE
or O
greater O
than O
or O
equal O
to O
60 O
ms O
change O
from O
baseline O
with O
Torsade B-NonOSE_AE
de I-NonOSE_AE
pointes I-NonOSE_AE
or O
polymorphic B-NonOSE_AE
ventricular I-NonOSE_AE
tachycardia I-NonOSE_AE
or O
signs/symptoms O
of O
serious B-NonOSE_AE
arrhythmia I-NonOSE_AE
. O

Withhold O
XALKORI O
in O
patients O
who O
develop O
QTc B-NonOSE_AE
greater I-NonOSE_AE
than I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
ms I-NonOSE_AE
on O
at O
least O
2 O
separate O
ECGs O
until O
recovery O
to O
a O
QTc O
less O
than O
or O
equal O
to O
480 O
ms O
, O
then O
resume O
XALKORI O
at O
a O
reduced O
dose O
as O
described O
in O
Table O
2 O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Clinical O
Pharmacology O
( O
12.2 O
) O
] O
. O

5.4 O
Bradycardia O
Symptomatic O
bradycardia B-OSE_Labeled_AE
can O
occur O
in O
patients O
receiving O
XALKORI O
. O

Across O
clinical O
trials O
, O
bradycardia B-OSE_Labeled_AE
occurred O
in O
219 O
( O
12.7 O
% O
) O
of O
1719 O
patients O
treated O
with O
XALKORI O
. O

Grade O
3 O
syncope B-OSE_Labeled_AE
occurred O
in O
2.4 O
% O
of O
XALKORI-treated O
patients O
and O
in O
0.6 O
% O
of O
the O
chemotherapy-treated O
patients O
. O

Avoid O
using O
XALKORI O
in O
combination O
with O
other O
agents O
known O
to O
cause O
bradycardia B-NonOSE_AE
( O
e.g. O
, O
beta-blockers O
, O
non-dihydropyridine O
calcium O
channel O
blockers O
, O
clonidine O
, O
and O
digoxin O
) O
to O
the O
extent O
possible O
. O

Monitor O
heart O
rate O
and O
blood O
pressure O
regularly O
. O

In O
cases O
of O
symptomatic B-NonOSE_AE
bradycardia I-NonOSE_AE
that O
is O
not O
life-threatening O
, O
hold O
XALKORI O
until O
recovery O
to O
asymptomatic O
bradycardia B-NonOSE_AE
or O
to O
a O
heart O
rate O
of O
60 O
bpm O
or O
above O
, O
re-evaluate O
the O
use O
of O
concomitant O
medications O
, O
and O
adjust O
the O
dose O
of O
XALKORI O
. O

Permanently O
discontinue O
for O
life-threatening O
bradycardia B-NonOSE_AE
due O
to O
XALKORI O
; O
however O
, O
if O
associated O
with O
concomitant O
medications O
known O
to O
cause O
bradycardia B-NonOSE_AE
or O
hypotension B-NonOSE_AE
, O
hold O
XALKORI O
until O
recovery O
to O
asymptomatic O
bradycardia B-NonOSE_AE
or O
to O
a O
heart O
rate O
of O
60 O
bpm O
or O
above O
, O
and O
if O
concomitant O
medications O
can O
be O
adjusted O
or O
discontinued O
, O
restart O
XALKORI O
at O
250 O
mg O
once O
daily O
with O
frequent O
monitoring O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

5.5 O
Severe O
Visual O
Loss O
Across O
all O
clinical O
trials O
, O
the O
incidence O
of O
Grade O
4 O
visual B-OSE_Labeled_AE
field I-OSE_Labeled_AE
defect I-OSE_Labeled_AE
with O
vision B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
was O
0.2 O
% O
( O
4/1719 O
) O
. O

Optic B-OSE_Labeled_AE
atrophy I-OSE_Labeled_AE
and O
optic B-OSE_Labeled_AE
nerve I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
have O
been O
reported O
as O
potential O
causes O
of O
vision B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
. O

Discontinue O
XALKORI O
in O
patients O
with O
new O
onset O
of O
severe O
visual B-NonOSE_AE
loss I-NonOSE_AE
( O
best O
corrected O
vision O
less O
than O
20/200 O
in O
one O
or O
both O
eyes O
) O
. O

Perform O
an O
ophthalmological O
evaluation O
consisting O
of O
best O
corrected O
visual O
acuity O
, O
retinal O
photographs O
, O
visual O
fields O
, O
optical O
coherence O
tomography O
( O
OCT O
) O
and O
other O
evaluations O
as O
appropriate O
for O
new O
onset O
of O
severe O
visual B-NonOSE_AE
loss I-NonOSE_AE
. O

There O
is O
insufficient O
information O
to O
characterize O
the O
risks O
of O
resumption O
of O
XALKORI O
in O
patients O
with O
a O
severe O
visual B-NonOSE_AE
loss I-NonOSE_AE
; O
a O
decision O
to O
resume O
XALKORI O
should O
consider O
the O
potential O
benefits O
to O
the O
patient O
. O

5.6 O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Based O
on O
its O
mechanism O
of O
action O
, O
XALKORI O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
. O

In O
animal O
reproduction O
studies O
, O
oral O
administration O
of O
crizotinib O
in O
pregnant B-NonOSE_AE
rats O
during O
organogenesis O
at O
exposures O
similar O
to O
those O
observed O
with O
the O
maximum O
recommended O
human O
dose O
resulted O
in O
embryotoxicity B-NonOSE_AE
and O
fetotoxicity B-NonOSE_AE
. O

Advise O
pregnant B-Not_AE_Candidate
women O
of O
the O
potential O
risk B-OSE_Labeled_AE
to I-OSE_Labeled_AE
a I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

Advise O
females O
of O
reproductive O
potential O
to O
use O
effective O
contraception O
during O
treatment O
with O
XALKORI O
and O
for O
at O
least O
45 O
days O
following O
the O
final O
dose O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
, O
8.3 O
) O
] O
. O

Advise O
male O
patients O
with O
female O
partners O
of O
reproductive O
potential O
to O
use O
condoms O
during O
treatment O
with O
XALKORI O
and O
for O
at O
least O
90 O
days O
after O
the O
final O
dose O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.3 O
) O
and O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
also O
discussed O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Increased O
risk O
of O
stroke B-NonOSE_AE
after O
discontinuation O
in O
nonvalvular B-Not_AE_Candidate
atrial I-Not_AE_Candidate
fibrillation I-Not_AE_Candidate
[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Bleeding B-OSE_Labeled_AE
risk O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
, O
5.4 O
, O
5.5 O
, O
5.6 O
, O
5.7 O
) O
] O
* O
Spinal B-OSE_Labeled_AE
/epidural O
hematoma I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
EXCERPT O
: O
The O
most O
common O
adverse O
reaction O
( O
> O
5 O
% O
) O
was O
bleeding O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Janssen O
Pharmaceuticals O
, O
Inc O
. O
at O
1-800-526-7736 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

During O
clinical O
development O
for O
the O
approved O
indications O
, O
18560 O
patients O
were O
exposed O
to O
XARELTO O
. O

These O
included O
7111 O
patients O
who O
received O
XARELTO O
15 O
mg O
or O
20 O
mg O
orally O
once O
daily O
for O
a O
mean O
of O
19 O
months O
( O
5558 O
for O
12 O
months O
and O
2512 O
for O
24 O
months O
) O
to O
reduce O
the O
risk O
of O
stroke B-Not_AE_Candidate
and O
systemic B-Not_AE_Candidate
embolism I-Not_AE_Candidate
in O
nonvalvular B-Not_AE_Candidate
atrial I-Not_AE_Candidate
fibrillation I-Not_AE_Candidate
( O
ROCKET O
AF O
) O
; O
6962 O
patients O
who O
received O
XARELTO O
15 O
mg O
orally O
twice O
daily O
for O
three O
weeks O
followed O
by O
20 O
mg O
orally O
once O
daily O
to O
treat O
DVT B-Not_AE_Candidate
or O
PE B-Not_AE_Candidate
( O
EINSTEIN O
DVT B-Not_AE_Candidate
, O
EINSTEIN O
PE B-Not_AE_Candidate
) O
, O
10 O
mg O
or O
20 O
mg O
orally O
once O
daily O
( O
EINSTEIN O
Extension O
, O
EINSTEIN O
CHOICE O
) O
to O
reduce O
the O
risk O
of O
recurrence O
of O
DVT B-Not_AE_Candidate
and/or O
PE B-Not_AE_Candidate
; O
and O
4487 O
patients O
who O
received O
XARELTO O
10 O
mg O
orally O
once O
daily O
for O
prophylaxis O
of O
DVT B-Not_AE_Candidate
following O
hip O
or O
knee O
replacement O
surgery O
( O
RECORD O
1-3 O
) O
. O

Hemorrhage B-OSE_Labeled_AE
The O
most O
common O
adverse O
reactions O
with O
XARELTO O
were O
bleeding B-OSE_Labeled_AE
complications I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Nonvalvular B-Not_AE_Candidate
Atrial I-Not_AE_Candidate
Fibrillation I-Not_AE_Candidate
In O
the O
ROCKET O
AF B-Not_AE_Candidate
trial O
, O
the O
most O
frequent O
adverse O
reactions O
associated O
with O
permanent O
drug O
discontinuation O
were O
bleeding B-OSE_Labeled_AE
events O
, O
with O
incidence O
rates O
of O
4.3 O
% O
for O
XARELTO O
vs O
. O
3.1 O
% O
for O
warfarin O
. O

The O
incidence O
of O
discontinuations O
for O
non B-NonOSE_AE
- I-NonOSE_AE
bleeding I-NonOSE_AE
adverse I-NonOSE_AE
events I-NonOSE_AE
was O
similar O
in O
both O
treatment O
groups O
. O

Table O
1 O
shows O
the O
number O
of O
patients O
experiencing O
various O
types O
of O
bleeding B-NonOSE_AE
events O
in O
the O
ROCKET O
AF B-Not_AE_Candidate
trial O
. O

Table O
1 O
: O
Bleeding O
Events O
in O
ROCKET O
AFMajor O
bleeding O
events O
within O
each O
subcategory O
were O
counted O
once O
per O
patient O
, O
but O
patients O
may O
have O
contributed O
events O
to O
multiple O
subcategories O
. O

These O
events O
occurred O
during O
treatment O
or O
within O
2 O
days O
of O
stopping O
treatment.- O
On O
Treatment O
Plus O
2 O
Days O
Parameter O
XARELTON=7111n O
( O
% O
/year O
) O
WarfarinN=7125n O
( O
% O
/year O
) O
XARELTO O
vs O
. O
WarfarinHR O
( O
95 O
% O
CI O
) O
Abbreviations O
: O
HR O
= O
Hazard O
Ratio O
, O
CI O
= O
Confidence O
interval O
, O
CRNM O
= O
Clinically O
Relevant O
Non-Major O
. O

Major O
Bleeding B-OSE_Labeled_AE
[ O
note O
: O
Defined O
as O
clinically O
overt O
bleeding B-OSE_Labeled_AE
associated O
with O
a O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
of O
> O
=2 O
g/dL O
, O
a O
transfusion O
of O
> O
=2 O
units O
of O
packed O
red O
blood O
cells O
or O
whole O
blood O
, O
bleeding B-OSE_Labeled_AE
at O
a O
critical O
site O
, O
or O
with O
a O
fatal O
outcome O
. O
] O

395 O
( O
3.6 O
) O
386 O
( O
3.5 O
) O
1.04 O
( O
0.90 O
, O
1.20 O
) O
Intracranial B-OSE_Labeled_AE
Hemorrhage I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ICH I-OSE_Labeled_AE
) O
[ O
note O
: O
Intracranial B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
events I-OSE_Labeled_AE
included O
intraparenchymal O
, O
intraventricular O
, O
subdural O
, O
subarachnoid B-OSE_Labeled_AE
and/or O
epidural O
hematoma I-OSE_Labeled_AE
. O
] O

55 O
( O
0.5 O
) O
84 O
( O
0.7 O
) O
0.67 O
( O
0.47 O
, O
0.93 O
) O
Hemorrhagic B-OSE_Labeled_AE
Stroke I-OSE_Labeled_AE
[ O
note O
: O
Hemorrhagic B-OSE_Labeled_AE
stroke I-OSE_Labeled_AE
in O
this O
table O
specifically O
refers O
to O
non-traumatic O
intraparenchymal B-OSE_Labeled_AE
and/or O
intraventricular O
hematoma I-OSE_Labeled_AE
in O
patients O
on O
treatment O
plus O
2 O
days O
. O
] O

36 O
( O
0.3 O
) O
58 O
( O
0.5 O
) O
0.63 O
( O
0.42 O
, O
0.96 O
) O
Other O
ICH B-OSE_Labeled_AE
19 O
( O
0.2 O
) O
26 O
( O
0.2 O
) O
0.74 O
( O
0.41 O
, O
1.34 O
) O
Gastrointestinal B-OSE_Labeled_AE
( I-OSE_Labeled_AE
GI I-OSE_Labeled_AE
) O
[ O
note O
: O
Gastrointestinal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
events O
included O
upper B-OSE_Labeled_AE
GI I-OSE_Labeled_AE
, O
lower O
GI O
, O
and O
rectal O
bleeding I-OSE_Labeled_AE
. O
] O

221 O
( O
2.0 O
) O
140 O
( O
1.2 O
) O
1.61 O
( O
1.30 O
, O
1.99 O
) O
Fatal O
Bleeding B-OSE_Labeled_AE
[ O
note O
: O
Fatal O
bleeding B-OSE_Labeled_AE
is O
adjudicated O
death O
with O
the O
primary O
cause O
of O
death O
from O
bleeding B-OSE_Labeled_AE
. O
] O

27 O
( O
0.2 O
) O
55 O
( O
0.5 O
) O
0.50 O
( O
0.31 O
, O
0.79 O
) O
ICH B-OSE_Labeled_AE
24 O
( O
0.2 O
) O
42 O
( O
0.4 O
) O
0.58 O
( O
0.35 O
, O
0.96 O
) O
Non-intracranial O
3 O
( O
0.0 O
) O
13 O
( O
0.1 O
) O
0.23 O
( O
0.07 O
, O
0.82 O
) O
Figure O
1 O
shows O
the O
risk O
of O
major O
bleeding B-NonOSE_AE
events O
across O
major O
subgroups O
. O

Figure O
1 O
: O
Risk O
of O
Major O
Bleeding O
Events O
by O
Baseline O
Characteristics O
in O
ROCKET O
AF O
- O
On O
Treatment O
Plus O
2 O
Days O
Note O
: O
The O
figure O
above O
presents O
effects O
in O
various O
subgroups O
all O
of O
which O
are O
baseline O
characteristics O
and O
all O
of O
which O
were O
pre-specified O
( O
diabetic B-NonOSE_AE
status O
was O
not O
pre-specified O
in O
the O
subgroup O
, O
but O
was O
a O
criterion O
for O
the O
CHADS2 O
score O
) O
. O

The O
95 O
% O
confidence O
limits O
that O
are O
shown O
do O
not O
take O
into O
account O
how O
many O
comparisons O
were O
made O
, O
nor O
do O
they O
reflect O
the O
effect O
of O
a O
particular O
factor O
after O
adjustment O
for O
all O
other O
factors O
. O

Apparent O
homogeneity O
or O
heterogeneity O
among O
groups O
should O
not O
be O
over-interpreted O
. O

Figure O
1 O
Treatment O
of O
Deep O
Vein O
Thrombosis O
( O
DVT O
) O
and/or O
Pulmonary O
Embolism O
( O
PE O
) O
EINSTEIN O
DVT B-Not_AE_Candidate
and O
EINSTEIN O
PE B-Not_AE_Candidate
Studies O
In O
the O
pooled O
analysis O
of O
the O
EINSTEIN O
DVT B-Not_AE_Candidate
and O
EINSTEIN O
PE B-Not_AE_Candidate
clinical O
studies O
, O
the O
most O
frequent O
adverse O
reactions O
leading O
to O
permanent O
drug O
discontinuation O
were O
bleeding B-OSE_Labeled_AE
events O
, O
with O
XARELTO O
vs O
. O
enoxaparin/Vitamin O
K O
antagonist O
( O
VKA O
) O
incidence O
rates O
of O
1.7 O
% O
vs O
. O
1.5 O
% O
, O
respectively O
. O

The O
mean O
duration O
of O
treatment O
was O
208 O
days O
for O
XARELTO-treated O
patients O
and O
204 O
days O
for O
enoxaparin/VKA-treated O
patients O
. O

Table O
2 O
shows O
the O
number O
of O
patients O
experiencing O
major O
bleeding B-NonOSE_AE
events O
in O
the O
pooled O
analysis O
of O
the O
EINSTEIN O
DVT B-Not_AE_Candidate
and O
EINSTEIN O
PE B-Not_AE_Candidate
studies O
. O

Table O
2 O
: O
Bleeding O
EventsBleeding O
event O
occurred O
after O
randomization O
and O
up O
to O
2 O
days O
after O
the O
last O
dose O
of O
study O
drug O
. O

Although O
a O
patient O
may O
have O
had O
2 O
or O
more O
events O
, O
the O
patient O
is O
counted O
only O
once O
in O
a O
category O
. O

in O
the O
Pooled O
Analysis O
of O
EINSTEIN O
DVT B-Not_AE_Candidate
and O
EINSTEIN O
PE B-Not_AE_Candidate
Studies O
Parameter O
XARELTO O
[ O
note O
: O
Treatment O
schedule O
in O
EINSTEIN O
DVT B-Not_AE_Candidate
and O
EINSTEIN O
PE B-Not_AE_Candidate
studies O
: O
XARELTO O
15 O
mg O
twice O
daily O
for O
3 O
weeks O
followed O
by O
20 O
mg O
once O
daily O
; O
enoxaparin/VKA O
[ O
enoxaparin O
: O
1 O
mg/kg O
twice O
daily O
, O
VKA O
: O
individually O
titrated O
doses O
to O
achieve O
a O
target O
INR O
of O
2.5 O
( O
range O
: O
2.0-3.0 O
) O
] O
] O
N=4130n O
( O
% O
) O
Enoxaparin/VKAN=4116n O
( O
% O
) O
Major O
bleeding B-OSE_Labeled_AE
event O
40 O
( O
1.0 O
) O
72 O
( O
1.7 O
) O
Fatal O
bleeding B-OSE_Labeled_AE
3 O
( O
< O
0.1 O
) O
8 O
( O
0.2 O
) O
Intracranial O
2 O
( O
< O
0.1 O
) O
4 O
( O
< O
0.1 O
) O
Non-fatal O
critical O
organ O
bleeding B-OSE_Labeled_AE
10 O
( O
0.2 O
) O
29 O
( O
0.7 O
) O
Intracranial B-OSE_Labeled_AE
[ O
note O
: O
Treatment-emergent O
major O
bleeding I-OSE_Labeled_AE
events O
with O
at O
least O
> O
2 O
subjects O
in O
any O
pooled O
treatment O
group O
] O
3 O
( O
< O
0.1 O
) O
10 O
( O
0.2 O
) O
Retroperitoneal O
1 O
( O
< O
0.1 O
) O
8 O
( O
0.2 O
) O
Intraocular O
3 O
( O
< O
0.1 O
) O
2 O
( O
< O
0.1 O
) O
Intra-articular O
0 O
4 O
( O
< O
0.1 O
) O
Non-fatal O
non-critical O
organ O
bleeding B-OSE_Labeled_AE
[ O
note O
: O
Major O
bleeding B-OSE_Labeled_AE
which O
is O
not O
fatal O
or O
in O
a O
critical O
organ O
, O
but O
resulting O
in O
a O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Hb I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
g I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
and/or O
transfusion O
of O
> O
=2 O
units O
of O
whole O
blood O
or O
packed O
red O
blood O
cells O
] O
27 O
( O
0.7 O
) O
37 O
( O
0.9 O
) O
Decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Hb I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
g I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
28 O
( O
0.7 O
) O
42 O
( O
1.0 O
) O
Transfusion O
of O
> O
=2 O
units O
of O
whole O
blood O
or O
packed O
red O
blood O
cells O
18 O
( O
0.4 O
) O
25 O
( O
0.6 O
) O
Clinically O
relevant O
non-major O
bleeding B-OSE_Labeled_AE
357 O
( O
8.6 O
) O
357 O
( O
8.7 O
) O
Any O
bleeding B-OSE_Labeled_AE
1169 O
( O
28.3 O
) O
1153 O
( O
28.0 O
) O
Reduction O
in O
the O
Risk O
of O
Recurrence O
of O
DVT O
and/or O
PE O
EINSTEIN O
CHOICE O
Study O
In O
the O
EINSTEIN O
CHOICE O
clinical O
study O
, O
the O
most O
frequent O
adverse O
reactions O
associated O
with O
permanent O
drug O
discontinuation O
were O
bleeding B-OSE_Labeled_AE
events O
, O
with O
incidence O
rates O
of O
1 O
% O
for O
XARELTO O
10 O
mg O
, O
2 O
% O
for O
XARELTO O
20 O
mg O
, O
and O
1 O
% O
for O
acetylsalicylic O
acid O
( O
aspirin O
) O
100 O
mg O
. O

The O
mean O
duration O
of O
treatment O
was O
293 O
days O
for O
XARELTO O
10 O
mg-treated O
patients O
and O
286 O
days O
for O
aspirin O
100 O
mg-treated O
patients O
. O

Table O
3 O
shows O
the O
number O
of O
patients O
experiencing O
bleeding B-NonOSE_AE
events O
in O
the O
EINSTEIN O
CHOICE O
study O
. O

Table O
3 O
: O
Bleeding O
EventsBleeding O
event O
occurred O
after O
the O
first O
dose O
and O
up O
to O
2 O
days O
after O
the O
last O
dose O
of O
study O
drug O
. O

Although O
a O
patient O
may O
have O
had O
2 O
or O
more O
events O
, O
the O
patient O
is O
counted O
only O
once O
in O
a O
category O
. O

in O
EINSTEIN O
CHOICE O
Parameter O
XARELTO O
[ O
note O
: O
Treatment O
schedule O
: O
XARELTO O
10 O
mg O
once O
daily O
or O
aspirin O
100 O
mg O
once O
daily O
. O
] O

10 O
mgN=1127n O
( O
% O
) O
Acetylsalicylic O
Acid O
( O
aspirin O
) O
100 O
mgN=1131n O
( O
% O
) O
Major O
bleeding B-OSE_Labeled_AE
event O
5 O
( O
0.4 O
) O
3 O
( O
0.3 O
) O
Fatal O
bleeding B-OSE_Labeled_AE
0 O
1 O
( O
< O
0.1 O
) O
Non-fatal O
critical O
organ O
bleeding B-OSE_Labeled_AE
2 O
( O
0.2 O
) O
1 O
( O
< O
0.1 O
) O
Non-fatal O
non-critical O
organ O
bleeding B-OSE_Labeled_AE
[ O
note O
: O
Major O
bleeding B-OSE_Labeled_AE
which O
is O
not O
fatal O
or O
in O
a O
critical O
organ O
, O
but O
resulting O
in O
a O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Hb I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
g I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
and/or O
transfusion O
of O
> O
= O
2 O
units O
of O
whole O
blood O
or O
packed O
red O
blood O
cells O
. O
] O

3 O
( O
0.3 O
) O
1 O
( O
< O
0.1 O
) O
Clinically O
relevant O
non-major O
( O
CRNM O
) O
bleeding B-OSE_Labeled_AE
[ O
note O
: O
Bleeding B-OSE_Labeled_AE
which O
was O
clinically O
overt O
, O
did O
not O
meet O
the O
criteria O
for O
major O
bleeding B-NonOSE_AE
, O
but O
was O
associated O
with O
medical O
intervention O
, O
unscheduled O
contact O
with O
a O
physician O
, O
temporary O
cessation O
of O
treatment O
, O
discomfort O
for O
the O
patient O
, O
or O
impairment B-NonOSE_AE
of I-NonOSE_AE
activities I-NonOSE_AE
of I-NonOSE_AE
daily I-NonOSE_AE
life I-NonOSE_AE
. O
] O

22 O
( O
2.0 O
) O
20 O
( O
1.8 O
) O
Any O
bleeding B-OSE_Labeled_AE
151 O
( O
13.4 O
) O
138 O
( O
12.2 O
) O
In O
the O
EINSTEIN O
CHOICE O
study O
, O
there O
was O
an O
increased O
incidence O
of O
bleeding B-OSE_Labeled_AE
, O
including O
major O
and O
CRNM O
bleeding B-OSE_Labeled_AE
in O
the O
XARELTO O
20 O
mg O
group O
compared O
to O
the O
XARELTO O
10 O
mg O
or O
aspirin O
100 O
mg O
groups O
. O

Prophylaxis O
of O
Deep O
Vein O
Thrombosis O
Following O
Hip O
or O
Knee O
Replacement O
Surgery O
In O
the O
RECORD O
clinical O
trials O
, O
the O
overall O
incidence O
rate O
of O
adverse O
reactions O
leading O
to O
permanent O
treatment O
discontinuation O
was O
3.7 O
% O
with O
XARELTO O
. O

The O
rates O
of O
major O
bleeding B-NonOSE_AE
events O
and O
any O
bleeding B-NonOSE_AE
events O
observed O
in O
patients O
in O
the O
RECORD O
clinical O
trials O
are O
shown O
in O
Table O
4 O
. O

Table O
4 O
: O
Bleeding O
EventsBleeding O
events O
occurring O
any O
time O
following O
the O
first O
dose O
of O
double-blind O
study O
medication O
( O
which O
may O
have O
been O
prior O
to O
administration O
of O
active O
drug O
) O
until O
two O
days O
after O
the O
last O
dose O
of O
double-blind O
study O
medication O
. O

Patients O
may O
have O
more O
than O
one O
event O
. O

in O
Patients O
Undergoing O
Hip O
or O
Knee O
Replacement O
Surgeries O
( O
RECORD O
1-3 O
) O
XARELTO O
10 O
mg O
Enoxaparin O
[ O
note O
: O
Includes O
the O
placebo-controlled O
period O
for O
RECORD O
2 O
, O
enoxaparin O
dosing O
was O
40 O
mg O
once O
daily O
( O
RECORD O
1-3 O
) O
] O
Total O
treated O
patients O
N=4487n O
( O
% O
) O
N=4524n O
( O
% O
) O
Major O
bleeding B-OSE_Labeled_AE
event O
14 O
( O
0.3 O
) O
9 O
( O
0.2 O
) O
Fatal O
bleeding B-OSE_Labeled_AE
1 O
( O
< O
0.1 O
) O
0 O
Bleeding B-OSE_Labeled_AE
into O
a O
critical O
organ O
2 O
( O
< O
0.1 O
) O
3 O
( O
0.1 O
) O
Bleeding B-OSE_Labeled_AE
that O
required O
re-operation O
7 O
( O
0.2 O
) O
5 O
( O
0.1 O
) O
Extra-surgical O
site O
bleeding B-OSE_Labeled_AE
requiring O
transfusion O
of O
> O
2 O
units O
of O
whole O
blood O
or O
packed O
cells O
4 O
( O
0.1 O
) O
1 O
( O
< O
0.1 O
) O
Any O
bleeding B-OSE_Labeled_AE
event O
[ O
note O
: O
Includes O
major O
bleeding B-OSE_Labeled_AE
events O
] O
261 O
( O
5.8 O
) O
251 O
( O
5.6 O
) O
Hip O
Surgery O
Studies O
N=3281n O
( O
% O
) O
N=3298n O
( O
% O
) O
Major O
bleeding B-OSE_Labeled_AE
event O
7 O
( O
0.2 O
) O
3 O
( O
0.1 O
) O
Fatal O
bleeding B-OSE_Labeled_AE
1 O
( O
< O
0.1 O
) O
0 O
Bleeding B-OSE_Labeled_AE
into O
a O
critical O
organ O
1 O
( O
< O
0.1 O
) O
1 O
( O
< O
0.1 O
) O
Bleeding B-OSE_Labeled_AE
that O
required O
re-operation O
2 O
( O
0.1 O
) O
1 O
( O
< O
0.1 O
) O
Extra-surgical O
site O
bleeding B-OSE_Labeled_AE
requiring O
transfusion O
of O
> O
2 O
units O
of O
whole O
blood O
or O
packed O
cells O
3 O
( O
0.1 O
) O
1 O
( O
< O
0.1 O
) O
Any O
bleeding B-OSE_Labeled_AE
event O
201 O
( O
6.1 O
) O
191 O
( O
5.8 O
) O
Knee O
Surgery O
Study O
N=1206n O
( O
% O
) O
N=1226n O
( O
% O
) O
Major O
bleeding B-OSE_Labeled_AE
event O
7 O
( O
0.6 O
) O
6 O
( O
0.5 O
) O
Fatal O
bleeding B-OSE_Labeled_AE
0 O
0 O
Bleeding B-OSE_Labeled_AE
into O
a O
critical O
organ O
1 O
( O
0.1 O
) O
2 O
( O
0.2 O
) O
Bleeding B-OSE_Labeled_AE
that O
required O
re-operation O
5 O
( O
0.4 O
) O
4 O
( O
0.3 O
) O
Extra-surgical O
site O
bleeding B-OSE_Labeled_AE
requiring O
transfusion O
of O
> O
2 O
units O
of O
whole O
blood O
or O
packed O
cells O
1 O
( O
0.1 O
) O
0 O
Any O
bleeding B-OSE_Labeled_AE
event O
60 O
( O
5.0 O
) O
60 O
( O
4.9 O
) O
Following O
XARELTO O
treatment O
, O
the O
majority O
of O
major O
bleeding B-OSE_Labeled_AE
complications O
( O
> O
=60 O
% O
) O
occurred O
during O
the O
first O
week O
after O
surgery O
. O

Other O
Adverse O
Reactions O
Non B-NonOSE_AE
- I-NonOSE_AE
hemorrhagic I-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
reported O
in O
> O
=1 O
% O
of O
XARELTO-treated O
patients O
in O
the O
EINSTEIN O
DVT B-Not_AE_Candidate
and O
EINSTEIN O
PE B-Not_AE_Candidate
studies O
are O
shown O
in O
Table O
5 O
. O

Table O
5 O
: O
Other O
Adverse O
ReactionsAdverse O
reaction O
with O
Relative O
Risk O
> O
1.5 O
for O
XARELTO O
versus O
comparator O
Reported O
by O
> O
=1 O
% O
of O
XARELTO-Treated O
Patients O
in O
EINSTEIN O
DVT O
and O
EINSTEIN O
PE O
Studies O
Body O
SystemAdverse O
Reaction O
EINSTEIN O
DVT B-Not_AE_Candidate
Study O
XARELTO O
20 O
mgN=1718n O
( O
% O
) O
Enoxaparin/VKAN=1711n O
( O
% O
) O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
46 O
( O
2.7 O
) O
25 O
( O
1.5 O
) O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
24 O
( O
1.4 O
) O
15 O
( O
0.9 O
) O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
50 O
( O
2.9 O
) O
31 O
( O
1.8 O
) O
Muscle B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
23 O
( O
1.3 O
) O
13 O
( O
0.8 O
) O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
38 O
( O
2.2 O
) O
22 O
( O
1.3 O
) O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
Anxiety B-OSE_Labeled_AE
24 O
( O
1.4 O
) O
11 O
( O
0.6 O
) O
Depression B-OSE_Labeled_AE
20 O
( O
1.2 O
) O
10 O
( O
0.6 O
) O
Insomnia B-OSE_Labeled_AE
28 O
( O
1.6 O
) O
18 O
( O
1.1 O
) O
EINSTEIN O
PE B-Not_AE_Candidate
Study O
XARELTO O
20 O
mgN=2412n O
( O
% O
) O
Enoxaparin/VKAN=2405n O
( O
% O
) O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Pruritus B-OSE_Labeled_AE
53 O
( O
2.2 O
) O
27 O
( O
1.1 O
) O
Non B-NonOSE_AE
- I-NonOSE_AE
hemorrhagic I-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
reported O
in O
> O
=1 O
% O
of O
XARELTO-treated O
patients O
in O
RECORD O
1-3 O
studies O
are O
shown O
in O
Table O
6 O
. O

Table O
6 O
: O
Other O
Adverse O
Drug O
ReactionsAdverse O
reaction O
occurring O
any O
time O
following O
the O
first O
dose O
of O
double-blind O
medication O
, O
which O
may O
have O
been O
prior O
to O
administration O
of O
active O
drug O
, O
until O
two O
days O
after O
the O
last O
dose O
of O
double-blind O
study O
medication O
Reported O
by O
> O
=1 O
% O
of O
XARELTO-Treated O
Patients O
in O
RECORD O
1-3 O
Studies O
Body O
SystemAdverse O
Reaction O
XARELTO10 O
mgN=4487n O
( O
% O
) O
Enoxaparin O
[ O
note O
: O
Includes O
the O
placebo-controlled O
period O
of O
RECORD O
2 O
, O
enoxaparin O
dosing O
was O
40 O
mg O
once O
daily O
( O
RECORD O
1-3 O
) O
] O
N=4524n O
( O
% O
) O
Injury B-NonOSE_AE
, I-NonOSE_AE
poisoning I-NonOSE_AE
and I-NonOSE_AE
procedural I-NonOSE_AE
complications I-NonOSE_AE
Wound B-OSE_Labeled_AE
secretion I-OSE_Labeled_AE
125 O
( O
2.8 O
) O
89 O
( O
2.0 O
) O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
74 O
( O
1.7 O
) O
55 O
( O
1.2 O
) O
Muscle B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
52 O
( O
1.2 O
) O
32 O
( O
0.7 O
) O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Syncope B-OSE_Labeled_AE
55 O
( O
1.2 O
) O
32 O
( O
0.7 O
) O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Pruritus B-OSE_Labeled_AE
96 O
( O
2.1 O
) O
79 O
( O
1.8 O
) O
Blister B-OSE_Labeled_AE
63 O
( O
1.4 O
) O
40 O
( O
0.9 O
) O
Other O
clinical O
trial O
experience O
: O
In O
an O
investigational O
study O
of O
acute O
medically O
ill O
patients O
being O
treated O
with O
XARELTO O
10 O
mg O
tablets O
, O
cases O
of O
pulmonary B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
and O
pulmonary B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
with O
bronchiectasis B-OSE_Labeled_AE
were O
observed O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
XARELTO O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
agranulocytosis B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
retroperitoneal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
Hepatobiliary B-NonOSE_AE
disorders I-NonOSE_AE
: O
jaundice B-OSE_Labeled_AE
, O
cholestasis B-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
( O
including O
hepatocellular B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
) O
Immune B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
hypersensitivity B-OSE_Labeled_AE
, O
anaphylactic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
anaphylactic B-OSE_Labeled_AE
shock I-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
cerebral B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
subdural B-OSE_Labeled_AE
hematoma I-OSE_Labeled_AE
, O
epidural B-OSE_Labeled_AE
hematoma I-OSE_Labeled_AE
, O
hemiparesis B-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE

BOXED O
WARNING O
: O
WARNING O
: O
( O
A O
) O
PREMATURE O
DISCONTINUATION O
OF O
XARELTO O
INCREASES O
THE O
RISK O
OF O
THROMBOTIC O
EVENTS O
, O
( O
B O
) O
SPINAL/EPIDURAL O
HEMATOMA O
WARNING O
: O
( O
A O
) O
PREMATURE O
DISCONTINUATION O
OF O
XARELTO O
INCREASES O
THE O
RISK O
OF O
THROMBOTIC O
EVENTS O
, O
( O
B O
) O
SPINAL/EPIDURAL O
HEMATOMA O
EXCERPT O
: O
WARNING O
: O
( O
A O
) O
PREMATURE O
DISCONTINUATION O
OF O
XARELTO O
INCREASES O
THE O
RISK O
OF O
THROMBOTIC O
EVENTS O
, O
( O
B O
) O
SPINAL/EPIDURAL O
HEMATOMA O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
( O
A O
) O
Premature O
discontinuation O
of O
XARELTO O
increases O
the O
risk O
of O
thrombotic O
events O
Premature O
discontinuation O
of O
any O
oral O
anticoagulant O
, O
including O
XARELTO O
, O
increases O
the O
risk O
of O
thrombotic O
events O
. O

To O
reduce O
this O
risk O
, O
consider O
coverage O
with O
another O
anticoagulant O
if O
XARELTO O
is O
discontinued O
for O
a O
reason O
other O
than O
pathological O
bleeding O
or O
completion O
of O
a O
course O
of O
therapy O
( O
2.3 O
, O
2.8 O
, O
5.1 O
, O
14.1 O
) O
. O

( O
B O
) O
Spinal/epidural O
hematoma O
Epidural O
or O
spinal O
hematomas O
have O
occurred O
in O
patients O
treated O
with O
XARELTO O
who O
are O
receiving O
neuraxial O
anesthesia O
or O
undergoing O
spinal O
puncture O
. O

These O
hematomas O
may O
result O
in O
long-term O
or O
permanent O
paralysis O
( O
5.2 O
, O
5.3 O
, O
6.2 O
) O
. O

Monitor O
patients O
frequently O
for O
signs O
and O
symptoms O
of O
neurological O
impairment O
and O
if O
observed O
, O
treat O
urgently O
. O

Consider O
the O
benefits O
and O
risks O
before O
neuraxial O
intervention O
in O
patients O
who O
are O
or O
who O
need O
to O
be O
anticoagulated O
( O
5.3 O
) O
. O

A O
. O

Premature O
discontinuation O
of O
XARELTO O
increases O
the O
risk O
of O
thrombotic B-NonOSE_AE
events I-NonOSE_AE
Premature O
discontinuation O
of O
any O
oral O
anticoagulant O
, O
including O
XARELTO O
, O
increases O
the O
risk O
of O
thrombotic B-NonOSE_AE
events I-NonOSE_AE
. O

If O
anticoagulation O
with O
XARELTO O
is O
discontinued O
for O
a O
reason O
other O
than O
pathological O
bleeding B-NonOSE_AE
or O
completion O
of O
a O
course O
of O
therapy O
, O
consider O
coverage O
with O
another O
anticoagulant O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
, O
2.8 O
) O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
and O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

B O
. O
Spinal/epidural O
hematoma O
Epidural B-OSE_Labeled_AE
or O
spinal O
hematomas I-OSE_Labeled_AE
have O
occurred O
in O
patients O
treated O
with O
XARELTO O
who O
are O
receiving O
neuraxial O
anesthesia O
or O
undergoing O
spinal O
puncture O
. O

These O
hematomas B-NonOSE_AE
may O
result O
in O
long-term O
or O
permanent O
paralysis B-NonOSE_AE
. O

Consider O
these O
risks O
when O
scheduling O
patients O
for O
spinal O
procedures O
. O

Factors O
that O
can O
increase O
the O
risk O
of O
developing O
epidural B-NonOSE_AE
or O
spinal O
hematomas I-NonOSE_AE
in O
these O
patients O
include O
: O
* O
use O
of O
indwelling O
epidural O
catheters O
* O
concomitant O
use O
of O
other O
drugs O
that O
affect O
hemostasis O
, O
such O
as O
non-steroidal O
anti-inflammatory O
drugs O
( O
NSAIDs O
) O
, O
platelet O
inhibitors O
, O
other O
anticoagulants O
* O
a O
history O
of O
traumatic O
or O
repeated O
epidural O
or O
spinal O
punctures O
* O
a O
history O
of O
spinal O
deformity O
or O
spinal O
surgery O
* O
optimal O
timing O
between O
the O
administration O
of O
XARELTO O
and O
neuraxial O
procedures O
is O
not O
known O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
, O
5.3 O
) O
and O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

Monitor O
patients O
frequently O
for O
signs O
and O
symptoms O
of O
neurological B-NonOSE_AE
impairment I-NonOSE_AE
. O

If O
neurological B-NonOSE_AE
compromise I-NonOSE_AE
is O
noted O
, O
urgent O
treatment O
is O
necessary O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

Consider O
the O
benefits O
and O
risks O
before O
neuraxial O
intervention O
in O
patients O
anticoagulated O
or O
to O
be O
anticoagulated O
for O
thromboprophylaxis B-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Risk O
of O
bleeding O
: O
XARELTO O
can O
cause O
serious O
and O
fatal O
bleeding O
. O

Promptly O
evaluate O
signs O
and O
symptoms O
of O
blood O
loss O
. O

( O
5.2 O
) O
* O
Pregnancy-related O
hemorrhage O
: O
Use O
XARELTO O
with O
caution O
in O
pregnant O
women O
due O
to O
the O
potential O
for O
obstetric O
hemorrhage O
and/or O
emergent O
delivery O
. O

Promptly O
evaluate O
signs O
and O
symptoms O
of O
blood O
loss O
. O

( O
5.7 O
) O
* O
Prosthetic O
heart O
valves O
: O
XARELTO O
use O
not O
recommended O
( O
5.8 O
) O
5.1 O
Increased O
Risk O
of O
Thrombotic O
Events O
after O
Premature O
Discontinuation O
Premature O
discontinuation O
of O
any O
oral O
anticoagulant O
, O
including O
XARELTO O
, O
in O
the O
absence O
of O
adequate O
alternative O
anticoagulation O
increases O
the O
risk O
of O
thrombotic B-NonOSE_AE
events I-NonOSE_AE
. O

An O
increased O
rate O
of O
stroke B-NonOSE_AE
was O
observed O
during O
the O
transition O
from O
XARELTO O
to O
warfarin O
in O
clinical O
trials O
in O
atrial B-Not_AE_Candidate
fibrillation I-Not_AE_Candidate
patients O
. O

If O
XARELTO O
is O
discontinued O
for O
a O
reason O
other O
than O
pathological O
bleeding B-NonOSE_AE
or O
completion O
of O
a O
course O
of O
therapy O
, O
consider O
coverage O
with O
another O
anticoagulant O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
, O
2.8 O
) O
and O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

5.2 O
Risk O
of O
Bleeding O
XARELTO O
increases O
the O
risk O
of O
bleeding B-OSE_Labeled_AE
and O
can O
cause O
serious O
or O
fatal B-NonOSE_AE
bleeding B-OSE_Labeled_AE
. O

In O
deciding O
whether O
to O
prescribe O
XARELTO O
to O
patients O
at O
increased O
risk O
of O
bleeding B-NonOSE_AE
, O
the O
risk O
of O
thrombotic B-NonOSE_AE
events I-NonOSE_AE
should O
be O
weighed O
against O
the O
risk O
of O
bleeding B-NonOSE_AE
. O

Promptly O
evaluate O
any O
signs O
or O
symptoms O
of O
blood B-NonOSE_AE
loss I-NonOSE_AE
and O
consider O
the O
need O
for O
blood O
replacement O
. O

Discontinue O
XARELTO O
in O
patients O
with O
active O
pathological O
hemorrhage B-Not_AE_Candidate
. O

The O
terminal O
elimination O
half-life O
of O
rivaroxaban O
is O
5 O
to O
9 O
hours O
in O
healthy O
subjects O
aged O
20 O
to O
45 O
years O
. O

Concomitant O
use O
of O
other O
drugs O
that O
impair B-NonOSE_AE
hemostasis I-NonOSE_AE
increases O
the O
risk O
of O
bleeding B-NonOSE_AE
. O

These O
include O
aspirin O
, O
P2Y12platelet O
inhibitors O
, O
other O
antithrombotic O
agents O
, O
fibrinolytic O
therapy O
, O
non-steroidal O
anti-inflammatory O
drugs O
( O
NSAIDs O
) O
[ O
see O
Drug O
Interactions O
( O
7.4 O
) O
] O
, O
selective O
serotonin O
reuptake O
inhibitors O
, O
and O
serotonin O
norepinephrine O
reuptake O
inhibitors O
. O

Concomitant O
use O
of O
drugs O
that O
are O
known O
combined O
P-gp O
and O
strong O
CYP3A4 O
inhibitors O
increases O
rivaroxaban O
exposure O
and O
may O
increase O
bleeding B-NonOSE_AE
risk O
[ O
see O
Drug O
Interactions O
( O
7.2 O
) O
] O
. O

Reversal O
of O
Anticoagulant O
Effect O
A O
specific O
antidote O
for O
rivaroxaban O
is O
not O
available O
. O

Because O
of O
high O
plasma O
protein O
binding O
, O
rivaroxaban O
is O
not O
expected O
to O
be O
dialyzable O
[ O
see O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

Protamine O
sulfate O
and O
vitamin O
K O
are O
not O
expected O
to O
affect O
the O
anticoagulant O
activity O
of O
rivaroxaban O
. O

Partial O
reversal O
of O
prothrombin O
time O
prolongation O
has O
been O
seen O
after O
administration O
of O
prothrombin O
complex O
concentrates O
( O
PCCs O
) O
in O
healthy O
volunteers O
. O

The O
use O
of O
other O
procoagulant O
reversal O
agents O
like O
activated O
prothrombin O
complex O
concentrate O
( O
APCC O
) O
or O
recombinant O
factor O
VIIa O
( O
rFVIIa O
) O
has O
not O
been O
evaluated O
. O

5.3 O
Spinal/Epidural O
Anesthesia O
or O
Puncture O
When O
neuraxial B-Not_AE_Candidate
anesthesia I-Not_AE_Candidate
( O
spinal B-Not_AE_Candidate
/epidural O
anesthesia I-Not_AE_Candidate
) O
or O
spinal O
puncture O
is O
employed O
, O
patients O
treated O
with O
anticoagulant O
agents O
for O
prevention B-Not_AE_Candidate
of I-Not_AE_Candidate
thromboembolic I-Not_AE_Candidate
complications I-Not_AE_Candidate
are O
at O
risk O
of O
developing O
an O
epidural B-OSE_Labeled_AE
or O
spinal O
hematoma I-OSE_Labeled_AE
which O
can O
result O
in O
long-term O
or O
permanent O
paralysis B-NonOSE_AE
[ O
see O
Boxed O
Warning O
] O
. O

To O
reduce O
the O
potential O
risk O
of O
bleeding B-NonOSE_AE
associated O
with O
the O
concurrent O
use O
of O
XARELTO O
and O
epidural B-NonOSE_AE
or O
spinal O
anesthe O
sia B-NonOSE_AE
/ I-NonOSE_AE
analgesia I-NonOSE_AE
  I-NonOSE_AE
I I-NonOSE_AE
- I-NonOSE_AE
NonOSE_AE O
or O
spinal O
puncture O
, O
consider O
the O
pharmacokinetic O
profile O
of O
XARELTO O
[ O
see O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

Placement O
or O
removal O
of O
an O
epidural O
catheter O
or O
lumbar O
puncture O
is O
best O
performed O
when O
the O
anticoagulant O
effect O
of O
XARELTO O
is O
low O
; O
however O
, O
the O
exact O
timing O
to O
reach O
a O
sufficiently O
low O
anticoagulant O
effect O
in O
each O
patient O
is O
not O
known O
. O

An O
indwelling O
epidural O
or O
intrathecal O
catheter O
should O
not O
be O
removed O
before O
at O
least O
2 O
half-lives O
have O
elapsed O
( O
i.e. O
, O
18 O
hours O
in O
young O
patients O
aged O
20 O
to O
45 O
years O
and O
26 O
hours O
in O
elderly O
patients O
aged O
60 O
to O
76 O
years O
) O
, O
after O
the O
last O
administration O
of O
XARELTO O
[ O
see O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

The O
next O
XARELTO O
dose O
should O
not O
be O
administered O
earlier O
than O
6 O
hours O
after O
the O
removal O
of O
the O
catheter O
. O

If O
traumatic O
puncture O
occurs O
, O
delay O
the O
administration O
of O
XARELTO O
for O
24 O
hours O
. O

Should O
the O
physician O
decide O
to O
administer O
anticoagulation O
in O
the O
context O
of O
epidural B-NonOSE_AE
or O
spinal O
anesthesia I-NonOSE_AE
/analgesia O
or O
lumbar O
puncture O
, O
monitor O
frequently O
to O
detect O
any O
signs O
or O
symptoms O
of O
neurological B-NonOSE_AE
impairment I-NonOSE_AE
, O
such O
as O
midline B-NonOSE_AE
back I-NonOSE_AE
pain I-NonOSE_AE
, O
sensory B-NonOSE_AE
and O
motor O
deficits I-NonOSE_AE
( O
numbness B-NonOSE_AE
, O
tingling B-NonOSE_AE
, O
or O
weakness B-NonOSE_AE
in I-NonOSE_AE
lower I-NonOSE_AE
limbs I-NonOSE_AE
) O
, O
bowel B-NonOSE_AE
and/or O
bladder O
dysfunction I-NonOSE_AE
. O

Instruct O
patients O
to O
immediately O
report O
if O
they O
experience O
any O
of O
the O
above O
signs O
or O
symptoms O
. O

If O
signs O
or O
symptoms O
of O
spinal B-NonOSE_AE
hematoma I-NonOSE_AE
are O
suspected O
, O
initiate O
urgent O
diagnosis O
and O
treatment O
including O
consideration O
for O
spinal B-NonOSE_AE
cord I-NonOSE_AE
decompression I-NonOSE_AE
even O
though O
such O
treatment O
may O
not O
prevent O
or O
reverse O
neurological B-NonOSE_AE
sequelae I-NonOSE_AE
. O

5.4 O
Use O
in O
Patients O
with O
Renal O
Impairment O
Nonvalvular O
Atrial O
Fibrillation O
Periodically O
assess O
renal O
function O
as O
clinically O
indicated O
( O
i.e. O
, O
more O
frequently O
in O
situations O
in O
which O
renal B-NonOSE_AE
function I-NonOSE_AE
may I-NonOSE_AE
decline I-NonOSE_AE
) O
and O
adjust O
therapy O
accordingly O
[ O
see O
Dosage O
and O
Administration O
( O
2.4 O
) O
] O
. O

Consider O
dose O
adjustment O
or O
discontinuation O
of O
XARELTO O
in O
patients O
who O
develop O
acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
while O
on O
XARELTO O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
] O
. O

Treatment O
of O
Deep O
Vein O
Thrombosis O
( O
DVT O
) O
, O
Pulmonary O
Embolism O
( O
PE O
) O
, O
and O
Reduction O
in O
the O
Risk O
of O
Recurrence O
of O
DVT O
and O
of O
PE O
Avoid O
the O
use O
of O
XARELTO O
in O
patients O
with O
CrCl B-Not_AE_Candidate
< I-Not_AE_Candidate
3 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
due O
to O
an O
expected O
increase O
in O
rivaroxaban O
exposure O
and O
pharmacodynamic O
effects O
in O
this O
patient O
population O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
] O
. O

Prophylaxis O
of O
Deep O
Vein O
Thrombosis O
Following O
Hip O
or O
Knee O
Replacement O
Surgery O
Avoid O
the O
use O
of O
XARELTO O
in O
patients O
with O
CrCl B-Not_AE_Candidate
< I-Not_AE_Candidate
3 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
due O
to O
an O
expected O
increase O
in O
rivaroxaban O
exposure O
and O
pharmacodynamic O
effects O
in O
this O
patient O
population O
. O

Observe O
closely O
and O
promptly O
evaluate O
any O
signs O
or O
symptoms O
of O
blood B-NonOSE_AE
loss I-NonOSE_AE
in O
patients O
with O
CrCl B-Not_AE_Candidate
3 I-Not_AE_Candidate
0 I-Not_AE_Candidate
to I-Not_AE_Candidate
5 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
. O

Patients O
who O
develop O
acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
while O
on O
XARELTO O
should O
discontinue O
the O
treatment O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
] O
. O

5.5 O
Use O
in O
Patients O
with O
Hepatic O
Impairment O
No O
clinical O
data O
are O
available O
for O
patients O
with O
severe O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
. O

Avoid O
use O
of O
XARELTO O
in O
patients O
with O
moderate O
( O
Child B-Not_AE_Candidate
- I-Not_AE_Candidate
Pugh I-Not_AE_Candidate
B I-Not_AE_Candidate
) O
and O
severe O
( O
Child B-Not_AE_Candidate
- I-Not_AE_Candidate
Pugh I-Not_AE_Candidate
C I-Not_AE_Candidate
) O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
or O
with O
any O
hepatic B-Not_AE_Candidate
disease I-Not_AE_Candidate
associated I-Not_AE_Candidate
with I-Not_AE_Candidate
coagulopathy I-Not_AE_Candidate
since O
drug O
exposure O
and O
bleeding B-NonOSE_AE
risk O
may O
be O
increased O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.7 O
) O
] O
. O

5.6 O
Use O
with O
P-gp O
and O
Strong O
CYP3A4 O
Inhibitors O
or O
Inducers O
Avoid O
concomitant O
use O
of O
XARELTO O
with O
known O
combined O
P-gp O
and O
strong O
CYP3A4 O
inhibitors O
[ O
see O
Drug O
Interactions O
( O
7.2 O
) O
] O
. O

Avoid O
concomitant O
use O
of O
XARELTO O
with O
drugs O
that O
are O
known O
combined O
P-gp O
and O
strong O
CYP3A4 O
inducers O
[ O
see O
Drug O
Interactions O
( O
7.3 O
) O
] O
. O

5.7 O
Risk O
of O
Pregnancy B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Related I-OSE_Labeled_AE
Hemorrhage I-OSE_Labeled_AE
In O
pregnant B-Not_AE_Candidate
women O
, O
XARELTO O
should O
be O
used O
only O
if O
the O
potential O
benefit O
justifies O
the O
potential O
risk B-NonOSE_AE
to I-NonOSE_AE
the O
mother O
and O
fetus I-NonOSE_AE
. O

XARELTO O
dosing O
in O
pregnancy B-Not_AE_Candidate
has O
not O
been O
studied O
. O

The O
anticoagulant O
effect O
of O
XARELTO O
can O
not O
be O
monitored O
with O
standard O
laboratory O
testing O
nor O
readily O
reversed O
. O

Promptly O
evaluate O
any O
signs O
or O
symptoms O
suggesting O
blood B-NonOSE_AE
loss I-NonOSE_AE
( O
e.g. O
, O
a O
drop B-NonOSE_AE
in I-NonOSE_AE
hemoglobin O
and/or O
hematocrit I-NonOSE_AE
, O
hypotension B-NonOSE_AE
, O
or O
fetal B-NonOSE_AE
distress I-NonOSE_AE
) O
. O

5.8 O
Patients O
with O
Prosthetic O
Heart O
Valves O
The O
safety O
and O
efficacy O
of O
XARELTO O
have O
not O
been O
studied O
in O
patients O
with O
prosthetic O
heart O
valves O
. O

Therefore O
, O
use O
of O
XARELTO O
is O
not O
recommended O
in O
these O
patients O
. O

5.9 O
Acute O
PE O
in O
Hemodynamically O
Unstable O
Patients O
or O
Patients O
Who O
Require O
Thrombolysis O
or O
Pulmonary O
Embolectomy O
Initiation O
of O
XARELTO O
is O
not O
recommended O
acutely O
as O
an O
alternative O
to O
unfractionated O
heparin O
in O
patients O
with O
pulmonary B-Not_AE_Candidate
embolism I-Not_AE_Candidate
who O
present O
with O
hemodynamic B-Not_AE_Candidate
instability I-Not_AE_Candidate
or O
who O
may O
receive O
thrombolysis B-Not_AE_Candidate
or O
pulmonary O
embolectomy O
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
The O
most O
commonly O
reported O
adverse O
reactions O
during O
the O
first O
3 O
months O
in O
controlled O
clinical O
trials O
( O
occurring O
in O
greater O
than O
or O
equal O
to O
2 O
% O
of O
patients O
treated O
with O
XELJANZ O
monotherapy O
or O
in O
combination O
with O
DMARDs O
) O
were O
upper O
respiratory O
tract O
infections O
, O
headache O
, O
diarrhea O
and O
nasopharyngitis O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Pfizer O
, O
Inc O
at O
1-800-438-1985 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trial O
Experience O
Because O
clinical O
studies O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
studies O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
studies O
of O
another O
drug O
and O
may O
not O
predict O
the O
rates O
observed O
in O
a O
broader O
patient O
population O
in O
clinical O
practice O
. O

Although O
other O
doses O
have O
been O
studied O
, O
the O
recommended O
dose O
of O
XELJANZ O
is O
5 O
mg O
twice O
daily O
. O

The O
following O
data O
includes O
two O
Phase O
2 O
and O
five O
Phase O
3 O
double-blind O
, O
controlled O
, O
multicenter O
trials O
. O

In O
these O
trials O
, O
patients O
were O
randomized O
to O
doses O
of O
XELJANZ O
5 O
mg O
twice O
daily O
( O
292 O
patients O
) O
and O
10 O
mg O
twice O
daily O
( O
306 O
patients O
) O
monotherapy O
, O
XELJANZ O
5 O
mg O
twice O
daily O
( O
1044 O
patients O
) O
and O
10 O
mg O
twice O
daily O
( O
1043 O
patients O
) O
in O
combination O
with O
DMARDs O
( O
including O
methotrexate O
) O
and O
placebo O
( O
809 O
patients O
) O
. O

All O
seven O
protocols O
included O
provisions O
for O
patients O
taking O
placebo O
to O
receive O
treatment O
with O
XELJANZ O
at O
Month O
3 O
or O
Month O
6 O
either O
by O
patient O
response O
( O
based O
on O
uncontrolled O
disease O
activity O
) O
or O
by O
design O
, O
so O
that O
adverse O
events O
can O
not O
always O
be O
unambiguously O
attributed O
to O
a O
given O
treatment O
. O

Therefore O
some O
analyses O
that O
follow O
include O
patients O
who O
changed O
treatment O
by O
design O
or O
by O
patient O
response O
from O
placebo O
to O
XELJANZ O
in O
both O
the O
placebo O
and O
XELJANZ O
group O
of O
a O
given O
interval O
. O

Comparisons O
between O
placebo O
and O
XELJANZ O
were O
based O
on O
the O
first O
3 O
months O
of O
exposure O
, O
and O
comparisons O
between O
XELJANZ O
5 O
mg O
twice O
daily O
and O
XELJANZ O
10 O
mg O
twice O
daily O
were O
based O
on O
the O
first O
12 O
months O
of O
exposure O
. O

The O
long-term O
safety O
population O
includes O
all O
patients O
who O
participated O
in O
a O
double-blind O
, O
controlled O
trial O
( O
including O
earlier O
development O
phase O
studies O
) O
and O
then O
participated O
in O
one O
of O
two O
long-term O
safety O
studies O
. O

The O
design O
of O
the O
long-term O
safety O
studies O
allowed O
for O
modification O
of O
XELJANZ O
doses O
according O
to O
clinical O
judgment O
. O

This O
limits O
the O
interpretation O
of O
the O
long-term O
safety O
data O
with O
respect O
to O
dose O
. O

The O
most O
common O
serious O
adverse O
reactions O
were O
serious O
infections B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

The O
proportion O
of O
patients O
who O
discontinued O
treatment O
due O
to O
any O
adverse O
reaction O
during O
the O
0 O
to O
3 O
months O
exposure O
in O
the O
double-blind O
, O
placebo-controlled O
trials O
was O
4 O
% O
for O
patients O
taking O
XELJANZ O
and O
3 O
% O
for O
placebo-treated O
patients O
. O

Overall O
Infections O
In O
the O
seven O
controlled O
trials O
, O
during O
the O
0 O
to O
3 O
months O
exposure O
, O
the O
overall O
frequency O
of O
infections B-OSE_Labeled_AE
was O
20 O
% O
and O
22 O
% O
in O
the O
5 O
mg O
twice O
daily O
and O
10 O
mg O
twice O
daily O
groups O
, O
respectively O
, O
and O
18 O
% O
in O
the O
placebo O
group O
. O

The O
most O
commonly O
reported O
infections B-OSE_Labeled_AE
with O
XELJANZ O
were O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
, O
and O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
( O
4 O
% O
, O
3 O
% O
, O
and O
2 O
% O
of O
patients O
, O
respectively O
) O
. O

Serious O
Infections O
In O
the O
seven O
controlled O
trials O
, O
during O
the O
0 O
to O
3 O
months O
exposure O
, O
serious O
infections B-OSE_Labeled_AE
were O
reported O
in O
1 O
patient O
( O
0.5 O
events O
per O
100 O
patient-years O
) O
who O
received O
placebo O
and O
11 O
patients O
( O
1.7 O
events O
per O
100 O
patient-years O
) O
who O
received O
XELJANZ O
5 O
mg O
or O
10 O
mg O
twice O
daily O
. O

The O
rate O
difference O
between O
treatment O
groups O
( O
and O
the O
corresponding O
95 O
% O
confidence O
interval O
) O
was O
1.1 O
( O
-0.4 O
, O
2.5 O
) O
events O
per O
100 O
patient-years O
for O
the O
combined O
5 O
mg O
twice O
daily O
and O
10 O
mg O
twice O
daily O
XELJANZ O
group O
minus O
placebo O
. O

In O
the O
seven O
controlled O
trials O
, O
during O
the O
0 O
to O
12 O
months O
exposure O
, O
serious O
infections B-OSE_Labeled_AE
were O
reported O
in O
34 O
patients O
( O
2.7 O
events O
per O
100 O
patient-years O
) O
who O
received O
5 O
mg O
twice O
daily O
of O
XELJANZ O
and O
33 O
patients O
( O
2.7 O
events O
per O
100 O
patient-years O
) O
who O
received O
10 O
mg O
twice O
daily O
of O
XELJANZ O
. O

The O
rate O
difference O
between O
XELJANZ O
doses O
( O
and O
the O
corresponding O
95 O
% O
confidence O
interval O
) O
was O
-0.1 O
( O
-1.3 O
, O
1.2 O
) O
events O
per O
100 O
patient-years O
for O
10 O
mg O
twice O
daily O
XELJANZ O
minus O
5 O
mg O
twice O
daily O
XELJANZ O
. O

The O
most O
common O
serious O
infections B-OSE_Labeled_AE
included O
pneumonia B-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
, O
and O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Tuberculosis O
In O
the O
seven O
controlled O
trials O
, O
during O
the O
0 O
to O
3 O
months O
exposure O
, O
tuberculosis B-NonOSE_AE
was O
not O
reported O
in O
patients O
who O
received O
placebo O
, O
5 O
mg O
twice O
daily O
of O
XELJANZ O
, O
or O
10 O
mg O
twice O
daily O
of O
XELJANZ O
. O

In O
the O
seven O
controlled O
trials O
, O
during O
the O
0 O
to O
12 O
months O
exposure O
, O
tuberculosis B-OSE_Labeled_AE
was O
reported O
in O
0 O
patients O
who O
received O
5 O
mg O
twice O
daily O
of O
XELJANZ O
and O
6 O
patients O
( O
0.5 O
events O
per O
100 O
patient-years O
) O
who O
received O
10 O
mg O
twice O
daily O
of O
XELJANZ O
. O

The O
rate O
difference O
between O
XELJANZ O
doses O
( O
and O
the O
corresponding O
95 O
% O
confidence O
interval O
) O
was O
0.5 O
( O
0.1 O
, O
0.9 O
) O
events O
per O
100 O
patient-years O
for O
10 O
mg O
twice O
daily O
XELJANZ O
minus O
5 O
mg O
twice O
daily O
XELJANZ O
. O

Cases O
of O
disseminated B-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
were O
also O
reported O
. O

The O
median O
XELJANZ O
exposure O
prior O
to O
diagnosis O
of O
tuberculosis B-OSE_Labeled_AE
was O
10 O
months O
( O
range O
from O
152 O
to O
960 O
days O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Opportunistic O
Infections O
( O
excluding O
tuberculosis O
) O
In O
the O
seven O
controlled O
trials O
, O
during O
the O
0 O
to O
3 O
months O
exposure O
, O
opportunistic B-NonOSE_AE
infections I-NonOSE_AE
were O
not O
reported O
in O
patients O
who O
received O
placebo O
, O
5 O
mg O
twice O
daily O
of O
XELJANZ O
, O
or O
10 O
mg O
twice O
daily O
of O
XELJANZ O
. O

In O
the O
seven O
controlled O
trials O
, O
during O
the O
0 O
to O
12 O
months O
exposure O
, O
opportunistic B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
were O
reported O
in O
4 O
patients O
( O
0.3 O
events O
per O
100 O
patient-years O
) O
who O
received O
5 O
mg O
twice O
daily O
of O
XELJANZ O
and O
4 O
patients O
( O
0.3 O
events O
per O
100 O
patient-years O
) O
who O
received O
10 O
mg O
twice O
daily O
of O
XELJANZ O
. O

The O
rate O
difference O
between O
XELJANZ O
doses O
( O
and O
the O
corresponding O
95 O
% O
confidence O
interval O
) O
was O
0 O
( O
-0.5 O
, O
0.5 O
) O
events O
per O
100 O
patient-years O
for O
10 O
mg O
twice O
daily O
XELJANZ O
minus O
5 O
mg O
twice O
daily O
XELJANZ O
. O

The O
median O
XELJANZ O
exposure O
prior O
to O
diagnosis O
of O
an O
opportunistic B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
was O
8 O
months O
( O
range O
from O
41 O
to O
698 O
days O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Malignancy O
In O
the O
seven O
controlled O
trials O
, O
during O
the O
0 O
to O
3 O
months O
exposure O
, O
malignancies B-OSE_Labeled_AE
excluding O
NMSC B-NonOSE_AE
were O
reported O
in O
0 O
patients O
who O
received O
placebo O
and O
2 O
patients O
( O
0.3 O
events O
per O
100 O
patient-years O
) O
who O
received O
either O
XELJANZ O
5 O
mg O
or O
10 O
mg O
twice O
daily O
. O

The O
rate O
difference O
between O
treatment O
groups O
( O
and O
the O
corresponding O
95 O
% O
confidence O
interval O
) O
was O
0.3 O
( O
-0.1 O
, O
0.7 O
) O
events O
per O
100 O
patient-years O
for O
the O
combined O
5 O
mg O
and O
10 O
mg O
twice O
daily O
XELJANZ O
group O
minus O
placebo O
. O

In O
the O
seven O
controlled O
trials O
, O
during O
the O
0 O
to O
12 O
months O
exposure O
, O
malignancies B-OSE_Labeled_AE
excluding O
NMSC B-NonOSE_AE
were O
reported O
in O
5 O
patients O
( O
0.4 O
events O
per O
100 O
patient-years O
) O
who O
received O
5 O
mg O
twice O
daily O
of O
XELJANZ O
and O
7 O
patients O
( O
0.6 O
events O
per O
100 O
patient-years O
) O
who O
received O
10 O
mg O
twice O
daily O
of O
XELJANZ O
. O

The O
rate O
difference O
between O
XELJANZ O
doses O
( O
and O
the O
corresponding O
95 O
% O
confidence O
interval O
) O
was O
0.2 O
( O
-0.4 O
, O
0.7 O
) O
events O
per O
100 O
patient-years O
for O
10 O
mg O
twice O
daily O
XELJANZ O
minus O
5 O
mg O
twice O
daily O
XELJANZ O
. O

One O
of O
these O
malignancies B-OSE_Labeled_AE
was O
a O
case O
of O
lymphoma B-OSE_Labeled_AE
that O
occurred O
during O
the O
0 O
to O
12 O
month O
period O
in O
a O
patient O
treated O
with O
XELJANZ O
10 O
mg O
twice O
daily O
. O

The O
most O
common O
types O
of O
malignancy B-OSE_Labeled_AE
, O
including O
malignancies B-OSE_Labeled_AE
observed O
during O
the O
long-term O
extension O
, O
were O
lung B-OSE_Labeled_AE
and O
breast O
cancer I-OSE_Labeled_AE
, O
followed O
by O
gastric B-OSE_Labeled_AE
, O
colorectal O
, O
renal O
cell O
, O
prostate O
cancer I-OSE_Labeled_AE
, O
lymphoma B-OSE_Labeled_AE
, O
and O
malignant B-OSE_Labeled_AE
melanoma I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Laboratory O
Abnormalities O
Lymphopenia B-OSE_Labeled_AE
In O
the O
controlled O
clinical O
trials O
, O
confirmed O
decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
absolute I-OSE_Labeled_AE
lymphocyte I-OSE_Labeled_AE
counts I-OSE_Labeled_AE
below O
500 O
cells/mm O
3 O
occurred O
in O
0.04 O
% O
of O
patients O
for O
the O
5 O
mg O
twice O
daily O
and O
10 O
mg O
twice O
daily O
XELJANZ O
groups O
combined O
during O
the O
first O
3 O
months O
of O
exposure O
. O

Confirmed O
lymphocyte B-OSE_Labeled_AE
counts I-OSE_Labeled_AE
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
cells I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mm I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
were O
associated O
with O
an O
increased O
incidence O
of O
treated O
and O
serious O
infections B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

Neutropenia B-OSE_Labeled_AE
In O
the O
controlled O
clinical O
trials O
, O
confirmed O
decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
ANC I-OSE_Labeled_AE
below O
1000 O
cells/mm O
3 O
occurred O
in O
0.07 O
% O
of O
patients O
for O
the O
5 O
mg O
twice O
daily O
and O
10 O
mg O
twice O
daily O
XELJANZ O
groups O
combined O
during O
the O
first O
3 O
months O
of O
exposure O
. O

There O
were O
no O
confirmed O
decreases B-NonOSE_AE
in I-NonOSE_AE
ANC I-NonOSE_AE
below O
500 O
cells/mm O
3 O
observed O
in O
any O
treatment O
group O
. O

There O
was O
no O
clear O
relationship O
between O
neutropenia B-NonOSE_AE
and O
the O
occurrence O
of O
serious O
infections B-NonOSE_AE
. O

In O
the O
long-term O
safety O
population O
, O
the O
pattern O
and O
incidence O
of O
confirmed O
decreases B-NonOSE_AE
in I-NonOSE_AE
ANC I-NonOSE_AE
remained O
consistent O
with O
what O
was O
seen O
in O
the O
controlled O
clinical O
trials O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

Liver O
Enzyme O
Elevations O
Confirmed O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
enzymes I-OSE_Labeled_AE
greater O
than O
3 O
times O
the O
upper O
limit O
of O
normal O
( O
3* O
ULN O
) O
were O
observed O
in O
patients O
treated O
with O
XELJANZ O
. O

In O
patients O
experiencing O
liver B-OSE_Labeled_AE
enzyme I-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
, O
modification O
of O
treatment O
regimen O
, O
such O
as O
reduction O
in O
the O
dose O
of O
concomitant O
DMARD O
, O
interruption O
of O
XELJANZ O
, O
or O
reduction O
in O
XELJANZ O
dose O
, O
resulted O
in O
decrease B-NonOSE_AE
or O
normalization O
of O
liver I-NonOSE_AE
enzymes I-NonOSE_AE
. O

In O
the O
controlled O
monotherapy O
trials O
( O
0-3 O
months O
) O
, O
no O
differences O
in O
the O
incidence O
of O
ALT B-NonOSE_AE
or O
AST O
elevations I-NonOSE_AE
were O
observed O
between O
the O
placebo O
, O
and O
XELJANZ O
5 O
mg O
, O
and O
10 O
mg O
twice O
daily O
groups O
. O

In O
the O
controlled O
background O
DMARD O
trials O
( O
0-3 O
months O
) O
, O
ALT B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
greater O
than O
3* O
ULN O
were O
observed O
in O
1.0 O
% O
, O
1.3 O
% O
and O
1.2 O
% O
of O
patients O
receiving O
placebo O
, O
5 O
mg O
, O
and O
10 O
mg O
twice O
daily O
, O
respectively O
. O

In O
these O
trials O
, O
AST B-NonOSE_AE
elevations I-NonOSE_AE
greater O
than O
3* O
ULN O
were O
observed O
in O
0.6 O
% O
, O
0.5 O
% O
and O
0.4 O
% O
of O
patients O
receiving O
placebo O
, O
5 O
mg O
, O
and O
10 O
mg O
twice O
daily O
, O
respectively O
. O

One O
case O
of O
drug B-OSE_Labeled_AE
- I-OSE_Labeled_AE
induced I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
injury I-OSE_Labeled_AE
was O
reported O
in O
a O
patient O
treated O
with O
XELJANZ O
10 O
mg O
twice O
daily O
for O
approximately O
2.5 O
months O
. O

The O
patient O
developed O
symptomatic O
elevations B-OSE_Labeled_AE
of O
AST I-OSE_Labeled_AE
and O
ALT O
greater O
than O
3* O
ULN O
and O
bilirubin B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
greater O
than O
2* O
ULN O
, O
which O
required O
hospitalizations O
and O
a O
liver O
biopsy O
. O

Lipid O
Elevations O
In O
the O
controlled O
clinical O
trials O
, O
dose-related O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
lipid I-OSE_Labeled_AE
parameters O
( O
total O
cholesterol O
, O
LDL O
cholesterol O
, O
HDL O
cholesterol O
, O
triglycerides O
) O
were O
observed O
at O
one O
month O
of O
exposure O
and O
remained O
stable O
thereafter O
. O

Changes O
in O
lipid O
parameters O
during O
the O
first O
3 O
months O
of O
exposure O
in O
the O
controlled O
clinical O
trials O
are O
summarized O
below O
: O
* O
Mean O
LDL B-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
by O
15 O
% O
in O
the O
XELJANZ O
5 O
mg O
twice O
daily O
arm O
and O
19 O
% O
in O
the O
XELJANZ O
10 O
mg O
twice O
daily O
arm O
. O

* O
Mean O
HDL B-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
by O
10 O
% O
in O
the O
XELJANZ O
5 O
mg O
twice O
daily O
arm O
and O
12 O
% O
in O
the O
XELJANZ O
10 O
mg O
twice O
daily O
arm O
. O

* O
Mean O
LDL/HDL O
ratios O
were O
essentially O
unchanged O
in O
XELJANZ-treated O
patients O
. O

In O
a O
controlled O
clinical O
trial O
, O
elevations B-NonOSE_AE
in I-NonOSE_AE
LDL I-NonOSE_AE
cholesterol I-NonOSE_AE
and O
ApoB O
decreased O
to O
pretreatment O
levels O
in O
response O
to O
statin O
therapy O
. O

In O
the O
long-term O
safety O
population O
, O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
lipid I-OSE_Labeled_AE
parameters O
remained O
consistent O
with O
what O
was O
seen O
in O
the O
controlled O
clinical O
trials O
. O

Serum O
Creatinine O
Elevations O
In O
the O
controlled O
clinical O
trials O
, O
dose-related O
elevations B-OSE_Labeled_AE
in O
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
were O
observed O
with O
XELJANZ O
treatment O
. O

The O
mean O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
was O
< O
0.1 O
mg/dL O
in O
the O
12-month O
pooled O
safety O
analysis O
; O
however O
with O
increasing O
duration O
of O
exposure O
in O
the O
long-term O
extensions O
, O
up O
to O
2 O
% O
of O
patients O
were O
discontinued O
from O
XELJANZ O
treatment O
due O
to O
the O
protocol-specified O
discontinuation O
criterion O
of O
an O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
by O
more O
than O
50 O
% O
of O
baseline O
. O

The O
clinical O
significance O
of O
the O
observed O
serum B-NonOSE_AE
creatinine I-NonOSE_AE
elevations I-NonOSE_AE
is O
unknown O
. O

Other O
Adverse O
Reactions O
Adverse O
reactions O
occurring O
in O
2 O
% O
or O
more O
of O
patients O
on O
5 O
mg O
twice O
daily O
or O
10 O
mg O
twice O
daily O
XELJANZ O
and O
at O
least O
1 O
% O
greater O
than O
that O
observed O
in O
patients O
on O
placebo O
with O
or O
without O
DMARD O
are O
summarized O
in O
Table O
4 O
. O

Table O
4 O
: O
Adverse O
Reactions O
Occurring O
in O
at O
Least O
2 O
% O
or O
More O
of O
Patients O
on O
5 O
or O
10 O
mg O
Twice O
Daily O
XELJANZ O
With O
or O
Without O
DMARD O
( O
0-3 O
months O
) O
and O
at O
Least O
1 O
% O
Greater O
Than O
That O
Observed O
in O
Patients O
on O
Placebo O
XELJANZ5 O
mg O
Twice O
Daily O
XELJANZ10 O
mg O
Twice O
Daily O
Placebo O
Preferred O
Term O
N O
= O
1336 O
( O
% O
) O
N O
= O
1349 O
( O
% O
) O
N O
= O
809 O
( O
% O
) O
N O
reflects O
randomized O
and O
treated O
patients O
from O
the O
seven O
clinical O
trials O
Diarrhea B-OSE_Labeled_AE
4.0 O
2.9 O
2.3 O
Nasopharyngitis B-OSE_Labeled_AE
3.8 O
2.8 O
2.8 O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
4.5 O
3.8 O
3.3 O
Headache B-OSE_Labeled_AE
4.3 O
3.4 O
2.1 O
Hypertension B-OSE_Labeled_AE
1.6 O
2.3 O
1.1 O
Other O
adverse O
reactions O
occurring O
in O
controlled O
and O
open-label O
extension O
studies O
included O
: O
Blood B-NonOSE_AE
and O
lymphatic O
system O
disorders I-NonOSE_AE
: O
Anemia B-OSE_Labeled_AE
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
: O
Diverticulitis B-OSE_Labeled_AE
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
: O
Dehydration B-OSE_Labeled_AE
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
: O
Insomnia B-OSE_Labeled_AE
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
Paresthesia B-OSE_Labeled_AE
Respiratory B-NonOSE_AE
, O
thoracic O
and O
mediastinal O
disorders I-NonOSE_AE
: O
Dyspnea B-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
sinus B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
gastritis B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
Hepatobiliary B-NonOSE_AE
disorders I-NonOSE_AE
: O
Hepatic B-OSE_Labeled_AE
steatosis I-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
Rash B-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
Musculoskeletal B-NonOSE_AE
, I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
and I-NonOSE_AE
bone I-NonOSE_AE
disorders I-NonOSE_AE
: O
Musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
, O
tendonitis B-OSE_Labeled_AE
, O
joint B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
Neoplasms B-NonOSE_AE
benign I-NonOSE_AE
, I-NonOSE_AE
malignant I-NonOSE_AE
and I-NonOSE_AE
unspecified I-NonOSE_AE
( I-NonOSE_AE
including I-NonOSE_AE
cysts I-NonOSE_AE
and I-NonOSE_AE
polyps I-NonOSE_AE
) O
: O
Non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
melanoma I-OSE_Labeled_AE
skin I-OSE_Labeled_AE
cancers I-OSE_Labeled_AE
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
: O
Pyrexia B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
Clinical O
Experience O
in O
Methotrexate-Naive O
Patients O
Study O
VI O
was O
an O
active-controlled O
clinical O
trial O
in O
methotrexate-naive O
patients O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

The O
safety O
experience O
in O
these O
patients O
was O
consistent O
with O
Studies O
I-V O
. O

BOXED O
WARNING O
: O
WARNING O
: O
SERIOUS O
INFECTIONS O
AND O
MALIGNANCY O
WARNING O
: O
SERIOUS O
INFECTIONS O
AND O
MALIGNANCY O
EXCERPT O
: O
WARNING O
: O
SERIOUS O
INFECTIONS O
AND O
MALIGNANCY O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Serious O
infections O
leading O
to O
hospitalization O
or O
death O
, O
including O
tuberculosis O
and O
bacterial O
, O
invasive O
fungal O
, O
viral O
, O
and O
other O
opportunistic O
infections O
, O
have O
occurred O
in O
patients O
receiving O
XELJANZ O
. O

( O
5.1 O
) O
* O
If O
a O
serious O
infection O
develops O
, O
interrupt O
XELJANZ O
until O
the O
infection O
is O
controlled O
. O

( O
5.1 O
) O
* O
Prior O
to O
starting O
XELJANZ O
, O
perform O
a O
test O
for O
latent O
tuberculosis O
; O
if O
it O
is O
positive O
, O
start O
treatment O
for O
tuberculosis O
prior O
to O
starting O
XELJANZ O
. O

( O
5.1 O
) O
* O
Monitor O
all O
patients O
for O
active O
tuberculosis O
during O
treatment O
, O
even O
if O
the O
initial O
latent O
tuberculosis O
test O
is O
negative O
. O

( O
5.1 O
) O
* O
Lymphoma O
and O
other O
malignancies O
have O
been O
observed O
in O
patients O
treated O
with O
XELJANZ O
. O

Epstein O
Barr O
Virus-associated O
post-transplant O
lymphoproliferative O
disorder O
has O
been O
observed O
at O
an O
increased O
rate O
in O
renal O
transplant O
patients O
treated O
with O
XELJANZ O
and O
concomitant O
immunosuppressive O
medications O
. O

( O
5.2 O
) O
SERIOUS O
INFECTIONS O
Patients O
treated O
with O
XELJANZ O
are O
at O
increased O
risk O
for O
developing O
serious O
infections B-OSE_Labeled_AE
that O
may O
lead O
to O
hospitalization O
or O
death B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Most O
patients O
who O
developed O
these O
infections B-NonOSE_AE
were O
taking O
concomitant O
immunosuppressants B-NonOSE_AE
such O
as O
methotrexate O
or O
corticosteroids O
. O

If O
a O
serious O
infection B-NonOSE_AE
develops O
, O
interrupt O
XELJANZ O
until O
the O
infection B-NonOSE_AE
is O
controlled O
. O

Reported O
infections B-OSE_Labeled_AE
include O
: O
* O
Active B-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
, O
which O
may O
present O
with O
pulmonary B-OSE_Labeled_AE
or O
extrapulmonary O
disease I-OSE_Labeled_AE
. O

Patients O
should O
be O
tested O
for O
latent B-NonOSE_AE
tuberculosis I-NonOSE_AE
before O
XELJANZ O
use O
and O
during O
therapy O
. O

Treatment O
for O
latent B-Not_AE_Candidate
infection I-Not_AE_Candidate
should O
be O
initiated O
prior O
to O
XELJANZ O
use O
. O

* O
Invasive B-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
including O
cryptococcosis B-OSE_Labeled_AE
and O
pneumocystosis B-OSE_Labeled_AE
. O

Patients O
with O
invasive B-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
may O
present O
with O
disseminated O
, O
rather O
than O
localized O
, O
disease O
. O

* O
Bacterial B-OSE_Labeled_AE
, O
viral O
, O
and O
other O
infections I-OSE_Labeled_AE
due O
to O
opportunistic I-OSE_Labeled_AE
pathogens O
. O

The O
risks O
and O
benefits O
of O
treatment O
with O
XELJANZ O
should O
be O
carefully O
considered O
prior O
to O
initiating O
therapy O
in O
patients O
with O
chronic O
or O
recurrent O
infection B-Not_AE_Candidate
. O

Patients O
should O
be O
closely O
monitored O
for O
the O
development O
of O
signs O
and O
symptoms O
of O
infection B-NonOSE_AE
during O
and O
after O
treatment O
with O
XELJANZ O
, O
including O
the O
possible O
development O
of O
tuberculosis B-NonOSE_AE
in O
patients O
who O
tested B-Not_AE_Candidate
negative I-Not_AE_Candidate
for I-Not_AE_Candidate
latent I-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
infection I-Not_AE_Candidate
prior O
to O
initiating O
therapy O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

MALIGNANCIES O
Lymphoma B-OSE_Labeled_AE
and O
other O
malignancies B-OSE_Labeled_AE
have O
been O
observed O
in O
patients O
treated O
with O
XELJANZ O
. O

Epstein B-NonOSE_AE
Barr I-NonOSE_AE
Virus I-NonOSE_AE
- I-NonOSE_AE
associated I-NonOSE_AE
post I-NonOSE_AE
- I-NonOSE_AE
transplant I-NonOSE_AE
lymphoproliferative I-NonOSE_AE
disorder I-NonOSE_AE
has O
been O
observed O
at O
an O
increased O
rate O
in O
renal B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
treated O
with O
XELJANZ O
and O
concomitant O
immunosuppressive O
medications O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Avoid O
use O
of O
XELJANZ O
during O
an O
active O
serious O
infection O
, O
including O
localized O
infections O
. O

( O
5.1 O
) O
* O
Gastrointestinal O
Perforations O
- O
Use O
with O
caution O
in O
patients O
that O
may O
be O
at O
increased O
risk O
. O

( O
5.3 O
) O
* O
Laboratory O
Monitoring O
-Recommended O
due O
to O
potential O
changes O
in O
lymphocytes O
, O
neutrophils O
, O
hemoglobin O
, O
liver O
enzymes O
and O
lipids O
. O

( O
5.4 O
) O
* O
Immunizations O
- O
Live O
vaccines O
: O
Avoid O
use O
with O
XELJANZ O
. O

( O
5.5 O
) O
5.1 O
Serious O
Infections O
Serious O
and O
sometimes O
fatal O
infections B-OSE_Labeled_AE
due O
to O
bacterial I-OSE_Labeled_AE
, O
mycobacterial O
, O
invasive O
fungal O
, O
viral O
, O
or O
other O
opportunistic I-OSE_Labeled_AE
pathogens O
have O
been O
reported O
in O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
patients O
receiving O
XELJANZ O
. O

The O
most O
common O
serious O
infections B-OSE_Labeled_AE
reported O
with O
XELJANZ O
included O
pneumonia B-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
and O
diverticulitis B-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Among O
opportunistic B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
tuberculosis B-OSE_Labeled_AE
and O
other O
mycobacterial B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
cryptococcosis B-OSE_Labeled_AE
, O
esophageal B-OSE_Labeled_AE
candidiasis I-OSE_Labeled_AE
, O
pneumocystosis B-OSE_Labeled_AE
, O
multidermatomal B-OSE_Labeled_AE
herpes I-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
, O
cytomegalovirus B-OSE_Labeled_AE
, O
and O
BK B-OSE_Labeled_AE
virus I-OSE_Labeled_AE
were O
reported O
with O
XELJANZ O
. O

Some O
patients O
have O
presented O
with O
disseminated O
rather O
than O
localized O
disease O
, O
and O
were O
often O
taking O
concomitant O
immunomodulating O
agents O
such O
as O
methotrexate O
or O
corticosteroids O
. O

Other O
serious O
infections B-NonOSE_AE
that O
were O
not O
reported O
in O
clinical O
studies O
may O
also O
occur O
( O
e.g. O
, O
histoplasmosis B-NonOSE_AE
, O
coccidioidomycosis B-NonOSE_AE
, O
and O
listeriosis B-NonOSE_AE
) O
. O

Avoid O
use O
of O
XELJANZ O
in O
patients O
with O
an O
active O
, O
serious O
infection B-Not_AE_Candidate
, O
including O
localized B-Not_AE_Candidate
infections I-Not_AE_Candidate
. O

The O
risks O
and O
benefits O
of O
treatment O
should O
be O
considered O
prior O
to O
initiating O
XELJANZ O
in O
patients O
: O
* O
with O
chronic B-Not_AE_Candidate
or O
recurrent O
infection I-Not_AE_Candidate
* O
who O
have O
been O
exposed B-Not_AE_Candidate
to I-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
* O
with O
a O
history O
of O
a O
serious O
or O
an O
opportunistic B-Not_AE_Candidate
infection I-Not_AE_Candidate
* O
who O
have O
resided O
or O
traveled O
in O
areas O
of O
endemic O
tuberculosis B-Not_AE_Candidate
or O
endemic O
mycoses B-Not_AE_Candidate
; O
or O
* O
with O
underlying O
conditions O
that O
may O
predispose B-Not_AE_Candidate
them O
to I-Not_AE_Candidate
infection I-Not_AE_Candidate
. O

Patients O
should O
be O
closely O
monitored O
for O
the O
development O
of O
signs O
and O
symptoms O
of O
infection B-NonOSE_AE
during O
and O
after O
treatment O
with O
XELJANZ O
. O

XELJANZ O
should O
be O
interrupted O
if O
a O
patient O
develops O
a O
serious O
infection B-NonOSE_AE
, O
an O
opportunistic B-NonOSE_AE
infection I-NonOSE_AE
, O
or O
sepsis B-NonOSE_AE
. O

A O
patient O
who O
develops O
a O
new O
infection B-NonOSE_AE
during O
treatment O
with O
XELJANZ O
should O
undergo O
prompt O
and O
complete O
diagnostic O
testing O
appropriate O
for O
an O
immunocompromised B-Not_AE_Candidate
patient I-Not_AE_Candidate
; O
appropriate O
antimicrobial O
therapy O
should O
be O
initiated O
, O
and O
the O
patient O
should O
be O
closely O
monitored O
. O

Tuberculosis O
Patients O
should O
be O
evaluated O
and O
tested O
for O
latent O
or O
active O
infection B-Not_AE_Candidate
prior O
to O
administration O
of O
XELJANZ O
. O

Anti B-NonOSE_AE
- I-NonOSE_AE
tuberculosis I-NonOSE_AE
therapy I-NonOSE_AE
should O
also O
be O
considered O
prior O
to O
administration O
of O
XELJANZ O
in O
patients O
with O
a O
past O
history O
of O
latent B-Not_AE_Candidate
or O
active O
tuberculosis I-Not_AE_Candidate
in O
whom O
an O
adequate O
course O
of O
treatment O
can O
not O
be O
confirmed O
, O
and O
for O
patients O
with O
a O
negative O
test O
for O
latent B-NonOSE_AE
tuberculosis I-NonOSE_AE
but O
who O
have O
risk O
factors O
for O
tuberculosis B-Not_AE_Candidate
infection I-Not_AE_Candidate
. O

Consultation O
with O
a O
physician O
with O
expertise O
in O
the O
treatment O
of O
tuberculosis B-NonOSE_AE
is O
recommended O
to O
aid O
in O
the O
decision O
about O
whether O
initiating O
anti B-NonOSE_AE
- I-NonOSE_AE
tuberculosis I-NonOSE_AE
therapy I-NonOSE_AE
is O
appropriate O
for O
an O
individual O
patient O
. O

Patients O
should O
be O
closely O
monitored O
for O
the O
development O
of O
signs O
and O
symptoms O
of O
tuberculosis B-NonOSE_AE
, O
including O
patients O
who O
tested O
negative O
for O
latent B-NonOSE_AE
tuberculosis I-NonOSE_AE
infection I-NonOSE_AE
prior O
to O
initiating O
therapy O
. O

Patients O
with O
latent B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
should O
be O
treated O
with O
standard O
antimycobacterial O
therapy O
before O
administering O
XELJANZ O
. O

Viral O
Reactivation O
Viral B-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
, O
including O
cases O
of O
herpes B-OSE_Labeled_AE
virus I-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
( O
e.g. O
, O
herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
) O
, O
were O
observed O
in O
clinical O
studies O
with O
XELJANZ O
. O

The O
impact O
of O
XELJANZ O
on O
chronic O
viral B-NonOSE_AE
hepatitis I-NonOSE_AE
reactivation I-NonOSE_AE
is O
unknown O
. O

Patients O
who O
screened O
positive O
for O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
or O
C O
were O
excluded O
from O
clinical O
trials O
. O

Screening O
for O
viral B-NonOSE_AE
hepatitis I-NonOSE_AE
should O
be O
performed O
in O
accordance O
with O
clinical O
guidelines O
before O
starting O
therapy O
with O
XELJANZ O
. O

The O
risk O
of O
herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
is O
increased O
in O
patients O
treated O
with O
XELJANZ O
and O
appears O
to O
be O
higher O
in O
patients O
treated O
with O
XELJANZ O
in O
Japan O
. O

5.2 O
Malignancy O
and O
Lymphoproliferative O
Disorders O
Consider O
the O
risks O
and O
benefits O
of O
XELJANZ O
treatment O
prior O
to O
initiating O
therapy O
in O
patients O
with O
a O
known O
malignancy B-Not_AE_Candidate
other O
than O
a O
successfully O
treated O
non B-Not_AE_Candidate
- I-Not_AE_Candidate
melanoma I-Not_AE_Candidate
skin I-Not_AE_Candidate
cancer I-Not_AE_Candidate
( I-Not_AE_Candidate
NMSC I-Not_AE_Candidate
) O
or O
when O
considering O
continuing O
XELJANZ O
in O
patients O
who O
develop O
a O
malignancy B-NonOSE_AE
. O

Malignancies B-OSE_Labeled_AE
were O
observed O
in O
clinical O
studies O
of O
XELJANZ O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

In O
the O
seven O
controlled O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
clinical O
studies O
, O
11 O
solid B-OSE_Labeled_AE
cancers I-OSE_Labeled_AE
and O
one O
lymphoma B-OSE_Labeled_AE
were O
diagnosed O
in O
3328 O
patients O
receiving O
XELJANZ O
with O
or O
without O
DMARD O
, O
compared O
to O
0 O
solid B-NonOSE_AE
cancers I-NonOSE_AE
and O
0 O
lymphomas B-NonOSE_AE
in O
809 O
patients O
in O
the O
placebo O
with O
or O
without O
DMARD O
group O
during O
the O
first O
12 O
months O
of O
exposure O
. O

Lymphomas B-OSE_Labeled_AE
and O
solid B-OSE_Labeled_AE
cancers I-OSE_Labeled_AE
have O
also O
been O
observed O
in O
the O
long-term O
extension O
studies O
in O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
patients O
treated O
with O
XELJANZ O
. O

In O
Phase O
2B O
, O
controlled O
dose-ranging O
trials O
in O
de-novo O
renal B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
, O
all O
of O
whom O
received O
induction O
therapy O
with O
basiliximab O
, O
high-dose O
corticosteroids O
, O
and O
mycophenolic O
acid O
products O
, O
Epstein B-NonOSE_AE
Barr I-NonOSE_AE
Virus I-NonOSE_AE
- I-NonOSE_AE
associated I-NonOSE_AE
post-transplant O
lymphoproliferative I-NonOSE_AE
disorder I-NonOSE_AE
was O
observed O
in O
5 O
out O
of O
218 O
patients O
treated O
with O
XELJANZ O
( O
2.3 O
% O
) O
compared O
to O
0 O
out O
of O
111 O
patients O
treated O
with O
cyclosporine O
. O

Non-Melanoma O
Skin O
Cancer O
Non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
melanoma I-OSE_Labeled_AE
skin I-OSE_Labeled_AE
cancers I-OSE_Labeled_AE
( I-OSE_Labeled_AE
NMSCs I-OSE_Labeled_AE
) O
have O
been O
reported O
in O
patients O
treated O
with O
XELJANZ O
. O

Periodic O
skin O
examination O
is O
recommended O
for O
patients O
who O
are O
at O
increased O
risk O
for O
skin B-NonOSE_AE
cancer I-NonOSE_AE
. O

5.3 O
Gastrointestinal O
Perforations O
Events O
of O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
have O
been O
reported O
in O
clinical O
studies O
with O
XELJANZ O
in O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
patients O
, O
although O
the O
role O
of O
JAK B-NonOSE_AE
inhibition I-NonOSE_AE
in O
these O
events O
is O
not O
known O
. O

XELJANZ O
should O
be O
used O
with O
caution O
in O
patients O
who O
may O
be O
at O
increased O
risk O
for O
gastrointestinal B-Not_AE_Candidate
perforation I-Not_AE_Candidate
( O
e.g. O
, O
patients O
with O
a O
history O
of O
diverticulitis B-Not_AE_Candidate
) O
. O

Patients O
presenting O
with O
new O
onset O
abdominal B-NonOSE_AE
symptoms I-NonOSE_AE
should O
be O
evaluated O
promptly O
for O
early O
identification O
of O
gastrointestinal B-NonOSE_AE
perforation I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.4 O
Laboratory O
Abnormalities O
Lymphocyte O
Abnormalities O
Treatment O
with O
XELJANZ O
was O
associated O
with O
initial O
lymphocytosis B-OSE_Labeled_AE
at O
one O
month O
of O
exposure O
followed O
by O
a O
gradual O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
mean I-OSE_Labeled_AE
absolute I-OSE_Labeled_AE
lymphocyte I-OSE_Labeled_AE
counts I-OSE_Labeled_AE
below O
the O
baseline O
of O
approximately O
10 O
% O
during O
12 O
months O
of O
therapy O
. O

Lymphocyte B-OSE_Labeled_AE
counts I-OSE_Labeled_AE
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
cells I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mm I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
were O
associated O
with O
an O
increased O
incidence O
of O
treated O
and O
serious O
infections B-OSE_Labeled_AE
. O

Avoid O
initiation O
of O
XELJANZ O
treatment O
in O
patients O
with O
a O
low B-Not_AE_Candidate
lymphocyte I-Not_AE_Candidate
count I-Not_AE_Candidate
( O
i.e. O
, O
less O
than O
500 O
cells/mm O
3 O
) O
. O

In O
patients O
who O
develop O
a O
confirmed O
absolute B-NonOSE_AE
lymphocyte I-NonOSE_AE
count I-NonOSE_AE
less I-NonOSE_AE
than I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
cells I-NonOSE_AE
/ I-NonOSE_AE
mm I-NonOSE_AE
3 I-NonOSE_AE
treatment O
with O
XELJANZ O
is O
not O
recommended O
. O

Monitor O
lymphocyte O
counts O
at O
baseline O
and O
every O
3 O
months O
thereafter O
. O

For O
recommended O
modifications O
based O
on O
lymphocyte O
counts O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
. O

Neutropenia O
Treatment O
with O
XELJANZ O
was O
associated O
with O
an O
increased O
incidence O
of O
neutropenia B-OSE_Labeled_AE
( O
less O
than O
2000 O
cells/mm O
3 O
) O
compared O
to O
placebo O
. O

Avoid O
initiation O
of O
XELJANZ O
treatment O
in O
patients O
with O
a O
low B-Not_AE_Candidate
neutrophil I-Not_AE_Candidate
count I-Not_AE_Candidate
( O
i.e. O
, O
ANC B-Not_AE_Candidate
less I-Not_AE_Candidate
than I-Not_AE_Candidate
1 I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
cells I-Not_AE_Candidate
/ I-Not_AE_Candidate
mm I-Not_AE_Candidate
3 I-Not_AE_Candidate
) O
. O

For O
patients O
who O
develop O
a O
persistent B-OSE_Labeled_AE
ANC I-OSE_Labeled_AE
of I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
- I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
cells I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mm I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
, O
interrupt O
XELJANZ O
dosing O
until O
ANC O
is O
greater O
than O
or O
equal O
to O
1000 O
cells/mm O
3 O
. O

In O
patients O
who O
develop O
an O
ANC B-NonOSE_AE
less I-NonOSE_AE
than I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
cells I-NonOSE_AE
/ I-NonOSE_AE
mm I-NonOSE_AE
3 O
, O
treatment O
with O
XELJANZ O
is O
not O
recommended O
. O

Monitor O
neutrophil O
counts O
at O
baseline O
and O
after O
4-8 O
weeks O
of O
treatment O
and O
every O
3 O
months O
thereafter O
. O

For O
recommended O
modifications O
based O
on O
ANC O
results O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
. O

Anemia B-OSE_Labeled_AE
Avoid O
initiation O
of O
XELJANZ O
treatment O
in O
patients O
with O
a O
low B-Not_AE_Candidate
hemoglobin I-Not_AE_Candidate
level I-Not_AE_Candidate
( O
i.e O
. O

less O
than O
9 O
g/dL O
) O
. O

Treatment O
with O
XELJANZ O
should O
be O
interrupted O
in O
patients O
who O
develop O
hemoglobin B-OSE_Labeled_AE
levels I-OSE_Labeled_AE
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
8 I-OSE_Labeled_AE
g I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
or O
whose O
hemoglobin B-OSE_Labeled_AE
level I-OSE_Labeled_AE
drops I-OSE_Labeled_AE
greater O
than O
2 O
g/dL O
on O
treatment O
. O

Monitor O
hemoglobin O
at O
baseline O
and O
after O
4-8 O
weeks O
of O
treatment O
and O
every O
3 O
months O
thereafter O
. O

For O
recommended O
modifications O
based O
on O
hemoglobin O
results O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
. O

Liver O
Enzyme O
Elevations O
Treatment O
with O
XELJANZ O
was O
associated O
with O
an O
increased O
incidence O
of O
liver B-OSE_Labeled_AE
enzyme I-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
compared O
to O
placebo O
. O

Most O
of O
these O
abnormalities O
occurred O
in O
studies O
with O
background O
DMARD O
( O
primarily O
methotrexate O
) O
therapy O
. O

Routine O
monitoring O
of O
liver O
tests O
and O
prompt O
investigation O
of O
the O
causes O
of O
liver B-NonOSE_AE
enzyme I-NonOSE_AE
elevations I-NonOSE_AE
is O
recommended O
to O
identify O
potential O
cases O
of O
drug B-NonOSE_AE
- I-NonOSE_AE
induced I-NonOSE_AE
liver I-NonOSE_AE
injury I-NonOSE_AE
. O

If O
drug B-NonOSE_AE
- I-NonOSE_AE
induced I-NonOSE_AE
liver I-NonOSE_AE
injury I-NonOSE_AE
is O
suspected O
, O
the O
administration O
of O
XELJANZ O
should O
be O
interrupted O
until O
this O
diagnosis O
has O
been O
excluded O
. O

Lipid O
Elevations O
Treatment O
with O
XELJANZ O
was O
associated O
with O
increases B-OSE_Labeled_AE
in O
lipid O
parameters O
including O
total O
cholesterol O
, O
low-density O
lipoprotein O
( O
LDL O
) O
cholesterol O
, O
and O
high I-OSE_Labeled_AE
- I-OSE_Labeled_AE
density I-OSE_Labeled_AE
lipoprotein I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HDL I-OSE_Labeled_AE
) I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
. O

Maximum O
effects O
were O
generally O
observed O
within O
6 O
weeks O
. O

The O
effect O
of O
these O
lipid B-NonOSE_AE
parameter I-NonOSE_AE
elevations I-NonOSE_AE
on O
cardiovascular O
morbidity O
and O
mortality B-NonOSE_AE
has O
not O
been O
determined O
. O

Assessment O
of O
lipid O
parameters O
should O
be O
performed O
approximately O
4-8 O
weeks O
following O
initiation O
of O
XELJANZ O
therapy O
. O

Manage O
patients O
according O
to O
clinical O
guidelines O
[ O
e.g. O
, O
National O
Cholesterol O
Educational O
Program O
( O
NCEP O
) O
] O
for O
the O
management O
of O
hyperlipidemia B-NonOSE_AE
. O

5.5 O
Vaccinations O
No O
data O
are O
available O
on O
the O
response O
to O
vaccination O
or O
on O
the O
secondary B-NonOSE_AE
transmission I-NonOSE_AE
of I-NonOSE_AE
infection I-NonOSE_AE
by I-NonOSE_AE
live I-NonOSE_AE
vaccines I-NonOSE_AE
to O
patients O
receiving O
XELJANZ O
. O

Avoid O
use O
of O
live O
vaccines O
concurrently O
with O
XELJANZ O
. O

Update O
immunizations O
in O
agreement O
with O
current O
immunization O
guidelines O
prior O
to O
initiating O
XELJANZ O
therapy O
. O

6 O
ADVERSE O
REACTIONS O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
> O
=30 O
% O
) O
were O
diarrhea O
, O
hand-and-foot O
syndrome O
, O
nausea O
, O
vomiting O
, O
abdominal O
pain O
, O
fatigue/weakness O
, O
and O
hyperbilirubinemia O
. O

Other O
adverse O
reactions O
, O
including O
serious O
adverse O
reactions O
, O
have O
been O
reported O
. O

( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Genentech O
at O
1-888-835-2555 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Adjuvant O
Colon O
Cancer O
Table O
4 O
shows O
the O
adverse O
reactions O
occurring O
in O
> O
=5 O
% O
of O
patients O
from O
one O
phase O
3 O
trial O
in O
patients O
with O
Dukes B-Not_AE_Candidate
' I-Not_AE_Candidate
C I-Not_AE_Candidate
colon I-Not_AE_Candidate
cancer I-Not_AE_Candidate
who O
received O
at O
least O
one O
dose O
of O
study O
medication O
and O
had O
at O
least O
one O
safety O
assessment O
. O

A O
total O
of O
995 O
patients O
were O
treated O
with O
1250 O
mg/m O
2 O
twice O
a O
day O
of O
XELODA O
administered O
for O
2 O
weeks O
followed O
by O
a O
1-week O
rest O
period O
, O
and O
974 O
patients O
were O
administered O
5-FU O
and O
leucovorin O
( O
20 O
mg/m O
2 O
leucovorin O
IV O
followed O
by O
425 O
mg/m O
2 O
IV O
bolus O
5-FU O
on O
days O
1-5 O
every O
28 O
days O
) O
. O

The O
median O
duration O
of O
treatment O
was O
164 O
days O
for O
capecitabine-treated O
patients O
and O
145 O
days O
for O
5-FU/LV-treated O
patients O
. O

A O
total O
of O
112 O
( O
11 O
% O
) O
and O
73 O
( O
7 O
% O
) O
capecitabine O
and O
5-FU/LV-treated O
patients O
, O
respectively O
, O
discontinued O
treatment O
because O
of O
adverse O
reactions O
. O

A O
total O
of O
18 O
deaths B-NonOSE_AE
due O
to O
all O
causes O
occurred O
either O
on O
study O
or O
within O
28 O
days O
of O
receiving O
study O
drug O
: O
8 O
( O
0.8 O
% O
) O
patients O
randomized O
to O
XELODA O
and O
10 O
( O
1.0 O
% O
) O
randomized O
to O
5-FU/LV O
. O

Table O
5 O
shows O
grade O
3/4 O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
occurring O
in O
> O
=1 O
% O
of O
patients O
from O
one O
phase O
3 O
trial O
in O
patients O
with O
Dukes B-Not_AE_Candidate
' I-Not_AE_Candidate
C I-Not_AE_Candidate
colon I-Not_AE_Candidate
cancer I-Not_AE_Candidate
who O
received O
at O
least O
one O
dose O
of O
study O
medication O
and O
had O
at O
least O
one O
safety O
assessment O
. O

Table O
4 O
Percent O
Incidence O
of O
Adverse O
Reactions O
Reported O
in O
> O
=5 O
% O
of O
Patients O
Treated O
With O
XELODA O
or O
5-FU/LV O
for O
Colon O
Cancer O
in O
the O
Adjuvant O
Setting O
( O
Safety O
Population O
) O
Adjuvant O
Treatment O
for O
Colon O
Cancer O
( O
N=1969 O
) O
XELODA O
( O
N=995 O
) O
5-FU/LV O
( O
N=974 O
) O
Body O
System/Adverse O
Event O
All O
Grades O
Grade O
3/4 O
All O
Grades O
Grade O
3/4 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
47 O
12 O
65 O
14 O
Nausea B-OSE_Labeled_AE
34 O
2 O
47 O
2 O
Stomatitis B-OSE_Labeled_AE
22 O
2 O
60 O
14 O
Vomiting B-OSE_Labeled_AE
15 O
2 O
21 O
2 O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
14 O
3 O
16 O
2 O
Constipation B-OSE_Labeled_AE
9 O
- O
11 O
< O
1 O
Upper B-OSE_Labeled_AE
Abdominal I-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
7 O
< O
1 O
7 O
< O
1 O
Dyspepsia B-OSE_Labeled_AE
6 O
< O
1 O
5 O
- O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
and I-OSE_Labeled_AE
- I-OSE_Labeled_AE
Foot I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
60 O
17 O
9 O
< O
1 O
Alopecia B-OSE_Labeled_AE
6 O
- O
22 O
< O
1 O
Rash B-OSE_Labeled_AE
7 O
- O
8 O
- O
Erythema B-OSE_Labeled_AE
6 O
1 O
5 O
< O
1 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
16 O
< O
1 O
16 O
1 O
Pyrexia B-OSE_Labeled_AE
7 O
< O
1 O
9 O
< O
1 O
Asthenia B-OSE_Labeled_AE
10 O
< O
1 O
10 O
1 O
Lethargy B-OSE_Labeled_AE
10 O
< O
1 O
9 O
< O
1 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
6 O
< O
1 O
6 O
- O
Headache B-OSE_Labeled_AE
5 O
< O
1 O
6 O
< O
1 O
Dysgeusia B-OSE_Labeled_AE
6 O
- O
9 O
- O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Anorexia B-OSE_Labeled_AE
9 O
< O
1 O
11 O
< O
1 O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Conjunctivitis B-OSE_Labeled_AE
5 O
< O
1 O
6 O
< O
1 O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
2 O
< O
1 O
8 O
5 O
Respiratory B-NonOSE_AE
Thoracic I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Epistaxis B-OSE_Labeled_AE
2 O
- O
5 O
- O
Table O
5 O
Percent O
Incidence O
of O
Grade O
3/4 O
Laboratory O
Abnormalities O
Reported O
in O
> O
=1 O
% O
of O
Patients O
Receiving O
XELODA O
Monotherapy O
for O
Adjuvant O
Treatment O
of O
Colon O
Cancer O
( O
Safety O
Population O
) O
Adverse O
Event O
XELODA O
( O
n=995 O
) O
Grade O
3/4 O
% O
IV O
5-FU/LV O
( O
n=974 O
) O
Grade O
3/4 O
% O
Increased B-OSE_Labeled_AE
ALAT I-OSE_Labeled_AE
( I-OSE_Labeled_AE
SGPT I-OSE_Labeled_AE
) O
1.6 O
0.6 O
Increased B-OSE_Labeled_AE
calcium I-OSE_Labeled_AE
1.1 O
0.7 O
Decreased B-OSE_Labeled_AE
calcium I-OSE_Labeled_AE
2.3 O
2.2 O
Decreased B-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
1.0 O
1.2 O
Decreased B-OSE_Labeled_AE
lymphocytes I-OSE_Labeled_AE
13.0 O
13.0 O
Decreased B-OSE_Labeled_AE
neutrophils I-OSE_Labeled_AE
[ O
note O
: O
The O
incidence O
of O
grade O
3/4 O
white B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
was O
1.3 O
% O
in O
the O
XELODA O
arm O
and O
4.9 O
% O
in O
the O
IV O
5-FU/LV O
arm O
. O
] O

2.2 O
26.2 O
Decreased B-OSE_Labeled_AE
neutrophils I-OSE_Labeled_AE
/granulocytes O
2.4 O
26.4 O
Decreased B-OSE_Labeled_AE
platelets I-OSE_Labeled_AE
1.0 O
0.7 O
Increased B-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
[ O
note O
: O
It O
should O
be O
noted O
that O
grading O
was O
according O
to O
NCIC O
CTC O
Version O
1 O
( O
May O
, O
1994 O
) O
. O

In O
the O
NCIC-CTC O
Version O
1 O
, O
hyperbilirubinemia B-NonOSE_AE
grade O
3 O
indicates O
a O
bilirubin B-NonOSE_AE
value I-NonOSE_AE
of I-NonOSE_AE
1 I-NonOSE_AE
. I-NonOSE_AE
5 I-NonOSE_AE
to I-NonOSE_AE
3 I-NonOSE_AE
. I-NonOSE_AE
0 I-NonOSE_AE
* I-NonOSE_AE
upper I-NonOSE_AE
limit I-NonOSE_AE
of I-NonOSE_AE
normal I-NonOSE_AE
( I-NonOSE_AE
ULN I-NonOSE_AE
) I-NonOSE_AE
range I-NonOSE_AE
, O
and O
grade O
4 O
a O
value O
of O
> O
3.0 O
* O
ULN O
. O

The O
NCI O
CTC O
Version O
2 O
and O
above O
define O
a O
grade O
3 O
bilirubin B-NonOSE_AE
value I-NonOSE_AE
of I-NonOSE_AE
> I-NonOSE_AE
3 I-NonOSE_AE
. I-NonOSE_AE
0 I-NonOSE_AE
to I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
. I-NonOSE_AE
0 I-NonOSE_AE
* I-NonOSE_AE
ULN I-NonOSE_AE
, O
and O
grade O
4 O
values O
> O
10.0 O
* O
ULN O
. O
] O

20 O
6.3 O
6.2 O
Metastatic O
Colorectal O
Cancer O
Monotherapy O
Table O
6 O
shows O
the O
adverse O
reactions O
occurring O
in O
> O
=5 O
% O
of O
patients O
from O
pooling O
the O
two O
phase O
3 O
trials O
in O
first O
line O
metastatic B-Not_AE_Candidate
colorectal I-Not_AE_Candidate
cancer I-Not_AE_Candidate
. O

A O
total O
of O
596 O
patients O
with O
metastatic B-Not_AE_Candidate
colorectal I-Not_AE_Candidate
cancer I-Not_AE_Candidate
were O
treated O
with O
1250 O
mg/m O
2 O
twice O
a O
day O
of O
XELODA O
administered O
for O
2 O
weeks O
followed O
by O
a O
1-week O
rest O
period O
, O
and O
593 O
patients O
were O
administered O
5-FU O
and O
leucovorin O
in O
the O
Mayo O
regimen O
( O
20 O
mg/m O
2 O
leucovorin O
IV O
followed O
by O
425 O
mg/m O
2 O
IV O
bolus O
5-FU O
, O
on O
days O
1-5 O
, O
every O
28 O
days O
) O
. O

In O
the O
pooled O
colorectal O
database O
the O
median O
duration O
of O
treatment O
was O
139 O
days O
for O
capecitabine-treated O
patients O
and O
140 O
days O
for O
5-FU/LV-treated O
patients O
. O

A O
total O
of O
78 O
( O
13 O
% O
) O
and O
63 O
( O
11 O
% O
) O
capecitabine O
and O
5-FU/LV-treated O
patients O
, O
respectively O
, O
discontinued O
treatment O
because O
of O
adverse O
reactions/intercurrent O
illness O
. O

A O
total O
of O
82 O
deaths B-NonOSE_AE
due O
to O
all O
causes O
occurred O
either O
on O
study O
or O
within O
28 O
days O
of O
receiving O
study O
drug O
: O
50 O
( O
8.4 O
% O
) O
patients O
randomized O
to O
XELODA O
and O
32 O
( O
5.4 O
% O
) O
randomized O
to O
5-FU/LV O
. O

Table O
6 O
Pooled O
Phase O
3 O
Colorectal O
Trials O
: O
Percent O
Incidence O
of O
Adverse O
Reactions O
in O
> O
=5 O
% O
of O
Patients O
Adverse O
Event O
XELODA O
( O
n=596 O
) O
5-FU/LV O
( O
n=593 O
) O
Total O
% O
Grade O
3 O
% O
Grade O
4 O
% O
Total O
% O
Grade O
3 O
% O
Grade O
4 O
% O
- O
Not O
observed O
NA O
= O
Not O
Applicable O
Number O
of O
Patients O
With O
> O
One O
Adverse O
Event O
96 O
52 O
9 O
94 O
45 O
9 O
Body O
System/Adverse O
Event O
GI B-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
55 O
13 O
2 O
61 O
10 O
2 O
Nausea B-OSE_Labeled_AE
43 O
4 O
- O
51 O
3 O
< O
1 O
Vomiting B-OSE_Labeled_AE
27 O
4 O
< O
1 O
30 O
4 O
< O
1 O
Stomatitis B-OSE_Labeled_AE
25 O
2 O
< O
1 O
62 O
14 O
1 O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
35 O
9 O
< O
1 O
31 O
5 O
- O
Gastrointestinal B-OSE_Labeled_AE
Motility I-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
10 O
< O
1 O
- O
7 O
< O
1 O
- O
Constipation B-OSE_Labeled_AE
14 O
1 O
< O
1 O
17 O
1 O
- O
Oral B-OSE_Labeled_AE
Discomfort I-OSE_Labeled_AE
10 O
- O
- O
10 O
- O
- O
Upper B-OSE_Labeled_AE
GI I-OSE_Labeled_AE
Inflammatory I-OSE_Labeled_AE
Disorders I-OSE_Labeled_AE
8 O
< O
1 O
- O
10 O
1 O
- O
Gastrointestinal B-OSE_Labeled_AE
Hemorrhage I-OSE_Labeled_AE
6 O
1 O
< O
1 O
3 O
1 O
- O
Ileus B-OSE_Labeled_AE
6 O
4 O
1 O
5 O
2 O
1 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
and I-OSE_Labeled_AE
- I-OSE_Labeled_AE
Foot I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
54 O
17 O
NA O
6 O
1 O
NA O
Dermatitis B-OSE_Labeled_AE
27 O
1 O
- O
26 O
1 O
- O
Skin B-OSE_Labeled_AE
Discoloration I-OSE_Labeled_AE
7 O
< O
1 O
- O
5 O
- O
- O
Alopecia B-OSE_Labeled_AE
6 O
- O
- O
21 O
< O
1 O
- O
General B-NonOSE_AE
Fatigue B-OSE_Labeled_AE
/ O
Weakness B-OSE_Labeled_AE
42 O
4 O
- O
46 O
4 O
- O
Pyrexia B-OSE_Labeled_AE
18 O
1 O
- O
21 O
2 O
- O
Edema B-OSE_Labeled_AE
15 O
1 O
- O
9 O
1 O
- O
Pain B-OSE_Labeled_AE
12 O
1 O
- O
10 O
1 O
- O
Chest B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
6 O
1 O
- O
6 O
1 O
< O
1 O
Neurological B-NonOSE_AE
Peripheral B-OSE_Labeled_AE
Sensory I-OSE_Labeled_AE
Neuropathy I-OSE_Labeled_AE
10 O
- O
- O
4 O
- O
- O
Headache B-OSE_Labeled_AE
10 O
1 O
- O
7 O
- O
- O
Dizziness B-OSE_Labeled_AE
[ O
note O
: O
Excluding O
vertigo B-NonOSE_AE
] O
8 O
< O
1 O
- O
8 O
< O
1 O
- O
Insomnia B-OSE_Labeled_AE
7 O
- O
- O
7 O
- O
- O
Taste B-OSE_Labeled_AE
Disturbance I-OSE_Labeled_AE
6 O
1 O
- O
11 O
< O
1 O
1 O
Metabolism B-NonOSE_AE
Appetite B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
26 O
3 O
< O
1 O
31 O
2 O
< O
1 O
Dehydration B-OSE_Labeled_AE
7 O
2 O
< O
1 O
8 O
3 O
1 O
Eye B-NonOSE_AE
Eye B-OSE_Labeled_AE
Irritation I-OSE_Labeled_AE
13 O
- O
- O
10 O
< O
1 O
- O
Vision B-OSE_Labeled_AE
Abnormal I-OSE_Labeled_AE
5 O
- O
- O
2 O
- O
- O
Respiratory B-NonOSE_AE
Dyspnea B-OSE_Labeled_AE
14 O
1 O
- O
10 O
< O
1 O
1 O
Cough B-OSE_Labeled_AE
7 O
< O
1 O
1 O
8 O
- O
- O
Pharyngeal B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
5 O
- O
- O
5 O
- O
- O
Epistaxis B-OSE_Labeled_AE
3 O
< O
1 O
- O
6 O
- O
- O
Sore B-OSE_Labeled_AE
Throat I-OSE_Labeled_AE
2 O
- O
- O
6 O
- O
- O
Musculoskeletal B-NonOSE_AE
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
10 O
2 O
- O
9 O
< O
1 O
- O
Arthralgia B-OSE_Labeled_AE
8 O
1 O
- O
6 O
1 O
- O
Vascular B-NonOSE_AE
Venous B-OSE_Labeled_AE
Thrombosis I-OSE_Labeled_AE
8 O
3 O
< O
1 O
6 O
2 O
- O
Psychiatric B-NonOSE_AE
Mood B-OSE_Labeled_AE
Alteration I-OSE_Labeled_AE
5 O
- O
- O
6 O
< O
1 O
- O
Depression B-OSE_Labeled_AE
5 O
- O
- O
4 O
< O
1 O
- O
Infections B-NonOSE_AE
Viral O
5 O
< O
1 O
- O
5 O
< O
1 O
- O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
Anemia B-OSE_Labeled_AE
80 O
2 O
< O
1 O
79 O
1 O
< O
1 O
Neutropenia B-OSE_Labeled_AE
13 O
1 O
2 O
46 O
8 O
13 O
Hepatobiliary B-NonOSE_AE
Hyperbilirubinemia B-OSE_Labeled_AE
48 O
18 O
5 O
17 O
3 O
3 O
6.3 O
Breast O
Cancer O
In O
Combination O
with O
Docetaxel O
The O
following O
data O
are O
shown O
for O
the O
combination O
study O
with O
XELODA O
and O
docetaxel O
in O
patients O
with O
metastatic B-Not_AE_Candidate
breast I-Not_AE_Candidate
cancer I-Not_AE_Candidate
in O
Table O
7 O
and O
Table O
8 O
. O

In O
the O
XELODA O
and O
docetaxel O
combination O
arm O
the O
treatment O
was O
XELODA O
administered O
orally O
1250 O
mg/m O
2 O
twice O
daily O
as O
intermittent O
therapy O
( O
2 O
weeks O
of O
treatment O
followed O
by O
1 O
week O
without O
treatment O
) O
for O
at O
least O
6 O
weeks O
and O
docetaxel O
administered O
as O
a O
1-hour O
intravenous O
infusion O
at O
a O
dose O
of O
75 O
mg/m O
2 O
on O
the O
first O
day O
of O
each O
3-week O
cycle O
for O
at O
least O
6 O
weeks O
. O

In O
the O
monotherapy O
arm O
docetaxel O
was O
administered O
as O
a O
1-hour O
intravenous O
infusion O
at O
a O
dose O
of O
100 O
mg/m O
2 O
on O
the O
first O
day O
of O
each O
3-week O
cycle O
for O
at O
least O
6 O
weeks O
. O

The O
mean O
duration O
of O
treatment O
was O
129 O
days O
in O
the O
combination O
arm O
and O
98 O
days O
in O
the O
monotherapy O
arm O
. O

A O
total O
of O
66 O
patients O
( O
26 O
% O
) O
in O
the O
combination O
arm O
and O
49 O
( O
19 O
% O
) O
in O
the O
monotherapy O
arm O
withdrew O
from O
the O
study O
because O
of O
adverse O
reactions O
. O

The O
percentage O
of O
patients O
requiring O
dose O
reductions O
due O
to O
adverse O
reactions O
was O
65 O
% O
in O
the O
combination O
arm O
and O
36 O
% O
in O
the O
monotherapy O
arm O
. O

The O
percentage O
of O
patients O
requiring O
treatment O
interruptions O
due O
to O
adverse O
reactions O
in O
the O
combination O
arm O
was O
79 O
% O
. O

Treatment O
interruptions O
were O
part O
of O
the O
dose O
modification O
scheme O
for O
the O
combination O
therapy O
arm O
but O
not O
for O
the O
docetaxel O
monotherapy-treated O
patients O
. O

Table O
7 O
Percent O
Incidence O
of O
Adverse O
Events O
Considered O
Related O
or O
Unrelated O
to O
Treatment O
in O
> O
=5 O
% O
of O
Patients O
Participating O
in O
the O
XELODA O
and O
Docetaxel O
Combination O
vs O
Docetaxel O
Monotherapy O
Study O
Adverse O
Event O
XELODA O
1250 O
mg/m O
2 O
/bid O
With O
Docetaxel75 O
mg/m O
2 O
/3 O
weeks O
Docetaxel100 O
mg/m O
2 O
/3 O
weeks O
( O
n=251 O
) O
( O
n=255 O
) O
Total O
% O
Grade O
3 O
% O
Grade O
4 O
% O
Total O
% O
Grade O
3 O
% O
Grade O
4 O
% O
- O
Not O
observed O
NA O
= O
Not O
Applicable O
Number O
of O
Patients O
With O
at O
Least O
One O
Adverse O
Event O
99 O
76.5 O
29.1 O
97 O
57.6 O
31.8 O
Body O
System/Adverse O
Event O
GI B-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
67 O
14 O
< O
1 O
48 O
5 O
< O
1 O
Stomatitis B-OSE_Labeled_AE
67 O
17 O
< O
1 O
43 O
5 O
- O
Nausea B-OSE_Labeled_AE
45 O
7 O
- O
36 O
2 O
- O
Vomiting B-OSE_Labeled_AE
35 O
4 O
1 O
24 O
2 O
- O
Constipation B-OSE_Labeled_AE
20 O
2 O
- O
18 O
- O
- O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
30 O
< O
3 O
< O
1 O
24 O
2 O
- O
Dyspepsia B-OSE_Labeled_AE
14 O
- O
- O
8 O
1 O
- O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
6 O
< O
1 O
- O
5 O
- O
- O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
and I-OSE_Labeled_AE
- I-OSE_Labeled_AE
Foot I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
63 O
24 O
NA O
8 O
1 O
NA O
Alopecia B-OSE_Labeled_AE
41 O
6 O
- O
42 O
7 O
- O
Nail B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
14 O
2 O
- O
15 O
- O
- O
Dermatitis B-OSE_Labeled_AE
8 O
- O
- O
11 O
1 O
- O
Rash B-OSE_Labeled_AE
Erythematous I-OSE_Labeled_AE
9 O
< O
1 O
- O
5 O
- O
- O
Nail B-OSE_Labeled_AE
Discoloration I-OSE_Labeled_AE
6 O
- O
- O
4 O
< O
1 O
- O
Onycholysis B-OSE_Labeled_AE
5 O
1 O
- O
5 O
1 O
- O
Pruritus B-OSE_Labeled_AE
4 O
- O
- O
5 O
- O
- O
General B-NonOSE_AE
Pyrexia B-OSE_Labeled_AE
28 O
2 O
- O
34 O
2 O
- O
Asthenia B-OSE_Labeled_AE
26 O
4 O
< O
1 O
25 O
6 O
- O
Fatigue B-OSE_Labeled_AE
22 O
4 O
- O
27 O
6 O
- O
Weakness B-OSE_Labeled_AE
16 O
2 O
- O
11 O
2 O
- O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Limb I-OSE_Labeled_AE
13 O
< O
1 O
- O
13 O
2 O
- O
Lethargy B-OSE_Labeled_AE
7 O
- O
- O
6 O
2 O
- O
Pain B-OSE_Labeled_AE
7 O
< O
1 O
- O
5 O
1 O
- O
Chest B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
( I-OSE_Labeled_AE
non I-OSE_Labeled_AE
- I-OSE_Labeled_AE
cardiac I-OSE_Labeled_AE
) O
4 O
< O
1 O
- O
6 O
2 O
- O
Influenza B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
Illness I-OSE_Labeled_AE
5 O
- O
- O
5 O
- O
- O
Neurological B-NonOSE_AE
Taste B-OSE_Labeled_AE
Disturbance I-OSE_Labeled_AE
16 O
< O
1 O
- O
14 O
< O
1 O
- O
Headache B-OSE_Labeled_AE
15 O
3 O
- O
15 O
2 O
- O
Paresthesia B-OSE_Labeled_AE
12 O
< O
1 O
- O
16 O
1 O
- O
Dizziness B-OSE_Labeled_AE
12 O
- O
- O
8 O
< O
1 O
- O
Insomnia B-OSE_Labeled_AE
8 O
- O
- O
10 O
< O
1 O
- O
Peripheral B-OSE_Labeled_AE
Neuropathy I-OSE_Labeled_AE
6 O
- O
- O
10 O
1 O
- O
Hypoaesthesia B-OSE_Labeled_AE
4 O
< O
1 O
- O
8 O
< O
1 O
- O
Metabolism B-NonOSE_AE
Anorexia B-OSE_Labeled_AE
13 O
1 O
- O
11 O
< O
1 O
- O
Appetite B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
10 O
- O
- O
5 O
- O
- O
Weight B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
7 O
- O
- O
5 O
- O
- O
Dehydration B-OSE_Labeled_AE
10 O
2 O
- O
7 O
< O
1 O
< O
1 O
Eye B-NonOSE_AE
Lacrimation B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
12 O
- O
- O
7 O
< O
1 O
- O
Conjunctivitis B-OSE_Labeled_AE
5 O
- O
- O
4 O
- O
- O
Eye B-OSE_Labeled_AE
Irritation I-OSE_Labeled_AE
5 O
- O
- O
1 O
- O
- O
Musculoskeletal B-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
15 O
2 O
- O
24 O
3 O
- O
Myalgia B-OSE_Labeled_AE
15 O
2 O
- O
25 O
2 O
- O
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
12 O
< O
1 O
- O
11 O
3 O
- O
Bone B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
8 O
< O
1 O
- O
10 O
2 O
- O
Cardiac B-NonOSE_AE
Edema B-OSE_Labeled_AE
33 O
< O
2 O
- O
34 O
< O
3 O
1 O
Blood B-NonOSE_AE
Neutropenic B-OSE_Labeled_AE
Fever I-OSE_Labeled_AE
16 O
3 O
13 O
21 O
5 O
16 O
Respiratory B-NonOSE_AE
Dyspnea B-OSE_Labeled_AE
14 O
2 O
< O
1 O
16 O
2 O
- O
Cough B-OSE_Labeled_AE
13 O
1 O
- O
22 O
< O
1 O
- O
Sore B-OSE_Labeled_AE
Throat I-OSE_Labeled_AE
12 O
2 O
- O
11 O
< O
1 O
- O
Epistaxis B-OSE_Labeled_AE
7 O
< O
1 O
- O
6 O
- O
- O
Rhinorrhea B-OSE_Labeled_AE
5 O
- O
- O
3 O
- O
- O
Pleural B-OSE_Labeled_AE
Effusion I-OSE_Labeled_AE
2 O
1 O
- O
7 O
4 O
- O
Infection B-NonOSE_AE
Oral B-OSE_Labeled_AE
Candidiasis I-OSE_Labeled_AE
7 O
< O
1 O
- O
8 O
< O
1 O
- O
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
6 O
< O
1 O
- O
4 O
- O
- O
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
4 O
- O
- O
5 O
1 O
- O
Vascular B-NonOSE_AE
Flushing B-OSE_Labeled_AE
5 O
- O
- O
5 O
- O
- O
Lymphoedema B-OSE_Labeled_AE
3 O
< O
1 O
- O
5 O
1 O
- O
Psychiatric B-NonOSE_AE
Depression B-OSE_Labeled_AE
5 O
- O
- O
5 O
1 O
- O
Table O
8 O
Percent O
of O
Patients O
With O
Laboratory O
Abnormalities O
Participating O
in O
the O
XELODA O
and O
Docetaxel O
Combination O
vs O
Docetaxel O
Monotherapy O
Study O
Adverse O
Event O
XELODA O
1250 O
mg/m O
2 O
/bid O
With O
Docetaxel75 O
mg/m O
2 O
/3 O
weeks O
Docetaxel100 O
mg/m O
2 O
/3 O
weeks O
( O
n=251 O
) O
( O
n=255 O
) O
Body O
System/Adverse O
Event O
Total O
% O
Grade O
3 O
% O
Grade O
4 O
% O
Total O
% O
Grade O
3 O
% O
Grade O
4 O
% O
Hematologic B-NonOSE_AE
Leukopenia B-OSE_Labeled_AE
91 O
37 O
24 O
88 O
42 O
33 O
Neutropenia B-OSE_Labeled_AE
/ O
Granulocytopenia B-OSE_Labeled_AE
86 O
20 O
49 O
87 O
10 O
66 O
Thrombocytopenia B-OSE_Labeled_AE
41 O
2 O
1 O
23 O
1 O
2 O
Anemia B-OSE_Labeled_AE
80 O
7 O
3 O
83 O
5 O
< O
1 O
Lymphocytopenia B-OSE_Labeled_AE
99 O
48 O
41 O
98 O
44 O
40 O
Hepatobiliary B-NonOSE_AE
Hyperbilirubinemia B-OSE_Labeled_AE
20 O
7 O
2 O
6 O
2 O
2 O
Monotherapy O
The O
following O
data O
are O
shown O
for O
the O
study O
in O
stage B-Not_AE_Candidate
IV I-Not_AE_Candidate
breast I-Not_AE_Candidate
cancer I-Not_AE_Candidate
patients O
who O
received O
a O
dose O
of O
1250 O
mg/m O
2 O
administered O
twice O
daily O
for O
2 O
weeks O
followed O
by O
a O
1-week O
rest O
period O
. O

The O
mean O
duration O
of O
treatment O
was O
114 O
days O
. O

A O
total O
of O
13 O
out O
of O
162 O
patients O
( O
8 O
% O
) O
discontinued O
treatment O
because O
of O
adverse O
reactions/intercurrent O
illness B-Not_AE_Candidate
. O

Table O
9 O
Percent O
Incidence O
of O
Adverse O
Reactions O
Considered O
Remotely O
, O
Possibly O
or O
Probably O
Related O
to O
Treatment O
in O
> O
=5 O
% O
of O
Patients O
Participating O
in O
the O
Single O
Arm O
Trial O
in O
Stage O
IV O
Breast O
Cancer O
Adverse O
Event O
Phase O
2 O
Trial O
in O
Stage O
IV O
Breast O
Cancer O
( O
n=162 O
) O
Body O
System/Adverse O
Event O
Total O
% O
Grade O
3 O
% O
Grade O
4 O
% O
- O
Not O
observed O
NA O
= O
Not O
Applicable O
GI B-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
57 O
12 O
3 O
Nausea B-OSE_Labeled_AE
53 O
4 O
- O
Vomiting B-OSE_Labeled_AE
37 O
4 O
- O
Stomatitis B-OSE_Labeled_AE
24 O
7 O
- O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
20 O
4 O
- O
Constipation B-OSE_Labeled_AE
15 O
1 O
- O
Dyspepsia B-OSE_Labeled_AE
8 O
- O
- O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
and I-OSE_Labeled_AE
- I-OSE_Labeled_AE
Foot I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
57 O
11 O
NA O
Dermatitis B-OSE_Labeled_AE
37 O
1 O
- O
Nail B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
7 O
- O
- O
General B-NonOSE_AE
Fatigue B-OSE_Labeled_AE
41 O
8 O
- O
Pyrexia B-OSE_Labeled_AE
12 O
1 O
- O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Limb I-OSE_Labeled_AE
6 O
1 O
- O
Neurological B-NonOSE_AE
Paresthesia B-OSE_Labeled_AE
21 O
1 O
- O
Headache B-OSE_Labeled_AE
9 O
1 O
- O
Dizziness B-OSE_Labeled_AE
8 O
- O
- O
Insomnia B-OSE_Labeled_AE
8 O
- O
- O
Metabolism B-NonOSE_AE
Anorexia B-OSE_Labeled_AE
23 O
3 O
- O
Dehydration B-OSE_Labeled_AE
7 O
4 O
1 O
Eye B-NonOSE_AE
Eye B-OSE_Labeled_AE
Irritation I-OSE_Labeled_AE
15 O
- O
- O
Musculoskeletal B-NonOSE_AE
Myalgia B-OSE_Labeled_AE
9 O
- O
- O
Cardiac B-NonOSE_AE
Edema B-OSE_Labeled_AE
9 O
1 O
- O
Blood B-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
26 O
2 O
2 O
Thrombocytopenia B-OSE_Labeled_AE
24 O
3 O
1 O
Anemia B-OSE_Labeled_AE
72 O
3 O
1 O
Lymphopenia B-OSE_Labeled_AE
94 O
44 O
15 O
Hepatobiliary B-NonOSE_AE
Hyperbilirubinemia B-OSE_Labeled_AE
22 O
9 O
2 O
6.4 O
Clinically O
Relevant O
Adverse O
Events O
in O
< O
5 O
% O
of O
Patients O
Clinically O
relevant O
adverse O
events O
reported O
in O
< O
5 O
% O
of O
patients O
treated O
with O
XELODA O
either O
as O
monotherapy O
or O
in O
combination O
with O
docetaxel O
that O
were O
considered O
at O
least O
remotely O
related O
to O
treatment O
are O
shown O
below O
; O
occurrences O
of O
each O
grade O
3 O
and O
4 O
adverse O
event O
are O
provided O
in O
parentheses O
. O

Monotherapy O
( O
Metastatic O
Colorectal O
Cancer O
, O
Adjuvant O
Colorectal O
Cancer O
, O
Metastatic O
Breast O
Cancer O
) O
Gastrointestinal B-NonOSE_AE
: O
abdominal B-OSE_Labeled_AE
distension I-OSE_Labeled_AE
, O
dysphagia B-OSE_Labeled_AE
, O
proctalgia B-OSE_Labeled_AE
, O
ascites B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
gastric B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
ileus B-OSE_Labeled_AE
( O
0.3 O
% O
) O
, O
toxic B-OSE_Labeled_AE
dilation I-OSE_Labeled_AE
of I-OSE_Labeled_AE
intestine I-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
( O
0.1 O
% O
) O
Skin B-NonOSE_AE
& I-NonOSE_AE
Subcutan I-NonOSE_AE
. O

: O
nail B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
sweating B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
photosensitivity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
skin B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
radiation B-OSE_Labeled_AE
recall I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( O
0.2 O
% O
) O
General B-NonOSE_AE
: O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
0.2 O
% O
) O
, O
influenza B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
illness I-OSE_Labeled_AE
, O
hot B-OSE_Labeled_AE
flushes I-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
hoarseness B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
difficulty B-OSE_Labeled_AE
in I-OSE_Labeled_AE
walking I-OSE_Labeled_AE
, O
thirst B-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
mass I-OSE_Labeled_AE
, O
collapse B-OSE_Labeled_AE
, O
fibrosis B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
hemorrhage B-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
sedation B-OSE_Labeled_AE
Neurological B-NonOSE_AE
: O
insomnia B-OSE_Labeled_AE
, O
ataxia B-OSE_Labeled_AE
( O
0.5 O
% O
) O
, O
tremor B-OSE_Labeled_AE
, O
dysphasia B-OSE_Labeled_AE
, O
encephalopathy B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
abnormal B-OSE_Labeled_AE
coordination I-OSE_Labeled_AE
, O
dysarthria B-OSE_Labeled_AE
, O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
( O
0.2 O
% O
) O
, O
impaired B-OSE_Labeled_AE
balance I-OSE_Labeled_AE
Metabolism B-NonOSE_AE
: O
increased B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
, O
cachexia B-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
hypertriglyceridemia B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
hypokalemia B-OSE_Labeled_AE
, O
hypomagnesemia B-OSE_Labeled_AE
Eye B-NonOSE_AE
: O
conjunctivitis B-OSE_Labeled_AE
Respiratory B-NonOSE_AE
: O
cough B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
epistaxis B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
asthma B-OSE_Labeled_AE
( O
0.2 O
% O
) O
, O
hemoptysis B-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
distress I-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
dyspnea B-OSE_Labeled_AE
Cardiac B-NonOSE_AE
: O
tachycardia B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
bradycardia B-OSE_Labeled_AE
, O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
extrasystoles I-OSE_Labeled_AE
, O
extrasystoles B-OSE_Labeled_AE
, O
myocarditis B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
pericardial B-OSE_Labeled_AE
effusion I-OSE_Labeled_AE
Infections B-NonOSE_AE
: O
laryngitis B-OSE_Labeled_AE
( O
1.0 O
% O
) O
, O
bronchitis B-OSE_Labeled_AE
( O
0.2 O
% O
) O
, O
pneumonia B-OSE_Labeled_AE
( O
0.2 O
% O
) O
, O
bronchopneumonia B-OSE_Labeled_AE
( O
0.2 O
% O
) O
, O
keratoconjunctivitis B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
( O
0.3 O
% O
) O
, O
fungal B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
( O
including O
candidiasis B-OSE_Labeled_AE
) O
( O
0.2 O
% O
) O
Musculoskeletal B-NonOSE_AE
: O
myalgia B-OSE_Labeled_AE
, O
bone B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
arthritis B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
muscle B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
Blood B-NonOSE_AE
& I-NonOSE_AE
Lymphatic I-NonOSE_AE
: O
leukopenia B-OSE_Labeled_AE
( O
0.2 O
% O
) O
, O
coagulation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
bone B-OSE_Labeled_AE
marrow I-OSE_Labeled_AE
depression I-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
idiopathic B-OSE_Labeled_AE
thrombocytopenia I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
( O
1.0 O
% O
) O
, O
pancytopenia B-OSE_Labeled_AE
( O
0.1 O
% O
) O
Vascular B-NonOSE_AE
: O
hypotension B-OSE_Labeled_AE
( O
0.2 O
% O
) O
, O
hypertension B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
lymphoedema B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
( O
0.2 O
% O
) O
, O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
( O
0.1 O
% O
) O
Psychiatric B-NonOSE_AE
: O
depression B-OSE_Labeled_AE
, O
confusion B-OSE_Labeled_AE
( O
0.1 O
% O
) O
Renal B-NonOSE_AE
: O
renal B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
( O
0.6 O
% O
) O
Ear B-NonOSE_AE
: O
vertigo B-OSE_Labeled_AE
Hepatobiliary B-NonOSE_AE
: O
hepatic B-OSE_Labeled_AE
fibrosis I-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
hepatitis B-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
cholestatic B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
( O
0.1 O
% O
) O
, O
abnormal B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
Immune B-NonOSE_AE
System I-NonOSE_AE
: O
drug B-OSE_Labeled_AE
hypersensitivity I-OSE_Labeled_AE
( O
0.1 O
% O
) O
Postmarketing O
: O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
lacrimal B-OSE_Labeled_AE
duct I-OSE_Labeled_AE
stenosis I-OSE_Labeled_AE
, O
acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
secondary O
to O
dehydration B-OSE_Labeled_AE
including O
fatal B-NonOSE_AE
outcome O
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
, O
cutaneous B-OSE_Labeled_AE
lupus I-OSE_Labeled_AE
erythematosus I-OSE_Labeled_AE
, O
corneal B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
including O
keratitis B-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
leukoencephalopathy I-OSE_Labeled_AE
, O
severe O
skin B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
such O
as O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
and O
Toxic B-OSE_Labeled_AE
Epidermal I-OSE_Labeled_AE
Necrolysis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TEN I-OSE_Labeled_AE
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
, O
persistent O
or O
severe O
hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
and I-OSE_Labeled_AE
- I-OSE_Labeled_AE
foot I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
can O
eventually O
lead O
to O
loss B-NonOSE_AE
of I-NonOSE_AE
fingerprints I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
XELODA O
In O
Combination O
With O
Docetaxel O
( O
Metastatic O
Breast O
Cancer O
) O
Gastrointestinal B-NonOSE_AE
: O
ileus B-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
necrotizing B-OSE_Labeled_AE
enterocolitis I-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
esophageal B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
hemorrhagic B-OSE_Labeled_AE
diarrhea I-OSE_Labeled_AE
( O
0.8 O
% O
) O
Neurological B-NonOSE_AE
: O
ataxia B-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
syncope B-OSE_Labeled_AE
( O
1.2 O
% O
) O
, O
taste B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
( O
0.8 O
% O
) O
, O
polyneuropathy B-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
migraine O
( O
0.4 O
% O
) O
Cardiac B-NonOSE_AE
: O
supraventricular B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
( O
0.4 O
% O
) O
Infection B-NonOSE_AE
: O
neutropenic B-OSE_Labeled_AE
sepsis I-OSE_Labeled_AE
( O
2.4 O
% O
) O
, O
sepsis B-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
bronchopneumonia B-OSE_Labeled_AE
( O
0.4 O
% O
) O
Blood B-NonOSE_AE
& I-NonOSE_AE
Lymphatic I-NonOSE_AE
: O
agranulocytosis B-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
prothrombin B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
( O
0.4 O
% O
) O
Vascular B-NonOSE_AE
: O
hypotension B-OSE_Labeled_AE
( O
1.2 O
% O
) O
, O
venous B-OSE_Labeled_AE
phlebitis I-OSE_Labeled_AE
and O
thrombophlebitis B-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
postural B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
( O
0.8 O
% O
) O
Renal B-NonOSE_AE
: O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
0.4 O
% O
) O
Hepatobiliary B-NonOSE_AE
: O
jaundice B-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
abnormal B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
hepatic B-OSE_Labeled_AE
coma I-OSE_Labeled_AE
( O
0.4 O
% O
) O
, O
hepatotoxicity B-OSE_Labeled_AE
( O
0.4 O
% O
) O
Immune B-NonOSE_AE
System I-NonOSE_AE
: O
hypersensitivity B-OSE_Labeled_AE
( O
1.2 O
% O
) O

BOXED O
WARNING O
: O
WARNING O
: O
XELODA-WARFARIN O
INTERACTION O
WARNING O
: O
XELODA-WARFARIN O
INTERACTION O
XELODA O
Warfarin O
Interaction O
: O
Patients O
receiving O
concomitant O
capecitabine O
and O
oral O
coumarin-derivative O
anticoagulant O
therapy O
should O
have O
their O
anticoagulant O
response O
( O
INR O
or O
prothrombin O
time O
) O
monitored O
frequently O
in O
order O
to O
adjust O
the O
anticoagulant O
dose O
accordingly O
. O

A O
clinically O
important O
XELODA-Warfarin O
drug O
interaction O
was O
demonstrated O
in O
a O
clinical O
pharmacology O
trial O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
and O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

Altered B-NonOSE_AE
coagulation I-NonOSE_AE
parameters I-NonOSE_AE
and/or O
bleeding B-NonOSE_AE
, O
including O
death B-NonOSE_AE
, O
have O
been O
reported O
in O
patients O
taking O
XELODA O
concomitantly O
with O
coumarin-derivative O
anticoagulants O
such O
as O
warfarin O
and O
phenprocoumon O
. O

Postmarketing O
reports O
have O
shown O
clinically O
significant O
increases B-NonOSE_AE
in I-NonOSE_AE
prothrombin I-NonOSE_AE
time I-NonOSE_AE
( O
PT O
) O
and O
INR O
in O
patients O
who O
were O
stabilized O
on O
anticoagulants O
at O
the O
time O
XELODA O
was O
introduced O
. O

These O
events O
occurred O
within O
several O
days O
and O
up O
to O
several O
months O
after O
initiating O
XELODA O
therapy O
and O
, O
in O
a O
few O
cases O
, O
within O
1 O
month O
after O
stopping O
XELODA O
. O

These O
events O
occurred O
in O
patients O
with O
and O
without O
liver B-Not_AE_Candidate
metastases I-Not_AE_Candidate
. O

Age O
greater O
than O
60 O
and O
a O
diagnosis O
of O
cancer B-Not_AE_Candidate
independently O
predispose O
patients O
to O
an O
increased O
risk O
of O
coagulopathy B-NonOSE_AE
. O

EXCERPT O
: O
WARNING O
: O
XELODA-WARFARIN O
INTERACTION O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

Patients O
receiving O
concomitant O
XELODA O
and O
oral O
coumarin-derivative O
anticoagulants O
such O
as O
warfarin O
and O
phenprocoumon O
should O
have O
their O
anticoagulant O
response O
( O
INR O
or O
prothrombin O
time O
) O
monitored O
frequently O
in O
order O
to O
adjust O
the O
anticoagulant O
dose O
accordingly O
. O

Altered O
coagulation O
parameters O
and/or O
bleeding O
, O
including O
death O
, O
have O
been O
reported O
during O
concomitant O
use O
. O

* O
Occurrence O
: O
Within O
several O
days O
and O
up O
to O
several O
months O
after O
initiating O
XELODA O
therapy O
; O
may O
also O
be O
seen O
within O
1 O
month O
after O
stopping O
XELODA O
* O
Predisposing O
factors O
: O
age O
> O
60 O
and O
diagnosis O
of O
cancer O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Coagulopathy O
: O
May O
result O
in O
bleeding O
, O
death O
. O

Monitor O
anticoagulant O
response O
( O
e.g. O
, O
INR O
) O
and O
adjust O
anticoagulant O
dose O
accordingly O
. O

( O
5.1 O
) O
* O
Diarrhea O
: O
May O
be O
severe O
. O

Interrupt O
XELODA O
treatment O
immediately O
until O
diarrhea O
resolves O
or O
decreases O
to O
grade O
1 O
. O

Recommend O
standard O
antidiarrheal O
treatments O
. O

( O
5.2 O
) O
* O
Cardiotoxicity O
: O
Common O
in O
patients O
with O
a O
prior O
history O
of O
coronary O
artery O
disease O
. O

( O
5.3 O
) O
* O
Increased O
Risk O
of O
Severe O
or O
Fatal O
Adverse O
Reactions O
in O
Patients O
with O
Low O
or O
Absent O
Dihydropyrimidine O
Dehydrogenase O
( O
DPD O
) O
Activity O
: O
Withhold O
or O
permanently O
discontinue O
XELODA O
in O
patients O
with O
evidence O
of O
acute O
early-onset O
or O
unusually O
severe O
toxicity O
, O
which O
may O
indicate O
near O
complete O
or O
total O
absence O
of O
DPD O
activity O
. O

No O
XELODA O
dose O
has O
been O
proven O
safe O
in O
patients O
with O
absent O
DPD O
activity O
. O

( O
5.4 O
) O
* O
Dehydration O
and O
Renal O
Failure O
: O
Interrupt O
XELODA O
treatment O
until O
dehydration O
is O
corrected O
. O

Potential O
risk O
of O
acute O
renal O
failure O
secondary O
to O
dehydration O
. O

Monitor O
and O
correct O
dehydration O
. O

( O
5.5 O
) O
. O

* O
Embryo-Fetal O
Toxicity O
: O
Can O
cause O
fetal O
harm O
. O

Advise O
females O
of O
reproductive O
potential O
of O
the O
potential O
risk O
to O
a O
fetus O
and O
to O
use O
effective O
contraception O
. O

( O
5.6 O
, O
8.1 O
, O
8.3 O
) O
* O
Mucocutaneous O
and O
Dermatologic O
Toxicity O
: O
Severe O
mucocutaneous O
reactions O
, O
Steven-Johnson O
Syndrome O
( O
SJS O
) O
and O
Toxic O
Epidermal O
Necrolysis O
( O
TEN O
) O
, O
have O
been O
reported O
. O

XELODA O
should O
be O
permanently O
discontinued O
in O
patients O
who O
experience O
a O
severe O
mucocutaneous O
reaction O
during O
treatment O
. O

XELODA O
may O
induce O
hand-and-foot O
syndrome O
. O

Persistent O
or O
severe O
hand-and-foot O
syndrome O
can O
lead O
to O
loss O
of O
fingerprints O
which O
could O
impact O
patient O
identification O
. O

Interrupt O
XELODA O
treatment O
until O
the O
hand-and-foot O
syndrome O
event O
resolves O
or O
decreases O
in O
intensity O
. O

( O
5.7 O
) O
* O
Hyperbilirubinemia O
: O
Interrupt O
XELODA O
treatment O
immediately O
until O
the O
hyperbilirubinemia O
resolves O
or O
decreases O
in O
intensity O
. O

( O
5.8 O
) O
* O
Hematologic O
: O
Do O
not O
treat O
patients O
with O
neutrophil O
counts O
< O
1.5 O
* O
10 O
9 O
/L O
or O
thrombocyte O
counts O
< O
100 O
* O
10 O
9 O
/L O
. O

If O
grade O
3-4 O
neutropenia O
or O
thrombocytopenia O
occurs O
, O
stop O
therapy O
until O
condition O
resolves O
. O

( O
5.9 O
) O
5.1 O
Coagulopathy B-NonOSE_AE
Patients O
receiving O
concomitant O
capecitabine O
and O
oral O
coumarin-derivative O
anticoagulant O
therapy O
should O
have O
their O
anticoagulant O
response O
( O
INR O
or O
prothrombin O
time O
) O
monitored O
closely O
with O
great O
frequency O
and O
the O
anticoagulant O
dose O
should O
be O
adjusted O
accordingly O
[ O
see O
Boxed O
Warning O
and O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

5.2 O
Diarrhea O
XELODA O
can O
induce O
diarrhea B-OSE_Labeled_AE
, O
sometimes O
severe O
. O

Patients O
with O
severe O
diarrhea B-NonOSE_AE
should O
be O
carefully O
monitored O
and O
given O
fluid O
and O
electrolyte O
replacement O
if O
they O
become O
dehydrated O
. O

In O
875 O
patients O
with O
either O
metastatic O
breast B-Not_AE_Candidate
or O
colorectal O
cancer I-Not_AE_Candidate
who O
received O
XELODA O
monotherapy O
, O
the O
median O
time O
to O
first O
occurrence O
of O
grade O
2 O
to O
4 O
diarrhea B-OSE_Labeled_AE
was O
34 O
days O
( O
range O
from O
1 O
to O
369 O
days O
) O
. O

The O
median O
duration O
of O
grade O
3 O
to O
4 O
diarrhea B-OSE_Labeled_AE
was O
5 O
days O
. O

National O
Cancer O
Institute O
of O
Canada O
( O
NCIC O
) O
grade O
2 O
diarrhea B-NonOSE_AE
is O
defined O
as O
an O
increase B-NonOSE_AE
of I-NonOSE_AE
4 I-NonOSE_AE
to I-NonOSE_AE
6 I-NonOSE_AE
stools I-NonOSE_AE
/ I-NonOSE_AE
day I-NonOSE_AE
or I-NonOSE_AE
nocturnal I-NonOSE_AE
stools I-NonOSE_AE
, O
grade O
3 O
diarrhea B-NonOSE_AE
as O
an O
increase B-NonOSE_AE
of I-NonOSE_AE
7 I-NonOSE_AE
to I-NonOSE_AE
9 I-NonOSE_AE
stools I-NonOSE_AE
/ I-NonOSE_AE
day I-NonOSE_AE
or O
incontinence B-NonOSE_AE
and O
malabsorption B-NonOSE_AE
, O
and O
grade O
4 O
diarrhea B-NonOSE_AE
as O
an O
increase B-NonOSE_AE
of I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
stools I-NonOSE_AE
/ I-NonOSE_AE
day I-NonOSE_AE
or O
grossly B-NonOSE_AE
bloody I-NonOSE_AE
diarrhea I-NonOSE_AE
or O
the O
need O
for O
parenteral O
support O
. O

If O
grade O
2 O
, O
3 O
or O
4 O
diarrhea B-NonOSE_AE
occurs O
, O
administration O
of O
XELODA O
should O
be O
immediately O
interrupted O
until O
the O
diarrhea B-NonOSE_AE
resolves O
or O
decreases O
in O
intensity O
to O
grade O
1 O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

Standard O
antidiarrheal O
treatments O
( O
e.g. O
, O
loperamide O
) O
are O
recommended O
. O

Necrotizing B-OSE_Labeled_AE
enterocolitis I-OSE_Labeled_AE
( O
typhlitis B-OSE_Labeled_AE
) O
has O
been O
reported O
. O

5.3 O
Cardiotoxicity O
The O
cardiotoxicity B-OSE_Labeled_AE
observed O
with O
XELODA O
includes O
myocardial B-OSE_Labeled_AE
infarction/ O
ischemia I-OSE_Labeled_AE
, O
angina B-OSE_Labeled_AE
, O
dysrhythmias B-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
, O
electrocardiographic B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
, O
and O
cardiomyopathy B-OSE_Labeled_AE
. O

These O
adverse O
reactions O
may O
be O
more O
common O
in O
patients O
with O
a O
prior O
history O
of O
coronary B-Not_AE_Candidate
artery I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

5.4 O
Dihydropyrimidine O
Dehydrogenase O
Deficiency O
Based O
on O
postmarketing O
reports O
, O
patients O
with O
certain O
homozygous O
or O
certain O
compound O
heterozygous O
mutations O
in O
the O
DPD O
gene O
that O
result O
in O
complete O
or O
near O
complete O
absence B-Not_AE_Candidate
of I-Not_AE_Candidate
DPD I-Not_AE_Candidate
activity I-Not_AE_Candidate
are O
at O
increased O
risk O
for O
acute O
early-onset O
of O
toxicity O
and O
severe O
, O
life-threatening O
, O
or O
fatal B-NonOSE_AE
adverse O
reactions O
caused O
by O
XELODA O
( O
e.g. O
, O
mucositis B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
and O
neurotoxicity B-OSE_Labeled_AE
) O
. O

Patients O
with O
partial O
DPD O
activity O
may O
also O
have O
increased O
risk O
of O
severe O
, O
life-threatening O
, O
or O
fatal B-NonOSE_AE
adverse O
reactions O
caused O
by O
XELODA O
. O

Withhold O
or O
permanently O
discontinue O
XELODA O
based O
on O
clinical O
assessment O
of O
the O
onset O
, O
duration O
and O
severity O
of O
the O
observed O
toxicities O
in O
patients O
with O
evidence O
of O
acute O
early-onset O
or O
unusually O
severe O
toxicity O
, O
which O
may O
indicate O
near O
complete O
or O
total O
absence O
of O
DPD O
activity O
. O

No O
XELODA O
dose O
has O
been O
proven O
safe O
for O
patients O
with O
complete O
absence O
of O
DPD O
activity O
. O

There O
is O
insufficient O
data O
to O
recommend O
a O
specific O
dose O
in O
patients O
with O
partial O
DPD O
activity O
as O
measured O
by O
any O
specific O
test O
. O

5.5 O
Dehydration O
and O
Renal O
Failure O
Dehydration B-OSE_Labeled_AE
has O
been O
observed O
and O
may O
cause O
acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
which O
can O
be O
fatal B-NonOSE_AE
. O

Patients O
with O
pre-existing O
compromised B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
or O
who O
are O
receiving O
concomitant O
XELODA O
with O
known O
nephrotoxic B-NonOSE_AE
agents I-NonOSE_AE
are O
at O
higher O
risk O
. O

Patients O
with O
anorexia B-Not_AE_Candidate
, O
asthenia B-Not_AE_Candidate
, O
nausea B-Not_AE_Candidate
, O
vomiting B-Not_AE_Candidate
or O
diarrhea B-Not_AE_Candidate
may O
rapidly O
become O
dehydrated B-NonOSE_AE
. O

Monitor O
patients O
when O
XELODA O
is O
administered O
to O
prevent O
and O
correct O
dehydration B-NonOSE_AE
at O
the O
onset O
. O

If O
grade O
2 O
( O
or O
higher O
) O
dehydration B-NonOSE_AE
occurs O
, O
XELODA O
treatment O
should O
be O
immediately O
interrupted O
and O
the O
dehydration B-NonOSE_AE
corrected O
. O

Treatment O
should O
not O
be O
restarted O
until O
the O
patient O
is O
rehydrated O
and O
any O
precipitating O
causes O
have O
been O
corrected O
or O
controlled O
. O

Dose O
modifications O
should O
be O
applied O
for O
the O
precipitating O
adverse O
event O
as O
necessary O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

Patients O
with O
moderate O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
at O
baseline O
require O
dose O
reduction O
[ O
see O
Dosage O
and O
Administration O
( O
2.4 O
) O
] O
. O

Patients O
with O
mild O
and O
moderate O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
at O
baseline O
should O
be O
carefully O
monitored O
for O
adverse O
reactions O
. O

Prompt O
interruption O
of O
therapy O
with O
subsequent O
dose O
adjustments O
is O
recommended O
if O
a O
patient O
develops O
a O
grade O
2 O
to O
4 O
adverse O
event O
as O
outlined O
in O
Table O
2 O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.7 O
) O
, O
and O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

5.6 O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Based O
on O
findings O
from O
animal O
reproduction O
studies O
and O
its O
mechanism O
of O
action O
, O
XELODA O
may O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
given O
to O
a O
pregnant B-Not_AE_Candidate
woman O
[ O
see O
Clinical O
Pharmacology O
( O
12.1 O
) O
] O
. O

Limited O
available O
data O
are O
not O
sufficient O
to O
inform O
use O
of O
XELODA O
in O
pregnant B-Not_AE_Candidate
women O
. O

In O
animal O
reproduction O
studies O
, O
administration O
of O
capecitabine O
to O
pregnant B-NonOSE_AE
animals O
during O
the O
period O
of O
organogenesis O
caused O
embryolethality B-NonOSE_AE
and O
teratogenicity B-NonOSE_AE
in O
mice O
and O
embryolethality B-NonOSE_AE
in O
monkeys O
at O
0.2 O
and O
0.6 O
times O
the O
exposure O
( O
AUC O
) O
in O
patients O
receiving O
the O
recommended O
dose O
respectively O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

Apprise O
pregnant B-Not_AE_Candidate
women O
of O
the O
potential O
risk B-OSE_Labeled_AE
to I-OSE_Labeled_AE
a I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

Advise O
females O
of O
reproductive O
potential O
to O
use O
effective O
contraception O
during O
treatment O
and O
for O
6 O
months O
following O
the O
last O
dose O
of O
XELODA O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.3 O
) O
] O
. O

5.7 O
Mucocutaneous B-OSE_Labeled_AE
and O
Dermatologic O
Toxicity I-OSE_Labeled_AE
Severe O
mucocutaneous B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
some O
with O
fatal B-NonOSE_AE
outcome O
, O
such O
as O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
and O
Toxic B-OSE_Labeled_AE
Epidermal I-OSE_Labeled_AE
Necrolysis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TEN I-OSE_Labeled_AE
) O
can O
occur O
in O
patients O
treated O
with O
XELODA O
[ O
see O
Adverse O
Reactions O
( O
6.4 O
) O
] O
. O

XELODA O
should O
be O
permanently O
discontinued O
in O
patients O
who O
experience O
a O
severe O
mucocutaneous B-NonOSE_AE
reaction I-NonOSE_AE
possibly O
attributable O
to O
XELODA O
treatment O
. O

Hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
and I-OSE_Labeled_AE
- I-OSE_Labeled_AE
foot I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( O
palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
erythrodysesthesia I-OSE_Labeled_AE
or O
chemotherapy B-OSE_Labeled_AE
- I-OSE_Labeled_AE
induced I-OSE_Labeled_AE
acral I-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
) O
is O
a O
cutaneous B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
. O

Median O
time O
to O
onset O
was O
79 O
days O
( O
range O
from O
11 O
to O
360 O
days O
) O
with O
a O
severity O
range O
of O
grades O
1 O
to O
3 O
for O
patients O
receiving O
XELODA O
monotherapy O
in O
the O
metastatic O
setting O
. O

Grade O
1 O
is O
characterized O
by O
any O
of O
the O
following O
: O
numbness B-NonOSE_AE
, O
dysesthesia B-NonOSE_AE
/ O
paresthesia B-NonOSE_AE
, O
tingling B-NonOSE_AE
, O
painless B-NonOSE_AE
swelling I-NonOSE_AE
or O
erythema O
of I-NonOSE_AE
the I-NonOSE_AE
hands I-NonOSE_AE
and/or O
feet O
and/or O
discomfort O
which O
does O
not O
disrupt O
normal O
activities O
. O

Grade O
2 O
hand B-NonOSE_AE
- I-NonOSE_AE
and I-NonOSE_AE
- I-NonOSE_AE
foot I-NonOSE_AE
syndrome I-NonOSE_AE
is O
defined O
as O
painful B-NonOSE_AE
erythema I-NonOSE_AE
and O
swelling O
of I-NonOSE_AE
the I-NonOSE_AE
hands I-NonOSE_AE
and/or O
feet O
and/or O
discomfort O
affecting O
the O
patient O
's O
activities O
of O
daily O
living O
. O

Grade O
3 O
hand B-NonOSE_AE
- I-NonOSE_AE
and I-NonOSE_AE
- I-NonOSE_AE
foot I-NonOSE_AE
syndrome I-NonOSE_AE
is O
defined O
as O
moist B-NonOSE_AE
desquamation I-NonOSE_AE
, O
ulceration O
, O
blistering O
or O
severe O
pain O
of O
the O
hands I-NonOSE_AE
and/or O
feet O
and/or O
severe O
discomfort O
that O
causes O
the O
patient O
to O
be O
unable B-NonOSE_AE
to I-NonOSE_AE
work I-NonOSE_AE
or I-NonOSE_AE
perform I-NonOSE_AE
activities I-NonOSE_AE
of I-NonOSE_AE
daily I-NonOSE_AE
living I-NonOSE_AE
. O

Persistent O
or O
severe O
hand B-NonOSE_AE
- I-NonOSE_AE
and I-NonOSE_AE
- I-NonOSE_AE
foot I-NonOSE_AE
syndrome I-NonOSE_AE
( O
grade O
2 O
and O
above O
) O
can O
eventually O
lead O
to O
loss B-NonOSE_AE
of I-NonOSE_AE
fingerprints I-NonOSE_AE
which O
could O
impact O
patient O
identification O
. O

If O
grade O
2 O
or O
3 O
hand B-NonOSE_AE
- I-NonOSE_AE
and I-NonOSE_AE
- I-NonOSE_AE
foot I-NonOSE_AE
syndrome I-NonOSE_AE
occurs O
, O
administration O
of O
XELODA O
should O
be O
interrupted O
until O
the O
event O
resolves O
or O
decreases O
in O
intensity O
to O
grade O
1 O
. O

Following O
grade O
3 O
hand B-NonOSE_AE
- I-NonOSE_AE
and I-NonOSE_AE
- I-NonOSE_AE
foot I-NonOSE_AE
syndrome I-NonOSE_AE
, O
subsequent O
doses O
of O
XELODA O
should O
be O
decreased O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.8 O
Hyperbilirubinemia O
In O
875 O
patients O
with O
either O
metastatic O
breast B-Not_AE_Candidate
or O
colorectal O
cancer I-Not_AE_Candidate
who O
received O
at O
least O
one O
dose O
of O
XELODA O
1250 O
mg/m O
2 O
twice O
daily O
as O
monotherapy O
for O
2 O
weeks O
followed O
by O
a O
1-week O
rest O
period O
, O
grade O
3 O
( O
1.5-3 O
* O
ULN O
) O
hyperbilirubinemia B-OSE_Labeled_AE
occurred O
in O
15.2 O
% O
( O
n=133 O
) O
of O
patients O
and O
grade O
4 O
( O
> O
3 O
* O
ULN O
) O
hyperbilirubinemia B-OSE_Labeled_AE
occurred O
in O
3.9 O
% O
( O
n=34 O
) O
of O
patients O
. O

Of O
566 O
patients O
who O
had O
hepatic B-Not_AE_Candidate
metastases I-Not_AE_Candidate
at O
baseline O
and O
309 O
patients O
without O
hepatic B-NonOSE_AE
metastases I-NonOSE_AE
at O
baseline O
, O
grade O
3 O
or O
4 O
hyperbilirubinemia B-OSE_Labeled_AE
occurred O
in O
22.8 O
% O
and O
12.3 O
% O
, O
respectively O
. O

Of O
the O
167 O
patients O
with O
grade O
3 O
or O
4 O
hyperbilirubinemia B-OSE_Labeled_AE
, O
18.6 O
% O
( O
n=31 O
) O
also O
had O
postbaseline O
elevations B-OSE_Labeled_AE
( O
grades O
1 O
to O
4 O
, O
without O
elevations O
at O
baseline O
) O
in O
alkaline I-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
and O
27.5 O
% O
( O
n=46 O
) O
had O
postbaseline O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
at O
any O
time O
( O
not O
necessarily O
concurrent O
) O
. O

The O
majority O
of O
these O
patients O
, O
64.5 O
% O
( O
n=20 O
) O
and O
71.7 O
% O
( O
n=33 O
) O
, O
had O
liver B-Not_AE_Candidate
metastases I-Not_AE_Candidate
at O
baseline O
. O

In O
addition O
, O
57.5 O
% O
( O
n=96 O
) O
and O
35.3 O
% O
( O
n=59 O
) O
of O
the O
167 O
patients O
had O
elevations B-OSE_Labeled_AE
( O
grades O
1 O
to O
4 O
) O
at O
both O
prebaseline O
and O
postbaseline O
in O
alkaline O
phosphatase O
or O
transaminases I-OSE_Labeled_AE
, O
respectively O
. O

Only O
7.8 O
% O
( O
n=13 O
) O
and O
3.0 O
% O
( O
n=5 O
) O
had O
grade O
3 O
or O
4 O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
alkaline O
phosphatase O
or O
transaminases I-OSE_Labeled_AE
. O

In O
the O
596 O
patients O
treated O
with O
XELODA O
as O
first-line O
therapy O
for O
metastatic O
colorectal B-Not_AE_Candidate
cancer I-Not_AE_Candidate
, O
the O
incidence O
of O
grade O
3 O
or O
4 O
hyperbilirubinemia B-OSE_Labeled_AE
was O
similar O
to O
the O
overall O
clinical O
trial O
safety O
database O
of O
XELODA O
monotherapy O
. O

The O
median O
time O
to O
onset O
for O
grade O
3 O
or O
4 O
hyperbilirubinemia B-OSE_Labeled_AE
in O
the O
colorectal B-Not_AE_Candidate
cancer I-Not_AE_Candidate
population O
was O
64 O
days O
and O
median O
total B-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
from O
8 O
um/L O
at O
baseline O
to O
13 O
um/L O
during O
treatment O
with O
XELODA O
. O

Of O
the O
136 O
colorectal B-Not_AE_Candidate
cancer I-Not_AE_Candidate
patients O
with O
grade O
3 O
or O
4 O
hyperbilirubinemia B-OSE_Labeled_AE
, O
49 O
patients O
had O
grade O
3 O
or O
4 O
hyperbilirubinemia B-OSE_Labeled_AE
as O
their O
last O
measured O
value O
, O
of O
which O
46 O
had O
liver B-Not_AE_Candidate
metastases I-Not_AE_Candidate
at O
baseline O
. O

In O
251 O
patients O
with O
metastatic O
breast B-Not_AE_Candidate
cancer I-Not_AE_Candidate
who O
received O
a O
combination O
of O
XELODA O
and O
docetaxel O
, O
grade O
3 O
( O
1.5 O
to O
3 O
* O
ULN O
) O
hyperbilirubinemia B-OSE_Labeled_AE
occurred O
in O
7 O
% O
( O
n=17 O
) O
and O
grade O
4 O
( O
> O
3 O
* O
ULN O
) O
hyperbilirubinemia B-OSE_Labeled_AE
occurred O
in O
2 O
% O
( O
n=5 O
) O
. O

If O
drug-related O
grade O
3 O
to O
4 O
elevations B-NonOSE_AE
in I-NonOSE_AE
bilirubin I-NonOSE_AE
occur O
, O
administration O
of O
XELODA O
should O
be O
immediately O
interrupted O
until O
the O
hyperbilirubinemia B-NonOSE_AE
decreases I-NonOSE_AE
to O
< O
=3.0 O
* O
ULN O
[ O
see O
recommended O
dose O
modifications O
under O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.9 O
Hematologic O
In O
875 O
patients O
with O
either O
metastatic O
breast B-Not_AE_Candidate
or O
colorectal O
cancer I-Not_AE_Candidate
who O
received O
a O
dose O
of O
1250 O
mg/m O
2 O
administered O
twice O
daily O
as O
monotherapy O
for O
2 O
weeks O
followed O
by O
a O
1-week O
rest O
period O
, O
3.2 O
% O
, O
1.7 O
% O
, O
and O
2.4 O
% O
of O
patients O
had O
grade O
3 O
or O
4 O
neutropenia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
or O
decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
, O
respectively O
. O

In O
251 O
patients O
with O
metastatic O
breast B-Not_AE_Candidate
cancer I-Not_AE_Candidate
who O
received O
a O
dose O
of O
XELODA O
in O
combination O
with O
docetaxel O
, O
68 O
% O
had O
grade O
3 O
or O
4 O
neutropenia B-OSE_Labeled_AE
, O
2.8 O
% O
had O
grade O
3 O
or O
4 O
thrombocytopenia B-OSE_Labeled_AE
, O
and O
9.6 O
% O
had O
grade O
3 O
or O
4 O
anemia B-OSE_Labeled_AE
. O

Patients O
with O
baseline O
neutrophil B-Not_AE_Candidate
counts I-Not_AE_Candidate
of I-Not_AE_Candidate
< I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
5 I-Not_AE_Candidate
* I-Not_AE_Candidate
1 I-Not_AE_Candidate
0 I-Not_AE_Candidate
9 I-Not_AE_Candidate
/ I-Not_AE_Candidate
L I-Not_AE_Candidate
and/or O
thrombocyte B-Not_AE_Candidate
counts I-Not_AE_Candidate
of I-Not_AE_Candidate
< I-Not_AE_Candidate
1 I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
* I-Not_AE_Candidate
1 I-Not_AE_Candidate
0 I-Not_AE_Candidate
9 I-Not_AE_Candidate
/ I-Not_AE_Candidate
L I-Not_AE_Candidate
should O
not O
be O
treated O
with O
XELODA O
. O

If O
unscheduled O
laboratory O
assessments O
during O
a O
treatment O
cycle O
show O
grade O
3 O
or O
4 O
hematologic B-NonOSE_AE
toxicity I-NonOSE_AE
, O
treatment O
with O
XELODA O
should O
be O
interrupted O
. O

5.10 O
Geriatric O
Patients O
Patients O
> O
=80 O
years O
old O
may O
experience O
a O
greater O
incidence O
of O
grade O
3 O
or O
4 O
adverse O
reactions O
. O

In O
875 O
patients O
with O
either O
metastatic O
breast B-Not_AE_Candidate
or O
colorectal O
cancer I-Not_AE_Candidate
who O
received O
XELODA O
monotherapy O
, O
62 O
% O
of O
the O
21 O
patients O
> O
=80 O
years O
of O
age O
treated O
with O
XELODA O
experienced O
a O
treatment-related O
grade O
3 O
or O
4 O
adverse O
event O
: O
diarrhea B-OSE_Labeled_AE
in O
6 O
( O
28.6 O
% O
) O
, O
nausea B-OSE_Labeled_AE
in O
3 O
( O
14.3 O
% O
) O
, O
hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
and I-OSE_Labeled_AE
- I-OSE_Labeled_AE
foot I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
in O
3 O
( O
14.3 O
% O
) O
, O
and O
vomiting B-OSE_Labeled_AE
in O
2 O
( O
9.5 O
% O
) O
patients O
. O

Among O
the O
10 O
patients O
70 O
years O
of O
age O
and O
greater O
( O
no O
patients O
were O
> O
80 O
years O
of O
age O
) O
treated O
with O
XELODA O
in O
combination O
with O
docetaxel O
, O
30 O
% O
( O
3 O
out O
of O
10 O
) O
of O
patients O
experienced O
grade O
3 O
or O
4 O
diarrhea B-OSE_Labeled_AE
and O
stomatitis B-OSE_Labeled_AE
, O
and O
40 O
% O
( O
4 O
out O
of O
10 O
) O
experienced O
grade O
3 O
hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
and I-OSE_Labeled_AE
- I-OSE_Labeled_AE
foot I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
. O

Among O
the O
67 O
patients O
> O
=60 O
years O
of O
age O
receiving O
XELODA O
in O
combination O
with O
docetaxel O
, O
the O
incidence O
of O
grade O
3 O
or O
4 O
treatment-related O
adverse O
reactions O
, O
treatment-related O
serious O
adverse O
reactions O
, O
withdrawals O
due O
to O
adverse O
reactions O
, O
treatment O
discontinuations O
due O
to O
adverse O
reactions O
and O
treatment O
discontinuations O
within O
the O
first O
two O
treatment O
cycles O
was O
higher O
than O
in O
the O
< O
60 O
years O
of O
age O
patient O
group O
. O

In O
995 O
patients O
receiving O
XELODA O
as O
adjuvant O
therapy O
for O
Dukes B-Not_AE_Candidate
' I-Not_AE_Candidate
C I-Not_AE_Candidate
colon I-Not_AE_Candidate
cancer I-Not_AE_Candidate
after O
resection B-Not_AE_Candidate
of I-Not_AE_Candidate
the I-Not_AE_Candidate
primary I-Not_AE_Candidate
tumor I-Not_AE_Candidate
, O
41 O
% O
of O
the O
398 O
patients O
> O
=65 O
years O
of O
age O
treated O
with O
XELODA O
experienced O
a O
treatment-related O
grade O
3 O
or O
4 O
adverse O
event O
: O
hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
and I-OSE_Labeled_AE
- I-OSE_Labeled_AE
foot I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
in O
75 O
( O
18.8 O
% O
) O
, O
diarrhea B-OSE_Labeled_AE
in O
52 O
( O
13.1 O
% O
) O
, O
stomatitis B-OSE_Labeled_AE
in O
12 O
( O
3.0 O
% O
) O
, O
neutropenia B-OSE_Labeled_AE
/ O
granulocytopenia B-OSE_Labeled_AE
in O
11 O
( O
2.8 O
% O
) O
, O
vomiting B-OSE_Labeled_AE
in O
6 O
( O
1.5 O
% O
) O
, O
and O
nausea B-OSE_Labeled_AE
in O
5 O
( O
1.3 O
% O
) O
patients O
. O

In O
patients O
> O
=65 O
years O
of O
age O
( O
all O
randomized O
population O
; O
capecitabine O
188 O
patients O
, O
5-FU/LV O
208 O
patients O
) O
treated O
for O
Dukes B-Not_AE_Candidate
' I-Not_AE_Candidate
C I-Not_AE_Candidate
colon I-Not_AE_Candidate
cancer I-Not_AE_Candidate
after O
resection B-Not_AE_Candidate
of I-Not_AE_Candidate
the I-Not_AE_Candidate
primary I-Not_AE_Candidate
tumor I-Not_AE_Candidate
, O
the O
hazard O
ratios O
for O
disease-free O
survival O
and O
overall O
survival O
for O
XELODA O
compared O
to O
5-FU/LV O
were O
1.01 O
( O
95 O
% O
C.I O
. O

0.80 O
- O
1.27 O
) O
and O
1.04 O
( O
95 O
% O
C.I O
. O

0.79 O
- O
1.37 O
) O
, O
respectively O
. O

5.11 O
Hepatic O
Insufficiency O
Patients O
with O
mild O
to O
moderate O
hepatic B-Not_AE_Candidate
dysfunction I-Not_AE_Candidate
due O
to O
liver B-Not_AE_Candidate
metastases I-Not_AE_Candidate
should O
be O
carefully O
monitored O
when O
XELODA O
is O
administered O
. O

The O
effect O
of O
severe O
hepatic B-NonOSE_AE
dysfunction I-NonOSE_AE
on O
the O
disposition O
of O
XELODA O
is O
not O
known O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
and O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

5.12 O
Combination O
With O
Other O
Drugs O
Use O
of O
XELODA O
in O
combination O
with O
irinotecan O
has O
not O
been O
adequately O
studied O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
another O
section O
of O
the O
label O
: O
* O
Bone B-OSE_Labeled_AE
Marrow I-OSE_Labeled_AE
Suppression I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
EXCERPT O
: O
The O
most O
common O
adverse O
drug O
reactions O
( O
> O
= O
10 O
% O
) O
in O
patients O
receiving O
Xofigo O
were O
nausea O
, O
diarrhea O
, O
vomiting O
, O
and O
peripheral O
edema O
. O

The O
most O
common O
hematologic O
laboratory O
abnormalities O
( O
> O
= O
10 O
% O
) O
were O
anemia O
, O
lymphocytopenia O
, O
leukopenia O
, O
thrombocytopenia O
, O
and O
neutropenia O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Bayer O
HealthCare O
Pharmaceuticals O
Inc O
. O
at O
1-888-842-2937 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

In O
the O
randomized O
clinical O
trial O
in O
patients O
with O
metastatic B-Not_AE_Candidate
castration I-Not_AE_Candidate
- I-Not_AE_Candidate
resistant I-Not_AE_Candidate
prostate I-Not_AE_Candidate
cancer I-Not_AE_Candidate
with O
bone B-Not_AE_Candidate
metastases I-Not_AE_Candidate
, O
600 O
patients O
received O
intravenous O
injections O
of O
50 O
kBq/kg O
( O
1.35 O
microcurie/kg O
) O
of O
Xofigo O
and O
best O
standard O
of O
care O
and O
301 O
patients O
received O
placebo O
and O
best O
standard O
of O
care O
once O
every O
4 O
weeks O
for O
up O
to O
6 O
injections O
. O

Prior O
to O
randomization O
, O
58 O
% O
and O
57 O
% O
of O
patients O
had O
received O
docetaxel O
in O
the O
Xofigo O
and O
placebo O
arms O
, O
respectively O
. O

The O
median O
duration O
of O
treatment O
was O
20 O
weeks O
( O
6 O
cycles O
) O
for O
Xofigo O
and O
18 O
weeks O
( O
5 O
cycles O
) O
for O
placebo O
. O

The O
most O
common O
adverse O
reactions O
( O
> O
= O
10 O
% O
) O
in O
patients O
receiving O
Xofigo O
were O
nausea B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
and O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
( O
Table O
3 O
) O
. O

Grade O
3 O
and O
4 O
adverse O
events O
were O
reported O
among O
57 O
% O
of O
Xofigo-treated O
patients O
and O
63 O
% O
of O
placebo-treated O
patients O
. O

The O
most O
common O
hematologic B-OSE_Labeled_AE
laboratory I-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
in O
Xofigo-treated O
patients O
( O
> O
= O
10 O
% O
) O
were O
anemia B-OSE_Labeled_AE
, O
lymphocytopenia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
and O
neutropenia B-OSE_Labeled_AE
( O
Table O
4 O
) O
. O

Treatment O
discontinuations O
due O
to O
adverse O
events O
occurred O
in O
17 O
% O
of O
patients O
who O
received O
Xofigo O
and O
21 O
% O
of O
patients O
who O
received O
placebo O
. O

The O
most O
common O
hematologic B-OSE_Labeled_AE
laboratory I-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
leading O
to O
discontinuation O
for O
Xofigo O
were O
anemia B-OSE_Labeled_AE
( O
2 O
% O
) O
and O
thrombocytopenia B-OSE_Labeled_AE
( O
2 O
% O
) O
. O

Table O
3 O
shows O
adverse O
reactions O
occurring O
in O
> O
= O
2 O
% O
of O
patients O
and O
for O
which O
the O
incidence O
for O
Xofigo O
exceeds O
the O
incidence O
for O
placebo O
. O

Table O
3 O
: O
Adverse O
Reactions O
in O
the O
Randomized O
Trial O
System/Organ O
ClassPreferred O
Term O
Xofigo O
( O
n=600 O
) O
Placebo O
( O
n=301 O
) O
Grades O
1-4 O
% O
Grades O
3-4 O
% O
Grades O
1-4 O
% O
Grades O
3-4 O
% O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Pancytopenia B-OSE_Labeled_AE
2 O
1 O
0 O
0 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
36 O
2 O
35 O
2 O
Diarrhea B-OSE_Labeled_AE
25 O
2 O
15 O
2 O
Vomiting B-OSE_Labeled_AE
19 O
2 O
14 O
2 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
13 O
2 O
10 O
1 O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
Renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
and O
impairment O
3 O
1 O
1 O
1 O
Laboratory O
Abnormalities O
Table O
4 O
shows O
hematologic B-NonOSE_AE
laboratory I-NonOSE_AE
abnormalities I-NonOSE_AE
occurring O
in O
> O
10 O
% O
of O
patients O
and O
for O
which O
the O
incidence O
for O
Xofigo O
exceeds O
the O
incidence O
for O
placebo O
. O

Table O
4 O
: O
Hematologic O
Laboratory O
Abnormalities O
Hematologic O
Laboratory O
Abnormalities O
Xofigo O
( O
n=600 O
) O
Placebo O
( O
n=301 O
) O
Grades O
1-4 O
% O
Grades O
3-4 O
% O
Grades O
1-4 O
% O
Grades O
3-4 O
% O
Anemia B-OSE_Labeled_AE
93 O
6 O
88 O
6 O
Lymphocytopenia B-OSE_Labeled_AE
72 O
20 O
53 O
7 O
Leukopenia B-OSE_Labeled_AE
35 O
3 O
10 O
< O
1 O
Thrombocytopenia B-OSE_Labeled_AE
31 O
3 O
22 O
< O
1 O
Neutropenia B-OSE_Labeled_AE
18 O
2 O
5 O
< O
1 O
Laboratory O
values O
were O
obtained O
at O
baseline O
and O
prior O
to O
each O
4-week O
cycle O
. O

As O
an O
adverse O
reaction O
, O
grade O
3-4 O
thrombocytopenia B-OSE_Labeled_AE
was O
reported O
in O
6 O
% O
of O
patients O
on O
Xofigo O
and O
in O
2 O
% O
of O
patients O
on O
placebo O
. O

Among O
patients O
who O
received O
Xofigo O
, O
the O
laboratory B-NonOSE_AE
abnormality I-NonOSE_AE
grade O
3-4 O
thrombocytopenia B-OSE_Labeled_AE
occurred O
in O
1 O
% O
of O
docetaxel O
naive O
patients O
and O
in O
4 O
% O
of O
patients O
who O
had O
received O
prior O
docetaxel O
. O

Grade O
3-4 O
neutropenia B-OSE_Labeled_AE
occurred O
in O
1 O
% O
of O
docetaxel O
naive O
patients O
and O
in O
3 O
% O
of O
patients O
who O
have O
received O
prior O
docetaxel O
. O

Fluid O
Status O
Dehydration B-OSE_Labeled_AE
occurred O
in O
3 O
% O
of O
patients O
on O
Xofigo O
and O
1 O
% O
of O
patients O
on O
placebo O
. O

Xofigo O
increases O
adverse O
reactions O
such O
as O
diarrhea B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
and O
vomiting B-OSE_Labeled_AE
which O
may O
result O
in O
dehydration B-NonOSE_AE
. O

Monitor O
patients O
' O
oral O
intake O
and O
fluid O
status O
carefully O
and O
promptly O
treat O
patients O
who O
display O
signs O
or O
symptoms O
of O
dehydration B-NonOSE_AE
or O
hypovolemia B-NonOSE_AE
. O

Injection B-OSE_Labeled_AE
Site I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
Erythema B-OSE_Labeled_AE
, O
pain O
, O
and O
edema O
at I-OSE_Labeled_AE
the I-OSE_Labeled_AE
injection I-OSE_Labeled_AE
site I-OSE_Labeled_AE
were O
reported O
in O
1 O
% O
of O
patients O
on O
Xofigo O
. O

Secondary O
Malignant O
Neoplasms O
Xofigo O
contributes O
to O
a O
patient O
's O
overall O
long-term O
cumulative O
radiation O
exposure O
. O

Long-term O
cumulative O
radiation O
exposure O
may O
be O
associated O
with O
an O
increased B-OSE_Labeled_AE
risk I-OSE_Labeled_AE
of I-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
and O
hereditary B-OSE_Labeled_AE
defects I-OSE_Labeled_AE
. O

Due O
to O
its O
mechanism O
of O
action O
and O
neoplastic B-NonOSE_AE
changes I-NonOSE_AE
, O
including O
osteosarcomas B-NonOSE_AE
, O
in O
rats O
following O
administration O
of O
radium-223 O
dichloride O
, O
Xofigo O
may O
increase O
the O
risk O
of O
osteosarcoma B-OSE_Labeled_AE
or O
other O
secondary B-OSE_Labeled_AE
malignant I-OSE_Labeled_AE
neoplasms I-OSE_Labeled_AE
[ O
see O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
. O

However O
, O
the O
overall O
incidence O
of O
new O
malignancies B-NonOSE_AE
in O
the O
randomized O
trial O
was O
lower O
on O
the O
Xofigo O
arm O
compared O
to O
placebo O
( O
< O
1 O
% O
vs O
. O
2 O
% O
; O
respectively O
) O
, O
but O
the O
expected O
latency O
period O
for O
the O
development O
of O
secondary B-NonOSE_AE
malignancies I-NonOSE_AE
exceeds O
the O
duration O
of O
follow O
up O
for O
patients O
on O
the O
trial O
. O

Subsequent O
Treatment O
with O
Cytotoxic O
Chemotherapy O
In O
the O
randomized O
clinical O
trial O
, O
16 O
% O
patients O
in O
the O
Xofigo O
group O
and O
18 O
% O
patients O
in O
the O
placebo O
group O
received O
cytotoxic B-NonOSE_AE
chemotherapy I-NonOSE_AE
after O
completion O
of O
study O
treatments O
. O

Adequate O
safety O
monitoring O
and O
laboratory O
testing O
was O
not O
performed O
to O
assess O
how O
patients O
treated O
with O
Xofigo O
will O
tolerate O
subsequent O
cytotoxic B-NonOSE_AE
chemotherapy I-NonOSE_AE
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
Bone O
Marrow O
Suppression O
: O
Measure O
blood O
counts O
prior O
to O
treatment O
initiation O
and O
before O
every O
dose O
of O
Xofigo O
. O

Discontinue O
Xofigo O
if O
hematologic O
values O
do O
not O
recover O
within O
6 O
to O
8 O
weeks O
after O
treatment O
. O

Monitor O
patients O
with O
compromised O
bone O
marrow O
reserve O
closely O
. O

Discontinue O
Xofigo O
in O
patients O
who O
experience O
life-threatening O
complications O
despite O
supportive O
care O
measures O
. O

( O
5.1 O
) O
5.1 O
Bone O
Marrow O
Suppression O
In O
the O
randomized O
trial O
, O
2 O
% O
of O
patients O
on O
the O
Xofigo O
arm O
experienced O
bone B-OSE_Labeled_AE
marrow I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
or O
ongoing O
pancytopenia B-OSE_Labeled_AE
compared O
to O
no O
patients O
treated O
with O
placebo O
. O

There O
were O
two O
deaths B-NonOSE_AE
due O
to O
bone B-NonOSE_AE
marrow I-NonOSE_AE
failure I-NonOSE_AE
and O
for O
7 O
of O
13 O
patients O
treated O
with O
Xofigo O
, O
bone B-NonOSE_AE
marrow I-NonOSE_AE
failure I-NonOSE_AE
was O
ongoing O
at O
the O
time O
of O
death B-NonOSE_AE
. O

Among O
the O
13 O
patients O
who O
experienced O
bone B-NonOSE_AE
marrow I-NonOSE_AE
failure I-NonOSE_AE
, O
54 O
% O
required O
blood O
transfusions O
. O

Four O
percent O
( O
4 O
% O
) O
of O
patients O
on O
the O
Xofigo O
arm O
and O
2 O
% O
on O
the O
placebo O
arm O
permanently O
discontinued O
therapy O
due O
to O
bone B-OSE_Labeled_AE
marrow I-OSE_Labeled_AE
suppression I-OSE_Labeled_AE
. O

In O
the O
randomized O
trial O
, O
deaths B-NonOSE_AE
related O
to O
vascular B-NonOSE_AE
hemorrhage I-NonOSE_AE
in O
association O
with O
myelosuppression B-NonOSE_AE
were O
observed O
in O
1 O
% O
of O
Xofigo-treated O
patients O
compared O
to O
0.3 O
% O
of O
patients O
treated O
with O
placebo O
. O

The O
incidence O
of O
infection B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
deaths B-NonOSE_AE
( O
2 O
% O
) O
, O
serious O
infections B-NonOSE_AE
( O
10 O
% O
) O
, O
and O
febrile B-NonOSE_AE
neutropenia I-NonOSE_AE
( O
< O
1 O
% O
) O
were O
similar O
for O
patients O
treated O
with O
Xofigo O
and O
placebo O
. O

Myelosuppression B-OSE_Labeled_AE
; O
notably O
thrombocytopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
pancytopenia B-OSE_Labeled_AE
, O
and O
leukopenia B-OSE_Labeled_AE
; O
has O
been O
reported O
in O
patients O
treated O
with O
Xofigo O
. O

In O
the O
randomized O
trial O
, O
complete O
blood O
counts O
( O
CBCs O
) O
were O
obtained O
every O
4 O
weeks O
prior O
to O
each O
dose O
and O
the O
nadir O
CBCs O
and O
times O
of O
recovery O
were O
not O
well O
characterized O
. O

In O
a O
separate O
single-dose O
phase O
1 O
study O
of O
Xofigo O
, O
neutrophil O
and O
platelet O
count O
nadirs O
occurred O
2 O
to O
3 O
weeks O
after O
Xofigo O
administration O
at O
doses O
that O
were O
up O
to O
1 O
to O
5 O
times O
the O
recommended O
dose O
, O
and O
most O
patients O
recovered O
approximately O
6 O
to O
8 O
weeks O
after O
administration O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

Hematologic O
evaluation O
of O
patients O
must O
be O
performed O
at O
baseline O
and O
prior O
to O
every O
dose O
of O
Xofigo O
. O

Before O
the O
first O
administration O
of O
Xofigo O
, O
the O
absolute B-NonOSE_AE
neutrophil I-NonOSE_AE
count I-NonOSE_AE
( I-NonOSE_AE
ANC I-NonOSE_AE
) I-NonOSE_AE
should I-NonOSE_AE
be I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
. I-NonOSE_AE
5 I-NonOSE_AE
x I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
9 I-NonOSE_AE
/L O
, O
the O
platelet B-NonOSE_AE
count I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
x I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
9 I-NonOSE_AE
/ I-NonOSE_AE
L I-NonOSE_AE
and O
hemoglobin B-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
g I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
. O

Before O
subsequent O
administrations O
of O
Xofigo O
, O
the O
ANC B-NonOSE_AE
should I-NonOSE_AE
be I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
x I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
9 I-NonOSE_AE
/ I-NonOSE_AE
L I-NonOSE_AE
and O
the O
platelet B-NonOSE_AE
count I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
x I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
9 I-NonOSE_AE
/ I-NonOSE_AE
L I-NonOSE_AE
. O

If O
there O
is O
no O
recovery O
to O
these O
values O
within O
6 O
to O
8 O
weeks O
after O
the O
last O
administration O
of O
Xofigo O
, O
despite O
receiving O
supportive O
care O
, O
further O
treatment O
with O
Xofigo O
should O
be O
discontinued O
. O

Patients O
with O
evidence O
of O
compromised B-NonOSE_AE
bone I-NonOSE_AE
marrow I-NonOSE_AE
reserve I-NonOSE_AE
should O
be O
monitored O
closely O
and O
provided O
with O
supportive O
care O
measures O
when O
clinically O
indicated O
. O

Discontinue O
Xofigo O
in O
patients O
who O
experience O
life-threatening O
complications O
despite O
supportive O
care O
for O
bone B-NonOSE_AE
marrow I-NonOSE_AE
failure I-NonOSE_AE
. O

The O
safety O
and O
efficacy O
of O
concomitant O
chemotherapy O
with O
Xofigo O
have O
not O
been O
established O
. O

Outside O
of O
a O
clinical O
trial O
, O
concomitant O
use O
with O
chemotherapy O
is O
not O
recommended O
due O
to O
the O
potential O
for O
additive O
myelosuppression B-NonOSE_AE
. O

If O
chemotherapy O
, O
other O
systemic O
radioisotopes O
or O
hemibody O
external O
radiotherapy O
are O
administered O
during O
the O
treatment O
period O
, O
Xofigo O
should O
be O
discontinued O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
is O
discussed O
in O
more O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Seizure B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Posterior B-OSE_Labeled_AE
Reversible I-OSE_Labeled_AE
Encephalopathy I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PRES I-OSE_Labeled_AE
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
( O
> O
= O
10 O
% O
) O
are O
asthenia/fatigue O
, O
back O
pain O
, O
decreased O
appetite O
, O
constipation O
, O
arthralgia O
, O
diarrhea O
, O
hot O
flush O
, O
upper O
respiratory O
tract O
infection O
, O
peripheral O
edema O
, O
dyspnea O
, O
musculoskeletal O
pain O
, O
weight O
decreased O
, O
headache O
, O
hypertension O
, O
and O
dizziness/vertigo O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Astellas O
Pharma O
US O
, O
Inc O
. O
at O
1-800-727-7003 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trial O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Three O
randomized O
clinical O
trials O
enrolled O
patients O
with O
metastatic B-Not_AE_Candidate
prostate I-Not_AE_Candidate
cancer I-Not_AE_Candidate
that O
has O
progressed O
on O
androgen O
deprivation O
therapy O
( O
GnRH O
therapy O
or O
bilateral O
orchiectomy O
) O
, O
a O
disease O
setting O
that O
is O
also O
defined O
as O
metastatic B-Not_AE_Candidate
CRPC I-Not_AE_Candidate
. O

Two O
trials O
were O
placebo-controlled O
( O
Studies O
1 O
and O
2 O
) O
, O
and O
one O
trial O
was O
bicalutamide-controlled O
( O
Study O
3 O
) O
. O

In O
Studies O
1 O
and O
2 O
, O
patients O
received O
XTANDI O
160 O
mg O
or O
placebo O
orally O
once O
daily O
. O

In O
Study O
3 O
, O
patients O
received O
XTANDI O
160 O
mg O
or O
bicalutamide O
50 O
mg O
orally O
once O
daily O
. O

All O
patients O
continued O
androgen O
deprivation O
therapy O
. O

Patients O
were O
allowed O
, O
but O
not O
required O
, O
to O
take O
glucocorticoids O
. O

The O
most O
common O
adverse O
reactions O
( O
> O
= O
10 O
% O
) O
that O
occurred O
more O
commonly O
( O
> O
= O
2 O
% O
over O
placebo O
) O
in O
the O
XTANDI-treated O
patients O
from O
the O
two O
randomized O
placebo-controlled O
clinical O
trials O
were O
asthenia B-OSE_Labeled_AE
/ O
fatigue B-OSE_Labeled_AE
, O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
hot B-OSE_Labeled_AE
flush I-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
and O
dizziness B-OSE_Labeled_AE
/ O
vertigo B-OSE_Labeled_AE
. O

Study O
1 O
: O
XTANDI O
versus O
Placebo O
in O
Metastatic O
CRPC O
Following O
Chemotherapy O
Study O
1 O
enrolled O
1199 O
patients O
with O
metastatic B-Not_AE_Candidate
CRPC I-Not_AE_Candidate
who O
had O
previously O
received O
docetaxel O
. O

The O
median O
duration O
of O
treatment O
was O
8.3 O
months O
with O
XTANDI O
and O
3.0 O
months O
with O
placebo O
. O

During O
the O
trial O
, O
48 O
% O
of O
patients O
on O
the O
XTANDI O
arm O
and O
46 O
% O
of O
patients O
on O
the O
placebo O
arm O
received O
glucocorticoids O
. O

Grade O
3 O
and O
higher O
adverse O
reactions O
were O
reported O
among O
47 O
% O
of O
XTANDI-treated O
patients O
and O
53 O
% O
of O
placebo-treated O
patients O
. O

Discontinuations O
due O
to O
adverse O
events O
were O
reported O
for O
16 O
% O
of O
XTANDI-treated O
patients O
and O
18 O
% O
of O
placebo-treated O
patients O
. O

The O
most O
common O
adverse O
reaction O
leading O
to O
treatment O
discontinuation O
was O
seizure B-OSE_Labeled_AE
, O
which O
occurred O
in O
0.9 O
% O
of O
the O
XTANDI-treated O
patients O
compared O
to O
none O
( O
0 O
% O
) O
of O
the O
placebo-treated O
patients O
. O

Table O
1 O
shows O
adverse O
reactions O
reported O
in O
Study O
1 O
that O
occurred O
at O
a O
> O
= O
2 O
% O
higher O
frequency O
in O
the O
XTANDI O
arm O
compared O
to O
the O
placebo O
arm O
. O

Table O
1 O
. O

Adverse O
Reactions O
in O
Study O
1 O
XTANDI O
N O
= O
800 O
Placebo O
N O
= O
399 O
Grade O
1-4a O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
Grade O
1-4 O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Asthenic B-OSE_Labeled_AE
Conditions I-OSE_Labeled_AE
b O
50.6 O
9.0 O
44.4 O
9.3 O
Peripheral B-OSE_Labeled_AE
Edema I-OSE_Labeled_AE
15.4 O
1.0 O
13.3 O
0.8 O
Musculoskeletal B-NonOSE_AE
And I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
26.4 O
5.3 O
24.3 O
4.0 O
Arthralgia B-OSE_Labeled_AE
20.5 O
2.5 O
17.3 O
1.8 O
Musculoskeletal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
15.0 O
1.3 O
11.5 O
0.3 O
Muscular B-OSE_Labeled_AE
Weakness I-OSE_Labeled_AE
9.8 O
1.5 O
6.8 O
1.8 O
Musculoskeletal B-OSE_Labeled_AE
Stiffness I-OSE_Labeled_AE
2.6 O
0.3 O
0.3 O
0.0 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
21.8 O
1.1 O
17.5 O
0.3 O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
Hot B-OSE_Labeled_AE
Flush I-OSE_Labeled_AE
20.3 O
0.0 O
10.3 O
0.0 O
Hypertension B-OSE_Labeled_AE
6.4 O
2.1 O
2.8 O
1.3 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
12.1 O
0.9 O
5.5 O
0.0 O
Dizziness B-OSE_Labeled_AE
c O
9.5 O
0.5 O
7.5 O
0.5 O
Spinal B-OSE_Labeled_AE
Cord I-OSE_Labeled_AE
Compression I-OSE_Labeled_AE
and O
Cauda B-OSE_Labeled_AE
Equina I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
7.4 O
6.6 O
4.5 O
3.8 O
Paresthesia B-OSE_Labeled_AE
6.6 O
0.0 O
4.5 O
0.0 O
Mental B-OSE_Labeled_AE
Impairment I-OSE_Labeled_AE
Disordersd I-OSE_Labeled_AE
4.3 O
0.3 O
1.8 O
0.0 O
Hypoesthesia B-OSE_Labeled_AE
4.0 O
0.3 O
1.8 O
0.0 O
Infections B-NonOSE_AE
And I-NonOSE_AE
Infestations I-NonOSE_AE
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
e O
10.9 O
0.0 O
6.5 O
0.3 O
Lower B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
And O
Lung O
Infection I-OSE_Labeled_AE
f O
8.5 O
2.4 O
4.8 O
1.3 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
8.8 O
0.0 O
6.0 O
0.5 O
Anxiety B-OSE_Labeled_AE
6.5 O
0.3 O
4.0 O
0.0 O
Renal B-NonOSE_AE
And I-NonOSE_AE
Urinary I-NonOSE_AE
Disorders I-NonOSE_AE
Hematuria B-OSE_Labeled_AE
6.9 O
1.8 O
4.5 O
1.0 O
Pollakiuria B-OSE_Labeled_AE
4.8 O
0.0 O
2.5 O
0.0 O
Injury B-NonOSE_AE
, I-NonOSE_AE
Poisoning I-NonOSE_AE
And I-NonOSE_AE
Procedural I-NonOSE_AE
Complications I-NonOSE_AE
Fall B-OSE_Labeled_AE
4.6 O
0.3 O
1.3 O
0.0 O
Non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
pathologic I-OSE_Labeled_AE
Fractures I-OSE_Labeled_AE
4.0 O
1.4 O
0.8 O
0.3 O
Skin B-NonOSE_AE
And I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Pruritus B-OSE_Labeled_AE
3.8 O
0.0 O
1.3 O
0.0 O
Dry B-OSE_Labeled_AE
Skin I-OSE_Labeled_AE
3.5 O
0.0 O
1.3 O
0.0 O
Respiratory B-NonOSE_AE
Disorders I-NonOSE_AE
Epistaxis B-OSE_Labeled_AE
3.3 O
0.1 O
1.3 O
0.3 O
a O
CTCAE O
v4 O
b O
Includes O
asthenia B-OSE_Labeled_AE
and O
fatigue B-OSE_Labeled_AE
. O

c O
Includes O
dizziness B-OSE_Labeled_AE
and O
vertigo B-OSE_Labeled_AE
. O

d O
Includes O
amnesia B-OSE_Labeled_AE
, O
memory B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
cognitive B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
and O
disturbance B-OSE_Labeled_AE
in I-OSE_Labeled_AE
attention I-OSE_Labeled_AE
. O

e O
Includes O
nasopharyngitis B-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
, O
rhinitis B-OSE_Labeled_AE
, O
pharyngitis B-OSE_Labeled_AE
, O
and O
laryngitis B-OSE_Labeled_AE
. O

f O
Includes O
pneumonia B-OSE_Labeled_AE
, O
lower B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
, O
and O
lung B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
. O

Study O
2 O
: O
XTANDI O
versus O
Placebo O
in O
Chemotherapy-naive O
Metastatic O
CRPC O
Study O
2 O
enrolled O
1717 O
patients O
with O
metastatic B-Not_AE_Candidate
CRPC I-Not_AE_Candidate
who O
had O
not O
received O
prior O
cytotoxic B-NonOSE_AE
chemotherapy I-NonOSE_AE
, O
of O
whom O
1715 O
received O
at O
least O
one O
dose O
of O
study O
drug O
. O

The O
median O
duration O
of O
treatment O
was O
17.5 O
months O
with O
XTANDI O
and O
4.6 O
months O
with O
placebo O
. O

Grade O
3-4 O
adverse O
reactions O
were O
reported O
in O
44 O
% O
of O
XTANDI-treated O
patients O
and O
37 O
% O
of O
placebo-treated O
patients O
. O

Discontinuations O
due O
to O
adverse O
events O
were O
reported O
for O
6 O
% O
of O
XTANDI-treated O
patients O
and O
6 O
% O
of O
placebo-treated O
patients O
. O

The O
most O
common O
adverse O
reaction O
leading O
to O
treatment O
discontinuation O
was O
fatigue B-OSE_Labeled_AE
/ O
asthenia B-OSE_Labeled_AE
, O
which O
occurred O
in O
1 O
% O
of O
patients O
on O
each O
treatment O
arm O
. O

Table O
2 O
includes O
adverse O
reactions O
reported O
in O
Study O
2 O
that O
occurred O
at O
a O
> O
= O
2 O
% O
higher O
frequency O
in O
the O
XTANDI O
arm O
compared O
to O
the O
placebo O
arm O
. O

Table O
2 O
. O

Adverse O
Reactions O
in O
Study O
2 O
XTANDI O
N O
= O
871 O
Placebo O
N O
= O
844 O
Grade O
1-4 O
a O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
Grade O
1-4 O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Asthenic B-OSE_Labeled_AE
Conditions I-OSE_Labeled_AE
b O
46.9 O
3.4 O
33.0 O
2.8 O
Peripheral B-OSE_Labeled_AE
Edema I-OSE_Labeled_AE
11.5 O
0.2 O
8.2 O
0.4 O
Musculoskeletal B-NonOSE_AE
And I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
28.6 O
2.5 O
22.4 O
3.0 O
Arthralgia B-OSE_Labeled_AE
21.4 O
1.6 O
16.1 O
1.1 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Constipation B-OSE_Labeled_AE
23.2 O
0.7 O
17.3 O
0.4 O
Diarrhea B-OSE_Labeled_AE
16.8 O
0.3 O
14.3 O
0.4 O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
Hot B-OSE_Labeled_AE
Flush I-OSE_Labeled_AE
18.0 O
0.1 O
7.8 O
0.0 O
Hypertension B-OSE_Labeled_AE
14.2 O
7.2 O
4.1 O
2.3 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
c O
11.3 O
0.3 O
7.1 O
0.0 O
Headache B-OSE_Labeled_AE
11.0 O
0.2 O
7.0 O
0.4 O
Dysgeusia B-OSE_Labeled_AE
7.6 O
0.1 O
3.7 O
0.0 O
Mental B-OSE_Labeled_AE
Impairment I-OSE_Labeled_AE
Disordersd I-OSE_Labeled_AE
5.7 O
0.0 O
1.3 O
0.1 O
Restless B-OSE_Labeled_AE
Legs I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
2.1 O
0.1 O
0.4 O
0.0 O
Respiratory B-NonOSE_AE
Disorders I-NonOSE_AE
Dyspneae B-OSE_Labeled_AE
11.0 O
0.6 O
8.5 O
0.6 O
Infections B-NonOSE_AE
And I-NonOSE_AE
Infestations I-NonOSE_AE
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
f O
16.4 O
0.0 O
10.5 O
0.0 O
Lower B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
And O
Lung O
Infection I-OSE_Labeled_AE
g O
7.9 O
1.5 O
4.7 O
1.1 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
8.2 O
0.1 O
5.7 O
0.0 O
Renal B-NonOSE_AE
And I-NonOSE_AE
Urinary I-NonOSE_AE
Disorders I-NonOSE_AE
Hematuria B-OSE_Labeled_AE
8.8 O
1.3 O
5.8 O
1.3 O
Injury B-NonOSE_AE
, I-NonOSE_AE
Poisoning I-NonOSE_AE
And I-NonOSE_AE
Procedural I-NonOSE_AE
Complications I-NonOSE_AE
Fall B-OSE_Labeled_AE
12.7 O
1.6 O
5.3 O
0.7 O
Non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Pathological I-OSE_Labeled_AE
Fracture I-OSE_Labeled_AE
8.8 O
2.1 O
3.0 O
1.1 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
18.9 O
0.3 O
16.4 O
0.7 O
Investigations B-NonOSE_AE
Weight B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
12.4 O
0.8 O
8.5 O
0.2 O
Reproductive B-NonOSE_AE
System I-NonOSE_AE
and I-NonOSE_AE
Breast I-NonOSE_AE
disorders I-NonOSE_AE
Gynecomastia B-OSE_Labeled_AE
3.4 O
0.0 O
1.4 O
0.0 O
a O
CTCAE O
v4 O
b O
Includes O
asthenia B-OSE_Labeled_AE
and O
fatigue B-OSE_Labeled_AE
. O

c O
Includes O
dizziness B-OSE_Labeled_AE
and O
vertigo B-OSE_Labeled_AE
. O

d O
Includes O
amnesia B-OSE_Labeled_AE
, O
memory B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
cognitive B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
and O
disturbance B-OSE_Labeled_AE
in I-OSE_Labeled_AE
attention I-OSE_Labeled_AE
. O

e O
Includes O
dyspnea B-OSE_Labeled_AE
, O
exertional B-OSE_Labeled_AE
dyspnea I-OSE_Labeled_AE
, O
and O
dyspnea B-OSE_Labeled_AE
at I-OSE_Labeled_AE
rest I-OSE_Labeled_AE
. O

f O
Includes O
nasopharyngitis B-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
, O
rhinitis B-OSE_Labeled_AE
, O
pharyngitis B-OSE_Labeled_AE
, O
and O
laryngitis B-OSE_Labeled_AE
. O

g O
Includes O
pneumonia B-OSE_Labeled_AE
, O
lower B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
, O
and O
lung B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
. O

Study O
3 O
: O
XTANDI O
versus O
Bicalutamide O
in O
Chemotherapy-naive O
Metastatic O
CRPC O
Study O
3 O
enrolled O
375 O
patients O
with O
metastatic B-Not_AE_Candidate
CRPC I-Not_AE_Candidate
who O
had O
not O
received O
prior O
cytotoxic B-NonOSE_AE
chemotherapy I-NonOSE_AE
, O
of O
whom O
372 O
received O
at O
least O
one O
dose O
of O
study O
drug O
. O

The O
median O
duration O
of O
treatment O
was O
11.6 O
months O
with O
XTANDI O
and O
5.8 O
months O
with O
bicalutamide O
. O

Discontinuations O
with O
an O
adverse O
event O
as O
the O
primary O
reason O
were O
reported O
for O
7.6 O
% O
of O
XTANDI-treated O
patients O
and O
6.3 O
% O
of O
bicalutamide-treated O
patients O
. O

The O
most O
common O
adverse O
reactions O
leading O
to O
treatment O
discontinuation O
were O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
and O
pathological B-OSE_Labeled_AE
fracture I-OSE_Labeled_AE
, O
which O
occurred O
in O
3.8 O
% O
of O
XTANDI-treated O
patients O
for O
each O
event O
and O
in O
2.1 O
% O
and O
1.6 O
% O
of O
bicalutamide-treated O
patients O
, O
respectively O
. O

Table O
3 O
shows O
overall O
and O
common O
adverse O
reactions O
( O
> O
= O
10 O
% O
) O
in O
XTANDI-treated O
patients O
. O

Table O
3 O
. O

Adverse O
Reactions O
in O
Study O
3 O
XTANDI O
( O
N=183 O
) O
Bicalutamide O
( O
N=189 O
) O
Grade O
1-4 O
a O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
Grade O
1-4 O
a O
( O
% O
) O
Grade O
3-4 O
( O
% O
) O
Overall O
94.0 O
38.8 O
94.2 O
37.6 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Asthenic B-OSE_Labeled_AE
Conditions I-OSE_Labeled_AE
b O
31.7 O
1.6 O
22.8 O
1.1 O
Musculoskeletal B-NonOSE_AE
And I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
19.1 O
2.7 O
18.0 O
1.6 O
Musculoskeletal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
c O
16.4 O
1.1 O
14.3 O
0.5 O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
Hot B-OSE_Labeled_AE
Flush I-OSE_Labeled_AE
14.8 O
0 O
11.1 O
0 O
Hypertension B-OSE_Labeled_AE
14.2 O
7.1 O
7.4 O
4.2 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
14.2 O
0 O
17.5 O
0 O
Constipation B-OSE_Labeled_AE
12.6 O
1.1 O
13.2 O
0.5 O
Diarrhea B-OSE_Labeled_AE
11.5 O
0 O
9.0 O
1.1 O
Infections B-NonOSE_AE
And I-NonOSE_AE
Infestations I-NonOSE_AE
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
d O
12.0 O
0 O
6.3 O
0.5 O
Investigational B-NonOSE_AE
Weight B-OSE_Labeled_AE
Loss I-OSE_Labeled_AE
10.9 O
0.5 O
7.9 O
0.5 O
a O
CTCAE O
v O
4b O
Including O
asthenia B-OSE_Labeled_AE
and O
fatigue B-OSE_Labeled_AE
.c O
Including O
musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
and O
pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
d O
Including O
nasopharyngitis B-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
, O
rhinitis B-OSE_Labeled_AE
, O
pharyngitis B-OSE_Labeled_AE
, O
and O
laryngitis B-OSE_Labeled_AE
Laboratory O
Abnormalities O
In O
the O
two O
randomized O
placebo-controlled O
clinical O
trials O
, O
Grade O
1-4 O
neutropenia B-OSE_Labeled_AE
occurred O
in O
15 O
% O
of O
patients O
treated O
with O
XTANDI O
( O
1 O
% O
Grade O
3-4 O
) O
and O
in O
6 O
% O
of O
patients O
treated O
with O
placebo O
( O
0.5 O
% O
Grade O
3-4 O
) O
. O

The O
incidence O
of O
Grade O
1-4 O
thrombocytopenia B-OSE_Labeled_AE
was O
6 O
% O
of O
patients O
treated O
with O
XTANDI O
( O
0.3 O
% O
Grade O
3-4 O
) O
and O
5 O
% O
of O
patients O
treated O
with O
placebo O
( O
0.5 O
% O
Grade O
3-4 O
) O
. O

Grade O
1-4 O
elevations B-NonOSE_AE
in I-NonOSE_AE
ALT I-NonOSE_AE
occurred O
in O
10 O
% O
of O
patients O
treated O
with O
XTANDI O
( O
0.2 O
% O
Grade O
3-4 O
) O
and O
16 O
% O
of O
patients O
treated O
with O
placebo O
( O
0.2 O
% O
Grade O
3-4 O
) O
. O

Grade O
1-4 O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
occurred O
in O
3 O
% O
of O
patients O
treated O
with O
XTANDI O
( O
0.1 O
% O
Grade O
3-4 O
) O
and O
2 O
% O
of O
patients O
treated O
with O
placebo O
( O
no O
Grade O
3-4 O
) O
. O

Infections O
In O
Study O
1 O
, O
1 O
% O
of O
patients O
treated O
with O
XTANDI O
compared O
to O
0.3 O
% O
of O
patients O
treated O
with O
placebo O
died B-NonOSE_AE
from O
infections B-NonOSE_AE
or O
sepsis B-NonOSE_AE
. O

In O
Study O
2 O
, O
1 O
patient O
in O
each O
treatment O
group O
( O
0.1 O
% O
) O
had O
an O
infection B-NonOSE_AE
resulting O
in O
death B-NonOSE_AE
. O

Falls O
and O
Fall-related O
Injuries O
In O
the O
two O
randomized O
placebo-controlled O
clinical O
trials O
, O
falls B-OSE_Labeled_AE
including O
fall B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
injuries I-OSE_Labeled_AE
, O
occurred O
in O
9 O
% O
of O
patients O
treated O
with O
XTANDI O
compared O
to O
4 O
% O
of O
patients O
treated O
with O
placebo O
. O

Falls B-NonOSE_AE
were O
not O
associated O
with O
loss B-NonOSE_AE
of I-NonOSE_AE
consciousness I-NonOSE_AE
or O
seizure B-NonOSE_AE
. O

Fall B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
injuries I-OSE_Labeled_AE
were O
more O
severe O
in O
patients O
treated O
with O
XTANDI O
and O
included O
non-pathologic O
fractures O
, O
joint O
injuries O
, O
and O
hematomas O
. O

Hypertension O
In O
the O
two O
randomized O
placebo-controlled O
trials O
, O
hypertension B-OSE_Labeled_AE
was O
reported O
in O
11 O
% O
of O
patients O
receiving O
XTANDI O
and O
4 O
% O
of O
patients O
receiving O
placebo O
. O

No O
patients O
experienced O
hypertensive B-NonOSE_AE
crisis I-NonOSE_AE
. O

Medical O
history O
of O
hypertension B-Not_AE_Candidate
was O
balanced O
between O
arms O
. O

Hypertension B-OSE_Labeled_AE
led O
to O
study O
discontinuation O
in O
< O
1 O
% O
of O
patients O
in O
each O
arm O
. O

6.2 O
Post-Marketing O
Experience O
The O
following O
additional O
adverse O
reactions O
have O
been O
identified O
during O
post O
approval O
use O
of O
XTANDI O
. O

Because O
these O
reactions O
were O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
the O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
: O
hypersensitivity B-OSE_Labeled_AE
( O
tongue B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
lip B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
and O
pharyngeal B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
) O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
: O
vomiting B-OSE_Labeled_AE
Neurological B-NonOSE_AE
Disorders I-NonOSE_AE
: O
posterior B-OSE_Labeled_AE
reversible I-OSE_Labeled_AE
encephalopathy I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PRES I-OSE_Labeled_AE
) O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
rash B-OSE_Labeled_AE

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Seizure O
occurred O
in O
0.5 O
% O
of O
patients O
receiving O
XTANDI O
. O

In O
patients O
with O
predisposing O
factors O
, O
seizures O
were O
reported O
in O
2.2 O
% O
of O
patients O
. O

Permanently O
discontinue O
XTANDI O
in O
patients O
who O
develop O
a O
seizure O
during O
treatment O
. O

( O
5.1 O
) O
* O
Posterior O
reversible O
encephalopathy O
syndrome O
( O
PRES O
) O
: O
Discontinue O
XTANDI O
. O

( O
5.2 O
) O
5.1 O
Seizure O
Seizure B-OSE_Labeled_AE
occurred O
in O
0.5 O
% O
of O
patients O
receiving O
XTANDI O
in O
clinical O
studies O
. O

In O
these O
trials O
patients O
with O
predisposing O
factors O
for O
seizure B-NonOSE_AE
were O
generally O
excluded O
. O

Seizure B-OSE_Labeled_AE
occurred O
from O
31 O
to O
603 O
days O
after O
initiation O
of O
XTANDI O
. O

Patients O
experiencing O
seizure B-NonOSE_AE
were O
permanently O
discontinued O
from O
therapy O
and O
all O
seizure B-NonOSE_AE
events O
resolved O
. O

In O
a O
single-arm O
trial O
designed O
to O
assess O
the O
risk O
of O
seizure B-NonOSE_AE
in O
patients O
with O
pre-disposing O
factors O
for O
seizure B-NonOSE_AE
, O
8 O
of O
366 O
( O
2.2 O
% O
) O
XTANDI-treated O
patients O
experienced O
a O
seizure B-OSE_Labeled_AE
. O

Three O
of O
the O
8 O
patients O
experienced O
a O
second O
seizure B-OSE_Labeled_AE
during O
continued O
treatment O
with O
XTANDI O
after O
their O
first O
seizure B-NonOSE_AE
resolved O
. O

It O
is O
unknown O
whether O
anti-epileptic O
medications O
will O
prevent O
seizures B-NonOSE_AE
with O
XTANDI O
. O

Patients O
in O
the O
study O
had O
one O
or O
more O
of O
the O
following O
pre-disposing O
factors O
: O
the O
use O
of O
medications O
that O
may O
lower B-NonOSE_AE
the I-NonOSE_AE
seizure I-NonOSE_AE
threshold I-NonOSE_AE
( O
~ O
54 O
% O
) O
, O
history O
of O
traumatic B-Not_AE_Candidate
brain I-Not_AE_Candidate
or I-Not_AE_Candidate
head I-Not_AE_Candidate
injury I-Not_AE_Candidate
( O
~ O
28 O
% O
) O
, O
history O
of O
cerebrovascular B-Not_AE_Candidate
accident I-Not_AE_Candidate
or O
transient B-Not_AE_Candidate
ischemic I-Not_AE_Candidate
attack I-Not_AE_Candidate
( O
~ O
24 O
% O
) O
, O
and O
Alzheimer B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
meningioma B-Not_AE_Candidate
, O
or O
leptomeningeal B-Not_AE_Candidate
disease I-Not_AE_Candidate
from O
prostate B-Not_AE_Candidate
cancer I-Not_AE_Candidate
, O
unexplained O
loss B-Not_AE_Candidate
of I-Not_AE_Candidate
consciousness I-Not_AE_Candidate
within O
the O
last O
12 O
months O
, O
past O
history O
of O
seizure B-Not_AE_Candidate
, O
presence O
of O
a O
space B-Not_AE_Candidate
occupying I-Not_AE_Candidate
lesion I-Not_AE_Candidate
of I-Not_AE_Candidate
the I-Not_AE_Candidate
brain I-Not_AE_Candidate
, O
history O
of O
arteriovenous B-Not_AE_Candidate
malformation I-Not_AE_Candidate
, O
or O
history O
of O
brain B-Not_AE_Candidate
infection I-Not_AE_Candidate
( O
all O
< O
5 O
% O
) O
. O

Approximately O
17 O
% O
of O
patients O
had O
more O
than O
one O
risk O
factor O
. O

Advise O
patients O
of O
the O
risk O
of O
developing O
a O
seizure B-NonOSE_AE
while O
receiving O
XTANDI O
and O
of O
engaging O
in O
any O
activity O
where O
sudden O
loss B-NonOSE_AE
of I-NonOSE_AE
consciousness I-NonOSE_AE
could O
cause O
serious O
harm O
to O
themselves O
or O
others O
. O

Permanently O
discontinue O
XTANDI O
in O
patients O
who O
develop O
a O
seizure B-NonOSE_AE
during O
treatment O
. O

5.2 O
Posterior O
Reversible O
Encephalopathy O
Syndrome O
( O
PRES O
) O
There O
have O
been O
reports O
of O
posterior B-OSE_Labeled_AE
reversible I-OSE_Labeled_AE
encephalopathy I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PRES I-OSE_Labeled_AE
) O
in O
patients O
receiving O
XTANDI O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

PRES B-NonOSE_AE
is O
a O
neurological B-NonOSE_AE
disorder I-NonOSE_AE
which O
can O
present O
with O
rapidly O
evolving O
symptoms O
including O
seizure B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
lethargy B-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
blindness B-NonOSE_AE
, O
and O
other O
visual B-NonOSE_AE
and O
neurological O
disturbances I-NonOSE_AE
, O
with O
or O
without O
associated O
hypertension B-NonOSE_AE
. O

A O
diagnosis O
of O
PRES B-NonOSE_AE
requires O
confirmation O
by O
brain O
imaging O
, O
preferably O
magnetic O
resonance O
imaging O
( O
MRI O
) O
. O

Discontinue O
XTANDI O
in O
patients O
who O
develop O
PRES B-NonOSE_AE
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
elsewhere O
in O
the O
labeling O
: O
* O
Hemorrhage B-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Gastrointestinal B-OSE_Labeled_AE
Perforation I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Compromised B-OSE_Labeled_AE
Wound I-OSE_Labeled_AE
Healing I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Fistula B-OSE_Labeled_AE
Formation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Hypertension B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Arterial B-OSE_Labeled_AE
Thromboembolic I-OSE_Labeled_AE
Events I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Proteinuria B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Neutropenia B-OSE_Labeled_AE
and O
Neutropenic B-NonOSE_AE
Complications I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Diarrhea B-OSE_Labeled_AE
and O
Dehydration B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Reversible B-OSE_Labeled_AE
Posterior I-OSE_Labeled_AE
Leukoencephalopathy I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
RPLS I-OSE_Labeled_AE
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
all O
grades O
, O
> O
=20 O
% O
incidence O
and O
at O
least O
2 O
% O
greater O
incidence O
for O
the O
ZALTRAP/FOLFIRI O
regimen O
) O
were O
leukopenia O
, O
diarrhea O
, O
neutropenia O
, O
proteinuria O
, O
AST O
increased O
, O
stomatitis O
, O
fatigue O
, O
thrombocytopenia O
, O
ALT O
increased O
, O
hypertension O
, O
weight O
decreased O
, O
decreased O
appetite O
, O
epistaxis O
, O
abdominal O
pain O
, O
dysphonia O
, O
serum O
creatinine O
increased O
, O
and O
headache O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
sanofi-aventis O
at O
1-800-633-1610 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trial O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
varying O
designs O
and O
in O
different O
patient O
populations O
, O
the O
adverse O
reaction O
rates O
reported O
in O
one O
clinical O
trial O
may O
not O
be O
easily O
compared O
to O
those O
rates O
reported O
in O
another O
clinical O
trial O
, O
and O
may O
not O
reflect O
the O
rates O
actually O
observed O
in O
clinical O
practice O
. O

The O
safety O
of O
ZALTRAP O
in O
combination O
with O
FOLFIRI O
was O
evaluated O
in O
1216 O
previously O
treated O
patients O
with O
metastatic B-Not_AE_Candidate
colorectal I-Not_AE_Candidate
cancer I-Not_AE_Candidate
( O
Study O
1 O
) O
who O
were O
treated O
with O
ZALTRAP O
4 O
mg O
per O
kg O
intravenous O
( O
N=611 O
) O
or O
placebo O
( O
N=605 O
) O
every O
two O
weeks O
( O
one O
cycle O
) O
in O
a O
randomized O
( O
1:1 O
) O
, O
double-blind O
, O
placebo-controlled O
Phase O
3 O
study O
. O

Patients O
received O
a O
median O
of O
9 O
cycles O
of O
ZALTRAP/FOLFIRI O
or O
8 O
cycles O
of O
placebo/FOLFIRI O
. O

The O
most O
common O
adverse O
reactions O
( O
all O
grades O
, O
> O
=20 O
% O
incidence O
) O
reported O
at O
a O
higher O
incidence O
( O
2 O
% O
or O
greater O
between-arm O
difference O
) O
in O
the O
ZALTRAP/FOLFIRI O
arm O
, O
in O
order O
of O
decreasing O
frequency O
, O
were O
leukopenia B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
proteinuria B-OSE_Labeled_AE
, O
AST B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
fatigue O
, O
thrombocytopenia B-OSE_Labeled_AE
, O
ALT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
dysphonia B-OSE_Labeled_AE
, O
serum B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
and O
headache B-OSE_Labeled_AE
( O
see O
Table O
1 O
) O
. O

The O
most O
common O
Grade O
3-4 O
adverse O
reactions O
( O
> O
=5 O
% O
) O
reported O
at O
a O
higher O
incidence O
( O
2 O
% O
or O
greater O
between-arm O
difference O
) O
in O
the O
ZALTRAP/FOLFIRI O
arm O
, O
in O
order O
of O
decreasing O
frequency O
, O
were O
neutropenia B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
proteinuria B-OSE_Labeled_AE
, O
and O
asthenia B-OSE_Labeled_AE
( O
see O
Table O
1 O
) O
. O

The O
most O
frequent O
adverse O
reactions O
leading O
to O
permanent O
discontinuation O
in O
> O
=1 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
regimen O
were O
asthenia B-OSE_Labeled_AE
/ O
fatigue B-OSE_Labeled_AE
, O
infections B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
and O
proteinuria B-OSE_Labeled_AE
. O

The O
ZALTRAP O
dose O
was O
reduced O
and/or O
omitted O
in O
17 O
% O
of O
patients O
compared O
to O
placebo-dose O
modification O
in O
5 O
% O
of O
patients O
. O

Cycle O
delays O
> O
7 O
days O
occurred O
in O
60 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
compared O
with O
43 O
% O
of O
patients O
treated O
with O
placebo/FOLFIRI O
. O

The O
most O
common O
adverse O
reactions O
and O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
during O
study O
treatment O
in O
Study O
1 O
where O
the O
incidence O
was O
> O
=5 O
% O
( O
all O
grades O
) O
in O
patients O
receiving O
ZALTRAP O
in O
combination O
with O
FOLFIRI O
and O
which O
occurred O
at O
> O
=2 O
% O
higher O
frequency O
in O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
compared O
to O
placebo/FOLFIRI O
are O
shown O
in O
Table O
1 O
. O

Table O
1 O
- O
Selected O
Adverse O
Reactions O
and O
Laboratory O
Findings O
in O
Study O
1 O
: O
Primary O
System O
Organ O
Class O
Preferred O
Term O
( O
% O
) O
Placebo/FOLFIRI O
( O
N=605 O
) O
ZALTRAP/FOLFIRI O
( O
N=611 O
) O
All O
grades O
Grades O
3-4 O
All O
grades O
Grades O
3-4 O
Note O
: O
Adverse O
Reactions O
are O
reported O
using O
MedDRA O
version O
MEDDRA13.1 O
and O
graded O
using O
NCI O
CTC O
version O
3.0 O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
6 O
% O
0.8 O
% O
9 O
% O
0.8 O
% O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Leukopenia B-OSE_Labeled_AE
72 O
% O
12 O
% O
78 O
% O
16 O
% O
Neutropenia B-OSE_Labeled_AE
57 O
% O
30 O
% O
67 O
% O
37 O
% O
Thrombocytopenia B-OSE_Labeled_AE
35 O
% O
2 O
% O
48 O
% O
3 O
% O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
24 O
% O
2 O
% O
32 O
% O
3 O
% O
Dehydration B-OSE_Labeled_AE
3 O
% O
1 O
% O
9 O
% O
4 O
% O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
9 O
% O
0.3 O
% O
22 O
% O
2 O
% O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
11 O
% O
1.5 O
% O
41 O
% O
19 O
% O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Epistaxis B-OSE_Labeled_AE
7 O
% O
0 O
28 O
% O
0.2 O
% O
Dysphonia B-OSE_Labeled_AE
3 O
% O
0 O
25 O
% O
0.5 O
% O
Dyspnea B-OSE_Labeled_AE
9 O
% O
0.8 O
% O
12 O
% O
0.8 O
% O
Oropharyngeal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
3 O
% O
0 O
8 O
% O
0.2 O
% O
Rhinorrhea B-OSE_Labeled_AE
2 O
% O
0 O
6 O
% O
0 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
57 O
% O
8 O
% O
69 O
% O
19 O
% O
Stomatitis B-OSE_Labeled_AE
33 O
% O
5 O
% O
50 O
% O
13 O
% O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
24 O
% O
2 O
% O
27 O
% O
4 O
% O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
Upper I-OSE_Labeled_AE
8 O
% O
1 O
% O
11 O
% O
1 O
% O
Hemorrhoids B-OSE_Labeled_AE
2 O
% O
0 O
6 O
% O
0 O
Rectal B-OSE_Labeled_AE
Hemorrhage I-OSE_Labeled_AE
2 O
% O
0.5 O
% O
5 O
% O
0.7 O
% O
Proctalgia B-OSE_Labeled_AE
2 O
% O
0.3 O
% O
5 O
% O
0.3 O
% O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Plantar I-OSE_Labeled_AE
Erythrodysesthesia I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
4 O
% O
0.5 O
% O
11 O
% O
3 O
% O
Skin B-OSE_Labeled_AE
Hyperpigmentation I-OSE_Labeled_AE
3 O
% O
0 O
8 O
% O
0 O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
Proteinuria B-OSE_Labeled_AE
41 O
% O
1 O
% O
62 O
% O
8 O
% O
Serum B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
19 O
% O
0.5 O
% O
23 O
% O
0 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
39 O
% O
8 O
% O
48 O
% O
13 O
% O
Asthenia B-OSE_Labeled_AE
13 O
% O
3 O
% O
18 O
% O
5 O
% O
Investigations B-NonOSE_AE
AST B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
54 O
% O
2 O
% O
62 O
% O
3 O
% O
ALT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
39 O
% O
2 O
% O
50 O
% O
3 O
% O
Weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
14 O
% O
0.8 O
% O
32 O
% O
3 O
% O
Infections B-OSE_Labeled_AE
occurred O
at O
a O
higher O
frequency O
in O
patients O
receiving O
ZALTRAP/FOLFIRI O
( O
46 O
% O
, O
all O
grades O
; O
12 O
% O
, O
Grade O
3-4 O
) O
than O
in O
patients O
receiving O
placebo/FOLFIRI O
( O
33 O
% O
, O
all O
grades O
; O
7 O
% O
, O
Grade O
3-4 O
) O
, O
including O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
catheter B-OSE_Labeled_AE
site I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
and O
tooth B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
. O

In O
patients O
with O
mCRC B-Not_AE_Candidate
, O
severe O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
have O
been O
reported O
with O
ZALTRAP/FOLFIRI O
( O
0.3 O
% O
) O
and O
placebo/FOLFIRI O
( O
0.5 O
% O
) O
. O

In O
patients O
with O
mCRC B-Not_AE_Candidate
, O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
( I-OSE_Labeled_AE
VTE I-OSE_Labeled_AE
) O
, O
consisting O
primarily O
of O
deep B-OSE_Labeled_AE
venous I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
and O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
occurred O
in O
9 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
and O
7 O
% O
of O
patients O
treated O
with O
placebo/FOLFIRI O
. O

Grade O
3-4 O
VTE B-OSE_Labeled_AE
occurred O
in O
8 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
and O
in O
6 O
% O
of O
patients O
treated O
with O
placebo/FOLFIRI O
. O

Pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
occurred O
in O
5 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
and O
3.4 O
% O
of O
patients O
treated O
with O
placebo/FOLFIRI O
. O

6.2 O
Immunogenicity O
As O
with O
all O
therapeutic O
proteins O
, O
there O
is O
a O
potential O
for O
immunogenicity B-OSE_Labeled_AE
. O

In O
patients O
with O
various O
cancers B-Not_AE_Candidate
across O
15 O
studies O
, O
1.4 O
% O
( O
41/2862 O
) O
of O
patients O
tested O
positive B-NonOSE_AE
for I-NonOSE_AE
anti I-NonOSE_AE
- I-NonOSE_AE
product I-NonOSE_AE
antibody I-NonOSE_AE
( I-NonOSE_AE
APA I-NonOSE_AE
) O
at O
baseline O
. O

The O
incidence O
of O
APA B-OSE_Labeled_AE
development I-OSE_Labeled_AE
was O
3.1 O
% O
( O
53/1687 O
) O
in O
patients O
receiving O
intravenous O
ziv-aflibercept O
and O
1.7 O
% O
( O
19/1134 O
) O
in O
patients O
receiving O
placebo O
. O

Among O
patients O
who O
tested O
positive B-OSE_Labeled_AE
for I-OSE_Labeled_AE
APA I-OSE_Labeled_AE
and O
had O
sufficient O
samples O
for O
further O
testing O
, O
neutralizing B-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
were I-OSE_Labeled_AE
detected I-OSE_Labeled_AE
in O
17 O
of O
48 O
ziv-aflibercept-treated O
patients O
and O
in O
2 O
of O
40 O
patients O
receiving O
placebo O
. O

The O
mean O
free O
ziv-aflibercept O
trough O
concentrations O
were O
lower O
in O
patients O
with O
positive B-NonOSE_AE
neutralizing I-NonOSE_AE
antibodies I-NonOSE_AE
than O
in O
the O
overall O
population O
. O

The O
impact O
of O
neutralizing B-NonOSE_AE
antibodies I-NonOSE_AE
on O
efficacy O
and O
safety O
could O
not O
be O
assessed O
based O
on O
limited O
available O
data O
. O

Immunogenicity B-NonOSE_AE
data O
are O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
. O

Additionally O
, O
the O
observed O
incidence O
of O
antibody B-NonOSE_AE
positivity I-NonOSE_AE
in O
an O
assay O
may O
be O
influenced O
by O
several O
factors O
, O
including O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
ZALTRAP I-NonOSE_AE
with O
the O
incidence O
of O
antibodies B-NonOSE_AE
to O
other O
products O
may O
be O
misleading O
. O

BOXED O
WARNING O
: O
WARNING O
: O
HEMORRHAGE O
, O
GASTROINTESTINAL O
PERFORATION O
, O
COMPROMISED O
WOUND O
HEALING O
WARNING O
: O
HEMORRHAGE O
, O
GASTROINTESTINAL O
PERFORATION O
, O
COMPROMISED O
WOUND O
HEALING O
Hemorrhage B-NonOSE_AE
: O
Severe O
and O
sometimes O
fatal B-NonOSE_AE
hemorrhage B-OSE_Labeled_AE
, O
including O
gastrointestinal B-OSE_Labeled_AE
( O
GI O
) O
hemorrhage I-OSE_Labeled_AE
, O
has O
been O
reported O
in O
the O
patients O
who O
have O
received O
ZALTRAP O
in O
combination O
with O
FOLFIRI O
. O

Monitor O
patients O
for O
signs O
and O
symptoms O
of O
GI B-NonOSE_AE
bleeding I-NonOSE_AE
and O
other O
severe O
bleeding B-NonOSE_AE
. O

Do O
not O
administer O
ZALTRAP O
to O
patients O
with O
severe O
hemorrhage B-Not_AE_Candidate
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Gastrointestinal B-NonOSE_AE
Perforation I-NonOSE_AE
: O
Gastrointestinal B-OSE_Labeled_AE
( I-OSE_Labeled_AE
GI I-OSE_Labeled_AE
) I-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
including O
fatal B-NonOSE_AE
GI B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
can O
occur O
in O
patients O
receiving O
ZALTRAP O
. O

Discontinue O
ZALTRAP O
therapy O
in O
patients O
who O
experience O
GI B-NonOSE_AE
perforation I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
, O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Compromised B-NonOSE_AE
Wound I-NonOSE_AE
Healing I-NonOSE_AE
: O
Severe O
compromised B-OSE_Labeled_AE
wound I-OSE_Labeled_AE
healing I-OSE_Labeled_AE
can O
occur O
in O
patients O
receiving O
ZALTRAP/FOLFIRI O
. O

Discontinue O
ZALTRAP O
in O
patients O
with O
compromised B-NonOSE_AE
wound I-NonOSE_AE
healing I-NonOSE_AE
. O

Suspend O
ZALTRAP O
for O
at O
least O
4 O
weeks O
prior O
to O
elective O
surgery O
, O
and O
do O
not O
resume O
ZALTRAP O
for O
at O
least O
4 O
weeks O
following O
major O
surgery O
and O
until O
the O
surgical O
wound O
is O
fully O
healed O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
, O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
HEMORRHAGE O
, O
GASTROINTESTINAL O
PERFORATION O
, O
COMPROMISED O
WOUND O
HEALING O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Hemorrhage O
: O
Severe O
and O
sometimes O
fatal O
hemorrhage O
, O
including O
gastrointestinal O
( O
GI O
) O
hemorrhage O
, O
has O
been O
reported O
in O
patients O
who O
have O
received O
ZALTRAP O
. O

Do O
not O
administer O
ZALTRAP O
to O
patients O
with O
severe O
hemorrhage O
. O

( O
5.1 O
) O
* O
Gastrointestinal O
Perforation O
: O
Discontinue O
ZALTRAP O
therapy O
in O
patients O
who O
experience O
GI O
perforation O
. O

( O
5.2 O
) O
* O
Compromised O
Wound O
Healing O
: O
Discontinue O
ZALTRAP O
in O
patients O
with O
compromised O
wound O
healing O
. O

Suspend O
ZALTRAP O
for O
at O
least O
4 O
weeks O
prior O
to O
elective O
surgery O
, O
and O
do O
not O
resume O
for O
at O
least O
4 O
weeks O
following O
major O
surgery O
and O
until O
the O
surgical O
wound O
is O
fully O
healed O
. O

( O
5.3 O
) O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
Adverse O
reactions O
, O
sometimes O
severe O
and O
life-threatening O
or O
fatal O
, O
have O
been O
seen O
in O
clinical O
trials O
with O
ZALTRAP O
, O
including O
: O
* O
Fistula O
Formation O
: O
Discontinue O
ZALTRAP O
if O
fistula O
occurs O
. O

( O
2.2 O
, O
5.4 O
) O
* O
Hypertension O
: O
Monitor O
blood O
pressure O
and O
treat O
hypertension O
. O

Temporarily O
suspend O
ZALTRAP O
if O
hypertension O
is O
not O
controlled O
. O

Discontinue O
ZALTRAP O
if O
hypertensive O
crisis O
develops O
. O

( O
2.2 O
, O
5.5 O
) O
* O
Arterial O
Thromboembolic O
Events O
( O
ATE O
) O
( O
e.g. O
, O
transient O
ischemic O
attacks O
, O
cerebrovascular O
accident O
, O
angina O
pectoris O
) O
: O
Discontinue O
ZALTRAP O
if O
ATE O
develops O
. O

( O
5.6 O
) O
* O
Proteinuria O
: O
Monitor O
urine O
protein O
. O

Suspend O
ZALTRAP O
when O
proteinuria O
> O
= O
2 O
grams O
per O
24 O
hours O
. O

Discontinue O
ZALTRAP O
if O
nephrotic O
syndrome O
or O
thrombotic O
microangiopathy O
( O
TMA O
) O
develops O
. O

( O
2.2 O
, O
5.7 O
) O
* O
Neutropenia O
and O
Neutropenic O
Complications O
: O
Delay O
administration O
of O
ZALTRAP/FOLFIRI O
until O
neutrophil O
count O
is O
> O
= O
1.5 O
* O
10 O
9 O
/L O
. O

( O
5.8 O
) O
* O
Diarrhea O
and O
Dehydration O
: O
Incidence O
of O
severe O
diarrhea O
and O
dehydration O
is O
increased O
. O

Monitor O
elderly O
patients O
more O
closely O
. O

( O
5.9 O
, O
8.5 O
) O
* O
Reversible O
Posterior O
Leukoencephalopathy O
Syndrome O
( O
RPLS O
) O
: O
Discontinue O
ZALTRAP O
. O

( O
5.10 O
) O
5.1 O
Hemorrhage O
Patients O
treated O
with O
ZALTRAP O
have O
an O
increased O
risk O
of O
hemorrhage B-OSE_Labeled_AE
, O
including O
severe O
and O
sometimes O
fatal B-NonOSE_AE
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
. O

In O
patients O
with O
mCRC B-Not_AE_Candidate
, O
bleeding B-OSE_Labeled_AE
/ O
hemorrhage B-OSE_Labeled_AE
( O
all O
grades O
) O
were O
reported O
in O
38 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
compared O
to O
19 O
% O
of O
patients O
treated O
with O
placebo/FOLFIRI O
. O

Grade O
3-4 O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
including O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
hematuria B-OSE_Labeled_AE
, O
and O
post B-OSE_Labeled_AE
- I-OSE_Labeled_AE
procedural I-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
were O
reported O
in O
3 O
% O
of O
patients O
receiving O
ZALTRAP/FOLFIRI O
compared O
with O
1 O
% O
of O
patients O
receiving O
placebo/FOLFIRI O
. O

Severe O
intracranial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
and O
pulmonary B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
/ O
hemoptysis B-OSE_Labeled_AE
including O
fatal B-NonOSE_AE
events O
have O
also O
occurred O
in O
patients O
receiving O
ZALTRAP O
. O

Monitor O
patients O
for O
signs O
and O
symptoms O
of O
bleeding B-NonOSE_AE
. O

Do O
not O
initiate O
ZALTRAP O
in O
patients O
with O
severe O
hemorrhage B-Not_AE_Candidate
. O

Discontinue O
ZALTRAP O
in O
patients O
who O
develop O
severe O
hemorrhage B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.2 O
Gastrointestinal O
Perforation O
Gastrointestinal B-OSE_Labeled_AE
( I-OSE_Labeled_AE
GI I-OSE_Labeled_AE
) I-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
including O
fatal B-NonOSE_AE
GI B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
can O
occur O
in O
patients O
receiving O
ZALTRAP O
. O

Across O
three O
Phase O
3 O
placebo-controlled O
clinical O
studies O
( O
colorectal B-Not_AE_Candidate
, O
pancreatic O
, O
and O
lung O
cancer I-Not_AE_Candidate
populations O
) O
, O
the O
incidence O
of O
GI B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
( O
all O
grades O
) O
was O
0.8 O
% O
for O
patients O
treated O
with O
ZALTRAP O
and O
0.3 O
% O
for O
patients O
treated O
with O
placebo O
. O

Grade O
3-4 O
GI B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
events O
occurred O
in O
0.8 O
% O
of O
patients O
treated O
with O
ZALTRAP O
and O
0.2 O
% O
of O
patients O
treated O
with O
placebo O
. O

Monitor O
patients O
for O
signs O
and O
symptoms O
of O
GI B-NonOSE_AE
perforation I-NonOSE_AE
. O

Discontinue O
ZALTRAP O
therapy O
in O
patients O
who O
experience O
GI B-NonOSE_AE
perforation I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.3 O
Compromised O
Wound O
Healing O
ZALTRAP O
impairs B-NonOSE_AE
wound I-NonOSE_AE
healing I-NonOSE_AE
in O
animal O
models O
[ O
see O
Nonclinical O
Toxicology O
( O
13.2 O
) O
] O
. O

Grade O
3 O
compromised B-OSE_Labeled_AE
wound I-OSE_Labeled_AE
healing I-OSE_Labeled_AE
was O
reported O
in O
2 O
patients O
( O
0.3 O
% O
) O
treated O
with O
ZALTRAP/FOLFIRI O
regimen O
and O
in O
none O
of O
the O
patients O
treated O
with O
placebo/FOLFIRI O
regimen O
. O

Suspend O
ZALTRAP O
for O
at O
least O
4 O
weeks O
prior O
to O
elective O
surgery O
. O

Do O
not O
resume O
ZALTRAP O
for O
at O
least O
4 O
weeks O
following O
major O
surgery O
and O
until O
the O
surgical O
wound O
is O
fully O
healed O
. O

For O
minor O
surgery O
such O
as O
central O
venous O
access O
port O
placement O
, O
biopsy O
, O
and O
tooth O
extraction O
, O
ZALTRAP O
may O
be O
initiated/resumed O
once O
the O
surgical O
wound O
is O
fully O
healed O
. O

Discontinue O
ZALTRAP O
in O
patients O
with O
compromised B-NonOSE_AE
wound I-NonOSE_AE
healing I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.4 O
Fistula O
Formation O
Fistula B-OSE_Labeled_AE
formation I-OSE_Labeled_AE
involving O
gastrointestinal I-OSE_Labeled_AE
and O
non-gastrointestinal O
sites O
occurs O
at O
a O
higher O
incidence O
in O
patients O
treated O
with O
ZALTRAP O
. O

In O
patients O
with O
mCRC B-Not_AE_Candidate
, O
fistulas B-OSE_Labeled_AE
( I-OSE_Labeled_AE
anal I-OSE_Labeled_AE
, O
enterovesical O
, O
enterocutaneous O
, O
colovaginal O
, O
intestinal O
sites O
) O
were O
reported O
in O
9 O
of O
611 O
patients O
( O
1.5 O
% O
) O
treated O
with O
ZALTRAP/FOLFIRI O
regimen O
and O
3 O
of O
605 O
patients O
( O
0.5 O
% O
) O
treated O
with O
placebo/FOLFIRI O
regimen O
. O

Grade O
3 O
GI B-OSE_Labeled_AE
fistula I-OSE_Labeled_AE
formation O
occurred O
in O
2 O
patients O
treated O
with O
ZALTRAP O
( O
0.3 O
% O
) O
and O
in O
1 O
placebo-treated O
patient O
( O
0.2 O
% O
) O
. O

Discontinue O
ZALTRAP O
therapy O
in O
patients O
who O
develop O
fistula B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.5 O
Hypertension O
ZALTRAP O
increases O
the O
risk O
of O
Grade O
3-4 O
hypertension B-OSE_Labeled_AE
. O

There O
is O
no O
clinical O
trial O
experience O
administering O
ZALTRAP O
to O
patients O
with O
NYHA B-Not_AE_Candidate
class I-Not_AE_Candidate
III I-Not_AE_Candidate
or I-Not_AE_Candidate
IV I-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
. O

In O
patients O
with O
mCRC B-Not_AE_Candidate
, O
Grade O
3 O
hypertension B-OSE_Labeled_AE
( O
defined O
as O
requiring O
adjustment O
in O
existing O
anti B-NonOSE_AE
- I-NonOSE_AE
hypertensive I-NonOSE_AE
therapy I-NonOSE_AE
or O
treatment O
with O
more O
than O
one O
drug O
) O
was O
reported O
in O
1.5 O
% O
of O
patients O
treated O
with O
placebo/FOLFIRI O
and O
19 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
. O

Grade O
4 O
hypertension B-OSE_Labeled_AE
( O
hypertensive B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
) O
was O
reported O
in O
1 O
patient O
( O
0.2 O
% O
) O
treated O
with O
ZALTRAP/FOLFIRI O
. O

Among O
those O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
developing O
Grade O
3-4 O
hypertension B-OSE_Labeled_AE
, O
54 O
% O
had O
onset O
during O
the O
first O
two O
cycles O
of O
treatment O
. O

Monitor O
blood O
pressure O
every O
two O
weeks O
or O
more O
frequently O
as O
clinically O
indicated O
during O
treatment O
with O
ZALTRAP O
. O

Treat O
with O
appropriate O
anti B-NonOSE_AE
- I-NonOSE_AE
hypertensive I-NonOSE_AE
therapy I-NonOSE_AE
and O
continue O
monitoring O
blood O
pressure O
regularly O
. O

Temporarily O
suspend O
ZALTRAP O
in O
patients O
with O
uncontrolled B-NonOSE_AE
hypertension I-NonOSE_AE
until O
controlled O
, O
and O
permanently O
reduce O
ZALTRAP O
dose O
to O
2 O
mg O
per O
kg O
for O
subsequent O
cycles O
. O

Discontinue O
ZALTRAP O
in O
patients O
with O
hypertensive B-NonOSE_AE
crisis I-NonOSE_AE
or O
hypertensive B-NonOSE_AE
encephalopathy I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.6 O
Arterial O
Thromboembolic O
Events O
Arterial B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ATE I-OSE_Labeled_AE
) O
, O
including O
transient B-OSE_Labeled_AE
ischemic I-OSE_Labeled_AE
attack I-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
and O
angina B-OSE_Labeled_AE
pectoris I-OSE_Labeled_AE
, O
occurred O
more O
frequently O
in O
patients O
who O
have O
received O
ZALTRAP O
. O

In O
patients O
with O
mCRC B-Not_AE_Candidate
, O
ATE B-OSE_Labeled_AE
was O
reported O
in O
2.6 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
and O
1.7 O
% O
of O
patients O
treated O
with O
placebo/FOLFIRI O
. O

Grade O
3-4 O
events O
occurred O
in O
11 O
patients O
( O
1.8 O
% O
) O
treated O
with O
ZALTRAP/FOLFIRI O
and O
4 O
patients O
( O
0.7 O
% O
) O
treated O
with O
placebo/FOLFIRI O
. O

Discontinue O
ZALTRAP O
in O
patients O
who O
experience O
an O
ATE B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.7 O
Proteinuria O
Severe O
proteinuria B-OSE_Labeled_AE
, O
nephrotic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
and O
thrombotic B-OSE_Labeled_AE
microangiopathy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TMA I-OSE_Labeled_AE
) O
occurred O
more O
frequently O
in O
patients O
treated O
with O
ZALTRAP O
. O

In O
patients O
with O
mCRC B-Not_AE_Candidate
, O
proteinuria B-OSE_Labeled_AE
was O
reported O
in O
62 O
% O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
compared O
to O
41 O
% O
patients O
treated O
with O
placebo/FOLFIRI O
. O

Grade O
3-4 O
proteinuria B-OSE_Labeled_AE
occurred O
in O
8 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
to O
1 O
% O
of O
patients O
treated O
with O
placebo/FOLFIRI O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Nephrotic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
occurred O
in O
2 O
patients O
( O
0.5 O
% O
) O
treated O
with O
ZALTRAP/FOLFIRI O
compared O
to O
none O
of O
the O
patients O
treated O
with O
placebo/FOLFIRI O
. O

TMA B-OSE_Labeled_AE
was O
reported O
in O
3 O
of O
2258 O
patients O
with O
cancer B-Not_AE_Candidate
enrolled O
across O
completed O
studies O
. O

Monitor O
proteinuria B-NonOSE_AE
by O
urine O
dipstick O
analysis O
and/or O
urinary O
protein O
creatinine O
ratio O
( O
UPCR O
) O
for O
the O
development O
or O
worsening O
of O
proteinuria B-NonOSE_AE
during O
ZALTRAP O
therapy O
. O

Patients O
with O
a O
dipstick O
of O
> O
=2+ O
for O
protein O
or O
a O
UPCR O
greater O
than O
1 O
should O
undergo O
a O
24-hour O
urine O
collection O
. O

Suspend O
ZALTRAP O
administration O
for O
proteinuria B-NonOSE_AE
2 O
grams O
per O
24 O
hours O
or O
more O
, O
and O
resume O
when O
proteinuria B-NonOSE_AE
is O
less O
than O
2 O
grams O
per O
24 O
hours O
. O

If O
recurrent O
, O
suspend O
until O
proteinuria B-NonOSE_AE
is O
less O
than O
2 O
grams O
per O
24 O
hours O
and O
then O
permanently O
reduce O
the O
ZALTRAP O
dose O
to O
2 O
mg O
per O
kg O
. O

Discontinue O
ZALTRAP O
in O
patients O
who O
develop O
nephrotic B-NonOSE_AE
syndrome I-NonOSE_AE
or O
TMA B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.8 O
Neutropenia O
and O
Neutropenic O
Complications O
A O
higher O
incidence O
of O
neutropenic B-OSE_Labeled_AE
complications I-OSE_Labeled_AE
( O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
and O
neutropenic B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
) O
occurred O
in O
patients O
receiving O
ZALTRAP O
. O

In O
patients O
with O
mCRC B-Not_AE_Candidate
, O
Grade O
3-4 O
neutropenia B-OSE_Labeled_AE
occurred O
in O
37 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
compared O
to O
30 O
% O
patients O
treated O
with O
placebo/FOLFIRI O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Grade O
3-4 O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
occurred O
in O
4 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
compared O
to O
2 O
% O
of O
patients O
treated O
with O
placebo/FOLFIRI O
. O

Grade O
3-4 O
neutropenic B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
/sepsis O
occurred O
in O
1.5 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
and O
1.2 O
% O
of O
patients O
treated O
with O
placebo/FOLFIRI O
. O

Monitor O
CBC O
with O
differential O
count O
at O
baseline O
and O
prior O
to O
initiation O
of O
each O
cycle O
of O
ZALTRAP O
. O

Delay O
ZALTRAP/FOLFIRI O
until O
neutrophil O
count O
is O
at O
or O
above O
1.5 O
* O
10 O
9 O
/L O
. O

5.9 O
Diarrhea O
and O
Dehydration O
The O
incidence O
of O
severe O
diarrhea B-OSE_Labeled_AE
is O
increased O
in O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
. O

In O
patients O
with O
mCRC B-Not_AE_Candidate
, O
Grade O
3-4 O
diarrhea B-OSE_Labeled_AE
was O
reported O
in O
19 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
compared O
to O
8 O
% O
of O
patients O
treated O
with O
placebo/FOLFIRI O
. O

Grade O
3-4 O
dehydration B-OSE_Labeled_AE
was O
reported O
in O
4 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
compared O
to O
1 O
% O
of O
patients O
treated O
with O
placebo/FOLFIRI O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

The O
incidence O
of O
diarrhea B-NonOSE_AE
is O
increased O
in O
patients O
who O
are O
age O
65 O
years O
or O
older O
as O
compared O
to O
patients O
younger O
than O
65 O
years O
of O
age O
[ O
see O
Geriatric O
Use O
( O
8.5 O
) O
] O
. O

Monitor O
elderly O
patients O
closely O
for O
diarrhea B-NonOSE_AE
. O

5.10 O
Reversible O
Posterior O
Leukoencephalopathy O
Syndrome O
( O
RPLS O
) O
RPLS B-OSE_Labeled_AE
( O
also O
known O
as O
posterior B-OSE_Labeled_AE
reversible I-OSE_Labeled_AE
encephalopathy I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
) O
was O
reported O
in O
0.5 O
% O
of O
3795 O
patients O
treated O
with O
ZALTRAP O
monotherapy O
or O
in O
combination O
with O
chemotherapy O
. O

Confirm O
the O
diagnosis O
of O
RPLS B-NonOSE_AE
with O
MRI O
and O
discontinue O
ZALTRAP O
in O
patients O
who O
develop O
RPLS B-NonOSE_AE
. O

Symptoms O
usually O
resolve O
or O
improve O
within O
days O
, O
although O
some O
patients O
have O
experienced O
ongoing O
neurologic B-NonOSE_AE
sequelae I-NonOSE_AE
or O
death B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

